FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Putro, JN
   Ismadji, S
   Gunarto, C
   Yuliana, M
   Santoso, SP
   Soetaredjo, FE
   Ju, YH
AF Putro, Jindrayani Nyoo
   Ismadji, Suryadi
   Gunarto, Chintya
   Yuliana, Maria
   Santoso, Sheila Permatasari
   Soetaredjo, Felycia Edi
   Ju, Yi Hsu
TI The effect of surfactants modification on nanocrystalline cellulose for
   paclitaxel loading and release study
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE Nanocrystalline cellulose; Surfactant; Paclitaxel; Drug delivery
ID SUSTAINED RELEASE; DRUG DELIVERY; PARTICLE SIZE; NANOPARTICLES;
   RISPERIDONE; BARRIERS; KINETICS; BINDING; DESIGN; COLON
AB The Nanocrystalline cellulose (NCC) was prepared from filter paper by acid hydrolysis process. The modification of NCC with cationic, anionic, and nonionic surfactant did not have a tremendous effect on the chemical structure of material based on the characterization of XRD and FTIR. The modified NCCs were employed as a drug carrier for paclitaxel (PTX). Increasing concentration of ionic surfactants can enhance the loading of the hydrophobic drug, while the opposite trend was observed for nonionic surfactant modified nanocrystals. The attachment of surfactant toward the particle was a more likely physical aggregation of micelle on the surface of nanocrystals. Larger particle size was observed after the modification of nanocrystal cellulose. The fitting of Higuchi and sigmoidal models were applied in the release profile to investigate the kinetic release mechanism of paclitaxel at pH 5.8 and 7.4. Cell viability was determined to check the biocompatibility of the materials toward mouse osteoblast cells 7F2 using MIT assay. Toxic behavior was not observed for NCC, while CTAB was completely not compatible with cells. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Putro, Jindrayani Nyoo; Gunarto, Chintya] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, 43,Sect 4,Keelung Rd, Taipei 10607, Taiwan.
   [Ismadji, Suryadi; Yuliana, Maria; Santoso, Sheila Permatasari; Soetaredjo, Felycia Edi] Widya Mandala Surabaya Catholic Univ, Dept Chem Engn, Kalijudan 37, Surabaya 60114, Indonesia.
   [Ju, Yi Hsu] Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, 43,Sect 4,Keelung Rd, Taipei 10607, Taiwan.
C3 National Taiwan University of Science & Technology; Universitas Katolik
   Widya Mandala Surabaya; National Taiwan University of Science &
   Technology
RP Ismadji, S (通讯作者)，Widya Mandala Surabaya Catholic Univ, Dept Chem Engn, Kalijudan 37, Surabaya 60114, Indonesia.; Ju, YH (通讯作者)，Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, 43,Sect 4,Keelung Rd, Taipei 10607, Taiwan.
EM suryadiismadji@yahoo.com; yhju@mail.ntust.edu.tw
RI Ismadji, Suryadi/B 2806 2008; Gunarto, Chintya/AAV 5709 2021; Santoso,
   Shella Permatasari/O 8808 2018; Putro, Jindrayani/P 9035 2015;
   Edi Soetaredjo, Felycia/G 6463 2012; Yuliana, Maria/AAQ 1710 2020;
   Santoso, Shella/O 8808 2018
OI Santoso, Shella Permatasari/0000 0003 4698 583X; Putro,
   Jindrayani/0000 0002 1970 9314; Yuliana, Maria/0000 0002 3915 9401;
   Ismadji, Suryadi/0000 0002 5005 2824; 
CR An T, 2016, INT J PHARMACEUT, V503, P8, DOI 10.1016/j.ijpharm.2016.02.023
   Attwood D., 1983, SURFACTANT SYSTEMS T
   BARTNIK FG, 1992, ANIONIC SURFACTANTS, P1
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Chen WL, 2017, MOL PHARMACEUT, V14, P459, DOI 10.1021/acs.molpharmaceut.6b00896
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Duvvuri S, 2006, PHARM RES DORDR, V23, P215, DOI 10.1007/s11095 005 9042 6
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959 8049(01)00171 X
   HUIZING MT, 1995, CANCER INVEST, V13, P381, DOI 10.3109/07357909509031919
   Ishikawa S, 2002, J APPL MICROBIOL, V93, P302, DOI 10.1046/j.1365 2672.2002.01690.x
   Jackson JK, 2011, INT J NANOMED, V6, P321, DOI 10.2147/IJN.S16749
   Kobayashi H, 2014, THERANOSTICS, V4, P81, DOI 10.7150/thno.7193
   LANGENBUCHER F, 1972, J PHARM PHARMACOL, V24, P979, DOI 10.1111/j.2042 7158.1972.tb08930.x
   Lozoya Agullo I, 2015, J PHARM SCI US, V104, P3136, DOI 10.1002/jps.24447
   Mohanta V, 2014, ACS APPL MATER INTER, V6, P20093, DOI 10.1021/am505681e
   Nakajima T, 2018, J PHARM SCI US, V107, P1896, DOI 10.1016/j.xphs.2018.02.022
   Narvekar M, 2014, AAPS PHARMSCITECH, V15, P822, DOI 10.1208/s12249 014 0107 x
   Ortiz Tafoya MC, 2018, DATA BRIEF, V19, P642, DOI 10.1016/j.dib.2018.05.064
   PAUL DR, 1976, J MEMBRANE SCI, V1, P33, DOI 10.1016/S0376 7388(00)82256 5
   Qing WX, 2016, APPL SURF SCI, V366, P404, DOI 10.1016/j.apsusc.2016.01.133
   Shang Q, 2018, POLYM ADVAN TECHNOL, V29, P384, DOI 10.1002/pat.4125
   Surapaneni Madhu S, 2012, ISRN Pharmacol, V2012, P623139, DOI 10.5402/2012/623139
   Sutradhar KB., 2014, ISRN Nanotechnol, P12, DOI 10.1155/2014/939378
   Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978 1 61779 012 6_9
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168 3659(01)00299 1
   Tu HW, 2010, CARBOHYD POLYM, V82, P440, DOI 10.1016/j.carbpol.2010.04.086
   Viana RB, 2012, ADV PHYS CHEM, DOI 10.1155/2012/903272
   Wang CY, 2015, CARBOHYD POLYM, V130, P275, DOI 10.1016/j.carbpol.2015.05.007
   Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14 04 0916
   Yamada H, 2014, ACS APPL MATER INTER, V6, P3491, DOI 10.1021/am405633r
   Zainuddin N, 2017, CARBOHYD POLYM, V163, P261, DOI 10.1016/j.carbpol.2017.01.036
   Zhang YP, 2017, CARBOHYD POLYM, V164, P358, DOI 10.1016/j.carbpol.2017.01.096
   Zhong LX, 2012, CARBOHYD POLYM, V90, P644, DOI 10.1016/j.carbpol.2012.05.091
NR 34
TC 33
Z9 33
U1 1
U2 74
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167 7322
EI 1873 3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD MAY 15
PY 2019
VL 282
BP 407
EP 414
DI 10.1016/j.molliq.2019.03.037
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Physics
GA HU1VR
UT WOS:000465060400044
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Dudakovic, A
   Gluscevic, M
   Paradise, CR
   Dudakovic, H
   Khani, F
   Thaler, R
   Ahmed, FS
   Li, XD
   Dietz, AB
   Stein, GS
   Montecino, MA
   Deyle, DR
   Westendorf, JJ
   Van Wijnen, AJ
AF Dudakovic, Amel
   Gluscevic, Martina
   Paradise, Christopher R.
   Dudakovic, Halil
   Khani, Farzaneh
   Thaler, Roman
   Ahmed, Farah S.
   Li, Xiaodong
   Dietz, Allan B.
   Stein, Gary S.
   Montecino, Martin A.
   Deyle, David R.
   Westendorf, Jennifer J.
   van Wijnen, Andre J.
TI Profiling of human epigenetic regulators using a semi automated
   real time qPCR platform validated by next generation sequencing
SO GENE
LA English
DT Article
DE Mesenchymal stem cell; Adipose tissue derived stromal cells;
   Epigenetics; Histone; Epigenetic regulators; Deacetylase;
   Methyltransferase
ID MESENCHYMAL STEM CELLS; HISTONE DEACETYLASE INHIBITOR; BONE MINERAL
   DENSITY; OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; OSTEOGENIC
   DIFFERENTIATION; CHROMATIN STRUCTURE; OSTEOCALCIN GENE; RUNX2 PROMOTER;
   STROMAL CELLS
AB Epigenetic mechanisms control phenotypic commitment of mesenchymal stromal/stem cells (MSCs) into osteogenic, chondrogenic or adipogenic lineages. To investigate enzymes and chromatin binding proteins controlling the epigenome, we developed a hybrid expression screening strategy that combines semi automated real time qPCR (RT qPCR), next generation RNA sequencing (RNA seq), and a novel data management application (FileMerge). This strategy was used to interrogate expression of a large cohort (n> 300) of human epigenetic regulators (EpiRegs) that generate, interpret and/or edit the histone code. We find that EpiRegs with similar enzymatic functions are variably expressed and specific isoforms dominate over others in human MSCs. This principle is exemplified by analysis of key histone acetyl transferases (HATs) and deacetylases (HDACs), H3 lysine methyltransferases (e.g., EHMTs) and demethylases (KDMs), as well as bromodomain (BRDs) and chromobox (CBX) proteins. Our results show gender specific expression of H3 lysine 9 [H3K9] demethylases (e.g., KDM5D and UTY) as expected and upregulation of distinct EpiRegs (n > 30) during osteogenic differentiation of MSCs (e.g., HDAC5 and HDAC7). The functional significance of HDAC5 in osteogenic lineage commitment of MSCs was functionally validated using panobinostat (LBH 589). This pan deacetylase inhibitor suppresses osteoblastic differentiation as evidenced by reductions in bone specific mRNA markers (e.g., ALPL), alkaline phosphatase activity and calcium deposition (i.e., Alizarin Red staining). Thus, our RT qPCR platform identifies candidate EpiRegs by expression screening, predicts biological outcomes of their corresponding inhibitors, and enables manipulation of the human epigenome using molecular or pharmacological approaches to control stem cell differentiation. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Dudakovic, Amel; Gluscevic, Martina; Paradise, Christopher R.; Khani, Farzaneh; Thaler, Roman; Ahmed, Farah S.; Li, Xiaodong; Westendorf, Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
   [Westendorf, Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Biochem & Mol Biol, Rochester, MN USA.
   [van Wijnen, Andre J.] Mayo Clin, Physiol & Biomed Engn, Rochester, MN USA.
   [Dudakovic, Halil] Mayo Clin, Informat Technol, Rochester, MN USA.
   [Dietz, Allan B.] Mayo Clin, Lab Med & Pathol, Rochester, MN USA.
   [Deyle, David R.] Mayo Clin, Med Genet, Rochester, MN USA.
   [Stein, Gary S.] Univ Vermont Med Sch, Dept Biochem, Burlington, VT USA.
   [Montecino, Martin A.] Univ Andres Bello, Fac Biol Sci, Ctr Biomed Res, Santiago, Chile.
   [Montecino, Martin A.] Univ Andres Bello, Fac Med, Santiago, Chile.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo
   Clinic; Universidad Andres Bello; Universidad Andres Bello
RP Van Wijnen, AJ (通讯作者)，200 First St SW, Rochester, MN 55905 USA.
EM vanwijnen.andre@mayo.edu
RI Dietz, Allan/H 7414 2015; Dietz, Allan/AAI 6976 2021; van Wijnen,
   Andre/AAG 3578 2019
OI Dietz, Allan/0000 0003 3410 9621; Montecino, Martin/0000 0002 6025 0023;
   Dudakovic, Amel/0000 0002 8850 3977; Baban, Farah/0000 0002 0068 5199;
   Paradise, Christopher/0000 0002 5882 709X; van Wijnen, Andre
   J./0000 0002 4458 0946
FU National Institutes of Health [F32 AR066508, R01 AR049069, R01 AR068103,
   R01 DE020194, R01 AR039588]; Fondo de Finaciamiento de Centros de
   Investigacion en Areas Prioritarias [15090007]; Fondo Nacional de
   Ciencia y Tecnologia [FONDECYT 1130706]; Center for Regenerative
   Medicine at Mayo Clinic
FX This work was supported, in whole or in part, by National Institutes of
   Health grants F32 AR066508 (AD), R01 AR049069 (AJvW), R01 AR068103
   (JJW), R01 DE020194 (JJW), and R01 AR039588 (GSS), as well as by grants
   from Fondo de Finaciamiento de Centros de Investigacion en Areas
   Prioritarias (15090007; to MM) and Fondo Nacional de Ciencia y
   Tecnologia (FONDECYT 1130706; to MM). Additional support was provided by
   intramural grants from the Center for Regenerative Medicine at Mayo
   Clinic. We also appreciate the generous philanthropic support of William
   H. and Karen J. Eby.
CR Bajpe PK, 2015, ONCOGENE, V34, P531, DOI 10.1038/onc.2013.588
   Barutcu AR, 2014, NUCLEIC ACIDS RES, V42, P10360, DOI 10.1093/nar/gku712
   Björkman M, 2012, ONCOGENE, V31, P3444, DOI 10.1038/onc.2011.512
   Boluk A, 2004, PHARMACOL RES, V50, P93, DOI 10.1016/j.phrs.2003.11.011
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Camilleri ET, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0370 8
   Cellot S, 2013, BLOOD, V122, P1545, DOI 10.1182/blood 2013 04 496281
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Cori F., 2001, J BIOL CHEM, V276, P46515
   Crespo Diaz R, 2011, CELL TRANSPLANT, V20, P797, DOI 10.3727/096368910X543376
   de Wit E, 2012, GENE DEV, V26, P11, DOI 10.1101/gad.179804.111
   Di Bernardo G, 2009, STEM CELLS DEV, V18, P573, DOI 10.1089/scd.2008.0172
   Dudakovic A., 2015, J BIOL CHEM
   Dudakovic A, 2016, J BIOL CHEM, V291, P24594, DOI 10.1074/jbc.M116.740571
   Dudakovic A, 2015, J CELL PHYSIOL, V230, P52, DOI 10.1002/jcp.24680
   Dudakovic A, 2014, J CELL BIOCHEM, V115, P1816, DOI 10.1002/jcb.24852
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Elliott JO, 2007, SEIZURE EUR J EPILEP, V16, P22, DOI 10.1016/j.seizure.2006.10.001
   Farzaneh K., 2016, J CELL BIOCH
   Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Gori F, 2006, DEV BIOL, V295, P498, DOI 10.1016/j.ydbio.2006.02.031
   Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296 474
   Haberland M, 2010, J BIOL CHEM, V285, P14663, DOI 10.1074/jbc.M109.081679
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang HT, 2013, NAT CELL BIOL, V15, P1516, DOI 10.1038/ncb2870
   Hui TQ, 2014, J ENDODONT, V40, P1132, DOI 10.1016/j.joen.2014.01.031
   IWAMI K, 1993, INT J BIOCHEM, V25, P1631, DOI 10.1016/0020 711X(93)90522 G
   Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104
   Jing H., 2015, MOL THER
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Lee JY, 2006, MOL CELLS, V22, P182
   Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365 2184.2009.00633.x
   Liu LH, 2012, BIOINFORMATICS, V28, P2205, DOI 10.1093/bioinformatics/bts340
   Mader EK, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 20
   McGee Lawrence ME, 2011, BONE, V48, P1117, DOI 10.1016/j.bone.2011.01.007
   Meyer MB, 2014, J BIOL CHEM, V289, P16016, DOI 10.1074/jbc.M114.552216
   Pike JW., 2015, BONE
   Pratap J, 2010, MOL CANCER THER, V9, P3210, DOI 10.1158/1535 7163.MCT 10 0572
   Rando OJ, 2009, ANNU REV BIOCHEM, V78, P245, DOI 10.1146/annurev.biochem.78.071107.134639
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Riester S. M., 2016, STEM CELLS TRANSLATI
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Senn SM, 2010, EPILEPSIA, V51, P984, DOI 10.1111/j.1528 1167.2009.02516.x
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200
   SHETH RD, 1995, J PEDIATR US, V127, P256, DOI 10.1016/S0022 3476(95)70304 7
   Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722
   St John HC, 2014, MOL ENDOCRINOL, V28, P1150, DOI 10.1210/me.2014 1091
   Tai PWL, 2014, GENE, V550, P1, DOI 10.1016/j.gene.2014.05.044
   Thaler R., 2016, J BIOL CHEM
   Varela N, 2016, J CELL PHYSIOL, V231, P1001, DOI 10.1002/jcp.25188
   Vestergaard P, 2004, EPILEPSIA, V45, P1330, DOI 10.1111/j.0013 9580.2004.18804.x
   Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113
   WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Zaidi SK, 2010, NAT REV GENET, V11, P583, DOI 10.1038/nrg2827
   Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154 06
NR 68
TC 25
Z9 26
U1 0
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD APR 20
PY 2017
VL 609
BP 28
EP 37
DI 10.1016/j.gene.2017.01.019
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA EM9CS
UT WOS:000395609400004
PM 28132772
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, SX
   Li, H
AF Wang Shi Xiang
   Li Han
TI Salmon calcitonin in prevention of osteoporosis in maintenance dialysis
   patients
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE dialysis; oestoporosis; bone mass density; salmon calcitonin
ID BONE MINERAL DENSITY; SECONDARY HYPERPARATHYROIDISM; POSTMENOPAUSAL
   WOMEN; KIDNEY DISEASE; METABOLISM; MECHANISMS; CALCIUM; MEN; PTH
AB Background Renal osteodystrophy is one of the commonest complications of chronic renal failure. It may have a severe impact on the quality of life of patients on maintenance dialysis therapy. Besides post menopausal women and elderly people, the dialysis patients are another high risk group. But at present, there is no research on how to prevent osteoporosis in maintenance dialysis patients. This study was conducted to observe the bone density of maintenance dialysis patients and to evaluate the clinical outcombs and safety of different administration dosage of salmon calcitonin to prevent osteoporosis in maintenance dialysis patients.
   Methods One hundred and forty eight patients on maintenance dialysis were involved in the 12 month, randomized, controlled trial. Fifty patients (experiment I group) received subcutaneous injection of salmon calcitonin (50 U) three times a week for 12 months. Fifty patients (experiment 11 group) received subcutaneous injection of salmon calcitonin (100 U) three times a week for 12 months. At the same time, both of them received oral calcium carbonate 1500 mg tid and rocaltrol 0.25 mu g qn for 12 months. The control group only received oral calcium carbonate 1500 mg tid and rocaltrol 0.25 mu g qn for 12 months. The levels of bone mass density (BMD) of the lumbar spine and femoral neck, serum intact parathyroid hormone (iPTH), osteocalcin (OC), calcium, phosphorus, alkaline phosphatase (ALP) were assessed at baseline and then again after 3, 6 and 12 months of treatment.
   Results The values of BMD at the lumbar spine and femoral neck before the treatment were not significantly different from those 3, 6, and 12 months after the treatment in trial groups I and II (all P > 0.05) and there were no significant differences in the BMD values at different time points between trial groups I and II. In the control group, the BMD values at the lumbar spine and femoral neck 3, 6, and 12 months after the beginning of trial were significantly lower than those before the trial, and significantly lower than the corresponding values of trial groups I and II (all P < 0.05). The serum OC 3, 6, and 12 months after the treatment was significantly lower than that before the experiment (all P < 0.05) in the control group. However, there was no significant difference in the value of serum OC before and 3, 6, and 12 months after the treatment in trial groups I and II (all P > 0.05).
   Conclusions The dose of salmon calcitonin 50 U three times a week plus calcium carbonate and active vitamin D can effectively preserve the BMD and prevent bone loss in maintenance dialysis patients, and it is well tolerated by patients on maintenance dialysis.
C1 [Wang Shi Xiang; Li Han] Capital Med Univ, Bejing Chaoyang Hosp, Blood Purificat Ctr, Beijing 100020, Peoples R China.
C3 Capital Medical University
RP Li, H (通讯作者)，Capital Med Univ, Bejing Chaoyang Hosp, Blood Purificat Ctr, Beijing 100020, Peoples R China.
EM lihandp@yahoo.com.cn
CR Aucella F, 2005, J NEPHROL, V18, P537
   Bai RJ, 2006, CHINESE MED J PEKING, V119, P1248, DOI 10.1097/00029330 200608010 00004
   Chung SY, 2005, BREAST, V14, P399, DOI 10.1016/j.breast.2004.08.012
   Dai Y, 2007, CHINESE MED J PEKING, V120, P2017, DOI 10.1097/00029330 200711020 00015
   Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409
   Eknoyan G, 2004, KIDNEY INT, V66, P1310, DOI 10.1111/j.1523 1755.2004.00894.x
   Ensrud KE, 2005, J CLIN ENDOCR METAB, V90, P1998, DOI 10.1210/jc.2004 1805
   Greenberg JA, 2007, TOP STROKE REHABIL, V14, P62, DOI 10.1310/tsr1402 62
   Guven Z, 2007, AGING MALE, V10, P197, DOI 10.1080/13685530701661051
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Muraki S, 2004, OSTEOPOROSIS INT, V15, P724, DOI 10.1007/s00198 004 1600 y
   Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18
   Papadokostakis G, 2006, EUR SPINE J, V15, P356, DOI 10.1007/s00586 005 0916 4
   Peñalba A, 2003, NEFROLOGIA, V23, P112
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   Sit D, 2007, ADV THER, V24, P987, DOI 10.1007/BF02877703
   Vistoropsky Y, 2007, HUM MOL GENET, V16, P1233, DOI 10.1093/hmg/ddm071
   Yin YX, 2007, CHINESE MED J PEKING, V120, P204, DOI 10.1097/00029330 200702010 00006
NR 20
TC 6
Z9 9
U1 0
U2 7
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366 6999
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD JUL 20
PY 2008
VL 121
IS 14
BP 1280
EP 1284
DI 10.1097/00029330 200807020 00007
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 330KW
UT WOS:000257941000006
PM 18713548
OA gold
DA 2025 08 17
ER

PT J
AU Ashton, JA
   Farese, JP
   Milner, RJ
   Lee Ambrose, LM
   van Gilder, JM
AF Ashton, JA
   Farese, JP
   Milner, RJ
   Lee Ambrose, LM
   van Gilder, JM
TI Investigation of the effect of pamidronate disodium on the in vitro
   viability of osteosarcoma cells from dogs
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
ID BISPHOSPHONATES INDUCE APOPTOSIS; CANINE OSTEOSARCOMA; APPENDICULAR
   OSTEOSARCOMA; BONE; CANCER; GROWTH; PHARMACOKINETICS; ALENDRONATE;
   MECHANISMS; ESTABLISHMENT
AB Objective To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non neoplastic cells from dogs.
   Sample Population 3 osteosarcoma and 1 fibroblast cell lines derived from dogs.
   Procedure Cell counts and cell viability assays were performed in cultures of osteosarcoma cells (POS, HMPOS, and COS31 cell lines) and fibroblasts after 24, 48, and 72 hours of incubation with pamidronate at concentrations of 0.001 to 1,000 mu M or with no drug (control treatment). Percentage viability was determined in cell samples for each concentration of pamidronate and each incubation time. A DNA fragmentation analysis was performed to assess bisphosphonate induced apoptosis.
   Results Osteosarcoma cell viability decreased significantly in a concentration  and time dependent manner at pamidronate concentrations ranging from 100 to 1,000 mu M, most consistently after 48 and 72 hours' exposure. In treated osteosarcoma cells, the lowest percentage cell viability was 34% (detected after 72 hours' exposure to 1,000 mu M pamidronate). Conversely, 72 hours' exposure to 1,000 mu M pamidronate did not significantly reduce fibroblast viability (the lowest percentage viability was 76%). After 72 hours of exposure, pamidronate did not cause DNA fragmentation in POS or HMPOS cells.
   Conclusions and Clinical Relevance Results indicate that pamidronate may have the potential to inhibit osteosarcoma growth in dogs, possibly through a nonapoptotic mechanism. The clinical relevance of these in vitro findings remains to be determined, but administration of pamidronate may potentially be indicated as an adjuvant treatment in chemotherapeutic protocols used in dogs.
C1 Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida
RP Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA.
CR Barroga EF, 1999, J VET MED SCI, V61, P361
   Berenson JR, 1997, J CLIN PHARMACOL, V37, P285, DOI 10.1002/j.1552 4604.1997.tb04304.x
   Berg J, 1996, VET CLIN N AM SMALL, V26, P111, DOI 10.1016/S0195 5616(96)50010 0
   Body JJ, 2001, SEMIN ONCOL, V28, P49, DOI 10.1016/S0093 7754(01)90232 5
   BRODEY RS, 1969, CLIN ORTHOP RELAT R, P54
   Coleman RE, 2001, SEMIN ONCOL, V28, P11, DOI 10.1053/sonc.2001.24155
   Dernell WS., 2001, Small Animal Clinical Oncology, P378
   Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097 0142(20000615)88:12+<3080::AID CNCR27>3.0.CO;2 W
   El Abdaimi K, 2003, INT J ONCOL, V22, P883
   Farese JP, 2004, JAVMA J AM VET MED A, V225, P1567, DOI 10.2460/javma.2004.225.1567
   Farese JP, 2004, IN VITRO CELL DEV AN, V40, P113, DOI 10.1290/1543 706X(2004)040<0113:TEOTBA>2.0.CO;2
   FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495 199141020 00009
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   KADOSAWA T, 1994, J VET MED SCI, V56, P1167, DOI 10.1292/jvms.56.1167
   Lee MV, 2001, CANCER RES, V61, P2602
   LEYVRAZ S, 1992, J NATL CANCER I, V84, P788, DOI 10.1093/jnci/84.10.788
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Mathov I, 2001, J BONE MINER RES, V16, P2050, DOI 10.1359/jbmr.2001.16.11.2050
   Morello E, 2001, J SMALL ANIM PRACT, V42, P61, DOI 10.1111/j.1748 5827.2001.tb01993.x
   OBRIEN MG, 1993, COMP CONT EDUC PRACT, V15, P939
   OISO Y, 1994, ENDOCR J, V41, P655, DOI 10.1507/endocrj.41.655
   Poirier V J, 2003, Vet Comp Oncol, V1, P207, DOI 10.1111/j.1476 5810.2003.00026.x
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Shoieb AM, 1998, IN VIVO, V12, P463
   Slingerland J.M., 1998, BASIC SCI ONCOLOGY, P134
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   SPODNICK GJ, 1992, J AM VET MED ASSOC, V200, P995
   Straw RC., 1996, MacEwen EG: Small animal clinical oncology, V2, P287
   TENENBAUM HC, 1992, BONE, V13, P249, DOI 10.1016/8756 3282(92)90205 B
   Tomlin JL, 2000, VET REC, V147, P129, DOI 10.1136/vr.147.5.129
NR 41
TC 18
Z9 18
U1 0
U2 8
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173 4360 USA
SN 0002 9645
EI 1943 5681
J9 AM J VET RES
JI Am. J. Vet. Res.
PD MAY
PY 2005
VL 66
IS 5
BP 885
EP 891
DI 10.2460/ajvr.2005.66.885
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 922CT
UT WOS:000228814200019
PM 15934617
OA Bronze
DA 2025 08 17
ER

PT J
AU Joshi, R
   Suryawanshi, T
   Mukherjee, S
   Shukla, S
   Majumder, A
AF Joshi, Rohit
   Suryawanshi, Tejas
   Mukherjee, Sourav
   Shukla, Shobha
   Majumder, Abhijit
TI Chromatin Condensation Delays Senescence in Human Mesenchymal Stem Cells
   by Safeguarding Nuclear Damages during In Vitro Expansion
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
ID BONE MARROW; EPIGENETIC REGULATION; SUBSTRATE STIFFNESS; MECHANICAL
   FORCES; DIFFERENTIATION; PROLIFERATION; MORPHOLOGY
AB Human mesenchymal stem cells (hMSCs) are multipotent cells that differentiate into adipocytes, chondrocytes, and osteoblasts. Owing to their differentiation potential, hMSCs are among the cells most frequently used for therapeutic applications in tissue engineering and regenerative medicine. However, the number of cells obtained through isolation alone is insufficient for hMSC based therapies and basic research, which necessitates in vitro expansion. Conventionally, this is often performed on rigid surfaces such as tissue culture plates (TCPs). However, during in vitro expansion, hMSCs lose their proliferative ability and multilineage differentiation potential, rendering them unsuitable for clinical use. Although multiple approaches have been attempted to maintain hMSC stemness during prolonged expansion, finding a suitable culture system remains an unmet need. Recently, a few research groups have shown that hMSCs maintain their stemness over long passages when cultured on soft substrates. In addition, it has been shown that hMSCs cultured on soft substrates have more condensed chromatin and lower levels of histone acetylation compared to those cultured on stiff substrates. Furthermore, it has also been shown that condensing/decondensing chromatin by deacetylation/acetylation can delay replicative senescence in hMSCs during long term expansion on TCPs. However, the mechanism by which chromatin condensation/decondensation influences nuclear morphology and DNA damage, which are strongly related to the onset of senescence, remains unknown. To answer this question, we cultured hMSCs for long duration in the presence of epigenetic modifiers, histone acetyltransferase inhibitor (HATi), which promotes chromatin condensation by preventing histone acetylation, and histone deacetylase inhibitor (HDACi), which promotes chromatin decondensation, and investigated their effects on various nuclear markers related to senescence. We found that consistent acetylation causes severe nuclear abnormalities, whereas chromatin condensation by deacetylation helps to safeguard the nucleus from damage caused by in vitro expansion.
C1 [Joshi, Rohit; Mukherjee, Sourav; Majumder, Abhijit] Indian Inst Technol Bombay Powai, Dept Chem Engn, Mumbai 400076, India.
   [Suryawanshi, Tejas] Indian Inst Technol, Ctr Res Nano Technol & Sci, Mumbai 400076, India.
   [Shukla, Shobha] Indian Inst Technol, Dept Met Engn & Mat Sci, Mumbai 400076, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Bombay; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT)   Bombay; Indian Institute
   of Technology System (IIT System); Indian Institute of Technology (IIT)
     Bombay
RP Majumder, A (通讯作者)，Indian Inst Technol Bombay Powai, Dept Chem Engn, Mumbai 400076, India.
EM rohitjoshi013@gmail.com; tejasys2012@gmail.com; srv.iitb@gmail.com;
   sshukla@iitb.ac.in; abhijitm@iitb.ac.in
RI ; Majumder, Abhijit/HKP 0646 2023
OI Suryawanshi, Tejas/0000 0001 5237 5400; Shukla,
   Shobha/0000 0003 3659 7841; Joshi, Rohit/0000 0001 8875 4576; Mukherjee,
   Sourav/0000 0003 2186 103X
CR Arezoumand KS, 2017, ARTIF CELL NANOMED B, V45, P1255, DOI 10.1080/21691401.2016.1246452
   Baell JB, 2018, NATURE, V560, P253, DOI 10.1038/s41586 018 0387 5
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   Bunpetch V, 2019, BIOMATERIALS, V196, P67, DOI 10.1016/j.biomaterials.2017.11.023
   Cakouros D, 2019, AGING DIS, V10, P174, DOI 10.14336/AD.2017.1213
   Cheleuitte D, 1998, J CLIN ENDOCR METAB, V83, P2043, DOI 10.1210/jc.83.6.2043
   Crouch J, 2022, CELLS BASEL, V11, DOI 10.3390/cells11040672
   Crowder SW, 2016, CELL STEM CELL, V18, P39, DOI 10.1016/j.stem.2015.12.012
   De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Evason K, 2008, AGING CELL, V7, P305, DOI 10.1111/j.1474 9726.2008.00375.x
   Heckenbach I, 2022, NATURE AGING, V2, P742, DOI 10.1038/s43587 022 00263 3
   Heo SJ, 2023, NAT BIOMED ENG, V7, P177, DOI 10.1038/s41551 022 00910 5
   Joshi R., 2022, BioRxiv, V14, P2022
   Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018 009 0242 9
   Kalinin AA, 2021, MOL BIOL CELL, V32, P1624, DOI 10.1091/mbc.E20 08 0502
   Killaars AR, 2019, ADV SCI, V6, DOI 10.1002/advs.201801483
   Kureel SK, 2019, BIOL OPEN, V8, DOI 10.1242/bio.039453
   Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552
   Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365 2184.2009.00633.x
   Madrigal M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0260 8
   Majumder A., 2023, bioRxiv
   Mao AS, 2016, BIOMATERIALS, V98, P184, DOI 10.1016/j.biomaterials.2016.05.004
   Miroshnikova YA, 2017, J CELL SCI, V130, P2243, DOI 10.1242/jcs.202192
   Mogha P, 2019, RSC ADV, V9, P10174, DOI 10.1039/c9ra00781d
   Pathak RU, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101264
   Rao VV, 2019, BIOENG TRANSL MED, V4, P51, DOI 10.1002/btm2.10104
   Ren GW, 2012, STEM CELL TRANSL MED, V1, P51, DOI 10.5966/sctm.2011 0019
   Sen P, 2016, CELL, V166, P822, DOI 10.1016/j.cell.2016.07.050
   Sidler C, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00138
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Stephens AD, 2018, MOL BIOL CELL, V29, P220, DOI 10.1091/mbc.E17 06 0410
   Sun YP, 2023, GENES DIS, V10, P2443, DOI 10.1016/j.gendis.2022.10.030
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Turinetto V, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071164
   Vining KH, 2017, NAT REV MOL CELL BIO, V18, P728, DOI 10.1038/nrm.2017.108
   Wagner W, 2010, TISSUE ENG PART B RE, V16, P445, DOI [10.1089/ten.teb.2009.0825, 10.1089/ten.TEB.2009.0825]
   Warren DT, 2011, BIOCHEM SOC T, V39, P1780, DOI 10.1042/BST20110703
   Witkowska Zimny M, 2013, CELL BIOL INT, V37, P608, DOI 10.1002/cbin.10078
   Yi BC, 2022, BIOACT MATER, V15, P82, DOI 10.1016/j.bioactmat.2021.12.005
   Yu RF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22257 2
   Zaim M, 2012, ANN HEMATOL, V91, P1175, DOI 10.1007/s00277 012 1438 x
NR 42
TC 0
Z9 0
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD MAY 10
PY 2024
VL 2024
AR 1543849
DI 10.1155/2024/1543849
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA RI1Q0
UT WOS:001226947300001
PM 40225747
OA gold
DA 2025 08 17
ER

PT J
AU Du, XY
   Man, DP
   Li, DW
   Kang, N
   Dong, P
   Fang, DJ
   Zhu, XF
   Zhou, YM
AF Du, Xiaoyan
   Man, Dapeng
   Li, Dongwen
   Kang, Ning
   Dong, Ping
   Fang, Dianji
   Zhu, Xiaofeng
   Zhou, Yanmin
TI The Effect of Specific Oligonucleotides on the Proliferation of Human
   Bone Marrow Mesenchymal Stem Cells
SO JOURNAL OF HARD TISSUE BIOLOGY
LA English
DT Article
DE Human Bone marrow mesenchymal stem cells (hBMSCs); Proliferation;
   Oligonucleotide (ODN)
ID CPG OLIGODEOXYNUCLEOTIDES; ODN; MODULATION; OSTEOBLAST; IMMUNITY;
   THERAPY; CYCLE
AB The objectives of this study were to screen for the better Oligonucleotide (ODN) that promotes the proliferation of human bone marrow mesenchymal stem cells (hBMSCs) and to investigate the mechanism of action of the ODN that has the greatest effect on the hBMSCs cell cycle. hBMSCs were isolated, cultured to the third passage and subjected to osteogenic, adipogenic and chondrogenic induction in order to examine their capacities for multi differentiation. The hBMSCs were seeded at different plating densities (3.0x10(3)/cm(2), 6.0x10(3)/cm(2), 1.2x10(4)/cm(2), 2.4x10(4)/cm(2)) and tested for seven consecutive days to determine the better plating density. A total of 12 experimental groups and 1 control group of hBMSCs (4 replicate wells in each group) were established and treated with ODN types MT01, FC003, or SAT05f at concentrations of 0.5mg/l, 1.0 mg/l, 2.0 mg/l or 4.0 mg/l; the control group was treated with an equal volume of PBS. Proliferation of hBMSCs was determined for 3 consecutive days after treatment via CCK 8 assay. The type and concentration of ODN that had a significant facilitatory effect on hBMSCs proliferation was selected and cell cycle analysis was done on days 1, 2 and 3 after ODN treatment; control groups were treated with an equal amount of PBS. The expressions of cyclin A, cyclin D1, cyclin dependent kinase (CDK) 2 and CDK 4 in hBMSCs were measured on day 2 after treatment using fluorescent quantitative real time PCR. The isolated and cultured hBMSCs were found to have osteogenic, adipogenic and chondrogenic differentiation capacities. The better cell growth curve was found to occur at a plating density of 6.0x10(3)/cm(2). Optical density was significantly increased in hBMSCs treated with 0.5 mg/L FC003 on day 1 (P<0.01) compared to the control group. Optical density was significantly decreased on day 1 after treatment with 1.0 mg/L and 4.0 mg/l of SAT05f (P<0.01 and P<0.05, respectively). Optical density was significantly increased on days 1, 2 and 3 after treatment with a final concentration of 2.0 mg/L of MT01 (P<0.01, P<0.05, P<0.05, respectively). The percentage of cells in phase G0/G1 was significantly reduced, and the percentage of cells in phases S and G2/M was significantly increased (P<0.01) after treatment with 2.0 mg/l MT01 compared to the control group. Furthermore, the expressions of cyclin A, cyclin D1, CDK 2 and CDK 4 were significantly elevated (P<0.01) compared with the control group. In conclusion, a 2.0 mg/l concentration of MT01 significantly promotes hBMSCs proliferation as evidenced by the decrease in the percentage of cells in phase G0/G1 and the increase in the percentage of cells in phases S and G2/M. The underlying molecular mechanisms may include, but are not limited to, elevated expressions of cyclin A, cyclin D1, CDK 2 and CDK 4.
C1 [Zhou, Yanmin] Jilin Univ, Stomatol Hosp, Implant Ctr, Changchun 130021, Jilin Province, Peoples R China.
   [Du, Xiaoyan; Man, Dapeng; Li, Dongwen; Fang, Dianji] Jiamusi Univ, Affiliated Hosp 2, Jiamusi, Heilongjiang Pr, Peoples R China.
   [Kang, Ning; Dong, Ping] CAMS, Plast Surg Hosp, Res Ctr, Beijing, Peoples R China.
   [Kang, Ning; Dong, Ping] PUMC, Beijing, Peoples R China.
   [Zhu, Xiaofeng] Jiamusi Univ, Neurosci Res Inst, Jiamusi, Heilongjiang Pr, Peoples R China.
C3 Jilin University; Jiamusi University; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Plastic Surgery Hospital  
   CAMS; Chinese Academy of Medical Sciences   Peking Union Medical
   College; Peking Union Medical College; Jiamusi University
RP Zhou, YM (通讯作者)，Jilin Univ, Stomatol Hosp, Implant Ctr, Changchun 130021, Jilin Province, Peoples R China.
EM zhouym62@126.com
RI Li, Dongwen/LFV 4599 2024; Kang, Ning/LDF 0801 2024
FU Stomatological Hospital of Jilin University; Second Affiliated Hospital
   of Jiamusi University; Research Center of Plastic Surgery Hospital, CAMS
   PUMC; national natural science foundation of China [81170935]; college
   science and technology innovation teammof Heilongjiang Province
   [2012TD013]
FX This work was supported by Stomatological Hospital of Jilin University,
   The Second Affiliated Hospital of Jiamusi University and Research Center
   of Plastic Surgery Hospital, CAMS & PUMC. This study was financially
   supported by funds from the national natural science foundation of China
   (NO. 81170935) and the college science and technology innovation teammof
   Heilongjiang Province (NO.2012TD013).
CR Amcheslavsky A, 2005, J BONE MINER RES, V20, P1692, DOI 10.1359/JBMR.050515
   Bai JY, 2012, CAN J MICROBIOL, V58, P752, DOI [10.1139/W2012 045, 10.1139/w2012 045]
   Bao MS, 2006, CLIN IMMUNOL, V118, P180, DOI 10.1016/j.clim.2005.09.014
   Cerkovnik P, 2011, INT J ONCOL, V38, P1749, DOI 10.3892/ijo.2011.974
   Dai L, 2013, CANCER LETT, V333, P103, DOI 10.1016/j.canlet.2013.01.025
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Echalier A, 2010, BBA PROTEINS PROTEOM, V1804, P511, DOI 10.1016/j.bbapap.2009.10.002
   Feng ZQ, 2011, EXP MOL PATHOL, V91, P569, DOI 10.1016/j.yexmp.2011.06.004
   Feng ZY, 2011, INT J MOL SCI, V12, P2543, DOI 10.3390/ijms12042543
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   Klinman D, 2008, J LEUKOCYTE BIOL, V84, P958, DOI 10.1189/jlb.1107775
   Liu CS, 2010, VACCINE, V28, P4153, DOI 10.1016/j.vaccine.2010.04.016
   Lou YY, 2011, J IMMUNOTHER, V34, P279, DOI 10.1097/CJI.0b013e31820d2a05
   Mascarenhas NM, 2008, EUR J MED CHEM, V43, P2807, DOI 10.1016/j.ejmech.2007.10.016
   [秦雁雁 Qin Yanyan], 2012, [吉林大学学报. 医学版, Journal of Jilin Univeristy. Medicine edition], V38, P876
   [任春霞 Ren Chunxia], 2013, [口腔医学研究, Journal of Oral Science Research], V29, P799
   Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365 2222.2008.03191.x
   Shen YQ, 2009, J ORAL SCI RES, V25, P723
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Wang T, 2010, PROGR CLIN RES BONE
   Wu S, 2012, FOOD CHEM TOXICOL, V50, P3100, DOI 10.1016/j.fct.2012.06.029
   Xie GH, 2013, CHIN J VET SCI, V03, P436
   Yang T., 2010, CELL BIOL
   Zhang C, 2010, ANTI CANCER DRUG, V21, P766, DOI 10.1097/CAD.0b013e32833d26a9
   Zhang HH, 2008, CRTER J CLIN REHABIL, V12, P5671
NR 25
TC 0
Z9 0
U1 1
U2 17
PU JOURNAL HARD TISSUE BIOLOGY
PI MINATO KU
PA NIHON GAKUKUTSU KYORYOKU ZAIDAN, 3  24  20, NISHIAZABU, MINATO KU, TOKYO
   106 0031, JAPAN
SN 1341 7649
J9 J HARD TISSUE BIOL
JI J. Hard Tissue Biol.
PD JUL
PY 2014
VL 23
IS 3
BP 343
EP 349
DI 10.2485/jhtb.23.343
PG 7
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA AL9KR
UT WOS:000339460500010
OA Bronze
DA 2025 08 17
ER

PT J
AU Iwata, T
   Kaneda Ikeda, E
   Takahashi, K
   Takeda, K
   Nagahara, T
   Kajiya, M
   Sasaki, S
   Ishida, S
   Yoshioka, M
   Matsuda, S
   Ouhara, K
   Fujita, T
   Kurihara, H
   Mizuno, N
AF Iwata, Tomoyuki
   Kaneda Ikeda, Eri
   Takahashi, Keita
   Takeda, Katsuhiro
   Nagahara, Takayoshi
   Kajiya, Mikihito
   Sasaki, Shinya
   Ishida, Shu
   Yoshioka, Minami
   Matsuda, Shinji
   Ouhara, Kazuhisa
   Fujita, Tsuyoshi
   Kurihara, Hidemi
   Mizuno, Noriyoshi
TI Regulation of osteogenesis in bone marrow derived mesenchymal stem cells
   via histone deacetylase 1 and 2 co cultured with human gingival
   fibroblasts and periodontal ligament cells
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE gingival fibroblast; histone acetylation; histone deacetylase;
   Mesenchymal stem cell; periodontal ligament cells; trichostatin A
ID TRANSCRIPTION FACTOR; TISSUE REGENERATION; GENE EXPRESSION;
   DIFFERENTIATION; OSTEOBLASTS; INHIBITOR; IDENTIFICATION; PROLIFERATION;
   INDUCTION; CARTILAGE
AB Objective This study aimed to determine the regulatory mechanism of bone marrow derived mesenchymal stem cell (BM MSC) differentiation mediated by humoral factors derived from human periodontal ligament (HPL) cells and human gingival fibroblasts (HGFs). We analyzed histone deacetylase (HDAC) expression and activity involved in BM MSC differentiation and determined their regulatory effects in co cultures of BM MSCs with HPL cells or HGFs. Background BM MSCs can differentiate into various cell types and can, thus, be used in periodontal regenerative therapy. However, the mechanism underlying their differentiation remains unclear. Transplanted BM MSCs are affected by periodontal cells via direct contact or secretion of humoral factors. Therefore, their activity is regulated by humoral factors derived from HPL cells or HGFs. Methods BM MSCs were indirectly co cultured with HPL cells or HGFs under osteogenic or growth conditions and then analyzed for osteogenesis, HDAC1 and HDAC2 expression and activity, and histone H3 acetylation. BM MSCs were treated with trichostatin A, or their HDAC1 or HDAC2 expression was silenced or overexpressed during osteogenesis. Subsequently, they were evaluated for osteogenesis or the effects of HDAC activity. Results BM MSCs co cultured with HPL cells or HGFs showed suppressed osteogenesis, HDAC1 and HDAC2 expression, and HDAC phosphorylation; however, histone H3 acetylation was enhanced. Trichostatin A treatment remarkably suppressed osteogenesis, decreasing HDAC expression and enhancing histone H3 acetylation. HDAC1 and HDAC2 silencing negatively regulated osteogenesis in BM MSCs to the same extent as that achieved by indirect co culture with HPL cells or HGFs. Conversely, their overexpression positively regulated osteogenesis in BM MSCs. Conclusion The suppressive effects of HPL cells and HGFs on BM MSC osteogenesis were regulated by HDAC expression and histone H3 acetylation to a greater extent than that mediated by HDAC activity. Therefore, regulation of HDAC expression has prospects in clinical applications for effective periodontal regeneration, mainly, bone regeneration.
C1 [Iwata, Tomoyuki; Kaneda Ikeda, Eri; Takahashi, Keita; Takeda, Katsuhiro; Nagahara, Takayoshi; Kajiya, Mikihito; Sasaki, Shinya; Ishida, Shu; Yoshioka, Minami; Matsuda, Shinji; Ouhara, Kazuhisa; Fujita, Tsuyoshi; Kurihara, Hidemi; Mizuno, Noriyoshi] Hiroshima Univ, Dept Periodontal Med, Grad Sch Biomed & Hlth Sci, Hiroshima 7348553, Japan.
   [Takeda, Katsuhiro] Hiroshima Univ, Dept Biol Endodont, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan.
   [Kajiya, Mikihito] Hiroshima Univ Hosp, Ctr Oral Clin Examinat, Hiroshima, Japan.
C3 Hiroshima University; Hiroshima University; Hiroshima University
RP Iwata, T (通讯作者)，Hiroshima Univ, Dept Periodontal Med, Grad Sch Biomed & Hlth Sci, Hiroshima 7348553, Japan.
EM iwatat@hiroshima u.ac.jp
RI Ouhara, Kazuhisa/G 5251 2019; Kajiya, Mikihito/A 4288 2018; Kurihara,
   Hidemi/G 5730 2019; Matsuda, Shinji/AAB 7387 2019
OI Kajiya, Mikihito/0000 0001 6652 0007; Matsuda,
   Shinji/0000 0002 4281 3216
FU Research Facility of Hiroshima University Faculty of Dentistry;
   Grants in Aid for Scientific Research [22K09983, 20K09975] Funding
   Source: KAKEN
FX This study did not receive any specific grant from the public,
   commercial, or not for profit funding agencies. We thank Dr. Ai Okanobu
   for his helpful supports. A part of this work was carried out with
   material support from the Research Facility of Hiroshima University
   Faculty of Dentistry.
CR Ali D, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2379546
   Chen FM, 2010, TISSUE ENG PART B RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chen WS, 2016, BBA MOL CELL RES, V1863, P2881, DOI 10.1016/j.bbamcr.2016.09.010
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dou C, 2016, AM J PHYSIOL CELL PH, V310, pC780, DOI 10.1152/ajpcell.00351.2015
   Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330
   Dragoo JL, 2003, J BONE JOINT SURG BR, V85B, P740, DOI 10.1302/0301 620X.85B5.13587
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Han S, 2007, IMMUNOL LETT, V108, P143, DOI 10.1016/j.imlet.2006.12.001
   Hasegawa N, 2006, J PERIODONTOL, V77, P1003, DOI 10.1902/jop.2006.050341
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Hu XQ, 2014, DEV GROWTH DIFFER, V56, P206, DOI 10.1111/dgd.12119
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099331
   Huynh NCN, 2016, J CELL BIOCHEM, V117, P1384, DOI 10.1002/jcb.25429
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Ishii M, 2005, BIOCHEM BIOPH RES CO, V332, P297, DOI 10.1016/j.bbrc.2005.04.118
   Iwata T, 2021, CELL BIOCHEM BIOPHYS, V79, P321, DOI 10.1007/s12013 021 00969 y
   Iwata T, 2006, EUR J CELL BIOL, V85, P423, DOI 10.1016/j.ejcb.2005.12.007
   Iwata T, 2022, J PERIODONTOL, V93, P269, DOI 10.1002/JPER.21 0064
   Iwata T, 2021, J PERIODONTAL RES, V56, P69, DOI 10.1111/jre.12794
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jeong SG, 2013, NEUROSCI LETT, V554, P22, DOI 10.1016/j.neulet.2013.08.059
   Jung ID, 2009, INT J IMMUNOPATH PH, V22, P501, DOI 10.1177/039463200902200227
   Kaneda Ikeda E, 2020, J BONE MINER METAB, V38, P442, DOI 10.1007/s00774 019 01080 2
   Kaneda Ikeda E, 2020, DIFFERENTIATION, V112, P47, DOI 10.1016/j.diff.2020.01.001
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kawaguchi H, 2004, J PERIODONTOL, V75, P1281, DOI 10.1902/jop.2004.75.9.1281
   Kawamoto T, 2004, BIOCHEM BIOPH RES CO, V313, P117, DOI 10.1016/j.bbrc.2003.11.099
   Kim DW, 2003, MOL CELL BIOL, V23, P8704, DOI 10.1128/MCB.23.23.8704 8717.2003
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Kubo H, 2009, GENES CELLS, V14, P407, DOI 10.1111/j.1365 2443.2009.01281.x
   Kwon DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10492
   Li FF, 2020, FASEB J, V34, P6934, DOI 10.1096/fj.201903127R
   Maroni P, 2012, BIOCHEM BIOPH RES CO, V428, P271, DOI 10.1016/j.bbrc.2012.10.044
   Mizuno N, 2008, J PERIODONTOL, V79, P2361, DOI 10.1902/jop.2008.070577 
   Nagahara T, 2015, J PERIODONTOL, V86, P456, DOI 10.1902/jop.2014.140384
   Noshiro M, 2020, GENES CELLS, V25, P232, DOI 10.1111/gtc.12752
   Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272
   Ouchi T, 2020, REGEN THER, V14, P72, DOI 10.1016/j.reth.2019.12.011
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sasamoto T, 2016, INT J MOL MED, V38, P876, DOI 10.3892/ijmm.2016.2660
   Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600 051X.1998.tb02419.x
   Sun D, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11869
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takewaki M, 2017, J DENT RES, V96, P984, DOI 10.1177/0022034517708770
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365 2141.2003.04284.x
   Xing J, 2015, DIFFERENTIATION, V89, P128, DOI 10.1016/j.diff.2015.06.001
   Xu S, 2013, ACTA PHARMACOL SIN, V34, P699, DOI 10.1038/aps.2012.182
   Xu XY, 2019, STEM CELL TRANSL MED, V8, P392, DOI 10.1002/sctm.18 0181
   Yang BN, 2019, J CELL PHYSIOL, V234, P14007, DOI 10.1002/jcp.28088
   Yildirim F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095465
   Yu Y, 2022, CELLS BASEL, V11, DOI 10.3390/cells11030534
   Zhang N, 2019, CELL DEATH DIFFER, V26, P843, DOI 10.1038/s41418 018 0158 8
NR 59
TC 10
Z9 11
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD FEB
PY 2023
VL 58
IS 1
BP 83
EP 96
DI 10.1111/jre.13070
EA NOV 2022
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 7X5AG
UT WOS:000879777500001
PM 36346011
DA 2025 08 17
ER

PT J
AU Itoi, E
   Uemura, Y
   Ohta, H
   Nakamura, T
   Fukunaga, M
   Orimo, H
   Shiraki, M
AF Itoi, Eiji
   Uemura, Yukari
   Ohta, Hiroaki
   Nakamura, Toshitaka
   Fukunaga, Masao
   Orimo, Hajime
   Shiraki, Masataka
TI Impact of bone mineral density in reducing fracture risk in patients
   receiving alendronate plus alfacalcidol therapy
SO JOURNAL OF ORTHOPAEDIC SCIENCE
LA English
DT Article
ID YEARLY ZOLEDRONIC ACID; PLAIN VITAMIN D; VERTEBRAL FRACTURE;
   POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; PREVENTION; REDUCTION; DENOSUMAB;
   FALLERS; NUMBER
AB Backgroud: Changes in bone mineral density (BMD) are a potential surrogate marker for fracture end points in clinical trials. However little is known whether the increase in BMD in response to combination treatment with alendronate plus alfacalcidol is associated with fracture risk reduction. We aimed to evaluate the impact of BMD on fracture risk in osteoporosis patients, using the data from the randomized clinical trial comparing alendronate plus alfacalcidol with alendronate alone. Methods: We selected 412 patients with two or more prevalent vertebral fractures and who had BMD measurements at baseline and after 6, 12, and/or 24 months out of 2022 patients from the database of the Japanese Osteoporosis Intervention Trial. Patients in this subset who received combination treatment with alendronate plus alfacalcidol had shown a lower risk of fracture than patients treated with alendronate alone. We used Poisson regression model analysis to calculate the proportion of treatment effect (PTE) that was attributable to BMD increases in patients receiving combination treatment. Results: The highest PTE attributable to changes in BMD was 1.2% in patients with a BMD increase of 3% or more in the lumbar spine. For BMD measurements of the radius, the highest PTE was 2.8% with a BMD increase of 0% or more. For BMD measurements of the metacarpal bone, the highest PTE was 1.2% with a BMD increase of 3% or more. In patients with a BMD greater than or equal to 70% of the young adult mean in the lumbar spine, the PTE attributable to BMD was 0.2%. In patients with a BMD greater than or equal to 70% of the young adult mean in the radius, the PTE attributable to BMD was 0.3%. Conclusions: The additional effects of alfacalcidol in reducing fracture risk do not likely result from increased BMD; other mechanisms remain a possibility. (c) 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.
C1 [Itoi, Eiji] Tohoku Univ, Dept Orthopaed Surg, Sch Med, Sendai, Miyagi, Japan.
   [Uemura, Yukari] Tokyo Univ Hosp, Clin Res Support Ctr, Biostat Div, Tokyo, Japan.
   [Ohta, Hiroaki] Int Univ Hlth & Welf, Clin Med Ctr, Tokyo, Japan.
   [Nakamura, Toshitaka; Orimo, Hajime] Japan Osteoporosis Fdn, Tokyo, Japan.
   [Fukunaga, Masao] Kawasaki Med Sch, Okayama, Japan.
   [Shiraki, Masataka] Res Inst & Practice Involut Dis, Dept Internal Med, Nagano, Japan.
C3 Tohoku University; University of Tokyo; International University of
   Health & Welfare; Kawasaki Medical School
RP Uemura, Y (通讯作者)，Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Data Sci, Shinjuku Ku, 1 21 1 Toyoma, Tokyo 1628655, Japan.
EM yuemura@hosp.ncgm.go.jp
OI Uemura, Yukari/0000 0002 3013 7775
FU Public Health Research Foundation
FX The authors thank the investigators at all 186 facilities involved in
   this study. The authors also express sincere thanks to themembers of the
   A TOP research group, Dr. Yasuo Ohashi (Department of Integrated Science
   and Engineering for Sustainable Society, Chuo University), Dr. Takayuki
   Hosoi (Kenkoin Clinic), Dr. Satoshi Mori (Bone andJoint Surgery,
   SeireiHamamatsuGeneralHospital), Dr. Toshitsugu Sugimoto (Internal
   Medicine 1, Shimane University Faculty of Medicine), Dr. Shiro Tanaka
   (Division of Clinical Trial Design and Management, Translational
   Research Center, Kyoto University), Dr. Shigeto Morimoto (Geriatric
   Medicine, Kanazawa Medical University), Dr. Akira Itabashi (Saitama
   Center for Bone Research, Kubojima Clinic), Dr. Toshihiko Yamashita
   (Department of Orthopaedic Surgery, Sapporo Medical University School of
   Medicine), Dr. Itsuo Gorai (DepartmentofObstetrics andGynecology,
   HoriHospital), Dr. Hideaki Kishimoto (Department of Orthopedic Surgery,
   Nojima Hospital), Dr. Hideki Mizunuma (Department of Obstetrics and
   Gynecology, Hirosaki University School of Medicine), Dr. Naoto Endo
   (Division of Orthopedic Surgery, Niigata UniversityMedical and Dental
   Hospital), Dr. Yoshiki Nishizawa (Osaka City University), and Dr. Kunio
   Takaoka (Hanwa Joint Reconstruction Center Hospital) for their help in
   the study design. We also express special thanks to Mr. Nobuaki Miyakawa
   (Public Health Research Foundation) for his help in preparing the
   manuscript, and to Ms. Akiko Ishizuka for her contributions to data
   management. The authors express sincere thanks to the Public Health
   Research Foundation, which supported the JOINT 02 study.
CR Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dukas L, 2004, J AM GERIATR SOC, V52, P230, DOI 10.1111/j.1532 5415.2004.52060.x
   Dukas L, 2010, ARZNEIMITTELFORSCH, V60, P519, DOI 10.1055/s 0031 1296321
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Felsenberg D, 2011, J MUSCULOSKEL NEURON, V11, P34
   FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hochberg MC, 1999, ARTHRITIS RHEUM US, V42, P1246, DOI 10.1002/1529 0131(199906)42:6<1246::AID ANR22>3.0.CO;2 U
   Jacques RM, 2012, J BONE MINER RES, V27, P1627, DOI 10.1002/jbmr.1644
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuroda T, 2012, J CLIN DENSITOM, V15, P392, DOI 10.1016/j.jocd.2012.02.005
   Kushida K, 2002, CURR THER RES CLIN E, V63, P606, DOI 10.1016/S0011 393X(02)80065 0
   Li Z., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P64
   Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097 0258(19970715)16:13<1515::AID SIM572>3.0.CO;2 1
   Norman AW, 2010, EXP BIOL MED, V235, P1034, DOI 10.1258/ebm.2010.010014
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Orimo H, 2011, CURR MED RES OPIN, V27, P1273, DOI 10.1185/03007995.2011.580341
   Ringe JD, 2007, RHEUMATOL INT, V27, P425, DOI 10.1007/s00296 006 0288 z
   Ringe JD, 2009, RHEUMATOL INT, V29, P1177, DOI 10.1007/s00296 008 0835 x
   Ringe JD, 2004, RHEUMATOL INT, V24, P189, DOI 10.1007/s00296 004 0454 0
   Shiraki M, 2011, J BONE MINER METAB, V29, P37, DOI 10.1007/s00774 010 0188 x
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0949 2658
EI 1436 2023
J9 J ORTHOP SCI
JI J. Orthop. Sci.
PD NOV
PY 2021
VL 26
IS 6
BP 1085
EP 1093
DI 10.1016/j.jos.2020.10.017
EA NOV 2021
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA WW6OA
UT WOS:000718032200025
PM 33358235
DA 2025 08 17
ER

PT J
AU Alishiri, G
   Heshmat Ghandarijani, K
   Hashemi, M
   Zavar, R
   Farahani, MM
AF Alishiri, Gholamhossein
   Heshmat Ghandarijani, Kiyan
   Hashemi, Mohammad
   Zavar, Reihaneh
   Farahani, Maryam Moshkani
TI Alendronate slows down aortic stenosis progression in osteoporotic
   patients: An observational prospective study
SO JOURNAL OF RESEARCH IN MEDICAL SCIENCES
LA English
DT Article
DE Alendronate; aortic stenosis; N terminal prohormone of brain natriuretic
   peptide; osteoporosis
ID CONVERTING ENZYME INHIBITORS; NATRIURETIC PEPTIDE; VALVE STENOSIS;
   BISPHOSPHONATES; CALCIFICATION; DISEASE
AB Background: Aortic stenosis (AS) is the most common primary valvular disease. Currently, there is no pharmacological approach for the medical management of AS. We investigated the effect of osteoporosis therapy with alendronate on hemodynamic progression in patients concurrently affected by AS and osteoporosis. Materials and Methods: In this observational prospective study, we enrolled 37 women more than 60 years old with diagnosis of AS and concurrent osteoporosis from August 2017 to December 2019. These patients were treated with alendronate 70 mg every week added to their routine treatment for AS, and their outcomes were compared with 33 patients only affected by AS. Echocardiographic changes and N terminal prohormone of brain natriuretic peptide (NT pro BNP) level were evaluated during about 2 years of follow up. Results: The mean follow up time for the treated and nontreated groups was 20.89 +/  2.73 and 20.84 +/  2.76 months, respectively. Mean gradient (P = 0.02) and peak gradient (P = 0.04) of aortic valve were significantly different between the groups after follow up. Aortic valve area was decreased 0.09 cm(2) in the treated group by alendronate and 0.23 cm(2) in the other group (P = 0.001). Furthermore, NT pro BNP was significantly decreased in patients treated by alendronate (P = 0.01), but it was increased in nontreated patients (P = 0.04). Conclusion: Treatment with alendronate in patients with AS and concurrent osteoporosis slows down the progression of stenosis and improves their prognosis. This study could open a new pathway for the treatment of AS. Further studies, particularly randomized controlled clinical trial, should be done for providing more evidence.
C1 [Alishiri, Gholamhossein] Baqiyatallah Univ Med Sci, Chem Injuries Res Ctr, Syst Biol & Poisonings Inst, Tehran, Iran.
   [Heshmat Ghandarijani, Kiyan; Farahani, Maryam Moshkani] Baqiyatallah Univ Med Sci, Atherosclerosis Res Ctr, Tehran, Iran.
   [Hashemi, Mohammad] Isfahan Univ Med Sci, Intervent Cardiol Res Ctr, Cardiovasc Res Inst, Esfahan, Iran.
   [Zavar, Reihaneh] Isfahan Univ Med Sci, Cardiac Rehabil Res Ctr, Cardiovasc Res Inst, Esfahan, Iran.
C3 Baqiyatallah University of Medical Sciences (BMSU); Baqiyatallah
   University of Medical Sciences (BMSU); Isfahan University of Medical
   Sciences; Isfahan University of Medical Sciences
RP Farahani, MM (通讯作者)，Baqiyatallah Univ Med Sci, Atherosclerosis Res Ctr, Tehran, Iran.
EM moshkani_farahani@yahoo.com
RI Moshkani, Maryam/U 1239 2019; zavar, reihaneh/B 7519 2018; Alishiri,
   Gholamhosein/W 3704 2019; Heshmat, Kiyan/AAP 4974 2021
OI Heshmat Ghahdarijani, Kiyan/0000 0002 4861 7128; Alishiri,
   Gholamhosein/0000 0002 0545 8462
CR Aksoy O, 2012, J AM COLL CARDIOL, V59, P1452, DOI 10.1016/j.jacc.2012.01.024
   Bossé Y, 2008, J AM COLL CARDIOL, V51, P1327, DOI 10.1016/j.jacc.2007.12.031
   Chan KL, 2010, CIRCULATION, V121, P306, DOI 10.1161/CIRCULATIONAHA.109.900027
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Elmariah S, 2010, J AM COLL CARDIOL, V56, P1752, DOI 10.1016/j.jacc.2010.05.050
   Freeman RV, 2005, CIRCULATION, V111, P3316, DOI 10.1161/CIRCULATIONAHA.104.486738
   Helske S, 2004, J AM COLL CARDIOL, V44, P1859, DOI 10.1016/j.jacc.2004.07.054
   Innasimuthu AL, 2011, ECHOCARDIOGR J CARD, V28, P1, DOI 10.1111/j.1540 8175.2010.01256.x
   Ito S, 2020, AM J CARDIOL, V125, P1566, DOI 10.1016/j.amjcard.2020.02.004
   Kaden JJ, 2005, CARDIOVASC PATHOL, V14, P80, DOI 10.1016/j.carpath.2005.01.002
   Ledwoch J, 2017, HERZ, V42, P528, DOI 10.1007/s00059 017 4584 z
   Izquierdo Gómez MM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5178631
   Maréchaux S, 2011, ECHOCARDIOGR J CARD, V28, P695, DOI 10.1111/j.1540 8175.2011.01418.x
   Mills WR, 2004, AM J CARDIOL, V94, P1196, DOI 10.1016/j.amjcard.2004.07.095
   Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI [10.1016/j.jacc.2014.02.537, 10.1016/j.jacc.2014.02.536, 10.1016/j.jtcvs.2014.05.014]
   O'Brien KD, 2005, ARCH INTERN MED, V165, P858, DOI 10.1001/archinte.165.8.858
   Parikh V, 2015, CIRC HEART FAIL, V8, P373, DOI 10.1161/CIRCHEARTFAILURE.114.001649
   Pfister R, 2010, CLIN RES CARDIOL, V99, P301, DOI 10.1007/s00392 010 0118 x
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rashedi Nina, 2015, J Cardiovasc Ultrasound, V23, P59, DOI 10.4250/jcu.2015.23.2.59
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rosenhek R, 2004, CIRCULATION, V110, P1291, DOI 10.1161/01.CIR.0000140723.15274.53
   Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602
   Skolnick AH, 2009, AM J CARDIOL, V104, P122, DOI 10.1016/j.amjcard.2009.02.051
   Solberg OG, 2012, SCAND CARDIOVASC J, V46, P278, DOI 10.3109/14017431.2012.687836
   Sterbakova G, 2010, CARDIOLOGY, V117, P184, DOI 10.1159/000321418
NR 27
TC 6
Z9 6
U1 0
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1735 1995
EI 1735 7136
J9 J RES MED SCI
JI J. Res. Med. Sci.
PD JUN
PY 2020
VL 25
DI 10.4103/jrms.JRMS_408_20
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA MQ1LM
UT WOS:000552659100011
PM 33088302
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, YX
   Wang, J
   Ren, ML
   Li, M
   Chen, DY
   Chen, JS
   Shi, FF
   Wang, XY
   Dou, J
AF Zhang, Yunxia
   Wang, Jing
   Ren, Mulan
   Li, Miao
   Chen, Dengyu
   Chen, Junsong
   Shi, Fangfang
   Wang, Xiaoying
   Dou, Jun
TI Gene therapy of ovarian cancer using IL 21 secreting human umbilical
   cord mesenchymal stem cells in nude mice
SO JOURNAL OF OVARIAN RESEARCH
LA English
DT Article
DE Umbilical cord mesenchymal stem cells; Interleukin 21; Ovarian cancer;
   Gene therapy
ID TARGETED DELIVERY; BLOOD; EXPRESSION; PROMOTES; VEHICLES; PROTEIN;
   STROMA
AB Background: The human umbilical cord mesenchymal stem cells (hUCMSCs) have the ability to migrate into tumors and therefore have been considered as an alternative source of mesenchymal progenitors for the therapy of malignant diseases. The present study was aimed to investigate effect of hUCMSCs as vehicles for a constant source of transgenic interleukin 21 (IL 21) on ovarian cancer in vivo.
   Methods: The hUCMSCs were engineered to express IL 21 via lentiviral vector designated 'hUCMSCs LV IL 21', and then were transplanted into SKOV3 ovarian cancer xenograft bearing nude mice. The therapeutic efficacy and mechanisms of this procedure on ovarian cancer was evaluated.
   Results: The isolated hUCMSCs were induced to differentiate efficiently into osteoblast and adipocyte lineages in vitro. The expressed IL 21 in the supernatant from hUCMSCs LV IL 21 obviously stimulated splenocyte's proliferation. The hUCMSCs LV IL 21 significantly reduced SKOV3 ovarian cancer burden in mice indicated by tumor sizes compared with control mice. The expressed IL 21 not only regulated the levels of IFN gamma and TNF alpha in the mouse serum but also increased the expression of NKG2D and MIC A molecules in the tumor tissues. The down regulation of beta catenin and cyclin D1 in the tumor tissues may refer to the inhibition of SKOV3 ovarian cancer growth in mice. In addition, hUCMSCs did not form gross or histological teratomas up to 60 days posttransplantation in murine lung, liver, stomach and spleen.
   Conclusion: These results clearly indicate a safety and usability of hUCMSCs LV IL 21 in ovarian cancer gene therapy, suggesting the strategy may be a promising new method for clinical treatment of ovarian cancer.
C1 [Zhang, Yunxia; Wang, Jing; Ren, Mulan; Dou, Jun] Southeast Univ, Sch Med, Dept Gynecol & Obstet, Zhongda Hosp, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhang, Yunxia; Li, Miao; Chen, Dengyu; Chen, Junsong; Wang, Xiaoying; Dou, Jun] Southeast Univ, Coll Med, Dept Pathogen Biol & Immunol, Nanjing 210009, Jiangsu, Peoples R China.
   [Shi, Fangfang] Southeast Univ, Zhongda Hosp, Dept Oncol, Nanjing 210009, Jiangsu, Peoples R China.
C3 Southeast University   China; Southeast University   China; Southeast
   University   China
RP Ren, ML (通讯作者)，Southeast Univ, Sch Med, Dept Gynecol & Obstet, Zhongda Hosp, Nanjing 210009, Jiangsu, Peoples R China.
EM renmulan@seu.edu.cn; njdoujun@seu.edu.cn
RI Wang, Xiaoying/MSY 7160 2025; Dou, Jun/HTM 0073 2023; chen,
   Junsong/AHC 7356 2022
FU 973 National Nature Science Foundation of People's Republic of China
   [2011CB933500]; National Natural Science Foundation of China [81071769,
   81202372]
FX This work was supported in part by the 973 National Nature Science
   Foundation of People's Republic of China (2011CB933500) and part by the
   National Natural Science Foundation of China (No. 81071769, No.
   81202372).
CR Bailey MM, 2007, TISSUE ENG, V13, P2003, DOI 10.1089/ten.2006.0150
   Banerjee S, 2004, P NATL ACAD SCI USA, V101, P12652, DOI 10.1073/pnas.0404347101
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Castillo Melendez M, 2013, FRONT NEUROSCI SWITZ, V7, DOI 10.3389/fnins.2013.00194
   Chen DY, 2013, J OVARIAN RES, V6, DOI 10.1186/1757 2215 6 50
   Dou J., 2004, CELL MOL IMMUNOL, V1, P388
   Dou J, 2007, CANCER BIOL THER, V6, P1871, DOI 10.4161/cbt.6.12.4960
   Dou J, 2006, J GASTROEN HEPATOL, V21, P1794, DOI 10.1111/j.1440 1746.2006.04380.x
   Dou J, 2009, IMMUNOBIOLOGY, V214, P483, DOI 10.1016/j.imbio.2008.11.002
   Ferrandina G, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 221
   FRIEDENSTEIN A, 1961, ACTA ANAT, V45, P31
   Ghaedi M, 2011, J GENE MED, V13, P171, DOI 10.1002/jgm.1552
   Hakkarainen T, 2003, CLIN CANCER RES, V9, P619
   Hu WH, 2011, CELL TRANSPLANT, V20, P669, DOI 10.3727/096368910X536509
   Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006 0286
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim Schulze S, 2009, MOL THER, V17, P380, DOI 10.1038/mt.2008.249
   Kristiansen G, 2002, AM J PATHOL, V161, P1215, DOI 10.1016/S0002 9440(10)64398 2
   Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022 1759(01)00359 3
   Lee DH, 2009, CLIN CANCER RES, V15, P4925, DOI 10.1158/1078 0432.CCR 08 3076
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Liu J, 2013, PLOS ONE, V30
   Mateos J, 2013, STEM CELL RES, V11, P1137, DOI 10.1016/j.scr.2013.07.004
   Perez SA, 2006, INT IMMUNOL, V18, P49, DOI 10.1093/intimm/dxh348
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quiros RM, 2008, GYNECOL ONCOL, V110, P99, DOI 10.1016/j.ygyno.2008.03.006
   Rachakatla RS, 2007, CANCER GENE THER, V14, P828, DOI 10.1038/sj.cgt.7701077
   Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21 1 105
   Ryu CH, 2011, HUM GENE THER, V22, P733, DOI 10.1089/hum.2010.187
   Shu S, 2006, CANCER METAST REV, V25, P233, DOI 10.1007/s10555 006 8503 7
   Steiner D, 2009, STEM CELLS, V27, P1932, DOI 10.1002/stem.111
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007 0439
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wei BB, 2010, J BIOMED RES, V24, P58, DOI 10.1016/S1674 8301(10)60009 7
   Yang F, 2006, CELL SIGNAL, V18, P679, DOI 10.1016/j.cellsig.2005.06.015
   Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607
NR 37
TC 41
Z9 50
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 2215
J9 J OVARIAN RES
JI J. Ovarian Res.
PD JAN 20
PY 2014
VL 7
AR 8
DI 10.1186/1757 2215 7 8
PG 10
WC Reproductive Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Reproductive Biology
GA AD3AU
UT WOS:000333109900002
PM 24444073
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rodríguez, AJ
   Nerlekar, N
   Ebeling, PR
AF Rodriguez, Alexander J.
   Nerlekar, Nitesh
   Ebeling, Peter R.
TI Cardiac adverse events in bisphosphonate and teriparatide users: An
   international pharmacovigilance study
SO BONE
LA English
DT Article
DE Osteoporosis; Cardiovascular; Pharmacovigilance; Bisphosphonate;
   Teriparatide
ID ZOLEDRONIC ACID; ATRIAL FIBRILLATION; ALENDRONATE; FRACTURES; MORTALITY;
   WOMEN; RISK
AB Background: Cardiovascular effects of osteoporosis medications have recently been highlighted. Although oral and intravenous bisphosphonates are assumed to have similar cardiovascular safety, few head to head com parisons exist. The cardiovascular safety of teriparatide is unknown. Aim We conducted a pharmacovigilance safety study of cardiac events using real life adverse event reports from alendronate, zoledronic acid and teriparatide users.Methods: Adverse drug reactions were obtained from Vigibase, a WHO database of individual case safety reports (ICSRs) from 130 countries (1967 2020). ISCRs for atrial fibrillation (AF), angina pectoris, arteriosclerosis coronary artery (ACA), cardiac arrhythmias, coronary artery disease (CAD), thromboembolic events (TE), ischaemic heart disease (IHD), torsade de pointes/QT prolongation (TDP) associated with alendronate, zole dronic acid and teriparatide use were extracted. Data were included in a disproportionality analysis where the lower end of the 95 % credibility interval for the information component (IC025), showing a statistical association when >0. Head to head comparisons of ISCRs were estimated by age adjusted odds ratios and 95 % confidence intervals.Results: 465 episodes of angina, 287 ACA, 13,385 arrhythmias, 792 CAD, 6743 TE, 3264 IHD, 1037 myocardial infarcts, and 3714 TDP events were recorded across 50,365 alendronate, 52,436 zoledronic acid and 137,629 teriparatide users. There was a significant association between alendronate and zoledronate with all outcomes except MI. Teriparatide use was associated with AF, arrythmias and angina only. In head to head comparisons, teriparatide use was associated with fewer ACA and CAD events than alendronate and fewer ACA than zoledronic acid.Discussion: Osteoporosis medication use is associated with adverse cardiac events, except for MI, and these appear to be more common with oral and intravenous bisphosphonates than teriparatide. Our data do not support differential effects of oral and intravenous bisphosphonates on cardiac events. Mechanisms whereby teriparatide may be cardio protective warrant further investigation.
C1 [Rodriguez, Alexander J.; Ebeling, Peter R.] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Clin Sci, Dept Med,Bone & Muscle Hlth Res Grp, Clayton, Australia.
   [Rodriguez, Alexander J.] Edith Cowan Univ, Sch Med & Hlth Sci, Disorders Mineralisat Res Grp, Joondalup, Australia.
   [Nerlekar, Nitesh] Monash Univ & Monash Heart, Monash Hlth, Monash Cardiovasc Res Ctr, 246 Clayton Rd, Clayton, Vic 3168, Australia.
   [Nerlekar, Nitesh; Ebeling, Peter R.] Monash Univ, Dept Med, Clayton, Vic, Australia.
   [Ebeling, Peter R.] Monash Hlth, Dept Endocrinol, Clayton, Australia.
C3 Monash University; Edith Cowan University; Monash University; Monash
   Health; Monash University; Monash Health
RP Rodríguez, AJ (通讯作者)，Edith Cowan Univ, Sch Med & Hlth Sci, Disorders Mineralisat Res Grp, Joondalup, Australia.; Rodríguez, AJ (通讯作者)，Monash Univ, Dept Med, Bone & Muscle Res Grp, Level 7,Translat Res Facil MHTP Bldg,51 Kanooka G, Clayton, Vic 3168, Australia.
EM alexander.rodriguez@monash.edu
RI Ebeling, Peter/A 9129 2012; Rodriguez, Alexander/ABD 3767 2021
OI Nerlekar, Nitesh/0000 0002 3437 8648
FU National Health and Medical Research Council Australia Investigator
   Grant [GNT1197958]; Amgen; Eli Lilly; Alexion
FX The salary of AJR is supported by a National Health and Medical Research
   Council Australia Investigator Grant (GNT1197958) . PRE has received
   grant funding to his institution from Amgen, Eli Lilly and Alexion, and
   honoraria from Amgen and Sanofi.
CR Barrett Connor E, 2012, OSTEOPOROSIS INT, V23, P233, DOI 10.1007/s00198 011 1546 9
   Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   Bhuriya R, 2010, INT J CARDIOL, V142, P213, DOI 10.1016/j.ijcard.2009.11.041
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Boonen S, 2012, NEW ENGL J MED, V367, P1714, DOI 10.1056/NEJMoa1204061
   Cosman F, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa450
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   Haïssaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003
   Kelesoglu S., 2021, ENDOKRYNOL POL, DOI [10.22541/au.160562674.48133610/v1, DOI 10.22541/AU.160562674.48133610/V1]
   Kemeny Suss N, 2009, VASC PHARMACOL, V51, P350, DOI 10.1016/j.vph.2009.09.002
   Kim DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122646
   Lindquist M, 2008, DRUG INF J, V42, P409, DOI 10.1177/009286150804200501
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Martin TJ., 2000, Aust Prescriber, V23, P130
   Moreland Head LN, 2021, J CARDIOVASC PHARM T, V26, P341, DOI 10.1177/1074248420984082
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Norén GN, 2013, STAT METHODS MED RES, V22, P57, DOI 10.1177/0962280211403604
   Pijnenburg L, 2021, EUR J ENDOCRINOL, V184, P437, DOI 10.1530/EJE 20 0650
   Reid IR, 2020, J BONE MINER RES, V35, P20, DOI 10.1002/jbmr.3860
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Rodríguez AJ, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa481
   Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001
   Rubin KH, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115296
   Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470 2045(18)30608 9
   Sharma A, 2014, AM J CARDIOL, V113, P1815, DOI 10.1016/j.amjcard.2014.03.008
   Sing CW, 2018, J BONE MINER RES, V33, P1422, DOI 10.1002/jbmr.3448
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wickham H., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI DOI 10.21105/JOSS.01686
   Zhuang HF, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.928637
NR 30
TC 18
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2023
VL 168
AR 116647
DI 10.1016/j.bone.2022.116647
EA DEC 2022
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 7Z5HP
UT WOS:000915590500001
PM 36543300
DA 2025 08 17
ER

PT J
AU Pitarresi, JR
   Norgard, RJ
   Chiarella, AM
   Suzuki, K
   Bakir, B
   Sahu, V
   Li, JY
   Zhao, J
   Marchand, B
   Wengyn, MD
   Hsieh, A
   Kim, IK
   Zhang, A
   Sellin, K
   Lee, V
   Takano, S
   Miyahara, Y
   Ohtsuka, M
   Maitra, A
   Notta, F
   Kremer, R
   Stanger, B
   Rustgi, AK
AF Pitarresi, Jason R.
   Norgard, Robert J.
   Chiarella, Anna M.
   Suzuki, Kensuke
   Bakir, Basil
   Sahu, Varun
   Li, Jinyang
   Zhao, Jun
   Marchand, Benoit
   Wengyn, Maximilian D.
   Hsieh, Antony
   Kim, Il Kyu
   Zhang, Amy
   Sellin, Karine
   Lee, Vivian
   Takano, Shigetsugu
   Miyahara, Yoji
   Ohtsuka, Masayuki
   Maitra, Anirban
   Notta, Faiyaz
   Kremer, Richard
   Stanger, Ben Z.
   Rustgi, Anil K.
TI PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New
   Therapeutic Vulnerability
SO CANCER DISCOVERY
LA English
DT Article
ID HORMONE RELATED PROTEIN; EPITHELIAL PLASTICITY; CELLS; PEPTIDE; TUMOR;
   EXPRESSION; SURVIVAL; SUBTYPES; SECRETION; MODELS
AB Pancreatic cancer metastasis is a leading cause of cancer related deaths, yet very little is understood regarding the underlying biology. As a result, targeted therapies to inhibit metastasis are lacking. Here, we report that the parathyroid hormone related protein (PTHrP encoded by PTHLH) is frequently amplified as part of the KRAS amplicon in patients with pancreatic cancer. PTHrP upregulation drives the growth of both primary and metastatic tumors in mice and is highly enriched in pancreatic ductal adenocarcinoma metastases. Loss of PTHrP either genetically or pharmacologically dramatically reduces tumor burden, eliminates metastasis, and enhances overall survival. These effects are mediated in part through a reduction in epithelial to mesenchymal transition, which reduces the ability of tumor cells to initiate metastatic cascade. Spp1, which encodes osteopontin, is revealed to be a downstream effector of PTHrP. Our results establish a new paradigm in pancreatic cancer whereby PTHrP is a driver of disease progression and emerges as a novel therapeutic vulnerability.
   SIGNIFICANCE: Pancreatic cancer often presents with metastases, yet no strategies exist to pharmacologically inhibit this process. Herein, we establish the oncogenic and prometastatic roles of PTHLH, a novel amplified gene in pancreatic ductal adenocarcinoma. We demonstrate that blocking PTHrP activity reduces primary tumor growth, prevents metastasis, and prolongs survival in mice.
C1 [Pitarresi, Jason R.; Norgard, Robert J.; Bakir, Basil; Li, Jinyang; Marchand, Benoit; Wengyn, Maximilian D.; Hsieh, Antony; Kim, Il Kyu; Stanger, Ben Z.] Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
   [Chiarella, Anna M.; Suzuki, Kensuke; Sahu, Varun; Rustgi, Anil K.] Columbia Univ, Dept Med, Herbert Irving Comprehens Canc Ctr, Div Digest & Liver Dis,Vagelos Coll Phys & Surg,I, New York, NY 10032 USA.
   [Zhao, Jun; Maitra, Anirban] Univ Texas MD Anderson Canc Ctr, Sheikh Ahmed Ctr Pancreat Canc Res, Houston, TX 77030 USA.
   [Zhao, Jun; Maitra, Anirban] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Zhang, Amy; Notta, Faiyaz] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Sellin, Karine; Kremer, Richard] McGill Univ, Dept Med, Div Endocrinol & Metab, Montreal, PQ, Canada.
   [Sellin, Karine; Kremer, Richard] McGill Univ, Hlth Ctr, Montreal, PQ, Canada.
   [Lee, Vivian] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Takano, Shigetsugu; Miyahara, Yoji; Ohtsuka, Masayuki] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba, Japan.
C3 University of Pennsylvania; Columbia University; University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center; University of Toronto; McGill University; McGill
   University; University of Pennsylvania; Chiba University
RP Rustgi, AK (通讯作者)，Columbia Univ, Herbert Irving Comprehens Canc Ctr, Irving Med Ctr, 1130 St Nicholas Ave, New York, NY 10032 USA.
EM akr2164@cumc.columbia.edu
RI ; Stangert, Ben Z./JQI 2514 2023
OI Li, Jinyang/0000 0001 8125 6603; Kim, Il Kyu/0000 0002 4661 0133;
   Marchand, Benoit/0000 0001 9302 6688; Chiarella,
   Anna/0000 0003 1224 9324; Pitarresi, Jason/0000 0001 9549 4768
FU American Gastroenterology Association Bern Schwartz Research Scholar
   Award in Pancreatic Cancer; National Cancer Institute (NCI) National
   Institutes of Health (NIH) National Research Service Award
   [F32CA221094]; NIH Loan Repayment Program; Hopper Belmont Foundation
   Inspiration Award; NCI NIH [R01CA229803]; National Institute of Diabetes
   and Digestive and Kidney Diseases NIH [R01DK060694]; U.S. Department of
   Defense [W81XWH 15 1 0723]; Canadian Institutes of Health Research
   [MOP142287, PF 19 227 01 CMS]
FX This work was supported by an American Gastroenterology Association Bern
   Schwartz Research Scholar Award in Pancreatic Cancer (J.R. Pitarresi);
   National Cancer Institute (NCI) National Institutes of Health (NIH)
   National Research Service Award (F32CA221094 to J.R. Pitarresi); NIH
   Loan Repayment Program (J. R. Pitarresi); Hopper Belmont Foundation
   Inspiration Award (J. R. Pitarresi); NCI NIH grant (P30CA01369644 to
   A.K. Rustgi); National Institute of Diabetes and Digestive and Kidney
   Diseases NIH grant (R01DK060694 to A.K. Rustgi); NCI NIH grant
   (R01CA229803 to B.Z. Stanger); U.S. Department of Defense contract
   (W81XWH 15 1 0723 to R.  Kremer); Canadian Institutes of Health Research
   grant (MOP142287); and American Cancer Society Fairfield County Comedy
   Against Cancer Postdoctoral Fellowship (PF 19 227 01 CMS to A.M.
   Chiarella). The authors thank the following core facilities through the
   Herbert Irving Comprehensive Cancer Center: Molecular Pathology,
   Genetically Engineered Mouse Models, and Flow Cytometry. They thank Iok
   In Christine Chio (Columbia University) for the human PDAC organoids,
   Karine Sellin (McGill University Health Centre) for the production of
   anti PTHrP monoclonal antibodies, and Mary Ann Crissey (University of
   Pennsylvania) for mouse colony maintenance.
CR Aiello N. M., 2016, Cold Spring Harb Protoc, V2016, ppdb.prot078360
   Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027
   Ardura JA, 2013, KIDNEY INT, V83, P825, DOI 10.1038/ki.2012.476
   Assaker G, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz063
   Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021
   Cebrian A, 2002, DIABETES, V51, P3003, DOI 10.2337/diabetes.51.10.3003
   Chan Seng Yue M, 2020, NAT GENET, V52, P231, DOI 10.1038/s41588 019 0566 9
   Chang WM, 2017, SCI REP UK, V7, DOI 10.1038/srep41131
   Chiou SH, 2017, CANCER DISCOV, V7, P1184, DOI 10.1158/2159 8290.CD 17 0250
   Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575 019 0109 y
   Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344
   Connor AA, 2019, CANCER CELL, V35, P267, DOI 10.1016/j.ccell.2018.12.010
   Fleming NI, 2009, CANCER RES, V69, P7473, DOI 10.1158/0008 5472.CAN 09 0194
   Franses JW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17150 3
   Hamdan FH, 2018, P NATL ACAD SCI USA, V115, pE12343, DOI 10.1073/pnas.1812915116
   He B, 2001, ENDOCRINOLOGY, V142, P2070, DOI 10.1210/en.142.5.2070
   He SY, 2018, AM J PATHOL, V188, P1374, DOI 10.1016/j.ajpath.2018.03.003
   HENDERSON J, 1991, CANCER RES, V51, P6521
   Henderson MA, 2001, JNCI J NATL CANCER I, V93, P234, DOI 10.1093/jnci/93.3.234
   Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008 5472.CAN 05 2168
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kremer R, 1996, AM J MED, V100, P406, DOI 10.1016/S0002 9343(97)89515 0
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Li JR, 2011, J CLIN INVEST, V121, P4655, DOI 10.1172/JCI46134
   Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006
   Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200
   Liu Y, 2016, NATURE, V531, P471, DOI 10.1038/nature17157
   Lv ZJ, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046 014 0100 y
   Mallory TB., 1941, NEW ENGL J MED, V225, P789
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398
   Muller FL, 2015, TRENDS CANCER, V1, P161, DOI 10.1016/j.trecan.2015.10.002
   Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008 5472.CAN 14 0155
   Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166
   Reichert M, 2018, DEV CELL, V45, P696, DOI 10.1016/j.devcel.2018.05.025
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Richard V, 2005, CRIT REV EUKAR GENE, V15, P115, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.30
   SEBAG M, 1994, AM J PHYSIOL, V267, pC723, DOI 10.1152/ajpcell.1994.267.3.C723
   Soki FN, 2012, FUTURE ONCOL, V8, P803, DOI [10.2217/fon.12.76, 10.2217/FON.12.76]
   Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051
   Tang J, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1342 1
   Toribio RE, 2010, FASEB J, V24, P1947, DOI 10.1096/fj.09 147033
   Truong NU, 2003, AM J MED, V115, P115, DOI 10.1016/S0002 9343(03)00310 3
   Urosevic J, 2014, NAT CELL BIOL, V16, P685, DOI 10.1038/ncb2977
   Walia MK, 2016, ELIFE, V5, DOI 10.7554/eLife.13446
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048
   Williams K, 2011, DIABETOLOGIA, V54, P2867, DOI 10.1007/s00125 011 2260 z
   Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
NR 53
TC 32
Z9 35
U1 2
U2 24
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 2159 8274
EI 2159 8290
J9 CANCER DISCOV
JI Cancer Discov.
PD JUL
PY 2021
VL 11
IS 7
BP 1774
EP 1791
DI 10.1158/2159 8290.CD 20 1098
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA TF2MH
UT WOS:000670545600032
PM 33589425
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Maran, A
   Dadsetan, M
   Buenz, CM
   Shogren, KL
   Lu, LC
   Yaszemski, MJ
AF Maran, Avudaiappan
   Dadsetan, Mahrokh
   Buenz, Colleen M.
   Shogren, Kristen L.
   Lu, Lichun
   Yaszemski, Michael J.
TI Hydrogel PLGA delivery system prolongs 2 methoxyestradiol mediated
   anti tumor effects in osteosarcoma cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE oligo(polyethylene glycol) fumarate; 2 methoxyestradiol; poly
   (lactic co glycolic acid); osteosarcoma; hydrogel
ID ENDOGENOUS ESTROGEN METABOLITE; GLYCOL) FUMARATE) HYDROGELS;
   PROSTATE CANCER; IN VITRO; ORAL 2 METHOXYESTRADIOL; CYCLE PROGRESSION;
   MOLECULAR WEIGHT; DRUG DELIVERY; PEG PLGA; APOPTOSIS
AB Osteosarcoma is a bone tumor that affects children and young adults. 2 Methoxyestradiol (2 ME), a naturally occurring estrogen metabolite, kills osteosarcoma cells, but does not affect normal osteoblasts. In order to effectively target osteosarcoma and improve the therapeutic index of the drug 2 ME, we have encapsulated 2 ME in a composite of oligo (polyethylene glycol) fumarate (OPF) hydrogel and poly (lactic co glycolic acid) (PLGA) microspheres and investigated the effect of polymer composition on 2 ME release kinetics and osteosarcoma cell survival. The in vitro study shows that 2 ME can be released in a controlled manner over 21 days. The initial burst releases observed on day 1 were 50% and 32% for OPF and OPF/PLGA composites, respectively. The extended release kinetics show that 100% of the encapsulated 2 ME is released by day 12 from OPF, whereas the OPF/PLGA composites showed a release of 85% on day 21. 2 ME released from the polymers was biologically active and blocked osteosarcoma cell proliferation in vitro. Also, comparison of 2 ME delivery in osteosarcoma cells in culture, shows that direct treatment has no effect after 3 days, whereas polymer mediated delivery produces anti tumor effects that could be sustained for 21 days. These findings show that the OPF and PLGA polymeric system may prove to be useful in controlled and sustained delivery of 2 ME and could be further explored in the treatment of osteosarcoma. (c) 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 101A: 2491 2499, 2013.
C1 [Maran, Avudaiappan; Dadsetan, Mahrokh; Buenz, Colleen M.; Shogren, Kristen L.; Lu, Lichun; Yaszemski, Michael J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Maran, Avudaiappan; Dadsetan, Mahrokh; Buenz, Colleen M.; Lu, Lichun; Yaszemski, Michael J.] Mayo Clin, Dept Biomed Engn, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Maran, A (通讯作者)，Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
EM maran.avudai@mayo.edu
FU Mayo Clinic Cancer Center Bridging to Success Award; Mayo Clinic
FX This work was supported by Mayo Clinic Cancer Center Bridging to Success
   Award (Fraternal order of Eagles) and the Mayo Clinic. The authors thank
   Mr. James Herrick for editorial assistance.
CR Bhardwaj Upkar, 2008, J Diabetes Sci Technol, V2, P1016
   Burke SE, 2000, J CARDIOVASC PHARM, V35, P838, DOI 10.1097/00005344 200006000 00002
   Changez M, 2004, BIOMATERIALS, V25, P139, DOI 10.1016/S0142 9612(03)00466 6
   Dadsetan M, 2009, J BIOMED MATER RES A, V91A, P1170, DOI 10.1002/jbm.a.32291
   Dadsetan M, 2008, BIOMATERIALS, V29, P2193, DOI 10.1016/j.biomaterials.2008.01.006
   Dadsetan M, 2007, BIOMACROMOLECULES, V8, P1702, DOI 10.1021/bm070052h
   Dadsetan M, 2012, ACTA BIOMATER, V8, P1430, DOI 10.1016/j.actbio.2011.12.031
   Dadsetan M, 2010, BIOMATERIALS, V31, P8051, DOI 10.1016/j.biomaterials.2010.06.054
   Dahut WL, 2006, CANCER BIOL THER, V5, P22, DOI 10.4161/cbt.5.1.2349
   Desai KGH, 2008, EUR J PHARM BIOPHARM, V70, P187, DOI 10.1016/j.ejpb.2008.03.007
   Dinerman AA, 2002, BIOMATERIALS, V23, P4203, DOI 10.1016/S0142 9612(02)00164 3
   Fong YC, 2007, J ORTHOP RES, V25, P1106, DOI 10.1002/jor.20364
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   Ganapathy M, 2009, CLIN CANCER RES, V15, P1601, DOI 10.1158/1078 0432.CCR 08 1389
   Golebiewska J, 2002, ACTA BIOCHIM POL, V49, P59
   Hickey T, 2002, BIOMATERIALS, V23, P1649, DOI 10.1016/S0142 9612(01)00291 5
   Jo S, 2001, BIOMACROMOLECULES, V2, P255, DOI 10.1021/bm000107e
   Kempen DHR, 2006, J BIOMED MATER RES A, V77A, P103, DOI 10.1002/jbm.a.30336
   Khodaverdi E, 2012, AAPS PHARMSCITECH, V13, P590, DOI 10.1208/s12249 012 9781 8
   Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046
   LOTTERING ML, 1992, CANCER RES, V52, P5926
   Maran A, 2006, J CELL BIOCHEM, V99, P425, DOI 10.1002/jcb.20924
   Maran A, 2002, BONE, V30, P393, DOI 10.1016/S8756 3282(01)00681 0
   Maran A, 2008, J CELL BIOCHEM, V104, P1937, DOI 10.1002/jcb.21758
   Matei D, 2009, GYNECOL ONCOL, V115, P90, DOI 10.1016/j.ygyno.2009.05.042
   Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835
   Park H, 2005, BIOMATERIALS, V26, P7095, DOI 10.1016/j.biomaterials.2005.05.083
   Park H, 2007, BIOMATERIALS, V28, P3217, DOI 10.1016/j.biomaterials.2007.03.030
   Patel B, 2012, J CONTROL RELEASE, V162, P310, DOI 10.1016/j.jconrel.2012.07.003
   Petratos PB, 2002, J SURG RES, V103, P55, DOI 10.1006/jsre.2001.6340
   Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478
   Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320
   Reiser F, 1998, P SOC EXP BIOL MED, V219, P211
   Risbud MV, 2000, DRUG DELIV, V7, P69
   Schumacher G, 1999, CLIN CANCER RES, V5, P493
   Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960 0760(97)00043 5
   Shogren KL, 2007, J BONE MINER RES, V22, P29, DOI 10.1359/JBMR.060914
   Sweeney C, 2005, CLIN CANCER RES, V11, P6625, DOI 10.1158/1078 0432.CCR 05 0440
   Temenoff JS, 2004, BIOMACROMOLECULES, V5, P5, DOI 10.1021/bm030067p
   Temenoff JS, 2002, J BIOMED MATER RES, V59, P429, DOI 10.1002/jbm.1259
   Tevaarwerk AJ, 2009, CLIN CANCER RES, V15, P1460, DOI 10.1158/1078 0432.CCR 08 1599
   WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849
   Yang H, 2012, ACS NANO, V6, P7595, DOI 10.1021/nn301873v
   Yokota H, 1999, ANAL CHEM, V71, P1663, DOI 10.1021/ac981370x
   Zhu BT, 1998, CANCER RES, V58, P2269
NR 45
TC 7
Z9 7
U1 1
U2 42
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD SEP
PY 2013
VL 101
IS 9
BP 2491
EP 2499
DI 10.1002/jbm.a.34550
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 186RN
UT WOS:000322061900005
PM 23355512
DA 2025 08 17
ER

PT J
AU Li, YY
   Chang, JWC
   Hsieh, LL
   Chen, SM
   Yeh, KY
AF Li, Ying Ying
   Chang, John W.  C.
   Hsieh, Ling Ling
   Chen, Shu Mei
   Yeh, Kun Yun
TI Low dose zoledronic acid reduces spinal cord metastasis in pulmonary
   adenocarcinoma with neuroendocrine differentiation
SO ANTI CANCER DRUGS
LA English
DT Article
DE lung adenocarcinoma; neural cell adhesion molecule; neuroendocrine
   differentiation; spinal cord metastasis; zoledronic acid
ID CELL ADHESION MOLECULE; LUNG CANCER; PLASMINOGEN ACTIVATOR;
   NERVOUS SYSTEM; VEGF D; NCAM; BISPHOSPHONATES; EXPRESSION; CARCINOMA;
   INVASION
AB Zoledronic acid (ZOL), a nitrogen containing compound, is effective in the treatment of skeletal disorders, but its long term use in high doses gives rise to complications such as osteonecrosis. We aimed to investigate the effect of low dose ZOL on the expression of the neural cell adhesion molecule (NCAM), which may be correlated with tumor growth and spinal cord metastasis in lung adenocarcinoma with neuroendocrine differentiation. First, we used the small hairpin RNA technique to directly knock down NCAM expression in cells of a murine lung adenocarcinoma line, line 1 cells, and found that the tumor cells generated showed lower invasive capacity, slower tumor growth, and lesser tendency for spinal cord metastasis than control cells. Further, ZOL decreased NCAM expression and invasiveness in line 1 tumor cells in vitro. Line 1/lacZ cells, a stable clone tagged with the lacZ gene, were introduced into mice, followed by ZOL treatment (1 lg/kg/weekly). Low dose ZOL significantly reduced spinal cord metastasis probably through reduced NCAM expression in vivo. These findings indicated that NCAM is involved in tumor growth and spinal cord metastasis of lung adenocarcinoma with neuroendocrine differentiation. Treatment with low dose ZOL can reduce NCAM expression that may contribute toward reduced spinal cord metastasis, suggesting that NCAM is an alternative therapeutic target and that the low dose ZOL treatment protocol is a reasonable approach for its treatment. Anti Cancer Drugs 23: 970 978 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Li, Ying Ying; Yeh, Kun Yun] Keelung & Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Internal Med,Div Hematooncol, Keelung, Taiwan.
   [Chang, John W.  C.] Kwei Shan & Chang Gung Univ, Kwei Shan, Taiwan.
   [Hsieh, Ling Ling] Chang Gung Univ, Coll Med, Inst Basic Med, Tao Yuan, Taiwan.
   [Chen, Shu Mei] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Tao Yuan, Taiwan.
   Chang Gung Memory Hosp, Tao Yuan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University; Chang Gung Memorial Hospital
RP Yeh, KY (通讯作者)，Keelung & Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Internal Med,Div Hematooncol, 222 Maijin Rd, Keelung, Taiwan.
EM yehtyng@gmail.com
RI Chuang, Wen Yu/I 8013 2019
FU Chung Gang Memorial Hospital [CMRPG280131, CMRP280132]
FX This study was supported by grants (CMRPG280131 and CMRP280132) from the
   Chung Gang Memorial Hospital.
CR Bujanda DA, 2007, ANN ONCOL, V18, P556, DOI 10.1093/annonc/mdl408
   ALIZADEH H, 1995, CURR EYE RES, V14, P449, DOI 10.3109/02713689509003755
   Amoureux MC, 2000, J NEUROSCI, V20, P3631, DOI 10.1523/JNEUROSCI.20 10 03631.2000
   Berenson J, 2000, P AN M AM SOC CLIN, V19, P814
   Boissier S, 1997, CANCER RES, V57, P3890
   Buttner B, 2008, NEUROCHEM RES, V33, P1915
   Campodónico PB, 2010, MOL CARCINOGEN, V49, P386, DOI 10.1002/mc.20611
   CHUONG CM, 1984, J NEUROSCI, V4, P2354
   Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104
   del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609
   Ditlevsen DK, 2003, J NEUROCHEM, V84, P546, DOI 10.1046/j.1471 4159.2003.01538.x
   Ditlevsen DK, 2008, J NEUROSCI RES, V86, P727, DOI 10.1002/jnr.21551
   Edvardsen K, 1997, APMIS, V105, P919, DOI 10.1111/j.1699 0463.1997.tb05103.x
   EDVARDSEN K, 1993, INT J DEV NEUROSCI, V11, P681, DOI 10.1016/0736 5748(93)90055 I
   El Hilali N, 2002, LAB INVEST, V82, P1563, DOI 10.1097/01.LAB.0000036877.36379.1F
   Feng YK, 2010, ANAT REC, V293, P802, DOI 10.1002/ar.21096
   Gattenlöhner S, 2009, AM J PATHOL, V174, P1160, DOI 10.2353/ajpath.2009.080647
   Hage R, 1998, CHEST, V114, P1316, DOI 10.1378/chest.114.5.1316
   Howe MC, 2005, HISTOPATHOLOGY, V46, P195, DOI 10.1111/j.1365 2559.2005.02047.x
   Ionescu DN, 2007, AM J SURG PATHOL, V31, P26, DOI 10.1097/01.pas.0000213319.04919.97
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Li YY, 2011, ANTI CANCER DRUG, V22, P89, DOI 10.1097/CAD.0b013e3283400a05
   Losada I, 2010, AUTOIMMUN REV, V9, P547, DOI 10.1016/j.autrev.2010.03.002
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   OKAMOTO H, 1993, CANCER, V72, P2583, DOI 10.1002/1097 0142(19931101)72:9<2583::AID CNCR2820720912>3.0.CO;2 K
   Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Papastefanaki F, 2007, BRAIN, V130, P2159, DOI 10.1093/brain/awm155
   Potti A, 2001, LUNG CANCER J IASLC, V31, P319, DOI 10.1016/S0169 5002(00)00177 X
   Prag S, 2002, J CELL SCI, V115, P283
   Rabbani SA, 1998, INT J ONCOL, V12, P911
   Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531 5565(98)00040 0
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saba N, 2005, ONCOLOGY BASEL, V68, P18, DOI 10.1159/000084518
   SANTONI MJ, 1987, NUCLEIC ACIDS RES, V15, P8621, DOI 10.1093/nar/15.21.8621
   Scarpino S, 2007, J PATHOL, V212, P411, DOI 10.1002/path.2183
   Schiff D, 1996, NEUROLOGY, V47, P906, DOI 10.1212/WNL.47.4.906
   Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097 4695(199903)38:4<542::AID NEU9>3.3.CO;2 T
   Schrötzlmair F, 2010, J CELL MOL MED, V14, P2760, DOI 10.1111/j.1582 4934.2009.00951.x
   Sisková Z, 2006, MOL CELL NEUROSCI, V33, P150, DOI 10.1016/j.mcn.2006.07.001
   Son H, 2002, BIOCHEM BIOPH RES CO, V298, P262, DOI 10.1016/S0006 291X(02)02453 1
   Sterlacci W, 2009, VIRCHOWS ARCH, V455, P125, DOI 10.1007/s00428 009 0812 0
   Storms SD, 1996, CELL ADHES COMMUN, V3, P497, DOI 10.3109/15419069609081026
   Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124
   Storms SD, 1996, EXP CELL RES, V223, P385, DOI 10.1006/excr.1996.0093
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Xu XXS, 1998, J BIOL CHEM, V273, P33230, DOI 10.1074/jbc.273.50.33230
   YAMASHITA JI, 1992, INT J CLIN LAB RES, V21, P227, DOI 10.1007/BF02591651
   YUHAS JM, 1974, CANCER RES, V34, P2005
   Zhang S, 2010, NEUROCHEM INT, V56, P919, DOI 10.1016/j.neuint.2010.03.023
NR 50
TC 3
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0959 4973
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD OCT
PY 2012
VL 23
IS 9
BP 970
EP 978
DI 10.1097/CAD.0b013e328355f0ec
PG 9
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 001FL
UT WOS:000308445800009
PM 22713592
DA 2025 08 17
ER

PT J
AU Ordikhani, F
   Tamjid, E
   Simchi, A
AF Ordikhani, F.
   Tamjid, E.
   Simchi, A.
TI Characterization and antibacterial performance of electrodeposited
   chitosan vancomycin composite coatings for prevention of
   implant associated infections
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Biodegradable coating; Electrophoretic deposition; Antibacterial;
   Chitosan; Drug release; Cytotoxicity
ID ELECTROPHORETIC DEPOSITION; ELECTROCHEMICAL DEPOSITION; ANTIMICROBIAL
   PEPTIDES; TITANIUM; RELEASE; ANTIBIOTICS; PROPHYLAXIS; TOPOGRAPHY
AB Orthopaedic implant associated infections are one of the most serious complications in orthopaedic surgery and a major cause of implant failure. In the present work, drug eluting coatings based on chitosan containing various amounts of vancomycin were prepared by a cathodic electrophoretic deposition process on titanium foils. A three step release mechanism of the antibiotic from the films in a phosphate buffered saline solution was noticed. At the early stage, physical encapsulation of the drug in the hydrogel network controlled the release rate. At the late stage, however, in vitro degradation/deattachment of chitosan was responsible for the controlled release. Cytotoxicity evaluation of the drug eluting coatings via culturing in human osteosarcoma cells (MG 63 osteoblast like cell line) showed no adverse effect on the biocompatibility. Antibacterial tests against Gram positive Staphylococcus aureus also demonstrated that the infection risk of titanium foils was significantly reduced due to the antibiotic release. Additionally, in vitro electrochemical corrosion studies by polarization technique revealed that the corrosion current density was significantly lower for the titanium foils with drug eluting coatings compared to that of uncoated titanium. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ordikhani, F.; Simchi, A.] Sharif Univ Technol, Dept Mat Sci & Engn, Tehran, Iran.
   [Tamjid, E.; Simchi, A.] Sharif Univ Technol, Inst Nanosci & Nanotechnol, Tehran, Iran.
C3 Sharif University of Technology; Sharif University of Technology
RP Simchi, A (通讯作者)，Sharif Univ Technol, Dept Mat Sci & Engn, Azadi Ave,POB 11365 9466, Tehran, Iran.
EM simchi@sharif.edu
RI Simchi, Abdolreza/X 7831 2018
OI Simchi, Abdolreza/0000 0002 9111 2977
CR Alt V, 2006, BIOMATERIALS, V27, P4627, DOI 10.1016/j.biomaterials.2006.04.035
   Alt V, 2011, ACTA BIOMATER, V7, P1274, DOI 10.1016/j.actbio.2010.11.012
   Bae K, 2006, CLIN ORAL INVEST, V10, P102, DOI 10.1007/s00784 006 0038 3
   Besra L, 2007, PROG MATER SCI, V52, P1, DOI 10.1016/j.pmatsci.2006.07.001
   Boccaccini AR, 2010, J R SOC INTERFACE, V7, pS581, DOI 10.1098/rsif.2010.0156.focus
   Cai QY, 2011, POLYM BULL, V67, P571, DOI 10.1007/s00289 010 0398 3
   Campoccia D, 2006, BIOMATERIALS, V27, P2331, DOI 10.1016/j.biomaterials.2005.11.044
   Cataldo MA, 2010, J INFECTION, V61, P443, DOI 10.1016/j.jinf.2010.09.033
   Chen ZG, 2008, CARBOHYD POLYM, V72, P410, DOI 10.1016/j.carbpol.2007.09.018
   Cheng Y, 2010, SOFT MATTER, V6, P3177, DOI 10.1039/c0sm00124d
   Croisier F, 2013, EUR POLYM J, V49, P780, DOI 10.1016/j.eurpolymj.2012.12.009
   Deligianni DD, 2001, BIOMATERIALS, V22, P1241, DOI 10.1016/S0142 9612(00)00274 X
   Dhawade PP, 2012, ADV APPL SCI RES, V3, P1372
   Di Martino A, 2005, BIOMATERIALS, V26, P5983, DOI 10.1016/j.biomaterials.2005.03.016
   Edmiston CE, 2006, J AM COLL SURGEONS, V203, P481, DOI 10.1016/j.jamcollsurg.2006.06.026
   Gebhardt F, 2012, MATER LETT, V66, P302, DOI 10.1016/j.matlet.2011.08.088
   Glinel K, 2012, ACTA BIOMATER, V8, P1670, DOI 10.1016/j.actbio.2012.01.011
   Goodman SB, 2013, BIOMATERIALS, V34, P3174, DOI 10.1016/j.biomaterials.2013.01.074
   Han T., 2012, J BIOMEDICAL SCI ENG, V5, P15, DOI DOI 10.4236/JBISE.2012.51003
   Hickok NJ, 2012, ADV DRUG DELIVER REV, V64, P1165, DOI 10.1016/j.addr.2012.03.015
   Hong Y, 2007, ACTA BIOMATER, V3, P23, DOI 10.1016/j.actbio.2006.06.007
   Jayakumar R., 2011, CHITOSAN BIOMATERIAL, P19
   Kazemzadeh Narbat M, 2013, BIOMATERIALS, V34, P5969, DOI 10.1016/j.biomaterials.2013.04.036
   Kazemzadeh Narbat M, 2010, BIOMATERIALS, V31, P9519, DOI 10.1016/j.biomaterials.2010.08.035
   Knaepler H, 2012, INT J SURG, V10, pS15, DOI 10.1016/j.ijsu.2012.05.020
   Leceta I, 2013, CARBOHYD POLYM, V93, P339, DOI 10.1016/j.carbpol.2012.04.031
   Liao YZ, 2007, CHINESE CHEM LETT, V18, P213, DOI 10.1016/j.cclet.2006.12.024
   Liu XY, 2004, MAT SCI ENG R, V47, P49, DOI 10.1016/j.mser.2004.11.001
   Ma CF, 2012, ACTA BIOMATER, V8, P860, DOI 10.1016/j.actbio.2011.09.021
   Mehdipour M, 2012, APPL SURF SCI, V258, P9832, DOI 10.1016/j.apsusc.2012.06.038
   Milella E, 2001, BIOMATERIALS, V22, P1425, DOI 10.1016/S0142 9612(00)00300 8
   Patel KD, 2012, J MATER CHEM, V22, P24945, DOI 10.1039/c2jm33830k
   Pattnaik S, 2011, INT J BIOL MACROMOL, V49, P1167, DOI 10.1016/j.ijbiomac.2011.09.016
   Pishbin F, 2013, ACTA BIOMATER, V9, P7469, DOI 10.1016/j.actbio.2013.03.006
   Pishbin F, 2011, SURF COAT TECH, V205, P5260, DOI 10.1016/j.surfcoat.2011.05.026
   Pon On W, 2013, MAT SCI ENG C MATER, V33, P1423, DOI 10.1016/j.msec.2012.12.046
   Sarasam AR, 2008, J MATER SCI MATER M, V19, P1083, DOI 10.1007/s10856 007 3072 z
   Shukla A, 2012, J CONTROL RELEASE, V157, P64, DOI 10.1016/j.jconrel.2011.09.062
   Simchi A, 2011, NANOMED NANOTECHNOL, V7, P22, DOI 10.1016/j.nano.2010.10.005
   Simchi A, 2009, MATER LETT, V63, P2253, DOI 10.1016/j.matlet.2009.07.046
   Sinha VR, 2004, INT J PHARMACEUT, V274, P1, DOI 10.1016/j.ijpharm.2003.12.026
   Stigter M, 2002, BIOMATERIALS, V23, P4143, DOI 10.1016/S0142 9612(02)00157 6
   Stigter M, 2004, J CONTROL RELEASE, V99, P127, DOI 10.1016/j.jconrel.2004.06.011
   Teterycz D, 2010, INT J INFECT DIS, V14, pE913, DOI 10.1016/j.ijid.2010.05.014
   Vester H, 2010, INJURY, V41, P1053, DOI 10.1016/j.injury.2010.05.010
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Wang JC, 2011, MICROPOR MESOPOR MAT, V146, P216, DOI 10.1016/j.micromeso.2011.04.005
   Xie WM, 2002, CARBOHYD POLYM, V50, P35, DOI 10.1016/S0144 8617(01)00370 8
   Yang CC, 2013, MAT SCI ENG C MATER, V33, P2203, DOI 10.1016/j.msec.2013.01.038
   Yang CC, 2011, J ELECTROCHEM SOC, V158, pE152, DOI 10.1149/2.105112jes
   Yang SY, 2013, MAT SCI ENG C MATER, V33, P1689, DOI 10.1016/j.msec.2012.12.081
   Zhitomirsky D, 2009, J MATER PROCESS TECH, V209, P1853, DOI 10.1016/j.jmatprotec.2008.04.034
   Zhu XL, 2004, BIOMATERIALS, V25, P4087, DOI 10.1016/j.biomaterials.2003.11.011
   Zilberman M, 2008, J CONTROL RELEASE, V130, P202, DOI 10.1016/j.jconrel.2008.05.020
NR 54
TC 91
Z9 97
U1 2
U2 85
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD AUG 1
PY 2014
VL 41
BP 240
EP 248
DI 10.1016/j.msec.2014.04.036
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AK7KH
UT WOS:000338606700028
PM 24907757
DA 2025 08 17
ER

PT J
AU Paglia, DN
   Kanjilal, D
   Kadkoy, Y
   Moskonas, S
   Wetterstrand, C
   Lin, A
   Galloway, J
   Tompson, J
   Culbertson, MD
   O'Connor, JP
AF Paglia, David N.
   Kanjilal, Deboleena
   Kadkoy, Yazan
   Moskonas, Spiro
   Wetterstrand, Charlene
   Lin, Anthony
   Galloway, Joseph
   Tompson, Jeffrey
   Culbertson, Maya D.
   O'Connor, J. Patrick
TI Naproxen treatment inhibits articular cartilage loss in a rat model of
   osteoarthritis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE acetaminophen; DMM; knee; naproxen; NSAIDs; osteoarthritis; rat
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTEOGLYCAN METABOLISM;
   SYNOVIAL FLUID; BONE; ACETAMINOPHEN; CYCLOOXYGENASE; DESTABILIZATION;
   RECOMMENDATIONS; PARACETAMOL; MECHANISM
AB The effects of naproxen, a nonsteroidal anti inflammatory drug (NSAID), on articular cartilage degeneration in female Sprague Dawley rats was examined. Osteoarthritis (OA) was induced by destabilization of the medial meniscus (DMM) in each knee. Rats were treated with acetaminophen (60 mg/kg), naproxen (8 mg/kg), or 1% carboxymethylcellulose (placebo) by oral gavage twice daily for 3 weeks, beginning 2 weeks after surgery. OA severity was assessed by histological Osteoarthritis Research Society International (OARSI) scoring and by measuring proximal tibia cartilage depth using contrast enhanced mu CT (n = 6 per group) in specimens collected at 2, 5, and 7 weeks after surgery as well as on pristine knees. Medial cartilage OARSI scores from the DMM knees of naproxen treated rats were statistically lower (i.e., better) than the medial cartilage OARSI scores from the DMM knees of placebo treated rats at 5 weeks (8.7 +/  3.6 vs. 13.2 +/  2.4, p = 0.025) and 7 weeks (9.5 +/  1.2 vs. 12.5 +/  2.5, p = 0.024) after surgery. At 5 weeks after DMM surgery, medial articular cartilage depth in the proximal tibia specimens was significantly greater in the naproxen (1.78 +/  0.26 mm, p = 0.005) and acetaminophen (1.94 +/  0.12 mm, p < 0.001) treated rats as compared with placebo treated rats (1.34 +/  0.24 mm). However, at 7 weeks (2 weeks after drug withdrawal), medial articular cartilage depth for acetaminophen treated rats (1.36 +/  0.29 mm) was significantly reduced compared with specimens from the naproxen treated rats (1.88 +/  0.14 mm; p = 0.004). The results indicate that naproxen treatment reduced articular cartilage degradation in the rat DMM model during and after naproxen treatment.
C1 [Paglia, David N.; Kanjilal, Deboleena; Kadkoy, Yazan; Lin, Anthony; Galloway, Joseph; Tompson, Jeffrey; Culbertson, Maya D.; O'Connor, J. Patrick] Rutgers New Jersey Med Sch, Dept Orthopaed, Med Sci Bldg,Room E 659,185 South Orange Ave, Newark, NJ 07103 USA.
   [Kanjilal, Deboleena; Wetterstrand, Charlene; O'Connor, J. Patrick] Rutgers Sch Grad Studies, Newark Hlth Sci Campus, Newark, NJ USA.
   [Moskonas, Spiro] Rutgers Sch Engn, Dept Biomed Engn, New Brunswick, NJ USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System
RP O'Connor, JP (通讯作者)，Rutgers New Jersey Med Sch, Dept Orthopaed, Med Sci Bldg,Room E 659,185 South Orange Ave, Newark, NJ 07103 USA.
EM oconnojp@njms.rutgers.edu
OI Paglia, David/0000 0002 6079 4629; Kadkoy, Yazan/0000 0002 4705 7026;
   Wetterstrand, Charlene/0000 0003 1366 3447; O'Connor, J.
   Patrick/0000 0003 0282 1104
FU Bayer Healthcare LLC; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health
   [R01AR069044]
FX Bayer Healthcare LLC; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the National Institutes of Health,
   Grant/Award Number: R01AR069044
CR ACKERMAN NR, 1979, ARTHRITIS RHEUM US, V22, P1365, DOI 10.1002/art.1780221208
   Almaawi A, 2013, TISSUE ENG PT A, V19, P1039, DOI [10.1089/ten.TEA.2012.0129, 10.1089/ten.tea.2012.0129]
   Antoniou J, 2015, TISSUE ENG PT A, V21, P2136, DOI [10.1089/ten.tea.2014.0668, 10.1089/ten.TEA.2014.0668]
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Borges PD, 2014, OSTEOARTHR CARTILAGE, V22, P1419, DOI 10.1016/j.joca.2014.07.014
   Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520
   BRANDT KD, 1990, J PHARM PHARMACOL, V42, P738, DOI 10.1111/j.2042 7158.1990.tb06573.x
   BRANDT KD, 1987, AM J MED, V83, P29, DOI 10.1016/0002 9343(87)90848 5
   BRUNO R, 1988, BRIT J CLIN PHARMACO, V26, P41, DOI 10.1111/j.1365 2125.1988.tb03361.x
   Cho H, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/595273
   Conaghan PG, 2019, DRUG AGING, V36, P7, DOI 10.1007/s40266 019 00658 9
   Cottrell JA, 2009, PAIN, V142, P116, DOI 10.1016/j.pain.2008.12.019
   DINGLE JT, 1993, ANN RHEUM DIS, V52, P292, DOI 10.1136/ard.52.4.292
   DOHERTY NS, 1977, ANN RHEUM DIS, V36, P244, DOI 10.1136/ard.36.3.244
   Fang H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21184 5
   Felson DT, 2006, NEW ENGL J MED, V354, P841, DOI 10.1056/NEJMcp051726
   Fukai A, 2012, ARTHRITIS RHEUM US, V64, P198, DOI 10.1002/art.33324
   Gerwin N, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.05.030
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Golden Harvey E, 2004, Am J Ther, V11, P85, DOI 10.1097/00045391 200403000 00002
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Greco KV, 2011, BIOCHEM PHARMACOL, V82, P1919, DOI 10.1016/j.bcp.2011.09.009
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Iijima H, 2014, OSTEOARTHR CARTILAGE, V22, P1036, DOI 10.1016/j.joca.2014.05.009
   ITO A, 1995, FEBS LETT, V360, P75, DOI 10.1016/0014 5793(95)00085 N
   Katri A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1819 9
   KUJUBU DA, 1991, J BIOL CHEM, V266, P12866
   LANE N, 1990, J BONE MINER RES, V5, P1029
   LYSZ TW, 1982, J NEUROCHEM, V38, P1111, DOI 10.1111/j.1471 4159.1982.tb05355.x
   MARTEL RR, 1984, AGENTS ACTIONS, V15, P403, DOI 10.1007/BF01972379
   Mastbergen SC, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1846
   MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693
   Nakata K, 2018, OSTEOARTHR CARTILAGE, V26, P1263, DOI 10.1016/j.joca.2018.05.021
   Ou YS, 2012, MED SCI MONITOR, V18, pBR247, DOI 10.12659/MSM.882901
   OWEN SG, 1994, BRIT J CLIN PHARMACO, V38, P349, DOI 10.1111/j.1365 2125.1994.tb04365.x
   Paglia DN, 2014, J ORTHOP RES, V32, P727, DOI 10.1002/jor.22570
   PALMOSKI MJ, 1980, ARTHRITIS RHEUM US, V23, P1010, DOI 10.1002/art.1780230908
   Ratcliffe A, 1993, Agents Actions Suppl, V39, P207
   RATCLIFFE A, 1993, J ORTHOPAED RES, V11, P163, DOI 10.1002/jor.1100110203
   ROSENBERG L, 1971, J BONE JOINT SURG AM, VA 53, P69, DOI 10.2106/00004623 197153010 00007
   Sakurai Y, 2019, PAIN, V160, P895, DOI 10.1097/j.pain.0000000000001466
   Seed M. P., 2005, Inflammopharmacology, V12, P551
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   SIEGERS CP, 1978, PHARMACOLOGY, V16, P273, DOI 10.1159/000136779
   Smith RL, 1997, J ORTHOP RES, V15, P919, DOI 10.1002/jor.1100150619
   Temple AR, 2006, CLIN THER, V28, P222, DOI 10.1016/j.clinthera.2006.02.004
   Theken KN, 2018, PROSTAG OTH LIPID M, V139, P63, DOI 10.1016/j.prostaglandins.2018.10.005
   VANDERKRAAN PM, 1990, AGENTS ACTIONS, V29, P218
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   WILLIAMS HJ, 1993, ARTHRITIS RHEUM US, V36, P1196, DOI 10.1002/art.1780360904
NR 52
TC 11
Z9 13
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD OCT
PY 2021
VL 39
IS 10
BP 2252
EP 2259
DI 10.1002/jor.24937
EA DEC 2020
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA UQ9LG
UT WOS:000598510000001
PM 33274763
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Yan, HQ
   Chen, XQ
   Feng, MX
   Shi, ZF
   Zhang, W
   Wang, Y
   Ke, CR
   Lin, Q
AF Yan, Huiqiong
   Chen, Xiuqiong
   Feng, Meixi
   Shi, Zaifeng
   Zhang, Wei
   Wang, Yue
   Ke, Chaoran
   Lin, Qiang
TI Entrapment of bacterial cellulose nanocrystals stabilized Pickering
   emulsions droplets in alginate beads for hydrophobic drug delivery
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Bacterial cellulose nanocrystals; Pickering emulsions; Alginate
   composite beads; Interfacial assembly; Encapsulation; Sustained release
ID IN VITRO RELEASE; SODIUM ALGINATE; COMPOSITE MICROSPHERES; FACILE
   FABRICATION; MONTMORILLONITE; DISSOLUTION; MECHANISM; MEMBRANES;
   HYDROGELS; CALCIUM
AB In this work, the interfacial assembly of amphiphilic bacterial cellulose nanocrystals (BCNs) by Pickering emulsion method was proposed to improve the compatibility between the alginate and hydrophobic drug. BCNs prepared by sulfuric acid hydrolysis of biosynthesized bacterial cellulose was used as the particulate emulsifiers, whereas the model drug, alfacalcidol, dissolved in CH2Cl2 was used as the oil phase. The oil in water Pickering emulsions were prepared by ultrasonic dispersion method and then they were well dispersed in alginate solution. Ultimately, the drug loaded alginate composite beads were successfully fabricated by external gelation. The characterization results revealed that BCNs possessed good colloidal property and could form flocculated fibril network, which was beneficial to stabilize Pickering emulsions. The irreversible adsorption of BCNs at the oil water interface could make the Pickering emulsions preserve the droplets against coalescence and Ostwald ripening when they were dispersed in alginate solution. The interfacial assembly of amphiphilic BCNs and the hydrogel shells of the alginate composite beads formed by external gelation achieved the loading and sustained release of alfacalcidol. The release curves were well fitted by Korsmeyer Peppas model and the release mechanism of alfacalcidol from the composite beads was attributed to non Fickian transport. In addition, the resultant alginate composite beads exhibited low cytotoxicity and good capabilities for osteoblast differentiation.
C1 [Yan, Huiqiong; Chen, Xiuqiong; Lin, Qiang] Hainan Normal Univ, Key Lab Trop Med Plant Chem, Coll Chem & Chem Engn, Minist Educ, Haikou 571158, Hainan, Peoples R China.
   [Yan, Huiqiong; Chen, Xiuqiong; Feng, Meixi; Shi, Zaifeng; Zhang, Wei; Wang, Yue; Ke, Chaoran; Lin, Qiang] Hainan Normal Univ, Coll Chem & Chem Engn, Key Lab Water Pollut Treatment & Resource Reuse H, Haikou 571158, Hainan, Peoples R China.
C3 Hainan Normal University; Hainan Normal University
RP Lin, Q (通讯作者)，Hainan Normal Univ, Key Lab Trop Med Plant Chem, Coll Chem & Chem Engn, Minist Educ, Haikou 571158, Hainan, Peoples R China.
EM linqianggroup@163.com
FU Natural Science Foundation of Hainan Province [218QN233]; National
   Natural Science Foundation of China [21566009]
FX We gratefully acknowledge the financial support from the Natural Science
   Foundation of Hainan Province (218QN233) and the National Natural
   Science Foundation of China (21566009).
CR Bidarra SJ, 2014, ACTA BIOMATER, V10, P1646, DOI 10.1016/j.actbio.2013.12.006
   Binks BP, 2005, COLLOID SURFACE A, V253, P105, DOI 10.1016/j.colsurfa.2004.10.116
   Blaker JJ, 2009, GREEN CHEM, V11, P1321, DOI 10.1039/b913740h
   Chan ES, 2011, CARBOHYD POLYM, V84, P1267, DOI 10.1016/j.carbpol.2011.01.015
   Dankovich TA, 2011, J ADHES SCI TECHNOL, V25, P699, DOI 10.1163/016942410X525885
   Donzelli E, 2007, ARCH ORAL BIOL, V52, P64, DOI 10.1016/j.archoralbio.2006.07.007
   Dragan ES, 2014, CHEM ENG J, V243, P572, DOI 10.1016/j.cej.2014.01.065
   Duan LL, 2009, LANGMUIR, V25, P3467, DOI 10.1021/la8041617
   Habibi Y, 2010, CHEM REV, V110, P3479, DOI 10.1021/cr900339w
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hu Z, 2015, J COLLOID INTERF SCI, V439, P139, DOI 10.1016/j.jcis.2014.10.034
   Jia YY, 2016, CARBOHYD POLYM, V151, P907, DOI 10.1016/j.carbpol.2016.05.099
   Kalashnikova I, 2011, LANGMUIR, V27, P7471, DOI 10.1021/la200971f
   Kaygusuz H, 2013, REACT FUNCT POLYM, V73, P1420, DOI 10.1016/j.reactfunctpolym.2013.07.014
   Kevadiya BD, 2010, J BIOMATER APPL, V25, P161, DOI 10.1177/0885328209344003
   Kevadiya BD, 2010, INT J PHARMACEUT, V388, P280, DOI 10.1016/j.ijpharm.2010.01.002
   Kulkarni RV, 2010, INT J BIOL MACROMOL, V47, P520, DOI 10.1016/j.ijbiomac.2010.07.009
   Lawrie G, 2007, BIOMACROMOLECULES, V8, P2533, DOI 10.1021/bm070014y
   Li QA, 2011, J AGR FOOD CHEM, V59, P1962, DOI 10.1021/jf1020347
   Li Z, 2015, CARBOHYD POLYM, V120, P115, DOI 10.1016/j.carbpol.2014.11.061
   Lin N, 2014, EUR POLYM J, V59, P302, DOI 10.1016/j.eurpolymj.2014.07.025
   Lindman B, 2010, J MOL LIQ, V156, P76, DOI 10.1016/j.molliq.2010.04.016
   Liu HX, 2016, MATER LETT, V166, P55, DOI 10.1016/j.matlet.2015.12.026
   Ma QY, 2016, INT J BIOL MACROMOL, V86, P606, DOI 10.1016/j.ijbiomac.2016.01.104
   Mo YF, 2015, COLLOID SURFACE B, V132, P177, DOI 10.1016/j.colsurfb.2015.05.029
   Moriana R, 2016, CARBOHYD POLYM, V139, P139, DOI 10.1016/j.carbpol.2015.12.020
   Nuti R, 2006, RHEUMATOL INT, V26, P445, DOI 10.1007/s00296 005 0073 4
   Paques JP, 2013, FOOD HYDROCOLLOID, V31, P428, DOI 10.1016/j.foodhyd.2012.11.012
   Paximada P, 2016, CARBOHYD POLYM, V150, P5, DOI 10.1016/j.carbpol.2016.04.125
   Paximada P, 2016, FOOD HYDROCOLLOID, V53, P225, DOI 10.1016/j.foodhyd.2014.12.003
   Qin Z, 2014, CARBOHYD POLYM, V101, P947, DOI 10.1016/j.carbpol.2013.09.068
   RITGER RL, 1987, J CONTROL RELEASE, V5, P23
   Sheltami RM, 2012, CARBOHYD POLYM, V88, P772, DOI 10.1016/j.carbpol.2012.01.062
   Stark WJ, 2011, ANGEW CHEM INT EDIT, V50, P1242, DOI 10.1002/anie.200906684
   Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409
   Swamy BY, 2015, INT J BIOL MACROMOL, V77, P114, DOI 10.1016/j.ijbiomac.2015.03.019
   Talukder R, 2004, DRUG DEV IND PHARM, V30, P405, DOI 10.1081/DDC 120030935
   Tzoumaki MV, 2011, FOOD HYDROCOLLOID, V25, P1521, DOI 10.1016/j.foodhyd.2011.02.008
   Voo WP, 2016, EUR POLYM J, V75, P343, DOI 10.1016/j.eurpolymj.2015.12.029
   Wang WH, 2016, CARBOHYD POLYM, V151, P1, DOI 10.1016/j.carbpol.2016.05.052
   Wei ZJ, 2012, COLLOID SURFACE B, V91, P97, DOI 10.1016/j.colsurfb.2011.10.044
   Wen CX, 2014, CARBOHYD POLYM, V112, P695, DOI 10.1016/j.carbpol.2014.06.051
   Xiao J, 2017, FOOD HYDROCOLLOID, V62, P35, DOI 10.1016/j.foodhyd.2016.07.025
   Yan HQ, 2016, POLYM BULL, V73, P1185, DOI 10.1007/s00289 015 1542 x
   Yan HQ, 2016, CARBOHYD POLYM, V136, P757, DOI 10.1016/j.carbpol.2015.09.104
   Yang JM, 2014, J MEMBRANE SCI, V457, P139, DOI 10.1016/j.memsci.2014.01.034
   Yang JS, 2011, CARBOHYD POLYM, V84, P33, DOI 10.1016/j.carbpol.2010.11.048
   Yang LQ, 2007, CARBOHYD POLYM, V68, P218, DOI 10.1016/j.carbpol.2006.12.020
   Yue YY, 2016, CARBOHYD POLYM, V147, P155, DOI 10.1016/j.carbpol.2016.04.005
   Zhong LX, 2012, CARBOHYD POLYM, V90, P644, DOI 10.1016/j.carbpol.2012.05.091
   Zhou GF, 2013, REACT FUNCT POLYM, V73, P1537, DOI 10.1016/j.reactfunctpolym.2013.08.004
NR 51
TC 89
Z9 95
U1 6
U2 139
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD MAY 1
PY 2019
VL 177
BP 112
EP 120
DI 10.1016/j.colsurfb.2019.01.057
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA HZ3AU
UT WOS:000468720700013
PM 30716696
DA 2025 08 17
ER

PT J
AU Sapundzhiev, L
   Sapundzhieva, T
   Klinkanov, K
   Mitev, M
   Simitchiev, K
   Batalov, A
AF Sapundzhiev, Lyubomir
   Sapundzhieva, Tanya
   Klinkanov, Kamen
   Mitev, Martin
   Simitchiev, Kiril
   Batalov, Anastas
TI Endophenotypes of Primary Osteoarthritis of the Hip Joint in the
   Bulgarian Population over 60 Years Old
SO LIFE BASEL
LA English
DT Article
DE pHOA; endophenotypes; THR
ID CLINICAL TRIALS; RADIOGRAPHIC PATTERNS; AMERICAN COLLEGE;
   HYALURONIC ACID; HEALTH STATUS; PROGRESSION; PATIENT; RISK; BONE;
   REPLACEMENT
AB Aim. To identify subgroups of patients with primary osteoarthritis of the hip joint (pHOA) with similar imaging and laboratory findings, disease evolution, and response to conventional therapies. Methods. We performed further statistical analyses on patient data from two published, double blind, randomized, and placebo controlled studies (DB RCTs), which examined the effects of intra articular corticosteroids (ia CSs), hyaluronic acid (ia HA) K & Icy; 109 3 0008/14.01.2014, and intravenous bisphosphonates (iv BPs)  K & Icy;  109 3 0009/14.01.2014 compared to the country's standard pHOA therapy. The data span an 8 year follow up of 700 patients with pHOA, including: 1. Clinical parameters (WOMAC A, B, C, and T; PtGA). 2. Laboratory markers (serum calcium and phosphate levels; 25 OH D and PTH, markers for bone sCTX I and cartilage uCTX II turnover). 3. Radiological indicators: X ray stage (Kellgren Lawrence (K/L) and model (Bombelli/OOARSI), width (mJSW), speed (JSN mm/year), and zone of maximum narrowing of the joint space (max JSN) determining the type of femoral head migration (FHM). 4. DXA indicators: bone geometry (HAL; NSA; and MNW); changes in regional and total bone mineral density (TH BMD, LS BMD, and TB BMD). 5. Therapeutic responses (OARSI/MCII; mJSW; JSNmm/yearly) to different drug regimens (iv BP  zoledronic acid (ZA/ 5 mg/yearly for 3 years)); ia CS 40 mg methylprednisolone acetate, twice every 6 months; and ia HA with intermediate molecular weight (20 mg/2 mL x 3 weekly applications, two courses every 6 months) were compared to standard of care therapy (Standard of Care/SC/), namely D3 supplementation according to serum levels (20 120 ng/mL; target level of 60 ng/mL), simple analgesics (paracetamol, up to 2.0 g/24 h), and physical exercises. The abovementioned data were integrated into a non supervised hierarchical agglomerative clustering analysis (NHACA) using Ward's linkage method and the squared Euclidean distance to identify different endophenotypes (EFs). Univariate and multivariate multinomial logistic regression analyses were performed to determine the impact of sex and FHM on clinical and radiographic regression of pHOA. Results. A baseline cluster analysis using incoming (M0) patient data identified three EFs: hypertrophic H HOA, atrophic A HOA, and intermediate I HOA. These EFs had characteristics that were similar to those of patients grouped by radiographic stage and pattern ('H' RPs, 'I' RPs, and 'A' RPs), p < 0.05). The repeated cluster analysis of M36 data identified four EF pHOAs: 1. Hypertrophic (slow progressors, the influence of the type of femoral head migration (FHM) outweighing the influence of sex on progression), progressing to planned total hip replacement (THR) within 5 (K/LIII) to 10 (K/LII) years. 2. Intermediate (sex is more important than the FHM type for progression) with two subgroups: 2#: male associated (slow progressors), THR within 4 (K/LIII) to 8 years. (K/LII). 2* Female associated (rapid progressors), THR within 3 (K/LIII) to 5 (K/LII) years. 3. Atrophic (rapid progressors; the influence of FHM type outweighs that of sex), THR within 2 (K/LIII) to 4 (K/LII) years. Each EF, in addition to the patient's individual progression rate, was also associated with a different response to the aforementioned therapies. Conclusions. Clinical endophenotyping provides guidance for a personalized approach in patients with pHOA, simultaneously assisting the creation of homogeneous patient groups necessary for conducting modern genetic and therapeutic scientific studies.
C1 [Sapundzhiev, Lyubomir; Sapundzhieva, Tanya; Klinkanov, Kamen; Batalov, Anastas] Med Univ Plovdiv, Med Fac, Dept Propedeut Internal Dis, Plovdiv 4001, Bulgaria.
   [Sapundzhiev, Lyubomir; Sapundzhieva, Tanya; Klinkanov, Kamen; Mitev, Martin] Univ Hosp Pulmed Plovdiv, Rheumatol Dept, Plovdiv 4002, Bulgaria.
   [Simitchiev, Kiril] Paisij Hilendarski Univ Plovdiv, Fac Chem, Dept Analyt Chem & Comp Chem, Plovdiv 4001, Bulgaria.
   [Batalov, Anastas] Univ Hosp Kaspela, Rheumatol Clin, Plovdiv 4000, Bulgaria.
C3 Medical University Plovdiv; Plovdiv University; Medical University
   Plovdiv
RP Sapundzhiev, L (通讯作者)，Med Univ Plovdiv, Med Fac, Dept Propedeut Internal Dis, Plovdiv 4001, Bulgaria.; Sapundzhiev, L (通讯作者)，Univ Hosp Pulmed Plovdiv, Rheumatol Dept, Plovdiv 4002, Bulgaria.
EM sapoundjiev@abv.bg; taniasapundjieva@abv.bg; kamenklinkanov@gmail.com;
   m.mitev97@gmail.com; abatalov@hotmail.com
RI Sapundzhieva, Tanya/AAM 4823 2020; Batalov, Anastas/J 4921 2019;
   Simitchiev, Kiril/AAD 6122 2019; Sapundzhiev, Lyubomir/AAM 5540 2020
OI Sapundzhieva, Tanya/0000 0002 2061 6473; KLINKANOV,
   KAMEN/0000 0002 5133 4284; Sapundzhiev, Lyubomir/0000 0001 7198 3532;
   Batalov, Anastas/0000 0001 8857 0574; Simitchiev,
   Kiril/0000 0003 2564 3291; 
CR ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502
   Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, pA1, DOI 10.1016/j.joca.2006.11.009
   Altman RD, 2004, OSTEOARTHR CARTILAGE, V12, P515, DOI 10.1016/j.joca.2004.04.004
   [Anonymous], Oxford English Dictionary
   Arends RHGP, 2017, OSTEOARTHR CARTILAGE, V25, P866, DOI 10.1016/j.joca.2017.01.006
   Atchia I, 2011, ANN RHEUM DIS, V70, P110, DOI 10.1136/ard.2009.127183
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Baraliakos X, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X20906040
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Berenbaum F, 2019, ANN RHEUM DIS, V78, P3, DOI 10.1136/annrheumdis 2018 213864
   Bergink AP, 2019, ARTHRITIS RHEUMATOL, V71, P361, DOI 10.1002/art.40735
   Betancourt MCC, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2845
   Binvignat M, 2023, ARTHRIT CARE RES, V75, P1494, DOI 10.1002/acr.25047
   Boer CG, 2021, ANN RHEUM DIS, V80, P367, DOI 10.1136/annrheumdis 2020 217834
   Bombelli R., 1983, OSTEOARTHRITIS HIP C
   Bonchi F, 2013, KNOWL INF SYST, V35, P1, DOI 10.1007/s10115 012 0522 9
   Borissova AM, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0133 4
   Borissova Anna Maria, 2011, Arch Osteoporos, V6, P189, DOI 10.1007/s11657 011 0064 x
   Brander V, 2019, OSTEOARTHR CARTILAGE, V27, P59, DOI 10.1016/j.joca.2018.08.018
   Castaño Betancourt MC, 2013, ARTHRITIS RHEUM US, V65, P693, DOI 10.1002/art.37792
   Conrozier T, 2007, OSTEOARTHR CARTILAGE, V15, P462, DOI 10.1016/j.joca.2006.09.002
   Conrozier T, 2004, CLIN EXP RHEUMATOL, V22, P403
   Dell'Isola A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191045
   Deveza LA, 2019, CLIN EXP RHEUMATOL, V37, P64
   Deveza LA, 2018, RHEUMATOLOGY, V57, P34, DOI 10.1093/rheumatology/kex417
   Dougados M, 1996, ANN RHEUM DIS, V55, P356, DOI 10.1136/ard.55.6.356
   Eastell R, 2018, EUR J ENDOCRINOL, V178, pR19, DOI 10.1530/EJE 17 0585
   Felson DT, 2010, OSTEOARTHR CARTILAGE, V18, P601, DOI 10.1016/j.joca.2010.01.007
   FLANAGAN J, 1988, ANN ROY COLL SURG, V70, P156
   Garnero P, 2020, OSTEOARTHR CARTILAGE, V28, P468, DOI 10.1016/j.joca.2019.12.012
   Gold GE, 2015, OSTEOARTHR CARTILAGE, V23, P716, DOI 10.1016/j.joca.2015.03.004
   Hannon CP, 2023, J ARTHROPLASTY, V38, P2193, DOI 10.1016/j.arth.2023.09.003
   Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543
   Hennig C, 2007, COMPUT STAT DATA AN, V52, P258, DOI 10.1016/j.csda.2006.11.025
   Henrotin Y, 2022, OSTEOARTHR CARTILAGE, V30, P237, DOI 10.1016/j.joca.2021.11.001
   HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Karsdal MA, 2019, OSTEOARTHR CARTILAGE, V27, P484, DOI 10.1016/j.joca.2018.12.001
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kimes PK, 2017, BIOMETRICS, V73, P811, DOI 10.1111/biom.12647
   Kirilova E, 2022, ORTHOP REV, V14, DOI 10.52965/001c.57622
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Lane NE, 2015, OSTEOARTHR CARTILAGE, V23, P761, DOI 10.1016/j.joca.2015.03.006
   Lanyon P, 2004, ANN RHEUM DIS, V63, P259, DOI 10.1136/ard.2002.003780
   LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P263, DOI 10.1136/ard.52.4.263
   LEDINGHAM J, 1992, ANN RHEUM DIS, V51, P1111, DOI 10.1136/ard.51.10.1111
   Lievense AM, 2002, ARTHRIT RHEUM ARTHR, V47, P556, DOI 10.1002/art.10660
   MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245
   Nielsen F., 2016, Introduction to HPC with MPI for Data Science, P195, DOI [10.1007/978 3 319 21903 5.pdf, DOI 10.1007/978 3 319 21903 5.PDF, 10.1007/978 3 319 21903 5_8, DOI 10.1007/978 3 319 21903 5_8, 10.1007/978 3 319 21903 5]
   Nishii T, 2013, CLIN RHEUMATOL, V32, P1759, DOI 10.1007/s10067 013 2338 8
   Panoutsopoulou K, 2017, ANN RHEUM DIS, V76, P1199, DOI 10.1136/annrheumdis 2016 210373
   PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650 198903001 00018
   Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001
   Plant MJ, 1997, ANN RHEUM DIS, V56, P476, DOI 10.1136/ard.56.8.476
   Qvistgaard E, 2006, OSTEOARTHR CARTILAGE, V14, P163, DOI 10.1016/j.joca.2005.09.007
   Richette P, 2009, ARTHRITIS RHEUM US, V60, P824, DOI 10.1002/art.24301
   Sapundzhiev L., 2023, J. Rheum. Dis. Treat, V9, P100, DOI [10.23937/2469 5726/1510100, DOI 10.23937/2469 5726/1510100]
   Sapundzhiev L., 2021, Rheumatology, V29, P21, DOI [10.35465/29.4.2021.pp53 85, DOI 10.35465/29.4.2021.PP53 85]
   Sapundzhiev L, 2023, LIFE BASEL, V13, DOI 10.3390/life13020421
   Shepherd JA, 2015, J CLIN DENSITOM, V18, P274, DOI 10.1016/j.jocd.2015.06.013
   SOLOMON L, 1982, ANN RHEUM DIS, V41, P118, DOI 10.1136/ard.41.2.118
   Sturgeon CM, 2017, CLIN CHIM ACTA, V467, P42, DOI 10.1016/j.cca.2016.10.016
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis 2018 214827
   Tanaka Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061241
   Teirlinck CH, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1969 9
   Tibshirani R, 2001, J ROY STAT SOC B, V63, P411, DOI 10.1111/1467 9868.00293
   Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905
   van Spil WE, 2010, OSTEOARTHR CARTILAGE, V18, P605, DOI 10.1016/j.joca.2010.01.012
   Van Spil WE, 2019, BIOCHEM PHARMACOL, V165, P41, DOI 10.1016/j.bcp.2019.02.037
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Wright AA, 2009, ARTHRIT RHEUM ARTHR, V61, P925, DOI 10.1002/art.24641
NR 72
TC 1
Z9 1
U1 1
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2075 1729
J9 LIFE BASEL
JI Life Basel
PD MAY
PY 2024
VL 14
IS 5
AR 622
DI 10.3390/life14050622
PG 28
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Microbiology
GA SC7S3
UT WOS:001232330500001
PM 38792642
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, MH
   Kim, HM
   Jeong, HJ
AF Kim, Min Ho
   Kim, Hyung Min
   Jeong, Hyun Ja
TI Estrogen like osteoprotective effects of glycine in in vitro and in vivo
   models of menopause
SO AMINO ACIDS
LA English
DT Article
DE Menopause; Glycine; Ovariectomy; Alkaline phosphatase; Bone mineral
   density; 17 beta Estradiol
ID HORMONE REPLACEMENT THERAPY; OVARIECTOMIZED RATS; GENE EXPRESSION;
   RECEPTOR ALPHA; ER ALPHA; OSTEOPOROSIS; CELLS; DIFFERENTIATION;
   PROLIFERATION; MICE
AB Recently, the placenta mesotherapy has been widely used to treat menopause. Placenta contains amino acids, peptides, minerals, and estrogen. Here, we investigated the estrogen like osteoprotective effects of glycine (a main ingredient of placenta) in in vitro and in vivo models of menopause. We assessed the effect of glycine on MG 63 osteoblast cell line, MCF 7 estrogen dependent cell line, and ovariectomized (OVX) mice. Glycine significantly increased the MG 63 cell proliferation in a dose dependent manner. Activity of alkaline phosphatase (ALP) and phosphorylation of extracellular signal regulated kinase were increased by glycine in MG 63 cells. Glycine also increased the BrdU incorporation and Ki 67 mRNA expression in MCF 7 cells. Glycine induced the up regulation of estrogen receptor beta mRNA expression and estrogen response element luciferase activity in MG 63 and MCF 7 cells. In OVX mice, glycine was administered orally at a daily dose of 10 mg/kg per day for 8 weeks. Glycine resulted in the greatest decrease in weight gain caused by ovariectomy. Meanwhile, vaginal weight reduced by ovariectomy was increased by glycine. Glycine significantly increased the ALP activity in OVX mice. MicroCT analysis showed that glycine significantly enhanced bone mineral density, trabecular number, and connectivity density in OVX mice. Moreover, glycine significantly increased the serum 17 beta estradiol levels reduced by ovariectomy. Glycine has an estrogen like osteoprotective effect in menopause models. Therefore, we suggest that glycine may be useful for the treatment of menopause.
C1 [Kim, Min Ho] Sohae Coll, Dept Comp Aided Mech Engn, Gunsan 573717, Jeonbuk, South Korea.
   [Kim, Hyung Min] Kyung Hee Univ, Dept Pharmacol, Coll Korean Med, 26 Kyungheedae Ro, Seoul 130701, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Dept Food Technol, 20 Hoseo Ro 79Beon Gil, Asan 336795, Chungcheongnam, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Biochip Res Ctr, 20 Hoseo Ro 79Beon Gil, Asan 336795, Chungcheongnam, South Korea.
C3 Kyung Hee University; Hoseo University; Hoseo University
RP Jeong, HJ (通讯作者)，Hoseo Univ, Dept Food Technol, 20 Hoseo Ro 79Beon Gil, Asan 336795, Chungcheongnam, South Korea.; Jeong, HJ (通讯作者)，Hoseo Univ, Biochip Res Ctr, 20 Hoseo Ro 79Beon Gil, Asan 336795, Chungcheongnam, South Korea.
EM hjjeong@hoseo.edu
CR Abdallah HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098559
   Ahn HN, 2014, BIOMOL THER, V22, P347, DOI 10.4062/biomolther.2014.050
   Auro K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5708
   Bakhsh A, 2013, NUTRITION, V29, P667, DOI 10.1016/j.nut.2012.09.005
   Boucetta KQ, 2015, CLIN INTERV AGING, V10, P339, DOI 10.2147/CIA.S71684
   Burger HG, 2007, HUM REPROD UPDATE, V13, P559, DOI 10.1093/humupd/dmm020
   Camporez JPG, 2013, ENDOCRINOLOGY, V154, P1021, DOI 10.1210/en.2012 1989
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Dall'Acqua S, 2009, J ETHNOPHARMACOL, V122, P424, DOI 10.1016/j.jep.2009.02.012
   Doyle BJ, 2007, DRUG FUTURE, V32, P897, DOI 10.1358/dof.2007.032.10.1133260
   Doyle BJ, 2009, MENOPAUSE, V16, P748, DOI 10.1097/gme.0b013e3181a4c76a
   Fini M, 2001, BIOMED PHARMACOTHER, V55, P213, DOI 10.1016/S0753 3322(01)00054 3
   Fu SW, 2014, NUTR RES, V34, P467, DOI 10.1016/j.nutres.2014.05.003
   Camporez JPG, 2011, J PHYSIOL LONDON, V589, P2585, DOI 10.1113/jphysiol.2011.206078
   GRUBER HE, 1984, METABOLISM, V33, P295, DOI 10.1016/0026 0495(84)90187 2
   Guay MP, 2007, PHARMACOEPIDEM DR S, V16, P17, DOI 10.1002/pds.1273
   Hyun H, 2014, KOREAN J PHYSIOL PHA, V18, P347, DOI 10.4196/kjpp.2014.18.4.347
   Ji MY, 2007, BIOSCI BIOTECH BIOCH, V71, P1327, DOI 10.1271/bbb.60217
   Karimian E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067859
   Kim DG, 2012, BONE, V51, P868, DOI 10.1016/j.bone.2012.08.124
   Kim HK, 2014, MOLECULES, V19, P12909, DOI 10.3390/molecules190912909
   Kim MH, 2014, FOOD FUNCT, V5, P1594, DOI 10.1039/c4fo00133h
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Le Donne M, 2011, ARCH GYNECOL OBSTET, V283, P1319, DOI 10.1007/s00404 010 1545 7
   Lovejoy JC, 2008, INT J OBESITY, V32, P949, DOI 10.1038/ijo.2008.25
   Mahady Gail B, 2006, Womens Health (Lond), V2, P773, DOI 10.2217/17455057.2.5.773
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Merenbakh Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008 5472.CAN 13 1197
   Mishra R, 2011, FOOD CHEM TOXICOL, V49, P434, DOI 10.1016/j.fct.2010.11.020
   Moon PD, 2014, CAN J PHYSIOL PHARM, V92, P937, DOI 10.1139/cjpp 2014 0068
   Parazzini F, 2015, MINERVA GINECOL, V67, P1
   김민호, 2014, [CELLMED, 셀메드], V4, P14, DOI 10.5667/tang.2014.0020
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008 1405
   SAUNDERS PTK, 1997, J ENDOCRINOL, V154, P13
   Shimatsu A, 2013, ENDOCR J, V60, P1131
   Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039 128X(98)00054 3
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003 0023
   Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003 1682
   Xu Y, 2014, INT J MOL SCI, V15, P7827, DOI 10.3390/ijms15057827
NR 39
TC 13
Z9 14
U1 3
U2 26
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4 6, PO BOX 89, A 1201 WIEN, AUSTRIA
SN 0939 4451
EI 1438 2199
J9 AMINO ACIDS
JI Amino Acids
PD MAR
PY 2016
VL 48
IS 3
BP 791
EP 800
DI 10.1007/s00726 015 2127 6
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA DE7LJ
UT WOS:000370817900013
PM 26563333
DA 2025 08 17
ER

PT J
AU Khan, MUA
   Abd Razak, SI
   Haider, S
   Mannan, HA
   Hussain, J
   Hasan, A
AF Khan, Muhammad Umar Aslam
   Abd Razak, Saiful Izwan
   Haider, Sajjad
   Mannan, Hafiz Abdul
   Hussain, Javed
   Hasan, Anarwul
TI Sodium alginate f GO composite hydrogels for tissue regeneration and
   antitumor applications
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Antibacterial; Antitumor; Drug release kinetics; Biopolymers; Tissue
   regeneration
ID GRAPHENE BASED MATERIALS; DRUG RELEASE; DEGRADATION; MECHANISMS; OXIDE
AB Biopolymer based composite hydrogels have attracted tremendous attention for tissue regeneration and antitumor applications. Since sodium alginate is a biopolymer, they offer excellent therapeutic options with longterm drug release and low side effects. To prepare multifunctional composite hydrogels with anticancer and tissue regeneration capabilities, sodium alginate (SA) and graphene oxide (GO) were covalently linked and crosslinked with tetraethyl orthosilicate (TEOS) by the solvothermal method. The structural and morphological results show that the hydrogels exhibit the desired functionality and porosity. The swelling of hydrogels in an aqueous and PBS medium was investigated. SGT 4 had the highest swelling in both aqueous and PBS media. Swelling and biodegradation of the hydrogel were inversely related. The drug release of SGT 4 was determined in different pH media (pH 6.4, 7.4, and 8.4) and the kinetics of drug release was determined according to the Higuchi model (R2 = 0.93587). Antibacterial activities were evaluated against severe infectious agents. Uppsala (U87) and osteoblast (MC3T3 E1) cell lines were used to determine the anticancer and biocompatibility of the composite hydrogels, respectively. These results suggest that the composite hydrogels could be used as potential biomaterials for tissue regeneration and antitumor applications.
C1 [Khan, Muhammad Umar Aslam; Hasan, Anarwul] Qatar Univ, Dept Mech & Ind Engn, Doha 2713, Qatar.
   [Khan, Muhammad Umar Aslam; Hasan, Anarwul] Qatar Univ, Biomed Res Ctr, Doha 2713, Qatar.
   [Abd Razak, Saiful Izwan] Univ Teknol Malaysia, BioInspired Device & Tissue Engn Res Grp, Sch Biomed Engn & Hlth Sci, Fac Engn, Skudai 81300, Johor, Malaysia.
   [Abd Razak, Saiful Izwan] Univ Teknol Malaysia, Ctr Adv Composite Mat, Skudai, Johor, Malaysia.
   [Haider, Sajjad] King Saud Univ, Dept Chem Engn, Coll Engn, POB 800, Riyadh 11421, Saudi Arabia.
   [Mannan, Hafiz Abdul] Univ Punjab, Inst Polymer & Text Engn, Quaid E Azam Campus, Lahore 54590, Pakistan.
   [Hussain, Javed] Quaid I Azam Univ, Natl Ctr Phys, Islamabad Campus, Islamabad 44000, Pakistan.
C3 Qatar University; Qatar University; Universiti Teknologi Malaysia;
   Universiti Teknologi Malaysia; King Saud University; University of
   Punjab; National Centre for Physics   Pakistan; Quaid I Azam University
RP Khan, MUA (通讯作者)，Qatar Univ, Biomed Res Ctr, Doha 2713, Qatar.
EM umar007khan@gmail.com
RI ; Razak, Saiful/AAM 6136 2020; Haider, Sajjad/C 2913 2011; Mannan,
   Hafiz/J 9419 2018; Khan, Muhammad Umar Aslam/ABG 5839 2021
OI Aslam Khan, Muhammad Umar/0000 0001 8105 2651; Haider,
   Sajjad/0000 0002 2140 2469; Abdul Mannan, Hafiz/0000 0003 2730 8112;
   Hussain, Javed/0009 0006 6807 4219
FU Qatar National Research Fund (a part of Qatar Foundation)
   [NPRP12S 0310 190276]
FX Acknowledgment This article was made possible by the NPRP12S 0310 190276
   grant funded by Qatar National Research Fund (a part of Qatar
   Foundation) . The statements made here are the sole responsibility of
   the authors.
CR Applegate MB, 2015, P NATL ACAD SCI USA, V112, P12052, DOI 10.1073/pnas.1509405112
   Khan MUA, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12061238
   Azad A.K., INT J BIOL MACROMOL, V185, P861
   Chitra G, 2017, INT J BIOL MACROMOL, V95, P363, DOI 10.1016/j.ijbiomac.2016.11.068
   Dai TJ, 2018, ACS APPL MATER INTER, V10, P15163, DOI 10.1021/acsami.8b02527
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Dashti SR, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/6/E10
   Deng Z., MATER CHEM FRONT, V5, P2092
   Dhandayuthapani B, 2011, INT J POLYM SCI, V2011, DOI 10.1155/2011/290602
   Dong RN, 2021, NANO TODAY, V41, DOI 10.1016/j.nantod.2021.101290
   Fan LH, 2006, CARBOHYD POLYM, V65, P447, DOI 10.1016/j.carbpol.2006.01.031
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Hanif Farina, 2017, Asian Pac J Cancer Prev, V18, P3
   Haque T, 2015, EUR J PHARM SCI, V77, P279, DOI 10.1016/j.ejps.2015.06.013
   Hong Y, 2007, ACTA BIOMATER, V3, P23, DOI 10.1016/j.actbio.2006.06.007
   Hu KS, 2013, ADV MATER, V25, P2301, DOI 10.1002/adma.201300179
   Hussain M.I., 2019, FOOD BIOSCI
   Jaworski S, 2013, B VET I PULAWY, V57, P593, DOI 10.2478/bvip 2013 0101
   Jiglaire CJ, 2014, EXP CELL RES, V321, P99, DOI 10.1016/j.yexcr.2013.12.010
   Khan M.U.A., ACSOMEGA, V6, P4335
   Khan M.U.A., POLYMERS BASEL, V13, P3703
   Khan M.U.A., POLYMERS BASEL, V13, P3124
   Khan MUA, 2021, INT J BIOL MACROMOL, V192, P820, DOI 10.1016/j.ijbiomac.2021.10.033
   Khan MUA, 2021, MOLECULES, V26, DOI 10.3390/molecules26195937
   Khan MUA, 2020, J TISSUE ENG REGEN M, V14, P1488, DOI 10.1002/term.3115
   Khan MUA, 2020, MATERIALS, V13, DOI 10.3390/ma13040971
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Li M., CHEM ENG J, V427
   Liang L, 2000, LANGMUIR, V16, P8016, DOI 10.1021/la0010929
   Liang YQ, 2021, ACS NANO, V15, P7078, DOI 10.1021/acsnano.1c00204
   Mc Bath RA, 2010, POLYM CHEM UK, V1, P860, DOI 10.1039/c0py00074d
   Nazir S, 2021, ARAB J CHEM, V14, DOI 10.1016/j.arabjc.2021.103120
   Ou LL, 2017, INT J NANOMED, V12, P6633, DOI 10.2147/IJN.S140526
   Qu J, 2018, ACTA BIOMATER, V72, P55, DOI 10.1016/j.actbio.2018.03.018
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Sa'adon Shafizah, 2019, Procedia Computer Science, V158, P436, DOI 10.1016/j.procs.2019.09.073
   Santhosh K., 2017, J NANO RES SW, V5, P1
   Selvamani PS, 2021, J ELECTROANAL CHEM, V895, DOI 10.1016/j.jelechem.2021.115401
   Shen H, 2012, THERANOSTICS, V2, P283, DOI 10.7150/thno.3642
   Shin SR, 2016, ADV DRUG DELIVER REV, V105, P255, DOI 10.1016/j.addr.2016.03.007
   Valencia C, 2018, MOLECULES, V23, DOI 10.3390/molecules23102651
   Wang Q, 2010, CARBOHYD POLYM, V82, P842, DOI 10.1016/j.carbpol.2010.06.004
   Zhao Y, 2005, POLYMER, V46, P5368, DOI 10.1016/j.polymer.2005.04.015
NR 43
TC 63
Z9 63
U1 1
U2 75
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAY 31
PY 2022
VL 208
BP 475
EP 485
DI 10.1016/j.ijbiomac.2022.03.091
EA MAR 2022
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 1D1RF
UT WOS:000793584400007
PM 35318081
DA 2025 08 17
ER

PT J
AU Zhou, PY
   Xia, DM
   Wang, Y
   Lv, HD
   Wang, ZQ
   Xing, M
   Zhao, QJ
   Xu, SG
AF Zhou, Panyu
   Xia, Demeng
   Wang, Yang
   Lv, Hongdi
   Wang, Ziqin
   Xing, Malcolm
   Zhao, Qingjie
   Xu, Shuogui
TI Matrine derivate MASM protects murine MC3T3 E1 osteoblastic cells
   against dexamethasone induced apoptosis via the regulation of USP14/p53
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Matrine; dexamethasone; osteoblast; USP14; ubiquitination
ID INHIBITING APOPTOSIS; IN VITRO; P53; MECHANISMS; DEUBIQUITINATION;
   GLUCOCORTICOIDS; PROLIFERATION; INFLAMMATION; EXPRESSION; OSTEOCYTES
AB Matrine derivative MASM (M19) is a quinolizine alkaloid with diverse pharmacological effects including preventing postmenopausal osteoporosis. In the current study, we observed that pretreatment with M19 inhibited cell apoptosis of murine osteoblastic MC3T3 E1 and primary osteoblasts induced by 1 mu M dexamethasone in a dose dependent manner. Our study also showed that pretreatment with M19 significantly prevented the upregulation of p53 that is caused by dexamethasone but had no effect on the p53 mRNA expression levels. Further immunoprecipitation (IP) experiments showed that M19 treatment increases the ubiquitination of p53 in dexamethasone treated MC3T3 E1 cells. The expression of USP14, a deubiquitinating enzyme, increased with dexamethasone and decreased with M19 pretreatment. Co IP experiments demonstrated the interaction between USP14 and p53, and the induced effect of a USP14 inhibitor (IU1) on p53 ubiquitination, which indicated that USP14 is a potential deubiquitinase for p53. Furthermore, pretreatment with IU1 or a p53 inhibitor (PFT alpha) partially blocked dexamethasone induced apoptosis of MC3T3 E1 cells. The overexpression of USP14 or p53 reversed the antiapoptotic effect of M19 in dexamethasone treated MC3T3 E1 cells. In addition, PFT alpha treatment remarkably blocked the effects of USP14 overexpression. In summary, our findings suggest that M19 exerts protective effects on dexamethasone treated MC3T3 E1 cells by regulating USP14/p53.
C1 [Zhou, Panyu; Xia, Demeng; Wang, Yang; Xu, Shuogui] Naval Mil Med Univ, Changhai Hosp, Dept Emergency, 168 Changhai Rd, Shanghai 200433, Peoples R China.
   [Zhou, Panyu; Wang, Yang; Xu, Shuogui] Naval Mil Med Univ, Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Lv, Hongdi] Nine Nine Zero Hosp Peoples Liberat Army, Dept Logist, Zhengzhou, Henan, Peoples R China.
   [Wang, Ziqin] Armed Police Henan Corps Hosp, Dept Nutr, Zhengzhou, Henan, Peoples R China.
   [Xing, Malcolm] Univ Manitoba, Coll Mech Engn, Winnipeg, MB, Canada.
   [Zhao, Qingjie] Naval Mil Med Univ, Sch Pharmcy, Dept Organ Chem, 80 Guohe Rd, Shanghai 200433, Peoples R China.
C3 Naval Medical University; Naval Medical University; University of
   Manitoba; Naval Medical University
RP Xu, SG (通讯作者)，Naval Mil Med Univ, Changhai Hosp, Dept Emergency, 168 Changhai Rd, Shanghai 200433, Peoples R China.; Zhao, QJ (通讯作者)，Naval Mil Med Univ, Sch Pharmcy, Dept Organ Chem, 80 Guohe Rd, Shanghai 200433, Peoples R China.
EM qjzhao@smmu.edu.cn; shuogui126@126.com
RI Xia, Demeng/ADR 6215 2022
OI Xia, Demeng/0000 0002 1476 2052
FU Shanghai Rising Star Program [18QA1405400]; National Natural Science
   Foundation of China [81601910, 81571887, 21502225]; China Postdoctoral
   Science Foundation [2016M592936]; Shanghai Health and Family Planning
   Commission Funds [201540380]; Military Medical Research Foundation from
   the Secondary Military Medical University [2017JS15]
FX This work was supported by Shanghai Rising Star Program [18QA1405400],
   the National Natural Science Foundation of China [81601910, 81571887,
   and 21502225], the China Postdoctoral Science Foundation Grant
   [2016M592936], the Shanghai Health and Family Planning Commission Funds
   [201540380], and the Military Medical Research Foundation from the
   Secondary Military Medical University [2017JS15].
CR Amaral JD, 2010, DISCOV MED, V9, P145
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Cho YR, 2018, MOL ONCOL, V12, P1203, DOI 10.1002/1878 0261.12324
   Civitelli R, 2008, J Endocrinol Invest, V31, P2
   Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002
   Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Hu Mei Jie, 2005, Chin J Dig Dis, V6, P68, DOI 10.1111/j.1443 9573.2005.00201.x
   Huang JL, 2016, CURR TOP MED CHEM, V16, P3365, DOI 10.2174/1568026616666160506131012
   Kan QC, 2013, IMMUNOL RES, V56, P189, DOI 10.1007/s12026 013 8393 z
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kwon SK, 2017, BBA REV CANCER, V1868, P404, DOI 10.1016/j.bbcan.2017.08.001
   Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77
   Li HL, 2010, AM J CHINESE MED, V38, P1115, DOI 10.1142/S0192415X10008512
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737
   Li SB, 2018, EXP THER MED, V16, P643, DOI 10.3892/etm.2018.6199
   Liang CZ, 2012, CANCER CHEMOTH PHARM, V69, P317, DOI 10.1007/s00280 011 1699 4
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu TY, 2010, BIOL PHARM BULL, V33, P1740, DOI 10.1248/bpb.33.1740
   Liu XS, 2006, PLANTA MED, V72, P501, DOI 10.1055/s 2006 931534
   Liu Y, 2017, ACTA PHARMACOL SIN, V38, P120, DOI 10.1038/aps.2016.104
   Liu ZW, 2017, EUR J PHARMACOL, V804, P21, DOI 10.1016/j.ejphar.2017.03.061
   Luo C, 2007, TOXICOLOGY, V229, P245, DOI 10.1016/j.tox.2006.10.020
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Sun DQ, 2016, BIOCHEM BIOPH RES CO, V477, P83, DOI 10.1016/j.bbrc.2016.06.024
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141
   Xu X, 2017, J PHARM BIOMED SCI, V7, P77
   Yang NM, 2015, PHARMACOL REP, V67, P388, DOI 10.1016/j.pharep.2014.10.016
   Yang YJ, 2012, MOLECULES, V17, P10370, DOI 10.3390/molecules170910370
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Yu JB, 2014, MOL MED REP, V10, P3199, DOI 10.3892/mmr.2014.2642
   Zhao P, 2015, INT J MOL MED, V36, P633, DOI 10.3892/ijmm.2015.2260
NR 41
TC 11
Z9 13
U1 0
U2 47
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD DEC 4
PY 2019
VL 47
IS 1
BP 3720
EP 3728
DI 10.1080/21691401.2019.1664563
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA IY0AQ
UT WOS:000486053400001
PM 31523993
OA gold
DA 2025 08 17
ER

PT J
AU Charette, JR
   Earp, SE
   Bell, BA
   Ackert Bicknell, CL
   Godfrey, DA
   Rao, S
   Anand Apte, B
   Nishina, PM
   Peachey, NS
AF Charette, Jeremy R.
   Earp, Sarah E.
   Bell, Brent A.
   Ackert Bicknell, Cheryl L.
   Godfrey, Dana A.
   Rao, Sujata
   Anand Apte, Bela
   Nishina, Patsy M.
   Peachey, Neal S.
TI A mutagenesis derived Lrp5 mouse mutant with abnormal retinal
   vasculature and low bone mineral density
SO MOLECULAR VISION
LA English
DT Article
ID FAMILIAL EXUDATIVE VITREORETINOPATHY; RECEPTOR RELATED PROTEIN 5;
   MUTATIONS; MICE; MODELS; GENE; MASS; VASCULARIZATION; FRIZZLED 4;
   RESOLUTION
AB Purpose: Familial exudative vitreoretinopathy (FEVR) is caused by mutations in the genes encoding low density lipoprotein receptor related protein (LRP5) or its interacting partners, namely frizzled class receptor 4 (FZD4) and norrin cystine knot growth factor (NDP). Mouse models for Lrp5, Fzd4, and Ndp have proven to be important for understanding the retinal pathophysiology underlying FEVR and systemic abnormalities related to defective Wnt signaling. Here, we report a new mouse mutant, tvrm111B, which was identified by electroretinogram (ERG) screening of mice generated in the Jackson Laboratory Translational Vision Research Models (TVRM) mutagenesis program.
   Methods: ERGs were used to examine outer retinal physiology. The retinal vasculature was examined by in vivo retinal imaging, as well as by histology and immunohistochemistry. The tvrm111B locus was identified by genetic mapping of mice generated in a cross to DBA/2J, and subsequent sequencing analysis. Gene expression was examined by real time PCR of retinal RNA. Bone mineral density (BMD) was examined by peripheral dual energy X ray absorptiometry.
   Results: The tvrm111B allele is inherited as an autosomal recessive trait. Genetic mapping of the decreased ERG b wave phenotype of tvrm111B mice localized the mutation to a region on chromosome 19 that included Lrp5. Sequencing of Lrp5 identified the insertion of a cytosine (c.4724_4725insC), which is predicted to cause a frameshift that disrupts the last three of five conserved PPPSPxS motifs in the cytoplasmic domain of LRP5, culminating in a premature termination. In addition to a reduced ERG b  wave, Lrp5(tvrm111B) homozygotes have low BMD and abnormal features of the retinal vasculature that have been reported previously in Lrp5 mutant mice, including persistent hyaloid vessels, leakage on fluorescein angiography, and an absence of the deep retinal capillary bed.
   Conclusions: The phenotype of the Lrp5(tvrm111B) mutant includes abnormalities of the retinal vasculature and of BMD. This model may be a useful resource to further our understanding of the biological role of LRP5 and to evaluate experimental therapies for FEVR or other conditions associated with LRP5 dysfunction.
C1 [Charette, Jeremy R.; Ackert Bicknell, Cheryl L.; Nishina, Patsy M.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
   [Earp, Sarah E.; Rao, Sujata; Anand Apte, Bela; Peachey, Neal S.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA.
   [Earp, Sarah E.; Bell, Brent A.; Rao, Sujata; Anand Apte, Bela; Peachey, Neal S.] Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Ackert Bicknell, Cheryl L.; Godfrey, Dana A.] Univ Rochester, Dept Orthopaed, Ctr Musculoskeletal Res, Rochester, NY USA.
   [Peachey, Neal S.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
C3 Jackson Laboratory; Cleveland Clinic Foundation; University System of
   Ohio; Case Western Reserve University; Cleveland Clinic Foundation;
   University of Rochester; University System of Ohio; Case Western Reserve
   University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Louis Stokes Cleveland Veterans Affairs Medical
   Center
RP Peachey, NS (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM peachen@ccf.org
RI Ackert Bicknell, Cheryl/AAC 6833 2019; Peachey, Neal/G 5533 2010
OI Peachey, Neal/0000 0002 4419 7226; Ackert Bicknell,
   Cheryl/0000 0003 4253 4775
FU USA National Institutes of Health [R01EY016501, R01EY11996, P30CA34196,
   R01EY016490, R01EY020861, R01EY026181, R01EY027077]; Knights Templar Eye
   Foundation [KTEF1401SR]; Research to Prevent Blindness [RBP1503SR]; USA
   Veterans Administration Medical Research Service; Foundation Fighting
   Blindness Center Grant; Research to Prevent Blindness; Wolf Family
   Foundation; Llura and Gordon Gund Foundation
FX This research was supported by grants from the USA National Institutes
   of Health (R01EY016501 and R01EY11996 to PMN; P30CA34196 The Jackson
   Laboratory Cancer Center Core Grant; R01EY016490, R01EY020861 and
   R01EY026181 to BA A and R01EY027077 to SR), Knights Templar Eye
   Foundation (KTEF1401SR) and Research to Prevent Blindness (RBP1503SR),
   the USA Veterans Administration Medical Research Service, a Foundation
   Fighting Blindness Center Grant to the Cole Eye Institute, Cleveland
   Clinic, an unrestricted award from Research to Prevent Blindness to the
   Department of Ophthalmology, Cleveland Clinic Lerner College of
   Medicine, The Wolf Family Foundation, and the Llura and Gordon Gund
   Foundation.
CR Ackert Bicknell CL, 2009, ENDOCRINOLOGY, V150, P1330, DOI 10.1210/en.2008 0936
   Bell BA, 2015, EXP EYE RES, V135, P192, DOI 10.1016/j.exer.2015.04.009
   Bell BA, 2014, EXP EYE RES, V127, P280, DOI 10.1016/j.exer.2014.01.001
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Charette JR, 2016, ADV EXP MED BIOL, V854, P177, DOI 10.1007/978 3 319 17121 0_24
   Chen J, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756 3305 5 279
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Haeseleer F, 2004, NAT NEUROSCI, V7, P1079, DOI 10.1038/nn1320
   Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149
   Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812
   Hodges E, 2009, NAT PROTOC, V4, P960, DOI 10.1038/nprot.2009.68
   Jablonski MM, 2005, MOL VIS, V11, P569
   Jiao XD, 2004, AM J HUM GENET, V75, P878, DOI 10.1086/425080
   Justice MJ, 2000, MAMM GENOME, V11, P484, DOI 10.1007/s003350010094
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Levasseur R, 2005, JOINT BONE SPINE, V72, P207, DOI 10.1016/j.jbspin.2004.10.008
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05 0174
   NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0
   Nordgård O, 2006, ANAL BIOCHEM, V356, P182, DOI 10.1016/j.ab.2006.06.020
   Paques M, 2006, VISION RES, V46, P1336, DOI 10.1016/j.visres.2005.09.037
   Pardue MT, 2014, DOC OPHTHALMOL, V128, P77, DOI 10.1007/s10633 013 9424 8
   Peachey NS, 2012, J NEUROPHYSIOL, V108, P2442, DOI 10.1152/jn.00137.2012
   Pinto LH, 2004, VISION RES, V44, P3335, DOI 10.1016/j.visres.2004.07.025
   Rao S, 2007, DEVELOPMENT, V134, P4449, DOI 10.1242/dev.012187
   Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450
   TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253
   TAYLOR BA, 1994, GENOMICS, V21, P626, DOI 10.1006/geno.1994.1323
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Wang T, 2015, P NATL ACAD SCI USA, V112, pE440, DOI 10.1073/pnas.1423216112
   Won J, 2012, ADV EXP MED BIOL, V723, P391, DOI 10.1007/978 1 4614 0631 0_50
   Won JY, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/391384
   Xia CH, 2008, HUM MOL GENET, V17, P1605, DOI 10.1093/hmg/ddn047
   Xia CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011676
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092 8674(04)00216 8
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
NR 37
TC 10
Z9 11
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090 0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 18
PY 2017
VL 23
BP 140
EP 148
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA EQ4FV
UT WOS:000398031600003
PM 28356706
DA 2025 08 17
ER

PT J
AU Ishikawa, J
   Takahashi, N
   Matsumoto, T
   Yoshioka, Y
   Yamamoto, N
   Nishikawa, M
   Hibi, H
   Ishigro, N
   Ueda, M
   Furukawa, K
   Yamamoto, A
AF Ishikawa, Jun
   Takahashi, Nobunori
   Matsumoto, Takuya
   Yoshioka, Yutaka
   Yamamoto, Noriyuki
   Nishikawa, Masaya
   Hibi, Hideharu
   Ishigro, Naoki
   Ueda, Minoru
   Furukawa, Koichi
   Yamamoto, Akihito
TI Factors secreted from dental pulp stem cells show multifaceted benefits
   for treating experimental rheumatoid arthritis
SO BONE
LA English
DT Article
DE Dental pulp stem cells; Conditioned medium; Macrophages; Osteoclasts;
   Rheumatoid arthritis; Inflammation
ID COLLAGEN INDUCED ARTHRITIS; RAT SPINAL CORD; FUNCTIONAL RECOVERY;
   INJURY; OSTEOCLASTOGENESIS; MACROPHAGES; ACTIVATION; PHENOTYPE;
   RECEPTOR; THERAPY
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial hyperplasia and chronic inflammation, which lead to the progressive destruction of cartilage and bone in the joints. Numerous studies have reported that administrations of various types of MSCs improve arthritis symptoms in animal models, by paracrine mechanisms. However, the therapeutic effects of the secreted factors alone, without the cell graft, have been uncertain. Here, we show that a single intravenous administration of serum free conditioned medium (CM) from human deciduous dental pulp stem cells (SHED CM) into anti collagen type II antibody induced arthritis (CAIA), a mouse model of rheumatoid arthritis (RA), markedly improved the arthritis symptoms and joint destruction. The therapeutic efficacy of SHED CM was associated with an induction of anti inflammatory M2 macrophages in the CAIA joints and the abrogation of RANKL expression. SHED CM specifically depleted of an M2 macrophage inducer, the secreted ectodomain of sialic acid binding Ig like lectin 9 (ED Siglec 9), exhibited a reduced ability to induce M2 related gene expression and attenuate CAIA. SHED CM also inhibited the RANKL induced osteoclastogenesis in vitro. Collectively, our findings suggest that SHED CM provides multifaceted therapeutic effects for treating CAIA, including the ED Siglec 9 dependent induction of M2 macrophage polarization and inhibition of osteoclastogenesis. Thus, SHED CM may represent a novel anti inflammatory and reparative therapy for RA. (c) 2015 Elsevier Inc. All rights reserved.
C1 [Ishikawa, Jun; Yamamoto, Noriyuki; Nishikawa, Masaya; Hibi, Hideharu; Ueda, Minoru; Yamamoto, Akihito] Dept Oral & Maxillofacial Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
   [Takahashi, Nobunori; Matsumoto, Takuya; Yoshioka, Yutaka; Ishigro, Naoki; Yamamoto, Akihito] 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Furukawa, Koichi] Nagoya Univ, Grad Sch Med, Biochem 2, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Yamamoto, A (通讯作者)，65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan.
EM akihito@med.nagoya u.ac.jp
RI Takahashi, Nobunori/I 7437 2014; Matsumoto, Takuya/I 3835 2014; Hibi,
   Hideharu/E 4443 2015
OI Hibi, Hideharu/0000 0003 0248 7476
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [22390372]; Grants in Aid for Scientific Research [15K15080, 22390372,
   25293408] Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research on
   Priority Areas from the Ministry of Education, Culture, Sports, Science,
   and Technology of Japan (22390372).
CR Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Brancato SK, 2011, AM J PATHOL, V178, P19, DOI 10.1016/j.ajpath.2010.08.003
   Chen MG, 2013, ARTHRITIS RHEUM US, V65, P1181, DOI 10.1002/art.37894
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   de Almeida FM, 2011, J NEUROTRAUM, V28, P1939, DOI 10.1089/neu.2010.1317
   Djouad F, 2009, NAT REV RHEUMATOL, V5, P392, DOI 10.1038/nrrheum.2009.104
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gandia C, 2008, STEM CELLS, V26, P638, DOI 10.1634/stemcells.2007 0484
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Inoue T, 2013, TISSUE ENG PT A, V19, P24, DOI [10.1089/ten.tea.2011.0385, 10.1089/ten.TEA.2011.0385]
   Joosten L., 2008, ARTHRITIS RHEUM, V58, P22
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Lin H, 2012, ARTHRITIS RHEUM US, V64, P2878, DOI 10.1002/art.34523
   Liu YY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3187
   Matsubara K, 2015, J NEUROSCI, V35, P2452, DOI 10.1523/JNEUROSCI.4088 14.2015
   McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Okunishi K, 2007, J IMMUNOL, V179, P5504, DOI 10.4049/jimmunol.179.8.5504
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Sakai K, 2012, J CLIN INVEST, V122, P80, DOI 10.1172/JCI59251
   Sarkar S, 2013, ARTHRITIS RHEUM US, V65, P960, DOI 10.1002/art.37849
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Secundino I., 2015, J MOL MED BERL
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Stuhlmeier KM, 2006, WIEN MED WOCHENSCHR, V156, P563, DOI 10.1007/s10354 006 0351 0
   Taghipour Z, 2012, STEM CELLS DEV, V21, P1794, DOI 10.1089/scd.2011.0408
   Takahashi T, 2013, MOL MED, V19, P183, DOI 10.2119/molmed.2012.00309
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Tyndall A, 2014, NAT REV RHEUMATOL, V10, P117, DOI 10.1038/nrrheum.2013.166
   Wakayama H, 2015, CYTOTHERAPY, V17, P1119, DOI 10.1016/j.jcyt.2015.04.009
   Watson SL, 2010, BRIT J OPHTHALMOL, V94, P1067, DOI 10.1136/bjo.2009.165837
   Yamagata M, 2013, STROKE, V44, P551, DOI 10.1161/STROKEAHA.112.676759
   Yamamoto A, 2014, NEUROSCI RES, V78, P16, DOI 10.1016/j.neures.2013.10.010
   Yamaza T, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt5
   Zhou B, 2011, CLIN IMMUNOL, V141, P328, DOI 10.1016/j.clim.2011.08.014
NR 41
TC 72
Z9 79
U1 0
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2016
VL 83
BP 210
EP 219
DI 10.1016/j.bone.2015.11.012
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DB5RJ
UT WOS:000368571000026
PM 26603475
DA 2025 08 17
ER

PT J
AU Yang, L
   Liu, ZL
   Chen, C
   Cong, XF
   Li, Z
   Zhao, SS
   Ren, M
AF Yang, Lei
   Liu, Ziling
   Chen, Chen
   Cong, Xiaofeng
   Li, Zhi
   Zhao, Shasha
   Ren, Meng
TI Low dose radiation modulates human mesenchymal stem cell proliferation
   through regulating CDK and Rb
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Low dose radiation; bone marrow mesenchymal stem cells; CDK; Rb
ID STROMAL CELLS; ACTIVATION; DIFFERENTIATION; RESPONSES; MAPK/ERK; TRIAL;
   BETA
AB Low dose radiation (LDR) has been known to stimulate cell proliferation. The effect of LDR on human bone marrow mesenchymal stem cells (BMSCs), however, remains to be determined. The current study, therefore, aimed to investigate the effect of LDR on human BMSC proliferation and its mechanisms. To accomplish this, human BMSCs were isolated from ribs and cultured with or without exposition to LDR (75 mGy) for 24 h. Cell proliferation was assessed by MTT assay, the cytokines secreted by the BMSCs were quantified by ELISA, and the proteins associated with cell proliferation and cell cycle were evaluated by immunoblot analysis. BMSCs isolated from human ribs were capable of differentiating into osteoblasts and adipocytes. LDR stimulated human BMSC proliferation (0.580 +/  0.106 vs 0.419 +/  0.026 on day 4, P < 0.05; 0.794 +/  0.025 vs 0.689 +/  0.047 on day 7, P < 0.05) and increased S phase proportion. LDR significantly enhanced the production of SCF, GM CSF, and IL 11. Moreover, BMSCs modulated T cell proliferation, and LDR further augmented the modulatory effect of BMSCs on T cell proliferation. Cell cycle associated proteins, such as Rb, CDK1, and CDC25B, appeared to mediate the stimulatory effect of LDR on BMSC proliferation. The findings of the current study indicate that physical stimulants, such as LDR, could be used for the large scale expansion of human BMSCs, and thus may be used for MSC cellular therapy in clinic.
C1 [Yang, Lei; Liu, Ziling; Chen, Chen; Cong, Xiaofeng; Li, Zhi; Zhao, Shasha; Ren, Meng] Jilin Univ, Hosp 1, Canc Ctr, 71 Xinmin St, Changchun 130021, Peoples R China.
C3 Jilin University
RP Yang, L (通讯作者)，Jilin Univ, Hosp 1, Canc Ctr, 71 Xinmin St, Changchun 130021, Peoples R China.
EM yangleihlm@163.com
RI Luo, Yang/C 2406 2011; Li, Zh/GLR 2952 2022
OI Yang, Lei/0009 0007 7489 8908; 
CR Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Cao MD, 2011, INT J RADIAT BIOL, V87, P71, DOI 10.3109/09553002.2010.518208
   Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469
   Griffin MD, 2013, IMMUNOL CELL BIOL, V91, P40, DOI 10.1038/icb.2012.67
   Ina Y, 2005, RADIAT RES, V163, P153, DOI 10.1667/RR3289
   Kim CS, 2007, J RADIAT RES, V48, P407, DOI 10.1269/jrr.07032
   Kornasio R, 2009, BBA MOL CELL RES, V1793, P755, DOI 10.1016/j.bbamcr.2008.12.017
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Li W, 2004, EXP HEMATOL, V32, P1088, DOI 10.1016/j.exphem.2004.07.015
   Liang XY, 2016, DOSE RESPONSE, V14, DOI 10.1177/1559325815622174
   Liang XY, 2011, J RADIAT RES, V52, P380, DOI 10.1269/jrr.10121
   Liu GW, 2006, RADIAT RES, V165, P379, DOI 10.1667/RR3528.1
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Mirzaie Joniani H, 2002, CANCER, V94, P1210, DOI 10.1002/cncr.10287
   Nemeth K, 2010, P NATL ACAD SCI USA, V107, P5652, DOI 10.1073/pnas.0910720107
   OLIVIERI G, 1984, SCIENCE, V223, P594, DOI 10.1126/science.6695170
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Reissfelder C, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 419
   Sensebé L, 2009, TRANSPLANTATION, V87, pS49, DOI 10.1097/TP.0b013e3181a28635
   Shimura T, 2016, CELL CYCLE, V15, P1410, DOI 10.1080/15384101.2016.1170271
   Shu C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112890
   Weiss DJ, 2013, CHEST, V143, P1590, DOI 10.1378/chest.12 2094
   Ye F, 2009, NUTR CANCER, V61, P530, DOI 10.1080/01635580902803719
   Zhang LY, 2010, INT J RADIAT BIOL, V86, P329, DOI 10.3109/09553000903564018
NR 24
TC 11
Z9 16
U1 0
U2 7
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2017
VL 9
IS 4
BP 1914
EP 1921
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA ET7OZ
UT WOS:000400487800032
PM 28469796
DA 2025 08 17
ER

PT J
AU Li, XH
   Ha, CT
   Fu, DD
   Xiao, M
AF Li, Xiang Hong
   Ha, Cam T.
   Fu, Dadin
   Xiao, Mang
TI Micro RNA30c Negatively Regulates REDD1 Expression in Human
   Hematopoietic and Osteoblast Cells after Gamma Irradiation
SO PLOS ONE
LA English
DT Article
ID MIR 30 FAMILY; RADIATION THERAPY; KAPPA B; MICRORNAS; PROGENITORS; GENE;
   RNA; DIFFERENTIATION; TARGET; MODEL
AB We recently demonstrated that a novel cell stress response gene REDD1 protects human fetal osteoblast cell line (hFOB) cells from c radiation induced premature senescence. Here we show that levels of endogenous REDD1 are very low in human hematopoietic progenitor CD34+ cells regardless of radiation, but highly expressed in differentiated hematopoietic cells (14 day cultured CD34+ cells) in response to radiation, which might be associated with radiation tolerance of the latter cells. To further understand the mechanisms of radiation induced damage in different cells, microRNA (miRNA) arrays were performed using purified miRNAs from CD34+ and hFOB cells before and post irradiation and real time reverse transcription (RT) PCR was used to validate the expression profiles of miRNAs in the radiation damaged cells. The results indicate that gamma radiation downregulated 16 miRNAs in CD34+ cells and 14 in hFOB cells. Radiation induced upregulation was observed for 15 miRNAs in CD34+ cells and 18 miRNAs in hFOB cells. The profiles of radiation induced miRNA expression were completely different in CD34+ vs. hFOB cells. Radiation up regulated miRNA (miR) 30b, miR 30c and miR 30d in CD34+ cells, whereas it inhibited miR 30c expression in hFOB cells. Since miR 30 has potential target sites located in the 3'untranslated region (UTR) of the REDD1 gene and radiation regulated miR 30c expression in both CD34+ and hFOB cells, we further explored the effects of miR 30c on REDD1 expression using miR 30c inhibitor and precursor (pre miR 30c). The results show that pre miR 30c transfection suppressed REDD1 expression in 14 day cultured CD34+ cells and hFOB cells and resulted in hFOB cell death. In contrast, inhibition of miR 30c expression significantly enhanced clonogenicity in CD34+ cells. Our data suggest that CD34+ and hFOB cells have different miRNA expression patterns after irradiation and miR 30c plays a key role in radiation induced cell damage which might be through regulation of REDD1 expression.
C1 [Li, Xiang Hong; Ha, Cam T.; Fu, Dadin; Xiao, Mang] Uniformed Serv Univ Hlth Sci, Radiat Countermeasures Program, Armed Forces Radiobiol Res Inst, Bethesda, MD 20814 USA.
C3 United States Department of Defense; Uniformed Services University of
   the Health Sciences   USA
RP Xiao, M (通讯作者)，Uniformed Serv Univ Hlth Sci, Radiat Countermeasures Program, Armed Forces Radiobiol Res Inst, Bethesda, MD 20814 USA.
EM mang.xiao@usuhs.edu
FU Armed Forces Radiobiology Research Institute intramural grant [RAB2EI];
   American Congressional Grant [G1B2EP]
FX This study was supported by Armed Forces Radiobiology Research Institute
   intramural grant (RAB2EI) to MX and American Congressional Grant
   (G1B2EP) to MX. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Bentzen SM, 2006, NAT REV CANCER, V6, P702, DOI 10.1038/nrc1950
   Boominathan L, 2010, CANCER METAST REV, V29, P613, DOI 10.1007/s10555 010 9257 9
   Chaudhry MA, 2010, INT J RADIAT BIOL, V86, P569, DOI 10.3109/09553001003734568
   Dickey JS, 2011, RADIAT ENVIRON BIOPH, V50, P491, DOI 10.1007/s00411 011 0386 5
   Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138
   Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097 2765(02)00706 2
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042
   Joglekar MV, 2009, ISLETS, V1, P137, DOI 10.4161/isl.1.2.9578
   Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027
   Li Jun cai, 2010, Xibei Zhiwu Xuebao, V30, P30
   Li XH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036604, 10.1371/journal.pone.0039690]
   Li XH, 2010, HAEMATOL HEMATOL J, V95, P1996, DOI 10.3324/haematol.2010.026492
   Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108
   Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005
   Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600 0609.2008.01111.x
   Özcan S, 2009, ISLETS, V1, P283, DOI 10.4161/isl.1.3.9968
   Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378 1119(01)00674 6
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   Saito T, 2010, NEW BIOTECHNOL, V27, P243, DOI 10.1016/j.nbt.2010.02.016
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283 2293.2002
   Wu TT, 2012, J BIOL CHEM, V287, P7503, DOI 10.1074/jbc.M111.292722
   Xiao M, 2007, MOL PHARMACOL, V72, P370, DOI 10.1124/mol.107.035394
   Xiao Mang, 2009, Curr Mol Pharmacol, V2, P122
   Xiao M, 2009, EXP HEMATOL, V37, P52, DOI 10.1016/j.exphem.2008.09.001
   Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006 0295
   Zaragosi LE, 2011, GENOME BIOL, V12, DOI 10.1186/gb 2011 12 7 r64
   Zhang JC, 2012, BIOCHEM BIOPH RES CO, V417, P1100, DOI 10.1016/j.bbrc.2011.12.121
NR 29
TC 15
Z9 18
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2012
VL 7
IS 11
AR e48700
DI 10.1371/journal.pone.0048700
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 048TK
UT WOS:000311935800102
PM 23144934
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Guan, J
   Yuan, ZC
   He, JL
   Wu, ZJ
   Liu, B
   Lin, X
   Mo, LG
   Mo, H
AF Guan, Jian
   Yuan, Zhenchao
   He, Juliang
   Wu, Zhenjie
   Liu, Bin
   Lin, Xiang
   Mo, Ligen
   Mo, Hao
TI Overexpression of caveolin 1 reduces Taxol resistance in human
   osteosarcoma cells by attenuating PI3K Akt JNK dependent autophagy
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE caveolin 1; Taxol resistance; osteosarcoma cell; Janus kinase; autophagy
ID CANCER; EXPRESSION; PATHWAY; BIOLOGY
AB Caveolin 1 (CAV 1), which is an oncoprotein and a tumor suppressor, is highly expressed in normal osteoblasts. Although researchers have investigated its role in human osteosarcoma, the mechanism of caveolin 1 action in osteosarcoma remains unknown. In the present study, Saos 2 and U 2 OS cells were cultured with a continuous induction protocol of gradually increasing Taxol concentration for 6 months to establish drug resistant cell lines. CAV 1 expression levels in osteosarcoma cells were detected via western blotting and quantitative polymerase chain reaction. CAV 1 knockdown was achieved using a short hair pin RNA lentivirus vector, and cell viability was analyzed by MTT assay. The effect of caveolin 1 on autophagy was investigated, and the downregulation of caveolin 1 and increased autophagy was identified in Taxol resistant osteosarcoma cells. In addition, the results of the present study demonstrated that downregulation of caveolin 1 promotes autophagy and induces osteosarcoma cell resistance to Taxol. Notably, overexpression of CAV 1 resensitized drug resistant cells to Taxol via declined autophagy. In conclusion, CAV 1 was demonstrated to be downregulated in Taxol resistant osteosarcoma cells, and overexpression of CAV 1 in human osteosarcoma cells suppressed Taxol resistance by attenuating PI3K Akt JNK dependent autophagy. The present findings suggest that further investigation into CAV 1's role in Taxol resistance is warranted. In the future, detection of CAV 1 may be used as an indicator to evaluate the treatment and prognosis of patients with osteosarcoma.
C1 [Guan, Jian; Yuan, Zhenchao; He, Juliang; Wu, Zhenjie; Liu, Bin; Lin, Xiang; Mo, Ligen; Mo, Hao] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Bone & Soft Tissue Neurosurg, 71 He Di Rd, Nanning 530021, Guangxi, Peoples R China.
C3 Guangxi Medical University
RP Mo, H (通讯作者)，Guangxi Med Univ, Affiliated Tumor Hosp, Dept Bone & Soft Tissue Neurosurg, 71 He Di Rd, Nanning 530021, Guangxi, Peoples R China.
EM mohaogxzlyy@sina.com
RI Yuan, zhen/HLW 3443 2023
FU Science Computing and Intelligent Information processing of GuangXi
   Higher Education Key Laboratory [GXSCIIP201502]
FX This work was supported by Science Computing and Intelligent Information
   processing of GuangXi Higher Education Key Laboratory (grant no.
   GXSCIIP201502).
CR Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Bao XH, 2010, INT J MOL MED, V25, P493, DOI 10.3892/ijmm_00000369
   Chen SN, 2016, TUMOR BIOL, V37, P2321, DOI 10.1007/s13277 015 3800 9
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721
   Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Giuliano S, 2015, AUTOPHAGY, V11, P1891, DOI 10.1080/15548627.2015.1085742
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li YT, 2011, ONCOL REP, V25, P303, DOI 10.3892/or.2010.1111
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Pu J, 2015, DEV CELL, V33, P176, DOI 10.1016/j.devcel.2015.02.011
   Shi Y, 2015, AUTOPHAGY, V11, P769, DOI 10.1080/15548627.2015.1034411
   Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273
   Shiroto T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087871
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sun NK, 2015, ONCOTARGET, V6, P27065, DOI 10.18632/oncotarget.4824
   Wang L, 2015, ONCOL REP, V34, P2969, DOI 10.3892/or.2015.4278
   Wang ZY, 2014, CARCINOGENESIS, V35, P2346, DOI 10.1093/carcin/bgu155
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Williams TM, 2005, AM J PHYSIOL CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004
   Wu KN, 2011, CELL CYCLE, V10, P4250, DOI 10.4161/cc.10.24.18551
   Zhang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6775
   Zhao Z, 2015, WORLD J GASTROENTERO, V21, P1140, DOI 10.3748/wjg.v21.i4.1140
NR 27
TC 17
Z9 19
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD NOV
PY 2016
VL 12
IS 5
BP 2815
EP 2822
DI 10.3892/etm.2016.3713
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA ED4ME
UT WOS:000388822000003
PM 27882079
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Omoigui, S
AF Omoigui, Sota
TI The biochemical origin of pain   Proposing a new law of pain: The origin
   of all pain is inflammation and the inflammatory response. Part 1 of 3  
   A unifying law of pain
SO MEDICAL HYPOTHESES
LA English
DT Article
ID TUMOR NECROSIS FACTOR; SPINAL CORD INJURY; INTERLEUKIN 6 PRODUCTION;
   RHEUMATOID ARTHRITIS; SOLUBLE INTERLEUKIN 6; NEUROPATHIC PAIN;
   GENE EXPRESSION; BONE RESORPTION; LUMBAR SPINE; OSTEOBLASTS
AB We are proposing a unifying theory or taw of pain, which states: the origin of all pain is inflammation and the inflammatory response. The biochemical mediators of inflammation include cytokines, neuropeptides, growth. factors and neurotransmitters. Irrespective of the type of pain whether it is acute or chronic pain, peripheral or central pain, nociceptive or neuropathic pain, the underlying origin is inflammation and the inflammatory response. Activation of pain receptors, transmission and modulation of pain signals, neuro plasticity and central sensitization are all. one continuum of inflammation and the inflammatory response. Irrespective of the characteristic of the pain, whether it is sharp, dull, aching, burning, stabbing, numbing or tingling, all pain arise from inflammation and the inflammatory response. We are proposing a re classification and treatment of pain syndromes based upon their inflammatory profile. Treatment of pain syndromes should be based on these principles: 1. Determination of the inflammatory profile of the pain syndrome; 2. Inhibition or suppression of production of the appropriate inflammatory mediators, e.g. with inflammatory mediator blockers or surgical intervention where appropriate; 3. Inhibition or suppression of neuronal afferent and efferent (motor) transmission, e.g. with anti seizure drugs or local anesthetic blocks; 4. Modulation of neuronal transmission, e.g. with opioid medication.
   At the L.A. Pain Clinic, we have successfully treated a variety of pain syndromes by utilizing these principles. This theory of the biochemical origin of pain is compatible with, inclusive of, and unifies existing theories and knowledge of the mechanism of pain including the gate control theory, and theories of pre emptive analgesia, windup and central sensitization. (c) 2006 Elsevier Ltd. All rights reserved.
C1 LA Pain Clin, Div Inflammat & Pain Res, Hawthorne, CA 90250 USA.
RP Omoigui, S (通讯作者)，LA Pain Clin, Div Inflammat & Pain Res, 4019 W Rosecrans Ave, Hawthorne, CA 90250 USA.
EM medicinechief@aol.com
FU NIAMS NIH HHS [F32 AR008429] Funding Source: Medline
CR AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065 2776(08)60532 5
   [Anonymous], 1979, Pain, V6, P249
   [Anonymous], ANESTHESIA BIOL FDN
   AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065 2776(08)60535 0
   Arruda JL, 2000, BRAIN RES, V879, P216, DOI 10.1016/S0006 8993(00)02807 9
   Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851
   Black JA, 1997, NEUROREPORT, V8, P2331, DOI 10.1097/00001756 199707070 00046
   BLACK KS, 1991, J BONE MINER RES  S1, V6, pS271
   BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623 199072030 00013
   BOIVIE J, 1996, PAIN 1996 UPDATED RE, P23
   Boos N, 2000, SPINE, V25, P1484, DOI 10.1097/00007632 200006150 00006
   Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1 2.90
   DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990
   Dickenson AH, 2002, BRIT J ANAESTH, V88, P755, DOI 10.1093/bja/88.6.755
   DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193
   DICKENSON AH, 1997, ANESTHESIA BIOL FDN, P611
   DRAY A, 1995, BRIT J ANAESTH, V75, P125, DOI 10.1093/bja/75.2.125
   Dubner R., 1994, Textbook of Pain, V3, P225
   Everill B, 1999, J NEUROPHYSIOL, V82, P700, DOI 10.1152/jn.1999.82.2.700
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   Goldbach Mansky R, 2000, ARTHRITIS RES, V2, P145, DOI 10.1186/ar79
   Gravallese EM, 2000, ARTHRITIS RHEUM US, V43, P2143, DOI 10.1002/1529 0131(200010)43:10<2143::AID ANR1>3.3.CO;2 J
   GREENFIELD EM, 1995, J CLIN INVEST, V96, P1238, DOI 10.1172/JCI118157
   HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304 3940(89)90600 9
   He C, 1996, CANCER LETT, V106, P185, DOI 10.1016/0304 3835(96)04318 2
   Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313
   HOUSSIAU FA, 1988, ARTHRITIS RHEUM US, V31, P784, DOI 10.1002/art.1780310614
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   *JC LIEB HIST PAIN, ONL EXH PAIN SUFF HI
   JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201
   JENSEN TS, 1996, PAIN UPDATED REV, P7
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Kameda Hideto, 2003, Nihon Rinsho, V61, P292
   Kayama S, 1996, SPINE, V21, P2539, DOI 10.1097/00007632 199611150 00002
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Kotani N, 2000, NEW ENGL J MED, V343, P1514, DOI 10.1056/NEJM200011233432102
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Laughlin TM, 2000, PAIN, V84, P159, DOI 10.1016/S0304 3959(99)00195 5
   Livingstone WK., 1943, PAIN MECH
   LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006 291x(89)90851 6
   McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959 4388(93)90062 4
   MELZACK R, 1993, CAN J EXP PSYCHOL, V47, P615, DOI 10.1037/h0078871
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Merskey HM., 1994, CLASSIFICATION CHRON, V2nd, P211
   Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301 0082(98)00048 3
   MIYAURA C, 1995, J BONE MINER RES, V10, P1365
   Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259
   Myers RR, 1999, Cytokines and pain, P133
   OHSAKI Y, 1992, ENDOCRINOLOGY, V131, P2229, DOI 10.1210/en.131.5.2229
   Olgart L, 1997, Lakartidningen, V94, P4461
   OLMARKER K, 1993, SPINE, V18, P1425
   OLMARKER K, 1998, PAIN, V78, P9
   OMOIGUI S, 2002, BIOCH ORIGIN PAIN NE
   Oyelese AA, 1997, J NEUROPHYSIOL, V78, P31, DOI 10.1152/jn.1997.78.1.31
   PASSERI G, 1991, J BONE MINER RES  S1, V6, pS263
   Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604
   Ramer MS, 1999, EUR J NEUROSCI, V11, P837, DOI 10.1046/j.1460 9568.1999.00491.x
   RANNEY D, 1996, ONT INT PAIN C WAT
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Sakaue G, 2001, NEUROREPORT, V12, P2079, DOI 10.1097/00001756 200107200 00008
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   SAMAT TA, 2001, NATURE, V410, P427
   Sehgal PB, 1995, ANN NY ACAD SCI, V762, P1
   Sherrington C., 1961, INTEGRATIVE ACTION N
   Suzuki R, 2000, NEUROREPORT, V11, pR17, DOI 10.1097/00001756 200008210 00001
   TABIBZADEH S, 1995, HUM REPROD, V10, P2793, DOI 10.1093/oxfordjournals.humrep.a135793
   Takaoka Y, 1999, J BIOCHEM TOKYO, V126, P553, DOI 10.1093/oxfordjournals.jbchem.a022485
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   VANLENT PLEM, 1995, J RHEUMATOL, V22, P2250
   WANAGAT J, 1996, FRONT BIOSCI, V1, pD340
   Waxman S.G., 1999, Pain Supplement, V6, P133
   ZIMMERMANN M, 1991, CLIN J PAIN, V7, pS8
NR 72
TC 60
Z9 68
U1 0
U2 15
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2007
VL 69
IS 1
BP 70
EP 82
DI 10.1016/j.mehy.2006.11.028
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 178PP
UT WOS:000247232900017
PM 17240081
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, H
   Zhang, Y
   Sun, Y
   Zhang, P
   Chu, F
   Guo, Z
   Zhang, H
   Zhong, D
AF Xu, H.
   Zhang, Y.
   Sun, Y.
   Zhang, P.
   Chu, F.
   Guo, Z.
   Zhang, H.
   Zhong, D.
TI Metabolism and excretion of imrecoxib in rat
SO XENOBIOTICA
LA English
DT Article
DE imrecoxib; metabolism
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE 2 INHIBITOR; COX 2
   INHIBITORS; OSTEOARTHRITIS; NSAIDS
AB The metabolism and excretion of imrecoxib, a novel and moderately selective cyclooxygenase II inhibitor, were investigated in rat. The structures of metabolites were identified by mass spectrometry (MSn) and nuclear magnetic resonance. Metabolic profiles of imrecoxib in urine, bile and faeces were obtained by HPLC and LC/MSn, and cumulative excretion was determined by LC/MSn. Imrecoxib was extensively metabolized in rat after intravenous administration, with less than 2% of the dose excreted as parent drug in either urine or faeces. The major metabolic pathway was that the 4'  methyl group of imrecoxib was first oxidized to the 4' hydroxymethyl metabolite (M4), followed by additional oxidation to 4' carboxylic acid metabolite (M2). The dihydroxylated metabolite, 4' hydroxymethyl 5 hydroxyl imrecoxib (M3), was further oxidized to 4' hydroxymethyl 5 carbonyl metabolite (M5), and glucuronide conjugates of M2 4 were formed. After intravenous (5mg kg( 1)) administration, the majority of the dose was recovered in the faeces. The dose was primarily excreted as the carboxylic acid metabolite in addition to the 4' hydroxymethyl metabolite. The carboxylic acid metabolite was mainly excreted in faeces, while the 4' hydroxymethyl metabolite was mainly excreted in urine.
C1 Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   Shenyang Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, Shenyang 110016, Peoples R China.
   Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China.
   Peking Union Med Coll, Beijing 100050, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS;
   Shenyang Pharmaceutical University; Chinese Academy of Medical Sciences
     Peking Union Medical College; Institute of Materia Medica   CAMS;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College
RP Zhong, D (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, 646 Songtao Rd, Shanghai 201203, Peoples R China.
EM zhongdf@china.com
RI Zhong, Dafang/C 1304 2014
CR [Anonymous], NATURE
   Bai AP, 2001, CHINESE CHEM LETT, V12, P775
   Chen XH, 2004, ACTA PHARMACOL SIN, V25, P927
   Davies NM, 2004, J PHARM PHARM SCI, V7, P332
   Dogné JM, 2005, J MED CHEM, V48, P2251, DOI 10.1021/jm0402059
   Donnelly MT, 1997, ALIMENT PHARM THER, V11, P227, DOI 10.1046/j.1365 2036.1997.154330000.x
   Jouzeau JY, 1997, DRUGS, V53, P563, DOI 10.2165/00003495 199753040 00003
   Kassahun K, 2001, DRUG METAB DISPOS, V29, P813
   Lane NE, 1997, J RHEUMATOL, V24, P20
   Mangold JB, 2004, DRUG METAB DISPOS, V32, P566, DOI 10.1124/dmd.32.5.566
   MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228
   NEEDLEMAN P, 1997, J RHEUMATOL, V24, P9
   Parente L, 2003, BIOCHEM PHARMACOL, V65, P153, DOI 10.1016/S0006 2952(02)01422 3
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P308
   Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp 75 9 1088
   Shen F, 2002, ACTA PHARMACOL SIN, V23, P762
   Simon LS, 1998, ARTHRITIS RHEUM US, V41, P1591, DOI 10.1002/1529 0131(199809)41:9<1591::AID ART9>3.0.CO;2 J
   SMITH JB, 1971, NATURE NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0
   Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065 2776(08)60430 7
   Thomas LG, 2005, LANCET, V365, P1538, DOI 10.1016/S0140 6736(05)66448 3
   Yuan JJ, 2002, DRUG METAB DISPOS, V30, P1013, DOI 10.1124/dmd.30.9.1013
NR 21
TC 11
Z9 14
U1 2
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0049 8254
J9 XENOBIOTICA
JI Xenobiotica
PD MAY
PY 2006
VL 36
IS 5
BP 441
EP 455
DI 10.1080/00498250600595524
PG 15
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 060XG
UT WOS:000238834600006
PM 16854781
DA 2025 08 17
ER

PT J
AU Lee, AM
   Gabe, SM
   Nightingale, JM
   Burke, M
AF Lee, A. M.
   Gabe, S. M.
   Nightingale, J. M.
   Burke, M.
TI Intestinal failure and home parenteral nutrition: Implications for oral
   health and dental care
SO CLINICAL NUTRITION
LA English
DT Article
DE Intestinal failure; Home parenteral nutrition; Oral health; Dental care
ID INFLAMMATORY BOWEL DISEASE; ADAPTIVE HYPERPHAGIA; CROHNS DISEASE;
   BONE DISEASE; DOUBLE BLIND; DRY MOUTH; PROPHYLAXIS; MANAGEMENT; LIFE;
   COMPLICATIONS
AB Background & aims: Background disease processes, medication and therapies in people with intestinal failure receiving home parenteral nutrition may affect their oral health. To inform oral health advice for this group a study of their oral health status was carried out.
   Methods: Fifty two HPN outpatients recruited from specialised nutrition clinics at a national referral centre listed their medical and medication history, perceived oral health and dental treatment experience in a structured interview and underwent an oral health examination. Findings were compared with 2009 UK Adult Dental Health Survey data, using one sample t tests.
   Results: Oral health of the HPN cohort was poorer than the UK norm; patients had more decay (p <0.001), fewer teeth (p <0.001) and fewer sound and untreated teeth (p = 0.023) despite similar dental attendance. Hyperphagia, sip feeds, oral rehydration fluids and polypharmacy (in 96%) are identifiable risk factors for caries, xerostomia (in 81%) and thus oral infection risk (including oral candidiasis). Patients were experiencing current problems (60%) and psychological discomfort (56%) from poor oral health. The patient pathway does not include oral health information.
   Conclusion: Dental teams should be aware of the management and prevention of HPN related complications with bisphosphonates, anticoagulant therapy, and parenteral antibiotic prophylaxis. HPN patients may benefit from increased awareness of their oral health risk factors. (C) 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
C1 [Lee, A. M.] North West London Hosp NHS Trust, SDO NHS Hillingdon, Dept Oral & Maxillofacial Surg, Harrow HA1 3UJ, Middx, England.
   [Gabe, S. M.] St Marks Hosp, Lennard Jones Intestinal Failure Unit, London, England.
   [Nightingale, J. M.] St Marks Hosp, Lennard Jones Intestinal Failure Unit, Imperial Coll, London, England.
   [Burke, M.] Guys & St Thomas NHS Fdn Trust, London, England.
C3 Imperial College London; Imperial College London; Guy's & St Thomas' NHS
   Foundation Trust
RP Lee, AM (通讯作者)，North West London Hosp NHS Trust, SDO NHS Hillingdon, Dept Oral & Maxillofacial Surg, Watford Rd, Harrow HA1 3UJ, Middx, England.
EM alisonlee5@nhs.net
RI Gabe, Simon/V 2186 2017
CR Alibhai SMH, 2005, CAN MED ASSOC J, V172, P773, DOI 10.1503/cmaj.1031527
   [Anonymous], INTESTINAL FAILURE
   [Anonymous], 2009, ADULT DENT HLTH SURV
   [Anonymous], 2009, BRIT NATL FORMULARY
   Autio Gold J, 2008, OPER DENT, V33, P710, DOI 10.2341/08 3
   Baca P, 2009, J DENT, V37, P679, DOI 10.1016/j.jdent.2009.05.001
   BARNETT ML, 2006, J AM DENT ASSOC S, V137, P16
   Boulétreau PH, 2006, AM J CLIN NUTR, V83, P1429, DOI 10.1093/ajcn/83.6.1429
   Buchman AL, 2000, CLIN NUTR, V19, P217, DOI 10.1054/clnu.1999.0083
   BUDTZJORGENSEN E, 1990, ACTA ODONTOL SCAND, V48, P61, DOI 10.3109/00016359009012735
   Cassolato Sandra F, 2003, Gerodontology, V20, P64, DOI 10.1111/j.1741 2358.2003.00064.x
   Cohen SM, 2000, BRIT DENT J, V189, P385, DOI 10.1038/sj.bdj.4800777a
   Cohen Solal M, 2003, J BONE MINER RES, V18, P1989, DOI 10.1359/jbmr.2003.18.11.1989
   COSNES J, 1990, GASTROENTEROLOGY, V99, P1814, DOI 10.1016/0016 5085(90)90492 J
   Crenn P, 1997, GASTROENTEROLOGY, V112, pA356
   Culkin A, 2008, EUR J CLIN NUTR, V62, P575, DOI 10.1038/sj.ejcn.1602754
   Culkin A., 2007, COMMUNICATION
   Daniels T E, 2000, J Calif Dent Assoc, V28, P933
   Davis D M, 2001, Eur J Prosthodont Restor Dent, V9, P53
   Department of Health, 1994, OR HLTH STRAT ENGL
   DiPietro L, 2001, J GERONTOL A BIOL, V56, P13, DOI 10.1093/gerona/56.suppl_2.13
   Dougall A, 2008, BRIT DENT J, V204, P605, DOI 10.1038/sj.bdj.2008.457
   Dumitrescu Alexandrina L, 2008, J Contemp Dent Pract, V9, P38
   Ellepola ANB, 2001, ORAL DIS, V7, P211, DOI 10.1034/j.1601 0825.2001.70402.x
   Ellervall E, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472 6947 8 57
   Femiano F, 2002, J EUR ACAD DERMATOL, V16, P353, DOI 10.1046/j.1468 3083.2002.00461.x
   Fiske J, 1998, BRIT DENT J, V184, P90, DOI 10.1038/sj.bdj.4809551
   FLEMMIG TF, 1991, J CLIN PERIODONTOL, V18, P690, DOI 10.1111/j.1600 051X.1991.tb00111.x
   Friedlander AH, 2002, ORAL SURG ORAL MED O, V94, P404, DOI 10.1067/moe.2002.122434
   Goddard M, 2009, HEALTH ECON POLICY L, V4, P195, DOI 10.1017/S174413310900485X
   Goodlad R., 2001, INTESTINAL ADAPTATIO, P243
   Greenspan D, 1996, Oncology (Williston Park), V10, P7
   Grössner Schreiber B, 2006, J CLIN PERIODONTOL, V33, P478, DOI 10.1111/j.1600 051X.2006.00942.x
   Guchelaar HJ, 1997, SUPPORT CARE CANCER, V5, P281, DOI 10.1007/s005200050075
   HATLEBAKK JG, 1995, SCAND J GASTROENTERO, V30, P1053, DOI 10.3109/00365529509101606
   Hollister M C, 1993, J Dent Educ, V57, P901
   Home Parenteral Nutrition, 2002, TRAIN IND
   Howard L, 2003, GASTROENTEROLOGY, V124, P1651, DOI 10.1016/S0016 5085(03)00326 3
   Huisman de Waal G, 2007, CLIN NUTR, V26, P275, DOI 10.1016/j.clnu.2006.10.002
   Ireton Jones C, 2005, NUTRITION, V21, P156, DOI 10.1016/j.nut.2004.04.024
   Irving MH, 2001, INTESTINAL FAILURE, P469
   Jedrychowski JR, 1979, J ORAL MED, V35, P18
   JOHNSON DA, 1993, CARIOLOGY 90S, P367
   Jones B. J. M., 2001, Artificial nutrition support in clinical practice, P485
   Kalantzis A, 2005, ORAL SURG ORAL MED O, V100, P52, DOI 10.1016/j.tripleo.2004.08.020
   Kalmar J R, 1994, Periodontol 2000, V6, P101, DOI 10.1111/j.1600 0757.1994.tb00030.x
   Kaviani MJ, 2003, ALIMENT PHARM THER, V17, P211, DOI 10.1046/j.1365 2036.2003.01416.x
   Klerk CPW, 2003, ARCH INTERN MED, V163, P1913, DOI 10.1001/archinte.163.16.1913
   Kozuch PL, 2005, ALIMENT PHARM THER, V21, P201, DOI 10.1111/j.1365 2036.2005.02269.x
   Lal S, 2006, ALIMENT PHARM THER, V24, P19, DOI 10.1111/j.1365 2036.2006.02941.x
   LAMSTER IB, 1982, J PERIODONTOL, V53, P231, DOI 10.1902/jop.1982.53.4.231
   Leao JC, 2004, ALIMENT PHARM THER, V20, P1019, DOI 10.1111/j.1365 2036.2004.02205.x
   Lee AM, 2012, BRIT DENT J, V212, P86, DOI 10.1038/sj.bdj.2012.71
   Llena Puy Carmen, 2006, Med Oral Patol Oral Cir Bucal, V11, pE449
   Luoma H, 1992, Proc Finn Dent Soc, V88, P147
   MACHUCA G, 2007, J DISABILITY ORAL HL, V8, P73
   Mc Grath C, 2001, BRIT DENT J, V190, P262, DOI 10.1038/sj.bdj.4800944a
   MESSING B, 1995, EUR J GASTROEN HEPAT, V7, P507
   MESSING B, 1991, GASTROENTEROLOGY, V100, P1502, DOI 10.1016/0016 5085(91)90645 2
   Migliorati CA, 2007, CLIN MICROBIOL INFEC, V13, P11, DOI 10.1111/j.1469 0691.2007.01799.x
   Moore Paul A, 2008, Compend Contin Educ Dent, V29, P50
   Muzyka Brian C, 2005, Dent Clin North Am, V49, P49, DOI 10.1016/j.cden.2004.07.007
   *NAT I CLIN EXC, 2006, CLIN GUID NAT I CLIN, V32
   Nightingale JMD, 2003, BEST PRACT RES CL GA, V17, P907, DOI 10.1016/S1521 6918(03)00108 2
   NIGHTINGALE JMD, 1995, J ROY SOC MED, V88, P258
   NIGHTINGALE JMD, 1993, THESIS U LONDON
   PENNINGTON CR, 2001, INTESTINAL FAILURE, P497
   Phoa K H, 2003, Ned Tijdschr Tandheelkd, V110, P457
   Pironi L, 2002, CLIN NUTR, V21, P289, DOI 10.1054/clnu.2002.0548
   Porter SR, 2004, ORAL SURG ORAL MED O, V97, P28, DOI 10.1016/j.tripleo.2003.07.010
   Richards DM, 2001, INTESTINAL FAILURE, P449
   Richmond S, 2007, COMMUNITY DENT ORAL, V35, P89, DOI 10.1111/j.1600 0528.2007.00296.x
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Scheper HJ, 2002, INT DENT J, V52, P163, DOI 10.1111/j.1875 595X.2002.tb00622.x
   Scully C, 2006, ORAL DIS, V12, P229, DOI 10.1111/j.1601 0825.2006.01258.x
   Scully C, 2003, ORAL DIS, V9, P165, DOI 10.1034/j.1601 0825.2003.03967.x
   SEYMOUR RA, 1992, J CLIN PERIODONTOL, V19, P1, DOI 10.1111/j.1600 051X.1992.tb01140.x
   Ship JA, 1997, J GERONTOL A BIOL, V52, pM310
   Siegel MA, 1999, ORAL SURG ORAL MED O, V87, P12, DOI 10.1016/S1079 2104(99)70287 8
   Siepler J, 2007, NUTR CLIN PRACT, V22, P340, DOI 10.1177/0115426507022003340
   Smith T., 2010, ARTIFICIAL NUTR SUPP
   Stein RB, 2000, DRUG SAFETY, V23, P429, DOI 10.2165/00002018 200023050 00006
   SUNDH B, 1982, ACTA CHIR SCAND, V148, P531
   TEARE JP, 1995, SCAND J GASTROENTERO, V30, P216, DOI 10.3109/00365529509093266
   Tiller S, 2001, Community Dent Health, V18, P167
   Tolle S L, 2008, Int J Dent Hyg, V6, P77, DOI 10.1111/j.1601 5037.2008.00292.x
   Von Wowern N, 1997, UGESKR LAGER, V159, P4982
   WOOD RE, 1988, ORAL SURG ORAL MED O, V65, P172, DOI 10.1016/0030 4220(88)90161 2
   WRIGHT KB, 1991, J PERIODONTOL, V62, P272, DOI 10.1902/jop.1991.62.4.272
   Wylie Ian, 2003, Gerodontology, V20, P60
   Xu KT, 2002, HEALTH SERV RES, V37, P1509, DOI 10.1111/1475 6773.10524
NR 91
TC 7
Z9 7
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0261 5614
EI 1532 1983
J9 CLIN NUTR
JI Clin. Nutr.
PD FEB
PY 2013
VL 32
IS 1
BP 77
EP 82
DI 10.1016/j.clnu.2012.05.018
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 094GS
UT WOS:000315251600011
PM 22727546
OA Bronze
DA 2025 08 17
ER

PT J
AU Pilato, CA
   Stadiotti, I
   Maione, AS
   Saverio, V
   Catto, V
   Tundo, F
   Dello Russo, A
   Tondo, C
   Pompilio, G
   Casella, M
   Sommariva, E
AF Pilato, Chiara Assunta
   Stadiotti, Ilaria
   Maione, Angela Serena
   Saverio, Valentina
   Catto, Valentina
   Tundo, Fabrizio
   Dello Russo, Antonio
   Tondo, Claudio
   Pompilio, Giulio
   Casella, Michela
   Sommariva, Elena
TI Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from
   Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Developmental Biology; Issue 132; Endomyocardial biopsy; Arrhythmogenic
   Cardiomyopathy; Cardiac Mesenchymal Stromal Cells; Adipogenesis; ARVC;
   isolation; characterization; differentiation
ID STEM CELLS; BONE MARROW; BIOPSY; HEART; FIBROBLASTS; STATEMENT;
   DIAGNOSIS; CRITERIA; THERAPY; FAILURE
AB A normal adult heart is composed of several different cell types, among which cardiac mesenchymal stromal cells represent an abundant population. The isolation of these cells offers the possibility of studying their involvement in cardiac diseases, and, in addition, provides a useful primary cell model to investigate biological mechanisms.
   Here, the method for the isolation of C MSC from arrhythmogenic cardiomyopathy patients' bioptic samples is described. The endomyocardial biopsy sampling is guided in the right ventricular areas adjacent to the scar visualized by electro anatomical mapping. The digestion of the biopsies in collagenase and their plating on a plastic dish in culture medium to allow C MSC growth is described. The isolated cells can be expanded in culture for several passages. To confirm their mesenchymal phenotype, the description of immuno phenotypical characterization is provided. C MSC are able to differentiate into several cell types like adipocytes, chondrocytes, and osteoblasts: in the context of ACM, characterized by adipocyte deposits in patients' hearts, the protocols for the adipogenic differentiation of C MSC and the characterization of lipid droplet accumulation are described.
C1 [Pilato, Chiara Assunta; Stadiotti, Ilaria; Maione, Angela Serena; Saverio, Valentina; Pompilio, Giulio; Sommariva, Elena] Ctr Cardiol Monzino IRCCS, Vasc Biol & Regenerat Med Unit, Milan, Italy.
   [Pilato, Chiara Assunta; Tondo, Claudio; Pompilio, Giulio] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Catto, Valentina; Tundo, Fabrizio; Dello Russo, Antonio; Tondo, Claudio; Casella, Michela] Ctr Cardiol Monzino IRCCS, Heart Rhythm Ctr, Milan, Italy.
C3 IRCCS Centro Cardiologico Monzino; University of Milan; IRCCS Centro
   Cardiologico Monzino
RP Sommariva, E (通讯作者)，Ctr Cardiol Monzino IRCCS, Vasc Biol & Regenerat Med Unit, Milan, Italy.
EM esommariva@ccfm.it
RI Dello Russo, Antonio/AAB 5030 2022; Sommariva, Elena/K 4078 2016; Tondo,
   Claudio/S 4671 2019; saverio, valentina/KDM 8352 2024; Casella,
   Michela/F 6737 2018; Catto, Valentina/AAA 8186 2019; Saverio,
   Valentina/KDM 8352 2024; Stadiotti, Ilaria/F 4017 2018; Casella,
   Michela/Y 9354 2019; Pompilio, Giulio/J 6701 2014; Maione,
   Angela/H 3123 2018
OI Casella, Michela/0000 0002 5322 1742; Saverio,
   Valentina/0000 0002 1770 2661; Pilato, Chiara
   Assunta/0000 0002 5632 2653; Tondo, Claudio/0000 0002 8500 8313;
   Stadiotti, Ilaria/0000 0002 5963 8338; Pompilio,
   Giulio/0000 0003 2581 5735; 
FU Italian Ministry of Health, Ricerca Corrente
FX This work was funded by Italian Ministry of Health, Ricerca Corrente to
   Centro Cardiologico Monzino IRCCS.
CR Bassetti B, 2016, CIRC RES, V119, P988, DOI 10.1161/CIRCRESAHA.116.309619
   Beltrami AR, 2007, BLOOD, V110, P3438, DOI 10.1182/blood 2006 11 055566
   Brooke G, 2007, SEMIN CELL DEV BIOL, V18, P846, DOI 10.1016/j.semcdb.2007.09.012
   Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Casella M, 2017, EXPERT REV MED DEVIC, V14, P609, DOI 10.1080/17434440.2017.1351875
   Casella M, 2015, CIRC ARRHYTHMIA ELEC, V8, P625, DOI 10.1161/CIRCEP.114.002216
   Cencioni C, 2017, PHARMACOL THERAPEUT, V171, P43, DOI 10.1016/j.pharmthera.2016.10.005
   Cooper LT, 2007, EUR HEART J, V28, P3076, DOI 10.1093/eurheartj/ehm456
   Czapla J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158745
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Detert S, 2017, J TISSUE ENG REGEN M
   Di Maggio S., 2017, BIOCH BIOPHYS ACTA
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Doppler SA, 2017, J THORAC DIS, V9, pS36, DOI 10.21037/jtd.2017.03.122
   From AM, 2011, MAYO CLIN PROC, V86, P1095, DOI 10.4065/mcp.2011.0296
   Gambini E, 2011, CARDIOVASC RES, V89, P362, DOI 10.1093/cvr/cvq292
   Germani A, 2015, J MOL MED, V93, P735, DOI 10.1007/s00109 015 1290 2
   Gourdie RG, 2016, NAT REV DRUG DISCOV, V15, P620, DOI 10.1038/nrd.2016.89
   Ikebe C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/951512
   Jugdutt BI, 2003, CIRCULATION, V108, P1395, DOI 10.1161/01.CIR.0000085658.98621.49
   Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301 472X(03)00110 3
   Leone O, 2012, CARDIOVASC PATHOL, V21, P245, DOI 10.1016/j.carpath.2011.10.001
   Marcus FI, 2010, CIRCULATION, V121, P1533, DOI 10.1161/CIRCULATIONAHA.108.840827
   Miteva K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028513
   Monsanto MM, 2017, CIRC RES, V121, P113, DOI 10.1161/CIRCRESAHA.116.310494
   Moore Morris T, 2015, J MOL MED, V93, P823, DOI 10.1007/s00109 015 1314 y
   Nigro P, 2017, PHARM RES
   Pieroni M, 2009, J AM COLL CARDIOL, V53, P681, DOI 10.1016/j.jacc.2008.11.017
   Rossini A, 2011, CARDIOVASC RES, V89, P650, DOI 10.1093/cvr/cvq290
   Sommariva E, 2016, EUR HEART J, V37, P1835, DOI 10.1093/eurheartj/ehv579
   Sommariva E, 2017, DIS MODEL MECH, V10, P823, DOI 10.1242/dmm.029363
   Souders CA, 2009, CIRC RES, V105, P1164, DOI 10.1161/CIRCRESAHA.109.209809
NR 33
TC 29
Z9 29
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD FEB
PY 2018
IS 132
AR e57263
DI 10.3791/57263
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FX9UK
UT WOS:000426453400092
PM 29553539
OA Bronze, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU An, JH
   Kim, SU
   Park, MK
   Choi, JW
AF An, Jeung Hee
   Kim, Seung U.
   Park, Mi Kyung
   Choi, Jeong Woo
TI Electrochemical Detection of Human Mesenchymal Stem Cell Differentiation
   on Fabricated Gold Nano Dot Cell Chips
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Human Mesenchymal Stem Cells; Differentiation; Cell Chip;
   Electrochemical Signal
ID SINGLE CELL; MICROSCOPY
AB Human mesenchymal stem cells (MSCs) have the capacity for self renewal and maintain pluripotency, which is defined by their ability to differentiate into cells such as osteoblasts, neurons, and glial cells. In this study, we report a method for defining the status of human MSCs based on electrochemical detection systems. Gold nano dot structures were fabricated using a nanoporous alumina mask, and the structural formations were confirmed by scanning electron microscopy (SEM). Human MSCs were allowed to attach to RGD (Arg Gly Asp) peptide nanopatterned surfaces, and electrochemical tools were applied to the MSCs attached on the chip surface. The cultured MSCs were shown to differentiate into neural cell types, as indicated by immunocytochemical staining for tyrosine hydroxylase and beta tubulin III. Following treatment with basic fibroblast growth factor (bFGF) for 14 days, most of the B10 cells exhibited bipolar or multipolar morphology with branched processes, and the proportion of B10 cells expressing neuronal cell markers considerably increased. Electrophysiological recordings from MSCs treated with bFGF for 5 14 days were examined with cyclic voltammetry, and the electrochemical signals were shown to increase during differentiation from MSCs to neuronal cells. This human MSC cell line is a useful tool for studying organogenesis, specifically neurogenesis, and in addition, the cell line provides a valuable source of cells for cell therapy. The electrochemical measurement system proposed here could be utilized in electrical cell chips for numerous applications, including cell differentiation, disease diagnosis, drug detection, and on site monitoring.
C1 [An, Jeung Hee] Konkuk Univ, Div Food Biosci, Chungju 380701, South Korea.
   [Kim, Seung U.] Chung Ang Univ, Coll Med, Med Res Inst, Seoul 156756, South Korea.
   [Kim, Seung U.] Univ British Columbia, UBC Hosp, Dept Med, Div Neurol, Vancouver, BC V6T 2B5, Canada.
   [Park, Mi Kyung] Kyungpook Natl Univ, Sch Food Sci & Biotechnol, Taegu 702701, South Korea.
   [Choi, Jeong Woo] Sogang Univ, Dept Biomol & Chem Engn, Seoul 121742, South Korea.
C3 Konkuk University; Chung Ang University; Chung Ang University Hospital;
   University of British Columbia; Kyungpook National University (KNU);
   Sogang University
RP Choi, JW (通讯作者)，Sogang Univ, Dept Biomol & Chem Engn, Seoul 121742, South Korea.
RI ; Kim, Sun/L 4239 2013; Park, Mi Kyung/J 9643 2017; An,
   Jeung/AAR 3327 2021
OI An, Jeung Hee/0000 0002 2431 144X; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [2014R1A1A2058817]; National
   Research Foundation of Korea (NRF)   Korea government (MSIP)
   [2014R1A2A1A10051725]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2014R1A1A2058817) and by the National Research Foundation
   of Korea (NRF) grant funded by the Korea government (MSIP) (No.
   2014R1A2A1A10051725).
CR BARD AJ, 1989, ANAL CHEM, V61, P132, DOI 10.1021/ac00177a011
   Bard AJ, 2006, BIOSENS BIOELECTRON, V22, P461, DOI 10.1016/j.bios.2006.04.028
   Cui HF, 2006, ANAL CHEM, V78, P6347, DOI 10.1021/ac060018d
   Dwyer DS, 1999, J CELL PHYSIOL, V178, P93, DOI 10.1002/(SICI)1097 4652(199901)178:1<93::AID JCP12>3.0.CO;2 U
   El Said WA, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/45/455501
   El Said WA, 2009, BIOSENS BIOELECTRON, V24, P1259, DOI 10.1016/j.bios.2008.07.037
   Fasching RJ, 2006, MICROELECTRON ENG, V83, P1638, DOI 10.1016/j.mee.2006.01.262
   Jung M, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/23/235304
   Kafi MA, 2010, BIOSENS BIOELECTRON, V26, P1359, DOI 10.1016/j.bios.2010.07.049
   Kasai S, 2006, ANAL CHIM ACTA, V566, P55, DOI 10.1016/j.aca.2006.02.061
   Kaya T, 2003, BIOSENS BIOELECTRON, V18, P1379, DOI 10.1016/S0956 5663(03)00083 6
   Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760
   Lu HW, 1999, ANAL CHEM, V71, P2821, DOI 10.1021/ac9811773
   MATSUNAGA T, 1984, ANAL CHEM, V56, P798, DOI 10.1021/ac00268a047
   Mei XY, 2003, J CRYST GROWTH, V251, P253, DOI 10.1016/S0022 0248(02)02421 1
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nagai A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001272
   Yea CH, 2007, BIOCHIP J, V1, P219
   Zhang XL, 2006, ANAL CHIM ACTA, V558, P110, DOI 10.1016/j.aca.2005.11.032
   Zhu LY, 2007, J AM CHEM SOC, V129, P3524, DOI 10.1021/ja068452k
NR 20
TC 7
Z9 7
U1 2
U2 22
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1533 4880
EI 1533 4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD OCT
PY 2015
VL 15
IS 10
SI SI
BP 7929
EP 7934
DI 10.1166/jnn.2015.11225
PG 6
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA CX2VJ
UT WOS:000365554600098
PM 26726442
DA 2025 08 17
ER

PT J
AU Hall, SF
   Edmonds, SW
   Lou, YY
   Cram, P
   Roblin, DW
   Saag, KG
   Wright, NC
   Jones, MP
   Wolinsky, FD
AF Hall, Sylvie F.
   Edmonds, Stephanie W.
   Lou, Yiyue
   Cram, Peter
   Roblin, Douglas W.
   Saag, Kenneth G.
   Wright, Nicole C.
   Jones, Michael P.
   Wolinsky, Fredric D.
TI Patient reported reasons for nonadherence to recommended osteoporosis
   pharmacotherapy
SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
LA English
DT Article
ID RANDOMIZED CONTROLLED TRIAL; MEDICATION ADHERENCE; PHARMACEUTICAL CARE;
   ORAL BISPHOSPHONATES; FRACTURE RATES; THERAPY; WOMEN; BELIEFS;
   INTERVENTIONS; PHARMACISTS
AB Objectives: As many as one half of patients recommended for osteoporosis pharmacotherapy do not take their medications. To identify intervention targets, we examined patient characteristics associated with nonadherence to recommended pharmacotherapy and their reasons for nonadherence.
   Methods: Data come from the Patient Activation after DXA Result Notification (PAADRN) study, a randomized controlled trial of 7749 patients aged 50 years or older presenting for dual energy X ray absorptiometry (DXA) at 3 health centers in the United States. We focused on the 790 patients who reported receiving a recommendation for new pharmacotherapy at baseline. Using Pearson chi squared tests for categorical variables, 2 sample t tests for continuous variables, and multivariable multinomial logistic regression, we compared those who reported starting the recommended medication (adherers) with temporary nonadherers and nonadherers on demographics, health habits, DXA impression, 10 year probability of fracture using the assessment tool, and osteoporosis knowledge, and we examined their stated reasons for nonadherence.
   Results: Mean age was 66.8 years (SD = 8.9); 87.2% were women, and 84.2% were white. One fourth of patients (24.8%) reported that they did not start their recommended pharmacotherapy. In the unadjusted analyses, the only factor significantly associated with nonadherence was osteoporosis knowledge, with those having better knowledge being less likely to take their medications (P < 0.05). The most common reasons for nonadherence were fear of adverse effects (53.3%), a dislike of taking medicine (25.3%), and the belief that the medication would not help their condition (16.7%).
   Conclusion: One in 4 patients recommended for osteoporosis pharmacotherapy declined treatment because they feared potential adverse effects, did not like taking medicine, or believed that the medication would not help their condition. Improved patient counseling on the potential adverse effects of osteoporosis treatment and the risk benefit ratio for these medications may increase adherence. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Hall, Sylvie F.] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA.
   [Edmonds, Stephanie W.] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA.
   [Lou, Yiyue; Jones, Michael P.; Wolinsky, Fredric D.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA.
   [Cram, Peter] Univ Toronto, Div Internal Med, Dept Med, Toronto, ON, Canada.
   [Cram, Peter] Mt Sinai UHN Hosp, Toronto, ON, Canada.
   [Roblin, Douglas W.] Georgia State Univ, Coll Publ Hlth, Atlanta, GA 30303 USA.
   [Saag, Kenneth G.] Univ Alabama Birmingham, Coll Med, Birmingham, AL USA.
   [Wright, Nicole C.] Univ Alabama Birmingham, Coll Publ Hlth, Birmingham, AL USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Toronto; University of Toronto; Sinai Health System Toronto;
   University Health Network Toronto; University System of Georgia; Georgia
   State University; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Hall, SF (通讯作者)，Univ Iowa, 5231 Westlawn, Iowa City, IA 52242 USA.
EM Sylvie hall@uiowa.edu
RI Cram, Peter/K 4472 2014; Wolinsky, Fredric/F 9231 2011; Lou,
   Yiyue/ABE 4040 2021; Hall, Sylvie/AAD 6404 2021; Edmonds,
   Stephanie/AAE 3494 2020
OI Wright, Nicole/0000 0001 8414 4842; 
FU NIA at NIH [R01 AG033035]; NIAMS at NIH [K24 AR062133, K24 AR052361]
FX This work was supported by grant number R01 AG033035 from NIA at NIH to
   Peter Cram and Fredric D. Wolinsky. Peter Cram is also supported by
   grant number K24 AR062133 from NIAMS at NIH. Kenneth G. Saag is also
   supported by grant number K24 AR052361 from NIAMS at NIH. NIA, NIAMS,
   and NIH had no role in the design and conduct of the study; collection,
   management, analysis, and interpretation of the data; preparation,
   review, or approval of the manuscript; or the decision to submit the
   manuscript for publication.
CR [Anonymous], 2004, Bone Health and Osteoporosis: A Report of the Surgeon General
   Brenneman SK, 2002, J BONE MINER RES, V17, pS466
   Cadarette SM, 2010, CURR OPIN RHEUMATOL, V22, P397, DOI 10.1097/BOR.0b013e32833ac7fe
   Calvert SB, 2012, AM HEART J, V163, P657, DOI 10.1016/j.ahj.2012.01.019
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Chisholm Burns MA, 2010, MED CARE, V48, P923, DOI 10.1097/MLR.0b013e3181e57962
   Cram P, 2016, OSTEOPOROSIS INT, V27, P3513, DOI 10.1007/s00198 016 3681 9
   Curtis JR, 2008, J BONE MINER RES, V23, P1435, DOI 10.1359/JBMR.080418
   Edmonds SW, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1227 0
   Edmonds SW, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/s12911 014 0101 y
   Edmonds SW, 2013, CONTEMP CLIN TRIALS, V34, P90, DOI 10.1016/j.cct.2012.10.002
   Elliott JO, 2015, J RENAL NUTR, V25, P111, DOI 10.1053/j.jrn.2014.08.006
   Eussen SRBM, 2010, ANN PHARMACOTHER, V44, P1905, DOI 10.1345/aph.1P281
   Foot H, 2016, PATIENT EDUC COUNS, V99, P706, DOI 10.1016/j.pec.2015.11.004
   Harvey NC, 2010, J DEV ORIG HLTH DIS, V1, P35, DOI 10.1017/S2040174409990055
   Henderson KC, 2011, AIDS PATIENT CARE ST, V25, P221, DOI 10.1089/apc.2010.0324
   Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022 3999(99)00057 4
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Joost R, 2014, NEPHROL DIAL TRANSPL, V29, P1597, DOI 10.1093/ndt/gfu207
   Kamatari M, 2007, J BONE MINER METAB, V25, P302, DOI 10.1007/s00774 007 0768 6
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kertes J, 2008, ISR MED ASSOC J, V10, P207
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   LaPointe NMA, 2011, AM HEART J, V161, P855, DOI 10.1016/j.ahj.2011.02.009
   Lau E, 2008, CAN FAM PHYSICIAN, V54, P394
   Ma A, 2010, AIDS CARE, V22, P1189, DOI 10.1080/09540121003668102
   Mann DM, 2009, J BEHAV MED, V32, P278, DOI 10.1007/s10865 009 9202 y
   McHorney CA, 2007, CURR MED RES OPIN, V23, P3137, DOI 10.1185/030079907X242890
   Medicare Current Beneficiary Survey (MCBS), 2012, 2012 NAT HEALTHC QUA
   Parthan Anju, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P325, DOI 10.1586/14737167.6.3.325
   Recker RR, 2005, MAYO CLIN PROC, V80, P856, DOI 10.4065/80.7.856
   Rickles NM, 2005, J AM PHARM ASSOC, V45, P344, DOI 10.1331/1544345054003732
   Robinson JD, 2010, ANN PHARMACOTHER, V44, P88, DOI 10.1345/aph.1L289
   Ryan R, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007768.pub2
   Sampalis JS, 2012, J BONE MINER RES, V27, P202, DOI 10.1002/jbmr.533
   Shah Mansi, 2013, J Pharm Pract, V26, P120, DOI 10.1177/0897190012451907
   Sheehy O, 2009, OSTEOPOROSIS INT, V20, P1369, DOI 10.1007/s00198 008 0795 8
   Simpson RJ, 2006, JAMA J AM MED ASSOC, V296, P2614, DOI 10.1001/jama.296.21.jed60074
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Siris ES, 2011, J BONE MINER RES, V26, P3, DOI 10.1002/jbmr.189
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Stuurman Bieze AGG, 2014, OSTEOPOROSIS INT, V25, P1807, DOI 10.1007/s00198 014 2659 8
   Taitel M, 2012, PATIENT PREFER ADHER, V6, P323, DOI 10.2147/PPA.S29353
   Unson CG, 2003, J WOMENS HEALTH, V12, P1037, DOI 10.1089/154099903322643965
   van Boven JFM, 2014, J MANAG CARE SPEC PH, V20, P786, DOI 10.18553/jmcp.2014.20.8.786
   Van Wijk BLG, 2005, ANN PHARMACOTHER, V39, P319, DOI 10.1345/aph.1E027
   Wolinsky FD, 2016, J CLIN DENSITOM
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
NR 50
TC 22
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1544 3191
EI 1544 3450
J9 J AM PHARM ASSOC
JI J. Am. Pharm. Assoc.
PD JUL AUG
PY 2017
VL 57
IS 4
BP 503
EP 509
DI 10.1016/j.japh.2017.05.003
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Pharmacology & Pharmacy
GA FE5BF
UT WOS:000408226300017
PM 28602783
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Park, JS
   Yoo, SH
   Lim, MA
   Ryu, JG
   Oh, HJ
   Hwang, SH
   Yang, S
   Jung, KA
   Yoon, S
   Park, BC
   Park, SH
   Kim, HY
   Cho, ML
   Park, YW
AF Park, Jin Sil
   Yoo, Seok Ho
   Lim, Mi Ae
   Ryu, Jun Geol
   Oh, Hye Joa
   Hwang, Sun Hee
   Yang, SeungCheon
   Jung, Kyung Ah
   Yoon, Sunha
   Park, Bum Chan
   Park, Sung Hwan
   Kim, Ho Youn
   Cho, Mi La
   Park, Young woo
TI A bispecific soluble receptor fusion protein that targets TNF α and
   IL 21 for synergistic therapy in inflammatory arthritis
SO FASEB JOURNAL
LA English
DT Article
DE bispecific fusion protein; cytokine; IL 17 producing T cells; rheumatoid
   arthritis; osteoclastogenesis
ID TUMOR NECROSIS FACTOR; RHEUMATOID ARTHRITIS; PROMOTES
   OSTEOCLASTOGENESIS; AUTOIMMUNE ARTHRITIS; INCREASED RISK; ANIMAL MODELS;
   TH17 CELLS; B CELLS; INTERLEUKIN 21; GENERATION
AB This study was aimed at investigating the therapeutic effects of BITRAP, a bispecific fusion protein targeting TNF alpha and IL 21, on the development of autoimmune arthritis in humans and mice. To verify the effects of BITRAP in human, peripheral blood mononuclear cells were cultured with BITRAP under IL 17 producing T (Th17) cell polarizing conditions or osteoclast differentiation conditions. BITRAP treatment inhibited the production of IL 17 and vascular endothelial growth factor but increased the production of IL 10 in CD4(+) T cells, as well as directly suppressed osteoclastogenesis. Collagen induced arthritis (CIA) and IL 1R antagonist (IL 1Ra) knockout mice were treated with BITRAP. Following injection in CIA mice, BITRAP rapidly migrated into the inflamed joints and remained there for 72 hours. Application of BITRAP attenuated the severity of autoimmune arthritis in CIA and IL 1Ra knockout mice by reducing the numbers of inflammatory cytokine expressing cells and Th17 cells and antibody secretion. Finally, BITRAP suppressed STAT3 phosphorylation, as well as production of IL 17 and TNF alpha, in murine splenic CD4(+) T cells. These findings suggest that BITRAP, a bispecific fusion protein targeting TNF alpha and IL 21, may be an effective treatment to overcome the limitations of anti TNF therapy for patients with rheumatoid arthritis.
C1 [Park, Jin Sil; Lim, Mi Ae; Ryu, Jun Geol; Oh, Hye Joa; Hwang, Sun Hee; Yang, SeungCheon; Jung, Kyung Ah; Park, Sung Hwan; Kim, Ho Youn; Cho, Mi La] Catholic Univ Korea, Coll Med, Catholic Res Inst Med Sci, Rheumatism Res Ctr, Seoul, South Korea.
   [Yoo, Seok Ho; Yoon, Sunha; Park, Bum Chan; Park, Young woo] Y Biol, Daejeon, South Korea.
   [Park, Sung Hwan] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Seoul, South Korea.
   [Cho, Mi La] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, Seoul, South Korea.
   [Cho, Mi La] Catholic Univ Korea, Coll Med, Dept Med Lifesci, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea; Catholic University of Korea; Catholic University
   of Korea
RP Cho, ML (通讯作者)，Catholic Univ Korea, Catholic Inst Med Sci, Rheumatism Res Ctr, 222 Banpo Daero, Seoul 06591, South Korea.
EM iammila@catholic.ac.kr
RI Kim, Ho/AAK 8895 2020
FU National Research Foundation of Korea (NRF) [20100029601]; Ministry for
   health and welfare, Republic of Korea [HI14C3417]
FX National Research Foundation of Korea (NRF), Grant/Award Number:
   20100029601; Ministry for health and welfare, Republic of Korea,
   Grant/Award Number: HI14C3417
CR Ali T, 2013, DRUG HEALTHC PATIENT, V5, P79, DOI 10.2147/DHPS.S28801
   Alzabin S, 2012, ANN RHEUM DIS, V71, P1741, DOI 10.1136/annrheumdis 2011 201024
   Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Buch MH, 2007, RHEUMATOLOGY, V46, P1153, DOI 10.1093/rheumatology/kem075
   Burmester GR, 2014, NAT REV RHEUMATOL, V10, P77, DOI 10.1038/nrrheum.2013.168
   Cho ML, 2002, ARTHRITIS RHEUM US, V46, P42, DOI 10.1002/1529 0131(200201)46:1<42::AID ART10026>3.0.CO;2 A
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Genovese MC, 2018, ARTHRITIS RHEUMATOL, V70, P1710, DOI 10.1002/art.40580
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Hu YP, 2013, CLIN RHEUMATOL, V32, P161, DOI 10.1007/s10067 012 2041 1
   Jablonska Trypuc A, 2016, J ENZYM INHIB MED CH, V31, P177, DOI 10.3109/14756366.2016.1161620
   Jüngel A, 2004, ARTHRITIS RHEUM, V50, P1468, DOI 10.1002/art.20218
   Kalden JR, 2017, NAT REV RHEUMATOL, V13, P707, DOI 10.1038/nrrheum.2017.187
   Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217
   Kim Y, 2016, SCI REP UK, V6, DOI 10.1038/srep20150
   Koenders MI, 2008, ARTHRITIS RHEUM US, V58, P3461, DOI 10.1002/art.23957
   Kollias G, 2011, ANN RHEUM DIS, V70, P1357, DOI 10.1136/ard.2010.148551
   Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970
   Kwok SK, 2012, ARTHRITIS RHEUM US, V64, P740, DOI 10.1002/art.33390
   Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688
   Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738
   Liu ZH, 2018, INT J PHARMACEUT, V547, P72, DOI 10.1016/j.ijpharm.2018.05.058
   Lloyd S, 2010, RHEUMATOLOGY, V49, P2313, DOI 10.1093/rheumatology/keq169
   Long D, 2019, J AUTOIMMUN, V99, P1, DOI 10.1016/j.jaut.2019.01.013
   Mease PJ, 2018, ARTHRITIS RHEUMATOL, V70, P1778, DOI 10.1002/art.40579
   Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969
   Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009
   Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676
   Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002
   Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997
   Park JS, 2017, AM J PATHOL, V187, P2034, DOI 10.1016/j.ajpath.2017.05.008
   Park JS, 2013, AM J PATHOL, V183, P857, DOI 10.1016/j.ajpath.2013.05.027
   Park JS, 2013, ARTHRITIS RHEUM US, V65, P949, DOI 10.1002/art.37841
   Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810
   ROSLONIEC E.F., 2001, CURR PROTOC IMMUNOL
   Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783
   So MK, 2006, NAT BIOTECHNOL, V24, P339, DOI 10.1038/nbt1188
   Spolski R, 2008, CURR OPIN IMMUNOL, V20, P295, DOI 10.1016/j.coi.2008.02.004
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001
   Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200
   Westhovens R, 2009, ANN RHEUM DIS, V68, P1870, DOI 10.1136/ard.2008.101121
   Xing R, 2016, SCAND J IMMUNOL, V83, P64, DOI 10.1111/sji.12396
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 49
TC 5
Z9 5
U1 0
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2020
VL 34
IS 1
BP 248
EP 262
DI 10.1096/fj.201900816RR
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KC6TY
UT WOS:000507308900019
PM 31914604
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Li, M
   You, L
   Li, HM
   Ni, L
   Gu, Y
   Hao, CM
   Chen, J
AF Zhang, Qian
   Li, Ming
   You, Li
   Li, Haiming
   Ni, Li
   Gu, Yong
   Hao, Chuanming
   Chen, Jing
TI Effects and Safety of Calcimimetics in End Stage Renal Disease Patients
   with Secondary Hyperparathyroidism: A Meta Analysis
SO PLOS ONE
LA English
DT Article
ID DOSE VITAMIN D; PARATHYROID HORMONE LEVELS; HEMODIALYSIS PATIENTS;
   VASCULAR CALCIFICATION; CINACALCET HCL; DIALYSIS PATIENTS; BONE
   TURNOVER; AMG 073; AGENT; PHARMACODYNAMICS
AB Purpose: Secondary hyperparathyroidism (SHPT) is one of the most common abnormalities of mineral metabolism in patients with chronic kidney disease. We performed a meta analysis to determine the effect and safety of cinacalcet in SHPT patients receiving dialysis.
   Methods: The meta analysis was performed to determine the effect and safety of cinacalcet in SHPT patients receiving dialysis by using the search terms 'cinacalcet' or 'mimpara' or 'sensipar' or 'calcimimetic' or 'R586' on MEDLINE and EMBASE (January 1990 to February 2012).
   Results: Fifteen trials were included, all of which were performed between 2000 and 2011 enrolling a total of 3387 dialysis patients. Our study showed that calcimimetic agents effectively ameliorated iPTH levels(WMD,  294.36 pg/mL; 95% CI,  322.76 to  265.95, P<0.001) in SHPT patients and reduced serum calcium (WMD,  0.81 mg/dL; 95% CI,  0.89 to  0.72, P<0.001) and phosphorus disturbances(WMD,  0.29 mg/dL; 95% CI,  0.41 to  0.17, P<0.001). The percentage of patients in whom there was a 30% decrease in serum iPTH levels by the end of the dosing was higher in cinacalcet group than that in control group(OR = 10.75, 95% CI: 6.65 17.37, P<0.001). However, no significant difference was found in all cause mortality and all adverse events between calcimimetics and control groups(OR = 0.86, 95% CI: 0.46 1.60, P = 0.630; OR = 1.30, 95% CI: 0.78 2.18, P = 0.320, respectively). Compared with the control therapy, there was a significant increase in the episodes of hypocalcemia (OR = 2.46, 95% CI: 1.58 3.82, P<0.001), nausea (OR = 2.45, 95% CI: 1.29 4.66, P = 0.006), vomiting(OR = 2.78, 95% CI: 2.14 3.62, P<0.001), diarrhea(OR = 1.51, 95% CI: 1.04 2.20, P = 0.030) and upper respiratory tract infection (OR = 1.79, 95% CI: 1.20 2.66, P = 0.004) in calcimimetics group.
   Conclusions: Calcimimetic treatment effectively improved biochemical parameters of SHPT patients receiving dialysis without increasing all cause mortality and all adverse events.
C1 [Zhang, Qian; You, Li; Li, Haiming; Ni, Li; Gu, Yong; Hao, Chuanming; Chen, Jing] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Div Nephrol, Shanghai 200433, Peoples R China.
   [Li, Ming] Tongji Univ, Dept Resp Med, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [Hao, Chuanming] Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN USA.
C3 Fudan University; Tongji University; Vanderbilt University
RP Chen, J (通讯作者)，Fudan Univ, Shanghai Med Coll, Huashan Hosp, Div Nephrol, Shanghai 200433, Peoples R China.
EM chenjing_1998@yahoo.com.cn
RI fang, li/JNS 8415 2023; Chen, Jing/AAM 2184 2021
FU China Natural Science Foundation [30971373, 81170684]; New Century Grant
   for the Talented People by National Education Committee of China
FX This work was supported in part by China Natural Science Foundation
   30971373 and 81170684 (to Jing Chen) and New Century Grant for the
   Talented People by National Education Committee of China (to Jing Chen).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akiba T, 2008, THER APHER DIAL, V12, P117, DOI 10.1111/j.1744 9987.2008.00556.x
   BINDELS RJM, 1993, J EXP BIOL, V184, P89
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   BRICKMAN AS, 1977, AM J CLIN NUTR, V30, P1064, DOI 10.1093/ajcn/30.7.1064
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Egger M, 1997, BMJ BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferreira A, 1998, NEPHROL DIAL TRANSPL, V13, P29, DOI 10.1093/ndt/13.suppl_3.29
   Fishbane S, 2008, CLIN J AM SOC NEPHRO, V3, P1718, DOI 10.2215/CJN.01040308
   Floege J, 2010, NEPHROL DIAL TRANSPL, V25, P1916, DOI 10.1093/ndt/gfp762
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   GONZALEZ EA, 1995, NEPHROL DIAL TRANSPL, V10, P13, DOI 10.1093/ndt/10.supp3.13
   Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523 1755.2000.00183.x
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017
   Harris RZ, 2004, AM J KIDNEY DIS, V44, P1070, DOI 10.1053/j.ajkd.2004.08.029
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, Vxxi
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197 2456(95)00134 4
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003 4819 127 9 199711010 00008
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523 1755.2003.00720.x
   Malluche HH, 2008, CLIN NEPHROL, V69, P269
   Martin KJ, 2005, KIDNEY INT, V68, P1236, DOI 10.1111/j.1523 1755.2005.00517.x
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Parfitt AM, 1997, KIDNEY INT, V52, P3, DOI 10.1038/ki.1997.297
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Salgueira M, 2003, KIDNEY INT, V63, pS119, DOI 10.1046/j.1523 1755.63.s85.28.x
   SCHULZ KF, 1995, JAMA J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Shireman TI, 2010, AM J KIDNEY DIS, V56, P1108, DOI 10.1053/j.ajkd.2010.07.012
   Sterrett JR, 2007, CLIN NEPHROL, V68, P10
   Strippoli GFM, 2006, AM J KIDNEY DIS, V47, P715, DOI 10.1053/j.ajkd.2006.01.015
   Urena P, 1996, J AM SOC NEPHROL, V7, P506
   Wada M, 1998, KIDNEY INT, V53, P448, DOI 10.1046/j.1523 1755.1998.00782.x
   Wada M, 1997, J CLIN INVEST, V100, P2977, DOI 10.1172/JCI119851
   Wetmore JB, 2010, CLIN J AM SOC NEPHRO, V5, P110, DOI 10.2215/CJN.03630509
   Wilkie M, 2009, NEPHRON CLIN PRACT, V112, pC41, DOI 10.1159/000212102
NR 41
TC 23
Z9 25
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 25
PY 2012
VL 7
IS 10
AR e48070
DI 10.1371/journal.pone.0048070
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 026GE
UT WOS:000310261800039
PM 23133549
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Walter, S
   Baruch, A
   Alexander, ST
   Janes, J
   Sho, E
   Dong, J
   Yin, Q
   Maclean, D
   Mendel, DB
   Karim, F
   Johnson, RM
AF Walter, Sarah
   Baruch, Amos
   Alexander, Shawn T.
   Janes, Julie
   Sho, Eiketsu
   Dong, Jin
   Yin, Qun
   Maclean, Derek
   Mendel, Dirk B.
   Karim, Felix
   Johnson, Randolph M.
TI Comparison of AMG 416 and cinacalcet in rodent models of uremia
SO BMC NEPHROLOGY
LA English
DT Article
DE Calcium sensing receptor; Secondary hyperparathyroidism (SHPT); Chronic
   kidney disease (CKD); Uremic rat model; AMG 416
ID SECONDARY HYPERPARATHYROIDISM; RAT MODEL; HCL; PHARMACODYNAMICS;
   CALCIFICATION; HEMODIALYSIS; HYPERPLASIA; RECEPTOR; BONE
AB Background: AMG 416 is a novel peptide agonist of the calcium sensing receptor (CaSR). This report describes the activity of AMG 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis.
   Methods: AMG 416 was administered as a single intravenous (IV) bolus in a severe, acute model of renal insufficiency (the "1K1C" model) and plasma parathyroid hormone (PTH) and serum calcium levels were monitored for 24 hours. In a chronic, less severe model of renal dysfunction, the 5/6 nephrectomy (5/6 Nx) model, AMG 416 was administered as a once daily IV bolus for 28 days. Both studies included a control (vehicle) group and a comparison cinacalcet group (po dosing at 30 mg/kg and 10 mg/kg for the 1K1C and 5/6 Nx studies, respectively).
   Results: Administration of AMG 416 by IV bolus injection into rats with acute renal dysfunction (1K1C model) resulted in a sustained reduction in plasma PTH from the initial elevated values. Following a single IV bolus (0.5 mg/kg), AMG 416 caused a substantial drop in PTH levels which remained approximately 50% below their initial level at 24 hrs. In the same model, oral treatment with cinacalcet (30 mg/kg) resulted in an acute drop in PTH which almost returned to the starting level by 24 hours after dosing. In the 5/6 Nx chronic uremia model, daily IV dosing of AMG 416 over 4 weeks (1 mg/kg) resulted in a sustained reduction in PTH, with approximately 50% of the initial level observed 48 hours post treatment throughout the study. Cinacalcet treatment (10 mg/kg) in the same model resulted in acutely lowered plasma PTH levels which returned to placebo levels by 24 hours post dose. Consistent with the reductions in plasma PTH, reductions in serum calcium were observed in both AMG 416  and cinacalcet treated animals.
   Conclusions: As a long acting CaSR agonist suitable for administration by the IV route, AMG 416 is a potential new therapy for the treatment of CKD patients with SHPT receiving hemodialysis.
C1 [Walter, Sarah; Baruch, Amos; Alexander, Shawn T.; Janes, Julie; Sho, Eiketsu; Dong, Jin; Yin, Qun; Maclean, Derek; Mendel, Dirk B.; Karim, Felix; Johnson, Randolph M.] Amgen Inc, San Francisco, CA 94080 USA.
C3 Amgen
RP Maclean, D (通讯作者)，Amgen Inc, 1120 Vet Blvd, San Francisco, CA 94080 USA.
EM dmaclean@amgen.com
RI ; Walter, Sarah/JLM 8101 2023
OI Baruch, Amos/0000 0003 3831 3806; Alexander, Shawn/0009 0006 6633 5614
CR Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA BG, 2012, 49 ERA EDTA C MAY 26
   Borchhardt KA, 2008, TRANSPLANTATION, V86, P919, DOI 10.1097/TP.0b013e318186b7fb
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Colloton M, 2005, KIDNEY INT, V67, P467, DOI 10.1111/j.1523 1755.2005.67103.x
   DRUEKE TB, 1995, KIDNEY INT, V48, P259, DOI 10.1038/ki.1995.292
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Henley C, 2005, NEPHROL DIAL TRANSPL, V20, P1370, DOI 10.1093/ndt/gfh834
   Kawata T, 2008, KIDNEY INT, V74, P1270, DOI 10.1038/ki.2008.407
   Martin KJ, 2013, KIDNEY INT
   Martin KJ, ASN M 2011
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Padhi D, 2008, CLIN DRUG INVEST, V28, P635, DOI 10.2165/00044011 200828100 00004
   Padhi D, 2009, CLIN PHARMACOKINET, V48, P303, DOI 10.2165/00003088 200948050 00002
   Quarles LD, 2008, J CLIN INVEST, V118, P3820, DOI 10.1172/JCI36479
   Ritter CS, 2008, J MOL ENDOCRINOL, V40, P13, DOI 10.1677/JME 07 0085
   Walter S, 2013, J PHARMACOL EXP THER, V346, P229, DOI 10.1124/jpet.113.204834
NR 17
TC 22
Z9 24
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD MAY 19
PY 2014
VL 15
AR 81
DI 10.1186/1471 2369 15 81
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA AH5MW
UT WOS:000336175200001
PM 24884838
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nyffeler, J
   Willis, C
   Harris, FR
   Taylor, LW
   Judson, R
   Everett, LJ
   Harrill, JA
AF Nyffeler, Johanna
   Willis, Clinton
   Harris, Felix R.
   Taylor, Laura W.
   Judson, Richard
   Everett, Logan J.
   Harrill, Joshua A.
TI Combining phenotypic profiling and targeted RNA Seq reveals linkages
   between transcriptional perturbations and chemical effects on cell
   morphology: Retinoic acid as an example
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE High Throughput Phenotypic Profiling; Cell Painting;
   Concentration Response; Computational Toxicology
ID X RECEPTOR; METABOLISM; EXPRESSION; INHIBITOR; MECHANISM; POTENT; BETA;
   DIFFERENTIATION; LIAROZOLE; APOPTOSIS
AB The United States Environmental Protection Agency has proposed a tiered testing strategy for chemical hazard evaluation based on new approach methods (NAMs). The first tier includes in vitro profiling assays applicable to many (human) cell types, such as high throughput transcriptomics (HTTr) and high throughput phenotypic profiling (HTPP). The goals of this study were to: (1) harmonize the seeding density of U 2 OS human osteosarcoma cells for use in both assays; (2) compare HTTr versus HTPP derived potency estimates for 11 mechanistically diverse chemicals; (3) identify candidate reference chemicals for monitoring assay performance in future screens; and (4) characterize the transcriptional and phenotypic changes in detail for all trans retinoic acid (ATRA) as a model compound known for its adverse effects on osteoblast differentiation. The results of this evaluation showed that (1) HTPP conducted at low (400 cells/well) and high (3000 cells/well) seeding densities yielded comparable potency estimates and similar phenotypic profiles for the tested chemicals; (2) HTPP and HTTr resulted in comparable potency estimates for changes in cellular morphology and gene expression, respectively; (3) three test chemicals (etoposide, ATRA, dexamethasone) produced concentration dependent effects on cellular morphology and gene expression that were consistent with known modes of action, demonstrating their suitability for use as reference chemicals for monitoring assay performance; and (4) ATRA produced phenotypic changes that were highly similar to other retinoic acid receptor activators (AM580, arotinoid acid) and some retinoid X receptor activators (bexarotene, methoprene acid). This phenotype was observed concurrently with autoregulation of the RARB gene. Both effects were prevented by pre treating U 2 OS cells with pharmacological antagonists of their respective receptors. Thus, the observed phenotype could be considered characteristic of retinoic acid pathway activation in U 2 OS cells. These findings lay the groundwork for combinatorial screening of chemicals using HTTr and HTPP to generate complementary information for the first tier of a NAM based chemical hazard evaluation strategy.
C1 [Nyffeler, Johanna; Willis, Clinton; Harris, Felix R.; Taylor, Laura W.; Judson, Richard; Everett, Logan J.; Harrill, Joshua A.] US Environm Protect Agcy, Ctr Computat Toxicol & Exposure, Off Res & Dev, Durham, NC 27711 USA.
   [Nyffeler, Johanna] Oak Ridge Inst Sci & Educ ORISE Postdoctoral Fello, Oak Ridge, TN 37831 USA.
   [Harris, Felix R.] Oak Ridge Associated Univ ORAU Natl Student Serv C, Oak Ridge, TN 37831 USA.
   [Harrill, Joshua A.] US Environm Protect Agcy, Ctr Computat Toxicol & Exposure CCTE, 109 TW Alexander Dr, Res Triangle Pk, Durham, NC 27709 USA.
C3 United States Environmental Protection Agency; United States
   Environmental Protection Agency
RP Harrill, JA (通讯作者)，US Environm Protect Agcy, Ctr Computat Toxicol & Exposure, Off Res & Dev, Durham, NC 27711 USA.; Harrill, JA (通讯作者)，US Environm Protect Agcy, Ctr Computat Toxicol & Exposure CCTE, 109 TW Alexander Dr, Res Triangle Pk, Durham, NC 27709 USA.
EM harrill.joshua@epa.gov
RI Harris, Felix/MZS 2353 2025; Judson, Richard/AEC 6432 2022; Everett,
   Logan/AAK 1523 2021; Harrill, Joshua/AAW 9331 2020; Nyffeler,
   Jo/GPX 1848 2022
OI Harris, Felix/0000 0002 0256 7452; Word, Laura/0000 0001 8564 2114;
   Nyffeler, Jo/0000 0002 6155 9743; Harrill, Joshua/0000 0003 4317 6391; 
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   AKTIPIS S, 1981, BIOCHIM BIOPHYS ACTA, V655, P278, DOI 10.1016/0005 2787(81)90038 1
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Becker T., 2020, BIORXIV, DOI [10.1101/2020.12.15.422887,2020.2012.2015.422887, DOI 10.1101/2020.12.15.422887,2020.2012.2015.422887]
   Blaskovich MA, 2003, CANCER RES, V63, P1270
   BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014
   Bray MA, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/giw014
   Bray MA, 2016, NAT PROTOC, V11, P1757, DOI 10.1038/nprot.2016.105
   Brinks J, 2018, INVEST OPHTH VIS SCI, V59, P5682, DOI 10.1167/iovs.18 25054
   BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003 9861(92)90290 D
   Conaway HH, 2013, ENDOCR REV, V34, P766, DOI 10.1210/er.2012 1071
   CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489
   de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Duan QN, 2014, NUCLEIC ACIDS RES, V42, pW449, DOI 10.1093/nar/gku476
   Ghyselinck NB, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.167502
   Gibb Steven, 2008, Reprod Toxicol, V25, P136, DOI 10.1016/j.reprotox.2007.10.013
   Gilardi F, 2014, SUBCELL BIOCHEM, V70, P75, DOI 10.1007/978 94 017 9050 5_5
   Graczyk PP, 2007, J MED CHEM, V50, P5773, DOI 10.1021/jm070562u
   Gustafsdottir SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080999
   Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959 8049(98)00228 7
   HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157
   Harrill JA, 2021, TOXICOL SCI, V181, P68, DOI 10.1093/toxsci/kfab009
   Henning P, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00031
   Herlin M, 2021, REPROD TOXICOL, V105, P25, DOI 10.1016/j.reprotox.2021.07.013
   Huang RL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00445
   Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360
   Imran M, 2020, J DRUG DELIV SCI TEC, V60, DOI 10.1016/j.jddst.2020.101959
   Janesick A, 2015, CELL MOL LIFE SCI, V72, P1559, DOI 10.1007/s00018 014 1815 9
   Judson R, 2009, ENVIRON HEALTH PERSP, V117, P685, DOI 10.1289/ehp.0800168
   KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021
   Kanayama T, 2005, MOL PHARMACOL, V67, P766, DOI 10.1124/mol.104.008409
   KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755
   Kikuchi K, 2001, BIOORG MED CHEM LETT, V11, P1215, DOI 10.1016/S0960 894X(01)00177 9
   Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587 019 0201 4
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Lapins M., 2019, bioRxiv, DOI [DOI 10.1101/580654, 10.1101/580654]
   le Maire A, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111392
   Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003 MCP200
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp100]
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOELIGER P, 1980, EUR J MED CHEM, V15, P9
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Marill J, 2003, CURR DRUG METAB, V4, P1, DOI 10.2174/1389200033336900
   MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804
   Meister B, 1998, ANTICANCER RES, V18, P1777
   Nahoum V, 2007, P NATL ACAD SCI USA, V104, P17323, DOI 10.1073/pnas.0705356104
   Nakanishi T, 2005, MOL ENDOCRINOL, V19, P2502, DOI 10.1210/me.2004 0397
   NRC, 1984, TOX TEST STRAT DET N
   Nyffeler J, 2021, SLAS DISCOV, V26, P292, DOI 10.1177/2472555220950245
   Nyffeler J, 2020, TOXICOL APPL PHARM, V389, DOI 10.1016/j.taap.2019.114876
   Nyffeler J, 2018, ARCH TOXICOL, V92, P1225, DOI 10.1007/s00204 017 2125 4
   Nyffeler J, 2017, ALTEX ALTERN ANIM EX, V34, P75, DOI 10.14573/altex.1605031
   OBRIG TG, 1971, J BIOL CHEM, V246, P174
   Ocaya PA, 2011, J VASC RES, V48, P23, DOI 10.1159/000317397
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Piñero J, 2015, DATABASE OXFORD, DOI 10.1093/database/bav028
   Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591 10603.2005
   RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272
   ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333
   ROWE A, 1991, DEVELOPMENT, V111, P1007
   Sheffield T, 2022, BIOINFORMATICS, V38, P1157, DOI 10.1093/bioinformatics/btab779
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972
   TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006 291X(86)90008 2
   Tanaka M, 1996, DEV BIOL, V175, P239, DOI 10.1006/dbio.1996.0111
   Thomas RS, 2019, TOXICOL SCI, V169, P317, DOI 10.1093/toxsci/kfz058
   TUKEY JW, 1977, EXPLORATORY DATA ANA
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   van Mierlo T, 2016, NETW MODEL ANAL HLTH, V5, DOI 10.1007/s13721 016 0140 7
   VANWAUWE J, 1994, BIOCHEM PHARMACOL, V47, P737, DOI 10.1016/0006 2952(94)90137 6
   VANWAUWE J, 1992, J PHARMACOL EXP THER, V261, P773
   Warchal SJ, 2016, ASSAY DRUG DEV TECHN, V14, P395, DOI 10.1089/adt.2016.730
   Wawer MJ, 2014, P NATL ACAD SCI USA, V111, P10911, DOI 10.1073/pnas.1410933111
   Willis C, 2020, SLAS DISCOV, V25, P755, DOI 10.1177/2472555220928004
   Yeakley JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178302
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 80
TC 18
Z9 18
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JUN 1
PY 2022
VL 444
AR 116032
DI 10.1016/j.taap.2022.116032
EA APR 2022
PG 16
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 1J0VC
UT WOS:000797642900003
PM 35483669
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, WJ
   Bae, J
   Lee, EH
   Kim, J
   Kim, PJ
   Ma, PX
   Woo, KM
AF Kim, Woo Jin
   Bae, Jieun
   Lee, Eun Hye
   Kim, Jaehyung
   Kim, Pil Jong
   Ma, Peter X.
   Woo, Kyung Mi
TI Long noncoding RNA MALAT1 mediates fibrous topography driven pathologic
   calcification through trans differentiation of myoblasts
SO MATERIALS TODAY BIO
LA English
DT Article
DE Prosthesis induced pathologic calcification; Fibrous ECM mimicry;
   Trans differentiation; Malat1
ID OSTEOBLAST DIFFERENTIATION; MYOGENIC DIFFERENTIATION; IN VITRO;
   PROGRESSION; PROMOTE; YAP/TAZ; CELLS
AB Prosthesis induced pathological calcification is a significant challenge in biomaterial applications and is often associated with various reconstructive medical procedures. It is uncertain whether the fibrous extracellular matrix (ECM) adjacent to biomaterials directly triggers osteogenic trans differentiation in nearby cells. To investigate this possibility, we engineered a heterogeneous polystyrene fibrous matrix (PSF) designed to mimic the ECM. Our findings revealed that the myoblasts grown on this PSF acquired osteogenic properties, resulting in mineralization both in vitro and in vivo. Transcriptomic analyses indicated a notable upregulation in the expression of the long noncoding RNA metastsis associated lung adenocarcinoma transcript 1 (Malat1) in the C2C12 myoblasts cultured on PSF. Intriguingly, silencing Malat1 curtailed the PSF induced mineralization and downregulated the expression of bone morphogenetic proteins (Bmps) and osteogenic markers. Further, we found that PSF prompted the activation of Yap1 signaling and epigenetic modifications in the Malat1 promoter, crucial for the expression of Malat1. These results indicate that the fibrous matrix adjacent to biomaterials can instigate Malat1 upregulation, subsequently driving osteogenic trans differentiation in myoblasts and ectopic calcification through its transcriptional regulation of osteogenic genes, including Bmps. Our findings point to a novel therapeutic avenue for mitigating prosthesis induced pathological calcification, heralding new possibilities in the field of biomaterial based therapies.
C1 [Kim, Woo Jin; Bae, Jieun; Lee, Eun Hye; Kim, Jaehyung; Woo, Kyung Mi] Seoul Natl Univ, Sch Dent, Dept Mol Genet, Seoul 08826, South Korea.
   [Kim, Woo Jin; Bae, Jieun; Lee, Eun Hye; Kim, Jaehyung; Woo, Kyung Mi] Seoul Natl Univ, Dent Res Inst, Seoul 08826, South Korea.
   [Kim, Pil Jong] Seoul Natl Univ, Dent Res Inst, Biomed Knowledge Engn Lab, Seoul 08826, South Korea.
   [Ma, Peter X.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.
   [Woo, Kyung Mi] Seoul Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Seoul 08826, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Seoul National University (SNU)
RP Woo, KM (通讯作者)，1 Gwanak Ro, Seoul 08826, South Korea.
EM kmwoo@snu.ac.kr
RI Woo, Kyung Mi/A 2793 2009; Lee, Jaewoong/IQS 0514 2023; Kim,
   Pil/A 5884 2013; Woo, Kyung/A 2793 2009
OI Woo, Kyung Mi/0000 0002 2782 1189; 
FU National Research Foundation of Korea [NRF 2018R1A5A2024418,
   NRF 2019R1A2C2008113]
FX wish to acknowledge the financial support from National Research
   Foundation of Korea (NRF 2018R1A5A2024418, NRF 2019R1A2C2008113) .
CR Abudhahir M, 2021, J BIOMED MATER RES B, V109, P654, DOI 10.1002/jbm.b.34729
   ANDERSON HC, 1988, RHEUM DIS CLIN N AM, V14, P303
   Brown JA, 2014, NAT STRUCT MOL BIOL, V21, P633, DOI 10.1038/nsmb.2844
   Chanda J, 1998, BIOMATERIALS, V19, P1651, DOI 10.1016/S0142 9612(98)00038 6
   Chang YZ, 2021, CANCER LETT, V511, P36, DOI 10.1016/j.canlet.2021.04.020
   Chen XN, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.2
   Denchai A, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00155
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Ebrahimi R, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098 020 00544 0
   El Fray M, 2006, BIOMACROMOLECULES, V7, P844, DOI 10.1021/bm050971c
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Gao Y, 2018, J CELL BIOCHEM, V119, P6986, DOI 10.1002/jcb.26907
   Gu LN, 2019, MED SCI MONITOR, V25, P6894, DOI 10.12659/MSM.915598
   Guerrero ME, 2023, JACC CARDIOVASC INTE, V16, P2195, DOI 10.1016/j.jcin.2023.06.044
   Han JP, 2024, ADV MATER, V36, DOI 10.1002/adma.202209778
   Han N, 2020, J CELL PHYSIOL, V235, P1309, DOI 10.1002/jcp.29047
   Hoshi K, 1999, J BONE MINER RES, V14, P273, DOI 10.1359/jbmr.1999.14.2.273
   Huang AR, 2021, J MOL MED, V99, P75, DOI 10.1007/s00109 020 02014 6
   Huang XZ, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01422 0
   Jover E, 2018, FASEB J, V32, P4459, DOI 10.1096/fj.201700653R
   Kawai M, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 62
   Kempf H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.759702
   Keshvardoostchokami M, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11010021
   Kim J, 2018, NAT GENET, V50, P1705, DOI 10.1038/s41588 018 0252 3
   Koo JH, 2018, CELL METAB, V28, P196, DOI 10.1016/j.cmet.2018.07.010
   Kostyunin A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207434
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Laufer BI, 2020, HUM MOL GENET, V29, P3465, DOI 10.1093/hmg/ddaa218
   Lejay A, 2023, EJVES VASC FORUM, V60, P1, DOI 10.1016/j.ejvsvf.2023.05.013
   Li D, 2019, AGING US, V11, P8792, DOI 10.18632/aging.102265
   Li J, 2022, MOL BIOL REP, V49, P6847, DOI 10.1007/s11033 022 07136 3
   Liao ZL, 2024, J CARDIOVASC PHARM, V84, P515, DOI 10.1097/FJC.0000000000001521
   Matuszyk J, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00516 2
   Mignemi NA, 2017, J BONE MINER RES, V32, P294, DOI 10.1002/jbmr.2973
   Oort MJHV, 2024, CARDIOVASC REVASCULA, V61, P16, DOI 10.1016/j.carrev.2023.10.013
   Prasopthum A, 2019, ACS APPL MATER INTER, V11, P18896, DOI 10.1021/acsami.9b01472
   Rahman SU, 2018, ACS APPL MATER INTER, V10, P17526, DOI 10.1021/acsami.7b19782
   Shum L, 2003, INT J DEV BIOL, V47, P423
   Song JH, 2015, BIOMATERIALS, V58, P1, DOI 10.1016/j.biomaterials.2015.04.021
   Tang Y, 2020, PHYSIOL GENOMICS, V52, P517, DOI 10.1152/physiolgenomics.00074.2020
   THINAKARAN G, 1993, FEBS LETT, V319, P271, DOI 10.1016/0014 5793(93)80561 8
   Vidavsky N, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001271
   Wang J, 2024, ONCOL LETT, V27, DOI 10.3892/ol.2023.14138
   Wang RK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2377 4
   Wang R, 2022, HUM CELL, V35, P1671, DOI 10.1007/s13577 022 00764 8
   Wang XY, 2021, DEV CELL, V56, P702, DOI 10.1016/j.devcel.2021.01.015
   Was N, 2023, RNA, V29, P69, DOI 10.1261/rna.079436.122
   Wen SY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.909801
   Xiao XX, 2017, INT J CARDIOL, V243, P404, DOI 10.1016/j.ijcard.2017.05.037
   Xu SW, 2023, DIAGNOSTICS, V13, DOI 10.3390/diagnostics13162632
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yanagawa B, 2012, J THORAC CARDIOV SUR, V144, P256, DOI 10.1016/j.jtcvs.2011.10.097
   Yi JY, 2019, CELL TISSUE RES, V376, P113, DOI 10.1007/s00441 018 2963 2
   Yin JH, 2022, PEERJ, V10, DOI 10.7717/peerj.13355
   Ying XX, 2017, ONCOTARGET, V8, P18348, DOI 10.18632/oncotarget.15442
   Yip CYY, 2011, CARDIOVASC PATHOL, V20, P177, DOI 10.1016/j.carpath.2010.12.001
   You Jin Oh, 2010, J Biol Eng, V4, P15, DOI 10.1186/1754 1611 4 15
   Yu L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020944
   Yu QF, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578 019 0299 6
   Zhang Q, 2017, BIOMATERIALS, V149, P77, DOI 10.1016/j.biomaterials.2017.10.007
   Zhang YZ, 2024, MOL BIOTECHNOL, V66, P3538, DOI 10.1007/s12033 023 00953 2
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zhou Y, 2023, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.922560
   Zhu XL, 2008, BIOMACROMOLECULES, V9, P1795, DOI 10.1021/bm800476u
NR 64
TC 1
Z9 1
U1 2
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD OCT
PY 2024
VL 28
AR 101182
DI 10.1016/j.mtbio.2024.101182
EA AUG 2024
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA D2Y2J
UT WOS:001294886500001
PM 39205874
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Akashi, M
   Ando, T
   Hamashima, T
   Yoshita, H
   Nanjo, S
   Mihara, H
   Fujinami, H
   Kajiura, S
   Nishikawa, J
   Miura, Y
   Hosokawa, A
   Sugiyama, T
AF Akashi, Momoko
   Ando, Takayuki
   Hamashima, Takeru
   Yoshita, Hiroki
   Nanjo, Sohachi
   Mihara, Hiroshi
   Fujinami, Haruka
   Kajiura, Shinya
   Nishikawa, Jun
   Miura, Yoshiaki
   Hosokawa, Ayumu
   Sugiyama, Toshiro
TI Multiple Colon Ulcers with Typical Small Intestinal Lesions Induced by
   Non Steroidal Anti Inflammatory Drugs
SO INTERNAL MEDICINE
LA English
DT Article
DE NSAID induced ulcer; total colon; colonoscopy; capsule endoscopy
ID GASTROINTESTINAL TOXICITY; RHEUMATOID ARTHRITIS; ENDOSCOPIC FEATURES;
   OSTEOARTHRITIS; INHIBITION; DICLOFENAC; MECHANISMS; CELECOXIB; INJURY;
   TRIAL
AB The diagnosis of NSAID induced colon ulcers is difficult when the distribution or endoscopic findings are not typical. An 83 year old woman was transferred to our hospital for hemorrhagic diarrhea. Colonoscopy showed multiple ulcers in the entire colon, particularly longitudinal ulcers in the transverse colon. These were unusual for NSAID induced colopathy, although she had been on meloxicam. However, capsule endoscopy revealed multiple scars and erosions, characteristic of NSAIDs users. The final diagnosis was NSAID induced enteropathy, and all lesions were in remission after meloxicam discontinuation. We herein emphasize the value of an endoscopic assessment of the entire digestive tract in the diagnosis of NSAID induced mucosal lesions.
C1 [Akashi, Momoko; Ando, Takayuki; Yoshita, Hiroki; Nanjo, Sohachi; Mihara, Hiroshi; Fujinami, Haruka; Kajiura, Shinya; Nishikawa, Jun; Miura, Yoshiaki; Hosokawa, Ayumu; Sugiyama, Toshiro] Toyama Univ, Fac Med, Dept Gastroenterol & Hematol, Toyama, Japan.
   [Hamashima, Takeru] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pathol, Toyama, Japan.
C3 University of Toyama; University of Toyama
RP Sugiyama, T (通讯作者)，Toyama Univ, Fac Med, Dept Gastroenterol & Hematol, Toyama, Japan.
EM tsugi@med.u toyama.ac.jp
RI Fujinami, Haruka/HJA 1887 2022; Mihara, Hiroshi/ISU 2768 2023;
   Nishikawa, Jun/AAE 5355 2020
FU Grants in Aid for Scientific Research [25293093] Funding Source: KAKEN
CR Aftab AR, 2010, J GASTROINTEST LIVER, V19, P89
   Amano Y, 2004, AM J GASTROENTEROL, V99, P1193, DOI 10.1111/j.1572 0241.2004.30220.x
   Argüelles Arias F, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/529136
   Chan FKL, 2010, LANCET, V376, P173, DOI 10.1016/S0140 6736(10)60673 3
   El Hajj Ihab, 2009, J Med Liban, V57, P274
   Fujimori S, 2009, GASTROINTEST ENDOSC, V69, P1339, DOI 10.1016/j.gie.2008.08.017
   Jones MK, 1999, NAT MED, V5, P1418
   Kurahara K, 2001, AM J GASTROENTEROL, V96, P473
   Lim YJ, 2012, CLIN ENDOSC, V45, P138, DOI [10.5217/ir.2017.15.4.446, 10.5946/ce.2012.45.2.138]
   Matsumoto T, 2006, DIGEST DIS SCI, V51, P1357, DOI 10.1007/s10620 006 9080 x
   Matsumoto Takayuki, 2000, Stomach and Intestine (Tokyo), V35, P1147
   Niwa Y, 2008, J GASTROENTEROL, V43, P270, DOI 10.1007/s00535 007 2155 4
   Perini R, 2004, CAN J GASTROENTEROL, V18, P229, DOI 10.1155/2004/890585
   Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Ueda H, 2000, GASTROENTEROLOGICAL, V42, P1316
   Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
NR 18
TC 3
Z9 3
U1 0
U2 3
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34 3 3 CHOME HONGO BUNKYO KU, TOKYO, 113, JAPAN
SN 0918 2918
EI 1349 7235
J9 INTERNAL MED
JI Intern. Med.
PY 2015
VL 54
IS 16
BP 1995
EP 1999
DI 10.2169/internalmedicine.54.3919
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CP8MU
UT WOS:000360148800008
PM 26278290
OA gold
DA 2025 08 17
ER

PT J
AU Li, HW
   Zhu, H
   Liu, Y
   He, FC
   Xie, P
   Zhang, LQ
AF Li, Haiwen
   Zhu, Heng
   Liu, Yang
   He, Fuchu
   Xie, Ping
   Zhang, Lingqiang
TI Itch promotes the neddylation of JunB and regulates JunB dependent
   transcription
SO CELLULAR SIGNALLING
LA English
DT Article
DE Neddylation ligase; Itch; JunB; Transcriptional activity
ID COVALENT MODIFIER NEDD8; E3 LIGASE ITCH; UBIQUITIN LIGASE; OSTEOBLAST
   DIFFERENTIATION; NEDD8 ACTIVATING ENZYME; CELL PROLIFERATION;
   CANCER THERAPY; DEGRADATION; SYSTEM; CONJUGATION
AB Protein neddylation is essential for the viability of most organisms and is widely involved in the regulation of immunity, DNA damage and repair, cell signaling and cell cycle. Unlike RING type neddylation ligases, HECT type neddylation ligase remains less defined. Here, we show that Itch is a novel HECT type neddylation E3 ligase and we identify JunB as a substrate of Nedd8 modification by Itch. JunB neddylation attenuates its transcriptional activity. In addition, JunB neddylation mediated by Itch promotes its ubiquitination dependent degradation. Therefore, these findings define a new HECT type neddylation ligase and its neddylation substrate. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Li, Haiwen; He, Fuchu; Xie, Ping; Zhang, Lingqiang] Collaborat Innovat Ctr Canc Med, Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing 100850, Peoples R China.
   [Zhang, Lingqiang] Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Liaoning Provin, Peoples R China.
   [Xie, Ping] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100069, Peoples R China.
   [Zhu, Heng] Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China.
   [Liu, Yang] Guiyang Coll Tradit Chinese Med, Hosp 1, Guiyang 550002, Peoples R China.
C3 Academy of Military Medical Sciences   China; Dalian Medical University;
   Capital Medical University; Academy of Military Medical Sciences  
   China; Institute of Basic Medical Sciences (IBMS); Guizhou University of
   Traditional Chinese Medicine
RP Xie, P; Zhang, LQ (通讯作者)，Collaborat Innovat Ctr Canc Med, Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing 100850, Peoples R China.
EM xpxp922@163.com; zhanglq@nic.bmi.ac.cn
RI He, FC/KGL 6713 2024; zhu, dingdingabc/AAZ 7892 2020; Li,
   Haiwen/ITR 8920 2023
OI Li, Haiwen/0000 0003 4801 085X
FU Chinese National Basic Research Programs [2015CB910401, 2012CB910304];
   Chinese National Natural Science Foundation [31470035, 31125010,
   81221004]
FX This work was supported by Chinese National Basic Research Programs
   (2015CB910401, 2012CB910304) and Chinese National Natural Science
   Foundation Projects (31470035, 31125010, 81221004).
CR Aki D, 2015, IMMUNOL REV, V266, P6, DOI 10.1111/imr.12301
   Aoki I, 2013, ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428
   Broemer M, 2010, MOL CELL, V40, P810, DOI 10.1016/j.molcel.2010.11.011
   Dharmasiri S, 2003, EMBO J, V22, P1762, DOI 10.1093/emboj/cdg190
   Duncan K, 2012, FUTURE ONCOL, V8, P1461, DOI [10.2217/FON.12.131, 10.2217/fon.12.131]
   Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795
   Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919
   Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763
   Gao F, 2006, NAT CELL BIOL, V8, P1171, DOI 10.1038/ncb1483
   Garaude J, 2008, J IMMUNOL, V180, P5983, DOI 10.4049/jimmunol.180.9.5983
   Harper JW, 2004, CELL, V118, P2, DOI 10.1016/j.cell.2004.06.015
   Huang DT, 2009, MOL CELL, V33, P483, DOI 10.1016/j.molcel.2009.01.011
   Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020
   Jones D, 2000, DEV BIOL, V226, P152, DOI 10.1006/dbio.2000.9847
   Jung SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3562
   Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kurz T, 2008, MOL CELL, V29, P23, DOI 10.1016/j.molcel.2007.12.012
   Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914
   Lee MR, 2008, BIOCHEM BIOPH RES CO, V366, P976, DOI 10.1016/j.bbrc.2007.12.066
   Li TT, 2014, J CELL SCI, V127, P2238, DOI 10.1242/jcs.138891
   Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208
   Liu J, 2013, CYTOTHERAPY, V15, P185, DOI 10.1016/j.jcyt.2012.09.005
   Loftus SJ, 2012, EMBO REP, V13, P811, DOI 10.1038/embor.2012.113
   Ma T, 2013, MOL CELL, V49, P897, DOI 10.1016/j.molcel.2013.01.006
   Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60
   Mergner J, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00103
   Nawrocki ST, 2012, EXPERT OPIN INV DRUG, V21, P1563, DOI 10.1517/13543784.2012.707192
   Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475
   Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263
   Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402
   Passegué E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969
   Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690
   Ryu JH, 2011, J BIOL CHEM, V286, P6963, DOI 10.1074/jbc.M110.188706
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Takashima O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058911
   Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035
   Wang M, 2011, EXPERT OPIN THER TAR, V15, P253, DOI 10.1517/14728222.2011.550877
   Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200
   Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733
   You FP, 2009, NAT IMMUNOL, V10, P1300, DOI 10.1038/ni.1815
   Zhang HW, 2013, STEM CELLS, V31, P1574, DOI 10.1002/stem.1395
   Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532
   Zhang L, 2014, CELL RES, V24, P742, DOI 10.1038/cr.2014.53
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zuo W, 2013, MOL CELL, V49, P499, DOI 10.1016/j.molcel.2012.12.002
NR 47
TC 27
Z9 32
U1 1
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD SEP
PY 2016
VL 28
IS 9
BP 1186
EP 1195
DI 10.1016/j.cellsig.2016.05.016
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DS2JJ
UT WOS:000380595500006
PM 27245101
OA hybrid
DA 2025 08 17
ER

PT J
AU Shen, BQ
   Sankaranarayanan, I
   Price, TJ
   Tavares Ferreira, D
AF Shen, Breanna Q. Q.
   Sankaranarayanan, Ishwarya
   Price, Theodore J.
   Tavares Ferreira, Diana
TI Sex differences in prostaglandin signaling: a semi systematic review and
   characterization of PTGDS expression in human sensory neurons
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENDER DIFFERENCES; PAIN; MOUSE; INFLAMMATION; INHIBITION; ALLODYNIA;
   OSTEOARTHRITIS; SENSITIZATION; EPIDEMIOLOGY; PROSTANOIDS
AB There is increasing evidence of sex differences in underlying mechanisms causing pain in preclinical models, and in clinical populations. There are also important disconnects between clinical pain populations and the way preclinical pain studies are conducted. For instance, osteoarthritis pain more frequently affects women, but most preclinical studies have been conducted using males in animal models. The most widely used painkillers, nonsteroidal anti inflammatory drugs (NSAIDs), act on the prostaglandin pathway by inhibiting cyclooxygenase (COX) enzymes. The purpose of this study was to analyze the preclinical and clinical literature on the role of prostaglandins and COX in inflammation and pain. We aimed to specifically identify studies that used both sexes and investigate whether any sex differences in the action of prostaglandins and COX inhibition had been reported, either in clinical or preclinical studies. We conducted a PubMed search and identified 369 preclinical studies and 100 clinical studies that matched our inclusion/exclusion criteria. Our analysis shows that only 17% of preclinical studies on prostaglandins used both sexes and, out of those, only 19% analyzed or reported data separated by sex. In contrast, 79% of the clinical studies analyzed used both sexes. However, only 6% of those reported data separated by sex. Interestingly, 14 out of 15 preclinical studies and 5 out of 6 clinical studies that analyzed data separated by sex have identified sex differences. This builds on the increasing evidence of sex differences in prostaglandin signaling and the importance of sex as a biological variable in data analysis. The preclinical literature identifies a sex difference in prostaglandin D 2 synthase (PTGDS) expression where it is higher in female than in male rodents in the nervous system. We experimentally validated that PTGDS expression is higher in female human dorsal root ganglia (DRG) neurons recovered from organ donors. Our semi systematic literature review reveals a need for continued inclusivity of both male and female animals in prostaglandins studies and data analysis separated by sex in preclinical and clinical studies. Our finding of sex differences in neuronal PTGDS expression in humans exemplifies the need for a more comprehensive understanding of how the prostaglandin system functions in the DRG in rodents and humans.
C1 [Price, Theodore J.; Tavares Ferreira, Diana] Univ Texas Dallas, Dept Neurosci, 800 W Campbell Rd, Richardson, TX 75080 USA.
   Univ Texas Dallas, Ctr Adv Pain Studies, 800 W Campbell Rd, Richardson, TX 75080 USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas System; University of Texas Dallas
RP Price, TJ; Tavares Ferreira, D (通讯作者)，Univ Texas Dallas, Dept Neurosci, 800 W Campbell Rd, Richardson, TX 75080 USA.
EM Theodore.price@utdallas.edu; Diana.TavaresFerreira@utdallas.edu
RI ; Price, Theodore/A 5094 2010; Tavares Ferreira, Diana/GXM 8736 2022
OI Shen, Breanna/0000 0003 0261 9192; 
CR Alshammari TK, 2021, PROG NEURO PSYCHOPH, V105, DOI 10.1016/j.pnpbp.2020.110120
   Antonova M, 2011, CEPHALALGIA, V31, P1532, DOI 10.1177/0333102411423314
   Arout CA, 2018, J WOMENS HEALTH, V27, P1035, DOI 10.1089/jwh.2017.6622
   Ashina M, 2003, CEPHALALGIA, V23, P109, DOI 10.1046/j.1468 2982.2003.00520.x
   Avona A, 2021, ANN NEUROL, V89, P1129, DOI 10.1002/ana.26070
   Avona A, 2019, J NEUROSCI, V39, P4323, DOI 10.1523/JNEUROSCI.0364 19.2019
   Barrachina J, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10102468
   Buisseret B, 2019, TRENDS MOL MED, V25, P882, DOI 10.1016/j.molmed.2019.04.009
   Burke JG, 2003, SPINE, V28, P2685, DOI 10.1097/01.BRS.0000103341.45133.F3
   Butcher BE, 2012, EUR J PAIN, V16, P1005, DOI 10.1002/j.1532 2149.2011.00104.x
   Chen LH, 2013, PROSTAG OTH LIPID M, V104, P58, DOI 10.1016/j.prostaglandins.2012.08.006
   Chen ZY, 2022, PAIN, V163, P1636, DOI 10.1097/j.pain.0000000000002556
   Chillingworth NL, 2006, AM J PHYSIOL REG I, V291, pR327, DOI 10.1152/ajpregu.00901.2005
   Cullen L, 1998, J PHARMACOL EXP THER, V287, P578
   Davidson S, 2016, PAIN, V157, P2081, DOI 10.1097/j.pain.0000000000000621
   Dekker MJHJ, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.643028
   Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726
   Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001
   Fisher JL, 2022, BIOL SEX DIFFER, V13, DOI 10.1186/s13293 022 00420 8
   Fosbol EL, 2008, PHARMACOEPIDEM DR S, V17, P822, DOI 10.1002/pds.1592
   Gottesdiener K, 1999, CLIN THER, V21, P1301, DOI 10.1016/S0149 2918(99)80031 9
   Ito S, 2001, NEUROSCI RES, V41, P299, DOI 10.1016/S0168 0102(01)00289 9
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Labaka A, 2018, BIOL RES NURS, V20, P383, DOI 10.1177/1099800418776082
   Langford RM, 2006, BIOMED PHARMACOTHER, V60, P323, DOI 10.1016/j.biopha.2006.06.017
   Liang XB, 2005, J NEUROCHEM, V92, P477, DOI 10.1111/j.1471 4159.2004.02870.x
   Liu L, 2020, THERANOSTICS, V10, P1694, DOI 10.7150/thno.41309
   Minami T, 1997, BRIT J PHARMACOL, V122, P605, DOI 10.1038/sj.bjp.0701421
   Minami T, 1996, J PHARMACOL EXP THER, V278, P1146
   Mogil JS, 2020, NAT REV NEUROSCI, V21, P353, DOI 10.1038/s41583 020 0310 6
   Mogil JS, 2017, LAB ANIMAL, V46, P136, DOI 10.1038/laban.1223
   Namer B, 2015, EUR J PAIN, V19, P159, DOI 10.1002/ejp.532
   Natura G, 2013, P NATL ACAD SCI USA, V110, P13648, DOI 10.1073/pnas.1300820110
   Nishimura M, 2002, ORAL SURG ORAL MED O, V94, P328, DOI 10.1067/moe.2002.124106
   North RY, 2019, BRAIN, V142, P1215, DOI 10.1093/brain/awz063
   OGOROCHI T, 1984, J NEUROCHEM, V43, P71, DOI 10.1111/j.1471 4159.1984.tb06680.x
   OHKUBO T, 1983, JPN J PHARMACOL, V33, P264, DOI 10.1254/jjp.33.264
   Page GG, 2002, J PAIN, V3, P301, DOI 10.1054/jpai.2002.125184
   Paige C, 2022, J NEUROSCI, V42, P1930, DOI 10.1523/JNEUROSCI.1137 21.2022
   Patil M, 2019, J NEUROENDOCRINOL, V31, DOI 10.1111/jne.12759
   Paulsen G, 2010, SCAND J MED SCI SPOR, V20, pE195, DOI 10.1111/j.1600 0838.2009.00947.x
   Rácz D, 2005, NEUROREPORT, V16, P2025, DOI 10.1097/00001756 200512190 00011
   Ray P, 2018, PAIN, V159, P1325, DOI 10.1097/j.pain.0000000000001217
   Ray PR, 2023, BRAIN, V146, P749, DOI 10.1093/brain/awac266
   Ray PR, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00037
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Rizzo SJS, 2020, HANDB EXP PHARMACOL, V257, P147, DOI 10.1007/164_2019_282
   Rosen S, 2017, J NEUROSCI RES, V95, P500, DOI 10.1002/jnr.23831
   Scheff NN, 2011, J NEUROPHYSIOL, V106, P1662, DOI 10.1152/jn.00196.2011
   Sekeroglu A, 2017, PHARMACOL REP, V69, P50, DOI 10.1016/j.pharep.2016.09.015
   Shaik JSB, 2014, J CHROMATOGR B, V945, P207, DOI 10.1016/j.jchromb.2013.11.041
   Shiers SI, 2021, J COMP NEUROL, V529, P2771, DOI 10.1002/cne.25122
   SHIMIZU T, 1979, P NATL ACAD SCI USA, V76, P6231, DOI 10.1073/pnas.76.12.6231
   Solheim N, 2018, ACTA ANAESTH SCAND, V62, P829, DOI 10.1111/aas.13104
   Steinberg JR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.13749
   Sycha T, 2003, BRIT J CLIN PHARMACO, V56, P165, DOI 10.1046/j.0306 5251.2003.01869.x
   Tavares Ferreira D, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj8186
   Tavares Ferreira D, 2022, BIOL PSYCHIAT, V91, P129, DOI 10.1016/j.biopsych.2020.09.022
   Theken KN, 2019, CLIN PHARMACOL THER, V106, P632, DOI 10.1002/cpt.1446
   UDA R, 1990, BRAIN RES, V510, P26, DOI 10.1016/0006 8993(90)90723 O
   Urade Y, 1999, BBA MOL CELL BIOL L, V1436, P606, DOI 10.1016/S0005 2760(98)00163 5
   Vetvik KG, 2017, LANCET NEUROL, V16, P76, DOI 10.1016/S1474 4422(16)30293 9
   Vina ER, 2018, CURR OPIN RHEUMATOL, V30, P160, DOI 10.1097/BOR.0000000000000479
   Vonkeman HE, 2010, SEMIN ARTHRITIS RHEU, V39, P294, DOI 10.1016/j.semarthrit.2008.08.001
   Walker JS, 1998, ANESTH ANALG, V86, P1257, DOI 10.1097/00000539 199806000 00023
   Wang TA, 2019, NEURON, V103, P309, DOI 10.1016/j.neuron.2019.04.035
   Wangzhou A, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abe1648
   Wangzhou A, 2020, PAIN, V161, P1497, DOI 10.1097/j.pain.0000000000001866
   Weinberger AH, 2010, J WOMENS HEALTH, V19, P1727, DOI 10.1089/jwh.2009.1784
   Wilcox CM, 2005, J RHEUMATOL, V32, P2218
   Yuan QJ, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110187
   Zaveri S, 2022, WORLD J SURG, V46, P1660, DOI 10.1007/s00268 022 06532 x
   Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021
   Zhang P, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1154 0
NR 74
TC 17
Z9 18
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 22
PY 2023
VL 13
IS 1
AR 4670
DI 10.1038/s41598 023 31603 x
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA F7NL7
UT WOS:000984173800041
PM 36949072
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, ST
   Wu, TT
   Yu, PY
   Chen, RM
AF Lee, S.  T.
   Wu, T.  T.
   Yu, P.  Y.
   Chen, R.  M.
TI Apoptotic insults to human HepG2 cells induced by S (+) ketamine
   occurs through activation of a Bax mitochondria caspase protease pathway
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE anaesthetics i.v., ketamine; liver, hepatotoxicity; metabolism, ATP,
   DNA; theories of anaesthetic action, cellular mechanisms
ID OXIDE PROTECTS OSTEOBLASTS; CYTOCHROME C; MACROPHAGE FUNCTIONS;
   ENDOTHELIAL CELLS; KETAMINE; INDUCTION; LIVER; PHARMACOKINETICS;
   6 NITROCHRYSENE; TRANSLOCATION
AB Background. Ketamine is widely used as an i.v. anaesthetic agent and as a drug of abuse. Hepatocytes contribute to the metabolism of endogenous and exogenous substances. This study evaluated the toxic effects of S (+) ketamine and possible mechanisms using human hepatoma HepG2 cells as the experimental model.
   Methods. HepG2 cells were exposed to S (+) ketamine. Cell viability and the release of lactate dehydrogenase (LDH) and gamma glutamyl transpeptidase (GPT) were measured to determine the toxicity of S (+) ketamine to HepG2 cells. Cell morphology, DNA fragmentation, and apoptotic cells were analysed to evaluate the mechanism of S (+) ketamine induced cell death. Amounts of Bax, an apoptotic protein, and cytochrome c in the cytoplasm or mitochondria were quantified by immunoblotting. Cellular adenosine triphosphate levels were analysed using a bioluminescence assay. Caspases 3,  9, and  6 were measured fluorometrically.
   Results. Exposure of HepG2 cells to S (+) ketamine increased the release of LDH and GPT, but decreased cell viability (all P < 0.01). S (+) Ketamine time dependently caused shrinkage of HepG2 cells. Exposure to S (+) ketamine led to significant DNA fragmentation and cell apoptosis (P=0.003 and 0.002). S (+) Ketamine increased translocation of Bax from the cytoplasm to mitochondria, but decreased the mitochondrial membrane potential and cellular adenosine triphosphate levels (all P < 0.01). Sequentially, cytosolic cytochrome c levels and activities of caspases 9,  3, and  6 were augmented after S (+) ketamine administration (all P < 0.001). Z VEID FMK, an inhibitor of caspase 6, alleviated the S (+) ketamine induced augmentation of caspase 6 activity, DNA fragmentation, and cell apoptosis (all P < 0.001).
   Conclusions. This study shows that S (+) ketamine can induce apoptotic insults to human HepG2 cells via a Bax mitochondria caspase protease pathway. Thus, we suggest that S (+) ketamine at a clinically relevant or an abused concentration may induce liver dysfunction possibly due to its toxicity to hepatocytes.
C1 [Yu, P.  Y.; Chen, R.  M.] Taipei Med Univ, Wan Fang Hosp, Coll Med, Grad Inst Med Sci, Taipei 110, Taiwan.
   [Lee, S.  T.] Cathay Gen Hosp, Dept Pediat, Taipei, Taiwan.
   [Lee, S.  T.; Wu, T.  T.] Taipei Med Univ, Wan Fang Hosp, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.
   [Chen, R.  M.] Taipei Med Univ, Wan Fang Hosp, Core Labs, Taipei 110, Taiwan.
   [Chen, R.  M.] Taipei Med Univ, Wan Fang Hosp, Dept Anaesthesiol, Taipei 110, Taiwan.
   [Wu, T.  T.] Taipei Cty Hosp, Dept Internal Med, Taipei, Taiwan.
   [Yu, P.  Y.] Taipei Cty Hosp, Dept Anaesthesiol, Renai Branch, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Municipal WanFang Hospital; Cathay
   General Hospital; Taipei Medical University; Taipei Municipal WanFang
   Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University;
   Taipei Medical University; Taipei Municipal WanFang Hospital
RP Chen, RM (通讯作者)，Taipei Med Univ, Wan Fang Hosp, Coll Med, Grad Inst Med Sci, 250 Wu Hsing St, Taipei 110, Taiwan.
EM rmchen@tmu.edu.tw
RI Yun, Pil Young/D 5753 2012
FU Cathay General Hospital [97CGH TMU 14]; Taipei City Hospital
   [095XDAA00251]; Taipei County Hospital [096 R 0010]; National Bureau of
   Controlled Drug, Department of Health [DOH97 NNB 1037]
FX This study was supported by the Cathay General Hospital (97CGH TMU 14),
   Taipei City Hospital (095XDAA00251), Taipei County Hospital
   (096 R 0010), and National Bureau of Controlled Drug, Department of
   Health (DOH97 NNB 1037), Taipei, Taiwan.
CR Blom WM, 2003, J BIOL CHEM, V278, P12467, DOI 10.1074/jbc.M201264200
   Chan WH, 2005, J TOXICOL ENV HEAL A, V68, P1581, DOI 10.1080/15287390590967522
   Chang CC, 2006, J ORTHOP RES, V24, P1917, DOI 10.1002/jor.20244
   Chang Y, 2005, TOXICOL APPL PHARM, V204, P27, DOI 10.1016/j.taap.2004.08.011
   Chen RM, 1998, ARCH TOXICOL, V72, P395, DOI 10.1007/s002040050519
   Chen RM, 2000, TOXICOL LETT, V117, P69, DOI 10.1016/S0378 4274(00)00242 3
   Chen RM, 2005, J ORTHOP RES, V23, P462, DOI 10.1016/j.orthres.2004.08.011
   Chen RM, 2005, CRIT CARE MED, V33, P1044, DOI 10.1097/01.CCM.0000163246.33366.51
   Chen RM, 2003, ANESTHESIOLOGY, V98, P1178, DOI 10.1097/00000542 200305000 00021
   Chen RM, 2002, J ORTHOP RES, V20, P295, DOI 10.1016/S0736 0266(01)00086 9
   Chen TG, 2007, TOXICOL APPL PHARM, V219, P42, DOI 10.1016/j.taap.2006.11.031
   Cherng YG, 2008, J ORTHOP RES, V26, P1018, DOI 10.1002/jor.20578
   CLEMENTS JA, 1981, BRIT J ANAESTH, V53, P27, DOI 10.1093/bja/53.1.27
   Cobb JP, 1996, BRIT J ANAESTH, V77, P3, DOI 10.1093/bja/77.1.3
   DAWSON JR, 1985, FEBS LETT, V183, P219, DOI 10.1016/0014 5793(85)80780 8
   DOMINO EF, 1982, ANESTH ANALG, V61, P87
   Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092 8674(01)00276 8
   Hijazi Y, 2002, DRUG METAB DISPOS, V30, P853, DOI 10.1124/dmd.30.7.853
   Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016
   Kimura F, 1991, Masui, V40, P1371
   KRUMHOLZ W, 1995, BRIT J ANAESTH, V75, P66, DOI 10.1093/bja/75.1.66
   Ku NO, 2007, HEPATOLOGY, V46, P1639, DOI 10.1002/hep.21976
   Lankenau SE, 2007, DRUG ALCOHOL DEPEN, V87, P183, DOI 10.1016/j.drugalcdep.2006.08.015
   Larenza MP, 2007, BRIT J ANAESTH, V98, P204, DOI 10.1093/bja/ael336
   Navarro VJ, 2006, NEW ENGL J MED, V354, P731, DOI 10.1056/NEJMra052270
   Papeleu P, 2005, CRIT REV TOXICOL, V35, P363, DOI 10.1080/10408440590935639
   Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441
   Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590
   SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104
   SCHMIDT H, 1995, CRIT CARE MED, V23, P2008, DOI 10.1097/00003246 199512000 00009
   Tai YT, 2007, J ORTHOP RES, V25, P625, DOI 10.1002/jor.20365
   Wang C, 2005, NEUROSCIENCE, V132, P967, DOI 10.1016/j.neuroscience.2005.01.053
   WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542 198202000 00007
NR 35
TC 75
Z9 80
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007 0912
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JAN
PY 2009
VL 102
IS 1
BP 80
EP 89
DI 10.1093/bja/aen322
PG 10
WC Anesthesiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology
GA 380HS
UT WOS:000261457400013
PM 19001360
OA Bronze
DA 2025 08 17
ER

PT J
AU Wu, D
   Lima, CJG
   Moreau, SL
   Kulkarni, K
   Zeymo, A
   Burman, KD
   Wartofsky, L
   Van Nostrand, D
AF Wu, Di
   Lima, Cristiane J. Gomes
   Moreau, Shari L.
   Kulkarni, Kanchan
   Zeymo, Alexander
   Burman, Kenneth D.
   Wartofsky, Leonard
   Van Nostrand, Douglas
TI Improved Survival After Multimodal Approach with <SUP>131</SUP>I
   Treatment in Patients with Bone Metastases Secondary to Differentiated
   Thyroid Cancer
SO THYROID
LA English
DT Article
DE differentiated thyroid cancer; bone metastases; I 131 treatment;
   multimodal treatment; overall survival; prognostic factors
ID RADIOACTIVE IODINE TREATMENT; DISTANT METASTASES; PROGNOSTIC FACTORS;
   RADIOIODINE TREATMENT; CARCINOMA; THERAPY; MANAGEMENT; PAPILLARY;
   INSTITUTION; OUTCOMES
AB Background: The objective of this study was to evaluate the overall survival (OS) of radioiodine (I 131) treatments alone or combined with non I 131 treatments in patients with bone metastases (BM) of differentiated thyroid cancer (DTC). Methods: This was a retrospective study of patients who were evaluated between 2001 and 2018 at MedStar Washington Hospital Center and who had DTC, BM, and at least one I 131 treatment after the diagnosis of BM. The OS was analyzed by Kaplan Meier survival curves and was compared by log rank test between two groups: patients who received I 131 treatments alone and those who received treatments combining I 131 with non I 131 treatments (CombTx). Non I 131 treatments include surgery, radiofrequency ablation, cryotherapy, arterial embolization, external beam radiation, Cyberknife, systemic targeted therapy, and anti resorptive medication. Results: A total of 77 patients met the above criteria and were followed up to 41 years. Thirty percent (23/77) of patients received I 131 treatment alone, and 70% (54/77) received CombTx. For I 131 treatment alone, the median survival was 3.9 years, and the 1 , 2 , 3 , 5 , and 10 year OS rates were 86%, 81%, 61%, 35%, and 23%, respectively. For CombTx, the median survival was 7.7 years, and the 1 , 2 , 3 , 5 , and 10 year OS rates were 96%, 92%, 86%, 69%, and 30%, respectively. Patients who had undergone initial I 131 therapy within six months post thyroidectomy demonstrated a better median survival after BM diagnosis than those whose initial I 131 therapy was six months or more after thyroidectomy (6.5 vs. 0.5 years; p < 0.001). Patients who received external beam radiation therapy demonstrated a better median survival than those who did not (7.8 vs. 4.4 years; p = 0.016). Patients who received denosumab demonstrated a better median survival than those who did not (7.7 vs. 5.2 years; p = 0.03). Patients who were <55 years of age at the initial diagnosis of DTC or at the initial diagnosis of BM had a better median OS than those diagnosed at >= 55 years of age (both p = 0.01). In the multivariate analysis, only age at initial diagnosis of DTC and initial I 131 therapy within six months post thyroidectomy, and multiple I 131 treatments were independent prognostic factors. Conclusions: In patients with DTC with BM, I 131 treatment in combination with one or more non I 131 direct and systemic treatments was associated with a significant increase in OS compared with those patients who were treated by I 131 treatment alone.
C1 [Wu, Di; Lima, Cristiane J. Gomes; Van Nostrand, Douglas] MedStar Clin Res Ctr, Hyattsville, MD USA.
   [Zeymo, Alexander] MedStar Hlth Res Inst, Dept Biostat & Biomed Informat, Hyattsville, MD USA.
   [Wu, Di; Van Nostrand, Douglas] MedStar Washington Hosp Ctr, Nucl Med Res, Washington, DC USA.
   [Lima, Cristiane J. Gomes; Burman, Kenneth D.; Wartofsky, Leonard] MedStar Washington Hosp Ctr, Div Endocrinol, Washington, DC USA.
   [Moreau, Shari L.; Kulkarni, Kanchan] MedStar Washington Hosp Ctr, Div Nucl Med, Washington, DC USA.
C3 MedStar Health Research Institute; MedStar Washington Hospital Center;
   MedStar Washington Hospital Center; MedStar Washington Hospital Center
RP Van Nostrand, D (通讯作者)，MedStar Washington Hosp Ctr, MedStar Hlth Res Inst, Nucl Med Res, Suite GA60F,110 Irving St,NW, Washington, DC 20010 USA.
EM douglas.van.nostrand@medstar.net
OI Wu, Di/0000 0003 1567 1977
CR Bernier MO, 2001, J CLIN ENDOCR METAB, V86, P1568, DOI 10.1210/jc.86.4.1568
   CASARA D, 1991, TUMORI, V77, P432, DOI 10.1177/030089169107700512
   Cazzato RL, 2015, EJSO EUR J SURG ONC, V41, P1247, DOI 10.1016/j.ejso.2015.06.005
   Choi YM, 2016, EUR J ENDOCRINOL, V175, P165, DOI 10.1530/EJE 16 0237
   DINNEEN SF, 1995, J CLIN ENDOCR METAB, V80, P2041, DOI 10.1210/jc.80.7.2041
   Dorn R, 2003, J NUCL MED, V44, P451
   Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005 2838
   Eustatia Rutten CFA, 2003, J CLIN ENDOCR METAB, V88, P3184, DOI 10.1210/jc.2003 030231
   Haq M, 2005, CLIN ENDOCRINOL, V63, P87, DOI 10.1111/j.1365 2265.2005.02304.x
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Huang IC, 2012, CLIN ENDOCRINOL, V76, P439, DOI 10.1111/j.1365 2265.2011.04231.x
   Jentzen W, 2016, J NUCL MED, V57, P1499, DOI 10.2967/jnumed.115.170571
   Kallel Faouzi, 2014, Indian J Endocrinol Metab, V18, P185, DOI 10.4103/2230 8210.129109
   Kato S, 2016, CANCER MED US, V5, P2343, DOI 10.1002/cam4.823
   KHORJEKAR G, 2010, J NUCL MED S2, V51
   Lang BHH, 2013, ANN SURG ONCOL, V20, P1329, DOI 10.1245/s10434 012 2711 x
   Lin JD, 1999, THYROID, V9, P1227, DOI 10.1089/thy.1999.9.1227
   MARCOCCI C, 1989, SURGERY, V106, P960
   MAXON HR, 1983, NEW ENGL J MED, V309, P937, DOI 10.1056/NEJM198310203091601
   Maxon HR, 1997, THYROID, V7, P183, DOI 10.1089/thy.1997.7.183
   Mazziotti G, 2018, ENDOCRINE, V59, P90, DOI 10.1007/s12020 017 1455 6
   Mishra A, 2016, WORLD J SURG, V40, P562, DOI 10.1007/s00268 016 3402 8
   Orita Y, 2015, ANN SURG ONCOL, V22, P4008, DOI 10.1245/s10434 015 4497 0
   Orita Y, 2010, SURGERY, V147, P424, DOI 10.1016/j.surg.2009.10.009
   Petrich T, 2001, EUR J NUCL MED, V28, P203, DOI 10.1007/s002590000420
   Pittas AG, 2000, THYROID, V10, P261, DOI 10.1089/thy.2000.10.261
   PROYE CAG, 1992, WORLD J SURG, V16, P640, DOI 10.1007/BF02067343
   Qiu ZL, 2015, THYROID, V25, P229, DOI 10.1089/thy.2014.0233
   Qiu ZL, 2011, J CLIN ENDOCR METAB, V96, P3078, DOI 10.1210/jc.2011 0093
   RUEGEMER JJ, 1988, J CLIN ENDOCR METAB, V67, P501, DOI 10.1210/jcem 67 3 501
   SCHLUMBERGER M, 1986, J CLIN ENDOCR METAB, V63, P960
   Schlumberger M, 1996, J NUCL MED, V37, P598
   Van Nostrand D, 2002, THYROID, V12, P121, DOI 10.1089/105072502753522356
   Van Nostrand D, 2017, ENDOCRIN METAB CLIN, V46, P783, DOI 10.1016/j.ecl.2017.04.007
   Wells K, 2008, J NUCL MED, V49, p238P
   Wexler JA., 2016, Thyroid Cancer: A Comprehensive Guide to Clinical Management [Internet], P723, DOI [10.1007/978 1 4939 3314 3_65, DOI 10.1007/978 1 4939 3314 3_65]
   Wu K, 2008, CLIN MED INSIGHTS ON, V2, P129
NR 37
TC 31
Z9 36
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050 7256
EI 1557 9077
J9 THYROID
JI Thyroid
PD JUL 1
PY 2019
VL 29
IS 7
BP 971
EP 978
DI 10.1089/thy.2018.0582
EA MAY 2019
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IJ3IC
UT WOS:000469474500001
PM 31017051
DA 2025 08 17
ER

PT J
AU Pourgonabadi, S
   Mousavi, SH
   Tayarani Najaran, Z
   Ghorbani, A
AF Pourgonabadi, Solmaz
   Mousavi, Seyed Hadi
   Tayarani Najaran, Zahra
   Ghorbani, Ahmad
TI Effect of zoledronate, a third generation bisphosphonate, on
   proliferation and apoptosis of human dental pulp stem cells
SO CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE apoptosis; bisphosphonates; dental pulp; proliferation; stem cells;
   zoledronate
ID CANCER PATIENTS; ACID; OSTEONECROSIS; JAW; PHARMACODYNAMICS;
   PHARMACOKINETICS; ROLES
AB Clinical use of zoledronate is accompanied by osteonecrosis of the jaw but the pathogenesis is not well understood. We assumed that zoledronate may have cytotoxicity against stem cells of the oral cavity and in this way helps to initiate or promote osteonecrosis. Dental pulp stem cells (DPSCs) and gingival fibroblasts (GFs) were isolated from volunteers who were undergoing a third molar extraction. The proliferation of DPSCs and GFs was evaluated using the thiazolyl blue tetrazolium bromide assay. The effect of zoledronate on apoptosis was determined by propidium iodide staining and Western blotting analysis. Incubation with zoledronate for 72 h and 7 days significantly decreased proliferation of DPSCs and GFs at concentrations of more than 0.4 mu mol/L (p < 0.001). The IC50 of zoledronate was lower for DPSCs than for GFs (0.92 versus 3.5 mu mol/L for 7 days of treatment). After 72 h of treatment with zoledronate, the percentage of apoptotic DPSCs significantly increased, which was accompanied by an increased level of pro apoptotic proteins caspase 3 and Bax and decreased the level of the anti apoptotic protein Bcl 2. In conclusion, zoledronate has anti proliferative and pro apoptotic effects in DPSCs. These effects may be involved in promoting zoledronate induced osteonecrosis and suggest an unfavorable impact of this drug on regenerative potentials of the body stem cells.
C1 [Pourgonabadi, Solmaz; Mousavi, Seyed Hadi] Mashhad Univ Med Sci, Dept Pharmacol, Fac Med, Mashhad, Iran.
   [Mousavi, Seyed Hadi; Ghorbani, Ahmad] Mashhad Univ Med Sci, Pharmacol Res Ctr Med Plants, Mashhad, Iran.
   [Mousavi, Seyed Hadi] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Iran.
   [Tayarani Najaran, Zahra] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmacodynam & Toxicol, Mashhad, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences
RP Ghorbani, A (通讯作者)，Mashhad Univ Med Sci, Pharmacol Res Ctr Med Plants, Mashhad, Iran.
EM ghorbania@mums.ac.ir
RI Pourgonabadi, Solmaz/JOZ 4197 2023; Mousavi, Seyed/AAM 6802 2020;
   Ghorbani, Ahmad/S 8164 2016; Tayarani Najaran, Zahra/I 1999 2014
OI naseri, shahrokh/0000 0001 8974 2120; 
FU Research Council of Mashhad University of Medical Sciences, Mashhad,
   Iran [911212]
FX This work was a part of the Ph.D. thesis of one of the authors (S.
   Pourgonabadi) and supported by a grant (No. 911212) from the Research
   Council of Mashhad University of Medical Sciences, Mashhad, Iran. The
   authors would like to thank Mohammad Malaekeh Nikouei for his assistance
   in flow cytometry. We acknowledge the Negin Daro Noavar Company for the
   generous gift of zoledronate.
CR Agis H, 2010, J DENT RES, V89, P40, DOI 10.1177/0022034509354298
   Alinejad B, 2015, DARU, V23, DOI 10.1186/s40199 015 0100 2
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   Basso Fernanda Goncalves, 2013, Braz. Dent. J., V24, P551
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Colucci A, 2009, OCUL IMMUNOL INFLAMM, V17, P267, DOI 10.1080/09273940902916111
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Feizpour A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108974
   Gallo M, 2012, ANN ONCOL, V23, P597, DOI 10.1093/annonc/mdr159
   Ghorbani A, 2014, DARU, V22, DOI 10.1186/2008 2231 22 26
   Ghorbani A, 2014, TISSUE CELL, V46, P54, DOI 10.1016/j.tice.2013.11.002
   Gong X., 2015, J CRANIOMAXILLOFAC S, V1, DOI [10.3969/j.issn.1005 4979.2015.01.005, DOI 10.3969/J.ISSN.1005 4979.2015.01.005]
   Green JR, 2005, J ORGANOMET CHEM, V690, P2439, DOI 10.1016/j.jorganchem.2004.09.069
   Heino TJ, 2016, ACTA ORTHOP, V87, P412, DOI 10.1080/17453674.2016.1188258
   Rodríguez Lozano FJ, 2015, J CRANIO MAXILL SURG, V43, P855, DOI 10.1016/j.jcms.2015.04.012
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Li EC, 2003, CLIN THER, V25, P2669, DOI 10.1016/S0149 2918(03)80327 2
   Misra J, 2016, STEM CELLS, V34, P756, DOI 10.1002/stem.2255
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mortazavian Seyed Mohsen, 2013, Int J Alzheimers Dis, V2013, P121068, DOI 10.1155/2013/121068
   Ruggiero SL, 2007, CLIN CASES MINER BON, V4, P37
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Sloan AJ, 2007, ORAL DIS, V13, P151, DOI 10.1111/j.1601 0825.2006.01346.x
   Tadrous M, 2014, OSTEOPOROSIS INT, V25, P1225, DOI 10.1007/s00198 013 2576 2
   Wellington K, 2003, DRUGS, V63, P417, DOI 10.2165/00003495 200363040 00009
   Wessel JH, 2008, J ORAL MAXIL SURG, V66, P625, DOI 10.1016/j.joms.2007.11.032
   Wu TY, 2014, CURR STEM CELL RES T, V9, P424, DOI 10.2174/1574888X09666140616125446
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
NR 31
TC 7
Z9 8
U1 0
U2 3
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008 4212
EI 1205 7541
J9 CAN J PHYSIOL PHARM
JI Can. J. Physiol. Pharmacol.
PD FEB
PY 2018
VL 96
IS 2
BP 137
EP 144
DI 10.1139/cjpp 2016 0348
PG 8
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA FU6QC
UT WOS:000423976100005
PM 28772088
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, XX
   Barua, S
   Rege, K
   Vogt, BD
AF Li, Xinxin
   Barua, Sutapa
   Rege, Kaushal
   Vogt, Bryan D.
TI Tuning Stability of Mesoporous Silica Films under Biologically Relevant
   Conditions through Processing with Supercritical CO2
SO LANGMUIR
LA English
DT Article
ID THIN FILMS; HYDROTHERMAL STABILITY; MCM 41; TEMPLATES; DESIGN
AB Mesoporous materials have been proposed for use in numerous biological environments such as substrates for cell culture and controlled release for drug delivery. Although mesoporous silica synthesis is facile, recent reports (Dunphy et al. Langmuir 2003, 19, 10403; Bass et al. Chem. Mater. 2007, 19, 4349) have demonstrated instability (dissolution) of pure mesoporous silica films under biologically relevant conditions. In this work, we demonstrate a simple processing handle (pressure) to control the dissolution of mesoporous silica films that are synthesized using preformed template films and supercritical CO2. Spectroscopic ellipsometry is utilized to quantify changes in both the film thickness and porosity; these properties provide insight into the dissolution mechanism. The pore size increases as the films are exposed to phosphate buffered saline (PBS) through preferential dissolution at the pore wall in comparison to the film surface; a mechanism reminiscent of bulk erosion of scaffolds for drug delivery. Thin mesoporous silica film lifetimes can be extended from several hours using traditional sol gel approaches to days by using CO2 processing for identical film thickness. Osteoblast attachment and viability on these films was found to correlate with their increased stability. This enhanced stability opens new possibilities for the utilization of mesoporous silica for biological applications, including drug delivery and tissue engineering.
C1 [Li, Xinxin; Barua, Sutapa; Rege, Kaushal; Vogt, Bryan D.] Arizona State Univ, Dept Chem Engn, Tempe, AZ 85284 USA.
C3 Arizona State University; Arizona State University Tempe
RP Vogt, BD (通讯作者)，Arizona State Univ, Dept Chem Engn, Tempe, AZ 85284 USA.
EM bryan.vogt@asu.edu
FU National Science Foundation [ENG 0746664]; State of Arizona
FX The authors acknowledge support from the National Science Foundation
   (ENG 0746664) and partial financial support from the State of Arizona.
   We thank DuPont Electronic Materials (Jim Sounik and Michael Sheehan)
   for donation of the poly(4 hydroxystyrene). The authors thank Dr.
   Christine Pauken, Harrington Department of Bioengineering, for providing
   the osteoblasts for the cell studies. We acknowledge the use of
   facilities in the LeRoy Erying Center for Solid State Science. The
   authors thank Jerry Y.S. Lin for access to XRD instrumentation. We
   acknowledge the assistance of Barry O'Brien at the ASU Flexible Display
   Center for assistance with FTIR measurements.
CR Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Baklanov MR, 2000, J VAC SCI TECHNOL B, V18, P1385, DOI 10.1116/1.591390
   Bass JD, 2007, CHEM MATER, V19, P4349, DOI 10.1021/cm071305g
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521 4095(199905)11:7<579::AID ADMA579>3.0.CO;2 R
   Brinker CJ, 2013, SOL GEL SCI PHYS CHE, DOI 10.1016/C2009 0 22386 5
   Chen LY, 1997, MICROPOROUS MATER, V12, P323, DOI 10.1016/S0927 6513(97)00079 5
   Coakley KM, 2003, APPL PHYS LETT, V83, P3380, DOI 10.1063/1.1616197
   Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n
   Das D, 1999, CHEM COMMUN, P473, DOI 10.1039/a809815h
   Doadrio AL, 2004, J CONTROL RELEASE, V97, P125, DOI 10.1016/j.jconrel.2004.03.005
   Dunphy DR, 2003, LANGMUIR, V19, P10403, DOI 10.1021/la035183s
   Fan HY, 2007, NAT MATER, V6, P418, DOI 10.1038/nmat1913
   Fang H, 2006, J NON CRYST SOLIDS, V352, P2279, DOI 10.1016/j.jnoncrysol.2006.02.057
   Hartmann M, 2005, CHEM MATER, V17, P4577, DOI 10.1021/cm0485658
   Hayward RC, 2005, ADV MATER, V17, P2591, DOI 10.1002/adma.200500334
   Impéror Clerc M, 2000, J AM CHEM SOC, V122, P11925, DOI 10.1021/ja002245h
   Kale S, 2000, NAT BIOTECHNOL, V18, P954, DOI 10.1038/79439
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Lai ZP, 2003, SCIENCE, V300, P456, DOI 10.1126/science.1082169
   Li XX, 2008, CHEM MATER, V20, P3229, DOI 10.1021/cm8003479
   Li X, 2008, J PHYS CHEM C, V112, P53, DOI [10.1021/jp0762727, 10.1021/jp807535v]
   Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699
   Mercier L, 1997, ADV MATER, V9, P500, DOI 10.1002/adma.19970090611
   Mokaya R, 2000, J PHYS CHEM B, V104, P8279, DOI 10.1021/jp001494p
   Nagarajan S, 2008, CHEM MATER, V20, P604, DOI 10.1021/cm702397b
   Nagarajan S, 2008, ADV MATER, V20, P246, DOI 10.1002/adma.200701766
   Nicole L, 2005, J MATER CHEM, V15, P3598, DOI 10.1039/b506072a
   Pai RA, 2006, ADV MATER, V18, P241, DOI 10.1002/adma.200401928
   Pai RA, 2004, SCIENCE, V303, P507, DOI 10.1126/science.1092627
   Palik ED, 1985, HDB OPTICAL CONSTANT, DOI DOI 10.1016/B978 012544415 6.500002 9
   Pham JQ, 2004, J PHYS CHEM B, V108, P3457, DOI 10.1021/jp036765l
   Quick DJ, 2004, J CONTROL RELEASE, V97, P333, DOI 10.1016/j.jconrel.2004.03.001
   Sanchez C, 2008, CHEM MATER, V20, P682, DOI 10.1021/cm702100t
   Stein A, 2003, ADV MATER, V15, P763, DOI 10.1002/adma.200300007
   Tanaka S, 2004, J AM CHEM SOC, V126, P4854, DOI 10.1021/ja039267z
   Tanaka S, 2006, CHEM MATER, V18, P5461, DOI 10.1021/cm0614463
   Tirumala VR, 2007, CHEM MATER, V19, P5868, DOI 10.1021/cm070792x
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
   Vogel BM, 2005, BIOMATERIALS, V26, P721, DOI 10.1016/j.biomaterials.2004.03.024
   Yamamoto T, 2008, J PHYS CHEM C, V112, P328, DOI 10.1021/jp710189p
   Yang PD, 1998, NATURE, V396, P152
   Yang S, 2001, CHEM MATER, V13, P2762, DOI 10.1021/cm0102786
NR 42
TC 12
Z9 13
U1 0
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743 7463
J9 LANGMUIR
JI Langmuir
PD OCT 21
PY 2008
VL 24
IS 20
BP 11935
EP 11941
DI 10.1021/la801849n
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 360HT
UT WOS:000260049300083
PM 18795807
DA 2025 08 17
ER

PT J
AU Liu, L
   Wang, TY
   Huang, DM
   Song, DZ
AF Liu, Liu
   Wang, Tianyi
   Huang, Dingming
   Song, Dongzhe
TI Comprehensive Analysis of Differentially Expressed Genes in Clinically
   Diagnosed Irreversible Pulpitis by Multiplatform Data Integration Using
   a Robust Rank Aggregation Approach
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Dental pulp; diagnosis; integrated analysis; noncoding RNA; pulpitis
ID INFLAMMATION; MARKER
AB Introduction: Molecular diagnosis may overcome the limitations of clinical and histologic diagnosis in pulpitis, thereby benefiting many treatment techniques, such as vital pulp therapies. In this study, integrated microarray data on pulpitis were used to obtain a list of normalized differentially expressed (DE) genes for analyzing the molecular mechanisms underlying pulpitis and identifying potential diagnostic biomarkers. Methods: A systematic search of public microarray and sequencing databases was performed to obtain expression data of pulpitis. Robust rank aggregation (RRA) was used to obtain DE gene lists (RRA_DEmRNAs and RRA_DEIncRNAs) between inflamed pulp and normal samples. DE genes were evaluated by functional enrichment analyses, correlation analyses for inflammation related RRA_DEmRNAs, and protein protein interaction and competing endogenous RNA network construction. Quantitative real time polymerase chain reaction validation was applied in snap frozen pulp tissues. Results: Using the GSE77459 and GSE92681 data sets, 280 RRA_DEmRNAs and 90 RRA_DEIncRNAs were identified. RRA_DEmRNAs were significantly enriched in inflammation related biological processes and osteoclast differentiation and tumor necrosis factor, chemokine, and B cell receptor signaling pathways. The molecular complex detection and cytoHubba methods identified 2 clusters and 10 hub genes in the protein protein interaction network. The competing endogenous RNA network was composed of 2 long noncoding RNAs (ADAMTS9 AS2 and LINC00290), 2 microRNAs (hsa miR 30a 5p and hsa miR 128 3p), and 3 messenger RNAs (ABCA1, FBLN5, and SOCS3). The expression between most top inflammation related RRA_DEmRNAs in pulpitis showed positive correlations. Quantitative real time polymerase chain reacation validated the expression trends of selected genes, including /TGAX, TREM1, CD86, FCGR2A, ADAMTS9 AS2, LINC00290, hsa miR 30a 5p, hsa miR 128 3p, RASGRP3, IL3RA, CCDC178, CRISPLD1, LINC01857, AC007991.2, ARHGEF26 AS1, and AL021408.1. Conclusions: The identified biomarkers provide insight into the pathology and may aid in the molecular diagnosis of pulpitis.
C1 [Liu, Liu; Wang, Tianyi; Huang, Dingming; Song, Dongzhe] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Liu, Liu; Wang, Tianyi; Huang, Dingming; Song, Dongzhe] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Liu, Liu; Huang, Dingming; Song, Dongzhe] Sichuan Univ, West China Hosp Stomatol, Dept Conservat Dent & Endodont, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Song, DZ (通讯作者)，West China Hosp Stomatol, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
EM dongzhesong@scu.edu.cn
RI ; SONG, DONGZHE/JSK 3963 2023; Liu, Liu/AFB 2400 2022
OI Liu, Liu/0000 0001 8681 3413; SONG, DONGZHE/0000 0001 5241 2013; Huang,
   Dingming/0000 0002 0779 5729; 
FU National Natural Science Foundation of China [81900996, 81771063]; China
   Postdoctoral Science Foundation [2019M653441]
FX Supported by the National Natural Science Foundation of China (grant
   nos. 81900996 [D.Z.S] and 81771063[D.M.H]) and China Postdoctoral
   Science Foundation (grant no. 2019M653441 [D.Z.S]).
CR Aminoshariae A, 2018, J ENDODONT, V44, P1361, DOI 10.1016/j.joen.2018.06.011
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Brizuela C, 2020, INT ENDOD J, V53, P1181, DOI 10.1111/iej.13343
   Campain A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471 2105 11 408
   Chen M, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01266 5
   Chen XY, 2019, ORGANOGENESIS, V15, P55, DOI 10.1080/15476278.2019.1633871
   Cifci A, 2020, BRATISL MED J, V121, P259, DOI 10.4149/BLL_2020_039
   Dincer GA, 2020, J ENDODONT, V46, P1428, DOI 10.1016/j.joen.2020.07.013
   Dong N, 2019, CURR EYE RES, V44, P1236, DOI 10.1080/02713683.2019.1632350
   Franciscatto GJ, 2020, INT ENDOD J, V53, P887, DOI 10.1111/iej.13293
   Galicia JC, 2016, GENES IMMUN, V17, P239, DOI 10.1038/gene.2016.14
   Glickman G.N, 2009, J ENDODONT, V35, P1634, DOI [10.1016/j.joen.2009.09.035, DOI 10.1016/J.JOEN.2009.09.035]
   Haug SR, 2019, J ORAL FACIAL PAIN H, V33, P227, DOI 10.11607/ofph.2007
   Huang MJ, 2019, MOL THER NUCL ACIDS, V18, P533, DOI 10.1016/j.omtn.2019.08.027
   Huang X, 2018, J ENDODONT, V44, P62, DOI 10.1016/j.joen.2017.08.022
   Koh EH, 2018, DIABETES, V67, P2541, DOI 10.2337/db17 1378
   Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709
   Lei FC, 2019, PEERJ, V7, DOI 10.7717/peerj.7135
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Mahale P, 2019, INDIAN J MED MICROBI, V37, P192, DOI 10.4103/ijmm.IJMM_19_169
   McLachlan JL, 2005, BBA MOL BASIS DIS, V1741, P271, DOI 10.1016/j.bbadis.2005.03.007
   Mente J, 2016, J ENDODONT, V42, P190, DOI 10.1016/j.joen.2015.10.020
   Ricucci D, 2019, J DENT, V86, P41, DOI 10.1016/j.jdent.2019.05.022
   Ricucci D, 2014, J ENDODONT, V40, P1932, DOI 10.1016/j.joen.2014.08.010
   Rung J, 2013, NAT REV GENET, V14, P89, DOI 10.1038/nrg3394
   Shim JS, 2020, ALLERGY, V75, P381, DOI 10.1111/all.14017
   vanSchie RCAA, 1997, J IMMUNOL METHODS, V208, P91, DOI 10.1016/S0022 1759(97)00132 4
   Wu LZ, 2020, BIOCHEM BIOPH RES CO, V521, P98, DOI 10.1016/j.bbrc.2019.10.083
   Xi XX, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/8831948
   Yoshiba N, 2020, J DENT RES, V99, P329, DOI 10.1177/0022034519894957
   Zanini M, 2017, J ENDODONT, V43, P1033, DOI 10.1016/j.joen.2017.02.009
   Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590 019 0378 1
   Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0694 1
   Zhong S, 2012, J ENDODONT, V38, P746, DOI 10.1016/j.joen.2012.02.020
NR 34
TC 22
Z9 23
U1 2
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0099 2399
EI 1878 3554
J9 J ENDODONT
JI J. Endod.
PD SEP
PY 2021
VL 47
IS 9
BP 1365
EP 1375
DI 10.1016/j.joen.2021.07.007
EA AUG 2021
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA UE4UC
UT WOS:000687884300006
PM 34260959
DA 2025 08 17
ER

PT J
AU Coleman, R
   Hall, A
   Albanell, J
   Hanby, A
   Bell, R
   Cameron, D
   Dodwell, D
   Marshall, H
   Jean Mairet, J
   Tercero, JC
   Rojo, F
   Gregory, W
   Gomis, RR
AF Coleman, Robert
   Hall, Andrew
   Albanell, Joan
   Hanby, Andrew
   Bell, Richard
   Cameron, David
   Dodwell, David
   Marshall, Helen
   Jean Mairet, Joel
   Tercero, Juan Carlos
   Rojo, Federico
   Gregory, Walter
   Gomis, Roger R.
TI Effect of MAF amplification on treatment outcomes with adjuvant
   zoledronic acid in early breast cancer: a secondary analysis of the
   international, open label, randomised, controlled, phase 3 AZURE (BIG
   01/04) trial
SO LANCET ONCOLOGY
LA English
DT Article
ID CLINICAL PRACTICE; BONE; BISPHOSPHONATES; THERAPY
AB Background Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid.
   Methods The study population included patients enrolled in the international, open label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples. Patients were randomly assigned (1: 1) to receive standard adjuvant systemic therapy alone (control group) or with zoledronic acid every 3 4 weeks for six doses, then every 3 6 months until the end of 5 years. Minimisation took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen receptor status, type and timing of systemic therapy, menopausal status, statin use, and treating centre. The primary endpoint was disease free survival; the secondary endpoint, invasive disease free survival, was the primary disease endpoint for the analysis in this report. MAF amplification was assessed by fluorescence in situ hybridisation of two cores of breast tumour tissue in a microarray, done in a central laboratory by technicians unaware of treatment assignment. We used multivariate analyses to assess disease outcomes by intention to treat. We also assessed interactions between MAF positive status and menopausal status on efficacy of zoledronic acid. The AZURE trial is registered with the International Standard Randomised Controlled Trial Registry, number ISRCTN79831382.
   Findings 1739 AZURE patients contributed primary tumour samples, of whom 865 (50%) had two assessable cores (445 in the control groups and 420 in the zoledronic acid group).184 (21%) tumours were MAF positive (85 in the control groups and 99 in the zoledronic acid group) and the remaining tumours were MAF negative. At a median follow up of 84 . 6 months (IQR 72.0 95.8), MAF status was not prognostic for invasive disease free survival in the control group (MAF positive vs MAF negative: hazard ratio [HR] 0.92, 95% CI 0.59 1.41), but was in the zoledronic acid group (0.52, 0.36 0.75). In patients with MAF negative tumours, zoledronic acid was associated with higher invasive disease free survival than was control treatment (HR 0.74, 95% CI 0.56 0.98), but not in patients who had MAF positive tumours. Additionally, among 121 patients not postmenopausal at randomisation with MAF positive tumours, zoledronic acid was associated with lower invasive disease free survival (HR 2.47, 95% CI 1.23 4.97) and overall survival (2.27, 95% CI 1.04 4.93) than control treatment.
   Interpretation MAF status can predict likelihood of benefit from adjuvant zoledronic acid and merits further investigation as a potential companion diagnostic.
C1 [Coleman, Robert] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
   [Hall, Andrew; Marshall, Helen; Gregory, Walter] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England.
   [Hanby, Andrew] Univ Leeds, Inst Canc & Pathol, Leeds, W Yorkshire, England.
   [Albanell, Joan; Gomis, Roger R.] IMIM CIBERONC, Barcelona, Spain.
   [Albanell, Joan] Hosp del Mar, Med Oncol Dept, Barcelona, Spain.
   [Albanell, Joan] Pompeu Fabra Univ, Barcelona, Spain.
   [Bell, Richard] Deakin Univ, Geelong, Vic, Australia.
   [Cameron, David] Univ Edinburgh, MRC Inst Genet & Mol Med, Canc Res UK Edinburgh Ctr, Edinburgh, Midlothian, Scotland.
   [Dodwell, David] St James Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
   [Jean Mairet, Joel] Inbiomotion, Barcelona, Spain.
   [Rojo, Federico] Fdn Jimenez Diaz, Madrid, Spain.
   [Rojo, Federico] CIBERONC, Madrid, Spain.
   [Gomis, Roger R.] Inst Res Biomed IRB Barcelona, Barcelona, Spain.
   [Gomis, Roger R.] ICREA, Barcelona, Spain.
C3 Weston Park Hospital; University of Leeds; University of Leeds; CIBER  
   Centro de Investigacion Biomedica en Red; CIBERONC; Hospital del Mar
   Research Institute; Hospital del Mar; Pompeu Fabra University; Deakin
   University; University of Edinburgh; Saint James's University Hospital;
   CIBER   Centro de Investigacion Biomedica en Red; CIBERONC; Barcelona
   Institute of Science & Technology; Institute for Research in Biomedicine
     IRB Barcelona; ICREA
RP Coleman, R (通讯作者)，Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
EM r.e.coleman@sheffield.ac.uk
RI Cameron, David/C 7781 2013; Albanell, Joan/R 9470 2019; Coleman,
   Robert/E 4346 2019; Rojo, Federico/S 6551 2016; Gomis, Roger/E 9788 2016
OI Cameron, David/0000 0002 2717 7979; Rojo, Federico/0000 0001 9989 0290;
   Darby, Sarah C/0000 0003 4046 0573; Marshall, Helen/0000 0003 0944 0152;
   Hall, Andrew/0000 0003 1165 706X; Gomis, Roger/0000 0001 6473 2858
FU Novartis Global; Inbiomotion; Medical Research Council [MC_U137686858]
   Funding Source: researchfish; Versus Arthritis; Cancer Research UK
   [21133] Funding Source: researchfish; MRC [MC_U137686858] Funding
   Source: UKRI
FX Novartis Global and Inbiomotion.
CR Blouin MJ, 2015, BREAST CANCER RES TR, V149, P577, DOI 10.1007/s10549 015 3268 8
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Pavlovic M, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv256
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Westbrook JA, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv360
NR 16
TC 45
Z9 49
U1 4
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1470 2045
EI 1474 5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD NOV
PY 2017
VL 18
IS 11
BP 1543
EP 1552
DI 10.1016/S1470 2045(17)30603 4
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FL3OZ
UT WOS:000414134100061
PM 29037984
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Córdoba, A
   Satué, M
   Gómez Florit, M
   Hierro Oliva, M
   Petzold, C
   Lyngstadaas, SP
   González Martín, ML
   Monjo, M
   Ramis, JM
AF Cordoba, Alba
   Satue, Maria
   Gomez Florit, Manuel
   Hierro Oliva, Margarita
   Petzold, Christiane
   Lyngstadaas, Staale P.
   Luisa Gonzalez Martin, Maria
   Monjo, Marta
   Ramis, Joana M.
TI Flavonoid Modified Surfaces: Multifunctional Bioactive Biomaterials with
   Osteopromotive, Anti Inflammatory, and Anti Fibrotic Potential
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bioactivity; biomaterials; flavonoids; surface functionalization;
   titanium
ID SELF ASSEMBLED MONOLAYERS; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; TITANIUM; ADHESION; GROWTH;
   3 AMINOPROPYLTRIETHOXYSILANE; CHEMISTRY
AB Flavonoids are small polyphenolic molecules of natural origin with antioxidant, anti inflammatory, and antibacterial properties. Here, a bioactive surface based on the covalent immobilization of flavonoids taxifolin and quercitrin on titanium substrates is presented, using (3 aminopropyl)triethoxysilane (APTES) as coupling agent. FTIR and XPS measurements confirm the grafting of the flavonoids to the surfaces. Using 2 aminoethyl diphenylborinate (DPBA, a flavonoid specific dye), the modified surfaces are imaged by fluorescence microscopy. The bioactivity of the flavonoid modified surfaces is evaluated in vitro with human umbilical cord derived mesenchymal stem cells (hUC MSCs) and human gingival fibroblasts (HGFs) and compared to that of simple flavonoid coatings prepared by drop casting. Flavonoid modified surfaces show anti inflammatory and anti fibrotic potential on HGF. In addition, Ti surfaces covalently functionalized with flavonoids promote the differentiation of hUC MSCs to osteoblastsenhancing the expression of osteogenic markers, increasing alkaline phosphatase activity and calcium deposition; while drop casted surfaces do not. These findings could have a high impact in the development of advanced implantable medical devices like bone implants. Given the broad range of bioactivities of flavonoid compounds, these surfaces are ready to be explored for other biomedical applications, e.g., as stent surface or tumor targeted functionalized nanoparticles for cardiovascular or cancer therapies.
C1 [Cordoba, Alba; Satue, Maria; Gomez Florit, Manuel; Monjo, Marta; Ramis, Joana M.] Univ Balearic Isl, Res Inst Hlth Sci IUNICS, Grp Cell Therapy & Tissue Engn, Palma De Mallorca 07122, Spain.
   [Hierro Oliva, Margarita; Luisa Gonzalez Martin, Maria] Univ Extremadura, Fac Ciencias, Dept Fis Aplicada, Badajoz, Spain.
   [Hierro Oliva, Margarita; Luisa Gonzalez Martin, Maria] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain.
   [Petzold, Christiane; Lyngstadaas, Staale P.] Univ Oslo, Dept Biomat, N 0317 Oslo, Norway.
C3 Universitat de les Illes Balears; IUNICS; Universidad de Extremadura;
   CIBER   Centro de Investigacion Biomedica en Red; CIBERBBN; University
   of Oslo
RP Monjo, M (通讯作者)，Univ Balearic Isl, Res Inst Hlth Sci IUNICS, Grp Cell Therapy & Tissue Engn, Ctra Valldemossa Km 7 5, Palma De Mallorca 07122, Spain.
EM marta.monjo@uib.es; joana.ramis@uib.es
RI Monjo, Marta/JCE 0468 2023; Gomez Florit, Manuel/I 9408 2014; González
   Martín, María Luisa/L 3476 2014; Petzold, Christiane/G 5409 2012; Ramis,
   Joana/AAF 4892 2020; Cordoba, Alba/V 2448 2017
OI Gomez Florit, Manuel/0000 0001 7758 1251; Monjo,
   Marta/0000 0002 2731 9527; Hierro Oliva, Margarita/0000 0002 9741 4503;
   Ramis, Joana Maria/0000 0001 9109 8362; Petzold,
   Christiane/0000 0002 4861 7523; Cordoba, Alba/0000 0002 2726 5119;
   Lyngstadaas, Staale Petter/0000 0002 6361 7644
FU Ministerio de Ciencia e Innovacion del Gobierno de Espana; Gobierno de
   Extremadura [GR10149]; Technology Funds from Invest in Spain [C2_10_32];
   COST Action [MP1005]
FX This work was supported by the Ministerio de Ciencia e Innovacion del
   Gobierno de Espana (Torres Quevedo contract to M.G.F. and J.M.R., and
   Ramon y Cajal contract to M.M.), Gobierno de Extremadura (GR10149) and
   Technology Funds from Invest in Spain (C2_10_32). A.C. acknowledges the
   COST Action MP1005 (NAMABIO network) for an STSM Grant. M.S. and M.G.F.
   contributed equally to this work. The authors thank Dr. Antoni Gaya and
   Dr. Javier Calvo for the isolation of hUC MSCs, Dr. Ferran Hierro
   (University of the Balearic Islands) for his technical contribution with
   SEM, and SAIUEx for technical support with XPS.
CR Amic D, 2007, CURR MED CHEM, V14, P827, DOI 10.2174/092986707780090954
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Asenath Smith E, 2008, LANGMUIR, V24, P12405, DOI 10.1021/la802234x
   Bauer S, 2013, PROG MATER SCI, V58, P261, DOI 10.1016/j.pmatsci.2012.09.001
   Bhowmick DK, 2012, SMALL, V8, P592, DOI 10.1002/smll.201101941
   Bodet C, 2007, EUR J ORAL SCI, V115, P64, DOI 10.1111/j.1600 0722.2007.00415.x
   Buer CS, 2007, PLANT PHYSIOL, V145, P478, DOI 10.1104/pp.107.101824
   Cado G, 2013, ADV FUNCT MATER, V23, P4801, DOI 10.1002/adfm.201300416
   Collart Dutilleul PY, 2014, ACS APPL MATER INTER, V6, P1719, DOI 10.1021/am4046316
   Crivillers N, 2007, ANGEW CHEM INT EDIT, V46, P2215, DOI 10.1002/anie.200603599
   Dangles O, 2006, FLAVONOIDS CHEM BIOC
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ernst IMA, 2010, PHARMACOL RES, V61, P253, DOI 10.1016/j.phrs.2009.10.006
   Gomez Florit M., 2014, J PERIODONTOL, V18, P18
   Guardingo M, 2014, SMALL, V10, P1594, DOI 10.1002/smll.201302406
   Guillot R, 2013, BIOMATERIALS, V34, P5737, DOI 10.1016/j.biomaterials.2013.03.067
   Heim KE, 2002, J NUTR BIOCHEM, V13, P572, DOI 10.1016/S0955 2863(02)00208 5
   Howarter JA, 2006, LANGMUIR, V22, P11142, DOI 10.1021/la061240g
   Hu XF, 2012, BIOMATERIALS, V33, P8082, DOI 10.1016/j.biomaterials.2012.07.057
   Jeon O, 2013, ADV FUNCT MATER, V23, P4765, DOI 10.1002/adfm.201300529
   Jung RE, 2008, CLIN ORAL IMPLAN RES, V19, P119, DOI 10.1111/j.1600 0501.2007.01453.x
   Junker R, 2009, CLIN ORAL IMPLAN RES, V20, P185, DOI 10.1111/j.1600 0501.2009.01777.x
   Lamolle SF, 2009, J BIOMED MATER RES A, V88A, P581, DOI 10.1002/jbm.a.31898
   Lamolle SF, 2009, BIOMATERIALS, V30, P736, DOI 10.1016/j.biomaterials.2008.10.052
   Lee JH, 1997, BIOMATERIALS, V18, P351, DOI 10.1016/S0142 9612(96)00128 7
   Lee MH, 2006, BIOMATERIALS, V27, P1907, DOI 10.1016/j.biomaterials.2005.11.003
   Li Y, 2011, LANGMUIR, V27, P4848, DOI 10.1021/la104853t
   Lim JY, 2005, BIOMACROMOLECULES, V6, P3319, DOI 10.1021/bm0503423
   Ramis JM, 2012, TISSUE ENG PT A, V18, P1253, DOI 10.1089/ten.tea.2011.0404
   Martin HJ, 2007, LANGMUIR, V23, P6645, DOI 10.1021/la063284v
   Murphy A, 2000, PLANTA, V211, P315, DOI 10.1007/s004250000300
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Park J, 2009, SMALL, V5, P666, DOI 10.1002/smll.200801476
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rodrigues MT, 2014, ACTA BIOMATER, V10, P4175, DOI 10.1016/j.actbio.2014.05.026
   Satué M, 2013, ACTA BIOMATER, V9, P5759, DOI 10.1016/j.actbio.2012.11.021
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Sedó J, 2013, ADV MATER, V25, P653, DOI 10.1002/adma.201202343
   Shephard P, 2004, AM J PATHOL, V164, P2055, DOI 10.1016/S0002 9440(10)63764 9
   Sjöström T, 2013, ADV HEALTHC MATER, V2, P1285, DOI 10.1002/adhm.201200353
   Song YY, 2010, SURF SCI, V604, P346, DOI 10.1016/j.susc.2009.11.027
   Srivastava S, 2013, PHYTOMEDICINE, V20, P683, DOI 10.1016/j.phymed.2013.03.001
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Toworfe GK, 2009, J TISSUE ENG REGEN M, V3, P26, DOI 10.1002/term.131
   Treccani L, 2013, ACTA BIOMATER, V9, P7115, DOI 10.1016/j.actbio.2013.03.036
   Ukaji E, 2007, APPL SURF SCI, V254, P563, DOI 10.1016/j.apsusc.2007.06.061
   Wall PE, 2005, RSC CHROMATOGR MONOG, P1
   Watari S, 2012, BIOMATERIALS, V33, P128, DOI 10.1016/j.biomaterials.2011.09.058
   Welch A, 2012, J BONE MINER RES, V27, P1872, DOI 10.1002/jbmr.1649
NR 51
TC 66
Z9 70
U1 0
U2 100
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD MAR 11
PY 2015
VL 4
IS 4
BP 540
EP 549
DI 10.1002/adhm.201400587
PG 10
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA CD6UR
UT WOS:000351225700009
PM 25335455
DA 2025 08 17
ER

PT J
AU Cao, RL
   Shao, JL
   Hu, YB
   Wang, L
   Li, ZZ
   Sun, GD
   Gao, XL
AF Cao, Riliang
   Shao, Jianli
   Hu, Yabin
   Wang, Liang
   Li, Zhizhong
   Sun, Guodong
   Gao, Xiaoliang
TI microRNA 338 3p inhibits proliferation, migration, invasion, and EMT in
   osteosarcoma cells by targeting activator of 90 kDa heat shock protein
   ATPase homolog 1
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Osteosarcoma; microRNA 338 3p; Activator of 90 kDa heat shock protein
   ATPase homolog 1; Tumor suppressor; Translational repression
ID GASTRIC CANCER CELLS; MIR 338 3P; METASTASIS; THERAPY; GROWTH
AB Background: Osteosarcoma (OS) is a rare, malignant bone tumor that primarily affects adolescents and has a high degree of malignancy and high incidence of recurrence and metastasis. Our study aimed to explore the role of miR 338 3p in OS cells.
   Methods: qRT qPCR was performed to quantify miR 338 3p expression levels in OS tissue samples and in three common OS cell lines. MG 63 and Saos2 cells were separately transfected with miR 338 3p or NC mimics and miR 338 3p expression levels was determined by qRT PCR. Cell proliferation was monitored using the Cell Counting Kit 8. Flow cytometer analysis was carried out to determine the distribution of cell cycle stages and apoptosis. Transwell assay was performed to measure the migratory and invasive capacities of MG 63 and Saos2 cells. The expression of Vimentin and E cadherin was detected by western blot. Luciferase reporter assay, qRT PCR and western blotting were performed to confirm the target of miR 338 3p.
   Results: Analysis by qRT PCR revealed that miR 338 3p was downregulated in the tissue samples of 20 OS patients when compared with that in their matched adjacent non tumor tissues. Furthermore, miR 338 3p was significantly downregulated in three common OS cell lines, namely, MG 63, Saos2, and HOS, when compared with that in the human osteoblast cell line hFOB1.19. Analysis by luciferase reporter assay, qRT PCR, and western blotting revealed that activator of 90 kDa heat shock protein ATPase homolog 1 (AHSA1) is a direct target of miR 338 3p. miR 338 3p overexpression led to significant reduction in AHSA1 protein levels in MG63 and Saos2 cells. miR 338 3p overexpression reduced cell viability and migration and invasion behavior of MG63 and Saos2 cells. In addition, miR 338 3p overexpression suppressed epithelial mesenchymal transition (EMT), induced a significant G1 phase arrest and did not affect the apoptosis in both MG 63 and Saos2 cells. Moreover, overexpression of AHSA1 reversed the inhibitory effect of miR 338 3p overexpression on proliferation, cell cycle, apoptosis, EMT, migration, and invasion of MG63 and Saos2 cells, thereby suggesting that miR 338 3p acts as a tumor suppressor in OS cells by targeting AHSA1.
   Conclusions: miR 338 3p/AHSA1 can serve as a potential therapeutic target for OS therapy.
C1 [Cao, Riliang] Guangdong Women & Children Hosp, Dept Pediat Surg, Guangzhou 511400, Guangdong, Peoples R China.
   [Shao, Jianli; Li, Zhizhong; Sun, Guodong] Jinan Univ, Affiliated Hosp 1, Dept Orthoped & Traumatol, Guangzhou 510632, Guangdong, Peoples R China.
   [Hu, Yabin; Gao, Xiaoliang] Xinjiang Med Univ, Affiliated Hosp 6, Dept Spinal Surg, Urumqi 830002, Xinjiang, Peoples R China.
   [Wang, Liang] Jinan Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Xinjiang Medical University; Jinan University
RP Shao, JL (通讯作者)，Jinan Univ, Affiliated Hosp 1, Dept Orthoped & Traumatol, Guangzhou 510632, Guangdong, Peoples R China.; Hu, YB (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 6, Dept Spinal Surg, Urumqi 830002, Xinjiang, Peoples R China.
EM tshaojianli@126.com; hyb4499@126.com
OI sun, guodong/0000 0001 5336 368X
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   An X, 2017, ACTA PHARM SIN B, V7, P38, DOI 10.1016/j.apsb.2016.09.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Chen JT, 2015, INT J CLIN EXP PATHO, V8, P10922
   Chen X, 2013, FEBS LETT, V587, P3729, DOI 10.1016/j.febslet.2013.09.044
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097 0142(19950101)75:1+<203::AID CNCR2820751308>3.0.CO;2 V
   Huang N, 2015, ONCOTARGET, V6, P15222, DOI 10.18632/oncotarget.3835
   Jafri MA, 2017, SEMIN CANCER BIOL, V44, P117, DOI 10.1016/j.semcancer.2017.02.004
   Li Y, 2016, AM J CANCER RES, V6, P127
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200
   Mallory AC, 2008, TRENDS PLANT SCI, V13, P359, DOI 10.1016/j.tplants.2008.03.007
   Nana Sinkam SP, 2011, TRANSL RES, V157, P216, DOI 10.1016/j.trsl.2011.01.013
   Shao JL, 2016, BIOMED PHARMACOTHER, V77, P45, DOI 10.1016/j.biopha.2015.11.008
   Sun K, 2013, WORLD J GASTROENTERO, V19, P2197, DOI 10.3748/wjg.v19.i14.2197
   Thorsen SB, 2012, CANCER J, V18, P275, DOI 10.1097/PPO.0b013e318258b5d6
   Zhang P, 2017, AM J CANCER RES, V7, P53
   Zhang YT, 2016, AM J TRANSL RES, V8, P3266
   Zhou WY, 2014, DISCOV MED, V17, P301
NR 21
TC 37
Z9 38
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475 2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD APR 2
PY 2018
VL 18
AR 49
DI 10.1186/s12935 018 0551 x
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GB2LV
UT WOS:000428885400001
PM 29618948
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yokose, S
   Kato, Y
   Matsumoto, K
   Klokkevold, PR
   Takei, HH
   Kawazu, H
   Sakagami, H
AF Yokose, Satoshi
   Kato, Yuka
   Matsumoto, Katsutoshi
   Klokkevold, Perry R.
   Takei, Henry H.
   Kawazu, Hiroshi
   Sakagami, Hiroshi
TI Enamel Matrix Derivative in Diffusion Chamber Implanted Subcutaneously
   in Rat Induces Formation of Fibrous Connective Tissue Containing
   Abundant Blood Vessels
SO IN VIVO
LA English
DT Article
DE Enamel matrix derivative; diffusion chamber; connective tissue; blood
   vessels; rat
ID DIFFERENTIATION; PROLIFERATION; OSTEOBLASTS; CELLS
AB Background: Enamel matrix derivative (EMD) is widely used for regeneration therapy in dental clinical situations, but the mechanism of EMD bioactivity remains obscure. To clarify this mechanism, we focused on the formation of connective tissue and blood vessels. The aim of this study was to confirm whether EMD induces the formation of connective tissue and blood vessels by using the diffusion chamber (DC) technique. Materials and Methods: Individual DCs containing EMD (DC EMD) or propylene glycol alginate (PGA) were implanted subcutaneously in rat dorsum. At 4 weeks after the implantation, histological analysis of DCs was performed using azan staining. Results: DC EMD induced the formation of much larger amounts of connective tissue containing abundant blood vessels than did DC PGA. Conclusion: The results indicated that EMD can induce the formation of both connective tissue and blood vessels. This bioactivity may contribute to the mechanism whereby EMD induces tissue regeneration.
C1 [Yokose, Satoshi; Kato, Yuka; Matsumoto, Katsutoshi] Meikai Univ, Sch Dent, Div Endodont & Operat Dent, Dept Restorat & Biomat Sci, 1 1 Keyakidai, Saitama 3500283, Japan.
   [Klokkevold, Perry R.; Takei, Henry H.] Univ Calif Los Angeles, Sch Dent, Div Constitut & Regenerat Sci, Sect Periodont, Los Angeles, CA 90024 USA.
   [Kawazu, Hiroshi] Meikai Univ, Sect Continuous Educ, Sch Dent, Saitama, Japan.
   [Sakagami, Hiroshi] Meikai Univ, Res Insititute Odontol M RIO, Sch Dent, Saitama, Japan.
C3 Meikai University; University of California System; University of
   California Los Angeles; Meikai University; Meikai University
RP Yokose, S (通讯作者)，Meikai Univ, Sch Dent, Div Endodont & Operat Dent, Dept Restorat & Biomat Sci, 1 1 Keyakidai, Saitama 3500283, Japan.
EM s yokose@dent.meikai.ac.jp
RI ; Klokkevold, Perry/AAH 9123 2020
OI Sakagami, Hiroshi/0000 0001 8001 2121; 
CR Aspriello SD, 2011, J PERIODONTOL, V82, P606, DOI 10.1902/jop.2010.100180
   BREUING K, 1992, J SURG RES, V52, P50, DOI 10.1016/0022 4804(92)90278 8
   Esposito M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003875.pub3
   Fukuda K, 2014, BIOSCI TRENDS, V8, P212, DOI 10.5582/bst.2014.01090
   Hama H, 2008, J PERIODONTAL RES, V43, P179, DOI 10.1111/j.1600 0765.2007.01010.x
   He JN, 2004, ORAL SURG ORAL MED O, V97, P239, DOI 10.1016/j.tripleo.2003.10.005
   Kauvar AS, 2010, J PERIODONTOL, V81, P1196, DOI 10.1902/jop.2010.090441
   Kémoun P, 2011, BIOMATERIALS, V32, P7375, DOI 10.1016/j.biomaterials.2011.06.043
   Ma JW, 2019, LASER MED SCI, V34, P149, DOI 10.1007/s10103 018 2649 8
   Miron RJ, 2016, CLIN ORAL INVEST, V20, P2037, DOI 10.1007/s00784 015 1702 2
   Okubo K, 2003, J PERIODONTAL RES, V38, P1, DOI 10.1034/j.1600 0765.2003.01607.x
   Sculean A, 2007, MED PRIN PRACT, V16, P167, DOI 10.1159/000100386
   Ten Cate AR, 2003, 10 CATES ORAL HISTOL, P397
   Wada Y, 2008, J PERIODONTOL, V79, P341, DOI [10.1902/jop.2008.070197, 10.1902/jop.2008.070197 ]
   Wang HH, 2018, J ENDODONT, V44, P1066, DOI 10.1016/j.joen.2018.02.012
   Yokose S, 1996, ENDOCRINOLOGY, V137, P469, DOI 10.1210/en.137.2.469
   Zou R, 2018, HISTOL HISTOPATHOL, V33, P825, DOI 10.14670/HH 11 978
NR 17
TC 1
Z9 1
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258 851X
EI 1791 7549
J9 IN VIVO
JI In Vivo
PD JAN FEB
PY 2021
VL 35
IS 1
BP 313
EP 317
DI 10.21873/invivo.12261
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA PQ7XQ
UT WOS:000606758800005
PM 33402479
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Senkal Turhan, S
   Bulut Okumus, E
   Aydin, M
   Türkmen, NB
   Taslidere, A
   Sahin, F
   Yilmaz, S
   Süt, PA
   Dogan, A
AF Senkal Turhan, Selinay
   Bulut Okumus, Ezgi
   Aydin, Muhterem
   Turkmen, Nese Basak
   Taslidere, Asli
   Sahin, Fikrettin
   Yilmaz, Sahin
   Sut, Pinar Akkus
   Dogan, Aysegul
TI Induced Pluripotent Stem Cell Derived Parathyroid Organoids Resemble
   Parathyroid Morphology and Function
SO ADVANCED SCIENCE
LA English
DT Article
DE 3D culture; hypoparathyroidism; organoid; parathyroid; parathyroid
   organoid; pluripotent stem cell
ID LONG TERM EXPANSION; IN VITRO; TOOL; ALLOTRANSPLANTATION; PANTHER;
   MOUSE; MODEL; GENE; RNA
AB The primary role of the parathyroid glands is to maintain calcium homeostasis through the secretion of parathyroid hormone (PTH). The limited proliferative capacity and differentiation of parathyroid cells hinder the generation of cell therapy options. In this study, parathyroid organoids are successfully generated from human induced pluripotent stem cells (hiPSCs). At the end of the 20 days of differentiation, the parathyroid organoids exhibited distinct parathyroid morphology. Stereomicroscope, scanning electron microscopy (SEM), and transmission electron microscopy (TEM) analysis demonstrated the 3D arrangement of the cell layers in which intracellular structures of parathyroid cells resemble human parathyroid cellular morphology. Comprehensive molecular analyses, including RNA sequencing (RNA Seq) and liquid chromatography/mass spectrometry (LC MS/MS), confirmed the expression of key parathyroid related markers. Protein expression of CasR, CxCr4, Gcm2, and PTH are observed in parathyroid organoids. Parathyroid organoids secrete PTH, demonstrate active intercellular calcium signaling, and induce osteogenic differentiation via their secretome. The tissue integration potential of parathyroid organoids is determined by transplantation into parathyroidectomized rats. The organoid transplanted animals showed significant elevations in PTH related markers (CasR, CxCr4, Foxn1, Gcm2, and PTH). PTH secretion is detected in organoid transplanted animals. The findings represent a significant advancement in parathyroid organoid culture and may offer a cellular therapy for treating PTH related diseases, including hypoparathyroidism.
   iPSC derived parathyroid organoids express PTH related markers at the protein and gene levels. The transplantation of parathyroid organoids into parathyroidectomized rats shows their functional activity and tissue integration capability. iPSC derived parathyroid organoids successfully release PTH both in vitro and in vivo. Parathyroid organoid technology may improve defective parathyroid function and related diseases. image
C1 [Senkal Turhan, Selinay; Bulut Okumus, Ezgi; Sahin, Fikrettin; Yilmaz, Sahin; Sut, Pinar Akkus; Dogan, Aysegul] Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, TR 34755 Istanbul, Turkiye.
   [Aydin, Muhterem] Firat Univ, Fac Vet Med, Dept Vet Obstet & Gynecol, TR 23119 Elazig, Turkiye.
   [Turkmen, Nese Basak] Univ Inonu, Fac Pharm, Dept Pharmaceut Toxicol, TR 44280 Malatya, Turkiye.
   [Taslidere, Asli] Univ Inonu, Fac Med, Dept Histol & Embryol, TR 44280 Malatya, Turkiye.
C3 Yeditepe University; Firat University; Inonu University; Inonu
   University
RP Dogan, A (通讯作者)，Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, TR 34755 Istanbul, Turkiye.
EM aysegul.dogan@yeditepe.edu.tr
RI Şenkal Turhan, Selinay/GPT 0437 2022; Başak türkmen, neşe/ABH 5495 2020;
   Taşlıdere, Aslı/ABI 8274 2020; Doğan, Ayşegül/AAD 3223 2019;
   Bulut Okumuş, Ezgi/ADN 8335 2022
OI Dogan, Aysegul/0000 0003 4160 2270; 
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [219S665]; TUBITAK [2211 C]; Turkish Academy of Sciences Outstanding
   Young Scientists Award [TBA GEBIdot;P 2020]; Yeditepe University Writing
   Center
FX This study was supported by Scientific and Technological Research
   Council of Turkey (TUBITAK) under the Grant Number 219S665. The authors
   thank TUBITAK for their support. Ay & scedil;eguel Do & gbreve;an was
   supported by Turkish Academy of Sciences Outstanding Young Scientists
   Award (TUEBA GEB & Idot;P 2020). Selinay & Scedil;enkal Turhan was
   supported by the TUBITAK 2211 C programme. The authors would like to
   thank Hande Yuece for her help during animal necropsy. The authors would
   like to thank Taha Bartu Hayal for his help during dot blot analysis.
   The authors would like to thank Yeditepe University Writing Center and
   Hakan & Scedil;entuerk for their proofreading support.
CR Akpinar G, 2021, J MEMBRANE BIOL, V254, P409, DOI 10.1007/s00232 021 00190 1
   Asal M, 2023, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1058846
   Asher SA, 2008, LARYNGOSCOPE, V118, P1014, DOI 10.1097/MLG.0b013e3181671b61
   Asutay A. B., 2022, STEM CELL REV REP, V18, P278
   Bezerra IPS, 2021, CYTOTHERAPY, V23, P9
   Bingham EL, 2009, STEM CELLS DEV, V18, P1071, DOI 10.1089/scd.2008.0337
   Block G. A., 2004, CINACALCET SECONDARY
   Cabané P, 2009, TRANSPL P, V41, P3879, DOI 10.1016/j.transproceed.2009.06.211
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chapelle T, 2009, TRANSPL P, V41, P599, DOI 10.1016/j.transproceed.2008.12.026
   Cipriani NA, 2014, PATHOBIOLOGY OF HUMAN DISEASE: A DYNAMIC ENCYCLOPEDIA OF DISEASE MECHANISMS, P1234, DOI 10.1016/B978 0 12 386456 7.03708 4
   Corrò C, 2020, AM J PHYSIOL CELL PH, V319, pC151, DOI 10.1152/ajpcell.00120.2020
   Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51
   Dogan A, 2013, APPL BIOCHEM BIOTECH, V171, P1819, DOI 10.1007/s12010 013 0472 z
   Fewins J, 2003, OTOLARYNG CLIN N AM, V36, P189, DOI 10.1016/S0030 6665(02)00129 9
   Ge SX, 2020, BIOINFORMATICS, V36, P2628, DOI 10.1093/bioinformatics/btz931
   Gordon J, 2001, MECH DEVELOP, V103, P141, DOI 10.1016/S0925 4773(01)00333 1
   Günther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111
   Hasse C, 1997, LANCET, V350, P1296, DOI 10.1016/S0140 6736(05)62473 7
   Hayal, 2022, CYTOTECHNOLOGY, V74, P293
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859 015 0611 3
   Hicks G, 2017, GLAND SURG, V6, pS75, DOI 10.21037/gs.2017.09.15
   Hu HL, 2018, CELL, V175, P1591, DOI 10.1016/j.cell.2018.11.013
   Huch M, 2015, DEVELOPMENT, V142, P3113, DOI 10.1242/dev.118570
   Ignatoski K. M. W., 2011, TISSUE ENG PART C ME, V17, P0170
   ili H. B., 2020, CELL MOL NEUROBIOL, V42, P753
   Jorgensen M, 2021, STAR PROTOC, V2, DOI 10.1016/j.xpro.2021.100696
   Jung H. Y., 2022, BIOMEDICINES, V10
   Kadota T, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12124
   Kawata T, 2006, J BONE MINER METAB, V24, P300, DOI 10.1007/s00774 006 0687 y
   Khan, 2018, PHYSL PARATHYROID HO
   Kim J, 2020, NAT REV MOL CELL BIO, V21, P571, DOI 10.1038/s41580 020 0259 3
   Kohen MC, 2018, MOL VIS, V24, P239
   Lehmann R, 2019, MOL BIOL CELL, V30, P1129, DOI 10.1091/mbc.E19 03 0135
   Liu W, 2001, J ENDOCRINOL, V168, P417, DOI 10.1677/joe.0.1680417
   Liu Y, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201165
   Lofrese JJ., 2023, StatPearls
   Marti M, 2013, NAT PROTOC, V8, P223, DOI 10.1038/nprot.2012.154
   Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
   Mi HY, 2021, NUCLEIC ACIDS RES, V49, pD394, DOI 10.1093/nar/gkaa1106
   Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596 019 0128 8
   Nevi L, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111443
   Noltes ME, 2022, STEM CELL REP, V17, P2518, DOI 10.1016/j.stemcr.2022.09.015
   Okabe M, 2004, P NATL ACAD SCI USA, V101, P17716, DOI 10.1073/pnas.0406116101
   Park YS, 2015, BIOMATERIALS, V65, P140, DOI 10.1016/j.biomaterials.2015.06.044
   Poleganov MA, 2015, HUM GENE THER, V26, P751, DOI 10.1089/hum.2015.045
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Ritter CS, 2012, J CLIN ENDOCR METAB, V97, pE1499, DOI 10.1210/jc.2011 3366
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sui Y, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1575 4
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Tizro P, 2019, METHODS MOL BIOL, V1897, P417, DOI 10.1007/978 1 4939 8935 5_33
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Volarevic V, 2018, INT J MED SCI, V15, P36, DOI 10.7150/ijms.21666
   Wang G, 2024, CELL PROLIFERAT, V57, DOI 10.1111/cpr.13634
   Ward E, 2017, STEM CELLS DEV, V26, P1087, DOI 10.1089/scd.2017.0067
   Yamada T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210662
NR 61
TC 3
Z9 3
U1 6
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD NOV
PY 2024
VL 11
IS 43
DI 10.1002/advs.202407567
EA SEP 2024
PG 16
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA N5A8G
UT WOS:001321491200001
PM 39331961
OA gold
DA 2025 08 17
ER

PT J
AU Larochelle, A
   Gillette, JM
   Desmond, R
   Ichwan, B
   Cantilena, A
   Cerf, A
   Barrett, AJ
   Wayne, AS
   Lippincott Schwartz, J
   Dunbar, CE
AF Larochelle, Andre
   Gillette, Jennifer M.
   Desmond, Ronan
   Ichwan, Brian
   Cantilena, Amy
   Cerf, Alexandra
   Barrett, A. John
   Wayne, Alan S.
   Lippincott Schwartz, Jennifer
   Dunbar, Cynthia E.
TI Bone marrow homing and engraftment of human hematopoietic stem and
   progenitor cells is mediated by a polarized membrane domain
SO BLOOD
LA English
DT Article
ID SCID REPOPULATING CELLS; CD34(+) CELLS; NICHE; TETRASPANINS;
   TRANSDUCTION; METASTASIS; EXPANSION; CD82/KAI1; PROTEINS; LEUKEMIA
AB Manipulation of hematopoietic stem/progenitor cells (HSPCs) ex vivo is of clinical importance for stem cell expansion and gene therapy applications. However, most cultured HSPCs are actively cycling, and show a homing and engraftment defect compared with the predominantly quiescent noncultured HSPCs. We previously showed that HSPCs make contact with osteoblasts in vitro via a polarized membrane domain enriched in adhesion molecules such as tetraspanins. Here we show that increased cell cycling during ex vivo culture of HSPCs resulted in disruption of this membrane domain, as evidenced by disruption of polarity of the tetraspanin CD82. Chemical disruption or antibody mediated blocking of CD82 on noncultured HSPCs resulted in decreased stromal cell adhesion, homing, and engraftment in nonobese diabetic/severe combined immunodeficiency IL 2 gamma(null) (NSG) mice compared with HSPCs with an intact domain. Most leukemic blasts were actively cycling and correspondingly displayed a loss of domain polarity and decreased homing in NSG mice compared with normal HSPCs. We conclude that quiescent cells, unlike actively cycling cells, display a polarized membrane domain enriched in tetraspanins that mediates homing and engraftment, providing a mechanistic explanation for the homing/engraftment defect of cycling cells and a potential new therapeutic target to enhance engraftment. (Blood. 2012; 119(8):1848 1855)
C1 [Larochelle, Andre; Desmond, Ronan; Ichwan, Brian; Cantilena, Amy; Barrett, A. John; Dunbar, Cynthia E.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
   [Gillette, Jennifer M.; Cerf, Alexandra; Lippincott Schwartz, Jennifer] NICHHD, Cell Biol & Metab Program, NIH, Bethesda, MD 20892 USA.
   [Wayne, Alan S.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Heart Lung &
   Blood Institute (NHLBI); National Institutes of Health (NIH)   USA; NIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD); National Institutes of Health (NIH)   USA; NIH
   National Cancer Institute (NCI)
RP Dunbar, CE (通讯作者)，NHLBI, Hematol Branch, NIH, 9000 Rockville Pike,Bldg 10CRC,Rm 4E 5132, Bethesda, MD 20892 USA.
EM dunbarc@nhlbi.nih.gov
RI Larochelle, Andre/P 1342 2016; Wayne, Alan/JVZ 3654 2024
OI Larochelle, Andre/0000 0003 0685 2186; Dunbar,
   Cynthia/0000 0002 7645 838X; 
FU NHLBI; National Institute of Child Health and Human Development; Center
   for Cancer Research, National Cancer Institute of the NIH
FX This work was supported by the intramural research programs of the NHLBI
   (C.E.D. and A.J.B.), the National Institute of Child Health and Human
   Development (J.L.S.), and the Center for Cancer Research, National
   Cancer Institute of the NIH (A.S.W.). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the paper.
CR Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301 472X(98)00037 X
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797 730
   Burchert A, 1999, BRIT J HAEMATOL, V107, P494, DOI 10.1046/j.1365 2141.1999.01741.x
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Case SS, 1999, P NATL ACAD SCI USA, V96, P2988, DOI 10.1073/pnas.96.6.2988
   Charrin S, 2009, BIOCHEM J, V420, P133, DOI 10.1042/BJ20082422
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669
   Desmond R, 2011, BLOOD, V117, P5774, DOI 10.1182/blood 2011 01 332031
   Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood 2008 08 077941
   Gan OI, 1997, BLOOD, V90, P641, DOI 10.1182/blood.V90.2.641.641_641_650
   Gillette JM, 2009, NAT CELL BIOL, V11, P303, DOI 10.1038/ncb1838
   Gothot A, 1998, BLOOD, V92, P2641, DOI 10.1182/blood.V92.8.2641.420k36_2641_2649
   Greaves M, 2010, SEMIN CANCER BIOL, V20, P65, DOI 10.1016/j.semcancer.2010.03.002
   Hemler ME, 2008, NAT REV DRUG DISCOV, V7, P747, DOI 10.1038/nrd2659
   Iwasaki H, 2009, CANCER SCI, V100, P1166, DOI 10.1111/j.1349 7006.2009.01177.x
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489
   Leung KT, 2011, BLOOD, V117, P1840, DOI 10.1182/blood 2010 04 281329
   LI CL, 1994, BLOOD, V84, P408, DOI 10.1182/blood.V84.2.408.bloodjournal842408
   Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008 5472.CAN 05 3986
   Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023
   PETERS SO, 1995, EXP HEMATOL, V23, P461
   Peters SO, 1996, BLOOD, V87, P30
   Sutton RE, 1999, J VIROL, V73, P3649, DOI 10.1128/JVI.73.5.3649 3660.1999
   Takatoku M, 2001, J CLIN INVEST, V108, P447, DOI 10.1172/JCI200112593
   Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011
   Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031
   Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004
   Yáñez Mó M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 32
TC 44
Z9 51
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD FEB 23
PY 2012
VL 119
IS 8
BP 1848
EP 1855
DI 10.1182/blood 2011 08 371583
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 898CU
UT WOS:000300713800012
PM 22228628
OA Green Published
DA 2025 08 17
ER

PT J
AU Yuan, WX
   Huang, MT
   Wu, YE
   Liu, JQ
   Zhou, XM
   Wang, J
   Liu, J
AF Yuan, Wenxiu
   Huang, Maotuan
   Wu, Yange
   Liu, Jiaqi
   Zhou, Xueman
   Wang, Jun
   Liu, Jin
TI Agaricus blazei Murrill Polysaccharide Attenuates Periodontitis via
   H2S/NRF2 Axis Boosted Appropriate Level of Autophagy in PDLCs
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Agaricus blazei Murrill polysaccharides; autophagy; H2S; NRF2;
   periodontitis
ID HYDROGEN SULFIDE; MURILL; CELL; EXPRESSION; ANTITUMOR; THERAPY; EXTRACT;
   NRF2
AB Scope: Periodontitis is one of the most prevalent chronic inflammatory diseases with impaired autophagy. Agaricus blazei Murrill polysaccharide (ABMP) shows beneficial effects in various inflammatory diseases. However, whether ABMP is involved in autophagy regulation and periodontitis attenuation remains to be elucidated.Methods and results: This study firstly shows the dynamic changes in inflammatory and autophagy levels in silk ligature periodontitis model. Then the positive regulation effect of autophagy on inflammation and its vital role in ABMP inhibiting PDLCs inflammatory response are testified in LPS treated PDLCs. Secondly, the Micro CT, quantitative RT PCR, Western Blot, TRAP, and immunofluorescence staining analysis are performed to assess the effects of ABMP on periodontitis and autophagy. The data show the augmented autophagy and alleviated gingival recession, inflammatory cell infiltration, alveolar bone resorption, and reduced osteoclasts in periodontitis by ABMP treatment. Further experiments using chemical inhibitors demonstrate the vital role of H2S/NRF2 axis in ABMP induced appropriate level of autophagy augmentation against periodontitis.Conclusions: Collectively, the findings not only reveal the unrecognized capacity and mechanism of ABMP as an effective and potential dietary intake against periodontitis, but also suggest the possibility for ABMP to be used in the treatment of other autophagy related diseases.
C1 [Yuan, Wenxiu; Wu, Yange; Liu, Jiaqi; Zhou, Xueman; Liu, Jin] Sichuan Univ, State Key Lab Biotherapy, Lab Aging Res, Chengdu 610041, Sichuan, Peoples R China.
   [Yuan, Wenxiu; Wu, Yange; Liu, Jiaqi; Zhou, Xueman; Liu, Jin] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China.
   [Yuan, Wenxiu; Wu, Yange; Liu, Jiaqi; Zhou, Xueman; Wang, Jun] Sichuan Univ, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Yuan, Wenxiu; Wu, Yange; Liu, Jiaqi; Zhou, Xueman; Wang, Jun] Sichuan Univ, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Yuan, Wenxiu; Wu, Yange; Liu, Jiaqi; Zhou, Xueman; Wang, Jun] Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China.
   [Huang, Maotuan] Fujian Med Univ, Dept Hepatobiliary Surg, Fuzhou 350000, Fujian, Peoples R China.
   [Huang, Maotuan] Fujian Med Univ, Union Hosp, Fujian Inst Hepatobiliary Surg, Fuzhou 350000, Fujian, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University; Fujian Medical University; Fujian
   Medical University
RP Liu, J (通讯作者)，Sichuan Univ, State Key Lab Biotherapy, Lab Aging Res, Chengdu 610041, Sichuan, Peoples R China.; Liu, J (通讯作者)，Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China.; Wang, J (通讯作者)，Sichuan Univ, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Wang, J (通讯作者)，Sichuan Univ, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Wang, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China.
EM wangjunv@scu.edu.cn; liujin@scu.edu.cn
RI LIU, JIN/CAE 9169 2022; Wang, Jun/ABB 1429 2020
OI Zhou, Xueman/0000 0002 3052 6703; liu, jin/0000 0003 1063 9791; Wang,
   Jun/0000 0002 9040 6295
FU This research was supported by National Natural Science Foundation of
   China (No. 82271019 and 81970967), Sichuan Health Commission Medical
   Science and Technology Program (21ZD003) and Research and Develop
   Program, West China Hospital of Stomatology Sichuan [82271019,
   81970967]; National Natural Science Foundation of China [21ZD003];
   Sichuan Health Commission Medical Science and Technology Program
   [RD 03 202101]; Research and Develop Program, West China Hospital of
   Stomatology Sichuan University
FX This research was supported by National Natural Science Foundation of
   China (No. 82271019 and 81970967), Sichuan Health Commission Medical
   Science and Technology Program (21ZD003) and Research and Develop
   Program, West China Hospital of Stomatology Sichuan University
   (RD 03 202101) to J.W. The authors thank Lin Bai and Dr. Jie Zhang from
   Histology and Imaging platform, Core Facilities of West China Hospital,
   Sichuan University for technical support with microscopy.
CR An Y, 2016, J CLIN PERIODONTOL, V43, P618, DOI 10.1111/jcpe.12549
   Beck JD, 2019, J DENT RES, V98, P1053, DOI 10.1177/0022034519846113
   Calvert JW, 2010, CIRCULATION, V122, P11, DOI 10.1161/CIRCULATIONAHA.109.920991
   Chen H, 2019, ARTIF CELL NANOMED B, V47, P2098, DOI 10.1080/21691401.2019.1620256
   Corsello T, 2018, ANTIOXIDANTS BASEL, V7, DOI 10.3390/antiox7100129
   David L., 2022, AUTOPHAGY, V8, P2913
   Dong J, 2022, ACTA PHARMACOL SIN, V43, P1793, DOI 10.1038/s41401 021 00782 6
   Du WW, 2021, INFLAMMATION, V44, P1607, DOI 10.1007/s10753 021 01445 8
   Fang XY, 2022, J DENT RES, V101, P569, DOI 10.1177/00220345211050324
   Filipovic MR, 2018, CHEM REV, V118, P377, DOI 10.1021/acs.chemrev.7b00205
   Gugliandolo E, 2018, PHARMACOL RES, V132, P220, DOI 10.1016/j.phrs.2017.12.022
   Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577 020 00488 6
   Hetland G, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051339
   Huang HY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33492 6
   Iglesias Linares A, 2017, J DENT RES, V96, P145, DOI 10.1177/0022034516677539
   Jiang M, 2020, ORAL DIS, V26, P259, DOI 10.1111/odi.13045
   Jönsson D, 2011, J PERIODONTAL RES, V46, P153, DOI 10.1111/j.1600 0765.2010.01331.x
   Jungbauer G, 2022, PERIODONTOL 2000, V89, P59, DOI 10.1111/prd.12429
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kang SK, 2015, J PERIODONTAL RES, V50, P602, DOI 10.1111/jre.12240
   Kimura Y, 2004, CANCER SCI, V95, P758, DOI 10.1111/j.1349 7006.2004.tb03258.x
   Kitada M, 2021, NAT REV ENDOCRINOL, V17, P647, DOI 10.1038/s41574 021 00551 9
   Kocak M, 2022, AUTOPHAGY, V18, P473, DOI 10.1080/15548627.2021.1936359
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lei Q, 2021, CIRC RES, V129, P1141, DOI 10.1161/CIRCRESAHA.121.318908
   Li YX, 2020, FOOD SCI NUTR, V8, P2758, DOI 10.1002/fsn3.1568
   Lindequist U, 2005, EVID BASED COMPL ALT, V2, P285, DOI 10.1093/ecam/neh107
   Liu CC, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00439
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Liu Y, 2015, IMMUNOLOGY, V146, P379, DOI 10.1111/imm.12508
   Marchesan J, 2018, NAT PROTOC, V13, P2247, DOI 10.1038/s41596 018 0035 4
   Ni KR, 2021, INT IMMUNOPHARMACOL, V93, DOI 10.1016/j.intimp.2021.107399
   Ni WY, 2013, IN VIVO, V27, P779
   Odle RI, 2020, AUTOPHAGY, V16, P775, DOI 10.1080/15548627.2020.1725405
   Pinheiro F, 2003, FOOD CHEM TOXICOL, V41, P1543, DOI 10.1016/S0278 6915(03)00171 6
   Rakian A, 2022, J DENT RES, V101, P1205, DOI 10.1177/00220345221090879
   Schieffer L, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11010149
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev biochem 061516 045037
   Sui ZF, 2010, INT J BIOL MACROMOL, V47, P155, DOI 10.1016/j.ijbiomac.2010.05.006
   Tang H, 2022, HUM CELL, V35, P803, DOI 10.1007/s13577 022 00678 5
   Tian YJ, 2022, BIOACT MATER, V9, P428, DOI 10.1016/j.bioactmat.2021.07.033
   Viecilli RF, 2013, J DENT RES, V92, P346, DOI 10.1177/0022034513480794
   Wang Y, 2022, BIOACT MATER, V17, P320, DOI 10.1016/j.bioactmat.2022.01.026
   Wang Y, 2022, FREE RADICAL BIO MED, V186, P1, DOI 10.1016/j.freeradbiomed.2022.04.014
   Wu XW, 2022, J PERIODONTAL RES, V57, P381, DOI 10.1111/jre.12969
   Xin SS, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.779287
   Xu DC, 2020, NATURE, V587, P133, DOI 10.1038/s41586 020 2757 z
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yang GD, 2013, ANTIOXID REDOX SIGN, V18, P1906, DOI 10.1089/ars.2012.4645
   Yeh MY, 2015, MOL MED REP, V12, P133, DOI 10.3892/mmr.2015.3454
   Zhang Y, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00150 4
   Zhou XM, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110750
NR 52
TC 8
Z9 8
U1 4
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1613 4125
EI 1613 4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD NOV
PY 2023
VL 67
IS 22
DI 10.1002/mnfr.202300112
EA SEP 2023
PG 12
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA AM7I0
UT WOS:001075111400001
PM 37775336
DA 2025 08 17
ER

PT J
AU Lai, YX
   Xie, C
   Zhang, Z
   Lu, WY
   Ding, JD
AF Lai, Yuxiao
   Xie, Cao
   Zhang, Zheng
   Lu, Weiyue
   Ding, Jiandong
TI Design and synthesis of a potent peptide containing both specific and
   non specific cell adhesion motifs
SO BIOMATERIALS
LA English
DT Article
DE Surface modification; Cell adhesion; RGD peptide; Cell spreading
ID GLY ASP PEPTIDES; MESENCHYMAL STEM CELLS; RGD PEPTIDES; OSTEOBLAST
   ADHESION; SURFACE MODIFICATION; PERICELLULAR COAT; MEDIATED ADHESION;
   GEOMETRIC CONTROL; IN VITRO; HYALURONAN
AB This article reports a potent chemical to promote cell adhesion on a substrate by combination of both moieties for specific and non specific adhesion. The cyclic ( RGDfK ) (R: arginine, G: glycine, D: aspartic acid, f: u phenylalanine, K: lysine) is employed to trigger specific cell adhesion, and a linear tripeptide KKK is introduced to enhance early non specific cell adhesion. A series of cyclic and linear peptides with different charges were synthesized and then functionalized with thiol end group. All the peptides were immobilized on gold layers, which were later passivated by bovine serum albumin. The coverage of NIH/3T3 fibroblast cells on the substrate modified by the linker containing both cyclic ( RGDfK ) and linear KKK is, surprisingly, significantly better than the summation using one of them, which reveals the strong cooperativity of specific and non specific cell adhesions. The resultant cell adhesion on the substrates modified by appropriate linkers was much better than on tissue culture plates. The cooperativity principle and the design strategy of the combined linker might be helpful for fundamental research of cell material or cell extracellular matrix interactions, and for modification of new biomaterials in regenerative medicine and targeted drug delivery. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Lai, Yuxiao; Zhang, Zheng; Ding, Jiandong] Fudan Univ, Adv Mat Lab, Dept Macromol Sci, Minist Educ,Key Lab Mol Engn Polymers, Shanghai 200433, Peoples R China.
   [Xie, Cao; Lu, Weiyue] Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University
RP Ding, JD (通讯作者)，Fudan Univ, Adv Mat Lab, Dept Macromol Sci, Minist Educ,Key Lab Mol Engn Polymers, Shanghai 200433, Peoples R China.
EM jdding1@fudan.edu.cn
RI Lu, Weiyue/E 7938 2010; Lai, Yuxiao/AFN 1336 2022
FU Chinese Ministry of Science and Technology [2009CB930000]; NSF of China
   [20774020]; Science and Technology Developing Foundation of Shanghai
   [074319117, 07JC14005]
FX The authors are grateful for the financial supports from Chinese
   Ministry of Science and Technology (973 program No. 2009CB930000), NSF
   of China (grant No. 20774020), Science and Technology Developing
   Foundation of Shanghai (grants No. 074319117 and No. 07JC14005).
CR Arnold M, 2004, CHEMPHYSCHEM, V5, P383, DOI 10.1002/cphc.200301014
   Arnold M, 2009, SOFT MATTER, V5, P72, DOI 10.1039/b815634d
   Auernheimer J, 2005, J AM CHEM SOC, V127, P16107, DOI 10.1021/ja053648q
   Benton JA, 2009, BIOMATERIALS, V30, P6593, DOI 10.1016/j.biomaterials.2009.08.031
   Blümmel J, 2007, BIOMATERIALS, V28, P4739, DOI 10.1016/j.biomaterials.2007.07.038
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Chen K, 2009, BIOMATERIALS, V30, P6912, DOI 10.1016/j.biomaterials.2009.08.045
   Chen R, 2006, BIOMATERIALS, V27, P4453, DOI 10.1016/j.biomaterials.2006.04.011
   Chollet C, 2009, BIOMATERIALS, V30, P711, DOI 10.1016/j.biomaterials.2008.10.033
   Chun C, 2009, BIOMATERIALS, V30, P6295, DOI 10.1016/j.biomaterials.2009.08.011
   Cohen M, 2006, EMBO J, V25, P302, DOI 10.1038/sj.emboj.7600960
   Cohen M, 2004, CHEMBIOCHEM, V5, P1393, DOI 10.1002/cbic.200400162
   Cohen M, 2003, BIOPHYS J, V85, P1996, DOI 10.1016/S0006 3495(03)74627 X
   Cohen M, 2007, SOFT MATTER, V3, P327, DOI 10.1039/b613770a
   Curran JM, 2010, BIOMATERIALS, V31, DOI 10.1016/j.biomaterials.2009.11.090
   Curran JM, 2005, BIOMATERIALS, V26, P7057, DOI 10.1016/j.biomaterials.2005.05.008
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   George PA, 2009, BIOMATERIALS, V30, P4732, DOI 10.1016/j.biomaterials.2009.05.039
   Graeter SV, 2007, NANO LETT, V7, P1413, DOI 10.1021/nl070098g
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432 1033.1992.tb17495.x
   Haubner R, 1997, ANGEW CHEM INT EDIT, V36, P1375
   Haubner R, 1996, J AM CHEM SOC, V118, P7461, DOI 10.1021/ja9603721
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Hoover DK, 2008, J AM CHEM SOC, V130, P3280, DOI 10.1021/ja711016m
   Houseman BT, 2001, BIOMATERIALS, V22, P943, DOI 10.1016/S0142 9612(00)00259 3
   Hozumi K, 2010, BIOMATERIALS, V31, P3237, DOI 10.1016/j.biomaterials.2010.01.043
   Huang JH, 2009, NANO LETT, V9, P1111, DOI 10.1021/nl803548b
   Hunt JA, 2008, NAT MATER, V7, P617, DOI 10.1038/nmat2242
   Ito F, 2010, BIOMATERIALS, V31, P58, DOI 10.1016/j.biomaterials.2009.09.026
   Janssen ML, 2002, CANCER RES, V62, P6146
   Kaneshiro TL, 2009, BIOMATERIALS, V30, P5660, DOI 10.1016/j.biomaterials.2009.06.026
   Kantlehner M, 2000, CHEMBIOCHEM, V1, P107, DOI 10.1002/1439 7633(20000818)1:2<107::AID CBIC107>3.0.CO;2 4
   Kantlehner M, 1999, ANGEW CHEM INT EDIT, V38, P560, DOI 10.1002/(SICI)1521 3773(19990215)38:4<560::AID ANIE560>3.0.CO;2 F
   Kok RJ, 2002, BIOCONJUGATE CHEM, V13, P128, DOI 10.1021/bc015561+
   Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057
   Lee ST, 2010, BIOMATERIALS, V31, P1219, DOI 10.1016/j.biomaterials.2009.10.054
   Liu SQ, 2009, BIOMATERIALS, V30, P1453, DOI 10.1016/j.biomaterials.2008.11.023
   Liu S, 2009, BIOCONJUGATE CHEM, V20, P2199, DOI 10.1021/bc900167c
   Luo W, 2008, LANGMUIR, V24, P12129, DOI 10.1021/la802836g
   Markó K, 2008, BIOCONJUGATE CHEM, V19, P1757, DOI 10.1021/bc8000134
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   Michael J, 2009, BIOCONJUGATE CHEM, V20, P710, DOI 10.1021/bc800372e
   MULLER G, 1992, ANGEW CHEM INT EDIT, V31, P326, DOI 10.1002/anie.199203261
   Ohga Y, 2009, BIOMATERIALS, V30, P6731, DOI 10.1016/j.biomaterials.2009.08.044
   Oya K, 2009, BIOMATERIALS, V30, P1281, DOI 10.1016/j.biomaterials.2008.11.030
   Perlin L, 2008, SOFT MATTER, V4, P2331, DOI 10.1039/b801646a
   Petty RT, 2007, J AM CHEM SOC, V129, P8966, DOI 10.1021/ja0735709
   Salinas CN, 2008, BIOMATERIALS, V29, P2370, DOI 10.1016/j.biomaterials.2008.01.035
   Schottelius M, 2009, ACCOUNTS CHEM RES, V42, P969, DOI 10.1021/ar800243b
   Shen H, 2009, BIOMATERIALS, V30, P3150, DOI 10.1016/j.biomaterials.2009.02.004
   Shin H, 2002, J BIOMED MATER RES, V61, P169, DOI 10.1002/jbm.10193
   SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320
   Stefonek Puccinelli TJ, 2008, ANN BIOMED ENG, V36, P2121, DOI 10.1007/s10439 008 9581 1
   Sun JG, 2008, BIOMACROMOLECULES, V9, P2569, DOI 10.1021/bm800477s
   Sun JG, 2009, CHINESE SCI BULL, V54, P3154, DOI 10.1007/s11434 009 0240 1
   Tang J, 2010, BIOMATERIALS, V31, P2470, DOI 10.1016/j.biomaterials.2009.12.006
   Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027
   Wilson JT, 2009, J AM CHEM SOC, V131, P18228, DOI 10.1021/ja908887v
   Wu LB, 2006, BIOMATERIALS, V27, P185, DOI 10.1016/j.biomaterials.2005.05.105
   Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038
   Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Zhang HN, 2009, BIOMATERIALS, V30, P4063, DOI 10.1016/j.biomaterials.2009.04.015
   Zhang L, 2009, BIOMATERIALS, V30, P1309, DOI 10.1016/j.biomaterials.2008.11.020
   Zimmerman E, 2002, BIOPHYS J, V82, P1848, DOI 10.1016/S0006 3495(02)75535 5
NR 66
TC 77
Z9 88
U1 0
U2 120
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2010
VL 31
IS 18
BP 4809
EP 4817
DI 10.1016/j.biomaterials.2010.02.064
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 597SY
UT WOS:000277783100004
PM 20346502
DA 2025 08 17
ER

PT J
AU Sanfélix Gimeno, G
   Librero López, J
   Modroño Riaño, G
   Peiró, S
   Rodríguez Bernal, CL
AF Sanfelix Gimeno, Gabriel
   Librero Lopez, Julian
   Modrono Riano, Gracia
   Peiro, Salvador
   Rodriguez Bernal, Clara L.
CA Drug Utilization Spanish Natl Hlth
TI Variation in Antiosteoporotic Drug Prescribing and Spending Across
   Spain. A Population Based Ecological Cross Sectional Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoporosis; geographical variation; pharmaceutical utilization;
   expenditure; medication; hip fracture prevention
ID HIP FRACTURE; GEOGRAPHIC VARIATION; OSTEOPOROSIS MEDICATION;
   REGIONAL VARIATION; ESOSVAL COHORT; PRIMARY CARE; US; PREVALENCE;
   WORLDWIDE; TRENDS
AB Introduction: Evidence has shown that utilization of antiosteoporotic medications does not correspond with risk, and studies on other therapies have shown that adequacy of pharmaceutical prescribing might vary between regions. Nevertheless, very few studies have addressed the variability in osteoporotic drug consumption. We aimed to describe variations in pharmaceutical utilization and spending on osteoporotic drugs between Health Areas (HA) in Spain.
   Methods: Population based cross sectional ecological study of expenditure and utilization of the five therapeutic groups marketed for osteoporosis treatment in Spain in 2009. Small area variation analysis (SAVA) methods were used. The units of analysis were the 168 HA of 13 Spanish regions, including 7.2 million women aged 50 years and older. The main outcomes were the defined daily dose (DDD) per 1000 inhabitants and day (DDD/1000/Day) dispensed according to the pharmaceutical claims reimbursed, and the expenditure on antiosteoporotics at retail price per woman >= 50 years old and per year.
   Results: The average osteoporosis drug consumption was 116.8 DDD/1000W/Day, ranging from 78.5 to 158.7 DDD/1000W/Day between the HAs in the 5th and 95th percentiles. Seventy five percent of the antiosteoporotics consumed was bisphosphonates, followed by raloxifene, strontium ranelate, calcitonins, and parathyroid hormones including teriparatide. Regarding variability by therapeutic groups, biphosphonates showed the lowest variation, while calcitonins and parathyroid hormones showed the highest variation. The annual expenditure on antiosteoporotics was (sic)426.5 million, translating into an expenditure of (sic)59.2 for each woman >= 50 years old and varying between (sic)38.1 and (sic)83.3 between HAs in the 5th and 95th percentiles. Biphosphonates, despite accounting for 79% of utilization, only represented 63% of total expenditure, while parathyroid hormones with only 1.6% of utilization accounted for 15% of the pharmaceutical spending.
   Conclusion: This study highlights a marked geographical variation in the prescription of antiosteoporotics, being more pronounced in the case of costly drugs such as parathyroid hormones. The differences in rates of prescribing explained almost all of the variance in drug spending, suggesting that the difference in prescription volume between territories, and not the price of the drugs, is the main source of variation in this setting. Data on geographical variation of prescription can help guide policy proposals for targeting areas with inadequate antiosteoporotic drug use.
C1 [Sanfelix Gimeno, Gabriel; Librero Lopez, Julian; Peiro, Salvador; Rodriguez Bernal, Clara L.] Fdn Fomento Invest Sanitaria & Biomed Comunitat V, Valencia, Spain.
   [Sanfelix Gimeno, Gabriel; Librero Lopez, Julian; Peiro, Salvador; Rodriguez Bernal, Clara L.] Red Invest Serv Salud Enfermedades Cron REDISSEC, Valencia, Spain.
   [Librero Lopez, Julian] Ctr Invest Biomed Gobierno Navarra Navarrabiomed, Edificio Invest, Pamplona, Spain.
   [Modrono Riano, Gracia] Serv Farm Atenc Primaria & Especializada, Gijon, Spain.
   [Modrono Riano, Gracia] Serv Salud Principado Asturias, Oviedo, Spain.
C3 Navarrabiomed
RP Sanfélix Gimeno, G (通讯作者)，Fdn Fomento Invest Sanitaria & Biomed Comunitat V, Valencia, Spain.; Sanfélix Gimeno, G (通讯作者)，Red Invest Serv Salud Enfermedades Cron REDISSEC, Valencia, Spain.
EM sanfelix_gab@gva.es
RI Sanfélix Gimeno, Gabriel/E 9140 2012; Librero, Julian/F 4947 2017;
   Rodriguez Bernal, Clara/ABF 9659 2021; Peiro, Salvador/H 5778 2017;
   Sanfelix Gimeno, Gabriel/E 9140 2012
OI Librero, Julian/0000 0002 4859 9054; bernal,
   enrique/0009 0001 1753 9104; Peiro, Salvador/0000 0002 3902 569X;
   Sanfelix Gimeno, Gabriel/0000 0001 7098 4576; Rodriguez Bernal,
   Clara/0000 0003 2617 8635
FU Instituto de Salud Carlos III from the Spanish Ministry of Science and
   Innovation   European Regional Development Fund [PI09/90882, PI13/01721]
FX This project was supported by the Instituto de Salud Carlos III from the
   Spanish Ministry of Science and Innovation (Grant Nos. PI09/90882 and
   PI13/01721), co funded by the European Regional Development Fund.
CR Anis AH, 1996, CAN MED ASSOC J, V154, P635
   Bernal Delgado E, 2014, HEALTH POLICY, V114, P15, DOI 10.1016/j.healthpol.2013.07.013
   Bernal Delgado E, 2013, GAC SANIT, V27, P7, DOI 10.1016/j.gaceta.2012.02.004
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1856, DOI 10.1210/jc.2009 2157
   CIOMS WHO, 2008, INT ETH GUID EP STUD
   Crilly RG, 2014, OSTEOPOROSIS INT, V25, P205, DOI 10.1007/s00198 013 2453 z
   de Felipe R, 2010, ATEN PRIM, V42, P559, DOI 10.1016/j.aprim.2009.10.022
   Devold HM, 2010, EUR J CLIN PHARMACOL, V66, P299, DOI 10.1007/s00228 009 0746 0
   Donohue JM, 2012, NEW ENGL J MED, V366, P530, DOI 10.1056/NEJMsa1104816
   Dubois RW, 2002, HEALTH AFFAIR, V21, P240, DOI 10.1377/hlthaff.21.1.240
   Eisenberg JM, 2002, MED CARE, V40, P1016, DOI 10.1097/00005650 200211000 00004
   Gauld R, 2011, AM J MED QUAL, V26, P120, DOI 10.1177/1062860610375107
   Hernlund E., 2013, ARCH OSTEOPOROS, V8, P1, DOI DOI 10.1007/S11657 013 0136 1
   Hurtado I, 2014, J CLIN ENDOCR METAB, V99, P142, DOI 10.1210/jc.2013 3448
   Ibáñez B, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472 6963 9 60
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Martín Merino E, 2017, BONE, V105, P292, DOI 10.1016/j.bone.2017.08.031
   Martin Moreno JM, 2009, BMJ BRIT MED J, V338, DOI 10.1136/bmj.b1170
   Mays N, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d1849
   Mercuri M, 2011, J EVAL CLIN PRACT, V17, P671, DOI 10.1111/j.1365 2753.2011.01689.x
   RICHARDS M., 2010, Extent and causes of international variations in drug usage: a report for the Secretary of State for Health by Professor Sir Mike Richards CBE
   Rocha Olavo, 2006, Acta Med Port, V19, P373
   Sanfélix Genovés J, 2013, OSTEOPOROSIS INT, V24, P1045, DOI 10.1007/s00198 012 2018 6
   Sanfélix Genovés J, 2014, MED CLIN BARCELONA, V142, P15, DOI 10.1016/j.medcli.2012.10.025
   Shah A, 2017, OSTEOPOROSIS INT, V28, P169, DOI 10.1007/s00198 016 3811 4
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Wang L, 2013, PRIM HEALTH CARE RES, V14, P1, DOI 10.1017/S1463423612000114
   World Health Organization, 2012, COLL CTR DRUG STAT M, V16th
   Yu YM, 2017, MATURITAS, V103, P54, DOI 10.1016/j.maturitas.2017.06.021
   Zhang YT, 2012, NEW ENGL J MED, V367, P1724, DOI 10.1056/NEJMsa1203980
   Zhang YT, 2011, AM ECON REV, V101, P393, DOI 10.1257/aer.101.3.393
   Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872
NR 33
TC 0
Z9 0
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 13
PY 2018
VL 9
AR 342
DI 10.3389/fphar.2018.00342
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GC7EF
UT WOS:000429954800001
PM 29706889
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kaneda Ikeda, E
   Iwata, T
   Mizuno, N
   Nagahara, T
   Kajiya, M
   Takeda, K
   Hirata, R
   Ishida, S
   Yoshioka, M
   Fujita, T
   Kawaguchi, H
   Kurihara, H
AF Kaneda Ikeda, Eri
   Iwata, Tomoyuki
   Mizuno, Noriyoshi
   Nagahara, Takayoshi
   Kajiya, Mikihito
   Takeda, Katsuhiro
   Hirata, Reika
   Ishida, Shu
   Yoshioka, Minami
   Fujita, Tsuyoshi
   Kawaguchi, Hiroyuki
   Kurihara, Hidemi
TI Periodontal ligament cells regulate osteogenesis via miR 299 5p in
   mesenchymal stem cells
SO DIFFERENTIATION
LA English
DT Article
DE MSC; Periodontal ligament cell; miR 299 5p; SOX11; Runx2; POSTN
ID BONE MARROW; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; MICRORNA
   EXPRESSION; GENE EXPRESSION; STROMAL CELLS; PERIOSTIN; IDENTIFICATION;
   OSTERIX; PROTEIN
AB Background: The periodontal ligament contains periodontal ligament cells, which is a heterogeneous cell population, and includes progenitor cells that can differentiate into osteoblasts/cementoblasts. Mesenchymal stem cells (MSCs) can differentiate into various cells and can be used for periodontal regenerative therapy. Therefore, transplanted MSCs can be affected by humoral factors from periodontal ligament cells via the transcription factors or microRNAs (miRNAs) of MSCs. In addition, periostin (POSTN) is secreted from HPL cells and can regulate periodontal regeneration and homeostasis. To clarify the regulatory mechanism of humoral factors from periodontal ligament cells, we attempted to identify key genes, specifically microRNAs, involved in this process.
   Methods: Human MSCs (hMSCs) were indirectly co cultured with human periodontal ligament cells (HPL cells) and then evaluated for osteogenesis, undifferentiated MSCs markers, and miRNA profiles. Furthermore, hMSCs were indirectly co cultured with HPL cells in the presence of anti POSTN monoclonal antibody (anti POSTN Ab) to block the effect of POSTN from HPL cells, and then evaluated for osteogenesis or undifferentiated MSC markers. Moreover, hMSCs showed alterations in miRNA expression or cultured with HPL were challenged with POSTN during osteogenesis, and cells were evaluated for osteogenesis or undifferentiated MSC markers.
   Results: hMSCs co cultured with HPL cells showed suppressed osteogenesis and characteristic expression of SOX11, an undifferentiated MSC marker, as well as miR 299 5p. Overexpression of miR 299 5p regulated osteogenesis and SOX11 expression as observed with indirect co culture with HPL cells. Furthermore, MSCs cocultured with HPL cells were recovered from the suppression of osteogenesis and SOX11 mRNA expression by anti POSTN Ab. However, POSTN induced miR 299 5p and SOX11 expression, and enhanced osteogenesis.
   Conclusion: Humoral factors from HPL cells suppressed osteogenesis in hMSCs. The suppressive effect was mediated by miR 299 5p and SOX11 in hMSCs.
C1 [Kaneda Ikeda, Eri; Iwata, Tomoyuki; Mizuno, Noriyoshi; Nagahara, Takayoshi; Kajiya, Mikihito; Takeda, Katsuhiro; Hirata, Reika; Ishida, Shu; Yoshioka, Minami; Fujita, Tsuyoshi; Kawaguchi, Hiroyuki; Kurihara, Hidemi] Hiroshima Univ, Dept Periodontal Med, Grad Sch Biomed & Hlth Sci, Hiroshima 7348553, Japan.
   [Takeda, Katsuhiro] Hiroshima Univ, Dept Biol Endodont, Grad Sch Biomed & Hlth Sci, Hiroshima 7348553, Japan.
   [Kawaguchi, Hiroyuki] Hiroshima Univ Hosp, Dept Gen Dent, Hiroshima 7348553, Japan.
C3 Hiroshima University; Hiroshima University; Hiroshima University
RP Iwata, T (通讯作者)，Hiroshima Univ, Dept Periodontal Med, Grad Sch Biomed & Hlth Sci, Hiroshima 7348553, Japan.
EM iwatat@hiroshima u.ac.jp
RI Kajiya, Mikihito/A 4288 2018; Kurihara, Hidemi/G 5730 2019
OI Kajiya, Mikihito/0000 0001 6652 0007; Iwata,
   Tomoyuki/0000 0001 7345 7480
CR Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Cai CM, 2007, MOL ENDOCRINOL, V21, P1835, DOI 10.1210/me.2006 0480
   Fang G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061208
   Feng JS, 2019, EUR REV MED PHARMACO, V23, P4089, DOI 10.26355/eurrev_201905_17910
   Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451
   Fujita T, 2007, J PERIODONTAL RES, V42, P283, DOI 10.1111/j.1600 0765.2006.00944.x
   Guo L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/907420
   Guo L, 2012, GENE, V511, P187, DOI 10.1016/j.gene.2012.09.066
   Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097 0177(199710)210:2<79::AID AJA1>3.0.CO;2 6
   Hasegawa N, 2006, J PERIODONTOL, V77, P1003, DOI 10.1902/jop.2006.050341
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Huang J, 2010, E POLYMERS
   Igarashi A, 2007, TISSUE ENG, V13, P2405, DOI 10.1089/ten.2006.0340
   Ishii M, 2005, BIOCHEM BIOPH RES CO, V332, P297, DOI 10.1016/j.bbrc.2005.04.118
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kashiwai K, 2016, J CELL BIOCHEM, V117, P1543, DOI 10.1002/jcb.25446
   Kawaguchi H, 2004, J PERIODONTOL, V75, P1281, DOI 10.1902/jop.2004.75.9.1281
   Kim YS, 2009, J PERIODONTOL, V80, P2045, DOI 10.1902/jop.2009.090145
   Kittaka M, 2015, CYTOTHERAPY, V17, P860, DOI 10.1016/j.jcyt.2015.01.007
   Komaki M, 2007, J CELL BIOCHEM, V100, P303, DOI 10.1002/jcb.21038
   Kruzynska Frejtag A, 2004, DEV DYNAM, V229, P857, DOI 10.1002/dvdy.10453
   Kubo H, 2009, GENES CELLS, V14, P407, DOI 10.1111/j.1365 2443.2009.01281.x
   Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008 5472.CAN 05 4540
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Li J, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3674 x
   Li ZH, 2017, AM J TRANSL RES, V9, P1680
   Litvin J, 2004, J CELL BIOCHEM, V92, P1044, DOI 10.1002/jcb.20115
   Liu GX, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0048 7
   Liu T, 2019, FASEB J, V33, P1565, DOI 10.1096/fj.201701355RR
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   MCCULLOCH CAG, 1985, ANAT RECORD, V211, P258, DOI 10.1002/ar.1092110305
   Mizuno N, 2008, J PERIODONTOL, V79, P2361, DOI 10.1902/jop.2008.070577 
   Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165
   Morsczeck C, 2006, CALCIFIED TISSUE INT, V78, P98, DOI 10.1007/s00223 005 0146 0
   Nagatomo K, 2006, J PERIODONTAL RES, V41, P303, DOI 10.1111/j.1600 0765.2006.00870.x
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nohutcu RM, 1997, J PERIODONTOL, V68, P320, DOI 10.1902/jop.1997.68.4.320
   Norris RA, 2007, J CELL BIOCHEM, V101, P695, DOI 10.1002/jcb.21224
   OGATA Y, 1995, CELL BIOL INT, V19, P637, DOI 10.1006/cbir.1995.1113
   Ogata Y, 2014, J ORAL SCI, V56, P253, DOI 10.2334/josnusd.56.253
   Oku E, 2008, INT J HEMATOL, V88, P57, DOI 10.1007/s12185 008 0095 2
   Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272
   Park IH, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.87
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Roche S, 2013, INT J PHARMACEUT, V440, P72, DOI 10.1016/j.ijpharm.2011.12.041
   SAMUEL CE, 1979, VIROLOGY, V93, P281, DOI 10.1016/0042 6822(79)90300 3
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271
   Takewaki M, 2017, J DENT RES, V96, P984, DOI 10.1177/0022034517708770
   Tamura S, 2004, NEUROSCIENCE, V124, P261, DOI 10.1016/j.neuroscience.2003.11.036
   Tang Y, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12369
   Tolosa E, 2018, NEUROBIOL AGING, V69, P283, DOI 10.1016/j.neurobiolaging.2018.05.032
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Tornero Esteban P, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0652 9
   Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777
   Wu SQ, 2016, ONCOL LETT, V12, P741, DOI 10.3892/ol.2016.4621
   Wu Z, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0039 0
   Xie Q, 2017, SCI REP UK, V7, DOI 10.1038/srep42840
   Xue H, 2016, ONCOL REP, V35, P1771, DOI 10.3892/or.2016.4548
   Yamada S, 2007, J BIOL CHEM, V282, P23070, DOI 10.1074/jbc.M611181200
   Yang N, 2017, DIFFERENTIATION, V97, P33, DOI 10.1016/j.diff.2017.08.004
   Zhang GP, 2017, J CELL MOL MED, V21, P254, DOI 10.1111/jcmm.12961
NR 63
TC 16
Z9 16
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD MAR APR
PY 2020
VL 112
BP 47
EP 57
DI 10.1016/j.diff.2020.01.001
PG 11
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA KZ9YW
UT WOS:000523615700007
PM 31951879
DA 2025 08 17
ER

PT J
AU Lima, SMF
   Freire, MS
   Cantuária, APC
   Martins, DCM
   Amorim, IA
   Dantas, EMGL
   Farias, JO
   Castro, MB
   Silva, JS
   Barriviera, FA
   Barriviera, M
   Almeida, JA
   Uehara, IA
   Silva, MJB
   Oliveira, APL
   Silva, ON
   Hancock, REW
   Franco, OL
   Rezende, TMB
AF Lima, Stella M. F.
   Freire, Mirna S.
   Cantuaria, Ana Paula C.
   Martins, Danilo C. M.
   Amorim, Ingrid A.
   Dantas, Elaine M. G. L.
   Farias, Jade O.
   Castro, Marcio B.
   Silva, Jackson S.
   Barriviera, Fernando A.
   Barriviera, Mauricio
   Almeida, Jeeser A.
   Uehara, Isadora A.
   Silva, Marcelo J. B.
   Oliveira, Ana Paula L.
   Silva, Osmar N.
   Hancock, Robert E. W.
   Franco, Octavio L.
   Rezende, Taia M. B.
TI The use of host defense peptides in root canal therapy in rats
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Host defense peptides; Synoeca MP; HHC 10; Apical periodontitis;
   Antimicrobial peptide
ID CALCIUM HYDROXIDE; ANTIMICROBIAL PEPTIDE; PRIMARY TEETH; IN VITRO;
   ANTIBIOTICS; MECHANISMS; RESISTANCE; PROTEINS; DISEASES; REPAIR
AB Objectives In order to evaluate host defense peptides (HDPs) HHC 10 and synoeca MP activity in in vitro osteoclastogenesis process and in vivo induced apical periodontitis, testing the effect of molecules in the inflammatory response and in apical periodontitis size/volume after root canal treatment. Materials and methods In vitro osteoclastogenesis was assessed on bone marrow cell cultures extracted from mice, while in vivo endodontic treatment involved rats treated with Ca(OH)(2) or HDPs. In vitro osteoclasts were subjected to TRAP staining, and in vivo samples were evaluated by radiographic and tomographic exams, as well as histologic analysis. Results None of the substances downregulated the in vitro osteoclastogenesis. Nevertheless, all treatments affected the average of apical periodontitis size in rats, although only teeth treated with HDPs demonstrated lower levels of the inflammatory process. These results demonstrated the in vivo potential of HDPs. Radiographic analysis suggested that HHC 10 and synoeca MP treated animals presented a similar lesion size than Ca(OH)(2) treated animals after 7 day of endodontic treatment. However, tomography analysis demonstrated smaller lesion volume in synoeca MP treated animals than HHC 10 and Ca(OH)(2) treated animals, after 7 days. Conclusions These molecules demonstrated an auxiliary effect in endodontic treatment that might be related to its immunomodulatory ability, broad spectrum antimicrobial activity, and possible induction of tissue repair at low concentrations. These results can encourage further investigations on the specific mechanisms of action in animal models to clarify the commercial applicability of these biomolecules for endodontic treatment. Clinical significance HDPs have the potential to be adjuvant substances in endodontic therapy due to its potential to reduce inflammation in apical periodontitis.
C1 [Lima, Stella M. F.; Martins, Danilo C. M.; Dantas, Elaine M. G. L.; Farias, Jade O.; Rezende, Taia M. B.] Univ Catolica Brasilia, Curso Odontol, Brasilia, DF, Brazil.
   [Lima, Stella M. F.; Freire, Mirna S.; Cantuaria, Ana Paula C.; Martins, Danilo C. M.; Amorim, Ingrid A.; Dantas, Elaine M. G. L.; Farias, Jade O.; Franco, Octavio L.; Rezende, Taia M. B.] Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, Programa Posgrad Ciencias Genom & Biotecnol, SGAN916N,Ave W5,Campus 2,Modulo C,Room C 221, BR 70790160 Brasilia, DF, Brazil.
   [Freire, Mirna S.; Franco, Octavio L.] Univ Brasilia, Programa Doutorado Rede Ctr Oeste, Brasilia, DF, Brazil.
   [Freire, Mirna S.] Fac Integradas Uniao Educ Planalto Cent, Curso Odontol, Brasilia, DF, Brazil.
   [Cantuaria, Ana Paula C.; Martins, Danilo C. M.; Rezende, Taia M. B.] Univ Brasilia, Programa Posgrad Ciencias Saude, Brasilia, DF, Brazil.
   [Castro, Marcio B.] Univ Brasilia, Lab Patol Vet, Brasilia, DF, Brazil.
   [Silva, Jackson S.] Ctr Univ Dist Fed, Curso Odontol, Brasilia, DF, Brazil.
   [Silva, Jackson S.; Barriviera, Fernando A.; Barriviera, Mauricio] Fenelon Radiol, Brasilia, DF, Brazil.
   [Almeida, Jeeser A.] Univ Fed Mato Grosso do Sul, Programa Posgrad Saude & Desenvolvimento Regia Ct, Campo Grande, MS, Brazil.
   [Uehara, Isadora A.; Silva, Marcelo J. B.] Univ Fed Uberlandia, Lab Biomarcadores Tumorais & Osteoimunol, Uberlandia, MG, Brazil.
   [Oliveira, Ana Paula L.] Univ Fed Uberlandia, Fac Odontol, Uberlandia, MG, Brazil.
   [Silva, Osmar N.; Franco, Octavio L.] Univ Catolica Dom Bosco, S Inova Biotech, Posgrad Biotecnol, Catol Dom Bosco, Campo Grande, MS, Brazil.
   [Hancock, Robert E. W.] Univ British Columbia, Ctr Microbial Dis & Immun Res, Vancouver, BC, Canada.
C3 Universidade Catolica de Brasilia; Universidade Catolica de Brasilia;
   Universidade de Brasilia; Universidade de Brasilia; Universidade de
   Brasilia; Centro Universitario do Distrito Federal; Universidade Federal
   de Mato Grosso do Sul; Universidade Federal de Uberlandia; Universidade
   Federal de Uberlandia; Universidade Catolica Dom Bosco (UCDB);
   University of British Columbia
RP Rezende, TMB (通讯作者)，Univ Catolica Brasilia, Curso Odontol, Brasilia, DF, Brazil.; Rezende, TMB (通讯作者)，Univ Catolica Brasilia, Ctr Anal Prote & Bioquim, Programa Posgrad Ciencias Genom & Biotecnol, SGAN916N,Ave W5,Campus 2,Modulo C,Room C 221, BR 70790160 Brasilia, DF, Brazil.; Rezende, TMB (通讯作者)，Univ Brasilia, Programa Posgrad Ciencias Saude, Brasilia, DF, Brazil.
EM taiambr@gmail.com
RI Freire, Mirna/E 4441 2014; Silva, Marcelo/J 4298 2012; Silva, Marcelo J.
   B./J 4298 2012; Rezende, Taia/D 3732 2015; Oliveira, Ana
   Paula/M 6700 2013; Castro, Márcio/ABE 6941 2022; Almeida,
   Jeeser/O 2912 2014; Franco, Octavio/T 3020 2017; de Freitas Lima,
   Stella/A 4501 2014; Hancock, Robert/E 1145 2013; Silva,
   Osmar/B 3183 2012
OI Silva, Marcelo J. B./0000 0002 5807 4286; Oliveira, Ana
   Paula/0000 0001 6532 1700; Castro, Marcio Botelho
   de/0000 0002 3996 0856; almeida, jeeser/0000 0002 3409 8005; Franco,
   Octavio/0000 0001 9546 0525; Hancock, Robert/0000 0001 5989 8503;
   Rezende, Taia/0000 0002 4148 0659; Maris de Freitas Lima,
   Stella/0000 0003 1359 8761; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [409196/2018 5]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES); Fundacao de Apoio a Pesquisa do Distrito Federal
   (FAPDF) [0193.001702/2017]; Fundacao de Apoio ao Desenvolvimento do
   Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT);
   Canadian Institutes for Health Research [FDN 154287]
FX The work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) Grant number 409196/2018 5, Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de
   Apoio a Pesquisa do Distrito Federal (FAPDF) Grant number
   0193.001702/2017 and Fundacao de Apoio ao Desenvolvimento do Ensino,
   Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) and
   support from the Canadian Institutes for Health Research FDN 154287 to
   REWH. REWH holds a Canada Research Chair in Health and Genomics and a
   UBC Killam Professorship.
CR Akashi M, 2017, J MAXILLOFAC ORAL SU, V16, P58, DOI 10.1007/s12663 016 0915 5
   Aminoshariae A, 2017, J ENDODONT, V43, P514, DOI 10.1016/j.joen.2016.11.008
   Anan H, 1996, J ENDODONT, V22, P668, DOI 10.1016/S0099 2399(96)80061 6
   Bagheri M, 2020, ACS APPL MATER INTER, V12, P26852, DOI 10.1021/acsami.0c04336
   Barbosa Ribeiro M, 2019, CLIN ORAL INVEST, V23, P2759, DOI 10.1007/s00784 018 2719 0
   Bommarius B, 2010, PEPTIDES, V31, P1957, DOI 10.1016/j.peptides.2010.08.008
   Carrotte P, 2004, BRIT DENT J, V197, P735, DOI 10.1038/sj.bdj.4811897
   Cherkasov A, 2009, ACS CHEM BIOL, V4, P65, DOI 10.1021/cb800240j
   Cotti E, 2014, J ENDODONT, V40, P1902, DOI 10.1016/j.joen.2014.08.013
   Dammaschke T, 2005, ACTA ODONTOL SCAND, V63, P143, DOI 10.1080/00016350510019801
   Lima SMD, 2015, BIOTECHNOL ADV, V33, P203, DOI 10.1016/j.biotechadv.2014.10.013
   de Sousa DL, 2011, PEDIATR DENT, V33, P307
   Ferreira DCD, 2009, J DENT CHILD, V76, P194
   Epand RM, 1999, BBA BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005 2736(99)00198 4
   Estrela C, 1995, Braz Dent J, V6, P85
   Evans M, 2002, INT ENDOD J, V35, P221, DOI 10.1046/j.1365 2591.2002.00504.x
   Freire DO, 2020, PEPTIDE SCI, V112, DOI 10.1002/pep2.24141
   Georgiou AC, 2019, J ENDODONT, V45, P1279, DOI 10.1016/j.joen.2019.07.017
   Graunaite I., 2012, J ORAL MAXILLOFAC RE, V2, pE1, DOI DOI 10.5037/jomr.2011.2401
   Han B, 2014, J ENDODONT, V40, P1977, DOI 10.1016/j.joen.2014.08.008
   Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317
   Heithersay G S, 1975, J Br Endod Soc, V8, P74
   Hilchie AL, 2013, NAT CHEM BIOL, V9, P761, DOI [10.1038/NCHEMBIO.1393, 10.1038/nchembio.1393]
   Ishida M, 2004, J BONE MINER METAB, V22, P415, DOI 10.1007/s00774 004 0503 5
   Kajiya M, 2010, J ENDODONT, V36, P1009, DOI 10.1016/j.joen.2010.02.028
   KAKEHASHI S, 1965, ORAL SURG ORAL MED O, V20, P340, DOI 10.1016/0030 4220(65)90166 0
   Kassebaum NJ, 2017, J DENT RES, V96, P380, DOI 10.1177/0022034517693566
   Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545
   Leonardo MR, 2006, ORAL SURG ORAL MED O, V102, P680, DOI 10.1016/j.tripleo.2006.03.021
   López Abarrategui C, 2012, BIOCHIMIE, V94, P968, DOI 10.1016/j.biochi.2011.12.016
   Matsumoto A, 1998, J ENDODONT, V24, P811, DOI 10.1016/S0099 2399(98)80008 3
   Porto LVMG, 2015, J FORENSIC LEG MED, V36, P4, DOI 10.1016/j.jflm.2015.07.007
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   MURPHY JB, 1960, BIOCHIM BIOPHYS ACTA, V45, P382, DOI 10.1016/0006 3002(60)91464 5
   Mutoh N, 2013, DENT MATER J, V32, P413, DOI 10.4012/dmj.2012 218
   Nair PNR, 2006, INT ENDOD J, V39, P249, DOI 10.1111/j.1365 2591.2006.01099.x
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   PRYOR WA, 1993, J BIOL CHEM, V268, P3120
   Rocha T, 2007, TOXICON, V50, P589, DOI 10.1016/j.toxicon.2007.05.003
   Segura Egea JJ, 2018, INT ENDOD J, V51, P20, DOI 10.1111/iej.12781
   Sharma A, 2018, ARTIF CELL NANOMED B, V46, pS156, DOI 10.1080/21691401.2018.1489823
   Shen Y, 2016, SCI REP UK, V6, DOI 10.1038/srep27537
   Siqueira JF, 2001, INT ENDOD J, V34, P1, DOI 10.1046/j.1365 2591.2001.00396.x
   STASHENKO P, 1994, ORAL SURG ORAL MED O, V78, P494, DOI 10.1016/0030 4220(94)90044 2
   Supanchart C, 2012, J DENT RES, V91, P1071, DOI 10.1177/0022034512460402
   Tanomaru M, 2002, J ENDODONT, V28, P295, DOI 10.1097/00004770 200204000 00009
   VANDELOOSDRECHT AA, 1991, J IMMUNOL METHODS, V141, P15, DOI 10.1016/0022 1759(91)90205 T
   Virtej A, 2013, J ENDODONT, V39, P605, DOI 10.1016/j.joen.2012.12.017
   Wang D, 2017, J ENDODONT, V43, P1862, DOI 10.1016/j.joen.2017.06.037
   Wang ZJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132512
   Wimley WC, 2019, ADV EXP MED BIOL, V1117, P241, DOI 10.1007/978 981 13 3588 4_13
   Llamas González YY, 2013, MICROB DRUG RESIST, V19, P124, DOI 10.1089/mdr.2012.0149
   Zhang T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166997
   Zhang ZF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013985
NR 54
TC 7
Z9 7
U1 0
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JUN
PY 2021
VL 25
IS 6
BP 3623
EP 3632
DI 10.1007/s00784 020 03684 9
EA NOV 2020
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA SF3ON
UT WOS:000590004400003
PM 33200281
DA 2025 08 17
ER

PT J
AU Banche Niclot, F
   Montalbano, G
   Fiorilli, S
   Vitale Brovarone, C
AF Banche Niclot, Federica
   Montalbano, Giorgia
   Fiorilli, Sonia
   Vitale Brovarone, Chiara
TI PEG Coated Large Mesoporous Silicas as Smart Platform for Protein
   Delivery and Their Use in a Collagen Based Formulation for 3D Printing
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mesoporous silica particles; large pores; growth factor; pH triggered
   release; type I collagen; 3D printing; hydrothermal treatment
ID TEMPERATURE; SBA 15
AB Silica based mesoporous systems have gained great interest in drug delivery applications due to their excellent biocompatibility and high loading capability. However, these materials face challenges in terms of pore size limitations since they are characterized by nanopores ranging between 6 8 nm and thus unsuitable to host large molecular weight molecules such as proteins, enzymes and growth factors (GFs). In this work, for an application in the field of bone regeneration, large pore mesoporous silicas (LPMSs) were developed to vehicle large biomolecules and release them under a pH stimulus. Considering bone remodeling, the proposed pH triggered mechanism aims to mimic the release of GFs encased in the bone matrix due to bone resorption by osteoclasts (OCs) and the associated pH drop. To this aim, LPMSs were prepared by using 1,3,5 trimethyl benzene (TMB) as a swelling agent and the synthesis solution was hydrothermally treated and the influence of different process temperatures and durations on the resulting mesostructure was investigated. The synthesized particles exhibited a cage like mesoporous structure with accessible pores of diameter up to 23 nm. LPMSs produced at 140 degrees C for 24 h showed the best compromise in terms of specific surface area, pores size and shape and hence, were selected for further experiments. Horseradish peroxidase (HRP) was used as model protein to evaluate the ability of the LPMSs to adsorb and release large biomolecules. After HRP loading, LPMSs were coated with a pH responsive polymer, poly(ethylene glycol) (PEG), allowing the release of the incorporated biomolecules in response to a pH decrease, in an attempt to mimic GFs release in bone under the acidic pH generated by the resorption activity of OCs. The reported results proved that PEG coated carriers released HRP more quickly in an acidic environment, due to the protonation of PEG at low pH that catalyzes polymer hydrolysis reaction. Our findings indicate that LPMSs could be used as carriers to deliver large biomolecules and prove the effectiveness of PEG as pH responsive coating. Finally, as proof of concept, a collagen based suspension was obtained by incorporating PEG coated LPMS carriers into a type I collagen matrix with the aim of designing a hybrid formulation for 3D printing of bone scaffolds.
C1 [Banche Niclot, Federica; Montalbano, Giorgia; Fiorilli, Sonia; Vitale Brovarone, Chiara] Politecn Torino, Dept Appl Sci & Technol, I 10029 Turin, Italy.
   [Banche Niclot, Federica] Univ Torino, Dept Surg Sci, I 10029 Turin, Italy.
   [Vitale Brovarone, Chiara] RU Politecn Torino, Natl Interuniv Consortium Mat Sci & Technol, I 50121 Florence, Italy.
C3 Polytechnic University of Turin; University of Turin
RP Vitale Brovarone, C (通讯作者)，Politecn Torino, Dept Appl Sci & Technol, I 10029 Turin, Italy.; Vitale Brovarone, C (通讯作者)，RU Politecn Torino, Natl Interuniv Consortium Mat Sci & Technol, I 50121 Florence, Italy.
EM federica.banche@polito.it; giorgia.montalbano@polito.it;
   sonia.fiorilli@polito.it; chiara.vitale@polito.it
RI Niclot, Federica/AEZ 1523 2022; MONTALBANO, GIORGIA/AAC 9027 2022;
   Brovarone, Chiara/G 9630 2012
OI MONTALBANO, GIORGIA/0000 0003 2348 2949; Banche Niclot,
   Federica/0000 0002 5855 4490; 
FU European Research Council (ERC) under the European Union's Horizon 2020
   research and innovation programme [681798BOOST]
FX This project has received funding from the European Research Council
   (ERC) under the European Union's Horizon 2020 research and innovation
   programme, grant agreement No. 681798BOOST (www.ercprojectboost.eu
   (accessed on 1 May 2016)) and by the Italian Minister of Education,
   Universities and Research (MIUR), Progetto FARE Ricerca in Italia
   (GRACE).
CR Aksay IA, 1996, SCIENCE, V273, P892, DOI 10.1126/science.273.5277.892
   Alcantar NA, 2000, J BIOMED MATER RES, V51, P343, DOI 10.1002/1097 4636(20000905)51:3<343::AID JBM7>3.0.CO;2 D
   [Anonymous], 2015, Biomed. Glas, DOI [DOI 10.1515/BGLASS 2015 0014, 10.1515/bglass 2015 0014]
   Arap W, 2013, CURR MED CHEM, V20, P2195, DOI 10.2174/0929867311320170005
   Bitar A, 2012, DRUG DISCOV TODAY, V17, P1147, DOI 10.1016/j.drudis.2012.06.014
   Blin JL, 2002, LANGMUIR, V18, P5303, DOI 10.1021/la020042w
   Blin JL, 2000, LANGMUIR, V16, P4229, DOI 10.1021/la9914615
   Boahene PE, 2011, APPL CATAL A GEN, V402, P31, DOI 10.1016/j.apcata.2011.05.005
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Bunker A, 2012, PHYSCS PROC, V34, P24, DOI 10.1016/j.phpro.2012.05.004
   Cao L, 2010, COLLOID SURFACE A, V357, P91, DOI 10.1016/j.colsurfa.2009.09.019
   Carlsson N, 2014, ADV COLLOID INTERFAC, V205, P339, DOI 10.1016/j.cis.2013.08.010
   Catauro M, 2016, MAT SCI ENG C MATER, V68, P205, DOI 10.1016/j.msec.2016.05.082
   Chau DYS, 2005, BIOMATERIALS, V26, P6518, DOI 10.1016/j.biomaterials.2005.04.017
   Chen L, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1573
   Chen Y, 2013, ADV MATER, V25, P3100, DOI 10.1002/adma.201204685
   Chouyyok W, 2009, J MOL CATAL B ENZYM, V56, P246, DOI 10.1016/j.molcatb.2008.05.009
   D'souza AA, 2016, EXPERT OPIN DRUG DEL, V13, P1257, DOI 10.1080/17425247.2016.1182485
   Dhivya R, 2017, MAT SCI ENG C MATER, V80, P59, DOI 10.1016/j.msec.2017.05.128
   Dou QQ, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8090341
   Egger SM, 2015, CHEM MATER, V27, P3193, DOI 10.1021/cm504448u
   Fam SY, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10040787
   Fan J, 2003, CHEM COMMUN, P2140, DOI 10.1039/b304391f
   Farjadian F, 2019, CHEM ENG J, V359, P684, DOI 10.1016/j.cej.2018.11.156
   Feng PY, 2000, LANGMUIR, V16, P5304, DOI 10.1021/la991444f
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fortunati D, 2014, AMINO ACIDS, V46, P1751, DOI 10.1007/s00726 014 1732 0
   Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297 1032
   Gidi Y, 2018, ACS APPL MATER INTER, V10, P39505, DOI 10.1021/acsami.8b15796
   Gisbert Garzarán M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010083
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169 409X(95)00026 4
   Hamam F, 2020, SAUDI J MED MED SCI, V8, P17, DOI 10.4103/sjmms.sjmms_2_19
   Heller J., 1980, The Biomaterials: Silver Jubilee Compendium, P1, DOI [10.1016/B978 008045154 1.50001 0, DOI 10.1016/B978 008045154 1.50001 0]
   Hinton TJ, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500758
   Howard MD, 2008, J BIOMED NANOTECHNOL, V4, P133, DOI 10.1166/jbn.2008.021
   Huang L, 2012, J COLLOID INTERF SCI, V365, P137, DOI 10.1016/j.jcis.2011.09.044
   Hwang YK, 2001, CHEM COMMUN, P1738, DOI 10.1039/b104699n
   Iturrioz Rodríguez N, 2019, INT J NANOMED, V14, P3389, DOI 10.2147/IJN.S198848
   Izquierdo Barba I, 2008, J NANOMATER, V2008, DOI 10.1155/2008/106970
   Jafari S, 2019, BIOMED PHARMACOTHER, V109, P1100, DOI 10.1016/j.biopha.2018.10.167
   Jang HJ, 2015, TOXICOL RES GER, V31, P105
   Joralemon MJ, 2010, CHEM COMMUN, V46, P1377, DOI 10.1039/b920570p
   Juère E, 2018, MICROPOR MESOPOR MAT, V270, P109, DOI 10.1016/j.micromeso.2018.04.031
   Kim MH, 2011, ACS NANO, V5, P3568, DOI 10.1021/nn103130q
   Knezevic NZ, 2015, NANOSCALE, V7, P2199, DOI 10.1039/c4nr06114d
   Kobayashi M, 2014, J MECH BEHAV BIOMED, V38, P33, DOI 10.1016/j.jmbbm.2014.06.003
   Kruk M, 2012, ACCOUNTS CHEM RES, V45, P1678, DOI 10.1021/ar200343s
   Labouta HI, 2013, NANOMED NANOTECHNOL, V9, P39, DOI 10.1016/j.nano.2012.04.004
   Lawrence G, 2015, SCI TECHNOL ADV MAT, V16, DOI 10.1088/1468 6996/16/2/024806
   Lee CH, 2009, NANO TODAY, V4, P165, DOI 10.1016/j.nantod.2009.02.001
   Lei CH, 2002, J AM CHEM SOC, V124, P11242, DOI 10.1021/ja026855o
   Licini C, 2019, CYTOKINE GROWTH F R, V49, P59, DOI 10.1016/j.cytogfr.2019.09.001
   Ma GC, 2010, J AM CHEM SOC, V132, P9596, DOI 10.1021/ja1027524
   Ma JJ, 2015, MICRO NANO LETT, V10, P140, DOI 10.1049/mnl.2014.0413
   Man T, 2014, DESIGN WELL DEFINED
   Mazinani B, 2012, AIP CONF PROC, V1502, P272, DOI 10.1063/1.4769150
   Montalbano G, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10091681
   Montalbano G, 2020, J EUR CERAM SOC, V40, P3689, DOI 10.1016/j.jeurceramsoc.2020.02.018
   Montalbano G, 2019, MATERIALS, V12, DOI 10.3390/ma12223719
   Montalbano G, 2018, MATERIALS, V11, DOI 10.3390/ma11050700
   MORTENSEN K, 1993, MACROMOLECULES, V26, P805, DOI 10.1021/ma00056a035
   Narayan R, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030118
   Nguyen TPB, 2008, MICROPOR MESOPOR MAT, V110, P560, DOI 10.1016/j.micromeso.2007.06.054
   Niu DC, 2010, J AM CHEM SOC, V132, P15144, DOI 10.1021/ja1070653
   Orban JM, 2004, J BIOMED MATER RES A, V68A, P756, DOI 10.1002/jbm.a.20110
   Pan Z, 2020, NANO RES, V13, P373, DOI 10.1007/s12274 020 2619 x
   Pasqua L, 2019, NANOSCALE ADV, V1, P3269, DOI 10.1039/c9na00249a
   Paxton N, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa8dd8
   Quignard S, 2017, COLLOID SURFACE B, V155, P530, DOI 10.1016/j.colsurfb.2017.04.049
   Rosenholm JM, 2008, J CONTROL RELEASE, V128, P157, DOI 10.1016/j.jconrel.2008.02.013
   Schmidt Winkel P, 1999, J AM CHEM SOC, V121, P254, DOI 10.1021/ja983218i
   Schwab A, 2020, CHEM REV, V120, P10850, DOI 10.1021/acs.chemrev.0c00084
   Schwarcz HP, 2017, FRONT PHYS, V5, DOI 10.3389/fphy.2017.00039
   Seker A, 2019, MOLECULES, V24, DOI 10.3390/molecules24122199
   Shadjou N, 2015, J BIOMED MATER RES A, V103, P3703, DOI 10.1002/jbm.a.35504
   Shan WJ, 2015, J NON CRYST SOLIDS, V425, P183, DOI 10.1016/j.jnoncrysol.2015.06.007
   Shi Z., 2020, smart mater. res, V1, P32, DOI DOI 10.1016/J.SMAIM.2020.05.002
   Shirshahi V, 2015, CONTRAST MEDIA MOL I, V10, P1, DOI 10.1002/cmmi.1611
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Song HM, 2019, RSC ADV, V9, P4380, DOI 10.1039/c8ra10517k
   Stillman Z, 2020, POLYM CHEM UK, V11, P568, DOI 10.1039/c9py01206k
   Sun JM, 2006, CHEM COMMUN, P1322, DOI 10.1039/b516930e
   Sun JM, 2005, CHEM COMMUN, P5343, DOI 10.1039/b509713d
   Sun QR, 2017, FORENSIC SCI INT, V277, P1, DOI 10.1016/j.forsciint.2017.04.022
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Thi TTH, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12020298
   Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230 973X.96920
   Totovao R., 2017, THESIS U STRASBOURG
   Tu J, 2016, ACS APPL MATER INTER, V8, P32211, DOI 10.1021/acsami.6b11324
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
   Vivero Escoto JL, 2012, CHEM SOC REV, V41, P2673, DOI 10.1039/c2cs15229k
   Washmon Kriel L, 2000, J MOL CATAL B ENZYM, V10, P453, DOI 10.1016/S1381 1177(99)00123 X
   Wei J, 2011, J AM CHEM SOC, V133, P20369, DOI 10.1021/ja207525e
   Witharana C, 2017, INT J MED RES HEALTH, V6, P11
   Xia W, 2006, J CONTROL RELEASE, V110, P522, DOI 10.1016/j.jconrel.2005.11.002
   Xin CL, 2014, J COLLOID INTERF SCI, V433, P176, DOI 10.1016/j.jcis.2014.07.021
   Zhang H, 2004, J AM CHEM SOC, V126, P7440, DOI 10.1021/ja048630e
   Zhou YX, 2018, ACTA PHARM SIN B, V8, P165, DOI 10.1016/j.apsb.2018.01.007
NR 99
TC 21
Z9 21
U1 2
U2 49
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 4
AR 1718
DI 10.3390/ijms22041718
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QP5IB
UT WOS:000623869000001
PM 33572076
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, CS
   Sun, HW
   Zhong, YM
AF Wang, Chunsheng
   Sun, Huanwei
   Zhong, Yiming
TI Notoginsenoside R1 promotes MC3T3 E1 differentiation by up regulating
   miR 23a via MAPK and JAK1/STAT3 pathways
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Notoginsenoside R1; microRNA 23a; preosteoblast differentiation
ID IN VITRO; CELLS; THERAPY; GROWTH; ROLES; MOUSE; MODEL; RUNX2; VIVO
AB Growing evidence have probed a stimulatory influence of Notoginsenoside R1 (NGR1) with osteoblastic probability. miR 23a plays a crucial role in osteoblast differentiation. Whereas whether there exists a miRs related mechanism by which NGR1 promotes preosteoblast differentiation remains unexplored. We pre treated MC3T3 E1 with NGR1 to anatomize Runx 2 and Osx expression as well as ALP activity. Phosphorylation of regulators was evaluated by Western blot. SB203580 and Ruxolitinib were used to reduce the phosphorylation of regulators. The effects of NGR1 on miR 23a were verified by qRT PCR. We analyzed the expression of Runx 2 and Osx, ALP activity as well as phosphorylation of regulators in MC3T3 E1 stimulated with NGR1 and transfected with miR 23a inhibitor. We found that NGR1 enhanced Runx 2 and Osx expression as well as ALP activity in a concentration dependent manner. NGR1 might exhibit an efficacious promotion on Runx 2, Osx and ALP activity by increased phosphorylation of MAPK, JAK1, and STAT3. NGR1 resulted in miR 23a overexpression which positively modulated Runx 2 and Osx expression as well as ALP activity. Our results showed that miR 23a inhibitor reduced the phosphorylation of MAPK, JAK1 and STAT3 in MC3T3 E1 pre treated with NGR1. In conclusion, NGR1 exhibited an efficacious promotion on preosteoblast differentiation by up regulating miR 23a through MAPK and JAK1/STAT3 pathways.
   HIGHLIGHTS:
   1. NGR1 induces MC3T3 E1 differentiation;
   2. miR 23a is positively regulated by NGR1;
   3. NGR1 regulates MAPK/JAK1/STAT3 through miR 23a.
C1 [Wang, Chunsheng; Sun, Huanwei; Zhong, Yiming] Dalian Med Univ, Dalian Municipal Cent Hosp, Dept Hand & Foot Microsurg, 42 Xuegong St, Dalian 116033, Peoples R China.
C3 Dalian Medical University
RP Wang, CS (通讯作者)，Dalian Med Univ, Dalian Municipal Cent Hosp, Dept Hand & Foot Microsurg, 42 Xuegong St, Dalian 116033, Peoples R China.
EM wangchunsheng213@sina.com
RI Wang, Chunsheng/GLR 4364 2022
CR Aghaee Bakhtiari S, 2015, TUMOR BIOL, V36, P4203, DOI 10.1007/s13277 015 3057 3
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Dalagiorgou G, 2017, CELL MOL LIFE SCI, V74, P921, DOI 10.1007/s00018 016 2394 8
   Fischer V, 2018, EUR CELLS MATER, V35, P365, DOI 10.22203/eCM.v035a25
   Furuta T, 2016, STEM CELL TRANSL MED, V5, P1620, DOI 10.5966/sctm.2015 0285
   Godfrey TC, 2018, J BIOL CHEM, V293, P17646, DOI 10.1074/jbc.RA118.003052
   Guan J, 2007, J PHARMACEUT BIOMED, V44, P996, DOI 10.1016/j.jpba.2007.03.032
   Guo Q, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.22
   Haffner N, 2016, INJURY, V47, P1506, DOI 10.1016/j.injury.2016.04.010
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105
   Huang ZF, 2018, EXP THER MED, V15, P5159, DOI 10.3892/etm.2018.6127
   Ji Z, 2015, IN VITRO CELL DEV AN, V51, P950, DOI 10.1007/s11626 015 9915 x
   Jia CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099849
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kurkewich JL, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006887
   Liu Y, 2016, INT J MOL MED, V38, P537, DOI 10.3892/ijmm.2016.2652
   Meng X, 2014, FREE RADICAL RES, V48, P445, DOI 10.3109/10715762.2014.885117
   Millan Jose Luis, 2006, Purinergic Signal, V2, P335, DOI 10.1007/s11302 005 5435 6
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Röck K, 2015, J INVEST DERMATOL, V135, P369, DOI 10.1038/jid.2014.422
   Shan ZM, 2018, EXP THER MED, V15, P55, DOI 10.3892/etm.2017.5405
   Taiani JT, 2014, BONE, V64, P263, DOI 10.1016/j.bone.2014.04.019
   Wang KP, 2008, J BIOL CHEM, V283, P34029, DOI 10.1074/jbc.M803012200
   Wang T, 2015, BIOCHEM BIOPH RES CO, V466, P232, DOI 10.1016/j.bbrc.2015.09.014
   Wu XD, 2017, ONCOTARGET, V8, P58072, DOI 10.18632/oncotarget.19489
   Yang BR, 2016, CHIN J INTEGR MED, V22, P420, DOI 10.1007/s11655 014 1954 8
   Yu YL, 2016, SCI REP UK, V6, DOI 10.1038/srep21730
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
   Zhao S, 2017, INT IMMUNOPHARMACOL, V47, P118, DOI 10.1016/j.intimp.2017.03.018
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 34
TC 17
Z9 20
U1 1
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2019
VL 47
IS 1
BP 603
EP 609
DI 10.1080/21691401.2019.1573189
PG 7
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HN6EZ
UT WOS:000460279500001
PM 30831034
OA gold
DA 2025 08 17
ER

PT J
AU Yu, YX
   Deng, P
   Yu, B
   Szymanski, JM
   Aghaloo, T
   Hong, C
   Wang, CY
AF Yu, Yongxin
   Deng, Peng
   Yu, Bo
   Szymanski, John M.
   Aghaloo, Tara
   Hong, Christine
   Wang, Cun Yu
TI Inhibition of EZH2 Promotes Human Embryonic Stem Cell Differentiation
   into Mesoderm by Reducing H3K27me3
SO STEM CELL REPORTS
LA English
DT Article
ID MESENCHYMAL STEM; KAPPA B; METHYLTRANSFERASES; REGULATORS
AB Mesoderm derived from human embryonic stem cells (hESCs) is a major source of the mesenchymal stem/stromal cells (MSCs) that can differentiate into osteoblasts and chondrocytes for tissue regeneration. While significant progress has been made in understanding of molecular mechanisms of hESC differentiation into mesodermal cells, little is known about epigenetic factors controlling hESC fate toward mesoderm and MSCs. Identifying potential epigenetic factors that control hESC differentiation will undoubtedly lead to advancements in regenerative medicine. Here, we conducted an epigenome wide analysis of hESCs and MSCs and uncovered that EZH2 was enriched in hESCs and was downregulated significantly in MSCs. The specific EZH2 inhibitor GSK126 directed hESC differentiation toward mesoderm and generated more MSCs by reducing H3K27me3. Our results provide insights into epigenetic landscapes of hESCs and MSCs and suggest that inhibiting EZH2 promotes mesodermal differentiation of hESCs.
C1 [Yu, Yongxin; Deng, Peng; Yu, Bo; Szymanski, John M.; Wang, Cun Yu] Univ Calif Los Angeles, Sch Dent, Lab Mol Signaling, Div Oral Biol & Med, Los Angeles, CA 90095 USA.
   [Aghaloo, Tara] Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Sect Oral & Maxillofacial Surg, Los Angeles, CA 90095 USA.
   [Hong, Christine] Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Sect Orthodont, Los Angeles, CA 90095 USA.
   [Wang, Cun Yu] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Broad Stem Cell Res Inst, Los Angeles, CA 90095 USA.
   [Wang, Cun Yu] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Wang, CY (通讯作者)，Univ Calif Los Angeles, Sch Dent, Lab Mol Signaling, Div Oral Biol & Med, Los Angeles, CA 90095 USA.; Hong, C (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Sect Orthodont, Los Angeles, CA 90095 USA.; Wang, CY (通讯作者)，Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Broad Stem Cell Res Inst, Los Angeles, CA 90095 USA.; Wang, CY (通讯作者)，Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA.
EM chong@dentistry.ucla.edu; cwang@dentistry.ucla.edu
FU Shapiro Family Charitable Funds; NIH [P30CA016042, 5P30AI028697];
   National Cancer Institute [P30CA016042] Funding Source: NIH RePORTER
FX This work was supported by the Shapiro Family Charitable Funds. Flow
   cytometry was performed in the UCLA Flow Cytometry Core Facility that is
   supported by NIH awards P30CA016042 and 5P30AI028697.
CR Alvarez R, 2015, INT J ORAL SCI, V7, P213, DOI 10.1038/ijos.2015.42
   Barlow S, 2008, STEM CELLS DEV, V17, P1095, DOI 10.1089/scd.2007.0154
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Brown SE, 2009, CELLS TISSUES ORGANS, V189, P256, DOI 10.1159/000151746
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chédin F, 2011, PROG MOL BIOL TRANSL, V101, P255, DOI 10.1016/B978 0 12 387685 0.00007 X
   Deng P, 2016, STEM CELL REP, V6, P456, DOI 10.1016/j.stemcr.2016.02.006
   Deng P, 2015, INT J ORAL SCI, V7, P197, DOI 10.1038/ijos.2015.41
   Giuliani M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019988
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Xie W, 2013, CELL, V153, P1134, DOI 10.1016/j.cell.2013.04.022
   Yu PZ, 2011, CELL STEM CELL, V8, P326, DOI 10.1016/j.stem.2011.01.001
NR 16
TC 36
Z9 43
U1 0
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213 6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD SEP 12
PY 2017
VL 9
IS 3
BP 752
EP 761
DI 10.1016/j.stemcr.2017.07.016
PG 10
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FG4WO
UT WOS:000410279200004
PM 28826853
OA Green Published
DA 2025 08 17
ER

PT J
AU Bromhead, C
   Miller, JH
   McDonald, FJ
AF Bromhead, Collette
   Miller, John H.
   McDonald, Fiona J.
TI Regulation of T cadherin by hormones, glucocorticoid and EGF
SO GENE
LA English
DT Article
DE H cadherin; cell adhesion; real time RT PCR; transcription; promoter;
   osteoblasts
ID EPIDERMAL GROWTH FACTOR; H CADHERIN; CELL ADHESION; EXPRESSION; CDH13;
   GENE; OSTEOSARCOMA; CANCER; GLYCOPROTEIN; ADIPONECTIN
AB The cell adhesion molecule T cadherin is an unusual member of the cadherin superfamily that lacks a cytoplasmic domain, binding instead to the cell membrane via a glycophosphatidyl inositol anchor. T cadherin is a receptor for hexameric Acrp30/adiponectin and binds low density lipoproteins in endothelial cells. T cadherin is expressed widely in the brain and cardiovascular system, but expression is absent or decreased in several cancers. Little is known about the mechanisms and factors that control T cadherin expression. Therefore, to investigate regulation of T cadherin expression, we analysed 3.9 kb of the 5' flanking region of human T cadherin for promoter activity and identified potential transcription factor binding sites. Western blotting and a quantitative real time RT PCR assay developed for T cadherin showed that estradiol, progesterone, EGF, dexamethasone and factors in serum were involved in transcriptional and post transcriptional regulation of T cadherin in human osteosarcoma cells; the effects observed were opposite to those described for T cadberin's ligand, adiponectin. The data suggest that T cadherin is regulated in a complex manner indicative of a role in hormone and drug induced changes in bone morphology and pathology. (c) 2006 Elsevier B.V. All rights reserved.
C1 Med Lab Wellington, Wellington, New Zealand.
   Victoria Univ Wellington, Sch Biol Sci, Wellington, New Zealand.
   Univ Otago, Dept Physiol, Dunedin, New Zealand.
C3 Victoria University Wellington; University of Otago
RP Bromhead, C (通讯作者)，6th Floor CMC Bldg,89 Courtenay Pl, Wellington 6001, New Zealand.
EM cbromhead@medlabwellington.co.nz
RI Bromhead, Collette/AGL 1760 2022
CR ADACHI Y, 2005, VIRCHOWS ARCH, P1
   Angst BD, 2001, J CELL SCI, V114, P629
   CAVALLARO U, 2005, EXP CELL RES
   Chen JJG, 1998, ADV OCCUP ERGO SAF, V2, P633
   Crandall C, 2002, J WOMEN HEALTH GEN B, V11, P211, DOI 10.1089/152460902753668420
   Fallo F, 2004, EUR J ENDOCRINOL, V150, P339, DOI 10.1530/eje.0.1500339
   Feltus FA, 2003, ENDOCRINOLOGY, V144, P1847, DOI 10.1210/en.2000 201486
   Fredette BJ, 1996, DEVELOPMENT, V122, P3163
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Ibáñez L, 2004, J CLIN ENDOCR METAB, V89, P1592, DOI 10.1210/jc.2003 031281
   Jarrard DF, 1997, CLIN CANCER RES, V3, P2121
   Jones CD, 2003, AM J CLIN PATHOL, V120, P42, DOI 10.1309/60A9C8WGEGHRNXEE
   Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931
   Kuzmenko YS, 1998, BIOCHEM BIOPH RES CO, V246, P489, DOI 10.1006/bbrc.1998.8645
   Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014 5793(98)00977 6
   Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796 776
   Lenchik L, 2003, BONE, V33, P646, DOI 10.1016/S8756 3282(03)00237 0
   Niermann T, 2000, BIOCHEM BIOPH RES CO, V276, P1240, DOI 10.1006/bbrc.2000.3465
   Niermann T, 2003, BIOCHEM BIOPH RES CO, V300, P943, DOI 10.1016/S0006 291X(02)02970 4
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Pfaffl M.W., 2004, AZ Quant. PCR, V1, P89
   RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896 6273(91)90291 7
   RANSCHT B, 1991, DEVELOPMENT, V111, P15
   RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460 2075.1987.tb02697.x
   Rubina K, 2005, MOL CELL BIOCHEM, V273, P33, DOI 10.1007/s11010 005 0250 5
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Takeuchi T, 2000, HISTOPATHOLOGY, V37, P193, DOI 10.1046/j.1365 2559.2000.00985 5.x
   Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471 4159.2000.0741489.x
   Takeuchi T, 2001, HISTOL HISTOPATHOL, V16, P1287, DOI 10.14670/HH 16.1287
   Thway TM, 2002, BIOL REPROD, V67, P972, DOI 10.1095/biolreprod.101.001057
   Toyooka S, 2002, CANCER RES, V62, P3382
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451
   Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200
   Whyte DA, 1999, AM J PHYSIOL RENAL, V277, pF587, DOI 10.1152/ajprenal.1999.277.4.F587
   Zucchini C, 2004, BONE, V34, P672, DOI 10.1016/j.bone.2003.12.008
NR 37
TC 25
Z9 30
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 1119
J9 GENE
JI Gene
PD JUN 7
PY 2006
VL 374
BP 58
EP 67
DI 10.1016/j.gene.2006.01.013
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 053KN
UT WOS:000238304100007
PM 16516410
DA 2025 08 17
ER

PT J
AU Idaszek, J
   Kijenska Gawronska, E
   Lojkowski, M
   Swieszkowski, W
AF Idaszek, J.
   Kijenska Gawronska, Ewa
   Lojkowski, M.
   Swieszkowski, W.
TI How important are scaffolds and their surface properties in regenerative
   medicine
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Proceedings Paper
CT E MRS Fall Meeting / 12th International Symposium D on
   Electrochemical/Chemical Reactivity of New Materials (ECRNM)
CY SEP 15 18, 2015
CL Warsaw, POLAND
SP E MRS, PAS, Inst Phys Chem, Mazovia Ctr Surf Anal, PAS, Inst Phys Chem PAS, Phys Chem Mat Ctr, WUT, Fac Mat Sci & Engn, Univ Portsmouth, Sch Earth & Environm Sci, Fac Sci, COMEF, Int Soc Electrochemistry, Div 4, OCI, Vacuum Microengineering Inc, Patpool, European & Polish Patent & Trade Mark Attorneys, PRE VAC, Univ Warszawski, Wydzial Chemii
DE Scaffolds; Additive manufacturing; Electrospinning; Architecture;
   Surface properties; Tissue engineering
ID MESENCHYMAL PROGENITOR CELLS; MECHANICAL PROPERTIES; OSTEOBLAST
   RESPONSE; NANOFIBER MESHES; MOLECULAR WEIGHT; PLASMA TREATMENT; TISSUE;
   FABRICATION; ADHESION; POLYCAPROLACTONE
AB The ability of cells to sense various cues present within their natural habitat gives a tremendous opportunity to steer their fate in vitro within artificial matrices (scaffolds). However, the variety of signals and their chemical and physical origin makes engineering of the scaffolds quite challenging and requires careful design in order to obtained the desired outcome. Herein, we discuss the effect of architecture and surface of scaffolds fabricated by means of additive manufacturing and electrospinning on cell retention, spreading, proliferation and differentiation. Additionally, we present some of the reported surface and bulk modifications of the scaffolds, which positively affected cell performance. Finally, in the last part we discuss application of multicellular spheroids as a useful tool to study cell performance within three dimensional and porous structures. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Idaszek, J.; Kijenska Gawronska, Ewa; Lojkowski, M.; Swieszkowski, W.] Warsaw Univ Technol, Fac Mat Sci & Engn, 141 Woloska Str, PL 02507 Warsaw, Poland.
C3 Warsaw University of Technology
RP Swieszkowski, W (通讯作者)，Warsaw Univ Technol, Fac Mat Sci & Engn, 141 Woloska Str, PL 02507 Warsaw, Poland.
EM wojciech.swieszkowski@inmat.pw.edu.pl
RI ; Łojkowski, Maciej/N 6950 2019; Kijeńska Gawrońska, Ewa/R 4984 2019
OI Idaszek, Joanna/0000 0001 7106 0105; Kijenska Gawronska,
   Ewa/0000 0002 2614 2838; Swieszkowski, Wojciech/0000 0003 4216 9974
CR [Anonymous], BIOFABRICATION
   [Anonymous], J NANOMATER UNPUB
   [Anonymous], J BIOMED MAT RES A
   [Anonymous], J FIBER BIOENG INFOR
   [Anonymous], INT J POLYM MAT POLY
   [Anonymous], UNPUB
   Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013
   Aviss KJ, 2010, EUR CELLS MATER, V19, P193, DOI 10.22203/eCM.v019a19
   Bacakova L, 2011, BIOTECHNOL ADV, V29, P739, DOI 10.1016/j.biotechadv.2011.06.004
   Bartnikowski M, 2014, BIOTECHNOL BIOENG, V111, P1440, DOI 10.1002/bit.25200
   Bettahalli NMS, 2013, ACTA BIOMATER, V9, P6928, DOI 10.1016/j.actbio.2013.02.029
   Bruinink A, 2014, J BIOMED MATER RES A, V102, P275, DOI 10.1002/jbm.a.34691
   CEBE P, 1987, J APPL POLYM SCI, V33, P487, DOI 10.1002/app.1987.070330217
   Chang HI, 2011, REGENERATIVE MEDICINE AND TISSUE ENGINEERING   CELLS AND BIOMATERIALS, P569
   Chehroudi B, 1997, J BIOMED MATER RES, V34, P279
   Chia HN, 2015, J BIOL ENG, V9, DOI 10.1186/s13036 015 0001 4
   Chim H, 2006, INT J ORAL MAX SURG, V35, P928, DOI 10.1016/j.ijom.2006.03.024
   Choi JS, 2008, BIOMATERIALS, V29, P2899, DOI 10.1016/j.biomaterials.2008.03.031
   Chum ZZ, 2009, ACTA BIOMATER, V5, P3305, DOI 10.1016/j.actbio.2009.05.015
   Davis KA, 2011, BIOMATERIALS, V32, P2285, DOI 10.1016/j.biomaterials.2010.12.006
   Domingos M, 2013, ACTA BIOMATER, V9, P5997, DOI 10.1016/j.actbio.2012.12.031
   Endres M, 2003, TISSUE ENG, V9, P689, DOI 10.1089/107632703768247386
   Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006 3495(04)74140 5
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Hammer C.F., 1959, J. Appl. Polym. Sci, V1, P169, DOI DOI 10.1002/APP.1959.070010207
   He LM, 2010, ACTA BIOMATER, V6, P2960, DOI 10.1016/j.actbio.2010.02.039
   Hendrikson WJ, 2015, RSC ADV, V5, P54510, DOI 10.1039/c5ra08048g
   Hoque ME, 2009, TISSUE ENG PT A, V15, P3013, DOI [10.1089/ten.tea.2008.0355, 10.1089/ten.TEA.2008.0355]
   Hoque ME, 2005, J BIOMAT SCI POLYM E, V16, P1595, DOI 10.1163/156856205774576709
   Hutmacher DW, 2001, J BIOMED MATER RES, V55, P203, DOI 10.1002/1097 4636(200105)55:2<203::AID JBM1007>3.3.CO;2 Z
   Hutmacher DW, 2004, TRENDS BIOTECHNOL, V22, P354, DOI 10.1016/j.tibtech.2004.05.005
   Idaszek J, 2015, J BIOMED MATER RES A, V103, P2394, DOI 10.1002/jbm.a.35377
   Ito Y, 1999, BIOMATERIALS, V20, P2333, DOI 10.1016/S0142 9612(99)00162 3
   Jenkins MJ, 2006, POLYM ADVAN TECHNOL, V17, P474, DOI 10.1002/pat.733
   Kai D, 2011, J BIOMED MATER RES B, V98B, P379, DOI 10.1002/jbm.b.31862
   Kijenska Gawronska E, 2012, J BIOMED MATER RES B, V100B, P1093, DOI 10.1002/jbm.b.32676
   Kim JY, 2009, BIOFABRICATION, V1, DOI 10.1088/1758 5082/1/1/015002
   Kunzler TP, 2007, BIOMATERIALS, V28, P2175, DOI 10.1016/j.biomaterials.2007.01.019
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee JS, 2012, J BIOMED MATER RES A, V100A, P1846, DOI 10.1002/jbm.a.34149
   Liang D, 2007, ADV DRUG DELIVER REV, V59, P1392, DOI 10.1016/j.addr.2007.04.021
   Lim JY, 2005, BIOMACROMOLECULES, V6, P3319, DOI 10.1021/bm0503423
   Malda J, 2005, BIOMATERIALS, V26, P63, DOI 10.1016/j.biomaterials.2004.02.046
   Melchels FPW, 2012, PROG POLYM SCI, V37, P1079, DOI 10.1016/j.progpolymsci.2011.11.007
   Moczulska M, 2012, J BIOMED MATER RES A, V100A, P882, DOI 10.1002/jbm.a.34023
   Murugan R, 2007, TISSUE ENG, V13, P1845, DOI 10.1089/ten.2006.0078
   Ouyang HW, 2002, MAT SCI ENG C BIO S, V20, P63, DOI 10.1016/S0928 4931(02)00014 0
   Park H, 2007, MACROMOL RES, V15, P238, DOI 10.1007/BF03218782
   Prabhakaran MP, 2013, BIOTECHNOL BIOENG, V110, P2775, DOI 10.1002/bit.24937
   Rai B, 2010, BIOMATERIALS, V31, P7960, DOI 10.1016/j.biomaterials.2010.07.001
   Rath SN, 2008, VIRTUAL PHYS PROTOTY, V3, P209, DOI 10.1080/17452750802598117
   Safaeijavan R, 2014, IRAN J BASIC MED SCI, V17, P903
   Schantz JT, 2005, J MATER SCI MATER M, V16, P807, DOI 10.1007/s10856 005 3584 3
   Shim JH, 2013, TISSUE ENG PT A, V19, P317, DOI [10.1089/ten.TEA.2011.0730, 10.1089/ten.tea.2011.0730]
   Shim JH, 2012, J MATER SCI MATER M, V23, P2993, DOI 10.1007/s10856 012 4761 9
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   TAMADA Y, 1993, J COLLOID INTERF SCI, V155, P334, DOI 10.1006/jcis.1993.1044
   TAMADA Y, 1994, J BIOMED MATER RES, V28, P783, DOI 10.1002/jbm.820280705
   Viana T, 2013, PROCEDIA ENGINEER, V59, P255, DOI 10.1016/j.proeng.2013.05.119
   Washburn NR, 2004, BIOMATERIALS, V25, P1215, DOI 10.1016/j.biomaterials.2003.08.043
   Xu CY, 2004, BIOMATERIALS, V25, P877, DOI 10.1016/S0142 9612(03)00593 3
   Yan D, 2013, J BIOMED MATER RES A, V101, P963, DOI 10.1002/jbm.a.34398
   Yildirim ED, 2008, VIRTUAL PHYS PROTOTY, V3, P199, DOI 10.1080/17452750802547338
   Yilgor P, 2008, MACROMOL SYMP, V269, P92, DOI 10.1002/masy.200850911
   Zein I, 2002, BIOMATERIALS, V23, P1169, DOI 10.1016/S0142 9612(01)00232 0
   Zhang S, 2015, J BIOMATER APPL, V29, P1394, DOI 10.1177/0885328214568467
   Zhou YF, 2007, POLYM INT, V56, P333, DOI 10.1002/pi.2138
NR 67
TC 53
Z9 55
U1 0
U2 57
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169 4332
EI 1873 5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD DEC 1
PY 2016
VL 388
BP 762
EP 774
DI 10.1016/j.apsusc.2016.03.038
PN B
PG 13
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Chemistry; Materials Science; Physics
GA DX7ND
UT WOS:000384573600023
DA 2025 08 17
ER

PT J
AU Yoshikawa, N
   Tsuno, NH
   Okaji, Y
   Kawai, K
   Shuno, Y
   Nagawa, H
   Oshima, N
   Takahashi, K
AF Yoshikawa, Naoyuki
   Tsuno, Nelson H.
   Okaji, Yurai
   Kawai, Kazushige
   Shuno, Yasutaka
   Nagawa, Hirokazu
   Oshima, Noriko
   Takahashi, Koki
TI Isoprenoid geranylgeranylacetone inhibits human colon cancer cells
   through induction of apoptosis and cell cycle arrest
SO ANTI CANCER DRUGS
LA English
DT Article
DE apoptosis; cell cycle arrest; colon cancer; geranylgeranylacetone;
   isoprenoid; p21; p27; phosphorylated retinoblastoma protein
ID COA REDUCTASE INHIBITORS; ACTIVITY IN VIVO; MEVALONATE SYNTHESIS;
   OSTEOCLAST FORMATION; MEDIATED INHIBITION; POTENTIAL MEDIATOR; DEPENDENT
   KINASES; PLAUNOTOL; PROGRESSION; INVASION
AB Geranylgeranylacetone (GGA), an isoprenoid compound, is a widely used antiulcer drug developed in Japan. GGA is structurally similar to plaunotol and geranylgeraniol, another isoprenoid reported to exert strong anticancer effects. In an earlier study, GGA was shown to inhibit ovarian cancer invasion by attenuating not only Rho activation, but also Ras MAPK activation. In this study, we aimed to test whether GGA could have a therapeutic effect on colon cancer cells. As a result, we found that GGA induced a dose dependent decrease in the proliferative activity through induction of cell apoptosis and cell cycle arrest in the G(1) phase. The induction of apoptosis was mediated by the activation of both caspase 8 and caspase 9 pathways. The induction of G(1) arrest was mediated by the increase of p21 and p27, and also the decrease of phosphorylated retinoblastoma protein levels. This study showed the potential anticancer activity of GGA. As this drug is already available in Japan for clinical use as an antiulcer/antigastritis agent, clinical trials will be designed to confirm its potential usefulness for cancer patients. Anti Cancer Drugs 21:850 860 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Yoshikawa, Naoyuki; Tsuno, Nelson H.; Okaji, Yurai; Takahashi, Koki] Univ Tokyo, Dept Transfus Med, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Tsuno, Nelson H.; Kawai, Kazushige; Shuno, Yasutaka; Nagawa, Hirokazu] Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Okaji, Yurai] Univ Tokyo, Frontier Res Initiat, Inst Med Sci, Minato Ku, Tokyo 1138655, Japan.
   [Oshima, Noriko] Toho Univ, Fac Sci, Dept Biomol Sci, Div Mol Med, Chiba 2748510, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo; Toho
   University
RP Yoshikawa, N (通讯作者)，Univ Tokyo, Dept Transfus Med, Fac Med, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138655, Japan.
EM yoshikawan blo@h.u tokyo.ac.jp
RI Kawai, Kazushige/AAF 4334 2020
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Ministry of Health, Labor and Welfare of Japan
FX This study was supported partly by a Grant in Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan, and partly by a grant from the Ministry of Health,
   Labor and Welfare of Japan.
CR Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021 9150(97)00319 5
   Burke YD, 1997, LIPIDS, V32, P151, DOI 10.1007/s11745 997 0019 y
   Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347
   DIAZ JF, 1993, BIOCHEMISTRY US, V32, P2747, DOI 10.1021/bi00062a003
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092 8674(93)90500 P
   Elson CE, 1999, P SOC EXP BIOL MED, V221, P294, DOI 10.1046/j.1525 1373.1999.d01 87.x
   GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0
   HARPER JW, 1993, CELL, V75, P805
   Hashimoto K, 2005, CANCER AM CANCER SOC, V103, P1529, DOI 10.1002/cncr.20941
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V356, P72, DOI 10.1016/j.bbrc.2007.02.102
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199
   Hiruma Y, 2004, BIOCHEM BIOPH RES CO, V314, P24, DOI 10.1016/j.bbrc.2003.12.051
   Kanno Tomoko, 2002, Physiological Chemistry and Physics and Medical NMR, V34, P1
   Kawai K, 2005, ANTI CANCER DRUG, V16, P401, DOI 10.1097/00001813 200504000 00006
   KOHDA I, 1991, CHEM PHARM BULL, V39, P1828
   Kusama T, 2001, CANCER RES, V61, P4885
   Matsumoto Y, 1998, MICROBIOS, V96, P149
   Miquel K, 1996, BIOCHEM BIOPH RES CO, V225, P869, DOI 10.1006/bbrc.1996.1265
   Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701
   NAKAZAWA S, 1983, INT J CLIN PHARM TH, V21, P267
   NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063
   Ohizumi H, 1997, ANTICANCER RES, V17, P1051
   OHIZUMI H, 1995, J BIOCHEM TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695
   OKABE N, 1995, DIGEST DIS SCI, V40, P2321, DOI 10.1007/BF02063232
   Okada S, 1999, CELL STRUCT FUNCT, V24, P161, DOI 10.1247/csf.24.161
   Ooie T, 2001, CIRCULATION, V104, P1837, DOI 10.1161/hc3901.095771
   POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092 8674(94)90572 X
   Rokutan K, 2000, J GASTROENTEROL, V35, P673, DOI 10.1007/s005350070046
   Sawada K, 2002, CANCER RES, V62, P6015
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092 8674(94)90540 1
   Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001
   Takeda Y, 2001, JPN J CANCER RES, V92, P918, DOI 10.1111/j.1349 7006.2001.tb01181.x
   Tanaka M, 1996, EUR J CANCER, V32A, P226, DOI 10.1016/0959 8049(95)00500 5
   Tomozawa S, 1999, BRIT J CANCER, V81, P1274, DOI 10.1038/sj.bjc.6694262
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092 8674(94)90573 8
   USHIYAMA S, 1987, BIOCHEM PHARMACOL, V36, P369, DOI 10.1016/0006 2952(87)90296 6
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Wang XX, 2002, J BONE MINER RES, V17, P91, DOI 10.1359/jbmr.2002.17.1.91
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Yamada J, 2007, PLANTA MED, V73, P1068, DOI 10.1055/s 2007 981578
   Yasunari K, 2001, ARTERIOSCL THROM VAS, V21, P937, DOI 10.1161/01.ATV.21.6.937
   Yoshida M, 1998, J IMMUNOL, V161, P933
   Yoshikawa N, 2009, J SURG RES, V153, P246, DOI 10.1016/j.jss.2008.04.021
NR 46
TC 12
Z9 16
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0959 4973
J9 ANTI CANCER DRUG
JI Anti Cancer Drugs
PD OCT
PY 2010
VL 21
IS 9
BP 850
EP 860
DI 10.1097/CAD.0b013e32833e53cf
PG 11
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 647LY
UT WOS:000281621200007
PM 20724917
DA 2025 08 17
ER

PT J
AU Lascombes, P
   Mamie, C
AF Lascombes, P.
   Mamie, C.
TI Complex regional pain syndrome type I in children: What is new?
SO ORTHOPAEDICS & TRAUMATOLOGY SURGERY & RESEARCH
LA English
DT Article; Proceedings Paper
CT Congress of the French Society for Orthopedic Surgery and Traumatology
   (SofCOT)
CY NOV 08 11, 2016
CL Paris, FRANCE
SP French Soc Orthoped Surg & Traumatol
DE Complex regional pain syndrome type I; Paediatrics; Reflex sympathetic
   dystrophy syndrome; Allodynia
ID REFLEX SYMPATHETIC DYSTROPHY; MANAGEMENT; RECOVERY
AB Complex regional pain syndrome type I (CRPS I), although first described by the French surgeon Ambroise Pare as far back as the 16th century, nevertheless remains shrouded in mystery. The most common symptoms are pain in an entire hand or foot, allodynia, functional impairment induced by the pain, local oedema and skin color changes and transient sweating abnormalities. Most cases occur after a minor injury (i.e., a sprain or fracture), although there may be no identifiable triggering event, particularly in children. Primarily cold CRPS I is by far the most common variant in children. Development of the Budapest criteria has benefited the diagnosis. These criteria are clinical and no specific diagnostic investigation is available. In vitro and in vivo studies have established that several pathogenic mechanisms can be involved concomitantly. However, there is no satisfactory explanation to the full clinical spectrum. Blood tests and imaging studies are useful for ruling out other diagnoses then monitoring the course of the condition, which may involve the development of demineralisation or osteopenia. High resolution peripheral quantitative computed tomography may be helpful, as it provides quantitative assessments of the cortical and trabecular bone. CRPS I has several specific characteristics in children compared to adults and whether the condition is the same entity in these two age groups is a legitimate question. The optimal management involves an early diagnosis followed by a multidisciplinary management programme of functional rehabilitation therapy and cognitive behavioral therapy. Analgesics are useful only during the phase of acute pain and to facilitate physical therapy. Studies in adults showed that bisphosphonates were effective within the first 12 months after symptom onset and calcitonin in longer lasting cases. No high quality clinical research studies into the aetiopathogenesis and treatment of CRPS I in children and adolescents are available to date. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Lascombes, P.] Hop Univ Geneve, Div Orthopedie Pediat, Dept Enfant & Adolescent, Rue Willy Donze 6, CH 1211 Geneva, Switzerland.
   [Mamie, C.] Hop Univ Geneve, Unite Anesthesie Pediat, Dept Anesthesiol Pharmacol & Soins Intensifs, CH 1211 Geneva, Switzerland.
C3 University of Geneva; University of Geneva
RP Lascombes, P (通讯作者)，Hop Univ Geneve, Div Orthopedie Pediat, Dept Enfant & Adolescent, Rue Willy Donze 6, CH 1211 Geneva, Switzerland.
EM pierre.lascombes@hcuge.ch; chantal.mamie@hcuge.ch
CR Bayle Iniguez X, 2015, ORTHOP TRAUMATOL SUR, V101, P745, DOI 10.1016/j.otsr.2015.06.013
   Bowering KJ, 2013, J PAIN, V14, P3, DOI 10.1016/j.jpain.2012.09.007
   Ceroni D, 2013, J BONE JOINT SURG AM, V95A, P1037, DOI 10.2106/JBJS.L.00809
   Cossins L, 2013, EUR J PAIN, V17, P158, DOI 10.1002/j.1532 2149.2012.00217.x
   Dadure C, 2004, ANESTH ANALG, V98, P1653, DOI 10.1213/01.ANE.0000114084.01266.E5
   Goldschneider KR, 2012, PAIN RES MANAG, V17, P386, DOI 10.1155/2012/854159
   Harden RN, 2013, PAIN MED, V14, P180, DOI 10.1111/pme.12033
   Hechler T, 2010, EUR J PAIN, V14, P97, DOI 10.1016/j.ejpain.2009.03.002
   Hind Karen, 2014, J Med Case Rep, V8, P165, DOI 10.1186/1752 1947 8 165
   KOCH E, 1991, AM J ROENTGENOL, V156, P113, DOI 10.2214/ajr.156.1.1898542
   Lebel A, 2008, BRAIN, V131, P1854, DOI 10.1093/brain/awn123
   Lee BH, 2002, J PEDIATR US, V141, P135, DOI 10.1067/mpd.2002.124380
   Low AK, 2007, J PEDIATR ORTHOPED, V27, P567, DOI 10.1097/BPO.0b013e318070cc4d
   Maihöfner C, 2004, NEUROLOGY, V63, P693, DOI 10.1212/01.WNL.0000134661.46658.B0
   Murray CS, 2000, ARCH DIS CHILD, V82, P231, DOI 10.1136/adc.82.3.231
   Nishida Y, 2009, INTERNAL MED, V48, P209, DOI 10.2169/internalmedicine.48.1611
   Pachowicz M, 2014, NUCL MED REV, V17, P115, DOI 10.5603/NMR.2014.0029
   Sabsovich I, 2008, PAIN, V138, P47, DOI 10.1016/j.pain.2007.11.004
   SCHWEITZER ME, 1995, RADIOLOGY, V195, P211, DOI 10.1148/radiology.195.1.7892471
   SHERRY DD, 1988, PEDIATRICS, V81, P572
   Sherry DD, 1999, CLIN J PAIN, V15, P218, DOI 10.1097/00002508 199909000 00009
   Simm PJ, 2010, BONE, V46, P885, DOI 10.1016/j.bone.2009.11.034
   Varenna M, 2015, CLIN CASES MINER BON, V12, P27, DOI 10.11138/ccmbm/2015.12.1.027
   Varni JW, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477 7525 4 26
   Vieyra MA, 1991, J PAIN SYMPTOM MANAG, V6, P144
   Weber M, 2001, PAIN, V91, P251, DOI 10.1016/S0304 3959(00)00445 0
   Wertli MM, 2014, PAIN MED, V15, P1575, DOI 10.1111/pme.12466
   Wheeler DS, 2000, PEDIATR NEUROL, V22, P220, DOI 10.1016/S0887 8994(99)00139 3
   WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623 199274060 00013
   Zernikow B, 2012, SCHMERZ, V26, P389, DOI 10.1007/s00482 012 1164 2
NR 30
TC 15
Z9 18
U1 0
U2 2
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY LES MOULINEAUX, 92442 PARIS, FRANCE
SN 1877 0568
J9 ORTHOP TRAUMATOL SUR
JI Orthop. Traumatol. Surg. Res.
PD FEB
PY 2017
VL 103
IS 1
SU S
BP S135
EP S142
DI 10.1016/j.otsr.2016.04.017
PG 8
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Orthopedics; Surgery
GA FX5QU
UT WOS:000426135500016
PM 27979741
DA 2025 08 17
ER

PT J
AU Yi, HY
   Li, GP
   Long, YK
   Liang, WZ
   Cui, HN
   Zhang, B
   Tan, Y
   Li, YF
   Shen, LC
   Deng, DQ
   Tang, YS
   Mao, CY
   Tian, SY
   Cai, YT
   Zhu, QH
   Hu, YH
   Chen, W
   Fang, L
AF Yi, Hongyang
   Li, Guipeng
   Long, Yongkang
   Liang, Weizheng
   Cui, Huanhuan
   Zhang, Bin
   Tan, Ying
   Li, Yunfei
   Shen, Luochen
   Deng, Daqi
   Tang, Yisen
   Mao, Chenyu
   Tian, Shuye
   Cai, Yunting
   Zhu, Qionghua
   Hu, Yuhui
   Chen, Wei
   Fang, Liang
TI Integrative multi omics analysis of a colon cancer cell line with
   heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of
   EMT
SO ONCOGENE
LA English
DT Article
ID EPITHELIAL MESENCHYMAL TRANSITION; CONSENSUS MOLECULAR SUBTYPES;
   TRANSCRIPTION FACTOR RUNX2; STEM CELLS; TGF BETA; OSTEOBLAST
   DIFFERENTIATION; INTRATUMOR HETEROGENEITY; EXPRESSION; GENERATION;
   PLASTICITY
AB Epithelial mesenchymal transition (EMT) program, which facilitates tumor metastasis, stemness and therapy resistance, is a reversible biological process that is largely orchestrated at the epigenetic level under the regulation of different cell signaling pathways. EMT state is often heterogeneous within individual tumors, though the epigenetic drivers underlying such heterogeneity remain elusive. In colon cancer, hyperactivation of the Wnt/beta catenin signaling not only drives tumor initiation, but also promotes metastasis in late stage by promoting EMT program. However, it is unknown whether the intratumorally heterogeneous Wnt activity could directly drive EMT heterogeneity, and, if so, what are the underlying epigenetic driver(s). Here, by analyzing a phenotypically and molecularly heterogeneous colon cancer cell line using single cell RNA sequencing, we identified two distinct cell populations with positively correlated Wnt activity and EMT state. Integrative multi omics analysis of these two cell populations revealed RUNX2 as a critical transcription factor epigenetically driving the EMT heterogeneity. Both in vitro and in vivo genetic perturbation assays validated the EMT enhancing effect of RUNX2, which remodeled chromatin landscape and activated a panel of EMT associated genes through binding to their promoters and/or potential enhancers. Finally, by exploring the clinical data, we showed that RUNX2 expression is positively correlated with metastasis development and poor survival of colon cancer patients, as well as patients afflicted with other types of cancer. Taken together, our work revealed RUNX2 as a new EMT promoting epigenetic regulator in colon cancer, which may potentially serve as a prognostic marker for tumor metastasis.
C1 [Yi, Hongyang; Liang, Weizheng] Harbin Inst Technol, Harbin, Peoples R China.
   [Yi, Hongyang; Li, Guipeng; Long, Yongkang; Liang, Weizheng; Cui, Huanhuan; Tan, Ying; Li, Yunfei; Shen, Luochen; Deng, Daqi; Tang, Yisen; Mao, Chenyu; Tian, Shuye; Cai, Yunting; Zhu, Qionghua; Hu, Yuhui; Chen, Wei; Fang, Liang] Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China.
   [Li, Guipeng; Cui, Huanhuan; Hu, Yuhui; Chen, Wei; Fang, Liang] Southern Univ Sci & Technol, Acad Adv Interdisciplinary Studies, Shenzhen, Peoples R China.
   [Zhang, Bin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.
C3 Harbin Institute of Technology; Southern University of Science &
   Technology; Southern University of Science & Technology; National
   University of Singapore
RP Hu, YH; Chen, W; Fang, L (通讯作者)，Southern Univ Sci & Technol, Dept Biol, Shenzhen, Peoples R China.; Hu, YH; Chen, W; Fang, L (通讯作者)，Southern Univ Sci & Technol, Acad Adv Interdisciplinary Studies, Shenzhen, Peoples R China.
EM huyh@sustech.edu.cn; chenw@sustech.edu.cn; fangl@sustech.edu.cn
RI Yi, Hongyang/ISS 1654 2023; TAN, YING/AAT 4671 2020; Fang,
   Liang/V 5019 2018; Chen, Yuwei/AAW 7005 2021; chen, wei/AFV 4999 2022;
   Cui, Huanhuan/R 1836 2018
OI Fang, Liang/0000 0003 4502 1756; Long, Yongkang/0000 0003 0953 7325; Li,
   Guipeng/0000 0002 3244 5499; Cui, Huanhuan/0000 0002 6190 6135; 
FU National Natural Science Foundation of China [31701237]; Shenzhen
   Science and Technology Program [JCYJ20170817110925887,
   KQTD20180411143432337, GJHZ20170310161947503]; Center for Computational
   Science and Engineering of Southern University of Science and
   Technology; Laboratory Animal Center of Southern University of Science
   and Technology
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 31701237) and the Shenzhen Science and Technology
   Program (Grant No. JCYJ20170817110925887, KQTD20180411143432337, and
   GJHZ20170310161947503). Bioinformatic analysis was supported by the
   Center for Computational Science and Engineering of Southern University
   of Science and Technology. Animal experiments were supported by the
   Laboratory Animal Center of Southern University of Science and
   Technology.
CR Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl 2015 310912
   Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 258
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Barnes GL, 2003, CANCER RES, V63, P2631
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627
   Bian SH, 2018, SCIENCE, V362, P1060, DOI 10.1126/science.aao3791
   Blois SM, 2014, MUCOSAL IMMUNOL, V7, P348, DOI 10.1038/mi.2013.53
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580 018 0080 4
   Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344
   Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008 5472.CAN 15 1519
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586 019 1186 3
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hinohara K, 2018, CANCER CELL, V34, P939, DOI 10.1016/j.ccell.2018.10.014
   Hu Y, 2018, GENE CHROMOSOME CANC, V57, P140, DOI 10.1002/gcc.22512
   Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200
   Jagan I, 2013, ONCOGENE, V32, P1305, DOI 10.1038/onc.2012.140
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513
   Lee JG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10579 1
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818
   Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012
   Lin CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13867
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Niu DF, 2012, LAB INVEST, V92, P1181, DOI 10.1038/labinvest.2012.84
   Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586 018 0040 3
   Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Sánchez Tilló E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108
   Sanchez Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677
   Stark AL, 2010, AM J HUM GENET, V87, P829, DOI 10.1016/j.ajhg.2010.10.018
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078 0432.CCR 17 1234
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   van Staalduinen J, 2018, ONCOGENE, V37, P6195, DOI 10.1038/s41388 018 0378 x
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yang J, 2001, CANCER RES, V61, P5652
   Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897
   Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
NR 66
TC 33
Z9 38
U1 4
U2 26
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD JUL 9
PY 2020
VL 39
IS 28
BP 5152
EP 5164
DI 10.1038/s41388 020 1351 z
EA JUN 2020
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA MH4RK
UT WOS:000539953300003
PM 32535615
OA Bronze
DA 2025 08 17
ER

PT J
AU Bedouet, L
   Pascale, F
   Bonneau, M
   Laurent, A
AF Bedouet, Laurent
   Pascale, Florentina
   Bonneau, Michel
   Laurent, Alexandre
TI In vitro evaluation of S (+) ibuprofen as drug candidate for
   intra articular drug delivery system
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Cartilage; co culture; drug delivery systems; osteoarthritis;
   S (+) ibuprofen
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NITRIC OXIDE; ARTICULAR CARTILAGE;
   PROSTAGLANDIN E 2; EQUINE CHONDROCYTES; S ENANTIOMERS; TNF ALPHA;
   IBUPROFEN; OSTEOARTHRITIS; DEGRADATION
AB Intra articular drug delivery systems (DDSs) are envisaged as interesting alternative to locally release non steroidal anti inflammatory drugs (NSAIDs) such as ibuprofen to reduce pain in patients with osteoarthritis. The present study examines the efficacy of S (+) ibuprofen on cartilage degradation as drug candidate for DDS loading. Humeral cartilage and joint capsule explants were collected from healthy sheep shoulder joints and they were cultured in mono or in co culture for 13 days with LPS in combination with S (+) ibuprofen at 50 mu M and 1 mM. S (+) ibuprofen ( 50 mu M) blocked prostaglandins production in LPS activated explants but did not reduce cartilage degradation. By contrast, 1mM S (+) ibuprofen treatment of cartilage explants reduced nitric oxide synthesis by 51% (p = 0.0072), proteoglycans degradation by 35% (p = 0.0114) and expression of serum amyloid protein  the main protein induced upon LPS challenge   by 44% (p<0.0001). On contrary, in presence of synovial membrane, the protective effects of S (+) ibuprofen on cartilage damages were significantly diminished. At 1mM, S (+) ibuprofen reduced the cell lysis during culture of cartilage and joint capsule either in mono or in co culture. This study performed on sheep explants shows that 1mM S (+) ibuprofen inhibited cartilage degradation via a mechanism independent of cyclooxygenase inhibition. Reduction of prostaglandins synthesis at 50 mu M in all treatment groups and reduction of cartilage degradation observed at 1mM suggest that S (+) ibuprofen could be considered as a promising drug candidate for the loading of intra articular DDS.
C1 [Bedouet, Laurent; Laurent, Alexandre] Occlugel SAS, F 78350 Jouy En Josas, France.
   [Pascale, Florentina; Bonneau, Michel; Laurent, Alexandre] AP HP, INRA, Ctr Res Intervent Imaging CR2i, Jouy En Josas, France.
   [Laurent, Alexandre] Lariboisiere Hosp, AP HP, Dept Intervent Neuroradiol, Paris, France.
C3 INRAE; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Lariboisiere Fernand Widal   APHP
RP Bedouet, L (通讯作者)，Occlugel SAS, 12 Rue Charles Gaulle, F 78350 Jouy En Josas, France.
EM l.bedouet@hotmail.fr
CR Abramson SB, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2463
   ADAMS SS, 1976, J PHARM PHARMACOL, V28, P256, DOI 10.1111/j.2042 7158.1976.tb04144.x
   Adatia A, 2012, J PHARM PHARMACOL, V64, P626, DOI 10.1111/j.2042 7158.2012.01456.x
   Alvarez Soria MA, 2006, ANN RHEUM DIS, V65, P998, DOI 10.1136/ard.2005.046920
   Armstrong S, 2002, J VET PHARMACOL THER, V25, P145, DOI 10.1046/j.1365 2885.2002.00397.x
   Armstrong S, 1999, AM J VET RES, V60, P98
   ARSENIS C, 1989, AGENTS ACTIONS, V27, P261, DOI 10.1007/BF01972791
   Bédouet L, 2011, TOXICOL IN VITRO, V25, P1944, DOI 10.1016/j.tiv.2011.06.018
   Boureau F, 2004, ANN RHEUM DIS, V63, P1028, DOI 10.1136/ard.2003.011403
   Bozdag S, 2001, J MICROENCAPSUL, V18, P443, DOI 10.1080/02652040010018641
   Caviglioli G, 2002, J PHARMACEUT BIOMED, V30, P499, DOI 10.1016/S0731 7085(02)00400 4
   Driban JB, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/691412
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304 4165(86)90306 5
   FELL HB, 1977, ARTHRITIS RHEUM US, V20, P1359, DOI 10.1002/art.1780200710
   Fenton JI, 2000, OSTEOARTHR CARTILAGE, V8, P258, DOI 10.1053/joca.1999.0299
   Fernández Carballido A, 2004, INT J PHARMACEUT, V279, P33, DOI 10.1016/j.ijpharm.2004.04.003
   Fung HB, 1999, CLIN THER, V21, P1131, DOI 10.1016/S0149 2918(00)80018 1
   Gineyts E, 2004, ANN RHEUM DIS, V63, P857, DOI 10.1136/ard.2003.007302
   Greenberg DD, 2006, OSTEOARTHR CARTILAGE, V14, P814, DOI 10.1016/j.joca.2006.02.006
   Haglund L, 2008, MATRIX BIOL, V27, P107, DOI 10.1016/j.matbio.2007.09.009
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   Hawel R, 2003, INT J CLIN PHARM TH, V41, P153
   Ibold Y, 2007, J BIOMOL SCREEN, V12, P956, DOI 10.1177/1087057107307147
   Jacobsen S, 2006, VET IMMUNOL IMMUNOP, V110, P325, DOI 10.1016/j.vetimm.2005.10.012
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Larsen C, 2008, J PHARM SCI US, V97, P4622, DOI 10.1002/jps.21346
   Lee JH, 2009, ARCH BIOCHEM BIOPHYS, V489, P118, DOI 10.1016/j.abb.2009.07.006
   Levis KA, 2003, INT J PHARM, V253, P49, DOI 10.1016/S0378 5173(02)00645 2
   Lu Y, 2007, J MICROENCAPSUL, V24, P515, DOI 10.1080/02652040701433479
   Manicourt Daniel Henri, 2005, Drugs R D, V6, P261, DOI 10.2165/00126839 200506050 00002
   Martel Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049 0172(03)00134 3
   Migita K, 2009, RHEUMATOLOGY, V48, P741, DOI 10.1093/rheumatology/kep089
   MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693
   Moore N, 2007, J ROY SOC MED, V100, P2
   Mukherjee P, 2001, CLIN EXP RHEUMATOL, V19, pS7
   NETTER P, 1989, CLIN PHARMACOKINET, V17, P145, DOI 10.2165/00003088 198917030 00002
   Notoya K, 2000, J IMMUNOL, V165, P3402, DOI 10.4049/jimmunol.165.6.3402
   Oliveira RB, 2012, DRUG DEV IND PHARM, V38, P1, DOI 10.3109/03639045.2011.587433
   Panico AM, 2005, INFLAMMATION, V29, P119, DOI 10.1007/s10753 006 9003 1
   Patwari P, 2009, SCAND J MED SCI SPOR, V19, P528, DOI 10.1111/j.1600 0838.2009.00911.x
   Reijman M, 2005, ARTHRITIS RHEUM US, V52, P3137, DOI 10.1002/art.21357
   Sanchez C, 2002, J RHEUMATOL, V29, P772
   Shin BK, 2012, DRUG DEV IND PHARM, DOI [10.3109/036399045.2012.665925., DOI 10.3109/036399045.2012.665925]
   Stevens AL, 2008, OSTEOARTHR CARTILAGE, V16, P489, DOI 10.1016/j.joca.2007.07.015
   STOCK KP, 1991, RHEUMATOL INT, V11, P199, DOI 10.1007/BF00332562
   Stratman NC, 1997, MOL BRAIN RES, V50, P107, DOI 10.1016/S0169 328X(97)00168 X
   Stuhlmeier KM, 1999, BIOCHEM PHARMACOL, V57, P313, DOI 10.1016/S0006 2952(98)00301 3
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01 0390rev
   Thakkar H, 2005, AAPS PHARMSCITECH, V6
   Thompson CJ, 2008, DRUG DEV IND PHARM, V34, P877, DOI [10.1080/03639040801929075, 10.1080/03639040801929075 ]
   Tunçay M, 2000, INT J PHARM, V195, P179, DOI 10.1016/S0378 5173(99)00394 4
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200
NR 53
TC 4
Z9 4
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363 9045
EI 1520 5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD JAN
PY 2015
VL 41
IS 1
BP 85
EP 94
DI 10.3109/03639045.2013.850704
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CA5BQ
UT WOS:000348922800011
PM 24168233
DA 2025 08 17
ER

PT J
AU Enomoto, H
   Fujikoshi, S
   Tsuji, T
   Sasaki, N
   Tokuoka, H
   Uchio, Y
AF Enomoto, Hiroyuki
   Fujikoshi, Shinji
   Tsuji, Toshinaga
   Sasaki, Nao
   Tokuoka, Hirofumi
   Uchio, Yuji
TI Efficacy of duloxetine by prior NSAID use in the treatment of chronic
   osteoarthritis knee pain: A post hoc subgroup analysis of a randomized,
   placebo controlled, phase 3 study in Japan
SO JOURNAL OF ORTHOPAEDIC SCIENCE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LIFE SETTING TRIALS; DOUBLE BLIND;
   PHYSICAL ACTIVITY; CLINICAL TRIALS; III TRIAL; MANAGEMENT; SAFETY;
   MECHANISMS; RECOMMENDATIONS
AB Background: A previously conducted placebo controlled, randomized, phase 3 study of 353 Japanese patients with knee osteoarthritis (OA) showed significant improvements for duloxetine vs placebo in pain and health related quality of life (HRQoL) (ClinicalTrials.gov Identifier: NCT02248480). Reported here are post hoc subgroup analyses evaluating the efficacy of duloxetine according to the pattern of prior nonsteroidal anti inflammatory drug (NSAID) use.
   Methods: Patients with knee OA pain received once daily duloxetine or placebo for 14 weeks. Pain was evaluated using the Brief Pain Inventory (BPI) and HRQoL was evaluated using the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC). Patients were divided into four subgroups based on their prior NSAID use: (i) no prior NSAID use; (ii) low frequency NSAID use (<14 days/month); (iii) high frequency transdermal NSAID use (transdermal NSAIDs only; >= 14 days/month for the 3 months before study entry); and (iv) high frequency other NSAID use (eg, oral NSAIDs only, both oral and transdermal NSAIDs; >= 14 days/month for the 3 months before study entry).
   Results: In each of the four prior NSAID use subgroups, there were greater reductions in BPI average pain severity score for duloxetine vs placebo at all timepoints during the 14 week treatment period; the treatment*prior NSAID use interaction was not statistically significant. In each subgroup, the proportion of patients achieving a >= 50% reduction in BPI average pain severity score was higher for duloxetine vs placebo. In each subgroup, there were greater reductions in WOMAC total score for duloxetine vs placebo at all timepoints; the treatment*prior NSAID use interaction was not statistically significant. In each subgroup, there were greater reductions at Week 14 in WOMAC pain, stiffness, physical function, and total scores for duloxetine vs placebo.
   Conclusions: Duloxetine was consistently effective with respect to pain relief and HRQoL in Japanese patients with knee OA pain, regardless of the pattern of prior NSAID use. (C) 2018 The Authors. Published by Elsevier B.V. on behalf of The Japanese Orthopaedic Association.
C1 [Enomoto, Hiroyuki; Tokuoka, Hirofumi] Eli Lilly Japan KK, Med Dev Unit Japan, Minato Ku, 4 15 1 13F Akasaka, Tokyo 1070052, Japan.
   [Fujikoshi, Shinji; Sasaki, Nao] Eli Lilly Japan KK, Med Dev Unit Japan, Chuo Ku, 7 1 5 Isogamidori, Kobe, Hyogo 6510086, Japan.
   [Tsuji, Toshinaga] Shionogi & Co Ltd, Med Affairs Dept, Kita Ku, 12F Hankyu Terminal Bldg,1 4 Shibata,1 Chome, Osaka 5300012, Japan.
   [Uchio, Yuji] Shimane Univ, Sch Med, Dept Orthopaed Surg, 89 1 Enya Cho, Izumo, Shimane 6938501, Japan.
C3 Eli Lilly; Eli Lilly; Shionogi & Company Limited; Shimane University
RP Enomoto, H (通讯作者)，Eli Lilly Japan KK, Med Dev Unit Japan, Minato Ku, 4 15 1 13F Akasaka, Tokyo 1070052, Japan.
EM enomoto_hiroyuki@lilly.com
OI Tsuji, Toshinaga/0000 0003 3685 0763
FU Shionogi Co., Ltd.; Eli Lilly Japan K.K.; Eli Lilly and Company
FX This study was sponsored by Shionogi & Co., Ltd., Eli Lilly Japan K.K.,
   and Eli Lilly and Company. Medical writing assistance was provided by
   Justine Southby, PhD, CMPP, and Tania Dickson, PhD, CMPP, of ProScribe  
   Envision Pharma Group, and was funded by Eli Lilly Japan K.K.
   ProScribe's services complied with international guidelines for Good
   Publication Practice (GPP3).
CR American College of Rheumatology, W ONT MCMAST U OST I
   Arendt Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003
   Axford J, 2008, J PSYCHOSOM RES, V64, P461, DOI 10.1016/j.jpsychores.2007.11.009
   Bally M, 2017, BMJ BRIT MED J, V357, DOI 10.1136/bmj.j1909
   Bondeson J, 2010, ARTHRITIS RHEUM US, V62, P647, DOI 10.1002/art.27290
   Brummett CM, 2016, PAIN, V157, P1205, DOI 10.1097/j.pain.0000000000000506
   Büchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042
   Chappell AS, 2011, PAIN PRACT, V11, P33, DOI 10.1111/j.1533 2500.2010.00401.x
   Chappell AS, 2009, PAIN, V146, P253, DOI 10.1016/j.pain.2009.06.024
   Chou R, 2011, AHRQ PUBLICATION, V11
   Fanelli A, 2017, THER ADV DRUG SAF, V8, P173, DOI 10.1177/2042098617690485
   Fingleton C, 2015, OSTEOARTHR CARTILAGE, V23, P1043, DOI 10.1016/j.joca.2015.02.163
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140 6736(09)61706 2
   Finniss DG, 2005, PAIN, V114, P3, DOI 10.1016/j.pain.2004.12.012
   Frakes EP, 2011, CURR MED RES OPIN, V27, P2361, DOI 10.1185/03007995.2011.633502
   Fukutani N, 2016, CLIN RHEUMATOL, V35, P2307, DOI 10.1007/s10067 016 3251 8
   Häuser W, 2011, PAIN, V152, P1709, DOI 10.1016/j.pain.2011.01.050
   Hashimoto Hideki, 2003, J Orthop Sci, V8, P288, DOI 10.1007/s10776 002 0629 0
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Konno S, 2016, SPINE, V41, P1709, DOI 10.1097/BRS.0000000000001707
   Lo GH, 2015, ARTHRITIS RHEUMATOL, V67, P2897, DOI 10.1002/art.39271
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003
   Mease PJ, 2011, J RHEUMATOL, V38, P1546, DOI 10.3899/jrheum.100759
   Mendoza T, 2006, EUR J PAIN, V10, P353, DOI 10.1016/j.ejpain.2005.06.002
   Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI 10.1056/NEJMoa1611593
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Perrot S, 2015, BEST PRACT RES CL RH, V29, P90, DOI 10.1016/j.berh.2015.04.017
   Phillips K, 2011, BEST PRACT RES CL RH, V25, P141, DOI 10.1016/j.berh.2011.02.005
   Rannou F, 2016, SEMIN ARTHRITIS RHEU, V45, pS18, DOI 10.1016/j.semarthrit.2015.11.007
   Sheehan D V., 2003, Mini International Neuropsychiatric Interview English Version 5.0.0
   Smith HS, 2012, THER CLIN RISK MANAG, V8, P267, DOI 10.2147/TCRM.S17428
   Tétreault P, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002570
   Tuttle AH, 2015, PAIN, V156, P2616, DOI 10.1097/j.pain.0000000000000333
   Uchio Y, 2018, J PAIN RES, V11, P809, DOI 10.2147/JPR.S164128
   Uki J, 1998, J PAIN SYMPTOM MANAG, V16, P364, DOI 10.1016/S0885 3924(98)00098 0
NR 37
TC 8
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0949 2658
EI 1436 2023
J9 J ORTHOP SCI
JI J. Orthop. Sci.
PD NOV
PY 2018
VL 23
IS 6
BP 1019
EP 1026
DI 10.1016/j.jos.2018.07.008
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA GZ8CF
UT WOS:000449713300028
PM 30126675
OA hybrid
DA 2025 08 17
ER

PT J
AU Zakaria, N
   Yusoff, NM
   Zakaria, Z
   Lim, MN
   Baharuddin, PJN
   Fakiruddin, KS
   Yahaya, B
AF Zakaria, Norashikin
   Yusoff, Narazah Mohd
   Zakaria, Zubaidah
   Lim, Moon Nian
   Baharuddin, Puteri J. Noor
   Fakiruddin, Kamal Shaik
   Yahaya, Badrul
TI Human non small cell lung cancer expresses putative cancer stem cell
   markers and exhibits the transcriptomic profile of multipotent cells
SO BMC CANCER
LA English
DT Article
DE Cancer stem cells; Non small cell lung cancer; Cell surface marker;
   Transcriptome
ID TUMOR INITIATING CELLS; STROMAL FIBROBLASTS; CD133 EXPRESSION;
   IDENTIFICATION; GROWTH; RISE; POPULATIONS; STATISTICS; FEATURES; DISPLAY
AB Background: Despite significant advances in staging and therapies, lung cancer remains a major cause of cancer related lethality due to its high incidence and recurrence. Clearly, a novel approach is required to develop new therapies to treat this devastating disease. Recent evidence indicates that tumours contain a small population of cells known as cancer stem cells (CSCs) that are responsible for tumour maintenance, spreading and resistant to chemotherapy. The genetic composition of CSCs so far is not fully understood, but manipulation of the specific genes that maintain their integrity would be beneficial for developing strategies to combat cancer. Therefore, the goal of this study isto identify the transcriptomic composition and biological functions of CSCs from non small cell lung cancer (NSCLC).
   Methods: We isolated putative lung CSCs from lung adenocarcinoma cells (A549 and H2170) and normal stem cells from normal bronchial epithelial cells (PHBEC) on the basis of positive expression of stem cell surface markers (CD166, CD44, and EpCAM) using fluorescence activated cell sorting. The isolated cells were then characterised for their self renewal characteristics, differentiation capabilities, expression of stem cell transcription factor and in vivo tumouregenicity. The transcriptomic profiles of putative lung CSCs then were obtained using microarray analysis. Significantly regulated genes (p < 0.05, fold change (FC) > 2.0) in putative CSCs were identified and further analysed for their biological functions using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).
   Results: The putative lung CSCs phenotypes of CD166(+)/CD44(+) and CD166(+)/EpCAM(+) showed multipotent characteristics of stem cells, including the ability to differentiate into adipogenic and osteogenic cells, self renewal, and expression of stem cell transcription factors such as Sox2 and Oct3/4. Moreover, the cells also shows the in vivo tumouregenicity characteristic when transplanted into nude mice. Microarray and bioinformatics data analyses revealed that the putative lung CSCs have molecular signatures of both normal and cancer stem cells and that the most prominent biological functions are associated with angiogenesis, migration, pro apoptosis and anti apoptosis, osteoblast differentiation, mesenchymal cell differentiation, and mesenchyme development. Additionally, self renewal pathways such as the Wnt and hedgehog signalling pathways, cancer pathways, and extracellular matrix (ECM) receptor interaction pathways are significantly associated with the putative lung CSCs.
   Conclusion: This study revealed that isolated lung CSCs exhibit the characteristics of multipotent stem cells and that their genetic composition might be valuable for future gene and stem cells therapy for lung cancer.
C1 [Zakaria, Norashikin; Yusoff, Narazah Mohd; Yahaya, Badrul] Univ Sains Malaysia, AMDI, Regenerat Med Cluster, Kepala Batas 13200, Pulau Pinang, Malaysia.
   [Zakaria, Zubaidah; Lim, Moon Nian; Baharuddin, Puteri J. Noor] IMR, Canc Res Ctr, Stem Cell Lab, Haematol Unit, Kuala Lumpur, Malaysia.
C3 Universiti Sains Malaysia; Kementerian Kesihatan Malaysia
RP Yahaya, B (通讯作者)，Univ Sains Malaysia, AMDI, Regenerat Med Cluster, Kepala Batas 13200, Pulau Pinang, Malaysia.
EM badrul@amdi.usm.edu.my
RI Fakiruddin, Kamal/V 1915 2019; Yahaya, Badrul/I 2983 2012; Mohd Yusoff,
   Narazah/I 3203 2017; Yahaya, Badrul/AAG 6801 2021; Yusoff,
   Narazah/I 3203 2017; Zakaria, Norashikin/AAV 7490 2020
OI Shaik Mohd Fakiruddin, Shaik Ahmad Kamal/0000 0003 3646 3317; Yahaya,
   Badrul/0000 0002 3295 9676; Mohd Yusoff, Narazah/0000 0001 6801 2508;
   Zakaria, Norashikin/0000 0003 2589 1543; 
FU Research University Grant scheme of Universiti Sains Malaysia [1001/
   CIPPT/811204]
FX This study was supported by grants from the Research University Grant
   scheme (1001/ CIPPT/811204) of Universiti Sains Malaysia.
CR Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alexander CM, 2009, CELL STEM CELL, V5, P579, DOI 10.1016/j.stem.2009.11.008
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Howard BM, 2008, NEUROSURGERY, V62, pN8, DOI 10.1227/01.neu.0000333287.44491.dd
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 9 r183
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Leung ELH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014062
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008 5472.CAN 06 2030
   Malanchi Ilaria, 2013, Bonekey Rep, V2, P371, DOI 10.1038/bonekey.2013.105
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mathers C, 2008, GLOBAL BURDEN OF DISEASE: 2004 UPDATE, P1
   Meng XJ, 2009, CANCER SCI, V100, P1040, DOI 10.1111/j.1349 7006.2009.01144.x
   Muraro MG, 2012, STEM CELL TRANSL MED, V1, P592, DOI 10.5966/sctm.2012 0003
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Özbek S, 2010, MOL BIOL CELL, V21, P4300, DOI 10.1091/mbc.E10 03 0251
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020
   Raymond K, 2009, CURR OPIN CELL BIOL, V21, P623, DOI 10.1016/j.ceb.2009.05.004
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Ricci Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Salnikov AV, 2010, INT J CANCER, V126, P950, DOI 10.1002/ijc.24822
   Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324
   Teng Y, 2010, BIOCHEM BIOPH RES CO, V392, P373, DOI 10.1016/j.bbrc.2010.01.028
   Tirino V, 2009, EUR J CARDIO THORAC, V36, P446, DOI 10.1016/j.ejcts.2009.03.063
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Wang PH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052088, 10.1371/journal.pone.0057020]
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Whittaker CA, 2006, DEV BIOL, V300, P252, DOI 10.1016/j.ydbio.2006.07.044
   Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012
   Zhang H. Z., 2010, CELL MOL BIOL, V56
   Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
NR 45
TC 108
Z9 114
U1 0
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 25
PY 2015
VL 15
AR 84
DI 10.1186/s12885 015 1086 3
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CC4MJ
UT WOS:000350327200003
PM 25881239
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Titushkin, I
   Cho, M
AF Titushkin, Igor
   Cho, Michael
TI Regulation of Cell Cytoskeleton and Membrane Mechanics by Electric
   Field: Role of Linker Proteins
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID MESENCHYMAL STEM CELLS; VASCULAR ENDOTHELIAL CELLS; ATOMIC FORCE
   MICROSCOPE; ERM PROTEINS; OSTEOGENIC DIFFERENTIATION;
   CLINICAL APPLICATIONS; CALCIUM OSCILLATIONS; NERVE REGENERATION; BINDING
   PROTEINS; LIVING CELLS
AB Cellular mechanics is known to play an important role in the cell homeostasis including proliferation, motility, and differentiation. Significant variation in the mechanical properties between different cell types suggests that control of the cell metabolism is feasible through manipulation of the cell mechanical parameters using external physical stimuli. We investigated the electrocoupling mechanisms of cellular biomechanics modulation by an electrical stimulation in two mechanically distinct cell types human mesenchymal stem cells and osteoblasts. Application of a 2 V/cm direct current electric field resulted in approximately a twofold decrease in the cell elasticity and depleted intracellular ATP. Reduction in the ATP level led to inhibition of the linker proteins that are known to physically couple the cell membrane and cytoskeleton. The membrane separation from the cytoskeleton was confirmed by up to a twofold increase in the membrane tether length that was extracted from the cell membrane after an electrical stimulation. In comparison to human mesenchymal stem cells, the membrane cytoskeleton attachment in osteoblasts was much stronger but, in response to the same electrical stimulation, the membrane detachment from the cytoskeleton was found to be more pronounced. The observed effects mediated by an electric field are cell type  and serum dependent and can potentially be used for electrically assisted cell manipulation. An in depth understanding and control of the mechanisms to regulate cell mechanics by external physical stimulus (e.g., electric field) may have great implications for stem cell based tissue engineering and regenerative medicine.
C1 [Titushkin, Igor; Cho, Michael] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Cho, M (通讯作者)，Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
EM mcho@uic.edu
OI Cho, Myoung Rae/0000 0002 8191 8045
FU National Institutes of Health [EB006067]; Office of Navy Research
   [N00014 06 1 0100]; Defense University Research Instrument Program
   [N00014 04 1 0805]
FX This work was supported, in pan, by National Institutes of Health grant
   EB006067 and by a grant from the Office of Navy Research
   (N00014 06 1 0100). The AFM used to measure the cellular mechanical
   properties was purchased with Defense University Research Instrument
   Program grant N00014 04 1 0805.
CR Bai H, 2004, ARTERIOSCL THROM VAS, V24, P1234, DOI 10.1161/01.ATV.0000131265.76828.8a
   Boscolo P, 2007, Int J Immunopathol Pharmacol, V20, P59
   Chen HF, 2007, BIOPHYS J, V92, P1399, DOI 10.1529/biophysj.106.094896
   Chen J, 2001, AM J PHYSIOL RENAL, V280, pF619, DOI 10.1152/ajprenal.2001.280.4.F619
   Cho MR, 2002, IEEE T PLASMA SCI, V30, P1504, DOI 10.1109/TPS.2002.804200
   Cho MR, 1999, FASEB J, V13, P677, DOI 10.1096/fasebj.13.6.677
   CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677
   Cho MR, 1996, FASEB J, V10, P1552, DOI 10.1096/fasebj.10.13.8940302
   Ciombor Deborah McK, 2005, Foot Ankle Clin, V10, P579, DOI 10.1016/j.fcl.2005.06.006
   COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765
   Dai JW, 1998, J NEUROSCI, V18, P6681
   Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002
   Fiévet B, 2007, BBA MOL CELL RES, V1773, P653, DOI 10.1016/j.bbamcr.2006.06.013
   Gordon GA, 2007, J CELL PHYSIOL, V212, P579, DOI 10.1002/jcp.21025
   HOTARY KB, 1994, DEV BIOL, V166, P789, DOI 10.1006/dbio.1994.1357
   Huang Jing, 2004, Human Genomics, V1, P287
   HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970
   Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05 5424rev
   Janigro D, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 72
   Janmey PA, 2007, ANNU REV BIOMED ENG, V9, P1, DOI 10.1146/annurev.bioeng.9.060906.151927
   Jena BP, 2007, CURR OPIN STRUC BIOL, V17, P437, DOI 10.1016/j.sbi.2007.07.002
   KATSURAGI T, 1993, LIFE SCI, V53, P961, DOI 10.1016/0024 3205(93)90449 D
   Kawano S, 2006, CELL CALCIUM, V39, P313, DOI 10.1016/j.ceca.2005.11.008
   Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04 1814fje
   Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P319, DOI 10.1097/00004630 199305000 00003
   Li XF, 2002, J VASC RES, V39, P391, DOI 10.1159/000064517
   Lim CT, 2006, J BIOMECH, V39, P195, DOI 10.1016/j.jbiomech.2004.12.008
   Louvet Vallée S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248 4900(00)01078 9
   Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962 8924(99)01544 5
   Markov MS, 2007, ELECTROMAGN BIOL MED, V26, P257, DOI 10.1080/15368370701580806
   McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004
   McCaig CD, 2000, DEV DYNAM, V217, P299, DOI 10.1002/(SICI)1097 0177(200003)217:3<299::AID DVDY8>3.0.CO;2 G
   Morris CE, 2001, J MEMBRANE BIOL, V179, P79, DOI 10.1007/s002320010040
   Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125
   Neuman KC, 2004, REV SCI INSTRUM, V75, P2787, DOI 10.1063/1.1785844
   Nuccitelli R, 2003, CURR TOP DEV BIOL, V58, P1, DOI 10.1016/S0070 2153(03)58001 2
   Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006
   Paavilainen VO, 2004, TRENDS CELL BIOL, V14, P386, DOI 10.1016/j.tcb.2004.05.002
   POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333
   Radmacher M, 2002, METHOD CELL BIOL, V68, P67
   Raucher D, 1999, BIOPHYS J, V77, P1992, DOI 10.1016/S0006 3495(99)77040 2
   REVEST PA, 1994, BRAIN RES, V652, P76, DOI 10.1016/0006 8993(94)90319 0
   Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097 4644(19991215)75:4<710::AID JCB16>3.0.CO;2 Z
   Sauer H, 2002, J CELL SCI, V115, P3265
   Seegers JC, 2002, MED HYPOTHESES, V58, P171, DOI 10.1054/mehy.2001.1506
   Sheetz MP, 2006, ANNU REV BIOPH BIOM, V35, P417, DOI 10.1146/annurev.biophys.35.040405.102017
   Shieh AC, 2003, ANN BIOMED ENG, V31, P1, DOI 10.1114/1.1535415
   SISKEN BF, 1993, J CELL BIOCHEM, V51, P404, DOI 10.1002/jcb.2400510404
   Song B, 2004, J CELL SCI, V117, P4681, DOI 10.1242/jcs.01341
   Sun M, 2007, J CELL SCI, V120, P2223, DOI 10.1242/jcs.001370
   Sun S, 2007, FASEB J, V21, P1472, DOI 10.1096/fj.06 7153com
   Sun S, 2006, BIOELECTROCHEMISTRY, V69, P133, DOI 10.1016/j.bioelechem.2005.11.007
   Titushkin I, 2006, BIOPHYS J, V90, P2582, DOI 10.1529/biophysj.105.073775
   Titushkin IA, 2004, IEEE T PLASMA SCI, V32, P1614, DOI 10.1109/TPS.2004.832625
   Titushkin I, 2007, BIOPHYS J, V93, P3693, DOI 10.1529/biophysj.107.107797
   Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736 0266(03)00150 5
   Wang ET, 2003, EXP EYE RES, V76, P29, DOI 10.1016/S0014 4835(02)00257 9
   Wang JHC, 2007, GENE, V391, P1, DOI 10.1016/j.gene.2007.01.014
   Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020
   Wojtczak L, 1996, ACTA BIOCHIM POL, V43, P361
   Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259
   Zhao M, 2004, J CELL SCI, V117, P397, DOI 10.1242/jcs.00868
NR 62
TC 141
Z9 173
U1 1
U2 60
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0006 3495
EI 1542 0086
J9 BIOPHYS J
JI Biophys. J.
PD JAN 21
PY 2009
VL 96
IS 2
BP 717
EP 728
DI 10.1016/j.bpj.2008.09.035
PG 12
WC Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics
GA 450BY
UT WOS:000266377200038
PM 19167316
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kawabata, A
   Kawao, N
   Hironaka, Y
   Ishiki, T
   Matsunami, M
   Sekiguchi, F
AF Kawabata, Atsufumi
   Kawao, Naoyuki
   Hironaka, Yoshimi
   Ishiki, Tsuyoshi
   Matsunami, Maho
   Sekiguchi, Fumiko
TI Antiallodynic effect of etidronate, a bisphosphonate, in rats with
   adjuvant induced arthritis:: Involvement of ATP sensitive K<SUP>+</SUP>
   channels
SO NEUROPHARMACOLOGY
LA English
DT Article
DE etidronate; bisphosphonate; allodynia; pain; analgesia; adjuvant
ID REFLEX SYMPATHETIC DYSTROPHY; PERIPHERAL ANTINOCICEPTION; ACTIVATION;
   BONE; CLODRONATE; THERAPY; JOINT; SULFONYLUREA; ALENDRONATE; NEURONS
AB Bisphosphonates, pyrophosphate analogues, known as inhibitors of bone resorption, appear to cause analgesia in certain clinical painful situations. To detect clinically relevant analgesic property of etidronate, a non aminobisphosphonate, we examined and characterized its antiallodynic effect in the rat with adjuvant induced arthritis, in comparison with alendronate, an aminobisphosphonate, as determined by the von Frey test. Repeated systemic administration of etidronate at 10 40 mg/kg/day suppressed the adjuvant induced mechanical allodynia in rat hindpaw, an effect reaching a plateau in approximately 10 days. Systemic or intraplantar (i.pl.) administration of ATP sensitive K+ (K ATP(+)) channel inhibitors, glibenclamide and/or tolbutamide, completely reversed the antiallodynic effect of etidronate within 1 h in the arthritic rats, without affecting the nociceptive scores in naive or arthritic animals that had not received etidronate. Alendronate, administered repeatedly, also revealed similar glibenclamide reversible antiallodynic effect. In contrast, the antiallodynic effect of repeated systemic indomethacin was resistant to i.pl. glibenclamide in the arthritic rats. Repeated administration of etidronate or alendronate only slightly attenuated the adjuvant evoked hindpaw edema. Among K ATP(+) channel subunits, mRNAs for Kir6.1, SUR1, SUR2A and SUR2B were abundant in rat dorsal root ganglia, while Kir6.2 mRNA was poor. Our data demonstrate that repeated etidronate as well as alendronate exhibits antiallodynic activity in arthritic rats, which might be clinically relevant, and suggest involvement of K ATP(+) channels in the underlying mechanisms. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Kinki Univ, Sch Pharmaceut Sci, Div Physiol & Pathophysiol, Higashiosaka, Osaka 5778502, Japan.
C3 Kindai University (Kinki University)
RP Kawabata, A (通讯作者)，Kinki Univ, Sch Pharmaceut Sci, Div Physiol & Pathophysiol, 3 4 1 Kowakae, Higashiosaka, Osaka 5778502, Japan.
EM kawabata@phar.kindai.ac.jp
RI Kawabata, Atsufumi/AAI 1887 2021
OI Kawao, Naoyuki/0000 0002 4148 5476; Kawabata,
   Atsufumi/0000 0002 3163 807X
CR Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201
   Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   Barrera P, 2000, ARTHRITIS RHEUM US, V43, P1951, DOI 10.1002/1529 0131(200009)43:9<1951::AID ANR5>3.0.CO;2 K
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bonabello A, 2003, BONE, V33, P567, DOI 10.1016/S8756 3282(03)00229 1
   Bonabello A, 2001, PAIN, V91, P269, DOI 10.1016/S0304 3959(00)00447 4
   Cao K, 2002, BIOCHEM BIOPH RES CO, V296, P463, DOI 10.1016/S0006 291X(02)00892 6
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   FORYS VA, 1991, JAMA J AM MED ASSOC, V265, P2807, DOI 10.1001/jama.1991.03460210053013
   Goicoechea C, 1999, JPN J PHARMACOL, V79, P433, DOI 10.1254/jjp.79.433
   Goldring SR, 2004, ARTHRITIS RHEUM US, V50, P2044, DOI 10.1002/art.20383
   Harada H, 2004, INFLAMM RES, V53, P45, DOI 10.1007/s00011 003 1214 4
   Kato S, 2002, J PHARMACOL EXP THER, V303, P503, DOI 10.1124/jpet.102.040659
   Kawabata A, 2001, NEUROREPORT, V12, P715, DOI 10.1097/00001756 200103260 00020
   Kubalek I, 2001, RHEUMATOLOGY, V40, P1394, DOI 10.1093/rheumatology/40.12.1394
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lohmann AB, 1999, EUR J PHARMACOL, V385, P119, DOI 10.1016/S0014 2999(99)00618 4
   Oelzner P, 2000, INFLAMM RES, V49, P424, DOI 10.1007/s000110050611
   Pacheco DF, 2005, EUR J PHARMACOL, V512, P23, DOI 10.1016/j.ejphar.2005.02.018
   Picolo G, 2003, EUR J PHARMACOL, V469, P57, DOI 10.1016/S0014 2999(03)01676 5
   Proks P, 2002, DIABETES, V51, pS368, DOI 10.2337/diabetes.51.2007.S368
   Ristoiu V, 2002, J CELL MOL MED, V6, P271, DOI 10.1111/j.1582 4934.2002.tb00194.x
   Sachs D, 2004, P NATL ACAD SCI USA, V101, P3680, DOI 10.1073/pnas.0308382101
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Saito J, 2003, MOL BRAIN RES, V113, P124, DOI 10.1016/S0169 328X(03)00129 3
   Sarantopoulos C, 2003, NEUROSCI LETT, V343, P185, DOI 10.1016/S0304 3940(03)00383 5
   Soares AC, 2001, BRIT J PHARMACOL, V134, P127, DOI 10.1038/sj.bjp.0704224
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   Takasaki K, 2004, J PHARMACOL SCI, V95, P291, DOI 10.1254/jphs.SC0040043
   Varenna M, 2000, J RHEUMATOL, V27, P1477
   Yokoshiki H, 1998, AM J PHYSIOL CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25
NR 31
TC 17
Z9 17
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028 3908
EI 1873 7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD AUG
PY 2006
VL 51
IS 2
BP 182
EP 190
DI 10.1016/j.neuropharm.2006.03.015
PG 9
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 079GI
UT WOS:000240163400002
PM 16678221
DA 2025 08 17
ER

PT J
AU Shoji, T
   Nakasa, T
   Yoshizuka, M
   Yamasaki, T
   Yasunaga, Y
   Adachi, N
   Ochi, M
AF Shoji, Takeshi
   Nakasa, Tomoyuki
   Yoshizuka, Masaaki
   Yamasaki, Takuma
   Yasunaga, Yuji
   Adachi, Nobuo
   Ochi, Mitsuo
TI Comparison of fibrin clots derived from peripheral blood and bone marrow
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Bone marrow; fibrin clot; fibroblast proliferation; growth factor;
   osteogenic differentiation
ID MESENCHYMAL STEM CELLS; STROMAL CELLS; IN VITRO; DIFFERENTIATION;
   REPAIR; TENDON; ANGIOGENESIS; OSTEOGENESIS; MECHANISMS; CULTURE
AB Background: Autologous fibrin clots derived from peripheral blood (pb fibrin clot) and bone marrow (bm fibrin clot) are thought to be effective for tissue regeneration. However, there is no report detailing the amount of growth factors in pb /bm fibrin clot. In this study we evaluated the amount of growth factors in human pb /bm fibrin clot, and prove the validity of fibrin clot for clinical use. Methods: Human pb /bm fibrin clots were obtained during surgery. In the first experiment, enzyme linked immunosorbent assay (ELISA) was performed for detecting the amount of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin like growth factor 1 (IGF 1), fibroblast growth factor basic (bFGF), hepatocyte growth factor (HGF), transforming growth factor beta (TGF ), platelet derived growth factors AB (PDGF AB), and stromal cell derived factor 1 (SDF 1). In the second experiment, the efficacy of fibrin clot on the osteogenic differentiation and fibroblast proliferation was evaluated. Pb /bm fibrin clots were incubated in human osteoblast derived from mesenchymal stromal cells (MSCs) or human skin fibroblast. Alizarin red staining and real time PCR (COL1A1, RUNX2) were performed for the detection of osteogenic potential. Cell growth assay (WST 8) and real time PCR (COL1A1) were also performed for the detection of the potential of fibroblast proliferation. Results: ELISA analysis revealed that the amount of VEGF, HGF, bFGF, IGF 1, and SDF 1 of bm fibrin clot group is higher than that of pb fibrin clot group with statistical differences. Besides, we confirmed that bm fibrin clot has much potential for the osteogenic differentiation and fibroblast proliferation. Conclusion: The positive outcomes confirm the efficacy of pb /bm fibrin clot, and bm fibrin clot was proved to have much potential for tissue regeneration compared with pb fibrin clot. The current study showed the potential of a strategy for regenerative medicine using bm fibrin clot.
C1 [Shoji, Takeshi; Nakasa, Tomoyuki; Yoshizuka, Masaaki; Yamasaki, Takuma; Adachi, Nobuo; Ochi, Mitsuo] Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthopaed Surg, Hiroshima, Japan.
   [Yasunaga, Yuji] Hiroshima Prefectural Rehabil Ctr, Dept Orthopaed Surg, Hiroshima, Japan.
C3 Hiroshima University
RP Shoji, T (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthopaed Surg, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348551, Japan.
EM readymade_jpn@yahoo.co.jp
CR ARNOCZKY SP, 1988, J BONE JOINT SURG AM, V70A, P1209, DOI 10.2106/00004623 198870080 00012
   Awad HA, 1999, TISSUE ENG, V5, P267, DOI 10.1089/ten.1999.5.267
   Awad HA, 2000, J BIOMED MATER RES, V51, P233, DOI 10.1002/(SICI)1097 4636(200008)51:2<233::AID JBM12>3.0.CO;2 B
   Bernardo ME, 2007, CONNECT TISSUE RES, V48, P132, DOI 10.1080/03008200701228464
   Carter AM, 2007, ARTERIOSCL THROM VAS, V27, P2783, DOI 10.1161/ATVBAHA.107.153221
   Catelas I, 2008, TISSUE ENG PART C ME, V14, P119, DOI 10.1089/ten.tec.2007.0262
   Cetrulo CL Jr, 2005, PLAST RECONSTR SURG, V116, P1053, DOI 10.1097/01.prs.0000178403.79051.70
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Chen Ying Chieh, 2007, J Chin Med Assoc, V70, P222
   Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Giannotti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073893
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Jäger M, 2011, J ORTHOP RES, V29, P173, DOI 10.1002/jor.21230
   Kim HJ, 2007, CONNECT TISSUE RES, V48, P309, DOI 10.1080/03008200701692610
   Kim MD, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.49
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   KNIGHTON DR, 1982, ANN SURG, V196, P379, DOI 10.1097/00000658 198210000 00001
   Li Y, 2006, CIRCULATION, V114, P84
   Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538 7836.2005.01365.x
   Murphy JM, 2003, ARTHRITIS RHEUM US, V48, P3464, DOI 10.1002/art.11365
   Olinescu RM, 2001, J NUTR BIOCHEM, V12, P162, DOI 10.1016/S0955 2863(00)00147 9
   Proctor CS, 2012, ARTHROSC TEC, V1, pE79, DOI 10.1016/j.eats.2012.03.002
   Schildhauer TA, 2007, MATERIALWISS WERKST, V38, P1012, DOI 10.1002/mawe.200700239
   Seybold D, 2010, LANGENBECK ARCH SURG, V395, P719, DOI 10.1007/s00423 009 0588 3
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Trombi L, 2008, J ORTHOP RES, V26, P176, DOI 10.1002/jor.20490
   Undas A, 2011, ARTERIOSCL THROM VAS, V31, pE88, DOI 10.1161/ATVBAHA.111.230631
   Wakitani S, 2002, MICROSC RES TECHNIQ, V58, P14, DOI 10.1002/jemt.10111
   Whatley JS, 2000, ARTHROSCOPY, V16, P127, DOI 10.1016/S0749 8063(00)90025 2
   Wolberg AS, 2003, BLOOD, V101, P3008, DOI 10.1182/blood 2002 08 2527
   Zhang LC, 2014, J MATER SCI MATER M, V25, P1165, DOI 10.1007/s10856 013 5138 4
NR 32
TC 18
Z9 18
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD APR
PY 2017
VL 58
IS 2
BP 208
EP 214
DI 10.1080/03008207.2016.1215443
PG 7
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA EN1CV
UT WOS:000395749000007
PM 27462987
DA 2025 08 17
ER

PT J
AU Fiorentini, C
   Bodei, S
   Bedussi, F
   Fragni, M
   Bonini, SA
   Simeone, C
   Zani, D
   Berruti, A
   Missale, C
   Memo, M
   Spano, P
   Sigala, S
AF Fiorentini, Chiara
   Bodei, Serena
   Bedussi, Francesca
   Fragni, Martina
   Bonini, Sara Anna
   Simeone, Claudio
   Zani, Danilo
   Berruti, Alfredo
   Missale, Cristina
   Memo, Maurizio
   Spano, PierFranco
   Sigala, Sandra
TI GPNMB/OA protein increases the invasiveness of human metastatic prostate
   cancer cell lines DU145 and PC3 through MMP 2 and MMP 9 activity
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE GPNMB/osteoactivin; Prostate cancer; Invasivity; Apoptosis;
   Metalloproteinases
ID NERVE GROWTH FACTOR; NF KAPPA B; MATRIX METALLOPROTEINASE ACTIVITY;
   UROKINASE PLASMINOGEN ACTIVATOR; ANTIBODY DRUG CONJUGATE; TISSUE
   INHIBITORS; OSTEOBLAST DIFFERENTIATION; GLEMBATUMUMAB VEDOTIN;
   THERAPEUTIC TARGET; FACTOR RECEPTOR
AB Non metastatic glycoprotein melanoma protein B (GPNMB), also known as osteoactivin (OA) is expressed in a wide array of tumors and represents an emerging target for drug development.
   In this study, we investigated the role of GPNMB/OA in the progression of human metastatic DU145 and PC3 prostate cancer cells.
   GPNMB/OA contribution in PCa malignant phenotype has been analyzed by small interfering RNA induced GPNMB/OA silencing. We found that following GPNMB/OA silencing the migration capability of both DU145 and PC3 cells, evaluated by using in vitro invasivity assay, as well as the metalloproteinases MMP 2 and MMP 9 activity were equally strongly inhibited. By contrast knocking down GPNMB/OA weakly attenuated cell proliferation rate of DU145, an effect that paralleled with an increase number of apoptotic cells. However, PC3 cell growth seems to be not affected by GPNMB/OA. Together, these data reveal that GPNMB/OA acts as a critical molecular mediator promoting the acquisition of the more aggressive, pro metastatic phenotype distinctive of human DU145 and PC3 cell lines. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Fiorentini, Chiara; Bodei, Serena; Bedussi, Francesca; Fragni, Martina; Bonini, Sara Anna; Missale, Cristina; Memo, Maurizio; Spano, PierFranco; Sigala, Sandra] Univ Brescia, Pharmacol Sect, Dept Mol & Translat Med, I 25124 Brescia, Italy.
   [Simeone, Claudio; Zani, Danilo] Univ Brescia, Dept Surg Radiol & Publ Hlth, Div Urol, I 25124 Brescia, Italy.
   [Berruti, Alfredo] Univ Brescia, Dept Surg Radiol & Publ Hlth, I 25124 Brescia, Italy.
C3 University of Brescia; University of Brescia; University of Brescia
RP Sigala, S (通讯作者)，Univ Brescia, Pharmacol Sect, Dept Mol & Translat Med, Vle Europa 11, I 25124 Brescia, Italy.
EM sigala@med.unibs.it
RI ; Bonini, Sara/K 7688 2016; sigala, sandra/X 3786 2018; Memo,
   Maurizio/AAK 7197 2020; Spano, Pier/E 7621 2010; Berruti,
   Alfredo/AAC 2069 2019; SPANO, PIERFRANCO/J 9944 2016; Simeone,
   Claudio/R 7485 2019
OI MEMO, Maurizio/0000 0002 7543 0289; Bonini, Sara/0000 0001 6571 5910;
   FIORENTINI, Chiara/0000 0003 0676 9833; SPANO,
   PIERFRANCO/0000 0002 9906 0964; 
FU Fondazione Guido Berlucchi per la Ricerca sul cancro onlus (Borgonato,
   Bs, Italy)
FX This project was supported by the Fondazione Guido Berlucchi per la
   Ricerca sul cancro onlus (Borgonato, Bs, Italy).
CR Aalinkeel R, 2011, IMMUNOL INVEST, V40, P447, DOI 10.3109/08820139.2011.557795
   Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Allen J, 2005, EXP CELL RES, V304, P69, DOI 10.1016/j.yexcr.2004.10.020
   Allen J, 2004, ANTICANCER RES, V24, P2997
   Arrighi N, 2010, GROWTH FACTORS, V28, P191, DOI 10.3109/08977190903578678
   Babykutty S, 2012, MOL CARCINOGEN, V51, P475, DOI 10.1002/mc.20812
   Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002 9440(10)63553 5
   Brehmer B, 2003, PROSTATE CANCER P D, V6, P217, DOI 10.1038/sj.pcan.4500657
   Brew K, 2010, BBA MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307
   Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542
   Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097 0045(20000201)42:2<150::AID PROS10>3.0.CO;2 H
   Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365 2249.2004.02342.x
   Escaff S, 2010, BRIT J CANCER, V102, P922, DOI 10.1038/sj.bjc.6605569
   Farré D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Fiorentini C, 2002, EUR J ENDOCRINOL, V147, P371, DOI 10.1530/eje.0.1470371
   Fiorentini C, 2002, MOL ENDOCRINOL, V16, P353, DOI 10.1210/me.16.2.353
   Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036
   Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   GRAHAM CW, 1992, J UROLOGY, V147, P1444, DOI 10.1016/S0022 5347(17)37590 0
   Guan HC, 2005, J BIOL CHEM, V280, P9957, DOI 10.1074/jbc.M412180200
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones JL, 1997, J PATHOL, V183, P377, DOI 10.1002/(SICI)1096 9896(199712)183:4<377::AID PATH951>3.0.CO;2 R
   Keir CH, 2012, EXPERT OPIN BIOL TH, V12, P259, DOI 10.1517/14712598.2012.642357
   Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078 0432.CCR 05 2797
   Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749 6632.1999.tb07690.x
   London CA, 2003, CANCER GENE THER, V10, P823, DOI 10.1038/sj.cgt.7700642
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Mironova EV, 2007, J NEUROSCI METH, V163, P1, DOI 10.1016/j.jneumeth.2007.02.010
   MISSALE C, 1993, P NATL ACAD SCI USA, V90, P7961, DOI 10.1073/pnas.90.17.7961
   Missale C, 1998, P NATL ACAD SCI USA, V95, P5366, DOI 10.1073/pnas.95.9.5366
   Missale C, 1996, MOL ENDOCRINOL, V10, P272, DOI 10.1210/me.10.3.272
   Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088
   Morgia G, 2005, UROL RES, V33, P44, DOI 10.1007/s00240 004 0440 8
   Moses MA, 1998, CANCER RES, V58, P1395
   Mouraviev V, 2009, NAT REV UROL, V6, P205, DOI 10.1038/nrurol.2009.29
   Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb 2011 12 11 233
   Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961
   Nalbandian A, 2005, DIFFERENTIATION, V73, P385, DOI 10.1111/j.1432 0436.2005.00040.x
   Nalbandian A, 2006, CLIN EXP METASTAS, V23, P107, DOI 10.1007/s10585 006 9009 y
   Nalla AK, 2010, CANCER GENE THER, V17, P599, DOI 10.1038/cgt.2010.16
   Naumovski L, 2010, CURR OPIN MOL THER, V12, P248
   Nelson PS, 2012, J CLIN ONCOL, V30, P644, DOI 10.1200/JCO.2011.39.1300
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140 6736(02)08270 3
   Nonsrijun N, 2013, ASIAN PAC J CANCER P, V14, P3331, DOI 10.7314/APJCP.2013.14.5.3331
   Onaga M, 2003, J HEPATOL, V39, P779, DOI 10.1016/S0168 8278(03)00361 1
   Pereda MP, 2000, MOL CELL ENDOCRINOL, V167, P99, DOI 10.1016/S0303 7207(00)00286 0
   Perez M, 1997, PROSTATE, V30, P274, DOI 10.1002/(SICI)1097 0045(19970301)30:4<274::AID PROS8>3.0.CO;2 L
   Pflug B, 1998, MOL CARCINOGEN, V23, P106, DOI 10.1002/(SICI)1098 2744(199810)23:2<106::AID MC7>3.0.CO;2 W
   Pollack VA, 2007, CANCER CHEMOTH PHARM, V60, P423, DOI 10.1007/s00280 007 0490 z
   Qian XZ, 2008, MOL ONCOL, V2, P81, DOI 10.1016/j.molonc.2008.02.002
   Reis ST, 2011, INT J BIOL MARKER, V26, P255, DOI 10.5301/JBM.2011.8831
   Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200
   Roomi MW, 2011, ONCOL REP, V26, P1407, DOI 10.3892/or.2011.1434
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093
   Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078 0432.CCR 09 1611
   Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259
   Sanchez Sweatman Otto H., 1998, Invasion and Metastasis, V18, P297, DOI 10.1159/000024522
   Selim AA, 2003, CRIT REV EUKAR GENE, V13, P265, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
   Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030
   Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200
   Sigala S, 2008, MOL CELL ENDOCRINOL, V284, P11, DOI 10.1016/j.mce.2007.12.015
   Sigala S, 1999, CLIN CANCER RES, V5, P1211
   Sigala S, 2002, EUR J ENDOCRINOL, V147, P407, DOI 10.1530/eje.0.1470407
   Singh M, 2010, CRIT REV EUKAR GENE, V20, P341, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.50
   Tan CT, 2008, CARCINOGENESIS, V29, P1519, DOI 10.1093/carcin/bgn108
   Tomihari M, 2010, CANCER RES, V70, P5778, DOI 10.1158/0008 5472.CAN 09 2538
   Trudel D, 2003, CANCER RES, V63, P8511
   Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078 0432.CCR 05 2018
   Tsui KH, 2012, PROSTATE, V72, P1431, DOI 10.1002/pros.22494
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
   Williams MD, 2010, MELANOMA RES, V20, P184, DOI 10.1097/CMR.0b013e3283364a08
   Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388
   Xiao Yun bei, 2011, Beijing Da Xue Xue Bao Yi Xue Ban, V43, P496
   Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097 2765(02)00477 X
   Zhong WD, 2008, ONCOLOGY BASEL, V75, P230, DOI 10.1159/000163852
   Zhou LT, 2012, NEOPLASMA, V59, P1, DOI 10.4149/neo_2012_001
   Zivi A, 2010, CLIN GENITOURIN CANC, V8, P17, DOI 10.3816/CGC.2010.n.003
NR 81
TC 67
Z9 82
U1 0
U2 15
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD APR 15
PY 2014
VL 323
IS 1
BP 100
EP 111
DI 10.1016/j.yexcr.2014.02.025
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA AE3GS
UT WOS:000333865600009
PM 24589892
OA Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Zlei, M
   Egert, S
   Wider, D
   Ihorst, G
   Wäsch, R
   Engelhardt, M
AF Zlei, Mihaela
   Egert, Sabine
   Wider, Dagmar
   Ihorst, Gabriele
   Waesch, Ralph
   Engelhardt, Monika
TI Characterization of in vitro growth of multiple myeloma cells
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID BONE MARROW; PLASMA CELLS; B CELLS; MODEL; MICROENVIRONMENT;
   DIFFERENTIATION; PROLIFERATION; APOPTOSIS; LEUKEMIA; RECEPTOR
AB Objective. To develop an in vitro culture system for rapid assessment of multiple myeloma (MM) cell growth.
   Methods. MM cells lines (MMCLs) L363, U266, and RPMI 8226, and bone marrow (BM)derived plasma cells (PCs) from MM patients were evaluated for their in vitro growth using various stroma (BMSC, M210 114, and osteoclasts [OCs]) and cytokine support combinations (combination A: interleukin [IL] 6, vascular endothelial growth factor, insulin like growth factor 1 vs combination B: A plus hepatocyte growth factor, IL 13 vs combination C: IL 6, insulin like growth factor  1, stromal derived growth factor 1, Galectin 1, IL 1 alpha).
   Results. We found a significant effect of stroma, notably affecting growth of L363 cells. Cytokine combination A had the highest growth impact, whereas B and C were of lesser benefit. The contribution of combined cytokines and stroma for MMCL growth was moderate and the viability of MMCLs was best preserved with OCs. One of the most commonly used PC marker CD138, expressed on all MMCLs on day 0, showed a gradual downmodulation upon all culture conditions, possibly induced as a stroma triggered phenotypic change, and leading to the ability of MM cells to dedifferentiate into immature, resilient phenotypes. PC enriched BM samples from 7 of 10 MM patients could be maintained in culture, again profiting from stroma more than cytokines alone.
   Conclusions. Our data demonstrate a consistent growth advantage provided by BMSCs on MMCLs and primary MM cells, preserved viability with OCs, and phenotypic and morphologic heterogeneity of primary MM cells during culture. Further identification of key components involved in MM cell growth, coupled with our understanding of drug sensitivity offers the potential to better define the disease pathogenesis and to identify novel therapeutic targets. (c) 2007 ISEH Society for Hematology and Stem Cells. Published by Elsevier Inc.
C1 Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D 79106 Freiburg, Germany.
   Clin Hosp St Spiridon Hosp, Lab Immunol & Genet, Iasi, Romania.
   Univ Freiburg, Ctr Med, Ctr Clin Trials, D 79106 Freiburg, Germany.
C3 University of Freiburg; Grigore T Popa University of Medicine &
   Pharmacy; University of Freiburg
RP Engelhardt, M (通讯作者)，Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter Str 55, D 79106 Freiburg, Germany.
EM monika.engelhardt@uniklinik freiburg.de
RI Ihorst, Gabriele/AAA 7445 2021; Waesch, Ralph/F 6282 2019
CR Abroun S, 2006, BLOOD, V108, p343B, DOI 10.1182/blood.V108.11.5020.5020
   Asosingh K, 2003, BLOOD, V101, P3136, DOI 10.1182/blood 2002 10 3000
   Barker J, 2000, LEUKEMIA, V14, P1614, DOI 10.1038/sj.leu.2401869
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756
   Bruno B, 2005, LEUKEMIA, V19, P1729, DOI 10.1038/sj.leu.2403905
   Burger JA, 2000, BLOOD, V96, P2655
   Chilosi M, 1999, MODERN PATHOL, V12, P1101
   Denz U, 2006, EUR J CANCER, V42, P1591, DOI 10.1016/j.ejca.2005.11.040
   Engelhardt M, 2000, CANCER RES, V60, P610
   Engelhardt M, 2001, BONE MARROW TRANSPL, V27, P249, DOI 10.1038/sj.bmt.1702788
   Engelhardt M, 1997, BLOOD, V90, P182
   Engelhardt M, 2006, EUR J CANCER, V42, P1507, DOI 10.1016/j.ejca.2006.05.003
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Jego G, 1999, BLOOD, V94, P701, DOI 10.1182/blood.V94.2.701.414k16_701_712
   Kawano MM, 2002, INT J HEMATOL, V76, P329, DOI 10.1007/BF03165278
   Kukreja A, 2006, J EXP MED, V203, P1859, DOI 10.1084/jem.20052136
   Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood 2003 09 3064
   Matsuo Y, 2000, BRIT J HAEMATOL, V109, P54, DOI 10.1046/j.1365 2141.2000.01985.x
   McCullagh P., 2019, GEN LINEAR MODELS
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737
   Rème T, 2001, BRIT J HAEMATOL, V114, P406, DOI 10.1046/j.1365 2141.2001.02947.x
   Sanz Rodríguez F, 1999, BRIT J HAEMATOL, V107, P825, DOI 10.1046/j.1365 2141.1999.01762.x
   Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610
   Yaccoby S, 2005, CLIN CANCER RES, V11, P7599, DOI 10.1158/1078 0432.CCR 05 0523
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
NR 31
TC 44
Z9 53
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 472X
EI 1873 2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD OCT
PY 2007
VL 35
IS 10
BP 1550
EP 1561
DI 10.1016/j.exphem.2007.06.016
PG 12
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Research & Experimental Medicine
GA 218VK
UT WOS:000250043100010
PM 17889722
OA Bronze
DA 2025 08 17
ER

PT J
AU Bednarz Knoll, N
   Efstathiou, A
   Gotzhein, F
   Wiknnan, H
   Mueller, V
   Kang, YB
   Pante, K
AF Bednarz Knoll, Natalia
   Efstathiou, Antonia
   Gotzhein, Frauke
   Wiknnan, Harriet
   Mueller, Volkmar
   Kang, Yibin
   Pante, Klaus
TI Potential Involvement of Jagged1 in Metastatic Progression of Human
   Breast Carcinomas
SO CLINICAL CHEMISTRY
LA English
DT Article
ID BIOLOGICAL INSIGHTS; CANCER; GROWTH; JAG1; EXPRESSION; CELLS; POOR
AB BACKGROUND: Jagged1, the ligand of Notch, has been shown to be involved in formation of bone metastases in an experimental study. Here, clinical relevance of Jagged1 expression in tumor progression was assessed in human breast carcinomas.
   METHODS: Jagged1 expression was evaluated by immunohistochemistry in 228 tumor tissue samples and compared to clinicopathologic parameters and patients' outcomes. Furthermore, circulating tumor cells (CTCs) from peripheral blood of 100 unmatched metastatic cancer patients with progressive disease were enriched using Ficoll density gradient centrifugation and detected by pan keratin/Jagged1/CD45 immunofluorescent staining.
   RESULTS: Jagged1 expression was detected in 50% of 228 tumors. Jagged1 expression was correlated with higher tumor grade (P = 0.047), vascular invasion (P = 0.026), luminal B subtype (P = 0.016), overexpression of Her 2 (P = 0.001), high Ki 67 expression (P = 0.035), and aldehyde dehydrogenase 1 (ALDH1) positivity (P = 0.013). Jagged 1 expression indicated shorter disease free survival (DFS) (P = 0.040) and metastasis free survival (P = 0.048) in lymph node negative breast cancer for which it was the only independent predictor of DFS (multivariate analysis, P = 0.046). Tumors characterized by the strongest Jagged1 staining intensity (7.5% of cases) correlated with lymph node positivity (P = 0.037), metastatic relapse (P = 0.049), and higher number of disseminated tumor cells in bone marrow aspirates (P = 0.041). Twenty one unmatched metastatic breast cancer patients with progressive disease were positive for CTCs, and 85.7% of the CTCs also expressed Jagged1. The presence of Jagged1 (+) CTCs was significantly associated with shorter progression free survival in patients treated with bisphosphonates (P = 0.013).
   CONCLUSIONS: Jagged1 expression characterizes more aggressive breast carcinoma and might be involved in tumor cell dissemination, metastatic progression, and resistance to bone targeting therapy in breast cancer patients. (C) 2015 American Association for Clinical Chemistry
C1 [Bednarz Knoll, Natalia; Efstathiou, Antonia; Gotzhein, Frauke; Wiknnan, Harriet; Pante, Klaus] Univ Med Ctr Hamburg Eppendorf, Dept Tumour Biol, Martinistr 52, D 20246 Hamburg, Germany.
   [Mueller, Volkmar] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, D 20246 Hamburg, Germany.
   [Kang, Yibin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   Princeton University
RP Pante, K (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Tumour Biol, Martinistr 52, D 20246 Hamburg, Germany.
EM pantel@uke.de
RI Bednarz Knoll, Natalia/D 3663 2011
OI Bednarz Knoll, Natalia/0000 0001 9506 942X; Kang,
   Yibin/0000 0002 1626 6730
FU Bonenet European Training Network on Cancer Induced Bone Disease;
   BONE NET Marie Curie 7th FP EU
FX Bonenet European Training Network on Cancer Induced Bone Disease; K.
   Pantel, BONE NET Marie Curie 7th FP EU.
CR Alix Panabières C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258
   Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252
   Bednarz Knoll N, 2015, ONCOTARGET, V6, P26789, DOI 10.18632/oncotarget.4628
   Dai Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.137
   Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Jemal A., 2011, CA: Cancer J. Clin., V61, P69, DOI [DOI 10.3322/CAAC.20107, DOI 10.3322/CAAC.70009]
   Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Li D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00254
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549 006 9242 8
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008 5472.CAN 05 1069
   Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549 007 9805 3
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Tolia M, 2014, ANTICANCER RES, V34, P23
   Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391
   Xing F, 2013, EMBO MOL MED, V5, P384, DOI 10.1002/emmm.201201623
   Yao K, 2011, INT J SURG PATHOL, V19, P607, DOI 10.1177/1066896910362080
NR 20
TC 26
Z9 33
U1 0
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0009 9147
EI 1530 8561
J9 CLIN CHEM
JI Clin. Chem.
PD FEB
PY 2016
VL 62
IS 2
BP 378
EP 386
DI 10.1373/clinchem.2015.246686
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA DC8KR
UT WOS:000369468900013
PM 26721293
OA Bronze
DA 2025 08 17
ER

PT J
AU Yang, YY
   Liu, N
   Liao, JL
   Pu, MF
   Liu, YB
   Wei, M
   Jin, JN
AF Yang, Yuanyou
   Liu, Ning
   Liao, Jiali
   Pu, Manfei
   Liu, Yebin
   Wei, Min
   Jin, Jiannan
TI Preparation and preliminary evaluation of <SUP>211</SUP>At labeled
   amidobisphophonates
SO JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
LA English
DT Article
DE At 211; At 211 SAPC APB; Bone tumor; Bisphophonates; Biodistribution
ID BISPHOSPHONATES; AT 211; MANAGEMENT; STABILITY; THERAPY; BREAST
AB In this paper, 3 amino 1 hydroxypropylidene 1,1 bisphosphonate(APB), a amidobisphophonate was synthesized and labeled with the alpha emitter At 211 by an indirect method using N succinimidyl 5 (tributylstannyl) 3 pyridinecarboxylate (SPC) as a bi functional linker, and the conjugated amidobisphophonate (At 211 SAPC APB) was preliminarily evaluated in vitro and in vivo by comparison with free astatide (At 211( )) and Tc 99m MDP. 3 amino 1 hydroxypropylidene 1,1 bisphosphonate(APB) was prepared using beta alanine as the starting material. With SPC bi functional linker, APB was conjugated with At 211 in a labeling yield of 80 90% with radiochemical purity of more than 99%. The conjugated amidobisphophonate (At 211 SAPC APB) exhibited considerable stability in vitro, in that the radiochemical purity of At 211 SAPC APB was still more than 98% in 0.1 mol/L PBS (pH 7.6) or in fetal calf serum, even stayed for 24 h at room temperature (RT). Biodistribution of At 211 SAPC APB was investigated in NIH strain mice by I.V injection. The results showed that At 211 SAPC APB could rapidly locate in shank, with the maximum uptake of 23.70 +/  A 2.29% I.D/g at 6 h, earlier than that of Tc 99m MDP at 12 h, and stayed in the bone for long time. Moreover, At 211 SAPC APB uptake in some key organs or tissues, especially in thyriod, stomach, lung and spleen, was much less than that of free astatide (At 211( )), implying that At 211 SAPC APB was constantly stable in vivo as well as in vitro. These results indicated that At 211 SAPC APB will be a suitable candidate for the targeted radiotherapy of bone metastases and should be further investigated.
C1 [Yang, Yuanyou; Liu, Ning; Liao, Jiali; Wei, Min; Jin, Jiannan] Sichuan Univ, Key Lab Radiat Phys & Technol, Minist Educ, Inst Nucl Sci & Technol, Chengdu 610064, Peoples R China.
   [Pu, Manfei; Liu, Yebin] CAEP, Inst Nucl Phys & Chem, Mianyang 621900, Peoples R China.
C3 Sichuan University; Chinese Academy of Engineering Physics
RP Liu, N (通讯作者)，Sichuan Univ, Key Lab Radiat Phys & Technol, Minist Educ, Inst Nucl Sci & Technol, Chengdu 610064, Peoples R China.
EM nliu720@scu.edu.cn
RI Liao, JIA/IQU 9509 2023; Li, Yan/JRW 0176 2023
FU China National Natural Science Foundation [20671065]; Specialized
   Research Fund for the Doctoral Program of Higher Education (China)
   [20030610016]; Science and Technology Tackle Key Problem Program of
   Sichuan Province (China) [006Z02 033]
FX This work was financially supported by China National Natural Science
   Foundation (Grant No. 20671065), Specialized Research Fund for the
   Doctoral Program of Higher Education (China) (Grant No. 20030610016) and
   Science and Technology Tackle Key Problem Program of Sichuan Province
   (China) (Grant No. 006Z02 033).
CR Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Body JJ, 2001, J MAMMARY GLAND BIOL, V6, P477, DOI 10.1023/A:1014795216669
   BROWN I, 1986, APPL RADIAT ISOTOPES, V37, P789, DOI 10.1016/0883 2889(86)90273 X
   Bruland OS, 1997, EUR J CANCER, V33, P1725, DOI 10.1016/S0959 8049(97)00252 9
   Bruland OS, 1996, ACTA ONCOL, V35, P381, DOI 10.3109/02841869609101655
   Chen YW, 2007, KAOHSIUNG J MED SCI, V23, P639, DOI 10.1016/S1607 551X(08)70064 0
   COLLEEN MC, 2009, LANCET ONCOL, V10, P606
   Fleisch H., 1995, BISPHOSPHONATES BONE
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   GARG S, 1991, BIOCONJUGATE CHEM, V2, P50, DOI 10.1021/bc00007a009
   GARRET R, 1993, SEMIN ONCOL, V72, P3433
   Hoff P, 2000, ACTA PHYS POL B, V31, P33
   JONATHAN RG, 2003, CANCER S, V97, P840
   KANIS JA, 1995, BONE, V17, pS101, DOI 10.1016/8756 3282(95)00194 I
   Larsen RH, 1996, APPL RADIAT ISOTOPES, V47, P135, DOI 10.1016/0969 8043(95)00285 5
   Larsen RH, 1999, J NUCL MED, V40, P1197
   Lewington VJ, 1996, PHYS MED BIOL, V41, P2027, DOI 10.1088/0031 9155/41/10/012
   Murud KM, 1999, NUCL MED BIOL, V26, P397, DOI 10.1016/S0969 8051(98)00119 X
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   POLLEN JJ, 1984, UROLOGY, V24, P632, DOI 10.1016/0090 4295(84)90122 5
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Ryan PJ, 1997, SEMIN NUCL MED, V27, P291, DOI 10.1016/S0001 2998(97)80030 X
   Silberstein EB, 1996, J NUCL MED, V37, P249
   TIMOTHY AP, 2003, CANCER S, V97, P854
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Yang YY, 2006, J RADIOANAL NUCL CH, V268, P205, DOI 10.1556/JRNC.268.2006.2.5
   ZALUTSKY MR, 1987, APPL RADIAT ISOTOPES, V38, P1051, DOI 10.1016/0883 2889(87)90069 4
NR 28
TC 9
Z9 11
U1 0
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0236 5731
EI 1588 2780
J9 J RADIOANAL NUCL CH
JI J. Radioanal. Nucl. Chem.
PD FEB
PY 2010
VL 283
IS 2
BP 329
EP 335
DI 10.1007/s10967 009 0384 0
PG 7
WC Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Nuclear Science & Technology
GA 554LM
UT WOS:000274436500009
DA 2025 08 17
ER

PT J
AU Yan, ZQ
   Hang, DH
   Guo, CA
   Chen, ZR
AF Yan, Zuoqin
   Hang, Donghua
   Guo, Changan
   Chen, Zhengrong
TI Fate of Mesenchymal Stem Cells Transplanted to Osteonecrosis of Femoral
   Head
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE mesenchymal stem cells; osteonecrosis; differentiation
ID BONE MARROW TRANSPLANTATION; NONTRAUMATIC OSTEONECROSIS; OSTEOGENIC
   DIFFERENTIATION; CORE DECOMPRESSION; AVASCULAR NECROSIS; FOLLOW UP;
   THERAPY; IMMUNOFLUORESCENCE; SECTIONS; BEHAVIOR
AB The purpose of this study was to investigate the survival and differentiation status of MSCs transplanted to ONFH. Traumatic ONFH was surgically produced in skeletally mature mongrel dogs. Osteonecrosis was treated with either saline (control) or autologous mesenchymal stem cells (MSCs) transplantation after decompression. Green fluorescent protein (GFP) was used to track the transplanted MSCs, the differentiation of MSCs were evaluated by fluorescent double labeling with GFP between osteocalcin or von Willebrand factor (vWF) at 2nd, 8th, and 12th week after the transplantation. It was demonstrated that GFP positive cells were present in the necrotic area up to 12 weeks after the transplantation, their number increased from 15% at 2nd week to 38% at 12th week (p < 0.05). Neither osteocalcin nor vWF was detected by immunocytochemistry in GFP labeled MSCs in vitro, but osteocalcin was immunohistochemically positive in 90% of the GFP labeled MSCs in vivo, while vWF was still negative. The vWF expression was of no significant difference between the control group and MSCs transplanted group. The percentages of trabeculae bone volume were 9.36% and 8.42% at 2nd week (p > 0.05), 22.82% and 14.72% at 8th week, and 31.08% and 20.66% at 12th week (p < 0.05) in MSCs transplanted group and control group, respectively; new trabeculae bone in MSCs transplanted group was significantly increased as compared to that of control group at 8th and 12th week. The results demonstrated that the transplanted MSCs could survive, proliferate, and differentiate into osteoblasts directly, which contributed to the accelerated repair process. The possible mechanism is site dependant differentiation. (C) 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:442 446, 2009
C1 [Yan, Zuoqin; Guo, Changan; Chen, Zhengrong] Fudan Univ, Dept Orthopaed, Zhongshan Hosp, Shanghai 200032, Peoples R China.
   [Hang, Donghua] Shanghai Jiao Tong Univ, Dept Orthopaed Surg, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
C3 Fudan University; Shanghai Jiao Tong University
RP Yan, ZQ (通讯作者)，Fudan Univ, Dept Orthopaed, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM yan.zuoqin@zs hospital.sh.cn
RI ; Chen, Zhengrong/KBQ 6787 2024
OI Hang, Donghua/0000 0002 1715 2292; 
FU Shanghai Natural Science Foundation [07ZR14023]
FX This work was supported by the Shanghai Natural Science Foundation
   (07ZR14023).
CR Bataille F, 2006, APPL IMMUNOHISTO M M, V14, P225, DOI 10.1097/01.pai.0000162009.31931.10
   BONFIGLIO M, 1954, SURG GYNECOL OBSTET, V98, P591
   Compere EL, 1942, J BONE JOINT SURG, V24, P831
   FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0
   Gangji V, 2005, EXPERT OPIN BIOL TH, V5, P437, DOI 10.1517/14712598.5.4.437
   Gangji V, 2004, J BONE JOINT SURG AM, V86A, P1153, DOI 10.2106/00004623 200406000 00006
   Hasegawa N, 2006, J PERIODONTOL, V77, P1003, DOI 10.1902/jop.2006.050341
   Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79
   Hernigou P, 1999, J BONE JOINT SURG BR, V81B, P349, DOI 10.1302/0301 620X.81B2.8818
   Hernigou P, 2005, J BONE JOINT SURG BR, V87B, P896, DOI 10.1302/0301 620X.87B7.16289
   Hernigou P, 1997, J BONE JOINT SURG AM, V79A, P1726, DOI 10.2106/00004623 199711000 00015
   Izuta Y, 2005, KNEE, V12, P217, DOI 10.1016/j.knee.2001.06.001
   Lee HS, 2003, STEM CELLS, V21, P190, DOI 10.1634/stemcells.21 2 190
   Lee JS, 2006, J ORTHOP RES, V24, P604, DOI 10.1002/jor.20078
   Lieberman JR, 2004, CLIN ORTHOP RELAT R, P29
   Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395
   Mason DY, 2000, J PATHOL, V191, P452
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041
   Nöth U, 2007, ORTHOPADE, V36, P466, DOI 10.1007/s00132 007 1087 2
   Oshima Y, 2005, J HISTOCHEM CYTOCHEM, V53, P207, DOI 10.1369/jhc.4A6280.2005
   Petrigliano FA, 2007, CLIN ORTHOP RELAT R, P53, DOI 10.1097/BLO.0b013e3181591c92
   Potier E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325
   Potier E, 2007, BONE, V40, P1078, DOI 10.1016/j.bone.2006.11.024
   Sakai D, 2005, SPINE, V30, P2379, DOI 10.1097/01.brs.0000184365.28481.e3
   Scully SP, 1998, J BONE JOINT SURG AM, V80A, P1270, DOI 10.2106/00004623 199809000 00004
   Suh KT, 2005, CLIN ORTHOP RELAT R, P220, DOI 10.1097/01.blo.0000150568.16133.3c
   URBANIAK JR, 1995, J BONE JOINT SURG AM, V77A, P681, DOI 10.2106/00004623 199505000 00004
   YAN ZQ, 2006, CHIN J TRAUMATOL, V2, P3
NR 28
TC 86
Z9 90
U1 0
U2 27
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0736 0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD APR
PY 2009
VL 27
IS 4
BP 442
EP 446
DI 10.1002/jor.20759
PG 5
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 417OE
UT WOS:000264084800004
PM 18925660
OA Bronze
DA 2025 08 17
ER

PT J
AU Xiaoling, GL
   Shuaibin, LB
   Kailu, LL
AF Gan, Xiaoling
   Liu, Shuaibin
   Liang, Kailu
TI MicroRNA 19b 3p promotes cell proliferation and osteogenic
   differentiation of BMSCs by interacting with lncRNA H19
SO BMC MEDICAL GENETICS
LA English
DT Article
DE miR 19b 3p; lncRNA H19; Osteoporosis; Postmenopausal; BMSC
ID POSTMENOPAUSAL OSTEOPOROSIS; DRUGS
AB Background To investigated the role of miR 19b 3p in regulating bone marrow mesenchymal stem cell (BMSC) proliferation and osteoblast differentiation. Methods The expression of miR 19b 3p and lncRNA H19 were measured in postmenopausal osteoporosis patients and BMP 22 induced BMSCs using qRT PCR. MiR 19b 3p mimic or inhibitor was transfected into BMP 2 induced BMSCs. Cell proliferation was measured by BrdU method. Protein expression of RUNX2 and COL1A1 were measured by western blot. PcDNA3.1 lncRNA H19 with or without miR 19b 3p mimic was transfected into BMP 2 induced BMSCs. Results The expression of miR 19b 3p was significantly up regulated in postmenopausal osteoporosis patients and BMP 2 induced BMSCs. MiR 19b 3p overexpression dramatically elevated, while miR 19b 3p inhibition decreased cell proliferation of BMSCs. Additionally, protein expression levels of RUNX2 and COL1A1, as well as ALP activity were significantly promoted by miR 19b 3p mimic transfection and inhibited by miR 19b 3p inhibitor transfection. LncRNA H19 was obviously down regulated in postmenopausal osteoporosis patients. H19 overexpression significantly decreased cell proliferation and differentiation by down regulating miR 19b 3p. Moreover, the expression of miR 19b 3p was inhibited, while H19 elvated in 17 beta estradiol (E2) treated BMSCs in a dose dependent manner. Conclusion These data were the first to reveal the critical role of H19/miR 19b 3p in postmenopausal osteoporosis, and provided a new therapeutic target for OP.
C1 [Gan, Xiaoling; Liu, Shuaibin] Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400016, Peoples R China.
   [Liang, Kailu] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Kailu, LL (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped, Chongqing 400016, Peoples R China.
EM liangkailucmu@163.com
FU national natural science foundation of China [81301573]; chongqing
   science and technology commission project [cstc2013jcyjA10090]; project
   of chongqing municipal commission of health [2017MSXM031]
FX This study was supported by the national natural science foundation of
   China (No. 81301573), chongqing science and technology commission
   project (No. cstc2013jcyjA10090), and project of chongqing municipal
   commission of health (No. 2017MSXM031).
CR Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Bernardo BC, 2015, FUTURE MED CHEM, V7, P1771, DOI 10.4155/fmc.15.107
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Fuhrman BJ, 2014, J CLIN ENDOCR METAB, V99, P4632, DOI 10.1210/jc.2014 2222
   Futrega K, 2018, CELL TISSUE RES, V374, P541, DOI 10.1007/s00441 018 2894 y
   Hiligsmann M, 2015, PHARMACOECONOMICS, V33, P205, DOI 10.1007/s40273 014 0231 1
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43
   Jing H, 2017, FASEB J, V31, P4422, DOI 10.1096/fj.201700118R
   Jing ZF, 2019, ONCOTARGETS THER, V12, P2713, DOI 10.2147/OTT.S199238
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Lambert MNT, 2017, AM J CLIN NUTR, V106, P909, DOI 10.3945/ajcn.117.153353
   Li ZJ, 2019, GENE, V715, DOI 10.1016/j.gene.2019.144012
   Liu H, 2019, NEOPLASIA, V21, P765, DOI 10.1016/j.neo.2019.05.007
   Liu X, 2016, ACTA BIOMATER, V42, P378, DOI 10.1016/j.actbio.2016.06.019
   Liu XD, 2015, BIOL CHEM, V396, P339, DOI 10.1515/hsz 2014 0268
   Liu Y, 2018, BIOSCI TRENDS, V12, P275, DOI 10.5582/bst.2018.01046
   McKiernan PJ, 2020, J INNATE IMMUN, V12, P90, DOI 10.1159/000500419
   Pan L, 2018, J CELL BIOCHEM, V119, P10165, DOI 10.1002/jcb.27357
   Paspaliaris V, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/1730978
   Qiu J, 2018, MOL MED REP, V17, P6301, DOI 10.3892/mmr.2018.8713
   Stumpf U, 2019, Z GERONTOL GERIATR, V52, P414, DOI 10.1007/s00391 019 01571 x
   van Oostwaard M., 2018, Osteoporosis and the Nature of Fragility Fracture: An Overview, Fragility Fracture Nursing: Holistic Care and Management of the Orthogeriatric Patient, P1, DOI [10.1007/978 3 319 76681 2_1, DOI 10.1007/978 3 319 76681 2_1]
   Wang J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0747 0
   Wang QJ, 2017, BIOMED PHARMACOTHER, V89, P1178, DOI 10.1016/j.biopha.2017.02.090
   Wu G, 2018, J CELL PHYSIOL, V233, P4194, DOI 10.1002/jcp.26233
   Xin ZL, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104334
   Yu XB, 2019, ASIA PAC J CLIN ONCO, V15, P364, DOI 10.1111/ajco.13225
   Zhao Z, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2019.116900
   Zhou P, 2019, J CELL PHYSIOL, V234, P13799, DOI 10.1002/jcp.28060
NR 29
TC 56
Z9 61
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JAN 9
PY 2020
VL 21
IS 1
AR 11
DI 10.1186/s12881 020 0948 y
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA KW5DX
UT WOS:000521186400001
PM 31918667
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Guo, JC
   Yang, YJ
   Xiang, Y
   Guo, XY
   Zhang, SF
AF Guo, Juncheng
   Yang, Yijun
   Xiang, Yang
   Guo, Xueyi
   Zhang, Shufang
TI Pluronic F127 hydrogel loaded extracellular vesicles from
   adipose derived mesenchymal stem cells promote tracheal cartilage
   regeneration via SCNN1B delivery
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Pluronic F127 hydrogel; AMSC EVs; Osteogenic differentiation; SCNN1B;
   Tracheal cartilage regeneration
ID REGULATES OSTEOBLAST DIFFERENTIATION; STRESS RESPONSE; EXPRESSION;
   PACLITAXEL; GROWTH
AB Extracellular vesicles (EVs) derived from adipose  derived mesenchymal stem cells (AMSC EVs) have been highlighted as a cell  free therapy due to their regenerative capability to enhance tissue and organ regeneration. Herein, we aimed to examine the mechanism of PF127 hydrogel@AMSC EVs in promoting tracheal cartilage defect repair. Based on bioinformatics methods, SCNN1B was identified as a key gene for the osteogenic differentiation of AMSCs induced by AMSC EVs. EVs were isolated from rat AMSCs and then loaded onto thermosensitive PF 127 hydrogel to develop PF127 hydrogel@AMSC EVs. It was established that PF127hydrogel@AMSC EVs could effectively deliver SCNN1B into AMSCs, where SCNN1B promoted AMSC osteogenic differentiation. The promotive effect was evidenced by enhanced ALP activity, extracellular matrix mineralization, and expression of s glycosaminoglycan, RUNX2, OCN, collagen II, PERK, and ATF4. Furthermore, the in vivo experiments revealed that PF127 hydrogel@AMSC SCNN1B EVs stimulated tracheal cartilage regeneration in rats through PERK/ATF4 signaling axis activation. Therefore, PF127 hydrogel@AMSC SCNN1BEVs may be a novel cell  free biomaterial to facilitate tracheal cartilage regeneration and cartilage injury repair.
C1 [Guo, Juncheng; Zhang, Shufang] Cent South Univ, Cent Lab, Xiangya Sch Med, Cent Lab,Haikou Affiliated Hosp, Haikou 570208, Peoples R China.
   [Yang, Yijun; Xiang, Yang] Cent South Univ, Haikou Affiliated Hosp, Xiangya Sch Med, Haikou 570208, Peoples R China.
   [Guo, Xueyi] Cent South Univ, Changsha 410083, Peoples R China.
C3 Central South University
RP Zhang, SF (通讯作者)，Cent South Univ, Cent Lab, Xiangya Sch Med, Cent Lab,Haikou Affiliated Hosp, Haikou 570208, Peoples R China.; Guo, XY (通讯作者)，Cent South Univ, Changsha 410083, Peoples R China.
EM guoxueyi0509@163.com; zshufang202305@163.com
RI Xiang, Yang/ABI 7171 2020; Guo, Juncheng/GSN 4269 2022
FU Hainan Provincial Clinical Medical Research Center [LCYX202302]
FX The 2023 project of Hainan Provincial Clinical Medical Research Center,
   project number: LCYX202302.
CR Abo T, 2010, ACTA HISTOCHEM CYTOC, V43, P89, DOI 10.1267/ahc.10006
   Akash MSH, 2015, J CONTROL RELEASE, V209, P120, DOI 10.1016/j.jconrel.2015.04.032
   Allahverdiyev AM, 2018, ARTIF CELL NANOMED B, V46, pS755, DOI 10.1080/21691401.2018.1511573
   Becker T, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 79804 y
   Cao JY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01719 2
   Chen S, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12669
   Chen WJ, 2009, J ORTHOP RES, V27, P1631, DOI 10.1002/jor.20925
   Dal T, 2000, OTOLARYNG HEAD NECK, V123, P607, DOI 10.1067/mhn.2000.109475
   Diniz IMA, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5493 4
   Fan L, 2022, ADV SCI, V9, DOI 10.1002/advs.202105586
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02583 0
   Feldman AT, 2014, METHODS MOL BIOL, V1180, P31, DOI 10.1007/978 1 4939 1050 2_3
   Gao MC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05518 3
   Gupta M, 2011, J BONE MINER RES, V26, P1261, DOI 10.1002/jbmr.333
   Ha DH, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051157
   Huan J, 2013, CANCER RES, V73, P918, DOI 10.1158/0008 5472.CAN 12 2184
   Huang YS, 2021, BIOL DIRECT, V16, DOI 10.1186/s13062 021 00302 w
   Jeon WJ, 2017, LIFE SCI, V178, P94, DOI 10.1016/j.lfs.2017.04.012
   Kant V, 2014, ACTA HISTOCHEM, V116, P5, DOI 10.1016/j.acthis.2013.04.010
   Kim IG, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61405 4
   Li SL, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01086 x
   Li T, 2022, J TISSUE ENG, V13, DOI 10.1177/20417314221132093
   Li XN, 2014, BIOL TRACE ELEM RES, V158, P113, DOI 10.1007/s12011 014 9897 7
   Li ZB, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01953 8
   Liang L, 2022, BIOACT MATER, V9, P147, DOI 10.1016/j.bioactmat.2021.07.024
   Lin J, 2018, INT J NANOMED, V13, P805, DOI 10.2147/IJN.S152395
   Liu F, 2015, DRUG DISCOV THER, V9, P38, DOI 10.5582/ddt.2015.01008
   Liu Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.648098
   Ma SQ, 2022, MATER TODAY BIO, V13, DOI 10.1016/j.mtbio.2021.100195
   Mercado G, 2018, NEUROBIOL DIS, V112, P136, DOI 10.1016/j.nbd.2018.01.004
   Mrowczynski Oliver D, 2018, Oncotarget, V9, P36083, DOI 10.18632/oncotarget.26300
   Nie SF, 2011, INT J NANOMED, V6, P151, DOI 10.2147/IJN.S15057
   Olaizola P, 2018, BBA MOL BASIS DIS, V1864, P1293, DOI 10.1016/j.bbadis.2017.06.026
   Park JH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 38565 z
   Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008 5472.CAN 16 1595
   Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954
   Shen Y, 2019, ASIAN J ANDROL, V21, P525, DOI 10.4103/aja.aja_112_18
   Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193
   Silva AKA, 2018, ACS NANO, V12, P9800, DOI 10.1021/acsnano.8b00117
   Tan SSH, 2021, TISSUE ENG PART B RE, V27, P1, DOI [10.1089/ten.teb.2019.0326, 10.1089/ten.TEB.2019.0326]
   Taniguchi D, 2018, INTERACT CARDIOV TH, V26, P745, DOI 10.1093/icvts/ivx444
   Tsujimaru K, 2020, REGEN THER, V15, P305, DOI 10.1016/j.reth.2020.08.004
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wang CG, 2019, THERANOSTICS, V9, P65, DOI 10.7150/thno.29766
   Wang DG, 2016, NANO LETT, V16, P5503, DOI 10.1021/acs.nanolett.6b01994
   Wang N, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01138 2
   Wang WG, 2012, DEVELOPMENT, V139, P601, DOI 10.1242/dev.069575
   Wang XC, 2021, BIOENGINEERED, V12, P1126, DOI 10.1080/21655979.2021.1905259
   Wu Q, 2018, J MOL NEUROSCI, V65, P234, DOI 10.1007/s12031 018 1093 3
   Xiang LS, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01928 9
   Xiang ZC, 2021, ACS BIOMATER SCI ENG, V7, P3256, DOI 10.1021/acsbiomaterials.0c01802
   Xiao WC, 2018, J CELL PHYSIOL, V233, P6148, DOI 10.1002/jcp.26463
   Xie WQ, 2021, AGING DIS, V12, P297, DOI 10.14336/AD.2020.0519
   Yan BY, 2021, LAB INVEST, V101, P1427, DOI 10.1038/s41374 021 00635 0
   Yan FL, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00675 6
   Yang JY, 2020, INT J NANOMED, V15, P5911, DOI 10.2147/IJN.S249129
   Yang SY, 2016, CELL SIGNAL, V28, P880, DOI 10.1016/j.cellsig.2016.04.003
   Yang SY, 2020, J MOL HISTOL, V51, P125, DOI 10.1007/s10735 020 09863 y
   Yang TL, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211001545
   Yang WT, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 06892 3
   Yoneshima E, 2016, J CELL PHYSIOL, V231, P1321, DOI 10.1002/jcp.25235
   Yong KW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165816
   Yoshida T, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.585640
   Yu X, 2019, J CELL PHYSIOL, V234, P21284, DOI 10.1002/jcp.28733
   Zhang D, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02037 3
   Zhang KF, 2019, AM J PHYSIOL ENDOC M, V316, pE590, DOI 10.1152/ajpendo.00371.2018
   Zhou Y, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02980 3
NR 69
TC 1
Z9 1
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JUN
PY 2024
VL 58
AR 102748
DI 10.1016/j.nano.2024.102748
EA MAY 2024
PG 14
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA TT8X7
UT WOS:001243612100001
PM 38663789
DA 2025 08 17
ER

PT J
AU Hu, YP
   Li, JC
   Qin, L
   Chen, WX
   Lai, YX
   Yue, Y
   Ren, PG
   Pan, XH
   Zhang, P
AF Hu, Yiping
   Li, Jinchao
   Qin, Ling
   Chen, Wenxiang
   Lai, Yuxiao
   Yue, Ye
   Ren, Peigen
   Pan, Xiaohua
   Zhang, Peng
TI Study in Treatment of Collagen Induced Arthritis in DBA/1 Mice Model by
   Genistein
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Collagen Induced Arthritis; genistein; inflammation; rheumatoid
   arthritis
ID NECROSIS FACTOR ALPHA; ENDOTHELIAL GROWTH FACTOR; FACTOR KAPPA B;
   RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; REDUCES INFLAMMATION;
   GAMMA RECEPTOR; IN VIVO; INHIBITION; PROTEIN
AB Background: This work aimed to evaluate the effects of genistein treatment in Collagen Induced Arthritis (CIA) mouse model.
   Methods: CIA was elicited in DBA/1 Mice by an intradermal injection of 100 mu L of an emulsion of bovine type II collagen (CII) in isovolumic incomplete Freund's adjuvant (IFA) at the base of the tail. Twenty one days later, a second injection of CII in IFA was administered at the base of the tail. After the symptoms of arthritis showed in mouse model, we divided animals into two groups according to their clinical symptom scores. The treatment group was intraperitoneally injected daily with genistein (based on the pre experiment data and literature reported, 5 mg/kg dose was selected and tested) for 12 days, while the control group was injected with phosphate buffered saline. Inflammatory cytokines titer, radiological, and histological observations were completed at different time's points after treatment. CT analysis was conducted 3 months after the treatment to observe the articular structures. Immunohistochemical analysis was performed to investigate the expression and distribution of VEGF in joint tissues.
   Results: Genistein suppressed the expressions of IL 1 beta, IL 6 and TNF alpha in the serum. Radiological results showed that bone degradation was inhibited by the treatment. Moreover, hematoxylin and eosin staining showed that the degree of inflammation was relieved. In the cartilage area, TRAP stain positive cells were detected, which was notably reduced in the treatment group compared to the control group. Micro CT 3D images clearly exhibited that the joint adhered and structures destroyed in the control group with less destruction in the treatment group. Furthermore, genistein suppressed VEGF expression, and blocked angiogenesis in the synovial tissue.
   Conclusion: Our work provides further data regarding the effects of genistein as a potential treatment drug for RA, as well as the role of genistein in the anti inflammatory pathway in RA therapy.
C1 [Hu, Yiping; Li, Jinchao; Qin, Ling; Chen, Wenxiang; Lai, Yuxiao; Yue, Ye; Ren, Peigen; Zhang, Peng] Chinese Acad Sci, Shen Zhen Inst Adv Technol, Ctr Translat Med Res & Dev, Shenzhen 518055, Guangdong, Peoples R China.
   [Hu, Yiping] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China.
   [Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Musculoskeletal Res Lab, Hong Kong 999077, Hong Kong, Peoples R China.
   [Pan, Xiaohua] Baoan Peoples Hosp, Dept Orthopaed, Shenzhen 518100, Guangdong, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS; Chinese University of Hong Kong
RP Pan, XH (通讯作者)，Baoan Peoples Hosp, Dept Orthopaed, Shenzhen 518100, Guangdong, Peoples R China.; Zhang, P (通讯作者)，1068 Xueyuan Ave, Shenzhen 518055, Peoples R China.
EM szpxh4141@163.net; zhangpengteam@163.com
RI Qin, Ling/J 9047 2018; qin, ling/KIB 1029 2024; Lai,
   Yuxiao/AFN 1336 2022
OI Qin, Ling/0000 0001 6173 6167; 
FU National Natural Science Foundation of China [81271952, 51573206];
   science and technology innovation fund of Shenzhen
   [JCYJ20140610151856738, GJHZ20130417171414738]; Guangdong science and
   technology planning project [2013B050800005]; Shenzhen bioactive
   materials engineering lab for medicine   Shanghai Key Laboratory of
   Orthopedic Implants; Shenzhen Fundamental Research Foundation
   [JCYJ20150731154850925]
FX This research was supported by the National Natural Science Foundation
   of China (no. 81271952), the science and technology innovation fund of
   Shenzhen (no. JCYJ20140610151856738, GJHZ20130417171414738), Guangdong
   science and technology planning project (no. 2013B050800005), Shenzhen
   bioactive materials engineering lab for medicine, Support by Shanghai
   Key Laboratory of Orthopedic Implants, the National Natural Science
   Foundation of China (no. 51573206), Shenzhen Fundamental Research
   Foundation (no. JCYJ20150731154850925).
CR Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Cheng Y, 2015, INT J CLIN EXP PATHO, V8, P394
   Edwards RR, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2684
   Fautrel B, 2012, B ACAD NATL MED, V196
   Fautrel B, 2012, B ACAD NAT MED PARIS, V196, P1295, DOI 10.1016/S0001 4079(19)31711 X
   Ganai AA, 2015, TOXICOL APPL PHARM, V283, P139, DOI 10.1016/j.taap.2015.01.012
   Geboes L, 2007, ARTHRITIS RHEUM US, V56, P2595, DOI 10.1002/art.22791
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   HOLMDAHL R, 1989, APMIS, V97, P575, DOI 10.1111/j.1699 0463.1989.tb00446.x
   Hu YP, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/325875
   Huang ZY, 2010, FEBS LETT, V584, P22, DOI 10.1016/j.febslet.2009.11.026
   Kim HR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124909
   KOCH AE, 1994, J IMMUNOL, V152, P4149
   Kong XY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0440 1
   Kulkarni RN, 2012, BIOCHEM BIOPH RES CO, V420, P11, DOI 10.1016/j.bbrc.2012.02.099
   Leung L, 2015, CELL PHYSIOL BIOCHEM, V35, P1317, DOI 10.1159/000373953
   Li JC, 2014, DRUG DES DEV THER, V8, P315, DOI 10.2147/DDDT.S52354
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Matthys P, 1999, J IMMUNOL, V163, P3503
   Mohammad Shahi M, 2011, BIOIMPACTS, V1, P161, DOI 10.5681/bi.2011.022
   Montecucco F, 2009, RHEUMATOLOGY, V48, P11, DOI 10.1093/rheumatology/ken395
   Mould AW, 2003, ARTHRITIS RHEUM US, V48, P2660, DOI 10.1002/art.11232
   Ogdie A, 2014, ANN RHEUM DIS, V73, P149, DOI 10.1136/annrheumdis 2012 202424
   Park CE, 2010, J MED FOOD, V13, P815, DOI 10.1089/jmf.2009.1359
   Pathak JL, 2015, CALCIFIED TISSUE INT, V97, P169, DOI 10.1007/s00223 015 9999 z
   Rusin A, 2010, ACTA BIOCHIM POL, V57, P23
   Schett G, 2005, ARTHRITIS RHEUM US, V52, P1604, DOI 10.1002/art.21021
   Schett G, 2009, ARTHRITIS RHEUM US, V60, P2644, DOI 10.1002/art.24767
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140 6736(98)09403 3
   Suetsugi M, 2003, MOL CANCER RES, V1, P981
   Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529 0131(199912)42:12<2532::AID ANR5>3.0.CO;2 2
   Tower RJ, 2015, BONE, V74, P171, DOI 10.1016/j.bone.2015.01.009
   Tsukuda Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040136
   van Holten J, 2004, ARTHRITIS RES THER, V6, pR239, DOI 10.1186/ar1165
   Wang JX, 2008, MATURITAS, V59, P405, DOI 10.1016/j.maturitas.2008.04.003
   Yang S, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480 9222 15 8
   Yoo SA, 2005, J IMMUNOL, V174, P5846, DOI 10.4049/jimmunol.174.9.5846
   Yoo SA, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/129873
   Zhang P, 2008, INFLAMM RES, V57, P322, DOI 10.1007/s00011 008 8070 1
   Zhang Y., 2008, Inflammopharmacology, V16, P213, DOI 10.1007/s10787 008 8018 7
   Zhang YJ, 2012, INFLAMMATION, V35, P377, DOI 10.1007/s10753 011 9365 x
NR 42
TC 20
Z9 21
U1 4
U2 33
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 46
BP 6975
EP 6981
DI 10.2174/1381612822666161025150403
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EI9XY
UT WOS:000392864100011
PM 27784235
DA 2025 08 17
ER

PT J
AU Wookey, PJ
   Lutz, TA
   Andrikopoulos, S
AF Wookey, Peter J.
   Lutz, Thomas A.
   Andrikopoulos, Sof
TI Amylin in the periphery II: An updated mini review
SO THESCIENTIFICWORLDJOURNAL
LA English
DT Article
DE amylin; hormone; growth factor; amyloidogenesis; beta cell integrity;
   diabetes; brain; feeding; kidney; receptors
ID ISLET AMYLOID POLYPEPTIDE; GENE RELATED PEPTIDE; ACTIVITY MODIFYING
   PROTEINS; BLOOD BRAIN BARRIER; SUBFORNICAL ORGAN NEURONS;
   RENIN ANGIOTENSIN SYSTEM; CENTRAL NERVOUS SYSTEM; PANCREATIC BETA CELLS;
   CALCITONIN RECEPTOR; DIABETES MELLITUS
AB Amylin is a polypeptide that is cosecreted with insulin from the beta cells of the pancreas. Therefore, in states of diabetes in which the beta cell mass is largely depleted or dysfunctional, insulin and amylin secretion are also lost or dysregulated. While the soluble monomeric form of amylin acts as a hormone that alters physiological responses related to feeding and acts as a specific growth factor, there has been renewed interest in the less soluble oligomeric and insoluble polymeric forms of human (also monkey and cat) amylin that may contribute to the establishment of a pathophysiological pathway to overt diabetes. With this discovery has grown the hope of minimizing, with appropriate therapy, these toxic forms to preserve the functional ss cell mass. Human beta cells may also be more vulnerable to these forms and one risk factor, a higher fat diet, may promote toxic forms. The generation and utilities of transgenic rodent models, which express enhanced levels of human amylin, have been accompanied by strategies that may lead to the reduction of toxic forms and associated risk factors. The successful definition and faithful expression of the physiological receptors (and complexes) for amylin that may differ for each target organ is an important development in the field of amylin research generally. Besides the heuristic value for the understanding of the molecular biology of receptors, the opportunity to screen and identify nonpeptide analogues that bind the physiological receptors has important implications for biomedicine and clinical practice in relation to treatments for diabetic complications, bone diseases, and eating disorders. In particular, in their capacities to mimic the effects of amylin as a growth factor, amylin analogues may prove useful in the stimulation of beta cell mass (in conjunction with other factors), reduce the activity of the osteoclast population, and stimulate the regeneration of proximal tubules following toxic insult (and thus avoid the development of renal insufficiency).
C1 Univ Melbourne, Dept Med, Heidelberg Hts, Vic, Australia.
   Univ Zurich, Inst Vet Physiol, CH 8006 Zurich, Switzerland.
   Univ Zurich, Zurich Ctr Integrat Human Physiol, CH 8006 Zurich, Switzerland.
C3 University of Melbourne; University of Zurich; University of Zurich;
   Zurich Center Integrative Human Physiology (ZIHP)
RP Wookey, PJ (通讯作者)，Univ Melbourne, Dept Med, Repatriat Campus, Heidelberg Hts, Vic, Australia.
EM pwookey@unimelb.edu.au; tomlutz@vetphys.unizh.ch; sof@unimelb.edu.au
OI Wookey, Peter/0000 0002 3937 1621
CR Aston Mourney K, 2005, EXPERT OPIN INV DRUG, V14, P1241, DOI 10.1517/13543784.14.10.1241
   Banks WA, 1997, PEPTIDES, V18, P1577, DOI 10.1016/S0196 9781(97)00238 6
   Banks WA, 2006, ENDOCRINOLOGY, V147, P2609, DOI 10.1210/en.2006 0335
   Barth SW, 2004, BRAIN RES, V997, P97, DOI 10.1016/j.brainres.2003.10.040
   Becskei C, 2004, BRAIN RES, V1030, P221, DOI 10.1016/j.brainres.2004.10.012
   Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200
   BRASIER AR, 1986, J BIOL CHEM, V261, P6148
   Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304
   Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509
   Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200
   Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235
   Clowes JA, 2005, J BONE MINER RES, V20, P1497, DOI 10.1359/JBMR.050524
   Colagiuri S, 2002, EUR J CLIN NUTR, V56, pS30, DOI 10.1038/sj.ejcn.1601351
   COOPER GJS, 1994, ENDOCR REV, V15, P163, DOI 10.1210/er.15.2.163
   COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628
   Cornish J, 1999, J BONE MINER RES, V14, P1302, DOI 10.1359/jbmr.1999.14.8.1302
   Cornish J, 2001, BONE, V29, P162, DOI 10.1016/S8756 3282(01)00494 X
   Cornish J, 1998, AM J PHYSIOL ENDOC M, V274, pE827, DOI 10.1152/ajpendo.1998.274.5.E827
   CORNISH J, 1995, BIOCHEM BIOPH RES CO, V207, P133, DOI 10.1006/bbrc.1995.1163
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   DALESSIO DA, 1994, DIABETES, V43, P1457, DOI 10.2337/diabetes.43.12.1457
   Evdokiou A, 2000, J MOL ENDOCRINOL, V25, P195, DOI 10.1677/jme.0.0250195
   Evdokiou A, 1999, MOL ENDOCRINOL, V13, P1738, DOI 10.1210/me.13.10.1738
   Foord SM, 2005, J MOL NEUROSCI, V26, P265, DOI 10.1385/JMN:26:2 3:265
   FOX N, 1993, FEBS LETT, V323, P40, DOI 10.1016/0014 5793(93)81444 5
   Gebre Medhin S, 1998, MOL BRAIN RES, V63, P180, DOI 10.1016/S0169 328X(98)00269 1
   Harris PJ, 1997, AM J PHYSIOL RENAL, V272, pF13
   Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218
   Hoppener Jo W. M., 1993, Biochemical Society Transactions, V21, p28S
   Höppener JWM, 1999, DIABETOLOGIA, V42, P427, DOI 10.1007/s001250051175
   Horcajada Molteni MN, 2001, J BONE MINER RES, V16, P958, DOI 10.1359/jbmr.2001.16.5.958
   Hull RL, 2003, DIABETES, V52, P372, DOI 10.2337/diabetes.52.2.372
   Jagger C, 1999, ENDOCRINOLOGY, V140, P492, DOI 10.1210/en.140.1.492
   Jagger C, 2000, BIOCHEM BIOPH RES CO, V274, P124, DOI 10.1006/bbrc.2000.3093
   KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634
   Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241
   Karlsson E, 2001, DIABETOLOGIA, V44, P1015, DOI 10.1007/s001250100601
   Konarkowska B, 2006, FEBS J, V273, P3614, DOI 10.1111/j.1742 4658.2006.05367.x
   Lau T, 2004, DIABETOLOGIA, V47, P240, DOI 10.1007/s00125 003 1295 1
   Leung PS, 2005, PANCREAS, V30, P293, DOI 10.1097/01.mpa.0000158028.76666.76
   LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502
   LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243
   Ludvigsen E, 2005, EUR J ENDOCRINOL, V153, P445, DOI 10.1530/eje.1.01986
   Lutz TA, 2005, CURR DRUG TARGETS, V6, P181, DOI 10.2174/1389450053174596
   Lutz TA, 1998, PEPTIDES, V19, P309, DOI 10.1016/S0196 9781(97)00292 1
   Lutz TA, 2006, APPETITE BODY WEIGHT, P143
   MACINTYRE I, 1989, LANCET, V2, P1026
   Matveyenko AV, 2006, DIABETES, V55, P2106, DOI 10.2337/db05 1672
   McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666
   Meier JJ, 2006, AM J PHYSIOL ENDOC M, V291, pE1317, DOI 10.1152/ajpendo.00082.2006
   MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959
   Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924
   MULDER H, 1995, J NEUROSCI, V15, P7625
   Mulder H, 1997, PEPTIDES, V18, P771, DOI 10.1016/S0196 9781(97)00008 9
   O'Brien TD, 2002, MOL CELL ENDOCRINOL, V197, P213, DOI 10.1016/S0303 7207(02)00265 4
   Reidelberger RD, 2001, AM J PHYSIOL REG I, V280, pR605, DOI 10.1152/ajpregu.2001.280.3.R605
   Riediger T, 1999, AM J PHYSIOL REG I, V276, pR514, DOI 10.1152/ajpregu.1999.276.2.R514
   Riediger T, 1999, BRAIN RES, V837, P161, DOI 10.1016/S0006 8993(99)01697 2
   Riediger T, 2001, AM J PHYSIOL REG I, V281, pR1833, DOI 10.1152/ajpregu.2001.281.6.R1833
   RINDI G, 1991, AM J PATHOL, V138, P1321
   Rydgren T, 2006, DIABETES, V55, P1407, DOI 10.2337/db05 1273
   Sawada H, 2006, ENDOCRINOLOGY, V147, P2043, DOI 10.1210/en.2005 1226
   Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534
   Sexton PM, 2006, ANN NY ACAD SCI, V1070, P90, DOI 10.1196/annals.1317.076
   Soeller WC, 1998, DIABETES, V47, P743, DOI 10.2337/diabetes.47.5.743
   Storling J, 2005, DIABETOLOGIA, V48, P2039, DOI 10.1007/s00125 005 1912 2
   Tabuchi E, 2002, BRAIN RES, V951, P270, DOI 10.1016/S0006 8993(02)03173 6
   Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052
   Thavanathan R, 2006, REGUL PEPTIDES, V133, P90, DOI 10.1016/j.regpep.2005.09.025
   Tikellis C, 2004, DIABETES, V53, P989, DOI 10.2337/diabetes.53.4.989
   Tikellis C, 2003, KIDNEY INT, V63, P416, DOI 10.1046/j.1523 1755.2003.00754.x
   Tilakaratne N, 2000, J PHARMACOL EXP THER, V294, P61
   Tolcos M, 2003, J COMP NEUROL, V456, P29, DOI 10.1002/cne.10478
   Verchere CB, 1996, P NATL ACAD SCI USA, V93, P3492, DOI 10.1073/pnas.93.8.3492
   Villa I, 1997, PEPTIDES, V18, P537, DOI 10.1016/S0196 9781(97)00056 9
   Volkoff H, 2006, COMP BIOCHEM PHYS A, V144, P325, DOI 10.1016/j.cbpa.2005.10.026
   WESTERMARK G, 1995, MOL MED, V1, P542, DOI 10.1007/BF03401591
   Westermark GT, 2000, MOL MED, V6, P998, DOI 10.1007/BF03402051
   WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881
   Wilson ME, 2002, MECH DEVELOP, V115, P171, DOI 10.1016/S0925 4773(02)00118 1
   Woods SC, 2006, PHILOS T R SOC B, V361, P1219, DOI 10.1098/rstb.2006.1858
   Wookey P. J., THESCIENTIFICWORLDJO, V3, P163
   Wookey PJ, 1996, AM J PHYSIOL RENAL, V270, pF289, DOI 10.1152/ajprenal.1996.270.2.F289
   Wookey PJ, 1998, KIDNEY INT, V53, P25, DOI 10.1046/j.1523 1755.1998.00722.x
   Young Andrew, 2005, Adv Pharmacol, V52, P47, DOI 10.1016/S1054 3589(05)52003 9
   Yu YM, 2006, ENDOCRINOLOGY, V147, P2611, DOI 10.1210/en.2006 0020
   ZAIDI M, 1993, TRENDS ENDOCRIN MET, V4, P255, DOI 10.1016/1043 2760(93)90095 V
   ZAIDI M, 1990, EXP PHYSIOL, V75, P529, DOI 10.1113/expphysiol.1990.sp003429
NR 88
TC 27
Z9 34
U1 0
U2 1
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537 744X
J9 THESCIENTIFICWORLDJO
JI TheScientificWorldJOURNAL
PY 2006
VL 6
BP 1642
EP 1655
DI 10.1100/tsw.2006.263
PG 14
WC Environmental Sciences; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Science & Technology   Other Topics
GA 227DF
UT WOS:000250636700012
PM 17173182
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Uskokovic, V
   Desai, TA
AF Uskokovic, Vuk
   Desai, Tejal A.
TI In Vitro Analysis of Nanoparticulate Hydroxyapatite/Chitosan
   Composites as Potential Drug Delivery Platforms for the Sustained
   Release of Antibiotics in the Treatment of Osteomyelitis
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE antiinfectives; biomaterials; calcium phosphate; cell culture; chitosan;
   light scattering (dynamic); nanoparticles; osteoblast; osteogenesis;
   osteomyelitis; PCR
ID THIOLATED CHITOSAN NANOPARTICLES; CALCIUM PHOSPHATE NANOPARTICLES;
   PHASE COMPOSITION CONTROL; MOLECULAR WEIGHT; NANO HYDROXYAPATITE; ORAL
   ABSORPTION; BONE CEMENT; VIVO DRUG; PROLIFERATION; BIOCOMPATIBILITY
AB Nanoparticulate composites of hydroxyapatite (HAp) and chitosan were synthesized by ultrasound assisted sequential precipitation and characterized for their microstructure at the atomic scale, surface charge, drug release properties, and combined antibacterial and osteogenic response. Crystallinity of HAp nanoparticles was reduced because of the interference of the surface layers of chitosan with the dissolution/reprecipitation mediated recrystallization mechanism that conditions the transition from the as precipitated amorphous calcium phosphate phase to the most thermodynamically stable one HAp. Embedment of 5 10 nm sized, narrowly dispersed HAp nanoparticles within the polymeric matrix mitigated the burst release of the small molecule model drug, fluorescein, bound to HAp by physisorption, and promoted sustained release kinetics throughout the 3 weeks of release time. The addition of chitosan to the particulate drug carrier formulation, however, reduced the antibacterial efficacy against S aureus. Excellent cell spreading and proliferation of osteoblastic MC3T3 E1 cells evidenced on microscopic conglomerates of HAp nanoparticles in vitro also markedly diminished on HAp/chitosan composites. Mitochondrial dehydrogenase activity exhibited normal values only for HAp/chitosan particle concentrations of up to 2 mg/cm(2) and significantly dropped, by about 50%, at higher particle concentrations (4 and 8 mg/cm(2)). The gene expression of osteocalcin, a mineralization inductor, and the transcription factor Runx2 was downregulated in cells incubated in the presence of 3 mg/cm(2) HAp/chitosan composite particles, whereas the expression of osteopontin, a potent mineralization inhibitor, was upregulated, further demonstrating the partially unfavorable osteoblastic cell response to the given particles. The peak in the expression of osteogenic markers paralleling the osteoblastic differentiation was also delayed most for the cell population incubated with HAp/chitosan particles. Overall, the positive effect of chitosan coating on the drug elution profile of HAp nanoparticles as carriers for the controlled delivery of antibiotics in the treatment of osteomyelitis was compensated for by the lower bacteriostatic efficiency and the comparatively unviable cell response to the composite material, especially at higher dosages. (C) 2013 Wiley Periodicals, Inc.
C1 [Uskokovic, Vuk; Desai, Tejal A.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, Therapeut Micro & Nanotechnol Lab, San Francisco, CA 94158 USA.
C3 University of California System; University of California San Francisco
RP Uskokovic, V (通讯作者)，Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, Therapeut Micro & Nanotechnol Lab, San Francisco, CA 94158 USA.
EM vuk21@yahoo.com
RI Uskokovic, Vuk/S 7986 2018; Desai, Tejal/AAN 7626 2021
OI Uskokovic, Vuk/0000 0003 3256 1606; 
FU NIH/NIDCR [K99 DE021416]; Office of Science, Office of Basic Energy
   Sciences of the US Department of Energy [DE AC02 05CH11231]
FX Presented are the results of a study supported by the NIH/NIDCR grant
   number K99 DE021416. Confocal microscopy data were acquired at the Nikon
   Imaging Center at UCSF. HR TEM analyses were performed at the National
   Center for Electron Microscopy supported by the Office of Science,
   Office of Basic Energy Sciences of the US Department of Energy under
   contract number. DE AC02 05CH11231. The authors acknowledge the
   assistance of Chengyu Song. We also thank Juliane Nguyen and Francis
   Szoka of UCSF for allowing the use of Zetasizer, and Dragana Jugovic
   from the Institute of Technical Sciences of the Serbian Academy of
   Sciences and Arts for carrying out the XRD measurements.
CR Amidi M, 2010, ADV DRUG DELIVER REV, V62, P59, DOI 10.1016/j.addr.2009.11.009
   Arancibia R, 2013, J DENT RES, V92, P740, DOI 10.1177/0022034513494816
   Baldrick P, 2010, REGUL TOXICOL PHARM, V56, P290, DOI 10.1016/j.yrtph.2009.09.015
   Benowitz LI, 2011, CURR OPIN NEUROL, V24, P577, DOI 10.1097/WCO.0b013e32834c208d
   Bernkop Schnürch A, 2012, EUR J PHARM BIOPHARM, V81, P463, DOI 10.1016/j.ejpb.2012.04.007
   Bozic KJ, 2010, CLIN ORTHOP RELAT R, V468, P45, DOI 10.1007/s11999 009 0945 0
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Caroni ALPF, 2012, COLLOID SURFACE B, V100, P222, DOI 10.1016/j.colsurfb.2012.05.024
   CarrenoGomez B, 1997, INT J PHARM, V148, P231, DOI 10.1016/S0378 5173(96)04847 8
   Celetti A, 2005, CLIN CANCER RES, V11, P8019, DOI 10.1158/1078 0432.CCR 05 0641
   Chae SY, 2005, J CONTROL RELEASE, V102, P383, DOI 10.1016/j.jconrel.2004.10.012
   Chaudhury A, 2011, AAPS PHARMSCITECH, V12, P10, DOI 10.1208/s12249 010 9561 2
   Chen JD, 2012, COLLOID SURFACE B, V93, P100, DOI 10.1016/j.colsurfb.2011.12.022
   Cheng QY, 2013, REGUL TOXICOL PHARM, V65, P294, DOI 10.1016/j.yrtph.2013.01.003
   Chung YC, 2004, ACTA PHARMACOL SIN, V25, P932
   Combes C, 2010, ACTA BIOMATER, V6, P3362, DOI 10.1016/j.actbio.2010.02.017
   Correlo VM, 2007, MACROMOL BIOSCI, V7, P354, DOI 10.1002/mabi.200600233
   D'Este M, 2013, ACTA BIOMATER, V9, P5421, DOI 10.1016/j.actbio.2012.11.022
   Duceppe N, 2010, EXPERT OPIN DRUG DEL, V7, P1191, DOI 10.1517/17425247.2010.514604
   Fan HL, 2010, BIOMACROMOLECULES, V11, P2345, DOI 10.1021/bm100470q
   Fan JJ, 2012, J MATER SCI MATER M, V23, P399, DOI 10.1007/s10856 011 4491 4
   Fazil M, 2012, EUR J PHARM SCI, V47, P6, DOI 10.1016/j.ejps.2012.04.013
   Fosca M, 2012, ACS APPL MATER INTER, V4, P6202, DOI 10.1021/am301809y
   Gogia Jaspaul S, 2009, Semin Plast Surg, V23, P100, DOI 10.1055/s 0029 1214162
   Harris I, 2005, ANZ J SURG, V75, P1041, DOI 10.1111/j.1445 2197.2005.03618.x
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945
   Hu CS, 2012, INT J NANOMED, V7, P4861, DOI 10.2147/IJN.S34770
   Hu YL, 2011, INT J NANOMED, V6, P3351, DOI 10.2147/IJN.S25853
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Ing LY, 2012, INT J BIOMATER, V2012, DOI 10.1155/2012/632698
   Jeevitha D, 2013, COLLOID SURFACE B, V101, P126, DOI 10.1016/j.colsurfb.2012.06.019
   Kim BS, 2013, J BIOMED MATER RES A, V101, P1550, DOI 10.1002/jbm.a.34456
   Kim H, 2011, J BIOMED MATER RES A, V97A, P395, DOI 10.1002/jbm.a.33070
   Kim SW, 2005, BONE, V37, P359, DOI 10.1016/j.bone.2005.04.020
   Kowapradit J, 2010, DRUG DELIV, V17, P301, DOI 10.3109/10717541003706273
   Kurtz SM, 2008, J ARTHROPLASTY, V23, P984, DOI 10.1016/j.arth.2007.10.017
   Lee HS, 2012, J COLLOID INTERF SCI, V385, P235, DOI 10.1016/j.jcis.2012.06.074
   Lee J, 2012, BIOCONJUGATE CHEM, V23, P1174, DOI 10.1021/bc2006219
   Liu H, 2006, J BIOMED MATER RES A, V78A, P798, DOI 10.1002/jbm.a.30734
   Liu SQ., 2007, BIOREGENERATIVE ENG
   Liu TY, 2006, J CONTROL RELEASE, V112, P88, DOI 10.1016/j.jconrel.2006.01.017
   Loh JW, 2012, TOXICOL APPL PHARM, V262, P273, DOI 10.1016/j.taap.2012.04.037
   Loh JW, 2010, TOXICOL APPL PHARM, V249, P148, DOI 10.1016/j.taap.2010.08.029
   Loretz B, 2007, NANOTOXICOLOGY, V1, P139, DOI 10.1080/17435390701554200
   Lu HH, 2000, J BIOMED MATER RES, V51, P80, DOI 10.1002/(SICI)1097 4636(200007)51:1<80::AID JBM11>3.0.CO;2 6
   Ma T, 2011, J BIOMAT SCI POLYM E, V22, P1669, DOI 10.1163/092050611X570644
   Ma ZS, 2003, PHARM RES DORDR, V20, P1812, DOI 10.1023/B:PHAM.0000003379.76417.3e
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Narayanan D, 2012, J BIOMED NANOTECHNOL, V8, P98, DOI 10.1166/jbn.2012.1367
   Onuma K, 1998, CHEM MATER, V10, P3346, DOI 10.1021/cm980062c
   Opanasopit P, 2007, PHARM DEV TECHNOL, V12, P447, DOI 10.1080/10837450701555901
   Palazzo B, 2011, INT J IMMUNOPATH PH, V24, P73, DOI 10.1177/03946320110241S214
   Paluska SA., 2004, CLIN FAM PRACT, V6, P127
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095 007 9303 7
   Paul W, 2008, WOODHEAD PUBL MATER, P67, DOI 10.1533/9781845695033.2.67
   Peng HJ, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957 4484/23/48/485102
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Qi LF, 2005, WORLD J GASTROENTERO, V11, P5136
   Rajam M, 2011, INT J PHARMACEUT, V410, P145, DOI 10.1016/j.ijpharm.2011.02.065
   Ranjan OP, 2011, ARCH PHARM RES, V34, P1919, DOI 10.1007/s12272 011 1112 1
   Ren DW, 2005, CARBOHYD RES, V340, P2403, DOI 10.1016/j.carres.2005.07.022
   Rhoades J, 2000, APPL ENVIRON MICROB, V66, P80, DOI 10.1128/AEM.66.1.80 86.2000
   Rousseau M, 2008, J BIOMED MATER RES A, V85A, P487, DOI 10.1002/jbm.a.31553
   Saper RB, 2004, AM FAM PHYSICIAN, V70, P1731
   Saremi S, 2011, INT J NANOMED, V6, P119, DOI 10.2147/IJN.S15500
   Shi PJ, 2010, J BIOMED MATER RES A, V93A, P1020, DOI 10.1002/jbm.a.32598
   Singha K, 2011, NUCLEIC ACID THER, V21, P133, DOI 10.1089/nat.2011.0293
   Smelcerovic A, 2008, CURR PHARM DESIGN, V14, P3168, DOI 10.2174/138161208786404254
   Tanaka Y, 1997, BIOMATERIALS, V18, P591, DOI 10.1016/S0142 9612(96)00182 2
   Tanase CE, 2012, J BIOMED MATER RES B, V100B, P700, DOI 10.1002/jbm.b.32502
   Thanyaphoo S, 2012, J PHARM SCI US, V101, P2870, DOI 10.1002/jps.23230
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Tripathi A, 2012, INT J BIOL MACROMOL, V50, P294, DOI 10.1016/j.ijbiomac.2011.11.013
   Uskokovic PS, 2007, J EUR CERAM SOC, V27, P1559, DOI 10.1016/j.jeurceramsoc.2006.04.122
   Uskokovic V, 2013, MAT SCI ENG C MATER, V33, P3362, DOI 10.1016/j.msec.2013.04.023
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1416, DOI 10.1002/jbm.a.34426
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1427, DOI 10.1002/jbm.a.34437
   Uskokovic V, 2012, J DISPER SCI TECHNOL, V33, P1762, DOI 10.1080/01932691.2011.625523
   Venkatesan P, 2011, BIOMATERIALS, V32, P3794, DOI 10.1016/j.biomaterials.2011.01.027
   Vinsová J, 2011, CURR PHARM DESIGN, V17, P3596, DOI 10.2174/138161211798194468
   Wenk HR, 1999, BONE, V24, P361, DOI 10.1016/S8756 3282(98)00192 6
   Wilson OC, 2008, MAT SCI ENG C BIO S, V28, P434, DOI 10.1016/j.msec.2007.04.005
   Xu CY, 2004, J BIOMED MATER RES A, V71A, P154, DOI 10.1002/jbm.a.30143
   Yeh TH, 2011, BIOMATERIALS, V32, P6164, DOI 10.1016/j.biomaterials.2011.03.056
   YENSON A, 1983, OTOLARYNG HEAD NECK, V91, P173, DOI 10.1177/019459988309100211
   Yin H, 2009, CURR TOP MED CHEM, V9, P1546, DOI 10.2174/156802609789909795
   Zhang JZ, 2012, DRUG DELIV, V19, P264, DOI 10.3109/10717544.2012.704093
   Zhou G, 2007, J BIOMED MATER RES A, V83A, P931, DOI 10.1002/jbm.a.31427
   Zou Q, 2009, J BIOMED MATER RES A, V89A, P1108, DOI 10.1002/jbm.a.32199
NR 91
TC 87
Z9 94
U1 5
U2 107
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD FEB
PY 2014
VL 103
IS 2
BP 567
EP 579
DI 10.1002/jps.23824
PG 13
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA AO4LW
UT WOS:000341311100025
PM 24382825
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Guo, N
   Ye, S
   Zhang, K
   Yu, XL
   Cui, HY
   Yang, XM
   Lin, P
   Lv, MH
   Miao, JL
   Zhang, Y
   Han, Q
   Zhang, RG
   Chen, ZN
   Zhu, P
AF Guo, Na
   Ye, Sheng
   Zhang, Kui
   Yu, Xiaoling
   Cui, Hongyong
   Yang, Xiangmin
   Lin, Peng
   Lv, Minghua
   Miao, Jinlin
   Zhang, Yang
   Han, Qing
   Zhang, Rongguang
   Chen, Zhinan
   Zhu, Ping
TI A critical epitope in CD147 facilitates memory CD4<SUP>+</SUP> T cell
   hyper activation in rheumatoid arthritis
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE CD4(+) Memory T cell; CD147; Monoclonal Antibody; Rheumatoid arthritis;
   Immunotherapy
ID PERIPHERAL BLOOD; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL ANTIBODY;
   CRYSTAL STRUCTURE; SYNOVIAL FLUID; CD4+T CELLS; EXPRESSION;
   HAB18G/CD147; ANTIGEN; BINDING
AB The abnormal activation of CD4(+)CD45RO(+) memory T (Tm) cells plays an important role in the pathogenesis of rheumatoid arthritis (RA). Previous studies have shown that CD147 participates in T cell activation. However, it remains unclear whether CD147 is involved in abnormal Tm cell activation in RA patients. In this study, we demonstrated that CD147 was predominantly upregulated in Tm cells derived from RA patients. The anti CD147 mAb 5A12 specifically inhibited Tm cell activation and proliferation and further restrained osteoclastogenesis. Using a structural functional approach, we depicted the interface between 5A12 and CD147. This allowed us to identify two critical residues, Lys63 and Asp65, as potential targets for RA treatment, as the double mutation K63A/D65A inhibited Tm cell activation, mimicking the neutralization by 5A12. This study provides not only a theoretical basis for a "CD147 Tm/Osteoclast RA chain" for the potential prevention and treatment of RA or other T cell mediated autoimmune diseases but also a new target for related drug design and development.
C1 [Guo, Na; Zhang, Kui; Lv, Minghua; Miao, Jinlin; Han, Qing; Zhu, Ping] Xi Jing Hosp, Dept Clin Immunol, Xian 710032, Shaanxi, Peoples R China.
   [Guo, Na; Zhang, Kui; Yu, Xiaoling; Cui, Hongyong; Yang, Xiangmin; Lin, Peng; Zhang, Yang; Chen, Zhinan; Zhu, Ping] Fourth Mil Med Univ, Dept Cell Biol, Natl Translat Sci Ctr Mol Med, Xian 710032, Shaanxi, Peoples R China.
   [Ye, Sheng; Zhang, Rongguang] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   [Zhang, Rongguang] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Natl Ctr Prot Sci Shanghai, Shanghai 201203, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Chinese
   Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of
   Sciences; Center for Excellence in Molecular Cell Science, CAS
RP Zhu, P (通讯作者)，Xi Jing Hosp, Dept Clin Immunol, Xian 710032, Shaanxi, Peoples R China.; Chen, ZN; Zhu, P (通讯作者)，Fourth Mil Med Univ, Dept Cell Biol, Natl Translat Sci Ctr Mol Med, Xian 710032, Shaanxi, Peoples R China.; Zhang, RG (通讯作者)，Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.; Zhang, RG (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Natl Ctr Prot Sci Shanghai, Shanghai 201203, Peoples R China.
EM rzhang@ibp.ac.cn; znchen@fmmu.edu.cn; zhuping@fmmu.edu.cn
RI YU, Xiaoling/M 8815 2018; Han, Qing Long/B 6635 2013
OI YU, Xiaoling/0000 0001 6035 3906; Miao, Jinlin/0000 0001 9038 5175;
   Chen, Zhi Nan/0000 0001 5512 4623; 
FU National Basic Research Program of China [2015CB553704]; National
   Science and Technology Major Project of China [2013ZX09301301,
   2014ZX09508002 002]; National Key Research Project of China
   [2017YFC0909002]; National Natural Science Foundation of China
   [31470792]; Strategic Priority Research Program of the Chinese Academy
   of Sciences [XDB08030102]
FX This research was supported by grant (2015CB553704) from the National
   Basic Research Program of China, grants (2013ZX09301301 and
   2014ZX09508002 002) from the National Science and Technology Major
   Project of China, grant (2017YFC0909002) from the National Key Research
   Project of China, grant (31470792) from the National Natural Science
   Foundation of China and grant (XDB08030102) from the Strategic Priority
   Research Program of the Chinese Academy of Sciences.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   AFELTRA A, 1993, ANN RHEUM DIS, V52, P457, DOI 10.1136/ard.52.6.457
   Agrawal SM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 64
   Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517
   Brennan FM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2390
   Bugelski PJ, 2009, EXPERT REV CLIN IMMU, V5, P499, DOI 10.1586/ECI.09.31
   Carpenter PA, 2002, BLOOD, V99, P2712, DOI 10.1182/blood.V99.8.2712
   CONLON K, 1995, EUR J IMMUNOL, V25, P644, DOI 10.1002/eji.1830250303
   Cope AP, 2007, CLIN EXP RHEUMATOL, V25, pS4
   Damsker JM, 2007, J LEUKOCYTE BIOL, V82, P613, DOI 10.1189/jlb.0506317
   Damsker JM, 2009, IMMUNOLOGY, V126, P55, DOI 10.1111/j.1365 2567.2008.02877.x
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567
   Guo N, 2015, MOL IMMUNOL, V63, P253, DOI 10.1016/j.molimm.2014.07.005
   Gwinn WM, 2006, J IMMUNOL, V177, P4870, DOI 10.4049/jimmunol.177.7.4870
   Hu JS, 2010, J CELL MOL MED, V14, P2132, DOI 10.1111/j.1582 4934.2010.01012.x
   Huang WJ, 2012, CELL RES, V22, P473, DOI 10.1038/cr.2012.24
   Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980
   Jia JF, 2009, RHEUMATOLOGY, V48, P721, DOI 10.1093/rheumatology/kep099
   Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200
   KASINRERK W, 1992, J IMMUNOL, V149, P847
   Kendrick AA, 2017, ONCOTARGET, V8, P6742, DOI 10.18632/oncotarget.14272
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896
   Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777
   Kohem CL, 1996, ARTHRITIS RHEUM, V39, P844, DOI 10.1002/art.1780390518
   Kong LM, 2011, J CELL MOL MED, V15, P1415, DOI 10.1111/j.1582 4934.2010.01124.x
   Kosmaczewska A, 2014, PATHOL ONCOL RES, V20, P235, DOI 10.1007/s12253 013 9687 0
   Kwok SK, 2012, ARTHRITIS RHEUM US, V64, P740, DOI 10.1002/art.33390
   McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   McKinstry KK, 2010, IMMUNOLOGY, V130, P1, DOI 10.1111/j.1365 2567.2010.03259.x
   Neidhart M, 1996, RHEUMATOL INT, V15, P201, DOI 10.1007/BF00290522
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Pistol G, 2007, J CELL MOL MED, V11, P339, DOI 10.1111/j.1582 4934.2007.00022.x
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Semerano L, 2016, TRENDS MOL MED, V22, P214, DOI 10.1016/j.molmed.2016.01.005
   Solstad T, 2011, BLOOD, V118, P5141, DOI 10.1182/blood 2011 02 339242
   Staffler G, 2003, J IMMUNOL, V171, P1707, DOI 10.4049/jimmunol.171.4.1707
   von Kempis J, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13581
   Wang CH, 2011, J CELL MOL MED, V15, P850, DOI 10.1111/j.1582 4934.2010.01084.x
   Wang XX, 2012, NAT STRUCT MOL BIOL, V19, P424, DOI 10.1038/nsmb.2255
   Woodhead VE, 2000, INT IMMUNOL, V12, P1051, DOI 10.1093/intimm/12.7.1051
   Yang Y, 2008, RHEUMATOLOGY, V47, P1299, DOI 10.1093/rheumatology/ken225
   Yao H, 2014, INT J BIOL SCI, V10, P43, DOI 10.7150/ijbs.6818
   Yu XL, 2008, J BIOL CHEM, V283, P18056, DOI 10.1074/jbc.M802694200
   Zhu P, 2005, ARTHRITIS RES THER, V7, pR1023, DOI 10.1186/ar1778
   ARTHRITIS RES, V2, P415
NR 48
TC 26
Z9 27
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672 7681
EI 2042 0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD JUN
PY 2019
VL 16
IS 6
BP 568
EP 579
DI 10.1038/s41423 018 0012 4
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA HY7WV
UT WOS:000468349100006
PM 29563614
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Kreck, S
   Klaus, J
   Leidl, R
   von Tirpitz, C
   Konnopka, A
   Matschinger, H
   König, HH
AF Kreck, Simon
   Klaus, Jochen
   Leidl, Reiner
   von Tirpitz, Christian
   Konnopka, Alexander
   Matschinger, Herbert
   Koenig, Hans Helmut
TI Cost effectiveness of ibandronate for the prevention of fractures in
   inflammatory bowel disease related osteoporosis  : Cost utility analysis
   using a Markov model
SO PHARMACOECONOMICS
LA English
DT Article
ID BONE MINERAL DENSITY; INCIDENT VERTEBRAL FRACTURE; HIP FRACTURE;
   POSTMENOPAUSAL WOMEN; CROHNS DISEASE; EXCESS MORTALITY; ANTIRESORPTIVE
   AGENTS; ECONOMIC EVALUATIONS; RISK REDUCTION; ALENDRONATE
AB Background: Osteoporosis is a frequent complication in patients with inflammatory bowel disease. Recent studies have shown bisphosphonates to considerably reduce fracture risk in patients with osteoporosis, and preventing fractures with bisphosphonates has been reported to be cost effective in older populations. However, no studies of the cost effectiveness of these agents in preventing fractures in patients with inflammatory bowel disease are available.
   Objective: To investigate the cost effectiveness of the bisphosphonate ibandronate combined with calcium/colecalciferol ('ibandronate') in patients with osteopenia or osteoporosis due to inflammatory bowel disease in Germany. Treatment strategies used for comparison were sodium fluoride combined with calcium/colecalciferol ('fluoride') and calcium/colecalciferol ('calcium') alone.
   Study design and methods: A cost utility analysis was conducted using data from a randomized controlled trial (RCT). Changes in bone mineral density (BMD) were adjusted and predicted for a standardized population receiving each respective treatment. A Markov model was developed, with probabilities of transition to fracture states consisting of BMD dependent and  independent components. The BMD dependent component was assessed using predicted change in BMD from the RCT. The independent component captured differences in bone quality and micro architecture resulting from prevalent fractures or treatment with anti resorptive drugs.
   The analysis was conducted for a population with a mean age of the RCT patients (women aged 36 years, men aged 38 years) with osteopenia (T score about  2.0 at baseline), a population of the same age with osteoporosis (T score of  3.0 at baseline) and for an older population (both sexes aged 65 years) with osteoporosis (T score of  3.0). Outcomes were measured as costs per QALY gained from a societal perspective. The treatment duration in the RCT was 42 months. A 5 year period was assumed to follow, during which the treatment effects linearly declined to 0. The simulation time was 10 years.
   Prices for medication and treatment were presented as year 2004 values; costs and effects were discounted at 5%. To test the robustness of the results, univariate and probabilistic sensitivity analyses (Monte Carlo simulation) were conducted.
   Results: The calcium strategy dominated the fluoride strategy. When the ibandronate strategy was compared with the calcium strategy, the base case cost effectiveness ratios (costs per QALY gained) were between (sic)407 375 for an older female population with osteoporosis and (sic)6 516 345 for a younger female population with osteopenia. Univariate sensitivity analyses resulted in variations between 4% of base case results and dominance of calcium. In Monte Carlo simulations, conducted for the various populations, the probability of an ICER of ibandronate below (sic)50 000 per QALY was never greater than 20.2%. Conclusion: The ibandronate strategy is unlikely to be considered cost effective by decision makers in men or women with characteristics of those in the target population of the RCT, or in older populations with osteoporosis.
C1 [Kreck, Simon; Konnopka, Alexander; Koenig, Hans Helmut] Univ Leipzig, Dept Psychiat, Hlth Econ Res Unit, D 04317 Leipzig, Germany.
   [Klaus, Jochen; von Tirpitz, Christian] Ulm Univ Hosp, Dept Internal Med 1, Ulm, Germany.
   [Leidl, Reiner] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Hlth Econ & Hlth Care Management, Neuherberg, Germany.
C3 Leipzig University; Ulm University; Helmholtz Association;
   Helmholtz Center Munich   German Research Center for Environmental
   Health
RP König, HH (通讯作者)，Univ Leipzig, Dept Psychiat, Hlth Econ Res Unit, Johannisallee 20, D 04317 Leipzig, Germany.
RI ; König, Hans Helmut/P 1211 2018; Leidl, Reiner/GQY 7389 2022
OI Koenig, Hans Helmut/0000 0001 5711 6862; Matschinger,
   Herbert/0000 0001 7146 6770; 
CR Arden NK, 2003, EUR J GASTROEN HEPAT, V15, P865, DOI 10.1097/00042737 200308000 00005
   BERNSTEIN CN, 1995, J BONE MINER RES, V10, P250
   Bjarnason I, 1997, GUT, V40, P228, DOI 10.1136/gut.40.2.228
   Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Borgström F, 2004, BONE, V34, P1064, DOI 10.1016/j.bone.2003.12.028
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Cefalu CA, 2004, CURR MED RES OPIN, V20, P341, DOI 10.1185/030079903125003062
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Claxton K, 2005, HEALTH AFFAIR, V24, P93, DOI 10.1377/hlthaff.24.1.93
   Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167 6296(98)00039 3
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   *DCCV, DTSCH MORB CROHN COL
   De Laet CEDH, 1998, J BONE MINER RES, V13, P1587, DOI 10.1359/jbmr.1998.13.10.1587
   DeLaet CEDH, 1997, BRIT MED J, V315, P221, DOI 10.1136/bmj.315.7102.221
   Delmas PD, 2004, J BONE MINER RES, V19, P330, DOI 10.1359/JBMR.0301228
   Delmas PD, 2004, BONE, V34, P599, DOI 10.1016/j.bone.2003.12.022
   Fleurence RL, 2006, OSTEOPOROSIS INT, V17, P29, DOI 10.1007/s00198 005 1943 z
   Forsén L, 1999, OSTEOPOROSIS INT, V10, P73, DOI 10.1007/s001980050197
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Johnell O, 2003, PHARMACOECONOMICS, V21, P305, DOI 10.2165/00019053 200321050 00002
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P862, DOI 10.1007/s00198 004 1643 0
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P15, DOI 10.1007/s00198 004 1688 0
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P108, DOI 10.1007/s00198 003 1516 y
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P20, DOI 10.1007/s00198 003 1463 7
   Kanis JA, 2003, BONE, V32, P468, DOI 10.1016/S8756 3282(03)00061 9
   Klaus J, 2002, GUT, V51, P654, DOI 10.1136/gut.51.5.654
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Li ZQ, 2001, STAT MED, V20, P3175, DOI 10.1002/sim.984
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Melton LJ, 1999, OSTEOPOROSIS INT, V9, P29, DOI 10.1007/s001980050113
   Meyer HE, 2000, OSTEOPOROSIS INT, V11, P228, DOI 10.1007/s001980050285
   O'Neill TW, 2002, J BONE MINER RES, V17, P2214, DOI 10.1359/jbmr.2002.17.12.2214
   O'Neill TW, 2001, OSTEOPOROSIS INT, V12, P555, DOI 10.1007/s001980170076
   Philips Z, 2006, PHARMACOECONOMICS, V24, P355, DOI 10.2165/00019053 200624040 00006
   *ROT LIST SERV GMB, 2004, RED LIST 2004 CAT DR
   ROUX C, 1995, OSTEOPOROSIS INT, V5, P156, DOI 10.1007/BF02106094
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Schousboe JT, 2005, ANN INTERN MED, V142, P734, DOI 10.7326/0003 4819 142 9 200505030 00008
   Semeao EJ, 1997, GASTROENTEROLOGY, V112, P1710, DOI 10.1016/S0016 5085(97)70055 6
   Stark R, 2005, VALUE HEALTH, V8, pA121, DOI 10.1016/S1098 3015(10)67518 3
   *STAT BUND, 2004, STAT YB 2004
   Stevenson M, 2005, HEALTH TECHNOL ASSES, V9, P1
   Tosteson ANA, 2001, OSTEOPOROSIS INT, V12, P849, DOI 10.1007/s001980170036
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P624, DOI 10.1007/s001980200084
   *VDR, 2000, STAT REH 1999
   Vestergaard P, 2000, GUT, V46, P176, DOI 10.1136/gut.46.2.176
   von Tirpitz C, 2005, GASTROENTEROLOGY, V128, pA588
   Von Tirpitz Ch., 1999, Zeitschrift fuer Gastroenterologie, V37, P5
   Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   Wildner M, 2001, OSTEOPOROSIS INT, V12, P136, DOI 10.1007/s001980170146
   Zethraeus N, 2002, OSTEOPOROSIS INT, V13, P841, DOI 10.1007/s001980200117
   2007, SOZIALGESETZBUCH 11
NR 58
TC 9
Z9 10
U1 0
U2 7
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1170 7690
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2008
VL 26
IS 4
BP 311
EP 328
DI 10.2165/00019053 200826040 00004
PG 18
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 292AO
UT WOS:000255239000004
PM 18370566
DA 2025 08 17
ER

PT J
AU Haq, SA
AF Haq, Syed Atiqul
TI Treatment of osteoporosis: facing the challenges in the Asia Pacific
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE clinical aspects; disease aetiology and pathogenesis; epidemiology;
   osteoporosis; rehabilitation
ID BONE MINERAL DENSITY; HIP FRACTURE; ASSESSMENT TOOL; RISK INDEXES;
   PREVENTION; TRENDS; MEN; BISPHOSPHONATES; EPIDEMIOLOGY; PREVALENCE
AB The prevalence of osteoporosis and fractures is projected to increase rapidly in the Asia Pacific region in coming decades. At the societal level, healthcare providers will face the challenges of paucity of information, lack of awareness among physicians, resource constraints, lack of organization, absence of policies of cost reimbursement, insufficient representation of the problem in curricula and lack of effective, inexpensive and convenient therapy. Poverty, illiteracy, lack of awareness and interest in future quality of life, and co morbidities with seemingly greater importance, will all act as challenges at the level of individual patients. Lack of compliance is a function of lack of awareness and motivation, cost, complexity of administration, side effects and absence of immediately perceivable benefit. The challenges may be overcome through systematic collection of data, formation or activation of national osteoporosis planning and coordinating groups, development of national guidelines, programs of education of healthcare providers, patients and the general public, adoption of a population based prevention strategy, cost effective opportunistic screening using clinical decision rules like the osteoporosis self assessment tool for Asians, use of the fracture risk assessment tool for therapeutic decision making, giving due emphasis to the problem in curricula and development of mechanisms for cost reimbursement. The Asia Pacific League of Associations for Rheumatology may take a lead in stimulating, organizing and coordinating these activities.
C1 [Haq, Syed Atiqul] Bangabandhu Sheikh Mujib Med Univ, Dhaka 1000, Bangladesh.
C3 Bangabandhu Sheikh Mujib Medical University (BSMMU)
RP Haq, SA (通讯作者)，Aptt 3B,House 11,Rd 10,Dhanmondi RA, Dhaka 1205, Bangladesh.
EM syedatiqulhaq@yahoo.com
OI Haq, Syed Atiqul/0000 0003 4154 7283
CR *ACC EC, 2001, OST AUSTR ACC EC PTY
   [Anonymous], 1998, Osteoporosis Int, V8, pS1
   Barrett Connor E, 1998, OSTEOPOROSIS INT, V8, pS2
   Bauer DC, 2000, AM J MED, V109, P338, DOI 10.1016/S0002 9343(00)00541 6
   Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072
   Blanchard F, 1998, REPORT OSTEOPOROSIS
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   CHAIYAKUNAPRUK N, 2003, J AM PHARM ASSOC, V46, P391
   Chan SP, 2006, OSTEOPOROSIS INT, V17, P1182, DOI 10.1007/s00198 005 0051 4
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   DARMAWAN J, 1992, ANN RHEUM DIS, V51, P525, DOI 10.1136/ard.51.4.525
   Edwards L, 1997, BAILLIERE CLIN RHEUM, V11, P631, DOI 10.1016/S0950 3579(97)80024 6
   Freedman KB, 2000, J BONE JOINT SURG AM, V82A, P1063, DOI 10.2106/00004623 200008000 00001
   Fujiwara S, 2008, OSTEOPOROSIS INT, V19, P429, DOI 10.1007/s00198 007 0544 4
   Gehlbach SH, 2002, AM J PUBLIC HEALTH, V92, P271, DOI 10.2105/AJPH.92.2.271
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Harrington JT, 2002, ARTHRIT RHEUM ARTHR, V47, P651, DOI 10.1002/art.10787
   Ip TP, 2004, OSTEOPOROSIS INT, V15, P329, DOI 10.1007/s00198 003 1523 z
   Johnson LA, 1997, J COMPUT ASSIST TOMO, V21, P103, DOI 10.1097/00004728 199701000 00019
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782
   Kanis JA, 1999, BONE, V24, P279, DOI 10.1016/S8756 3282(99)00010 1
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Keramat A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 28
   KHAW KT, 1992, STRATEGY PREVENTIVE, P88
   Koh LKH, 2001, OSTEOPOROSIS INT, V12, P699, DOI 10.1007/s001980170070
   Kung AWC, 2005, OSTEOPOROSIS INT, V16, P849, DOI 10.1007/s00198 004 1778 z
   KUNG AWC, 1996, HLTH ELDERLY, P161
   LAU EMC, 1990, INT J EPIDEMIOL, V19, P1119, DOI 10.1093/ije/19.4.1119
   Lau EMC, 2000, CALCIFIED TISSUE INT, V66, P47, DOI 10.1007/s002230050009
   LAU EMC, 1993, P 4 INT S OST CONS D, P58
   Lerttrakul Songkiat, 2005, J Med Assoc Thai, V88 Suppl 5, pS80
   Li Yu JT, 2005, OSTEOPOROSIS INT, V16, P1789, DOI 10.1007/s00198 005 1929 x
   Lim Sung Kil, 1993, Yonsei Medical Journal, V34, P57
   LIU Y, 2003, J HEALTH POPUL NUTR, V21, P403
   Lu ChunYan, 2006, J Orthop Surg Res, V1, P14, DOI 10.1186/1749 799X 1 14
   MELTON L., 1995, Osteoporosis   Etiology, diagnosis, and management, P225
   Melton LJ, 1998, OSTEOPOROSIS INT, V8, P68
   MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204
   Meunier PJ, 1999, OSTEOPOROSIS INT, V9, P48, DOI 10.1007/PL00004161
   NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335
   NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111
   Nguyen TV, 2004, MED J AUSTRALIA, V180, pS18
   Nguyen TV., 1999, Osteoporosis in Men, P335
   Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003 4819 124 2 199601150 00001
   Pasion EG, 2007, J BONE MINER METAB, V25, P105, DOI 10.1007/s00774 006 0735 7
   PECK WA, 1993, AM J MED, V94, P646
   Pongchaiyakul C, 2005, OSTEOPOROSIS INT, V16, P1444, DOI 10.1007/s00198 005 1996 z
   Pongchaiyakul Chatlert, 2008, Journal of the Medical Association of Thailand, V91, P153
   RAJATANAVIN R, 1994, P 10 ANN M THAI ROYA
   Randell A, 1995, OSTEOPOROSIS INT, V5, P427, DOI 10.1007/BF01626603
   Randell AG, 2000, OSTEOPOROSIS INT, V11, P460, DOI 10.1007/s001980070115
   Roy NC, 2001, J HEALTH POPUL NUTR, V19, P291
   Royal College of Physicians, 1999, OST CLIN GUID PREV T
   SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173
   Tao B, 2008, J BONE MINER METAB, V26, P60, DOI 10.1007/s00774 007 0798 0
   van Schoor NM, 2003, JAMA J AM MED ASSOC, V289, P1957, DOI 10.1001/jama.289.15.1957
   *WHO, 1994, WHO TECHN REP SER, V843
   *WHO SCI GROUP, 2003, PREV MAN OST
   YONG SJ, 1988, KOREAN J INTERN MED, V31, P13
NR 60
TC 0
Z9 0
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1756 1841
EI 1756 185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PY 2008
VL 11
IS 4
BP 327
EP 334
DI 10.1111/j.1756 185X.2008.00395.x
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 450HO
UT WOS:000266391800003
DA 2025 08 17
ER

PT J
AU Chukir, T
   Liu, Y
   Hoffman, K
   Bilezikian, JP
   Farooki, A
AF Chukir, Tariq
   Liu, Yi
   Hoffman, Katherine
   Bilezikian, John P.
   Farooki, Azeez
TI Calcitriol Elevation Is Associated with a Higher Risk of Refractory
   Hypercalcemia of Malignancy in Solid Tumors
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE hypercalcemia; parathyroid hormone related peptide; calcitriol; vitamin
   D; hypercalcemia of malignancy
ID D MEDIATED HYPERCALCEMIA; VITAMIN D METABOLISM; 25 HYDROXYVITAMIN
   D 1 ALPHA HYDROXYLASE; PRIMARY HYPERPARATHYROIDISM; HUMORAL
   HYPERCALCEMIA; PHOSPHATE TREATMENT; BONE RESORPTION; PROTEIN; PTHRP;
   PHOSPHORUS
AB Background: Hypercalcemia of malignancy (HCM) is a common complication of advanced cancer. PTH independent HCM may be mediated through different mechanisms: (1) humoral HCM, caused by the secretion of PTH related peptide (PTHrP), (2) local osteolysis resulting from metastatic lesions, and (3) calcitriol mediated hypercalcemia. Calcitriol mediated HCM in patients with nonlymphomatous solid tumors is thought to be rare.
   Methods: We performed a retrospective chart review from 2008 to 2017 to characterize further patients at our institution with solid tumors who had HCM with concomitant elevations in calcitriol. Patients with PTH dependent hypercalcemia and patients with evidence of granulomatous disease were excluded, as were patients with hematologic malignancies. We hypothesized that patients with HCM and elevated calcitriol levels would respond less favorably to treatment with antiresorptive therapy compared with patients with HCM but without calcitriol elevation. We also aimed to assess mortality and determine if PTHrP and phosphorus levels correlate with calcitriol because both factors may alter calcitriol levels.
   Results: Of 101 eligible patients, calcitriol was elevated in 45 (45%). PTHrP was elevated in 76% of patients with elevated calcitriol compared with 52% of patients without calcitriol elevation. The mean PTHrP value did not differ between patients with HCM and elevated calcitriol (36.3 +/  22 pg/mL) and those without calcitriol elevation (37.4 +/  19 pg/mL). Those with elevated calcitriol levels generally did not respond completely to antiresorptive treatment (80% incomplete response rate), whereas most patients without an elevation in calcitriol responded well to antiresorptive treatment (78% response rate: P < .001). There was no significant difference in the percentage of patients with metastatic bone disease among the 2 groups (49% vs. 55%, respectively). There was no difference in mortality between the 2 groups (P = .14). A weak but significant negative correlation was found between phosphorus and calcitriol (Pearson r =  0.261, P = .016). This correlation was only significant in patients without calcitriol elevation (Pearson r =  0.4, P = .0082). Also, a significant negative correlation was found between PTHrP and phosphorus, again only in patients without calcitriol elevation.
   Discussion: In the setting of HCM, patients with calcitriol elevation are much less likely to respond to antiresorptive therapy than patients without calcitriol elevation. Because calcitriol elevation did not appear to be correlated with hypophosphatemia or elevated PTHrP, it would appear that calcitriol production under these conditions is autonomous, and not subject to normal physiological controls. These observations indicate that calcitriol elevations in patients with HCM have clinical significance.
C1 [Chukir, Tariq; Farooki, Azeez] Mem Sloan Kettering Canc Ctr, Dept Med, Endocrinol Serv, 1275 York Ave, New York, NY 10021 USA.
   [Chukir, Tariq] NewYork Presbyterian Weill Cornell Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, New York, NY 10065 USA.
   [Liu, Yi] Lahey Hosp & Med Ctr, Dept Med, Burlington, MA 01805 USA.
   [Hoffman, Katherine] Weill Cornell Med, Dept Healthcare Policy & Res, Div Biostat & Epidemiol, New York Presbyterian Hosp, New York, NY 10065 USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
C3 Memorial Sloan Kettering Cancer Center; Cornell University; Weill
   Cornell Medicine; Lahey Hospital & Medical Center; NewYork Presbyterian
   Hospital; Cornell University; Weill Cornell Medicine; Columbia
   University
RP Chukir, T (通讯作者)，Weill Cornell Med Ctr, NewYork Presbyterian Hosp, New York, NY 10065 USA.
EM tac2007@nyp.org
FU NIH/NCI Cancer Center Support Grant [P30 CA008748]
FX This research was supported in part by the NIH/NCI Cancer Center Support
   Grant P30 CA008748.
CR AKAI PS, 1989, CLIN INVEST MED, V12, P212
   Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006 0021
   AXELROD DM, 1987, CANCER AM CANCER SOC, V60, P1620, DOI 10.1002/1097 0142(19871001)60:7<1620::AID CNCR2820600733>3.0.CO;2 3
   BURTIS WJ, 1987, J BIOL CHEM, V262, P7151
   Chong WH, 2011, ENDOCR RELAT CANCER, V18, pR53, DOI 10.1530/ERC 11 0006
   Conron M, 2000, SARCOIDOSIS VASC DIF, V17, P277
   DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990
   Donovan PJ, 2015, J CLIN ENDOCR METAB, V100, P2024, DOI 10.1210/jc.2014 4250
   Donovan PJ, 2013, J CLIN ENDOCR METAB, V98, P4023, DOI 10.1210/jc.2013 2016
   FUSS M, 1992, CLIN RHEUMATOL, V11, P28, DOI 10.1007/BF02207080
   GOLDSMITH RS, 1966, NEW ENGL J MED, V274, P1, DOI 10.1056/NEJM196601062740101
   Gomes LD, 2015, ARCH ENDOCRIN METAB, V59, P84
   Hewison M, 2003, J BONE MINER RES, V18, P579, DOI 10.1359/jbmr.2003.18.3.579
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Hu MI, 2014, J CLIN ENDOCR METAB, V99, P3144, DOI 10.1210/jc.2014 1001
   Latifyan SB, 2014, BMJ CASE REP, V2014
   Liamis G, 2010, QJM INT J MED, V103, P449, DOI 10.1093/qjmed/hcq039
   Lieben L, 2012, J CLIN INVEST, V122, P1803, DOI 10.1172/JCI45890
   McCarthy K, 2009, ANTICANCER RES, V29, P155
   Mundy GR, 2008, J AM SOC NEPHROL, V19, P672, DOI 10.1681/ASN.2007090981
   Perwad F, 2011, MOL CELL ENDOCRINOL, V347, P17, DOI 10.1016/j.mce.2011.08.030
   Rosner MH, 2014, ADV CHRONIC KIDNEY D, V21, P7, DOI 10.1053/j.ackd.2013.05.005
   ROSOL TJ, 1988, J BONE MINER RES, V3, P699
   SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801
   SEYMOUR JF, 1994, ANN INTERN MED, V121, P633, DOI 10.7326/0003 4819 121 9 199411010 00001
   SEYMOUR JF, 1993, BLOOD, V82, P1383
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Tangpricha V, 2001, LANCET, V357, P1673, DOI 10.1016/S0140 6736(00)04831 5
   Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016 1070
   THALASSINOS N, 1968, BMJ BRIT MED J, V4, P14, DOI 10.1136/bmj.4.5622.14
   TORRING O, 1992, ENDOCRINOLOGY, V131, P5, DOI 10.1210/en.131.1.5
   Uy HL, 1997, CANCER RES, V57, P3194
NR 32
TC 21
Z9 21
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2020
VL 105
IS 4
AR dgz278
DI 10.1210/clinem/dgz278
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LD3RP
UT WOS:000525950100109
PM 31841590
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Chen, LL
   Song, Z
   Wu, JY
   Huang, QT
   Shen, ZS
   Wei, X
   Lin, ZM
AF Chen, Lingling
   Song, Zhi
   Wu, Jinyan
   Huang, Qiting
   Shen, Zongshan
   Wei, Xi
   Lin, Zhengmei
TI LncRNA DANCR sponges miR 216a to inhibit odontoblast differentiation
   through upregulating c Cbl
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE DANCR; Cell differentiation; Odontogenesis; MiR 216a; c Cbl
ID HUMAN DENTAL PULP; PROMOTE OSTEOBLAST DIFFERENTIATION; ODONTOGENIC
   DIFFERENTIATION; CELLS
AB Enhanced odontoblast differentiation of human dental pulp cells (hDPCs) is considered a keystone in dentin pulp complex formation. We have revealed lncRNA DANCR was implicated in this differentiation program, however, its mechanism in odontoblast differentiation of hDPCs remains further explored. In this study, by employing loss of function approach, we identified downregulation of DANCR drived odontoblast differentiaion of hDPCs. Bioinformatics analysis was utilized to show that DANCR contained binding site for miR 216a and an inverse correlation between DANCR and miR 216a was obtained. Dual luciferase reporter assay and RNA binding protein immunoprecipitation (RIP) were applied to further confirm that DANCR conferred its functions by directly binding to miR 216a. Notably, miR 216a was able to bind to the 3' UTR of c Cbl and repressed its expression. In addition, the protein level of c CBL was Significantly downregulated during hDPCs differentiation while c Cbl overexpression inhibited odontoblast differentiation of hDPCs. Moreover, downregulation of miR 216a efficiently reversed the suppression of c Cbl level and odontoblast differentiation induced by knockdown of DANCR. Taken together, these analyses indicated that DANCR positively regulated the expression of c Cbl, through sponging miR 216a, and inhibited odontoblast differentiation of hDPCs. Our results will extend the field of clinical application for cell based therapy in regenerative medicine.
C1 [Chen, Lingling; Song, Zhi; Wu, Jinyan; Huang, Qiting; Shen, Zongshan; Wei, Xi; Lin, Zhengmei] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Operat Dent & Endodont, Guangzhou 510055, Guangdong, Peoples R China.
   [Chen, Lingling; Song, Zhi; Wu, Jinyan; Huang, Qiting; Shen, Zongshan; Wei, Xi; Lin, Zhengmei] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Wei, X; Lin, ZM (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, 56 Lingyuan West Rd, Guangzhou 510055, Peoples R China.
EM chenlling5@mail.sysu.edu.cn; songzh@mail.sysu.edu.cn;
   wujinyan@mail2.sysu.edu.cn; huangqt25@mail.sysu.edu.cn;
   shenzsh@mail2.sysu.edu.cn; weixi@mail.sysu.edu.cn;
   linzhm@mail.sysu.edu.cn
RI ; JINYAN, WU/IQR 4321 2023; Wei, Xi/AGY 9165 2022
OI Wei, Xi/0000 0002 5749 2910; Shen, Zongshan/0000 0003 2652 3507; Wu,
   Jinyan/0000 0001 7346 8542; 
FU National Natural Science Foundation of China [81900990, 81670984]; China
   Postdoctoral Science Foundation [2018M633252]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81900990, 81670984) and China
   Postdoctoral Science Foundation Funded Project (Project No.
   2018M633252). The authors declare that they do not have any conflicting
   financial interests.
CR [Anonymous], 2017, BIOSCI REP
   Carlevaro Fita J, 2019, MOL CELL, V73, P869, DOI 10.1016/j.molcel.2019.02.008
   Chen LL, 2016, CELL TISSUE RES, V364, P309, DOI 10.1007/s00441 015 2333 2
   Choi YH, 2015, BONE, V75, P201, DOI 10.1016/j.bone.2015.02.026
   Fiscon G, 2018, GENES BASEL, V9, DOI 10.3390/genes9090437
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Jiang N, 2017, CANCER LETT, V405, P46, DOI 10.1016/j.canlet.2017.06.009
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Liang HL, 2019, J CELL PHYSIOL, V234, P7266, DOI 10.1002/jcp.27484
   Liu FX, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1146 8
   Martín González J, 2019, ARCH ORAL BIOL, V98, P126, DOI 10.1016/j.archoralbio.2018.11.019
   Namekawa SH, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2010.195
   Ozeki N, 2016, EXP CELL RES, V341, P92, DOI 10.1016/j.yexcr.2016.01.010
   Phung S, 2017, J DENT RES, V96, P107, DOI 10.1177/0022034516675152
   Sardina DS, 2017, BRIEF BIOINFORM, V18, P1071, DOI 10.1093/bib/bbw084
   Scanlon V, 2017, BONE, V95, P124, DOI 10.1016/j.bone.2016.11.020
   Sen R, 2014, SCI WORLD J, DOI 10.1155/2014/896206
   Sohn S, 2015, J DENT RES, V94, P1560, DOI 10.1177/0022034515608128
   Song Z, 2017, INT ENDOD J, V50, P685, DOI 10.1111/iej.12678
   Song Z, 2017, J ENDODONT, V43, P315, DOI 10.1016/j.joen.2016.10.021
   Ulitsky I, 2018, FEBS LETT, V592, P2874, DOI 10.1002/1873 3468.13085
   Wang F, 2019, EXP CELL RES, V375, P1, DOI 10.1016/j.yexcr.2018.11.005
   Wu XS, 2017, EMBO REP, V18, P1837, DOI 10.15252/embr.201744147
   Xiao XX, 2017, INT J CARDIOL, V243, P404, DOI 10.1016/j.ijcard.2017.05.037
   Yang L, 2019, MOL THER, V27, P394, DOI 10.1016/j.ymthe.2018.11.019
   Yang XR, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1094 8
   Yi JY, 2019, CELL TISSUE RES, V376, P113, DOI 10.1007/s00441 018 2963 2
   Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180
   Yuan H., 2019, CELL DEATH DIFFER
   Yuan X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 0951 9
   Zhao Y, 2018, J DENT RES, V97, P1047, DOI 10.1177/0022034518763151
NR 31
TC 13
Z9 13
U1 0
U2 13
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD FEB 1
PY 2020
VL 387
IS 1
AR 111751
DI 10.1016/j.yexcr.2019.111751
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA KF7LN
UT WOS:000509420800015
PM 31805275
DA 2025 08 17
ER

PT J
AU Hartl, A
   Sieper, J
   Syrbe, U
   Listing, J
   Hermann, KG
   Rudwaleit, M
   Poddubnyy, D
AF Hartl, Agnes
   Sieper, Joachim
   Syrbe, Uta
   Listing, Joachim
   Hermann, Kay Geert
   Rudwaleit, Martin
   Poddubnyy, Denis
TI Serum levels of leptin and high molecular weight adiponectin are
   inversely associated with radiographic spinal progression in patients
   with ankylosing spondylitis: results from the ENRADAS trial
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Axial spondyloarthritis; Ankylosing spondylitis; Leptin; Adiponectin;
   Adipokine; Radiographic progression; Syndesmophytes
ID SPONDYLOARTHRITIS INCEPTION COHORT; SYMPATHETIC NERVOUS SYSTEM; MAPK
   SIGNALING PATHWAY; STRUCTURAL DAMAGE; AXIAL SPONDYLOARTHRITIS; HUMAN
   OSTEOBLASTS; DISEASE ACTIVITY; BONE METABOLISM; SYNDESMOPHYTE FORMATION;
   INSULIN RESISTANCE
AB Background: Previous research indicates a role of adipokines in inflammation and osteogenesis. Hence adipokines might also have a pathophysiological role in inflammation and new bone formation in patients with ankylosing spondylitis (AS). The aim of this study was to investigate the role of adipokine serum levels as predictors of radiographic spinal progression in patients with AS.
   Methods: A total of 120 patients with definite AS who completed a 2 year follow up in the ENRADAS trial were included in the current study. Radiographic spinal progression was defined as: (1) worsening of the modified Stoke Ankylosing Spondylitis spine (mSASSS) score by >= 2 points and/or (2) new syndesmophyte formation or progression of existing syndesmophytes after 2 years. Serum levels of adipokines (adiponectin (APN) and its high molecular weight form (HMW APN), chemerin, leptin, lipocalin 2, omentin, resistin, visfatin) were measured using enzyme linked immunosorbent assays.
   Results: There was a significant association between radiographic spinal progression and both leptin and HMW APN. Baseline serum levels of both adipokines were lower in patients who showed radiographic spinal progression after 2 years. This association was especially evident in men; they had generally lower leptin and HMW APN serum levels as compared to women. The inverse association between adipokines and radiographic spinal progression was confirmed in the logistic regression analysis: the odds ratios (OR) for the outcome "no mSASSS progression >= 2 points" were 1.16 (95% CI 1.03 to 1.29) and 1.17 (95% CI 0.99 to 1.38), for leptin and HMW APN, respectively; for "no syndesmophyte formation/progression" the respective OR were 1.29 (95% CI 1.11 to 1.50) and 1.18 (95% CI 0.98 to 1.42), adjusted for the presence of syndesmophytes at baseline, C reactive protein at baseline, sex, body mass index (BMI), non steroidal anti inflammatory drugs intake score over 2 years, and smoking status at baseline.
   Conclusion: Serum leptin and HMW APN predict protection from spinal radiographic progression in patients with AS. Women generally have higher leptin and HMW APN serum levels that might explain why they have less structural damage in the spine as compared to male patients with AS.
C1 [Hartl, Agnes; Sieper, Joachim; Syrbe, Uta; Poddubnyy, Denis] Charite, Dept Gastroenterol Infectiol & Rheumatol, Hindenburgdamm 30, D 12203 Berlin, Germany.
   [Listing, Joachim; Poddubnyy, Denis] German Rheumatism Res Ctr, Charite Pl 1, D 10117 Berlin, Germany.
   [Hermann, Kay Geert] Charite, Dept Radiol, Charite Pl 1, D 10117 Berlin, Germany.
   [Rudwaleit, Martin] Klinikum Bielefeld Rosenhohe, Rosenhohe 27, D 33647 Bielefeld, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Leibniz Association; Deutsches
   Rheuma Forschungszentrum (DRFZ); Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Poddubnyy, D (通讯作者)，Charite, Dept Gastroenterol Infectiol & Rheumatol, Hindenburgdamm 30, D 12203 Berlin, Germany.; Poddubnyy, D (通讯作者)，German Rheumatism Res Ctr, Charite Pl 1, D 10117 Berlin, Germany.
EM denis.poddubnyy@charite.de
RI Syrbe, Uta/T 7557 2017; Poddubnyy, Denis/V 1985 2019; Rudwaleit,
   Martin/AAK 7838 2020; Hermann, Kay Geert/I 6267 2019
OI Syrbe, Uta/0000 0001 8463 7890; Poddubnyy, Denis/0000 0002 4537 6015;
   Hermann, Kay Geert A/0000 0001 6142 3814
FU German Ministry of Education and Research (Bundesministerium for Bildung
   und Forschung   BMBF) [FKZ 01KG0801]; BMBF [FKZ 01EC1407A, FKZ
   01EC1401A]; clinical research unit (CRU) of the Berlin Institute of
   Health (BIH)
FX This ENRADAS trial was funded by the German Ministry of Education and
   Research (Bundesministerium for Bildung und Forschung   BMBF), grant
   number: FKZ 01KG0801. The biomarker analysis was conducted as a part of
   METARTHROS (grant number FKZ 01EC1407A) and ArthroMark (FKZ 01EC1401A)
   projects funded by BMBF; additional support was obtained from the
   clinical research unit (CRU) of the Berlin Institute of Health (BIH).
   The initial study drug diclofenac was provided by Novartis as a
   donation.
CR Abella V, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/343746
   Andreasson AN, 2012, AM J HUM BIOL, V24, P595, DOI 10.1002/ajhb.22279
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P1819, DOI 10.1136/annrheumdis 2013 203425
   Baraliakos X, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2496
   Baraliakos X, 2009, J RHEUMATOL, V36, P997, DOI 10.3899/jrheum.080871
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Biver E, 2011, J CLIN ENDOCR METAB, V96, P2703, DOI 10.1210/jc.2011 0047
   Chen XX, 2015, J BONE MINER METAB, V33, P474, DOI 10.1007/s00774 014 0569 7
   Creemers MCW, 2005, ANN RHEUM DIS, V64, P127, DOI 10.1136/ard.2004.020503
   Derdemezis CS, 2010, CLIN EXP RHEUMATOL, V28, P880
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Feldtkeller E, 2000, CURR OPIN RHEUMATOL, V12, P239, DOI 10.1097/00002281 200007000 00002
   Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156
   Hamrick MW, 2004, BONE, V34, P376, DOI 10.1016/j.bone.2003.11.020
   Hara K, 2006, DIABETES CARE, V29, P1357, DOI 10.2337/dc05 1801
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Huang CY, 2010, J CELL PHYSIOL, V224, P475, DOI 10.1002/jcp.22145
   Kim KJ, 2012, CLIN RHEUMATOL, V31, P1231, DOI 10.1007/s10067 012 1999 z
   Landewé R, 2009, ANN RHEUM DIS, V68, P863, DOI 10.1136/ard.2008.091793
   Lew J, 2017, CIRCULATION, V135, P544, DOI 10.1161/CIRCULATIONAHA.116.023005
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Machado P, 2010, ANN RHEUM DIS, V69, P1465, DOI 10.1136/ard.2009.124206
   Machado PM, 2016, ANN RHEUM DIS, V75, P1486, DOI 10.1136/annrheumdis 2015 208011
   Maksymowych WP, 2007, ARTHRITIS RHEUM US, V56, P1846, DOI 10.1002/art.22589
   Martin A, 2007, ENDOCRINOLOGY, V148, P3419, DOI 10.1210/en.2006 1541
   Mei YJ, 2016, ARCH MED RES, V47, P111, DOI 10.1016/j.arcmed.2016.03.001
   Miranda Filloy JA, 2013, CLIN EXP RHEUMATOL, V31, P538
   Neumann E, 2011, ARTHRITIS RHEUM US, V63, P1159, DOI 10.1002/art.30291
   Neumann E, 2016, NAT REV RHEUMATOL, V12, P296, DOI 10.1038/nrrheum.2016.49
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200
   Park MC, 2007, SCAND J RHEUMATOL, V36, P101, DOI 10.1080/03009740600991760
   Poddubnyy D, 2016, ANN RHEUM DIS, V75, P2114, DOI 10.1136/annrheumdis 2016 209209
   Poddubnyy D, 2014, ANN RHEUM DIS, V73, P2137, DOI 10.1136/annrheumdis 2013 203824
   Poddubnyy D, 2013, ANN RHEUM DIS, V72, P1430, DOI 10.1136/annrheumdis 2012 203148
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Ramiro S, 2015, ANN RHEUM DIS, V74, P52, DOI 10.1136/annrheumdis 2013 204055
   Ramiro S, 2014, ANN RHEUM DIS, V73, P1455, DOI 10.1136/annrheumdis 2014 205178
   Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426
   Sari I, 2007, CLIN RHEUMATOL, V26, P1427, DOI 10.1007/s10067 006 0509 6
   Scotece M, 2014, EXPT OPIN DRUG DISCO, V24, P1
   Sieper J, 2016, ANN RHEUM DIS, V75, P1438, DOI 10.1136/annrheumdis 2015 207897
   Sodi R, 2009, CLIN BIOCHEM, V42, P1375, DOI 10.1016/j.clinbiochem.2009.06.003
   Syrbe U, 2015, ARTHRITIS RHEUMATOL, V67, P678, DOI 10.1002/art.38968
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Toussirot É, 2007, METABOLISM, V56, P1383, DOI 10.1016/j.metabol.2007.05.009
   Toussirot É, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00453
   Turina MC, 2014, ANN RHEUM DIS, V73, P1746, DOI 10.1136/annrheumdis 2014 205506
   Vadacca M, 2011, CELL MOL IMMUNOL, V8, P203, DOI 10.1038/cmi.2010.75
   van der Heijde D, 2012, ANN RHEUM DIS, V71, P369, DOI 10.1136/annrheumdis 2011 200208
   van Tubergen A, 2012, ANN RHEUM DIS, V71, P518, DOI 10.1136/annrheumdis 2011 200411
   Wang Y, 2007, CLIN CHEM, V53, P34, DOI [10.1373/clinchem.2006.075614, 10.1007/s11461 007 0005 4]
NR 58
TC 42
Z9 44
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JUN 15
PY 2017
VL 19
AR 140
DI 10.1186/s13075 017 1350 9
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA EY4LK
UT WOS:000403949300003
PM 28619118
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yaqoob, Z
   Batool, SA
   Basit, MA
   Konain, K
   Malik, RA
   Rehman, SU
   Hussain, SW
   Alrobei, H
   Rehman, MAU
AF Yaqoob, Zahida
   Batool, Syeda Ammara
   Basit, Muhammad Abdul
   Konain, Kiran
   Malik, Rizwan Ahmed
   Rehman, Saeed Ur
   Hussain, Syed Wilayat
   Alrobei, Hussein
   Rehman, Muhammad Atiq Ur
TI Hydrothermal synthesis of carbon dots incorporated in magnetite iron
   oxide nanoparticles for potential targeted brain cancer therapy:
   In Vitro study
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE Carbon dots; Magnetite nanoparticles; Magnetic behavior; Brain cancer
   therapy; Biocompatible
ID FE3O4 NANOPARTICLES; QUANTUM DOTS; DIAGNOSIS; TOXICITY; REMOVAL
AB Surface modification of magnetite (Fe3O4) nanoparticles (NPs) using carbon dots (CDs) is a promising approach in biomedical applications due to excellent biocompatibility. Herein, the CDs were incorporated in the Fe3O4 NPs to observe the performance of CDs Fe3O4 NPs for targeted brain cancer therapy. Scanning electron microscopy (SEM) images revealed the morphology of Fe3O4 NPs is rough and agglomerated. X ray diffraction (XRD) diffraction pattern exhibits that the CDs are successfully incorporated in Fe3O4 NPs. Furthermore, magnetic properties evaluated using vibrating sample magnetometer (VSM) exhibited significant magnetization (51.362 emu/g) attributed to the greater occupancy of Fe+2 ions in the crystal lattice. XRD pattern confirmed the formation of NPs. Furthermore, functional groups of the NPs were validated through Fourier transform infrared spectroscopy (FT IR). The measurement of zeta potential affirmed the stability of the as prepared Fe3O4 NPs, CDs, and CDs Fe3O4 NPs, indicating a value of  7.64 mV,  0.5754 mV and  3.881 mV, respectively. Fe3O4 NPs exhibited a surface area of 58.6 m2/g as determined by Brunauer Emmett Teller (BET) analysis. The anticancer activity of the synthesized CDs Fe3O4 NPs demonstrated inhibition against MG U87 cells. Therefore, the synthesized CDs Fe3O4 NPs hold potential for application in brain cancer therapy. In addition, CDs Fe3O4 NPs exhibited exceptional biocompatibility and low cytotoxicity against osteoblast cells, establishing them as a safe biomaterial for biomedical applications.
C1 [Yaqoob, Zahida; Rehman, Muhammad Atiq Ur] Govt Coll Univ Lahore, Ctr Excellence Biomat & Tissue Engn, Lahore 54000, Pakistan.
   [Yaqoob, Zahida; Batool, Syeda Ammara; Basit, Muhammad Abdul; Hussain, Syed Wilayat] Inst Space Technol, Dept Mat Sci & Engn, Islamabad 44000, Pakistan.
   [Malik, Rizwan Ahmed; Alrobei, Hussein] Prince Sattam bin Abdulaziz Univ, Coll Engn, Dept Mech Engn, Al kharj 11942, Saudi Arabia.
   [Konain, Kiran] Khyber Med Univ, Inst Basic Med Sci, Mol Biol, Peshawar 25000, Pakistan.
   [Rehman, Saeed Ur] Khyber Med Univ, Inst Basic Med Sci, Oral Biol, Peshawar 25000, Pakistan.
C3 Government College University Lahore; Prince Sattam Bin Abdulaziz
   University; Khyber Medical University; Khyber Medical University
RP Alrobei, H (通讯作者)，Prince Sattam bin Abdulaziz Univ, Coll Engn, Dept Mech Engn, Al kharj 11942, Saudi Arabia.
EM H.alrobei@psau.edu.sa
RI Reman, Saeed/U 8587 2019; Ur Rehman, Muhammad Atiq/KZT 8481 2024;
   Rahman, Saeed Ur/H 1957 2018; Basit, Muhammad/AAA 2162 2020; Malik,
   Rizwan Ahmed/O 1146 2016; Alrobei, Hussein/GQH 3287 2022; Ur Rehman,
   Muhammad Atiq/P 8835 2017; Batool, SyedaAmmara/KHZ 1095 2024
OI konain, kiran/0000 0002 1084 7630; Rahman, Saeed Ur/0000 0003 2234 2274;
   Ur Rehman, Muhammad Atiq/0000 0001 5201 973X; Batool, Syeda
   Ammara/0000 0001 8012 828X; 
FU Prince Sattam bin Abdulaziz University [PSAU/2024/R/1445]
FX This study is supported via funding from Prince Sattam bin Abdulaziz
   University project number (PSAU/2024/R/1445) .
CR Ahmed SR, 2019, ACS APPL NANO MATER, V2, P2076, DOI 10.1021/acsanm.9b00071
   Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571 019 0177 5
   Bhattacharya T, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15031019
   Cailotto S, 2018, ACS MED CHEM LETT, V9, P832, DOI 10.1021/acsmedchemlett.8b00240
   Chung SK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.711534
   Costley D, 2015, INT J HYPERTHER, V31, P107, DOI 10.3109/02656736.2014.992484
   Deotale AJ, 2016, MATER TODAY PROC, V3, P2069, DOI 10.1016/j.matpr.2016.04.110
   Dheyab MA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67869 8
   Dordevic L, 2022, NAT NANOTECHNOL, V17, P112, DOI 10.1038/s41565 021 01051 7
   Ebadi M, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15040971
   Ehteshamzadeh T, 2021, J SUPERCOND NOV MAGN, V34, P3345, DOI 10.1007/s10948 021 05952 5
   Figuerola A, 2010, PHARMACOL RES, V62, P126, DOI 10.1016/j.phrs.2009.12.012
   Ilyas Sultan, 2019, Nano Structures & Nano Objects, V20, P101, DOI 10.1016/j.nanoso.2019.100396
   Jiang WQ, 2023, CANCERS, V15, DOI 10.3390/cancers15030585
   Jin CC, 2020, INT J MED SCI, V17, P2964, DOI 10.7150/ijms.49801
   Joshi B, 2022, DRUG DELIV TRANSL RE, V12, P1588, DOI 10.1007/s13346 021 01063 9
   Kadry H, 2020, FLUIDS BARRIERS CNS, V17, DOI 10.1186/s12987 020 00230 3
   Konain K., 2023, Precision medicine communications biomarker guided drug repurposing and angiotensin 2 receptor type 1 in brain tumor molecular validation of 3, P27, DOI [10.55627/pmc.003.001.0296, DOI 10.55627/PMC.003.001.0296]
   Li HT, 2012, J MATER CHEM, V22, P24230, DOI 10.1039/c2jm34690g
   Li L, 2019, SUSTAIN ENERG FUELS, V3, P1749, DOI 10.1039/c9se00240e
   Loh KS, 2008, SENSORS BASEL, V8, P5775, DOI 10.3390/s8095775
   Lu F, 2019, MATER RES EXPRESS, V6, DOI 10.1088/2053 1591/ab0c55
   Luo N, 2019, ACS APPL NANO MATER, V2, P3951, DOI 10.1021/acsanm.9b00854
   Ma X, 2016, MATER TECHNOL, V31, P23, DOI 10.1080/10667857.2016.1232644
   Magrez A, 2006, NANO LETT, V6, P1121, DOI 10.1021/nl060162e
   Maleki Ghaleh H, 2016, J MATER ENG PERFORM, V25, P2331, DOI 10.1007/s11665 016 2086 4
   Mehdinia A, 2020, J FOOD MEAS CHARACT, V14, P725, DOI 10.1007/s11694 019 00319 w
   Mohammadi H, 2021, TOXICOL REP, V8, P331, DOI 10.1016/j.toxrep.2021.01.012
   Nafchi RF, 2022, LANGMUIR, V38, P3804, DOI 10.1021/acs.langmuir.1c03458
   Nalbandian L, 2016, CURR NANOSCI, V12, P455, DOI 10.2174/1573413712666151210230002
   Nan XY, 2017, ACS APPL MATER INTER, V9, P9986, DOI 10.1021/acsami.6b16486
   Peng S, 2011, ANGEW CHEM INT EDIT, V50, P3158, DOI 10.1002/anie.201007794
   Radu T, 2017, APPL SURF SCI, V405, P337, DOI 10.1016/j.apsusc.2017.02.002
   Rahman MSU, 2020, RSC ADV, V10, P21413, DOI 10.1039/c9ra09349d
   Ren QL, 2021, ACS OMEGA, V6, P6361, DOI 10.1021/acsomega.0c06276
   Rezayan AH, 2016, J MAGN MAGN MATER, V420, P210, DOI 10.1016/j.jmmm.2016.07.003
   Shaikh AF, 2019, J NANOSCI NANOTECHNO, V19, P2339, DOI 10.1166/jnn.2019.16537
   Shao JX, 2019, J NANOPART RES, V21, DOI 10.1007/s11051 019 4518 1
   Siddique A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28021 9
   Stachowska JD, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12040674
   Sutanto H, 2020, AIP ADV, V10, DOI 10.1063/5.0004595
   Tang MY, 2020, NEW J CHEM, V44, P6635, DOI 10.1039/d0nj00275e
   Wagner AM, 2019, ACTA BIOMATER, V94, P44, DOI 10.1016/j.actbio.2019.05.022
   Wang CX, 2019, ACS OMEGA, V4, P1652, DOI 10.1021/acsomega.8b03157
   Wang H, 2014, BIOMATER SCI UK, V2, P915, DOI 10.1039/c3bm60297d
   Wang XQ, 2021, BIOMATERIALS, V266, DOI 10.1016/j.biomaterials.2020.120474
   Pham XN, 2016, ADV NAT SCI NANOSCI, V7, DOI 10.1088/2043 6262/7/4/045010
   Yang XL, 2015, SCI REP UK, V5, DOI 10.1038/srep10632
   Zhang L, 2018, NANO LETT, V18, P7609, DOI 10.1021/acs.nanolett.8b03178
   Zhang M, 2018, CHEM ENG J, V338, P526, DOI 10.1016/j.cej.2018.01.081
   Zhang Q, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27071 4
   Zheng M, 2015, ACS NANO, V9, P11455, DOI 10.1021/acsnano.5b05575
   Zheng XT, 2015, SMALL, V11, P1620, DOI 10.1002/smll.201402648
   Zhu LZ, 2009, COLLOID SURFACE B, V68, P1, DOI 10.1016/j.colsurfb.2008.07.020
NR 54
TC 6
Z9 6
U1 2
U2 7
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254 0584
EI 1879 3312
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD SEP 15
PY 2024
VL 324
AR 129698
DI 10.1016/j.matchemphys.2024.129698
EA JUL 2024
PG 10
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA YY1A2
UT WOS:001271944900001
DA 2025 08 17
ER

PT J
AU Hrubi, E
   Imre, L
   Robaszkiewicz, A
   Virág, L
   Kerényi, F
   Nagy, K
   Varga, G
   Jenei, A
   Hegedüs, C
AF Hrubi, Edit
   Imre, Laszlo
   Robaszkiewicz, Agnieszka
   Virag, Laszlo
   Kerenyi, Farkas
   Nagy, Krisztina
   Varga, Gabor
   Jenei, Attila
   Hegedus, Csaba
TI Diverse effect of BMP 2 homodimer on mesenchymal progenitors of
   different origin
SO HUMAN CELL
LA English
DT Article
DE Stem cells; Osteogenic differentiation; Alizarin red; Alkaline
   phosphatase; Growth factor
ID ENHANCE OSTEOGENIC DIFFERENTIATION; BETA GLYCEROPHOSPHATE; STEM CELLS;
   BONE; MECHANISM; THERAPY
AB Bone morphogenetic protein 2 (BMP 2), is a potential factor to enhance osseointegration of dental implants. However, the appropriate cellular system to investigate the osteogenic effect of BMP 2 in vitro in a standardized manner still needs to be defined. The aim of this study was to examine the effect of BMP 2 on the cell proliferation and osteogenic differentiation of human osteogenic progenitors of various origins: dental pulp stem cells (DPSC), human osteosarcoma cell line (Saos 2) and human embryonic palatal mesenchymal cell line (HEPM). For induction of osteogenic differentiation, cell culture medium was supplemented with BMP 2 homodimer alone or in combination with conventionally used differentiation inducing agents. Differentiation was monitored for 6 18 days. To assess differentiation, proliferation rate, alkaline phosphatase activity, calcium deposition and the expression level of osteogenic differentiation marker genes (Runx2, BMP 2) were measured. BMP 2 inhibited cell proliferation in a concentration and time dependent manner. In a concentration which caused maximal cell proliferation, BMP 2 did not induce osteogenic differentiation in any of the tested systems. However, it had a synergistic effect with the osteoinductive medium in both DPSC and Saos 2, but not in HEPM cells. We also found that the differentiation process was faster in Saos 2 than in DPSCs. Osteogenic differentiation could not be induced in the osteoblast progenitor HEPM cells. Our data suggest that in a concentration that inhibits proliferation the differentiation inducing effect of BMP 2 is evident only in the presence of permissive osteoinductive components. beta glycerophosphate, was identified interacting with BMP 2 in a synergistic manner.
C1 [Hrubi, Edit; Kerenyi, Farkas; Hegedus, Csaba] Univ Debrecen, Fac Dent, Nagyerdei Krt 98, H 4012 Debrecen, Hungary.
   [Imre, Laszlo; Jenei, Attila] Univ Debrecen, Dept Biophys & Cell Biol, Fac Med, Egyet Ter 1, H 4032 Debrecen, Hungary.
   [Robaszkiewicz, Agnieszka] Univ Lodz, Inst Biophys, Fac Biol & Environm Protect, Dept Gen Biophys, Pomorska 141 143, PL 90236 Lodz, Poland.
   [Robaszkiewicz, Agnieszka; Virag, Laszlo] Univ Debrecen, Dept Med Chem, Fac Med, Egyet Ter 1, H 4032 Debrecen, Hungary.
   [Nagy, Krisztina; Varga, Gabor] Semmelweis Univ, Dept Oral Biol, Nagyvarad Ter 4, H 1089 Budapest, Hungary.
C3 University of Debrecen; University of Debrecen; University of Lodz;
   University of Debrecen; Semmelweis University
RP Hrubi, E (通讯作者)，Univ Debrecen, Fac Dent, Nagyerdei Krt 98, H 4012 Debrecen, Hungary.
EM hrubi.edit@dental.unideb.hu
RI Varga, Gábor/O 8858 2017; Robaszkiewicz, Agnieszka/W 8394 2018; Virag,
   Laszlo/E 6124 2010
OI Robaszkiewicz, Agnieszka/0000 0002 6265 5585; Varga,
   Gabor/0000 0002 5506 8198; Virag, Laszlo/0000 0002 7099 6718
FU Nemzeti Kivalosag Program [TAMOP 4.2.4.A/2 11 1 2012 0001]; National
   Research, Development and Innovation Office Grants
   [GINOP 2.3.2 15 2016 00020 TUMORDNS,
   GINOP 2.3.2 15 2016 00048 STAYALIVE, OTKA K112336]; 
   [TAMOP 4.2.2.A 11/1/KONV 2012 0036]
FX This work was supported by TAMOP 4.2.2.A 11/1/KONV 2012 0036 and L. I.
   is supported by TAMOP 4.2.4.A/2 11 1 2012 0001 Nemzeti Kivalosag
   Program, L. V. is supported by the National Research, Development and
   Innovation Office Grants GINOP 2.3.2 15 2016 00020 TUMORDNS",
   GINOP 2.3.2 15 2016 00048 STAYALIVE, and OTKA K112336.
CR AHLERS J, 1975, BIOCHEM J, V149, P535, DOI 10.1042/bj1490535
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Boskey AL, 1996, J BONE MINER RES, V11, P1694
   Cruz ACC, 2012, J APPL ORAL SCI, V20, P628, DOI 10.1590/S1678 77572012000600007
   CHUNG CH, 1992, CALCIFIED TISSUE INT, V51, P305, DOI 10.1007/BF00334492
   Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523 1755.2000.00081.x
   He YL, 2015, STEM CELLS, V33, P1304, DOI 10.1002/stem.1925
   Kadar K, 2009, J PHYSIOL PHARMACOL, V60, P167
   Kaebisch C, 2015, COMPUT STRUCT BIOTEC, V13, P75, DOI 10.1016/j.csbj.2014.11.003
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Kerenyi Farkas, 2016, Fogorv Sz, V109, P29
   Khanna Jain R, 2010, GROWTH FACTORS, V28, P437, DOI 10.3109/08977194.2010.495719
   Kim HJ, 2010, BONE, V47, P657, DOI 10.1016/j.bone.2010.06.018
   Kim IS, 2008, DEV GROWTH DIFFER, V50, P553, DOI 10.1111/j.1440 169X.2008.01052.x
   Kim S, 2011, J BIOMED MATER RES B, V99B, P380, DOI 10.1002/jbm.b.31909
   Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Luther G, 2011, CURR GENE THER, V11, P229
   Maus U, 2008, J BIOMATER APPL, V22, P559, DOI 10.1177/0885328207083311
   Moustakas A, 2001, J CELL SCI, V114, P4359
   Nie XG, 2006, INT J DEV BIOL, V50, P511, DOI 10.1387/ijdb.052101.xn
   Robaszkiewicz A, 2012, FREE RADICAL BIO MED, V53, P1552, DOI 10.1016/j.freeradbiomed.2012.08.567
   Rutherford RB, 2003, J DENT RES, V82, P293, DOI 10.1177/154405910308200410
   Xia K, 2006, PLOS COMPUT BIOL, V2, P1482, DOI 10.1371/journal.pcbi.0020145
   Yamada Y, 2010, TISSUE ENG PT A, V16, P1891, DOI [10.1089/ten.tea.2009.0732, 10.1089/ten.TEA.2009.0732]
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yildirim S, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4682875
   Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821
NR 29
TC 19
Z9 23
U1 0
U2 14
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 1749 0774
J9 HUM CELL
JI Hum. Cell
PD APR
PY 2018
VL 31
IS 2
BP 139
EP 148
DI 10.1007/s13577 018 0202 5
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FZ5BN
UT WOS:000427606500006
PM 29442285
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Desancé, M
   Contentin, R
   Bertoni, L
   Gomez Leduc, T
   Branly, T
   Jacquet, S
   Betsch, JM
   Batho, A
   Legendre, F
   Audigié, F
   Galéra, P
   Demoor, M
AF Desance, Melanie
   Contentin, Romain
   Bertoni, Lelia
   Gomez Leduc, Tangni
   Branly, Thomas
   Jacquet, Sandrine
   Betsch, Jean Marc
   Batho, Agnes
   Legendre, Florence
   Audigie, Fabrice
   Galera, Philippe
   Demoor, Magali
TI Chondrogenic Differentiation of Defined Equine Mesenchymal Stem Cells
   Derived from Umbilical Cord Blood for Use in Cartilage Repair Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mesenchymal stem cells; umbilical cord blood; horse; cartilage
   engineering; chondrogenesis; extracellular matrix; RNA interference
ID MARROW STROMAL CELLS; BONE MARROW; ADIPOSE TISSUE; CLINICAL APPLICATION;
   MATRIX SYNTHESIS; SYNOVIAL FLUID; IN VITRO; CHONDROCYTES; COLLAGEN;
   MODEL
AB Cartilage engineering is a new strategy for the treatment of cartilage damage due to osteoarthritis or trauma in humans. Racehorses are exposed to the same type of cartilage damage and the anatomical, cellular, and biochemical properties of their cartilage are comparable to those of human cartilage, making the horse an excellent model for the development of cartilage engineering. Human mesenchymal stem cells (MSCs) differentiated into chondrocytes with chondrogenic factors in a biomaterial appears to be a promising therapeutic approach for direct implantation and cartilage repair. Here, we characterized equine umbilical cord blood derived MSCs (eUCB MSCs) and evaluated their potential for chondrocyte differentiation for use in cartilage repair therapy. Our results show that isolated eUCB MSCs had high proliferative capacity and differentiated easily into osteoblasts and chondrocytes, but not into adipocytes. A three dimensional (3D) culture approach with the chondrogenic factors BMP 2 and TGF 1 potentiated chondrogenic differentiation with a significant increase in cartilage specific markers at the mRNA level (Col2a1, Acan, Snorc) and the protein level (type II and IIB collagen) without an increase in hypertrophic chondrocyte markers (Col10a1 and Mmp13) in normoxia and in hypoxia. However, these chondrogenic factors caused an increase in type I collagen, which can be reduced using small interfering RNA targeting Col1a2. This study provides robust data on MSCs characterization and demonstrates that eUCB MSCs have a great potential for cartilage tissue engineering.
C1 [Desance, Melanie; Contentin, Romain; Gomez Leduc, Tangni; Branly, Thomas; Batho, Agnes; Legendre, Florence; Galera, Philippe; Demoor, Magali] UNICAEN, Normandie Univ, BIOTARGEN, F 14000 Caen, France.
   [Bertoni, Lelia; Jacquet, Sandrine; Audigie, Fabrice] Univ Paris Est, Ctr Imaging & Res Locomotor Affect Equines, Ecole Vet Alfort, F 14430 Goustranville, France.
   [Betsch, Jean Marc] Clin Vet Equine Meheudin, F 61150 Meheudin, Ecouche, France.
   [Batho, Agnes] EFS Caen, F 4EFS Caen, France.
C3 Universite de Caen Normandie; Ecole Nationale Veterinaire d'Alfort
   (ENVA)
RP Galéra, P; Demoor, M (通讯作者)，UNICAEN, Normandie Univ, BIOTARGEN, F 14000 Caen, France.
EM melanie359@hotmail.fr; romaincontentin@hotmail.fr;
   lelia.bertoni@vet alfort.fr; tangnigl@free.fr; tbranly@gmail.com;
   sandrine.jacquet@vet alfort.fr; jmbetsch@cvem.fr;
   Agnes.BATHO@efs.sante.fr; florence.legendre@unicaen.fr;
   fabrice.audigie@vet alfort.fr; philippe.galera@unicaen.fr;
   magali.demoor@unicaen.fr
RI Guibon, Sandrine/K 3929 2019
OI GALERA, Philippe/0000 0002 7797 2284; Demoor,
   Magali/0000 0002 8975 7055; Contentin, Romain/0000 0001 5917 7298;
   Bertoni, Lelia/0000 0001 6367 3040; Desance,
   Melanie/0000 0002 8639 3233; legendre, florence/0000 0002 9951 1585
FU French National Research Agency (ANR) [917RB072]; Regional Council of
   Basse Normandie through the ANR TecSan PROMOCART program [917RB020];
   French Ministry of Research and Technology; ERDF (European Regional
   Development Funds) [2897/33535, 917RB148, HIPPOCART 917CB174]; Regional
   Council of Basse Normandie program [2013 AGRI 236/13P07492, 917CB166];
   Fonds Eperon (EQUISTEM) [N80 2014, 917CB194]; ERDF; Regional Council of
   Basse Normandie grant (Centaure Biotechnologies) [917CB213]; Regional
   Council of Basse Normandie grant (Centaure PREACH); Regional Council of
   Basse Normandie; Fonds Eperon
FX We thank Ecuries Lebourgeois, the veterinary clinics CAP'VET
   (Saint Julien sur Sarthe, France) and Meheudin (Meheudin, Ecouche,
   France) for collecting equine umbilical cord blood. We are grateful to
   Marylin Guillamin for her help with flow cytometry analyses and to
   Marie Christine Enos for her administrative and technical support. This
   research was funded by the French National Research Agency (ANR) and by
   the Regional Council of Basse Normandie through the ANR TecSan PROMOCART
   program to Philippe Galera (917RB020 and 917RB072 respectively), by the
   French Ministry of Research and Technology to Philippe Galera, by two
   ERDF (European Regional Development Funds) grants to Philippe Galera and
   Magali Demoor (HIPPOCART 1 no. 2897/33535, 917RB148; HIPPOCART
   917CB174), by a Regional Council of Basse Normandie program to Philippe
   Galera and Magali Demoor (HIPPOCART No 2013 AGRI 236/13P07492,
   917CB166), by Fonds Eperon to Philippe Galera and Magali Demoor
   (EQUISTEM, N80 2014, 917CB194), by ERDF and Regional Council of
   Basse Normandie grant to Philippe Galera and Magali Demoor in the CPER
   Centaure program (2015 2020, Centaure Biotechnologies 2015 No 917CB213
   and Centaure PREACH 2016 17). Melanie Desance was recipient of a PhD
   fellowship from the Regional Council of Basse Normandie. Thomas Branly
   and Tangni Gomez Leduc were supported by a PhD scholarship from the
   French Ministry of Research and Technology, and Romain Contentin by a
   PhD scholarship co financed by the Fonds Eperon and the Regional Council
   of Basse Normandie.
CR Aigner T, 2003, ADV DRUG DELIVER REV, V55, P1569, DOI 10.1016/j.addr.2003.08.009
   Aigner T, 2010, OSTEOARTHR CARTILAGE, V18, pS2, DOI 10.1016/j.joca.2010.07.013
   Aubert Foucher E, 2014, MATRIX BIOL, V34, P80, DOI 10.1016/j.matbio.2013.09.001
   Barberini DJ, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt414
   BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092 8674(78)90056 9
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Branly T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020435
   Braun J, 2010, AM J VET RES, V71, P1228, DOI 10.2460/ajvr.71.10.1228
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   Chen XB, 2013, INJURY, V44, P540, DOI 10.1016/j.injury.2012.09.024
   Co C, 2014, OSTEOARTHR CARTILAGE, V22, P472, DOI 10.1016/j.joca.2013.12.021
   Cooke ME, 2011, OSTEOARTHR CARTILAGE, V19, P1210, DOI 10.1016/j.joca.2011.07.005
   De Schauwer C, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt395
   De Schauwer C, 2012, CYTOM PART A, V81A, P312, DOI 10.1002/cyto.a.22026
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duval E, 2009, ARTHRITIS RHEUM US, V60, P3038, DOI 10.1002/art.24851
   Freyria AM, 2012, INJURY, V43, P259, DOI 10.1016/j.injury.2011.05.035
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014 4827(92)90186 C
   Gardner OFW, 2013, HISTOL HISTOPATHOL, V28, P23, DOI 10.14670/HH 28.23
   Gómez Leduc T, 2016, SCI REP UK, V6, DOI 10.1038/srep32786
   Hackett CH, 2011, STEM CELLS DEV, V20, P721, DOI 10.1089/scd.2010.0175
   Handorf AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022887
   Hardingham TE, 2010, INT J EXP PATHOL, V91, P203, DOI 10.1111/j.1365 2613.2010.00719.x
   Hillmann A, 2016, CELL TRANSPLANT, V25, P109, DOI 10.3727/096368915X687822
   Iacono E, 2015, J EQUINE VET SCI, V35, P130, DOI 10.1016/j.jevs.2014.12.010
   Indrawattana N, 2004, BIOCHEM BIOPH RES CO, V320, P914, DOI 10.1016/j.bbrc.2004.06.029
   Jin HJ, 2013, INT J MOL SCI, V14, P17986, DOI 10.3390/ijms140917986
   Kafienah W, 2007, ARTHRITIS RHEUM, V56, P177, DOI 10.1002/art.22285
   Kang JG, 2013, J VET SCI, V14, P367
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kisiday JD, 2008, J ORTHOP RES, V26, P322, DOI 10.1002/jor.20508
   Kisiday JD, 2013, AM J VET RES, V74, P801, DOI 10.2460/ajvr.74.5.801
   Kobolak J, 2016, METHODS, V99, P62, DOI 10.1016/j.ymeth.2015.09.016
   Koch TG, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472 6750 7 26
   Koch TG, 2009, CYTOTHERAPY, V11, P443, DOI 10.1080/14653240902887259
   Kopesky PW, 2010, MATRIX BIOL, V29, P427, DOI 10.1016/j.matbio.2010.02.003
   Legendre F, 2013, TISSUE ENG PART C ME, V19, P550, DOI [10.1089/ten.tec.2012.0508, 10.1089/ten.TEC.2012.0508]
   Mauck RL, 2006, OSTEOARTHR CARTILAGE, V14, P179, DOI 10.1016/j.joca.2005.09.002
   McIlwraith CW, 2012, BONE JOINT RES, V1, P297, DOI 10.1302/2046 3758.111.2000132
   McIlwraith CW, 2011, CARTILAGE, V2, P317, DOI 10.1177/1947603511406531
   McIlwraith CW, 2011, ARTHROSCOPY, V27, P1552, DOI 10.1016/j.arthro.2011.06.002
   Murata D, 2014, VET J, V202, P53, DOI 10.1016/j.tvjl.2014.07.029
   Murphy MK, 2015, STEM CELLS, V33, P762, DOI 10.1002/stem.1890
   Nixon AJ, 2011, J ORTHOP RES, V29, P1121, DOI 10.1002/jor.21366
   Ortved KF, 2016, VET J, V208, P1, DOI 10.1016/j.tvjl.2015.10.027
   Perkins NR, 2005, NEW ZEAL VET J, V53, P59, DOI 10.1080/00480169.2005.36470
   Perrier E, 2011, BIOTECHNOL LETT, V33, P2091, DOI 10.1007/s10529 011 0653 1
   Pigott JH, 2013, VET IMMUNOL IMMUNOP, V156, P99, DOI 10.1016/j.vetimm.2013.09.003
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ranera B, 2013, VET J, V195, P248, DOI 10.1016/j.tvjl.2012.06.008
   Ronzière MC, 2010, BIO MED MATER ENG, V20, P145, DOI 10.3233/BME 2010 0626
   Solchaga LA, 2010, TISSUE ENG PT A, V16, P1009, DOI [10.1089/ten.tea.2009.0100, 10.1089/ten.TEA.2009.0100]
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Tessier L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122954
   Vieira NM, 2010, CELL TRANSPLANT, V19, P279, DOI 10.3727/096368909X481764
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Wilke MM, 2007, J ORTHOP RES, V25, P913, DOI 10.1002/jor.20382
   Williams LB, 2016, EQUINE VET J, V48, P619, DOI 10.1111/evj.12477
   Yang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021679
   Zhang X, 2011, J CELL BIOCHEM, V112, P1206, DOI 10.1002/jcb.23042
   Zhou CH, 2011, CELL IMMUNOL, V272, P33, DOI 10.1016/j.cellimm.2011.09.010
NR 62
TC 42
Z9 45
U1 0
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2018
VL 19
IS 2
AR 537
DI 10.3390/ijms19020537
PG 33
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FZ3YN
UT WOS:000427527400221
PM 29439436
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Shahrara, S
   Proudfoot, AEI
   Woods, JM
   Ruth, JH
   Amin, MA
   Park, CC
   Haas, CS
   Pope, RM
   Haines, GK
   Zha, YY
   Koch, AE
AF Shahrara, S
   Proudfoot, AEI
   Woods, JM
   Ruth, JH
   Amin, MA
   Park, CC
   Haas, CS
   Pope, RM
   Haines, GK
   Zha, YY
   Koch, AE
TI Amelioration of rat adjuvant induced arthritis by Met RANTES
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION FACTOR; MACROPHAGE INFLAMMATORY
   PROTEIN 1 ALPHA; THERAPY REDUCES INFLAMMATION; COLONY STIMULATING
   FACTOR; RHEUMATOID ARTHRITIS; OSTEOPROTEGERIN LIGAND; CHEMOKINE
   RECEPTORS; PERIPHERAL BLOOD; BONY DESTRUCTION; EXPRESSION
AB Objective. CC chemokines and their receptors play a fundamental role in trafficking and activation of leukocytes at sites of inflammation, contributing to joint damage in rheumatoid arthritis. Met RANTES, an amino terminal modified methionylated form of RANTES (CCL5), antagonizes the binding of the chemokines RANTES and macrophage inflammatory protein la (MIP 1 alpha; CCL3) to their receptors CCR1 and CCR5, respectively. The aim of this study was to investigate whether Met RANTES could ameliorate adjuvant induced arthritis (AIA) in the rat.
   Methods. Using immunohistochemistry, enzymelinked immunosorbent assay, real time reverse transcription polymerase chain reaction, Western blot analysis, adoptive transfer, and chemotaxis, we defined joint inflammation, bony destruction, neutrophil and macrophage migration, Met RANTES binding affinity to rat receptors, proinflammatory cytokine and bone marker levels, CCR1 and CCR5 expression and activation, and macrophage homing into joints with AIA.
   Results. Administration of Met RANTES as a preventative reduced the severity of joint inflammation. Administration of Met RANTES to ankles with AIA showed decreases in inflammation, radiographic soft tissue swelling, and bone erosion. Met RANTES significantly reduced the number of neutrophils and macrophages at the peak of arthritis compared with saline injected controls. Competitive chemotaxis in peripheral blood mononuclear cells demonstrated that MetRANTES inhibited MIP 1 alpha and MIP 1 beta at 50% inhibition concentrations of 5 nM and 2 nM, respectively. Furthermore, levels of tumor necrosis factor a, interleukin 1 beta, macrophage colony stimulating factor, and RANKL were decreased in joints with AIA in the Met RANTES group compared with the control group. Interestingly, the expression and activation of CCR1 and CCR5 in the joint were down regulated in the Met RANTES group compared with the control group. Functionally, Met RANTES administration decreased adoptively transferred peritoneal macrophage homing into the joint.
   Conclusion. The data suggest that the targeting of Th1 associated chemokine receptors reduce joint inflammation, bone destruction, and cell recruitment into joints with AIA.
C1 Northwestern Univ, Feinberg Sch Med, Dept Med, Rheumatol Sect, Chicago, IL 60611 USA.
   Pharmaceut Res Inst, Geneva, Switzerland.
   Midwestern Univ, Chicago Coll Osteopath Med, Downers Grove, IL 60515 USA.
   Univ Michigan, Med Ctr & Vet Adm, Ann Arbor, MI 48109 USA.
   Vet Adm Chicago Hlth Care Syst, Chicago, IL USA.
C3 Northwestern University; Feinberg School of Medicine; Midwestern
   University; Midwestern University   Chicago College of Osteopathic
   Medicine; Midwestern University   Downers Grove; University of Michigan
   System; University of Michigan
RP Shahrara, S (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Med, Rheumatol Sect, McGaw Pavil,240 E Huron,Suite 2220, Chicago, IL 60611 USA.
EM s shahrara@northwestern.edu
RI Park, Christy/AAH 1543 2020; Haas, Christian/L 5279 2016; Koch,
   Alisa/B 6894 2011
OI , G. Kenneth Haines III/0009 0005 6401 7981; Pope, Richard
   M./0000 0003 2416 8660; Shahrara, Shiva/0000 0002 6698 8491; 
FU NHLBI NIH HHS [R01 HL058695, HL 58695] Funding Source: Medline; NIAID
   NIH HHS [AI 40987, R01 AI040987] Funding Source: Medline; NIAMS NIH HHS
   [R01 AR048269, AR 049353, R03 AR056099, R01 AR049217, AR 48267, K01
   AR049353, AR 048269, R01 AR048267, AR 049217] Funding Source: Medline
CR Ajuebor MN, 2001, J IMMUNOL, V166, P552, DOI 10.4049/jimmunol.166.1.552
   Barnes DA, 1998, J CLIN INVEST, V101, P2910, DOI 10.1172/JCI2172
   Brodmerkel CN, 2004, ARTHRITIS RHEUM, V50, pS369
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cheng SS, 2001, J IMMUNOL, V166, P1178, DOI 10.4049/jimmunol.166.2.1178
   Favy DA, 2000, BIOCHEM BIOPH RES CO, V274, P73, DOI 10.1006/bbrc.2000.3100
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fischer FR, 2001, J IMMUNOL, V167, P1637, DOI 10.4049/jimmunol.167.3.1637
   Gröne HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371
   Halloran MM, 1996, ARTHRITIS RHEUM US, V39, P810, DOI 10.1002/art.1780390514
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   HOSAKA S, 1994, CLIN EXP IMMUNOL, V97, P451
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Katschke KJ, 2001, ARTHRITIS RHEUM, V44, P1022, DOI 10.1002/1529 0131(200105)44:5<1022::AID ANR181>3.0.CO;2 N
   Kaufmann A, 2001, J LEUKOCYTE BIOL, V69, P248
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SC, 2000, J IMMUNOL, V164, P3392, DOI 10.4049/jimmunol.164.6.3392
   Luo Y, 2002, GLIA, V39, P19, DOI 10.1002/glia.10079
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875
   PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165 2478(97)00075 8
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Quinones MP, 2004, J CLIN INVEST, V113, P856, DOI 10.1172/JCI200420126
   ROSEN H, 1990, EUR J IMMUNOL, V20, P1251, DOI 10.1002/eji.1830200609
   Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167 5699(98)01346 2
   Shahrara S, 2003, ARTHRITIS RHEUM US, V48, P3568, DOI 10.1002/art.11344
   Song EW, 2002, KIDNEY INT, V61, P676, DOI 10.1046/j.1523 1755.2002.00148.x
   SZEKANECZ Z, 1995, CLIN IMMUNOL IMMUNOP, V76, P187, DOI 10.1006/clin.1995.1114
   Veillard NR, 2004, CIRC RES, V94, P253, DOI 10.1161/01.RES.0000109793.17591.4E
   Volin MV, 1998, CLIN IMMUNOL IMMUNOP, V89, P44, DOI 10.1006/clin.1998.4590
   WATANABE K, 1991, EXP MOL PATHOL, V55, P30, DOI 10.1016/0014 4800(91)90016 Q
   WILTROUT RH, 1983, J RETICULOENDOTH SOC, V34, P253
   Woods JM, 2002, HUM GENE THER, V13, P381, DOI 10.1089/10430340252792512
   Woods JM, 2001, J IMMUNOL, V166, P1214, DOI 10.4049/jimmunol.166.2.1214
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 42
TC 97
Z9 107
U1 0
U2 1
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004 3591
J9 ARTHRITIS RHEUM
JI Arthritis Rheum.
PD JUN
PY 2005
VL 52
IS 6
BP 1907
EP 1919
DI 10.1002/art.21033
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 934PW
UT WOS:000229721700036
PM 15934086
OA Green Accepted
DA 2025 08 17
ER

PT J
AU De Maria, R
   Miretti, S
   Iussich, S
   Olivero, M
   Morello, E
   Bertotti, A
   Christensen, JG
   Biolatti, B
   Levine, RA
   Buracco, P
   Di Renzo, MF
AF De Maria, Raffaella
   Miretti, Silvia
   Iussich, Selina
   Olivero, Martina
   Morello, Emanuela
   Bertotti, Andrea
   Christensen, James G.
   Biolatti, Bartolomeo
   Levine, Roy A.
   Buracco, Paolo
   Di Renzo, Maria Flavia
TI met oncogene activation qualifies spontaneous canine osteosarcoma
   as a suitable pre clinical model of human osteosarcoma
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE osteosarcoma; MET oncogene; receptor tyrosine kinase;
   immunohistochemistry
ID C MET; TYROSINE KINASE; MET/HGF RECEPTOR; GROWTH; CANCER; EXPRESSION;
   INHIBITORS; OVEREXPRESSION; IDENTIFICATION; SENSITIVITY
AB The Met receptor tyrosine kinase (RTK) is aberrantly expressed in human osteosarcoma and is an attractive molecular target for cancer therapy. We studied spontaneous canine osteosarcoma (OSA) as a potential pre clinical model for evaluation of Met targeted therapies. The canine MET oncogene exhibits 90% homology compared with human MET, indicating that cross species functional studies are a viable strategy. Expression and activation of the canine Met receptor were studied utilizing immunohistochemical techniques in 39 samples of canine osteosarcoma, including 35 primary tumours and four metastases. Although the Met RTK is barely detectable in primary culture of canine osteoblasts, high expression of Met protein was observed in 80% of canine osteosarcoma samples acquired from various breeds. Met protein overexpression was also concordant with its activation as indicated by phosphorylation of critical tyrosine residues. In addition, Met was expressed and constitutively activated in canine osteosarcoma cell lines. OSA cells expressing high levels of Met demonstrated activation of downstream transducers, elevated spontaneous motility, and invasiveness which were impaired by both a small molecule inhibitor of Met catalytic activity (PHA 665752) and met specific, stable RNA interference obtained by means of lentiviral vector. Similar to observations in human OSA, these data suggest that Met is commonly overexpressed and activated in canine OSA and that inhibition of Met impairs the invasive and motogenic properties of canine OSA cells. These data implicate Met as a potentially important factor for canine OSA progression and indicate that it represents a viable model to study Met targeted therapies. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Miretti, Silvia; Olivero, Martina; Bertotti, Andrea; Di Renzo, Maria Flavia] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, I 10060 Turin, Italy.
   [De Maria, Raffaella; Iussich, Selina; Morello, Emanuela; Biolatti, Bartolomeo; Buracco, Paolo] Univ Turin, Sch Vet Med, Dept Anim Pathol, I 10060 Turin, Italy.
   [Miretti, Silvia; Olivero, Martina; Di Renzo, Maria Flavia] Univ Turin, Sch Med, Dept Oncol Sci, I 10060 Turin, Italy.
   [Christensen, James G.] Pfizer Global Res & Dev, La Jolla Labs, Dept Canc Biol, La Jolla, CA USA.
   [Levine, Roy A.] Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.
C3 IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin;
   University of Turin; University of Turin; Pfizer; Pfizer USA; Cornell
   University
RP Di Renzo, MF (通讯作者)，Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, SP 142,KM 3 95, I 10060 Turin, Italy.
EM mariaflavia.direnzo@ircc.it
RI ; olivero, martina/J 4811 2018; DI RENZO, Maria Flavia/B 6091 2012;
   Olivero, Martina/J 4811 2018; DI RENZO, Maria/B 6091 2012; Buracco,
   Paolo/J 8251 2014
OI Bertotti, Andrea/0000 0001 8196 7608; DI RENZO, Maria
   Flavia/0000 0002 5093 3373; Olivero, Martina/0000 0002 6815 3498;
   IUSSICH, Selina/0000 0003 0361 131X; BIOLATTI,
   Bartolomeo/0000 0003 3657 3954; MIRETTI, SILVIA/0000 0002 6693 2527;
   Buracco, Paolo/0000 0002 0181 0887; MORELLO, Emanuela
   Maria/0000 0002 9801 6646; DE MARIA, RAFFAELLA/0000 0002 7028 2280
FU Italian Ministry of Health (Ministero Salute Ricerca Finalizzata 2005),
   Regione Piemonte; Italian Association for Cancer Research, AIRC
FX This Study was supported by grants from the Italian Ministry of Health
   (Ministero Salute Ricerca Finalizzata 2005), Regione Piemonte, and the
   Italian Association for Cancer Research, AIRC (MF Di Renzo)
CR Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044
   Christensen JG, 2003, CANCER RES, V63, P7345
   Coltella N, 2003, FASEB J, V17, P1162, DOI 10.1096/fj.02 0576fje
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697
   Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005
   De Maria R, 2005, CANCER RES, V65, P907
   FERRACINI R, 1995, ONCOGENE, V10, P739
   GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0
   Hansen K, 2004, EUR J CANCER, V40, P858, DOI 10.1016/j.ejca.2003.11.031
   Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   KNUDSEN BS, 2008, CURR OPIN GENE DEV, V9, P9
   Levine RA, 2000, VET PATHOL, V37, P54, DOI 10.1354/vp.37 1 54
   Liao AT, 2007, VET COMP ONCOL, V5, P177, DOI 10.1111/j.1476 5829.2007.00137.x
   Liao AT, 2006, ANIM GENET, V37, P248, DOI 10.1111/j.1365 2052.2006.01415.x
   LONGATI P, 1994, ONCOGENE, V9, P49
   LORUSSO PM, 2008, AACR ANN M 2006 SAN
   MacEwen EG, 2004, J CELL BIOCHEM, V92, P77, DOI 10.1002/jcb.20046
   MacEwen EG, 2003, CLIN EXP METASTAS, V20, P421
   McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104
   Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078 0432.CCR 06 0362
   Nakamura Y, 2007, CANCER SCI, V98, P1006, DOI 10.1111/j.1349 7006.2007.00493.x
   Oda Y, 2000, HUM PATHOL, V31, P709, DOI 10.1053/hupa.2000.8230
   Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097 0215(19990827)82:5<640::AID IJC4>3.3.CO;2 Y
   Patané S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008 5472.CAN 05 4422
   Paoloni M, 2008, NAT REV CANCER, V8, P147, DOI 10.1038/nrc2273
   Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078 0432.CCR 06 0818
   POZNERMOULIS S, 2007, LAB INVEST, V29, P29
   Scotlandi K, 1996, AM J PATHOL, V149, P1209
   Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
   Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008 5472.CAN 04 1043
   Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103
   Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008 5472.CAN 05 4292
   Tester AM, 2004, CANCER RES, V64, P652, DOI 10.1158/0008 5472.CAN 0384 2
   Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779
   Tward AD, 2007, P NATL ACAD SCI USA, V104, P14771, DOI 10.1073/pnas.0706578104
   Vail DM, 2000, CANCER INVEST, V18, P781, DOI 10.3109/07357900009012210
   Wallenius V, 2000, AM J PATHOL, V156, P821, DOI 10.1016/S0002 9440(10)64950 4
NR 40
TC 34
Z9 38
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3417
EI 1096 9896
J9 J PATHOL
JI J. Pathol.
PD JUL
PY 2009
VL 218
IS 3
BP 399
EP 408
DI 10.1002/path.2549
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA 465UL
UT WOS:000267613300012
PM 19402129
OA Green Published
DA 2025 08 17
ER

PT J
AU Janarthanan, G
   Tran, HN
   Cha, E
   Lee, C
   Das, D
   Noh, I
AF Janarthanan, Gopinathan
   Hao Nguyen Tran
   Cha, Eunchong
   Lee, Chibum
   Das, Dipankar
   Noh, Insup
TI 3D printable and injectable lactoferrin loaded carboxymethyl
   cellulose glycol chitosan hydrogels for tissue engineering applications
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE 3D printing; Bioink; Hydrogels; Cellulose; Chitosan; Tissue engineering
ID BONE REGENERATION; DRUG DELIVERY; RELEASE; BIOMATERIAL; FABRICATION;
   MECHANISM; MEMBRANE; NETWORKS; ALBUMIN; CARRIER
AB In this study, carboxymethyl cellulose (CMC) glycol chitosan (GC) hydrogel, a potential three dimensional (3D) printing biomaterial ink for tissue engineering applications was synthesized using simple, biocompatible in situgelling Schiff's base reaction and ionic interactions. Different grades of hydrogels (C70G30, C50G50 and C30G70) were synthesized at physiological conditions. The oxidation of CMC and imine bond formation in the hydrogel were confirmed spectroscopically. Scanning electron microscopic images revealed the crosslinked interconnected pores in the cross sectioned hydrogels (dried). Swelling (equilibrium: 1 h), porosity (similar to 75%), in vitro degradation (> 30 days) and thermal gravimetric analyses of the dried gels were studied. Initially, cytotoxicity assay was evaluated using mouse osteoblastic cells (MC3T3). These experiments revealed that CMC GC gels formed stable hydrogel networks and were biocompatible. Particularly, C50G50 gels showed high printability (continuous extrusion) and post printing stability (without secondary crosslinking). Gel 3D printing was optimized by varying the air pressure, temperature, needle size and nozzle speed, to obtain stable lattice structures (2 to 16 layers). The printed (2 and 5 layers) hydrogels showed high stability in phosphate buffer saline (PBS) solution (1 h), under UV light (1 h) and after autoclaving. The strut dimensions and porosity of the printed gels before and after the stability tests were analyzed. The hydrogel stability may be attributed to both the imine bond and ionic interaction between the cationic and anionic polymer side chains. Lactoferrin (glycoprotein) incorporated C50G50 gels showed sustained release up to 21 days in PBS (pH 7.4) solution and demonstrated increased biocompatibility (> 80%) during in vitro cytotoxicity assays (MC3T3 cells and bone marrow mesenchymal stem cells) and Live/Dead assay (MC3T3 cells). A higher number of live osteoblast cells on the C50G50 hydrogels with increasing lactoferrin concentration was observed. These results show that the CMCGC gels are promising bio ink candidates for 3D printing and loading proteins or drugs for tissue engineering applications.
C1 [Janarthanan, Gopinathan; Hao Nguyen Tran; Cha, Eunchong; Das, Dipankar; Noh, Insup] Seoul Natl Univ Sci & Technol, Dept Chem & Biomol Engn, Seoul 01811, South Korea.
   [Janarthanan, Gopinathan; Cha, Eunchong; Das, Dipankar; Noh, Insup] Seoul Natl Univ Sci & Technol, Convergence Inst Biomed Engn & Biomat, Seoul 01811, South Korea.
   [Lee, Chibum] Seoul Natl Univ Sci & Technol, Dept Mech Syst Design Engn, Seoul 01811, South Korea.
C3 Seoul National University of Science & Technology; Seoul National
   University of Science & Technology; Seoul National University of Science
   & Technology
RP Noh, I (通讯作者)，Seoul Natl Univ Sci & Technol, Dept Chem & Biomol Engn, Seoul 01811, South Korea.
EM insup@seoultech.ac.kr
RI JANARTHANAN, GOPINATHAN/U 6554 2018; Das, Dipankar/HJY 7548 2023; Noh,
   Insup/S 4467 2019
OI Janarthanan, Gopinathan/0000 0002 0851 2874; Das,
   Dipankar/0000 0001 9298 6871; Tran, Hao/0000 0003 1347 5585
FU National Research Foundation of Korea (NRF) Grant [2015R1A2A1A10054592,
   2019R1H1A2101084]
FX This work was supported by the National Research Foundation of Korea
   (NRF) Grant (2015R1A2A1A10054592 and 2019R1H1A2101084).
CR Abd Elwakil MM, 2018, NANOMEDICINE UK, V13, P2015, DOI 10.2217/nnm 2018 0039
   Actor JK, 2009, CURR PHARM DESIGN, V15, P1956, DOI 10.2174/138161209788453202
   Adlerova L, 2008, VET MED CZECH, V53, P457, DOI 10.17221/1978 VETMED
   Amini AA, 2014, ADV HEALTHC MATER, V3, P897, DOI 10.1002/adhm.201300496
   Ashammakhi N., 2019, MAT TODAY BIO
   Ashammakhi N, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801048
   Bang S, 2018, TISSUE ENG REGEN MED, V15, P25, DOI 10.1007/s13770 017 0089 3
   Bastos AR, 2019, MATERIALS, V12, DOI 10.3390/ma12132074
   Bezemer JM, 2000, J CONTROL RELEASE, V64, P179, DOI 10.1016/S0168 3659(99)00127 3
   Bharadwaj S, 2009, OSTEOPOROSIS INT, V20, P1603, DOI 10.1007/s00198 009 0839 8
   Bharadwaz A, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110698
   Bhattacharya M, 2012, J CONTROL RELEASE, V164, P291, DOI 10.1016/j.jconrel.2012.06.039
   Cerchiara T, 2016, CARBOHYD POLYM, V143, P124, DOI 10.1016/j.carbpol.2016.02.020
   Chang CY, 2011, CARBOHYD POLYM, V84, P40, DOI 10.1016/j.carbpol.2010.12.023
   Chao A, 2016, MACROMOLECULES, V49, P6277, DOI 10.1021/acs.macromol.6b01443
   Chen HQ, 2008, J BIOACT COMPAT POL, V23, P38, DOI 10.1177/0883911507085070
   Chen NS, 2019, CARBOHYD POLYM, V225, DOI 10.1016/j.carbpol.2019.115207
   Chimene D, 2020, ADV MATER, V32, DOI 10.1002/adma.201902026
   Cho Ik Sung, 2018, [Biomaterials Research, 생체재료학회지], V22, P249, DOI 10.1186/s40824 018 0137 7
   Cho MO, 2016, NPG ASIA MATER, V8, DOI 10.1038/am.2016.130
   Coutinho DF, 2010, BIOMATERIALS, V31, P7494, DOI 10.1016/j.biomaterials.2010.06.035
   Das D., 2017, NANOMATERIALS BASEL, V7
   Das D, 2019, MAT SCI ENG C MATER, V98, P42, DOI 10.1016/j.msec.2018.12.127
   Das D, 2018, COLLOID SURFACE B, V170, P64, DOI 10.1016/j.colsurfb.2018.05.059
   Gao HL, 2010, ACTA PHARMACOL SIN, V31, P237, DOI 10.1038/aps.2009.199
   Gillispie G, 2020, BIOFABRICATION, V12, DOI 10.1088/1758 5090/ab6f0d
   González Chávez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020
   Gopinathan J, 2018, TISSUE ENG REGEN MED, V15, P531, DOI 10.1007/s13770 018 0152 8
   Gopinathan Janarthanan, 2018, Biomater Res, V22, P11, DOI 10.1186/s40824 018 0122 1
   Groll J, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/aaec52
   Hamdi M, 2020, INT J BIOL MACROMOL, V152, P1252, DOI 10.1016/j.ijbiomac.2019.10.222
   Haque MA, 2012, POLYMER, V53, P1805, DOI 10.1016/j.polymer.2012.03.013
   Hausmann MK, 2018, ACS NANO, V12, P6926, DOI 10.1021/acsnano.8b02366
   He CB, 2014, J AM CHEM SOC, V136, P12253, DOI 10.1021/ja507333c
   Hu WK, 2019, BIOMATER SCI UK, V7, P843, DOI 10.1039/c8bm01246f
   Huang M, 2007, MACROMOLECULES, V40, P6658, DOI 10.1021/ma062482q
   Huang YX, 2016, RSC ADV, V6, P33529, DOI 10.1039/c5ra26160k
   Icriverzi M, 2020, CURR MED CHEM, V27, P838, DOI 10.2174/0929867326666190503121546
   Ionov L, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800412
   Jeong YH, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10080839
   Jessop ZM, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab0631
   Jiang YN, 2020, J MATER SCI, V55, P2618, DOI 10.1007/s10853 019 04186 0
   Karimi AR, 2018, INT J BIOL MACROMOL, V118, P1863, DOI 10.1016/j.ijbiomac.2018.07.037
   Kathan M, 2016, ANGEW CHEM INT EDIT, V55, P13882, DOI 10.1002/anie.201605311
   Kelner A, 2005, J CONTROL RELEASE, V101, P13, DOI 10.1016/j.jconrel.2004.09.010
   Kim SW, 2019, BIOMACROMOLECULES, V20, P1860, DOI 10.1021/acs.biomac.8b01589
   Kitakaze T, 2018, MOL MED REP, V17, P5912, DOI 10.3892/mmr.2018.8603
   Kiyotake EA, 2019, ACTA BIOMATER, V95, P176, DOI 10.1016/j.actbio.2019.01.041
   Komoto D, 2019, INT J BIOL MACROMOL, V126, P54, DOI 10.1016/j.ijbiomac.2018.12.195
   Kumar A, 2020, BIOFABRICATION, V12, DOI 10.1088/1758 5090/ab736e
   Latza V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9313
   Lee J, 2017, INT J PRECIS ENG MAN, V18, P605, DOI 10.1007/s12541 017 0072 x
   Lee Jin Hyun, 2018, Biomater Res, V22, P27
   LEVAY PF, 1995, HAEMATOLOGICA, V80, P252
   Li J, 2020, ACS APPL MATER INTER, V12, P2023, DOI 10.1021/acsami.9b17180
   Li VCF, 2018, ACS SUSTAIN CHEM ENG, V6, P2011, DOI 10.1021/acssuschemeng.7b03439
   Li WY, 2015, CLIN ORTHOP RELAT R, V473, P2383, DOI 10.1007/s11999 015 4270 5
   Liu C, 2018, ARTIF CELL NANOMED B, V46, pS721, DOI 10.1080/21691401.2018.1434662
   Liu J, 2020, INT J BIOL MACROMOL, V147, P653, DOI 10.1016/j.ijbiomac.2020.01.005
   Liu L, 2020, FOOD CHEM, V310, DOI 10.1016/j.foodchem.2019.125919
   Liu SL, 2018, CHEM ENG J, V334, P2222, DOI 10.1016/j.cej.2017.11.103
   Lü SY, 2010, CHEM ENG J, V160, P779, DOI 10.1016/j.cej.2010.03.072
   Michl J, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0393 7
   Ming JF, 2016, MAT SCI ENG C MATER, V59, P185, DOI 10.1016/j.msec.2015.10.013
   Montalbano G, 2018, MAT SCI ENG C MATER, V91, P236, DOI 10.1016/j.msec.2018.04.101
   Morgan FLC, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901798
   Moroni L, 2018, NAT REV MATER, V3, DOI 10.1038/s41578 018 0020 01
   Naot D, 2005, CLIN MED RES, V3, P93, DOI 10.3121/cmr.3.2.93
   Noh I, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0152 8
   Oh HM, 2019, J IND ENG CHEM, V80, P820, DOI 10.1016/j.jiec.2019.07.002
   Piras CC, 2017, BIOMATER SCI UK, V5, P1988, DOI 10.1039/c7bm00510e
   Rasool A, 2019, CARBOHYD POLYM, V203, P423, DOI 10.1016/j.carbpol.2018.09.083
   Resmi R, 2020, CARBOHYD POLYM, V234, DOI 10.1016/j.carbpol.2020.115902
   Richardson BM, 2019, ACTA BIOMATER, V83, P71, DOI 10.1016/j.actbio.2018.11.014
   Sabaa MW, 2019, MAT SCI ENG C MATER, V94, P1044, DOI 10.1016/j.msec.2018.10.040
   Safaeian Leila, 2015, Adv Biomed Res, V4, P188, DOI 10.4103/2277 9175.164010
   Sarkar C, 2018, CARBOHYD POLYM, V181, P710, DOI 10.1016/j.carbpol.2017.11.091
   Shen XP, 2016, GREEN CHEM, V18, P53, DOI 10.1039/c5gc02396c
   Shi PJ, 2017, COLLOID SURFACE B, V155, P477, DOI 10.1016/j.colsurfb.2017.04.042
   Sultan S, 2018, NANOSCALE, V10, P4421, DOI 10.1039/c7nr08966j
   Takaoka R, 2011, J BIOMAT SCI POLYM E, V22, P1581, DOI 10.1163/092050610X517095
   Takayama Y, 2009, J BIOSCI BIOENG, V107, P191, DOI 10.1016/j.jbiosc.2008.09.018
   Tang SC, 2014, MACROMOLECULES, V47, P791, DOI 10.1021/ma401684w
   Tayebi L, 2018, MAT SCI ENG C MATER, V84, P148, DOI 10.1016/j.msec.2017.11.027
   Thambi T, 2016, MACROMOL RAPID COMM, V37, P1881, DOI 10.1002/marc.201600371
   Tonda Turo C., 2020, BIOPRINTING, V18
   Wang QQ, 2018, CELLULOSE, V25, P4275, DOI 10.1007/s10570 018 1888 y
   Wei Z, 2018, BIOMATERIALS, V185, P86, DOI 10.1016/j.biomaterials.2018.09.003
   Wei Z, 2015, ADV FUNCT MATER, V25, P1352, DOI 10.1002/adfm.201401502
   Whang M, 2016, TISSUE ENG REGEN MED, V13, P126, DOI 10.1007/s13770 016 0026 x
   Wu QH, 2018, ACS BIOMATER SCI ENG, V4, P2643, DOI 10.1021/acsbiomaterials.8b00415
   Xia LW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3226
   Xu JP, 2019, MOLECULES, V24, DOI 10.3390/molecules24163005
   Yoshimaki T, 2013, J ORAL SCI, V55, P343, DOI 10.2334/josnusd.55.343
   Zhang JC, 2018, INT J NANOMED, V13, P3039, DOI 10.2147/IJN.S161163
NR 95
TC 70
Z9 73
U1 10
U2 204
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD AUG
PY 2020
VL 113
AR 111008
DI 10.1016/j.msec.2020.111008
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LU4FI
UT WOS:000537712500007
PM 32487412
DA 2025 08 17
ER

PT J
AU Crepaldi, C
   Possidoni, A
   Caputo, F
   Dell'Aquila, R
   Galli, EG
   Costanzo, AM
   Gualberti, G
   Paparatti, UD
   Russo, R
AF Crepaldi, Carlo
   Possidoni, Alessandro
   Caputo, Flavia
   Dell'Aquila, Roberto
   Galli, Emilio Giulio
   Costanzo, Anna Maria
   Gualberti, Giuliana
   Paparatti, Umberto di Luzio
   Russo, Roberto
CA ATENA Study Grp
TI Clinical management of patients on peritoneal dialysis in Italy: results
   from the ATENA study
SO CLINICAL KIDNEY JOURNAL
LA English
DT Article
DE anaemia; chronic kidney disease; metabolic bone disorders; peritoneal
   dialysis; secondary hyperparathyroidism
ID HEMODIALYSIS; MORTALITY; INFLAMMATION; POPULATION; METABOLISM; ADEQUACY;
   THERAPY; DISEASE; RISK
AB Background: In Italy, few studies have examined the clinical management of peritoneal dialysis (PD) patients, resulting in a lack of information and awareness.
   Methods: A total of 378 PD patients (64.7 +/  14.3 years, 58.9% males) were enrolled across 15 centres in a 12 month retrospective and 6 month prospective study. The primary objective was to evaluate the achievement of Kidney Disease Outcomes Quality Initiative and Kidney Disease Improving Global Outcomes guidelines on recommended target values for anaemia, high blood pressure and mineral metabolism. Comorbidities, hospitalizations, treatment and quality of life were also assessed.
   Results: Frequent comorbidities included hypertension (87.8%) and cardiovascular disease (39.7%). Peritonitis was the leading cause of hospitalization [12 admissions per 100 person years (95% confidence interval 9.3 15.2)]. At 6 months, anaemia corrected by erythropoiesis stimulating agents was observed in 30% of patients and 73% received erythropoiesis stimulating agents. Systolic and diastolic blood pressures were recorded in 50% and 20% of patients, respectively. Sixty four percent of echocardiograms revealed left ventricular hypertrophy and 30% of patients had vitamin D <10 ng/mL. Medication to treat intact parathyroid hormone (PTH) included calcitriol (36.3%), paricalcitol (29.2%), cholecalciferol (23.6%) and cinacalcet (21.5%). In a subgroup of patients matched for baseline PTH treated for 1 year, a significant reduction in PTH with paricalcitol ( 41%; P < 0.001) but not cinacalcet (+2%; P = 0.63) was observed. Comparison of quality of life domains revealed significant differences for symptoms (P = 0.049), cognitive function (P = 0.019) and social support (P = 0.04) (baseline versus 6 months).
   Conclusions: Hypertension and cardiovascular diseases were frequent comorbidities and peritonitis was the leading cause of hospitalization. Secondary hyperparathyroidism and anaemia were common, thus necessitating frequent monitoring of PTH, calcium, phosphorus and haemoglobin.
C1 [Crepaldi, Carlo] ULSS6 Vicenza Osped San Bortolo UOC Nefrol, Dialisi & Trapianto Renale, Vicenza, Italy.
   [Possidoni, Alessandro; Costanzo, Anna Maria; Gualberti, Giuliana; Paparatti, Umberto di Luzio] AbbVie Italy Srl, Campoverde Di Aprilia, LT, Italy.
   [Caputo, Flavia] ARNAS Osp Civ Cristina Benfratelli UO Nefrol 2, Dialisi & Trapianto, Palermo, Italy.
   [Dell'Aquila, Roberto] Azienda ULSS 7 PEDEMONTANA Struttura Complessa Ne, Vicenza, Italy.
   [Galli, Emilio Giulio] Azienda Osped Treviglio Caravaggio Nefrol, Bergamo, Italy.
   [Russo, Roberto] AOU Policlin Bari UOC Nefrol, Bari, Italy.
C3 ULSS 8 Berica; Ospedale San Bortolo di Vicenza; Ospedale di
   Treviglio Caravaggio
RP Costanzo, AM (通讯作者)，AbbVie Italy Srl, Campoverde Di Aprilia, LT, Italy.
EM annamaria.costanzo@abbvie.com
FU AbbVie Italy
FX This study was sponsored by AbbVie Italy.
CR Agenzia Italiana del Farmaco AIFA, 2008, GUID OBS STUD
   [Anonymous], USRDS 2011 ANN DAT R
   Cabiddu G, GENSIMENTO 2012 GRUP
   Cancarini, 2003, G ITAL NEFROL S24, V20, pS109
   Cocchi R, 1999, NEPHROL DIAL TRANSPL, V14, P1536, DOI 10.1093/ndt/14.6.1536
   Coronel F, 2003, J NEPHROL, V16, P697
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Fontán MP, 2005, PERITON DIALYSIS INT, V25, P274
   Hassan K, 2014, CLIN NEPHROL, V81, P159, DOI 10.5414/CN108104
   Hays R.D., 1995, Kidney disease quality of life short form (KDQOLSFTM)
   Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112
   Jaar BG, 2005, ANN INTERN MED, V143, P174, DOI 10.7326/0003 4819 143 3 200508020 00003
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049
   Lukowsky LR, 2013, CLIN J AM SOC NEPHRO, V8, P619, DOI 10.2215/CJN.04810512
   LUPO A, 1994, AM J KIDNEY DIS, V24, P826, DOI 10.1016/S0272 6386(12)80678 0
   Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37
   Marinangeli G, 2012, PERITON DIALYSIS INT, V32, P558, DOI 10.3747/pdi.2011.00112
   Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771
   Mozos I, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/109275
   Noordzij M, 2006, NEPHROL DIAL TRANSPL, V21, P2513, DOI 10.1093/ndt/gfl257
   Pecoits Filho R, 2004, PERITON DIALYSIS INT, V24, P327
   Peritoneal Dialysis Adequacy 2006 Work Group, 2006, Am J Kidney Dis, V48 Suppl 1, pS91
   Pippias M, 2015, CLIN KIDNEY J, V8, P248, DOI 10.1093/ckj/sfv014
   Ronco C, 2009, CONTRIBUTIONS NEPHRO, V163, P102
   Sahin G, 2009, INT UROL NEPHROL, V41, P989, DOI 10.1007/s11255 009 9561 x
   SHANY S, 1984, NEPHRON, V36, P111, DOI 10.1159/000183128
   Sinnakirouchenan R, 2011, ADV CHRONIC KIDNEY D, V18, P428, DOI 10.1053/j.ackd.2011.09.001
   Smith DH, 2009, J RENAL NUTR, V19, P334, DOI 10.1053/j.jrn.2009.01.013
   Snyder JJ, 2004, J AM SOC NEPHROL, V15, P174, DOI 10.1097/01.ASN.0000102475.94185.54
   Stankovic Popovic V, 2011, CLIN NEPHROL, V76, P314, DOI 10.5414/CN106991
   Termorshuizen F, 2003, J AM SOC NEPHROL, V14, P2851, DOI 10.1097/01.ASN.0000091585.45723.9E
   Tsimihodimos V, 2008, AM J NEPHROL, V28, P958, DOI 10.1159/000144024
   Van Biesen W, 2007, EUR HEART J, V28, P478, DOI 10.1093/eurheartj/ehl455
   Virga G, 2013, J NEPHROL, V26, pS96, DOI 10.5301/JN.2013.11636
   Wang AYM, 2011, CLIN J AM SOC NEPHRO, V6, P805, DOI 10.2215/CJN.07130810
   Zaza G, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0051 3
NR 37
TC 4
Z9 5
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048 8505
EI 2048 8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD APR
PY 2018
VL 11
IS 2
BP 275
EP 282
DI 10.1093/ckj/sfx092
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA GZ5RH
UT WOS:000449483800020
PM 29644071
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Clark, AR
   Mauntel, TC
   Goldman, SM
   Dearth, CL
AF Clark, Andrew R.
   Mauntel, Timothy C.
   Goldman, Stephen M.
   Dearth, Christopher L.
TI Repurposing existing products to accelerate injury recovery (REPAIR) of
   military relevant musculoskeletal conditions
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE military personnel; musculoskeletal diseases; trauma; wound healing;
   drug development
ID BONE MASS; IGF I; MUSCLE; DIFFERENTIATION; TESTOSTERONE; PGC 1 ALPHA;
   ACTIVATION; DENOSUMAB; MEN
AB Musculoskeletal injuries (MSKIs) are a great hindrance to the readiness of the United States Armed Forces through lost duty time and reduced operational capabilities. While most musculoskeletal injuries result in return to duty/activity with no (functional) limitations, the healing process is often long. Long healing times coupled with the high frequency of musculoskeletal injuries make them a primary cause of lost/limited duty days. Thus, there exists an urgent, clinically unmet need for interventions to expedite tissue healing kinetics following musculoskeletal injuries to lessen their impact on military readiness and society as a whole. There exist several treatments with regulatory approval for other indications that have pro regenerative/healing properties, but few have an approved indication for treating musculoskeletal injuries. With the immediate need for treatment options for musculoskeletal injuries, we propose a paradigm of Repurposing Existing Products to Accelerate Injury Recovery (REPAIR). Developing treatments via repurposing existing therapeutics for other indications has shown monumental advantages in both cost effectiveness and reduced time to bring to market compared to novel candidates. Thus, undertaking the needed research efforts to evaluate the effectiveness of promising REPAIR themed candidates has the potential to enable near term solutions for optimizing musculoskeletal injuries recovery, thereby addressing a top priority within the United States. Armed Forces. Herein, the REPAIR paradigm is presented, including example targets of opportunity as well as practical considerations for potential technical solutions for the translation of existing therapeutics into clinical practice for musculoskeletal injuries.
C1 [Clark, Andrew R.; Mauntel, Timothy C.; Goldman, Stephen M.; Dearth, Christopher L.] DoD VA Extrem Trauma & Amputat Ctr Excellence, Res & Surveillance Div, Bethesda, MD 20814 USA.
   [Clark, Andrew R.; Mauntel, Timothy C.; Goldman, Stephen M.; Dearth, Christopher L.] Uniformed Serv Univ Hlth Sci, Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD 20814 USA.
   [Mauntel, Timothy C.] Womack Army Med Ctr, Ft Bragg, NC USA.
C3 Walter Reed National Military Medical Center; Uniformed Services
   University of the Health Sciences   USA; United States Department of
   Defense; United States Army
RP Dearth, CL (通讯作者)，DoD VA Extrem Trauma & Amputat Ctr Excellence, Res & Surveillance Div, Bethesda, MD 20814 USA.; Dearth, CL (通讯作者)，Uniformed Serv Univ Hlth Sci, Walter Reed Natl Mil Med Ctr, Dept Surg, Bethesda, MD 20814 USA.
EM Christopher.L.Dearth.civ@health.mil
RI Goldman, Stephen/AAT 7318 2020
OI Clark, Andrew/0000 0003 1273 9630
FU DoD VA Extremity Trauma and Amputation Center of Excellence
   [HU00012020038]
FX Funding Support was provided by the DoD VA Extremity Trauma and
   Amputation Center of Excellence (Award# HU00012020038).
CR ABRAMS J, 1985, AM HEART J, V110, P216, DOI 10.1016/0002 8703(85)90490 9
   Aicale R, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 1017 5
   Albano GD, 2021, HEALTHCARE BASEL, V9, DOI 10.3390/healthcare9010097
   [Anonymous], 2020, MSMR, V27, P2
   [Anonymous], 2016, BURDEN MUSCULOSKELET, V4th eds
   Arendt Nielsen L, 2011, J MAN MANIP THER, V19, P186, DOI 10.1179/106698111X13129729551903
   Baldelli S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.458
   Betts JG, 2013, Anatomy physiology
   Boyne PJ, 2005, J ORAL MAXIL SURG, V63, P1693, DOI 10.1016/j.joms.2005.08.018
   Buckwalter JA, 2004, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000131638.81519.de
   Cameron KL, 2016, J ATHL TRAINING, V51, P952, DOI 10.4085/1062 6050 51.5.03
   Chen S, 2015, MOL GENET METAB, V115, P53, DOI 10.1016/j.ymgme.2015.02.006
   Demling Robert H, 2009, Eplasty, V9, pe9
   Dhillon H, 2017, INDIAN J ORTHOP, V51, P529, DOI 10.4103/ortho.IJOrtho_226_17
   Disser NP, 2019, FASEB J, V33, P12680, DOI 10.1096/fj.201901503R
   Dixit M, 2021, MOL CELL ENDOCRINOL, V519, DOI 10.1016/j.mce.2020.111052
   Ellegaard M, 2010, CALCIFIED TISSUE INT, V87, P1, DOI 10.1007/s00223 010 9360 5
   Fenwick SA, 2002, ARTHRITIS RES, V4, P252, DOI 10.1186/ar416
   Fintini Danilo, 2009, Ther Clin Risk Manag, V5, P553
   Garg K, 2014, J APPL PHYSIOL, V117, P1120, DOI 10.1152/japplphysiol.00689.2014
   Gerber C, 2015, AM J SPORT MED, V43, P2393, DOI 10.1177/0363546515596411
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450
   Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603
   Halcox JPJ, 2002, J AM COLL CARDIOL, V40, P1232, DOI 10.1016/S0735 1097(02)02139 3
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hashimoto K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61825 2
   Hauret KG, 2010, AM J PREV MED, V38, pS61, DOI 10.1016/j.amepre.2009.10.021
   Isaacs Jonathan, 2011, Hand (N Y), V6, P142, DOI 10.1007/s11552 011 9331 y
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Kawakami Y, 2005, P NATL ACAD SCI USA, V102, P2414, DOI 10.1073/pnas.0407510102
   Kenny AM, 2010, J AM GERIATR SOC, V58, P1134, DOI 10.1111/j.1532 5415.2010.02865.x
   Kim SM, 2020, P NATL ACAD SCI USA, V117, P14386, DOI 10.1073/pnas.2000950117
   Komen JC, 2014, BRIT J PHARMACOL, V171, P1818, DOI 10.1111/bph.12413
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   MalekiGorji M, 2020, J KOR ASSOC ORAL MAX, V46, P258, DOI 10.5125/jkaoms.2020.46.4.258
   Molloy JM, 2020, MIL MED, V185, pE1461, DOI 10.1093/milmed/usaa027
   Nindl Bradley C, 2013, US Army Med Dep J, P5
   Pålsson McDermott EM, 2020, CELL RES, V30, P300, DOI 10.1038/s41422 020 0291 z
   Provenzano Paolo P., 2007, BMC Physiology, V7, P2, DOI 10.1186/1472 6793 7 2
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rajkumar DSR, 2013, J OSTEOPOROS, V2013, DOI 10.1155/2013/325693
   Roberts SJ, 2018, CURR OSTEOPOROS REP, V16, P289, DOI 10.1007/s11914 018 0440 1
   Ruscio BA, 2010, AM J PREV MED, V38, pS19, DOI 10.1016/j.amepre.2009.10.004
   Sangadala S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081900
   Schneider GA, 2000, AM J PREV MED, V18, P156, DOI 10.1016/S0749 3797(99)00177 4
   Shyh Chang N, 2017, GENE DEV, V31, P336, DOI 10.1101/gad.293167.116
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Song YH, 2013, TRENDS ENDOCRIN MET, V24, P310, DOI 10.1016/j.tem.2013.03.004
   Southern WM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40606 6
   Stahlman Shauna, 2018, MSMR, V25, P2
   STEINBERG H, 1988, J CARDIOVASC PHARM, V11, P84, DOI 10.1097/00005344 198801000 00013
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Suresh S, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01534
   Tahimic Candice G T, 2013, Front Endocrinol (Lausanne), V4, P6, DOI 10.3389/fendo.2013.00006
   URBAN RJ, 1995, AM J PHYSIOL ENDOC M, V269, pE820, DOI 10.1152/ajpendo.1995.269.5.E820
   Utsunomiya H., 2019, ORTHOP J SPORTS MED, V7, DOI DOI 10.1177/2325967119S00263
   Vall H., 2022, TERIPARATIDE
   Velnar T, 2009, J INT MED RES, V37, P1528, DOI 10.1177/147323000903700531
   Walsh NE, 2008, ARCH PHYS MED REHAB, V89, P1830, DOI 10.1016/j.apmr.2008.04.009
   Wang LJ, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02156 5
   Wang YH, 2007, AM J PHYSIOL ENDOC M, V292, pE594, DOI 10.1152/ajpendo.00216.2006
   Wascher DC, 2014, CURR REV MUSCULOSKE, V7, P387, DOI 10.1007/s12178 014 9242 y
   Wu BW, 2014, BMC SURG, V14, DOI 10.1186/1471 2482 14 102
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yoshida T, 2020, CELLS BASEL, V9, DOI 10.3390/cells9091970
   Yuan J, 2003, INFLAMM RES, V52, P230, DOI 10.1007/s00011 003 1167 7
   Zhao XL, 2014, ARTHRITIS RHEUMATOL, V66, P3073, DOI 10.1002/art.38791
NR 69
TC 1
Z9 3
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD JAN 9
PY 2023
VL 10
AR 1105599
DI 10.3389/fbioe.2022.1105599
PG 7
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 8E5TK
UT WOS:000919035200001
PM 36698630
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Payer, J
   Bilezikian, JP
   Holzer, G
   Lakatos, P
   Lesnyak, O
   Lorenc, R
   Zendeli, A
   Resch, H
AF Payer, Juraj
   Bilezikian, John P.
   Holzer, Gerold
   Lakatos, Peter
   Lesnyak, Olga
   Lorenc, Roman
   Zendeli, Afrodite
   Resch, Heinrich
TI Congress Report: 5th Central and Eastern Europe (CEE) Summit on
   Osteoporosis in Bratislava, 2 3 December 2011
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Central and Eastern Europe; Meeting report; Osteoporosis; Epidemiology;
   FRAX (R)
ID SCLEROSTIN; TARGET
AB Major aims of the 5th Central and Eastern Europe (CEE) Summit on Osteoporosis held in Bratislava, Slovakia, on 2 and 3 December 2011, were to provide participants with state of the art knowledge in the fields of osteoporosis research, diagnosis, and therapy and to evaluate, compare, and discuss the very heterogeneous health care situations and related challenges in the different countries in CEE and elsewhere. The summit was attended by 70 delegates from 15 countries. State of the art lectures given by international authorities on osteoporosis covered a broad spectrum of topics ranging from osteoporosis in the male population, novel therapies in osteoporosis such as cathepsin K and sclerostin inhibitors, and the implementation and use of FRAX (R) in CEE, to an update on denosumab for the management of osteoporosis. Workshops organized to enable the exchange of individual experiences addressed the importance and current availability of osteology training for physicians and the impact of patient training programs on therapy compliance. Furthermore, the availability of and need for standardized quality controls and therapy guidelines in different CEE countries were discussed. Finally, based on a questionnaire, a very up to date analysis of all participating countries regarding incidences of osteoporosis, commonly used diagnostic and therapeutic measures, the number of specialists and specialized hospitals, and differences in the reimbursement situation in the different countries was generated and presented. On the whole, the very authentic contributions and the synergistic exchange of ideas allowed the identification of both positive developments as well as still existing issues and needs in diagnosis and therapy of osteoporosis.
C1 [Payer, Juraj] Comenius Univ, Fac Med, Univ Hosp Bratislava, Dept Internal Med 5, Bratislava 82606, Slovakia.
   [Bilezikian, John P.] Columbia Univ Coll Phys & Surg, Metab Bone Dis Unit, Div Endocrinol, New York, NY 10032 USA.
   [Holzer, Gerold] Med Univ Vienna, Dept Orthopaed, A 1090 Vienna, Austria.
   [Lakatos, Peter] Semmelweis Univ, Dept Med 1, Sch Med, H 1083 Budapest, Hungary.
   [Lesnyak, Olga] Ural State Med Acad, Dept Family Med, Ekaterinburg 620102, Russia.
   [Lorenc, Roman] Childrens Mem Hlth Inst, Dept Biochem & Expt Med, PL 04730 Warsaw, Poland.
   [Zendeli, Afrodite; Resch, Heinrich] Med Univ Vienna, Acad Teaching Hosp, St Vincent Hosp, Med Dept KH Barmherzige Schwestern, Stumpergasse 13, A 1060 Vienna, Austria.
C3 Comenius University Bratislava; Slovak Medical University Bratislava;
   Columbia University; Medical University of Vienna; Semmelweis
   University; Ural State Medical University; Children's Memorial Health
   Institute; Medical University of Vienna
RP Resch, H (通讯作者)，Med Univ Vienna, Acad Teaching Hosp, St Vincent Hosp, Med Dept KH Barmherzige Schwestern, Stumpergasse 13, A 1060 Vienna, Austria.
EM payer@ru.unb.sk; jpb2@columbia.edu; gerold.holzer@meduniwien.ac.at;
   lakpet@bell.sote.hu; olga.m.lesnyak@yandex.ru; biochemistry@czd.pl;
   afrodite.zendeli@bhs.at; heinrich.resch@bhs.at
RI Lesnyak, Olga/J 5512 2013; Holzer, Gerold/AAD 6905 2021; Payer,
   Juraj/AAG 1606 2019
OI Lesnyak, Olga/0000 0002 0143 0614; 
CR Anastasilakis AD, 2011, CURR OPIN ENDOCRINOL, V18, P383, DOI 10.1097/MED.0b013e32834afff2
   [Anonymous], ANN REP 2010
   [Anonymous], 2011, OSTEOLOGIE
   Binkley N, 2011, J BONE MINER RES S1, V26
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Gennari L, 2007, ENDOCRIN METAB CLIN, V36, P399, DOI 10.1016/j.ecl.2007.03.008
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2789, DOI 10.1007/s00198 011 1632 z
   Kanis JA, 2010, OSTEOPOROSIS INT, V21, P407, DOI 10.1007/s00198 010 1253 y
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Lakatos Peter, 2011, Arch Osteoporos, V6, P1, DOI 10.1007/s11657 010 0048 2
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Lorenc Roman S, 2009, Arch Osteoporos, V4, P1
   McCloskey Eugene V, 2009, Curr Osteoporos Rep, V7, P77
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Pohlídal A, 2003, CLIN CHEM LAB MED, V41, P74, DOI 10.1515/CCLM.2003.013
   Wagner Eric R, 2011, Curr Mol Pharmacol, V4, P14
NR 18
TC 0
Z9 0
U1 0
U2 61
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD DEC
PY 2013
VL 8
IS 1 2
AR 123
DI 10.1007/s11657 013 0123 6
PG 6
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA V42WW
UT WOS:000209644900010
PM 23400563
DA 2025 08 17
ER

PT J
AU Mazzaferro, S
   Tartaglione, L
   Cascone, C
   Di Daniele, N
   Pani, A
   Morosetti, M
   Francisco, M
   Nordio, M
   Leonardi, M
   Martello, M
   Grimaldi, C
   Cozzolino, M
   Rotondi, S
   Pasquali, M
AF Mazzaferro, Sandro
   Tartaglione, Lida
   Cascone, Carmelo
   Di Daniele, Nicola
   Pani, Antonello
   Morosetti, Massimo
   Francisco, Marco
   Nordio, Maurizio
   Leonardi, Maria
   Martello, Mauro
   Grimaldi, Cristina
   Cozzolino, Mario
   Rotondi, Silverio
   Pasquali, Marzia
CA Italian Study Grp Mineral Met
TI Multicenter study on parathyroidectomy (PTX) in Italy: preliminary
   results
SO JOURNAL OF NEPHROLOGY
LA English
DT Article
DE Parathyroidectomy; Hemodialysis; Peritoneal dialysis; Secondary
   hyperparathyroidism
ID PATIENTS RECEIVING HEMODIALYSIS; DIALYSIS PATIENTS; CARDIOVASCULAR
   CALCIFICATIONS; MINERAL METABOLISM; SERUM CALCIUM; BONE; SURVIVAL;
   HYPERPARATHYROIDISM; NKF K/DOQI(TM); MORTALITY
AB Background When medical therapy is unable to achieve biochemical control of secondary hyperparathyroidism, parathyroidectomy (PTX) is indicated, fortunately in a minority of patients. Thus, data on PTX prevalence and biochemical control are limited and, in particular in Italy, date back to 1999.
   Methods We designed a prospective, observational and multicenter study to collect data from dialysis units distributed throughout the Italian regions. Clinical data were collected with a dedicated data sheet.
   Results From January to December 2010, 149 Centers serving a total of 12,515 patients provided data on 528 living PTX cases (PTX prevalence = 4.2%). Prevalence was higher in hemo  than in peritoneal dialysis (4.5 vs. 1.9%, X 2 = 21.52; p < 0.001), with non significant regional differences (range 0.8 7.4%). PTX patients were younger (57.6 +/  12.5 vs. 67.1 +/  14.5 years; p < 0.001), more frequently female (56 vs. 38%, X 2 = 68.05, p < 0.001) and had been on dialysis for a longer time (14.63 +/  8.37 vs. 4.8 +/  6.0 years, p < 0.001) compared to the 11,987 who did not undergo neck surgery. Median time since surgery was 6.0 years (3.0 9.0; 50%, IQR). The most frequent type of surgery was subtotal PTX (sPTX = 55.0%), significantly higher than total PTX (tPTX = 38.7%) or total PTX plus auto transplantation (aPTX = 6.3%) (X 2 = 5.18; Bonferroni post hoc test, sPTX vs. tPTX + aPTX = p < 0.05). As for parathyroid hormone (PTH), calcium and phosphate control, cases targeting the KDOQI ranges were 18, 50.1 and 54.4%, respectively. The most prevalent biochemical condition was low PTH (62.7%).
   Conclusion PTX prevalence in Italy is stable compared to previous observations, is higher in hemodialysis than in peritoneal dialysis and results in a suboptimal biochemical control.
C1 [Mazzaferro, Sandro; Tartaglione, Lida] Sapienza Univ Rome, Dept Cardiovasc Resp Nephrol & Geriatr Sci, Viale Policlin 155, I 00161 Rome, Italy.
   [Mazzaferro, Sandro; Pasquali, Marzia] Azienda Policlin Umberto I, Nephrol Unit, Rome, Italy.
   [Cascone, Carmelo] Osped Ca Foncello, Nephrol Unit, Treviso, Italy.
   [Di Daniele, Nicola] Policlin Tor Vergata, Nephrol & Dialysis Unit, Rome, Italy.
   [Pani, Antonello] Azienda Osped G Brotzu, Div Nephrol & Dialysis, Cagliari, Italy.
   [Morosetti, Massimo] GB Grassi Hosp, Nephrol Unit, Rome, Italy.
   [Francisco, Marco] Osped Civile Ivrea, Nephrol & Dialysis Unit, Turin, Italy.
   [Nordio, Maurizio] Prov Hosp, Nephrol & Dialysis Unit, Padua, Italy.
   [Leonardi, Maria] Osped Santa Maria Goretti, Nephrol & Dialysis Unit, Latina, Italy.
   [Martello, Mauro] Azienda Osped Osped Riuniti Marche Nord Presidio, Nephrol & Dialysis Unit, Presidio S Salvatore, Pesaro, Italy.
   [Grimaldi, Cristina] Firenze 1 & Empoli, Nephrol Unit, Florence, Italy.
   [Cozzolino, Mario] ASST Santi Paolo & Carlo, Presidio San Paolo, Nephrol & Dialysis Unit, Milan, Italy.
   [Mazzaferro, Sandro; Rotondi, Silverio] Polo Pontino Sapienza Univ Rome, ICOT Hosp, Nephrol & Dialysis Unit, Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome; University Hospital
   Sapienza Rome; ULSS 2 Marca TV; Ospedale Ca' Foncello Treviso;
   University of Rome Tor Vergata; Policlin Tor Vergata
RP Mazzaferro, S (通讯作者)，Sapienza Univ Rome, Dept Cardiovasc Resp Nephrol & Geriatr Sci, Viale Policlin 155, I 00161 Rome, Italy.; Mazzaferro, S (通讯作者)，Azienda Policlin Umberto I, Nephrol Unit, Rome, Italy.; Mazzaferro, S (通讯作者)，Polo Pontino Sapienza Univ Rome, ICOT Hosp, Nephrol & Dialysis Unit, Rome, Italy.
EM sandro.mazzaferro@uniroma1.it
RI ; Tartaglione, Lida/AAA 9895 2019; Pani, Antonello/HDN 3366 2022;
   Mazzaferro, Sandro/E 9321 2012; Rotondi, silverio/AAM 5845 2020; Nordio,
   Maurizio/ABH 1719 2020; Cozzolino, Mario/AAB 9965 2022
OI Tartaglione, Lida/0000 0003 4537 0876; Rotondi,
   Silverio/0000 0003 4553 1756; Mazzaferro, Sandro/0000 0003 3071 1893;
   Cozzolino, Mario/0000 0002 8494 6252; 
FU Amgen
FX This study was funded with an unrestricted grant by Amgen.
CR Akaberi S, 2014, BMC NEPHROL, V15, DOI 10.1186/1471 2369 15 75
   Bell S, 2015, QJM INT J MED, V108, P127, DOI 10.1093/qjmed/hcu170
   Bellasi A, 2018, J NEPHROL, V31, P585, DOI 10.1007/s40620 018 0481 7
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Bover J, 2015, NEPHROL DIAL TRANSPL, V30, P345, DOI 10.1093/ndt/gfv020
   de Oliveira RA, 2015, KIDNEY INT, V87, P1039, DOI 10.1038/ki.2014.372
   Drüeke TB, 2016, KIDNEY INT, V89, P289, DOI 10.1016/j.kint.2015.12.004
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Farcomeni A, 2008, STAT METHODS MED RES, V17, P347, DOI 10.1177/0962280206079046
   Gallieni M, 2016, J NEPHROL, V29, P71, DOI 10.1007/s40620 015 0202 4
   Gupta A, 2000, J AM SOC NEPHROL, V11, P330, DOI 10.1681/ASN.V112330
   Ivarsson KM, 2015, NEPHROL DIAL TRANSPL, V30, P2027, DOI 10.1093/ndt/gfv334
   Iwasaki Ishizuka Y, 2005, NEPHROL DIAL TRANSPL, V20, P1904, DOI 10.1093/ndt/gfh876
   Kestenbaum B, 2004, KIDNEY INT, V66, P2010, DOI 10.1111/j.1523 1755.2004.00972.x
   Kestenbaum B, 2004, KIDNEY INT, V65, P282, DOI 10.1111/j.1523 1755.2004.00368.x
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kovacevic B, 2012, LANGENBECK ARCH SURG, V397, P413, DOI 10.1007/s00423 011 0901 9
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   Fernandez Martín JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099
   Malberti F, 2001, J AM SOC NEPHROL, V12, P1242, DOI 10.1681/ASN.V1261242
   MALLUCHE HH, 1992, KIDNEY INT, V42, pS62
   Mazzaferro S, 2008, NEPHROL DIAL TRANSPL, V23, P2319, DOI 10.1093/ndt/gfm931
   Mazzaferro S, 2014, SEMIN NEPHROL, V34, P598, DOI 10.1016/j.semnephrol.2014.09.006
   Mazzaferro S, 2011, J NEPHROL, V24, P225, DOI 10.5301/JN.2010.6193
   Minuto M, 2014, G ITAL NEFROL, V31, P1
   Parfrey PS, 2013, J CLIN ENDOCR METAB, V98, P4834, DOI 10.1210/jc.2013 2975
   Rault R, 1996, ASAIO J, V42, pM901, DOI 10.1097/00002480 199609000 00123
   SATO S, 1995, MINER ELECTROL METAB, V21, P67
   Scialla JJ, 2015, KIDNEY INT, V88, P220, DOI 10.1038/ki.2015.123
   Tartaglione L, 2017, J NEPHROL, V30, P689, DOI 10.1007/s40620 017 0410 1
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Torres PAU, 2012, KIDNEY INT, V82, P19, DOI 10.1038/ki.2012.69
   Wermers RA, 1997, ANN INTERN MED, V126, P433, DOI 10.7326/0003 4819 126 6 199703150 00003
   Wetmore JB, 2016, BMC SURG, V16, DOI 10.1186/s12893 016 0193 7
   Yamamoto S, 2017, J NEPHROL, V30, P623, DOI 10.1007/s40620 017 0406 x
   Yamamoto T, 2001, AM J KIDNEY DIS, V38, pS161, DOI 10.1053/ajkd.2001.27428
   Yasunaga C, 1999, AM J SURG, V178, P332, DOI 10.1016/S0002 9610(99)00194 4
NR 38
TC 4
Z9 4
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1121 8428
EI 1724 6059
J9 J NEPHROL
JI J. Nephrol.
PD OCT
PY 2018
VL 31
IS 5
BP 767
EP 773
DI 10.1007/s40620 018 0527 x
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA GV8PP
UT WOS:000446407100016
PM 30155676
DA 2025 08 17
ER

PT J
AU Fukao, W
   Hasuike, Y
   Yamakawa, T
   Toyoda, K
   Aichi, M
   Masachika, S
   Kantou, M
   Takahishi, S
   Iwasaki, T
   Yahiro, M
   Nanami, M
   Nagasawa, Y
   Kuragano, T
   Nakanishi, T
AF Fukao, Wataru
   Hasuike, Yukiko
   Yamakawa, Tomo
   Toyoda, Kazuhiro
   Aichi, Makoto
   Masachika, Satoko
   Kantou, Mari
   Takahishi, Shoko (Ikeda)
   Iwasaki, Takahide
   Yahiro, Mana
   Nanami, Masatoshi
   Nagasawa, Yasuyuki
   Kuragano, Takahiro
   Nakanishi, Takeshi
TI Oral Versus Intravenous Iron Supplementation for the Treatment of Iron
   Deficiency Anemia in Patients on Maintenance Hemodialysis Effect on
   Fibroblast Growth Factor 23 Metabolism
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID FGF23; POLYMALTOSE; ACTIVATION; MANAGEMENT; REGULATOR
AB Objective: Iron administration affects serum levels of intact (I ) fibroblast growth factor 23 (FGF23) and its cleavage product C terminal (C ) FGF23 in iron deficient patients on maintenance hemodialysis (MHD). The objective of this study was to compare the effect of oral or intravenous iron administration on serum levels of I FGF23 and C FGF23 in iron deficient patients on MHD.
   Design and Methods: A prospective randomized study.
   Subjects: Participants on MHD with severe iron deficiency (n = 61).
   Intervention: Participants were randomized to receive oral iron (50 mg of sodium ferrous citrate daily; oral group, n = 29) or intravenous iron (40 mg of saccharated ferric oxide weekly; IV group, n = 32).
   Main Outcome Measure: Changes in I FGF23 and C FGF23 after 10 weeks of treatment.
   Results: Iron supplementation significantly increased hemoglobin, mean corpuscular volume, ferritin, and transferrin saturation rate, and decreased erythropoiesis stimulating agent dose and erythropoiesis stimulating agent resistance index value. Serum phosphate, calcium, and intact parathyroid hormone levels did not change significantly during the study. I FGF23 levels increased significantly in the IV group and did not change in the oral group, whereas C FGF23 levels were significantly reduced in both groups. Serum interleukin 6 and tumor necrosis factor alpha levels were increased in both groups. Multiple regression analysis indicated the relationship between iron or erythropoiesis and FGF23 metabolism.
   Conclusion: Iron administration to patients on MHD with severe iron deficiency decreased C FGF23 levels, whereas intravenous iron increased I FGF23 levels though oral iron did not. If the target of chronic kidney disease mineral and bone disorder therapy is reducing I FGF23 levels, we suggest the use of oral iron. (C) 2018 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Fukao, Wataru; Hasuike, Yukiko; Aichi, Makoto; Masachika, Satoko; Kantou, Mari; Takahishi, Shoko (Ikeda); Iwasaki, Takahide; Yahiro, Mana; Nanami, Masatoshi; Nagasawa, Yasuyuki; Kuragano, Takahiro; Nakanishi, Takeshi] Hyogo Coll Med, Dept Internal Med, Div Kidney & Dialysis, 1 1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
   [Fukao, Wataru; Yamakawa, Tomo; Toyoda, Kazuhiro] Meiwa Hosp, Dept Kidney & Dialysis, Nishinomiya, Hyogo, Japan.
C3 Hyogo Medical University
RP Hasuike, Y (通讯作者)，Hyogo Coll Med, Dept Internal Med, Div Kidney & Dialysis, 1 1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
EM cherry39@hyo med.ac.jp
CR Beshara S, 2003, BRIT J HAEMATOL, V120, P853, DOI 10.1046/j.1365 2141.2003.03590.x
   Braithwaite V, 2014, ENDOCR CONNECT, V3, P1, DOI 10.1530/EC 13 0070
   Coe LM, 2014, J BIOL CHEM, V289, P9795, DOI 10.1074/jbc.M113.527150
   David V, 2016, KIDNEY INT, V89, P135, DOI 10.1038/ki.2015.290
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Francis C, 2016, CURR OPIN NEPHROL HY, V25, P325, DOI 10.1097/MNH.0000000000000232
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Grabner A, 2015, CELL METAB, V22, P1020, DOI 10.1016/j.cmet.2015.09.002
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Iguchi A, 2015, NEPHRON, V131, P161, DOI 10.1159/000440968
   Kovesdy CP, 2013, NEPHRON CLIN PRACT, V123, P194, DOI 10.1159/000353593
   Li JP, 2013, BIOMED REP, V1, P85, DOI 10.3892/br.2012.6
   Lofruthe N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158599
   Roberts MA, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882 016 0391 7
   Sindrilaru A, 2011, J CLIN INVEST, V121, P985, DOI 10.1172/JCI44490
   Sonnweber T, 2011, NEPHROL DIAL TRANSPL, V26, P977, DOI 10.1093/ndt/gfq483
   Takeda Y, 2011, AM J NEPHROL, V33, P421, DOI 10.1159/000327019
   Tan SJ, 2017, EUR J CLIN NUTR, V71, P180, DOI 10.1038/ejcn.2016.217
   Touchberry CD, 2013, AM J PHYSIOL ENDOC M, V304, pE863, DOI 10.1152/ajpendo.00596.2012
   Tsai MH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003049
   Weiss G, 2003, KIDNEY INT, V64, P572, DOI 10.1046/j.1523 1755.2003.00099.x
   WINCHESTER JF, 1986, SEMIN NEPHROL, V6, P22
   Wolf M, 2014, CURR OPIN NEPHROL HY, V23, P411, DOI 10.1097/01.mnh.0000447020.74593.6f
   Wolf M, 2013, J BONE MINER RES, V28, P1793, DOI 10.1002/jbmr.1923
   Wolf M, 2011, J AM SOC NEPHROL, V22, P956, DOI 10.1681/ASN.2010080894
   Yamamoto H., 2017, Ren Replace Ther, V3, DOI DOI 10.1186/S41100 017 0114 Y
   Yamashita K, 2016, NEPHROLOGY, V21, P693
   Yokoyama K, 2014, J RENAL NUTR, V24, P261, DOI 10.1053/j.jrn.2014.03.006
   Zoller H, 2017, CURR OPIN NEPHROL HY, V26, P266, DOI 10.1097/MNH.0000000000000329
NR 29
TC 25
Z9 25
U1 1
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1051 2276
EI 1532 8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2018
VL 28
IS 4
BP 270
EP 277
DI 10.1053/j.jrn.2017.12.009
PG 8
WC Nutrition & Dietetics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Urology & Nephrology
GA GL0HB
UT WOS:000436649500010
PM 29703633
DA 2025 08 17
ER

PT J
AU Vidailhet, M
   Mallet, E
   Bocquet, A
   Bresson, JL
   Briend, A
   Chouraqui, JP
   Darmaun, D
   Dupont, C
   Frelut, ML
   Ghisolfi, J
   Girardet, JP
   Goulet, O
   Hankard, R
   Rieu, D
   Simeoni, U
   Turck, D
AF Vidailhet, M.
   Mallet, E.
   Bocquet, A.
   Bresson, J.  L.
   Briend, A.
   Chouraqui, J.  P.
   Darmaun, D.
   Dupont, C.
   Frelut, M.  L.
   Ghisolfi, J.
   Girardet, J.  P.
   Goulet, O.
   Hankard, R.
   Rieu, D.
   Simeoni, U.
   Turck, D.
CA Soc Francaise Pediat
TI Vitamin D: Still a topical matter in children and adolescents. A
   position paper by the Committee on Nutrition of the French Society of
   Paediatrics
SO ARCHIVES DE PEDIATRIE
LA English
DT Article
ID SERUM 25 HYDROXYVITAMIN D; PARATHYROID HORMONE CONCENTRATIONS; D
   DEFICIENCY; D SUPPLEMENTATION; CALCIUM ABSORPTION; BONE DENSITY; GIRLS;
   PREVALENCE; 25(OH)D; RICKETS
AB The aims of the present position paper by the Committee on Nutrition of the French Society of Paediatrics were to summarize the recently published data on vitamin D in infants, children and adolescents, i.e., on metabolism, physiological effects, and requirements and to make recommendations on supplementation after careful review of the evidence. Scientific evidence indicates that calcium and vitamin D play key roles in bone health. The current evidence, limited to observational studies, however, does not support other benefits for vitamin D. More targeted research should continue, especially interventional studies. In the absence of any underlying risk of vitamin D deficiency, the recommendations are as follows: pregnant women: a single dose of 80,000 to 100,000 IU at the beginning of the 7th month of pregnancy; breastfed infants: 1000 to 1200 IU/day; children less than 18 months of age, receiving milk supplemented with vitamin D: an additional daily dose of 600 to 800 I U; children less than 1.8 months of age receiving milk not supplemented with vitamin D: daily dose of 1000 to 1200 IU; children from 18 months to 5 years of age: 2 doses of 80,000 to 100,000 IU every winter (November and February). In the presence of an underlying risk of vitamin D deficiency (dark skin; lack of exposure of the skin to ultraviolet B[UVB] radiation from sunshine in summer; skin disease responsible for decreased exposure of the skin to UVB radiation from sunshine in summer; wearing skin covering clothes in summer; intestinal malabsorption or maldigestion; cholestasis; renal insufficiency; nephrotic syndrome; drugs [rifampicin; antiepileptic treatment: phenobarbital, phenytoin]; obesity; vegan diet), it may be justified to start vitamin D supplementation in winter in children 5 to 10 years of age as well as to maintain supplementation of vitamin D every 3 months all year long in children 1. to 10 years of age and in adolescents. In some pathological conditions, closes of vitamin D can be increased. If necessary, the determination of 25(OH) vitamin D serum concentration will help determine the level of vitamin D supplementation. (C) 2011 Elsevier Masson SAS. All rights reserved.
C1 [Vidailhet, M.] Univ Henri Poincare, Serv Pediat & Genet Clin, Hop Enfants, F 54511 Vandoeuvre Les Nancy, France.
   [Mallet, E.] Univ Rouen, F 76183 Rouen, France.
   [Bocquet, A.] CHU Besancon, Cabinet Pediat, F 25030 Besancon, France.
   [Bresson, J.  L.; Goulet, O.] Univ Paris 05, F 75015 Paris, France.
   [Briend, A.] Inst Rech Sur Dev, F 13572 Marseille, France.
   [Chouraqui, J.  P.] Univ Grenoble 1, F 38042 Grenoble, France.
   [Darmaun, D.] Univ Nantes Atlantique, F 44035 Nantes, France.
   [Dupont, C.; Frelut, M.  L.; Girardet, J.  P.] Univ Paris 06, F 75005 Paris, France.
   [Ghisolfi, J.] Univ Toulouse 3, F 31062 Toulouse, France.
   [Hankard, R.] Univ Poitiers, F 86034 Poitiers, France.
   [Rieu, D.] Univ Montpellier I, F 34060 Montpellier, France.
   [Simeoni, U.] Univ Marseille, F 13005 Marseille, France.
   [Turck, D.] Univ Lille Nord France, F 59000 Lille, France.
C3 CHU de Nancy; Universite de Lorraine; Universite de Rouen Normandie;
   Universite Marie et Louis Pasteur; CHU Besancon; Universite Paris Cite;
   Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA);
   Nantes Universite; Sorbonne Universite; Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; Universite de Poitiers;
   Universite de Montpellier; Aix Marseille Universite; Universite de Lille
RP Vidailhet, M (通讯作者)，Univ Henri Poincare, Serv Pediat & Genet Clin, Hop Enfants, Allee Morvan, F 54511 Vandoeuvre Les Nancy, France.
EM michel.vidailhet@wanadoo.fr
RI Turck, Dominique/S 2382 2018; Simeoni, Umberto/GRO 6971 2022; Darmaun,
   Dominique/X 8453 2018; HANKARD, Regis/A 8771 2009; SIMEONI,
   Umberto/AAQ 1870 2021
OI Turck, Dominique/0000 0003 1370 4667; HANKARD,
   Regis/0000 0001 8450 5839; Darmaun, Dominique/0000 0002 0366 3227;
   Simeoni, Umberto/0000 0003 0730 9337; 
CR Abrams SA, 2009, J CLIN ENDOCR METAB, V94, P2421, DOI 10.1210/jc.2008 2587
   Alix D, 1991, JOURN PAR PED PAR FL, P59
   Andersen R, 2005, EUR J CLIN NUTR, V59, P533, DOI 10.1038/sj.ejcn.1602108
   [Anonymous], 1992, J OFFICIEL REPU 0304, P3243
   [Anonymous], ACT SOC HEBDO, V767, P17
   Bacchetta J, 2010, ARCH PEDIATRIE, V17, P1687, DOI 10.1016/j.arcped.2010.09.003
   Bischoff Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010 0442
   Cashman KD, 2008, AM J CLIN NUTR, V87, P1039, DOI 10.1093/ajcn/87.4.1039
   Cashman KD, 2007, POSTGRAD MED J, V83, P230, DOI 10.1136/pgmj.2006.052787
   Cashman KD, 2011, AM J CLIN NUTR, V93, P549, DOI 10.3945/ajcn.110.006577
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Cheng SL, 2003, AM J CLIN NUTR, V78, P485, DOI 10.1093/ajcn/78.3.485
   Cranney A, 2008, AM J CLIN NUTR, V88, p513S, DOI 10.1093/ajcn/88.2.513S
   Duhamel JF, 2004, ARCH PEDIATR, P148
   El Hajj Fuleihan G, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.4.e53
   El Hajj Fuleihan G, 2006, J CLIN ENDOCR METAB, V91, P405, DOI 10.1210/jc.2005 1436
   Esterle L, 2010, J BONE MINER RES, V25, P2392, DOI 10.1002/jbmr.134
   Esterle L, 2009, J BONE MINER RES, V24, P1389, DOI [10.1359/jbmr.090301, 10.1359/JBMR.090301]
   Etude individuelle nationale des consommations alimentaires (INCA 2), 2006, ETUDE INVIDIDUELLE N
   European food safety authority (EFSA), 2006, TOL UPP LEV VIT MIN
   Fantino M, 2008, ARCH PEDIATRIE, V15, P446, DOI 10.1016/j.arcped.2008.03.002
   Feillet F, 2011, METABOLISME PHOSPHOC, P97
   Garabédian M, 2005, ARCH PEDIATRIE, V12, P410, DOI 10.1016/j.arcped.2004.09.031
   GARABEDIAN M, 1983, J PEDIATR US, V103, P381, DOI 10.1016/S0022 3476(83)80407 7
   Garabedian M, 2011, METABOLISME PHOSPHOC, P1
   Ghisolfi J, 2011, ARCH PEDIATRIE, V18, P355, DOI 10.1016/j.arcped.2010.12.023
   Gordon CM, 2008, ARCH PEDIAT ADOL MED, V162, P505, DOI 10.1001/archpedi.162.6.505
   Heaney RP, 2011, J BONE MINER RES, V26, P455, DOI 10.1002/jbmr.328
   Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287
   Hill KM, 2010, J NUTR, V140, P1983, DOI 10.3945/jn.110.124966
   Hill TR, 2010, OSTEOPOROSIS INT, V21, P695, DOI 10.1007/s00198 009 0959 1
   Hintzpeter B, 2008, J NUTR, V138, P1482, DOI 10.1093/jn/138.8.1482
   Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004 2364
   Holick MF, 2008, J CLIN ENDOCR METAB, V93, P677, DOI 10.1210/jc.2007 2308
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001
   Holick MF, 2008, MOL ASPECTS MED, V29, P361, DOI 10.1016/j.mam.2008.08.008
   Hollis BW, 2004, AM J CLIN NUTR, V80, p1752S, DOI 10.1093/ajcn/80.6.1752S
   Hyppönen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140 6736(01)06580 1
   Institute of Medicine, 2010, DIET REF INT CALC VI
   JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801
   Koutkia P, 2001, NEW ENGL J MED, V345, P66, DOI 10.1056/NEJM200107053450115
   Kreiter SR, 2000, J PEDIATR US, V137, P153, DOI 10.1067/mpd.2000.109009
   Lapatsanis D, 2005, CALCIFIED TISSUE INT, V77, P348, DOI 10.1007/s00223 004 0096 y
   Lehtonen Veromaa MKM, 2002, AM J CLIN NUTR, V76, P1446, DOI 10.1093/ajcn/76.6.1446
   Lips P, 1999, OSTEOPOROSIS INT, V9, P394, DOI 10.1007/s001980050162
   Lips P, 2007, J BONE MINER RES, V22, P1668, DOI 10.1359/JBMR.070716
   Mahon P, 2010, J BONE MINER RES, V25, P14, DOI 10.1359/jbmr.090701
   Mallet E, 2005, ARCH PEDIATRIE, V12, P1797, DOI 10.1016/j.arcped.2005.09.004
   Mallet E, 2004, ARCH PEDIATRIE, V11, P871, DOI 10.1016/j.arcped.2004.04.013
   Mallet E, 2010, ARCH PEDIATRIE, V17, P1042, DOI 10.1016/j.arcped.2010.04.013
   MALLET E, 1986, OBSTET GYNECOL, V68, P300, DOI 10.1097/00006250 198609000 00002
   Mallet E, 2010, EMC
   Mallet E, 2011, C SOC FRANC PED MARS
   Manaseki Holland S, 2010, TROP MED INT HEALTH, V15, P1148, DOI 10.1111/j.1365 3156.2010.02578.x
   MARKESTAD T, 1987, AM J CLIN NUTR, V46, P652, DOI 10.1093/ajcn/46.4.652
   Misra M, 2008, PEDIATRICS, V122, P398, DOI 10.1542/peds.2007 1894
   Norman AW, 2008, AM J CLIN NUTR, V88, p491S, DOI 10.1093/ajcn/88.2.491S
   Outila TA, 2001, AM J CLIN NUTR, V74, P206
   Rajakumar K, 2007, AM J PUBLIC HEALTH, V97, P2121, DOI 10.2105/AJPH.2006.091736e
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Seamans KM, 2009, AM J CLIN NUTR, V89, p1997S, DOI 10.3945/ajcn.2009.27230D
   Sinotte M, 2009, AM J CLIN NUTR, V89, P634, DOI 10.3945/ajcn.2008.26445
   Sullivan SS, 2005, J AM DIET ASSOC, V105, P971, DOI 10.1016/j.jada.2005.03.002
   Thacher TD, 2010, NUTR REV, V68, P682, DOI 10.1111/j.1753 4887.2010.00338.x
   Tylavsky FA, 2007, J AM COLL NUTR, V26, P462, DOI 10.1080/07315724.2007.10719637
   Vervel C, 1997, ARCH PEDIATRIE, V4, P126, DOI 10.1016/S0929 693X(97)86154 4
   Vieth R, 1999, AM J CLIN NUTR, V69, P842
   Vieth R, 2004, J STEROID BIOCHEM, V89 90, P575, DOI 10.1016/j.jsbmb.2004.03.038
   Vieth R, 2007, AM J CLIN NUTR, V85, P649, DOI 10.1093/ajcn/85.3.649
   Viljakainen HT, 2006, J BONE MINER RES, V21, P836, DOI [10.1359/jbmr.060302, 10.1359/JBMR.060302]
   Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542/peds.2008 1862
   Weisberg P, 2004, AM J CLIN NUTR, V80, p1697S, DOI 10.1093/ajcn/80.6.1697S
   Winzenberg T, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7254
   ZEGHOUD F, 1995, ARCH PEDIATRIE, V2, P221, DOI 10.1016/0929 693X(96)81131 6
   Zeghoud F, 1997, AM J CLIN NUTR, V65, P771, DOI 10.1093/ajcn/65.3.771
   2008, J OFFICIEL REPU 0423
NR 78
TC 95
Z9 101
U1 1
U2 36
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0929 693X
EI 1769 664X
J9 ARCH PEDIATRIE
JI Arch. Pediatr.
PD MAR
PY 2012
VL 19
IS 3
BP 316
EP 328
DI 10.1016/j.arcped.2011.12.015
PG 13
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA 913ZB
UT WOS:000301914800020
PM 22284232
DA 2025 08 17
ER

PT J
AU Chua, CW
   Chiu, YT
   Yuen, HF
   Chan, KW
   Man, K
   Wang, XH
   Ling, MT
   Wong, YC
AF Chua, Chee Wai
   Chiu, Yung Tuen
   Yuen, Hiu Fung
   Chan, Kwok Wah
   Man, Kwan
   Wang, Xianghong
   Ling, Ming Tat
   Wong, Yong Chuan
TI Suppression of Androgen Independent Prostate Cancer Cell Aggressiveness
   by FTY720: Validating Runx2 as a Potential Antimetastatic Drug Screening
   Platform
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID N CADHERIN EXPRESSION; IMMUNOSUPPRESSIVE AGENT; TRANSCRIPTION FACTOR;
   OSTEOMIMETIC PROPERTIES; FUNGUS METABOLITE; GROWTH; OSTEOBLAST;
   METASTASIS; APOPTOSIS; PATHWAYS
AB Purpose: Previously, FTY720 was found to possess potent anticancer effects on various types of cancer. In the present study, we aimed to first verify the role of Runx2 in prostate cancer progression and metastasis, and, subsequently, assessed if FTY720 could modulate Runx2 expression, thus interfering downstream events regulated by this protein.
   Experimental Design: First, the association between Runx2 and prostate cancer progression was assessed using localized prostate cancer specimens and mechanistic investigation of Runx2 induced cancer aggressiveness was then carried out. Subsequently, the effect of FTY720 on Runx2 expression and transcriptional activity was investigated using PC 3 cells, which highly expressed Runx2 protein. Last, the involvement of Runx2 in FTY720 induced anticancer effects was evaluated by modulating Runx2 expression in various prostate cancer Cell lines.
   Results: Runx2 nuclear expression was found to be up regulated in prostate cancer and its expression could be used as a predictor of metastasis in prostate cancer. Further mechanistic studies indicated that Runx2 accelerated prostate cancer aggressiveness through promotion of cadherin switching, invasion toward Collagen 1, and Akt activation. Subsequently, we found that FTY720 treatment down regulated Runx2 expression and its transcriptional activity, as well as inhibited its regulated downstream events. More importantly, silencing Runx2 in PC 3 enhanced FTY720 induced anticancer effects as well as cell viability inhibition, whereas overexpressing Runx2 in 22Rv1 that expressed very low endogenous Runx2 protein conferred resistance in the same events.
   Conclusion: This study provided a novel mechanism for the anticancer effect of FTY720 on advanced prostate cancer, thus highlighting the therapeutic potential of this drug in treating this disease.
C1 [Chua, Chee Wai; Chiu, Yung Tuen; Wang, Xianghong; Ling, Ming Tat; Wong, Yong Chuan] Univ Hong Kong, Dept Anat, Fac Med, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China.
   [Yuen, Hiu Fung; Chan, Kwok Wah] Univ Hong Kong, Dept Pathol, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Man, Kwan] Univ Hong Kong, Dept Surg, Fac Med, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong
RP Wong, YC (通讯作者)，Univ Hong Kong, Dept Anat, Fac Med, Canc Biol Grp, Lab Block,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.
EM patling@hkucc.hku.hk; ycwong@hkucc.hku.hk
RI Chua, Chee/G 4135 2014; Chan, Kelvin/HGA 3097 2022
OI Chua, Chee Wai/0000 0002 9634 7265
FU RGC [HKU7490/03M, HKU7470/04M]; HKU Foundation Seed Funding; NSFC/RGC;
   NHKU [738/03]
FX RGC grants HKU7490/03M, HKU7470/04M, HKU Foundation Seed Funding/03,
   NSFC/RGC, NHKU738/03 (YC.Wong).
CR Abate Shen C, 2003, CANCER RES, V63, P3886
   Åberg T, 2004, DEV BIOL, V270, P76, DOI 10.1016/j.ydbio.2004.02.012
   Algan Ö, 1999, RADIAT ONCOL INVEST, V7, P106, DOI 10.1002/(SICI)1520 6823(1999)7:2<106::AID ROI6>3.0.CO;2 J
   Azuma H, 2002, CANCER RES, V62, P1410
   Azuma H, 2003, J UROLOGY, V169, P2372, DOI 10.1097/01.ju.0000064938.32318.91
   Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008 5472.CAN 05 3558
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   BRACKE ME, 2001, METASTASIS RES PROTO, P81
   Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233
   Chua CW, 2005, INT J CANCER, V117, P1039, DOI 10.1002/ijc.21243
   D'Ippolito G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103
   DAmico AV, 1997, UROLOGY, V49, P23, DOI 10.1016/S0090 4295(97)00165 9
   Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097 4644(20010401)81:1<68::AID JCB1024>3.0.CO;2 S
   Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801
   Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022 5347(17)59889 4
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078 0432.CCR 07 1263
   GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439
   Hecht J, 2007, GENE EXPR PATTERNS, V7, P102, DOI 10.1016/j.modgep.2006.05.014
   Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097 0215(20000101)85:1<60::AID IJC11>3.0.CO;2 B
   Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kaplan Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215
   Kim MJ, 2002, CANCER RES, V62, P2999
   Knerr K, 2004, INT J CANCER, V111, P152, DOI 10.1002/ijc.20223
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008 5472.CAN 04 3785
   Lee TK, 2005, CLIN CANCER RES, V11, P8458, DOI 10.1158/1078 0432.CCR 05 0447
   Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776
   Ling MT, 2005, CARCINOGENESIS, V26, P1668, DOI 10.1093/carcin/bgi128
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Matsuda T, 1998, TRANSPLANT P, V30, P2355, DOI 10.1016/S0041 1345(98)00652 6
   MIYAMOTO KK, 1993, J UROLOGY, V149, P1015, DOI 10.1016/S0022 5347(17)36284 5
   ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Shinomiya T, 1997, IMMUNOLOGY, V91, P594, DOI 10.1046/j.1365 2567.1997.d01 2281.x
   Sonoda Y, 2001, BIOCHEM BIOPH RES CO, V281, P282, DOI 10.1006/bbrc.2001.4352
   Tomita K, 2000, CANCER RES, V60, P3650
   Wang JD, 1999, PROSTATE, V40, P50
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   ZAGARS GK, 1995, INT J RADIAT ONCOL, V32, P293, DOI 10.1016/0360 3016(95)00077 C
   Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200
   Zhou C, 2006, CANCER LETT, V233, P36, DOI 10.1016/j.canlet.2005.02.039
NR 50
TC 51
Z9 58
U1 1
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 1
PY 2009
VL 15
IS 13
BP 4322
EP 4335
DI 10.1158/1078 0432.CCR 08 3157
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 482SF
UT WOS:000268908300012
PM 19509141
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Lee, HM
   Kwon, UH
   Kim, H
   Kim, HJ
   Kim, B
   Park, JO
   Moon, ES
   Moon, SH
AF Lee, Hwan Mo
   Kwon, Un Hye
   Kim, Hyang
   Kim, Ho Joong
   Kim, Boram
   Park, Jin Oh
   Moon, Eun Soo
   Moon, Seong Hwan
TI Pulsed Electromagnetic Field Stimulates Cellular Proliferation in Human
   Intervertebral Disc Cells
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Electromagnetic fields; intervertebral disc; nitric oxide; prostaglandin
   E2
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST LIKE CELLS; GENE THERAPY;
   EXPRESSION; DIFFERENTIATION; FRACTURES
AB Purpose: The purpose of this study is to investigate the mechanism of cellular proliferation of electromagnetic field (EMF) on human intervertebral disc (IVD) cells. Materials and Methods: Human IVD cells were cultured three dimensionally in alginate beads. EMF was exposed to IVD cells with 650 Omega, 1.8 millitesla magnetic flux density, 60 Hz sinusoidal wave. Cultures were divided into a control and EMF group. Cytotoxicity, DNA synthesis and proteoglycan synthesis were measured by MTT assay, [H 3] thymidine, and [S 35] sulfate incorporation. To detect phenotypical expression, reverse transcription polymerase chain reactions (RT PCR) were performed for aggrecan, collagen type I, and type II mRNA expression. To assess action mechanism of EMF, IVD cells were exposed to EMF with N G Monomethyl L arginine (NMMA) and acetylsalicylic acid (ASA). Results: There was no cytotoxicity in IVD cells with the EMF group in MTT assay. Cellular proliferation was observed in the EMF group (p < 0.05). There was no difference in newly synthesized proteoglycan normalized by DNA synthesis between the EMF group and the control. Cultures with EMF showed no significant change in the expression of aggrecan, type I, and type II collagen mRNA compared to the control group. Cultures with NMMA (blocker of nitric oxide) or ASA (blocker of prostaglandin E2) exposed to EMF demonstrated decreased DNA synthesis compared to control cultures without NMMA or ASA (p < 0.05). Conclusion: EMF stimulated DNA synthesis in human IVD cells while no significant effect on proteoglycan synthesis and chondrogenic phenotype expressions. DNA synthesis was partially mediated by nitric oxide and prostaglandin E2. EMF can be utilized to stimulate proliferation of IVD cells, which may provide efficient cell amplification in cell therapy to degenerative disc disease.
C1 [Lee, Hwan Mo; Kim, Ho Joong; Kim, Boram; Park, Jin Oh; Moon, Eun Soo; Moon, Seong Hwan] Yonsei Univ, Coll Med, Dept Orthopaed Surg, Seoul 102752, South Korea.
   [Kwon, Un Hye; Kim, Hyang; Moon, Seong Hwan] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 102752, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Moon, SH (通讯作者)，Yonsei Univ, Coll Med, Dept Orthopaed Surg, 250 Seongsan Ro, Seoul 102752, South Korea.
EM shmoon@yuhs.ac
RI ; Lee, Jung Bok/HHZ 3200 2022
OI Lee, Jung Bok/0000 0001 9227 2027; Lee, Hwan Mo/0000 0002 5405 3832; 
FU Yonsei University College of Medicine
FX This research is supported, in part, by Brain Korea 21 Project for
   Medical Science and Yuhan CMB, Yonsei University College of Medicine.
CR BORSALINO G, 1988, CLIN ORTHOP RELAT R, P256
   CHELBERG MK, 1995, J ANAT, V186, P43
   Ciombor DM, 2002, J ORTHOP RES, V20, P40
   COLSON DJ, 1988, J BIOMED ENG, V10, P301, DOI 10.1016/0141 5425(88)90058 1
   De Mattei M, 2005, BIOELECTROMAGNETICS, V26, P207, DOI 10.1002/bem.20068
   FITZSIMMONS RJ, 1994, CLIN PLAST SURG, V21, P401
   FITZSIMMONS RJ, 1995, J BONE MINER RES, V10, P812
   Foley KT, 2008, SPINE J, V8, P436, DOI 10.1016/j.spinee.2007.06.006
   Frazer A, 1994, Osteoarthritis Cartilage, V2, P235
   Hiyama A, 2008, J ORTHOP RES, V26, P589, DOI 10.1002/jor.20584
   HOLMES GB, 1994, FOOT ANKLE INT, V15, P552, DOI 10.1177/107110079401501006
   Hoogendoorn R, 2008, SPINE, V33, P1714, DOI 10.1097/BRS.0b013e31817d2468
   Katz JN, 2006, J BONE JOINT SURG AM, V88A, P21, DOI 10.2106/JBJS.E.01273
   Kim DJ, 2003, SPINE, V28, P2679, DOI 10.1097/01.BRS.0000101445.46487.16
   Kim H, 2009, SPINE, V34, P1834, DOI 10.1097/BRS.0b013e3181ae18ba
   Lin HY, 2010, J ORTHOP RES, V28, P265, DOI 10.1002/jor.20964
   MALDONADO BA, 1992, J ORTHOP RES, V10, P677, DOI 10.1002/jor.1100100510
   McLeod KJ, 2000, RADIAT RES, V153, P706, DOI 10.1667/0033 7587(2000)153[0706:SOADRI]2.0.CO;2
   Moon SH, 2008, SPINE, V33, P1850, DOI 10.1097/BRS.0b013e31817e1cd7
   Nishida K, 1999, SPINE, V24, P2419, DOI 10.1097/00007632 199912010 00002
   Roberts S, 2006, J BONE JOINT SURG AM, V88A, P10, DOI 10.2106/JBJS.F.00019
   Schnoke M, 2007, J ORTHOP RES, V25, P933, DOI 10.1002/jor.20373
   THOMPSON JP, 1990, SPINE, V15, P411, DOI 10.1097/00007632 199005000 00012
   Yang XL, 2009, EUR SPINE J, V18, P1564, DOI 10.1007/s00586 009 1092 8
   YENPATTON GPA, 1988, J CELL PHYSIOL, V134, P37, DOI 10.1002/jcp.1041340105
NR 25
TC 20
Z9 22
U1 1
U2 10
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50 1 YONSEI RO, SEODAEMUN GU, SEOUL 120 752, SOUTH KOREA
SN 0513 5796
EI 1976 2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD NOV 1
PY 2010
VL 51
IS 6
BP 954
EP 959
DI 10.3349/ymj.2010.51.6.954
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 672CN
UT WOS:000283560700023
PM 20879066
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Ugarteburu, M
   Cardoso, L
   Richter, CP
   Carriero, A
AF Ugarteburu, Maialen
   Cardoso, Luis
   Richter, Claus Peter
   Carriero, Alessandra
TI Treatments for hearing loss in osteogenesis imperfecta: a systematic
   review and meta analysis on their efficacy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STAPES SURGERY; COCHLEAR IMPLANTATION; 3RD GENERATION BISPHOSPHONATES;
   TEMPORAL BONE; TERM; STAPEDOTOMY; PATIENT; HISTOPATHOLOGY; OTOSCLEROSIS;
   CHILDREN
AB About 70% of people with osteogenesis imperfecta (OI) experience hearing loss. There is no cure for OI, and therapies to ameliorate hearing loss rely on conventional treatments for auditory impairments in the general population. The success rate of these treatments in the OI population with poor collagenous tissues is still unclear. Here, we conduct a systematic review and meta analysis on the efficacy of treatments addressing hearing loss in OI. This study conforms to the reporting standards of the Preferred Reporting Items for Systematic Reviews and Meta analyses (PRISMA). Data sources include published articles in Medline via PubMed, Web of Science, Scopus, and Embase, from their inception to November 2020. Studies included individuals with OI undergoing a hearing loss treatment, having pre  and postoperative objective assessment of hearing function at a specified follow up length. Our search identified 1144 articles, of which 67 were reviewed at full text screening. A random effects meta analysis was conducted on the selected articles (n = 12) of people with OI that underwent stapes surgery. Success was assessed as the proportion of ears with a postoperative Air Bone Gap (ABG) <= 10 dB. A systematic review was conducted on the remaining articles (n = 13) reporting on other treatments. No meta analysis was conducted on the latter due to the low number of articles on the topic and the nature of single case studies. The meta analysis shows that stapes surgeries have a low success rate of 59.08 (95% CI 45.87 to 71.66) in the OI population. The systematic review revealed that cochlear implants, bone anchored hearing aids, and other implantable hearing aids proved to be feasible, although challenging, in the OI population, with only 2 unsuccessful cases among the 16 reviewed single cases. This analysis of published data on OI shows poor clinical outcomes for the procedures addressing hearing loss. Further studies on hearing loss treatments for OI people are needed. Notably, the mechanisms of hearing loss in OI need to be determined to develop successful and possibly non invasive treatment strategies.
C1 [Ugarteburu, Maialen; Cardoso, Luis; Carriero, Alessandra] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA.
   [Richter, Claus Peter] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA.
   [Richter, Claus Peter] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Richter, Claus Peter] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA.
   [Richter, Claus Peter] Northwestern Univ, Hugh Knowles Ctr, Evanston, IL USA.
C3 City University of New York (CUNY) System; City College of New York
   (CUNY); Northwestern University; Feinberg School of Medicine;
   Northwestern University; Northwestern University; Northwestern
   University
RP Carriero, A (通讯作者)，CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA.
EM acarriero@ccny.cuny.edu
RI Cardoso, Luis Guilherme/KXR 4696 2024; Carriero, Alessandra/D 7893 2013
OI Carriero, Alessandra/0000 0001 8103 4795
FU National Science Foundation [CBET 1829310]
FX This work was supported by the National Science Foundation
   (CBET 1829310).
CR Albahnasawy L, 2001, CLIN OTOLARYNGOL, V26, P473, DOI 10.1046/j.1365 2273.2001.00504.x
   ARMSTRONG BW, 1984, ANN OTO RHINOL LARYN, V93, P634, DOI 10.1177/000348948409300618
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BERGER G, 1985, LARYNGOSCOPE, V95, P193
   BERGSTROM L, 1981, CLIN ORTHOP RELAT R, P58
   Brodd I., 2011, KLINIC VETENSKAP, V108, P1906
   BROSNAN M, 1977, ARCH OTOLARYNGOL, V103, P294
   Carré F, 2019, EUR ANN OTORHINOLARY, V136, P379, DOI 10.1016/j.anorl.2019.05.004
   Coutinho MB, 2015, J LARYNGOL OTOL, V129, P1133, DOI 10.1017/S0022215115002510
   COX JR, 1982, SOUTHERN MED J, V75, P1222, DOI 10.1097/00007611 198210000 00016
   CREMERS C, 1989, AM J OTOL, V10, P474
   Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142
   Otavio ACD, 2020, EUR ARCH OTO RHINO L, V277, P1005, DOI 10.1007/s00405 020 05799 x
   De Paolis A, 2021, J STRUCT BIOL, V213, DOI 10.1016/j.jsb.2021.107708
   Dieler R, 1997, EUR ARCH OTO RHINO L, V254, P120, DOI 10.1007/BF02471274
   Doi K, 2007, ADV OTO RHINO LARYNG, V65, P226, DOI 10.1159/000098827
   Egger M, 1997, BMJ BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   El Dib R, 2013, ACTA CIR BRAS, V28, P870, DOI 10.1590/S0102 86502013001200010
   Ferekidis E, 2000, J LARYNGOL OTOL, V114, P424
   Garretsen AJTM, 1997, ANN OTO RHINOL LARYN, V106, P575, DOI 10.1177/000348949710600709
   GARRETSEN TJTM, 1991, ANN NY ACAD SCI, V630, P240, DOI 10.1111/j.1749 6632.1991.tb19594.x
   GARRETSEN TJTM, 1991, ANN OTO RHINOL LARYN, V100, P120
   GARRETSEN TJTM, 1990, ARCH OTOLARYNGOL, V116, P317
   Hartikka H, 2004, HUM MUTAT, V24, P147, DOI 10.1002/humu.20071
   Heimert Tamra L, 2002, Radiology, V224, P166, DOI 10.1148/radiol.2241001707
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang TS, 1998, AM J OTOLARYNG, V19, P209, DOI 10.1016/S0196 0709(98)90090 4
   Hulcrantz M., 2020, STAPES SURG OSTEOGEN, P1
   Imani P, 2003, CLIN OTOLARYNGOL, V28, P199, DOI 10.1046/j.1365 2273.2003.00685.x
   Jan TA, 2017, LARYNGOSCOPE INVEST, V2, P262, DOI 10.1002/lio2.91
   Kontorinis G, 2011, OTOL NEUROTOL, V32, P589, DOI 10.1097/MAO.0b013e318213b0f1
   Kuurila K, 2000, EUR J PEDIATR, V159, P515, DOI 10.1007/s004310051322
   Kuurila K, 2004, ANN OTO RHINOL LARYN, V113, P187, DOI 10.1177/000348940411300303
   Kuurila K, 2002, ANN OTO RHINOL LARYN, V111, P939, DOI 10.1177/000348940211101014
   허준영, 2009, [Korean Journal of Otorhinolaryngology Head and Neck Surgery, 대한이비인후과학회지 두경부외과학], V52, P289
   Lim ZW, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 60979 3
   Ma XY, 2020, ACTA OTO LARYNGOL, V140, P930, DOI 10.1080/00016489.2020.1786161
   Machol K, 2020, AM J MED GENET A, V182, P697, DOI 10.1002/ajmg.a.61464
   Makizumi Y, 2013, AURIS NASUS LARYNX, V40, P510, DOI 10.1016/j.anl.2012.10.006
   Marfatia H, 2020, COCHLEAR IMPLANTS IN, V21, P121, DOI 10.1080/14670100.2019.1678894
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Mens LHM, 2002, ANN OTO RHINOL LARYN, V111, P370, DOI 10.1177/000348940211100415
   Mezzedimi C., 2013, J RHINOLARYNGO OTOL, V1, P11
   Migirov L, 2003, INT J PEDIATR OTORHI, V67, P677, DOI 10.1016/S0165 5876(03)00073 9
   Muñoz A, 2021, CURR OSTEOPOROS REP, V19, P510, DOI 10.1007/s11914 021 00696 6
   National Health Lunch and Blood Institute (NHLBI), 2020, STUD QUAL ASS TOOLS
   OCEBM O.C.f.E.B.M, 2021, OXF LEV EV 2
   Palomo T, 2017, CURR OPIN ENDOCRINOL, V24, P381, DOI 10.1097/MED.0000000000000367
   Pedersen U, 1985, Acta Otolaryngol Suppl, V415, P1
   PEDERSEN U, 1983, ORL J OTO RHIN LARYN, V45, P330, DOI 10.1159/000275663
   PEDERSEN U, 1984, SCAND AUDIOL, V13, P67, DOI 10.3109/01050398409043042
   Pillion JP, 2008, J AM ACAD AUDIOL, V19, P595, DOI 10.3766/jaaa.19.8.3
   Pillion JP, 2011, GENET RES INT, V2011, DOI 10.4061/2011/983942
   Quesnel AM, 2012, OTOL NEUROTOL, V33, P1308, DOI 10.1097/MAO.0b013e318268d1b3
   RIEDNER ED, 1980, ARCH OTOLARYNGOL, V106, P737
   Rotteveel LJC, 2008, AUDIOL NEURO OTOL, V13, P73, DOI 10.1159/000111779
   Sainz M, 2009, ACTA OTORRINOLAR ESP, V60, P126
   Santos F, 2012, OTOL NEUROTOL, V33, P1562, DOI 10.1097/MAO.0b013e31826bf19b
   SHEA JJ, 1982, ARCH OTOLARYNGOL, V108, P467
   SILLENCE D, 1981, CLIN ORTHOP RELAT R, P11
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Skarzynski H, 2019, AURIS NASUS LARYNX, V46, P853, DOI 10.1016/j.anl.2019.04.001
   Skarzynski H, 2018, J INT ADV OTOL, V14, P478, DOI 10.5152/iao.2018.5643
   STEWART EJ, 1989, CLIN OTOLARYNGOL, V14, P509, DOI 10.1111/j.1365 2273.1989.tb00414.x
   Streubel SO, 2005, OTOLARYNG HEAD NECK, V132, P735, DOI 10.1016/j.otohns.2004.12.012
   Swinnen FKR, 2012, AUDIOL NEURO OTOL, V17, P198, DOI 10.1159/000336211
   Swinnen FKR, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 88
   Swinnen FKR, 2012, LARYNGOSCOPE, V122, P401, DOI 10.1002/lary.22408
   Swinnen FKR, 2012, OTOL NEUROTOL, V33, P115, DOI 10.1097/MAO.0b013e31823e28e9
   Swinnen FKR, 2009, LARYNGOSCOPE, V119, P1171, DOI 10.1002/lary.20155
   Szilvassy J., 1998, Acta Oto Rhino Laryngologica Belgica, V52, P253
   Ting TH, 2012, CLIN OTOLARYNGOL, V37, P229, DOI 10.1111/j.1749 4486.2012.02476.x
   van der Rijt AJM, 2003, OTOL NEUROTOL, V24, P717, DOI 10.1097/00129492 200309000 00004
   Vianna MF, 2013, OTOL NEUROTOL, V34, pE113, DOI 10.1097/MAO.0b013e31829420e4
   Vincent R, 2005, OTOL NEUROTOL, V26, P859, DOI 10.1097/01.mao.0000172410.85992.21
   Vincent R, 2006, OTOL NEUROTOL, V27, pS25, DOI 10.1097/01.mao.0000235311.80066.df
   Vincent R, 2014, OTOL NEUROTOL, V35, P1785, DOI 10.1097/MAO.0000000000000372
   World Health Organization W, DEAFN HEAR LOSS
NR 78
TC 9
Z9 10
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 12
PY 2022
VL 12
IS 1
AR 17125
DI 10.1038/s41598 022 20169 9
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 5H0FU
UT WOS:000867364300075
PM 36224204
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bekic, M
   Vasiljevic, M
   Stojanovic, D
   Kokol, V
   Mihajlovic, D
   Vucevic, D
   Uskokovic, P
   Colic, M
   Tomic, S
AF Bekic, Marina
   Vasiljevic, Milos
   Stojanovic, Dusica
   Kokol, Vanja
   Mihajlovic, Dusan
   Vucevic, Dragana
   Uskokovic, Petar
   Colic, Miodrag
   Tomic, Sergej
TI Phosphonate Modified Cellulose Nanocrystals Potentiate the Th1
   Polarising Capacity of Monocyte Derived Dendritic Cells via GABA B
   Receptor
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE cellulose nanocrystals; phosphonates; dendritic cells; immunomodulation;
   GABA B receptor
ID REGULATORY T CELLS; TR1 CELLS; INDUCTION; MECHANISMS; PROTEIN; ACID;
   FUNCTIONALIZATION; BISPHOSPHONATES; DIFFERENTIATION; EXPRESSION
AB Purpose: Phosphonates, like 3 AminoPropylphosphonic Acid (ApA), possess a great potential for the therapy of bone tumours, and their delivery via cellulose nanocrystals (CNCs) seems a promising approach for their increased efficacy in target tissues. However, the immunological effects of CNC phosphonates have not been investigated thoroughly. The main aim was to examine how the modification of CNCs with phosphonate affects their immunomodulatory properties in human cells.Methods: Wood based native (n) CNCs were modified via oxidation (ox CNCs) and subsequent conjugation with ApA (ApA CNCs). CNCs were characterised by atomic force microscopy (AFM) and nanoindentation. Cytotoxicity and immunomodulatory potential of CNCs were investigated in cultures of human peripheral blood mononuclear cells (PBMCs) and monocyte derived dendritic cells (MoDCs)/T cells co cultures by monitoring phenotype, cytokines production, allostimulatory and Th/Treg polarisation capacity. Results: AFM showed an increase in CNCs' thickens, elasticity modulus and hardness during the modification with ApA. When applied at non toxic doses, nCNCs showed a tolerogenic potential upon internalisation by MoDCs, as judged by their increased capacity to up regulate tolerogenic markers and induce regulatory T cells (Treg), especially when present during the differentiation of MoDCs. In contrast, ox and ApA CNCs induced oxidative stress and autophagy in MoDCs, which correlated with their stimulatory effect on the maturation of MoDCs, but also inhibition of MoDCs differentiation. ApA CNC treated MoDCs displayed the highest allostimulatory and Th1/CTL polarising activity in co cultures with T cells. These effects of ApA CNCs were mediated via GABA B receptor induced lowering of cAMP levels in MoDCs, and they could be blocked by GABA B receptor inhibitor. Moreover, the Th1 polarising and allostimulatory capacity of MoDCs differentiated with ApA CNC were largely preserved upon the maturation of MoDCs, whereas nCNC and ox CNC differentiated MoDCs displayed an increased tolerogenic potential. Conclusion: The delivery of ApA via CNCs induces potent DC mediated Th1 polarisation, which could be beneficial in their potential application in tumour therapy.
C1 [Bekic, Marina; Colic, Miodrag; Tomic, Sergej] Univ Belgrade, Inst Applicat Nucl Energy, Dept Immunol & Immunoparasitol, Belgrade, Serbia.
   [Vasiljevic, Milos; Mihajlovic, Dusan; Vucevic, Dragana; Colic, Miodrag] Univ East Sarajevo, Med Fac Foca, Ctr Biomed Sci, Foca, Bosnia & Herceg.
   [Stojanovic, Dusica; Uskokovic, Petar] Univ Belgrade, Fac Technol & Met, Dept Construct & Special Mat, Belgrade, Serbia.
   [Kokol, Vanja] Univ Maribor, Fac Mech Engn, Dept Text Mat & Design, Maribor, Slovenia.
   [Colic, Miodrag] Serbian Acad Arts & Sci, Belgrade, Serbia.
   [Tomic, Sergej] Univ Belgrade, Inst Applicat Nucl Energy, Banatska 31b, Belgrade 11080, Serbia.
C3 University of Belgrade; University of East Sarajevo; University of
   Belgrade; University of Maribor; Serbian Academy of Sciences & Arts;
   University of Belgrade
RP Tomic, S (通讯作者)，Univ Belgrade, Inst Applicat Nucl Energy, Dept Immunol & Immunoparasitol, Belgrade, Serbia.; Tomic, S (通讯作者)，Univ Belgrade, Inst Applicat Nucl Energy, Banatska 31b, Belgrade 11080, Serbia.
EM sergej.tomic@inep.co.rs
RI ; Stojanovic, Dusica/AAH 8516 2020
OI Bekic, Marina/0000 0002 6945 4241; Tomic, Sergej/0000 0003 2570 1295;
   Stojanovic, Dusica/0000 0001 6308 7586
FU Ministry of Education, Science and Technological Development [451 
   03 9/2021 14/200019]; Science Fund of the Republic of Serbia [6062673]
FX Acknowledgments This research was supported by the Ministry of
   Education, Science and Technological Development (Contract No. 451 
   03 9/2021 14/200019) and the Science Fund of the Republic of Serbia
   (PROMIS, #6062673, Nano MDSC Thera) . The authors are grateful to Bojan
   Joksimovi?, Marija Drakul and Nata?a Ili? for kind help during the
   experiments.
CR Asadzadeh Z, 2017, CELL IMMUNOL, V322, P15, DOI 10.1016/j.cellimm.2017.10.015
   Aue G, 2018, J IMMUNOL, V201, P1967, DOI 10.4049/jimmunol.1800570
   Bauer K, 2009, Cell Commun. Signal., V7, pA68, DOI 10.1186/1478 811X 7 S1 A68
   Bazhin AV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02129
   Bhandage AK, 2021, CELL MOL LIFE SCI, V78, P5667, DOI 10.1007/s00018 021 03881 z
   Bhattacharjee S, 2016, J CONTROL RELEASE, V235, P337, DOI 10.1016/j.jconrel.2016.06.017
   Black JB, 2016, SEMIN CELL DEV BIOL, V50, P95, DOI 10.1016/j.semcdb.2015.12.015
   Body JJ, 2002, SUPPORT CARE CANCER, V10, P399, DOI 10.1007/s005200100292
   Catalán J, 2015, ENVIRON MOL MUTAGEN, V56, P171, DOI 10.1002/em.21913
   Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008
   Cheong TC, 2015, ACS CHEM BIOL, V10, P757, DOI 10.1021/cb5009124
   Colic M, 2020, IMMUNOL LETT, V222, P80, DOI 10.1016/j.imlet.2020.04.004
   Colic M, 2015, CELLULOSE, V22, P763, DOI 10.1007/s10570 014 0524 8
   Colic M, 2014, CARBON, V67, P273, DOI 10.1016/j.carbon.2013.09.090
   Colombo L, 2015, BIOMACROMOLECULES, V16, P2862, DOI 10.1021/acs.biomac.5b00805
   Conley K, 2016, CARBOHYD POLYM, V135, P285, DOI 10.1016/j.carbpol.2015.08.029
   Crowley T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00284
   Del Prete A, 2008, FREE RADICAL BIO MED, V44, P1443, DOI 10.1016/j.freeradbiomed.2007.12.037
   Deleyto Seldas N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.655731
   Demirci G, 2021, ACS APPL POLYM MATER, V3, P3776, DOI 10.1021/acsapm.1c00297
   Despres HW, 2019, TOXICOL IN VITRO, V55, P124, DOI 10.1016/j.tiv.2018.12.009
   Dokic J, 2013, EUR J IMMUNOL, V43, P1862, DOI 10.1002/eji.201243010
   Drogat N, 2011, Photodiagn. Photodyn. Ther, V8, P157, DOI [10.1016/j.pdpdt.2011.03.114, DOI 10.1016/J.PDPDT.2011.03.114]
   Endes C, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0230 9
   Endo R, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47799 w
   Erdem JS, 2019, BIOMATERIALS, V203, P31, DOI 10.1016/j.biomaterials.2019.02.025
   Forteza MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00950
   Ghislat G, 2018, CELL MOL IMMUNOL, V15, P944, DOI 10.1038/cmi.2018.2
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Gorgieva S, 2017, CELLULOSE, V24, P4235, DOI 10.1007/s10570 017 1432 5
   Grkovic M, 2017, COMPOS PART B ENG, V121, P58, DOI 10.1016/j.compositesb.2017.03.024
   Guo JT, 2015, CELL MOL IMMUNOL, V12, P525, DOI 10.1038/cmi.2015.12
   Guo P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02588 9
   Heystek HC, 2003, INT IMMUNOL, V15, P827, DOI 10.1093/intimm/dxg079
   Hillmer EJ, 2016, CYTOKINE GROWTH F R, V31, P1, DOI 10.1016/j.cytogfr.2016.05.001
   HILLS JM, 1989, BRIT J PHARMACOL, V97, P1292, DOI 10.1111/j.1476 5381.1989.tb12591.x
   Hoeger I, 2011, SOFT MATTER, V7, P1957, DOI 10.1039/c0sm01113d
   Huang SC, 2015, J CELL PHYSIOL, V230, P1438, DOI 10.1002/jcp.24884
   Jahnke W, 2015, ANGEW CHEM INT EDIT, V54, P14575, DOI 10.1002/anie.201507064
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Krishnamachari P, 2012, CELL CHEM TECHNOL, V46, P13
   Kupnik K, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12122825
   Landry V, 2011, FOREST PROD J, V61, P104, DOI 10.13073/0015 7473 61.2.104
   Lee HL, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40078 8
   Li M, 2010, CELL SIGNAL, V22, P1469, DOI 10.1016/j.cellsig.2010.05.015
   Li QS, 2016, J IMMUNOL, V197, P962, DOI 10.4049/jimmunol.1502615
   Lin N, 2014, EUR POLYM J, V59, P302, DOI 10.1016/j.eurpolymj.2014.07.025
   Ma NN, 2013, J NANOSCI NANOTECHNO, V13, P6485, DOI 10.1166/jnn.2013.7525
   MacDonald AS, 2002, J IMMUNOL, V168, P537, DOI 10.4049/jimmunol.168.2.537
   Meliilo JA, 2010, J IMMUNOL, V184, P2638, DOI 10.4049/jimmunol.0902960
   Ng THS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00129
   Njoroge JM, 2018, INT J NANOMED, V13, P8365, DOI 10.2147/IJN.S174184
   Oliver WC, 2004, J MATER RES, V19, P3, DOI 10.1557/jmr.2004.19.1.3
   Pavlovic B, 2015, CYTOTHERAPY, V17, P1763, DOI 10.1016/j.jcyt.2015.08.001
   Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood 2005 05 2044
   Pot C, 2011, SEMIN IMMUNOL, V23, P438, DOI 10.1016/j.smim.2011.08.003
   Prins MMC, 2021, J IMMUNOL METHODS, V497, DOI 10.1016/j.jim.2021.113106
   Qin WT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02298
   Qu CF, 2014, INT J INFECT DIS, V19, P1, DOI 10.1016/j.ijid.2013.09.023
   Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569
   Ray P, 2021, J IMMUNOL SCI, V5, P19, DOI [10.29245/2578 3009/2021/1.1206, DOI 10.29245/2578 3009/2021/1.1206]
   Rotta G, 2003, J EXP MED, V198, P1253, DOI 10.1084/jem.20030335
   Salazar F, 2017, SCI REP UK, V7, DOI 10.1038/srep43337
   SANSOM DM, 1993, IMMUNOLOGY, V80, P242
   Shvedova AA, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989 016 0140 x
   Stankovic JA, 2004, LIFE SCI, V75, P3053, DOI 10.1016/j.lfs.2004.06.007
   Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040
   Sunasee Rajesh, 2015, Biochem Biophys Rep, V4, P1, DOI 10.1016/j.bbrep.2015.08.008
   TASHIRO K, 1991, POLYMER, V32, P1516, DOI 10.1016/0032 3861(91)90435 L
   Tomic S, 2018, INT J NANOMED, V13, P6941, DOI 10.2147/IJN.S183510
   Tomic S, 2017, BIOMATERIALS, V146, P13, DOI 10.1016/j.biomaterials.2017.08.040
   Tomic S, 2016, SCI REP UK, V6, DOI 10.1038/srep31618
   Tomic S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096584
   Tuerxun D, 2019, EUR POLYM J, V116, P352, DOI 10.1016/j.eurpolymj.2019.04.021
   Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366
   Vlad G, 2008, HUM IMMUNOL, V69, P681, DOI 10.1016/j.humimm.2008.08.286
   Wang X, 2019, SMALL, V15, DOI 10.1002/smll.201901642
   Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood 2002 06 1688
   Wu Q, 2013, IND CROP PROD, V48, P28, DOI 10.1016/j.indcrop.2013.03.032
   Yanamala N, 2014, ACS SUSTAIN CHEM ENG, V2, P1691, DOI 10.1021/sc500153k
   Yang MY, 2021, BIOACT MATER, V6, P1973, DOI 10.1016/j.bioactmat.2020.12.010
   Yao Y, 2015, J IMMUNOL, V195, P488, DOI 10.4049/jimmunol.1403225
   Yong MK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01506
   Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200
   Zeng HY, 2015, CELL MOL IMMUNOL, V12, P566, DOI 10.1038/cmi.2015.44
   Zhang RL, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34667 2
   Zhou ZK, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1146
   Zoia L, 2020, NANOMEDICINE UK, V15, P2271, DOI 10.2217/nnm 2020 0139
NR 88
TC 6
Z9 6
U1 5
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2022
VL 17
BP 3191
EP 3216
DI 10.2147/IJN.S362038
PG 26
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA 3I7KH
UT WOS:000832890200001
PM 35909813
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, JY
   Song, L
   Hou, M
   Wang, P
   Wei, LL
   Song, H
AF Li, Jingyuan
   Song, Ling
   Hou, Meng
   Wang, Ping
   Wei, Lingling
   Song, Hui
TI Carbon monoxide releasing molecule 3 promotes the osteogenic
   differentiation of rat bone marrow mesenchymal stem cells by releasing
   carbon monoxide
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE carbon monoxide releasing molecule 3; bone marrow mesenchymal stem
   cells; osteogenic differentiation; runt related transcription factor 2;
   osteocalcin; osteopontin
ID PROTEIN KINASE PATHWAY; HEME OXYGENASE 1; GENE EXPRESSION; MORPHOGENETIC
   PROTEINS; GROWTH FACTORS; LUNG INJURY; OSTEOBLASTS; REGENERATION; RUNX2;
   ROAD
AB Stem cell based therapies are promising strategies to stimulate bone regeneration. Carbon monoxide releasing molecule 3 (CORM 3) exhibits multiple regulatory effects in a number of cells by releasing carbon monoxide (CO). The present study aimed to investigate the influence of CORM 3 on the osteogenic differentiation of rat bone marrow mesenchymal stem cells (BMSCs). BMSCs were divided into five groups: A CORM 3 osteogenic group, in which cells were pretreated with CORM 3 and subjected to osteogenic differentiation induction using osteogenic medium; an osteogenic group, in which cells were cultured in osteogenic medium; a degassed CORM 3 osteogenic group, in which cells were pretreated with degassed CORM 3 and subjected to osteogenic differentiation induction; a CORM 3 group, in which cells were cultured in control medium containing CORM 3; and a control group, in which cells were cultured in control medium alone. The osteo specific mRNA and protein expression of runt related transcription factor 2 (Runx2), osteocalcin (OCN) and osteopontin (OPN) were assessed using reverse transcription quantitative polymerase chain reaction and western blot analysis. Alkaline phosphatase (ALP) activity was also examined and mineralization was detected using alizarin red staining. Levels of Runx2, OCN and OPN mRNA and protein in the CORM 3 osteogenic group were significantly increased compared with the osteogenic group (P<0.05), with the exception of OCN protein levels on day 3. The mRNA and protein expression of Runx2, OCN and OPN in the degassed CORM 3 osteogenic and osteogenic groups were similar. In addition, the mRNA and protein expression of Runx2, OCN and OPN in the CORM 3 and control group were similar. ALP activity in the CORM 3 osteogenic group was increased from day 3 and remained significantly higher compared with all other groups on days 3, 5 and 7 (P<0.05). Additionally, the results indicated that the optical density value of alizarin red staining in the CORM 3 osteogenic group was significantly increased compared with the other groups (P<0.05). Therefore, the present study demonstrated that CORM 3 may promote the osteogenic differentiation of BMSCs by releasing CO.
C1 [Li, Jingyuan; Wang, Ping; Wei, Lingling; Song, Hui] Shandong Univ, Sch Dent, Shandong Prov Key Lab Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.
   [Song, Ling] Qingdao Municipal Hosp, Dept Stomatol, Qingdao 266011, Shandong, Peoples R China.
   [Hou, Meng] Med Coll Jining, Sch Stomatol, Jining 272000, Shandong, Peoples R China.
C3 Shandong University; Qingdao Municipal Hospital
RP Song, H (通讯作者)，Shandong Univ, Sch Dent, 44 1 Wenhua Xilu, Jinan 250012, Shandong, Peoples R China.
EM songhui@sdu.edu.cn
RI hou, meng/ISS 7950 2023; song, ling/GQZ 5934 2022; ping,
   wang/JJC 2265 2023
FU Shandong Province Natural Science Foundation [ZR2015HM019]; Special
   Funds for Education and Awards of Shandong Province [Lu Cai Jiao Zhi
   (2014) 94]; Jinan College and University Science and Technology
   Innovation Program [201401259]
FX The present study was supported by Shandong Province Natural Science
   Foundation (grant no. ZR2015HM019), Jinan College and University Science
   and Technology Innovation Program (grant no. 201401259) and Special
   Funds for Education and Awards of Shandong Province [grant no. Lu Cai
   Jiao Zhi (2014) 94].
CR [Anonymous], STEM CELLS INT
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Bathoorn E, 2007, EUR RESPIR J, V30, P1131, DOI 10.1183/09031936.00163206
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Ching HS, 2017, CURR STEM CELL RES T, V12, P71, DOI 10.2174/1574888X11666160815095733
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Jiang L, 2016, INFLAMM RES, V65, P905, DOI 10.1007/s00011 016 0973 7
   Jones E, 2011, INJURY, V42, P562, DOI 10.1016/j.injury.2011.03.030
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Levitt DG, 2015, CLIN PHARMACOL ADV A, V7, P37, DOI 10.2147/CPAA.S79626
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loesche WJ, 2001, CLIN MICROBIOL REV, V14, P727, DOI 10.1128/CMR.14.4.727 752.2001
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Matsumoto M, 2003, J AM SOC NEPHROL, V14, P1825, DOI 10.1097/01.ASN.0000074239.22357.06
   Mesfin A, 2013, J BONE JOINT SURG AM, V95A, P1546, DOI 10.2106/JBJS.L.01730
   Motterlini R, 2003, CURR PHARM DESIGN, V9, P2525, DOI 10.2174/1381612033453785
   Motterlini R, 1998, CIRC RES, V83, P568, DOI 10.1161/01.RES.83.5.568
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680
   Otterbein LE, 2016, CIRC RES, V118, P1940, DOI 10.1161/CIRCRESAHA.116.306588
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rauh J, 2011, TISSUE ENG PART B RE, V17, P263, DOI [10.1089/ten.teb.2010.0612, 10.1089/ten.TEB.2010.0612]
   Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sikorski EM, 2004, AM J PHYSIOL RENAL, V286, pF425, DOI 10.1152/ajprenal.00297.2003
   Terkeltaub RA, 2001, AM J PHYSIOL CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1
   Tsai TL, 2017, STEM CELL REP, V8, P387, DOI 10.1016/j.stemcr.2017.01.004
   Vahabi Surena, 2016, J Long Term Eff Med Implants, V26, P133, DOI 10.1615/JLongTermEffMedImplants.2016014611
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wei Lingling, 2014, Hua Xi Kou Qiang Yi Xue Za Zhi, V32, P23
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Xiao Y, 2010, INT J ORAL SCI, V2, P127, DOI 10.4248/IJOS10045
   Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200
   Zhao Huaqiang, 2013, Hua Xi Kou Qiang Yi Xue Za Zhi, V31, P420
NR 42
TC 17
Z9 17
U1 1
U2 35
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2018
VL 41
IS 4
BP 2297
EP 2305
DI 10.3892/ijmm.2018.3437
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FY9BQ
UT WOS:000427160600053
PM 29393384
OA Bronze
DA 2025 08 17
ER

PT J
AU Bakan, F
AF Bakan, Feray
TI A Systematic Study of the Effect of pH on the Initialization of
   Ca deficient Hydroxyapatite to  TCP Nanoparticles
SO MATERIALS
LA English
DT Article
DE  tricalcium phosphate; Ca deficient hydroxyapatite; wet chemical
   precipitation; nanobiomaterials; nanocharacterization
ID CALCIUM PHOSPHATE NANOPARTICLES; BETA TRICALCIUM PHOSPHATE;
   DRUG DELIVERY; POLYMERIC NANOPARTICLES; CELL ATTACHMENT; STEM CELLS;
   DIFFERENTIATION; TRANSFORMATION; TRANSFECTION; MECHANISMS
AB The formation of  tricalcium phosphate ( TCP) nanoparticles via a wet precipitation technique was studied in a systematical way, taking reaction pH and sintering temperature parameters into account. A full transformation of Ca deficient hydroxyapatite (CDHA) to  TCP at 750 degrees C in under 3 h from Ca++ and PO43  precursor solutions prepared under a pH of 5.5 was observed. For pH values higher than 6.5, CDHA can only partially transform into  TCP and only at temperatures higher than 750 degrees C confirmed using X Ray diffraction and Raman spectroscopy. The morphologies of the particles were also examined by Transmission electron microscopy. The lower temperatures and the shorter sintering time allow for a fine needle like morphology, but with a high crystallinity, likely eliminating the possibility of excessive grain growth that is otherwise expected to occur under high temperature treatment with long process times. We show that sintering of nanostructured, high crystallinity  TCP at relatively low temperatures is possible via adjustment of the precursor solution parameters. Such an outcome is important for the use of  TCP with a fine morphology imitating that of the skeletal tissues, enhancing the osteointegration of a base, load bearing alloy to the host tissue. MTT analysis was used to test the effect of the obtained  TCP particles on the viability of MG 63 human osteoblast like cells.
C1 [Bakan, Feray] Sabanci Univ, SUNUM Nanotechnol Res Ctr, TR 34956 Istanbul, Turkey.
C3 Sabanci University
RP Bakan, F (通讯作者)，Sabanci Univ, SUNUM Nanotechnol Res Ctr, TR 34956 Istanbul, Turkey.
EM feraybakan@sabanciuniv.edu
RI BAKAN MISIRLIOGLU, Feray/AEB 9649 2022
CR Abadeer NS, 2016, J PHYS CHEM C, V120, P4691, DOI 10.1021/acs.jpcc.5b11232
   Abou Neel EA, 2010, ACTA BIOMATER, V6, P2695, DOI 10.1016/j.actbio.2010.01.012
   Bakan F, 2017, COLLOID SURFACE B, V158, P175, DOI 10.1016/j.colsurfb.2017.06.028
   Bakan F, 2013, POWDER TECHNOL, V233, P295, DOI 10.1016/j.powtec.2012.08.030
   Bakan Feray, 2018, HydroxyapatiteAdvances in Composite Nanomaterials, Biomedical Applications and Its Technological Facets, P157, DOI [10.5772/intechopen.71062, DOI 10.5772/INTECHOPEN.71062]
   Cao BR, 2014, ADV MATER, V26, P4627, DOI 10.1002/adma.201401550
   Chapman S, 2013, NANO TODAY, V8, P454, DOI 10.1016/j.nantod.2013.06.001
   Chernousova S, 2017, GENE THER, V24, P282, DOI 10.1038/gt.2017.13
   Cusco R, 1998, J EUR CERAM SOC, V18, P1301, DOI 10.1016/S0955 2219(98)00057 0
   Danilchenko SN, 2002, CRYST RES TECHNOL, V37, P1234, DOI 10.1002/1521 4079(200211)37:11<1234::AID CRAT1234>3.0.CO;2 X
   deAza PN, 1997, CHEM MATER, V9, P916, DOI 10.1021/cm9604266
   Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628
   Dorozhkina EI, 2002, CHEM MATER, V14, P4267, DOI 10.1021/cm0203060
   Engin NÖ, 2000, J AM CERAM SOC, V83, P1581
   Fiorillo M, 2015, ONCOTARGET, V6, P3553, DOI 10.18632/oncotarget.3348
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Landi E, 2000, J EUR CERAM SOC, V20, P2377, DOI 10.1016/S0955 2219(00)00154 0
   LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351
   Liou SC, 2002, BIOMATERIALS, V23, P4541, DOI 10.1016/S0142 9612(02)00198 9
   Liu LL, 2018, J NANOMATER, V2018, DOI 10.1155/2018/7083416
   Mascolo MC, 2013, MATERIALS, V6, P5549, DOI 10.3390/ma6125549
   Masood F, 2016, MAT SCI ENG C MATER, V60, P569, DOI 10.1016/j.msec.2015.11.067
   Meena R, 2012, J NANOPART RES, V14, DOI 10.1007/s11051 011 0712 5
   Rasmussen JW, 2010, EXPERT OPIN DRUG DEL, V7, P1063, DOI 10.1517/17425247.2010.502560
   Rescignano N, 2015, J COLLOID INTERF SCI, V445, P31, DOI 10.1016/j.jcis.2014.12.032
   Ridi F, 2017, ADV COLLOID INTERFAC, V244, P281, DOI 10.1016/j.cis.2016.03.006
   Shah M, 2015, MATERIALS, V8, P7278, DOI 10.3390/ma8115377
   Singh N., 2016, Eng. Nanobiomaterials, P307
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Smilgies DM, 2009, J APPL CRYSTALLOGR, V42, P1030, DOI [10.1107/S00218898090401, 10.1107/S0021889809040126]
   TenHuisen KS, 1999, J AM CERAM SOC, V82, P2813
   Xidaki D, 2018, MATERIALS, V11, DOI 10.3390/ma11040595
   Xiong HM, 2013, ADV MATER, V25, P5329, DOI 10.1002/adma.201301732
   Yang YH, 2013, J MATER CHEM B, V1, P2447, DOI 10.1039/c3tb20365d
   Yokogawa Y., 1991, J CERAM SOC JPN, V99, P28, DOI [10.2109/jcersj.99.211, DOI 10.2109/JCERSJ.99.211]
NR 35
TC 21
Z9 22
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1996 1944
J9 MATERIALS
JI Materials
PD FEB 1
PY 2019
VL 12
IS 3
AR 354
DI 10.3390/ma12030354
PG 12
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA HO2TB
UT WOS:000460768000023
OA Green Published, gold, Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Bonfiglio, R
   Sisto, R
   Casciardi, S
   Palumbo, V
   Scioli, MP
   Giacobbi, E
   Servadei, F
   Melino, G
   Mauriello, A
   Scimeca, M
AF Bonfiglio, Rita
   Sisto, Renata
   Casciardi, Stefano
   Palumbo, Valeria
   Scioli, Maria Paola
   Giacobbi, Erica
   Servadei, Francesca
   Melino, Gerry
   Mauriello, Alessandro
   Scimeca, Manuel
TI Aluminium bioaccumulation in colon cancer, impinging on
   epithelial mesenchymal transition and cell death
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE Aluminium; Colon cancer; Toxicology; Epithelial to mesenchymal
   transition; Cell death; Exposome
ID OSTEOBLAST LIKE CELLS; BREAST CANCER; HEALTH; EXPRESSION; EXPOSURE;
   MARKERS
AB We investigated the presence of aluminium (Al) in human colon cancer samples and its potential association with biological processes involved in cancer progression, such as epithelial to mesenchymal transition (EMT) and cell death. 25 consecutive colon samples were collected from patients undergoing colonic resection. Both neoplastic and normal mucosa were collected from each patient and subjected to histological, ultrastructural and immu nohistochemical analyses. Moreover, colon samples from two Al positive patients underwent multi omic ana lyses, including whole genome sequencing and RNA sequencing (RNAseq). Morin staining, used to identify in situ aluminium bioaccumulation, showed the presence of Al in tumor areas of 24 % of patients. Transmission electron microscopy and energy dispersive X ray microanalysis confirmed the presence of Al specifically in intra cytoplasmic electrondense nanodeposits adjacent to mitochondria of colon cancer cells. Immunohistochemical analyses for vimentin and nuclear beta catenin were performed to highlight the occurrence of the EMT phenomenon in association to Al bioaccumulation. Al positive samples showed a significant increase in both the number of vimentin positive and nuclear beta catenin positive cancer cells compared to Al negative samples. Moreover, Al  positive samples exhibited a significant decrease in the number of apoptotic cells, as well as the expression of the anti apoptotic molecule BCL 2. Multi omic analyses revealed a higher tumor mutational burden (TMB) in Al  positive colon cancers (n = 2) compared to a control cohort (n = 100). Additionally, somatic mutations in genes associated with EMT (GATA3) and apoptosis (TP53) were observed in Al positive colon cancers. In conclusion, this study provides the first evidence of Al bioaccumulation in colon cancer and its potential role in modulating molecular pathways involved in cancer progression, such as EMT and apoptosis. Understanding the molecular mechanisms underlying Al toxicity might contribute to improve strategies for prevention, early detection, and targeted therapies for the management of colon cancer patients.
C1 [Bonfiglio, Rita; Palumbo, Valeria; Scioli, Maria Paola; Giacobbi, Erica; Servadei, Francesca; Melino, Gerry; Mauriello, Alessandro; Scimeca, Manuel] Univ Roma Tor Vergata, Dept Expt Med, TOR, I 00133 Rome, Italy.
   [Sisto, Renata; Casciardi, Stefano] INAIL Res, Dept Occupat & Environm Med Epidemiol & Hyg, I 00078 Rome, Italy.
C3 University of Rome Tor Vergata
RP Scimeca, M (通讯作者)，Univ Roma Tor Vergata, Dept Expt Med, TOR, I 00133 Rome, Italy.
EM rita.bonfiglio@uniroma2.it; r.sisto@inail.it; s.casciardi@inail.it;
   melino@uniroma2.it; alessandro.mauriello@uniroma2.it;
   manuel.scimeca@uniroma2.it
RI Sisto, Renata/J 6547 2018; Casciardi, Stefano/AAC 4947 2022; Servadei,
   Francesca/MGT 2574 2025
OI MELINO, GERRY/0000 0001 9428 5972; Scioli, Maria
   Paola/0009 0004 8190 4526; Palumbo, Valeria/0000 0001 7756 6676;
   Casciardi, Stefano/0000 0002 3551 2546; Renata,
   Sisto/0000 0002 5086 7003; Servadei, Francesca/0000 0003 2619 9153
FU Associazione Italiana per la Ricerca contro il Cancro (AIRC) [BRIC2022
   ID58, PNC E3 2022 23683266]; INAIL [BRIC2022 ID58, 27366]; PNCHLS DA
   [PNC E3 2022 23683266]; Associazione Italiana per la Ricerca contro il
   Cancro (AIRC) [27366]
FX This work has been supported by the BRIC2022 ID58# (INAIL) by MS and by
   "Diagnostica Avanzata" PNC E3 2022 23683266 PNCHLS DA to GM, AL, EC, MS,
   MA and by Associazione Italiana per la Ricerca contro il Cancro (AIRC)
   to GM (IG 2022 ID 27366; 2023 2027)
CR Al Dera HS, 2016, SAUDI MED J, V37, P369, DOI 10.15537/smj.2016.4.13611
   Amelio I, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.42
   Amelio I, 2018, P NATL ACAD SCI USA, V115, pE10869, DOI 10.1073/pnas.1808314115
   Angelucci S, 2000, ARCH BIOCHEM BIOPHYS, V373, P435, DOI 10.1006/abbi.1999.1569
   atsdr.cdc, About Us
   Bai F, 2021, THERANOSTICS, V11, P8218, DOI 10.7150/thno.59280
   Bian XK, 2022, CELL BIOL INT, V46, P1128, DOI 10.1002/cbin.11791
   Bischetti S, 2017, NUTR METAB CARDIOVAS, V27, P768, DOI 10.1016/j.numecd.2017.05.006
   Bonfiglio R, 2021, SEMIN CANCER BIOL, V72, P11, DOI 10.1016/j.semcancer.2020.10.008
   Bonfiglio R., 2023, Sci. Total Environ., V7
   Bonfiglio R, 2023, ARCH TOXICOL, V97, P2997, DOI 10.1007/s00204 023 03581 6
   Bonfiglio R, 2023, SCI TOTAL ENVIRON, V902, DOI 10.1016/j.scitotenv.2023.166219
   Bonfiglio R, 2018, FUTURE ONCOL, V14, P3097, DOI 10.2217/fon 2018 0624
   Brylinski L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24087228
   Cancer Genome Atlas N, 2012, NATURE, V487, P330, DOI DOI 10.1038/nature11252
   Cariati I, 2021, J FUNCT MORPHOL KIN, V6, DOI 10.3390/jfmk6040101
   Cariati Ida, 2020, J Funct Morphol Kinesiol, V5, DOI 10.3390/jfmk5030053
   Cassandri M, 2020, ONCOGENE, V39, P4331, DOI 10.1038/s41388 020 1277 5
   Chkheidze R, 2017, J NEUROPATH EXP NEUR, V76, P323, DOI 10.1093/jnen/nlx011
   Colangelo T, 2022, CELL DEATH DIFFER, V29, P1552, DOI 10.1038/s41418 022 00935 y
   Cooke MS, 2023, SCI TOTAL ENVIRON, V856, DOI 10.1016/j.scitotenv.2022.159192
   Darbre PD, 2021, ADV PHARMACOL, V92, P485, DOI 10.1016/bs.apha.2021.04.006
   Allam MF, 2016, CENT EUR J PUBL HEAL, V24, P245, DOI 10.21101/cejph.a4475
   Favaloro B, 1998, BIOCHEM J, V335, P573, DOI 10.1042/bj3350573
   Fishe J, 2022, SCI TOTAL ENVIRON, V806, DOI 10.1016/j.scitotenv.2021.150352
   Gaillet S, 2015, FOOD CHEM TOXICOL, V77, P58, DOI 10.1016/j.fct.2014.12.019
   Gallo M, 2005, INT J IMMUNOPATH PH, V18, P95, DOI 10.1177/039463200501800111
   Ganini C, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116198
   Ganini C, 2021, MOL ONCOL, V15, P2823, DOI 10.1002/1878 0261.13056
   Gao J, 2021, CELL DEATH DIFFER, V28, P2818, DOI 10.1038/s41418 021 00786 z
   gco.iarc, about us
   Gendoo DMA, 2016, BIOINFORMATICS, V32, P1097, DOI 10.1093/bioinformatics/btv693
   Ha G, 2014, GENOME RES, V24, P1881, DOI 10.1101/gr.180281.114
   Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962
   Huang MN, 2015, SCI REP UK, V5, DOI 10.1038/srep13321
   Igbokwe Ikechukwu Onyebuchi, 2019, Interdiscip Toxicol, V12, P45, DOI 10.2478/intox 2019 0007
   Jang HR, 2021, CELL DEATH DIFFER, V28, P2745, DOI 10.1038/s41418 021 00781 4
   Jeong CH, 2020, FOOD CHEM TOXICOL, V141, DOI 10.1016/j.fct.2020.111402
   Kawasaki H, 2015, INHAL TOXICOL, V27, P363, DOI 10.3109/08958378.2015.1066905
   Kennedy MC, 2022, CELL DEATH DIFFER, V29, P983, DOI 10.1038/s41418 022 00989 y
   Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592 018 0051 x
   King LE, 2022, CELL DEATH DIFFER, V29, P2262, DOI 10.1038/s41418 022 01013 z
   Klotz K, 2017, DTSCH ARZTEBL INT, V114, P653, DOI 10.3238/arztebl.2017.0653
   Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373
   Kozima ET, 2020, EXP LUNG RES, V46, P64, DOI 10.1080/01902148.2020.1728595
   Kumar V, 2009, ARCH TOXICOL, V83, P965, DOI 10.1007/s00204 009 0455 6
   Kvande H, 2014, J OCCUP ENVIRON MED, V56, pS23, DOI 10.1097/JOM.0000000000000062
   Laabbar W, 2021, J CHEM NEUROANAT, V112, DOI 10.1016/j.jchemneu.2020.101915
   Le Guerroué F, 2021, CELL DEATH DIFFER, V28, P439, DOI 10.1038/s41418 020 00667 x
   Levine AJ, 2022, CELL DEATH DIFFER, V29, P893, DOI 10.1038/s41418 022 00986 1
   Li SW, 2023, ENVIRON SCI TECHNOL, V57, P2864, DOI 10.1021/acs.est.2c07389
   Lima DD, 2020, EXP MOL PATHOL, V116, DOI 10.1016/j.yexmp.2020.104486
   Lin B., 2023, Sci. Total Environ., V20
   Lin HY, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389 018 0069 z
   Lu XT, 2018, ADV EXP MED BIOL, V1091, P85, DOI 10.1007/978 981 13 1370 7_5
   Mammarella E, 2021, BIOL DIRECT, V16, DOI 10.1186/s13062 021 00296 5
   Manders F, 2022, BMC GENOMICS, V23, DOI 10.1186/s12864 022 08357 3
   Melino S, 2009, BIOCHEMISTRY US, V48, P242, DOI 10.1021/bi801407w
   Moneim AEA, 2013, TOXICOL MECH METHOD, V23, P624, DOI 10.3109/15376516.2013.823634
   Montanaro M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010395
   Ofoe R, 2023, FRONT PLANT SCI, V13, DOI 10.3389/fpls.2022.1085998
   Palma Lara I, 2020, REGUL TOXICOL PHARM, V110, DOI 10.1016/j.yrtph.2019.104539
   Panatta E, 2021, BIOL DIRECT, V16, DOI 10.1186/s13062 021 00298 3
   Pentimalli F, 2019, GENES IMMUN, V20, P539, DOI 10.1038/s41435 018 0052 x
   Peto MV, 2010, REJUV RES, V13, P589, DOI 10.1089/rej.2009.0995
   Pitolli C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246241
   Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378
   Sainero Alcolado L, 2022, CELL DEATH DIFFER, V29, P1304, DOI 10.1038/s41418 022 01022 y
   Salles FJ, 2023, INT J ENV RES PUB HE, V20, DOI 10.3390/ijerph20010531
   Saotome M, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.820532
   Schillaci O, 2019, CONTRAST MEDIA MOL I, DOI 10.1155/2019/9429761
   Schmidt MF, 2021, CELL DEATH DIFFER, V28, P570, DOI 10.1038/s41418 020 00706 7
   Scimeca M, 2014, EUR J HISTOCHEM, V58, P233, DOI 10.4081/ejh.2014.2403
   Scimeca M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9061381
   Scimeca M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225633
   Scimeca M, 2019, NUTR METAB CARDIOVAS, V29, P1330, DOI 10.1016/j.numecd.2019.08.009
   Scimeca M, 2018, BRIT J CANCER, V119, P1129, DOI 10.1038/s41416 018 0255 y
   Scimeca M, 2018, CLIN BREAST CANCER, V18, pE659, DOI 10.1016/j.clbc.2017.11.020
   Scimeca M, 2018, FUTURE ONCOL, V14, P1013, DOI 10.2217/fon 2017 0698
   Scimeca M, 2018, MICROSC RES TECHNIQ, V81, P745, DOI 10.1002/jemt.23031
   Scimeca M, 2018, EUR J HISTOCHEM, V62, P88, DOI 10.4081/ejh.2018.2841
   Scimeca M, 2018, FUTURE ONCOL, V14, P9, DOI 10.2217/fon 2017 0472
   Scimeca M, 2016, TUMOR BIOL, V37, P5427, DOI 10.1007/s13277 015 4361 7
   Scimeca M, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 286
   Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490
   Tarantino Umberto, 2020, Cell Physiol Biochem, V54, P736, DOI 10.33594/000000252
   Thomas AF, 2022, CELL DEATH DIFFER, V29, P961, DOI 10.1038/s41418 022 00996 z
   Tietz T, 2019, ARCH TOXICOL, V93, P3503, DOI 10.1007/s00204 019 02599 z
   Urbano N, 2022, MOL CELL BIOCHEM, V477, P2319, DOI 10.1007/s11010 022 04439 8
   Urbano N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101657
   Urbano N, 2018, PERS MED, V15, P457, DOI 10.2217/pme 2018 0050
   Vermeulen R, 2020, SCIENCE, V367, P392, DOI 10.1126/science.aay3164
   Vitale I, 2023, CELL DEATH DIFFER, V30, P1097, DOI 10.1038/s41418 023 01153 w
   Willhite CC, 2014, CRIT REV TOXICOL, V44, P1, DOI 10.3109/10408444.2014.934439
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
   Yang Y, 2022, CELL DEATH DIFFER, V29, P2177, DOI 10.1038/s41418 022 01007 x
   Yokel RA, 2008, FOOD CHEM TOXICOL, V46, P2261, DOI 10.1016/j.fct.2008.03.004
   Zampieri C, 2022, MOL ONCOL, V16, P1259, DOI 10.1002/1878 0261.13161
   Zhang GY, 2022, CELL DEATH DIFFER, V29, P750, DOI 10.1038/s41418 021 00889 7
NR 99
TC 11
Z9 11
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048 9697
EI 1879 1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD JAN 15
PY 2024
VL 908
AR 168335
DI 10.1016/j.scitotenv.2023.168335
EA NOV 2023
PG 12
WC Environmental Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology
GA Z3XH4
UT WOS:001111435100001
PM 37939965
OA hybrid
DA 2025 08 17
ER

PT J
AU Matsuzaki, S
   Hiratsuka, T
   Taniguchi, M
   Shingaki, K
   Kubo, T
   Kiya, K
   Fujiwara, T
   Kanazawa, S
   Kanematsu, R
   Maeda, T
   Takamura, H
   Yamada, K
   Miyoshi, K
   Hosokawa, K
   Tohyama, M
   Katayama, T
AF Matsuzaki, Shinsuke
   Hiratsuka, Toru
   Taniguchi, Manabu
   Shingaki, Kenta
   Kubo, Tateki
   Kiya, Koichiro
   Fujiwara, Toshihiro
   Kanazawa, Shigeyuki
   Kanematsu, Ryutaro
   Maeda, Tameyasu
   Takamura, Hironori
   Yamada, Kohe
   Miyoshi, Ko
   Hosokawa, Ko
   Tohyama, Masaya
   Katayama, Taiichi
TI Physiological ER Stress Mediates the Differentiation of Fibroblasts
SO PLOS ONE
LA English
DT Article
ID PLASMA CELL DIFFERENTIATION; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR;
   GRANULATION TISSUE; TRANSDUCER OASIS; CONTRACTION; APOPTOSIS; ALPHA;
   BETA; MYOFIBROBLASTS
AB Recently, accumulating reports have suggested the importance of endoplasmic reticulum (ER) stress signaling in the differentiation of several tissues and cells, including myoblasts and osteoblasts. Secretory cells are easily subjected to ER stress during maturation of their secreted proteins. Skin fibroblasts produce and release several proteins, such as collagens, matrix metalloproteinases (MMPs), the tissue inhibitors of metalloproteinases (TIMPs) and glycosaminoglycans (GAGs), and the production of these proteins is increased at wound sites. Differentiation of fibroblasts into myofibroblasts is one of the key factors for wound healing and that TGF beta can induce fibroblast differentiation into myofibroblasts, which express a smooth muscle actin. Well differentiated myofibroblasts show increased production of collagen and TGF beta, and bring about wound healing. In this study, we examined the effects of ER stress signaling on the differentiation of fibroblasts, which is required for wound healing, using constitutively ER stress activated primary cultured fibroblasts. The cells expressed positive a smooth muscle actin signals without TGF beta stimulation compared with control fibroblasts. Gel contraction assays suggested that ER stress treated primary fibroblasts caused stronger shrinkage of collagen gels than control cells. These results suggest that ER stress signaling could accelerate the differentiation of fibroblasts to myofibroblasts at injured sites. The present findings may provide important insights for developing therapies to improve wound healing.
C1 [Matsuzaki, Shinsuke; Hiratsuka, Toru; Taniguchi, Manabu; Shingaki, Kenta; Maeda, Tameyasu; Tohyama, Masaya] Osaka Univ, Dept Anat & Neurosci, Grad Sch Med, Osaka, Japan.
   [Matsuzaki, Shinsuke; Kanematsu, Ryutaro; Takamura, Hironori; Yamada, Kohe; Miyoshi, Ko; Tohyama, Masaya; Katayama, Taiichi] Osaka Univ, United Grad Sch Child Dev, Dept Child Dev & Mol Brain Sci, Suita, Osaka, Japan.
   [Matsuzaki, Shinsuke; Takamura, Hironori; Yamada, Kohe; Miyoshi, Ko] Osaka Univ, United Grad Sch Child Dev, Mol Res Ctr Childrens Mental Dev, Suita, Osaka, Japan.
   [Shingaki, Kenta] Noevir Co Ltd, Dept Res & Dev, Higashiomi, Shiga, Japan.
   [Kubo, Tateki; Kiya, Koichiro; Fujiwara, Toshihiro; Kanazawa, Shigeyuki; Hosokawa, Ko] Osaka Univ, Grad Sch Med, Dept Plast Surg, Suita, Osaka, Japan.
   [Yamada, Kohe] Hamamatsu Univ Sch Med, Res Ctr Child Mental Dev, Hamamatsu, Shizuoka 4313192, Japan.
   [Tohyama, Masaya] Kinki Univ, Res Inst Tradit Oriental Med, Div Mol Brain Sci, Sayama, Osaka, Japan.
C3 University of Osaka; University of Osaka; University of Osaka;
   University of Osaka; Hamamatsu University School of Medicine; Kindai
   University (Kinki University)
RP Matsuzaki, S (通讯作者)，Osaka Univ, Dept Anat & Neurosci, Grad Sch Med, Osaka, Japan.
EM matsuzaki@ugscd.osaka u.ac.jp
RI MIYOSHI, Ko/B 2273 2011
OI Hiratsuka, Toru/0000 0002 5359 2690
FU Program for Creating Future Wisdom, Osaka University [60403193,
   23790224]; Cosmetology Research Foundation; Osaka University Graduate
   School of Medicine; Program for Advancing Strategic International
   Networks to Accelerate the Circulation of Talented Researchers [S2603]
FX This work was supported by Grant in Aid for Young Scientists (B)
   #60403193 https://kaken.nii.ac.jp/d/p/21790181.ja.html, Grant in Aid for
   Young Scientists (B) #23790224
   https://kaken.nii.ac.jp/d/p/23790224.ja.html, The Program for Creating
   Future Wisdom, Osaka University, selected in 2014.
   http://www.osaka u.ac.jp/en/news/topics/2014/07/20140717_01, Project
   MEET, Osaka University Graduate School of Medicine
   http://www.dmi.med.osaka u.ac.jp/meet/index.html, and Cosmetology
   Research Foundation http://www.cosmetology.or.jp/.Noevir Co., Ltd.,
   provided partial support in the form of a salary for author SK, but did
   not have any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. Program
   for Advancing Strategic International Networks to Accelerate the
   Circulation of Talented Researchers (Grant No. S2603). The specific
   roles of the authors are articulated in the 'author contributions'
   section.
CR Asada R, 2012, J BIOL CHEM, V287, P8144, DOI 10.1074/jbc.M111.332593
   Butler PD, 2011, J SURG RES, V167, P151, DOI 10.1016/j.jss.2009.04.036
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   DANS MJ, 1994, J INVEST DERMATOL, V102, P118, DOI 10.1111/1523 1747.ep12371743
   DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103
   DESMOULIERE A, 1992, EXP CELL RES, V201, P64, DOI 10.1016/0014 4827(92)90348 C
   GABBIANI G, 1972, AM J PATHOL, V66, P131
   GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719
   Garner Warren L., 1995, Wound Repair and Regeneration, V3, P185, DOI 10.1046/j.1524 475X.1995.30210.x
   GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469 185X.1951.tb00774.x
   Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537
   Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Hu QR, 2006, HUM MOL GENET, V15, P3379, DOI 10.1093/hmg/ddl414
   Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907
   Iwakoshi NN, 2003, IMMUNOL REV, V194, P29, DOI 10.1034/j.1600 065X.2003.00057.x
   Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kondo S, 2011, IUBMB LIFE, V63, P233, DOI 10.1002/iub.433
   Ladin Daniel A., 1995, Wound Repair and Regeneration, V3, P6, DOI 10.1046/j.1524 475X.1995.30106.x
   Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903
   Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778
   Modarressi A, 2010, J INVEST DERMATOL, V130, P2818, DOI 10.1038/jid.2010.224
   MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894
   Moulin V, 1998, EXP CELL RES, V238, P283, DOI 10.1006/excr.1997.3827
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Murray J., 1992, Wound Healing: Biochemical and Clinical Aspects, P500
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nakanishi K, 2007, FASEB J, V21, P2994, DOI 10.1096/fj.06 6408com
   Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784
   Rudolph R., 1992, WOUND HEALING BIOCHE, P96
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Saito A, 2009, NAT CELL BIOL, V11, P1197, DOI 10.1038/ncb1962
   Schröder M, 2005, MUTAT RES FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056
   Tanaka K, 2013, BIOCHEM BIOPH RES CO, V438, P463, DOI 10.1016/j.bbrc.2013.07.126
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Vedrenne N, 2012, PATHOL BIOL, V60, P20, DOI 10.1016/j.patbio.2011.10.002
NR 37
TC 55
Z9 60
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2015
VL 10
IS 4
AR e0123578
DI 10.1371/journal.pone.0123578
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CH0MA
UT WOS:000353713100018
PM 25928708
OA gold, Green Submitted, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Xiao, HH
   Lu, L
   Poon, CCW
   Chan, CO
   Wang, LJ
   Zhu, YX
   Zhou, LP
   Cao, SS
   Yu, WX
   Wong, KY
   Mok, DKW
   Wong, MS
AF Xiao, Hui Hui
   Lu, Lu
   Poon, Christina Chui Wa
   Chan, Chi On
   Wang, Li Jing
   Zhu, Yu Xin
   Zhou, Li Ping
   Cao, Sisi
   Yu, Wen Xuan
   Wong, Ka Ying
   Mok, Daniel Kam Wah
   Wong, Man Sau
TI The lignan rich fraction from Sambucus Williamsii Hance ameliorates
   dyslipidemia and insulin resistance and modulates gut microbiota
   composition in ovariectomized rats
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Lignan rich fraction; Sambucus williamsii Hance; Dyslipidemia; Insulin
   resistance; Ovariectomized rat; Actinobacteria
ID CHINESE HERBAL MEDICINE; HIGH FAT DIET; POSTMENOPAUSAL WOMEN;
   PARATHYROID HORMONE; LIPID METABOLISM; BONE LOSS; INFLAMMATION;
   SENSITIVITY; ADIPOSITY; LIPOLYSIS
AB Menopausal women are susceptible to have high risk of cardiovascular diseases, type II diabetes and osteoporosis due to the metabolic disorder caused by estrogen deficiency. Accumulating evidence supports that gut micro biota is a key regulator of metabolic diseases. Our previous metabolomics study interestingly demonstrated that the anti osteoporotic effects of lignan rich fraction (SWCA) from Sambucus wialliamsii Hance were related to the restoration of a series of lipid and glucose metabolites. This study aims to investigate how SWCA modulates lipid and glucose metabolism and the underlying mechanism. Our results show that oral administration of SWCA (140 mg/kg and 280 mg/kg) for 10 weeks alleviated dyslipidemia, improved liver functions, prevented glucose tolerance and insulin actions, attenuated system inflammation and improved intestinal barrier in OVX rats. It also induced a high abundance of Actinobacteria, and restored microbial composition. We are the first to report the protective effects of the lignan rich fraction from S. williamsii on dyslipidemia and insulin resistance. Our findings provide strong evidence for the application of this lignan rich fraction to treat menopausal lipid disorder and insulin resistance related diseases.
   Menopausal women are susceptible to have high risk of cardiovascular diseases, type II diabetes and osteoporosis due to the metabolic disorder caused by estrogen deficiency. Accumulating evidence supports that gut microbiota is a key regulator of metabolic diseases. Our previous metabolomics study interestingly demonstrated that the anti osteoporotic effects of lignan rich fraction (SWCA) from Sambucus wialliamsii Hance were related to the restoration of a series of lipid and glucose metabolites. This study aims to investigate how SWCA modulates lipid and glucose metabolism and the underlying mechanism. Our results show that oral administration of SWCA (140 mg/kg and 280 mg/kg) for 10 weeks alleviated dyslipidemia, improved liver functions, prevented glucose tolerance and insulin actions, attenuated system inflammation and improved intestinal barrier in OVX rats. It also induced a high abundance of Actinobacteria, and restored microbial composition. We are the first to report the protective effects of the lignan rich fraction from S. williamsii on dyslipidemia and insulin resistance. Our findings provide strong evidence for the application of this lignan rich fraction to treat menopausal lipid disorder and insulin resistance related diseases.
C1 [Xiao, Hui Hui; Lu, Lu; Wang, Li Jing; Zhu, Yu Xin; Mok, Daniel Kam Wah; Wong, Man Sau] Hong Kong Polytech Univ, State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen Res Inst, Shenzhen 518057, Peoples R China.
   [Xiao, Hui Hui; Poon, Christina Chui Wa; Chan, Chi On; Zhou, Li Ping; Cao, Sisi; Yu, Wen Xuan; Wong, Ka Ying; Mok, Daniel Kam Wah; Wong, Man Sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University; Hong Kong Polytechnic University
RP Xiao, HH; Wong, MS (通讯作者)，Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.
EM huihui.xiao@polyu.edu.hk; bcmswong@polyu.edu.hk
RI Yu, wx/KRQ 8572 2024; Mok, Daniel/K 5826 2013; Wong, Man
   Sau/F 2059 2015; Cao, Sisi/ADV 0612 2022
OI Zhou, Liping/0000 0002 9941 7812; Wong, Man Sau/0000 0002 0729 8618;
   Cao, Sisi/0000 0002 7413 295X; Poon, Chui Wa
   Christina/0000 0002 4569 876X; 
FU Shenzhen Basic Research Program [JCYJ20170818104152702]; National
   Natural Science Foundation of China [81903616]; Hong Kong Midstream
   Research Programme for Universities [MRP/012/18X]; General Research Fund
   of the Research Grant Council of the Hong Kong Special Administrative
   Region [15302718]; Collaborative Research Fund (CRF) of the Research
   Grant Council of the Hong Kong Special Administrative Region [C5031 14E,
   C5033 19E]; Hong Kong Chinese Materia Medica Standards Project, Hong
   Kong Polytechnic University [YBU0]; Large Equipment Funds; University
   Research Facility in Chemical and Environmental Analysis of the Hong
   Kong Polytechnic University; Life Sciences of the Hong Kong Polytechnic
   University
FX The study was supported by Shenzhen Basic Research Program
   (JCYJ20170818104152702), National Natural Science Foundation of China
   (81903616), The Hong Kong Midstream Research Programme for Universities
   (MRP/012/18X), General Research Fund (Project No. 15302718) and
   Collaborative Research Fund (CRF Grant No. C5031 14E, C5033 19E) of the
   Research Grant Council of the Hong Kong Special Administrative Region,
   the Hong Kong Chinese Materia Medica Standards Project, Hong Kong
   Polytechnic University financial support (Project No. YBU0), the Large
   Equipment Funds and University Research Facility in Chemical and
   Environmental Analysis and Life Sciences of the Hong Kong Polytechnic
   University.
CR Alexopoulos N, 2013, J AM COLL CARDIOL, V61, P1956, DOI 10.1016/j.jacc.2012.12.051
   Almeida, 2015, PANACEA J MED SCI, V5, P158
   Cauley JA, 2019, J CLIN ENDOCR METAB, V104, P2412, DOI 10.1210/jc.2018 02047
   Chen X, 2020, AGING DIS, V11, P629, DOI 10.14336/AD.2019.0613
   Cobleigh MA, 2013, AM J PATHOL, V182, P21, DOI 10.1016/j.ajpath.2012.08.043
   D'Amelio P, 2015, BONE, V76, P177, DOI 10.1016/j.bone.2015.03.018
   de Melo CL, 2009, J AGR FOOD CHEM, V57, P8776, DOI 10.1021/jf900768w
   Dodin S, 2008, NUTRITION, V24, P23, DOI 10.1016/j.nut.2007.09.003
   Fayaz E, 2019, NUTRITION, V65, P173, DOI 10.1016/j.nut.2019.03.009
   FREIER TA, 1994, INT J SYST BACTERIOL, V44, P137, DOI 10.1099/00207713 44 1 137
   Fu JY, 2015, CIRC RES, V117, P817, DOI 10.1161/CIRCRESAHA.115.306807
   Geach Tim, 2016, Nat Rev Endocrinol, V12, P310, DOI 10.1038/nrendo.2016.57
   Guo M, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/163036
   Hamedi J., 2017, Biology and Biotechnology of Actinobacteria, P29
   Howitt MR, 2012, NAT MED, V18, P1188, DOI 10.1038/nm.2895
   Hu XG, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 47
   Kang L, 2014, MENOPAUSE, V21, P1239, DOI [10.1097/GME.0000000000000232, 10.1097/gme.0000000000000232]
   Kang YB, 2016, REV MED MICROBIOL, V27, P141, DOI 10.1097/MRM.0000000000000085
   Khorsand Imaneh, 2018, J Menopausal Med, V24, P183, DOI 10.6118/jmm.2018.24.3.183
   Kirtikar U, 2020, J MID LIFE HEALTH, V11, P22, DOI 10.4103/jmh.JMH_65_19
   Kuang HX, 2018, NAT PROD RES, V32, P2008, DOI 10.1080/14786419.2017.1361948
   Larsson S, 2016, CELL SIGNAL, V28, P204, DOI 10.1016/j.cellsig.2015.12.012
   Lasram MM, 2015, DRUG CHEM TOXICOL, V38, P227, DOI 10.3109/01480545.2014.933348
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Libertucci J, 2018, AM J PHYSIOL GASTR L, V315, pG420, DOI 10.1152/ajpgi.00411.2017
   Liland KH, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859 017 1583 2
   Lima Júnior RCP, 2007, INFLAMM RES, V56, P487, DOI 10.1007/s00011 007 7023 4
   Liu CQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00469
   Liu M, 2018, J FUNCT FOODS, V48, P220, DOI 10.1016/j.jff.2018.07.006
   Liu ML, 2004, INT J CARDIOL, V97, P485, DOI 10.1016/j.ijcard.2003.11.046
   Lovegrove JA, 2002, INT J OBESITY, V26, P475, DOI 10.1038/sj.ijo.0801963
   Lv H, 2015, INT J FOOD ENG, V11, P383, DOI 10.1515/ijfe 2014 0234
   Morisset AS, 2009, BRIT J NUTR, V102, P195, DOI 10.1017/S0007114508162092
   Nagamani M, 2008, FERTIL STERIL, V89, P614, DOI 10.1016/j.fertnstert.2007.03.083
   Nagy C, 2018, JOVE J VIS EXP, DOI 10.3791/56672
   Pan A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001148
   Park O, 2011, HEPATOLOGY, V54, P252, DOI 10.1002/hep.24339
   Petta S, 2018, LIVER INT, V38, P2060, DOI 10.1111/liv.13743
   Qian XB, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864 020 6703 0
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Ranjit PM., 2015, Asian J Med Sci, V6, P25, DOI 10.3126/ajms.v6i6.12209
   Rodríguez García C, 2019, MOLECULES, V24, DOI 10.3390/molecules24050917
   Scheid V, 2017, COMPLEMENT THER MED, V32, P33, DOI 10.1016/j.ctim.2017.03.008
   Serino M, 2018, J MOL BIOL, V430, P581, DOI 10.1016/j.jmb.2018.01.010
   SINHA TK, 1976, METABOLISM, V25, P251, DOI 10.1016/0026 0495(76)90083 4
   Sookoian S, 2017, ALIMENT PHARM THER, V46, P85, DOI 10.1111/apt.14112
   TANIGUCHI A, 1987, J LIPID RES, V28, P490
   Tawfik SH, 2015, BIOCHEM RES INT, V2015, DOI 10.1155/2015/567945
   TDA SF, 2013, MENOPAUSE, V20, P1264
   Teede HJ, 2010, CLIMACTERIC, V13, P203, DOI 10.3109/13697130903296909
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Valeri M, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw111
   Veloso A. G. B., 2017, Journal of Morphological Sciences, V34, P207, DOI 10.4322/jms.340301
   Veras K, 2014, FEBS OPEN BIO, V4, P141, DOI 10.1016/j.fob.2014.01.005
   Wu XK, 2010, CURR MICROBIOL, V61, P69, DOI 10.1007/s00284 010 9582 9
   Xiao HH, 2019, J NAT PROD, V82, P1733, DOI 10.1021/acs.jnatprod.8b00891
   Xiao HH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00932
   Xiao HH, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0106 9
   Xiao HH, 2011, BRIT J NUTR, V106, P1802, DOI 10.1017/S0007114511002546
   Yang XB, 2020, FOOD FUNCT, V11, P2953, DOI [10.1039/D0FO00178C, 10.1039/d0fo00178c]
   Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023
   Zhang CH, 2010, ISME J, V4, P232, DOI 10.1038/ismej.2009.112
   Zhang JH, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944 018 0669 9
   Zhang Y, 2011, OSTEOPOROSIS INT, V22, P703, DOI 10.1007/s00198 010 1240 3
   Zhuang Y, 2015, GUT, V64, P1368, DOI 10.1136/gutjnl 2014 307020
NR 66
TC 16
Z9 17
U1 6
U2 35
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2021
VL 137
AR 111372
DI 10.1016/j.biopha.2021.111372
EA FEB 2021
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA RC8NB
UT WOS:000633049500003
PM 33761598
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yudoh, K
   Karasawa, R
   Masuko, K
   Kato, T
AF Yudoh, Kazuo
   Karasawa, Rie
   Masuko, Kayo
   Kato, Tomohiro
TI Water soluble fullerene (C60) inhibits the development of arthritis in
   the rat model of arthritis
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE fullerene; inflammation; arthritis; synovitis; bone resorption
ID NECROSIS FACTOR ALPHA; ADJUVANT INDUCED ARTHRITIS; HUMAN SKIN
   KERATINOCYTES; KAPPA B LIGAND; RHEUMATOID ARTHRITIS; OSTEOCLAST
   DIFFERENTIATION; RECEPTOR ACTIVATOR; OXIDATIVE STRESS; GENE THERAPY;
   CRUCIAL ROLE
AB Recently, it has been demonstrated that oxygen free radicals have an important role as a signaling messenger in the development of inflammation and osteoclastogenesis, suggesting the implication of oxygen free radicals in the pathogenesis of arthritis. The aim of this study was to examine the potential of a strong free radical scavenger, water soluble fullerene (C60), as a protective agent against synovitis in arthritis, both in vitro and in vivo. In the presence or absence of C60 (0.1, 1.0, 10.0 mu M), human synovial fibroblasts, synovial infiltrating lymphocytes or macrophages were incubated with tumor necrosis factor alpha (TNF alpha) (10.0 ng/mL), and the production of proinflammatory cytokines by the individual cells were analyzed. C60 significantly suppressed the TNF alpha induced production of proinflammatory cytokines in synovial fibroblasts, synovial infiltrating lymphocytes and macrophages in vitro. Adjuvant induced arthritic rats were used as an animal model of arthritis. Rats were divided into two subgroups: control and treatment with C60 at 10.0 mu M. The left ankle joint was injected intraarticularly with water soluble C60 (20 mu l) in the C60 treated group, while, as a control, the left ankle joint in the control rats received phosphate buffered saline (20 mu l), once weekly for eight weeks. Ankle joint tissues were prepared for histological analysis. In adjuvant induced arthritic rats, intra articular treatment with C60 in vivo reduced synovitis and alleviated bone resorption and destruction in the joints, while control ankle joints showed progression of synovitis and joint destruction with time. These findings indicate that C60 is a potential therapeutic agent for inhibition of arthritis.
C1 [Yudoh, Kazuo] St Marianna Univ, Sch Med, Inst Med Sci, Dept Frontier Med,Miyamae Ku, Kawasaki, Kanagawa 2168512, Japan.
   [Masuko, Kayo; Kato, Tomohiro] St Marianna Univ, Sch Med, Dept Biochem, Kawasaki, Kanagawa 2168512, Japan.
C3 Saint Marianna University; Saint Marianna University
RP Yudoh, K (通讯作者)，St Marianna Univ, Sch Med, Inst Med Sci, Dept Frontier Med,Miyamae Ku, 2 16 1 Sugao, Kawasaki, Kanagawa 2168512, Japan.
EM yudo@marianna u.ac.jp
RI ; Masuko, Kayo/H 7032 2019
OI Masuko, Kayo/0000 0001 6058 6363; 
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Ministry of Health, Labour and Welfare of Japan
FX This study was supported by grants from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan, The Ministry of
   Health, Labour and Welfare of Japan. The authors report no conflicts of
   interest in this work.
CR Aletaha D, 2008, ANN RHEUM DIS, V67, P238, DOI 10.1136/ard.2007.071415
   Alnaeeli M, 2007, J BONE MINER RES, V22, P775, DOI 10.1359/JBMR.070314
   Babbar N, 2006, CANCER RES, V66, P11125, DOI 10.1158/0008 5472.CAN 06 3174
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Connell L, 2006, BEST PRACT RES CL RH, V20, P865, DOI 10.1016/j.berh.2006.05.011
   CUSH JJ, 1992, ARTHRITIS RHEUM, V35, P1434, DOI 10.1002/art.1780351206
   Dixon WG, 2007, ARTHRITIS RHEUM, V56, P2896, DOI 10.1002/art.22808
   Dugan LL, 2001, PARKINSONISM RELAT D, V7, P243, DOI 10.1016/S1353 8020(00)00064 X
   FIRESTEIN GS, 1998, RHEUMATOLOGY, P1
   Genovese MC, 2008, ANN RHEUM DIS, V67, P547, DOI 10.1136/ard.2007.074773
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Haas CS, 2006, ARTHRITIS RHEUM, V54, P2402, DOI 10.1002/art.22034
   Haruna Y, 2007, ARTHRITIS RHEUM US, V56, P1827, DOI 10.1002/art.22632
   Jamaluddin M, 2007, CELL SIGNAL, V19, P1419, DOI 10.1016/j.cellsig.2007.01.020
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Köhler HBK, 2001, VET DERMATOL, V12, P129, DOI 10.1046/j.1365 3164.2001.00237.x
   KRATSCHMER W, 1990, NATURE, V318, P162
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0
   KRUSIC PJ, 1991, SCIENCE, V254, P1183, DOI 10.1126/science.254.5035.1183
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee YH, 2006, RHEUMATOL INT, V27, P157, DOI 10.1007/s00296 006 0175 7
   Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200
   Mori T, 2006, TOXICOLOGY, V225, P48, DOI 10.1016/j.tox.2006.05.001
   ROONEY M, 1988, ARTHRITIS RHEUM US, V31, P956, DOI 10.1002/art.1780310803
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Shi MM, 1996, J BIOL CHEM, V271, P5878, DOI 10.1074/jbc.271.10.5878
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tambar Siddharth, 2007, Manag Care Interface, V20, P18
   Tao F, 2003, FREE RADICAL BIO MED, V35, P327, DOI 10.1016/S0891 5849(03)00280 6
   TSUCHIYA T, 1995, BIOCHEM BIOPH RES CO, V206, P885, DOI 10.1006/bbrc.1995.1126
   Varanasi SS, 2005, BONE, V36, P243, DOI 10.1016/j.bone.2004.09.021
   Vlahopoulos S, 1999, BLOOD, V94, P1878, DOI 10.1182/blood.V94.6.1878
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wolfe F, 2007, ARTHRITIS RHEUM, V56, P2886, DOI 10.1002/art.22864
   Woods JM, 2001, J IMMUNOL, V166, P1214, DOI 10.4049/jimmunol.166.2.1214
   Xiao L, 2006, BIOORG MED CHEM LETT, V16, P1590, DOI 10.1016/j.bmcl.2005.12.011
   Xiao L, 2005, BIOMED PHARMACOTHER, V59, P351, DOI 10.1016/j.biopha.2005.02.004
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Yudoh K, 2007, ARTHRITIS RHEUM US, V56, P3307, DOI 10.1002/art.22917
NR 42
TC 59
Z9 70
U1 0
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2009
VL 4
BP 217
EP 225
PG 9
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA 525RB
UT WOS:000272232900010
PM 19918368
DA 2025 08 17
ER

PT J
AU Yuan, XH
   Han, HY
   Luo, ZH
   Wang, QX
   Tang, PJ
   Zhang, ZH
   Fu, YJ
   Gu, CB
AF Yuan, Xiaohan
   Han, Haiyan
   Luo, Zhaohui
   Wang, Qiuxue
   Tang, Peijia
   Zhang, Zhihui
   Fu, Yujie
   Gu, Chengbo
TI Enhancing Effect of Vitexin on Osteogenic Activity of Murine
   Pre Osteoblastic MC3T3 E1 Cells
SO SAINS MALAYSIANA
LA English
DT Article
DE Anti osteoporosis; dexamethasone; MC3T3 E1 cells; osteogenic activity;
   vitexin
ID ALKALINE PHOSPHATASE; OSTEOPOROSIS; MECHANISMS; DIFFERENTIATION;
   MINERALIZATION; INHIBITION; FLAVONOIDS; PREVENTION; ESTROGEN; SERMS
AB Vitexin (5,7,4 frihydroxyflavone 8 glucoside), a natural flavone present in a variety of plants, is well known for its rich pharmacological properties. However, its osteogenic activity remains unclear to date. The purpose of this study was to explore the effects of vitexin on osteogenic activity in murine pre osteoblastic MC3T3 E1 cells using the MTT assay for cell proliferation, alkaline phosphatase (ALP) activity assay for cell differentiation, and Von Kossa staining for cell mineralization. Quantitative real time PCR was used for the detection of osteocalcin (OCN) mRNA expression in cells. Furthermore, effects of vitexin on the differentiation and mafrix mineralization of dexamethasone (DEX) suppressed cells was also investigated. The results showed vitexin could significantly enhance cell proliferation in a low concentration range of 10( 10) 10( 6) mu g mL( 1). ALP activity was significantly increased after the cells were treated with vitexin at 10( 8) and 10( 6) mu g mL( 1). The expression levels of the osteogenic OCN gene in cells treated with vitexin at 10( 6), 10( 8), and 10( 6) pg mL( 1) were improved by 3.1 fold, 5.8 fold, and 4.2 fold over the control, respectively. Additionally, vitexin (10( 8) mu g mL( 1)) significantly alleviated the inhibitory effect of osteoblast differentiation and mineralization induced by DEX. Collectively, our findings suggest vitexin could enhance cell proliferation and osteogenic differentiation of MC3T3 E1 cells, as well as rescue the inhibitory effect of cell differentiation and mafrix mineralization induced by DEX. Therefore, vitexin may be useful as a promising therapeutic agent for bone disease and plays an important role in the prevention of glucocorticoid induced osteoporosis.
C1 [Yuan, Xiaohan; Gu, Chengbo] Northeast Agr Univ, Key Lab Agr Microbiol, Heilongjiang Prov Sci & Technol Dept, Harbin 150030, Peoples R China.
   [Han, Haiyan; Wang, Qiuxue; Tang, Peijia; Zhang, Zhihui; Fu, Yujie; Gu, Chengbo] Northeast Agr Univ, Minist Educ, Key Lab Forest Plant Ecol, Harbin 150030, Peoples R China.
   [Luo, Zhaohui] Shenzhen Zhongjin Lingnan Nonfemet Co Ltd, Fankou Lead Zinc Mine Staff Hosp, Renhua 512325, Peoples R China.
C3 Northeast Agricultural University   China; Northeast Agricultural
   University   China
RP Gu, CB (通讯作者)，Northeast Agr Univ, Key Lab Agr Microbiol, Heilongjiang Prov Sci & Technol Dept, Harbin 150030, Peoples R China.; Gu, CB (通讯作者)，Northeast Agr Univ, Minist Educ, Key Lab Forest Plant Ecol, Harbin 150030, Peoples R China.
EM dilisatis@163.com
RI Zhaohui, Luo/JVZ 6419 2024; GU, Chengbo/GWV 1823 2022
FU open project of Northeast Agricultural University/Key Laboratory of
   Agricultural Microbiology of Heilongjiang Provincial Science and
   Technology Department, P.R. China [NW2017005]; Natural Science
   Foundation of Heilongjiang Province of P.R. China [C2017021, C2017004];
   Heilongjiang Touyan Innovation Team Program (Tree Genetics and Breeding
   Innovation Team)
FX This research was supported by the open project of Northeast
   Agricultural University/Key Laboratory of Agricultural Microbiology of
   Heilongjiang Provincial Science and Technology Department, P.R. China
   (No. NW2017005), Natural Science Foundation of Heilongjiang Province of
   P.R. China (No. C2017021, No. C2017004) and Heilongjiang Touyan
   Innovation Team Program (Tree Genetics and Breeding Innovation Team).
CR Adami G, 2019, CURR OPIN RHEUMATOL, V31, P388, DOI 10.1097/BOR.0000000000000608
   Adler RA, 2019, J CLIN DENSITOM, V22, P20, DOI 10.1016/j.jocd.2018.03.004
   Balasubramanian A, 2018, J BONE MINER RES, V33, P1881, DOI 10.1002/jbmr.3523
   Bolognese MA, 2010, REV ENDOCR METAB DIS, V11, P253, DOI 10.1007/s11154 010 9137 1
   Canalis E, 2003, CURR OPIN RHEUMATOL, V15, P454, DOI 10.1097/00002281 200307000 00013
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Caplan A, 2017, J AM ACAD DERMATOL, V76, P201, DOI 10.1016/j.jaad.2016.02.1241
   Chang EJ, 2003, ARCH PHARM RES, V26, P620, DOI 10.1007/BF02976711
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen LR, 2014, INT J GERONTOL, V8, P183, DOI 10.1016/j.ijge.2014.06.001
   Arriero MD, 2012, CELL PHYSIOL BIOCHEM, V30, P974, DOI 10.1159/000341474
   Dong LY, 2011, FOOD CHEM TOXICOL, V49, P3211, DOI 10.1016/j.fct.2011.09.040
   Feng YL, 2014, CHEM BIOL INTERACT, V207, P26, DOI 10.1016/j.cbi.2013.11.004
   Fu YJ, 2007, J CHROMATOGR A, V1139, P206, DOI 10.1016/j.chroma.2006.11.015
   Gu CB, 2017, MOLECULES, V22, DOI 10.3390/molecules22112038
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Hadji P, 2012, CLIMACTERIC, V15, P513, DOI 10.3109/13697137.2012.688079
   He M, 2016, FITOTERAPIA, V115, P74, DOI 10.1016/j.fitote.2016.09.011
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Kim JH, 2005, ARCH PHARM RES, V28, P195, DOI 10.1007/BF02977715
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Kulak J, 2010, ARQ BRAS ENDOCRINOL, V54, P200, DOI 10.1590/S0004 27302010000200016
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lin Z, 2017, BIOMED PHARMACOTHER, V90, P237, DOI 10.1016/j.biopha.2017.03.042
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Ma XQ, 2013, PHYTOCHEM LETT, V6, P118, DOI 10.1016/j.phytol.2012.12.004
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Miron RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071008
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Nix A, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064 015 0906 x
   Pereira Rosa Maria Rodrigues, 2012, Rev. Bras. Reumatol., V52, P580
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   PRABHAKAR MC, 1981, PLANTA MED, V43, P396, DOI 10.1055/s 2007 971532
   Wang WZ, 2012, J ETHNOPHARMACOL, V142, P168, DOI 10.1016/j.jep.2012.04.033
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wu ZY, 2018, BIOCHEM BIOPH RES CO, V505, P945, DOI 10.1016/j.bbrc.2018.10.039
   Yuan J, 2005, ZHONGYAOXINYAO YU LI, V16, P185
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zhang JC, 2010, PHARM BIOL, V48, P89, DOI 10.3109/13880200903046179
   Zhang YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090955
   [周晨慧 Zhou Chenhui], 2014, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V31, P405
NR 44
TC 1
Z9 1
U1 0
U2 15
PU UNIV KEBANGSAAN MALAYSIA
PI SELANGOR
PA FACULTY SCIENCE & TECHNOLOGY, BANGI, SELANGOR, 43600, MALAYSIA
SN 0126 6039
J9 SAINS MALAYS
JI Sains Malays.
PD JUN
PY 2020
VL 49
IS 6
BP 1389
EP 1400
DI 10.17576/jsm 2020 4906 17
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ND4VE
UT WOS:000561899000017
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, Y
   Alves, T
   Miao, MZ
   Wu, Y
   Li, G
   Lou, J
   Hasturk, H
   Van Dyke, TE
   Kantarci, A
   Wu, D
AF Yang, Y.
   Alves, T.
   Miao, M. Z.
   Wu, Y. C.
   Li, G.
   Lou, J.
   Hasturk, H.
   Van Dyke, T. E.
   Kantarci, A.
   Wu, D.
TI Single Cell Transcriptomic Analysis of Dental Pulp and Periodontal
   Ligament Stem Cells
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE single cell RNA seq; osteoblast; fibroblast; regenerative medicine, stem
   cell, tooth
ID SMOOTH MUSCLE; EXPRESSION; PACKAGE; ALPHA
AB The regeneration of periodontal, periapical, and pulpal tissues is a complex process requiring the direct involvement of cells derived from pluripotent stem cells in the periodontal ligament and dental pulp. Dental pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLSCs) are spatially distinct with the potential to differentiate into similar functional and phenotypic cells. We aimed to identify the cell heterogeneity of DPSCs and PDLSCs and explore the differentiation potentials of their specialized organ specific functions using single cell transcriptomic analysis. Our results revealed 7 distinct clusters, with cluster 3 showing the highest potential for differentiation. Clusters 0 to 2 displayed features similar to fibroblasts. The trajectory route of the cell state transition from cluster 3 to clusters 0, 1, and 2 indicated the distinct nature of cell differentiation. PDLSCs had a higher proportion of cells (78.6%) at the G1 phase, while DPSCs had a higher proportion of cells at the S and G2/M phases (36.1%), mirroring the lower cell proliferation capacity of PDLSCs than DPSCs. Our study suggested the heterogeneity of stemness across PDLSCs and DPSCs, the similarities of these 2 stem cell compartments to be potentially integrated for regenerative strategies, and the distinct features between them potentially particularized for organ specific functions of the dental pulp and periodontal ligament for a targeted regenerative dental tissue repair and other regeneration therapies.
C1 [Yang, Y.] Univ North Carolina Chapel Hill, Sch Med, Dept Genet, Chapel Hill, NC USA.
   [Alves, T.; Miao, M. Z.; Wu, D.] Univ North Carolina Chapel Hill, Adams Sch Dent, Div Oral & Craniofacial Hlth Sci, Chapel Hill, NC 27599 USA.
   [Miao, M. Z.] Univ North Carolina Chapel Hill, Sch Med, Div Rheumatol Allergy & Immunol, Thurston Arthrit Res Ctr, Chapel Hill, NC USA.
   [Miao, M. Z.] NIDCR, Cell Biol Sect, NIH, Bethesda, MD USA.
   [Wu, Y. C.; Hasturk, H.; Van Dyke, T. E.; Kantarci, A.] Forsyth Inst, Cambridge, MA USA.
   [Li, G.] Univ Washington, Dept Genome Sci, Seattle, WA USA.
   [Li, G.] Univ Washington, Esci Inst, Seattle, WA USA.
   [Lou, J.; Wu, D.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
   [Kantarci, A.] Forsyth Inst, 245 First St, Cambridge, MA 02142 USA.
   [Wu, D.] Univ North Carolina Chapel Hill, Dept Biostat, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine; National Institutes of Health (NIH)   USA; NIH National
   Institute of Dental & Craniofacial Research (NIDCR); Harvard University;
   Harvard University Medical Affiliates; Forsyth Institute; University of
   Washington; University of Washington Seattle; University of Washington;
   University of Washington Seattle; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina
   School of Medicine; Harvard University; Harvard University Medical
   Affiliates; Forsyth Institute; University of North Carolina; University
   of North Carolina Chapel Hill; University of North Carolina School of
   Medicine
RP Wu, D (通讯作者)，Univ North Carolina Chapel Hill, Adams Sch Dent, Div Oral & Craniofacial Hlth Sci, Chapel Hill, NC 27599 USA.; Kantarci, A (通讯作者)，Forsyth Inst, 245 First St, Cambridge, MA 02142 USA.; Wu, D (通讯作者)，Univ North Carolina Chapel Hill, Dept Biostat, Chapel Hill, NC 27599 USA.
EM AKantarci@forsyth.org; dwu@unc.edu
RI Alves da Silva Neto, Tomaz/S 7949 2017; KANTARCI, Alpdogan/KLC 3979 2024
OI Li, Gang/0000 0003 0759 9063; Alves da Silva Neto,
   Tomaz/0000 0002 3377 725X
FU NIH/NIA [AG062496]; NIH/NIDCR [DE025020]; University of North Carolina
   Computational Medicine Program Award 2020; J. William Fulbright
   scholarship (CAPES) [001]; Intramural Research Program of the National
   Institutes of Health, National Institute of Dental and Craniofacial
   Research [ZIA DE000719, ZIE DE000727]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by NIH/NIA (AG062496), NIH/NIDCR (DE025020) grants, University
   of North Carolina Computational Medicine Program Award 2020. T. Alves
   holds a J. William Fulbright scholarship (CAPES finance code 001). M.Z.
   Miao is supported by the Intramural Research Program of the National
   Institutes of Health, National Institute of Dental and Craniofacial
   Research ZIA DE000719 and ZIE DE000727.
CR Aguilar SV, 2020, NAT IMMUNOL, V21, P700, DOI 10.1038/s41590 020 0687 4
   Albuquerque Souza E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585530
   Alves T, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 19520 x
   Bai F, 2013, J MUSCLE RES CELL M, V34, P295, DOI 10.1007/s10974 013 9343 z
   Baran Gale J, 2018, BRIEF FUNCT GENOMICS, V17, P233, DOI 10.1093/bfgp/elx035
   Caton JG, 2018, J CLIN PERIODONTOL, V45, pS1, DOI 10.1111/jcpe.12935
   Chiba Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00841
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Gadomski S, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107572
   Guo MZ, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw1278
   Gusev NB, 2001, BIOCHEMISTRY MOSCOW+, V66, P1112, DOI 10.1023/A:1012480829618
   Haque A, 2017, GENOME MED, V9, DOI 10.1186/s13073 017 0467 4
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Iwata T, 2010, J CLIN PERIODONTOL, V37, P1088, DOI 10.1111/j.1600 051X.2010.01597.x
   Kotova AV, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111606
   Krivanek J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18512 7
   Lee S, 2022, J ENDODONT, V48, P240, DOI 10.1016/j.joen.2021.11.005
   Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188
   Liao KA., 2021, AM J PHYSIOL HEART C, V321
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154
   Oya R, 2021, JARO J ASSOC RES OTO, V22, P425, DOI 10.1007/s10162 021 00796 1
   Pagella P, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102405
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Sowmya S, 2015, TISSUE ENG PART C ME, V21, P1044, DOI [10.1089/ten.tec.2014.0603, 10.1089/ten.TEC.2014.0603]
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Sun J, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.593966
   Talele NP, 2015, STEM CELL REP, V4, P1016, DOI 10.1016/j.stemcr.2015.05.004
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Williams DW, 2021, CELL, V184, P4090, DOI 10.1016/j.cell.2021.05.013
   Wu TT, 2020, ACTA BIOCH BIOPH SIN, V52, P1016, DOI 10.1093/abbs/gmaa082
   Yang H, 2013, BIOMATERIALS, V34, P7033, DOI 10.1016/j.biomaterials.2013.05.025
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhao YF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25534 2
NR 39
TC 12
Z9 13
U1 6
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JAN
PY 2024
VL 103
IS 1
BP 71
EP 80
DI 10.1177/00220345231205283
EA NOV 2023
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CR2D3
UT WOS:001104723000001
PM 37982164
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, JX
   Tian, NY
   Hu, YF
   Jin, T
AF Yu, Junxia
   Tian, Ningyan
   Hu, Yanfen
   Jin, Ting
TI RANKL/RANK contributes to the pathological process of type 2 diabetes
   mellitus through TRAF3 activation of NIK
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Diabetes mellitus; RANKL/RANK; NIK; TRAF3; Apoptosis
ID PANCREATIC BETA CELLS; OSTEOCLASTOGENESIS; EXPRESSION; MICE; STEM
AB Diabetic osteoporosis is a complication of diabetes mellitus (DM). Denosumab (DMB) is an effective antiosteoporotic drug functions by inhibiting NF kappa B kappa B ligand receptor activating factor (RANKL). Previous study found that osteoprotegerin (OPG) regulated (3 cell homeostasis through the RNAK/RANKL pathway. The present study aimed to investigate the effect of RANKL/RANK on the pathological process of DM and the underlying mechanism. We used D glucose induced RINm5F cells to construct in vitro type 2 diabetes models (T2DM). A high fat diet combined with intraperitoneal injection of streptozotocin (STZ) was used to establish a T2DM model in SD rats. The apoptosis of (3  cells was determined by TdT mediated dUTP nick end labeling (TUNEL) analysis. qRT PCR and western blotting assays were used to explore the mRNA and protein expression of the TRAF3 (Tumor necrosis factor receptor associated factor)/NIK (NF kappa B inducible kappa B inducible kinase) pathway. Furthermore, insulin expression was detected by ELISA and immunohistochemistry assay. The islet morphology was analyzed by H&E. &E. In vivo experiments demonstrated that sRANKL IN 3 down regulated insulin secretion levels by significantly ameliorating pancreatic tissue damage and mitigating apoptosis of high glucose induced (3  cells. Subsequently, sRANKL IN 3, acting as an inhibitor of RANKL, mitigated functional decline in (3  cells induced by high glucose, mainly manifested by the low expression of PDX 1 (pancreatic duodenal homeobox 1), BETA2 (beta 2 adrenoceptors), INS 1 (insulin 1), and INS 2 (insulin 2). Mechanistic studies revealed that deletion of TRAF3 combined with sRANKL IN 3 administration reduced the activity of NIK, NF kappa B2, kappa B2, and RelB in RINm5F cells. In addition, our study demonstrated that inhibition of either RANKL or TRAF3 had a protective effect on high glucose induced apoptosis. Moreover, the combined action of sRANKL IN 3 and shTRAF3 had a more pronounced inhibitory effect on high glucose induced apoptosis. In summary, RANKL/RANK deficiency may attenuate apoptosis of (3  cells, a phenomenon associated with the TRAF3/NIK pathway. Therefore, RANKL/RANK could be regarded as potential therapeutic strategy for DM.
C1 [Yu, Junxia; Tian, Ningyan; Hu, Yanfen] Xi An Jiao Tong Univ, Cadre Ward, Affiliated Hosp 2, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China.
   [Jin, Ting] Hancheng Peoples Hosp, Dept Anesthesiol, Hancheng 715499, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Yu, JX (通讯作者)，Xi An Jiao Tong Univ, Cadre Ward, Affiliated Hosp 2, 157 West 5th Rd, Xian 710004, Shaanxi, Peoples R China.
EM yujunxia1981@xjtu.edu.cn
OI Hu, Yanfen/0000 0002 5191 158X
FU Key research and development plan of Shaanxi Province [2022SF 175]
FX This work was supported by key research and development plan of Shaanxi
   Province (grant numbers 2022SF 175) .
CR Al Khawaga S, 2018, BIOL REV, V93, P364, DOI 10.1111/brv.12349
   Amoli MM, 2005, CYTOTECHNOLOGY, V48, P75, DOI 10.1007/s10616 005 3586 5
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Brulport M, 2007, HEPATOLOGY, V46, P861, DOI 10.1002/hep.21745
   Chen Z, 2015, AM J PHYSIOL ENDOC M, V308, pE460, DOI 10.1152/ajpendo.00470.2014
   De Magalhaes DA, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001 3765201920180314
   El Shitany NA, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109567
   Ilchovska D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102741
   Kerper N, 2022, CSH PERSPECT BIOL, V14, DOI 10.1101/cshperspect.a040741
   Khalid M, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12040542
   Kondegowda NG, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf5238
   Lin SC, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241210289
   Maloney CA, 2011, J NUTR, V141, P95, DOI 10.3945/jn.109.119453
   Meyerovich K, 2018, J MOL ENDOCRINOL, V61, pF1, DOI 10.1530/JME 16 0183
   Moh AMC, 2020, DIABETES RES CLIN PR, V161, DOI 10.1016/j.diabres.2019.107992
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Mori K, 2022, J ENDOCRINOL, V254, P27, DOI 10.1530/JOE 21 0424
   Ohshima D, 2011, BIOCHEM BIOPH RES CO, V408, P530, DOI 10.1016/j.bbrc.2011.04.049
   Schrader J, 2007, DIABETOLOGIA, V50, P1243, DOI 10.1007/s00125 007 0672 6
   Shiode Y, 2023, HEPATOLOGY, V77, P395, DOI 10.1002/hep.32317
   Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600 065X.2011.01088.x
   Sun Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108576
   Tan W, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.967151
   Taniguchi R, 2014, J BIOL CHEM, V289, P7349, DOI 10.1074/jbc.M113.538314
   Wang J, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa045
   Wang Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867516
   Wang Fischer Y, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8054073
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xiao XH, 2019, DIABETES METAB SYNDR, V12, P2325, DOI 10.2147/DMSO.S226055
   Xing BD, 2023, THER ADV ENDOCRINOL, V14, DOI 10.1177/20420188231170754
   Ye XS, 2022, ACTA BIOCH BIOPH SIN, V54, P1080, DOI 10.3724/abbs.2022094
   Yoo S, 2020, FREE RADICAL BIO MED, V153, P17, DOI 10.1016/j.freeradbiomed.2020.04.012
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zhang BX, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01751 3
   Zhao YQ, 2018, ANIM MODEL EXP MED, V1, P152, DOI 10.1002/ame2.12023
   Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151
   Zhou Y, 2021, EXP BIOL MED, V246, P2502, DOI 10.1177/15353702211032133
   Zhuang LF, 2023, EBIOMEDICINE, V95, DOI 10.1016/j.ebiom.2023.104744
   Zimmet P, 2016, NAT REV ENDOCRINOL, V12, P616, DOI 10.1038/nrendo.2016.105
NR 39
TC 1
Z9 1
U1 5
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC 5
PY 2024
VL 142
AR 113008
DI 10.1016/j.intimp.2024.113008
EA AUG 2024
PN A
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA E8R8E
UT WOS:001305624500001
PM 39217877
DA 2025 08 17
ER

PT J
AU Rajkovic, ST
   Dinic, BR
   Mitic, B
   Radovic, VD
   Jovanovic, M
AF Rajkovic, Snezana Tesic
   Dinic, Biljana Radovanovic
   Mitic, Branka
   Radovic, Violeta Dinic
   Jovanovic, Maja
TI Hyperparathyroidism as a cause of recurrent acute pancreatitis   A case
   report
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE pancreatitis; hyperparathyroidism; comorbidity; diagnosis; differential;
   kidney failure; chronic
ID MUTATIONS; CALCIUM; RISK
AB Introduction. One of the more uncommon etiological factors responsible for the development of acute pancreatitis (AP) is hypercalcemia. Hyperparathyroidism (HPT), as a cause of hypercalcemia, is responsible for 1.5 13% of AP according to a number of studies. A mechanism of the development of AP in hyperparathyroidism is still unclear. Case report. We presented a 47 year old female patient, who had five episodes of AP in total before the etiological factors were finally determined. The patient had certain comorbidities which were considered to be potential causes of AP. She had chronic renal insufficiency (she was on a regular hemodialysis program), systemic lupus erythematosus and mioma uteri. She used to regularly take an antiepileptic drug (combination of sodium valproate and valproic acid). During the fifth episode of AP, the serum calcium level was for the first time elevated to twice the normal value. Level of parathyroid hormone was several times higher. A static scintigraphy found hyperplasia or hyperfunctional adenoma of the right inferior and superior parathyroid glands. Abdominal multislice computed tomography (MSCT) scan verified the enlargement of the entire pancreas, as well as the presence of heterogeneous structures with diffuse amorphous calcifications. The lytic lesions in the pelvic bones could be seen in both sides. Parathyroidectomy was being postponed by an endocrine surgeon because of the poor overall condition of the patient. In the next period the patient had five more episodes of AP. The condition was significantly contributed by increasingly more frequent and longer episodes of metrorrhagia. Despite all therapeutic measures that were taken, systemic inflammatory response syndrome (SIRS) developed, and fatal outcome occurred. Conclusion. In case of recurrent pancreatitis, hyperparathyroidism is to be considered even if a significant elevation of serum calcium is not present. This is especially the case for patients with chronic renal insufficiency or impaired vitamin D metabolism, who have a higher risk of secondary hyperthyroidism.
C1 [Rajkovic, Snezana Tesic; Dinic, Biljana Radovanovic; Radovic, Violeta Dinic] Clin Ctr Nis, Clin Gastroenterol & Hepatol, Bulevar Dr Zorana Dindica 48, Nish 18000, Serbia.
   [Mitic, Branka] Clin Ctr Nis, Inst Nephrol & Hemodialysis, Nish, Serbia.
   [Jovanovic, Maja] Clin Ctr Nis, Clin Infect Dis, Nish, Serbia.
   [Dinic, Biljana Radovanovic; Mitic, Branka] Univ Nis, Fac Med, Nish, Serbia.
C3 University of Nis
RP Rajkovic, ST (通讯作者)，Clin Ctr Nis, Clin Gastroenterol & Hepatol, Bulevar Dr Zorana Dindica 48, Nish 18000, Serbia.
EM snezanatesic@yahoo.com
OI Mitic, Branka/0000 0001 9370 8865; TESIC RAJKOVIC,
   SNEZANA/0000 0003 0158 5883
CR Abdullah M, 2003, Med J Malaysia, V58, P600
   Bai HX, 2012, J CLIN GASTROENTEROL, V46, P656, DOI 10.1097/MCG.0b013e31825c446c
   Banks PA, 2006, AM J GASTROENTEROL, V101, P2379, DOI 10.1111/j.1572 0241.2006.00856.x
   Braun C, 2007, REV MED INTERNE, V28, P116, DOI 10.1016/j.revmed.2006.11.005
   Cannata Andia JB, 2008, NEPHROL DIAL TRAN S1, V1, P29
   Carnaille B, 1998, AUST NZ J SURG, V68, P117, DOI 10.1111/j.1445 2197.1998.tb04719.x
   Chowdhury SD, 2014, INDIAN J GASTROENTER, V33, P175, DOI 10.1007/s12664 013 0430 2
   Felderbauer P, 2006, SCAND J GASTROENTERO, V41, P343, DOI 10.1080/00365520510024214
   Felderbauer P, 2008, AM J GASTROENTEROL, V103, P368, DOI 10.1111/j.1572 0241.2007.01695.x
   Frossard JL, 2008, LANCET, V371, P143, DOI 10.1016/S0140 6736(08)60107 5
   Jacob JJ, 2006, ANZ J SURG, V76, P740, DOI 10.1111/j.1445 2197.2006.03845.x
   Kanno Kaori, 2007, Fukushima J Med Sci, V53, P51
   Khoo TK, 2009, J CLIN ENDOCR METAB, V94, P2115, DOI 10.1210/jc.2008 1965
   KOPPELBERG T, 1994, DEUT MED WOCHENSCHR, V119, P719, DOI 10.1055/s 2008 1058752
   Manguilar LA, 2013, REV ENDOCRINOL NUTR, V21, P132
   MITHOFER K, 1995, GASTROENTEROLOGY, V109, P239, DOI 10.1016/0016 5085(95)90290 2
   RANSON JHC, 1982, AM J GASTROENTEROL, V77, P633
   Shah AU, 2009, AM J PHYSIOL GASTR L, V297, pG967, DOI 10.1152/ajpgi.00181.2009
   WARD JB, 1995, LANCET, V346, P1016, DOI 10.1016/S0140 6736(95)91695 4
NR 19
TC 1
Z9 1
U1 0
U2 1
PU MILITARY MEDICAL ACAD INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33 35, BELGRADE, 11040, SERBIA
SN 0042 8450
EI 2406 0720
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PY 2016
VL 73
IS 11
BP 1064
EP 1067
DI 10.2298/VSP150210121T
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EC6QZ
UT WOS:000388262500012
PM 29341554
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Hashizume, M
   Hayakawa, N
   Mihara, M
AF Hashizume, M.
   Hayakawa, N.
   Mihara, M.
TI IL 6 trans signalling directly induces RANKL on fibroblast like synovial
   cells and is involved in RANKL induction by TNF α and IL 17
SO RHEUMATOLOGY
LA English
DT Article
DE Fibroblast like synoviocytes; Receptor activator of nuclear factor kappa
   B ligand; Tocilizumab; Soluble IL 6 receptor; Interleukin 6; Tumour
   necrosis factor alpha; Interleukin 17; Interleukin 1; Janus
   kinase/signal transducer and activator of transcription;
   Mitogen activated protein kinase
ID NECROSIS FACTOR ALPHA; SOLUBLE INTERLEUKIN 6 RECEPTORS;
   RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN
   LIGAND; OSTEOBLASTIC CELLS; T CELL; ACTIVATION; EXPRESSION; CYTOKINE
AB Objectives. We investigated the influence of cytokines on the expression of RANK ligand (RANKL) in fibroblast like synoviocytes from RA patients (RA FLS).
   Methods. RA FLS were stimulated by IL 6, TNF alpha, IL 17 and IL 1 beta with or without soluble IL 6 receptor (sIL 6R) for 24 h. The expression of RANKL was measured by real time PCR, western blotting and immunostaining. In proliferation assay, RA FLS were cultured with cytokines for 3 days. RA FLS were co cultured with RAW cell in the presence of IL 6/sIL 6R for 3 days and then NFATc1 mRNA expression in RAW cells was examined. RA FLS was cultured with parthenolide [PAR, signal transducer and activator of transcription (STAT) inhibitor] or PD98059 (PD, mitogen activated protein kinase inhibitor) in the presence of IL 6/sIL 6R and then the influence of these drugs on phosphorylation of STAT3 and ERK1/2, and RANKL expression was examined.
   Results. RANKL expression was induced by IL 6/sIL 6R (but not IL 6 alone) and by IL 1 beta. On the other hand, TNF alpha and IL 17 did not induce RANKL expression, although TNF alpha, IL 17 or IL 1 beta stimulated cell growth and IL 6 production. However, in the presence of sIL 6R, TNF alpha or IL 17 induced RANKL expression. By the co culture of RA FLS, NFATc1 mRNA expression was induced in RAW cells. Finally, IL 6/sIL 6R induced phosphorylation of STAT3 and ERK1/2 in RA FLS, and was completely inhibited by PAR and PD, respectively. PAR completely inhibited IL 6/sIL 6R induced RANKL expression, but PD did not.
   Conclusions. IL 6/sIL 6R directly induced RANKL expression in RA FLS and it is essential for RANKL induction by TNF alpha and IL 17. Moreover, RANKL induction by IL 6/sIL 6R is mediated by the janus kinase/STAT signalling pathway.
C1 [Hashizume, M.; Hayakawa, N.; Mihara, M.] Chugai Pharmaceut Co Ltd, Prod Res Dept, Shizuoka 4128513, Japan.
C3 Chugai Pharmaceutical Co., Ltd.; Roche Holding; Roche Holding Japan
RP Mihara, M (通讯作者)，Chugai Pharmaceut Co Ltd, Prod Res Dept, 1 135 Komakado, Shizuoka 4128513, Japan.
EM miharamsh@chugai pharm.co.jp
CR ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Beklen A, 2007, J DENT RES, V86, P347, DOI 10.1177/154405910708600409
   Desgeorges A, 1997, J RHEUMATOL, V24, P1510
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Franchimont N, 2005, ARTHRITIS RHEUM, V52, P84, DOI 10.1002/art.20727
   Fujikawa Y, 1996, BRIT J RHEUMATOL, V35, P213
   Furst DE, 2004, CLIN THER, V26, P1960, DOI 10.1016/j.clinthera.2004.12.019
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092 8674(90)90411 7
   Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359 6101(98)80005 1
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Kubota A, 2004, J RHEUMATOL, V31, P426
   Kutukculer N, 1998, CLIN RHEUMATOL, V17, P288, DOI 10.1007/BF01451007
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Legendre F, 2003, J BIOL CHEM, V278, P2903, DOI 10.1074/jbc.M110773200
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   MADSON KL, 1994, J RHEUMATOL, V21, P2359
   MIHARA M, 1995, BRIT J RHEUMATOL, V34, P321
   MULLBERG J, 1994, J IMMUNOL, V152, P4958
   Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Sobota R, 2000, BIOCHEM BIOPH RES CO, V267, P329, DOI 10.1006/bbrc.1999.1948
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
NR 31
TC 276
Z9 313
U1 0
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD NOV
PY 2008
VL 47
IS 11
BP 1635
EP 1640
DI 10.1093/rheumatology/ken363
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 361NJ
UT WOS:000260134100009
PM 18786965
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Xue, Y
   Zhang, L
   Liu, FW
   Dai, F
   Kong, L
   Ma, DY
   Han, Y
AF Xue, Yang
   Zhang, Lan
   Liu, Fuwei
   Dai, Fang
   Kong, Liang
   Ma, Dayan
   Han, Yong
TI Alkaline ?Nanoswords? Coordinate Ferroptosis like Bacterial Death for
   Antibiosis and Osseointegration
SO ACS NANO
LA English
DT Article; Early Access
DE Nanosword like titanite; ferroptosis; proton disturbance; physical
   puncture; antibiosis
ID HYDROXYAPATITE NANORODS; NACA2HSI3O9 NANORODS; IN VITRO; TI;
   BIOINTEGRATION; IRRADIATION; RESISTANCE; PHOSPHATE; IMPLANTS; TITANIUM
AB Ferroptosis is an iron dependent cell death and is associated with cancer therapy. Can it play a role in resistance of postoperative infection of implants, especially with an extracellular supplement of Fe ions in a non cytotoxic dose? To answer this, "nanoswords" of Fe doped titanite are fabricated on a Ti implant surface to resist bacterial invasion by a synergistic action of ferroptosis like bacteria killing, proton disturbance, and physical puncture. The related antibiosis mechanism is explored by atomic force microscopy and genome sequencing. The nanoswords induce an increased local pH value, which not only weakens the proton motive force, reducing adenosine triphosphate synthesis of Staphylococcus aureus, but also decreases the membrane modulus, making the nanoswords distort and even puncture a bacterial membrane easily. Simultaneously, more Fe ions are taken by bacteria due to increased bacterial membrane permeability, resulting in ferroptosis like death of bacteria, and this is demonstrated by intracellular iron enrichment, lipid peroxidation, and glutathione depletion. Interestingly, a microenvironment constructed by these nanoswords improves osteoblast behavior in vitro and bone regeneration in vivo. Overall, the nanoswords can induce ferroptosis like bacterial death without cytotoxicity and have great promise in applications with clinical implants for outstanding antibiosis and biointegration performance.
C1 [Xue, Yang; Zhang, Lan; Dai, Fang; Ma, Dayan; Han, Yong] Xi An Jiao Tong Univ, State key Lab Mech Behav Mat, Xian 710049, Peoples R China.
   [Liu, Fuwei; Kong, Liang] Fourth Mil Med Univ, Xian 710038, Peoples R China.
C3 Xi'an Jiaotong University; Air Force Medical University
RP Zhang, L; Han, Y (通讯作者)，Xi An Jiao Tong Univ, State key Lab Mech Behav Mat, Xian 710049, Peoples R China.
EM lan.zhang@mail.xjtu.edu.cn; yonghan@mail.xjtu.edu.cn
OI Liu, Fuwei/0000 0001 8942 6697; Zhang, Lan/0000 0002 2162 3333
FU Research Fund for the National Natural Science Foundation of China
   [51771142, 51971171, 82072075]; Natural Science Foundation of Shaanxi
   Province [2021JC 07, 2023 JC ZD 20]
FX We appreciate Research Fund for the National Natural Science Foundation
   of China (Grant Nos. 51771142, 51971171, and 82072075) and Natural
   Science Foundation of Shaanxi Province (Nos. 2021JC 07 and
   2023 JC ZD 20) for financially supporting this work.
CR Ashraf MA, 2021, INT J BIOL MACROMOL, V169, P436, DOI 10.1016/j.ijbiomac.2020.12.049
   Buton A, 2021, G3 GENES GENOM GENET, V11, DOI 10.1093/g3journal/jkaa054
   Cai JY, 2021, BIOACT MATER, V6, P783, DOI 10.1016/j.bioactmat.2020.08.037
   Cao FF, 2020, ANGEW CHEM INT EDIT, V59, P5108, DOI 10.1002/anie.201912182
   Chae K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb0025
   Chandrangsu P, 2017, NAT REV MICROBIOL, V15, P338, DOI 10.1038/nrmicro.2017.15
   Chen MW, 2022, CHEM ENG J, V427, DOI 10.1016/j.cej.2021.130982
   Feng XB, 2022, ACS NANO, V16, P2546, DOI 10.1021/acsnano.1c09189
   Fu JN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27217 4
   Fu JN, 2021, ADV MATER, V33, DOI 10.1002/adma.202102926
   Gonciarz RL, 2021, TRENDS PHARMACOL SCI, V42, P7, DOI 10.1016/j.tips.2020.11.003
   Guan GL, 2021, J HAZARD MATER, V402, DOI 10.1016/j.jhazmat.2020.123542
   Han Y, 2013, RSC ADV, V3, P11169, DOI 10.1039/c3ra23425h
   Jeckelmann JM, 2020, PFLUG ARCH EUR J PHY, V472, P1129, DOI 10.1007/s00424 020 02379 0
   Lee MK, 2022, BIOACT MATER, V9, P239, DOI 10.1016/j.bioactmat.2021.07.003
   Li JF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21435 6
   Li J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12429 6
   Li J, 2017, ACS NANO, V11, P11250, DOI 10.1021/acsnano.7b05620
   Li K, 2021, CHEM ENG J, V423, DOI 10.1016/j.cej.2021.130133
   Li K, 2020, BIOMATER SCI UK, V8, P6004, DOI 10.1039/d0bm01290d
   Li K, 2020, BIOACT MATER, V5, P116, DOI 10.1016/j.bioactmat.2020.01.001
   Li K, 2020, J MATER CHEM B, V8, P691, DOI 10.1039/c9tb02321f
   Li K, 2019, J MATER CHEM B, V7, P5265, DOI 10.1039/c9tb01096c
   Li K, 2019, ACS BIOMATER SCI ENG, V5, P2208, DOI 10.1021/acsbiomaterials.9b00073
   Li Y, 2022, ACS NANO, DOI 10.1021/acsnano.2c05756
   Liu HP, 2021, ACS NANO, V15, P18505, DOI 10.1021/acsnano.1c08409
   Liu JH, 2022, CHEM ENG J, V443, DOI 10.1016/j.cej.2022.136299
   Makabenta JMV, 2021, NAT REV MICROBIOL, V19, P23, DOI 10.1038/s41579 020 0420 1
   Manivannan P, 2014, INTERDISCIP SCI, V6, P63, DOI 10.1007/s12539 014 0189 x
   Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0720 y
   Pacholak A, 2021, J HAZARD MATER, V407, DOI 10.1016/j.jhazmat.2020.124352
   Robinson A, 2012, CURR DRUG TARGETS, V13, P352, DOI 10.2174/138945012799424598
   Sadowska JM, 2021, MATER TODAY, V46, P136, DOI 10.1016/j.mattod.2020.12.018
   Seck A, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003 022 03064 x
   Shen XY, 2020, NANO TODAY, V35, DOI 10.1016/j.nantod.2020.100981
   Shi Y, 2020, TALANTA, V210, DOI 10.1016/j.talanta.2019.120637
   Soe YM, 2021, CELL MICROBIOL, V23, DOI 10.1111/cmi.13317
   Su K, 2020, ACS NANO, V14, P2077, DOI 10.1021/acsnano.9b08686
   Tan J, 2018, ACS APPL MATER INTER, V10, P42018, DOI 10.1021/acsami.8b15724
   Tang HZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202107300
   Tanuka S., 2022, ANTIMICROB AGENTS CH, V66, P7
   Tran TN, 2022, J HAZARD MATER, V430, DOI 10.1016/j.jhazmat.2022.128488
   Toyoda Takao, 2010, J Oral Sci, V52, P561, DOI 10.2334/josnusd.52.561
   Tzeng JH, 2021, CHEM ENG J, V421, DOI 10.1016/j.cej.2020.127880
   Wang GM, 2020, ADV SCI, V7, DOI 10.1002/advs.201902089
   Wang H, 2021, ADV SCI, V8, DOI 10.1002/advs.202101778
   Wang SJ, 2019, ADV MATER, V31, DOI 10.1002/adma.201904341
   Wang XY, 2022, CHEM ENG J, V446, DOI 10.1016/j.cej.2022.136987
   Wang YX, 2021, J HAZARD MATER, V416, DOI 10.1016/j.jhazmat.2021.126236
   Wang Z, 2022, BIOMATERIALS, V280, DOI 10.1016/j.biomaterials.2021.121249
   Wang Z, 2022, BIOMATERIALS, V290, DOI 10.1016/j.biomaterials.2022.121842
   Wei SB, 2021, NANO TODAY, V37, DOI 10.1016/j.nantod.2021.101090
   Xue Y, 2021, J MATER SCI TECHNOL, V88, P240, DOI 10.1016/j.jmst.2021.01.074
   Xue Y, 2022, BIOACT MATER, V8, P1, DOI 10.1016/j.bioactmat.2021.06.029
   Yamashita T, 2008, APPL SURF SCI, V254, P2441, DOI 10.1016/j.apsusc.2007.09.063
   Yang RH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg3816
   Yang ZJ, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120534
   Ye J, 2022, BIOACT MATER, V11, P181, DOI 10.1016/j.bioactmat.2021.09.019
   Ye J, 2020, ACTA BIOMATER, V107, P313, DOI 10.1016/j.actbio.2020.02.036
   Yin HM, 2019, ACS APPL MATER INTER, V11, P42956, DOI 10.1021/acsami.9b14800
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
   Zhang GN, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120634
   Zhang L, 2021, ACS APPL MATER INTER, V13, P28764, DOI 10.1021/acsami.1c04895
   Zhang L, 2021, ANGEW CHEM INT EDIT, V60, P3469, DOI 10.1002/anie.202012487
   Zhang W, 2022, ADV MATER, V34, DOI 10.1002/adma.202105738
   Zhang W, 2020, INT J BIOL MACROMOL, V165, P222, DOI 10.1016/j.ijbiomac.2020.09.152
   Zhang XY, 2021, BIOACT MATER, V6, P12, DOI 10.1016/j.bioactmat.2020.07.017
   Zheng HZ, 2021, NANOSCALE, V13, P2266, DOI 10.1039/d0nr08478f
   Zheng QY, 2021, CHEM SOC REV, V50, P5086, DOI 10.1039/d1cs00056j
   Zhu XN, 2011, FOODBORNE PATHOG DIS, V8, P495, DOI 10.1089/fpd.2010.0697
NR 70
TC 54
Z9 58
U1 30
U2 223
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD 2023 JAN 20
PY 2023
DI 10.1021/acsnano.2c10960
EA JAN 2023
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 8L8ZH
UT WOS:000924067600001
PM 36662033
DA 2025 08 17
ER

PT J
AU Marasinghe, CK
   Je, JY
AF Marasinghe, Chathuri K.
   Je, Jae Young
TI Heme oxygenase 1 induction by gallic acid g chitosan is an
   important event in modulating adipocyte differentiation
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article
DE anti adipogenesis; chitosan; HO 1; mesenchymal stem cells;
   pro inflammatory cytokines; ROS
ID IMPROVES INSULIN SENSITIVITY; GRAFTED CHITOSAN; INFLAMMATORY RESPONSES;
   ADIPOSE TISSUE; PPAR GAMMA; ADIPOGENESIS; OBESITY; SUPPRESSES;
   OLIGOSACCHARIDES; OSTEOBLASTS
AB Obesity, one of the common worldwide chronic health diseases co relates with adipogenesis. Adipogenesis is a complex biological action of the emergence of mature adipocytes from the differentiation of pre adipocytes and the disfunction of this process leads to the development of metabolic issues in obesity. Recently, much attention has been paid to utilizing natural compounds to discover their biological activities. This study focused on investigating the probable anti adipogenic effects of gallic acid g chitosan (GAC) and plain chitosan (PC) through regulating the heme oxygenase 1 (HO 1)/Nrf2 pathway on mesenchymal stem cells. Gallic acid is grafted onto the PC backbone to improve its specific physical and biological properties. GAC showed promising anti adipogenic effects by enhancing HO 1 expression and lipolysis and as well as suppressing lipid accumulation, reactive oxygen species, and pro inflammatory cytokines production, transcription factor expression compared to the PC treatment. On the contrary, zinc protoporphyrin CYRILLIC CAPITAL LETTER BYELORUSSIAN UKRAINIAN IX (ZnPP), a HO 1 inhibitor reversed these effects of GAC on adipogenesis. Taken all together, this study revealed that grafting GA onto the chitosan improved potential anti adipogenic activity by induction of the HO 1/Nrf2 pathway on mesenchymal stem cells (MSCs). Practical applications GAC is a well known copolymer with versatile bioactivities such as antimicrobial, antioxidant, and anti diabetic activity. However, the anti adipogenic effect of GAC has not been explored in MSCs. This study demonstrated that GAC inhibited adipocyte differentiation in MSCs through HO 1 activation. These findings suggest that GAC can be applied practically from different perspectives. GAC can be applied in the pharmacological industry to the development of anti obesity drugs, medicinal perspectives for the treatment of obesity and obesity related diseases, and in the food industry as a functional food to promote health and decrease the risk of diseases.
C1 [Marasinghe, Chathuri K.] Pukyong Natl Univ, Dept Food & Life Sci, Busan, South Korea.
   [Je, Jae Young] Pukyong Natl Univ, Div Smart Healthcare, Major Human Bioconvergence, Busan 48513, South Korea.
C3 Pukyong National University; Pukyong National University
RP Je, JY (通讯作者)，Pukyong Natl Univ, Div Smart Healthcare, Major Human Bioconvergence, Busan 48513, South Korea.
EM jjy1915@pknu.ac.kr
OI Je, Jae Young/0000 0002 4800 0566
FU Pukyong National University
FX Pukyong National University
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Ahn CB, 2016, INFLAMMATION, V39, P366, DOI 10.1007/s10753 015 0258 2
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Cho EJ, 2008, J MICROBIOL BIOTECHN, V18, P80
   Cho YS, 2011, CARBOHYD POLYM, V83, P1617, DOI 10.1016/j.carbpol.2010.10.019
   Divella R, 2016, J CANCER, V7, P2346, DOI 10.7150/jca.16884
   Drummond GS, 2019, ARCH BIOCHEM BIOPHYS, V673, DOI 10.1016/j.abb.2019.108073
   El Hafidi M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153657
   Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955 0674(98)80138 5
   Findeisen HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018532
   Furukawa S., 2004, Journal of Clinical Investigation, V114, P1752, DOI 10.1172/JCI21625
   Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580 018 0093 z
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973 1296.99285
   Gummersbach C, 2009, DIFFERENTIATION, V77, P115, DOI 10.1016/j.diff.2008.09.009
   Hu QB, 2016, J AGR FOOD CHEM, V64, P5893, DOI 10.1021/acs.jafc.6b02255
   Imhoff BR, 2010, DIFFERENTIATION, V80, P31, DOI 10.1016/j.diff.2010.04.005
   Kanda Y, 2011, LIFE SCI, V89, P250, DOI 10.1016/j.lfs.2011.06.007
   Karadeniz F, 2011, CARBOHYD POLYM, V86, P666, DOI 10.1016/j.carbpol.2011.05.005
   Kim CY, 2018, BIOMED PHARMACOTHER, V108, P1507, DOI 10.1016/j.biopha.2018.09.169
   Kim DH, 2015, J CARBOHYD CHEM, V34, P163, DOI 10.1080/07328303.2015.1018993
   Lai CS, 2012, J AGR FOOD CHEM, V60, P1094, DOI 10.1021/jf204862d
   Lee DS, 2014, CAN J MICROBIOL, V60, P629, DOI 10.1139/cjm 2014 0286
   Lee DS, 2013, J AGR FOOD CHEM, V61, P6574, DOI 10.1021/jf401254g
   Lee H, 2009, J BIOL CHEM, V284, P10601, DOI 10.1074/jbc.M808742200
   Lee JY, 2021, MOLECULES, V26, DOI 10.3390/molecules26020331
   Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001
   Li M, 2008, DIABETES, V57, P1526, DOI 10.2337/db07 1764
   Liu J, 2020, INT J BIOL MACROMOL, V156, P1539, DOI 10.1016/j.ijbiomac.2019.11.202
   Liu J, 2016, INT J BIOL MACROMOL, V89, P518, DOI 10.1016/j.ijbiomac.2016.04.089
   Liu J, 2014, INT J BIOL MACROMOL, V65, P97, DOI 10.1016/j.ijbiomac.2014.01.021
   Liu J, 2013, INT J BIOL MACROMOL, V62, P321, DOI 10.1016/j.ijbiomac.2013.09.032
   Lodhi G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/654913
   Madsen MS, 2014, MOL CELL BIOL, V34, P939, DOI 10.1128/MCB.01344 13
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Ndisang JF, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/359732
   Nicolai A, 2009, HYPERTENSION, V53, P508, DOI 10.1161/HYPERTENSIONAHA.108.124701
   Oh Y, 2021, INT J BIOL MACROMOL, V183, P1410, DOI 10.1016/j.ijbiomac.2021.05.122
   Oh Y, 2020, FOOD RES INT, V136, DOI 10.1016/j.foodres.2020.109603
   Pan HT, 2018, MAR DRUGS, V16, DOI 10.3390/md16060198
   Rahman MA, 2008, PROTEOMICS, V8, P569, DOI 10.1002/pmic.200700888
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Savopoulos C, 2011, HIPPOKRATIA, V15, P18
   Senevirathne M, 2012, CARBOHYD POLYM, V87, P876, DOI 10.1016/j.carbpol.2011.08.080
   Seo HA, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/184598
   Sousa F, 2009, PROCESS BIOCHEM, V44, P749, DOI 10.1016/j.procbio.2009.03.009
   Tanaka H, 2009, BIOCHEM BIOPH RES CO, V381, P566, DOI 10.1016/j.bbrc.2009.02.086
   Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wang WJ, 2020, INT J BIOL MACROMOL, V164, P4532, DOI 10.1016/j.ijbiomac.2020.09.042
   Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955 0674(99)00037 X
   Yang Jinwoo, 2017, Prev Nutr Food Sci, V22, P306, DOI 10.3746/pnf.2017.22.4.306
   Yang LH, 2007, PHARMACOL RES, V56, P202, DOI 10.1016/j.phrs.2007.05.007
   Zhou Y, 2020, BIOSCI BIOTECH BIOCH, V84, P1460, DOI 10.1080/09168451.2020.1744110
NR 53
TC 2
Z9 3
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0145 8884
EI 1745 4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
PD AUG
PY 2022
VL 46
IS 8
AR e14179
DI 10.1111/jfbc.14179
EA APR 2022
PG 10
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA 3P1XV
UT WOS:000779230500001
PM 35393708
OA gold
DA 2025 08 17
ER

PT J
AU Ferreira, M
   Pinto, SN
   Aires da Silva, F
   Bettencourt, A
   Aguiar, SI
   Gaspar, MM
AF Ferreira, Magda
   Pinto, Sandra N.
   Aires da Silva, Frederico
   Bettencourt, Ana
   Aguiar, Sandra I.
   Gaspar, Maria Manuela
TI Liposomes as a Nanoplatform to Improve the Delivery of Antibiotics into
   Staphylococcus aureus Biofilms
SO PHARMACEUTICS
LA English
DT Article
DE Staphylococcus aureus; biofilms; liposomes; infection; transwell model
ID NANOSTRUCTURES ENCAPSULATING GENTAMICIN; CATIONIC LIPOSOMES;
   DRUG DELIVERY; FUSOGENIC LIPOSOMES; TARGETED DELIVERY; INFECTIONS;
   LEVOFLOXACIN; EFFICACY; NANOPARTICLES; VANCOMYCIN
AB Staphylococcus aureus biofilm associated infections are a major public health concern. Current therapies are hampered by reduced penetration of antibiotics through biofilm and low accumulation levels at infected sites, requiring prolonged usage. To overcome these, repurposing antibiotics in combination with nanotechnological platforms is one of the most appealing fast track and cost effective approaches. In the present work, we assessed the potential therapeutic benefit of three antibiotics, vancomycin, levofloxacin and rifabutin (RFB), through their incorporation in liposomes. Free RFB displayed the utmost antibacterial effect with MIC and MBIC50 below 0.006 mu g/mL towards a methicillin susceptible S. aureus (MSSA). RFB was selected for further in vitro studies and the influence of different lipid compositions on bacterial biofilm interactions was evaluated. Although positively charged RFB liposomes displayed the highest interaction with MSSA biofilms, RFB incorporated in negatively charged liposomes displayed lower MBIC50 values in comparison to the antibiotic in the free form. Preliminary safety assessment on all RFB formulations towards osteoblast and fibroblast cell lines demonstrated that a reduction on cell viability was only observed for the positively charged liposomes. Overall, negatively charged RFB liposomes are a promising approach against biofilm S. aureus infections and further in vivo studies should be performed.
C1 [Ferreira, Magda; Aires da Silva, Frederico; Aguiar, Sandra I.] Univ Lisbon, Fac Vet Med, Ctr Interdisciplinary Res Anim Hlth CIISA, P 1300477 Lisbon, Portugal.
   [Ferreira, Magda; Bettencourt, Ana; Gaspar, Maria Manuela] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, P 1649003 Lisbon, Portugal.
   [Pinto, Sandra N.] Univ Lisbon, Inst Super Tecn, Dept Bioengn, Inst Bioengn & Biosci, P 1049001 Lisbon, Portugal.
C3 Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa
RP Aguiar, SI (通讯作者)，Univ Lisbon, Fac Vet Med, Ctr Interdisciplinary Res Anim Hlth CIISA, P 1300477 Lisbon, Portugal.; Gaspar, MM (通讯作者)，Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, P 1649003 Lisbon, Portugal.
EM mscferreira@ff.ulisboa.pt; sandrapinto@ist.utl.pt;
   fasilva@fmv.ulisboa.pt; asimao@ff.ulisboa.pt; saguiar@fmv.ulisboa.pt;
   mgaspar@ff.ulisboa.pt
RI ; Aguiar, Sandra/A 3500 2009; Gaspar, Maria Manuela/C 2024 2014; de
   campos simao bettencourt, ana/ABG 2839 2021; Ferreira,
   Magda/Q 7286 2017; Bettencourt, Ana/M 4219 2013; Gaspar, Maria
   Manuela/AAM 2706 2020; Pinto, Sandra/H 8446 2016; Silva, Frederico
   Aires/ABD 9602 2021
OI Aires da Silva, Frederico/0000 0002 3821 419X; Aguiar,
   Sandra/0000 0002 3041 383X; Gaspar, Maria Manuela/0000 0001 6814 7226;
   Bettencourt, Ana/0000 0002 8498 5892; Pinto, Sandra/0000 0002 3205 9459;
   Ferreira, Magda/0000 0001 7147 5458; 
FU Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/MED QUI/31721/2017,
   PPBI POCI 01 0145 FEDER 022122, SAICTPAC/0019/2015, UIDB/04138/2020,
   UIDP/04138/2020, UIDB/00276/2020, UIDB/04565/2020]; Fundação para a
   Ciência e a Tecnologia [PTDC/MED QUI/31721/2017] Funding Source: FCT
FX This research was funded by Fundacao para a Ciencia e Tecnologia (FCT)
   projects PTDC/MED QUI/31721/2017, PPBI POCI 01 0145 FEDER 022122,
   SAICTPAC/0019/2015, UIDB/04138/2020, UIDP/04138/2020, UIDB/00276/2020
   and UIDB/04565/2020.
CR Albano M, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00959 19
   Alhariri M, 2013, EXPERT OPIN DRUG DEL, V10, P1515, DOI 10.1517/17425247.2013.822860
   Aramaki Y, 2001, ARCH BIOCHEM BIOPHYS, V392, P245, DOI 10.1006/abbi.2001.2458
   Arisaka M, 2010, FEBS LETT, V584, P1016, DOI 10.1016/j.febslet.2010.01.055
   Asseray N, 2016, INT J ANTIMICROB AG, V47, P478, DOI 10.1016/j.ijantimicag.2016.03.003
   Bhatia E, 2021, J MATER CHEM B, V9, P864, DOI 10.1039/d0tb02036b
   Bhattacharjee S, 2018, THER DELIV, V9, P419, DOI 10.4155/tde 2017 0116
   Bhattacharya M, 2015, EXPERT REV ANTI INFE, V13, P1499, DOI 10.1586/14787210.2015.1100533
   Bhise K, 2018, MATERIALS, V11, DOI 10.3390/ma11071245
   Blaskovich MAT, 2018, ACS INFECT DIS, V4, P715, DOI 10.1021/acsinfecdis.7b00258
   Bolotin Elijah M., 1994, Journal of Liposome Research, V4, P455, DOI 10.3109/08982109409037057
   Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861
   Brambilla LZS, 2017, REV BRAS FARMACOGN, V27, P112, DOI 10.1016/j.bjp.2016.08.008
   Bui LMG, 2017, ESSAYS BIOCHEM, V61, P71, DOI 10.1042/EBC20160061
   Calvet X, 2013, HELICOBACTER, V18, P5, DOI 10.1111/hel.12071
   Chartpitak T, 2018, J DRUG DELIV SCI TEC, V47, P223, DOI 10.1016/j.jddst.2018.07.016
   Clinical and Laboratory Standards Institute, 2014, M100S24 CLSI WAYN PA
   Conlon BP, 2014, BIOESSAYS, V36, P991, DOI 10.1002/bies.201400080
   Croom KF, 2003, DRUGS, V63, P2769, DOI 10.2165/00003495 200363240 00008
   Cruz CD, 2018, BMC MICROBIOL, V18, DOI 10.1186/s12866 018 1321 6
   Czech T, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249 019 1333 z
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Dong D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131806
   Donlan RM, 2002, EMERG INFECT DIS, V8, P881, DOI 10.3201/eid0809.020063
   Doub JB, 2020, ANTIBIOTICS BASEL, V9, DOI 10.3390/antibiotics9060326
   Elron Gross I, 2009, INT J PHARMACEUT, V376, P84, DOI 10.1016/j.ijpharm.2009.04.025
   Ferreira M, 2017, INT J PHARMACEUT, V532, P241, DOI 10.1016/j.ijpharm.2017.08.089
   Fish DN, 1997, CLIN PHARMACOKINET, V32, P101, DOI 10.2165/00003088 199732020 00002
   Forier K, 2014, J CONTROL RELEASE, V190, P607, DOI 10.1016/j.jconrel.2014.03.055
   Gaspar MM, 2008, CURR TOP MED CHEM, V8, P579, DOI 10.2174/156802608783955629
   Gaspar MM, 2008, INT J ANTIMICROB AG, V31, P37, DOI 10.1016/j.ijantimicag.2007.08.008
   Gaspar MM, 2015, NANOMED NANOTECHNOL, V11, P1851, DOI 10.1016/j.nano.2015.06.008
   Gaspar MM, 1996, CANCER CHEMOTH PHARM, V38, P373, DOI 10.1007/s002800050497
   Gaspar MM, 2000, ANTIMICROB AGENTS CH, V44, P2424, DOI 10.1128/AAC.44.9.2424 2430.2000
   Gomes M, 2014, HELICOBACTER, V19, P137
   Grassi L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02409
   Grohs P, 2003, ANTIMICROB AGENTS CH, V47, P418, DOI 10.1128/AAC.47.1.418 420.2003
   Harriott MM, 2009, ANTIMICROB AGENTS CH, V53, P3914, DOI 10.1128/AAC.00657 09
   Ibaraki H, 2020, J DRUG DELIV SCI TEC, V57, DOI 10.1016/j.jddst.2020.101754
   Iwaoka S, 2006, J LEUKOCYTE BIOL, V79, P184, DOI 10.1189/jlb.0405181
   Kadry AA, 2004, J ANTIMICROB CHEMOTH, V54, P1103, DOI 10.1093/jac/dkh465
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   KIRBY C, 1984, BIO TECHNOL, V2, P979, DOI 10.1038/nbt1184 979
   Konreddy AK, 2019, CURR MED CHEM, V26, P5363, DOI 10.2174/0929867325666180706101404
   Koo H, 2017, NAT REV MICROBIOL, V15, P740, DOI 10.1038/nrmicro.2017.99
   Kose N., 2016, Musculoskelet Res Basic Sci, P3, DOI [DOI 10.1007/978 3 319 20777 3, 10.1007/978 3 319 20777 3_1, DOI 10.1007/978 3 319 20777 3_1]
   Lemaire S, 2008, CLIN MICROBIOL INFEC, V14, P766, DOI 10.1111/j.1469 0691.2008.02035.x
   Long Q. X., 2020, ANTIBODY RESPONSES S, DOI [DOI 10.1038/S41591 020 0897 1, DOI 10.1101/2020.03.18.20038018]
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Macià MD, 2014, CLIN MICROBIOL INFEC, V20, P981, DOI 10.1111/1469 0691.12651
   MELL JB, 2019, J ORTHOP RES, V37, P1604, DOI DOI 10.1002/JOR.24291
   Messiaen AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079220
   Nave M, 2016, NANOMEDICINE UK, V11, P1817, DOI 10.2217/nnm 2016 0086
   Nicolosi D, 2010, INT J ANTIMICROB AG, V35, P553, DOI 10.1016/j.ijantimicag.2010.01.015
   Pinho JO, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9101455
   Parastan R, 2020, GENE REP, V20, DOI 10.1016/j.genrep.2020.100739
   Pinheiro M, 2019, CHEM PHYS LIPIDS, V222, P36, DOI 10.1016/j.chemphyslip.2019.05.002
   Pinho JO, 2019, NANOMEDICINE UK, V14, P835, DOI 10.2217/nnm 2018 0388
   Pinto SN, 2019, J ANTIMICROB CHEMOTH, V74, P2617, DOI 10.1093/jac/dkz223
   Pontes C, 2016, INT J PHARMACEUT, V513, P697, DOI 10.1016/j.ijpharm.2016.09.074
   Portilla S, 2020, ANTIBIOTICS BASEL, V9, DOI 10.3390/antibiotics9050242
   Ranjan A, 2010, ANTIMICROB AGENTS CH, V54, P3524, DOI 10.1128/AAC.01522 09
   Ranjan A, 2009, INT J NANOMED, V4, P289
   ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316
   Rukavina Z, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8020018
   Sahukhal GS, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866 017 1129 9
   Santos Ferreira I, 2015, NANOMEDICINE UK, V10, P3131, DOI 10.2217/nnm.15.134
   Santos Rebelo A, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040216
   Scriboni AB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01401
   van den Hoven JM, 2011, MOL PHARMACEUT, V8, P1002, DOI 10.1021/mp2000742
   WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003 2697(75)90363 2
   Wang DY, 2020, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00872
   Zhang XK, 2009, J DRUG TARGET, V17, P399, DOI 10.1080/10611860902795407
   Zimmerli W, 2017, APMIS, V125, P353, DOI 10.1111/apm.12687
NR 74
TC 42
Z9 43
U1 0
U2 37
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD MAR
PY 2021
VL 13
IS 3
AR 321
DI 10.3390/pharmaceutics13030321
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA RE3WJ
UT WOS:000634088400001
PM 33801281
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Xia, ZL
   Wang, Y
   Sun, QD
   Du, XF
AF Xia, Z L
   Wang, Y.
   Sun, Q D
   Du, X F
TI MiR 203 is involved in osteoporosis by regulating DKK1 and inhibiting
   osteogenic differentiation of MSCs
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE MiR 203; MSCs; Osteogenic differentiation; DKK1; Osteoporosis
ID MICRORNAS; EXPRESSION; MECHANISMS; CARCINOMA; THERAPY; GENES; CELLS
AB OBJECTIVE: To investigate whether miR 203 is involved in the osteogenic differentiation of rat mesenchymal stem cells (MSCs) by regulating DDK1. thus participating in the pathogenesis of osteoporosis.
   PATIENTS AND METHODS: miR 203 expression in serum samples of 60 osteoporosis patients and 60 normal subjects was detected using Real time fluorescence quantitative polymerase chain reaction (qRT PCR) assay. MSCs were isolated from bone marrow of rats and then identified. Subsequently, the effects of miR 203 and DKK1 on osteogenic differentiation were estimated by alkaline phosphatase (ALP) activity, alizarin red staining, ALP staining, respectively. Expression levels of osteogenic specific genes were detected by Western blot. Rescue experiments were conducted to confirm whether miR203 could promote osteogenic differentiation of MSCs by inhibiting DKK1.
   RESULTS: Serum level of miR 203 in osteoporosis patients was significantly lower than that of the normal subjects. Overexpressed miR 203 in MSCs enhanced ALP activity, expression of osteogenic marker genes and the number of calcified cells. Additionally, miR 203 could bind to DKK1. The regulatory effect of miR 203 on osteogenic differentiation in MSCs was reversed by DKK1.
   CONCLUSIONS: MiR 203 promotes the differentiation of rat MSCs into osteoblast like cells, which may be associated with the regulation of DKK1 expression.
C1 [Xia, Z L] Linyi Cent Hosp, Dept Neurol, Linyi, Peoples R China.
   [Wang, Y.] Shanxian Cent Hosp, Dept Endocrinol, Shanxian, Peoples R China.
   [Sun, Q D] Linyi Cent Hosp, Dept Gen Surg, Linyi, Peoples R China.
   [Du, X F] Peoples Hosp Rizhao, Dept Orthoped, Rizhao, Peoples R China.
RP Du, XF (通讯作者)，Peoples Hosp Rizhao, Dept Orthoped, Rizhao, Peoples R China.
EM feigee0223@126.com
CR Bae YJ, 2012, HUM MOL GENET, V21, P2991, DOI 10.1093/hmg/dds129
   Banerjee J, 2011, PHYSIOL GENOMICS, V43, P543, DOI 10.1152/physiolgenomics.00157.2010
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bo JJ, 2011, FEBS J, V278, P786, DOI 10.1111/j.1742 4658.2010.07997.x
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109
   Ferrari SL, 2005, WORLD REV NUTR DIET, V95, P35, DOI 10.1159/000088271
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365 2184.1987.tb01309.x
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Ge DW, 2017, EUR REV MED PHARMACO, V21, P4784
   Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hessert D, 2013, J CATARACT REFR SURG, V39, P539, DOI 10.1016/j.jcrs.2012.11.024
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mathé EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078 0432.CCR 09 1467
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Pandey R, 1996, ACTA ORTHOP SCAND, V67, P221, DOI 10.3109/17453679608994677
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Tsui NBY, 2002, CLIN CHEM, V48, P1647
   Yu AM, 2016, DRUG METAB DISPOS, V44, P308, DOI 10.1124/dmd.115.067470
   Zhang Y, 2016, EUR REV MED PHARMACO, V20, P433
NR 23
TC 20
Z9 21
U1 1
U2 6
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD AUG
PY 2018
VL 22
IS 16
BP 5098
EP 5105
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GU2OD
UT WOS:000445108700009
PM 30178828
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Hao, SL
   Wei, GY
   Liu, XY
   Miao, Y
AF Zhang, Qian
   Hao, Shuli
   Wei, Guangyou
   Liu, Xiangyu
   Miao, Yang
TI The p53 mediated cell cycle regulation is a potential mechanism for
   emodin suppressing osteosarcoma cells
SO HELIYON
LA English
DT Article
DE p53; Cell cycle; Emodin; Osteosarcoma
ID P53 GENE; OSTEOPOROSIS; EXPRESSION; RNA; CUPROPTOSIS; APOPTOSIS;
   ICARIIN; GROWTH
AB Background: As the most common primary bone cancer, the therapy of osteosarcoma requires further study. An anthraquinone derivative, emodin, has been found to have anticancer potential. We proposed that emodin suppresses osteosarcoma by cell cycle regulation mediated by p53. Methods: This study determined the effect of emodin on viability and apoptosis of 6 osteosarcoma cell lines (p53 null cells MG63, G292, and A 673; p53 mutated cells HOS and SK PN DW; p53 expressing cells U2OS and 2 osteoblast cell lines), then knockdown p53 in U2OS, and observed the impacts of emodin on p53, p21, cyclin proteins, and cell cycle. Results: High dose emodin (40 160 mu M) induced cell death and apoptosis of all the cell lines; medium dose emodin (20 mu M) preferentially inhibited osteosarcoma cells; low dose emodin (1 10 mu M) preferentially inhibited p53 expressing osteosarcoma cells. Emodin dose  dependently inhibited p53 and p21 in U2OS. Emodin at 10 mu M decreased the expression of Cdk2, E2F, and Cdk1; and increased RB but had no effects on cyclin E and cyclin B. The knockdown of p53 almost eliminated all the impacts of 10 mu M emodin on cell cycle proteins. Conclusions: Emodin suppresses U2OS by p53  mediated cell cycle regulation.
C1 [Zhang, Qian] Anhui Med Univ, Dept Pharm, Affiliated Bozhou Hosp, Bozhou 236800, Anhui, Peoples R China.
   [Hao, Shuli] Anhui Med Univ, Dept Stomatol, Affiliated Bozhou Hosp, Bozhou 236800, Anhui, Peoples R China.
   [Wei, Guangyou] Bozhou City Peoples Hosp, Dept Pediat, Bozhou 236800, Anhui, Peoples R China.
   [Liu, Xiangyu] Bozhou City Peoples Hosp, Dept Sci & Educ, Bozhou 236800, Anhui, Peoples R China.
   [Miao, Yang] Anhui Med Univ, Dept Neurol, Affiliated Bozhou Hosp, Bozhou 236800, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University
RP Zhang, Q; Miao, Y (通讯作者)，Anhui Med Univ, Affiliated Bozhou Hosp, 616 Eucommia Rd, Bozhou City, Anhui, Peoples R China.
EM QZhoncology@gmail.com; yangmiao004@163.com
CR Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931
   Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Aryee DNT, 2013, BRIT J CANCER, V109, P2696, DOI 10.1038/bjc.2013.635
   Bao ZQ, 2019, CELL CYCLE, V18, P1379, DOI 10.1080/15384101.2019.1618119
   Catania MG, 2001, J NEUROPATH EXP NEUR, V60, P711, DOI 10.1093/jnen/60.7.711
   CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Chen YX, 2018, BIOMED PHARMACOTHER, V107, P226, DOI 10.1016/j.biopha.2018.07.168
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Clements BA, 2007, BIOMATERIALS, V28, P4693, DOI 10.1016/j.biomaterials.2007.07.023
   Dalton S, 2015, TRENDS CELL BIOL, V25, P592, DOI 10.1016/j.tcb.2015.07.007
   DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772
   Engeland K, 2022, CELL DEATH DIFFER, V29, P946, DOI 10.1038/s41418 022 00988 z
   Fang ZH, 2020, CANCER RES, V80, P4399, DOI 10.1158/0008 5472.CAN 20 1031
   Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927
   Ganjavi H, 2006, CANCER GENE THER, V13, P415, DOI 10.1038/sj.cgt.7700909
   Hengrui Liu J.P.D., 2020, PHARMACOL THER DENT
   Hsu SC, 2012, BIOMEDICINE TAIWAN, V2, P108, DOI 10.1016/j.biomed.2012.03.003
   Jin ZS, 2022, RECENT PAT ANTI CANC, V17, P326, DOI 10.2174/1574892817666220119121204
   Kang DM, 2014, ACAD RADIOL, V21, P457, DOI 10.1016/j.acra.2013.12.009
   Lee MH, 2011, J AGR FOOD CHEM, V59, P9135, DOI 10.1021/jf201577f
   LI R, 2018, P AM ASS CANC RES AN, P2162
   Li R, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871 018 0543 3
   Li R, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4576 2
   Li XY, 2017, BIOCHEM BIOPH RES CO, V493, P100, DOI 10.1016/j.bbrc.2017.09.068
   Li YX, 2022, CANCER BIOMARK, V34, P359, DOI 10.3233/CBM 210340
   Li Y, 2021, AQUAC RES, V52, P3843, DOI 10.1111/are.15229
   Liu H, 2023, bioRxiv
   Liu H., 2020, BJSTR, V30, P23548, DOI DOI 10.26717/BJSTR.2020.30.004979
   Liu H, 2020, Glob J Cancer Ther, V6, DOI DOI 10.17352/2581 5407.000026
   Liu H., 2020, Global J Med Res, V25, P18927
   Liu H., 2020, Gaz Med Sci, V1, P030, DOI 10.46766/thegms.pharmaco.20072104
   Liu H., 2020, Glob J Cancer Ther, V6, P5
   Liu H.A., 2020, GLOBAL J MED RES
   Liu HR, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 45774 0
   Liu HR, 2023, CANCER GENET NY, V278, P91, DOI 10.1016/j.cancergen.2023.10.001
   Liu HR, 2023, J AFFECT DISORDERS, V335, P152, DOI 10.1016/j.jad.2023.05.020
   Liu HR, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 34426 y
   Liu HR, 2023, AM J TRANSL RES, V15, P2140
   Liu HR, 2023, J TRADIT CHIN MED, V43, P209, DOI 10.19852/j.cnki.jtcm.2023.02.001
   Liu HR, 2023, CANCER GENET NY, V274 275, P21, DOI 10.1016/j.cancergen.2023.03.002
   Liu HR, 2022, PHARMACOL THERAPEUT, V240, DOI 10.1016/j.pharmthera.2022.108302
   Liu HR, 2022, J TRADIT CHIN MED, V42, P1019, DOI 10.19852/j.cnki.jtcm.20220815.005
   Liu HR, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.952290
   Liu HR, 2022, AM J CANCER RES, V12, P4074
   Liu HR, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.858756
   Liu HR, 2022, GENE, V822, DOI 10.1016/j.gene.2022.146325
   Liu HR, 2021, CANCERS, V13, DOI 10.3390/cancers13020234
   Liu HR, 2020, PHARMACOL THERAPEUT, V212, DOI 10.1016/j.pharmthera.2020.107558
   Liu HR, 2020, CANCERS, V12, DOI 10.3390/cancers12010131
   Liu HR, 2018, J ETHNOPHARMACOL, V221, P126, DOI 10.1016/j.jep.2018.04.035
   Liu HR, 2017, EXP THER MED, V13, P1360, DOI 10.3892/etm.2017.4128
   Liu XG, 2018, BIOMED PHARMACOTHER, V104, P742, DOI 10.1016/j.biopha.2018.04.044
   Ma YS, 2018, ONCOL REP, V40, P2648, DOI 10.3892/or.2018.6694
   Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68
   Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428
   Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960 9822(02)01225 3
   Naqvi S., 2010, DNA DEGRADATION AQUE
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Prater S., 2020, StatPearls., StatPearls Publishing Copyright
   Shrimali D, 2013, CANCER LETT, V341, P139, DOI 10.1016/j.canlet.2013.08.023
   Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552
   Velletri T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.367
   Wang C., 2016, J. Pharm. Biomed. Sci, V6
   Wang HX, 2020, J TRADIT CHIN MED, V40, P17
   Wang H, 2017, J AGR FOOD CHEM, V65, P10630, DOI 10.1021/acs.jafc.7b04434
   Wang JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024498
   Wang MJ, 2012, J ETHNOPHARMACOL, V139, P287, DOI 10.1016/j.jep.2011.11.022
   Wang Y, 2012, MED ONCOL, V29, P1328, DOI 10.1007/s12032 011 9848 5
   Wei WT, 2013, ONCOL REP, V30, P2555, DOI 10.3892/or.2013.2741
   Wu XY, 2013, RADIOL ONCOL, V47, P42, DOI 10.2478/v10019 012 0043 x
   Wu ZD, 2017, BIOMED PHARMACOTHER, V94, P1, DOI 10.1016/j.biopha.2017.07.071
   Yang Y, 2018, INT J MOL MED, V41, P3366, DOI 10.3892/ijmm.2018.3519
   Yang YC, 2003, J AGR FOOD CHEM, V51, P7629, DOI 10.1021/jf034727t
   Yu X, 2014, ONCOTARGET, V5, P8879, DOI 10.18632/oncotarget.2432
   Zhang X, 2015, AFR HEALTH SCI, V15, P97, DOI 10.4314/ahs.v15i1.13
NR 76
TC 2
Z9 2
U1 4
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD MAR 15
PY 2024
VL 10
IS 5
AR e26850
DI 10.1016/j.heliyon.2024.e26850
EA MAR 2024
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NQ8H5
UT WOS:001202006200001
PM 38495151
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wandiyanto, JV
   Truong, VK
   Al Kobaisi, M
   Juodkazis, S
   Thissen, H
   Bazaka, O
   Bazaka, K
   Crawford, RJ
   Ivanova, EP
AF Wandiyanto, Jason V.
   Truong, Vi Khanh
   Al Kobaisi, Mohammad
   Juodkazis, Saulius
   Thissen, Helmut
   Bazaka, Olha
   Bazaka, Kateryna
   Crawford, Russell J.
   Ivanova, Elena P.
TI The Fate of Osteoblast Like MG 63 Cells on Pre Infected Bactericidal
   Nanostructured Titanium Surfaces
SO MATERIALS
LA English
DT Article
DE mechano bactericidal surfaces; competitive colonization; titanium; MG 63
ID ANTIBACTERIAL; VINCULIN; BIOCOMPATIBILITY; FABRICATION; VIRULENCE;
   ADHESION; ARRAYS
AB Biomaterials that have been newly implanted inside the body are the substratum targets for a race for the surface, in which bacterial cells compete against eukaryotic cells for the opportunity to colonize the surface. A victory by the former often results in biomaterial associated infections, which can be a serious threat to patient health and can undermine the function and performance of the implant. Moreover, bacteria can often have a head start' if implant contamination has taken place either prior to or during the surgery. Current prevention and treatment strategies often rely on systemic antibiotic therapies, which are becoming increasingly ineffective due to a growing prevalence of antibiotic resistant bacteria. Nanostructured surfaces that kill bacteria by physically rupturing bacterial cells upon contact have recently emerged as a promising solution for the mitigation of bacterial colonization of implants. Furthermore, these nanoscale features have been shown to enhance the adhesion and proliferation of eukaryotic cells, which is a key to, for example, the successful osseointegration of load bearing titanium implants. The bactericidal activity and biocompatibility of such nanostructured surfaces are often, however, examined separately, and it is not clear to what extent bacterial cell surface interactions would affect the subsequent outcomes of host cell attachment and osseointegration processes. In this study, we investigated the ability of bactericidal nanostructured titanium surfaces to support the attachment and growth of osteoblast like MG 63 human osteosarcoma cells, despite them having been pre infected with pathogenic bacteria. MG 63 is a commonly used osteoblastic model to study bone cell viability, adhesion, and proliferation on the surfaces of load bearing biomaterials, such as titanium. The nanostructured titanium surfaces used here were observed to kill the pathogenic bacteria, whilst simultaneously enhancing the growth of MG 63 cells in vitro when compared to that occurring on sterile, flat titanium surfaces. These results provide further evidence in support of nanostructured bactericidal surfaces being used as a strategy to help eukaryotic cells win the race for the surface against bacterial cells on implant materials.
C1 [Wandiyanto, Jason V.; Al Kobaisi, Mohammad] Swinburne Univ Technol, Sch Sci, Fac Sci Engn & Technol, Hawthorn, Vic 3122, Australia.
   [Truong, Vi Khanh; Bazaka, Olha; Crawford, Russell J.; Ivanova, Elena P.] RMIT Univ, Coll Sci Engn & Hlth, Sch Sci, Melbourne, Vic 3000, Australia.
   [Juodkazis, Saulius] Swinburne Univ Technol, Fac Sci Engn & Technol, Ctr Microphoton, Hawthorn, Vic 3122, Australia.
   [Thissen, Helmut] CSIRO Mfg, Clayton, Vic 3168, Australia.
   [Bazaka, Kateryna] Queensland Univ Technol, Inst Future Environm, GPO Box 2434, Brisbane, Qld 4001, Australia.
C3 Swinburne University of Technology; Royal Melbourne Institute of
   Technology (RMIT); Swinburne University of Technology; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO); Queensland
   University of Technology (QUT)
RP Ivanova, EP (通讯作者)，RMIT Univ, Coll Sci Engn & Hlth, Sch Sci, Melbourne, Vic 3000, Australia.
EM jwandiyanto@swin.eud.au; vi.khanh.truong@rmit.edu.au;
   makobaisi@swin.edu.au; Sjoudkazis@swin.edu.au;
   helmut.thiessen@csiro.com; olga.bazaka@rmit.edu.au;
   katerina.bazaka@qut.edu.au; russell.crawford@rmit.edu.au;
   elena.ivanova@rmit.edu.au
RI Truong, Vi/AAS 1155 2020; Thissen, Helmut/D 3835 2011; Bazaka,
   Kateryna/D 8678 2011; Kobaisi, Mohammad/ABC 3491 2020; Juodkazis,
   Saulius/D 7615 2011; Juodkazis, Saulius/Q 6943 2019; Ivanova,
   Elena/B 1255 2019; Truong, Vi Khanh/M 1054 2018
OI Juodkazis, Saulius/0000 0003 3542 3874; Ivanova,
   Elena/0000 0002 5509 8071; Truong, Vi Khanh/0000 0002 6016 6438
CR Agustina Hasrayati, 2018, Patholog Res Int, V2018, P6346409, DOI 10.1155/2018/6346409
   Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636
   Baranov O, 2018, MATER HORIZ, V5, DOI 10.1039/c8mh00326b
   Baranov O, 2017, APPL PHYS REV, V4, DOI 10.1063/1.5007869
   Bazaka K, 2018, NANOSCALE, V10, P17494, DOI 10.1039/c8nr06502k
   Bazaka K, 2015, RSC ADV, V5, P48739, DOI 10.1039/c4ra17244b
   Bazaka K, 2013, ELECTRONICS SWITZ, V2, P1, DOI 10.3390/electronics2010001
   Bazaka K, 2012, APPL MICROBIOL BIOT, V95, P299, DOI 10.1007/s00253 012 4144 7
   Bazaka K, 2011, BIOTECHNOL J, V6, P1103, DOI 10.1002/biot.201100027
   Bazaka K, 2011, ADV EXP MED BIOL, V715, P213, DOI 10.1007/978 94 007 0940 9_13
   Bhadra CM, 2015, SCI REP UK, V5, DOI 10.1038/srep16817
   De Rossi A, 2016, J ENDODONT, V42, P1251, DOI 10.1016/j.joen.2016.05.009
   Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<92::AID JCB13>3.0.CO;2 A
   Doll K., 2016, BioNanoMaterials, V17, P53, DOI [10.1515/bnm 2015 0024, DOI 10.1515/BNM 2015 0024]
   Emmerson M, 1998, NEW HORIZ SCI PRACT, V6, pS3
   Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945 053X(00)00108 6
   Govindaraj S., 2015, International Journal of ChemTech Research, V8, P897
   Grashoff C, 2010, NATURE, V466, P263, DOI 10.1038/nature09198
   Grassi L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02409
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Groza A, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8040131
   He M, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6141 6
   Hsieh IS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109550
   Iconaru SL, 2016, J SPECTROSC, V2016, DOI 10.1155/2016/4361051
   Iconaru SL, 2017, MOLECULES, V22, DOI 10.3390/molecules22040604
   Ivanova EP, 2017, ACTA BIOMATER, V59, P148, DOI 10.1016/j.actbio.2017.07.004
   Ivanova EP, 2012, SMALL, V8, P2489, DOI 10.1002/smll.201200528
   Ivanova EP, 2010, LANGMUIR, V26, P1973, DOI 10.1021/la902623c
   Jäger M, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/69036
   Jäger M, 2017, MATERIALS, V10, DOI 10.3390/ma10111302
   Jeong WS, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa734e
   Jiang YL, 2002, INFECT IMMUN, V70, P3143, DOI 10.1128/IAI.70.6.3143 3148.2002
   LAJEUNESSE D, 1991, BONE MINER, V14, P237, DOI 10.1016/0169 6009(91)90025 U
   Leibbrandt A, 2009, ADV EXP MED BIOL, V647, P130, DOI 10.1007/978 0 387 89520 8_9
   Levchenko I, 2018, ADV MATER, V30, DOI 10.1002/adma.201702226
   Li NB, 2018, NANOTECHNOLOGY, V29, DOI 10.1088/1361 6528/aa9daa
   Li Z, 2017, MAT SCI ENG C MATER, V76, P684, DOI 10.1016/j.msec.2017.03.148
   Linklater DP, 2018, ACS NANO, V12, P6657, DOI 10.1021/acsnano.8b01665
   Liu LT, 2017, INT J NANOMED, V12, P8711, DOI 10.2147/IJN.S148065
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Del Pozo JL, 2018, EXPERT REV ANTI INFE, V16, P51, DOI 10.1080/14787210.2018.1417036
   Marinucci L, 2014, J CELL PHYSIOL, V229, P2038, DOI 10.1002/jcp.24661
   Martinez Perez M, 2017, BONE JOINT RES, V6, P315, DOI 10.1302/2046 3758.65.BJR 2016 0226.R2
   Norambuena GA, 2017, CLIN ORTHOP RELAT R, V475, P722, DOI 10.1007/s11999 016 4713 7
   Ohmori T, 2010, J BIOL CHEM, V285, P31763, DOI 10.1074/jbc.M109.099085
   PAVLOVSKIS OR, 1978, INFECT IMMUN, V19, P29, DOI 10.1128/IAI.19.1.29 33.1978
   Pérez Tanoira R, 2017, J BIOMED MATER RES A, V105, P62, DOI 10.1002/jbm.a.35863
   Pogodin S, 2013, BIOPHYS J, V104, P835, DOI 10.1016/j.bpj.2012.12.046
   Prasad K, 2017, MATERIALS, V10, DOI 10.3390/ma10080884
   Prasad K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 01669 5
   Predoi D, 2018, COATINGS, V8, DOI 10.3390/coatings8080276
   Schmid Hempel P, 2007, PLOS PATHOG, V3, P1372, DOI 10.1371/journal.ppat.0030147
   SEWELL DL, 1995, CLIN MICROBIOL REV, V8, P389, DOI 10.1128/CMR.8.3.389
   Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140 6736(01)05321 1
   Tian B, 2016, J MECH BEHAV BIOMED, V61, P345, DOI 10.1016/j.jmbbm.2016.04.002
   Tîlmaciu CM, 2015, ACTA BIOMATER, V15, P266, DOI 10.1016/j.actbio.2014.12.020
   Tsai SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031200
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Veesenmeyer JL, 2009, CRIT CARE MED, V37, P1777, DOI 10.1097/CCM.0b013e31819ff137
   Walderhaug M., 2014, Bad Bug Book: Foodborne Pathogenic Microorganisms and Natural Toxins Handbook, V2
   Wandiyanto JV, 2018, MATERIALS, V11, DOI 10.3390/ma11040605
   Wang GS, 2018, MATER LETT, V212, P247, DOI 10.1016/j.matlet.2017.10.040
   Zhu C, 2016, APPL SURF SCI, V389, P7, DOI 10.1016/j.apsusc.2016.07.080
NR 63
TC 35
Z9 36
U1 1
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1996 1944
J9 MATERIALS
JI Materials
PD MAY 2
PY 2019
VL 12
IS 10
AR 1575
DI 10.3390/ma12101575
PG 16
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA IC5MP
UT WOS:000471012500004
PM 31091694
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Franco Trepat, E
   Alonso Pérez, A
   Guillán Fresco, M
   Jorge Mora, A
   Crespo Golmar, A
   López Fagúndez, M
   Pazos Pérez, A
   Gualillo, O
   Bravo, SB
   Bahamonde, RG
AF Franco Trepat, Eloi
   Alonso Perez, Ana
   Guillan Fresco, Maria
   Jorge Mora, Alberto
   Crespo Golmar, Antia
   Lopez Fagundez, Miriam
   Pazos Perez, Andres
   Gualillo, Oreste
   Belen Bravo, Susana
   Gomez Bahamonde, Rodolfo
TI Amitriptyline blocks innate immune responses mediated by toll like
   receptor 4 and IL 1 receptor: Preclinical and clinical evidence in
   osteoarthritis and gout
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE chondrocytes; cohort study; gout; innate immunity; osteoarthritis
ID CONCISE GUIDE; LIPOPOLYSACCHARIDE RECOGNITION; INFLAMMATION; MECHANISMS;
   RESISTANCE
AB Background and Purpose Osteoarthritis, a major cause of disability in developed countries does not have effective treatment. Activation of TLR4 and innate immune response factors contribute to osteoarthritis progressive cartilage degradation. There are no clinically available TLR4 inhibitors. Interestingly, the antidepressant amitriptyline could block this receptor. Thus, we evaluated amitriptyline anti TLR4 effects on human osteoarthritis chondrocytes in order to repurpose it as an inhibitor of innate immune response in joint inflammatory pathologies. Experimental Approach Using in silico docking analysis, RT PCR, siRNA, elisa, proteomics and clinical data mining of drug consumption, we explored the clinical relevance of amitriptyline blockade of TLR4 mediated innate immune responses in human osteoarthritis chondrocytes. Key Results Amitriptyline bound TLR4 but not IL 1 receptor. Interestingly, amitriptyline binding to TLR4 inhibited TLR4  and IL 1 receptor mediated innate immune responses in human osteoarthritis chondrocytes, synoviocytes and osteoblasts cells. Amitriptyline reduced basal innate immune responses and promoted anabolic effects in human osteoarthritis chondrocytes. Supporting its anti innate immune response effects, amitriptyline down regulated basal and induced expression of NLRP3, an inflammasome member from IL 1 receptor signalling linked to osteoarthritis and gout pathologies. Accordingly, mining of dissociated and aggregated drug consumption data from 107,172 elderly patients (>65 years) revealed that amitriptyline consumption was significantly associated with lower colchicine consumption associated with inflammatory gout flare treatment. Conclusion and Implications Amitriptyline blocks TLR4 , IL 1 receptor and NLRP3 dependent innate immune responses. This together with clinical data amitriptyline could be repurposed for systemic or local innate immune response management in diverse joint inflammatory pathologies.
C1 [Franco Trepat, Eloi; Alonso Perez, Ana; Guillan Fresco, Maria; Jorge Mora, Alberto; Crespo Golmar, Antia; Lopez Fagundez, Miriam; Pazos Perez, Andres; Gomez Bahamonde, Rodolfo] Santiago Univ Clin Hosp CHUS, Inst IDIS, SERGAS, Musculoskeletal Pathol Grp, Santiago De Compostela, Spain.
   [Gualillo, Oreste] Santiago Univ Clin Hosp CHUS, Inst IDIS, NEIRID Lab, SERGAS, Santiago De Compostela, Spain.
   [Belen Bravo, Susana] Santiago Univ Clin Hosp CHUS, Inst IDIS, Prote Unit, Santiago De Compostela, Spain.
RP Bahamonde, RG (通讯作者)，Santiago Univ Clin Hosp, Inst IDIS, Musculoskeletal Pathol Grp, Edificio B,Planta 2, Santiago De Compostela 15706, Spain.
EM rodolfo.gomez.bahamonde@sergas.es
RI ; Gomez, Rodolfo/B 4642 2012; Gomez Bahamonde, Rodolfo/B 4642 2012;
   Lopez, Susana/F 8487 2016; Guillán Fresco, María/IWM 5573 2023; Bravo
   Lopez, Susana Belen/F 8487 2016; GUALILLO, ORESTE/B 8223 2008;
   Jorge Mora, Alberto/AAB 3156 2019; Franco Trepat, Eloi/AAD 7837 2020;
   Gualillo, Oreste/B 8223 2008
OI Franco Trepat, Eloi/0000 0001 7514 4672; Gomez Bahamonde,
   Rodolfo/0000 0002 1309 1023; Crespo Golmar, Antia/0000 0002 2709 0670;
   Bravo Lopez, Susana Belen/0000 0001 7615 3079; GUALILLO,
   ORESTE/0000 0002 7154 1328; Lopez Fagundez, Miriam/0000 0002 4577 737X;
   Pazos Perez, Andres/0000 0001 8598 9476; Jorge Mora, Alberto
   Agustin/0000 0003 0143 1323; Guillan Fresco, Maria/0000 0002 6269 5130;
   Alonso Perez, Ana/0000 0001 5830 0960
FU Fundacion Mutua Madrilena [MMA 2018, MMA 2020]; Instituto de
   Investigacion Sanitaria de Santiago de Compostela; Servizo Galego de
   Saude; Fundacion Espanola para la Ciencia y la Tecnologia; Ministerio de
   Ciencia e Innovacion [FPU17/01706, STOP ARTROSIS  PR250]; European
   Regional Development Fund; Instituto de Salud Carlos III [CP15/00007,
   FI20/00210, PI14/00016, PI16/01870, PI17/00409, PI19/01446]
FX Fundacion Mutua Madrilena, Grant/Award Numbers: MMA 2018, MMA 2020;
   Instituto de Investigaci~on Sanitaria de Santiago de Compostela,
   Grant/Award Number: Fellowship; Servizo Galego de Saude; Fundaci~on
   Espanola para la Ciencia y la Tecnologia; Ministerio de Ciencia e
   Innovaci~on, Grant/Award Numbers: FECYT  PRECIPITA, FPU17/01706, STOP
   ARTROSIS  PR250; European Regional Development Fund; Instituto de Salud
   Carlos III, Grant/Award Numbers: CP15/00007, FI20/00210, Miguel Servet
   II, PI14/00016, PI16/01870, PI17/00409, PI19/01446
CR Abdollahi Roodsaz S, 2007, ARTHRITIS RHEUM, V56, P2957, DOI 10.1002/art.22848
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS247, DOI 10.1111/bph.14751
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS297, DOI [10.1111/bph.14752, 10.1111/bph.14749]
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS229, DOI 10.1111/bph.14750
   Alonso Pérez A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00504
   Aouba A, 2015, MEDIAT INFLAMM, V2015, P1, DOI 10.1155/2015/792173
   Bruno K, 2018, PAIN, V159, P1908, DOI 10.1097/j.pain.0000000000001306
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Clancy RM, 2004, OSTEOARTHR CARTILAGE, V12, P552, DOI 10.1016/j.joca.2004.04.003
   Couch JR, 2011, HEADACHE, V51, P33, DOI 10.1111/j.1526 4610.2010.01800.x
   Couselo Seijas M, 2019, J CELL PHYSIOL, V234, P10512, DOI 10.1002/jcp.27723
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Dejban P, 2021, PHYTOTHER RES, V35, P835, DOI 10.1002/ptr.6866
   Chantada Vázquez MD, 2020, J PROTEOMICS, V212, DOI 10.1016/j.jprot.2019.103581
   Demidowich AP, 2016, MED HYPOTHESES, V92, P67, DOI 10.1016/j.mehy.2016.04.039
   Franco Trepat E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081178
   Gómez R, 2015, NAT REV RHEUMATOL, V11, P159, DOI 10.1038/nrrheum.2014.209
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Hellings JA, 2017, EXPERT OPIN PHARMACO, V18, P581, DOI 10.1080/14656566.2017.1308483
   Hussey SE, 2013, BIOSCIENCE REP, V33, P37, DOI 10.1042/BSR20120098
   Hutchinson MR, 2010, NEUROSCIENCE, V168, P551, DOI 10.1016/j.neuroscience.2010.03.067
   KELLY D, 1973, P ROY SOC MED, V66, P252, DOI 10.1177/003591577306600325
   Krasselt M, 2019, EXPERT OPIN PHARMACO, V20, P1689, DOI 10.1080/14656566.2019.1645123
   Kuzmich NN, 2017, VACCINES BASEL, V5, DOI 10.3390/vaccines5040034
   Li XX, 2005, J MOL MED, V83, P258, DOI 10.1007/s00109 004 0622 4
   Loiarro M, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/674363
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Martin MU, 2002, BBA MOL CELL RES, V1592, P265, DOI 10.1016/S0167 4889(02)00320 8
   McAllister MJ, 2018, OSTEOARTHR CARTILAGE, V26, P612, DOI 10.1016/j.joca.2018.02.901
   Mertens M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005121.pub3
   Oblak A, 2015, MOL IMMUNOL, V63, P134, DOI 10.1016/j.molimm.2014.06.034
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Park H, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74544 5
   Parvathaneni V, 2019, DRUG DISCOV TODAY, V24, P2076, DOI 10.1016/j.drudis.2019.06.014
   Pascart T, 2017, EXPERT OPIN PHARMACO, V18, P1201, DOI 10.1080/14656566.2017.1351945
   Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455
   Qing YF, 2013, GENE, V524, P412, DOI 10.1016/j.gene.2013.04.039
   Rico Villademoros F, 2015, EXPERT REV NEUROTHER, V15, P1123, DOI 10.1586/14737175.2015.1091726
   Saddichha S, 2010, ANN INDIAN ACAD NEUR, V13, P94, DOI 10.4103/0972 2327.64628
   Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050 MCP200
   Shimoda K, 1997, PSYCHIAT CLIN NEUROS, V51, P35, DOI 10.1111/j.1440 1819.1997.tb02364.x
   So AK, 2017, NAT REV RHEUMATOL, V13, P639, DOI 10.1038/nrrheum.2017.155
   Sohn KM, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e343
   Szekanecz Z, 2019, ARCH BIOCHEM BIOPHYS, V670, P82, DOI 10.1016/j.abb.2019.01.031
   Thomas C, 2012, NAT STRUCT MOL BIOL, V19, P455, DOI 10.1038/nsmb.2260
   Togbe D, 2007, INT J EXP PATHOL, V88, P387, DOI 10.1111/j.1365 2613.2007.00566.x
   Tong ZC, 2017, ONCOTARGET, V8, P83563, DOI 10.18632/oncotarget.18745
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   Villalvilla A, 2016, SCI REP UK, V6, DOI 10.1038/srep29243
   Villalvilla A, 2014, MOL NUTR FOOD RES, V58, P256, DOI 10.1002/mnfr.201200833
   Vincent Tonia L, 2019, F1000Res, V8, DOI 10.12688/f1000research.18831.1
   Wang MN, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4133
   Zamyatina A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585146
NR 53
TC 26
Z9 28
U1 2
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JAN
PY 2022
VL 179
IS 2
BP 270
EP 286
DI 10.1111/bph.15707
EA DEC 2021
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XW2QT
UT WOS:000729318900001
PM 34643941
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Roepke, M
   Diestel, A
   Bajbouj, K
   Walluscheck, D
   Schonfeld, P
   Roessner, A
   Schneider Stock, R
   Gali Muhtasib, H
AF Roepke, Martin
   Diestel, Antje
   Bajbouj, Khuloud
   Walluscheck, Diana
   Schonfeld, Peter
   Roessner, Albert
   Schneider Stock, Regine
   Gali Muhtasib, Hala
TI Lack of p53 augments thymoquinone induced apoptosis and caspase
   activation in human osteosarcoma cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE apoptosis; caspases; osteosarcoma; oxidative stress; thymoquinone
ID ANTITUMOR ACTIVITY; DNA DAMAGE; PATHWAY; BCL 2; SUPEROXIDE; MECHANISM;
   LEUKEMIA; GROWTH; LINES; GENE
AB We have recently shown that thymoquinone (TQ) is an antineoplastic drug that induces p53   dependent apoptosis in human colon cancer cells. This study evaluated the antiproliferative and pro   apoptotic effects of TQ in two human osteosarcoma cell lines with different p53 mutation status. TQ decreased cell survival dose   dependently and, more significantly, in p53   null MG63 cells (IC50 = 17 mu M) than in p53   mutant MNNG/HOS cells ( IC50 = 38 mM). Cell viability was reduced more selectively in MG63 tumor cells than in normal human osteoblasts. Flow cytometric analysis showed that TQ induced a much greater increase in the PreG(1) ( apoptotic) cell population, but no cell cycle arrest in MG63. G(2)/M arrest in MNNG/HOS cells was associated with p21(WAF1) upregulation. Using three DNA damage assays, TQ was confirmed to result in a significantly greater extent of apoptosis in p53 null MG63 cells. Although the Bax/Bcl 2 ratios were not differentially modulated in both cell lines, the mitochondrial pathway appeared to be involved in TQ   induced apoptosis in MG63 by showing the cleavage of caspases 9 and   3. Oxidative stress and mitochondrial O 2(center dot ) generation in isolated rat mitochondria were enhanced by TQ as measured by the dose   dependent reduction in aconitase enzyme activity and Amplex Red oxidation respectively. TQ   induced oxidative damage, reflected by an increase in gamma H2AX foci and increased protein expression levels of gamma H2AX and the DNA repair enzyme, NBS1, was more pronounced in MNNG/HOS than in MG63. We suggest that the resistance of MNNG/HOS cells to drug   induced apoptosis is caused by the up   regulation of p21(WAF1) by the mutant p53 ( transcriptional activity was shown by p53 siRNA treatment) which induces cell cycle arrest and allows to repair DNA damage. Collectively, these findings show that TQ induces p53   independent apoptosis in human osteosarcoma cells. As the loss of p53 function is frequently observed in osteosarcoma patients, our data suggest the potential clinical usefulness of TQ for the treatment of these malignancies.
C1 Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
   Otto Von Guericke Univ, Dept Pathol, Magdeburg, Germany.
   Otto Von Guericke Univ, Dept Biochem, Magdeburg, Germany.
C3 American University of Beirut; Otto von Guericke University; Otto von
   Guericke University
RP Gali Muhtasib, H (通讯作者)，Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
EM Regine.Schneider Stock@medizin.uni magdeburg.de; amro@aub.edu.lb
RI ; Schneider Stock, Regine/H 8863 2012
OI Bajbouj, Khuloud/0000 0001 7344 6095; 
CR Al Majed AA, 2006, EUR J PHARMACOL, V543, P40, DOI 10.1016/j.ejphar.2006.05.046
   Andreyev AI, 2005, BIOCHEMISTRY MOSCOW+, V70, P200, DOI 10.1007/s10541 005 0102 7
   Badary OA, 1997, CAN J PHYSIOL PHARM, V75, P1356, DOI 10.1139/cjpp 75 12 1356
   Badary OA, 2003, DRUG CHEM TOXICOL, V26, P87, DOI 10.1081/DCT 120020404
   Chang GC, 2004, EUR J PHARMACOL, V502, P169, DOI 10.1016/j.ejphar.2004.09.006
   El Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002/ijc.21205
   Gali Muhtasib H, 2004, INT J ONCOL, V25, P857
   Gali Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016/j.biocel.2005.10.009
   Gali Muhtasib HU, 2004, ANTI CANCER DRUG, V15, P389, DOI 10.1097/00001813 200404000 00012
   Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014 5793(97)01282 9
   Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076 6879(02)49317 2
   Iida K, 2003, ONCOL REP, V10, P1961
   Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661 670.2005
   MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716
   Nuñez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581
   Porcedda P, 2006, DNA REPAIR, V5, P904, DOI 10.1016/j.dnarep.2006.05.002
   Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Sharpe JC, 2004, BBA MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016
   Shoieb AM, 2003, INT J ONCOL, V22, P107
   STEINBRECHT I, 1970, ACTA BIOL MED GER, V25, P731
   Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097 2765(02)00520 8
   Worthen DR, 1998, ANTICANCER RES, V18, P1527
   Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898
   Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097 0215(19991210)83:6<790::AID IJC15>3.0.CO;2 6
NR 25
TC 155
Z9 170
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4047
EI 1555 8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD FEB
PY 2007
VL 6
IS 2
BP 160
EP 169
DI 10.4161/cbt.6.2.3575
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 159FW
UT WOS:000245851800018
PM 17218778
OA Bronze
DA 2025 08 17
ER

PT J
AU Das, N
   Bhattacharya, A
   Mandal, SK
   Debnath, U
   Dinda, B
   Mandal, SC
   Sinhamahapatra, PK
   Kumar, A
   Choudhury, MD
   Maiti, S
   Palit, P
AF Das, Niranjan
   Bhattacharya, Abhijit
   Mandal, Sudip Kumar
   Debnath, Utsab
   Dinda, Biswanath
   Mandal, Subhash C.
   Sinhamahapatra, Prabir Kumar
   Kumar, Amresh
   Choudhury, M. Dutta
   Maiti, Sabyasachi
   Palit, Partha
TI Ichnocarpus frutescens (L.) R. Br. root derived phyto steroids
   defends inflammation and algesia by pulling down the pro inflammatory
   and nociceptive pain mediators: An in vitro and in vivo
   appraisal
SO STEROIDS
LA English
DT Article
DE Ichnocarpus frutescens; Plant sterol; Cyclooxygenase 2; Proteinase;
   Cytokine; Anti inflammatory
ID ANTIINFLAMMATORY ACTIVITY; BETA SITOSTEROL; CHEMICAL CONSTITUENTS;
   LEAVES; DRUGS; CARRAGEENAN; INHIBITORS; ARTHRITIS; FRACTION; MODEL
AB Ichnocarpus frutescens, a climber plant, is distributed all over India. As its different parts are used as anti inflammatory agent, so we re investigated the roots to isolate compounds and evaluate its biological efficacy. Also, in silico molecular docking was carried out to elucidate the structure activity relationship (SAR) of isolated compounds toward identifies the drug target enzyme with validation, which was further supported by antiinflammatory in vitro and in vivo experimental models. The compounds have been undertaken mainly to investigate the anti inflammatory and analgesic efficacy along with molecular docking investigation followed by anti proteinase, anti denaturation and cyclooxygenase (COX) inhibition studies. Inflammatory cytokines like TNF alpha and IL 6 were assayed from lipopolysaccharides (LPS) and Concavallin (CON A) stimulated human PBMC derived macrophages by Enyme linked immune sorbent assay (ELISA) method. The purity index of the lead compound was determined by HPLC. The compounds were illustrated as 2 hydroxy tricosanoic acid (1), stigmasterol glucoside (2), stigmasterol (3), beta sitosterol (4) and beta sitosterol glucoside (5). The test molecules showed significant anti denaturation, anti proteinase and analgesic effect validated with docking study. Compounds exhibited anti inflammatory and pain killing action due to dexamethasone like phytosterol property. Promising anti denaturation and anti proteinase activity offered by the compound 5, may hold its promise to fight against arthritis by rejuvenating the osteoblast cells and destroying the bone resorpting complex of hydrated protein, bone minerals by secreting the acid and an enzyme collagenase along with pain management. The lead bioactive compound i.e. beta sitosterol glucoside (compound 5) demonstrated considerable anti inflammatory activity showing more than 90% protection against the inflammatory cytokines at 50 mu M dose. The anti denaturation and COX 2 inhibition shown by the compound 5 was also noteworthy with the significant IC50 (ranging from 0.25 to 2.56 mu M) that also supporting its future promise for developing as anti inflammatory agent. Since the most bioactive compound (5) elicit promising acute anti inflammatory action and peripheral anti nociceptive pain killing action with a significant ED50 dose of 3.95 & 2.84 mg/kg i.p. respectively in the in vivo animal model. It could suggest its potentiality as a good in vivo bio available agent to be an emerging anti inflammatory drug regimen scaffold in the future. It also establishes significant in vitro and in vivo result co relation.
   Therefore, the compound 5 could be believed as a potent lead for designing anti inflammatory, anti arthritic drug or pain killer without showing any untoward effect.
C1 [Das, Niranjan; Bhattacharya, Abhijit] Netaji Subhas Mahavidyalaya, Dept Chem, Udaipur 799114, Gomati Tripura, India.
   [Mandal, Sudip Kumar] BC Roy Coll Pharm & Allied Hlth Sci, Durgapur 713206, India.
   [Debnath, Utsab] Bose Inst, Div Mol Med, Kolkata 700054, India.
   [Dinda, Biswanath] Tripura Univ, Dept Chem, Suryamaninagar 799022, Tripura, India.
   [Mandal, Subhash C.] Jadavpur Univ, Dept Pharmaceut Technol, Div Pharmacognosy, Pharmacognosy & Phytotherapy Res Lab, Kolkata 700032, India.
   [Sinhamahapatra, Prabir Kumar] Inst Pharm & Technol, Div Pharmaceut Chem, Cuttack 754202, Odisha, India.
   [Kumar, Amresh; Choudhury, M. Dutta] Assam Univ, Dept Life Sci & Bioinformat, Biotech Hub, Silchar 788011, Assam, India.
   [Maiti, Sabyasachi] Indira Gandhi Natl Tribal Univ, Dept Pharm, Amarkantak 484887, Madhya Pradesh, India.
   [Palit, Partha] Assam Univ, Dept Pharmaceut Sci, Drug Discovery Res Lab, Div Pharmacognosy, Silchar 788011, Assam, India.
C3 Department of Science & Technology (India); Bose Institute; Tripura
   University; Jadavpur University; Assam University; Indira Gandhi
   National Tribal University; Assam University
RP Das, N (通讯作者)，Netaji Subhas Mahavidyalaya, Dept Chem, Udaipur 799114, Gomati Tripura, India.; Palit, P (通讯作者)，Assam Univ, Dept Pharmaceut Sci, Drug Discovery Res Lab, Div Pharmacognosy, Silchar 788011, Assam, India.
EM ndnsmu@gmail.com; itspartha_p@yahoo.com
RI kumar, amresh/IVH 9365 2023; Choudhury, Manabendra/AAP 1817 2021; Maiti,
   Sabyasachi/E 1856 2017; PALIT, PARTHA/C 1681 2019; Mandal, Dr Sudip
   Kumar/AAM 3756 2020; Mandal, Subhash Chandra/IWU 3535 2023; debnath,
   utsab/AAY 8919 2021
OI debnath, utsab/0000 0001 9776 2391; Maiti,
   Sabyasachi/0000 0002 7725 6253; Mandal, Subhash
   Chandra/0000 0002 9079 489X; 
FU UGC NERO, Guwahati, India [F. 5 32/2010(MRP/NERO)/5289]; DST (SERB),
   Govt of India [SB/FT/LS 269/2012]; DBT JRF fellowship
   [DBT/JRF/BET 16/I/2016/AL/90 466]
FX All authors are grateful to IICB, Kolkata for spectral facility & in
   vitro cell culture work support and Prof. B.K.Datta, Department of
   Botany, Tripura University, Suryamaninagar, India for identification of
   plant material. Funding Sources: This work was supported in part by a
   grant in aid [No. F. 5 32/2010(MRP/NERO)/5289] in terms of minor
   research project from UGC NERO, Guwahati, India. Authors are grateful to
   DST (SERB), Govt of India for funding (Ref. No. SB/FT/LS 269/2012) and
   DBT JRF fellowship ref. no. DBT/JRF/BET 16/I/2016/AL/90 466 to undertake
   the wet lab in vitro study and docking work.
CR [Anonymous], 1972, DICT INDIAN RAW MAT, P162
   [Anonymous], MED AROMATIC PLANTS
   [Anonymous], 2013, VET MED
   Bouic P J, 1999, Altern Med Rev, V4, P170
   BROWN JH, 1968, P SOC EXP BIOL MED, V128, P225
   Chell S, 2006, BBA REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002
   COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476 5381.1968.tb00973.x
   DANIEL M, 1978, INDIAN J EXP BIOL, V16, P512
   Das N., 2013, INDO AM J PHARM RES, V3, P4031
   Dash D. K., 2007, Natural Product Sciences, V13, P54
   Deb D. B., 1983, FLORA TRIPURA STATE, P17
   García MD, 2004, J ETHNOPHARMACOL, V91, P69, DOI 10.1016/j.jep.2003.11.018
   GRANT NH, 1970, BIOCHEM PHARMACOL, V19, P715, DOI 10.1016/0006 2952(70)90234 0
   Hu QL, 2017, J SCI FOOD AGR, V97, P4103, DOI 10.1002/jsfa.8277
   Husain A., 1992, DICT INDIAN MED PLAN, P465
   KHAN MSY, 1995, J INDIAN CHEM SOC, V72, P65
   Khanapure SP, 2007, CURR TOP MED CHEM, V7, P311, DOI 10.2174/156802607779941314
   Khastgir H. N., 1960, BR J APPL CHEM, V23, P111
   Kirtikar K.R., 1998, INDIAN MED PLANTS, P1590
   Kumarappan CT, 2012, SAUDI J BIOL SCI, V19, DOI 10.1016/j.sjbs.2012.04.004
   Lakshmi D.K., 1985, INDIAN DRUGS, V22, P552
   Lategan K., 2018, NANOMATERIALS, V8
   Laufer S, 2002, OSTEOARTHR CARTILAGE, V10, P961, DOI 10.1053/joca.2002.0851
   Le CF, 2017, INT IMMUNOPHARMACOL, V44, P203, DOI 10.1016/j.intimp.2017.01.013
   Lee CL, 2013, PHYTOCHEMISTRY, V95, P315, DOI 10.1016/j.phytochem.2013.06.015
   Lee IA, 2012, PLANTA MED, V78, P896, DOI 10.1055/s 0031 1298486
   Lottenberg AM, 2012, IUBMB LIFE, V64, P296, DOI 10.1002/iub.1006
   Minchona PK, 1980, PHYTOCHEMISTRY, V19, P2053
   Mishra A., 2009, INT J PHARM SCI, V1, P280
   Mizushima Y, 1966, Rheumatism, V22, P16
   Morisset S, 1998, J RHEUMATOL, V25, P1146
   Nadkarni K.M., 1982, INDIAN MAT MED, P674
   Nirmal Sunil A., 2012, Inflammopharmacology, V20, P219, DOI 10.1007/s10787 011 0110 8
   OYEDAPO OO, 1995, INT J PHARMACOGN, V33, P65, DOI 10.3109/13880209509088150
   Palit P, 2018, INFLAMMOPHARMACOLOGY, V26, P235, DOI 10.1007/s10787 017 0403 7
   Palit P, 2016, INT IMMUNOPHARMACOL, V41, P106, DOI 10.1016/j.intimp.2016.10.024
   Pandurangan A., 2009, IRANIAN J PHARM THER, V8, P47
   Rainsford K. D., 2007, V42, P3
   SADIQUE J, 1989, Fitoterapia, V60, P525
   Sharma S, 2014, PHYTOCHEMISTRY, V100, P132, DOI 10.1016/j.phytochem.2014.01.002
   SINGH RP, 1987, J INDIAN CHEM SOC, V64, P715
   Singh S., 1997, Fitoterapia, V68, P9
   THOMSON AW, 1981, AGENTS ACTIONS, V11, P265, DOI 10.1007/BF01967625
   Tsai WJ, 2006, BIOORG MED CHEM LETT, V16, P4440, DOI 10.1016/j.bmcl.2006.06.036
   VERMA R K, 1987, Fitoterapia, V58, P271
   Verma R. K., 1988, CHEMINFORM, V19
   Villaseñor IM, 2002, PHYTOTHER RES, V16, P417, DOI 10.1002/ptr.910
   VINEGAR R, 1969, J PHARMACOL EXP THER, V166, P96
   Wang SS, 2016, J ETHNOPHARMACOL, V187, P42, DOI 10.1016/j.jep.2016.04.031
   Yang BY, 2014, STEROIDS, V87, P26, DOI 10.1016/j.steroids.2014.05.003
NR 50
TC 9
Z9 9
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD NOV
PY 2018
VL 139
BP 18
EP 27
DI 10.1016/j.steroids.2018.09.005
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GX9EK
UT WOS:000448101100003
PM 30217788
DA 2025 08 17
ER

PT J
AU Xue, L
   Li, YH
   Chen, J
AF Xue, Li
   Li, Yaohui
   Chen, Jun
TI Duration of simulated microgravity affects the differentiation of
   mesenchymal stem cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE microgravity; regeneration; cytoskeletal tension; differentiation
ID IN VITRO; OSTEOGENIC DIFFERENTIATION; ACTIN CYTOSKELETON; ADIPOGENESIS;
   INCREASES; CULTURE; RHO; PROLIFERATION; MODULATION; EXPRESSION
AB Previous evidence has suggested that physical microenvironments and mechanical stresses, independent of soluble factors, influence mesenchymal stem cell (MSC) fate. In the present study, simulated microgravity (SMG) was demonstrated to regulate the differentiation of mesenchymal stem cells. This may be a novel strategy for tissue engineering and regenerative medicine. Rat MSCs were cultured for 72 h or 10 days in either normal gravity or a clinostat to model microgravity, followed with culture in diverse differential media. A short period of stimulation (72 h) promoted MSCs to undergo endothelial, neuronal and adipogenic differentiation. In comparison, extended microgravity (10 days) promoted MSCs to differentiate into osteoblasts. A short period of exposure to SMG significantly decreased ras homolog family member A (RhoA) activity. However, RhoA activity significantly increased following prolonged exposure to SMG. When RhoA activity was inhibited, the effects of prolonged exposure to SMG were reversed. These results demonstrated that the duration of SMG regulates the differentiation fate of MSCs via the RhoA associated pathway.
C1 [Xue, Li] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Urol, Xian 710014, Shaanxi, Peoples R China.
   [Li, Yaohui] Tradit Chinese Med Hosp Shaanxi, Dept Pneumol, Xian 710014, Shaanxi, Peoples R China.
   [Chen, Jun] Tradit Chinese Med Hosp Shaanxi, Dept Encephalopathy, Xian 710014, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Chen, J (通讯作者)，Tradit Chinese Med Hosp Shaanxi Prov, Dept Encephalopathy, 2 Xi Huamen St, Xian 710014, Shaanxi, Peoples R China.
EM chj2002819@163.com
RI Li, Yaohui/AAM 7796 2020
OI Xue, Li/0000 0003 2774 9110
FU National Natural Science Foundation of China [81402055]; Natural Science
   Foundation of Shaanxi Province [2016JM8014]
FX The authors would like to thank Dr Austin Cape at ASJ Editors for
   careful reading and feedback. Confocal laser scanning microscopy was
   performed at the Department of Anatomy and K.K. Leung Brain Research
   Center, The Fourth Military Medical University (Xi'an, China). The
   present study was funded by the National Natural Science Foundation of
   China (grant no. 81402055), Natural Science Foundation of Shaanxi
   Province (grant no. 2016JM8014).
CR Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Buravkova L, 2005, ACTA ASTRONAUT, V57, P67, DOI 10.1016/j.actaastro.2005.03.012
   Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891
   Chen J, 2011, NEUROSCI LETT, V505, P171, DOI 10.1016/j.neulet.2011.10.014
   Dai ZQ, 2007, CELL PROLIFERAT, V40, P671, DOI 10.1111/j.1365 2184.2007.00461.x
   Grimm D, 2002, FASEB J, V16, P604, DOI 10.1096/fj.01 0673fje
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hochleitner B, 2005, ARTIF ORGANS, V29, P58, DOI 10.1111/j.1525 1594.2004.29014.x
   Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093
   Huang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 87
   HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jiang JJ, 2010, NEUROSCI RES, V66, P46, DOI 10.1016/j.neures.2009.09.1711
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895
   Marquette ML, 2007, IN VITRO CELL DEV AN, V43, P255, DOI 10.1007/s11626 007 9054 0
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Schatten H, 2001, ACTA ASTRONAUT, V49, P399, DOI 10.1016/S0094 5765(01)00116 3
   Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092 8674(03)00271 X
   SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092 8674(83)90098 3
   Uva BM, 2002, BRAIN RES, V934, P132, DOI 10.1016/S0006 8993(02)02415 0
   Wang X, 1997, ACTA BIOPHYSICA SINI, V13, P161
   Xiang Y, 2007, CELL BIOL INT, V31, P444, DOI 10.1016/j.cellbi.2006.11.012
   Young KG, 2010, BBA MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017
   Yuge L, 2006, STEM CELLS DEV, V15, P921, DOI 10.1089/scd.2006.15.921
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
NR 29
TC 36
Z9 41
U1 1
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2017
VL 15
IS 5
BP 3011
EP 3018
DI 10.3892/mmr.2017.6357
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EU5JZ
UT WOS:000401068700079
PM 28339035
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Fattahpour, S
   Shamanian, M
   Tavakoli, N
   Fathi, M
   Sheykhi, SR
   Fattahpour, S
AF Fattahpour, Shohreh
   Shamanian, Morteza
   Tavakoli, Naser
   Fathi, Mohammadhossein
   Sheykhi, Saeid Reza
   Fattahpour, Shirin
TI Design and optimization of alginate chitosan pluronic nanoparticles as a
   novel meloxicam drug delivery system
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE biomaterials; composites; drug delivery systems
ID IN VITRO; CONTROLLED RELEASE; ENCAPSULATION; NANOEMULSION; FORMULATION;
   CARRIER; GEL
AB The inflammation and pain associated with osteoarthritis are treated with nonsteroidal anti inflammatory drugs (NSAIDs). This treatment is accompanied by several side effects; therefore local intra articular (IA) NSAID injection can be more efficient and safe than systemic administration or topical use. In this study, alginate chitosan pluronic nanoparticles were considered as a new vehicle for IA meloxicam delivery. These novel nanoparticles were prepared using an ionotropic gelation method and were optimized for variables such as alginate to chitosan mass ratio, pluronic concentration, and meloxicam concentration using a 3 factor in 3 level Box Behnken design. To optimize the formulation, the dependent variables considered were particle size, zeta potential, entrapment efficiency, and mean dissolution time (MDT). The nanoparticles morphology was characterized by FESEM and AFM. The potential interactions of the drug polymers were investigated by ATR FTIR and DSC, and the delivery profile of meloxicam from the nanoparticles was obtained. The average particle size of the optimized nanoparticles was 283 nm, the zeta potential was  16.9 mV, the meloxicam entrapment efficiency was 55%, and the MDT was 8.9 hours. The cumulative released meloxicam amount from the composite nanoparticles was 85% at pH 7.4 within 96 h. The release profile showed an initial burst release followed by a sustained release phase. The release mechanism was non Fickian diffusion. (c) 2015 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015, 132, 42241.
C1 [Fattahpour, Shohreh; Shamanian, Morteza; Fathi, Mohammadhossein] Isfahan Univ Technol, Biomat Res Grp, Dept Mat Engn, Esfahan 84145683111, Iran.
   [Fattahpour, Shohreh; Tavakoli, Naser; Sheykhi, Saeid Reza] Isfahan Univ Med Sci, Isfahan Pharmaceut Sci Res Ctr, Esfahan 81745359, Iran.
   [Tavakoli, Naser] Isfahan Univ Med Sci, Sch Pharm, Dept Pharmaceut, Esfahan, Iran.
   [Fathi, Mohammadhossein] Isfahan Univ Med Sci, Dent Mat Res Ctr, Esfahan, Iran.
   [Fattahpour, Shirin] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran.
C3 Isfahan University of Medical Sciences; Isfahan University of Medical
   Sciences; Isfahan University of Medical Sciences
RP Fattahpour, S (通讯作者)，Isfahan Univ Technol, Biomat Res Grp, Dept Mat Engn, Esfahan 84145683111, Iran.
EM sh.fattahpour@gmail.com; tavakoli@pharm.mui.ac.ir
RI Fattahpour, Shirin/AAA 2924 2020; Shamanian, Morteza/JTU 0934 2023;
   Tavakoli, Naser/W 1982 2017
OI Shamanian, Morteza/0000 0002 1986 6379; Tavakoli,
   Naser/0000 0003 0654 7675
FU Isfahan Pharmaceutical Sciences Research Centre of the Isfahan
   University of Medical Sciences [290367]; Isfahan University of
   Technology
FX This work was supported by research grant No.290367 from Isfahan
   Pharmaceutical Sciences Research Centre of the Isfahan University of
   Medical Sciences and Isfahan University of Technology. Authors
   gratefully appreciate Dr Behshid Behdadfar's assistance. The authors
   also thank Miss Elaheh Moazeni for her cooperation.
CR Albuquerque B, 2013, POLYM ENG SCI, V53, P146, DOI 10.1002/pen.23256
   Aquino RP, 2012, CARBOHYD POLYM, V89, P740, DOI 10.1016/j.carbpol.2012.04.003
   Bang SH, 2009, J MICROENCAPSUL, V26, P722, DOI 10.3109/02652040902726994
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Butoescu N, 2008, J MICROENCAPSUL, V25, P339, DOI 10.1080/02652040801999551
   Chen SL, 2008, INT J PHARMACEUT, V349, P180, DOI 10.1016/j.ijpharm.2007.08.029
   Dai Y., 2008, INT J BIOMED SCI, V4, P221
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Das RK, 2010, NANOMED NANOTECHNOL, V6, P153, DOI 10.1016/j.nano.2009.05.009
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Domaratzki RE, 2013, J APPL POLYM SCI, V128, P2173, DOI 10.1002/app.38354
   Dong YC, 2004, BIOMATERIALS, V25, P2843, DOI 10.1016/j.biomaterials.2003.09.055
   Douglas KL, 2005, J BIOMAT SCI POLYM E, V16, P43, DOI 10.1163/1568562052843339
   Escobar Chávez JJ, 2006, J PHARM PHARM SCI, V9, P339
   Finotelli PV, 2010, COLLOID SURFACE B, V81, P206, DOI 10.1016/j.colsurfb.2010.07.008
   Gerwin N, 2006, ADV DRUG DELIVER REV, V58, P226, DOI 10.1016/j.addr.2006.01.018
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Hosseini SF, 2013, CARBOHYD POLYM, V95, P50, DOI 10.1016/j.carbpol.2013.02.031
   Ianiski FR, 2012, BEHAV BRAIN RES, V230, P100, DOI 10.1016/j.bbr.2012.01.055
   Kasoju N, 2012, J BIOMED MATER RES B, V100B, P1854, DOI 10.1002/jbm.b.32753
   Khalil RM, 2014, PHARM DEV TECHNOL, V19, P304, DOI 10.3109/10837450.2013.778872
   Khurana S, 2013, LIFE SCI, V92, P383, DOI 10.1016/j.lfs.2013.01.005
   Kürti L, 2013, EUR J PHARM SCI, V50, P86, DOI 10.1016/j.ejps.2013.03.012
   Li GY, 2011, INT J BIOL MACROMOL, V49, P970, DOI 10.1016/j.ijbiomac.2011.08.019
   Liu J, 2012, BIORESOURCES, V7, P2121
   Martinez A, 2011, CARBOHYD POLYM, V83, P1311, DOI 10.1016/j.carbpol.2010.09.038
   Ming J. W., 2010, J APPL POLYM SCI, V117, P3001
   Motwani SK, 2008, EUR J PHARM BIOPHARM, V68, P513, DOI 10.1016/j.ejpb.2007.09.009
   RAJAONARIVONY M, 1993, J PHARM SCI, V82, P912, DOI 10.1002/jps.2600820909
   Ramana LN, 2014, BBA GEN SUBJECTS, V1840, P476, DOI 10.1016/j.bbagen.2013.10.002
   Sahu A, 2009, J MATER SCI MATER M, V20, P171, DOI 10.1007/s10856 008 3549 4
   Sengel Türk CT, 2012, DRUG DEV IND PHARM, V38, P1107, DOI 10.3109/03639045.2011.641562
   Shaji Jessy, 2013, Journal of Pharmaceutical Investigation, V43, P405, DOI 10.1007/s40005 013 0085 0
   Shalviri A., 2013, COLLOID SURFACE B, P101
   Shinde N.C., 2012, Res J Pharm Bio Chem Sci, V3, P922
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169 409X(01)00112 0
   Villar AMS, 2012, INT J PHARMACEUT, V431, P161, DOI 10.1016/j.ijpharm.2012.04.001
   Simsek Ege FA, 2003, J APPL POLYM SCI, V88, P346, DOI 10.1002/app.11989
   Sood S, 2014, COLLOID SURFACE B, V113, P330, DOI 10.1016/j.colsurfb.2013.09.030
   Stoop R, 2008, INJURY, V39, pS77, DOI 10.1016/j.injury.2008.01.036
   Tan HP, 2009, BIOMATERIALS, V30, P2499, DOI 10.1016/j.biomaterials.2008.12.080
   Türkoglu T, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40019
   Xing JF, 2010, J APPL POLYM SCI, V117, P2354, DOI 10.1002/app.32083
   Yadav N., 2013, Int J App Pharm, V5, P8, DOI DOI 10.9790/3013 26103444
   Zhou X, 2013, J APPL POLYM SCI, V127, P4433, DOI 10.1002/app.38003
NR 45
TC 30
Z9 31
U1 1
U2 93
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 8995
EI 1097 4628
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD JUL 20
PY 2015
VL 132
IS 28
AR 42241
DI 10.1002/app.42241
PG 12
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA CH3XJ
UT WOS:000353964000018
DA 2025 08 17
ER

PT J
AU Entz Werle, N
   Lavaux, T
   Metzger, N
   Stoetzel, C
   Lasthaus, C
   Marec, P
   Kalifa, C
   Brugieres, L
   Pacquement, H
   Schmitt, C
   Tabone, MD
   Gentet, JC
   Lutz, P
   Babin, A
   Oudet, P
   Gaub, MP
   Perrin Schmitt, F
AF Entz Werle, Natacha
   Lavaux, Thomas
   Metzger, Nadia
   Stoetzel, Corinne
   Lasthaus, Christelle
   Marec, Perrine
   Kalifa, Chantal
   Brugieres, Laurence
   Pacquement, Helene
   Schmitt, Claudine
   Tabone, Marie Dominique
   Gentet, Jean Claude
   Lutz, Patrick
   Babin, Annie
   Oudet, Pierre
   Gaub, Marie Pierre
   Perrin Schmitt, Fabienne
TI Involvement of MET/TWIST/APC combination or the potential role of
   ossification factors in pediatric high grade osteosarcoma oncogenesis
SO NEOPLASIA
LA English
DT Article
DE pediatric osteosarcoma; osteogenesis; TWIST; APC; MET
ID HEPATOCYTE GROWTH FACTOR; FGFR4 ARG388 ALLELE; FACTOR RECEPTOR 4;
   PROSTATE CANCER; TWIST GENE; BONE; EXPRESSION; OVEREXPRESSION;
   MUTATIONS; SURVIVAL
AB Dysregulated cell growth or differentiation due to mis expression of developmental critical factors seems to be a decisive event in oncogenesis. As osteosarcomas are histologically defined by malignant osteoblasts producing an osteoid component, we prospected in pediatric osteosarcomas treated with OS94 protocol the genomic status of several genes implied in ossification processes. In 91 osteosarcoma cases, we focused on the analysis of the fibroblast growth factor receptors (FGFRs) TWIST, APC, and MET by allelotyping, real time quantitative polymerase chain reaction, gene sequencing, and protein polymorphism study. Our study supports the frequent role of TWIST, APC, and MET as osteosarcoma markers (50%, 62%, and 50%, respectively). TWIST and MET were mainly found to be deleted, and no additional APC mutation was identified. Surprisingly, FGFRs are abnormal in only < 30%. Most of these factors and their abnormalities seem to be linked more or less to one clinical subgroup, but the most significant correlation is the link of MET, TWIST, and APC abnormalities to a worse outcome and their combination within abnormal tumors. A wider cohort is mandatory to define more robust molecular conclusions, but these results are to be considered as the beginning of a more accurate basis for diagnosis, in search of targeted therapies, and to further characterize prognostic markers.
C1 CHRU Hautepierre, Lab Biochim & Biol, F 67098 Strasbourg, France.
   INSERM, U682, F 67200 Strasbourg, France.
   ULP, Fac Med, EA 3949, Med Genet Lab, F 67200 Strasbourg, France.
   Ctr Leon Berard, Serv Oncol Pediat, F 69373 Lyon 08, France.
   Inst Gustave Roussy, Serv Oncol Pediat, F 94809 Villejuif, France.
   Inst Curie, Serv Pediat Oncol, F 75231 Paris, France.
   CHRU Nancy, Hop Brabois, Serv Pediat Oncohematol, F 54000 Nancy, France.
   Hop Trousseau, Serv Pediat Oncohematol, F 75571 Paris 12, France.
   Hop Enfants La Timone, Serv Pediat Oncol, F 13005 Marseille, France.
C3 CHU Strasbourg; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; UNICANCER; Centre Leon Berard;
   UNICANCER; Gustave Roussy; UNICANCER; Universite PSL; Institut Curie;
   CHU de Nancy; Assistance Publique Hopitaux Paris (APHP); Sorbonne
   Universite; Hopital Universitaire Armand Trousseau   APHP; Aix Marseille
   Universite; Assistance Publique Hopitaux de Marseille
RP Entz Werle, N (通讯作者)，CHRU Hautepierre, Lab Biochim & Biol, Ave Moliere, F 67098 Strasbourg, France.
EM natacha.entz werle@chru strasbourg.fr
CR Bange J, 2002, CANCER RES, V62, P840
   Blanquaert F, 1999, ENDOCRINOLOGY, V140, P1069, DOI 10.1210/en.140.3.1069
   COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861
   Colnot C, 2005, J CELL BIOCHEM, V95, P688, DOI 10.1002/jcb.20449
   Ducy P, 2001, M S MED SCI, V17, P1242, DOI 10.1051/medsci/200117121242
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Eames B. Frank, 2003, Birth Defects Research, V69, P93, DOI 10.1002/bdrc.10016
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352
   Entz Werlé N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068
   Entz Werle N, 2003, BRIT J CANCER, V88, P1925, DOI 10.1038/sj.bjc.6600968
   Entz Werle N, 2007, INT J CANCER, V120, P2510, DOI 10.1002/ijc.22593
   FERRACINI R, 1995, ONCOGENE, V10, P739
   Grumbles RM, 1996, BONE, V19, P255, DOI 10.1016/8756 3282(96)00180 9
   Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hernández S, 2006, J CLIN ONCOL, V24, P3664, DOI 10.1200/JCO.2005.05.1771
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008 5472.CAN 04 4567
   Karsenty G, 1998, DEV GENET, V22, P301, DOI 10.1002/(SICI)1520 6408(1998)22:4<301::AID DVG1>3.0.CO;2 A
   Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008 5472.CAN 04 3785
   Le Deley MC, 2007, EUR J CANCER, V43, P752, DOI 10.1016/j.ejca.2006.10.023
   Lefebvre V, 1998, MATRIX BIOL, V16, P529
   Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008 5472.CAN 05 1946
   Mendoza S, 2005, CANCER GENET CYTOGEN, V158, P142, DOI 10.1016/j.cancergencyto.2004.08.035
   Mhawrech Fauceglia P, 2006, EJSO EUR J SURG ONC, V32, P231, DOI 10.1016/j.ejso.2005.11.018
   Morimoto Y, 2003, CANCER, V98, P2245, DOI 10.1002/cncr.11778
   NASAKI MC, 1996, NAT GENET, V13, P233
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Pajer P, 2003, ONCOGENE, V22, P665, DOI 10.1038/sj.onc.1206105
   Patané S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008 5472.CAN 05 4422
   Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876
   Qiu WH, 2005, WORLD J GASTROENTERO, V11, P5266, DOI 10.3748/wjg.v11.i34.5266
   Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200
   Rice DPC, 2003, EUR J ORTHODONT, V25, P139, DOI 10.1093/ejo/25.2.139
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Sasaki Teruo, 2003, Brain Tumor Pathol, V20, P59, DOI 10.1007/BF02483448
   Schneider A, 2000, CANCER RES, V60, P4617
   Sessa C, 2006, EUR J CANCER, V42, P171, DOI 10.1016/j.ejca.2005.09.033
   St Bernard R, 2005, ENDOCRINOLOGY, V146, P1145, DOI 10.1210/en.2004 1134
   Streit S, 2004, INT J CANCER, V111, P213, DOI 10.1002/ijc.20204
   Tenta R, 2006, ANTICANCER RES, V26, P283
   Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587
   Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078 0432.CCR 04 0408
   Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240
   Wood JM, 2000, MEDICINA BUENOS AIRE, V60, P41
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yoshikawa H, 2004, J ORTHOP SCI, V9, P334, DOI 10.1007/s00776 004 0764 9
   Zauber NP, 1999, CANCER, V86, P31, DOI 10.1002/(SICI)1097 0142(19990701)86:1<31::AID CNCR6>3.0.CO;2 O
   Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925 4773(01)00428 2
NR 50
TC 43
Z9 51
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476 5586
J9 NEOPLASIA
JI Neoplasia
PD AUG
PY 2007
VL 9
IS 8
BP 678
EP 688
DI 10.1593/neo.07367
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 211VR
UT WOS:000249551900008
PM 17786187
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Iniguez, E
   Sánchez, A
   Vasquez, MA
   Martínez, A
   Olivas, J
   Sattler, A
   Sánchez Delgado, RA
   Maldonado, RA
AF Iniguez, Eva
   Sanchez, Antonio
   Vasquez, Miguel A.
   Martinez, Alberto
   Olivas, Joanna
   Sattler, Aaron
   Sanchez Delgado, Roberto A.
   Maldonado, Rosa A.
TI Metal drug synergy: new ruthenium(II) complexes of ketoconazole are
   highly active against Leishmania major and Trypanosoma
   cruzi and nontoxic to human or murine normal cells
SO JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
LA English
DT Article
DE Leishmaniasis; Chagas disease; Ketoconazole; Ruthenium; Metal drug
   synergy
ID TROPICAL DISEASES; CHEMOTHERAPEUTIC AGENTS; BIOLOGICAL ACTIVITY;
   CRYSTAL STRUCTURES; CHAGAS DISEASE; LATIN AMERICA; DNA; CLOTRIMAZOLE;
   LIGANDS; MALARIA
AB In our ongoing search for new metal based chemotherapeutic agents against leishmaniasis and Chagas disease, six new ruthenium ketoconazole (KTZ) complexes have been synthesized and characterized, including two octahedral coordination complexes cis,fac [(RuCl2) Cl II(DMSO)(3)(KTZ)] (1) and cis [(RuCl2) Cl II(bipy)(DMSO)(KTZ)] (2) (where DMSO is dimethyl sulfoxide and bipy is 2,2' bipyridine) and four organometallic compounds [Ru II(eta(6) p cymene)Cl 2(KTZ)] (3), [Ru II(eta(6) p cymene)(en)(KTZ)][BF4](2) (4), [Ru II(eta(6) p cymene)(bipy)(KTZ)][BF4](2) (5), and [Ru II(eta(6) p cymene)(acac)(KTZ)][BF4] (6) (where en is ethylenediamine and acac is acetylacetonate); the crystal structure of 3 is described. The central hypothesis of our work is that combining a bioactive compound such as KTZ and a metal in a single molecule results in a synergy that can translate into improved activity and/or selectivity against parasites. In agreement with this hypothesis, complexation of KTZ with Ru II in compounds 3 5 produces a marked enhancement of the activity toward promastigotes and intracellular amastigotes of Leishmania major, when compared with uncomplexed KTZ, or with similar ruthenium compounds not containing KTZ. Importantly, the selective toxicity of compounds 3 5 toward the leishmania parasites, in relation to human fibroblasts and osteoblasts or murine macrophages, is also superior to the selective toxicities of the individual constituents of the drug. When tested against Trypanosoma cruzi epimastigotes, some of the organometallic complexes displayed activity and selectivity comparable to those of free KTZ. A dual target mechanism is suggested to account for the antiparasitic properties of these complexes.
C1 [Iniguez, Eva; Vasquez, Miguel A.; Olivas, Joanna; Maldonado, Rosa A.] Univ Texas El Paso, Dept Biol Sci, Border Biomed Res Ctr, El Paso, TX 79968 USA.
   [Sanchez, Antonio; Sanchez Delgado, Roberto A.] CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA.
   [Sanchez, Antonio; Sanchez Delgado, Roberto A.] CUNY, Grad Ctr, Brooklyn, NY 11210 USA.
   [Martinez, Alberto] CUNY, New York City Coll Technol, Dept Chem, Brooklyn, NY 11210 USA.
   [Sattler, Aaron] Columbia Univ, Dept Chem, New York, NY 10027 USA.
C3 University of Texas System; University of Texas El Paso; City University
   of New York (CUNY) System; Brooklyn College (CUNY); City University of
   New York (CUNY) System; City University of New York (CUNY) System;
   Columbia University
RP Maldonado, RA (通讯作者)，Univ Texas El Paso, Dept Biol Sci, Border Biomed Res Ctr, El Paso, TX 79968 USA.
EM Rsdelgado@brooklyn.cuny.edu; ramaldonado@utep.edu
RI ; Maldonado, Rosa/A 8363 2009; Vásquez, Miguel/AAS 5987 2021
OI Maldonado, Rosa/0000 0003 3180 7192; 
FU NIMHD [G12MD007592]; BBRC [NIMHD/G12MD007592]; University of Texas URI;
   NIH RISE [2R25GM069621 10]; NIH [5SC1GM089558]; National Science
   Foundation [CHE 0619638]
FX We thank the staff of the Cell Culture and High Throughput Screening
   (HTS, #20) Core Facility of the University of Texas at El Paso for
   services and facilities provided; this core facility is supported by
   NIMHD grant G12MD007592. We thank the BBRC for a small grant
   (NIMHD/G12MD007592) and the University of Texas URI for a grant (to R.
   A. M.). M. A. V. was supported by NIH RISE (2R25GM069621 10). We also
   thank the NIH for support through grant 5SC1GM089558 (to R.A.S. D.) and
   the National Science Foundation (CHE 0619638) for the acquisition of an
   X ray diffractometer for Columbia University.
CR Alessio E, 1996, INORG CHEM, V35, P2538, DOI 10.1021/ic9509793
   [Anonymous], 2002, CONTR CHAG DIS
   Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140 6736(03)14694 6
   BENNETT MA, 1982, INORG SYN, V21, P74, DOI 10.1002/9780470132524.ch16
   CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93
   Capul AA, 2007, INFECT IMMUN, V75, P4629, DOI 10.1128/IAI.00735 07
   CARMONA D, 1990, J CHEM SOC DALTON, P1463, DOI 10.1039/dt9900001463
   Chen HM, 2003, J AM CHEM SOC, V125, P173, DOI 10.1021/ja027719m
   CRABTREE RH, 1977, J ORGANOMET CHEM, V141, P325, DOI 10.1016/S0022 328X(00)90856 8
   Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026
   de Souza Wanderley, 2009, Interdiscip Perspect Infect Dis, V2009, P642502, DOI 10.1155/2009/642502
   Demoro B, 2012, DALTON T, V41, P1534, DOI 10.1039/c1dt11519g
   den Boer M, 2011, CLIN MICROBIOL INFEC, V17, P1471, DOI 10.1111/j.1469 0691.2011.03635.x
   Dias JCP, 2002, MEM I OSWALDO CRUZ, V97, P603, DOI 10.1590/S0074 02762002000500002
   EVANS IP, 1973, J CHEM SOC DALTON, P204, DOI 10.1039/dt9730000204
   Fricker SP, 2008, J INORG BIOCHEM, V102, P1839, DOI 10.1016/j.jinorgbio.2008.05.010
   Habtemariam A, 2006, J MED CHEM, V49, P6858, DOI 10.1021/jm060596m
   HENN M, 1991, INORG CHIM ACTA, V187, P39, DOI 10.1016/S0020 1693(00)82975 8
   Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300
   Kirchhoff LV, 2011, ADV PARASIT, V75, P1, DOI 10.1016/B978 0 12 385863 4.00001 0
   Lara D, 2010, J PARASITOL, V96, P638, DOI 10.1645/GE 2329.1
   Lincoln P, 1998, J PHYS CHEM B, V102, P9583, DOI 10.1021/jp9824914
   Martínez A, 2012, J MED CHEM, V55, P3867, DOI 10.1021/jm300070h
   Merlino A, 2011, EUR J MED CHEM, V46, P2639, DOI 10.1016/j.ejmech.2011.03.046
   Navarro M, 2001, INORG CHEM, V40, P6879, DOI 10.1021/ic0103087
   Navarro M, 2000, POLYHEDRON, V19, P2319, DOI 10.1016/S0277 5387(00)00495 2
   Navarro M, 2007, J INORG BIOCHEM, V101, P111, DOI 10.1016/j.jinorgbio.2006.08.015
   Navarro M, 2006, ARZNEIMITTELFORSCH, V56, P600
   Navarro M, 2010, DRUG DISCOV TODAY, V15, P1070, DOI 10.1016/j.drudis.2010.10.005
   Nohara LL, 2010, PARASITOL INT, V59, P565, DOI 10.1016/j.parint.2010.07.007
   Otero L, 2006, J MED CHEM, V49, P3322, DOI 10.1021/jm0512241
   Peeters OM, 2004, ACTA CRYSTALLOGR E, V60, pO367, DOI 10.1107/S1600536804003046
   Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166 6851(02)00280 3
   Sánchez Delgado RA, 2004, MET IONS BIOL SYST, V41, P379
   Sánchez Delgado RA, 2004, MINI REV MED CHEM, V4, P23, DOI 10.2174/1389557043487493
   Sanchez Delgado RA, 1998, INORG CHIM ACTA, V276, P528
   SANCHEZDELGADO RA, 1993, J MED CHEM, V36, P2041, DOI 10.1021/jm00066a014
   Sheldrick G.M., 1981, SHELXTL INTEGRATED S
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Song H, 2012, NAT CHEM, V4, P615, DOI [10.1038/nchem.1375, 10.1038/NCHEM.1375]
   Thalhofer Colin J, 2010, J Vis Exp, DOI 10.3791/1980
   Toyama M, 2006, B CHEM SOC JPN, V79, P1525, DOI 10.1246/bcsj.79.1525
   Uphoff Cord C, 2005, Methods Mol Biol, V290, P13
   Urbina JA, 2010, DRUG FUTURE, V35, P409, DOI 10.1358/dof.2010.035.05.1484391
   Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001
   Urbina JA, 2010, ACTA TROP, V115, P55, DOI 10.1016/j.actatropica.2009.10.023
   Urbina JA, 2009, MEM I OSWALDO CRUZ, V104, P311, DOI 10.1590/S0074 02762009000900041
   Vieites M, 2008, J INORG BIOCHEM, V102, P1033, DOI 10.1016/j.jinorgbio.2007.12.005
   Vieites M, 2009, J INORG BIOCHEM, V103, P411, DOI 10.1016/j.jinorgbio.2008.12.004
   Vock CA, 2006, J MED CHEM, V49, P5552, DOI 10.1021/jm060495o
   WHO, 2010, WHO TECH REP SER, V949, P1
NR 51
TC 79
Z9 83
U1 0
U2 55
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0949 8257
EI 1432 1327
J9 J BIOL INORG CHEM
JI J. Biol. Inorg. Chem.
PD OCT
PY 2013
VL 18
IS 7
BP 779
EP 790
DI 10.1007/s00775 013 1024 2
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 221CX
UT WOS:000324636200006
PM 23881220
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jones, G
AF Jones, Glenville
TI Expanding role for vitamin D in chronic kidney disease:: Importance of
   blood 25 OH D levels and extra renal 1α hydroxylase in the classical and
   nonclassical actions of 1α,25 dihydroxyvitamin D3
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID PARATHYROID HORMONE; D DEFICIENCY; D RECEPTOR; 25 HYDROXYVITAMIN D
   1 ALPHA HYDROXYLASE; RENAL PRODUCTION; CALCITROIC ACID; RAT KIDNEY;
   1,25 DIHYDROXYVITAMIN D3; BONE; INACTIVATION
AB Recent advances in the understanding of vitamin D have revolutionized our view of this old nutritional factor and suggested that it has much wider effects on the body than ever believed before. In addition to its well known effects on calcium/phosphate homeostasis, vitamin D, through its hormonal form, 1 alpha,25 dihydroxyvitamin D 3 or calcitriol, is a cell differentiating factor and anti proliferative agent with actions on a variety of tissues around the body (e.g., skin, muscle, immune system). By influencing gene expression in multiple tissues, calcitriol influences many physiological processes besides calcium/phosphate homeostasis including muscle and keratinocyte differentiation, insulin secretion, blood pressure regulation, and the immune response. The incidence of various diseases including epithelial cancers, multiple sclerosis, muscle weakness as well as bone related disorders has been correlated with vitamin D deficiency/insufficiency and has led to a re evaluation of recommended daily intakes both in the normal subject and CKD patient. Critical developments have been the emergence of the value of blood 25 OH D measurement as a tool in predicting vitamin D related problems and this has in turn emphasized the importance of the extra renal version of the la hydroxylase, the enzyme responsible for the final step in vitamin D activation. The widespread expression of this extra renal enzyme supports the view that it exists to boost intracellular concentrations of calcitriol within some target tissues in order to modulate a unique set of genes specifically in those tissues, a process which is therefore dependent upon circulating 25 OH D. For CKD patients with their tendency to vitamin D substrate insufficiency coupled with their documented loss of the renal la hydroxylase in late stages, this new information has profound implications. Physicians must start to manage the vitamin D insufficiency by vitamin D supplements throughout stages 1 5 whilst continuing to provide calcitriol replacement therapy, in the form of calcitriol or its analogs, in stages 3 5.
C1 Queens Univ, Dept Biochem & Med, Kingston, ON K7L 3N6, Canada.
C3 Queens University   Canada
RP Jones, G (通讯作者)，Queens Univ, Dept Biochem & Med, Kingston, ON K7L 3N6, Canada.
EM gj1@post.queensu.ca
CR ADAMS JS, 1986, ANN NY ACAD SCI, V465, P587, DOI 10.1111/j.1749 6632.1986.tb18535.x
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004 0360
   Armbrecht HJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P298, DOI 10.1016/S0003 9861(02)00636 7
   BARBOUR GL, 1981, NEW ENGL J MED, V305, P440, DOI 10.1056/NEJM198108203050807
   Bikle DD, 2004, J INVEST DERMATOL, V122, P984, DOI 10.1111/j.0022 202X.2004.22424.x
   Bischoff Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029
   Bischoff Ferrari HA, 2004, AM J CLIN NUTR, V80, P752
   Bises G, 2004, J HISTOCHEM CYTOCHEM, V52, P985, DOI 10.1369/jhc.4B6271.2004
   *CAN DERM SOC CAN, 2006, KEY FIND UV VIT D HL
   Cheng JB, 2004, P NATL ACAD SCI USA, V101, P7711, DOI 10.1073/pnas.0402490101
   Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135
   Dawson Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198 005 1867 7
   DUSSO A, 1988, KIDNEY INT, V34, P368, DOI 10.1038/ki.1988.190
   DUSSO AS, 1991, J CLIN ENDOCR METAB, V72, P157, DOI 10.1210/jcem 72 1 157
   Dusso AS, 1997, J CLIN ENDOCR METAB, V82, P2222, DOI 10.1210/jc.82.7.2222
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   ESVELT RP, 1979, BIOCHEMISTRY US, V18, P3977, DOI 10.1021/bi00585a021
   FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   GOODMAN WG, 1992, ANNU REV MED, V43, P227
   Grant WB, 2004, NUTR CANCER, V48, P115, DOI 10.1207/s15327914nc4802_1
   Grant WB, 2002, J INTERN MED, V252, P178, DOI 10.1046/j.1365 2796.2002.01016.x
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Heaney RP, 2005, J STEROID BIOCHEM, V97, P13, DOI 10.1016/j.jsbmb.2005.06.020
   Hewison M, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1379
   HOLICK MF, 1973, J BIOL CHEM, V248, P6691
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   HOLICK MF, 1972, BIOCHEMISTRY US, V11, P4251, DOI 10.1021/bi00773a009
   Holick MF, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P37
   Hollis BW, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P931
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   HOLLIS BW, 1989, ENDOCRINOLOGY, V125, P1224, DOI 10.1210/endo 125 3 1224
   JONES G, 1987, Steroids, V49, P29, DOI 10.1016/0039 128X(87)90078 X
   Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193
   Jones G, 1999, ENDOCRINOLOGY, V140, P3303, DOI 10.1210/en.140.7.3303
   Jones G, 2006, ANTICANCER RES, V26, P2589
   JONGEN MJM, 1984, NEPHRON, V36, P230, DOI 10.1159/000183159
   LAMBERT PW, 1982, J CLIN INVEST, V69, P722, DOI 10.1172/JCI110501
   LAMBERT PW, 1982, METAB BONE DIS RELAT, V4, P7, DOI 10.1016/0221 8747(82)90003 0
   Lim HW, 2005, J AM ACAD DERMATOL, V52, P868, DOI 10.1016/j.jaad.2005.03.015
   Lohnes D., 1992, J NUTR SCI VITAMINOL, P75
   MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173
   MARTINLOF P, 1996, NORDIC J PHILOS LOGI, V1, P11
   Masuda S, 2005, ENDOCRINOLOGY, V146, P825, DOI 10.1210/en.2004 1116
   OHYAMA Y, 1991, J BIOL CHEM, V266, P8690
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201
   Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005
   Quarles LD, 2003, AM J PHYSIOL ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003
   REDDY GS, 1989, BIOCHEMISTRY US, V28, P1763, DOI 10.1021/bi00430a051
   Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244
   SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307
   SHINKI T, 1992, J BIOL CHEM, V267, P13757
   SHULTZ TD, 1983, P NATL ACAD SCI BIOL, V80, P1746, DOI 10.1073/pnas.80.6.1746
   SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639
   SORENSEN OH, 1986, ACTA MED SCAND, V219, P215
   St Arnaud R, 1999, BONE, V25, P127, DOI 10.1016/S8756 3282(99)00118 0
   St Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658
   StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552
   Stoffels K, 2006, J BONE MINER RES, V21, P37, DOI 10.1359/JBMR.050908
   STUMPF WE, 1995, HISTOCHEM CELL BIOL, V104, P417, DOI 10.1007/BF01464331
   TENENHOUSE HS, 1988, J CLIN INVEST, V81, P461, DOI 10.1172/JCI113342
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Vieth R, 2005, J ENDOCRINOL INVEST, V28, P183, DOI 10.1007/BF03345365
   Vieth R, 2004, J STEROID BIOCHEM, V89 90, P575, DOI 10.1016/j.jsbmb.2004.03.038
   White JH, 2004, J STEROID BIOCHEM, V89 90, P239, DOI 10.1016/j.jsbmb.2004.03.074
   Whitfield GK, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P219
   Willnow TE, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P153
   Yamamoto K, 2005, J BIOL CHEM, V280, P30511, DOI 10.1074/jbc.M505244200
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897 391
NR 70
TC 139
Z9 167
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0894 0959
EI 1525 139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD JUL AUG
PY 2007
VL 20
IS 4
BP 316
EP 324
DI 10.1111/j.1525 139X.2007.00302.x
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 194IV
UT WOS:000248339000006
PM 17635821
DA 2025 08 17
ER

PT J
AU Kjeldgaard, HK
   Holvik, K
   Abrahamsen, B
   Tell, GS
   Meyer, HE
   O'Flaherty, M
AF Kjeldgaard, Helena Kames
   Holvik, Kristin
   Abrahamsen, Bo
   Tell, Grethe S.
   Meyer, Haakon E.
   O'Flaherty, Martin
TI Explaining declining hip fracture rates in Norway: a population based
   modelling study
SO LANCET REGIONAL HEALTH EUROPE
LA English
DT Article
DE Hip fractures; Osteoporosis; Public health; Epidemiology; Epidemiologic
   methods
ID INCIDENT FRACTURES; RISK; OSTEOPOROSIS; HEALTH; ASSOCIATION; THERAPY
AB Background Although age standardised hip fracture incidence has declined in many countries during recent decades, the number of fractures is forecast to increase as the population ages. Understanding the drivers behind this decline is essential to inform policy for targeted preventive measures. We aimed to quantify how much of this decline could be explained by temporal trends in major risk factors and osteoporosis treatment.Methods We developed a new modelling approach, Hip IMPACT, based on the validated IMPACT coronary heart disease models. The model applied sex and age stratified hip fracture numbers and prevalence of pharmacologic treatments and risk/preventive factors in 1999 and 2019, and best available evidence for independent relative risks of hip fracture associated with each treatment and risk/preventive factor.Findings Hip IMPACT explained 91% (2500/2756) of the declining hip fracture rates during 1999 2019. Two thirds of the total decline was attributed to changes in risk/preventive factors and one fifth to osteoporosis medication. Increased prevalence of total hip replacements explained 474/2756 (17%), increased body mass index 698/2756 (25%), and increased physical activity 434/2756 (16%). Reduced smoking explained 293/2756 (11%), and reduced benzodiazepine use explained (366/2756) 13%. Increased uptake of alendronate, zoledronic acid, and denosumab explained 307/2756 (11%), 104/2756 (4%) and 161/2756 (6%), respectively. The explained decline was partially offset by increased prevalence of type 2 diabetes and users of glucocorticoids, z drugs, and opioids. Interpretation Two thirds of the decline in hip fractures from 1999 to 2019 was attributed to reductions in major risk factors and approximately one fifth to osteoporosis medication. Health 2023;30: Published 2023 https://doi.org/10. 1016/j.lanepe.2023. 100643
C1 [Kjeldgaard, Helena Kames; Holvik, Kristin; Meyer, Haakon E.] Norwegian Inst Publ Hlth, Dept Phys Hlth & Ageing, POB 222, N 0213 Oslo, Norway.
   [Kjeldgaard, Helena Kames; O'Flaherty, Martin] Univ Liverpool, Dept Publ Hlth Policy & Syst, Liverpool, England.
   [Abrahamsen, Bo] Univ Southern Denmark, Inst Clin Res, OPEN, Odense, Denmark.
   [Tell, Grethe S.] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway.
   [Meyer, Haakon E.] Univ Oslo, Dept Community Med & Global Hlth, Oslo, Norway.
C3 Norwegian Institute of Public Health (NIPH); University of Liverpool;
   University of Southern Denmark; University of Bergen; University of Oslo
RP Holvik, K (通讯作者)，Norwegian Inst Publ Hlth, Dept Phys Hlth & Ageing, POB 222, N 0213 Oslo, Norway.
EM kristin.holvik@fhi.no
RI Tell, Grethe/G 5639 2015; O'Flaherty, Martin/JXM 0484 2024; Meyer,
   Haakon/AAH 9333 2019; Holvik, Kristin/X 8678 2019; Meyer, Haakon
   E/AAH 9333 2019; Abrahamsen, Bo/B 8920 2008
OI Kjeldgaard, Helena Kames/0000 0003 3824 4927; Meyer, Haakon
   E/0000 0002 3262 8260; Abrahamsen, Bo/0000 0002 2730 6080
FU Research Council of Norway
FX Funding The Research Council of Norway.
CR Abrahamsen B, 2019, BONE, V120, P476, DOI 10.1016/j.bone.2018.12.016
   Ackerman IN, 2017, ARTHRIT CARE RES, V69, P1659, DOI 10.1002/acr.23197
   Andreasen C, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.5701
   Bajekal M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001237
   Beard JR, 2016, LANCET, V387, P2145, DOI 10.1016/S0140 6736(15)00516 4
   Berg C., 2018, NORWEGIAN PRESCRIPTI
   Bolland MJ, 2018, LANCET DIABETES ENDO, V6, P847, DOI [10.1016/S2213 8587(18)30265 1, 10.1016/s2213 8587(18)30265 1]
   Borgström F, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0706 y
   Bye EK, 2020, NORD STUD ALCOHOL DR, V37, P444, DOI 10.1177/1455072520954325
   Cauley JA, 2014, NAT REV ENDOCRINOL, V10, P338, DOI 10.1038/nrendo.2014.51
   Eliasaf A, 2016, J CLIN PHARMACOL, V56, P1416, DOI 10.1002/jcph.738
   Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935
   Hoff M, 2021, OSTEOPOROSIS INT, V32, P1395, DOI 10.1007/s00198 021 05845 2
   Hotchkiss JW, 2014, BMJ BRIT MED J, V348, DOI 10.1136/bmj.g1088
   Javaid MK, 2011, OSTEOPOROSIS INT, V22, P69, DOI 10.1007/s00198 010 1224 3
   Kanis JA, 2000, BONE, V27, P585, DOI 10.1016/S8756 3282(00)00381 1
   Kanis JA, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00871 9
   Kjeldgaard HK, 2022, J BONE MINER RES, V37, P1936, DOI 10.1002/jbmr.4660
   LaMonte MJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.14084
   Morseth B, 2010, EUR J EPIDEMIOL, V25, P325, DOI 10.1007/s10654 010 9450 8
   Mpalaris V, 2015, OBES REV, V16, P225, DOI 10.1111/obr.12244
   Olsen KR, 2013, OSTEOPOROSIS INT, V24, P2639, DOI 10.1007/s00198 013 2365 y
   Omsland TK, 2014, OSTEOPOROSIS INT, V25, P2493, DOI 10.1007/s00198 014 2781 7
   Ramsey KA, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101266
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rosengren BE, 2017, OSTEOPOROSIS INT, V28, P139, DOI 10.1007/s00198 016 3768 3
   Shen J, 2016, J CLIN ENDOCR METAB, V101, P476, DOI 10.1210/jc.2015 3123
   Sogaard AJ, 2020, OSTEOPOROSIS INT, V31, P131, DOI 10.1007/s00198 019 05191 4
   Sogaard AJ, 2016, OSTEOPOROSIS INT, V27, P2217, DOI 10.1007/s00198 016 3516 8
   Söreskog E, 2020, OSTEOPOROSIS INT, V31, P1499, DOI 10.1007/s00198 020 05372 6
   Strand BH, 2019, J GERONTOL A BIOL, V74, P528, DOI 10.1093/gerona/gly234
   Tricco AC, 2017, JAMA J AM MED ASSOC, V318, P1687, DOI 10.1001/jama.2017.15006
   Wu CH, 2018, BONE, V111, P92, DOI 10.1016/j.bone.2018.03.018
NR 33
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2666 7762
J9 LANCET REG HEALTH EU
JI Lancet Reg. Health Eur.
PD JUL
PY 2023
VL 30
AR 100643
DI 10.1016/j.lanepe.2023.100643
EA MAY 2023
PG 10
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA P8HF7
UT WOS:001053019900001
PM 37215491
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Oliveira, TC
   Bradaschia Correa, V
   Castro, JR
   Simoes, A
   Arana Chavez, VE
AF Oliveira, This C.
   Bradaschia Correa, Vivian
   Castro, Juliana R.
   Simoes, Alyne
   Arana Chavez, Victor E.
TI Ultrastructural and biochemical analysis of the effects of alendronate
   on salivary glands of young rats
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Parotid gland; Submandibular gland; Alendronate; Amylase; Rat
ID BISPHOSPHONATE RELATED OSTEONECROSIS; PAROTID ACINAR CELLS;
   SUBMANDIBULAR GLAND; SECRETORY RESPONSE; AMYLASE RELEASE; JAWS;
   PARAMETERS; PODOSOME; GTPASES; SNARES
AB Introduction: The bisphosphonates are drugs known by their antiresorptive potency and are widely prescribed for treating and preventing osteoporosis. In the past years the employment of this class of drugs had spread to other pathologies, and it is being prescribed to patients in a wide range of ages. Some adverse effects of bisphosphonate treatment have been highlighted recently, however, little is known about its potential side effects in salivary glands.
   Methods: Newborn rats received daily doses of 2.5 mg/kg/day of sodium alendronate during 30 days. On the thirtieth day the animals were stimulated with pilocarpine and their parotid and submandibular glands were collected, fixed and embedded for histological and ultrastructural analysis. Some glands were collected for analysis of protein content and amylase activity.
   Results: At light microscopy, the alendronate treated animals presented an accumulation of secretion granules in their cytoplasm, which was confirmed by the ultrastructural examination. Biochemical analysis revealed an increase in total protein content and decreased amylase levels of both glands in the alendronate treated animals in relation to the control.
   Conclusion: Based on the current findings, alendronate is probably interfering in secretory pathways of parotid and submandibular glands. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Oliveira, This C.; Bradaschia Correa, Vivian; Castro, Juliana R.; Simoes, Alyne; Arana Chavez, Victor E.] Univ Sao Paulo, Sch Dent, Dept Biomat & Oral Biol, BR 05508000 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Arana Chavez, VE (通讯作者)，Univ Sao Paulo, Sch Dent, Dept Biomat & Oral Biol, Ave Prof Lineu Prestes 2227, BR 05508000 Sao Paulo, Brazil.
EM vearana@usp.br
RI Bradaschia Correa, Vivian/N 7452 2013; Arana Chavez, V/G 4948 2012;
   Simoes, Alyne/G 2176 2012
OI Simoes, Alyne/0000 0002 4873 1393
FU FAPESP [2010/18153 0]; CNPq (Brazil)
FX This work was supported by FAPESP (grant #2010/18153 0) and CNPq
   (Brazil).
CR ANDERSON LC, 1991, COMP BIOCHEM PHYS A, V98, P363, DOI 10.1016/0300 9629(91)90548 Q
   Arana Chavez VE, 2009, INT J BIOCHEM CELL B, V41, P446, DOI 10.1016/j.biocel.2008.09.007
   Bagan J, 2014, J ORAL PATHOL MED, V43, P371, DOI 10.1111/jop.12151
   Bagan J, 2013, J ORAL PATHOL MED, V42, P405, DOI 10.1111/jop.12021
   BALL WD, 1984, EUR J CELL BIOL, V33, P112
   BALL WD, 1974, DEV BIOL, V41, P267, DOI 10.1016/0012 1606(74)90305 4
   Bradaschia Correa V, 2013, CELL TISSUE RES, V353, P79, DOI 10.1007/s00441 013 1623 9
   Busch L, 2002, ARCH ORAL BIOL, V47, P717, DOI 10.1016/S0003 9969(02)00057 2
   Evlo S, 2006, ORAL DIS, V12, P187
   Fischer E.H., 1961, Biochem. Prep, V8, P27
   Hecht R, 2000, ANAT REC, V258, P349, DOI 10.1002/(SICI)1097 0185(20000401)258:4<349::AID AR3>3.0.CO;2 9
   Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048
   Imai A, 2006, ARCH BIOCHEM BIOPHYS, V455, P127, DOI 10.1016/j.abb.2006.09.021
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Lawson MA, 2010, CURR PHARM DESIGN, V16, P3028
   Margaix Muñoz M, 2013, MED ORAL PATOL ORAL, V18, pE194, DOI 10.4317/medoral.18604
   Mese H, 2007, J ORAL REHABIL, V34, P711, DOI 10.1111/j.1365 2842.2007.01794.x
   Nogueira FN, 2005, CLIN CHIM ACTA, V353, P133, DOI 10.1016/j.cccn.2004.11.004
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   QUISSELL DO, 1980, AM J PHYSIOL, V238, pC99, DOI 10.1152/ajpcell.1980.238.3.C99
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   SCHNEYER CA, 1985, ARCH ORAL BIOL, V30, P137, DOI 10.1016/0003 9969(85)90105 0
   Simoes A, 2008, CLIN ORAL INVEST, V12, P25, DOI 10.1007/s00784 007 0135 y
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728
   Stoeckelhuber M, 2012, J HISTOCHEM CYTOCHEM, V60, P110, DOI 10.1369/0022155411432785
   Taylor Adam, 2011, Small GTPases, V2, P131
   Wang Y, 2006, MOL MEMBR BIOL, V23, P377, DOI 10.1080/09687860600776734
NR 28
TC 5
Z9 6
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD DEC
PY 2014
VL 59
IS 12
BP 1307
EP 1311
DI 10.1016/j.archoralbio.2014.07.020
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AS7LG
UT WOS:000344437000007
PM 25163848
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Cai, L
   Wei, RX
   Hu, H
   Jin, W
   Zhu, XB
AF Zhang, Yi
   Cai, Lin
   Wei, Ren Xiong
   Hu, Hao
   Jin, Wei
   Zhu, Xiao Bin
TI Different expression of alternative lengthening of telomere
   (ALT) associated proteins/mRNAs in osteosarcoma cell lines
SO ONCOLOGY LETTERS
LA English
DT Article
DE osteosarcoma; telomere maintenance mechanism; telomerase; alternative
   lengthening of telomeres
ID IN VIVO; MAMMALIAN TELOMERES; TUMOR CELLS; RNA; MAINTENANCE; CANCER;
   TEP1; STABILITY; MECHANISM; HTERT
AB Tumors, including osteosarcoma (OS), are capable of evading senescence and cell death, which is caused by telomere loss with cell division. Alternative lengthening of telomeres (ALT) is considered as the main telomere maintenance mechanism in OS. In this study, we investigated the expression of ALT associated proteins and mRNAs in human OS cell lines. Western blotting was used to detect the protein expression in OS cell lines, while the expression of mRNA was determined by reverse transcriptase PCR and quantitative real time PCR analysis. Whole genome expression arrays were used to analyze the expression of all the mRNAs involved in telomere maintenance mechanisms (TMMs) including human telomerase reverse transcriptase, promyelocytic leukemia proteins and other related proteins. OS and normal cell lines do not express telomerase reverse transcriptase (hTERT) as a key subunit of telomerase, although they show varying levels of ALT associated proteins and mRNAs such as PML, Rad52, MRE11 and FEN1 by Western blotting and quantitative real time PCR analysis. A number of mRNAs that play essential roles in ALT are expressed more in OS cell lines than in the osteoblast cell line, as shown by whole genome expression arrays. In conclusion, OS cell lines maintain their telomere length primarily through the ALT mechanism. There are numerous other proteins that regulate this process in OS; therefore, anti ALT therapy may be a more effective method to treat OS than anti telomerase therapy.
C1 [Zhang, Yi; Cai, Lin; Wei, Ren Xiong; Hu, Hao; Jin, Wei; Zhu, Xiao Bin] Wuhan Univ, Zhongnan Hosp, Dept Orthoped, Wuhan 430071, Hubei, Peoples R China.
C3 Wuhan University
RP Wei, RX (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Orthoped, Wuhan 430071, Hubei, Peoples R China.
EM feiyi030@126.com
FU National Natural Science Foundation of China [30772185]; Fundamental
   Research Funds for the Central Universities [303275884,
   201130302020010]; Hubei Provincial Natural Science Foundation
   [2009CDB288]; Zhongnan Hospital, Wuhan Universities [2009 22]
FX This study was supported by the National Natural Science Foundation of
   China (no. 30772185), the Fundamental Research Funds for the Central
   Universities (no. 303275884, 201130302020010), Hubei Provincial Natural
   Science Foundation (no. 2009CDB288) and the funds of Zhongnan Hospital,
   Wuhan Universities (no. 2009 22).
CR Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   Avilion AA, 1996, CANCER RES, V56, P645
   Bakkenist CJ, 2004, CANCER RES, V64, P3748, DOI 10.1158/0008 5472.CAN 04 0453
   Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329
   Bhattacharyya S, 2010, J CELL BIOCHEM, V109, P7, DOI 10.1002/jcb.22388
   BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492
   Brachner A, 2006, CANCER RES, V66, P3584, DOI 10.1158/0008 5472.CAN 05 2839
   Costa A, 2006, CANCER RES, V66, P8918, DOI 10.1158/0008 5472.CAN 06 0273
   di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118
   Endo Munoz L, 2010, BRIT J CANCER, V103, P73, DOI 10.1038/sj.bjc.6605723
   Fan Q, 2009, NUCLEIC ACIDS RES, V37, P1740, DOI 10.1093/nar/gkn995
   Fujiwara Akita H, 2005, INT J ONCOL, V26, P1009
   Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058
   Henson JD, 2009, NAT BIOTECHNOL, V27, P1181, DOI 10.1038/nbt.1587
   Herbert BS, 2005, ONCOGENE, V24, P5262, DOI 10.1038/sj.onc.1208760
   Jegou T, 2009, MOL BIOL CELL, V20, P2070, DOI 10.1091/mbc.E08 02 0108
   Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708 2721.2005
   Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712
   Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157
   Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178 8184.2000
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092 8674(00)81908 X
   Mankouri HW, 2007, TRENDS BIOCHEM SCI, V32, P538, DOI 10.1016/j.tibs.2007.09.009
   Miyazaki T, 2004, EMBO J, V23, P939, DOI 10.1038/sj.emboj.7600091
   Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198 65
   Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
   Pascolo E, 2002, J BIOL CHEM, V277, P15566, DOI 10.1074/jbc.M201266200
   Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862 3875.2001
   Raynard S, 2008, J BIOL CHEM, V283, P15701, DOI 10.1074/jbc.M802127200
   Saharia A, 2009, ONCOGENE, V28, P1162, DOI 10.1038/onc.2008.458
   Sanders RP, 2004, J CLIN ONCOL, V22, P3790, DOI 10.1200/JCO.2004.03.043
   Shay JW, 2000, NAT REV MOL CELL BIO, V1, P72, DOI 10.1038/35036093
   Smith CC, 2006, J GENE MED, V8, P175, DOI 10.1002/jgm.827
   Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960 9822(02)01179 X
   Sotillo Piñeiro E, 2004, PEDIATR RES, V55, P231, DOI 10.1203/01.PDR.0000102455.36737.3C
   Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097 2765(03)00269 7
   Tabori U, 2007, CANCER INVEST, V25, P197, DOI 10.1080/07357900701208683
   Terasaki T, 2004, ONCOL REP, V11, P1307
   Ulaner GA, 2003, CANCER RES, V63, P1759
   Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297 498
   Wu GK, 2003, CANCER RES, V63, P2589
   Xu ZX, 2005, MOL CELL, V17, P721, DOI 10.1016/j.molcel.2005.02.014
   Yu ST, 2009, INT J ONCOL, V35, P329, DOI 10.3892/ijo_00000344
   Zeng SC, 2009, NAT CELL BIOL, V11, P616, DOI 10.1038/ncb1867
NR 45
TC 16
Z9 19
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV DEC
PY 2011
VL 2
IS 6
BP 1327
EP 1332
DI 10.3892/ol.2011.403
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 826YF
UT WOS:000295390800052
PM 22848311
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pabst, AM
   Krüger, M
   Ziebart, T
   Jacobs, C
   Walter, C
AF Pabst, A. M.
   Krueger, M.
   Ziebart, T.
   Jacobs, C.
   Walter, C.
TI Isoprenoid geranylgeraniol: the influence on cell characteristics of
   endothelial progenitor cells after bisphosphonate therapy in vitro
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Endothelial progenitor cells; EPC; Bisphosphonate; Geranylgeraniol;
   Bisphosphonate associated osteonecrosis of the jaws
ID PROSTATE CANCER CELLS; MEVALONATE PATHWAY; INDUCED OSTEONECROSIS;
   HYPERBARIC OXYGEN; JAW; NEOVASCULARIZATION; APOPTOSIS; FIBROBLASTS; RAS
AB Geranylgeraniol (GGOH) has been reported as a potential treatment option for bisphosphonate associated osteonecrosis of the jaws (BP ONJ). The aim of this study was to analyze the effects of GGOH on endothelial progenitor cells (EPC) after bisphosphonate treatment in vitro.
   EPC were incubated with different nitrogen (N BPs: ibandronate, pamidronate, zoledronate) and a non nitrogen containing bisphosphonates (NN BP: clodronate) with and without GGOH. Cell viability was measured by MTT and PrestoBlue assay. Migration ability was analyzed with a Boyden and Scratch assay. Apoptosis rates were determined by colony forming, Tunel and ToxiLight assays.
   Negative effects of N BPs on EPC were shown in all tests without GGOH. The substitution of GGOH demonstrated significantly increased cell viability (MTT: p each N BP a parts per thousand currency sign0.004; PrestoBlue: p each N BP < 0.001) and migration ability (Boyden: p each N BP < 0.001; Scratch: p each N BP < 0.001). Concerning the apoptosis rates, increased EPC colony densities (p each N BP a parts per thousand currency sign0.009), decreased numbers of apoptotic cells in the Tunel assay (p each N BP < 0.001), and a decreased adenylate kinase release in the ToxiLight assay (p each N BP a parts per thousand currency sign0.03) were observed. For the clodronate treated cells, no significant differences could be detected with or without GGOH in any assay (p each N BP/NN BP > 0.05).
   GGOH cell treatment reversed the negative effects of bisphosphonates on EPC.
   These findings support the hypothesis that systemic or local GGOH treatment might lead to new therapeutic strategies for BP ONJ.
C1 [Pabst, A. M.; Krueger, M.; Ziebart, T.; Walter, C.] Univ Med Ctr Mainz, Dept Oral & Maxillofacial Surg, D 55131 Mainz, Germany.
   [Jacobs, C.] Univ Med Ctr Mainz, Dept Orthodont, D 55131 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz
RP Walter, C (通讯作者)，Univ Med Ctr Mainz, Dept Oral & Maxillofacial Surg, Augustuspl 2, D 55131 Mainz, Germany.
EM christian.walter@unimedizin mainz.de
RI Ziebart, Thomas/C 7048 2017; Jacobs, Collin/KMY 3514 2024
OI Ziebart, Thomas/0000 0001 8504 4958; Ziebart, Thomas/0000 0003 3296 7630
FU Roche; Riemser; Novartis
FX The authors declare that there is no conflict of interest. Christian
   Walter has received speaker fees from Roche and Riemser and funding from
   Novartis for a different study.
CR Aicher A, 2008, CIRC RES, V103, P796, DOI 10.1161/CIRCRESAHA.107.172718
   Allegra A, 2007, HEMATOL ONCOL, V25, P164, DOI 10.1002/hon.819
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   Freiberger JJ, 2007, J ORAL MAXIL SURG, V65, P1321, DOI 10.1016/j.joms.2007.03.019
   Freiberger JJ, 2009, J ORAL MAXIL SURG, V67, P96, DOI 10.1016/j.joms.2008.12.003
   Hagelauer N, 2014, CLIN ORAL INVESTIG
   Iguchi K, 2006, CANCER LETT, V237, P223, DOI 10.1016/j.canlet.2005.06.006
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Pabst AM, 2014, CLIN ORAL INVEST, V18, P1015, DOI 10.1007/s00784 013 1060 x
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Shipman CM, 1998, CANCER RES, V58, P5294
   Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Van Poznak C, 2010, BREAST CANCER RES TR, V122, P189, DOI 10.1007/s10549 010 0933 9
   Vescovi P, 2010, LASER MED SCI, V25, P101, DOI 10.1007/s10103 009 0687 y
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Walter C, 2014, CLIN ORAL INVESTIG
   Walter C, 2014, CLIN ORAL INVEST, V18, P385, DOI 10.1007/s00784 013 0974 7
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
   Ziebart T, 2008, CIRC RES, V103, P1327, DOI 10.1161/CIRCRESAHA.108.180463
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 31
TC 10
Z9 11
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD SEP
PY 2015
VL 19
IS 7
BP 1625
EP 1633
DI 10.1007/s00784 014 1394 z
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CP3YV
UT WOS:000359819900009
PM 25589370
DA 2025 08 17
ER

PT J
AU Buduneli, E
   Vardar Sengül, S
   Buduneli, N
   Atilla, G
   Wahlgren, J
   Sorsa, T
AF Buduneli, Eralp
   Vardar Sengul, Saynur
   Buduneli, Nurcan
   Atilla, Gul
   Wahlgren, Jaana
   Sorsa, Timo
TI Matrix metalloproteinases, tissue inhibitor of matrix
   metalloproteinase 1, and laminin 5 γ2 chain immunolocalization in
   gingival tissue of endotoxin induced periodontitis in rats:: Effects of
   low dose doxycycline and alendronate
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE alendronate; bisphosphonates; doxycycline; laminin 5; MMPs; TIMP 1
ID MUCOPERIOSTEAL FLAP SURGERY; ALVEOLAR BONE RESORPTION; DISEASED HUMAN
   GINGIVA; CREVICULAR FLUID; ADULT PERIODONTITIS; PLASMINOGEN ACTIVATOR;
   COLLAGENASE 3 MMP 13; CLINICAL PARAMETERS; MESSENGER RNA; EXPRESSION
AB Background: Matrix metalloproteinases (MMPs) play important roles in tissue destruction mechanisms of periodontitis. MMP 8 and  13 are the major collagenases that act in extracellular matrix degradation in periodontal tissues. MMP 14 is a membrane type MMP, and laminin (Ln) 5 is a basal membrane component. The aim of the present study was to evaluate the effects of doxycycline and alendronate on gingival tissue expression of MMP 8,  13, and  14; tissue inhibitors of MMP (TIMP) 1; and Ln 5 gamma 2 chain in experimental periodontitis induced by Escherichia coli endotoxin (LPS) in rats.
   Methods: Experimental periodontitis was induced by repeated injection of LPS. Forty four adult male Sprague Dawley rats were divided into five study groups: saline control, LPS, LPS + doxycycline, LPS + alendronate, and LPS + doxycycline + alendronate. Doxycycline and alendronate were given as a single agent or as combination therapy during the 7 days of the experimental study period. On day 7, the rats were sacrificed, and the gingival tissues were analyzed immunohistochemically for expression of MMP 8,  13, and  14, Ln 5 gamma 2 chain, and TIMP 1. Alveolar bone loss was evaluated morphometrically under a stereomicroscope. Data were tested statistically by Kruskal Wallis and Mann Whitney tests and Spearman correlation analysis.
   Results: Alveolar bone loss was significantly higher in the LPS, doxycycline, alendronate, and combination groups than in the saline control group (all P < 0.01). MMP 8 expression was significantly higher in the LPS group than in the saline control group (P = 0.001). Individual administration of doxycycline or alendronate significantly decreased the expression of MMP 8 compared to LPS (P = 0.01). Combined drug administration reduced MMP 14 significantly compared to doxycycline (P = 0.004). No significant differences in Ln 5 gamma 2 chain expression were found between the study groups (P > 0.05). MMP 14 significantly correlated with the Ln 5 gamma 2 chain in the LPS + alendronate group (P = 0.04) and with the amount of alveolar bone loss in the LPS + doxycycline + alendronate group (P = 0.03).
   Conclusions: Our findings suggest that alendronate and/or doxycycline may inhibit MMP 8 expression significantly; particularly, their combined administration may provide beneficial effects in periodontal treatment. Moreover, individual administration of alendronate and doxycycline results in significant increases in TIMP I expression in gingiva. However, these effects of combined low dose doxycycline and alendronate on MMPs and TIMP should be verified by clinical human trials before these agents are used in dental practice.
C1 Ege Univ, Sch Dent, Dept Periodontol, TR 35100 Izmir, Turkey.
   Helsinki Univ Hosp, Dept Oral & Maxillofacial Dis, FIN 00170 Helsinki, Finland.
   Univ Helsinki, Inst Dent, FIN 00014 Helsinki, Finland.
C3 Ege University; University of Helsinki; Helsinki University Central
   Hospital; University of Helsinki
RP Buduneli, E (通讯作者)，Ege Univ, Sch Dent, Dept Periodontol, TR 35100 Izmir, Turkey.
EM eralp.buduneli@ege.edu.tr
RI Hagstrom, jaana/G 1468 2018; Atilla, F.Gül/Q 2157 2019; Hagström,
   Jaana/G 1468 2018; Buduneli, Nurcan/F 6869 2013
OI Hagstrom, jaana/0000 0001 6079 7881; Buduneli,
   Nurcan/0000 0002 1590 5801; 
CR Achong R, 2003, J PERIODONTOL, V74, P494, DOI 10.1902/jop.2003.74.4.494
   ADAMI S, 1994, BONE MINER, V25, P75, DOI 10.1016/S0169 6009(08)80249 8
   Aiba T, 1996, EUR J ORAL SCI, V104, P562, DOI 10.1111/j.1600 0722.1996.tb00142.x
   Alencar VBM, 2002, J PERIODONTOL, V73, P251, DOI 10.1902/jop.2002.73.3.251
   Atsuta I, 2005, BIOMATERIALS, V26, P6280, DOI 10.1016/j.biomaterials.2005.03.046
   Bezerra MM, 2002, BRAZ J MED BIOL RES, V35, P613, DOI 10.1590/S0100 879X2002000500015
   Binderman I, 2000, J PERIODONTOL, V71, P1236, DOI 10.1902/jop.2000.71.8.1236
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Buduneli E, 2004, J PERIODONTOL, V75, P1516, DOI 10.1902/jop.2004.75.11.1516
   Choi DH, 2004, J PERIODONTAL RES, V39, P20, DOI 10.1111/j.1600 0765.2004.00696.x
   Dahan M, 2001, J CLIN PERIODONTOL, V28, P128, DOI 10.1034/j.1600 051x.2001.028002128.x
   Ejeil AL, 2003, J PERIODONTOL, V74, P188, DOI 10.1902/jop.2003.74.2.188
   Emingil G, 2004, J PERIODONTOL, V75, P1387, DOI 10.1902/jop.2004.75.10.1387
   Emingil G, 2004, J PERIODONTOL, V75, P106, DOI 10.1902/jop.2004.75.1.106
   FULLER K, 1995, J CELL SCI, V108, P2221
   Golub LM, 1997, INFLAMM RES, V46, P310, DOI 10.1007/s000110050193
   Golub LM, 2001, J CLIN PERIODONTOL, V28, P146, DOI 10.1034/j.1600 051x.2001.028002146.x
   Gürses N, 1999, J CLIN PERIODONTOL, V26, P217, DOI 10.1034/j.1600 051X.1999.260404.x
   Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504
   Heikkilä P, 2002, ANTI CANCER DRUG, V13, P245, DOI 10.1097/00001813 200203000 00006
   HOWARD EW, 1991, J BIOL CHEM, V266, P13070
   Ingman T, 1996, J CLIN PERIODONTOL, V23, P1127, DOI 10.1111/j.1600 051X.1996.tb01814.x
   INGMAN T, 1994, SCAND J DENT RES, V102, P342
   Karimbux NY, 1998, J PERIODONTOL, V69, P34, DOI 10.1902/jop.1998.69.1.34
   Kaynak D, 2000, J PERIODONTOL, V71, P790, DOI 10.1902/jop.2000.71.5.790
   Kiili M, 2002, J CLIN PERIODONTOL, V29, P224, DOI 10.1034/j.1600 051x.2002.290308.x
   Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124
   Kornman KS, 1999, CLIN INFECT DIS, V28, P520, DOI 10.1086/515165
   Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615
   Lindy O, 1997, ARTHRITIS RHEUM US, V40, P1391, DOI 10.1002/art.1780400806
   Llavaneras A, 2001, J PERIODONTOL, V72, P1069, DOI 10.1902/jop.2001.72.8.1069
   Mitsuta T, 2002, J PERIODONTOL, V73, P479, DOI 10.1902/jop.2002.73.5.479
   Pirilä E, 2001, BIOCHEM BIOPH RES CO, V287, P766, DOI 10.1006/bbrc.2001.5653
   Prikk K, 2001, J PATHOL, V194, P232, DOI 10.1002/path.849
   PYKE C, 1995, CANCER RES, V55, P4132
   Ramamurthy N S., 1998, Biologic Mechanisms of Tooth Eruption, Resorption and Replacement by Implants, P271
   Ramamurthy NS, 2002, J PERIODONTOL, V73, P726, DOI 10.1902/jop.2002.73.7.726
   REDDY MS, 1995, J PERIODONTOL, V66, P211, DOI 10.1902/jop.1995.66.3.211
   Rocha M, 2001, J PERIODONTOL, V72, P204, DOI 10.1902/jop.2001.72.2.204
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SHOJI K, 1995, J PERIODONTAL RES, V30, P277, DOI 10.1111/j.1600 0765.1995.tb02134.x
   Soell M, 2002, J DENT RES, V81, P174, DOI 10.1177/154405910208100306
   Sorsa T, 1999, ANN NY ACAD SCI, V878, P130, DOI 10.1111/j.1749 6632.1999.tb07679.x
   Sorsa T, 2004, ORAL DIS, V10, P311, DOI 10.1111/j.1601 0825.2004.01038.x
   Teronen O, 1999, ANN NY ACAD SCI, V878, P453, DOI 10.1111/j.1749 6632.1999.tb07702.x
   Tervahartiala T, 2000, J DENT RES, V79, P1969, DOI 10.1177/00220345000790120801
   Uitto VJ, 2003, PERIODONTOL 2000, V31, P77, DOI 10.1034/j.1600 0757.2003.03106.x
   Wahlgren J, 2001, J PATHOL, V194, P217, DOI 10.1002/path.854
   YAFFE A, 1995, J PERIODONTOL, V66, P999, DOI 10.1902/jop.1995.66.11.999
NR 49
TC 33
Z9 37
U1 0
U2 2
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611 2690 USA
SN 0022 3492
J9 J PERIODONTOL
JI J. Periodont.
PD JAN
PY 2007
VL 78
IS 1
BP 127
EP 134
DI 10.1902/jop.2007.050451
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 127GH
UT WOS:000243572900018
PM 29539192
DA 2025 08 17
ER

PT J
AU Gerits, E
   Van der Massen, I
   Vandamme, K
   De Cremer, K
   De Brucker, K
   Thevissen, K
   Cammue, BPA
   Beullens, S
   Fauvart, M
   Verstraeten, N
   Michiels, J
AF Gerits, Evelien
   Van der Massen, Isolde
   Vandamme, Katleen
   De Cremer, Kaat
   De Brucker, Katrijn
   Thevissen, Karin
   Cammue, Bruno P. A.
   Beullens, Serge
   Fauvart, Maarten
   Verstraeten, Natalie
   Michiels, Jan
TI In vitro activity of the antiasthmatic drug zafirlukast against
   the oral pathogens Porphyromonas gingivalis and Streptococcus
   mutans
SO FEMS MICROBIOLOGY LETTERS
LA English
DT Article
DE Zafirlukast; oral pathogens; biofilms; Porphyromonas gingivalis;
   Streptococcus mutans
ID PERIODONTAL PATHOGENS; ANTIBIOTIC RESISTANCE; PERI IMPLANTITIS;
   INFECTIONS; MECHANISMS; BIOFILMS
AB Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the antiasthma drug zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of zafirlukast to be used as a new antibiotic against oral pathogens.
C1 [Gerits, Evelien; Van der Massen, Isolde; De Cremer, Kaat; De Brucker, Katrijn; Thevissen, Karin; Cammue, Bruno P. A.; Beullens, Serge; Fauvart, Maarten; Verstraeten, Natalie; Michiels, Jan] Katholieke Univ Leuven, Ctr Microbial & Plant Genet, Dept Microbial & Mol Syst, B 3001 Leuven, Belgium.
   [Vandamme, Katleen] UZ Leuven, Restorat Dent KU Leuven, BIOMAT, Dept Oral Hlth Sci, B 3000 Leuven, Belgium.
   [De Cremer, Kaat; Cammue, Bruno P. A.] VIB, Dept Plant Syst Biol, B 9052 Ghent, Belgium.
   [Fauvart, Maarten] IMEC, Dept Life Sci Technol, Smart Syst & Emerging Technol Unit, B 3001 Leuven, Belgium.
C3 KU Leuven; KU Leuven; University Hospital Leuven; Flanders Institute for
   Biotechnology (VIB); Interuniversity Microelectronics Centre
RP Michiels, J (通讯作者)，Katholieke Univ Leuven, Ctr Microbial & Plant Genet, Kasteelpk Arenberg 20 Box 2460, B 3001 Leuven, Belgium.
EM Jan.Michiels@kuleuven.be
RI Verstraeten, Natalie/AAH 3963 2019; Fauvart, Maarten/B 1612 2010;
   Michiels, Jan/F 1601 2010; Cammue, Bruno/M 9575 2013; Thevissen,
   Karin/B 7003 2015
OI Verstraeten, Natalie/0000 0002 9548 4647; Fauvart,
   Maarten/0000 0002 6256 9193; Michiels, Jan/0000 0001 5829 0897;
   Beullens, Serge/0009 0008 9685 1323; Thevissen,
   Karin/0000 0003 0275 9072
FU Industrial Research Fund of KU Leuven [IOF/KP/11/007]; Flemish
   government via the Hercules Foundation [ZW09 09]; Research Foundation  
   Flanders FWO [G.0413.10, G.0471.12N, G0B2515N]; Interuniversity
   Attraction Poles Program; Belgian Science Policy Office; European
   Commission [278425]
FX The research leading to these results has received funding from the
   Industrial Research Fund of KU Leuven by the knowledge platform
   IOF/KP/11/007, the Flemish government via the Hercules Foundation
   (project ZW09 09), Research Foundation   Flanders FWO (G.0413.10,
   G.0471.12N, G0B2515N), the Interuniversity Attraction Poles Program
   initiated by the Belgian Science Policy Office and the European
   Commission's Seventh Framework Program (FP7/2007 2013) under the grant
   agreement COATIM (project no 278425).
CR [Anonymous], PERIODONTOL
   Arita Moriok K, 2015, ANTIMICROB AGENTS CH, V59, P633, DOI 10.1128/AAC.04465 14
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Belibasakis GN, 2015, VIRULENCE, V6, P173, DOI 10.1080/21505594.2015.1025191
   Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, pS238, DOI 10.1164/ajrccm.157.6.mar6
   CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431
   Cesa LC, 2013, ACS CHEM BIOL, V8, P1988, DOI 10.1021/cb400356m
   Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a
   Costerton J.W., 1985, BACTERIAL ADHESION, P3, DOI 10.1007/978 1 4615 6514 71
   Dekhuijzen PNR, 2002, CLIN PHARMACOKINET, V41, P105, DOI 10.2165/00003088 200241020 00003
   Delattin N, 2014, J ANTIMICROB CHEMOTH, V69, P1035, DOI 10.1093/jac/dkt449
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167 193.2002
   El Kholy K, 2015, TRENDS ENDOCRIN MET, V26, P315, DOI 10.1016/j.tem.2015.03.001
   Fischbach MA, 2009, SCIENCE, V325, P1089, DOI 10.1126/science.1176667
   Gerits E, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01846 16
   Gerits E, 2016, J ORTHOP RES, V34, P2191, DOI 10.1002/jor.23238
   Grosgogeat B, 1999, BIOMATERIALS, V20, P933, DOI 10.1016/S0142 9612(98)00248 8
   Guo LH, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00328
   HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0
   Janssens JCA, 2008, APPL ENVIRON MICROB, V74, P6639, DOI 10.1128/AEM.01262 08
   Junka AF, 2015, J ORAL MAXIL SURG, V73, P451, DOI 10.1016/j.joms.2014.09.019
   Lee DG, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 10 r90
   Lewis K, 2013, NAT REV DRUG DISCOV, V12, P371, DOI 10.1038/nrd3975
   Liebens V, 2014, BIOORG MED CHEM LETT, V24, P5404, DOI 10.1016/j.bmcl.2014.10.039
   Liebens V, 2014, PATHOG DIS, V71, P39, DOI 10.1111/2049 632X.12174
   Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966 842X(00)01913 2
   Matesanz Pérez P, 2013, J CLIN PERIODONTOL, V40, P227, DOI 10.1111/jcpe.12026
   Mavrogenis AF, 2009, J MUSCULOSKEL NEURON, V9, P61
   Merritt K, 2000, J BIOMED MATER RES, V53, P131, DOI 10.1002/(SICI)1097 4636(2000)53:2<131::AID JBM1>3.0.CO;2 I
   NIKAIDO H, 1985, MICROBIOL REV, V49, P1
   O'Neill AJ, 2010, LETT APPL MICROBIOL, V51, P358, DOI 10.1111/j.1472 765X.2010.02885.x
   Pinault L, 2013, ANTIMICROB AGENTS CH, V57, P2134, DOI 10.1128/AAC.02407 12
   Prathapachandran Jayachandran, 2012, Dent Res J (Isfahan), V9, P516
   Rams TE, 2014, J PERIODONTOL, V85, P160, DOI 10.1902/jop.2013.130142
   Rams TE, 2014, CLIN ORAL IMPLAN RES, V25, P82, DOI 10.1111/clr.12160
   Rangel Vega A, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00282
   Saini Rajiv, 2011, J Nat Sci Biol Med, V2, P71, DOI 10.4103/0976 9668.82317
   Smeets R, 2014, HEAD FACE MED, V10, DOI 10.1186/1746 160X 10 34
   Strydonck DAC, 2012, J CLIN PERIODONTOL, V39, P1042, DOI 10.1111/j.1600 051X.2012.01883.x
   van Winkelhoff AJ, 2000, CLIN ORAL IMPLAN RES, V11, P511, DOI 10.1034/j.1600 0501.2000.011006511.x
   van Winkelhoff AJ, 2012, EUR J ORAL IMPLANTOL, V5, pS43
   Wang HY, 2015, ACTA BIOMATER, V25, P150, DOI 10.1016/j.actbio.2015.07.031
NR 42
TC 22
Z9 23
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0378 1097
EI 1574 6968
J9 FEMS MICROBIOL LETT
JI FEMS Microbiol. Lett.
PD JAN
PY 2017
VL 364
IS 2
AR fnx005
DI 10.1093/femsle/fnx005
PG 7
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA EO9TQ
UT WOS:000397031400008
PM 28087617
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Riveroll, AL
   Skyba Lewin, S
   Lynn, KD
   Mubyeyi, G
   Abd El Aziz, A
   Kibenge, FST
   Kibenge, MJT
   Cohen, AM
   Esparza Gonsalez, B
   McDuffee, L
   Montelpare, WJ
AF Riveroll, Angela L.
   Skyba Lewin, Sabrina
   Lynn, K. Devon
   Mubyeyi, Glady's
   Abd El Aziz, Ahmad
   Kibenge, Frederick S. T.
   Kibenge, Molly J. T.
   Cohen, Alejandro M.
   Esparza Gonsalez, Blanca
   McDuffee, Laurie
   Montelpare, William J.
TI Selection and Validation of Reference Genes for Gene Expression Studies
   in an Equine Adipose Derived Mesenchymal Stem Cell Differentiation Model
   by Proteome Analysis and Reverse Transcriptase Quantitative Real Time
   PCR
SO GENES
LA English
DT Article
DE equine adipose derived mesenchymal stem cell differentiation; reference
   genes; gene expression; protein expression; FABP5; RUNX2; CCDC97; ACTB;
   EPHA2
ID BONE MARROW; TISSUE
AB Adipose derived stem cells (ADSCs) are used in tissue regeneration therapies. The objective of this study is to identify stable reference genes (RGs) for use in gene expression studies in a characterized equine adipose derived mesenchymal stem cell (EADMSC) differentiation model. ADSCs were differentiated into adipocytes (ADs) or osteoblasts (OBs), and the proteomes from these cells were analyzed by liquid chromatography tandem mass spectrometry. Proteins that were stably expressed in all three cells types were identified, and the mRNA expression stabilities for their corresponding genes were validated by RT qPCR. PPP6R1, CCDC97, and then either ACTB or EPHA2 demonstrated the most stable mRNA levels. Normalizing target gene C q data with at least three of these RGs simultaneously, as per MIQE guidelines (PPP6R1 and CCDC97 with either ACTB or EPHA2), resulted in congruent conclusions. FABP5 expression was increased in ADs (5.99 and 8.00 fold, p = 0.00002 and p = 0.0003) and in OBs (5.18 and 5.91 fold, p = 0.0011 and p = 0.0023) relative to ADSCs. RUNX2 expression was slightly higher in ADs relative to ADSCs (1.97 and 2.65 fold, p = 0.04 and p = 0.01), but not in OBs (0.9 and 1.03 fold, p = 0.58 and p = 0.91).
C1 [Riveroll, Angela L.; Montelpare, William J.] Univ Prince Edward Isl, Dept Appl Human Sci, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.
   [Riveroll, Angela L.] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Pathol & Microbiol, Diagnost Serv & Adjunct, Charlottetown, PE C1A 4P3, Canada.
   [Skyba Lewin, Sabrina; Lynn, K. Devon; Mubyeyi, Glady's; Abd El Aziz, Ahmad] Univ Prince Edward Isl, Dept Biol, Charlottetown, PE C1A 4P3, Canada.
   [Kibenge, Frederick S. T.; Kibenge, Molly J. T.] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Pathol & Microbiol, Charlottetown, PE C1A 4P3, Canada.
   [Cohen, Alejandro M.] Dalhousie Univ, Biol Mass Spectrometry Core Facil, Halifax, NS B3H 4R2, Canada.
   [Esparza Gonsalez, Blanca; McDuffee, Laurie] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Hlth Management, Charlottetown, PE C1A 4P3, Canada.
C3 University of Prince Edward Island; University of Prince Edward Island;
   University of Prince Edward Island; University of Prince Edward Island;
   Dalhousie University; University of Prince Edward Island
RP Riveroll, AL (通讯作者)，Univ Prince Edward Isl, Dept Appl Human Sci, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.; Riveroll, AL (通讯作者)，Univ Prince Edward Isl, Atlantic Vet Coll, Dept Pathol & Microbiol, Diagnost Serv & Adjunct, Charlottetown, PE C1A 4P3, Canada.
EM anriveroll@upei.ca
RI ; AbdElAziz, Ahmad/KIW 9391 2024
OI Riveroll, Angela/0000 0002 2338 6626; Abd El Aziz,
   Ahmad/0000 0002 6741 0755; 
CR Abd El Aziz A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23137233
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008 5472.CAN 04 0496
   Bradburn S., 2018, ANAL QPCR RES WITH M
   Bradburn S., 2018, PERFORM PFAFFL METHO
   Bunnell Bruce A., 2008, V456, P155, DOI 10.1007/978 1 59745 245 8_12
   Busato Sebastiano, 2019, Gene, V721S, P100003, DOI 10.1016/j.gene.2018.100003
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589
   Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 2 r19
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Nazari Fatemeh, 2015, Journal of Animal Science and Technology, V57, P18, DOI 10.1186/s40781 015 0050 8
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Radtke CL, 2013, AM J VET RES, V74, P790, DOI 10.2460/ajvr.74.5.790
   Ranera B, 2012, EQUINE VET J, V44, P33, DOI 10.1111/j.2042 3306.2010.00353.x
   Ranera B, 2011, VET IMMUNOL IMMUNOP, V144, P147, DOI 10.1016/j.vetimm.2011.06.033
   Silver N, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471 2199 7 33
   Taylor SC, 2019, TRENDS BIOTECHNOL, V37, P761, DOI 10.1016/j.tibtech.2018.12.002
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Vedula P, 2021, ELIFE, V10, DOI 10.7554/eLife.68712
   Xie FL, 2012, PLANT MOL BIOL, V80, P75, DOI 10.1007/s11103 012 9885 2
   Yamamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167825
   Zhang YY, 2012, MOL ENDOCRINOL, V26, P798, DOI 10.1210/me.2011 1287
   Zhang YWW, 2009, VET IMMUNOL IMMUNOP, V130, P114, DOI 10.1016/j.vetimm.2009.01.012
NR 24
TC 4
Z9 4
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD MAR
PY 2023
VL 14
IS 3
AR 673
DI 10.3390/genes14030673
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA A5QK6
UT WOS:000955663300001
PM 36980946
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Illnait, J
   Terry, W
   Más, R
   Fernández, L
   Carbajal, D
AF Illnait, J
   Terry, W
   Más, R
   Fernández, L
   Carbajal, D
TI Effects of D 002, a product isolated from beeswax, on gastric symptoms
   of patients with osteoarthritis treated with piroxicam:: A pilot study
SO JOURNAL OF MEDICINAL FOOD
LA English
DT Article
DE beeswax alcohols; D 002; non steroidal anti inflammatory drug induced
   gastric disturbances; nonsteroidal anti inflammatory drug related
   adverse effects; piroxicam
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACID RELATED DISORDERS;
   FREE RADICALS; LIPID PEROXIDATION; MUCOSAL INJURY; RHEUMATIC DISEASES;
   PRIMARY ALCOHOLS; RATS; INDOMETHACIN; PATHOGENESIS
AB Non steroidal anti inflammatory drugs (NSAIDs) are indicated for treatment of rheumatoid arthritis and osteoarthritis, but often induce gastric adverse experiences (AE), including gastric ulcers and complications. Inhibitors of proton pump and H 2 antagonists are very effective for duodenal ulcer; meanwhile, cytoprotective drugs are more effective for gastric ulcer. D 002 is a mixture of higher aliphatic alcohols obtained from beeswax, wherein triacontanol is the most abundant. D 002 induces anti ulcer effects through a cytoprotective mechanism, being more effective in protecting against ethanol and NSAID induced ulcers. The present double blind, placebo controlled clinical study was undertaken to investigate the effects of D 002 on gastric symptoms associated to piroxicam use on patients suffering osteoarthritis. Fifty nine patients, all taking piroxicam, 20 mg/day, were randomized to placebo or D 002 (40 or 100 mg/day) for 14 days. The primary efficacy variable was the reduction on the frequency of patients with gastric AE compared with placebo. Pain evolution was investigated to discard any influence on D 002 on the analgesic effect of piroxicam. The frequency of patients treated with D 002, 40 and 100 mg/day, reporting acidity [0 of 18 (0%) and 1 of 21 (4.8%), respectively] was lower (P < .05) than in placebo [6 of 20 (30%)]. Also, the frequency of patients treated with 100 mg/day reporting some gastric AE [5 of 21 (23.8%)] was lower (P < .05) than in placebo [13 of 20 (65.0%)]. The analgesic effect of piroxicam was unaffected with D 002. Treatment was well tolerated. Two patients discontinued from the study because of gastrointestinal AE: one in the placebo group and the other treated with D 002, 40 mg/day. Other three patients discontinued because of other AE: mildly uncontrolled hypertension (one in the placebo group, one treated with D 002, 40 mg/day) and headache (one treated with D 200, 100 mg/day). It is concluded that D 002 could be useful for controlling gastric AE of patients treated with NSAIDs, although further studies with a larger sample size and longer follow up are needed for definitive conclusions.
C1 Natl Ctr Sci Res, Ctr Nat Prod, CNIC, Havana, Cuba.
RP Natl Ctr Sci Res, Ctr Nat Prod, CNIC, Ave 25 & 158,POB 6880, Havana, Cuba.
EM clinica@enet.cu
CR ALEMAN CL, 2000, J APPL TOXICOL, V20, P427
   Aly A, 1997, Nord Med, V112, P195
   Carbajal D, 2000, PHARMACOL RES, V42, P329, DOI 10.1006/phrs.2000.0693
   Carbajal D, 1998, PROSTAG LEUKOTR ESS, V59, P235, DOI 10.1016/S0952 3278(98)90135 1
   CARBAJAL D, 1995, J PHARM PHARMACOL, V47, P731, DOI 10.1111/j.2042 7158.1995.tb06732.x
   Carbajal D, 1996, J PHARM PHARMACOL, V48, P858, DOI 10.1111/j.2042 7158.1996.tb03987.x
   DIMARIO F, 1990, ITAL J GASTROENTEROL, V22, P24
   FELTS W, 1989, J RHEUMATOL, V16, P867
   Gamez R, 1999, REV CNIC, V30, P70
   *GISU, 1994, CURR THER RES CLIN E, V55, P1117
   GLAZIER R, 1995, ARTHRITIS RHEUM, V38, P533, DOI 10.1002/art.1780380412
   HANO O, IN PRESS CURR THER R
   Hawkey CJ, 2000, BEST PRACT RES CL GA, V14, P173, DOI 10.1053/bega.1999.0067
   HOLT S, 1991, SOUTH MED J, V84, P1078, DOI 10.1097/00007611 199109000 00006
   HUDSON N, 1993, GUT, V34, P742, DOI 10.1136/gut.34.6.742
   MAS R, IN PRESS DRUGS FUTUR
   Menéndez R, 2000, BRAZ J MED BIOL RES, V33, P85, DOI 10.1590/S0100 879X2000000100012
   Menendez R., 2001, J Med Food, V4, P71, DOI 10.1089/109662001300341725
   MENENDEZ R, IN PRESS ARCH MED RE
   Molina Vivian, 2001, J Med Food, V4, P79, DOI 10.1089/109662001300341734
   Rastogi L, 1998, PHARMACOL RES, V38, P125, DOI 10.1006/phrs.1998.0343
   Rodeiro I, 1998, DRUG CHEM TOXICOL, V21, P151, DOI 10.3109/01480549809011644
   Rodeiro I, 1999, REV CENIC CIEN BIOL, V30, P73
   Rodeiro I, 1998, REV ESP TOXICOL, V15, P117
   Rodriguez MD, 1998, J APPL TOXICOL, V18, P313, DOI 10.1002/(SICI)1099 1263(1998090)18:5<313::AID JAT513>3.0.CO;2 8
   SALIM AS, 1990, DIGESTION, V47, P24, DOI 10.1159/000200472
   SALIM AS, 1990, J PHARM PHARMACOL, V42, P64, DOI 10.1111/j.2042 7158.1990.tb05354.x
   SALLINGOVA Z, 1994, PHYSIOL RES, V43, P95
   SHIKAWA T, 1990, J CLIN GASTROENTEROL, V12, P65
   Slomiany B L, 1991, J Physiol Pharmacol, V42, P147
   SPENCER CM, 1994, DRUGS, V48, P404, DOI 10.2165/00003495 199448030 00007
   TAKEUCHI K, 1991, DIGESTION, V49, P175, DOI 10.1159/000200718
   TASHIKAZU T, 1997, FREE RADICAL BIO MED, V23, P243
   TASMANJONES C, 1986, SCAND J GASTROEN S22, V19, P1
   VAANANEN PM, 1991, AM J PHYSIOL, V261, pG470, DOI 10.1152/ajpgi.1991.261.3.G470
   WADA K, 1996, LIFE SCI, V59, P295
   WALLACE JL, 1992, TRENDS PHARMACOL SCI, V13, P129, DOI 10.1016/0165 6147(92)90046 9
   WILDE MI, 1994, DRUGS, V48, P91, DOI 10.2165/00003495 199448010 00008
   YOSHIKAWA T, 1989, FREE RADICAL RES COM, V7, P285, DOI 10.3109/10715768909087953
NR 39
TC 10
Z9 12
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096 620X
EI 1557 7600
J9 J MED FOOD
JI J. Med. Food
PD SPR
PY 2005
VL 8
IS 1
BP 63
EP 68
DI 10.1089/jmf.2005.8.63
PG 6
WC Chemistry, Medicinal; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology; Nutrition &
   Dietetics
GA 920AB
UT WOS:000228658100012
DA 2025 08 17
ER

PT J
AU Watanabe, S
   Fujii, H
   Kono, K
   Watanabe, K
   Goto, S
   Nishi, S
AF Watanabe, Shuhei
   Fujii, Hideki
   Kono, Keiji
   Watanabe, Kentaro
   Goto, Shunsuke
   Nishi, Shinichi
TI Influence of oxidative stress on vascular calcification in the setting
   of coexisting chronic kidney disease and diabetes mellitus
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CARDIOVASCULAR DISEASE; HEMODIALYSIS PATIENTS; AORTIC CALCIFICATION;
   CORONARY EVENTS; RENAL FAILURE; PROGRESSION; POPULATION; RISK;
   INFLAMMATION; NEPHROPATHY
AB Vascular calcification (VC) is a common complication in patients with chronic kidney disease (CKD). Particularly, CKD patients with diabetes mellitus (DM) develop severe VC. Specific mechanisms of VC remain unclear; this study aimed to investigate them in the context of coexisting CKD and DM, mainly regarding oxidative stress. Sprague Dawley rats were randomly divided into six groups as follows: control rats (Control), 5/6 nephrectomized rats (CKD), streptozotocin injected rats (DM), 5/6 nephrectomized and streptozotocin injected rats (CKD+DM), CKD+DM rats treated with insulin (CKD+DM+INS), and CKD+DM rats treated with antioxidant apocynin (CKD+DM+APO). At 18 weeks old, the rats were sacrificed for analysis. Compared to the control, DM and CKD groups, calcification of aortas significantly increased in the CKD+DM group. Oxidative stress and osteoblast differentiation related markers considerably increased in the CKD+DM group compared with the other groups. Moreover, apocynin considerably reduced oxidative stress, osteoblast differentiation related markers, and aortic calcification despite high blood glucose levels. Our data indicate that coexisting CKD and DM hasten VC primarily through an increase in oxidative stress; anti oxidative therapy may prevent the VC progression.
C1 [Watanabe, Shuhei; Fujii, Hideki; Kono, Keiji; Watanabe, Kentaro; Goto, Shunsuke; Nishi, Shinichi] Kobe Univ, Grad Sch Med, Div Nephrol, Chuo Ku, 7 5 2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
   [Watanabe, Shuhei; Fujii, Hideki; Kono, Keiji; Watanabe, Kentaro; Goto, Shunsuke; Nishi, Shinichi] Kobe Univ, Grad Sch Med, Kidney Ctr, Chuo Ku, 7 5 2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Kobe University
RP Fujii, H (通讯作者)，Kobe Univ, Grad Sch Med, Div Nephrol, Chuo Ku, 7 5 2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM fhideki@med.kobe u.ac.jp
RI ; Fujii, Hideki/AAF 6610 2020
OI Goto, Shunsuke/0000 0002 7102 2843; Fujii, Hideki/0000 0001 7610 1068
CR Asaba K, 2005, KIDNEY INT, V67, P1890, DOI 10.1111/j.1523 1755.2005.00287.x
   Bayés B, 2006, NEPHROL DIAL TRANSPL, V21, P984, DOI 10.1093/ndt/gfi294
   Beloqui O, 2017, FREE RADICAL RES, V51, P389, DOI 10.1080/10715762.2017.1321745
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Cottone S, 2008, J NEPHROL, V21, P175
   Csiszar A, 2009, ANTIOXID REDOX SIGN, V11, P1683, DOI [10.1089/ars.2008.2401, 10.1089/ARS.2008.2401]
   Detrano R, 2008, NEW ENGL J MED, V358, P1336, DOI 10.1056/NEJMoa072100
   Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203
   Foley RN, 1998, J AM SOC NEPHROL, V9, P23
   Fujii H, 2015, CARDIOVASC DRUG THER, V29, P499, DOI 10.1007/s10557 015 6629 y
   Fujii H, 2009, NEPHROL DIAL TRANSPL, V24, P2089, DOI 10.1093/ndt/gfp007
   García Redondo AB, 2016, PHARMACOL RES, V114, P110, DOI 10.1016/j.phrs.2016.10.015
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goto S, 2013, CLIN EXP NEPHROL, V17, P365, DOI 10.1007/s10157 012 0717 0
   Goto S, 2011, AM J NEPHROL, V34, P281, DOI 10.1159/000330853
   Hanafusa N, 2015, KIDNEY INT SUPPL, V5, P15, DOI 10.1038/kisup.2015.5
   Ishimura E, 2002, DIABETOLOGIA, V45, P1446, DOI 10.1007/s00125 002 0920 8
   Keith DS, 2004, ARCH INTERN MED, V164, P659, DOI 10.1001/archinte.164.6.659
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kono K, 2013, AM J NEPHROL, V37, P167, DOI 10.1159/000346808
   Liu M, 2014, EUR REV MED PHARMACO, V18, P2918
   Luan JJ, 2012, J PHARMACOL SCI, V119, P167, DOI 10.1254/jphs.12002FP
   Manzoor S, 2018, KIDNEY INT REP, V3, P1328, DOI 10.1016/j.ekir.2018.07.011
   Mera K, 2005, HYPERTENS RES, V28, P973, DOI 10.1291/hypres.28.973
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Murdoch CE, 2006, CARDIOVASC RES, V71, P208, DOI 10.1016/j.cardiores.2006.03.016
   Nakai K, 2014, AM J HYPERTENS, V27, P586, DOI 10.1093/ajh/hpt160
   Ohta M, 2010, DIABETIC MED, V27, P1017, DOI 10.1111/j.1464 5491.2010.03049.x
   Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016
   Petronio MS, 2013, MOLECULES, V18, P2821, DOI 10.3390/molecules18032821
   Prabhakar S, 2007, J AM SOC NEPHROL, V18, P2945, DOI 10.1681/ASN.2006080895
   Shah SV, 2007, J AM SOC NEPHROL, V18, P16, DOI 10.1681/ASN.2006050500
   Tada Y, 2013, HORM METAB RES, V45, P267, DOI 10.1055/s 0032 1329965
   Taniwaki H, 2005, NEPHROL DIAL TRANSPL, V20, P2472, DOI 10.1093/ndt/gfi039
   Tepel M, 2003, CIRCULATION, V107, P992, DOI 10.1161/01.CIR.0000050628.11305.30
   Tonelli M, 2012, LANCET, V380, P807, DOI 10.1016/S0140 6736(12)60572 8
   Usberti M, 2002, NEPHRON, V91, P25, DOI 10.1159/000057601
   Wang CC, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882 019 1534 4
   Watanabe R, 2010, CLIN J AM SOC NEPHRO, V5, P189, DOI 10.2215/CJN.06240909
   Wei Qin, 2013, BMC Cardiovasc Disord, V13, P13, DOI 10.1186/1471 2261 13 13
   Yahagi K, 2017, ARTERIOSCL THROM VAS, V37, P191, DOI 10.1161/ATVBAHA.116.306256
   Yamada S, 2017, BONE, V100, P87, DOI 10.1016/j.bone.2016.11.012
   Yamada S, 2012, J BONE MINER RES, V27, P474, DOI 10.1002/jbmr.539
   Yamagishi S, 2011, EXP GERONTOL, V46, P217, DOI 10.1016/j.exger.2010.11.007
NR 44
TC 14
Z9 15
U1 1
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 26
PY 2020
VL 10
IS 1
AR 20708
DI 10.1038/s41598 020 76838 0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA PB4ZB
UT WOS:000596329600064
PM 33244056
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, SS
   Wen, WY
   Prowse, P
   Hamilton, DW
AF Kim, Shawna S.
   Wen, Weiyan
   Prowse, Paul
   Hamilton, Douglas W.
TI Regulation of matrix remodelling phenotype in gingivalfibroblasts by
   substratum topography
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE dental implant; gingival fibroblasts; substratum topography; adhesion
   formation; integrins; titanium
ID FOCAL ADHESION KINASE; CONNECTIVE TISSUE ATTACHMENT; TITANIUM IMPLANT
   SURFACES; EXTRACELLULAR MATRIX; MYOFIBROBLAST DIFFERENTIATION;
   OSTEOBLAST ADHESION; SIGNAL TRANSDUCTION; DENTAL IMPLANTS; CELL MATRIX;
   IN VITRO
AB Gingival connective tissue often has a composition resembling that of scar surrounding dental implant abutments. Increased cell adhesion,  smooth muscle actin ( SMA) expression and increased extracellular matrix deposition are a hallmark of fibrotic cells, but how topographic features influence gingival fibroblast adhesion and adoption of the  SMA positive myofibroblast phenotype associated with scarring is unknown. The purpose of the present study was to demonstrate whether implant topographies that limit adhesion formation would reduce myofibroblast differentiation and extracellular matrix deposition. Human gingival fibroblasts were cultured on PT (smooth) and SLA (roughened) titanium discs for varying time points. At 1 and 2weeks after seeding, incorporation of  SMA into stress fibre bundles and fibronectin deposition was significantly higher on PT than SLA surfaces indicating differentiation of the cells towards a myofibroblast phenotype. Analysis of adhesion formation demonstrated that cells formed larger adhesions and more stable adhesions on PT, with more nascent adhesions observed on SLA. Gene expression analysis identified up regulation of 15 genes at 24hrs on SLA versus PT associated with matrix remodelling. Pharmacological inhibition of Src/FAK signalling in gingival fibroblasts on PT reduced fibronectin deposition and CCN2 expression. We conclude that topographical features that reduce focal adhesion stability could be applied to inhibit myofibroblast differentiation in gingival fibroblasts.
C1 [Kim, Shawna S.; Hamilton, Douglas W.] Univ Western Ontario, Dept Anat & Cell Biol, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada.
   [Wen, Weiyan; Hamilton, Douglas W.] Univ Western Ontario, Div Oral Biol, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada.
   [Prowse, Paul; Hamilton, Douglas W.] Univ Western Ontario, Grad Program Biomed Engn, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)
RP Hamilton, DW (通讯作者)，Univ Western Ontario, Div Oral Biol, Schulich Sch Med & Dent, Dent Sci Bldg, London, ON N6A 5C1, Canada.
EM dhamil2@uwo.ca
RI Hamilton, Douglas/L 8932 2015
FU Natural Sciences and Engineering Research Council of Canada
   [355615 2009]; Canadian Foundation for Innovation Leaders Opportunity
   Fund [18742]; Canadian Institutes of Health Research; Ontario Ministry
   of Research and Innovation
FX The authors extend special thanks to Institut Straumann AG (Basel,
   Switzerland) who supplied all the titanium surfaces used in the study.
   This work was funded by the Natural Sciences and Engineering Research
   Council of Canada (Grant Number: 355615 2009) and the Canadian
   Foundation for Innovation Leaders Opportunity Fund (Grant no: 18742) to
   DWH. SSK is a recipient of a Canadian Institutes of Health Research
   Doctoral Award scholarship. DWH is a recipient of the Ontario Ministry
   of Research and Innovation Early Researcher Award.
CR Berglundh T, 1991, CLIN ORAL IMPLAN RES, V2, P81, DOI 10.1034/j.1600 0501.1991.020206.x
   Biggs MJP, 2009, J BIOMED MATER RES A, V91A, P195, DOI 10.1002/jbm.a.32196
   BRUNETTE DM, 1983, J DENT RES, V62, P1045, DOI 10.1177/00220345830620100701
   Carisey A, 2013, CURR BIOL, V23, P271, DOI 10.1016/j.cub.2013.01.009
   Cassidy JW, 2014, ACTA BIOMATER, V10, P651, DOI 10.1016/j.actbio.2013.11.008
   CHEHROUDI B, 1992, J BIOMED MATER RES, V26, P493, DOI 10.1002/jbm.820260407
   Degidi M, 2013, INT J ORAL MAX IMPL, V28, P1546, DOI 10.11607/jomi.2502
   Elliott CG, 2012, J CELL SCI, V125, P121, DOI 10.1242/jcs.087841
   Furuhashi A, 2012, ODONTOLOGY, V100, P199, DOI 10.1007/s10266 011 0029 y
   Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036
   Giannandrea M, 2014, DIS MODEL MECH, V7, P193, DOI 10.1242/dmm.012062
   Grössner Schreiber B, 2006, CLIN ORAL IMPLAN RES, V17, P736, DOI 10.1111/j.1600 0501.2006.01277.x
   Guo F, 2014, MOL BIOL CELL, V25, P1151, DOI 10.1091/mbc.E13 08 0451
   Guo F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027097
   Hamilton DW, 2006, CALCIFIED TISSUE INT, V78, P314, DOI 10.1007/s00223 005 0238 x
   Hamilton DW, 2007, BIOMATERIALS, V28, P1806, DOI 10.1016/j.biomaterials.2006.11.041
   Hinz B, 2006, EUR J CELL BIOL, V85, P175, DOI 10.1016/j.ejcb.2005.09.004
   Hinz B, 2003, THROMB HAEMOSTASIS, V90, P993, DOI 10.1160/TH03 05 0328
   Hinz Boris, 2009, Curr Rheumatol Rep, V11, P120
   Keselowsky BG, 2007, J BIOMED MATER RES A, V80A, P700, DOI 10.1002/jbm.a.30898
   Khankan R, 2011, INVEST OPHTH VIS SCI, V52, P5068, DOI 10.1167/iovs.11 7191
   Kim H, 2006, INT J ORAL MAX IMPL, V21, P354
   Kokubu E, 2009, J BIOMED MATER RES A, V91A, P663, DOI 10.1002/jbm.a.32273
   Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03 1273rev
   Leask A, 2013, ADV WOUND CARE, V2, P160, DOI 10.1089/wound.2012.0365
   Leask A, 2013, ADV WOUND CARE, V2, P247, DOI 10.1089/wound.2012.0363
   Linkevicius Tomas, 2008, Stomatologija, V10, P27
   Liu SX, 2009, ARTHRITIS RHEUM US, V60, P2817, DOI 10.1002/art.24801
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miron RJ, 2010, BIOMATERIALS, V31, P449, DOI 10.1016/j.biomaterials.2009.09.075
   Moon IS, 1999, J CLIN PERIODONTOL, V26, P658, DOI 10.1034/j.1600 051X.1999.261005.x
   Mustafa K, 2005, BIOMATERIALS, V26, P373, DOI 10.1016/j.biomaterials.2004.02.037
   Nwomeh BC, 1999, J SURG RES, V81, P189, DOI 10.1006/jsre.1998.5495
   Oates CJ, 2011, MATERIALS, V4, P893, DOI 10.3390/ma4050893
   Oates TW, 2005, J PERIODONTOL, V76, P1743, DOI 10.1902/jop.2005.76.10.1743
   Ogawa E, 2000, J MOL CELL CARDIOL, V32, P765, DOI 10.1006/jmcc.2000.1119
   Okuda K, 1998, J ORAL PATHOL MED, V27, P463
   Park JH, 2012, BIOMATERIALS, V33, P7386, DOI 10.1016/j.biomaterials.2012.06.066
   Prowse PDH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058898
   Rustad KC, 2013, DIFFERENTIATION, V86, P87, DOI 10.1016/j.diff.2013.02.003
   Schwartz Z, 2007, J STEROID BIOCHEM, V103, P606, DOI 10.1016/j.jsbmb.2006.12.083
   Schwarz F, 2007, J PERIODONTOL, V78, P2171, DOI 10.1902/jop.2007.070157
   Schwarz F, 2007, CLIN ORAL INVEST, V11, P245, DOI 10.1007/s00784 007 0110 7
   Schwarz F, 2010, J CLIN PERIODONTOL, V37, P551, DOI 10.1111/j.1600 051X.2010.01568.x
   Sculean A, 2014, J CLIN PERIODONTOL, V41, pS6, DOI 10.1111/jcpe.12206
   Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955 0674(98)80035 5
   Shi F, 2011, J CELL SCI, V124, P4039, DOI 10.1242/jcs.087858
   Teo BKK, 2013, ACS NANO, V7, P4785, DOI 10.1021/nn304966z
   Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200
   Walcott S, 2011, BIOPHYS J, V101, P2919, DOI 10.1016/j.bpj.2011.11.010
   Wierzbicka Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670
   Yamano S, 2011, CLIN ORAL IMPLAN RES, V22, P815, DOI 10.1111/j.1600 0501.2010.02059.x
   Yeung SCH, 2008, AUST DENT J, V53, pS39, DOI 10.1111/j.1834 7819.2008.00040.x
   Yokoi H, 2002, AM J PHYSIOL RENAL, V282, pF933, DOI 10.1152/ajprenal.00122.2001
   Zaidel Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416
   Zaidel Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792
NR 56
TC 16
Z9 20
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2015
VL 19
IS 6
BP 1183
EP 1196
DI 10.1111/jcmm.12451
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CJ2RP
UT WOS:000355332500003
PM 25766369
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Song, HS
   Jang, S
   Kang, SC
AF Song, Hae Seong
   Jang, Sunphil
   Kang, Se Chan
TI Bavachalcone from Cullen corylifolium induces apoptosis and
   autophagy in HepG2 cells
SO PHYTOMEDICINE
LA English
DT Article
DE C. corylifolium; Bavachalcone; Apoptosis; Cell cycle; Autophagy
ID PSORALEA CORYLIFOLIA; CANCER; P21; DEATH; INHIBITOR; KINASES; DISEASE;
   MICE; TOR; L.
AB Background: Cullen corylifolium is a plant widely used in traditional Chinese medicine for its stomachic, anthelmintic, and diuretic properties. Bavachalcone, which is known as a component of C. corylifolium has been reported to inhibit osteoclast differentiation. However, the anticancer efficacy and mechanism of C. corylifolium and bavachalcone have not been studied.
   Hypothesis/Purpose: Our aim is to determine whether C. corylifolium has an anticancer effect and to identify the apoptosis and autophagy mechanism of bavachalcone.
   Study design/Method: The anti proliferative activity of C. corylifolium and bavachalcone was measured with MTT assay. Apoptosis was analyzed using Annexin V and propidium iodide staining. The expression of apoptosis, cell cycle and autophagy related gene was evaluated by western blot. Cell cycle stage was investigated with Tali. image based cytometer. Autophagic activity was assessed using monodansylcadaverine (MDC) staining.
   Result: C. corylifolium exhibited potent effect on apoptosis in HepG2 cells. To identify which compound in C. corylifolium is responsible for this effect, we determined the effects of psoralen, psoralidin, bavachalcone, and isobavachalcone on the activity of bid, caspase 3, and PARP. Of all the studied compounds, bavachalcone was the most potent inducer of apoptosis and acted via crosstalk between the intrinsic and extrinsic pathways. In addition, bavachalcone caused cell cycle arrest and decreased the levels of early cell cycle regulatory proteins such as CDK 4 and CDK 2, whereas p21 and p27 levels were increased. We also investigated the extent to which bavachalcone induced autophagy and apoptosis were related. Phosphorylation and expression of Akt and mTOR were decreased, while the LC3. to LC3. ratio was increased in bavachalcone treated cells. These results suggest that bavachalcone has anticancer activity by promoting both autophagy and apoptosis in HepG2 cells.
   Conclusion: C. corylifolium has an anticancer effect. Especially, bavachalcone has excellent anticancer ability among other components of C. corylifolium by inducing apoptosis and autophagy.
C1 [Song, Hae Seong; Kang, Se Chan] Kyung Hee Univ, Coll Life Sci, Dept Oriental Med Biotechnol, 1732 Deogyeong Daero, Yongin 17104, Gyeonggi Do, South Korea.
   [Jang, Sunphil] GENENCELL Co Ltd, Suite 2201,UTOWER,120 Heungdeokjungang Ro, Yongin 17104, Gyeonggi Do, South Korea.
C3 Kyung Hee University
RP Kang, SC (通讯作者)，Kyung Hee Univ, Coll Life Sci, Dept Oriental Med Biotechnol, 1732 Deogyeong Daero, Yongin 17104, Gyeonggi Do, South Korea.
EM sckang@khu.ac.kr
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962 8924(02)00043 0
   Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097 0215(19980130)75:3<347::AID IJC4>3.0.CO;2 2
   Eisenberg Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019
   Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156
   Guo JM, 2005, FOOD CHEM, V91, P287, DOI 10.1016/j.foodchem.2004.04.029
   HARPER JW, 1993, CELL, V75, P805
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Latha PG, 1999, J ETHNOPHARMACOL, V68, P295, DOI 10.1016/S0378 8741(99)00062 8
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Mar W, 2001, ARCH PHARM RES, V24, P211, DOI 10.1007/BF02978259
   Massagué J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Park CK, 2008, BIOCHEM PHARMACOL, V75, P2175, DOI 10.1016/j.bcp.2008.03.007
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092 8674(00)00117 3
   Scovassi AI, 1999, MOL CELL BIOCHEM, V199, P125
   Seo E., 2016, NUTRIENTS, V8
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sugamoto K, 2011, TETRAHEDRON, V67, P5346, DOI 10.1016/j.tet.2011.04.104
   Szliszka E, 2011, PHARMACOL REP, V63, P139, DOI 10.1016/S1734 1140(11)70408 X
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang Y, 2011, EVID BASED COMPL ALT, V2011, DOI DOI 10.1093/ECAM/NEN087
   Wu CY, 2013, FITOTERAPIA, V91, P205, DOI 10.1016/j.fitote.2013.09.005
   XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0
   Zhao LH, 2005, J CHROMATOGR B, V821, P67, DOI 10.1016/j.jchromb.2005.04.008
NR 30
TC 29
Z9 34
U1 1
U2 19
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944 7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD FEB 1
PY 2018
VL 40
BP 37
EP 47
DI 10.1016/j.phymed.2017.12.030
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA FX6GQ
UT WOS:000426182000005
PM 29496173
DA 2025 08 17
ER

PT J
AU Kolodziej, A
   Weselucha Birczynska, A
   Swietek, M
   Horák, D
   Blazewicz, M
AF Kolodziej, Anna
   Weselucha Birczynska, Aleksandra
   Swietek, Malgorzata
   Horak, Daniel
   Blazewicz, Marta
TI A 2D Raman correlation spectroscopy analysis of the polymeric
   nanocomposites with magnetic nanoparticles
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE Magnetic iron oxide nanoparticles (MIONPs); Raman micro spectroscopy; 2D
   correlation Raman spectroscopy; Magnetic nanocomposites
ID OXIDE; RAMAN
AB Magnetic iron oxide nanoparticles (MNPs) possess peculiar physical properties which make them possible to use in a variety of applications such as magnetic resonance imaging (MRI), drug delivery, hyperthermia treatment, as well as bone tissue engineering. The MNPs have been already proven to enhance and accelerate the proliferation of osteoblast cells and new extracellular matrix (ECM) secretion. In the presented study MNPs, that varied in concentration of oleic acid (OA) used during their modification (that resulted in MNPs' coating and surface functionalization by OA), were introduced into a polymeric matrix of PCL. The impact of MNPs on membranes' structure was investigated, and the difference of MNPs production was also taken into consideration. The study included classical materials engineering techniques, such as water contact angle measurements, surface energy testing, and also spectroscopic methods: Raman micro spectroscopy and 2D correlation Raman spectroscopy. The results show that polymeric nu(C=O) vibration and delta(CH2) vibration of OA are structurally significant for magnetic membranes. A clear insight into the interfacial relations of both chemically similar phases (polymer matrix and MNPs' coating) was obtained and it was revealed that CH2 vibrations of OA precedes and induces changes occurring in CH2 of PCL. Also, the interactions of polymer C=O groups with MNPs was observed, but it is a need to be noted that 2D COS signals coming from MNPs' coating are more characteristic. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Kolodziej, Anna; Weselucha Birczynska, Aleksandra] Jagiellonian Univ, Fac Chem, Gronostajowa 2, PL 30387 Krakow, Poland.
   [Swietek, Malgorzata; Horak, Daniel] Czech Acad Sci, Inst Macromol Chem, Prague, Czech Republic.
   [Blazewicz, Marta] AGH Univ Sci & Technol, Krakow, Poland.
C3 Jagiellonian University; Czech Academy of Sciences; Institute of
   Macromolecular Chemistry of the Czech Academy of Sciences; AGH
   University of Krakow
RP Weselucha Birczynska, A (通讯作者)，Jagiellonian Univ, Fac Chem, Gronostajowa 2, PL 30387 Krakow, Poland.
EM birczyns@chemia.uj.edu.pl
RI Kołodziej, Anna/HHN 5167 2022; Świętek, Małgorzata/E 5688 2017; Horak,
   Daniel/G 3487 2014
OI Kolodziej, Anna/0000 0002 5068 5090; 
FU Faculty of Chemistry of the Jagiellonian University in Krakow, Poland;
   EU (European Union) Project [POWR.03.02.00e00 I004/16]; Czech Science
   Foundation [20 07015S]
FX The study was funded by the research part of the subsidy of the Faculty
   of Chemistry of the Jagiellonian University in Krakow, Poland; AK has
   been partly supported by the EU (European Union) Project
   POWR.03.02.00e00 I004/16; Czech partneres were supported by grant No.
   20 07015S of the Czech Science Foundation.
CR Atef E, 2018, AAPS PHARMSCITECH, V19, P114, DOI 10.1208/s12249 017 0800 7
   Chandra S, 2011, ADV DRUG DELIVER REV, V63, P1267, DOI 10.1016/j.addr.2011.06.003
   Chernyshova IV, 2007, PHYS CHEM CHEM PHYS, V9, P1736, DOI 10.1039/b618790k
   Evgenov NV, 2006, NAT MED, V12, P144, DOI 10.1038/nm1316
   Figuerola A, 2010, PHARMACOL RES, V62, P126, DOI 10.1016/j.phrs.2009.12.012
   Generalized Noda, 2000, FOCAL POINT, V54
   Gloria A, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0833
   Huang DM, 2009, BIOMATERIALS, V30, P3645, DOI 10.1016/j.biomaterials.2009.03.032
   Jung YM, 2006, APPL SPECTROSC REV, V41, P515, DOI 10.1080/05704920600845868
   Kalambur VS, 2005, NANOTECHNOLOGY, V16, P1221, DOI 10.1088/0957 4484/16/8/041
   Kalbacova M, 2007, CARBON, V45, P2266, DOI 10.1016/j.carbon.2007.06.025
   Kempe H, 2010, BIOMATERIALS, V31, P9499, DOI 10.1016/j.biomaterials.2010.07.107
   KOENIG JL, 1971, APPL SPECTROSC REV, V4, P233, DOI 10.1080/05704927108082605
   Kolodziej A, 2019, INT J POLYM MATER PO, V68, P44, DOI 10.1080/00914037.2018.1525722
   Li P, 2018, J MATER CHEM B, V6, P4952, DOI 10.1039/c8tb00985f
   Machunsky S, 2009, COLLOID SURFACE A, V348, P186, DOI 10.1016/j.colsurfa.2009.07.014
   Mangual JO, 2011, J MAGN MAGN MATER, V323, P1903, DOI 10.1016/j.jmmm.2011.02.038
   Meng J, 2013, SCI REP UK, V3, DOI 10.1038/srep02655
   NODA I, 1993, APPL SPECTROSC, V47, P1329, DOI 10.1366/0003702934067694
   Numata Y, 2019, J MOL STRUCT, V1185, P200, DOI 10.1016/j.molstruc.2019.02.110
   Panseri S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038710
   Park Y, 2015, FRONT CHEM, V3, DOI [10.3389/fchem.2015.00014, 10.3389/fchern.2015.00014]
   Siesler HW, 2011, INT J POLYM ANAL CH, V16, P519, DOI 10.1080/1023666X.2011.620234
   Sommertune J, 2015, INT J MOL SCI, V16, P19752, DOI 10.3390/ijms160819752
   Swietek M, 2014, ACTA PHYS POL A, V125, P891
   Swietek M., EFFECT POLYM M UNPUB
   Swietek M, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109913
   Weselucha Birczynska A, 2015, ANALYST, V140, P2311, DOI 10.1039/c4an02284j
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Zhang JH, 2014, J MATER CHEM B, V2, P7583, DOI 10.1039/c4tb01063a
   Zhang LJ, 2009, NANO TODAY, V4, P66, DOI 10.1016/j.nantod.2008.10.014
   Zhao SY, 2004, COLLOID SURFACE A, V242, P145, DOI 10.1016/j.colsurfa.2004.04.071
NR 32
TC 5
Z9 5
U1 1
U2 31
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022 2860
EI 1872 8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD SEP 5
PY 2020
VL 1215
AR 128294
DI 10.1016/j.molstruc.2020.128294
PG 7
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA LT7BF
UT WOS:000537221300009
DA 2025 08 17
ER

PT J
AU Broderick, JM
   Kelly, DJ
   Mulhall, KJ
AF Broderick, James M.
   Kelly, Daniel J.
   Mulhall, Kevin J.
TI Optimizing Stem Cell Engineering for Orthopaedic Applications
SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
LA English
DT Article
ID ARTICULAR CARTILAGE; MECHANICAL PROPERTIES; MESENCHYMAL STEM;
   REGENERATION
AB Articular cartilage repair remains a significant challenge in orthopaedic surgery and this has led to increased interest in cell based therapies for cartilage regeneration. Although autologous chondrocyte implantation has been used with reasonable success, there are several disadvantages associated with this technique, such as donor site availability and morbidity, dedifferentiation of the isolated chondrocytes during monolayer expansion, and poor integration of repair tissue into the native cartilage. This has led to a growing interest in the use of mesenchymal stem cells (MSCs) as an alternative cell source. MSCs are easy to isolate and are self renewing, have a high expansion potential, and are capable of differentiating into several cell lineages, including chondrocytes and osteoblasts. Here, we highlight recent advances in the field of tissue engineering that seek to combine MSCs, biomaterial scaffolds, and chondrogenic signals (the so called tissue engineering triad) to create functional cartilage tissue replacements.
C1 [Broderick, James M.; Mulhall, Kevin J.] Mater Misericordiae Univ Hosp, Dublin, Ireland.
   [Kelly, Daniel J.] Univ Dublin Trinity Coll, Trinity Ctr Bioengn, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Kelly, Daniel J.] Univ Dublin Trinity Coll, Dept Mech & Mfg Engn, Sch Engn, Dublin 2, Ireland.
C3 University College Dublin; Mater Misericordiae University Hospital;
   Trinity College Dublin; Trinity College Dublin
RP Broderick, JM (通讯作者)，Mater Misericordiae Univ Hosp, Dublin, Ireland.
OI Kelly, Daniel/0000 0003 4091 0992
CR Coburn JM, 2012, P NATL ACAD SCI USA, V109, P10012, DOI 10.1073/pnas.1121605109
   Huang AH, 2010, EUR CELLS MATER, V19, P72, DOI 10.22203/eCM.v019a08
   Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140 6736(10)60668 X
   Liu YR, 2012, TISSUE ENG PT A, V18, P1531, DOI [10.1089/ten.tea.2011.0575, 10.1089/ten.TEA.2011.0575]
   Nguyen LH, 2011, BIOMATERIALS, V32, P6946, DOI 10.1016/j.biomaterials.2011.06.014
   Nguyen LH, 2011, BIOMATERIALS, V32, P1327, DOI 10.1016/j.biomaterials.2010.10.009
   Re'em T, 2012, ACTA BIOMATER, V8, P3283, DOI 10.1016/j.actbio.2012.05.014
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Thorpe SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060764
   Veronesi F, 2013, J BIOMED MAT RES A
   Ye K, 2013, REGEN MED, V8, P333, DOI [10.2217/rme.13.28, 10.2217/RME.13.28]
NR 11
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067 151X
J9 J AM ACAD ORTHOP SUR
JI J. Am. Acad. Orthop. Surg.
PD JAN
PY 2014
VL 22
IS 1
BP 63
EP 65
DI 10.5435/JAAOS 22 01 63
PG 4
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA CB2IS
UT WOS:000349451200008
PM 24382881
OA Bronze
DA 2025 08 17
ER

PT J
AU Naik, AD
   Woofter, AL
   Skinner, JM
   Abraham, NS
AF Naik, Aanand D.
   Woofter, Aaron L.
   Skinner, Jessica M.
   Abraham, Neena S.
TI Pharmaceutical Company Influence on Nonsteroidal Anti Inflammatory Drug
   Prescribing Behaviors
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID PHYSICIANS; QUALITY; OSTEOARTHRITIS; PRESCRIPTION; STRATEGIES;
   GUIDELINES; INHIBITORS; ADHERENCE; CARE
AB Objectives: To describe the taxonomy of methods used by pharmaceutical companies to influence physicians' nonsteroidal anti inflammatory drug (NSAID) prescribing behaviors and to elicit physicians' perceptions of and counterbalances to these influences.
   Study Design: In depth interviews analyzed using the constant comparative method of qualitative data analysis.
   Methods: Qualitative interviews were conducted with physicians representing various clinical specialties. Interviews were transcribed and coded inductively using grounded theory. Recruitment was stopped at 25 participants after the attainment of thematic saturation, when no new concepts emerged from ongoing analysis of consecutive interviews.
   Results: Physicians described a variety of influences that shaped their NSAID prescribing behaviors, including detailing and direct contact with pharmaceutical representatives, requests from patients inspired by direct to consumer advertisements, and marketing during medical school and residency training. Physicians described practice guidelines, peer reviewed evidence, and opinions of local physician experts as important counterweights to pharmaceutical company influence. Local physician experts interpreted and provided context for new clinical evidence, practice guidelines, and NSAID related marketing.
   Conclusions: The social and communicative strategies used by pharmaceutical companies can be adapted to improve physicians' adoption of guidelines for safer NSAID prescribing. Communicative interactions between local experts and other physicians who prescribe NSAIDs may be the critical target for future interventions to promote safer NSAID prescribing.
C1 [Naik, Aanand D.; Woofter, Aaron L.; Abraham, Neena S.] Michael E DeBakey VA Med Ctr, Res & Dev Ctr Excellence, Gastroenterol Outcomes Geriatr Unit Hlth Serv, Houston, TX USA.
   [Woofter, Aaron L.] Duke Univ, Div Gastroenterol, Raleigh, NC USA.
   [Naik, Aanand D.; Skinner, Jessica M.; Abraham, Neena S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College Medical Hospital; Duke
   University; Baylor College of Medicine
RP Naik, AD (通讯作者)，Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.tmc.edu
RI Naik, Aanand/K 2400 2019
FU Houston Center for Quality of Care & Utilization Studies; Houston
   Veterans Affairs Health Sciences Research and Development Center of
   Excellence [HFP90 020]; National Institute on Aging Career Development
   Award [5K23AG027144]; American Gastroenterological Association
   Foundation Sucampo Association of Specialty Professors Designated
   Research Award in Geriatric Gastroenterology; Department of Veterans
   Affairs [VA IIR 115 05]
FX This study was supported by resources and use of facilities at the
   Houston Center for Quality of Care & Utilization Studies, Houston
   Veterans Affairs Health Sciences Research and Development Center of
   Excellence (HFP90 020). Dr Naik is supported by a National Institute on
   Aging Career Development Award (5K23AG027144). Dr Abraham is supported
   by an American Gastroenterological Association
   Foundation Sucampo Association of Specialty Professors Designated
   Research Award in Geriatric Gastroenterology and by a Merit Review Award
   from the Department of Veterans Affairs (VA IIR 115 05). No funding
   agencies had a role in the design and conduct of the study, analysis and
   interpretation of data, or preparation and approval of the manuscript.
   The views expressed herein are those of the authors and do not
   necessarily reflect those of the Department of Veterans Affairs or
   Baylor College of Medicine.
CR Abraham NS, 2008, AM J GASTROENTEROL, V103, P323, DOI 10.1111/j.1572 0241.2007.01595.x
   Abraham NS, 2005, GASTROENTEROLOGY, V129, P1171, DOI 10.1053/j.gastro.2005.08.003
   [Anonymous], 2001, ANN INTERN MED, V135, P653, DOI 10.7326/0003 4819 135 8_Part_2 200110161 00004
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bradford WD, 2006, HEALTH AFFAIR, V25, P1371, DOI 10.1377/hlthaff.25.5.1371
   Cabana MD, 1999, JAMA J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458
   CARDARELLI R, 2006, BMC FAM PRACT, V7, pE13
   Dai CL, 2005, ARCH INTERN MED, V165, P171, DOI 10.1001/archinte.165.2.171
   Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716
   Goldstein JL, 2006, CLIN GASTROENTEROL H, V4, P1337, DOI 10.1016/j.cgh.2006.08.016
   Gooch K, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.02.015
   Grimshaw J, 2006, J GEN INTERN MED, V21, pS14, DOI 10.1111/j.1525 1497.2006.00357.x
   Hernández Díaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093
   Higashi T, 2004, ANN INTERN MED, V140, P714, DOI 10.7326/0003 4819 140 9 200405040 00011
   Hill Cynthia D, 2002, Manag Care Q, V10, P18
   Klein D, 2006, FAM PRACT, V23, P659, DOI 10.1093/fampra/cml048
   Klein WMP, 2007, CA CANCER J CLIN, V57, P147, DOI 10.3322/canjclin.57.3.147
   Kravitz RL, 2005, JAMA J AM MED ASSOC, V294, P2436
   Kravitz RL, 2005, JAMA J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995
   Laine L, 2001, GASTROENTEROLOGY, V120, P594, DOI 10.1053/gast.2001.21907
   MacLean CH, 2001, ANN INTERN MED, V135, P711, DOI 10.7326/0003 4819 135 8_Part_2 200110161 00010
   McLeod PJ, 1997, CAN MED ASSOC J, V156, P385
   Miles M., 1994, QUALITATIVE DATA ANA, DOI DOI 10.1016/S0272 4944(05)80231 2
   Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003 4819 135 9 200111060 00012
   Scott Ian, 2007, Evid Based Med, V12, P4, DOI 10.1136/ebm.12.1.4
   Silverman D., 2000, DOING QUALITATIVE RE
   Smalley W, 2002, ARTHRITIS RHEUM, V46, P2195, DOI 10.1002/art.10425
   Spence MM, 2005, MED CARE RES REV, V62, P544, DOI 10.1177/1077558705279314
   Steinman MA, 2007, PLOS MED, V4, P743, DOI 10.1371/journal.pmed.0040134
   Strauss E, 1998, CLIN ORTHOP RELAT R, P2
   Weideman RA, 2002, AM J MANAG CARE, V8, P869
NR 31
TC 10
Z9 10
U1 0
U2 8
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088 0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD APR
PY 2009
VL 15
IS 4
BP E9
EP E15
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA 433WS
UT WOS:000265237100007
PM 19341315
DA 2025 08 17
ER

PT J
AU Sarkar, S
   Mahapatra, R
AF Sarkar, S.
   Mahapatra, R.
TI 3D Advanced Micro Chip for Osteoblast Intra Organelle Nanoporation
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Picoseconds Pulsed Electric Field (psPEF); Bi Metallic Electrode;
   Intrigrated Bio Micro Chip; Dense Osteoblast Cell; Intra Organelle;
   Nanoporation; Neural Fuzzy Network
ID STANDARD OPERATING PROCEDURES; GENE ELECTROTRANSFER; ELECTRIC PULSES;
   ELECTROPORATION; NANOSECOND; ELECTROCHEMOTHERAPY; FIELDS
AB A number of Different works have been reported about the effects of electrical pulse on biological cells but till now the information regarding the effect of nano pulse in microfloudic environment on rigid biological cell like osteoblast cell is limited. On the other hand, the nanoporation process itself in these micro floudic devices is relatively complex and more sophisticated. The microfloudic device with complete smart control over the that process as well as cell debris separation and subsequent intracellular cell content analysis have not been reported yet. Therefore, it is expected that integrated devices where combinations of nanoporation, separation and analysis occur will emerge, such as devices with integrated chromatography, electrophoresis or isoelectric focusing steps for separation, and mass spectroscopic, electrochemical and fluorescent methods for analysis. Secondly, the present designs usually require multiple manual steps in order to insert the cells, electroporation them and measure the effects. Until now, no devices have been reported where all of these steps have been integrated in an automated way, preferably with multiple parallel samples, which could greatly enhance the application of micro technological analysis and drug delivery system. This research presents the numerical and experimental study of intra organelle nano poration of multi layer osteoblast cell placed in a 3D non uniform advanced microfloudic chip composed of bi metallic heterogeneous micro electrode under the influences of smart control FPGA based pico pulse generator along with cell trapping and separation and images of intra organelle nanoporation are recognized by neural fuzzy network. The complete design of the micro chip is thoroughly analytically and numerically explained. It is observed that at the time of the micro pulse is applied the cell starts to response but it is unable to penetrate the intra cellular nucleus membrane where as the expected results will come when the Pico pulse is applied on the cell, a number of nana pores are generated on the intra organelle and chemicals are entered into the cell. It is also exposed that the key parameter of nanoporation such as intra organelle voltage, pore radius, pore density, pressure, surface tension and ion uptake are externally controlled by user defined hybrid 3D micro chip and FPGA based pico pulse generator. The mechanism for osteoblast cell trapping and cell separation are logically explain and verified. The application of neural fuzzy network for succesfull reorganization of nanoporative image is completely explore.
C1 [Sarkar, S.] Sikkim Manipal Inst Technol, Dept Appl Elect & Instrumentat, Sikkim 737132, India.
   [Mahapatra, R.] Natl Inst Technol, Dept Elect, Durgapur 713209, India.
   [Mahapatra, R.] Natl Inst Technol, Dept Commun Engn, Durgapur 713209, India.
C3 Sikkim Manipal University; Sikkim Manipal Institute of Technology;
   National Institute of Technology (NIT System); National Institute of
   Technology Durgapur; National Institute of Technology (NIT System);
   National Institute of Technology Durgapur
RP Sarkar, S (通讯作者)，Sikkim Manipal Inst Technol, Dept Appl Elect & Instrumentat, Sikkim 737132, India.
RI Sarkar, Swarup/AAT 7154 2020; Mahapatra, Rajat/MFI 5625 2025
OI Mahapatra, Rajat/0000 0001 6091 8233; sarkar, swarup/0000 0001 7344 0873
CR André FM, 2008, HUM GENE THER, V19, P1261, DOI [10.1089/hum.2008.060, 10.1089/hgt.2008.060]
   Beebe S. J., 2005, CELL BIOL, V22, P785
   Beebe SJ, 2005, J BIOMED BIOTECHNOL, P297, DOI 10.1155/JBB.2005.297
   Berenger JP, 1996, J COMPUT PHYS, V127, P363, DOI 10.1006/jcph.1996.0181
   Bowman AM, 2010, J MEMBRANE BIOL, V236, P15, DOI 10.1007/s00232 010 9269 y
   Buescher E. S., 2010, PLASMA SCI IEEE T, V32, P1563
   Dalmay, 2010, SENS ACTUAT A
   Dalmay C., 2011, BIOSENS BIOELECTRON, V26, P12
   El Amari S, 2010, IEEE PHOTONIC TECH L, V22, P1577, DOI 10.1109/LPT.2010.2073458
   Foster KR, 2000, IEEE T PLASMA SCI, V28, P15, DOI 10.1109/27.842819
   Gehl J, 1998, ANTI CANCER DRUG, V9, P319, DOI 10.1097/00001813 199804000 00005
   Gothelf A, 2010, CURR GENE THER, V10, P287, DOI 10.2174/156652310791823443
   GROSSE C, 1992, BIOPHYS J, V63, P1632, DOI 10.1016/S0006 3495(92)81740 X
   Heller LC, 2006, HUM GENE THER, V17, P890, DOI 10.1089/hum.2006.17.890
   Huang Y, 2001, SENSOR ACTUAT A PHYS, V89, P242, DOI 10.1016/S0924 4247(00)00557 4
   Ibey BL, 2009, BIOELECTROMAGNETICS, V30, P92, DOI 10.1002/bem.20451
   Kenaan M, 2011, IEEE T BIO MED ENG, V58, P207, DOI 10.1109/TBME.2010.2081670
   Kotnik T, 1998, BIOELECTROCH BIOENER, V45, P3, DOI 10.1016/S0302 4598(97)00093 7
   Kotnik T, 2000, BIOELECTROMAGNETICS, V21, P385, DOI 10.1002/1521 186X(200007)21:5<385::AID BEM7>3.0.CO;2 F
   Kotnik T, 2000, IEEE T BIO MED ENG, V47, P1074, DOI 10.1109/10.855935
   Kotnik T., 1966, BIOELECTROCH BIOENER, V43, P285
   Krishnaswamy P, 2007, IEEE T DIELECT EL IN, V14, P871, DOI 10.1109/TDEI.2007.4286518
   Labanauskiene J, 2007, BIOELECTROCHEMISTRY, V70, P78, DOI 10.1016/j.bioelechem.2006.03.009
   Le Pioufle B, 2000, MAT SCI ENG C BIO S, V12, P77, DOI 10.1016/S0928 4931(00)00162 4
   Lee WG, 2009, INTEGR BIOL UK, V1, P242, DOI 10.1039/b819201d
   LEVEQUE P, 1992, ELECTRON LETT, V28, P539, DOI 10.1049/el:19920340
   MARSZALEK P, 1990, BIOPHYS J, V58, P1053, DOI 10.1016/S0006 3495(90)82447 4
   Marty M, 2006, EJC SUPPL, V4, P3, DOI 10.1016/j.ejcsup.2006.08.002
   Mir LM, 2006, EJC SUPPL, V4, P14, DOI 10.1016/j.ejcsup.2006.08.003
   MORSE PM, 1953, METHODS THEORETICAL
   Movahed S, 2013, J MEMBRANE BIOL, V246, P151, DOI 10.1007/s00232 012 9515 6
   Sarkar S., 2013, J BIOMATER TISS ENG, V3, P1
   Sarkar S., 2014, INT J COMPUTER APPL, V87, P17
   Sarkar S., 2013, INT J ENG RES DEV, V5, P22
   Sarkar S., 2013, INT J ELECT ELECT EN, V3, P51
   Sarkar S., 2013, EUROPEAN SCI J, V9, P25
   Sarkar S., 2013, INT J ENG RES DEV, V8, P98
   Sarkar S., 2013, INT J COMPUTER APPL, V79
   Sarkar S., 2014, EUROPEAN SC IN PRESS, V10
   TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006 3495(91)82054 9
   Vernier PT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 37
   Vernier PT, 2004, IEEE T PLASMA SCI, V32, P1620, DOI 10.1109/TPS.2004.831754
   Wang SF, 2009, BIOPHYS J, V96, P1640, DOI 10.1016/j.bpj.2008.11.011
   YEE KS, 1966, IEEE T ANTENN PROPAG, VAP14, P302
NR 44
TC 0
Z9 0
U1 0
U2 21
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD MAY
PY 2014
VL 4
IS 5
BP 339
EP 348
DI 10.1166/jbt.2014.1178
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AK9RM
UT WOS:000338764400001
DA 2025 08 17
ER

PT J
AU Glowacka, U
   Magierowski, M
   Sliwowski, Z
   Cieszkowski, J
   Szetela, M
   Wójcik Grzybek, D
   Chmura, A
   Brzozowski, T
   Wallace, JL
   Magierowska, K
AF Glowacka, Urszula
   Magierowski, Marcin
   Sliwowski, Zbigniew
   Cieszkowski, Jakub
   Szetela, Malgorzata
   Wojcik Grzybek, Dagmara
   Chmura, Anna
   Brzozowski, Tomasz
   Wallace, John L.
   Magierowska, Katarzyna
TI Hydrogen Sulfide Releasing Indomethacin Derivative (ATB 344) Prevents
   the Development of Oxidative Gastric Mucosal Injuries
SO ANTIOXIDANTS
LA English
DT Article
DE hydrogen sulfide; non steroidal anti inflammatory drugs; indomethacin;
   ATB 344; gastric oxidative injury
ID ISCHEMIA REPERFUSION; CARBON MONOXIDE; HYPOXIA; CYCLOOXYGENASE 2;
   INFLAMMATION; METABOLISM; NAPROXEN; STRESS; DAMAGE; ULCER
AB Hydrogen sulfide (H2S) emerged recently as an anti oxidative signaling molecule that contributes to gastrointestinal (GI) mucosal defense and repair. Indomethacin belongs to the class of non steroidal anti inflammatory drugs (NSAIDs) and is used as an effective intervention in the treatment of gout  or osteoarthritis related inflammation. However, its clinical use is strongly limited since indomethacin inhibits gastric mucosal prostaglandin (PG) biosynthesis, predisposing to or even inducing ulcerogenesis. The H2S moiety was shown to decrease the GI toxicity of some NSAIDs. However, the GI safety and anti oxidative effect of a novel H2S releasing indomethacin derivative (ATB 344) remain unexplored. Thus, we aimed here to compare the impact of ATB 344 and classic indomethacin on gastric mucosal integrity and their ability to counteract the development of oxidative gastric mucosal injuries. Wistar rats were pretreated intragastrically (i.g.) with vehicle, ATB 344 (7 28 mg/kg i.g.), or indomethacin (5 20 mg/kg i.g.). Next, animals were exposed to microsurgical gastric ischemia reperfusion (I/R). Gastric damage was assessed micro  and macroscopically. The volatile H2S level was assessed in the gastric mucosa using the modified methylene blue method. Serum and gastric mucosal PGE(2) and 8 hydroxyguanozine (8 OHG) concentrations were evaluated by ELISA. Molecular alterations for gastric mucosal barrier specific targets such as cyclooxygenase 1 (COX) 1, COX 2, heme oxygenase 1 (HMOX) 1, HMOX 2, superoxide dismutase 1 (SOD) 1, SOD 2, hypoxia inducible factor (HIF) 1 alpha, xanthine oxidase (XDH), suppressor of cytokine signaling 3 (SOCS3), CCAAT enhancer binding protein (C/EBP), annexin A1 (ANXA1), interleukin 1 beta (IL 1 beta), interleukin 1 receptor type I (IL 1R1), interleukin 1 receptor type II (IL 1R2), inducible nitric oxide synthase (iNOS), tumor necrosis factor receptor 2 (TNFR2), or H2S producing enzymes, cystathionine gamma lyase (CTH), cystathionine beta synthase (CBS), or 3 mercaptopyruvate sulfur transferase (MPST), were assessed at the mRNA level by real time PCR. ATB 344 (7 mg/kg i.g.) reduced the area of gastric I/R injuries in contrast to an equimolar dose of indomethacin. ATB 344 increased gastric H2S production, did not affect gastric mucosal PGE(2) content, prevented RNA oxidation, and maintained or enhanced the expression of oxidation sensitive HMOX 1 and SOD 2 in line with decreased IL 1 beta and XDH. We conclude that due to the H2S releasing ability, i.g., treatment with ATB 344 not only exerts dose dependent GI safety but even enhances gastric mucosal barrier capacity to counteract acute oxidative injury development when applied at a low dose of 7 mg/kg, in contrast to classic indomethacin. ATB 344 (7 mg/kg) inhibited COX activity on a systemic level but did not affect cytoprotective PGE(2) content in the gastric mucosa and, as a result, evoked gastroprotection against oxidative damage.
C1 [Glowacka, Urszula; Magierowski, Marcin; Sliwowski, Zbigniew; Cieszkowski, Jakub; Szetela, Malgorzata; Wojcik Grzybek, Dagmara; Chmura, Anna; Brzozowski, Tomasz; Magierowska, Katarzyna] Jagiellonian Univ Med Coll, Dept Physiol, 16 Grzegorzecka St, PL 31531 Krakow, Poland.
   [Glowacka, Urszula] Jagiellonian Univ Med Coll, Doctoral Sch Med & Hlth Sci, PL 31530 Krakow, Poland.
   [Wallace, John L.] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 1N4, Canada.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University;
   University of Calgary
RP Magierowska, K (通讯作者)，Jagiellonian Univ Med Coll, Dept Physiol, 16 Grzegorzecka St, PL 31531 Krakow, Poland.
EM katarzyna.magierowska@uj.edu.pl
RI Magierowski, Marcin/AFO 9432 2022; Szetela, Małgorzata/MEP 4929 2025;
   Magierowska, Katarzyna/LCE 2970 2024; Szetela, Malgorzata/MEP 4929 2025;
   Glowacka, Urszula/KLD 3817 2024
OI Magierowski, Marcin/0000 0003 0175 5600; Wojcik Grzybek,
   Dagmara/0000 0003 3098 9617; Magierowska, Katarzyna/0000 0002 4866 1102;
   Szetela, Malgorzata/0000 0003 1415 5065; Brzozowski,
   Thomas/0000 0002 5805 0065; Glowacka, Urszula/0000 0002 1552 3117
FU Jagiellonian University Medical College [N41/DBS/000578, N41/DBS/000877,
   N41/DBS/000784, N41/DBS/001140, N41/DBS/000602]
FX This study was supported by the statutory grants for K.M.
   (N41/DBS/000578, N41/DBS/000877) and for M.M. (N41/DBS/000784,
   N41/DBS/001140) received from Jagiellonian University Medical College.
   U.G. received the statutory grant from Jagiellonian University Medical
   College (N41/DBS/000602).
CR Bakalarz D, 2021, ACTA PHARM SIN B, V11, P456, DOI 10.1016/j.apsb.2020.08.005
   Bhatia M, 2021, ANTIOXID REDOX SIGN, V34, P1368, DOI 10.1089/ars.2020.8211
   Bibli SI, 2021, CIRCULATION, V143, P935, DOI 10.1161/CIRCULATIONAHA.120.051877
   Brzozowski T, 1999, EUR J PHARMACOL, V385, P47, DOI 10.1016/S0014 2999(99)00681 0
   Brzozowski T, 2000, EUR J PHARMACOL, V398, P147, DOI 10.1016/S0014 2999(00)00287 9
   Cao X, 2019, ANTIOXID REDOX SIGN, V31, P1, DOI 10.1089/ars.2017.7058
   Chan MV, 2013, AM J PHYSIOL GASTR L, V305, pG467, DOI 10.1152/ajpgi.00169.2013
   Chatterjee PK, 2003, KIDNEY INT, V63, P853, DOI 10.1046/j.1523 1755.2003.00802.x
   Chen Y, 2019, EXP THER MED, V17, P2901, DOI 10.3892/etm.2019.7288
   Corrado C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165611
   Corsello T, 2018, ANTIOXIDANTS BASEL, V7, DOI 10.3390/antiox7100129
   Cui J, 2013, EXP THER MED, V5, P689, DOI 10.3892/etm.2012.870
   Danielak A, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.657457
   Deb P.K., 2017, Nonsteroidal AntiInflammatory Drugs, V2, P64
   Domán A, 2023, REDOX BIOL, V60, DOI 10.1016/j.redox.2023.102617
   El Ashmawy NE, 2016, J IMMUNOTOXICOL, V13, P580, DOI 10.3109/1547691X.2016.1142488
   Elsheikh W, 2014, NITRIC OXIDE BIOL CH, V41, P131, DOI 10.1016/j.niox.2014.04.006
   Filipovic MR, 2018, CHEM REV, V118, P377, DOI 10.1021/acs.chemrev.7b00205
   Flannigan KL, 2015, FASEB J, V29, P1591, DOI 10.1096/fj.14 266015
   Flannigan KL, 2014, P NATL ACAD SCI USA, V111, P13559, DOI 10.1073/pnas.1413390111
   Flannigan KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071962
   Flynn JM, 2013, FREE RADICAL BIO MED, V62, P4, DOI 10.1016/j.freeradbiomed.2013.05.027
   Gemici B, 2015, METHOD ENZYMOL, V555, P169, DOI 10.1016/bs.mie.2014.11.034
   Gemici B, 2010, J SURG RES, V161, P126, DOI 10.1016/j.jss.2009.07.018
   Giovinazzo D, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017225118
   Glowacka U, 2022, ANTIOXID REDOX SIGN, V36, P189, DOI 10.1089/ars.2020.8240
   Granger DN, 2015, REDOX BIOL, V6, P524, DOI 10.1016/j.redox.2015.08.020
   Katsouda A, 2022, J EXP MED, V219, DOI 10.1084/jem.20211894
   Kuyrukluyildiz U, 2021, ACTA CIR BRAS, V36, DOI [10.1590/acb360104, 10.1590/ACB360104]
   Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1
   Li QY, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12310
   Li ZW, 2006, IUBMB LIFE, V58, P581, DOI 10.1080/15216540600946456
   Loor G, 2008, CELL DEATH DIFFER, V15, P686, DOI 10.1038/cdd.2008.13
   Lv SY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.681676
   Magierowska K, 2022, J CONTROL RELEASE, V348, P321, DOI 10.1016/j.jconrel.2022.05.051
   Magierowska K, 2019, FREE RADICAL BIO MED, V145, P198, DOI 10.1016/j.freeradbiomed.2019.09.032
   Magierowski M, 2017, J PHYSIOL PHARMACOL, V68, P749
   Magierowski M, 2017, BRIT J PHARMACOL, V174, P3654, DOI 10.1111/bph.13968
   Magierowski M, 2017, MOLECULES, V22, DOI 10.3390/molecules22020295
   Magierowski M, 2016, PHARMACOL RES, V114, P235, DOI 10.1016/j.phrs.2016.11.001
   Mard SA, 2015, BRAZ J PHARM SCI, V51, P637, DOI 10.1590/S1984 82502015000300015
   Martemucci G, 2022, OXYGEN BASEL, V2, P48, DOI 10.3390/oxygen2020006
   Matsui H, 2011, J CLIN BIOCHEM NUTR, V48, P107, DOI 10.3164/jcbn.10 79
   McEvoy L, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.684162
   Nagy P, 2020, ANTIOXID REDOX SIGN, V33, P1174, DOI 10.1089/ars.2020.8077
   Nalamachu S, 2014, POSTGRAD MED, V126, P92, DOI 10.3810/pgm.2014.07.2787
   Olson KR, 2018, BIOCHEM PHARMACOL, V149, P77, DOI 10.1016/j.bcp.2017.12.010
   Palma FR, 2020, ANTIOXID REDOX SIGN, V32, P701, DOI 10.1089/ars.2019.7962
   Panagaki T, 2022, REDOX BIOL, V51, DOI 10.1016/j.redox.2022.102233
   Paul BD, 2015, TRENDS BIOCHEM SCI, V40, P687, DOI 10.1016/j.tibs.2015.08.007
   Paul BD, 2014, NATURE, V509, P96, DOI 10.1038/nature13136
   Pedre B, 2023, NAT CHEM BIOL, V19, P507, DOI 10.1038/s41589 022 01244 8
   Peglow S, 2011, J HEPATO BIL PAN SCI, V18, P137, DOI 10.1007/s00534 010 0328 7
   Polishchuk S, 2022, J PHYSIOL PHARMACOL, V73, DOI 10.26402/jpp.2022.1.07
   Santos SS, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12030647
   Sapalidis Konstantinos, 2013, J Emerg Trauma Shock, V6, P203, DOI 10.4103/0974 2700.115346
   Scheid S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810099
   Schilling D, 2023, CURR OPIN CHEM BIOL, V76, DOI 10.1016/j.cbpa.2023.102368
   Shen F, 2019, MED GAS RES, V9, P88, DOI 10.4103/2045 9912.260650
   Shore R, 2017, WORLD J GASTROENTERO, V23, P426, DOI 10.3748/wjg.v23.i3.426
   Suleyman H, 2010, INFLAMMATION, V33, P224, DOI 10.1007/s10753 009 9176 5
   Szyller J, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6678457
   Takeuchi K, 2012, WORLD J GASTROENTERO, V18, P2147, DOI 10.3748/wjg.v18.i18.2147
   Tan ZL, 2021, J PHYSIOL PHARMACOL, V72, DOI 10.26402/jpp.2021.3.13
   Villar Martínez MD, 2021, HEADACHE, V61, P700, DOI 10.1111/head.14111
   Wallace JL, 2007, FASEB J, V21, P4070, DOI 10.1096/fj.07 8669com
   Wallace JL, 2020, BRIT J PHARMACOL, V177, P769, DOI 10.1111/bph.14641
   Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476 5381.2009.00611.x
   Wisen WP, 2022, FASEB J, V36, DOI 10.1096/fasebj.2022.36.S1.R5443
   Wu DD, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/186908
   Xie ZZ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6043038
   Yang MX, 2022, J PHYSIOL PHARMACOL, V73, DOI 10.26402/jpp.2022.1.08
   Yapca OE, 2013, EURASIAN J MED, V45, P126, DOI 10.5152/eajm.2013.24
   Yoshida T, 2001, CIRCULATION, V103, P1695, DOI 10.1161/01.CIR.103.12.1695
   Zhou P., 2007, Handbook of Neurochemistry and Molecular Neurobiology: Acute Ischemic Injury and Repair in the Nervous System, P33, DOI DOI 10.1007/978 0 387 30383 3_3
   Zivanovic J, 2019, CELL METAB, V30, P1152, DOI 10.1016/j.cmet.2019.10.007
NR 76
TC 5
Z9 6
U1 5
U2 23
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD AUG
PY 2023
VL 12
IS 8
AR 1545
DI 10.3390/antiox12081545
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA Q3YN2
UT WOS:001056908500001
PM 37627540
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hurst, EA
   Pang, LY
   Argyle, DJ
AF Hurst, Emma A.
   Pang, Lisa Y.
   Argyle, David J.
TI The selective cyclooxygenase 2 inhibitor mavacoxib (Trocoxil) exerts
   anti tumour effects in vitro independent of cyclooxygenase 2 expression
   levels
SO VETERINARY AND COMPARATIVE ONCOLOGY
LA English
DT Article
DE canine; comparative oncology; COX 2; COX 2 independent effects;
   mavacoxib
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSITIONAL CELL CARCINOMA;
   INFLAMMATORY MAMMARY CARCINOMA; LUNG CANCER CELLS; PHASE II TRIAL; COX 2
   EXPRESSION; URINARY BLADDER; BREAST CANCER; PROSTAGLANDIN E 2; CANINE
   MODEL
AB The inducible inflammatory enzyme cyclooxygenase 2 (COX 2) and its product prostaglandin E2 (PGE(2)) are prominent tumour promoters, and expression of COX 2 is elevated in a number of tumours of both humans and canines. Targeting COX 2 in cancer is an attractive option because of readily available non steroidal anti inflammatory drugs (NSAIDs), and there is a clear epidemiological link between NSAID use and cancer risk. In this study, we aim to establish the anti tumourigenic effects of the selective, long acting COX 2 inhibitor mavacoxib. We show here that mavacoxib is cytotoxic to a panel of human and canine osteosarcoma, mammary and bladder carcinoma cancer cell lines; that it can induce apoptosis and inhibit the migration of these cells. Interestingly, we establish that mavacoxib can exert these effects independently of elevated COX 2 expression. This study highlights the potential novel use of mavacoxib as a cancer therapeutic, suggesting that mavacoxib may be an effective anti cancer agent independent of tumour COX 2 expression.
C1 [Hurst, Emma A.; Pang, Lisa Y.; Argyle, David J.] Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland.
   [Hurst, Emma A.; Pang, Lisa Y.; Argyle, David J.] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh EH25 9RG, Midlothian, Scotland.
C3 UK Research & Innovation (UKRI); Biotechnology and Biological Sciences
   Research Council (BBSRC); Roslin Institute; University of Edinburgh;
   University of Edinburgh
RP Hurst, EA (通讯作者)，Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland.; Hurst, EA (通讯作者)，Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh EH25 9RG, Midlothian, Scotland.
EM emma.hurst@roslin.ed.ac.uk
OI Hurst, Emma/0000 0002 3061 704X
FU University of Edinburgh
FX University of Edinburgh
CR Adhim Z, 2011, BRIT J CANCER, V105, P393, DOI 10.1038/bjc.2011.262
   Attiga FA, 2000, CANCER RES, V60, P4629
   Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901
   Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013
   Brandao RD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3409
   Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200
   Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723
   Calaluce R, 2000, CANCER EPIDEM BIOMAR, V9, P1287
   Cancedda S, 2015, VET RADIOL ULTRASOUN, V56, P335, DOI 10.1111/vru.12246
   Cekanova M, 2013, CANCER PREV RES, V6, P466, DOI 10.1158/1940 6207.CAPR 12 0358
   Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253
   Che DH, 2017, MOL IMMUNOL, V90, P197, DOI 10.1016/j.molimm.2017.06.018
   Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097 0215(200102)9999:9999<894::AID IJC1146>3.3.CO;2 R
   Chi F, 2016, ONCOTARGETS THER, V9, P2709, DOI 10.2147/OTT.S96197
   Chon E, 2012, VET COMP ONCOL, V10, P184, DOI 10.1111/j.1476 5829.2011.00265.x
   Clària J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054
   Cox SR, 2011, J VET PHARMACOL THER, V34, P1, DOI 10.1111/j.1365 2885.2010.01183.x
   Czachorowski MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045025
   De Monte C, 2015, CURR MED CHEM, V22, P2812, DOI 10.2174/0929867322666150716113501
   Del Prete A, 2011, BIOCHEM MEDICA, V21, P264
   Din FVN, 2010, GUT, V59, P1670, DOI 10.1136/gut.2009.203000
   Doré M, 2003, VET PATHOL, V40, P207, DOI 10.1354/vp.40 2 207
   Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330
   Elmets CA, 2010, JNCI J NATL CANCER I, V102, P1835, DOI 10.1093/jnci/djq442
   ELSE RW, 1982, BRIT J CANCER, V46, P675, DOI 10.1038/bjc.1982.254
   Fabi A, 2008, CANCER CHEMOTH PHARM, V62, P717, DOI 10.1007/s00280 007 0650 1
   Fan XM, 2006, DIGESTION, V73, P75, DOI 10.1159/000092747
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140 6736(07)60747 8
   Fujii R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756 9966 33 40
   Gridelli C, 2007, LANCET ONCOL, V8, P500, DOI 10.1016/S1470 2045(07)70146 8
   Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078 0432.CCR 13 1573
   Gurpinar E, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00181
   Harris RE, 2003, CANCER RES, V63, P6096
   Harris RE, 2000, CANCER RES, V60, P2101
   Henry CJ, 2003, CLIN CANCER RES, V9, P906
   Hida T, 1998, CANCER RES, V58, P3761
   Hong SH, 2011, VET COMP ONCOL, V9, P207, DOI 10.1111/j.1476 5829.2010.00249.x
   Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455
   Jeon YW, 2015, TUMOR BIOL, V36, P6349, DOI 10.1007/s13277 015 3322 5
   KARAYANNOPOULOU M, 2007, REV MED VET, V167, P192
   Kim TaeWon Kim TaeWon, 2013, American Journal of Animal and Veterinary Sciences, V8, P89
   Knapp DW, 2016, BLADDER CANCER, V2, P241, DOI 10.3233/BLC 150044
   Knapp DW, 2000, UROL ONCOL, V5, P47, DOI 10.1016/S1078 1439(99)00006 X
   KNAPP DW, 1994, J VET INTERN MED, V8, P273, DOI 10.1111/j.1939 1676.1994.tb03232.x
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008 5472.CAN 05 0216
   Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lavalle GE, 2012, IN VIVO, V26, P375
   Leahy KM, 2002, CANCER RES, V62, P625
   Lee EJ, 2007, EXP MOL MED, V39, P469, DOI 10.1038/emm.2007.51
   Lees P, 2014, VET PHARM THER, V38, P1
   Li F, 2010, SIAM J IMAGING SCI, V3, P1, DOI 10.1137/090748421
   Liu YQ, 2014, BMC MED, V12, DOI 10.1186/1741 7015 12 55
   Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Marconato L, 2011, JAVMA J AM VET MED A, V238, P1004, DOI 10.2460/javma.238.8.1004
   Masferrer JL, 2000, CANCER RES, V60, P1306
   Mazhar D, 2006, BRIT J CANCER, V94, P346, DOI 10.1038/sj.bjc.6602942
   Millanta F, 2006, BREAST CANCER RES TR, V98, P115, DOI 10.1007/s10549 005 9138 z
   Mohammed SI, 1999, CANCER RES, V59, P5647
   Mohammed SI, 2002, CANCER RES, V62, P356
   Monnier Yan, 2005, Current Drug Targets   Inflammation and Allergy, V4, P31, DOI 10.2174/1568010053622975
   Mullins MN, 2004, J VET INTERN MED, V18, P859, DOI 10.1892/0891 6640(2004)18<859:CEICAO>2.0.CO;2
   Mutsaers AJ, 2002, J AM VET MED ASSOC, V220, P1813, DOI 10.2460/javma.2002.220.1813
   Nantajit Danupon, 2015, J Cancer Res Clin Oncol, V141, P1697, DOI 10.1007/s00432 014 1840 y
   Naruse T, 2006, CARCINOGENESIS, V27, P584, DOI 10.1093/carcin/bgi240
   Nasir K, 2000, AM J VET RES, V61, P478, DOI 10.2460/ajvr.2000.61.478
   Ng K, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/dju345
   Pan MR, 2008, CELL SIGNAL, V20, P1134, DOI 10.1016/j.cellsig.2008.02.004
   Pang LY, 2014, BMC VET RES, V10, DOI 10.1186/s12917 014 0184 9
   Pang Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095635
   Payne Johnson M, 2014, VET REC
   Pérez Herrero E, 2015, EUR J PHARM BIOPHARM, V93, P52, DOI 10.1016/j.ejpb.2015.03.018
   Polton G, 2018, VET COMP ONCOL, V16, P399, DOI 10.1111/vco.12393
   Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448
   Queiroga FL, 2005, ANTICANCER RES, V25, P4269
   Rader JS, 2017, GYNECOL ONCOL, V145, P291, DOI 10.1016/j.ygyno.2017.02.040
   Raposo TP, 2017, VET COMP ONCOL, V15, P655, DOI 10.1111/vco.12209
   Rayburn Elizabeth R, 2009, Mol Cell Pharmacol, V1, P29
   Rodriguez NI, 2008, J PEDIAT HEMATOL ONC, V30, P507, DOI 10.1097/MPH.0b013e31816e238c
   Royals SR, 2005, AM J VET RES, V66, P1961, DOI 10.2460/ajvr.2005.66.1961
   Sagnella SM, 2014, NANOMED NANOTECHNOL, V10, P1131, DOI 10.1016/j.nano.2014.04.012
   Salman MC, 2006, MED HYPOTHESES, V66, P1179, DOI 10.1016/j.mehy.2005.11.044
   Sato A, 2017, J NEURO ONCOL, V132, P231, DOI 10.1007/s11060 017 2380 5
   Schiffmann S, 2008, BIOCHEM PHARMACOL, V76, P179, DOI 10.1016/j.bcp.2008.04.017
   Sheng HM, 1998, CANCER RES, V58, P362
   Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200
   Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400
   Sorenmo K U, 2004, Vet Comp Oncol, V2, P13, DOI 10.1111/j.1476 5810.2004.00035.x
   Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097 0142(20001215)89:12<2637::AID CNCR17>3.0.CO;2 B
   Souza CHD, 2009, CAN VET J, V50, P506
   Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200
   Stolfi C, 2013, INT J MOL SCI, V14, P17972, DOI 10.3390/ijms140917972
   Thun MJ, 2002, JNCI J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336
   TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092 8674(95)90127 2
   Turchanowa L, 2001, EUR J CLIN INVEST, V31, P887, DOI 10.1046/j.1365 2362.2001.00901.x
   Urakawa H, 2009, CLIN ORTHOP RELAT R, V467, P2932, DOI 10.1007/s11999 009 0814 x
   Vidal AC, 2015, CLIN CANCER RES, V21, P756, DOI 10.1158/1078 0432.CCR 14 2235
   Walton MB, 2014, VET REC, V175, DOI 10.1136/vr.102435
   Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008 5472.CAN 03 1945
   Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651
   Wolfesberger B, 2006, RES VET SCI, V80, P308, DOI 10.1016/j.rvsc.2005.07.013
   Wolfesberger B, 2006, J VET PHARMACOL THER, V29, P15, DOI 10.1111/j.1365 2885.2006.00704.x
   Xia JJ, 2010, J INT MED RES, V38, P1294, DOI 10.1177/147323001003800411
   XU L, 2014, CANCER, V6
   Xu XY, 2015, TRENDS MOL MED, V21, P223, DOI 10.1016/j.molmed.2015.01.001
   Yip Schneider MT, 2003, PANCREAS, V27, P337, DOI 10.1097/00006676 200311000 00012
   Yokouchi H, 2014, MOL CLIN ONCOL, V2, P744, DOI 10.3892/mco.2014.319
   Zimmerman MA, 2013, SEMIN RADIAT ONCOL, V23, P288, DOI 10.1016/j.semradonc.2013.05.003
NR 111
TC 23
Z9 24
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1476 5810
EI 1476 5829
J9 VET COMP ONCOL
JI Vet. Comp. Oncol.
PD JUN
PY 2019
VL 17
IS 2
BP 194
EP 207
DI 10.1111/vco.12470
PG 14
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA HU5TD
UT WOS:000465341100009
PM 30767381
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Luo, J
   Deng, ZL
   Luo, X
   Tang, N
   Song, WX
   Chen, J
   Sharff, KA
   Luu, HH
   Haydon, RC
   Kinzler, KW
   Vogelstein, B
   He, TC
AF Luo, Jinyong
   Deng, Zhong Liang
   Luo, Xiaoji
   Tang, Ni
   Song, Wen Xin
   Chen, Jin
   Sharff, Katie A.
   Luu, Hue H.
   Haydon, Rex C.
   Kinzler, Kenneth W.
   Vogelstein, Bert
   He, Tong Chuan
TI A protocol for rapid generation of recombinant adenoviruses using the
   AdEasy system
SO NATURE PROTOCOLS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; CRE MEDIATED EXCISION; HUMAN GENE THERAPY;
   OSTEOBLAST DIFFERENTIATION; EFFICIENT GENERATION; VECTORS; DNA; GENOME;
   TYPE 5; SIGNAL
AB Recombinant adenoviruses provide a versatile system for gene expression studies and therapeutic applications. We have developed an approach that simplifies the generation and production of such viruses called the AdEasy system. A recombinant adenoviral plasmid is generated with a minimum of enzymatic manipulations, employing homologous recombination in bacteria rather than in eukaryotic cells. After transfection of such plasmids into a mammalian packaging cell line, viral production is conveniently followed with the aid of GFP encoded by a gene incorporated into the viral backbone. This system has expedited the process of generating and testing recombinant adenoviruses for a variety of purposes. In this protocol, we describe the practical aspects of using the AdEasy system for generating recombinant adenoviruses. The full protocol usually takes 4 5 weeks to complete.
C1 [Luo, Jinyong; Luo, Xiaoji; Tang, Ni; Chen, Jin; He, Tong Chuan] Chongqing Med Univ, Minist Educ, Key Lab Diag Med, Chongqing 400046, Peoples R China.
   [Luo, Jinyong; Deng, Zhong Liang; Luo, Xiaoji; Tang, Ni; Song, Wen Xin; Chen, Jin; Sharff, Katie A.; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan] Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Deng, Zhong Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Chongqing, Peoples R China.
   [Kinzler, Kenneth W.; Vogelstein, Bert] Kimmel Comprehens Canc Ctr Johns Hopkins, Howard Hughes Med Inst, Baltimore, MD 21231 USA.
   [Kinzler, Kenneth W.; Vogelstein, Bert] Ludwig Ctr Canc Genet & Therapeut, Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA.
C3 Chongqing Medical University; University of Chicago; University of
   Chicago Medical Center; Chongqing Medical University; Johns Hopkins
   University; Johns Hopkins Medicine; Howard Hughes Medical Institute;
   Johns Hopkins University; Johns Hopkins Medicine
RP Vogelstein, B (通讯作者)，Chongqing Med Univ, Minist Educ, Key Lab Diag Med, Chongqing 400046, Peoples R China.
EM vogelbe@jhmi.edu; tche@surgery.bsd.uchicago.edu
RI Tang, Ni/Z 5133 2019; Chen, Jiahao/KPA 0985 2024
OI Tang, Ni/0000 0001 5830 8786; 
CR BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911 5921.1993
   Breyer Benjamin, 2001, Current Gene Therapy, V1, P149, DOI 10.2174/1566523013348689
   Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805 4810.1996
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Fisher KJ, 1996, VIROLOGY, V217, P11, DOI 10.1006/viro.1996.0088
   Graham F L, 1992, Biotechnology, V20, P363
   GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331
   GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022 1317 36 1 59
   HANAHAN D, 1984, MOL CELL BIOL, V4, P302, DOI 10.1128/MCB.4.2.302
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HE TC, 2001, ADENOVIRAL VECTORS C
   IMLER JL, 1995, GENE THER, V2, P263
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   KETNER G, 1994, P NATL ACAD SCI USA, V91, P6186, DOI 10.1073/pnas.91.13.6186
   Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731
   Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944 8960.1996
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   McConnell MJ, 2004, HUM GENE THER, V15, P1022, DOI 10.1089/1043034042431119
   MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0
   Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320
   MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191
   Nadeau I, 2003, BIOTECHNOL ADV, V20, P475, DOI 10.1016/S0734 9750(02)00030 7
   Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Shenk T., 1996, FIELDS VIROLOGY, V2, P2111
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Zeng M, 2001, BIOTECHNIQUES, V31, P260, DOI 10.2144/01312bm04
NR 27
TC 728
Z9 924
U1 2
U2 54
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754 2189
EI 1750 2799
J9 NAT PROTOC
JI Nat. Protoc.
PY 2007
VL 2
IS 5
BP 1236
EP 1247
DI 10.1038/nprot.2007.135
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 262HD
UT WOS:000253138700022
PM 17546019
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, BP
   Li, B
   Gao, ST
   Li, YT
   Cao, R
   Cheng, JY
   Li, RP
   Wang, ER
   Guo, YM
   Zhang, KL
   Liang, J
   Liu, B
AF Zhang, Baoping
   Li, Bo
   Gao, Shuting
   Li, Yiting
   Cao, Rui
   Cheng, Jingyang
   Li, Ruiping
   Wang, Errui
   Guo, Yumeng
   Zhang, Kailiang
   Liang, Jun
   Liu, Bin
TI Y doped TiO2 coating with superior bioactivity and
   antibacterial property prepared via plasma electrolytic oxidation
SO MATERIALS & DESIGN
LA English
DT Article
DE Bioactivity; Antibacterial; Yttrium; Plasma electrolytic oxidation; TiO2
   coating
ID YTTRIUM OXIDE NANOPARTICLES; HYDROXYAPATITE COATINGS; SURFACE
   MODIFICATION; TITANIUM IMPLANTS; DRUG RELEASE; OSTEOBLASTS; ROUGHNESS;
   CELLS; CYTOTOXICITY; MECHANISM
AB To improve the bioactivity and antibacterial properties of implant materials. In this study, the biomedical titanium alloy (Ti 6Al 4V) was covered by yttrium doped titanium dioxide (Y TiO2) coating via a plasma electrolytic oxidation (PEO) method. By changing the concentration of yttrium acetate in the electrolyte, Y TiO2 coating with different mass ratios of yttrium were obtained. The structure morphology and chemical composition of the Y TiO2 coating were systematically characterized. The results indicated that the porous and micro nanostructured Y TiO2 coatings were constructed by the pores smaller than 4 mu m. Definitely yttrium was not only distributed on the surface but also embedded in the coating. Yttrium mainly existed in form of Y2O3 and Y3+ state in prepared TiO2 coating. Element release profiles confirmed that yttrium release slowly from Y TiO2 for 32 days. Cell culture tests demonstrated that Y TiO2 coating exhibited good biocompatibility on osteoblastic precursor cells and fibroblasts cells with increasing doping concentration of yttrium. Bacteriostasis experiments revealed that Y TiO2 coating possess excellent antibacterial property against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). Thus, the prepared Y TiO2 coating with outstanding biocompatibility and antibacte rial capacity provided a preferred strategy for the repair and reconstruction of bone tissues in dentistry and orthopedics. (C) 2020 Published by Elsevier Ltd.
C1 [Zhang, Baoping; Li, Bo; Gao, Shuting; Li, Yiting; Cao, Rui; Cheng, Jingyang; Li, Ruiping; Wang, Errui; Guo, Yumeng; Zhang, Kailiang; Liu, Bin] Lanzhou Univ, Sch Stomatol, Lanzhou 730000, Peoples R China.
   [Li, Bo; Liang, Jun] Chinese Acad Sci, Lanzhou Inst Chem Phys, Lanzhou 730000, Peoples R China.
   [Zhang, Baoping] Lanzhou Univ, Minist Educ, Key Lab Mech Disaster & Environm Western China, Lanzhou 730000, Peoples R China.
   [Zhang, Baoping] Lanzhou Univ, Inst Biomech & Med Engn, Lanzhou 730000, Peoples R China.
C3 Lanzhou University; Chinese Academy of Sciences; Lanzhou Institute of
   Chemical Physics, CAS; Lanzhou University; Lanzhou University
RP Zhang, KL; Liang, J; Liu, B (通讯作者)，Lanzhou Univ, Dept Stomatol, Donggang West Rd 199, Lanzhou 730000, Gansu, Peoples R China.
EM zhangkl@lzu.edu.cn; jliang@licp.cas.cn; binliulzu@163.com
RI zhang, ping/L 3901 2017; 李, 博/LZE 8479 2025; Liang, Jun/E 9091 2010
OI Zhang, Ping/0000 0001 9163 6191; Gao, Shuting/0009 0009 3582 2526; gao,
   shuting/0000 0002 2545 7715; 
FU National Natural Science Foundation of China [81970976, 81773942,
   31670379]; Fundamental Research Funds for the Central Universities
   [lzujbky 2020 cd03]
FX This work is supported by grants from the National Natural Science
   Foundation of China (No. 81970976, Bin Liu), (No. 81773942, Wang Jing),
   and (No. 31670379, Xiaodong Xie) and the Fundamental Research Funds for
   the Central Universities (lzujbky 2020 cd03, Baoping Zhang). The authors
   declare no conflict of interest with this work Z. kailiang, L. jun and
   B. liu: Supervision, Funding acquisition. Z. baoping: Methodology,
   Writing  Review& Editing. L. bo and L. bin: Writing   Original Draft. G.
   shuting and C. rui: Investigation and Formal analysis. C. jingyang and
   G. yumeng: Resources. W. errui and L. ruiping: Resources.
CR Agarwal A, 2010, BIOMATERIALS, V31, P680, DOI 10.1016/j.biomaterials.2009.09.092
   Akin FA, 2001, J BIOMED MATER RES, V57, P588, DOI 10.1002/1097 4636(20011215)57:4<588::AID JBM1206>3.0.CO;2 Y
   Mariano Torres JA, 2018, MATER TRANS, V59, P1915, DOI 10.2320/matertrans.M2018248
   Att W, 2009, BIOMATERIALS, V30, P4268, DOI 10.1016/j.biomaterials.2009.04.048
   Bakhsheshi Rad HR, 2018, MATER DESIGN, V139, P212, DOI 10.1016/j.matdes.2017.10.072
   Brunello G, 2019, MATERIALS, V12, DOI 10.3390/ma12182929
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Campoccia D, 2013, BIOMATERIALS, V34, P8533, DOI 10.1016/j.biomaterials.2013.07.089
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Du XL, 2002, EUR J BIOCHEM, V269, P6082, DOI 10.1046/j.1432 1033.2002.03326.x
   Dunne WM, 2002, CLIN MICROBIOL REV, V15, P155, DOI 10.1128/CMR.15.2.155 166.2002
   Dupraz A, 1999, BIOMATERIALS, V20, P663, DOI 10.1016/S0142 9612(98)00222 1
   Garner JP, 2005, BURNS, V31, P539, DOI 10.1016/j.burns.2005.01.014
   GRISTINA AG, 1989, MED PROG TECHNOL, V14, P205
   Han Y, 2008, ACTA BIOMATER, V4, P1518, DOI 10.1016/j.actbio.2008.03.005
   Hansson S, 1999, J BIOMECH, V32, P829, DOI 10.1016/S0021 9290(99)00058 5
   Harris LG, 2006, INJURY, V37, P3, DOI 10.1016/j.injury.2006.04.003
   Hartle JE, 1996, J BONE MINER RES, V11, P789
   Heo S, 2014, THIN SOLID FILMS, V558, P27, DOI 10.1016/j.tsf.2014.02.025
   Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b
   Hovgaard MB, 2008, J PHYS CHEM B, V112, P8241, DOI 10.1021/jp801103n
   Hu H, 2012, ACTA BIOMATER, V8, P904, DOI 10.1016/j.actbio.2011.09.031
   Hu HJ, 2010, SURF COAT TECH, V204, P3265, DOI 10.1016/j.surfcoat.2010.03.028
   Kannan SK, 2015, B MATER SCI, V38, P945, DOI 10.1007/s12034 015 0927 7
   Li B, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 49941 0
   Li LH, 2004, BIOMATERIALS, V25, P2867, DOI 10.1016/j.biomaterials.2003.09.048
   Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142 9612(98)00144 6
   Liu J, 2005, IPEC: 2005 INTERNATIONAL POWER ENGINEERING CONFERENCE, VOLS 1 AND 2, P47
   Liu P, 2004, J INORG BIOCHEM, V98, P68, DOI 10.1016/j.jinorgbio.2003.08.012
   Liu SM, 2016, APPL SURF SCI, V362, P109, DOI 10.1016/j.apsusc.2015.11.086
   Liu XY, 2004, MAT SCI ENG R, V47, P49, DOI 10.1016/j.mser.2004.11.001
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Olivares Navarrete R, 2008, P NATL ACAD SCI USA, V105, P15767, DOI 10.1073/pnas.0805420105
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2728, DOI 10.1016/j.biomaterials.2009.12.029
   Pegueroles M, 2010, ACTA BIOMATER, V6, P291, DOI 10.1016/j.actbio.2009.07.030
   Pigatto PD, 2009, CLIN ORAL IMPLAN RES, V20, P857, DOI 10.1111/j.1600 0501.2009.01749.x
   QUARLES LD, 1994, J CELL BIOCHEM, V56, P106, DOI 10.1002/jcb.240560115
   Radin S, 1997, BIOMATERIALS, V18, P777, DOI 10.1016/S0142 9612(96)00190 1
   Rao JS, 2016, INT J ELECTROCHEM SC, V11, P2408
   Sato M, 2006, BIOMATERIALS, V27, P2358, DOI 10.1016/j.biomaterials.2005.10.041
   Shah AK, 1999, BIOL CELL, V91, P131, DOI 10.1016/S0248 4900(99)80037 9
   Stigter M, 2004, J CONTROL RELEASE, V99, P127, DOI 10.1016/j.jconrel.2004.06.011
   Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002
   Takebe J, 2000, J BIOMED MATER RES, V51, P398, DOI 10.1002/1097 4636(20000905)51:3<398::AID JBM14>3.0.CO;2 #
   Vasilev K, 2010, NANO LETT, V10, P202, DOI 10.1021/nl903274q
   Wang P, 2018, J MATER CHEM B, V6, P966, DOI 10.1039/c7tb02784b
   Wang Y, 2015, MATER DESIGN, V85, P640, DOI 10.1016/j.matdes.2015.07.086
   Wang YZ, 2014, VACUUM, V107, P28, DOI 10.1016/j.vacuum.2014.03.026
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   Webster TJ, 2002, J BIOMED MATER RES, V59, P312, DOI 10.1002/jbm.1247
   Yamamoto A, 1999, J BIOMED MATER RES, V47, P396, DOI 10.1002/(SICI)1097 4636(19991205)47:3<396::AID JBM15>3.0.CO;2 R
   Yamamoto A, 1998, J BIOMED MATER RES, V39, P331, DOI 10.1002/(SICI)1097 4636(199802)39:2<331::AID JBM22>3.0.CO;2 E
   YAMAMURA K, 1992, J BIOMED MATER RES, V26, P1053, DOI 10.1002/jbm.820260807
   Yang JH, 2011, J ALLOY COMPD, V509, P3606, DOI 10.1016/j.jallcom.2010.12.102
   Yao XH, 2014, APPL SURF SCI, V292, P944, DOI 10.1016/j.apsusc.2013.12.083
   Yao ZQ, 2010, ACTA BIOMATER, V6, P2816, DOI 10.1016/j.actbio.2009.12.053
   Yerokhin AL, 1999, SURF COAT TECH, V122, P73, DOI 10.1016/S0257 8972(99)00441 7
   Yu WZ, 2018, MATER DESIGN, V139, P351, DOI 10.1016/j.matdes.2017.11.018
   Zhang BP, 2016, SCI REP UK, V6, DOI 10.1038/srep35131
   Zhang BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112624
   Zhang KL, 2019, J MECH BEHAV BIOMED, V100, DOI 10.1016/j.jmbbm.2019.07.021
   Zhang QJ, 2016, ACS SUSTAIN CHEM ENG, V4, P1794, DOI 10.1021/acssuschemeng.5b01783
   Zhao G, 2007, BIOMATERIALS, V28, P2821, DOI 10.1016/j.biomaterials.2007.02.024
   Zhao LZ, 2009, J BIOMED MATER RES B, V91B, P470, DOI 10.1002/jbm.b.31463
NR 64
TC 39
Z9 40
U1 4
U2 67
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD AUG
PY 2020
VL 192
AR 108758
DI 10.1016/j.matdes.2020.108758
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA NN4TT
UT WOS:000568783400012
OA gold
DA 2025 08 17
ER

PT J
AU Chen, XA
   Zhang, LJ
   He, ZJ
   Wang, WW
   Xu, B
   Zhong, Q
   Shuai, XT
   Yang, LQ
   Deng, YB
AF Chen, Xiao Ai
   Zhang, Li Jun
   He, Zhi Jie
   Wang, Wei Wei
   Xu, Bo
   Zhong, Qian
   Shuai, Xin Tao
   Yang, Li Qun
   Deng, Yu Bin
TI Plasmid encapsulated polyethylene glycol grafted polyethylenimine
   nanoparticles for gene delivery into rat mesenchymal stem cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE stem cells; gene delivery; nanoparticles; atomic force microscopy
ID MARROW STROMAL CELLS; HUMAN BONE MARROW; CLINICAL APPLICATION;
   THERAPEUTIC BENEFIT; CEREBRAL ISCHEMIA; CATIONIC POLYMERS; IN VITRO;
   PEI; DNA; MIGRATION
AB Background: Mesenchymal stem cell transplantation is a promising method in regenerative medicine. Gene modified mesenchymal stem cells possess superior characteristics of specific tissue differentiation, resistance to apoptosis, and directional migration. Viral vectors have the disadvantages of potential immunogenicity, carcinogenicity, and complicated synthetic procedures. Polyethylene glycol grafted polyethylenimine (PEG PEI) holds promise in gene delivery because of easy preparation and potentially targeting modification.
   Methods: A PEG8k PEI25k graft copolymer was synthesized. Agarose gel retardation assay and dynamic light scattering were used to determine the properties of the nanoparticles. MTT reduction, wound and healing, and differentiation assays were used to test the cytobiological characteristics of rat mesenchymal stem cells, fluorescence microscopy and flow cytometry were used to determine transfection efficiency, and atomic force microscopy was used to evaluate the interaction between PEG PEI/plasmid nanoparticles and mesenchymal stem cells.
   Results: After incubation with the copolymer, the bionomics of mesenchymal stem cells showed no significant change. The mesenchymal stem cells still maintained high viability, resettled the wound area, and differentiated into adipocytes and osteoblasts. The PEG PEI completely packed plasmid and condensed plasmid into stable nanoparticles of 100 150 nm diameter. After optimizing the N/P ratio, the PEG PEI/plasmid microcapsules delivered plasmid into mesenchymal stem cells and obtained an optimum transfection efficiency of 15% 21%, which was higher than for cationic liposomes.
   Conclusion: These data indicate that PEG PEI is a valid gene delivery agent and has better transfection efficiency than cationic liposomes in mesenchymal stem cells.
C1 [Chen, Xiao Ai; Xu, Bo; Zhong, Qian; Deng, Yu Bin] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhang, Li Jun] Futian Affiliated Hosp, Guangdong Med Coll, Shenzhen, Peoples R China.
   [He, Zhi Jie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China.
   [Wang, Wei Wei; Shuai, Xin Tao; Yang, Li Qun] Sun Yat Sen Univ, Sch Chem & Chem Engn, Inst Polymer Sci, BME Ctr,State Key Lab Optoelect Mat & Technol, Guangzhou 510275, Guangdong, Peoples R China.
   [Chen, Xiao Ai] Yunnan Canc Hosp, Affiliated Hosp 3, Kunming Med Coll, Kunming, Peoples R China.
C3 Sun Yat Sen University; Guangdong Medical University; Sun Yat Sen
   University; Sun Yat Sen University; Kunming Medical University
RP Deng, YB (通讯作者)，Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510275, Guangdong, Peoples R China.
EM dengyub@mail.sysu.edu.cn
RI Wang, Weilong/K 1440 2019; Shuai, Xintao/C 5819 2008
FU Sun Yat sen University [50000 3126203]; National Natural Science
   Foundation of China; Science and Technology Planning Project of
   Guangdong Province, China
FX This work was supported by the Sun Yat sen University Postgraduates'
   Training Project, the Yi xian Innovators' Training Project by
   Outstanding Mentor(s) at Sun Yat sen University (NO:50000 3126203), the
   Graduates' internationally cooperated research project of Sun Yat sen
   University (2008 2009), the National Natural Science Foundation of
   China, and the Science and Technology Planning Project of Guangdong
   Province, China.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   AHN HH, 2008, COLLOID SURF A, P313
   Ahn HH, 2008, BIOMATERIALS, V29, P2415, DOI 10.1016/j.biomaterials.2008.02.006
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908
   Banerjee P, 2006, BIOCONJUGATE CHEM, V17, P125, DOI 10.1021/bc050083e
   Bivalacqua TJ, 2007, AM J PHYSIOL HEART C, V292, pH1278, DOI 10.1152/ajpheart.00685.2006
   Breen A, 2006, J BIOMED MATER RES A, V78A, P702, DOI 10.1002/jbm.a.30735
   Brunot C, 2007, BIOMATERIALS, V28, P632, DOI 10.1016/j.biomaterials.2006.09.026
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022 510X(01)00557 3
   Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374
   Dai F, 2006, TISSUE ENG, V12, P2583, DOI 10.1089/ten.2006.12.2583
   FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385
   Farrell LL, 2007, EUR J PHARM BIOPHARM, V65, P388, DOI 10.1016/j.ejpb.2006.11.026
   Gou SM, 2010, CELLS TISSUES ORGANS, V191, P185, DOI 10.1159/000240246
   Hong SP, 2006, BIOCONJUGATE CHEM, V17, P728, DOI 10.1021/bc060077y
   Kim MS, 2006, BIOORG MED CHEM LETT, V16, P5572, DOI 10.1016/j.bmcl.2006.08.030
   Kircheis R, 2001, ADV DRUG DELIVER REV, V53, P341, DOI 10.1016/S0169 409X(01)00202 2
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514
   Lin Z, 2006, TISSUE ENG, V12, P1971, DOI 10.1089/ten.2006.12.1971
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169 409X(02)00046 7
   Nguyen HK, 2000, GENE THER, V7, P126, DOI 10.1038/sj.gt.3301052
   Nimesh S, 2006, INT J PHARMACEUT, V320, P143, DOI 10.1016/j.ijpharm.2006.03.050
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Palmer JA, 2000, J VIROL, V74, P5604, DOI 10.1128/JVI.74.12.5604 5618.2000
   Park J, 2003, GENE THER, V10, P1089, DOI 10.1038/sj.gt.3301960
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Pochampally RR, 2005, GENE THER, V12, P1119, DOI 10.1038/sj.gt.3302514
   Settleman J, 2004, MOL CELL, V14, P148, DOI 10.1016/S1097 2765(04)00207 2
   Su CJ, 2007, LANGMUIR, V23, P975, DOI 10.1021/la0624642
   Thomas CH, 2002, P NATL ACAD SCI USA, V99, P1972, DOI 10.1073/pnas.032668799
   Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068
   Weiss SI, 2006, BIOMATERIALS, V27, P2302, DOI 10.1016/j.biomaterials.2005.11.011
   Wen YT, 2010, J BIOMAT SCI POLYM E, V21, P1103, DOI 10.1163/092050609X12459295750316
   Wu Y, 2010, INT J NANOMED, V5, P129
   Zhu WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005 0121
NR 40
TC 14
Z9 16
U1 0
U2 33
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2011
VL 6
DI 10.2147/IJN.S17155
PG 11
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA 752SQ
UT WOS:000289714800001
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tandon, A
   Sharma, A
   Rodier, JT
   Klibanov, AM
   Rieger, FG
   Mohan, RR
AF Tandon, Ashish
   Sharma, Ajay
   Rodier, Jason T.
   Klibanov, Alexander M.
   Rieger, Frank G.
   Mohan, Rajiv R.
TI BMP7 Gene Transfer via Gold Nanoparticles into Stroma Inhibits Corneal
   Fibrosis In Vivo
SO PLOS ONE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; CHRONIC KIDNEY DISEASE; MITOMYCIN C;
   PHOTOREFRACTIVE KERATECTOMY; MYOFIBROBLAST DIFFERENTIATION; PTERYGIUM
   SURGERY; HAZE; EXPRESSION; CELLS; PROLIFERATION
AB This study examined the effects of BMP7 gene transfer on corneal wound healing and fibrosis inhibition in vivo using a rabbit model. Corneal haze in rabbits was produced with the excimer laser performing  9 diopters photorefractive keratectomy. BMP7 gene was introduced into rabbit keratocytes by polyethylimine conjugated gold nanoparticles (PEI2 GNPs) transfection solution single 5 minute topical application on the eye. Corneal haze and ocular health in live animals was gauged with stereo and slit lamp biomicroscopy. The levels of fibrosis [alpha smooth muscle actin (alpha SMA), F actin and fibronectin], immune reaction (CD11b and F4/80), keratocyte apoptosis (TUNEL), calcification (alizarin red, vonKossa and osteocalcin), and delivered BMP7 gene expression in corneal tissues were quantified with immunofluorescence, western blotting and/or real time PCR. Human corneal fibroblasts (HCF) and in vitro experiments were used to characterize the molecular mechanism mediating BMP7's anti fibrosis effects. PEI2 GNPs showed substantial BMP7 gene delivery into rabbit keratocytes in vivo (2x10(4) gene copies/mu g DNA). Localized BMP7 gene therapy showed a significant corneal haze decrease (1.68 +/  0.31 compared to 3.2 +/  0.43 in control corneas; p<0.05) in Fantes grading scale. Immunostaining and immunoblot analyses detected significantly reduced levels of alpha SMA (46 +/  5% p<0.001) and fibronectin proteins (48 +/  5% p<0.01). TUNEL, CD11b, and F4/80 assays revealed that BMP7 gene therapy is nonimmunogenic and nontoxic for the cornea. Furthermore, alizarin red, vonKossa and osteocalcin analyses revealed that localized PEI2 GNP mediated BMP7 gene transfer in rabbit cornea does not cause calcification or osteoblast recruitment. Immunofluorescence of BMP7 transefected HCFs showed significantly increased pSmad 1/5/8 nuclear localization (>88%; p<0.0001), and immunoblotting of BMP7 transefected HCFs grown in the presence of TGF beta demonstrated significantly enhanced pSmad 1/5/8 (95%; p<0.001) and Smad6 (53%, p<0.001), and decreased alpha SMA (78%; p<0.001) protein levels. These results suggest that localized BMP7 gene delivery in rabbit cornea modulates wound healing and inhibits fibrosis in vivo by counter balancing TGF beta 1 mediated profibrotic Smad signaling.
C1 [Tandon, Ashish; Sharma, Ajay; Rodier, Jason T.; Rieger, Frank G.; Mohan, Rajiv R.] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA.
   [Tandon, Ashish; Sharma, Ajay; Rodier, Jason T.; Mohan, Rajiv R.] Univ Missouri, Sch Med, Mason Eye Inst, Columbia, MO USA.
   [Klibanov, Alexander M.] MIT, Dept Chem, Cambridge, MA 02139 USA.
   [Klibanov, Alexander M.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Mohan, Rajiv R.] Univ Missouri, Coll Vet Med, Columbia, MO USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Harry S. Truman Memorial Veterans' Hospital; University of Missouri
   System; University of Missouri Columbia; Massachusetts Institute of
   Technology (MIT); Massachusetts Institute of Technology (MIT);
   University of Missouri System; University of Missouri Columbia
RP Mohan, RR (通讯作者)，Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA.
EM mohanr@health.missouri.edu
FU Veteran Health Affairs Merit [1I01BX000357 01]; National Eye Institute,
   National Institutes of Health [RO1EY17294]; National Institutes of
   Health [RO1EB000244]; Research to Prevent Blindness Unrestricted (Mason
   Eye Institute) grants
FX The work was supported by 1I01BX000357 01Veteran Health Affairs Merit
   (RRM), RO1EY17294 National Eye Institute, National Institutes of Health
   (RRM), RO1EB000244 National Institutes of Health (AMK), and Research to
   Prevent Blindness Unrestricted (Mason Eye Institute) grants. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bedei A, 2006, EUR J OPHTHALMOL, V16, P229, DOI 10.1177/112067210601600206
   Buijs JT, 2010, CURR PHARM DESIGN, V16, P1291
   Camellin M, 2004, J REFRACT SURG, V20, pS693
   Campolongo MJ, 2010, ADV DRUG DELIVER REV, V62, P606, DOI 10.1016/j.addr.2010.03.004
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cho YK, 2012, INVEST OPHTH VIS SCI, V53, P2328, DOI 10.1167/iovs.11 8393
   Davies MR, 2003, J AM SOC NEPHROL, V14, P1559, DOI 10.1097/01.ASN.0000068404.57780.DD
   Dougherty PJ, 1996, CORNEA, V15, P537
   DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795
   Gould SE, 2002, KIDNEY INT, V61, P51, DOI 10.1046/j.1523 1755.2002.00103.x
   Hung FC, 2002, VISION RES, V42, P427, DOI 10.1016/S0042 6989(01)00242 5
   Irache JM, 2011, VET PARASITOL, V180, P47, DOI 10.1016/j.vetpar.2011.05.028
   Jang JW, 2009, INVEST OPHTHALMOL VI, V50
   Jani PD, 2007, INVEST OPHTH VIS SCI, V48, P2030, DOI 10.1167/iovs.06 0853
   Jester JV, 2012, MOL VIS, V18, P1828
   Jester JV, 1999, PROG RETIN EYE RES, V18, P311, DOI 10.1016/S1350 9462(98)00021 4
   Kim M, 2011, BMB REP, V44, P619, DOI 10.5483/BMBRep.2011.44.10.619
   Kinoshita K, 2007, GUT, V56, P706, DOI 10.1136/gut.2006.092460
   Mitu G, 2008, FRONT BIOSCI LANDMRK, V13, P4726, DOI 10.2741/3035
   Mohan RR, 2011, CURR MOL MED, V11, P110
   Mohan RR, 2012, PROG RETIN EYE RES, V31, P43, DOI 10.1016/j.preteyeres.2011.09.001
   Mohan RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018771
   Mohan RR, 2010, EXP EYE RES, V91, P238, DOI 10.1016/j.exer.2010.05.013
   Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626
   Mohan RR, 2003, EXP EYE RES, V76, P71, DOI 10.1016/S0014 4835(02)00251 8
   Mohan RR, 2007, IOVS, V48
   Murray LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004039
   Netto MV, 2006, J REFRACT SURG, V22, P562
   Nien CJ, 2011, J CATARACT REFR SURG, V37, P937, DOI 10.1016/j.jcrs.2010.11.035
   Piscione TD, 2001, AM J PHYSIOL RENAL, V280, pF19, DOI 10.1152/ajprenal.2001.280.1.F19
   RUBINFELD RS, 1992, OPHTHALMOLOGY, V99, P1647
   Safianik B, 2002, BRIT J OPHTHALMOL, V86, P357, DOI 10.1136/bjo.86.3.357
   Saika S, 2005, LAB INVEST, V85, P474, DOI 10.1038/labinvest.3700247
   Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873
   Sharma A, 2011, NANOMED NANOTECHNOL, V7, P505, DOI 10.1016/j.nano.2011.01.006
   Sharma A, 2009, INVEST OPHTH VIS SCI, V50, P2695, DOI 10.1167/iovs.08 2919
   Srinivasan M, 2012, ARCH OPHTHALMOL CHIC, V130, P143, DOI 10.1001/archophthalmol.2011.315
   Tandon A, 2010, CURR MOL MED, V10, P565
   Tandon A, 2012, J REFRACT SURG, V28, P285, DOI 10.3928/1081597X 20120210 01
   Teli MK, 2010, CURR PHARM DESIGN, V16, P1882
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Thornton I, 2008, J REFRACT SURG, V24, P68, DOI 10.3928/1081597X 20080101 13
   Vega E, 2012, INT J NANOMED, V7, P1357, DOI 10.2147/IJN.S28481
   Vesaluoma M, 1997, CURR EYE RES, V16, P19, DOI 10.1076/ceyr.16.1.19.5119
   WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493
   Wei Y, 2006, CYTOTHERAPY, V8, P570, DOI 10.1080/14653240600987690
   Wesselinova D, 2011, CURR CANCER DRUG TAR, V11, P164, DOI 10.2174/156800911794328484
   Wordinger RJ, 2007, EXP BIOL MED, V232, P979, DOI 10.3181/0510 MR 345
   Wu KY, 1999, J OCUL PHARMACOL TH, V15, P401, DOI 10.1089/jop.1999.15.401
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
   You LT, 2002, INVEST OPHTH VIS SCI, V43, P72
   You LT, 1999, INVEST OPHTH VIS SCI, V40, P296
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
   Zeisberg M, 2008, PEDIATR NEPHROL, V23, P1395, DOI 10.1007/s00467 008 0818 x
   Zouvelou V, 2009, INT J DEV BIOL, V53, P597, DOI 10.1387/ijdb.082648vz
NR 55
TC 94
Z9 98
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 14
PY 2013
VL 8
IS 6
AR e66434
DI 10.1371/journal.pone.0066434
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 163UV
UT WOS:000320363300082
PM 23799103
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, WT
   Gu, YX
   Sun, QL
   Siegel, DS
   Tolias, P
   Yang, Z
   Lee, WY
   Zilberberg, J
AF Zhang, Wenting
   Gu, Yexin
   Sun, Qiaoling
   Siegel, David S.
   Tolias, Peter
   Yang, Zheng
   Lee, Woo Y.
   Zilberberg, Jenny
TI Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells
   through the Optimization of the Osteoblastic Niche
SO PLOS ONE
LA English
DT Article
ID MEDIATED DRUG RESISTANCE; MESENCHYMAL STEM CELLS; OSTEOGENIC
   DIFFERENTIATION; EXPRESSION PROFILES; GENE EXPRESSION; GROWTH FACTORS;
   BONE DISEASE; CANCER CELLS; N CADHERIN; MARROW
AB We previously reported a new approach for culturing difficult to preserve primary patient derived multiple myeloma cells (MMC) using an osteoblast (OSB) derived 3D tissue scaffold constructed in a perfused microfluidic environment and a culture medium supplemented with patient plasma. In the current study, we used this biomimetic model to show, for the first time, that the long term survival of OSB is the most critical factor in maintaining the ex vivo viability and proliferative capacity of MMC. We found that the adhesion and retention of MMC to the tissue scaffold was meditated by osteoblastic N cadherin, as one of potential mechanisms that regulate MMC OSB interactions. However, in the presence of MMC and patient plasma, the viability and osteogenic activity of OSB became gradually compromised, and consequently MMC could not remain viable over 3 weeks. We demonstrated that the long term survival of both OSB and MMC could be enhanced by: (1) optimizing perfusion flow rate and patient derived plasma composition in the culture medium and (2) replenishing OSB during culture as a practical means of prolonging MMC's viability beyond several weeks. These findings were obtained using a high throughput well plate based perfusion device from the perspective of optimizing the ex vivo preservation of patient  derived MM biospecimens for downstream use in biological studies and chemosensitivity analyses.
C1 [Zhang, Wenting; Gu, Yexin; Sun, Qiaoling; Lee, Woo Y.] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
   [Siegel, David S.; Zilberberg, Jenny] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ 07601 USA.
   [Tolias, Peter] Stevens Inst Technol, Dept Chem Chem Biol & Biomed Engn, Hoboken, NJ 07030 USA.
   [Tolias, Peter] Stevens Inst Technol, Ctr Healthcare Innovat, Hoboken, NJ 07030 USA.
   [Yang, Zheng; Zilberberg, Jenny] Hackensack Univ, Med Ctr, Res Dept, Hackensack, NJ 07601 USA.
C3 Stevens Institute of Technology; Hackensack University Medical Center;
   Stevens Institute of Technology; Stevens Institute of Technology;
   Hackensack University Medical Center
RP Zilberberg, J (通讯作者)，Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ 07601 USA.
EM JZilberberg@HackensackUMC.org
RI ; Zhang, Wenting/AAU 5182 2020
OI Zilberberg, Jenny/0000 0002 4139 2616; 
FU NHI/NCI Innovative Molecular Analysis Technologies Program grant
   [R21CA174543]; Provost Office of the Stevens Institute of Technology
   (Stevens); John Theurer Cancer Center at Hackensack University Medical
   Center (HackensackUMC)
FX This study was supported in part by the NHI/NCI Innovative Molecular
   Analysis Technologies Program grant R21CA174543 (to W.Y.L and J.Z), the
   Provost Office of the Stevens Institute of Technology (Stevens), and the
   John Theurer Cancer Center at Hackensack University Medical Center
   (HackensackUMC).
CR Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Blaschuk OW, 2009, EUR J PHARMACOL, V625, P195, DOI 10.1016/j.ejphar.2009.05.033
   Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756
   Calimeri T, 2011, LEUKEMIA, V25, P707, DOI 10.1038/leu.2010.300
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Fryer RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057641
   Fu JX, 2010, ARCH MED SCI, V6, P496, DOI 10.5114/aoms.2010.14459
   Gillet JP, 2013, JNCI J NATL CANCER I, V105, P452, DOI 10.1093/jnci/djt007
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Giuliani N, 2009, EXP HEMATOL, V37, P879, DOI 10.1016/j.exphem.2009.04.004
   Goldstein AS, 2001, BIOMATERIALS, V22, P1279, DOI 10.1016/S0142 9612(00)00280 5
   Groen RWJ, 2011, HAEMATOL HEMATOL J, V96, P1653, DOI 10.3324/haematol.2010.038133
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Gurkan UA, 2008, ANN BIOMED ENG, V36, P1978, DOI 10.1007/s10439 008 9577 x
   Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Huang ZN, 2007, TISSUE ENG, V13, P2311, DOI 10.1089/ten.2006.0423
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Karadag A, 2000, BRIT J HAEMATOL, V108, P383
   Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood 2008 02 142430
   Lawson MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119546
   Li AG, 2008, MOL CANCER RES, V6, P21, DOI 10.1158/1541 7786.MCR 07 0280
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Porat Z, 2011, J CELL PHYSIOL, V226, P3197, DOI 10.1002/jcp.22680
   Rajkumar SV, 2013, AM J HEMATOL, V88, P225, DOI 10.1002/ajh.23390
   Rajkumar SV, 2011, NAT REV CLIN ONCOL, V8, P479, DOI 10.1038/nrclinonc.2011.63
   Ramachandran IR, 2013, J IMMUNOL, V190, P3815, DOI 10.4049/jimmunol.1203373
   Reagan MR, 2014, BLOOD, V124, P3250, DOI 10.1182/blood 2014 02 558007
   Roodman GD, 2011, BONE, V48, P135, DOI 10.1016/j.bone.2010.06.016
   Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102
   Schmidmaier R, 2006, INT J BIOL MARKER, V21, P218, DOI 10.1177/172460080602100404
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236
   Vejlgaard T, 1997, EUR J HAEMATOL, V58, P104
   Yan YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035709
   Yata K, 2007, LEUKEMIA, V18, P1891
   Zhang WT, 2014, TISSUE ENG PART C ME, V20, P663, DOI [10.1089/ten.tec.2013.0490, 10.1089/ten.TEC.2013.0490]
   Zlei M, 2007, EXP HEMATOL, V35, P1550, DOI 10.1016/j.exphem.2007.06.016
NR 40
TC 40
Z9 44
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR e0125995
DI 10.1371/journal.pone.0125995
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CI2AC
UT WOS:000354545600036
PM 25973790
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Grzanna, MW
   Secor, EJ
   Fortuno, LV
   Au, AY
   Frondoza, CG
AF Grzanna, Mark W.
   Secor, Erica J.
   Fortuno, Lowella, V
   Au, Angela Y.
   Frondoza, Carmelita G.
TI Anti Inflammatory Effect of Carprofen Is Enhanced by Avocado/Soybean
   Unsaponifiables, Glucosamine and Chondroitin Sulfate Combination in
   Chondrocyte Microcarrier Spinner Culture
SO CARTILAGE
LA English
DT Article
DE chondrocytes; carprofen; avocado; soybean unsaponifiables; glucosamine;
   chondroitin sulfate
ID AVOCADO SOYBEAN UNSAPONIFIABLES; FISH OIL OMEGA 3 FATTY ACIDS;
   PROSTAGLANDIN E 2 PRODUCTION; HUMAN NASAL CHONDROCYTES; ARTICULAR
   CHONDROCYTES; MANGANESE ASCORBATE; GENE EXPRESSION; DIETARY
   SUPPLEMENTATION; PERIPHERAL MECHANISMS; KNEE OSTEOARTHRITIS
AB Objective Osteoarthritis is a painful, chronic joint disease affecting man and animals with no known curative therapies. Palliative nonsteroidal anti inflammatory drugs (NSAIDs) are commonly used but they cause adverse side effects prompting the search for safer alternatives. To address this need, we evaluated the anti inflammatory activity of avocado/soybean unsaponifiables (ASU), glucosamine (GLU), and chondroitin sulfate (CS) with or without the NSAID carprofen. Design Canine chondrocytes were propagated in microcarrier spinner culture and incubated with (1) control medium, (2) ASU (8.3 mu g/mL) + GLU (11 mu g/mL) + CS (20 mu g/mL) combination for 24 hours; and/or carprofen (40 ng/mL). Cultures were next incubated with control medium alone or IL 1 beta (10 ng/mL) for another 24 hours. Production of PGE(2), IL 6, IL 8, and MCP 1 (also known as CCL 2) were measured by ELISA. Results Chondrocytes proliferated in microcarrier spinner culture and produced type II collagen and aggrecan. Stimulation with IL 1 beta induced significant increases in PGE(2), IL 6, IL 8, and MCP 1 production. The increases in production were suppressed by carprofen as well as [ASU+GLU+CS]. The combination of carprofen and [ASU+GLU+CS] reduced PGE(2) production significantly more than either preparation alone. The inhibitory effect of carprofen on IL 6, IL 8, and MCP 1 production was significantly less than that of [ASU+GLU+CS], whereas the combination did not reduce the production of these molecules significantly more than [ASU+GLU+CS] alone. Conclusions The potentiating effect of [ASU+GLU+CS] on low dose carprofen was identified in chondrocyte microcarrier spinner cultures. Our results suggest that the combination of low dose NSAIDs like carprofen with [ASU+GLU+CS] could offer a safe, effective management for joint pain.
C1 [Grzanna, Mark W.; Secor, Erica J.; Fortuno, Lowella, V; Au, Angela Y.; Frondoza, Carmelita G.] Nutramax Labs Inc, Dept Res & Dev, Edgewood, MD USA.
   [Secor, Erica J.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA.
   [Frondoza, Carmelita G.] Johns Hopkins Univ, Dept Orthopaed Surg, Sch Med, Baltimore, MD 21287 USA.
   [Frondoza, Carmelita G.] Mississippi State Univ, Coll Vet Med, Dept Clin Sci, Mississippi State, MS 39762 USA.
C3 Cornell University; Johns Hopkins University; Mississippi State
   University
RP Frondoza, CG (通讯作者)，Johns Hopkins Univ, Dept Orthopaed Surg, 601 Caroline St, Baltimore, MD 21287 USA.
EM cgfrondo@jhmi.edu
RI Au, Angela/U 4131 2019
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   Arthritis Foundation, OSTEOARTHRITIS
   Attur M, 2008, J IMMUNOL, V181, P5082, DOI 10.4049/jimmunol.181.7.5082
   Au RY, 2007, OSTEOARTHR CARTILAGE, V15, P1249, DOI 10.1016/j.joca.2007.07.009
   BIRRELL GJ, 1991, NEUROSCI LETT, V124, P5, DOI 10.1016/0304 3940(91)90809 8
   Boileau C, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2649
   Bolten WW, 2010, ORTHOP RES REV, V2, P75, DOI 10.2147/ORR.S7324
   Borzì RM, 2000, ARTHRITIS RHEUM, V43, P1734, DOI 10.1002/1529 0131(200008)43:8<1734::AID ANR9>3.0.CO;2 B
   Bouchet BY, 2000, J BIOMED MATER RES, V52, P716, DOI 10.1002/1097 4636(20001215)52:4<716::AID JBM17>3.3.CO;2 K
   Canapp SO, 1999, AM J VET RES, V60, P1552
   Chan PS, 2005, AM J VET RES, V66, P1870, DOI 10.2460/ajvr.2005.66.1870
   Chen AL, 2017, J PREV MED HLTH, V1, P1017
   Cheng T, 2012, J ORTHOP RES, V30, P234, DOI 10.1002/jor.21503
   Clark TP, 2003, J VET PHARMACOL THER, V26, P187, DOI 10.1046/j.1365 2885.2003.00475.x
   Cuellar JM, 2009, J BONE JOINT SURG AM, V91A, P2313, DOI 10.2106/JBJS.H.00835
   Das A Jr, 2000, OSTEOARTHR CARTILAGE, V8, P343, DOI 10.1053/joca.1999.0308
   Doherty M, 2011, ANN RHEUM DIS, V70, P1534, DOI 10.1136/ard.2011.154047
   du Souich P, 2009, J CELL MOL MED, V13, P1451, DOI 10.1111/j.1582 4934.2009.00826.x
   Eitner A, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00349
   Fritsch DA, 2010, JAVMA J AM VET MED A, V236, P535, DOI 10.2460/javma.236.5.535
   Frondoza C, 1996, BIOMATERIALS, V17, P879, DOI 10.1016/0142 9612(96)83283 2
   Frondoza CG, 2011, AM J VET RES, V72, P51, DOI 10.2460/ajvr.72.1.51
   GRUBB BD, 1991, EXP BRAIN RES, V84, P383
   Grzanna MW, 2010, J COMPLEMENTARY INTE, V7
   Harlan RS, 2012, J EQUINE VET SCI, V32, P12, DOI 10.1016/j.jevs.2011.06.005
   Heinecke LF, 2010, OSTEOARTHR CARTILAGE, V18, P220, DOI 10.1016/j.joca.2009.08.015
   Henrotin Y, 2011, OSTEOARTHR CARTILAGE, V19, P1, DOI 10.1016/j.joca.2010.10.017
   Henrotin YE, 2003, J RHEUMATOL, V30, P1825
   Hochberg MC, 2016, ANN RHEUM DIS, V75, P37, DOI 10.1136/annrheumdis 2014 206792
   Homandberg GA, 2006, OSTEOARTHR CARTILAGE, V14, P793, DOI 10.1016/j.joca.2006.02.003
   Jerosch J, 2011, INT J RHEUMATOL, V2011, DOI 10.1155/2011/969012
   JOHNSON JA, 1994, VET COMP ORTHOPAED, V7, P56
   Johnson KA, 2001, OSTEOARTHR CARTILAGE, V9, P14, DOI 10.1053/joca.2000.0345
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Largo R, 2003, OSTEOARTHR CARTILAGE, V11, P290, DOI 10.1016/S1063 4584(03)00028 1
   Lee AS, 2013, GENE, V527, P440, DOI 10.1016/j.gene.2013.05.069
   Leffler CT, 1999, MIL MED, V164, P85, DOI 10.1093/milmed/164.2.85
   Lippiello L, 2008, EVID BASED COMPL ALT, V5, P191, DOI 10.1093/ecam/nem132
   Lipscomb VJ, 2002, VET REC, V150, P684, DOI 10.1136/vr.150.22.684
   Livshits G, 2009, ARTHRITIS RHEUM US, V60, P2037, DOI 10.1002/art.24598
   Malda J, 2003, TISSUE ENG, V9, P939, DOI 10.1089/107632703322495583
   Malda J, 2006, TRENDS BIOTECHNOL, V24, P299, DOI 10.1016/j.tibtech.2006.04.009
   Marlovits S, 2004, J BONE JOINT SURG BR, V86B, P286, DOI 10.1302/0301 620X.86B2.14918
   Miller RE, 2014, CYTOKINE, V70, P185, DOI 10.1016/j.cyto.2014.06.019
   Navarro SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117534
   Neiger R, 2003, J VET INTERN MED, V17, P259, DOI 10.1892/0891 6640(2003)17<259:ENGAEI>2.0.CO;2
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 144
   Papich MG, 2008, VET CLIN N AM SMALL, V38, P1243, DOI 10.1016/j.cvsm.2008.09.002
   Pavelka K, 2010, CLIN RHEUMATOL, V29, P659, DOI 10.1007/s10067 010 1384 8
   Provenza JR, 2015, CLIN RHEUMATOL, V34, P1455, DOI 10.1007/s10067 014 2757 1
   Roush JK, 2010, JAVMA J AM VET MED A, V236, P67, DOI 10.2460/javma.236.1.67
   Scanzello CR, 2017, J ORTHOP RES, V35, P735, DOI 10.1002/jor.23471
   Schaible HG, 2002, ANN NY ACAD SCI, V966, P343, DOI 10.1111/j.1749 6632.2002.tb04234.x
   Schrobback K, 2011, J ORTHOP RES, V29, P539, DOI 10.1002/jor.21264
   Scolnik M, 2011, OPEN ACCESS RHEUMATO, V3, P53, DOI 10.2147/OARRR.S14568
   Secor E. J., 2018, Pharmacology and Pharmacy, V9, P10, DOI 10.4236/pp.2018.91002
   Sessions JK, 2005, AM J VET RES, V66, P812, DOI 10.2460/ajvr.2005.66.812
   Shikani AH, 2004, AM J RHINOL, V18, P105, DOI 10.1177/194589240401800207
   Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007
   Stannus OP, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3022
   Syx D, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0716 6
   Wildi LM, 2011, ANN RHEUM DIS, V70, P982, DOI 10.1136/ard.2010.140848
   Wooten JG, 2009, AM J VET RES, V70, P1243, DOI 10.2460/ajvr.70.10.1243
   Yuan GH, 2001, ARTHRITIS RHEUM US, V44, P1056, DOI 10.1002/1529 0131(200105)44:5<1056::AID ANR186>3.3.CO;2 L
NR 64
TC 10
Z9 10
U1 0
U2 25
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1947 6035
EI 1947 6043
J9 CARTILAGE
JI Cartilage
PD JAN
PY 2020
VL 11
IS 1
BP 108
EP 116
DI 10.1177/1947603518783495
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA JW3CH
UT WOS:000502932900011
PM 29938530
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Puiu, RA
   Balaure, PC
   Constantinescu, E
   Grumezescu, AM
   Andronescu, E
   Oprea, OC
   Vasile, BS
   Grumezescu, V
   Negut, I
   Nica, IC
   Stan, MS
AF Puiu, Rebecca Alexandra
   Balaure, Paul Catalin
   Constantinescu, Ema
   Grumezescu, Alexandru Mihai
   Andronescu, Ecaterina
   Oprea, Ovidiu Cristian
   Vasile, Bogdan Stefan
   Grumezescu, Valentina
   Negut, Irina
   Nica, Ionela Cristina
   Stan, Miruna Silvia
TI Anti Cancer Nanopowders and MAPLE Fabricated Thin Films Based on SPIONs
   Surface Modified with Paclitaxel Loaded β Cyclodextrin
SO PHARMACEUTICS
LA English
DT Article
DE paclitaxel; beta Cyclodextrin; SPIONs
ID IRON OXIDE NANOPARTICLES; MAGNETIC NANOPARTICLES; DRUG DELIVERY;
   NANOCARRIERS; BIOCOMPATIBILITY; CHITOSAN; CITRATE
AB Globally, cancer is the second most common cause of death, and Europe accounts for almost 25% of the global cancer burden, although its people make up only 10% of the world's population. Conventional systemically administered anti cancer drugs come with important drawbacks such as inefficiency due to poor bioavailability and improper biodistribution, severe side effects associated with low therapeutic indices, and the development of multidrug resistance. Therefore, smart nano engineered targeted drug delivery systems with tailored pharmacokinetics and biodistribution which can selectively deliver anti cancer agents directly to the tumor site are the solution to most difficulties encountered with conventional therapeutic tools. Here, we report on the synthesis, physicochemical characterization, and in vitro evaluation of biocompatibility and anti tumor activity of novel magnetically targetable SPIONs based on magnetite (Fe3O4) nanoparticles' surface modified with beta cyclodextrin (CD) and paclitaxel (PTX) guest host inclusion complexes (Fe3O4@beta CD/PTX). Both pristine Fe3O4@beta CD nanopowders and PTX loaded thin films fabricated by MAPLE technique were investigated. Pristine Fe3O4@beta CD and Fe3O4@beta CD/PTX thin films were physicochemically characterized by X ray diffraction (XRD), Fourier transform infrared spectroscopy (FT IR), thermal analysis, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). The biocompatibility of bare magnetic nanocomposite thin films was evaluated by MTT cell viability assay on a normal 3T3 osteoblast cell line culture and by measuring the level of NO in the culture medium. No significant modifications, neither in cell viability nor in NO level, could be observed, thereby demonstrating the excellent biocompatibility of the SPIONs thin films. Inverted phase contrast microscopy showed no evident adverse effect on the morphology of normal osteoblasts. On the other hand, Fe3O4@beta CD/PTX films decreased the cell viability of the MG 63 osteosarcoma cell line by 85%, demonstrating excellent anti tumor activity. The obtained results recommend these magnetic hybrid films as promising candidates for future delivery, and hyperthermia applications in cancer treatment.
C1 [Puiu, Rebecca Alexandra; Constantinescu, Ema; Grumezescu, Alexandru Mihai; Andronescu, Ecaterina; Vasile, Bogdan Stefan] Politeh Univ Bucharest, Fac Appl Chem & Mat Sci, Dept Sci & Engn Oxide Mat & Nanomat, Bucharest 011061, Romania.
   [Balaure, Paul Catalin] Politeh Univ Bucharest, Fac Appl Chem & Mat Sci, Costin Nenitzescu Dept Organ Chem, Bucharest 011061, Romania.
   [Grumezescu, Alexandru Mihai; Nica, Ionela Cristina; Stan, Miruna Silvia] Univ Bucharest, Univ Bucharest ICUB, Res Inst, Bucharest 050657, Romania.
   [Grumezescu, Alexandru Mihai] Acad Romanian Sci, Ilfov 3, Bucharest 50044, Romania.
   [Oprea, Ovidiu Cristian] Politeh Univ Bucharest, Dept Inorgan Chem Phys Chem & Electrochem, Bucharest 011061, Romania.
   [Grumezescu, Valentina; Negut, Irina] Natl Inst Lasers Plasma & Radiat Phys, Lasers Dept, Magurele 077125, Romania.
   [Nica, Ionela Cristina; Stan, Miruna Silvia] Univ Bucharest, Dept Biochem & Mol Biol, Fac Biol, Bucharest 050095, Romania.
C3 National University of Science & Technology POLITEHNICA Bucharest;
   National University of Science & Technology POLITEHNICA Bucharest;
   University of Bucharest; National University of Science & Technology
   POLITEHNICA Bucharest; National Institute for Laser, Plasma & Radiation
   Physics   Romania; University of Bucharest
RP Balaure, PC (通讯作者)，Politeh Univ Bucharest, Fac Appl Chem & Mat Sci, Costin Nenitzescu Dept Organ Chem, Bucharest 011061, Romania.
EM rebecca_alexandra92@yahoo.com; pbalaure@gmail.com;
   constantinescu.ema94@gmail.com; a.grumezescu@upb.ro;
   ecaterina.andronescu@upb.ro; ovidiu.oprea@upb.ro; bogdan.vasile@upb.ro;
   valentina.grumezescu@inflpr.ro; negut.irina@inflpr.ro;
   cristina.nica@drd.unibuc.ro; miruna.stan@bio.unibuc.ro
RI Negut, Irina/E 3279 2017; Grumezescu, Alexandru/I 8181 2012; Oprea,
   Ovidiu/F 1805 2011; Voinea, Cristina/GWU 9415 2022; Vasile,
   Bogdan/B 8685 2011; Grumezescu, Valentina/P 5911 2014; Stan,
   Miruna/C 7382 2014; Balaure, Paul/GON 4155 2022
OI Negut, Irina/0000 0003 4038 7548; Balaure, Paul
   Catalin/0000 0002 4810 2992; Oprea, Ovidiu/0000 0002 8145 1094;
   Grumezescu, Alexandru Mihai/0000 0003 3036 094X; Nica, Ionela
   Cristina/0000 0003 4883 3346; Puiu, Rebecca/0000 0002 3280 4922
CR Al Faraj A, 2015, NANOTOXICOLOGY, V9, P825, DOI 10.3109/17435390.2014.980450
   Alghuthaymi M, 2020, BIOINTERFACE RES APP, V10, P4972, DOI 10.33263/BRIAC102.972976
   Alifu N, 2017, OPT COMMUN, V399, P120, DOI 10.1016/j.optcom.2017.04.001
   Arzani H, 2019, BIOINTERFACE RES APP, V9, P4225, DOI 10.33263/BRIAC95.225231
   Badruddoza AZM, 2013, CARBOHYD POLYM, V95, P449, DOI 10.1016/j.carbpol.2013.02.046
   Bai L, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957 4484/26/16/165704
   Balaure PC, 2017, MICRO NANO TECHNOL, P153, DOI 10.1016/B978 0 323 41625 2.00006 5
   Balaure PC, 2018, CURR DRUG TARGETS, V19, P318, DOI 10.2174/1389450117666160401125034
   Balaure PC, 2015, CURR TOP MED CHEM, V15, P1424
   Chen JP, 2018, MOLECULES, V23, DOI 10.3390/molecules23051179
   Chen PF, 2019, NEW J CHEM, V43, P4282, DOI 10.1039/c8nj06131a
   Chen PF, 2017, RSC ADV, V7, P29025, DOI 10.1039/c7ra02398g
   Dulinska Litewka J, 2019, MATERIALS, V12, DOI 10.3390/ma12040617
   Elazab HA, 2019, BIOINTERFACE RES APP, V9, P3906, DOI 10.33263/BRIAC92.906911
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Grumezescu V, 2014, APPL SURF SCI, V302, P262, DOI 10.1016/j.apsusc.2013.09.081
   Gudovan D, 2015, CURR PHARM DESIGN, V21, P6038, DOI 10.2174/1381612821666151027151702
   Haroun AA, 2020, BIOINTERFACE RES APP, V10, P6000, DOI 10.33263/BRIAC104.000006
   Hu QD, 2014, ACCOUNTS CHEM RES, V47, P2017, DOI 10.1021/ar500055s
   Jain TK, 2008, BIOMATERIALS, V29, P4012, DOI 10.1016/j.biomaterials.2008.07.004
   Jayaprabha KN, 2015, RSC ADV, V5, P22117, DOI 10.1039/c4ra16044d
   Jeon H, 2016, J CONTROL RELEASE, V231, P68, DOI 10.1016/j.jconrel.2016.01.006
   Kemelbekov U, 2011, J INCL PHENOM MACRO, V69, P181, DOI 10.1007/s10847 010 9829 x
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Krishnan P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09140 1
   Laurent S, 2008, CHEM REV, V108, P2064, DOI 10.1021/cr068445e
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Liu SY, 2010, CHEMOTHERAPY, V56, P101, DOI 10.1159/000305257
   Loh GOK, 2016, ASIAN J PHARM SCI, V11, P536, DOI 10.1016/j.ajps.2016.02.009
   Mohamad A, 2019, BIOINTERFACE RES APP, V9, P4655, DOI 10.33263/BRIAC96.655662
   Monteiro APF, 2017, CARBOHYD POLYM, V163, P1, DOI 10.1016/j.carbpol.2016.11.091
   Mrówczynski R, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8030170
   Paczkowska M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120858
   Pereira C, 2012, CHEM MATER, V24, P1496, DOI 10.1021/cm300301c
   Piehler S, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10061016
   Piqué A, 1999, THIN SOLID FILMS, V355, P536, DOI 10.1016/S0257 8972(99)00376 X
   Rajendrachari S, 2020, BIOINTERFACE RES APP, V10, P5951, DOI 10.33263/BRIAC104.951959
   Sakina H, 2012, J INCL PHENOM MACRO, V74, P191, DOI 10.1007/s10847 011 0100 x
   Shen LZ, 2018, MATERIALS, V11, DOI 10.3390/ma11020324
   Shen QY, 2020, J LIPOSOME RES, V30, P12, DOI 10.1080/08982104.2019.1579838
   Silva AC, 2011, INT J NANOMED, V6, P591, DOI 10.2147/IJN.S14737
   Stoia M, 2016, J THERM ANAL CALORIM, V125, P1185, DOI 10.1007/s10973 016 5393 y
   Vangijzegem T, 2019, EXPERT OPIN DRUG DEL, V16, P69, DOI 10.1080/17425247.2019.1554647
   Velázquez NS, 2019, CARBOHYD RES, V486, DOI 10.1016/j.carres.2019.107828
   Wang YXJ, 2011, QUANT IMAG MED SURG, V1, P35, DOI 10.3978/j.issn.2223 4292.2011.08.03
   Ye YJ, 2015, INT J NANOMED, V10, P4309, DOI 10.2147/IJN.S83508
   Zhai YG, 2009, COLLOID SURFACE A, V332, P98, DOI 10.1016/j.colsurfa.2008.09.001
NR 47
TC 30
Z9 32
U1 4
U2 39
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD SEP
PY 2021
VL 13
IS 9
AR 1356
DI 10.3390/pharmaceutics13091356
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA UY3DR
UT WOS:000701408500001
PM 34575432
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lemaire, I
   Falzoni, S
   Zhang, B
   Pellegatti, P
   Di Virgilio, F
AF Lemaire, Irma
   Falzoni, Simonetta
   Zhang, Bin
   Pellegatti, Patrizia
   Di Virgilio, Francesco
TI The P2X7 Receptor and Pannexin 1 Are Both Required for the
   Promotion of Multinucleated Macrophages by the Inflammatory Cytokine
   GM CSF
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID GIANT CELL FORMATION; COLONY STIMULATING FACTORS; IN VITRO; OSTEOCLAST
   FORMATION; P2 RECEPTORS; INTERCELLULAR COMMUNICATION; MIMETIC PEPTIDES;
   GENE EXPRESSION; PORE FORMATION; OXIDIZED ATP
AB The P2X(7) receptor (P2X(7)R), an ATP gated ion channel, has been implicated in the process of cell to cell fusion into multinucleated macrophages (MA), but its contribution to MA fusion driven by physiological/pathological stimuli is not clearly established. Based on several lines of evidence, we demonstrate that P2X(7)R is critical for the induction of multinucleated MA by the inflammatory cytokine GM CSF: 1) pharmacological inhibition of P2X(7)R with oxidized ATP (oATP), KN 62, and the selective antagonist A740003 abrogated GM CSF action on rat alveolar MA and murine peritoneal MA; 2) a murine J774 P2X(7) low MA clone, selected for defective P2X(7)R function, was unresponsive; 3) MA from mice lacking P2X(7)R failed to respond to GM CSF, in contrast to wild type. GM CSF also stimulated ATP induced membrane permeabilization in J774 P2X(7) high MA and rat alveolar MA, an effect absent in the P2X(7) low MA clone and inhibited by the P2X(7) blockers oATP and KN 62. Notably, the stimulatory effects of GM CSF on pore formation and MA fusion were both inhibited by blocking functional Pannexin 1 (Panx 1), and GM CSF failed to stimulate MA fusion in cells from Panx 1 knockout mice. We provide further evidence that extracellular ATP release from peritoneal MA is dependent on P2X(7) but not on Panx 1 expression and that its metabolism to adenosine mediates P2X(7) dependent MA fusion. These data demonstrate that both P2X(7) and Panx 1 are required for GM CSF promotion of MA fusion but likely act independently through different signaling pathway(s). The Journal of Immunology, 2011, 187: 3878 3887.
C1 [Lemaire, Irma; Zhang, Bin] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.
   [Falzoni, Simonetta; Pellegatti, Patrizia; Di Virgilio, Francesco] Univ Ferrara, Sect Gen Pathol, Dept Expt & Diagnost Med, I 44100 Ferrara, Italy.
   [Falzoni, Simonetta; Pellegatti, Patrizia] Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I 44100 Ferrara, Italy.
C3 University of Ottawa; University of Ferrara; University of Ferrara
RP Lemaire, I (通讯作者)，Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.
EM ilemaire@uottawa.ca
RI Pellegatti, Patrizia/A 1891 2011; Di Virgilio, Francesco/J 3754 2018; DI
   VIRGILIO, Francesco/O 4634 2019
OI Falzoni, Simonetta/0000 0002 6594 0357; Di Virgilio,
   Francesco/0000 0003 3566 1362; 
FU Natural Sciences and Engineering Research Council of Canada; Canadian
   Institute of Health Research; Italian Association for Cancer Research
   [IG 5354]; Telethon of Italy [GGP06070]; Italian Space Agency;
   Commission of European Communities [HEALTH F2 2007 202231]; Regione
   Emilia Romagna (research programs "Innovative approaches to the
   diagnosis of inflammatory diseases" and "Moniter"); University of
   Ferrara
FX This work was supported by the Natural Sciences and Engineering Research
   Council of Canada, the Canadian Institute of Health Research, the
   Italian Association for Cancer Research (Grant IG 5354), Telethon of
   Italy (Grant GGP06070), the Italian Space Agency, the Commission of
   European Communities (7th Framework Program HEALTH F2 2007 202231), the
   Regione Emilia Romagna (research programs "Innovative approaches to the
   diagnosis of inflammatory diseases" and "Moniter"), and by institutional
   funds from the University of Ferrara.
CR Alloisio S, 2006, MOL PHARMACOL, V69, P1975, DOI 10.1124/mol.105.020164
   AlSaffar N, 1996, AM J CLIN PATHOL, V105, P628
   Anselmi F, 2008, P NATL ACAD SCI USA, V105, P18770, DOI [10.1073/pnas.0800793105, 10.1073/pnas.080079310S]
   Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599
   Banerjee SK, 2002, AM J PHYSIOL LUNG C, V282, pL169, DOI 10.1152/ajplung.00243.2001
   Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009
   Beigi RD, 2003, BRIT J PHARMACOL, V140, P507, DOI 10.1038/sj.bjp.0705470
   Bischof RJ, 2000, CLIN EXP IMMUNOL, V119, P361
   Bonnema H, 2003, J BIOMED MATER RES A, V64A, P502, DOI 10.1002/jbm.a.10404
   Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013
   Braet K, 2003, CELL CALCIUM, V33, P37, DOI 10.1016/S0143 4160(02)00180 X
   BRISSETTE WH, 1995, CYTOKINE, V7, P291, DOI 10.1006/cyto.1995.0035
   Brodbeck WG, 2009, CURR OPIN HEMATOL, V16, P53, DOI 10.1097/MOH.0b013e32831ac52e
   Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697
   Cui WG, 2006, BLOOD, V107, P796, DOI 10.1182/blood 2005 05 1902
   D'Andrea RJ, 2000, EXP HEMATOL, V28, P231, DOI 10.1016/S0301 472X(99)00159 9
   Das M, 2004, PLACENTA, V25, P396, DOI 10.1016/j.placenta.2003.11.004
   Di Virgilio F, 2003, BRIT J PHARMACOL, V140, P441, DOI 10.1038/sj.bjp.0705469
   Donnelly Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476 5381.2009.00233.x
   Evans WH, 2007, CELL COMMUN ADHES, V14, P265, DOI 10.1080/15419060801891034
   FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770
   Ferrari D, 2007, BRIT J PHARMACOL, V150, P445, DOI 10.1038/sj.bjp.0706994
   Fortes FSA, 2004, J CELL SCI, V117, P4717, DOI 10.1242/jcs.01345
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.160
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Gonzalez Juarrero M, 2005, J LEUKOCYTE BIOL, V77, P914, DOI 10.1189/jlb.1204723
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200
   Hashikawa T, 2004, FASEB J, V18, P131, DOI 10.1096/fj.03 0011fje
   Helming L, 2009, J CELL SCI, V122, P453, DOI 10.1242/jcs.037200
   Hiken JF, 2004, AM J PHYSIOL CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003
   HILL JO, 1992, J EXP MED, V175, P1685, DOI 10.1084/jem.175.6.1685
   Iglesias R, 2008, AM J PHYSIOL CELL PH, V295, pC752, DOI 10.1152/ajpcell.00228.2008
   Innocenti B, 2000, J NEUROSCI, V20, P1800
   JAGADHA V, 1985, AM J CLIN PATHOL, V84, P598, DOI 10.1093/ajcp/84.5.598
   Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347
   Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lemaire I, 2003, DRUG DEVELOP RES, V59, P118, DOI 10.1002/ddr.10209
   Lemaire I, 1996, J IMMUNOL, V157, P5118
   Lemaire I, 1996, J LEUKOCYTE BIOL, V60, P509, DOI 10.1002/jlb.60.4.509
   Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257
   Locovei S, 2007, FEBS LETT, V581, P483, DOI 10.1016/j.febslet.2006.12.056
   Luttikhuizen DT, 2004, CELL TISSUE RES, V317, P289, DOI 10.1007/s00441 004 0939 x
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074 7613(01)00229 1
   MacLauchlan S, 2009, J LEUKOCYTE BIOL, V85, P617, DOI 10.1189/jlb.1008588
   MANTEL C, 1995, LIPIDS, V30, P641, DOI 10.1007/BF02537001
   Merrill JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/1529 0131(199707)40:7<1308::AID ART16>3.0.CO;2 M
   Michel AD, 2007, BRIT J PHARMACOL, V152, P523, DOI 10.1038/sj.bjp.0707417
   Mizuno K, 2004, BRIT J DERMATOL, V150, P205, DOI 10.1111/j.1365 2133.2004.05768.x
   Mizuno K, 2001, J LEUKOCYTE BIOL, V70, P386
   Mizuno K, 2001, CLIN EXP IMMUNOL, V126, P151, DOI 10.1046/j.1365 2249.2001.01655.x
   Namba K, 2001, CELL IMMUNOL, V213, P104, DOI 10.1006/cimm.2001.1873
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   OHGIMOTO S, 1995, J IMMUNOL, V155, P3585
   Parti RP, 2010, AM J RESP CELL MOL, V42, P415, DOI 10.1165/rcmb.2009 0110OC
   Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05 03 0222
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Shemon AN, 2006, J BIOL CHEM, V281, P2079, DOI 10.1074/jbc.M507816200
   Stanton LA, 2003, INT J EXP PATHOL, V84, P289, DOI 10.1111/j.0959 9673.2003.00365.x
   Steinberg TH, 2007, PURINERG SIGNAL, V3, P53, DOI 10.1007/s11302 006 9036 9
   Takenouchi T, 2007, J NEUROCHEM, V102, P1518, DOI 10.1111/j.1471 4159.2007.04570.x
   van den Eijnde SM, 2001, J CELL SCI, V114, P3631
   Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123
   Wang JJ, 2007, AM J PHYSIOL CELL PH, V293, pC1112, DOI 10.1152/ajpcell.00097.2007
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yoshihara K, 2004, J VET MED SCI, V66, P1065, DOI 10.1292/jvms.66.1065
NR 70
TC 46
Z9 51
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2011
VL 187
IS 7
BP 3878
EP 3887
DI 10.4049/jimmunol.1002780
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 822IB
UT WOS:000295036400047
PM 21865551
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, H
   Teng, X
   Yang, R
   Guo, Q
   Xue, HM
   Xiao, L
   Duan, XC
   Tian, DY
   Feng, XH
   Wu, YM
AF Li, Hui
   Teng, Xu
   Yang, Rui
   Guo, Qi
   Xue, Hongmei
   Xiao, Lin
   Duan, Xiaocui
   Tian, Danyang
   Feng, Xiaohong
   Wu, Yuming
TI Hydrogen Sulfide Facilitates the Impaired Sensitivity of Carotid Sinus
   Baroreflex in Rats with Vascular Calcification.
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE baroreflex; endoplasmic reticulum stress; hydrogen sulfide; perfusion of
   isolated carotid sinus; vascular calcification
ID ARTERY CALCIFICATION; DYSFUNCTION; MECHANISMS; H2S
AB Arterial baroreflex is a general mechanism maintaining cardiovascular homeostasis; itssensitivity is reduced in vascular calcification (VC). Hydrogen sulfide (H2S) treatmentfacilitates baroreflexive sensitivity in normal and hypertensive rats. Here, we aimed todetect the effect of H2S on baroreflexive sensitivity in rats with VC. The rat VC modelwas induced by vitamin D3plus nicotine for 4 weeks. The sensitivity of baroreflex wasdetected by perfusing the isolated carotid sinus. VC was assessed by hematoxylin andeosin (H&E) staining, Ca(2+)content and alkaline phosphatase (ALP) activity. Protein levelswere detected by western blot analysis. Vitamin D3plus nicotine induced structuraldisorder and elevated Ca(2+)content in the aortic and carotid arteria l wall and increasedplasma ALP activity. In the calcified aorta and carotid artery, protein levels of contractil ephenotype markers of vascular smooth muscle cells (VSMCs) were downregulatedand that of osteoblast like phenotype markers and endoplasmic reticulum stress (ERS)markers were upre gulated. NaHS treatment ameliorated the histologic disorder and Ca(2+)content in the calcified aorta and carotid artery, inhibited the elevated plasma ALP activit y,and prevented the transformation of the VSMC phenotype and activation of ERS in ratswith VC. Chronic NaHS treatment pre ve nted the impairment of the baroreflex sensitivityand acute NaHS treatment dose dependently improved the sensitivity in rats with VC.Our results suggested that H2S could directly facilitate the impairment of baroreflex in ratswith VC and ameliorate VC, which might provide new target and strategy for regulationof the baroreflex and therapy of VC.
C1 [Li, Hui; Teng, Xu; Yang, Rui; Guo, Qi; Xue, Hongmei; Xiao, Lin; Duan, Xiaocui; Tian, Danyang; Feng, Xiaohong; Wu, Yuming] Hebei Med Univ, Inst Basic Med, Dept Physiol, Shijiazhuang, Hebei, Peoples R China.
   [Teng, Xu] Hebei Med Univ, Hebei Key Lab Lab Anim Sci, Shijiazhuang, Hebei, Peoples R China.
   [Wu, Yuming] Key Lab Vasc Med Hebei Prov, Shijiazhuang, Hebei, Peoples R China.
   [Wu, Yuming] Hebei Collaborat Innovat Ctr Cardiocerebrovasc Di, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University
RP Wu, YM (通讯作者)，Hebei Med Univ, Inst Basic Med, Dept Physiol, Shijiazhuang, Hebei, Peoples R China.; Wu, YM (通讯作者)，Key Lab Vasc Med Hebei Prov, Shijiazhuang, Hebei, Peoples R China.; Wu, YM (通讯作者)，Hebei Collaborat Innovat Ctr Cardiocerebrovasc Di, Shijiazhuang, Hebei, Peoples R China.
EM wuyum@yahoo.com
RI Wu, Yuming/LMP 5267 2024; Guo, Qi/LXA 4434 2024
OI Teng, Xu/0000 0003 2206 8308; Xue, Hongmei/0000 0002 9571 0843
FU National Natural Science Foundation of China [31171098, 31671185,
   81100229]; Specialized Research Fund for the Doctoral Program of Higher
   Education of China [20121323110008]; Hebei Province for Innovation
   Talents Support Plan [LJRC017]; Natural Science Foundation of Hebei
   [C2012206063, H2016206264]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31171098, 31671185, 81100229), the Specialized Research Fund
   for the Doctoral Program of Higher Education of China (No.
   20121323110008), the Hebei Province for Innovation Talents Support Plan
   (No. LJRC017) and the Natural Science Foundation of Hebei (No.
   C2012206063, H2016206264).
CR Benarroch EE, 2008, NEUROLOGY, V71, P1733, DOI 10.1212/01.wnl.0000335246.93495.92
   Bild DE, 2005, CIRCULATION, V111, P1313, DOI 10.1161/01.CIR.0000157730.94423.4B
   Boström KI, 2011, CIRC RES, V109, P564, DOI 10.1161/CIRCRESAHA.110.234278
   Cai Y, 2010, ACTA PHARMACOL SIN, V31, P1359, DOI 10.1038/aps.2010.89
   Cai Y, 2010, CARDIOVASC RES, V85, P864, DOI 10.1093/cvr/cvp366
   Chang JR, 2013, EXP BIOL MED, V238, P1136, DOI 10.1177/1535370213502619
   Chesterton LJ, 2005, NEPHROL DIAL TRANSPL, V20, P1140, DOI 10.1093/ndt/gfh808
   DeFilippis AP, 2011, J AM COLL CARDIOL, V58, P2076, DOI 10.1016/j.jacc.2011.08.022
   Detrano R, 2008, NEW ENGL J MED, V358, P1336, DOI 10.1056/NEJMoa072100
   Duan XC, 2015, AM J PHYSIOL HEART C, V308, pH603, DOI 10.1152/ajpheart.00693.2014
   El Sayed SS, 2016, EUR J PHARMACOL, V783, P73, DOI 10.1016/j.ejphar.2016.04.054
   Gu Q, 2013, MOL CELL BIOCHEM, V375, P199, DOI 10.1007/s11010 012 1542 1
   Guo Q, 2016, PHYSIOL RES, V65, P413, DOI 10.33549/physiolres.933050
   Guo Q, 2011, J PHARMACOL EXP THER, V338, P458, DOI 10.1124/jpet.111.180711
   Kaur Manpreet, 2016, World J Nephrol, V5, P53, DOI 10.5527/wjn.v5.i1.53
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Liu Y, 2010, REGUL PEPTIDES, V159, P35, DOI 10.1016/j.regpep.2009.09.005
   Masson GS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122850
   McIntyre CW, 2007, SEMIN DIALYSIS, V20, P122, DOI 10.1111/j.1525 139X.2007.00258.x
   Niederhoffer N, 1997, J VASC RES, V34, P386, DOI 10.1159/000159247
   Robinson TG, 2002, KIDNEY INT, V62, P1921, DOI 10.1046/j.1523 1755.2002.00659.x
   Shen YQ, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/925167
   Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs
   Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011
   Wu SY, 2006, ACTA PHARMACOL SIN, V27, P299, DOI 10.1111/j.1745 7254.2006.00283.x
   Xiao L, 2006, ACTA PHARMACOL SIN, V27, P294, DOI 10.1111/j.1745 7254.2006.00269.x
   Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667
   Yang GD, 2015, HANDB EXP PHARMACOL, V230, P85, DOI 10.1007/978 3 319 18144 8_4
   Yang R, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9095242
   Zavaczki E, 2011, KIDNEY INT, V80, P731, DOI 10.1038/ki.2011.212
   Zhang DZ, 2015, FRONT NEUROSCI SWITZ, V9, DOI 10.3389/fnins.2015.00382
   ZHAO G, 1993, CHIN J PHYSL SCI, V9, P68
   Zhou YB, 2012, EXP BIOL MED, V237, P50, DOI 10.1258/ebm.2011.011252
NR 35
TC 9
Z9 10
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 12
PY 2017
VL 8
AR 629
DI 10.3389/fphar.2017.00629
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FG5MZ
UT WOS:000410366900001
PM 28955233
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mori, H
   Okada, Y
   Yamaoka, K
   Saito, K
   Tanaka, Y
AF Mori, Hiroko
   Okada, Yosuke
   Yamaoka, Kunihiro
   Saito, Kazuyoshi
   Tanaka, Yoshiya
TI Marked improvement of calcinosis in adult dermatomyositis with
   etidronate therapy
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Calcinosis; Dermatomyositis; Etidronate; Osteoporosis; Soft tissue
   calcification
ID JUVENILE DERMATOMYOSITIS; IN VITRO; FREE BISPHOSPHONATES; CALCIFICATION;
   CELLS; MECHANISMS; CRYSTALS; IL 6
AB We report a 26 year old woman with severe calcinosis associated with dermatomyositis. Although calcinosis of the skin or muscles is unusual in adults with dermatomyositis, this patient developed subcutaneous calcinosis with tenderness on the arms, axillary areas, shoulder areas, chest, abdomen, pelvis, and limbs. The calcinosis steadily increased and spread until joint motions were severely limited. Radiographic examination showed extensive soft tissue calcification with a reticular pattern and severe osteoporosis. The patient was treated with oral etidronate (800 mg/day for 3 months every 6 months) to prevent calcification of the lesions. Three months later, the patient showed a dramatic improvement in symptoms with softening of the calcinosis, reduced pain, and marked increase in joint mobility. Radiographic examination showed marked decreases in the size of the calcified lesions compared to pre treatment findings, and this effect persisted with a constant progressive efficacy for 3 years. The 3 year course of etidronate therapy also resulted in marked improvement of the severe osteoporosis and the patient was able to return to work and enjoy a normal life. We propose etidronate as a beneficial and effective therapy for calcinosis with osteoporosis.
C1 [Mori, Hiroko; Okada, Yosuke; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya] Univ Occupat & Environm Hlth, Dept Internal Med 1, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan.
C3 University of Occupational & Environmental Health   Japan
RP Okada, Y (通讯作者)，Univ Occupat & Environm Hlth, Dept Internal Med 1, Sch Med, Yahatanishi Ku, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM y okada@med.uoeh u.ac.jp
RI Okada, Yosuke/AAT 3173 2020
FU Mitsubishi Tanabe Pharma; Pfizer Inc.; Takeda Pharmaceutical Co. Ltd;
   Abbott; Eisai Pharma; Chugai Pharma
FX Y. Tanaka has received consultant fees from Mitsubishi Tanabe Pharma,
   Pfizer Inc.; lecture fees from Mitsubishi Tanabe Pharma, Takeda
   Pharmaceutical Co. Ltd, Abbott, Eisai Pharma, Chugai Pharma. The other
   authors declare no conflict of interest.
CR Ambler GR, 2005, J RHEUMATOL, V32, P1837
   Ariyoshi T, 2006, CLIN DRUG INVEST, V26, P215, DOI 10.2165/00044011 200626040 00006
   Boulman N, 2005, SEMIN ARTHRITIS RHEU, V34, P805, DOI 10.1016/j.semarthrit.2005.01.016
   BOWYER SL, 1983, J PEDIATR US, V103, P882, DOI 10.1016/S0022 3476(83)80706 9
   Callen JP, 2000, LANCET, V355, P53, DOI 10.1016/S0140 6736(99)05157 0
   DAOUD AS, 1987, ATHEROSCLEROSIS, V67, P41, DOI 10.1016/0021 9150(87)90263 2
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Halbert A R, 1996, Australas J Dermatol, V37, P106, DOI 10.1111/j.1440 0960.1996.tb01018.x
   Jono S, 1997, ARTERIOSCL THROM VAS, V17, P1135, DOI 10.1161/01.ATV.17.6.1135
   KRAMSCH DM, 1978, CIRC RES, V42, P562, DOI 10.1161/01.RES.42.4.562
   LANDIS WJ, 1995, BONE, V16, P533, DOI 10.1016/8756 3282(95)00076 P
   Puche AM, 2010, CLIN EXP RHEUMATOL, V28, P135
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   Mukamel M, 2001, J PEDIATR US, V138, P763, DOI 10.1067/mpd.2001.112473
   Oliveri MB, 1996, J RHEUMATOL, V23, P2152
   Pachman LM, 1999, ADOLESCENT RHEUMATOLOGY, P127
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Rider L, 1998, ARTHRITIS RHEUM, V41, pS265
   ROBERTSO.WG, 1973, CALC TISS RES, V11, P311, DOI 10.1007/BF02547230
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Slimani S, 2010, JOINT BONE SPINE, V77, P70, DOI 10.1016/j.jbspin.2009.04.011
   VANROOIJEN N, 1984, CELL TISSUE RES, V238, P355, DOI 10.1007/BF00217308
   Wananukul S, 1997, Australas J Dermatol, V38, P202
NR 26
TC 12
Z9 13
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2012
VL 30
IS 1
BP 114
EP 118
DI 10.1007/s00774 011 0289 1
PG 5
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 880AG
UT WOS:000299375800015
PM 21710176
DA 2025 08 17
ER

PT J
AU Liang, XZ
   Luo, D
   Chen, YR
   Li, JC
   Yan, BZ
   Guo, YB
   Wen, MT
   Xu, B
   Li, G
AF Liang, Xue Zhen
   Luo, Di
   Chen, Yan Rong
   Li, Jia Cheng
   Yan, Bo Zhao
   Guo, Yan Bo
   Wen, Ming Tao
   Xu, Bo
   Li, Gang
TI Identification of potential autophagy related genes in steroid induced
   osteonecrosis of the femoral head via bioinformatics analysis and
   experimental verification
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Steroid induced osteonecrosis of the femoral head; Autophagy;
   Bioinformatics analysis; Gene Expression Omnibus
ID INHIBITS OSTEOBLAST APOPTOSIS
AB Purpose Steroid induced osteonecrosis of the femoral head (SONFH) is a refractory orthopaedic hip joint disease that occurs in young  and middle aged people. Previous experimental studies have shown that autophagy might be involved in the pathological process of SONFH, but the pathogenesis of autophagy in SONFH remains unclear. We aimed to identify and validate the key potential autophagy related genes involved in SONFH to further illustrate the mechanism of autophagy in SONFH through bioinformatics analysis. Methods The GSE123568 mRNA expression profile dataset, including 10 non SONFH (following steroid administration) samples and 30 SONFH samples, was downloaded from the Gene Expression Omnibus (GEO) database. Autophagy related genes were obtained from the Human Autophagy Database (HADb). The autophagy related genes involved in SONFH were screened by intersecting the GSE123568 dataset with the set of autophagy genes. The differentially expressed autophagy related genes involved in SONFH were identified with R software. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the differentially expressed autophagy related genes involved in SONFH were conducted by using R software. Then, the correlations between the expression levels of the differentially expressed autophagy related genes involved in SONFH were confirmed with R software. Moreover, the protein protein interaction (PPI) network was analysed by using the Search Tool for the Retrieval of Interacting Genes (STRING), significant gene cluster modules were identified with the MCODE Cytoscape plugin, and hub genes among the differentially expressed autophagy related genes involved in SONFH were screened by using the CytoHubba Cytoscape plugin. Finally, the expression levels of the hub genes of the differentially expressed autophagy related genes involved in SONFH were validated in hip articular cartilage specimens from necrotic femur heads (NFHs) by using the GSE74089 dataset and further verification by qRT PCR. Results A total of 34 differentially expressed autophagy related genes were identified between the peripheral blood samples of SONFH patients and non SONFH patients based on the defined criteria, including 25 upregulated genes and 9 downregulated genes. The GO and KEGG pathway enrichment analyses revealed that these 34 differentially expressed autophagy related genes involved in SONFH were particularly enriched in death domain receptors, the FOXO signalling pathway and apoptosis. Correlation analysis revealed significant correlations among the 34 differentially expressed autophagy related genes involved in SONFH. The PPI results demonstrated that the 34 differentially expressed autophagy related genes interacted with each other. Ten hub genes were identified by using the MCC algorithms of CytoHubba. The GSE74089 dataset showed that TNFSF10, PTEN and CFLAR were significantly upregulated while BCL2L1 was significantly downregulated in the hip cartilage specimens, which was consistent with the GSE123568 dataset. TNFSF10, PTEN and BCL2L1 were detected with consistent expression by qRT PCR. Conclusions Thirty four potential autophagy related genes involved in SONFH were identified via bioinformatics analysis. TNFSF10, PTEN and BCL2L1 might serve as potential drug targets and biomarkers because they regulate autophagy. These results expand the autophagy related understanding of SONFH and might be useful in the diagnosis and prognosis of SONFH.
C1 [Liang, Xue Zhen; Luo, Di; Chen, Yan Rong; Guo, Yan Bo; Xu, Bo; Li, Gang] Shandong Univ Tradit Chinese Med, Orthopaed Microsurg, Affiliated Hosp, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
   [Liang, Xue Zhen; Li, Jia Cheng; Yan, Bo Zhao; Wen, Ming Tao; Li, Gang] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan 250355, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine
RP Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Orthopaed Microsurg, Affiliated Hosp, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
EM sdszylg@163.com
RI LIANG, Xuezhen/HGA 4207 2022; Guo, Yanbo/ABI 3574 2020
OI Wen, Mingtao/0000 0002 1654 2264; 
FU National Natural Science Foundation of China [81774333, 82074453];
   National Natural Science Foundation of Shandong province [ZR2021QH004];
   Development Plan of Shandong Medical and Health Technology [2019WS577];
   Development Plan of Shandong Traditional Chinese Medicine Science and
   Technology [2020Q009]; Innovation Program of Jinan Clinical Medicine
   Science and Technology [202019056]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81774333 and No. 82074453); the National
   Natural Science Foundation of Shandong province (No. ZR2021QH004); the
   Development Plan of Shandong Medical and Health Technology (No.
   2019WS577); the Development Plan of Shandong Traditional Chinese
   Medicine Science and Technology (No. 2020Q009); and the Innovation
   Program of Jinan Clinical Medicine Science and Technology
   (No.202019056).
CR [Anonymous], 2015, EUR REV MED PHARMACO, V19
   C TA, 2020, FRONT CELL DEV BIOL, V8
   Daniel P, 2019, EFORT OPEN REV
   Demontis F, 2010, CELL, V143, P813, DOI 10.1016/j.cell.2010.10.007
   Gov E, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05298 w
   Huang B, 2019, J CELL BIOCHEM, P120
   Huang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.777697
   Jean Philippe H, 2016, INT ORTHOP, P40
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li T, 2019, BONE, V122
   Li TX, 2019, BONE, V122, P199, DOI 10.1016/j.bone.2019.03.008
   Liu F, 2013, J BONE MINERAL RES, P28
   Liu W, 2018, INT J MOL MED
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   MD ZqZ, 2020, ORTHOP SURG, V12
   Migliorini F, 2021, EXPERT OPIN BIOL TH, V21, P423, DOI 10.1080/14712598.2021.1862790
   Moriishi T, 2016, J BONE MINER RES, V31, P1366, DOI 10.1002/jbmr.2808
   Moussay E, 2011, AUTOPHAGY, V7, P760, DOI 10.4161/auto.7.7.15454
   Puji P, 2020, FEBS OPEN BIO, V11
   Qing Yu Z, 2018, CHINESE MED J PEKING, V131
   Quaranta M, 2021, BRIT MED BULL, V137, P98, DOI 10.1093/bmb/ldaa044
   Sadile F, 2016, BRIT MED BULL, V118, P35, DOI 10.1093/bmb/ldw010
   ShenYao Z, 2021, KAOHSIUNG J MED SCI
   Wang XY, 2020, EUR J PHARMACOL, V880, DOI 10.1016/j.ejphar.2020.173212
   Wei Z, 2011, DEV CELL, V21
   Wu XJ, 2015, GENE, V565, P22, DOI 10.1016/j.gene.2015.03.072
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Xing Y., 2019, BONE RES, V7, P16, DOI [10.1038/s41413 019 0064 9, DOI 10.1038/S41413 019 0064 9]
   Xu K, ENVIRON TOXICOL
   Xu ZH, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105960
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495 013 0867 x
   Yao XD, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01658 y
   Yong Ming G, 2015, CHINESE MED J PEKING, V128
   Youm YS, 2010, CLIN ORTHOP SURG, V2, P250, DOI 10.4055/cios.2010.2.4.250
   Zhang H, 2017, BIOCHEM BIOPH RES CO, V490, P1399, DOI 10.1016/j.bbrc.2017.07.046
   Zhang M, 2020, AM J TRANSL RES, V12, P2136
   Zhipeng H, 2021, BIOMED PHARMACOTHER, V139
NR 38
TC 14
Z9 17
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD FEB 12
PY 2022
VL 17
IS 1
AR 86
DI 10.1186/s13018 022 02977 x
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA YX9BS
UT WOS:000754390400002
PM 35151359
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Maman, E
   Somjen, D
   Maman, E
   Katzburg, S
   Sharfman, ZT
   Stern, N
   Dolkart, O
AF Maman, Eran
   Somjen, Dalia
   Maman, Ettie
   Katzburg, Sarah
   Sharfman, Zachary T.
   Stern, Naftali
   Dolkart, Oleg
TI The response of cells derived from the supraspinatus tendon to estrogen
   and calciotropic hormone stimulations: in vitro study
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE estrogen receptors; Calciotropic hormones; cell proliferation;
   estrogens; tendon derived cells
ID ROTATOR CUFF REPAIR; ENDOTHELIAL PROGENITOR CELLS; VITAMIN D DEFICIENCY;
   BONE MARROW; DIFFERENTIATION; EXPRESSION; SCLERAXIS; WOMEN; MEN;
   TENOCYTES
AB Purpose: The most frequent complications after rotator cuff repair (RCR) are non healing and re tear. Age and gender are both proven risk factors for faulty RCR. This study analyzed the effects of female sex steroids and calciotropic hormones on tendon derived cell characteristics. Methods: Tendon derived cells from rat supraspinatus were treated with estradiol 17 beta (E 2); soy isoflavones (daidzein, genistein, biochainin A); raloxifene and estrogen receptors alpha and beta agonists and antagonists; and less calcemic vitamin D analog, parathyroid hormone, and vehicle control for 24 h. Cell proliferation and mRNA expression of estrogen receptor alpha and beta, vitamin D receptor (VDR), scleraxis, and collagen 1 were assessed. Results: E2, Biochainin A, raloxifene, and vitamin D significantly increased tendon derived cell proliferation. Estrogen receptor alpha antagonists neutralized tendon derived cells response to estradiol 17 beta; however, estrogen receptor beta antagonists did not have an effect. Scleraxis expression decreased following estradiol 17 beta and vitamin D treatments. Vitamin D significantly reduced collagen 1 expression, while estradiol 17 beta had no effect. Vitamin D and estradiol 17 beta upregulated VDR expression. Conclusions: Significant tendon derived cell proliferation can be achieved with commonly prescribed female sex and calciotropic hormones. However, collagen 1 expression remained constant or decreased following the administration of these hormones. Female sex steroids and vitamin D promoted tendon derived cell proliferation via estrogen receptor alpha and VDR, not estrogen receptor beta. Amplified cell proliferation was not associated with increased scleraxis and collagen 1 expression. These results have important implications to the properties of healing tendon and possible pharmaceutical therapies for patients with torn RC. Further research is warranted to expose the underling mechanisms of these effects.
C1 [Maman, Eran; Sharfman, Zachary T.; Dolkart, Oleg] Tel Aviv Univ, Tel Aviv Med Ctr, Div Orthoped Surg, Shoulder Unit, IL 64239 Tel Aviv, Israel.
   [Maman, Eran; Somjen, Dalia; Katzburg, Sarah; Sharfman, Zachary T.; Stern, Naftali; Dolkart, Oleg] Tel Aviv Univ, Sackler Fac Med, 6 Weizman St, IL 64239 Tel Aviv, Israel.
   [Somjen, Dalia; Katzburg, Sarah; Stern, Naftali] Tel Aviv Univ, Tel Aviv Med Ctr, Inst Endocrinol Metab & Hypertens, IL 64239 Tel Aviv, Israel.
   [Maman, Ettie] Tel Aviv Univ, Sheba Med Ctr, Dept Obstet & Gynecol, IVF Unit, IL 64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv University; Chaim Sheba Medical Center
RP Dolkart, O (通讯作者)，Tel Aviv Univ, Sackler Fac Med, 6 Weizman St, IL 64239 Tel Aviv, Israel.; Dolkart, O (通讯作者)，Tel Aviv Univ, Tel Aviv Med Ctr, Orthoped Surg Div, 6 Weizman St, IL 64239 Tel Aviv, Israel.
EM dolkarto@gmail.com
OI Sharfman, Zachary/0000 0002 6597 6341
CR Angeline ME, 2014, AM J SPORT MED, V42, P27, DOI 10.1177/0363546513505421
   Bahar Shany K, 2010, J CELL PHYSIOL, V222, P729, DOI 10.1002/jcp.22004
   Basak P, 2015, ENDOCR RELAT CANCER, V22, P505, DOI 10.1530/ERC 15 0105
   Bogunovic L, 2010, J BONE JOINT SURG AM, V92A, P2300, DOI 10.2106/JBJS.I.01231
   Boileau P, 2005, J BONE JOINT SURG AM, V87A, P1229, DOI 10.2106/JBJS.D.02035
   Bridgeman JT, 2010, FOOT ANKLE INT, V31, P1081, DOI 10.3113/FAI.2010.1081
   Chen X, 2012, SCI REP UK, V2, DOI 10.1038/srep00977
   Cho NS, 2011, AM J SPORT MED, V39, P2108, DOI 10.1177/0363546510397171
   CSERJESI P, 1995, DEVELOPMENT, V121, P1099
   Fan CL, 2003, ACTA PHARMACOL SIN, V24, P212
   Fermont AJM, 2014, J ORTHOP SPORT PHYS, V44, P153, DOI 10.2519/jospt.2014.4832
   Hart DA, 1998, CLIN ORTHOP RELAT R, P44
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Imanishi T, 2005, HYPERTENS RES, V28, P763, DOI 10.1291/hypres.28.763
   Kovats S, 2012, HORM BEHAV, V62, P254, DOI 10.1016/j.yhbeh.2012.04.011
   Léjard V, 2007, J BIOL CHEM, V282, P17665, DOI 10.1074/jbc.M610113200
   Magnusson SP, 2007, INT J EXP PATHOL, V88, P237, DOI 10.1111/j.1365 2613.2007.00551.x
   MILGROM C, 1995, J BONE JOINT SURG BR, V77B, P296, DOI 10.1302/0301 620X.77B2.7706351
   Mirkin S, 2015, MATURITAS, V81, P28, DOI 10.1016/j.maturitas.2015.02.266
   Pauly S, 2010, EUR CELLS MATER, V20, P84, DOI 10.22203/eCM.v020a08
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Schweitzer R, 2001, DEVELOPMENT, V128, P3855
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Somjen D, 2008, J CELL BIOCHEM, V103, P1826, DOI 10.1002/jcb.21565
   Somjen D, 2005, CIRCULATION, V111, P1666, DOI 10.1161/01.CIR.0000160353.27927.70
   Somjen D, 2014, J STEROID BIOCHEM, V140, P1, DOI 10.1016/j.jsbmb.2013.11.007
   Somjen D, 2011, J ENDOCRINOL INVEST, V34, P106, DOI [10.1007/BF03347039, 10.3275/7108]
   Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959
   Somjen D, 2011, J STEROID BIOCHEM, V125, P226, DOI 10.1016/j.jsbmb.2011.03.006
   Sorensen AKB, 2007, J SHOULDER ELB SURG, V16, P174, DOI 10.1016/j.jse.2006.06.010
   Tashjian RZ, 2010, AM J SPORT MED, V38, P2435, DOI 10.1177/0363546510382835
   Wagenhäuser MU, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 140
   Yamaguchi K, 2006, J BONE JOINT SURG AM, V88A, P1699, DOI 10.2106/JBJS.E.00835
NR 33
TC 10
Z9 11
U1 1
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD MAR 3
PY 2016
VL 57
IS 2
BP 124
EP 130
DI 10.3109/03008207.2015.1114615
PG 7
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA DH5PQ
UT WOS:000372844400005
PM 26646255
DA 2025 08 17
ER

PT J
AU Wu, JH
   Chen, X
   Bao, QY
   Duan, R
   Jin, YC
   Shui, YF
   Yao, B
   Lu, XD
   Wang, Y
   Cui, HY
   Li, LY
   Yuan, HY
   Ma, CY
AF Wu, Jiahui
   Chen, Xiang
   Bao, Qianyi
   Duan, Rui
   Jin, Yucui
   Shui, Yifang
   Yao, Bing
   Lu, Xiangdong
   Wang, Yue
   Cui, Hongyan
   Li, Lingyun
   Yuan, Hongyan
   Ma, Changyan
TI Osterix Decreases the Chemosensitivity of Breast Cancer Cells by
   Upregulating GALNT14
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Osterix; GALNT14; Chemosensitivity; Breast cancer
ID N ACETYLGALACTOSAMINYLTRANSFERASE 6; ACETYL D GALACTOSAMINE;
   O GLYCOSYLATION; OVARIAN CANCER; EXPRESSION;
   N ACETYLGALACTOSAMINYLTRANSFERASE 6; DIFFERENTIATION; INCREASES;
   CARCINOMA; MIGRATION
AB Background/Aims: Osterix (Osx), a key regulator of osteoblast differentiation and bone formation, has been recently reported to be associated with the progression of breast cancer. However, the precise roles of Osx in breast cancer remain unclear. Methods: Drug sensitivity of the cancer cells was assessed using an 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyl 2 Htetrazolium bromide (MTT) assay. Target genes were obtained by high throughput Illumina sequencing and were confirmed in vitro and in vivo. Apoptosis was analysed by Hoechst staining and western blotting. A tissue microarray including 129 samples from breast cancer patients was used for immunohistochemistry (IHC) assays. Results: Overexpression of Osx decreased the chemosensitivity of breast cancer cells, while knockdown of Osx increased the chemosensitivity of breast cancer cells. In particular, we found that the decreased chemosensitivity effect was significantly associated with elevated expression of the polypeptide N acetylgalactosaminyltransferase 14 (GALNT14). Silencing of GALNT14 in Osx overexpressed cells restored the decreased chemosensitivity. Conversely, overexpression of GALNT14 in Osx knockdown cells abrogated the increased chemosensitivity in breast cancer cells. In addition, we revealed that Osx decreased GALNT14 dependent chemosensitivity by enhancing antiapoptosis. GALNT14 expression exhibited a significant association with breast cancer stages as well as the disease free survival (DFS) rate. Conclusion: Osx plays an important role in the chemosensitivity and inhibition of Osx expression may represent a therapeutic strategy to enhance the chemosensitivity of breast cancer. (C) 2017 The Author(s) Published by S. Karger AG, Basel.
C1 [Wu, Jiahui; Bao, Qianyi; Duan, Rui; Jin, Yucui; Shui, Yifang; Yao, Bing; Li, Lingyun; Ma, Changyan] Nanjing Med Univ, Dept Dev Genet, Longmian Rd 101, Nanjing, Jiangsu, Peoples R China.
   [Chen, Xiang] Jiangsu Univ, Affiliated Yixing Hosp, Dept Gen Surg, Yixing, Peoples R China.
   [Lu, Xiangdong] Southeast Univ, Jiangyin Hosp, Med Coll, Dept Oncol, Jiangsu Jiangyin, Peoples R China.
   [Wang, Yue; Cui, Hongyan] Nanjing Med Univ, Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Cui, Hongyan] Dept Oncol, Washington, DC USA.
   [Cui, Hongyan] Lombardi Comprehens Canc Ctr, Washington, DC USA.
C3 Nanjing Medical University; Jiangsu University; Southeast University  
   China; Nanjing Medical University
RP Ma, CY (通讯作者)，Nanjing Med Univ, Dept Dev Genet, Longmian Rd 101, Nanjing, Jiangsu, Peoples R China.
EM cyma@njmu.edu.cn
RI Wu, Jane/CAI 7607 2022; Yao, Bing/HCH 0626 2022
OI Yao, Bing/0000 0002 6657 2760
FU National Natural Science Foundation of China [81372320, 81570804,
   81502303]; Natural Science Foundation of Jiangsu Educational Committee
   [15KJB310006]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions; Key Project of Science and Technology
   Development Foundation of Nanjing Medical University [2014NJMUZD009];
   Jiangsu Higher College Students' Innovative Entrepreneurial Training
   Program [201510312019Z]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81372320, 81570804, 81502303), Natural Science
   Foundation of Jiangsu Educational Committee (No. 15KJB310006), the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions, the Key Project of Science and Technology Development
   Foundation of Nanjing Medical University (No. 2014NJMUZD009), and
   Jiangsu Higher College Students' Innovative Entrepreneurial Training
   Program (No. 201510312019Z).
CR Abaza MSI, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1358 8
   Berois N, 2006, J HISTOCHEM CYTOCHEM, V54, P317, DOI 10.1369/jhc.5A6783.2005
   Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743
   Cheng S, 2003, PHYSIOL GENOMICS, V45, P917
   Choi HS, 2016, MOL CELL BIOCHEM, V45, P1
   Dai QS, 2015, ONCOL LETT, V10, P1870, DOI 10.3892/ol.2015.3448
   Dirks Naylor AJ, 2013, J CACHEXIA SARCOPENI, V4, P239, DOI 10.1007/s13539 013 0104 z
   Dosaka Akita H, 2002, BRIT J CANCER, V87, P751, DOI 10.1038/sj.bjc.6600536
   Gong JP, 2016, ONCOL LETT, V12, P3905, DOI 10.3892/ol.2016.5139
   Gornes J, 2009, J HISTOCHEM CYTOCHEM, V57, P79, DOI 10.1369/jhc.2008.952283
   Greco F, 2009, ADV DRUG DELIVER REV, V61, P1203, DOI 10.1016/j.addr.2009.05.006
   He DY, 2016, NAT NEUROSCI, V19, P678, DOI 10.1038/nn.4258
   He Y, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906 015 0710 8
   Kelly G, 2003, GLYCOBIOLOGY, V13, P1
   Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148 011 0040 8
   Li Z, 2011, BRIT J CANCER, V104, P1882, DOI 10.1038/bjc.2011.166
   Lin WR, 2014, MOL CLIN ONCOL, V2, P630, DOI 10.3892/mco.2014.294
   Lu JL, 2016, ONCOTARGET, V7, P37471, DOI 10.18632/oncotarget.9650
   Lu XD, 2016, ONCOTARGET, V7, P37177, DOI 10.18632/oncotarget.9287
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Noordhuis P, 2004, ANN ONCOL, V15, P1025, DOI 10.1093/annonc/mdh264
   Park JH, 2011, NEOPLASIA, V13, P320, DOI 10.1593/neo.101440
   Park JH, 2010, CANCER RES, V70, P2759, DOI 10.1158/0008 5472.CAN 09 3911
   Patani Neill, 2008, Cancer Genomics & Proteomics, V5, P333
   Peng YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056451
   Sims JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055509
   Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623
   Tan XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0435 5
   Tarp MA, 2008, BBA GEN SUBJECTS, V1780, P546, DOI 10.1016/j.bbagen.2007.09.010
   Tian HN, 2015, MOL CARCINOGEN, V54, P1159, DOI 10.1002/mc.22186
   Wang JY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111148
   Wang RR, 2013, ONCOL REP, V30, P667, DOI 10.3892/or.2013.2493
   Wu C, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 123
   Wu YL, 2016, ONCOL LETT, V11, P3597, DOI 10.3892/ol.2016.4489
   Xia T., 2016, PHARM DEV TECHNOL, P1
   Xiao WL, 2015, CELL PHYSIOL BIOCHEM, V36, P1015, DOI 10.1159/000430275
   Xu YX, 2015, FEBS LETT, V589, P857, DOI 10.1016/j.febslet.2015.02.021
   Yang J, 2016, BIOMED PHARMACOTHER, V80, P381, DOI 10.1016/j.biopha.2015.12.027
   Yeh CT, 2014, INT J CANCER, V134, P1214, DOI 10.1002/ijc.28439
   Zhang L, 2016, CELL PHYSIOL BIOCHEM, V39, P1391, DOI 10.1159/000447843
NR 40
TC 6
Z9 7
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 44
IS 3
BP 998
EP 1010
DI 10.1159/000485400
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FQ8KR
UT WOS:000418612200012
PM 29227978
OA gold
DA 2025 08 17
ER

PT J
AU Qiu, JL
   Wang, XT
   Zhou, HW
   Zhang, CS
   Wang, YJ
   Huang, JH
   Liu, M
   Yang, PS
   Song, AM
AF Qiu, Jiling
   Wang, Xiaotong
   Zhou, Haowen
   Zhang, Chunshu
   Wang, Yijia
   Huang, Jiahui
   Liu, Meng
   Yang, Pishan
   Song, Aimei
TI Enhancement of periodontal tissue regeneration by conditioned media from
   gingiva derived or periodontal ligament derived mesenchymal stem cells:
   a comparative study in rats
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Gingiva derived mesenchymal stem cells; Periodontal ligament stem cells;
   Conditioned medium; Periodontal regeneration; Rats
ID BONE LOSS; DIFFERENTIATION; MACROPHAGES; MECHANISMS
AB Background Evidence has demonstrated conditioned medium (CM) from periodontal ligament stem cells (PDLSCs) improved periodontal regeneration. Gingival mesenchymal stem cells (GMSCs) have been considered an alternative strategy for regenerative medicine. To determine whether GMSC CM could promote periodontal wound healing, we compared the effects of GMSC CM and PDLSC CM on periodontal regeneration and the underlying mechanisms in rat periodontal defects. Methods Cell free CMs were collected from PDLSCs, GMSCs, and gingival fibroblasts (GFs) using ultracentrifugation (100 fold concentration). Periodontal defects were created on the buccal side of the first molar in the left mandible of 90 rats by a surgical method. Collagen membranes loaded with concentrated CMs (alpha MEM, GF CM, GMSC CM, PDLSC CM) were transplanted into periodontal defects. After 1, 2, and 4 weeks, the animals were sacrificed and specimens including the first molar and the surrounding tissues were separated and decalcified. Hematoxylin eosin and Masson's trichrome staining were performed to evaluate periodontal regeneration. Immunohistochemical staining for tumor necrosis factor (TNF) alpha, interleukin (IL) 1 beta, and IL 10 was conducted to analyze inflammation. Immunohistochemistry of BSP II and Runx2 was performed to analyze osteoblast differentiation. Results Histological analysis showed the amount of newly formed periodontal tissue was significantly higher in both the GMSC CM and PDLSC CM groups than in the other groups, with no significant difference between these two groups. At 1 and 2 weeks, the expression levels of TNF alpha and IL 1 beta were significantly lower in the GMSC CM and PDLSC CM groups than in the other three groups, while there was no significant difference between these two groups. IL 10 expression was significantly higher in the GMSC CM group than in the PDLSC CM group and the other three groups. At 1, 2, and 4 weeks, BSP II and Runx2 expressions were significantly higher in the GMSC CM and PDLSC CM groups than in the other three groups, with no significant difference between the two groups. Conclusions Our results demonstrate that GMSC CM transplantation can significantly promote periodontal regeneration in rats and achieve the same effect as PDLSC CM. The mechanism of periodontal regeneration may involve the regulation of inflammatory factors and the promotion of osteogenic differentiation of bone progenitor cells in the wound region by CMs from MSCs.
C1 [Qiu, Jiling; Wang, Xiaotong; Zhou, Haowen; Wang, Yijia; Huang, Jiahui; Liu, Meng; Yang, Pishan; Song, Aimei] Shandong Univ, Sch & Hosp Stomatol, Dept Periodontol, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Qiu, Jiling; Wang, Xiaotong; Zhou, Haowen; Zhang, Chunshu; Wang, Yijia; Huang, Jiahui; Liu, Meng; Yang, Pishan; Song, Aimei] Shandong Prov Key Lab Oral Tissue Regenerat, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Qiu, Jiling; Wang, Xiaotong; Zhou, Haowen; Zhang, Chunshu; Wang, Yijia; Huang, Jiahui; Liu, Meng; Yang, Pishan; Song, Aimei] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University
RP Yang, PS; Song, AM (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Dept Periodontol, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
EM yangps@sdu.edu.cn; sam1972@sdu.edu.cn
RI Wang, Yijia/MGV 6373 2025; Liu, Mengyuan/HZL 2276 2023
FU National Natural Science Foundation of China [81771076]
FX This research was supported by the National Natural Science Foundation
   of China, No. 81771076 (to YPS).
CR Al Rasheed A, 2003, J DENT RES, V82, P632, DOI 10.1177/154405910308200812
   Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
   Assuma R, 1998, J IMMUNOL, V160, P403
   Bartold PM, 2010, PERIODONTOL 2000, V53, P55, DOI 10.1111/j.1600 0757.2010.00347.x
   BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854
   Chung E, 2014, TISSUE ENG REGEN MED, V11, P431
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   D'Aiuto F, 2007, TREATMENT PERIODONTI
   Diomede F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020329
   Du LQ, 2016, J DENT SCI, V11, P304, DOI 10.1016/j.jds.2016.03.010
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
   Fukuoka H, 2015, EPLASTY, V15
   Gao Y, 2014, INT J MOL SCI, V15, P20982, DOI 10.3390/ijms151120982
   Gay IC, 2007, ORTHOD CRANIOFAC RES, V21, P330
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gronthos S, 2006, CALCIFIED TISSUE INT, V79, P310, DOI 10.1007/s00223 006 0040 4
   Inukai T, 2013, BIOCHEM BIOPH RES CO, V430, P763, DOI 10.1016/j.bbrc.2012.11.074
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jin SH, 2015, J PERIODONTAL RES, V50, P461, DOI 10.1111/jre.12228
   Kao RT, 2015, J PERIODONTOL, V86, pS77, DOI 10.1902/jop.2015.130685
   Kawai T, 2015, CYTOTHERAPY, V17, P369, DOI 10.1016/j.jcyt.2014.11.009
   Keshtkar S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0791 7
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Madrigal M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0260 8
   Maeda H, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt74
   Menicanin D, 2014, STEM CELLS DEV, V23, P1001, DOI 10.1089/scd.2013.0490
   Mushahary D, 2018, CYTOM PART A, V93A, P19, DOI 10.1002/cyto.a.23242
   Nagata M, 2017, TISSUE ENG PT A, V23, P367, DOI [10.1089/ten.tea.2016.0274, 10.1089/ten.TEA.2016.0274]
   Nagatomo K, 2006, J PERIODONTAL RES, V41, P303, DOI 10.1111/j.1600 0765.2006.00870.x
   Nikbakht MR., 2015, SCI J KURDISTAN U ME, V20, P113
   Oates TW, 2002, J CLIN PERIODONTOL, V29, P137, DOI 10.1034/j.1600 051x.2002.290208.x
   Page RC, 1997, PERIODONTOL 2000, V14, P216, DOI 10.1111/j.1600 0757.1997.tb00199.x
   Pawitan JA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/965849
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prakoeswa CRS, 2018, J DERMATOL TREAT, V29, P835, DOI 10.1080/09546634.2018.1467541
   Rajan TS, 2017, INT J IMMUNOPATH PH, V30, P383, DOI 10.1177/0394632017740976
   Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17 0129
   Santamaría S, 2017, CLIN ORAL INVEST, V21, P1095, DOI 10.1007/s00784 016 1867 3
   Sumer AP, 2007, J PERIODONTOL, V78, P493, DOI 10.1902/jop.2007.060309
   Venkatesh Deepak, 2017, J Oral Maxillofac Pathol, V21, P296, DOI 10.4103/jomfp.JOMFP_162_17
   Vizoso FJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091852
   Wang F, 2011, STEM CELLS DEV, V20, P2093, DOI 10.1089/scd.2010.0523
   Xu QC, 2014, INT J CLIN EXP PATHO, V7, P4922
   Yu XB, 2013, CELLS TISSUES ORGANS, V198, P428, DOI 10.1159/000360276
   Zaher W, 2014, ARCH TOXICOL, V88, P1069, DOI 10.1007/s00204 014 1232 8
   Zhang CS, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 1799 1
   Zhang QZ, 2012, J DENT RES, V91, P1011, DOI 10.1177/0022034512461016
   Zhang QZ, 2010, STEM CELLS, V28, P1856, DOI 10.1002/stem.503
   Zhou BR, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/519126
NR 54
TC 79
Z9 82
U1 4
U2 35
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD FEB 3
PY 2020
VL 11
IS 1
AR 42
DI 10.1186/s13287 019 1546 9
PG 15
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KV4LW
UT WOS:000520454700001
PM 32014015
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Alkan, FÜ
   Üstüner, O
   Bakirel, T
   Çinar, S
   Erten, G
   Deniz, G
AF Alkan, Fulya Ustun
   Ustuner, Oya
   Bakirel, Tulay
   Cinar, Suzan
   Erten, Gaye
   Deniz, Gunnur
TI The Effects of Piroxicam and Deracoxib on Canine Mammary Tumour Cell
   Line
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANCER IN VITRO; COX 2 INHIBITION;
   CYCLOOXYGENASE 2 EXPRESSION; OSTEOSARCOMA CELLS; BLADDER CANCER; GLAND
   TUMORS; CYCLE ARREST; APOPTOSIS; GROWTH
AB Cyclooxygenase (COX) inhibitors, already widely used for the treatment of pain and inflammation, are considered as promising compounds for the prevention and treatment of neoplasia. The aim of our study was to determine the direct antiproliferative effects of nonsteroidal anti inflammatory drugs (NSAIDs), piroxicam and deracoxib, at a variety of concentrations as both single and combined treatments on canine mammary carcinoma cell line CMT U27 and to understand the mechanisms of cell death. MTT assay was performed to determine cell viability, and flow cytometric analyses were performed to evaluate apoptosis and cell cycle alterations. Significant decrease in cell viability was observed at high concentrations of piroxicam and deracoxib in both single and combined treatments after 72 h incubation. Combined treatment produced a significantly greater inhibition than that caused by either agent alone. Also apoptotic cell number was increased by both drugs at the cytotoxic concentrations. However, concomitant treatment of cells with piroxicam and deracoxib resulted in significant induction of apoptosis at lower concentrations and accumulation of cells in the G(0)/G(1) phase. Significant cytotoxic effects exhibited by the combination of piroxicam and deracoxib against canine mammary carcinoma cells in vitro suggest an attractive approach for the treatment of canine mammary carcinoma.
C1 [Alkan, Fulya Ustun; Ustuner, Oya; Bakirel, Tulay] Istanbul Univ, Fac Vet Med, Dept Pharmacol & Toxicol, TR 34320 Istanbul, Turkey.
   [Cinar, Suzan; Erten, Gaye; Deniz, Gunnur] Istanbul Univ, Inst Expt Med, Dept Immunol, TR 34093 Istanbul, Turkey.
C3 Istanbul University; Istanbul University
RP Alkan, FÜ (通讯作者)，Istanbul Univ, Fac Vet Med, Dept Pharmacol & Toxicol, TR 34320 Istanbul, Turkey.
EM fustun@istanbul.edu.tr
RI Bakirel, Tülay/D 8328 2019; USTUN ALKAN, Fulya/D 7406 2019; USTUNER,
   OYA/D 7617 2019; erten yurdagul, gaye/AAB 9556 2020; ustuner,
   oya/D 7617 2019; ALKAN, FULYA/D 7406 2019; , Gunnur Deniz/AAC 2909 2020;
   cinar, suzan/J 4770 2019
OI Cinar, Suzan/0000 0002 8330 7010; USTUN ALKAN,
   Fulya/0000 0003 1782 9467; Bakirel, Tulay/0000 0001 5805 2178; ustuner,
   oya/0000 0002 4354 8207; Deniz, Gunnur/0000 0002 0721 6213
FU Research Fund of Istanbul University [459/27122005]
FX The authors would like to thank Assoc Professor EvaHellmen of the
   Department of Anatomy and Physiology, Uppsala University for kind
   donation of the CMT U27 cell line. This study was supported by the
   Research Fund of Istanbul University (project no. 459/27122005).
CR Baba A.I., 2007, COMP ONCOLOGY CHAP 3
   Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099
   Cheong E, 2004, CARCINOGENESIS, V25, P1945, DOI 10.1093/carcin/bgh184
   Chiu LCM, 2005, BIOMED PHARMACOTHER, V59, pS293, DOI 10.1016/S0753 3322(05)80049 6
   Cox SK, 2005, J CHROMATOGR B, V819, P181, DOI 10.1016/j.jchromb.2005.01.025
   Ding HM, 2003, INT J CANCER, V107, P830, DOI 10.1002/ijc.11499
   Doré M, 2011, VET PATHOL, V48, P254, DOI 10.1177/0300985810379434
   Farivar Mohseni H, 2004, AM J SURG, V188, P505, DOI 10.1016/j.amjsurg.2004.07.025
   Grösch S, 2006, JNCI J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   HELLMEN E, 1993, J REPROD FERTILITY, P489
   KNAPP DW, 1995, AM J VET RES, V56, P801
   Knottenbelt C, 2006, J SMALL ANIM PRACT, V47, P14, DOI 10.1111/j.1748 5827.2006.00006.x
   Krol M, 2009, J PHYSIOL PHARMACOL, V60, P95
   McFadden DW, 2006, INT J ONCOL, V29, P1019
   Mohammed SI, 2002, CANCER RES, V62, P356
   Moore BC, 2000, CURR MED CHEM, V7, P1131, DOI 10.2174/0929867003374273
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Novosad CA, 2003, CLIN TECH SMALL AN P, V18, P107, DOI 10.1053/svms.2003.36625
   Pang Lisa Y, 2011, Cancers (Basel), V3, P1744, DOI 10.3390/cancers3021744
   Qin J, 2009, BIOMED PHARMACOTHER, V63, P241, DOI 10.1016/j.biopha.2008.04.007
   Rao CV, 2004, CURR CANCER DRUG TAR, V4, P29, DOI 10.2174/1568009043481632
   Royals SR, 2005, AM J VET RES, V66, P1961, DOI 10.2460/ajvr.2005.66.1961
   Sandler AB, 2004, SEMIN ONCOL, V31, P45, DOI 10.1053/j.seminoncol.2004.03.045
   Schmidt BR, 2001, J AM VET MED ASSOC, V218, P1783, DOI 10.2460/javma.2001.218.1783
   Singh B, 2008, J SURG RES, V147, P240, DOI 10.1016/j.jss.2008.02.026
   Sonzogni Desautels K, 2011, VET COMP ONCOL, V9, P161, DOI 10.1111/j.1476 5829.2010.00242.x
   Sorenmo K, 2003, VET CLIN N AM SMALL, V33, P573, DOI 10.1016/S0195 5616(03)00020 2
   Souza CHD, 2009, CAN VET J, V50, P506
   Steele VE, 2003, MUTAT RES FUND MOL M, V523, P137, DOI 10.1016/S0027 5107(02)00329 9
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097 0320(19980101)31:1<1::AID CYTO1>3.0.CO;2 R
   Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286
   Wolfesberger B, 2006, RES VET SCI, V80, P308, DOI 10.1016/j.rvsc.2005.07.013
   Zhang H, 2008, DIGEST DIS SCI, V53, P2195, DOI 10.1007/s10620 007 0139 0
NR 34
TC 20
Z9 25
U1 0
U2 29
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537 744X
J9 SCI WORLD J
JI Sci. World J.
PY 2012
AR 976740
DI 10.1100/2012/976740
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 055BH
UT WOS:000312389500001
PM 23251109
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kuljanin, M
   Brown, CFC
   Raleigh, MJ
   Lajoie, GA
   Flynn, LE
AF Kuljanin, Miljan
   Brown, Cody F. C.
   Raleigh, Matthew J.
   Lajoie, Gilles A.
   Flynn, Lauren E.
TI Collagenase treatment enhances proteomic coverage of low abundance
   proteins in decellularized matrix bioscaffolds
SO BIOMATERIALS
LA English
DT Article
DE Decellularization; Extracellular matrix; Matrisome; Proteomics; Mass
   spectrometry; Microenvironment; Adipose tissue; Bone
ID ADIPOSE TISSUE MICROCARRIERS; EXTRACELLULAR MATRIX; MASS SPECTROMETRY;
   OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; PREADIPOCYTE
   COMMITMENT; COMPUTATIONAL PLATFORM; BIOLOGIC SCAFFOLDS; COPY NUMBER;
   QUANTIFICATION
AB There is great interest in the application of advanced proteomic techniques to characterize decellularized tissues in order to develop a deeper understanding of the effects of the complex extracellular matrix (ECM) composition on the cellular response to these pro regenerative bioscaffolds. However, the identification of proteins in ECM derived bioscaffolds is hindered by the high abundance of collagen in the samples, which can interfere with the detection of lower abundance constituents that may be important regulators of cell function. To address this limitation, we developed a novel multi enzyme digestion approach using treatment with a highly purified collagenase derived from Clostridium Histolyticum to selectively deplete collagen from ECM derived protein extracts, reducing its relative abundance from up to 90% to below 10%. Moreover, we applied this new method to characterize the proteome of human decellularized adipose tissue (DAT), human decellularized cancellous bone (DCB), and commercially available bovine tendon collagen (BTC). We successfully demonstrated with all three sources that collagenase treatment increased the depth of detection and enabled the identification of a variety of signaling proteins that were masked by collagen in standard digestion protocols with trypsin/LysC, increasing the number of proteins identified in the DAT by similar to 2.2 fold, the DCB by similar to 1.3 fold, and the BTC by similar to 1.6 fold. In addition, quantitative proteomics using label free quantification demonstrated that the DAT and DCB extracts were compositionally distinct, and identified a number of adipogenic and osteogenic proteins that were consistently more highly expressed in the DAT and DCB respectively. Overall, we have developed a new processing method that may be applied in advanced mass spectrometry studies to improve the high throughput proteomic characterization of bioscaffolds derived from mammalian tissues. Further, our study provides new insight into the complex ECM composition of two human decellularized tissues of interest as cell instructive platforms for regenerative medicine. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Kuljanin, Miljan; Lajoie, Gilles A.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada.
   [Brown, Cody F. C.; Flynn, Lauren E.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada.
   [Raleigh, Matthew J.] Univ Western Ontario, Schulich Sch Med & Dent, Undergrad Med Educ, London, ON N6A 5C1, Canada.
   [Flynn, Lauren E.] Univ Western Ontario, Dept Chem & Biochem Engn, Thompson Engn Bldg, London, ON N6A 5B9, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario)
RP Lajoie, GA (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada.; Flynn, LE (通讯作者)，Univ Western Ontario, Dept Chem & Biochem Engn, Thompson Engn Bldg, London, ON N6A 5B9, Canada.
EM glajoie@uwo.ca; lauren.flynn@uwo.ca
RI Flynn, Lauren/C 9967 2015
OI Flynn, Lauren/0000 0001 6227 0928; Lajoie, Gilles/0009 0004 5424 1851
FU Canadian Institutes of Health Research [FRN 119394]; Ontario Ministry of
   Research and Innovation; NSERC Research Tools and Instruments (RTI)
   [NSERC R 3095A03]; Summer Research Training Program (SRTP) in the
   Schulich School of Medicine and Dentistry; Body Bequeathal Programme in
   the Department of Anatomy & Cell Biology at The University of Western
   Ontario
FX Operational funding to support this work was provided by the Canadian
   Institutes of Health Research (FRN 119394), with infrastructure support
   from the Canada Foundation for Innovation (IOF 28946, JELF 32868), the
   Ontario Ministry of Research and Innovation, and the NSERC Research
   Tools and Instruments (RTI) (NSERC R 3095A03) Program. Scholarship
   support for Matthew Raleigh was provided by the Summer Research Training
   Program (SRTP) in the Schulich School of Medicine and Dentistry. The
   authors,would like to thank Dr. Modupeola Sowole for technical
   assistance with fractionation in the extraction buffer refinement study,
   as well as Drs. Aaron Grant, Brian Evans, and Robert Richards for their
   clinical collaborations and provision of adipose tissue samples.
   Finally, we would like to acknowledge our tissue donors and the support
   of the Body Bequeathal Programme in the Department of Anatomy & Cell
   Biology at The University of Western Ontario, as well as Ms. Danielle
   Heinbuch for her assistance with bone tissue collection.
CR Aamodt JM, 2016, BIOMATERIALS, V86, P68, DOI 10.1016/j.biomaterials.2016.02.003
   Agmon G, 2016, CURR OPIN SOLID ST M, V20, P193, DOI 10.1016/j.cossms.2016.02.001
   Akhyari P, 2011, TISSUE ENG PART C ME, V17, P915, DOI [10.1089/ten.tec.2011.0210, 10.1089/ten.TEC.2011.0210]
   [Anonymous], 2015, PLOS ONE
   Badylak SF, 2014, ANN BIOMED ENG, V42, P1517, DOI 10.1007/s10439 013 0963 7
   Bhumiratana S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5904
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955 0674(02)00361 7
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Calle EA, 2016, ACTA BIOMATER, V46, P91, DOI 10.1016/j.actbio.2016.09.043
   Cawthorn WP, 2012, J LIPID RES, V53, P227, DOI 10.1194/jlr.R021089
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng CW, 2014, BIOTECHNOL ADV, V32, P462, DOI 10.1016/j.biotechadv.2013.12.012
   Cheung HK, 2014, BIOMATERIALS, V35, P1914, DOI 10.1016/j.biomaterials.2013.11.067
   Choi JS, 2011, J BIOMED MATER RES A, V97A, P292, DOI 10.1002/jbm.a.33056
   Chun SY, 2007, BIOMATERIALS, V28, P4251, DOI 10.1016/j.biomaterials.2007.05.020
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057
   Decaris ML, 2014, MOL CELL PROTEOMICS, V13, P1741, DOI 10.1074/mcp.M113.037267
   Didangelos A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.008128
   Didangelos A, 2010, MOL CELL PROTEOMICS, V9, P2048, DOI 10.1074/mcp.M110.001693
   Duarte AS, 2016, CRIT REV MICROBIOL, V42, P106, DOI 10.3109/1040841X.2014.904270
   Eckhard U, 2014, J PROTEOMICS, V100, P102, DOI 10.1016/j.jprot.2013.10.004
   Flynn LE, 2010, BIOMATERIALS, V31, P4715, DOI 10.1016/j.biomaterials.2010.02.046
   Fonslow BR, 2013, NAT METHODS, V10, P54, DOI [10.1038/NMETH.2250, 10.1038/nmeth.2250]
   Gentleman E, 2006, ANN BIOMED ENG, V34, P726, DOI 10.1007/s10439 005 9058 4
   Giansanti P, 2016, NAT PROTOC, V11, P993, DOI 10.1038/nprot.2016.057
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Hammarstedt A, 2013, P NATL ACAD SCI USA, V110, P2563, DOI 10.1073/pnas.1211255110
   Han TTY, 2015, BIOMATERIALS, V72, P125, DOI 10.1016/j.biomaterials.2015.08.053
   Haralson M., 1995, EXTRACELL MATRIX PRA, P404
   Highberger JH., 1939, J AM CHEM SOC, V61, P2302, DOI [DOI 10.1021/JA01878A010, 10.1021/ja01878a010]
   Hill RC, 2015, MOL CELL PROTEOMICS, V14, P961, DOI 10.1074/mcp.M114.045260
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Hoshiba T., 2015, STEM CELLS INT, V2016
   Hu LL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015917
   Hung BP, 2016, ACS BIOMATER SCI ENG, V2, P1806, DOI 10.1021/acsbiomaterials.6b00101
   Jafari M, 2012, ELECTROPHORESIS, V33, P2516, DOI 10.1002/elps.201200031
   Johnson TD, 2016, PROTEOM CLIN APPL, V10, P75, DOI 10.1002/prca.201500048
   Kabir SM, 2014, ADIPOCYTE, V3, P97, DOI 10.4161/adip.28110
   Keane TJ, 2015, METHODS, V84, P25, DOI 10.1016/j.ymeth.2015.03.005
   Keane TJ, 2012, BIOMATERIALS, V33, P1771, DOI 10.1016/j.biomaterials.2011.10.054
   Keats EC, 2014, STEM CELLS, V32, P1649, DOI 10.1002/stem.1659
   Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE 10 0377
   Kulak NA, 2014, NAT METHODS, V11, P319, DOI [10.1038/NMETH.2834, 10.1038/nmeth.2834]
   Kushnir Mark M, 2009, J Biomol Tech, V20, P101
   Laganowsky A, 2013, NAT PROTOC, V8, P639, DOI 10.1038/nprot.2013.024
   Lee DJ, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416680306
   Li QY, 2016, BIOMATERIALS, V75, P37, DOI 10.1016/j.biomaterials.2015.10.011
   Maghsoudlou P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155324
   Mahn A, 2011, J CHROMATOGR B, V879, P3645, DOI 10.1016/j.jchromb.2011.09.024
   Mazza G, 2015, SCI REP UK, V5, DOI 10.1038/srep13079
   Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557
   Merline R, 2009, J CELL COMMUN SIGNAL, V3, P323, DOI 10.1007/s12079 009 0066 2
   Millioni R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019603
   Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706
   Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003
   Naba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014647
   OAKLEY CL, 1950, J GEN MICROBIOL, V4, P365, DOI 10.1099/00221287 4 3 365
   Parisuthiman D, 2005, J BONE MINER RES, V20, P1878, DOI 10.1359/JBMR.050612
   Peloso A, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0089 y
   Raouf A, 2002, MATRIX BIOL, V21, P361, DOI 10.1016/S0945 053X(02)00027 6
   Sasaki Y., 2015, PLOS ONE, V10, P1
   Schwanhäusser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takei Y, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/729352
   Tapias LF, 2014, CURR OPIN ORGAN TRAN, V19, P145, DOI 10.1097/MOT.0000000000000051
   Tello Montoliu A, 2006, J THROMB HAEMOST, V4, P1864, DOI 10.1111/j.1538 7836.2006.01995.x
   Turner AEB, 2012, BIOMATERIALS, V33, P4490, DOI 10.1016/j.biomaterials.2012.03.026
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003 2697(84)90782 6
   Wisniewski JR, 2014, J PROTEOMICS, V109, P322, DOI 10.1016/j.jprot.2014.07.012
   Wisniewski JR, 2014, MOL CELL PROTEOMICS, V13, P3497, DOI 10.1074/mcp.M113.037309
   Wisniewski JR, 2012, ANAL CHEM, V84, P2631, DOI 10.1021/ac300006b
   Yang CX, 2012, J BIOL CHEM, V287, P40598, DOI 10.1074/jbc.M112.406850
   Yates Karen E., 2005, Cell and Tissue Banking, V6, P45, DOI 10.1007/s10561 005 5810 0
   Yu C, 2017, BIOMATERIALS, V120, P66, DOI 10.1016/j.biomaterials.2016.12.017
   Yu C, 2013, BIOMATERIALS, V34, P3290, DOI 10.1016/j.biomaterials.2013.01.056
   Yu Y., 2016, ONCOTARGET, V7
NR 83
TC 43
Z9 57
U1 1
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2017
VL 144
BP 130
EP 143
DI 10.1016/j.biomaterials.2017.08.012
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FH8CS
UT WOS:000411420000012
PM 28829951
DA 2025 08 17
ER

PT J
AU Nonaka, T
   Tsurui, N
   Mannen, T
   Kikuchi, Y
   Shiraki, K
AF Nonaka, Takahiro
   Tsurui, Noriko
   Mannen, Teruhisa
   Kikuchi, Yoshimi
   Shiraki, Kentaro
TI Non chromatographic purification of Teriparatide with a pH responsive
   CspB tag
SO PROTEIN EXPRESSION AND PURIFICATION
LA English
DT Article
DE CORYNEX (R); pH responsive CspB tag; Precipitation redissolution;
   Non chromatographic purification; Teriparatide
ID STREPTOVERTICILLIUM MOBARAENSE TRANSGLUTAMINASE; ARGININE TRANSLOCATION
   PATHWAY; PARATHYROID HORMONE ANALOG; ELASTIN LIKE POLYPEPTIDE;
   HIGH LEVEL EXPRESSION; CORYNEBACTERIUM GLUTAMICUM; RECOMBINANT
   PRODUCTION; PRO TRANSGLUTAMINASE; LAYER PROTEIN; SECRETION
AB Cell surface protein B (CspB) from Corynebacterium glutamicum is used as a pH responsive peptide tag to enable a simple solid liquid separation method for isolating a CspB fusion protein. Here we demonstrate the first application of a CspB tag for the purification of Teriparatide, which is a biologic drug that is prescribed for osteoporosis. The Teriparatide was constructed as CspB50TEV Teriparatide, comprising 50 amino acid residues of CspB, the cleavage site of TEV protease, and Teriparatide. CspB50TEV Teriparatide was expressed in a culture supernatant by C. glutamicum secretion system at 3.0 g/L (equivalent to approximately 1.2 g/L Teriparatide). The CspB50TEV Teriparatide was precipitated by reducing the pH of the culture supernatant, and the precipitate was then dissolved in a neutral buffer. A TEV protease treatment was applied to cleave the Teriparatide from the CspB50TEV Teriparatide. Then, the remaining digested CspB50TEV, undigested CspB50TEV Teriparatide, and TEV protease were precipitated in an acidic pH, whereas the soluble Teriparatide remained in the supernatant. The process had a yield of 96.5% and resulted in Teriparatide with a purity of 98.0% and productivity of 1.1 g/L of C. glutamicum culture. Thus, tag free Teriparatide was successfully purified from the CspB fusion protein using only pH changes, centrifugation, and protease digestion without the need for chromatography. This versatile purification protocol is expected to be applicable to various proteins from laboratory to industrial scales.
C1 [Nonaka, Takahiro; Tsurui, Noriko; Mannen, Teruhisa; Kikuchi, Yoshimi] Ajinomoto Co Inc, Res Inst Biosci Prod & Fine Chem, 1 1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan.
   [Nonaka, Takahiro; Shiraki, Kentaro] Univ Tsukuba, Fac Pure & Appl Sci, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058573, Japan.
C3 Ajinomoto Co Inc; University of Tsukuba
RP Nonaka, T (通讯作者)，Ajinomoto Co Inc, Res Inst Biosci Prod & Fine Chem, 1 1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan.; Nonaka, T; Shiraki, K (通讯作者)，Univ Tsukuba, Fac Pure & Appl Sci, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058573, Japan.
EM takahiro_nonaka@ajinomoto.com; shiraki@bk.tsukuba.ac.jp
FU JSPS KAKENHI [18H02383]; Grants in Aid for Scientific Research
   [18H02383] Funding Source: KAKEN
FX This work was partly supported by JSPS KAKENHI (grant number 18H02383).
   We also thank all members of the research group of Ajinomoto Co., Inc.,
   for helpful discussions and R. N. for excellent experimental support.
CR Audu CO, 2013, J PEPT SCI, V19, P504, DOI 10.1002/psc.2528
   Banki MR, 2005, NAT METHODS, V2, P659, DOI 10.1038/nmeth787
   Bataille L, 2016, PROTEIN EXPRES PURIF, V121, P81, DOI 10.1016/j.pep.2016.01.010
   Chami M, 1997, MOL MICROBIOL, V23, P483, DOI 10.1046/j.1365 2958.1997.d01 1868.x
   Date M, 2003, APPL ENVIRON MICROB, V69, P3011, DOI 10.1128/AEM.69.5.3011 3014.2003
   Date M, 2004, J BIOTECHNOL, V110, P219, DOI 10.1016/j.jbiotec.2004.02.011
   Hamedifar Haleh, 2013, Avicenna Journal of Medical Biotechnology, V5, P193
   Hirano A, 2008, J BIOCHEM, V144, P363, DOI 10.1093/jb/mvn078
   Itaya H, 2008, APPL MICROBIOL BIOT, V78, P621, DOI 10.1007/s00253 007 1340 y
   Kanaori K, 1997, EUR J BIOCHEM, V249, P878, DOI 10.1111/j.1432 1033.1997.00878.x
   Kikuchi Y, 2003, APPL ENVIRON MICROB, V69, P358, DOI 10.1128/AEM.69.1.358 366.2003
   Kikuchi Y, 2008, APPL MICROBIOL BIOT, V78, P67, DOI 10.1007/s00253 007 1283 3
   Kikuchi Y, 2006, APPL ENVIRON MICROB, V72, P7183, DOI 10.1128/AEM.01528 06
   Kikuchi Y, 2009, APPL ENVIRON MICROB, V75, P603, DOI 10.1128/AEM.01874 08
   Kimple M. E., 2013, CURR PROTOC PROTEIN, DOI [10.1002/0471140864.ps0909s739.9.1 9.9.23, DOI 10.1002/0471140864.PS0909S739.9.1 9.9.23]
   Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958
   Matsuda Y, 2014, MICROB CELL FACT, V13, DOI 10.1186/1475 2859 13 56
   Merutka G, 2016, EUR J PHARM BIOPHARM, V99, P84, DOI 10.1016/j.ejpb.2015.11.012
   Meyer DE, 1999, NAT BIOTECHNOL, V17, P1112, DOI 10.1038/15100
   Nonaka T, 2018, PROTEIN EXPRES PURIF, V146, P91, DOI 10.1016/j.pep.2018.02.004
   Oki S, 2018, PROTEIN EXPRES PURIF, V146, P85, DOI 10.1016/j.pep.2018.02.001
   OLDENBURG KR, 1994, PROTEIN EXPRES PURIF, V5, P278, DOI 10.1006/prep.1994.1042
   Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420
   PEYRET JL, 1993, MOL MICROBIOL, V9, P97, DOI 10.1111/j.1365 2958.1993.tb01672.x
   Pina AS, 2014, BIOTECHNOL ADV, V32, P366, DOI 10.1016/j.biotechadv.2013.12.001
   Shiraki K, 2002, J BIOCHEM, V132, P591, DOI 10.1093/oxfordjournals.jbchem.a003261
   Sung WL, 2000, IUBMB LIFE, V49, P131
   Suzuki Y, 1998, APPL ENVIRON MICROB, V64, P526
   Trabbic Carlson K, 2004, PROTEIN ENG DES SEL, V17, P57, DOI 10.1093/protein/gzh006
   Umakoshi M, 2011, J BIOSCI BIOENG, V112, P595, DOI 10.1016/j.jbiosc.2011.08.011
   Wood DW, 2014, CURR OPIN STRUC BIOL, V26, P54, DOI 10.1016/j.sbi.2014.04.006
   Zhao XY, 2013, J ANAL METHODS CHEM, V2013, DOI 10.1155/2013/581093
   ZULL JE, 1990, J BIOL CHEM, V265, P5671
NR 33
TC 8
Z9 8
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1046 5928
EI 1096 0279
J9 PROTEIN EXPRES PURIF
JI Protein Expr. Purif.
PD MAR
PY 2019
VL 155
BP 66
EP 71
DI 10.1016/j.pep.2018.11.008
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA HJ1ET
UT WOS:000456905400011
PM 30485791
DA 2025 08 17
ER

PT J
AU Stavrinou, E
   Sarafidis, P
   Koumaras, C
   Loutradis, C
   Giamalis, P
   Tziomalos, K
   Karagiannis, A
   Papagianni, A
AF Stavrinou, Eirini
   Sarafidis, PantelisA.
   Koumaras, Charalampos
   Loutradis, Charalampos
   Giamalis, Panagiotis
   Tziomalos, Konstantinos
   Karagiannis, Asterios
   Papagianni, Aikaterini
TI Increased Sclerostin, but Not Dickkopf 1 Protein, Is Associated with
   Elevated Pulse Wave Velocity in Hemodialysis Subjects
SO KIDNEY & BLOOD PRESSURE RESEARCH
LA English
DT Article
DE Sclerostin; Dickkopf 1 protein; Hemodialysis; Pulse wave velocity;
   Arterial stiffness
ID CHRONIC KIDNEY DISEASE; ARTERIAL STIFFNESS; SERUM SCLEROSTIN; VASCULAR
   CALCIFICATIONS; CIRCULATING SCLEROSTIN; CARDIOVASCULAR EVENTS; AORTIC
   STIFFNESS; RENAL FUNCTION; MORTALITY; MANAGEMENT
AB Background: Sclerostin and Dickkopf 1 (Dkk 1) proteins are inhibitors of the canonical Wnt/beta catenin bone pathway. Pilot data suggest that sclerostin may be involved in vascular changes in chronic kidney disease (CKD), but data on the effects of Dkk 1 are scarce. This is the first study investigating simultaneously the associations of sclerostin and Dkk 1 with arterial stiffness in hemodialysis patients. Methods: A total of 80 patients on chronic hemodialysis had carotid femoral pulse wave velocity (PWV), central blood pressure (BP), and wave reflections evaluated with applanation tonometry (Sphygmocor) on a midweek non dialysis day. Serum levels of sclerostin and Dkk 1 were measured with ELISA. A large set of demographic, comorbid, laboratory, and drug parameters were used in the analyses. Results: Subjects with PWV >9.5 m/s (high arterial stiffness group, n = 40) were older, had higher BMI, higher prevalence of hypertension, diabetes, and coronary heart disease, and higher peripheral systolic BP, central systolic BP, C reactive protein, and serum sclerostin (p = 0.02), but similar Dkk 1, compared to subjects with low PWV. When dichotomizing the population by sclerostin levels, those with high sclerostin had higher PWV than patients with low sclerostin levels (10.63 +/  2.71 vs. 9.77 +/  3.13, p = 0.048). Increased sclerostin (>200 pg/mL) was significantly associated with increased PWV (>9.5 m/s; HR 2.778, 95% CI 1.123 6.868 per pg/mL increase); this association remained significant after stepwise adjustment for Dkk 1, intact parathyroid hormone, and calcium x phosphate product. In contrast, no association was noted between Dkk 1 and PWV (HR 1.000, 95% CI 0.416 2.403). Conclusion: Serum sclerostin is associated with PWV independently of routine markers of CKD MBD in hemodialysis patients. In contrast, Dkk 1 has no association with arterial stiffness and is not pathophysiologically involved in relevant vascular changes. (C) 2019 The Author(s) Published by S. Karger AG, Basel
C1 [Stavrinou, Eirini; Sarafidis, PantelisA.; Loutradis, Charalampos; Giamalis, Panagiotis; Papagianni, Aikaterini] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Nephrol, Konstantinoupoleos 49, GR 54642 Thessaloniki, Greece.
   [Koumaras, Charalampos; Karagiannis, Asterios] Aristotle Univ Thessaloniki, Hippokrat Hosp, Propaedeut Dept Internal Med 2, Thessaloniki, Greece.
   [Tziomalos, Konstantinos] Aristotle Univ Thessaloniki, AHEPA Hosp, Propaedeut Dept Internal Med 1, Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; Aristotle University of Thessaloniki; Ahepa University
   Hospital
RP Sarafidis, P (通讯作者)，Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Nephrol, Konstantinoupoleos 49, GR 54642 Thessaloniki, Greece.
EM psarafidis11@yahoo.gr
RI ; PAPAGIANNI, ANDROMACHI/Q 9789 2016; Sarafidis, Pantelis/AFO 2131 2022
OI Sarafidis, Pantelis/0000 0002 9174 4018; Papagianni,
   Aikaterini/0000 0003 0437 5208; Loutradis,
   Charalampos/0000 0001 6387 4176; 
CR Cannata Andía JB, 2006, J AM SOC NEPHROL, V17, pS267, DOI 10.1681/ASN.2006080925
   Delanaye P, 2018, NEPHROL DIAL TRANSPL, V33, P1404, DOI 10.1093/ndt/gfx282
   Delanaye P, 2014, NEPHRON CLIN PRACT, V128, P127, DOI 10.1159/000366449
   DeLoach SS, 2008, CLIN J AM SOC NEPHRO, V3, P184, DOI 10.2215/CJN.03340807
   Desjardins L, 2014, NEPHROL THER, V10, P463, DOI 10.1016/j.nephro.2014.04.002
   Drechsler C, 2015, NEPHROL DIAL TRANSPL, V30, P288, DOI 10.1093/ndt/gfu301
   Ford ML, 2010, HYPERTENSION, V55, P1110, DOI 10.1161/HYPERTENSIONAHA.109.143024
   Gaudio A, 2017, MOL MED REP, V15, P3420, DOI 10.3892/mmr.2017.6390
   Gelir GK, 2018, BLOOD PURIFICAT, V46, P118, DOI 10.1159/000487223
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goliasch G, 2012, ATHEROSCLEROSIS, V222, P251, DOI 10.1016/j.atherosclerosis.2012.02.017
   Hampson G, 2013, BONE, V56, P42, DOI 10.1016/j.bone.2013.05.010
   Hsu BG, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003300
   Jin S, 2016, BIOMARK MED, V10, P689, DOI 10.2217/bmm 2016 0031
   Kanbay M, 2014, J CLIN ENDOCR METAB, V99, pE1854, DOI 10.1210/jc.2014 2042
   Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254
   Mancia G, 2013, J HYPERTENS, V31, P1281, DOI 10.1097/01.hjh.0000431740.32696.cc
   Mill C, 2012, CARDIOVASC RES, V95, P233, DOI 10.1093/cvr/cvs141
   Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Morales Santana S, 2013, DIABETES CARE, V36, P1667, DOI 10.2337/dc12 1691
   Morena M, 2015, NEPHROL DIAL TRANSPL, V30, P1345, DOI 10.1093/ndt/gfv081
   Moysés RMA, 2015, SEMIN DIALYSIS, V28, P578, DOI 10.1111/sdi.12415
   Naves M, 2008, OSTEOPOROSIS INT, V19, P1161, DOI 10.1007/s00198 007 0539 1
   Nowak A, 2015, KIDNEY BLOOD PRESS R, V40, P266, DOI 10.1159/000368502
   Pelletier S, 2013, CLIN J AM SOC NEPHRO, V8, P819, DOI 10.2215/CJN.07670712
   Register TC, 2013, J CLIN ENDOCR METAB, V98, pE60, DOI 10.1210/jc.2012 3038
   Thambiah S, 2012, CALCIFIED TISSUE INT, V90, P473, DOI 10.1007/s00223 012 9595 4
   Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085
   Ueland T, 2009, ARTERIOSCL THROM VAS, V29, P1228, DOI 10.1161/ATVBAHA.109.189761
   Verbeke F, 2011, CLIN J AM SOC NEPHRO, V6, P153, DOI 10.2215/CJN.05120610
   Zhu DX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019595
NR 33
TC 13
Z9 15
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1420 4096
EI 1423 0143
J9 KIDNEY BLOOD PRESS R
JI Kidney Blood Pressure Res.
PY 2019
VL 44
IS 4
BP 679
EP 689
DI 10.1159/000501205
PG 11
WC Physiology; Urology & Nephrology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Urology & Nephrology; Cardiovascular System & Cardiology
GA IU8UQ
UT WOS:000483857700019
PM 31382263
OA gold
DA 2025 08 17
ER

PT J
AU Shen, YF
   Ho, CC
   Shie, MY
   Wang, K
   Fang, HY
AF Shen, Yu Fang
   Ho, Chia Che
   Shie, Ming You
   Wang, Kan
   Fang, Hsin Yuan
TI Hinokitiol Loaded Mesoporous Calcium Silicate Nanoparticles Induce
   Apoptotic Cell Death through Regulation of the Function of MDR1 in Lung
   Adenocarcinoma Cells
SO MATERIALS
LA English
DT Article
DE mesoporous calcium silicate; hinokitiol; apoptosis; multiple drug
   resistance protein 1; caspase 3/ 9
ID DRUG DELIVERY; IN VITRO; TRICALCIUM PHOSPHATE; CANCER CELLS; RELEASE;
   CEMENT; ANTIBACTERIAL; OSTEOBLAST; RESISTANCE; RESPONSES
AB Hinokitiol is a tropolone related compound found in heartwood cupressaceous plants. Hinokitiol slows the growth of a variety of cancers through inhibition of cell proliferation. The low water solubility of hinokitiol leads to less bioavailability. This has been highlighted as a major limiting factor. In this study, mesoporous calcium silicate (MCS) nanoparticles, both pure and hinokitiol loaded, were synthesized and their effects on A549 cells were analyzed. The results indicate that Hino MCS nanoparticles induce apoptosis in higher concentration loads (>12.5 mu g/mL) for A549 cells. Hino MCS nanoparticles suppress gene and protein expression levels of multiple drug resistance protein 1 (MDR1). In addition, both the activity and the expression levels of caspase 3/ 9 were measured in Hino MCS nanoparticle treated A549 cells. The Hino MCS nanoparticles triggered apoptosis was blocked by inhibitors of pan caspase, caspase 3/ 9, and antioxidant agents (N acetylcysteine; NAC). The Hino MCS nanoparticles enhance reactive oxygen species production and the protein expression levels of caspase 3/ 9. Our data suggest that Hino MCS nanoparticles trigger an intrinsic apoptotic pathway through regulating the function of MDR1 and the production of reactive oxygen species in A549 cells. Therefore, we believe that Hino MCS nanoparticles may be efficacious in the treatment of drug resistant human lung cancer in the future.
C1 [Shen, Yu Fang; Ho, Chia Che; Shie, Ming You; Fang, Hsin Yuan] China Med Univ Hosp, Printing Med Res Ctr 3D, Taichung 40447, Taiwan.
   [Ho, Chia Che; Wang, Kan] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA.
   [Ho, Chia Che; Wang, Kan] Georgia Inst Technol, Georgia Tech Mfg Inst, Atlanta, GA 30332 USA.
   [Fang, Hsin Yuan] China Med Univ Hosp, Dept Thorac Surg, Taichung 40447, Taiwan.
   [Fang, Hsin Yuan] China Med Univ, Sch Med, Taichung 40447, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital  
   Taiwan; University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology; China
   Medical University Taiwan; China Medical University Hospital   Taiwan;
   China Medical University Taiwan
RP Fang, HY (通讯作者)，China Med Univ Hosp, Printing Med Res Ctr 3D, Taichung 40447, Taiwan.; Fang, HY (通讯作者)，China Med Univ Hosp, Dept Thorac Surg, Taichung 40447, Taiwan.; Fang, HY (通讯作者)，China Med Univ, Sch Med, Taichung 40447, Taiwan.
EM cherryuf@gmail.com; sfox1223@gmail.com; eviltacasi@gmail.com;
   kan.wang@gatech.edu; eric@www.cmuh.org.tw
RI Ho, Chia Che/T 6786 2019; Wang, Kan/D 2927 2015; Shen,
   Yao chun/AAB 4394 2019
OI Shie, Ming You/0000 0002 0650 4344; Ho, Chia Che/0000 0002 2825 3398
FU China Medical University Hospital of Taiwan [DMR 105 002]
FX The authors acknowledge the receipt of a grant from the China Medical
   University Hospital grants (DMR 105 002) of Taiwan.
CR Baba T, 1998, J INVEST DERMATOL, V110, P24, DOI 10.1046/j.1523 1747.1998.00078.x
   Canitrot Y, 1998, CANCER LETT, V130, P133, DOI 10.1016/S0304 3835(98)00128 1
   Chang NJ, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/5/055004
   Chang PY, 2013, INT J ONCOL, V43, P1141, DOI 10.3892/ijo.2013.2050
   Chen YW, 2016, MAT SCI ENG C MATER, V60, P374, DOI 10.1016/j.msec.2015.11.064
   Chen YW, 2015, J MATER CHEM B, V3, P7099, DOI 10.1039/c5tb00713e
   Gan Q, 2015, J MATER CHEM B, V3, P2056, DOI 10.1039/c4tb01897d
   Gan Q, 2012, BIOMED MICRODEVICES, V14, P259, DOI 10.1007/s10544 011 9604 9
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Ho CC, 2013, J MATER SCI MATER M, V24, P2381, DOI 10.1007/s10856 013 4994 2
   Hsu FY, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/2/025007
   Hsu TT, 2015, J ENDODONT, V41, P1073, DOI 10.1016/j.joen.2015.02.031
   Huang MH, 2016, MAT SCI ENG C MATER, V65, P1, DOI 10.1016/j.msec.2016.04.016
   Huang MH, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5484 5
   Islam MS, 2015, J MATER CHEM B, V3, P1001, DOI 10.1039/c4tb01911c
   Jayakumar T, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/840487
   Lai WY, 2015, MATERIALS, V8, P4491, DOI 10.3390/ma8074491
   Lee H, 2014, J MATER CHEM B, V2, P5785, DOI 10.1039/c4tb00931b
   Li LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104203
   Li N, 2015, J MATER CHEM B, V3, P8558, DOI 10.1039/c5tb01423a
   Lin Q, 2016, MAT SCI ENG C MATER, V58, P774, DOI 10.1016/j.msec.2015.09.032
   Lin YS, 2011, CHEM COMMUN, V47, P532, DOI 10.1039/c0cc02923h
   Lin YS, 2010, J AM CHEM SOC, V132, P4834, DOI 10.1021/ja910846q
   Liu F, 2015, J MATER CHEM B, V3, P2206, DOI 10.1039/c4tb02073a
   Lu JX, 2012, MICROPOR MESOPOR MAT, V163, P221, DOI 10.1016/j.micromeso.2012.06.037
   Mao C, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/2/025005
   Mendes LS, 2013, MAT SCI ENG C MATER, V33, P4427, DOI 10.1016/j.msec.2013.06.040
   Shadjou N, 2015, MAT SCI ENG C MATER, V55, P401, DOI 10.1016/j.msec.2015.05.027
   Shie MY, 2011, ACTA BIOMATER, V7, P2604, DOI 10.1016/j.actbio.2011.02.023
   Shih YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094941
   Shih YH, 2013, MICROBIOL RES, V168, P254, DOI 10.1016/j.micres.2012.12.007
   Su CC, 2014, MAT SCI ENG C MATER, V37, P156, DOI 10.1016/j.msec.2014.01.010
   Tu MG, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5607 z
   Valerio P, 2004, BIOMATERIALS, V25, P2941, DOI 10.1016/j.biomaterials.2003.09.086
   Wang WK, 2016, ENVIRON TOXICOL, V31, P77, DOI 10.1002/tox.22023
   Wu CT, 2013, J MATER CHEM B, V1, P2710, DOI 10.1039/c3tb20275e
   Wu CT, 2012, J MATER CHEM, V22, P16801, DOI 10.1039/c2jm33387b
   Xiong L, 2015, J MATER CHEM B, V3, P1712, DOI 10.1039/c4tb01601g
   Yang PS, 2015, MOLECULES, V20, P8198, DOI 10.3390/molecules20058198
   Ye J, 2015, EYE, V29, P964, DOI 10.1038/eye.2015.62
   Ye MX, 2012, PHYTOMEDICINE, V19, P779, DOI 10.1016/j.phymed.2012.03.005
   Zhang C, 2015, J MATER CHEM B, V3, P1261, DOI 10.1039/c4tb01701c
NR 42
TC 12
Z9 12
U1 1
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1996 1944
J9 MATERIALS
JI Materials
PD MAY
PY 2016
VL 9
IS 5
AR 306
DI 10.3390/ma9050306
PG 13
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA DP6SG
UT WOS:000378628500001
PM 28773431
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Lei, JX
   Hui, DY
   Huang, WJ
   Liao, Y
   Yang, L
   Liu, LS
   Zhang, Q
   Qi, GL
   Song, W
   Zhang, YY
   Xiang, AP
   Zhou, Q
AF Lei, Junxia
   Hui, Dayang
   Huang, Weijun
   Liao, Yan
   Yang, Lan
   Liu, Longshan
   Zhang, Qi
   Qi, Guolong
   Song, Wu
   Zhang, Yuanyuan
   Xiang, Andy Peng
   Zhou, Qing
TI Heterogeneity of the biological properties and gene expression profiles
   of murine bone marrow stromal cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Mesenchymal stromal cells; Biological properties;Immunosuppression; Gene
   expression
ID MESENCHYMAL STEM CELLS; NITRIC OXIDE; IN VITRO; DIFFERENTIATION;
   PROLIFERATION; IMMUNOSUPPRESSION; PHENOTYPE; APOPTOSIS; THERAPY; STRAINS
AB Although mesenchymal stromal cells (MSCs) have demonstrated great therapeutic potential, the heterogeneity of MSCs may be responsible for the incongruent data obtained in MSC based preclinical studies and clinical trials. Here, four mouse clonal MSC lines, termed MSC1, MSC2, MSC3, and MSC4, were isolated and extensively characterized. MSC4 cells grew most rapidly and formed colonies of the largest size, whereas MSC3 cells exhibited the slowest growth and formed only a few tiny clusters. MSC4 cells could differentiate into adipocytes, osteoblasts, and chondrocytes in vitro, and more importantly, establish hematopoietic microenvironment in vivo; whereas the other lines displayed uni adipogenic, osteo chondrogenic, or non differentiation potential. All lines were positive for Sca 1, CD106, and CD44; MSC4 Was also positive for CD90.2. In terms of immunosuppressive capacity, MSC2, MSC3, and MSC4 cells exerted clear inhibitory effects on lymphocyte proliferation, whereas MSC1 did not. Further investigation revealed that the NO and not the PGE2 pathway may play a role in the different immunomodulatory effects of the cell lines. To clarify the molecular basis of this heterogeneity, we employed RNA sequencing to compare the gene expression profiles of the four subtypes, revealing a relationship between gene expression and variability in subtype function. This study provides novel information about the heterogeneity of MSCs and insight into the selection of optimal cell sources for therapeutic applications. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Lei, Junxia; Hui, Dayang; Huang, Weijun; Liao, Yan; Yang, Lan; Xiang, Andy Peng] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, Guangzhou 510080, Guangdong, Peoples R China.
   [Hui, Dayang] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510630, Guangdong, Peoples R China.
   [Liu, Longshan] Sun Yat Sen Univ, Affiliated Hosp 1, Lab Gen Surg, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhang, Qi; Xiang, Andy Peng] Sun Yat Sen Univ, Affiliated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou 510630, Guangdong, Peoples R China.
   [Qi, Guolong] Jinan Univ, Sch Med, Dept Med Informat, Guangzhou 510632, Guangdong, Peoples R China.
   [Song, Wu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Pancreat Surg, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhang, Yuanyuan] Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA.
   [Zhou, Qing] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510630, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; Jinan University; Sun Yat Sen University; Wake
   Forest University; Jinan University
RP Xiang, AP (通讯作者)，Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Ctr Stem Cell Biol & Tissue Engn, Guangzhou 510080, Guangdong, Peoples R China.
EM xiangp@mail.sysu.edu.cn; kerryzh@163.com
RI ; Liu, Longshan/GWD 0798 2022; Weijun, Huang/HKE 5161 2023
OI Xiang, Peng/0000 0003 3409 5012; 
FU National Basic Research Program of China [2012CBA01302, 2009CB522104,
   2010CB945401]; National Natural Science Foundation of China [U0932006,
   31171398, 81170367, 81270646]; Key Scientific and Technological Projects
   of Guangdong Province [2007A032100003]; Key Scientific and Technological
   Program of Guangzhou City [2008A1 E4011 5, 2010U1 E00551]
FX This work was funded by National Basic Research Program of China
   (2012CBA01302, 2009CB522104 and 2010CB945401), National Natural Science
   Foundation of China (U0932006, 31171398, 81170367, and 81270646), Key
   Scientific and Technological Projects of Guangdong Province
   (2007A032100003), Key Scientific and Technological Program of Guangzhou
   City (2008A1 E4011 5 and 2010U1 E00551).
CR Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Bae S, 2011, STEM CELLS DEV, V20, P197, DOI 10.1089/scd.2010.0127
   Bae S, 2009, CELL TISSUE RES, V335, P565, DOI 10.1007/s00441 008 0729 y
   Bassi EJ, 2012, STEM CELL REV REP, V8, P329, DOI 10.1007/s12015 011 9311 1
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bunnell BA, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt34
   Caimi PF, 2010, CURR OPIN HEMATOL, V17, P505, DOI 10.1097/MOH.0b013e32833e5b18
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116
   Eslaminejad MB, 2009, IN VITRO CELL DEV AN, V45, P451, DOI 10.1007/s11626 009 9198 1
   Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002
   Ghannam S, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt2
   Götherström C, 2005, HAEMATOLOGICA, V90, P1017
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kuznetsov SA, 1997, J BONE MINER RES, V12, P1335, DOI 10.1359/jbmr.1997.12.9.1335
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Lim JH, 2010, J IMMUNOL, V185, P4022, DOI 10.4049/jimmunol.0902723
   Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007 0454
   Ma Teng, 2010, World J Stem Cells, V2, P13, DOI 10.4252/wjsc.v2.i2.13
   Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365 2141.2003.04669.x
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006 291X(02)00661 7
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Pevsner Fischer M, 2011, STEM CELL REV REP, V7, P560, DOI 10.1007/s12015 011 9229 7
   Phinney DG, 2012, J CELL BIOCHEM, V113, P2806, DOI 10.1002/jcb.24166
   Plumas J, 2005, LEUKEMIA, V19, P1597, DOI 10.1038/sj.leu.2403871
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Rosenzweig A, 2006, NEW ENGL J MED, V355, P1274, DOI 10.1056/NEJMe068172
   Russell KC, 2011, BIOTECHNOL BIOENG, V108, P2716, DOI 10.1002/bit.23193
   Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood 2006 02 002246
   Satomura K, 2000, J CELL BIOCHEM, V78, P391
   Schurgers E, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2939
   Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
   Shu ST, 2010, LEUKEMIA LYMPHOMA, V51, P702, DOI 10.3109/10428191003646697
   Siegel G, 2009, TRANSPLANTATION, V87, pS45, DOI 10.1097/TP.0b013e3181a285b0
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Wang J, 2011, EXPERT OPIN BIOL TH, V11, P893, DOI 10.1517/14712598.2011.574119
NR 46
TC 31
Z9 33
U1 0
U2 25
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD NOV
PY 2013
VL 45
IS 11
BP 2431
EP 2443
DI 10.1016/j.biocel.2013.07.015
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 264XR
UT WOS:000327914800009
PM 23911306
DA 2025 08 17
ER

PT J
AU Yu, XL
   Zhou, JN
   Zhao, FL
   Liu, X
   Mao, YH
   Diao, L
   Wen, CJ
   Liu, M
AF Yu, Xiaolu
   Zhou, Junnan
   Zhao, Fuli
   Liu, Xuan
   Mao, Yuhang
   Diao, Li
   Wen, Chuanjun
   Liu, Mei
TI Tomatidine Suppresses the Destructive Behaviors of Fibroblast Like
   Synoviocytes and Ameliorates Type II Collagen Induced Arthritis in Rats
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE tomatidine; rheumatoid arthritis; fibroblast like synoviocytes;
   collagen induced arthritis; MAPK; NF kappa B
ID NF KAPPA B; RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; T CELL;
   INFLAMMATION; REGULATOR; PATHWAYS; INHIBIT; GROWTH; LIVER
AB Fibroblast like synoviocytes (FLSs) are the prominent non immune cells in synovium and play a pivotal role in rheumatoid arthritis (RA) pathogenesis. Searching for natural compounds that may suppress the pathological phenotypes of FLSs is important for the development of RA treatment. Tomatidine (Td), a steroidal alkaloid derived from the solanaceae family, has been reported to have anti inflammatory, anti tumor and immunomodulatory effects. However, its effect on RA remains unknown. Here, we examined the inhibitory effect of Td on TNF alpha induced arthritic FLSs, and subsequently investigated its therapeutic effect on collagen induced arthritis (CIA) rats. Our results revealed that Td significantly inhibited TNF alpha induced proliferation and migration of arthritic FLSs. In addition, we found that Td treatment could efficaciously ameliorate synovial inflammation and joint destruction of rats with CIA. Both in vitro and in vivo studies showed that Td significantly suppressed the production of pro inflammatory cytokines including IL 1 beta, IL 6 and TNF alpha, and downregulated the expression of MMP 9 and RANKL. Further molecular mechanism studies revealed that the inhibitory effect of Td on RA might attribute to the decreased activations of MAPKs (ERK and JNK) and NF kappa B. These findings provide evidence that Td has the potential to be developed into a complementary or alternative agent for RA therapy.
C1 [Yu, Xiaolu; Zhou, Junnan; Zhao, Fuli; Liu, Xuan; Mao, Yuhang; Diao, Li; Wen, Chuanjun; Liu, Mei] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Peoples R China.
C3 Nanjing Normal University
RP Wen, CJ; Liu, M (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Peoples R China.
EM wenchuanjun@hotmail.com; meiliunj@163.com
FU National Natural Science Foundation of China [31870895, 32071165,
   31171135]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD)
FX Funding This study was supported by National Natural Science Foundation
   of China (Grant No. 31870895; 32071165; 31171135) and the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD).
CR Ath A.J.F., 1991, ATLAS SYNOVIAL FLUID
   Athanasou NA, 1996, J BONE JOINT SURG AM, V78A, P1096, DOI 10.2106/00004623 199607000 00016
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Bogoyevitch MA, 2010, BBA PROTEINS PROTEOM, V1804, P463, DOI 10.1016/j.bbapap.2009.11.002
   Cai X, 2007, J ETHNOPHARMACOL, V110, P39, DOI 10.1016/j.jep.2006.09.008
   Chiu FL, 2008, FEBS LETT, V582, P2407, DOI 10.1016/j.febslet.2008.05.049
   Danks L, 2002, ANN RHEUM DIS, V61, P916, DOI 10.1136/ard.61.10.916
   Dyle MC, 2014, J BIOL CHEM, V289, P14913, DOI 10.1074/jbc.M114.556241
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Friedman M, 2009, J AGR FOOD CHEM, V57, P5727, DOI 10.1021/jf900364j
   Fujiwara Y, 2012, J AGR FOOD CHEM, V60, P2472, DOI 10.1021/jf204197r
   Giannelli G, 2004, CLIN EXP RHEUMATOL, V22, P335
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Gruber BL, 1996, CLIN IMMUNOL IMMUNOP, V78, P161, DOI 10.1006/clin.1996.0025
   Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007
   Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357 4310(99)01544 0
   Hu B, 2019, FASEB J, V33, P2574, DOI 10.1096/fj.201800920R
   Jeon S, 2019, CHEM BIOL INTERACT, V313, DOI 10.1016/j.cbi.2019.108826
   Kim KW, 2009, IMMUNOL LETT, V124, P9, DOI 10.1016/j.imlet.2009.02.006
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691
   Lahoti TS, 2014, J PHARMACOL EXP THER, V348, P236, DOI 10.1124/jpet.113.209726
   Lange F, 2005, ANN RHEUM DIS, V64, P599, DOI 10.1136/ard.2004.026120
   Laragione T, 2008, ARTHRITIS RHEUM US, V58, P2296, DOI 10.1002/art.23610
   Lee KR, 2004, J AGR FOOD CHEM, V52, P2832, DOI 10.1021/jf030526d
   Lee ST, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018915
   Liu CF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/626038
   Liu M, 2018, J CELL PHYSIOL, V233, P6291, DOI 10.1002/jcp.26517
   Liu ZZ, 2018, J CELL PHYSIOL, V233, P8740, DOI 10.1002/jcp.26754
   Ma YY, 2005, CURR PHARM DESIGN, V11, P569, DOI 10.2174/1381612053381927
   Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300
   Mor A, 2005, CLIN IMMUNOL, V115, P118, DOI 10.1016/j.clim.2004.12.009
   Neidhart M, 2003, ARTHRITIS RHEUM, V48, P1873, DOI 10.1002/art.11166
   Noss EH, 2008, IMMUNOL REV, V223, P252, DOI 10.1111/j.1600 065X.2008.00648.x
   Qiu HW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051514
   Senolt L, 2009, AUTOIMMUN REV, V9, P102, DOI 10.1016/j.autrev.2009.03.010
   Shieh JM, 2011, CELL BIOCHEM BIOPHYS, V60, P297, DOI 10.1007/s12013 011 9152 1
   Skapenko A, 2005, ARTHRITIS RES THER, V7, pS4, DOI 10.1186/ar1703
   Song SE, 2018, MOL CELL BIOCHEM, V444, P17, DOI 10.1007/s11010 017 3226 3
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Tchetverikov I, 2004, ANN RHEUM DIS, V63, P881, DOI 10.1136/ard.2003.013243
   Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007
   Ueland T, 2005, CIRCULATION, V111, P2461, DOI 10.1161/01.CIR.0000165119.62099.14
   Yan KH, 2013, CHEM BIOL INTERACT, V203, P580, DOI 10.1016/j.cbi.2013.03.016
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yuan HY, 2015, EXPERT OPIN THER PAT, V25, P909, DOI 10.1517/13543776.2015.1044972
NR 46
TC 19
Z9 19
U1 1
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 26
PY 2021
VL 12
AR 670707
DI 10.3389/fphar.2021.670707
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XN1XI
UT WOS:000729305200001
PM 34512321
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Palit, S
   Kendrick, J
AF Palit, Shyamal
   Kendrick, Jessica
TI Vascular Calcification in Chronic Kidney Disease: Role of Disordered
   Mineral Metabolism
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Vascular calcification; chronic kidney disease; mineral metabolism;
   phosphorus
ID CORONARY ARTERY CALCIFICATION; FIBROBLAST GROWTH FACTOR 23;
   SMOOTH MUSCLE CELLS; STAGE RENAL DISEASE; CALCIUM SENSING RECEPTOR;
   RENIN ANGIOTENSIN SYSTEM; OSTEOCLAST LIKE CELLS; VITAMIN D;
   HEMODIALYSIS PATIENTS; CARDIOVASCULAR DISEASE
AB In patients with chronic kidney disease (CKD), vascular calcification is associated with significant morbidity and mortality. The prevalence of vascular calcification increases as glomerular filtration rate (GFR) declines and calcification occurs years earlier in CKD patients than in the general population. The mechanisms of vascular calcification in CKD patients are complex and not completely understood but likely involve non traditional risk factors, which may be unique to patients with CKD. These unique risk factors may predispose patients to early and more accelerated calcification. Experimental and clinical studies show that disorders in mineral metabolisms including calcium and phosphorus homeostasis initiate and promote vascular calcification in patients with CKD. It is currently unknown if vascular calcification can be prevented or reversed with therapies aimed at maintaining calcium and phosphorus homeostasis. This review focuses on the potential mechanisms by which disordered mineral metabolism may promote vascular calcification in patients with CKD.
C1 [Palit, Shyamal; Kendrick, Jessica] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO USA.
   [Kendrick, Jessica] Denver Hlth Med Ctr, Denver, CO USA.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; Denver Health Medical Center
RP Kendrick, J (通讯作者)，Univ Colorado, Div Renal Dis & Hypertens, Denver Hlth Med Ctr, 660 Bannock St Mail Code 4000, Denver, CO 80204 USA.
EM Jessica.Kendrick@ucdenver.edu
FU National Institute of Diabetes and Digestive and Kidney Disease [K23
   DK087859]
FX Financial Support: National Institute of Diabetes and Digestive and
   Kidney Disease Grant K23 DK087859
CR Adeney KL, 2009, J AM SOC NEPHROL, V20, P381, DOI 10.1681/ASN.2008040349
   Alam M, 2009, CARDIOVASC RES, V81, P260, DOI 10.1093/cvr/cvn279
   [Anonymous], [No title captured]
   Balci M, 2010, HEMODIAL INT, V14, P425, DOI 10.1111/j.1542 4758.2010.00480.x
   Barreto DV, 2008, NEPHRON CLIN PRACT, V110, pC273, DOI 10.1159/000170783
   Benet Pagès A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Bleyer AJ, 2005, AM J KIDNEY DIS, V46, P464, DOI 10.1053/j.ajkd.2005.04.035
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Callister TQ, 1998, NEW ENGL J MED, V339, P1972, DOI 10.1056/NEJM199812313392703
   Chen NX, 2002, KIDNEY INT, V62, P1724, DOI 10.1046/j.1523 1755.2002.00625.x
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Chue CD, 2013, J AM SOC NEPHROL, V24, P842, DOI 10.1681/ASN.2012070719
   Doherty TM, 2002, FASEB J, V16, DOI 10.1096/fj.01 0898hyp
   Drueke T, 2007, COMPREHENSIVE CLIN N, P123
   El Abbadi MM, 2009, KIDNEY INT, V75, P1297, DOI 10.1038/ki.2009.83
   Ewence AE, 2008, CIRC RES, V103, pE28, DOI 10.1161/CIRCRESAHA.108.181305
   Fritsch S, 2004, J AM SOC NEPHROL, V15, P2588, DOI 10.1097/01.ASN.0000141040.77536.AF
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Giachelli CM, 2005, CIRC RES, V96, P717, DOI 10.1161/01.RES.0000161997.24797.c0
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Gutiérrez OM, 2009, CIRCULATION, V119, P2545, DOI 10.1161/CIRCULATIONAHA.108.844506
   Heyliger A, 2009, SURGERY, V146, P1042, DOI 10.1016/j.surg.2009.09.024
   Hu MC, 2011, J AM SOC NEPHROL, V22, P124, DOI 10.1681/ASN.2009121311
   Hunt J, 2002, POETRY WALES, V37, P33
   Ivanovski O, 2009, ATHEROSCLEROSIS, V205, P55, DOI 10.1016/j.atherosclerosis.2008.10.043
   Jacoby DS, 2003, ARCH INTERN MED, V163, P1155, DOI 10.1001/archinte.163.10.1155
   Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P948, DOI 10.1093/ndt/gfn571
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kawata T, 2008, KIDNEY INT, V74, P1270, DOI 10.1038/ki.2008.407
   Kendrick J, 2012, AM J KIDNEY DIS, V60, P567, DOI 10.1053/j.ajkd.2012.04.014
   Kendrick J, 2011, J AM SOC NEPHROL, V22, P1913, DOI 10.1681/ASN.2010121224
   Kendrick J, 2011, AM J KIDNEY DIS, V58, P826, DOI 10.1053/j.ajkd.2011.07.020
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, KIDNEY INT S, pS1
   Koh N, 2001, BIOCHEM BIOPH RES CO, V280, P1015, DOI 10.1006/bbrc.2000.4226
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   London GM, 2007, J AM SOC NEPHROL, V18, P613, DOI 10.1681/ASN.2006060573
   Mansfield K, 1999, J CELL PHYSIOL, V179, P276, DOI 10.1002/(SICI)1097 4652(199906)179:3<276::AID JCP5>3.0.CO;2 #
   Mansfield K, 2003, CALCIFIED TISSUE INT, V73, P161, DOI 10.1007/s00223 002 1056 z
   Massy ZA, 2008, DIABETES METAB, V34, pS16, DOI 10.1016/S1262 3636(08)70098 3
   McIntyre CW, 2008, SEMIN DIALYSIS, V21, P38, DOI 10.1111/j.1525 139X.2007.00368.x
   Mozar A, 2008, J CELL PHYSIOL, V215, P47, DOI 10.1002/jcp.21283
   Nasrallah MM, 2010, NEPHROL DIAL TRANSPL, V25, P2679, DOI 10.1093/ndt/gfq089
   Ohanian J, 2005, AM J PHYSIOL HEART C, V288, pH1756, DOI 10.1152/ajpheart.00739.2004
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Qunibi W, 2008, AM J KIDNEY DIS, V51, P952, DOI 10.1053/j.ajkd.2008.02.298
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Rebsamen MC, 2002, CIRC RES, V91, P17, DOI 10.1161/01.RES.0000025269.60668.0F
   Rostand SG, 1999, KIDNEY INT, V56, P383, DOI 10.1046/j.1523 1755.1999.00575.x
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   Sage AP, 2011, KIDNEY INT, V79, P414, DOI 10.1038/ki.2010.390
   Scialla JJ, 2013, KIDNEY INT, V83, P1159, DOI 10.1038/ki.2013.3
   Shalhoub V, 2006, CALCIFIED TISSUE INT, V79, P431, DOI 10.1007/s00223 006 0126 z
   Shavelle DM, 2002, LANCET, V359, P1125, DOI 10.1016/S0140 6736(02)08161 8
   Smith JC, 2000, J CLIN ENDOCR METAB, V85, P3515, DOI 10.1210/jc.85.10.3515
   Somjen D, 2005, CIRCULATION, V111, P1666, DOI 10.1161/01.CIR.0000160353.27927.70
   Son BK, 2006, CIRC RES, V98, P1024, DOI 10.1161/01.RES.0000218859.90970.8d
   Stubbs J, 2007, SEMIN DIALYSIS, V20, P302, DOI 10.1111/j.1525 139X.2007.00308.x
   Tamei N, 2011, J ATHEROSCLER THROMB, V18, P217, DOI 10.5551/jat.5595
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wu Wong JR, 2006, J PHARMACOL EXP THER, V318, P90, DOI 10.1124/jpet.106.101261
   Zoccali C, 2006, J AM SOC NEPHROL, V17, pS169, DOI 10.1681/ASN.2006080910
NR 67
TC 108
Z9 112
U1 1
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 37
BP 5829
EP 5833
DI 10.2174/1381612820666140212194926
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3YZ
UT WOS:000342015200005
PM 24533939
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yuan, Y
   Yan, GG
   He, MY
   Lei, H
   Li, LQ
   Wang, Y
   He, XQ
   Li, GH
   Wang, Q
   Gao, YL
   Qu, ZZ
   Mei, ZT
   Shen, ZH
   Pu, JY
   Wang, A
   Zhao, W
   Jiang, HW
   Du, WJ
   Yang, L
AF Yuan, Ye
   Yan, Gege
   He, Mingyu
   Lei, Hong
   Li, Linqiang
   Wang, Yang
   He, Xiaoqi
   Li, Guanghui
   Wang, Quan
   Gao, Yuelin
   Qu, Zhezhe
   Mei, Zhongting
   Shen, Zhihua
   Pu, Jiaying
   Wang, Ao
   Zhao, Wei
   Jiang, Huiwei
   Du, Weijie
   Yang, Lei
TI ALKBH5 suppresses tumor progression via an m<SUP>6</SUP>A dependent
   epigenetic silencing of pre miR 181b 1/YAP signaling axis in
   osteosarcoma
SO CELL DEATH & DISEASE
LA English
DT Article
ID MESSENGER RNA; METHYLATION; YAP/TAZ; EPIDEMIOLOGY
AB ALKBH5 is the main enzyme for m(6)A based demethylation of RNAs and it has been implicated in many biological and pathophysiological processes. Here, we aimed to explore the potential involvement of ALKBH5 in osteosarcoma and decipher the underlying cellular/molecular mechanisms. We discovered downregulated levels of demethylase ALKBH5 were correlated with increased m(6)A methylation in osteosarcoma cells/tissues compared with normal osteoblasts cells/tissues. ALKBH5 overexpression significantly suppressed osteosarcoma cell growth, migration, invasion, and trigged cell apoptosis. In contrast, inhibition of ALKBH5 produced the opposite effects. Whereas ALKBH5 silence enhanced m(6)A methylations of pre miR 181b 1 and YAP mRNA exerting oncogenic functions in osteosarcoma. Moreover, upregulation of YAP or downregulation of mature miR 181b 5p displayed a remarkable attenuation of anti tumor activities caused by ALKBH5. Further results revealed that m(6)A methylated pre miR 181b 1 was subsequently recognized by m(6)A binding protein YTHDF2 to mediate RNA degradation. However, methylated YAP transcripts were recognized by YTHDF1 to promote its translation. Therefore, ALKBH5 based m(6)A demethylation suppressed osteosarcoma cancer progression through m(6)A based direct/indirect regulation of YAP. Thus, ALKBH5 overexpression might be considered a new approach of replacement therapy for osteosarcoma treatment.
C1 [Yuan, Ye; Yan, Gege; He, Mingyu; Lei, Hong; He, Xiaoqi; Li, Guanghui; Wang, Quan; Gao, Yuelin; Qu, Zhezhe; Mei, Zhongting; Zhao, Wei; Jiang, Huiwei; Du, Weijie; Yang, Lei] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped, Key Lab Cardiovasc Med Res,Minist Educ,Coll Pharm, Harbin 150086, Peoples R China.
   [Yuan, Ye; Yan, Gege; He, Mingyu; Lei, Hong; He, Xiaoqi; Li, Guanghui; Wang, Quan; Gao, Yuelin; Qu, Zhezhe; Mei, Zhongting; Zhao, Wei; Jiang, Huiwei; Du, Weijie; Yang, Lei] Harbin Med Univ, Dept Pharmacol, Coll Pharm, Key Lab Cardiovasc Med Res,Minist Educ, Harbin 150086, Peoples R China.
   [Yuan, Ye; Wang, Yang; Shen, Zhihua; Pu, Jiaying; Wang, Ao; Zhao, Wei; Jiang, Huiwei] Harbin Med Univ, Dept Pharm, Affiliated Hosp 2, Harbin 150086, Peoples R China.
   [Wang, Yang; Shen, Zhihua; Pu, Jiaying; Wang, Ao] Harbin Med Univ, Dept Clin Pharmacol, Coll Pharm, Harbin 150086, Peoples R China.
   [Yuan, Ye] Chinese Acad Med Sci, Res Unit Noninfect Chron Dis Frigid Zone, Harbin 2019RU070, Peoples R China.
   [Li, Linqiang] Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 1, Harbin 150001, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University; Harbin Medical University; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Harbin Medical University
RP Du, WJ; Yang, L (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped, Key Lab Cardiovasc Med Res,Minist Educ,Coll Pharm, Harbin 150086, Peoples R China.; Du, WJ; Yang, L (通讯作者)，Harbin Med Univ, Dept Pharmacol, Coll Pharm, Key Lab Cardiovasc Med Res,Minist Educ, Harbin 150086, Peoples R China.
EM adugo@163.com; yangray83@vip.qq.com
RI ; Lei, Hong/ABH 1356 2020
OI Du, Weijie/0000 0003 1197 1462; 
FU National Natural Science Fund of China [81972117]; Natural Science
   Foundation of Heilongjiang Province of China for outstanding youth
   [YQ2020H019]; College of Pharmacy, Harbin Medical University Excellent
   Young Talents Funding [2019 YQ 13]; Heilongjiang Innovative Talent
   Training Fund for Young Teachers [UNPYSCT 2017073]; Special Fund for the
   Development of Local Colleges and Universities   Central Finance
   (Outstanding Young Talents Support Project) [0103/30011190007]; Youth
   Reserve Talent Fund of Harbin Science and Technology Bureau
   [2017RAQXJ163]
FX This work was supported by grants from the National Natural Science Fund
   of China (81972117), Natural Science Foundation of Heilongjiang Province
   of China for outstanding youth (YQ2020H019), College of Pharmacy, Harbin
   Medical University Excellent Young Talents Funding (2019 YQ 13),
   Heilongjiang Innovative Talent Training Fund for Young Teachers
   (UNPYSCT 2017073), Special Fund for the Development of Local Colleges
   and Universities supported by the Central Finance (Outstanding Young
   Talents Support Project, 0103/30011190007), and Youth Reserve Talent
   Fund of Harbin Science and Technology Bureau (2017RAQXJ163).
CR Ahmed AA, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1295127
   Bai Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00332
   Cao GC, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160003
   Chan LH, 2014, ONCOGENE, V33, P4857, DOI 10.1038/onc.2013.433
   Cho Sung Hwan, 2018, Ann Hepatobiliary Pancreat Surg, V22, P305, DOI 10.14701/ahbps.2018.22.4.305
   DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971
   Dixit D, 2017, CANCER CELL, V31, P474, DOI 10.1016/j.ccell.2017.03.010
   Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 117
   Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004
   Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556 018 0045 z
   Lan Q, 2019, CANCER RES, V79, P1285, DOI 10.1158/0008 5472.CAN 18 2965
   Lee JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09755 0
   Li JA, 2019, CLIN EXP MED, V19, P211, DOI 10.1007/s10238 018 00543 6
   Li J, 2019, BIOCHEM BIOPH RES CO, V512, P479, DOI 10.1016/j.bbrc.2019.03.093
   Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017
   Li Z, 2017, J CELL MOL MED, V21, P315, DOI 10.1111/jcmm.12966
   Lin XY, 2023, NAT COMMUN, V14, DOI [10.1038/s41467 023 43307 x, 10.1038/s41467 019 09865 9]
   Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432
   Lund E, 2006, COLD SPRING HARB SYM, V71, P59, DOI 10.1101/sqb.2006.71.050
   Maugeri Saccà M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011
   Miao WJ, 2019, BIOCHEM BIOPH RES CO, V516, P719, DOI 10.1016/j.bbrc.2019.06.128
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1004 4
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0590 8
   Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3
   Seo J, 2019, CANCER RES, V79, P6139, DOI 10.1158/0008 5472.CAN 19 1339
   Wang DY, 2016, CHIN J CANCER, V35, P1, DOI 10.1186/s40880 016 0109 z
   Wang SN, 2017, MOL THER, V25, P2140, DOI 10.1016/j.ymthe.2017.05.018
   Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014
   Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730
   Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1007 1
   Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10669 0
   Yang XY, 2019, ONCOGENE, V38, P2778, DOI 10.1038/s41388 018 0609 1
   Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422 018 0040 8
   Yang ZZ, 2017, THERANOSTICS, V7, P3106, DOI 10.7150/thno.19016
   Yeh CM, 2017, ONCOTARGET, V8, P90545, DOI 10.18632/oncotarget.20079
   Yuan GK, 2017, ONCOTARGETS THER, V10, P2745, DOI 10.2147/OTT.S136621
   Yue YN, 2015, GENE DEV, V29, P1343, DOI 10.1101/gad.262766.115
   Zanconato F, 2016, CURR OPIN PHARMACOL, V29, P26, DOI 10.1016/j.coph.2016.05.002
   Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005
   Zhang XD, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0882 1
   Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015
   Zhou X, 2019, CELL REP, V27, P1176, DOI 10.1016/j.celrep.2019.03.028
NR 45
TC 92
Z9 95
U1 1
U2 26
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN 11
PY 2021
VL 12
IS 1
AR 60
DI 10.1038/s41419 020 03315 x
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA PV3KA
UT WOS:000609888600006
PM 33431791
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Malhotra, H
   Garg, V
   Singh, G
   Dutt, R
AF Malhotra, Hitesh
   Garg, Vandana
   Singh, Govind
   Dutt, Rohit
TI Ethanol extract of Ziziphus nummularia ameliorates
   formaldehyde induced arthritis in rats by regulating oxidative stress
   biomarkers and haematological profile
SO INFLAMMOPHARMACOLOGY
LA English
DT Article
DE Antioxidant; Arthritis; Formaldehyde; Hematology; Inflammation; Ziziphus
   nummularia
ID ULCERATIVE COLITIS; NATURAL HISTORY; ITACONATE; INHIBITION; METABOLITE;
   MUCUS; NRF2
AB Background Rheumatoid arthritis is an autoimmune inflammatory disorder that mainly affects bone and cartilage architecture. The continuous use of NSAIDs and DMARDs is associated with severe toxic effects. Therefore, the current study was designed to scrutinize herb based therapy for the treatment of RA. Aim To evaluate the anti arthritic activity of ethanol extract of Ziziphus nummularia using formaldehyde induced arthritic model in rats and elucidate the possible mechanism for anti arthritic activity. Materials and methods Anti arthritic activity of ETZN was studied at three oral doses, i.e., 200, 400, and 600 mg/kg. Selected doses were studied using various clinical parameters viz. paw volume, inflammatory index, motility test, stair test, anti nociceptive efficacy, walking track analysis, and motor activity) from day 1 to day 10. On the last day, the animals were killed for the evaluation of hematological parameters, oxidative stress biomarkers, and histological and radiographic studies of the hind paw. Results Treatment with ETZN 400 mg/kg and 600 mg/kg markedly elicited a significant reduction in paw volume, inflammatory index, and nociceptive action compared to diseased animals. Furthermore, the anti inflammatory activity was confirmed by increased latency of pain threshold in thermal and mechanical algesia models. The anti arthritic activity is mainly attributed to a reduction in oxidative stress biomarkers as well as restoration of haematological profile in treated animals when compared to diseased animals. Lastly, the anti arthritic potential was confirmed by histological and radiological analysis which revealed a marked reduction in inflammatory cells and bone destruction as compared to diseased animals. Conclusion The study revealed that ETZN exhibits significant anti arthritic activity via modulation of oxidative stress biomarkers, restoration of hematological profile, and reduction in bone erosion.
C1 [Malhotra, Hitesh] Guru Gobind Singh Coll Pharm, Haryana 135001, India.
   [Garg, Vandana; Singh, Govind] Maharshi Dayanand Univ, Rohtak, Haryana, India.
   [Dutt, Rohit] GMN Coll, Ambala, Haryana, India.
C3 Maharshi Dayanand University; Gandhi Memorial National College
RP Garg, V (通讯作者)，Maharshi Dayanand Univ, Rohtak, Haryana, India.
EM vandugarg@rediffmail.com
RI ; Dutt, Rohit/AAC 6213 2021
OI garg, vandana/0000 0002 5727 215X; 
FU Department of Pharmaceutical Sciences, Maharshi Dayanand University
FX The present study was supported by the Department of Pharmaceutical
   Sciences, Maharshi Dayanand University, Rohtak.
CR Aletaha D, 2003, ANN RHEUM DIS, V62, P482, DOI 10.1136/ard.62.5.482
   Ansari MM, 2015, CHEM BIOL INTERACT, V238, P55, DOI 10.1016/j.cbi.2015.06.001
   AWASTHI YC, 1979, BIOCHEM J, V177, P471, DOI 10.1042/bj1770471
   BENNETT JC, 1978, ARTHRITIS RHEUM, V21, P531, DOI 10.1002/art.1780210507
   Bihani G.V., 2014, Biomed Aging Pathol, V4, P197, DOI DOI 10.1016/J.BIOMAG.2014.04.007
   Bodroth R. P., 2012, African Journal of Biotechnology, V11, P4929
   Brahn E, 1998, J RHEUMATOL, V25, P1785
   CHANCE B, 1950, BIOCHEM J, V46, P402, DOI 10.1042/bj0460402
   Dief AE, 2015, EUR REV MED PHARMACO, V19, P1537
   FRIES JF, 1993, ARTHRITIS RHEUM, V36, P297, DOI 10.1002/art.1780360303
   Ghildiyal Shivani, 2013, J Ayurveda Integr Med, V4, P23, DOI 10.4103/0975 9476.109546
   Goyal M, 2011, INT J PHARMACOL, V7, P333, DOI 10.3923/ijp.2011.333.339
   Haddad PS, 2005, EVID BASED COMPL ALT, V2, P513, DOI 10.1093/ecam/neh125
   Kotzé M, 2002, S AFR J BOT, V68, P62, DOI 10.1016/S0254 6299(15)30442 7
   Lawrence RC, 1998, ARTHRITIS RHEUM US, V41, P778, DOI 10.1002/1529 0131(199805)41:5<778::AID ART4>3.0.CO;2 V
   MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432 1033.1974.tb03714.x
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mythilypriya R., 2008, Inflammopharmacology, V16, P21, DOI 10.1007/s10787 007 1602 4
   NRC, 1996, Guide for the Care and Use of Laboratory Animals
   Paval J, 2009, CLINICS, V64, P357, DOI 10.1590/S1807 59322009000400015
   Prajapati S., 2019, Res Rev J Life Sci, V9, P109
   RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409
   Rathore M., 2009, Journal of Horticulture and Frestry, V1, P103, DOI DOI 10.5897/JHF.9000079
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   SHAH A H, 1990, Fitoterapia, V61, P469
   Soeken KL, 2003, RHEUMATOLOGY, V42, P652, DOI 10.1093/rheumatology/keg183
   Suksamrarn S, 2005, TETRAHEDRON, V61, P1175, DOI 10.1016/j.tet.2004.11.053
   UTLEY HG, 1967, ARCH BIOCHEM BIOPHYS, V118, P29, DOI 10.1016/0003 9861(67)90273 1
   van Vollenhoven RF., 2016, General treatment aspects, Biologics for the Treatment of Rheumatoid Arthritis, DOI [10.1007/978 3 319 13108 5, DOI 10.1007/978 3 319 13108 5]
   Wahane VD, 2010, PHARMACOL RES, V61, P329, DOI 10.1016/j.phrs.2009.11.006
   WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
   Zuo J, 2014, J ETHNOPHARMACOL, V153, P352, DOI 10.1016/j.jep.2014.02.015
NR 32
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925 4692
EI 1568 5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
PD AUG
PY 2024
VL 32
IS 4
BP 2463
EP 2476
DI 10.1007/s10787 023 01377 9
EA MAY 2024
PG 14
WC Immunology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA A8D2N
UT WOS:001221498300001
PM 38739176
DA 2025 08 17
ER

PT J
AU Pandya, KD
   Shah, N
   Gohil, DY
   Seth, AK
   Aundhia, CJ
   Patel, SS
AF Pandya, K. D.
   Shah, N., V
   Gohil, D. Y.
   Seth, A. K.
   Aundhia, C. J.
   Patel, S. S.
TI Development of Risedronate Sodium loaded Nanosponges by Experimental
   Design: Optimization and in vitro Characterization
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Risedronate sodium nanosponges; quasi emulsion solvent diffusion; 32
   full factorial design; in vitro buoyancy; in vitro drug release
ID ORAL BIOAVAILABILITY ENHANCEMENT; DRUG DELIVERY; BISPHOSPHONATES;
   GUIDELINES; RALOXIFENE; FRACTURES; DIAGNOSIS
AB The present investigation focussed on the development of a novel strategy to enhance the bioavailability of risedronate sodium, which has poor and erratic absorption. Nanosponges were statistically developed by full 32 factorial design using Design of Experiment software considering concentration of polymer and stabilizer as independent variables and particle size and entrapment efficiency as experimental responses by utilizing the modified quasi emulsion solvent diffusion technique. Optimized formulation showed 67.27 +/  1.05 % entrapment efficiency, 155.8 +/  2.17 nm particle size and  35.4 mV of zeta potential. The data from in vitro release study showed burst release for initial 2 h followed by slow and sustained release up to 24 h, which followed a diffusion controlled release mechanism by the Higuchi model. Scanning electron microscopy study showed uniformly discrete spherical particles with porous surface without any agglomeration. Stability study demonstrated no significant changes in particle size, entrapment efficiency and in vitro release, which indicated that the nanosponge formulation was stable. In conclusion, it appeared that the nanosponges were a suitable nanocarrier system that could play a significant role in improving osteoporotic condition.
C1 [Pandya, K. D.; Shah, N., V; Gohil, D. Y.; Seth, A. K.; Aundhia, C. J.; Patel, S. S.] Sumandeep Vidyapeeth, Dept Pharm, Piparia 391760, Vadodara, India.
C3 Sumandeep Vidyapeeth
RP Shah, N (通讯作者)，Sumandeep Vidyapeeth, Dept Pharm, Piparia 391760, Vadodara, India.
RI ; Patel, Shivkant/AAE 2953 2022; Aundhia, Chintan/AAM 1195 2020; Seth,
   Avinash/AAC 4526 2020; shah, nirmal/J 3835 2019; Gohil,
   Dipti/AAC 6481 2020
OI Shah, Nirmal/0000 0003 1282 937X; Patel, Shivkant/0000 0001 5748 1798;
   SETH, Dr. A. K./0000 0003 4970 727X; 
CR [Anonymous], 2014, Int. J. Pharm. Tech. Res
   [Anonymous], 2014, Asian Pac J Trop Dis
   Biernacka J, 2013, ACTA POL PHARM, V70, P877
   Brown JP, 2002, CAN MED ASSOC J, V167, pS1
   Dave VS, 2017, DRUG DEV IND PHARM, V43, P177, DOI 10.1080/03639045.2016.1269122
   Guo LL, 2008, MATER CHEM PHYS, V111, P322, DOI 10.1016/j.matchemphys.2008.04.016
   Kanis JA, 2002, OSTEOPOROSIS INT, V13, P527, DOI 10.1007/s001980200069
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Mitchell DY, 1999, BRIT J CLIN PHARMACO, V48, P536, DOI 10.1046/j.1365 2125.1999.00035.x
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Rawat P, 2015, J PHARM INNOV, V10, P130, DOI 10.1007/s12247 015 9213 x
   Shah N., 2015, INT J PHARMACYAND PH, V7, P205
   Shah N, 2018, DRUG DEV IND PHARM, V44, P687, DOI 10.1080/03639045.2017.1408643
   Shah NV, 2016, J ADV RES, V7, P423, DOI 10.1016/j.jare.2016.03.002
   Shah NV, 2011, PHARM SCI MONIT, V2, pS31
   Shah NV, 2011, INDO AM J PHARM RES, V1, P110
   Silverman SL, 2007, OSTEOPOROSIS INT, V18, P25, DOI 10.1007/s00198 006 0274 z
   Singh BN, 2000, J CONTROL RELEASE, V63, P235, DOI 10.1016/S0168 3659(99)00204 7
   Srinivas P., 2013, INT J DRUG DEV RES, V5, P55
   Subramanian S, 2012, J PHARM PHARM SCI, V15, P103
   Tambe RS, 2015, Am J Pharmtech Res, V5, P215
   Tamkhane V, 2014, INT J CURR PHARM RES, V4, P1186
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
NR 24
TC 6
Z9 7
U1 2
U2 11
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250 474X
EI 1998 3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PD MAR APR
PY 2019
VL 81
IS 2
BP 309
EP 316
DI 10.4172/pharmaceutical sciences.1000512
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HY1DA
UT WOS:000467853300015
DA 2025 08 17
ER

PT J
AU Phillips, K
   Clauw, DJ
AF Phillips, Kristine
   Clauw, Daniel J.
TI Central pain mechanisms in chronic pain states   Maybe it is all in
   their head
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Central pain; Peripheral pain; Chronic pain; Neuroimaging;
   Osteoarthritis; Fibromyalgia
ID CHRONIC WIDESPREAD PAIN; NOXIOUS CONDITIONING STIMULATION;
   O METHYLTRANSFERASE GENE; LOW BACK PAIN; FIBROMYALGIA SYNDROME;
   SOMATOSENSORY PERCEPTION; INTERSTITIAL CYSTITIS; KNEE OSTEOARTHRITIS;
   CEREBROSPINAL FLUID; FIBROSITIS SYNDROME
AB Mechanisms underlying chronic pain differ from those underlying acute pain. In chronic pain states, central nervous system (CNS) factors appear to play particularly prominent roles. In the absence of anatomical causes of persistent pain, medical sub specialities have historically applied wide ranging labels (e.g., fibromyalgia (FM), irritable bowel syndrome, interstitial cystitis and somatisation) for what now is emerging as a single common set of CNS processes. The hallmark of these 'centrally driven' pain conditions is a diffuse hyperalgesic state identifiable using experimental sensory testing, and corroborated by functional neuroimaging. The characteristic symptoms of these central pain conditions include multifocal pain, fatigue, insomnia, memory difficulties and a higher rate of co morbid mood disorders. In contrast to acute and peripheral pain states that are responsive to non steroidal anti inflammatory drugs (NSAIDs) and opioids, central pain conditions respond best to CNS neuromodulating agents, such as serotonin norepinephrine reuptake inhibitors (SNRIs) and anticonvulsants. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Phillips, Kristine; Clauw, Daniel J.] Univ Michigan, Chron Pain & Fatigue Res Ctr, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Phillips, K (通讯作者)，Univ Michigan, Chron Pain & Fatigue Res Ctr, Ann Arbor, MI 48109 USA.
EM kphill@med.umich.edu
OI CLAUW, Daniel/0000 0002 8114 7818
FU American College of Rheumatology Research and Education Foundation;
   National Institutes of Health from the National Center for Research
   Resources [UL1RR024986, 1K23AR060241]
FX Dr. Phillips has received support from the American College of
   Rheumatology Research and Education Foundation and the National
   Institutes of Health, grant number UL1RR024986 from the National Center
   for Research Resources, grant number 1K23AR060241.
CR Aaron LA, 1996, ARTHRITIS RHEUM US, V39, P436, DOI 10.1002/art.1780390311
   Allen KD, 2008, J RHEUMATOL, V35, P1102
   Armitage R, 2009, J PSYCHOSOM RES, V66, P51, DOI 10.1016/j.jpsychores.2008.08.004
   Arnold BS, 2008, EUR J PAIN, V12, P329, DOI 10.1016/j.ejpain.2007.06.007
   Arnold LM, 2007, PAIN MED, V8, P633, DOI 10.1111/j.1526 4637.2007.00332.x
   Arnold LM, 2004, ARTHRITIS RHEUM US, V50, P944, DOI 10.1002/art.20042
   ARROYO JF, 1993, J RHEUMATOL, V20, P1925
   Bajaj P, 2001, PAIN, V93, P107, DOI 10.1016/S0304 3959(01)00300 1
   Baraniuk JN, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 48
   Bengtsson A, 1989, J Rheumatol Suppl, V19, P144
   Bennett R M, 1989, J Rheumatol Suppl, V19, P185
   BENNETT R M, 1989, Journal of Rheumatology, V16, P28
   BENNETT RM, 1981, WESTERN J MED, V134, P405
   Bergman S, 2007, BEST PRACT RES CL RH, V21, P153, DOI 10.1016/j.berh.2006.10.001
   Brooks JCW, 2007, PAIN, V128, P1, DOI 10.1016/j.pain.2006.12.025
   Bryson HM, 1996, DRUG AGING, V8, P459, DOI 10.2165/00002512 199608060 00008
   Rodríguez MAB, 2009, J UROLOGY, V182, P2123, DOI 10.1016/j.juro.2009.07.036
   Buskila D, 1997, J RHEUMATOL, V24, P941
   Buskila D, 2007, BEST PRACT RES CL RH, V21, P535, DOI 10.1016/j.berh.2007.02.011
   Buskila D, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2005
   Chan K. W., 2009, Hong Kong Medical Journal, V15, P168
   Chappell AS, 2009, PAIN, V146, P253, DOI 10.1016/j.pain.2009.06.024
   Clauw DJ, 2007, JCR J CLIN RHEUMATOL, V13, P102, DOI 10.1097/01. rhu.0b013e318053d9bc
   Clauw DJ, 2009, ARTHRITIS RHEUM US, V60, P321, DOI 10.1002/art.24326
   Clauw DJ, 1997, NEUROIMMUNOMODULAT, V4, P134, DOI 10.1159/000097332
   Clauw DJ, 1997, J PSYCHIAT RES, V31, P125, DOI 10.1016/S0022 3956(96)00051 9
   Craig AD, 2003, ANNU REV NEUROSCI, V26, P1, DOI 10.1146/annurev.neuro.26.041002.131022
   Craig KD, 2004, PAIN, V107, P5, DOI 10.1016/S0304 3959(03)00264 1
   Creamer P, 1997, BRIT J RHEUMATOL, V36, P726
   Deuster PA, 1996, WOMEN HEALTH ISS, V6, P320, DOI 10.1016/S1049 3867(96)00059 X
   Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013
   Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024
   Diatchenko L, 2006, PAIN, V123, P226, DOI 10.1016/j.pain.2006.04.015
   Drossman DA, 2005, GUT, V54, P569, DOI 10.1136/gut.2004.058446
   Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008
   Farrell M, 2000, J RHEUMATOL, V27, P441
   Fukuda K, 1998, JAMA J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981
   Geisser ME, 2007, EUR J PAIN, V11, P202, DOI 10.1016/j.ejpain.2006.02.001
   GERSTER JC, 1984, J RHEUMATOL, V11, P678
   GIBSON SJ, 1994, PAIN, V58, P185, DOI 10.1016/0304 3959(94)90198 8
   Giesecke T, 2005, ARTHRITIS RHEUM US, V52, P1577, DOI 10.1002/art.21008
   Giesecke T, 2003, ARTHRITIS RHEUM, V48, P2916, DOI 10.1002/art.11272
   Giesecke T, 2004, ARTHRITIS RHEUM US, V50, P613, DOI 10.1002/art.20063
   Giovengo SL, 1999, J RHEUMATOL, V26, P1564
   Gracely RH, 2003, BEST PRACT RES CL RH, V17, P593, DOI 10.1016/S1521 6942(03)00036 6
   Gracely RH, 2002, ARTHRITIS RHEUM US, V46, P1333, DOI 10.1002/art.10225
   GRANGES G, 1993, J RHEUMATOL, V20, P344
   GRANGES G, 1993, ARTHRITIS RHEUM, V36, P642, DOI 10.1002/art.1780360510
   Gwilym SE, 2009, ARTHRIT RHEUM ARTHR, V61, P1226, DOI 10.1002/art.24837
   Harden RN, 2003, PAIN, V106, P393, DOI 10.1016/j.pain.2003.08.009
   Harris RE, 2008, ARTHRITIS RHEUM, V58, P903, DOI 10.1002/art.23223
   Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849 07.2007
   Holliday KL, 2009, MOL PAIN, V5, DOI 10.1186/1744 8069 5 56
   Hudson J I, 1989, J Rheumatol Suppl, V19, P15
   HUDSON JI, 1985, AM J PSYCHIAT, V142, P441
   Kato K, 2009, PSYCHOL MED, V39, P497, DOI 10.1017/S0033291708003784
   Kato K, 2006, ARCH INTERN MED, V166, P1649, DOI 10.1001/archinte.166.15.1649
   Kato K, 2006, ARTHRITIS RHEUM US, V54, P1682, DOI 10.1002/art.21798
   Kosek E, 2000, EUR J PAIN, V4, P229, DOI 10.1053/eujp.2000.0175
   Kosek E, 2000, PAIN, V88, P69, DOI 10.1016/S0304 3959(00)00310 9
   Kosek E, 1997, PAIN, V70, P41, DOI 10.1016/S0304 3959(96)03295 2
   Kroenke K, 2009, GEN HOSP PSYCHIAT, V31, P206, DOI 10.1016/j.genhosppsych.2008.12.006
   LANGEMARK M, 1993, ARCH NEUROL CHICAGO, V50, P1061, DOI 10.1001/archneur.1993.00540100056015
   Lynch M, 2001, Adv Nurse Pract, V9, P28
   Maixner W, 1995, PAIN, V63, P341, DOI 10.1016/0304 3959(95)00068 2
   McLean SA, 2004, MED HYPOTHESES, V63, P653, DOI 10.1016/j.mehy.2004.03.022
   MOLDOFSKY H, 1975, ARCH GEN PSYCHIAT, V32, P193
   MOLDOFSKY H, 1980, ELECTROEN CLIN NEURO, V50, P71, DOI 10.1016/0013 4694(80)90324 7
   Murphy SL, 2008, ARTHRIT RHEUM ARTHR, V59, P849, DOI 10.1002/art.23710
   Neogi T, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b2844
   Ness TJ, 2005, CURR OPIN ANESTHESIO, V18, P555, DOI 10.1097/01.aco.0000182567.70798.a7
   ODRISCOLL SL, 1975, ANN RHEUM DIS, V34, P195, DOI 10.1136/ard.34.2.195 b
   Petzke F, 1999, J PAIN SYMPTOM MANAG, V17, P391, DOI 10.1016/S0885 3924(99)00023 8
   Petzke F, 2003, PAIN, V105, P403, DOI 10.1016/S0304 3959(03)00204 5
   Petzke F, 2001, SUPPORT CARE CANCER, V9, P48
   Petzke F, 2001, J RHEUMATOL, V28, P2568
   Raphael KG, 2002, PAIN, V100, P131, DOI 10.1016/S0304 3959(02)00273 7
   Rapps N, 2008, J PSYCHOSOM RES, V64, P599, DOI 10.1016/j.jpsychores.2008.02.018
   Russell IJ, 1998, Z RHEUMATOL, V57, P63
   RUSSELL TS, 1994, J RHEUMATOL, V21, P579
   Sarchielli Paola, 2007, Curr Pain Headache Rep, V11, P343, DOI 10.1007/s11916 007 0216 2
   Simms RW, 1998, AM J MED SCI, V315, P346, DOI 10.1097/00000441 199806000 00002
   Staud R, 2008, CNS SPECTRUMS, V13, P12, DOI 10.1017/S109285290002678X
   Tracey Irene, 2007, Curr Opin Support Palliat Care, V1, P109, DOI 10.1097/SPC.0b013e3282efc58b
   Turk DC, SEMINARS ARTHRITIS R, V39, P477
   van Meurs JBJ, 2009, ARTHRITIS RHEUM, V60, P628, DOI 10.1002/art.24175
   van Ophoven A, 2005, J UROLOGY, V174, P1837, DOI 10.1097/01.ju.0000176741.10094.e0
   Williams CS, 2005, GERONTOLOGIST, V45, P68, DOI 10.1093/geront/45.suppl_1.68
   Williams DA, 2009, RHEUM DIS CLIN N AM, V35, P339, DOI 10.1016/j.rdc.2009.05.007
   Williams DA, 2009, J PAIN, V10, P777, DOI 10.1016/j.jpain.2009.06.001
   Williams Heather, 2003, Nurs Times, V99, P42
   Wolfe F, 1997, ANN RHEUM DIS, V56, P268, DOI 10.1136/ard.56.4.268
   WOLFE F, 1995, ARTHRITIS RHEUM US, V38, P19, DOI 10.1002/art.1780380104
   Wolfe F, 1997, J RHEUMATOL, V24, P555
   Wolfe F, 2006, J RHEUMATOL, V33, P2291
   Woolf CJ, 2004, LIFE SCI, V74, P2605, DOI 10.1016/j.lfs.2004.01.003
   Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003 4819 140 8 200404200 00010
   Yunus M B, 1984, Compr Ther, V10, P21
   Yunus MB, 2008, SEMIN ARTHRITIS RHEU, V37, P339, DOI 10.1016/j.semarthrit.2007.09.003
   Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546
NR 100
TC 246
Z9 280
U1 0
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD APR
PY 2011
VL 25
IS 2
BP 141
EP 154
DI 10.1016/j.berh.2011.02.005
PG 14
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 861OF
UT WOS:000298028400003
PM 22094191
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Petersen, KK
   Simonsen, O
   Olesen, AE
   Morch, CD
   Arendt Nielsen, L
AF Petersen, Kristian Kjaer
   Simonsen, Ole
   Olesen, Anne Estrup
   Morch, Carsten Dahl
   Arendt Nielsen, Lars
TI Pain inhibitory mechanisms and response to weak analgesics in patients
   with knee osteoarthritis
SO EUROPEAN JOURNAL OF PAIN
LA English
DT Article
ID CHRONIC POSTOPERATIVE PAIN; OFFSET ANALGESIA; TEMPORAL SUMMATION;
   MODULATION; HYPERALGESIA; RECOMMENDATIONS; STIMULATION; MANAGEMENT;
   ALGOMETRY; MAGNITUDE
AB Background Conditioned pain modulation (CPM) and offset analgesia are different features of descending pain inhibition. This study investigated CPM, offset analgesia and clinical pain measures in patients with knee osteoarthritis (KOA) before and after treatment with the combination of a non steroidal anti inflammatory drug (NSAIDs) plus acetaminophen. Methods Forty two patients with KOA received Ibuprofen 1.2 g/daily and acetaminophen 3.0 g/daily for three weeks. Before administration, CPM magnitude was assessed as the difference between cuff pain detection (cPDT) with and without a conditioning stimulus (evoked by tourniquet pain). Offset analgesia was assessed as the pain intensities evoked by a constant 46 degrees C for 30 s stimulus compared to an offset analgesia paradigm of 46 degrees C for 5 s, 47 degrees C for 5 s and 46 degrees C for 20 s. The worst pain within the last 24 hr and pain during activity were assessed before and after treatment. Results Clinical pain significantly decreased after treatment (p < 0.001) and less efficient CPM before treatment was associated with weaker analgesic effect (R = 0.354, p = 0.043). No significant modulation of CPM or offset analgesia was found for the treatment. Conclusion This study found that less efficient CPM is associated with reduced analgesic effect of NSAIDs plus acetaminophen in patients with KOA whereas the treatment did not modulate CPM nor offset analgesia magnitude. Significance This study demonstrated that conditioned pain modulation is correlated with the response to a standard pharmaceutical interventions treating osteoarthritis pain. Furthermore, we demonstrated that a decrease in clinical pain intensity is not associated with a normalization of conditioned pain modulation or offset analgesia, which questions if restoring these descending pain inhibitory mechanisms are pain intensity driven.
C1 [Petersen, Kristian Kjaer; Morch, Carsten Dahl; Arendt Nielsen, Lars] Aalborg Univ, Sch Med, Dept Hlth Sci & Technol, SMI, Fredrik Bajers Vej 7 D3, DK 9220 Aalborg, Denmark.
   [Petersen, Kristian Kjaer; Morch, Carsten Dahl] Aalborg Univ, Sch Med, Dept Hlth Sci & Technol, Ctr Neuroplast & Pain, Aalborg, Denmark.
   [Simonsen, Ole; Olesen, Anne Estrup] Aalborg Univ, Dept Clin Med, Aalborg, Denmark.
   [Simonsen, Ole] Aalborg Univ Hosp, Dept Orthoped Surg, Aalborg, Denmark.
   [Olesen, Anne Estrup] Aalborg Univ Hosp, Dept Clin Pharmacol, Aalborg, Denmark.
C3 Aalborg University; Aalborg University; Aalborg University; Aalborg
   University; Aalborg University Hospital; Aalborg University; Aalborg
   University Hospital
RP Petersen, KK (通讯作者)，Aalborg Univ, Sch Med, Dept Hlth Sci & Technol, SMI, Fredrik Bajers Vej 7 D3, DK 9220 Aalborg, Denmark.
EM kkp@hst.aau.dk
RI ; Petersen, Kristian Kjaer Staal/Q 4311 2017; Petersen,
   Kristian/Q 4311 2017; Mørch, Carsten/J 5639 2019; Olesen, Anne
   Estrup/B 3127 2016; Arendt Nielsen, Lars/T 4885 2018; Olesen,
   Anne/B 3127 2016
OI Arendt Nielsen, Lars/0000 0003 0892 1579; Petersen, Kristian
   Kjaer Staal/0000 0003 4506 000X; Morch, Carsten
   Dahl/0000 0001 6693 2028; Olesen, Anne Estrup/0000 0001 9365 1918; 
FU Aalborg University Talent Management Programme [771126]; Shionogi
   Science Program; TaNeDS Europe Grant; Danish National Research
   Foundation [DNRF121]
FX The Aalborg University Talent Management Programme (j.no. 771126), The
   Shionogi Science Program, and The TaNeDS Europe Grant. Center for
   Neuroplasticity and Pain (CNAP) is supported by the Danish National
   Research Foundation (DNRF121).
CR Ahn DK, 2007, PAIN, V132, P23, DOI 10.1016/j.pain.2007.01.015
   Arendt Nielsen L, 2018, EUR J PAIN, V22, P216, DOI 10.1002/ejp.1140
   Bannister K, 2017, EUR J PAIN, V21, P750, DOI 10.1002/ejp.979
   BOUHASSIRA D, 1992, BRAIN RES, V571, P140, DOI 10.1016/0006 8993(92)90520 J
   Doherty M, 2011, ANN RHEUM DIS, V70, P1534, DOI 10.1136/ard.2011.154047
   Edwards RR, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1124 6
   Ghione S, 1996, HYPERTENSION, V28, P494, DOI 10.1161/01.HYP.28.3.494
   Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787 013 0172 x
   Graven Nielsen T, 2017, EUR J PAIN, V21, P552, DOI 10.1002/ejp.958
   Graven Nielsen T, 2012, ARTHRITIS RHEUM US, V64, P2907, DOI 10.1002/art.34466
   Graven Nielsen T, 2015, PAIN, V156, P2193, DOI 10.1097/j.pain.0000000000000294
   Graven Nielsen T, 2010, NAT REV RHEUMATOL, V6, P599, DOI 10.1038/nrrheum.2010.107
   Grill JD, 2002, J NEUROPHYSIOL, V87, P2205, DOI 10.1152/jn.00730.2001
   Grosen K, 2013, EUR J PAIN, V17, P1267, DOI 10.1002/j.1532 2149.2013.00330.x
   Heredia Rizo AM, 2019, CLIN J PAIN, V35, P65, DOI 10.1097/AJP.0000000000000656
   Hermans L, 2016, PAIN PHYSICIAN, V19, P307
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Holden S, 2018, PAIN, V159, P2530, DOI 10.1097/j.pain.0000000000001356
   Honigman L, 2013, EXP BRAIN RES, V228, P493, DOI 10.1007/s00221 013 3580 7
   Imai Y, 2016, SOMATOSENS MOT RES, V33, P169, DOI 10.1080/08990220.2016.1229178
   Izumi M, 2017, PAIN, V158, P323, DOI 10.1097/j.pain.0000000000000764
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Kobinata H, 2017, PAIN, V158, P1951, DOI 10.1097/j.pain.0000000000000989
   Kosek E, 2000, PAIN, V88, P69, DOI 10.1016/S0304 3959(00)00310 9
   Kurien T, 2018, J PAIN, V19, P1329, DOI 10.1016/j.jpain.2018.05.011
   LAMOTTE RH, 1983, J NEUROPHYSIOL, V50, P1
   LEBARS D, 1979, PAIN, V6, P305, DOI 10.1016/0304 3959(79)90050 2
   LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304 3959(79)90049 6
   Ligato D, 2018, EUR J PAIN, V22, P142, DOI 10.1002/ejp.1110
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Martini C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128997
   Martucci KT, 2012, PAIN, V153, P1232, DOI 10.1016/j.pain.2012.02.035
   Nahman Averbuch H, 2016, PHYSIOL BEHAV, V154, P40, DOI 10.1016/j.physbeh.2015.11.004
   Nahman Averbuch H, 2014, PAIN, V155, P2491, DOI 10.1016/j.pain.2014.07.008
   Neziri AY, 2012, PAIN, V153, P2083, DOI 10.1016/j.pain.2012.06.025
   Niesters M, 2014, BRIT J ANAESTH, V113, P148, DOI 10.1093/bja/aeu056
   Niesters M, 2011, ANESTHESIOLOGY, V115, P1063, DOI 10.1097/ALN.0b013e31822fd03a
   Niesters M, 2011, PAIN, V152, P656, DOI 10.1016/j.pain.2010.12.015
   Olesen AE, 2018, BASIC CLIN PHARMACOL, V123, P727, DOI 10.1111/bcpt.13078
   Petersen KK, 2018, EUR J PAIN, V22, P1678, DOI 10.1002/ejp.1250
   Petersen KK, 2018, CLIN J PAIN, V34, P193, DOI 10.1097/AJP.0000000000000528
   Petersen KK, 2018, SCAND J PAIN, V18, P479, DOI 10.1515/sjpain 2018 0054
   Petersen KK, 2016, PAIN, V157, P1400, DOI 10.1097/j.pain.0000000000000531
   Petersen KK, 2015, PAIN, V156, P55, DOI 10.1016/j.pain.0000000000000022
   Rathleff MS, 2016, PAIN MED, V17, P980, DOI 10.1093/pm/pnv017
   Reinold H, 2005, J CLIN INVEST, V115, P673
   Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P17, DOI 10.1186/1477 7525 1 17
   Sangesland A, 2017, SCAND J PAIN, V15, P44, DOI 10.1016/j.sjpain.2016.12.002
   Suzan E, 2015, PAIN MED, V16, P168, DOI 10.1111/pme.12565
   THURSTON CL, 1992, J NEUROPHYSIOL, V67, P180, DOI 10.1152/jn.1992.67.1.180
   Vaegter HB, 2017, CLIN J PAIN, V33, P475, DOI 10.1097/AJP.0000000000000428
   Vaegter HB, 2016, PAIN, V157, P1480, DOI 10.1097/j.pain.0000000000000543
   Van Den Houte M, 2018, PAIN MED, V19, P1587, DOI 10.1093/pm/pnx165
   Wilder Smith Oliver Hamilton, 2010, J Pain Palliat Care Pharmacother, V24, P119, DOI 10.3109/15360281003706069
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140
   Yarnitsky D, 2008, PAIN, V138, P22, DOI 10.1016/j.pain.2007.10.033
   Yarnitsky D, 2012, PAIN, V153, P1193, DOI 10.1016/j.pain.2012.02.021
   Yarnitsky D, 2010, EUR J PAIN, V14, P339, DOI 10.1016/j.ejpain.2010.02.004
NR 58
TC 41
Z9 41
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1090 3801
EI 1532 2149
J9 EUR J PAIN
JI Eur. J. Pain
PD NOV
PY 2019
VL 23
IS 10
BP 1904
EP 1912
DI 10.1002/ejp.1465
EA AUG 2019
PG 9
WC Anesthesiology; Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology; Neurosciences & Neurology
GA JG6SJ
UT WOS:000482264800001
PM 31376308
OA Green Published
DA 2025 08 17
ER

PT J
AU Boulmier, A
   Feng, XX
   Oms, O
   Mialane, P
   Rivière, E
   Shin, CJ
   Yao, JQ
   Kubo, T
   Furuta, T
   Oldfield, E
   Dolbecq, A
AF Boulmier, Amandine
   Feng, Xinxin
   Oms, Olivier
   Mialane, Pierre
   Riviere, Eric
   Shin, Christopher J.
   Yao, Jiaqi
   Kubo, Tadahiko
   Furuta, Taisuke
   Oldfield, Eric
   Dolbecq, Anne
TI Anticancer Activity of Polyoxometalate Bisphosphonate Complexes:
   Synthesis, Characterization, In Vitro and In Vivo Results
SO INORGANIC CHEMISTRY
LA English
DT Article
ID TUMOR CELL LINES; ANTITUMOR ACTIVITY; LIPOPHILIC BISPHOSPHONATES;
   BREAST CANCER; INHIBITORS; LIGANDS; CHEMISTRY; THERAPY; GROWTH; BONE
AB We synthesized a series of polyoxometalatebisphosphonate complexes containing Mov106 octahedra, zoledronate, or an N alkyl (n C 6 or n C 8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC(6), ZolC(8)) and MO4L2Mn = Zol, ZolC(8)) were characterized by using single crystal X ray crystallography and/or IR spectroscopy, elemental and energy dispersive X ray analysis and P 31 NMR. We found promising activity against human nonsmall cell lung cancer (NCI H460) cells with IC50 values for growth inhibition of 5 fiM per bisphosphonate ligand. The effects of bisphosphonate complexation on IC50 decreased with increasing bisphosphonate chain length: C 0 approximate to 6.1x, C 6 approximate to 3.4x, and C8 approximate to 1.1x. We then determined the activity of One of the most potent compounds in the series, Mo(4)Zol(2)Mn(III), against SK ES 1 sarcoma cells in a mouse xenograft system finding a similar to 5x decrease in tumor volume than found with the parent compound zoledronate at the same compound dosing, (5 mu g/mouse). Overall, the, results are of interest since we show for the first time that heteropolyoxomolybdate bisphosphonate hybrids kill tumor cells in vitro and significantly decrease tumor growth) in vivo, opening up new possibilities for targeting both Ras as, well as epidermal growth factor receptor driyen cancers.
C1 [Boulmier, Amandine; Oms, Olivier; Mialane, Pierre; Dolbecq, Anne] Univ Paris Saclay, Univ Versailles St Quentin Yvelines, Inst Lavoisier Versailles, UMR 8180, 45 Ave Etats Unis, F 78035 Versailles, France.
   [Feng, Xinxin; Shin, Christopher J.; Yao, Jiaqi; Oldfield, Eric] Univ Illinois, Dept Chem, 600 South Mathews Ave, Urbana, IL USA.
   [Oldfield, Eric] Univ Illinois, Ctr Biophys & Quantitat Biol, 1110 W Green St, Urbana, IL 61801 USA.
   [Kubo, Tadahiko; Furuta, Taisuke] Hiroshima Univ, Grad Sch Biomed Sci, Dept Orthoped Surg, Hiroshima, Japan.
   [Riviere, Eric] Univ Paris Saclay, Univ Paris Sud, Inst Chim Mol & Mat Orsay, UMR 8182, F 91405 Orsay, France.
C3 Universite Paris Saclay; Centre National de la Recherche Scientifique
   (CNRS); CNRS   Institute of Chemistry (INC); University of Illinois
   System; University of Illinois Urbana Champaign; University of Illinois
   System; University of Illinois Urbana Champaign; Hiroshima University;
   Centre National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Chemistry (INC); Universite Paris Saclay
RP Dolbecq, A (通讯作者)，Univ Paris Saclay, Univ Versailles St Quentin Yvelines, Inst Lavoisier Versailles, UMR 8180, 45 Ave Etats Unis, F 78035 Versailles, France.; Oldfield, E (通讯作者)，Univ Illinois, Dept Chem, 600 South Mathews Ave, Urbana, IL USA.; Oldfield, E (通讯作者)，Univ Illinois, Ctr Biophys & Quantitat Biol, 1110 W Green St, Urbana, IL 61801 USA.
EM eo@chad.scs.uiuc.edu; anne.dolbecq@uvsq.fr
RI ; Feng, Xinixn/HPD 6503 2023; Shin, Christopher/KPY 2523 2024
OI Riviere, Eric/0000 0003 1261 3149; 
FU United States Public Health Service (National Institutes of Health)
   [GM065307, CA158191]; Centre National de la Recherche Scientifique,
   Universite de Versailles Saint Quentin en Yvelines, L'Agence Nationale
   de la Recherche [ANR 11 BS07 011 01 BIOOPOM]
FX This work was supported by Centre National de la Recherche Scientifique,
   Universite de Versailles Saint Quentin en Yvelines, L'Agence Nationale
   de la Recherche (Grant ANR 11 BS07 011 01 BIOOPOM), and by the United
   States Public Health Service (National Institutes of Health Grants
   GM065307 and CA158191). Flavien Bourdreux, Gregoire Paille, and Tarik
   Benali are gratefully acknowledged for the NMR measurements, the SEM
   images and the synthesis of lipophilic bisphosphonates, respectively.
CR Banerjee A, 2012, CHEM SOC REV, V41, P7590, DOI 10.1039/c2cs35153f
   BLESSING RH, 1995, ACTA CRYSTALLOGR A, V51, P33, DOI 10.1107/S0108767394005726
   Clemente Juan JM, 2012, CHEM SOC REV, V41, P7464, DOI 10.1039/c2cs35205b
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Compain JD, 2010, CHEM EUR J, V16, P13741, DOI 10.1002/chem.201001626
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Dolbecq A, 2012, CHEM COMMUN, V48, P8299, DOI 10.1039/c2cc31667f
   Dolbecq A, 2010, CHEM REV, V110, P6009, DOI 10.1021/cr1000578
   Dong ZX, 2011, EUR J MED CHEM, V46, P2477, DOI 10.1016/j.ejmech.2011.03.036
   El Moll H, 2012, INORG CHEM, V51, P7921, DOI 10.1021/ic3010079
   Hasenknopf B, 2005, FRONT BIOSCI LANDMRK, V10, P275, DOI 10.2741/1527
   Hill CL, 1998, CHEM REV, V98, P1, DOI 10.1021/cr960395y
   Kubo T, 2006, J ORTHOP RES, V24, P1138, DOI 10.1002/jor.20177
   Lv HJ, 2012, CHEM SOC REV, V41, P7572, DOI 10.1039/c2cs35292c
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Nada MH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425 017 0209 6
   Ogata A, 2005, BIOMED PHARMACOTHER, V59, P240, DOI 10.1016/j.biopha.2004.11.008
   Prudent R, 2008, CHEM BIOL, V15, P683, DOI 10.1016/j.chembiol.2008.05.018
   Saad A, 2015, CHEM EUR J, V21, P10537, DOI 10.1002/chem.201406565
   She S, 2016, SCI REP UK, V6, DOI 10.1038/srep33529
   She S, 2014, CHEM EUR J, V20, P16987, DOI 10.1002/chem.201404317
   Sheldrick G.M., 1997, SADABS, Program for scaling and absorption correction of area detector data
   Sheldrick G. M., 1994, SHELX TL VERSION 5 0
   Singh AP, 2010, ANTIMICROB AGENTS CH, V54, P2987, DOI 10.1128/AAC.00198 10
   Song YC, 2009, J MED CHEM, V52, P976, DOI 10.1021/jm801023u
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Sun TD, 2016, ADV MATER, V28, P7397, DOI 10.1002/adma.201601778
   TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012
   Thiel J, 2009, J AM CHEM SOC, V131, P4180, DOI 10.1021/ja809422k
   Walsh JJ, 2016, COORDIN CHEM REV, V306, P217, DOI 10.1016/j.ccr.2015.06.016
   Wang SS, 2015, CHEM REV, V115, P4893, DOI 10.1021/cr500390v
   Wang XH, 1999, POLYHEDRON, V18, P2293, DOI 10.1016/S0277 5387(99)00118 7
   Wang XH, 2005, J INORG BIOCHEM, V99, P452, DOI 10.1016/j.jinorgbio.2004.10.020
   Wang XH, 2003, J INORG BIOCHEM, V94, P279, DOI 10.1016/S0162 0134(02)00631 1
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Yamase T, 2005, J MATER CHEM, V15, P4773, DOI 10.1039/b504585a
   YAMASE T, 1988, INORG CHIM A BIOINOR, V151, P15, DOI 10.1016/S0020 1693(00)83477 5
   Yang HK, 2013, BIOORG MED CHEM LETT, V23, P1462, DOI 10.1016/j.bmcl.2012.12.081
   Yang P, 2016, INORG CHEM, V55, P3718, DOI 10.1021/acs.inorgchem.6b00107
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Zhang YH, 2007, J MED CHEM, V50, P6067, DOI 10.1021/jm700991k
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhang ZM, 2016, CHEM SCI, V7, P4220, DOI 10.1039/c5sc04408a
   Zheng ST, 2012, CHEM SOC REV, V41, P7623, DOI 10.1039/c2cs35133a
NR 46
TC 43
Z9 45
U1 1
U2 91
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020 1669
EI 1520 510X
J9 INORG CHEM
JI Inorg. Chem.
PD JUL 3
PY 2017
VL 56
IS 13
BP 7558
EP 7565
DI 10.1021/acs.inorgchem.7b01114
PG 8
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EZ9NF
UT WOS:000405056400029
PM 28631925
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Berniak, K
   Ura, DP
   Piórkowski, A
   Stachewicz, U
AF Berniak, Krzysztof
   Ura, Daniel P.
   Piorkowski, Adam
   Stachewicz, Urszula
TI Cell Material Interplay in Focal Adhesion Points
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE focal adhesion; fibers; scaffold; paxillin; vinculin; AiryScan;
   clusteranalysis
ID SUPERRESOLUTION MICROSCOPY; NANOSCALE ARCHITECTURE; MATRIX;
   MECHANOTRANSDUCTION; MORPHOLOGY; PAXILLIN; VINCULIN; DYNAMICS
AB The complex interplay between cells and materials is a key focus of this research, aiming to develop optimal scaffolds for regenerative medicine. The need for tissue regeneration underscores understanding cellular behavior on scaffolds, especially cell adhesion to polymer fibers forming focal adhesions. Key proteins, paxillin and vinculin, regulate cell signaling, migration, and mechanotransduction in response to the extracellular environment. This study utilizes advanced microscopy, specifically the AiryScan technique, along with advanced image analysis employing the Density Based Spatial Clustering of Applications with Noise (DBSCAN) cluster algorithm, to investigate protein distribution during osteoblast cell adhesion to polymer fibers and glass substrates. During cell attachment to both glass and polymer fibers, a noticeable shift in the local maxima of paxillin and vinculin signals is observed at the adhesion sites. The focal adhesion sites on polymer fibers are smaller and elliptical but exhibit higher protein density than on the typical glass surface. The characteristics of focal adhesions, influenced by paxillin and vinculin, such as size and density, can potentially reflect the strength and stability of cell adhesion. Efficient adhesion correlates with well organized, larger focal adhesions characterized by increased accumulation of paxillin and vinculin. These findings offer promising implications for enhancing scaffold design, evaluating adhesion to various substrates, and refining cellular interactions in biomedical applications.
C1 [Berniak, Krzysztof; Ura, Daniel P.; Stachewicz, Urszula] AGH Univ Krakow, Fac Met Engn & Ind Comp Sci, PL 30059 Krakow, Poland.
   [Piorkowski, Adam] AGH Univ Krakow, Dept Biocybernet & Biomed Engn, PL 30059 Krakow, Poland.
C3 AGH University of Krakow; AGH University of Krakow
RP Stachewicz, U (通讯作者)，AGH Univ Krakow, Fac Met Engn & Ind Comp Sci, PL 30059 Krakow, Poland.
EM ustachew@agh.edu.pl
RI Piorkowski, Adam/L 2704 2016; Stachewicz, Urszula/AAF 6050 2019;
   Berniak, Krzysztof/JQW 5421 2023; Ura, Daniel/AAH 4474 2019
OI Piorkowski, Adam/0000 0003 4773 5322; Stachewicz,
   Urszula/0000 0001 5102 8685; Berniak, Krzysztof/0000 0003 2389 314X;
   Ura, Daniel/0000 0001 6330 6873
FU / POIR.04.04.00 00  4571/17 00 , Fundacja na rzecz Nauki Polskiej;
   Foundation for Polish Science [POIR.04.04.00 00 4571/17 00]; European
   Union under the European Regional Development Fund
FX This study was conducted within the "Nanofiber based sponges for atopic
   skin treatment" project carried out within the First TEAM program of the
   Foundation for Polish Science cofinanced by the European Union under the
   European Regional Development Fund, project no.
   POIR.04.04.00 00 4571/17 00.
CR Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018 017 2511 3
   Bertocchi C, 2017, NAT CELL BIOL, V19, P28, DOI 10.1038/ncb3456
   Busolo T, 2019, NANO ENERGY, V57, P500, DOI 10.1016/j.nanoen.2018.12.037
   Changede R, 2019, NAT MATER, V18, P1366, DOI 10.1038/s41563 019 0460 y
   Chen CS, 2004, ANNU REV BIOMED ENG, V6, P275, DOI 10.1146/annurev.bioeng.6.040803.140040
   Chen S, 2019, INT HEART J, V60, P374, DOI 10.1536/ihj.18 073
   Chiquet M, 2009, BBA MOL CELL RES, V1793, P911, DOI 10.1016/j.bbamcr.2009.01.012
   Cui ZK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11511 3
   Gawlak G, 2014, FASEB J, V28, P3249, DOI 10.1096/fj.13 245142
   Goldmann WH, 2016, CELL BIOL INT, V40, P241, DOI 10.1002/cbin.10563
   Hirata H, 2008, J CELL SCI, V121, P2795, DOI 10.1242/jcs.030320
   Hu SQ, 2015, CYTOSKELETON, V72, P235, DOI 10.1002/cm.21223
   Huff J, 2019, NAT METHODS, V16
   Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896
   Jacobs T, 2012, PLASMA CHEM PLASMA P, V32, P1039, DOI 10.1007/s11090 012 9394 8
   Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621
   Kaniuk L, 2022, J DRUG DELIV SCI TEC, V77, DOI 10.1016/j.jddst.2022.103855
   Karbowniczek JE, 2023, J COLLOID INTERF SCI, V650, P1371, DOI 10.1016/j.jcis.2023.07.066
   Khater IM, 2020, PATTERNS, V1, DOI 10.1016/j.patter.2020.100038
   Kiuchi T, 2015, NAT METHODS, V12, P743, DOI [10.1038/NMETH.3466, 10.1038/nmeth.3466]
   Kolossov VL, 2018, MICROSC RES TECHNIQ, V81, P115, DOI 10.1002/jemt.22968
   Krysiak ZJ, 2022, BIOMATER ADV, V136, DOI 10.1016/j.bioadv.2022.212786
   Legerstee K, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10111189
   Legland D, 2016, BIOINFORMATICS, V32, P3532, DOI 10.1093/bioinformatics/btw413
   Liu Z, 2016, NAT METHODS, V13, P143, DOI [10.1038/nmeth.3689, 10.1038/NMETH.3689]
   Maraspini R, 2020, J PHYS D APPL PHYS, V53, DOI 10.1088/1361 6463/ab45df
   Metwally S, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109883
   Mitrousis N, 2018, NAT REV MATER, V3, P441, DOI 10.1038/s41578 018 0057 0
   Mousson A, 2021, CANCERS, V13, DOI 10.3390/cancers13081871
   Pageon SV, 2016, MOL BIOL CELL, V27, P3627, DOI 10.1091/mbc.E16 07 0478
   Piórkowski A, 2016, ADV INTELL SYST, V471, P3, DOI 10.1007/978 3 319 39796 2_1
   Polak M, 2023, APPL SURF SCI, V621, DOI 10.1016/j.apsusc.2023.156835
   Ringer P, 2017, NAT METHODS, V14, P1090, DOI [10.1038/nmeth.4431, 10.1038/NMETH.4431]
   Scalisi S, 2021, MEMBRANES BASEL, V11, DOI 10.3390/membranes11110878
   Seong J, 2013, J CELL MOL MED, V17, P597, DOI 10.1111/jcmm.12045
   Stachewicz U., 2023, Functional Biomaterials: Design and Development for Biotechnology, Pharmacology, and Biomedicine, P445
   Stachewicz U, 2015, ACTA BIOMATER, V27, P88, DOI 10.1016/j.actbio.2015.09.003
   Stubb A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12611 w
   Swain S, 2018, ACS CHEM NEUROSCI, V9, P3094, DOI 10.1021/acschemneuro.8b00297
   Szewczyk PK, 2023, NANOSCALE, V15, P6890, DOI 10.1039/d3nr00014a
   Szewczyk PK, 2020, ADV COLLOID INTERFAC, V286, DOI 10.1016/j.cis.2020.102315
   Ura DP, 2022, MACROMOL MATER ENG, V307, DOI 10.1002/mame.202100843
   Ura DP, 2019, BIOENGINEERING BASEL, V6, DOI 10.3390/bioengineering6020041
   Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094
   Williamson DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15293 x
   Wusener AEG, 2021, J CELL SCI, V134, DOI 10.1242/jcs.258769
   Yang LT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05599 2
   Zamir E, 2001, J CELL SCI, V114, P3583
   Ziegler WH, 2008, BIOCHEM SOC T, V36, P235, DOI 10.1042/BST0360235
NR 49
TC 7
Z9 7
U1 6
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB 14
PY 2024
VL 16
IS 8
BP 9944
EP 9955
DI 10.1021/acsami.3c19035
EA FEB 2024
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA IZ9T6
UT WOS:001164705100001
PM 38354103
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Peng, T
   Liu, LN
   MacLean, AL
   Wong, CW
   Zhao, WA
   Nie, Q
AF Peng, Tao
   Liu, Linan
   MacLean, Adam L.
   Wong, Chi Wut
   Zhao, Weian
   Nie, Qing
TI A mathematical model of mechanotransduction reveals how mechanical
   memory regulates mesenchymal stem cell fate decisions
SO BMC SYSTEMS BIOLOGY
LA English
DT Article
DE Mesenchymal stem cell; ECM; YAP/TAZ; Cell fate decision; Stiffness
   sensing; Memory; Bistability; Nonlinear dynamics; Mathematical modeling
ID STOCHASTIC GENE EXPRESSION; EXTRACELLULAR MATRIX; MYOGENIC
   DIFFERENTIATION; BONE MARROW; STIFFNESS; TAZ; LANDSCAPE; NETWORKS;
   ROBUSTNESS; STABILITY
AB Background: Mechanical and biophysical properties of the cellular microenvironment regulate cell fate decisions. Mesenchymal stem cell (MSC) fate is influenced by past mechanical dosing (memory), but the mechanisms underlying this process have not yet been well defined. We have yet to understand how memory affects specific cell fate decisions, such as the differentiation of MSCs into neurons, adipocytes, myocytes, and osteoblasts.
   Results: We study a minimal gene regulatory network permissive of multi lineage MSC differentiation into four cell fates. We present a continuous model that is able to describe the cell fate transitions that occur during differentiation, and analyze its dynamics with tools from multistability, bifurcation, and cell fate landscape analysis, and via stochastic simulation. Whereas experimentally, memory has only been observed during osteogenic differentiation, this model predicts that memory regions can exist for each of the four MSC derived cell lineages. We can predict the substrate stiffness ranges over which memory drives differentiation; these are directly testable in an experimental setting. Furthermore, we quantitatively predict how substrate stiffness and culture duration co regulate the fate of a stem cell, and we find that the feedbacks from the differentiating MSC onto its substrate are critical to preserve mechanical memory. Strikingly, we show that re seeding MSCs onto a sufficiently soft substrate increases the number of cell fates accessible.
   Conclusions: Control of MSC differentiation is crucial for the success of much lauded regenerative therapies based on MSCs. We have predicted new memory regions that will directly impact this control, and have quantified the size of the memory region for osteoblasts, as well as the co regulatory effects on cell fates of substrate stiffness and culture duration. Taken together, these results can be used to develop novel strategies to better control the fates of MSCs in vitro and following transplantation.
C1 [Zhao, Weian; Nie, Qing] Univ Calif Irvine, Dept Math, Ctr Complex Biol Syst, Irvine, CA 92697 USA.
   [Peng, Tao; Wong, Chi Wut; Nie, Qing] Univ Calif Irvine, Ctr Math & Computat Biol, Irvine, CA 92697 USA.
   [MacLean, Adam L.; Zhao, Weian] Chao Family Comprehens Canc Ctr, Dept Biomed Engn, 845 Hlth Sci Rd, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Nie, Q (通讯作者)，Univ Calif Irvine, Dept Math, Ctr Complex Biol Syst, Irvine, CA 92697 USA.
EM qnie@uci.edu
RI Wong, Chi Wut/GRS 6973 2022
OI Wong, Chi Wut/0000 0002 1703 785X
FU NSF [DMS1161621, DMS1562176]; NIH [P50GM076516, R01GM107264,
   R01NS095355, 1DP2CA195763]; Direct For Mathematical & Physical Scien;
   Division Of Mathematical Sciences [1562176, 1161621] Funding Source:
   National Science Foundation
FX QN was partially supported by NSF grants DMS1161621, and DMS1562176, and
   NIH grants P50GM076516, R01GM107264, and R01NS095355. WZ was partially
   supported by the NIH grant 1DP2CA195763.
CR Adler M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003781
   Alarcón C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035
   Allen E., 2007, Modeling with Ito stochastic differential equations
   Allgower E. L., 2012, Numerical Continuation Methods
   [Anonymous], 1994, Stochastic Forces and Nonlinear Systems
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Baker WL, 1989, LANDSCAPE ECOL, V2, P112
   Bernabé BP, 2016, INTEGR BIOL UK, V8, P844, DOI 10.1039/c6ib00093b
   Burke DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040737
   Chalancon G, 2012, TRENDS GENET, V28, P221, DOI 10.1016/j.tig.2012.01.006
   Chen M, 2013, ACS SYNTH BIOL, V2, P587, DOI 10.1021/sb400044g
   Choi B, 2016, MACROMOL BIOSCI, V16, P199, DOI 10.1002/mabi.201500273
   Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
   de Leon SBT, 2009, DEV BIOL, V325, P317, DOI 10.1016/j.ydbio.2008.10.043
   Dhooge A, 2008, MATH COMP MODEL DYN, V14, P147, DOI 10.1080/13873950701742754
   Dingal PCDP, 2015, NAT MATER, V14, P951, DOI [10.1038/NMAT4350, 10.1038/nmat4350]
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Gattazzo F, 2014, BBA GEN SUBJECTS, V1840, P2506, DOI 10.1016/j.bbagen.2014.01.010
   Gesztelyi R, 2012, ARCH HIST EXACT SCI, V66, P427, DOI 10.1007/s00407 012 0098 5
   Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Holmes WR, 2014, BIOPHYS J, V106, P1528, DOI 10.1016/j.bpj.2014.02.010
   Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Ingalls B., 2013, MATH MODELLING SYSTE
   Ivanovska IL, 2015, TRENDS CELL BIOL, V25, P523, DOI 10.1016/j.tcb.2015.04.003
   Mousavi SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124529
   Jeong H, 2010, FASEB J, V24, P3310, DOI 10.1096/fj.09 151324
   Kang KT, 2011, TISSUE ENG REGEN MED, V8, P359
   Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Li CH, 2014, P NATL ACAD SCI USA, V111, P14130, DOI 10.1073/pnas.1408628111
   Li CH, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003165
   Li CH, 2012, ACS SYNTH BIOL, V1, P229, DOI 10.1021/sb300020f
   Li Q, 2016, P NATL ACAD SCI USA, V113, P2672, DOI 10.1073/pnas.1519210113
   Lu DY, 2014, BIOMATERIALS, V35, P3945, DOI 10.1016/j.biomaterials.2014.01.066
   Lv HW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0083 4
   Maharam E, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.15
   Matsuoka F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055082
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mendez MG, 2012, INT J BIOCHEM CELL B, V44, P728, DOI 10.1016/j.biocel.2012.02.003
   Murphy WL, 2014, NAT MATER, V13, P547, DOI [10.1038/NMAT3937, 10.1038/nmat3937]
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Peng T, 2014, IEEE J BIOMED HEALTH, V18, P484, DOI 10.1109/JBHI.2013.2281774
   Prinz Heino, 2010, J Chem Biol, V3, P37, DOI 10.1007/s12154 009 0029 3
   Raghunathan VK, 2013, INVEST OPHTH VIS SCI, V54, P378, DOI 10.1167/iovs.12 11007
   Rehfeldt F, 2012, INTEGR BIOL UK, V4, P422, DOI 10.1039/c2ib00150k
   Rogov I. A., 2012, Sel'skokhozyaistvennaya Biologiya, P66
   Sasai M, 2003, P NATL ACAD SCI USA, V100, P2374, DOI 10.1073/pnas.2627987100
   Smolen P, 2000, B MATH BIOL, V62, P247, DOI 10.1006/bulm.1999.0155
   Stops AJF, 2010, J BIOMECH, V43, P618, DOI 10.1016/j.jbiomech.2009.10.037
   Sun M, 2016, BIOPHYS J, V110, P2540, DOI 10.1016/j.bpj.2016.04.040
   Sun YB, 2012, ANNU REV BIOPHYS, V41, P519, DOI 10.1146/annurev biophys 042910 155306
   Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104
   Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]
   van Kampen NG, 1985, STOCHASTIC PROCESSES
   Wang J, 2008, P NATL ACAD SCI USA, V105, P12271, DOI 10.1073/pnas.0800579105
   Wang J, 2011, P NATL ACAD SCI USA, V108, P8257, DOI 10.1073/pnas.1017017108
   Wang J, 2010, P NATL ACAD SCI USA, V107, P8195, DOI 10.1073/pnas.0910331107
   Wen JH, 2014, NAT MATER, V13, P979, DOI [10.1038/NMAT4051, 10.1038/nmat4051]
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
NR 67
TC 44
Z9 55
U1 2
U2 52
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752 0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD MAY 16
PY 2017
VL 11
AR 55
DI 10.1186/s12918 017 0429 x
PG 15
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematical & Computational Biology
GA EV2VD
UT WOS:000401613500001
PM 28511648
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ye, YP
   Bloch, S
   Xu, BG
   Achilefu, S
AF Ye, YP
   Bloch, S
   Xu, BG
   Achilefu, S
TI Design, synthesis, and evaluation of near infrared fluorescent
   multimeric RGD peptides for targeting tumors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ALPHA V INTEGRINS; ARG GLY ASP; IN VIVO; CELL ADHESION; CONTRAST AGENTS;
   ALPHA 3 BETA 1 INTEGRIN; OSTEOCLAST PRECURSORS; SIGNAL TRANSDUCTION;
   MOLECULAR PROBES; PROTEIN KINASE
AB Molecular interactions between RGD peptides and integrins are known to mediate many biological and pathological processes. This has led to an increased interest in the development of RGD compounds with high affinity and improved selectivity for integrin receptors. In this study, we synthesized and evaluated a series of multimeric RGD compounds constructed on a dicarboxylic acid containing near infrared (NIR) fluorescent dye (cypate) for tumor targeting. An array of NIR fluorescent RGD compounds was prepared efficiently, including one RGD monomer (cypate (RGD)(2) NH2), two RGD dimers (cypate (RGD)(2) NH2 and cypate (RGD NH2)(2)), one trimer (cypate (RGD)3 NH2), two tetramers (cypate (RGD)(4) NH2 and cypate(2)](2)), and one octamer (cypate [(RGD)(4) NH2](2)). The binding [(RGD)(2) NH2](2)), one hexamer (cypate [(RGD)3 NHI C, affinity of the multimeric RGD compounds for alpha(v)beta(3) integrin receptor (ABIR) showed a remarkable increase relative to the monomer cypate RGD NH2. Generally, the divalent linear arrays of the multimeric RGD units bound the ABIR with slightly higher affinity than their monovalent analogues. These results suggest that the receptor binding affinity was not only dependent on the number of RGD moieties but also on the spatial alignments of the pendant peptides. Internalization of the compounds by ABIR positive tumor cells (A549) was monitored by NIR fluorescence microscopy. The data showed that endocytosis of the octameric RGD derivative was significantly higher by comparison to other compounds in this study. In vivo noninvasive optical imaging and biodistribution data showed that the compounds were retained in A549 tumor tissue. These results clearly demonstrated that an array of simple RGD tripeptides on a NIR fluorescent dye core can be recognized by ABIR. Optimization of the spatial alignment of the RGD moieties through careful en molecular design and library construction could induce multivalent ligand receptor interactions useful for in vivo tumor imaging and tumor targeted therapy.
C1 Washington Univ, Dept Radiol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Washington Univ, Dept Radiol, St Louis, MO 63110 USA.
EM achilefus@mir.wustl.edu
RI ; Achilefu, Samuel/AAC 2401 2019
OI Achilefu, Samuel/0000 0002 3133 6717; 
FU NCI NIH HHS [R21 CA100972, R24 CA083060, R33 CA100972, R01 CA109754, R24
   CA83060] Funding Source: Medline
CR Achilefu S, 2000, INVEST RADIOL, V35, P479, DOI 10.1097/00004424 200008000 00004
   Achilefu S, 2005, P NATL ACAD SCI USA, V102, P7976, DOI 10.1073/pnas.0503500102
   Achilefu S, 2004, TECHNOL CANCER RES T, V3, P393, DOI 10.1177/153303460400300410
   Allen CM, 1999, PHOTOCHEM PHOTOBIOL, V70, P512
   AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014 5793(91)81101 D
   BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925 5932.1994
   Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005 0102
   Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582
   Bloch S, 2004, P SOC PHOTO OPT INS, V5329, P222, DOI 10.1117/12.533160
   Boturyn D, 2004, J AM CHEM SOC, V126, P5730, DOI 10.1021/ja049926n
   Bugaj JE, 2001, J BIOMED OPT, V6, P122, DOI 10.1117/1.1352748
   Burnett CA, 2005, BIOORGAN MED CHEM, V13, P3763, DOI 10.1016/j.bmc.2005.03.024
   Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463
   BUSK M, 1992, J BIOL CHEM, V267, P5790
   Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765
   Carreiras F, 2002, INT J CANCER, V99, P800, DOI 10.1002/ijc.10433
   Chen XY, 2004, CANCER RES, V64, P8009, DOI 10.1158/0008 5472.CAN 04 1956
   Cheng Z, 2005, BIOCONJUGATE CHEM, V16, P1433, DOI 10.1021/bc0501698
   Cordes N, 2004, STRAHLENTHER ONKOL, V180, P157, DOI 10.1007/s00066 004 1144 2
   Davison E, 2001, J GENE MED, V3, P550, DOI 10.1002/jgm.223
   Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g
   Dirksen A, 2005, CHEM COMMUN, P2811, DOI 10.1039/b502347e
   Enns A, 2005, EUR J CANCER, V41, P1065, DOI 10.1016/j.ejca.2004.12.031
   Fondevila C, 2005, TRANSPL P, V37, P1679, DOI 10.1016/j.transproceed.2005.04.006
   Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749 6632.1996.tb52952.x
   Gottschalk KE, 2002, ANGEW CHEM INT EDIT, V41, P3767, DOI 10.1002/1521 3773(20021018)41:20<3767::AID ANIE3767>3.0.CO;2 T
   Haubner R, 2004, BIOCONJUGATE CHEM, V15, P61, DOI 10.1021/bc034170n
   Haubner R, 2001, J NUCL MED, V42, P326
   Inoue M, 1998, MOL ENDOCRINOL, V12, P1955, DOI 10.1210/me.12.12.1955
   Ke CY, 2004, ADV DRUG DELIVER REV, V56, P1143, DOI 10.1016/j.addr.2004.01.004
   Kessler T, 2005, CLIN CANCER RES, V11, P6317, DOI 10.1158/1078 0432.CCR 05 0389
   Kintscher U, 2002, CIRC RES, V91, pE35, DOI 10.1161/01.RES.0000046017.96083.34
   Kumar CC, 1997, J PHARMACOL EXP THER, V283, P843
   Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555 005 1572 1
   Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017
   Leamon CP, 2004, ADV DRUG DELIVER REV, V56, P1127, DOI 10.1016/j.addr.2004.01.008
   Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494
   Lubin FD, 2003, IMMUNOLOGY, V108, P204, DOI 10.1046/j.1365 2567.2003.01577.x
   Lygoe KA, 2004, WOUND REPAIR REGEN, V12, P461, DOI 10.1111/j.1067 1927.2004.12402.x
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Mitra A, 2005, J CONTROL RELEASE, V102, P191, DOI 10.1016/j.jconrel.2004.09.023
   Mousa SA, 2000, CORONARY ARTERY DIS, V11, P563, DOI 10.1097/00019501 200010000 00008
   NAKAMURA I, 2004, RECENT RES DEV IMMUN, V6, P79
   Nisato Riccardo E., 2003, Angiogenesis, V6, P105, DOI 10.1023/B:AGEN.0000011801.98187.f2
   Oyama T, 2003, CANCER LETT, V202, P219, DOI 10.1016/j.canlet.2003.08.011
   Paik JY, 2005, NUCL MED BIOL, V32, P561, DOI 10.1016/j.nucmedbio.2005.04.016
   Pedchenko V, 2004, J BIOL CHEM, V279, P2772, DOI 10.1074/jbc.M311901200
   Pidgeon GP, 2003, CANCER RES, V63, P4258
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   PIERSCHBACHER MD, 1985, J CELL BIOCHEM, V28, P115, DOI 10.1002/jcb.240280205
   Pottratz ST, 1997, EUR J CLIN INVEST, V27, P17, DOI 10.1046/j.1365 2362.1997.620612.x
   REILLY PL, 1995, J IMMUNOL, V155, P529
   Roy R, 2003, TRENDS GLYCOSCI GLYC, V15, P291, DOI 10.4052/tigg.15.291
   RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092 8674(86)90259 X
   Ruoslahti E, 2003, MATRIX BIOL, V22, P459, DOI 10.1016/S0945 053X(03)00083 0
   Sacchettini JC, 2001, BIOCHEMISTRY US, V40, P3009, DOI 10.1021/bi002544j
   Sago K, 1999, J BONE MINER RES, V14, P32, DOI 10.1359/jbmr.1999.14.1.32
   Sharma SD, 1996, P NATL ACAD SCI USA, V93, P13715, DOI 10.1073/pnas.93.24.13715
   Taverna D, 2005, CANCER RES, V65, P10324, DOI 10.1158/0008 5472.CAN 04 4098
   Thumshirn G, 2003, CHEM EUR J, V9, P2717, DOI 10.1002/chem.200204304
   Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856 5862.2000
   Tsuji T, 2004, J MEMBRANE BIOL, V200, P115, DOI 10.1007/s00232 004 0696 5
   Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722
   Tung CH, 2002, CHEMBIOCHEM, V3, P784, DOI 10.1002/1439 7633(20020802)3:8<784::AID CBIC784>3.0.CO;2 X
   Wang W, 2004, MOL IMAGING, V3, P343, DOI 10.1162/1535350042973481
   Watson SP, 2005, J THROMB HAEMOST, V3, P1752, DOI 10.1111/j.1538 7836.2005.01429.x
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933
   Winnard P, 2003, J CELL BIOCHEM, V90, P454, DOI 10.1002/jcb.10616
   Ye YP, 2004, J AM CHEM SOC, V126, P7740, DOI 10.1021/ja049441z
   Ye YP, 2005, BIOCONJUGATE CHEM, V16, P51, DOI 10.1021/bc049790i
   Ye YP, 2003, J AM CHEM SOC, V125, P7766, DOI 10.1021/ja034186o
NR 72
TC 127
Z9 154
U1 6
U2 89
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 6
PY 2006
VL 49
IS 7
BP 2268
EP 2275
DI 10.1021/jm050947h
PG 8
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 029VU
UT WOS:000236593300016
PM 16570923
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Schubert, M
   Klatte, I
   Linek, W
   Müller, B
   Döring, K
   Eckelt, U
   Hemprich, A
   Berger, U
   Hendricks, J
AF Schubert, Marika
   Klatte, Ingolf
   Linek, Wigbert
   Mueller, Bianca
   Doering, Karli
   Eckelt, Uwe
   Hemprich, Alexander
   Berger, Uwe
   Hendricks, Joerg
TI The Saxon Bisphosphonate Register   Therapy and prevention of
   bisphosphonate related osteonecrosis of the jaws
SO ORAL ONCOLOGY
LA English
DT Article
DE Bisphosphonates; Osteonecrosis; Jaw; Bisphosphonate related
   osteonecrosis; BRONJ; Tooth extraction
ID RISK FACTORS; SURGICAL MANAGEMENT; TOOTH EXTRACTION; INTRAVENOUS
   BISPHOSPHONATES; CANCER PATIENTS; CASE SERIES; RESECTION; PROTOCOL;
   OUTCOMES
AB In 2009, a study group of three Saxon hospitals set up a Saxon register with the aim of including all patients with bisphosphonate (BP) medication. In addition, specific concepts for surgical approach were developed. The target is to define relevant treatment and prevention strategies of bisphosphonate related osteonecrosis of the jaws (BRONJ) based on high patient population statistics. Since July 2009, all patients with oral or intravenous BP medication have been registered in the 3 Saxon hospitals. Data was systematically acquired in detailed forms. Totally, 258 patients (male: 83, female: 175) were registered by October 2010. 100 patients out of this already had BRONJ which preferably affected the mandible (70%) and was mostly associated with intravenous medication. In 54 cases, treatment was carried out by surgery according to the strategy developed. The criterion for success was absence of symptoms at least for 3 months after surgery. The following stage dependent success rates were obtained: stage I (13 patients)   84.6%, stage II (22 patients)   95.5%, stage III (14 patients)   85.7%, stage IV (5 patients)   80%. Under preventive aspects, teeth were extracted after a predefined scheme in 68 of all patients registered as being asymptomatic. No BRONJ was observed in 98.5%; the criterion also being absence of symptoms for a minimum period of 3 months after surgery. Surgical treatment is the treatment of choice in cases of BRONJ. Tooth extractions are rather unproblematic in asymptomatic patients if the predefined scheme is followed. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Schubert, Marika; Eckelt, Uwe] Tech Univ Dresden, Dept Oral & Maxillofacial Surg, Univ Hosp Carl Gustav Carus, D 01307 Dresden, Germany.
   [Klatte, Ingolf; Linek, Wigbert; Doering, Karli] Hosp Chemnitz, Dept Oral & Maxillofacial Surg, D 09116 Chemnitz, Germany.
   [Mueller, Bianca; Hemprich, Alexander; Hendricks, Joerg] Univ Hosp Leipzig, Dept Oral & Maxillofacial Surg, D 04103 Leipzig, Germany.
C3 Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Chemnitz Clinic; Leipzig University
RP Schubert, M (通讯作者)，Univ Hosp Carl Gustav Carus Dresden, Dept Oral & Maxillofacial Surg, Fetscherstr 74, D 01307 Dresden, Germany.
EM marika.schubert@uniklinikum dresden.de
RI Hemprich, Alexander/JXL 9631 2024
CR Abu Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008
   Aguirre JI, 2010, ORAL DIS, V16, P674, DOI 10.1111/j.1601 0825.2010.01677.x
   Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   American Association of Endodontists (AAE), 2010, AAE POS STAT END IMP
   American Dental Association (ADA) Council on Scientific Affairs, 2006, J AM DENT ASSOC, V137, P1144
   [Anonymous], BISPH DAT STRUKT MUL
   Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), 2007, LEITL SEPT CHIR DTSC
   Bartl R., 2005, Bisphosphonat Manual
   Bedogni A, 2011, ORAL ONCOL, V47, P420, DOI 10.1016/j.oraloncology.2011.02.024
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Curi MM, 2011, J ORAL MAXIL SURG, V69, P2465, DOI 10.1016/j.joms.2011.02.078
   Frohlich M, 2007, ARZTEBLATT SACHSEN, P84
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Lazarovici TS, 2009, J ORAL MAXIL SURG, V67, P850, DOI 10.1016/j.joms.2008.11.015
   Linek W, 2008, ZAHNARZTEBLATT SACHS, V7+8, P32
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Lodi G, 2010, J ORAL MAXIL SURG, V68, P107, DOI 10.1016/j.joms.2009.07.068
   Markose G, 2009, BRIT J ORAL MAX SURG, V47, P294, DOI 10.1016/j.bjoms.2009.01.007
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Mücke T, 2011, J CANCER RES CLIN, V137, P907, DOI 10.1007/s00432 010 0953 1
   Otto S, 2009, J ORAL MAXIL SURG, V67, P589, DOI 10.1016/j.joms.2008.09.028
   Pautke C, 2010, J ORAL MAXIL SURG, V68, P125, DOI 10.1016/j.joms.2009.05.442
   Piesold JU, 2006, ORAL MAXILLOFAC SURG, V10, P287, DOI 10.1007/s10006 006 0017 5
   Reich W, 2008, ARZTEBLATT SACHSEN A, P14
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saia G, 2010, J ORAL MAXIL SURG, V68, P797, DOI 10.1016/j.joms.2009.10.026
   Scoletta M, 2010, ORAL SURG ORAL MED O, V110, P46, DOI 10.1016/j.tripleo.2010.02.020
   Stanton DC, 2009, J ORAL MAXIL SURG, V67, P943, DOI 10.1016/j.joms.2008.12.057
   Stockmann P, 2010, SUPPORT CARE CANCER, V18, P449, DOI 10.1007/s00520 009 0688 1
   Thumbigere Math V, 2009, J ORAL MAXIL SURG, V67, P1904, DOI 10.1016/j.joms.2009.04.051
   Vassiliou V, 2010, STRAHLENTHER ONKOL, V186, P367, DOI 10.1007/s00066 010 2066 9
   Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007
   Walter C, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 11
   Walter C, 2009, CANCER AM CANCER SOC, V115, P1631, DOI 10.1002/cncr.24119
   Wilde F, 2011, ORAL SURG ORAL MED O, V111, P153, DOI 10.1016/j.tripleo.2010.04.015
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
   Wutzl A, 2008, HEAD NECK J SCI SPEC, V30, P1224, DOI 10.1002/hed.20864
NR 40
TC 60
Z9 65
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368 8375
J9 ORAL ONCOL
JI Oral Oncol.
PD APR
PY 2012
VL 48
IS 4
BP 349
EP 354
DI 10.1016/j.oraloncology.2011.11.004
PG 6
WC Oncology; Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 918RD
UT WOS:000302267200011
PM 22130456
DA 2025 08 17
ER

PT J
AU Zhuo, WK
   Ge, WM
   Meng, GL
   Jia, SJ
   Zhou, X
   Liu, J
AF Zhuo, Wenkun
   Ge, Weiming
   Meng, Guolin
   Jia, Shuaijun
   Zhou, Xiang
   Liu, Jian
TI MicroRNA 20a promotes the proliferation and cell cycle of human
   osteosarcoma cells by suppressing early growth response 2 expression
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE microRNA 20a; osteosarcoma; early growth response 2; cell proliferation;
   cell cycle
ID CANCER; PROGRESSION; EGR2; METASTASIS; THERAPY; MIR 20A; SARCOMA;
   PROTEIN; FAMILY; G(1)
AB MicroRNAs (miRNAs) are crucial in cancer development. However, the underlying mechanisms of miRNAs in osteosarcoma (OS) remain largely uncharacterized. The present study investigated the role of miR 20a in OS cell proliferation. It was determined that miR 20a expression is markedly upregulated in OS tissues and cells compared with the matched adjacent normal tissues and h FOB human osteoblast cell lines. Ectopic expression of miR 20a promoted the proliferation and anchorage independent growth of OS cells, whereas inhibition of miR 20a reduced this effect. Bioinformatics analysis further revealed early growth response 2 (EGR2), as a potential target of miR 20a. Data from luciferase reporter assays showed that miR 20a directly binds to the 3' untranslated region (3' UTR) of EGR2 mRNA and represses expression at the transcriptional and translational levels. In functional assays, miR 20a promoted OS cell proliferation and the cell cycle, which could be suppressed by an inhibitor of miR 20a. In conclusion, the data provide compelling evidence that miR 20a functions as an onco miRNA, which is important in promoting cell proliferation in OS, and its oncogenic effect is mediated primarily through direct suppression of EGR2 expression.
C1 [Zhuo, Wenkun; Meng, Guolin; Zhou, Xiang; Liu, Jian] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped & Traumatol, Dept Orthoped & Traumatol, Xian 710000, Shanxi, Peoples R China.
   [Zhuo, Wenkun] Jinan Mil Gen Hosp, Dept Orthoped & Traumatol, Jinan 250000, Shandong, Peoples R China.
   [Ge, Weiming] PLA Fifth Thirty Four Hosp, Dept Orthoped & Traumatol, Luoyang 471000, Henan, Peoples R China.
   [Jia, Shuaijun] Shanxi Hosp Chinese Armed Police Forces, Dept Orthoped, Xian 710000, Shanxi, Peoples R China.
C3 Air Force Medical University
RP Liu, J (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped & Traumatol, Dept Orthoped & Traumatol, 169 Changlexi Rd, Xian 710000, Shanxi, Peoples R China.
EM jianliuxian@163.com
FU Institute of Orthopedics and Traumatology, Xijing Hospital
FX This study was supported by the Institute of Orthopedics and
   Traumatology, Xijing Hospital.
CR Ahmed AA, 2014, CANCER CHEMOTH PHARM, V73, P657, DOI 10.1007/s00280 014 2392 1
   Arabi Leila, 2014, Genes Cancer, V5, P56
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cao ZQ, 2013, ASIAN PAC J CANCER P, V14, P7081, DOI 10.7314/APJCP.2013.14.12.7081
   Chang YX, 2013, J HEPATOL, V59, P518, DOI 10.1016/j.jhep.2013.04.034
   Constantinidou A, 2013, EXPERT REV ANTICANC, V13, P211, DOI [10.1586/ERA.12.161, 10.1586/era.12.161]
   Esquela Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164
   Li XS, 2013, INT J MOL SCI, V14, P16226, DOI 10.3390/ijms140816226
   Masamha CP, 2009, CANCER RES, V69, P6565, DOI 10.1158/0008 5472.CAN 09 0913
   Miao JL, 2013, TUMOR BIOL, V34, P2093, DOI 10.1007/s13277 013 0940 7
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Sumitomo Shuji, 2013, JAKSTAT, V2, pe23952, DOI 10.4161/jkst.23952
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080
   Tian Q, 2014, EJSO EUR J SURG ONC, V40, P67, DOI 10.1016/j.ejso.2013.08.024
   Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608
   van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107
   Wang ZZ, 2010, INT J ONCOL, V37, P1315, DOI 10.3892/ijo_00000783
   Xiong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096103
   Xu JQ, 2013, TUMOR BIOL, V34, P3871, DOI 10.1007/s13277 013 0974 x
   Yang M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100216
   Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079
   Zhao S, 2013, GENET TEST MOL BIOMA, V17, P631, DOI 10.1089/gtmb.2013.0085
NR 25
TC 22
Z9 26
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2015
VL 12
IS 4
BP 4989
EP 4994
DI 10.3892/mmr.2015.4098
PN A
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CT7MQ
UT WOS:000362999200024
PM 26238942
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Cozin, M
   Pinker, BM
   Solemani, K
   Zuniga, JM
   Dadaian, SC
   Cremers, S
   Landesberg, R
   Raghavan, S
AF Cozin, Matthew
   Pinker, Bradley M.
   Solemani, Kimberley
   Zuniga, Jeremy M.
   Dadaian, Stephen C.
   Cremers, Serge
   Landesberg, Regina
   Raghavan, Srikala
TI Novel Therapy to Reverse the Cellular Effects of Bisphosphonates on
   Primary Human Oral Fibroblasts
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
AB Purpose: Osteonecrosis of the jaws (ONJ) is a clinical condition that is characterized by a nonhealing breach in the oral mucosa resulting in exposure of bone and has been increasingly reported in patients receiving bisphosphonate (BP) therapy. Although the pathogenesis and natural history of ONJ remain ill defined, it appears that the oral soft tissues play a critical role in the development of this condition. We examined the effects of the nitrogen containing BPs pamidronate and zoledronate on primary human gingival fibroblasts.
   Materials and Methods: Primary gingival fibroblasts were exposed to clinically relevant closes of pamidronate and zoledronate. Cellular proliferation was measured with an MTS/PMS reagent  based kit (Promega, Madison, WD, scratch wound assays were performed to measure cellular migration, and apoptosis was measured by use of terminal deoxynucleotidyl transferase mediated dUTP FITC end labeling and caspase assays. The BP exposed cells were treated with 10 ng/mL recombinant human platelet derived growth factor BB (rhPDGF BB) and 50 mu mol/L geranylgeraniol (GGOH).
   Results: Gingival fibroblasts are significantly more sensitive to inhibition of proliferation by zoledronate compared with pamidronate. Exposure of these cells to pamidronate but not zoledronate resulted in an increase in cellular apoptosis. Furthermore, exposure of gingival fibroblasts to pamidronate or zoledronate resulted in a decrease in cellular migration. We show that these defects are clue to a loss of cell substratum adhesion and a reduction of F actin bundles. Finally, we show that the addition of rhPDGF BB and GGOH in vitro is able to partially rescue the cell proliferation, migration, and adhesion defects.
   Conclusion: The cytotoxic effects of BPs on oral fibroblasts and their significant reversal by the addition of GGOH and rhPDGF BB provide both the potential mechanism and treatment options for ONJ. (C) 2011 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 69:2564 2578, 2011
C1 [Raghavan, Srikala] Columbia Univ, Coll Dent Med, Div Oral Surg, New York, NY 10032 USA.
   [Cremers, Serge] Columbia Univ, Dept Med Endocrinol, New York, NY 10032 USA.
   [Landesberg, Regina] Univ Connecticut, Sch Dent Med, Ctr Hlth, Div Oral & Maxillofacial Surg, Farmington, CT 06032 USA.
   [Raghavan, Srikala] Columbia Univ, Dept Dermatol, New York, NY 10032 USA.
C3 Columbia University; Columbia University; University of Connecticut;
   Columbia University
RP Raghavan, S (通讯作者)，Columbia Univ, Coll Dent Med, Div Oral Surg, P&S Box 20,630 W 168th St, New York, NY 10032 USA.
EM sr2309@columbia.edu
OI Raghavan, Srikala/0000 0002 9011 767X
FU National Institutes of Health [5R21DE17164]; Irving Research Scholar
   Grant
FX This work was funded by National Institutes of Health grant 5R21DE17164
   to R.L. and S.C. and an Irving Research Scholar Grant to S.R.
CR Agis H, 2010, J DENT RES, V89, P40, DOI 10.1177/0022034509354298
   AMLER MH, 1969, ORAL SURG ORAL MED O, V27, P309, DOI 10.1016/0030 4220(69)90357 0
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Dodson TB, 2009, J ORAL MAXIL SURG, V67, P44, DOI 10.1016/j.joms.2008.12.004
   Elsubeihi ES, 2004, ARCH ORAL BIOL, V49, P401, DOI 10.1016/j.archoralbio.2003.12.003
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Green J, 2010, CANCER INVEST, V28, P944, DOI 10.3109/07357907.2010.512598
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hollinger JO, 2008, J BONE JOINT SURG AM, V90A, P48, DOI 10.2106/JBJS.G.01231
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kos M, 2010, J CRANIO MAXILL SURG, V38, P255, DOI 10.1016/j.jcms.2009.06.005
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Major P, 2002, ONCOLOGIST, V7, P481, DOI 10.1634/theoncologist.7 6 481
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McLeod NMH, 2011, BRIT J ORAL MAX SURG, V49, P335, DOI 10.1016/j.bjoms.2010.08.005
   Mehrotra B, 2009, J ORAL MAXIL SURG, V67, P19, DOI 10.1016/j.joms.2009.01.012
   Nogawa M, 2005, ONCOL RES, V15, P1
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Pellegrini G, 2009, J DENT RES, V88, P1065, DOI 10.1177/0022034509349748
   Raghavan S, 2003, DEV CELL, V5, P415, DOI 10.1016/S1534 5807(03)00261 2
   Ravosa MJ, 2011, ARCH ORAL BIOL, V56, P491, DOI 10.1016/j.archoralbio.2010.11.003
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006
   Rosen LS, 2001, CANCER J, V7, P377
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741 5214(95)70245 8
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Suyama K, 2007, ONCOL REP, V18, P1291
   Thumbigere Math V, 2009, J ORAL MAXIL SURG, V67, P1904, DOI 10.1016/j.joms.2009.04.051
   TWISS IM, 1994, J PHARM SCI, V83, P699, DOI 10.1002/jps.2600830521
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   Usui T, 1997, INT J CLIN PHARM TH, V35, P239
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Van Poznak Catherine H, 2002, Cancer Control, V9, P480
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Wallace JL, 1999, ALIMENT PHARM THER, V13, P1675
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Wang EP, 2007, J ORAL MAXIL SURG, V65, P1328, DOI 10.1016/j.joms.2007.03.006
   Yoneda T, 2010, J BONE MINER METAB, V28, P365, DOI 10.1007/s00774 010 0162 7
   Young CS, 2009, J CONTROL RELEASE, V140, P250, DOI 10.1016/j.jconrel.2009.06.030
   Zamir E, 2001, J CELL SCI, V114, P3583
   Zhong WB, 2005, ENDOCR RELAT CANCER, V12, P615, DOI 10.1677/erc.1.01012
NR 61
TC 38
Z9 40
U1 0
U2 8
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD OCT
PY 2011
VL 69
IS 10
BP 2564
EP 2578
DI 10.1016/j.joms.2011.03.005
PG 15
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 835XV
UT WOS:000296071200018
PM 21807448
OA Green Accepted
DA 2025 08 17
ER

PT J
AU DeCarlo, AA
   Belousova, M
   Ellis, AL
   Petersen, D
   Grenett, H
   Hardigan, P
   O'Grady, R
   Lord, M
   Whitelock, JM
AF DeCarlo, Arthur A.
   Belousova, Maria
   Ellis, April L.
   Petersen, Donald
   Grenett, Hernan
   Hardigan, Patrick
   O'Grady, Robert
   Lord, Megan
   Whitelock, John M.
TI Perlecan domain 1 recombinant proteoglycan augments BMP 2 activity and
   osteogenesis
SO BMC BIOTECHNOLOGY
LA English
DT Article
DE Osteogenesis; BMP 2; Heparan sulfate; Chondroitin sulfate; Proteoglycan;
   TCP; Bone graft; Implant; Osteoblast; Perlecan
ID FIBROBLAST GROWTH FACTOR; CHONDROITIN SULFATE E; HEPARAN SULFATE;
   COLLAGEN; BINDING; FGF; DIFFERENTIATION; HYDROXYAPATITE; INVOLVEMENT;
   EXPRESSION
AB Background: Many growth factors, such as bone morphogenetic protein (BMP) 2, have been shown to interact with polymers of sulfated disacharrides known as heparan sulfate (HS) glycosaminoglycans (GAGs), which are found on matrix and cell surface proteoglycans throughout the body. HS GAGs, and some more highly sulfated forms of chondroitin sulfate (CS), regulate cell function by serving as co factors, or co receptors, in GF interactions with their receptors, and HS or CS GAGs have been shown to be necessary for inducing signaling and GF activity, even in the osteogenic lineage. Unlike recombinant proteins, however, HS and CS GAGs are quite heterogenous due, in large part, to post translational addition, then removal, of sulfate groups to various positions along the GAG polymer. We have, therefore, investigated whether it would be feasible to deliver a DNA pro drug to generate a soluble HS/CS proteoglycan in situ that would augment the activity of growth factors, including BMP 2, in vivo.
   Results: Utilizing a purified recombinant human perlecan domain 1 (rhPln.D1) expressed from HEK 293 cells with HS and CS GAGs, tight binding and dose enhancement of rhBMP 2 activity was demonstrated in vitro. In vitro, the expressed rhPln.D1 was characterized by modification with sulfated HS and CS GAGs. Dose enhancement of rhBMP 2 by a pln.D1 expression plasmid delivered together as a lyophilized single phase on a particulate tricalcium phosphate scaffold for 6 or more weeks generated up to 9 fold more bone volume de novo on the maxillary ridge in a rat model than in control sites without the pln.D1 plasmid. Using a significantly lower BMP 2 dose, this combination provided more than 5 times as much maxillary ridge augmentation and greater density than rhBMP 2 delivered on a collagen sponge (InFuse (TM)).
   Conclusions: A recombinant HS/CS PG interacted strongly and functionally with BMP 2 in binding and cell based assays, and, in vivo, the pln.247 expression plasmid significantly improved the dose effectiveness of BMP 2 osteogenic activity for in vivo de novo bone generation when delivered together on a scaffold as a single phase. The use of HS/CS PGs may be useful to augment GF therapeutics, and a plasmid based approach has been shown here to be highly effective.
C1 [DeCarlo, Arthur A.; Belousova, Maria; Ellis, April L.; Petersen, Donald; Grenett, Hernan] Agenta Biotechnol Inc, Birmingham, AL 35203 USA.
   [Hardigan, Patrick] Univ Sydney, Grad Sch Biomed Engn, Sydney, NSW 2006, Australia.
   [O'Grady, Robert; Lord, Megan; Whitelock, John M.] Nova SE Univ, Ctr Stat Consulting, Ft Lauderdale, FL 33328 USA.
C3 University of Sydney; Nova Southeastern University
RP DeCarlo, AA (通讯作者)，Agenta Biotechnol Inc, 1500 1st Ave N,Unit 31, Birmingham, AL 35203 USA.
EM decarlo@agentabiotechnologies.com
RI Hardigan, Patrick/L 2077 2015; Lord, Megan/D 4673 2013
OI Lord, Megan/0000 0002 0506 9811; DeCarlo, Arthur/0000 0002 2057 623X;
   Whitelock, John/0000 0003 1835 802X
FU Agenta Biotechnologies, Inc.; NIDCR, an NIH institute [DE016771]; SBIR
   program
FX Agenta Biotechnologies, Inc. financed the processing of this manuscript,
   holds patents relating, in part, to the content of the manuscript
   describing nucleic acid delivery of perlecan as a therapeutic in
   mammals, and may benefit indirectly from its publication. Authors
   DeCarlo, Belousova, Ellis, Petersen, Grenett, Hardigan, and Whitelock
   have all received fees, funding, stock, stock options, or salary from
   Agenta Biotechnologies, Inc. There are no other financial or
   non financial competing interests relating to the publication of this
   manuscript.This publication was supported by Grant Number DE016771 from
   the NIDCR, an NIH institute, and was awarded through the SBIR program.
   Its contents are solely the responsibility of the authors and Agenta
   Biotechnologies and do not necessarily represent the official views of
   the NIDCR.
CR Abramsson A, 2007, GENE DEV, V21, P316, DOI 10.1101/gad.398207
   Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053
   Casper CL, 2007, BIOMACROMOLECULES, V8, P1116, DOI 10.1021/bm061003s
   Chuang CY, 2010, BIOCHEMISTRY US, V49, P5524, DOI 10.1021/bi1005199
   Cool SM, 2006, J CELL BIOCHEM, V99, P1040, DOI 10.1002/jcb.20936
   DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961
   DeCarlo AA, 2006, J DENT RES, V85, P122, DOI 10.1177/154405910608500203
   Deepa SS, 2007, GLYCOBIOLOGY, V17, P631, DOI 10.1093/glycob/cwm021
   Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200
   Dombrowski C, 2009, STEM CELLS DEV, V18, P661, DOI 10.1089/scd.2008.0157
   Ellis AL, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472 6750 10 66
   Eyckmans J, 2010, J CELL MOL MED, V14, P1845, DOI 10.1111/j.1582 4934.2009.00807.x
   Gandhi NS, 2012, BIOCH BIOPHYSICA ACT
   Gao T, 1996, INT ORTHOP, V20, P321, DOI 10.1007/s002640050086
   Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006 291X(03)01500 6
   Ito Y, 2005, GLYCOBIOLOGY, V15, P593, DOI 10.1093/glycob/cwi036
   Jha AK, 2009, BIOMATERIALS, V30, P6964, DOI 10.1016/j.biomaterials.2009.09.009
   Khan S, 2011, J BIOL CHEM, V286, P24842, DOI 10.1074/jbc.M111.226027
   Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200
   Kuboki Y, 1998, J BIOMED MATER RES, V39, P190, DOI 10.1002/(SICI)1097 4636(199802)39:2<190::AID JBM4>3.0.CO;2 K
   Lamoureux F, 2007, BIOESSAYS, V29, P758, DOI 10.1002/bies.20612
   Li FC, 2007, J BIOL CHEM, V282, P2956, DOI 10.1074/jbc.M609296200
   Miyazaki T, 2008, J CELL PHYSIOL, V217, P769, DOI 10.1002/jcp.21557
   Muthusamy A, 2010, BMC BIOCHEM, V11, DOI 10.1186/1471 2091 11 43
   Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521 1878(200002)22:2<108::AID BIES2>3.0.CO;2 M
   Qiu XX, 1996, J IMMUNOL, V156, P3350
   Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200
   Rudd TR, 2010, ORG BIOMOL CHEM, V8, P5390, DOI 10.1039/c0ob00246a
   Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432 1033.1996.0295n.x
   Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097 2765(00)00073 3
   Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188
   Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200
   URIST MR, 1984, CLIN ORTHOP RELAT R, P277
   URIST MR, 1987, CLIN ORTHOP RELAT R, P295
   van den Born J, 2005, J BIOL CHEM, V280, P20516, DOI 10.1074/jbc.M502065200
   Whitelock JM, 2005, CHEM REV, V105, P2745, DOI 10.1021/cr010213m
   Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079
   Woodruff MA, 2007, J MOL HISTOL, V38, P425, DOI 10.1007/s10735 007 9137 y
   Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200
   Yang WD, 2005, TISSUE ENG, V11, P76, DOI 10.1089/ten.2005.11.76
   Yang WD, 2006, TISSUE ENG, V12, P2009, DOI 10.1089/ten.2006.12.2009
NR 41
TC 26
Z9 29
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6750
J9 BMC BIOTECHNOL
JI BMC Biotechnol.
PD SEP 11
PY 2012
VL 12
AR 60
DI 10.1186/1472 6750 12 60
PG 16
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 029WO
UT WOS:000310528000001
PM 22967000
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rajon, DA
   Canter, BS
   Leung, CN
   Bäck, TA
   Fritton, JC
   Azzam, EI
   Howell, RW
AF Rajon, Didier A.
   Canter, Brian S.
   Leung, Calvin N.
   Back, Tom A.
   Fritton, J. Christopher
   Azzam, Edouard I.
   Howell, Roger W.
TI Modeling bystander effects that cause growth delay of breast cancer
   xenografts in bone marrow of mice treated with radium 223
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article
DE Bystander effect; breast cancer; RBE; Monte Carlo; alpha particle;
   Radium 223
ID MONTE CARLO SIMULATION; EMITTING RA 223; CELLULAR UPTAKE; RADIATION;
   CELLS; POPULATIONS; IRRADIATION; METASTASES; OSTEOBLAST; SURVIVAL
AB Rationale The role of radiation induced bystander effects in cancer therapy with alpha particle emitting radiopharmaceuticals remains unclear. With renewed interest in using alpha particle emitters to sterilize disseminated tumor cells, micrometastases, and tumors, a better understanding of the direct effects of alpha particles and the contribution of the bystander responses they induce is needed to refine dosimetric models that help predict clinical benefit. Accordingly, this work models and quantifies the relative importance of direct effects (DE) and bystander effects (BE) in the growth delay of human breast cancer xenografts observed previously in the tibiae of mice treated with (RaCl2) Ra 223. Methods A computational model of MDA MB 231 and MCF 7 human breast cancer xenografts in the tibial bone marrow of mice administered (RaCl2) Ra 223 was created. A Monte Carlo radiation transport simulation was performed to assess individual cell absorbed doses. The responses of the breast cancer cells to direct alpha particle irradiation and gamma irradiation were needed as input data for the model and were determined experimentally using a colony forming assay and compared to the responses of preosteoblast MC3T3 E1 and osteocyte like MLO Y4 bone cells. Using these data, a scheme was devised to simulate the dynamic proliferation of the tumors in vivo, including DE and BE propagated from the irradiated cells. The parameters of the scheme were estimated semi empirically to fit experimental tumor growth. Results A robust BE component, in addition to a much smaller DE component, was required to simulate the in vivo tumor proliferation. We also found that the relative biological effectiveness (RBE) for cell killing by alpha particle radiation was greater for the bone cells than the tumor cells. Conclusion This modeling study demonstrates that DE of radiation alone cannot explain experimental observations of (RaCl2) Ra 223 induced growth delay of human breast cancer xenografts. Furthermore, while the mechanisms underlying BE remain unclear, the addition of a BE component to the model is necessary to provide an accurate prediction of the growth delay. More complex models are needed to further comprehend the extent and complexity of (RaCl2) Ra 223 induced BE.
C1 [Rajon, Didier A.] Univ Florida, Dept Neurosurg, POB 100265, Gainesville, FL 32610 USA.
   [Canter, Brian S.; Leung, Calvin N.; Azzam, Edouard I.; Howell, Roger W.] Rutgers State Univ, New Jersey Med Sch, Dept Radiol, Newark, NJ USA.
   [Back, Tom A.] Univ Gothenburg, Sahlgrenska Acad, Dept Radiat Phys, Gothenburg, Sweden.
   [Fritton, J. Christopher] CUNY City Coll, Dept Biomed Engn, New York, NY USA.
   [Azzam, Edouard I.] Canadian Nucl Labs, Radiobiol & Hlth Branch, Chalk River, ON, Canada.
C3 State University System of Florida; University of Florida; Rutgers
   University System; Rutgers University Newark; Rutgers University New
   Brunswick; Rutgers University Biomedical & Health Sciences; University
   of Gothenburg; City University of New York (CUNY) System; City College
   of New York (CUNY); Canadian Nuclear Labs
RP Rajon, DA (通讯作者)，Univ Florida, Dept Neurosurg, POB 100265, Gainesville, FL 32610 USA.
EM didier@ufl.edu
RI ; Rajon, Didier/O 9412 2014; Howell, Roger/GXZ 5412 2022
OI Howell, Roger/0000 0002 7057 8110; Fritton, James/0000 0002 6475 7622; 
FU NIH [1R01CA198073]; New Jersey Commission on Cancer Research
   Pre doctoral Fellowship [DFHS15PPC009, DFHS17PPC029]
FX This study was supported in part by grant [1R01CA198073] from the NIH,
   and New Jersey Commission on Cancer Research Pre doctoral Fellowship
   Grants #[DFHS15PPC009] (CNL) and #[DFHS17PPC029] (BSC).
CR Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168 9002(03)01368 8
   Akudugu JM, 2012, INT J RADIAT BIOL, V88, P1028, DOI 10.3109/09553002.2012.683511
   Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098
   Belyakov OV, 2005, P NATL ACAD SCI USA, V102, P14203, DOI 10.1073/pnas.0505020102
   Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054
   Brady D, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00215
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Brewster AM, 2008, JNCI J NATL CANCER I, V100, P1179, DOI 10.1093/jnci/djn233
   Brown HK, 2012, CLIN EXP METASTAS, V29, P927, DOI 10.1007/s10585 012 9481 5
   Canter BS, 2021, MOL CANCER RES, V19, P1739, DOI 10.1158/1541 7786.MCR 21 0005
   Dondossola E, 2019, JNCI J NATL CANCER I, V111, P1042, DOI 10.1093/jnci/djz007
   Duangmano S, 2012, J ONCOL, V2012, DOI 10.1155/2012/601682
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   FOX CH, 1985, J HISTOCHEM CYTOCHEM, V33, P845, DOI 10.1177/33.8.3894502
   Gaillard S, 2009, RADIAT RES, V171, P513, DOI 10.1667/RR1658.1
   Gevorgyan A, 2008, PLAST RECONSTR SURG, V122, P1025, DOI 10.1097/PRS.0b013e3181845931
   GRUBER HE, 1986, MINER ELECTROL METAB, V12, P246
   Henriksen G, 2003, J NUCL MED, V44, P252
   Henriksen G, 2002, CANCER RES, V62, P3120
   HIDDEMANN W, 1982, BLOOD, V59, P216
   Hobbs RF, 2012, PHYS MED BIOL, V57, P3207, DOI 10.1088/0031 9155/57/10/3207
   Howell RW, 2012, INT J RADIAT BIOL, V88, P115, DOI 10.3109/09553002.2011.602379
   HOWELL RW, 1990, RADIAT PROT DOSIM, V31, P325
   ICRP, 1994, ANN ICRP PUBL
   Leung CN, 2020, J NUCL MED, V61, P89, DOI 10.2967/jnumed.119.227835
   Lundberg P, 2007, BIOCHEM BIOPH RES CO, V352, P444, DOI 10.1016/j.bbrc.2006.11.057
   Moreira HMR, 2019, INT J RADIAT ONCOL, V103, P1221, DOI 10.1016/j.ijrobp.2018.12.015
   Mouton P.R., 2002, Principles and practices of unbiased stereology: An introduction for bioscientists
   Neti PVSV, 2004, RADIAT RES, V161, P732, DOI 10.1667/RR3181
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pinto GM, 2020, PHYS MED BIOL, V65, DOI 10.1088/1361 6560/ab6b42
   Rajon DA, 2006, PHYS MED BIOL, V51, P4447, DOI 10.1088/0031 9155/51/18/002
   Rajon D, 2013, MED PHYS, V40, DOI 10.1118/1.4769409
   Rajon D, 2011, J NUCL MED, V52, P926, DOI 10.2967/jnumed.110.080044
   SANDKUHLER S, 1956, BLOOD, V11, P856, DOI 10.1182/blood.V11.9.856.856
   Secondini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016078
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Shao CL, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 184
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Suominen MI, 2013, JNCI J NATL CANCER I, V105, P908, DOI 10.1093/jnci/djt116
   Svetlicic M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051165
   Travlos GS, 2006, TOXICOL PATHOL, V34, P548, DOI 10.1080/01926230600939856
   Vaziri B, 2014, J NUCL MED, V55, P1557, DOI 10.2967/jnumed.113.131037
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
NR 45
TC 9
Z9 9
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955 3002
EI 1362 3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD SEP 2
PY 2021
VL 97
IS 9
BP 1217
EP 1228
DI 10.1080/09553002.2021.1951392
EA JUL 2021
PG 12
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA UI7IP
UT WOS:000678376400001
PM 34232830
OA Green Accepted
DA 2025 08 17
ER

PT J
AU de la Rochefoucauld, J
   Lhote, R
   Benassarou, MA
   Schouman, T
   Bertolus, C
   Amoura, Z
   Hié, M
AF de la Rochefoucauld, Jeanne
   Lhote, Raphael
   Benassarou, Mourad Azzedine
   Schouman, Thomas
   Bertolus, Chloe
   Amoura, Zahir
   Hie, Miguel
TI TNF alpha blockade in primary chronic non bacterial osteomyelitis of the
   mandible
SO RHEUMATOLOGY
LA English
DT Article
DE osteomyelitis; etanercept; tumor necrosis factor inhibitors; adalimumab;
   acquired hyperostosis syndrome
ID DIFFUSE SCLEROSING OSTEOMYELITIS; RECURRENT MULTIFOCAL OSTEOMYELITIS;
   SAPHO SYNDROME
AB Objectives Primary chronic non bacterial osteomyelitis of the mandible (CNOM) is a rare auto inflammatory disease of unknown aetiology that bears pathophysiological resemblance to both SAPHO syndrome in adults and chronic recurrent multifocal osteomyelitis (CRMO) in children. Both SAPHO and CRMO respond to TNF alpha blockade. Previously reported treatment regimens in CNOM including NSAIDs, corticosteroids, antibiotics, anti resorptive therapy and surgery all bear disappointing results. TNF alpha blockade is suggested as a treatment option by some experts but this is not backed by any clinical data. We sought to retrospectively and exhaustively report our experience of anti TNF alpha therapy in refractory CNOM.Methods Fifteen patients with refractory CNOM and high disease burden were referred to our centre. TNF alpha blockade was attempted in 10 cases, given its efficacy in neighbouring diseases, its good tolerance profile and failure of previous treatment strategies. We herein retrospectively report detailed outcomes for all patients having received anti TNF alpha therapy for this indication in our centre.Results TNF alpha targeting therapy resulted in a rapid and sustained remission in a majority of patients with CNOM, without serious adverse events. Treatment was tapered and stopped without relapse in some patients despite a refractory course of several years. Male sex seems to be associated with a poorer outcome.Conclusion Our results suggest that blocking TNF alpha is efficient and safe in CNOM.
C1 [de la Rochefoucauld, Jeanne; Lhote, Raphael; Amoura, Zahir; Hie, Miguel] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, French Natl Reference Ctr Rare Syst Dis,Inst E3M,D, 47 83 Blvd Hop, F 75013 Paris, France.
   [Benassarou, Mourad Azzedine; Schouman, Thomas; Bertolus, Chloe] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Dept Oral & Maxillofacial Surg, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie Salpetriere   APHP; Sorbonne Universite; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie Salpetriere   APHP
RP Hié, M (通讯作者)，Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, French Natl Reference Ctr Rare Syst Dis,Inst E3M,D, 47 83 Blvd Hop, F 75013 Paris, France.
EM miguel.hie@aphp.fr
OI Hie, Miguel/0000 0002 8036 9312; de La Rochefoucauld,
   Jeanne/0000 0002 1457 9565
CR Andre CV, 2017, J STOMATOL ORAL MAXI, V118, P261, DOI 10.1016/j.jormas.2017.04.007
   Girschick HJ, 2007, NAT CLIN PRACT RHEUM, V3, P733, DOI 10.1038/ncprheum0653
   Hayem G, 1999, SEMIN ARTHRITIS RHEU, V29, P159, DOI 10.1016/S0049 0172(99)80027 4
   JACOBSSON S, 1984, INT J ORAL MAXILLOF, V13, P363, DOI 10.1016/S0300 9785(84)80062 9
   Jia KK, 2021, J ORAL MAXIL SURG, V79, P2292, DOI 10.1016/j.joms.2021.06.024
   KAHN MF, 1994, ORAL SURG ORAL MED O, V78, P594, DOI 10.1016/0030 4220(94)90170 8
   Kim SM, 2019, J KOR ASSOC ORAL MAX, V45, P68, DOI 10.5125/jkaoms.2019.45.2.68
   Ma L, 2022, PEDIATR RHEUMATOL, V20, DOI 10.1186/s12969 021 00657 4
   Marí A, 2014, J CRANIO MAXILL SURG, V42, P1990, DOI 10.1016/j.jcms.2014.09.004
   Otto S, 2018, J CRANIO MAXILL SURG, V46, P534, DOI 10.1016/j.jcms.2017.10.011
   Suei Y, 2005, ORAL SURG ORAL MED O, V100, P207, DOI 10.1016/j.tripleo.2004.11.006
   Timme M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051737
   Tronconi E, 2018, RHEUMATOL INT, V38, P153, DOI 10.1007/s00296 017 3877 0
   van de Meent MM, 2020, BRIT J ORAL MAX SURG, V58, P385, DOI 10.1016/j.bjoms.2020.01.012
   van de Meent MM, 2022, J CRANIO MAXILL SURG, V50, P599, DOI 10.1016/j.jcms.2022.05.011
   Wipff J, 2015, ARTHRITIS RHEUMATOL, V67, P1128, DOI 10.1002/art.39013
   Zhao SZ, 2018, IMMUNOTHERAPY UK, V10, P433, DOI 10.2217/imt 2017 0155
NR 17
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD APR
PY 2025
VL 64
IS 4
BP 1770
EP 1774
DI 10.1093/rheumatology/keae380
EA AUG 2024
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 1IS9U
UT WOS:001290600700001
PM 39042221
DA 2025 08 17
ER

PT J
AU Zhang, YJ
   Remy, M
   Leste Lasserre, T
   Durrieu, MC
AF Zhang, Yujie
   Remy, Murielle
   Leste Lasserre, Thierry
   Durrieu, Marie Christine
TI Manipulating Stem Cell Fate with Disordered Bioactive Cues on Surfaces:
   The Role of Bioactive Ligand Selection
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE spray; micropatterning; surface modification; peptides; cell
   differentiation
ID REAL TIME PCR; DIFFERENTIATION; BMP 2; RGD; OSTEOBLAST; ADHESION;
   CROSSTALK; PEPTIDES; MATRICES; BEHAVIOR
AB The development of 2D or 3D bioactive platforms for rapidly isolating pure populations of cells from adult stem cells holds promise for advancing the understanding of cellular mechanisms, drug testing, and tissue engineering. Over the years, methods have emerged to synthesize bioactive micro  and nanostructured 2D materials capable of directing stem cell fate. We introduce a novel method for randomly micro  or nanopatterning any protein/peptide onto both 2D and 3D scaffolds via spray technology. Our goal is to investigate the impact of arranging bioactive micropatterns (ordered vs disordered) on surfaces to guide human mesenchymal stem cell (hMSC) differentiation. The spray technology efficiently coats materials with controlled, cost effective bioactive micropatterns in various sizes and shapes. BMP 2 mimetic peptides were covalently grafted, individually or in combination with RGD peptides, onto activated polyethylene terephthalate (PET) surfaces through a spraying process, incorporating nano/microscale parameters like size, shape, and composition. The study explores different peptide distributions on surfaces and various peptide combinations. Four surfaces were homogeneously functionalized with these peptides (M1 to M4 with various densities of peptides), and six surfaces with disordered micro  and nanopatterns of peptides (S0 to S5 with different sizes of peptide patterns) were synthesized. Fluorescence microscopy assessed peptide distribution, followed by hMSC culture for 2 weeks, and evaluated osteogenic differentiation via immunocytochemistry and RT qPCR for osteoblast and osteocyte markers. Cells on uniformly peptide functionalized surfaces exhibited cuboidal forms, while those on surfaces with disordered patterns tended toward columnar or cuboidal shapes. Surfaces S4 and S5 showed dendrite like formations resembling an osteocyte morphology. S5 showed significant overexpression of osteoblast (OPN) and osteocyte markers (E11, DMP1, and SOST) compared to control surfaces and other micropatterned surfaces. Notably, despite sharing an equivalent quantity of peptides with a homogeneous functionalized surface, S5 displayed a distinct distribution of peptides, resulting in enhanced osteogenic differentiation of hMSCs.
C1 [Zhang, Yujie; Remy, Murielle; Durrieu, Marie Christine] Univ Bordeaux, CNRS, Bordeaux INP, CBMN,UMR 5248, F 33600 Pessac, France.
   [Leste Lasserre, Thierry] Univ Bordeaux, INSERM, PUMA, U1215,NeuroctrMagendie, F 33077 Bordeaux, France.
C3 Universite de Bordeaux; Centre National de la Recherche Scientifique
   (CNRS); CNRS   Institute of Chemistry (INC); Universite de Bordeaux;
   Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Durrieu, MC (通讯作者)，Univ Bordeaux, CNRS, Bordeaux INP, CBMN,UMR 5248, F 33600 Pessac, France.
EM marie christine.durrieu@inserm.fr
RI zhang, yujie/JAA 9367 2023; DURRIEU, Marie Christine/I 4358 2016
OI Remy, Murielle/0009 0008 9567 1144; DURRIEU,
   Marie Christine/0000 0003 0583 9289; LESTE LASSERRE,
   Thierry/0000 0001 8328 3816
FU Agence Nationale de la Recherche [ANR 21 CE06 0031 02]; French "Agence
   Nationale de la Recherche"; China Scholarship Council (CSC); Agence
   Nationale de la Recherche (ANR) [ANR 21 CE06 0031] Funding Source:
   Agence Nationale de la Recherche (ANR)
FX The authors thank Professor Gaetan Laroche from Laval University for his
   help in the design of the spray technique. This work was supported by
   the French "Agence Nationale de la Recherche" (ANR 21 CE06 0031 02)
   (M. C.D.). The financial support from the China Scholarship Council
   (CSC) is also acknowledged.
CR Ayala R, 2011, BIOMATERIALS, V32, P3700, DOI 10.1016/j.biomaterials.2011.02.004
   Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Bhagoria P, 2020, MATER TODAY PROC, V26, P3048, DOI 10.1016/j.matpr.2020.02.633
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Bilem I, 2018, J BIOMED MATER RES A, V106, P959, DOI 10.1002/jbm.a.36296
   Bilem I, 2016, ACTA BIOMATER, V36, P132, DOI 10.1016/j.actbio.2016.03.032
   Bilem I, 2017, ACS BIOMATER SCI ENG, V3, P2514, DOI 10.1021/acsbiomaterials.7b00279
   Boudaoud A, 2014, NAT PROTOC, V9, P457, DOI 10.1038/nprot.2014.024
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Carthew J, 2022, ACS APPL MATER INTER, V14, P23066, DOI 10.1021/acsami.1c22109
   Celik N, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125230
   Chen YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104703
   Cheng ZA, 2013, NANO LETT, V13, P3923, DOI 10.1021/nl4020149
   Chollet C, 2009, BIOMATERIALS, V30, P711, DOI 10.1016/j.biomaterials.2008.10.033
   Cui JT, 2023, J BIOMED MATER RES A, V111, P1358, DOI 10.1002/jbm.a.37538
   Cunha A, 2015, NANOMEDICINE UK, V10, P725, DOI [10.2217/nnm.15.19, 10.2217/NNM.15.19]
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Das RK, 2013, ACS NANO, V7, P3351, DOI 10.1021/nn4001325
   Decker D, 2019, ADV MATER TECHNOL US, V4, DOI 10.1002/admt.201800436
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Eftekhari BS, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907792
   Esfahani SN, 2021, NANO TODAY, V41, DOI 10.1016/j.nantod.2021.101310
   Fourel L, 2016, J CELL BIOL, V212, P693, DOI 10.1083/jcb.201508018
   Fu JP, 2010, NAT METHODS, V7, P733, DOI 10.1038/nmeth.1487
   Gagne L, 2007, ADV MATER RES SWITZ, V15 17, P77, DOI 10.4028/www.scientific.net/AMR.15 17.77
   Gagné L, 2006, BIOMATERIALS, V27, P5430, DOI 10.1016/j.biomaterials.2006.06.006
   Gaharwar AK, 2014, ACS NANO, V8, P9833, DOI 10.1021/nn503719n
   Giam LR, 2012, P NATL ACAD SCI USA, V109, P4377, DOI 10.1073/pnas.1201086109
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Gultian KA, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 12143 2
   Guo R, 2022, ADV SCI, V9, DOI 10.1002/advs.202104331
   He XZ, 2008, LANGMUIR, V24, P12508, DOI 10.1021/la802447v
   Hosoyama K, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00205
   Hou Y, 2020, SMALL, V16, DOI 10.1002/smll.201905422
   Huang BL, 2020, APPL MATER TODAY, V19, DOI 10.1016/j.apmt.2020.100599
   Kanchanawong P, 2023, NAT REV MOL CELL BIO, V24, P142, DOI 10.1038/s41580 022 00531 5
   Kim Y, 2014, BIOMATER SCI UK, V2, P1110, DOI 10.1039/c3bm60333d
   Klimek K, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12040844
   Koepsel JT, 2012, J MATER CHEM, V22, P19474, DOI 10.1039/c2jm32242k
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lei YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041163
   Li ZQ, 2021, ADV MATER TECHNOL US, V6, DOI 10.1002/admt.202000897
   Liu GQ, 2020, CHEM REV, V120, P6009, DOI 10.1021/acs.chemrev.9b00725
   Luo JJ, 2022, BIOACT MATER, V15, P145, DOI 10.1016/j.bioactmat.2021.11.024
   Nishida K, 2022, BIOMATER SCI UK, V10, P2953, DOI 10.1039/d2bm00093h
   Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169
   Padiolleau L, 2018, ACS APPL BIO MATER, V1, P1800, DOI 10.1021/acsabm.8b00236
   Pedrosa CR, 2019, ACS APPL MATER INTER, V11, P8858, DOI 10.1021/acsami.8b21393
   Pountos I, 2016, BMC MED, V14, DOI 10.1186/s12916 016 0646 y
   Prouvé E, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202100069
   Ron A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02218 4
   Royer C, 2018, EXP CELL RES, V370, P389, DOI 10.1016/j.yexcr.2018.07.001
   Singh A, 2022, CHEM COMMUN, V58, P13059, DOI 10.1039/d2cc05221k
   Skottke J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081998
   Sousa MP, 2019, SMALL, V15, DOI 10.1002/smll.201901228
   Stamnitz S, 2021, CELLS BASEL, V10, DOI 10.3390/cells10081925
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240
   Tsiapalis D, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040991
   Wang LS, 2017, ACS APPL MATER INTER, V9, P42, DOI 10.1021/acsami.6b13815
   Watt FM, 2013, NAT REV MOL CELL BIO, V14, P467, DOI 10.1038/nrm3620
   Xie F. L., 2012, Plant Molecular Biology, V80, P75, DOI 10.1007/s11103 012 9885 2
   Yadav TC, 2023, J MATER CHEM B, V11, P7834, DOI 10.1039/d3tb01040f
   Yang K, 2013, ACS APPL MATER INTER, V5, P10529, DOI 10.1021/am402156f
   Yao X, 2013, BIOMATERIALS, V34, P9001, DOI 10.1016/j.biomaterials.2013.08.013
   Yim EKF, 2007, EXP CELL RES, V313, P1820, DOI 10.1016/j.yexcr.2007.02.031
   Zhang YJ, 2023, BIOMATER SCI UK, V11, P6116, DOI 10.1039/d3bm00605k
   Zouani OF, 2013, BIOMATERIALS, V34, P2157, DOI 10.1016/j.biomaterials.2012.12.007
   Zouani OF, 2012, J CELL SCI, V125, P1217, DOI 10.1242/jcs.093229
   Zouani OF, 2010, BIOMATERIALS, V31, P8245, DOI 10.1016/j.biomaterials.2010.07.042
NR 70
TC 6
Z9 6
U1 5
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD APR 6
PY 2024
VL 16
IS 15
BP 18474
EP 18489
DI 10.1021/acsami.4c00262
EA APR 2024
PG 16
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA NZ0J4
UT WOS:001200610500001
PM 38581548
DA 2025 08 17
ER

PT J
AU Ng, TK
   Carballosa, CM
   Pelaez, D
   Wong, HK
   Choy, KW
   Pang, CP
   Cheung, HS
AF Ng, Tsz Kin
   Carballosa, Carlos M.
   Pelaez, Daniel
   Wong, Hoi Kin
   Choy, Kwong Wai
   Pang, Chi Pui
   Cheung, Herman S.
TI Nicotine Alters MicroRNA Expression and Hinders Human Adult Stem Cell
   Regenerative Potential
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; DOWN REGULATION;
   SMOKING; PROLIFERATION; INVOLVEMENT; TARGETS; MIR 21; RUNX2
AB Adult stem cells are critical for the healing process in regenerative medicine. However, cigarette smoking inhibits stem cell recruitment to tissues and delays the wound healing process. This study investigated the effect of nicotine, a major constituent in the cigarette smoke, on the regenerative potentials of human mesenchymal stem cells (MSC) and periodontal ligament derived stem cells (PDLSC). The cell proliferation of 1.0 mu M nicotine treated MSC and PDLSC was significantly reduced when compared to the untreated control. Moreover, nicotine also retarded the locomotion of these adult stem cells. Furthermore, their osteogenic differentiation capabilities were reduced in the presence of nicotine as evidenced by gene expression (RUNX2, ALPL, BGLAP, COL1A1, and COL1A2), calcium deposition, and alkaline phosphatase activity analyses. In addition, the microRNA (miRNA) profile of nicotine treated PDLSC was altered; suggesting miRNAs might play an important role in the nicotine effects on stem cells. This study provided the possible mechanistic explanations on stem cell associated healing delay in cigarette smoking.
C1 [Ng, Tsz Kin; Pelaez, Daniel; Cheung, Herman S.] Miami Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Miami, FL 33125 USA.
   [Carballosa, Carlos M.; Cheung, Herman S.] Univ Miami, Dept Biomed Engn, Coll Engn, Coral Gables, FL 33124 USA.
   [Wong, Hoi Kin; Choy, Kwong Wai] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China.
   [Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Geriatric Research Education & Clinical Center; University of Miami;
   Chinese University of Hong Kong; Chinese University of Hong Kong
RP Cheung, HS (通讯作者)，Miami Vet Affairs Med Ctr, 1201 NW 16th St, Miami, FL 33125 USA.
EM hcheung@med.maimi.edu
RI ; Ng, Tsz/I 8061 2014; Choy, Richard/AAW 8230 2020; Pang,
   Chi/I 5388 2014
OI Ng, Tsz Kin/0000 0001 7863 7229; Pelaez, Daniel/0000 0002 4483 5160;
   Choy, Kwong Wai/0000 0002 3616 6200
FU VA Merit Review Grant; Senior VA Research Career Scientist Award, Miami;
   University Grants Committee Hong Kong; Endowment Fund for Lim Por Yen
   Eye Genetics Research Centre, Hong Kong
FX This work was supported, in part, by the VA Merit Review Grant and the
   Senior VA Research Career Scientist Award, Miami, and a block grant of
   the University Grants Committee Hong Kong and the Endowment Fund for Lim
   Por Yen Eye Genetics Research Centre, Hong Kong
CR Alemdaroglu KB, 2009, INJURY, V40, P1151, DOI 10.1016/j.injury.2008.12.011
   Arita NA, 2011, BIOCHEM BIOPH RES CO, V405, P564, DOI 10.1016/j.bbrc.2011.01.068
   Benowitz NL, 2010, NEW ENGL J MED, V362, P2295, DOI 10.1056/NEJMra0809890
   BOYLAND E, 1964, NATURE, V202, P1126, DOI 10.1038/2021126a0
   Chang YC, 2002, J PERIODONTAL RES, V37, P279, DOI 10.1034/j.1600 0765.2002.01612.x
   Chen YH, 2011, INT ORTHOP, V35, P1267, DOI 10.1007/s00264 011 1243 5
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Frescaline G, 2012, STEM CELL RES, V8, P180, DOI 10.1016/j.scr.2011.09.005
   Giannopoulou C, 1999, J CLIN PERIODONTOL, V26, P49, DOI 10.1034/j.1600 051X.1999.260109.x
   Gibon E, 2012, TISSUE ENG PT A, V18, P968, DOI [10.1089/ten.tea.2011.0545, 10.1089/ten.TEA.2011.0545]
   Han EKH, 2004, ANTICANCER RES, V24, P3899
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hoogduijn MJ, 2009, STEM CELLS DEV, V18, P103, DOI 10.1089/scd.2008.0032
   Huang CYC, 2009, REGEN MED, V4, P809, DOI 10.2217/RME.09.55
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang WH, 2009, INT J NEUROPSYCHOPH, V12, P537, DOI 10.1017/S1461145708009528
   Kim BS, 2012, LIFE SCI, V90, P109, DOI 10.1016/j.lfs.2011.10.019
   Kim SY, 2012, MOL CELLS, V33, P343, DOI 10.1007/s10059 012 2172 x
   Krannitz KW, 2009, J FOOT ANKLE SURG, V48, P525, DOI 10.1053/j.jfas.2009.04.008
   Li HH, 2012, CELL TISSUE RES, V348, P371, DOI 10.1007/s00441 012 1393 9
   Li Q, 2011, NEW ENGL J MED, V364, P2469, DOI 10.1056/NEJMc1102459
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Ludwig A, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472 6874 10 20
   Maarcher Ann, 2011, Morbidity and Mortality Weekly Report, V60, P1513
   Maccani MA, 2010, EPIGENETICS US, V5, P583, DOI 10.4161/epi.5.7.12762
   Morsczeck C, 2008, CLIN ORAL INVEST, V12, P113, DOI 10.1007/s00784 007 0170 8
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ruiz JP, 2012, CELL HEALTH CYTOSKEL, V4, P29, DOI 10.2147/CHC.S24381
   Schraufstatter I, 2010, J STEM CELLS, V4, P203
   Shan HL, 2009, CARDIOVASC RES, V83, P465, DOI 10.1093/cvr/cvp130
   Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240
   Shin VY, 2002, EXP BIOL MED, V227, P114, DOI 10.1177/153537020222700206
   Sorensen LT, 2012, ARCH SURG CHICAGO, V147, P373, DOI 10.1001/archsurg.2012.5
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Wang XJ, 2010, CELL TISSUE RES, V340, P347, DOI 10.1007/s00441 010 0949 9
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   WYNDER EL, 1979, NEW ENGL J MED, V300, P894, DOI 10.1056/NEJM197904193001605
   Zhou YP, 2011, REPROD TOXICOL, V31, P123, DOI 10.1016/j.reprotox.2010.10.007
NR 40
TC 50
Z9 61
U1 0
U2 33
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAR
PY 2013
VL 22
IS 5
DI 10.1089/scd.2012.0434
PG 10
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 090JM
UT WOS:000314975300010
PM 23030247
DA 2025 08 17
ER

PT J
AU Kaur, K
   Jewett, A
AF Kaur, Kawaljit
   Jewett, Anahid
TI Osteoclasts and Probiotics Mediate Significant Expansion, Functional
   Activation and Supercharging in NK, γδ T, and CD3+T Cells: Use in Cancer
   Immunotherapy
SO CELLS
LA English
DT Article
DE osteoclasts; NK cells; supercharged NK cells; CD3+T cells; gamma delta T
   cells; IFN gamma; humanized BLT mice
ID NATURAL KILLER CELLS; ANTITUMOR ACTIVITY; IN VIVO; EXPRESSION; MELANOMA;
   PROLIFERATION; RECEPTORS; MOUSE; MODULATION; NKG2D
AB Our previous studies have introduced osteoclasts (OCs) as major activators of NK cells. It was found that OCs exhibit the capabilities of inducing cell expansion as well as increasing the cytotoxic activity of NK cells by granule release and increasing the secretion of TNF alpha and TRAIL, leading to increased lysis of tumors in short term as well as long term periods, respectively. OC  induced expanded NK cells were named supercharged NK cells (sNK) due to their significantly high functional activity as well as their significantly higher cell expansion rate. It is, however, unclear whether the OC mediated effect in NK cells is specific or whether other cytotoxic immune cells can also be expanded and activated by OCs. We chose to focus on gamma delta T cells and pan T cells, which also include CD8+ T cells. In this paper, we report that OCs are capable of expanding and functionally activating both gamma delta T cells and pan T cells. Expanded gamma delta T and pan T cells were capable of secreting high levels of INF gamma, albeit with different dynamics to those of NK cells, and, moreover, they are unable to kill NK specific targets. Since we used humanized BLT (hu BLT) mice as a model of human disease, we next determined whether NK and T cell activation through OCs is also evident in cells obtained from hu BLT mice. Similar to humans, OCs were capable of increasing the cell expansion and secretion of IFN gamma in the culture of either NK or T cells from hu BLT mice, providing yet further evidence that these mice are appropriate models to study human disease. Therefore, these studies indicated that CD3+ T or gamma delta T cells can proliferate and be supercharged by OCs similar to the NK cells; thus, they can be used individually or in combination in the cell therapy of cancers.
C1 [Kaur, Kawaljit; Jewett, Anahid] Univ Calif Los Angeles, Sch Dent & Med, Div Oral Biol & Oral Med, Los Angeles, CA 90095 USA.
   [Jewett, Anahid] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Dent & Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   UCLA Jonsson Comprehensive Cancer Center
RP Jewett, A (通讯作者)，Univ Calif Los Angeles, Sch Dent & Med, Div Oral Biol & Oral Med, Los Angeles, CA 90095 USA.; Jewett, A (通讯作者)，Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Dent & Med, Los Angeles, CA 90095 USA.
EM drkawalmann@g.ucla.edu; ajewett@ucla.edu
RI Kaur, Kawaljit/A 3222 2013
OI Kaur, Kawaljit/0000 0003 1936 5985
FU UCLA Academic senate
FX No Statement Available
CR Alici E, 2008, BLOOD, V111, P3155, DOI 10.1182/blood 2007 09 110312
   Allen MR, 2011, IBMS BoneKEy, V8, P141
   Alves LC, 2020, EMBO REP, V21, DOI 10.15252/embr.201948789
   Amajala Krishna Chaitanya, 2023, Critical Reviews in Oncogenesis, V28, P41, DOI 10.1615/CritRevOncog.2023049893
   Angelo LS, 2015, IMMUNOL RES, V62, P341, DOI 10.1007/s12026 015 8664 y
   Balsamo M, 2009, P NATL ACAD SCI USA, V106, P20847, DOI 10.1073/pnas.0906481106
   Becker PSA, 2016, CANCER IMMUNOL IMMUN, V65, P477, DOI 10.1007/s00262 016 1792 y
   Berg M, 2009, CYTOTHERAPY, V11, P341, DOI 10.1080/14653240902807034
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bruno A, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju200
   Bui VT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00576
   Burke S, 2010, TRENDS IMMUNOL, V31, P339, DOI 10.1016/j.it.2010.06.003
   Carlens S, 2001, HUM IMMUNOL, V62, P1092, DOI 10.1016/S0198 8859(01)00313 5
   Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100
   CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403
   Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471 4906(01)02060 9
   Deng JC, 2022, EUR J PHARMACOL, V919, DOI 10.1016/j.ejphar.2022.174803
   Dong HL, 2012, BRIT J NUTR, V108, P459, DOI 10.1017/S0007114511005824
   Durgeau A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00014
   Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001
   Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782
   Fildes JE, 2008, TRANSPL IMMUNOL, V19, P1, DOI 10.1016/j.trim.2008.01.004
   Fujisaki H, 2009, CANCER RES, V69, P4010, DOI 10.1158/0008 5472.CAN 08 3712
   Gail LM, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1199422
   Gallois A, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.946365
   Ganapathy T, 2023, CANCER IMMUNOL IMMUN, V72, P277, DOI 10.1007/s00262 022 03260 y
   Garg TK, 2012, HAEMATOL HEMATOL J, V97, P1348, DOI 10.3324/haematol.2011.056747
   Giles JR, 2023, IMMUNITY, V56, P2231, DOI 10.1016/j.immuni.2023.09.005
   Goff SL, 2021, CLIN BREAST CANCER, V21, pE63, DOI 10.1016/j.clbc.2020.06.011
   Gubbels JAA, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 11
   Guillerey C, 2020, ADV EXP MED BIOL, V1273, P69, DOI 10.1007/978 3 030 49270 0_4
   Ham H, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.871106
   HERSEY P, 1979, BRIT J CANCER, V40, P113, DOI 10.1038/bjc.1979.147
   Igarashi T, 2004, BLOOD, V104, P170, DOI 10.1182/blood 2003 12 4438
   Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140 6736(00)03231 1
   Kabelitz D, 2020, CELL MOL IMMUNOL, V17, P925, DOI 10.1038/s41423 020 0504 x
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kaur K, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1132807
   Kaur K, 2021, CANCERS, V13, DOI 10.3390/cancers13020239
   Kaur K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 76702 1
   Kaur K, 2020, CANCERS, V12, DOI 10.3390/cancers12010063
   Kaur K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426518
   Kaur K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00297
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kozlowska AK, 2017, J CANCER, V8, P537, DOI 10.7150/jca.15989
   Kucuksezer UC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622306
   Kylmäoja E, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00780
   Lamers Kok N, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045 022 01382 5
   Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526
   LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572
   Larsen Stine K., 2014, Critical Reviews in Oncogenesis, V19, P91
   Li YR, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04575 9
   LONDON L, 1986, J IMMUNOL, V137, P3845
   Martinovic KMM, 2014, MELANOMA RES, V24, P295, DOI 10.1097/CMR.0000000000000072
   Mensurado S, 2023, NAT REV CLIN ONCOL, V20, P178, DOI 10.1038/s41571 022 00722 1
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   MILLER JS, 1992, BLOOD, V80, P2221
   Navarro AG, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00202
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   PERUSSIA B, 1987, NAT IMMUN CELL GROW, V6, P171
   Philip M, 2022, NAT REV IMMUNOL, V22, P209, DOI 10.1038/s41577 021 00574 3
   Pietra G, 2012, CANCER RES, V72, P1407, DOI 10.1158/0008 5472.CAN 11 2544
   RABINOWICH H, 1991, CELL IMMUNOL, V135, P454, DOI 10.1016/0008 8749(91)90290 R
   Rahim MK, 2023, CELL, V186, P1127, DOI 10.1016/j.cell.2023.02.021
   Raskov H, 2021, BRIT J CANCER, V124, P359, DOI 10.1038/s41416 020 01048 4
   Richardson JR, 2021, CANCERS, V13, DOI 10.3390/cancers13040596
   Riggan L, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1238
   ROBERTSON MJ, 1993, J IMMUNOL, V150, P1705
   Rozenbaum M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01347
   Russick J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 001054
   Saura Esteller J, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.915837
   Sawaisorn P, 2019, IMMUNOL INVEST, V48, P11, DOI 10.1080/08820139.2018.1529039
   Sayegh M, 2023, CURR OPIN ONCOL, V35, P446, DOI 10.1097/CCO.0000000000000968
   Shah N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076781
   Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood 2009 04 215855
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Sivori S, 2021, MOL ASPECTS MED, V80, DOI 10.1016/j.mam.2020.100870
   Speiser DE, 2023, NAT CANCER, V4, P317, DOI 10.1038/s43018 023 00521 2
   Srivastava S, 2008, CYTOTHERAPY, V10, P775, DOI 10.1080/14653240802648181
   Stoddart CA, 2011, VIROLOGY, V417, P154, DOI 10.1016/j.virol.2011.05.013
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Sun HY, 2013, CELL MOL IMMUNOL, V10, P202, DOI 10.1038/cmi.2013.9
   Tao LL, 2017, TRENDS IMMUNOL, V38, P181, DOI 10.1016/j.it.2016.12.007
   Terrén I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02278
   TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065 2776(08)60664 1
   TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Tumino N, 2023, INT J CANCER, V152, P1698, DOI 10.1002/ijc.34389
   Vatakis DN, 2012, JOVE J VIS EXP, DOI 10.3791/4181
   Vatakis DN, 2011, P NATL ACAD SCI USA, V108, pE1408, DOI 10.1073/pnas.1115050108
   Vitale M, 2014, EUR J IMMUNOL, V44, P1582, DOI 10.1002/eji.201344272
   Zakeri N, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29012 1
NR 92
TC 2
Z9 2
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD FEB
PY 2024
VL 13
IS 3
AR 213
DI 10.3390/cells13030213
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HQ9J0
UT WOS:001161086400001
PM 38334605
OA gold
DA 2025 08 17
ER

PT J
AU He, JY
   Cheng, M
   Ye, JL
   Peng, CH
   Chen, J
   Luo, B
   Zhang, XY
   Fu, Q
AF He, Jian Ying
   Cheng, Min
   Ye, Jia Lian
   Peng, Chuan Hua
   Chen, Jian
   Luo, Bin
   Zhang, Xian Yu
   Fu, Qiang
TI YY1 induced lncRNA XIST inhibits cartilage differentiation of BMSCs by
   binding with TAF15 to stabilizing FUT1 expression
SO REGENERATIVE THERAPY
LA English
DT Article
DE Osteoarthritis; XIST; Chondrogenic differentiation; BMSCs; YY1
ID LONG NONCODING RNAS; KNEE OSTEOARTHRITIS; OSTEOBLAST DIFFERENTIATION;
   CELL DIFFERENTIATION; YY1; CHONDROCYTES; DEGRADATION; MODELS
AB Introduction: The functional roles and mechanism of the XIST in osteoarthritis and the chondrogenic differentiation of BMSCs were clarified. Methods: The expression levels of XIST, TAF15, FUT1 and YY1 were detected through quantitative RT PCR. The protein expression of Sox9, ACAN, COL2A1 and FUT1 were detected by western blot and immunohistochemistry. The damage of cartilage tissue was detected by HE staining, and Safranin O fast green. Alcian Blue and Alizarin red S staining were performed to evaluate BMSCs chondrogenic differ entiation. The relationship between XIST and TAF15, XIST and TAF15 were analyzed by RNA immuno precipitation assay. Luciferase reporter assays and chromatin immunoprecipitation were performed to detect the interaction relationship between XIST and YY1. In addition, osteoarthritis mice were built to assess the function of XIST in vivo. Results: The levels of XIST, TAF15 and FUT1 were upregulated in cartilage tissues from osteoarthritis patient. The level of XIST was decreased in BMSCs during chondrogenic differentiation. XIST over expression inhibited the chondrogenic differentiation of BMSCs. Moreover, silencing of FUT1 reversed the effects of XIST overexpression on BMSCs chondrogenic differentiation. Mechanistically, in BMSCs, YY1 induced the expression of XIST in BMSCs, and XIST regulated FUT1 mRNA stability through targeting TAF15. Furthermore, silencing of XIST alleviated the symptoms of cartilage injury in OA mice. Conclusion: Taken together, these results suggested that YY1 induced XIST was closely related to the chondrogenic differentiation of BMSCs and the progression of osteoarthritis by TAF15/FUT1 axis, and may be a new OA therapeutic target. (c) 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/ 4.0/).
C1 [He, Jian Ying] Nanchang Med Coll, JiangXi Provinvcial Peoples Hosp, Orthoped Dept, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
   [Cheng, Min; Ye, Jia Lian; Peng, Chuan Hua; Chen, Jian; Luo, Bin] Peoples Hosp Poyang Cty, Orthoped Dept, Shangrao 333100, Jiangxi, Peoples R China.
   [Zhang, Xian Yu] Shangrao Peoples Hosp, Orthoped Dept, Shangrao 333400, Jiangxi, Peoples R China.
   [Fu, Qiang] Nanchang Med Coll, JiangXi Provinvcial Peoples Hosp, Dept Rheumatol, Affiliated Hosp 1, 92 Aiguo Rd, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang Medical College; Nanchang Medical College
RP Fu, Q (通讯作者)，Nanchang Med Coll, JiangXi Provinvcial Peoples Hosp, Dept Rheumatol, Affiliated Hosp 1, 92 Aiguo Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM qqaaffuu987@163.com
RI Zhang, Xianyu/T 9474 2019; FU, Qiang/JEF 7577 2023
FU Health Commission of Jiangxi Provincial [202130032]
FX This work was supported by Analysis of YY1 activated IncRNA XIST
   regulating cartilage differentiation through RBP pathway, Health
   Commission of Jiangxi Provincial (No.202130032) .
CR Aoyama T, 2010, J BIOL CHEM, V285, P29842, DOI 10.1074/jbc.M110.116319
   Aspden RM, 2001, LANCET, V357, P1118, DOI 10.1016/S0140 6736(00)04264 1
   Ballarino M, 2013, ONCOGENE, V32, P4646, DOI 10.1038/onc.2012.490
   Chen H, 2020, DOSE RESPONSE, V18, DOI [10.1177/1559325820942718.1559325820942718, DOI 10.1177/1559325820942718.1559325820942718]
   Chen HW, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2033 5
   Chen SJ, 2020, AGING DIS, V11, P1058, DOI 10.14336/AD.2019.0724
   Chen YH, 2018, AM J CANCER RES, V8, P514
   Chen YP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156676
   Dy P, 2012, DEV CELL, V22, P597, DOI 10.1016/j.devcel.2011.12.024
   Fu M, 2015, OSTEOARTHR CARTILAGE, V23, P423, DOI 10.1016/j.joca.2014.12.001
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Huang MJ, 2019, MOL THER NUCL ACIDS, V18, P533, DOI 10.1016/j.omtn.2019.08.027
   Kangari P, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02001 1
   Katz JN, 2021, JAMA J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Kawamura K, 2021, MOL CELL BIOL, V41, DOI 10.1128/MCB.00047 21
   Kuyinu EL, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018 016 0346 5
   LATCHMAN DS, 1993, INT J EXP PATHOL, V74, P417
   Le LTT, 2016, J MOL MED, V94, P583, DOI 10.1007/s00109 015 1374 z
   Li L, 2018, BIOCHEM BIOPH RES CO, V503, P2555, DOI 10.1016/j.bbrc.2018.07.015
   Li ZC, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9283
   Lieberthal J, 2015, OSTEOARTHR CARTILAGE, V23, P1825, DOI 10.1016/j.joca.2015.08.015
   Liu L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091477
   Lu J, 2017, MOL THER, V25, P2676, DOI 10.1016/j.ymthe.2017.08.009
   Makhlouf M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5878
   Makris EA, 2015, NAT REV RHEUMATOL, V11, P21, DOI 10.1038/nrrheum.2014.157
   Matsuzaki T, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan0746
   Neefjes M, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9090290
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Nguyen L, 2006, MENT RETARD DEV D R, V12, P85, DOI 10.1002/mrdd.20103
   Nukavarapu SP, 2013, BIOTECHNOL ADV, V31, P706, DOI 10.1016/j.biotechadv.2012.11.004
   Orozco L, 2013, TRANSPLANTATION, V95, P1535, DOI 10.1097/TP.0b013e318291a2da
   Ryu JS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218366
   Sarvagalla S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01230
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   Singh JA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005614.pub2
   Sun H, 2019, AM J TRANSL RES, V11, P16
   Syrett CM, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007050
   Tang SA, 2019, STEM CELLS, V37, P270, DOI 10.1002/stem.2937
   Thysen S, 2015, DIS MODEL MECH, V8, P17, DOI 10.1242/dmm.016881
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140 6736(12)61729 2
   Wang JC, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4966
   Wang L, 2015, BIOCHEM BIOPH RES CO, V456, P459, DOI 10.1016/j.bbrc.2014.11.106
   Wang T, 2019, INT J MOL MED, V44, P630, DOI 10.3892/ijmm.2019.4240
   Whitney KE, 2017, ANN NY ACAD SCI, V1410, P26, DOI 10.1111/nyas.13554
   Yamasaki S, 2014, CARTILAGE, V5, P196, DOI 10.1177/1947603514534681
   Yang HQ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01791 8
   Zhang R, 2019, AM J TRANSL RES, V11, P6275
   Zhou GD, 2006, TISSUE ENG, V12, P3209, DOI 10.1089/ten.2006.12.3209
NR 48
TC 10
Z9 12
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD JUN
PY 2022
VL 20
BP 41
EP 50
DI 10.1016/j.reth.2022.02.002
EA MAR 2022
PG 10
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 0Z6QR
UT WOS:000791201100004
PM 35402663
OA Green Published
DA 2025 08 17
ER

PT J
AU Madaj, R
   Pawlowska, R
   Chworos, A
AF Madaj, Rafal
   Pawlowska, Roza
   Chworos, Arkadiusz
TI In silico exploration of binding of selected
   bisphosphonate derivatives to placental alkaline phosphatase via docking
   and molecular dynamics
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Alkaline phosphatase; Bisphosphonate derivatives; Molecular docking;
   Molecular dynamics; MM; GBSA; Multiple sequence alignment; Zoledronic
   acid
ID ZOLEDRONIC ACID; ATP ANALOG; INORGANIC PYROPHOSPHATE;
   ADENINE NUCLEOTIDES; MOUSE EMBRYO; CANCER CELLS; HUMAN FETUS;
   INHIBITION; CLODRONATE; APOPTOSIS
AB Bisphosphonates constitute a group of pyrophosphate analogues therapeutically active against bone diseases. Numerous studies confirm their anticancer and antimetastatic potential as well as ability to relieve pathological pain. Although this is a known class of compounds, many aspects of their action remain unexplained and their new interaction partners are still being discovered. Due to the structural similarity to pyrophosphate, their interaction with pyrophosphate recognizing enzymes seems to be feasible. In current work, the placental alkaline phosphatase (PLAP) is considered as a potential target for these class of compounds. PLAP is one of the enzymes responsible for degradation of pyrophosphate with high clinical significance. An elevation of PLAP level are considered as a potential cancer marker. An in silico study of complexes formed between selected phosphate derivatives and PLAP was performed. It indicates that all tested compounds: alendronic acid, clodronic acid, etidronic acid, zoledronic acid, imidodiphosphoric acid, pyrophosphoric acid, medronic acid, chloromethylenediphosphonic acid and hypophosphoric acid form a complexes with PLAP, stabilized by hydrogen bonds, hydrophobic and van der Waals interactions. Zoledronic acid, drug used in prevention of bone complications during cancer treatment was found to have the lowest estimated energy of binding ( 6.6 kcal/mol). In silico study yielded very low energy of binding also for hypophosphate, equal 6.4 kcal/mol, despite having no identified hydrogen bonds. Subsequent molecular dynamic simulations, followed by molecular mechanics generalized born surface area with pairwise decomposition calculations confirmed the stability of protein ligand complexes. The results indicate that selected phosphate derivatives may potentially interact with the enzyme, changing its function, what should be investigated during in vitro studies.
   (c) 2020 Elsevier Inc. All rights reserved.
C1 [Madaj, Rafal; Pawlowska, Roza; Chworos, Arkadiusz] Polish Acad Sci, Ctr Mol & Macromol Studies, Sienkiewicza 112, PL 90363 Lodz, Poland.
C3 Polish Academy of Sciences; Centre of Molecular & Macromolecular Studies
   of the Polish Academy of Sciences
RP Madaj, R (通讯作者)，Polish Acad Sci, Ctr Mol & Macromol Studies, Sienkiewicza 112, PL 90363 Lodz, Poland.
EM rmadaj@cbmm.lodz.pl
RI Pawlowska, Roza/GWZ 9037 2022; Madaj, Rafal/AAP 8888 2020; Chworos,
   Arkadiusz/AAF 9169 2020
OI Pawlowska, Roza/0000 0002 3123 8949; Madaj, Rafal/0000 0002 6330 6344;
   Chworos, Arkadiusz/0000 0001 9924 0503; 
FU Centre of Molecular and Macromolecular Studies of Polish Academy of
   Sciences
FX The funding of this research was provided by Centre of Molecular and
   Macromolecular Studies of Polish Academy of Sciences.
CR Aihara Y, 2019, J NEUROSURG, V131, P687, DOI 10.3171/2018.3.JNS172520
   Boissier S, 2000, CANCER RES, V60, P2949
   Brunner F, 2009, EUR J PAIN, V13, P17, DOI 10.1016/j.ejpain.2008.03.005
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Dw E. H. M, ENZYMOLOGIA, V31, P31
   FISHMAN WH, 1968, CLIN CHIM ACTA, V19, P71, DOI 10.1016/0009 8981(68)90190 3
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   HORDER M, 1974, BIOCHIM BIOPHYS ACTA, V350, P400, DOI 10.1016/0005 2744(74)90514 2
   HORDER M, 1974, BIOCHIM BIOPHYS ACTA, V341, P41, DOI 10.1016/0005 2744(74)90063 1
   Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781
   Iqbal Z, 2019, DRUG DEVELOP RES, V80, P646, DOI 10.1002/ddr.21542
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Kato Y, 2017, P NATL ACAD SCI USA, V114, pE6297, DOI 10.1073/pnas.1704847114
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   LARSEN M, 1969, SCIENCE, V166, P1510, DOI 10.1126/science.166.3912.1510
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee MV, 2001, CANCER RES, V61, P2602
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Llinas P, 2005, J MOL BIOL, V350, P441, DOI 10.1016/j.jmb.2005.04.068
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Malwal SR, 2018, J AM CHEM SOC, V140, P7568, DOI 10.1021/jacs.8b02363
   Miliutina M, 2017, EUR J MED CHEM, V126, P408, DOI 10.1016/j.ejmech.2016.11.036
   Millan Jose Luis, 2006, Purinergic Signal, V2, P335, DOI 10.1007/s11302 005 5435 6
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mukaiyama K, 2015, TOHOKU J EXP MED, V237, P339, DOI 10.1620/tjem.237.339
   Muratore M, 2011, DRUG DES DEV THER, V5, P445, DOI 10.2147/DDDT.S12139
   Nguyen H, 2013, J CHEM THEORY COMPUT, V9, P2020, DOI 10.1021/ct3010485
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Ravenni N, 2014, MABS AUSTIN, V6, P86, DOI 10.4161/mabs.27230
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   She QB, 2000, FEBS LETT, V469, P163, DOI 10.1016/S0014 5793(00)01273 4
   She QB, 2000, CELL SIGNAL, V12, P659, DOI 10.1016/S0898 6568(00)00117 0
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799
   Stec B, 2010, ACTA CRYSTALLOGR F, V66, P866, DOI 10.1107/S1744309110019767
   SUSSMAN HH, 1968, BIOCHIM BIOPHYS ACTA, V151, P281, DOI 10.1016/0005 2744(68)90186 1
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Touw WG, 2015, NUCLEIC ACIDS RES, V43, pD364, DOI 10.1093/nar/gku1028
   Tripathi K.D., 2013, Essentials of medical pharmacology
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   VANHOOF VO, 1994, CRIT REV CL LAB SCI, V31, P197, DOI 10.3109/10408369409084677
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wennberg C, 2002, HUM MUTAT, V19, P258, DOI 10.1002/humu.10052
   Zaher DM, 2020, ARCH PHARM, V353, DOI 10.1002/ardp.202000011
NR 58
TC 7
Z9 7
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093 3263
EI 1873 4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD MAR
PY 2021
VL 103
AR 107801
DI 10.1016/j.jmgm.2020.107801
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA RX9DW
UT WOS:000647518200005
PM 33296741
DA 2025 08 17
ER

PT J
AU Duan, R
   Milton, P
   Sittplangkoon, C
   Liu, X
   Sui, ZN
   Boyce, BF
   Yao, ZQ
AF Duan, Rong
   Milton, Philip
   Sittplangkoon, Chutamath
   Liu, Xin
   Sui, Zhining
   Boyce, Brendan F.
   Yao, Zhenqiang
TI Chimeric antigen receptor dendritic cells targeted delivery of a single
   tumoricidal factor for cancer immunotherapy
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE Breast cancer; Dendritic cell (DC); Tumor necrosis factor alpha (TNF);
   Chimeric antigen receptor (CAR) cell therapy; Mucin1; Inhibitor of
   apoptosis proteins (IAPs); IAP antagonist; Patient derived xenograft
   (PDX) model
ID TUMOR NECROSIS FACTOR; SMAC MIMETIC BIRINAPANT; APOPTOSIS PROTEINS;
   PHASE I; FACTOR ALPHA; TNF THERAPY; INHIBITOR; MUC1; BISPHOSPHONATES;
   ACTIVATION
AB Background Chimeric antigen receptor (CAR) T cells have been used to treat blood cancers by producing a wide variety of cytokines. However, they are not effective in treating solid cancers and can cause severe side effects, including cytokine release syndrome. TNF alpha is a tumoricidal cytokine, but it markedly increases the protein levels of cIAP1 and cIAP2, the members of inhibitor of apoptosis protein (IAP) family of E3 ubiquitin ligase that limits caspase induced apoptosis. Degradation of IAP proteins by an IAP antagonist does not effectively kill cancer cells but enables TNF alpha to strongly induce cancer cell apoptosis. It would be a promising approach to treat cancers by targeted delivery of TNF alpha through an inactive adoptive cell in combination with an IAP antagonist. Methods Human dendritic cells (DCs) were engineered to express a single tumoricidal factor, TNF alpha, and a membrane anchored Mucin1 antibody scFv, named Mucin 1 directed DCs expressing TNF alpha (M DCsTNF). The efficacy of M DCsTNF in recognizing and treating breast cancer was tested in vitro and in vivo. Results Mucin1 was highly expressed on the surface of a wide range of human breast cancer cell lines. M DCsTNF directly associated with MDA MB 231 cells in the bone of NSG mice. M DCsTNF plus an IAP antagonist, SM 164, but neither alone, markedly induce MDA MB 231 breast cancer cell apoptosis, which was blocked by TNF antibody. Importantly, M DCsTNF combined with SM 164, but not SM 164 alone, inhibited the growth of patient derived breast cancer in NSG mice. Conclusion An adoptive cell targeting delivery of TNF alpha combined with an IAP antagonist is a novel effective approach to treat breast cancer and could be expanded to treat other solid cancers. Unlike CAR T cell, this novel adoptive cell is not activated to produce a wide variety of cytokines, except for additional overexpressed TNF, and thus could avoid the severe side effects such as cytokine release syndrome.
C1 [Duan, Rong; Milton, Philip; Sittplangkoon, Chutamath; Liu, Xin; Boyce, Brendan F.; Yao, Zhenqiang] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.
   [Milton, Philip] Univ Rochester, Sch Engn, Rochester, NY 14627 USA.
   [Sui, Zhining] Univ Rochester, Dept Biostat & Computat Biol, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.
   [Liu, Xin] Tianjin Hosp, Dept Orthoped, Tianjin 300021, Peoples R China.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Yao, ZQ (通讯作者)，Univ Rochester, Dept Pathol & Lab Med, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM zhenqiang_yao@urmc.rochester.edu
OI Sui, Zhining/0009 0007 8820 1147; Yao, Zhenqiang/0000 0002 4664 3648
FU National Institutes of Health [NIH/NIAMS P30 AR069655]; Core Services at
   Center for Musculoskeletal Research (CMSR); University of Rochester
   Medical Center
FX We sincerely thank Sarah Magri, Tinalyn Denton and Mackenzie Kirkland at
   Department of Pathology & Laboratory Medicine to do blood draw from
   donor individual, Lindsay Schnur for micro CT imaging and analysis, and
   the Core Services at Center for Musculoskeletal Research (CMSR)
   (NIH/NIAMS P30 AR069655), University of Rochester Medical Center.
CR Amaravadi RK, 2015, MOL CANCER THER, V14, P2569, DOI 10.1158/1535 7163.MCT 15 0475
   Aroca R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094558
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Baruch A, 1999, CANCER RES, V59, P1552
   Boissier S, 2000, CANCER RES, V60, P2949
   Chen MY, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109654
   Chen YJ, 2009, IMMUNOPHARM IMMUNOT, V31, P499, DOI 10.1080/08923970902814103
   DiPersio JF, 2015, CL LYMPH MYELOM LEUK, V15, P443, DOI 10.1016/j.clml.2015.02.020
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092 8674(00)00008 8
   Silveira CRF, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.947648
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078 0432.CCR 13 0227
   Gaither A, 2007, CANCER RES, V67, P11493, DOI 10.1158/0008 5472.CAN 07 5173
   Gonzalez Mejia ME, 2009, FRONT BIOSCI LANDMRK, V14, P2413, DOI 10.2741/3387
   Horimasu Y, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3272 y
   Horzum U, 2021, CANCER IMMUNOL IMMUN, V70, P75, DOI 10.1007/s00262 020 02656 y
   Huang HK, 2000, J BIOL CHEM, V275, P26661
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hurwitz HI, 2015, CANCER CHEMOTH PHARM, V75, P851, DOI 10.1007/s00280 015 2709 8
   Infante JR, 2014, J CLIN ONCOL, V32, P3103, DOI 10.1200/JCO.2013.52.3993
   Kamath AT, 2002, BLOOD, V100, P1734, DOI 10.1182/blood.V100.5.1734.h81702001734_1734_1741
   Khan AN, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.886546
   Khawar MB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.707542
   Klichinsky M, 2020, NAT BIOTECHNOL, V38, P947, DOI 10.1038/s41587 020 0462 y
   Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158
   Lanitis E, 2021, J EXP MED, V218, DOI 10.1084/jem.20192203
   Lei W, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64018 z
   LENK H, 1989, CANCER CHEMOTH PHARM, V24, P391
   Li BX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0703 9
   Liu X, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.906357
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   Monaco C, 2015, INT IMMUNOL, V27, P55, DOI 10.1093/intimm/dxu102
   Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16
   Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007
   Noonan AM, 2016, CANCER AM CANCER SOC, V122, P588, DOI 10.1002/cncr.29783
   Probst BL, 2010, CELL DEATH DIFFER, V17, P1645, DOI 10.1038/cdd.2010.44
   Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914
   Schubert ML, 2021, ANN ONCOL, V32, P34, DOI 10.1016/j.annonc.2020.10.478
   Shen GY, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101767
   Smole A, 2022, CANCER CELL, V40, P1470, DOI 10.1016/j.ccell.2022.11.006
   Sorensen AL, 2006, GLYCOBIOLOGY, V16, P96, DOI 10.1093/glycob/cwj044
   Spencer DIR, 1999, BIOSPECTROSCOPY, V5, P79, DOI 10.1002/(SICI)1520 6343(1999)5:2<79::AID BSPY2>3.0.CO;2 #
   SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111
   Sun HY, 2008, ACCOUNTS CHEM RES, V41, P1264, DOI 10.1021/ar8000553
   Tomasik J, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1034707
   Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745 7254.2008.00889.x
   WHITEHEAD RP, 1990, J BIOL RESP MODIF, V9, P588
   Wong H, 2013, DRUG METAB DISPOS, V41, P2104, DOI 10.1124/dmd.113.053926
   Yang C, 2013, CANCER DISCOV, V3, P212, DOI 10.1158/2159 8290.CD 12 0271
   Yi XJ, 2021, J BONE MINER RES, V36, P2426, DOI 10.1002/jbmr.4447
   Yoon J, 2007, J IMMUNOL, V179, P8454, DOI 10.4049/jimmunol.179.12.8454
   Young RM, 2022, CANCER DISCOV, V12, P1625, DOI 10.1158/2159 8290.CD 21 1683
   Zaretsky JZ, 2006, MOL CANCER, V5, DOI 10.1186/1476 4598 5 57
NR 54
TC 3
Z9 3
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340 7004
EI 1432 0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD AUG 6
PY 2024
VL 73
IS 10
AR 203
DI 10.1007/s00262 024 03788 1
PG 12
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Immunology
GA A8Y3S
UT WOS:001285334500017
PM 39105847
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Fujita, M
   Kohanbash, G
   Fellows Mayle, W
   Hamilton, RL
   Komohara, Y
   Decker, SA
   Ohlfest, JR
   Okada, H
AF Fujita, Mitsugu
   Kohanbash, Gary
   Fellows Mayle, Wendy
   Hamilton, Ronald L.
   Komohara, Yoshihiro
   Decker, Stacy A.
   Ohlfest, John R.
   Okada, Hideho
TI COX 2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid Derived
   Suppressor Cells
SO CANCER RESEARCH
LA English
DT Article
ID REGULATORY T CELLS; DENDRITIC CELLS; POLYMORPHISMS; GLIOBLASTOMA;
   EXPRESSION; IDENTIFICATION; MIGRATION; ARGINASE; PROMOTES; SURVIVAL
AB Epidemiologic studies have highlighted associations between the regular use of nonsteroidal anti inflammatory drugs (NSAID) and reduced glioma risks in humans. Most NSAIDs function as COX 2 inhibitors that prevent production of prostaglandin E 2 (PGE(2)). Because PGE(2) induces expansion of myeloid derived suppressor cells (MDSC), we hypothesized that COX 2 blockade would suppress gliomagenesis by inhibiting MDSC development and accumulation in the tumor microenvironment (TME). In mouse models of glioma, treatment with the COX 2 inhibitors acetylsalicylic acid (ASA) or celecoxib inhibited systemic PGE(2) production and delayed glioma development. ASA treatment also reduced the MDSC attracting chemokine CCL2 (C C motif ligand 2) in the TME along with numbers of CD11b(+)Ly6G(hi)Ly6C(lo) granulocytic MDSCs in both the bone marrow and the TME. In support of this evidence that COX 2 blockade blocked systemic development of MDSCs and their CCL2 mediated accumulation in the TME, there were defects in these processes in glioma bearing Cox2 deficient and Ccl2 deficient mice. Conversely, these mice or ASA treated wild type mice displayed enhanced expression of CXCL10 (C X C motif chemokine 10) and infiltration of cytotoxic T lymphocytes (CTL) in the TME, consistent with a relief of MDSC mediated immunosuppression. Antibody mediated depletion of MDSCs delayed glioma growth in association with an increase in CXCL10 and CTLs in the TME, underscoring a critical role for MDSCs in glioma development. Finally, Cxcl10 deficient mice exhibited reduced CTL infiltration of tumors, establishing that CXCL10 limited this pathway of immunosuppression. Taken together, our findings show that the COX 2 pathway promotes gliomagenesis by directly supporting systemic development of MDSCs and their accumulation in the TME, where they limit CTL infiltration. Cancer Res; 71(7); 2664 74. (C)2011 AACR.
C1 [Fujita, Mitsugu; Fellows Mayle, Wendy; Komohara, Yoshihiro; Okada, Hideho] Univ Pittsburgh, Dept Neurol Surg, Sch Med, Pittsburgh, PA 15213 USA.
   [Fujita, Mitsugu; Kohanbash, Gary; Hamilton, Ronald L.; Komohara, Yoshihiro; Okada, Hideho] Univ Pittsburgh, Brain Tumor Program, Inst Canc, Pittsburgh, PA 15213 USA.
   [Hamilton, Ronald L.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA.
   [Okada, Hideho] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15213 USA.
   [Okada, Hideho] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA 15213 USA.
   [Kohanbash, Gary] Univ Pittsburgh, Dept Infect Dis & Microbiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
   [Decker, Stacy A.; Ohlfest, John R.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of
   Minnesota System; University of Minnesota Twin Cities
RP Okada, H (通讯作者)，Univ Pittsburgh, Dept Neurol Surg, Sch Med, Off Suite 1 19E,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM okadah@upmc.edu
RI Kohanbash, Gary/AGV 0484 2022; Fujita, Mitsugu/A 6690 2009
OI Kohanbash, Gary/0000 0002 3953 8022; Fujita, Mitsugu/0000 0002 0000 9879
FU NIH [1R01NS055140, 2P01NS40923, 1P01CA132714, 1R21NS055738]; American
   Cancer Society [RSG 09 189 01 LIB]; Pittsburgh Foundation [D2008 0433];
   Cancer Center [P3CA047904]
FX This work was supported by the following grants from the NIH
   (1R01NS055140 to H. Okada, 2P01NS40923 to H. Okada, 1P01CA132714 to H.
   Okada, and 1R21NS055738 to J.R. Ohlfest); American Cancer Society
   (RSG 09 189 01 LIB to J.R. Ohlfest); Pittsburgh Foundation (D2008 0433
   to M. Fujita); and the Cancer Center Support Grant (P3CA047904 to
   University of Pittsburgh Cancer Institute).
CR [Anonymous], 2005, Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
   Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Dzenko KA, 2005, MICROVASC RES, V70, P53, DOI 10.1016/j.mvr.2005.04.005
   Fujita M, 2008, J IMMUNOL, V180, P2089, DOI 10.4049/jimmunol.180.4.2089
   Fujita M, 2010, CLIN CANCER RES, V16, P3409, DOI 10.1158/1078 0432.CCR 10 0644
   Fujita M, 2009, CANCER RES, V69, P1587, DOI 10.1158/0008 5472.CAN 08 2915
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Greifenberg V, 2009, EUR J IMMUNOL, V39, P2865, DOI 10.1002/eji.200939486
   Huang B, 2007, CANCER LETT, V252, P86, DOI 10.1016/j.canlet.2006.12.012
   Jimeno A, 2006, MOL CANCER THER, V5, P3240, DOI 10.1158/1535 7163.MCT 06 0565
   Jordan JT, 2008, CANCER IMMUNOL IMMUN, V57, P123, DOI 10.1007/s00262 007 0336 x
   LEVY G, 1972, NEW ENGL J MED, V287, P430, DOI 10.1056/NEJM197208312870903
   Mantovani A, 2009, HUM IMMUNOL, V70, P325, DOI 10.1016/j.humimm.2009.02.008
   Mathew A, 2005, J IMMUNOL, V174, P2212, DOI 10.4049/jimmunol.174.4.2212
   MILIARAS S, 2004, TECH COLOPROCTOL, V1, pS59
   Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood 2007 07 099226
   Muthuswamy R, 2008, CANCER RES, V68, P5972, DOI 10.1158/0008 5472.CAN 07 6818
   Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078 0432.CCR 06 2197
   Ostrand Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740
   Padovan E, 2002, J LEUKOCYTE BIOL, V71, P669
   Park W, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756 9966 27 66
   Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96
   Rodero M, 2008, J CLIN ONCOL, V26, P5957, DOI 10.1200/JCO.2008.17.2833
   Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715
   Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140 6736(10)62110 1
   Scheurer ME, 2008, CLIN CANCER RES, V14, P6640, DOI 10.1158/1078 0432.CCR 07 4681
   Scheurer ME, 2008, CANCER EPIDEM BIOMAR, V17, P1277, DOI 10.1158/1055 9965.EPI 07 2621
   Schönthal AH, 2008, EXPERT OPIN INV DRUG, V17, P197, DOI 10.1517/13543784.17.2.197
   Schwartzbaum J, 2005, CANCER RES, V65, P6459, DOI 10.1158/0008 5472.CAN 04 3728
   Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008 5472.CAN 05 0141
   Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008 5472.CAN 06 4174
   Sivak Sears NR, 2004, AM J EPIDEMIOL, V159, P1131, DOI 10.1093/aje/kwh153
   Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809
   Wiesner SM, 2009, CANCER RES, V69, P431, DOI 10.1158/0008 5472.CAN 08 1800
   Wrensch M, 2006, CANCER RES, V66, P4531, DOI 10.1158/0008 5472.CAN 05 4032
   Yoshida S, 2003, LAB INVEST, V83, P1385, DOI 10.1097/01.LAB.0000090159.53224.B9
   Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791
NR 38
TC 313
Z9 361
U1 3
U2 32
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2011
VL 71
IS 7
BP 2664
EP 2674
DI 10.1158/0008 5472.CAN 10 3055
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 743YW
UT WOS:000289057600027
PM 21324923
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Farkouh, ME
   Greenberg, JD
   Jeger, RV
   Ramanathan, K
   Verheugt, FWA
   Chesebro, JH
   Kirshner, H
   Hochman, JS
   Lay, CL
   Ruland, S
   Mellein, B
   Matchaba, PT
   Fuster, V
   Abramson, SB
AF Farkouh, M. E.
   Greenberg, J. D.
   Jeger, R. V.
   Ramanathan, K.
   Verheugt, F. W. A.
   Chesebro, J. H.
   Kirshner, H.
   Hochman, J. S.
   Lay, C. L.
   Ruland, S.
   Mellein, B.
   Matchaba, P. T.
   Fuster, V.
   Abramson, S. B.
TI Cardiovascular outcomes in high risk patients with osteoarthritis
   treated with ibuprofen, naproxen or lumiracoxib
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THERAPEUTIC ARTHRITIS RESEARCH;
   GASTROINTESTINAL EVENT TRIAL; LOW DOSE ASPIRIN; MYOCARDIAL INFARCTION;
   INHIBITORS PARECOXIB; ENDOTHELIAL FUNCTION; ROFECOXIB; CORONARY;
   CELECOXIB
AB Background: Evidence suggests that both selective cyclooxygenase (COX)  2 inhibitors and non selective nonsteroidal anti inflammatory drugs (NSAIDs) increase the risk of cardiovascular events. However, evidence from prospective studies of currently available COX 2 inhibitors and non selective NSAIDs is lacking in patients at high cardiovascular risk who are taking aspirin.
   Objective: To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
   Methods: The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) of 18 325 patients with osteoarthritis comprised two parallel substudies, comparing lumiracoxib (COX 2 inhibitor) with either ibuprofen or naproxen. A post hoc analysis by baseline cardiovascular risk, treatment assignment, and low dose aspirin use was performed. The primary composite end point was cardiovascular mortality, non fatal myocardial infarction, and stroke at 1 year; a secondary end point was the development of congestive heart failure (CHF).
   Results: In high risk patients among aspirin users, patients in the ibuprofen substudy had more primary events with ibuprofen than lumiracoxib (2.14% vs 0.25%, p = 0.038), whereas in the naproxen substudy rates were similar for naproxen and lumiracoxib (1.58% vs 1.48%, p = 0.899). High risk patients not taking aspirin had fewer primary events with naproxen than with lumiracoxib (0% vs 1.57%, p = 0.027), but not for ibuprofen versus lumiracoxib (0.92% vs 0.80%, p = 0.920). Overall, CHF developed more often with ibuprofen than lumiracoxib (1.28% vs 0.14%; p = 0.031), whereas no difference existed between naproxen and lumiracoxib.
   Conclusions: These data suggest that ibuprofen may confer an increased risk of thrombotic and CHF events relative to lumiracoxib among aspirin users at high cardiovascular risk. The study indicates that naproxen may be associated with lower risk relative to lumiracoxib among non aspirin users. This study is subject to inherent limitations, and therefore should be interpreted as a hypothesis generating study.
C1 Mt Sinai Med Ctr, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA.
   Mt Sinai Med Ctr, Marie Josee & Henry R Kravis Ctr Cardivasc Hlth, New York, NY 10029 USA.
   NYU, Sch Med, Cardiovasc Clin Res Ctr, New York, NY 10003 USA.
   NYU, Hosp Joint Dis, New York, NY 10003 USA.
   Vanderbilt Univ, Sch Med, Dept Neurol, Nashville, TN 37212 USA.
   Mayo Clin, Div Cardiol, Jacksonville, FL 32224 USA.
   St Lukes Roosevelt Hosp, Dept Neurol, New York, NY USA.
   Univ Illinois, Dept Neurol & Rehabil, Chicago, IL 60680 USA.
   Novartis Pharmaceut, Basel, Switzerland.
   Novartis Pharmaceut, E Hanover, NJ USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; New York University; New York University; NYU Langone
   Medical Center; Hospital for Joint Disease NYULMC; Vanderbilt
   University; Mayo Clinic; Mount Sinai St. Luke's; Mount Sinai West;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Novartis; Novartis; Novartis
   USA
RP Farkouh, ME (通讯作者)，Mt Sinai Sch Med, Mt Sinai Cardiovasc Inst, 1 Gustave L Levy Pl,Box 1074, New York, NY 10029 USA.
EM michael.farkouh@mssm.edu
RI Jeger, Raban/ABG 1678 2021; Verheugt, F.W.A./H 8105 2014; Fuster,
   Valentin/H 4319 2015; Kirshner, Howard/HZM 5507 2023
OI Jeger, Raban/0000 0003 1290 5491; Abramson, Steven/0000 0002 0668 6344;
   Fuster, Valentin/0000 0002 9043 9986; Kirshner,
   Howard/0000 0002 0188 3306; Hochman, Judith/0000 0002 5889 5981
CR Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735 1097(00)00804 4
   ALTMAN R, 1994, BMJ BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Altman R, 2002, CIRCULATION, V106, P191, DOI 10.1161/01.CIR.0000021599.56755.A1
   Bogaty P, 2004, CIRCULATION, V110, P934, DOI 10.1161/01.CIR.0000139338.12464.5F
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   BROCHIER ML, 1993, EUR HEART J, V14, P951, DOI 10.1093/eurheartj/14.7.951
   Capone ML, 2004, CIRCULATION, V109, P1468, DOI 10.1161/01.CIR.0000124715.27937.78
   Capone ML, 2005, J AM COLL CARDIOL, V45, P1295, DOI 10.1016/j.jacc.2005.01.045
   Catella Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199
   Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A
   Curtis JP, 2004, J AM COLL CARDIOL, V43, P991, DOI 10.1016/j.jacc.2004.01.001
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140 6736(05)17864 7
   Griffin MR., 1998, The American Journal of Medicine, V104, p23S, DOI DOI 10.1016/S0002 9343(97)00207 6
   GRIFFIN MR, 1998, AM J MED, V104, P41
   Grundy SM, 1999, J AM COLL CARDIOL, V34, P1348, DOI 10.1016/S0735 1097(99)00387 3
   Harrington RA, 2004, CHEST, V126, p513S, DOI 10.1378/chest.126.3_suppl.513S
   Hawkey CJ, 2004, ALIMENT PHARM THER, V20, P51, DOI 10.1111/j.1365 2036.2004.02026.x
   Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140 6736(04)17514 4
   Kimmel SE, 2004, J AM COLL CARDIOL, V43, P985, DOI 10.1016/j.jacc.2003.08.064
   Kimmel SE, 2005, ANN INTERN MED, V142, P157, DOI 10.7326/0003 4819 142 3 200502010 00005
   Kurth T, 2003, CIRCULATION, V108, P1191, DOI 10.1161/01.CIR.0000087593.07533.9B
   MacDonald TM, 2003, LANCET, V361, P573, DOI 10.1016/S0140 6736(03)12509 3
   Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330
   Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022 5223(03)00125 9
   Patel TN, 2004, ARCH INTERN MED, V164, P852, DOI 10.1001/archinte.164.8.852
   Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75
   Rothschild B M, 2004, Reumatismo, V56, P89
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
NR 34
TC 90
Z9 96
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2007
VL 66
IS 6
BP 764
EP 770
DI 10.1136/ard.2006.066001
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 169LW
UT WOS:000246594700009
PM 17412741
OA Green Published
DA 2025 08 17
ER

PT J
AU Ozden, FO
   Demir, E
   Lutfioglu, M
   Acarel, EE
   Bilgici, B
   Atmaca, A
AF Ozden, Feyza Otan
   Demir, Esra
   Lutfioglu, Muge
   Acarel, Elif Eser
   Bilgici, Birsen
   Atmaca, Aysegul
TI Effects of periodontal and bisphosphonate treatment on the gingival
   crevicular levels of sclerostin and dickkopf 1 in postmenopausal
   osteoporosis with and without periodontitis
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE bisphophonates; dickkopf 1; osteoporosis; periodontal treatment;
   therapy; periodontitis; sclerostin
ID 1 PERCENT ALENDRONATE GEL; PERI IMPLANT DISEASES; 2017 WORLD WORKSHOP;
   KAPPA B LIGAND; CLINICAL EFFICACY; RECEPTOR ACTIVATOR; CONSENSUS REPORT;
   ZOLEDRONIC ACID; BONE; WOMEN
AB Objective and Background Both periodontitis and osteoporosis are associated with osteoclast related bone resorption. Bone metabolism is regulated by wingless type MMTV integration site family (WNT), and WNT/beta catenin signals are controlled by physiological antagonists including dickkopf 1 (DKK 1) and sclerostin (SOST). This study examined the effects of periodontal and bisphosphonate (BP) treatment on the gingival crevicular fluid (GCF) sclerostin (SOST) and dickkopf related protein 1 (DKK 1) levels in osteoporotic and systemically healthy postmenopausal women with and without periodontitis. Materials and Methods A total of 48 postmenopausal women were divided into 4 groups (n = 12) according to periodontal health and osteoporosis status, as follows: Group OP/P: subjects with both osteoporosis and periodontitis; Group P: systemically healthy subjects with periodontitis; Group OP: periodontally healthy subjects with osteoporosis; Group H: systemically and periodontally healthy controls. Clinical data and GCF SOST and DKK 1 levels of the participants were collected at baseline and at 6 and 12 months following the initiation of periodontal and/or BP treatment in the experimental groups. GCF SOST and DKK 1 data were obtained by ELISA. Results Clinical improvements were observed in all experimental groups. GCF SOST and DKK1 baseline levels varied significantly between groups due to periodontal disease (p < .001). Following treatment, significant increases in SOST and DKK 1 concentrations and significant decreases in total amounts of SOST were observed in both periodontitis groups (OP/P, P). However, while total amounts of DKK 1 decreased in Group OP/P, in Group P, these amounts had significantly increased at 12 months post treatment (p < .05). At both 6 and 12 months post treatment, SOST and DDK1 total amounts in Groups OP/P, OP, and H were similar (p > .05), whereas significant differences were observed between Groups H and P, indicating a deviation from periodontal health in Group P (p < .01). Conclusions Significant changes in GCF SOST and DKK 1 levels were observed among women with osteoporosis who received both periodontal and BP treatment. A more detailed examination of how these treatment protocols can be combined may lead to new therapeutic approaches towards periodontal disease.
C1 [Ozden, Feyza Otan; Lutfioglu, Muge; Acarel, Elif Eser] Ondokuz Mayis Univ, Fac Dent, Dept Periodontol, Samsun, Turkey.
   [Demir, Esra] Bezmialem Vakif Univ, Fac Dent, Dept Periodontol, Istanbul, Turkey.
   [Bilgici, Birsen] Ondokuz Mayis Univ, Fac Med, Dept Biochem, Samsun, Turkey.
   [Atmaca, Aysegul] Ondokuz Mayis Univ, Fac Med, Dept Internal Med, Div Endocrinol & Metab, Samsun, Turkey.
C3 Ondokuz Mayis University; Bezmialem Vakif University; Ondokuz Mayis
   University; Ondokuz Mayis University
RP Ozden, FO (通讯作者)，Ondokuz Mayis Univ, Fac Dent, Dept Periodontol, Samsun, Turkey.
EM feyza_otan@yahoo.com
RI ; DEMİR, ESRA/D 8299 2019; LUTFIOGLU, MUGE/ABB 7390 2020; Mert,
   Meral/KXR 1439 2024
OI DEMIR, ESRA/0000 0002 7442 1778; OTAN OZDEN, Feyza/0000 0003 3258 3979;
   Bilgici, Birsen/0000 0001 7783 5039
FU Scientific Research Fund of Ondokuz Mayis University [1901.16.003]
FX Scientific Research Fund of Ondokuz Mayis University, Grant/Award
   Number: 1901.16.003
CR Adriaens PA, 2004, PERIODONTOL 2000, V36, P121, DOI 10.1111/j.1600 0757.2004.03676.x
   AINAMO J, 1975, INT DENT J, V25, P229
   Anastasilakis AD, 2013, J CLIN ENDOCR METAB, V98, P3206, DOI 10.1210/jc.2013 1402
   Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1
   Balli U, 2015, J PERIODONTOL, V86, P1396, DOI 10.1902/jop.2015.150270
   Bao JQ, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110935
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Buduneli N, 2009, J PERIODONTOL, V80, P1274, DOI 10.1902/jop.2009.090106
   Chapple ILC, 2018, J CLIN PERIODONTOL, V45, pS68, DOI 10.1111/jcpe.12940
   Chatzopoulos GS, 2019, J PERIODONTAL RES, V54, P555, DOI 10.1111/jre.12659
   Daoussis D, 2011, SEMIN ARTHRITIS RHEU, V41, P170, DOI 10.1016/j.semarthrit.2011.01.006
   Gatti D, 2014, BONE, V67, P189, DOI 10.1016/j.bone.2014.06.037
   Gatti D, 2012, BONE, V50, P739, DOI 10.1016/j.bone.2011.11.028
   Giannobile WV, 2008, J PERIODONTOL, V79, P1592, DOI 10.1902/jop.2008.080174
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Graziani F, 2009, J CLIN PERIODONTOL, V36, P419, DOI 10.1111/j.1600 051X.2009.01388.x
   Gupta S, 2020, J FAM MED PRIM CARE, V9, P4919, DOI 10.4103/jfmpc.jfmpc_724_20
   Jeffcoat M K, 1998, Ann Periodontol, V3, P312, DOI 10.1902/annals.1998.3.1.312
   Jeffcoat Marjorie K, 2007, J Int Acad Periodontol, V9, P70
   Juluri Ravichandra, 2015, J Int Oral Health, V7, P119
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Lane N, 2005, J PERIODONTOL, V76, P1113, DOI 10.1902/jop.2005.76.7.1113
   Lerner UH, 2006, J DENT RES, V85, P596, DOI 10.1177/154405910608500704
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Lim Y, 2016, CALCIFIED TISSUE INT, V99, P350, DOI 10.1007/s00223 016 0160 4
   LOE HARALD, 1963, ACTA ODONTOL SCAND, V21, P533, DOI 10.3109/00016356309011240
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Napimoga MH, 2014, J CLIN PERIODONTOL, V41, P550, DOI 10.1111/jcpe.12245
   Papapanou PN, 2018, J CLIN PERIODONTOL, V45, pS162, DOI 10.1111/jcpe.12946
   Penoni DC, 2017, J DENT RES, V96, P261, DOI 10.1177/0022034516682017
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Reddy Michael S, 2002, Compend Contin Educ Dent, V23, P21
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rocha ML, 2004, J PERIODONTOL, V75, P1579, DOI 10.1902/jop.2004.75.12.1579
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Salvi GE, 1997, PERIODONTOL 2000, V14, P173, DOI 10.1111/j.1600 0757.1997.tb00197.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schwarz F, 2006, J CLIN PERIODONTOL, V33, P491, DOI 10.1111/j.1600 051X.2006.00936.x
   Sharma A, 2012, J PERIODONTOL, V83, P11, DOI 10.1902/jop.2011.110091
   Sharma A, 2012, J PERIODONTOL, V83, P19, DOI 10.1902/jop.2011.110206
   SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968
   Silverman SL, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/941419
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Wactawski Wende J, 2001, Ann Periodontol, V6, P197, DOI 10.1902/annals.2001.6.1.197
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 48
TC 5
Z9 6
U1 2
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD AUG
PY 2022
VL 57
IS 4
BP 849
EP 858
DI 10.1111/jre.13023
EA JUN 2022
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 3B1BE
UT WOS:000805790700001
PM 35665506
DA 2025 08 17
ER

PT J
AU Socol, G
   Preda, N
   Socol, M
   Sima, L
   Luculescu, CR
   Sima, F
   Miroiu, M
   Axente, E
   Visan, A
   Stefan, N
   Cristescu, R
   Dorcioman, G
   Stanculescu, A
   Radulescu, L
   Mihailescu, IN
AF Socol, G.
   Preda, N.
   Socol, M.
   Sima, L.
   Luculescu, C. R.
   Sima, F.
   Miroiu, M.
   Axente, E.
   Visan, A.
   Stefan, N.
   Cristescu, R.
   Dorcioman, G.
   Stanculescu, A.
   Radulescu, L.
   Mihailescu, I. N.
TI MAPLE DEPOSITION OF PLGA MICRO  AND NANOPARTICLES EMBEDDED INTO
   POLYMERIC COATINGS
SO DIGEST JOURNAL OF NANOMATERIALS AND BIOSTRUCTURES
LA English
DT Article
DE PLGA; chitosan; BSA; nanoparticles; MAPLE
ID THIN FILMS; STABILITY; ENCAPSULATION; BSA
AB We report the film deposition of Poly(D, L lactide co glycolide) (PLGA) particle systems by matrix assisted pulsed laser evaporation (MAPLE) technique. PLGA+polyvinyl alcohol (PVA), PLGA+PVA+ bovine serum albumin (BSA) and PLGA+PVA+chitosan (CH) nanoparticles were prepared by an oil in water emulsion diffusion evaporation method. The average diameter of PLGA particles was between 180 250 nm. The coatings were obtained by laser evaporation of frozen targets prepared by mixing appropriate PLGA aqueous suspensions and dimethyl sulfoxide (DMSO) in three ratios. Depending on the DMSO content, we deposited PLGA particles embedded into polymeric layer mainly obtained due to the entirely or partially dissolving of nanoparticles into the initial solution. In vitro results showed that the distribution and morphology of osteoblast like SaOs 2 cells on some PLGA particle coatings were similar with that of the positive control. The purpose of this study was to develop layers of PLGA particles for local controlled drug delivery.
C1 [Socol, G.; Luculescu, C. R.; Sima, F.; Miroiu, M.; Axente, E.; Visan, A.; Stefan, N.; Cristescu, R.; Dorcioman, G.; Mihailescu, I. N.] Natl Inst Lasers Plasma & Radiat Phys, Magurele, Ilfov, Romania.
   [Preda, N.; Socol, M.; Stanculescu, A.] Natl Inst Mat Phys, Magurele, Ilfov, Romania.
   [Sima, L.] Inst Biochem, Bucharest, Romania.
   [Radulescu, L.] Inst Cellular Biol & Pathol N Simionescu, Bucharest, Romania.
C3 National Institute for Laser, Plasma & Radiation Physics   Romania;
   National Institute of Materials Physics   Romania; Romanian Academy;
   Institute of Biochemistry, Bucharest; Romanian Academy; Nicolae
   Simionescu Institute of Cellular Biology & Pathology
RP Socol, G (通讯作者)，Natl Inst Lasers Plasma & Radiat Phys, Magurele, Ilfov, Romania.
EM gabriel.socol@inflpr.ro
RI Cristescu, Rodica/F 1961 2010; MIROIU, Floralice/C 5044 2011; STEFAN,
   Nicolaie/C 9857 2011; Dorcioman, Gabriela/C 5875 2011; Preda,
   Nicoleta/B 6789 2012; IVAN, Radulescu, LUMINITA/AAM 6128 2021;
   Stanculescu, Anca/C 3802 2011; socol, marcela/B 6045 2012; Socol,
   Gabriel/A 5405 2011; Sima, Livia/C 2882 2011; Mihailescu,
   Ion/A 5403 2011; SIMA, Felix/C 2734 2011; Visan, Anita
   Ioana/I 7288 2016; Sima, Livia/M 4389 2019; Luculescu,
   Catalin/A 7999 2010; AXENTE, Emanuel/C 4812 2011
OI Cristescu, Rodica/0000 0002 3092 6168; Sima, Felix/0000 0001 5911 0288;
   STEFAN, Nicolaie/0000 0001 6101 5976; Dorcioman,
   Gabriela/0000 0002 8323 9150; Preda, Nicoleta/0000 0002 6448 6201;
   Socol, Marcela/0000 0003 2010 7318; Stanculescu,
   Anca/0000 0001 7755 1685; Socol, Gabriel/0000 0002 1992 7346; Sima,
   Livia/0000 0002 3404 4162; AXENTE, Emanuel/0000 0003 1946 5863;
   Luculescu, Catalin/0000 0001 6852 401X; 
FU European Social Fund POSDRU [POSDRU/89/1.5/S/60746]; Romanian National
   Authority for Scientific Research, CNCS UEFISCDI [PCCA 153/02.07.2012]
FX Human osteosarcoma SaOs2 cells were a kind gift from Dr. Karine Anselme,
   IS2M, Mulhouse, France. G. Socol, F. Sima, L. E. Sima and L. Radulescu
   acknowledge the financial support from the European Social Fund POSDRU
   2007 2013 through the contract POSDRU/89/1.5/S/60746. This work was
   supported by the Romanian National Authority for Scientific Research,
   CNCS UEFISCDI, project number PCCA 153/02.07.2012.
CR Barichello JM, 1999, DRUG DEV IND PHARM, V25, P471, DOI 10.1081/DDC 100102197
   Bezemer JM, 2000, J CONTROL RELEASE, V67, P249, DOI 10.1016/S0168 3659(00)00212 1
   Caricato AP, 2009, SENSORS BASEL, V9, P2682, DOI 10.3390/s90402682
   Cristescu R, 2007, APPL SURF SCI, V253, P7702, DOI 10.1016/j.apsusc.2007.02.042
   Cristescu R, 2007, APPL SURF SCI, V253, P6476, DOI 10.1016/j.apsusc.2007.01.064
   Feczko T, 2008, COLLOID SURFACE A, V319, P188, DOI 10.1016/j.colsurfa.2007.07.011
   Giteau A, 2008, EUR J PHARM BIOPHARM, V70, P127, DOI 10.1016/j.ejpb.2008.03.006
   Ho ML, 2008, J CONTROL RELEASE, V128, P142, DOI 10.1016/j.jconrel.2008.02.012
   Karal Yilmaz O, 2013, J MATER SCI MATER M, V24, P147, DOI 10.1007/s10856 012 4784 2
   Kim JH, 2005, J CONTROL RELEASE, V109, P86, DOI 10.1016/j.jconrel.2005.09.016
   Kim TH, 2011, J CONTROL RELEASE, V150, P63, DOI 10.1016/j.jconrel.2010.10.037
   Lee KY, 2007, PROG POLYM SCI, V32, P669, DOI 10.1016/j.progpolymsci.2007.04.001
   Lin YT, 2012, J MATER SCI MATER M, V23, P2453, DOI 10.1007/s10856 012 4723 2
   Manca ML, 2008, COLLOID SURFACE B, V67, P166, DOI 10.1016/j.colsurfb.2008.08.010
   Nafee N, 2009, INT J PHARMACEUT, V381, P130, DOI 10.1016/j.ijpharm.2009.04.049
   Nam SH, 2007, B KOREAN CHEM SOC, V28, P397
   Socol G, 2009, APPL SURF SCI, V255, P5611, DOI 10.1016/j.apsusc.2008.07.206
   Son S, 2009, INT J PHARMACEUT, V368, P178, DOI 10.1016/j.ijpharm.2008.09.061
   Taetz S, 2009, EUR J PHARM BIOPHARM, V72, P358, DOI 10.1016/j.ejpb.2008.07.011
   Wang MB, 2011, POLYM DEGRAD STABIL, V96, P107, DOI 10.1016/j.polymdegradstab.2010.10.010
   Zhigilei LV, 2011, APPL PHYS A MATER, V105, P529, DOI 10.1007/s00339 011 6595 6
NR 21
TC 9
Z9 9
U1 0
U2 44
PU INST MATERIALS PHYSICS
PI BUCHAREST
PA NATL INST R&D MATERIALS PHYSICS, ATOMISTILOR STR, 105 BIS, BUCHAREST,
   077125, ROMANIA
SN 1842 3582
J9 DIG J NANOMATER BIOS
JI Dig. J. Nanomater. Biostruct.
PD APR JUN
PY 2013
VL 8
IS 2
BP 621
EP 630
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA 195XQ
UT WOS:000322737500015
DA 2025 08 17
ER

PT J
AU Micheli, L
   Bozdag, M
   Akgul, O
   Carta, F
   Guccione, C
   Bergonzi, MC
   Bilia, AR
   Cinci, L
   Lucarini, E
   Parisio, C
   Supuran, CT
   Ghelardini, C
   Mannelli, LD
AF Micheli, Laura
   Bozdag, Murat
   Akgul, Ozlem
   Carta, Fabrizio
   Guccione, Clizia
   Bergonzi, Maria Camilla
   Bilia, Anna Rita
   Cinci, Lorenzo
   Lucarini, Elena
   Parisio, Carmen
   Supuran, Claudiu T.
   Ghelardini, Carla
   Mannelli, Lorenzo Di Cesare
TI Pain Relieving Effect of NSAIDs CAIs Hybrid Molecules: Systemic and
   Intra Articular Treatments against Rheumatoid Arthritis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE carbonic anhydrase inhibitors (CAIs); dual hybrids; inflammation;
   hypersensitivity; rheumatoid arthritis; CFA
ID CARBONIC ANHYDRASE INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   OSTEOARTHRITIS; PATENT; PH; TISSUE; RISK; ACID; IX
AB To study new target oriented molecules that are active against rheumatoid arthritis dependent pain, new dual inhibitors incorporating both a carbonic anhydrase (CA) binding moiety and a cyclooxygenase inhibitor (NSAID) were tested in a rat model of rheumatoid arthritis induced by CFA intra articular (i.a.) injection. A comparison between a repeated per os treatment and a single i.a. injection was performed. CFA (50 mu L) was injected in the tibiotarsal joint, and the effect of per os repeated treatment (1 mg kg( 1)) or single i.a injection (1 mg mL( 1), 50 mu L) with NSAIDs CAIs hybrid molecules, named 4 and 5, was evaluated. The molecules 4 and 5, which were administered daily for 14 days, significantly prevented CFA induced hypersensitivity to mechanical noxious (Paw pressure test) and non noxious stimuli (von Frey test), the postural unbalance related to spontaneous pain (Incapacitance test) and motor alterations (Beam balance test). Moreover, to study a possible localized activity, 4 and 5 were formulated in liposomes (lipo 4 and lipo 5, both 1 mg mL( 1)) and directly administered by a single i.a. injection seven days after CFA injection. Lipo 5 decreased the mechanical hypersensitivity to noxious and non noxious stimuli and improved motor coordination. Oral and i.a. treatments did not rescue the joint, as shown by the histological analysis. This new class of potent molecules, which is able to inhibit at the same time CA and cyclooxygenase, shows high activity in a preclinical condition of rheumatoid arthritis, strongly suggesting a novel attractive pharmacodynamic profile.
C1 [Micheli, Laura; Cinci, Lorenzo; Lucarini, Elena; Parisio, Carmen; Ghelardini, Carla; Mannelli, Lorenzo Di Cesare] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, NEUROFARBA, Pharmacol & Toxicol Sect, Viale Gaetano Pieraccini 6, I 50139 Florence, Italy.
   [Bozdag, Murat; Carta, Fabrizio; Supuran, Claudiu T.] Univ Florence, Dept Neurosci Psychol Drug Res & Childs Hlth NEUR, Sect Pharmaceut & Nutraceut Sci, Via Ugo Schiff 6, I 50019 Florence, Italy.
   [Akgul, Ozlem] Ege Univ Bornova, Fac Pharm, Dept Pharmaceut Chem, TR 35100 Izmir, Turkey.
   [Guccione, Clizia; Bergonzi, Maria Camilla; Bilia, Anna Rita] Univ Florence, Dept Chem, Via U Schiff 6, I 50019 Florence, Italy.
C3 University of Florence; University of Florence; Ege University;
   University of Florence
RP Mannelli, LD (通讯作者)，Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, NEUROFARBA, Pharmacol & Toxicol Sect, Viale Gaetano Pieraccini 6, I 50139 Florence, Italy.
EM laura.micheli@unifi.it; bozdag.murat@unifi.it; ozlem.akgul@ege.edu.tr;
   fabrizio.carta@unifi.it; clizia.guccione@unifi.it;
   mariacamilla.bergonzi@unifi.it; annarita.bilia@unifi.it;
   lorenzo.cinci@unifi.it; elena.lucarini@unifi.it;
   carmen.parisio@unifi.it; claudiu.supuran@unifi.it;
   carla.ghelardini@unifi.it; lorenzo.mannelli@unifi.it
RI Micheli, Laura/F 5712 2019; akgul, ozlem/AAZ 2985 2020; carta,
   fabrizio/Y 2333 2019; Lucarini, Elena/ABF 6308 2020; Bilia,
   Anna/AAL 2963 2020; Di Cesare Mannelli, Lorenzo/A 1641 2015; Mannelli,
   Lorenzo/A 7165 2012; Supuran, Claudiu/A 5151 2008; BOZDAG,
   Murat/AAE 6525 2019
OI BOZDAG, Murat/0000 0002 5010 0355; carta, fabrizio/0000 0002 1141 6146;
   Cinci, Lorenzo/0000 0002 1799 4828; Micheli, Laura/0000 0001 8834 5801;
   Di Cesare Mannelli, Lorenzo/0000 0001 8374 4432; Supuran,
   Claudiu/0000 0003 4262 0323; Parisio, Carmen/0000 0003 0746 0774; 
FU Università degli Studi di Firenze [.] Funding Source: Medline
CR Agca R, 2017, ANN RHEUM DIS, V76, P17, DOI 10.1136/annrheumdis 2016 209775
   Akgul O, 2018, J MED CHEM, V61, P4961, DOI 10.1021/acs.jmedchem.8b00420
   Andersson SE, 1999, J RHEUMATOL, V26, P2018
   Band PA, 2015, OSTEOARTHR CARTILAGE, V23, P70, DOI 10.1016/j.joca.2014.09.017
   Bononi G, 2018, EUR J MED CHEM, V157, P817, DOI 10.1016/j.ejmech.2018.08.038
   Bua S, 2017, J MED CHEM, V60, P1159, DOI 10.1021/acs.jmedchem.6b01607
   BUTLER SH, 1992, PAIN, V48, P73, DOI 10.1016/0304 3959(92)90133 V
   Carta F, 2015, BIOORGAN MED CHEM, V23, P1828, DOI 10.1016/j.bmc.2015.02.027
   Carta F, 2013, EXPERT OPIN THER PAT, V23, P681, DOI 10.1517/13543776.2013.780598
   Chang XT, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 279
   CUMMINGS NA, 1966, ARTHRITIS RHEUM US, V9, P47, DOI 10.1002/art.1780090106
   da Costa BR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003115.pub4
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Fakhari A, 2013, ACTA BIOMATER, V9, P7081, DOI 10.1016/j.actbio.2013.03.005
   Goldring MB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2592
   Huffman KM, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 016 1215 7
   Isacchi B, 2011, EUR J PHARM SCI, V44, P552, DOI 10.1016/j.ejps.2011.09.019
   Langley PC, 2010, CURR MED RES OPIN, V26, P239, DOI 10.1185/03007990903426787
   Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522
   LEIGHTON GE, 1988, BRIT J PHARMACOL, V93, P553, DOI 10.1111/j.1476 5381.1988.tb10310.x
   Liu CG, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/354594
   Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008 5472.CAN 10 4261
   Mannelli LD, 2016, J ENZYM INHIB MED CH, V31, P894, DOI 10.3109/14756366.2015.1113407
   Mannelli LDC, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/894732
   Mannelli LD, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/905360
   Maresca M, 2016, J ETHNOPHARMACOL, V193, P456, DOI 10.1016/j.jep.2016.09.032
   Margheri F, 2016, J ENZYM INHIB MED CH, V31, P60, DOI 10.1080/14756366.2016.1217857
   Masini E, 2013, EXPERT OPIN THER PAT, V23, P705, DOI 10.1517/13543776.2013.794788
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Piazzini V, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030128
   Righeschi C, 2014, COLLOID SURFACE B, V116, P121, DOI 10.1016/j.colsurfb.2013.12.019
   Roberts E, 2016, ANN RHEUM DIS, V75, P552, DOI 10.1136/annrheumdis 2014 206914
   Roman Blas JA, 2016, EXPERT OPIN PHARMACO, V17, P1745, DOI 10.1080/14656566.2016.1201070
   Sakurai M, 2009, PAIN, V147, P165, DOI 10.1016/j.pain.2009.09.003
   Scozzafava A, 2013, EXPERT OPIN THER PAT, V23, P725, DOI 10.1517/13543776.2013.790957
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Snekhalatha U, 2013, Z RHEUMATOL, V72, P375, DOI 10.1007/s00393 012 1083 8
   Supuran CT, 2012, J ENZYM INHIB MED CH, V27, P759, DOI 10.3109/14756366.2012.672983
   Taylor PC, 2017, NEW ENGL J MED, V376, P652, DOI 10.1056/NEJMoa1608345
   Tsiklauri N, 2008, Georgian Med News, P40
   van Walsem A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0554 0
   Vande Walle L, 2014, NATURE, V512, P69, DOI 10.1038/nature13322
   Waksman BH, 2002, SCAND J IMMUNOL, V56, P12, DOI 10.1046/j.1365 3083.2002.01106.x
   Yousri NA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05439 1
   Zheng YB, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 256
NR 45
TC 28
Z9 28
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR 2
PY 2019
VL 20
IS 8
AR 1923
DI 10.3390/ijms20081923
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HX8ID
UT WOS:000467648700121
PM 31003542
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Tsupykov, O
   Ustymenko, A
   Kyryk, V
   Smozhanik, E
   Yatsenko, K
   Butenko, G
   Skibo, G
AF Tsupykov, Oleg
   Ustymenko, Alina
   Kyryk, Vitaliy
   Smozhanik, Ekaterina
   Yatsenko, Kateryna
   Butenko, Gennadii
   Skibo, Galina
TI Ultrastructural Study of Mouse Adipose derived Stromal Cells Induced
   Towards Osteogenic Direction
SO MICROSCOPY RESEARCH AND TECHNIQUE
LA English
DT Article
DE electron microscopy; adipose derived stem/stromal cells; directed
   osteogenic differentiation
ID MESENCHYMAL STEM CELLS; STEM/STROMAL CELLS; BONE MARROW;
   DIFFERENTIATION; THERAPY; CULTURE; TISSUE
AB We investigated the ultrastructural characteristics of mouse adipose derived stem/stromal cells (ASCs) induced towards osteogenic lineage. ASCs were isolated from adipose tissue of FVB Cg Tg(GFPU)5Nagy/J mice and expanded in monolayer culture. Flow cytometry, histochemical staining, and electron microscopy techniques were used to characterize the ASCs with respect to their ability for osteogenic differentiation capacity. Immunophenotypically, ASCs were characterized by high expression of the CD44 and CD90 markers, while the relative content of cells expressing CD45, CD34 and CD117 markers was <2%. In assays of differentiation, the positive response to osteogenic differentiation factors was observed and characterized by deposition of calcium in the extracellular matrix and alkaline phosphatase production. Electron microscopy analysis revealed that undifferentiated ASCs had a rough endoplasmic reticulum with dilated cisterns and elongated mitochondria. At the end of the osteogenic differentiation, the ASCs transformed from their original fibroblast like appearance to having a polygonal osteoblast like morphology. Ultrastructurally, these cells were characterized by large euchromatic nucleus and numerous cytoplasm containing elongated mitochondria, a very prominent rough endoplasmic reticulum, Golgi apparatus and intermediate filament bundles. Extracellular matrix vesicles of variable size similar to the calcification nodules were observed among collagen fibrils. Our data provide the ultrastructural basis for further studies on the cellular mechanisms involved in osteogenic differentiation of mouse adipose derived stem/stromal cells. (C) 2016 Wiley Periodicals, Inc.
C1 [Tsupykov, Oleg; Smozhanik, Ekaterina; Yatsenko, Kateryna; Skibo, Galina] AA Bogomolets Physiol Inst, Dept Cytol, Bogomoletz Str 4, UA 01024 Kiev, Ukraine.
   [Tsupykov, Oleg; Ustymenko, Alina; Kyryk, Vitaliy; Butenko, Gennadii; Skibo, Galina] State Inst Genet & Regenerat Med, Cell & Tissue Technol Dept, Kiev, Ukraine.
C3 National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of
   Physiology; National Academy of Medical Sciences of Ukraine; Institute
   of Genetic & Regenerative Medicine NAMS Ukraine
RP Tsupykov, O (通讯作者)，AA Bogomolets Physiol Inst, Dept Cytol, Bogomoletz Str 4, UA 01024 Kiev, Ukraine.
EM tsupykov@gmail.com
RI Kyryk, Vitalii/R 6575 2019; Butenko, Gennadii/JTV 3373 2023; Tsupykov,
   Oleg/P 3453 2015; Ustymenko, Аlina/AIC 0757 2022
OI Kyryk, Vitalii/0000 0001 7636 1302; Ustymenko,
   Alina/0000 0002 0774 2109; Skibo, Galyna/0000 0003 2187 6178; Butenko,
   Gennadii/0009 0000 7327 8511; Tsupykov, Oleg/0000 0002 2107 651X; 
FU NAS of Ukraine; Science and Technology Center in Ukraine [5977]
FX Contract grant sponsor: NAS of Ukraine and Science and Technology Center
   in Ukraine; Contract grant number: 5977.
CR Ahn HH, 2009, TISSUE ENG PT A, V15, P1821, DOI 10.1089/ten.tea.2008.0386
   ANDERSON HC, 1989, LAB INVEST, V60, P320
   Chang KA, 2014, J PHARMACOL SCI, V126, P293, DOI 10.1254/jphs.14R10CP
   D'souza N, 2015, BMC MED, V13, DOI 10.1186/s12916 015 0426 0
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Escacena N, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/895714
   Garimella MG, 2015, J IMMUNOL, V195, P5136, DOI 10.4049/jimmunol.1500332
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Hanson SE, 2013, AESTHET SURG J, V33, P888, DOI 10.1177/1090820X13496115
   Haversath M, 2016, J BIOMED MATER RES A, V104, P145, DOI 10.1002/jbm.a.35550
   Hoffding MK, 2015, STEM CELL RES, V14, P39, DOI 10.1016/j.scr.2014.11.003
   Jose AA, 2013, REGENERATIVE MED TIS
   Karaoz E, 2009, HISTOCHEM CELL BIOL, V132, P533, DOI 10.1007/s00418 009 0629 6
   KASSEM M, 1992, APMIS, V100, P490, DOI 10.1111/j.1699 0463.1992.tb00901.x
   Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f
   Kobolak J, 2015, METHODS         0915, V15
   Lee JW, 2004, YONSEI MED J, V45, P41
   Lendeckel S, 2004, J CRANIO MAXILL SURG, V32, P370, DOI 10.1016/j.jcms.2004.06.002
   Li CY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0066 5
   Lin Lin, 2016, Curr Stem Cell Res Ther, V11, P122
   Manea CM, 2014, ROM J MORPHOL EMBRYO, V55, P1363
   MARTINO LJ, 1979, CALCIFIED TISSUE INT, V27, P57, DOI 10.1007/BF02441162
   Mesimäki K, 2009, INT J ORAL MAX SURG, V38, P201, DOI 10.1016/j.ijom.2009.01.001
   Mohammadian M, 2015, ARTIF CELL NANOMED B, V44, P1
   Pasquinelli G, 2013, ULTRASTRUCT PATHOL, V37, P318, DOI 10.3109/01913123.2013.810683
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Richardson SM, 2015, METHODS         0915, V15
   Ripoll CB, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 3
   Salehi H, 2015, STEM CELL REV
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Sibov TT, 2010, CELL REPROGRAM, V12, P391, DOI 10.1089/cell.2009.0087
   Tanavde V, 2015, CYTOTHERAPY, V17, P1169, DOI 10.1016/j.jcyt.2015.07.008
   Tsupykov O, 2015, MICROSC RES TECHNIQ, V78, P128, DOI 10.1002/jemt.22454
   Zielins ER, 2015, JOVE J VIS EXP, DOI 10.3791/52181
NR 34
TC 4
Z9 4
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1059 910X
EI 1097 0029
J9 MICROSC RES TECHNIQ
JI Microsc. Res. Tech.
PD JUN
PY 2016
VL 79
IS 6
BP 557
EP 564
DI 10.1002/jemt.22670
PG 8
WC Anatomy & Morphology; Biology; Microscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Life Sciences & Biomedicine   Other Topics;
   Microscopy
GA DN4HS
UT WOS:000377025900013
PM 27087359
DA 2025 08 17
ER

PT J
AU Choi, Y
   Kim, J
   Rhee, Y
   Park, JH
   Nam, W
   Park, W
AF Choi, Yiseul
   Kim, Jaeyeon
   Rhee, Yumie
   Park, Jin Hoo
   Nam, Woong
   Park, Wonse
TI The assessment of halitosis with a new screening tool in
   medication related osteonecrosis of the jaw
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Osteoporosis; Medication related osteonecrosis of the jaw; Halitosis;
   Volatile sulfur compounds; Hydrogen sulfide; Methyl mercaptan
ID ORAL MALODOR; SULFUR COMPOUNDS; BISPHOSPHONATES; MECHANISMS
AB ObjectivesThis study aimed to identify the levels of halitosis in patients with Medication related osteonecrosis of the jaw (MRONJ) and osteoporosis and to suggest a new MRONJ screening method using halitosis measurement.Materials and MethodsFrom October 2019 to April 2023, participants aged 19 years or older without periodontal disease were selected. Seventy five participants, 25 in each group, were divided into an MRONJ group, an osteoporosis group without MRONJ, and a control group without osteoporosis and not taking osteoporosis drugs or antibiotics. Each participant underwent halitosis assessment twice using an exhaled breath analyzer to measure halitosis twice by blowing a straw for 1 min. Measured concentrations of hydrogen, hydrogen sulfide, and methyl mercaptan were compared between groups.ResultsData from 22 patients in the MRONJ group, 25 in the osteoporosis group, and 25 in the control group were analyzed. The concentrations of hydrogen sulfide and methyl mercaptan were significantly higher in the MRONJ group than in the other groups, but the concentrations of hydrogen did not differ between the groups. When comparing the concentrations of hydrogen sulfide and methyl mercaptan in osteoporosis patients and solid cancer patients in the MRONJ group, there was a significant difference in hydrogen sulfide concentration, but there was no significant difference in methyl mercaptan.ConclusionsQuantifying the level of halitosis can be used to screen for MRONJ in patients taking bisphosphonates, such as patients with osteoporosis, prostate cancer, and breast cancer.Clinical RelevanceMRONJ is accompanied by bad breath, and the concentrations of hydrogen sulfide and methyl mercaptan are associated with MRONJ.
C1 [Choi, Yiseul; Park, Wonse] Yonsei Univ, Inst Innovat Digital Healthcare, Seoul, South Korea.
   [Choi, Yiseul; Kim, Jaeyeon] Yonsei Univ, Coll Dent, Dept Adv Gen Dent, Seoul, South Korea.
   [Rhee, Yumie] Yonsei Univ, Endocrine Res Inst, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Park, Jin Hoo; Nam, Woong] Yonsei Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Seoul, South Korea.
   [Park, Wonse] Yonsei Univ, Human Identificat Res Inst, Coll Dent, Dept Adv Gen Dent, Seoul, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System
RP Park, W (通讯作者)，Yonsei Univ, Inst Innovat Digital Healthcare, Seoul, South Korea.; Park, W (通讯作者)，Yonsei Univ, Human Identificat Res Inst, Coll Dent, Dept Adv Gen Dent, Seoul, South Korea.
EM wonse@yuhs.ac
RI ; Rhee, Yumie/L 8020 2019; Choi, Yiseul/LFF 9210 2024
OI Nam, Woong/0000 0003 0146 3624; Park, Wonse/0000 0002 2081 1156; Rhee,
   Yumie/0000 0003 4227 5638
FU Yonsei University College of Dentistry Fund [6 2017 0025]
FX This study was supported by the Yonsei University College of Dentistry
   Fund (6 2017 0025).
CR Assael LA, 2009, J ORAL MAXIL SURG, V67, P35, DOI 10.1016/j.joms.2009.01.003
   Brening RH., 1939, J DENT RES, V18, P127, DOI [10.1177/00220345390180020201, DOI 10.1177/00220345390180020201]
   Calabria E, 2023, DENT J BASEL, V11, DOI 10.3390/dj11060147
   Cohen J., 2013, Statistical Power Analysis for the Behavioral Sciences, V2nd, DOI DOI 10.4324/9780203771587
   Tornier SD, 2021, SUPPORT CARE CANCER, V29, P6713, DOI 10.1007/s00520 021 06275 w
   Ewald F, 2021, CLIN ORAL INVEST, V25, P2801, DOI 10.1007/s00784 020 03595 9
   Figueiredo LC, 2002, J PERIODONTOL, V73, P1338, DOI 10.1902/jop.2002.73.11.1338
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Janovska Zuzana, 2012, Acta Medica (Hradec Kralove), V55, P111
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   ROSENBERG M, 1991, J PERIODONTOL, V62, P487, DOI 10.1902/jop.1991.62.8.487
   ROSENBERG M, 1991, J DENT RES, V70, P1436, DOI 10.1177/00220345910700110801
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Cassiano LS, 2021, J CLIN PERIODONTOL, V48, P1458, DOI 10.1111/jcpe.13530
   Scully C, 2012, ORAL DIS, V18, P333, DOI 10.1111/j.1601 0825.2011.01890.x
   Shimura M, 1996, J PERIODONTOL, V67, P396, DOI 10.1902/jop.1996.67.4.396
   Silva MF, 2018, CLIN ORAL INVEST, V22, P47, DOI 10.1007/s00784 017 2164 5
   Svejda B., 2015, Stomatologie, V112, P241, DOI [10.1007/s00715 015 0064 3, DOI 10.1007/S00715 015 0064 3, 10.1007/S00715 015 0064 3]
   Tanaka S, 2008, J CLIN PEDIATR DENT, V32, P195, DOI 10.17796/jcpd.32.3.vp657177815618l1
   TONZETICH J, 1971, ARCH ORAL BIOL, V16, P587, DOI 10.1016/0003 9969(71)90062 8
   TONZETICH J, 1977, J PERIODONTOL, V48, P13, DOI 10.1902/jop.1977.48.1.13
   TONZETICH J, 1978, INT DENT J, V28, P309
   Torresyap G, 2003, J CLIN PERIODONTOL, V30, P1003, DOI 10.1034/j.1600 051X.2003.00377.x
   YAEGAKI K, 1992, J PERIODONTOL, V63, P783, DOI 10.1902/jop.1992.63.9.783
NR 26
TC 0
Z9 0
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JAN 17
PY 2024
VL 28
IS 1
AR 102
DI 10.1007/s00784 024 05506 8
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA FC3O1
UT WOS:001143512700001
PM 38233664
DA 2025 08 17
ER

PT J
AU Falasinnu, T
   Lu, D
   Baker, MC
AF Falasinnu, Titilola
   Lu, Di
   Baker, Matthew C.
TI Annual trends in pain management modalities in patients with newly
   diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an
   administrative claims  based study
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID OUTCOMES
AB Background Autoimmune rheumatic diseases have distinct pathogenic mechanisms and are causes of disability and increased mortality worldwide. In this study, we aimed to examine annual trends in pain management modalities among patients with autoimmune rheumatic diseases. Methods We identified newly diagnosed patients with ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, Sj & ouml;gren's syndrome, systemic sclerosis, or systemic lupus erythematosus (SLE) in the Merative Marketscan Research Databases from 2007 to 2021. The database includes deidentified inpatient and outpatient health encounters with employment sponsored health insurance claims in the USA. We found minimal occurrences of multiple overlapping conditions and included only the initial recorded diagnosis for each patient. We determined the annual incidence of patients treated with opioids, anticonvulsants, antidepressants, skeletal muscle relaxants, non steroidal antiinflammatory drugs (NSAIDs), topical analgesics, and physical therapy in the year following diagnosis. Logistic regression was used to estimate the association between calendar year and outcomes, adjusted for age, sex, and region. Findings We included 141 962 patients: 10 927 with ankylosing spondylitis, 21 438 with psoriatic arthritis, 71 393 with rheumatoid arthritis, 16 718 with Sj & ouml;gren's syndrome, 18 018 with SLE, and 3468 with systemic sclerosis. 107 475 (75<middle dot>7%) were women and 34 487 (24<middle dot>3%) were men. Overall, the incidence of opioid use increased annually until 2014 by 4% (adjusted odds ratio [aOR] 1<middle dot>04 [95% CI 1<middle dot>03 1<middle dot>04]) and decreased annually by 15% after 2014 (0<middle dot>85 [0<middle dot>84 0<middle dot>86]). The incidence of physical therapy use increased annually by 5% until 2014 (aOR 1<middle dot>05 [95% CI 1<middle dot>04 1<middle dot>06]), with a slight decrease annually by 1% after 2014 (0<middle dot>99 [0<middle dot>98 1<middle dot>00]). The incidence of anticonvulsant use increased annually by 7% until 2014 (aOR 1<middle dot>07 [95% CI 1<middle dot>07 1<middle dot>08]) and did not significantly change after 2014 (1<middle dot>00 [0<middle dot>99 1<middle dot>00]). Before 2014, the incidence of NSAIDs use increased by 2% annually (aOR 1<middle dot>02 [95% CI 1<middle dot>02 1<middle dot>03]); however, after 2014, the incidence decreased annually by 5% (0<middle dot>95 [0<middle dot>95 0<middle dot>96]). These trends did not differ by sex except for NSAID use before 2014 (p interaction =0<middle dot>02) and topical analgesic use after 2014 (pinteraction=0<middle dot>0100). interaction = 0 <middle dot> 0100 ). Interpretation Since 2014, the use of non opioid pain management modalities has increased or stabilised, whereas opioid and NSAID use has declined. Future studies are needed to evaluate the effectiveness of these changes, and the effects they have had on outcomes such as quality of life, disability, and function. Copyright (c) 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
C1 [Falasinnu, Titilola; Baker, Matthew C.] Stanford Univ, Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94304 USA.
   [Falasinnu, Titilola] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA USA.
   [Lu, Di] Stanford Univ, Sch Med, Quantitat Sci Unit, Stanford, CA USA.
C3 Stanford University; Stanford University; Stanford University
RP Falasinnu, T (通讯作者)，Stanford Univ, Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94304 USA.
EM tof@stanford.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
FX <B>Acknowledgments</B> This study is funded by the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases.
CR Anastasiou C, 2022, CURR OPIN RHEUMATOL, V34, P95, DOI 10.1097/BOR.0000000000000868
   Baser O, 2023, J HEALTH ECON OUTCOM, V10, P44, DOI [10.36469/001c.87538, 10.36469/jheor.2023.87538]
   Birt JA, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/lupus 2020 000435
   Borenstein D, 2010, ARTHRIT CARE RES, V62, P590, DOI 10.1002/acr.20005
   Borenstein David G, 2017, Clin Exp Rheumatol, V35 Suppl 107, P2
   Carsons SE, 2017, ARTHRIT CARE RES, V69, P517, DOI 10.1002/acr.22968
   Chen SK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 027495
   Cuzdan N, 2018, CLIN RHEUMATOL, V37, P1845, DOI 10.1007/s10067 018 4107 1
   Dau JD, 2018, J RHEUMATOL, V45, P188, DOI 10.3899/jrheum.170630
   Desquilbet L, 2010, STAT MED, V29, P1037, DOI 10.1002/sim.3841
   Di Franco M, 2015, BEST PRACT RES CL RH, V29, P53, DOI 10.1016/j.berh.2015.05.006
   Dowell D, 2016, JAMA J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Drug Enforcement Administration Department of Justice, 2014, Fed Regist, V79, P49661
   England BR, 2017, ARTHRITIS RHEUMATOL, V69, P2351, DOI 10.1002/art.40236
   Evers C, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02421 1
   Falasinnu T, 2022, ACR OPEN RHEUMATOL, V4, P890, DOI 10.1002/acr2.11488
   Figueroa Parra G, 2023, J RHEUMATOL, V50, P504, DOI 10.3899/jrheum.220822
   Frank JW, 2019, PAIN MED, V20, P869, DOI 10.1093/pm/pny149
   Giuggioli D, 2010, PAIN MED, V11, P1500, DOI 10.1111/j.1526 4637.2010.00849.x
   Guseva N. G., 1994, Terapevticheskii Arkhiv, V66, P20
   Lee YC, 2019, ARTHRITIS RHEUMATOL, V71, P670, DOI 10.1002/art.40789
   Ludwig CA, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 35520 x
   McGinty EE, 2023, ANN INTERN MED, V176, P904, DOI 10.7326/M23 0053
   Pauly NJ, 2020, J MANAG CARE SPEC PH, V26, P246, DOI 10.18553/jmcp.2020.26.3.246
   Seago S, 2016, J INVEST MED, V64, P543, DOI 10.1136/jim 2015 000035.137
   Somers EC, 2019, MMWR MORBID MORTAL W, V68, P819, DOI 10.15585/mmwr.mm6838a2
   Sood A, 2023, JCR J CLIN RHEUMATOL, V29, P262, DOI 10.1097/RHU.0000000000001972
   Soprano SE, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7664
   Taylor MT, 2021, BRIT J DERMATOL, V185, P200, DOI 10.1111/bjd.19865
   Tharp AM, 2019, J FORENSIC SCI, V64, P1105, DOI 10.1111/1556 4029.14021
NR 30
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665 9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD AUG
PY 2024
VL 6
IS 8
BP e518
EP e527
DI 10.1016/S2665 9913(24)00120 6
EA JUL 2024
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA ZX0H5
UT WOS:001278462200001
PM 38945137
OA Bronze
DA 2025 08 17
ER

PT J
AU Maver, U
   Xhanari, K
   Zizek, M
   Korte, D
   Gradisnik, L
   Franko, M
   Finsgar, M
AF Maver, Uros
   Xhanari, Klodian
   Zizek, Marko
   Korte, Dorota
   Gradisnik, Lidija
   Franko, Mladen
   Finsgar, Matjaz
TI A combination of interdisciplinary analytical tools for evaluation of
   multi layered coatings on medical grade stainless steel for biomedical
   applications
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Multi layered coatings; Biomedical application; Drug release; Thermal
   diffusivity and conductivity analysis; Photothermal beam deflection
   spectroscopy; Electrochemical impedance spectroscopy; AFM; ATR FTIR;
   Biocompatibility; Method validation
ID SCANNING ELECTRON MICROSCOPY; WOUND DRESSING MATERIALS; DRUG RELEASE;
   IN VITRO; SURFACE MODIFICATION; COLORIMETRIC ASSAY; BIOCOMPATIBILITY;
   IMPLANTS; SILICA; HYDROXYAPATITE
AB In this comprehensive study several analytical techniques were used in order to evaluate multi layered biomedical surface coatings composed of a drug (diclofenac) and a polymer (chitosan). Such a thorough examination is of paramount importance in order to assure safety and prove efficiency of potential biomedical materials already at the in vitro level, hence leading to their potentially faster introduction to clinical trials.
   For the first time a novel technique based on thermal diffusivity and conductivity measurements (photothermal beam deflection spectroscopy   BDS) was employed in order to analyse in a non destructive way the thickness of respective layers, together with their thermal diffusivity and conductivity. In addition to attenuated total reflection Fourier transform infrared spectroscopy (ATR FTIR), BDS confirmed successive surface layers of the prepared coatings. Scanning electron microscopy and atomic force microscopy were used to examine structural information on the macro  and micro/nano scale, respectively. Surface hydrophobicity was measured with the contact angle analysis, which clearly showed differences in hydrophobicity between coated and noncoated samples. Considering the targeted application of the prepared coatings (as implant in orthopaedic treatments), the in vitro drug release was analysed spectrophotometrically to examine the coatings potential for a controlled drug release. Furthermore, the material was also tested by electrochemical impedance spectroscopy and cyclic polarisation techniques, which were able to detect even minor differences between the performance of the coated and non coated materials. As the final test, the biocompatibility of the coatings with human osteoblasts was determined.
C1 [Maver, Uros; Gradisnik, Lidija] Univ Maribor, Fac Med, Inst Biomed Sci, Taborska Ul 8, SI 2000 Maribor, Slovenia.
   [Maver, Uros] Univ Maribor, Fac Med, Dept Pharmacol, Taborska Ul 8, SI 2000 Maribor, Slovenia.
   [Xhanari, Klodian; Zizek, Marko; Finsgar, Matjaz] Univ Maribor, Fac Chem & Chem Engn, Lab Analyt Chem & Ind Anal, Smetanova Ul 17, SI 2000 Maribor, Slovenia.
   [Xhanari, Klodian] Univ Tirana, Fac Nat Sci, Blvd Zogu I, AL 1001 Tirana, Albania.
   [Korte, Dorota; Franko, Mladen] Univ Nova Gorica, Lab Environm & Life Sci, Vipavska 13, SI 5001 Nova Gorica, Slovenia.
C3 University of Maribor; University of Maribor; University of Maribor;
   University of Tirana (UT); University of Nova Gorica
RP Maver, U (通讯作者)，Univ Maribor, Fac Med, Inst Biomed Sci, Taborska Ul 8, SI 2000 Maribor, Slovenia.; Finsgar, M (通讯作者)，Univ Maribor, Fac Chem & Chem Engn, Lab Analyt Chem & Ind Anal, Smetanova Ul 17, SI 2000 Maribor, Slovenia.
EM uros.maver@um.si; matjaz.finsgar@um.si
RI Maver, Uroš/D 8796 2012; Xhanari, Klodian/AAO 2150 2021; Finsgar,
   Matjaz/ISU 9511 2023; Maver, Uros/D 8796 2012; Franko,
   Mladen/AFZ 8241 2022
OI Korte, Dorota/0000 0002 5437 4564; Xhanari, Klodian/0000 0003 4223 9530;
   Maver, Uros/0000 0002 2237 3786; Zizek, Marko/0000 0002 2800 2089
FU Slovenian Research Agency [P1 0034, P3 0036, P2 0032]
FX The authors would like to acknowledge the financial support for this
   project received from the Slovenian Research Agency (grant numbers:
   P1 0034, P3 0036 and P2 0032).
CR Aguzzi C, 2010, MATER TECHNOL, V25, P205, DOI 10.1179/175355510X12723642365566
   [Anonymous], UHLIG CORROSION HDB
   Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975 1483.66810
   Balla V. K., 2017, J BIOMED MAT RES B
   Balla VK, 2013, MAT SCI ENG C MATER, V33, P4594, DOI 10.1016/j.msec.2013.07.015
   Ballarre J, 2010, ACTA BIOMATER, V6, P1601, DOI 10.1016/j.actbio.2009.10.015
   Banaszkiewicz P. A., 2014, CLASSIC PAPERS ORTHO, P61
   Buhagiar J, 2012, J MATER SCI MATER M, V23, P271, DOI 10.1007/s10856 011 4516 z
   Delfour MC, 2012, ACTA APPL MATH, V118, P161, DOI 10.1007/s10440 012 9683 5
   Engel JB, 2017, INT J FOOD MICROBIOL, V252, P18, DOI 10.1016/j.ijfoodmicro.2017.04.003
   FERRARI M, 1990, J IMMUNOL METHODS, V131, P165, DOI 10.1016/0022 1759(90)90187 Z
   Finsgar M, 2015, MATER CORROS, V66, P1299, DOI 10.1002/maco.201408222
   Finsgar M, 2016, CORROS SCI, V111, P370, DOI 10.1016/j.corsci.2016.05.028
   Finsgar M, 2016, SCI REP UK, V6, DOI 10.1038/srep26653
   Finsgar M, 2014, CORROS SCI, V83, P164, DOI 10.1016/j.corsci.2014.02.016
   Finsgar M, 2014, CORROS SCI, V80, P82, DOI 10.1016/j.corsci.2013.11.022
   Finsgar M, 2013, CORROS SCI, V72, P82, DOI 10.1016/j.corsci.2013.03.011
   Finsgar M, 2013, CORROS SCI, V68, P51, DOI 10.1016/j.corsci.2012.10.032
   Finsgar M, 2010, CORROS SCI, V52, P2430, DOI 10.1016/j.corsci.2010.04.001
   Gasparic P, 2017, CARBOHYD POLYM, V177, P388, DOI 10.1016/j.carbpol.2017.08.111
   Godec A, 2007, INT J PHARMACEUT, V343, P131, DOI 10.1016/j.ijpharm.2007.05.022
   Gui WY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00204 w
   Horcas I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2432410
   Horvat G, 2017, CARBOHYD POLYM, V166, P365, DOI 10.1016/j.carbpol.2017.03.008
   Iso I., 2009, 1099352009 ISO
   Jargelius Pettersson RFA, 1998, J ELECTROCHEM SOC, V145, P1462, DOI 10.1149/1.1838505
   Kang HK, 2016, EUR J ORTHODONT, V38, P154, DOI 10.1093/ejo/cjv017
   Kato K, 2013, MAT SCI ENG C MATER, V33, P2736, DOI 10.1016/j.msec.2013.02.038
   KORSMEYER RW, 1983, J PHARM SCI US, V72, P1189, DOI 10.1002/jps.2600721021
   Korte D, 2016, LASER PHYS LETT, V13, DOI 10.1088/1612 2011/13/12/125701
   Korte D, 2015, INT J THERMOPHYS, V36, P2462, DOI 10.1007/s10765 015 1923 2
   Lehmann DM, 2010, TOXICOL IN VITRO, V24, P1306, DOI 10.1016/j.tiv.2010.02.018
   Li MH, 2017, MAT SCI ENG C MATER, V73, P198, DOI 10.1016/j.msec.2016.12.070
   Li MH, 2014, MAT SCI ENG C MATER, V43, P641, DOI 10.1016/j.msec.2014.06.038
   Li WJ, 2015, BIOMED REP, V3, P617, DOI 10.3892/br.2015.481
   Li XM, 2016, J BIOMED MATER RES A, V104, P2117, DOI 10.1002/jbm.a.35743
   Looney M., 2017, REGULATORY ASPECTS B, P181
   Madl AK, 2015, NANOMED NANOTECHNOL, V11, P1285, DOI 10.1016/j.nano.2015.02.006
   Madl AK, 2015, NANOMED NANOTECHNOL, V11, P1201, DOI 10.1016/j.nano.2014.12.005
   Manero JM, 2003, MICROSC RES TECHNIQ, V61, P469, DOI 10.1002/jemt.10358
   MANSFELD F, 1981, CORROSION, V37, P545, DOI 10.5006/1.3580804
   Mansur HS, 2013, J MATER CHEM B, V1, P1696, DOI 10.1039/c3tb00498h
   Martínez Carmona M, 2016, MICROPOR MESOPOR MAT, V225, P399, DOI 10.1016/j.micromeso.2016.01.019
   Massart D. L., HDB CHEMOMETRICS Q A
   Maver T, 2017, INT J PHARMACEUT, V529, P576, DOI 10.1016/j.ijpharm.2017.07.043
   Maver T, 2015, RSC ADV, V5, P77873, DOI 10.1039/c5ra11972c
   Maver T, 2015, CELLULOSE, V22, P749, DOI 10.1007/s10570 014 0515 9
   Maver U, 2013, MATER RES BULL, V48, P137, DOI 10.1016/j.materresbull.2012.10.021
   Maver U, 2007, INT J PHARMACEUT, V330, P164, DOI 10.1016/j.ijpharm.2006.09.024
   Maver U, 2016, TRAC TREND ANAL CHEM, V80, P96, DOI 10.1016/j.trac.2016.03.014
   Merl DK, 2013, CORROS SCI, V69, P359, DOI 10.1016/j.corsci.2013.01.002
   Miswan Z, 2016, INT J PHARMACEUT, V515, P460, DOI 10.1016/j.ijpharm.2016.10.056
   Mohan T, 2014, COLLOID SURFACE B, V123, P533, DOI 10.1016/j.colsurfb.2014.09.053
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nadrah P, 2013, ACS APPL MATER INTER, V5, P3908, DOI 10.1021/am400604d
   Pabst AM, 2017, BRIT J ORAL MAX SURG, V55, P736, DOI 10.1016/j.bjoms.2017.05.010
   PEPPAS NA, 1983, J BIOMED MATER RES, V17, P1079, DOI 10.1002/jbm.820170615
   Raistrick ID, 2005, IMPEDANCE SPECTROSCOPY: THEORY, EXPERIMENT, AND APPLICATIONS, 2ND EDITION, P27, DOI 10.1002/0471716243.ch2
   Reeve L, 2017, EXPERT REV MED DEVIC, V14, P161, DOI 10.1080/17434440.2017.1280392
   Rozman KZ, 2012, MATER CHEM PHYS, V133, P218, DOI 10.1016/j.matchemphys.2012.01.013
   Salahinejad E, 2013, J BIOMED NANOTECHNOL, V9, P1327, DOI 10.1166/jbn.2013.1619
   Talha M, 2013, MAT SCI ENG C MATER, V33, P3563, DOI 10.1016/j.msec.2013.06.002
   Ukmar T, 2011, J CONTROL RELEASE, V155, P409, DOI 10.1016/j.jconrel.2011.06.038
   Ukmar T, 2012, J MATER CHEM, V22, P1112, DOI 10.1039/c1jm13493k
   Vaid S., 2016, TYPES PROSTHETIC HIP
   VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022 1759(94)90034 5
   Velnar T, 2016, GLOBAL SPINE J, V06
   Yang K, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014105
   Yin C, 2011, INT J PHARMACEUT, V418, P78, DOI 10.1016/j.ijpharm.2010.12.009
NR 69
TC 31
Z9 31
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939 6411
EI 1873 3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD JUL
PY 2018
VL 128
BP 230
EP 246
DI 10.1016/j.ejpb.2018.05.002
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GK7KJ
UT WOS:000436382800023
PM 29730258
DA 2025 08 17
ER

PT J
AU Inoue, A
   Takahashi, KA
   Mazda, O
   Arai, Y
   Saito, M
   Kishida, T
   Shin Ya, M
   Morihara, T
   Tonomura, H
   Sakao, K
   Imanishi, J
   Kubo, T
AF Inoue, Atsuo
   Takahashi, Kenji A.
   Mazda, Osam
   Arai, Yuji
   Saito, Masazumi
   Kishida, Tsunao
   Shin Ya, Masaharu
   Morihara, Toru
   Tonomura, Hitoshi
   Sakao, Kei
   Imanishi, Jiro
   Kubo, Toshikazu
TI Comparison of anti rheumatic effects of local RNAi based therapy in
   collagen induced arthritis rats using various cytokine genes as
   molecular targets
SO MODERN RHEUMATOLOGY
LA English
DT Article
DE Collagen induced arthritis; Cytokines; Electroporation; Small
   interfering RNA
ID TUMOR NECROSIS FACTOR; SMALL INTERFERING RNA; AMELIORATES JOINT DISEASE;
   RHEUMATOID ARTHRITIS; FACTOR ALPHA; GROWTH FACTOR; II COLLAGEN; IN VIVO;
   OSTEOCLAST DIFFERENTIATION; TNF ALPHA
AB RNA interference (RNAi) provides a powerful means of sequence specific gene silencing. Several studies show that RNAi may provide promising strategies to treat human diseases by suppressing disease responsible genes in vivo. In locomotor diseases, the progression of collagen induced arthritis (CIA) is suppressed by tumor necrosis factor alpha (TNF alpha) specific small interfering RNA (siRNA) delivered into the joint. The aim of this study, is to compare the effects of intraarticularly administered siRNAs targeting TNF alpha, interleukin 1 beta (IL 1 beta), interleukin 6 (IL 6) and receptor activator of NF kappa B ligand (RANKL) on CIA in rats. We confirmed that the silencing effects of siRNA duplexes specific for rat TNF alpha, IL 1 beta, IL 6 and RANKL in vitro. Each siRNA was also delivered into the knee joint of CIA rats by the in vivo electroporation method 7, 10, 13 and 16 days after immunization with collagen. Local delivery of TNF alpha or IL 1 beta specific siRNA ameliorated CIA in rats effectively at the gross morphological, radiographical and histological evaluations. Our results suggested that TNF alpha and IL 1 beta were the cytokines to be targeted in the joint for the treatment of rheumatoid arthritis. The in vivo siRNA transfection method may be useful for selection of target molecules to be silenced for treatment of joint diseases.
C1 [Inoue, Atsuo; Takahashi, Kenji A.; Arai, Yuji; Saito, Masazumi; Morihara, Toru; Tonomura, Hitoshi; Sakao, Kei; Kubo, Toshikazu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, Kyoto 6028566, Japan.
   [Mazda, Osam; Kishida, Tsunao; Shin Ya, Masaharu; Imanishi, Jiro] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Microbiol, Kamigyo Ku, Kyoto 6028566, Japan.
   [Inoue, Atsuo] Kyoto First Red Cross Hosp, Dept Orthopaed, Kyoto 6050981, Japan.
   [Kishida, Tsunao] Louis Pasteur Ctr Med Res, Kyoto 6068225, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine
RP Takahashi, KA (通讯作者)，Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.
EM kenji am@koto.kpu m.ac.jp
OI Tonomura, Hitoshi/0000 0003 2995 9488
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [17791010]; Hip Joint Foundation of Japan, Inc; Grants in Aid for
   Scientific Research [17791010] Funding Source: KAKEN
FX This study was supported by a Grant in Aid for Scientific Research (No.
   17791010) from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan and Hip Joint Foundation of Japan, Inc.
CR Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008 5472.CAN 04 0961
   Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bakharevski O, 1998, J RHEUMATOL, V25, P1945
   BALCH HW, 1977, RHEUMATOL REHABIL, V16, P137, DOI 10.1093/rheumatology/16.3.137
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Bokarewa M, 2003, ANN RHEUM DIS, V62, P783, DOI 10.1136/ard.62.8.783
   BRENNAN FM, 1989, LANCET, V2, P244
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Choy EHS, 2002, ARTHRITIS RHEUM US, V46, P3143, DOI 10.1002/art.10623
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Conti F, 2005, ARTHRITIS RHEUM US, V52, P1224, DOI 10.1002/art.20979
   Cuzzocrea S, 2003, ARTHRITIS RHEUM US, V48, P3544, DOI 10.1002/art.11351
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fujisawa K, 1996, ARTHRITIS RHEUM US, V39, P197, DOI 10.1002/art.1780390205
   Ikeda T, 1998, J RHEUMATOL, V25, P1666
   Inoue A, 2006, ARTHRITIS RHEUM US, V54, P264, DOI 10.1002/art.21561
   Inoue A, 2005, BIOCHEM BIOPH RES CO, V336, P903, DOI 10.1016/j.bbrc.2005.08.198
   JOOSTEN LAB, 1994, CLIN EXP IMMUNOL, V97, P204
   Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513
   Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   Kishida T, 2004, J GENE MED, V6, P105, DOI 10.1002/jgm.456
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kushibiki T, 2005, J CONTROL RELEASE, V105, P318, DOI 10.1016/j.jconrel.2005.02.030
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   Nakamura H, 2004, MOL VIS, V10, P703
   Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578
   Ohashi S, 2002, BIOCHEM BIOPH RES CO, V293, P1530, DOI 10.1016/S0006 291X(02)00386 8
   Ragab AA, 2002, AM J PHYSIOL CELL PH, V283, pC679, DOI 10.1152/ajpcell.00421.2001
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Saito M, 2007, J ORTHOP RES, V25, P1308, DOI 10.1002/jor.20392
   Schett G, 2005, ARTHRITIS RHEUM US, V52, P1604, DOI 10.1002/art.21021
   Schiffelers RM, 2005, ARTHRITIS RHEUM, V52, P1314, DOI 10.1002/art.20975
   Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828
   Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529 0131(199812)41:12<2117::AID ART6>3.3.CO;2 G
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008 5472.CAN 03 2682
   Thakker DR, 2004, P NATL ACAD SCI USA, V101, P17270, DOI 10.1073/pnas.0406214101
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Weinberger A, 2003, ARTHRITIS RHEUM US, V48, P846, DOI 10.1002/art.10850
   Wesche DE, 2005, J LEUKOCYTE BIOL, V78, P325, DOI 10.1189/jlb.0105017
   WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784
   Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076
   Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 48
TC 19
Z9 22
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1439 7595
EI 1439 7609
J9 MOD RHEUMATOL
JI Mod. Rheumatol.
PD APR
PY 2009
VL 19
IS 2
BP 125
EP 133
DI 10.1007/s10165 008 0131 3
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 428KX
UT WOS:000264847800003
PM 19030778
DA 2025 08 17
ER

PT J
AU Aft, R
   Naughton, M
   Trinkaus, K
   Watson, M
   Ylagan, L
   Chavez MacGregor, M
   Zhai, J
   Kuo, S
   Shannon, W
   Diemer, K
   Herrmann, V
   Dietz, J
   Ali, A
   Ellis, M
   Weiss, P
   Eberlein, T
   Ma, C
   Fracasso, PM
   Zoberi, I
   Taylor, M
   Gillanders, W
   Pluard, T
   Mortimer, J
   Weilbaecher, K
AF Aft, Rebecca
   Naughton, Michael
   Trinkaus, Kathryn
   Watson, Mark
   Ylagan, Lourdes
   Chavez MacGregor, Mariana
   Zhai, Jing
   Kuo, Socha
   Shannon, William
   Diemer, Kathryn
   Herrmann, Virginia
   Dietz, Jill
   Ali, Amjad
   Ellis, Matthew
   Weiss, Peter
   Eberlein, Timothy
   Ma, Cynthia
   Fracasso, Paula M.
   Zoberi, Imran
   Taylor, Marie
   Gillanders, William
   Pluard, Timothy
   Mortimer, Joanne
   Weilbaecher, Katherine
TI Effect of zoledronic acid on disseminated tumour cells in women with
   locally advanced breast cancer: an open label, randomised, phase 2 trial
SO LANCET ONCOLOGY
LA English
DT Article
ID ADJUVANT ENDOCRINE THERAPY; PREVENTS BONE LOSS; POSTMENOPAUSAL WOMEN;
   PREMENOPAUSAL WOMEN; FOLLOW UP; CHEMOTHERAPY; METASTASES; MARROW;
   BISPHOSPHONATE; MECHANISMS
AB Background Treatment with bisphosphonates decreases bone loss and can increase disease free survival in patients with breast cancer. The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer.
   Methods Patients were recruited for this open label, phase 2 randomised trial between March 17, 2003, and May 19, 2006, at a single centre. Eligible patients had clinical stage II III (>= T2 and/or >= N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function. 120 women were randomly assigned, using allocation concealment, to receive 4 mg zoledronic acid intravenously every 3 weeks (n=60), or no zoledronic acid (n=60), for 1 year concomitant with four cycles of neoadjuvant epirubicin (75 mg/m(2)) plus docetaxel (75 mg/m(2)) and two cycles of adjuvant epirubicin plus docetaxel. The primary endpoint was the number of patients with detectable DTCs at 3 months. Final analysis was done 1 year after the last patient was enrolled. Analyses were done for all patients with available data at 3 months. This study is registered with ClinicalTrials.gov, number NCT00242203.
   Findings Of the 120 patients initially enrolled, one withdrew after signing consent and one patient's baseline bone marrow was not available. Both of these patients were in the control group. At 3 months, 109 bone marrow samples were available for analysis. In the zoledronic acid group, bone marrow was not collected from one patient because of disease progression, one patient was taken off study because of severe diarrhoea, and two patients had not consented at the time of surgery. In the control group, bone marrow was not collected from two patients because of disease progression, one patient withdrew consent, and three patients were not consented at the time of surgery. At baseline, DTCs were detected in 26 of 60 patients in the zoledronic acid group and 28 of 58 patients in the control group. At 3 months, 17 of 56 patients receiving zoledronic acid versus 25 of 53 patients who did not receive zoledronic acid had detectable DTCs (p=0.054). The most common grade 3 4 toxicities were infection (five of 60 patients in the zoledronic acid group and six of 59 in the control group) and thrombosis (five of 60 in the zoledronic acid and two of 59 in the control group). There was one documented case of osteonecrosis in the zoledronic acid group.
   Interpretation Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery. Our study supports the hypothesis that the antimetastatic effects of zoledronic acid may be through effects on DTCs.
C1 [Aft, Rebecca; Kuo, Socha; Herrmann, Virginia; Dietz, Jill; Eberlein, Timothy; Gillanders, William] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Naughton, Michael; Trinkaus, Kathryn; Chavez MacGregor, Mariana; Shannon, William; Diemer, Kathryn; Ali, Amjad; Ellis, Matthew; Weiss, Peter; Ma, Cynthia; Fracasso, Paula M.; Pluard, Timothy; Weilbaecher, Katherine] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
   [Aft, Rebecca; Naughton, Michael; Watson, Mark; Ylagan, Lourdes; Zhai, Jing; Ellis, Matthew; Eberlein, Timothy; Ma, Cynthia; Fracasso, Paula M.; Zoberi, Imran; Taylor, Marie; Gillanders, William; Pluard, Timothy; Weilbaecher, Katherine] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA.
   [Watson, Mark; Ylagan, Lourdes] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Trinkaus, Kathryn; Shannon, William] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA.
   [Zoberi, Imran; Taylor, Marie] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA.
   [Aft, Rebecca] Cochran Vet Adm Hosp, St Louis, MO USA.
   [Chavez MacGregor, Mariana] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA.
   [Herrmann, Virginia] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
   [Dietz, Jill] Cleveland Clin, Dept Surg, OB Gyn & Womens Hlth Inst, Cleveland, OH 44106 USA.
   [Fracasso, Paula M.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA.
   [Mortimer, Joanne] City Hope Comprehens Canc Ctr, Div Med Oncol & Expt Therapeut, Duarte, CA USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Siteman Cancer Center; Washington University
   (WUSTL); Washington University (WUSTL); Washington University (WUSTL);
   University of Texas System; UTMD Anderson Cancer Center; Medical
   University of South Carolina; Cleveland Clinic Foundation; University of
   Virginia; City of Hope
RP Aft, R (通讯作者)，Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave, St Louis, MO 63110 USA.
EM aftr@wustl.edu
RI Gregor, Mariana/AAL 1455 2020; Dietz, Jill/AAN 1276 2021
OI Mortimer, Joanne/0000 0002 2935 1934; Chavez Mac Gregor,
   Mariana/0000 0002 7189 0763
FU Novartis Pharmaceuticals; Pfizer Inc
FX Funding Novartis Pharmaceuticals and Pfizer Inc.
CR [Anonymous], CANC RES
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Braun S, 2000, J CLIN ONCOL, V18, P80, DOI 10.1200/JCO.2000.18.1.80
   Brufsky A, 2008, ONCOLOGIST, V13, P503, DOI 10.1634/theoncologist.2007 0206
   Brufsky A, 2007, J CLIN ONCOL, V25, P829, DOI 10.1200/JCO.2005.05.3744
   BRUGGER W, 1994, BLOOD, V83, P636
   Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   COLEMAN R, 2009, CANC RES S, V70, P4082
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   El Hajj Fuleihan G, 2005, J CLIN ENDOCR METAB, V90, P3209, DOI 10.1210/jc.2004 1444
   Fehm T, 2006, CANCER AM CANCER SOC, V107, P885, DOI 10.1002/cncr.22076
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gnant MFX, 2007, J CLIN ONCOL, V25, P820, DOI 10.1200/JCO.2005.02.7102
   Greenspan SL, 2008, J CLIN ONCOL, V26, P2644, DOI 10.1200/JCO.2007.15.2967
   Greep NC, 2003, AM J MED, V114, P653, DOI 10.1016/S0002 9343(03)00127 X
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hershman DL, 2008, J CLIN ONCOL, V26, P4739, DOI 10.1200/JCO.2008.16.4707
   Hirbe A, 2006, CLIN CANCER RES, V12, p6309S, DOI 10.1158/1078 0432.CCR 06 0652
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kunzmann V, 2000, BLOOD, V96, P384
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Nagy Z, 2005, PATHOL ONCOL RES, V11, P186, DOI 10.1007/BF02893400
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Rack B, 2008, DEUT MED WOCHENSCHR, V133, P285, DOI 10.1055/s 2008 1046707
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Saad Fred, 2005, Future Oncol, V1, P149, DOI 10.1517/14796694.1.2.149
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   SHPALL EJ, 1994, BLOOD, V83, P623
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   Winter S, 2009, CANCER RES, V69
NR 40
TC 235
Z9 246
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1470 2045
EI 1474 5488
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAY
PY 2010
VL 11
IS 5
BP 421
EP 428
DI 10.1016/S1470 2045(10)70054 1
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 607DL
UT WOS:000278478800017
PM 20362507
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, C
   Li, XM
   Dang, HX
   Liu, P
   Zhang, B
   Xu, F
AF Wang, Chao
   Li, Xiaoming
   Dang, Hongxing
   Liu, Ping
   Zhang, Bo
   Xu, Feng
TI Insulin like growth factor 2 regulates the proliferation and
   differentiation of rat adipose derived stromal cells via IGF 1R and IR
SO CYTOTHERAPY
LA English
DT Article
DE adipose derived stromal cells (ADSCs); insulin like growth factor 2
   (IGF2); multipotency; stem cell therapy
ID FACTOR II; STEM CELLS; INTERNATIONAL SOCIETY; RECEPTOR ISOFORMS; FETAL;
   MECHANISMS; IDENTIFICATION; PLURIPOTENCY; MAINTENANCE; ACTIVATION
AB Background: Insulin like growth factor 2 (IGF2), an essential component of the stem cell niche, has been reported to modulate the proliferation and differentiation of stem cells. Previously, a continuous expression of IGF2 in tissues was reported to maintain the self renewal ability of several types of stem cells. Therefore, in this study, we investigated the expression of IGF2 in adipose tissues and explored the effects of IGF2 on adipose derived stromal cells (ADSCs) in vitro. Methods: The expression pattern of IGF2 in rat adipose tissues was determined by gene expression and protein analyses. The effect of IGF2 on proliferation, stemness related marker expression and adipogenic and osteogenic differentiation was systematically investigated. Furthermore, antagonists of IGF2 specific receptors namely, BMS 754807 and picropodophyllin were added to explore the underlying signal transduction mechanisms. Results: IGF2 levels displayed a tendency to decrease with age in rat adipose tissues. After the addition of IGF2, isolated ADSCs displayed higher proliferation and expression of the stemness related markers NANOG, OCT4 and SOX2 and greater differentiation potential to adipocytes and osteoblasts. Additionally, both type 1 insulin like growth factor receptor (IGF 1R) and insulin receptor (IR) participated in the IGF2 mediated promotion of stemness in ADSCs. Conclusions: Our findings indicate that IGF2 could enhance the stemness of rat ADSCs via IGF 1R and IR and may highlight an effective method for the expansion of ADSCs for clinical application.
C1 [Wang, Chao; Dang, Hongxing; Xu, Feng] Chongqing Med Univ, Childrens Hosp, Minist Educ, Key Lab Child Dev & Disorders,Dept PICU, 136 Zhongshan 2 Rd, Chongqing 400014, Peoples R China.
   [Wang, Chao; Dang, Hongxing; Xu, Feng] China Int Sci & Technol Cooperat Base Child Dev &, Chongqing 400014, Peoples R China.
   [Wang, Chao; Dang, Hongxing; Xu, Feng] Chongqing Med Univ, Childrens Hosp, Chongqing Engn Res Ctr Stem Cell Therapy, Chongqing, Peoples R China.
   [Li, Xiaoming; Liu, Ping; Zhang, Bo] Army Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Chongqing 400042, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Army Medical
   University
RP Xu, F (通讯作者)，Chongqing Med Univ, Childrens Hosp, Minist Educ, Key Lab Child Dev & Disorders,Dept PICU, 136 Zhongshan 2 Rd, Chongqing 400014, Peoples R China.
EM xufeng9899@163.com
FU National Program on Key Basic Research Project of China [2011CB964701]
FX This work was supported by the National Program on Key Basic Research
   Project of China (2011CB964701).
CR Avnet S, 2012, DIFFERENTIATION, V83, P242, DOI 10.1016/j.diff.2012.02.002
   Bacakova L, 2018, BIOTECHNOL ADV, V36, P1111, DOI 10.1016/j.biotechadv.2018.03.011
   Bäck K, 2011, MOL CELL ENDOCRINOL, V339, P130, DOI 10.1016/j.mce.2011.04.005
   Barreto S, 2017, ACTA BIOMATER, V53, P59, DOI 10.1016/j.actbio.2017.02.031
   Baxter RC, 2009, TRENDS ENDOCRIN MET, V20, P499, DOI 10.1016/j.tem.2009.07.002
   Belfiore A, 2017, ENDOCR REV, V38, P379, DOI 10.1210/er.2017 00073
   Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   BROWN AL, 1986, J BIOL CHEM, V261, P3144
   Bunpetch V, 2017, STEM CELLS DEV, V26, P1662, DOI 10.1089/scd.2017.0104
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fan J, 2016, STEM CELLS, V34, P1615, DOI 10.1002/stem.2305
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   Han H, 2017, INT J MOL SCI, V18
   Han SM, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.28
   HONEGGER A, 1986, J BIOL CHEM, V261, P569
   Jia D, 2000, BONE, V27, P785, DOI 10.1016/S8756 3282(00)00400 2
   Lee CCI, 2006, STEM CELLS DEV, V15, P209, DOI 10.1089/scd.2006.15.209
   Li ZW, 2012, CELL STEM CELL, V10, P171, DOI 10.1016/j.stem.2011.12.016
   Lynch K, 2014, ORGANOGENESIS, V10, P289, DOI 10.4161/15476278.2014.970089
   Maredziak M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2152435
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Motoike T, 1999, J NEUROSCI RES, V56, P386, DOI 10.1002/(SICI)1097 4547(19990515)56:4<386::AID JNR6>3.3.CO;2 4
   Nahum N, 2017, IUBMB LIFE, V69, P489, DOI 10.1002/iub.1626
   Oh J, 2014, NAT MED, V20, P870, DOI 10.1038/nm.3651
   Qiu Q, 2007, ENDOCRINOLOGY, V148, P4803, DOI 10.1210/en.2007 0535
   Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17 0129
   Schilling T, 2007, J Stem Cells Regen Med, V2, P41
   SULLIVAN KA, 1994, ENDOCRINOLOGY, V135, P540, DOI 10.1210/en.135.2.540
   Tu CJ, 2018, J PROTEOME RES, V17, P2963, DOI 10.1021/acs.jproteome.8b00135
   Wang L, 2007, BLOOD, V110, P4111, DOI 10.1182/blood 2007 03 082586
   Wankhade UD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3206807
   Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307
   Yao C, 2016, STEM CELLS, V34, P820, DOI 10.1002/stem.2320
   Youssef A, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4576327
   Youssef A, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9453108
   Ziegler AN, 2015, NAT REV ENDOCRINOL, V11, P161, DOI 10.1038/nrendo.2014.208
   Ziegler AN, 2012, STEM CELLS, V30, P1265, DOI 10.1002/stem.1095
NR 39
TC 23
Z9 25
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD JUN
PY 2019
VL 21
IS 6
BP 619
EP 630
DI 10.1016/j.jcyt.2018.11.010
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA ID5EJ
UT WOS:000471699000006
PM 30956007
DA 2025 08 17
ER

PT J
AU Yang, SY
   Sun, JS
   Liu, CH
   Tsuang, YH
   Chen, LT
   Hong, CY
   Yang, HC
   Horng, HE
AF Yang, Shieh Yueh
   Sun, Jui Sheng
   Liu, Cheng Heng
   Tsuang, Yang Hwei
   Chen, Li Ting
   Hong, Chin Yih
   Yang, Hong Chang
   Horng, Herng Er
TI Ex vivo magnetofection with magnetic nanoparticles: A novel platform for
   nonviral tissue engineering
SO ARTIFICIAL ORGANS
LA English
DT Article
DE ex vivo; magnetofection; magnetic nanoparticles complex; liposome
ID TARGETING GENE DELIVERY; SUPERPARAMAGNETIC NANOPARTICLES;
   PHYSICOCHEMICAL CHARACTERISTICS; HIGHLY EFFICIENT; MAMMALIAN CELLS;
   CONTRAST AGENTS; IN VITRO; THERAPY; MUSCLE; VIRUS
AB Several methods have been described to introduce DNA expression vectors into mammalian cells both in vitro and in vivo. Each system has benefits and limitations, and to date there is still no ideal method for gene transfer. In this study, we introduced a novel method of gene transfer by using Fe3O4 nanoparticles. The magnetic nanoparticles composed of Fe3O4, and the transfected genes used are Lac Z and enhanced green fluorescence protein gene (EGFG). Four different groups of preparations included in this study were homemade liposome enveloped EGFP DNA/Fe3O4, homemade liposome EGFP DNA gene without magnetic Fe3O4 nanoparticles, lipofectamine 2000 enveloped EGFP DNA, and EGFP DNA gene only. Mice osteoblast and He99 lung cancer cell line were used as host cells for gene transfection. The time dependent EGFP gene expression was monitored and analyzed. The results showed that the diameter of the complex was less than 100 nm. There was no cytotoxicity observed at any of the magnetic Fe3O4 nanoparticle concentrations tested. In the presence of magnetic field, the liposome enveloped EGFP DNA/Fe3O4 complex exhibited a much higher efficiency for transfecting EGFP DNA into osteoblast cells under external magnetic fields. The gene can be transfected into cells with an aid of magnetic vectors and magnetic force. Under a gradient magnetic field, the efficiency of magnetofection is enhanced as compared to that without magnetic field.
C1 [Sun, Jui Sheng] Natl Yang Ming Univ, Sch Med Technol & Engn, Inst Biomed Engn, Taipei 11221, Taiwan.
   [Yang, Shieh Yueh; Liu, Cheng Heng; Horng, Herng Er] Natl Taiwan Normal Univ, Inst Electroopt Sci & Technol, Taipei, Taiwan.
   [Sun, Jui Sheng] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei, Taiwan.
   [Tsuang, Yang Hwei] Taipei City Hosp, Dept Orthoped Surg, Taipei, Taiwan.
   [Chen, Li Ting] Hlthbanks Biotechnol Corp Ltd, Dept Res & Dev, Taipei, Taiwan.
   [Hong, Chin Yih] Da Yeh Univ, Dept Mech & Automat Engn, Changhua, Taiwan.
   [Yang, Hong Chang] Natl Taiwan Univ, Dept Phys, Tainan, Taiwan.
C3 National Yang Ming Chiao Tung University; National Taiwan Normal
   University; National Taiwan University; National Taiwan University
   Hospital; Taipei City Hospital; Da Yeh University; National Taiwan
   University
RP Sun, JS (通讯作者)，Natl Yang Ming Univ, Sch Med Technol & Engn, Inst Biomed Engn, 155,Sec 2,Linong St,Beitou Dist, Taipei 11221, Taiwan.
EM jssun@ym.edu.tw
RI SUN, Jus Sheng/ITU 1253 2023; Hongchang Yang, Hongchang
   Yang/HSH 2714 2023; Lin, Lung chun/LHA 3783 2024
OI SUN, JUI SHENG/0000 0001 5142 8777
CR Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998 867
   Belletti B, 2005, CURR MED CHEM, V12, P1589, DOI 10.2174/0929867054367149
   Benns JM, 2000, J DRUG TARGET, V8, P1, DOI 10.3109/10611860009009205
   Berkowitz RD, 2001, VIROLOGY, V279, P116, DOI 10.1006/viro.2000.0659
   BLAESE RM, 1993, PATHOL BIOL, V41, P672
   Bonnemain B, 1998, J DRUG TARGET, V6, P167, DOI 10.3109/10611869808997890
   CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195 39
   CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   Eastman SJ, 1997, BBA BIOMEMBRANES, V1325, P41, DOI 10.1016/S0005 2736(96)00242 8
   FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042 6822(73)90341 3
   GUENZBURG WH, 1997, MOL MED TODAY, V1, P410
   Högemann D, 2002, BIOCONJUGATE CHEM, V13, P116, DOI 10.1021/bc015549h
   Huth S, 2004, J GENE MED, V6, P923, DOI 10.1002/jgm.577
   Jiang WQ, 2004, J MAGN MAGN MATER, V283, P210, DOI 10.1016/j.jmmm.2004.05.022
   Kielian T, 1999, NAT MED, V5, P1237, DOI 10.1038/15188
   Koropchak JA, 1999, ANAL CHEM, V71, p386A, DOI 10.1021/ac990442x
   KREUTER J, 1979, J PHARM SCI US, V68, P1443, DOI 10.1002/jps.2600681129
   Krötz F, 2003, MOL THER, V7, P700, DOI 10.1016/S1525 0016(03)00065 0
   Krötz F, 2003, J VASC RES, V40, P425, DOI 10.1159/000073901
   Lanza GM, 2002, CIRCULATION, V106, P2842, DOI 10.1161/01.CIR.0000044020.27990.32
   Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977
   LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005 2736(90)90017 I
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Mathiesen I, 1999, GENE THER, V6, P508, DOI 10.1038/sj.gt.3300847
   Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262
   Mitchell DG, 1997, J MAGN RESON IMAGING, V7, P1, DOI 10.1002/jmri.1880070102
   Muzyczka N, 2005, HUM GENE THER, V16, P408, DOI 10.1089/hum.2005.16.408
   NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6 649
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169 409X(02)00228 4
   Pardridge WM, 2003, METHOD ENZYMOL, V373, P507
   Petersein J, 1996, Magn Reson Imaging Clin N Am, V4, P53
   Plank C, 2003, J LIPOSOME RES, V13, P29, DOI 10.1081/LPR 120017486
   Plank C, 2003, EXPERT OPIN BIOL TH, V3, P745, DOI 10.1517/14712598.3.5.745
   Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082
   PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168 9525(00)89090 3
   Prow T, 2006, MOL VIS, V12, P606
   Robbins PD, 1998, PHARMACOL THERAPEUT, V80, P35, DOI 10.1016/S0163 7258(98)00020 5
   Sawai K, 1998, BIOCHEM BIOPH RES CO, V248, P315, DOI 10.1006/bbrc.1998.8922
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624
   THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742
   Tomlinson E, 1996, J CONTROL RELEASE, V39, P357, DOI 10.1016/0168 3659(95)00166 2
   Vijayanathan V, 2002, BIOCHEMISTRY US, V41, P14085, DOI 10.1021/bi0203987
   Violante M R, 1990, Acta Radiol Suppl, V374, P153
   Wang YXJ, 2001, EUR RADIOL, V11, P2319, DOI 10.1007/s003300100908
   Winter PM, 2003, CANCER RES, V63, P5838
   WONG TK, 1982, BIOCHEM BIOPH RES CO, V107, P584, DOI 10.1016/0006 291X(82)91531 5
   Yang Y, 1996, GENE THER, V3, P137
NR 51
TC 39
Z9 48
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0160 564X
EI 1525 1594
J9 ARTIF ORGANS
JI Artif. Organs
PD MAR
PY 2008
VL 32
IS 3
BP 195
EP 204
DI 10.1111/j.1525 1594.2007.00526.x
PG 10
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Transplantation
GA 268UN
UT WOS:000253605300004
PM 18201284
DA 2025 08 17
ER

PT J
AU Liang, JL
   Bonvino, NP
   Hung, A
   Karagiannis, TC
AF Liang, Julia
   Bonvino, Natalie P.
   Hung, Andrew
   Karagiannis, Tom C.
TI In silico characterisation of olive phenolic compounds as
   potential cyclooxygenase modulators. Part 2
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Cyclooxygenase; COX enzymes; Inflammation; Olive phenolics;
   Non steroidal anti inflammatory drugs; Phenolic compounds; Molecular
   docking; Molecular dynamics simulation
ID LOCAL FEATURE ANALYSIS; MOLECULAR DYNAMICS; CRYSTAL STRUCTURE;
   FORCE FIELD; STATISTICAL THEORY; RECOMMENDATIONS; OSTEOARTHRITIS;
   TRANSITIONS; MANAGEMENT; PROGRAM
AB Non steroidal anti inflammatory drugs (NSAIDs) are commonly used to reduce pain, and function by targeting cyclooxygenase (COX) enzymes to inhibit the production of prostaglandins that facilitate inflammation. Since oleocanthal derived from Olea europaea is known to inhibit COX, we sought to characterise novel olive compounds with COX inhibitory activity using in silico techniques. Following on from part 1 of this study which identified 1 oleyltyrosol (1OL) and ligstroside derivative 2 (LG2) with COX inhibitory potential, the mechanisms of COX interactions by these selected compounds were further examined using molecular dynamics (MD) simulations. Classical MD simulations were carried out on COX 1 and COX 2 complexed with 1OL and LG2 to determine the stability and protein backbone fluctuation. Protein dynamics were examined using essential dynamics methods and network analysis, which identified that the N terminal epidermal growth factor like domain and membrane bound domains of COX 1 and  2 exhibited altered motions when ligands were bound. Distinct dynamical modules were identified, and that COX 2 inter residue communications were more sensitive to ligand binding compared to COX 1. The use of various network metrics presents a novel approach in the characterisation of network behaviour of different ligands. It is proposed that inter residue network metrics provide additional measures of the potential bioactivity of ligands, which may form a useful adjunct to conventional direct predictions of binding affinity, in determining the efficacy of potential small molecule inhibitors. Overall, this two part study characterises anti inflammatory effects of low dosage dietary COX inhibitors, and provides a possible avenue for the development of therapeutics in inflammatory diseases. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Liang, Julia; Bonvino, Natalie P.] Monash Univ, Cent Clin Sch, Dept Diabet, Epigen Med, Melbourne, Vic 3004, Australia.
   [Liang, Julia; Bonvino, Natalie P.; Hung, Andrew; Karagiannis, Tom C.] RMIT Univ, Sch Sci, Melbourne, Vic 3001, Australia.
   [Karagiannis, Tom C.] Univ Melbourne, Dept Clin Pathol, Parkville, Vic 3052, Australia.
C3 Monash University; Royal Melbourne Institute of Technology (RMIT);
   University of Melbourne
RP Karagiannis, TC (通讯作者)，Monash Univ, Dept Diabet, Head Epigen Med Program, Cent Clin Sch, Melbourne, Vic 3004, Australia.
EM tom.karagiannis@monash.edu
RI ; Liang, Julia J/LKM 6635 2024; Liang, Julia/LKM 6635 2024
OI Karagiannis, Tom/0000 0002 9967 1546; Hung, Andrew/0000 0003 3569 2951;
   Liang, Julia J/0000 0002 3031 3169; 
FU McCord Research (Iowa, USA); Australian Government Research Training
   Program Scholarship; Australian Government
FX We would like to acknowledge intellectual and financial support by
   McCord Research (Iowa, USA). JL is supported by an Australian Government
   Research Training Program Scholarship. This research was undertaken with
   the assistance of resources and services from Melbourne Bioinformatics,
   the National Computational Infrastructure (NCI) and the Pawsey
   Supercomputing Centre, which are supported by the Australian Government.
   We acknowledge the Partnership for Advanced Computing in Europe (PRACE)
   for awarding us access to Piz Daint at CSCS, Switzerland.
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Allain A, 2014, FARADAY DISCUSS, V169, P303, DOI 10.1039/c4fd00024b
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   [Anonymous], 2000, Arthritis Rheumatism, V43, P1905
   [Anonymous], 2014, AMBER
   Balsera MA, 1996, J PHYS CHEM US, V100, P2567, DOI 10.1021/jp9536920
   Bastian M., 2009, Association for the Advancement of Artificial Intelligence
   Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010 4655(95)00042 E
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Bonvino NP, 2018, DATABASE OXFORD, DOI 10.1093/database/bay016
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959 440X(05)80111 3
   Caramia G, 2012, EUR J LIPID SCI TECH, V114, P375, DOI 10.1002/ejlt.201100164
   Chennubhotla C, 2007, PLOS COMPUT BIOL, V3, P1716, DOI 10.1371/journal.pcbi.0030172
   Conaghan PG, 2012, RHEUMATOL INT, V32, P1491, DOI 10.1007/s00296 011 2263 6
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Beauchene IC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003749
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s47, 10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15]
   GARAVITO RM, 1994, CURR OPIN STRUC BIOL, V4, P529, DOI 10.1016/S0959 440X(94)90215 1
   Garavito RM, 2002, PROSTAG OTH LIPID M, V68 9, P129
   Hennekens CH, 2002, AM J MANAG CARE, V8, pS691
   Hess B, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031910
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096 987X(199709)18:12<1463::AID JCC4>3.0.CO;2 H
   Hess B, 2000, PHYS REV E, V62, P8438, DOI 10.1103/PhysRevE.62.8438
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lucido MJ, 2016, BIOCHEMISTRY US, V55, P1226, DOI 10.1021/acs.biochem.5b01378
   Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196 927
   Page L., 1999, WEB C
   PARRINELLO M, 1982, J CHEM PHYS, V76, P2662, DOI 10.1063/1.443248
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010 4655(95)00041 D
   Penev PS, 1996, NETWORK COMP NEURAL, V7, P477, DOI 10.1088/0954 898X/7/3/002
   Pfaller MA, 2001, AM J MED, V111, P4, DOI 10.1016/S0002 9343(01)01025 7
   PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0
   Schulz R, 2009, BIOPHYS J, V96, P3116, DOI 10.1016/j.bpj.2009.01.021
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886
   Zhang ZY, 2006, PROTEINS, V64, P391, DOI 10.1002/prot.20983
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 48
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1093 3263
EI 1873 4243
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD DEC
PY 2020
VL 101
AR 107743
DI 10.1016/j.jmgm.2020.107743
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA OI6HW
UT WOS:000583378100028
PM 32920237
DA 2025 08 17
ER

PT J
AU Wang, C
   Ji, LH
   Wang, JH
   Zhang, JX
   Qiu, L
   Chen, SQ
   Ni, XY
AF Wang, Cheng
   Ji, Lihua
   Wang, Jianhao
   Zhang, Jiaxing
   Qiu, Lin
   Chen, Shaoqing
   Ni, Xinye
TI Amifostine loaded lipid calcium carbonate nanoparticles as an oral drug
   delivery system for radiation protection
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Amifostine; Hybrid lipid nanoparticles; Calcium carbonate; Radiation
   protection; Oral delivery
ID OSTEOBLAST PROMOTION; TRANSPORT; SUPPLEMENT; PROTEINS
AB Amifostine (AMF) as the first line radiation protection drug, usually suffered from low compliance and short halflife upon clinical applications. The development of oral drug delivery system (DDS) for AMF is a promising solution. However, the inherent shortages of AMF present significant challenges in the design of suitable oral DDS. Here in this study, we utilized the ability of calcium ions to bind with AMF and prepared AMF loaded calcium carbonate (CC) core, CC/AMF, using phase transferred coprecipitation method. We further modified the CC/AMF using phospholipids to prepare AMF loaded lipid calcium carbonate (LCC) hybrid nanoparticles (LCC/ AMF) via a thin film dispersion method. LCC/AMF combines the oral advantages of lipid nanoparticles with the drug loading capabilities of CC, which was shown as uniform nano sized formulation with decent stability in aqueous solution. With favorable intestinal transport and absorption effects, it effectively enhances the in vivo radiation protection efficacy of AMF through oral administration. More importantly, we further investigated the cellular accumulation profile and intracellular transport mechanism of LCC/AMF using MDCK and Caco 2 cell lines as models. This research not only alters the current administration method of AMF to enhance its convenience and compliance, but also provides insights and guidance for the development of more suitable oral DDS for AMF in the future.
C1 [Wang, Cheng; Ji, Lihua; Wang, Jianhao; Zhang, Jiaxing; Qiu, Lin] Changzhou Univ, Sch Pharm, Changzhou, Jiangsu, Peoples R China.
   [Chen, Shaoqing; Ni, Xinye] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Changzhou, Jiangsu, Peoples R China.
   [Chen, Shaoqing; Ni, Xinye] Jiangsu Prov Engn Res Ctr Med Phys, Changzhou 213003, Jiangsu, Peoples R China.
C3 Changzhou University; Nanjing Medical University
RP Qiu, L (通讯作者)，Changzhou Univ, Sch Pharm, Changzhou, Jiangsu, Peoples R China.; Chen, SQ; Ni, XY (通讯作者)，Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Changzhou, Jiangsu, Peoples R China.; Chen, SQ; Ni, XY (通讯作者)，Jiangsu Prov Engn Res Ctr Med Phys, Changzhou 213003, Jiangsu, Peoples R China.
EM linqiu@cczu.edu.cn; chenshaoqing@zju.edu.cn; nxy@njmu.edu.cn
FU National Natural Science Foundation of China [82303692]; Natural Science
   Foundation of Jiangsu Province [BK20210851]; China Postdoctoral Science
   Foundation [2021M690482]
FX Our project was supported by the funding from National Natural Science
   Foundation of China (No. 82303692) , Natural Science Foundation of
   Jiangsu Province (No. BK20210851) and China Postdoctoral Science
   Foundation Funded Project (No. 2021M690482) . The authors acknowledge
   the TEM imaging provided by Zhenjiang ZhuanBo Detection Technology Co.,
   Ltd. (Zhenjiang, China) and the animal experiment condition provided by
   Cavens animal center (Changzhou, China) . References
CR Boucrot E, 2006, EXP CELL RES, V312, P4036, DOI 10.1016/j.yexcr.2006.09.025
   Brown TD, 2020, NAT REV MATER, V5, P127, DOI 10.1038/s41578 019 0156 6
   Bulin AL, 2020, ADV SCI, V7, DOI 10.1002/advs.202001675
   Cao J, 2020, CHEM ENG J, V384, DOI 10.1016/j.cej.2019.123363
   Chai GH, 2016, ACS APPL MATER INTER, V8, P5929, DOI 10.1021/acsami.6b00821
   Chai GH, 2014, MOL PHARMACEUT, V11, P3716, DOI 10.1021/mp5004674
   Chai GH, 2016, RSC ADV, V6, P70433, DOI 10.1039/c6ra12978a
   Dizaj SM, 2019, EXPERT OPIN DRUG DEL, V16, P331, DOI 10.1080/17425247.2019.1587408
   Du WW, 2013, BIOMATERIALS, V34, P794, DOI 10.1016/j.biomaterials.2012.10.003
   Gan LSL, 1997, ADV DRUG DELIVER REV, V23, P77, DOI 10.1016/S0169 409X(96)00427 9
   Gula A, 2013, INT J PHARMACEUT, V453, P441, DOI 10.1016/j.ijpharm.2013.06.019
   Haddadzadegan S, 2022, ADV DRUG DELIVER REV, V182, DOI 10.1016/j.addr.2021.114097
   Ji LH, 2023, MOL PHARMACEUT, V20, P5383, DOI 10.1021/acs.molpharmaceut.3c00600
   Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389
   Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600 0854.2009.00878.x
   Khatri P, 2017, COLLOID SURFACE B, V153, P237, DOI 10.1016/j.colsurfb.2017.02.024
   Lin XN, 2020, COLLOID SURFACE A, V599, DOI 10.1016/j.colsurfa.2020.124886
   Lin XN, 2020, COLLOID SURFACE B, V195, DOI 10.1016/j.colsurfb.2020.111200
   Lu HY, 2023, CHEM ENG J, V470, DOI 10.1016/j.cej.2023.144371
   McKibbin T, 2010, CLIN CANCER RES, V16, P1049, DOI 10.1158/1078 0432.CCR 09 1997
   Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600 0854.2003.00128.x
   Peng C, 2022, J CONTROL RELEASE, V345, P625, DOI 10.1016/j.jconrel.2022.03.031
   Peng YA, 2023, ADV SCI, V10, DOI 10.1002/advs.202300614
   Qi C, 2018, CHEM SOC REV, V47, P357, DOI 10.1039/c6cs00746e
   Rodriguez Boulan E, 2004, CURR OPIN CELL BIOL, V16, P436, DOI 10.1016/j.ceb.2004.06.013
   Salah E, 2020, COLLOID SURFACE B, V196, DOI 10.1016/j.colsurfb.2020.111305
   Singh VK, 2019, EXPERT OPIN DRUG SAF, V18, P1077, DOI 10.1080/14740338.2019.1666104
   Talegaonkar S, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249 019 1337 8
   Tao S, 2021, J CONTROL RELEASE, V329, P121, DOI 10.1016/j.jconrel.2020.11.059
   Phan TNQ, 2019, J CONTROL RELEASE, V304, P146, DOI 10.1016/j.jconrel.2019.05.011
   Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230 973X.96920
   Trushina DB, 2022, MATER TODAY ADV, V14, DOI 10.1016/j.mtadv.2022.100214
   Wang C, 2022, J DRUG DELIV SCI TEC, V77, DOI 10.1016/j.jddst.2022.103824
   Wang C, 2023, MOL PHARMACEUT, V20, P2891, DOI 10.1021/acs.molpharmaceut.2c01033
   Wang C, 2021, SMALL, V17, DOI 10.1002/smll.202007953
   Wang C, 2019, INT J NANOMED, V14, P1503, DOI 10.2147/IJN.S193976
   Wang C, 2018, ADV MATER, V30, DOI 10.1002/adma.201706407
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Wang L, 2020, ACS APPL MATER INTER, V12, P44534, DOI 10.1021/acsami.0c14000
   Weisz OA, 2003, TRAFFIC, V4, P57, DOI 10.1034/j.1600 0854.2003.40201.x
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734 1140(12)70901 5
   Wu L, 2018, MOL PHARMACEUT, V15, P4273, DOI 10.1021/acs.molpharmaceut.8b00713
   Xing LY, 2021, J MATER CHEM B, V9, P1707, DOI 10.1039/d0tb02848g
   Xu Q, 2016, DRUG DEV IND PHARM, V42, P701, DOI 10.3109/03639045.2015.1075028
   Yu X, 2020, ACTA BIOMATER, V112, P87, DOI 10.1016/j.actbio.2020.05.025
   Yuan H, 2011, MOL PHARMACEUT, V8, P225, DOI 10.1021/mp100289v
   Zelevinsky V, 2019, PROG PART NUCL PHYS, V105, P180, DOI 10.1016/j.ppnp.2018.12.001
   Zhang RY, 2021, J CONTROL RELEASE, V339, P430, DOI 10.1016/j.jconrel.2021.10.004
   Zhang YS, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901778
   Zhao XH, 2023, ACS APPL MATER INTER, V15, P15203, DOI 10.1021/acsami.3c00502
   Zheng LN, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2301067120
   Zhong DN, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abi9265
NR 52
TC 2
Z9 2
U1 7
U2 17
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD AUG
PY 2024
VL 177
AR 117029
DI 10.1016/j.biopha.2024.117029
EA JUL 2024
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA I9P5Z
UT WOS:001333501500001
PM 38991305
OA gold
DA 2025 08 17
ER

PT J
AU Bonilla, X
   Dakir, EH
   Mollinedo, F
   Gajate, C
AF Bonilla, Ximena
   Dakir, El Habib
   Mollinedo, Faustino
   Gajate, Consuelo
TI Endoplasmic reticulum targeting in Ewing's sarcoma by the
   alkylphospholipid analog edelfosine
SO ONCOTARGET
LA English
DT Article
DE Ewing's sarcoma; endoplasmic reticulum; apoptosis; xenograft animal
   model; ether phospholipid; edelfosine
ID HUMAN LEUKEMIC CELLS; LIPID RAFTS; ET 18 OCH3 EDELFOSINE; IN VIVO;
   SELECTIVE APOPTOSIS; ENRICHED RAFTS; STEM CELLS; PHASE II; METFORMIN;
   CANCER
AB Ewing's sarcoma (ES) is the second most common bone cancer in children and young people. Edelfosine (1 O octadecyl 2 O methyl rac glycero 3 phosphocholine) is the prototype of a family of synthetic antitumor compounds, collectively known as alkylphospholipid analogs (APLs). We have found that APLs ranked edelfosine>perifosine>erucylphosphocholine>miltefosine for their capacity to promote apoptosis in ES cells. Edelfosine accumulated in the endoplasmic reticulum (ER) and triggered an ER stress response that eventually led to caspase dependent apoptosis in ES cells. This apoptotic response involved mitochondrial mediated processes, with cytochrome c release, caspase 9 activation and generation of reactive oxygen species. Edelfosine induced apoptosis was also dependent on sustained c Jun NH2 terminal kinase activation. Oral administration of edelfosine showed a potent in vivo antitumor activity in an ES xenograft animal model. Histochemical staining gave evidence for ER stress response and apoptosis in the ES tumors isolated from edelfosine treated mice. Edelfosine showed a preferential action on ES tumor cells as compared to non transformed osteoblasts, and appeared to be well suited for combination therapy regimens. These results demonstrate in vitro and in vivo antitumor activity of edelfosine against ES cells that is mediated by caspase activation and ER stress, and provide the proof of concept for a putative edelfosine and ER stress mediated approach for ES treatment.
C1 [Bonilla, Ximena; Dakir, El Habib; Mollinedo, Faustino; Gajate, Consuelo] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E 37008 Salamanca, Spain.
   [Mollinedo, Faustino; Gajate, Consuelo] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain.
   [Dakir, El Habib] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Centro de
   Investigacion del Cancer (CIC); CSIC USAL   Instituto de Biologia
   Molecular y Celular del Cancer de Salamanca (IBMCC); University of
   Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC);
   CSIC USAL   Instituto de Biologia Molecular y Celular del Cancer de
   Salamanca (IBMCC); Queens University Belfast
RP Gajate, C (通讯作者)，Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel de Unamuno, E 37008 Salamanca, Spain.
EM fmollin@usal.es; cgajate@usal.es
RI DAKIR, EL/O 1383 2015; Mollinedo, Faustino/M 9024 2016
OI Gajate, Consuelo/0000 0003 0604 6459
FU Spanish Ministerio de Ciencia e Innovacion [SAF2011 30518,
   SAF2014 59716 R]; European Community [HEALTH F2 2011 256986]; Spanish
   Ministerio de Economia y Competitividad (Red Tematica de Investigacion
   Cooperativa en Cancer, Instituto de Salud Carlos III by Fondo Europeo de
   Desarrollo Regional of the European Union) [RD12/0036/0065]; Fondo de
   Investigacion Sanitaria; European Commission (FIS FEDER) [PS09/01915];
   Junta de Castilla y Leon [CSI052A11 2]; Ministerio de Ciencia e
   Innovacion of Spain
FX This work was funded by grants from Spanish Ministerio de Ciencia e
   Innovacion (SAF2011 30518, SAF2014 59716 R), European Community's
   Seventh Framework Programme FP7 2007 2013 (grant HEALTH F2 2011 256986,
   PANACREAS), Spanish Ministerio de Economia y Competitividad
   (RD12/0036/0065 from Red Tematica de Investigacion Cooperativa en
   Cancer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de
   Desarrollo Regional of the European Union), Fondo de Investigacion
   Sanitaria and European Commission (FIS FEDER PS09/01915), Junta de
   Castilla y Leon (CSI052A11 2 and Biomedicine Project 2010 2011). CG was
   supported by the Ramon y Cajal Program from the Ministerio de Ciencia e
   Innovacion of Spain.
CR Bailey HH, 2006, CANCER AM CANCER SOC, V107, P2462, DOI 10.1002/cncr.22308
   Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059
   Cuesta Marbán A, 2013, J BIOL CHEM, V288, P8405, DOI 10.1074/jbc.M112.425769
   Cufí S, 2012, ONCOTARGET, V3, P395, DOI 10.18632/oncotarget.488
   Del Barco S, 2011, ONCOTARGET, V2, P896, DOI 10.18632/oncotarget.387
   Dela Cruz FS, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00168
   Emadi A, 2009, NAT REV CLIN ONCOL, V6, P638, DOI 10.1038/nrclinonc.2009.146
   Esiashvili N, 2008, J PEDIAT HEMATOL ONC, V30, P425, DOI 10.1097/MPH.0b013e31816e22f3
   de Mendoza AEH, 2009, CLIN CANCER RES, V15, P858, DOI 10.1158/1078 0432.CCR 08 1654
   Fensterle J, 2014, ANTI CANCER AGENT ME, V14, P629, DOI 10.2174/1871520614666140309225912
   Fulda S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00022
   Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097 0215(20000301)85:5<674::AID IJC13>3.0.CO;2 Z
   Gajate C, 2000, CANCER RES, V60, P2651
   Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213
   Gajate C, 2012, ONCOGENE, V31, P2627, DOI 10.1038/onc.2011.446
   Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097 0215(20000415)86:2<208::AID IJC10>3.0.CO;2 E
   Gajate C, 2003, CLIN CANCER RES, V9, P1535
   Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225
   Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860
   Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602
   Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood 2006 04 016824
   Gajate C, 2014, ANTI CANCER AGENT ME, V14, P509, DOI 10.2174/1871520614666140309222259
   Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044
   Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095
   Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890
   Gritti M, 2014, ONCOTARGET, V5, P11252, DOI 10.18632/oncotarget.2617
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   He H, 2015, CANCER J, V21, P70, DOI 10.1097/PPO.0000000000000103
   Hunold A, 2006, PEDIATR BLOOD CANCER, V47, P795, DOI 10.1002/pbc.20719
   Iida K, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 21
   Iwasawa R, 2011, EMBO J, V30, P556, DOI 10.1038/emboj.2010.346
   Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169
   Knowling M, 2006, INVEST NEW DRUG, V24, P435, DOI 10.1007/s10637 006 6406 7
   Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864
   Ledgerwood EC, 2009, CLIN CANCER RES, V15, P420, DOI 10.1158/1078 0432.CCR 08 1172
   Leonard R, 2001, J CLIN ONCOL, V19, P4150, DOI 10.1200/JCO.2001.19.21.4150
   Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523
   Lin YC, 2014, ONCOTARGET, V5, P298, DOI 10.18632/oncotarget.1628
   Lissat A, 2012, ISRN ONCOL, V2012
   Ludwig JA, 2008, CURR OPIN ONCOL, V20, P412, DOI 10.1097/CCO.0b013e328303ba1d
   Mackintosh C, 2010, CANCER BIOL THER, V9, P655, DOI 10.4161/cbt.9.9.11511
   Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330
   Mollinedo F, 1997, CANCER RES, V57, P1320
   Mollinedo F, 2005, IDRUGS, V8, P127
   Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703
   Mollinedo F, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.41
   MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458
   Mollinedo F, 2010, ONCOGENE, V29, P3748, DOI 10.1038/onc.2010.131
   Mollinedo F, 2007, EXPERT OPIN THER PAT, V17, P385, DOI 10.1517/13543776.17.4.385
   Mollinedo F, 2014, ANTI CANCER AGENT ME, V14, P495, DOI 10.2174/1871520614999140313160011
   Mollinedo F, 2010, CLIN CANCER RES, V16, P2046, DOI 10.1158/1078 0432.CCR 09 2456
   Mollinedo F, 2010, FUTURE ONCOL, V6, P811, DOI 10.2217/FON.10.34
   Mollinedo F, 2009, J PHARMACOL EXP THER, V329, P439, DOI 10.1124/jpet.108.148254
   Morgillo F, 2013, CLIN CANCER RES, V19, P3508, DOI 10.1158/1078 0432.CCR 12 2777
   Nakatani F, 2012, J PATHOL, V226, P796, DOI 10.1002/path.3007
   Nieto Miguel T, 2007, CANCER RES, V67, P10368, DOI 10.1158/0008 5472.CAN 07 0278
   Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302
   Pierotti MA, 2013, ONCOGENE, V32, P1475, DOI 10.1038/onc.2012.181
   Quattrini I, 2014, ONCOL REP, V31, P370, DOI 10.3892/or.2013.2862
   Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009
   Ross Keir A, 2013, ISRN Oncol, V2013, P759725, DOI 10.1155/2013/759725
   Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020
   Sonnemann J, 2007, J CANCER RES CLIN, V133, P847, DOI 10.1007/s00432 007 0227 8
   Subbiah V, 2009, CURR TREAT OPTION ON, V10, P126, DOI 10.1007/s11864 009 0104 6
   Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259
   Suvà ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008 5472.CAN 08 2242
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042 7158.2012.01567.x
   van Blitterswijk WJ, 2008, CURR PHARM DESIGN, V14, P2061, DOI 10.2174/138161208785294636
   Verrill MW, 1997, ANN ONCOL, V8, P1099, DOI 10.1023/A:1008264902857
   Vujic I, 2015, ONCOTARGET, V6, P969, DOI 10.18632/oncotarget.2824
   Whelan J, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 12
   Yamamuro A, 2011, J PHARMACOL SCI, V115, P239, DOI 10.1254/jphs.10217SC
   Yao C, 2013, CELL BIOCHEM BIOPHYS, V65, P217, DOI 10.1007/s12013 012 9423 5
   Zi FM, 2015, CANCER LETT, V356, P443, DOI 10.1016/j.canlet.2014.09.050
NR 74
TC 17
Z9 17
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 10
PY 2015
VL 6
IS 16
BP 14596
EP 14613
DI 10.18632/oncotarget.4053
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CO2TR
UT WOS:000359010000060
PM 25999349
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Hu, JP
   Feng, ZW
   Ma, SF
   Zhang, Y
   Tong, Q
   Alqarni, MH
   Gou, XJ
   Xie, XQ
AF Hu, Jianping
   Feng, Zhiwei
   Ma, Shifan
   Zhang, Yu
   Tong, Qin
   Alqarni, Mohammed Hamed
   Gou, Xiaojun
   Xie, Xiang Qun
TI Difference and Influence of Inactive and Active States of Cannabinoid
   Receptor Subtype CB2: From Conformation to Drug Discovery
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID PROTEIN COUPLED RECEPTOR; MOLECULAR DYNAMICS SIMULATIONS; BETA(2)
   ADRENERGIC RECEPTOR; CRYSTAL STRUCTURE; OSTEOCLAST INHIBITORS;
   BIOLOGICAL EVALUATION; BINDING MECHANISMS; SELECTIVE LIGANDS; INVERSE
   AGONISTS; GPCR STRUCTURE
AB Cannabinoid receptor 2 (CB2), a G protein coupled receptor (GPCR), is a promising target for the treatment of neuropathic pain, osteoporosis, immune system, cancer, and drug abuse. The lack of an experimental three dimensional CB2 structure has hindered not only the development of studies of conformational differences between the inactive and active CB2 but also the rational discovery of novel functional compounds targeting CB2. In this work, we constructed models of both inactive and active CB2 by homology modeling. Then we conducted two comparative 100 ns molecular dynamics (MD) simulations on the two systems the active CB2 bound with both the agonist and G protein and the inactive CB2 bound with inverse agonist to analyze the conformational difference of CB2 proteins and the key residues involved in molecular recognition. Our results showed that the inactive CB2 and the inverse agonist remained stable during the MD simulation. However, during the MD simulations, we observed dynamical details about the breakdown of the "ionic lock" between R131(3.50) and D240(6.30) as well as the outward/inward movements of transmembrane domains of the active CB2 that bind with G proteins and agonist (TMS, TM6, and TM7). All of these results are congruent with the experimental data and recent reports. Moreover, our results indicate that W258(6.48) in TM6 and residues in TM4 (V164(4.56) L169(4.61)) contribute greatly to the binding of the agonist on the basis of the binding energy decomposition, while residues S180 F183 in extracellular loop 2 (ECL2) may be of importance in recognition of the inverse agonist. Furthermore, pharmacophore modeling and virtual screening were carried out for the inactive and active CB2 models in parallel. Among all 10 hits, two compounds exhibited novel scaffolds and can be used as novel chemical probes for future studies of CB2. Importantly, our studies show that the hits obtained from the inactive CB2 model mainly act as inverse agonist(s) or neutral antagonist(s) at low concentration. Moreover, the hit from the active CB2 model also behaves as a neutral antagonist at low concentration. Our studies provide new insight leading to a better understanding of the structural and conformational differences between two states of CB2 and illuminate the effects of structure on virtual screening and drug design.
C1 [Hu, Jianping; Feng, Zhiwei; Ma, Shifan; Zhang, Yu; Tong, Qin; Alqarni, Mohammed Hamed; Xie, Xiang Qun] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
   [Hu, Jianping; Feng, Zhiwei; Ma, Shifan; Zhang, Yu; Tong, Qin; Alqarni, Mohammed Hamed; Xie, Xiang Qun] Univ Pittsburgh, Computat Chem Genom Screening Ctr, Natl Ctr Excellence Computat Drug Abuse Res, NIH,Sch Pharm,Drug Discovery Inst, Pittsburgh, PA 15260 USA.
   [Hu, Jianping; Feng, Zhiwei; Ma, Shifan; Zhang, Yu; Tong, Qin; Alqarni, Mohammed Hamed; Xie, Xiang Qun] Univ Pittsburgh, Dept Computat Biol & Struct Biol, Sch Med, Pittsburgh, PA 15260 USA.
   [Hu, Jianping] Leshan Normal Univ, Coll Chem, Leshan 614004, Sichuan, Peoples R China.
   [Hu, Jianping; Gou, Xiaojun] Chengdu Univ, Key Lab Med & Edible Plants Resources Dev, Sch Pharm & Bioengn, Chengdu 610106, Sichuan, Peoples R China.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; National Institutes of Health (NIH)  
   USA; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Leshan Normal University; Chengdu University
RP Xie, XQ (通讯作者)，Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.; Xie, XQ (通讯作者)，Univ Pittsburgh, Computat Chem Genom Screening Ctr, Natl Ctr Excellence Computat Drug Abuse Res, NIH,Sch Pharm,Drug Discovery Inst, Pittsburgh, PA 15260 USA.; Xie, XQ (通讯作者)，Univ Pittsburgh, Dept Computat Biol & Struct Biol, Sch Med, Pittsburgh, PA 15260 USA.
EM xix15@pitt.edu
RI Zhang, Yu/AAE 3574 2022; FENG, ZHIWEI/L 5072 2014; Alqarni, Mohammed
   H./AGY 9343 2022; qin, tong/JEZ 6348 2023; Alqarni,
   Mohammed/AGY 9343 2022
OI FENG, ZHIWEI/0000 0001 6533 8932; Alqarni, Mohammed
   H./0000 0002 7061 9111; 
FU NIH NIDA [P30 DA035778A1]; NIH [R01 DA025612]; National Natural Science
   Foundation of China [11147175, 11247018]; Sichuan Provincial Education
   Bureau [12ZA066]; Leshan Science and Technology Administration
   [14GZD022]
FX The project was supported by funding provided to the Xie laboratory by
   NIH NIDA (P30 DA035778A1) and NIH (R01 DA025612) and in part by the
   National Natural Science Foundation of China (11147175 and 11247018),
   the Key Project of Sichuan Provincial Education Bureau (12ZA066), and
   the Project of Leshan Science and Technology Administration (14GZD022).
CR [Anonymous], 2010, SYBYL X VERS 1 3
   [Anonymous], CURRENT PROTOCOLS BI
   Bai QF, 2014, PHYS CHEM CHEM PHYS, V16, P15874, DOI 10.1039/c4cp01185f
   Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129
   Bhattacharya S, 2008, J MOL BIOL, V382, P539, DOI 10.1016/j.jmb.2008.06.084
   Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432 1033.1996.0704p.x
   Chen JZ, 2007, J CHEM INF MODEL, V47, P1626, DOI 10.1021/ci7000814
   Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577
   Daga PR, 2012, PROTEINS, V80, P1948, DOI 10.1002/prot.24077
   Deupi X, 2010, PHYSIOLOGY, V25, P293, DOI 10.1152/physiol.00002.2010
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Feng Zhiwei, 2015, Journal of Chemical Biology, V8, P79, DOI 10.1007/s12154 015 0131 7
   Feng ZW, 2015, J CHEM INF MODEL, V55, P572, DOI 10.1021/ci5007189
   Feng ZW, 2014, J CHEM INF MODEL, V54, P2483, DOI 10.1021/ci5002718
   Feng ZW, 2012, J MOL MODEL, V18, P5051, DOI 10.1007/s00894 012 1509 x
   Feng ZW, 2012, J CHEM INF MODEL, V52, P1005, DOI 10.1021/ci200594d
   Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105
   Gouldson P, 2000, EUR J PHARMACOL, V401, P17, DOI 10.1016/S0014 2999(00)00439 8
   Hou TJ, 2007, J MED CHEM, V50, P1177, DOI 10.1021/jm0609162
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hurst DP, 2010, J BIOL CHEM, V285, P17954, DOI 10.1074/jbc.M109.041590
   Jain AN, 1996, J COMPUT AID MOL DES, V10, P427, DOI 10.1007/BF00124474
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kalé L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Kapur A, 2007, MOL PHARMACOL, V71, P1512, DOI 10.1124/mol.107.034645
   Kofuku Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2046
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Louet M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002595
   Manglik A, 2014, CURR OPIN CELL BIOL, V27, P136, DOI 10.1016/j.ceb.2014.01.008
   Marriott KSC, 2008, CURR TOP MED CHEM, V8, P187
   Martí Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Mnpotra JS, 2014, J BIOL CHEM, V289, P20259, DOI 10.1074/jbc.M113.539916
   Nebane NM, 2008, BIOCHEMISTRY US, V47, P13811, DOI 10.1021/bi8007802
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Pedretti A, 2002, J MOL GRAPH MODEL, V21, P47, DOI 10.1016/S1093 3263(02)00123 7
   Poso A, 2008, BRIT J PHARMACOL, V153, P335, DOI 10.1038/sj.bjp.0707567
   Raduner S, 2006, J BIOL CHEM, V281, P14192, DOI 10.1074/jbc.M601074200
   Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361
   Reggio PH, 2006, AAPS J, V8, pE322
   Salon JA, 2011, PHARMACOL REV, V63, P901, DOI 10.1124/pr.110.003350
   Singh R, 2002, J PEPT RES, V60, P357, DOI 10.1034/j.1399 3011.2002.21065.x
   SITKOFF D, 1994, J PHYS CHEM US, V98, P1978, DOI 10.1021/j100058a043
   Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263 7855(97)00009 X
   Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y
   Song ZH, 1999, MOL PHARMACOL, V56, P834
   Stern E, 2006, J MED CHEM, V49, P70, DOI 10.1021/jm050467q
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097 0282(2000)56:4<275::AID BIP10024>3.0.CO;2 E
   Tuccinardi T, 2006, J MED CHEM, V49, P984, DOI 10.1021/jm050875u
   Vemuri VK, 2008, PHYSIOL BEHAV, V93, P671, DOI 10.1016/j.physbeh.2007.11.012
   Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896
   WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092 8674(95)90220 1
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096 987X(19990130)20:2<217::AID JCC4>3.0.CO;2 A
   Wenthur CJ, 2014, ANNU REV PHARMACOL, V54, P165, DOI 10.1146/annurev pharmtox 010611 134525
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511
   Xu L, 2016, MOL BIOSYST, V12, P379, DOI 10.1039/c5mb00781j
   Xu L, 2015, PHYS CHEM CHEM PHYS, V17, P3370, DOI 10.1039/c4cp05095a
   Xu L, 2014, J MED CHEM, V57, P3737, DOI 10.1021/jm401908w
   Yang P, 2013, J MED CHEM, V56, P2045, DOI 10.1021/jm3017464
   Yang P, 2012, J MED CHEM, V55, P9973, DOI 10.1021/jm301212u
   Zhang HY, 2014, P NATL ACAD SCI USA, V111, pE5007, DOI 10.1073/pnas.1413210111
   Zhang YX, 2011, INT IMMUNOPHARMACOL, V11, P1303, DOI 10.1016/j.intimp.2011.04.013
NR 64
TC 31
Z9 32
U1 0
U2 40
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549 9596
EI 1549 960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD JUN
PY 2016
VL 56
IS 6
SI SI
BP 1152
EP 1163
DI 10.1021/acs.jcim.5b00739
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA DP9OX
UT WOS:000378826800024
PM 27186994
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Feng, WL
   Dean, DC
   Hornicek, FJ
   Spentzos, D
   Hoffman, RM
   Shi, HR
   Duan, ZF
AF Feng, Wenlong
   Dean, Dylan C.
   Hornicek, Francis J.
   Spentzos, Dimitrios
   Hoffman, Robert M.
   Shi, Huirong
   Duan, Zhenfeng
TI 被撤回的出版物: Myc is a prognostic biomarker and potential therapeutic target
   in osteosarcoma (Retracted article. See vol. 15, 2023)
SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Myc; osteosarcoma; prognostic marker; therapeutic target; tissue
   microarray
ID B CELL LYMPHOMA; C MYC; INHIBITS PROLIFERATION; POOR PROGNOSIS; CANCER;
   10058 F4; DIMERIZATION; ONCOPROTEIN; APOPTOSIS; CYCLE
AB Background:
   Over the past four decades, outcomes for osteosarcoma patients have plateaued as there have been few emerging therapies showing clinical results. Thus, the identification of novel biomarkers and therapeutic strategies are urgently needed to address these primary obstacles in patient care. Although the Myc oncogene has known roles in oncogenesis and cancer cell growth, its expression and function in osteosarcoma are largely unknown.
   Methods:
   Expression of Myc was determined by Western blotting of osteosarcoma cell lines and patient tissues, and by immunohistochemistry of a unique osteosarcoma tissue microarray (TMA) constructed from 70 patient samples with extensive follow up data. Myc specific siRNA and inhibitor 10058 F4 were applied to examine the effect of Myc inhibition on osteosarcoma cell proliferation. The clonogenicity and migration activity was determined by clonogenic and wound healing assays. A mimic in vivo assay, three dimensional (3D) cell culture model, was performed to further validate the effect of Myc inhibition on osteosarcoma cell tumorigenic markers.
   Results:
   Myc was significantly overexpressed in human osteosarcoma cell lines compared with normal human osteoblasts, and also highly expressed in fresh osteosarcoma tissues. Higher Myc expression correlated significantly with metastasis and poor prognosis. Through the addition of Myc specific siRNA and inhibitor, we significantly reduced Myc protein expression, resulting in decreased osteosarcoma cell proliferation. Inhibition of Myc also suppressed the migration, clonogenicity, and spheroid growth of osteosarcoma cells.
   Conclusion:
   Our results support Myc as an emerging prognostic biomarker and therapeutic target in osteosarcoma therapy.
C1 [Feng, Wenlong; Shi, Huirong] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Feng, Wenlong; Dean, Dylan C.; Hornicek, Francis J.; Duan, Zhenfeng] UCLA, David Geffen Sch Med, Dept Orthopaed Surg, 615 Charles,E Young Dr South, Los Angeles, CA 90095 USA.
   [Spentzos, Dimitrios] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg Musculoskeletal Oncol Serv, Boston, MA 02115 USA.
   [Hoffman, Robert M.] AntiCanc Inc, San Diego, CA USA.
   [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
C3 Zhengzhou University; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Harvard University;
   Harvard Medical School; Harvard University Medical Affiliates;
   Massachusetts General Hospital; AntiCancer, Inc.; University of
   California System; University of California San Diego
RP Shi, HR (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.; Duan, ZF (通讯作者)，UCLA, David Geffen Sch Med, Dept Orthopaed Surg, 615 Charles,E Young Dr South, Los Angeles, CA 90095 USA.
EM fccshihr@zzu.edu.cn; zduan@mednet.ucla.edu
RI shi, hui/JNS 2378 2023
OI Hornicek, Francis/0000 0002 6916 8042
FU Zhengzhou University of China; Sarcoma Foundation of America (SFA)
   [222433]; National Cancer Institute (NCI)/National Institutes of Health
   (NIH) [CA151452 01]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: WF is
   supported by an overseas visiting scholarship from the Zhengzhou
   University of China. ZD is supported, in part, through a Grant from
   Sarcoma Foundation of America (SFA) (222433), and a Grant from National
   Cancer Institute (NCI)/National Institutes of Health (NIH), UO1,
   CA151452 01.
CR AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460 2075.1993.tb06202.x
   AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092 8674(93)90663 B
   Amati B, 2001, BBA REV CANCER, V1471, pM135, DOI 10.1016/S0304 419X(01)00020 8
   [Anonymous], 2013, WHO classification of tumours of soft tissue and bone, P281
   Arvanitis C, 2006, SEMIN CANCER BIOL, V16, P313, DOI 10.1016/j.semcancer.2006.07.012
   Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947
   Bashash D, 2019, INT J BIOCHEM CELL B, V108, P7, DOI 10.1016/j.biocel.2019.01.005
   Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999
   Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002
   Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392 018 0008 7
   Chen YC, 2010, MOL THER, V18, P828, DOI 10.1038/mt.2009.291
   Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467
   Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008 5472.CAN 09 3556
   Farrell AS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01967 6
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Follis AV, 2009, BIOORG MED CHEM LETT, V19, P807, DOI 10.1016/j.bmcl.2008.12.025
   Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241
   Gao ST, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa7fdb
   García Gutiérrez L, 2019, GENES BASEL, V10, DOI 10.3390/genes10030244
   Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111
   Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108
   Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Lamoureux F, 2014, ONCOTARGET, V5, P7805, DOI 10.18632/oncotarget.2308
   Li XY, 2019, J ORTHOP RES, V37, P510, DOI 10.1002/jor.24189
   Li Y, 2014, J INTERN MED, V276, P52, DOI 10.1111/joim.12237
   Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100
   Lin CP, 2007, ANTI CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424
   Lüscher B, 2012, GENE, V494, P145, DOI 10.1016/j.gene.2011.12.027
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Ma H, 2018, EBIOMEDICINE, DOI [10.1016/j.ebiom.2018.12.022, DOI 10.1016/J.EBIOM.2018.12.022.]
   Moore Drew D, 2014, Cancer Treat Res, V162, P65, DOI 10.1007/978 3 319 07323 1_4
   Mu QT, 2014, ONCOL LETT, V8, P1355, DOI 10.3892/ol.2014.2277
   Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261
   Niu ZX, 2015, ACTA BIOCH BIOPH SIN, V47, P183, DOI 10.1093/abbs/gmu129
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008 5472.CAN 10 4633
   Ryan SL, 2012, ACTA NEUROPATHOL, V123, P501, DOI 10.1007/s00401 011 0923 y
   Sasaki N, 2011, EXP HEMATOL, V39, P817, DOI 10.1016/j.exphem.2011.05.002
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003
   Shachaf CM, 2005, CANCER RES, V65, P4471, DOI 10.1158/0008 5472.CAN 05 1172
   Sheikh Zeineddini N, 2019, J CELL BIOCHEM, V120, P14004, DOI 10.1002/jcb.28675
   Singh AM, 2009, CELL STEM CELL, V5, P141, DOI 10.1016/j.stem.2009.07.003
   Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421
   Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260
   Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159 8290.CD 15 0507
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015
   Xia B, 2015, LEUKEMIA RES, V39, P92, DOI 10.1016/j.leukres.2014.11.004
   Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641
   Zhang Y, 2013, BIOMATERIALS, V34, P8459, DOI 10.1016/j.biomaterials.2013.07.050
NR 55
TC 49
Z9 51
U1 0
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1758 8340
EI 1758 8359
J9 THER ADV MED ONCOL
JI Ther. Adv. Med. Oncol.
PD MAY
PY 2020
VL 12
AR 1758835920922055
DI 10.1177/1758835920922055
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA LR5SG
UT WOS:000535754000001
PM 32426053
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Horikawa, Y
   Wang, Y
   Nagano, S
   Kamizono, J
   Ikeda, M
   Komiya, S
   Kosai, K
AF Horikawa, Y.
   Wang, Y.
   Nagano, S.
   Kamizono, J.
   Ikeda, M.
   Komiya, S.
   Kosai, K i
TI Assessment of an altered E1B promoter on the specificity and
   potency of triple regulated conditionally replicating adenoviruses:
   implications for the generation of ideal m CRAs
SO CANCER GENE THERAPY
LA English
DT Article
DE conditionally replicating adenovirus (oncolytic adenovirus); E1B
   promoter activity; survivin; osteocalcin; osteosarcoma
ID ARMED ONCOLYTIC ADENOVIRUS; EMBRYONIC STEM CELL; GENE EXPRESSION;
   IN VIVO; EFFICIENT CONSTRUCTION; TUMOR CELLS; CANCER; SURVIVIN;
   OSTEOSARCOMA; OSTEOCALCIN
AB Although previous studies modified two components of conditionally replicating adenoviruses (CRAs), which selectively replicate in and kill cancer cells, the most accurate ways to achieve increased cancer specificity (that is, safety) without reducing the anticancer (that is, therapeutic) effects are unknown. Here, we generated two types of survivin responsive m CRAs (Surv.m CRAs), Surv.m CRA CMVp and Surv.m CRA OCp, which use two and three different mechanisms to target cancer, that is, early region 1A (E1A) regulated by the survivin promoter and mutated E1B Delta 55K regulated by the ubiquitously active cytomegalovirus promoter and cancer/tissue specific osteocalcin promoter, respectively, and carefully examined their safety and anticancer effects. Endogenous osteocalcin mRNA was expressed and further enhanced by vitamin D(3) in all osteosarcoma and prostate cancer cell lines and human osteoblasts, but not in human fibroblasts. The osteocalcin promoter activity was weak even with vitamin D(3) treatment in these osteocalcin expressing cancers, leading to low E1BD55K expression after Surv.m CRA OCp infection. Nevertheless, Surv.m CRA OCp had significantly increased cancer specificity without reduced anticancer effects in both in vitro and in vivo experiments. The unexpected but favorable fact that strong activity of an altered E1B promoter is unnecessary indicates that the majority of cancer/tissue specific promoters may be used to generate ideal m CRAs and will advance the development of m CRA based cancer therapies. Cancer Gene Therapy (2011) 18, 724 733; doi: 10.1038/cgt.2011.44; published online 12 August 2011
C1 [Horikawa, Y.; Wang, Y.; Ikeda, M.; Kosai, K i] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Gene Therapy & Regenerat Med, Kagoshima 8908544, Japan.
   [Horikawa, Y.; Nagano, S.; Kamizono, J.; Komiya, S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Orthopaed Surg, Kagoshima 8908544, Japan.
C3 Kagoshima University; Kagoshima University
RP Kosai, K (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Gene Therapy & Regenerat Med, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
EM kosai@m2.kufm.kagoshima u.ac.jp
OI Nagano, Satoshi/0000 0003 2015 1730
FU Japan Society and Technology Agency; Ministry of Health, Labour and
   Welfare of Japan; Grants in Aid for Scientific Research [21591920]
   Funding Source: KAKEN
FX We thank S Yamashita for technical assistance. This work was supported
   by a grant for Promoting Business using Advanced Technology from the
   Japan Society and Technology Agency, and Health and Labor Science
   Research Grants for Third Term Comprehensive Control Research for Cancer
   from the Ministry of Health, Labour and Welfare of Japan.
CR Ahn BC, 2011, GENE THER, V18, P606, DOI 10.1038/gt.2011.5
   Alemany Ramon, 2009, V542, P57, DOI 10.1007/978 1 59745 561 9_2
   Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471 4914(01)02243 2
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897 917
   Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373
   Chang JH, 2009, CANCER BIOL THER, V8, P676, DOI 10.4161/cbt.8.8.7913
   Fanburg Smith JC, 1999, HUM PATHOL, V30, P32, DOI 10.1016/S0046 8177(99)90297 6
   Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251
   Guo ZS, 1996, GENE THER, V3, P802
   Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474
   Jounaidi Y, 2007, CURR CANCER DRUG TAR, V7, P285, DOI 10.2174/156800907780618301
   Kamizono J, 2005, CANCER RES, V65, P5284, DOI 10.1158/0008 5472.CAN 04 2657
   Kawai T, 2004, CIRC J, V68, P691, DOI 10.1253/circj.68.691
   Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108
   Li YH, 2005, CLIN CANCER RES, V11, P8845, DOI 10.1158/1078 0432.CCR 05 1757
   Messerschmitt PJ, 2009, J AM ACAD ORTHOP SUR, V17, P515, DOI 10.5435/00124635 200908000 00005
   Mizuguchi H, 1998, HUM GENE THER, V9, P2577, DOI 10.1089/10430349850019418
   Murofushi Y, 2006, INT J ONCOL, V29, P681
   Nagano S, 2005, GENE THER, V12, P1385, DOI 10.1038/sj.gt.3302540
   Nagano S, 2004, INT J ONCOL, V24, P549
   Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262
   Osaka E, 2007, J ORTHOP RES, V25, P116, DOI 10.1002/jor.20291
   Sneddon WB, 1999, J CELL BIOCHEM, V73, P400, DOI 10.1002/(SICI)1097 4644(19990601)73:3<400::AID JCB11>3.3.CO;2 F
   Takahashi T, 2006, MOL THER, V14, P673, DOI 10.1016/j.ymthe.2006.05.010
   Terazaki Y, 2003, HEPATOLOGY, V37, P155, DOI 10.1053/jhep.2003.50018
   Ushikoshi H, 2005, LAB INVEST, V85, P862, DOI 10.1038/labinvest.3700282
   WHITE E, 1988, J VIROL, V62, P3445, DOI 10.1128/JVI.62.9.3445 3454.1988
   White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861
   Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200
   Yuge K, 2005, INT J ONCOL, V27, P77
   Zhang JF, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756 9966 29 52
   Zhang Q, 2006, CLIN CANCER RES, V12, P6523, DOI 10.1158/1078 0432.CCR 06 1491
NR 32
TC 11
Z9 13
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929 1903
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD OCT
PY 2011
VL 18
IS 10
BP 724
EP 733
DI 10.1038/cgt.2011.44
PG 10
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA 821QW
UT WOS:000294990500005
PM 21836631
DA 2025 08 17
ER

PT J
AU Darabi, MK
   Nazeri, Z
   Rafeeinia, A
   Pezeshki, SP
   Kheirollah, A
   Farbood, Y
   Adelipour, M
   Azizidoost, S
   Cheraghzadeh, M
AF Darabi, Mehrnaz Karimi
   Nazeri, Zahra
   Rafeeinia, Arash
   Pezeshki, Seyedeh Pardis
   Kheirollah, Alireza
   Farbood, Yaghoob
   Adelipour, Maryam
   Azizidoost, Shirin
   Cheraghzadeh, Maryam
TI Adipose Tissue Derived Mesenchymal Stem Cells Alter Metabolites of Brain
   Cholesterol Homeostasis in An Alzheimer's Model
SO CELL JOURNAL
LA English
DT Article
DE Alzheimer's Disease; Desmosterol; 7 Dehydrocholesterol;
   24 Hydroxycholesterol; 27 Hydroxycholesterol
ID DISEASE
AB Objective: Disruption of cholesterol homeostasis in Alzheimer's disease (AD) plays a crucial role in disease pathogenesis, making it a potential therapeutic target. Mesenchymal stem cells (MSCs) show promise in treating cognitive impairment and provide a novel therapeutic approach. This study aims to investigate the effects of MSCs on specific metabolites associated with brain cholesterol homeostasis in an AD rat model. Materials and Methods: In this experimental study, animals were divided into three groups: control, AD, and AD+MSCs. AD was induced using amyloid beta (A beta) and confirmed through the Morris water maze (MWM) behavioural test and Congo red staining. MSCs were extracted, characterised via flow cytometry, subjected to osteoblast and adipose differentiation, and injected intraventricularly. The cholesterol metabolite levels were measured using gas chromatography mass spectrometry (GC) MS and compared among the groups. Results: Treatment with MSCs significantly improved memory function in the AD+MSCs group compared to the AD group and the number of beta amyloid plaques decreased according to histological assessment. Disturbances in the brain cholesterol metabolites that included desmosterol, 7 dehydrocholesterol, 24S hydroxycholesterol, 27 hydroxycholesterol and cholesterol were observed in the AD group compared to the control group. Treatment with MSCs resulted in significant alterations in the levels of these metabolites. Conclusion: The findings indicate that MSC therapy has the potential to improve AD by modulating brain cholesterol homeostasis and promoting the differentiation of stem cells into nerve cells. The results emphasize the importance of investigating the role of cholesterol metabolites in the context of MSC therapy to gain deeper insights into underlying mechanisms of the therapeutic efficacy of MSCs in AD.
C1 [Darabi, Mehrnaz Karimi; Nazeri, Zahra; Pezeshki, Seyedeh Pardis; Kheirollah, Alireza; Adelipour, Maryam; Cheraghzadeh, Maryam] Ahvaz Jundishapur Univ Med Sci, Fac Med, Dept Clin Biochem, Ahvaz, Iran.
   [Darabi, Mehrnaz Karimi; Nazeri, Zahra; Pezeshki, Seyedeh Pardis; Kheirollah, Alireza; Cheraghzadeh, Maryam] Ahvaz Jundishapur Univ Med Sci, Med Basic Sci Res Inst, Cellular & Mol Res Ctr, Ahvaz, Iran.
   [Darabi, Mehrnaz Karimi; Nazeri, Zahra; Pezeshki, Seyedeh Pardis] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran.
   [Rafeeinia, Arash] Sirjan Sch Med Sci, Sirjan, Iran.
   [Kheirollah, Alireza] Geisel Sch Med Dartmouth, Surg Dept, Hanover, NH USA.
   [Farbood, Yaghoob] Ahvaz Jundishapur Univ Med Sci, Fac Med, Dept Physiol, Ahvaz, Iran.
   [Farbood, Yaghoob] Ahvaz Jundishapur Univ Med Sci, Basic Med Sci Res Inst, Persian Gulf Physiol Res Ctr, Ahvaz, Iran.
   [Azizidoost, Shirin] Ahvaz Jundishapur Univ Med Sci, Atherosclerosis Res Ctr, Ahvaz, Iran.
   [Cheraghzadeh, Maryam] Ahvaz Jundishapur Univ Med Sci, Fac Med, Dept Clin Biochem, PO Box 6135715794, Ahvaz, Iran.
C3 Ahvaz Jundishapur University of Medical Sciences (AJUMS); Ahvaz
   Jundishapur University of Medical Sciences (AJUMS); Ahvaz Jundishapur
   University of Medical Sciences (AJUMS); Dartmouth College; Ahvaz
   Jundishapur University of Medical Sciences (AJUMS); Ahvaz Jundishapur
   University of Medical Sciences (AJUMS); Ahvaz Jundishapur University of
   Medical Sciences (AJUMS); Ahvaz Jundishapur University of Medical
   Sciences (AJUMS)
RP Cheraghzadeh, M (通讯作者)，Ahvaz Jundishapur Univ Med Sci, Fac Med, Dept Clin Biochem, PO Box 6135715794, Ahvaz, Iran.
EM cheraghzade_m@ajums.ac.ir
RI Cheraghzadeh, Maryam/AIC 3581 2022; karimi darabi,
   mehrnaz/JMC 0064 2023; Adelipour, Maryam/AAA 9384 2021; rafeeinia,
   arash/IAR 4500 2023; Azizidoost, Shirin/ABH 8036 2020; Kheirollah,
   Alireza/K 6264 2018
FU Cellular and Molecular Research Centre, Medical Basic Sciences Research
   Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
   [CMRC 0059]
FX We are grateful to all of our colleagues in the Cellular and Molecular
   Research Centre of Ahvaz Jundishapur University of Medical Sciences.
   This work was financially supported by the Vice Chancellor for Research
   Affairs, Cellular and Molecular Research Centre, Medical Basic Sciences
   Research Institute, Ahvaz Jundishapur University of Medical Sciences,
   Ahvaz, Iran [grant numbers: CMRC 0059] and is a part of a PhD thesis.
   All authors declare that there is no conflict of interest.
CR Bhattarai A, 2021, STEROIDS, V173, DOI 10.1016/j.steroids.2021.108878
   Borràs C, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169356
   Cheraghzadeh M, 2018, IRAN RED CRESCENT ME, V20, DOI 10.5812/ircmj.81828
   Chiroma SM, 2018, BIOMED PHARMACOTHER, V103, P1602, DOI 10.1016/j.biopha.2018.04.152
   Feringa FM, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.690372
   Gamba P, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10050740
   Gliozzi M, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105215
   Hosseini SA, 2018, J CELL BIOCHEM, V119, P8723, DOI 10.1002/jcb.27202
   Jahn T, 2021, J STEROID BIOCHEM, V205, DOI 10.1016/j.jsbmb.2020.105785
   Li DF, 2022, TRENDS NEUROSCI, V45, P401, DOI 10.1016/j.tins.2022.01.002
   Lo Furno D, 2018, J CELL PHYSIOL, V233, P3982, DOI 10.1002/jcp.26192
   Loera Valencia R, 2019, J STEROID BIOCHEM, V190, P104, DOI 10.1016/j.jsbmb.2019.03.003
   Luu W, 2015, J LIPID RES, V56, P888, DOI 10.1194/jlr.M056986
   Marsh SE, 2017, NEUROCHEM INT, V106, P94, DOI 10.1016/j.neuint.2017.02.006
   Martin LF., 2018, Retrospective study on the species distribution and common diseases in exotic pets
   Mohamed A., 2015, Alzheimer's disease   challenges for the future, DOI DOI 10.5772/59904
   Naaldijk Y, 2017, NEUROPATH APPL NEURO, V43, P299, DOI 10.1111/nan.12319
   Nazeri Z, 2021, AVICENNA J PHYTOMEDI, V11, P473, DOI [10.22038/AJP.2021.17834, 10.22038/ajp.2021.17834]
   Paxinos G., 2006, The rat brain in stereotaxic coordinates: hard cover edition, V6th
   Petrov AM, 2016, ACTA NATURAE, V8, P58, DOI 10.32607/20758251 2016 8 1 58 73
   Petrov AM, 2019, NEUROTHERAPEUTICS, V16, P635, DOI 10.1007/s13311 019 00731 6
   Raskin J, 2015, CURR ALZHEIMER RES, V12, P712, DOI 10.2174/1567205012666150701103107
   Rudajev V, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.937056
   Sepiani A, 2021, META GENE, V30, DOI 10.1016/j.mgene.2021.100961
   Shen ZW, 2017, J NEUROSCI RES, V95, P2420, DOI 10.1002/jnr.24066
   Varma VR, 2021, NPJ AGING MECH DIS, V7, DOI 10.1038/s41514 021 00064 9
   Weigel Thaddeus K, 2019, Neuronal Signal, V3, pNS20190068, DOI 10.1042/NS20190068
   Zhang J, 2015, PROTEIN CELL, V6, P254, DOI 10.1007/s13238 014 0131 3
NR 28
TC 1
Z9 1
U1 1
U2 2
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395 4644, TEHRAN, 00000, IRAN
SN 2228 5806
EI 2228 5814
J9 CELL J
JI Cell J.
PD NOV
PY 2023
VL 25
IS 11
BP 764
EP 771
DI 10.22074/CELLJ.2023.1999622.1272
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CH9W9
UT WOS:001124490900008
PM 38071408
DA 2025 08 17
ER

PT J
AU Zhang, JN
   Sun, BH
   Zhao, HX
   Zhang, T
   He, DQ
   Lin, JX
   Chen, F
AF Zhang, Jieni
   Sun, Bohui
   Zhao, Huaxiang
   Zhang, Ting
   He, Danqing
   Lin, Jiuxiang
   Chen, Feng
TI Apolipoprotein E is an effective biomarker for orthodontic tooth
   movement in patients treated with transmission straight wire appliances
SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS
LA English
DT Article
ID GINGIVAL CREVICULAR FLUID; CELLS; IL 6; OSTEOBLASTS; STRESS; ALPHA;
   RANKL; MICE
AB Introduction: Orthodontic tooth movement (OTM) is the core component of orthodontic treatment and is increasingly popular for treating malocclusions. In this study, we aimed to investigate the role of apolipoprotein E (ApoE) in OTM. Methods: Thirty patients treated with transmission straight wire technology were selected and longitudinally tracked at 2 different stages of orthodontic treatment (initial 2 months and 12 months of orthodontic treatment). Total saliva was collected and analyzed by matrix assisted laser desorption/ionization time of flight mass spectrometry. Western blotting was used to detect the difference in ApoE expression in the saliva samples of the 2 groups. The expression of ApoE was further verified by immunohistochemical staining in a mouse model of tooth movement. Results: The results of matrix assisted laser desorption/ionization time of  flight mass spectrometry showed significant differences in the components of the salivary peptides in the 2 groups and peptides with a molecular weight of 2010.7 Da were predicted to be ApoE by database analysis. Western blotting further verified a significant difference in the expression of salivary ApoE in the 2 groups. In addition, an OTM model was successfully constructed in mice. The immunohistochemical staining results showed that ApoE expression significantly increased after force loading in the OTM model. Conclusions: This study indicated that ApoE participated in and played a role during OTM in patients treated with transmission straight wire technology. This relationship might be related to alveolar bone reconstruction and root resorption. The results provide new ideas for research on the mechanism of tooth movement using precision medicine based on saliva detection.
C1 [Zhang, Jieni; Sun, Bohui; Zhao, Huaxiang; Zhang, Ting; He, Danqing; Lin, Jiuxiang] Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Chen, Feng] Peking Univ, Dept Cent Lab, Sch & Hosp Stomatol, 22 Zhongguancun South Ave, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Lin, JX (通讯作者)，Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.; Chen, F (通讯作者)，Peking Univ, Dept Cent Lab, Sch & Hosp Stomatol, 22 Zhongguancun South Ave, Beijing, Peoples R China.
EM jxlin@pku.edu.cn; chenfeng2011@bjmu.edu.cn
OI Zhang, Jieni/0000 0003 1186 7307
FU National Natural Science Foundation of China, China [81900984, 81870747]
FX This study was supported by the National Natural Science Foundation of
   China, China (No. 81900984 and 81870747).
CR Allen RK, 2019, ORTHOD CRANIOFAC RES, V22, P14, DOI 10.1111/ocr.12258
   Amado F, 2019, ADV EXP MED BIOL, V1073, P23, DOI 10.1007/978 3 030 12298 0_2
   Amado F, 2010, EXPERT REV PROTEOMIC, V7, P709, DOI [10.1586/epr.10.48, 10.1586/EPR.10.48]
   Andrade I, 2007, J DENT RES, V86, P1089, DOI 10.1177/154405910708601113
   Aqrawi LA, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1961 4
   Bakker AD, 2014, J DENT RES, V93, P394, DOI 10.1177/0022034514522485
   Castagnola M, 2012, EXPERT REV PROTEOMIC, V9, P33, DOI [10.1586/EPR.11.77, 10.1586/epr.11.77]
   Castagnola M, 2011, TRENDS BIOTECHNOL, V29, P409, DOI 10.1016/j.tibtech.2011.04.002
   Chiappin S, 2007, CLIN CHIM ACTA, V383, P30, DOI 10.1016/j.cca.2007.04.011
   Csosz E, 2017, J PROTEOMICS, V153, P30, DOI 10.1016/j.jprot.2016.08.009
   Campos MJD, 2011, PAIN MED, V12, P1162, DOI 10.1111/j.1526 4637.2011.01185.x
   Taddei SRD, 2012, J BIOMECH, V45, P2729, DOI 10.1016/j.jbiomech.2012.09.006
   Dimberg L, 2015, EUR J ORTHODONT, V37, P238, DOI 10.1093/ejo/cju046
   Frank D, 2019, J CELL MOL MED, V23, P6251, DOI 10.1111/jcmm.14509
   Gao SS, 2019, BIOCHEM BIOPH RES CO, V519, P861, DOI 10.1016/j.bbrc.2019.09.085
   He D, 2015, J DENT RES, V94, P1286, DOI 10.1177/0022034515589714
   Huang R, 2019, JCI INSIGHT, P4
   Iwasaki LR, 2009, ORTHOD CRANIOFAC RES, V12, P129, DOI 10.1111/j.1601 6343.2009.01446.x
   Jayaprakash PK, 2019, J FAM MED PRIM CARE, V8, P1602, DOI 10.4103/jfmpc.jfmpc_204_19
   Kikuta J, 2015, J DENT RES, V94, P140, DOI 10.1177/0022034514555364
   Kragt L, 2016, CLIN ORAL INVEST, V20, P1881, DOI 10.1007/s00784 015 1681 3
   Masella RS, 2006, AM J ORTHOD DENTOFAC, V129, P458, DOI 10.1016/j.ajodo.2005.12.013
   Murphy S, 2019, BIOCHEM BIOPHYS REP, V18, DOI 10.1016/j.bbrep.2018.05.006
   Newman P, 2002, J BONE MINER RES, V17, P426, DOI 10.1359/jbmr.2002.17.3.426
   Noguchi T, 2018, BIOCHEM BIOPH RES CO, V503, P644, DOI 10.1016/j.bbrc.2018.06.055
   Oh JH, 2017, MOL CELLS, V40, P371, DOI 10.14348/molcells.2017.0025
   Peros K, 2011, ANGLE ORTHOD, V81, P901, DOI 10.2319/012111 44.1
   Quadras Dilip Daniel, 2019, Dent Res J (Isfahan), V16, P209
   Rego EB, 2011, ARCH ORAL BIOL, V56, P1238, DOI 10.1016/j.archoralbio.2011.05.007
   SAITO M, 1991, AM J ORTHOD DENTOFAC, V99, P226, DOI 10.1016/0889 5406(91)70005 H
   Schilling AF, 2005, J BONE MINER RES, V20, P274, DOI 10.1359/JBMR.041101
   Schroeder A, 2019, EUR J ORAL SCI, V127, P386, DOI 10.1111/eos.12643
   Sokos D, 2015, J PERIODONTAL RES, V50, P152, DOI 10.1111/jre.12197
   STOREY E, 1973, AM J ORTHOD DENTOFAC, V63, P292, DOI 10.1016/0002 9416(73)90353 9
   Yamaguchi M, 2006, J DENT RES, V85, P751, DOI 10.1177/154405910608500812
   Yamaguchi M, 2005, ARCH IMMUNOL THER EX, V53, P388
   Yang IH, 2011, ANGLE ORTHOD, V81, P326, DOI 10.2319/062210 343.1
   Yang J, 2012, CLIN EXP MED, V12, P79, DOI 10.1007/s10238 011 0149 2
   Zhang JN, 2012, BIOCHEM BIOPH RES CO, V421, P844, DOI 10.1016/j.bbrc.2012.04.100
   Zhang XG, 2019, CELL CYCLE, V18, P1759, DOI 10.1080/15384101.2019.1632638
NR 40
TC 3
Z9 4
U1 2
U2 17
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0889 5406
EI 1097 6752
J9 AM J ORTHOD DENTOFAC
JI Am. J. Orthod. Dentofac. Orthop.
PD FEB
PY 2022
VL 161
IS 2
BP 255
EP +
DI 10.1016/j.ajodo.2020.08.020
EA JAN 2022
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA YW6BY
UT WOS:000753498900022
PM 34756485
DA 2025 08 17
ER

PT J
AU Kuramochi, K
   Matsushima, K
AF Kuramochi, Kosei
   Matsushima, Kiyoshi
TI Role of Sphingosine 1 Phosphate in Human Dental Pulp Cells to Form Hard
   Tissue
SO JOURNAL OF HARD TISSUE BIOLOGY
LA English
DT Article
DE Calcification; Human dental pulp cells; Intracellular calcium ion
   concentration; Sphingosine 1 phosphate
ID S1P SIGNALING PATHWAY; ENDOPLASMIC RETICULUM; ACTIVATION; EXPRESSION;
   THERAPY; TEETH
AB Preservation of the dental pulp depends on the stimulation of hard tissue formation within the pulp itself. The presence of sphingosine 1 phosphate (S1P) in vivo has attracted considerable attention. S1P reportedly promotes osteoblast differentiation, and is believed to be involved in hard tissue formation. In the present study, we assessed the ability of S1P to induce hard tissue formation in cultured human dental pulp cells (hDPCs). hDPCs were cultured from aseptically extracted pulp tissue obtained from the first premolar of 20s  year  old patients that required orthodontic treatment. The effect of S1P on hard tissue formation was observed by measuring alkaline phosphatase (ALP) activity and performing alizarin red staining. Additionally, BMP 2 mRNA, and BMP 2 and DSPP protein expression levels were examined to confirm hard tissue formation. We also investigated the expression of the S1P receptor mRNA in without stimulation by S1P and changes in intracellular calcium ion concentration ([Ca2+]i) dynamics in S1P stimulated hDPCs. Stimulation of cultured hDPCs with S1P increased ALP activity and enhanced alizarin red staining. Additionally, S1P elevated BMP 2 mRNA expression, BMP2 and DSPP protein levels. Moreover, mRNA expressions of S1P receptors 1 3 were also observed in cultured hDPCs. S1P enhanced hard tissue formation and the expressions of markers of hard tissue formation including BMP 2 and DSPP incltured hDPCs. Moreover, S1P induces an increase in [Ca2+]i levels by facilitating the release of Ca2+ from the endoplasmic reticulum via S1P receptor 1 3.
C1 [Kuramochi, Kosei; Matsushima, Kiyoshi] Nihon Univ, Dept Endodont, Sch Dent Matsudo, Matsudo, Chiba, Japan.
   [Kuramochi, Kosei] Nihon Univ, Dept Endodont, Sch Dent Matsudo, Matsudo, Chiba 2718587, Japan.
C3 Nihon University; Nihon University
RP Kuramochi, K (通讯作者)，Nihon Univ, Dept Endodont, Sch Dent Matsudo, Matsudo, Chiba 2718587, Japan.
EM mako20007@g.nihon u.ac.jp
FU Japan Society for the Promotion of Science KAKENHI [20K099790, 23K09175]
FX Acknowledgments This study was supported by the Japan Society for the
   Promotion of Science KAKENHI Grant  in  Aid for Scientific Research
   (#20K099790, #23K09175) . We would like to thank Editage (
   www.editage.jp) for Eng  lish language editing.
CR Adachi T, 2013, Int J Oral  Med Sci, V11, P268
   Aeinehchi M, 2003, INT ENDOD J, V36, P225, DOI 10.1046/j.1365 2591.2003.00652.x
   Asghar MY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196992
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Chi HB, 2011, TRENDS PHARMACOL SCI, V32, P16, DOI 10.1016/j.tips.2010.11.002
   Chiba Kenji, 2009, Nihon Rinsho Meneki Gakkai Kaishi, V32, P92
   Dupont G, 2014, WIRES SYST BIOL MED, V6, P227, DOI 10.1002/wsbm.1261
   EBIHARA T, 1996, JPN J CONSERV DENT, V39, P1288
   Fernández Pisonero I, 2012, J IMMUNOL, V189, P5402, DOI 10.4049/jimmunol.1201309
   FITZGERALD M, 1991, OPER DENT, V16, P101
   Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006
   Fukai J, 2018, Jpn J Conserv dent, V61, P1
   GOSEKI M, 1990, J DENT RES, V69, P909, DOI 10.1177/00220345900690031601
   Grewe JM, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00205 0
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hayama T, 2016, J CELL BIOCHEM, V117, P1522, DOI 10.1002/jcb.25437
   Higashi K, 2016, BONE, V93, P1, DOI 10.1016/j.bone.2016.09.003
   Ishida Y, 2004, Japanese J Clin Chem, V33, P36
   Kamio N, 2008, BIOCHEM PHARMACOL, V75, P1974, DOI 10.1016/j.bcp.2008.02.018
   Kimura M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11071010
   Linu S, 2017, J ENDODONT, V43, P1635, DOI 10.1016/j.joen.2017.06.017
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsuzaki E, 2022, J DENT SCI, V17, P787, DOI 10.1016/j.jds.2021.10.004
   Matsuzaki E, 2020, JPN DENT SCI REV, V56, P127, DOI 10.1016/j.jdsr.2020.09.002
   Meshcheryakova A, 2017, EXPERT OPIN THER TAR, V21, P725, DOI 10.1080/14728222.2017.1332180
   Nakashima M, 2011, Jpn J Conserv Dent, V54, P157
   Niisato N, 1996, J PERIODONTAL RES, V31, P113, DOI 10.1111/j.1600 0765.1996.tb00472.x
   OHSHIMA M, 1988, Journal of Nihon University School of Dentistry, V30, P208
   Okabe T, 2006, J ENDODONT, V32, P198, DOI 10.1016/j.joen.2005.10.041
   Okada Taro, 2012, Seikagaku, V84, P92
   Okiji T, 2009, INT J DENT, V2009, DOI 10.1155/2009/464280
   Sakamoto M, 2003, Jpn J Conserv Dent, V46, P454
   Sato C, 2012, BIOCHEM BIOPH RES CO, V423, P200, DOI 10.1016/j.bbrc.2012.05.130
   SOMERMAN MJ, 1988, J DENT RES, V67, P66, DOI 10.1177/00220345880670011301
   Takahashi M, 2009, Shinshu Med J, V57, P127
   Takuwa Y, 2018, JOS, V18, P333
   Tsai HC, 2016, DRUGS, V76, P1067, DOI 10.1007/s40265 016 0603 2
   Ushioda R, 2016, P NATL ACAD SCI USA, V113, pE6055, DOI 10.1073/pnas.1605818113
   Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004
   Walter DH, 2007, ARTERIOSCL THROM VAS, V27, P275, DOI 10.1161/01.ATV.0000254669.12675.70
NR 40
TC 0
Z9 0
U1 1
U2 2
PU JOURNAL HARD TISSUE BIOLOGY
PI MINATO KU
PA NIHON GAKUKUTSU KYORYOKU ZAIDAN, 3  24  20, NISHIAZABU, MINATO KU, TOKYO
   106 0031, JAPAN
SN 1341 7649
J9 J HARD TISSUE BIOL
JI J. Hard Tissue Biol.
PY 2024
VL 33
IS 1
BP 1
EP 10
PG 10
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA KN6V4
UT WOS:001180692800001
DA 2025 08 17
ER

PT J
AU Zhou, J
   Zeng, F
   Cheng, SR
   Dong, XH
   Jiang, NN
   Zhang, XY
   Tang, CJ
   He, WH
   Chen, Y
   Sun, N
   Zhou, YF
   Li, XL
   Hu, SJ
   Sun, RR
   Wintermark, M
   Yang, WH
   Liang, FR
   Li, ZJ
AF Zhou, Jun
   Zeng, Fang
   Cheng, Shirui
   Dong, Xiaohui
   Jiang, Nannan
   Zhang, Xinyue
   Tang, Chenjian
   He, Wenhua
   Chen, Yang
   Sun, Ning
   Zhou, Yuanfang
   Li, Xinling
   Hu, Shengjie
   Sun, Ruirui
   Wintermark, Max
   Yang, Weihua
   Liang, Fanrong
   Li, Zhengjie
TI Modulation effects of different treatments on periaqueductal gray
   resting state functional connectivity in knee osteoarthritis knee pain
   patients
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Article
DE acupuncture; celecoxib; fMRI; knee osteoarthritis; periaqueductal gray;
   placebo; resting state functional connectivity
ID ACUPUNCTURE; SENSITIZATION; DISEASE; NSAIDS; CLASSIFICATION;
   METAANALYSIS; VALIDATION; MECHANISMS; ARTHRITIS; THERAPY
AB Background: The analgesic effect of acupuncture is widely recognized, but the mechanical characteristics of acupuncture for pain relief, compared to non steroidal anti inflammatory (NSAIDs) and placebo medication, remain unknown.Aims: To compare the modulation effects of acupuncture treatment with NSAIDs and placebo medication on descending pain modulation system (DPMS) in knee osteoarthritis (KOA) patients.Methods: This study recruited 180 KOA patients with knee pain and 41 healthy controls (HCs). Individuals with KOA knee pain were divided randomly into groups of verum acupuncture (VA), sham acupuncture (SA), celecoxib (SC), placebo (PB), and waiting list (WT), with 36 patients in each group. VA and SA groups included ten sessions of puncturing acupoints or puncturing non acupoints acupuncture treatment for two successive weeks. Celecoxib capsules were continuously given orally to patients in the SC group at a dosage of 200 mg daily for 2 weeks. In the PB group, patients received a placebo capsule once a day for 2 weeks at the same dosage as celecoxib capsules. In the WL group, patients did not receive any treatment. Patients underwent a resting state BOLD fMRI scan pre  and post receiving the therapy, whereas HCs only underwent a baseline scan. Seed (ventrolateral periaqueductal gray, vlPAG, a key node in DPMS) based resting state functional connectivity (rs FC) was applied in the data analysis.Results: All groups demonstrated improved knee pain scores relative to the initial state. There was no statistical difference between the VA and SA groups in all clinical outcomes, and vlPAG rs FC alterations. KOA knee pain individuals reported higher vlPAG rs FC in the bilateral thalamus than HCs. KOA knee pain patients in the acupuncture group (verum + sham, AG) exhibited increased vlPAG rs FC with the right dorsolateral prefrontal cortex (DLPFC) and the right angular, which is associated with knee pain improvement. In contrast with the SC and PB group, the AG exhibited significantly increased vlPAG rs FC with the right DLPFC and angular. Contrary to the WT group, the AG showed greater vlPAG rs FC with the right DLPFC and precuneus.Conclusions: Acupuncture treatment, celecoxib, and placebo medication have different modulation effects on vlPAG DPMS in KOA knee pain patients. Acupuncture could modulate vlPAG rs FC with brain regions associated with cognitive control, attention, and reappraisal for knee pain relief in KOA patients, compared with celecoxib and placebo medication.
C1 [Zhou, Jun; Zeng, Fang; Cheng, Shirui; Dong, Xiaohui; Jiang, Nannan; Zhang, Xinyue; Chen, Yang; Zhou, Yuanfang; Li, Xinling; Hu, Shengjie; Sun, Ruirui; Liang, Fanrong; Li, Zhengjie] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
   [Zeng, Fang; Cheng, Shirui; Dong, Xiaohui; Zhang, Xinyue; Sun, Ruirui; Li, Zhengjie] Chengdu Univ Tradit Chinese Med, Acupuncture & Brain Res Ctr, Chengdu, Peoples R China.
   [Tang, Chenjian] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
   [He, Wenhua] Univ Tradit Chinese Med, Affiliated Hosp Shanxi 2, Taiyuan, Peoples R China.
   [Sun, Ning] Sichuan Univ, West China Hosp, Rehabil Med Ctr, Chengdu, Peoples R China.
   [Sun, Ning] Sichuan Univ, West China Hosp, Inst Rehabil Med, Chengdu, Peoples R China.
   [Sun, Ning] Key Lab Rehabil Med Sichuan Prov, Chengdu, Peoples R China.
   [Wintermark, Max] Stanford Univ, Radiol Dept, Stanford, CA USA.
   [Yang, Weihua] Dali Bai Autonomous Prefecture Chinese Med Hosp, Dali, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine; Sichuan University; Sichuan University; Stanford
   University
RP Liang, FR; Li, ZJ (通讯作者)，Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
EM acuresearch@126.com; lzjbenjamin@163.com
RI ; Sun, Ruirui/U 8007 2017; 周, 俊/ISS 4050 2023; li,
   xinling/LGY 9132 2024; Li, Zhengjie/L 9250 2013; Hu,
   shengjie/JCP 5531 2023
OI Sun, Ning/0000 0002 1064 5705; 
FU National Natural Science Foundation of China [81603708, 81774400,
   81973958, 82225050]; Innovation Team and Talents Cultivation Program of
   National Administration of Traditional Chinese Medicine
   [ZYYCXTD D 202003]; China Postdoctoral Science Foundation [2017M610593,
   2018T110954, PC2019012]
FX National Natural Science Foundation of China, Grant/Award Number:
   81603708, 81774400, 81973958 and 82225050; Innovation Team and Talents
   Cultivation Program of National Administration of Traditional Chinese
   Medicine, Grant/Award Number: ZYYCXTD D 202003; China Postdoctoral
   Science Foundation, Grant/Award Number: 2017M610593, 2018T110954 and
   PC2019012
CR ALTMAN RD, 1991, SEMIN ARTHRITIS RHEU, V20, P40, DOI 10.1016/0049 0172(91)90026 V
   An X, 1998, J COMP NEUROL, V401, P455
   Arendt Nielsen L, 2017, CLIN EXP RHEUMATOL, V35, pS68
   Baker KR, 2004, ARTHRITIS RHEUM US, V50, P1815, DOI 10.1002/art.20261
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Bannuru RR, 2015, ANN INTERN MED, V163, P365, DOI 10.7326/M15 0623
   BEHBEHANI MM, 1995, PROG NEUROBIOL, V46, P575, DOI 10.1016/0301 0082(95)00009 K
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Burian M, 2005, PHARMACOL THERAPEUT, V107, P139, DOI 10.1016/j.pharmthera.2005.02.004
   Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516
   Cao J, 2021, PSYCHOSOM MED, V83, P870, DOI 10.1097/PSY.0000000000000984
   Chae Y, 2013, J PAIN, V14, P215, DOI 10.1016/j.jpain.2012.11.011
   Chen WH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423 0127 18 82
   Chen ZY, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194 017 0747 9
   Cheng SR, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.835050
   Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755
   Curtis CE, 2003, J COGNITIVE NEUROSCI, V15, P409, DOI 10.1162/089892903321593126
   Deng KF, 2020, WORLD J ACUPUNCT MOX, V30, P178, DOI 10.1016/j.wjam.2020.06.003
   Egorova N, 2015, NEUROIMAGE CLIN, V9, P430, DOI 10.1016/j.nicl.2015.09.012
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003 4819 133 8 200010170 00016
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Gang Jiahong, 2016, Zhongguo Zhen Jiu, V36, P467
   Garner S., 2002, COCHRANE DB SYST REV, V4, pCD003831
   Gecse K, 2022, SCI REP UK, V12, DOI 10.1038/s41598 021 04647 0
   Gollub RL, 2018, J PAIN, V19, P515, DOI 10.1016/j.jpain.2017.12.260
   Guo J, 2019, TRIALS, V20, DOI 10.1186/s13063 019 3233 7
   Gwilym SE, 2009, ARTHRIT RHEUM ARTHR, V61, P1226, DOI 10.1002/art.24837
   Hadjipavlou G, 2006, PAIN, V123, P169, DOI 10.1016/j.pain.2006.02.027
   Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012
   Helmick CG, 2008, ARTHRITIS RHEUM US, V58, P15, DOI 10.1002/art.23177
   Hinman RS, 2014, JAMA J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Imoto AM, 2019, RHEUMATOL INT, V39, P1159, DOI 10.1007/s00296 019 04289 6
   Kalisch R, 2006, J COGNITIVE NEUROSCI, V18, P1266, DOI 10.1162/jocn.2006.18.8.1266
   Kohn MD, 2016, CLIN ORTHOP RELAT R, V474, P1886, DOI 10.1007/s11999 016 4732 4
   Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524
   Kong J, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0067485, 10.1371/journal.pone.0081049]
   Kong J, 2010, BEHAV BRAIN RES, V211, P215, DOI 10.1016/j.bbr.2010.03.042
   Kong J, 2010, PAIN, V148, P257, DOI 10.1016/j.pain.2009.11.008
   Kumar JSD., 2018, MOLECULES, V23, P1
   Lau WK, 2010, NEUROSCIENCE, V170, P655, DOI 10.1016/j.neuroscience.2010.07.031
   Leith JL, 2014, J PHYSIOL LONDON, V592, P5093, DOI 10.1113/jphysiol.2014.275909
   Leung YY, 2017, OSTEOARTHR CARTILAGE, V25, P1420, DOI 10.1016/j.joca.2017.04.001
   Li ZJ, 2016, SCI REP UK, V6, DOI 10.1038/srep20298
   Linnman C, 2012, NEUROIMAGE, V60, P505, DOI 10.1016/j.neuroimage.2011.11.095
   Liu BY, 2021, ACUPUNCT HERB MED, V1, P65, DOI 10.1097/HM9.0000000000000017
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586 021 04001 4
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Liu T, 2017, NEUROSCI BIOBEHAV R, V83, P451, DOI 10.1016/j.neubiorev.2017.09.018
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lv QY, 2019, FRONT INTEGR NEUROSC, V13, DOI 10.3389/fnint.2019.00038
   Madsen MV, 2009, BMJ BRIT MED J, V338, DOI 10.1136/bmj.a3115
   Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537
   Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186
   Mäntyselka P, 2001, PAIN, V89, P175, DOI 10.1016/S0304 3959(00)00361 4
   Mao JJ, 2007, EXPLORE NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   McDougall JJ, 2017, OSTEOARTHR CARTILAGE, V25, P926, DOI 10.1016/j.joca.2016.08.016
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304 3959(87)91074 8
   Menant O, 2016, J CHEM NEUROANAT, V77, P110, DOI 10.1016/j.jchemneu.2016.06.003
   Micklewright R, 2003, ALIMENT PHARM THER, V17, P321, DOI 10.1046/j.1365 2036.2003.01454.x
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Napadow V, 2009, NEUROIMAGE, V47, P289, DOI 10.1016/j.neuroimage.2009.03.060
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Ong WY, 2019, MOL NEUROBIOL, V56, P1137, DOI 10.1007/s12035 018 1130 9
   Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91
   Peciña M, 2015, MOL PSYCHIATR, V20, P416, DOI 10.1038/mp.2014.164
   Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018
   Prabhakaran J, 2021, MOLECULES, V26, DOI 10.3390/molecules26113208
   Pujol J, 2017, PAIN, V158, P1831, DOI 10.1097/j.pain.0000000000000985
   Puljak L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009865.pub2
   Qiu YH, 2009, NEUROSCI BULL, V25, P277, DOI 10.1007/s12264 009 0907 2
   Radojcic MR, 2017, PAIN, V158, P1254, DOI 10.1097/j.pain.0000000000000908
   Richmond J, 2010, J BONE JOINT SURG AM, V92A, P990, DOI 10.2106/JBJS.I.00982
   Safiri S, 2020, ANN RHEUM DIS, V79, P819, DOI 10.1136/annrheumdis 2019 216515
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003 4819 145 1 200607040 00005
   Schwedt TJ, 2014, PAIN MED, V15, P154, DOI 10.1111/pme.12267
   Schweinhardt P, 2009, J NEUROSCI, V29, P4882, DOI 10.1523/JNEUROSCI.5634 08.2009
   Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028
   Seghier ML, 2013, NEUROSCIENTIST, V19, P43, DOI 10.1177/1073858412440596
   Seminowicz DA, 2017, J PAIN, V18, P1027, DOI 10.1016/j.jpain.2017.03.008
   Shin MC, 2003, BRAIN RES BULL, V59, P251, DOI 10.1016/S0361 9230(02)00872 9
   Soni A, 2019, ARTHRITIS RHEUMATOL, V71, P550, DOI 10.1002/art.40749
   Sun ZW, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/9167956
   Tang CJ, 2019, TRIALS, V20, DOI 10.1186/s13063 018 3111 8
   Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022 3999(02)00428 2
   Tsagareli N, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110722
   Tsiklauri N, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360 017 0193 y
   Tsiklauri N, 2017, PHARMACOL REP, V69, P168, DOI 10.1016/j.pharep.2016.10.004
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   van den Berg Wolf M, 2014, AM J MED, V127, pE23, DOI 10.1016/j.amjmed.2014.06.022
   Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976
   Wang L, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.636202
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650 199603000 00003
   WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405
   Wiech K, 2008, TRENDS COGN SCI, V12, P306, DOI 10.1016/j.tics.2008.05.005
   Wiech K, 2022, J PAIN, V23, P680, DOI 10.1016/j.jpain.2021.11.006
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140 6736(05)66871 7
   Wu DL, 2014, EXP BRAIN RES, V232, P527, DOI 10.1007/s00221 013 3761 4
   Xu H, 2022, CNS NEUROSCI THER, V28, P714, DOI 10.1111/cns.13803
   Yan CG, 2016, NEUROINFORMATICS, V14, P339, DOI 10.1007/s12021 016 9299 4
   Yu RJ, 2014, NEUROIMAGE CLIN, V6, P100, DOI 10.1016/j.nicl.2014.08.019
   Yu SY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061719
   Zyloney CE, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 80
NR 104
TC 14
Z9 16
U1 3
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1755 5930
EI 1755 5949
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD JUL
PY 2023
VL 29
IS 7
BP 1965
EP 1980
DI 10.1111/cns.14153
EA MAR 2023
PG 16
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA M2LH5
UT WOS:000946167800001
PM 36890655
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, D
   Tang, D
   Liu, PT
   Tao, L
   Lu, LM
AF Zhang, Duo
   Tang, Di
   Liu, Pen tao
   Tao, Lei
   Lu, Li ming
TI Isolation of tumor stem like cells from primary laryngeal squamous cell
   carcinoma cells (FD LS 6)
SO HUMAN CELL
LA English
DT Article
DE Laryngeal squamous cell carcinoma; LSCC; LSCC sphere forming cells;
   LSCSCs; Cancer stem like cells; CSCs; Epithelial mesenchymal transition;
   EMT
ID CANCER; HEAD; ESTABLISHMENT; PLASTICITY; FEATURES; ADULT; MODEL; CD133
AB The development of efficient treatments for laryngeal squamous cell carcinoma (LSCC) is hindered by the lack of applicable tumor cell lines and animal models of the disease, especially those related to cancer stem like cells (CSCs). CSCs play critical roles in tumor propagation and pathogenesis whereas no CSCs lines have been developed to date. In this study, we establish an LSCC cell line (FD LS 6) from primary LSCC tumor tissue (not experienced single cell cloning) and adapted a culturing condition for the expansion of potential stem cells (EPSCs) to isolate CSCs from FD LS 6. We successfully derived novel CSCs and named them as LSCC sphere forming cells (LSCSCs) which were subsequently characterized for their CSC properties. We showed that LSCSCs shared many properties of CSCs, including CSC marker, robust self renewal capacity, tumorigenesis ability, potential to generate other cell types such as adipocytes and osteoblasts, and resistance to chemotherapy. Compared to parental cells, LSCSCs were significantly more potent in forming tumors in vivo in mice and more resistant to chemotherapy. LSCSCs have higher expressions of epithelial mesenchymal transition proteins and chemotherapy resistance factors, and exhibit an activated COX2/PEG2 signaling pathway. Altogether, our work establishes the first CSCs of LSCC (FD LS 6) and provides a tool to study tumorigenesis and metastasis of LSCC and help the development of anticancer therapies.
C1 [Lu, Li ming] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
   [Zhang, Duo; Tang, Di; Tao, Lei] Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Otolaryngol HNS, Sch Med,Shanghai Key Clin Disciplines Otorhinolary, 83 Fenyang Rd, Shanghai 200031, Peoples R China.
   [Zhang, Duo; Tang, Di; Tao, Lei] Fudan Univ, Sch Med, Dept Pudong Hosp, 2800 Gongwei Rd, Shanghai 201300, Peoples R China.
   [Liu, Pen tao] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Stem Cell & Regenerat Med Consortium, 5 Sassoon Rd, Hong Kong, Peoples R China.
   [Liu, Pen tao] Ctr Translat Stem Cell Biol, Sci & Technol Pk,6 8 Harbour Rd, Hong Kong, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Jiao Tong University; Fudan
   University; Fudan University; University of Hong Kong
RP Lu, LM (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.; Tao, L (通讯作者)，Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Otolaryngol HNS, Sch Med,Shanghai Key Clin Disciplines Otorhinolary, 83 Fenyang Rd, Shanghai 200031, Peoples R China.; Tao, L (通讯作者)，Fudan Univ, Sch Med, Dept Pudong Hosp, 2800 Gongwei Rd, Shanghai 201300, Peoples R China.
EM doctortaolei@163.com; lulunew2003@163.com
FU National Natural Science Foundation of China [82103316, 82203506,
   30801283, 30972691, 82071856, 81671579, 31370904]; Science and
   Technology Commission of Shanghai Municipality [22490760400]; Shanghai
   Municipal Commission of Health, Scientific Research Program of
   Traditional Chinese medicine [2020JP009]; Shuguang Planning of Shanghai
   Municipal Education Commission [16SG14]; National Key Research and
   Development Program [2020YFA0113101]
FX This study was supported by the National Natural Science Foundation of
   China under Grand (82103316, 82203506, 30801283, 30972691, 82071856,
   81671579, 31370904). Program for scientific and technological innovation
   from the Science and Technology Commission of Shanghai Municipality
   (22490760400); Shanghai Municipal Commission of Health, Scientific
   Research Program of Traditional Chinese medicine(2020JP009); Shuguang
   Planning of Shanghai Municipal Education Commission (16SG14); The
   National Key Research and Development Program (2020YFA0113101)
CR Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008 5472.CAN 09 3463
   Almotiri A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI129115
   Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Bielecka ZF, 2017, BIOL REV, V92, P1505, DOI 10.1111/brv.12293
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   Chao HM, 2018, J FORMOS MED ASSOC, V117, P1046, DOI 10.1016/j.jfma.2018.06.013
   Chu EA, 2008, OTOLARYNG CLIN N AM, V41, P673, DOI 10.1016/j.otc.2008.01.016
   Dittfeld C, 2010, RADIOTHER ONCOL, V94, P375, DOI 10.1016/j.radonc.2009.10.010
   Dzobo K, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081896
   Gao XF, 2019, NAT CELL BIOL, V21, P687, DOI 10.1038/s41556 019 0333 2
   Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797
   Jariyal H, 2019, STEM CELL REV REP, V15, P755, DOI 10.1007/s12015 019 09912 4
   Jeong EM, 2018, STEM CELL REP, V10, P600, DOI 10.1016/j.stemcr.2017.12.007
   Jung JG, 2016, CANCER RES, V76, P6351, DOI 10.1158/0008 5472.CAN 16 0980
   Kim HS, 2016, METHODS MOL BIOL, V1395, P241, DOI 10.1007/978 1 4939 3347 1_14
   Kim SY, 1997, ACTA OTO LARYNGOL, V117, P775, DOI 10.3109/00016489709113477
   Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108
   Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034
   Liao JW, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0623 x
   Lim YC, 2011, ORAL ONCOL, V47, P83, DOI 10.1016/j.oraloncology.2010.11.011
   Lin MC, 2018, INT J CANCER, V143, P1440, DOI 10.1002/ijc.31523
   Liotta F, 2015, BRIT J CANCER, V112, P745, DOI 10.1038/bjc.2015.15
   Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McDermott Sarah C, 2018, Oncotarget, V9, P25148, DOI 10.18632/oncotarget.25358
   Montesinos JJ, 2009, CYTOTHERAPY, V11, P163, DOI 10.1080/14653240802582075
   Oliphant MUJ, 2019, CANCER RES, V79, P720, DOI 10.1158/0008 5472.CAN 18 1791
   Ooki A, 2018, CANCER RES, V78, P168, DOI 10.1158/0008 5472.CAN 17 0836
   Osei Sarfo K, 2013, CARCINOGENESIS, V34, P2673, DOI 10.1093/carcin/bgt223
   Peitzsch C, 2019, CANCERS, V11, DOI 10.3390/cancers11050616
   Prasmickaite L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010731
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033358
   Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006
   Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005
   Wang SY, 2018, CANCER LETT, V439, P78, DOI 10.1016/j.canlet.2018.09.026
   Wang XT, 2023, J BIOMED MATER RES B, V111, P1499, DOI 10.1002/jbm.b.35249
   Wei XD, 2009, HEAD NECK J SCI SPEC, V31, P94, DOI 10.1002/hed.20935
   Weiswald LB, 2009, BRIT J CANCER, V101, P473, DOI 10.1038/sj.bjc.6605173
   Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004
   Yang J, 2017, NATURE, V550, P393, DOI 10.1038/nature24052
   Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044
   Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311
   Zhou Yan jiao, 2019, Nature Communications, V10, DOI [10.1038/s41467 019 12821 2, 10.1038/s41467 019 13698 x]
NR 45
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 7470
EI 1749 0774
J9 HUM CELL
JI Hum. Cell
PD JAN
PY 2024
VL 37
IS 1
BP 323
EP 336
DI 10.1007/s13577 023 00984 6
EA SEP 2023
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GC3Q7
UT WOS:001076663300001
PM 37759147
DA 2025 08 17
ER

PT J
AU Li, BF
   Huang, GY
   Ma, ZH
   Qin, SR
AF Li, Baofeng
   Huang, Guiyun
   Ma, Zhenhe
   Qin, Shourong
TI Ultrasound assisted transdermal delivery of alendronate for the
   treatment of osteoporosis
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE sonophoresis; alendronate nanoparticles; rat; osteoporosis; transdermal
   patch
ID LOW FREQUENCY SONOPHORESIS; BISPHOSPHONATES; MECHANISMS
AB The aim of the current research work was to develop sonophoresis assisted transdermal patches for the treatment of osteoporosis. In the present investigation, we formulated alendronate chitosan nanoparticles by ionotropic external gelation method. The prepared nanoparticles were found to be smooth and free flowing. The optimized formulation showed 82.7% of drug release over a period of 12 hours with 99.54% EE, the particle size of 250 nm, PDI 0.22 and zeta potential of 28 mV. The solvent casting evaporation method was used for the development of the patches using HPMC as rate controlling polymer and dibutyl phthalate as the plasticizer. The optimized patch formulation was found acceptable in terms of physical characteristics (appearance, thickness, folding endurance, weight variation, moisture loss and uptake). The drug content was found to be 99.66 +/  0.9 % with 69.44% of drug permeation through the rat skin. The TP3 formulation had drug content of 99.96% which was the highest among all of the formulations and showed relatively controlled skin permeation of 69.44% over the period of 12 hours. Nearly six time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis. Over the period of seven days, the plasma calcium concentration in the rat model was decreased from 16 mg/dl to 4 mg/dl (4 times) in rat groups treated with the transdermal patches containing CS ALN NP while the concentration dropped only to 12 mg/dl in case of the transdermal patches containing pure Alendronate. These findings (enhanced skin permeation, enhanced bioavailability and suppression of the plasma calcium level) regarding the transdermal delivery system suggest a promising approach for the treatment of osteoporosis.
C1 [Li, Baofeng] Shandong Prov Hosp Tradit Chinese Med, Dept Minimally Invas Orthopaed, Jinan 250011, Shandong, Peoples R China.
   [Huang, Guiyun] Jiyang Publ Hosp Shandong Prov, Dept Orthopaed, Jinan 251400, Shandong, Peoples R China.
   [Ma, Zhenhe] Ningjin Cty Hosp Tradit Chinese Med, Dept Rehabil, Dezhou 253400, Shandong, Peoples R China.
   [Qin, Shourong] Taian City Cent Hosp, Dept Traumat Orthopaed, 29 Longtan Rd, Tai An 271000, Shandong, Peoples R China.
RP Qin, SR (通讯作者)，Taian City Cent Hosp, Dept Traumat Orthopaed, 29 Longtan Rd, Tai An 271000, Shandong, Peoples R China.
EM shourongqin@sina.com
CR ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
   Dolatabadi JEN, 2014, COLLOID SURFACE B, V117, P21, DOI 10.1016/j.colsurfb.2014.01.055
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   FLEISCH H, 1987, CLIN ORTHOP RELAT R, P72
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Haddad Patricia Tanios, 2015, Rev. bras. ortop., V50, P100, DOI 10.1016/j.rboe.2014.12.007
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kaveh K, 2010, J ANIM VET ADV, V9, P1055, DOI 10.3923/javaa.2010.1055.1067
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   McCarthy EA, 2002, PEDIATR RES, V52, P660, DOI 10.1203/01.PDR.0000032068.76811.0D
   Morimoto Y, 2005, J CONTROL RELEASE, V103, P587, DOI 10.1016/j.jconrel.2005.01.005
   Paliwal S, 2006, J INVEST DERMATOL, V126, P1095, DOI 10.1038/sj.jid.5700248
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   Saunders Y, 2004, PALLIATIVE MED, V18, P418, DOI 10.1191/0269216304pm914ra
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wen L.D., 2009, POLYMER, V75, P385, DOI DOI 10.1016/j.carbpol.2008.07.039
NR 25
TC 5
Z9 5
U1 1
U2 29
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02 093 WARSAW, POLAND
SN 0001 527X
EI 1734 154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2020
VL 67
IS 2
BP 173
EP 179
DI 10.18388/abp.2020_5162
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA MB9PL
UT WOS:000542929500005
PM 32558528
OA gold
DA 2025 08 17
ER

PT J
AU Asici, GSE
   Kiral, F
AF Asici, G. S. Ekren
   Kiral, F.
TI Cytotoxic and apoptotic effects of zoledronic acid on D 17 canine
   osteosarcoma cell line
SO IRANIAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
DE Apoptosis; Bisphosphonates; Caspase; Survivin
ID ALKALINE PHOSPHATASE ACTIVITY; EXPRESSION; DIFFERENTIATION;
   MINERALIZATION; INDUCTION; SURVIVIN; SUPPRESSES; SAOS 2
AB Background: Pets are exposed to a multitude of carcinogenic substances in the modern world. Consequently, high rates of cancer are observed, particularly in middle aged cats and dogs. Although bisphosphonates have been incorporated into the treatment of human cancers, there are few animal specific studies. As the number of cancer cases in animals continues to rise, it becomes increasingly important to evaluate anticancer drugs on a species specific basis. Aims: The present study aimed to examine the impact of zoledronic acid (ZA) on apoptotic pathways in canine osteosarcoma (OSA) cell lines. Methods: The apoptotic effects of ZA administration on D 17 canine OSA cells were analysed by determining apoptotic DNA breaks, caspase 3, 8 and 9 levels by ELISA method and Bax/Bcl 2 ratio by qRT PCR. The effect of ZA on the colony formation capacity of cells was evaluated by crystal violet staining method. The mineral binding capacity of ZA application in cells was investigated by Alizarin Red S staining technique. The change in alkaline phosphatase enzyme activity in OSA cells due to ZA treatment was determined using the colorimetric method. The antimetastatic effect was determined using the wound healing method, which evaluated the migration potential of cells. Results: While ZA application did not show a significant cytotoxic effect in the cells in the first 24 h, a decrease observed in the viability of the cells depending on the increasing dose and time. Low dose ZA (1, 5, 7.5, 10 mu M) concentrations increased mineral content and alkaline phosphatase enzyme activity. A significant decrease was found in the expression levels of survivin, which determines the cell survival, depending on the dose and time. Conclusion: It is expected that our obtained data will contribute to the more effective treatment of the disease by creating different treatment options for clinicians in the light of increasing knowledge in cancer cell biology.
C1 [Asici, G. S. Ekren; Kiral, F.] Aydin Adnan Menderes Univ, Fac Vet Med, Dept Biochem, Aydin, Turkiye.
C3 Adnan Menderes University
RP Asici, GSE (通讯作者)，Aydin Adnan Menderes Univ, Fac Vet Med, Dept Biochem, Aydin, Turkiye.
EM gamze.ekren@adu.edu.tr
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Al Khan AA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 58524 3
   ALI NN, 1993, BONE, V14, P847, DOI 10.1016/8756 3282(93)90314 Z
   Basso FG, 2013, GERONTOLOGY, V59, P534, DOI 10.1159/000351194
   Boerman I, 2012, BMC VET RES, V8, DOI 10.1186/1746 6148 8 56
   Bruzzese F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.406
   Caraglia M, 2010, EXPERT OPIN PHARMACO, V11, P141, DOI 10.1517/14656560903485664
   Cheung LC, 2018, LEUKEMIA, V32, P2326, DOI 10.1038/s41375 018 0144 7
   Christou A, 2023, CLIN EXP MED, V23, P3041, DOI 10.1007/s10238 022 00961 7
   Conry RM, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0046 2
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   FARLEY JR, 1989, CLIN CHEM, V35, P223
   Forest V, 2005, CRYOBIOLOGY, V50, P29, DOI 10.1016/j.cryobiol.2004.09.007
   Fu DH, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 146
   Ge XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101207
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Kavya N, 2017, VET WORLD, V10, P1286, DOI 10.14202/vetworld.2017.1286 1291
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Liu L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6661534
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Ory B, 2008, J CELL MOL MED, V12, P928, DOI 10.1111/j.1582 4934.2008.00141.x
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Poirier V J, 2003, Vet Comp Oncol, V1, P207, DOI 10.1111/j.1476 5810.2003.00026.x
   Poradowski D, 2021, ANIMALS BASEL, V11, DOI 10.3390/ani11113135
   Ren HY, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/160835
   Rodriguez Luis G., 2004, V294, P23
   Ryu K, 2010, ANTICANCER RES, V30, P2713
   Shoeneman JK, 2012, CANCER RES, V72, P249, DOI 10.1158/0008 5472.CAN 11 2315
   Smith AA, 2023, VET MED SCI, V9, P59, DOI 10.1002/vms3.1000
   Suva LJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115711
   Szewczyk M, 2015, VET RES COMMUN, V39, P61, DOI 10.1007/s11259 014 9623 0
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   TIETZ NW, 1983, CLIN CHEM, V29, P751
   TOBIAS JH, 1993, BONE, V14, P619, DOI 10.1016/8756 3282(93)90083 M
   Uchide T, 2005, DNA SEQUENCE, V16, P329, DOI 10.1080/10425170500213696
   Ullén A, 2009, SCAND J UROL NEPHROL, V43, P98, DOI 10.1080/00365590802475904
   Wilson H, 2008, VET J, V175, P69, DOI 10.1016/j.tvjl.2007.07.025
   Yu JQ, 2013, PHYTOTHER RES, V27, P251, DOI 10.1002/ptr.4703
   Zhang R, 2015, BMC VET RES, V11, DOI 10.1186/s12917 015 0331 y
NR 43
TC 0
Z9 0
U1 1
U2 1
PU SHIRAZ UNIV
PI SHIRAZ
PA SCHOOL VETERINARY MEDICINE, SHIRAZ, 71344, IRAN
SN 1728 1997
J9 IRAN J VET RES
JI Iran J. Veterinary Res.
PY 2024
VL 25
IS 3
DI 10.22099/ijvr.2024.47475.6877
PG 11
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA U8B0K
UT WOS:001413967900002
PM 39925838
DA 2025 08 17
ER

PT J
AU Taki, N
   Tatro, JM
   Lowe, R
   Goldberg, VM
   Greenfield, EM
AF Taki, Naoya
   Tatro, Joscelyn M.
   Lowe, Robert
   Goldberg, Victor M.
   Greenfield, Edward M.
TI Comparison of the roles of IL 1, IL 6, and TNFα in cell culture and
   murine models of aseptic loosening
SO BONE
LA English
DT Article
DE aseptic loosening; IL 1; IL 6; osteolysis; TNF alpha
ID DEBRIS INDUCED OSTEOLYSIS; TOTAL HIP ARTHROPLASTY; WEAR DEBRIS; TITANIUM
   PARTICLES; BONE RESORPTION; GENE THERAPY; PERIPROSTHETIC OSTEOLYSIS;
   CYTOKINE PRODUCTION; ADHERENT ENDOTOXIN; IN VITRO
AB Pro inflammatory cytokines, such as IL 1, IL 6, and TNF, are considered to be major mediators of osteolysis and ultimately aseptic loosening. This study demonstrated that synergistic interactions among these cytokines are required for the in vitro stimulation of osteoclast differentiation by titanium particles. In contrast, genetic knock out of these cytokines or their receptors does not protect murine calvaria from osteolysis induced by titanium particles. Thus, the extent of osteolysis was not substantially altered in single knock out mice lacking either the IL 1 receptor or IL 6. Osteolysis also was not substantially altered in double knock out mice lacking both the IL 1 receptor and IL 6 or in double knock out mice lacking both TNF receptor 1 and TNF receptor 2. The differences between the in vivo and the cell culture results make it difficult to conclude whether the pro inflammatory cytokines contribute to aseptic loosening. One alternative is that in vivo experiments are more physiological and that therefore the current results do not support a role for the pro inflammatory cytokines in aseptic loosening. We however favor the alternative that, in this case, the cell culture experiments can be more informative. We favor this alternative because the role of the pro inflammatory cytokines may be obscured in vivo by compensation by other cytokines or by the low signal to noise ratio found in measurements of particle induced osteolysis. (c) 2006 Elsevier Inc. All rights reserved.
C1 Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA.
   Case Med Ctr, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University
RP Greenfield, EM (通讯作者)，Case Western Reserve Univ, Dept Orthopaed, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM emg3@po.cwru.edu
FU NIAMS NIH HHS [R01 AR043769, R01 AR43769] Funding Source: Medline
CR Akisue T, 2002, J BIOMED MATER RES, V59, P507, DOI 10.1002/jbm.1264
   AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065 2776(08)60535 0
   Bi YM, 2001, J BONE MINER RES, V16, P2082, DOI 10.1359/jbmr.2001.16.11.2082
   Bi YM, 2001, J BONE JOINT SURG AM, V83A, P501, DOI 10.2106/00004623 200104000 00004
   CARMODY E, 2002, T ORTHOP RES SOC, V27, P1052
   Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231 4236.1999
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Childs LM, 2001, J BONE MINER RES, V16, P338, DOI 10.1359/jbmr.2001.16.2.338
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Epstein NJ, 2005, J ORTHOP RES, V23, P501, DOI 10.1016/j.orthres.2004.10.004
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Goodman SB, 1998, J BONE JOINT SURG BR, V80B, P531, DOI 10.1302/0301 620X.80B3.8158
   Gordon A, 2003, J BONE MINER RES, V18, pS326
   GREENFIELD E, 2006, ENCY BIOMATERIALS BI
   Greenfield EM, 2005, J BIOMED MATER RES B, V72B, P179, DOI 10.1002/jbm.b.30150
   Haddad JJ, 2002, BIOCHEM BIOPH RES CO, V297, P700, DOI 10.1016/S0006 291X(02)02287 8
   Hicks DG, 1996, J BONE JOINT SURG AM, V78A, P482, DOI 10.2106/00004623 199604000 00002
   JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623 199306000 00007
   Kaar SG, 2001, J ORTHOPAED RES, V19, P171, DOI 10.1016/S0736 0266(00)00033 4
   Kassiotis G, 2001, J CLIN INVEST, V107, P1507, DOI 10.1172/JCI13362
   Keystone EC, 2005, J RHEUMATOL, V32, P8
   Kobayashi Y, 2005, J ORTHOP SCI, V10, P62, DOI 10.1007/s00776 004 0846 8
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Konttinen YT, 2002, CLIN EXP RHEUMATOL, V20, P485
   Konttinen YT, 1996, CLIN EXP RHEUMATOL, V14, P255
   Maloney WJ, 1996, CLIN ORTHOP RELAT R, P268
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Moro T, 2004, NAT MATER, V3, P829, DOI 10.1038/nmat1233
   NALEPKA JL, 2001, T ORTHOP RES SOC, V26, P40
   Nelson CL, 2005, CLIN ORTHOP RELAT R, P25, DOI 10.1097/01.blo.0000175715.68624.3d
   Ohishi M, 2005, J IMMUNOL, V174, P3024, DOI 10.4049/jimmunol.174.5.3024
   Perry J, 1996, BRIT J RHEUMATOL, V35, P943
   Ragab AA, 1999, J ORTHOPAED RES, V17, P803, DOI 10.1002/jor.1100170603
   Ragab AA, 2002, AM J PHYSIOL CELL PH, V283, pC679, DOI 10.1152/ajpcell.00421.2001
   Riggs L, 2000, BONE, V27, P761
   Rychly DJ, 2005, PHARMACOTHERAPY, V25, P1181, DOI 10.1592/phco.2005.25.9.1181
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   SHANBHAG AS, 1995, J ORTHOPAED RES, V13, P792, DOI 10.1002/jor.1100130520
   Shimizu S, 2005, J BONE MINER RES, V20, pS258
   Stea S, 2000, CYTOKINE, V12, P1575, DOI 10.1006/cyto.2000.0753
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   TAKI N, 2002, T ORTHOP RES SOC, V27, P1045
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Wilkinson JM, 2003, J BONE MINER RES, V18, P1995, DOI 10.1359/jbmr.2003.18.11.1995
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Wright T.M., 2001, IMPLANT WEAR TOTAL J
   Xu JW, 1996, CLIN EXP RHEUMATOL, V14, P643
   Yang SY, 2005, J BONE JOINT SURG AM, V87A, P1088, DOI 10.2106/JBJS.D.02052
   Yang SY, 2004, GENE THER, V11, P483, DOI 10.1038/sj.gt.3302192
NR 52
TC 67
Z9 82
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2007
VL 40
IS 5
BP 1276
EP 1283
DI 10.1016/j.bone.2006.12.053
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 162ZS
UT WOS:000246128700013
PM 17236833
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Leon, IE
   Di Virgilio, AL
   Porro, V
   Muglia, CI
   Naso, LG
   Williams, PAM
   Bollati Fogolin, M
   Etcheverry, SB
AF Leon, I. E.
   Di Virgilio, A. L.
   Porro, V.
   Muglia, C. I.
   Naso, L. G.
   Williams, P. A. M.
   Bollati Fogolin, M.
   Etcheverry, S. B.
TI Antitumor properties of a vanadyl(IV) complex with the flavonoid chrysin
   [VO(chrysin)2EtOH]2 in a human osteosarcoma model:
   the role of oxidative stress and apoptosis
SO DALTON TRANSACTIONS
LA English
DT Article
ID IN VITRO; DNA DAMAGE; HYDROGEN PEROXIDE; SENSITIVE METHOD;
   GROWTH FACTOR; COMET ASSAY; VANADIUM; CELLS; OSTEOBLAST; PROLIFERATION
AB Flavonoids, a polyphenolic compound family, and the vanadium compounds have interesting biological, pharmacological, and medicinal properties. We report herein the antitumor actions of the complex [VO(chrysin)(2)EtOH](2) (VOchrys) on the MG 63 human osteosarcoma cell line. Oxovanadium(IV), chrysin and VOchrys caused a concentration dependent inhibition of cell viability. The complex was the strongest antiproliferative agent (p < 0.05). Cytotoxicity and genotoxicity studies also showed a concentration effect. Reactive oxygen species (ROS) and the alterations in the GSH/GSSG ratio underlie the main mechanisms of action of VOchrys. Additions of ROS scavengers (vitamin C plus vitamin E) or GSH to the viability experiments demonstrated beneficial effects (p < 0.01). Besides, the complex triggered apoptosis, disruption of the mitochondria membrane potential (MMP), increased levels of caspase 3 and DNA fragmentation measured by the sub G1 peak in cell cycle arrest experiments (p < 0.01). Collectively, VOchrys is a cell death modulator and a promissory complex to be used in cancer treatments.
C1 [Leon, I. E.; Di Virgilio, A. L.; Etcheverry, S. B.] Univ Nacl La Plata, Catedra Bioquim Patol, Fac Ciencias Exactas, RA 1900 La Plata, Argentina.
   [Leon, I. E.; Di Virgilio, A. L.; Naso, L. G.; Williams, P. A. M.; Etcheverry, S. B.] Univ Nacl La Plata, Ctr Quim Inorgan CEQUINOR, Fac Ciencias Exactas, RA 1900 La Plata, Argentina.
   [Porro, V.; Bollati Fogolin, M.] Inst Pasteur Montevideo, Unidad Biol Celular, Montevideo 11400, Uruguay.
   [Muglia, C. I.] Univ Nacl La Plata, Lab Invest Sistema Inmune LISIN, Fac Ciencias Exactas, RA 1900 La Plata, Argentina.
C3 National University of La Plata; National University of La Plata;
   Pasteur Network; Institut Pasteur de Montevideo; National University of
   La Plata
RP Etcheverry, SB (通讯作者)，Univ Nacl La Plata, Catedra Bioquim Patol, Fac Ciencias Exactas, 47 & 115, RA 1900 La Plata, Argentina.
EM etcheverry@biol.unlp.edu.ar
RI ; leon, i/GZL 2093 2022
OI leon, ignacio/0000 0003 1010 3997; Williams,
   Patricia/0000 0002 1549 5873; Bollati Fogolin,
   Mariela/0000 0001 6829 3135
FU UNLP from Argentina [11X/554]; CONICET from Argentina [PIP 1125, 0938];
   ANPCyT from Argentina [PICT 2008 2218, PICT 2010 0981]; ANPCyT,
   Argentina; CONICET, Argentina
FX This work was partly supported by UNLP (11X/554), CONICET (PIP 1125 and
   0938), and ANPCyT (PICT 2008 2218 and PICT 2010 0981) from Argentina.
   ALDV, CIM and SBE are members of the Carrera del Investigador, CONICET,
   Argentina. IEL has a fellowship from ANPCyT, Argentina. VP and MBF are
   members of the Sistema Nacional de Investigadores (SNI) of the Agencia
   Nacional de Investigacion e Innovacion (ANII) from Uruguay. LGN is a
   fellowship from CONICET, Argentina and PAMW is member of the Carrera del
   Investigador CICPBA. Besides, the authors would like to thank Ines
   Tiscornia for management of the cells and Prof. Maria del Carmen Bernal
   for her careful revision of the manuscript.
CR [Anonymous], 2019, (the "Gold Book")
   [Anonymous], 2000, CANCER RES
   Barrio DA, 2006, CAN J PHYSIOL PHARM, V84, P765, DOI 10.1139/Y06 021
   Baumgartner HK, 2007, AM J PHYSIOL GASTR L, V293, pG296, DOI 10.1152/ajpgi.00103.2007
   Bhuiyan MS, 2009, J PHARMACOL SCI, V110, P1, DOI 10.1254/jphs.09R01CR
   Borenfreund E., 1984, Journal of Tissue Culture Methods, V9, P7, DOI [10.1007/BF01666038, DOI 10.1007/BF01666038]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Capella M. A. M., 2008, CELL BIOL INT, V32, P224
   Cárdenas M, 2006, BIOORGAN MED CHEM, V14, P2966, DOI 10.1016/j.bmc.2005.12.021
   Collins AR, 1997, MUTAT RES FUND MOL M, V375, P183, DOI 10.1016/S0027 5107(97)00013 4
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300 483X(00)00181 5
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   D'Cruz OJ, 1999, BIOL REPROD, V60, P435, DOI 10.1095/biolreprod60.2.435
   DARZYNKIEWICZ Z, 1982, CANCER RES, V42, P799
   Di Virgilio AL, 2011, BIOMETALS, V24, P1153, DOI 10.1007/s10534 011 9474 x
   DJORDJEVIC C, 1995, MET IONS BIOL SYST, V31, P595
   Djordjevic C., 1995, MED CHEM COPPER VANA, V31, P595
   Etcheverry SB, 2008, J BIOL INORG CHEM, V13, P435, DOI 10.1007/s00775 007 0332 9
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   Fenech M, 2000, MUTAT RES FUND MOL M, V455, P81, DOI 10.1016/S0027 5107(00)00065 8
   FENECH M, 1993, MUTAT RES, V285, P35, DOI 10.1016/0027 5107(93)90049 L
   Goncalves A. P., 2011, LIFE SCI, V12, P11
   GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184
   Griffiths EJ, 2000, CARDIOVASC RES, V46, P24, DOI 10.1016/S0008 6363(00)00020 1
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003 2697(76)90326 2
   Hosseini M J., 2012, Adv. Biosci. Biotechnol, V3, P1096, DOI [10.4236/abb.2012.38134, DOI 10.4236/ABB.2012.38134]
   Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200
   HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409
   Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891 5849(99)00275 0
   Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532
   Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280 002 0522 7
   Koc AN, 2005, MYCOSES, V48, P205, DOI 10.1111/j.1439 0507.2005.01128.x
   Kuntic V, 2011, MOLECULES, V16, P1378, DOI 10.3390/molecules16021378
   León IE, 2012, METALLOMICS, V4, P1287, DOI 10.1039/c2mt20091k
   Li X, 2011, TOXICOL IN VITRO, V25, P630, DOI 10.1016/j.tiv.2010.12.013
   Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016
   Montiel Dávalos A, 2012, J APPL TOXICOL, V32, P26, DOI 10.1002/jat.1695
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Naso L, 2010, J BIOL INORG CHEM, V15, P889, DOI 10.1007/s00775 010 0652 z
   Ngwa HA, 2009, TOXICOL APPL PHARM, V240, P273, DOI 10.1016/j.taap.2009.07.025
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022 1759(91)90198 O
   NIELSEN FH, 1995, MET IONS BIOL SYST, V31, P543
   Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724
   OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201
   Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004
   Rice Evans C., 2003, Flavonoids in health and disease
   Rivadeneira J, 2010, MED CHEM, V6, P9, DOI 10.2174/157340610791208754
   Rivadeneira J, 2009, J INORG BIOCHEM, V103, P633, DOI 10.1016/j.jinorgbio.2008.11.009
   Rodríguez Mercado JJ, 2011, TOXICOL IN VITRO, V25, P1996, DOI 10.1016/j.tiv.2011.07.009
   SABBIONI E, 1993, CARCINOGENESIS, V14, P2565, DOI 10.1093/carcin/14.12.2565
   Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214
   SAXENA AK, 1993, BIOCHEM PHARMACOL, V45, P539, DOI 10.1016/0006 2952(93)90124 F
   Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074 7742(09)85026 5
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014 4827(88)90265 0
   Slebodnick C, 1997, STRUCT BOND, V89, P51
   Srivastava AK, 2005, DIABETIC MED, V22, P2, DOI 10.1111/j.1464 5491.2004.01381.x
   Stopper H, 1997, TOXICOL IN VITRO, V11, P661, DOI 10.1016/S0887 2333(97)00084 2
   Sugihara N, 1999, FREE RADICAL BIO MED, V27, P1313, DOI 10.1016/S0891 5849(99)00167 7
   SUZUKI H, 1969, J ANTIBIOT, V22, P446, DOI 10.7164/antibiotics.22.446
   UMANSKY SR, 1981, BIOCHIM BIOPHYS ACTA, V655, P9, DOI 10.1016/0005 2787(81)90060 5
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Villani P, 2007, TOXICOL LETT, V170, P11, DOI 10.1016/j.toxlet.2006.07.343
   Wang CCC, 2008, CANCER LETT, V259, P82, DOI 10.1016/j.canlet.2007.10.005
   Ye JP, 1999, MOL CELL BIOCHEM, V202, P9, DOI 10.1023/A:1007078915585
   Yu XM, 2013, CANCER AM CANCER SOC, V119, P774, DOI 10.1002/cncr.27742
   Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464
   Zhao YB, 2010, J INORG BIOCHEM, V104, P371, DOI 10.1016/j.jinorgbio.2009.11.007
   Zheng X, 2003, BIOORG MED CHEM LETT, V13, P881, DOI 10.1016/S0960 894X(02)01081 8
NR 72
TC 82
Z9 84
U1 3
U2 31
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477 9226
EI 1477 9234
J9 DALTON T
JI Dalton Trans.
PY 2013
VL 42
IS 33
BP 11868
EP 11880
DI 10.1039/c3dt50524c
PG 13
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 192YY
UT WOS:000322525100014
PM 23760674
OA Green Published
DA 2025 08 17
ER

PT J
AU Hashimoto, K
   Morishige, KI
   Sawada, K
   Tahara, M
   Shimizu, S
   Sakata, M
   Tasaka, K
   Murata, Y
AF Hashimoto, K
   Morishige, KI
   Sawada, K
   Tahara, M
   Shimizu, S
   Sakata, M
   Tasaka, K
   Murata, Y
TI Geranylgeranylacetone inhibits lysophosphatidic acid induced invasion of
   human ovarian carcinoma cells in vitro
SO CANCER
LA English
DT Article
DE geranylgeranylacetone; invasion; lysophosphatidic acid; Rho;
   geranylgeranylation; ovarian carcinoma
ID COA REDUCTASE INHIBITORS; CANCER CELLS; OSTEOCLAST FORMATION; POTENT
   INDUCER; TUMOR CELLS; RHO; APOPTOSIS; MIGRATION; DIFFERENTIATION;
   PRENYLATION
AB BACKGROUND. Lysophosphatidic acid (LPA) induced a dose dependent increase of cancer cell invasion by promoting Rho/Rho associated kinase signaling. Prenylation of Rho is essential for regulating cell growth, motility, and invasion. Geranylgeranylacetone (GGA), an isoprenoid compound, is used clinically as an anti ulcer drug. Recent findings suggested that GGA might inhibit the small GTPase activation by suppressing prenylation. The authors hypothesized that the anticancer effects of GGA result from the inhibition of Rho activation.
   METHODS. The authors examined the effect of GGA using an in vitro invasion assay in human ovarian carcinoma cells, and analyzed the mechanism of the GGA effect on Rho activation, stress fiber formation and focal adhesion assembly, which are essential processes for cell invasion.
   RESULTS. The induction of ovarian carcinoma cell invasion by LPA was inhibited by the addition of GGA in a dose dependent manner. Treatment of cancer cells with GGA resulted in inactivation of Rho, changes in cell morphology, loss of stress fiber formation and focal adhesion assembly, and the suppression of tyrosine phosphorylation of focal adhesion proteins. The effect of GGA on cancer cells was partially prevented by the addition of geranylgeraniol, which is an intermediate of geranylgeranyl pyrophosphate and compensates geranylgeranylation of Rho.
   CONCLUSIONS. The inhibition of LPA induced invasion by GGA was, at least in part, derived from suppressed Rho activation by preventing geranylgeranylation. (c) 2005 American Cancer Society.
C1 Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan.
   Osaka Med Ctr Canc & Cardiovasc Dis, Dept Gynecol, Osaka, Japan.
C3 University of Osaka; Osaka Medical Center for Cancer & Cardiovascular
   Diseases
RP Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM mken@gyne.med.osaka u.ac.jp
CR Baker DL, 2002, JAMA J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081
   Bar Or D, 2003, CRIT CARE MED, V31, P2700, DOI 10.1097/01.CCM.0000092457.89851.EB
   Bellosta S, 1998, ATHEROSCLEROSIS, V137, pS101, DOI 10.1016/S0021 9150(97)00319 5
   CASEY PJ, 1992, J LIPID RES, V33, P1731
   ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   Fishman DA, 2001, CANCER RES, V61, P3194
   Hara M, 2001, NEPHROLOGY, V6, P179, DOI 10.1046/j.1440 1797.2001.00064.x
   Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199
   Hiruma Y, 2004, BIOCHEM BIOPH RES CO, V314, P24, DOI 10.1016/j.bbrc.2003.12.051
   Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102
   Hoskins WJ, 1995, J CELL BIOCHEM, P189
   Ichikawa T, 2001, BIOCHEM BIOPH RES CO, V280, P933, DOI 10.1006/bbrc.2000.4228
   Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587
   Kanno Tomoko, 2002, Physiological Chemistry and Physics and Medical NMR, V34, P1
   Kikuchi S, 2002, J NEUROSCI RES, V69, P373, DOI 10.1002/jnr.10298
   Kusama T, 2001, CANCER RES, V61, P4885
   Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179
   NAKAZAWA S, 1983, INT J CLIN PHARM TH, V21, P267
   NANKE K, 2003, ASBMR, pSU244
   OHIZUMI H, 1995, J BIOCHEM TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695
   Okada S, 1999, CELL STRUCT FUNCT, V24, P161, DOI 10.1247/csf.24.161
   Ooie T, 2001, CIRCULATION, V104, P1837, DOI 10.1161/hc3901.095771
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rokutan K, 2000, J GASTROENTEROL, V35, P673, DOI 10.1007/s005350070046
   SAKAI I, 1993, BIOCHEM BIOPH RES CO, V191, P873, DOI 10.1006/bbrc.1993.1298
   Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831
   Sawada K, 2002, CANCER RES, V62, P6015
   Unoshima M, 2003, ANTIMICROB AGENTS CH, V47, P2914, DOI 10.1128/AAC.47.9.2914 2921.2003
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Wang XX, 2002, J BONE MINER RES, V17, P91, DOI 10.1359/jbmr.2002.17.1.91
   Yasunari K, 2001, ARTERIOSCL THROM VAS, V21, P937, DOI 10.1161/01.ATV.21.6.937
NR 33
TC 19
Z9 19
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0008 543X
EI 1097 0142
J9 CANCER AM CANCER SOC
JI Cancer
PD APR 1
PY 2005
VL 103
IS 7
BP 1529
EP 1536
DI 10.1002/cncr.20941
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 908EO
UT WOS:000227770400027
PM 15739201
OA Bronze
DA 2025 08 17
ER

PT J
AU Moghanian, A
   Firoozi, S
   Tahriri, M
   Sedghi, A
AF Moghanian, Amirhossein
   Firoozi, Sadegh
   Tahriri, Mohammadreza
   Sedghi, Arman
TI 被撤回的出版物: A comparative study on the in vitro formation of
   hydroxyapatite, cytotoxicity and antibacterial activity of 58S bioactive
   glass substituted by Li and Sr (Retracted article. See vol. 151, 2023)
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article; Retracted Publication
DE Sol gel processes; Bioactivity; Lithium; Strontium; Proliferation;
   Biomedical applications
ID BONE TISSUE; CELL RESPONSE; ION RELEASE; STRONTIUM; LITHIUM; SCAFFOLDS;
   45S5; BIOGLASS(R); PROLIFERATION; DEGRADATION
AB Lithium and strontium up to 10 mol% have been substituted for calcium in 58S bioactive glasses in order to enhance specific biological properties such as proliferation, alkaline phosphatase (ALP) activity of cells as well as antibacterial activity. In vitro formation of hydroxyapatite was studied using X ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), inductively coupled plasma atomic emission spectrometry (ICP AES) and scanning electron microscopy (SEM). Substitution of either Li or Sr for Ca in the composition had a retarding effect on the bioactivity while Li decreased and Sr increased the rate of ion release in the simulated body fluid solution. The dissolution rate showed to be inversely proportional to oxygen density of the bioactive glasses. The proposed mechanisms for the lowered bioactivity are a lower supersaturation degree for nucleation of apatite in Li substituted bioactive glasses and blocking of the active growth sites of calcium phosphate by Sr2+ in Sr substituted bioactive glasses. The proliferation rate and alkaline phosphate activity of osteoblast cell line MC3T3 E1 treated with Li and Sr bioactive glasses were studied. 3 (4,5dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) and alkaline phosphate assay showed that all synthesized bioactive glasses with exception of 58S with 10 mol% SrO, exhibited statistically significant increase in both cell proliferation and alkaline phosphatase activity. Finally, 58S bioactive glass with 5 mol% Li2O substitution for CaO was considered as a potential biomaterial in bone repair/regeneration therapies with enhanced biocompatibility, and alkaline phosphate activity, with a negligible loss in the bioactivity compared to the 58S bioglass. At the same time this composition had the highest antibacterial activity against methicillin resistant Staphylococcus aureus bacteria among all synthesized Li and Sr substituted bioactive glasses.
C1 [Moghanian, Amirhossein; Firoozi, Sadegh] Amirkabir Univ Technol, Dept Min & Met Engn, 424 Hafez Ave, Tehran 158754413, Iran.
   [Moghanian, Amirhossein; Sedghi, Arman] Imam Khomeini Int Univ, Dept Mat Engn, Qazvin 3414916818, Peoples R China.
   [Tahriri, Mohammadreza] Marquette Univ, Sch Dent, Milwaukee, WI 53233 USA.
C3 Amirkabir University of Technology; Marquette University
RP Moghanian, A (通讯作者)，Amirkabir Univ Technol, Dept Min & Met Engn, 424 Hafez Ave, Tehran 158754413, Iran.
EM moghanian@aut.ac.ir
RI Moghanian, Amirhossein/AAH 6269 2019; Firoozi, Sadegh/B 6089 2018
OI Sedghi, Arman/0000 0003 0158 8590; 
CR Allan I, 2001, BIOMATERIALS, V22, P1683, DOI 10.1016/S0142 9612(00)00330 6
   [Anonymous], 2017, J EUR CERAM SOC, V38, P1311
   Arcos D, 2003, J BIOMED MATER RES A, V65A, P344, DOI 10.1002/jbm.a.10503
   Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   Baino F, 2016, J NON CRYST SOLIDS, V432, P15, DOI 10.1016/j.jnoncrysol.2015.02.015
   Best SM, 2008, J EUR CERAM SOC, V28, P1319, DOI 10.1016/j.jeurceramsoc.2007.12.001
   Brauer D. S., 2016, BIOMED GLAS, V2
   Brückner R, 2016, J MATER CHEM B, V4, P3121, DOI 10.1039/c5tb02426a
   Christie JK, 2017, J MATER SCI, V52, P9014, DOI 10.1007/s10853 017 1155 x
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   da Silva JG, 2017, J MATER SCI, V52, P8832, DOI 10.1007/s10853 017 0838 7
   Dorozhkin SV, 2002, ANGEW CHEM INT EDIT, V41, P3130, DOI 10.1002/1521 3773(20020902)41:17<3130::AID ANIE3130>3.0.CO;2 1
   Du JC, 2012, J NON CRYST SOLIDS, V358, P1059, DOI 10.1016/j.jnoncrysol.2011.12.114
   ELGENDY HM, 1993, BIOMATERIALS, V14, P263, DOI 10.1016/0142 9612(93)90116 J
   Enright MC, 2002, P NATL ACAD SCI USA, V99, P7687, DOI 10.1073/pnas.122108599
   Erol M, 2012, J EUR CERAM SOC, V32, P2747, DOI 10.1016/j.jeurceramsoc.2012.01.015
   Farlay D, 2010, J BONE MINER METAB, V28, P433, DOI 10.1007/s00774 009 0146 7
   Francis L, 2010, ACTA BIOMATER, V6, P2773, DOI 10.1016/j.actbio.2009.12.054
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Gerhardt LC, 2010, MATERIALS, V3, P3867, DOI 10.3390/ma3073867
   Goel A, 2011, ACTA BIOMATER, V7, P4071, DOI 10.1016/j.actbio.2011.06.047
   Gorustovich AA, 2010, J BIOMED MATER RES A, V92A, P232, DOI 10.1002/jbm.a.32355
   Han PP, 2012, BIOMATERIALS, V33, P6370, DOI 10.1016/j.biomaterials.2012.05.061
   He FP, 2015, MAT SCI ENG C MATER, V50, P257, DOI 10.1016/j.msec.2015.02.019
   Hesaraki S, 2010, MAT SCI ENG C MATER, V30, P383, DOI 10.1016/j.msec.2009.12.001
   Hesaraki S, 2010, J MATER SCI MATER M, V21, P695, DOI 10.1007/s10856 009 3920 0
   Hu S, 2011, J WUHAN UNIV TECHNOL, V26, P227, DOI 10.1007/s11595 011 0202 8
   Hu S, 2009, J MATER SCI MATER M, V20, P281, DOI 10.1007/s10856 008 3564 5
   Huang K, 2014, SURF COAT TECH, V240, P137, DOI 10.1016/j.surfcoat.2013.12.026
   Jones JR, 2006, J MATER SCI MATER M, V17, P989, DOI 10.1007/s10856 006 0434 x
   Joughehdoust S, 2012, MATER SCI POLAND, V30, P45, DOI 10.2478/s13536 012 0007 2
   Kargozar S, 2016, J NON CRYST SOLIDS, V449, P133, DOI 10.1016/j.jnoncrysol.2016.07.025
   Katti KS, 2004, COLLOID SURFACE B, V39, P133, DOI 10.1016/j.colsurfb.2003.12.002
   Kaur G, 2014, J BIOMED MATER RES A, V102, P254, DOI 10.1002/jbm.a.34690
   Kavitha R J., 2014, Int. J. Innov. Res. Sci. Eng. ISSN (Online), P2347
   Khorami M, 2011, MAT SCI ENG C MATER, V31, P1584, DOI 10.1016/j.msec.2011.07.011
   Khvostenko D, 2016, DENT MATER, V32, P73, DOI 10.1016/j.dental.2015.10.007
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   Lao J, 2009, J MATER CHEM, V19, P2940, DOI 10.1039/b822214b
   Lao J, 2008, CHEM MATER, V20, P4969, DOI 10.1021/cm800993s
   LI R, 1991, J APPL BIOMATER, V2, P231, DOI 10.1002/jab.770020403
   Li YM, 2017, J NON CRYST SOLIDS, V458, P69, DOI 10.1016/j.jnoncrysol.2016.12.010
   Lieb J, 2007, MED HYPOTHESES, V69, P8, DOI 10.1016/j.mehy.2006.12.005
   Liu J, 2016, DENT MATER, V32, P412, DOI 10.1016/j.dental.2015.12.013
   Mami M, 2008, APPL SURF SCI, V254, P7386, DOI 10.1016/j.apsusc.2008.05.340
   Miguez Pacheco V, 2016, J NON CRYST SOLIDS, V432, P65, DOI 10.1016/j.jnoncrysol.2015.03.027
   Moghanian A., 2018, CERAM INT
   Moghanian A., 2017, Ceram. Int., V43
   Moghanian A, 2017, CERAM INT, V43, P12835, DOI 10.1016/j.ceramint.2017.06.174
   Mozafari M, 2010, J NON CRYST SOLIDS, V356, P1470, DOI 10.1016/j.jnoncrysol.2010.04.040
   Nielsen SP, 2004, BONE, V35, P583, DOI 10.1016/j.bone.2004.04.026
   OGINO M, 1980, J NON CRYST SOLIDS, V38 9, P673, DOI 10.1016/0022 3093(80)90514 1
   Oyane A, 2003, J BIOMED MATER RES A, V65A, P188, DOI 10.1002/jbm.a.10482
   Özarslan AC, 2016, MAT SCI ENG C MATER, V68, P350, DOI 10.1016/j.msec.2016.06.004
   Qiu K, 2006, BIOMATERIALS, V27, P1277, DOI 10.1016/j.biomaterials.2005.08.006
   Querido W, 2016, MICRON, V80, P122, DOI 10.1016/j.micron.2015.10.006
   Rabiee SM, 2015, CERAM INT, V41, P7241, DOI 10.1016/j.ceramint.2015.02.140
   Rainer A, 2008, ACTA BIOMATER, V4, P362, DOI 10.1016/j.actbio.2007.08.007
   Saghiri MA, 2017, DENT MATER J, V36, P8, DOI 10.4012/dmj.2015 425
   Sepulveda P, 2001, J BIOMED MATER RES, V58, P734, DOI 10.1002/jbm.10026
   Shahrabi S, 2011, CERAM INT, V37, P2737, DOI 10.1016/j.ceramint.2011.04.025
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   Soulié J, 2009, PHYS CHEM CHEM PHYS, V11, P10473, DOI 10.1039/b913771h
   Taherkhani S, 2016, J SOL GEL SCI TECHN, V78, P539, DOI 10.1007/s10971 016 3995 2
   Tylkowski M, 2013, J NON CRYST SOLIDS, V376, P175, DOI 10.1016/j.jnoncrysol.2013.05.039
   Usuda Kan, 2007, Environmental Health and Preventive Medicine, V12, P231, DOI 10.1007/BF02898029
   Wang XP, 2011, ACTA BIOMATER, V7, P3638, DOI 10.1016/j.actbio.2011.06.029
   Wen J, 2015, J MATER CHEM B, V3, P4790, DOI 10.1039/c5tb00128e
   Wopenka B, 2005, MAT SCI ENG C BIO S, V25, P131, DOI 10.1016/j.msec.2005.01.008
   Wu CT, 2008, J BIOMED MATER RES A, V86A, P402, DOI 10.1002/jbm.a.31623
   Wu CT, 2007, BIOMATERIALS, V28, P3171, DOI 10.1016/j.biomaterials.2007.04.002
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   Wu XL, 2015, MAT SCI ENG C MATER, V52, P242, DOI 10.1016/j.msec.2015.03.057
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Yan XX, 2006, BIOMATERIALS, V27, P3396, DOI 10.1016/j.biomaterials.2006.01.043
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
   Yuan K, 2014, INT J ORAL MAX IMPL, V29, P32, DOI 10.11607/jomi.2436
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zhang JH, 2014, ACTA BIOMATER, V10, P2269, DOI 10.1016/j.actbio.2014.01.001
   Zhang WB, 2011, ACTA BIOMATER, V7, P800, DOI 10.1016/j.actbio.2010.08.031
   Zhao XX, 2011, NANOTOXICOLOGY, V5, P182, DOI 10.3109/17435390.2010.503943
NR 82
TC 68
Z9 70
U1 0
U2 94
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD OCT 1
PY 2018
VL 91
BP 349
EP 360
DI 10.1016/j.msec.2018.05.058
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GR0GI
UT WOS:000442192000036
PM 30033264
DA 2025 08 17
ER

PT J
AU Noguchi, S
   Ukai, T
   Kuramoto, A
   Yoshinaga, Y
   Nakamura, H
   Takamori, Y
   Yamashita, Y
   Hara, Y
AF Noguchi, S.
   Ukai, T.
   Kuramoto, A.
   Yoshinaga, Y.
   Nakamura, H.
   Takamori, Y.
   Yamashita, Y.
   Hara, Y.
TI The histopathological comparison on the destruction of the periodontal
   tissue between normal junctional epithelium and long junctional
   epithelium
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE histopathological study; immunization; long junctional epithelium;
   periodontal destruction
ID GINGIVAL CREVICULAR FLUID; ANTIBODY TITERS; RATS; ATTACHMENT; SURGERY;
   SULCUS; TRAPS
AB Background and ObjectiveThe barrier function of long junctional epithelium is thought to be important after periodontal initial therapy and periodontal surgery. Although the difference between long junctional epithelium and normal junctional epithelium regarding their resistance to destruction of periodontal tissue has been investigated, the mechanism still remains unclear. Using our rat experimental periodontitis model in which loss of attachment and resorption of alveolar bone is induced by the formation of immune complexes, we investigated the resistance of periodontal tissue containing long junctional epithelium and normal junctional epithelium to destruction.
   Material and MethodsRats were divided into four groups. In the immunized long junctional epithelium (I LJE) group, rats were immunized with lipopolysaccharide (LPS), and curettage and root planing procedures were performed on the palatal gingiva of the maxillary first molars to obtain reattachment by long junctional epithelium. In the immunized normal junctional epithelium (I JE) group, rats were immunized without curettage and root planing procedures. In the nonimmunized long junctional epithelium (nI LJE) group, rats were not immunized but curettage and root planing procedures were performed. In the control group, neither immunization nor curettage and root planing was performed. In all rats, periodontal inflammation was induced by topical application of LPS into the palatal gingival sulcus of maxillary first molars. The rats were killed at baseline and after the third and fifth applications of LPS. Attachment loss and the number of inflammatory cells and osteoclasts in the four groups were compared histopathologically and histometrically.
   ResultsAfter the third application of LPS in the I LJE group, attachment loss showed a greater increase than in control and nI LJE groups, and inflammatory cell infiltration and osteoclasts were increased more than in the other groups. After the fifth application of LPS, attachment loss was greater and there was a higher degree of inflammatory cell infiltration in nI LJE and I LJE groups than in control and I JE groups.
   ConclusionOur findings suggest that the destruction of periodontal tissue is increased in tissue containing long junctional epithelium compared with normal junctional epithelium and that the immunized condition accelerates the destruction by forming immune complexes.
C1 [Noguchi, S.; Ukai, T.; Kuramoto, A.; Yoshinaga, Y.; Nakamura, H.; Takamori, Y.; Yamashita, Y.; Hara, Y.] Nagasaki Univ, Dept Periodontol, Grad Sch Biomed Sci, 1 7 1 Sakamoto, Nagasaki 8528588, Japan.
C3 Nagasaki University
RP Hara, Y (通讯作者)，Nagasaki Univ, Dept Periodontol, Grad Sch Biomed Sci, 1 7 1 Sakamoto, Nagasaki 8528588, Japan.
EM harasen@nagasaki u.ac.jp
RI ; yasunori, yamashita/GOP 2260 2022; Yoshinaga, Yasunori/HLH 3963 2023
OI yamashita, yasunori/0000 0002 5791 9005; 
FU JSPS [23792481, 24593127]; Grants in Aid for Scientific Research
   [24593127, 24593126, 15K11394, 23792481] Funding Source: KAKEN
FX We thank the staff of the Biomedical Research Center, the Center for
   Frontier Life Sciences, Nagasaki University, for the maintenance of the
   experimental animals and Dr Yoshihiro Abe for his methodology
   suggestions. This study was supported by JSPS KAKENHI Grant No. 23792481
   and 24593127.
CR ABE Y, 1994, J PERIODONTAL RES, V29, P418, DOI 10.1111/j.1600 0765.1994.tb01243.x
   BARRINGTON EP, 1981, J PERIODONTOL, V52, P518, DOI 10.1902/jop.1981.52.9.518
   BEAUMONT RH, 1984, J PERIODONTOL, V55, P213, DOI 10.1902/jop.1984.55.4.213
   CATON J, 1980, J CLIN PERIODONTOL, V7, P212, DOI 10.1111/j.1600 051X.1980.tb01964.x
   CATON JG, 1979, J PERIODONTOL, V50, P462, DOI 10.1902/jop.1979.50.9.462
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   GARNICK JJ, 1977, J PERIODONTOL, V48, P722, DOI 10.1902/jop.1977.48.11.722
   Ignatius A, 2011, J CELL BIOCHEM, V112, P2594, DOI 10.1002/jcb.23186
   KATAYAMA I, 1972, CANCER AM CANCER SOC, V29, P157, DOI 10.1002/1097 0142(197201)29:1<157::AID CNCR2820290124>3.0.CO;2 0
   KONAKAJIMA Y, 1990, ARCH ORAL BIOL, V35, pS181, DOI 10.1016/0003 9969(90)90153 2
   Kuramoto A, 2012, J PERIODONTAL RES, V47, P455, DOI 10.1111/j.1600 0765.2011.01453.x
   LAMSTER IB, 1990, J CLIN PERIODONTOL, V17, P419, DOI 10.1111/j.1600 051X.1990.tb02340.x
   LISTGARTEN MA, 1982, J PERIODONTOL, V53, P659, DOI 10.1902/jop.1982.53.11.659
   MAGNUSSON I, 1983, J CLIN PERIODONTOL, V10, P333, DOI 10.1111/j.1600 051X.1983.tb01282.x
   Masaoka T, 2009, J PERIODONTAL RES, V44, P489, DOI 10.1111/j.1600 0765.2008.01142.x
   Nagano F, 2013, J PERIODONTAL RES, V48, P420, DOI 10.1111/jre.12021
   Nakatsu S, 2014, J PERIODONTAL RES, V49, P314, DOI 10.1111/jre.12109
   Noguchi S, 2017, J PERIODONTAL RES, V52, P74, DOI 10.1111/jre.12370
   Pussinen PJ, 2011, J CLIN PERIODONTOL, V38, P405, DOI 10.1111/j.1600 051X.2011.01703.x
   ROMANOWSKI AW, 1988, J PERIODONTAL RES, V23, P81, DOI 10.1111/j.1600 0765.1988.tb01338.x
   SATO Y, 1986, AM J PATHOL, V125, P431
   Shimono M, 2003, J ELECTRON MICROSC, V52, P627, DOI 10.1093/jmicro/52.6.627
   Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577
   STAHL SS, 1977, J PERIODONTOL, V48, P67, DOI 10.1902/jop.1977.48.2.67
   TAKATA T, 1986, J PERIODONTOL, V57, P776, DOI 10.1902/jop.1986.57.12.776
   TAUBMAN MA, 1992, J PERIODONTAL RES, V27, P511, DOI 10.1111/j.1600 0765.1992.tb01825.x
   TEW JG, 1985, INFECT IMMUN, V49, P487, DOI 10.1128/IAI.49.3.487 493.1985
   Uno T, 1998, J PERIODONTAL RES, V33, P298, DOI 10.1111/j.1600 0765.1998.tb02203.x
   Vitkov L, 2009, J PERIODONTAL RES, V44, P664, DOI 10.1111/j.1600 0765.2008.01175.x
   Vitkov L, 2010, ULTRASTRUCT PATHOL, V34, P25, DOI 10.3109/01913120903419989
   Yoshinaga Y, 2012, J PERIODONTAL RES, V47, P674, DOI 10.1111/j.1600 0765.2012.01486.x
NR 31
TC 18
Z9 21
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD FEB
PY 2017
VL 52
IS 1
BP 74
EP 82
DI 10.1111/jre.12370
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EJ4DB
UT WOS:000393165200008
PM 26957231
DA 2025 08 17
ER

PT J
AU He, L
   Sheng, YY
   Huang, CY
   Huang, GY
AF He, Lan
   Sheng, Youyu
   Huang, Chunyun
   Huang, Guoying
TI Identification of Differentially Expressed Genes in Kawasaki Disease
   Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics
   Analysis
SO PEDIATRIC CARDIOLOGY
LA English
DT Article
DE Kawasaki disease; Differentially expressed genes (DEGs); Biomarker;
   IVIG related sensitivity
ID INTRAVENOUS IMMUNOGLOBULIN TREATMENT; CORONARY ARTERY ANEURYSMS;
   GENOME WIDE ASSOCIATION; GAMMA GLOBULIN THERAPY; OSTEOCLAST
   DIFFERENTIATION; RESISTANCE; PREDICTION; DIAGNOSIS; SUSCEPTIBILITY;
   CYTOKINE
AB Kawasaki disease (KD) is a leading cause of acquired heart disease predominantly affecting infants and young children. Intravenous immunoglobulin (IVIG) is applied as the most favorable treatment against KD, but IVIG resistant remains exist. Although several clinical scoring systems have been developed to identify children at highest risk of IVIG resistance, there is a need to identify sufficiently sensitive biomarkers for IVIG treatment. Some differentially expressed genes (DEGs) could be the promising potential biomarkers for IVIG related sensitivity diagnosis. We employed a systematic and integrative bioinformatics framework to identify such kind of genes. The performance of the candidate genes was evaluated by hierarchical clustering, ROC analysis and literature mining. By analyzing three datasets of KD patients, 34 DEGs of the three groups have been found to be associated with IVIG related sensitivity. A module of 12 genes could predict resistant group patients with high accuracy, and a module of ten genes could predict responsive group patients effectively with accuracy of 96 %. And three of them are most likely to serve as drug targets or diagnostic biomarkers in the future. Compared with unsupervised hierarchical clustering analysis, our modules could distinct IVIG resistant patients efficiently. Two groups of DEGs could predict IVIG related sensitivity with high accuracy, which are potential biomarkers for the clinical diagnosis and prediction of IVIG treatment response in KD patients, improving the prognosis of patients.
C1 [He, Lan; Huang, Guoying] Fudan Univ, Childrens Hosp, Pediat Heart Ctr, Shanghai, Peoples R China.
   [Sheng, Youyu; Huang, Chunyun] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai, Peoples R China.
C3 Fudan University; Fudan University
RP Huang, GY (通讯作者)，Fudan Univ, Childrens Hosp, Pediat Heart Ctr, Shanghai, Peoples R China.
EM guoying huang@hotmail.com
CR Abe Jun, 2013, Nihon Rinsho Meneki Gakkai Kaishi, V36, P27
   Ashouri N, 2008, J PEDIATR US, V153, P365, DOI 10.1016/j.jpeds.2008.03.014
   Chang EJ, 2007, J CELL SCI, V120, P166, DOI 10.1242/jcs.03310
   Choe CH, 2015, FEBS LETT, V589, P836, DOI 10.1016/j.febslet.2015.02.018
   DAJANI AS, 1993, CIRCULATION, V87, P1776, DOI 10.1161/01.CIR.87.5.1776
   Davies S, 2015, ARCH DIS CHILD, V100, P366, DOI 10.1136/archdischild 2014 307397
   Diboun I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 252
   Dominguez SR, 2013, CURR OPIN PEDIATR, V25, P103, DOI 10.1097/MOP.0b013e32835c1122
   Egami K, 2006, J PEDIATR US, V149, P237, DOI 10.1016/j.jpeds.2006.03.050
   Eleftheriou D, 2014, ARCH DIS CHILD, V99, P74, DOI 10.1136/archdischild 2012 302841
   Fury W, 2010, HUM IMMUNOL, V71, P865, DOI 10.1016/j.humimm.2010.06.008
   Galeotti C, 2015, TRENDS MOL MED, V21, P145, DOI 10.1016/j.molmed.2015.01.005
   Gerding R, 2011, J PEDIATR HEALTH CAR, V25, P379, DOI 10.1016/j.pedhc.2011.07.007
   Guo MMH, 2015, ALLERGY, V70, P310, DOI 10.1111/all.12558
   Hedrich CM, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546 0096 11 47
   Hoang LT, 2014, GENOME MED, V6, DOI 10.1186/s13073 014 0102 6
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   John JMM, 2010, ALLERGY, V65, P875, DOI 10.1111/j.1398 9995.2009.02297.x
   Joyseeree R, 2015, STUD HEALTH TECHNOL, V210, P850, DOI 10.3233/978 1 61499 512 8 850
   Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981
   Kim DS, 2006, YONSEI MED J, V47, P759, DOI 10.3349/ymj.2006.47.6.759
   Kobayashi T, 2006, CIRCULATION, V113, P2606, DOI 10.1161/CIRCULATIONAHA.105.592865
   Kuo HC, 2012, SCI WORLD J, DOI 10.1100/2012/520865
   Kuo HC, 2012, PEDIATR NEONATOL, V53, P4, DOI 10.1016/j.pedneo.2011.11.003
   Kuo HC, 2011, J HUM GENET, V56, P161, DOI 10.1038/jhg.2010.154
   Kuo HC, 2010, ACTA PAEDIATR, V99, P1578, DOI 10.1111/j.1651 2227.2010.01875.x
   Liu RX, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356362
   Mori M, 1995, J CLIN IMMUNOL, V18, P282, DOI DOI 10.2177/JSCI.18.282
   Newburger JW, 2004, CIRCULATION, V110, P2747, DOI 10.1161/01.CIR.0000145143.19711.78
   Ogata S, 2009, PEDIATR RES, V66, P577, DOI 10.1203/PDR.0b013e3181baa3c2
   Ogawa Shunichi, 2014, Nihon Rinsho, V72, P1578
   Ogihara Y, 2014, PEDIATR RES, V76, P287, DOI 10.1038/pr.2014.92
   Onouchi Y, 2008, NAT GENET, V40, P35, DOI 10.1038/ng.2007.59
   Onouchi Y, 2012, NAT GENET, V44, P517, DOI 10.1038/ng.2220
   Ren XW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126742
   Roosild TP, 2011, J STRUCT BIOL, V176, P229, DOI 10.1016/j.jsb.2011.08.002
   ROWLEY AH, 1988, J PEDIATR US, V113, P290, DOI 10.1016/S0022 3476(88)80267 1
   Sandrine B, 2014, J DTSCH DERMATOL GES, V12, P124, DOI [10.1111/ddg.12252, 10.1111/ddg.12252_suppl]
   Sano T, 2007, EUR J PEDIATR, V166, P131, DOI 10.1007/s00431 006 0223 z
   Seki M, 2011, PEDIATR INFECT DIS J, V30, P145, DOI 10.1097/INF.0b013e3181f386db
   Shangguan Wen, 2014, Zhonghua Yi Xue Za Zhi, V94, P938
   Sleeper LA, 2011, J PEDIATR US, V158, P831, DOI 10.1016/j.jpeds.2010.10.031
   Soltner E, 2009, JOINT BONE SPINE, V76, P559, DOI 10.1016/j.jbspin.2009.01.006
   Stiehm ER, 2006, J PEDIATR US, V148, P6, DOI 10.1016/j.jpeds.2005.09.019
   Tremoulet AH, 2008, J PEDIATR US, V153, P117, DOI 10.1016/j.jpeds.2007.12.021
   Wang CL, 2005, PEDIATR INFECT DIS J, V24, P998, DOI 10.1097/01.inf.0000183786.70519.fa
   Wang YY, 2010, RES J BIOTECHNOL, V5, P5
   Wang YJ, 2013, ARTHRITIS RHEUM US, V65, P805, DOI 10.1002/art.37815
   Weng KP, 2011, J CHIN MED ASSOC, V74, P481, DOI 10.1016/j.jcma.2011.09.001
NR 50
TC 2
Z9 4
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0172 0643
EI 1432 1971
J9 PEDIATR CARDIOL
JI Pediatr. Cardiol.
PD AUG
PY 2016
VL 37
IS 6
BP 1003
EP 1012
DI 10.1007/s00246 016 1381 z
PG 10
WC Cardiac & Cardiovascular Systems; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Pediatrics
GA DT1YZ
UT WOS:000381279300002
PM 27160104
DA 2025 08 17
ER

PT J
AU Krawetz, RJ
   Wu, YE
   Martin, L
   Rattner, JB
   Matyas, JR
   Hart, DA
AF Krawetz, Roman J.
   Wu, Yiru Elizabeth
   Martin, Liam
   Rattner, Jerome B.
   Matyas, John R.
   Hart, David A.
TI Synovial Fluid Progenitors Expressing CD90+from Normal but Not
   Osteoarthritic Joints Undergo Chondrogenic Differentiation without
   Micro Mass Culture
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; PARTIAL THICKNESS DEFECTS; STROMAL CELLS;
   AGGREGATION; CLUSTERS; CRITERIA; THERAPY; REPAIR
AB Objective: Mesenchymal progenitor cells (MPCs) can differentiate into osteoblasts, adipocytes, and chondrocytes, and are in part responsible for maintaining tissue integrity. Recently, a progenitor cell population has been found within the synovial fluid that shares many similarities with bone marrow MPCs. These synovial fluid MPCs (sfMPCs) share the ability to differentiate into bone and fat, with a bias for cartilage differentiation. In this study, sfMPCs were isolated from human and canine synovial fluid collected from normal individuals and those with osteoarthritis (human: clinician diagnosed, canine: experimental) to compare the differentiation potential of CD90+ vs. CD90  sfMPCs, and to determine if CD90 (Thy 1) is a predictive marker of synovial fluid progenitors with chondrogenic capacity in vitro.
   Methods: sfMPCs were derived from synovial fluid from normal and OA knee joints. These cells were induced to differentiate into chondrocytes and analyzed using quantitative PCR, immunofluorescence, and electron microscopy.
   Results: The CD90+ subpopulation of sfMPCs had increased chondrogenic potential compared to the CD90  population. Furthermore, sfMPCs derived from healthy joints did not require a micro mass step for efficient chondrogenesis. Whereas sfMPCs from OA synovial fluid retain the ability to undergo chondrogenic differentiation, they require micro mass culture conditions.
   Conclusions: Overall, this study has demonstrated an increased chondrogenic potential within the CD90+ fraction of human and canine sfMPCs and that this population of cells derived from healthy normal joints do not require a micro mass step for efficient chondrogenesis, while sfMPCs obtained from OA knee joints do not differentiate efficiently into chondrocytes without the micro mass procedure. These results reveal a fundamental shift in the chondrogenic ability of cells isolated from arthritic joint fluids, and we speculate that the mechanism behind this change of cell behavior is exposure to the altered milieu of the OA joint fluid, which will be examined in further studies.
C1 [Krawetz, Roman J.; Wu, Yiru Elizabeth; Hart, David A.] Univ Calgary, Dept Surg, Calgary, AB, Canada.
   [Krawetz, Roman J.; Rattner, Jerome B.] Univ Calgary, Dept Cell Biol & Anat, Calgary, AB, Canada.
   [Martin, Liam] Univ Calgary, Dept Med, Calgary, AB, Canada.
   [Matyas, John R.] Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary;
   University of Calgary
RP Krawetz, RJ (通讯作者)，Univ Calgary, Dept Surg, Calgary, AB, Canada.
EM rkrawetz@ucalgary.ca
OI Wu, Elizabeth/0000 0002 0660 9306
FU Pfizer; Alberta Innovates Health Solutions; Canadian Institutes for
   Health Research [MOP 79384]; Pfizer Inc.
FX This study was supported by research grants from Pfizer, Alberta
   Innovates Health Solutions team grant in osteoarthritis, and Canadian
   Institutes for Health Research (MOP 79384). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.The authors have the following interest:
   This study was partly funded by Pfizer Inc. There are no patents,
   products in development or marketed products to declare. This does not
   alter the authors' adherence to all the PLOS ONE policies on sharing
   data and materials, as detailed online in the guide for authors.
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Ando W, 2007, BIOMATERIALS, V28, P5462, DOI 10.1016/j.biomaterials.2007.08.030
   Ando W, 2008, TISSUE ENG PT A, V14, P2041, DOI 10.1089/ten.tea.2008.0015
   Archer Charles W., 2003, Birth Defects Research, V69, P144, DOI 10.1002/bdrc.10015
   Barker TH, 2009, BBA MOL CELL RES, V1793, P921, DOI 10.1016/j.bbamcr.2008.10.004
   Bradley EW, 2011, J CELL PHYSIOL, V226, P1683, DOI 10.1002/jcp.22499
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fan JB, 2009, TISSUE ENG PART B RE, V15, P75, DOI 10.1089/ten.teb.2008.0586
   Gao F, 2008, TRANSL RES, V151, P293, DOI 10.1016/j.trsl.2008.03.003
   Gigout A, 2008, J BIOL CHEM, V283, P31522, DOI 10.1074/jbc.M804234200
   Han HS, 2010, J ORTHOP RES, V28, P1283, DOI 10.1002/jor.21129
   Heng B, 2008, CYTOTECHNOLOGY, V58, P69, DOI 10.1007/s10616 008 9174 8
   Horie M, 2009, STEM CELLS, V27, P878, DOI 10.1634/stemcells.2008 0616
   Hunziker EB, 1996, J BONE JOINT SURG AM, V78A, P721, DOI 10.2106/00004623 199605000 00012
   Hunziker EB, 2001, OSTEOARTHR CARTILAGE, V9, P22, DOI 10.1053/joca.2000.0346
   Jones E, 2010, ANN RHEUM DIS, V69, P450, DOI 10.1136/ard.2008.106435
   Jones EA, 2008, ARTHRITIS RHEUM US, V58, P1731, DOI 10.1002/art.23485
   Kanamoto Takashi, 2008, Clin Calcium, V18, P1744, DOI CliCa081217441749
   Koelling S, 2009, EXPERT OPIN BIOL TH, V9, P1399, DOI 10.1517/14712590903246370
   Koga H, 2008, CELL TISSUE RES, V333, P207, DOI 10.1007/s00441 008 0633 5
   Koga H, 2007, STEM CELLS, V25, P689, DOI 10.1634/stemcells.2006 0281
   Koga H, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2460
   Kurth TB, 2011, ARTHRITIS RHEUM US, V63, P1289, DOI 10.1002/art.30234
   Lim JJ, 2011, BIOTECHNOL BIOENG, V108, P151, DOI 10.1002/bit.22909
   Lorda Diez CI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024546
   Luo WJ, 2008, EXP CELL RES, V314, P3382, DOI 10.1016/j.yexcr.2008.07.003
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   McGonagle D, 2008, RHEUMATOLOGY, V47, P1114, DOI 10.1093/rheumatology/ken236
   Morito T, 2008, RHEUMATOLOGY, V47, P1137, DOI 10.1093/rheumatology/ken114
   Nagase T, 2008, ARTHRITIS RHEUM, V58, P1389, DOI 10.1002/art.23418
   Okura H, 2010, TISSUE ENG PART C ME, V16, P761, DOI 10.1089/ten.TEC.2009.0208
   P Mafi, 2011, Open Orthop J, V5, P253, DOI 10.2174/1874325001105010253
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Wei CJ, 2006, J CELL PHYSIOL, V206, P322, DOI 10.1002/jcp.20459
NR 34
TC 50
Z9 54
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2012
VL 7
IS 8
AR e43616
DI 10.1371/journal.pone.0043616
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 997ZC
UT WOS:000308206000044
PM 22952721
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Ayan, H
   Akilli, R
   Kaya, B
   Paydas, S
   Kara, E
   Cureoglu, A
AF Ayan, Hatice
   Akilli, Rabia
   Kaya, Bulent
   Paydas, Saime
   Kara, Ertan
   Cureoglu, Asligul
TI Relationship Between SCUBE1 Levels and Echocardiography and
   Electrocardiography Findings and Epicardial Adipose Tissue/Carotid
   Intima Media Thickness in Patients Receiving Renal Replacement Therapy
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Cardiovascular disease; Chronic kidney disease; SCUBE1
ID CHRONIC KIDNEY DISEASE; CARDIOVASCULAR MORTALITY; ALL CAUSE;
   ASSOCIATION; PROTEIN; RISK; HEMODIALYSIS; INFLAMMATION; GUIDELINES;
   DOMAIN
AB Objectives: In patients with advanced stage chronic kidney disease, renal insufficiency, arterial stiffness, and vascular calcification are strong predictors of cardiovascular risk. Signal peptide CUB EGF like protein 1 (SCUBE1) levels increase during platelet activation and acute ischemic events. Here, we evaluated associations between SCUBE1 levels and electrocardiographic/echocardiographic findings, epicardial adipose tissue thickness, and carotid intimamedia thickness in patients with chronic kidney disease.
   Materials and Methods: Our study included 21 renal transplant recipients, 20 peritoneal dialysis patients, 20 hemodialysis patients, 20 predialysis patients with glomerular filtration rate < 30 mL/min, and 16 healthy volunteers.
   Results: We found no differences in SCUBE1 levels between patient groups and healthy volunteers, regardless of history of diabetes mellitus, myocardial infarction, cerebrovascular events, and hypertension. SCUBE1 levels correlated with C reactive protein in renal transplant recipients; magnesium in peritoneal dialysis patients; erythrocyte sedimentation rate in predialysis patients; and parathyroid hormone, platelet count, calcium phosphate product, and calcium in hemodialysis patients. No associations were shown between SCUBE1 levels and electrocardiographic/echocardiographic findings. Elevated C reactive protein in predialysis patients was associated with cardiac valvular pathologies. In hemodialysis patients, SCUBE1 levels increased after hemodialysis (P= .007). Levels were higher in healthy individuals with normal echocardiography and predialysis patients with left ventricular diastolic dysfunction. Positive correlations were found between carotid intima media thickness and SCUBE1 levels in dialysis patients (P < .05), but no study groups showed correlations regarding epicardial adipose tissue thickness.
   Conclusions: Hemodialysis may contribute to cardiovascular events because of increased SCUBE1 levels after hemodialysis; however, no association was shown between SCUBE1 and electrocardiography/ echocardiography findings. We found no correlations between epicardial adipose tissue thickness and SCUBE1 levels, and levels were significantly higher in healthy patients and in predialysis patients without left ventricular diastolic dysfunction. However, correlations were shown between SCUBE1 levels and carotid intima media thickness and secondary hyperparathyroidism markers, indicating associations with atherosclerosis and bone mineral disease in dialysis patients.
C1 [Ayan, Hatice] Cukurova Univ, Fac Med, Dept Internal Med, Adana, Turkey.
   [Akilli, Rabia] Cukurova Univ, Fac Med, Dept Cardiol, Adana, Turkey.
   [Kaya, Bulent; Paydas, Saime] Cukurova Univ, Fac Med, Dept Nephrol, Adana, Turkey.
   [Kara, Ertan] Cukurova Univ, Fac Med, Dept Publ Hlth, Adana, Turkey.
   [Cureoglu, Asligul] Kahta State Hosp, Adiyaman, Turkey.
C3 Cukurova University; Cukurova University; Cukurova University; Cukurova
   University; Kahta State Hospital
RP Paydas, S (通讯作者)，Cukurova Univ, Fac Med, Dept Nephrol, Adana, Turkey.
EM spaydas@cu.edu.tr
RI ; KARA, Ertan/JAO 0085 2023; KARA, ERTAN/J 7911 2018
OI kaya, bulent/0000 0003 4697 4815; KARA, ERTAN/0000 0003 2486 8683
FU Cukurova University Research Fund [TTU 2017 8016]
FX The authors have no conflicts of interest to declare. This study was
   supported by Cukurova University Research Fund (TTU 2017 8016).
CR Costa E, 2008, J CLIN IMMUNOL, V28, P268, DOI 10.1007/s10875 007 9168 x
   Covic A, 2009, NEPHROL DIAL TRANSPL, V24, P1506, DOI 10.1093/ndt/gfn613
   Dai DF, 2008, J AM COLL CARDIOL, V51, P2173, DOI 10.1016/j.jacc.2008.01.060
   Farshid A, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 280
   Kim MK, 2013, KOREAN J INTERN MED, V28, P35
   Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005
   Menon V, 2005, KIDNEY INT, V68, P766, DOI 10.1111/j.1523 1755.2005.00455.x
   Moens SJB, 2017, J AM SOC NEPHROL, V28, P1278, DOI 10.1681/ASN.2016030317
   Nakanishi K, 2017, EUR J PREV CARDIOL, V24, P392, DOI 10.1177/2047487316679903
   Reiner Z, 2011, EUR HEART J, V32, P1769, DOI [10.1016/j.atherosclerosis.2011.06.012, 10.1093/eurheartj/ehr158]
   Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c
   Shlipak MG, 2005, JAMA J AM MED ASSOC, V293, P1737, DOI 10.1001/jama.293.14.1737
   Tu CF, 2008, J BIOL CHEM, V283, P12478, DOI 10.1074/jbc.M705872200
   Tu CF, 2006, CARDIOVASC RES, V71, P486, DOI 10.1016/j.cardiores.2006.04.010
   Ulusoy S, 2012, CLIN BIOCHEM, V45, P1444, DOI 10.1016/j.clinbiochem.2012.07.103
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   Yilmaz A, 2016, NEPHROL THER, V12, P94, DOI 10.1016/j.nephro.2015.08.003
NR 17
TC 3
Z9 3
U1 0
U2 8
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304 0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD JAN
PY 2019
VL 17
SU 1
BP 181
EP 187
DI 10.6002/ect.MESOT2018.P58
PG 7
WC Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation
GA HS5XA
UT WOS:000463943200035
PM 30777551
DA 2025 08 17
ER

PT J
AU Wang, SY
   Zhang, R
   Wang, S
   Guo, Q
   Yin, DH
   Song, Y
   She, XH
   Wang, XY
   Duan, JJ
AF Wang, Shuyun
   Zhang, Rui
   Wang, Song
   Guo, Qian
   Yin, Donghong
   Song, Yan
   She, Xianhua
   Wang, Xuyan
   Duan, Jinju
TI Osteonecrosis of the jaw in patients with clear cell renal cell
   carcinoma treated with targeted agents: a case series and large scale
   pharmacovigilance analysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE tyrosine kinase inhibitors; immune checkpoint inhibitors; osteonecrosis
   of jaw; FAERS; pharmacovigilance
ID MEDICATION RELATED OSTEONECROSIS; SUNITINIB; BISPHOSPHONATES; CANCER;
   NECROSIS; UPDATE
AB Objective To optimize the use of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) for cancer patients, we characterized and evaluated ONJ related to TKIs and ICIs by analyzing a public database and reviewing the relevant literature. TKIs and ICIs are limited to drugs that treat renal cancer recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Kidney Cancer.Methods We described a case series of patients experiencing ONJ while on TKIs or ICIs. We also analyzed spontaneous reports submitted to the FAERS in an observational and retrospective manner between January 2004 and December 2022. Selecting ONJ' adverse events to TKIs and ICIs. Associations between TKIs, ICIs and ONJ were assessed using reporting odds ratios (ROR), drug interaction signals based on the Omega shrinkage measure.Results 29 patients with ONJ events while on TKIs and ICIs were included in our case series. 240 were related to ONJ AEs. Specifically, 32.1% ICSRs were linked to sunitinib, 16.7% to lenvatinib, 12.9% to pazopanib, 12.5% to nivolumab, 10.0% to axitinib, 5.4% to sorafenib, 5.0% to pembrolizumab, 4.2% to cabozantinib, and 1.3% to ipilimumab. More ICSRs were generally seen in male and reported in Europe. The median age was 63 years. Renal cancer and lung cancer was the most common indication for TKIs and ICIs, respectively. Excluding missing data, the prevalence of mortality was highest for sunitinib related ONJ ICSRs (18.5%), followed by sorafenib related ONJ ICSRs (15.4%). With the criteria of ROR, sunitinib and lenvatinib were significantly associated with ONJ AEs. With the criteria of Omega, nivolumab + cabozantinib was significantly associated with ONJ AEs.Conclusion TKIs and ICIs have been reported to have significant ONJ side effects. Patients and physicians need to recognize and monitor these potentially fatal adverse events.
C1 [Wang, Shuyun; Zhang, Rui; Wang, Song; Guo, Qian] Shanxi Med Univ, Sch Pharm, Dept Pharm, Taiyuan, Shanxi, Peoples R China.
   [Wang, Shuyun; Guo, Qian; Yin, Donghong; Song, Yan; She, Xianhua; Duan, Jinju] Shanxi Med Univ, Hosp 2, Dept Pharm, Taiyuan, Shanxi, Peoples R China.
   [Wang, Xuyan] Shanxi Hosp Integrated Tradit & Western Med, Cent Lab, Taiyuan, Shanxi, Peoples R China.
C3 Shanxi Medical University; Shanxi Medical University
RP Duan, JJ (通讯作者)，Shanxi Med Univ, Hosp 2, Dept Pharm, Taiyuan, Shanxi, Peoples R China.
EM duanjinju@163.com
RI XiaoXia, Li/AAE 6415 2019
FU Second Hospital of Shanxi Medical University Science Foundation
   [202202 7]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This study was
   supported by the Second Hospital of Shanxi Medical University Science
   Foundation (Grant number 202202 7).
CR Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Agrillo A, 2012, EUR REV MED PHARMACO, V16, P952
   Ancker OV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010010
   Ancker OV, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030625
   Ashrafi F, 2017, J RES PHARM PRACT, V6, P182, DOI 10.4103/jrpp.JRPP_17_36
   Bellmunt J, 2011, CRIT REV ONCOL HEMAT, V78, P24, DOI 10.1016/j.critrevonc.2010.03.006
   Belum VR, 2016, CLIN EXP DERMATOL, V41, P8, DOI 10.1111/ced.12694
   Bozas G, 2010, ONKOLOGIE, V33, P321, DOI 10.1159/000313680
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Cirmi S, 2020, CANCERS, V12, DOI 10.3390/cancers12040826
   Evangelista GFD, 2022, IMMUNOTHER ADV, V2, DOI 10.1093/immadv/ltac008
   Decaux J, 2020, J STOMATOL ORAL MAXI, V121, P740, DOI 10.1016/j.jormas.2020.05.001
   Egeberg A, 2023, BRIT J DERMATOL, V188, P793, DOI 10.1093/bjd/ljad039
   Eguia A, 2020, MED ORAL PATOL ORAL, V25, pE71, DOI 10.4317/medoral.23191
   Fleissig Y, 2012, OR SURG OR MED OR PA, V113, pE1, DOI 10.1016/j.tripleo.2011.06.023
   Fusco V, 2015, CLIN GENITOURIN CANC, V13, P287, DOI 10.1016/j.clgc.2014.12.002
   Gianoukakis AG, 2018, ENDOCR RELAT CANCER, V25, P699, DOI 10.1530/ERC 18 0049
   Guida A, 2021, CLIN CASE REP, V9, P61, DOI 10.1002/ccr3.3418
   Guo Q, 2023, INT IMMUNOPHARMACOL, V114, DOI 10.1016/j.intimp.2022.109490
   He LN, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 020 00093 2
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Hu MMI, 2019, ENDOCR RELAT CANCER, V26, P241, DOI 10.1530/ERC 18 0258
   Huang JJ, 2020, SEMIN NEPHROL, V40, P28, DOI 10.1016/j.semnephrol.2019.12.004
   Iannantuono GM, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073995
   Kim M, 2018, THYROID, V28, P340, DOI 10.1089/thy.2017.0356
   Kim S, 2017, J BONE MINER RES, V32, P309, DOI 10.1002/jbmr.2985
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Kuroshima S, 2022, GENESIS, V60, DOI 10.1002/dvg.23500
   Lee KH, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 2129 3
   Marino R, 2015, AUST DENT J, V60, P528, DOI 10.1111/adj.12254
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mavroidis P, 2009, ACTA ONCOL, V48, P610, DOI 10.1080/02841860802657250
   Melloni C, 2016, EUR J PLAST SURG, V39, P161, DOI 10.1007/s00238 015 1112 3
   Mohamed HAM, 2018, OR SURG OR MED OR PA, V125, P157, DOI 10.1016/j.oooo.2017.10.010
   Monteiro Luis, 2021, J Clin Exp Dent, V13, pe626, DOI 10.4317/jced.58323
   Nicolatou Galitis O, 2012, OR SURG OR MED OR PA, V113, P234, DOI 10.1016/j.tripleo.2011.08.024
   Noguchi Y, 2020, PHARM RES DORDR, V37, DOI 10.1007/s11095 020 02801 3
   Noguchi Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01319
   Norén GN, 2008, STAT MED, V27, P3057, DOI 10.1002/sim.3247
   Owosho AA, 2015, ORAL ONCOL, V51, pE100, DOI 10.1016/j.oraloncology.2015.08.014
   Paragliola RM, 2023, CANCERS, V15, DOI 10.3390/cancers15020529
   Patel V, 2017, OR SURG OR MED OR PA, V124, pE257, DOI 10.1016/j.oooo.2017.08.003
   Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]
   Powles T, 2021, ANN ONCOL, V32, P422, DOI 10.1016/j.annonc.2020.11.016
   Pundole X, 2020, IMMUNOTHERAPY UK, V12, P1213, DOI 10.2217/imt 2020 0108
   Sánchez Gastaldo A, 2017, CANCER TREAT REV, V60, P77, DOI 10.1016/j.ctrv.2017.08.010
   Schwartz HC, 2015, J ORAL MAXIL SURG, V73, P377, DOI 10.1016/j.joms.2014.10.035
   Soós B, 2015, ORVOSI HETILAP, V156, P1865, DOI 10.1556/650.2015.30292
   Tran J, 2022, JCO ONCOL PRACT, V18, P187, DOI 10.1200/OP.21.00419
   Vallina C, 2019, MED ORAL PATOL ORAL, V24, pE326, DOI 10.4317/medoral.22858
   Viviano M, 2017, J KOR ASSOC ORAL MAX, V43, P120, DOI 10.5125/jkaoms.2017.43.2.120
   Wehrhan F, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 102
   Xia S, 2023, CANCERS, V15, DOI 10.3390/cancers15010240
NR 55
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 29
PY 2024
VL 15
AR 1309148
DI 10.3389/fphar.2024.1309148
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA L7B3I
UT WOS:001352227800001
PM 39534085
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Huang, J
   Qu, SX
   Wang, J
   Yang, D
   Duan, K
   Weng, J
AF Huang, Jie
   Qu, Shuxin
   Wang, Jing
   Yang, Dan
   Duan, Ke
   Weng, Jie
TI Reciprocating sliding wear behavior of alendronate sodium loaded UHMWPE
   under different tribological conditions
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE UHMWPE; Bisphosphonates; Wear; Wear conditions; Osteolysis; Friction
ID MOLECULAR WEIGHT POLYETHYLENE; HIP PROSTHESIS; JOINT; MECHANISMS;
   OSTEONECROSIS; LUBRICATION; FRICTION; RELEASE; DEBRIS; MODEL
AB The aim of this study is to investigate the tribological behaviors and wear mechanisms of ultra high molecular weight polyethylene (UHMWPE) loaded with alendronate sodium (ALN), a potential drug to treat osteolysis, under different normal loads and lubrication conditions. A mixture of UHMWPE powder and ALN (1.0 wt.%) solution was dried and hot pressed. The static and dynamic friction coefficients of UHMWPE ALN were slightly higher than those of UHMWPE except under normal load as 10 N and in 25 v/v % calf serum. The specific wear rates of UHMWPE ALN and UHMWPE were the lowest in 25 v/v % calf serum compared to those in deionized water or physiological saline. In particular, the specific wear rate of UHMWPE ALN was lower than that of UHMWPE at 50 N in 25 v/v % calf serum. The main wear mechanisms of UHMWPE and UHMWPE ALN in deionized water and UHMWPE in physiological saline were abrasive. The main wear mechanism of UHMWPE ALN in physiological saline was micro fatigue. In 25 v/v % calf serum, the main wear mechanism of UHMWPE and UHMWPE ALN was abrasive wear accompanied with plastic deformation. The results of Micro XRD indicated that the molecular deformation of UHMWPE ALN and UHMWPE under the lower stress were in the amorphous region but in the crystalline region at the higher stress. These results showed that the wear of UHMWPE ALN would be reduced under calf serum lubricated, which would be potentially applied to treat osteolysis. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Huang, Jie; Qu, Shuxin; Wang, Jing; Duan, Ke; Weng, Jie] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, Chengdu 610031, Peoples R China.
   [Yang, Dan] Southwest Jiaotong Univ, Sch Mech Engn, Tribol Res Inst, Key Lab Adv Technol Mat,Minist Educ, Chengdu 610031, Peoples R China.
C3 Southwest Jiaotong University; Southwest Jiaotong University
RP Qu, SX (通讯作者)，Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, Chengdu 610031, Peoples R China.
EM qushuxin@swjtu.edu.cn
RI ; Weng, Jie/B 3005 2010; Yang, Dan/JBS 2391 2023
OI Weng, Jie/0000 0002 7034 3215; 
FU National Basic Research Program of China (973 Program) [2012CB933602];
   National Natural Science Foundation of China [50975239]; Key Project of
   Chinese Ministry of Education [109137]; Fundamental Research Funds for
   the Central Universities [SWJTU11CX118, SWJTU11ZT05]
FX The present study was supported by National Basic Research Program of
   China (973 Program, 2012CB933602), National Natural Science Foundation
   of China (50975239), the Key Project of Chinese Ministry of Education
   (no. 109137) and the Fundamental Research Funds for the Central
   Universities (SWJTU11CX118 and SWJTU11ZT05). We thank Mr. Chongxi Jiang
   and Mrs. Ru Sheng for kindly providing SEM and FTIR observation and
   analysis.
CR Abtahi J, 2010, INT J ORAL MAX SURG, V39, P673, DOI 10.1016/j.ijom.2010.04.002
   AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, P7
   Angker L, 2004, ARCH ORAL BIOL, V49, P99, DOI 10.1016/j.archoralbio.2003.08.006
   Anissian HL, 1999, ACTA ORTHOP SCAND, V70, P578, DOI 10.3109/17453679908997845
   [Anonymous], 142421 ISO
   Antoine JF, 2006, J TRIBOL T ASME, V128, P660, DOI 10.1115/1.2197850
   Åstrand J, 2004, J ORTHOP RES, V22, P244, DOI 10.1016/j.orthres.2003.08.008
   BOWDEN PB, 1974, J MATER SCI, V9, P2034, DOI 10.1007/BF00540553
   Cho HJ, 2004, MATER CHEM PHYS, V88, P9, DOI 10.1016/j.matchemphys.2003.10.021
   Edwards SHR, 2011, VET J, V190, P15, DOI 10.1016/j.tvjl.2010.09.019
   Fruh HJ, 1997, BIOMATERIALS, V18, P873, DOI 10.1016/S0142 9612(97)00005 7
   Galetz MC, 2010, TRIBOL LETT, V38, P1, DOI 10.1007/s11249 009 9563 y
   Galvin AL, 2005, WEAR, V259, P972, DOI 10.1016/j.wear.2005.02.016
   Ge SR, 2008, WEAR, V264, P571, DOI 10.1016/j.wear.2007.05.001
   Gispert MP, 2006, WEAR, V260, P149, DOI 10.1016/j.wear.2004.12.040
   Gossec L, 2006, BEST PRACT RES CL RH, V20, P131, DOI 10.1016/j.berh.2005.09.005
   Halling J., 1975, Principles of tribology
   Heuberger MP, 2005, BIOMATERIALS, V26, P1165, DOI 10.1016/j.biomaterials.2004.05.020
   Kumar R, 2002, WEAR, V252, P445, DOI 10.1016/S0043 1648(01)00895 X
   Kurtz S.M., 2004, The UHMWPE Handbook: UltraHigh Molecular Weight Polyethylene in Total Joint Replacement
   Leng Y., 2008, Materials Characterization: Introduction to Microscopic and Spectroscopic Methods, P45
   Lerf R, 2010, BIOMATERIALS, V31, P3643, DOI 10.1016/j.biomaterials.2010.01.076
   Li S., 2001, OPER TECH ORTHOP, V11, P288, DOI DOI 10.1016/S1048 6666(01)80044 6
   Linny A., 2004, ARCH ORAL BIOL, V49, P369
   Liu XM, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/6/065008
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Martin DC, 2010, J ORAL MAXIL SURG, V68, P508, DOI 10.1016/j.joms.2009.09.055
   Matuana LM, 1998, POLYM COMPOSITE, V19, P446, DOI 10.1002/pc.10119
   Oral E, 2006, J ARTHROPLASTY, V21, P580, DOI 10.1016/j.arth.2005.07.009
   PERERSON JM, 1966, J APPL PHYS, V37, P4051, DOI 10.1063/1.1707974
   Qu SX, 2013, J BIOMED MATER RES A, V101, P394, DOI 10.1002/jbm.a.34327
   Rahaman MN, 2007, J AM CERAM SOC, V90, P1965, DOI 10.1111/j.1551 2916.2007.01725.x
   Saikko V, 2003, J TRIBOL T ASME, V125, P638, DOI 10.1115/1.1537751
   Shi W, 2000, MAT SCI ENG A STRUCT, V291, P27, DOI 10.1016/S0921 5093(00)00972 2
   Silverman SL, 2007, SEMIN ARTHRITIS RHEU, V37, P1, DOI 10.1016/j.semarthrit.2006.12.003
   Song KE, 2008, CURR THER RES CLIN E, V69, P356, DOI 10.1016/j.curtheres.2008.08.003
   Srinath G, 2005, J MATER SCI, V40, P2897, DOI 10.1007/s10853 005 2439 0
   von Knoch F, 2005, BIOMATERIALS, V26, P3549, DOI 10.1016/j.biomaterials.2004.09.043
   vonEisenhartRothe R, 1997, ANAT EMBRYOL, V195, P279, DOI 10.1007/s004290050047
   WANG A, 1995, WEAR, V181, P241, DOI 10.1016/0043 1648(94)07027 X
   Wang A, 1998, TRIBOL INT, V31, P17, DOI 10.1016/S0301 679X(98)00005 X
   Wang QL, 2009, J BIONIC ENG, V6, P378, DOI 10.1016/S1672 6529(08)60139 0
   Xiong DS, 2001, WEAR, V250, P242, DOI 10.1016/S0043 1648(01)00647 0
   Yang D, 2012, APPL SURF SCI, V262, P207, DOI 10.1016/j.apsusc.2012.05.012
   Yang D, 2012, MAT SCI ENG C MATER, V32, P83, DOI 10.1016/j.msec.2011.09.012
   Zheng J., 2012, TRIBOL INT, DOI DOI 10.1016/J.TRIB0INT.2012.04.019
NR 46
TC 20
Z9 23
U1 7
U2 83
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD JUL 1
PY 2013
VL 33
IS 5
BP 3001
EP 3009
DI 10.1016/j.msec.2013.03.030
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 153VH
UT WOS:000319630100069
PM 23623125
DA 2025 08 17
ER

PT J
AU Suhara, Y
   Murakami, A
   Nakagawa, K
   Mizuguchi, Y
   Okano, T
AF Suhara, Yoshitonio
   Murakami, Aya
   Nakagawa, Kimie
   Mizuguchi, Yukari
   Okano, Toshio
TI Comparative uptake, metabolism, and utilization of menaquinone 4 and
   phylloquinone in human cultured cell lines
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE vitamin K cycle; menaquinone 4; phylloquinone; uptake; metabolism;
   LC APCI MS/MS
ID TANDEM MASS SPECTROMETRY; K DEPENDENT CARBOXYLASE; VITAMIN K;
   HEPATOCELLULAR CARCINOMA; BONE; CALCIFICATION; OSTEOBLASTS; TRANSPORT;
   PROTEIN; LIVER
AB It is generally accepted that the availability of vitamin K in vivo depends on its homologues, the biological activities of which would differ among organs. To test this hypothesis, we examined the uptake, metabolism, and utilization of menaquinone 4 (MK 4) and phylloquinone (PK) using O 18 labeled compounds in two cultured human cell lines (HepG2 and MG 63). Lipid extracts were prepared from the cells and media after 1, 3, and 6 It of incubation. The detection of the vitamin K analogues (O 18 , O 16 quinone, and epoxide forms) was carried out with LC APCI MS/MS as previously reported. The 180 of vitamin K was replaced with atmospheric 1 6 02 during the formation of vitamin K epoxide with a carboxylative catalytic reaction. As a result, a significant difference was observed between MK 4 and PK in the amounts taken up into the cells. The O 18 labeled MK 4 was rapidly and remarkably well absorbed into the cells and metabolized to the epoxide form via a hydroquinone form as compared to the O 18 labeled PK. The difference in uptake of MK 4 and PK was not affected by treatment with warfarin although the metabolism of both compounds was markedly inhibited. This methodology should be utilized to clarify some of the actions of vitamin K in target cells and facilitate the development of new vitamin K drugs. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Kobe Pharmaceut Univ, Dept Hyg Sci, Higashinada Ku, Kobe, Hyogo 6588558, Japan.
C3 Kobe Pharmaceutical University
RP Okano, T (通讯作者)，Kobe Pharmaceut Univ, Dept Hyg Sci, Higashinada Ku, 4 19 1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.
EM t okano@kobepharma u.ac.jp
RI ; Nakayama, Kei/C 1182 2009
OI Suhara, Yoshitomo/0000 0002 4770 2910; 
CR DOWD P, 1992, J AM CHEM SOC, V114, P7613, DOI 10.1021/ja00046a001
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Erkkilä AT, 2004, METABOLISM, V53, P215, DOI 10.1016/j.metabol.2003.08.015
   FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092 8674(88)90567 3
   Habu D, 2004, JAMA J AM MED ASSOC, V292, P358, DOI 10.1001/jama.292.3.358
   Ham SW, 1997, CHEM COMMUN, P929, DOI 10.1039/a701091e
   Lamson Davis W, 2003, Altern Med Rev, V8, P303
   Landes N, 2003, MOL ASPECTS MED, V24, P337, DOI 10.1016/S0098 2997(03)00029 3
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   NAGANATHAN S, 1994, J AM CHEM SOC, V116, P9831, DOI 10.1021/ja00101a003
   Newman P, 2002, J BONE MINER RES, V17, P426, DOI 10.1359/jbmr.2002.17.3.426
   Otsuka M, 2005, LIFE SCI, V76, P2473, DOI 10.1016/j.lfs.2004.12.020
   Otsuka M, 2004, HEPATOLOGY, V40, P243, DOI 10.1002/hep.20260
   Sano Y, 1997, ANAL SCI, V13, P67, DOI 10.2116/analsci.13.67
   Sano Y., 1995, JPN PHARMACOL THER, V23, P207
   Sato T, 2002, BRIT J NUTR, V87, P307, DOI 10.1079/BJN2001519
   Schurgers LJ, 2002, BBA GEN SUBJECTS, V1570, P27, DOI 10.1016/S0304 4165(02)00147 2
   Spronk HMH, 2003, J VASC RES, V40, P531, DOI 10.1159/000075344
   Suhara Y, 2005, ANAL CHEM, V77, P757, DOI 10.1021/ac0489667
   SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331
   Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200
   TADANO K, 1989, J PHARMACOBIO DYNAM, V12, P640, DOI 10.1248/bpb1978.12.640
NR 22
TC 17
Z9 24
U1 0
U2 7
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD OCT 1
PY 2006
VL 14
IS 19
BP 6601
EP 6607
DI 10.1016/j.bmc.2006.06.004
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 086CK
UT WOS:000240650500015
PM 16798001
DA 2025 08 17
ER

PT J
AU Chijcheapaza Flores, H
   Tabary, N
   Chai, F
   Maton, M
   Staelens, JN
   Cazaux, F
   Neut, C
   Martel, B
   Blanchemain, N
   Garcia Fernandez, MJ
AF Chijcheapaza Flores, Henry
   Tabary, Nicolas
   Chai, Feng
   Maton, Mickael
   Staelens, Jean Noel
   Cazaux, Frederic
   Neut, Christel
   Martel, Bernard
   Blanchemain, Nicolas
   Garcia Fernandez, Maria Jose
TI Injectable Chitosan Based Hydrogels for Trans Cinnamaldehyde Delivery in
   the Treatment of Diabetic Foot Ulcer Infections
SO GELS
LA English
DT Article
DE hydrogels; drug delivery; diabetic foot ulcers; antimicrobial treatment;
   cyclodextrins; chitosan
ID RELEASE; CYCLODEXTRINS; MANAGEMENT; COMPLEXES; MECHANISM; DRUGS
AB Diabetic foot ulcers (DFU) are among the most common complications in diabetic patients and affect 6.8% of people worldwide. Challenges in the management of this disease are decreased blood diffusion, sclerotic tissues, infection, and antibiotic resistance. Hydrogels are now being used as a new treatment option since they can be used for drug delivery and to improve wound healing. This project aims to combine the properties of hydrogels based on chitosan (CHT) and the polymer of beta cyclodextrin (PCD) for local delivery of cinnamaldehyde (CN) in diabetic foot ulcers. This work consisted of the development and characterisation of the hydrogel, the evaluation of the CN release kinetics and cell viability (on a MC3T3 pre osteoblast cell line), and the evaluation of the antimicrobial and antibiofilm activity (S. aureus and P. aeruginosa). The results demonstrated the successful development of a cytocompatible (ISO 10993 5) injectable hydrogel with antibacterial (99.99% bacterial reduction) and antibiofilm activity. Furthermore, a partial active molecule release and an increase in hydrogel elasticity were observed in the presence of CN. This leads us to hypothesise that a reaction between CHT and CN (a Schiff base) can occur and that CN could act as a physical crosslinker, thus improving the viscoelastic properties of the hydrogel and limiting CN release.
C1 [Chijcheapaza Flores, Henry; Chai, Feng; Maton, Mickael; Blanchemain, Nicolas; Garcia Fernandez, Maria Jose] CHU Lille, Univ Lille, INSERM, U1008 Adv Drug Delivery Syst & Biomat, F 59000 Lille, France.
   [Tabary, Nicolas; Staelens, Jean Noel; Cazaux, Frederic; Martel, Bernard] Univ Lille, Unite Mat & Transformat, CNRS,Cent Lille, INRAE, F 59000 Lille, France.
   [Neut, Christel] CHU Lille, Univ Lille, INSERM, U1286 INFIN, F 59000 Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Lille; CHU Lille; Centre National de la Recherche
   Scientifique (CNRS); Universite de Lille; Centrale Lille; INRAE;
   Universite de Lille; Institut National de la Sante et de la Recherche
   Medicale (Inserm); CHU Lille
RP Garcia Fernandez, MJ (通讯作者)，CHU Lille, Univ Lille, INSERM, U1008 Adv Drug Delivery Syst & Biomat, F 59000 Lille, France.
EM maria jose.garcia fernandez@univ lille.fr
RI Neut, Christel/AAA 5153 2021; TABARY, Nicolas/AAJ 4320 2021
OI STAELENS, Jean Noel/0000 0002 7092 7165; Neut,
   Christel/0000 0002 2036 6152; Maton, Mickael/0009 0002 8291 0296; Garcia
   Fernandez, Maria Jose/0000 0003 1918 616X; CHIJCHEAPAZA FLORES, Henry
   Richard/0000 0002 7555 0109; Martel, Bernard/0000 0001 5329 3028;
   TABARY, Nicolas/0000 0001 9237 0196; CAZAUX,
   Frederic/0000 0001 8861 9905; chai, feng/0000 0002 1839 6221
FU MOBLILEX scholarship
FX This research was funded by the 2018 2019 MOBLILEX scholarship.
CR Andreica BI, 2020, EUR POLYM J, V139, DOI 10.1016/j.eurpolymj.2020.110016
   Caccavo D, 2017, CURR DRUG DELIV, V14, P179, DOI 10.2174/1567201813666160808102106
   Carneiro SB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030642
   Chen G, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11091420
   Chouhan D, 2019, BIOMATERIALS, V216, DOI 10.1016/j.biomaterials.2019.119267
   Deng YM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02962 z
   Djekic L, 2020, PHARM DEV TECHNOL, V25, P332, DOI 10.1080/10837450.2019.1701495
   Domadia P, 2007, BIOCHEM PHARMACOL, V74, P831, DOI 10.1016/j.bcp.2007.06.029
   Dumitriu RP, 2015, MATERIALS, V8, P317, DOI 10.3390/ma8010317
   Everett E, 2018, ANN NY ACAD SCI, V1411, P153, DOI 10.1111/nyas.13569
   Firmino Diego F, 2018, ScientificWorldJournal, V2018, P7405736, DOI 10.1155/2018/7405736
   Flores C, 2017, CARBOHYD POLYM, V173, P535, DOI 10.1016/j.carbpol.2017.06.026
   Hemmingsen LM, 2021, MAR DRUGS, V19, DOI 10.3390/md19120697
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   HIGUCHI T, 1965, ADV ANAL CHEM INSTRU, V4, P117, DOI DOI 10.1016/S0076 6879(82)87029 8
   Hill LE, 2013, LWT FOOD SCI TECHNOL, V51, P86, DOI 10.1016/j.lwt.2012.11.011
   Hua YY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010313
   Ji JY, 2022, INT J NANOMED, V17, P3163, DOI 10.2147/IJN.S363827
   Kaczmarek B, 2018, INT J BIOL MACROMOL, V118, P938, DOI 10.1016/j.ijbiomac.2018.06.175
   Kanjickal D, 2005, J BIOMED MATER RES A, V74A, P454, DOI 10.1002/jbm.a.30374
   Kfoury M, 2018, MOLECULES, V23, DOI 10.3390/molecules23051204
   Kfoury M, 2015, CARBOHYD POLYM, V131, P264, DOI 10.1016/j.carbpol.2015.06.014
   KORSMEYER RW, 1981, J MEMBRANE SCI, V9, P211, DOI 10.1016/S0376 7388(00)80265 3
   Kravanja G, 2019, MOLECULES, V24, DOI 10.3390/molecules24101960
   Loftsson T, 2019, INT J PHARMACEUT, V560, P228, DOI 10.1016/j.ijpharm.2019.02.004
   Malheiro JF, 2019, INT BIODETER BIODEGR, V141, P71, DOI 10.1016/j.ibiod.2018.06.003
   Martel B, 2005, J APPL POLYM SCI, V97, P433, DOI 10.1002/app.21391
   Matica MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235889
   Mogrovejo Valdivia A, 2019, INT J PHARMACEUT, V556, P301, DOI 10.1016/j.ijpharm.2018.12.018
   Palomino Durand C, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11020214
   Rieger KA, 2014, CARBOHYD POLYM, V113, P561, DOI 10.1016/j.carbpol.2014.06.075
   Rohner NA, 2019, MOL PHARMACEUT, V16, P1766, DOI 10.1021/acs.molpharmaceut.9b00144
   Shao JL, 2017, NANOMEDICINE UK, V12, P2771, DOI 10.2217/nnm 2017 0172
   Sun QM, 2018, CARBOHYD POLYM, V194, P294, DOI 10.1016/j.carbpol.2018.04.055
   Topa SH, 2018, MICROBIOL SGM, V164, P1087, DOI 10.1099/mic.0.000692
   Xu JM, 2022, ANTIBIOTICS BASEL, V11, DOI 10.3390/antibiotics11101403
   Yildiz ZI, 2019, J AGR FOOD CHEM, V67, P11066, DOI 10.1021/acs.jafc.9b02789
   Zarrintaj P, 2021, TISSUE ENG PT A, V27, P821, DOI [10.1089/ten.tea.2020.0341, 10.1089/ten.TEA.2020.0341]
   Zhang PZ, 2017, ANN MED, V49, P106, DOI 10.1080/07853890.2016.1231932
   Zhong YJ, 2022, CARBOHYD POLYM, V298, DOI 10.1016/j.carbpol.2022.120103
   Zhong YJ, 2021, BIOMACROMOLECULES, V22, P1654, DOI 10.1021/acs.biomac.1c00086
   Zhong YJ, 2020, BIOMACROMOLECULES, V21, P2983, DOI 10.1021/acs.biomac.0c00760
   Zhou ZQ, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.968065
NR 43
TC 10
Z9 10
U1 9
U2 43
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2310 2861
J9 GELS BASEL
JI Gels
PD MAR
PY 2023
VL 9
IS 3
AR 262
DI 10.3390/gels9030262
PG 17
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA C0GK0
UT WOS:000958805800001
PM 36975711
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jiang, HH
   Xu, LQ
   Liu, W
   Xiao, M
   Ke, J
   Long, X
AF Jiang, Henghua
   Xu, Liqin
   Liu, Wen
   Xiao, Mian
   Ke, Jin
   Long, Xing
TI Chronic Pain Causes Peripheral and Central Responses in MIA Induced
   TMJOA Rats
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Temporomandibular joint osteoarthritis; Chronic pain; Monosodium
   iodoacetate; CGRP; IB4
ID GENE RELATED PEPTIDE; TEMPOROMANDIBULAR JOINT; SUBCHONDRAL BONE; MODEL;
   OSTEOARTHRITIS; MECHANISMS; DISORDERS; BEHAVIOR; NEURONS; CARTILAGE
AB Chronic pain is the predominant symptom that drives temporomandibular joint osteoarthritis (TMJOA) patients to seek medical care; however, currently used treatment modalities remain less effective. This study aimed to investigate chronic pain and the peripheral and central responses in monoiodoacetate (MIA) induced TMJOA rats. First, the appropriate dose of MIA was determined based on pain behavior assessment in rats. Alterations of the condylar structure in TMJOA rats were evaluated by histological staining and micro computed tomography (micro CT). Second, the period of TMJOA chronic pain was further explored by assessing the numbers of glial fibrillary acidic protein (GFAP) positive astrocytes and ionized calcium binding adaptor molecule 1 (IBA 1) positive microglia in the trigeminal spinal nucleus (TSN) and performing nonsteroidal anti inflammatory drug (NSAID) efficacy experiments. Finally, the expression of neurofilament 200 (NF200), calcitonin gene related peptide (CGRP), and isolectin B4 (IB4) in the trigeminal ganglion (TG) and TSN was assessed by immunofluorescence. MIA at 4 mg/kg was considered an appropriate dose. Gradual MIA induced alterations of the condylar structure were correlated with temporomandibular joint (TMJ) pain. The numbers of GFAP  and IBA 1 positive cells were increased at 2, 3, and 4 weeks after MIA injection. NSAIDs failed to alleviate pain behavior 10 days after MIA injection. CGRP and IB4 levels in the TG and TSN were upregulated at 2 and 4 weeks. These results suggest that TMJOA related chronic pain emerged 2 weeks after MIA injection. CGRP  and IB4 positive afferents in both the peripheral and central nervous systems may be involved in MIA induced TMJOA related chronic pain in rats.
C1 [Jiang, Henghua; Xu, Liqin; Liu, Wen; Xiao, Mian; Ke, Jin] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
   [Jiang, Henghua; Xu, Liqin; Liu, Wen; Xiao, Mian; Ke, Jin] Wuhan Univ, Sch & Hosp Stomatol, Key Lab Oral Biomed, Minist Educ, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
   [Long, Xing] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University
RP Ke, J (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.; Ke, J (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Key Lab Oral Biomed, Minist Educ, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.; Long, X (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
EM kejin@whu.edu.cn; longxing@whu.edu.cn
RI long, xing/X 6361 2018; xiao, mian/HHD 0005 2022
FU National Science Foundation of China [81771100, 81870789]
FX This study was funded by the National Science Foundation of China (Grant
   Numbers 81771100 and 81870789).
CR Alvarez P, 2012, J NEUROPHYSIOL, V108, P2545, DOI 10.1152/jn.00576.2012
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Calvo M, 2012, EXP NEUROL, V234, P271, DOI 10.1016/j.expneurol.2011.08.018
   Cirillo G, 2010, CELL MOL NEUROBIOL, V30, P51, DOI 10.1007/s10571 009 9430 2
   Clements KM, 2009, OSTEOARTHR CARTILAGE, V17, P805, DOI 10.1016/j.joca.2008.11.002
   Coskun U, 2019, J CRANIO MAXILL SURG, V47, P357, DOI 10.1016/j.jcms.2018.12.004
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Ferreira Gomes J, 2010, ARTHRITIS RHEUM US, V62, P3677, DOI 10.1002/art.27713
   GARRISON CJ, 1991, BRAIN RES, V565, P1, DOI 10.1016/0006 8993(91)91729 K
   Gowler PR, 2018, OSTEOARTHR CARTILAGE, V26, pS15, DOI 10.1016/j.joca.2018.02.048
   Güler N, 2011, INT J ORAL MAX SURG, V40, P1289, DOI 10.1016/j.ijom.2011.07.908
   Gupta PK, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1195 7
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Hald A, 2009, CELL MOL NEUROBIOL, V29, P609, DOI 10.1007/s10571 009 9390 6
   Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P415, DOI 10.1016/j.joca.2007.12.017
   Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Jiao K, 2011, BONE, V48, P362, DOI 10.1016/j.bone.2010.09.010
   Kameoka S, 2010, DENTOMAXILLOFAC RAD, V39, P441, DOI 10.1259/dmfr/37174063
   La JH, 2016, PAIN, V157, P348, DOI 10.1097/j.pain.0000000000000380
   Li ZW, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194 016 0685 y
   Miyagi M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1792 x
   Mujakperuo HR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004715.pub2
   Neugebauer V, 1996, NEUROSCIENCE, V71, P1095, DOI 10.1016/0306 4522(95)00473 4
   Nwosu LN, 2016, OSTEOARTHR CARTILAGE, V24, P1910, DOI 10.1016/j.joca.2016.06.012
   Okun A, 2012, PAIN, V153, P924, DOI 10.1016/j.pain.2012.01.022
   Oroszova Z, 2017, CELL MOL NEUROBIOL, V37, P545, DOI 10.1007/s10571 016 0396 6
   PERRY MJ, 1991, J NEUROCYTOL, V20, P746, DOI 10.1007/BF01187848
   Philpott HT, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2096 3
   Sagar DR, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 88
   Sannajust S, 2019, PAIN, V160, P2036, DOI 10.1097/j.pain.0000000000001598
   Schaible HG, 2002, ANN NY ACAD SCI, V966, P343, DOI 10.1111/j.1749 6632.2002.tb04234.x
   Schiffman E, 2014, J ORAL FACIAL PAIN H, V28, P6, DOI 10.11607/jop.1151
   Scrivani SJ, 2008, NEW ENGL J MED, V359, P2693, DOI 10.1056/NEJMra0802472
   Senye M, 2012, J OROFAC PAIN, V26, P26
   Tanaka E, 2008, J DENT RES, V87, P296, DOI 10.1177/154405910808700406
   Taves S, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/753656
   Vermeirsch H, 2007, PHARMACOL BIOCHEM BE, V87, P349, DOI 10.1016/j.pbb.2007.05.010
   Wang XD, 2015, J DENT RES, V94, P666, DOI 10.1177/0022034515574770
   Wang XH, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0047703, 10.1371/journal.pone.0032405]
   WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0
   Wright EF, 2010, BR DENT J, V209, P322
   Xu LQ, 2019, MOL PAIN, V15, DOI 10.1177/1744806919866340
   Xu ZZ, 2015, NAT MED, V21, P1326, DOI 10.1038/nm.3978
   YAMASHITA T, 1990, J BONE JOINT SURG AM, V72A, P865, DOI 10.2106/00004623 199072060 00011
   Zarb GA, 1999, J OROFAC PAIN, V13, P295
   Zhang L, 2019, GLIA, V67, P1062, DOI 10.1002/glia.23588
   Zhang LP, 2001, PAIN, V89, P265, DOI 10.1016/S0304 3959(00)00378 X
NR 48
TC 26
Z9 28
U1 0
U2 28
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272 4340
EI 1573 6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD JUL
PY 2022
VL 42
IS 5
BP 1441
EP 1451
DI 10.1007/s10571 020 01033 8
EA JAN 2021
PG 11
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 1N7VI
UT WOS:000604200200002
PM 33387118
DA 2025 08 17
ER

PT J
AU Ahmad, M
   Sahabjada
   Akhtar, J
   Hussain, A
   Badaruddeen
   Arshad, M
   Mishra, A
AF Ahmad, Mohammad
   Sahabjada
   Akhtar, Juber
   Hussain, Arshad
   Badaruddeen
   Arshad, Md
   Mishra, Anuradha
TI DEVELOPMENT OF A NEW RUTIN NANOEMULSION AND ITS APPLICATION ON PROSTATE
   CARCINOMA PC3 CELL LINE
SO EXCLI JOURNAL
LA English
DT Article
DE rutin; nanoemulsion; water titration method; cell viability; prostate
   cancer; reactive oxygen species
ID PRIMARY RAT OSTEOBLASTS; RUNX2 GENE EXPRESSION; DRUG DELIVERY SYSTEM;
   VITAMIN P; IN VIVO; CANCER; OPTIMIZATION; FLAVONOIDS; CYCLE
AB Biological effects of rutin bioactive are limited due to its poor oral bioavailability and its degradation in aqueous environments. For the purpose of bioenhancement, different nanoemulsion systems of rutin were developed by aqueous titration method using water as dispersion media. The nanoemulsion systems were characterized for surface morphology, droplet size, polydispersity index, zeta potential, in vitro release profile and the formulations were optimized. The anticancer potential of optimized nanoemulsion was evaluated by cells viability (MTT) assay, nuclear condensation, and ROS activity using human prostate cancer (PC3) cell line. On the basis of cell viability data the inhibitory concentration (IC50) value for optimized nanoemulsion formulation on PC3 cancer cells was found to be 11.8 mu M. Fluorescent microscopic analysis and intracellular ROS generation demonstrated significant ROS induction that might lead to triggering the apoptosis pathway. In conclusion, developed nanoemulsion displayed significant efficacy against prostate carcinoma cells.
C1 [Ahmad, Mohammad; Akhtar, Juber; Badaruddeen; Mishra, Anuradha] Integral Univ, Fac Pharm, Herbal Bioact Res Lab, Lucknow, Uttar Pradesh, India.
   [Sahabjada; Arshad, Md] Univ Lucknow, Dept Zool, Mol Endocrinol Lab, Lucknow, Uttar Pradesh, India.
   [Hussain, Arshad] King Khalid Univ, Coll Pharm, Abha, Saudi Arabia.
   [Hussain, Arshad] Integral Univ, Fac Pharm, Lucknow, Uttar Pradesh, India.
C3 Integral University; Lucknow University; King Khalid University;
   Integral University
RP Mishra, A (通讯作者)，Integral Univ, Fac Pharm, Dept Pharmacol, Lucknow 226026, UP, India.
EM misra.anuradha@gmail.com
RI Mishra, Anuradha/J 2840 2019; ., Badruddeen/AIB 1089 2022; Siddiqui,
   Sahabjada/E 8383 2015; Hussain, Arshad/ACF 7480 2022
OI Siddiqui, Sahabjada/0000 0003 0982 1465; Mishra, Prof
   Anuradha/0000 0002 2675 3479; 
FU Uttar Pradesh Council for Science and Technology, Uttar Pradesh, India
   [CST/YSS/D 1203]
FX This work was supported by the Uttar Pradesh Council for Science and
   Technology (File No. CST/YSS/D 1203), Uttar Pradesh, India. We are
   thankful to Dr. Amit Mishra (Head Pharmaceutics Division) for providing
   the Malvern Zetasizer facilities available at Central Drug Research
   Institute (CSIRCDRI), Lucknow (U.P.), India. Thanks to Ms. Vaishali
   Meghare (Indian Commercial Company Pvt. Ltd. Mumbai) for providing
   Sefsol 218 as a gift samples from Nikko Chemicals Tokyo, Japan. The
   authors offer their sincere thanks to Dean Research & Development,
   Integral University for providing technical support and assigning
   Communication no. (IU/R&D/2017 MCN00082).
CR Akhtar J, 2014, CURR DRUG DELIV, V11, P243, DOI 10.2174/156720181102140411160817
   Al Dhabi NA, 2015, EXCLI J, V14, P59, DOI 10.17179/excli2014 663
   AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   Ikeda NEA, 2015, CHEM BIOL INTERACT, V239, P184, DOI 10.1016/j.cbi.2015.06.011
   Biçer E, 2014, RUSS J ELECTROCHEM+, V50, P1058, DOI 10.1134/S1023193514060032
   Chen HY, 2013, SCI WORLD J, DOI 10.1155/2013/269165
   COUCH JF, 1946, SCIENCE, V103, P197, DOI 10.1126/science.103.2668.197
   Couch JF, 1951, CROPS PEACE WAR YB A, P742
   ECCLESTON J, 1994, ENCY PHARM TECHNOLOG, P375
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300 9084(02)01369 X
   Fraga M, 2008, PHARMAZIE, V63, P667, DOI 10.1691/ph.2008.8093
   Ghiasi M, 2012, COMPUT THEOR CHEM, V996, P28, DOI 10.1016/j.comptc.2012.07.009
   Grzybowski A, 2013, CLIN DERMATOL, V31, P327, DOI 10.1016/j.clindermatol.2012.08.001
   Gupta S., 2013, ISRN PHARM, V2013
   Huang RFS, 2015, INT J NANOMED, V10, P2823, DOI 10.2147/IJN.S79107
   Kaur H, 2014, J PHARMACEUTICS, V2014, DOI 10.1155/2014/180845
   KREWSON CF, 1950, J AM PHARM ASSOC SCI, V39, P163, DOI 10.1002/jps.3030390312
   Kumar S, 2006, J ETHNOPHARMACOL, V105, P246, DOI 10.1016/j.jep.2005.11.006
   Lawrence MJ, 2012, ADV DRUG DELIVER REV, V64, P175, DOI 10.1016/j.addr.2012.09.018
   Lin JP, 2012, ENVIRON TOXICOL, V27, P480, DOI 10.1002/tox.20662
   Lin JP, 2009, LEUKEMIA RES, V33, P823, DOI 10.1016/j.leukres.2008.09.032
   Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483
   Liu RH, 2013, J FOOD SCI, V78, pA18, DOI 10.1111/1750 3841.12101
   Louzada S, 2012, PLOS ONE, V7, P206, DOI 10.1371/journal.pone.0029923
   Macedo AS, 2014, PHARM DEV TECHNOL, V19, P677, DOI 10.3109/10837450.2013.823989
   Marzouk MS, 2007, NAT PROD RES, V21, P436, DOI 10.1080/14786410600943288
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365 2184.2012.00845.x
   Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   Rahman MA, 2011, CURR DRUG DELIV, V8, P330
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   SCHUNCK E, 1860, MEM LIT PHIL SOC M 2, V15, P122
   Shafiq un Nabi S, 2007, AAPS PHARMSCITECH, V18, pE12
   Sharma S, 2013, EXPERT OPIN INV DRUG, V22, P1063, DOI 10.1517/13543784.2013.805744
   Siddiqui S, 2015, CELL PROLIFERAT, V48, P443, DOI 10.1111/cpr.12195
   Siddiqui S, 2014, DARU, V22, DOI 10.1186/s40199 014 0072 7
   Singh AK, 2008, AAPS PHARMSCITECH, V9, P628, DOI 10.1208/s12249 008 9080 6
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Ullén A, 2005, ACTA ONCOL, V44, P490, DOI 10.1080/02841860510029888
   Vargo Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Wang LJ, 2009, J COLLOID INTERF SCI, V330, P443, DOI 10.1016/j.jcis.2008.10.077
NR 40
TC 31
Z9 34
U1 1
U2 15
PU EXCLI JOURNAL MANAGING OFFICE
PI DORTMUND
PA LEIBNIZ RESEARCH CENTRE WORKING ENVIRONMENT & HUMAN FACTORS EXCLI
   JOURNAL, ARDEYSTR 67, DORTMUND, D 44139, GERMANY
SN 1611 2156
J9 EXCLI J
JI EXCLI J.
PY 2017
VL 16
BP 810
EP 823
DI 10.17179/excli2016 668
PG 14
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA FB6SG
UT WOS:000406272100014
PM 28694767
DA 2025 08 17
ER

PT J
AU Lee, M
   Lee, HI
   Song, K
   Choi, HS
   Suh, J
   Kim, SH
   Chae, HW
   Kang, HC
   Lee, JS
   Kim, HD
   Kim, HS
   Kwon, A
AF Lee, Myeongseob
   Lee, Hae In
   Song, Kyungchul
   Choi, Han Saem
   Suh, Junghwan
   Kim, Se Hee
   Chae, Hyun Wook
   Kang, Hoon Chul
   Lee, Joon Soo
   Kim, Heung Dong
   Kim, Ho Seong
   Kwon, Ahreum
TI Association of hypercalciuria with vitamin D supplementation in patients
   undergoing ketogenic dietary therapy
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE vitamin D; vitamin D deficiency; ketogenic diet; hypercalciuria;
   urolithiasis
ID CALCIUM ABSORPTION; D DEFICIENCY; 25 HYDROXYVITAMIN D; MECHANISMS; RISK
AB BackgroundKetogenic dietary therapy (KDT) is used as an effective treatment for epilepsy. However, KDT carries the risk of bone health deterioration; therefore, vitamin D supplementation is required. Vitamin D replacement therapy in KDT has not been established because it may be related to hypercalciuria/urolithiasis, which are common adverse effects of KDT. Hence, this study aimed to evaluate the dose dependent association between vitamin D 3 and hypercalciuria/urolithiasis in patients undergoing KDT and dose optimization for renal complications. Materials and methodsOverall, 140 patients with intractable childhood epilepsy started 3:1 KDT (lipid to non lipid ratio) at the Severance Children's Hospital from January 2016 to December 2019. Regular visits were recommended after KDT initiation. Participants were assessed for height, weight, serum 25 hydroxyvitamin D (25 OH D 3) level, parathyroid hormone level, and ratio of urinary excretion of calcium and creatinine (Uca/Ucr). Kidney sonography was conducted annually. Patients who already had urolithiasis and were taking hydrochlorothiazide before KDT, failed to maintain KDT for 3 months, did not visit the pediatric endocrine department regularly, did not take prescribed calcium and vitamin D3 properly, or needed hospitalization for > 1 degrees month because of serious medical illness were excluded. Data from patients who started diuretic agents, e.g., hydrochlorothiazide, were excluded from that point because the excretion of calcium in the urine may be altered in these patients. ResultIn total, 49 patients were included in this study. Uca/Ucr ratio significantly decreased with increasing levels of 25 OH D 3 (p = 0.027). The odds ratio for hypercalciuria was 0.945 (95% confidence interval, 0.912 0.979; p = 0.002) per 1.0 ng/mL increment in 25 OH D 3 level. Based on findings of receiver operating characteristic curve analysis and Youden's J statistic, the cut off 25 OH D 3 level for preventing hypercalciuria was > 39.1 ng/mL at 6 months. Furthermore, the vitamin D 3 supplementation dose cut off was > 49.5 IU/kg for hypercalciuria prevention. ConclusionAn inverse relationship between Uca/Ucr ratio and 25 OH D 3 level was noted, which means that vitamin D supplementation is helpful for preventing hypercalciuria related to KDT. We suggest that the recommended 25 OH D 3 level is > 40 ng/mL for hypercalciuria prevention and that KDT for children with epilepsy can be optimized by vitamin D 3 supplementation at 50 IU/kg.
C1 [Lee, Myeongseob; Song, Kyungchul; Suh, Junghwan; Chae, Hyun Wook; Kim, Ho Seong; Kwon, Ahreum] Yonsei Univ, Severance Childrens Hosp, Endocrine Res Inst, Dept Pediat,Coll Med, Seoul, South Korea.
   [Lee, Hae In] CHA Univ, CHA Gangnam Med Ctr, Dept Pediat, Seoul, South Korea.
   [Choi, Han Saem] Catholic Kwandong Univ, Int St Marys Hosp, Dept Pediat, Incheon, South Korea.
   [Kim, Se Hee; Kang, Hoon Chul; Lee, Joon Soo; Kim, Heung Dong] Yonsei Univ, Severance Childrens Hosp, Dept Pediat, Div Pediat Neurol,Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Pochon Cha
   University; Catholic Kwandong University; Yonsei University; Yonsei
   University Health System
RP Kwon, A (通讯作者)，Yonsei Univ, Severance Childrens Hosp, Endocrine Res Inst, Dept Pediat,Coll Med, Seoul, South Korea.
EM armea@yuhs.ac
RI ; Kim, sung Koo/J 3859 2019; LEE, SOOYEON/KAM 6204 2024; Song,
   Kyungchul/ABH 8506 2020
OI Kim, Se Hee/0000 0001 7773 1942; Kang, Hoon Chul/0000 0002 3659 8847;
   Lee, Joon Soo/0000 0001 9036 9343; Kim, Ho Seong/0000 0003 1135 099X;
   Suh, Junghwan/0000 0002 2092 2585; LEE, MYEONGSEOB/0000 0001 7055 3100;
   Kim, Heung Dong/0000 0002 8031 7336; Song,
   Kyungchul/0000 0002 8497 5934; Kwon, Ahreum/0000 0002 9692 2135; Chae,
   Hyun Wook/0000 0001 5016 8539
CR Aloia JF, 2008, AM J CLIN NUTR, V87, P1952
   Asselman M, 2003, J AM SOC NEPHROL, V14, P3155, DOI 10.1097/01.ASN.0000099380.18995.F7
   Bischoff Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Boison D, 2017, CURR OPIN NEUROL, V30, P187, DOI 10.1097/WCO.0000000000000432
   Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528 1167.2007.00915.x
   Cai QY, 2017, WORLD J PEDIATR, V13, P528, DOI 10.1007/s12519 017 0053 2
   Ferraro PM, 2017, J UROLOGY, V197, P405, DOI 10.1016/j.juro.2016.08.084
   Furth SL, 2000, PEDIATR NEPHROL, V15, P125, DOI 10.1007/s004670000443
   Hernandez JD, 2015, JAMA PEDIATR, V169, P964, DOI 10.1001/jamapediatrics.2015.1419
   Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Hu HL, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030301
   Ismailova A, 2022, REV ENDOCR METAB DIS, V23, P265, DOI 10.1007/s11154 021 09679 5
   Kang HC, 2004, EPILEPSIA, V45, P1116, DOI 10.1111/j.0013 9580.2004.10004.x
   Khan SR, 2013, J UROLOGY, V189, P803, DOI 10.1016/j.juro.2012.05.078
   Kossoff EH, 2002, EPILEPSIA, V43, P1168, DOI 10.1046/j.1528 1157.2002.11302.x
   Kossoff Eric H, 2018, Epilepsia Open, V3, P175, DOI 10.1002/epi4.12225
   Kuo RL, 2003, KIDNEY INT, V64, P2150, DOI 10.1046/j.1523 1755.2003.00316.x
   Leaf DE, 2012, CLIN J AM SOC NEPHRO, V7, P829, DOI 10.2215/CJN.11331111
   Letavernier E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030366
   Leyssens C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00122
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   Malihi Z, 2016, AM J CLIN NUTR, V104, P1039, DOI 10.3945/ajcn.116.134981
   Oliveira B, 2016, AM J PHYSIOL RENAL, V311, pF1243, DOI 10.1152/ajprenal.00211.2016
   PAK CYC, 1972, J CLIN ENDOCR METAB, V35, P261, DOI 10.1210/jcem 35 2 261
   Sakhaee K, 2009, KIDNEY INT, V75, P585, DOI 10.1038/ki.2008.626
   Schöttker B, 2014, BMJ BRIT MED J, V348, DOI 10.1136/bmj.g3656
   Shakhssalim N, 2011, UROL RES, V39, P1, DOI 10.1007/s00240 010 0276 3
   Girón Prieto MS, 2016, INT UROL NEPHROL, V48, P1243, DOI 10.1007/s11255 016 1290 3
   Song K, 2020, CHILDREN BASEL, V7, DOI 10.3390/children7110241
   Tavasoli S, 2019, INT UROL NEPHROL, V51, P101, DOI 10.1007/s11255 018 1965 z
   Ticinesi A, 2016, UROLOGY, V87, P40, DOI 10.1016/j.urology.2015.10.009
   Tiselius HG, 2011, UROL RES, V39, P231, DOI 10.1007/s00240 010 0349 3
   Wöbke TK, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00244
   Worcester EM, 2010, NEW ENGL J MED, V363, P954, DOI 10.1056/NEJMcp1001011
NR 36
TC 1
Z9 1
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 861X
J9 FRONT NUTR
JI Front. Nutr.
PD SEP 2
PY 2022
VL 9
AR 970467
DI 10.3389/fnut.2022.970467
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 5P1BN
UT WOS:000872895000001
PM 36118750
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xie, HJ
   Zhao, J
   Wang, S
   Kong, L
   Li, XT
   Aga, E
   Ga, LZG
   Ye, BG
AF Xie, Hongjun
   Zhao, Jing
   Wang, Shuo
   Kong, Liang
   Li, Xuetao
   Aga, Erbu
   Ga, Lan Zi Gong
   Ye, Bengui
TI PH sensitive BSA modified resveratrol micelles targeting macrophages
   alleviate symptoms of rheumatoid arthritis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE BSA; Resveratrol; Micelles; pH sensitive; Macrophages; Rheumatoid
   arthritis
ID MATRIX METALLOPROTEINASES; DELIVERY; ART
AB Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, leading to severe inflammatory infiltration and joint damage, accompanied by a decrease in pH of joint microenvironment. Macrophages play an important role in the pathogenesis of RA, with high expression of bovine serum albumin (BSA) receptors on the surface of macrophages. Resveratrol (Res) has strong anti inflammatory effects, but its application is limited due to its poor water solubility and low bioavailability. Therefore, we constructed pH  sensitive micelles by encapsulating Res and modifying BSA on the surface of the micelles (BSA Res@Ms), thereby greatly improving the therapeutic effect of RA. Our research results indicated that BSA Res@Ms had a smooth and uniform appearance, small particle size, high drug encapsulation efficiency, good stability, and pH  sensitive properties. In vitro, BSARes@Ms increased the uptake of Res by RAW264.7 cells, reduced the levels of pro  inflammatory cytokines and cleared excess ROS produced by activated RAW264.7 cells, and inhibited the generation of osteoclasts. In vivo, BSA Res@Ms could target inflamed joint sites, significantly alleviate joint inflammation symptoms, inhibit activated macrophages, improve synovial hyperplasia and inflammatory cell infiltration, and protect cartilage. BSA Res@Ms provide a very promising method for the treatment of RA, which can effectively improve the inflammatory manifestations of RA.
C1 [Wang, Shuo; Ga, Lan Zi Gong; Ye, Bengui] Tibet Univ, Coll Sci, 10 Zangda East Rd, Tibet 850000, Peoples R China.
   [Aga, Erbu] Liaoning Univ Tradit Chinese Med, Sch Pharm, Dalian 116600, Peoples R China.
C3 Xizang University; Liaoning University of Traditional Chinese Medicine
RP Ga, LZG; Ye, BG (通讯作者)，Tibet Univ, Coll Sci, 10 Zangda East Rd, Tibet 850000, Peoples R China.
EM 35173588@qq.com; benguiye513@163.com
RI ; Li, Xue tao/AAH 2890 2020
OI wang, shuo/0009 0007 4420 7862; 
FU Science & technology major projects of Tibet [XZ202201ZD0001G06];
   National Natural Science Foundation of China [82060588]
FX The science & technology major projects of Tibet (Grant No,
   XZ202201ZD0001G06) , the National Natural Science Foundation of China
   (Grant No. 82060588) .
CR Al Rahim AM, 2023, ANIM BIOTECHNOL, V34, P166, DOI 10.1080/10495398.2021.1951282
   Aletaha D, 2019, NAT REV RHEUMATOL, V15, P633, DOI 10.1038/s41584 019 0279 6
   Chen X, 2019, NANOSCALE, V11, P18209, DOI 10.1039/c9nr05922a
   Chimento A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061381
   Croia C, 2019, CLIN EXP RHEUMATOL, V37, P347
   Cutolo M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867260
   Dai JL, 2018, ARTIF CELL NANOMED B, V46, P860, DOI 10.1080/21691401.2018.1470528
   Giordo R, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10020224
   Gowd V, 2022, J NUTR BIOCHEM, V109, DOI 10.1016/j.jnutbio.2022.109101
   Guan F, 2021, RSC ADV, V11, P7280, DOI 10.1039/d0ra08817j
   Guo CJ, 2023, INT J BIOL MACROMOL, V234, DOI 10.1016/j.ijbiomac.2023.123677
   Guo LN, 2022, SMALL, V18, DOI 10.1002/smll.202202604
   Han J., 2023, Molecules, V28
   Hannemann N, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2020.105091
   Jaiswal J, 2022, J SCI FOOD AGR, V102, P5468, DOI 10.1002/jsfa.11901
   Jia N, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01499 0
   Karimi A, 2022, INT J RHEUM DIS, V25, P827, DOI 10.1111/1756 185X.14356
   Kim J, 2019, ACS NANO, V13, P3206, DOI 10.1021/acsnano.8b08785
   Kondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010922
   Kumari S, 2022, MOLECULES, V27, DOI 10.3390/molecules27217561
   Li CH, 2017, J CONTROL RELEASE, V246, P133, DOI 10.1016/j.jconrel.2016.12.027
   Li M, 2022, DRUG DELIV, V29, P2751, DOI 10.1080/10717544.2022.2115162
   Li Y, 2017, COLLOID SURFACE B, V154, P397, DOI 10.1016/j.colsurfb.2017.03.045
   Li YF, 2022, ACTA BIOMATER, V152, P406, DOI 10.1016/j.actbio.2022.08.054
   Lin WJ, 2023, J ETHNOPHARMACOL, V301, DOI 10.1016/j.jep.2022.115802
   Maeda K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052871
   Makhija M., 2023, Recent Pat Nanotechnol.
   Malemud CJ, 2017, PROG MOL BIOL TRANSL, V148, P305, DOI 10.1016/bs.pmbts.2017.03.003
   Meng TT, 2021, MOLECULES, V26, DOI 10.3390/molecules26010229
   Min HK, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 16285 1
   Nautiyal G, 2024, RECENT PAT NANOTECH, V18, P433, DOI 10.2174/1872210517666230822100324
   Pulik L, 2023, REUMATOLOGIA, V61, P191, DOI 10.5114/reum/168503
   Ramli I, 2023, FRONT BIOSCI LANDMRK, V28, DOI 10.31083/j.fbl2809198
   Shaito A, 2023, CURR NEUROPHARMACOL, V21, P1184, DOI 10.2174/1570159X20666221012122855
   Shaito A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062084
   Shan SB, 2019, J BIOMED NANOTECHNOL, V15, P674, DOI 10.1166/jbn.2019.2721
   Shen Y, 2022, J ETHNOPHARMACOL, V284, DOI 10.1016/j.jep.2021.114791
   Sheng SY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829677
   Singh H, 2023, BIOMATERIALS, V303, DOI 10.1016/j.biomaterials.2023.122390
   Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749 6632.2010.05842.x
   Wang Q, 2021, ACTA PHARM SIN B, V11, P1158, DOI 10.1016/j.apsb.2021.03.013
   Wang S, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249 019 1491 z
   Wang X, 2018, ARTIF CELL NANOMED B, V46, P1154, DOI 10.1080/21691401.2018.1481082
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Wu D, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1051082
   Xia XL, 2022, PHARM DEV TECHNOL, V27, P829, DOI 10.1080/10837450.2022.2122506
   Xu A, 2022, J DRUG TARGET, V30, P961, DOI 10.1080/1061186X.2022.2070173
   Yang GL, 2018, J AGR FOOD CHEM, V66, P12953, DOI 10.1021/acs.jafc.8b05047
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Yu CW, 2022, DRUG DELIV, V29, P454, DOI 10.1080/10717544.2022.2032482
   Yu XZ, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5618 9
   Zamudio Cuevas Y, 2022, CELL MOL BIOL, V68, P174, DOI 10.14715/cmb/2022.68.6.28
   Zhang CL, 2022, MOLECULES, V27, DOI 10.3390/molecules27248645
   Zhang JX, 2021, SCI CHINA LIFE SCI, V64, P1187, DOI 10.1007/s11427 020 1920 5
   Zhang N, 2018, DRUG DELIV, V25, P1182, DOI 10.1080/10717544.2018.1472677
   Zhang WJ, 2022, J CONTROL RELEASE, V345, P851, DOI 10.1016/j.jconrel.2022.04.001
   Zhong YM, 2022, CYTOKINE, V152, DOI 10.1016/j.cyto.2022.155835
NR 57
TC 4
Z9 4
U1 4
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL 30
PY 2024
VL 136
AR 112324
DI 10.1016/j.intimp.2024.112324
EA MAY 2024
PG 14
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA UP6C9
UT WOS:001249291600006
PM 38820967
DA 2025 08 17
ER

PT J
AU Jeong, JH
   Moon, SJ
   Jhun, JY
   Yang, EJ
   Cho, ML
   Min, JK
AF Jeong, Jeong Hee
   Moon, Su Jin
   Jhun, Joo Yeon
   Yang, Eun Ji
   Cho, Mi La
   Min, Jun Ki
TI Eupatilin Exerts Antinociceptive and Chondroprotective Properties in a
   Rat Model of Osteoarthritis by Downregulating Oxidative Damage and
   Catabolic Activity in Chondrocytes
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF KAPPA B; GENE EXPRESSION;
   ARTICULAR CARTILAGE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PAIN;
   DEGRADATION; ASSOCIATION; INHIBITION
AB Increases in oxidative stress are thought to be associated with the development of osteoarthritis (OA). Eupatilin, one of the major compounds present in artemisia species, was shown to have both anti oxidative and anti inflammatory properties. Here, we investigated the in vivo effects of eupatilin on pain severity and cartilage degradation in an experimental rat model of OA, along with the mechanisms of action underlying these effects. Experimental OA was induced via an intra articular injection of monosodium iodoacetate (MIA), with oral administration of eupatilin initiated on the day of MIA injection. Pain was assessed by measuring the paw withdrawal latency and threshold. Cartilage destruction was analyzed macroscopically and histomorphologically. The effects of eupatilin on mRNA expression were investigated in interleukin 1 beta (IL 1 beta) stimulated human OA chondrocytes. Eupatilin treatment exhibited clear antinociceptive effects, along with an attenuation of cartilage degradation in OA rats. Additionally, the number of osteoclasts present in the subchondral bone region was significantly decreased following eupatilin treatment. Eupatilin reduced the expression of interleukin 1 beta (IL 1 beta), interleukin 6 (IL 6), nitrotyrosine and inducible nitric oxide synthase (iNOS) in cartilage. mRNA levels of matrix metalloproteinase 3 (MMP 3), MMP13, and a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) were reduced in IL 1 beta stimulated human OA chondrocytes, while tissue inhibitor of metalloproteinases 1 (TIMP 1) was induced. Phosphorylated protein levels of the c jun N terminal kinase (JNK) was reduced by eupatilin. Taken together, these results suggest that eupatilin suppresses oxidative damage and reciprocally enhances extracellular matrix production in articular chondrocytes, making eupatilin a promising therapeutic option for the treatment of OA.
C1 [Jeong, Jeong Hee; Jhun, Joo Yeon; Yang, Eun Ji; Cho, Mi La] Catholic Univ Korea, Rheumatism Res Ctr, Catholic Res Inst Med Sci, Seoul, South Korea.
   [Moon, Su Jin; Min, Jun Ki] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Min, JK (通讯作者)，Catholic Univ Korea, Rheumatism Res Ctr, Catholic Res Inst Med Sci, Seoul, South Korea.
EM min6403@catholic.ac.kr
FU National Research Foundation (NRF)   Korean government (MEST)
   [2012M3A9C6049783]
FX This research was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation (NRF) funded by the Korean
   government (MEST) (No. 2012M3A9C6049783).
CR Abramson SB, 2006, NAT CLIN PRACT RHEUM, V2, P304, DOI 10.1038/ncprheum0193
   Abramson SB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2655
   Ahn BO, 2001, INT J COLORECTAL DIS, V16, P174, DOI 10.1007/s003840000282
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   BLANCO FJ, 1995, AM J PATHOL, V146, P75
   BULSTRA SK, 1989, CLIN ORTHOP RELAT R, P294
   Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200
   Chang MC, 2005, OSTEOARTHR CARTILAGE, V13, P1004, DOI 10.1016/j.joca.2005.06.011
   Cheong JH, 2011, J GASTRIC CANCER, V11, P16, DOI 10.5230/jgc.2011.11.1.16
   Choi EJ, 2008, PHARM RES, V25, P1355, DOI 10.1007/s11095 008 9531 5
   Cifuentes DJ, 2010, OSTEOARTHR CARTILAGE, V18, P1088, DOI 10.1016/j.joca.2010.04.004
   Davies CM, 2008, OSTEOARTHR CARTILAGE, V16, P624, DOI 10.1016/j.joca.2007.09.012
   Del Carlo M, 2003, ARTHRITIS RHEUM US, V48, P3419, DOI 10.1002/art.11338
   Felson DT, 2001, ANN INTERN MED, V134, P541, DOI 10.7326/0003 4819 134 7 200104030 00007
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Hahm KB, 1998, PANCREAS, V17, P153, DOI 10.1097/00006676 199808000 00007
   Henrotin Y, 2005, OSTEOARTHR CARTILAGE, V13, P643, DOI 10.1016/j.joca.2005.04.002
   Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563
   Hill CL, 2001, J RHEUMATOL, V28, P1330
   Jeon JI, 2015, SCAND J IMMUNOL, V81, P166, DOI 10.1111/sji.12263
   Ji HY, 2010, MOLECULES, V15, P6466, DOI 10.3390/molecules15096466
   Jiang LP, 2013, J ORTHOP RES, V31, P364, DOI 10.1002/jor.22250
   Alcaraz MJ, 2010, BIOCHEM PHARMACOL, V80, P13, DOI 10.1016/j.bcp.2010.02.017
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kobayashi K, 2003, J VET MED SCI, V65, P1195, DOI 10.1292/jvms.65.1195
   Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212
   Lanas A, 2006, ANN MED, V38, P415, DOI 10.1080/07853890600925843
   Lim JC, 2012, KOREAN J PHYSIOL PHA, V16, P313, DOI 10.4196/kjpp.2012.16.5.313
   Lubberts E, 2000, ARTHRITIS RHEUM US, V43, P1300, DOI 10.1002/1529 0131(200006)43:6<1300::AID ANR12>3.0.CO;2 D
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529 0131(200004)43:4<801::AID ANR10>3.0.CO;2 4
   Pelletier JP, 1999, J RHEUMATOL, V26, P2002
   Ruiz Romero C, 2009, MOL CELL PROTEOMICS, V8, P172, DOI 10.1074/mcp.M800292 MCP200
   Sahebjam S, 2007, ARTHRITIS RHEUM, V56, P905, DOI 10.1002/art.22427
   Scott JL, 2010, ANN RHEUM DIS, V69, P1502, DOI 10.1136/ard.2009.119966
   Shakibaei M, 2005, ANN ANAT, V187, P487, DOI 10.1016/j.aanat.2005.06.007
   Tiku ML, 2000, J BIOL CHEM, V275, P20069, DOI 10.1074/jbc.M907604199
   Tsutsumi R, 2008, RHEUMATOL INT, V28, P727, DOI 10.1007/s00296 007 0511 6
   Wluka A, 2004, ANN RHEUM DIS, V63, P264, DOI 10.1136/ard/2003.007666
   Wolfe F, 2000, ARTHRITIS RHEUM US, V43, P378, DOI 10.1002/1529 0131(200002)43:2<378::AID ANR18>3.0.CO;2 2
   Wu GJ, 2007, J CELL BIOCHEM, V101, P1520, DOI 10.1002/jcb.21268
NR 45
TC 53
Z9 61
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 17
PY 2015
VL 10
IS 6
AR e0130882
DI 10.1371/journal.pone.0130882
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CK9NS
UT WOS:000356567400163
PM 26083352
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Sampalis, JS
   Brownell, LA
AF Sampalis, John S.
   Brownell, Lidia Alfaro
TI A randomized, double blind, placebo and active comparator controlled
   pilot study of UP446, a novel dual pathway inhibitor anti inflammatory
   agent of botanical origin
SO NUTRITION JOURNAL
LA English
DT Article
DE NSAIDs; Anti inflammatory; COX 2; LOX; UP446
ID C REACTIVE PROTEIN; FUNCTIONAL STATUS; LEUKOTRIENE B 4; OSTEOARTHRITIS
AB Background: Current use of prescribed or over the counter non steroidal anti inflammatory drugs (NSAIDs) for pain and osteoarthritis (OA) have untoward gastrointestinal and cardiovascular related side effects, as a result the need for a safe and effective alternative has become unequivocally crucial.
   Method: A randomized, double blind, placebo and active controlled pilot study of a novel dual pathway, COX1/2 and LOX, inhibitor anti inflammatory agent of botanical origin, UP446 was conducted. Sixty subjects (age 40 75) with symptomatic OA of the hip or knee were assigned to 4 treatment groups (n = 15); Group A0 (Placebo, CMC capsule), Group A1 (UP446 250 mg/day), Group A2 (UP446 500 mg/day) and Group A3 (Celecoxib, 200 mg/day). MOS SF 36 and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) data were collected at baseline and after 30, 60 and 90 days of treatment as a measure of efficacy. Erythrocyte sedimentation rate, C reactive protein, plasma thrombin time (PTT), fructosamine, Hematology, clinical chemistry and fecal occult blood were monitored for safety.
   Results: Statistically significant decrease in WOMAC pain score were observed for Group A1 at day 90, Group A2 at 30 and 90 days and Group A3 at 60 and 90 days. Statistically significant decrease in WOMAC stiffness score were observed for Group A1 and Group A2 at 30, 60 and 90 days; but not for Group A0 and Group A3. The mean change in WOMAC functional impairment scores were statistically significant for Group A1 and Group A2 respectively at 30 days (p = 0.006 and p = 0.006), at 60 days (p = 0.016 and p = 0.002) and at 90 days (p = 0.018 and p = 0.002), these changes were not significant for Group A0 and Group A3. Based on MOS  SF 36 questionnaires, statistically significant improvements in physical function, endurance and mental health scores were observed for all active treatment groups compared to placebo. No significant changes suggestive of toxicity in routine hematologies, serum chemistries, liver enzymes or PTT were noted in any of the treatment groups.
   Conclusion: Based on current findings UP446 is safe and efficacious alternative to established anti inflammatory medications for alleviating OA symptoms as measured by the WOMAC Index.
C1 [Brownell, Lidia Alfaro] Unigen Inc, Lacey, WA 98516 USA.
   [Sampalis, John S.] JSS Med Res Inc, Montreal, PQ, Canada.
   [Sampalis, John S.] Surg & Epidemiol McGill Univ, Montreal, PQ, Canada.
   [Sampalis, John S.] Univ Montreal, Montreal, PQ, Canada.
C3 Universite de Montreal
RP Brownell, LA (通讯作者)，Unigen Inc, 2260 Willamette Dr NE, Lacey, WA 98516 USA.
EM lbrownell@unigen.net
CR Angst F, 2001, ANN RHEUM DIS, V60, P834
   [Anonymous], 2002, JIACM
   Bertolini A, 2001, PHARMACOL RES, V44, P437, DOI 10.1006/phrs.2001.0872
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003 4819 133 8 200010170 00016
   FELSON DT, 1993, RHEUM DIS CLIN N AM, V19, P607
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   He W, 2002, J RHEUMATOL, V29, P546
   LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140 6736(91)90744 A
   Lau DCW, 2005, AM J PHYSIOL HEART C, V288, pH2031, DOI 10.1152/ajpheart.01058.2004
   Nakajima T, 2001, PLANTA MED, V67, P132, DOI 10.1055/s 2001 11532
   Ong CKS, 2007, CLIN MED RES, V5, P17, DOI 10.3121/cmr.2007.698
   Paredes Y, 2002, ARTHRITIS RHEUM, V46, P1804, DOI 10.1002/art.10357
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   RAINSFORD KD, 1993, AGENTS ACTIONS, V39, pC24, DOI 10.1007/BF01972709
   Rainsford KD, 1996, J PHARM PHARMACOL, V48, P46, DOI 10.1111/j.2042 7158.1996.tb05875.x
   Rockey DC, 2005, GASTROENTEROL CLIN N, V34, P699, DOI 10.1016/j.gtc.2005.08.010
   Terwee CB, 2006, J CLIN EPIDEMIOL, V59, P724, DOI 10.1016/j.jclinepi.2005.11.019
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969 2126(99)80023 9
   Van Loom IM, 1997, ALTERN MED REV, V2, P472
   Zhang YQ, 2002, AM J EPIDEMIOL, V156, P1021, DOI 10.1093/aje/kwf141
   Zhao SZ, 1999, PHARMACOTHERAPY, V19, P1269, DOI 10.1592/phco.19.16.1269.30879
NR 22
TC 15
Z9 15
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475 2891
J9 NUTR J
JI Nutr. J.
PD APR 5
PY 2012
VL 11
AR 21
DI 10.1186/1475 2891 11 21
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 942NO
UT WOS:000304051600001
PM 22480204
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Saito Yabe, M
   Kasuya, Y
   Yoshigae, Y
   Yamamura, N
   Suzuki, Y
   Fukuda, N
   Honma, M
   Yano, K
   Mochizuki, S
   Okada, F
   Okada, A
   Nagayama, Y
   Tsuda, E
   Fischer, T
   Höpner, U
   Zaja, S
   Mueller, J
   Okada, J
   Kurihara, A
   Ikeda, T
   Okazaki, O
AF Saito Yabe, Motoko
   Kasuya, Yuji
   Yoshigae, Yasushi
   Yamamura, Naotoshi
   Suzuki, Yukie
   Fukuda, Nao
   Honma, Masashi
   Yano, Kazuki
   Mochizuki, Shin ichi
   Okada, Fumihiko
   Okada, Akiko
   Nagayama, Yuki
   Tsuda, Eisuke
   Fischer, Thomas
   Hoepner, Ursula
   Zaja, Silvia
   Mueller, Juergen
   Okada, Junichi
   Kurihara, Atsushi
   Ikeda, Toshihiko
   Okazaki, Osamu
TI PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor
   (OPG/OCIF) results in decreased uptake into rats and human liver
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE osteoclastogenesis inhibitory factor; osteoprotegerin; PEGylation;
   pharmacokinetics; tissue distribution
ID HEPATOCYTE GROWTH FACTOR; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN;
   MUTAGENESIS; CLEARANCE; MECHANISM; DENSITY
AB Objectives
   Our aim was to investigate the effect of PEGylation on the uptake of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) into rat liver, kidney and spleen, and human liver.
   Methods
   Copolymer of polyethyleneglycol allylmethylether and maleamic acid sodium salt with OCIF (poly(PEG) OCIF) (0.5 mg/kg) was administered to rats and the concentrations of poly(PEG) OCIF in the liver, kidney and spleen at 15 min after administration were measured by ELISA. For human liver uptake, the liver perfusion of OCIF and 3H labelled poly(PEG) OCIF was conducted using fresh human liver block.
   Key findings
   The tissue uptake of poly(PEG) OCIF in rats was significantly lower compared with that of OCIF. In fresh human liver perfusion, 3H poly(PEG) OCIF was rarely taken up into the liver. On the other hand, more than 50% of the perfused OCIF was taken up.
   Conclusions
   PEGylation of OCIF using poly(PEG) dramatically suppressed the uptake of OCIF into human liver as well as into rat liver and could be a promising approach for improving the pharmacokinetic and pharmacological effects of OCIF in the clinical setting.
C1 [Saito Yabe, Motoko] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan.
   [Kasuya, Yuji; Suzuki, Yukie; Fukuda, Nao; Honma, Masashi] Daiichi Sankyo Co Ltd, Formulat Technol Res Labs, Tokyo 1408710, Japan.
   [Yano, Kazuki; Okada, Fumihiko; Okada, Akiko; Nagayama, Yuki; Tsuda, Eisuke] Daiichi Sankyo Co Ltd, Biol Res Labs 3, Tokyo 1408710, Japan.
   [Mochizuki, Shin ichi] Daiichi Sankyo Co Ltd, Clin Dev Dept 2, Tokyo 1408710, Japan.
   [Fischer, Thomas; Hoepner, Ursula; Zaja, Silvia; Mueller, Juergen] Daiichi Sankyo Europe GmbH, Dept Drug Metab, Martinsried, Germany.
   [Okada, Junichi] Daiichi Sankyo Pharma Dev Inc, Edison, NJ USA.
C3 Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi
   Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo
   Company Limited; Daiichi Sankyo Company Limited
RP Saito Yabe, M (通讯作者)，Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, 1 2 58 Hiromachi, Tokyo 1408710, Japan.
EM saito.motoko.zf@daiichisankyo.co.jp
CR BARTON DHR, 1982, TETRAHEDRON LETT, V23, P651, DOI 10.1016/S0040 4039(00)86913 0
   Bell SJ, 2008, BIOCONJUGATE CHEM, V19, P299, DOI 10.1021/bc070131q
   Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717
   CZUPRYN MJ, 1995, J BIOL CHEM, V270, P978, DOI 10.1074/jbc.270.2.978
   Dhalluin C, 2005, BIOCONJUGATE CHEM, V16, P504, DOI 10.1021/bc049781+
   Ichinose Y, 2004, CALCIFIED TISSUE INT, V75, P338, DOI 10.1007/s00223 004 0028 x
   KATO Y, 1994, HEPATOLOGY, V20, P417
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   LIU KX, 1993, HEPATOLOGY, V17, P651, DOI 10.1002/hep.1840170420
   LIU KX, 1998, AM J PHYSIOL GASTR L, V274, P21
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mochizuki S, 2002, J BONE MINER METAB, V20, P14, DOI 10.1007/s774 002 8441 x
   Pettit DK, 1997, J BIOL CHEM, V272, P2312
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith BB, 2003, INT J TOXICOL, V22, P403, DOI 10.1080/713936670
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Thasler Wolfgang E., 2003, Cell and Tissue Banking, V4, P49, DOI 10.1023/A:1026392429112
   Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Tsunoda S, 2001, BRIT J HAEMATOL, V112, P181, DOI 10.1046/j.1365 2141.2001.02508.x
   Wang YS, 2002, ADV DRUG DELIVER REV, V54, P547, DOI 10.1016/S0169 409X(02)00027 3
   Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 25
TC 6
Z9 7
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD AUG
PY 2010
VL 62
IS 8
BP 985
EP 994
DI 10.1111/j.2042 7158.2010.01120.x
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 629ME
UT WOS:000280202300004
PM 20663032
OA Bronze
DA 2025 08 17
ER

PT J
AU Suda, M
   Suyama, Y
   Ohde, S
   Tsuda, T
   Sawada, H
   Kishimoto, M
   Okada, M
AF Suda, Masei
   Suyama, Yasuhiro
   Ohde, Sachiko
   Tsuda, Tokutaro
   Sawada, Haruki
   Kishimoto, Mitsumasa
   Okada, Masato
TI Effects of quality indicator monitoring for glucocorticoid induced
   osteoporosis and trends of drug treatment in a Japanese hospital
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE bisphosphonates; clinical practice guidelines; glucocorticoid;
   osteoporosis; quality indicators
ID DOUBLE BLIND; PREVENTION; FRACTURES; RISK; CARE; RISEDRONATE;
   ALENDRONATE; MANAGEMENT; ADHERENCE; PATTERNS
AB AimsGlobally, the appropriate prescription rate for glucocorticoid induced osteoporosis (GIOP) is low. Thus, we aimed to examine the improvement in real world GIOP care using a hospital wide systematic approach with quality indicator (QI) monitoring.
   MethodsWe defined a novel QI for GIOP care for the prescription rate of anti osteoporotic drugs according to 2010 American College of Rheumatology GIOP management recommendations, with the target being patients prescribed 7.5mg prednisolone daily or its equivalent for 3months. We monitored the glucocorticoid and osteoporotic medication dose for all patients who visited our hospital. From May 2011, we began interventions to improve QI: monthly QI monitoring providing QI trend feedback to each department in a hospital wide QI meeting every 3months and organizing lectures on GIOP. We retrospectively analyzed QI trends from 2010 to 2013. We categorized groups by sex and age for subanalyses: group A, men; group B, women, aged <50years; group C, women, aged 50years.
   ResultsThe numbers of participants were 401, 420, 520 and 513 in 2010, 2011, 2012 and 2013, respectively, with pooled QI rates of 45.8%, 51.3%, 55.0% and 54.8%, respectively. Changes in QI between each consecutive 2years were statistically significant. Subanalyses showed statistically significant QI improvements in groups A and C. We observed a decreasing trend of daily bisphosphonate use throughout the study period, especially at the Immuno Rheumatology Center.
   ConclusionsQuality indicator monitoring for GIOP significantly improved appropriate anti osteoporotic drug prescriptions, especially in men and postmenopausal women.
C1 [Suda, Masei; Suyama, Yasuhiro; Tsuda, Tokutaro; Sawada, Haruki; Kishimoto, Mitsumasa; Okada, Masato] St Lukes Int Univ, St Lukes Int Hosp, Immunorheumatol Ctr, Tokyo, Japan.
   [Ohde, Sachiko] St Lukes Int Univ, Grad Sch Publ Hlth, OMURA Susumu & Mieko Mem St Lukes Ctr Clin Acad, Tokyo, Japan.
C3 St. Luke's International Hospital; St. Luke's International Hospital
RP Suda, M (通讯作者)，St Lukes Int Univ, St Lukes Int Hosp, Immunorheumatol Ctr, Chuo Ku, 9 1 Akashi Cho, Tokyo 1048560, Japan.
EM msuda@luke.ac.jp
RI Sawada, Haruki/MVY 3685 2025; Ohde, Sachiko/AAC 6496 2019; Suyama,
   Yasuhiro/J 8298 2019
OI Ohde, Sachiko/0000 0001 9137 0047; Sawada, Haruki/0000 0002 2458 5918
CR Adler RA, 2011, J ENDOCRINOL INVEST, V34, P481, DOI [10.1007/BF03346716, 10.3275/7753]
   Campbell SM, 2002, QUAL SAF HEALTH CARE, V11, P358, DOI 10.1136/qhc.11.4.358
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Confavreux CB, 2012, EUR J ENDOCRINOL, V166, P735, DOI 10.1530/EJE 11 0959
   Curtis JR, 2005, ARTHRITIS RHEUM US, V52, P2485, DOI 10.1002/art.21194
   Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920
   Feldstein AC, 2005, OSTEOPOROSIS INT, V16, P2168, DOI 10.1007/s00198 005 2016 z
   Glasziou Paul, 2005, Evid Based Nurs, V8, P36, DOI 10.1136/ebn.8.2.36
   Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
   Homik J., 2000, COCHRANE DB SYST REV, V2000
   Ivers N, 2012, COCHRANE DB SYST REV, V2003
   JCAHO, 1998, QRB QUAL REV B, V15, P330
   Kanis JA, 2011, OSTEOPOROSIS INT, V22, P809, DOI 10.1007/s00198 010 1524 7
   King AB, 2005, OSTEOPOROSIS INT, V16, P1545, DOI 10.1007/s00198 005 1869 5
   Kirigaya D, 2011, INTERNAL MED, V50, P2793, DOI 10.2169/internalmedicine.50.5266
   Kohler MJ, 2013, J GEN INTERN MED, V28, P825, DOI 10.1007/s11606 013 2360 1
   Majumdar SR, 2012, J CLIN ENDOCR METAB, V97, P1236, DOI 10.1210/jc.2011 2645
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Reid DM, 2000, J BONE MINER RES, V15, P1006, DOI 10.1359/jbmr.2000.15.6.1006
   Saag KG, 2013, J RHEUMATOL, V40, P1640, DOI 10.3899/jrheum.130980
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Teng Gim Gee, 2008, Curr Rheumatol Rep, V10, P123, DOI 10.1007/s11926 008 0022 9
   Tory HO, 2015, SEMIN ARTHRITIS RHEU, V44, P483, DOI 10.1016/j.semarthrit.2014.09.011
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Van Staa TP, 2005, J BONE MINER RES, V20, P1486, DOI 10.1359/jbmr.2005.20.8.1486
   Yood RA, 2001, ARCH INTERN MED, V161, P1322, DOI 10.1001/archinte.161.10.1322
NR 28
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1756 1841
EI 1756 185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD MAY
PY 2018
VL 21
IS 5
BP 975
EP 981
DI 10.1111/1756 185X.13310
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA GI1GK
UT WOS:000434118500009
PM 29878618
DA 2025 08 17
ER

PT J
AU Lin, YH
   Tang, HJ
   Teng, HC
   Feng, WY
   Li, FC
   Liu, SY
   Liu, Y
   Wei, QJ
AF Lin, Yunhua
   Tang, Haijun
   Teng, Hongcai
   Feng, Wenyu
   Li, Feicui
   Liu, Shangyu
   Liu, Yun
   Wei, Qingjun
TI Development and validation of neutrophil extracellular traps derived
   signature to predict the prognosis for osteosarcoma patients
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteosarcoma; Neutrophil extracellular traps; Prognosis; Therapeutic
   response; Tumor immune microenvironment
ID CANCER; PROMOTE; CELLS
AB Neutrophil extracellular traps (NETs) have been reported to be crucial in tumorigenesis and malignant progression. However, their prognostic significance, association with tumor immune microenvironment (TIME), and therapeutic response in osteosarcoma (OS) stills remain unclear. Hence, TARGET and GSE21257 cohorts were included for analysis. Single sample gene set enrichment analysis (ssGSEA) and weighted gene co expression network analysis (WGCNA) were conducted to extract NETs derived genes. Subsequently, the NETs score (NETScore) model, consisting of 4 signature genes, was established and validated with the least absolute shrinkage and selection operator (LASSO) and Cox regression analysis. Our results indicated that NETScore has satisfactory predictability of the patient's overall survival, with AUC values at 1 , 3  and 5 year in the training cohort of 0.798, 0.792 and 0.804, respectively; similar prominent prediction performance was obtained in three validation cohorts. Further, real time quantitative PCR (RT qPCR) assay was conducted to determine the expression of signature genes in human osteoblasts and OS cells. Besides, NETScore and clinical factors (age, gender, metastatic status) were integrated to construct a nomogram. C index and AUC values at 1 , 3 , and 5 year were above 0.800, displaying robust predictive performance. Patients with high and low NETScore had different immune statuses and drug sensitivity. Meanwhile, several positive regulatory immune function pathways, including T cell proliferation, activation and migration, were significantly suppressed among patients with high NETScore. Summarily, we established a novel NETScore that can accurately predict OS patients' prognosis, which correlated closely with the immune landscape and therapeutic response and might help to guide clinical decision making.
C1 [Lin, Yunhua; Wei, Qingjun] Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Nanning, Guangxi, Peoples R China.
   [Tang, Haijun; Li, Feicui; Liu, Shangyu; Liu, Yun] Guangxi Med Univ, Affiliated Hosp 1, Dept Spine & Osteopath Surg, Nanning, Guangxi, Peoples R China.
   [Feng, Wenyu] Guangxi Med Univ, Affiliated Hosp 2, Dept Orthoped, Nanning, Guangxi, Peoples R China.
   [Liu, Yun] Guangxi Med Univ, Affiliated Hosp 1, Dept Spine & Osteopath Surg, Nanning 530021, Guangxi, Peoples R China.
   [Wei, Qingjun] Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Nanning 5300021, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; Guangxi Medical University
RP Liu, Y (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Spine & Osteopath Surg, Nanning 530021, Guangxi, Peoples R China.; Wei, QJ (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Trauma Orthoped & Hand Surg, Nanning 5300021, Guangxi, Peoples R China.
EM liuyun200450250@sina.com; weiqingjungxnn@163.com
RI Lin, Yunhua/IZQ 4037 2023; Teng, Hongcai/KIH 6989 2024
OI , Yun Hua Lin/0000 0003 3216 3456
FU Natural Science Foundation of Guangxi Province [2020GXNSFAA259088];
   National Natural Science Foundation of China [81960768, 82260814,
   82360822]; First Affiliated Hospital of Guangxi Medical University;
   Youth Science and Technology Project of the First Affiliated Hospital of
   Guangxi Medical University [201903038]
FX This study was supported by the Natural Science Foundation of Guangxi
   Province (2020GXNSFAA259088) , the National Natural Science Foundation
   of China (81960768, 82260814, 82360822) , "Medical Excellence Award"
   Funded by the Creative Research Development Grant from the First
   Affiliated Hospital of Guangxi Medical University, and Youth Science and
   Technology Project of the First Affiliated Hospital of Guangxi Medical
   University (201903038) .
CR Chen NF, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.833771
   Chen Q, 2021, CANCERS, V13, DOI 10.3390/cancers13112832
   Davis LE, 2019, J CLIN ONCOL, V37, P1424, DOI 10.1200/JCO.18.02374
   Demkow U, 2021, CANCERS, V13, DOI 10.3390/cancers13174495
   Deng JY, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146133
   Du XT, 2022, J CLIN LAB ANAL, V36, DOI 10.1002/jcla.24214
   Evangelista EA, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00828
   Fang C, 2021, AGING US, V13, P17864, DOI 10.18632/aging.203289
   Hayashi S, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864 018 5169 9
   He M, 2017, INT J ONCOL, V50, P1590, DOI 10.3892/ijo.2017.3928
   Huang LH, 2022, BOSNIAN J BASIC MED, V22, P992, DOI 10.17305/bjbms.2022.7416
   Inoue M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07550 x
   Ireland AS, 2020, IMMUNITY, V52, P729, DOI 10.1016/j.immuni.2020.04.009
   Johnson AM, 2020, J IMMUNOL, V204, P2295, DOI 10.4049/jimmunol.1900778
   Kaltenmeier CT, 2021, HPB, V23, P309, DOI 10.1016/j.hpb.2020.06.012
   Lei T, 2021, CANCER SCI, V112, P4785, DOI 10.1111/cas.15131
   Li QL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1019967
   Lin AF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00964
   Liu BF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.944158
   Liu MF, 2022, CANCERS, V14, DOI 10.3390/cancers14122896
   Ma K, 2020, CELL CYCLE, V19, P2327, DOI 10.1080/15384101.2020.1805552
   Mao XY, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1202725
   Morrow JJ, 2018, NAT MED, V24, P176, DOI 10.1038/nm.4475
   Nelson A, 2021, CANCERS, V13, DOI 10.3390/cancers13205174
   Sun SJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.743724
   Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001
   Tohme S, 2016, CANCER RES, V76, P1367, DOI 10.1158/0008 5472.CAN 15 1591
   Tripathi SC, 2017, CANCER RES, V77, P4414, DOI 10.1158/0008 5472.CAN 16 2874
   Wang GY, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.954840
   Wang ZN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01114
   Xiao YS, 2021, CANCER CELL, V39, P423, DOI 10.1016/j.ccell.2020.12.012
   Yuan QH, 2021, BIOENGINEERED, V12, P2432, DOI 10.1080/21655979.2021.1933868
   Zeng WC, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/2698869
   Zhang FX, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.836892
   Zhang SJ, 2018, UROL ONCOL SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.01.013
   Zhang Y, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc 2021 004210
   Zhao ZP, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.755511
   Zhou FG, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1015283
   Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20059 6
   Zhou ZH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12346
   Zhu KP, 2017, INT J BIOL SCI, V13, P1180, DOI 10.7150/ijbs.21722
   Zhu TY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.907550
NR 42
TC 6
Z9 6
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JAN 25
PY 2024
VL 127
AR 111364
DI 10.1016/j.intimp.2023.111364
EA DEC 2023
PG 13
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA EG3X7
UT WOS:001137741100001
PM 38101221
DA 2025 08 17
ER

PT J
AU Hill, GE
   Fenwick, S
   Matthews, BJ
   Chivers, RA
   Southgate, J
AF Hill, GE
   Fenwick, S
   Matthews, BJ
   Chivers, RA
   Southgate, J
TI The effect of low intensity pulsed ultrasound on repair of epithelial
   cell monolayers in vitro
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE wound healing; ultrasound; migration; proliferation; in vitro;
   re epithelialization; epithelium; urothelium
ID THERAPEUTIC ULTRASOUND; PROLIFERATION; MICROENVIRONMENT; ACCELERATION;
   OSTEOBLASTS; UROTHELIUM; FRACTURES; RATS
AB Low intensity pulsed ultrasound (LIPUS) is widely used to accelerate tissue regeneration following injury, but the biological mechanisms of this effect are poorly understood. An in vitro model of epithelial wound healing was used to investigate the effect of LIPUS on the reepithelialization of scrape wounds in normal human urothelial (NHU) cell monolayers. The effects of clinical doses of ultrasound treatment on NHU cell growth and migration were investigated in cells grown under optimal conditions, without growth supplements and in media containing low vs. physiological calcium concentrations. No differences in cell growth or migration were observed. We conclude that there is no direct effect upon uro epithelial regeneration by therapeutic ultrasound in vitro and suggest that any stimulation of epithelial wound repair in vivo may occur indirectly, for example by modulating the extracellular matrix composition and/or production of paracrine factors by the stroma. (c) 2005 World Federation for Ultrasound in Medicine & Biology.
C1 Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5YW, N Yorkshire, England.
   Smith & Nephew Res Ctr, York, N Yorkshire, England.
   Biomat & Tissue Engn Ctr Ind Collaborat, Leeds, W Yorkshire, England.
C3 University of York   UK; Smith & Nephew
RP Southgate, J (通讯作者)，Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5YW, N Yorkshire, England.
EM js35@york.ac.uk
RI Southgate, Jennifer/AAJ 9089 2021
OI Southgate, Jennifer/0000 0002 0135 480X
CR BYL NN, 1993, J ORTHOP SPORT PHYS, V18, P619, DOI 10.2519/jospt.1993.18.5.619
   Cook SD, 2001, CLIN ORTHOP RELAT R, pS231
   Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335
   Doan N, 1999, J ORAL MAXIL SURG, V57, P409, DOI 10.1016/S0278 2391(99)90281 1
   ENWEMEKA CS, 1990, ULTRASOUND MED BIOL, V16, P801, DOI 10.1016/0301 5629(90)90044 D
   Gan BS, 1995, J HAND SURG BRIT EUR, V20B, P809, DOI 10.1016/S0266 7681(95)80054 9
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469 185X.1975.tb01057.x
   Ito M, 2000, ULTRASOUND MED BIOL, V26, P161, DOI 10.1016/S0301 5629(99)00110 6
   Kitchen SS., 1990, Physiotherapy, V76, P593
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Ramirez A, 1997, MED SCI SPORT EXER, V29, P326, DOI 10.1097/00005768 199703000 00007
   Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623 200102000 00015
   Scriven SD, 1997, J UROLOGY, V158, P1147, DOI 10.1016/S0022 5347(01)64407 0
   Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580
   Smith BA, 2001, CANCER RES, V61, P1678
   SOUTHGATE J, 1994, LAB INVEST, V71, P583
   Southgate J, 1999, ADV EXP MED BIOL, V462, P19
   Southgate J., 2002, Culture of epithelial cells, P381, DOI DOI 10.1002/0471221201.CH12
   STEWART FA, 1986, BRIT J CANCER, V53, P280
   Sun JS, 2001, J BIOMED MATER RES, V57, P449, DOI 10.1002/1097 4636(20011205)57:3<449::AID JBM1188>3.0.CO;2 0
   Takakura Y, 2002, J ULTRAS MED, V21, P283, DOI 10.7863/jum.2002.21.3.283
   Taskan I, 1997, PLAST RECONSTR SURG, V100, P966
   Varley C, 2005, EXP CELL RES, V306, P216, DOI 10.1016/j.yexcr.2005.02.004
   Vicenti EAM, 2003, VET OPHTHALMOL, V6, P255, DOI 10.1046/j.1463 5224.2003.00303.x
   Walker DC, 2004, BIOSYSTEMS, V76, P89, DOI 10.1016/j.biosystems.2004.05.025
   Warden SJ, 2003, SPORTS MED, V33, P95, DOI 10.2165/00007256 200333020 00002
   Warden SJ, 2000, CALCIFIED TISSUE INT, V66, P157, DOI 10.1007/s002230010031
   YOUNG SR, 1990, ULTRASOUND MED BIOL, V16, P809, DOI 10.1016/0301 5629(90)90045 E
   YOUNG SR, 1990, ULTRASONICS, V28, P175, DOI 10.1016/0041 624X(90)90082 Y
NR 30
TC 22
Z9 30
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD DEC
PY 2005
VL 31
IS 12
BP 1701
EP 1706
DI 10.1016/j.ultrasmedbio.2005.08.001
PG 6
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 993UX
UT WOS:000233981900014
PM 16344132
DA 2025 08 17
ER

PT J
AU Yue, OY
   Wang, XC
   Hou, MD
   Zheng, MH
   Hao, DY
   Bai, ZX
   Zou, XL
   Cui, BQ
   Liu, CL
   Liu, XH
AF Yue, Ouyang
   Wang, Xuechuan
   Hou, Mengdi
   Zheng, Manhui
   Hao, Dongyu
   Bai, Zhongxue
   Zou, Xiaoliang
   Cui, Boqiang
   Liu, Chunlin
   Liu, Xinhua
TI Smart nanoengineered electronic scaffolds based on triboelectric
   nanogenerators as tissue batteries for integrated cartilage therapy
SO NANO ENERGY
LA English
DT Article
DE Articular cartilage; Tissue battery; Triboelectric nanogenerator;
   Cartilage repair; In  situ black  box detection
ID OSTEOBLASTS PROLIFERATION; REPAIR
AB At present, cartilage defect therapy requires a long term repair period and does not permit real time detection of the cartilage repair state named "black box". Inspired by the electroactive nature of living organisms, next  generation tissue trauma therapy with integrated bioelectronics promises to achieve the desired therapeutic effects. Here, a tissue battery for integrated cartilage therapy was nanoengineered through the on demand integration of intelligent scaffolds with a porous three dimensional structure and multi convex triboelectric nanogenerator (TENG) based sensor. The proposed cartilage tissue battery is repair induced, self powered, highly sensitive, implantable, intelligently degradable, and anti interference. The sensor based on the contact separation TENG mechanism has a high sensitivity (52.5 V MPa 1) within the pressure range of joint movement (0 1.8 MPa), enabling the tissue battery to in situ detect the real time status of cartilage repair in the "black box". Additionally, in vitro and in vivo experiments demonstrated that the tissue battery converts mechanical energy into electricity to stimulate chondrocyte proliferation in the scaffold, thereby shortening the cartilage repair period. The proposed tissue battery for tissue repair under electrical stimulation is beneficial for reducing pain and treatment costs for patients with cartilage defects and is a promising strategy for bioelectronic implants.
C1 [Yue, Ouyang; Wang, Xuechuan; Zheng, Manhui; Bai, Zhongxue; Zou, Xiaoliang; Cui, Boqiang; Liu, Xinhua] Shaanxi Univ Sci & Technol, Coll Bioresources Chem & Mat Engn, Xian 710021, Shaanxi, Peoples R China.
   [Liu, Chunlin] Engn Tsinghua Univ, Sch Mat Sci, Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.
   [Wang, Xuechuan; Hao, Dongyu] Shaanxi Univ Sci & Technol, Coll Chem & Chem Engn, Xian 710021, Shaanxi, Peoples R China.
   [Yue, Ouyang; Zheng, Manhui; Hao, Dongyu; Bai, Zhongxue; Zou, Xiaoliang; Cui, Boqiang; Liu, Xinhua] Shaanxi Univ Sci &Technol, Natl Demonstrat Ctr Expt Light Chem Engn Educ, Xian 710021, Shaanxi, Peoples R China.
   [Hou, Mengdi] Shaanxi Univ Chinese Med, Grad Sch, Xianyang 712000, Peoples R China.
C3 Shaanxi University of Science & Technology; Shaanxi University of
   Science & Technology; Shaanxi University of Science & Technology;
   Shaanxi University of Chinese Medicine
RP Wang, XC; Liu, XH (通讯作者)，Shaanxi Univ Sci & Technol, Coll Bioresources Chem & Mat Engn, Xian 710021, Shaanxi, Peoples R China.; Liu, CL (通讯作者)，Engn Tsinghua Univ, Sch Mat Sci, Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.; Wang, XC (通讯作者)，Shaanxi Univ Sci & Technol, Coll Chem & Chem Engn, Xian 710021, Shaanxi, Peoples R China.; Liu, XH (通讯作者)，Shaanxi Univ Sci &Technol, Natl Demonstrat Ctr Expt Light Chem Engn Educ, Xian 710021, Shaanxi, Peoples R China.
EM wangxc@sust.edu.cn; liuchunlin@mail.tsinghua.edu.cn;
   liuxinhua@sust.edu.cn
RI Zou, Xiaoliang/HGB 0817 2022; Liu, Xinhua/D 3025 2016; Liu,
   Jian/I 5571 2014; Ouyang, Yue/GYA 3782 2022
FU National Natural Science Foundation of China [22278257, 22078183];
   Fellowship of China Postdoctoral Science Foundation [2021M692000]; Key
   R&D Program of Shaanxi Province [2022GY 272]; Shaanxi Provincial
   Education Department [22JY013]; Young Talent Support Program Project of
   Shaanxi University Science and Technology Association [20200424];
   Department of Education's Production Study Research Combined Innovation
   Funding "Blue Fire Plan (Huizhou)" of 2018 [CXZJHZ201801]
FX This work was financially supported by the National Natural Science
   Foundation of China (22278257 and 22078183), Fellowship of China
   Postdoctoral Science Foundation (2021M692000), Key R&D Program of
   Shaanxi Province (2022GY 272), Scientific Research Program Funded by
   Shaanxi Provincial Education Department (22JY013), Young Talent Support
   Program Project of Shaanxi University Science and Technology Association
   (20200424), and Department of Education's Production Study Research
   Combined Innovation Funding "Blue Fire Plan (Huizhou)" of 2018
   (CXZJHZ201801).
CR [Anonymous], 2020, P P 2020 C FAIRNESS
   BAKER B, 1974, ANN NY ACAD SCI, V238, P491, DOI 10.1111/j.1749 6632.1974.tb26815.x
   Baker MP, 2010, CURR DRUG SAF, V5, P308, DOI 10.2174/157488610792246000
   Brighton CT, 2008, J BONE JOINT SURG AM, V90A, P833, DOI 10.2106/JBJS.F.01437
   Cai L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27003 2
   Choi MC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070734
   Crowley SG, 2021, CARTILAGE, V13, p1801S, DOI 10.1177/19476035211025818
   Cui QH, 2019, NANO ENERGY, V66, DOI 10.1016/j.nanoen.2019.104120
   Damaraju SM, 2017, BIOMATERIALS, V149, P51, DOI 10.1016/j.biomaterials.2017.09.024
   Darvish DM, 2022, MATER TODAY BIO, V15, DOI 10.1016/j.mtbio.2022.100322
   Deng CJ, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201806068
   Feng HQ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701298
   Gosangi B, 2020, RADIOGRAPHICS, V40, P859, DOI 10.1148/rg.2020190173
   Guo T, 2018, BIOMATERIALS, V185, P219, DOI 10.1016/j.biomaterials.2018.09.022
   Hong H, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119679
   Hu LD, 2018, BIOMATERIALS, V163, P154, DOI 10.1016/j.biomaterials.2018.02.029
   Huang XY, 2018, SMALL, V14, DOI 10.1002/smll.201800994
   Jin F, 2021, ADV MATER, V33, DOI 10.1002/adma.202104175
   Joshi D, 2020, ARTIF INTELL REV, V53, P4475, DOI 10.1007/s10462 019 09799 0
   Karampinos DC, 2018, J MAGN RESON IMAGING, V47, P332, DOI 10.1002/jmri.25769
   Kogan JR, 2011, MED EDUC, V45, P1048, DOI 10.1111/j.1365 2923.2011.04025.x
   Kwon H, 2019, NAT REV RHEUMATOL, V15, P550, DOI 10.1038/s41584 019 0255 1
   Lai YH, 2021, NANO ENERGY, V90, DOI 10.1016/j.nanoen.2021.106545
   Lausch AJ, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804730
   Li HJ, 2018, RSC ADV, V8, P3736, DOI 10.1039/c7ra11593h
   Li SL, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01086 x
   Li Z, 2010, ADV MATER, V22, P2534, DOI 10.1002/adma.200904355
   Lin WF, 2021, ADV MATER, V33, DOI 10.1002/adma.202005513
   Liu WL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09464 8
   Liu YY, 2021, NANO ENERGY, V85, DOI 10.1016/j.nanoen.2021.105967
   Liu Z, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201808820
   Liu Z, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807560
   Lo KWH, 2014, TRENDS BIOTECHNOL, V32, P74, DOI 10.1016/j.tibtech.2013.12.002
   Mahapatra B, 2021, MATER TODAY PROC, V46, P5523, DOI 10.1016/j.matpr.2020.09.261
   Mainil Varlet P, 2003, J BONE JOINT SURG AM, V85A, P45, DOI 10.2106/00004623 200300002 00007
   Merkely G, 2021, CARTILAGE, V12, P155, DOI 10.1177/1947603519833136
   Murphy MP, 2020, NAT MED, V26, P1583, DOI 10.1038/s41591 020 1013 2
   Nie XL, 2020, BIOMATERIALS, V235, DOI 10.1016/j.biomaterials.2020.119821
   Niu XL, 2023, BIOACT MATER, V20, P574, DOI 10.1016/j.bioactmat.2022.06.011
   Oosterlaken BM, 2021, ADV MATER, V33, DOI 10.1002/adma.202004418
   Paatela T, 2020, J ORTHOP RES, V38, P555, DOI 10.1002/jor.24490
   Peng Z, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120555
   Qiu HJ, 2019, NANO ENERGY, V58, P536, DOI 10.1016/j.nanoen.2019.01.069
   Rathan S, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801501
   Sauvage F, 2020, NANO TODAY, V31, DOI 10.1016/j.nantod.2019.100837
   Shi BJ, 2019, ACS NANO, V13, P6017, DOI 10.1021/acsnano.9b02233
   Sorushanova A, 2019, ADV MATER, V31, DOI 10.1002/adma.201801651
   Tang W, 2015, ACS NANO, V9, P7867, DOI 10.1021/acsnano.5b03567
   Tian JJ, 2019, NANO ENERGY, V59, P705, DOI 10.1016/j.nanoen.2019.02.073
   Vaca González JJ, 2019, CARTILAGE, V10, P157, DOI 10.1177/1947603517730637
   Voinier D, 2020, ARTHRITIS RHEUMATOL, V72, P957, DOI 10.1002/art.41181
   Wang FX, 2020, ADV MATER INTERFACES, V7, DOI 10.1002/admi.202000536
   Wang L, 2022, BIOACT MATER, V9, P332, DOI 10.1016/j.bioactmat.2021.07.031
   Wang ZL, 2020, ADV ENERGY MATER, V10, DOI 10.1002/aenm.202000137
   Won SM, 2023, NAT BIOMED ENG, V7, P405, DOI 10.1038/s41551 021 00683 3
   Wu CS, 2019, ADV ENERGY MATER, V9, DOI 10.1002/aenm.201802906
   Yang FC, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202003451
   Yao G, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907312
   Ye TT, 2022, ADV MATER, V34, DOI 10.1002/adma.202105120
   Yu JB, 2020, NANO ENERGY, V69, DOI 10.1016/j.nanoen.2019.104437
   Yue OY, 2022, NANO ENERGY, V91, DOI 10.1016/j.nanoen.2021.106682
   Yue O, 2021, ADV SCI, V8, DOI 10.1002/advs.202004377
   Zhang H, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw0873
   Zhang JA, 2022, ADV MATER TECHNOL US, V7, DOI 10.1002/admt.202101086
   Zhang YB, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201903279
   Zheng MH, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121026
   Zhu MM, 2020, NANO ENERGY, V78, DOI 10.1016/j.nanoen.2020.105208
   Zhu PC, 2020, ADV ENERGY MATER, V10, DOI 10.1002/aenm.202001945
NR 68
TC 31
Z9 31
U1 15
U2 145
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2211 2855
EI 2211 3282
J9 NANO ENERGY
JI Nano Energy
PD MAR
PY 2023
VL 107
AR 108158
DI 10.1016/j.nanoen.2022.108158
EA JAN 2023
PG 14
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 8D5EI
UT WOS:000918315600001
DA 2025 08 17
ER

PT J
AU Tseng, KY
   Liu, KH
   Wu, HM
   Lin, SK
AF Tseng, Kuo Yun
   Liu, Ko Hung
   Wu, Hung Ming
   Lin, Shankung
TI The fatty acid synthase inhibitor C75 differentially affects the
   adipogenic differentiation of multipotent cells and preadipocytes
SO FEBS LETTERS
LA English
DT Article
DE adenosine receptor; adipogenesis; ageing; cAMP; GSK3 beta
ID OSTEOBLAST DIFFERENTIATION; ACTIVATION; ADENOSINE; OSTEOCLASTOGENESIS;
   RECEPTORS; THERAPY
AB Previously, we revealed the dual enhancing effect of netoglitazone, an agonist of the peroxisome proliferator activated receptor gamma, on adipogenesis and osteoblastogenesis, and reported that fatty acid synthase (FASN) knockdown selectively repressed its pro adipogenic effect. Here, we examined if a FASN inhibitor, C75, could selectively repress the pro adipogenic effect of netoglitazone. Surprisingly, C75 promoted the adipogenic differentiation of multipotent C3H10T1/2 cells but inhibited 3T3 L1 preadipocytes. By identifying glycogen synthase kinase 3 beta and intracellular cAMP levels as regulatory targets of C75, we ultimately found the differential expression of adenosine receptor 3 (AR3) and AR2a on these cells. Inhibition of AR3 on C3H10T1/2 and AR2a on 3T3 L1 inhibited the effects of C75 on the differentiation of these cells. Our findings imply that cell type specific AR expression might account for the differential adipogenic effects of C75.
C1 [Tseng, Kuo Yun] Natl Hlth Res Inst, Inst Infect Dis & Vaccinol, Zhunan, Taiwan.
   [Liu, Ko Hung; Wu, Hung Ming] Changhua Christian Hosp, Expt Anim Ctr, Changhua, Taiwan.
   [Wu, Hung Ming; Lin, Shankung] Changhua Christian Hosp, Inflammat Res & Drug Dev Ctr, 135 Nanxiao St, Changhua 500, Taiwan.
   [Wu, Hung Ming] Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan.
   [Wu, Hung Ming] China Med Univ, Grad Inst Acupuncture Sci, Taichung, Taiwan.
   [Lin, Shankung] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.
C3 National Health Research Institutes   Taiwan; Changhua Christian
   Hospital; Changhua Christian Hospital; Changhua Christian Hospital;
   China Medical University Taiwan; China Medical University Taiwan
RP Wu, HM (通讯作者)，Changhua Christian Hosp, Expt Anim Ctr, Changhua, Taiwan.; Lin, SK (通讯作者)，Changhua Christian Hosp, Inflammat Res & Drug Dev Ctr, 135 Nanxiao St, Changhua 500, Taiwan.
EM 18288@cch.org.tw; 181798@cch.org.tw
FU Ministry of Science and Technology [MOST 110 2314 B 371 002]; Changhua
   Christian Hospital, Taiwan, Republic of China [109 CCH IRP 084,
   109 CCH HCR 132]
FX We would like to thank Dr Shau Ku Huang for valuable advice in preparing
   this manuscript. This study was supported by the grants MOST
   110 2314 B 371 002 from the Ministry of Science and Technology, and
   109 CCH IRP 084 and 109 CCH HCR 132 from the Changhua Christian
   Hospital, Taiwan, Republic of China.
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Burnstock G, 2011, CURR TOP MED CHEM, V11, P973, DOI 10.2174/156802611795347627
   Chen CY, 2019, AGING US, V11, P2327, DOI 10.18632/aging.101916
   Chen JF, 2014, INT REV NEUROBIOL, V119, P257, DOI 10.1016/B978 0 12 801022 8.00012 X
   Cheng AYY, 2005, CAN MED ASSOC J, V172, P213, DOI 10.1503/cmaj.1031414
   Fredholm BB, 2014, J MOL MED, V92, P201, DOI 10.1007/s00109 013 1101 6
   Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285
   Glintborg D, 2008, J CLIN ENDOCR METAB, V93, P1696, DOI 10.1210/jc.2007 2249
   Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   LIANG CT, 1992, BONE, V13, P435, DOI 10.1016/8756 3282(92)90087 D
   Liu LH, 2004, ACTA PHARMACOL SIN, V25, P1052
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008 1020.2000
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Yki Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhou XM, 2013, AM J PHYSIOL RENAL, V304, pF908, DOI 10.1152/ajprenal.00591.2012
NR 22
TC 0
Z9 0
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0014 5793
EI 1873 3468
J9 FEBS LETT
JI FEBS Lett.
PD DEC
PY 2022
VL 596
IS 24
BP 3191
EP 3202
DI 10.1002/1873 3468.14424
EA JUN 2022
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 7I6KZ
UT WOS:000813946800001
PM 35689495
DA 2025 08 17
ER

PT J
AU Miladi, K
   Sfar, S
   Fessi, H
   Elaissari, A
AF Miladi, K.
   Sfar, S.
   Fessi, H.
   Elaissari, A.
TI Encapsulation of alendronate sodium by nanoprecipitation and double
   emulsion: From preparation to in vitro studies
SO INDUSTRIAL CROPS AND PRODUCTS
LA English
DT Article; Proceedings Paper
CT International Conference on Bio Based Materials and Composites (ICBMC
   14)
CY MAY 13 16, 2014
CL Montreal, CANADA
DE Alendronate sodium; Double emulsion evaporation; In vitro;
   Nanoparticles; Nanoprecipitation; Osteoporosis; Polycaprolactone
ID LOADED PLGA NANOPARTICLES; DELIVERY; FORMULATION; RELEASE; POLYMER;
   POLY(EPSILON CAPROLACTONE); BISPHOSPHONATES; NANOSUSPENSIONS;
   MICROSPHERES; CYTOTOXICITY
AB Alendronate sodium is an active molecule indicated as first line regimen for osteoporosis treatment. Use of this drug presents, however, some shortcomings such as low oral bioavailability and gastrointestinal mucosa irritation. Nanotechnology remains an attractive approach to overcome such limitations of conventional pharmaceutical forms. However, encapsulation of hydrophilic molecules like alendronate represents a real challenge. Preparation, characterization and drug release behavior of polycaprolactone based nanoparticles loaded with alendronate sodium were investigated in this work. Two strategies were used to prepare these nanocarriers: double emulsion evaporation and nanoprecipitation. Operating conditions were monitored to produce biocompatible nanopartides with good properties. Both techniques gave nanoparticles with mean diameter in the range of 200 450 nm. Encapsulation efficiency of selected formulae reached 34% for double emulsion and 18% for nanoprecipitation, respectively. Highest drug loading was 20.7% for double emulsion and 8.2% for nanoprecipitation, respectively. For both methods, an increase of polymer molecular weight and polymer amount led to an increase of particle size. For nanoprecipitation, oil to water phase exerted also a significant effect on particle size. The increase of stabilizer amount or the use of rotoevaporation rather than continuous stirring at ambient temperature decreased particles size. Prepared nanoparticles exhibited sustained release of alendronate. When the same polymer amount and molecular weight was used, drug release of the selected formulae was faster for nanoparticles formulated by the nanoprecipitation method. However, release profiles were similar for both techniques with a first rapid release phase followed by a more prolonged phase. Analysis of in vitro release data showed also that active release mechanism relied on a combination of drug diffusion and polymer relaxation phenomena. (C) 2015 Published by Elsevier B.V.
C1 [Miladi, K.; Fessi, H.; Elaissari, A.] Univ Lyon, F 69622 Lyon, France.
   [Miladi, K.; Fessi, H.; Elaissari, A.] Univ Lyon 1, F 69622 Villeurbanne, France.
   [Miladi, K.; Fessi, H.; Elaissari, A.] Univ Lyon 1, CNRS, UMR 5007, Lab Automat & Genie Proc,LAGEP CPE 308G, F 69622 Villeurbanne, France.
   [Miladi, K.; Sfar, S.] Univ Monastir, Lab Pharm Galen, Monastir 5000, Tunisia.
C3 Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1;
   Centre National de la Recherche Scientifique (CNRS); CNRS   Institute
   for Engineering & Systems Sciences (INSIS); Universite de Monastir
RP Fessi, H (通讯作者)，Univ Lyon, F 69622 Lyon, France.
EM fessi@lagep.univ lyon1.fr
RI Elaissari, Abdelhamid/M 3312 2017; Fessi, Hatem/ABD 8220 2021
OI Elaissari, Abdelhamid/0000 0002 2151 9894; 
FU Tunisian Ministry of Higher Education And Scientific Research
FX K. Miladi would like to acknowledge the support provided by Tunisian
   Ministry of Higher Education And Scientific Research by awarding a
   grant.
CR [Anonymous], 2009, The complete drug reference
   Bilati U, 2005, EUR J PHARM SCI, V24, P67, DOI 10.1016/j.ejps.2004.09.011
   Budhian A, 2007, INT J PHARM, V336, P367, DOI 10.1016/j.ijpharm.2006.11.061
   Grando CRC, 2013, J COLLOID SCI BIOTEC, V2, P140, DOI 10.1166/jcsb.2013.1044
   Cauchetier E, 2003, INT J PHARM, V250, P273, DOI 10.1016/S0378 5173(02)00556 2
   Chorny M, 2002, J CONTROL RELEASE, V83, P389, DOI 10.1016/S0168 3659(02)00211 0
   Cohen Sela E, 2006, J CONTROL RELEASE, V113, P23, DOI 10.1016/j.jconrel.2006.03.010
   Cohen Sela E, 2009, J CONTROL RELEASE, V133, P90, DOI 10.1016/j.jconrel.2008.09.073
   Contado C, 2013, ANAL BIOANAL CHEM, V405, P703, DOI 10.1007/s00216 012 6113 5
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Dash TK, 2012, J CONTROL RELEASE, V158, P15, DOI 10.1016/j.jconrel.2011.09.064
   de Araújo TM, 2013, J BIOMED NANOTECHNOL, V9, P1098, DOI 10.1166/jbn.2013.1607
   Dhanaraju MD, 2004, CHEM PHARM BULL, V52, P976, DOI 10.1248/cpb.52.976
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fasinu P, 2011, BIOPHARM DRUG DISPOS, V32, P185, DOI 10.1002/bdd.750
   FESSI H, 1989, INT J PHARMACEUT, V55, pR1, DOI 10.1016/0378 5173(89)90281 0
   FLORENCE AT, 1982, INT J PHARM, V11, P277, DOI 10.1016/0378 5173(82)90080 1
   Fonseca C, 2002, J CONTROL RELEASE, V83, P273, DOI 10.1016/S0168 3659(02)00212 2
   Han SY, 2013, COLLOID SURFACE B, V102, P833, DOI 10.1016/j.colsurfb.2012.09.010
   LANKVELD JM, 1972, J COLLOID INTERF SCI, V41, P466, DOI 10.1016/0021 9797(72)90370 0
   Lindfors L, 2006, LANGMUIR, V22, P906, DOI 10.1021/la0523661
   Lira AAM, 2013, J COLLOID SCI BIOTEC, V2, P123, DOI 10.1166/jcsb.2013.1041
   Martín Banderas L, 2012, INT J NANOMED, V7, P5793, DOI 10.2147/IJN.S34633
   Mazzaferro S, 2012, J COLLOID SCI BIOTEC, V1, P210, DOI 10.1166/jcsb.2012.1022
   Mishra PR, 2009, INT J PHARMACEUT, V371, P182, DOI 10.1016/j.ijpharm.2008.12.030
   Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016
   OSTOVIC D, 1993, PHARMACEUT RES, V10, P470, DOI 10.1023/A:1018969112754
   Perez C, 2001, J CONTROL RELEASE, V75, P211, DOI 10.1016/S0168 3659(01)00397 2
   Puga AM, 2012, ACTA BIOMATER, V8, P1507, DOI 10.1016/j.actbio.2011.12.020
   Campos EVR, 2013, J COLLOID SCI BIOTEC, V2, P106, DOI 10.1166/jcsb.2013.1040
   Riddick T.M, 1968, CONTROL COLLOID STAB
   Rosset V, 2012, J COLLOID SCI BIOTEC, V1, P218, DOI 10.1166/jcsb.2012.1023
   Sanna V, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556 276X 6 260
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   de Melo NFS, 2013, J COLLOID SCI BIOTEC, V2, P146, DOI 10.1166/jcsb.2013.1048
   Sinha VR, 2004, INT J PHARMACEUT, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   Van de Ven H, 2011, INT J PHARMACEUT, V420, P122, DOI 10.1016/j.ijpharm.2011.08.016
   Wang F, 2012, J COLLOID SCI BIOTEC, V1, P192, DOI 10.1166/jcsb.2012.1024
   Yadav Khushwant S., 2010, Current Drug Delivery, V7, P51
   Zili Z, 2005, INT J PHARM, V294, P261, DOI 10.1016/j.ijpharm.2005.01.020
NR 41
TC 44
Z9 46
U1 1
U2 105
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0926 6690
EI 1872 633X
J9 IND CROP PROD
JI Ind. Crop. Prod.
PD OCT 15
PY 2015
VL 72
SI SI
BP 24
EP 33
DI 10.1016/j.indcrop.2015.01.079
PG 10
WC Agricultural Engineering; Agronomy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Agriculture
GA CM5CR
UT WOS:000357704900005
DA 2025 08 17
ER

PT J
AU Zheng, LZ
   Wang, JL
   Kong, L
   Huang, L
   Tian, L
   Pang, QQ
   Wang, XL
   Qin, L
AF Zheng, Li Zhen
   Wang, Jia Li
   Kong, Ling
   Huang, Le
   Tian, Li
   Pang, Qian Qian
   Wang, Xin Luan
   Qin, Ling
TI Steroid associated osteonecrosis animal model in rats
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Animal model; Corticosteroid; Osteonecrosis
ID INDUCED OSTEOPOROSIS; BONE; INHIBITION; PREVENTION; THROMBOSIS
AB Objective: Established preclinical disease models are essential for not only studying aetiology and/or pathophysiology of the relevant diseases but more importantly also for testing prevention and/or treatment concept(s). The present study proposed and established a detailed induction and assessment protocol for a unique and cost effective preclinical steroid associated osteonecrosis (SAON) in rats with pulsed injections of lipopolysaccharide (LPS) and methylprednisolone (MPS).
   Methods: Sixteen 24 week old male SpragueeDawley rats were used to induce SAON by one intravenous injection of LPS (0.2 mg/kg) and three intraperitoneal injections of MPS (100 mg/kg) with a time interval of 24 hour, and then, MPS (40 mg/kg) was intraperitoneally injected three times a week from week 2 until sacrifice. Additional 12 rats were used as normal controls. Two and six weeks after induction, animals were scanned by metabolic dual energy Xray absorptiometry for evaluation of tissue composition; serum was collected for bone turnover markers, Microfil perfusion was performed for angiography, the liver was collected for histopathology and bilateral femora and bilateral tibiae were collected for histological examination.
   Results: Three rats died after LPS injection, i.e., with 15.8% (3/19) mortality. Histological evaluation showed 100% incidence of SAON at week 2. Dual energy X ray absorptiometry showed significantly higher fat percent and lower lean mass in SAON group at week 6. Micro computed tomography (Micro CT) showed significant bone degradation at proximal tibia 6 weeks after SAON induction. Angiography illustrated significantly less blood vessels in the proximal tibia and significantly more leakage particles in the distal tibia 2 weeks after SAON induction. Serum amino terminal propeptide of type I collagen and osteocalcin were significantly lower at both 2 and 6 weeks after SAON induction, and serum carboxy terminal telopeptide was significantly lower at 6 weeks after SAON induction. Histomorphometry revealed significantly lower osteoblast surface and higher marrow fat fraction and oedema area in SAON group. Hepatic oedema appeared 2 weeks after SAON induction, and lipid accumulation appeared in the liver of SAON rats 6 weeks after SAON induction.
   Conclusion: The present study successfully induced SAON in rats with pulsed injection of LPS and MPS, which was well simulating the clinical feature and pathology. Apart from available large animal models, such as bipedal emus or quadrupedal rabbits, our current SAON small model in rats could be a cost effective preclinical experimental model to study body metabolism, molecular mechanism of SAON and potential drugs developed for prevention or treatment of SAON.
   The translational potential of this article: The present study successfully induced SAON in a small animal model in rats with pulsed injection of LPS and MPS. The evaluation protocols with typical histopathologic ON features and advanced evaluation approaches to identify the metabolic disorders of SAON could be used in future rat SAON studies. The SAON rat model is a suitable and cost effective animal model to study molecular mechanism of SAON and potential drugs developed for prevention and treatment of SAON. (C) 2018 The Authors. Published by Elsevier(Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society.
C1 [Zheng, Li Zhen; Wang, Jia Li; Kong, Ling; Huang, Le; Tian, Li; Pang, Qian Qian; Qin, Ling] Chinese Univ Hong Kong, Dept Orthopaed Traumatol, Musculoskeletal Res Lab, Shatin, Hong Kong, Peoples R China.
   [Qin, Ling] Chinese Univ Hong Kong, Innovat Orthopaed Biomat & Drug Translat Res Lab, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Qin, Ling] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Hlth Engn, Translat Med R&D Ctr, Shenzhen, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS
RP Qin, L (通讯作者)，Prince Wales Hosp, Rm74026,5 F,Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM lingqin@cuhk.edu.hk
RI Zheng, Lizhen/C 6550 2014; Qin, Ling/JBR 9155 2023; Wang,
   Jiali/IQU 4490 2023; kong, lingpeng/NHQ 3170 2025; Qin, Ling/J 9047 2018
OI Qin, Ling/0000 0001 6173 6167
FU Research Grants Council of the Hong Kong Special Administrative Region,
   China [T13 402/17 N]
FX The work described on this article was fully supported by a grant from
   the Research Grants Council of the Hong Kong Special Administrative
   Region, China (Ref No. T13 402/17 N).
CR Bekler Halil, 2007, Acta Orthop Traumatol Turc, V41, P58
   Ben Shaul V, 1999, SHOCK, V12, P288, DOI 10.1097/00024382 199910000 00007
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cantatore FP, 2005, CELL BIOL INT, V29, P583, DOI 10.1016/j.cellbi.2005.03.011
   Chen SH, 2016, J ORTHOP TRANSL, V4, P14, DOI 10.1016/j.jot.2015.07.001
   Cui QJ, 1997, CLIN ORTHOP RELAT R, P8
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ding S, 2011, BMC MUSCOSKEL DISORD, P12
   Duvall CL, 2004, AM J PHYSIOL HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658 198709000 00016
   Foresta C, 2010, J CLIN ENDOCR METAB, V95, P3502, DOI 10.1210/jc.2009 2557
   Han N, 2010, CALCIFIED TISSUE INT, V87, P246, DOI 10.1007/s00223 010 9385 9
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Kanazawa I, 2015, WORLD J DIABETES, V6, P1345, DOI 10.4239/wjd.v6.i18.1345
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Niessen F, 2009, BLOOD, V113, P2859, DOI 10.1182/blood 2008 12 192385
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Okazaki S, 2009, RHEUMATOLOGY, V48, P227, DOI 10.1093/rheumatology/ken462
   Okazaki S, 2016, J ORTHOP RES, V34, P342, DOI 10.1002/jor.23008
   Powell C, 2010, AUTOIMMUN REV, V9, P721, DOI 10.1016/j.autrev.2010.06.007
   Qin L, 2006, BONE, V39, P863, DOI 10.1016/j.bone.2006.04.018
   Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002
   Research IoLA Sciences CoL Council NR., 1996, GUID CAR US LAB AN
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Sun W, 2016, SCI REP UK, V6, DOI 10.1038/srep29576
   Sun Y, 2010, J HISTOCHEM CYTOCHEM, V58, P1033, DOI 10.1369/jhc.2010.956771
   Tagliaferri C, 2015, AGEING RES REV, V21, P55, DOI 10.1016/j.arr.2015.03.002
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Xie XH, 2015, J ORTHOP TRANSL, V3, P58, DOI 10.1016/j.jot.2014.12.002
   Yamamoto T, 1997, ARTHRITIS RHEUM, V40, P2055, DOI 10.1002/art.1780401119
   Zhang G, 2007, BONE, V40, P685, DOI 10.1016/j.bone.2006.10.026
   Zhang G, 2009, ARTHRITIS RHEUM US, V60, P2966, DOI 10.1002/art.24847
   Zhang G, 2009, BONE, V44, P345, DOI 10.1016/j.bone.2008.10.035
   Zheng L, 2016, J ORTHOP TRANSLAT SC, V7, P116
NR 41
TC 51
Z9 59
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD APR
PY 2018
VL 13
BP 13
EP 24
DI 10.1016/j.jot.2018.01.003
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA GC4SW
UT WOS:000429776100004
PM 29662787
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jurca, T
   Józsa, L
   Suciu, R
   Pallag, A
   Marian, E
   Bácskay, I
   Muresan, M
   Stan, RL
   Cevei, M
   Cioara, F
   Vicas, L
   Fehér, P
AF Jurca, Tunde
   Jozsa, Liza
   Suciu, Ramona
   Pallag, Annamaria
   Marian, Eleonora
   Bacskay, Ildiko
   Muresan, Mariana
   Stan, Roxana Liana
   Cevei, Mariana
   Cioara, Felicia
   Vicas, Laura
   Feher, Palma
TI Formulation of Topical Dosage Forms Containing Synthetic and Natural
   Anti Inflammatory Agents for the Treatment of Rheumatoid Arthritis
SO MOLECULES
LA English
DT Article
DE rheumatoid arthritis; diclofenac sodium; Calendula officinalis extract;
   methyl salicylate; anti inflammatory agent; antioxidant; surfactants;
   topical formulation
ID ANTIOXIDANT; PENETRATION; KNEE; OSTEOARTHRITIS; MECHANISM; SYNOVITIS;
   DIAGNOSIS; RELEASE; GEL
AB Topical anti inflammatory and analgesic effect for the treatment of rheumatoid arthritis is of major interest because of their fewer side effects compared to oral therapy. The purpose of this study was to prepare different types of topical formulations (ointments and gels) containing synthetic and natural anti inflammatory agents with different excipients (e.g.,: surfactants, gel forming) for the treatment of rheumatoid arthritis. The combination of Non Steroidal Anti Inflammatory Drugs (NSAIDs), diclofenac sodium, a topical analgesic agent methyl salicylate, and a lyophilized extract of Calendula officinalis with antioxidant effect were used in our formulations. The aim was to select the appropriate excipients and dosage form for the formulation in order to enhance the diffusion of active substances and to certify the antioxidant, analgesic, and anti inflammatory effects of these formulations. To characterize the physicochemical properties of the formulations, rheological studies, and texture profile analysis were carried out. Membrane diffusion and permeability studies were performed with Franz diffusion method. The therapeutic properties of the formulations have been proven by an antioxidant assay and a randomized prospective study that was carried out on 115 patients with rheumatoid arthritis. The results showed that the treatment with the gel containing diclofenac sodium, methyl salicylate, and lyophilized Calendula officinalis as active ingredients, 2 propenoic acid homopolymer (Synthalen K) as gel forming excipient, distilled water, triethanolamine, and glycerol had a beneficial analgesic and local anti inflammatory effect.
C1 [Jurca, Tunde; Pallag, Annamaria; Marian, Eleonora; Vicas, Laura] Univ Oradea, Fac Med & Pharm, Dept Pharm, 1st December Sq 10, Oradea 410068, Romania.
   [Jozsa, Liza; Bacskay, Ildiko; Feher, Palma] Univ Debrecen, Dept Pharmaceut Technol, Fac Pharm, Nagyerdei Korut 98, H 4032 Debrecen, Hungary.
   [Jozsa, Liza; Bacskay, Ildiko; Feher, Palma] Univ Debrecen, Doctoral Sch Pharmaceut Sci, Nagyerdei Korut 98, H 4032 Debrecen, Hungary.
   [Jozsa, Liza; Bacskay, Ildiko; Feher, Palma] Univ Debrecen, Inst Healthcare Ind, Nagyerdei Korut 98, H 4032 Debrecen, Hungary.
   [Suciu, Ramona; Cevei, Mariana; Cioara, Felicia] Univ Oradea, Fac Med & Pharm, Dept Psychoneurosci & Rehabil Dept, 1st December Sq 10, Oradea 410068, Romania.
   [Muresan, Mariana] Univ Oradea, Fac Med & Pharm, Dept Preclin Disciplines, Ist December Sq 10, Oradea 410068, Romania.
   [Stan, Roxana Liana] Univ Med & Pharm Iuliu Hatieganu, Fac Pharm, Dept Pharmaceut Biochem & Clin Lab, Victor Babes St, Cluj Napoca 400000, Romania.
C3 University of Oradea; University of Debrecen; University of Debrecen;
   University of Debrecen; University of Oradea; University of Oradea;
   Iuliu Hatieganu University of Medicine & Pharmacy
RP Fehér, P (通讯作者)，Univ Debrecen, Dept Pharmaceut Technol, Fac Pharm, Nagyerdei Korut 98, H 4032 Debrecen, Hungary.; Fehér, P (通讯作者)，Univ Debrecen, Doctoral Sch Pharmaceut Sci, Nagyerdei Korut 98, H 4032 Debrecen, Hungary.; Fehér, P (通讯作者)，Univ Debrecen, Inst Healthcare Ind, Nagyerdei Korut 98, H 4032 Debrecen, Hungary.
EM jurcatunde@yahoo.com; jozsa.liza@euipar.unideb.hu;
   dr_ramona_suciu@yahoo.com; annamariapallag@gmail.com;
   marian_eleonora@yahoo.com; bacskay.ildiko@pharm.unideb.hu;
   marianamur2002@yahoo.com; roxanaluc@yahoo.com; cevei_mariana@yahoo.com;
   felicia_cioara@yahoo.com; laura.vicas@gmail.com;
   feher.palma@pharm.unideb.hu
RI SUCIU, NICOLETA/AAC 9378 2022; Lucaciu, Roxana/AAR 1641 2021; Marian,
   Eleonora/AAU 1934 2020; MURESAN, MARIANA/AAH 3095 2021; Mariana Lidia,
   Cevei/AAD 1127 2022; Vicas, Laura/K 7216 2019; Jurca, Tunde/N 3248 2015;
   Andronie Cioara, Felicia/AAC 6035 2022; Pallag, Annamaria/AAQ 4091 2020
OI Bacskay, Ildiko/0000 0001 8663 2890; Vicas, Laura
   Gratiela/0000 0001 5328 333X; Lucaciu (Stan), Roxana
   Liana/0000 0003 4920 4760; Jurca, Tunde/0000 0001 5591 7826; Pallag,
   Annamaria/0000 0002 7146 3040; Dr. Jozsa, Liza/0000 0001 5835 5304;
   Suciu, Ramona/0000 0002 3419 2165; 
FU Thematic Excellence Programme of the Ministry for Innovation and
   Technology in Hungary [TKP2020 IKA 04]; project Debrecen Venture
   Catapult [EFOP 3.6.1 16 2016 0002]; European Union; European Social
   Fund; "Developing Pharmaceutical Technology R&D Infrastructure on the
   University of Debrecen" project [GINOP 2.3.3 15 2016 00021]; European
   Regional Development Fund; "Domus Hungarica Scientiarum et Artium"
   research grant in 2018; University of Oradea [6/2016]
FX The research was supported by the Thematic Excellence Programme
   (TKP2020 IKA 04) of the Ministry for Innovation and Technology in
   Hungary. The research was carried out under the project Debrecen Venture
   Catapult (EFOP 3.6.1 16 2016 0002). The project is supported by the
   European Union, the Co funded by the European Social Fund. The
   work/publication is supported by the GINOP 2.3.3 15 2016 00021
   "Developing Pharmaceutical Technology R&D Infrastructure on the
   University of Debrecen" project. The project is co financed by the
   European Union and the European Regional Development Fund. The present
   work was supported by "Domus Hungarica Scientiarum et Artium" research
   grant in 2018 and Research contract University of Oradea, nr. 6/2016.
CR A sasutjarit R, 2005, PHARM RES DORDR, V22, P2134, DOI 10.1007/s11095 005 8244 2
   Aielo PB, 2014, MATER RES IBERO AM J, V17, P146, DOI 10.1590/S1516 14392014005000010
   Annil MahajanA., 2004, J Indian Rheumatol Assoc, V12, P139
   Araki Y, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6290682
   Ashwlayanvd K.A., 2018, PHARM PHARM INT, V6, P149, DOI DOI 10.15406/PPIJ.2018.06.00171
   Bahuguna A, 2017, BANGL J PHARMACOL, V12, P115, DOI 10.3329/bjp.v12i2.30892
   Revel FB, 2020, RHEUMATOL THER, V7, P217, DOI 10.1007/s40744 020 00196 6
   Birch JT, 2010, PRIMARY CARE, V37, P779, DOI 10.1016/j.pop.2010.07.001
   Bloom R., 2014, POLYPHENOLS FOOD SOU
   Bolla PK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020151
   Boonstra AM, 2008, INT J REHABIL RES, V31, P165, DOI 10.1097/MRR.0b013e3282fc0f93
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   BRAND WILLIAMS W, 1995, FOOD SCI TECHNOL LEB, V28, P25
   Butnariu M, 2012, CHEM CENT J, V6, DOI 10.1186/1752 153X 6 35
   Cázares Delgadillo J, 2005, INT J PHARMACEUT, V297, P204, DOI 10.1016/j.ijpharm.2005.03.020
   Chen MX, 2016, J PHARMACEUTICS, V2016, DOI 10.1155/2016/5754349
   Colombo I, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/7435621
   Counsil of Europe, 2019, EUROPEAN PHARMACOPOE
   Fonseca LJS, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7536805
   Dave Mittal B., 2017, J ORTHOP TRAUMA SURG, V12, P3
   de Leval X, 2000, CURR MED CHEM, V7, P1041
   Derry S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007402.pub3
   Dorwal D., 2012, INT J RES PHARM BIOM, V3, P983
   DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378
   Efe T, 2014, KNEE SURG SPORT TR A, V22, P345, DOI 10.1007/s00167 013 2408 0
   El Miedany Y, 2008, JOINT BONE SPINE, V75, P155, DOI 10.1016/j.jbspin.2007.04.021
   Farahmandfar R, 2017, INT J BIOL MACROMOL, V98, P820, DOI 10.1016/j.ijbiomac.2017.02.046
   Fehér P, 2016, MOLECULES, V21, DOI 10.3390/molecules21101269
   Filippucci E, 2019, RADIOL MED, V124, P1087, DOI 10.1007/s11547 019 01002 2
   Fürst R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/146832
   Hadfield R A., 2008, Foot Ankle J, V1, P1
   Hemke R, 2018, EUR RADIOL, V28, P1167, DOI 10.1007/s00330 017 5067 6
   Heyneman CA, 2000, DRUGS, V60, P555, DOI 10.2165/00003495 200060030 00004
   HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018
   Higuchi T., 1960, J SOC COSMET CHEM, V11, P85
   Jan MH, 2006, PHYS THER, V86, P236, DOI 10.1093/ptj/86.2.236
   Jurca T, 2017, REV CHIM BUCHAREST, V68, P1786
   Keen HI, 2015, RHEUMATOLOGY, V54, P1385, DOI 10.1093/rheumatology/keu529
   Köhler BM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070938
   Lambers H., 2006, International Journal of Cosmetic Science, V28, P359, DOI 10.1111/j.1467 2494.2006.00344.x
   Lane ME, 2013, INT J PHARMACEUT, V447, P12, DOI 10.1016/j.ijpharm.2013.02.040
   Parente LML, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/375671
   Lee SG, 2016, DRUG DEV IND PHARM, V42, P1636, DOI 10.3109/03639045.2016.1160107
   Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471 4159.1997.69020581.x
   Lu YR, 2000, FOOD CHEM, V68, P81, DOI 10.1016/S0308 8146(99)00167 3
   Manik ZH, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/5609132
   Marian E, 2017, FARMACIA, V65, P940
   Maroon Joseph C, 2010, Surg Neurol Int, V1, P80, DOI 10.4103/2152 7806.73804
   Mensor LL, 2001, PHYTOTHER RES, V15, P127, DOI 10.1002/ptr.687
   Mitali Bodhankar Mitali Bodhankar, 2012, Journal of Drug Delivery and Therapeutics, V2, P118
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Neviaser AS, 2011, J AM ACAD ORTHOP SUR, V19, P536, DOI 10.5435/00124635 201109000 00004
   Olennikov DN, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081685
   Otto A., 2009, International Journal of Cosmetic Science, V31, P1, DOI 10.1111/j.1468 2494.2008.00467.x
   Preethi KC, 2009, INDIAN J EXP BIOL, V47, P113
   Racz I., 1991, GYOGYSZER TECHNOLOGI, V3
   Romanet R, 2019, MOLECULES, V24, DOI 10.3390/molecules24071353
   Semisolid Drug Products Performance Tests, 2015, US PHARM NAT FORM US, P1625
   Shahin M, 2011, DRUG DEV IND PHARM, V37, P559, DOI 10.3109/03639045.2010.528768
   Som I, 2012, J PHARM BIOALLIED SC, V4, P2, DOI 10.4103/0975 7406.92724
   Stolarek R, 1998, INT J CLIN LAB RES, V28, P104, DOI 10.1007/s005990050028
   Sung YT, 2018, BEHAV RES METHODS, V50, P1694, DOI 10.3758/s13428 018 1041 8
   Tegeli V.S., 2011, INT J DRUG FORM RES, V2, P52
   Treffel P, 1996, ACTA DERM VENEREOL, V76, P341
   van Vugt RM, 2008, CLIN RHEUMATOL, V27, P771, DOI 10.1007/s10067 008 0848 6
   Wakefield RJ, 2005, J RHEUMATOL, V32, P2485
   Wasserman AM, 2011, AM FAM PHYSICIAN, V84, P1245
   Wenham CYJ, 2010, THER ADV MUSCULOSKEL, V2, P349, DOI 10.1177/1759720X10378373
   WILHELM KP, 1994, J AM ACAD DERMATOL, V31, P981, DOI 10.1016/S0190 9622(94)70268 3
   Wu J, 2018, J ETHNOPHARMACOL, V221, P100, DOI 10.1016/j.jep.2018.04.025
   Yadegari M., 2016, Journal of Ornamental Plants, V6, P271
   Younger J, 2009, CURR PAIN HEADACHE R, V13, P39, DOI 10.1007/s11916 009 0009 x
NR 72
TC 19
Z9 21
U1 1
U2 32
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2021
VL 26
IS 1
AR 24
DI 10.3390/molecules26010024
PG 26
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PQ0OC
UT WOS:000606249500001
PM 33374575
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sigmarsdottir, TB
   McGarrity, S
   de Lomana, ALG
   Kotronoulas, A
   Sigurdsson, S
   Yurkovich, JT
   Rolfsson, O
   Sigurjonsson, OE
AF Sigmarsdottir, Thora Bjorg
   McGarrity, Sarah
   de Lomana, Adrian Lopez Garcia
   Kotronoulas, Aristotelis
   Sigurdsson, Snaevar
   Yurkovich, James T.
   Rolfsson, Ottar
   Sigurjonsson, Olafur Eysteinn
TI Metabolic and Transcriptional Changes across Osteogenic Differentiation
   of Mesenchymal Stromal Cells
SO BIOENGINEERING BASEL
LA English
DT Article
DE mesenchymal stromal cells (MSCs); osteogenic differentiation;
   metabolites; metabolism; metabolic changes; glycolysis; oxidative
   phosphorylation; gene regulatory network
AB Mesenchymal stromal cells (MSCs) are multipotent post natal stem cells with applications in tissue engineering and regenerative medicine. MSCs can differentiate into osteoblasts, chondrocytes, or adipocytes, with functional differences in cells during osteogenesis accompanied by metabolic changes. The temporal dynamics of these metabolic shifts have not yet been fully characterized and are suspected to be important for therapeutic applications such as osteogenesis optimization. Here, our goal was to characterize the metabolic shifts that occur during osteogenesis. We profiled five key extracellular metabolites longitudinally (glucose, lactate, glutamine, glutamate, and ammonia) from MSCs from four donors to classify osteogenic differentiation into three metabolic stages, defined by changes in the uptake and secretion rates of the metabolites in cell culture media. We used a combination of untargeted metabolomic analysis, targeted analysis of C 13 glucose labelled intracellular data, and RNA sequencing data to reconstruct a gene regulatory network and further characterize cellular metabolism. The metabolic stages identified in this proof of concept study provide a framework for more detailed investigations aimed at identifying biomarkers of osteogenic differentiation and small molecule interventions to optimize MSC differentiation for clinical applications.
C1 [Sigmarsdottir, Thora Bjorg; McGarrity, Sarah; Sigurjonsson, Olafur Eysteinn] Reykjavik Univ, Sch Sci & Engn, IS 101 Reykjavik, Iceland.
   [McGarrity, Sarah; de Lomana, Adrian Lopez Garcia; Kotronoulas, Aristotelis; Rolfsson, Ottar] Univ Iceland, Ctr Syst Biol, IS 101 Reykjavik, Iceland.
   [Sigurdsson, Snaevar] Univ Iceland, Biomed Ctr, IS 101 Reykjavik, Iceland.
   [Yurkovich, James T.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
   [Sigurjonsson, Olafur Eysteinn] Landspitali Natl Univ Hosp Iceland, Dept RnD, Blood Blank, IS 101 Reykjavik, Iceland.
C3 Reykjavik University; University of Iceland; University of Iceland;
   University of California System; University of California San Diego
RP Sigurjonsson, OE (通讯作者)，Reykjavik Univ, Sch Sci & Engn, IS 101 Reykjavik, Iceland.; Sigurjonsson, OE (通讯作者)，Landspitali Natl Univ Hosp Iceland, Dept RnD, Blood Blank, IS 101 Reykjavik, Iceland.
EM thoras13@ru.is; sarahm@hi.is; adrian@hi.is; aris@hi.is; snaevar@hi.is;
   jyurkovich@ucsd.edu; ottarr@hi.is; oes@ru.is
RI ; de Lomana, Adrián/AAA 6857 2020; Sigurjonsson, Olafur/T 8190 2019
OI Rolfsson, Ottar/0000 0003 4258 6057; Sigurdsson,
   Snaevar/0000 0003 4860 6311; Sigurjonsson, Olafur/0000 0002 4968 842X;
   Yurkovich, James/0000 0002 9403 509X; Lopez Garcia de Lomana,
   Adrian/0000 0002 9748 347X; McGarrity, Sarah/0000 0002 2878 6194; 
FU Icelandic Research Fund [217005]; Academy of Finland (AKA) [217005]
   Funding Source: Academy of Finland (AKA)
FX FundingThis research was funded by the Icelandic Research Fund, grant
   number 217005.
CR Alekos NS, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.578194
   Bone Grafts & Substitutes Market Size, SHAR IND REP, P2026
   Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816 888d
   Brown PM, 2011, CALCIFIED TISSUE INT, V89, P472, DOI 10.1007/s00223 011 9537 6
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Brunk E, 2018, NAT BIOTECHNOL, V36, P272, DOI 10.1038/nbt.4072
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538
   Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chiarella E, 2018, STEM CELL REV REP, V14, P901, DOI 10.1007/s12015 018 9830 0
   Chiarello E, 2013, AGING CLIN EXP RES, V25, pS101, DOI 10.1007/s40520 013 0088 8
   Chiu M, 2020, CANCERS, V12, DOI 10.3390/cancers12113267
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Dobson PF, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68566 2
   Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534 5807(02)00190 9
   Flowers S, 2013, CANCER RES, V73, P2150, DOI 10.1158/0008 5472.CAN 12 1745
   Forni MF, 2016, STEM CELLS, V34, P743, DOI 10.1002/stem.2248
   Garcia Alonso L, 2019, GENOME RES, V29, P1363, DOI 10.1101/gr.240663.118
   Gazit Z., 2014, ESSENTIALS STEM CELL, V3rd ed., P255
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Huang TL, 2017, STEM CELLS, V35, P411, DOI 10.1002/stem.2470
   IsoCor, IS CORR MASS SPECTR
   Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772
   James N.A, ECP R PACKAGE NONPAR
   Kang XF, 2019, EXP THER MED, V17, P2113, DOI 10.3892/etm.2019.7170
   Kawai S, 2007, J BONE MINER RES, V22, P1362, DOI 10.1359/JBMR.070602
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Li SZ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003123
   Liu C, 2013, INT J MED SCI, V10, P1181, DOI 10.7150/ijms.6657
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luo K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44475 x
   Maneiro E, 2003, ARTHRITIS RHEUM, V48, P700, DOI 10.1002/art.10837
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Meleshina AV, 2016, SCI REP UK, V6, DOI 10.1038/srep21853
   Meyer MB, 2016, J BIOL CHEM, V291, P17829, DOI 10.1074/jbc.M116.736538
   Mirzayans F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049095
   Moris N, 2016, NAT REV GENET, V17, P693, DOI 10.1038/nrg.2016.98
   Nauth A, 2012, INDIAN J ORTHOP, V46, P19, DOI 10.4103/0019 5413.91630
   Neman J, 2012, BIOL TARGETS THER, V6, P47, DOI 10.2147/BTT.S22407
   Nicholas D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170975
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605
   Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Saint Antoine MM, 2020, CURR OPIN BIOTECH, V63, P89, DOI 10.1016/j.copbio.2019.12.002
   Saito H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08778 x
   Scheffer M, 2012, SCIENCE, V338, P344, DOI 10.1126/science.1225244
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Simon LM, 2014, BLOOD, V123, pE37, DOI 10.1182/blood 2013 12 544692
   Smith CO, 2021, STEM CELLS DEV, V30, P149, DOI 10.1089/scd.2020.0141
   Stechschulte Lance A, 2017, Curr Mol Biol Rep, V3, P107, DOI 10.1007/s40610 017 0056 8
   Stegen S, 2021, J BONE MINER RES, V36, P604, DOI 10.1002/jbmr.4219
   Stricker S, 2012, STEM CELLS DEV, V21, P623, DOI 10.1089/scd.2011.0154
   Tian G, 2014, ANTIOXID REDOX SIGN, V20, P2606, DOI 10.1089/ars.2013.5406
   Tominaga H, 2008, MOL BIOL CELL, V19, P5373, DOI 10.1091/mbc.E08 03 0329
   Vaishya Raju, 2013, J Clin Orthop Trauma, V4, P157, DOI 10.1016/j.jcot.2013.11.005
   Wood S., 2020, PACKAGE GAMM4 GEN AD
   Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097 2765(00)80306 8
   Yamauchi M, 2008, GENE, V426, P81, DOI 10.1016/j.gene.2008.08.015
   Zhang DY, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/867293
   Zhao Q., 2016, Journal of Cellular Immunotherapy, V2, P3, DOI DOI 10.1016/J.JOCIT.2014.12.001
   Zheng DL, 2018, MOL MED REP, V17, P400, DOI 10.3892/mmr.2017.7907
NR 68
TC 12
Z9 13
U1 2
U2 14
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2306 5354
J9 BIOENGINEERING BASEL
JI Bioengineering Basel
PD DEC
PY 2021
VL 8
IS 12
AR 208
DI 10.3390/bioengineering8120208
PG 27
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA XX3MT
UT WOS:000736205000001
PM 34940360
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tang, JH
   Chen, L
   Yan, DY
   Shen, ZJ
   Wang, BZ
   Weng, SJ
   Wu, ZY
   Xie, ZJ
   Shao, JC
   Yang, L
   Shen, LY
AF Tang, Jiahao
   Chen, Liang
   Yan, Deyi
   Shen, Zijian
   Wang, Bingzhang
   Weng, Sheji
   Wu, Zongyi
   Xie, Zhongjie
   Shao, Jiancan
   Yang, Lei
   Shen, Liyan
TI Surface Functionalization with Proanthocyanidins Provides an
   Anti Oxidant Defense Mechanism That Improves the Long Term Stability and
   Osteogenesis of Titanium Implants
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE proanthocyanidins; anti oxidant; ROS; layer by layer methodology;
   surface modification of titanium; osteogenesis
ID OXIDATIVE STRESS; POLARIZED CPTI; IN VITRO; APOPTOSIS; GROWTH; VOLTAGE;
   DIFFERENTIATION; FIBRONECTIN; ENHANCEMENT; ATTACHMENT
AB Purpose: Aseptic loosening is a major complication after total joint replacement. Reactive oxygen species generated by local tissue cells and liberated from implant surfaces have been suggested to cause implant failures. Surface modification of titanium (Ti) based implants with proanthocyanidins (PAC) is a promising approach for the development of anti oxidant defense mechanism to supplement the mechanical functions of Ti implants. In this study, a controlled PAC release system was fabricated on the surface of Ti substrates using the layer by layer (LBL) assembly.
   Materials and Methods: Polyethyleneimine (PEI) base layer was fabricated to enable layer by layer (LBL) deposition of hyaluronic acid/chitosan (HA/CS) multi layers without or with the PAC. Surface topography and wettability of the fabricated HA/CS PAC substrates were characterized by scanning electron microscopy (SEM), atomic force microscopy (AFM), Fourier transform infrared spectroscopy (FTIR) and contact angle measurement. PAC release profiles were investigated using drug release assays. MC3T3 E1 pre osteoblast cells were used to assess the osteo inductive effects of HA/CS PAC substrates under conditions H2O2  induced oxidative stress in vitro. A rat model of femoral intramedullary implantation evaluated the osseointegration and osteo inductive potential of the HA/CS PAC coated Ti implants in vivo.
   Results: SEM, AFM, FTIR and contact angle measurements verified the successful fabrication of Ti surfaces with multi layered HA/CS PAC coating. Drug release assays revealed controlled and sustained release of PAC over 14 days. In vitro, cell based assays showed high tolerability and enhanced the osteogenic potential of MC3T3 E1 cells on HA/CS PAC substrates when under conditions of H2O2  induced oxidative stress. In vivo evaluation of femoral bone 14 days after femoral intramedullary implantation confirmed the enhanced osteo inductive potential of the HA/CS PAC coated Ti implants.
   Conclusion: Multi layering of HA/CS PAC coating onto Ti based surfaces by the LBL deposition significantly enhances implant osseo integration and promotes osteogenesis under conditions of oxidative stress. This study provides new insights for future applications in the field of joint arthroplasty.
C1 [Tang, Jiahao; Chen, Liang; Yan, Deyi; Shen, Zijian; Wang, Bingzhang; Weng, Sheji; Wu, Zongyi; Xie, Zhongjie; Shao, Jiancan; Yang, Lei; Shen, Liyan] Wenzhou Med Univ, Sch Med 2, Wenzhou 325000, Zhejiang, Peoples R China.
   [Tang, Jiahao; Chen, Liang; Yan, Deyi; Shen, Zijian; Wang, Bingzhang; Weng, Sheji; Wu, Zongyi; Xie, Zhongjie; Shao, Jiancan; Yang, Lei; Shen, Liyan] Wenzhou Med Univ, Key Lab Orthoped Zhejiang Prov, Dept Orthoped, Affiliated Hosp 2, 109 Xueyuan West Rd, Wenzhou 325000, Zhejiang, Peoples R China.
   [Tang, Jiahao; Chen, Liang; Yan, Deyi; Shen, Zijian; Wang, Bingzhang; Weng, Sheji; Wu, Zongyi; Xie, Zhongjie; Shao, Jiancan; Yang, Lei; Shen, Liyan] Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan West Rd, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University
RP Yang, L; Shen, LY (通讯作者)，Wenzhou Med Univ, Key Lab Orthoped Zhejiang Prov, Dept Orthoped, Affiliated Hosp 2, 109 Xueyuan West Rd, Wenzhou 325000, Zhejiang, Peoples R China.; Yang, L; Shen, LY (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan West Rd, Wenzhou 325000, Zhejiang, Peoples R China.
EM yl190015@hotmail.com; uynixmm@163.com
FU Science and Technology Department of Zhejiang Province [:2016C37122];
   National Natural Science Foundation of China [41506091]; Wenzhou
   Science&Technology Bureau [Y20190021]
FX This work was funded by a research grant to Science and Technology
   Department of Zhejiang Province (Grant No.:2016C37122), National Natural
   Science Foundation of China (Grant No.:81772348), National Natural
   Science Foundation of China (41506091), and Wenzhou Science&Technology
   Bureau (Y20190021).
CR ALTANKOV G, 1994, J MATER SCI MATER M, V5, P732, DOI 10.1007/BF00120366
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Anderson JM, 2001, ANNU REV MATER RES, V31, P81, DOI 10.1146/annurev.matsci.31.1.81
   [Anonymous], CIRCULATION
   Arpornmaeklong P, 2007, INT J ORAL MAX SURG, V36, P328, DOI 10.1016/j.ijom.2006.09.023
   Azizi B, 2011, INVEST OPHTH VIS SCI, V52, P9291, DOI 10.1167/iovs.11 8312
   Bagchi D, 2002, ANN NY ACAD SCI, V957, P260, DOI 10.1111/j.1749 6632.2002.tb02922.x
   Bearinger JP, 2003, J BIOMED MATER RES A, V67A, P702, DOI 10.1002/jbm.a.10116
   Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292
   Chen JD, 2015, COLLOID SURFACE B, V134, P401, DOI 10.1016/j.colsurfb.2015.06.072
   Cho YD, 2016, CURR PHARM DESIGN, V22, P4729, DOI 10.2174/1381612822666160203143053
   Choi YJ, 2005, J NUTR, V135, P707, DOI 10.1093/jn/135.4.707
   Cooper SL, 2001, CURR OPIN MICROBIOL, V4, P222, DOI 10.1016/S1369 5274(00)00192 2
   CURTIS ASG, 1983, J CELL BIOL, V97, P1500, DOI 10.1083/jcb.97.5.1500
   Das K, 2009, J BIOMED MATER RES A, V90A, P225, DOI 10.1002/jbm.a.32088
   Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
   Ehrensberger MT, 2010, J BIOMED MATER RES A, V93A, P1500, DOI 10.1002/jbm.a.32622
   Forster Yvonne, 2012, Biomatter, V2, P149, DOI 10.4161/biom.21563
   Gilbert JL, 2015, J BIOMED MATER RES A, V103, P211, DOI 10.1002/jbm.a.35165
   Gu XN, 2012, ACTA BIOMATER, V8, P2360, DOI 10.1016/j.actbio.2012.02.018
   Haeri M, 2013, BIOELECTROCHEMISTRY, V94, P53, DOI 10.1016/j.bioelechem.2013.06.002
   Hamilton V, 2007, POLYM INT, V56, P641, DOI 10.1002/pi.2181
   Hartmann H, 2013, J CONTROL RELEASE, V168, P289, DOI 10.1016/j.jconrel.2013.03.026
   Hümmer W, 2008, MOL NUTR FOOD RES, V52, P1381, DOI 10.1002/mnfr.200700463
   Jeon S, 2015, COLLOID SURFACE B, V129, P7, DOI 10.1016/j.colsurfb.2015.03.018
   Jere D, 2009, EXPERT OPIN DRUG DEL, V6, P827, DOI 10.1517/17425240903029183
   Jing YJ, 2007, ACTA BIOL HUNG, V58, P75, DOI 10.1556/ABiol.57.2007.1.7
   Junter GA, 2016, ACTA BIOMATER, V30, P13, DOI 10.1016/j.actbio.2015.11.010
   Lee JY, 2002, J CONTROL RELEASE, V78, P187, DOI 10.1016/S0168 3659(01)00498 9
   Macdonald ML, 2011, BIOMATERIALS, V32, P1446, DOI 10.1016/j.biomaterials.2010.10.052
   Nandakumar V, 2008, CANCER LETT, V269, P378, DOI 10.1016/j.canlet.2008.03.049
   Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423
   Orsolic N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092746
   Park IS, 2008, J BIOMED MATER RES B, V84B, P422, DOI 10.1002/jbm.b.30887
   Park JI, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051377, 10.1371/journal.pone.0037010]
   Park JH, 2011, LANGMUIR, V27, P5976, DOI 10.1021/la2000415
   Pitt WG, 2004, J BIOMED MATER RES A, V68A, P95, DOI 10.1002/jbm.a.10170
   Pivec R, 2012, LANCET, V380, P1768, DOI 10.1016/S0140 6736(12)60607 2
   Prasad R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043064
   Puiggròs F, 2014, CRIT REV FOOD SCI, V54, P277, DOI 10.1080/10408398.2011.565456
   Romano C L, 2017, J Bone Jt Infect, V2, P63, DOI 10.7150/jbji.17705
   Ryer EJ, 2005, J BIOL CHEM, V280, P35310, DOI 10.1074/jbc.M507187200
   Salehi E, 2016, CARBOHYD POLYM, V152, P419, DOI 10.1016/j.carbpol.2016.07.033
   Sivan S, 2013, J BIOMED MATER RES B, V101, P1489, DOI 10.1002/jbm.b.32970
   Smith RC, 2009, ANGEW CHEM INT EDIT, V48, P8974, DOI 10.1002/anie.200902782
   Son YO, 2010, TOXICOL SCI, V113, P127, DOI 10.1093/toxsci/kfp259
   Song W, 2015, INT J NANOMED, V10, P2335, DOI 10.2147/IJN.S76513
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Tanabe S, 2011, MOLECULES, V16, P2365, DOI 10.3390/molecules16032365
   Thakur VK, 2016, CARBOHYD POLYM, V146, P148, DOI 10.1016/j.carbpol.2016.03.030
   Thiele K, 2015, J BONE JOINT SURG AM, V97A, P715, DOI 10.2106/JBJS.M.01534
   Tiganis T, 2011, TRENDS PHARMACOL SCI, V32, P82, DOI 10.1016/j.tips.2010.11.006
   Tofani I., 2004, Pediatr Dent J, V14, P47
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Zhang ZF, 2014, J TOXICOL SCI, V39, P803, DOI 10.2131/jts.39.803
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
   Zuldesmi M, 2015, MAT SCI ENG C MATER, V49, P430, DOI 10.1016/j.msec.2015.01.031
NR 57
TC 29
Z9 31
U1 2
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2020
VL 15
BP 1643
EP 1659
DI 10.2147/IJN.S231339
PG 17
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA KS8BO
UT WOS:000518530500001
PM 32210558
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Guo, JX
   Jiang, HZ
   Oguntuyo, K
   Rios, B
   Boodram, Z
   Huebsch, N
AF Guo, Jingxuan
   Jiang, Huanzhu
   Oguntuyo, Kasoorelope
   Rios, Brandon
   Boodram, Zoe
   Huebsch, Nathaniel
TI Interplay of Genotype and Substrate Stiffness in Driving the
   Hypertrophic Cardiomyopathy Phenotype in iPSC Micro Heart Muscle Arrays
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article
DE Induced pluripotent stem cells (iPSC); Hypertrophic cardiomyopathy
   (HCM); Overload
ID PLURIPOTENT STEM CELL; MYBPC3; MUTATION; PROLIFERATION; AFTERLOAD;
   DIFFERENTIATION; CARDIOMYOCYTES; CONTRACTILITY; CONSEQUENCES;
   DYSFUNCTION
AB Introduction In clinical and animal studies, Hypertrophic Cardiomyopathy (HCM) shares many similarities with non inherited cardiac hypertrophy induced by pressure overload (hypertension). This suggests a potential role for mechanical stress in priming tissues with mutation induced changes in the sarcomere to develop phenotypes associated with HCM, including hypercontractility and aberrant calcium handling. Here, we tested the hypothesis that heterozygous loss of function of Myosin Binding Protein C (MYBCP3(+/ ), mutations in which account for almost 50% of inherited HCM) combines with environmental stiffness to drive HCM phenotypes. Methods We differentiated isogenic control (WTC) and MYBPC3(+/ ) iPSC into cardiomyocytes using small molecule manipulation of Wnt signaling, and then purified them using lactate media. The purified cardiomyocytes were seeded into "dog bone" shaped stencil molds to form micro heart muscle arrays (mu HM). To mimic changes in myocardial stiffness stemming from pressure overload, we varied the rigidity of the substrates mu HM contract against. Stiffness levels ranged from those corresponding to fetal (5 kPa), healthy (15 kPa), pre fibrotic (30 kPa) to fibrotic (65 kPa) myocardium. Substrates were embedded with a thin layer of fluorescent beads to track contractile force, and parent iPSC were engineered to express the genetic calcium indicator, GCaMP6f. High speed video microscopy and image analysis were used to quantify calcium handling and contractility of mu HM. Results Substrate rigidity triggered physiological adaptation for both genotypes. However, MYBPC3(+/ ) mu HM showed a lower tolerance to substrate stiffness with the peak traction on 15 kPa, while WTC mu HM had peak traction on 30 kPa. MYBPC3(+/ ) mu HM exhibited hypercontractility, which was exaggerated by substrate rigidity. MYBPC3(+/ ) mu HM hypercontractility was associated with longer rise times for calcium uptake and force development, along with higher overall Ca2+ intake. Conclusion We found MYBPC3(+/ ) mutations cause iPSC mu HM to exhibit hypercontractility, and also a lower tolerance for mechanical stiffness. Understanding how genetics work in combination with mechanical stiffness to trigger and/or exacerbate pathophysiology may lead to more effective therapies for HCM.
C1 [Guo, Jingxuan] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63110 USA.
   [Jiang, Huanzhu; Oguntuyo, Kasoorelope; Rios, Brandon; Boodram, Zoe; Huebsch, Nathaniel] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA.
   [Huebsch, Nathaniel] McKelvey Sch Engn, NSF Sci & Technol Ctr Engn Mech, St Louis, MO USA.
   [Huebsch, Nathaniel] Washington Univ, Ctr Investigat Membrane Excitabil Dis, Ctr Cardiovasc Res, Ctr Regenerat Med, St Louis, MO 63130 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Huebsch, N (通讯作者)，Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA.
EM nhuebsch@wustl.edu
OI Jiang, Huanzhu/0000 0002 0781 896X; Oguntuyo,
   Kasoorelope/0000 0001 8479 8096; Huebsch, Nathaniel/0000 0002 3329 0214
FU Department of Biomedical Engineering at Washington University in St.
   Louis; American Heart Association [19CDA34730016, 828938]; National
   Institutes of Health MARC USTAR program at Washington University in St.
   Louis [T34GM083914]; American Heart Association (AHA) [19CDA34730016,
   828938] Funding Source: American Heart Association (AHA)
FX This work was supported by the Department of Biomedical Engineering at
   Washington University in St. Louis, the American Heart Association
   (19CDA34730016 to NH, predoctoral fellowship 828938 to JG). Brandon Rios
   acknowledges support from the National Institutes of Health MARC USTAR
   program at Washington University in St. Louis (T34GM083914). We thank
   Dr. Jonathan Moreno, Dr. Jonathan Silva, and Dr. Sharon Cresci for
   helpful discussions. We thank Dr. Srikanth Singamaneni and Dr. Jai Rudra
   for use of Li COR scanner and flow cytometer, along with Dr. Bruce R.
   Conklin and Mohammed A. Mandegar for generously providing the
   MYBPC3+/ iPSC line for these studies.
CR Barefield D, 2015, J MOL CELL CARDIOL, V79, P234, DOI 10.1016/j.yjmcc.2014.11.018
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI [10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000530]
   Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a
   Birket MJ, 2015, CELL REP, V13, P733, DOI 10.1016/j.celrep.2015.09.025
   Carrier L, 2015, GENE, V573, P188, DOI 10.1016/j.gene.2015.09.008
   Chang Huan J, 2009, JAMA, V302, P1720, DOI 10.1001/jama.302.15.1720
   Cohn R, 2019, STEM CELL REP, V12, P71, DOI 10.1016/j.stemcr.2018.11.015
   Coppini R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01391
   Coppini R, 2013, CIRCULATION, V127, P575, DOI 10.1161/CIRCULATIONAHA.112.134932
   Davis J, 2016, CELL, V165, P1147, DOI 10.1016/j.cell.2016.04.002
   Dutsch A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54665 2
   Fraysse B, 2012, J MOL CELL CARDIOL, V52, P1299, DOI 10.1016/j.yjmcc.2012.03.009
   Fridericia LS, 2003, ANN NONINVAS ELECTRO, V8, P343, DOI 10.1046/j.1542 474X.2003.08413.x
   García AJ, 1999, MOL BIOL CELL, V10, P785, DOI 10.1091/mbc.10.3.785
   Green EM, 2016, SCIENCE, V351, P617, DOI 10.1126/science.aad3456
   Gunda NSK, 2014, APPL SURF SCI, V305, P522, DOI 10.1016/j.apsusc.2014.03.130
   Guo J., 2020, Curr. Tissue Microenviron. Rep, DOI DOI 10.1007/S43152 020 00007 8
   Guo JX, 2021, ACS BIOMATER SCI ENG, V7, P2973, DOI 10.1021/acsbiomaterials.0c00318
   Hamilton PK, 2007, CLIN SCI, V113, P157, DOI 10.1042/CS20070080
   Harris SP, 2002, CIRC RES, V90, P594, DOI 10.1161/01.RES.0000012222.70819.64
   Helms AS, 2020, CIRC GENOM PRECIS ME, V13, P396, DOI 10.1161/CIRCGEN.120.002929
   Helms AS, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133782
   Hirt MN, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395 012 0307 z
   Huebsch N, 2016, SCI REP UK, V6, DOI 10.1038/srep24726
   Huebsch N, 2015, TISSUE ENG PART C ME, V21, P467, DOI [10.1089/ten.tec.2014.0283, 10.1089/ten.TEC.2014.0283]
   Jacques A, 2008, J MUSCLE RES CELL M, V29, P239, DOI 10.1007/s10974 009 9174 0
   Kuddannaya S, 2013, ACS APPL MATER INTER, V5, P9777, DOI 10.1021/am402903e
   Kumar A, 2019, NAT BIOMED ENG, V3, P137, DOI 10.1038/s41551 018 0344 5
   Kupfer ME, 2020, CIRC RES, V127, P207, DOI 10.1161/CIRCRESAHA.119.316155
   Lan F, 2013, CELL STEM CELL, V12, P101, DOI 10.1016/j.stem.2012.10.010
   Lee K, 2013, CHEM COMMUN, V49, P3028, DOI 10.1039/c3cc40799c
   Lehman SJ, 2019, CIRCULATION, V139, P1517, DOI 10.1161/CIRCULATIONAHA.118.034549
   Leonard A, 2018, J MOL CELL CARDIOL, V118, P147, DOI 10.1016/j.yjmcc.2018.03.016
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Lopes LR, 2019, INT J CARDIOL, V278, P173, DOI 10.1016/j.ijcard.2018.12.012
   Lorenzini M, 2020, J AM COLL CARDIOL, V76, P550, DOI 10.1016/j.jacc.2020.06.011
   Luan JY, 2016, ACS APPL MATER INTER, V8, P23509, DOI 10.1021/acsami.6b07252
   Luo Q, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57230 z
   Ma Z, 2018, NAT BIOMED ENG, V2, P955, DOI 10.1038/s41551 018 0280 4
   Marian AJ, 2017, CIRC RES, V121, P749, DOI 10.1161/CIRCRESAHA.117.311059
   Maron BJ, 2018, NEW ENGL J MED, V379, P655, DOI 10.1056/NEJMra1710575
   Maron BJ, 2013, LANCET, V381, P242, DOI 10.1016/S0140 6736(12)60397 3
   Marston S, 2012, J MUSCLE RES CELL M, V33, P75, DOI 10.1007/s10974 011 9268 3
   Marston SB, 2011, J CARDIOVASC TRANSL, V4, P245, DOI 10.1007/s12265 011 9266 2
   Mosqueira D, 2018, EUR HEART J, V39, P3879, DOI 10.1093/eurheartj/ehy249
   Nerbonne JM, 2001, CIRC RES, V89, P944, DOI 10.1161/hh2301.100349
   Ommen SR, 2020, CIRCULATION, V142, pe558, DOI 10.1161/CIR.0000000000000937
   Ong KC, 2016, EUR HEART J CARD IMG, V17, P604, DOI 10.1093/ehjci/jew024
   Palchesko RN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051499
   Ribeiro AJS, 2017, CIRC RES, V120, P1572, DOI 10.1161/CIRCRESAHA.116.310363
   Rodriguez ML, 2019, ACS BIOMATER SCI ENG, V5, P3663, DOI 10.1021/acsbiomaterials.8b01568
   Schmitt JP, 2003, CIRCULATION, V108, P1133, DOI 10.1161/01.CIR.0000086469.85750.48
   Seeger T, 2019, CIRCULATION, V139, P799, DOI 10.1161/CIRCULATIONAHA.118.034624
   Sen Chowdhry S, 2016, NAT REV CARDIOL, V13, P651, DOI 10.1038/nrcardio.2016.140
   Spudich JA, 2019, PFLUG ARCH EUR J PHY, V471, P701, DOI 10.1007/s00424 019 02259 2
   Stöhr A, 2013, J MOL CELL CARDIOL, V63, P189, DOI 10.1016/j.yjmcc.2013.07.011
   Taylor J, 2014, EUR HEART J, V35, P3081
   Teekakirikul P, 2010, J CLIN INVEST, V120, P3520, DOI 10.1172/JCI42028
   Toepfer CN, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat1199
   Tohyama S, 2013, CELL STEM CELL, V12, P127, DOI 10.1016/j.stem.2012.09.013
   Truitt R, 2018, JACC BASIC TRANSL SC, V3, P265, DOI 10.1016/j.jacbts.2017.12.007
   Undrovinas NA, 2010, J PHYSIOL SCI, V60, P245, DOI 10.1007/s12576 010 0092 0
   Van Driest SL, 2004, J AM COLL CARDIOL, V44, P1903, DOI 10.1016/j.jacc.2004.07.045
   Velicki L, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872 020 01807 4
   Wang G, 2014, NAT MED, V20, P616, DOI 10.1038/nm.3545
   Wu HD, 2019, EUR HEART J, V40, P3685, DOI 10.1093/eurheartj/ehz326
   Yoshie H, 2018, BIOPHYS J, V114, P2194, DOI 10.1016/j.bpj.2018.02.045
NR 67
TC 12
Z9 14
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1865 5025
EI 1865 5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD OCT
PY 2021
VL 14
IS 5
SI SI
BP 409
EP 425
DI 10.1007/s12195 021 00684 x
EA JUN 2021
PG 17
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biophysics; Engineering
GA WN0OY
UT WOS:000667021700001
PM 34777601
DA 2025 08 17
ER

PT J
AU Chu, GD
   Niu, HT
AF Chu, Guangdi
   Niu, Haitao
TI Knowledge mapping and global trends in the field of low intensity pulsed
   ultrasound and endocrine and metabolic diseases: a bibliometric and
   visual analysis from 2012 to 2022
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE low intensity pulsed ultrasound; bibliometrics; visualization; endocrine
   and metabolic diseases; global trend
ID PROMOTES; STIMULATION; LIPUS; REGENERATION; OSTEOBLASTS; THERAPY;
   RELEASE; IMPACT; CELLS
AB BackgroundLow intensity pulsed ultrasound (LIPUS) is a highly promising therapeutic method that has been widely used in rehabilitation, orthopedics, dentistry, urology, gynecology, and other multidisciplinary disease diagnoses and treatments. It has attracted extensive attention worldwide. However, there is currently a lack of comprehensive and systematic research on the current status and future development direction of the LIPUS field. Therefore, this study comprehensively analyzed LIPUS related reports from the past decade using bibliometrics methods, and further conducted research specifically focusing on its application in endocrine and metabolic diseases.MethodsWe downloaded LIPUS literature from 2012 to 2022 reported in the Web of Science Core Collection Science Citation Index Expanded and Social Sciences Citation Index, and used bibliometric analysis software such as VOSviewer and CiteSpace to execute the analysis and visualize the results.ResultsWe searched for 655 English articles published on LIPUS from 2012 to 2022. China had the highest number of published articles and collaborations between China and the United States were the closest in this field. Chongqing Medical University was the institution with the highest output, and ULTRASOUND IN MEDICINE AND BIOLOGY was the journal with the most related publications. In recent years, research on the molecular mechanisms of LIPUS has continued to deepen, and its clinical applications have also continued to expand. The application of LIPUS in major diseases such as oxidative stress, regeneration mechanism, and cancer is considered to be a future research direction, especially in the field of endocrinology and metabolism, where it has broad application value.ConclusionGlobal research on LIPUS is expected to continue to increase, and future research will focus on its mechanisms of action and clinical applications. This study comprehensively summarizes the current development status and global trends in the field of LIPUS, and its research progress in the field of endocrine and metabolic diseases, providing valuable reference for future research in this field.
C1 [Chu, Guangdi; Niu, Haitao] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao, Peoples R China.
C3 Qingdao University
RP Niu, HT (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao, Peoples R China.
EM niuht0532@126.com
RI Chu, Guangdi/AED 1835 2022
FU National Natural Science Foundation of China [82071750]; Taishan Scholar
   Program of Shandong Province [tstp20221165]
FX This work was supported by the National Natural Science Foundation of
   China under grant numbers 82071750; Taishan Scholar Program of Shandong
   Province under grant number tstp20221165.
CR Acheta J, 2022, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.812588
   Agarwal A, 2016, ASIAN J ANDROL, V18, P296, DOI 10.4103/1008 682X.171582
   Al Daghreer S, 2014, ULTRASOUND MED BIOL, V40, P1187, DOI 10.1016/j.ultrasmedbio.2013.12.016
   Bahammam M, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/4505063
   Busse JW, 2016, BMJ BRIT MED J, V355, DOI 10.1136/bmj.i5351
   Carina V, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0868 2
   Castellanos IS, 2017, ULTRASOUND MED BIOL, V43, P1210, DOI 10.1016/j.ultrasmedbio.2017.01.007
   Chan YS, 2010, ULTRASOUND MED BIOL, V36, P743, DOI 10.1016/j.ultrasmedbio.2010.02.010
   Chen HR, 2022, J SEX MED, V19, P1536, DOI 10.1016/j.jsxm.2022.06.009
   Chen YM, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03296 6
   Cheng K, 2014, ULTRASOUND MED BIOL, V40, P1609, DOI 10.1016/j.ultrasmedbio.2014.03.002
   Chiang PK, 2019, MED HYPOTHESES, V122, P19, DOI 10.1016/j.mehy.2018.10.014
   Claes L, 2007, PROG BIOPHYS MOL BIO, V93, P384, DOI 10.1016/j.pbiomolbio.2006.07.021
   El Bialy T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030804
   Fung CH, 2014, ULTRASONICS, V54, P1358, DOI 10.1016/j.ultras.2014.02.003
   Fung CH, 2012, ULTRASOUND MED BIOL, V38, P745, DOI 10.1016/j.ultrasmedbio.2012.01.022
   Griffin XL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008579.pub3
   Han S, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010418
   Harrison A, 2021, INJURY, V52, pS91, DOI 10.1016/j.injury.2021.05.002
   Harrison A, 2016, ULTRASONICS, V70, P45, DOI 10.1016/j.ultras.2016.03.016
   Hu JZ, 2014, J ORTHOP RES, V32, P204, DOI 10.1002/jor.22505
   Kaur H, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051303
   Kaur H, 2017, J ULTRAS MED, V36, P109, DOI 10.7863/ultra.15.06063
   Kip B, 2023, CURR DRUG DELIV, V20, P1380, DOI 10.2174/1567201819666220627100857
   Leighton R, 2017, INJURY, V48, P1339, DOI 10.1016/j.injury.2017.05.016
   Li ZTY, 2023, ANDROLOGY US, V11, P1188, DOI 10.1111/andr.13406
   Liang XZ, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1172750
   Moncion A, 2017, BIOMATERIALS, V140, P26, DOI 10.1016/j.biomaterials.2017.06.012
   Montalti CS, 2013, BRAZ J PHYS THER, V17, P343, DOI 10.1590/S1413 35552012005000101
   Müller A, 2008, EUR UROL, V53, P635, DOI 10.1016/j.eururo.2007.06.032
   Mykoniatis I, 2021, PROSTATE CANCER P D, V24, P370, DOI 10.1038/s41391 020 00284 2
   Nonogaki K, 2016, INT J CARDIOL, V215, P147, DOI 10.1016/j.ijcard.2016.04.062
   Poolman RW, 2017, BMJ BRIT MED J, V356, DOI 10.1136/bmj.j576
   Qin HC, 2023, INT J BIOL SCI, V19, P1123, DOI 10.7150/ijbs.79685
   Qin Y, 2022, INT J HYPERTHER, V39, P181, DOI 10.1080/02656736.2022.2025924
   Schandelmaier S, 2017, BMJ BRIT MED J, V356, DOI 10.1136/bmj.j656
   Song SR, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2021.103558
   Song WS, 2022, ULTRASOUND MED BIOL, V48, P265, DOI 10.1016/j.ultrasmedbio.2021.10.001
   Sun SX, 2021, ULTRASONICS, V113, DOI 10.1016/j.ultras.2021.106360
   Sun SX, 2020, ULTRASOUND MED BIOL, V46, P108, DOI 10.1016/j.ultrasmedbio.2019.08.025
   Sung CY, 2022, CEREB CORTEX, V32, P176, DOI 10.1093/cercor/bhab201
   Tan Y, 2021, ASIAN J ANDROL, V23, P602, DOI 10.4103/aja.aja_25_21
   Tanaka E, 2015, ANN BIOMED ENG, V43, P871, DOI 10.1007/s10439 015 1274 y
   Tang HJ, 2021, ULTRASOUND MED BIOL, V47, P2377, DOI 10.1016/j.ultrasmedbio.2021.04.022
   Tang L, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395 017 0145 7
   Toyama Y, 2012, CARDIOVASC RES, V95, P448, DOI 10.1093/cvr/cvs173
   Verze P, 2020, ASIAN J ANDROL, V22, P379, DOI 10.4103/aja.aja_121_19
   Wu FP, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.939433
   Wu SL, 2009, PATHOBIOLOGY, V76, P99, DOI 10.1159/000209387
   Xia P, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0733 9
   Xin ZC, 2016, TRANSL ANDROL UROL, V5, P255, DOI 10.21037/tau.2016.02.04
   Xu JK, 2012, J BIOL CHEM, V287, P26200, DOI 10.1074/jbc.M112.349811
   Yang BC, 2019, UROLOGY, V123, DOI 10.1016/j.urology.2018.09.020
   Yang FY, 2023, LIFE SCI, V325, DOI 10.1016/j.lfs.2023.121769
   Yang FY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231710034
   Ye K, 2023, CNS NEUROSCI THER, V29, P3239, DOI 10.1111/cns.14256
   Ying SQ, 2020, THERANOSTICS, V10, P9789, DOI 10.7150/thno.42508
   Zhang L, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1168744
   Zura R, 2015, INJURY, V46, P2036, DOI 10.1016/j.injury.2015.05.042
NR 59
TC 4
Z9 6
U1 1
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD SEP 5
PY 2023
VL 14
AR 1237864
DI 10.3389/fendo.2023.1237864
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA R8GD0
UT WOS:001066676600001
PM 37732128
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ma, CY
   Liu, GF
   Wang, CJ
   Guo, Y
   Guan, WJ
   Liu, CQ
   Wen, HB
AF Ma, Caiyun
   Liu, Gaofeng
   Wang, Chunjing
   Guo, Yu
   Guan, Weijun
   Liu, Changqing
   Wen, Hebao
TI In Vitro Culture and Multipotency Evaluation of Broiler Umbilical Cord
   Mesenchymal Stem Cells
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article
DE UMSCs; broiler; biological characteristics; multilineage potential;
   regenerative therapies
ID BIOLOGICAL CHARACTERISTICS; STROMAL CELLS; DIFFERENTIATION
AB Umbilical cord mesenchymal stem cells (UMSCs) from fetal tissues have become a valuable source of cell regeneration therapy due to their low immunogenicity, high plasticity and antimicrobial peptides. Most researches about UMSCs mainly focused on humans, mice, rabbits and other mammals, but it is still unknown in broiler. To the best of our knowledge, we first established a broiler derived UMSCs line from noncontroversial Wharton's jelly of umbilical cord. The detection of biological characteristics showed UMSCs showed the morphological characteristics of fibroblasts and could be cultured to 26 generations in vitro, and maintained diploid chromosomes (2n=78) by G banding analysis. Cell cycle of UMSCs showed the rate of G0/G1 was about 76.7 80.9%. Moreover, UMSCs could express mesenchymal markers (CD29, CD90, CD71, and CD44), but not hematopoietic marker (CD34) and endothelial marker (CD31). Additionally, UMSCs could be efficiently induced to transdifferentiate into three germ layer cells, such as adipocytes, osteoblasts, chondrocytes, hepatocytes, epithelia, and neurogenic cells. These results demonstrated UMSCs have the essential characteristics of MSCs, and can be used as an attractive candidate for cell regenerative therapy and the study of regulatory mechanisms associated with selective differentiation.
C1 [Ma, Caiyun; Liu, Gaofeng; Wang, Chunjing; Guo, Yu; Liu, Changqing; Wen, Hebao] Bengbu Med Coll, Sch Life Sci, Bengbu, Anhui, Peoples R China.
   [Guan, Weijun] Chinese Acad Agr Sci, Inst Beijing Anim Sci & Vet, Beijing, Peoples R China.
C3 Bengbu Medical University; Chinese Academy of Agricultural Sciences
RP Liu, CQ; Wen, HB (通讯作者)，Bengbu Med Coll, Sch Life Sci, Bengbu, Anhui, Peoples R China.
EM hebao_wen@126.com
RI Liu, Changqing/GRX 4397 2022; Wang, Chun Jing/J 7223 2019
OI Liu, Changqing/0000 0002 1059 6528; 
FU National Scientific Foundation of China [81771381]; Research Project of
   Anhui Educational Committee [KJ2021A0784, KJ2021A0774, KJ2021ZD0085,
   2022AH051434, SK2020ZD32]; Anhui Provincial Key Research and Development
   Project [2022e07020030, 2022e07020032]; Natural Science Research Project
   of Bengbu Medical College [2021byfy002]; Bengbu Medical College
   Department level Key Laboratory Open Project [202110367058];
   Undergraduate Training Program for Innovation and Entrepreneurship
   [2020byzd019];  [AHTT2022B001]
FX This research was funded by grants from the National Scientific
   Foundation of China (81771381) , the Research Project of Anhui
   Educational Committee (KJ2021A0784, KJ2021A0774, KJ2021ZD0085,
   2022AH051434, SK2020ZD32) , Anhui Provincial Key Research and
   Development Project (2022e07020030, 2022e07020032) , the Natural Science
   Research Project of Bengbu Medical College (2020byzd019, 2021byfy002) ,
   Bengbu Medical College Department level Key Laboratory Open Project
   (AHTT2022B001) and the Undergraduate Training Program for Innovation and
   Entrepreneurship (202110367058) .
CR Asano Takayuki, 2006, V329, P459
   Bai CY, 2013, MOL CELL BIOCHEM, V376, P95, DOI 10.1007/s11010 012 1553 y
   Borzou B, 2020, BIOPRESERV BIOBANK, V18, P389, DOI 10.1089/bio.2019.0103
   Chatgilialoglu A, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0487 4
   Chen FH, 2018, CAN J VET RES, V82, P216
   Panerari ACD, 2020, BRAZ ARCH BIOL TECHN, V63, DOI 10.1590/1678 4324 2020190260
   Gibellini L, 2015, EXP CELL RES, V337, P160, DOI 10.1016/j.yexcr.2015.07.031
   He B, 2012, GEN COMP ENDOCR, V176, P173, DOI 10.1016/j.ygcen.2012.01.012
   Ibrahim AM, 2015, MICROSC RES TECHNIQ, V78, P667, DOI 10.1002/jemt.22520
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Li XC, 2016, INT J BIOL SCI, V12, P53, DOI 10.7150/ijbs.12199
   Li YY, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/8834590
   Lysy PA, 2008, DIFFERENTIATION, V76, P1057, DOI 10.1111/j.1432 0436.2008.00287.x
   Ma CY, 2017, CRYOBIOLOGY, V75, P7, DOI 10.1016/j.cryobiol.2017.03.003
   Ma J, 2017, STEM CELL TRANSL MED, V6, P51, DOI 10.5966/sctm.2016 0038
   Ma YY, 2016, AM J TRANSL RES, V8, P5235
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Monaco E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032481
   Mu F, 2020, POULTRY SCI, V99, P6410, DOI 10.1016/j.psj.2020.09.086
   Niemeyer P, 2007, TISSUE ENG, V13, P111, DOI 10.1089/ten.2006.0114
   Niwa H, 2009, NATURE, V460, P118, DOI 10.1038/nature08113
   Park YB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165446
   Paunescu V, 2007, J CELL MOL MED, V11, P502, DOI 10.1111/j.1582 4934.2007.00041.x
   Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603
   Rodrigues CE, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0475 8
   Salvatore A, 2020, UROL J, V17, P391, DOI 10.22037/uj.v0i0.5351
   Do TK, 2020, BRAZ ARCH BIOL TECHN, V63, DOI 10.1590/1678 4324 2020200082
   Uranio MF, 2014, MOL REPROD DEV, V81, P539, DOI 10.1002/mrd.22322
   Waclawczyk S, 2010, J CELL PHYSIOL, V225, P545, DOI 10.1002/jcp.22237
   Wang JJ, 2018, BRIT POULTRY SCI, V59, P521, DOI 10.1080/00071668.2018.1490495
   Wecht S, 2016, RESPIROLOGY, V21, P1366, DOI 10.1111/resp.12911
   Yusoff Z, 2016, Med J Malaysia, V71, P105
NR 33
TC 0
Z9 0
U1 1
U2 15
PU INST TECNOLOGIA PARANA
PI CURITIBA PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775 CIC, 81350 010 CURITIBA PARANA,
   BRAZIL
SN 1516 8913
EI 1678 4324
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PY 2023
VL 66
AR e2023220031
DI 10.1590/1678 4324 2023220031
PG 11
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA J7KS8
UT WOS:001011380000001
OA gold
DA 2025 08 17
ER

PT J
AU Chiellini, G
   Rapposelli, S
   Zhu, JG
   Massarelli, I
   Saraceno, M
   Bianucci, AM
   Plum, LA
   Clagett Dame, M
   DeLuca, HF
AF Chiellini, Grazia
   Rapposelli, Simona
   Zhu, Jinge
   Massarelli, Ilaria
   Saraceno, Marilena
   Bianucci, Anna Maria
   Plum, Lori A.
   Clagett Dame, Margaret
   DeLuca, Hector F.
TI Synthesis and biological activities of vitamin D like inhibitors of
   CYP24 hydroxylase
SO STEROIDS
LA English
DT Article
DE 1,25 Dihydroxyvitamin D 3; Cytochrome P450 inhibitors; CYP24A1;
   Cyclopropylamines; Cancer therapy; Molecular docking
ID MECHANISM BASED INHIBITOR; 1 ALPHA,25 DIHYDROXYVITAMIN D 3; SELECTIVE
   INHIBITORS; INACTIVATION; OXIDASE; ANALOGS; BINDING; CANCER;
   KETOCONAZOLE; MUTATION
AB Selective inhibitors of CYP24A1 represent an important synthetic target in a search for novel vitamin D compounds of therapeutic value. In the present work, we show the synthesis and biological properties of two novel side chain modified 2 methylene 19 nor 1,25(OH)(2)D 3 analogs, the 22 imidazole 1 yl derivative 2 (VIMI) and the 25 N cyclopropylamine compound 3 (CPA1), which were efficiently prepared in convergent syntheses utilizing the Lythgoe type Horner Wittig olefination reaction. When tested in a cell free assay, both compounds were found to be potent competitive inhibitors of CYP24A1, with the cyclopropylamine analog 3 exhibiting an 80 1 selective inhibition of CYP24A1 over CYP27B1. Addition of 3 to a mouse osteoblast culture sustained the level of 1,25(OH)(2)D 3, further demonstrating its effectiveness in CYP24A1 inhibition. Importantly, the in vitro effects on human promyeloid leukemia (HL 60) cell differentiation by 3 were nearly identical to those of 1,25(OH)(2)D 3 and in vivo the compound showed low calcemic activity. Finally, the results of preliminary theoretical studies provide useful insights to rationalize the ability of analog 3 to selectively inhibit the cytochrome P450 isoform CYP24A1. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Chiellini, Grazia; Zhu, Jinge; Plum, Lori A.; Clagett Dame, Margaret; DeLuca, Hector F.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
   [Chiellini, Grazia] Univ Pisa, Dipartimento Sci Uomo & Ambiente, I 56126 Pisa, Italy.
   [Rapposelli, Simona; Saraceno, Marilena; Bianucci, Anna Maria] Univ Pisa, Dipartimento Sci Farmaceut, I 56126 Pisa, Italy.
   [Massarelli, Ilaria] Ist Nazl Sci & Tecnol Mat, I 50121 Florence, Italy.
   [Bianucci, Anna Maria] Int Ctr Studies & Res Biomed ICB, Luxembourg, Luxembourg.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Pisa; University of Pisa
RP DeLuca, HF (通讯作者)，Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.
EM deluca@bioChem.wisc.edu
RI Chiellini, Grazia/AAC 5877 2022; Rapposelli, Simona/D 1595 2010
OI Rapposelli, Simona/0000 0003 0146 6358
FU Wisconsin Alumni Research Foundation; NIH [P41RR02301, P41GM66326,
   RR02781, RR08438]; University of Wisconsin; NSF [DMB 8415048,
   OIA 9977486, BIR 9214394]; US Department of Agriculture
FX The work was supported in part by funds from the Wisconsin Alumni
   Research Foundation. We gratefully acknowledge Jean Prahl, and Jennifer
   Vaughan, for carrying out the in vitro studies, and Erin Gudmundson for
   conducting the in vivo studies. We thank Dr. Mark Anderson for his
   assistance in recording NMR spectra. This study made use of the National
   Magnetic Resonance Facility at Madison, which was supported by the NIH
   Grants P41RR02301 (BRTP/NCRR) and P41GM66326 (NIGMS). Additional
   equipment was purchased with funds from the University of Wisconsin, the
   NIH (RR02781 and RR08438), the NSF (DMB 8415048, OIA 9977486, and
   BIR 9214394), and the US Department of Agriculture. The authors
   gratefully acknowledge and wish to extent their deep appreciation to
   Prof. Aldo Balsamo for critically reviewing this manuscript.
CR Aboraia AS, 2010, BIOORGAN MED CHEM, V18, P4939, DOI 10.1016/j.bmc.2010.06.011
   ANGELASTRO MR, 1989, BIOCHEM BIOPH RES CO, V162, P1571, DOI 10.1016/0006 291X(89)90854 1
   Annalora AJ, 2010, J MOL BIOL, V396, P441, DOI 10.1016/j.jmb.2009.11.057
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bikle D, 2009, J CLIN ENDOCR METAB, V94, P26, DOI 10.1210/jc.2008 1454
   Chiellini G, 2008, BIOORGAN MED CHEM, V16, P8563, DOI 10.1016/j.bmc.2008.08.011
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   DeLuca HF, 2008, NUTR REV, V66, pS73, DOI 10.1111/j.1753 4887.2008.00105.x
   Eelen G, 2007, CURR MED CHEM, V14, P1893
   Glebocka A, 2006, J MED CHEM, V49, P2909, DOI 10.1021/jm051082a
   Grzywacz P, 2010, J MED CHEM, V53, P8642, DOI 10.1021/jm1010447
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   HANZLIK RP, 1979, J MED CHEM, V22, P759, DOI 10.1021/jm00193a002
   Holick MF, 2008, MOL ASPECTS MED, V29, P361, DOI 10.1016/j.mam.2008.08.008
   Jones G, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1777, DOI 10.1016/B978 0 12 373884 4.00087 2
   Kahraman M, 2004, J MED CHEM, V47, P6854, DOI 10.1021/jm040129+
   Lee HB, 2001, J AM CHEM SOC, V123, P11322, DOI 10.1021/ja017043f
   LEY SV, 1994, SYNTHESIS STUTTGART, P639
   Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071
   LYTHGOE B, 1976, J CHEM SOC PERK T 1, P2386, DOI 10.1039/p19760002386
   Mitchell DJ, 2001, BIOCHEMISTRY US, V40, P8523, DOI 10.1021/bi0105126
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096 987X(19981115)19:14<1639::AID JCC10>3.0.CO;2 B
   Njar VCO, 1995, J ENZYM INHIB, V10, P47, DOI 10.3109/14756369509021470
   Peehl DM, 2002, J UROLOGY, V168, P1583, DOI 10.1016/S0022 5347(05)64525 9
   Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059
   Polasek TM, 2006, BRIT J CLIN PHARMACO, V61, P570, DOI 10.1111/j.1365 2125.2006.02627.x
   Posner GH, 2004, J STEROID BIOCHEM, V89 90, P5, DOI 10.1016/j.jsbmb.2004.03.044
   Posner GH, 2001, BIOORGAN MED CHEM, V9, P2365, DOI 10.1016/S0968 0896(01)00159 6
   Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005
   REINHARDT TA, 1989, ARCH BIOCHEM BIOPHYS, V272, P459, DOI 10.1016/0003 9861(89)90240 3
   Schuster I, 2003, J CELL BIOCHEM, V88, P372, DOI 10.1002/jcb.10365
   Schuster I, 2001, STEROIDS, V66, P409, DOI 10.1016/S0039 128X(00)00159 8
   SHAH MA, 1993, J BIOL CHEM, V268, P11580
   Sicinski RR, 1998, J MED CHEM, V41, P4662, DOI 10.1021/jm9802618
   SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19
   Totah RA, 2002, J AM CHEM SOC, V124, P10000, DOI 10.1021/ja020559u
   Vintém APB, 2005, BIOORGAN MED CHEM, V13, P3487, DOI 10.1016/j.bmc.2005.02.061
   Yamamoto K, 2005, J BIOL CHEM, V280, P30511, DOI 10.1074/jbc.M505244200
   Yee SW, 2004, BIOORG MED CHEM LETT, V14, P5651, DOI 10.1016/j.bmcl.2004.08.040
   Zhu JG, 2010, BIOCHEMISTRY US, V49, P10403, DOI 10.1021/bi101488p
NR 40
TC 26
Z9 27
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD FEB
PY 2012
VL 77
IS 3
BP 212
EP 223
DI 10.1016/j.steroids.2011.11.007
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 895UV
UT WOS:000300523000006
PM 22133546
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Grossner, T
   Gotterbarm, T
   Gerbaudo, VH
   Haberkorn, U
   Spector, M
AF Grossner, Tobias
   Gotterbarm, Tobias
   Gerbaudo, Victor H.
   Haberkorn, Uwe
   Spector, Myron
TI <SUP>99m</SUP>Tc Methyl Diphosphonate Binding to Mineral Deposits in
   Cultures of Marrow Derived Mesenchymal Stem Cells in Osteogenic Medium
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE mesenchymal stem cells; osteogenic differentiation; mineral
   quantification; technetium
ID BONE SCINTIGRAPHY; IN VITRO; STROMAL CELLS; TISSUE; DIFFERENTIATION;
   CALCIFICATION; OSTEOBLASTS; MECHANISMS; THERAPY; REPAIR
AB Osteogenic differentiation of adult mesenchymal stem cells (MSCs) is a promising method for the therapy of critical size bone defects and other applications, drawing attention to the importance of in vitro assays for its evaluation. While there are standardized protocols to induce osteogenic differentiation in monolayer cultures, there is a lack of validated nondestructive procedures to quantify the osteogenic potential of MSCs directly by accessing the mineral deposition. In this study, we present a new method to determine the osteogenic potential of MSCs using the radioactive tracer, (99m)Technetium methylene diphosphonate (Tc 99m MDP), to bind in vitro to newly produced mineral deposits from osteogenic induced stem cells. Thirty five millimeter Petri dishes were seeded with goat and human MSCs and differentiated into the osteogenic lineage. Tc 99m MDP was applied to each dish, and acquisition of the bound tracer was imaged with a gamma camera. The results revealed a significantly higher uptake in the osteogenic differentiated MSCs for both goat and human cells (p < 0.008 goat; 0.01 human), compared with controls grown in expansion medium. We were able to show that Tc 99m MDP labeling is a suitable method to quantify the amount of extracellular mineral deposited by MSCs. Goat and human MSCs displayed similar uptake characteristics (Spearman Rho Correlation coefficient r = 0.603). The radionuclide method was validated by quantitative Alizarin Red staining, which showed a high correlation (Spearman Rho Correlation coefficient r = 0.668). This radionuclide method opens a new approach for evaluating osteogenic potential of MSCs and for longitudinal studies of the process. Impact Statement The work is notable for describing a highly sensitive, quantitative, and nondestructive method for evaluating the in vitro amount of mineral accompanying different types of osteogenic differentiation of mesenchymal stem cells in a monolayer cell culture. What is so unique and useful about the method is that it has the potential to be used to define the kinetics of the differentiation process, reflected in the mineralization, without destroying the monolayer. Therefore, it remains intact for further experiments.
C1 [Grossner, Tobias; Gotterbarm, Tobias] Univ Hosp Heidelberg, Clin Orthoped & Trauma Surg, Ctr Orthoped Trauma Surg & Paraplegiol, Schlierbacher Landstr 200 A, D 69118 Heidelberg, Germany.
   [Grossner, Tobias; Gotterbarm, Tobias; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn, Boston, MA USA.
   [Grossner, Tobias; Gotterbarm, Tobias; Spector, Myron] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
   [Gerbaudo, Victor H.] Harvard Med Sch, Brigham & Womens Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02115 USA.
   [Haberkorn, Uwe] Univ Hosp Heidelberg, Dept Nucl Med, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Harvard University; Harvard
   University Medical Affiliates; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Boston Healthcare System;
   Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Brigham & Women's Hospital; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Brigham & Women's
   Hospital; Ruprecht Karls University Heidelberg
RP Grossner, T (通讯作者)，Univ Hosp Heidelberg, Clin Orthoped & Trauma Surg, Ctr Orthoped Trauma Surg & Paraplegiol, Schlierbacher Landstr 200 A, D 69118 Heidelberg, Germany.
EM tobias.grossner@med.uni heidelberg.de
RI Gotterbarm, Tobias/AAM 3184 2020
OI Spector, Myron/0000 0003 3328 4858
FU U.S. Department of Veterans Affairs
FX Funding was provided, in part, by the U.S. Department of Veterans
   Affairs.
CR Abdallah BM, 2009, J CELL PHYSIOL, V218, P9, DOI 10.1002/jcp.21572
   Arinzeh Treena Livingston, 2005, Foot Ankle Clin, V10, P651, DOI 10.1016/j.fcl.2005.06.004
   Aspenberg P, 1996, ACTA ORTHOP SCAND, V67, P377, DOI 10.3109/17453679609002335
   BAGAMBISA FB, 1993, J BIOMED MATER RES, V27, P1047, DOI 10.1002/jbm.820270810
   Basdra E K, 1999, J Orofac Orthop, V60, P77, DOI 10.1007/BF01298958
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   BOYDE A, 1976, CELL TISSUE RES, V166, P65, DOI 10.1007/BF00215125
   BROWN ML, 1993, J NUCL MED, V34, P2236
   Bruder SP, 1999, CLIN ORTHOP RELAT R, pS68
   Clines GA, 2010, CURR OPIN ORGAN TRAN, V15, P73, DOI 10.1097/MOT.0b013e328333d52c
   COLLIER BD, 1993, J NUCL MED, V34, P2241
   Csaki C, 2008, ANN ANAT, V190, P395, DOI 10.1016/j.aanat.2008.07.007
   DiMarino AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00201
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   FOGELMAN I, 1993, J NUCL MED, V34, P2247
   Granero Molto F, 2008, EXPERT OPIN BIOL TH, V8, P255, DOI 10.1517/14712598.8.3.255 
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guilak F, 2010, CLIN ORTHOP RELAT R, V468, P2530, DOI 10.1007/s11999 010 1410 9
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   IRVING JT, 1968, CLIN ORTHOP RELAT R, P237
   IRVING JT, 1973, CLIN ORTHOP RELAT R, P225
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kwan MD, 2008, HUM MOL GENET, V17, pR93, DOI 10.1093/hmg/ddn071
   Layman DL, 1998, J BIOMED MATER RES, V40, P282, DOI 10.1002/(SICI)1097 4636(199805)40:2<282::AID JBM13>3.0.CO;2 O
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582 4934.2009.00857.x
   Slater BJ, 2008, EXPERT OPIN BIOL TH, V8, P885, DOI 10.1517/14712598.8.7.885 
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Squire MW, 1996, BIOMATERIALS, V17, P725, DOI 10.1016/0142 9612(96)86743 3
   Stanford CM, 2000, J BIOMECH, V33, P63, DOI 10.1016/S0021 9290(99)00173 6
   Undale AH, 2009, MAYO CLIN PROC, V84, P893, DOI 10.4065/84.10.893
   VILMANN H, 1969, J ANAT, V105, P533
   von Kóssa J, 1901, BEITR PATHOL ANAT AL, V29, P163
   Wang H, 2005, BONE, V36, P84, DOI 10.1016/j.bone.2004.08.021
   Welling M, 1995, Q J Nucl Med, V39, P89
   Wong KK, 2013, J NUCL MED, V54, P590, DOI 10.2967/jnumed.112.114298
   Yamamoto M, 1997, J BIOMED MATER RES, V37, P29, DOI 10.1002/(SICI)1097 4636(199710)37:1<29::AID JBM4>3.0.CO;2 L
NR 38
TC 8
Z9 8
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD JAN 1
PY 2019
VL 25
IS 1
BP 49
EP 57
DI 10.1089/ten.tec.2018.0299
PG 9
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA HU5AX
UT WOS:000465289000004
PM 30560717
DA 2025 08 17
ER

PT J
AU Bonelli, M
   Ferner, E
   Göschl, L
   Blüml, S
   Hladik, A
   Karonitsch, T
   Kiener, HP
   Byrne, R
   Niederreiter, B
   Steiner, CW
   Rath, E
   Bergmann, M
   Smolen, JS
   Scheinecker, C
AF Bonelli, M.
   Ferner, E.
   Goeschl, L.
   Blueml, S.
   Hladik, A.
   Karonitsch, T.
   Kiener, H. P.
   Byrne, R.
   Niederreiter, B.
   Steiner, C. W.
   Rath, E.
   Bergmann, M.
   Smolen, J. S.
   Scheinecker, C.
TI Abatacept (CTLA 4IG) treatment reduces the migratory capacity of
   monocytes in patients with rheumatoid arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID TRANSENDOTHELIAL MIGRATION; T CELL; ACTIVATION; COSTIMULATION;
   OSTEOCLASTS; ADHESION; SUBSETS
AB Objective The binding of abatacept (CTLA 4Ig) to the B7 ligands CD80 and CD86 prevents the engagement of CD28 on T cells and thereby prevents effector T cell activation. In addition, a direct effect of CTLA 4Ig on antigen presenting cells (APCs) could contribute to the therapeutic effect. To further elucidate the mechanism of CTLA 4Ig, we performed phenotype and functional analyses of APCs in patients with rheumatoid arthritis (RA) before and after the initiation of CTLA 4Ig therapy. Methods Peripheral blood mononuclear cells were analyzed before and at 2 and 4 weeks after the initiation of CTLA 4Ig therapy. Proportions of APCs were determined by flow cytometry. CD14+ monocytes were further analyzed for the expression of costimulatory and adhesion molecules and for their transendothelial migratory capacity in vitro. In addition, CD14+ monocytes from healthy controls were analyzed for their migratory and spreading capacity. Results Proportions and absolute numbers of monocytes were significantly increased in RA patients treated with CTLA 4Ig. The expression of several adhesion molecules was significantly diminished. In addition, monocytes displayed a significant reduction in their endothelial adhesion and transendothelial migratory capacity upon treatment with CTLA 4Ig. Likewise, isolated monocytes from healthy controls revealed a significant reduction in their migratory and spreading activity after preincubation with CTLA 4Ig or anti CD80 and anti CD86 antibodies. Conclusion We describe direct effects of CTLA 4Ig therapy on phenotype and functional characteristics of monocytes in RA patients that might interfere with the migration of monocytes to the synovial tissue. This additional mechanism of CTLA 4Ig might contribute to the beneficial effects of CTLA 4Ig treatment in RA patients.
C1 [Bonelli, M.; Ferner, E.; Goeschl, L.; Blueml, S.; Hladik, A.; Karonitsch, T.; Kiener, H. P.; Byrne, R.; Niederreiter, B.; Steiner, C. W.; Rath, E.; Bergmann, M.; Smolen, J. S.; Scheinecker, C.] Med Univ Vienna, A 1090 Vienna, Austria.
C3 Medical University of Vienna
RP Scheinecker, C (通讯作者)，Med Univ Vienna, Div Rheumatol, Gen Hosp Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM clemens.scheinecker@meduniwien.ac.at
RI Bonelli, Michael/JZC 7580 2024; Bergmann, Michael/GZK 7700 2022; Smolen,
   Josef/ADI 7087 2022; Goschl, lisa/MIU 4253 2025
OI Bonelli, Michael/0000 0002 6122 7482; Karonitsch,
   Thomas/0000 0001 8310 6211; Bluml, Stephan/0000 0002 2758 4400;
   Bergmann, Michael/0000 0001 8529 1166; 
FU Osterreichische Nationalbank Jubilaumsfond [12754]; European Union
   Seventh Framework Programme (project Masterswitch)
   [HEALTH F2 2008 223404]; Innovative Medicines Initiative Joint
   Undertaking under (BTCure) [115142]
FX Supported by the Osterreichische Nationalbank Jubilaumsfond (grant
   12754), the European Union Seventh Framework Programme (project
   Masterswitch; HEALTH F2 2008 223404), and the Innovative Medicines
   Initiative Joint Undertaking under grant agreement 115142 (BTCure).
CR Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100
   Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600 065X.2003.00009.x
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   BALIGA P, 1994, TRANSPLANTATION, V58, P1082, DOI 10.1097/00007890 199411270 00005
   Cairns AP, 2002, RHEUMATOL INT, V21, P189, DOI 10.1007/s00296 001 0165 8
   Carman JA, 2009, J CLIN IMMUNOL, V29, P479, DOI 10.1007/s10875 009 9282 z
   FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846
   Grohmann U, 2003, J IMMUNOL, V171, P2581, DOI 10.4049/jimmunol.171.5.2581
   Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201
   McInnes IB, 2000, ARTHRITIS RES, V2, P374, DOI 10.1186/ar115
   Munn DH, 2004, J IMMUNOL, V172, P4100, DOI 10.4049/jimmunol.172.7.4100
   Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235
   OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140
   PIETSCHMANN P, 1992, J IMMUNOL, V149, P1170
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Rossol M, 2012, ARTHRITIS RHEUM US, V64, P671, DOI 10.1002/art.33418
   Santos LL, 2009, CLIN CHIM ACTA, V399, P1, DOI 10.1016/j.cca.2008.09.014
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Suvas S, 2002, J BIOL CHEM, V277, P7766, DOI 10.1074/jbc.M105902200
NR 23
TC 58
Z9 63
U1 0
U2 3
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD MAR
PY 2013
VL 65
IS 3
BP 599
EP 607
DI 10.1002/art.37787
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 097CU
UT WOS:000315452400008
PM 23203906
OA Bronze
DA 2025 08 17
ER

PT J
AU Tseng, LL
   Cheng, HH
   Huang, CJ
   Liu, SI
   Kuo, CC
   Chen, WC
   Huang, JK
   Hsu, SS
   Chang, HT
   Kao, CH
   Ho, CM
   Jan, CR
AF Tseng, LL
   Cheng, HH
   Huang, CJ
   Liu, SI
   Kuo, CC
   Chen, WC
   Huang, JK
   Hsu, SS
   Chang, HT
   Kao, CH
   Ho, CM
   Jan, CR
TI Dual effect of flurbiprofen on cell proliferation and agonist induced
   Ca<SUP>2+</SUP> movement in human osteosarcoma cells
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
ID CALCIUM CHANNELS; CYCLOOXYGENASE INHIBITORS; ANTIINFLAMMATORY DRUG;
   PERIODONTITIS; MOBILIZATION; OSTEOBLASTS; ELEMENTARY; EXPRESSION;
   SIGNALS; GROWTH
AB In human MG63 osteosarcoma cells, the effect of flurbiprofen on intracellular Ca2+ concentrations ([Ca2+](i)) and proliferation was explored. The proliferation was enhanced by 20 120 mu M flurbiprofen, and was decreased by 140 200 mu M flurbiprofen. The effect of flurbiprofen on the increases in cytosolic free Ca2+ levels ([Ca2+](i)) induced by ATP, bradykinin, histamine and thapsigargin (an inhibitor of the endoplasmic reticulum Ca2+ ATPase), was examined. In cell preincubated with 20 or 80 mu M flurbiprofen, the [Ca2+](i) increases induced by all agonists were attenuated. In the presence of 20 mu M flurbiprofen, the decreased [Ca2+](i) responses with the agonists were attributed to a defective Ca2+ influx because this decrease was unobserved in agonists induced [Ca2+](i) increases in the absence of extracellular Ca2+. In the presence of 80 mu M flurbiprofen, both the Ca2+ influx component and the Ca2+ releasing (from organelles) component were defective. These results suggest that flurbiprofen could alter proliferation and inhibit [Ca2+](i) increases.
C1 Kaohsiung Vet Gen Hosp, Dept Dent, Kaohsiung 813, Taiwan.
   Chi Mei Med Ctr, Sect Allergy Immunol & Rheumatol, Tainan 710, Taiwan.
   Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 807, Taiwan.
   Tian Sheng Mem Hosp, Dept Psychiat, Ping Tong 900, Taiwan.
   Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung 813, Taiwan.
   Tzu Hui Inst Technol, Dept Nursery, Pingtung 900, Taiwan.
   Chi Mei Med Ctr, Dept Neurosurg, Tainan 710, Taiwan.
   Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan.
C3 Kaohsiung Veterans General Hospital; Chi Mei Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Veterans
   General Hospital; Chi Mei Hospital; Kaohsiung Veterans General Hospital
RP Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, 386 Ta Chung 1st Rd, Kaohsiung 813, Taiwan.
EM crjan@isca.vghks.gov.tw
RI Huang, Shu cheng/KTH 9549 2024; Huang, Chun/JMP 5950 2023
CR Annunziato L, 2003, TOXICOL LETT, V139, P125, DOI 10.1016/S0378 4274(02)00427 7
   Barry ELR, 2000, CALCIFIED TISSUE INT, V66, P145, DOI 10.1007/s002230010029
   BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0
   Berridge MJ, 1997, J PHYSIOL LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927
   Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092 8674(00)80420 1
   Doroschak AM, 1999, J ENDODONT, V25, P660, DOI 10.1016/S0099 2399(99)80350 1
   Duncan RL, 1998, SEMIN NEPHROL, V18, P178
   FUJIMORI A, 1989, J BONE MINER RES, V4, P697
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Gu Y, 2001, BIOCHEM BIOPH RES CO, V282, P536, DOI 10.1006/bbrc.2001.4615
   Gu Y, 1999, PFLUG ARCH EUR J PHY, V438, P553, DOI 10.1007/s004240051075
   Jan CR, 2002, PHARMACOLOGY, V66, P120, DOI 10.1159/000063798
   JEFFCOAT MK, 1995, J PERIODONTOL, V66, P329, DOI 10.1902/jop.1995.66.5.329
   King JG, 2001, ONCOGENE, V20, P6864, DOI 10.1038/sj.onc.1204907
   Kuo SY, 2003, LIFE SCI, V72, P1733, DOI 10.1016/S0024 3205(02)02479 7
   Lee HM, 2004, J PERIODONTOL, V75, P453, DOI 10.1902/jop.2004.75.3.453
   Lee KC, 2001, BIOCHEM PHARMACOL, V61, P1537, DOI 10.1016/S0006 2952(01)00622 0
   Lu YC, 2002, PHARMACOL TOXICOL, V91, P34, DOI 10.1034/j.1600 0773.2002.910106.x
   MacNeil RL, 1996, J DENT RES, V75, P903, DOI 10.1177/00220345960750030701
   McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552 4604.1996.tb05043.x
   PUBLICOVER SJ, 1994, CALCIFIED TISSUE INT, V54, P125, DOI 10.1007/BF00296063
   PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143 4160(86)90026 6
   Rezzonico R, 2002, J BONE MINER RES, V17, P869, DOI 10.1359/jbmr.2002.17.5.869
   ROGERS HJ, 1981, EUR J RHEUMATOL INFL, V4, P303
   Salvi GE, 2005, CURR PHARM DESIGN, V11, P1757, DOI 10.2174/1381612053764878
   Suresh D K, 2001, Indian J Dent Res, V12, P105
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01 0390rev
   THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466
   Wang JW, 2001, HORM RES, V55, P265, DOI 10.1159/000050011
NR 29
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 7835
EI 1742 7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD FEB
PY 2006
VL 98
IS 2
BP 160
EP 167
DI 10.1111/j.1742 7843.2006.pto_279.x
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 008CL
UT WOS:000235017700007
PM 16445589
OA Bronze
DA 2025 08 17
ER

PT J
AU Armstrong, ZB
   Boughner, DR
   Drangova, M
   Rogers, KA
AF Armstrong, Zachary B.
   Boughner, Derek R.
   Drangova, Maria
   Rogers, Kem A.
TI Angiotensin II type 1 receptor blocker inhibits arterial calcification
   in a pre clinical model
SO CARDIOVASCULAR RESEARCH
LA English
DT Article
DE Arterial calcification; Angiotensin receptor blocker; Pre clinical
   model; Vascular smooth muscle cells
ID SMOOTH MUSCLE CELLS; VASCULAR CALCIFICATION; AORTIC VALVE;
   INSULIN RESISTANCE; OXIDATIVE STRESS; MODULATION; EXPRESSION; STENOSIS;
   RANKL; RISK
AB Aims Arterial calcification is a common complication of several disorders and is a strong predictor of mortality. The mechanism underlying arterial calcification is not fully understood and as such, no pharmaceutical therapies are currently available which impede its progression. The aim of this study was to investigate the effects of an angiotensin II (AngII) type 1 receptor blocker (ARB) on arterial calcification.
   Methods and results Male New Zealand White rabbits were fed an atherogenic diet to induce atherosclerosis and arterial calcification over a period of 12 weeks, with an ARB administered in the final 4 weeks. Using clinically relevant micro computed tomography, we found that animals fed the atherogenic diet displayed extensive arterial calcification when compared with control. In contrast, administration of the ARB completely inhibited calcification (2.80 +/  1.17 vs. 0.01 +/  0.01% calcified tissue in cholesterol and ARB treated, respectively; n = 6 and 5; P < 0.05). Calcified regions were characterized by up regulation of bone morphogenetic protein 2, osteocalcin, and the AngII type 1 receptor and concomitant down regulation of a smooth muscle actin, consistent with a phenotypic switch from vascular to osteoblast like cells.
   Conclusion These data provide the first evidence that angiotensin receptor blockade can inhibit arterial calcification by disrupting vascular osteogenesis and suggest that ARBs may be a novel treatment option for patients suffering from vascular calcification.
C1 [Armstrong, Zachary B.; Rogers, Kem A.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada.
   [Boughner, Derek R.; Drangova, Maria] Univ Western Ontario, Schulich Sch Med & Dent, Dept Med Biophys, London, ON N6A 5C1, Canada.
   [Boughner, Derek R.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Med, London, ON N6A 5C1, Canada.
   [Boughner, Derek R.; Drangova, Maria] Univ Western Ontario, Robarts Res Inst, Imaging Res Labs, London, ON N6A 5C1, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario);
   University Western Ontario Hospital
RP Rogers, KA (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, Med Sci Bldg M426, London, ON N6A 5C1, Canada.
EM kem.rogers@schulich.uwo.ca
RI ; Boughner, Derek/G 3282 2011; Drangova, Maria/J 3123 2012
OI Rogers, Kem/0000 0002 6234 2634; Drangova, Maria/0000 0003 1856 9038
FU Heart & Stroke Foundation of Ontario [T6332]; Frederick Banting and
   Charles Best Canada Graduate Scholarship Program; CIHR
FX This work was supported by the Heart & Stroke Foundation of Ontario
   (grant number T6332). Salary support was provided by the Frederick
   Banting and Charles Best Canada Graduate Scholarship Program (to Z. B.
   A.) and the CIHR Strategic Training Program in Vascular Research (to Z.
   B. A.). Additional support was provided by the Heart and Stroke
   Foundation of Ontario Career Investigator program (to M. D.).
CR Aikawa E, 2009, CIRCULATION, V119, P1785, DOI 10.1161/CIRCULATIONAHA.108.827972
   Arishiro K, 2007, J AM COLL CARDIOL, V49, P1482, DOI 10.1016/j.jacc.2006.11.043
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Bas A, 2006, J BONE MINER RES, V21, P484, DOI 10.1359/JBMR.051211
   Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Drolet MC, 2003, J AM COLL CARDIOL, V41, P1211, DOI 10.1016/S0735 1097(03)00090 1
   El Abbadi MM, 2009, KIDNEY INT, V75, P1297, DOI 10.1038/ki.2009.83
   Fishbein GA, 2009, ARCH PATHOL LAB MED, V133, P1309, DOI 10.1043/1543 2165 133.8.1309
   Fliser D, 2004, CIRCULATION, V110, P1103, DOI 10.1161/01.CIR.0000140265.21608.8E
   Foley RN, 1998, J AM SOC NEPHROL, V9, P267
   Henriksen EJ, 2001, HYPERTENSION, V38, P884, DOI 10.1161/hy1101.092970
   Hoogwerf Byron J, 2010, Am J Cardiol, V105, p30A, DOI 10.1016/j.amjcard.2009.10.009
   Huang ZY, 2003, J CARDIOVASC PHARM, V42, P89, DOI 10.1097/00005344 200307000 00014
   Igarashi M, 2001, HYPERTENSION, V38, P1255, DOI 10.1161/hy1101.095537
   Jacobsen P, 2003, KIDNEY INT, V63, P1874, DOI 10.1046/j.1523 1755.2003.00940.x
   Jeffcoate WJ, 2009, DIABETOLOGIA, V52, P2478, DOI 10.1007/s00125 009 1521 6
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   Li XW, 2008, ATHEROSCLEROSIS, V199, P271, DOI 10.1016/j.atherosclerosis.2007.11.031
   Liu Y, 2010, REGUL PEPTIDES, V159, P35, DOI 10.1016/j.regpep.2009.09.005
   Micheletti RG, 2008, ARCH PATHOL LAB MED, V132, P43, DOI 10.1043/1543 2165(2008)132[43:MSRACO]2.0.CO;2
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Nakano Kurimoto R, 2009, AM J PHYSIOL HEART C, V297, pH1673, DOI 10.1152/ajpheart.00455.2009
   NELSON RG, 1988, DIABETES CARE, V11, P8, DOI 10.2337/diacare.11.1.8
   Ngo DTM, 2008, EUR J PHARMACOL, V590, P290, DOI 10.1016/j.ejphar.2008.05.051
   Panizo S, 2009, CIRC RES, V104, P1041, DOI 10.1161/CIRCRESAHA.108.189001
   Schiffrin EL, 2000, CIRCULATION, V101, P1653
   Shobeiri N, 2010, AM J NEPHROL, V31, P471, DOI 10.1159/000299794
   Shroff RC, 2007, SEMIN DIALYSIS, V20, P103, DOI 10.1111/j.1525 139X.2007.00255.x
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Takasu J, 2010, ATHEROSCLEROSIS, V209, P142, DOI 10.1016/j.atherosclerosis.2009.09.013
   Tanikawa T, 2009, J VASC RES, V46, P572, DOI 10.1159/000226225
   Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433 200110000 00012
   VIRCHOW R, 1989, NUTR REV, V47, P23
   Wu SY, 2003, PEPTIDES, V24, P1149, DOI 10.1016/j.peptides.2003.07.008
   Yang XP, 2009, J AM COLL CARDIOL, V53, P491, DOI 10.1016/j.jacc.2008.09.052
   You HZ, 2009, RENAL FAILURE, V31, P313, DOI 10.1080/08860220902875182
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
   Zeadin M, 2009, ARTERIOSCL THROM VAS, V29, P2069, DOI 10.1161/ATVBAHA.109.195255
NR 42
TC 55
Z9 59
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008 6363
EI 1755 3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD APR 1
PY 2011
VL 90
IS 1
BP 165
EP 170
DI 10.1093/cvr/cvq391
PG 6
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 737IV
UT WOS:000288563400022
PM 21156821
OA Bronze
DA 2025 08 17
ER

PT J
AU Zheng, L
   Feng, ZH
   Tao, SY
   Gao, JW
   Lin, Y
   Wei, XA
   Zheng, BJ
   Huang, B
   Zheng, ZY
   Zhang, XY
   Liu, JH
   Shan, Z
   Chen, YL
   Chen, J
   Zhao, FD
AF Zheng, Lin
   Feng, Zhenhua
   Tao, Siyue
   Gao, Jiawei
   Lin, Ye
   Wei, Xiaoan
   Zheng, Bingjie
   Huang, Bao
   Zheng, Zeyu
   Zhang, Xuyang
   Liu, Junhui
   Shan, Zhi
   Chen, Yilei
   Chen, Jian
   Zhao, Fengdong
TI Destabilization of macrophage migration inhibitory factor by 4 IPP
   reduces NF κB/P TEFb complex mediated c Myb transcription to suppress
   osteosarcoma tumourigenesis
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE 4 IPP; CDK9; c Myb; MIF; osteosarcoma; STUB1
ID D DOPACHROME TAUTOMERASE; PROTEIN PROTEIN; P TEFB; D DT; GROWTH; MIF;
   METASTASIS; PROMOTES; PHOSPHORYLATION; MOLECULE
AB Background As an inflammatory factor and oncogenic driver protein, the pleiotropic cytokine macrophage migration inhibitory factor (MIF) plays a crucial role in the osteosarcoma microenvironment. Although 4 iodo 6 phenylpyrimidine (4 IPP) can inactivate MIF biological functions, its anti osteosarcoma effect and molecular mechanisms have not been investigated. In this study, we identified the MIF inhibitor 4 IPP as a specific double effector drug for osteosarcoma with both anti tumour and anti osteoclastogenic functions. Methods The anti cancer effects of 4 IPP were evaluated by wound healing assay, cell cycle analysis, colony formation assay, CCK 8 assay, apoptosis analysis, and Transwell migration/invasion assays. Through the application of a luciferase reporter, chromatin immunoprecipitation assays, and immunofluorescence and coimmunoprecipitation analyses, the transcriptional regulation of the NF kappa B/P TEFb complex on c Myb  and STUB1 mediated proteasome dependent MIF protein degradation was confirmed. The effect of 4 IPP on tumour growth and metastasis was assessed using an HOS derived tail vein metastasis model and subcutaneous and orthotopic xenograft tumour models. Results In vitro, 4 IPP significantly reduced the proliferation and metastasis of osteosarcoma cells by suppressing the NF kappa B pathway. 4 IPP hindered the binding between MIF and CD74 as well as p65. Moreover, 4 IPP inhibited MIF to interrupt the formation of downstream NF kappa B/P TEFb complexes, leading to the down regulation of c Myb transcription. Interestingly, the implementation of 4 IPP can mediate small molecule induced MIF protein proteasomal degradation via the STUB1 E3 ligand. However, 4 IPP still interrupted MIF mediated communication between osteosarcoma cells and osteoclasts, thus promoting osteoclastogenesis. Remarkably, 4 IPP strongly reduced HOS derived xenograft osteosarcoma tumourigenesis and metastasis in an in vivo mouse model. Conclusions Our findings demonstrate that the small molecule 4 IPP targeting the MIF protein exerts an anti osteosarcoma effect by simultaneously inactivating the biological functions of MIF and promoting its proteasomal degradation. Direct destabilization of the MIF protein with 4 IPP may be a promising therapeutic strategy for treating osteosarcoma.
C1 [Chen, Jian; Zhao, Fengdong] Zhejiang Univ, Med Coll, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.
   [Chen, Jian; Zhao, Fengdong] Key Lab Musculoskeletal Syst Degenerat & Regenera, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Chen, J; Zhao, FD (通讯作者)，Zhejiang Univ, Med Coll, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.; Chen, J; Zhao, FD (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.
EM chenjian bio@zju.edu.cn; zhaofengdong@zju.edu.cn
RI Zheng, Lin/AAE 8093 2021; zhang, xuyang/GQH 3712 2022; Liu,
   Junhui/AAJ 1122 2021; zheng, zeyu/A 3867 2013
OI Zheng, Lin/0000 0002 7585 6968; Wei, Xiaoan/0000 0002 1132 8760; Chen,
   Jian/0000 0001 8568 9991
FU National Natural Science Foundation of China [82072466, 81902231,
   81802192, 81802188]; National Key R&D Program of China [2020YFC1107100]
FX This work was supported by grants from the National Natural Science
   Foundation of China (grant numbers: 82072466, 81902231, 81802192 and
   81802188) and the National Key R&D Program of China (grant number:
   2020YFC1107100).
CR Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097 2765(01)00314 8
   Bucala R, 2007, IMMUNITY, V26, P281, DOI 10.1016/j.immuni.2007.03.005
   Chao CC, 2020, CANCERS, V12, DOI 10.3390/cancers12020459
   Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36
   de Azevedo RA, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1846915
   Dodhiawala PB, 2020, J CLIN INVEST, V130, P4771, DOI 10.1172/JCI137660
   Fang L, 2014, NUCLEIC ACIDS RES, V42, P8416, DOI 10.1093/nar/gku529
   Feng SS, 2019, ACS APPL MATER INTER, V11, P7357, DOI 10.1021/acsami.8b18820
   Goguet Surmenian E, 2013, BRIT J CANCER, V109, P1579, DOI 10.1038/bjc.2013.482
   Gu R, 2015, CYTOKINE, V72, P135, DOI 10.1016/j.cyto.2014.11.015
   Guo DW, 2016, INT J CANCER, V139, P2056, DOI 10.1002/ijc.30278
   Huang SY, 2008, PROTEINS, V72, P557, DOI 10.1002/prot.21949
   Huang SY, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku077
   Huang WS, 2016, FISH SHELLFISH IMMUN, V50, P142, DOI 10.1016/j.fsi.2016.01.030
   Imaoka M, 2019, CANCER SCI, V110, P2273, DOI 10.1111/cas.14038
   Jankauskas SS, 2019, CELL SIGNAL, V57, P76, DOI 10.1016/j.cellsig.2019.01.006
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kim MJ, 2017, CELL SIGNAL, V34, P110, DOI 10.1016/j.cellsig.2017.03.007
   Krönke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851
   Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00299 9
   Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078 0432.CCR 15 0198
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Merk M, 2012, CYTOKINE, V59, P10, DOI 10.1016/j.cyto.2012.03.014
   Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320
   Mitra P, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.09.62
   Mitra P, 2012, NUCLEIC ACIDS RES, V40, P5988, DOI 10.1093/nar/gks286
   Mittelbronn M, 2011, ACTA NEUROPATHOL, V122, P353, DOI 10.1007/s00401 011 0858 3
   Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459
   Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900
   Noone AM, 2017, CANCER EPIDEM BIOMAR, V26, P632, DOI 10.1158/1055 9965.EPI 16 0520
   Ohguchi H, 2017, LEUKEMIA, V31, P2661, DOI 10.1038/leu.2017.141
   Pai MY, 2015, METHODS MOL BIOL, V1263, P287, DOI 10.1007/978 1 4939 2269 7_22
   Pantouris G, 2020, CELL CHEM BIOL, V27, P740, DOI 10.1016/j.chembiol.2020.05.001
   Pantouris G, 2018, ANGEW CHEM INT EDIT, V57, P7116, DOI 10.1002/anie.201803191
   Pereira LA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122919
   Rafiei S, 2019, MOL CANCER RES, V17, P263, DOI 10.1158/1541 7786.MCR 18 0412
   Rajasekaran D, 2014, FASEB J, V28, P4961, DOI 10.1096/fj.14 256636
   Ravalin M, 2019, NAT CHEM BIOL, V15, P786, DOI 10.1038/s41589 019 0322 6
   Rodrigues DAS, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008230
   Schindler L, 2018, REDOX BIOL, V15, P135, DOI 10.1016/j.redox.2017.11.028
   Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117
   Slabicki M, 2020, NATURE, V588, P164, DOI 10.1038/s41586 020 2925 1
   Soumoy L, 2019, CANCERS, V11, DOI 10.3390/cancers11040529
   Spencer ES, 2015, EUR J MED CHEM, V93, P501, DOI 10.1016/j.ejmech.2015.02.012
   Su HT, 2017, INFLAMM RES, V66, P209, DOI 10.1007/s00011 016 0995 1
   Tanese K, 2015, J INVEST DERMATOL, V135, P2901, DOI 10.1038/jid.2015.259
   Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801
   Varinelli L, 2015, ENDOCR RELAT CANCER, V22, P759, DOI 10.1530/ERC 15 0299
   Wang C, 2017, CANCER LETT, V403, P271, DOI 10.1016/j.canlet.2017.06.011
   Wang Q, 2020, BLOOD, V136, P2557, DOI 10.1182/blood.2020005795
   Winner M, 2008, CANCER RES, V68, P7253, DOI 10.1158/0008 5472.CAN 07 6227
   Wu Y, 2019, INFLAMMATION, V42, P874, DOI 10.1007/s10753 018 0942 0
   Xiao ZP, 2021, ANGEW CHEM INT EDIT, V60, P17514, DOI 10.1002/anie.202101864
   Yan YM, 2020, NAT PROTOC, V15, P1829, DOI 10.1038/s41596 020 0312 x
   Yan YM, 2017, NUCLEIC ACIDS RES, V45, pW365, DOI 10.1093/nar/gkx407
   Yan YM, 2017, PROTEINS, V85, P497, DOI 10.1002/prot.25234
   Yang TX, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0595 3
   Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
   Zhu Y, 2018, CANCER SCI, V109, P2412, DOI 10.1111/cas.13653
NR 62
TC 18
Z9 19
U1 1
U2 24
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001 1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD JAN
PY 2022
VL 12
IS 1
AR e652
DI 10.1002/ctm2.652
PG 23
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA YP0CG
UT WOS:000748298100008
PM 35060345
DA 2025 08 17
ER

PT J
AU Kempfle, JS
   Duro, MV
   Zhang, A
   Amador, CD
   Kuang, R
   Lu, RY
   Kashemirov, BA
   Edge, AS
   McKenna, CE
   Jung, DH
AF Kempfle, Judith S.
   Duro, Marlon, V
   Zhang, Andrea
   Amador, Carolina D.
   Kuang, Richard
   Lu, Ryan
   Kashemirov, Boris A.
   Edge, Albert S.
   McKenna, Charles E.
   Jung, David H.
TI A Novel Small Molecule Neurotrophin 3 Analogue Promotes Inner Ear
   Neurite Outgrowth and Synaptogenesis In vitro
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Article
DE inner ear; regeneration; synaptopathy; neurotrophin 3; bisphosphonate;
   small molecule; hidden hearing loss; sensorineural hearing loss
ID SPIRAL GANGLION NEURONS; COCHLEAR SYNAPTOPATHY; NERVE DEGENERATION;
   DRUG DELIVERY; TRKB AGONIST; HEARING LOSS; MOUSE MODEL; HAIR CELLS;
   BISPHOSPHONATE; RECEPTOR
AB Sensorineural hearing loss is irreversible and is associated with the loss of spiral ganglion neurons (SGNs) and sensory hair cells within the inner ear. Improving spiral ganglion neuron (SGN) survival, neurite outgrowth, and synaptogenesis could lead to significant gains for hearing impaired patients. There has therefore been intense interest in the use of neurotrophic factors in the inner ear to promote both survival of SGNs and re wiring of sensory hair cells by surviving SGNs. Neurotrophin 3 (NT 3) and brain derived neurotrophic factor (BDNF) represent the primary neurotrophins in the inner ear during development and throughout adulthood, and have demonstrated potential for SGN survival and neurite outgrowth. We have pioneered a hybrid molecule approach to maximize SGN stimulation in vivo, in which small molecule analogues of neurotrophins are linked to bisphosphonates, which in turn bind to cochlear bone. We have previously shown that a small molecule BDNF analogue coupled to risedronate binds to bone matrix and promotes SGN neurite outgrowth and synaptogenesis in vitro. Because NT 3 has been shown in a variety of contexts to have a greater regenerative capacity in the cochlea than BDNF, we sought to develop a similar approach for NT 3. 1Aa is a small molecule analogue of NT 3 that has been shown to activate cells through TrkC, the NT 3 receptor, although its activity on SGNs has not previously been described. Herein we describe the design and synthesis of 1Aa and a covalent conjugate of 1Aa with risedronate, Ris 1Aa. We demonstrate that both 1Aa and Ris 1Aa stimulate neurite outgrowth in SGN cultures at a significantly higher level compared to controls. Ris 1Aa maintained its neurotrophic activity when bound to hydroxyapatite, the primary mineral component of bone. Both 1Aa and Ris 1Aa promote significant synaptic regeneration in cochlear explant cultures, and both 1Aa and Ris 1Aa appear to act at least partly through TrkC. Our results provide the first evidence that a small molecule analogue of NT 3 can stimulate SGNs and promote regeneration of synapses between SGNs and inner hair cells. Our findings support the promise of hydroxyapatite targeting bisphosphonate conjugation as a novel strategy to deliver neurotrophic agents to SGNs encased within cochlear bone.
C1 [Kempfle, Judith S.; Zhang, Andrea; Kuang, Richard; Lu, Ryan; Edge, Albert S.; Jung, David H.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA.
   [Kempfle, Judith S.] Univ Med Ctr Tubingen, Dept Otolaryngol, Tubingen, Germany.
   [Duro, Marlon, V; Amador, Carolina D.; Kashemirov, Boris A.; McKenna, Charles E.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90007 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   Eye & Ear Infirmary; Harvard Medical School; Eberhard Karls University
   of Tubingen; Eberhard Karls University Hospital; University of Southern
   California
RP Jung, DH (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02115 USA.; McKenna, CE (通讯作者)，Univ Southern Calif, Dept Chem, Los Angeles, CA 90007 USA.
EM mckenna@usc.edu; david_jung@meei.harvard.edu
RI Edge, Albert/Q 5448 2019
OI Duro, Marlon Vincent/0000 0003 2590 2900
FU American Otological Society Research Grant; Hearing Health Foundation
   Emerging Research Grant; Department of Defense CDMRP Hearing Restoration
   Research Program Translational Research Award [W81XWH 19 1 0188]
FX This work was supported by an American Otological Society Research
   Grant, a Hearing Health Foundation Emerging Research Grant, and a
   Department of Defense CDMRP Hearing Restoration Research Program
   Translational Research Award, W81XWH 19 1 0188.
CR Akil O, 2019, HUM GENE THER, V30, P88, DOI 10.1089/hum.2018.028
   Aronov O, 2004, BIOCONJUGATE CHEM, V15, P814, DOI 10.1021/bc0499331
   Auerbach BD, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00206
   Aytan N, 2018, EUR J PHARMACOL, V828, P9, DOI 10.1016/j.ejphar.2018.02.045
   Bai YJ, 2010, INVEST OPHTH VIS SCI, V51, P4722, DOI 10.1167/iovs.09 5032
   Bailey EM, 2014, J NEUROSCI, V34, P13110, DOI 10.1523/JNEUROSCI.1014 14.2014
   Bharadwaj HM, 2015, J NEUROSCI, V35, P2161, DOI 10.1523/JNEUROSCI.3915 14.2015
   Bianchi LM, 1996, DEVELOPMENT, V122, P1965
   Bramhall NF, 2014, STEM CELL REP, V2, P311, DOI 10.1016/j.stemcr.2014.01.008
   Chambers AR, 2016, NEURON, V89, P867, DOI 10.1016/j.neuron.2015.12.041
   Chen HC, 2018, GENE THER, V25, P251, DOI 10.1038/s41434 018 0012 0
   Ernfors P, 1995, INT J DEV BIOL, V39, P799
   Evans AJ, 2009, J BIOMED MATER RES A, V91A, P241, DOI 10.1002/jbm.a.32228
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fernandez KA, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142572
   Fukui H, 2013, HEARING RES, V297, P99, DOI 10.1016/j.heares.2012.11.017
   Barriga GGD, 2017, HUM MOL GENET, V26, P3144, DOI 10.1093/hmg/ddx198
   Goycoolea MV, 2001, ACTA OTO LARYNGOL, V121, P437, DOI 10.1080/000164801300366552
   Green SH, 2012, ANAT REC, V295, P1877, DOI 10.1002/ar.22587
   Hao JS, 2019, EUR J PHARM SCI, V126, P82, DOI 10.1016/j.ejps.2018.05.020
   Hashimoto K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51724 6
   He JJ, 2016, SCI REP UK, V6, DOI 10.1038/srep34339
   JACKMAN AL, 1990, J MED CHEM, V33, P3067, DOI 10.1021/jm00173a025
   Jang SW, 2007, P NATL ACAD SCI USA, V104, P16329, DOI 10.1073/pnas.0706662104
   Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107
   Kang WS, 2015, OTOL NEUROTOL, V36, P953, DOI 10.1097/MAO.0000000000000786
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kempfle JS, 2018, BIOCONJUGATE CHEM, V29, P1240, DOI 10.1021/acs.bioconjchem.8b00022
   Kramer B, 2017, NEUROSCIENCE, V357, P75, DOI 10.1016/j.neuroscience.2017.05.053
   Kujawa SG, 2006, J NEUROSCI, V26, P2115, DOI 10.1523/JNEUROSCI.4985 05.2006
   Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845 09.2009
   Lee HB, 2004, J ORG CHEM, V69, P701, DOI 10.1021/jo034167x
   Lewis MA, 2006, MOL PHARMACOL, V69, P1396, DOI 10.1124/mol.105.020255
   Liberman MC, 2017, HEARING RES, V349, P138, DOI 10.1016/j.heares.2017.01.003
   Lin B, 2007, J PHARMACOL EXP THER, V322, P59, DOI 10.1124/jpet.106.118034
   Marinzi C, 2004, BIOORGAN MED CHEM, V12, P2749, DOI 10.1016/j.bmc.2004.02.039
   McKenna C.E., 2020, Encyclopedia of Bone Biology, P551, DOI DOI 10.1016/B978 0 12 801238 3.11260 7
   Noushi F, 2005, OTOL NEUROTOL, V26, P528, DOI 10.1097/01.mao.0000169780.84588.a5
   Nyberg S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aao0935
   Panagiotakou A, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154264
   Pattarawarapan M, 2002, J MED CHEM, V45, P4387, DOI 10.1021/jm0255421
   Peleshok J, 2006, BIOCHEM SOC T, V34, P612, DOI 10.1042/BST0340612
   Price RD, 2007, PHARMACOL THERAPEUT, V115, P292, DOI 10.1016/j.pharmthera.2007.03.005
   Ramekers D, 2015, J NEUROSCI, V35, P12331, DOI 10.1523/JNEUROSCI.0096 15.2015
   Salt AN, 2009, AUDIOL NEURO OTOL, V14, P350, DOI 10.1159/000241892
   SCHUKNECHT HF, 1993, ANN OTO RHINOL LARYN, V102, P1
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Seist R, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00087
   Sergeyenko Y, 2013, J NEUROSCI, V33, P13686, DOI 10.1523/JNEUROSCI.1783 13.2013
   SilosSantiago I, 1997, EUR J NEUROSCI, V9, P2045, DOI 10.1111/j.1460 9568.1997.tb01372.x
   Sly DJ, 2016, OTOL NEUROTOL, V37, P1223, DOI 10.1097/MAO.0000000000001191
   Stagni F, 2017, EXP NEUROL, V298, P79, DOI 10.1016/j.expneurol.2017.08.018
   Stankovic K, 2004, J NEUROSCI, V24, P8651, DOI 10.1523/JNEUROSCI.0733 04.2004
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Suzuki J, 2016, SCI REP UK, V6, DOI 10.1038/srep24907
   Swan EEL, 2008, ADV DRUG DELIVER REV, V60, P1583, DOI 10.1016/j.addr.2008.08.001
   Valero MD, 2017, HEARING RES, V353, P213, DOI 10.1016/j.heares.2017.07.003
   Viana LM, 2015, HEARING RES, V327, P78, DOI 10.1016/j.heares.2015.04.014
   Wan GQ, 2014, ELIFE, V3, DOI 10.7554/eLife.03564
   Wang Q, 2011, J NEUROSCI, V31, P7938, DOI 10.1523/JNEUROSCI.1434 10.2011
   Wu PZ, 2019, NEUROSCIENCE, V407, P8, DOI 10.1016/j.neuroscience.2018.07.053
   Wu PZ, 2020, J NEUROSCI, V40, P6357, DOI 10.1523/JNEUROSCI.0937 20.2020
   Xu L, 2011, BIOCHEMISTRY US, V50, P8311, DOI 10.1021/bi200930f
   Zaccaro MC, 2005, CHEM BIOL, V12, P1015, DOI 10.1016/j.chembiol.2005.06.015
NR 64
TC 11
Z9 12
U1 3
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1662 5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JUL 15
PY 2021
VL 15
AR 666706
DI 10.3389/fncel.2021.666706
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA TT9UY
UT WOS:000680689900001
PM 34335184
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Khan, A
   Hunter, RL
   Jagannath, C
AF Khan, Arshad
   Hunter, Robert L.
   Jagannath, Chinnaswamy
TI Emerging role of mesenchymal stem cells during tuberculosis: The fifth
   element in cell mediated immunity
SO TUBERCULOSIS
LA English
DT Article; Proceedings Paper
CT 4th Texas Tuberculosis Research Symposium (TTRS)
CY JAN 22, 2016
CL Houston Methodist Res Inst Campus, Houston, TX
SP Univ Texas, Houston McGovern Med Sch, Qiagen
HO Houston Methodist Res Inst Campus
DE Mesenchymal stem cells; Mycobacterium tuberculosis; Dormancy;
   Tuberculosis; Autophagy; Nitric oxide; Chemokines; Cytokines;
   Immunopathology
ID HOST DIRECTED THERAPIES; STAPHYLOCOCCUS AUREUS INFECTION;
   MYCOBACTERIUM TUBERCULOSIS; STROMAL CELLS; IN VITRO; GENE TRANSFER;
   PERSISTENCE; MULTIPOTENT; MACROPHAGES; DORMANCY
AB Mesenchymal stem cells (MSCs) are non hematopoietic cells that occur in almost all human tissues and can be cultured and expanded to large numbers in vitro. They secrete growth factors, cytokines, and chemokines and express Toll like receptors on their surface, although multiple cell biological mechanisms remain unclear. MSCs are multi potent and can differentiate into many cell types including adipocytes, neuronal cells and osteoclasts. Despite gaps in cell biology, because of their immunomodulatory and regenerative capacity, several hundred clinical trials have used MSCs for therapy of cancer, autoimmune diseases and control of inflammation during organ transplantation. MSCs secrete immune modulatory factors and are able to skew T cell responses and shift M1 to M2 differentiation of macrophages. We review the emerging role of MSCs to act as phagocytes for Mycobacterium tuberculosis and its role during the persistence of M. tuberculosis and spread of infection. Paradoxically, MSCs use innate defense mechanisms of autophagy and nitric oxide to inhibit the growth of intracellular M. tuberculosis. In addition, transplantation with autologous MSCs improved the clinical condition of patients with multidrug resistant tuberculosis. Thus, in addition to the well known immune defense played by macrophages, DCs, classical T cells and non classical immune cells, MSCs have emerged as a fifth element capable of regulating immune responses during tuberculosis. We discuss their immunomodulatory properties and innate defense mechanisms in the context of developing immunotherapeutic strategies for tuberculosis. Published by Elsevier Ltd.
C1 [Khan, Arshad; Hunter, Robert L.; Jagannath, Chinnaswamy] Univ Texas McGovern Med Sch, Dept Pathol & Lab Med, Houston, TX USA.
RP Jagannath, C (通讯作者)，Univ Texas Hlth Sci Ctr, Dept Pathol & Lab Med, MSB 2 200, Houston, TX 77030 USA.
EM Chinnaswamy.jagannath@uth.tmc.edu
RI Khan, Arshad/AAA 9450 2020; Khan, Arshad/E 6855 2015
OI Khan, Arshad/0000 0003 3655 2854
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Al Anazi KA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00231
   [Anonymous], MESENCHYMAL STROMAL
   Auletta JJ, 2012, BLOOD, V119, P1801, DOI 10.1182/blood 2011 10 384354
   Beamer G, 2014, AM J PATHOL, V184, P3170, DOI 10.1016/j.ajpath.2014.08.024
   Belema Bedada F, 2008, CELL STEM CELL, V2, P566, DOI 10.1016/j.stem.2008.03.003
   Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072
   Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365 2958.2002.02779.x
   Blander JM, 2007, CELL MICROBIOL, V9, P290, DOI 10.1111/j.1462 5822.2006.00864.x
   Blom B, 2002, HUM IMMUNOL, V63, P1072, DOI 10.1016/S0198 8859(02)00745 0
   Bonomi A, 2015, CYTOTHERAPY, V17, P1687, DOI 10.1016/j.jcyt.2015.09.005
   Bonomi A, 2015, CYTOTHERAPY, V17, P310, DOI 10.1016/j.jcyt.2014.09.009
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chan WK, 2008, EXP HEMATOL, V36, P1545, DOI 10.1016/j.exphem.2008.06.008
   Chávez Galán L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00263
   Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886
   Chen X, 2006, IMMUNOL CELL BIOL, V84, P413, DOI 10.1111/j.1440 1711.2006.01458.x
   Conget PA, 2000, EXP HEMATOL, V28, P382, DOI 10.1016/S0301 472X(00)00134 X
   Cotter EJ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 33
   Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017 5030.2004
   Das B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004912
   DelaRosa O, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00182
   Doorn J, 2011, BIOMATERIALS, V32, P6089, DOI 10.1016/j.biomaterials.2011.05.010
   Ehlers S, 2009, INFECTION, V37, P87, DOI 10.1007/s15010 009 8450 7
   El Badri NS, 2004, STEM CELLS DEV, V13, P463, DOI 10.1089/scd.2004.13.463
   Erokhin V V, 2008, Probl Tuberk Bolezn Legk, P3
   Fakhari Shohreh, 2014, Adv Biomed Res, V3, P19, DOI 10.4103/2277 9175.124650
   Flynn JL, 2015, IMMUNOL REV, V264, P60, DOI 10.1111/imr.12258
   Fratazzi C, 1999, J LEUKOCYTE BIOL, V66, P763, DOI 10.1002/jlb.66.5.763
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140 6736(03)14333 4
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Garhyan J, 2015, AM J PATHOL, V185, P1924, DOI 10.1016/j.ajpath.2015.03.028
   Gengenbacher M, 2012, FEMS MICROBIOL REV, V36, P514, DOI 10.1111/j.1574 6976.2012.00331.x
   Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003
   Gupta A, 2016, MOL PHARM
   Gupta A, 2016, PHARM RES DORDR, V33, P1899, DOI 10.1007/s11095 016 1926 0
   Hagedorn M, 2009, SCIENCE, V323, P1729, DOI 10.1126/science.1169381
   Ho IAW, 2008, CANCER GENE THER, V15, P553, DOI 10.1038/cgt.2008.27
   Hume DA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00370
   Humphreys BD, 2008, ANNU REV MED, V59, P311, DOI 10.1146/annurev.med.59.061506.154239
   Jacobs SA, 2013, CELL TRANSPLANT, V22, P1915, DOI 10.3727/096368912X657369
   Jacobs SA, 2013, IMMUNOL CELL BIOL, V91, P32, DOI 10.1038/icb.2012.64
   Kariminekoo S, 2016, ARTIF CELL NANOMED B, V13, P1
   Kean TJ, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/732742
   Kemp KC, 2005, LEUKEMIA LYMPHOMA, V46, P1531, DOI 10.1080/10428190500215076
   Khan A, 2016, MESENCHYMAL STEM CEL
   Kim H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011608
   Kol A, 2014, STEM CELLS DEV, V23, P1831, DOI 10.1089/scd.2014.0128
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Kyriakou C, 2008, HAEMATOL HEMATOL J, V93, P1457, DOI 10.3324/haematol.12553
   Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399
   Li Y, 2013, INT IMMUNOPHARMACOL, V15, P176, DOI 10.1016/j.intimp.2012.10.016
   Lipworth S, 2016, TUBERCULOSIS, V99, P131, DOI 10.1016/j.tube.2016.05.006
   Liu GY, 2015, ACTA PHARMACOL SIN, V36, P1473, DOI 10.1038/aps.2015.101
   Loebinger MR, 2009, CANCER RES, V69, P8862, DOI 10.1158/0008 5472.CAN 09 1912
   Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158
   MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243
   Mahon RN, 2015, CLIN INFECT DIS, V61, pS200, DOI 10.1093/cid/civ621
   Leite FRM, 2015, INFLAMMATION, V38, P1, DOI 10.1007/s10753 014 0001 4
   Mazzoni A, 2004, J LEUKOCYTE BIOL, V75, P721, DOI 10.1189/jlb.1003482
   Meisel R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/898630
   Mills CD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00212
   Miranda MS, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/139127
   Muñoz Elías EJ, 2005, INFECT IMMUN, V73, P546, DOI 10.1128/IAI.73.1.546 551.2005
   Park KS, 2010, TRANSPLANTATION, V89, P509, DOI 10.1097/TP.0b013e3181c7dc99
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400
   Raghuvanshi S, 2010, P NATL ACAD SCI USA, V107, P21653, DOI 10.1073/pnas.1007967107
   Rajararna MVS, 2014, SEMIN IMMUNOL, V26, P471, DOI 10.1016/j.smim.2014.09.010
   Ramakrishnan L, 2012, NAT REV IMMUNOL, V12, P352, DOI 10.1038/nri3211
   Rasmusson I, 2006, EXP CELL RES, V312, P2169, DOI 10.1016/j.yexcr.2006.03.019
   Ricks DM, 2008, STEM CELLS DEV, V17, P441, DOI 10.1089/scd.2007.0194
   Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781
   Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034
   Rustad KC, 2012, ADV WOUND CARE, V1, P147, DOI 10.1089/wound.2011.0314
   Rustad TR, 2009, CELL MICROBIOL, V11, P1151, DOI 10.1111/j.1462 5822.2009.01325.x
   Sachan M, 2016, CURR PHARM DESIGN, V22, P2599, DOI 10.2174/1381612822666160128150636
   Saunders BM, 2000, IMMUNOL CELL BIOL, V78, P334, DOI 10.1046/j.1440 1711.2000.00933.x
   Seebach E, 2015, ACTA BIOMATER, V21, P165, DOI 10.1016/j.actbio.2015.03.019
   Shaler CR, 2011, AM J PATHOL, V178, P1622, DOI 10.1016/j.ajpath.2010.12.022
   Singer NG, 2011, ANNU REV PATHOL MECH, V6, P457, DOI 10.1146/annurev pathol 011110 130230
   Singh CR, 2006, J IMMUNOL, V177, P3250, DOI 10.4049/jimmunol.177.5.3250
   Singhal A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009885
   Sisto F, 2014, CYTOTHERAPY, V16, P181, DOI 10.1016/j.jcyt.2013.11.009
   Skrahin A, 2014, LANCET RESP MED, V2, P108, DOI 10.1016/S2213 2600(13)70234 0
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463 496.2003
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   Stagg J, 2007, TISSUE ANTIGENS, V69, P1, DOI 10.1111/j.1399 0039.2006.00739.x
   Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17
   Sutton MT, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5303048
   Tasso R, 2009, INT IMMUNOPHARMACOL, V9, P596, DOI 10.1016/j.intimp.2009.01.014
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001
   Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416
   Van Crevel R, 2003, ADV EXP MED BIOL, V531, P241
   Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205
   Wakamoto Y, 2013, SCIENCE, V339, P91, DOI 10.1126/science.1229858
   Watts C, 2010, CURR OPIN IMMUNOL, V22, P124, DOI 10.1016/j.coi.2009.12.005
   WHO, 2015, GLOB TUB REP WHO
   Yagi H, 2010, CELL TRANSPLANT, V19, P667, DOI 10.3727/096368910X508762
   Yuan Y, 2014, CYTOTHERAPY, V16, P56, DOI 10.1016/j.jcyt.2013.06.002
   Zangi L, 2009, STEM CELLS, V27, P2865, DOI 10.1002/stem.217
   Zelenay S, 2013, TRENDS IMMUNOL, V34, P329, DOI 10.1016/j.it.2013.03.005
   Zheng GP, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/989473
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901 1028
   Zumla A, 2016, BMC MED, V14, DOI 10.1186/s12916 016 0635 1
   Zumla A, 2015, NAT REV DRUG DISCOV, V14, P511, DOI 10.1038/nrd4696
NR 108
TC 18
Z9 21
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472 9792
J9 TUBERCULOSIS
JI Tuberculosis
PD DEC
PY 2016
VL 101
SU S
BP S45
EP S52
DI 10.1016/j.tube.2016.09.019
PG 8
WC Immunology; Microbiology; Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Immunology; Microbiology; Respiratory System
GA EF5JE
UT WOS:000390365700007
PM 27743705
DA 2025 08 17
ER

PT J
AU Anitua, E
   Zalduendo, MM
   Troya, M
   Orive, G
AF Anitua, E.
   Zalduendo, M. M.
   Troya, M.
   Orive, G.
TI Ozone dosing alters the biological potential and therapeutic outcomes of
   plasma rich in growth factors
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE growth factors; ozone; plasma rich in growth factors; platelet rich
   plasma
ID TISSUE REGENERATION; PROLIFERATION; MIGRATION; BLOOD; TECHNOLOGY;
   MECHANISMS; DISEASE; CELLS
AB Background and ObjectiveUntil now, ozone has been used in a rather empirical way. This in vitro study investigates, for the first time, whether different ozone treatments of plasma rich in growth factors (PRGF) alter the biological properties and outcomes of this autologous platelet rich plasma.
   Material and MethodsHuman plasma rich in growth factors was treated with ozone using one of the following protocols: a continuous flow method; or a syringe method in which constant volumes of ozone and PRGF were mixed. In both cases, ozone was added before, during and after the addition of calcium chloride. Three ozone concentrations, of the therapeutic range 20, 40 and 80g/mL, were tested. Fibrin clot properties, growth factor content and the proliferative effect on primary osteoblasts and gingival fibroblasts were evaluated.
   ResultsOzone treatment of PRGF using the continuous flow protocol impaired formation of the fibrin scaffold, drastically reduced the levels of growth factors and significantly decreased the proliferative potential of PRGF on primary osteoblasts and gingival fibroblasts. In contrast, treatment of PRGF with ozone using the syringe method, before, during and after the coagulation process, did not alter the biological outcomes of the autologous therapy.
   ConclusionThese findings suggest that ozone dose and the way that ozone combines with PRGF may alter the biological potential and therapeutic outcomes of PRGF.
C1 [Anitua, E.; Zalduendo, M. M.; Troya, M.; Orive, G.] Fdn Eduardo Anitua, Vitoria, Spain.
RP Anitua, E (通讯作者)，Inst Eduardo Anitua, C Jose Maria Cagigal 19, Vitoria 10007, Spain.
EM eduardoanitua@eduardoanitua.com; gorka.orive@ehu.es
RI Troya, María/N 7897 2018; Troya, Maria/N 7897 2018; Anitua,
   Eduardo/O 1154 2018; , Mar/N 7896 2018; Zalduendo, Mar/N 7896 2018
OI Troya, Maria/0000 0002 5308 0505; Anitua, Eduardo/0000 0002 8386 5303; ,
   Mar/0000 0001 8458 6042; ORIVE, GORKA/0000 0002 0773 300X; Troya, Maria
   Isabel/0000 0002 9742 9094
FU Foundation Eduardo Anitua
FX We wish to thank Virginia Cuadrado Vega for her valuable contribution
   with the English grammar. We also thank Foundation Eduardo Anitua for
   its support in PRGF research.
CR Anitua E, 2013, J PERIODONTOL, V84, P1180, DOI 10.1902/jop.2012.120292
   Anitua E, 2012, OPER TECH ORTHOP, V22, P25, DOI 10.1053/j.oto.2012.01.004
   Anitua E, 2012, J PERIODONTOL, V83, P1028, DOI 10.1902/jop.2011.110505
   Anitua E, 2012, J CONTROL RELEASE, V157, P317, DOI 10.1016/j.jconrel.2011.11.011
   Anitua E, 2012, J CONTROL RELEASE, V157, P29, DOI 10.1016/j.jconrel.2011.07.004
   Anitua E, 2011, J BIOMED MATER RES A, V97A, P536, DOI 10.1002/jbm.a.33053
   Anraku M, 2013, BBA GEN SUBJECTS, V1830, P5465, DOI 10.1016/j.bbagen.2013.04.036
   Azarpazhooh A, 2008, J DENT, V36, P104, DOI 10.1016/j.jdent.2007.11.008
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524 475X.2008.00410.x
   Bocci V, 2004, MEDIAT INFLAMM, V13, P3, DOI 10.1080/0962935062000197083
   Bocci V, 1998, MEDIAT INFLAMM, V7, P313, DOI 10.1080/09629359890820
   Bocci VA, 2006, ARCH MED RES, V37, P425, DOI 10.1016/j.arcmed.2005.08.006
   Bocci V, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/26785
   Bocci V, 2009, MED RES REV, V29, P646, DOI 10.1002/med.20150
   Bocci VA, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 66
   Chen FM, 2010, TISSUE ENG PART B RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chen FM, 2011, J CONTROL RELEASE, V149, P92, DOI 10.1016/j.jconrel.2010.10.021
   Ciborowski M, 2012, J PROTEOME RES, V11, P6231, DOI 10.1021/pr3008946
   Creeper F, 2009, J PERIODONTAL RES, V44, P258, DOI 10.1111/j.1600 0765.2008.01125.x
   Davì G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014
   Dereka XE, 2006, GROWTH FACTORS, V24, P260, DOI 10.1080/08977190601060990
   Díaz Llera S, 2002, MUTAT RES GEN TOX EN, V517, P13, DOI 10.1016/S1383 5718(02)00022 0
   Eick S, 2012, CLIN ORAL INVEST, V16, P537, DOI 10.1007/s00784 011 0515 1
   Ferroni P, 2012, ANTIOXID REDOX SIGN, V17, P1447, DOI 10.1089/ars.2011.4324
   Hauser Gerspach I, 2012, CLIN ORAL INVEST, V16, P1049, DOI 10.1007/s00784 011 0603 2
   Huth KC, 2007, J DENT RES, V86, P451, DOI 10.1177/154405910708600512
   Huth KC, 2006, EUR J ORAL SCI, V114, P435, DOI 10.1111/j.1600 0722.2006.00390.x
   Laval Gilly P, 2000, J PHARMACOL TOXICOL, V44, P483, DOI 10.1016/S1056 8719(01)00114 9
   Lekovic V, 2012, J PERIODONTAL RES, V47, P409, DOI 10.1111/j.1600 0765.2011.01446.x
   Nurden AT, 2011, THROMB HAEMOSTASIS, V105, pS13, DOI 10.1160/THS10 11 0720
   Rodrigues M, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt32
   Sagai M, 2011, MED GAS RES, V1, DOI 10.1186/2045 9912 1 29
   Travagli V, 2007, INT J BIOL MACROMOL, V41, P504, DOI 10.1016/j.ijbiomac.2007.06.010
   Travagli V, 2010, INT J TOXICOL, V29, P165, DOI 10.1177/1091581809360069
   Uzun H, 2012, FOOD CHEM, V134, P647, DOI 10.1016/j.foodchem.2012.02.146
   Valacchi G, 2000, MEDIAT INFLAMM, V9, P271, DOI 10.1080/09629350020027573
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
NR 37
TC 5
Z9 6
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD APR
PY 2015
VL 50
IS 2
BP 240
EP 247
DI 10.1111/jre.12201
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CD2NH
UT WOS:000350914600012
PM 24957247
DA 2025 08 17
ER

PT J
AU Black, DM
   Bauer, DC
   Vittinghoff, E
   Lui, LY
   Grauer, A
   Marin, F
   Khosla, S
   de Papp, A
   Mitlak, B
   Cauley, JA
   McCulloch, CE
   Eastell, R
   Bouxsein, ML
AF Black, Dennis M.
   Bauer, Douglas C.
   Vittinghoff, Eric
   Lui, Li Yung
   Grauer, Andreas
   Marin, Fernando
   Khosla, Sundeep
   de Papp, Anne
   Mitlak, Bruce
   Cauley, Jane A.
   McCulloch, Charles E.
   Eastell, Richard
   Bouxsein, Mary L.
CA Fdn Natl Inst Hlth Bone Quality Pr
TI Treatment related changes in bone mineral density as a surrogate
   biomarker for fracture risk reduction: meta regression analyses of
   individual patient data from multiple randomised controlled trials
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Article
ID YEARLY ZOLEDRONIC ACID; X RAY ABSORPTIOMETRY; POSTMENOPAUSAL WOMEN;
   VERTEBRAL FRACTURE; ANTIFRACTURE EFFICACY; NONVERTEBRAL FRACTURE;
   CLINICAL TRIAL; END POINT; OSTEOPOROSIS; ALENDRONATE
AB Background The validation of bone mineral density (BMD) as a surrogate outcome for fracture would allow the size of future randomised controlled osteoporosis registration trials to be reduced. We aimed to determine the association between treatment related changes in BMD, assessed by dual energy x ray absorptiometry, and fracture outcomes, including the proportion of treatment effect explained by BMD changes.
   Methods We did a pooled analysis of individual patient data from multiple randomised placebo controlled clinical trials. We included data from multicentre, randomised, placebo controlled, double blind trials of osteoporosis medications that included women and men at increased osteoporotic fracture risk. Using individual patient data for each trial we calculated mean 24 month BMD percent change together with fracture reductions and did a meta regression of the association between treatment related differences in BMD changes (percentage difference, active minus placebo) and fracture risk reduction. We also used individual patient data to determine the proportion of anti fracture treatment effect explained by BMD changes and the BMD change needed in future trials to ensure fracture reduction efficacy.
   Findings Individual patient data from 91 779 participants of 23 randomised, placebo controlled trials were included. The trials had 1 9 years of follow up and included 12 trials of bisphosphonate, one of odanacatib, two of hormone therapy (one of conjugated equine oestrogen and one of conjugated equine oestrogen plus medroxyprogesterone acetate), three of PTH receptor agonists, one of denosumab, and four of selective oestrogen receptor modulator trials. The meta regression revealed significant associations between treatment related changes in hip, femoral neck, and spine BMD and reductions in vertebral (r(2) 0.73, p<0.0001; 0.59, p=0.0005; 0.61, p=0.0003), hip (0.41, p=0.014; 0.41, p=0.0074; 0.34, p=0.023) and non vertebral fractures (0.53, p=0.0021; 0.65, p<0.0001; 0.51, p=0.0019). Minimum 24 month percentage changes in total hip BMD providing almost certain fracture reductions in future trials ranged from 1.42% to 3.18%, depending on fracture site. Hip BMD changes explained substantial proportions (44 67%) of treatment related fracture risk reduction.
   Interpretation Treatment related BMD changes are strongly associated with fracture reductions across randomised trials of osteoporosis therapies with differing mechanisms of action. These analyses support BMD as a surrogate outcome for fracture outcomes in future randomised trials of new osteoporosis therapies and provide an important demonstration of the value of public access to individual patient data from multiple trials. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Black, Dennis M.; Bauer, Douglas C.; Vittinghoff, Eric; McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA.
   [Lui, Li Yung] Calif Pacific Med Ctr, San Francisco, CA USA.
   [Grauer, Andreas] Amgen Inc, Thousand Oaks, CA USA.
   [Grauer, Andreas] CorceptTherapeut, Menlo Pk, CA USA.
   [Marin, Fernando] Eli Lilly & Co, Lilly Res Ctr, Windlesham, Surrey, England.
   [Khosla, Sundeep] Mayo Clin, Coll Med, Rochester, MN USA.
   [de Papp, Anne] Merck & Co Inc, Kenilworth, NJ USA.
   [Mitlak, Bruce] Radius Hlth, Waltham, MA USA.
   [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
   [Eastell, Richard] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England.
   [Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Dept Orthoped Surg, Boston, MA 02215 USA.
   [Bouxsein, Mary L.] Harvard Med Sch, Boston, MA 02115 USA.
C3 University of California System; University of California San Francisco;
   California Pacific Medical Center; Amgen; Eli Lilly; Lilly Research
   Laboratories; Mayo Clinic; Merck & Company; Merck & Company USA; Radius
   Health, Inc.; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Sheffield; Harvard
   University; Harvard University Medical Affiliates; Beth Israel Deaconess
   Medical Center; Harvard University; Harvard Medical School
RP Black, DM (通讯作者)，Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA.
EM dblack@psg.ucsf.edu
RI Bauer, Denis/C 3903 2009; Eastell, Richard/G 5851 2011; Khosla,
   Sundeep/AAE 6170 2020; MARIN, FERNANDO/HKO 8917 2023
OI Bauer, Douglas/0000 0001 5261 7721; 
FU Foundation for National Institutes of Health; MRC [MR/P020941/1] Funding
   Source: UKRI
FX Foundation for National Institutes of Health.
CR Amur S, 2015, CLIN PHARMACOL THER, V98, P34, DOI 10.1002/cpt.136
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   [Anonymous], 1995, EXTENT POPULATION EX
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bajan K, 2015, INDIAN J CRIT CARE M, V19, P301, DOI 10.4103/0972 5229.158253
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Blake GM, 2005, J BONE MINER RES, V20, P1901, DOI 10.1359/JBMR.050810
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Bruyère O, 2012, CALCIFIED TISSUE INT, V91, P244, DOI 10.1007/s00223 012 9629 y
   Burzykowski T, 2006, PHARM STAT, V5, P173, DOI 10.1002/pst.207
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Ciani O, 2017, VALUE HEALTH, V20, P487, DOI 10.1016/j.jval.2016.10.011
   Ciani O, 2016, NAT REV DRUG DISCOV, V15, DOI 10.1038/nrd.2016.81
   Committee on Strategies for Responsible Sharing of Clinical Trial Data Board on Health Sciences Policy Institute of Medicine, 2015, SHARING CLIN TRIAL D
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140 6736(13)62422 8
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2011, J BONE MINER RES, V26, P397, DOI 10.1002/jbmr.191
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Drazen JM, 2015, NEW ENGL J MED, V372, P201, DOI 10.1056/NEJMp1415160
   EASTELL R, 1991, J BONE MINER RES, V6, P207
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   GENANT HK, 1994, J BONE MINER RES, V9, P1503
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Hanson J, 1997, J BONE MINER RES, V12, P1316, DOI 10.1359/jbmr.1997.12.8.1316
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Jackson RD, 2006, J BONE MINER RES, V21, P817, DOI 10.1359/JBMR.060312
   Jacques RM, 2012, J BONE MINER RES, V27, P1627, DOI 10.1002/jbmr.1644
   Johannesdottir F, 2017, BONE, V105, P93, DOI 10.1016/j.bone.2017.07.023
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Korn EL, 2016, ANN ONCOL, V27, P10, DOI 10.1093/annonc/mdv507
   Lassere MN, 2008, STAT METHODS MED RES, V17, P303, DOI 10.1177/0962280207082719
   Lassere MN, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471 2288 12 27
   Lewiecki EM, 2016, J CLIN DENSITOM, V19, P127, DOI 10.1016/j.jocd.2016.03.003
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   LOOKER AC, 1995, J BONE MINER RES, V10, P796
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   McClung MR, 2019, LANCET DIABETES ENDO, V7, P899, DOI 10.1016/S2213 8587(19)30346 8
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Miller PD, 2010, CALCIFIED TISSUE INT, V87, P305, DOI 10.1007/s00223 010 9403 y
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nielsen SP, 1999, J CLIN DENSITOM, V2, P371, DOI 10.1016/S1094 6950(06)60402 2
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Recker R, 2004, BONE, V34, P890, DOI 10.1016/j.bone.2004.01.008
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Simes RJ, 2002, CIRCULATION, V105, P1162, DOI 10.1161/hc1002.105136
   Singh S, 2012, TRIALS, V13, DOI 10.1186/1745 6215 13 138
   Taichman DB, 2016, ANN INTERN MED, V164, P505, DOI 10.7326/M15 2928
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   Watts NB, 2005, J BONE MINER RES, V20, P2097, DOI 10.1359/JBMR.050814
   Zysset P, 2015, J CLIN DENSITOM, V18, P359, DOI 10.1016/j.jocd.2015.06.011
NR 64
TC 155
Z9 162
U1 3
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2213 8587
EI 2213 8595
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD AUG
PY 2020
VL 8
IS 8
BP 672
EP 682
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MO3VT
UT WOS:000551458500003
PM 32707115
DA 2025 08 17
ER

PT J
AU He, W
   Elkhooly, TA
   Liu, XJ
   Cavallaro, A
   Taheri, S
   Vasilev, K
   Feng, QL
AF He, Wei
   Elkhooly, Tarek A.
   Liu, Xujie
   Cavallaro, Alex
   Taheri, Shima
   Vasilev, Krasimir
   Feng, Qingling
TI Silver nanoparticle based coatings enhance adipogenesis compared to
   osteogenesis in human mesenchymal stem cells through oxidative stress
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID ADIPOCYTE DIFFERENTIATION; FUNCTIONAL GROUPS; NADPH OXIDASES; MECHANISM;
   TOXICITY; EXPOSURE; ION
AB Silver nanoparticle (AgNP) based antibacterial surfaces were fabricated using plasma polymerization technology and their effects on differentiation of human bone marrow derived mesenchymal stem cells (hMSCs) were investigated in this study. The results showed that AgNP coated surfaces do not affect the initial adhesion, spreading and proliferation of hMSCs. Furthermore, the silver coated surface promoted adipogenic differentiation of hMSCs as demonstrated by more accumulation of lipid droplets and upregulation of adipogenesis related genes such as peroxisome proliferator activated receptor gamma (PPAR gamma), adipocyte determination and differentiation factor (ADD1) and CCAAT/enhancer binding protein alpha (C/EBP alpha). In addition, silver incorporation activated the expression of antioxidant enzymes as a consequence of the accumulation of intracellular reactive oxygen species (ROS) in adipogenic induced cells, which was correlated with the enhanced adipogenic capacity of hMSCs. ROS generation was enhanced due to silver ion release and consequently reduced osteogenesis at the early stage after 7 days of osteogenic induction as a result of reducing alkaline phosphatase (ALP) activity. However, the differentiation and mineralization capacity of osteoblasts were restored after 14 days of osteogenic induction, which indicated that adipogenesis favors intracellular ROS accumulation mediated by silver coatings compared to osteogenesis. None of the osteogenic related genes was affected by ROS mediated by AgNP dissolution. The findings in this work are instructive for the use of silver as an antibacterial agent in the areas of tissue engineering, stem cell therapies and implantable biomedical devices.
C1 [He, Wei; Elkhooly, Tarek A.; Liu, Xujie; Feng, Qingling] Tsinghua Univ, Sch Mat Sci & Engn, State Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.
   [Elkhooly, Tarek A.] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Physiol Chem, Duesbergweg 6, D 55128 Mainz, Germany.
   [Elkhooly, Tarek A.] Natl Res Ctr, Inorgan Chem Ind Div, Dept Ceram, Cairo 12622, Egypt.
   [Liu, Xujie] Tsinghua Univ, Grad Sch Shenzhen, Shenzhen 518055, Peoples R China.
   [Cavallaro, Alex; Taheri, Shima; Vasilev, Krasimir] Univ S Australia, Mawson Inst, Mawson Lakes, SA 5095, Australia.
   [Vasilev, Krasimir] Univ S Australia, Sch Adv Mfg, Mawson Lakes, SA 5095, Australia.
   [Feng, Qingling] Tsinghua Univ, Sch Mat Sci & Engn, Key Lab Adv Mat, Minist Educ China, Beijing 100084, Peoples R China.
C3 Tsinghua University; Johannes Gutenberg University of Mainz; Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC); Tsinghua
   University; Tsinghua Shenzhen International Graduate School; University
   of South Australia; University of South Australia; Tsinghua University
RP Feng, QL (通讯作者)，Tsinghua Univ, Sch Mat Sci & Engn, State Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.
EM biomater@mail.tsinghua.edu.cn
RI ; Vasilev, Krasimir/C 5248 2008; elkhooly, tarek/N 5908 2018; Taheri,
   Shima/D 1571 2011; Elkhooly, Tarek/N 5908 2018; He, Wei/MIP 2725 2025;
   Cavallaro, Alex/F 9242 2016; Xujie, Liu/AAC 2287 2021
OI Taheri, Shima/0000 0002 8959 1825; elkhooly, tarek/0000 0002 9278 0977;
   Vasilev, Krasimir/0000 0003 3534 4754; Cavallaro,
   Alex/0000 0002 7704 092X; Liu, Xujie/0000 0001 8713 4287
FU National Natural Science Foundation of China [51472139]; International
   S&T Cooperation of the Ministry of Science and Technology of China
   [2015DFG52490]
FX The authors are grateful for the financial support from National Natural
   Science Foundation of China (51472139) and International S&T Cooperation
   of the Ministry of Science and Technology of China (2015DFG52490).
CR Agarwal A, 2010, BIOMATERIALS, V31, P680, DOI 10.1016/j.biomaterials.2009.09.092
   Agnihotri S, 2013, NANOSCALE, V5, P7328, DOI 10.1039/c3nr00024a
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Buldak RJ, 2012, BIOELECTROMAGNETICS, V33, P641, DOI 10.1002/bem.21732
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen M, 2015, COLLOID SURFACE B, V134, P322, DOI 10.1016/j.colsurfb.2015.07.018
   Chernousova S, 2013, ANGEW CHEM INT EDIT, V52, P1636, DOI 10.1002/anie.201205923
   Coso S, 2012, ANTIOXID REDOX SIGN, V16, P1229, DOI 10.1089/ars.2011.4489
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dubey P, 2015, ADV COLLOID INTERFAC, V221, P4, DOI 10.1016/j.cis.2015.02.007
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Foldbjerg R, 2015, TOXICOL RES UK, V4, P563, DOI 10.1039/c4tx00110a
   Franco R, 2009, MUTAT RES GEN TOX EN, V674, P3, DOI 10.1016/j.mrgentox.2008.11.012
   Gaharwar AK, 2013, ADV MATER, V25, P3329, DOI 10.1002/adma.201300584
   Gao A, 2014, BIOMATERIALS, V35, P4223, DOI 10.1016/j.biomaterials.2014.01.058
   He W, 2016, J BIOMED NANOTECHNOL, V12, P525, DOI 10.1166/jbn.2016.2182
   Higuchi M, 2013, STEM CELLS DEV, V22, P878, DOI 10.1089/scd.2012.0306
   Hsin YH, 2008, TOXICOL LETT, V179, P130, DOI 10.1016/j.toxlet.2008.04.015
   Ivashenko O, 2013, CHEM PHYS LETT, V559, P76, DOI 10.1016/j.cplett.2012.12.060
   Kanda Y, 2011, LIFE SCI, V89, P250, DOI 10.1016/j.lfs.2011.06.007
   Kim JS, 2007, NANOMED NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Lee H, 2009, J BIOL CHEM, V284, P10601, DOI 10.1074/jbc.M808742200
   Lipski AM, 2007, ADV MATER, V19, P553, DOI 10.1002/adma.200502617
   Liu Guei Sheung, 2012, Cells, V1, P976, DOI 10.3390/cells1040976
   Liu XJ, 2015, ACS APPL MATER INTER, V7, P18473, DOI 10.1021/acsami.5b04635
   Liu XJ, 2014, J BIOMED NANOTECHNOL, V10, P1277, DOI 10.1166/jbn.2014.1824
   Loza K, 2014, J MATER CHEM B, V2, P1634, DOI 10.1039/c3tb21569e
   Melzer M, 2015, J HOSP INFECT, V91, P146, DOI 10.1016/j.jhin.2015.06.015
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Pauksch L, 2014, ACTA BIOMATER, V10, P439, DOI 10.1016/j.actbio.2013.09.037
   Piccoli C, 2008, STEM CELLS, V26, P2843, DOI 10.1634/stemcells.2007 0885
   Qin H, 2015, ACS APPL MATER INTER, V7, P10785, DOI 10.1021/acsami.5b01310
   Rahman MF, 2009, TOXICOL LETT, V187, P15, DOI 10.1016/j.toxlet.2009.01.020
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Ruiz JC, 2014, PLASMA PROCESS POLYM, V11, P888, DOI 10.1002/ppap.201400016
   Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005
   Singh RP, 2015, APPL MICROBIOL BIOT, V99, P1571, DOI 10.1007/s00253 014 6334 y
   Soenen SJ, 2015, CHEM REV, V115, P2109, DOI 10.1021/cr400714j
   Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405
   Taglietti A, 2014, BIOMATERIALS, V35, P1779, DOI 10.1016/j.biomaterials.2013.11.047
   Taheri S, 2014, BIOMATERIALS, V35, P4601, DOI 10.1016/j.biomaterials.2014.02.033
   Tormos KV, 2011, CELL METAB, V14, P537, DOI 10.1016/j.cmet.2011.08.007
   Vasilev K, 2014, PLASMA CHEM PLASMA P, V34, P545, DOI 10.1007/s11090 013 9506 0
   Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v
   Wang WM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120629
   Ye ZW, 2015, BBA GEN SUBJECTS, V1850, P1607, DOI 10.1016/j.bbagen.2014.11.010
NR 50
TC 47
Z9 47
U1 1
U2 67
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2016
VL 4
IS 8
BP 1466
EP 1479
DI 10.1039/c5tb02482j
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA DE6CI
UT WOS:000370720600010
PM 32263113
DA 2025 08 17
ER

PT J
AU Theocharidou, A
   Bakopoulou, A
   Kontonasaki, E
   Papachristou, E
   Hadjichristou, C
   Bousnaki, M
   Theodorou, G
   Papadopoulou, L
   Kantiranis, N
   Paraskevopoulos, K
   Koidis, P
AF Theocharidou, Anna
   Bakopoulou, Athina
   Kontonasaki, Eleana
   Papachristou, Eleni
   Hadjichristou, Christina
   Bousnaki, Maria
   Theodorou, George
   Papadopoulou, Lambrini
   Kantiranis, Nikolaos
   Paraskevopoulos, Konstantinos
   Koidis, Petros
TI Odontogenic differentiation and biomineralization potential of dental
   pulp stem cells inside Mg based bioceramic scaffolds under low level
   laser treatment
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Mg based; Zn doped bioceramic scaffolds; Dental pulp stem cells (DPSCs);
   Low level laser irradiation (LLLI); Odontogenic differentiation; Dentin
   regeneration; Photobiomodulation (PBM)
ID GENE EXPRESSION; IN VITRO; THERAPY; IRRADIATION; PROLIFERATION; RED;
   PHOTOACTIVATION; OSTEOBLAST; DENTISTRY; RESPONSES
AB This study aimed to investigate the potential of low level laser irradiation (LLLI) to promote odontogenic differentiation and biomineralization by dental pulp stem cells (DPSCs) seeded inside bioceramic scaffolds. Mg based, Zn doped bioceramic scaffolds, synthesized by the sol gel technique, were spotted with DPSCs and exposed to LLLI at 660 nm with maximum output power of 140 mw at fluencies (a) 2 and 4 J/cm(2) to evaluate cell viability/proliferation by the MTT assay and (b) 4 J/cm(2) to evaluate cell differentiation, using real time PCR (expression of odontogenic markers) and a p nitrophenylphosphate (pNPP) based assay for alkaline phosphatase (ALP) activity measurement. Scanning electron microscopy (SEM) and X ray diffraction (XRD) analysis were used for structural/chemical characterization of the regenerated tissues. Exposure of the DPSCs/scaffold complexes to the proposed LLLI scheme was associated with statistically significant increase of odontogenesis related markers (bone morphogenetic protein 2 (BMP 2): 22.4 fold, dentin sialophosphoprotein (DSPP): 28.4 fold, Osterix: 18.5 fold, and Runt related transcription factor 2 (Runx2): 3.4 fold). ALP activity was significantly increased at 3 and 7 days inside the irradiated compared to that in the non irradiated SC/DPSC complexes, but gradually decreased until 14 days. Newly formed Ca P tissue was formed on the SC/DPSC complexes after 28 days of culture that attained the characteristics of bioapatite. Overall, LLLI treatment proved to be beneficial for odontogenic differentiation and biomineralization of DPSCs inside the bioceramic scaffolds, making this therapeutic modality promising for targeted dentin engineering.
C1 [Theocharidou, Anna; Bakopoulou, Athina; Kontonasaki, Eleana; Papachristou, Eleni; Hadjichristou, Christina; Bousnaki, Maria; Koidis, Petros] Aristotle Univ Thessaloniki, Sch Dent, Dept Fixed Prosthesis & Implant Prosthodont, GR 54124 Thessaloniki, Greece.
   [Theodorou, George; Paraskevopoulos, Konstantinos] Aristotle Univ Thessaloniki, Dept Phys, Fac Sci, GR 54124 Thessaloniki, Greece.
   [Papadopoulou, Lambrini; Kantiranis, Nikolaos] Aristotle Univ Thessaloniki, Dept Geol, Fac Sci, GR 54124 Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; Aristotle University of Thessaloniki
RP Koidis, P (通讯作者)，Aristotle Univ Thessaloniki, Sch Dent, Dept Fixed Prosthesis & Implant Prosthodont, GR 54124 Thessaloniki, Greece.
EM pkoidis@dent.auth.gr
RI ΘΕΟΧΑΡΙΔΟΥ, ΑΝΝΑ/AFB 4372 2022; Papachristou, Eleni/IWD 6327 2023;
   Paraskeuopoulos, Konstantinos/F 9926 2011; Kantiranis,
   Nikolaos/K 9487 2015; Papadopoulou, Lambrini/R 3341 2017; Hadjichristou,
   Christina/KWT 3642 2024
OI Papachristou, Eleni/0000 0002 2037 1955; Theodorou,
   Georgios/0000 0002 3539 3735; 
FU action Excellence II [5105]; European Union (EU); National Resources
FX This study was conducted under the action Excellence II (Project: 5105)
   and funded by the European Union (EU) and National Resources.
CR Alipanah Y, 2011, Med Laser Appl, V26, P133, DOI [10.1016/j.mla.2011.05.005, DOI 10.1016/J.MLA.2011.05.005]
   Amid R, 2014, J LASERS MED SCI, V5, P163
   [Anonymous], STEM CELL REV
   [Anonymous], REGEN MED
   [Anonymous], 2015, J INVEST CLIN DENT
   Arany PR, 2016, J DENT RES, V95, P977, DOI 10.1177/0022034516648939
   Asnaashari M, 2013, J LASERS MED SCI, V4, P57
   Bakopoulou A, 2015, DENT MATER, V31, P542, DOI 10.1016/j.dental.2015.02.004
   Cerdeira CD, 2016, J BIOPHOTONICS, V9, P1180, DOI 10.1002/jbio.201600035
   Chen S, 2009, J DENT RES, V88, P904, DOI 10.1177/0022034509342873
   Eduardo FD, 2008, LASER SURG MED, V40, P433, DOI 10.1002/lsm.20646
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Engel KW, 2016, J BIOPHOTONICS, V9, P1148, DOI 10.1002/jbio.201600025
   Fabre HSC, 2015, J PHYS THER SCI, V27, P1645, DOI 10.1589/jpts.27.1645
   Feng J, 2015, INT J BIOCHEM CELL B, V66, P59, DOI 10.1016/j.biocel.2015.07.002
   Giannelli M, 2013, J CELL PHYSIOL, V228, P172, DOI 10.1002/jcp.24119
   Goel A, 2013, J MATER CHEM B, V1, P3073, DOI 10.1039/c3tb20163e
   Goudouri OM, 2014, MATER RES BULL, V49, P399, DOI 10.1016/j.materresbull.2013.09.027
   Gupta A, 2014, LASER MED SCI, V29, P257, DOI 10.1007/s10103 013 1319 0
   Hirata S, 2010, J CELL BIOCHEM, V111, P1445, DOI 10.1002/jcb.22872
   Hoppe A, 2013, BIOMATER SCI UK, V1, P254, DOI 10.1039/c2bm00116k
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Huang Y, 2009, BIOMATERIALS, V30, P5041, DOI 10.1016/j.biomaterials.2009.05.077
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751 1097.2008.00394.x
   Khan I, 2015, ADV WOUND CARE, V4, P724, DOI 10.1089/wound.2014.0623
   Kontonasaki E., 2015, BALK J DENT MED, V19, P75, DOI [10.1515/bjdm 2015 0039, DOI 10.1515/BJDM 2015 0039]
   Kushibiki T, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/974864
   Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P1926, DOI 10.1016/j.jcms.2015.08.026
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   Pan K, 2010, CELL PROLIFERAT, V43, P219, DOI 10.1111/j.1365 2184.2010.00670.x
   Pyo SJ, 2013, LASER MED SCI, V28, P543, DOI 10.1007/s10103 012 1109 0
   Qu TJ, 2014, TISSUE ENG PT A, V20, P2422, DOI [10.1089/ten.tea.2013.0741, 10.1089/ten.TEA.2013.0741]
   Rola P, 2014, ADV CLIN EXP MED, V23, P835, DOI 10.17219/acem/37263
   Saygun I, 2008, LASER MED SCI, V23, P211, DOI 10.1007/s10103 007 0477 3
   SMITH K C, 1991, Laser Therapy, V3, P19
   Soleimani M, 2012, LASER MED SCI, V27, P423, DOI 10.1007/s10103 011 0930 1
   Theodorou GS, 2016, INT J BIOMATER, V2016, DOI 10.1155/2016/3858301
   Wu Jian., 2012, Journal of Reviews on Global Economics, V1, P1, DOI [10.6000/1929 7092.2012.01.6, DOI 10.6000/1929 7092.2012.01.6]
   Zecha JAEM, 2016, SUPPORT CARE CANCER, V24, P2793, DOI 10.1007/s00520 016 3153 y
   Zhang YO, 2003, J INVEST DERMATOL, V120, P849, DOI 10.1046/j.1523 1747.2003.12133.x
NR 44
TC 39
Z9 41
U1 0
U2 27
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JAN
PY 2017
VL 32
IS 1
BP 201
EP 210
DI 10.1007/s10103 016 2102 9
PG 10
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA EH9HH
UT WOS:000392081900024
PM 27785631
DA 2025 08 17
ER

PT J
AU Vaddamanu, SK
   Alhamoudi, FH
   Vyas, R
   Gurumurthy, V
   Siurkel, Y
   Cicciu, M
   Minervini, G
AF Vaddamanu, Sunil Kumar
   Alhamoudi, Fahad Hussain
   Vyas, Rajesh
   Gurumurthy, Vishwanath
   Siurkel, Yulia
   Cicciu, Marco
   Minervini, Giuseppe
TI Attenuation of orthodontically induced inflammatory root resorption by
   using low intensity pulsed ultrasound as a therapeutic modality  a
   systematic review
SO BMC ORAL HEALTH
LA English
DT Article
DE Root resorption; Ultrasound; Orthodontic; Tooth movement; Low intensity
   pulsed ultrasound (LIPUS); Non invasive therapies
ID HORMONE RELATED PROTEIN; PHYSICAL PROPERTIES; STIMULATION; CEMENTUM;
   INTEGRIN; DIFFERENTIATION; OSTEOBLASTS; EXPRESSION; GROWTH;
   CYCLOOXYGENASE 2
AB Ultrasound is an effective tool for both diagnostic and therapeutic applications. As an imaging tool, ultrasound has mostly been used for real time noninvasive diagnostic imaging. As ultrasound propagates through a material, a reflected radio frequency (RF) signal is generated when encountering a mismatch in acoustic impedance. While traditionally recognized for its diagnostic imaging capabilities, the application of ultrasound has broadened to encompass therapeutic interventions, most notably in the form of Low Intensity Pulsed Ultrasound (LIPUS). Low Intensity Pulsed Ultrasound (LIPUS) is a form of mechanical energy transmitted transcutaneously by high frequency acoustic pressure waves. The intensity of LIPUS (30 mW/cm2) is within the range of ultrasound intensities used for diagnostic purposes (1 50 mW/cm2) and is regarded as non thermal, non destructive, permeating living tissues and triggering a cascade of biochemical responses at the cellular level. The LIPUS device produces a 200 mu s burst of 1.5 MHz acoustic sine waves, that repeats at a modulation frequency of 1 kHz and provides a peak pressure of 30 mW/cm2. Low intensity pulsed ultrasound (LIPUS) forms one of the currently available non invasive healing enhancing devices besides electro stimulation (pulsed electro magnetic field, PEMF). This modality has been leveraged to enhance drug delivery, expedite injury recovery, improve muscle mobility, alleviate joint stiffness and muscle pain, and enhance bone fracture healing. Although LIPUS has been embraced within various medical disciplines, its integration into standard dental practices is still in its nascent stages, signifying an unexplored frontier with potentially transformative implications. Low intensity pulsed ultrasound (LIPUS) has emerged as an attractive adjuvant therapy in various dental procedures, such as orthodontic treatment and maxillary sinus augmentation. Its appeal lies in its simplicity and non invasive nature, positioning LIPUS as a promising avenue for clinical innovation. One particular area of interest is orthodontically induced inflammatory root resorption (OIIRR), an oftenunavoidable outcome of the orthodontic intervention, resulting in the permanent loss of root structure. Notably, OIIRR is the second most common form of root resorption (RR), surpassed only by root resorption related to pulpal infection. Given the high prevalence and potential long term consequences of OIIRR, this literature review seeks to evaluate the efficacy of LIPUS as a therapeutic approach, with an emphasis on assessing its capacity to reduce the severity of OIIRR to a level of clinical significance. To conduct this systematic review, a comprehensive automated literature search was executed across multiple databases, including MEDLINE, Embase, PsycINFO, Web of Knowledge, Scopus, CINAHL, LILACS, SciELO, Cochrane, PubMed, trials registries, 3ie, and Google Scholar. Both forward and backward citation tracking was employed, encompassing studies published from database inception through January 2009 to April 2023. The review focused on randomized controlled trials (RCTs) that specifically evaluated the effects of low intensity pulsed ultrasound therapy on orthodontically induced inflammatory root resorption (OIIRR), without restrictions of publication date. A stringent selection criterion was applied, and only studies demonstrating high levels of statistical significance were included. Ultimately, fourteen studies met the inclusion criteria and were subjected to further analysis.
   The overall quality of the included randomized controlled trials (RCTs) was rigorously assessed utilizing the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. This analysis revealed certain methodological limitations that posed challenges in drawing definitive conclusions from the available evidence. Despite these constraints, the review offers invaluable insights that can inform and guide future research. Specifically, it delineates recommendations for targeted populations, necessary interventions, appropriate outcome measures, suitable study designs, and essential infrastructure to facilitate further investigations. The synthesis of these insights aims to enhance the development and application of low intensity pulsed ultrasound therapy within the field of dentistry, thereby contributing to improved patient outcomes.
C1 [Vaddamanu, Sunil Kumar; Alhamoudi, Fahad Hussain; Vyas, Rajesh; Gurumurthy, Vishwanath] King Khalid Univ, Coll Appl Med Sci, Dept Dent Technol, Abha 62529, Saudi Arabia.
   [Siurkel, Yulia] Int European Univ, Sch Med, Akademika Hlushkova Ave, 42В, UA 03187 Kiev, Ukraine.
   [Cicciu, Marco] Catania Univ, Dept Biomed & Surg & Biomed Sci, I 95123 Catania, Italy.
   [Minervini, Giuseppe] Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, Chennai, Tamil Nadu, India.
   [Minervini, Giuseppe] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Specialties, I 81100 Caserta, Italy.
C3 King Khalid University; International European University; University of
   Catania; Saveetha Institute of Medical & Technical Science; Saveetha
   Dental College & Hospital; Universita della Campania Vanvitelli
RP Vaddamanu, SK (通讯作者)，King Khalid Univ, Coll Appl Med Sci, Dept Dent Technol, Abha 62529, Saudi Arabia.; Siurkel, Y (通讯作者)，Int European Univ, Sch Med, Akademika Hlushkova Ave, 42В, UA 03187 Kiev, Ukraine.; Minervini, G (通讯作者)，Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, Chennai, Tamil Nadu, India.; Minervini, G (通讯作者)，Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Specialties, I 81100 Caserta, Italy.
EM snu@kku.edu.sa; yuliasiurkel@ieu.edu.ua;
   Giuseppe.minervini@unicampania.it
RI Gurumurthy, Vishwanath/KIL 4570 2024; Vyas, Rajesh/HIZ 9975 2022;
   vaddamanu, sunil/AAX 1781 2020; Cicciù, Marco/AAO 6713 2020; Alhamoudi,
   Fahad/GRE 9921 2022; minervini, giuseppe/AAM 9828 2021
OI vaddamanu, sunil/0000 0002 1583 3246; vyas, rajesh/0000 0001 5628 8355;
   Alhamoudi, Fahad/0000 0002 8391 1787; 
FU Deanship of Scientific Research at King Khalid University
FX The authors extend their appreciation to the Deanship of Scientific
   Research at King Khalid University for funding this work through review
   article project.
CR Al Daghreer S, 2014, ULTRASOUND MED BIOL, V40, P1187, DOI 10.1016/j.ultrasmedbio.2013.12.016
   Al Daghreer S, 2013, ULTRASOUND MED BIOL, V39, P1066, DOI 10.1016/j.ultrasmedbio.2012.12.005
   Al Daghreer S, 2012, ARCH ORAL BIOL, V57, P760, DOI 10.1016/j.archoralbio.2011.11.010
   Dalla Bona DA, 2006, ULTRASOUND MED BIOL, V32, P943, DOI 10.1016/j.ultrasmedbio.2006.01.015
   Bartley N, 2011, AM J ORTHOD DENTOFAC, V139, pE353, DOI 10.1016/j.ajodo.2010.01.033
   BAYRAMOGLU Z, 2023, Minerva Dent Oral Sci., V72
   Boabaid F, 2004, J PERIODONTOL, V75, P1247, DOI 10.1902/jop.2004.75.9.1247
   Bosshardt DD, 1997, PERIODONTOL 2000, V13, P41, DOI 10.1111/j.1600 0757.1997.tb00095.x
   BUCKLEY MJ, 1988, BONE MINER, V4, P225
   Busse JW, 2002, CAN MED ASSOC J, V166, P437
   Casa M A, 2001, J Orofac Orthop, V62, P285, DOI 10.1007/PL00001936
   Chan E, 2006, AM J ORTHOD DENTOFAC, V129, P504, DOI 10.1016/j.ajodo.2004.12.018
   CHANDAN C, 2023, Minerva Dent Oral Sci, V72
   CHAPMAN IV, 1980, ULTRASOUND MED BIOL, V6, P47, DOI 10.1016/0301 5629(80)90063 0
   Dalla Bona DA, 2008, ARCH ORAL BIOL, V53, P318, DOI 10.1016/j.archoralbio.2007.11.006
   Del Corso M, 2010, ORAL SURG ORAL MED O, V110, P418, DOI 10.1016/j.tripleo.2010.05.059
   Dovigo S, 2023, DENT MED PROBL, V60, P375, DOI 10.17219/dmp/154981
   El Bialy T, 2004, AM J ORTHOD DENTOFAC, V126, P186, DOI 10.1016/j.ajodo.2004.02.010
   El Bialy T, 2011, J DENT, V39, P693, DOI 10.1016/j.jdent.2011.08.001
   El Bialy TH, 2008, J DENT RES, V87, P953, DOI 10.1177/154405910808701018
   El Bialy T, 2014, ANN BIOMED ENG, V42, P1406, DOI 10.1007/s10439 014 1013 9
   El Bialy TH, 2003, AM J ORTHOD DENTOFAC, V124, P427, DOI 10.1016/S0889 5406(03)00408 6
   El Bialy TH, 2002, ANN BIOMED ENG, V30, P1251, DOI 10.1114/1.1529196
   Franco R, 2020, EUR REV MED PHARMACO, V24, P5036, DOI 10.26355/eurrev_202005_21196
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Hasuike A, 2011, ORAL SURG ORAL MED O, V111, pE12, DOI 10.1016/j.tripleo.2010.09.061
   Hsu HC, 2007, CELL SIGNAL, V19, P2317, DOI 10.1016/j.cellsig.2007.07.006
   Hu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095168
   Ikai H, 2008, J PERIODONTAL RES, V43, P212, DOI 10.1111/j.1600 0765.2007.01016.x
   Inubushi T, 2008, J PERIODONTOL, V79, P1984, DOI [10.1902/jop.2008.080081, 10.1902/jop.2008.080081 ]
   Inubushi T, 2013, BONE, V53, P497, DOI 10.1016/j.bone.2013.01.021
   Iwabuchi Y, 2014, J ORAL FACIAL PAIN H, V28, P261, DOI 10.11607/ofph.1156
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P138, DOI 10.2106/JBJS.G.01218
   Kim Sang Hun, 2010, J Periodontal Implant Sci, V40, P271, DOI 10.5051/jpis.2010.40.6.271
   Li JK, 2003, BIOMATERIALS, V24, P2379, DOI 10.1016/S0142 9612(03)00033 4
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Liu ZF, 2012, ANGLE ORTHOD, V82, P48, DOI 10.2319/030711 164.1
   Lo Russo L, 2023, BIOENGINEERING BASEL, V10, DOI 10.3390/bioengineering10070875
   Lyon R, 2003, J ORTHOPAED RES, V21, P865, DOI 10.1016/S0736 0266(03)00047 0
   Manaka S, 2015, FEBS LETT, V589, P310, DOI 10.1016/j.febslet.2014.12.013
   Minervini G, 2023, BMC ORAL HEALTH, V23, DOI 10.1186/s12903 023 03424 x
   Minervini G, 2023, J ORAL REHABIL, V50, P522, DOI 10.1111/joor.13446
   Miranda M, 2016, Oral Implantol (Rome), V9, P151, DOI 10.11138/orl/2016.9.3.151
   Mostafa NZ, 2009, ARCH ORAL BIOL, V54, P743, DOI 10.1016/j.archoralbio.2009.04.012
   Ouyang HJ, 2000, ENDOCRINOLOGY, V141, P4671, DOI 10.1210/en.141.12.4671
   Parvizi J, 2002, J ORTHOPAED RES, V20, P51, DOI 10.1016/S0736 0266(01)00069 9
   Pounder NM, 2008, ULTRASONICS, V48, P330, DOI 10.1016/j.ultras.2008.02.005
   Rapone B, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19020985
   Rathi S, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59020410
   Reddy LKV, 2022, J PERS MED, V12, DOI 10.3390/jpm12111920
   Rego EB, 2011, J PERIODONTAL RES, V46, P648, DOI 10.1111/j.1600 0765.2011.01384.x
   Rego Emanuel Braga, 2012, Open Dent J, V6, P220, DOI 10.2174/1874210601206010220
   Rego EB, 2010, ULTRASOUND MED BIOL, V36, P907, DOI 10.1016/j.ultrasmedbio.2010.03.008
   Reher P, 1999, CYTOKINE, V11, P416, DOI 10.1006/cyto.1998.0444
   REITAN K, 1974, ANGLE ORTHOD, V44, P68
   Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175
   Russell J, 2023, PROSTHESIS, V5, P453, DOI 10.3390/prosthesis5020031
   Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024
   Sato M, 2014, ANN BIOMED ENG, V42, P2156, DOI 10.1007/s10439 014 1081 x
   Scheven BA, 2009, ARCH ORAL BIOL, V54, P185, DOI 10.1016/j.archoralbio.2008.09.008
   Scheven BA, 2007, ULTRASOUND MED BIOL, V33, P1475, DOI 10.1016/j.ultrasmedbio.2007.03.010
   Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962 8924(97)01172 0
   Shaikh S, 2023, PROSTHESIS, V5, P550, DOI 10.3390/prosthesis5020038
   Shiraishi R, 2011, J PERIODONTOL, V82, P1498, DOI 10.1902/jop.2011.100627
   Smith NB, 2001, ULTRASOUND MED BIOL, V27, P1427, DOI 10.1016/S0301 5629(01)00454 9
   Soegiantho P, 2023, PROSTHESIS, V5, P378, DOI 10.3390/prosthesis5020028
   Tajali SB, 2012, AM J PHYS MED REHAB, V91, P349, DOI 10.1097/PHM.0b013e31822419ba
   Tanaka E, 2015, ANN BIOMED ENG, V43, P871, DOI 10.1007/s10439 015 1274 y
   Tortora C, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10040874
   Tsaklis P, 2010, Hum Mov, V11
   Vaddamanu SK, 2022, J PHARM BIOALLIED SC, V14, P530, DOI 10.4103/jpbs.jpbs_98_22
   Vaddamanu SK, 2019, TROP J PHARM RES, V18, P877, DOI 10.4314/tjpr.v18i4.28
   Vafaeian B, 2015, ULTRASOUND MED BIOL, V41, P2173, DOI 10.1016/j.ultrasmedbio.2015.03.027
   Vaid NR, 2023, SEMIN ORTHOD, V29, P1, DOI 10.1053/j.sodo.2023.02.002
   Verna C, 2006, Orthod Craniofac Res, V9, P57, DOI 10.1111/j.1601 6343.2006.00342.x
   Vozzo LM, 2023, PROSTHESIS, V5, P425, DOI 10.3390/prosthesis5020029
   Wang YJ, 2014, ULTRASONICS, V54, P1581, DOI 10.1016/j.ultras.2014.03.015
   Wierzbicki T, 2009, ANGLE ORTHOD, V79, P91, DOI 10.2319/112107 546.1
   WILLIAMS S, 1984, EUR J ORTHODONT, V6, P35, DOI 10.1093/ejo/6.1.35
   Xue H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0074366, 10.1371/journal.pone.0068926]
   Yokoyama M, 2023, PROSTHESIS, V5, P346, DOI 10.3390/prosthesis5020025
NR 81
TC 4
Z9 4
U1 2
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD JAN 10
PY 2024
VL 24
IS 1
AR 67
DI 10.1186/s12903 023 03741 1
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ES6A7
UT WOS:001140940200001
PM 38200481
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liang, XQ
   Zhao, J
   Hajivandi, M
   Wu, R
   Tao, J
   Amshey, JW
   Pope, RM
AF Liang, Xiquan
   Zhao, Jenson
   Hajivandi, Mahbod
   Wu, Rina
   Tao, Janet
   Amshey, Joseph W.
   Pope, R. Marshall
TI Quantification of membrane and membrane bound proteins in normal and
   malignant breast cancer cells isolated from the same patient with
   primary breast carcinoma
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE breast cancer; quantitative proteomics; SILAC; biomarkers; membrane
   proteins; immunohistochemistry (IHC)
ID TANDEM MASS SPECTROMETRY; OXYGEN REGULATED PROTEIN; PROSTATE CANCER;
   AMINO ACIDS; NUCLEAR RIBONUCLEOPROTEIN; QUANTITATIVE PROTEOMICS;
   LIQUID CHROMATOGRAPHY; STATISTICAL MODEL; AMINOPEPTIDASE N; CULTURE
   SILAC
AB More than 50% of all major drug targets are membrane proteins, and their role in cell cell interaction and signal transduction is a vital concern. By culturing normal and malignant breast cancer cells with light or heavy isotopes of amino acids (SILAC), followed by cell fractionation, 1D gel separation of crude membrane proteins, and analysis of the digests using nanoelectrospray LC MS/MS, we have quantified 1600 gene products that group into 997 protein families with approximately 830 membrane or membrane associated proteins; 100 unknown, unnamed, or hypothetical proteins; and 65 protein families classified as ribosomal, heat shock, or histone proteins. A number of proteins show increased expression levels in malignant breast cancer cells, such as autoantigen p542, osteoblast specific factor 2 (OSF 2), 4F2 heavy chain antigen, 34 kDa nucleolar scleroderma antigen, and apoptosis inhibitor 5. The expression of other proteins, such as membrane alanine aminopeptidase (CD13), epididymal protein, macroglobulin alpha2, PZP_HUMAN, and transglutaminase C, decreased in malignant breast cancer cells, whereas the majority of proteins remained unchanged when compared to the corresponding nonmalignant samples. Downregulation of CD13 and upregulation of OSF 2 were confirmed by immunohistochemistry using human tissue arrays with breast carcinomas. Furthermore, at least half the gene products displaying an expression change of 5 fold or higher have been described previously in the literature as having an association with cancerous malignancy. These results indicate that SILAC is a powerful technique that can be extended to the discovery of membrane bound antigens that may be used to phenotype diseased cells.
C1 Invitrogen Life Sci, Dept Proteom, Life Sci R&D, Prot Anal, Carlsbad, CA 92008 USA.
C3 Thermo Fisher Scientific
RP Pope, RM (通讯作者)，Invitrogen Life Sci, Dept Proteom, Life Sci R&D, Prot Anal, 5781 Van Alley Way, Carlsbad, CA 92008 USA.
EM marshall.pope@invitrogen.com
CR Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207
   Asahi H, 2002, BJU INT, V90, P462, DOI 10.1046/j.1464 410X.2002.02915.x
   Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790
   Bogenrieder T, 1997, PROSTATE, V33, P225
   CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046 8177(94)90003 5
   Celis JE, 2004, MOL CELL PROTEOMICS, V3, P327, DOI 10.1074/mcp.M400009 MCP200
   Chen X, 2000, ANAL CHEM, V72, P1134, DOI 10.1021/ac9911600
   Chetcuti A, 2001, CANCER RES, V61, P6331
   CHRISTENSEN U, 1989, BIOCHEMISTRY US, V28, P9324, DOI 10.1021/bi00450a012
   DeSouza L, 2005, J PROTEOME RES, V4, P377, DOI 10.1021/pr049821j
   Everley PA, 2004, MOL CELL PROTEOMICS, V3, P729, DOI 10.1074/mcp.M400021 MCP200
   Gillan L, 2002, CANCER RES, V62, P5358
   Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P310, DOI 10.1074/mcp.M400219 MCP200
   Gu S, 2004, J PROTEOME RES, V3, P1191, DOI 10.1021/pr049893a
   Gu S, 2004, MOL CELL PROTEOMICS, V3, P998, DOI 10.1074/mcp.M400033 MCP200
   Ibarrola N, 2004, J BIOL CHEM, V279, P15805, DOI 10.1074/jbc.M311714200
   Ibarrola N, 2003, ANAL CHEM, V75, P6043, DOI 10.1021/ac034931f
   Kanoh W, 2001, ANTICANCER RES, V21, P551
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kim DK, 2004, ANTICANCER RES, V24, P1671
   KREPELA E, 1989, NEOPLASMA, V36, P41
   LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Ong SE, 2004, NAT METHODS, V1, P119, DOI 10.1038/NMETH715
   Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025 MCP200
   Ong SE, 2003, J PROTEOME RES, V2, P173, DOI 10.1021/pr0255708
   Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522 2683(19991201)20:18<3551::AID ELPS3551>3.0.CO;2 2
   Rhodes GH, 1997, J AUTOIMMUN, V10, P447, DOI 10.1006/jaut.1997.9996
   Sechi S, 2003, CURR OPIN CHEM BIOL, V7, P70, DOI 10.1016/S1367 5931(02)00010 8
   SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999
   Shui WQ, 2005, J PROTEOME RES, V4, P83, DOI 10.1021/pr049850u
   Smitherman AB, 2004, J UROLOGY, V171, P916, DOI 10.1097/01.ju.0000104674.70170.cd
   Thomssen C, 1995, CLIN CANCER RES, V1, P741
   Tsukamoto Y, 1998, LAB INVEST, V78, P699
   Yoon JH, 2003, ANTICANCER RES, V23, P3877
   Zappacosta F, 2004, ANAL CHEM, V76, P6618, DOI 10.1021/ac049169b
   Zhang Xun, 2003, Zhonghua Zhongliu Zazhi, V25, P353
   Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037
   Zhu HN, 2002, ANAL CHEM, V74, P1687, DOI 10.1021/ac010853p
NR 39
TC 52
Z9 62
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD OCT 6
PY 2006
VL 5
IS 10
BP 2632
EP 2641
DI 10.1021/pr060125o
PG 10
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 091UF
UT WOS:000241053100015
PM 17022634
DA 2025 08 17
ER

PT J
AU Ueda, D
   Matsuda, N
   Takaba, Y
   Hirai, N
   Inoue, M
   Kameya, T
   Abe, T
   Tagaya, N
   Isogai, Y
   Kakihara, Y
   Bartels, F
   Christmann, M
   Shinada, T
   Yasuda, K
   Sato, T
AF Ueda, Daijiro
   Matsuda, Natsu
   Takaba, Yuka
   Hirai, Nami
   Inoue, Mao
   Kameya, Taichi
   Abe, Tohru
   Tagaya, Nao
   Isogai, Yasuhiro
   Kakihara, Yoshito
   Bartels, Florian
   Christmann, Mathias
   Shinada, Tetsuro
   Yasuda, Kaori
   Sato, Tsutomu
TI Analysis of vitamin D receptor binding affinities of enzymatically
   synthesized triterpenes including ambrein and unnatural onoceroids
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SQUALENE HOPENE CYCLASE; CATALYTIC MECHANISM; IDENTIFICATION;
   CYCLIZATION; OSTEOCLASTS; SYNTHASE
AB Onoceroids are a rare family of triterpenes. One representative onoceroid is ambrein, which is the main component of ambergris used as a traditional medicine. We have previously identified the onoceroid synthase, BmeTC, in Bacillus megaterium and succeeded in creating ambrein synthase by introducing mutations into BmeTC. Owing to the structural similarity of ambrein to vitamin D, a molecule with diverse biological activities, we hypothesized that some of the activities of ambergris may be induced by the binding of ambrein to the vitamin D receptor (VDR). We demonstrated the VDR binding ability of ambrein. By comparing the structure activity relationships of triterpenes with both the VDR affinity and osteoclastic differentiation promoting activity, we observed that the activity of ambrein was not induced via the VDR. Therefore, some of the activities of ambergris, but not all, can be attributed to its VDR interaction. Additionally, six unnatural onoceroids were synthesized using the BmeTC reactions, and these compounds exhibited higher VDR affinity than that of ambrein. Enzymatic syntheses of onoceroid libraries will be valuable in creating a variety of bioactive compounds beyond ambergris.
C1 [Ueda, Daijiro; Matsuda, Natsu; Takaba, Yuka; Hirai, Nami; Inoue, Mao; Kameya, Taichi; Abe, Tohru; Sato, Tsutomu] Niigata Univ, Grad Sch Sci & Technol, Niigata, Japan.
   [Tagaya, Nao; Isogai, Yasuhiro; Yasuda, Kaori] Toyama Prefectural Univ, Fac Engn, Dept Pharmaceut Engn, Imizu, Japan.
   [Kakihara, Yoshito] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan.
   [Bartels, Florian; Christmann, Mathias] Freie Unvers Berlin, Inst Chem & Biochem, Berlin, Germany.
   [Shinada, Tetsuro] Osaka Metropolitan Univ, Grad Sch Sci, Osaka, Japan.
C3 Niigata University; Toyama Prefectural University; Niigata University;
   Osaka Metropolitan University
RP Sato, T (通讯作者)，Niigata Univ, Grad Sch Sci & Technol, Niigata, Japan.; Yasuda, K (通讯作者)，Toyama Prefectural Univ, Fac Engn, Dept Pharmaceut Engn, Imizu, Japan.
EM kyasuda@pu toyama.ac.jp; satot@agr.niigata u.ac.jp
RI Ueda, Daijiro/U 8148 2019
OI Abe, Tohru/0000 0003 4868 3237
FU JSPS KAKENHI [20K15455, 23K13894, 19H04648, 23H04550]; Grants in Aid for
   Scientific Research [23H04560] Funding Source: KAKEN
FX This work was supported in part by the JSPS KAKENHI (Grant# 20K15455 and
   23K13894 to DU, and 19H04648 and 23H04550 to TSa). We would like to
   thank Editage for English language editing.
CR Akagi Y, 2018, J STEROID BIOCHEM, V177, P240, DOI 10.1016/j.jsbmb.2017.07.017
   Almeida A, 2018, PLANT PHYSIOL, V176, P1469, DOI 10.1104/pp.17.01369
   Araki T, 2016, CHEMBIOCHEM, V17, P288, DOI 10.1002/cbic.201500663
   Bartels F, 2017, CHEM SCI, V8, P8285, DOI 10.1039/c7sc03903d
   Chen K, 2021, NAT PROD REP, V38, P2261, DOI 10.1039/d1np00015b
   Eichhorn E, 2023, J AGR FOOD CHEM, V71, P5042, DOI 10.1021/acs.jafc.2c09010
   Gu JH, 2015, J STEROID BIOCHEM, V152, P25, DOI 10.1016/j.jsbmb.2015.04.003
   Hoshino T, 2002, CHEM COMMUN, P291, DOI 10.1039/b108995c
   Kawagoe F, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111639
   Mano H, 2018, J STEROID BIOCHEM, V178, P55, DOI 10.1016/j.jsbmb.2017.10.024
   Marchesini AM, 2009, J BRAZIL CHEM SOC, V20, P1598, DOI 10.1590/S0103 50532009000900006
   Nakata J, 2020, BIOCHEM BIOPH RES CO, V526, P547, DOI 10.1016/j.bbrc.2020.03.033
   Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097 2765(00)80413 X
   Saga Y, 2017, ORG LETT, V19, P496, DOI 10.1021/acs.orglett.6b03659
   Sato T, 1999, BIOSCI BIOTECH BIOCH, V63, P1171, DOI 10.1271/bbb.63.1171
   Sato T, 2011, J AM CHEM SOC, V133, P17540, DOI 10.1021/ja2060319
   Tenkovskaia L, 2017, CHEMBIOCHEM, V18, P1910, DOI 10.1002/cbic.201700329
   Ueda D, 2013, J AM CHEM SOC, V135, P18335, DOI 10.1021/ja4107226
   Vincent C, 2009, J BONE MINER METAB, V27, P114, DOI 10.1007/s00774 008 0018 6
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Yamabe Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 76624 y
   Yasuda K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111839
NR 22
TC 0
Z9 0
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JAN 16
PY 2024
VL 14
IS 1
AR 1419
DI 10.1038/s41598 024 52013 7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FO0U5
UT WOS:001146669200094
PM 38228813
OA gold
DA 2025 08 17
ER

PT J
AU Piccinno, MS
   Petrachi, T
   Resca, E
   Strusi, V
   Bergamini, V
   Mulas, GA
   Mari, G
   Dominici, M
   Veronesi, E
AF Piccinno, Maria Serena
   Petrachi, Tiziana
   Resca, Elisa
   Strusi, Valentina
   Bergamini, Valentina
   Mulas, Giuseppe Antonio
   Mari, Giorgio
   Dominici, Massimo
   Veronesi, Elena
TI Label free toxicology screening of primary human mesenchymal cells and
   iPS derived neurons
SO PLOS ONE
LA English
DT Article
ID GUIDE GRATING BIOSENSOR; DRUG DISCOVERY; OPTICAL BIOSENSORS; ASSAYS;
   CRANIOPLASTY; DEATH
AB The high throughput, label free Corning Epic assay has applications in drug discovery, pharmacogenomics, cell receptor signaling, cell migration, and viral titration. The utility of Epic technology for biocompatibility testing has not been well established. In manufacturing of medical devices, in vitro and in vivo biocompatibility assessments are mandatory, according to ISO 10993. The new medical device regulation MDR 745/2017 specifies that ex vivo assays that can closely recapitulate in vivo scenarios are needed to better evaluate biomedical devices. We propose herein that Epic technology which enables detection of variations in cell mass distribution is suitable for biocompatibility screening of compounds. In this study, we challenged primary human osteoblasts, endothelial cells, and neurons derived from induced pluripotent stem cells with specific concentrations of methyl methacrylate (MMA). Polymeric MMA has long been applied in cranioplasty, where it makes contact with multiple cell types. Application of Epic technology yielded real time cytotoxicity profiles for all considered cell types. The results were compared with those from microscopic observation of the same culture plate used in the Epic analyses. The Epic assay should be further examined for its utility for cell biology, genomics, and proteomics companion assays. Our results suggest that Epic technology can be applied to biocompatibility evaluation of human cells in medical device development.
C1 [Piccinno, Maria Serena; Petrachi, Tiziana; Resca, Elisa; Strusi, Valentina; Mulas, Giuseppe Antonio; Mari, Giorgio; Dominici, Massimo; Veronesi, Elena] Sci & Technol Pk Med TPM, Mirandola, Italy.
   [Piccinno, Maria Serena; Petrachi, Tiziana; Resca, Elisa; Bergamini, Valentina; Dominici, Massimo; Veronesi, Elena] Univ Hosp Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy.
C3 Universita di Modena e Reggio Emilia; Universita di Modena e Reggio
   Emilia Hospital
RP Piccinno, MS; Veronesi, E (通讯作者)，Sci & Technol Pk Med TPM, Mirandola, Italy.; Piccinno, MS; Veronesi, E (通讯作者)，Univ Hosp Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy.
EM mariaserena.piccinno@tpm.bio; elena.veronesi@tpm.bio
RI Dominici, Massimo/K 8014 2016; Bergamini, Valentina/HLQ 2200 2023;
   Veronesi, Elena/HZH 6902 2023; petrachi, tiziana/IQW 2628 2023; Resca,
   Elisa/F 2666 2019
OI PETRACHI, TIZIANA/0000 0001 9399 9957; Bergamini,
   Valentina/0000 0002 9214 1462; Veronesi, Elena/0000 0001 6262 1388;
   resca, elisa/0000 0001 6405 7522; 
FU Emilia Romagna region, POR FESR 2014 2020, Asse 1, Azione 1.2.2; project
   TECNO EN P
FX This work was funded by the Emilia Romagna region, POR FESR 2014 2020,
   Asse 1, Azione 1.2.2, and project TECNO EN P.
CR [Anonymous], 2016, 1099310 ISO
   [Anonymous], 2009, 10993 ISO
   Bortner CD, 2002, CELL DEATH DIFFER, V9, P1307, DOI 10.1038/sj.cdd.4401126
   Camp ND, 2016, PHARMACOL RES, V105, P13, DOI 10.1016/j.phrs.2016.01.003
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fang Y, 2005, FEBS LETT, V579, P4175, DOI 10.1016/j.febslet.2005.06.050
   Fang Y, 2006, ASSAY DRUG DEV TECHN, V4, P583, DOI 10.1089/adt.2006.4.583
   Fang Y, 2006, BIOPHYS J, V91, P1925, DOI [10.1529/biophysj.105.077818, 10.1529/biophysj.105.007818]
   Fang Y, 2014, COMB CHEM HIGH T SCR, V17, P566, DOI 10.2174/1386207317666140211100000
   Fang Y, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00052
   Fang Y, 2009, METHODS MOL BIOL, V552, P239, DOI 10.1007/978 1 60327 317 6_17
   Hou T, 2016, PHARMACOL RES, V108, P39, DOI 10.1016/j.phrs.2016.04.018
   International Organization for Standardization, 2007, 1099312ISO
   Li WJ, 2015, BIOMED REP, V3, P617, DOI 10.3892/br.2015.481
   Owens RM, 2009, J RECEPT SIG TRANSD, V29, P195, DOI 10.1080/10799890903079919
   Pikis S, 2015, J CLIN NEUROSCI, V22, P139, DOI 10.1016/j.jocn.2014.06.006
   Riss T.L., 2004, CELL VIABILITY ASSAY
   Riss TL, 2011, METHODS MOL BIOL, V740, P103, DOI 10.1007/978 1 61779 108 6_12
   Rodríguez Antona C, 2015, J INTERN MED, V277, P201, DOI 10.1111/joim.12321
   Schröder R, 2011, NAT PROTOC, V6, P1748, DOI 10.1038/nprot.2011.386
   van Tonder Alet, 2015, BMC Res Notes, V8, P47, DOI 10.1186/s13104 015 1000 8
   Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zheng W, 2013, DRUG DISCOV TODAY, V18, P1067, DOI 10.1016/j.drudis.2013.07.001
NR 24
TC 5
Z9 5
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2018
VL 13
IS 9
AR e0201671
DI 10.1371/journal.pone.0201671
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GT1IK
UT WOS:000444222400003
PM 30180158
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Courties, A
   Kouki, I
   Soliman, N
   Mathieu, S
   Sellam, J
AF Courties, Alice
   Kouki, Ines
   Soliman, Nadine
   Mathieu, Sylvain
   Sellam, Jeremie
TI Osteoarthritis year in review 2024: Epidemiology and therapy
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Osteoarthritis; Clinical trial; Randomized; Pain; Epidemiology
ID KNEE OSTEOARTHRITIS
AB This "Year in Review" presents a curated selection of research themes and individual studies within the clinical osteoarthritis (OA) field, focusing on epidemiology and therapy. The search was conducted in electronic database MEDLINE from March 4, 2023, to March 31, 2024, specifically targeting English language articles involving human participants. Inclusions were based on perceived importance and relevance to identifying risk factors or advancing OA treatments. A total of 6539 studies were screened by the 5 authors, resulting in 157 studies considered for potential inclusion. Ultimately, 44 studies were selected, uncovering six key OA related themes: i) the burden of OA (mostly from Global Burden of Disease studies), ii) pain drivers and trajectories, iii) impacts of sex/gender, iv) OA risk factors, and treatments for v) hand and vi) knee OA. The prevalence of OA continues to rise, particularly affecting women, with unclear distinctions in risk factors and treatment responses between sexes. Associations with atopy were demonstrated in two significant databases. Notably, the authors were particularly interested in recent high quality methodology randomized controlled trials focusing on hand (methotrexate, denosumab, colchicine, topical betamethasone) and knee OA with conflicting results about stem cell injection. These findings collectively contribute to show the growing burden of OA, but also to help the understanding of OA pathophysiology and inform ongoing efforts to enhance management for people with OA. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Courties, Alice; Kouki, Ines; Sellam, Jeremie] Hop St Antoine, AP HP, Serv Rhumatol, Paris, France.
   [Courties, Alice; Kouki, Ines; Soliman, Nadine; Sellam, Jeremie] Sorbonne Univ, Ctr Rech St Antoine CRSA, INSERM, UMRS 938, Paris, France.
   [Mathieu, Sylvain] CHU Gabriel Montpied, Serv Rhumatol, Clermont Ferrand, France.
C3 Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital
   Universitaire Saint Antoine   APHP; Institut National de la Sante et de
   la Recherche Medicale (Inserm); Sorbonne Universite; Universite Clermont
   Auvergne (UCA); CHU Clermont Ferrand
RP Courties, A (通讯作者)，Hop St Antoine, Serv Rhumatol, 184 Rue Faubourg St Antoine, F 75012 Paris, France.
EM Alice.courties@aphp.fr
OI Mathieu, Sylvain/0000 0003 2017 3227
FU French Society of Rheumatology
FX Nadine Soliman received a grant from the French Society of Rheumatology.
CR Ackerman IN, 2023, INTERN MED J, V53, P1875, DOI 10.1111/imj.15933
   Altamirano S, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0283717
   Aoyagi K, 2024, ARTHRIT CARE RES, V76, P403, DOI 10.1002/acr.25244
   Baker MC, 2023, ANN RHEUM DIS, V82, P866, DOI 10.1136/ard 2022 223640
   Bihlet AR, 2024, ACR OPEN RHEUMATOL, V6, P205, DOI 10.1002/acr2.11610
   Cai GQ, 2024, ARTHRITIS RHEUMATOL, V76, P1047, DOI 10.1002/art.42831
   Ching AEL, 2023, BMC MUSCULOSKEL DIS, V24, DOI 10.1186/s12891 023 06612 6
   Clement Lacroix P, 2022, OSTEOARTHR CARTILAGE, V30, P291, DOI 10.1016/j.joca.2021.08.012
   Costa D, 2023, BMC PUBLIC HEALTH, V23, DOI 10.1186/s12889 023 16167 9
   Ding Y, 2024, PUBLIC HEALTH, V226, P261, DOI 10.1016/j.puhe.2023.10.030
   Dong YW, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 04089 6
   Dossing A, 2023, RMD OPEN, V9, DOI 10.1136/rmdopen 2023 003030
   Dossing A, 2023, LANCET RHEUMATOL, V5, pE254, DOI 10.1016/S2665 9913(23)00065 6
   Espinosa Salas S, 2024, OSTEOARTHR CARTIL OP, V6, DOI 10.1016/j.ocarto.2024.100438
   Estee MM, 2023, OSTEOARTHR CARTIL OP, V5, DOI 10.1016/j.ocarto.2023.100404
   Ferrero S, 2021, SEMIN ARTHRITIS RHEU, V51, P831, DOI 10.1016/j.semarthrit.2021.04.016
   Glass N, 2014, OSTEOARTHR CARTILAGE, V22, P1100, DOI 10.1016/j.joca.2014.06.030
   Jiang LY, 2016, INT J RHEUM DIS, V19, P1244, DOI 10.1111/1756 185X.12895
   Kim KI, 2023, AM J SPORT MED, V51, P2243, DOI 10.1177/03635465231179223
   Kloppenburg M, 2019, ANN RHEUM DIS, V78, P16, DOI 10.1136/annrheumdis 2018 213826
   Lane NE, 2024, ACR OPEN RHEUMATOL, V6, P43, DOI 10.1002/acr2.11619
   Li HY, 2024, CLIN RHEUMATOL, V43, P1189, DOI 10.1007/s10067 024 06885 9
   Marchand NE, 2023, ARTHRITIS RHEUMATOL, V75, P1522, DOI 10.1002/art.42543
   Mautner K, 2023, NAT MED, DOI 10.1038/s41591 023 02632 w
   Migliorini F, 2023, KNEE SURG SPORT TR A, V31, P5485, DOI 10.1007/s00167 023 07600 y
   Mulrooney E, 2023, OSTEOARTHR CARTIL OP, V5, DOI 10.1016/j.ocarto.2023.100367
   Neogi T, 2023, NAT REV RHEUMATOL, V19, P613, DOI 10.1038/s41584 023 01021 4
   Pramhas S, 2023, LANCET REG HEALTH EU, V35, DOI 10.1016/j.lanepe.2023.100777
   Riedstra NS, 2023, SEMIN ARTHRITIS RHEU, V60, DOI 10.1016/j.semarthrit.2023.152194
   Russell ER, 2023, OCCUP MED OXFORD, V73, P547, DOI 10.1093/occmed/kqad132
   Sadri B, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03359 8
   Salis Z, 2024, OSTEOARTHR CARTIL OP, V6, DOI 10.1016/j.ocarto.2023.100427
   Salis Z, 2024, ACR OPEN RHEUMATOL, V6, P155, DOI 10.1002/acr2.11644
   Salis Z, 2024, ARTHRIT CARE RES, V76, P652, DOI 10.1002/acr.25284
   Schnitzer T, 2023, OSTEOARTHR CARTILAGE, V31, P985, DOI 10.1016/j.joca.2023.04.001
   Steinmetz JD, 2023, LANCET RHEUMATOL, V5, pE508, DOI 10.1016/S2665 9913(23)00163 7
   Szilagyi IA, 2023, RHEUMATOLOGY, V62, P2037, DOI 10.1093/rheumatology/keac688
   Tamimi I, 2023, J BONE JOINT SURG AM, V105, P1494, DOI 10.2106/JBJS.22.01189
   Taslakian B, 2023, OSTEOARTHR CARTIL OP, V5, DOI 10.1016/j.ocarto.2023.100342
   van der Meulen C, 2023, RHEUMATOLOGY, V62, P3035, DOI 10.1093/rheumatology/kead017
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Wang Q, 2019, ELIFE, V8, DOI 10.7554/eLife.39905
   Wang YN, 2023, ARTHRIT CARE RES, V75, P2134, DOI 10.1002/acr.25127
   Wang YY, 2023, LANCET, V402, P1764, DOI 10.1016/S0140 6736(23)01572 6
   Wang YY, 2023, OSTEOARTHR CARTIL OP, V5, DOI 10.1016/j.ocarto.2023.100382
   Weng QL, 2024, ANN RHEUM DIS, V83, P915, DOI 10.1136/ard 2023 225324
   Wittoek R, 2024, NAT MED, V30, P829, DOI 10.1038/s41591 024 02822 0
   Yang GM, 2023, ARTHRIT CARE RES, V75, P2489, DOI 10.1002/acr.25158
   Yang Y, 2023, ARTHRITIS RES THER, V25, DOI 10.1186/s13075 023 03134 3
   Zhou SL, 2024, ARCH GERONTOL GERIAT, V118, DOI 10.1016/j.archger.2023.105284
NR 50
TC 46
Z9 48
U1 22
U2 32
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD NOV
PY 2024
VL 32
IS 11
BP 1397
EP 1404
DI 10.1016/j.joca.2024.07.014
EA OCT 2024
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA K5F4I
UT WOS:001344126600001
PM 39103081
DA 2025 08 17
ER

PT J
AU Ritz, U
   Nusselt, T
   Sewing, A
   Ziebart, T
   Kaufmann, K
   Baranowski, A
   Rommens, PM
   Hofmann, A
AF Ritz, U.
   Nusselt, T.
   Sewing, A.
   Ziebart, T.
   Kaufmann, K.
   Baranowski, A.
   Rommens, P. M.
   Hofmann, Alexander
TI The effect of different collagen modifications for titanium and titanium
   nitrite surfaces on functions of gingival fibroblasts
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Titanium; Titanium nitride; Collagen; Surface modification; RGD;
   Gingival fibroblast
ID MODIFIED DENTAL IMPLANTS; INCREASED BONE FORMATION; MESENCHYMAL
   STEM CELLS; OSTEOBLAST LIKE CELLS; IN VITRO; ADHESION; ATTACHMENT; RGD;
   IMMOBILIZATION; BEHAVIOR
AB Targeted modifications of the bulk implant surfaces using bioactive agents provide a promising tool for improvement of the long term bony and soft tissue integration of dental implants. In this study, we assessed the cellular responses of primary human gingival fibroblasts (HGF) to different surface modifications of titanium (Ti) and titanium nitride (TiN) alloys with type I collagen or cyclic RGDfK peptide in order to define a modification improving long term implants in dental medicine.
   Employing Ti and TiN implants, we compared the performance of simple dip coating and anodic immobilization of type I collagen that provided collagen layers of two different thicknesses. HGF were seeded on the different coated implants, and adhesion, proliferation, and gene expression were analyzed.
   Although there were no strong differences in initial cell adhesion between the groups at 2 and 4 hours, we found that all surface modifications induced higher proliferation rates as compared to the unmodified controls. Consistently, gene expression levels of cell adhesion markers (focal adhesion kinase (FAK), integrin beta1, and vinculin), cell differentiation markers (FGFR1, TGFb R1), extracellular protein markers (type I collagen, vimentin), and cytoskeletal protein marker aktinin 1 were consistently higher in all surface modification groups at two different time points of investigation as compared to the unmodified controls.
   Our results indicate that simple dip coating of Ti and TiN with collagen is sufficient to induce in vitro cellular responses that are comparable to those of more reliable coating methods like anodic adsorption, chemical cross linking, or RGD coating. TiN alloys do not possess any positive or adverse effects on HGF.
   Our results demonstrate a simple, yet effective, method for collagen coating on titanium implants to improve the long term integration and stability of dental implants.
C1 [Ritz, U.; Nusselt, T.; Baranowski, A.; Rommens, P. M.; Hofmann, Alexander] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Orthoped & Traumatol, Langenbeckstr 1, D 55131 Mainz, Germany.
   [Sewing, A.] Biomet Deutschland GmbH, Berlin, Germany.
   [Ziebart, T.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Oral Maxillofacial & Plast Surg, Mainz, Germany.
   [Kaufmann, K.] Georg Speyer Haus, Frankfurt, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz
RP Hofmann, A (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Orthoped & Traumatol, Langenbeckstr 1, D 55131 Mainz, Germany.
EM hofmann.trauma surgery@gmx.net
RI Sewing, Andreas/B 8356 2016; Hofmann, Alexander/C 3943 2013; Ritz,
   Ulrike/N 6871 2016; Ziebart, Thomas/C 7048 2017
OI Baranowski, Andreas/0000 0001 7954 5289; Ziebart,
   Thomas/0000 0003 3296 7630; Sewing, Andreas/0009 0001 1100 693X;
   Kaufmann, Kerstin B./0000 0001 5013 6123; Ziebart,
   Thomas/0000 0001 8504 4958
FU Biomet GmbH Deutschland, Berlin, Germany
FX The work was supported by Biomet GmbH Deutschland, Berlin, Germany.
CR Annunziata M, 2011, J DENT, V39, P720, DOI 10.1016/j.jdent.2011.08.003
   Ao HY, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0070
   Auernheimer J, 2005, CHEMBIOCHEM, V6, P2034, DOI 10.1002/cbic.200500031
   Beurden HE, 2006, WOUND REPAIR REGEN, V14, P66, DOI 10.1111/j.1743 6109.2005.00090.x
   Beutner R, 2010, J R SOC INTERFACE, V7, pS93, DOI 10.1098/rsif.2009.0418.focus
   Beutner R, 2009, BIOMATERIALS, V30, P2774, DOI 10.1016/j.biomaterials.2009.01.047
   Brendel C, 2012, GENE THER, V19, P1018, DOI 10.1038/gt.2011.167
   BUSER D, 1992, J PERIODONTOL, V63, P225, DOI 10.1902/jop.1992.63.3.225
   Chien CC, 2008, DENT MATER, V24, P986, DOI 10.1016/j.dental.2007.11.020
   Chua PH, 2008, BIOMATERIALS, V29, P1412, DOI 10.1016/j.biomaterials.2007.12.019
   Clem WC, 2006, J BIOMED MATER RES A, V76A, P279, DOI 10.1002/jbm.a.30557
   Ferris DM, 1999, BIOMATERIALS, V20, P2323, DOI 10.1016/S0142 9612(99)00161 1
   Groessner Schreiber B, 2003, J BIOMED MATER RES A, V64A, P591, DOI 10.1002/jbm.a.10417
   Grössner Schreiber B, 2006, CLIN ORAL IMPLAN RES, V17, P736, DOI 10.1111/j.1600 0501.2006.01277.x
   Gronowicz G, 1996, J ORTHOPAED RES, V14, P878, DOI 10.1002/jor.1100140606
   Guida L, 2013, J DENT, V41, P900, DOI 10.1016/j.jdent.2013.07.009
   Hamilton DW, 2005, EXP CELL RES, V309, P429, DOI 10.1016/j.yexcr.2005.06.015
   Hamilton V, 2006, J MATER SCI MATER M, V17, P1373, DOI 10.1007/s10856 006 0613 9
   Hauser J, 2010, J BIOMED MATER RES A, V94A, P19, DOI 10.1002/jbm.a.32672
   Heydecke G, 1999, INT J PROSTHODONT, V12, P184
   HOWLETT CR, 1994, BIOMATERIALS, V15, P213, DOI 10.1016/0142 9612(94)90070 1
   Jin C, 2012, J BIOMED MATER RES B, V100B, P2167, DOI 10.1002/jbm.b.32784
   Kasemo B, 1988, Int J Oral Maxillofac Implants, V3, P247
   KASEMO B, 1988, J BIOMED MATER RES A, V22, P145, DOI 10.1002/jbm.820221307
   Kim H, 2006, INT J ORAL MAX IMPL, V21, P354
   Kundu AK, 2009, TISSUE ENG PT A, V15, P273, DOI 10.1089/ten.tea.2008.0055
   Li BE, 2014, J MATER SCI MATER M, V25, P199, DOI 10.1007/s10856 013 5064 5
   Li JG, 2014, MAT SCI ENG C MATER, V38, P235, DOI 10.1016/j.msec.2014.02.008
   Listgarten MA, 1991, CLIN ORAL IMPLAN RES, V2, P1, DOI 10.1034/j.1600 0501.1991.020101.x
   Marín Pareja N, 2014, COLLOID SURFACE B, V122, P601, DOI 10.1016/j.colsurfb.2014.07.038
   Park BS, 2005, J BIOMED MATER RES A, V74A, P640, DOI 10.1002/jbm.a.30326
   Piscanec S, 2004, ACTA MATER, V52, P1237, DOI 10.1016/j.actamat.2003.11.020
   Protivínsky J, 2007, INT J ORAL MAX IMPL, V22, P542
   Rössler S, 1999, J MATER SCI LETT, V18, P577, DOI 10.1023/A:1006647116608
   Sartori M, 2015, INT ORTHOP, V39, P2041, DOI 10.1007/s00264 015 2926 0
   Scarano Antonio, 2003, J Oral Implantol, V29, P80, DOI 10.1563/1548 1336(2003)029<0080:BAOTNA>2.3.CO;2
   Schuler M, 2006, BIOMATERIALS, V27, P4003, DOI 10.1016/j.biomaterials.2006.03.009
   Sculean A, 2014, J CLIN PERIODONTOL, V41, pS6, DOI 10.1111/jcpe.12206
   Shih YRV, 2006, STEM CELLS, V24, P2391, DOI 10.1634/stemcells.2006 0253
   Stadlinger B, 2009, J CLIN PERIODONTOL, V36, P698, DOI 10.1111/j.1600 051X.2009.01435.x
   Sverzut AT, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035007
   Tosatti S, 2004, J BIOMED MATER RES A, V68A, P458, DOI 10.1002/jbm.a.20082
   Tsuchiya S, 2008, CELL TISSUE RES, V331, P447, DOI 10.1007/s00441 007 0532 1
   van den Dolder J, 2007, J BIOMED MATER RES A, V83A, P712, DOI 10.1002/jbm.a.31428
   Wang YL, 2016, CLIN IMPLANT DENT R, V18, P618, DOI 10.1111/cid.12343
   Wolf Brandstetter C, 2006, J BIOMED MATER RES A, V79A, P882, DOI 10.1002/jbm.a.30826
   Zamir E, 2001, J CELL SCI, V114, P3583
NR 47
TC 33
Z9 35
U1 1
U2 36
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JAN
PY 2017
VL 21
IS 1
BP 255
EP 265
DI 10.1007/s00784 016 1784 5
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EG9OL
UT WOS:000391388300028
PM 26969500
DA 2025 08 17
ER

PT J
AU Patnaik, R
   Riaz, S
   Sivani, BM
   Faisal, S
   Naidoo, N
   Rizzo, M
   Banerjee, Y
AF Patnaik, Rajashree
   Riaz, Sumbal
   Sivani, Bala Mohan
   Faisal, Shemima
   Naidoo, Nerissa
   Rizzo, Manfredi
   Banerjee, Yajnavalka
TI Evaluating the potential of Vitamin D and curcumin to alleviate
   inflammation and mitigate the progression of osteoarthritis through
   their effects on human chondrocytes: A proof of concept investigation
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF KAPPA B; RECEPTOR GENE
   POLYMORPHISMS; MESENCHYMAL STEM CELLS; KNEE OSTEOARTHRITIS; D
   SUPPLEMENTATION; TNF ALPHA; SUBCHONDRAL BONE; DOUBLE BLIND; OSTEOCLAST
   DIFFERENTIATION
AB Osteoarthritis (OA) is a chronic degenerative joint disorder primarily affecting the elderly, characterized by a prominent inflammatory component. The long term side effects associated with current therapeutic approaches necessitate the development of safer and more efficacious alternatives. Nutraceuticals, such as Vitamin D and curcumin, present promising therapeutic potentials due to their safety, efficacy, and cost effectiveness. In this study, we utilized a proinflammatory human chondrocyte model of OA to assess the anti inflammatory properties of Vitamin D and curcumin, with a particular focus on the Protease Activated Receptor 2 (PAR 2) mediated inflammatory pathway. Employing a robust siRNA approach, we effectively modulated the expression of PAR 2 to understand its role in the inflammatory process. Our results reveal that both Vitamin D and curcumin attenuate the expression of PAR 2, leading to a reduction in the downstream proinflammatory cytokines, such as Tumor Necrosis Factor alpha (TNF alpha), Interleukin 6 (IL 6), and Interleukin 8 (IL 8), implicated in the OA pathogenesis. Concurrently, these compounds suppressed the expression of Receptor Activator of Nuclear Factor kappa Beta Ligand (RANKL) and its receptor RANK, which are associated with PAR 2 mediated TNF alpha stimulation. Additionally, Vitamin D and curcumin downregulated the expression of Interferon gamma (IFN gamma), known to elevate RANKL levels, underscoring their potential therapeutic implications in OA. This study, for the first time, provides evidence of the mitigating effect of Vitamin D and curcumin on PAR 2 mediated inflammation, employing an siRNA approach in OA. Thus, our findings pave the way for future research and the development of novel, safer, and more effective therapeutic strategies for managing OA.
C1 [Patnaik, Rajashree; Riaz, Sumbal; Sivani, Bala Mohan; Faisal, Shemima; Naidoo, Nerissa; Banerjee, Yajnavalka] Mohammed Bin Rashid Univ Med & Hlth Sci MBRU, Coll Med & Hlth Sci, Dubai, U Arab Emirates.
   [Rizzo, Manfredi] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy.
   [Banerjee, Yajnavalka] Univ Dundee, Ctr Med Educ, Dundee, Scotland.
   [Sivani, Bala Mohan] Lund Univ, Dept Mol Biol, Lund, Sweden.
C3 University of Palermo; University of Dundee; Lund University
RP Banerjee, Y (通讯作者)，Mohammed Bin Rashid Univ Med & Hlth Sci MBRU, Coll Med & Hlth Sci, Dubai, U Arab Emirates.; Rizzo, M (通讯作者)，Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy.; Banerjee, Y (通讯作者)，Univ Dundee, Ctr Med Educ, Dundee, Scotland.
EM manfredi.rizzo@unipa.it; yajnavalka.banerjee@mbru.ac.ae
RI RIZZO, MANFREDI/GZL 0551 2022; Banerjee, Yajnavalka/J 5890 2019
OI Naidoo, Nerissa/0000 0002 0924 8796; Banerjee,
   Yajnavalka/0000 0002 7546 8893; 
CR Leal LKAM, 2020, EUR J PHARMACOL, V879, DOI 10.1016/j.ejphar.2020.173099
   Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007
   Arden NK, 2016, OSTEOARTHR CARTILAGE, V24, P1858, DOI 10.1016/j.joca.2016.05.020
   Arroll B, 2004, BMJ BRIT MED J, V328, P869, DOI 10.1136/bmj.38039.573970.7C
   Babon JJ, 2014, SEMIN IMMUNOL, V26, P13, DOI 10.1016/j.smim.2013.12.004
   Bacchi S., 2012, Anti Inflammatory & Anti Allergy Agents in Medicinal Chemistry, V11, P52
   Barbour KE, 2017, MMWR MORBID MORTAL W, V66, P246, DOI 10.15585/mmwr.mm6609e1
   Baron JA, 2008, LANCET, V372, P1756, DOI 10.1016/S0140 6736(08)61490 7
   Beekhuizen M, 2013, OSTEOARTHR CARTILAGE, V21, P918, DOI 10.1016/j.joca.2013.04.002
   Benjamin O., 2023, DIS MODIFYING ANTIRH
   Bergholt NL, 2019, CARTILAGE, V10, P370, DOI 10.1177/1947603518764262
   Bergink AP, 2016, SEMIN ARTHRITIS RHEU, V45, P539, DOI 10.1016/j.semarthrit.2015.09.010
   Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369 5274(99)00046 6
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Buckland Jenny, 2013, Nat Rev Rheumatol, V9, P566, DOI 10.1038/nrrheum.2013.135
   Cao YL, 2013, RHEUMATOLOGY, V52, P1323, DOI 10.1093/rheumatology/ket132
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002 9440(10)64466 5
   Chen PF, 2014, BIOMATERIALS, V35, P2827, DOI 10.1016/j.biomaterials.2013.12.076
   Chevalier X, 2009, ARTHRIT RHEUM ARTHR, V61, P344, DOI 10.1002/art.24096
   Cohen SB, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3430
   Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930
   Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931
   Dahlberg LE, 2016, CLIN EXP RHEUMATOL, V34, P443
   Dell'Accio F, 2008, ARTHRITIS RHEUM US, V58, P1410, DOI 10.1002/art.23444
   Deshmukh V, 2018, OSTEOARTHR CARTILAGE, V26, P18, DOI 10.1016/j.joca.2017.08.015
   ELFORD PR, 1991, ARTHRITIS RHEUM, V34, P325, DOI 10.1002/art.1780340310
   Feldmann M, 2001, NAT IMMUNOL, V2, P771, DOI 10.1038/ni0901 771
   Ferrell WR, 2010, ANN RHEUM DIS, V69, P2051, DOI 10.1136/ard.2010.130336
   Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913
   Fleischmann RM, 2019, ARTHRITIS RHEUMATOL, V71, P1056, DOI 10.1002/art.40840
   Foster NE, 2023, OSTEOARTHR CARTILAGE, V31, P876, DOI 10.1016/j.joca.2023.03.008
   Gao XR, 2017, INT J SURG, V46, P14, DOI 10.1016/j.ijsu.2017.08.010
   Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001
   García Manrique M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 84582 2
   Gilbert SJ, 2022, BIOCHEM BIOPHYS REP, V32, DOI 10.1016/j.bbrep.2022.101323
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Han GT, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5558066
   Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hochberg MC, 2019, JAMA J AM MED ASSOC, V322, P1360, DOI 10.1001/jama.2019.14735
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hsueh MF, 2021, ARTHRITIS RHEUMATOL, V73, P89, DOI 10.1002/art.41486
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Hussain S, 2017, RHEUMATOL INT, V37, P1489, DOI 10.1007/s00296 017 3719 0
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Jackson MT, 2014, ARTHRITIS RHEUMATOL, V66, P3337, DOI 10.1002/art.38876
   Jin XZ, 2016, JAMA J AM MED ASSOC, V315, P1005, DOI 10.1001/jama.2016.1961
   Johansson U, 2005, J LEUKOCYTE BIOL, V78, P967, DOI 10.1189/jlb.0704422
   JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003 4819 121 4 199408150 00011
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kalogera S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 03346 0
   Kamiya N, 2019, OSTEOARTHR CARTILAGE, V27, P326, DOI 10.1016/j.joca.2018.10.010
   Kang SJ, 2021, EXP MOL MED, V53, P1116, DOI 10.1038/s12276 021 00649 0
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Karsdal MA, 2016, OSTEOARTHR CARTILAGE, V24, P2013, DOI 10.1016/j.joca.2016.07.017
   Kelso EB, 2007, ARTHRITIS RHEUM, V56, P765, DOI 10.1002/art.22423
   Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014 5793(98)01731 1
   KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569
   Kjelgaard Petersen CF, 2019, BIOCHEM PHARMACOL, V165, P91, DOI 10.1016/j.bcp.2018.07.034
   Kloppenburg M, 2019, ANN RHEUM DIS, V78, P413, DOI 10.1136/annrheumdis 2018 213336
   Kloppenburg M, 2018, ANN RHEUM DIS, V77, P1757, DOI 10.1136/annrheumdis 2018 213202
   Koh SM, 2020, KNEE, V27, P26, DOI 10.1016/j.knee.2019.10.028
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Komuro H, 2001, ARTHRITIS RHEUM, V44, P2768, DOI 10.1002/1529 0131(200112)44:12<2768::AID ART464>3.0.CO;2 I
   Kotake S, 2005, EUR J IMMUNOL, V35, P3353, DOI 10.1002/eji.200526141
   Kovács B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184653
   Kraus VB, 2015, OSTEOARTHR CARTILAGE, V23, P1233, DOI 10.1016/j.joca.2015.03.036
   Krzeski P, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2315
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lanas A, 2009, AM J MED SCI, V338, P96, DOI 10.1097/MAJ.0b013e3181ad8cd3
   Lane NE, 1997, AM J MED, V103, P25, DOI 10.1016/S0002 9343(97)90005 X
   Latourte A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209757
   LAZARUS GS, 1968, J CLIN INVEST, V47, P2622, DOI 10.1172/JCI105945
   Li HM, 2021, RHEUMATOLOGY, V60, P538, DOI 10.1093/rheumatology/keaa644
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lin JJ, 2023, J CLIN MED, V12, DOI 10.3390/jcm12051986
   Little CB, 2009, ARTHRITIS RHEUM US, V60, P3723, DOI 10.1002/art.25002
   Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626
   Liu HF, 2014, EXP BIOL MED, V239, P559, DOI 10.1177/1535370213514920
   Liu YK, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02859 x
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Losina E, 2015, ARTHRIT CARE RES, V67, P203, DOI 10.1002/acr.22412
   Lu Qinglie, 2017, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V31, P1517, DOI 10.7507/1002 1892.201705025
   Lu TJ, 2017, CELL TRANSPLANT, V26, P417, DOI 10.3727/096368916X693464
   Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604
   LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043 4666(92)90043 Q
   Mabey T, 2015, WORLD J ORTHOP, V6, P95, DOI 10.5312/wjo.v6.i1.95
   MacFarlane LA, 2020, ARTHRITIS RHEUMATOL, V72, P1836, DOI 10.1002/art.41416
   Magnano MD, 2007, J RHEUMATOL, V34, P1323
   Magni A, 2021, PAIN THER, V10, P783, DOI 10.1007/s40122 021 00260 1
   Maksymowych WP, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4044
   Maldonado RF, 2016, FEMS MICROBIOL REV, V40, P480, DOI 10.1093/femsre/fuw007
   Martínez Calatrava MJ, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3884
   McAlindon T, 2013, JAMA J AM MED ASSOC, V309, P155, DOI 10.1001/jama.2012.164487
   McCulloch K, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00257
   McGeough MD, 2017, J CLIN INVEST, V127, P4488, DOI 10.1172/JCI90699
   Milner JM, 2010, ARTHRITIS RHEUM US, V62, P1955, DOI 10.1002/art.27476
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Morrison RJM, 2022, EFORT OPEN REV, V7, P305, DOI 10.1530/EOR 21 0136
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219
   Nash DM, 2019, NEPHROL DIAL TRANSPL, V34, P1145, DOI 10.1093/ndt/gfz062
   Nees TA, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091343
   Osthoff AKR, 2018, ANN RHEUM DIS, V77, P1251, DOI 10.1136/annrheumdis 2018 213585
   Patnaik R, 2018, ENVIRON SCI POLLUT R, V25, P20606, DOI 10.1007/s11356 018 2164 2
   Paultre K, 2021, BMJ OPEN SPORT EXERC, V7, DOI 10.1136/bmjsem 2020 000935
   Perry TA, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2424 4
   Qu RZ, 2018, FASEB J, V32, P1044, DOI 10.1096/fj.201700265R
   Richard MJ, 2023, OSTEOARTHR CARTILAGE, V31, P458, DOI 10.1016/j.joca.2022.11.005
   Rose John S, 2017, CLIN PHARMACOL THER, V102, P591, DOI 10.1002/cpt.782
   Ryu JH, 2011, ARTHRITIS RHEUM US, V63, P2732, DOI 10.1002/art.30451
   Sanghi D, 2013, CLIN ORTHOP RELAT R, V471, P3556, DOI 10.1007/s11999 013 3201 6
   Scanzello CR, 2012, BONE, V51, P249, DOI 10.1016/j.bone.2012.02.012
   Schietzel S, 2019, AM J CLIN NUTR, V110, P246, DOI 10.1093/ajcn/nqz081
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Shep D, 2019, TRIALS, V20, DOI 10.1186/s13063 019 3327 2
   Sivani BM, 2022, METABOLITES, V12, DOI 10.3390/metabo12070639
   Sohn DH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3555
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Steen Louws C, 2018, OSTEOARTHR CARTILAGE, V26, P1127, DOI 10.1016/j.joca.2018.05.005
   Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849
   Styrkarsdottir U, 2018, NAT GENET, V50, P1681, DOI 10.1038/s41588 018 0247 0
   Tachmazidou I, 2019, NAT GENET, V51, P230, DOI 10.1038/s41588 018 0327 1
   Takahashi A, 2015, OSTEOARTHR CARTILAGE, V23, P1946, DOI 10.1016/j.joca.2015.02.168
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Tat SK, 2009, RHEUMATOLOGY, V48, P1482, DOI 10.1093/rheumatology/kep300
   Tat Steeve Kwan, 2009, Keio Journal of Medicine, V58, P29
   Tonge DP, 2014, OSTEOARTHR CARTILAGE, V22, P609, DOI 10.1016/j.joca.2014.03.004
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   Turk N, 2009, EUR J GASTROEN HEPAT, V21, P159, DOI 10.1097/MEG.0b013e3283200032
   Ugalde AP, 2010, METHODS MOL BIOL, V622, P3, DOI 10.1007/978 1 60327 299 5_1
   Upton AR, 2012, RHEUMATOL INT, V32, P535, DOI 10.1007/s00296 010 1733 6
   Vina ER, 2018, CURR OPIN RHEUMATOL, V30, P160, DOI 10.1097/BOR.0000000000000479
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang QY, 2017, J CELL BIOCHEM, V118, P3775, DOI 10.1002/jcb.26025
   Wang X, 2017, OSTEOARTHR CARTILAGE, V25, P1304, DOI 10.1016/j.joca.2017.02.804
   Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002 9149(02)02661 9
   Wilkinson DJ, 2019, BRIT J PHARMACOL, V176, P38, DOI 10.1111/bph.14173
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Wu XF, 2018, AM J TRANSL RES, V10, P1143
   Xiang Y, 2006, OSTEOARTHR CARTILAGE, V14, P1163, DOI 10.1016/j.joca.2006.04.015
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Yazici Y, 2017, OSTEOARTHR CARTILAGE, V25, P1598, DOI 10.1016/j.joca.2017.07.006
   Yu YH, 2021, Z ORTHOP UNFALLCHIR, V159, P281, DOI 10.1055/a 1098 8815
   Zengini E, 2018, NAT GENET, V50, P549, DOI 10.1038/s41588 018 0079 y
   Zhang F, 2021, GENOME MED, V13, DOI 10.1186/s13073 021 00881 3
   Zhang H, 2018, ANN NUTR METAB, V73, P121, DOI 10.1159/000490670
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   Zhang Z, 2017, OSTEOARTHR CARTILAGE, V25, P309, DOI 10.1016/j.joca.2016.09.010
   Zhao YP, 2015, ANN RHEUM DIS, V74, P2244, DOI 10.1136/annrheumdis 2014 205779
   Zhao YP, 2019, EBIOMEDICINE, V41, P556, DOI 10.1016/j.ebiom.2019.02.035
   Zhao ZX, 2021, AGING CLIN EXP RES, V33, P2393, DOI 10.1007/s40520 020 01778 8
   Zheng S, 2018, BRIT J NUTR, V120, P41, DOI 10.1017/S0007114518001174
   Zheng S, 2017, AM J MED, V130, P1211, DOI 10.1016/j.amjmed.2017.04.038
   Zhou XC, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5720360
   Zhu ZH, 2014, RHEUMATOLOGY, V53, P998, DOI 10.1093/rheumatology/ket418
NR 163
TC 6
Z9 6
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2023
VL 18
IS 12
AR e0290739
DI 10.1371/journal.pone.0290739
PG 40
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DZ5R9
UT WOS:001135936500015
PM 38157375
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU López Serrano, C
   Côté Paradis, Y
   Habenstein, B
   Loquet, A
   Le Coz, C
   Ruel, J
   Laroche, G
   Durrieu, MC
AF Lopez Serrano, Cristina
   Cote Paradis, Yeva
   Habenstein, Birgit
   Loquet, Antoine
   Le Coz, Cedric
   Ruel, Jean
   Laroche, Gaetan
   Durrieu, Marie Christine
TI Integrating Mechanics and Bioactivity: A Detailed Assessment of
   Elasticity and Viscoelasticity at Different Scales in 2D
   Biofunctionalized PEGDA Hydrogels for Targeted Bone Regeneration
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE hydrogel; mechanical properties; mesenchymalstem cell; viscoelasticity;
   osteogenic differentiation
ID POLY(ETHYLENE GLYCOL); MATRIX ELASTICITY; CELL; DENSITY; HETEROGENEITY;
   ORGANIZATION; MODULATION; PEPTIDE; BMP 2
AB Methods for promoting and controlling the differentiation of human mesenchymal stem cells (hMSCs) in vitro before in vivo transplantation are crucial for the advancement of tissue engineering and regenerative medicine. In this study, we developed poly(ethylene glycol) diacrylate (PEGDA) hydrogels with tunable mechanical properties, including elasticity and viscoelasticity, coupled with bioactivity achieved through the immobilization of a mixture of RGD and a mimetic peptide of the BMP 2 protein. Despite the key relevance of hydrogel mechanical properties for cell culture, a standard for its characterization has not been proposed, and comparisons between studies are challenging due to the different techniques employed. Here, a comprehensive approach was employed to characterize the elasticity and viscoelasticity of these hydrogels, integrating compression testing, rheology, and atomic force microscopy (AFM) microindentation. Distinct mechanical behaviors were observed across different PEGDA compositions, and some consistent trends across multiple techniques were identified. Using a photoactivated cross linker, we controlled the functionalization density independently of the mechanical properties. X ray photoelectrin spectroscopy and fluorescence microscopy were employed to evaluate the functionalization density of the materials before the culturing of hMSCs on them. The cells cultured on all functionalized hydrogels expressed an early osteoblast marker (Runx2) after 2 weeks, even in the absence of a differentiation inducing medium compared to our controls. Additionally, after only 1 week of culture with osteogenic differentiation medium, cells showed accelerated differentiation, with clear morphological differences observed among cells in the different conditions. Notably, cells on stiff but stress relaxing hydrogels exhibited an overexpression of the osteocyte marker E11. This suggests that the combination of the functionalization procedure with the mechanical properties of the hydrogel provides a potent approach to promoting the osteogenic differentiation of hMSCs.
C1 [Lopez Serrano, Cristina; Durrieu, Marie Christine] Univ Bordeaux, Bordeaux INP, CNRS, UMR 5248,CBMN, F 33600 Pessac, France.
   [Lopez Serrano, Cristina; Cote Paradis, Yeva; Laroche, Gaetan] Univ Laval, Ctr Rech Mat Avances, Lab Ingn Surface, Dept Genie Mines Met & Mat, Quebec City, PQ G1V 0A6, Canada.
   [Lopez Serrano, Cristina; Cote Paradis, Yeva; Laroche, Gaetan] Hop St Francois Assise, Ctr Hosp Univ Quebec, Axe Med Regeneratrice, Ctr Rech, Quebec City, PQ G1L 3L5, Canada.
   [Habenstein, Birgit; Loquet, Antoine] Univ Bordeaux, CNRS, INSERM, IECB,US1,UAR 3033, F 33600 Pessac, France.
   [Le Coz, Cedric] Univ Bordeaux, CNRS, Bordeaux INP, LCPO,UMR 5629, F 33600 Pessac, France.
   [Ruel, Jean] Univ Laval, Dept Genie Mecan, Quebec City, PQ G1V 0A6, Canada.
C3 Universite de Bordeaux; Centre National de la Recherche Scientifique
   (CNRS); CNRS   Institute of Chemistry (INC); Laval University; Laval
   University; Laval University Hospital; Universite de Bordeaux; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Bordeaux;
   Centre National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Chemistry (INC); Laval University
RP Durrieu, MC (通讯作者)，Univ Bordeaux, Bordeaux INP, CNRS, UMR 5248,CBMN, F 33600 Pessac, France.; Laroche, G (通讯作者)，Univ Laval, Ctr Rech Mat Avances, Lab Ingn Surface, Dept Genie Mines Met & Mat, Quebec City, PQ G1V 0A6, Canada.; Laroche, G (通讯作者)，Hop St Francois Assise, Ctr Hosp Univ Quebec, Axe Med Regeneratrice, Ctr Rech, Quebec City, PQ G1L 3L5, Canada.
EM gaetan.laroche@gmn.ulaval.ca; marie christine.durrieu@inserm.fr
RI DURRIEU, Marie Christine/I 4358 2016; Loquet, Antoine/A 1465 2010;
   Habenstein, Birgit/E 4425 2013
OI DURRIEU, Marie Christine/0000 0003 0583 9289; Lopez Serrano,
   Cristina/0009 0002 6867 6683; Laroche, Gaetan/0000 0003 0661 628X;
   Habenstein, Birgit/0000 0003 3723 9552; Ruel, Jean/0000 0001 6936 4943
FU IDEX University of Bordeaux [Cristina Lopez Serrano's PhD grant];
   Natural Sciences and Engineering Research Council of Canada (NSERC);
   Centre Quebecois sur les Materiaux Fonctionnels (CQMF); ANR
   [ANR 21 CE06 0031 02, ANR 20 SFRI 0001]; Agence Nationale de la
   Recherche (ANR) [ANR 21 CE06 0031, ANR 20 SFRI 0001] Funding Source:
   Agence Nationale de la Recherche (ANR)
FX The authors thank Christine Labrugere (PLACAMAT, Bordeaux, France) for
   the XPS experiments. We thank Murielle Remy and Andree Anne Guay Begin
   for helpful discussions. This work was supported by IDEX University of
   Bordeaux [Cristina Lopez Serrano's PhD grant] and the Natural Sciences
   and Engineering Research Council of Canada (NSERC), as well as the
   Centre Quebecois sur les Materiaux Fonctionnels (CQMF). The financial
   support of the ANR (ANR 21 CE06 0031 02 and ANR 20 SFRI 0001) (M.C.D.)
   is also acknowledged. We thank the Biophysical and Structural Chemistry
   Platform at IECB, CNRS UAR 3033, INSERM US001, University of Bordeaux
   for NMR measurements.
CR Abrego CJG, 2022, MACROMOL CHEM PHYS, V223, DOI 10.1002/macp.202100366
   Adebowale K, 2021, NAT MATER, V20, P1290, DOI 10.1038/s41563 021 00981 w
   Andronesi OC, 2005, J AM CHEM SOC, V127, P12965, DOI 10.1021/ja0530164
   Beamish JA, 2010, J BIOMED MATER RES A, V92A, P441, DOI 10.1002/jbm.a.32353
   Bilem I, 2016, ACTA BIOMATER, V36, P132, DOI 10.1016/j.actbio.2016.03.032
   Blackford SJI, 2023, BIOMATERIALS, V293, DOI 10.1016/j.biomaterials.2022.121982
   Böckmann A, 2009, J BIOMOL NMR, V45, P319, DOI 10.1007/s10858 009 9374 3
   Bush BG, 2015, SOFT MATTER, V11, P7191, DOI 10.1039/c5sm01210d
   Buxboim A, 2010, J PHYS CONDENS MAT, V22, DOI 10.1088/0953 8984/22/19/194116
   Cameron AR, 2011, BIOMATERIALS, V32, P5979, DOI 10.1016/j.biomaterials.2011.04.003
   Cao Y, 2016, J BIOMED MATER RES A, V104, P2401, DOI 10.1002/jbm.a.35779
   Chatterjee K, 2010, BIOMATERIALS, V31, P5051, DOI 10.1016/j.biomaterials.2010.03.024
   Chaudhuri O, 2020, NATURE, V584, P535, DOI 10.1038/s41586 020 2612 2
   Chaudhuri O, 2017, BIOMATER SCI UK, V5, P1480, DOI 10.1039/c7bm00261k
   Chaudhuri O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7365
   Chen JJ, 2019, ACS BIOMATER SCI ENG, V5, P1034, DOI 10.1021/acsbiomaterials.8b01046
   Chen YQ, 2024, MATER TODAY BIO, V26, DOI 10.1016/j.mtbio.2024.101058
   Cuenot S, 2022, J MECH BEHAV BIOMED, V133, DOI 10.1016/j.jmbbm.2022.105343
   De Belly H, 2022, NAT REV MOL CELL BIO, V23, P465, DOI 10.1038/s41580 022 00472 z
   de Molina PM, 2015, MACROMOLECULES, V48, P5402, DOI 10.1021/acs.macromol.5b01115
   Durrieu M. C., 2016, Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp 2, Patent No. [EP2968660A1, 2968660]
   Ekerdt BL, 2013, BIOTECHNOL J, V8, P1411, DOI 10.1002/biot.201300302
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fung BM, 2000, J MAGN RESON, V142, P97, DOI 10.1006/jmre.1999.1896
   Guimaraes CF, 2020, NAT REV MATER, V5, P351, DOI 10.1038/s41578 019 0169 1
   Herrick WG, 2013, BIOMACROMOLECULES, V14, P2294, DOI 10.1021/bm400418g
   Holland EN, 2024, BIOMATERIALS, V308, DOI 10.1016/j.biomaterials.2024.122542
   Huang YX, 2014, J POWER SOURCES, V252, P90, DOI 10.1016/j.jpowsour.2013.12.004
   Hui E, 2019, BIOMACROMOLECULES, V20, P4126, DOI 10.1021/acs.biomac.9b00965
   Huth S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220281
   Islam MR, 2021, EXP MECH, V61, P939, DOI 10.1007/s11340 021 00712 x
   Jamadi M, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600479
   Jekhmane S, 2019, ANGEW CHEM INT EDIT, V58, P16943, DOI 10.1002/anie.201907880
   Jun I, 2011, MACROMOL RES, V19, P911, DOI 10.1007/s13233 011 0909 6
   Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040
   Keith AN, 2020, ACS CENTRAL SCI, V6, P413, DOI 10.1021/acscentsci.9b01216
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lai Y, 2018, SOFT MATTER, V14, P2619, DOI 10.1039/c7sm02351k
   Li SJ, 2024, BIOMACROMOLECULES, V25, P890, DOI 10.1021/acs.biomac.3c01045
   Lian Q, 2020, CHEMOSPHERE, V248, DOI 10.1016/j.chemosphere.2020.126078
   Lopes D, 2018, BIOMATERIALS, V185, P240, DOI 10.1016/j.biomaterials.2018.09.028
   Lou JZ, 2022, NAT REV CHEM, V6, P726, DOI 10.1038/s41570 022 00420 7
   Mazzoccoli JP, 2010, J BIOMED MATER RES A, V93A, P558, DOI 10.1002/jbm.a.32563
   Moore NM, 2011, ACTA BIOMATER, V7, P2091, DOI 10.1016/j.actbio.2011.01.019
   Nalam PC, 2015, SOFT MATTER, V11, P8165, DOI 10.1039/c5sm01143d
   Nam S, 2019, BIOMATERIALS, V200, P15, DOI 10.1016/j.biomaterials.2019.02.004
   Neves SC, 2018, WOODH PUBL SER BIOM, P101, DOI 10.1016/B978 0 08 100803 4.00004 8
   Oh SH, 2016, ACTA BIOMATER, V35, P23, DOI 10.1016/j.actbio.2016.02.016
   Oliver Cervelló L, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001757
   Oyen ML, 2014, INT MATER REV, V59, P44, DOI 10.1179/1743280413Y.0000000022
   Padiolleau L, 2018, ACS APPL BIO MATER, V1, P1800, DOI 10.1021/acsabm.8b00236
   Pedrosa CR, 2019, ACS APPL MATER INTER, V11, P8858, DOI 10.1021/acsami.8b21393
   Pizzolitto C, 2023, CARBOHYD POLYM, V302, DOI 10.1016/j.carbpol.2022.120369
   Prouvé E, 2022, BIOMATER SCI UK, V10, P4978, DOI 10.1039/d2bm00485b
   Prouvé E, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202100069
   Maia FR, 2013, ACTA BIOMATER, V9, P8773, DOI 10.1016/j.actbio.2013.08.004
   Rekowska N, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15041039
   Richardson SA, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800351
   Richbourg NR, 2022, POLYMER, V258, DOI 10.1016/j.polymer.2022.125316
   Roca Cusachs P, 2017, NAT CELL BIOL, V19, P742, DOI 10.1038/ncb3564
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rowlands AS, 2008, AM J PHYSIOL CELL PH, V295, pC1037, DOI 10.1152/ajpcell.67.2008
   Smithmyer ME, 2018, ACS BIOMATER SCI ENG, V4, P3304, DOI 10.1021/acsbiomaterials.8b00491
   Teo B. K. K., 2010, STUDIES MECHANOBIOLO, P61, DOI [10.1007/841520104, DOI 10.1007/841520104]
   Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]
   Walker M, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202302571
   Xue RY, 2013, J ORTHOP RES, V31, P1360, DOI 10.1002/jor.22374
   Zhang YJ, 2023, BIOMATER SCI UK, V11, P6116, DOI 10.1039/d3bm00605k
   Zouani OF, 2013, BIOMATERIALS, V34, P2157, DOI 10.1016/j.biomaterials.2012.12.007
   Zouani OF, 2012, J CELL SCI, V125, P1217, DOI 10.1242/jcs.093229
NR 70
TC 3
Z9 3
U1 6
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUL 23
PY 2024
VL 16
IS 30
BP 39165
EP 39180
DI 10.1021/acsami.4c10755
EA JUL 2024
PG 16
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA A3H6R
UT WOS:001275875900001
PM 39041490
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Ricoldi, MST
   Furlaneto, FAC
   Oliveira, LFF
   Teixeira, GC
   Pischiotini, JP
   Moreira, ALG
   Ervolino, E
   de Oliveira, MN
   Bogsan, CSB
   Salvador, SL
   Messora, MR
AF Ricoldi, Milla S. T.
   Furlaneto, Flavia A. C.
   Oliveira, Luiz F. F.
   Teixeira, Gustavo C.
   Pischiotini, Jessica P.
   Moreira, Andre L. G.
   Ervolino, Edilson
   de Oliveira, Marice N.
   Bogsan, Cristina S. B.
   Salvador, Sergio L.
   Messora, Michel R.
TI Effects of the probiotic Bifidobacterium animalis subsp. lactis
   on the non surgical treatment of periodontitis. A histomorphometric,
   microtomographic and immunohistochemical study in rats
SO PLOS ONE
LA English
DT Article
ID SALIVARY MUTANS STREPTOCOCCI; LACTOBACILLUS RHAMNOSUS; ICE CREAM;
   MICROBIOTA; LOZENGES; INFLAMMATION; MECHANISMS; ADHESION; THERAPY;
   STRAINS
AB Lactobacillus probiotics have been investigated in periodontitis. However, the effects of the genus Bifidobacterium on periodontitis are hardly known. This study evaluated the effects of the probiotic (PROB) Bifidobacterium animalis subsp. lactis (B. lactis) HN019 as an adjunct to scaling and root planing (SRP) in rats with experimental periodontitis (EP). At baseline, 32 rats were assigned to 4 groups: C (control), PROB, EP SRP and EP SRP PROB. In groups EP SRP and EP SRP PROB, the mandibular first molars of the animals received a ligature. At day 14, the ligatures were removed and SRP was performed. Animals of groups PROB and EP SRP PROB were orally administered with 10 mL/day of 10(9) colony forming units of B. lactis HNO19 for 15 days, starting at day 14. Animals were euthanized at day 29. Histomorphometric, microtomographic and immunohistochemical analyses were performed. Microbiological effects of B. lactis on biofilm were also evaluated. Data were statistically analyzed (ANOVA, Tukey; Kruskal Wallis, Dunn's; Two tailed t test; p<0.05). Group EP SRP PROB presented reduced alveolar bone resorption and attachment loss when compared with Group EP SRP (p<0.05). Group EP SRP PROB showed significantly fewer osteoclasts, increased expression of anti inflammatory cytokines and reduced expression of proinflammatory cytokines compared with Group EP SRP (p<0.05). B. lactis promoted a higher ratio between aerobic and anaerobic bacteria in biofilm samples (p<0.05). B. lactis HNO19 may have a role in the treatment of EP in rats, as an adjunct to SRP.
C1 [Ricoldi, Milla S. T.; Furlaneto, Flavia A. C.; Oliveira, Luiz F. F.; Teixeira, Gustavo C.; Pischiotini, Jessica P.; Messora, Michel R.] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Oral & Maxillofacial Surg & Periodontol, Ribeirao Preto, SP, Brazil.
   [Ervolino, Edilson] UNESP Univ Estadual Paulista, Dent Sch Aracatuba, Div Histol, Dept Basic Sci, Aracatuba, SP, Brazil.
   [de Oliveira, Marice N.; Bogsan, Cristina S. B.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Biochem & Pharmaceut Technol, Sao Paulo, SP, Brazil.
   [Salvador, Sergio L.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade
   de Sao Paulo; Universidade de Sao Paulo
RP Messora, MR (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Oral & Maxillofacial Surg & Periodontol, Ribeirao Preto, SP, Brazil.
EM m.messora@forp.usp.br
RI ; Furlaneto, Flavia/C 4171 2013; Oliveira, Luiz/AAS 3717 2020; Ervolino,
   Edilson/D 1500 2018; Bogsan, Cristina/E 7911 2011; Salvador,
   Sergio/G 1015 2019; Tavares, Milla/LDF 9162 2024; Oliveira,
   Marice/C 4107 2013; Bogsan, Cristina Stewart Bittencourt/E 7911 2011;
   Messora, Michel/F 3480 2012
OI Salvador, Sergio Luiz/0000 0002 4867 7294; Ervolino,
   Edilson/0000 0003 4859 0583; Furlaneto, Flavia/0000 0002 8072 3983;
   Sprone Tavares, Milla/0000 0002 6757 4995; Bogsan, Cristina Stewart
   Bittencourt/0000 0003 1778 4043; Messora, Michel/0000 0001 8485 9645
FU Sao Paulo Research Foundation (FAPESP) [2012/18313 2, 2012/18785 1]; Sao
   Paulo Research Foundation (FAPESP scholarship)
FX This work was supported by Sao Paulo Research Foundation (FAPESP)  
   www.fapesp.br; Scholarship to GCT (#2012/18313 2); Scholarship to JPP
   (#2012/18785 1). The authors thank Sao Paulo Research Foundation (FAPESP
   scholarship to GCT and JPP). The authors also thank Marina Del Arco
   (Laboratory Assistant, Department Clinical Analyses, School of
   Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo USP,
   Ribeirao Preto / SP, Brazil) for technical support during the
   microbiological procedures.
CR Araya M., 2002, GUIDELINES EVALUATIO, DOI [10.1111/j.1469 0691.2012.03873, DOI 10.1111/J.1469 0691.2012.03873]
   Biavati B, 2000, ANN MICROBIOL, V50, P117
   Çaglar E, 2008, ACTA ODONTOL SCAND, V66, P154, DOI 10.1080/00016350802089467
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Dereka XE, 2006, GROWTH FACTORS, V24, P260, DOI 10.1080/08977190601060990
   Furlaneto FAC, 2014, J PERIODONTOL, V85, P1291, DOI 10.1902/jop.2014.130581
   Gill HS, 2000, BRIT J NUTR, V83, P167, DOI 10.1017/S0007114500000210
   Grössner Schreiber B, 2006, J CLIN PERIODONTOL, V33, P478, DOI 10.1111/j.1600 051X.2006.00942.x
   Haukioja A, 2006, ORAL MICROBIOL IMMUN, V21, P326, DOI 10.1111/j.1399 302X.2006.00299.x
   Hemarajata P, 2013, THER ADV GASTROENTER, V6, P39, DOI 10.1177/1756283X12459294
   Hoffman FA, 2008, CLIN INFECT DIS, V46, pS53, DOI 10.1086/523342
   Ince G, 2015, J PERIODONTOL, V86, P746, DOI 10.1902/jop.2015.140612
   Lisboa MRP, 2015, J PERIODONTOL, V86, P801, DOI 10.1902/jop.2015.140630
   Liu C, 2010, WORLD J GASTROENTERO, V16, P2283, DOI 10.3748/wjg.v16.i18.2283
   Maekawa T, 2014, J PERIODONTAL RES, V49, P785, DOI 10.1111/jre.12164
   Martins AKS, 2010, ARCH MICROBIOL, V192, P995, DOI 10.1007/s00203 010 0626 0
   Messora MR, 2016, ARCH ORAL BIOL, V66, P108, DOI 10.1016/j.archoralbio.2016.02.014
   Messora MR, 2013, J PERIODONTOL, V84, P1818, DOI 10.1902/jop.2013.120644
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Nissen L, 2014, ANN MICROBIOL, V64, P611, DOI 10.1007/s13213 013 0694 x
   Oliveira LFF, 2016, J PERIODONTOL, V23, P1
   Ouwehand AC, 2008, FEMS IMMUNOL MED MIC, V53, P18, DOI 10.1111/j.1574 695X.2008.00392.x
   Periasamy S, 2009, J BACTERIOL, V191, P6804, DOI 10.1128/JB.01006 09
   Prasad J, 1998, INT DAIRY J, V8, P993, DOI 10.1016/S0958 6946(99)00024 2
   Prescott SL, 2008, CLIN EXP ALLERGY, V38, P1606, DOI 10.1111/j.1365 2222.2008.03061.x
   Shah MP, 2013, J CLIN DIAGN RES, V7, P595, DOI 10.7860/JCDR/2013/5225.2834
   Singh R, 2011, ACTA ODONTOL SCAND, V69, P389, DOI 10.3109/00016357.2011.572289
   Tekce M, 2015, J CLIN PERIODONTOL, V42, P363, DOI 10.1111/jcpe.12387
   Teles RP, 2010, J CLIN PERIODONTOL, V37, P313, DOI 10.1111/j.1600 051X.2010.01534.x
   Teughels W, 2013, J CLIN PERIODONTOL, V40, P1025, DOI 10.1111/jcpe.12155
   Teughels W, 2011, J CLIN PERIODONTOL, V38, P159, DOI 10.1111/j.1600 051X.2010.01665.x
   Toiviainen A, 2015, CLIN ORAL INVEST, V19, P77, DOI 10.1007/s00784 014 1221 6
   Vanderpool C, 2008, INFLAMM BOWEL DIS, V14, P1585, DOI 10.1002/ibd.20525
   Vivekananda M R, 2010, J Oral Microbiol, V2, DOI 10.3402/jom.v2i0.5344
   Zhang Y, 2015, J PERIODONTAL RES, V50, P141, DOI 10.1111/jre.12193
NR 35
TC 57
Z9 58
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2017
VL 12
IS 6
AR e0179946
DI 10.1371/journal.pone.0179946
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EZ3JX
UT WOS:000404608300079
PM 28662142
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Domaniza, M
   Hluchy, M
   Cizkova, D
   Humenik, F
   Slovinska, L
   Hudakova, N
   Hornakova, L
   Vozar, J
   Trbolova, A
AF Domaniza, Michal
   Hluchy, Marian
   Cizkova, Dasa
   Humenik, Filip
   Slovinska, Lucia
   Hudakova, Nikola
   Hornakova, Lubica
   Vozar, Juraj
   Trbolova, Alexandra
TI Two Amnion Derived Mesenchymal Stem Cells Injections to Osteoarthritic
   Elbows in Dogs Pilot Study
SO ANIMALS
LA English
DT Article
DE osteoarthritis; dog; mesenchymal stem cells; regenerative medicine
ID TUMOR NECROSIS FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   CHEMOATTRACTANT PROTEIN 1 MCP 1; COLLAGEN INDUCED ARTHRITIS; KINEMATIC
   GAIT ANALYSIS; GLYCATION END PRODUCTS; INFRAPATELLAR FAT PAD;
   SYNOVIAL FLUID; GENE EXPRESSION; ADIPOSE TISSUE
AB Simple Summary Osteoarthritis is a degenerative disease of synovial joints characterized by joint inflammation, damage of articular cartilage, and degenerative changes in periarticular tissues. The onset of lameness, pain, and joint stiffness are usually the first clinical signs observed by the owner. In recent years, many conventional therapies (NSAIDs, opioids, paracetamol, and gabapentinoids) for osteoarthritis have been described. Due to the complex mechanism of pain, multimodal analgesia in OA treatment is necessary. Unfortunately, conventional therapy does not offer the regenerative abilities of damaged tissue. However, mesenchymal stem cells have a definite advantage in chondrogenic, immunomodulatory, anti apoptotic, and anti fibrotic effects in joint environments in contrast to conventional therapies. The aim of the study was to investigate the potential of cell based regenerative therapy for elbow joints affected by osteoarthritis. Interest was focused on two intra articular applications of amnion derived mesenchymal stem cells (A MSCs) to a group of different breeds of dogs with elbow osteoarthritis (13 joints). Two injections were performed 14 days apart. We evaluated synovial fluid biomarkers, such as IFN & gamma;, IL 6, IL 15, IL 10, MCP 1, TNF & alpha;, and GM CSF, by multiplex fluorescent micro bead immunoassay in the treated group of elbows (n = 13) (day 0, day 14, and day 28) and in the control group of elbows (n = 9). Kinematic gait analysis determined the joint range of motion (ROM) before and after each A MSCs application. Kinematic gait analysis was performed on day 0, day 14, and day 28. Kinematic gait analysis pointed out improvement in the average range of motion of elbow joints from day 0 (38.45 & PLUSMN; 5.74 & DEG;), day 14 (41.7 & PLUSMN; 6.04 & DEG;), and day 28 (44.78 & PLUSMN; 4.69 & DEG;) with statistical significance (p < 0.05) in nine elbows. Correlation analyses proved statistical significance (p < 0.05) in associations between ROM (day 0, day 14, and day 28) and IFN & gamma;, IL 6, IL 15, MCP 1, TNF & alpha;, and GM CSF concentrations (day 0, day 14, and day 28). IFN & gamma;, IL 6, IL 15, MCP 1, GM CSF, and TNF  & alpha; showed negative correlation with ROM at day 0, day 14, and day 28, while IL 10 demonstrated positive correlation with ROM. As a consequence of A MSC application to the elbow joint, we detected a statistically significant (p < 0.05) decrease in concentration levels between day 0 and day 28 for IFN & gamma;, IL 6, and TNF & alpha; and statistically significant increase for IL 10. Statistical significance (p < 0.05) was detected in TNF & alpha;, IFN & gamma;, and GM CSF concentrations between day 14 and the control group as well as at day 28 and the control group. IL 6 concentrations showed statistical significance (p < 0.05) between day 14 and the control group.
C1 [Domaniza, Michal; Hluchy, Marian; Hornakova, Lubica; Trbolova, Alexandra] Univ Vet Med & Pharm, Small Anim Hosp, Komenskeho 73, Kosice 04181, Slovakia.
   [Cizkova, Dasa; Humenik, Filip; Hudakova, Nikola; Vozar, Juraj] Univ Vet Med & Pharm, Ctr Expt & Clin Regenerat Med, Komenskeho 68 73, Kosice 04181, Slovakia.
   [Slovinska, Lucia] Safarik Univ, Fac Med, Associated Tissue Bank, Trieda SNP 1, Kosice 04011, Slovakia.
   [Slovinska, Lucia] L Pasteur Univ Hosp, Trieda SNP 1, Kosice 04011, Slovakia.
C3 University of Veterinary Medicine Kosice; University of Veterinary
   Medicine Kosice; University of Pavol Jozef Safarik Kosice
RP Domaniza, M (通讯作者)，Univ Vet Med & Pharm, Small Anim Hosp, Komenskeho 73, Kosice 04181, Slovakia.; Cizkova, D (通讯作者)，Univ Vet Med & Pharm, Ctr Expt & Clin Regenerat Med, Komenskeho 68 73, Kosice 04181, Slovakia.
EM domaniza.michal@gmail.com; cizkova.dasa@gmail.com
RI ; Cizkova, Dasa/AAF 8976 2019; Slovinská, Lucia/ITU 2485 2023
OI Slovinska, Lucia/0000 0002 9945 0655; Cizkova, Dasa/0000 0002 2504 3993
CR Agarwal N, 2021, CELLS BASEL, V10, DOI 10.3390/cells10061365
   Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Agostinho FS, 2011, VET COMP ORTHOPAED, V24, P185, DOI 10.3415/VCOT 10 03 0039
   Almaawi A, 2013, TISSUE ENG PT A, V19, P1039, DOI [10.1089/ten.TEA.2012.0129, 10.1089/ten.tea.2012.0129]
   Anderson KL, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00220
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Arafat S., 2020, EGYPT DENT J, V66, P2165, DOI [10.21608/edj.2020.41265.1239, DOI 10.21608/EDJ.2020.41265.1239]
   Asadi S., 2018, Social Determinants of Health, V4, P162, DOI 10.22037/sdh.v4i3.23869
   Babu G.S., 2021, Osteology, V1, P209, DOI [10.3390/osteology1040020, DOI 10.3390/OSTEOLOGY1040020]
   Baers G, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00422
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962 8924(01)02064 5
   Beekhuizen M, 2013, OSTEOARTHR CARTILAGE, V21, P918, DOI 10.1016/j.joca.2013.04.002
   Belinsky GS, 2013, BIOTECHNIQUES, V55, P79, DOI 10.2144/000114065
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Bilgic H, 2009, ARTHRITIS RHEUM US, V60, P3436, DOI 10.1002/art.24936
   Bjerre M, 2009, VET IMMUNOL IMMUNOP, V130, P53, DOI 10.1016/j.vetimm.2009.01.007
   Black L, 2008, VET THER, V9
   Black LL, 2007, VET THER, V8, P272
   Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968 0004(01)01995 8
   Boffa A, 2021, CARTILAGE, V13, p82S, DOI 10.1177/1947603520942941
   Bondeson J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2099
   Borghesi J, 2019, TISSUE CELL, V58, P99, DOI 10.1016/j.tice.2019.04.007
   Brondeel C, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.668881
   Bruecker KA, 2021, VET CLIN N AM SMALL, V51, P475, DOI 10.1016/j.cvsm.2020.12.008
   Cabon Q, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00010
   Cachon T, 2018, VET J, V235, P1, DOI 10.1016/j.tvjl.2018.02.017
   Catterall JB, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3216
   Centeno CJ, 2011, CURR STEM CELL RES T, V6, P368
   Chahal J, 2019, STEM CELL TRANSL MED, V8, P746, DOI 10.1002/sctm.18 0183
   Chen K, 2010, CLIN IMMUNOL, V135, P448, DOI 10.1016/j.clim.2010.01.015
   Chisari E, 2020, OSTEOARTHR CARTILAGE, V28, P708, DOI 10.1016/j.joca.2019.09.008
   Choi JJ, 2008, CLIN EXP IMMUNOL, V153, P269, DOI 10.1111/j.1365 2249.2008.03683.x
   Chun JL, 2019, J ANIM SCI TECHNOL, V61, P366, DOI 10.5187/jast.2019.61.6.366
   Cifù A, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/4058760
   Clements DN, 2008, OSTEOARTHR CARTILAGE, V16, P195, DOI 10.1016/j.joca.2007.06.013
   Clements DN, 2006, AM J VET RES, V67, P909, DOI 10.2460/ajvr.67.5.909
   Clockaerts S, 2012, ANN RHEUM DIS, V71, P1012, DOI 10.1136/annrheumdis 2011 200688
   Constantinescu CS, 2001, CYTOKINE, V13, P244, DOI 10.1006/cyto.2000.0818
   Cook AD, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4037
   Coopman F, 2008, VET REC, V163, P654, DOI 10.1136/vr.163.22.654
   Cuellar VG, 2010, ARTHROSCOPY, V26, P1296, DOI 10.1016/j.arthro.2010.02.011
   Cuervo B, 2014, INT J MOL SCI, V15, P13437, DOI 10.3390/ijms150813437
   Daems R, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4587594
   Dajani EZ, 2008, J PHYSIOL PHARMACOL, V59, P117
   DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041
   Davatchi F, 2011, INT J RHEUM DIS, V14, P211, DOI 10.1111/j.1756 185X.2011.01599.x
   De Souza MC, 2021, VET MED CZECH, V66, P8, DOI 10.17221/178/2019 VETMED
   DeGroot J, 2004, ARTHRITIS RHEUM, V50, P1207, DOI 10.1002/art.20170
   Deligne C, 2015, OSTEOARTHR CARTILAGE, V23, P1843, DOI 10.1016/j.joca.2014.12.007
   Deweese MD, 2019, VET COMP ORTHOPAED, V32, P126, DOI 10.1055/s 0039 1678550
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   Djouad F, 2007, STEM CELLS, V25, P2025, DOI 10.1634/stemcells.2006 0548
   Dutta P, 2018, BREAST CANCER RES TR, V170, P477, DOI 10.1007/s10549 018 4760 8
   Duval JM, 1999, J AM VET MED ASSOC, V215, P811
   Emadedin M, 2012, ARCH IRAN MED, V15, P422, DOI 012157/AIM.0010
   English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001
   Enomoto M, 2019, VET REC, V184, DOI 10.1136/vr.104590
   Evangelista M, 2008, CYTOTECHNOLOGY, V58, P33, DOI 10.1007/s10616 008 9162 z
   Eymard F, 2014, ARTHRITIS RHEUMATOL, V66, P2165, DOI 10.1002/art.38657
   Fan XL, 2020, CELL MOL LIFE SCI, V77, P2771, DOI 10.1007/s00018 020 03454 6
   Fernandes TL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00111
   Fiorentino DF, 2016, J IMMUNOL, V197, P1539
   Fitzpatrick N, 2009, VET SURG, V38, P213, DOI 10.1111/j.1532 950X.2008.00489.x
   Francisco V, 2018, J ORTHOP RES, V36, P594, DOI 10.1002/jor.23788
   Gierman LM, 2012, ARTHRITIS RHEUM US, V64, P1172, DOI 10.1002/art.33443
   Gilbert SJ, 2022, BIOCHEM BIOPHYS REP, V32, DOI 10.1016/j.bbrep.2022.101323
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goekoop RJ, 2010, OSTEOARTHR CARTILAGE, V18, P942, DOI 10.1016/j.joca.2010.03.016
   Goldring MB, 1999, CONNECT TISSUE RES, V40, P1, DOI 10.3109/03008209909005273
   Guercio A, 2013, CELL BIOL INT, V37, P789, DOI 10.1002/cbin.10090
   Guercio A, 2012, CELL BIOL INT, V36, P189, DOI 10.1042/CBI20110304
   Guest DJ, 2008, EQUINE VET J, V40, P178, DOI 10.2746/042516408X276942
   Gupta PK, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt116
   Ha CW, 2019, ARTHROSCOPY, V35, P277, DOI 10.1016/j.arthro.2018.07.028
   Hached F, 2017, BEST PRACT RES CL RH, V31, P730, DOI 10.1016/j.berh.2018.05.002
   Hall SA, 2019, METHODSX, V6, P1218, DOI 10.1016/j.mex.2019.05.013
   Hamdalla HM, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/1900403
   Hampel U, 2013, J IMMUNOL METHODS, V396, P134, DOI 10.1016/j.jim.2013.08.007
   Hao J, 2014, CELL SIGNAL, V26, P186, DOI 10.1016/j.cellsig.2013.11.006
   HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153
   Harman R, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00081
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Hebel M, 2021, BMC VET RES, V17, DOI 10.1186/s12917 021 02997 5
   Heng B, 2008, CYTOTECHNOLOGY, V58, P69, DOI 10.1007/s10616 008 9174 8
   Henrotin YE, 2000, OSTEOARTHR CARTILAGE, V8, P474, DOI 10.1053/joca.1999.0323
   Hoff P, 2013, INT ORTHOP, V37, P145, DOI 10.1007/s00264 012 1724 1
   Holler PJ, 2010, AM J VET RES, V71, P734, DOI 10.2460/ajvr.71.7.734
   Hottinger HA, 1996, AM J VET RES, V57, P381
   Hou YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076390
   Huang FF, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 021 02613 1
   Humenik F, 2022, ANIMALS BASEL, V12, DOI 10.3390/ani12121502
   Hunakova K, 2020, RES VET SCI, V132, P513, DOI 10.1016/j.rvsc.2020.08.004
   Hunt JR, 2015, VET J, V206, P183, DOI 10.1016/j.tvjl.2015.07.025
   Iannone F, 2001, CLIN EXP RHEUMATOL, V19, P139
   Ichiseki T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010203
   Ilancheran S, 2007, BIOL REPROD, V77, P577, DOI 10.1095/biolreprod.106.055244
   Issa RI, 2012, PATHOBIOL AGING AGE, V2, DOI 10.3402/pba.v2i0.17470
   Jiang W, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12712
   Jo CH, 2014, STEM CELLS, V32, P1254, DOI 10.1002/stem.1634
   Johannisson A, 2006, CYTOM PART A, V69A, P391, DOI 10.1002/cyto.a.20271
   Johnston SA, 2008, VET CLIN N AM SMALL, V38, P1449, DOI 10.1016/j.cvsm.2008.08.001
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kay AG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18144 w
   Kearney CM, 2022, FRONT VET SCI, V9, DOI 10.3389/fvets.2022.907616
   Kim SE, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00474
   Kleine SA, 2020, VET COMP ORTHOPAED, V33, P147, DOI 10.1055/s 0039 3399525
   Kon E, 2012, CURR REV MUSCULOSKE, V5, P236, DOI 10.1007/s12178 012 9135 x
   Kong L, 2017, J ORTHOP TRANSL, V9, P89, DOI 10.1016/j.jot.2017.03.006
   Kook MG, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 58221 1
   Kriston Pál É, 2017, CAN J VET RES, V81, P73
   KuKanich B, 2010, J VET PHARMACOL THER, V33, P15, DOI 10.1111/j.1365 2885.2009.01098.x
   Kuppa SS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113016
   Lamo Espinosa JM, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0998 2
   Lampropoulou Adamidou Kalliopi, 2014, Eur J Orthop Surg Traumatol, V24, P263, DOI 10.1007/s00590 013 1205 2
   Lane NE, 2011, OSTEOARTHR CARTILAGE, V19, P478, DOI 10.1016/j.joca.2010.09.013
   Larsson S, 2017, OSTEOARTHR CARTILAGE, V25, P1443, DOI 10.1016/j.joca.2017.05.009
   Lavrijsen ICM, 2014, PREV VET MED, V114, P114, DOI 10.1016/j.prevetmed.2014.02.001
   Lee KBL, 2012, ANN ACAD MED SINGAP, V41, P511
   Lee SH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09767 0
   Lee WJ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19807 y
   Leijs MJC, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00231
   Li HJ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9671206
   Li L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27737 y
   Li LP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9682757
   Nguyen LT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030601
   Little CB, 2012, OSTEOARTHR CARTILAGE, V20, P261, DOI 10.1016/j.joca.2012.01.017
   Liu SS, 2018, J INTERF CYTOK RES, V38, P406, DOI 10.1089/jir.2017.0140
   Lorke M, 2017, J VET SCI, V18, P521, DOI 10.4142/jvs.2017.18.4.521
   Louis C, 2020, J EXP MED, V217, DOI 10.1084/jem.20191421
   Maggini J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009252
   MALEFYT RD, 1991, J EXP MED, V174, P1209
   Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005
   Mammoto T, 2010, DEVELOPMENT, V137, P1407, DOI 10.1242/dev.024166
   Man G S, 2014, J Med Life, V7, P37
   Mancuso P, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00009
   Manicourt DH, 2000, ARTHRITIS RHEUM, V43, P281, DOI 10.1002/1529 0131(200002)43:2<281::AID ANR7>3.0.CO;2 7
   Martinet L, 2009, EUR J IMMUNOL, V39, P752, DOI 10.1002/eji.200838812
   McCoy AM, 2015, VET PATHOL, V52, P803, DOI 10.1177/0300985815588611
   McLaughlin RM, 2001, VET CLIN N AM SMALL, V31, P193, DOI 10.1016/S0195 5616(01)50045 5
   Meehan RT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10215027
   Meeson RL, 2019, NAT REV RHEUMATOL, V15, P273, DOI 10.1038/s41584 019 0202 1
   Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457
   Michelsen J, 2013, VET J, V196, P12, DOI 10.1016/j.tvjl.2012.11.009
   Mihailova A, 2022, CURR RHEUMATOL REV, V18, P230, DOI 10.2174/1874471015666220128113319
   Miller RE, 2014, CYTOKINE, V70, P185, DOI 10.1016/j.cyto.2014.06.019
   Min SC, 2017, CLIN RHEUMATOL, V36, P2351, DOI 10.1007/s10067 017 3690 x
   Miqueleto NSML, 2013, VET J, V195, P210, DOI 10.1016/j.tvjl.2012.06.021
   Molnar V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179208
   Monteiro B, 2019, VET CLIN N AM SMALL, V49, P993, DOI 10.1016/j.cvsm.2019.07.009
   Monteiro Steagall BP, 2013, J VET INTERN MED, V27, P1011, DOI 10.1111/jvim.12127
   Morrison NA, 2014, J CELL BIOCHEM, V115, P303, DOI 10.1002/jcb.24663
   Muir P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159095
   Nees TA, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091343
   Ni FF, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 02045 2
   Niada S, 2019, STEM CELL RES, V38, DOI 10.1016/j.scr.2019.101463
   O'Neill Dan G, 2020, Canine Med Genet, V7, P1, DOI 10.1186/s40575 020 0080 5
   O'Neill DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090501
   Oliveira RL, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9824698
   Onakpoya IJ, 2020, BMJ EVID BASED MED, V25, P40, DOI 10.1136/bmjebm 2019 111213
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 144
   Orozco L, 2013, TRANSPLANTATION, V95, P1535, DOI 10.1097/TP.0b013e318291a2da
   Ossendorff R, 2022, EUR CELLS MATER, V43, P98, DOI 10.22203/eCM.v043a09
   Page CE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2960
   Park KH, 2016, CELL TRANSPLANT, V25, P1057, DOI 10.3727/096368915X687949
   Patrignani Paola, 2011, Expert Rev Clin Pharmacol, V4, P605, DOI 10.1586/ecp.11.36
   Pearson MJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03759 w
   PELLETIER JP, 1993, AM J PATHOL, V142, P95
   Pers YM, 2015, OSTEOARTHR CARTILAGE, V23, P2027, DOI 10.1016/j.joca.2015.07.004
   Poole R, 2010, OSTEOARTHR CARTILAGE, V18, pS10, DOI 10.1016/j.joca.2010.05.027
   Pountos I, 2011, J CELL MOL MED, V15, P525, DOI 10.1111/j.1582 4934.2010.01006.x
   Preda MB, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03839 w
   Prislin M, 2022, ANIMALS BASEL, V12, DOI 10.3390/ani12091088
   Rabaan AA, 2021, VACCINES BASEL, V9, DOI 10.3390/vaccines9050436
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Rai MF, 2011, CRIT REV EUKAR GENE, V21, P131, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.30
   Rasheed Z, 2011, RHEUMATOLOGY, V50, P838, DOI 10.1093/rheumatology/keq380
   Redondo JI, 2007, J VET MED A, V54, P470, DOI 10.1111/j.1439 0442.2007.00987.x
   REGINATO AM, 1993, BIOCHEM J, V294, P761, DOI 10.1042/bj2940761
   Rosshirt N, 2019, CLIN EXP IMMUNOL, V195, P395, DOI 10.1111/cei.13230
   Salah SM, 2019, AM J PHYSIOL RENAL, V317, pF343, DOI 10.1152/ajprenal.00240.2018
   Saldaña L, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1156 6
   Salem O, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4614
   Sallander MH, 2006, J NUTR, V136, p2050S, DOI 10.1093/jn/136.7.2050S
   Sandberg GS, 2020, VET SURG, V49, P1088, DOI 10.1111/vsu.13477
   Sarsenova M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111592
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004 0166
   Saulnier N, 2015, OSTEOARTHR CARTILAGE, V23, P122, DOI 10.1016/j.joca.2014.09.007
   Savkovic V, 2014, CURR STEM CELL RES T, V9, P469, DOI 10.2174/1574888X09666140709111444
   Scanzello CR, 2009, OSTEOARTHR CARTILAGE, V17, P1040, DOI 10.1016/j.joca.2009.02.011
   SCHLAAK JF, 1995, ANN RHEUM DIS, V54, P560, DOI 10.1136/ard.54.7.560
   Schulze Tanzil G, 2009, CURR GENE THER, V9, P306, DOI 10.2174/156652309788921044
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Shah K, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7309201
   Shan YX, 2017, MOL MED REP, V15, P1095, DOI 10.3892/mmr.2017.6132
   Shegos CJ, 2021, ANN JOINT, DOI 10.21037/aoj 21 16
   Shimazawa Y, 2022, BIOTECHNOL J, V17, DOI 10.1002/biot.202100137
   Slattery C, 2018, CLIN ORTHOP RELAT R, V476, P2101, DOI 10.1007/s11999.0000000000000255
   Sok D, 2022, AM J SPORT MED, V50, P1389, DOI 10.1177/03635465221083610
   Song Y, 2018, REGEN MED, V13, P295, DOI 10.2217/rme 2017 0152
   Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004 0359
   Spasovski D, 2018, J GENE MED, V20, DOI 10.1002/jgm.3002
   Spector T. D., 2004, Osteoarthritis and Cartilage, V12, P39, DOI 10.1016/j.joca.2003.09.005
   Srzentic Drazilov S, 2018, ACTA VET HUNG, V66, P376, DOI 10.1556/004.2018.034
   Stankovic A, 2009, BRATISL MED J, V110, P641
   Stannus O, 2010, OSTEOARTHR CARTILAGE, V18, P1441, DOI 10.1016/j.joca.2010.08.016
   Sulzbacher I, 2013, WIEN MED WOCHENSCHR, V163, P212, DOI 10.1007/s10354 012 0168 y
   Sun JM, 2013, DIS MARKERS, V2013, P203, DOI 10.1155/2013/176278
   Sutton MT, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/516278
   Takemitsu H, 2012, BMC VET RES, V8, DOI 10.1186/1746 6148 8 150
   Tang MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01508
   Tao YL, 2015, INT J CLIN EXP PATHO, V8, P9112
   Taroni M, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00083
   Teeple E, 2013, AAPS J, V15, P438, DOI 10.1208/s12248 013 9454 x
   Teunis T, 2013, J HAND SURG AM, V38A, P1735, DOI 10.1016/j.jhsa.2013.06.023
   Tobias K M., 2018, Veterinary Surgery Small Animal, V2nd
   Tofiño Vian M, 2018, BIOCHEM PHARMACOL, V153, P134, DOI 10.1016/j.bcp.2018.02.004
   Toutain CE, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1566 1
   Tsai Shen Yang, 2014, World J Transplant, V4, P196, DOI 10.5500/wjt.v4.i3.196
   Tsezou A, 2014, OSTEOARTHR CARTILAGE, V22, P2017, DOI 10.1016/j.joca.2014.07.024
   Tsuchida AI, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4107
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   van Buul GM, 2012, OSTEOARTHR CARTILAGE, V20, P1186, DOI 10.1016/j.joca.2012.06.003
   Vangsness CT, 2014, J BONE JOINT SURG AM, V96A, P90, DOI 10.2106/JBJS.M.00058
   Vezzoni A, 2021, VET CLIN N AM SMALL, V51, P439, DOI 10.1016/j.cvsm.2020.12.007
   Vilar JM, 2016, BMC VET RES, V12, DOI 10.1186/s12917 016 0852 z
   Vilar JM, 2014, BMC VET RES, V10, DOI 10.1186/1746 6148 10 143
   Vilar JM, 2013, BMC VET RES, V9, DOI 10.1186/1746 6148 9 131
   Villatoro AJ, 2019, VET IMMUNOL IMMUNOP, V208, P6, DOI 10.1016/j.vetimm.2018.12.003
   VILLIGER PM, 1992, J CLIN INVEST, V90, P488, DOI 10.1172/JCI115885
   Vonkeman HE, 2010, SEMIN ARTHRITIS RHEU, V39, P294, DOI 10.1016/j.semarthrit.2008.08.001
   Vuolteenaho K, 2017, OSTEOARTHR CARTILAGE, V25, pS92, DOI 10.1016/j.joca.2017.02.147
   Wan PX, 2015, WORLD J STEM CELLS, V7, P448, DOI 10.4252/wjsc.v7.i2.448
   Wang Q, 2019, ELIFE, V8, DOI 10.7554/eLife.39905
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Wang YQ, 2001, CHINESE MED J PEKING, V114, P723
   Warner SC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01385
   Wesseling J, 2015, ANN RHEUM DIS, V74, P347, DOI 10.1136/annrheumdis 2013 203829
   Wicks IP, 2016, NAT REV RHEUMATOL, V12, P37, DOI 10.1038/nrrheum.2015.161
   Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292
   Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005
   Wits MI, 2020, GENET MOL BIOL, V43, DOI [10.1590/1678 4685 GMB 2019 0275, 10.1590/1678 4685 gmb 2019 0275]
   Yan B, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.854025
   Yan L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01658
   Yang Q, 2014, SCI WORLD J, DOI 10.1155/2014/127084
   Ylöstalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191
   Yun S, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018 016 0342 9
   Zhang BY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/1983025
   Zhang J, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02984 z
   Zhang XF, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03070 0
NR 251
TC 3
Z9 3
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 2076 2615
J9 ANIMALS BASEL
JI Animals
PD JUL
PY 2023
VL 13
IS 13
AR 2195
DI 10.3390/ani13132195
PG 32
WC Agriculture, Dairy & Animal Science; Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Veterinary Sciences; Zoology
GA M2PD3
UT WOS:001028642800001
PM 37443993
OA gold
DA 2025 08 17
ER

PT J
AU Haskó, G
   Pacher, P
AF Hasko, Gyorgy
   Pacher, Pal
TI Regulation of Macrophage Function by Adenosine
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE cytokines; G proteins; immune system; immunosuppressive therapy;
   macrophages
ID ENDOTHELIAL GROWTH FACTOR; NECROSIS FACTOR ALPHA; ALTERNATIVELY
   ACTIVATED MACROPHAGES; SYNERGISTIC UP REGULATION; A(2A) RECEPTOR
   AGONISTS; TNF ALPHA; MURINE MACROPHAGES; A2A RECEPTOR; EXPRESSION; A(2B)
AB Following its release into the extracellular space in response to metabolic disturbances, the endogenous nucleoside adenosine exerts a range of immunomodulatory effects and cells of the mononuclear phagocyte system are among its major targets. Adenosine governs mononuclear phagocyte functions via 4 G protein coupled cell membrane receptors, which are denoted A(1), A(2A), A(2B), and A(3) receptors. Adenosine promotes osteoclast differentiation via A(1) receptors and alters monocyte to dendritic cell differentiation through A(2B) receptors. Adenosine downregulates classical macrophage activation mainly through A(2A) receptors. In contrast A(2B) receptor activation upregulates alternative macrophage activation. Adenosine promotes angiogenesis, which is mediated by inducing the production of vascular endothelial growth factor by mononuclear phagocytes through A(2A), A(2B), and A(3) receptors. By regulating mononuclear phagocyte function adenosine dictates the course of inflammatory and vascular diseases and cancer. (Arterioscler Thromb Vasc Biol. 2012;32:865 869.)
C1 [Hasko, Gyorgy] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA.
   [Hasko, Gyorgy] Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Immun & Inflammat, Newark, NJ 07103 USA.
   [Pacher, Pal] NIAAA, Lab Physiol Studies, NIH, Bethesda, MD USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; National Institutes of Health (NIH)   USA; NIH National
   Institute on Alcohol Abuse & Alcoholism (NIAAA)
RP Haskó, G (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.
EM haskoge@umdnj.edu
RI Pacher, Pal/B 6378 2008
OI Pacher, Pal/0000 0001 7036 8108
FU National Institutes of Health [R01GM66189]; USAMRMC [09065004,
   W81XWH 10 1 1015]; NIH/NIAAA
FX This work was supported by National Institutes of Health Grant
   R01GM66189 (to G.H.), USAMRMC grant log #09065004 (Contract
   W81XWH 10 1 1015) (to G.H.), and Intramural Research Program of
   NIH/NIAAA (to P.P.).
CR Adair TH, 2005, AM J PHYSIOL REG I, V289, pR283, DOI 10.1152/ajpregu.00840.2004
   ALBINA JE, 1990, J IMMUNOL, V144, P3877
   Barczyk K, 2010, BLOOD, V116, P446, DOI 10.1182/blood 2009 10 247106
   Barnholt KE, 2009, J IMMUNOL, V183, P6767, DOI 10.4049/jimmunol.0900331
   Belikoff BG, 2011, J IMMUNOL, V186, P2444, DOI 10.4049/jimmunol.1001567
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Buenestado A, 2010, BRIT J PHARMACOL, V159, P1304, DOI 10.1111/j.1476 5381.2009.00614.x
   Cekic C, 2011, J IMMUNOLOGY
   Chen HJ, 2009, EXP HEMATOL, V37, P533, DOI 10.1016/j.exphem.2009.02.001
   Crane JK, 2002, AM J PHYSIOL GASTR L, V283, pG74, DOI 10.1152/ajpgi.00484.2001
   Csoka B, 2011, FASEB J
   Csóka B, 2007, PURINERG SIGNAL, V3, P447, DOI 10.1007/s11302 007 9075 x
   De Ponti C, 2007, J LEUKOCYTE BIOL, V82, P392, DOI 10.1189/jlb.0107060
   Ernens I, 2010, BIOCHEM BIOPH RES CO, V392, P351, DOI 10.1016/j.bbrc.2010.01.023
   Ernst PB, 2010, J IMMUNOL, V185, P1993, DOI 10.4049/jimmunol.1000108
   Fredholm BB, 2001, PHARMACOL REV, V53, P527
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Gessi S, 2010, ARTERIOSCL THROM VAS, V30, P90, DOI 10.1161/ATVBAHA.109.194902
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Haschemi A, 2007, J IMMUNOL, V178, P5921, DOI 10.4049/jimmunol.178.9.5921
   Haskó G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003
   Hasko G, 1996, J IMMUNOL, V157, P4634
   Haskó G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99 0508com
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   Haskó G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003
   Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09 147447
   Kara FM, 2010, ARTHRITIS RHEUM US, V62, P534, DOI 10.1002/art.27219
   Köröskényi K, 2011, J IMMUNOL, V186, P7144, DOI 10.4049/jimmunol.1002284
   Kreckler LM, 2009, J PHARMACOL EXP THER, V331, P1051, DOI 10.1124/jpet.109.157651
   Kreckler LM, 2006, J PHARMACOL EXP THER, V317, P172, DOI 10.1124/jpet.105.096016
   Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002
   Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002 9440(10)61170 4
   Leonard F, 2011, J LEUKOCYTE BIOL, V90, P199, DOI 10.1189/jlb.0910505
   Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002
   Martinez FO, 2008, FRONT BIOSCI LANDMRK, V13, P453, DOI 10.2741/2692
   McPherson JA, 2001, ARTERIOSCL THROM VAS, V21, P791, DOI 10.1161/01.ATV.21.5.791
   Merrill JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/1529 0131(199707)40:7<1308::AID ART16>3.0.CO;2 M
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409
   Németh ZH, 2005, J IMMUNOL, V175, P8260, DOI 10.4049/jimmunol.175.12.8260
   Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood 2008 02 136325
   Pinhal Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002 9440(10)63698 X
   Raes G, 2005, J LEUKOCYTE BIOL, V77, P321, DOI 10.1189/jlb.0304212
   Ramanathan M, 2007, MOL BIOL CELL, V18, P14, DOI 10.1091/mbc.E06 07 0596
   Ramanathan M, 2009, J LEUKOCYTE BIOL, V86, P681, DOI 10.1189/jlb.0109021
   Ruiz García A, 2011, J BIOL CHEM, V286, P19247, DOI 10.1074/jbc.M110.190298
   Ryzhov S, 2008, NEOPLASIA, V10, P987, DOI 10.1593/neo.08478
   Ryzhov S, 2008, J PHARMACOL EXP THER, V324, P694, DOI 10.1124/jpet.107.131540
   Scheibner KA, 2009, AM J RESP CELL MOL, V40, P251, DOI 10.1165/rcmb.2008 0168OC
   Semenza GL, 2010, ARTERIOSCL THROM VAS, V30, P648, DOI 10.1161/ATVBAHA.108.181644
   Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731
   Szabó C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040
   Tasca T, 2003, EXP PARASITOL, V105, P167, DOI 10.1016/j.exppara.2003.12.001
   Thammavongsa V, 2009, J EXP MED, V206, P2417, DOI 10.1084/jem.20090097
   Wang H, 2009, ARTERIOSCL THROM VAS, V29, P1046, DOI 10.1161/ATVBAHA.109.188839
   Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08 10 1005
   Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105
   Yegutkin GG, 2008, BBA MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Zhang JG, 2005, BIOCHEM PHARMACOL, V69, P883, DOI 10.1016/j.bcp.2004.12.008
NR 59
TC 185
Z9 195
U1 1
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079 5642
EI 1524 4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD APR
PY 2012
VL 32
IS 4
BP 865
EP 869
DI 10.1161/ATVBAHA.111.226852
PG 5
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 910VV
UT WOS:000301672300009
PM 22423038
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Li, JC
   Li, JJ
   Zhang, J
   Wang, XL
   Kawazoe, N
   Chen, GP
AF Li, Jingchao
   Li, Jia'En Jasmine
   Zhang, Jing
   Wang, Xinlong
   Kawazoe, Naoki
   Chen, Guoping
TI Gold nanoparticle size and shape influence on osteogenesis of
   mesenchymal stem cells
SO NANOSCALE
LA English
DT Article
ID MESOPOROUS SILICA NANOPARTICLES; IN VIVO; CELLULAR UPTAKE; PHOTOTHERMAL
   THERAPY; SURFACE CHEMISTRY; SIGNALING PATHWAY; IMAGING APPLICATIONS;
   FACILE PREPARATION; CARBON NANOTUBES; MAMMALIAN CELLS
AB Gold nanoparticles (AuNPs) have been extensively explored for biomedical applications due to their advantages of facile synthesis and surface functionalization. Previous studies have suggested that AuNPs can induce differentiation of stem cells into osteoblasts. However, how the size and shape of AuNPs affect the differentiation response of stem cells has not been elucidated. In this work, a series of bovine serum albumin (BSA) coated Au nanospheres, Au nanostars and Au nanorods with different diameters of 40, 70 and 110 nm were synthesized and their effects on osteogenic differentiation of human mesenchymal stem cells (hMSCs) were investigated. All the AuNPs showed good cytocompatibility and did not influence proliferation of hMSCs at the studied concentrations. Osteogenic differentiation of hMSCs was dependent on the size and shape of AuNPs. Sphere 40, sphere 70 and rod 70 significantly increased the alkaline phosphatase (ALP) activity and calcium deposition of cells while rod 40 reduced the ALP activity and calcium deposition. Gene profiling revealed that the expression of osteogenic marker genes was down regulated after incubation with rod 40. However, up regulation of these genes was found in the sphere 40, sphere 70 and rod 70 treatment. Moreover, it was found that the size and shape of AuNPs affected the osteogenic differentiation of hMSCs through regulating the activation of Yes associated protein (YAP). These results indicate that the size and shape of AuNPs had an influence on the osteogenic differentiation of hMSCs, which should provide useful guidance for the preparation of AuNPs with defined size and shape for their biomedical applications.
C1 [Li, Jingchao; Li, Jia'En Jasmine; Zhang, Jing; Wang, Xinlong; Kawazoe, Naoki; Chen, Guoping] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton, Tissue Regenerat Mat Unit, 1 1 Namiki, Tsukuba, Ibaraki 3050044, Japan.
   [Li, Jingchao; Zhang, Jing; Wang, Xinlong; Chen, Guoping] Univ Tsukuba, Grad Sch Pure & Appl Sci, Dept Mat Sci & Engn, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.
C3 National Institute for Materials Science; University of Tsukuba
RP Chen, GP (通讯作者)，Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton, Tissue Regenerat Mat Unit, 1 1 Namiki, Tsukuba, Ibaraki 3050044, Japan.; Chen, GP (通讯作者)，Univ Tsukuba, Grad Sch Pure & Appl Sci, Dept Mat Sci & Engn, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.
EM Guoping.CHEN@nims.go.jp
RI Li, Jingchao/AAK 6909 2021; Kawazoe, Naoki/AGK 1522 2022; Chen,
   Guoping/H 2593 2011; Wang, Xinlong/AFI 8800 2022
OI Kawazoe, Naoki/0000 0003 3916 0709; Chen, Guoping/0000 0001 6753 3678; 
FU World Premier International Research Center Initiative (WPI);
   "Nanotechnology Network Project" of the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT), Japan; NIMS microstructural
   characterization platform (NMCP) as a program of "Nanotechnology
   Platform" of Ministry of Education, Culture, Sports, Science and
   Technology (MEXT), Japan; Grants in Aid for Scientific Research
   [15J01781] Funding Source: KAKEN
FX This work was supported partially by the World Premier International
   Research Center Initiative (WPI) and partially by "Nanotechnology
   Network Project" of the Ministry of Education, Culture, Sports, Science
   and Technology (MEXT), Japan. This work was also supported partly by
   NIMS microstructural characterization platform (NMCP) as a program of
   "Nanotechnology Platform" of Ministry of Education, Culture, Sports,
   Science and Technology (MEXT), Japan.
CR Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev bioeng 071811 150124, 10.1146/annurev.bioeng 071811 150124]
   Alkilany AM, 2009, SMALL, V5, P701, DOI 10.1002/smll.200801546
   Amorim S, 2014, J MATER CHEM B, V2, P6939, DOI 10.1039/c4tb01071j
   Bartczak D, 2012, NANOSCALE, V4, P4470, DOI 10.1039/c2nr31064c
   Cao YY, 2015, J MATER CHEM B, V3, P286, DOI 10.1039/c4tb01542h
   Chen J, 2005, NANO LETT, V5, P473, DOI 10.1021/nl047950t
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cho EC, 2011, NAT NANOTECHNOL, V6, P385, DOI [10.1038/nnano.2011.58, 10.1038/NNANO.2011.58]
   Choi SY, 2015, INT J NANOMED, V10, P4383, DOI 10.2147/IJN.S78775
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Favi PM, 2015, J BIOMED MATER RES A, V103, P3449, DOI 10.1002/jbm.a.35491
   Gan Q, 2015, J MATER CHEM B, V3, P2056, DOI 10.1039/c4tb01897d
   Hauck TS, 2008, SMALL, V4, P153, DOI 10.1002/smll.200700217
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362
   Hou H, 2015, J MATER CHEM B, V3, P5189, DOI 10.1039/c5tb00556f
   Hutter E, 2010, ACS NANO, V4, P2595, DOI 10.1021/nn901869f
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Kim D, 2007, J AM CHEM SOC, V129, P7661, DOI 10.1021/ja071471p
   Ko WK, 2015, J COLLOID INTERF SCI, V438, P68, DOI 10.1016/j.jcis.2014.08.058
   Kong LD, 2015, ACS APPL MATER INTER, V7, P4833, DOI 10.1021/am508760w
   Lee DE, 2012, CHEM SOC REV, V41, P2656, DOI 10.1039/c2cs15261d
   Li JJ, 2015, BIOMATERIALS, V54, P226, DOI 10.1016/j.biomaterials.2015.03.001
   Li JC, 2015, J MATER CHEM B, V3, P5806, DOI 10.1039/c5tb00633c
   Li JC, 2014, PART PART SYST CHAR, V31, P1223, DOI 10.1002/ppsc.201400087
   Li JC, 2015, BIOMATERIALS, V38, P10, DOI 10.1016/j.biomaterials.2014.10.065
   Li JC, 2013, ACS APPL MATER INTER, V5, P10357, DOI 10.1021/am4034526
   Li YJ, 2014, SMALL, V10, P1544, DOI 10.1002/smll.201303234
   Liu DD, 2010, ACS NANO, V4, P2185, DOI 10.1021/nn901479w
   Liu H, 2014, NANOSCALE, V6, P4521, DOI 10.1039/c3nr06694k
   Liu XS, 2014, ACS APPL MATER INTER, V6, P5657, DOI 10.1021/am5001823
   Liu XS, 2013, NANOSCALE, V5, P3982, DOI 10.1039/c3nr00284e
   Maiorano G, 2011, NANOSCALE, V3, P2227, DOI 10.1039/c1nr10107b
   Mao HL, 2014, NANOSCALE, V6, P1552, DOI 10.1039/c3nr05273g
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Orza A, 2011, ACS NANO, V5, P4490, DOI 10.1021/nn1035312
   Pissuwan D, 2011, J CONTROL RELEASE, V149, P65, DOI 10.1016/j.jconrel.2009.12.006
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prabaharan M, 2009, BIOMATERIALS, V30, P6065, DOI 10.1016/j.biomaterials.2009.07.048
   Qi LS, 2014, J MATER CHEM B, V2, P8361, DOI 10.1039/c4tb01102c
   Qin JB, 2015, NANOSCALE, V7, P13991, DOI 10.1039/c5nr02521d
   Qiu Y, 2010, BIOMATERIALS, V31, P7606, DOI 10.1016/j.biomaterials.2010.06.051
   Rayavarapu RG, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/14/145101
   Ricles LM, 2014, J MATER CHEM B, V2, P8220, DOI 10.1039/c4tb00975d
   Schaeublin NM, 2011, NANOSCALE, V3, P410, DOI 10.1039/c0nr00478b
   Shao JD, 2015, J MATER CHEM B, V3, P5291, DOI 10.1039/c5tb00535c
   Sokolova V, 2015, J MATER CHEM B, V3, P4767, DOI 10.1039/c5tb00618j
   Terentyuk G, 2014, NANO RES, V7, P325, DOI 10.1007/s12274 013 0398 3
   Thanh NTK, 2002, ANAL CHEM, V74, P1624, DOI 10.1021/ac011127p
   Tsai SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076545
   Wang SG, 2012, J MATER CHEM, V22, P23357, DOI 10.1039/c2jm34249a
   Wang SJ, 2015, SMALL, V11, P1801, DOI 10.1002/smll.201403248
   Wang SJ, 2013, ADV MATER, V25, P3055, DOI 10.1002/adma.201204623
   Wang YT, 2011, BIOMATERIALS, V32, P7988, DOI 10.1016/j.biomaterials.2011.07.009
   Wang YC, 2013, ACS NANO, V7, P2068, DOI 10.1021/nn304332s
   Xiang YJ, 2008, J PHYS CHEM C, V112, P3203, DOI 10.1021/jp710505t
   Yan P, 2015, NANOSCALE, V7, P5281, DOI 10.1039/c5nr00481k
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yao YY, 2014, J NANOSCI NANOTECHNO, V14, P4851, DOI 10.1166/jnn.2014.8717
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang DW, 2014, MAT SCI ENG C MATER, V42, P70, DOI 10.1016/j.msec.2014.04.042
   Zhang JM, 2015, BIOMATERIALS, V42, P103, DOI 10.1016/j.biomaterials.2014.11.053
   Zhang LM, 2014, CHEM MATER, V26, P1794, DOI 10.1021/cm403109k
   Zhang W, 2015, J MATER CHEM B, V3, P1856, DOI 10.1039/c4tb02071e
   Zhang XQ, 2013, NANOSCALE, V5, P147, DOI 10.1039/c2nr32698a
   Zhang YS, 2013, THERANOSTICS, V3, P532, DOI 10.7150/thno.5369
   Zhang ZY, 2011, CHEM COMMUN, V47, P3906, DOI 10.1039/c0cc05693f
   Zhao F, 2011, SMALL, V7, P1322, DOI 10.1002/smll.201100001
   Zhou XJ, 2015, ACS APPL MATER INTER, V7, P15777, DOI 10.1021/acsami.5b02636
   Zhu JY, 2014, BIOMATERIALS, V35, P7635, DOI 10.1016/j.biomaterials.2014.05.046
NR 74
TC 199
Z9 210
U1 9
U2 243
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PY 2016
VL 8
IS 15
BP 7992
EP 8007
DI 10.1039/c5nr08808a
PG 16
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA DJ4FA
UT WOS:000374159600025
PM 27010117
DA 2025 08 17
ER

PT J
AU Agarwal, S
   Morshed, M
   Labour, MN
   Hoey, D
   Duffy, B
   Curtin, J
   Jaiswal, S
AF Agarwal, Sankalp
   Morshed, Muhammad
   Labour, Marie Noelle
   Hoey, David
   Duffy, Brendan
   Curtin, James
   Jaiswal, Swarna
TI Enhanced corrosion protection and biocompatibility of a PLGA silane
   coating on AZ31 Mg alloy for orthopaedic applications
SO RSC ADVANCES
LA English
DT Article
ID IN VIVO CORROSION; SIMULATED BODY FLUID; MAGNESIUM ALLOYS; VITRO
   DEGRADATION; LAYER; CYTOCOMPATIBILITY; PERFORMANCE; MECHANISMS;
   IMPLANTS; BEHAVIOR
AB This paper reports a multi step procedure to fabricate a novel corrosion resistant and biocompatible PLGA silane coating on the magnesium (Mg) alloy AZ31. The first step involves alkaline passivation followed by dip coating in a methyltriethoxysilane (MTES) and tetraethoxysilane (TEOS) mixture to produce a cross linked siloxane coating. The second step is to impart an amine functionalization to the silane modified surface by using 3 aminopropyl triethoxy silane (APTES) for promoting adhesion of the acid terminated poly (lactic co glycolic) acid (PLGA) as a final coating step. Static contact angle measurements, Fourier transform infrared spectroscopy and scanning electron microscopy analysis confirmed the successful assembly of coatings on the AZ31 Mg alloy. Potentiodynamic polarization and impedance spectroscopy studies showed the improved initial corrosion resistance of the coated AZ31 substrate. Measurements of magnesium ion release, pH changes and hydrogen evolution showed enhanced corrosion protection of coated substrate over uncoated AZ31 alloy for 21 and 14 days respectively. The MTT assay, live dead cells staining, DNA quantification and alkaline phosphatase activity assay were used to measure the biocompatibility, proliferation and differentiation of MC3T3 E1 osteoblast cells. Scanning electron microscopy was used to observe cell morphology and integration with the coated surface. The coated substrate showed improved cytocompatibility as compared to the uncoated AZ31 alloy surface. The application of such coatings on biodegradable Mg alloys enhanced their corrosion resistance and biocompatibility. An additional advantage is that the coating also served as a potential delivery vehicle for specific drugs and bio active molecules releasing from an implant surface as the coatings, such as PLGA, adapt during the corrosion process, thereby enhancing bone regeneration.
C1 [Agarwal, Sankalp; Morshed, Muhammad; Duffy, Brendan; Jaiswal, Swarna] Dublin Inst Technol, FOCAS Inst, Ctr Res Engn & Surface Technol, Kevin St, Dublin 8, Ireland.
   [Agarwal, Sankalp; Curtin, James] Dublin Inst Technol, Sch Food Sci & Environm Hlth, Cathal Brugha St, Dublin 1, Ireland.
   [Labour, Marie Noelle; Hoey, David] Trinity Coll Dublin, Trinity Biomed Sci Inst, Trinity Ctr Bioengn, Dublin 2, Ireland.
   [Labour, Marie Noelle; Hoey, David] Trinity Coll Dublin, Sch Engn, Dept Mech & Mfg Engn, Dublin 2, Ireland.
   [Hoey, David] Trinity Coll Dublin, Royal Coll Surg Ireland, Adv Mat & Bioengn Res Ctr, Dublin 2, Ireland.
C3 Technological University Dublin; Trinity College Dublin; Trinity College
   Dublin; Trinity College Dublin; Royal College of Surgeons   Ireland
RP Jaiswal, S (通讯作者)，Dublin Inst Technol, FOCAS Inst, Ctr Res Engn & Surface Technol, Kevin St, Dublin 8, Ireland.
EM swarna.jaiswal@dit.ie
RI Curtin, James/B 1669 2008; Jaiswal, Swarna/ABF 6709 2020; Hoey,
   David/X 9231 2019; Hoey, David/G 3301 2013
OI Curtin, James/0000 0002 9320 9254; Duffy, Brendan/0000 0003 2471 9063;
   Jaiswal, Swarna/0000 0003 1414 9052; Hoey, David/0000 0001 5898 0409
FU Dublin Institute of Technology; European Research Council (ERC) Starting
   Grant [336882]; Science Foundation Ireland ERC [SFI 13/ERC/L2864];
   European Research Council (ERC) [336882] Funding Source: European
   Research Council (ERC)
FX The authors would like to thank Dublin Institute of Technology for the
   financial support through Fiosraigh Scholarship Programme (2014). This
   study was also supported by a European Research Council (ERC) Starting
   Grant (#336882) and a Science Foundation Ireland ERC Support Grant SFI
   13/ERC/L2864.
CR Agarwal S, 2016, MAT SCI ENG C MATER, V68, P948, DOI 10.1016/j.msec.2016.06.020
   Bobe K, 2013, ACTA BIOMATER, V9, P8611, DOI 10.1016/j.actbio.2013.03.035
   Chou DT, 2013, ACTA BIOMATER, V9, P8518, DOI 10.1016/j.actbio.2013.06.025
   Dezfuli SN, 2014, PROG NAT SCI MATER, V24, P531, DOI 10.1016/j.pnsc.2014.08.009
   Dinodi N, 2013, J MAGNES ALLOY, V1, P201, DOI 10.1016/j.jma.2013.08.003
   Feliu S, 2015, APPL SURF SCI, V347, P736, DOI 10.1016/j.apsusc.2015.04.189
   Fischer J, 2011, MATER SCI ENG B ADV, V176, P1773, DOI 10.1016/j.mseb.2011.06.002
   Gallardo J, 2000, J SOL GEL SCI TECHN, V19, P393, DOI 10.1023/A:1008778909389
   Gaur S, 2014, MAT SCI ENG C MATER, V42, P91, DOI 10.1016/j.msec.2014.05.035
   Homayun B, 2014, J ALLOY COMPD, V607, P1, DOI 10.1016/j.jallcom.2014.04.059
   Hornberger H, 2012, ACTA BIOMATER, V8, P2442, DOI 10.1016/j.actbio.2012.04.012
   Hu RG, 2012, PROG ORG COAT, V73, P129, DOI 10.1016/j.porgcoat.2011.10.011
   Jia ZJ, 2016, J MATER CHEM B, V4, P2498, DOI 10.1039/c6tb00117c
   Khramov AN, 2009, PROG ORG COAT, V65, P381, DOI 10.1016/j.porgcoat.2009.03.001
   King AD, 2014, ELECTROCHIM ACTA, V121, P394, DOI 10.1016/j.electacta.2013.12.124
   Kirkland NT, 2012, ACTA BIOMATER, V8, P925, DOI 10.1016/j.actbio.2011.11.014
   Kunjukunju S, 2013, ACTA BIOMATER, V9, P8690, DOI 10.1016/j.actbio.2013.05.013
   Li JN, 2010, J MATER SCI, V45, P6038, DOI 10.1007/s10853 010 4688 9
   Liu J, 2016, ACS APPL MATER INTER, V8, P17842, DOI 10.1021/acsami.6b05038
   Liu X, 2013, ACTA BIOMATER, V9, P8671, DOI 10.1016/j.actbio.2012.12.025
   Majoul N, 2015, APPL SURF SCI, V331, P388, DOI 10.1016/j.apsusc.2015.01.107
   Minardi S, 2015, ACS APPL MATER INTER, V7, P16364, DOI 10.1021/acsami.5b03464
   Nemcová A, 2014, CORROS SCI, V82, P58, DOI 10.1016/j.corsci.2013.12.019
   Ostrowski N, 2013, ACTA BIOMATER, V9, P8704, DOI 10.1016/j.actbio.2013.05.010
   Ostrowski NJ, 2013, J MATER SCI MATER M, V24, P85, DOI 10.1007/s10856 012 4773 5
   Persaud Sharma Dharam, 2012, J Biomim Biomater Tissue Eng, V12, P25, DOI 10.4028/www.scientific.net/JBBTE.12.25
   Poinern G.E. J., 2012, American Journal of Biomedical Engineering, P218, DOI [10.5923/j.ajbe.20120206.02, DOI 10.5923/J.AJBE.20120206.02]
   Shi ZM, 2010, CORROS SCI, V52, P579, DOI 10.1016/j.corsci.2009.10.016
   Song GL, 2007, ADV ENG MATER, V9, P298, DOI 10.1002/adem.200600252
   Song J, 2003, J ADHES SCI TECHNOL, V17, P2191, DOI 10.1163/156856103772150788
   Srinivasan A, 2016, RSC ADV, V6, P49910, DOI 10.1039/c6ra08478h
   Subramanian V, 1998, CORROSION, V54, P204, DOI 10.5006/1.3284845
   Supplit R, 2007, CORROS SCI, V49, P3015, DOI 10.1016/j.corsci.2007.02.006
   Takagishi Y, 2006, TISSUE ENG, V12, P927, DOI 10.1089/ten.2006.12.927
   Thomann M, 2010, J BIOMED MATER RES A, V93A, P1609, DOI 10.1002/jbm.a.32639
   Uan JY, 2008, METALL MATER TRANS A, V39A, P3233, DOI 10.1007/s11661 008 9669 0
   Wagener V, 2013, COLLOID SURFACE B, V103, P586, DOI 10.1016/j.colsurfb.2012.10.060
   Wang D, 2009, PROG ORG COAT, V64, P327, DOI 10.1016/j.porgcoat.2008.08.010
   Wang SH, 2012, SURF COAT TECH, V213, P192, DOI 10.1016/j.surfcoat.2012.10.046
   Witte F, 2006, BIOMATERIALS, V27, P1013, DOI 10.1016/j.biomaterials.2005.07.037
   Witte F, 2005, BIOMATERIALS, V26, P3557, DOI 10.1016/j.biomaterials.2004.09.049
   Witte F, 2008, CURR OPIN SOLID ST M, V12, P63, DOI 10.1016/j.cossms.2009.04.001
   Xin YC, 2008, ACTA BIOMATER, V4, P2008, DOI 10.1016/j.actbio.2008.05.014
   Zheng YF, 2014, MAT SCI ENG R, V77, P1, DOI 10.1016/j.mser.2014.01.001
   Zomorodian A, 2015, MAT SCI ENG C MATER, V48, P434, DOI 10.1016/j.msec.2014.12.027
NR 45
TC 29
Z9 31
U1 1
U2 68
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 115
BP 113871
EP 113883
DI 10.1039/c6ra24382g
PG 13
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EH0ME
UT WOS:000391457400006
DA 2025 08 17
ER

PT J
AU Shivnath, N
   Rawat, V
   Siddiqui, S
   Verma, S
   Gupta, P
   Rais, J
   Khan, MS
   Arshad, M
AF Shivnath, Neelam
   Rawat, Vineeta
   Siddiqui, Sahabjada
   Verma, Sushma
   Gupta, Pragya
   Rais, Juhi
   Khan, Mohd Sajid
   Arshad, Md
TI Antiosteoarthritic effect ofPunica granatumL. peel extract on
   collagenase induced osteoarthritis rat by modulation ofCOL 2,MMP 3,
   andCOX 2 expression
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE articular cartilage; collagen; nonsteroidal antiinflammatory drug;
   osteoarthritis; proteoglycan
ID MATRIX METALLOPROTEINASES; INFLAMMATORY DISEASE; ANTIOXIDANT ACTIVITY;
   MODEL; GLYCOSAMINOGLYCANS; INJECTION; JOINT
AB Osteoarthritis (OA) is a chronic degenerative and musculoskeletal disorder. The toxicity associated with nonsteroidal antiinflammatory drugs (NSAIDs) limits its use in the management of OA. To ameliorate these toxicities, natural antioxidants can be used as substitutes for the management of OA. Therefore, this study is aimed to investigate the prophylactic mechanisms ofPunica granatumL. peel (PGP) in collagenase induced OA rat compared with indomethacin. OA was induced in femaleSprague Dawleyrats by intraarticular injection of collagenase type II and treated with PGP (250 and 500 mg/kg body wt) and a positive control (PC) indomethacin (3 mg/kg body wt). The results demonstrated that PGP reduced the collagenase induced OA as compared with indomethacin treated group through reducing blood ALP (P < .001) and significantly (P < .001) inhibited cartilage erosion as indicated in histological slides with retention of collagen and proteoglycan content. Quantitative real time PCR analysis revealed the considerable (P < .05) upregulation in the expression of COL 2 gene and downregulation of MMP 3 and COX 2 genes in the PGP treated group. The high phenolic content (633 +/  1.16 mg/GAE) and flavonoid content (420.3 +/  2.14 mg/RE) contribute to the strong antioxidant activity with IC(50)value (320 +/  2.2 mu g/mL) of DPPH free radical scavenging activity. These results need further validation in clinical studies and thus, PGP could be developed as a preventive drug treatment for OA.
C1 [Shivnath, Neelam; Rawat, Vineeta; Siddiqui, Sahabjada; Gupta, Pragya; Rais, Juhi; Arshad, Md] Univ Lucknow, Dept Zool, Mol Endocrinol Lab, Lucknow 226007, Uttar Pradesh, India.
   [Siddiqui, Sahabjada] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Biotechnol, Lucknow, Uttar Pradesh, India.
   [Verma, Sushma] Era Univ, Eras Lucknow Med Coll & Hosp, Dept Personalized & Mol Med, Lucknow, Uttar Pradesh, India.
   [Khan, Mohd Sajid] Integral Univ, Dept Biosci, Lucknow, Uttar Pradesh, India.
   [Khan, Mohd Sajid] Aligarh Muslim Univ, Dept Biochem, Aligarh, Uttar Pradesh, India.
   [Arshad, Md] Aligarh Muslim Univ, Dept Zool, Aligarh, Uttar Pradesh, India.
C3 Lucknow University; Integral University; Aligarh Muslim University;
   Aligarh Muslim University
RP Shivnath, N; Arshad, M (通讯作者)，Univ Lucknow, Dept Zool, Mol Endocrinol Lab, Lucknow 226007, Uttar Pradesh, India.
EM neelamshivnath@yahoo.co.in; arshadm123@rediffmail.com
RI Siddiqui, Sahabjada/E 8383 2015; Khan, Mohammad Shahiq/JMP 8399 2023;
   Rawat, Vineeta/HSB 5135 2023; Rais, Juhi/AFY 3218 2022
FU ICMR, New Delhi, India [45/46/2014/BMS/TRM]
FX Author Neelam Shivnath is thankful to ICMR, New Delhi, India for the
   award of Senior Research Fellowship (No. 45/46/2014/BMS/TRM). The
   Departmental Equipment Facility, Department of Zoology, University of
   Lucknow, provided by DST FIST PURSE is duly acknowledged. Department of
   Biotechnology, Era University, Lucknow, is acknowledged for antioxidant
   evaluation of PGP extract.
CR Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007
   Barathikannan K, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1237 3
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Bessone F, 2010, WORLD J GASTROENTERO, V16, P5651, DOI 10.3748/wjg.v16.i45.5651
   Bhowmik D., 2013, J Pharmacogn Phytochem, V1, P28, DOI 10.22271/phyto
   Blair Levy JM, 2008, ARTHRITIS RHEUM, V58, P1096, DOI 10.1002/art.23277
   Blom AB, 2007, ARTHRITIS RHEUM, V56, P147, DOI 10.1002/art.22337
   Christhudas IVSN, 2013, FOOD CHEM, V138, P1689, DOI 10.1016/j.foodchem.2012.11.051
   Dixit P, 2012, PHYTOCHEMISTRY, V81, P117, DOI 10.1016/j.phytochem.2012.06.005
   EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009 8981(80)90192 8
   Faria A, 2011, CRIT REV FOOD SCI, V51, P626, DOI 10.1080/10408391003748100
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304 4165(86)90306 5
   Gautam RK, 2018, J ENVIRON PATHOL TOX, V37, P53, DOI 10.1615/JEnvironPatholToxicolOncol.2018025137
   Ghoochani N, 2015, JENTASHAPIR J HLTH R, V6, DOI DOI 10.17795/JJHR 26558
   Gil MI, 2000, J AGR FOOD CHEM, V48, P4581, DOI 10.1021/jf000404a
   Gogebakan B, 2016, OSTEOARTHRITIS
   Haseeb A, 2017, PHYTOTHER RES, V31, P778, DOI 10.1002/ptr.5799
   Hauser R.A., 2010, Journal of Pelotherapy, V2, P305
   Huh JE, 2008, J PHARMACOL SCI, V107, P317, DOI 10.1254/jphs.08010FP
   Iqbal Erum, 2015, Journal of King Saud University Science, V27, P224, DOI 10.1016/j.jksus.2015.02.003
   Karadag A, 2009, FOOD ANAL METHOD, V2, P41, DOI 10.1007/s12161 008 9067 7
   Karsdal MA, 2008, OSTEOARTHR CARTILAGE, V16, P638, DOI 10.1016/j.joca.2008.01.014
   Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945 053X(02)00004 5
   MANKIN HJ, 1971, J CLIN INVEST, V50, P1712, DOI 10.1172/JCI106660
   Nirmal P, 2013, AM J CHINESE MED, V41, P1407, DOI 10.1142/S0192415X13500948
   Nirmal PS, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 016 1535 9
   Palaniswamy R., 2003, A guide to Medicinal Plants of Asian Origin and Culture
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Pelletier JP, 2001, ARTHRITIS RHEUM US, V44, P1237, DOI 10.1002/1529 0131(200106)44:6<1237::AID ART214>3.0.CO;2 F
   Rafraf M, 2017, IRAN RED CRESCENT ME, V19, P1
   Rahimi HR, 2012, IRAN J PHARM RES, V11, P385
   Rahmani A. H., 2017, Pharmacognosy Journal, V9, P689, DOI 10.5530/pj.2017.5.109
   Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016/S1567 5769(01)00204 1
   Sultana B, 2007, FOOD CHEM, V104, P1106, DOI 10.1016/j.foodchem.2007.01.019
   Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945 053X(02)00069 0
   Tsushima H, 2012, ANN RHEUM DIS, V71, P99, DOI 10.1136/annrheumdis 2011 200061
   VANDERKRAAN PM, 1990, J EXP PATHOL, V71, P19
   VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046
   Vogel B, 2015, METHODSX, V2, P124, DOI 10.1016/j.mex.2015.02.007
   Waris Adnan, 2014, J BIOCH PHARM RES, V2, P57
   Yeh TT, 2008, EUR SPINE J, V17, P734, DOI 10.1007/s00586 008 0594 0
   Youn J, 2003, J RHEUMATOL, V30, P1203
   Zarfeshany Aida, 2014, Adv Biomed Res, V3, P100, DOI 10.4103/2277 9175.129371
NR 44
TC 11
Z9 11
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD JAN
PY 2021
VL 36
IS 1
BP 5
EP 15
DI 10.1002/tox.23005
EA AUG 2020
PG 11
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA OZ3TM
UT WOS:000559476700001
PM 32794641
DA 2025 08 17
ER

PT J
AU Yu, M
   Park, C
   Son, YB
   Jo, SE
   Jeon, SH
   Kim, YJ
   Han, SB
   Hong, JT
   Son, DJ
AF Yu, Min
   Park, Cheoljin
   Son, Young Bae
   Jo, So Eun
   Jeon, Seong Hee
   Kim, Ye Jin
   Han, Sang Bae
   Hong, Jin Tae
   Son, Dong Ju
TI Time Dependent Effect of Eggshell Membrane on
   Monosodium Iodoacetate Induced Osteoarthritis: Early Stage Inflammation
   Control and Late Stage Cartilage Protection
SO NUTRIENTS
LA English
DT Article
DE osteoarthritis; eggshell membrane; Ovomet; inflammation;
   cartilage degrading enzyme
ID ARTICULAR CARTILAGE; MATRIX; PAIN; CHONDROCYTE; MANAGEMENT; MODEL
AB Osteoarthritis (OA) is a chronic degenerative joint disease that causes chronic pain, swelling, stiffness, disability, and significantly reduces the quality of life. Typically, OA is treated using painkillers and non steroidal anti inflammatory drugs (NSAIDs). While current pharmacologic treatments are common, their potential side effects have prompted exploration into functional dietary supplements. Recently, eggshell membrane (ESM) has emerged as a potential functional ingredient for joint and connective tissue disorders due to its clinical efficacy in relieving joint pain and stiffness. Despite promising clinical evidence, the effects of ESM on OA progression and its mechanism of action remain poorly understood. This study evaluated the efficacy of Ovomet (R), a powdered natural ESM, against joint pain and disease progression in a monosodium iodoacetate (MIA) induced rodent model of OA in mice and rats. The results demonstrate that ESM significantly alleviates joint pain and attenuates articular cartilage destruction in both mice and rats that received oral supplementation for 5 days prior to OA induction and for 28 days thereafter. Interestingly, ESM significantly inhibited mRNA expression levels of pro inflammatory cytokines including tumor necrosis factor alpha (TNF alpha), interleukin 1 beta (IL 1 beta), and interleukin 6 (IL 6), as well as inflammatory mediators, cyclooxygenase 2 (COX 2), and inducible nitric oxide synthase in the knee joint cartilage at the early stage of OA, within 7 days after OA induction. However, this effect was not observed in the late stage at 28 days after OA induction. ESM further attenuates the induction of protein expression for cartilage degrading enzymes like matrix metalloproteinase (MMPs) 3 and 13, and a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS 5), in the late stage. In addition, MIA induced reduction of the protein expression levels of cartilage components, cartilage oligomeric matrix protein (COMP), aggrecan (ACAN) and collagen type II alpha 1 chain (COL2 alpha 1), and cartilage extracellular matrix (ECM) synthesis promoting transcriptional factor SRY Box 9 (SOX 9) were increased via ESM treatment in the cartilage tissue. Our findings suggest that Ovomet (R), a natural ESM powder, is a promising dietary functional ingredient that can alleviate pain, inflammatory response, and cartilage degradation associated with the progression of OA.
C1 [Yu, Min; Park, Cheoljin; Son, Young Bae; Jo, So Eun; Jeon, Seong Hee; Kim, Ye Jin; Han, Sang Bae; Hong, Jin Tae; Son, Dong Ju] Chungbuk Natl Univ, Coll Pharm, 194 21 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.
C3 Chungbuk National University
RP Son, DJ (通讯作者)，Chungbuk Natl Univ, Coll Pharm, 194 21 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungbuk, South Korea.
EM yumin0413@chungbuk.ac.kr; cusimquar@hanmail.net; yb@chungbuk.ac.kr;
   lovel5508@chungbuk.ac.kr; shee@chungbuk.ac.kr; yejinee13@chungbuk.ac.kr;
   shan@chungbuk.ac.kr; jinthong@chungbuk.ac.kr; sondj1@chungbuk.ac.kr
OI Park, Cheoljin/0000 0001 9414 0327; SON, DONG JU/0000 0001 7520 6909;
   Han, Sang Bae/0000 0001 6656 6523; Hong, Jin Tae/0000 0002 6534 9575;
   Kim, YeJin/0000 0002 7402 1459
FU National Research Foundation of Korea (NRF)   Ministry of Education
   [[23] (2021RIS 001)]
FX This research work funded by "Regional Innovation Strategy (RIS)"
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education [23] (2021RIS 001).
CR Aguirre A., 2017, J. Trauma Treat, V6, P2, DOI [10.4172/2167 1222.1000371, DOI 10.4172/2167 1222.1000371]
   Ahmed TAE, 2017, J PROTEOMICS, V155, P49, DOI 10.1016/j.jprot.2017.01.002
   Benson KF, 2012, J MED FOOD, V15, P360, DOI 10.1089/jmf.2011.0197
   Bhosale AM, 2008, BRIT MED BULL, V87, P77, DOI 10.1093/bmb/ldn025
   Blasco JM ., 2016, Int J Clin Rheumtol, V11, P077
   Buckwalter JA, 1997, J BONE JOINT SURG AM, V79A, P600, DOI 10.2106/00004623 199704000 00021
   Cecchi F, 2008, OSTEOARTHR CARTILAGE, V16, P1039, DOI 10.1016/j.joca.2008.01.008
   D'Ambrosio C, 2008, J PROTEOME RES, V7, P3461, DOI 10.1021/pr800193y
   de Morais SV, 2016, ACTA CIR BRAS, V31, P765, DOI 10.1590/S0102 865020160110000010
   Dominick Kelli L, 2004, Health Qual Life Outcomes, V2, P5
   Ejaz P, 2004, J Assoc Physicians India, V52, P632
   Eyre DR, 2004, CLIN ORTHOP RELAT R, pS118, DOI 10.1097/01.blo.0000144855.48640.b9
   Gil Quintana E., 2018, J Osteopor Phys Act, V6, P1, DOI [10.4172/2329 9509.1000211, DOI 10.4172/2329 9509.1000211]
   Goldring MB, 2000, ARTHRITIS RHEUM US, V43, P1916, DOI 10.1002/1529 0131(200009)43:9<1916::AID ANR2>3.0.CO;2 I
   Henrotin Y, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0782 9
   Hewlings S, 2019, J MED FOOD, V22, P875, DOI 10.1089/jmf.2019.0068
   Jung JY, 2017, J AUDIOL OTOL, V21, P39, DOI 10.7874/jao.2017.21.1.39
   Kang YH, 2019, BIOMOL THER, V27, P503, DOI 10.4062/biomolther.2019.139
   Kiers JL, 2021, J MED FOOD, V24, P292, DOI 10.1089/jmf.2020.0034
   Kulshreshtha G, 2020, BIOMATER SCI UK, V8, P5346, DOI 10.1039/d0bm01110j
   LEACH RM, 1982, POULTRY SCI, V61, P2040, DOI 10.3382/ps.0612040
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Long HB, 2022, ARTHRITIS RHEUMATOL, V74, P1172, DOI 10.1002/art.42089
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Marker CL, 2012, METHODS MOL BIOL, V851, P239, DOI 10.1007/978 1 61779 561 9_18
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Neefjes M, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9090290
   Oesser S, 2003, CELL TISSUE RES, V311, P393, DOI 10.1007/s00441 003 0702 8
   Ohto Fujita E, 2019, CELL TISSUE RES, V376, P123, DOI 10.1007/s00441 018 2954 3
   Park P.W., 2023, Encyclopedia of Cell Biology (Second Edition), P335, DOI [10.1016/B978 0 12 821618 7.00145 0, DOI 10.1016/B978 0 12 821618 7.00145 0]
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Pillai MM, 2018, J BIOMED MATER RES A, V106, P1722, DOI 10.1002/jbm.a.36372
   Pitcher T, 2016, JOVE J VIS EXP, DOI 10.3791/53746
   Pozgan U, 2010, BIOL CHEM, V391, P571, DOI 10.1515/BC.2010.035
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Ramli NS, 2020, FOOD SCI NUTR, V8, P2512, DOI 10.1002/fsn3.1545
   Ruff KJ, 2018, CLIN INTERV AGING, V13, P285, DOI 10.2147/CIA.S153782
   Samuels J, 2008, BULL HOSP JT DIS, V66, P244
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Shi YN, 2021, FOODS, V10, DOI 10.3390/foods10092178
   Shi YN, 2014, J FUNCT FOODS, V11, P571, DOI 10.1016/j.jff.2014.08.017
   Shi YN, 2014, J FUNCT FOODS, V10, P35, DOI 10.1016/j.jff.2014.05.004
   Sim BooYong Sim BooYong, 2015, Journal of Nutrition and Health, V48, P310
   Smith R. K. W., 2008, Equine exercise physiology: the science of exercise in the athletic horse, P106, DOI 10.1016/B978 070202857 1.50007 X
   Vuong TT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201975
   Vuong TT, 2017, J INFLAMM RES, V10, P83, DOI 10.2147/JIR.S130974
   Xu JA, 2020, JOVE J VIS EXP, DOI 10.3791/60649
   Zheng LL, 2021, AGEING RES REV, V66, DOI 10.1016/j.arr.2020.101249
   Zhu LJ, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11122428
NR 49
TC 2
Z9 3
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2024
VL 16
IS 12
AR 1885
DI 10.3390/nu16121885
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA WR3I2
UT WOS:001256556600001
PM 38931240
OA gold
DA 2025 08 17
ER

PT J
AU Moore, RA
   Derry, S
   McQuay, HJ
AF Moore, R. Andrew
   Derry, Sheena
   McQuay, Henry J.
TI Cyclo oxygenase 2 selective inhibitors and nonsteroidal
   anti inflammatory drugs: balancing gastrointestinal and cardiovascular
   risk
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID THERAPEUTIC ARTHRITIS RESEARCH; PROTON PUMP INHIBITORS; EVENT TRIAL
   TARGET; CLINICAL TRIALS; ADVERSE EVENTS; RHEUMATOID ARTHRITIS; ULCER
   COMPLICATIONS; ELDERLY PATIENTS; DOUBLE BLIND; OSTEOARTHRITIS
AB Background: Differences between gastrointestinal and cardiovascular effects of traditional NSAID or cyclooxygenase 2 selective inhibitor (coxib) are affected by drug, dose, duration, outcome definition, and patient gastrointestinal and cardiovascular risk factors. We calculated the absolute risk for each effect.
   Methods: We sought studies with large amounts of information to calculate annualised rates for clearly defined gastrointestinal ( complicated upper gastrointestinal perforations, ulcers, or bleeds, but not symptomatic or endoscopic ulcers) and serious cardiovascular outcomes ( antiplatelet trial collaborators   APTC   outcome of fatal or nonfatal myocardial infarction or stroke, or vascular death).
   Results: Meta analyses and large randomised trials specifically analysing serious gastrointestinal bleeding or cardiovascular events occurring with five different coxibs had appropriate data. In total there were 439 complicated upper gastrointestinal events in 49,006 patient years of exposure and 948 serious cardiovascular events in 99,400 patient years of exposure. Complicated gastrointestinal events occurred less frequently with coxibs than NSAIDs; serious cardiovascular events occurred at approximately equal rates. For each coxib, the reduction in complicated upper gastrointestinal events was numerically greater than any increase in APTC events. In the overall comparison, for every 1000 patients treated for a year with coxib rather than NSAID, there would be eight fewer complicated upper gastrointestinal events, but one more fatal or nonfatal heart attack or stroke. Three coxib NSAID comparisons had sufficient numbers of events for individual comparisons. For every 1000 patients treated for a year with celecoxib rather than an NSAID there would be 12 fewer upper gastrointestinal complications, and two fewer fatal or nonfatal heart attacks or strokes. For rofecoxib there would be six fewer upper gastrointestinal complications, but three more fatal or nonfatal heart attacks or strokes. For lumiracoxib there would be eight fewer upper gastrointestinal complications, but one more fatal or nonfatal heart attack or stroke.
   Conclusion: Calculating annualised event rates for gastrointestinal and cardiovascular harm shows that while complicated gastrointestinal events occur more frequently with NSAIDs than coxibs, serious cardiovascular events occur at approximately equal rates. For each coxib, the reduction in complicated upper gastrointestinal events was numerically greater than any increase in APTC events.
C1 Univ Oxford, Pain Res & Nuffield Dept Anaesthet, Oxford OX3 7LJ, England.
C3 University of Oxford
RP Moore, RA (通讯作者)，Univ Oxford, Pain Res & Nuffield Dept Anaesthet, S Parks Rd, Oxford OX3 7LJ, England.
EM andrew.moore@pru.ox.ac.uk; sheena.derry@pru.ox.ac.uk;
   henry.mcquay@pru.ox.ac.uk
CR ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101
   ALTMAN R, 1994, BMJ BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Andersohn F, 2006, CIRCULATION, V113, P1950, DOI 10.1161/CIRCULATIONAHA.105.602425
   Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140 6736(06)69666 9
   Clarke M, 2001, INT J CLIN PRACT, V55, P240
   COUNSELL CE, 1994, BMJ BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677
   Curtis SP, 2003, ARTHRITIS RHEUM, V48, pS616
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   Flather MD, 1997, CONTROL CLIN TRIALS, V18, P568, DOI 10.1016/S0197 2456(97)00024 X
   Fries S, 2006, GASTROENTEROLOGY, V130, P55, DOI 10.1053/j.gastro.2005.10.002
   Goldstein JL, 2005, CLIN GASTROENTEROL H, V3, P133, DOI 10.1016/S1542 3565(04)00619 6
   Goldstein JL, 2004, ALIMENT PHARM THER, V20, P527, DOI 10.1111/j.1365 2036.2004.02118.x
   Griffin MR, 2000, AM J EPIDEMIOL, V151, P488
   Henry D, 1997, BRIT J CLIN PHARMACO, V44, P85, DOI 10.1046/j.1365 2125.1997.00631.x
   Hernández Díaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093
   Hernández Díaz S, 2006, BASIC CLIN PHARMACOL, V98, P266, DOI 10.1111/j.1742 7843.2006.pto_302.x
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Khuroo MS, 2005, J GASTROEN HEPATOL, V20, P11, DOI 10.1111/j.1440 1746.2004.03441.x
   Kolkman JJ, 1996, SCAND J GASTROENTERO, V31, P16, DOI 10.3109/00365529609094726
   Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078
   Kroenke K, 2001, JAMA J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947
   Laine L, 2002, GASTROENTEROLOGY, V123, P1006, DOI 10.1053/gast.2002.36013
   Laine L, 2007, LANCET, V369, P465, DOI 10.1016/S0140 6736(07)60234 7
   Lanas A, 1997, GASTROENTEROLOGY, V112, P683, DOI 10.1053/gast.1997.v112.pm9041228
   MacDonald TM, 2003, GUT, V52, P1265, DOI 10.1136/gut.52.9.1265
   Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481
   Mamdani M, 2002, BRIT MED J, V325, P624, DOI 10.1136/bmj.325.7365.624
   Matchaba P, 2005, CLIN THER, V27, P1196, DOI 10.1016/j.clinthera.2005.07.019
   Miceli Richard C, 2004, ANN RHEUM DIS, V63, P923, DOI 10.1136/ard.2003.017236
   Moore RA, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 79
   Moore RA, 2005, ARTHRITIS RES THER, V7, pR1046, DOI 10.1186/ar1782
   Moore RA, 2005, ARTHRITIS RES THER, V7, pR644, DOI 10.1186/ar1704
   Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304 3959(98)00140 7
   Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777
   Peura DA, 2005, ARTHRITIS RES THER, V7, pS7, DOI 10.1186/ar1793
   Ramey DR, 2005, CURR MED RES OPIN, V21, P715, DOI 10.1185/030079905X43686
   Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140 6736(02)11131 7
   Rodríguez LAG, 2003, EPIDEMIOLOGY, V14, P240
   ROSE G, 1991, J ROY COLL PHYS LOND, V25, P48
   Sarosi GA, 2005, AM J SURG, V190, P775, DOI 10.1016/j.amjsurg.2005.07.019
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   SHUSTER JJ, 1993, CONTROL CLIN TRIALS, V14, P198, DOI 10.1016/0197 2456(93)90003 V
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Simon G, 2001, JAMA J AM MED ASSOC, V286, P3003, DOI 10.1001/jama.286.23.3003
   Simon LS, 2005, ARTHRITIS RHEUM US, V52, pS406
   Sprangers MAG, 2000, J CLIN EPIDEMIOL, V53, P895, DOI 10.1016/S0895 4356(00)00204 3
   Sturkenboom MCJM, 2003, ALIMENT PHARM THER, V18, P1137, DOI 10.1046/j.1365 2036.2003.01795.x
   Taylor DW, 1999, LANCET, V353, P2179, DOI 10.1016/S0140 6736(99)05388 X
   Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690
   Tramèr MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304 3959(99)00267 5
   Watson DJ, 2004, CURR MED RES OPIN, V20, P1539, DOI 10.1185/030079904X3078
   White William B, 2004, Am J Ther, V11, P244, DOI 10.1097/01.mjt.0000127360.23508.04
   Wolfe F, 2004, J RHEUMATOL, V31, P355
NR 56
TC 85
Z9 93
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 3
PY 2007
VL 8
AR 73
DI 10.1186/1471 2474 8 73
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 204YQ
UT WOS:000249080300001
PM 17683540
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mady, MF
   Ortega, R
   Kelland, MA
AF Mady, Mohamed F.
   Ortega, Rocio
   Kelland, Malcolm A.
TI Exploring Modified Alendronic Acid as a New Inhibitor for Calcium Based
   Oilfield Scales
SO ENERGY & FUELS
LA English
DT Article
ID GYPSUM; CARBONATE
AB Organophosphorus compounds are well known as oilfield scale inhibitors. Earlier work showed that a series of new and well known bone targeting drugs incorporating non toxic bisphosphonates (BPs) (PO3H2 C PO3H2) gave good scale inhibition performance against calcite scale based on produced water from the Heidrun oilfield, Norwegian Sea, Norway. However, these chemicals showed only moderate calcium compatibility activity. In this project, we attempted to improve the inhibition performance and calcium tolerance of non toxic BPs by introducing various functional groups (phosphonate (SI 2), sulfonates (SI 3 and SI 5), and carboxylates (SI 4, SI 6, and SI 7)) in the inhibitor structure backbone. All modified alendronic acid derivatives were screened for calcite and gypsum scale inhibition according to the NACE Standard TM0374 2007 protocol. We also report the calcite scale inhibition performance of all synthesized SIs according to the Heidrun oilfield, Norwegian Sea, Norway. In addition, the calcium tolerance and thermal stability activities of all synthesized SIs are reported. The tolerance results showed that all SIs gave better calcium compatibility than BPs reported earlier, with SI 5 giving the best results at high calcium concentrations (10,000 ppm). The corresponding attachment of an iminodi methylene/ethylene sulfonic moiety (i.e., SI 3 and SI 5) showed worse performance against gypsum scaling, whereas the methylenephosphonate derivative (SI 2) and the carboxylated derivatives (SI 4, SI 6, and SI 7) showed improved performance. For calcite scaling, the NACE standard test gave significantly lower inhibition results than the Heidrun based produced water due to the former having a higher calcium concentration and calcite supersaturation. It was also found that SI 2, SI 5, and SI 7 showed good thermal stability at 130 degrees C for 1 week.
C1 [Mady, Mohamed F.; Ortega, Rocio; Kelland, Malcolm A.] Univ Stavanger, Fac Sci & Technol, Dept Chem Biosci & Environm Engn, N 4036 Stavanger, Norway.
   [Mady, Mohamed F.] Natl Res Ctr, Dept Green Chem, Cairo 12622, Egypt.
C3 Universitetet i Stavanger; Egyptian Knowledge Bank (EKB); National
   Research Centre (NRC)
RP Mady, MF (通讯作者)，Univ Stavanger, Fac Sci & Technol, Dept Chem Biosci & Environm Engn, N 4036 Stavanger, Norway.; Mady, MF (通讯作者)，Natl Res Ctr, Dept Green Chem, Cairo 12622, Egypt.
EM mohamed.mady@uis.no
RI Mady, Mohamed/AAA 6270 2021; Mady, Mohamed/D 2870 2013
OI Mady, Mohamed/0000 0002 4636 0066
CR Abd El Khalek DE, 2019, WATER SUPPLY, V19, P2140, DOI 10.2166/ws.2019.094
   ADAM US, 1983, J CHEM SOC FARAD T 1, V79, P2745, DOI 10.1039/f19837902745
   Al Roomi YM, 2016, DESALINATION, V393, P186, DOI 10.1016/j.desal.2015.07.025
   Amjad Z, 2010, SCIENCE AND TECHNOLOGY OF INDUSTRIAL WATER TREATMENT, P1, DOI 10.1201/9781420071450
   Amjad Z, 2012, DESALIN WATER TREAT, V37, P268, DOI 10.5004/dwt.2012.2702
   [Anonymous], 2007, TM0374NS NAT ASS COR
   Atkinson G, 1997, J PETROL SCI ENG, V17, P113, DOI 10.1016/S0920 4105(96)00060 5
   Baugh ThomasDavid., 2012, OFFSHORE TECHNOLOGY, DOI [10.4043/23150 MS, DOI 10.4043/23150 MS]
   Bazin B., 2004, SPE INT S OILFIELD S
   BROMLEY LA, 1993, LANGMUIR, V9, P3594, DOI 10.1021/la00036a040
   D19 Committee, TEST METH CALC MAGN, DOI [10.1520/D0511 14, DOI 10.1520/D0511 14]
   Dogan O''., 2002, ADV CRYSTAL GROWTH I, P197, DOI [10.1007/ 0 306 46924 3_14, DOI 10.1007/0 306 46924 3_14]
   El Dahan HA, 2000, DESALINATION, V127, P111, DOI 10.1016/S0011 9164(99)00196 4
   El Moll H, 2013, CHEM EUR J, V19, P6753, DOI 10.1002/chem.201204366
   Frenier W. W., 2008, FORMATION REMOVAL IN, DOI DOI 10.2118/9781555631406
   Graham GM, 2003, SPE PROD FACIL, V18, P28, DOI 10.2118/81825 PA
   Guo JH, 2004, IND ENG CHEM RES, V43, P5411, DOI 10.1021/ie049787i
   Kelland M A., 2016, Production chemicals for the oil and gas industry
   Mady MF, 2021, IND ENG CHEM RES, V60, P12175, DOI 10.1021/acs.iecr.1c02441
   Mady MF, 2021, IND ENG CHEM RES, V60, P8331, DOI 10.1021/acs.iecr.1c01473
   Mady MF, 2021, ACS OMEGA, V6, P6488, DOI 10.1021/acsomega.1c00379
   Mady MF, 2020, IND ENG CHEM RES, V59, P9808, DOI 10.1021/acs.iecr.0c01636
   Mady MF, 2019, ENERG FUEL, V33, P6197, DOI 10.1021/acs.energyfuels.9b01032
   Mady MF, 2019, ENERG FUEL, V33, P228, DOI 10.1021/acs.energyfuels.8b03531
   Mady MF, 2018, ENERG FUEL, V32, P6746, DOI 10.1021/acs.energyfuels.8b01168
   Mady MF, 2017, ENERG FUEL, V31, P4603, DOI 10.1021/acs.energyfuels.7b00708
   Mady MF, 2016, ENERG FUEL, V30, P9329, DOI 10.1021/acs.energyfuels.6b02117
   MOEDRITZ.K, 1966, J ORG CHEM, V31, P1603, DOI 10.1021/jo01343a067
   NACE International, 2001, LAB SCREEN TESTS DET
   Oshchepkov M, 2020, CRYSTALS, V10, DOI 10.3390/cryst10110992
   Oshchepkov M, 2021, SEP PURIF TECHNOL, V255, DOI 10.1016/j.seppur.2020.117382
   Oshchepkov M, 2019, CHEMNANOMAT, V5, P586, DOI 10.1002/cnma.201800660
   OSPAR, 2015, Guidelinesfor Completingthe Harmonised Offshore Chemical Notification Format (HOCNF)
   Pirri R., 2000, INT S OILF SCAL ONEP
   Prisciandaro M, 2012, IND ENG CHEM RES, V51, P12844, DOI 10.1021/ie302060t
   Prisciandaro M, 2009, IND ENG CHEM RES, V48, P10877, DOI 10.1021/ie900253f
   Nguyen TDT, 2016, SCI REP UK, V6, DOI 10.1038/srep36707
   Van Driessche AES, 2012, SCIENCE, V336, P69, DOI 10.1126/science.1215648
   Wat R. M. S., 2007, INT S OILF CHEM
   Zhang BR, 2010, CORROS SCI, V52, P3883, DOI 10.1016/j.corsci.2010.07.037
   ZHANG P., 2015, MINERAL SCALES DEPOS
NR 41
TC 14
Z9 14
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0887 0624
EI 1520 5029
J9 ENERG FUEL
JI Energy Fuels
PD FEB 17
PY 2022
VL 36
IS 4
BP 1863
EP 1873
DI 10.1021/acs.energyfuels.1c03936
PG 11
WC Energy & Fuels; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Energy & Fuels; Engineering
GA 1J4ZC
UT WOS:000797927200010
OA hybrid
DA 2025 08 17
ER

PT J
AU Bostancioglu, RB
   Gurbuz, M
   Akyurekli, AG
   Dogan, A
   Koparal, AS
   Koparal, AT
AF Bostancioglu, R. Beklem
   Gurbuz, Mevlut
   Akyurekli, Ayse Gul
   Dogan, Aydin
   Koparal, A. Savas
   Koparal, A. Tansu
TI Adhesion profile and differentiation capacity of human adipose tissue
   derived mesenchymal stem cells grown on metal ion (Zn, Ag and Cu) doped
   hydroxyapatite nano coated surfaces
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE hMSCs; Adhesion; Osteogenic differentiation; Nanomaterial; Biomaterial;
   Hydroxyapatite; Metal ion; Biocompability; Gene expression
ID REGENERATIVE MEDICINE; COMPOSITE SCAFFOLDS; ZINC; OSTEOBLAST; BEHAVIOR;
   MTT; CYTOSKELETON; TITANIUM; MATRIX; COPPER
AB Accelerated Mesenchymal Stem Cells (MSCs) condensation and robust MSC matrix and MSC MSC interactions on nano surfaces may provide critical factors contributing to such events, likely through the orchestrated signal cascades and cellular events modulated by the extracellular matrix. In this study, human adipose tissue derived mesenchymal stem cells (hMSC)', were grown on metal ion (Zn, Ag and Cu) doped hydroxyapatite (HAP) nano coated surfaces. These metal ions are known to have different chemical and surface properties; therefore we investigated their respective contributions to cell viability, cellular behavior, osteogenic differentiation capacity and substrate cell interaction. Nano powders were produced using a wet chemical process. Air spray deposition was used to accumulate the metal ion doped HAP films on a glass substrate. Cell viability was determined by MTT, LDH and DNA quantitation methods Osteogenic differentiation capacity of hMSCs was analyzed with Alizarin Red Staining and Alkaline Phosphatase Specific Activity. Adhesion of the hMSCs and the effect of cell adhesion on biomaterial biocompatibility were explored through cell adhesion assay, immunofluorescence staining for vinculin and f actin cytoskeleton components, SEM and microarray including 84 known extracellular matrix proteins and cell adhesion pathway genes, since, adhesion is the first step for good biocompability. The results demonstrate that the viability and osteogenic differentiation of the hMSCs (in growth media without osteogenic stimulation) and cell adhesion capability are higher on nanocoated surfaces that include Zn, Ag and/or Cu metal ions than commercial HAP. These results reveal that Zn, Ag and Cu metal ions contribute to the biocompatibility of exogenous material. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Bostancioglu, R. Beklem; Koparal, A. Tansu] Anadolu Univ, Dept Biol, TR 26470 Eskisehir, Turkey.
   [Gurbuz, Mevlut] Ondokuz Mayis Univ, Dept Mech Engn, TR 55139 Samsun, Turkey.
   [Akyurekli, Ayse Gul; Dogan, Aydin] Anadolu Univ, Dept Mat Sci & Engn, TR 26555 Eskisehir, Turkey.
   [Koparal, A. Savas] Anadolu Univ, Dept Environm Engn, TR 26555 Eskisehir, Turkey.
   [Bostancioglu, R. Beklem] Karolinska Inst, Dept Lab Med, Clin Res Ctr, Unit Mol Cell Biol & Gene Therapy Sci MCG KFC, Novum Plan 6,Room 614,Halsovagen 7, S 14157 Huddinge, Sweden.
C3 Anadolu University; Ondokuz Mayis University; Anadolu University;
   Anadolu University; Karolinska Institutet
RP Bostancioglu, RB (通讯作者)，Anadolu Univ, Dept Biol, TR 26470 Eskisehir, Turkey.; Bostancioglu, RB (通讯作者)，Karolinska Inst, Dept Lab Med, Clin Res Ctr, Unit Mol Cell Biol & Gene Therapy Sci MCG KFC, Novum Plan 6,Room 614,Halsovagen 7, S 14157 Huddinge, Sweden.
EM beklemb@gmail.com; mevlutgurbuz@gmail.com; aysegl_88@hotmail.com;
   adogan@anadolu.edu.tr; askopara@anadolu.edu.tr; akoparal@anadolu.edu.tr
RI Bostancioglu, R./M 4453 2015; Gürbüz, Mevlüt/AAG 4882 2019;
   Bostancioglu, R. Beklem/M 4453 2015
OI Bostancioglu, R. Beklem/0000 0001 6755 6968
FU Anadolu University, Commission of Scientific Research Projects
   [1104F075, 1306F197]
FX This work was financed by a grant from Anadolu University, Commission of
   Scientific Research Projects (1104F075 and 1306F197). The authors are
   grateful to the Scientific and Technological Research Council of Turkey
   (TUBITAK TBAG 112T412).
CR Arosarena Oneida, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P233, DOI 10.1097/01.moo.0000170526.51393.c5
   Badr Mohammadi MR, 2014, J MATER SCI MATER M, V25, P185, DOI 10.1007/s10856 013 5062 7
   Bernhardt A, 2010, J BIOMED MATER RES A, V95A, P848, DOI 10.1002/jbm.a.32856
   Bernhardt A, 2013, CLIN ORAL IMPLAN RES, V24, P441, DOI 10.1111/j.1600 0501.2011.02350.x
   Bostancioglu RB, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045024
   Chang TH, 2014, BIOMATERIALS, V35, P3934, DOI 10.1016/j.biomaterials.2014.01.028
   Chen L., 2017, STEM CELL RES
   CHENG YF, 1991, EXP CELL RES, V194, P69, DOI 10.1016/0014 4827(91)90131 D
   Ciobanu CS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/916218
   Ciobanu CS, 2011, NANOSCALE RES LETT, V6, P1, DOI 10.1186/1556 276X 6 613
   Costescu A, 2013, J NANOMATER, V2013, DOI 10.1155/2013/194854
   Faria RMB, 2008, CATAL TODAY, V133, P168, DOI 10.1016/j.cattod.2007.12.114
   Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001
   Fujii E, 2006, ACTA BIOMATER, V2, P69, DOI 10.1016/j.actbio.2005.09.002
   Gheorghiu I M, 2014, J Med Life, V7 Spec No. 2, P7
   Guan FX, 2014, SCI CHINA LIFE SCI, V57, P181, DOI 10.1007/s11427 014 4610 9
   He J, 2013, BIOMATERIALS, V34, P6580, DOI 10.1016/j.biomaterials.2013.05.056
   Howard D, 2008, J ANAT, V213, P66, DOI 10.1111/j.1469 7580.2008.00878.x
   Kasemo B, 1999, Adv Dent Res, V13, P8
   Khalili AA, 2015, INT J MOL SCI, V16, P18149, DOI 10.3390/ijms160818149
   Kilpadi KL, 2001, J BIOMED MATER RES, V57, P258, DOI 10.1002/1097 4636(200111)57:2<258::AID JBM1166>3.0.CO;2 R
   Kim HK, 2009, LIFE SCI, V84, P290, DOI 10.1016/j.lfs.2008.12.017
   Kobolak J, 2016, METHODS, V99, P62, DOI 10.1016/j.ymeth.2015.09.016
   Liu H, 2007, BIOMATERIALS, V28, P354, DOI 10.1016/j.biomaterials.2006.08.049
   Miyaji F, 2005, MATER RES BULL, V40, P209, DOI 10.1016/j.materresbull.2004.10.020
   Okumura A, 2001, BIOMATERIALS, V22, P2263, DOI 10.1016/S0142 9612(00)00415 4
   Ozeki N, 2016, BIOSCI TRENDS, V10, P365, DOI 10.5582/bst.2016.01153
   Park BS, 2005, J BIOMED MATER RES A, V74A, P640, DOI 10.1002/jbm.a.30326
   Park JS, 2015, METHODS, V84, P3, DOI 10.1016/j.ymeth.2015.03.002
   Piscitelli P, 2013, CLIN CASES MINER BON, V10, P97, DOI 10.11138/ccmbm/2013.10.2.097
   Pishbin F, 2013, ACTA BIOMATER, V9, P7469, DOI 10.1016/j.actbio.2013.03.006
   Rameshbabu N, 2007, J BIOMED MATER RES A, V80A, P581, DOI 10.1002/jbm.a.30958
   Reichert JC, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt316
   Rouchi AH, 2015, INT J TRANSPLANT MED, V6, P93
   Sadeghzade S, 2017, MAT SCI ENG C MATER, V71, P431, DOI 10.1016/j.msec.2016.10.042
   Stanic V, 2010, APPL SURF SCI, V256, P6083, DOI 10.1016/j.apsusc.2010.03.124
   Su WT, 2015, MAT SCI ENG C MATER, V52, P46, DOI 10.1016/j.msec.2015.03.025
   Tripathi A, 2012, INT J BIOL MACROMOL, V50, P294, DOI 10.1016/j.ijbiomac.2011.11.013
   Ulukaya E, 2008, TOXICOL IN VITRO, V22, P232, DOI 10.1016/j.tiv.2007.08.006
   Venkatasubbu GD, 2011, 3 BIOTECH, V1, P173, DOI 10.1007/s13205 011 0021 9
   Vial S, 2017, CURR OPIN SOLID ST M, V21, P92, DOI 10.1016/j.cossms.2016.03.006
   Wang YL, 1991, CURR OPIN CELL BIOL, V3, P27, DOI 10.1016/0955 0674(91)90162 R
   Weber GF, 2006, DEV BIOL, V295, P714, DOI 10.1016/j.ydbio.2006.03.056
   Xu ML, 2015, J PHARMACOL TOX MET, V71, P1, DOI 10.1016/j.vascn.2014.11.003
   Ye XY, 2010, J MATER SCI MATER M, V21, P1321, DOI 10.1007/s10856 009 3954 3
   Zhang N, 2009, FUNDAMENTALS TISSUE, P271, DOI DOI 10.1007/978 3 540 77755 7
NR 46
TC 31
Z9 33
U1 1
U2 72
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD JUL 1
PY 2017
VL 155
BP 415
EP 428
DI 10.1016/j.colsurfb.2017.04.015
PG 14
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA EY1PO
UT WOS:000403738000048
PM 28460304
DA 2025 08 17
ER

PT J
AU Zhang, J
   Fu, Q
   Ren, ZZ
   Wang, YJ
   Wang, CC
   Shen, T
   Wang, GB
   Wu, LN
AF Zhang, Jing
   Fu, Qin
   Ren, Zhaozhou
   Wang, Yanjun
   Wang, Chenchen
   Shen, Tao
   Wang, Guangbin
   Wu, Lina
TI Changes of serum cytokines related Th1/Th2/Th17 concentration in
   patients with postmenopausal osteoporosis
SO GYNECOLOGICAL ENDOCRINOLOGY
LA English
DT Article
DE Cytokine; osteoporosis; postmenopausal
ID BONE MINERAL DENSITY; GROWTH FACTOR BETA; T CELL ACTIVATION;
   RHEUMATOID ARTHRITIS; OSTEOCLAST FORMATION; ESTROGEN DEFICIENCY;
   INTERFERON GAMMA; DIFFERENTIATION; INTERLEUKIN 4; RECEPTOR
AB Background: Postmenopausal osteoporosis is now hypothetically considered to be an autoimmune and inflammatory process in which many pro inflammatory and T cell derived cytokines play important roles in the loss of bone mass. For instance, interleukin 2 (IL 2), interferon gamma (IFN gamma), and tumor necrosis factor alpha (TNF alpha) secreted by Thl and IL 6, IL 4, and IL 10 secreted by Th2 have been shown to be involved in the pathogenesis of osteoporosis. Interleukin 17 (IL 17) is a characteristic cytokine secreted by Th17 cells of the CD4 + subgroup. Although IL 17 has been shown to enhance bone resorption in ovariectomized mouse model, bone cells and genetic research, human related studies of IL 17 are few.
   Methods: According to WHO classification of osteoporosis by the T scores of BMD, the subjects were divided into the postmenopausal osteoporosis group (T scores <= 2.5), the postmenopausal osteopenia group ( 2.5 < T scores< 1), and the postmenopausal normal BMD group (T scores >= 1); 30 subjects in each group. Cytometric bead array (CBA) technique was employed for serum determination of the primary indexes including IL 17A, IL 2, IFN gamma, TNF alpha, IL 6, IL 4, and IL 10 concentrations in the 90 volunteers. In the meantime, serum calcium, phosphorus, magnesium, and alkaline phosphatase concentrations were also determined in the patients. One way analysis of variance (one way ANOVA) was employed in data analysis to determine whether the testing results of various parameters had significant differences. The bivariate correlation was tested with the Pearson correlation coefficient. When p < 0.05, the difference was considered to have statistical significance.
   Results: Serum IL 17A concentration was significantly higher in the postmenopausal osteoporosis group than in the postmenopausal osteopenia group and the postmenopausal normal BMD group, but the difference between the postmenopausal osteopenia group and the postmenopausal normal BMD group had no statistical significance. IL 17A was negatively correlated with BMD. To our knowledge, we discovered for the first time that serum concentrations of IFN gamma and IL 4 were significantly lower in the postmenopausal osteoporosis group than in the postmenopausal normal BMD group; IFN gamma and IL 4 were positively correlated with BMD. In addition, we also determined that BMI was negatively correlated with BMD; IL 17A was positively correlated with serum calcium. However, no significant differences in IL 6, TNF alpha, IL 2, and IL 10 were observed among the three groups; these three factors were not correlated with BMD.
   Conclusions: Our experiments have confirmed the roles of IL 17 in the pathogenesis of postmenopausal osteoporosis and in the promotion of bone resorption. Targeted therapy of IL 17, IFN gamma, and IL 4 may be beneficial in the treatment of patients with postmenopausal osteoporosis. Our experiments have also confirmed the roles of IFN gamma and IL 4 in the pathogenesis of postmenopausal osteoporosis and in the inhibition of bone resorption.
C1 [Zhang, Jing; Fu, Qin; Ren, Zhaozhou; Shen, Tao; Wang, Guangbin] China Med Univ, Dept Spine & Joint Surg, Shengjing Hosp, Shenyang 110004, Peoples R China.
   [Wang, Yanjun] China Med Univ, Dept Endocrinol 1, Shengjing Hosp, Shenyang 110004, Peoples R China.
   [Wang, Chenchen] China Med Univ, Rehabil Dept Outpatient Serv, Shengjing Hosp, Shenyang 110004, Peoples R China.
   [Wu, Lina] China Med Univ, Med Clin Lab, Shengjing Hosp, Shenyang 110004, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University; China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Dept Spine & Joint Surg, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM fuq@sj hospital.org
RI Ren, Zhaozhou/ADI 5080 2022; Shen, Tao/JQJ 5691 2023
FU Scientific Department of Liaoning province, China [2011225041]; National
   Natural Science Foundation of China [H0726/81300714]
FX The authors report that they have no conflict of interest. This project
   is supported by grants from the project of the Scientific Department of
   Liaoning province, China (no. 2011225041) and the National Natural
   Science Foundation of China (no. H0726/81300714).
CR Acosta Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200
   Cooper A, 2007, CLIN ORTHOP RELAT R, P6, DOI 10.1097/BLO.0b013e31803dee7c
   Czerny B, 2010, EUR J OBSTET GYN R B, V149, P82, DOI 10.1016/j.ejogrb.2009.12.010
   DeSelm CJ, 2012, J CELL BIOCHEM, V113, P2895, DOI 10.1002/jcb.24165
   Duque G, 2009, STEM CELLS, V27, P550, DOI 10.1634/stemcells.2008 0886
   Ershler WB, 1997, DEV COMP IMMUNOL, V21, P487, DOI 10.1016/S0145 305X(97)00029 3
   Evans KE, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 4
   Furuta I, 2004, CALCIFIED TISSUE INT, V74, P509, DOI 10.1007/s00223 003 0105 6
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gümüs P, 2013, ARCH ORAL BIOL, V58, P1302, DOI 10.1016/j.archoralbio.2013.07.010
   Gür A, 2002, RHEUMATOL INT, V22, P194, DOI 10.1007/s00296 002 0223 x
   Ji JD, 2009, J IMMUNOL, V183, P7223, DOI 10.4049/jimmunol.0900072
   KAMEL MS, 2005, BIOCHEM BIOPH RES CO, V329, P839
   LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367
   Li X, 2010, BIOCHEM BIOPH RES CO, V397, P131, DOI 10.1016/j.bbrc.2010.05.111
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Marsh K, 1997, LANCET, V349, P1
   MIOSSEC P, 1994, ARTHRITIS RHEUM, V37, P1715, DOI 10.1002/art.1780371202
   Molnár I, 2014, MENOPAUSE, V21, P749, DOI [10.1097/gme.0000000000000125, 10.1097/GME.0000000000000125]
   Morita Y, 1998, ARTHRITIS RHEUM, V41, P1669, DOI 10.1002/1529 0131(199809)41:9<1669::AID ART19>3.0.CO;2 G
   Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908
   Neumark DE, 2013, SEX HEALTH, V10, P583, DOI 10.1071/SHv10n6ab28
   Owens JM, 1996, J IMMUNOL, V157, P936
   Park BL, 2004, J BIOCHEM MOL BIOL, V37, P691
   Partsch G, 1998, ANN RHEUM DIS, V57, P691, DOI 10.1136/ard.57.11.691
   Pène J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423
   Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439
   RALSTON SH, 1994, J BONE MINER RES, V9, P883
   RIANCHO JA, 1993, BIOCHEM BIOPH RES CO, V196, P678, DOI 10.1006/bbrc.1993.2303
   Rifas L, 2006, J CELL BIOCHEM, V98, P706, DOI 10.1002/jcb.20933
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Shen F, 2008, CYTOKINE, V41, P92, DOI 10.1016/j.cyto.2007.11.013
   Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   WHITESIDE TL, 2002, BIOTECHNIQUES S4, V10, P12
   Xu ZQ, 2009, J BIOL CHEM, V284, P4658, DOI 10.1074/jbc.M804812200
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
NR 43
TC 65
Z9 79
U1 0
U2 24
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0951 3590
EI 1473 0766
J9 GYNECOL ENDOCRINOL
JI Gynecol. Endocrinol.
PD MAR
PY 2015
VL 31
IS 3
BP 183
EP 190
DI 10.3109/09513590.2014.975683
PG 8
WC Endocrinology & Metabolism; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Obstetrics & Gynecology
GA CN5KB
UT WOS:000358467100004
PM 25384921
DA 2025 08 17
ER

PT J
AU Tambiah, JRS
   Kennedy, S
   Swearingen, CJ
   Simsek, I
   Yazici, Y
   Farr, J
   Conaghan, PG
AF Tambiah, Jeyanesh R. S.
   Kennedy, Sarah
   Swearingen, Christopher J.
   Simsek, Ismail
   Yazici, Yusuf
   Farr, Jack
   Conaghan, Philip G.
TI Individual Participant Symptom Responses to Intra Articular Lorecivivint
   in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial
SO RHEUMATOLOGY AND THERAPY
LA English
DT Article
DE Alternative splicing; CLK2; DYRK1A; OMERACT OARSI; Patient reported
   outcomes; Wnt signaling pathway
ID CLINICAL TRIALS; OUTCOMES; CRITERIA; OARSI; SET; HIP
AB Introduction Established thresholds for patient reported outcomes (PROs) provide clinically relevant responder data from trials. Lorecivivint (LOR) is an intra articular (IA) therapy in development for knee osteoarthritis (OA). A post hoc analysis from a phase 2b trial (NCT03122860) determined proportions of LOR responders. Methods A 24 week, randomized trial of 0.07 mg LOR demonstrated PRO improvements compared with PBO in moderate to severe knee OA participants. Participants treated with LOR and PBO achieving 30%/50%/70% improvements at weeks 12 and 24 in Pain Numeric Rating Scale (NRS), WOMAC Pain/Function subscales, Patient Global Assessment (PtGA), and OMERACT OARSI responder criteria were determined. Odds ratios (ORs) and 95% confidence intervals [CIs] were compared with PBO. Results There were 115 and 116 participants in the LOR and PBO groups, respectively. For Pain NRS, LOR increased ORs of achieving 30% [week 12, OR = 2.47 (1.45, 4.19), P < 0.001; week 24, OR = 2.37 (1.40, 4.02), P < 0.01] and 50% [week 24, OR = 1.89 (1.11, 3.23), P < 0.05] improvements over baseline. For WOMAC Pain, LOR increased ORs of achieving 30% [week 24, OR = 1.79 (1.06, 3.01), P < 0.05] and 50% [week 12, OR = 1.79 (1.06, 3.03), P < 0.05; week 24, OR = 1.73 (1.02, 2.93), P < 0.05] improvements. For WOMAC Function, LOR increased ORs of achieving 30% [week 12, OR = 1.85 (1.10, 3.12), P < 0.05; week 24, OR = 1.93 (1.14, 3.26), P < 0.05] improvements. For PtGA, LOR increased ORs of achieving 50% [week 12, OR = 2.28 (1.25, 4.16), P < 0.01] improvements. LOR produced numerical increases at the 70% threshold. LOR increased ORs of achieving OMERACT OARSI responses [week 12, OR = 2.21 (1.29, 3.78); P < 0.01; week 24, OR = 2.57 (1.49, 4.43), P < 0.001] and strict responses [week 12, OR = 2.13 (1.26, 3.61), P < 0.01; week 24, OR = 2.05 (1.21, 3.47), P < 0.01]. Conclusions LOR (0.07 mg) demonstrated improved PRO threshold responses across single and composite measures of pain, function, and patient global assessment compared with PBO, with benefits sustained to 24 weeks.
   Plain Language Summary Lorecivivint (LOR) is a new injectable medicine being studied as a treatment for knee osteoarthritis (OA). An early (phase 2b) trial found participants with moderate to severe knee OA receiving LOR on average reported improved pain, function, and reduced impact of OA symptoms over 24 weeks compared with placebo. To consider how likely individuals were to respond to treatment, this study analyzed how many participants per group achieved different percentage levels of symptom improvement. Participants were given a single LOR or placebo injection into their most painful (target) knee at trial initiation. Participants reported their target knee status from day 1 (baseline) to week 24 using pain and function questionnaires. We analyzed the number of participants given 0.07 mg LOR and placebo whose symptom scores improved by 30, 50, and 70% over baseline scores at weeks 12 and 24. Results showed that 0.07 mg LOR treatment produced a higher likelihood beyond chance at week 12 of achieving a 30% improvement in some pain and function scores and a 50% improvement in other symptom scores compared with placebo. Similar 30% and 50% symptom score improvements were found at week 24. More complex scores, combining individual symptom scores into single index measures, also showed improvements beyond chance for 0.07 mg LOR from baseline compared with placebo at weeks 12 and 24. Thus, more participants with knee OA who were treated with 0.07 mg LOR demonstrated long lasting, meaningful improvements in pain and function compared to those given placebo.
C1 [Tambiah, Jeyanesh R. S.; Kennedy, Sarah; Swearingen, Christopher J.; Simsek, Ismail; Yazici, Yusuf] Biosplice Therapeut Inc, 9360 Towne Ctr Dr, San Diego, CA 92121 USA.
   [Yazici, Yusuf] NYU, Sch Med, New York, NY USA.
   [Farr, Jack] OrthoIndy Hosp, Indianapolis, IN USA.
   [Conaghan, Philip G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
   [Conaghan, Philip G.] NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England.
C3 New York University; University of Leeds; Leeds Biomedical Research
   Centre
RP Tambiah, JRS (通讯作者)，Biosplice Therapeut Inc, 9360 Towne Ctr Dr, San Diego, CA 92121 USA.
EM jeymi.tambiah@biosplice.com
RI Tambiah, Jeyanesh/KDN 7427 2024
OI Tambiah, Jeyanesh/0000 0003 1451 1584; Conaghan,
   Philip/0000 0002 3478 5665
FU Biosplice Therapeutics, Inc.
FX All studies described in this report, the journal's Rapid Service Fee,
   and the preparation of this manuscript were funded by Biosplice
   Therapeutics, Inc.
CR Bellamy N, 2005, OSTEOARTHR CARTILAGE, V13, P104, DOI 10.1016/j.joca.2004.10.016
   Conaghan PG, 2018, ARTHRITIS RHEUMATOL, V70, P204, DOI 10.1002/art.40364
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   Dakin P, 2019, ARTHRITIS RHEUMATOL, V71, P1824, DOI 10.1002/art.41012
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Hochberg MC, 2012, J RHEUMATOL, V39, P352, DOI 10.3899/jrheum.110307
   Pham T, 2003, J RHEUMATOL, V30, P1648
   Previtali D, 2021, CARTILAGE, V13, p185S, DOI 10.1177/1947603520906597
   Schnitzer TJ, 2018, OSTEOARTHR CARTILAGE, V26, pS299, DOI 10.1016/j.joca.2018.02.601
   Smith SM, 2020, PAIN, V161, P2446, DOI 10.1097/j.pain.0000000000001952
   Tubach F, 2005, ANN RHEUM DIS, V64, P34, DOI 10.1136/ard.2004.023028
   Yazici Y, 2021, OSTEOARTHR CARTILAGE, V29, P654, DOI 10.1016/j.joca.2021.02.004
   Yazici Y, 2020, ARTHRITIS RHEUMATOL, V72, P1694, DOI 10.1002/art.41315
NR 14
TC 13
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2198 6576
EI 2198 6584
J9 RHEUMATOL THER
JI Rheumatol. Ther.
PD JUN
PY 2021
VL 8
IS 2
BP 973
EP 985
DI 10.1007/s40744 021 00316 w
EA JUN 2021
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA SV9QT
UT WOS:000659007100001
PM 34101138
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhai, Y
   Yuan, XJ
   Zhao, YM
   Ge, LH
   Wang, YY
AF Zhai, Yue
   Yuan, Xiaojing
   Zhao, Yuming
   Ge, Lihong
   Wang, Yuanyuan
TI Potential Application of Human β Defensin 4 in Dental Pulp Repair
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE human beta defensin 4; dental pulp stem cells; anti inflammatory; stem
   cell differentiation; vital pulp therapy
ID MINERAL TRIOXIDE AGGREGATE; STEM CELLS; TEETH; DIFFERENTIATION;
   BETA DEFENSIN 4; REGENERATION; EXPRESSION; PEPTIDE; HBD 4
AB When pulp tissue is damaged by caries or trauma, vital pulp therapy (VPT) can help preserve the pulp tissue for long term retention of teeth. However, the choice of pulp capping agent used in VPT is important for the successful preservation of the pulp tissue. Here we investigated the expression and biological function of human beta defensin 4 (HBD4) in dental pulp stem cells (DPSC) and explored its potential as a pulp capping agent. We examined the expression of HBD4 in DPSCin vitrousing qPCR and immunofluorescence staining. We also looked at the effect of HBD4 on inflammatory factors in lipopolysaccharide (LPS) stimulated DPSC, and its effects on mineralizing cell phenotype differentiation, via qPCR and western blot. Finally, we examined the ability of HBD4 to promote the restoration of the pulp dentin complexin vivo, using male Wistar rats with reversible pulpitis. We found HBD4 was highly expressed in DPSC stimulated by TNF alpha and IL 1 alpha. HBD4 down regulated the expression of inflammatory mediators (i.e., IL 1 alpha, IL 1 beta, IL 6, TNF alpha) in LPS stimulated DPSC, and suppressed MAPK activity and the NF kappa B pathway. HBD4 also enhanced the differentiation of DPSC into osteoblasts or odontoblasts, potentially by modulating the Notch pathway. Furthermore, HBD4 controlled the degree of pulp inflammation in a rat model of reversible pulpitis and induced the formation of restorative dentin. Together our findings indicate HBD4 may be a useful pulp capping agent for use in VPT.
C1 [Zhai, Yue; Yuan, Xiaojing; Zhao, Yuming; Ge, Lihong; Wang, Yuanyuan] Peking Univ, Sch & Hosp Stomatol, Dept Pediat Dent, Beijing, Peoples R China.
C3 Peking University
RP Wang, YY (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Pediat Dent, Beijing, Peoples R China.
EM cwyyd@126.com
RI Ge, Li/T 3955 2018; Yuan, Xiaojing/Z 1704 2019; Zhang,
   Zhen/GXH 3666 2022; Wang, Wu/G 2683 2018
FU National Natural Science Foundation of China [303076129]; National
   Natural Science Youth Foundation of China [81500837]; Peking University
   Taisheng Stomatology Development Fund [94000 6672 H78]
FX This study has been supported by the National Natural Science Foundation
   of China (No. 303076129), the National Natural Science Youth Foundation
   of China (No. 81500837), and the Peking University Taisheng Stomatology
   Development Fund (No. 94000 6672 H78).
CR Alqahtani Q, 2018, J DENT RES, V97, P1460, DOI 10.1177/0022034518785124
   Bogen G, 2008, J AM DENT ASSOC, V139, P305, DOI 10.14219/jada.archive.2008.0160
   Cheng XY, 2019, ONCOTARGETS THER, V12, P3421, DOI 10.2147/OTT.S180954
   Cooper PR, 2010, J DENT, V38, P687, DOI 10.1016/j.jdent.2010.05.016
   Fang TJZ, 2019, CHEM ENG J, V370, P573, DOI 10.1016/j.cej.2019.03.151
   García JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00 0865fje
   Hernandez Delgadillo R, 2017, DENT MATER J, V36, P503, DOI 10.4012/dmj.2016 259
   Hou CH, 2015, MOL MED REP, V12, P4877, DOI 10.3892/mmr.2015.4008
   Huang YT, 2019, BMC ORAL HEALTH, V19, DOI [10.1186/s12903 019 0817 2, 10.1186/s12870 019 1876 x, 10.1186/s12889 019 7167 5]
   Iohara K, 2004, J DENT RES, V83, P590, DOI 10.1177/154405910408300802
   Jo YY, 2007, TISSUE ENG, V13, P767, DOI 10.1089/ten.2006.0192
   Kim DH, 2018, J ENDODONT, V44, P1534, DOI 10.1016/j.joen.2018.07.012
   Kojima K, 2004, ORAL SURG ORAL MED O, V97, P95, DOI 10.1016/j.tripleo.2003.07.006
   Lee JY, 2015, INT J NANOMED, V10, P5423, DOI 10.2147/IJN.S90014
   Lee SH, 2012, J ENDODONT, V38, P351, DOI 10.1016/j.joen.2011.12.026
   Li XY, 2016, ARCH ORAL BIOL, V66, P15, DOI 10.1016/j.archoralbio.2016.01.012
   Li ZF, 2015, J ENDODONT, V41, P1412, DOI 10.1016/j.joen.2015.04.012
   Long YZ, 2017, J ENDODONT, V43, P1647, DOI 10.1016/j.joen.2017.03.011
   Mikrogeorgis G, 2018, AUST ENDOD J, V44, P286, DOI 10.1111/aej.12240
   Musumeci G, 2012, ACTA HISTOCHEM, V114, P805, DOI 10.1016/j.acthis.2012.02.001
   Otte JM, 2009, EUR J CLIN INVEST, V39, P126, DOI 10.1111/j.1365 2362.2008.02071.x
   Pazgier M, 2006, CELL MOL LIFE SCI, V63, P1294, DOI 10.1007/s00018 005 5540 2
   Rao NQ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/2751475
   Russell AA, 2014, J ENDODONT, V40, P842, DOI 10.1016/j.joen.2013.11.005
   Saghiri MA, 2016, DENT MATER J, V35, P701, DOI 10.4012/dmj.2015 332
   Schmalz G, 2014, J ENDODONT, V40, pS2, DOI 10.1016/j.joen.2014.01.018
   Semple F, 2010, EUR J IMMUNOL, V40, P1073, DOI 10.1002/eji.200940041
   Seo DG, 2012, J ENDODONT, V38, P288, DOI 10.1016/j.joen.2011.11.017
   Sharma H, 2012, PEPTIDES, V38, P255, DOI 10.1016/j.peptides.2012.08.024
   Shi S, 2016, INT ENDOD J, V49, P154, DOI 10.1111/iej.12439
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Shin M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2071247
   Supp DM, 2009, BURNS, V35, P949, DOI 10.1016/j.burns.2009.02.016
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140 6736(12)61729 2
   Wang HH, 2018, J ENDODONT, V44, P1066, DOI 10.1016/j.joen.2018.02.012
   Widbiller M, 2018, INT ENDOD J, V51, P877, DOI 10.1111/iej.12897
   Xue D, 2018, ADV CLIN EXP MED, V27, P1615, DOI 10.17219/acem/75776
   Yanagi S, 2005, RESP RES, V6, DOI 10.1186/1465 9921 6 130
   Zhai Y, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01304
   Zhang C, 2008, J DENT RES, V87, P250, DOI 10.1177/154405910808700312
   Zhou M, 2018, NANOMED NANOTECHNOL, V14, P1227, DOI 10.1016/j.nano.2018.02.004
   Zhu NX, 2019, ACS BIOMATER SCI ENG, V5, P4624, DOI 10.1021/acsbiomaterials.9b00811
NR 42
TC 24
Z9 24
U1 2
U2 23
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD AUG 21
PY 2020
VL 11
AR 1077
DI 10.3389/fphys.2020.01077
PG 12
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA NM5WU
UT WOS:000568168100001
PM 32973567
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wilson, RL
   Sylvester, CB
   Wiltz, DC
   Kumar, A
   Malik, TH
   Morrisett, JD
   Grande Allen, KJ
AF Wilson, Reid L.
   Sylvester, Christopher B.
   Wiltz, Dena C.
   Kumar, Aditya
   Malik, Tahir H.
   Morrisett, Joel D.
   Grande Allen, K. Jane
TI The Ryanodine Receptor Contributes to the
   Lysophosphatidylcholine Induced Mineralization in Valvular Interstitial
   Cells
SO CARDIOVASCULAR ENGINEERING AND TECHNOLOGY
LA English
DT Article
DE Aortic valve; Calcification; Lipid; Ryanodine; Mineralization
ID AORTIC VALVE DISEASE; IN VITRO; COLORIMETRIC ASSAY; CELLULAR GROWTH;
   HEART; CALCIFICATION; PHARMACOLOGY; EXPRESSION; PHENOTYPES; CHANNELS
AB Purpose Fibrocalcific aortic valve disease (CAVD) is caused by the deposition of calcific nodules in the aortic valve leaflets, resulting in progressive loss of function that ultimately requires surgical intervention. This process is actively mediated by the resident valvular interstitial cells (VICs), which, in response to oxidized lipids, transition from a quiescent to an osteoblast like state. The purpose of this study was to examine if the ryanodine receptor, an intracellular calcium channel, could be therapeutically targeted to prevent this phenotypic conversion. Methods The expression of the ryanodine receptor in porcine aortic VICs was characterized by qRT PCR and immunofluorescence. Next, the VICs were exposed to lysophosphatidylcholine, an oxidized lipid commonly found in low density lipoprotein, while the activity of the ryanodine receptor was modulated with ryanodine. The cultures were analyzed for markers of cellular mineralization, alkaline phosphatase activity, proliferation, and apoptosis. Results Porcine aortic VICs predominantly express isoform 3 of the ryanodine receptors, and this protein mediates the cellular response to LPC. Exposure to LPC caused elevated intracellular calcium concentration in VICs, raised levels of alkaline phosphatase activity, and increased calcific nodule formation, but these changes were reversed when the activity of the ryanodine receptor was blocked. Conclusions Our findings suggest blocking the activity of the ryanodine receptor can attenuate the valvular mineralization caused by LPC. We conclude that oxidized lipids, such as LPC, play an important role in the development and progression of CAVD and that the ryanodine receptor is a promising target for pharmacological intervention.
C1 [Wilson, Reid L.; Sylvester, Christopher B.; Wiltz, Dena C.; Kumar, Aditya; Malik, Tahir H.; Grande Allen, K. Jane] Rice Univ, Dept Bioengn, 6100 Main St,MS 142, Houston, TX 77005 USA.
   [Morrisett, Joel D.] Baylor Coll Med, Dept Med & Biochem, One Baylor Plaza, Houston, TX 77030 USA.
   [Wilson, Reid L.; Sylvester, Christopher B.] Baylor Coll Med, Med Scientist Training Program, One Baylor Plaza, Houston, TX 77030 USA.
C3 Rice University; Baylor College of Medicine; Baylor College of Medicine
RP Grande Allen, KJ (通讯作者)，Rice Univ, Dept Bioengn, 6100 Main St,MS 142, Houston, TX 77005 USA.
EM grande@rice.edu
RI ; Grande Allen, Kathryn/P 4042 2014
OI Kumar, Aditya/0000 0001 9580 8245; Sylvester,
   Christopher/0000 0001 7576 7546; Wilson, Reid/0000 0002 4240 2361
FU National Heart, Lung and Blood Institute [R21HL104377, T32HL007812];
   National Institute of Diabetes and Digestive and Kidney Disease
   [F30DK108541]; National Institutes of Health
FX This work was supported by the National Heart, Lung and Blood Institute
   [R21HL104377 to K.J.G.A. and T32HL007812 to J.D.M.] and the National
   Institute of Diabetes and Digestive and Kidney Disease [F30DK108541 to
   R.L.W.] of the National Institutes of Health. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The authors thank
   Jennifer P. Connell for her critical reading of the manuscript and Marci
   Kang and Vaidya Parthasarathy for their suggestions regarding research
   directions.
CR Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Balaoing LR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130749
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI [10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000530]
   Bowler MA, 2015, CARDIOVASC PATHOL, V24, P1, DOI 10.1016/j.carpath.2014.08.003
   Chen JH, 2011, CIRC RES, V108, P1510, DOI 10.1161/CIRCRESAHA.110.234237
   Cheng H, 2017, J SURG RES, V213, P243, DOI 10.1016/j.jss.2017.02.028
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Drzazga A, 2017, BIOCHEM BIOPH RES CO, V489, P242, DOI 10.1016/j.bbrc.2017.05.145
   Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002
   Garg A, 2017, J INVASIVE CARDIOL, V29, P208
   Gomel MA, 2019, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00197
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gu XX, 2011, AM J PHYSIOL HEART C, V300, pH448, DOI 10.1152/ajpheart.01178.2009
   Hjortnaes J, 2016, J MOL CELL CARDIOL, V94, P13, DOI 10.1016/j.yjmcc.2016.03.004
   Hoffman BD, 2011, NATURE, V475, P316, DOI 10.1038/nature10316
   Huk DJ, 2016, ARTERIOSCL THROM VAS, V36, P328, DOI 10.1161/ATVBAHA.115.306091
   IANNOTTI JP, 1994, CLIN ORTHOP RELAT R, P222
   Jeong HJ, 2017, BIOCHEM BIOPH RES CO, V485, P301, DOI 10.1016/j.bbrc.2017.02.087
   Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302
   Kim KM, 1995, SCANNING MICROSCOPY, V9, P1137
   Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365 2044.2004.03658.x
   Li C, 2013, CARDIOVASC PATHOL, V22, P1, DOI 10.1016/j.carpath.2012.06.005
   Li XH, 2007, LIFE SCI, V80, P886, DOI 10.1016/j.lfs.2006.11.017
   Liu AC, 2007, AM J PATHOL, V171, P1407, DOI 10.2353/ajpath.2007.070251
   Mahmut A, 2014, J AM COLL CARDIOL, V63, P460, DOI 10.1016/j.jacc.2013.05.105
   Massaeli H, 2000, ARTERIOSCL THROM VAS, V20, P328, DOI 10.1161/01.ATV.20.2.328
   Mathieu P, 2014, CAN J CARDIOL, V30, P982, DOI 10.1016/j.cjca.2014.03.029
   MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413
   Mohty D, 2008, ARTERIOSCL THROM VAS, V28, P187, DOI 10.1161/ATVBAHA.107.154989
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nakamura Y, 2007, PFLUG ARCH EUR J PHY, V453, P455, DOI 10.1007/s00424 006 0141 y
   Parisi V, 2015, NUTR METAB CARDIOVAS, V25, P519, DOI 10.1016/j.numecd.2015.02.001
   Puperi DS, 2016, BIOMACROMOLECULES, V17, P1766, DOI 10.1021/acs.biomac.6b00180
   Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767
   Rodriguez KJ, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471 2261 14 29
   Rodriguez KJ, 2011, MATRIX BIOL, V30, P70, DOI 10.1016/j.matbio.2010.09.001
   Song R, 2012, ARTERIOSCL THROM VAS, V32, P2711, DOI 10.1161/ATVBAHA.112.300116
   Stephens EH, 2007, J HEART VALVE DIS, V16, P175
   Stephens EH, 2011, CARDIOVASC PATHOL, V20, P334, DOI [10.1016/j.carpath.2010.10.002, 10.1016/j.carpath.2010.07.004]
   Sutko JL, 1997, PHARMACOL REV, V49, P53
   Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978 1 61779 012 6_9
   Thayer P, 2011, ANN BIOMED ENG, V39, P1654, DOI 10.1007/s10439 011 0273 x
   Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161
   Towler DA, 2013, CIRC RES, V113, P198, DOI 10.1161/CIRCRESAHA.113.300155
   Van Petegem F, 2012, J BIOL CHEM, V287, P31624, DOI 10.1074/jbc.R112.349068
   Vater C, 2011, ACTA BIOMATER, V7, P463, DOI 10.1016/j.actbio.2010.07.037
   Wang H, 2013, P NATL ACAD SCI USA, V110, P19336, DOI 10.1073/pnas.1306369110
   Wiltz DC, 2014, CARDIOVASC ENG TECHN, V5, P371, DOI 10.1007/s13239 014 0197 3
   Wu Y, 2017, J TISSUE ENG REGEN M, V11, P1963, DOI 10.1002/term.2093
   Yip CYY, 2009, ARTERIOSCL THROM VAS, V29, P936, DOI 10.1161/ATVBAHA.108.182394
   Zeng QC, 2017, P NATL ACAD SCI USA, V114, P1631, DOI 10.1073/pnas.1619667114
   Zhang X, 2015, ACTA BIOMATER, V14, P11, DOI 10.1016/j.actbio.2014.11.042
NR 52
TC 4
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1869 408X
EI 1869 4098
J9 CARDIOVASC ENG TECHN
JI Cardiovasc. Eng. Technol.
PD JUN
PY 2020
VL 11
IS 3
BP 316
EP 327
DI 10.1007/s13239 020 00463 1
EA APR 2020
PG 12
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Engineering
GA LN5PY
UT WOS:000529706300001
PM 32356274
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, ZX
AF Li, Zhaoxu
TI Potential of human γδ T cells for immunotherapy of osteosarcoma
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Osteosarcoma; Immunotherapy; Adoptive; Receptors; Antigen; T cell;
   Gamma delta; Neoplasms
ID NATURAL KILLER CELLS; ADOPTIVE IMMUNOTHERAPY; IN VIVO; ZOLEDRONIC ACID;
   BREAST CANCER; ANTITUMOR CYTOTOXICITY; SOLID TUMORS;
   PROGNOSTIC SIGNIFICANCE; PEDIATRIC OSTEOSARCOMA; THERAPEUTIC APPROACH
AB Recurrent or metastatic osteosarcomas remain a challenging malignancy to treat. Therefore, development and testing of novel therapeutic strategies to target these patients are needed. Adoptive cellular therapy strategies are being evaluated intensively as a novel therapeutic strategy for cancer. Unlike alpha beta T cells requiring antigen processing and MHC restricted peptide displayed by antigen presenting cells, gamma delta T cells exhibit the potent MHC unrestricted lytic activity against various tumors in vitro and in vivo. The recent considerable success of gamma delta T cell based immunotherapy in lung metastasis of renal cell carcinoma warrants further efforts to apply this treatment to other cancers including osteosarcoma, especially recurrent and metastatic osteosarcomas. In this review, we summarize the available evidence on gamma delta T cell based immunotherapy for osteosarcoma that has been achieved to date. More importantly, we discuss potential strategies of the combination of expanded gamma delta T cells and bisphosphonates, and modification and expansion of alpha beta TCR modified gamma delta T cells for improving its efficacy for the treatment of osteosarcoma.
C1 Guilin Med Univ, Dept Orthopaed, Affiliated Hosp 2, Guilin 541004, Peoples R China.
C3 Guilin Medical University
RP Li, ZX (通讯作者)，Guilin Med Univ, Dept Orthopaed, Affiliated Hosp 2, 15 Lequn Rd, Guilin 541004, Peoples R China.
EM lizhaoxuglm@gmail.com
RI li, zhaoxu/MEO 7338 2025
OI , li chao xu/0000 0002 4239 8075
CR Ahmed N, 2009, MOL THER, V17, P1779, DOI 10.1038/mt.2009.133
   Alexander AAZ, 2008, CLIN CANCER RES, V14, P4232, DOI 10.1158/1078 0432.CCR 07 4912
   Ando K, 2011, EXPERT OPIN PHARMACO, V12, P285, DOI 10.1517/14656566.2011.543129
   Andreou D, 2011, ANN ONCOL, V22, P1228, DOI 10.1093/annonc/mdq589
   Bennouna J, 2008, CANCER IMMUNOL IMMUN, V57, P1599, DOI 10.1007/s00262 008 0491 8
   Bennouna J, 2010, CANCER IMMUNOL IMMUN, V59, P1521, DOI 10.1007/s00262 010 0879 0
   Benzaïd I, 2011, CANCER RES, V71, P4562, DOI 10.1158/0008 5472.CAN 10 3862
   Berghuis D, 2011, J PATHOL, V223, P347, DOI 10.1002/path.2819
   Bidwell J, 1997, MOL BIOL REP, V24, P271, DOI 10.1023/A:1006883528518
   Bielack SS, 2008, ANN ONCOL, V19, P155, DOI 10.1093/annonc/mdn436
   Bonneville M, 2006, CURR OPIN IMMUNOL, V18, P539, DOI 10.1016/j.coi.2006.07.002
   Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781
   Bouet Toussaint F, 2008, CANCER IMMUNOL IMMUN, V57, P531, DOI 10.1007/s00262 007 0391 3
   Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267
   Brandes M, 2009, P NATL ACAD SCI USA, V106, P2307, DOI 10.1073/pnas.0810059106
   Braza MS, 2011, HAEMATOL HEMATOL J, V96, P400, DOI 10.3324/haematol.2010.029520
   Bryant NL, 2011, J NEURO ONCOL, V101, P179, DOI 10.1007/s11060 010 0245 2
   Buddingh EP, 2011, CANCER IMMUNOL IMMUN, V60, P575, DOI 10.1007/s00262 010 0965 3
   Burjanadzé M, 2007, BRIT J HAEMATOL, V139, P206, DOI 10.1111/j.1365 2141.2007.06754.x
   Caldwell SA, 2003, J IMMUNOL, V171, P2402, DOI 10.4049/jimmunol.171.5.2402
   Capietto AH, 2011, J IMMUNOL, V187, P1031, DOI 10.4049/jimmunol.1100681
   Casetti R, 2008, CELL MOL IMMUNOL, V5, P161, DOI 10.1038/cmi.2008.20
   Castella B, 2011, J IMMUNOL, V187, P1578, DOI 10.4049/jimmunol.1002514
   Champagne E, 2011, ARCH IMMUNOL THER EX, V59, P117, DOI 10.1007/s00005 011 0118 1
   Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107
   Cho D, 2010, CLIN CANCER RES, V16, P3901, DOI 10.1158/1078 0432.CCR 10 0735
   Chodaczek G, 2012, NAT IMMUNOL, V13, P272, DOI 10.1038/ni.2240
   Coccoris M, 2008, J IMMUNOL, V180, P6536, DOI 10.4049/jimmunol.180.10.6536
   Corvaisier M, 2005, J IMMUNOL, V175, P5481, DOI 10.4049/jimmunol.175.8.5481
   D'Asaro M, 2010, J IMMUNOL, V184, P3260, DOI 10.4049/jimmunol.0903454
   Dai YM, 2012, J BIOL CHEM, V287, P16812, DOI 10.1074/jbc.M111.327650
   deBarros A, 2011, EUR J IMMUNOL, V41, P195, DOI 10.1002/eji.201040905
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Eberl M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000308
   Eyre R, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 357
   Fagioli F, 2008, BONE MARROW TRANSPL, V41, pS131, DOI 10.1038/bmt.2008.71
   Ferrarini M, 2008, J IMMUNOL, V181, P5857, DOI 10.4049/jimmunol.181.9.5857
   FISCH P, 1990, J EXP MED, V171, P1567, DOI 10.1084/jem.171.5.1567
   Gnant M, 2012, RECENT RESULTS CANC, V192, P65, DOI 10.1007/978 3 642 21892 7_3
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Gomes AQ, 2010, CANCER RES, V70, P10024, DOI 10.1158/0008 5472.CAN 10 3236
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Guo BL, 2005, BREAST CANCER RES TR, V93, P169, DOI 10.1007/s10549 005 4792 8
   Hanagiri T, 2012, CANCER SCI, V103, P1414, DOI 10.1111/j.1349 7006.2012.02337.x
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hiasa A, 2008, GENE THER, V15, P695, DOI 10.1038/sj.gt.3303099
   Hiasa A, 2009, GENE THER, V16, P620, DOI 10.1038/gt.2009.6
   Huber SA, 2010, IMMUNOLOGY, V131, P202, DOI 10.1111/j.1365 2567.2010.03292.x
   Jiang Hui, 2010, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V26, P1195
   June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635
   Kabelitz D, 2011, CELL MOL LIFE SCI, V68, P2331, DOI 10.1007/s00018 011 0696 4
   Kang N, 2009, CANCER BIOL THER, V8, P1540, DOI 10.4161/cbt.8.16.8950
   Kato Y, 2001, J IMMUNOL, V167, P5092, DOI 10.4049/jimmunol.167.9.5092
   KLEINERMAN ES, 1995, AM J CLIN ONCOL CANC, V18, P93, DOI 10.1097/00000421 199504000 00001
   Knutson KL, 2006, CANCER IMMUNOL IMMUN, V55, P96, DOI 10.1007/s00262 005 0706 1
   Kobayashi H, 2007, CANCER IMMUNOL IMMUN, V56, P469, DOI 10.1007/s00262 006 0199 6
   Kobayashi H, 2011, CANCER IMMUNOL IMMUN, V60, P1075, DOI 10.1007/s00262 011 1021 7
   Kobayashi H, 2010, ANTICANCER RES, V30, P575
   Lai DM, 2012, CANCER IMMUNOL IMMUN, V61, P979, DOI 10.1007/s00262 011 1166 4
   Lamb LS, 2005, BIOL BLOOD MARROW TR, V11, P161, DOI 10.1016/j.bbmt.2004.11.015
   Lang JM, 2011, CANCER IMMUNOL IMMUN, V60, P1447, DOI 10.1007/s00262 011 1049 8
   Li H, 2010, CLIN INVEST MED, V33, pE280
   Li YT, 2011, CANCER AM CANCER SOC, V117, P207, DOI 10.1002/cncr.25563
   Li ZX, 2012, J ORTHOP RES, V30, P824, DOI 10.1002/jor.21579
   Li ZX, 2011, INT IMMUNOPHARMACOL, V11, P496, DOI 10.1016/j.intimp.2011.01.001
   Liu ZY, 2009, J GASTROEN HEPATOL, V24, P900, DOI 10.1111/j.1440 1746.2008.05668.x
   Liu ZY, 2005, J UROLOGY, V173, P1552, DOI 10.1097/01.ju.0000154355.45816.0b
   Loeb DM, 2009, CANC TREAT, V152, P447, DOI 10.1007/978 1 4419 0284 9_25
   Lozupone F, 2004, CANCER RES, V64, P378, DOI 10.1158/0008 5472.CAN 03 1501
   Maniar A, 2010, BLOOD, V116, P1726, DOI 10.1182/blood 2009 07 234211
   Marina N, 2009, CANCER BIOL THER, V8, P981, DOI 10.4161/cbt.8.10.8602
   Martinet L, 2009, IMMUNOL LETT, V124, P1, DOI 10.1016/j.imlet.2009.03.011
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365 2249.2010.04167.x
   Merchant MS, 2007, CANCER IMMUNOL IMMUN, V56, P1037, DOI 10.1007/s00262 006 0257 0
   Messerschmitt PJ, 2009, J AM ACAD ORTHOP SUR, V17, P515, DOI 10.5435/00124635 200908000 00005
   Meyers PA, 2011, CANCER AM CANCER SOC, V117, P1736, DOI 10.1002/cncr.25744
   Moore C, 2010, PEDIATR BLOOD CANCER, V55, P1096, DOI 10.1002/pbc.22673
   Mori K, 2006, ONCOL REP, V15, P693
   Mori K, 2008, EXPERT REV ANTICANC, V8, P151, DOI 10.1586/14737140.8.2.151
   MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074 7613(95)90178 7
   Muraro M, 2007, CELL IMMUNOL, V249, P63, DOI 10.1016/j.cellimm.2007.11.005
   Muraro M, 2011, CELL IMMUNOL, V266, P123, DOI 10.1016/j.cellimm.2010.09.007
   Murayama M, 2008, ANTICANCER RES, V28, P2921
   Nakajima J, 2010, EUR J CARDIO THORAC, V37, P1191, DOI 10.1016/j.ejcts.2009.11.051
   Nedellec S, 2010, J IMMUNOL, V185, P55, DOI 10.4049/jimmunol.1000373
   Nicol AJ, 2011, BRIT J CANCER, V105, P778, DOI 10.1038/bjc.2011.293
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Otto M, 2005, CLIN CANCER RES, V11, P8486, DOI 10.1158/1078 0432.CCR 05 1184
   Pahl JHW, 2012, CLIN CANCER RES, V18, P432, DOI 10.1158/1078 0432.CCR 11 2277
   Picci P, 2010, ANN ONCOL, V21, P1366, DOI 10.1093/annonc/mdp502
   Rainusso N, 2012, CANCER GENE THER, V19, P212, DOI 10.1038/cgt.2011.83
   Ribot JC, 2011, CELL MOL LIFE SCI, V68, P2345, DOI 10.1007/s00018 011 0698 2
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   RIVOLTINI L, 1992, CANCER IMMUNOL IMMUN, V34, P241, DOI 10.1007/BF01741792
   Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355
   Rosenberg SA, 2009, CURR OPIN IMMUNOL, V21, P233, DOI 10.1016/j.coi.2009.03.002
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saitoh A, 2008, MED ONCOL, V25, P137, DOI 10.1007/s12032 007 9004 4
   Sakamoto M, 2011, J IMMUNOTHER, V34, P202, DOI 10.1097/CJI.0b013e318207ecfb
   Schnurr M, 2002, CANCER RES, V62, P2347
   Schumacher TNM, 2002, NAT REV IMMUNOL, V2, P512, DOI 10.1038/nri841
   Scotet E, 2005, IMMUNITY, V22, P71, DOI 10.1016/j.immuni.2004.11.012
   Siegers GM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016700
   Sudo T, 1997, J ORTHOPAED RES, V15, P128, DOI 10.1002/jor.1100150119
   Théoleyre S, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 123
   Todaro M, 2009, J IMMUNOL, V182, P7287, DOI 10.4049/jimmunol.0804288
   Tsukahara T, 2006, CANCER SCI, V97, P1374, DOI 10.1111/j.1349 7006.2006.00317.x
   Uckert W, 2009, CANCER IMMUNOL IMMUN, V58, P809, DOI 10.1007/s00262 008 0649 4
   van der Veken LT, 2009, J IMMUNOL, V182, P164, DOI 10.4049/jimmunol.182.1.164
   van der Veken LT, 2006, CANCER RES, V66, P3331, DOI 10.1158/0008 5472.CAN 05 4190
   Wang H, 2010, J IMMUNOL, V184, P6209, DOI 10.4049/jimmunol.1000231
   Witherden DA, 2010, SCIENCE, V329, P1205, DOI 10.1126/science.1192698
   Yabe H, 2011, J SURG ONCOL, V103, P380, DOI 10.1002/jso.21829
   Zhao H, 2010, MOL BIOL REP, V37, P2509, DOI 10.1007/s11033 009 9765 2
NR 114
TC 28
Z9 40
U1 0
U2 19
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JAN
PY 2013
VL 40
IS 1
BP 427
EP 437
DI 10.1007/s11033 012 2077 y
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 055RV
UT WOS:000312435500050
PM 23065272
DA 2025 08 17
ER

PT J
AU Wu, HF
   Liu, S
   Chen, SY
   Hua, YC
   Li, XF
   Zeng, Q
   Zhou, Y
   Yang, X
   Zhu, XD
   Tu, CQ
   Zhang, XD
AF Wu, Hongfeng
   Liu, Shuo
   Chen, Siyu
   Hua, Yuchen
   Li, Xiangfeng
   Zeng, Qin
   Zhou, Yong
   Yang, Xiao
   Zhu, Xiangdong
   Tu, Chongqi
   Zhang, Xingdong
TI A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using
   Hydroxyapatite Nanoparticles
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE hydroxyapatite nanoparticles; osteosarcoma; material features; cell
   line; mitochondrial apoptosis
ID NANO HYDROXYAPATITE; PHASE 2 TRIAL; CELL DEATH; CANCER; PATHWAY; GROWTH;
   CYTOTOXICITY; INHIBITION; DELIVERY; ARREST
AB Background: In recent years, using hydroxyapatite nanoparticles (HANPs) for tumor therapy attracted increasing attention because HANPs were found to selectively suppress the growth of tumor cells but exhibit ignorable toxicity to normal cells.Purpose: This study aimed to investigate the capacities of HANPs with different morphologies and particle sizes against two kinds of osteosarcoma (OS) cells, human OS 143B cells and rat OS UMR106 cells.Methods: Six kinds of HANPs with different morphologies and particle sizes were prepared by wet chemical method. Then, the antitumor effect of these nanoparticles was characterized by means of in vitro cell experiments and in vivo tumor bearing mice model. The underlying antitumor mechanism involving mitochondrial apoptosis was also investigated by analysis of intracellular calcium, expression of apoptosis related genes, reactive oxygen species (ROS), and the endocytosis efficiency of the particles in tumor cells.Results: Both in vitro cell experiments and in vivo mice model evaluation revealed the anti OS performance of HANPs depended on the concentration, morphology, and particle size of the nanoparticles, as well as the OS cell lines. Among the six HANPs, rod like HANPs (R HANPs) showed the best inhibitory activity on 143B cells, while needle like HANPs (N HANPs) inhibited the growth of UMR106 cells most efficiently. We further demonstrated that HANPs induced mitochondrial apoptosis by selectively raising intracellular Ca2+ and the gene expression levels of mitochondrial apoptosis related molecules, and depolarizing mitochondrial membrane potential in tumor cells but not in MC3T3 E1, a mouse pre osteoblast line. Additionally, the anti OS activity of HANPs also linked with the endocytosis efficiency of the particles in the tumor cells, and their ability to drive oxidative damage and immunogenic cell death (ICD). Conclusion: The current study provides an effective strategy for OS therapy where the effectiveness was associated with the particle morphology and cell line.
C1 [Wu, Hongfeng; Liu, Shuo; Chen, Siyu; Hua, Yuchen; Li, Xiangfeng; Zeng, Qin; Yang, Xiao; Zhu, Xiangdong; Zhang, Xingdong] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
   [Wu, Hongfeng; Liu, Shuo; Chen, Siyu; Hua, Yuchen; Li, Xiangfeng; Yang, Xiao; Zhu, Xiangdong] Sichuan Univ, Coll Biomed Engn, Chengdu 610064, Peoples R China.
   [Zeng, Qin; Zhang, Xingdong] Sichuan Univ, NMPA Key Lab Qual Res & Control Tissue Regenerat B, Chengdu 610064, Peoples R China.
   [Zeng, Qin; Zhang, Xingdong] Sichuan Univ, Inst Regulatory Sci Med Devices, Chengdu 610064, Peoples R China.
   [Zeng, Qin; Zhang, Xingdong] Sichuan Univ, NMPA Res Base Regulatory Sci Med Devices, Chengdu 610064, Peoples R China.
   [Zhou, Yong; Tu, Chongqi] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu 610041, Peoples R China.
   [Zeng, Qin; Zhu, Xiangdong] Sichuan Univ, Natl Engn Res Ctr Biomat, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University; Sichuan University; Sichuan University
RP Zeng, Q; Zhu, XD (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.
EM qzeng8156@scu.edu.cn; zhu_xd1973@scu.edu.cn
RI Chen, Siyu/R 9287 2019; Li, Xiangfeng/IXX 0393 2023
OI shuo, liu/0000 0001 9236 6912; Zhu, Xiangdong/0000 0002 3818 7419; 
FU National Key Research and Development Program of China [2017YFB0702600];
   Sichuan Science and Technology Program [2020YFS0039]; National Natural
   Science Foundation of China [81901685]; Fundamental Research Funds for
   the Central Universities [YJ201915]
FX Acknowledgments This work was supported by National Key Research and
   Development Program of China (grant No. 2017YFB0702600) , Sichuan
   Science and Technology Program (grant No. 2020YFS0039) , National
   Natural Science Foundation of China (grant No. 81901685) and the
   Fundamental Research Funds for the Central Universities (grant No.
   YJ201915) .
CR An JY, 2020, ACS NANO, V14, P7639, DOI 10.1021/acsnano.0c03881
   Aoki H., 1993, REP I MED DENT ENG, V27, P39
   Azevedo Barbosa H, 2019, TOXICOL IN VITRO, V59, P150, DOI 10.1016/j.tiv.2019.04.023
   Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048
   Cao JQ, 2017, INT J ONCOL, V51, P1115, DOI 10.3892/ijo.2017.4110
   Carrillo López N, 2016, KIDNEY INT, V90, P77, DOI 10.1016/j.kint.2016.01.024
   Chen Z, 2016, MED SCI MONITOR, V22, P1609, DOI 10.12659/MSM.898483
   Chohan TA, 2018, BIOMED PHARMACOTHER, V107, P1326, DOI 10.1016/j.biopha.2018.08.116
   Dai Z, 2020, NANO LETT, V20, P6246, DOI 10.1021/acs.nanolett.0c00713
   Dong XL, 2021, SMALL, V17, DOI 10.1002/smll.202007672
   Duan DD, 2020, ONCOTARGETS THER, V13, P8223, DOI 10.2147/OTT.S242344
   Feger M., 2017, Scientific reports, V7, P1
   Feng Y, 2021, OXID MED CELL LONGEV, V2021, P849
   Fu Z, 2021, J ORTHOP TRANSL, V28, P118, DOI 10.1016/j.jot.2021.02.005
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Garg AD, 2013, AUTOPHAGY, V9, P1292, DOI 10.4161/auto.25399
   Hagi T, 2020, BONE JOINT RES, V9, P821, DOI 10.1302/2046 3758.911.BJR 2020 0123.R1
   Hansen M. F., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P554
   Huang ST, 2014, MITOCHONDRION, V17, P22, DOI 10.1016/j.mito.2014.05.002
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007
   Lee WH, 2019, MAT SCI ENG C MATER, V99, P929, DOI 10.1016/j.msec.2019.02.030
   Li X, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120253
   Li ZT, 2020, NANO RES, V13, P2106, DOI 10.1007/s12274 020 2817 6
   Liao YF, 2017, ONCOTARGET, V8, P30276, DOI 10.18632/oncotarget.16326
   Lin LS, 2019, J AM CHEM SOC, V141, P9937, DOI 10.1021/jacs.9b03457
   Liu LN, 2014, ONCOL REP, V32, P1395, DOI 10.3892/or.2014.3388
   Lu PWA, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14060497
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Marchi S, 2018, CELL CALCIUM, V69, P62, DOI 10.1016/j.ceca.2017.05.003
   MARTIN TJ, 1976, NATURE, V260, P436, DOI 10.1038/260436a0
   Menéndez Proupin E, 2011, J MECH BEHAV BIOMED, V4, P1011, DOI 10.1016/j.jmbbm.2011.03.001
   Mirabello L, 2020, JAMA ONCOL, V6, P724, DOI 10.1001/jamaoncol.2020.0197
   Mortezaee K, 2019, J CELL PHYSIOL, V234, P12537, DOI 10.1002/jcp.28122
   Motskin M, 2009, BIOMATERIALS, V30, P3307, DOI 10.1016/j.biomaterials.2009.02.044
   Munir MU, 2018, INT J PHARMACEUT, V544, P112, DOI 10.1016/j.ijpharm.2018.04.029
   Munir MU, 2022, INT J NANOMED, V17, P1903, DOI 10.2147/IJN.S360670
   Munir MU, 2021, ARTIF CELL NANOMED B, V49, P717, DOI 10.1080/21691401.2021.2016785
   Munir MU, 2019, ACS OMEGA, V4, P7524, DOI 10.1021/acsomega.9b00541
   Noone AM, 2017, CANCER EPIDEM BIOMAR, V26, P632, DOI 10.1158/1055 9965.EPI 16 0520
   Pappo AS, 2014, CANCER AM CANCER SOC, V120, P2448, DOI 10.1002/cncr.28728
   Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165 4608(01)00575 1
   Quan HY, 2018, ACS APPL MATER INTER, V10, P25547, DOI 10.1021/acsami.8b09879
   Raimondi L, 2020, CARCINOGENESIS, V41, P666, DOI 10.1093/carcin/bgz130
   Rana A, 2020, J CLEAN PROD, V272, DOI 10.1016/j.jclepro.2020.122880
   Saraf AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00004
   Setyawati MI, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2655
   Tay CY, 2014, ACS APPL MATER INTER, V6, P6248, DOI 10.1021/am501266a
   TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Wang YF, 2016, ACS NANO, V10, P9927, DOI 10.1021/acsnano.6b03835
   Weigel B, 2014, PEDIATR BLOOD CANCER, V61, P452, DOI 10.1002/pbc.24605
   Wu HF, 2019, INT J NANOMED, V14, P1177, DOI 10.2147/IJN.S184792
   Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1007 1
   Xu ZL, 2012, J APPL TOXICOL, V32, P429, DOI 10.1002/jat.1745
   Yang S, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120791
   Yin YY, 2021, INT J PHARMACEUT, V606, DOI 10.1016/j.ijpharm.2021.120937
   Yuan Y, 2010, BIOMATERIALS, V31, P730, DOI 10.1016/j.biomaterials.2009.09.088
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6946
   Zhao H, 2018, ACS NANO, V12, P7838, DOI 10.1021/acsnano.8b01996
   Zhao XX, 2013, ARCH TOXICOL, V87, P1037, DOI 10.1007/s00204 012 0827 1
   Zhu KP, 2019, MOL THER, V27, P518, DOI 10.1016/j.ymthe.2019.01.001
   Zhu Y, 2019, CHEMOSPHERE, V237, DOI 10.1016/j.chemosphere.2019.124403
NR 63
TC 16
Z9 17
U1 4
U2 43
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2022
VL 17
BP 3691
EP 3710
DI 10.2147/IJN.S375950
PG 20
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA 5R8QF
UT WOS:000874769200001
PM 36046839
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nasi, S
   Ea, HK
   So, A
   Busso, N
AF Nasi, Sonia
   Ea, Hang Korng
   So, Alexander
   Busso, Nathalie
TI Revisiting the Role of Interleukin 1 Pathway in Osteoarthritis:
   Interleukin 1α and 1β, and NLRP3 Inflammasome Are Not Involved in the
   Pathological Features of the Murine Menisectomy Model of Osteoarthritis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE NLRP3 inflammasome; interleukin l beta; cartilage; knock out mice;
   animal model of OA
ID NECROSIS FACTOR ALPHA; RECEPTOR ANTAGONIST; KNEE OSTEOARTHRITIS;
   OSTEOCLAST DIFFERENTIATION; INTRAARTICULAR INJECTION; ARTICULAR
   CHONDROCYTES; INDUCED ARTHRITIS; INNATE PRODUCTION; DECOY RECEPTOR;
   DOUBLE BLIND
AB Background: Innate immune response components such as toll like receptors (TLRs) and NLRP3 inflammasome act in concert to increase IL 1 alpha/beta secretion by synovial macrophages. Previous results suggest that IL 1 alpha/beta) could be an important mediator involved in the pathogenesis of osteoarthritis (OA).
   Objectives: The aim of our study was to evaluate the role of NLRP3, IL 1 beta, and IL 1 alpha in the menisectomy (MNX) model of murine OA.
   Methods: Murine chondrocytes (CHs) and bone marrow derived machrophages (BMDM) were stimulated with hydroxyapatite (HA) crystals, a form of calcium containing crystal found in human OA, and IL 1 beta and IL 6 secretion assayed by ELISA.Conversely, the ability of IL l beta and IL 6 to induce CHs calcification was assessed in vitro by Alizarin red staining. Knees from 8 to 10 weeks old C57BI/6J wild type (WT) (n = 7), NLRP3( / )(n = 9), IL 1 alpha( / ) (n = 5), and IL 1 beta)( / )(n= 5) mice were menisectomized, using the sham operated contralateral knee as control. 8 weeks later, knee cartilage degradation and synovial inflammation were evaluated by histology. In addition, apoptotic chondrocytes, metalloproteases activity, and collagen type 2 expression were evaluated in all mice. Joint calcification and subchondral bone parameters were quantified by CT scan in WT and IL 1 beta( / ) menisectomized knees.
   Results: In vitro, HA crystals induced significant increased IL 6 secretion by CHs, while IL 1 beta) remained undetectable.Conversely, both IL 6 and IL 1 beta) were able to increase chondrocytes mineralization. In vivo, operated knees exhibited OA features compared to sham operated knees as evidenced by increased cartilage degradation and synovial inflammation. In menisectomized KO mice, severity and extent of cartilage lesions were similar (IL 1 alpha( / ) mice) or exacerbated (IL 1 beta( / ) and NLRP3( / ) mice) compared to that of menisectomized WT mice. Metalloproteases activity, collagen type 2 expression,chondrocytes apoptosis, and synovial inflammation were similar between KO and WT mice menisectomized knees. Moreover, the extent of joint calcification in osteoarthritic knees was comparable between IL 1 beta( / ) and WT mice.
   Conclusions: MNX knees recapitulated features of OA, i.e, cartilage destruction, synovial inflammation, cell death, and joint calcification. Deficiency of IL 1 alpha did not impact on the severity of these features, whereas deficiency of IL 1 beta or of NLRP3 led to increased cartilage erosion. Our results suggest that IL1 alpha and IL 1 beta,are not key mediators in this murine OA model and may explain the inefficiency of IL 1 targeted therapies in OA.
C1 [Nasi, Sonia; So, Alexander; Busso, Nathalie] CHU Vaudois, Serv Rheumatol, Dept Appareil Locomoteur, Lausanne, Switzerland.
   [Nasi, Sonia; So, Alexander; Busso, Nathalie] Univ Lausanne, Lausanne, Switzerland.
   [Ea, Hang Korng] Hosp Lariboisiere, UMR 1132, Inst Natl Sante & Rech Med, Paris, France.
   [Ea, Hang Korng] Univ Paris Diderot, UFR Med, Dept Rhumatol, Paris, France.
C3 University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   University of Lausanne; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Lariboisiere Fernand Widal
     APHP; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Paris Cite
RP Busso, N (通讯作者)，CHU Vaudois, Serv Rheumatol, Dept Appareil Locomoteur, Lausanne, Switzerland.
EM Nathalie.Busso@chuv.ch
RI Ea, HK/P 5527 2016; Nasi, Sonia/HJB 2860 2022
OI Ea, HK/0000 0002 2393 7475; 
FU Ponds National Suisse de la recherche scientifique [310030 130085/1];
   Institute of Arthritis Research; Fondation RMR; Fondation Jean and
   Linette Warnery; Swiss National Science Foundation (SNF) [310030_130085]
   Funding Source: Swiss National Science Foundation (SNF)
FX We would like to thank Veronique Chobaz (Laboratory of Rheumatology,
   CHUV, Lausanne CH) for her excellent technical support and Dr. Florence
   Morgenthaler (CIF, University of Lausanne CH) for her support in micro
   CT scan analysis. We also thank Dr. Peter van Lent (University of
   Nijmegen, The Netherlands) for his generous help with the anti VDIPEN
   staining experiment. This work was supported by the Ponds National
   Suisse de la recherche scientifique (grant 310030 130085/1), the
   Institute of Arthritis Research, the Fondation RMR, the Fondation Jean
   and Linette Warnery.
CR Abramson SB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2655
   Attur M, 2015, OSTEOARTHR CARTILAGE, V23, P1915, DOI 10.1016/j.joca.2015.08.006
   Attur MG, 2002, J IMMUNOL, V168, P2001, DOI 10.4049/jimmunol.168.4.2001
   Attur MG, 2000, J BIOL CHEM, V275, P40307, DOI 10.1074/jbc.M002721200
   Baltzer AWA, 2009, OSTEOARTHR CARTILAGE, V17, P152, DOI 10.1016/j.joca.2008.06.014
   Bigoni M, 2013, J ORTHOP RES, V31, P315, DOI 10.1002/jor.22208
   Botha Scheepers S, 2008, ANN RHEUM DIS, V67, P1165, DOI 10.1136/ard.2007.084657
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Caron JP, 1996, ARTHRITIS RHEUM, V39, P1535, DOI 10.1002/art.1780390914
   Chevalier X, 2009, ARTHRIT RHEUM ARTHR, V61, P344, DOI 10.1002/art.24096
   Chevalier X, 2005, J RHEUMATOL, V32, P1317
   Chiba K, 2012, OSTEOPOROSIS INT, V23, P589, DOI 10.1007/s00198 011 1585 2
   Clements KM, 2003, ARTHRITIS RHEUM US, V48, P3452, DOI 10.1002/art.11355
   Cohen SB, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3430
   de Hooge ASK, 2005, OSTEOARTHR CARTILAGE, V13, P66, DOI 10.1016/j.joca.2004.09.011
   Denoble AE, 2011, P NATL ACAD SCI USA, V108, P2088, DOI 10.1073/pnas.1012743108
   Di Paolo NC, 2016, NAT IMMUNOL, V17, P906, DOI 10.1038/ni.3503
   Ea HK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057352
   Ea HK, 2011, ARTHRITIS RHEUM US, V63, P10, DOI 10.1002/art.27761
   Ea HK, 2009, CURR OPIN RHEUMATOL, V21, P150, DOI 10.1097/BOR.0b013e3283257ba9
   Fernandes J, 1999, AM J PATHOL, V154, P1159, DOI 10.1016/S0002 9440(10)65368 0
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Frisbie DD, 2002, GENE THER, V9, P12, DOI 10.1038/sj.gt.3301608
   Furman BD, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4591
   GIBILISCO PA, 1985, ARTHRITIS RHEUM US, V28, P511, DOI 10.1002/art.1780280507
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Glasson SS, 2007, CURR DRUG TARGETS, V8, P367, DOI 10.2174/138945007779940061
   Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258
   Goldring MB, 2006, BEST PRACT RES CL RH, V20, P1003, DOI 10.1016/j.berh.2006.06.003
   GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gross Olaf, 2012, Immunity, V36, P388, DOI 10.1016/j.immuni.2012.01.018
   Hashizume M, 2010, BIOCHEM BIOPH RES CO, V403, P184, DOI 10.1016/j.bbrc.2010.10.135
   Iqbal Imran, 2007, Curr Rheumatol Rep, V9, P31, DOI 10.1007/s11926 007 0019 9
   JANDINSKI JJ, 1988, J ORAL PATHOL MED, V17, P145, DOI 10.1111/j.1600 0714.1988.tb01515.x
   Jin CC, 2011, P NATL ACAD SCI USA, V108, P14867, DOI 10.1073/pnas.1111101108
   Johnson K, 2001, AM J PATHOL, V159, P149, DOI 10.1016/S0002 9440(10)61682 3
   Joosten LAB, 1996, ARTHRITIS RHEUM, V39, P797, DOI 10.1002/art.1780390513
   Jules J, 2012, J BIOL CHEM, V287, P15728, DOI 10.1074/jbc.M111.296228
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Kolly L, 2010, IMMUNOLOGY, V129, P178, DOI 10.1111/j.1365 2567.2009.03174.x
   Kolly L, 2009, J IMMUNOL, V183, P4003, DOI 10.4049/jimmunol.0802173
   Latourte A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209757
   Livshits G, 2009, ARTHRITIS RHEUM US, V60, P2037, DOI 10.1002/art.24598
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Marks PH, 2005, ARTHROSCOPY, V21, P1342, DOI 10.1016/j.arthro.2005.08.034
   McCarthy Geraldine M, 2009, Curr Rheumatol Rep, V11, P141
   McNulty AL, 2013, J ORTHOP RES, V31, P1039, DOI 10.1002/jor.22334
   Murphy G, 2008, NAT CLIN PRACT RHEUM, V4, P128, DOI 10.1038/ncprheum0727
   Nakamura I, 2006, VITAM HORM, V74, P357, DOI 10.1016/S0083 6729(06)74015 8
   Nasi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158196
   Nasi S, 2016, ANN RHEUM DIS, V75, P1372, DOI 10.1136/annrheumdis 2015 207487
   Nasi S, 2014, JOINT BONE SPINE, V81, P320, DOI 10.1016/j.jbspin.2014.01.018
   Ning L, 2011, INT ORTHOP, V35, P831, DOI 10.1007/s00264 010 1045 1
   Palmer G, 2004, ANN RHEUM DIS, V63, P43, DOI 10.1136/ard.2002.005546
   Palmer G, 2002, ARTHRITIS RES, V4, P226, DOI 10.1186/ar411
   Pazár B, 2011, J IMMUNOL, V186, P2495, DOI 10.4049/jimmunol.1001284
   Pelletier JP, 1997, ARTHRITIS RHEUM US, V40, P1012, DOI 10.1002/art.1780400604
   Porée B, 2008, J BIOL CHEM, V283, P4850, DOI 10.1074/jbc.M706387200
   Prudhommeaux F, 1996, ARTHRITIS RHEUM, V39, P1319, DOI 10.1002/art.1780390809
   Re F, 1996, J EXP MED, V183, P1841, DOI 10.1084/jem.183.4.1841
   Riyazi N, 2005, ARTHRITIS RHEUM US, V52, P1443, DOI 10.1002/art.21014
   ROESSLER BJ, 1995, HUM GENE THER, V6, P307, DOI 10.1089/hum.1995.6.3 307
   Ryu JH, 2011, ARTHRITIS RHEUM US, V63, P2732, DOI 10.1002/art.30451
   Santangelo KS, 2012, OSTEOARTHR CARTILAGE, V20, P1610, DOI 10.1016/j.joca.2012.08.011
   Scanzello CR, 2012, BONE, V51, P249, DOI 10.1016/j.bone.2012.02.012
   Smith MD, 1997, J RHEUMATOL, V24, P365
   Sui YH, 2009, ARTHRITIS RHEUM US, V60, P2985, DOI 10.1002/art.24857
   Towle CA, 1997, OSTEOARTHR CARTILAGE, V5, P293, DOI 10.1016/S1063 4584(97)80008 8
   Van Dalen SCM, 2017, OSTEOARTHR CARTILAGE, V25, P385, DOI 10.1016/j.joca.2016.09.009
   VANBEUNINGEN HM, 1991, ARTHRITIS RHEUM, V34, P606, DOI 10.1002/art.1780340513
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Yang KGA, 2008, OSTEOARTHR CARTILAGE, V16, P498, DOI 10.1016/j.joca.2007.07.008
NR 74
TC 77
Z9 82
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 13
PY 2017
VL 8
AR 282
DI 10.3389/fphar.2017.00282
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EX3OF
UT WOS:000403141000001
PM 28659793
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Amini, SM
   Emami, T
   Rashidi, M
   Zrrinnahad, H
AF Amini, Seyed Mohammad
   Emami, Tara
   Rashidi, Mehdi
   Zrrinnahad, Hannaneh
TI Curcumin gold nanoformulation: Synthesis, characterizations and
   biomedical application
SO FOOD BIOSCIENCE
LA English
DT Article
DE Gold nanoparticles; Curcumin; Biocompatibility; Neurodegenerative
   diseases; Cancer; Cardiovascular diseases
ID TARGETED DRUG DELIVERY; OSTEOCLAST DIFFERENTIATION; SILVER
   NANOPARTICLES; CANCER; OXIDE; SURFACE; WATER; ANTIOXIDANT; SKIN; PH
AB Due to the different environmental and safety considerations, the green synthesized nanoparticles have been entered into various biomedical applications. As a result of the presence of numerous phytochemicals in the extracts, which often have different speeds and reaction paths and are unknown in many cases, metal nanoparticles synthesized from the extracts of various plants or other biological extracts usually have poor stability and low quality. Curcumin is a unique natural compound that not only presents many health benefits but also has been applied in the synthesis of many nanoparticle formulations of gold nanoparticles. In this review, every nanoformulation that contain gold nanoparticles and the natural phenolic compound of curcumin was investigated, and then the different aspect of synthesis and characterizations including biocompatibility, and antimicrobial and antioxidant efficacy of these formulation were reviewed. Due to the antioxidant properties of both gold nanoparticles and curcumin, most biological and medical applications of nanoparticles made or coated with curcumin are in the treatment or prevention of diseases such as diabetes, osteoarthritis, cancer, cardiovascular, and neurodegenerative diseases.
C1 [Amini, Seyed Mohammad] Iran Univ Med Sci IUMS, Radiat Biol Res Ctr, Tehran, Iran.
   [Emami, Tara] Agr Res Educ & Extens Org AREEO, Razi Vaccine & Serum Res Inst, Adjuvant & Vaccine Formulat Lab, Karaj, Iran.
   [Rashidi, Mehdi] Univ Salento, Dept Biol & Environm Sci & Technol, Via Lecce Monteroni, I 73100 Lecce, Italy.
   [Rashidi, Mehdi] Univ Salento, Dept Math & Phys E Giorgi, Via Lecce Arnesano, I 73100 Arnesano, Lecce, Italy.
   [Zrrinnahad, Hannaneh] Iran Univ Med Sci, Sch Med, Dept Biochem, Tehran, Iran.
C3 Iran University of Medical Sciences; Razi Vaccine & Serum Research
   Institute; University of Salento; University of Salento; Iran University
   of Medical Sciences
RP Amini, SM (通讯作者)，Iran Univ Med Sci IUMS, Radiat Biol Res Ctr, Tehran, Iran.
EM Amini.sm@iums.ac.ir
RI Amini, Seyed/O 9508 2017
FU Iran University of Medical Sciences (IUMS) [1402 3 68 26809,
   99 2 99 18901]
FX This manuscript was funded by Iran University of Medical Sciences (IUMS,
   grant numbers 1402 3 68 26809, 99 2 99 18901) .
CR Abo Elfadl MT, 2016, J PHOTOCH PHOTOBIO B, V164, P21, DOI 10.1016/j.jphotobiol.2016.09.012
   Adlia A, 2018, SCI PHARM, V86, DOI 10.3390/scipharm86040041
   Ahn JC, 2012, INT J ONCOL, V41, P2184, DOI 10.3892/ijo.2012.1661
   Akbari Abolfazl, 2022, Nanomedicine Research Journal, V7, P66, DOI 10.22034/nmrj.2022.01.006
   Al Ani LA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216725
   Alam MI, 2010, EUR J PHARM SCI, V40, P385, DOI 10.1016/j.ejps.2010.05.003
   Aldewachi H, 2018, NANOSCALE, V10, P18, DOI 10.1039/c7nr06367a
   Amanlou N, 2019, MATER CHEM PHYS, V226, P151, DOI 10.1016/j.matchemphys.2018.12.089
   Amini SM, 2023, MED ONCOL, V40, DOI 10.1007/s12032 023 01991 1
   Amini SM, 2023, CURR MICROBIOL, V80, DOI 10.1007/s00284 022 03172 1
   Amini SM, 2021, IET NANOBIOTECHNOL, V15, P329, DOI 10.1049/nbt2.12016
   Amini SM, 2019, J THERM BIOL, V79, P81, DOI 10.1016/j.jtherbio.2018.12.007
   Amini SM, 2018, ARTIF CELL NANOMED B, V46, P1452, DOI 10.1080/21691401.2017.1373656
   An HY, 2020, APPL NANOSCI, V10, P617, DOI 10.1007/s13204 019 01135 w
   Antoine R., 2020, Multidisciplinary digital
   Azharuddin M., 2015, CURR INDIAN EYE RES, V2, P71
   Badirzadeh A, 2022, J DRUG DELIV SCI TEC, V74, DOI 10.1016/j.jddst.2022.103576
   Betrouni N, 2013, IRBM, V34, P28, DOI 10.1016/j.irbm.2012.12.006
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bhatia NK, 2016, RSC ADV, V6, P103275, DOI 10.1039/c6ra24256a
   Bhattacharjee S, 2016, J CONTROL RELEASE, V235, P337, DOI 10.1016/j.jconrel.2016.06.017
   Bhilare NV, 2018, WORLD J HEPATOL, V10, P496, DOI 10.4254/wjh.v10.i7.496
   Bielak Zmijewska A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051239
   Binh N. T., 4 AC C NAT SCI YOUNG
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brasnjevic I, 2009, PROG NEUROBIOL, V87, P212, DOI 10.1016/j.pneurobio.2008.12.002
   Chattopadhyay I, 2004, CURR SCI INDIA, V87, P44
   Cheheltani R, 2016, BIOMATERIALS, V102, P87, DOI 10.1016/j.biomaterials.2016.06.015
   Chen Y, 2012, MOLECULES, V17, P5972, DOI 10.3390/molecules17055972
   Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218
   Costa R, 2017, POWDER TECHNOL, V322, P402, DOI 10.1016/j.powtec.2017.07.086
   Csaki C, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2850
   Cukic Vesna, 2017, Med Arch, V71, P212, DOI 10.5455/medarh.2017.71.212 214
   Campos WND, 2017, CIENC RURAL, V47, DOI 10.1590/0103 8478cr20161001
   Daisy P, 2012, INT J NANOMED, V7, P1189, DOI 10.2147/IJN.S26650
   Danafar H, 2018, IRAN J PHARM RES, V17, P480
   Danafar H, 2017, DRUG RES, V67, P698, DOI 10.1055/s 0043 115905
   Daraee H, 2016, ARTIF CELL NANOMED B, V44, P410, DOI 10.3109/21691401.2014.955107
   Darne PA, 2016, RSC ADV, V6, P68504, DOI 10.1039/c6ra13469f
   Dey S, 2015, J MATER CHEM B, V3, P824, DOI 10.1039/c4tb01731e
   Di Gen hong, 2003, Zhonghua Yi Xue Za Zhi, V83, P1764
   Ding WC, 2015, CHEMPHYSCHEM, V16, P447, DOI 10.1002/cphc.201402648
   Dobrovoiskaia MA, 2008, NANO LETT, V8, P2180, DOI 10.1021/nl0805615
   dos Santos Courrol D., 2016, Journal of Biomedical Engineering and Biosciences (JBEB), V3, P43
   El Kurdi R, 2017, TALANTA, V168, P82, DOI 10.1016/j.talanta.2017.03.021
   Elbialy NS, 2019, BIONANOSCIENCE, V9, P813, DOI 10.1007/s12668 019 00660 w
   Esmaeili bandboni A, 2018, IET NANOBIOTECHNOL, V12, P453, DOI 10.1049/iet nbt.2017.0174
   F Rahimi Moghaddam, 2019, J Biomed Phys Eng, V9, P473, DOI 10.31661/jbpe.v0i0.906
   Fadel M, 2018, DRUG DEV IND PHARM, V44, P1809, DOI 10.1080/03639045.2018.1496451
   Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028
   Gangwar RK, 2012, MAT SCI ENG C MATER, V32, P2659, DOI 10.1016/j.msec.2012.07.022
   Ghorbani M, 2018, EUR J PHARM SCI, V114, P175, DOI 10.1016/j.ejps.2017.12.008
   Gobin AM, 2007, NANO LETT, V7, P1929, DOI 10.1021/nl070610y
   Govindaraju S, 2018, BIOCONJUGATE CHEM, V29, P363, DOI 10.1021/acs.bioconjchem.7b00683
   Grama CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078217
   Gülçin I, 2006, LIFE SCI, V78, P803, DOI 10.1016/j.lfs.2005.05.103
   Gunes H, 2016, TOXICOL IND HEALTH, V32, P246, DOI 10.1177/0748233713498458
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440 1681.2011.05648.x
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   Henrique T. B., 2016, P WORLD C REC ADV NA, P115, DOI [10.11159/nddte16.115, DOI 10.11159/NDDTE16.115]
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hildenbrand G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190183
   Hoshikawa A, 2018, BIOL PHARM BULL, V41, P908, DOI 10.1248/bpb.b18 00010
   Huo SD, 2017, BIOCONJUGATE CHEM, V28, P239, DOI 10.1021/acs.bioconjchem.6b00488
   Innes JF, 2010, VET REC, V166, P226, DOI 10.1136/vr.c97
   Jagannathan R, 2012, J PHYS CHEM B, V116, P14533, DOI 10.1021/jp3050516
   Jana NR, 2003, J CHEM NEUROANAT, V26, P95, DOI 10.1016/S0891 0618(03)00029 2
   Jiménez Pérez ZE, 2018, J GINSENG RES, V42, P327, DOI 10.1016/j.jgr.2017.04.003
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Kapakos G, 2012, INDIAN J BIOCHEM BIO, V49, P306
   Kharat M, 2017, J AGR FOOD CHEM, V65, P1525, DOI 10.1021/acs.jafc.6b04815
   Kim KS, 2006, J MATER CHEM, V16, P1315, DOI 10.1039/b601478j
   Kiziltoprak H, 2019, WORLD J DIABETES, V10, P140, DOI 10.4239/wjd.v10.i3.140
   Kolarijani NR, 2023, WOUND REPAIR REGEN, V31, P804, DOI 10.1111/wrr.13126
   Laprise Pelletier M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701460
   Lee Jin Ho, 2018, Curr Drug Targets, V19, P271, DOI 10.2174/1389450118666170427150257
   Lee WH, 2013, CURR NEUROPHARMACOL, V11, P338, DOI 10.2174/1570159X11311040002
   Liang C., 2014, 2015 INT C MAT SCI A
   Lindner U, 2009, J UROLOGY, V182, P1371, DOI 10.1016/j.juro.2009.06.035
   Liu DD, 2010, CHINESE SCI BULL, V55, P1013, DOI 10.1007/s11434 010 0046 1
   Liu R, 2019, INT J NANOMED, V14, P4091, DOI 10.2147/IJN.S203222
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Manju S, 2012, J COLLOID INTERF SCI, V368, P144, DOI 10.1016/j.jcis.2011.11.024
   Masoudi N., 2019, Iranian Journal of Plant Pathology, V55, P105
   Mohammadi A, 2022, NEUROIMMUNOMODULAT, V29, P4, DOI 10.1159/000517901
   Mohammadi Elham, 2021, Nanomedicine Research Journal, V6, P105, DOI 10.22034/nmrj.2021.02.002
   MOORADIAN A, 1969, PHYS REV LETT, V22, P185, DOI 10.1103/PhysRevLett.22.185
   Muddineti OS, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/32/325101
   Nambiar S, 2018, APPL NANOSCI, V8, P347, DOI 10.1007/s13204 018 0728 6
   Neshastehriz A, 2020, ADV NAT SCI NANOSCI, V11, DOI 10.1088/2043 6254/abb8c7
   Orecchioni M, 2015, THERANOSTICS, V5, P710, DOI 10.7150/thno.11387
   Palmal S, 2014, CHEM EUR J, V20, P6184, DOI 10.1002/chem.201400079
   Patra D, 2015, 2015 IEEE 15TH INTERNATIONAL CONFERENCE ON NANOTECHNOLOGY (IEEE NANO), P401, DOI 10.1109/NANO.2015.7388621
   Pivari F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081837
   Rahimi Moghaddam F, 2018, LASER MED SCI, V33, P1769, DOI 10.1007/s10103 018 2538 1
   Rak MJ, 2014, GREEN CHEM, V16, P86, DOI 10.1039/c3gc41827h
   Ramakrishna S, 2021, DRY TECHNOL, V39, P711, DOI 10.1080/07373937.2020.1758492
   Rao W, 2014, ACTA BIOMATER, V10, P831, DOI 10.1016/j.actbio.2013.10.020
   Rejinold NS, 2014, RSC ADV, V4, P39408, DOI 10.1039/c4ra05727a
   Rezaeian A, 2022, LASER MED SCI, V37, P1333, DOI 10.1007/s10103 021 03399 7
   Salavati MS, 2022, NANO, V17, DOI 10.1142/S1793292022500527
   Scherrmann JM, 2002, VASC PHARMACOL, V38, P349, DOI 10.1016/S1537 1891(02)00202 1
   Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264
   Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023
   Selvakannan PR, 2003, LANGMUIR, V19, P3545, DOI 10.1021/la026906v
   Senft C, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 491
   Shaabani E, 2017, NANOMED J, V4, P115, DOI 10.22038/nmj.2017.21506.1227
   Shahidi F, 2010, EUR J LIPID SCI TECH, V112, P930, DOI 10.1002/ejlt.201000044
   Sharifiaghdam Z, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e14024
   Sharifiaghdam Z, 2022, CLIN EXP PHARMACOL P, V49, P70, DOI 10.1111/1440 1681.13579
   Sharma H, 2015, DRUG DISCOV TODAY, V20, P1143, DOI 10.1016/j.drudis.2015.05.009
   Shem PM, 2009, LANGMUIR, V25, P13279, DOI 10.1021/la903003n
   Siddiqui NA, 2015, PAK J PHARM SCI, V28, P299
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Sindhu K, 2014, RSC ADV, V4, P1808, DOI 10.1039/c3ra45345f
   Sindhu K, 2011, J BIOMED NANOTECHNOL, V7, P56, DOI 10.1166/jbn.2011.1199
   Singh DK, 2013, NANOSCALE, V5, P1882, DOI 10.1039/c2nr33776b
   Singh L. M., 2017, Journal of Applied Pharmaceutical Science, V7, P56
   Singh SP, 2018, INT J BIOL MACROMOL, V110, P375, DOI 10.1016/j.ijbiomac.2017.11.163
   Solgi M, 2014, PHYSIOL MOL BIOL PLA, V20, P279, DOI 10.1007/s12298 014 0237 3
   Song JB, 2015, ACS NANO, V9, P9199, DOI 10.1021/acsnano.5b03804
   Sreelakshmi C, 2013, NANOSCI NANOTECH LET, V5, P1258, DOI 10.1166/nnl.2013.1678
   SRIVASTAVA R, 1985, THROMB RES, V40, P413, DOI 10.1016/0049 3848(85)90276 2
   Stadelmann VA, 2008, EUR CELLS MATER, V16, P10, DOI 10.22203/eCM.v016a02
   Stark WJ, 2015, CHEM SOC REV, V44, P5793, DOI 10.1039/c4cs00362d
   Suryanarayana P, 2003, MOL VIS, V9, P223
   Taghipour Yasamin Davatgaran, 2018, Nanomedicine Research Journal, V3, P102, DOI 10.22034/nmrj.2018.02.007
   Tian BR, 2021, CARBOHYD POLYM, V251, DOI 10.1016/j.carbpol.2020.116871
   Tien HW, 2011, CARBON, V49, P1550, DOI 10.1016/j.carbon.2010.12.022
   Torrisi L, 2018, RADIAT EFF DEFECT S, V173, P729, DOI 10.1080/10420150.2018.1528598
   Umapathi A, 2020, COLLOID SURFACE A, V607, DOI 10.1016/j.colsurfa.2020.125484
   Vu TB, 2009, SPRINGER PROC PHYS, V127, P271
   Walter C, 2008, EUR UROL, V54, P1066, DOI 10.1016/j.eururo.2008.06.070
   Wang FP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/737264
   Wang XH, 2015, J MATER CHEM B, V3, P4036, DOI 10.1039/c5tb00134j
   Wongcharoen W, 2009, INT J CARDIOL, V133, P145, DOI 10.1016/j.ijcard.2009.01.073
   Yang CJ, 2019, AM J PHYSIOL CELL PH, V316, pC135, DOI 10.1152/ajpcell.00136.2018
   Yang XX, 2016, NANOSCALE, V8, P3040, DOI 10.1039/c5nr07918g
   Ye Y, 2014, INT J NANOMED, V9, P5157, DOI 10.2147/IJN.S71365
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
NR 141
TC 33
Z9 34
U1 6
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 4292
EI 2212 4306
J9 FOOD BIOSCI
JI Food Biosci.
PD FEB
PY 2024
VL 57
AR 103446
DI 10.1016/j.fbio.2023.103446
EA DEC 2023
PG 14
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA FO1C5
UT WOS:001146677300001
DA 2025 08 17
ER

PT J
AU Boersma, D
   Demontiero, O
   Amiri, ZM
   Hassan, S
   Suarez, H
   Geisinger, D
   Suriyaarachchi, P
   Sharma, A
   Duque, G
AF Boersma, D.
   Demontiero, O.
   Amiri, Z. Mohtasham
   Hassan, S.
   Suarez, H.
   Geisinger, D.
   Suriyaarachchi, P.
   Sharma, A.
   Duque, G.
TI Vitamin D status in relation to postural stability in the elderly
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Vitamin D; balance; falls; elderly; postural instability; gait velocity
ID PARKINSONS DISEASE; VESTIBULAR DISORDERS; FALL RISK; INSTABILITY;
   BALANCE; PREVENTION; FRACTURES; SPEED; BONE
AB Postural instability (PI) is an important risk factor for falls, especially in the frail older population. In this study, we investigated the impact of vitamin D deficiency on PI in a sample of community dwelling older subjects. Our objective was to determine the potential association between vitamin D deficiency and PI in older fallers.
   Cross sectional study.
   Falls and Fractures Clinic, Department of Geriatric Medicine, Nepean Hospital, Penrith, Australia.
   One hundred and forty five adults aged 65 years and older who have had at least one episode of a fall within the six months prior to assessment at the Falls and Fractures Clinic.
   Serum 25(OH) vitamin D3 [25(OH)D3] and parathyroid hormone concentrations were determined at baseline. Subjects were separated into 3 groups based on serum 25(OH)D3 levels with the following cut off values: < 30 nmol/L (deficient), 30 50 nmol/L (insufficient) and > 50 nmol/L (normal). Other baseline measurements included body mass index, mini nutritional assessment, grip strength, serum calcium concentration and creatinine clearance, which were used as covariables. PI was assessed using a computerized virtual reality system (Medicaa, Uruguay). Measured parameters included limits of stability (LOS) and centre of pressure (COP) under eyes closed on foam (ECF) and visio vestibular stimulation. The estimated swaying area, computed from the ellipse of confidence under eyes closed standing on foam (ECF), was also used as a PI parameter. Gait velocity (GV) was measured using a GaitRITE walkway system.
   Posture was impaired in vitamin D deficiency (< 30 nmol/L) as indicated by lower LOS (90 +/  18), higher ECF (25 +/  10) and slower GV (55 +/  7) as compared with the insufficient and normal groups. After adjustment for demographic, biochemical and anthropometric variables, vitamin D deficiency significantly correlated with low LOS and high COP under ECF.
   Low levels of vitamin D were associated with PI. This association could also have an effect on slow GV and increased risk of falls. In conclusion, using an objective method to measure balance in older fallers we have identified a novel role of vitamin D in balance control. Prospective studies are required to confirm the effect of vitamin D on PI and elucidate the mechanisms of this association.
C1 [Demontiero, O.; Suriyaarachchi, P.; Duque, G.] Univ Sydney, Ageing Bone Res Program, Sydney Med Sch Nepean, Penrith, NSW 2751, Australia.
   [Boersma, D.; Hassan, S.; Sharma, A.] Nepean Hosp, Dept Geriatr Med, Penrith, NSW 2751, Australia.
   [Amiri, Z. Mohtasham] Guilan Univ, Fac Med, Rasht, Iran.
   [Suarez, H.] British Hosp, CLAEH Sch Med, Montevideo, Uruguay.
C3 University of Sydney; Nepean Hospital; University of Sydney; University
   of Guilan
RP Duque, G (通讯作者)，Univ Sydney, Ageing Bone Res Program, Sydney Med Sch Nepean, POB 63, Penrith, NSW 2751, Australia.
EM gustavo.duque@sydney.edu.au
RI Duque, Gustavo/HDO 1243 2022; Mohtasham Amiri, Zahra/C 4469 2012; Duque,
   Gustavo/G 6656 2015
OI Mohtasham Amiri, Zahra/0000 0002 4896 6248; Duque,
   Gustavo/0000 0001 8126 0637
FU Nepean Medical Research Foundation
FX This study was supported by a research grant from the Nepean Medical
   Research Foundation. A/Prof. Duque holds a Fellowship from the
   University of Sydney Medical Research Foundation. Dr Demontiero holds a
   scholarship from The Rebecca Cooper Medical Research Foundation.
CR Annweiler C, 2010, J BONE MINER RES, V25, P1858, DOI 10.1002/jbmr.80
   Binkley N, 2010, ENDOCRIN METAB CLIN, V39, P287, DOI 10.1016/j.ecl.2010.02.008
   Bischoff Ferrari HA, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff Ferrari HA, 2006, OSTEOPOROSIS INT, V17, P656, DOI 10.1007/s00198 005 0030 9
   Bloem BR, 2001, ADV NEUROL, V87, P209
   Cherniack EP, 2008, J NUTR HEALTH AGING, V12, P366, DOI 10.1007/BF02982668
   Delbaere K, 2008, MED J AUSTRALIA, V189, P193, DOI 10.5694/j.1326 5377.2008.tb01980.x
   Djaldetti R, 2006, NEUROL SCI, V27, P412, DOI 10.1007/s10072 006 0720 x
   Espy DD, 2010, GAIT POSTURE, V32, P378, DOI 10.1016/j.gaitpost.2010.06.013
   Horlings CGC, 2008, NAT CLIN PRACT NEURO, V4, P504, DOI 10.1038/ncpneuro0886
   Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532 5415.2005.53455.x
   Minasyan A, 2009, J STEROID BIOCHEM, V114, P161, DOI 10.1016/j.jsbmb.2009.01.020
   Montero Odasso Manuel, 2005, Molecular Aspects of Medicine, V26, P203, DOI 10.1016/j.mam.2005.01.005
   NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111
   O'Donnell S, 2008, J BONE MINER METAB, V26, P531, DOI 10.1007/s00774 008 0868 y
   Robinson K, 2005, NEUROREHABILITATION, V20, P169
   Rossat A, 2010, J NUTR HEALTH AGING, V14, P787, DOI 10.1007/s12603 010 0089 7
   Shahar D, 2009, ANN NUTR METAB, V54, P59, DOI 10.1159/000207356
   Soer R, 2009, ARCH PHYS MED REHAB, V90, P1785, DOI 10.1016/j.apmr.2009.05.008
   Suarez H, 2003, ACTA OTO LARYNGOL, V123, P143, DOI 10.1080/0036554021000028109
   Suarez H, 2000, ACTA OTO LARYNGOL, V120, P168
   Suarez H, 2008, ACTA OTO LARYNGOL, V128, P398, DOI 10.1080/00016480701730018
   Suarez H, 2009, ACTA OTO LARYNGOL, V129, P354, DOI 10.1080/00016480802495446
   Visser JE, 2008, CLIN NEUROPHYSIOL, V119, P2424, DOI 10.1016/j.clinph.2008.07.220
NR 24
TC 37
Z9 42
U1 0
U2 21
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279 7707
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD MAR
PY 2012
VL 16
IS 3
BP 270
EP 275
DI 10.1007/s12603 011 0345 5
PG 6
WC Geriatrics & Gerontology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 929HD
UT WOS:000303051000014
PM 22456785
OA hybrid
DA 2025 08 17
ER

PT J
AU Illescas Montes, R
   Melguizo Rodríguez, L
   García Martínez, O
   de Luna Bertos, E
   Manzano Moreno, FJ
   Ruiz, C
   Ramos Torrecillas, J
AF Illescas Montes, Rebeca
   Melguizo Rodriguez, Lucia
   Garcia Martinez, Olga
   de Luna Bertos, Elvira
   Javier Manzano Moreno, Francisco
   Ruiz, Concepcion
   Ramos Torrecillas, Javier
TI Human Fibroblast Gene Expression Modulation Using 940 NM Diode Laser
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LOW LEVEL LASER; PLATELET RICH PLASMA; GROWTH FACTORS; WOUND REPAIR;
   CLINICAL IMPLICATIONS; THERAPY; DIFFERENTIATION; OSTEOBLAST;
   PHOTOTHERAPY; RADIATION
AB Low Level Laser Therapy is used as regenerative therapy in different clinical fields. This is due to its photobiomodulation effect via cell signaling on different cell populations, Including fibroblasts, cells involved in tissue regeneration and healing. The aim was to analyze the effect of 940 nm diode laser on the gene expression of different markers involved in fibroblast growth, differentiation, and migration. Real time polymerase chain reaction (q RT PCR) was used to quantify the expression of fibroblast growth factor (FGF), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), transforming growth factor beta 1 (TGF beta 1), TGF beta receptors (TGF beta R1, TGF beta R2, and TGF beta R3), discoidin domain receptor 2 (DDR2), matrix metalloproteinase 2 (MMP2), alpha actin, fibronectin, decorin, and elastin on human fibroblast, treated with single dose (T1) or two doses (T2) of diode laser at 0.5 Watts and 4 J/cm(2). A significant increase in the expression of FGF, TGF beta 1, TGF beta R1, TGF beta R2, alpha actin, fibronectin, decorin, DDR2 and MMP2 was observed after both treatments. A decrease was observed in expression of elastin (T1 and T2), and CTGF (T2). These changes underlie the biostimulatory effect of laser on fibroblasts, which translates into an increase in short term proliferation and in long term differentiation to myofibroblasts. These data support the therapeutic potential of diode laser for wound repair.
C1 [Illescas Montes, Rebeca; Melguizo Rodriguez, Lucia; Garcia Martinez, Olga; de Luna Bertos, Elvira; Ruiz, Concepcion; Ramos Torrecillas, Javier] Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada, Spain.
   [Illescas Montes, Rebeca; Melguizo Rodriguez, Lucia; Garcia Martinez, Olga; de Luna Bertos, Elvira; Javier Manzano Moreno, Francisco; Ruiz, Concepcion; Ramos Torrecillas, Javier] Ibs Granada, Inst Invest Biosanitaria Ibs Granada, C Doctor Azpitarte 4,4a Planta, Granada 18012, Spain.
   [Javier Manzano Moreno, Francisco] Univ Granada, Sch Dent, Dept Stomatol, Biomed Grp BIO277, Granada, Spain.
   [Ruiz, Concepcion] Univ Granada, Inst Neurosci, Ctr Invest Biorned CIBM, PTS, Granada, Spain.
C3 University of Granada; Instituto de Investigacion Biosanitaria IBS
   Granada; University of Granada; University of Granada
RP Ruiz, C (通讯作者)，Univ Granada, Fac Hlth Sci, Dept Nursing, Biomed Grp BIO277, Granada, Spain.; Ruiz, C (通讯作者)，Ibs Granada, Inst Invest Biosanitaria Ibs Granada, C Doctor Azpitarte 4,4a Planta, Granada 18012, Spain.; Ruiz, C (通讯作者)，Univ Granada, Inst Neurosci, Ctr Invest Biorned CIBM, PTS, Granada, Spain.
EM crr@ugr.es
RI Illescas Montes, Rebeca/N 5375 2018; Concepcion, Ruiz/L 2808 2014;
   Melguizo Rodríguez, Lucía/F 4683 2018; Ramos Torrecillas,
   Javier/F 3746 2012; Garcia Martinez, Olga/L 2782 2014; Manzano Moreno,
   Francisco/B 1771 2015; Ruiz, Concepcion/L 2808 2014; Illescas Montes,
   Rebeca/F 8700 2016; De Luna Bertos, Elvira/F 8544 2016; García Martínez,
   Olga/L 2782 2014
OI Illescas Montes, Rebeca/0000 0001 9795 8159; Concepcion,
   Ruiz/0000 0003 4332 6812; Ramos Torrecillas, Javier/0000 0002 6631 7866;
   Garcia Martinez, Olga/0000 0003 1912 4639; De Luna Bertos,
   Elvira/0000 0002 4381 5942; Melguizo  Rodriguez,
   Lucia/0000 0002 9176 6997; 
FU research group BIO277 (Junta de Andalucia); Department of Nursing
   (University of Granada); Ministerio de Educacion, Cultura y Deporte
   [FPU15 05635]
FX This study was supported by the research group BIO277 (Junta de
   Andalucia) and Department of Nursing (University of Granada). Ms. Lucia
   Melguizo Rodriguez's work has been founded by the Ministerio de
   Educacion, Cultura y Deporte
   (https://www.mecd.gob.es/mecd/servicios al ciudadano mecd/catalogo/gener
   al/educacion/998758/ficha/998758 2015#dr[5]) grant FPU15 05635.
CR Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524 475X.2008.00410.x
   Barrientos S, 2014, WOUND REPAIR REGEN, V22, P569, DOI 10.1111/wrr.12205
   Bjordal J. M., 2006, ACUTE PAIN, V8, P147
   Capon A, 2003, AM J CLIN DERMATOL, V4, P1, DOI 10.2165/00128071 200304010 00001
   Colombo Fabio, 2013, Braz. Dent. J., V24, P308, DOI 10.1590/0103 6440201301867
   Damante CA, 2009, LASER MED SCI, V24, P885, DOI 10.1007/s10103 008 0582 y
   Darby IA, 2014, CLIN COSMET INV DERM, V7, P301, DOI 10.2147/CCID.S50046
   De Donatis A, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 20
   Eckes B, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 4
   Eduardo CD, 2010, LASER MED SCI, V25, P781, DOI 10.1007/s10103 010 0812 y
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Szezerbaty SKF, 2018, LASER MED SCI, V33, P315, DOI 10.1007/s10103 017 2375 7
   Fiorio FB, 2017, LASER MED SCI, V32, P1769, DOI 10.1007/s10103 017 2254 2
   Santos JDF, 2018, PHOTOMED LASER SURG, V36, P298, DOI 10.1089/pho.2018.4455
   Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039
   Illescas Montes R, 2017, MATERIALS, V10, DOI 10.3390/ma10070793
   Manzano Moreno FJ, 2018, INT J MED SCI, V15, P359, DOI 10.7150/ijms.22627
   Khoo Nooshafarin Kazemi, 2014, Avicenna Journal of Medical Biotechnology, V6, P113
   Kinoda J, 2018, J RADIAT RES, V59, P27, DOI 10.1093/jrr/rrx044
   Klass BR, 2009, POSTGRAD MED J, V85, P9, DOI 10.1136/pgmj.2008.069831
   Kwan P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123054
   Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514
   Machado RS, 2017, LASER MED SCI, V32, P937, DOI 10.1007/s10103 017 2150 9
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P1926, DOI 10.1016/j.jcms.2015.08.026
   Márquez J, 2014, HISTOL HISTOPATHOL, V29, P1355, DOI 10.14670/HH 29.1355
   Martin P, 2015, BRIT J DERMATOL, V173, P370, DOI 10.1111/bjd.13954
   Huertas RM, 2014, BIOL RES NURS, V16, P191, DOI 10.1177/1099800413482695
   Medina Huertas R, 2014, LASER MED SCI, V29, P1479, DOI 10.1007/s10103 014 1557 9
   Nirodi CS, 2000, WOUND REPAIR REGEN, V8, P371, DOI 10.1111/j.1524 475X.2000.00371.x
   Ragni E, 2013, J CELL MOL MED, V17, P168, DOI 10.1111/j.1582 4934.2012.01660.x
   Ramos Torrecillas J, 2015, BIOL RES NURS, V17, P152, DOI 10.1177/1099800414535840
   Ramos Torrecillas J, 2014, ADV SKIN WOUND CARE, V27, P114, DOI 10.1097/01.ASW.0000443266.17665.19
   Rola P, 2014, ADV CLIN EXP MED, V23, P835, DOI 10.17219/acem/37263
   Schmitt L, 2017, LASER MED SCI, V32, P805, DOI 10.1007/s10103 017 2175 0
   Shu DY, 2017, PROG RETIN EYE RES, V60, P44, DOI 10.1016/j.preteyeres.2017.08.001
NR 35
TC 21
Z9 24
U1 1
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 19
PY 2019
VL 9
AR 12037
DI 10.1038/s41598 019 48595 2
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IR6ZQ
UT WOS:000481590200078
PM 31427686
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ghezzi, B
   Lagonegro, P
   Fukata, N
   Parisi, L
   Calestani, D
   Galli, C
   Salviati, G
   Macaluso, GM
   Rossi, F
AF Ghezzi, Benedetta
   Lagonegro, Paola
   Fukata, Naoki
   Parisi, Ludovica
   Calestani, Davide
   Galli, Carlo
   Salviati, Giancarlo
   Macaluso, Guido M.
   Rossi, Francesca
TI Sub Micropillar Spacing Modulates the Spatial Arrangement of Mouse
   MC3T3 E1 Osteoblastic Cells
SO NANOMATERIALS
LA English
DT Article
DE pillar; scaffold; osteoblasts; regenerative medicine
ID DENTAL IMPLANTS; MICROTUBULES; ADHESION; DIFFERENTIATION; TOPOGRAPHY;
   RESPONSES; DYNAMICS; ALLOY; MODEL
AB Surface topography is one of the main factors controlling cell responses on implanted devices and a proper definition of the characteristics that optimize cell behavior may be crucial to improve the clinical performances of these implants. Substrate geometry is known to affect cell shape, as cells try to optimize their adhesion by adapting to the irregularities beneath, and this in turn profoundly affects their activity. In the present study, we cultured murine calvaria MC3T3 E1 cells on surfaces with pillars arranged as hexagons with two different spacings and observed their morphology during adhesion and growth. Cells on these highly ordered substrates attached and proliferated effectively, showing a marked preference for minimizing the inter pillar distance, by following specific pathways across adjacent pillars and displaying consistent morphological modules. Moreover, cell behavior appeared to follow tightly controlled patterns of extracellular protein secretion, which preceded and matched cells and, on a sub cellular level, cytoplasmic orientation. Taken together, these results outline the close integration of surface features, extracellular proteins alignment and cell arrangement, and provide clues on how to control and direct cell spatial order and cell morphology by simply acting on inter pillar spacing.
C1 [Ghezzi, Benedetta; Parisi, Ludovica; Macaluso, Guido M.] Univ Parma, Ctr Univ Odontoiatria, Via Gramsci 14, I 43126 Parma, Italy.
   [Ghezzi, Benedetta; Parisi, Ludovica; Galli, Carlo; Macaluso, Guido M.] Univ Parma, Dipartimento Med & Chirurgia, Via Gramsci 14, I 43126 Parma, Italy.
   [Lagonegro, Paola] Inst Macromol Studies, ISMAC CNR, Via Corti 12, I 20133 Milan, Italy.
   [Lagonegro, Paola; Calestani, Davide; Salviati, Giancarlo; Macaluso, Guido M.; Rossi, Francesca] Inst Mat Elect & Magnetism, IMEM CNR, Parco Area Sci 37 A, I 43124 Parma, Italy.
   [Fukata, Naoki] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton, 1 1 Namiki, Tsukuba, Ibaraki 3050044, Japan.
   [Fukata, Naoki] Univ Tsukuba, Inst Appl Phys, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058573, Japan.
   [Parisi, Ludovica] Univ Bern, Lab Orale Mol Biol, Zahnmed Klin, Klin Kieferorthopadie, Freiburgstr 7, CH 3008 Bern, Switzerland.
C3 University of Parma; University Hospital of Parma; University of Parma;
   University Hospital of Parma; Consiglio Nazionale delle Ricerche (CNR);
   Istituto per lo Studio delle Macromolecole (ISMAC CNR); Consiglio
   Nazionale delle Ricerche (CNR); Istituto dei Materiali per l'Elettronica
   ed il Magnetismo (IMEM CNR); National Institute for Materials Science;
   University of Tsukuba; University of Bern
RP Ghezzi, B (通讯作者)，Univ Parma, Ctr Univ Odontoiatria, Via Gramsci 14, I 43126 Parma, Italy.; Ghezzi, B (通讯作者)，Univ Parma, Dipartimento Med & Chirurgia, Via Gramsci 14, I 43126 Parma, Italy.
EM benedetta.ghezzi@unipr.it; paola.lagonegro@gmail.com;
   FUKATA.Naoki@nims.go.jp; ludovica.parisi@unipr.it;
   davide.calestani@imem.cnr.it; carlo.galli1@unipr.it;
   giancarlo.salviati@cnr.it; guidomaria.macaluso@unipr.it;
   francesca.rossi@imem.cnr.it
RI Fukata, Naoki/H 2634 2011; Rossi, Francesca/A 5997 2012; FUKATA,
   Naoki/H 2634 2011; Calestani, Davide/C 9794 2009; GHEZZI,
   BENEDETTA/ABG 7646 2021; Salviati, Giancarlo/F 4947 2016; Galli,
   Carlo/D 4728 2014; Macaluso, Guido/D 5317 2013; Lagonegro,
   Paola/A 7497 2016
OI Fukata, Naoki/0000 0002 0986 8485; Galli, Carlo/0000 0001 7476 7181;
   Rossi, Francesca/0000 0003 1773 2542; Calestani,
   Davide/0000 0003 3344 8007; Salviati, Giancarlo/0000 0002 9828 6371;
   GHEZZI, BENEDETTA/0000 0002 8922 2915
CR Albert PJ, 2016, CELL ADHES MIGR, V10, P516, DOI 10.1080/19336918.2016.1148864
   Anselme K, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701154
   Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018 017 2511 3
   Boyan B D, 2016, Adv Dent Res, V28, P10, DOI 10.1177/0022034515624444
   Buser D, 2017, PERIODONTOL 2000, V73, P7, DOI 10.1111/prd.12185
   Calzado Martín A, 2011, ACTA BIOMATER, V7, P1890, DOI 10.1016/j.actbio.2010.11.035
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Galli C, 2011, J DENT RES, V90, P360, DOI 10.1177/0022034510386488
   Ganguly A, 2012, J BIOL CHEM, V287, P43359, DOI 10.1074/jbc.M112.423905
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Ghezzi B, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6241 y
   Ghibaudo M, 2011, LAB CHIP, V11, P805, DOI [10.1039/c0lc00221f, 10.1039/c01c00221f]
   Gittens RA, 2014, ACTA BIOMATER, V10, P2907, DOI 10.1016/j.actbio.2014.03.032
   Gittens RA, 2012, BIOMATERIALS, V33, P8986, DOI 10.1016/j.biomaterials.2012.08.059
   Hasturk O, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6059 z
   Hasturk O, 2019, COLLOID SURFACE B, V178, P44, DOI 10.1016/j.colsurfb.2019.02.037
   Jevasuwan W, 2017, JPN J APPL PHYS, V56, DOI 10.7567/JJAP.56.04CP01
   Khalili AA, 2015, INT J MOL SCI, V16, P18149, DOI 10.3390/ijms160818149
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Lagonegro P, 2018, DENT MATER J, V37, P278, DOI 10.4012/dmj.2017 008
   Luo YZ, 2008, J BIOMECH, V41, P2379, DOI 10.1016/j.jbiomech.2008.05.026
   Matschegewski C, 2010, BIOMATERIALS, V31, P5729, DOI 10.1016/j.biomaterials.2010.03.073
   Moerke C, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 5982 8
   Moerke C, 2016, BIOMATERIALS, V76, P102, DOI 10.1016/j.biomaterials.2015.10.030
   Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117
   Nardone G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15321
   Parisi L, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9101407
   RENNISON ME, 1992, J CELL SCI, V102, P239
   Rupp F, 2018, DENT MATER, V34, P40, DOI 10.1016/j.dental.2017.09.007
   Schmoranzer J, 2003, J CELL SCI, V116, P4513, DOI 10.1242/jcs.00748
   Seo CH, 2011, BIOMATERIALS, V32, P9568, DOI 10.1016/j.biomaterials.2011.08.077
   Smeets R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6285620
   Sundell G, 2017, ACTA BIOMATER, V48, P445, DOI 10.1016/j.actbio.2016.11.044
   Ting M, 2017, J ORAL IMPLANTOL, V43, P58, DOI 10.1563/aaid joi D 16 00079
   Toffoli A, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110250
   Tomakidi P, 2014, CELL TISSUE RES, V357, P515, DOI 10.1007/s00441 014 1945 2
   Truong D, 2018, INT J NUMER METH BIO, V34, DOI 10.1002/cnm.3097
   Ulmer J, 2008, SOFT MATTER, V4, P1998, DOI 10.1039/b808020h
   Yin CC, 2017, J BIOMED MATER RES A, V105, P757, DOI 10.1002/jbm.a.35941
   Zhang XL, 2019, ACS NANO, V13, P13403, DOI 10.1021/acsnano.9b06821
NR 42
TC 10
Z9 10
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4991
J9 NANOMATERIALS BASEL
JI Nanomaterials
PD DEC
PY 2019
VL 9
IS 12
AR 1701
DI 10.3390/nano9121701
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KB7MY
UT WOS:000506675800057
PM 31795174
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xiong, L
   Xiao, Q
   Chen, R
   Huang, LM
   Gao, J
   Wang, L
   Li, GS
   Li, Y
AF Xiong, Lin
   Xiao, Qiong
   Chen, Rong
   Huang, Liming
   Gao, Jun
   Wang, Li
   Li, Guisen
   Li, Yi
TI Histone deacetylase 9 promotes osteogenic trans differentiation of
   vascular smooth muscle cells via ferroptosis in chronic kidney disease
   vascular calcification
SO RENAL FAILURE
LA English
DT Article
DE HDAC9; ferroptosis; vascular calcification; vascular smooth muscle cell;
   osteogenic trans differentiation
AB Vascular calcification, a common complication of chronic kidney disease (CKD), remains an unmet therapeutic challenge. The trans differentiation of vascular smooth muscle cells (VSMCs) into osteoblast like cells is crucial in the pathogenesis of vascular calcification in CKD. Despite ferroptosis promotes vascular calcification in CKD, the upstream or downstream regulatory mechanisms involved remains unclear. In this study, we aimed to investigate the regulatory mechanism involved in ferroptosis in CKD vascular calcification. Transcriptome sequencing revealed a potential relationship between HDAC9 and ferroptosis in CKD vascular calcification. Subsequently, we observed increased expression of HDAC9 in calcified arteries of patients undergoing hemodialysis and in a rat model of CKD. We further demonstrated that knockout of HDAC9 attenuates osteogenic trans differentiation and ferroptosis in VSMCs stimulated by high calcium and phosphorus. In addition, RSL3 exacerbated ferroptosis and osteogenic trans differentiation of VSMCs exposed to high levels of calcium and phosphorus, and these effects were suppressed to some extent by HDAC9 knockout. In summary, our findings suggest that HDAC9 promotes VSMCs osteogenic trans differentiation involving ferroptosis, providing new insights for the therapy of CKD vascular calcification.
C1 [Xiong, Lin; Xiao, Qiong; Chen, Rong; Huang, Liming; Wang, Li; Li, Guisen; Li, Yi] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Clin Res Ctr Kidney Dis, Sch Med,Dept Nephrol,Clin Immunol Translat Med Key, Chengdu 610072, Peoples R China.
   [Xiong, Lin; Xiao, Qiong; Chen, Rong; Huang, Liming; Wang, Li; Li, Guisen; Li, Yi] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Clin Res Ctr Kidney Dis, Inst Nephrol,Sch Med,Clin Immunol Translat Med Key, Chengdu 610072, Peoples R China.
   [Gao, Jun] Sichuan Prov Ctr Dis Prevent & Control, Dept Toxicol Inspect, Chengdu, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China
RP Li, Y (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Clin Res Ctr Kidney Dis, Sch Med,Dept Nephrol,Clin Immunol Translat Med Key, Chengdu 610072, Peoples R China.
EM liyisn@med.uestc.edu.cn
RI Li, Guisen/AAS 9461 2021; LI, YI/IWE 3479 2023
FU National Natural Science Foundation of China [U21A20349, 82270729,
   82070690]; Projects from Department of Science and Technology of Sichuan
   Province [24NSFSC1735, 2023ZYD0170]
FX This work was supported by National Natural Science Foundation of China
   (U21A20349, 82270729, and 82070690); Projects from Department of Science
   and Technology of Sichuan Province (24NSFSC1735 and 2023ZYD0170).
CR Abbasian N, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070804
   Bai T, 2020, FREE RADICAL BIO MED, V160, P92, DOI 10.1016/j.freeradbiomed.2020.07.026
   Bikbov B, 2020, LANCET, V395, P709, DOI 10.1016/S0140 6736(20)30045 3
   Cantrell AC, 2024, J CARDIOVASC PHARM, V83, P23, DOI 10.1097/FJC.0000000000001496
   Chen J, 2017, JAMA CARDIOL, V2, P635, DOI 10.1001/jamacardio.2017.0363
   Chen Xinlei, 2020, AUTOPHAGY, DOI DOI 10.1080/15548627.2020.1810918
   Chen YB, 2020, ARTERIOSCL THROM VAS, V40, P1078, DOI 10.1161/ATVBAHA.120.313131
   Chung WS, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/6293185
   Cirovic A, 2021, J TRACE ELEM MED BIO, V68, DOI 10.1016/j.jtemb.2021.126822
   Cozzolino M, 2018, NEPHROL DIAL TRANSPL, V33, P28, DOI 10.1093/ndt/gfy174
   Ding NN, 2023, J CELL PHYSIOL, V238, P1160, DOI 10.1002/jcp.31021
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Hu CT, 2021, CLIN CHIM ACTA, V519, P101, DOI 10.1016/j.cca.2021.04.012
   Jin SJ, 2024, BIOMED PHARMACOTHER, V174, DOI 10.1016/j.biopha.2024.116457
   Johansen KL, 2023, AM J KIDNEY DIS, V81, pA8, DOI 10.1053/j.ajkd.2022.12.001
   Lan ZR, 2022, J PATHOL, V258, P213, DOI 10.1002/path.5992
   Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2298 2
   Li M, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04923 5
   Ma WQ, 2021, FREE RADICAL BIO MED, V165, P229, DOI 10.1016/j.freeradbiomed.2021.01.033
   Malhotra R, 2019, NAT GENET, V51, P1580, DOI 10.1038/s41588 019 0514 8
   Rukov JL, 2016, AM J PHYSIOL RENAL, V310, pF477, DOI 10.1152/ajprenal.00472.2015
   Swartling O, 2021, AM J KIDNEY DIS, V78, P190, DOI 10.1053/j.ajkd.2020.11.026
   Tian WB, 2022, LANCET REG HEALTH W, V23, DOI 10.1016/j.lanwpc.2022.100460
   Van den Bergh G, 2019, TRENDS MOL MED, V25, P1133, DOI 10.1016/j.molmed.2019.08.006
   Voelkl J, 2018, J CLIN INVEST, V128, P3024, DOI 10.1172/JCI96477
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xu X, 2024, BIOMED PHARMACOTHER, V171, DOI 10.1016/j.biopha.2023.116112
   Yang YF, 2024, REDOX BIOL, V70, DOI 10.1016/j.redox.2024.103067
   Ye YZ, 2022, KIDNEY INT, V102, P1259, DOI 10.1016/j.kint.2022.07.034
   Yun HR, 2022, J AM SOC NEPHROL, V33, P1590, DOI 10.1681/ASN.2022010080
   Yüzbasioglu Y, 2024, TOXICS, V12, DOI 10.3390/toxics12010069
   Zhang CH, 2024, LIFE SCI, V340, DOI 10.1016/j.lfs.2024.122439
   Zhang HT, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.10909
   Zhou XB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku310
NR 35
TC 0
Z9 1
U1 2
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0886 022X
EI 1525 6049
J9 RENAL FAILURE
JI Ren. Fail.
PD DEC 31
PY 2024
VL 46
IS 2
AR 2422435
DI 10.1080/0886022X.2024.2422435
PG 15
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA L2N7J
UT WOS:001349145500001
PM 39500708
OA gold
DA 2025 08 17
ER

PT J
AU Oertel, S
   Thiemann, M
   Richter, K
   Weber, KJ
   Huber, PE
   Perez, RL
   Brons, S
   Bischof, M
   Kulozik, AE
   Ehemann, V
   Debus, J
   Blattmann, C
AF Oertel, Susanne
   Thiemann, Markus
   Richter, Karsten
   Weber, Klaus J
   Huber, Peter E.
   Perez, Ramon Lopez
   Brons, Stephan
   Bischof, Marc
   Kulozik, Andreas E.
   Ehemann, Volker
   Debus, Juergen
   Blattmann, Claudia
TI Combination of suberoylanilide hydroxamic acid with heavy ion therapy
   shows promising effects in infantile sarcoma cell lines
SO RADIATION ONCOLOGY
LA English
DT Article
DE Infantile sarcoma; histone deacetylase inhibition; heavy ion
   radiotherapy; suberoylanilide hydroxamic acid; SAHA
ID HISTONE DEACETYLASE INHIBITORS; IN VITRO; H2AX PHOSPHORYLATION;
   RADIATION RESPONSE; GAMMA H2AX FOCI; CANCER THERAPY; STRAND BREAKS;
   RADIOTHERAPY; SENSITIVITY; APOPTOSIS
AB Introduction: The pan HDAC inhibitor (HDACI) suberoylanilide hydroxamic acid (SAHA) has previously shown to be a radio sensitizer to conventional photon radiotherapy (XRT) in pediatric sarcoma cell lines. Here, we investigate its effect on the response of two sarcoma cell lines and a normal tissue cell line to heavy ion irradiation (HIT).
   Materials and methods: Clonogenic assays after different doses of heavy ions were performed. DNA damage and repair were evaluated by measuring gamma H2AX via flow cytometry. Apoptosis and cell cycle analysis were also measured via flow cytometry. Protein expression of repair proteins, p53 and p21 were measured using immunoblot analysis. Changes of nuclear architecture after treatment with SAHA and HIT were observed in one of the sarcoma cell lines via light microscopy after staining towards chromatin and gamma H2AX.
   Results: Corresponding with previously reported photon data, SAHA lead to an increase of sensitivity to heavy ions along with an increase of DSB and apoptosis in the two sarcoma cell lines. In contrast, in the osteoblast cell line (hFOB 1.19), the combination of SAHA and HIT showed a significant radio protective effect. Laser scanning microscopy revealed no significant morphologic changes after HIT compared to the combined treatment with SAHA. Immunoblot analysis revealed no significant up or down regulation of p53. However, p21 was significantly increased by SAHA and combination treatment as compared to HIT only in the two sarcoma cell lines   again in contrast to the osteoblast cell line. Changes in the repair kinetics of DSB p53 independent apoptosis with p21 involvement may be part of the underlying mechanisms for radio sensitization by SAHA.
   Conclusion: Our in vitro data suggest an increase of the therapeutic ratio by the combination of SAHA with HIT in infantile sarcoma cell lines.
C1 [Oertel, Susanne; Thiemann, Markus; Weber, Klaus J; Bischof, Marc; Debus, Juergen] Univ Heidelberg, Dept Radiooncol, D 69120 Heidelberg, Germany.
   [Richter, Karsten] German Canc Res Ctr, Core Facil Elect Microscopy, D 69120 Heidelberg, Germany.
   [Huber, Peter E.; Perez, Ramon Lopez] German Canc Res Ctr, Dept Radiat Oncol, D 69120 Heidelberg, Germany.
   [Brons, Stephan] Heidelberger Ionentherapiezentrum HIT, D 69120 Heidelberg, Germany.
   [Kulozik, Andreas E.; Blattmann, Claudia] Univ Childrens Hosp, Dept Pediat Oncol Hematol & Immunol, D 69120 Heidelberg, Germany.
   [Ehemann, Volker] Univ Heidelberg, Inst Pathol, D 69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ); Helmholtz Association; German Cancer
   Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht
   Karls University Heidelberg
RP Oertel, S (通讯作者)，Univ Heidelberg, Dept Radiooncol, INF 400, D 69120 Heidelberg, Germany.
EM susanne.oertel@med.uni heidelberg.de
RI ; Kulozik, Andreas/AAO 2432 2020
OI Lopez Perez, Ramon/0000 0002 6876 2074; 
FU Dietmar Hopp Stiftung, Germany
FX We would like to thank Sylvia Trinh, Ludmilla Frick and Gabriele Becker
   for their excellent technical work. This work was supported by the
   Dietmar Hopp Stiftung, Germany.
CR Banáth JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008 5472.CAN 04 1433
   Baschnagel A, 2009, MOL CANCER THER, V8, P1589, DOI 10.1158/1535 7163.MCT 09 0038
   Blakely EA, 2009, CANCER J, V15, P271, DOI 10.1097/PPO.0b013e3181b666c5
   Blattmann C, 2010, INT J RADIAT ONCOL, V78, P237, DOI 10.1016/j.ijrobp.2010.03.010
   Blattmann C, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 96
   Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008 5472.CAN 03 2630
   Camphausen K, 2007, J CLIN ONCOL, V25, P4051, DOI 10.1200/JCO.2007.11.6202
   Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088
   Chung YL, 2009, CARCINOGENESIS, V30, P1387, DOI 10.1093/carcin/bgp079
   Dalgard CL, 2008, CLIN CANCER RES, V14, P3113, DOI 10.1158/1078 0432.CCR 07 4836
   DILLER KJ, 1990, MOL CELL BIOL, V10, P5772
   Furchert SE, 2007, INT J CANCER, V120, P1787, DOI 10.1002/ijc.22401
   Hada M, 2006, RADIAT RES, V165, P223, DOI 10.1667/RR3498.1
   Hamada N, 2010, J RADIAT RES, V51, P365, DOI 10.1269/jrr.09137
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Huo JX, 2004, CELL DEATH DIFFER, V11, P99, DOI 10.1038/sj.cdd.4401322
   Kano M, 2009, ANTICANCER RES, V29, P4433
   Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417
   Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095
   Mills J, 2011, MOL CANCER THER, V10, P313, DOI 10.1158/1535 7163.MCT 10 0724
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Munshi A, 2006, MOL CANCER THER, V5, P1967, DOI 10.1158/1535 7163.MCT 06 0022
   O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679
   Oishi T, 2008, NEUROPATHOLOGY, V28, P408, DOI 10.1111/j.1440 1789.2008.00899.x
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585
   STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85
   Storch K, 2010, CANCER RES, V70, P3925, DOI 10.1158/0008 5472.CAN 09 3848
   Takahashi A, 2005, INT J RADIAT BIOL, V81, P581, DOI 10.1080/09553000500280484
   Takahashi T, 2010, ANTICANCER RES, V30, P1961
   Vasireddy RS, 2010, BRIT J CANCER, V102, P1511, DOI 10.1038/sj.bjc.6605666
   Wilson AJ, 2010, CANCER RES, V70, P609, DOI 10.1158/0008 5472.CAN 09 2327
   Xu Y, 2011, CELL CYCLE, V10, P261, DOI 10.4161/cc.10.2.14543
   Yang C, 2011, CANCER CHEMOTH PHARM, V67, P439, DOI 10.1007/s00280 010 1344 7
NR 34
TC 15
Z9 17
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748 717X
J9 RADIAT ONCOL
JI Radiat. Oncol.
PD SEP 20
PY 2011
VL 6
AR 119
DI 10.1186/1748 717X 6 119
PG 11
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 845XD
UT WOS:000296859700001
PM 21933400
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, ZL
   Liu, CX
   Xie, ZH
   Song, PY
   Zhao, RCH
   Guo, L
   Liu, ZG
   Wu, YJ
AF Li, Zhilong
   Liu, Chenxiong
   Xie, Zhenhua
   Song, Pengyue
   Zhao, Robert C. H.
   Guo, Ling
   Liu, Zhigang
   Wu, Yaojiong
TI Epigenetic Dysregulation in Mesenchymal Stem Cell Aging and Spontaneous
   Differentiation
SO PLOS ONE
LA English
DT Article
ID STROMAL CELLS; MYOCARDIAL INFARCTION; HISTONE ACETYLATION; DNA
   METHYLATION; CARDIAC REPAIR; SELF RENEWAL; IN VITRO; TRANSPLANTATION;
   MICE; EXPRESSION
AB Background: Mesenchymal stem cells (MSCs) hold great promise for the treatment of difficult diseases. As MSCs represent a rare cell population, ex vivo expansion of MSCs is indispensable to obtain sufficient amounts of cells for therapies and tissue engineering. However, spontaneous differentiation and aging of MSCs occur during expansion and the molecular mechanisms involved have been poorly understood.
   Methodology/Principal Findings: Human MSCs in early and late passages were examined for their expression of genes involved in osteogenesis to determine their spontaneous differentiation towards osteoblasts in vitro, and of genes involved in self renewal and proliferation for multipotent differentiation potential. In parallel, promoter DNA methylation and hostone H3 acetylation levels were determined. We found that MSCs underwent aging and spontaneous osteogenic differentiation upon regular culture expansion, with progressive downregulation of TERT and upregulation of osteogenic genes such as Runx2 and ALP. Meanwhile, the expression of genes associated with stem cell self renewal such as Oct4 and Sox2 declined markedly. Notably, the altered expression of these genes were closely associated with epigenetic dysregulation of histone H3 acetylation in K9 and K14, but not with methylation of CpG islands in the promoter regions of most of these genes. bFGF promoted MSC proliferation and suppressed its spontaneous osteogenic differentiation, with corresponding changes in histone H3 acetylation in TERT, Oct4, Sox2, Runx2 and ALP genes.
   Conclusions/Significance: Our results indicate that histone H3 acetylation, which can be modulated by extrinsic signals, plays a key role in regulating MSC aging and differentiation.
C1 [Li, Zhilong; Liu, Chenxiong; Xie, Zhenhua; Song, Pengyue; Guo, Ling; Wu, Yaojiong] Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Shenzhen 518057, Peoples R China.
   [Li, Zhilong; Liu, Chenxiong; Liu, Zhigang] Shenzhen Univ, Sch Med, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China.
   [Zhao, Robert C. H.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Cell Biol, Ctr Excellence Tissue Engn, Beijing 100730, Peoples R China.
   [Zhao, Robert C. H.] Peking Union Med Coll, Sch Basic Med, Beijing 100021, Peoples R China.
C3 Tsinghua University; Tsinghua Shenzhen International Graduate School;
   State Key Laboratory of Respiratory Disease; Shenzhen University;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Basic Medical Sciences   CAMS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College
RP Li, ZL (通讯作者)，Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Shenzhen 518057, Peoples R China.
EM LZG@szu.edu.cn; wu.yaojiong@sz.tsinghua.edu.cn
RI zhao, chunhua/MZR 1130 2025; Guo, Ling/JVZ 8417 2024
OI Guo, Ling/0000 0003 1118 6798
FU Natural Science Foundation of China [30871273, 30971496, U1032003];
   National Basic Research Program [2009CB522108]
FX This work was supported by grants from the Natural Science Foundation of
   China (No. 30871273, 30971496, U1032003) to Y.W. and by the National
   Basic Research Program (No. 2009CB522108) to L.Z.G. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092 8674(02)01077 2
   Aguayo Mazzucato C, 2010, NAT REV ENDOCRINOL, V6, P139, DOI 10.1038/nrendo.2009.274
   Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
   Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027
   Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474 9726.2009.00535.x
   Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood 2006 12 063412
   Chen LW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007119
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Frith JE, 2010, TISSUE ENG PART C ME, V16, P735, DOI [10.1089/ten.tec.2009.0432, 10.1089/ten.TEC.2009.0432]
   Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22 5 649
   Gereige LM, 2009, NAT GENET, V41, P1164, DOI 10.1038/ng1109 1164
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Horwitz EM, 2006, CYTOTHERAPY, V8, P194, DOI 10.1080/14653240600758562
   Jin HK, 2002, J CLIN INVEST, V109, P1183, DOI 10.1072/JCI200214862
   Joggerst SJ, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001124
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Liao LM, 2008, STEM CELLS DEV, V17, P613, DOI 10.1089/scd.2008.0183
   Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e
   Liu LH, 2006, STEM CELLS DEV, V15, P349, DOI 10.1089/scd.2006.15.349
   Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092 8674(01)00490 1
   Lyssiotis CA, 2007, P NATL ACAD SCI USA, V104, P14982, DOI 10.1073/pnas.0707044104
   MacDonald VE, 2009, EPIGENETICS US, V4, P139, DOI 10.4161/epi.4.3.8484
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Martino G, 2010, NAT REV NEUROL, V6, P247, DOI 10.1038/nrneurol.2010.35
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   Nishida H, 2006, CHROMOSOME RES, V14, P203, DOI 10.1007/s10577 006 1036 7
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Philippe B, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/503593
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Potapova IA, 2008, J BIOL CHEM, V283, P13100, DOI 10.1074/jbc.M800184200
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Shi MX, 2007, HAEMATOLOGICA, V92, P897, DOI 10.3324/haematol.10669
   Sotiropoulou PA, 2006, STEM CELLS, V24, P462, DOI 10.1634/stemcells.2004 0331
   Szulc P, 2005, BONE, V36, P13, DOI 10.1016/j.bone.2004.09.004
   Tan J, 2008, J GENET GENOMICS, V35, P585, DOI 10.1016/S1673 8527(08)60079 X
   Wang SF, 2008, J BIOL CHEM, V283, P35929, DOI 10.1074/jbc.M804091200
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Wu YJ, 2010, STEM CELLS, V28, P905, DOI 10.1002/stem.420
   Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004 0098
   YU JM, 2010, AGING CELL
   Zhang HJ, 2008, PLACENTA, V29, P549, DOI 10.1016/j.placenta.2008.03.003
   Zhao SM, 2010, STEM CELLS DEV, V19, P607, DOI 10.1089/scd.2009.0345
NR 47
TC 169
Z9 194
U1 0
U2 46
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2011
VL 6
IS 6
AR e20526
DI 10.1371/journal.pone.0020526
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 777JX
UT WOS:000291612900013
PM 21694780
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Bobeica, C
   Rebegea, L
   Murariu, G
   Dobre, M
   Nechita, A
   Tatu, AL
   Niculet, E
   Anghel, L
   Fotea, S
   Craescu, M
AF Bobeica, Carmen
   Rebegea, Laura
   Murariu, Gabriel
   Dobre, Michaela
   Nechita, Aurel
   Tatu, Alin Laurentiu
   Niculet, Elena
   Anghel, Lucretia
   Fotea, Silvia
   Craescu, Mihaela
TI Cutaneous adverse reactions in a lung cancer patient treated with
   pembrolizumab: A case report
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE lung cancer; therapeutic strategy; pembrolizumab; cutaneous adverse
   effects; PD L1
AB Lung cancer is the main cause of oncological death in the US and worldwide, constituting a significant public health problem. The incidence of lung cancer is on the increase. In the present study, the diagnostic process was carried out and treatment options were considered to determine the therapeutic response of a patient diagnosed with lung cancer. The case of an early stage lung cancer patient who benefited from surgical treatment was presented. The pathology report stated the complete diagnosis to be pleomorphic lung cancer with an adenocarcinoma component, pT2aN0M0, with focal positivity for thyroid transcription factor 1 (TTF1), without epidermal growth factor receptor (EGFR) mutations and ALK recombinations, having an initial clinical stage of IB and programmed death ligand 1 (PD L1) positivity with a tumor proportion score of over 70%. The patient underwent radiotherapy treatment and was administered osteoclast inhibitors and immunotherapy, with no favorable therapeutic effect and with the presence of secondary cutaneous adverse effects to pembrolizumab. As a main cause of death, lung cancer registers a low general survival rate even in patients with targeted therapies or immunotherapy. By better identifying the patients at risk, one can establish a more efficient personalized treatment; the future objective of scientific studies is the follow up of adverse effects of new therapies.
C1 [Bobeica, Carmen; Dobre, Michaela; Niculet, Elena; Craescu, Mihaela] Univ Galatzi, Fac Med & Pharm, Dept Morphol & Funct Sci, 35 Alexandru Ioan Cuza St, Galati 800010, Romania.
   [Rebegea, Laura; Nechita, Aurel; Tatu, Alin Laurentiu; Anghel, Lucretia; Fotea, Silvia] Univ Galatzi, Fac Med & Pharm, Clin Med Dept, Galati 800010, Romania.
   [Murariu, Gabriel] Univ Galatzi, Fac Sci & Environm, Dept Chem Phys & Environm, 111 Domneasca St, Galati 800201, Romania.
   [Tatu, Alin Laurentiu] Univ Galatzi, Res Ctr Field Med & Pharmaceut Sci, ReFORM UDJ, Galati 800010, Romania.
   [Niculet, Elena] Sfantul Apostol Andrei Emergency Clin Hosp, Dept Pathol, Galati 800578, Romania.
   [Craescu, Mihaela] Sfantul Apostol Andrei Emergency Clin Hosp, Dept Clin Radiotherapy, Galati 800578, Romania.
C3 Dunarea De Jos University Galati; Dunarea De Jos University Galati;
   Dunarea De Jos University Galati; Dunarea De Jos University Galati
RP Niculet, E (通讯作者)，Univ Galatzi, Fac Med & Pharm, Dept Morphol & Funct Sci, 35 Alexandru Ioan Cuza St, Galati 800010, Romania.; Murariu, G (通讯作者)，Univ Galatzi, Fac Sci & Environm, Dept Chem Phys & Environm, 111 Domneasca St, Galati 800201, Romania.
EM gabriel_murariu@yahoo.com; helena_badiu@yahoo.com
RI Fotea, Silvia/AAB 5212 2021; Anghel, Lucretia/AAN 6597 2020; REBEGEA,
   LAURA/LZF 2725 2025; Dobre, Michaela/AAZ 4176 2020; Alin,
   Laurentiu/R 6812 2016; Niculet, Elena/AAC 5287 2020; Murariu,
   Gabriel/JXN 5841 2024
FU 'Dunarea de Jos' University of Galati, Romania, through the research
   center  Multidisciplinary Integrated Center of Dermatological Interface
   Research (MIC DIC) [Centrul Integrat Multidisciplinar de Cercetare de
   Interfata Dermatologica (CIM CID)]
FX The current work was academically supported by the 'Dunarea de Jos'
   University of Galati, Romania, through the research center
    Multidisciplinary Integrated Center of Dermatological Interface
   Research (MIC DIC) [Centrul Integrat Multidisciplinar de Cercetare de
   Interfata Dermatologica (CIM CID)].
CR Auperin A, 2010, LANCET, V375, P1267, DOI 10.1016/S0140 6736(10)60059 1
   Bhatlapenumarthi V, 2021, J CANCER RES CLIN, V147, P2789, DOI 10.1007/s00432 021 03610 w
   Biton J, 2018, CLIN CANCER RES, V24, P5710, DOI 10.1158/1078 0432.CCR 18 0163
   Blandino G, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0705 7
   Bobeica C, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9509
   Bobeica C, 2020, EXP THER MED, V20, P61, DOI 10.3892/etm.2020.8572
   Coleman Emily, 2018, JAAD Case Rep, V4, P669, DOI 10.1016/j.jdcr.2018.06.022
   Craescu M, 2019, ACTA MEDICA MEDITERR, V35, P1493, DOI 10.19193/0393 6384_2019_3_231
   Cretu A, 2015, MED SURG J, V119, P55
   Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001
   Dobre M, 2015, FARMACIA, V63, P402
   Fekete GL, 2019, EXP THER MED, V18, P5052, DOI 10.3892/etm.2019.8169
   Fekete GL, 2012, ACTA DERMATOVENER CR, V20, P34
   Fidler Benaoudia MM, 2020, INT J CANCER, V147, P811, DOI 10.1002/ijc.32809
   Flaten HK, 2017, CARDIOVASC DRUG THER, V31, P471, DOI 10.1007/s10557 017 6733 2
   Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824
   Gheorghe I, 2017, ROM BIOTECH LETT, V22, P12321
   Haanen J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 000604
   Hwang Shelley Ji Eun, 2018, Curr Probl Dermatol, V53, P82, DOI 10.1159/000478081
   Jáuregui Garrido B, 2012, NUTR HOSP, V27, P1866, DOI 10.3305/nh.2012.27.6.6127
   Johnson JA, 2012, ANN MED, V44, pS17, DOI 10.3109/07853890.2011.653399
   Joshi N, 2018, REACT WKLY, V1704, P304
   Lee Matthew, 2019, Case Rep Dermatol Med, V2019, P4065437, DOI 10.1155/2019/4065437
   Mohler J.L., 2019, J NATL COMPR CANC NE
   Niculet E, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9693
   Niculet E, 2020, CLIN COSMET INV DERM, V13, P1041, DOI 10.2147/CCID.S224211
   Nomori H, 2004, J THORAC CARDIOV SUR, V127, P1087, DOI 10.1016/j.jtcvs.2003.08.010
   Nwabudike LC, 2019, J EUR ACAD DERMATOL, V33, pE3, DOI 10.1111/jdv.15084
   Nwabudike LC, 2018, REV CHIM BUCHAREST, V69, P2557
   Ozmen S., 2020, J SURG MED, V4, P112
   Riihimäki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020
   Sanlorenzo M, 2015, JAMA DERMATOL, V151, P1206, DOI 10.1001/jamadermatol.2015.1916
   Simonsen AB, 2020, J AM ACAD DERMATOL, V83, P1415, DOI 10.1016/j.jaad.2020.04.058
   Sui HS, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6984948
   Tatu AL, 2019, EXP THER MED, V18, P955, DOI 10.3892/etm.2019.7504
   Tatu AL, 2018, REV CHIM BUCHAREST, V69, P2110
   Winer A, 2018, J THORAC DIS, V10, pS480, DOI 10.21037/jtd.2018.01.111
   Wu CH, 2019, CANCER MED US, V8, P5850, DOI 10.1002/cam4.2492
   Zhou HY, 2014, ONCOL LETT, V7, P1395, DOI 10.3892/ol.2014.1920
NR 39
TC 2
Z9 2
U1 0
U2 22
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2022
VL 23
IS 1
AR 15
DI 10.3892/etm.2021.10937
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA WY6AL
UT WOS:000719360500001
PM 34815767
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU van der Heijden, L
   Gibbons, CLMH
   Dijkstra, PDS
   Kroep, JR
   van Rijswijk, CSP
   Nout, RA
   Bradley, KM
   Athanasou, NA
   Hogendoorn, PCW
   van de Sande, MAJ
AF van der Heijden, L.
   Gibbons, C. L. M. H.
   Dijkstra, P. D. S.
   Kroep, J. R.
   van Rijswijk, C. S. P.
   Nout, R. A.
   Bradley, K. M.
   Athanasou, N. A.
   Hogendoorn, P. C. W.
   van de Sande, M. A. J.
TI The management of diffuse type giant cell tumour (pigmented villonodular
   synovitis) and giant cell tumour of tendon sheath (nodular
   tenosynovitis)
SO JOURNAL OF BONE AND JOINT SURGERY BRITISH VOLUME
LA English
DT Article
ID PARTIAL ARTHROSCOPIC SYNOVECTOMY; RADIATION TREATMENT;
   SURGICAL TREATMENT; LARGE JOINTS; KNEE; IMATINIB; TRANSLOCATION;
   OSTEOCLASTS; EXPRESSION; YTTRIUM 90
AB Giant cell tumours (GCT) of the synovium and tendon sheath can be classified into two forms: localised (giant cell tumour of the tendon sheath, or nodular tenosynovitis) and diffuse (diffuse type giant cell tumour or pigmented villonodular synovitis). The former principally affects the small joints. It presents as a solitary slow growing tumour with a characteristic appearance on MRI and is treated by surgical excision. There is a significant risk of multiple recurrences with aggressive diffuse disease. A multidisciplinary approach with dedicated MRI, histological assessment and planned surgery with either adjuvant radiotherapy or systemic targeted therapy is required to improve outcomes in recurrent and refractory diffuse type GCT.
   Although arthroscopic synovectomy through several portals has been advocated as an alternative to arthrotomy, there is a significant risk of inadequate excision and recurrence, particularly in the posterior compartment of the knee. For local disease partial arthroscopic synovectomy may be sufficient, at the risk of recurrence. For both local and diffuse intra articular disease open surgery is advised for recurrent disease. Marginal excision with focal disease will suffice, not dissimilar to the treatment of GCT of tendon sheath. For recurrent and extra articular soft tissue disease adjuvant therapy, including intra articular radioactive colloid or moderate dose external beam radiotherapy, should be considered.
C1 [van der Heijden, L.; Dijkstra, P. D. S.; van de Sande, M. A. J.] Leiden Univ, Med Ctr, Dept Orthoped Surg, NL 2300 RC Leiden, Netherlands.
   [Kroep, J. R.; Nout, R. A.] Leiden Univ, Med Ctr, Dept Clin Oncol, NL 2300 RC Leiden, Netherlands.
   [van Rijswijk, C. S. P.] Leiden Univ, Med Ctr, Dept Radiol, NL 2300 RC Leiden, Netherlands.
   [Hogendoorn, P. C. W.] Leiden Univ, Med Ctr, Dept Pathol, NL 2300 RC Leiden, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University   Excl LUMC; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University; Leiden
   University Medical Center (LUMC); Leiden University   Excl LUMC; Leiden
   University   Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC)
RP van der Heijden, L (通讯作者)，Leiden Univ, Med Ctr, Dept Orthoped Surg, Postzone J11 70,POB 9600, NL 2300 RC Leiden, Netherlands.
EM l.van_der_heijden@lumc.nl
RI van de Sande, Michiel/N 9607 2019; Kennedy, Kristen/B 4699 2008;
   Dijkstra, Sander/F 2513 2017; Hogendoorn, Pancras C W/H 5859 2015; van
   Rijswijk, Catharina/JOK 6416 2023; Hogendoorn, Pancras/H 5859 2015; van
   de Sande, Michiel/K 4611 2017; van der Heijden, Lizz/AAH 6707 2020
OI van der Heijden, Lizz/0000 0003 4440 793X; Bradley,
   Kevin/0000 0003 1911 3382; Hogendoorn, Pancras C W/0000 0002 1513 8104;
   Kroep, Judith/0000 0003 2671 1903; van de Sande,
   Michiel/0000 0002 9156 7656; 
CR Akinci O, 2011, ACTA ORTHOP TRAUMATO, V45, P149, DOI 10.3944/AOTT.2011.2442
   [Anonymous], 2002, PATHOLOGY GENETICS T
   Berger B, 2007, INT J RADIAT ONCOL, V67, P1130, DOI 10.1016/j.ijrobp.2006.10.016
   Bertoni F, 1997, AM J SURG PATHOL, V21, P153, DOI 10.1097/00000478 199702000 00004
   Blanco CER, 2001, ARTHROSCOPY, V17, P527, DOI 10.1053/jars.2001.24068
   Blay JY, 2008, ANN ONCOL, V19, P821, DOI 10.1093/annonc/mdn033
   Cassier PA, 2012, CANCER AM CANCER SOC, V118, P1649, DOI 10.1002/cncr.26409
   Chin KR, 2002, J BONE JOINT SURG AM, V84A, P2192, DOI 10.2106/00004623 200212000 00011
   Cupp JS, 2007, AM J SURG PATHOL, V31, P970, DOI 10.1097/PAS.0b013e31802b86f8
   Darling JM, 1997, AM J PATHOL, V150, P1383
   De Ponti A, 2003, ARTHROSCOPY, V19, P602, DOI 10.1016/S0749 8063(03)00127 0
   de Visser E, 1999, ARCH ORTHOP TRAUM SU, V119, P401, DOI 10.1007/s004020050009
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   FLANDRY FC, 1994, CLIN ORTHOP RELAT R, P183
   FRANSSEN MJAM, 1989, ANN RHEUM DIS, V48, P1007, DOI 10.1136/ard.48.12.1007
   Giannini C, 1996, J NEUROSURG, V84, P592, DOI 10.3171/jns.1996.84.4.0592
   Gibbons CLMH, 2002, J BONE JOINT SURG BR, V84B, P1000, DOI 10.1302/0301 620X.84B7.13115
   GUMPEL JM, 1991, ANN RHEUM DIS, V50, P531, DOI 10.1136/ard.50.8.531
   Hamlin BR, 1998, J BONE JOINT SURG AM, V80A, P76, DOI 10.2106/00004623 199801000 00013
   Heyd R, 2010, INT J RADIAT ONCOL, V78, P199, DOI 10.1016/j.ijrobp.2009.07.1747
   Horoschak M, 2009, INT J RADIAT ONCOL, V75, P183, DOI 10.1016/j.ijrobp.2008.10.058
   Jaffe HL, 1941, ARCH PATHOL, V31, P731
   JONES FE, 1969, J BONE JOINT SURG AM, VA 51, P76, DOI 10.2106/00004623 196951010 00005
   Kat S, 2000, NUKLEARMED NUCL MED, V39, P209
   Labek G, 2011, J BONE JOINT SURG BR, V93B, P293, DOI 10.1302/0301 620X.93B3.25467
   Lau YS, 2005, HUM PATHOL, V36, P945, DOI 10.1016/j.humpath.2005.07.005
   Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370
   Mahendra G, 2010, J CLIN PATHOL, V63, P75, DOI 10.1136/jcp.2009.070342
   Mankin H, 2011, J SURG ONCOL, V103, P386, DOI 10.1002/jso.21835
   MOORE JR, 1984, J HAND SURG AM, V9A, P412, DOI 10.1016/S0363 5023(84)80233 6
   Murphey MD, 2008, RADIOGRAPHICS, V28, P1493, DOI 10.1148/rg.285085134
   Nassar Wael A M, 2009, HSS J, V5, P19, DOI 10.1007/s11420 008 9104 5
   Neale SD, 1997, J CLIN PATHOL, V50, P605, DOI 10.1136/jcp.50.7.605
   O'Sullivan B, 2005, INT J RADIAT ONCOL, V63, pS50, DOI 10.1016/j.ijrobp.2005.07.088
   OGILVIEHARRIS DJ, 1992, J BONE JOINT SURG AM, V74A, P119, DOI 10.2106/00004623 199274010 00015
   OSULLIVAN B, 1995, INT J RADIAT ONCOL, V32, P777, DOI 10.1016/0360 3016(95)00514 Y
   Ottaviani S, 2011, SEMIN ARTHRITIS RHEU, V40, P539, DOI 10.1016/j.semarthrit.2010.07.005
   Ozturk H, 2008, SAUDI MED J, V29, P1197
   RAO AS, 1984, J BONE JOINT SURG AM, V66A, P76, DOI 10.2106/00004623 198466010 00012
   Ravi V, 2011, CURR OPIN ONCOL, V23, P361, DOI 10.1097/CCO.0b013e328347e1e3
   Salomao DR, 2002, OXFORD TXB ORTHOPAED, V1, P211
   SCHWARTZ HS, 1989, CLIN ORTHOP RELAT R, P243
   Shabat S, 2002, RHEUMATOLOGY, V41, P1113, DOI 10.1093/rheumatology/41.10.1113
   Sharma V, 2009, CLIN ORTHOP RELAT R, V467, P2852, DOI 10.1007/s11999 009 0922 7
   Somerhausen N de St. Aubain, 2002, PATHOLOGY GENETICS T, P112
   Taylor R, 2011, J PATHOL, V225, P151, DOI 10.1002/path.2937
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Vastel L, 2005, J BONE JOINT SURG AM, V87A, P1019, DOI 10.2106/JBJS.C.01297
   West RB, 2006, P NATL ACAD SCI USA, V103, P690, DOI 10.1073/pnas.0507321103
   WOOD GS, 1988, AM J SURG PATHOL, V12, P444, DOI 10.1097/00000478 198806000 00004
   Wu CC, 2007, KNEE, V14, P99, DOI 10.1016/j.knee.2006.10.014
   Zvijac JE, 1999, ARTHROSCOPY, V15, P613, DOI 10.1053/ar.1999.v15.015061
NR 52
TC 60
Z9 60
U1 0
U2 7
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 0301 620X
J9 J BONE JOINT SURG BR
JI J. Bone Joint Surg. Br. Vol.
PD JUL
PY 2012
VL 94B
IS 7
BP 882
EP 888
DI 10.1302/0301 620X.94B7.28927
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 980VZ
UT WOS:000306923600003
PM 22733940
DA 2025 08 17
ER

PT J
AU Sundaram, MS
   Hemshekhar, M
   Thushara, RM
   Santhosh, MS
   Kumar, SKN
   Paul, M
   Devaraja, S
   Kemparaju, K
   Rangappa, KS
   Girish, KS
AF Sundaram, Mahalingam Shanmuga
   Hemshekhar, Mahadevappa
   Thushara, Ram M.
   Santhosh, Martin Sebastin
   Kumar, Somanathapura K. Naveen
   Paul, Manoj
   Devaraja, Sannaningaiah
   Kemparaju, Kempaiah
   Rangappa, Kanchugarakoppal S.
   Girish, Kesturu S.
TI Tamarind seed extract mitigates the liver oxidative stress in arthritic
   rats
SO FOOD & FUNCTION
LA English
DT Article
ID MITOCHONDRIAL DYSFUNCTION; SYNOVIAL FLUID; GLUTATHIONE; BRAIN; ACID;
   CYTOKINES; ENZYMES; ASSAY
AB Although arthritis is primarily a joint disorder that mainly targets the articular cartilage and subchondral bone, several recent investigations have reported oxidative burst and vital organ damage that are being considered as secondary complications of arthritis. The continuous generation of free radicals like reactive oxygen and nitrogen species is considered as a key culprit in the initiation and propagation of oxidative damage. In addition, activation of T and B cells, macrophages, inflammatory mediators such as TNF alpha, IL 1 beta and IL 6 aggravates the oxidative damage of the vital organs, particularly the liver. The current piece of work demonstrates oxidative stress in the liver of arthritic rats and its amelioration by the procyanidin rich tamarind seed extract (TSE). The arthritic liver homogenate, mitochondrial and cytosolic fractions were found with increased levels of oxidative stress markers including free radicals. As a consequence, depletion in the levels of glutathione, total thiols, glutathione peroxidase and reductase was evident. Furthermore, the activities of endogenous antioxidant enzymes like superoxide dismutase, catalase and glutathione S transferase were found to be significantly altered. The increased and decreased activity of transaminases respectively in serum and liver, along with histological observations, further confirms the liver damage. Unfortunately, the commonly used drugs like NSAIDs and DMARDs have failed to prevent oxidative damage, rather they were found to be the inducers themselves. Interestingly, TSE supplementation was found to significantly inhibit oxidative burst in the liver and maintain homeostasis. Thus, the study clearly demonstrates the protective efficacy of TSE against arthritis associated oxidative liver damage, including mitochondrial oxidative burst and its associated secondary complications.
C1 [Sundaram, Mahalingam Shanmuga; Hemshekhar, Mahadevappa; Thushara, Ram M.; Santhosh, Martin Sebastin; Kumar, Somanathapura K. Naveen; Paul, Manoj; Kemparaju, Kempaiah; Girish, Kesturu S.] Univ Mysore, Dept Studies Biochem, Mysore 570006, Karnataka, India.
   [Devaraja, Sannaningaiah; Girish, Kesturu S.] Tumkur Univ, Dept Studies & Res Biochem, Tumkur 572103, Karnataka, India.
   [Rangappa, Kanchugarakoppal S.] Univ Mysore, Dept Studies Chem, Mysore 570006, Karnataka, India.
C3 University of Mysore; Tumkur University; University of Mysore
RP Sundaram, MS (通讯作者)，Univ Mysore, Dept Studies Biochem, Mysore 570006, Karnataka, India.
EM ksgbaboo@gmail.com
RI ; KS, Girish/GWZ 7128 2022; Paul, Manoj/NKP 3648 2025
OI Paul, Manoj/0009 0009 3111 2383; Mahalingam, Shanmuga
   Sundaram/0000 0001 6121 0771; Hemshekhar,
   Mahadevappa/0000 0002 5016 501X; KS, Girish/0000 0002 7284 3707
FU UGC BSR SAP
FX MSS thanks UGC BSR SAP for the research fellowship. MSS also thanks Dr
   Naveen S, Scientist, DFRL, Mysore, Mr Raghunandan P and Mr Manjunath MJ,
   CFTRI, Mysore for their timely help. The authors thank Central
   instrumentation facility, Institute of excellence (IOE), University of
   Mysore.
CR Aebi H, 1984, Methods Enzymol, V105, P121
   Aygün D, 2012, HISTOL HISTOPATHOL, V27, P417, DOI 10.14670/HH 27.417
   Biniecka M, 2011, ARTHRITIS RHEUM US, V63, P2172, DOI 10.1002/art.30395
   Botsoglou N, 2010, FOOD CHEM TOXICOL, V48, P944, DOI 10.1016/j.fct.2010.01.004
   CARLBERG I, 1985, METHOD ENZYMOL, V113, P484
   Chandankhede M. S., 2013, International Journal Biology Medical Research, V4, P3088
   Chandrashekar KN, 2010, AMINO ACIDS, V38, P817, DOI 10.1007/s00726 009 0288 x
   Comar JF, 2013, FREE RADICAL BIO MED, V58, P144, DOI 10.1016/j.freeradbiomed.2012.12.003
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Driver AS, 2000, NEUROTOXICOL TERATOL, V22, P175, DOI 10.1016/S0892 0362(99)00069 0
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003 9861(59)90090 6
   Fedatto ZJ, 2000, INFLAMM RES, V49, P128, DOI 10.1007/s000110050570
   Giustarini D, 2011, MECH AGEING DEV, V132, P141, DOI 10.1016/j.mad.2011.02.001
   GUTHENBERG C, 1985, METHOD ENZYMOL, V113, P507
   Hajizadeh S, 2003, ARTHRITIS RES THER, V5, pR234, DOI 10.1186/ar787
   Havinga RM, 2010, J ETHNOPHARMACOL, V127, P573, DOI 10.1016/j.jep.2009.11.028
   Hemshekhar M, 2013, BIOCHIMIE, V95, P1326, DOI 10.1016/j.biochi.2013.02.014
   Hemshekhar M, 2012, BIOCHIMIE, V94, P2723, DOI 10.1016/j.biochi.2012.08.013
   Hemshekhar M, 2011, NUTS AND SEEDS IN HEALTH AND DISEASE PREVENTION, P1107, DOI 10.1016/B978 0 12 375688 6.10131 8
   Islas Flores H, 2013, ECOTOX ENVIRON SAFE, V92, P32, DOI 10.1016/j.ecoenv.2013.01.025
   Kelmer Bracht AM, 2003, BBA MOL BASIS DIS, V1638, P50, DOI 10.1016/S0925 4439(03)00041 3
   KOSTYUK VA, 1989, BIOCHEM INT, V19, P1117
   Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891 5849(98)00216 0
   Kundu S, 2012, FREE RADICAL RES, V46, P1482, DOI 10.3109/10715762.2012.727991
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   Lohr G. W., 1974, METHOD ENZYMAT AN, P636
   López Armada MJ, 2013, MITOCHONDRION, V13, P106, DOI 10.1016/j.mito.2013.01.003
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MOKRASCH LC, 1984, ANAL BIOCHEM, V140, P506, DOI 10.1016/0003 2697(84)90201 X
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003 2697(79)90738 3
   Sharma S, 2011, FOOD CHEM TOXICOL, V49, P3395, DOI 10.1016/j.fct.2011.08.013
   Sudjaroen Y, 2005, FOOD CHEM TOXICOL, V43, P1673, DOI 10.1016/j.fct.2005.05.013
   Sutipornpalangkul W, 2009, INT J RHEUM DIS, V12, P324, DOI 10.1111/j.1756 185X.2009.01430.x
   Tastekin N, 2007, PHARMACOL RES, V56, P303, DOI 10.1016/j.phrs.2007.07.008
   Ushanandini S, 2006, PHYTOTHER RES, V20, P851, DOI 10.1002/ptr.1951
   Vaamonde García C, 2012, ARTHRITIS RHEUM US, V64, P2927, DOI 10.1002/art.34508
NR 36
TC 20
Z9 21
U1 0
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD MAR
PY 2014
VL 5
IS 3
BP 587
EP 597
DI 10.1039/c3fo60381d
PG 11
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA AD4MU
UT WOS:000333226000021
PM 24500568
DA 2025 08 17
ER

PT J
AU Aulin, C
   Lassacher, T
   Palmblad, K
   Harris, HE
AF Aulin, C.
   Lassacher, T.
   Palmblad, K.
   Harris, H. Erlandsson
TI Early stage blockade of the alarmin HMGB1 reduces cartilage destruction
   in experimental OA
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE HMGB1; Experimental osteoarthritis; HMGB1 blockade; Hyaluronan; Therapy;
   Cartilage protection
ID BOX CHROMOSOMAL PROTEIN 1; ARTICULAR CARTILAGE; GENE EXPRESSION;
   MOBILITY; OSTEOARTHRITIS; ARTHRITIS; MICE; PATHOGENESIS; INFLAMMATION;
   MEDIATOR
AB Objective: The alarmin HMGB1 is an endogenous molecule that is released into the extracellular space upon trauma or cell activation. Extracellular HMGB1 initiates innate immune responses and besides mediating inflammation, has osteoclast activating features and mediates pain, all important features in OA. The aim of this study was to examine the involvement of HMGB1 in experimental OA and to explore the effect of local anti HMGB1 therapy on disease progression.
   Method: OA was induced in mice by surgical destabilization of knee joints and HMGB1 expression and localization was assessed by immunohistochemistry. For therapy evaluation, HMGB1 neutralizing antibodies were injected intraarticularly, alone or encapsulated in an injectable hyaluronan based delivery vehicle. Human primary chondrocytes were stimulated with rHMGB1 and analyzed by qPCR and cytometric bead array.
   Results: HMGB1 immunostaining of mouse OA joints demonstrated intra  and pericellular expression in chondrocytes, overlapping with proteoglycan depleted areas. Intra articular injection of anti HMGB1 antibodies had cartilage protective effects, comparable to treatment with a TNF inhibitor. Direct and vehicle based delivery had similar ameliorating effects and the effect of a single, early injection could not be enhanced by repeated injections. In vitro stimulation of chondrocytes with rHMGB1 affected chondrocyte function by inducing protein expression of IL6 and IL8 and downregulating mRNA of COL2A1.
   Conclusions: Our results suggest that the alarmin HMGB1 might be a new target for OA therapy development as we could observe an aberrant HMGB1 expression in mouse OA joints, stimulation of chondrocytes with rHMGB1 induced cytokine production and decreased matrix production and finally that HMGB1 blockade suppressed disease progression. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
C1 [Aulin, C.; Lassacher, T.; Harris, H. Erlandsson] Karolinska Inst, Ctr Mol Med, Dept Med Solna, SE 17176 Stockholm, Sweden.
   [Aulin, C.; Lassacher, T.; Harris, H. Erlandsson] Karolinska Univ Hosp, Div Rheumatol, SE 17176 Stockholm, Sweden.
   [Palmblad, K.] Karolinska Univ Hosp, Karolinska Inst, Dept Women & Child Hlth, Unit Pediat Rheumatol, SE 17176 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska University
   Hospital; Karolinska Institutet; Karolinska University Hospital
RP Aulin, C (通讯作者)，Karolinska Univ Hosp, Karolinska Inst, Div Rheumatol, Ctr Mol Med,Dept Med Solna, SE 17176 Stockholm, Sweden.
EM cecilia.aulin@ki.se; teresa.lassacher2504@gmail.com;
   karin.palmblad@sll.se; helena.harris@ki.se
RI Erlandsson Harris, Helena/JIX 1073 2023; Aulin, Cecilia/HLX 8284 2023
OI Aulin, Cecilia/0000 0001 9408 7394; 
FU Ulla Hamberg Angeby and Lennart Angeby foundation; KI Research Board;
   Hagelens Foundation; Nanna Svartz Foundation; Swedish Research Council;
   af Ugglas Foundation
FX The authors wish to acknowledge Ulla Hamberg Angeby and Lennart Angeby
   foundation, KI Research Board, Hagelens Foundation, Nanna Svartz
   Foundation, the Swedish Research Council and af Ugglas Foundation for
   funding.
CR Agalave NM, 2014, MOL MED, V20, P569, DOI 10.2119/molmed.2014.00176
   Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365 2796.2003.01303.x
   Andersson U, 2018, EXPERT OPIN THER TAR, V22, P263, DOI 10.1080/14728222.2018.1439924
   [Anonymous], CLIN EXP RHEUMATOL
   Aulin C, 2017, OSTEOARTHR CARTILAGE, V25, P157, DOI 10.1016/j.joca.2016.08.011
   Aulin C, 2011, J TISSUE ENG REGEN M, V5, pE188, DOI 10.1002/term.415
   Bianchi ME, 2017, IMMUNOL REV, V280, P74, DOI 10.1111/imr.12601
   Ding L, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/2642549
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Hamada T, 2013, NAGOYA J MED SCI, V75, P101
   Heinola T, 2010, CLIN EXP RHEUMATOL, V28, P511
   Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548
   Jiang WW, 2007, NAT CLIN PRACT RHEUM, V3, P52, DOI 10.1038/ncprheum0379
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Ke XR, 2015, CLIN LAB, V61, P809, DOI 10.7754/Clin.Lab.2015.141205
   Kim S, 2013, MOL MED, V19, P88, DOI 10.2119/molmed.2012.00306
   Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161
   Kokkola R, 2002, ARTHRITIS RHEUM, V46, P2598, DOI 10.1002/art.10540
   Kyostio Moore S, 2011, COMPARATIVE MED, V61, P346
   Lee G, 2018, P NATL ACAD SCI USA, V115, pE4463, DOI 10.1073/pnas.1802893115
   Li WZ, 2019, CELL CYCLE, V18, P2268, DOI 10.1080/15384101.2019.1642680
   Liang S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01378
   Lundbäck P, 2016, HEPATOLOGY, V64, P1699, DOI 10.1002/hep.28736
   Rosenberg JH, 2017, MOL CELL BIOCHEM, V436, P59, DOI 10.1007/s11010 017 3078 x
   Schierbeck H, 2011, MOL MED, V17, P1039, DOI 10.2119/molmed.2010.00264
   Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739
   SUMMERS KL, 1995, J RHEUMATOL, V22, P1326
   Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859
   Terada C, 2011, ACTA MED OKAYAMA, V65, P369
   Vincent T, 2002, P NATL ACAD SCI USA, V99, P8259, DOI 10.1073/pnas.122033199
   Vincent TL, 2007, OSTEOARTHR CARTILAGE, V15, P752, DOI 10.1016/j.joca.2007.01.021
   Vincent TL, 2013, CURR OPIN PHARMACOL, V13, P449, DOI 10.1016/j.coph.2013.01.010
   Wagner G, 2021, CARTILAGE, V12, P484, DOI 10.1177/1947603519835897
   Wähämaa H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3450
   Yang H, 2015, J EXP MED, V212, P5, DOI 10.1084/jem.20141318
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 37
TC 32
Z9 36
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD MAY
PY 2020
VL 28
IS 5
BP 698
EP 707
DI 10.1016/j.joca.2020.01.003
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA NH1YW
UT WOS:000564473700018
PM 31982563
OA hybrid
DA 2025 08 17
ER

PT J
AU Lazennec, G
   Jorgensen, C
AF Lazennec, Gwendal
   Jorgensen, Christian
TI Concise review: Adult multipotent stromal cells and cancer: Risk or
   benefit?
SO STEM CELLS
LA English
DT Article
DE multipotent stromal cells; mesenchymal stem cells; cellular therapy;
   cancer; cellular proliferation; angiogenesis; chemokines
ID MESENCHYMAL STEM CELLS; PROLIFERATION IN VITRO; HUMAN ADIPOSE TISSUE;
   MULTI LINEAGE CELLS; VERSUS HOST DISEASE; PROGENITOR CELLS;
   TARGETED DELIVERY; TUMOR GROWTH; GENE TRANSFER; NK CELLS
AB stromal cells (MSCs) and carcinoma and the possible use of MSCs in cell based anticancer therapies. MSCs are present in multiple tissues and are defined as cells displaying the ability to differentiate in multiple lineages, including chondrocytes, osteoblasts, and adipocytes. Recent evidence also suggests that they could play a role in the progression of carcinogenesis and that MSCs could migrate toward primary tumors and metastatic sites. It is possible that MSCs could also be involved in the early stages of carcinogenesis through spontaneous transformation. In addition, it is thought that MSCs can modulate tumor growth and metastasis, although this issue remains controversial and not well understood. The immunosuppressive properties and proangiogenic properties of MSCs account, at least in part, for their effects on cancer development. On the other hand, cancer cells also have the ability to enhance MSC migration. This complex dialog between MSCs and cancer cells is certainly critical for the outcome of tumor development. Interestingly, several studies have shown that MSCs engineered to express antitumor factors could be an innovative choice as a cell mediated gene therapy to counteract tumor growth. More evidence will be needed to understand how MSCs positively or negatively modulate carcinogenesis and to evaluate the safety of MSC use in cell mediated gene strategies.
C1 [Lazennec, Gwendal; Jorgensen, Christian] INSERM, U844, F 34091 Montpellier 5, France.
   [Lazennec, Gwendal; Jorgensen, Christian] Univ Montpellier I, Montpellier, France.
C3 Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier
RP Lazennec, G (通讯作者)，INSERM, U844, Site St Eloi,Batiment INM,80 Rue Augustin Fliche, F 34091 Montpellier 5, France.
EM Gwendal.Lazennec@inserm.fr
OI Lazennec, Gwendal/0000 0002 8522 1763
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Ali S, 2007, CANCER METAST REV, V26, P401, DOI 10.1007/s10555 007 9073 z
   Angoulvant D, 2004, BIORHEOLOGY, V41, P469
   Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301 472X(01)00769 X
   Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008 5472.CAN 06 4690
   Bhatia Rinky, 2005, Congest Heart Fail, V11, P87, DOI 10.1111/j.1527 5299.2005.03618.x
   Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008 5472.CAN 04 2218
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648
   Chen MF, 2006, INT J RADIAT ONCOL, V66, P244, DOI 10.1016/j.ijrobp.2006.03.062
   Chen XC, 2006, CARCINOGENESIS, V27, P2434, DOI 10.1093/carcin/bgl069
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood 2005 07 2657
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165 2478(03)00108 1
   De Ugarte DA, 2003, CELLS TISSUES ORGANS, V174, P101, DOI 10.1159/000071150
   Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood 2002 06 1830
   Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood 2003 04 1193
   Djouad F, 2006, TRANSPLANTATION, V82, P1060, DOI 10.1097/01.tp.0000236098.13804.0b
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078 0432.CCR 07 0731
   Elzaouk L, 2006, EXP DERMATOL, V15, P865, DOI 10.1111/j.1600 0625.2006.00479.x
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Fierro FA, 2004, CLIN EXP METASTAS, V21, P313, DOI 10.1023/B:CLIN.0000046130.79363.33
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood 2004 09 3696
   Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005 0319
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513
   Hung SC, 2004, INT J CANCER, V110, P313, DOI 10.1002/ijc.20126
   Igura K, 2004, CYTOTHERAPY, V6, P543, DOI 10.1080/14653240410005366 1
   Kanehira M, 2007, CANCER GENE THER, V14, P894, DOI 10.1038/sj.cgt.7701079
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Koç ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Komarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535 7163.MCT 05 0334
   Kucerova L, 2007, CANCER RES, V67, P6304, DOI 10.1158/0008 5472.CAN 06 4024
   Kyriakou CA, 2006, J GENE MED, V8, P253, DOI 10.1002/jgm.840
   Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301 472X(03)00110 3
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Li H, 2007, CANCER RES, V67, P10889, DOI 10.1158/0008 5472.CAN 07 2665
   Li XQ, 2006, HEMATOL ONCOL, V24, P151, DOI 10.1002/hon.779
   Liu CH, 2005, CYTOKINE, V32, P270, DOI 10.1016/j.cyto.2005.11.003
   Maestroni GJM, 1999, CELL MOL LIFE SCI, V55, P663, DOI 10.1007/s000180050322
   Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005 0403
   Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008 5472.CAN 04 1874
   Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276
   Ohlsson LB, 2003, EXP MOL PATHOL, V75, P248, DOI 10.1016/j.yexmp.2003.06.001
   Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142
   Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495
   Pisati F, 2007, CANCER RES, V67, P3054, DOI 10.1158/0008 5472.CAN 06 1384
   Pittenger M., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P309
   Poggi A, 2005, J IMMUNOL, V175, P6352, DOI 10.4049/jimmunol.175.10.6352
   Potian JA, 2003, J IMMUNOL, V171, P3426, DOI 10.4049/jimmunol.171.7.3426
   Ramasamy R, 2007, LEUKEMIA, V21, P304, DOI 10.1038/sj.leu.2404489
   Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80
   Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008 5472.CAN 05 1696
   Ringdén O, 2005, APMIS, V113, P813, DOI 10.1111/j.1600 0463.2005.apm_336.x
   Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008 5472.CAN 04 4194
   Rubio D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001398
   Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07 8832com
   Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651
   Serakinci N, 2006, REGEN MED, V1, P125, DOI 10.2217/17460751.1.1.125
   Shima Y, 2007, BIOCHEM BIOPH RES CO, V353, P60, DOI 10.1016/j.bbrc.2006.11.137
   Sohara Y, 2005, CANCER RES, V65, P1129, DOI 10.1158/0008 5472.CAN 04 2853
   Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood 2005 07 2775
   Stoff Khalili MA, 2007, BREAST CANCER RES TR, V105, P157, DOI 10.1007/s10549 006 9449 8
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Studeny M, 2002, CANCER RES, V62, P3603
   Sudres M, 2006, J IMMUNOL, V176, P7761, DOI 10.4049/jimmunol.176.12.7761
   Sun B, 2005, STEM CELLS DEV, V14, P292, DOI 10.1089/scd.2005.14.292
   't Anker PS, 2003, EXP HEMATOL, V31, P881, DOI 10.1016/S0301 472X(03)00202 9
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027
   Tropel P, 2006, STEM CELLS, V24, P2868, DOI 10.1634/stemcells.2005 0636
   Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279
   Wang Y, 2005, CYTOTHERAPY, V7, P509, DOI 10.1080/14653240500363216
   Wülling M, 2003, HUM PATHOL, V34, P983, DOI 10.1053/S0046 8177(03)00413 1
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475
   Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood 2005 04 1496
   Zhu W, 2006, EXP MOL PATHOL, V80, P267, DOI 10.1016/j.yexmp.2005.07.004
   Zvaifler NJ, 2000, ARTHRITIS RES, V2, P477, DOI 10.1186/ar130
NR 93
TC 203
Z9 222
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD JUN
PY 2008
VL 26
IS 6
BP 1387
EP 1394
DI 10.1634/stemcells.2007 1006
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 315VF
UT WOS:000256907600001
PM 18388305
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, MY
   Zheng, HS
   Xu, K
   Yuan, QL
   Aihaiti, Y
   Cai, YS
   Xu, P
AF Yang, Mingyi
   Zheng, Haishi
   Xu, Ke
   Yuan, Qiling
   Aihaiti, Yirixaiti
   Cai, Yongsong
   Xu, Peng
TI A novel signature to guide osteosarcoma prognosis and immune
   microenvironment: Cuproptosis related lncRNA
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE osteosarcoma; LncRNA; immunity; prognosis; cuproptosis
ID IDENTIFICATION; APOPTOSIS; SURVIVAL; CELLS
AB ObjectiveOsteosarcoma (OS) is a common bone malignancy with poor prognosis. We aimed to investigate the relationship between cuproptosis related lncRNAs (CRLncs) and the survival outcomes of patients with OS. MethodsTranscriptome and clinical data of 86 patients with OS were downloaded from The Cancer Genome Atlas (TCGA). The GSE16088 dataset was downloaded from the Gene Expression Omnibus (GEO) database. The 10 cuproptosis related genes (CRGs) were obtained from a recently published article on cuproptosis in Science. Combined analysis of OS transcriptome data and the GSE16088 dataset identified differentially expressed CRGs related to OS. Next, pathway enrichment analysis was performed. Co expression analysis obtained CRLncs related to OS. Univariate COX regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were used to construct the risk prognostic model of CRLncs. The samples were divided evenly into training and test groups to verify the accuracy of the model. Risk curve, survival, receiver operating characteristic (ROC) curve, and independent prognostic analyses were performed. Next, principal component analysis (PCA) and t distributed stochastic neighbor embedding (t SNE) analysis were performed. Single sample gene set enrichment analysis (ssGSEA) was used to explore the correlation between the risk prognostic models and OS immune microenvironment. Drug sensitivity analysis identified drugs with potential efficacy in OS. Real time quantitative PCR, Western blotting, and immunohistochemistry analyses verified the expression of CRGs in OS. Real time quantitative PCR was used to verify the expression of CRLncs in OS. ResultsSix CRLncs that can guide OS prognosis and immune microenvironment were obtained, including three high risk CRLncs (AL645608.6, AL591767.1, and UNC5B AS1) and three low risk CRLncs (CARD8 AS1, AC098487.1, and AC005041.3). Immune cells such as B cells, macrophages, T helper type 2 (Th2) cells, regulatory T cells (Treg), and immune functions such as APC co inhibition, checkpoint, and T cell co inhibition were significantly downregulated in high risk groups. In addition, we obtained four drugs with potential efficacy for OS: AUY922, bortezomib, lenalidomide, and Z.LLNle.CHO. The expression of LIPT1, DLAT, and FDX1 at both mRNA and protein levels was significantly elevated in OS cell lines compared with normal osteoblast hFOB1.19. The mRNA expression level of AL591767.1 was decreased in OS, and that of AL645608.6, CARD8 AS1, AC005041.3, AC098487.1, and UNC5B AS1 was upregulated in OS. ConclusionCRLncs that can guide OS prognosis and the immune microenvironment and drugs that may have a potential curative effect on OS obtained in this study provide a theoretical basis for OS survival research and clinical decision making.
C1 [Yang, Mingyi; Zheng, Haishi; Xu, Ke; Yuan, Qiling; Aihaiti, Yirixaiti; Cai, Yongsong; Xu, Peng] Xi An Jiao Tong Univ, HongHui Hosp, Dept Joint Surg, Xian, Peoples R China.
C3 Xi'an Jiaotong University
RP Xu, P (通讯作者)，Xi An Jiao Tong Univ, HongHui Hosp, Dept Joint Surg, Xian, Peoples R China.
EM sousou369@163.com
RI Yuan, Qiling/AGX 7768 2022; Yang, Mingyi/JEF 3717 2023; Xu,
   Ke/HSH 1984 2023
OI Yang, Mingyi/0000 0001 8640 9795; Yuan, Qiling/0000 0002 4822 2513; Xu,
   Peng/0000 0003 2487 9163
FU National Natural Science Foundation of China;  [82072432]
FX Funding This work was financially supported by the National Natural
   Science Foundation of China (No. 82072432).
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Bu XX, 2021, J ONCOL, V2021, DOI 10.1155/2021/2182761
   Cai WS, 2020, PEERJ, V8, DOI 10.7717/peerj.8390
   Casali PG, 2018, ANN ONCOL, V29, P79, DOI 10.1093/annonc/mdy310
   Cascini C, 2021, CELLS BASEL, V10, DOI 10.3390/cells10071668
   Chen ZY, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.576298
   Cortini M, 2017, CANCER LETT, V405, P90, DOI 10.1016/j.canlet.2017.07.024
   Czarnecka AM, 2020, CANCERS, V12, DOI 10.3390/cancers12082130
   Ding WD, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.818905
   Fan QW, 2016, MED SCI MONITOR, V22, P5163, DOI 10.12659/MSM.902615
   Fu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.101
   Fu YC, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.633607
   Heymann MF, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.011
   Hua YQ, 2011, J PROTEOME RES, V10, P3513, DOI 10.1021/pr200147g
   Jiang F, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5523832
   Kim BE, 2008, NAT CHEM BIOL, V4, P176, DOI 10.1038/nchembio.72
   Li JY, 2021, BIOMED RES INT UK, V2021, DOI 10.1155/2021/5428425
   Li N, 2019, EPMA J, V10, P273, DOI 10.1007/s13167 019 00175 0
   Lin XY, 2018, MOL THER NUCL ACIDS, V13, P620, DOI 10.1016/j.omtn.2018.10.009
   Lou ZY, 2013, J INT MED RES, V41, P1505, DOI 10.1177/0300060513490618
   Lutsenko S, 2010, CURR OPIN CHEM BIOL, V14, P211, DOI 10.1016/j.cbpa.2010.01.003
   Qian H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.673827
   Raffa N, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2015224118
   Ren L, 2020, CANCER METAB, V8, DOI 10.1186/s40170 020 0209 8
   Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017
   Rowland EA, 2018, CURR OPIN CHEM BIOL, V42, P76, DOI 10.1016/j.cbpa.2017.11.003
   Savage Sharon A., 2011, Sarcoma, V2011, P548151, DOI 10.1155/2011/548151
   Shapovalov Y, 2010, INT J CANCER, V127, P67, DOI 10.1002/ijc.25024
   Solmonson A, 2018, J BIOL CHEM, V293, P7522, DOI 10.1074/jbc.TM117.000259
   Sun XR, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.835014
   Tan SF, 2020, EUR REV MED PHARMACO, V24, P2271, DOI [10.26355/eurrev_202003_20493, 10.26355/eurrev_202003_20536]
   Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529
   Tsvetkov P, 2019, NAT CHEM BIOL, V15, P681, DOI 10.1038/s41589 019 0291 9
   Wang YH, 2019, HUM CELL, V32, P334, DOI 10.1007/s13577 019 00242 8
   Wang ZT, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/2057782
   Wedekind MF, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27227
   Yoshida K, 2020, BMC CANCER, V20, DOI 10.1186/s12885 019 6499 y
   Zhang D, 2019, BIOCHEM BIOPH RES CO, V512, P360, DOI 10.1016/j.bbrc.2019.03.040
   Zhang YM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.780780
   Zhao Y, 2021, J ZHEJIANG UNIV SC B, V22, P885, DOI 10.1631/jzus.B2100029
   Zhong ZH, 2019, TALANTA, V204, P6, DOI 10.1016/j.talanta.2019.05.088
NR 41
TC 82
Z9 84
U1 0
U2 34
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 29
PY 2022
VL 13
AR 919231
DI 10.3389/fimmu.2022.919231
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 3T8RC
UT WOS:000840536000001
PM 35967366
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Khan, S
   Rafi, Z
   Mishra, P
   Al Keridis, LA
   Farooqui, A
   Mansoor, S
   Alshammari, N
   Al Saeed, FA
   Siddiqui, S
   Saeed, M
AF Khan, Salman
   Rafi, Zeshan
   Mishra, Pooja
   Al Keridis, Lamya Ahmed
   Farooqui, Alvina
   Mansoor, Shazia
   Alshammari, Nawaf
   Al Saeed, Fatimah A.
   Siddiqui, Samra
   Saeed, Mohd
TI Unleashing the Potential of Benincasa hispida Peel Extract:
   Synthesizing Selenium Nanoparticles with Remarkable Antibacterial and
   Anticancer Properties
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Article; Early Access
DE Selenium salt; Spherical selenium nanoparticles; Antibacterial agent; In
   vitro toxicity; Benincasa hispida
ID GREEN SYNTHESIS; STREPTOCOCCUS MUTANS; BIOFILM; GOLD; POLYSACCHARIDES
AB In this study, we successfully synthesized selenium nanoparticles (P SeNPs) using an environment friendly approach. This method involves utilizing the aqueous peel extract of Benincasa hispida (ash gourd) in combination with selenium salt. Through our innovative procedure, we harnessed the impressive bio reduction capabilities, therapeutic potential, and stabilizing attributes inherent in B. hispida. This results in the formation of P SeNPs with distinct and noteworthy qualities. Our findings were thoroughly substantiated through comprehensive characterizations employing various techniques, including ultraviolet visible spectroscopy (UV Vis), transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta potential analysis, and Fourier transform infrared spectroscopy (FTIR). The nanoparticles exhibited a spherical shape, considerable size (22.32 +/  2 nm), uniform distribution, and remarkable stability ( 24 mV), all of which signify the effective integration of the phytoconstituents of B. hispida. Furthermore, P SeNPs displayed robust antibacterial efficacy against pathogenic bacterial strains, as indicated by their low minimum inhibitory concentration values. Our research also revealed the remarkable ability of P SeNPs to fight cancer, as demonstrated by their impressive IC50 value of 0.19 mu g/mL against HeLa cells, while showing no harm to primary human osteoblasts, while simultaneously demonstrating no toxicity toward primary human osteoblasts. These pivotal findings underscore the transformative nature of P SeNPs, which holds promise for targeted antibacterial treatment and advancements in cancer therapeutics. The implications of these nanoparticles extend to their potential applications in therapies, diagnostics, and various biomedical contexts. Notably, the environmentally sustainable synthesis process and exceptional properties established this study as a significant milestone in the field of nanomedicine, paving the way for a more promising and health enhancing future.
C1 [Khan, Salman; Mishra, Pooja] Integral Univ, Dept Biosci, Nanotechnol & Nanomed Lab 6 IIRC, Lucknow 226026, India.
   [Rafi, Zeshan; Farooqui, Alvina] Integral Univ, Dept Bioengn, Lucknow 226026, India.
   [Al Keridis, Lamya Ahmed] Princess Nourah Bint Abdulrahman Univ, Fac Sci, Biol Dept, POB 84428, Riyadh 11671, Saudi Arabia.
   [Mansoor, Shazia] Jawaharlal Nehru Canc Hosp & Res Ctr, Dept Res, Bhopal, India.
   [Alshammari, Nawaf; Saeed, Mohd] Univ Hail, Coll Sci, Dept Biol, Hail 34464, Saudi Arabia.
   [Al Saeed, Fatimah A.] King Khalid Univ, Coll Sci, Dept Biol, Abha, Saudi Arabia.
   [Siddiqui, Samra] Coll Publ Hlth & Hlth Informat, Dept Hlth Serv Management, Hail, Saudi Arabia.
C3 Integral University; Integral University; Princess Nourah bint
   Abdulrahman University; University Ha'il; King Khalid University
RP Mishra, P (通讯作者)，Integral Univ, Dept Biosci, Nanotechnol & Nanomed Lab 6 IIRC, Lucknow 226026, India.; Al Keridis, LA (通讯作者)，Princess Nourah Bint Abdulrahman Univ, Fac Sci, Biol Dept, POB 84428, Riyadh 11671, Saudi Arabia.; Saeed, M (通讯作者)，Univ Hail, Coll Sci, Dept Biol, Hail 34464, Saudi Arabia.
EM salmank@iul.ac.in; zeddqazi@gmail.com; mishrapooja1893@gmail.com;
   laalkeridis@pnu.edu.sa; alvina@iul.ac.in; shaziamansoor2002@gmail.com;
   naib.alshammari@uoh.edu.sa; falsaed@kku.edu.sa; s.siddiqui@uoh.edu.sa;
   Mo.saeed@uoh.edu.sa
RI Mansoor, Shazia/AAP 9073 2021; Khan, Salman/AAR 7269 2021; Al Saeed,
   Fatimah/GLS 1235 2022; Farooqui, Alvina/IQT 2466 2023; Siddiqui,
   samra/AFI 8656 2022; Alkeridis, LAMYA/HJA 6487 2022; Alshammari,
   Nawaf/AAR 9366 2021; Saeed, Mohd/AAG 3896 2020
OI Al Saeed, Fatimah/0000 0002 5291 7334; Khan, Salman/0000 0001 5981 2562;
   Saeed, Mohd/0000 0003 3443 386X; Siddiqui, Samra/0000 0002 3880 7171; 
FU The authors are thankful to Integral University Lucknow, India, and
   Princess Nourah bint Abdulrahman University Saudi Arabia. The authors
   would like to thank Integral University, Lucknow, and the
   DST FIST funded Department of Biosciences for providing the; Integral
   University Lucknow, India [D/2023 MCN0001983]; Princess Nourah bint
   Abdulrahman University Saudi Arabia
FX The authors are thankful to Integral University Lucknow, India, and
   Princess Nourah bint Abdulrahman University Saudi Arabia. The authors
   would like to thank Integral University, Lucknow, and the
   DST FIST funded Department of Biosciences for providing the necessary
   infrastructure, and the research and development office for providing
   the manuscript communication number (IU/R & amp; D/2023 MCN0001983).
CR Abo Shama UH, 2020, INFECT DRUG RESIST, V13, P351, DOI 10.2147/IDR.S234425
   Abu Lila AS, 2022, MATERIALS, V15, DOI 10.3390/ma15165709
   Adil M, 2019, MOLECULES, V24, DOI 10.3390/molecules24234237
   Adil M, 2014, J GLOB ANTIMICROB RE, V2, P286, DOI 10.1016/j.jgar.2014.05.006
   Ahmad I, 2022, J KING SAUD UNIV SCI, V34, DOI 10.1016/j.jksus.2022.102110
   Al Hagbani T, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14040771
   Al Saqr A, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11030808
   Alshahrani MY, 2021, PLANTS BASEL, V10, DOI 10.3390/plants10112278
   Baharara Javad, 2016, Avicenna Journal of Medical Biotechnology, V8, P29
   Beltramini M, 1987, Experientia Suppl, V52, P237
   Bhat ZU, 2023, NEW J CHEM, V47, P7416, DOI 10.1039/d3nj00114h
   Boroumand S, 2019, MATER RES EXPRESS, V6, DOI 10.1088/2053 1591/ab2558
   Dayem AA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010120
   Fu PP, 2014, J FOOD DRUG ANAL, V22, P64, DOI 10.1016/j.jfda.2014.01.005
   Geoffrion LD, 2020, ACS OMEGA, V5, P2660, DOI 10.1021/acsomega.9b03172
   Islam MT, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6349041
   Kalagatur NK, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00610
   Kamnev AA, 2021, MOLECULES, V26, DOI 10.3390/molecules26041146
   Khan F, 2022, CHEMOSPHERE, V293, DOI 10.1016/j.chemosphere.2022.133571
   Khan R, 2012, PHYTOMEDICINE, V19, P747, DOI 10.1016/j.phymed.2012.04.004
   Khan S, 2022, J MOL LIQ, V348, DOI 10.1016/j.molliq.2021.118008
   Khan S, 2014, ADV SCI LETT, V20, P1061, DOI 10.1166/asl.2014.5481
   Khatoon A, 2018, LIFE SCI, V209, P430, DOI 10.1016/j.lfs.2018.08.046
   Kheradmand E, 2014, DARU, V22, DOI 10.1186/2008 2231 22 48
   Khurana A, 2019, BIOMED PHARMACOTHER, V111, P802, DOI 10.1016/j.biopha.2018.12.146
   Liao GL, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957 020 01850 7
   Liu X, 2022, RSC ADV, V12, P3862, DOI 10.1039/d1ra08658h
   Loh SH, 2013, TALANTA, V106, P200, DOI 10.1016/j.talanta.2012.12.032
   Ma YH, 2017, BIOMED PHARMACOTHER, V89, P351, DOI 10.1016/j.biopha.2017.02.009
   Mansour ATE, 2017, FISH SHELLFISH IMMUN, V68, P516, DOI 10.1016/j.fsi.2017.07.060
   Menon S, 2018, COLLOID SURFACE B, V170, P280, DOI 10.1016/j.colsurfb.2018.06.006
   Mujahid MH, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113791
   Park Y, 2011, IET NANOBIOTECHNOL, V5, P69, DOI 10.1049/iet nbt.2010.0033
   Rabiee N, 2022, MATERIALS, V15, DOI 10.3390/ma15051799
   Ramanan V, 2018, ACS SUSTAIN CHEM ENG, V6, P1627, DOI 10.1021/acssuschemeng.7b02852
   Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Saeed M, 2022, SEMIN CANCER BIOL, V86, P652, DOI 10.1016/j.semcancer.2021.05.018
   Shakibaie M, 2015, J TRACE ELEM MED BIO, V29, P235, DOI 10.1016/j.jtemb.2014.07.020
   Sohal IS, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989 018 0265 1
   Srivastava N, 2015, BIOPROC BIOSYST ENG, V38, P1723, DOI 10.1007/s00449 015 1413 8
   Toné S, 2007, EXP CELL RES, V313, P3635, DOI 10.1016/j.yexcr.2007.06.018
   Tran HV, 2022, MATERIALS, V15, DOI 10.3390/ma15020503
   Tran PA, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/4/045101
   Trivedi R, 2022, SCI TOTAL ENVIRON, V833, DOI 10.1016/j.scitotenv.2022.155085
   Trivedi R, 2022, PROCESSES, V10, DOI 10.3390/pr10020338
   Wadhwani SA, 2016, APPL MICROBIOL BIOT, V100, P2555, DOI 10.1007/s00253 016 7300 7
   Wang MY, 2023, J PHARM SCI US, V112, P336, DOI 10.1016/j.xphs.2022.08.004
   Zuverza Mena N, 2017, PLANT PHYSIOL BIOCH, V110, P236, DOI 10.1016/j.plaphy.2016.05.037
NR 49
TC 3
Z9 3
U1 3
U2 17
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1073 6085
EI 1559 0305
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD 2023 SEP 26
PY 2023
DI 10.1007/s12033 023 00884 y
EA SEP 2023
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA S6PU6
UT WOS:001072372100002
PM 37752300
DA 2025 08 17
ER

PT J
AU Chang, IC
   Chiang, TI
   Lo, C
   Lai, YH
   Yue, CH
   Liu, JY
   Hsu, LS
   Lee, CJ
AF Chang, I Chang
   Chiang, Tsay I
   Lo, Chun
   Lai, Yi Hua
   Yue, Chia Herng
   Liu, Jer Yuh
   Hsu, Li Sung
   Lee, Chia Jen
TI Anemone altaica Induces Apoptosis in Human Osteosarcoma Cells
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Anemone altaica; Osteosarcoma; Apoptosis
ID PROGNOSTIC FACTORS; OSTEOGENIC SARCOMA; CHEMOTHERAPY; RESISTANCE;
   SURVIVAL; CANCER; DRUG
AB In the past decade, no significant improvement has been made in chemotherapy for osteosarcoma (OS). To develop improved agents against OS, we screened 70 species of medicinal plants and treated two human OS cell lines with different agent concentrations. We then examined cell viability using the MTT assay. Results showed that a candidate plant, particularly the rhizomes of Anemone altaica Fisch. ex C. A. Mey aqueous extract (AAE), suppressed the viability of HOS and U2OS cells in a concentration dependent manner. Flow cytometry analysis revealed that AAE significantly increased the amount of cell shrinkage (Sub G1 fragments) in HOS and U2OS cells. Moreover, AAE increased cytosolic cytochrome c and Bax, but decreased Bcl 2. The amount of cleaved caspase 3 and poly (ADP ribose) polymerase 1 (PARP 1) were significantly increased. AAE suppressed the growth of HOS and U2OS through the intrinsic apoptotic pathway. Data suggest that AAE is cytotoxic to HOS and U2OS cells and has no significant influence on human osteoblast hFOB cells. The high mRNA levels of apoptosis related factors (PPP1R15A, SQSTM1, HSPA1B, and DDIT4) and cellular proliferation markers (SKA2 and BUB1B) were significantly altered by the AAE treatment of HOS and U2OS cells. Results show that the anticancer activity of AAE could up regulate the expression of a cluster of genes, especially those in the apoptosis related factor family and caspase family. Thus, AAE has great potential as a useful therapeutic drug for human OS.
C1 [Chang, I Chang] Chung Shan Med Univ, Sch Med, Taichung 402, Taiwan.
   [Chang, I Chang] Chung Shan Med Univ, Dept Orthoped Surg, Taichung 402, Taiwan.
   [Hsu, Li Sung] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan.
   [Chiang, Tsay I] Hungkuang Univ, Coll Med & Nursing, Dept Nursing, Taichung 433, Taiwan.
   [Lo, Chun; Liu, Jer Yuh] China Med Univ, Grad Inst Canc Biol, Taichung 40402, Taiwan.
   [Lai, Yi Hua] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.
   [Yue, Chia Herng] Tungs Taichung MetroHarbor Hosp, Dept Surg, Taichung 435, Taiwan.
   [Liu, Jer Yuh; Lee, Chia Jen] China Med Univ Hosp, Ctr Mol Med, Taichung 40402, Taiwan.
   [Hsu, Li Sung] Chung Shan Med Univ Hosp, Clin Lab, Taichung 40201, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University; Hungkuang University; China Medical University
   Taiwan; Asia University Taiwan; Tungs' Taichung MetroHarbor Hospital;
   China Medical University Taiwan; China Medical University Hospital  
   Taiwan; Chung Shan Medical University; Chung Shan Medical University
   Hospital
RP Liu, JY (通讯作者)，China Med Univ, Coll Med, Grad Inst Canc Biol, 6 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM jyl@mail.cmu.edu.tw; lshsu405@yahoo.com.tw; chiajenlee54@gmail.com
RI Liu, Yu/F 7469 2019
FU National Science Council, Republic of China [NSC 99 2632 B 039 001 MY3,
   NSC 102 2320 B 039 049, NSC 102 2911 I 002 303]; Taiwan, Republic of
   China [CMU98 asia 12]
FX This work was supported by grants from the National Science Council,
   Republic of China (NSC 99 2632 B 039 001 MY3, NSC 102 2320 B 039 049 and
   NSC 102 2911 I 002 303) and in part by the (CMU98 asia 12), Taiwan,
   Republic of China.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Chattopadhyay SK, 2006, J CHROMATOGR B, V844, P67, DOI 10.1016/j.jchromb.2006.07.045
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Feng Xuefeng, 1998, Zhongguo Zhongyao Zazhi, V23, P739
   Fraga CG, 2011, FREE RADICAL BIO MED, V51, P813, DOI 10.1016/j.freeradbiomed.2011.06.002
   Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005
   Krifa M, 2013, J ETHNOPHARMACOL, V146, P243, DOI 10.1016/j.jep.2012.12.038
   Lin CC, 2014, AM J CHINESE MED, V42, P743, DOI 10.1142/S0192415X14500487
   Longhi A, 2000, CANCER, V89, P1961, DOI 10.1002/1097 0142(20001101)89:9<1961::AID CNCR12>3.3.CO;2 #
   Man JM, 2012, CARBOHYD POLYM, V89, P571, DOI 10.1016/j.carbpol.2012.03.049
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Petrilli AS, 2006, J CLIN ONCOL, V24, P1161, DOI 10.1200/JCO.2005.03.5352
   Poon Kein Boon, 2004, Kaohsiung Journal of Medical Sciences, V20, P230, DOI 10.1016/S1607 551X(09)70111 1
   SAVILLE MW, 1995, LANCET, V346, P26, DOI 10.1016/S0140 6736(95)92654 2
   Schwartz CL, 2007, J CLIN ONCOL, V25, P2057, DOI 10.1200/JCO.2006.07.7776
   SLICHENMYER WJ, 1991, ANTI CANCER DRUG, V2, P519, DOI 10.1097/00001813 199112000 00002
   Stiller CA, 2000, BRIT J CANCER, V82, P1339, DOI 10.1054/bjoc.1999.1101
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Wu PK, 2009, JPN J CLIN ONCOL, V39, P514, DOI 10.1093/jjco/hyp057
   Wu TT, 2008, J CELL BIOCHEM, V103, P9, DOI 10.1002/jcb.21378
   Zou Zhong jie, 2008, Zhong Yao Cai, V31, P49
   Zou ZJ, 2005, J INTEGR PLANT BIOL, V47, P1145, DOI 10.1111/j.1744 7909.2005.00147.x
NR 24
TC 14
Z9 17
U1 0
U2 11
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2015
VL 43
IS 5
BP 1031
EP 1042
DI 10.1142/S0192415X15500597
PG 12
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA CQ2ES
UT WOS:000360412800011
PM 26224029
DA 2025 08 17
ER

PT J
AU Quang, HV
   Chang, CC
   Song, P
   Hauge, EM
   Kjems, J
AF Hieu Vu Quang
   Chang, Chi Chih
   Song, Ping
   Hauge, Ellen Margrethe
   Kjems, Jorgen
TI Caveolae mediated mesenchymal stem cell labelling by PSS coated PLGA
   PFOB nano contrast agent for MRI
SO THERANOSTICS
LA English
DT Article
DE stem cell therapy; MRI; contrast agent; caveolae mediated endocytosis;
   mesenchymal stem cells; nanoparticles
ID OSTEOGENIC DIFFERENTIATION; IN VITRO; NANOPARTICLES; TRACKING;
   PERFLUOROCARBONS; PROLIFERATION; CHALLENGES; RECEPTOR; CULTURE
AB Rationale: Non invasive tracking of transplanted cells is critical in evaluating delivery, migration and prognosis of cell therapies.
   Methods: We formulated a nano contrast agent consisting of a perfluorooctylbromide (PFOB) core within a shell of poly (lactic co glycolic acid) (PLGA) followed by a coat of polystyrene sulfonate (PSS) for F 19 MRI. The nano contrast agent (PSS NP) was characterised by DLS and the uptake efficiency of the nano contrast agent (PSS NP) was tested using flow cytometry, in vitro MRI and confocal microscopy. In vitro and in vivo assays of labelled cells were tested for their ability to provide an MRI signal while retaining their osteoblastic differentiation capabilities.
   Results: PSS NPs were internalised via caveolae mediated endocytosis in mesenchymal stromal/stem cells without affecting cell proliferation and differentiation in osteoblasts, both in vitro and in vivo. Furthermore, labelled cells were monitored by F 19 MRI for up to 2 months after transplantation in mice. In particular, PSS NP labelled cells can be used to monitor the enhanced immune rejection of grafted human cells in normal BALB/c mice compared to immune compromised NOD/SCID mice. One week after transplantation, 40% of the F 19 MRI signal was lost in normal mice, whereas only 10% was lost in immune compromised mice.
   Conclusion: Overall, these results show that PSS NPs can label MSCs effectively, and be employed in vivo as a novel nano contrast agent for non invasive cell tracking using clinically relevant F 19 MRI techniques.
C1 [Hieu Vu Quang; Chang, Chi Chih; Song, Ping; Kjems, Jorgen] Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Aarhus, Denmark.
   [Hieu Vu Quang; Chang, Chi Chih; Song, Ping; Kjems, Jorgen] Aarhus Univ, Ctr Cellular Signal Patterns CellPat, Aarhus, Denmark.
   [Hauge, Ellen Margrethe] Aarhus Univ, Dept Clin Med, Aarhus, Denmark.
   [Hauge, Ellen Margrethe] Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark.
C3 Aarhus University; Aarhus University; Aarhus University; Aarhus
   University
RP Chang, CC (通讯作者)，Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Aarhus, Denmark.; Chang, CC (通讯作者)，Aarhus Univ, Ctr Cellular Signal Patterns CellPat, Aarhus, Denmark.
EM chang@inano.au.dk
RI Vu Quang, Hieu/AAX 7751 2020; Kjems, Jorgen/I 3490 2016
OI Kjems, Jorgen/0000 0003 4128 9317; Chang, Chi Chih
   (Clare)/0000 0002 3154 1745; Song, Ping/0000 0002 5558 9890
FU Lundbeck Foundation; Innovation Fund Denmark (MUSTER project); Danish
   National Research Foundation (CellPat centre)
FX hMSC TERT and hMSC TERT GFP were kind gifts from Prof. Moustapha Kassem
   of Southern Denmark University. We would like to thank Dr. Maria Vad
   Jakobsen for helping us with animal studies and Dr Mads S Vinding for
   his insight on MRI. We are also grateful to Mr. Claus Bus and Ms. Rita
   Rosendahl at iNANO, and Ms. Jette Barlach at the Institute for Clinical
   Medicine (Aarhus University) for their technical assistance. This study
   was supported by the Lundbeck Foundation to the LUNA Centre (the
   Lundbeck Foundation Nanomedicine Centre for Individualized Management of
   Tissue Damage and Regeneration), Innovation Fund Denmark (MUSTER
   project) and the Danish National Research Foundation (CellPat centre).
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Accomasso L, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7920358
   Ahrens ET, 2014, MAGN RESON MED, V72, P1696, DOI 10.1002/mrm.25454
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Baker N, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0225 8
   Baker N, 2012, J CELL BIOCHEM, V113, P3773, DOI 10.1002/jcb.24252
   Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072
   Boehm Sturm P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029040
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Díaz López R, 2010, BIOMATERIALS, V31, P1723, DOI 10.1016/j.biomaterials.2009.11.044
   Edmundson M, 2013, THERANOSTICS, V3, P573, DOI 10.7150/thno.5477
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Gaudet JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118544
   Giraudeau C, 2010, MAGN RESON MED, V63, P1119, DOI 10.1002/mrm.22269
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hieu VQ, 2016, CARBOHYD POLYM, V136, P936, DOI 10.1016/j.carbpol.2015.09.076
   Himmelreich U, 2008, MINIM INVASIV THER, V17, P132, DOI 10.1080/13645700801969873
   Janjic JM, 2009, WIRES NANOMED NANOBI, V1, P492, DOI 10.1002/wnan.35
   Kim T, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201604213
   Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890 199704270 00003
   Li JM, 2016, ADV HEALTHC MATER, V5, P1049, DOI 10.1002/adhm.201500879
   Liu XJ, 2015, INT J CLIN EXP MED, V8, P10122
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101
   de Misquita MRDOF, 2016, J BIOMATER APPL, V31, P625, DOI 10.1177/0885328216656476
   Oughlis S, 2016, J BIOACT COMPAT POL, V31, P568, DOI 10.1177/0883911516643105
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600 0854.2002.30501.x
   Pisani E, 2006, LANGMUIR, V22, P4397, DOI 10.1021/la0601455
   Pisani E, 2009, SOFT MATTER, V5, P3054, DOI 10.1039/b902042j
   Qiu WM, 2010, J BIOL CHEM, V285, P14438, DOI 10.1074/jbc.M109.052001
   Rodriguez Porcel Martin, 2010, Curr Cardiol Rep, V12, P51, DOI 10.1007/s11886 009 0073 1
   Rohman G, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5539 7
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168 3659(02)00127 X
   SPENCE RK, 1995, ARTIF CELL BLOOD SUB, V23, P367, DOI 10.3109/10731199509117953
   Srinivas M, 2012, BIOMATERIALS, V33, P8830, DOI 10.1016/j.biomaterials.2012.08.048
   Srinivas M, 2010, TRENDS BIOTECHNOL, V28, P363, DOI 10.1016/j.tibtech.2010.04.002
   Srinivas M, 2010, BIOMATERIALS, V31, P7070, DOI 10.1016/j.biomaterials.2010.05.069
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Vedrine P, 2014, IEEE T APPL SUPERCON, V24, DOI 10.1109/TASC.2013.2286256
   Voigt J, 2014, P NATL ACAD SCI USA, V111, P2942, DOI 10.1073/pnas.1322356111
   Wang YQ, 2013, THERANOSTICS, V3, P544, DOI 10.7150/thno.5634
   Wu KM, 2013, ACS APPL MATER INTER, V5, P2733, DOI 10.1021/am400374c
   Zhang J, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0240 9
NR 45
TC 22
Z9 24
U1 3
U2 23
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2018
VL 8
IS 10
BP 2657
EP 2671
DI 10.7150/thno.23206
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GC6CU
UT WOS:000429878500005
PM 29774066
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Lenhert, S
   Sesma, A
   Hirtz, M
   Chi, LF
   Fuchs, H
   Wiesmann, HP
   Osbourn, AE
   Moerschbacher, BM
AF Lenhert, Steven
   Sesma, Ane
   Hirtz, Michael
   Chi, Lifeng
   Fuchs, Harald
   Wiesmann, Hans Peter
   Osbourn, Anne E.
   Moerschbacher, Bruno M.
TI Capillary induced contact guidance
SO LANGMUIR
LA English
DT Article
ID RICE BLAST FUNGUS; LANGMUIR BLODGETT LITHOGRAPHY; MAGNAPORTHE GRISEA;
   NANOSTRUCTURED SURFACES; APPRESSORIUM FORMATION; TOPOGRAPHICAL SIGNALS;
   STEM RUST; IN VITRO; MEMBRANE; CELLS
AB Topographical features are known to impose capillary forces on liquid droplets, and this phenomenon is exploited in applications such as printing, coatings, textiles and microfluidics. Surface topographies also influence the behavior of biological cells (i.e., contact guidance), with implications ranging from medicine to agriculture. An accurate physical description of how cells detect and respond to surface topographies is necessary in order to move beyond a purely heuristic approach to optimizing the topographies of biomaterial interfaces. Here, we have used a combination of Langmuir Blodgett lithography and nanoimprinting to generate a range of synthetic microstructured surfaces with grooves of subcellular dimensions in order to investigate the influence of capillary forces on the biological process of contact guidance. The physical chemical properties of these surfaces were assessed by measuring the anisotropic spreading of sessile water droplets. Having established the physical properties of each surface, we then investigated the influence of capillary forces on the processes of cellular contact guidance in biological organisms, using mammalian osteoblasts and germinating fungal spores as tester organisms. Our results demonstrate that capillary effects are present in topographical contact guidance and should therefore be considered in any physical model that seeks to predict how cells will respond to a particular surface topography.
C1 Univ Klinikum Munster, Klin & Poliklin Mund & Kiefer Gesichtschirurg, D 48149 Munster, Germany.
   Univ Munster, Inst Phys, D 48149 Munster, Germany.
   CeNTech, D 48149 Munster, Germany.
   Univ Munster, Inst Biochem & Biotechnol Pflanzen, D 48149 Munster, Germany.
   John Innes Ctr, Norwich NR4 7UH, Norfolk, England.
C3 University of Munster; University of Munster; University of Munster; UK
   Research & Innovation (UKRI); Biotechnology and Biological Sciences
   Research Council (BBSRC); John Innes Center
RP Lenhert, S (通讯作者)，Forschungszentrum Karlsruhe, Inst NanoTechnol, Hermann Helmholtz Pl 1, D 76344 Eggenstein Leopoldshafen, Germany.
EM lenhert@int.fzk.de
RI Sesma, Ane/A 8883 2010; Sesma, Ane/AAF 4796 2021; Fuchs,
   Harald/AAW 6196 2020; Chi, Lifeng/A 1419 2015; lenhert,
   steven/B 7689 2009; Hirtz, Michael/C 8821 2011; Moerschbacher,
   Bruno/C 2012 2017
OI Sesma, Ane/0000 0003 3982 8932; Hirtz, Michael/0000 0002 2647 5317; 
CR ALLEN EA, 1991, PHYTOPATHOLOGY, V81, P323, DOI 10.1094/Phyto 81 323
   [Anonymous], SOFT MATTER PHYS
   [Anonymous], REV MOD PHYS
   [Anonymous], STRUCTURE DYNAMICS M
   Apoga D, 2004, FUNGAL GENET BIOL, V41, P1, DOI 10.1016/j.fgb.2003.10.001
   Arnold M, 2004, CHEMPHYSCHEM, V5, P383, DOI 10.1002/cphc.200301014
   Brody S, 2006, TISSUE ENG, V12, P413, DOI 10.1089/ten.2006.12.413
   Buttiglieri S, 2003, BIOMATERIALS, V24, P2731, DOI 10.1016/S0142 9612(03)00088 7
   Carman ML, 2006, BIOFOULING, V22, P11, DOI 10.1080/08927010500484854
   Collins TJ, 2001, PHYSIOL MOL PLANT P, V58, P259, DOI 10.1006/pmpp.2001.0335
   COX RG, 1983, J FLUID MECH, V131, P1, DOI 10.1017/S0022112083001214
   Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142 9612(97)00144 0
   Curtis ASG, 2001, BIOPHYS CHEM, V94, P275, DOI 10.1016/S0301 4622(01)00247 2
   Dalby MJ, 2005, MED ENG PHYS, V27, P730, DOI 10.1016/j.medengphy.2005.04.005
   Dalby MJ, 2004, INT J BIOCHEM CELL B, V36, P2005, DOI 10.1016/j.biocel.2004.03.001
   Dalby MJ, 2004, BIOMATERIALS, V25, P5415, DOI 10.1016/j.biomaterials.2003.12.049
   Dalby MJ, 2004, CELL BIOL INT, V28, P229, DOI 10.1016/j.cellbi.2003.12.004
   Dalby MJ, 2003, EXP CELL RES, V284, P274, DOI 10.1016/S0014 4827(02)00053 8
   DeZwaan TM, 1999, PLANT CELL, V11, P2013, DOI 10.1105/tpc.11.10.2013
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng L, 2002, ADV MATER, V14, P1857, DOI 10.1002/adma.200290020
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Gerdes S, 1997, LANGMUIR, V13, P7258, DOI 10.1021/la970139w
   Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661
   Gilbert RD, 1996, PHYSIOL MOL PLANT P, V48, P335, DOI 10.1006/pmpp.1996.0027
   Gladfelter AS, 2006, NAT REV MICROBIOL, V4, P223, DOI 10.1038/nrmicro1345
   Gleiche M, 2001, CHEMPHYSCHEM, V2, P187, DOI 10.1002/1439 7641(20010316)2:3<187::AID CPHC187>3.0.CO;2 7
   Gleiche M, 2000, NATURE, V403, P173, DOI 10.1038/35003149
   Goldner JS, 2006, BIOMATERIALS, V27, P460, DOI 10.1016/j.biomaterials.2005.06.035
   GOW NAR, 1995, GROWNING FUNGUS
   Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685
   Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360
   Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359
   Ito Y, 1999, BIOMATERIALS, V20, P2333, DOI 10.1016/S0142 9612(99)00162 3
   JELITTO TC, 1994, PLANTA, V194, P471, DOI 10.1007/BF00714458
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789
   Lenhert S, 2005, CHEMPHYSCHEM, V6, P2495, DOI 10.1002/cphc.200500276
   Lenhert S, 2004, ADV MATER, V16, P619, DOI 10.1002/adma.200306203
   Lenhert S, 2005, BIOMATERIALS, V26, P563, DOI 10.1016/j.biomaterials.2004.02.068
   Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898 6568(00)00096 6
   MANIOTIS AJ, 1997, P NATL ACAD SCI USA, V94, P8499
   McHale G, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.036102
   MOERSCHBACHER BM, 1990, PLANT PHYSIOL, V93, P465, DOI 10.1104/pp.93.2.465
   Ottani V, 2001, MICRON, V32, P251, DOI 10.1016/S0968 4328(00)00042 1
   Pierres A, 2003, BIOPHYS J, V84, P2058, DOI 10.1016/S0006 3495(03)75013 9
   Pignataro B, 2000, BIOPHYS J, V78, P487, DOI 10.1016/S0006 3495(00)76611 2
   Rafelski SM, 2004, ANNU REV BIOCHEM, V73, P209, DOI 10.1146/annurev.biochem.73.011303.073844
   Raghavendra S, 2005, INT J ORAL MAX IMPL, V20, P425
   Rajnicek AM, 1997, J CELL SCI, V110, P2915
   Read ND, 1997, PLANTA, V202, P163, DOI 10.1007/s004250050115
   READ ND, 1992, SOC EXP BIOL SEMIN S, V48, P137, DOI 10.1017/CBO9780511565243.009
   Sackmann E, 2002, CHEMPHYSCHEM, V3, P262, DOI 10.1002/1439 7641(20020315)3:3<262::AID CPHC262>3.0.CO;2 U
   Selhuber C, 2006, NANO LETT, V6, P267, DOI 10.1021/nl052256e
   Sesma A, 2004, NATURE, V431, P582, DOI 10.1038/nature02880
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Talbot NJ, 2003, ANNU REV MICROBIOL, V57, P177, DOI 10.1146/annurev.micro.57.030502.090957
   Talbot NJ, 1996, PLANT CELL, V8, P985, DOI 10.1105/tpc.8.6.985
   TALBOT NJ, 1993, PLANT CELL, V5, P1575, DOI 10.1105/tpc.5.11.1575
   Tucker SL, 2001, ANNU REV PHYTOPATHOL, V39, P385, DOI 10.1146/annurev.phyto.39.1.385
   Walboomers XF, 1999, J BIOMED MATER RES, V46, P212, DOI 10.1002/(SICI)1097 4636(199908)46:2<212::AID JBM10>3.0.CO;2 Y
   WEISS P, 1945, J EXP ZOOL, V100, P353, DOI 10.1002/jez.1401000305
   Weiss P, 1934, J EXP ZOOL, V68, P393, DOI 10.1002/jez.1400680304
   Wenzel RN, 1936, IND ENG CHEM, V28, P988, DOI 10.1021/ie50320a024
   Wilkinson CDW, 1998, J VAC SCI TECHNOL B, V16, P3132, DOI 10.1116/1.590451
   ZHOU XL, 1991, SCIENCE, V253, P1415, DOI 10.1126/science.1716786
NR 66
TC 25
Z9 28
U1 0
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743 7463
J9 LANGMUIR
JI Langmuir
PD SEP 25
PY 2007
VL 23
IS 20
BP 10216
EP 10223
DI 10.1021/la701043f
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 211YL
UT WOS:000249560100040
PM 17760465
DA 2025 08 17
ER

PT J
AU Vural, P
   Akgul, C
   Canbaz, M
AF Vural, Pervin
   Akgul, Cemil
   Canbaz, Mukaddes
TI Effects of hormone replacement therapy on plasma pro inflammatory and
   anti inflammatory cytokines and some bone turnover markers in
   postmenopausal women
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE cytokines; hormone replacement therapy (HRT); bone turnover; menopause
ID IL 1 BETA PROMOTER ACTIVITY; BLOOD MONONUCLEAR CELLS; ESTROGEN
   REPLACEMENT; PERIPHERAL BLOOD; MENOPAUSAL WOMEN; NORMAL MICE; IN VITRO;
   INTERLEUKIN 1; RESORPTION; OSTEOPOROSIS
AB Objective: The present study was undertaken to evaluate plasma TNF alpha, IL 1 beta, IL 10; and urinary hydroxyproline (Hyp) and calcium (Ca) as bone resorption markers in postmenopausal women compared with premenopausal ones; and to assess the effects of HRT upon these cytokines and bone turnover markers.
   Patients and methods: The study involved 50 healthy postmenopausal women, and 25 healthy premenopausal women (control group). Postmenopausal women were randomly divided into two subgroups: women receiving cycle HRT schedule (0.625 mg conjugated estrogen from days I to 28 + 5 mg medroxyprogesterone, acetate from days 18 to 28) for 2 months (n = 25); and second subgroup consisted of women receiving continue HRT schedule (0.625 mg conjugated estrogen + 2.5 mg medroxyprogesterone acetate from days I to 28) for 2 months (n = 25). Plasma TNF alpha, IL 1 beta and IL 10 concentrations were measured with ELISA kits. Fasting urinary Hyp was measured by Ehrlich's spectrophotometric reaction. Ca was determined by oxalate precipitation and the redox titration procedure. Statistical significance was analysed by Kruskal Wallis plus post hoc Mann Whitney U tests for multiple comparisons, Wilcoxon signed ranks test for paired data, and Pearson correlation test.
   Results: Compared with premenopausal individuals, postmenopausal women have increased plasma TNF alpha, IL 10, IL 10 (p < 0.0001,p < 0.0001, and p < 0.001, respectively); and increased urinary Hyp and Ca concentrations (p < 0.05). HRT (both cycle and continue schedules) lead to a significant decrease in TNFa., IL 1 beta and urinary Hyp concentrations, and has no effect uppon IL 10 levels. HRT reverses increased urinary Hyp and Ca excretion to the premenopausal level. There is a significant positive correlation between pre  and post HRT IL 1 beta levels in both cycle and continue subgroups (r=0.437, p < 0.05; and r=0.656, p < 0.01, respectively), and between pre HRT IL 1 beta and urinary Ca (r=0.509, p < 0.01; and r=0.415, p < 0.05). There is a significant negative correlation between post HRT IL 10 and TNFa levels in continue HRT receiving group (r =  0.446, p < 0.05). Urinary Hyp in cycle and continue HRT received subgroups are correlated with post treatment values (r = 0.455, p < 0.05; and r = 0.776, p < 0.01).
   Conclusions: Plasma TNF alpha, IL 1 beta, IL 10; and urinary Hyp and Ca increase with menopause. We suggest that the increase of IL 10 is secondary to the elevation of TNFa and IL 1 beta and that the increase of IL 10 is a compensatory mechanism, by which this anti inflammatory cytokine counteracts to pro inflammatory TNF alpha and IL 1 beta, and thus balances their osteoclast activating and oxidative stress related effects. Two months duration HRT (cycle and continue schedule) lead to the significant decrease in plasma TNF alpha, IL 1 beta and urinary Hyp concentrations. HRT reverses increased Hyp and Ca excretion to the premenopausal level. So, HRT, decreasing Th1 cytokines (TNF alpha, IL 1 beta) probably improve the aberation of Th1/Th2 balance that is implicated in various pathological conditions. However, because of the relatively small number of participants and short duration of the therapy, further studies are necessary to establish a risk/benefit ratio for HRT to view effects on cytokine pattern and bone metabolism. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Istanbul Fac Med, Dept Biochem, Istanbul, Turkey.
   Istanbul Fac Med, Dept Obstet & Gynecol, Istanbul, Turkey.
C3 Istanbul University; Istanbul University
RP Vural, P (通讯作者)，Cad Hakan Apt 4 4, TR 34310 Istanbul, Turkey.
EM pervinvural@yahoo.com
RI Akgül, Cemil/AAP 6327 2020; Vural, Pervin/AAD 9095 2020
CR Akgül C, 1998, MATURITAS, V30, P79, DOI 10.1016/S0378 5122(98)00046 2
   [Anonymous], 1996, ADV IMMUNOLOGY
   Berg G, 2002, AM J REPROD IMMUNOL, V48, P63, DOI 10.1034/j.1600 0897.2002.01061.x
   Berger S, 1996, EUR J IMMUNOL, V26, P1297, DOI 10.1002/eji.1830260618
   BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo 125 3 1142
   Cioffi M, 2002, MATURITAS, V41, P187, DOI 10.1016/S0378 5122(01)00286 9
   COHENSOLAL ME, 1993, J CLIN ENDOCR METAB, V77, P1648, DOI 10.1210/jc.77.6.1648
   FAULKNER WR, 1982, FUNDAMENTALS CLIN CH, P975
   GENCI S, 2000, J CLIN INVEST, V106, P1229
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   GOWEN M, 1985, J CLIN INVEST, V75, P1223, DOI 10.1172/JCI111819
   Hannon R, 1999, J BONE MINER RES, V14, P471, DOI 10.1359/jbmr.1999.14.3.471
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   JOHNSON RA, 1989, ENDOCRINOLOGY, V124, P1424, DOI 10.1210/endo 124 3 1424
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066
   Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022
   LORENZO JA, 1987, ENDOCRINOLOGY, V121, P1164, DOI 10.1210/endo 121 3 1164
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Onoe Y, 1996, J IMMUNOL, V156, P758
   Pacifici R, 1999, CALCIFIED TISSUE INT, V65, P345, DOI 10.1007/s002239900710
   PACIFICI R, 1989, P NATL ACAD SCI USA, V86, P2398, DOI 10.1073/pnas.86.7.2398
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   Porter VR, 2001, EXP GERONTOL, V36, P311, DOI 10.1016/S0531 5565(00)00195 9
   RALSTON SH, 1994, J BONE MINER RES, V9, P883
   REVILARD JP, 1995, IMMUNOLOGIE
   Rogers A, 2001, BONE, V29, P30, DOI 10.1016/S8756 3282(01)00468 9
   Ruh MF, 1998, J STEROID BIOCHEM, V66, P203, DOI 10.1016/S0960 0760(98)00042 9
   Ruh MF, 1998, ENDOCRINE, V9, P207, DOI 10.1385/ENDO:9:2:207
   SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235
   Saucedo R, 2002, GYNECOL OBSTET INVES, V53, P114, DOI 10.1159/000053005
   Siggelkow H, 2003, J BONE MINER RES, V18, P529, DOI 10.1359/jbmr.2003.18.3.529
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   SWITZER BR, 1991, J NUTR BIOCHEM, V2, P229, DOI 10.1016/0955 2863(91)90021 V
   THOMSON BM, 1987, J IMMUNOL, V138, P775
   THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104
   TIETZ NW, 1982, FUNDAMENTALS CLIN CH, P849
   Vural P, 2005, ANN CLIN BIOCHEM, V42, P220, DOI 10.1258/0004563053857941
   WANG YP, 1992, AM J OBSTET GYNECOL, V167, P946, DOI 10.1016/S0002 9378(12)80017 2
   WOLINSKY H, 1972, CIRC RES, V30, P341, DOI 10.1161/01.RES.30.3.341
NR 44
TC 74
Z9 88
U1 0
U2 6
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD OCT
PY 2006
VL 54
IS 4
BP 298
EP 302
DI 10.1016/j.phrs.2006.06.006
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 094OZ
UT WOS:000241250100008
PM 16879975
DA 2025 08 17
ER

PT J
AU Orlowsky, EW
   Stabler, TV
   Montell, E
   Vergés, J
   Kraus, VB
AF Orlowsky, Eric W.
   Stabler, Thomas V.
   Montell, Eulalia
   Verges, Josep
   Kraus, Virginia Byers
TI Monosodium urate crystal induced macrophage inflammation is attenuated
   by chondroitin sulphate: pre clinical model for gout prophylaxis?
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID OF RHEUMATOLOGY GUIDELINES; OSTEOARTHRITIS; MANAGEMENT; THERAPY;
   INTERLEUKIN 8; GLUCOSAMINE; FLARES
AB Background: Chondroitin Sulphate (CS), a natural glycosaminoglycan of the extracellular matrix, has clinical benefit in symptomatic osteoarthritis but has never been tested in gout. In vitro, CS has anti inflammatory and positive effects on osteoarthritic chondrocytes, synoviocytes and subchondral bone osteoblasts, but its effect on macrophages is unknown. The purpose of our study was to evaluate the in vitro effects of CS on monosodium urate (MSU) stimulated cytokine production by macrophages.
   Methods: THP 1 monocytes were differentiated into mature macrophages using a phorbol ester, pretreated for 4 hours with CS in a physiologically achievable range of concentrations (10 200 mu g/ml) followed by MSU crystal stimulation for 24 hours. Cell culture media were analyzed by immunoassay for factors known to be upregulated during gouty inflammation including IL 1 beta, IL 8 and TNF alpha. The specificity of inflammasome activation by MSU crystals was tested with a caspase 1 inhibitor (0.01 mu M 10 mu M).
   Results: MSU crystals >= 10 mg/dl increased macrophage production of IL 1 beta, IL 8 and TNF alpha a mean 7 , 3  and 4 fold respectively. Induction of IL 1 beta by MSU was fully inhibited by a caspase 1 inhibitor confirming inflammasome activation as the mechanism for generating this cytokine. In a dose dependent manner, CS significantly inhibited IL 1 beta (p = 0.003), and TNF alpha (p = 0.02) production from macrophages in response to MSU. A similar trend was observed for IL 8 but was not statistically significant (p = 0.41).
   Conclusions: CS attenuated MSU crystal induced macrophage inflammation, suggesting a possible role for CS in gout prophylaxis.
C1 [Orlowsky, Eric W.; Kraus, Virginia Byers] Duke Univ, Sch Med, Dept Med, Div Rheumatol, Durham, NC 27706 USA.
   [Stabler, Thomas V.; Kraus, Virginia Byers] Duke Univ, Sch Med, Duke Mol Physiol Inst, Durham, NC 27706 USA.
   [Montell, Eulalia; Verges, Josep] Bioiberica, Pharmasci Div, Preclin R&D Area, Barcelona, Spain.
C3 Duke University; Duke University; Bioiberica
RP Kraus, VB (通讯作者)，Duke Univ, Sch Med, Dept Med, Div Rheumatol, Durham, NC 27706 USA.
EM vbk@duke.edu
OI Verges Milano, Josep/0000 0002 7883 5900
FU Bioiberica (Barcelona, Spain); NIH [5T32AI007217 30, P01 AR050245,
   AG028716]
FX This work was supported in part by Bioiberica (Barcelona, Spain), NIH
   5T32AI007217 30 (EO) and P01 AR050245 and AG028716 (VBK).
CR Bhole V, 2010, ARTHRITIS RHEUM US, V62, P1069, DOI 10.1002/art.27338
   Borstad GC, 2004, J RHEUMATOL, V31, P2429
   Busso N, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2952
   Calamia V, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013417
   Cantley MD, 2013, INFLAMMOPHARMACOLOGY, V21, P407, DOI 10.1007/s10787 013 0171 y
   Desideri G, 2014, EUR REV MED PHARMACO, V18, P1295
   du Souich P, 2014, PHARMACOL THERAPEUT, V142, P362, DOI 10.1016/j.pharmthera.2014.01.002
   du Souich P, 2009, J CELL MOL MED, V13, P1451, DOI 10.1111/j.1582 4934.2009.00826.x
   Harada A, 1996, MOL MED TODAY, V2, P482
   Hochberg M, 2013, CURR MED RES OPIN, V29, P259, DOI 10.1185/03007995.2012.753430
   Homandberg GA, 2006, OSTEOARTHR CARTILAGE, V14, P793, DOI 10.1016/j.joca.2006.02.003
   Jomphe C, 2008, BASIC CLIN PHARMACOL, V102, P59, DOI 10.1111/j.1742 7843.2007.00158.x
   Khanna D, 2012, ARTHRIT CARE RES, V64, P1431, DOI 10.1002/acr.21772
   Khanna D, 2012, ARTHRIT CARE RES, V64, P1447, DOI 10.1002/acr.21773
   Li Yu J, 2001, J RHEUMATOL, V28, P577
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   McAlindon TE, 2000, JAMA J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469
   Monfort J, 2008, ANN RHEUM DIS, V67, P735, DOI 10.1136/ard.2006.068882
   Nishimura A, 1997, J LEUKOCYTE BIOL, V62, P444, DOI 10.1002/jlb.62.4.444
   Pattison J, 2004, MED COLOR HDB SERIES, P240
   Pichert A, 2012, GLYCOBIOLOGY, V22, P134, DOI 10.1093/glycob/cwr120
   Reichenbach S, 2007, ANN INTERN MED, V146, P580, DOI 10.7326/0003 4819 146 8 200704170 00009
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Tat SK, 2010, J RHEUMATOL, V37, P656, DOI 10.3899/jrheum.090696
   Torres R, 2009, ANN RHEUM DIS, V68, P1602, DOI 10.1136/ard.2009.109355
   TSUCHIYA S, 1982, CANCER RES, V42, P1530
   Wortmann RL, 2010, CLIN THER, V32, P2386, DOI 10.1016/j.clinthera.2011.01.008
   Zhang W, 2006, ANN RHEUM DIS, V65, P1312, DOI 10.1136/ard.2006.055269
   Zhu YY, 2011, ARTHRITIS RHEUM US, V63, P3136, DOI 10.1002/art.30520
NR 29
TC 20
Z9 22
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD SEP 27
PY 2014
VL 15
AR 318
DI 10.1186/1471 2474 15 318
PG 6
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA AQ1CN
UT WOS:000342519100001
PM 25261974
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, WH
   Li, YY
   Yan, JL
   Xiong, P
   Li, QY
   Cheng, Y
   Zheng, YF
AF Zhou, Wenhao
   Li, Yangyang
   Yan, Jianglong
   Xiong, Pan
   Li, Qiyao
   Cheng, Yan
   Zheng, Yufeng
TI Construction of Self defensive Antibacterial and Osteogenic
   AgNPs/Gentamicin Coatings with Chitosan as Nanovalves for Controlled
   release
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESOPOROUS SILICA NANOPARTICLES; OSTEOBLAST FUNCTIONS; BIOMATERIALS;
   DELIVERY; SCAFFOLDS; BACTERIA; TITANIUM
AB To solve the Ti implants associated infection and poor osseointegration problems, we have constructed the AgNPs/gentamicin (Gen) loaded silk fibroin (SF) coating with acceptable antibacterial and osteogenic aptitude. Nevertheless, due to uncontrollably sustained drug release, this bactericidal coating encountered some tricky problems, such as local high Ag concentration, short life span and potential cytotoxicity. In this work, a chitosan (CS) barrier layer was constructed to prebuilt the SF based film by two means, dip coating (DCS) and spin coating (SCS). Intriguingly, the CS barrier layer constructed by spin coating highly improved the hydrophilic and protein absorbed performances. As verified in the release profile, both coatings showed a prolonged and pH dependent pattern of Ag+ with an accelerated release in acidic condition. Also, the multilayer coating with a SCS barrier layer showed an apparent bacteria trigged antibacterial and biofilm inhibited performances, whereas the improvements of antibacterial abilities of DCS coating were limited. The mechanisms could be explained that the pH decrease induced by the attachment and proliferation of bacteria triggered collapse of CS barrier layer, accelerating the release of bactericides. Moreover, benefitted from pH dependent release behavior of Ag and bioactive SCS layer, functional coatings highly enhanced the initial adhesion, migration and proliferation of preosteoblast MC3T3 E1 cells, and subsequently accelerated osteoblast differentiation (alkaline phosphatase production). A relevant aspect of this work was to demonstrate the essential effect of reasonable construction of self defensive barrier layer in achieving the balance between the high efficiency bacterial killing and osteogenic activity, and highlighted its excellent potential in clinical applications.
C1 [Zhou, Wenhao; Li, Yangyang; Yan, Jianglong; Xiong, Pan; Cheng, Yan; Zheng, Yufeng] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.
   [Zheng, Yufeng] Peking Univ, Coll Engn, Dept Adv Mat & Nanotechnol, Beijing 100871, Peoples R China.
   [Li, Qiyao] Penn State Univ, Huck Inst Life Sci, Res Inst, Dept Biomed Engn Mat, University Pk, PA 16802 USA.
C3 Peking University; Peking University; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania
   State University   University Park
RP Cheng, Y (通讯作者)，Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.
EM chengyan@pku.edu.cn
RI Yan, Jianglong/JDW 5655 2023; Xiong, Pan/ACK 9984 2022; Chen,
   Yinglong/D 2104 2011; YAN, Zheng Guang/HGC 8374 2022
OI Zheng, Y.F./0000 0002 7402 9979; Yan, Jianglong/0000 0001 9484 7138
FU National Natural Science Foundation of China [31670974, 31370954]
FX This work is jointly supported by National Natural Science Foundation of
   China (No. 31670974, No. 31370954).
CR Ahamed MIN, 2015, INT J BIOL MACROMOL, V72, P680, DOI 10.1016/j.ijbiomac.2014.08.055
   Amaral IF, 2005, J BIOMED MATER RES A, V75A, P387, DOI 10.1002/jbm.a.30436
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Campoccia D, 2013, BIOMATERIALS, V34, P8533, DOI 10.1016/j.biomaterials.2013.07.089
   Campoccia D, 2013, BIOMATERIALS, V34, P8018, DOI 10.1016/j.biomaterials.2013.07.048
   Castriciano MA, 2017, BIOMACROMOLECULES, V18, P1134, DOI 10.1021/acs.biomac.6b01752
   Chang CH, 2014, J MATER CHEM B, V2, P8496, DOI 10.1039/c4tb00992d
   Chinga Carrasco G, 2014, J BIOMATER APPL, V29, P423, DOI 10.1177/0885328214531511
   Di Martino A, 2005, BIOMATERIALS, V26, P5983, DOI 10.1016/j.biomaterials.2005.03.016
   Ding ZZ, 2017, J MATER CHEM B, V5, P4789, DOI [10.1039/C7TB00486A, 10.1039/c7tb00486a]
   Fei X, 2013, BIOMACROMOLECULES, V14, P4483, DOI 10.1021/bm4014149
   Gan Q, 2015, J MATER CHEM B, V3, P2056, DOI 10.1039/c4tb01897d
   Gao X, 2016, ACS APPL MATER INTER, V8, P3499, DOI 10.1021/acsami.5b12413
   Hadjesfandiari N, 2014, J MATER CHEM B, V2, P4968, DOI 10.1039/c4tb00550c
   Hu XX, 2014, CHEM ASIAN J, V9, P319, DOI 10.1002/asia.201301105
   Jafari H, 2016, INT J BIOL MACROMOL, V92, P461, DOI 10.1016/j.ijbiomac.2016.07.051
   Jia ZJ, 2016, ACS APPL MATER INTER, V8, P17151, DOI 10.1021/acsami.6b05198
   Jia ZJ, 2016, BIOMATERIALS, V75, P203, DOI 10.1016/j.biomaterials.2015.10.035
   Kazemzadeh Narbat M, 2013, BIOMATERIALS, V34, P5969, DOI 10.1016/j.biomaterials.2013.04.036
   Lahiji A, 2015, J BIOMEDICAL MAT RES, V51, P586
   Lee HS, 2015, BIOMACROMOLECULES, V16, P650, DOI 10.1021/bm501751v
   Lin WT, 2016, MATERIALS, V9, DOI 10.3390/ma9030155
   LogithKumar R, 2016, CARBOHYD POLYM, V151, P172, DOI 10.1016/j.carbpol.2016.05.049
   Lu HP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030334
   Lu YM, 2015, BIOMATERIALS, V45, P64, DOI 10.1016/j.biomaterials.2014.12.048
   Ma L, 2014, J MATER CHEM B, V2, P363, DOI 10.1039/c3tb21388a
   Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142 9612(99)00011 3
   Matos AC, 2014, MAT SCI ENG C MATER, V38, P218, DOI 10.1016/j.msec.2014.02.002
   Perera Costa D, 2014, LANGMUIR, V30, P4633, DOI 10.1021/la5001057
   Pourjavadi A, 2014, INT J POLYM MATER PO, V63, P692, DOI 10.1080/00914037.2013.862534
   Sanpui P, 2008, INT J FOOD MICROBIOL, V124, P142, DOI 10.1016/j.ijfoodmicro.2008.03.004
   Seib FP, 2013, ADV HEALTHC MATER, V2, P1606, DOI 10.1002/adhm.201300034
   Singh B. K., 2016, CHITIN CHITOSAN SILK
   Tang S, 2014, SURF COAT TECH, V251, P210, DOI 10.1016/j.surfcoat.2014.04.028
   Valle J, 2015, MACROMOL BIOSCI, V15, P1060, DOI 10.1002/mabi.201500107
   Wong S, 2014, J MATER CHEM B, V2, P595, DOI 10.1039/c3tb21344g
   Wu F, 2014, ACS APPL MATER INTER, V6, P10005, DOI 10.1021/am502537k
   Yan L, 2015, SMALL, V11, P4870, DOI 10.1002/smll.201501412
   Zhang F, 2008, BIOMATERIALS, V29, P4751, DOI 10.1016/j.biomaterials.2008.08.043
   Zhang JY, 2014, BIOMATERIALS, V35, P7690, DOI 10.1016/j.biomaterials.2014.05.069
   Zhang RZ, 2015, NANOMED NANOTECHNOL, V11, P1949, DOI 10.1016/j.nano.2015.07.016
   Zhou D, 2017, INT J NANOMED, V12, P2673, DOI 10.2147/IJN.S131251
   Zhou WH, 2017, ACS APPL MATER INTER, V9, P25830, DOI 10.1021/acsami.7b06757
NR 43
TC 25
Z9 28
U1 1
U2 54
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 7
PY 2018
VL 8
AR 13432
DI 10.1038/s41598 018 31843 2
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GS9FR
UT WOS:000444022800036
PM 30194357
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sagomonyants, K
   Mina, M
AF Sagomonyants, Karen
   Mina, Mina
TI Stage Specific Effects of Fibroblast Growth Factor 2 on the
   Differentiation of Dental Pulp Cells
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Odontoblast differentiation; Dental pulp; Progenitors; Fibroblast growth
   factor 2; Green fluorescent protein
ID STEM CELLS; IN VITRO; OSTEOBLAST LINEAGE; CONTROLLED RELEASE; GELATIN
   HYDROGELS; BONE FORMATION; FGF 2; MINERALIZATION; REGENERATION;
   EXPRESSION
AB Dentinogenesis is a complex and multistep process, which is regulated by various growth factors, including members of the fibroblast growth factor (FGF) family. Both positive and negative effects of FGFs on dentinogenesis have been reported, but the underlying mechanisms of these conflicting results are still unclear. To gain a better insight into the role of FGF2 in dentinogenesis, we used dental pulp cells from various transgenic mice, in which fluorescent protein expression identifies cells at different stages of odontoblast differentiation. Our results showed that the continuous exposure of pulp cells to FGF2 inhibited mineralization and revealed both the stimulatory and inhibitory effects of FGF2 on the expression of markers of dentinogenesis and various transgenes. During the proliferation phase of in vitro growth, FGF2 increased the expression of markers of dentinogenesis and the percentages of dentin matrix protein 1/green fluorescent protein (DMP1 GFP) positive functional odontoblasts and dentin sialophosphoprotein (DSPP) Cerulean positive odontoblasts. Additional exposure to FGF2 during the differentiation/mineralization phase of in vitro growth decreased the extent of mineralization and the expression of markers of dentinogenesis and of the DMP1 GFP and DSPP Cerulean transgenes. Recovery experiments showed that the inhibitory effects of FGF2 on dentinogenesis were related to the blocking of the differentiation of cells into mature odontoblasts. These observations together showed the stage specific effects of FGF2 on dentinogenesis by dental pulp cells, and they provide critical information for the development of improved treatments for vital pulp therapy and dentin regeneration. (C) 2015 S. Karger AG, Basel
C1 [Sagomonyants, Karen; Mina, Mina] Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Craniofacial Sci, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Mina, M (通讯作者)，Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Craniofacial Sci,Div Pediat Dent, Farmington, CT 06030 USA.
EM Mina@uchc.edu
RI Sagomonyants, Karen/S 5917 2017
OI Sagomonyants, Karen/0000 0002 5440 6036
FU National Institute of Health [R01 DE016689, T90 DE022526]
FX We would like to thank all individuals who provided reagents, valuable
   input and technical assistance for this study, including Drs. David
   Rowe, Peter Maye and Anamaria Balic, Gloria Gronowicz, Mrs. Barbara
   Rodgers and members of the Molecular Core and Flow Cytometry Facilities
   at UCHC. This work was supported by grants No. R01 DE016689 and
   T90 DE022526 from the National Institute of Health.
CR Balic A, 2011, BONE, V48, P927, DOI 10.1016/j.bone.2010.12.008
   Balic A, 2010, BONE, V47, P948, DOI 10.1016/j.bone.2010.08.009
   Balic A, 2010, BONE, V46, P1639, DOI 10.1016/j.bone.2010.02.019
   Braut A, 2003, INT J DEV BIOL, V47, P281
   Cooper PR, 2010, J DENT, V38, P687, DOI 10.1016/j.jdent.2010.05.016
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Eda H, 2008, BIOCHEM BIOPH RES CO, V366, P471, DOI 10.1016/j.bbrc.2007.11.140
   Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003
   Hatch NE, 2010, CRIT REV EUKAR GENE, V20, P295, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.20
   He HX, 2008, CELL BIOL INT, V32, P827, DOI 10.1016/j.cellbi.2008.03.013
   Ishimatsu H, 2009, J ENDODONT, V35, P858, DOI 10.1016/j.joen.2009.03.049
   James AW, 2008, PLAST RECONSTR SURG, V122, P53, DOI 10.1097/PRS.0b013e31817747b5
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006
   Kalajzic I, 2003, J CELL BIOCHEM, V88, P1168, DOI 10.1002/jcb.10459
   Kikuchi N, 2007, J ENDODONT, V33, P1198, DOI 10.1016/j.joen.2007.07.025
   Kim JC, 2014, ORAL DIS, V20, P191, DOI 10.1111/odi.12089
   Kim YS, 2010, J ENDODONT, V36, P1824, DOI 10.1016/j.joen.2010.08.020
   Kuhn LT, 2010, TISSUE ENG PART C ME, V16, P1357, DOI [10.1089/ten.tec.2009.0701, 10.1089/ten.TEC.2009.0701]
   Kyono A, 2012, J BONE MINER METAB, V30, P19, DOI 10.1007/s00774 011 0288 2
   Li CY, 2014, ODONTOLOGY, V102, P1, DOI 10.1007/s10266 013 0142 1
   Madan AK, 2005, J MOL HISTOL, V36, P171, DOI 10.1007/s10735 005 2684 1
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   Marie PJ, 2012, GROWTH FACTORS, V30, P117, DOI 10.3109/08977194.2012.656761
   Marie PJ, 2012, GENE, V498, P1, DOI 10.1016/j.gene.2012.01.086
   Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9
   Morito A, 2009, ARCH HISTOL CYTOL, V72, P51, DOI 10.1679/aohc.72.51
   Mulrooney JP, 2001, J CELL SCI, V114, P2525
   Nakao K, 2004, BIOCHEM BIOPH RES CO, V325, P1052, DOI 10.1016/j.bbrc.2004.10.136
   Nakayama Y, 2012, J ORAL SCI, V54, P251, DOI 10.2334/josnusd.54.251
   Osathanon T, 2011, J CELL BIOCHEM, V112, P1807, DOI 10.1002/jcb.23097
   Priam F, 2005, ARCH ORAL BIOL, V50, P271, DOI 10.1016/j.archoralbio.2004.10.007
   Roberts Clark DJ, 2000, ARCH ORAL BIOL, V45, P1013, DOI 10.1016/S0003 9969(00)00075 3
   Shimabukuro Y, 2009, J ENDODONT, V35, P1529, DOI 10.1016/j.joen.2009.08.010
   Smith AJ, 2012, ARCH ORAL BIOL, V57, P109, DOI 10.1016/j.archoralbio.2011.07.008
   Suzuki T, 2011, J DENT RES, V90, P1013, DOI 10.1177/0022034511408426
   Tsuboi T, 2003, CALCIFIED TISSUE INT, V73, P496, DOI 10.1007/s00223 002 4070 2
   Wu JY, 2012, J ENDODONT, V38, P614, DOI 10.1016/j.joen.2012.01.014
   Xiao LP, 2013, J BONE MINER RES, V28, P35, DOI 10.1002/jbmr.1721
   Xiao LP, 2009, J BIOL CHEM, V284, P3170, DOI 10.1074/jbc.M804900200
   Yamachika E, 2012, J MOL HISTOL, V43, P223, DOI 10.1007/s10735 011 9385 8
NR 41
TC 21
Z9 22
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2014
VL 199
IS 5 6
BP 311
EP 328
DI 10.1159/000371343
PG 18
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA CF5UQ
UT WOS:000352623100002
PM 25823776
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Migliorini, F
   Trivellas, A
   Eschweiler, J
   Driessen, A
   Tingart, M
   Maffulli, N
AF Migliorini, Filippo
   Trivellas, Andromahi
   Eschweiler, Joerg
   Driessen, Arne
   Tingart, Markus
   Maffulli, Nicola
TI NSAIDs for Prophylaxis for Heterotopic Ossification After Total Hip
   Arthroplasty: A Bayesian Network Meta analysis
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Heterotopic ossification; Total hip arthroplasty; NSAID
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE COX 2 INHIBITOR;
   BONE FORMATION; RANDOMIZED TRIAL; PREVENTION; INDOMETHACIN; REPLACEMENT;
   IBUPROFEN; RADIATION; CELECOXIB
AB Non steroidal anti inflammatory drugs (NSAID) have been recommended to prevent of heterotopic ossification (HO) after total hip arthroplasty (THA), but debates are still ongoing. The present Bayesian network meta analysis of randomized clinical trials (RCTs) compared all available pathways of NSAID treatment as prophylaxis for HO after THA. The present Bayesian network meta analysis was conducted according to The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta analyses of Health Care Interventions guidelines. All randomized clinical trials comparing two or more interventions to prevent HO after THA were considered for analysis. HO was classified according to Brooker. The quality of the methodological assessment was performed through the risk of bias summary tool of the Review Manager Software 5.3 (The Cochrane Collaboration, Copenhagen). The network meta analysis was performed through a STATA routine for Bayesian hierarchical random effects model analysis, with log odd ratio (LOR) effect measure. Data from 26 studies (6396 THAs; 58% females) were collected. The mean follow up was 10.50 +/  5.7 months. ANOVA showed good comparability among mean age and gender (P > 0.5). Celecoxib demonstrated the highest rate of Brooker class 0 (LOR 6.96), followed by diclofenac (LOR 6.94). Naproxen demonstrated the lowest rate of Brooker I HO (LOR 2.82), followed by celecoxib (LOR 3.52). Celecoxib demonstrated lowest rate of Brooker class II HO (LOR 1.66), class III (LOR), and class IV (LOR 0.25). The equation for global linearity detected no statistically significant inconsistency (P > 0.5) in all the comparisons. The present Bayesian network meta analysis encourages the use of celecoxib as a prophylaxis for HO. These conclusions must be interpreted in light of the limitations of the present study. Future investigations are required to establish more definitely the role of celecoxib. Level of Evidence: I, Bayesian network analysis of RCTs.
C1 [Migliorini, Filippo; Eschweiler, Joerg; Driessen, Arne; Tingart, Markus] RWTH Aachen Univ Clin, Dept Orthopaed, Pauwelstr 31, D 52074 Aachen, Germany.
   [Trivellas, Andromahi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
   [Maffulli, Nicola] Univ Salerno, Dept Med Surg & Dent, Via S Allende, I 84081 Baronissi, SA, Italy.
   [Maffulli, Nicola] Keele Univ, Sch Pharm & Bioengn, Sch Med, Thornburrow Dr, Stoke On Trent, Staffs, England.
   [Maffulli, Nicola] Queen Mary Univ London, Ctr Sports & Exercise Med, Mile End Hosp, Barts & London Sch Med & Dent, 275 Bancroft Rd, London E1 4DG, England.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of Salerno; Keele University; Barts Health NHS
   Trust; Mile End Hospital; University of London; Queen Mary University
   London
RP Maffulli, N (通讯作者)，Univ Salerno, Dept Med Surg & Dent, Via S Allende, I 84081 Baronissi, SA, Italy.; Maffulli, N (通讯作者)，Keele Univ, Sch Pharm & Bioengn, Sch Med, Thornburrow Dr, Stoke On Trent, Staffs, England.; Maffulli, N (通讯作者)，Queen Mary Univ London, Ctr Sports & Exercise Med, Mile End Hosp, Barts & London Sch Med & Dent, 275 Bancroft Rd, London E1 4DG, England.
EM n.maffulli@qmul.ac.uk
RI ; Trivellas, Andromahi/LFT 5326 2024; Migliorini, Filippo/AAZ 9529 2021;
   Maffulli, Nicola/A 1839 2014; Eschweiler, Joerg/KVZ 2914 2024
OI Eschweiler, Jorg/0000 0002 8477 4884; Migliorini,
   Filippo/0000 0001 7220 1221; Trivellas, Andromahi/0000 0002 3002 1764;
   Maffulli, Nicola/0000 0002 5327 3702; 
FU Universita degli Studi di Salerno within the CRUI CARE Agreement
FX Open access funding provided by Universita degli Studi di Salerno within
   the CRUI CARE Agreement. No external source of funding was used.
CR AHRENGART L, 1994, ACTA ORTHOP SCAND, V65, P139, DOI 10.3109/17453679408995421
   Alijanipour P, 2017, J ARTHROPLASTY, V32, P1323, DOI 10.1016/j.arth.2016.11.030
   Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053
   Barthel T, 2002, ACTA ORTHOP SCAND, V73, P611, DOI 10.3109/17453670209178023
   Bek D, 2009, J ARTHROPLASTY, V24, P226, DOI 10.1016/j.arth.2007.11.008
   Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468
   Board TN, 2007, J BONE JOINT SURG BR, V89B, P434, DOI 10.1302/0301 620X.89B4.18845
   BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623 197355080 00006
   Brunnekreef JJ, 2013, INT ORTHOP, V37, P583, DOI 10.1007/s00264 013 1781 0
   Burssens A, 1995, Acta Orthop Belg, V61, P205
   Buvanendran A, 2007, ANESTHESIOLOGY, V107, P358, DOI 10.1097/01.anes.0000271873.86164.74
   Cai LY, 2019, INT J SURG, V62, P74, DOI 10.1016/j.ijsu.2018.12.011
   Dorn U, 1998, ACTA ORTHOP SCAND, V69, P107, DOI 10.3109/17453679809117607
   ELMSTEDT E, 1985, ACTA ORTHOP SCAND, V56, P25, DOI 10.3109/17453678508992973
   Farris MK, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748 717X 7 140
   Fransen M, 2006, BRIT MED J, V333, P519, DOI 10.1136/bmj.38925.471146.4F
   Gebuhr P, 1996, ACTA ORTHOP SCAND, V67, P29, DOI 10.3109/17453679608995604
   GEBUHR P, 1991, ACTA ORTHOP SCAND, V62, P226, DOI 10.3109/17453679108993597
   Grohs JG, 2007, ACTA ORTHOP, V78, P95, DOI 10.1080/17453670610013484
   Howick J., The Oxford 2011 Levels of Evidence
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14 2385
   Iorio Richard, 2002, J Am Acad Orthop Surg, V10, P409
   Joice M, 2018, BONE JOINT J, V100B, P915, DOI 10.1302/0301 620X.100B7.BJJ 2017 1467.R1
   Kan SL, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000828
   Kienapfel H, 1999, ARCH ORTHOP TRAUM SU, V119, P296, DOI 10.1007/s004020050414
   KJAERSGAARDANDERSEN P, 1993, ACTA ORTHOP SCAND, V64, P639, DOI 10.3109/17453679308994587
   Knelles D, 1997, J BONE JOINT SURG BR, V79B, P596, DOI 10.1302/0301 620X.79B4.6829
   Kölbl O, 1998, INT J RADIAT ONCOL, V42, P397, DOI 10.1016/S0360 3016(98)00204 1
   Kolbl O, 1997, INT J RADIAT ONCOL, V39, P961, DOI 10.1016/S0360 3016(97)00496 3
   Lavernia CJ, 2014, J ARTHROPLASTY, V29, P390, DOI 10.1016/j.arth.2013.06.039
   Lee A., 2020, STATPEARLS
   Legenstein R, 2003, ARCH ORTHOP TRAUM SU, V123, P91, DOI 10.1007/s00402 003 0487 y
   Legosz P, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3860142
   Li TJ, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 79
   Macfarlane RJ, 2008, EXPERT OPIN PHARMACO, V9, P767, DOI 10.1517/14656566.9.5.767
   Migliorini F, 2021, Musculoskelet Surg, V105, P1, DOI 10.1007/s12306 020 00662 y
   Migliorini F, 2020, Musculoskelet Surg, V104, P257, DOI 10.1007/s12306 020 00657 9
   Migliorini F, 2020, ARCH ORTHOP TRAUM SU, V140, P1115, DOI 10.1007/s00402 020 03448 w
   Migliorini F, 2020, EUR J ORTHOP SURG TR, V30, P979, DOI 10.1007/s00590 020 02648 9
   Mourad WF, 2012, PRACT RADIAT ONCOL, V2, P151, DOI 10.1016/j.prro.2011.06.005
   Neal BC, 2000, ACTA ORTHOP SCAND, V71, P122, DOI 10.1080/000164700317413076
   Neal BC, 2000, ACTA ORTHOP SCAND, V71, P129, DOI 10.1080/000164700317413085
   Oni JK, 2014, HIP INT, V24, P256, DOI 10.5301/hipint.5000109
   Persson' PE, 1998, ACTA ORTHOP SCAND, V69, P111, DOI 10.3109/17453679809117608
   REIS HJ, 1992, INT ORTHOP, V16, P140, DOI 10.1007/BF00180205
   Saudan M, 2007, J BONE JOINT SURG BR, V89B, P155, DOI 10.1302/0301 620X.89B2.17747
   SCHMIDT SA, 1988, J BONE JOINT SURG AM, V70A, P834, DOI 10.2106/00004623 198870060 00005
   Sell S, 1998, J ARTHROPLASTY, V13, P854, DOI 10.1016/S0883 5403(98)90189 9
   van der Heide HJL, 2007, ARCH ORTHOP TRAUM SU, V127, P557, DOI 10.1007/s00402 006 0243 1
   van der Heide Huub J L, 2004, Acta Orthop Belg, V70, P240
   van der Heide HJL, 2007, ACTA ORTHOP, V78, P90, DOI 10.1080/17453670610013475
   Vielpeau C, 1999, CLIN ORTHOP RELAT R, P279
   WAHLSTROM O, 1991, ACTA ORTHOP SCAND, V62, P419, DOI 10.3109/17453679108996636
   Weber EWG, 2003, EUR J ANAESTH, V20, P963, DOI 10.1097/00003643 200312000 00005
   Winkler S, 2016, INT ORTHOP, V40, P673, DOI 10.1007/s00264 015 3077 z
   [赵伟光 Zhao Weiguang], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P9760
   Zhu XT, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011649
   Zhu YB, 2015, ARCH ORTHOP TRAUM SU, V135, P1307, DOI 10.1007/s00402 015 2277 8
NR 58
TC 30
Z9 31
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD FEB
PY 2021
VL 108
IS 2
BP 196
EP 206
DI 10.1007/s00223 020 00763 7
EA OCT 2020
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PU7PO
UT WOS:000577046600002
PM 33044630
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Tokunaga, T
   Ando, T
   Suzuki Karasaki, M
   Ito, T
   Onoe Takahashi, A
   Ochiai, T
   Soma, M
   Suzuki Karasaki, Y
AF Tokunaga, Tomohiko
   Ando, Takashi
   Suzuki Karasaki, Miki
   Ito, Tomohisa
   Onoe Takahashi, Asuka
   Ochiai, Toyoko
   Soma, Masayoshi
   Suzuki Karasaki, Yoshihiro
TI Plasma stimulated medium kills TRAIL resistant human malignant cells by
   promoting caspase independent cell death via membrane potential and
   calcium dynamics modulation
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE TRAIL; cold plasma stimulated medium; calcium; non apoptotic cell death;
   mitochondrial dynamics
ID HUMAN CANCER CELLS; MITOCHONDRIAL NETWORK; INDUCED APOPTOSIS; TARGETED
   THERAPY; MELANOMA CELLS; DEPOLARIZATION; ROS; SUSCEPTIBILITY;
   CHEMOTHERAPY; APO2L/TRAIL
AB Tumor necrosis factor related apoptosis inducing ligand (TRAIL) and cold plasma stimulated medium (PSM) have been shown to exhibit tumor selective cytotoxicity and have emerged as promising new tools for cancer treatment. However, to date, at least to the best of our knowledge, no data are available as to which substance is more potent in killing cancer cells. Thus, in this study, we systematically compared their abilities to kill human malignant cells from different origins. We found that PSM dose dependently killed TRAIL resistant melanoma, osteosarcoma and neuroblastoma cells. Moreover, PSM had little cytotoxicity toward osteoblasts. PSM was more potent than TRAIL in inducing caspase 3/7 activation, mitochondrial network aberration and caspase independent cell death. We also found that PSM was more potent in inducing plasma membrane depolarization (PMD) and disrupting endoplasmic mitochondrial Ca2+ homeostasis. Moreover, persistent PMD was caused by different membrane depolarizing agents; the use of the anti type II diabetes drug, glibenclamide, alone caused mitochondrial fragmentation and enhanced TRAIL induced Ca2+ modulation, mitochondrial network abnormalities and caspase independent cell killing. These results demonstrate that PSM has a therapeutic advantage over TRAIL owing to its greater capacity to evoke caspase independent cell death via mitochondrial network aberration by disrupting membrane potential and Ca2+ homeostasis. These findings may provide a strong rationale for developing PSM as a novel approach for the treatment of TRAIL resistant malignant cells.
C1 [Tokunaga, Tomohiko; Soma, Masayoshi] Nihon Univ, Div Gen Med, Sch Med, Tokyo 1738610, Japan.
   [Ando, Takashi] Yamanashi Univ, Dept Orthoped Surg, Sch Med, Chuo, Yamanashi 4093898, Japan.
   [Suzuki Karasaki, Miki; Suzuki Karasaki, Yoshihiro] Plasma ChemiBio Lab, 398 Takaatsu, Nasushiobara, Tochigi 3292813, Japan.
   [Suzuki Karasaki, Miki; Ito, Tomohisa] Nihon Univ, Dept Orthoped Surg, Sch Med, Tokyo 1738610, Japan.
   [Onoe Takahashi, Asuka; Ochiai, Toyoko] Nihon Univ Hosp, Dept Dermatol, Tokyo 1018309, Japan.
   [Suzuki Karasaki, Yoshihiro] Nihon Univ, Div Physiol, Dept Biomed Sci, Sch Med, Tokyo 1738610, Japan.
C3 Nihon University; University of Yamanashi; Nihon University; Nihon
   University; Nihon University
RP Suzuki Karasaki, Y (通讯作者)，Plasma ChemiBio Lab, 398 Takaatsu, Nasushiobara, Tochigi 3292813, Japan.
EM suzuki.pcbl@gmail.com
OI Suzuki Karasaki, Yoshihiro/0000 0003 1158 178X
FU JSPS KAKENHI [16K10851, 15K09792, 15K06883, 15K09750]; Grants in Aid for
   Scientific Research [15K09750, 16K10851, 15K06883, 15K09792] Funding
   Source: KAKEN
FX The authors would like to thank the Health Science Research Resource
   Bank (Osaka, Japan), Riken BioResource Center, and Dr Eugenie Kleinerman
   for providing the cell lines. This study was supported in part by JSPS
   KAKENHI grant nos. 16K10851 to T.A., 15K09792 to T.O., 15K06883 to M.S.
   and 15K09750 to Y.S. K.
CR Adachi T, 2016, ARCH BIOCHEM BIOPHYS, V606, P120, DOI 10.1016/j.abb.2016.07.019
   Adachi T, 2015, FREE RADICAL BIO MED, V79, P28, DOI 10.1016/j.freeradbiomed.2014.11.014
   Akita M, 2014, INT J ONCOL, V45, P1901, DOI 10.3892/ijo.2014.2608
   Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359 6101(03)00029 7
   Bonora M, 2015, ONCOGENE, V34, P1608, DOI [10.1038/onc.2014.462, 10.1038/onc.2014.96]
   Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200
   Cerchia C, 2017, CURR MED CHEM, V24, P2312, DOI 10.2174/0929867324666170414163937
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Danese A, 2017, BBA BIOENERGETICS, V1858, P615, DOI 10.1016/j.bbabio.2017.01.003
   de Miguel D, 2016, CELL DEATH DIFFER, V23, P733, DOI 10.1038/cdd.2015.174
   Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164
   Dyer MJS, 2007, J CLIN ONCOL, V25, P4505, DOI 10.1200/JCO.2007.13.1011
   Elgass K., 2013, BIOCHIM BIOPHYS ACTA, V1833, P150, DOI [DOI 10.1016/J.BBAMCR.2012.05.002, 10.1016/j.bbamcr.2012.05.002]
   Elustondo PA, 2017, J BIOENERG BIOMEMBR, V49, P113, DOI 10.1007/s10863 016 9676 6
   Galluzzi L, 2016, CELL MOL LIFE SCI, V73, P2405, DOI 10.1007/s00018 016 2209 y
   Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221
   Guerrero Preston R, 2014, INT J MOL MED, V34, P941, DOI 10.3892/ijmm.2014.1849
   Guiho R, 2015, FUTURE ONCOL, V11, P535, DOI 10.2217/fon.14.293
   Hattori N, 2015, INT J ONCOL, V47, P1655, DOI 10.3892/ijo.2015.3149
   He HT, 2014, ONCOL LETT, V7, P1352, DOI 10.3892/ol.2014.1935
   Hirst AM, 2015, BRIT J CANCER, V112, P1536, DOI 10.1038/bjc.2015.113
   Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048
   Ishaq M, 2014, MOL BIOL CELL, V25, P1523, DOI 10.1091/mbc.E13 10 0590
   Ishaq M, 2014, INT J CANCER, V134, P1517, DOI 10.1002/ijc.28323
   Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456
   Izzo V, 2016, TRENDS CELL BIOL, V26, P655, DOI 10.1016/j.tcb.2016.04.006
   Jardin I, 2016, BBA MOL CELL RES, V1863, P1418, DOI 10.1016/j.bbamcr.2015.10.003
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Judée F, 2016, SCI REP UK, V6, DOI 10.1038/srep21421
   Kalal BS, 2017, ONCOL REV, V11, P19, DOI 10.4081/oncol.2017.326
   Keidar M, 2011, BRIT J CANCER, V105, P1295, DOI 10.1038/bjc.2011.386
   Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074 7613(00)80212 5
   Kurake N, 2016, ARCH BIOCHEM BIOPHYS, V605, P102, DOI 10.1016/j.abb.2016.01.011
   Landes T, 2011, BBA MOL CELL RES, V1813, P540, DOI 10.1016/j.bbamcr.2011.01.021
   Lang F, 2007, METHOD ENZYMOL, V428, P209, DOI 10.1016/S0076 6879(07)28011 5
   LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187
   Li SY, 2015, TUMOR BIOL, V36, P1329, DOI 10.1007/s13277 015 3181 0
   Marchi S, 2016, CURR OPIN PHARMACOL, V29, P1, DOI 10.1016/j.coph.2016.03.002
   McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296
   Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18
   Nolte F, 2004, FEBS LETT, V578, P85, DOI 10.1016/j.febslet.2004.10.075
   Ohshima Y, 2017, INT J ONCOL, V51, P1146, DOI 10.3892/ijo.2017.4096
   Orrenius S, 2015, BIOCHEM BIOPH RES CO, V460, P72, DOI 10.1016/j.bbrc.2015.01.137
   Saito K, 2016, ONCOTARGET, V7, P19910, DOI 10.18632/oncotarget.7889
   Suzuki Y, 2012, INT J ONCOL, V41, P465, DOI 10.3892/ijo.2012.1483
   Suzuki Karasaki M, 2014, INT J ONCOL, V44, P616, DOI 10.3892/ijo.2013.2215
   Suzuki Karasaki Y, 2015, ONCOTARGET, V6, P21572, DOI 10.18632/oncotarget.4268
   Takata N, 2017, INT J ONCOL, V51, P193, DOI 10.3892/ijo.2017.4020
   Torii K, 2015, GASTRIC CANCER, V18, P635, DOI 10.1007/s10120 014 0395 6
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Utsumi F, 2016, ONCOL REP, V35, P3169, DOI 10.3892/or.2016.4726
   Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576
   Vandamme M, 2012, INT J CANCER, V130, P2185, DOI 10.1002/ijc.26252
   Wang MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072189
   Wang S, 2008, ONCOGENE, V27, P6207, DOI 10.1038/onc.2008.298
   Yin W, 2009, BIOCHEM PHARMACOL, V78, P191, DOI 10.1016/j.bcp.2009.03.025
   Zucker SN, 2012, CANCER BIOL THER, V13, P1299, DOI 10.4161/cbt.21787
NR 57
TC 17
Z9 18
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2018
VL 52
IS 3
BP 697
EP 708
DI 10.3892/ijo.2018.4251
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FW1HC
UT WOS:000425046800005
PM 29393427
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Salis, A
   Fanti, M
   Medda, L
   Nairi, V
   Cugia, F
   Piludu, M
   Sogos, V
   Monduzzi, M
AF Salis, Andrea
   Fanti, Maura
   Medda, Luca
   Nairi, Valentina
   Cugia, Francesca
   Piludu, Marco
   Sogos, Valeria
   Monduzzi, Maura
TI Mesoporous Silica Nanoparticles Functionalized with Hyaluronic Acid and
   Chitosan Biopolymers. Effect of Functionalization on Cell
   Internalization
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE nanomedicine; mesoporous silica nanoparticles; functionalization;
   biopolymers; hyaluronic acid; chitosan; cytotoxicity; transmission
   electron microscopy
ID TARGETED DRUG DELIVERY; BIOMEDICAL APPLICATIONS; MOLECULAR RECOGNITION;
   PHOSPHOTUNGSTIC ACID; OSTEOBLAST ADHESION; LYSOZYME ADSORPTION;
   CANCER THERAPY; SURFACE; PROTEINS; TOXICITY
AB Mesoporous silica nanoparticles (MSNs), based on the MCM 41 matrix, were functionalized with amino groups, and then with hyaluronic acid (HA) or chitosan (CHIT) to fabricate bioactive conjugates. The role of the functional groups toward cytotoxicity and cellular uptake was investigated using 3T3 mouse fibroblast cells. A very high biocompatibility of MSN NH2, MSN HA and MSN CHIT matrices was assessed through the MTS biological assay and Coulter counter evaluation. No significant differences in cytotoxicity data arise from the presence of different functional groups in the investigated MSNs. Fluorescence microscopy experiments performed using fluorescein isothiocyanate conjugated MSN NH2, MSN HA, and MSN CHIT, and transmission electron microscopy experiments performed on slices of the investigated systems embedded in epoxy resins give evidence of significant differences due to type of functionalization in terms of cellular uptake and stability of the particles in the biological medium. MSN NH2 and MSN HA conjugates are easily internalized, the uptake of the HA functionalized MSNs being much higher than that of the  NH2 functionalized MSNs. Differently, MSN CHIT conjugates tend to give large aggregates dispersed in the medium or localized at the external surface of the cell membranes. Both fluorescence microscopy and TEM images show that the MSNs are distributed in the cytoplasm of the cells in the case of MSN NH2 and MSN HA, whereas only a few particles are internalized in the case of MSN CHIT. Flow cytometry experiments confirmed quantitatively the selectively high cellular uptake of MSN HA particles.
C1 [Salis, Andrea; Medda, Luca; Nairi, Valentina; Cugia, Francesca; Monduzzi, Maura] Univ Cagliari, CSGI & CNBS, Dept Chem & Geol Sci, SS 554 Bivio Sestu, I 09042 Cagliari, Italy.
   [Fanti, Maura; Piludu, Marco; Sogos, Valeria] Univ Cagliari, Dept Biomed Sci, SS 554 Bivio Sestu, I 09042 Cagliari, Italy.
C3 University of Cagliari; University of Cagliari
RP Salis, A; Monduzzi, M (通讯作者)，Univ Cagliari, CSGI & CNBS, Dept Chem & Geol Sci, SS 554 Bivio Sestu, I 09042 Cagliari, Italy.
EM asalis@unica.it; monduzzi@unica.it
RI Salis, Andrea/B 7660 2011; Monduzzi, Maura/A 8932 2012; Sogos,
   Valeria/B 5471 2012
OI Sogos, Valeria/0000 0002 4021 1043; Salis, Andrea/0000 0001 5746 2693;
   MONDUZZI, MAURA/0000 0003 0200 7700; Medda, Luca/0000 0001 5437 8322;
   Fanti, Maura/0000 0002 8627 666X
FU MIUR, PRIN [2010BJ23MN 002]; Fondazione Banco di Sardegna
FX MIUR, PRIN 2010 2011 Grant 2010BJ23MN 002, and Fondazione Banco di
   Sardegna are thanked for financial support. Prof. M. Casula is thanked
   for TGA measurements. Marco Sanna and Gino Paolo Asuni are thanked for
   experimental support.
CR Baeza A, 2015, EXPERT OPIN DRUG DEL, V12, P319, DOI 10.1517/17425247.2014.953051
   Balas F, 2008, ACTA BIOMATER, V4, P514, DOI 10.1016/j.actbio.2007.11.009
   Bancos S., 2012, ISRN Nanotechnology, DOI 10.5402/2012/454072
   Bhattacharyya MS, 2010, J PHYS CHEM C, V114, P19928, DOI 10.1021/jp1078218
   Böcking D, 2014, NANOSCALE, V6, P1490, DOI 10.1039/c3nr04022d
   Chen Y, 2013, ADV MATER, V25, P3144, DOI 10.1002/adma.201205292
   Chen ZW, 2013, CHEM EUR J, V19, P1778, DOI 10.1002/chem.201202038
   Cugia F, 2013, RSC ADV, V3, P5882, DOI 10.1039/c3ra00063j
   Decuzzi P, 2010, BIOMATERIALS, V31, P173, DOI 10.1016/j.biomaterials.2009.09.018
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   El Ghannam A, 1999, J ORTHOPAED RES, V17, P340, DOI 10.1002/jor.1100170307
   FEIZI T, 1988, BIOCHEM SOC T, V16, P930, DOI 10.1042/bst0160930
   Feng W, 2014, ACS APPL MATER INTER, V6, P8447, DOI 10.1021/am501337s
   Fu CH, 2013, BIOMATERIALS, V34, P2565, DOI 10.1016/j.biomaterials.2012.12.043
   Gagner JE, 2012, J PHYS CHEM LETT, V3, P3149, DOI 10.1021/jz301253s
   Girish KS, 2007, LIFE SCI, V80, P1921, DOI 10.1016/j.lfs.2007.02.037
   Gómez Cerezo N, 2015, J MATER CHEM B, V3, P3810, DOI 10.1039/c5tb00268k
   Guarnieri D, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 013 2229 6
   Hakeem A, 2014, CHEM COMMUN, V50, P13268, DOI 10.1039/c4cc04383a
   Harris JR, 1999, MICRON, V30, P289, DOI 10.1016/S0968 4328(99)00034 7
   Hoffmann F, 2006, ANGEW CHEM INT EDIT, V45, P3216, DOI 10.1002/anie.200503075
   Hudson SP, 2008, BIOMATERIALS, V29, P4045, DOI 10.1016/j.biomaterials.2008.07.007
   Jordan AR, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00182
   Knudson W, 2004, CHEMISTRY AND BIOLOGY OF HYALURONAN, P83
   Kornu R, 1996, J ORTHOPAED RES, V14, P871, DOI 10.1002/jor.1100140605
   Kresge CT, 2013, CHEM SOC REV, V42, P3663, DOI 10.1039/c3cs60016e
   Lebeau B, 2013, CHEM SOC REV, V42, P3661, DOI 10.1039/c3cs90005c
   Li LL, 2010, ACS NANO, V4, P6874, DOI 10.1021/nn100918a
   Li X, 2013, BIOMATERIALS, V34, P1391, DOI 10.1016/j.biomaterials.2012.10.072
   LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409
   Mamaeva V, 2013, ADV DRUG DELIVER REV, V65, P689, DOI 10.1016/j.addr.2012.07.018
   Medda L, 2015, CHEM COMMUN, V51, P6663, DOI 10.1039/c5cc01538c
   Medda L, 2014, LANGMUIR, V30, P12996, DOI 10.1021/la503224n
   Medda L, 2013, LANGMUIR, V29, P15350, DOI 10.1021/la404249n
   Meng H, 2011, ACS NANO, V5, P4131, DOI 10.1021/nn200809t
   Monduzzi M, 2014, ADV COLLOID INTERFAC, V205, P48, DOI 10.1016/j.cis.2013.10.009
   Necas J, 2008, VET MED CZECH, V53, P397, DOI 10.17221/1930 VETMED
   Piludu M, 2015, LANGMUIR, V31, P9458, DOI 10.1021/acs.langmuir.5b02830
   Piras M, 2011, CHEM COMMUN, V47, P7338, DOI 10.1039/c1cc11840d
   PONOMAREV AP, 1979, VOP VIRUSOL+, P470
   Salis A, 2016, COLLOID SURFACE B, V137, P77, DOI 10.1016/j.colsurfb.2015.04.068
   Salis A, 2014, CHEM SOC REV, V43, P7358, DOI 10.1039/c4cs00144c
   Salis A, 2010, CHEMCATCHEM, V2, P322, DOI 10.1002/cctc.200900288
   Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]
   Senthilkumar R, 2015, BIOMATER SCI UK, V3, P103, DOI 10.1039/c4bm00278d
   Shahabi S, 2015, ACS APPL MATER INTER, V7, P13821, DOI 10.1021/acsami.5b01900
   SILVERMA.L, 1969, J CELL BIOL, V40, P761, DOI 10.1083/jcb.40.3.761
   Slowing I, 2006, J AM CHEM SOC, V128, P14792, DOI 10.1021/ja0645943
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Slowing II, 2007, J AM CHEM SOC, V129, P8845, DOI 10.1021/ja0719780
   Steri D, 2013, MICROPOR MESOPOR MAT, V170, P164, DOI 10.1016/j.micromeso.2012.12.002
   Vallet Regí M, 2005, SOLID STATE SCI, V7, P233, DOI 10.1016/j.solidstatesciences.2004.10.038
   Vallet Regí MA, 2006, J MATER CHEM, V16, P26, DOI 10.1039/b509744d
   Vasi AM, 2014, MAT SCI ENG C MATER, V38, P177, DOI 10.1016/j.msec.2014.01.052
   Wang EJ, 2001, CHEM RES TOXICOL, V14, P1596, DOI 10.1021/tx010125x
   Wang Y, 2015, NANOMED NANOTECHNOL, V11, P313, DOI 10.1016/j.nano.2014.09.014
   Yu MH, 2013, NANOSCALE, V5, P178, DOI 10.1039/c2nr32145a
   Yu T, 2012, ACS NANO, V6, P2289, DOI 10.1021/nn2043803
   Zhao QF, 2014, ACS APPL MATER INTER, V6, P20290, DOI 10.1021/am505824d
NR 59
TC 53
Z9 58
U1 6
U2 171
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD MAY
PY 2016
VL 2
IS 5
BP 741
EP 751
DI 10.1021/acsbiomaterials.5b00502
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA DL8LN
UT WOS:000375893600005
PM 33440571
OA Green Submitted
DA 2025 08 17
ER

PT J
AU D'Amico, E
   Pierfelice, TV
   Amoroso, R
   Cacciatore, I
   D'Arcangelo, C
   Lepore, S
   D'Ercole, S
   Di Pietro, N
   Di Rienzo, A
   Petrini, M
   Piattelli, A
   Ricci, A
   Zara, S
   Di Stefano, A
   Iezzi, G
   De Filippis, B
AF D'Amico, Emira
   Pierfelice, Tania Vanessa
   Amoroso, Rosa
   Cacciatore, Ivana
   D'Arcangelo, Camillo
   Lepore, Stefania
   D'Ercole, Simonetta
   Di Pietro, Natalia
   Di Rienzo, Annalisa
   Petrini, Morena
   Piattelli, Adriano
   Ricci, Alessia
   Zara, Susi
   Di Stefano, Antonio
   Iezzi, Giovanna
   De Filippis, Barbara
TI Emerging Effects of Resveratrol Derivatives in Cells Involved in Oral
   Wound Healing: A Preliminary Study
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE resveratrol derivatives; sulfonamides; gingival fibroblasts
   proliferation; endothelial cells; oral osteoblasts; mineralization; oral
   wound healing; chemical stability
ID NITRIC OXIDE; BIOAVAILABILITY; MECHANISMS; EXPRESSION; CHEMISTRY;
   PROTECTS
AB Recently, there has been an increasing interest in finding new approaches to manage oral wound healing. Although resveratrol (RSV) exhibited many biological properties, such as antioxidant and anti inflammatory activities, its use as a drug is limited by unfavorable bioavailability. This study aimed to investigate a series of RSV derivatives (1a j) with better pharmacokinetic profiles. At first, their cytocompatibility at different concentrations was tested on gingival fibroblasts (HGFs). Among them, derivatives 1d and 1h significantly increased cell viability compared to the reference compound RSV. Thus, 1d and 1h were investigated for cytotoxicity, proliferation, and gene expression in HGFs, endothelial cells (HUVECs), and oral osteoblasts (HOBs), which are the main cells involved in oral wound healing. For HUVECs and HGFs, the morphology was also evaluated, while for HOBs ALP and mineralization were observed. The results showed that both 1d and 1h did not exert negative effects on cell viability, and at a lower concentration (5 mu M) both even significantly enhanced the proliferative rate, compared to RSV. The morphology observations pointed out that the density of HUVECs and HGFs was promoted by 1d and 1h (5 mu M) and mineralization was promoted in HOBs. Moreover, 1d and 1h (5 mu M) induced a higher eNOS mRNA level in HUVECs, higher COL1 mRNA in HGFs, and higher OCN in HOBs, compared to RSV. The appreciable physicochemical properties and good enzymatic and chemical stability of 1d and 1h, along with their promising biological properties, provide the scientific basis for further studies leading to the development of RSV based agents useful in oral tissue repair.
C1 [D'Amico, Emira; Pierfelice, Tania Vanessa; D'Arcangelo, Camillo; Lepore, Stefania; D'Ercole, Simonetta; Di Pietro, Natalia; Petrini, Morena; Iezzi, Giovanna] Univ G Annunzio Chieti Pescara, Dept Med Oral & Biotechnol Sci, Via Vestini 31, I 66100 Chieti, Italy.
   [Amoroso, Rosa; Cacciatore, Ivana; Di Rienzo, Annalisa; Ricci, Alessia; Zara, Susi; Di Stefano, Antonio; De Filippis, Barbara] Univ G Annunzio Univ Chieti Pescara, Dept Pharm, Via Vestini 31, I 66100 Chieti, Italy.
   [Di Pietro, Natalia] Univ G Annunzio Chieti Pescara, Ctr Adv Studies & Technol CAST, I 66100 Chieti, Italy.
   [Piattelli, Adriano] St Camillus Int Univ Hlth & Med Sci, Sch Dent, Via St Alessandro 8, I 00131 Rome, Italy.
   [Piattelli, Adriano] UCAM Univ Catolica San Antonio Murcia, Fac Med, Murcia 30107, Spain.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; Universidad Catolica de Murcia
RP Iezzi, G (通讯作者)，Univ G Annunzio Chieti Pescara, Dept Med Oral & Biotechnol Sci, Via Vestini 31, I 66100 Chieti, Italy.
EM gio.iezzi@unich.it
RI DI STEFANO, Antonio/JBJ 1293 2023; Di Pietro, Natalia/K 1604 2016;
   Amoroso, Rosa/AAC 7833 2020; di stefano, antonio/JBJ 1293 2023;
   D'Ercole, Simonetta/ACP 1645 2022; Petrini, Morena/AAA 8334 2019
OI DI STEFANO, Antonio/0000 0002 3042 2234; Di Pietro,
   Natalia/0000 0001 9720 2116; D'AMICO, EMIRA/0000 0003 2414 7130; Ricci,
   Alessia/0000 0002 9033 0104; AMOROSO, Rosa/0000 0002 8282 8535;
   cacciatore, ivana/0000 0001 6253 0443; Zara, Susi/0000 0003 1705 6943;
   Pierfelice, Tania Vanessa/0000 0002 5886 2186; Petrini,
   Morena/0000 0002 3849 4304; De Filippis, Barbara/0000 0001 7718 5814;
   D'Ercole, Simonetta/0000 0002 4797 4019
FU FAR GRANT University of Chieti Pescara Fund
FX This work was supported by Giovanna Iezzi, Barbara De Filippis, Susi
   Zara, Ivana Cacciatore, Antonio Di Stefano FAR GRANT University of
   Chieti Pescara Fund.
CR Ahangar P, 2020, NPJ REGEN MED, V5, DOI 10.1038/s41536 020 00109 9
   Apaydin S, 2019, BIOORG MED CHEM LETT, V29, P2042, DOI 10.1016/j.bmcl.2019.06.041
   Avila Salas F, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11090447
   Birar VC, 2020, BIOGERONTOLOGY, V21, P817, DOI 10.1007/s10522 020 09896 6
   Birkett D.J., 1995, AUST PRESCR, V18, P102, DOI [10.18773/austprescr.1995.088, DOI 10.18773/AUSTPRESCR.1995.088]
   Borsani E, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4597321
   Cacciatore I, 2016, EUR J MED CHEM, V108, P553, DOI 10.1016/j.ejmech.2015.12.003
   Carradori S, 2022, MOLECULES, V27, DOI 10.3390/molecules27227816
   CONNOR NS, 1983, J CELL SCI, V63, P233
   De Angelis F, 2021, MATERIALS, V14, DOI 10.3390/ma14185225
   De Angelis M, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15091061
   De Filippis B, 2019, MED CHEM RES, V28, P984, DOI 10.1007/s00044 019 02351 3
   De Filippis B, 2019, DRUG DEVELOP RES, V80, P285, DOI 10.1002/ddr.21525
   Di Fermo P, 2020, ANTIBIOTICS BASEL, V9, DOI 10.3390/antibiotics9120891
   Di Filippo ES, 2020, MOLECULES, V25, DOI 10.3390/molecules25235770
   Di Tomo P, 2021, FASEB J, V35, DOI 10.1096/fj.202002072RR
   Fantacuzzi M, 2022, EUR J MED CHEM, V233, DOI 10.1016/j.ejmech.2022.114242
   Fantacuzzi M, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14100984
   Francioso A, 2014, MED CHEM, V10, P237, DOI 10.2174/15734064113096660053
   Galiniak S, 2019, ACTA BIOCHIM POL, V66, P13, DOI 10.18388/abp.2018_2749
   Gordish KL, 2014, AM J PHYSIOL RENAL, V306, pF542, DOI 10.1152/ajprenal.00437.2013
   Griffith A, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14081679
   Jayaprakash J.S., 2020, INT J RES PHARM SCI, V11, P1447, DOI [10.26452/ijrps.v11i2.2017, DOI 10.26452/IJRPS.V11I2.2017]
   Kaleci B, 2020, DERMATOL THER, V33, DOI 10.1111/dth.14357
   Kaur L., 2018, MAT SCI ENG C MATER, V7, P413, DOI [10.20959/wjpps20184 11234, DOI 10.20959/WJPPS20184 11234]
   Koh YC, 2021, J AGR FOOD CHEM, V69, P10036, DOI 10.1021/acs.jafc.1c03699
   Li LH, 2021, GENET MOL BIOL, V44, DOI [10.1590/1678 4685 GMB 2020 0349, 10.1590/1678 4685 gmb 2020 0349]
   Martelli G, 2018, EUR J MED CHEM, V158, P91, DOI 10.1016/j.ejmech.2018.09.009
   Moon DK, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01684 9
   Murgia D, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030094
   Neves AR, 2012, CURR MED CHEM, V19, P1663
   Neves AR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030131
   Petrini M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189871
   Pierfelice TV, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19106212
   Politis C, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00507
   Riccitiello F, 2018, EUR POLYM J, V99, P289, DOI 10.1016/j.eurpolymj.2017.12.035
   Robinson K, 2015, DRUG DEV IND PHARM, V41, P1464, DOI 10.3109/03639045.2014.958753
   Rossiter SE, 2017, CHEM REV, V117, P12415, DOI 10.1021/acs.chemrev.7b00283
   Schmidt M, 2015, J INVEST DERMATOL, V135, P1893, DOI 10.1038/jid.2015.86
   Sculean A, 2014, J CLIN PERIODONTOL, V41, pS6, DOI 10.1111/jcpe.12206
   Sheu SJ, 2009, KAOHSIUNG J MED SCI, V25, P381, DOI 10.1016/S1607 551X(09)70531 5
   Sozio P, 2015, EUR J MED CHEM, V90, P1, DOI 10.1016/j.ejmech.2014.11.012
   Sozio P, 2013, MOLECULES, V18, P10747, DOI 10.3390/molecules180910747
   Torre E, 2017, PHYTOCHEM REV, V16, P1183, DOI 10.1007/s11101 017 9529 x
   Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749 6632.2010.05842.x
   Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C
   Wang L, 2020, DRUG DES DEV THER, V14, P4451, DOI 10.2147/DDDT.S266502
   Wjpps|ABSTRACT, US
   Yang SR, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.816386
   Yang TT, 2015, PHARMAZIE, V70, P501, DOI 10.1691/ph.2015.5571
   Zou ML, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.713605
NR 51
TC 3
Z9 3
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2023
VL 24
IS 4
AR 3276
DI 10.3390/ijms24043276
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 9H9WZ
UT WOS:000939174900001
PM 36834684
OA gold
DA 2025 08 17
ER

PT J
AU Teramura, T
   Onodera, Y
   Takehara, T
   Frampton, J
   Matsuoka, T
   Ito, S
   Nakagawa, K
   Miki, Y
   Hosoi, Y
   Hamanishi, C
   Fukuda, K
AF Teramura, Takeshi
   Onodera, Yuta
   Takehara, Toshiyuki
   Frampton, John
   Matsuoka, Toshiki
   Ito, Syunsuke
   Nakagawa, Koichi
   Miki, Yoshihisa
   Hosoi, Yoshihiko
   Hamanishi, Chiaki
   Fukuda, Kanji
TI Induction of Functional Mesenchymal Stem Cells From Rabbit Embryonic
   Stem Cells by Exposure to Severe Hypoxic Conditions
SO CELL TRANSPLANTATION
LA English
DT Article
DE Rabbit embryonic stem cell (rESC); Mesenchyrnal stem cells (MSCs);
   Hypoxia; Chondrocyte
ID HUMAN EPITHELIAL CELLS; BONE MARROW STROMA; DOWN REGULATION; ARTICULAR
   CHONDROCYTES; RETINOBLASTOMA PROTEIN; P53 ACCUMULATION; SELF RENEWAL;
   DIFFERENTIATION; OXYGEN; PROLIFERATION
AB Embryonic stem cells (ESCs) have the potential to be used as an unlimited cell source for cell transplantation therapy, as well as for studying mechanisms of disease and early mammalian development. However, applications involving ESCs have been limited by the lack of reliable differentiation methods in many cases. Mesenchymal stem cells (MSCs) have also emerged as a promising cell source, but as suggested in recent studies, these cells display limited potential for proliferation and differentiation, thereby limiting their usefulness in the clinic and in the laboratory. Unfortunately, effective methods for induction of MSCs from pluripotent stem cells have not been established, and the development of such methods remains a major challenge facing stem cell biologists. Oxygen concentration is one of the most important factors regulating tissue development. It has profound effects on cell metabolism and physiology and can strongly influence stem cell fate. Here we demonstrate that severe low O 2 concentrations (1%) can function as a selective pressure for removing undifferentiated pluripotent cells during the induction of MSCs from rabbit ESCs (rESCs) and that MSCs induced under severe hypoxic conditions function as normal MSCs; that is, they repopulate after cloning, express specific markers (vimentin, CD29, CD90, CD 105, and CD140a) and differentiate into adipocytes, osteoblasts, and chondrocytes. Furthermore, we demonstrate that these cells can contribute to cartilage regeneration in an in vivo rabbit model for joint cartilage injury. These results support the notion that exposing ESCs to severe hypoxic conditions during differentiation can be used as a strategy for the preparation of functional MSCs from ESCs.
C1 [Teramura, Takeshi; Onodera, Yuta; Takehara, Toshiyuki; Fukuda, Kanji] Kinki Univ, Inst Adv Clin Med, Fac Med, Osaka 5898511, Japan.
   [Frampton, John; Matsuoka, Toshiki] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ito, Syunsuke] RIKEN, Ctr Dev Biol, Kobe, Hyogo, Japan.
   [Nakagawa, Koichi; Miki, Yoshihisa; Hamanishi, Chiaki; Fukuda, Kanji] Kinki Univ, Dept Orthopaed Surg, Fac Med, Osaka 5898511, Japan.
   [Hosoi, Yoshihiko] Kinki Univ, Dept Biol Oriented Sci & Technol, Wakayama, Japan.
C3 Kindai University (Kinki University); University of Michigan System;
   University of Michigan; RIKEN; Kindai University (Kinki University);
   Kindai University (Kinki University)
RP Teramura, T (通讯作者)，Kinki Univ, Inst Adv Clin Med, Fac Med, Div Cell Biol Regenerat Med, 377 2 Ohno Higashi, Osaka 5898511, Japan.
EM teramura@med.kindai.ac.jp
RI Teramura, Takeshi/ELU 7591 2022
OI Teramura, Takeshi/0000 0002 5310 4749; Frampton,
   John/0000 0001 6245 1147
CR Abaci HE, 2010, AM J PHYSIOL CELL PH, V298, pC1527, DOI 10.1152/ajpcell.00484.2009
   Alarcón R, 1999, CANCER RES, V59, P6046
   An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925
   ARCHER CW, 1990, J CELL SCI, V97, P361
   Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Bechard M, 2009, MOL CELL BIOL, V29, P2092, DOI 10.1128/MCB.01405 08
   Box AH, 2010, BBA MOL CELL RES, V1803, P951, DOI 10.1016/j.bbamcr.2010.03.011
   Cai X, 2008, P NATL ACAD SCI USA, V105, P16958, DOI 10.1073/pnas.0804608105
   Chen LW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007119
   Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906
   Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722
   de la Garza Rodea AS, 2012, CELL TRANSPLANT, V21, P153, DOI 10.3727/096368911X580554
   Dos Santos F, 2010, J CELL PHYSIOL, V223, P27, DOI 10.1002/jcp.21987
   Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008
   Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114
   Enver T, 2009, CELL STEM CELL, V4, P387, DOI 10.1016/j.stem.2009.04.011
   Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699
   Forristal CE, 2010, REPRODUCTION, V139, P85, DOI 10.1530/REP 09 0300
   Fukunaga N, 2010, CELL REPROGRAM, V12, P369, DOI [10.1089/cell.2009.0097, 10.1089/cell.2009.0086]
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Grayson WL, 2007, BIOCHEM BIOPH RES CO, V358, P948, DOI 10.1016/j.bbrc.2007.05.054
   Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008
   Honda A, 2010, J BIOL CHEM, V285, P31362, DOI 10.1074/jbc.M110.150540
   Honda A, 2009, EXP CELL RES, V315, P2033, DOI 10.1016/j.yexcr.2009.01.024
   Huang XP, 2010, CIRCULATION, V122, P2419, DOI 10.1161/CIRCULATIONAHA.110.955971
   Hung SP, 2012, J ORTHOP RES, V30, P260, DOI 10.1002/jor.21517
   Hwang NS, 2008, P NATL ACAD SCI USA, V105, P20641, DOI 10.1073/pnas.0809680106
   Jin YH, 2010, BIOCHEM BIOPH RES CO, V391, P1471, DOI 10.1016/j.bbrc.2009.12.096
   Kaneshiro N, 2007, EUR CELLS MATER, V13, P87, DOI 10.22203/eCM.v013a09
   Kelly KF, 2011, CELL STEM CELL, V8, P214, DOI 10.1016/j.stem.2010.12.010
   Kim JH, 2011, STEM CELLS DEV, V20, P1753, DOI 10.1089/scd.2010.0469
   Kim MJ, 2007, APOPTOSIS, V12, P707, DOI 10.1007/s10495 006 0002 3
   Koga H, 2007, STEM CELLS, V25, P689, DOI 10.1634/stemcells.2006 0281
   Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666
   Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297 1310.2001
   Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159
   Laurila JP, 2009, CYTOTHERAPY, V11, P726, DOI 10.3109/14653240903067299
   Lechler P, 2011, CLIN HEMORHEOL MICRO, V49, P279, DOI 10.3233/CH 2011 1478
   Lee CN, 2005, APOPTOSIS, V10, P887, DOI 10.1007/s10495 005 2946 0
   Lee EJ, 2010, TISSUE ENG PT A, V16, P705, DOI 10.1089/ten.tea.2008.0596
   Lee KH, 2010, P NATL ACAD SCI USA, V107, P69, DOI 10.1073/pnas.0909734107
   Lengner CJ, 2008, CELL CYCLE, V7, P725, DOI 10.4161/cc.7.6.5573
   Lengner CJ, 2010, CELL, V141, P872, DOI 10.1016/j.cell.2010.04.010
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Ma T, 2009, BIOTECHNOL PROGR, V25, P32, DOI 10.1002/btpr.128
   Matsumoto T, 2010, J CELL PHYSIOL, V225, P291, DOI 10.1002/jcp.22223
   Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102
   Miwa S, 2006, BIOCHEM BIOPH RES CO, V340, P54, DOI 10.1016/j.bbrc.2005.11.148
   Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200
   Munro S., 2012, Oncogene
   Nagano M, 2010, STEM CELLS DEV, V19, P1195, DOI 10.1089/scd.2009.0447
   Nichols J, 2009, CELL STEM CELL, V4, P487, DOI 10.1016/j.stem.2009.05.015
   Niebruegge S, 2009, BIOTECHNOL BIOENG, V102, P493, DOI 10.1002/bit.22065
   Oliva A, 2003, MOL CELL BIOCHEM, V247, P55, DOI 10.1023/A:1024192719178
   Olivier EN, 2006, STEM CELLS, V24, P1914, DOI 10.1634/stemcells.2005 0648
   Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200
   Philippe B, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/503593
   Prado Lopez S, 2010, STEM CELLS, V28, P407, DOI 10.1002/stem.295
   Prasad SM, 2009, CELL PROLIFERAT, V42, P63, DOI 10.1111/j.1365 2184.2008.00571.x
   Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804
   Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958
   Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763
   Roobrouck VD, 2008, EXP CELL RES, V314, P1937, DOI 10.1016/j.yexcr.2008.03.006
   Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Semenza GL, 2011, AM J PHYSIOL CELL PH, V301, pC550, DOI 10.1152/ajpcell.00176.2011
   Simpson DL, 2012, BIOTECHNOL BIOENG, V109, P274, DOI 10.1002/bit.23301
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Suemori H, 2006, BIOCHEM BIOPH RES CO, V345, P926, DOI 10.1016/j.bbrc.2006.04.135
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Takehara T, 2008, MOL HUM REPROD, V14, P627, DOI 10.1093/molehr/gan061
   Tsai CC, 2011, BLOOD, V117, P459, DOI 10.1182/blood 2010 05 287508
   Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486
   Wang GS, 2005, P NATL ACAD SCI USA, V102, P186, DOI 10.1073/pnas.0406266102
   Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310
   Westfall SD, 2008, STEM CELLS DEV, V17, P869, DOI 10.1089/scd.2007.0240
   Yen BL, 2009, STEM CELLS, V27, P451, DOI 10.1634/stemcells.2008 0390
   Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200
NR 85
TC 8
Z9 8
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963 6897
EI 1555 3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2013
VL 22
IS 2
BP 309
EP 329
DI 10.3727/096368912X653291
PG 21
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA 106PV
UT WOS:000316158100010
PM 22943955
OA Bronze
DA 2025 08 17
ER

PT J
AU Tian, F
   Ruan, QJ
   Zhang, Y
   Cao, H
   Ma, ZG
   Zhou, GL
   Wu, MH
AF Tian, Fang
   Ruan, Qun Jia
   Zhang, Ying
   Cao, Hui
   Ma, Zhi Guo
   Zhou, Gai Lian
   Wu, Meng Hua
TI Quantitative Analysis of Six Phenolic Acids in Artemisia
   capillaris (Yinchen) by HPLC DAD and Their Transformation Pathways
   in Decoction Preparation Process
SO JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY
LA English
DT Article
ID PERFORMANCE LIQUID CHROMATOGRAPHY; OSTEOCLAST DIFFERENTIATION; RAT
   PLASMA; YIN CHEN; COMPONENTS; CONSTITUENTS; HYPEROSIDE; APOPTOSIS
AB We aimed to establish a quantitative analysis method of six constituents (5 caffeoylquinic acid, 3 caffeoylquinic acid, 4 caffeoylquinic acid, 1,3 dicaffeoylquinic acid, 3,4 dicaffeoylquinic acid, and 4,5 dicaffeoylquinic acid) in Artemisia capillaris (Yinchen) and its decoction by using HPLC coupled with DAD. Besides, the transformation paths of the six constituents were analyzed in decoction preparation processing. The analytical method was fully validated in terms of linearity, sensitivity, precision, repeatability, and recovery and applied to assess the transformation trend and quantitative analysis of the six constituents in Yinchen decoction. The contents of six constituents varied greatly in Yinchen herb and Yinchen decoction, and there were inextricable internal relationships between them. Presumably 3 caffeoylquinic acid was isomerized to generate 5 caffeoylquinic acid and 4 caffeoylquinic acid. Similarly, 1,3 dicaffeoylquinic acid and 3,4 dicaffeoylquinic acid were produced by isomerization of 4,5 dicaffeoylquinic acid. In conclusion, this study provides a chemical basis for quality control of Yinchen decoction, and the changes of selected markers in decoction could give us some novel perspectives to study the relationship between substances and drug efficacy.
C1 [Tian, Fang; Ruan, Qun Jia; Zhang, Ying; Cao, Hui; Ma, Zhi Guo; Wu, Meng Hua] Jinan Univ, Coll Pharm, Guangzhou, Peoples R China.
   [Tian, Fang; Zhang, Ying; Cao, Hui; Ma, Zhi Guo; Wu, Meng Hua] Jinan Univ, Res Ctr TCM Lingnan Southern China, Guangzhou, Peoples R China.
   [Zhou, Gai Lian] Guangxi Univ Chinese Med, Nanning, Peoples R China.
   [Zhou, Gai Lian] Sun Yat Sen Univ, Guangzhou, Peoples R China.
   [Zhou, Gai Lian] Kangmei Pharmaceut Co Ltd, Shenzhen, Peoples R China.
C3 Jinan University; Jinan University; Guangxi University of Chinese
   Medicine; Sun Yat Sen University
RP Wu, MH (通讯作者)，Jinan Univ, Coll Pharm, Guangzhou, Peoples R China.; Wu, MH (通讯作者)，Jinan Univ, Res Ctr TCM Lingnan Southern China, Guangzhou, Peoples R China.; Zhou, GL (通讯作者)，Guangxi Univ Chinese Med, Nanning, Peoples R China.; Zhou, GL (通讯作者)，Sun Yat Sen Univ, Guangzhou, Peoples R China.; Zhou, GL (通讯作者)，Kangmei Pharmaceut Co Ltd, Shenzhen, Peoples R China.
EM zhgLLhw@126.com; zyfxwmh@163.com
OI Wu, Menghua/0000 0003 2947 0148
FU National Key Research and Development Project of China [2019YFC17115000]
FX This work was supported by the National Key Research and Development
   Project of China under Grant (no. 2019YFC17115000).
CR [Anonymous], 2015, CHINESE PHARMACOPOEI
   Chen LH, 2019, MOLECULES, V24, DOI 10.3390/molecules24061077
   Chen Shi Lin, 2016, Zhongguo Zhong Yao Za Zhi, V41, P1367, DOI 10.4268/cjcmm20160801
   [陈士林 Chen Shilin], 2019, [中草药, Chinese Traditional and Herbal Drugs], V50, P4519
   Choi JH, 2011, J NAT PROD, V74, P1055, DOI 10.1021/np200001x
   Du Y, 2016, J CHROMATOGR SCI, V54, P625, DOI 10.1093/chromsci/bmv239
   Fu ZW, 2014, BIOMED CHROMATOGR, V28, P475, DOI 10.1002/bmc.3057
   Ha H, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 100
   Han JM, 2013, EXP TOXICOL PATHOL, V65, P837, DOI 10.1016/j.etp.2012.12.002
   Hong JH, 2007, BIOFACTORS, V31, P43, DOI 10.1002/biof.5520310105
   Hong JH, 2009, BIOFACTORS, V35, P380, DOI 10.1002/biof.35
   Jang E, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/728137
   Jang M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/872718
   Karunanidhi A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/392058
   Lee CJ, 2016, AM J CHINESE MED, V44, P1675, DOI 10.1142/S0192415X16500944
   Lee SH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020322
   Luo R., 2017, J CHINESE MED MAT, V40, P2877, DOI [10.13863/j.issn1001 4454.2017.12.029, DOI 10.13863/J.ISSN1001 4454.2017.12.029]
   Park KM, 2012, ARCH PHARM RES, V35, P2153, DOI 10.1007/s12272 012 1213 5
   Tan XJ, 2008, J PHARMACEUT BIOMED, V47, P847, DOI 10.1016/j.jpba.2008.04.010
   Tien YC, 2011, INT J MOL SCI, V12, P4053, DOI 10.3390/ijms12064053
   Wang XJ, 2008, J PHARMACEUT BIOMED, V46, P477, DOI 10.1016/j.jpba.2007.11.014
   Wang XJ, 2011, ANALYST, V136, P5068, DOI 10.1039/c1an15752c
   Wu D, 2017, J CHROMATOGR B, V1060, P118, DOI 10.1016/j.jchromb.2017.06.003
   Yu FJ, 2018, J FOOD DRUG ANAL, V26, P788, DOI 10.1016/j.jfda.2017.04.003
   Zhang MQ, 2019, INT J AGR BIOL ENG, V12, P143, DOI 10.25165/j.ijabe.20191206.4914
   Zhang Qian, 2012, Zhongguo Zhong Yao Za Zhi, V37, P3564
NR 26
TC 12
Z9 14
U1 2
U2 36
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090 8865
EI 2090 8873
J9 J ANAL METHODS CHEM
JI J. Anal. Methods Chem.
PD APR 23
PY 2020
VL 2020
AR 8950324
DI 10.1155/2020/8950324
PG 8
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA LL6DD
UT WOS:000531647100001
PM 32377441
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Alessio, N
   Capasso, S
   Di Bernardo, G
   Cappabianca, S
   Casale, F
   Calarco, A
   Cipollaro, M
   Peluso, G
   Galderisi, U
AF Alessio, Nicola
   Capasso, Stefania
   Di Bernardo, Giovanni
   Cappabianca, Salvatore
   Casale, Fiorina
   Calarco, Anna
   Cipollaro, Marilena
   Peluso, Gianfranco
   Galderisi, Umberto
TI Mesenchymal stromal cells having inactivated RB1 survive
   following low irradiation and accumulate damaged DNA: Hints for side
   effects following radiotherapy
SO CELL CYCLE
LA English
DT Article
DE Apoptosis; DNA damage; mesenchymal stem cells; senescence
ID RETINOBLASTOMA GENE; RADIATION THERAPY; CELLULAR SENESCENCE; STEM CELLS;
   RISK; OSTEOSARCOMA; CANCER; DIFFERENTIATION; CHILDHOOD; PATTERNS
AB Following radiotherapy, bone sarcomas account for a significant percentage of recurring tumors. This risk is further increased in patients with hereditary retinoblastoma that undergo radiotherapy. We analyzed the effect of low and medium dose radiation on mesenchymal stromal cells (MSCs) with inactivated RB1 gene to gain insights on the molecular mechanisms that can induce second malignant neoplasm in cancer survivors.
   MSC cultures contain subpopulations of mesenchymal stem cells and committed progenitors that can differentiate into mesodermal derivatives: adipocytes, chondrocytes, and osteocytes. These stem cells and committed osteoblast precursors are the cell of origin in osteosarcoma, and RB1 gene mutations have a strong role in its pathogenesis. Following 40 and 2000 mGy X ray exposure, MSCs with inactivated RB1 do not proliferate and accumulate high levels of unrepaired DNA as detected by persistence of gamma H2AX foci. In samples with inactivated RB1 the radiation treatment did not increase apoptosis, necrosis or senescence versus untreated cells. Following radiation, CFU analysis showed a discrete number of cells with clonogenic capacity in cultures with silenced RB1.
   We extended our analysis to the other members of retinoblastoma gene family: RB2/P130 and P107. Also in the MSCs with silenced RB2/P130 and P107 we detected the presence of cells with unrepaired DNA following X ray irradiation. Cells with unrepaired DNA may represent a reservoir of cells that may undergo neoplastic transformation. Our study suggests that, following radiotherapy, cancer patients with mutations of retinoblastoma genes may be under strict controls to evaluate onset of secondary neoplasms following radiotherapy.
C1 [Alessio, Nicola; Capasso, Stefania; Di Bernardo, Giovanni; Cipollaro, Marilena; Galderisi, Umberto] Univ Naples 2, Biotechnol & Mol Biol Sect, Dept Expt Med, Naples, Italy.
   [Cappabianca, Salvatore; Peluso, Gianfranco] Univ Naples 2, Dept F Magrassi A Lanzara, Naples, Italy.
   [Casale, Fiorina] Univ Naples 2, Dipartimento Donna Bambino & Chirurg Gen Speciali, Naples, Italy.
   [Calarco, Anna] CNR, Inst Biosci & Bioresources, Via Pietro Castellino 111, I 80131 Naples, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; IRCCS Bambino Gesu; Universita della Campania Vanvitelli;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioscienze e
   Biorisorse (IBBR CNR)
RP Peluso, G (通讯作者)，CNR, Inst Biosci & Bioresources, Via Pietro Castellino 111, I 80131 Naples, Italy.; Galderisi, U (通讯作者)，Temple Univ, Ctr Biotechnol, 1900 North 12th St, Philadelphia, PA 19107 USA.
EM gianfranco.peluso@ibbr.cnr.it; tud23058@temple.edu
RI Calarco, Anna/P 2568 2019; Di Bernardo, Giovanni/ABF 4221 2021; Di
   Bernardo, Giovanni/AER 5012 2022; Alessio, Nicola/K 2119 2018
OI Alessio, Nicola/0000 0002 5019 2130; Calarco, Anna/0000 0002 1441 7662;
   Di Bernardo, Giovanni/0000 0002 4985 4029; 
FU European Union [323267]; Progetto PON   'Ricerca e Competitivita'
   [PON01_00802]
FX The research leading to these results has received funding from the
   European Union Euratom Seventh Framework Program RISK IR project under
   grant agreement no323267 to UG, and from Progetto PON   'Ricerca e
   Competitivita 2007  2013'   PON01_00802 entitled 'Sviluppo di molecole
   capaci di modulare vie metaboliche intracellulari redoxsensibili per la
   prevenzione e la cura di patologie infettive, tumorali,
   neurodegenerative e loro delivery mediante piattaforme nano
   tecnologiche' to GP.
CR Alessio N, 2015, ONCOTARGET, V6, P8155, DOI 10.18632/oncotarget.2692
   Alessio N, 2013, CELL MOL LIFE SCI, V70, P1637, DOI 10.1007/s00018 012 1224 x
   Freeman AK, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 27
   Fu SB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038465
   Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736
   Galderisi U, 2014, MED RES REV, V34, P1100, DOI 10.1002/med.21322
   Guijarro MV, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00189
   Helmbold H, 2012, J CELL PHYSIOL, V227, P508, DOI 10.1002/jcp.22786
   Johansen S, 2009, ACTA ONCOL, V48, P495, DOI 10.1080/02841860802657227
   Kadhim M, 2013, MUTAT RES REV MUTAT, V752, P84, DOI 10.1016/j.mrrev.2012.12.001
   Le Vu B, 1998, INT J CANCER, V77, P370, DOI 10.1002/(SICI)1097 0215(19980729)77:3<370::AID IJC11>3.0.CO;2 C
   MacLellan WR, 2005, MOL CELL BIOL, V25, P2486, DOI 10.1128/MCB.25.6.2486 2497.2005
   Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320
   Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100
   Rutqvist LE, 2003, ACTA ONCOL, V42, P532, DOI 10.1080/02841860310014444
   Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764
   Schwartz B, 2014, RADIAT ENVIRON BIOPH, V53, P381, DOI 10.1007/s00411 013 0510 9
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Vasavada RC, 2007, DIABETES, V56, P57, DOI 10.2337/db06 0517
   VvAa, 2006, RAD DOS FRACT
   WADAYAMA B, 1994, CANCER RES, V54, P3042
   Wong FL, 1997, JAMA J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262
NR 22
TC 20
Z9 21
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PY 2017
VL 16
IS 3
BP 251
EP 258
DI 10.1080/15384101.2016.1175798
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EL4WA
UT WOS:000394620400008
PM 27124644
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Castaneda, RT
   Khurana, A
   Khan, R
   Daldrup Link, HE
AF Castaneda, Rosalinda T.
   Khurana, Aman
   Khan, Ramsha
   Daldrup Link, Heike E.
TI Labeling Stem Cells with Ferumoxytol, an FDA Approved Iron Oxide
   Nanoparticle
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 57; USPIO; cell labeling; MR imaging; MRI; molecular
   imaging; iron oxides; ferumoxytol; cellular imaging; nanoparticles
AB Stem cell based therapies offer significant potential for the field of regenerative medicine. However, much remains to be understood regarding the in vivo kinetics of transplanted cells. A non invasive method to repetitively monitor transplanted stem cells in vivo would allow investigators to directly monitor stem cell transplants and identify successful or unsuccessful engraftment outcomes.
   A wide range of stem cells continues to be investigated for countless applications. This protocol focuses on 3 different stem cell populations: human embryonic kidney 293 (HEK293) cells, human mesenchymal stem cells (hMSC) and induced pluripotent stem (iPS) cells. HEK 293 cells are derived from human embryonic kidney cells grown in culture with sheared adenovirus 5 DNA. These cells are widely used in research because they are easily cultured, grow quickly and are easily transfected. hMSCs are found in adult marrow. These cells can be replicated as undifferentiated cells while maintaining multipotency or the potential to differentiate into a limited number of cell fates. hMSCs can differentiate to lineages of mesenchymal tissues, including osteoblasts, adipocytes, chondrocytes, tendon, muscle, and marrow stroma. iPS cells are genetically reprogrammed adult cells that have been modified to express genes and factors similar to defining properties of embryonic stem cells. These cells are pluripotent meaning they have the capacity to differentiate into all cell lineages (1). Both hMSCs and iPS cells have demonstrated tissue regenerative capacity in vivo.
   Magnetic resonance (MR) imaging together with the use of superparamagnetic iron oxide (SPIO) nanoparticle cell labels have proven effective for in vivo tracking of stem cells due to the near microscopic anatomical resolution, a longer blood half life that permits longitudinal imaging and the high sensitivity for cell detection provided by MR imaging of SPIO nanoparticles (2 4). In addition, MR imaging with the use of SPIOs is clinically translatable. SPIOs are composed of an iron oxide core with a dextran, carboxydextran or starch surface coat that serves to contain the bioreactive iron core from plasma components. These agents create local magnetic field inhomogeneities that lead to a decreased signal on T2 weighted MR images (5). Unfortunately, SPIOs are no longer being manufactured. Second generation, ultrasmall SPIOs (USPIO), however, offer a viable alternative. Ferumoxytol (FerahemeTM) is one USPIO composed of a non stoichiometric magnetite core surrounded by a polyglucose sorbitol carboxymethylether coat. The colloidal, particle size of ferumoxytol is 17 30 nm as determined by light scattering. The molecular weight is 750 kDa, and the relaxivity constant at 2T MRI field is 58.609 mM 1 sec 1 strength(4). Ferumoxytol was recently FDA approved as an iron supplement for treatment of iron deficiency in patients with renal failure (6). Our group has applied this agent in an "off label" use for cell labeling applications. Our technique demonstrates efficient labeling of stem cells with ferumoxytol that leads to significant MR signal effects of labeled cells on MR images. This technique may be applied for non invasive monitoring of stem cell therapies in pre clinical and clinical settings.
C1 [Castaneda, Rosalinda T.; Khurana, Aman; Khan, Ramsha; Daldrup Link, Heike E.] Stanford MIPS, Mol Imaging Program, Dept Radiol, Stanford, CA 94305 USA.
   [Castaneda, Rosalinda T.; Khurana, Aman; Khan, Ramsha] Stanford Univ, Stanford Sch Med, Stanford, CA 94305 USA.
C3 Stanford University
RP Daldrup Link, HE (通讯作者)，Stanford MIPS, Mol Imaging Program, Dept Radiol, Stanford, CA 94305 USA.
EM H.E.Daldrup Link@stanford.edu
RI ; Khurana, Aman/F 1496 2015; Daldrup Link, Heike/D 9829 2012
OI Daldrup Link, Heike/0000 0002 4929 819X; 
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [3R01AR054458 02S2]
FX This work was supported by a grant from the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases: 3R01AR054458 02S2.
CR Arbab Ali Syed, 2004, Mol Imaging, V3, P24, DOI 10.1162/153535004773861697
   Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood 2004 02 0655
   Babic M, 2008, BIOCONJUGATE CHEM, V19, P740, DOI 10.1021/bc700410z
   Bulte JWM, 2009, AM J ROENTGENOL, V193, P314, DOI 10.2214/AJR.09.3107
   Coyne DW, 2009, EXPERT OPIN PHARMACO, V10, P2563, DOI 10.1517/14656560903224998
   Golovko DM, 2010, EUR RADIOL, V20, P640, DOI 10.1007/s00330 009 1585 1
   Henning Tobias D, 2008, J Vis Exp, DOI 10.3791/685
   Henning TD, 2009, CONTRAST MEDIA MOL I, V4, P165, DOI 10.1002/cmmi.276
   JUNG CW, 1995, MAGN RESON IMAGING, V13, P661, DOI 10.1016/0730 725X(95)00024 B
   Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E
   Li ZJ, 2008, STEM CELLS, V26, P864, DOI 10.1634/stemcells.2007 0843
   Lu M, 2010, AM J HEMATOL, V85, P315, DOI 10.1002/ajh.21656
   Metz S, 2004, EUR RADIOL, V14, P1851, DOI 10.1007/s00330 004 2405 2
   Narsinh KH, 2011, MOL THER, V19, P635, DOI 10.1038/mt.2011.41
   Nedopil A. J., 2010, JOVE J VIS EXP, pe1793, DOI [10.3791/1793, DOI 10.3791/1793]
   Nedopil A, 2010, INVEST RADIOL, V45, P634, DOI 10.1097/RLI.0b013e3181ed566c
   Stuckey DJ, 2006, STEM CELLS, V24, P1968, DOI 10.1634/stemcells.2006 0074
   Tallheden T, 2006, LIFE SCI, V79, P999, DOI 10.1016/j.lfs.2006.05.021
NR 18
TC 82
Z9 91
U1 0
U2 24
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD NOV
PY 2011
IS 57
AR e3482
DI 10.3791/3482
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA V36OZ
UT WOS:000209222200040
PM 22083287
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, SS
   Luan, J
AF Li, Shangshan
   Luan, Jie
TI Recent Advances on Relationship Between Inorganic Phosphate and
   Pathologic Calcification: Is Calcification After Breast Augmentation
   with Fat Grafting Correlated with Locally Increased Concentration of
   Inorganic Phosphate?
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article
DE Inorganic phosphate; Pathological calcification; Fat graft
ID FIBROBLAST GROWTH FACTOR 23; SMOOTH MUSCLE CELLS; HUMAN AORTIC VALVE;
   VASCULAR CALCIFICATION; MATRIX VESICLES; IN VITRO;
   BETA GLYCEROPHOSPHATE; ASCORBIC ACID; BONE MARROW; ECTOPIC
   CALCIFICATIONS
AB Background Pathologic calcification has frequently occurred after breast augmentation with fat grafting as well as other conditions such as breast cancer, trauma, myocardial infarction, arteriosclerosis and even after reduction mammoplasty. Inorganic phosphate, correlated with fat metabolism, is an important factor that induces pathologic calcification such as vascular calcification.MethodsA literature search was conducted using PubMed with the keywords: calcification, inorganic phosphate, fat. Studies related to the process of pathologic calcification, correlation between inorganic phosphate and pathologic calcification, between inorganic phosphate and fat metabolism in pathologic calcification were collected.ResultsVarious mechanisms were referred to in pathologic calcification among which inorganic phosphate played an important role. Inorganic phosphate could be liberated, under the effect of various enzymes, in the process of fat metabolism. The authors hypothesized that a large scale necrotizing zone, which could occur in fat grafting with large amounts per cannula, might provide a high phosphate environment which might contribute to differentiation of surrounding cells such as stem cells or regenerated vessel cells into osteoblast like cells that induce pathologic calcification.ConclusionInorganic phosphate, which was correlated with fat metabolism, played a significant role in pathologic calcification. We firstly hypothesize that calcification after fat grafting may be related to locally increasing concentrations of phosphate in a necrotizing zone. Further research should be conducted to verify this hypothesis.Level of Evidence VThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
C1 [Li, Shangshan; Luan, Jie] Chinese Acad Med Sci, Peking Union Med Coll, Plast Surg Hosp, Dept Aesthet & Reconstruct Breast Surg, 33 Badachu Rd, Beijing 100144, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College; Plastic Surgery Hospital   CAMS
RP Luan, J (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Plast Surg Hosp, Dept Aesthet & Reconstruct Breast Surg, 33 Badachu Rd, Beijing 100144, Peoples R China.
EM luanjieplastic@126.com
OI Kang, Deni/0000 0002 8927 2648
CR Abedin M, 2006, CIRC RES, V98, P727, DOI 10.1161/01.RES.0000216009.68958.e6
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   ARSENAULT AL, 1991, CALCIFIED TISSUE INT, V48, P46, DOI 10.1007/BF02555795
   Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004 0233
   Bailey MT, 2003, J BIOMED MATER RES A, V66A, P93, DOI 10.1002/jbm.a.10543
   BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169 6009(92)90707 K
   Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139
   Blair B, 2000, Expert Opin Pharmacother, V1, P435, DOI 10.1517/14656566.1.3.435
   Chavkin NW, 2015, EXP CELL RES, V333, P39, DOI 10.1016/j.yexcr.2015.02.002
   Chen NX, 2008, J BONE MINER RES, V23, P1798, DOI 10.1359/JBMR.080604
   CHUNG CH, 1992, CALCIFIED TISSUE INT, V51, P305, DOI 10.1007/BF00334492
   Coelho MJ, 2000, BIOMATERIALS, V21, P1095, DOI 10.1016/S0142 9612(99)00192 1
   COLEMAN SR, 1995, AESTHET PLAST SURG, V19, P421, DOI 10.1007/BF00453875
   Coleman SR, 2015, CLIN PLAST SURG, V42, P301, DOI 10.1016/j.cps.2015.03.010
   Côté N, 2012, J MOL CELL CARDIOL, V52, P1191, DOI 10.1016/j.yjmcc.2012.02.003
   Cottignoli V, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/542687
   Cox RF, 2012, BRIT J CANCER, V106, P525, DOI 10.1038/bjc.2011.583
   Cox RF, 2013, BONE, V53, P437, DOI 10.1016/j.bone.2013.01.013
   Delo Dawn M, 2011, Cardiovasc Pathol, V20, pe69, DOI 10.1016/j.carpath.2010.03.001
   Delomenède M, 2009, ACTA BIOCHIM POL, V56, P301
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   DEMER LL, 1995, CIRCULATION, V92, P2029, DOI 10.1161/01.CIR.92.8.2029
   Dewanjee M K, 1986, ASAIO Trans, V32, P24
   Duan XH, 2009, BIOCHEM BIOPH RES CO, V387, P694, DOI 10.1016/j.bbrc.2009.07.085
   El Husseini D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053393
   El Abbadi MM, 2009, KIDNEY INT, V75, P1297, DOI 10.1038/ki.2009.83
   Ewence AE, 2008, CIRC RES, V103, pE28, DOI 10.1161/CIRCRESAHA.108.181305
   Giachelli C M, 2005, Orthod Craniofac Res, V8, P229, DOI 10.1111/j.1601 6343.2005.00345.x
   Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249 06
   Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107
   Golub EE, 2011, SEMIN IMMUNOPATHOL, V33, P409, DOI 10.1007/s00281 010 0230 z
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   GREENAWALT JW, 1964, J CELL BIOL, V23, P21, DOI 10.1083/jcb.23.1.21
   Gremse D A, 2001, Expert Opin Pharmacother, V2, P1663, DOI 10.1517/14656566.2.10.1663
   Grskovic I, 2012, J BONE MINER RES, V27, P2399, DOI 10.1002/jbmr.1682
   Gufler H, 2011, ACTA RADIOL, V52, P592, DOI 10.1258/ar.2011.100489
   Houston B, 1999, BBA MOL CELL RES, V1448, P500, DOI 10.1016/S0167 4889(98)00153 0
   Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c
   Huang MS, 2008, BIOCHEM BIOPH RES CO, V374, P553, DOI 10.1016/j.bbrc.2008.07.062
   Huesa C, 2011, BONE, V48, P1066, DOI 10.1016/j.bone.2011.01.010
   Ichikawa S, 2014, J BONE MINER RES, V29, P2017, DOI 10.1002/jbmr.2242
   Ichikawa S, 2011, ENDOCRINOLOGY, V152, P4504, DOI 10.1210/en.2011 1137
   Jono S, 2006, J BONE MINER METAB, V24, P176, DOI 10.1007/s00774 005 0668 6
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kachgal S, 2012, CELL ADHES MIGR, V6, P457, DOI 10.4161/cam.22164
   Kageyama A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068197
   Kamstrup PR, 2014, J AM COLL CARDIOL, V63, P470, DOI 10.1016/j.jacc.2013.09.038
   Kapustin AN, 2011, CIRC RES, V109, pE1, DOI 10.1161/CIRCRESAHA.110.238808
   Kato H, 2014, PLAST RECONSTR SURG, V133, p303E, DOI 10.1097/PRS.0000000000000066
   Kiffer Moreira T, 2013, J BONE MINER RES, V28, P81, DOI 10.1002/jbmr.1733
   Kim H, 2015, BREAST CANCER TOKYO, V22, P391, DOI 10.1007/s12282 013 0494 y
   KIM KM, 1976, FED PROC, V35, P156
   Kirsch T, 2006, CURR OPIN RHEUMATOL, V18, P174, DOI 10.1097/01.bor.0000209431.59226.46
   Kirsch T, 2008, CRIT REV EUKAR GENE, V18, P1, DOI 10.1615/CritRevEukarGeneExpr.v18.i1.10
   Kumata C, 2011, THER APHER DIAL, V15, P18, DOI 10.1111/j.1744 9987.2011.00921.x
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   KVAM BJ, 1992, MAGNET RESON MED, V25, P355, DOI 10.1002/mrm.1910250215
   Lau WL, 2010, THROMB HAEMOSTASIS, V104, P464, DOI 10.1160/TH09 12 0814
   LEBOY PS, 1989, J BIOL CHEM, V264, P17281
   Lee K, 2014, BIOCHEM BIOPH RES CO, V451, P436, DOI 10.1016/j.bbrc.2014.08.007
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Ling H, 2013, ASIA PAC J CLIN ONCO, V9, P139, DOI 10.1111/j.1743 7563.2012.01572.x
   Mahmut A, 2014, J AM COLL CARDIOL, V63, P460, DOI 10.1016/j.jacc.2013.05.105
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin SF, 2000, ANAL BIOCHEM, V278, P106, DOI 10.1006/abio.1999.4420
   Mathew G, 2008, INT J NANOMED, V3, P265
   Mathew S, 2008, J AM SOC NEPHROL, V19, P1092, DOI 10.1681/ASN.2007070760
   Mathieu P, 2014, CAN J CARDIOL, V30, P982, DOI 10.1016/j.cjca.2014.03.029
   Memon F, 2008, KIDNEY INT, V74, P566, DOI 10.1038/ki.2008.218
   Mineda K, 2014, PLAST RECONSTR SURG, V133, P1064, DOI 10.1097/PRS.0000000000000097
   Moe SM, 2003, KIDNEY INT, V63, P1003, DOI 10.1046/j.1523 1755.2003.00820.x
   Mori K, 1999, ARTERIOSCL THROM VAS, V19, P2112, DOI 10.1161/01.ATV.19.9.2112
   Mune S, 2009, CLIN EXP NEPHROL, V13, P571, DOI 10.1007/s10157 009 0208 0
   Nadra I, 2008, ATHEROSCLEROSIS, V196, P98, DOI 10.1016/j.atherosclerosis.2007.02.005
   Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08 114397
   New SEP, 2013, CIRC RES, V113, P72, DOI 10.1161/CIRCRESAHA.113.301036
   Nomura A, 2013, BIOCHEM BIOPH RES CO, V440, P780, DOI 10.1016/j.bbrc.2013.10.003
   O'Brien EJO, 2012, INT J EXP PATHOL, V93, P319, DOI 10.1111/j.1365 2613.2012.00829.x
   OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Pu LLQ, 2016, ANN PLAS SURG, V77, pS84, DOI 10.1097/SAP.0000000000000730
   Rajamannan NM, 2011, J AM COLL CARDIOL, V58, P298, DOI 10.1016/j.jacc.2011.01.047
   Razzaque MS, 2011, CLIN SCI, V120, P91, DOI 10.1042/CS20100377
   Razzaque MS, 2009, NAT REV ENDOCRINOL, V5, P611, DOI 10.1038/nrendo.2009.196
   Razzaque MS, 2011, IUBMB LIFE, V63, P240, DOI 10.1002/iub.437
   Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084
   Roberts S, 2007, J BONE MINER RES, V22, P617, DOI 10.1359/JBMR.070108
   Roberts SJ, 2004, BIOCHEM J, V382, P59, DOI 10.1042/BJ20040511
   Rubin JP, 2012, PLAST RECONSTR SURG, V129, P1029, DOI 10.1097/PRS.0b013e31824a2a8e
   Rucker R B, 1974, Adv Exp Med Biol, V48, P185
   Sage AP, 2011, KIDNEY INT, V79, P414, DOI 10.1038/ki.2010.390
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shen M, 2001, ANN THORAC SURG, V71, pS413, DOI 10.1016/S0003 4975(01)02521 8
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Sohshang Hesking L., 2000, Journal of Communicable Diseases, V32, P216
   Sonou T, 2015, J ATHEROSCLER THROMB, V22, P1197, DOI 10.5551/jat.28647
   Speer MY, 2004, CARDIOVASC PATHOL, V13, P63, DOI 10.1016/S1054 8807(03)00130 3
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Stewart AJ, 2003, PROTEIN ENG, V16, P889, DOI 10.1093/protein/gzg126
   Stewart AJ, 2006, BONE, V39, P1000, DOI 10.1016/j.bone.2006.05.014
   Stubbs J, 2007, SEMIN DIALYSIS, V20, P302, DOI 10.1111/j.1525 139X.2007.00308.x
   Tabcheh L, 2014, BIO MED MATER ENG, V24, pS37, DOI 10.3233/BME 140972
   Tenenbaum HC, 1981, J DENT RES
   Tenenhouse HS, 2007, J STEROID BIOCHEM, V103, P572, DOI 10.1016/j.jsbmb.2006.12.090
   Thanassoulis G, 2013, NEW ENGL J MED, V368, P503, DOI 10.1056/NEJMoa1109034
   Tintut Y, 2002, CIRCULATION, V105, P650, DOI 10.1161/hc0502.102969
   Tölle M, 2015, EUR J CLIN INVEST, V45, P976, DOI 10.1111/eci.12493
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Vattikuti R, 2004, AM J PHYSIOL ENDOC M, V286, pE686, DOI 10.1152/ajpendo.00552.2003
   Veber M, 2011, PLAST RECONSTR SURG, V127, P1289, DOI 10.1097/PRS.0b013e318205f38f
   Vervaet BA, 2009, KIDNEY INT, V75, P41, DOI 10.1038/ki.2008.450
   Villa Bellosta R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174998
   Villa Bellosta R, 2011, AM J PHYSIOL CELL PH, V300, pC210, DOI 10.1152/ajpcell.00229.2010
   Virkki LV, 2007, AM J PHYSIOL RENAL, V293, pF643, DOI 10.1152/ajprenal.00228.2007
   Wan XC, 2008, BIOCHEM BIOPH RES CO, V373, P488, DOI 10.1016/j.bbrc.2008.06.037
   WEINBACH EC, 1967, BIOCHIM BIOPHYS ACTA, V148, P256, DOI 10.1016/0304 4165(67)90301 7
   Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175
   White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664
   Xiao Z, 2009, J PROTEOMICS, V72, P34, DOI 10.1016/j.jprot.2008.11.011
   Yadav MC, 2011, J BONE MINER RES, V26, P286, DOI 10.1002/jbmr.195
   Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636
   Zhang RK, 2016, INT J SURG CASE REP, V29, P113, DOI 10.1016/j.ijscr.2016.09.041
   Zhang W, 2013, J DENT RES, V92, P1136, DOI 10.1177/0022034513507581
   Zocchi ML, 2008, AESTHET PLAST SURG, V32, P313, DOI 10.1007/s00266 007 9089 3
NR 127
TC 0
Z9 0
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364 216X
EI 1432 5241
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD FEB
PY 2019
VL 43
IS 1
BP 243
EP 252
DI 10.1007/s00266 018 1285 9
PG 10
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA HJ7TG
UT WOS:000457399600034
PM 30552471
DA 2025 08 17
ER

PT J
AU Lin, T
   Pajarinen, J
   Nabeshima, A
   Lu, L
   Nathan, K
   Yao, ZY
   Goodman, SB
AF Lin, Tzuhua
   Pajarinen, Jukka
   Nabeshima, Akira
   Lu, Laura
   Nathan, Karthik
   Yao, Zhenyu
   Goodman, Stuart B.
TI Establishment of NF κB sensing and interleukin 4 secreting mesenchymal
   stromal cells as an "on demand" drug delivery system to modulate
   inflammation
SO CYTOTHERAPY
LA English
DT Article
DE interleukin 4; macrophage polarization; mesenchymal stromal cells;
   NF kappa B
ID OSTEOBLAST LIKE CELLS; STEM CELLS; IN VITRO; MACROPHAGE POLARIZATION;
   ADOPTIVE TRANSFER; IL 4 DELIVERY; NITRIC OXIDE; MICE; INHIBITION;
   CYTOKINE
AB Chronic inflammation is associated with up regulation of the transcription factor nuclear factor kappa light chain enhancer of activated B cells (NF kappa B) and excessive inflammatory cytokine secretion by M1 macrophages. The anti inflammatory cytokine interleukin (IL) 4 converts pro inflammatory M1 macrophages into an anti inflammatory and tissue regenerative M2 phenotype, thus reducing inflammation and enhancing tissue regeneration. We have generated NF kappa B responsive, or constitutively active IL 4 expression lentiviral vectors transduced into murine bone marrow derived mesenchymal stromal cells (MSCs). MSCs with a constitutively active IL 4 expression vector produced large quantities of IL 4 continuously, whereas IL 4 secretion was significantly induced by lipopolysaccharide (LPS) in the NF kappa B sensing MSCs. In contrast, LPS had no effect on MSCs with IL 4 secretion driven by a constitutively active promoter. We also found that intermittent and continuous LPS treatment displayed distinct NF kappa B activation profiles, and this regulation was independent of IL 4 signaling. The supernatant containing IL 4 from the LPS treated MSCs suppressed M1 marker (inducible nitric oxide synthase [iNOS] and tumor necrosis factor alpha [TNF alpha]) expression and enhanced M2 marker (Arginase 1, CD206 and IL1 receptor antagonist [IL1Ra]) expression in primary murine macrophages. The IL 4 secretion at the basal, non LPS induced level was sufficient to suppress TNF alpha, and enhance Arginase 1 at a lower level, but had no significant effects on iNOS, CD206 and IL1Ra expression. Finally, IL 4 secretion at basal or LPS induced levels significantly suppressed osteogenic differentiation of MSCs. Our findings suggest that the IL 4 secreting MSCs driven by NF kappa B sensing or constitutive active promoter have great potential for mitigating the effects of chronic inflammation and promoting earlier tissue regeneration.
C1 [Lin, Tzuhua; Pajarinen, Jukka; Nabeshima, Akira; Lu, Laura; Nathan, Karthik; Yao, Zhenyu; Goodman, Stuart B.] Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA.
   [Goodman, Stuart B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Goodman, SB (通讯作者)，Stanford Univ, Sch Med, Dept Orthopaed Surg, 450 Broadway St, Redwood City, CA 94063 USA.
EM goodbone@stanford.edu
RI Nabeshima, Akira/JOH 3173 2023; Goodman, Stuart/AAZ 7499 2020
OI Goodman, Stuart/0000 0002 1919 3717
FU National Institutes of Health [2R01AR055650, 1R01AR063717]; Ellenburg
   Chair in Surgery at Stanford University; Jane and Aatos Erkko Foundation
FX This work was supported by National Institutes of Health grants
   2R01AR055650 and 1R01AR063717 and the Ellenburg Chair in Surgery at
   Stanford University. J.P. was supported by a grant from the Jane and
   Aatos Erkko Foundation.
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Aquino JB, 2010, GENE THER, V17, P692, DOI 10.1038/gt.2010.10
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Blonska M, 2012, J IMMUNOL, V188, P3160, DOI 10.4049/jimmunol.1102943
   Brown BN, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00510
   Chen C, 2015, J EXP MED, V212, P73, DOI 10.1084/jem.20140643
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fischer JE, 1997, J VIROL, V71, P8672, DOI 10.1128/JVI.71.11.8672 8677.1997
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gurung P, 2015, J CLIN INVEST, V125, P1329, DOI 10.1172/JCI79526
   Hu YL, 2012, MOL PHARMACEUT, V9, P2698, DOI 10.1021/mp300254s
   Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469
   Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024
   Koç ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Leblond AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137515
   Lee S, 2016, J CONTROL RELEASE, V240, P527, DOI 10.1016/j.jconrel.2016.07.018
   Lepperdinger G, 2011, CURR OPIN IMMUNOL, V23, P518, DOI 10.1016/j.coi.2011.05.007
   Lin TH, 2017, J ORTHOP RES, V35, P281, DOI 10.1002/jor.23270
   Lin TH, 2015, TISSUE ENG PT A, V21, P875, DOI [10.1089/ten.tea.2014.0144, 10.1089/ten.TEA.2014.0144]
   Lin TH, 2014, ACTA BIOMATER, V10, P3747, DOI 10.1016/j.actbio.2014.04.034
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Loi F, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0276 5
   Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007
   Maggini J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009252
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Michel T, 2011, J IMMUNOL, V186, P6497, DOI 10.4049/jimmunol.1001673
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Németh K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Pajarinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142736
   Pajarinen J, 2015, J BIOMED MATER RES A, V103, P1339, DOI 10.1002/jbm.a.35278
   Parsa R, 2012, DIABETES, V61, P2881, DOI 10.2337/db11 1635
   Pevsner Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood 2006 06 028704
   Rao AJ, 2013, J BIOMED MATER RES A, V101, P1925, DOI 10.1002/jbm.a.34486
   Relic B, 2001, J IMMUNOL, V166, P2775, DOI 10.4049/jimmunol.166.4.2775
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   RIANCHO JA, 1995, J ENDOCRINOL INVEST, V18, P174, DOI 10.1007/BF03347799
   Sadtler K, 2016, SCIENCE, V352, P366, DOI 10.1126/science.aad9272
   Sato T, 2016, J BIOMED MATER RES A, V104, P2255, DOI 10.1002/jbm.a.35759
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schmidt Weber CB, 2012, CHEM IMMUNOL ALLERGY, V96, P120, DOI 10.1159/000332235
   Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
   Silfverswärd CJ, 2010, SCAND J CLIN LAB INV, V70, P338, DOI 10.3109/00365513.2010.488698
   Spiller KL, 2015, BIOMATERIALS, V37, P194, DOI 10.1016/j.biomaterials.2014.10.017
   Ti DD, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0642 6
   UENO K, 1992, BIOCHEM BIOPH RES CO, V189, P1521, DOI 10.1016/0006 291X(92)90248 J
   Ura K, 2000, ENDOCR J, V47, P293, DOI 10.1507/endocrj.47.293
   Wang ZJ, 2009, CELL BIOL INT, V33, P665, DOI 10.1016/j.cellbi.2009.03.006
   Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Xu XF, 2011, BLOOD, V117, P1218, DOI 10.1182/blood 2010 05 285494
   Yorimitsu M, 2008, OSTEOARTHR CARTILAGE, V16, P764, DOI 10.1016/j.joca.2007.11.006
NR 55
TC 44
Z9 51
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD SEP
PY 2017
VL 19
IS 9
BP 1025
EP 1034
DI 10.1016/j.jcyt.2017.06.008
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA FE7QL
UT WOS:000408401900002
PM 28739167
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Maluf, F
   Soares, A
   Avanço, G
   Hada, AL
   Cardoso, APG
   Carneiro, A
   Herchenhorn, D
   Jardim, DLF
   Schutz, FA
   Kater, FR
   Pereira, FMT
   Monteiro, FSM
   Morbeck, IAP
   Reolon, JFN
   Trindade, KM
   Andrade, LMQD
   Nogueira, LM
   Furoni, R
   Natel, RA
   dos Reis, RB
   Fogace, RN
   Souza, VC
AF Maluf, Fernando
   Soares, Andrey
   Avanco, Guilherme
   Hada, Aline Lury
   Garcia Cardoso, Ana Paula
   Carneiro, Arie
   Herchenhorn, Daniel
   Fontes Jardim, Denis Leonardo
   Schutz, Fabio Augusto
   Kater, Fabio Roberto
   Toledo Pereira, Felipe Moraes
   Marques Monteiro, Fernando Sabino
   Protzner Morbeck, Igor Alexandre
   Navarro Reolon, Joao Francisco
   Trindade, Karine Martins
   da Silvo Andrade, Livia Maria Querino
   Nogueira, Lucas Mendes
   Furoni, Renato
   Natel, Ricardo Azze
   dos Reis, Rodolfo Borges
   Fogace, Rodrigo Nogueira
   Souza, Vinicius Carrera
TI Consensus on diagnosis and management of non metastatic castration
   resistant prostate cancer in Brazil: focus on patient, selection,
   treatment efficacy, side effects and physician's perception according to
   patient comorbidities
SO INTERNATIONAL BRAZ J UROL
LA English
DT Article
DE Prostate cancer; familial [Supplementary Concept]; Prostatic Neoplasms;
   Castration Resistant; Consensus
ID METASTASIS FREE SURVIVAL; OUTCOMES; PHASE 3; TRIAL; MEN
AB Background: Non metastatic castration resistant prostate cancer (MO CRPC) has seen important developments in drugs and diagnostic tools in the last two years. New hormonal agents have demonstrated improvement in metastasis free survival in MO CRPC patients and have been approved by regulatory agencies in Brazil. Additionally, newer and more sensitive imaging tools are able to detect metastasis earlier than before, which will impact the percentage of patients staged as MO CRPC. Based on the available international guidelines, a group of Brazilian urology and medical oncologyexperts developed and completed a survey on the diagnosis and treatment of MO CRPC in Brazil. These results are reviewed and summarized and associated recommendations are provided.
   Objective: To present survey results on management of MO CRPC in Brazil.
   Design, setting, and participants: A panel of six Brazilian prostate cancer experts determined 64 questions concerning the main areas of interest: 1) staging tools, 2) treatments, 3) side effects of systemic treatment/s, and 4) osteoclast targeted therapy. A larger panel of 28 Brazilian prostate cancer experts answered these questions in order to create country specific recommendations discussed in this manuscript.
   Outcome measurements and statistical analysis: The panel voted publicly but anonymously on the predefined questions. These answers are the panelists' opinions, not a literature review or meta analysis. Therapies not yet approved in Brazil were excluded from answer options. Each question had five to seven relevant answers including two non answers. Results were tabulated in real time.
   Conclusions: The results and recommendations presented can be used by Brazilian physicians to support the management of MO CRPC patients. Individual clinical decision making should be supported by available data, however, for Brazil, guidelines for diagnosis and management of MO CRPC patients have not been developed. This document will serve as a point of reference when confronting this disease stage.
C1 [Maluf, Fernando; Avanco, Guilherme; Garcia Cardoso, Ana Paula; Schutz, Fabio Augusto; Kater, Fabio Roberto; Toledo Pereira, Felipe Moraes; Navarro Reolon, Joao Francisco; Furoni, Renato] Hosp Beneficencia Portuguesa Sao Paulo, Dept Oncol, Rua Martiniano Carvalho 965, BR 01323900 Sao Paulo, SP, Brazil.
   [Maluf, Fernando; Hada, Aline Lury; Carneiro, Arie; Fogace, Rodrigo Nogueira] Hosp Israelita Albert Einstein, Dept Urol, Sao Paulo, SP, Brazil.
   [Soares, Andrey] Ctr Paulista Oncol, Sao Paulo, SP, Brazil.
   [Herchenhorn, Daniel] Grp Latino Americano Oncol Cooperat, Porto Alegre, RS, Brazil.
   [Fontes Jardim, Denis Leonardo] Hosp Sirio Libanes, Soc Beneficente Senhoras, Sao Paulo, SP, Brazil.
   [Marques Monteiro, Fernando Sabino] Hosp Univ Brasilia, Unidade Oncol, Brasilia, DF, Brazil.
   [Marques Monteiro, Fernando Sabino] Hosp Santa Lucia, Ctr Oncol & Hematol, Brasilia, DF, Brazil.
   [Protzner Morbeck, Igor Alexandre] Univ Catolica Brasilia, Disciplina Urol, Taguatinga, DF, Brazil.
   [Trindade, Karine Martins] Hosp Haroldo Juacaba, Serv Urol, Fortaleza, Ceara, Brazil.
   [da Silvo Andrade, Livia Maria Querino] Hosp Sao Rafael, Serv Urol, Salvador, BA, Brazil.
   [Nogueira, Lucas Mendes] Univ Fed Minas Gerais Belo Horizonte, Hosp Clin, Div Urol, Belo Horizonte, MG, Brazil.
   [Nogueira, Lucas Mendes] Univ Fed Minas Gerais Belo Horizonte, Hosp Clin, Dept Cirurgia, Belo Horizonte, MG, Brazil.
   [Natel, Ricardo Azze] Univ Cidade Sao Paulo, Sao Paulo, SP, Brazil.
   [dos Reis, Rodolfo Borges] Univ Sao Paulo, Fac Med, Ribeirao Preto, SP, Brazil.
   [Souza, Vinicius Carrera] Clin AMO, Salvador, BA, Brazil.
C3 Hospital Israelita Albert Einstein; Hospital Sirio Libanes; Universidade
   Catolica de Brasilia; Universidade Cidade de Sao Paulo; Universidade de
   Sao Paulo
RP Maluf, F (通讯作者)，Hosp Beneficencia Portuguesa Sao Paulo, Dept Oncol, Rua Martiniano Carvalho 965, BR 01323900 Sao Paulo, SP, Brazil.
EM maluffc@uol.com.br
RI NOGUEIRA, LUCAS/F 7887 2010; Monteiro, Fernando/S 8402 2019; Souza,
   Vinicius/AAJ 2548 2021; Carneiro, Arie/AAW 4703 2021; Cardoso,
   Ana/A 9191 2018; Reis, Rodolfo/F 5877 2014; Nogueira, Lucas/F 7887 2010
OI Soares, Andrey/0000 0003 4980 6729; Monteiro,
   Fernando/0000 0002 6621 8251; Nogueira, Lucas/0000 0002 3612 6524
CR Alpajaro SIR, 2019, PROSTATE CANCER P D, V22, P16, DOI 10.1038/s41391 018 0078 1
   Baker J, 2009, EUR J ONCOL NURS, V13, P49, DOI 10.1016/j.ejon.2008.10.003
   BROGDEN RN, 1989, DRUGS, V38, P185, DOI 10.2165/00003495 198938020 00003
   Crawford ED, 2019, J UROLOGY, V201, P682, DOI 10.1016/j.juro.2018.05.164
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   DePuy V, 2007, SUPPORT CARE CANCER, V15, P869, DOI 10.1007/s00520 006 0203 x
   Fendler Wolfgang, J CLIN ONCOLOGY, V36
   Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fradet Yves, 2004, Expert Rev Anticancer Ther, V4, P37, DOI 10.1586/14737140.4.1.37
   Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039
   Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536
   Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742 1241.2011.02799.x
   Liede A, 2013, J CLIN ONCOL S, V31
   Lowrance WT, 2018, J UROLOGY, V200, P1264, DOI 10.1016/j.juro.2018.07.090
   McKay R, 2017, PROSTATE CANCER P D, V20, P276, DOI 10.1038/pcan.2017.4
   NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, Non small cell lung cancer (Version3.2020)
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Nilsson S, 2012, EUR J CANCER, V48, P678, DOI 10.1016/j.ejca.2011.12.023
   Rauscher I, 2018, EUR UROL, V73, P656, DOI 10.1016/j.eururo.2018.01.006
   Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200/JCO.2009.24.1281
   Scher HI, 2011, J CLIN ONCOL, V29, P3695, DOI 10.1200/JCO.2011.35.8648
   Smith MR, 2015, ANN ONCOL, V26, P1274, DOI 10.1093/annonc/mdv155
   Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2011, CANCER AM CANCER SOC, V117, P2077, DOI 10.1002/cncr.25762
   Vickers AJ, 2012, J CLIN UROL, V5, P162, DOI 10.1016/j.bjmsu.2011.08.006
NR 27
TC 5
Z9 6
U1 1
U2 10
PU BRAZILIAN SOC UROL
PI RIO DE JANEIRO
PA RUA BAMBINA, 153, RIO DE JANEIRO, 2251 050, BRAZIL
SN 1677 5538
EI 1677 6119
J9 INT BRAZ J UROL
JI Int. Braz J Urol
PD MAR APR
PY 2021
VL 47
IS 2
BP 359
EP 373
DI 10.1590/S1677 5538.IBJU.2020.0249
PG 15
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA PA7QR
UT WOS:000595825700017
PM 33284538
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, C
   Xie, XD
   Huang, X
   Liang, ZH
   Zhou, CR
AF Wang, Chuang
   Xie, Xu dong
   Huang, Xun
   Liang, Zhi hong
   Zhou, Chang ren
TI A quantitative study of MC3T3 E1 cell adhesion, morphology and
   biomechanics on chitosan collagen blend films at single cell level
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Atomic force microscopy; Single cell force spectroscopy; Chitosan;
   Collagen; Young's modulus
ID ATOMIC FORCE MICROSCOPY; TISSUE ENGINEERING APPLICATIONS; STEM CELLS;
   VISCOELASTIC PROPERTIES; MECHANICS; SCAFFOLDS; SPECTROSCOPY;
   OSTEOBLASTS; ENVIRONMENT; ELASTICITY
AB The interaction between cells and biomaterials plays a key role in cell proliferation and differentiation in tissue engineering. However, a quantitative analysis of those interactions has been less well studied. The objective of this study was to quantitative recapitulate the difference of MC3T3 E1 cell adhesion, morphological and biomechanical properties on chitosan collagen films in terms of chemical composition. Here, the unbinding force between MC3T3 E1 cell and a series of chitosan collagen films was probed by a real time and in situ atomic force microscopy single cell force spectroscopy (AFM SCFS). Meanwhile, changes in cell morphology and Young's modulus on different chitosan collagen films were detected by AFM. The cell area and CCK 8 results showed that cell spreading and proliferation increased with increasing collagen content. AFM observations clearly showed cell height decreased and pseudopod fusion with the collagen content increased. Cell adhesive force increased from 0.76 +/  0.17 nN to 1.70 +/  0.19 nN. On the contrary, cells Young's modulus, which reflected biophysical changes of cells decreased from 11.94 +/  3.19 kPa to 1.81 +/  0.52 kPa, respectively. It suggested that stronger cell substrate interactions benefit cell adhesion, and better cell flexibility improve cell spreading. The findings indicate that cell morphology, adhesive force and Young's modulus are significant affected by various chitosan collagen substrates. Those methods and quantitative results have guiding significance for investigating the mechanism of chitosan and/or collagen based cell targeting drug carrier and the preparation of chitosan collagen composite biomaterials. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Wang, Chuang; Xie, Xu dong; Huang, Xun; Zhou, Chang ren] Jinan Univ, Dept Mat Sci & Engn, Guangzhou 510632, Guangdong, Peoples R China.
   [Wang, Chuang; Xie, Xu dong; Huang, Xun; Zhou, Chang ren] Minist Educ, Engn Res Ctr Artificial Organs & Mat, Guangzhou 510632, Guangdong, Peoples R China.
   [Liang, Zhi hong] Jinan Univ, Expt & Technol Ctr, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Jinan University
RP Liang, ZH (通讯作者)，Jinan Univ, Expt & Technol Ctr, Guangzhou 510632, Guangdong, Peoples R China.
EM zhihong3615@sina.com; tcrz9@jnu.edu.cn
FU National Natural Science Foundation China [81171459, 31370974]
FX This work was supported by research grants from National Natural Science
   Foundation China (Nos.: 81171459, 31370974).
CR Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636
   Anselme K, 2000, J BIOMED MATER RES, V49, P155, DOI 10.1002/(SICI)1097 4636(200002)49:2<155::AID JBM2>3.0.CO;2 J
   Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001
   Chen YH, 2012, BIOMATERIALS, V33, P1336, DOI 10.1016/j.biomaterials.2011.10.048
   Chiou YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077384
   CLARK P, 1990, DEVELOPMENT, V108, P635
   Cretel E, 2008, CELL MOL BIOENG, V1, P5, DOI 10.1007/s12195 008 0009 7
   Cross SE, 2007, NAT NANOTECHNOL, V2, P780, DOI 10.1038/nnano.2007.388
   Darling EM, 2008, J BIOMECH, V41, P454, DOI 10.1016/j.jbiomech.2007.06.019
   Domke J, 2000, COLLOID SURFACE B, V19, P367, DOI 10.1016/S0927 7765(00)00145 4
   Florczyk SJ, 2013, BIOMATERIALS, V34, P10143, DOI 10.1016/j.biomaterials.2013.09.034
   Friedrichs J, 2010, NAT PROTOC, V5, P1353, DOI 10.1038/nprot.2010.89
   Grinnell F, 2013, BIOMATERIALS, V34, P965, DOI 10.1016/j.biomaterials.2012.10.036
   Guck J, 2005, BIOPHYS J, V88, P3689, DOI 10.1529/biophysj.104.045476
   Guvendiren M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1792
   Hills CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071819
   Hoffman BD, 2006, P NATL ACAD SCI USA, V103, P10259, DOI 10.1073/pnas.0510348103
   Huang Y, 2005, BIOMATERIALS, V26, P7616, DOI 10.1016/j.biomaterials.2005.05.036
   Inzana JA, 2014, BIOMATERIALS, V35, P4026, DOI 10.1016/j.biomaterials.2014.01.064
   Jones GL, 2009, BIOMATERIALS, V30, P5376, DOI 10.1016/j.biomaterials.2009.07.028
   Kim IY, 2008, BIOTECHNOL ADV, V26, P1, DOI 10.1016/j.biotechadv.2007.07.009
   Kim KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030066
   Kim MS, 2010, MEASUREMENT, V43, P520, DOI 10.1016/j.measurement.2009.12.020
   Liu HJ, 2013, J BIOMECH, V46, P1967, DOI 10.1016/j.jbiomech.2013.05.001
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Nettles Dana L., 2002, TISSUE ENG PART A, V8, P1009
   Neves SC, 2011, BIOMATERIALS, V32, P1068, DOI 10.1016/j.biomaterials.2010.09.073
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092 8674(86)90259 X
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Sarasam A, 2005, BIOMATERIALS, V26, P5500, DOI 10.1016/j.biomaterials.2005.01.071
   Siamantouras E, 2014, FEBS LETT, V588, P1178, DOI 10.1016/j.febslet.2014.02.058
   Sionkowska A, 2004, BIOMATERIALS, V25, P795, DOI 10.1016/S0142 9612(03)00595 7
   Struszczyk MH, 2002, POLIMERY W, V47, P396, DOI 10.14314/polimery.2002.396
   Takai E, 2005, ANN BIOMED ENG, V33, P963, DOI 10.1007/s10439 005 3555 3
   Touhami A, 2003, LANGMUIR, V19, P4539, DOI 10.1021/la034136x
   Wang LM, 2010, BIOMATERIALS, V31, P3976, DOI 10.1016/j.biomaterials.2010.01.131
   WARD KA, 1991, BIORHEOLOGY, V28, P301
   Young DA, 2013, BIOMATERIALS, V34, P8581, DOI 10.1016/j.biomaterials.2013.07.103
   Zhang L, 2014, BIOSENS BIOELECTRON, V56, P271, DOI 10.1016/j.bios.2014.01.024
NR 40
TC 28
Z9 32
U1 0
U2 97
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD AUG 1
PY 2015
VL 132
BP 1
EP 9
DI 10.1016/j.colsurfb.2015.04.037
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA CN0HF
UT WOS:000358094000001
PM 25996415
DA 2025 08 17
ER

PT J
AU Hatoum, D
   Yagoub, D
   Ahadi, A
   Nassif, NT
   McGowan, EM
AF Hatoum, Diana
   Yagoub, Daniel
   Ahadi, Alireza
   Nassif, Najah T.
   McGowan, Eileen M.
TI Annexin/S100A Protein Family Regulation through p14ARF p53 Activation: A
   Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer
SO PLOS ONE
LA English
DT Article
ID INCREASES OSTEOCLAST FORMATION; A1 EXPRESSION; P53; ESTROGEN; RECEPTOR;
   ASSOCIATION; PROLIFERATION; APOPTOSIS; INVASION; ARREST
AB The annexin family and S100A associated proteins are important regulators of diverse calcium dependent cellular processes including cell division, growth regulation and apoptosis. Dysfunction of individual annexin and S100A proteins is associated with cancer progression, metastasis and cancer drug resistance. This manuscript describes the novel finding of differential regulation of the annexin and S100A family of proteins by activation of p53 in breast cancer cells. Additionally, the observed differential regulation is found to be beneficial to the survival of breast cancer cells and to influence treatment efficacy. We have used unbiased, quantitative proteomics to determine the proteomic changes occurring post p14ARF p53 activation in estrogen receptor (ER) breast cancer cells. In this report we identified differential regulation of the annexin/S100A family, through unique peptide recognition at the N terminal regions, demonstrating p14ARF p53 is a central orchestrator of the annexin/S100A family of calcium regulators in favor of pro survival functions in the breast cancer cell. This regulation was found to be cell type specific. Retrospective human breast cancer studies have demonstrated that tumors with functional wild type p53 (p53wt) respond poorly to some chemotherapy agents compared to tumors with a non functional p53. Given that modulation of calcium signaling has been demonstrated to change sensitivity of chemotherapeutic agents to apoptotic signals, in principle, we explored the paradigm of how p53 modulation of calcium regulators in ER+ breast cancer patients impacts and influences therapeutic outcomes.
C1 [Hatoum, Diana; Nassif, Najah T.; McGowan, Eileen M.] Univ Technol Sydney, Sch Life Sci, Fac Engn & IT, Fac Sci, Sydney, NSW, Australia.
   [Yagoub, Daniel] Univ New South Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
   [Ahadi, Alireza] Univ Technol Sydney, Fac Engn & IT, Sydney, NSW, Australia.
C3 University of Technology Sydney; University of New South Wales Sydney;
   University of Technology Sydney
RP McGowan, EM (通讯作者)，Univ Technol Sydney, Sch Life Sci, Fac Engn & IT, Fac Sci, Sydney, NSW, Australia.
EM Eileen.McGowan@uts.edu.au
RI ; Nassif, Najah/G 6214 2012
OI McGowan, Eileen/0000 0001 6371 3751; Hatoum, Diana/0000 0003 0512 171X;
   Nassif, Najah/0000 0003 2675 8322; ahadi, alireza/0000 0002 2018 3065
FU Australian Postgraduate Award (APA); Sydney Vital Research Scholarship
   Award; Translational Cancer Research Network (TCRN) top up Award
FX This research did not receive any specific grant from funding agencies
   in the public, commercial or not for profit sectors. DH is supported by
   an Australian Postgraduate Award (APA), a Sydney Vital Research
   Scholarship Award and a Translational Cancer Research Network (TCRN)
   top up Award.
CR Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915
   Alvarez Guaita A, 2015, BRIT J PHARMACOL, V172, P1677, DOI 10.1111/bph.13022
   Ang EZF, 2009, MOL CANCER RES, V7, P266, DOI 10.1158/1541 7786.MCR 08 0147
   Arii Y, 2015, BIOSCI BIOTECH BIOCH, V79, P978, DOI 10.1080/09168451.2014.1003131
   Bailey ST, 2012, P NATL ACAD SCI USA, V109, P18060, DOI 10.1073/pnas.1018858109
   Balmer MT, 2014, CANCER BIOL THER, V15, P1000, DOI 10.4161/cbt.29112
   Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098
   Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140 6736(02)09969 5
   Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090
   Bhardwaj A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127678
   Burgess A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00007
   Cao Y, 2008, APPL IMMUNOHISTO M M, V16, P530, DOI 10.1097/PAI.0b013e31817432c3
   Clarke R, 2015, MOL CELL ENDOCRINOL, V418, P220, DOI 10.1016/j.mce.2015.09.035
   Cmoch Anna, 2012, Postepy Biochem, V58, P429
   Crane EK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135101
   Deng SS, 2013, ONCOL LETT, V5, P107, DOI 10.3892/ol.2012.959
   Gallagher S, 2005, CELL CYCLE, V4, P465, DOI 10.4161/cc.4.3.1526
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Giorgi C, 2015, CELL CYCLE, V14, P933, DOI 10.1080/15384101.2015.1010973
   Gurpinar E, 2015, TRENDS CELL BIOL, V25, P486, DOI 10.1016/j.tcb.2015.04.001
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549 009 0674 9
   HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119
   Hedhli N, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/406273
   Hu H, 2015, TECHNOL CANC RES TRE
   Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027
   Jaiswal JK, 2015, CELL CYCLE, V14, P502, DOI 10.1080/15384101.2014.995495
   Jaiswal JK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4795
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Lehmann Che J, 2007, M S MED SCI, V23, P1021, DOI 10.1051/medsci/200723111021
   Liu WS, 2006, J BIOL CHEM, V281, P9837, DOI 10.1074/jbc.C600001200
   Liu YD, 2015, BRIT J PHARMACOL, V172, P1664, DOI 10.1111/bph.12978
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067
   McGowan EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042246
   McGowan EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020623
   McGowan EM, 1999, MOL ENDOCRINOL, V13, P1657, DOI 10.1210/me.13.10.1657
   Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374
   Mussunoor S, 2008, J PATHOL, V216, P131, DOI 10.1002/path.2400
   Okano M, 2015, ONCOL REP, V33, P1064, DOI 10.3892/or.2015.3720
   Ong SE, 2006, NAT PROTOC, V1, P2650, DOI 10.1038/nprot.2006.427
   Piljic A, 2006, MOL BIOL CELL, V17, P3318, DOI 10.1091/mbc.E06 01 0041
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008 5472.CAN 06 3724
   Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003
   Sobral Leite M, 2015, BMC MED, V13, DOI 10.1186/s12916 015 0392 6
   Stewart T. A., 2014, BIOCH BIOPHYSICA ACT
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162
   Wang CY, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/308976
   Wang T, 2015, ONCOTARGET, V6, P30975, DOI 10.18632/oncotarget.5199
   Xia LQ, 2004, CANCER RES, V64, P221, DOI 10.1158/0008 5472.CAN 03 0969
   Yagoub D, 2014, MOL ENDOCRINOL, V28, P1899, DOI 10.1210/me.2013 1423
   Yom CK, 2011, J BREAST CANCER, V14, P262, DOI 10.4048/jbc.2011.14.4.262
   Zuberi K, 2013, NUCLEIC ACIDS RES, V41, pW115, DOI 10.1093/nar/gkt533
NR 57
TC 19
Z9 19
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 9
PY 2017
VL 12
IS 1
AR e0169925
DI 10.1371/journal.pone.0169925
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EH5WO
UT WOS:000391843900080
PM 28068434
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Hollomon, MG
   Gordon, N
   Santiago O'Farrill, JM
   Kleinerman, ES
AF Hollomon, Mario G.
   Gordon, Nancy
   Santiago O'Farrill, Janice M.
   Kleinerman, Eugenie S.
TI Knockdown of autophagy related protein 5, ATG5, decreases oxidative
   stress and has an opposing effect on camptothecin induced cytotoxicity
   in osteosarcoma cells
SO BMC CANCER
LA English
DT Article
DE Autophagy; Osteosarcoma; Camptothecin; Oxidative stress
ID MURINE OSTEOSARCOMA; APOPTOSIS; DEATH; INHIBITION; DEPLETION; RELEASE;
   TARGET
AB Background: Autophagy induction can increase or decrease anticancer drug efficacy. Anticancer drug induced autophagy induction is poorly characterized in osteosarcoma (OS). In this study, we investigated the impact of autophagy inhibition on camptothecin (CPT) induced cytotoxicity in OS.
   Methods: Autophagy inhibited DLM8 and K7M3 metastatic murine OS cell lines were generated by infection with lentiviral shRNA directed against the essential autophagy protein ATG5. Knockdown of ATG5 protein expression and inhibition of autophagy was confirmed by immunoblot of ATG5 and LC3II proteins, respectively. Metabolic activity was determined by MTT assay and cell viability was determined by trypan blue exclusion. Acridine orange staining and immunoblotting for LC3II protein expression were used to determine autophagy induction. Oxidative stress was assessed by staining cells with HE and DCFH DA followed by flow cytometry analysis. Mitochondrial membrane potential was determined by staining cells with TMRE followed by flow cytometry analysis. Immunoblotting was used to detect caspase activation, Parp cleavage and p53 phosphorylation.
   Results: Autophagy inhibition caused a greater deficit in metabolic activity and cell growth in K7M3 cells compared to DLM8 cells. K7M3 cells exhibited higher basal autophagy levels than DLM8 cells and non transformed murine MCT3 osteoblasts. Autophagy inhibition did not affect CPT induced DNA damage. Autophagy inhibition decreased CPT induced cell death in DLM8 cells while increasing CPT induced cell death in K7M3 cells. Autophagy inhibition reduced CPT induced mitochondrial damage and CPT induced caspase activation in DLM8 cells.
   Buthionine sulfoximine (BSO) induced cell death was greater in autophagy competent DLM8 cells and was reversed by antioxidant pretreatment. Camptothecin induced and BSO induced autophagy induction was also reversed by antioxidant pretreatment. Significantly, autophagy inhibition not only reduced CPT induced oxidative stress but also reduced basal oxidative stress.
   Conclusions: The results of this study indicate that autophagy inhibition can have an opposing effect on CPTinduced cytotoxicity within OS. The cytoprotective mechanism of autophagy inhibition observed in DLM8 cells involves reduced CPT induced oxidative stress and not reduced DNA damage. Our results also reveal the novel finding that knockdown of ATG5 protein reduces both basal oxidative stress and drug induced oxidative stress.
C1 [Hollomon, Mario G.; Gordon, Nancy; Santiago O'Farrill, Janice M.; Kleinerman, Eugenie S.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77054 USA.
   [Hollomon, Mario G.] Texas So Univ, Dept Biol, Houston, TX 77004 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Texas Southern
   University
RP Hollomon, MG (通讯作者)，Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77054 USA.
EM hollomon_mg@tsu.edu
FU National Cancer Institute [R01CA042992]; Legends of Friendswood Research
   Award
FX This work was supported by National Cancer Institute grant R01CA042992
   (ESK) and Legends of Friendswood Research Award (MGH). We thank Dr. Joya
   Chandra for critical reading and comments regarding the manuscript.
CR Asai T, 1998, INT J CANCER, V76, P418, DOI 10.1002/(SICI)1097 0215(19980504)76:3<418::AID IJC21>3.3.CO;2 E
   AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Chen SN, 2010, BBA REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   DREW R, 1984, BIOCHEM PHARMACOL, V33, P2989, DOI 10.1016/0006 2952(84)90598 7
   Dupéré Richer D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.210
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107
   Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Li QY, 2006, CURR MED CHEM, V13, P2021, DOI 10.2174/092986706777585004
   Lin CI, 2009, SURGERY, V146, P1208, DOI 10.1016/j.surg.2009.09.019
   Martinez Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Miura T, 2008, CARCINOGENESIS, V29, P585, DOI 10.1093/carcin/bgm198
   Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013
   Paglin S, 2001, CANCER RES, V61, P439
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092 8674(00)80416 X
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Timur M, 2005, ACTA BIOCHIM POL, V52, P897
   Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541 7786.MCR 09 0562
   Wang LM, 2008, CHEM BIOL INTERACT, V176, P165, DOI 10.1016/j.cbi.2008.07.005
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Yuan Q, 2002, AM J PHYSIOL CELL PH, V282, pC1290, DOI 10.1152/ajpcell.00351.2001
   Zaragoza A, 2001, BRIT J PHARMACOL, V132, P1063, DOI 10.1038/sj.bjp.0703909
NR 25
TC 33
Z9 39
U1 0
U2 21
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 26
PY 2013
VL 13
AR 500
DI 10.1186/1471 2407 13 500
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 280JM
UT WOS:000329025100002
PM 24160177
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Singh, O
   Kakularam, KR
   Reddanna, P
   Aparoy, P
AF Singh, Omkar
   Kakularam, Kumar R.
   Reddanna, Pallu
   Aparoy, Polamarasetty
TI Understanding the Dual Inhibition of COX 2 and Carbonic Anhydrase II by
   Celecoxib and CG100649 Using Density Functional Theory Calculations and
   other Molecular Modelling Approaches
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE CA II; COX 2; docking; HOMO; ligand based pharmacophore; LUMO; receptor
   based pharmacophore
ID COLORECTAL ADENOMA; COMPUTATIONAL SIMULATION; MILD STEEL;
   CYCLOOXYGENASE 2; CORROSION; ACID
AB Recent developments in the dual inhibition studies of cyclooxygenase 2 (COX 2) and carbonic anhydrase (CA II) imply a promising platform for the development of new generations of nonsteroidal anti inflammatory drugs (NSAIDs). CG100649 is such a molecule that got recently approved by Korean Ministry of Food and Drug safety (MFDS) and is being marketed by the name polmacoxib for the treatment of osteoarthritis. CG100649 significantly inhibits CA II in blood and COX 2 in inflammatory tissues. However, the mechanism of CG100649 dual inhibition of COX 2/CA II is not well understood. In this study, we employed well known methods like pharmacophore modelling, a DFT based quantum chemical descriptors analysis, and molecular docking to explore the chemical features and to understand the binding behaviour of CG100649 along with other COX 2/CA II dual inhibitors. The HOMO LUMO and docking results indicated the prominent role of aryl sulphonamide in CG100649. The aryl sulphonamide moiety formed T shaped Pi center dot center dot center dot Pi interactions with His94 in the CA II active site, which was not observed in the case of celecoxib. Other crucial interactions were also observed which may aid in further understanding the action of dual inhibitors of this class.
C1 [Singh, Omkar; Aparoy, Polamarasetty] Cent Univ Himachal Pradesh, Sch Life Sci, Ctr Computat Biol & Bioinformat, Dharamshala 176215, Himachal Prades, India.
   [Kakularam, Kumar R.; Reddanna, Pallu] Univ Hyderabad, Sch Life Sci, Dept Anim Biol, Hyderabad 500046, Telangana, India.
C3 Central University of Himachal Pradesh; University of Hyderabad
RP Aparoy, P (通讯作者)，Cent Univ Himachal Pradesh, Sch Life Sci, Ctr Computat Biol & Bioinformat, Dharamshala 176215, Himachal Prades, India.
EM aparoy@cuhimachal.ac.in
RI ; Singh, Omkar/AAE 8963 2022; Polamarasetty, Aparoy/K 6254 2013
OI singh, omkar/0000 0002 4500 7519; Polamarasetty,
   Aparoy/0000 0002 4030 5699; 
FU UGC RGNF; CSIR SRF
FX We duly acknowledge the funding agencies UGC RGNF and CSIR SRF for
   providing financial support to OS and KKR, respectively. We thank
   Central University of Himachal Pradesh; Bioinformatics Infrastructure
   Facility (SLS, UoH), and Centre for Modeling, Simulation and Design
   (CMSD, UoH), for the computational facilities.
CR Aggarwal M, 2013, BIOORGAN MED CHEM, V21, P1526, DOI 10.1016/j.bmc.2012.08.019
   [Anonymous], 2013, Discovery Studio Modeling Environment
   Aparoy P, 2010, BIOORG MED CHEM LETT, V20, P1013, DOI 10.1016/j.bmcl.2009.12.047
   Aparoy P, 2012, CURR MED CHEM, V19, P3763, DOI 10.2174/092986712801661112
   Arooj M, 2011, INT J MOL SCI, V12, P9236, DOI 10.3390/ijms12129236
   Awad MK, 2010, J MOL STRUC THEOCHEM, V959, P66, DOI 10.1016/j.theochem.2010.08.008
   Becke A. D., 1993, Journal of Chemical Physics, V98, P5648, DOI 10.1063/1.464913
   Bertucci A, 2009, BIOORGAN MED CHEM, V17, P5054, DOI 10.1016/j.bmc.2009.05.063
   Brenneis C, 2006, FASEB J, V20, P1352, DOI 10.1096/fj.05 5346com
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   Catella Lawson F, 1999, J PHARMACOL EXP THER, V289, P735
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096 987X(19990115)20:1<129::AID JCC13>3.0.CO;2 A
   Choi HY, 2014, CLIN THER, V36, P115, DOI 10.1016/j.clinthera.2013.12.004
   Dogné JM, 2007, CURR TOP MED CHEM, V7, P885, DOI 10.2174/156802607780636717
   Ebenso EE, 2010, INT J MOL SCI, V11, P2473, DOI 10.3390/ijms11062473
   Gece G, 2009, CORROS SCI, V51, P1876, DOI 10.1016/j.corsci.2009.04.003
   Harris RC, 2006, J CARDIOVASC PHARM, V47, pS37, DOI 10.1097/00005344 200605001 00007
   HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kim MJ, 2015, CLIN THER, V37, P197, DOI 10.1016/j.clinthera.2014.07.007
   Kim SH, 2014, INVEST NEW DRUG, V32, P1105, DOI 10.1007/s10637 014 0144 z
   Koopmans T., 1934, physica, V1, P104, DOI DOI 10.1016/S0031 8914(34)90011 2
   Lee C., 2015, J PAIN, V9, P5
   Minisini B, 2007, J MOL MODEL, V13, P1227, DOI 10.1007/s00894 007 0244 1
   Obi Egbedi NO, 2011, INT J ELECTROCHEM SC, V6, P5649
   Pang X, 2012, OPEN C P J, V3, P70, DOI DOI 10.2174/2210289201203010070
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   Piyanzina I, 2015, J MOL MODEL, V21, DOI 10.1007/s00894 014 2540 x
   Puscas I, 1996, J PHARMACOL EXP THER, V277, P1464
   Reddy DB, 2009, J ETHNOPHARMACOL, V124, P506, DOI 10.1016/j.jep.2009.05.022
   Reddy TC, 2010, PROTEIN PEPTIDE LETT, V17, P1251
   Rega N., 2016, Gaussian 16
   Schmitt S, 2002, J MOL BIOL, V323, P387, DOI 10.1016/S0022 2836(02)00811 2
   Shin SS, 2004, J MED CHEM, V47, P792, DOI 10.1021/jm020545z
   Shulman Peleg A, 2008, NUCLEIC ACIDS RES, V36, pW260, DOI 10.1093/nar/gkn185
   Silva PJ, 2003, THEOR CHEM ACC, V110, P345, DOI 10.1007/s00214 003 0476 9
   Skarke C, 2012, CLIN PHARMACOL THER, V91, P986, DOI 10.1038/clpt.2012.3
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Sussman JL, 1998, ACTA CRYSTALLOGR D, V54, P1078, DOI 10.1107/S0907444998009378
   Talley JJ, 2000, J MED CHEM, V43, P775, DOI 10.1021/jm990577v
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Wang JL, 2010, BIOORG MED CHEM LETT, V20, P7159, DOI 10.1016/j.bmcl.2010.07.054
   Weber A, 2004, J MED CHEM, V47, P550, DOI 10.1021/jm030912m
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Yoshino T, 2005, ARZNEIMITTELFORSCH, V55, P394
   Yu SX, 2005, RAPID COMMUN MASS SP, V19, P250, DOI 10.1002/rcm.1777
NR 47
TC 10
Z9 10
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929 8665
EI 1875 5305
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PY 2015
VL 22
IS 10
BP 903
EP 912
DI 10.2174/0929866522666150622102131
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CQ1RH
UT WOS:000360375800006
PM 26095375
DA 2025 08 17
ER

PT J
AU Zhou, WH
   Jia, ZJ
   Xiong, P
   Yan, JL
   Li, M
   Cheng, Y
   Zheng, YF
AF Zhou, Wenhao
   Jia, Zhaojun
   Xiong, Pan
   Yan, Jianglong
   Li, Ming
   Cheng, Yan
   Zheng, Yufeng
TI Novel pH responsive tobramycin embedded micelles in nanostructured
   multilayer coatings of chitosan/heparin with efficient and sustained
   antibacterial properties
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Micelles; Layer by layer; Self assembly; Gentamycin; Heparin; Chitosan;
   Antibacterial coatings
ID BY LAYER ASSEMBLIES; ANTIMICROBIAL ACTIVITY; IN VITRO; OSTEOBLAST
   FUNCTIONS; POLYMERIC MICELLES; HEPARIN; FILMS; SURFACES; ANTIBIOTICS;
   INFECTIONS
AB To endow orthopaedic implants with satisfactory antibacterial properties, the design and development of antibiotic coating on the surface of implants is highly desired. In this work a novel and facile strategy was developed to form pH responsive layer by layer (LbL) films implanted with polymeric micelles as nano vehicles loaded with charge weak antibiotic drugs, enabling high drug loading efficiency. Negatively charged tobramycin (Tob) embeded heparin miscells (HET) and positively charged chitosan (CHT) were exploited as a pH responsive LBL multilayer building block, respectively. The formation mechanism and pH stimulated release behavior of the Tob contained heparin micelles were studied. The characterization on the morphologies, chemical compositions and hydrophilicity of the modified surface confirmed the successuful deposition of the Tob loaded CHT/HET multilayers coatings on the polydopamine modified Ti surface. The drug release profiles displayed fast release at pH 7.4 and slow release after exposure to weakly acidic environments. Antibacterial tests indicated that the Tobembed CHT/HET nanostructured multilayers not only strongly inhibited initial bacterial adhesion, but also disruptted biofilm formation. Particularly, this functional coatings showed "long term antibacterial" pattern in acid condition. Meanwhile, MC3T3 cells showed acceptable adhesion, spread and proliferation on the multilayer coatings in cytocompatible studies. In a word, these multilayer coatings incorporated with a wide variety of antibiotics show promisiong applications in preventing postoperative infection and resolving unmet clinical need.
C1 [Zhou, Wenhao; Jia, Zhaojun; Xiong, Pan; Yan, Jianglong; Cheng, Yan; Zheng, Yufeng] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.
   [Zheng, Yufeng] Peking Univ, Dept Adv Mat & Nanotechnol, Coll Engn, Beijing 100871, Peoples R China.
   [Li, Ming] Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing 100053, Peoples R China.
C3 Peking University; Peking University; Capital Medical University
RP Cheng, Y (通讯作者)，Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.
EM chengyan@pku.edu.cn
RI ; YAN, Zheng Guang/HGC 8374 2022; Xiong, Pan/ACK 9984 2022; Yan,
   Jianglong/JDW 5655 2023; Chen, Yinglong/D 2104 2011; Li,
   Ming/ACU 5300 2022; JIA, ZHAOJUN/AAK 6133 2021
OI Zheng, Y.F./0000 0002 7402 9979; Li, Ming/0000 0001 5823 8108; Yan,
   Jianglong/0000 0001 9484 7138
FU National Natural Science Foundation of China [31670974, 31370954];
   Project of Scientific and Technical Plan of Beijing [Z141100002814008];
   Beijing Natural Science Foundation [2164073]
FX This work is jointly supported by National Natural Science Foundation of
   China (No. 31670974, No. 31370954), the Project of Scientific and
   Technical Plan of Beijing (No. Z141100002814008), and Beijing Natural
   Science Foundation (2164073).
CR Arciola CR, 2012, BIOMATERIALS, V33, P5967, DOI 10.1016/j.biomaterials.2012.05.031
   Arpornmaeklong P, 2007, INT J ORAL MAX SURG, V36, P328, DOI 10.1016/j.ijom.2006.09.023
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Battogtokh G, 2015, J MATER CHEM B, V3, P9349, DOI 10.1039/c5tb01719j
   BRITT MR, 1972, ANTIMICROB AGENTS CH, V2, P236, DOI 10.1128/AAC.2.3.236
   BROGDEN RN, 1976, DRUGS, V12, P166, DOI 10.2165/00003495 197612030 00002
   Campoccia D, 2006, BIOMATERIALS, V27, P2331, DOI 10.1016/j.biomaterials.2005.11.044
   Cloutier M, 2015, TRENDS BIOTECHNOL, V33, P637, DOI 10.1016/j.tibtech.2015.09.002
   Cote B, 2015, J CONTROL RELEASE, V213, P128, DOI 10.1016/j.jconrel.2015.06.040
   DECHER G, 1992, THIN SOLID FILMS, V210, P831, DOI 10.1016/0040 6090(92)90417 A
   Deng L, 2008, ELECTROCHEM COMMUN, V10, P1012, DOI 10.1016/j.elecom.2008.05.001
   Dhand C, 2017, BIOMATERIALS, V138, P153, DOI 10.1016/j.biomaterials.2017.05.043
   Díez Aguilar M, 2015, ANTIMICROB AGENTS CH, V59, P6039, DOI 10.1128/AAC.00822 15
   Dobrynin AV, 2005, PROG POLYM SCI, V30, P1049, DOI 10.1016/j.progpolymsci.2005.07.006
   Dou QQ, 2015, RSC ADV, V5, P46817, DOI 10.1039/c5ra07968c
   Follmann HDM, 2016, J COLLOID INTERF SCI, V474, P9, DOI 10.1016/j.jcis.2016.04.008
   Fu JH, 2005, BIOMATERIALS, V26, P6684, DOI 10.1016/j.biomaterials.2005.04.034
   Hamilton V, 2007, POLYM INT, V56, P641, DOI 10.1002/pi.2181
   Hausser HJ, 2004, J CELL BIOCHEM, V91, P1062, DOI 10.1002/jcb.20007
   Hermann T, 2007, CELL MOL LIFE SCI, V64, P1841, DOI 10.1007/s00018 007 7034 x
   Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b
   Jiang L, 2016, SMALL, V12, P3609, DOI 10.1002/smll.201600327
   Kim BS, 2008, ACS NANO, V2, P386, DOI 10.1021/nn700408z
   Lakshminarayanan R, 2016, INVEST OPHTH VIS SCI, V57
   Lakshminarayanan R, 2014, INT J NANOMED, V9, P2439, DOI 10.2147/IJN.S58487
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Li JH, 2014, COLLOID SURFACE B, V113, P134, DOI 10.1016/j.colsurfb.2013.08.030
   Li ZB, 2016, RSC ADV, V6, P28947, DOI 10.1039/c6ra04531f
   Liang YK, 2014, ACTA BIOMATER, V10, P1588, DOI 10.1016/j.actbio.2013.07.031
   Lin YH, 2009, BIOMATERIALS, V30, P3332, DOI 10.1016/j.biomaterials.2009.02.036
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   Marambio Jones C, 2010, J NANOPART RES, V12, P1531, DOI 10.1007/s11051 010 9900 y
   Meng S, 2009, BIOMATERIALS, V30, P2276, DOI 10.1016/j.biomaterials.2008.12.075
   Misra RDK, 2013, ACTA BIOMATER, V9, P6245, DOI 10.1016/j.actbio.2012.12.003
   Moloney M. G., 2017, ANTIBACTERIAL DRUG R
   Mu HB, 2014, FOOD CONTROL, V38, P215, DOI 10.1016/j.foodcont.2013.10.032
   Neoh KG, 2012, BIOMATERIALS, V33, P2813, DOI 10.1016/j.biomaterials.2012.01.018
   Nguyen PM, 2007, CHEM MATER, V19, P5524, DOI 10.1021/cm070981f
   Pavaloiu RD, 2014, INT J BIOL MACROMOL, V68, P117, DOI 10.1016/j.ijbiomac.2014.04.040
   Pérez Anes A, 2015, ACS APPL MATER INTER, V7, P12882, DOI 10.1021/acsami.5b02402
   Ruan QC, 2009, J COLLOID INTERF SCI, V333, P725, DOI 10.1016/j.jcis.2009.02.003
   Ryou MH, 2011, ADV MATER, V23, P3066, DOI 10.1002/adma.201100303
   Scavone M, 2016, MATERIALS, V9, DOI 10.3390/ma9010037
   Shahab F, 2006, BIOMATERIALS, V27, P3532, DOI 10.1016/j.biomaterials.2006.02.027
   Shawar RM, 1999, ANTIMICROB AGENTS CH, V43, P2877, DOI 10.1128/AAC.43.12.2877
   Silva Bermudez P, 2013, SURF COAT TECH, V233, P147, DOI 10.1016/j.surfcoat.2013.04.028
   Simann M, 2015, BONE, V78, P102, DOI 10.1016/j.bone.2015.04.039
   Toskas G, 2013, CARBOHYD POLYM, V94, P713, DOI 10.1016/j.carbpol.2013.01.068
   Trampuz A, 2006, CURR OPIN INFECT DIS, V19, P349, DOI 10.1097/01.qco.0000235161.85925.e8
   Vasilev K, 2009, EXPERT REV MED DEVIC, V6, P553, DOI 10.1586/ERD.09.36
   Xie ZW, 2015, J BIOMED MATER RES A, V103, P3907, DOI 10.1002/jbm.a.35512
   Yui T, 2007, J PORPHYR PHTHALOCYA, V11, P428, DOI 10.1142/S1088424607000485
   Zaatreh S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151534
   Zhao Y, 2014, ACTA BIOMATER, V10, P544, DOI 10.1016/j.actbio.2013.10.012
   Zhou WH, 2017, ACS APPL MATER INTER, V9, P25830, DOI 10.1021/acsami.7b06757
   Zhu XY, 2015, BIOMATER SCI UK, V3, P1505, DOI 10.1039/c5bm00307e
NR 56
TC 47
Z9 50
U1 5
U2 180
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP 1
PY 2018
VL 90
BP 693
EP 705
DI 10.1016/j.msec.2018.04.069
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GJ8DN
UT WOS:000435619600074
PM 29853141
DA 2025 08 17
ER

PT J
AU Mease, P
   Kuritzky, L
   Wright, WL
   Mallick Searle, T
   Fountaine, R
   Yang, RY
   Sadrarhami, M
   Faison, W
   Johnston, E
   Viktrup, L
AF Mease, Philip
   Kuritzky, Louis
   Wright, Wendy L.
   Mallick Searle, Theresa
   Fountaine, Robert
   Yang, Ruoyong
   Sadrarhami, Mojgan
   Faison, Warachal
   Johnston, Elizabeth
   Viktrup, Lars
TI Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with
   moderate to severe hip or knee osteoarthritis and a history of
   depression, anxiety, or insomnia: post hoc analysis of phase 3 trials
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Analgesics; chronic pain; comorbidity; mood disorders
ID CLINICALLY IMPORTANT DIFFERENCE; CHRONIC PAIN; SLEEP DISTURBANCE;
   REPORTED OUTCOMES; MENTAL HEALTH; OLDER ADULTS; IMPACT; MECHANISMS;
   DETERMINANTS; METAANALYSIS
AB Objective: Treatment outcomes for chronic pain can be poor in patients with depression, anxiety, or insomnia. This analysis evaluated the efficacy and safety of subcutaneous tanezumab, nonsteroidal anti inflammatory drugs (NSAIDs), and placebo in patients with osteoarthritis (OA) and a history of these conditions using data from three phase 3 studies. Methods: A post hoc analysis of data from two pooled placebo controlled studies and one NSAID controlled study of subcutaneous tanezumab. All patients had moderate to severe knee or hip OA that was inadequately controlled with standard of care analgesics. Efficacy outcomes were least squares mean change from baseline to Week 16 in Western Ontario McMaster Universities OA Index (WOMAC) Pain, WOMAC Physical Function, Patient's global assessment of OA, and EQ 5D 5L scores. Results were summarized for patients with and without a history of depression, anxiety, or insomnia at baseline. Results: 1545 patients were treated in the pooled placebo controlled studies (history of depression, 12%; anxiety, 8%; insomnia, 10%; any, 23%) and 2996 in the NSAID controlled study (16%, 11%, 13%, 28%, respectively). In groups with positive histories, 38 80% took antidepressant or anxiolytic medications at baseline. Within treatments, largely similar improvements in efficacy outcomes were observed in patients with and without a history of depression, anxiety, or insomnia; the types of treatment emergent adverse events were similar. Conclusions: Patients with OA and a history of depression, anxiety, or insomnia did not appear to experience reduced efficacy outcomes or an altered safety profile in response to tanezumab or NSAID treatment as compared with those without. NCT02697773; NCT02709486; NCT02528188
C1 [Mease, Philip] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA.
   [Mease, Philip] Univ Washington, Seattle, WA 98195 USA.
   [Kuritzky, Louis] Univ Florida, Gainesville, FL USA.
   [Wright, Wendy L.] Wright & Associates Family Healthcare, Amherst, NH USA.
   [Mallick Searle, Theresa] Stanford Hlth Care, Redwood City, CA USA.
   [Fountaine, Robert] Pfizer Inc, Groton, CT 06340 USA.
   [Yang, Ruoyong; Sadrarhami, Mojgan; Faison, Warachal] Pfizer Inc, New York, NY USA.
   [Johnston, Elizabeth; Viktrup, Lars] Eli Lilly & Co, Indianapolis, IN 46285 USA.
C3 Swedish Medical Center; University of Washington; University of
   Washington Seattle; State University System of Florida; University of
   Florida; Pfizer; Pfizer USA; Pfizer; Pfizer USA; Eli Lilly
RP Mease, P (通讯作者)，Seattle Rheumatol Associates, 601 Broadway,Suite 600, Seattle, WA 98122 USA.
EM pmease@philipmease.com
RI ; Wright, Wendy/AAM 8059 2021
OI Mallick Searle, Theresa/0000 0003 0172 699X; Viktrup,
   Lars/0000 0002 8739 0544; 
FU Pfizer; Eli Lilly and Company
FX Medical writing support was provided by Jennifer Bodkin of Engage
   Scientific Solutions and funded by Pfizer and Eli Lilly and Company. L.
   Kuritzky is affiliated with the University of Florida. The opinions
   expressed in this article do not reflect the opinions of the University
   of Florida . W. Faison authored and approved the initial draft of this
   manuscript but passed away before acceptance for publication. The
   authors acknowledge the contribution of Warachal to this research and
   publication.
CR Agarwal P, 2015, J GEN INTERN MED, V30, P1803, DOI 10.1007/s11606 015 3393 4
   [Anonymous], 2021, PFIZER REPORTS 3 QUA
   [Anonymous], 2021, European Medicines Agency EMA/74208/2022 Jakavi EPAR (European Public Assessment Report): Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006
   [Anonymous], 2021, LILLY REPORTS ROBUST
   [Anonymous], 2021, JOINT M ARTHR ADV CO
   Berenbaum F, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14975
   Berenbaum F, 2022, ARTHRIT CARE RES, V74, P918, DOI 10.1002/acr.24637
   Berenbaum F, 2020, ANN RHEUM DIS, V79, P800, DOI 10.1136/annrheumdis 2019 216296
   Braden JB, 2009, GEN HOSP PSYCHIAT, V31, P564, DOI 10.1016/j.genhosppsych.2009.07.003
   Brown MT, 2022, J NEUROL SCI, V434, DOI 10.1016/j.jns.2022.120184
   Burston JJ, 2019, PAIN, V160, P658, DOI 10.1097/j.pain.0000000000001445
   Campbell CM, 2015, ARTHRIT CARE RES, V67, P1387, DOI 10.1002/acr.22609
   Cassano Giovanni B, 2002, Dialogues Clin Neurosci, V4, P271
   Clauw DJ, 2017, CLIN EXP RHEUMATOL, V35, pS79
   Colloca L, 2007, CURR OPIN ANESTHESIO, V20, P435, DOI 10.1097/ACO.0b013e3282b972fb
   Conner TS, 2006, PAIN, V126, P198, DOI 10.1016/j.pain.2006.06.033
   Dimitroulas T, 2014, SEMIN ARTHRITIS RHEU, V44, P145, DOI 10.1016/j.semarthrit.2014.05.011
   Ehrich EW, 2000, J RHEUMATOL, V27, P2635
   Erdogan BD, 2016, J RHEUMATOL, V43, P194, DOI 10.3899/jrheum.141150
   Gureje O, 2008, PAIN, V134, P3, DOI 10.1016/j.pain.2007.10.029
   Hochberg MC, 2021, ARTHRITIS RHEUMATOL, V73, P1167, DOI 10.1002/art.41674
   Holmes RD, 2016, PHARMACOGENOMICS J, V16, P491, DOI 10.1038/tpj.2016.15
   Holtz N, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03415 x
   Hooten WM, 2016, MAYO CLIN PROC, V91, P955, DOI 10.1016/j.mayocp.2016.04.029
   Institute for Health Metrics and Evaluation, 2021, GBD RES TOOL
   Khan A, 2017, WORLD PSYCHIATRY, V16, P181, DOI 10.1002/wps.20421
   Kim MS, 2021, AM J SPORT MED, V49, P2406, DOI 10.1177/03635465211016853
   Koffel E, 2020, PAIN MED, V21, P1162, DOI 10.1093/pm/pnz221
   Kroenke K, 2008, PAIN, V134, P209, DOI 10.1016/j.pain.2007.09.021
   Liu MH, 2019, ARTHRIT CARE RES, V71, P748, DOI 10.1002/acr.23695
   Lopez Olivo MA, 2011, ANN RHEUM DIS, V70, P1775, DOI 10.1136/ard.2010.146423
   Mallen CD, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002273
   Marks R, 2009, DISABIL HEALTH J, V2, P27, DOI 10.1016/j.dhjo.2008.10.001
   McCaffrey N, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955 016 0537 0
   Morin CM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18782
   Nazarinasab Masoumeh, 2017, Reumatologia (Warsaw), V55, P183, DOI 10.5114/reum.2017.69778
   Nemeroff CB, 2007, J CLIN PSYCHIAT, V68, P17
   Parmelee PA, 2015, ARTHRIT CARE RES, V67, P358, DOI 10.1002/acr.22459
   Pinto PR, 2013, J PAIN, V14, P502, DOI 10.1016/j.jpain.2012.12.020
   Rosemann T, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 79
   Schnitzer TJ, 2021, RHEUMATOL THER, V8, P1759, DOI 10.1007/s40744 021 00372 2
   Schnitzer TJ, 2019, JAMA J AM MED ASSOC, V322, P37, DOI 10.1001/jama.2019.8044
   Sharma A, 2016, OPEN ACCESS RHEUMATO, V8, P103, DOI 10.2147/OARRR.S93516
   Smagula SF, 2015, JAMA PSYCHIAT, V72, P1021, DOI 10.1001/jamapsychiatry.2015.1324
   Stubbs B, 2016, AGE AGEING, V45, P228, DOI 10.1093/ageing/afw001
   Taylor SS, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 1993 y
   Tennen H, 2006, HEALTH PSYCHOL, V25, P370, DOI 10.1037/0278 6133.25.3.370
   Tive L, 2019, J PAIN RES, V12, P975, DOI 10.2147/JPR.S191297
   Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905
   Vajapey Sravya P, 2021, J Clin Orthop Trauma, V18, P187, DOI 10.1016/j.jcot.2021.04.028
   Vitiello MV, 2014, PAIN, V155, P1547, DOI 10.1016/j.pain.2014.04.032
   Wang ZY, 2015, PAIN MED, V16, P1373, DOI 10.1111/pme.12800
   Weng C, 2020, OSTEOARTHR CARTILAGE, V28, P721, DOI 10.1016/j.joca.2020.03.001
   Wilcox S, 2000, J AM GERIATR SOC, V48, P1241, DOI 10.1111/j.1532 5415.2000.tb02597.x
   Woo Adam Km, 2010, Rev Pain, V4, P8, DOI 10.1177/204946371000400103
   Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015
   Zullig LL, 2015, CLIN RHEUMATOL, V34, P1435, DOI 10.1007/s10067 014 2707 y
NR 57
TC 6
Z9 6
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD NOV 2
PY 2022
VL 38
IS 11
BP 1909
EP 1922
DI 10.1080/03007995.2022.2113689
EA AUG 2022
PG 14
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 6M4LU
UT WOS:000847413900001
PM 35980115
DA 2025 08 17
ER

PT J
AU Jia, P
   Chen, G
   Qin, WY
   Zhong, Y
   Yang, J
   Rong, XF
AF Jia, Ping
   Chen, Gang
   Qin, Wen Yi
   Zhong, Yu
   Yang, Juan
   Rong, Xiao Feng
TI Xitong Wan attenuates inflammation development through inhibiting the
   activation of nuclear factor κB in rats with adjuvant induced arthritis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Xitong Wan; Nuclear factor kappa B; Adjuvant induced arthritis;
   Rheumatoid arthritis
ID COLLAGEN INDUCED ARTHRITIS; RHEUMATOID ARTHRITIS; THERAPEUTIC TARGETS;
   DISEASE; MICE; INTERLEUKIN 1; CONSTITUENTS; DESTRUCTION; CYTOKINES;
   RESPONSES
AB Ethnopharmacological relevance: Xitong Wan (XTW), a traditional Chinese herbs formula, has been used to treat "Bi Zheng" in the clinical practice of traditional Chinese medicine (TCM) for hundreds of years. However, no scientific validation is available on the anti rheumatic effect of XTW.
   Aim of study: This study was carried out to investigate the effects of XTW on joints swelling, joints destruction, production of inflammatory mediators and nuclear factor kappa B (NF kappa B) activation in rats with adjuvant induced arthritis (AIA).
   Materials and methods: AIA was induced by intradermal injection of Complete Freund's adjuvant in the footpad of Wistar rats. Paw volume was measured every 7 days during XTW treatment. Histological score was calculated by hematoxylin and eosin staining. osteoclast number in articular tissues was counted by tartrate resistant acid phosphatase staining. Levels of tumor necrosis factor (TNF) alpha, interleukin (IL) 1 beta and IL 6 in serum were detected by enzyme linked immunosorbent assay. Levels of NF kappa Bp65 and inhibitor of NF kappa B (I kappa B)alpha in synovium were analyzed by Western blot assay.
   Results: Compared with AIA group rats, XTW significantly decreased the paw volume of AIA rats. Meanwhile, XTW significantly reduced the histological score and osteoclast number in articular tissues of NA rats. In addition, XTW markedly abated the levels of TNF alpha, IL 1 beta and IL 6 in serum, as well as enhanced the level of I kappa B alpha in synovium of MA rats. However, XTW did not show significant effect on the level of p65 in synovium of AIA rats.
   Conclusions: These results suggest that XTW attenuates the inflammation development through inhibiting the NF kappa B mediated proinflammatory cytokines production in AIA rats. Our study provides the scientific evidence of XTW on treatment of rheumatoid arthritis in the clinical practice of TCM. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Jia, Ping; Qin, Wen Yi; Zhong, Yu; Yang, Juan; Rong, Xiao Feng] Chongqing Med Univ, Dept Combinat Chinese & Western Med, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
   [Chen, Gang] Chongqing Technol & Business Univ, Coll Environm & Resource, Chongqing 400067, Peoples R China.
C3 Chongqing Medical University; Chongqing Technology & Business University
RP Jia, P (通讯作者)，Chongqing Med Univ, Dept Combinat Chinese & Western Med, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
EM jiaping008@163.com
RI zhong, yuhuan/HHC 8699 2022
FU National Natural Science Foundation of China [81503420]
FX This work was supported by National Natural Science Foundation of China
   (81503420).
CR Amarasekara DS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/832127
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Cho ML, 2007, IMMUNOL LETT, V108, P121, DOI 10.1016/j.imlet.2006.11.005
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Emery P, 2013, ANN RHEUM DIS, V72, P1897, DOI 10.1136/annrheumdis 2013 203485
   Eyong KO, 2015, J ETHNOPHARMACOL, V174, P277, DOI 10.1016/j.jep.2015.08.014
   Gibofsky A, 2014, AM J MANAG CARE, V20, pS136
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Koenders MI, 2005, ARTHRITIS RHEUM US, V52, P975, DOI 10.1002/art.20885
   Lamacchia C, 2010, ARTHRITIS RHEUM US, V62, P452, DOI 10.1002/art.27235
   Li W., 2013, J TRADIT CHIN MED, V29, P65
   Lü SW, 2015, J ETHNOPHARMACOL, V176, P177, DOI 10.1016/j.jep.2015.10.010
   Lu Y, 2012, PHYTOMEDICINE, V19, P882, DOI 10.1016/j.phymed.2012.04.010
   Moon SJ, 2013, INT J MOL MED, V31, P769, DOI 10.3892/ijmm.2013.1269
   Park MA, 2007, ARCH PHARM RES, V30, P755, DOI 10.1007/BF02977639
   Sasai M, 1999, ARTHRITIS RHEUM, V42, P1635, DOI 10.1002/1529 0131(199908)42:8<1635::AID ANR11>3.0.CO;2 Q
   Siebert S, 2015, PHARMACOL REV, V67, P280, DOI 10.1124/pr.114.009639
   Spurlock CF, 2014, ARTHRITIS RHEUMATOL, V66, P2947, DOI 10.1002/art.38805
   Strand V, 2004, RHEUMATOLOGY, V43, P10, DOI 10.1093/rheumatology/keh202
   Sun HX, 2006, CHEM BIODIVERS, V3, P754, DOI 10.1002/cbdv.200690077
   Tsuboi H, 2003, ANN RHEUM DIS, V62, P196, DOI 10.1136/ard.62.3.196
   Waksman BH, 2002, SCAND J IMMUNOL, V56, P12, DOI 10.1046/j.1365 3083.2002.01106.x
   Wang ZM, 2011, J ETHNOPHARMACOL, V137, P774, DOI 10.1016/j.jep.2011.06.037
   Yoshida Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/698313
NR 27
TC 10
Z9 13
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD DEC 4
PY 2016
VL 193
BP 266
EP 271
DI 10.1016/j.jep.2016.08.006
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA ED7ZF
UT WOS:000389090600028
PM 27566198
DA 2025 08 17
ER

PT J
AU Molony, DA
   Stephens, BW
AF Molony, Donald A.
   Stephens, Brett W.
TI Derangements in Phosphate Metabolism in Chronic Kidney Diseases/Endstage
   Renal Disease: Therapeutic Considerations
SO ADVANCES IN CHRONIC KIDNEY DISEASE
LA English
DT Article
DE Phosphate metabolism
ID CORONARY ARTERY CALCIFICATION; CHRONIC HEMODIALYSIS PATIENTS;
   PARATHYROID HORMONE LEVELS; CALCIUM CARBONATE; MINERAL METABOLISM;
   LANTHANUM CARBONATE; SERUM PHOSPHORUS; MORTALITY RISK; BONE DISEASE;
   LONG TERM
AB The changes in phosphate (PO4) metabolism across the spectrum of chronic kidney disease (CKD) and specific strategies to address these abnormalities by reducing PO4 loads are discussed in this review. This review also addresses briefly the evidence for specific PO4 serum targets in CKD and endstage renal disease (ESRD) and the potential for other biomarkers such as fibroblast growth factor 23 (FGF 23) to define disease and monitor the effectiveness of therapy. As renal function declines, single nephron excretion of PO4 must increase to maintain PO4 balance. Abnormalities in PO4 metabolism occur early in CKD. Compensatory changes in renal PO4 handling are sufficient to maintain a normal serum PO4 level in early stages of CKD, but in more advanced CKD, these processes no longer suffice and overt hyperphosphatemia develops. The resulting increased PO4 burden contributes directly to development of secondary hyperparathyroidism. The FGF 23 increases early in CKD, likely in response to abnormal PO4 metabolism, and mediates processes that help restore serum PO4 levels to normal in CKD stage 3 and in early stage 4. The increased PO4 burden and subsequent overt hyperphosphatemia are associated with increased mortality and morbidity. Dietary PO4 restriction, modification of dialysis prescriptions, and administration of oral PO4 binders can restore PO4 balance. As CKD progresses, population based studies demonstrate that diet alone is typically not able to prevent or treat hyperphosphatemia. Dialysis modalities that are currently used often fail to remove sufficient PO4 to prevent hyperphosphatemia in patients with an inadequately controlled dietary PO4 load. This is particularly likely among patients without significant residual renal function. Thus, in the majority of ESRD patients, PO4 binders remain the mainstay of therapy for hyperphosphatemia. All currently available PO4 binders can restore serum PO4 to the required level when administered appropriately and in conjunction with dietary PO4 restrictions. PO4 binders differ regarding their potential side effects and impact on long term patient centered outcomes. Which of the PO4 binders might result in the most favorable survival and cardiovascular morbidity profiles and which remain uncertain, remains a subject of considerable clinical investigation. Compelling observational and more limited randomized controlled trial (RCT) evidence support the view that PO4 binders might differ in their effects on mortality and/or morbidity. The limited evidence from RCTs is mostly congruent with the findings from large observational studies. In particular, evidences from both epidemiologic and RCT support the view that excess calcium administration may independently increase the risk of cardiovascular disease in individuals with normal renal function and in patients with CKD and ESRD. Additional RCT evidence might help determine the degree at which any increased risk from oral calcium exposure can be mitigated with the use of noncalcium based PO4 binders.
   Judicious control of PO4 early in CKD, possibly monitored by measures of FGF 23, could potentially reduce the risk of development of renal secondary hyperparathyroidism and all of the adverse clinical consequences of poorly controlled CKD mineral and bone disorder. The mainstays of therapy are likely to include a balance of dietary restriction and PO4 binders to reduce PO4 input, and in ESRD patients, dialysis modalities to augment PO4 output. (C) 2011 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Molony, Donald A.] Univ Texas Houston, Div Renal Dis & Hypertens, Ctr Clin Res & Evidence Based Med, Sch Med, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston
RP Molony, DA (通讯作者)，Univ Texas Houston, Div Renal Dis & Hypertens, Ctr Clin Res & Evidence Based Med, Sch Med, 6431 Fannin Str,MSB 5 125, Houston, TX 77030 USA.
EM donald.a.molony@uth.tmc.edu
CR ALFREY AC, 1993, THER DRUG MONIT, V15, P593, DOI 10.1097/00007691 199312000 00025
   ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402
   ALTAMNN P, 2006, KIDNEY INT, V71, P252
   ANDREOLI SP, 1984, NEW ENGL J MED, V310, P1079, DOI 10.1056/NEJM198404263101704
   Andress Dennis L, 2008, Endocr Pract, V14, P18
   Asmus HG, 2005, NEPHROL DIAL TRANSPL, V20, P1653, DOI 10.1093/ndt/gfh894
   Autissier V, 2007, J PHARM SCI US, V96, P2818, DOI 10.1002/jps.20956
   Ayus JC, 2005, J AM SOC NEPHROL, V16, P2778, DOI 10.1681/ASN.2005040392
   Bammens B, 2003, KIDNEY INT, V64, P2238, DOI 10.1046/j.1523 1755.2003.00310.x
   Barsotti G, 2005, J RENAL NUTR, V15, P189, DOI 10.1053/j.jrn.2004.09.007
   Berndt TJ, 2005, AM J PHYSIOL RENAL, V289, pF1170, DOI 10.1152/ajprenal.00072.2005
   Bischoff Ferrari HA, 2007, AM J CLIN NUTR, V86, P1780
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   BLOCK GA, 2008, NEPHROL DIAL TRANSPL, P1
   Bolland MJ, 2008, BMJ BRIT MED J, V336, P262, DOI 10.1136/bmj.39440.525752.BE
   Bolland MJ, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c3691
   Braun J, 2004, CLIN NEPHROL, V62, P104
   Bugeja A, 2009, CLIN J AM SOC NEPHRO, V4, P778, DOI 10.2215/CJN.05221008
   Burke SK, 1997, NEPHROL DIAL TRANSPL, V12, P1640, DOI 10.1093/ndt/12.8.1640
   Caglar K, 2008, CLIN J AM SOC NEPHRO, V3, P61, DOI 10.2215/CJN.02810707
   Campbell A, 2002, NEPHROL DIAL TRANSPL, V17, P17, DOI 10.1093/ndt/17.suppl_2.17
   Cannata Andía JB, 2002, NEPHROL DIAL TRANSPL, V17, P9, DOI 10.1093/ndt/17.suppl_2.9
   Cannata Andía JB, 2001, SEMIN DIALYSIS, V14, P5, DOI 10.1046/j.1525 139x.2001.00002.x
   Charytan C, 2005, AM J KIDNEY DIS, V46, P58, DOI 10.1053/j.ajkd.2005.04.013
   Cheng SC, 2008, CLIN J AM SOC NEPHRO, V3, P1131, DOI 10.2215/CJN.04211007
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Coen G, 2005, J NEPHROL, V18, P117
   Coladonato JA, 2005, J AM SOC NEPHROL, V16, pS107, DOI 10.1681/ASN.2005060663
   Craver L, 2007, NEPHROL DIAL TRANSPL, V22, P1171, DOI 10.1093/ndt/gfl718
   Culleton BF, 2007, JAMA J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291
   D'Haese PC, 2003, KIDNEY INT, V63, pS73, DOI 10.1046/j.1523 1755.63.s85.18.x
   DELMEZ JA, 1992, J AM SOC NEPHROL, V3, P96
   Delmez JA, 1996, KIDNEY INT, V49, P163, DOI 10.1038/ki.1996.22
   DESOI CA, 1993, J AM SOC NEPHROL, V4, P1214
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   EMMETT M, 1991, AM J KIDNEY DIS, V17, P544, DOI 10.1016/S0272 6386(12)80496 3
   Emmett M, 2004, KIDNEY INT, V66, pS25, DOI 10.1111/j.1523 1755.2004.09005.x
   Felsenfeld AJ, 2007, CLIN J AM SOC NEPHRO, V2, P1283, DOI 10.2215/CJN.01520407
   Ferreira A, 2008, J AM SOC NEPHROL, V19, P405, DOI 10.1681/ASN.2006101089
   Finn WF, 2005, CURR MED RES OPIN, V21, P657, DOI 10.1185/030079905X41453
   Freemont AJ, 2005, CLIN NEPHROL, V64, P428
   Friedman EA, 2006, CLIN J AM SOC NEPHRO, V1, P704, DOI 10.2215/CJN.01831105
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Garside R, 2007, Health Technol Assess, V11, piii
   Garside R, 2007, HEALTH TECHNOL ASSES, V11, P1
   GARSIDE R, 2007, HEALTH TECHNOL ASSES, V11, pR11
   Giachelli CM, 2003, J AM SOC NEPHROL, V14, pS300, DOI 10.1097/01.ASN.0000081663.52165.66
   Gotch FA, 2003, BLOOD PURIFICAT, V21, P51, DOI 10.1159/000067866
   Guérin AP, 2000, NEPHROL DIAL TRANSPL, V15, P1014, DOI 10.1093/ndt/15.7.1014
   Guerin AP, 2001, CIRCULATION, V103, P987
   Gupta A, 2004, J CLIN ENDOCR METAB, V89, P4489, DOI 10.1210/jc.2004 0724
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Hutchison AJ, 2006, NEPHRON CLIN PRACT, V102, P61, DOI 10.1159/000088932
   *I MED NAT AC SCI, DIET REF INT CALC VI
   Isakova T, 2008, J AM SOC NEPHROL, V19, P615, DOI 10.1681/ASN.2007060673
   ITTEL TH, 1988, NEPHROL DIAL TRANSPL, V3, P617, DOI 10.1093/oxfordjournals.ndt.a091716
   Ix JH, 2010, NEPHROL DIAL TRANSPL, V25, P993, DOI 10.1093/ndt/gfp699
   Jüppner H, 2010, J BONE MINER RES, V25, P2091, DOI 10.1002/jbmr.170
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kanbay M, 2009, BLOOD PURIFICAT, V27, P220, DOI 10.1159/000197562
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Ketteler M, 2006, KIDNEY INT, V70, pS5, DOI 10.1038/sj.ki.5001996
   Kovesdy CP, 2008, INT UROL NEPHROL, V40, P427, DOI 10.1007/s11255 008 9346 7
   Kuhlmann MK, 2010, BLOOD PURIFICAT, V29, P137, DOI 10.1159/000245640
   KURZ P, 1994, KIDNEY INT, V46, P855, DOI 10.1038/ki.1994.342
   Larsson TE, 2010, ARTERIOSCL THROM VAS, V30, P333, DOI 10.1161/ATVBAHA.109.196675
   Leggat JE Jr, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Lindsay RM, 2003, AM J KIDNEY DIS, V42, pS24, DOI 10.1016/S0272 6386(03)00534 1
   Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723
   London GM, 2008, J AM SOC NEPHROL, V19, P1827, DOI 10.1681/ASN.2007050622
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   LOPEZHILKER S, 1990, AM J PHYSIOL, V259, pF432, DOI 10.1152/ajprenal.1990.259.3.F432
   LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272 6386(12)70364 5
   LYNCH KE, CLIN J AM S IN PRESS
   MAI ML, 1989, KIDNEY INT, V36, P690, DOI 10.1038/ki.1989.247
   Marco MP, 2003, KIDNEY INT, V63, pS111, DOI 10.1046/j.1523 1755.63.s85.26.x
   Masuyama R, 2006, J CLIN INVEST, V116, P3150, DOI 10.1172/JCI29463
   Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542
   Messa P, 1998, NEPHROL DIAL TRANSPL, V13, P43, DOI 10.1093/ndt/13.suppl_6.43
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98
   Molony DA, 2005, BLOOD PURIFICAT, V23, P2, DOI 10.1159/000083712
   Murphy Gutekunst L, 2005, J RENAL NUTR, V15, pE1, DOI 10.1016/j.jrn.2005.07.009
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Navarro JF, 1999, AM J KIDNEY DIS, V34, P43, DOI 10.1016/S0272 6386(99)70106 X
   Nelson R, 2002, LANCET, V360, P1483, DOI 10.1016/S0140 6736(02)11507 8
   Nikolov IG, 2006, KIDNEY INT, V70, pS16, DOI 10.1038/sj.ki.5001994
   Noordzij M, 2008, BLOOD PURIFICAT, V26, P231, DOI 10.1159/000118847
   Noordzij M, 2006, NEPHROL DIAL TRANSPL, V21, P2513, DOI 10.1093/ndt/gfl257
   Othmane Taha El Hadj, 2007, Hemodial Int, V11 Suppl 3, pS13
   Penne EL, 2010, AM J KIDNEY DIS, V55, P77, DOI 10.1053/j.ajkd.2009.09.023
   Pentti K, 2009, MATURITAS, V63, P73, DOI 10.1016/j.maturitas.2009.03.006
   Peter WLS, 2008, AM J KIDNEY DIS, V51, P445, DOI 10.1053/j.ajkd.2007.12.002
   Qunibi W, 2008, AM J KIDNEY DIS, V51, P952, DOI 10.1053/j.ajkd.2008.02.298
   Raggi P, 2005, J BONE MINER RES, V20, P764, DOI 10.1359/JBMR.041221
   RING T, 1993, NEPHROL DIAL TRANSPL, V8, P341
   Rodriguez Benot A, 2005, AM J KIDNEY DIS, V46, P68, DOI 10.1053/j.ajkd.2005.04.006
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   Russo D, 2004, AM J KIDNEY DIS, V44, P1024, DOI 10.1053/j.ajkd.2004.07.022
   Russo D, 2007, AM J NEPHROL, V27, P152, DOI 10.1159/000100044
   SALUSKY IB, 1991, NEW ENGL J MED, V324, P527, DOI 10.1056/NEJM199102213240804
   Salusky IB, 2005, J AM SOC NEPHROL, V16, P2501, DOI 10.1681/ASN.2004100885
   SCHAEFER K, 1991, NEPHROL DIAL TRANSPL, V6, P170, DOI 10.1093/ndt/6.3.170
   Shantouf R, 2008, AM J NEPHROL, V28, P275, DOI 10.1159/000111061
   Sigrist MK, 2009, J RENAL CARE, V35, P71, DOI 10.1111/j.1755 6686.2009.00064.x
   Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507
   Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701
   Slatopolsky EA, 1999, KIDNEY INT, V55, P299, DOI 10.1046/j.1523 1755.1999.00240.x
   Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275
   Spiegel DM, 2008, NAT CLIN PRACT NEPHR, V4, P118, DOI 10.1038/ncpneph0710
   Spiegel DM, 2007, J RENAL NUTR, V17, P416, DOI 10.1053/j.jrn.2007.08.005
   Strippoli GFM, 2006, AM J KIDNEY DIS, V47, P715, DOI 10.1053/j.ajkd.2006.01.015
   Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466
   Swearingen RA, 2002, J PHARMACEUT BIOMED, V29, P195, DOI 10.1016/S0731 7085(02)00007 9
   Takahashi Y, 2004, KIDNEY INT, V65, P1099, DOI 10.1111/j.1523 1755.2004.00482.x
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
   Tonelli M, 2009, AM J KIDNEY DIS, V54, P1108, DOI 10.1053/j.ajkd.2009.05.018
   Torres PU, 2007, KIDNEY INT, V71, P730, DOI 10.1038/sj.ki.5002163
   Uribarri J, 2003, SEMIN DIALYSIS, V16, P186, DOI 10.1046/j.1525 139X.2003.16037.x
   WILHELM M, 1990, PHARMACOL TOXICOL, V66, P4, DOI 10.1111/j.1600 0773.1990.tb00692.x
   Young DO, 2009, PERITON DIALYSIS INT, V29, P562
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 129
TC 28
Z9 32
U1 1
U2 20
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1548 5595
EI 1548 5609
J9 ADV CHRONIC KIDNEY D
JI Adv. Chronic Kidney Dis.
PD MAR
PY 2011
VL 18
IS 2
BP 120
EP 131
DI 10.1053/j.ackd.2011.02.004
PG 12
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 741BW
UT WOS:000288839100011
PM 21406297
OA Bronze
DA 2025 08 17
ER

PT J
AU Shu, Y
   Peng, J
   Feng, ZX
   Hu, KB
   Li, T
   Zhu, PJ
   Cheng, T
   Hao, L
AF Shu, Yuan
   Peng, Jie
   Feng, Zuxi
   Hu, Kaibo
   Li, Ting
   Zhu, Peijun
   Cheng, Tao
   Hao, Liang
TI Osteosarcoma subtypes based on platelet related genes and tumor
   microenvironment characteristics
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE platelet; cancer; immunology; prognosis; subtypes; microenvironment
ID CELLS; INHIBITION; PROGNOSIS; THERAPY; MICE
AB BackgroundOsteosarcoma is a common metastatic tumor in children and adolescents. Because of its easy metastasis, patients often show a poor prognosis. Recently, researchers have found that platelets are closely related to metastasis of a variety of malignant tumors, but the role of platelets related characteristics in osteosarcoma is still unknown. The purpose of this study is to explore the characteristics of platelet related subtypes and cell infiltration in tumor microenvironment. MethodsWe collected osteosarcoma cohorts from TCGA and GEO databases, and explored the molecular subtypes mediated by platelet related genes and the related TME cell infiltration according to the expression of platelet related genes in osteosarcoma. In addition, we also explored the differentially expressed genes (DEGs) among different molecular subtypes and established a protein protein interaction network (PPI). Then we constructed a platelet scoring model by Univariate cox regression and least absolute shrinkage and selection operator (Lasso) cox regression model to quantify the characteristics of platelet in a single tumor. RT PCR was used to investigate the expression of six candidate genes in osteosarcoma cell lines and normal osteoblast lines. Finally, we also predicted potential drugs with therapeutic effects on platelet related subtypes. ResultsWe found that platelet related genes (PRGs) can distinguish osteosarcoma into two different platelet related subtypes, C1 and C2. And the prognosis of the C2 subtype was significantly worse than that of C1 subtype. The results of ESTIMATE analysis and GO/KEGG enrichment showed that the differences between different subtypes were mainly concentrated in immune response pathways, and the immune response of C2 was inhibited relative to C1. We further studied the relationship between platelet related subtypes and immune cell infiltration. We found that the distribution of most immune cells in C1 subtype was higher than that in C2 subtype, and there was a correlation between C1 subtype and more immune cells. Finally, we screened the PRGs related to the prognosis of osteosarcoma through Univariate Cox regression, established independent prognostic platelet characteristics consisting of six genes to predict the prognosis of patients with OS, and predicted the drugs that may be used in the treatment of osteosarcoma. RT PCR was used to verify the expression of candidate genes in osteosarcoma cells. ConclusionPlatelet scoring model is a significant biomarker, which is of great significance to determine the prognosis, molecular subtypes, characteristics of TME cell infiltration and therapy in patients with OS.
C1 [Shu, Yuan; Peng, Jie; Feng, Zuxi; Hu, Kaibo; Li, Ting; Zhu, Peijun; Hao, Liang] Nanchang Univ, Affiliated Hosp 2, Dept Orthoped, Nanchang, Peoples R China.
   [Shu, Yuan; Peng, Jie; Feng, Zuxi; Hu, Kaibo; Li, Ting; Zhu, Peijun] Nanchang Univ, Clin Med Coll 2, Nanchang, Peoples R China.
   [Cheng, Tao] Shanghai Jiao Tong Univ, Affiliated Shanghai Peoples Hosp, Dept Orthopaed Surg, Shanghai, Peoples R China.
C3 Nanchang University; Nanchang University; Shanghai Jiao Tong University
RP Hao, L (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Orthoped, Nanchang, Peoples R China.
RI hao, liang/NBX 8636 2025; Peng, Jie/HIR 9161 2022; Li,
   Ting/JCN 8036 2023; Hu, Kaibo/HQZ 1869 2023
OI Peng, Jie/0000 0003 4040 0327; Hu, Kaibo/0000 0002 0060 6729; 
FU National Natural Science Foundation of China; National College Students
   Innovation and Entrepreneurship Training Program; Jiangxi Provincial
   Science Fund for Distinguished Young Scholars;  [82060492]; 
   [202110403003];  [20212ACB216011]
FX Funding The research project is supported by the National Natural
   Science Foundation of China (grant nos. 82060492), the National College
   Students Innovation and Entrepreneurship Training Program
   (202110403003), and the Jiangxi Provincial Science Fund for
   Distinguished Young Scholars (20212ACB216011).
CR Angelillo Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667
   Balkenhol J, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864 020 07215 4
   Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019
   Chen JX, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1076 1
   Chen XJ, 2022, J MED CHEM, V65, P5374, DOI 10.1021/acs.jmedchem.1c01732
   Crinier A, 2020, CELL, V180, P1280, DOI 10.1016/j.cell.2020.02.029
   Davis BP, 2014, CANCER IMMUNOL RES, V2, P1, DOI 10.1158/2326 6066.CIR 13 0196
   Duong L, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979 021 00215 2
   Egan K, 2014, CLIN EXP METASTAS, V31, P697, DOI 10.1007/s10585 014 9660 7
   Fu YC, 2021, J INFLAMM RES, V14, P6719, DOI 10.2147/JIR.S340477
   Gaertner F, 2019, NAT REV IMMUNOL, V19, P747, DOI 10.1038/s41577 019 0202 z
   Goubran HA, 2013, EUR J INTERN MED, V24, P393, DOI 10.1016/j.ejim.2013.01.017
   Green David, 2006, Hemodial Int, V10 Suppl 2, pS2, DOI 10.1111/j.1542 4758.2006.00119.x
   Gremmel T, 2016, SEMIN THROMB HEMOST, V42, P191, DOI 10.1055/s 0035 1564835
   Guérin M, 2016, HUM PATHOL, V50, P70, DOI 10.1016/j.humpath.2015.11.012
   Haemmerle M, 2018, CANCER CELL, V33, P965, DOI 10.1016/j.ccell.2018.03.002
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   He AD, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02801 1
   Huang XY, 2019, J BONE ONCOL, V16, DOI 10.1016/j.jbo.2019.100230
   Ichikawa J, 2020, J BONE MINER RES, V35, P1738, DOI 10.1002/jbmr.4045
   Kaste SC, 1999, CANCER AM CANCER SOC, V86, P1602, DOI 10.1002/(SICI)1097 0142(19991015)86:8<1602::AID CNCR31>3.0.CO;2 R
   Kopp HG, 2009, CANCER RES, V69, P7775, DOI 10.1158/0008 5472.CAN 09 2123
   Koupenova M, 2022, CIRC RES, V130, P288, DOI 10.1161/CIRCRESAHA.121.319821
   Kubo T, 2008, CANCER AM CANCER SOC, V112, P2119, DOI 10.1002/cncr.23437
   Marck RE, 2019, PLATELETS, V30, P396, DOI 10.1080/09537104.2018.1448379
   Michael JV, 2017, BLOOD, V130, P567, DOI 10.1182/blood 2016 11 751099
   Nieswandt B, 1999, CANCER RES, V59, P1295
   Niveditha D, 2019, BIOINFORMATICS, V35, P1701, DOI 10.1093/bioinformatics/bty868
   Pagel O, 2017, PLATELETS, V28, P119, DOI 10.1080/09537104.2016.1254762
   Pavlovic N, 2019, CANCERS, V11, DOI 10.3390/cancers11071022
   Provost P, 2017, CLIN CHEM LAB MED, V55, P657, DOI 10.1515/cclm 2016 0895
   Rothzerg E, 2020, EXP BIOL MED, V245, P1437, DOI 10.1177/1535370220949139
   Saito M, 2018, J BONE MINER RES, V33, P2048, DOI 10.1002/jbmr.3537
   Sajadi KR, 2004, CLIN ORTHOP RELAT R, P92, DOI 10.1097/01.blo.0000141496.52166.69
   Silva Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904
   Stone RL, 2012, NEW ENGL J MED, V366, P610, DOI 10.1056/NEJMoa1110352
   Szymanska Jachimczak E I, 1972, Czas Stomatol, V25, P693
   Takagi S, 2021, ONCOGENE, V40, P5548, DOI 10.1038/s41388 021 01956 6
   Tao DL, 2021, BLOOD, V137, P3201, DOI 10.1182/blood.2019003977
   Tao LL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0413 3
   Ward MP, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01347 1
   Wielders SJH, 2007, THROMB HAEMOSTASIS, V98, P1056, DOI 10.1160/TH07 05 0322
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
   Wu CC, 2020, ADV EXP MED BIOL, V1258, P21, DOI 10.1007/978 3 030 43085 6_2
   Xiao B, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.753414
   Xu XR, 2018, BLOOD, V131, P1777, DOI 10.1182/blood 2017 05 743187
   Yan GN, 2016, CANCER LETT, V370, P268, DOI 10.1016/j.canlet.2015.11.003
   Yeung J, 2018, PHARMACOL REV, V70, P526, DOI 10.1124/pr.117.014530
   Yoshida A, 2012, AM J SURG PATHOL, V36, P423, DOI 10.1097/PAS.0b013e31824230d0
   Yu GH, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109094
   Zhou CM, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.563142
NR 51
TC 14
Z9 14
U1 1
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 23
PY 2022
VL 12
AR 941724
DI 10.3389/fonc.2022.941724
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 5D4VU
UT WOS:000864942200001
PM 36212395
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ürkmez, AS
   Bayir, E
   Bilgi, E
   Özen, MÖ
AF Sendemir Urkmez, Aylin
   Bayir, Ece
   Bilgi, Eyup
   Ozen, Mehmet Ozgun
TI Biocompatible polymeric coatings do not inherently reduce the
   cytotoxicity of iron oxide nanoparticles
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE Iron oxide nanoparticles; poly(acrylic acid); chitosan; human
   osteoblast like cell line; cytotoxicity
ID OSTEOSARCOMA CELL LINES; BIOMEDICAL APPLICATIONS; SURFACE MODIFICATION;
   GOLD NANOPARTICLES; FUNCTIONAL CHARACTERIZATION; MAGNETIC NANOPARTICLES;
   FE3O4 NANOPARTICLES; DRUG DELIVERY; CANCER CELLS; TOXICITY
AB Nanotechnology in biomedical research is an emerging and promising tool for different purposes, like high resolution medical imaging, diagnostics, and targeted drug delivery. Although some experimental efforts focused on determination of the cytotoxicity of nanoparticles (NPs) are present, there are many controversial results. In this study, chitosan (CS)  and poly(acrylic acid) (PAA) coated iron oxide nanoparticles (IONPs) were used to investigate the possible cytotoxicity of coated IONPs on model mammalian cell line SaOs 2 by evaluating cellular viability and membrane integrity. Increasing concentrations of IONPs increased the cytotoxic effect on SaOs 2 cells with both CS and PAA coated IONPs. Cell viability on day 3 was as low as 40% and 48% at 1000 mu M concentration for PAA  and CS coated IONPs, respectively, in 1% FBS supplemented media. Cytotoxicity determined by the released lactate dehydrogenase (LDH) was as high as 163% with 1000 mu M concentration of CS IONPs, while there was no significant change in LDH release with PAA coated IONPs at any concentration. This study reveals that IONPs coated with a biocompatible polymer, which are usually assumed to be nontoxic, show cytotoxicity with increasing concentration and incubation time. The cytotoxicity of nanoparticles intended for biomedical purposes must be evaluated using more than one approach.
C1 [Sendemir Urkmez, Aylin; Bilgi, Eyup] Ege Univ, Fac Engn, Dept Bioengn, Izmir, Turkey.
   [Sendemir Urkmez, Aylin; Bayir, Ece] Ege Univ, Grad Sch Nat & Appl Sci, Dept Biomed Technol, Izmir, Turkey.
   [Sendemir Urkmez, Aylin; Bayir, Ece] Ege Univ, Applicat & Res Ctr Testing & Anal EGE MATAL, Izmir, Turkey.
   [Ozen, Mehmet Ozgun] Stanford Univ, Canary Ctr Stanford Canc Early Detect, Dept Radiol, Bioacoust MEMS Med BAMM Lab, Palo Alto, CA 94304 USA.
C3 Ege University; Ege University; Ege University; Stanford University
RP Ürkmez, AS (通讯作者)，Ege Univ, Fac Engn, Dept Bioengn, Izmir, Turkey.; Ürkmez, AS (通讯作者)，Ege Univ, Grad Sch Nat & Appl Sci, Dept Biomed Technol, Izmir, Turkey.; Ürkmez, AS (通讯作者)，Ege Univ, Applicat & Res Ctr Testing & Anal EGE MATAL, Izmir, Turkey.
EM aylin.sendemir@ege.edu.tr
RI ; Bayir, Ece/E 9908 2015; Bilgi, Eyüp/X 7865 2018; Sendemir,
   Aylin/A 6347 2014
OI BILGI, EYUP/0000 0001 9644 0403; Bayir, Ece/0000 0003 4886 3860; OZEN,
   MEHMET/0000 0003 4578 2598; Sendemir, Aylin/0000 0003 1818 6651
CR Ankamwar B, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/7/075102
   Au JLS, 2016, ADV DRUG DELIVER REV, V97, P280, DOI 10.1016/j.addr.2015.12.002
   Bähring F, 2013, IEEE T MAGN, V49, P383, DOI 10.1109/TMAG.2012.2222635
   Bao YP, 2016, J MATER SCI, V51, P513, DOI 10.1007/s10853 015 9324 2
   Bayir E, 2014, ADV CHEM MAT ENG B, P447, DOI 10.4018/978 1 4666 5824 0.ch018
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Carvalho SM, 2016, TOXICOL RES UK, V5, P1017, DOI 10.1039/c6tx00039h
   Coelho JF, 2010, EPMA J, V1, P164, DOI 10.1007/s13167 010 0001 x
   Dass CR, 2008, J MICROENCAPSUL, V25, P421, DOI 10.1080/02652040802033673
   Fang C, 2009, J MATER CHEM, V19, P6258, DOI 10.1039/b902182e
   Fröhlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111
   Fröhlich E, 2012, NANOTOXICOLOGY, V6, P424, DOI 10.3109/17435390.2011.586478
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Grabowski N, 2015, INT J PHARMACEUT, V482, P75, DOI 10.1016/j.ijpharm.2014.11.042
   Gudovan D, 2015, CURR PHARM DESIGN, V21, P6038, DOI 10.2174/1381612821666151027151702
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hong S, 2010, J KOREAN PHYS SOC, V56, P868, DOI 10.3938/jkps.56.868
   Huang QJ, 2014, MATER CHEM PHYS, V147, P550, DOI 10.1016/j.matchemphys.2014.05.030
   Hussain SM, 2009, ADV MATER, V21, P1549, DOI 10.1002/adma.200801395
   Hussain SM, 2005, TOXICOL IN VITRO, V19, P975, DOI 10.1016/j.tiv.2005.06.034
   Hwang TL, 2015, INT J NANOMED, V10, P371, DOI 10.2147/IJN.S73017
   Jeong S, 2010, J PHYS CHEM C, V114, P22277, DOI 10.1021/jp106994t
   Kadajji VG, 2011, POLYMERS BASEL, V3, P1972, DOI 10.3390/polym3041972
   Kaushika A, 2008, BIOSENS BIOELECTRON, V24, P676, DOI 10.1016/j.bios.2008.06.032
   Kim SK, 2014, CHITIN AND CHITOSAN DERIVATIVES: ADVANCES IN DRUG DISCOVERY AND DEVELOPMENTS, P1
   Kim ST, 2013, ACCOUNTS CHEM RES, V46, P681, DOI 10.1021/ar3000647
   Küçükdermenci S, 2013, MATER TEHNOL, V47, P71
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Li GY, 2008, J ALLOY COMPD, V466, P451, DOI 10.1016/j.jallcom.2007.11.100
   Li XY, 2012, INT J BIOL MACROMOL, V50, P1299, DOI 10.1016/j.ijbiomac.2012.03.008
   Li Y, 2010, J PHYS CHEM B, V114, P2749, DOI 10.1021/jp904550b
   Lin JQ, 2010, ACS NANO, V4, P5421, DOI 10.1021/nn1010792
   Ling DS, 2013, SMALL, V9, P1450, DOI 10.1002/smll.201202111
   Liu XS, 2013, LANGMUIR, V29, P9138, DOI 10.1021/la401556k
   Mahdavi M, 2013, MOLECULES, V18, P7533, DOI 10.3390/molecules18077533
   Mahmoudi M, 2011, ACS NANO, V5, P7263, DOI 10.1021/nn2021088
   Mahmoudi M, 2011, ADV DRUG DELIVER REV, V63, P24, DOI 10.1016/j.addr.2010.05.006
   Mahmoudi M, 2010, COLLOID SURFACE B, V75, P300, DOI 10.1016/j.colsurfb.2009.08.044
   Mansur AAP, 2016, INT J BIOL MACROMOL, V82, P780, DOI 10.1016/j.ijbiomac.2015.10.047
   Mikhaylova M, 2004, LANGMUIR, V20, P2472, DOI 10.1021/la035648e
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Morton SW, 2014, ADV HEALTHC MATER, V3, P867, DOI 10.1002/adhm.201300465
   Mura S, 2011, INT J NANOMED, V6, P2591, DOI 10.2147/IJN.S24552
   Nafee N, 2009, INT J PHARMACEUT, V381, P130, DOI 10.1016/j.ijpharm.2009.04.049
   Petri Fink A, 2005, BIOMATERIALS, V26, P2685, DOI 10.1016/j.biomaterials.2004.07.023
   Calatayud MP, 2014, BIOMATERIALS, V35, P6389, DOI 10.1016/j.biomaterials.2014.04.009
   Qin YG, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944 015 0068 4
   Schulze C, 2008, NANOTOXICOLOGY, V2, P51, DOI 10.1080/17435390802018378
   Shen Z, 2007, ADV MATER, V19, P349, DOI 10.1002/adma.200601740
   Soenen SJH, 2011, BIOMATERIALS, V32, P195, DOI 10.1016/j.biomaterials.2010.08.075
   Soenen SJH, 2010, SMALL, V6, P832, DOI 10.1002/smll.200902084
   Susa M, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 399
   Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181
   Tripathi SK, 2016, COLLOID SURFACE B, V140, P117, DOI 10.1016/j.colsurfb.2015.12.007
   Ucar S, 2016, J BIOACT COMPAT POL, V31, P304, DOI 10.1177/0883911515627471
   van der Valk J, 2010, TOXICOL IN VITRO, V24, P1053, DOI 10.1016/j.tiv.2010.03.016
   Wahajuddin, 2012, INT J NANOMED, V7, P3445, DOI 10.2147/IJN.S30320
   Wang JJ, 2011, INT J NANOMED, V6, P765, DOI 10.2147/IJN.S17296
   Xu YL, 2016, J APPL TOXICOL, V36, P543, DOI 10.1002/jat.3282
   Zhang XL, 2015, TROP J PHARM RES, V14, P1581, DOI 10.4314/tjpr.v14i9.6
NR 60
TC 4
Z9 4
U1 0
U2 33
PU Tubitak Scientific & Technological Research Council Turkey
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, TR 06100 ANKARA, TURKIYE
SN 1300 0152
EI 1303 6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2017
VL 41
IS 2
BP 322
EP 332
DI 10.3906/biy 1608 61
PG 11
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA ET3LI
UT WOS:000400179800008
OA Bronze
DA 2025 08 17
ER

PT J
AU Jin, Y
   Lee, JS
   Min, S
   Park, HJ
   Kang, TJ
   Cho, SW
AF Jin, Yoonhee
   Lee, Jung Seung
   Min, Sungjin
   Park, Hyun Ji
   Kang, Taek Jin
   Cho, Seung Woo
TI Bioengineered Extracellular Membranous Nanovesicles for Efficient
   Small Interfering RNA Delivery: Versatile Platforms for Stem Cell
   Engineering and In Vivo Delivery
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID GENE DELIVERY; OSTEOBLAST DIFFERENTIATION; MEDIATED ENDOCYTOSIS;
   NONVIRAL VECTORS; PROGENITOR CELLS; EXOSOME UPTAKE; E CADHERIN;
   VESICLES; SIRNA; PEPTIDES
AB Naturally derived nanovesicles secreted from various cell types and found in body fluids can provide effective platforms for the delivery of various cargoes because of their intrinsic ability to be internalized for intercellular signal transmission and membrane recycling. In this study, the versatility of bioengineered extracellular membranous nanovesicles as potent carriers of small interfering RNAs (siRNAs) for stem cell engineering and in vivo delivery has been explored. Here, exosomes have been engineered, one of the cell derived vesicle types, to overexpress exosomal proteins fused with cell adhesion or cell penetrating peptides for enhanced intracellular gene transfer. To devise a more effective delivery system with potential for mass production, a new siRNA delivery system has also been developed by artificially inducing the outward budding of plasma membrane nanovesicles. Those nanovesicles have been engineered by overexpressing E cadherin to facilitate siRNA delivery to human stem cells with resistance to intracellular gene transfer. Both types of engineered nanovesicles deliver siRNAs to human stem cells for lineage specification with negligible cytotoxicity. The nanovesicles are efficient in delivering siRNA in vivo, suggesting feasibility for gene therapy. Cell derived, bioengineered nanovesicles used for siRNA delivery can provide functional platforms enabling effective stem cell therapeutics and in vivo gene therapy.
C1 [Jin, Yoonhee; Lee, Jung Seung; Min, Sungjin; Park, Hyun Ji; Cho, Seung Woo] Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea.
   [Kang, Taek Jin] Dongguk Univ Seoul, Dept Chem & Biochem Engn, Seoul 100715, South Korea.
C3 Yonsei University; Dongguk University
RP Cho, SW (通讯作者)，Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea.
EM seungwoocho@yonsei.ac.kr
RI Cho, Seung Woo/AAU 1214 2021; Lee, Jung/U 4732 2019; Min,
   Sungjin/ISB 0496 2023; Park, Hyun Ji/ABA 6694 2021
OI Kang, Taek/0000 0001 6234 2880; Min, Sungjin/0000 0002 5041 8638; Park,
   Hyun Ji/0000 0001 9688 4418
FU National Research Foundation (NRF) of Korea [NRF 2013R1A1A2A10061422,
   2015M3C9A4053251, 2015R1A2A1A15053771]; Translational Research Center
   for Protein Function Control   National Research Foundation (NRF) of
   Korea [TRCP 2016R1A5A1004694]; BK21 PLUS program; National Research
   Foundation of Korea [2016R1A5A1004694] Funding Source: Korea Institute
   of Science & Technology Information (KISTI), National Science &
   Technology Information Service (NTIS)
FX Y.J. and J.S.L. contributed equally to this work. This work was
   supported by grants (NRF 2013R1A1A2A10061422, 2015M3C9A4053251, and
   2015R1A2A1A15053771) from the National Research Foundation (NRF) of
   Korea, and a grant from the Translational Research Center for Protein
   Function Control (TRCP 2016R1A5A1004694) funded by the National Research
   Foundation (NRF) of Korea. This work was also supported in part by the
   BK21 PLUS program. Human stem cells (hiPSCs and hNSCs) were kindly
   provided from Yonsei University College of Medicine with the approval of
   Institutional Review Board (IRB) of Yonsei University. All animal
   experiments were performed in accordance with the Korean Food and Drug
   Administration guidelines. Experimental protocols for in vivo imaging
   and siRNA delivery were reviewed and approved by the Yonsei Laboratory
   Animal Research Center (YLARC).
CR Abrajano JJ, 2010, P NATL ACAD SCI USA, V107, P16685, DOI 10.1073/pnas.0906917107
   Alvarez Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Bauer B, 2009, ANGEW CHEM INT EDIT, V48, P1656, DOI 10.1002/anie.200803898
   Buzas EI, 2014, NAT REV RHEUMATOL, V10, P356, DOI 10.1038/nrrheum.2014.19
   Cho SW, 2009, ADV FUNCT MATER, V19, P3112, DOI 10.1002/adfm.200900519
   CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092 8674(95)90298 8
   Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968
   Dubavik A, 2012, ACS NANO, V6, P2150, DOI 10.1021/nn204930y
   EL Andaloussi S, 2013, ADV DRUG DELIVER REV, V65, P391, DOI 10.1016/j.addr.2012.08.008
   El Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Escrevente C, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 108
   Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600 0854.2010.01041.x
   Fridriksson EK, 1999, BIOCHEMISTRY US, V38, P8056, DOI 10.1021/bi9828324
   Fuhrmann G, 2015, NANO TODAY, V10, P397, DOI 10.1016/j.nantod.2015.04.004
   Fuhrmann G, 2015, J CONTROL RELEASE, V205, P35, DOI 10.1016/j.jconrel.2014.11.029
   Gujrati V, 2014, ACS NANO, V8, P1525, DOI 10.1021/nn405724x
   Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806
   HOLOWKA D, 1984, J BIOL CHEM, V259, P3720
   Hung ME, 2015, J BIOL CHEM, V290, P8166, DOI 10.1074/jbc.M114.621383
   Jang SC, 2013, ACS NANO, V7, P7698, DOI 10.1021/nn402232g
   Jones CH, 2013, MOL PHARMACEUT, V10, P4082, DOI 10.1021/mp400467x
   Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294
   Kaneti L, 2016, NANO LETT, V16, P1574, DOI 10.1021/acs.nanolett.5b04237
   Kang JH, 2012, J CONTROL RELEASE, V163, P119, DOI 10.1016/j.jconrel.2012.08.030
   Kay MA, 2011, NAT REV GENET, V12, P316, DOI 10.1038/nrg2971
   Kutsuzawa K, 2006, BIOCHEM BIOPH RES CO, V350, P514, DOI 10.1016/j.bbrc.2006.09.081
   Lamichhane TN, 2015, MOL PHARMACEUT, V12, P3650, DOI 10.1021/acs.molpharmaceut.5b00364
   LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619
   Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317
   Li L, 2012, CELL ADHES MIGR, V6, P59, DOI 10.4161/cam.19583
   Liu YC, 2015, SCI REP UK, V5, DOI 10.1038/srep17543
   Low WC, 2012, DNA CELL BIOL, V31, P1148, DOI 10.1089/dna.2011.1557
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Mayer A, 2009, TOXICOLOGY, V258, P139, DOI 10.1016/j.tox.2009.01.015
   Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood 2004 03 0824
   Muralidharan Chari V, 2010, J CELL SCI, V123, P1603, DOI 10.1242/jcs.064386
   Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
   Park HJ, 2015, BIOMATERIALS, V50, P127, DOI 10.1016/j.biomaterials.2015.01.015
   Pignolo RJ, 2011, J BONE MINER RES, V26, P2647, DOI 10.1002/jbmr.481
   Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622
   Säälik P, 2011, J CONTROL RELEASE, V153, P117, DOI 10.1016/j.jconrel.2011.03.011
   SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435
   Seow Y, 2009, MOL THER, V17, P767, DOI 10.1038/mt.2009.41
   Sezgin E, 2012, NAT PROTOC, V7, P1042, DOI 10.1038/nprot.2012.059
   Svensson KJ, 2013, J BIOL CHEM, V288, P17713, DOI 10.1074/jbc.M112.445403
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052
   Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960 9822(02)00926 0
   TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Tian T, 2014, J BIOL CHEM, V289, P22258, DOI 10.1074/jbc.M114.588046
   Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169 409X(02)00183 7
   Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463
   Wang QL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2886
   Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004 0865
   Wittrup A, 2015, NAT REV GENET, V16, P543, DOI 10.1038/nrg3978
   Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406
   Xu J, 2015, CELL STEM CELL, V16, P119, DOI 10.1016/j.stem.2015.01.013
   Yang K, 2013, ACS APPL MATER INTER, V5, P10529, DOI 10.1021/am402156f
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang Y, 2012, MOL THER, V20, P1298, DOI 10.1038/mt.2012.79
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 62
TC 26
Z9 26
U1 2
U2 85
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD AUG 23
PY 2016
VL 26
IS 32
BP 5804
EP 5817
DI 10.1002/adfm.201601430
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA DW4JG
UT WOS:000383608400004
DA 2025 08 17
ER

PT J
AU Su, YH
   Goncalves, T
   Dias Santagata, D
   Hoang, MP
AF Su, Yuhua
   Goncalves, Theodore
   Dias Santagata, Dora
   Hoang, Mai P.
TI Immunohistochemical Detection of ROS1 Fusion
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE ROS1; Immunohistochemistry; Lung carcinoma; Colorectal carcinoma;
   Translocation
ID ALK FUSIONS; LUNG; REARRANGEMENTS; IDENTIFICATION; CANCER
AB Objectives: Patients whose tumors harbor ROS1 translocation may benefit from targeted therapy. Detection of ROS1 rearrangement can be done by three methods: immunohistochemistry, fluorescence in situ hybridization, and molecular assays. Immunohistochemistry would be a cost effective means to screen for ROS1 translocation, which is uncommon.
   Methods: ROS1 immunostain was performed on cases with known ROS1 translocation status detected either by fluorescence in situ hybridization or next generation sequencing.
   Results: Fifty seven cases, 10 lung carcinomas with ROS1 rearrangement and 47 cases without ROS1 rearrangement (25 lung carcinomas, 13 gastrointestinal carcinomas, three brain tumors, and six miscellaneous tumors), were included. ROS1 immunostain exhibited 100% sensitivity and 85% specificity, with staining seen in 10 (100%) of 10 cases with ROS1 rearrangement and in seven (15%) of 47 lung cases without ROS1 rearrangement. Weak or 1+ staining of reactive pneumocytes was seen in eight (14%) of 57 cases, and strong staining of osteoclast giant cells was seen in one case.
   Conclusions: Since ROS1 rearrangement is an infrequent event, immunohistochemistry is a cost effective screening method. Confirmation of all positive and equivocal/weak staining with molecular assays would exclude the false positive cases.
C1 [Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
   Harvard Med Sch, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School
RP Hoang, MP (通讯作者)，Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
EM mhoang@mgh.harvard.edu
RI Hoang, Mai/LMP 7115 2024
CR Aisner DL, 2014, MOL CANCER RES, V12, P111, DOI 10.1158/1541 7786.MCR 13 0479 T
   Antonescu CR, 2015, AM J SURG PATHOL, V39, P957, DOI 10.1097/PAS.0000000000000404
   Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345
   Birch AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028250
   Boyle TA, 2015, CLIN LUNG CANCER, V16, P106, DOI 10.1016/j.cllc.2014.10.003
   Cao B, 2015, ONCOTARGETS THER, V9, P131, DOI 10.2147/OTT.S94997
   Cha YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103333
   Charest A, 2003, GENE CHROMOSOME CANC, V37, P58, DOI 10.1002/gcc.10207
   Giacomini CP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003464
   Gu TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015640
   Hornick JL, 2015, MODERN PATHOL, V28, P732, DOI 10.1038/modpathol.2014.165
   Lee J, 2013, CANCER AM CANCER SOC, V119, P1627, DOI 10.1002/cncr.27967
   Marieres J, J CLIN ONCOL
   Mescam Mancini L, 2014, LUNG CANCER, V83, P168, DOI 10.1016/j.lungcan.2013.11.019
   Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078 0432.CCR 11 3351
   Rogers TM, 2015, J THORAC ONCOL, V10, P611, DOI 10.1097/JTO.0000000000000465
   Shan L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120422
   Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766
   Sholl LM, 2013, AM J SURG PATHOL, V37, P1441, DOI 10.1097/PAS.0b013e3182960fa7
   Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658
   Yoshida A, 2014, MODERN PATHOL, V27, P711, DOI 10.1038/modpathol.2013.192
   Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729
NR 22
TC 16
Z9 17
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002 9173
EI 1943 7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD JAN
PY 2017
VL 147
IS 1
BP 77
EP 82
DI 10.1093/AJCP/AQW201
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA EP0QI
UT WOS:000397091400009
PM 28007702
OA Bronze
DA 2025 08 17
ER

PT J
AU Topaloglu, N
   Bakay, E
   Yünlü, M
   Onak, G
AF Topaloglu, Nermin
   Bakay, Emel
   Yunlu, Merve
   Onak, Gunnur
TI Induced photo cytotoxicity on prostate cancer cells with the
   photodynamic action of toluidine Blue ortho
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Photodynamic therapy; Prostate cancer; Red laser light; Toluidine blue
   ortho
ID NITRIC OXIDE; SUBCELLULAR LOCALIZATION; STAPHYLOCOCCUS AUREUS;
   METHYLENE BLUE; IN VITRO; THERAPY; PHOTOSENSITIZERS; PROLIFERATION;
   INACTIVATION; OSTEOBLAST
AB Background: Photodynamic therapy (PDT) has become an advantageous therapeutic approach for the treatment of select cancers and microbial infections. PDT generates toxic reactive oxygen species as an end product of the interaction between the photosensitizer and light with an appropriate wavelength. Toluidine blue ortho is a photosensitizer that is commonly used in the photodynamic treatment of bacterial infection and a promising photosensitizer for cancer treatment. This study aims to evaluate the potential photo cytotoxicity of toluidine blue ortho mediated photodynamic therapy on PC 3 prostate cancer cells. Methods: In this study toluidine blue ortho mediated photodynamic therapy was assessed on PC 3 cancer cells with various photosensitizer concentrations and light energy densities of the 655 nm diode laser. MTT analysis was used for the determination of the cytotoxicity on the cells and viability/cytotoxicity assay was used for live/ dead cell staining after the applications. The mechanism of this application was further analyzed with the determination of intracellular reactive oxygen species and nitric oxide release. Results: The light applications and the photosensitizer alone did not inhibit the cell viability of PC 3 cells. 20 J/ cm2 laser energy density together with 100 mu M photosensitizer concentration resulted in maximum cancer cell death with a rate of approximately 89 %. The level of intracellular reactive oxygen species increased with the increasing parameters of the applications that resulted in more cell death. Conclusion: This study showed the successful anticancer activity of toluidine blue ortho upon irradiation with 655 nm of laser light against PC 3 cancer cells and it was mediated with the production of reactive oxygen species.
C1 [Topaloglu, Nermin; Yunlu, Merve] Izmir Katip Celebi Univ, Fac Engn & Architecture, Dept Biomed Engn, TR 35620 Turkey, Turkey.
   [Bakay, Emel; Onak, Gunnur] Izmir Katip Celebi Univ, Grad Sch Nat & Appl Sci, Dept Biomed Technol, TR 35620 Izmir, Turkey.
   [Yunlu, Merve] Bogazici Univ, Inst Biomed Engn, TR 34684 Istanbul, Turkey.
C3 Izmir Katip Celebi University; Izmir Katip Celebi University; Bogazici
   University
RP Topaloglu, N (通讯作者)，Izmir Katip Celebi Univ, Fac Engn & Architecture, Dept Biomed Engn, TR 35620 Turkey, Turkey.
EM nermin.topaloglu@ikcu.edu.tr; emelbakay@hotmail.com;
   merveyunlu85@gmail.com; gunnur.onak@ikcu.edu.tr
RI Topaloglu, Nermin/HKV 2223 2023; Pulat, Günnur/KFA 4423 2024; Yünlü,
   Merve/AAS 1075 2020
CR Abrahamse H, 2016, BIOCHEM J, V473, P347, DOI 10.1042/BJ20150942
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Castillejos Molina RA, 2016, SALUD PUBLICA MEXICO, V58, P279, DOI 10.21149/spm.v58i2.7797
   Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Baltazar LD, 2013, J ANTIMICROB CHEMOTH, V68, P354, DOI 10.1093/jac/dks414
   Blázquez Castro A, 2009, PHOTOCH PHOTOBIO SCI, V8, P371, DOI 10.1039/b818585a
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Buck S.TG., 2009, THESIS U SAO PAULO
   Calabro F, 2007, EUR UROL, V51, P17, DOI 10.1016/j.eururo.2006.08.013
   CANETE M, 1993, ANTI CANCER DRUG DES, V8, P471
   Carelle N, 2002, CANCER AM CANCER SOC, V95, P155, DOI 10.1002/cncr.10630
   DARZYNKIEWICZ Z, 1988, CANCER RES, V48, P1295
   Fulda Simone, 2010, Int J Cell Biol, V2010, P214074, DOI 10.1155/2010/214074
   Girotti AW, 2020, PHOTOCHEM PHOTOBIOL, V96, P500, DOI 10.1111/php.13163
   Girotti AW, 2016, CRIT REV ONCOGENESIS, V21, P353, DOI 10.1615/CritRevOncog.2017020909
   Girotti AW, 2016, CANCERS, V8, DOI 10.3390/cancers8100096
   Gomella LG, 2009, UROLOGY, V73, P28, DOI 10.1016/j.urology.2009.03.003
   Graciano TB, 2015, PHOTODIAGN PHOTODYN, V12, P98, DOI 10.1016/j.pdpdt.2014.11.003
   Gupta S, 1998, CANCER RES, V58, P1785
   Herkovits J, 2007, RES J CHEM ENVIRON, V11, P86
   Hinz A, 2009, UROL ONCOL SEMIN ORI, V27, P367, DOI 10.1016/j.urolonc.2008.02.003
   Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273
   Jiang Y, 2013, PHOTODIAGN PHOTODYN, V10, P600, DOI 10.1016/j.pdpdt.2013.06.004
   Kashef N, 2012, PHOTODIAGN PHOTODYN, V9, P355, DOI 10.1016/j.pdpdt.2012.05.001
   Nicolas Perez D, 2005, Gastroenterol Hepatol, V28, P337, DOI 10.1157/13076352
   Niemz M.H, 2019, LASER TISSUE INTERAC, P15
   Nyokong T., 2012, PHOTOSENSITIZERMED, P29
   Oliveira FA, 2016, J PHOTOCH PHOTOBIO B, V163, P14, DOI 10.1016/j.jphotobiol.2016.08.006
   Phoenix DA, 2003, TRENDS MOL MED, V9, P283, DOI 10.1016/S1471 4914(03)00115 1
   Pucelik B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185984
   Rapozzi V, 2013, NITRIC OXIDE BIOL CH, V30, P26, DOI 10.1016/j.niox.2013.01.002
   REDMAN RS, 1992, ORAL SURG ORAL MED O, V74, P473, DOI 10.1016/0030 4220(92)90299 6
   Renno ACM, 2007, PHOTOMED LASER SURG, V25, P275, DOI 10.1089/pho.2007.2055
   Sabnis R.W., 2010, HDB BIOL DYES STAINS
   Sahu K, 2009, J PHOTOCH PHOTOBIO B, V96, P9, DOI 10.1016/j.jphotobiol.2009.03.008
   Schuster U, 2001, J ENDODONT, V27, P259, DOI 10.1097/00004770 200104000 00004
   Siegel R.L., 2020, CA CANCER J CLIN, V70, P7
   Soh N, 2006, ANAL BIOANAL CHEM, V386, P532, DOI 10.1007/s00216 006 0366 9
   Sridharan Gokul, 2012, J Oral Maxillofac Pathol, V16, P251, DOI 10.4103/0973 029X.99081
   Stockert JC, 1996, CANCER CHEMOTH PHARM, V39, P167, DOI 10.1007/s002800050554
   Tegos GP, 2006, ANTIMICROB AGENTS CH, V50, P196, DOI 10.1128/AAC.50.1.196 203.2006
   Tewari AK, 2018, ADV EXP MED BIOL, V1095, P41, DOI 10.1007/978 3 319 95693 0_3
   Topaloglu N, 2016, LETT APPL MICROBIOL, V62, P230, DOI 10.1111/lam.12538
   Topaloglu N, 2020, PHOTODIAGN PHOTODYN, V31, DOI 10.1016/j.pdpdt.2020.101891
   Topaloglu N, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.2.028003
   Topaloglu N, 2013, PHOTOMED LASER SURG, V31, P155, DOI 10.1089/pho.2012.3430
   Tremblay JF, 2002, PHOTOCH PHOTOBIO SCI, V1, P852, DOI 10.1039/b204385h
   Vitiello G, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.642523
   Wondrak GT, 2007, FREE RADICAL BIO MED, V43, P178, DOI 10.1016/j.freeradbiomed.2007.03.035
NR 49
TC 12
Z9 13
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572 1000
EI 1873 1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2021
VL 34
AR 102306
DI 10.1016/j.pdpdt.2021.102306
EA APR 2021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA TE9FR
UT WOS:000670312500008
PM 33901692
DA 2025 08 17
ER

PT J
AU Stefanska, K
   Nemcova, L
   Blatkiewicz, M
   Pienkowski, W
   Rucinski, M
   Zabel, M
   Mozdziak, P
   Podhorska Okolów, M
   Dziegiel, P
   Kempisty, B
AF Stefanska, Katarzyna
   Nemcova, Lucie
   Blatkiewicz, Malgorzata
   Pienkowski, Wojciech
   Rucinski, Marcin
   Zabel, Maciej
   Mozdziak, Paul
   Podhorska Okolow, Marzenna
   Dziegiel, Piotr
   Kempisty, Bartosz
TI Apoptosis Related Human Wharton's Jelly Derived Stem Cells
   Differentiation into Osteoblasts, Chondrocytes, Adipocytes and
   Neural like Cells Complete Transcriptomic Assays
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Wharton's jelly; mesenchymal stem cells; RNAseq; MSC; differentiation;
   apoptosis
ID HUMAN UMBILICAL CORD; MESENCHYMAL STROMAL CELLS; GENE EXPRESSION;
   ADIPOSE TISSUE; OSTEOGENIC DIFFERENTIATION; ARTS PROTEIN; TNF ALPHA;
   IN VITRO; RNA SEQ; IDENTIFICATION
AB Wharton's jelly derived mesenchymal stem cells (WJ MSCs) exhibit multilineage differentiation potential, adhere to plastic, and express a specific set of surface markers CD105, CD73, CD90. Although there are relatively well established differentiation protocols for WJ MSCs, the exact molecular mechanisms involved in their in vitro long term culture and differentiation remain to be elucidated. In this study, the cells were isolated from Wharton's jelly of umbilical cords obtained from healthy full term deliveries, cultivated in vitro, and differentiated towards osteogenic, chondrogenic, adipogenic and neurogenic lineages. RNA samples were isolated after the differentiation regimen and analyzed using an RNA sequencing (RNAseq) assay, which led to the identification of differentially expressed genes belonging to apoptosis related ontological groups. ZBTB16 and FOXO1 were upregulated in all differentiated groups as compared to controls, while TGFA was downregulated in all groups. In addition, several possible novel marker genes associated with the differentiation of WJ MSCs were identified (e.g., SEPTIN4, ITPR1, CNR1, BEX2, CD14, EDNRB). The results of this study provide an insight into the molecular mechanisms involved in the long term culture in vitro and four lineage differentiation of WJ MSCs, which is crucial to utilize WJ MSCs in regenerative medicine.
C1 [Stefanska, Katarzyna; Blatkiewicz, Malgorzata; Rucinski, Marcin] Poznan Univ Med Sci, Dept Histol & Embryol, PL 60781 Poznan, Poland.
   [Stefanska, Katarzyna] Cellivia 3 SA, PL 61623 Poznan, Poland.
   [Nemcova, Lucie] Czech Acad Sci, Inst Anim Physiol & Genet, Libechov 27721, Czech Republic.
   [Pienkowski, Wojciech] Poznan Univ Med Sci, Div Perinatol & Womens Dis, PL 60535 Poznan, Poland.
   [Zabel, Maciej; Dziegiel, Piotr] Wroclaw Med Univ, Dept Human Morphol & Embryol, Div Histol & Embryol, PL 50368 Wroclaw, Poland.
   [Zabel, Maciej] Univ Zielona Gora, Div Anat & Histol, PL 65046 Zielona Gora, Poland.
   [Mozdziak, Paul] North Carolina State Univ, Prestage Dept Poultry Sci, Raleigh, NC 27695 USA.
   [Podhorska Okolow, Marzenna] Wroclaw Med Univ, Dept Human Morphol & Embryol, Div Ultrastruct Res, PL 50368 Wroclaw, Poland.
   [Kempisty, Bartosz] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL 87100 Torun, Poland.
   [Kempisty, Bartosz] Wroclaw Med Univ, Dept Human Morphol & Embryol, Div Anat, PL 50368 Wroclaw, Poland.
   [Kempisty, Bartosz] Univ Hosp, Dept Obstet & Gynecol, Brno 60177, Czech Republic.
   [Kempisty, Bartosz] Masaryk Univ, Brno 60177, Czech Republic.
   [Kempisty, Bartosz] North Carolina State Univ, Physiol Grad Fac, Raleigh, NC 27695 USA.
C3 Poznan University of Medical Sciences; Czech Academy of Sciences;
   Institute of Animal Physiology & Genetics of the Czech Academy of
   Sciences; Poznan University of Medical Sciences; Wroclaw Medical
   University; University of Zielona Gora; North Carolina State University;
   Wroclaw Medical University; Nicolaus Copernicus University; Wroclaw
   Medical University; University Hospital Brno; Masaryk University Brno;
   North Carolina State University
RP Kempisty, B (通讯作者)，Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL 87100 Torun, Poland.; Kempisty, B (通讯作者)，Wroclaw Med Univ, Dept Human Morphol & Embryol, Div Anat, PL 50368 Wroclaw, Poland.; Kempisty, B (通讯作者)，Univ Hosp, Dept Obstet & Gynecol, Brno 60177, Czech Republic.; Kempisty, B (通讯作者)，Masaryk Univ, Brno 60177, Czech Republic.; Kempisty, B (通讯作者)，North Carolina State Univ, Physiol Grad Fac, Raleigh, NC 27695 USA.
EM bartosz.kempisty@umw.edu.pl
RI Rucinski, Marcin/AID 3528 2022; Blatkiewicz, Malgorzata/C 8192 2018;
   Nemcova, Lucie/G 7125 2014; Blatkiewicz, Małgorzata/C 8192 2018;
   Stefanska, Katarzyna/MTB 9619 2025
OI Blatkiewicz, Malgorzata/0000 0001 5506 2397; Nemcova,
   Lucie/0000 0002 2594 3369; Rucinski, Marcin/0000 0002 2525 5777;
   mozdziak, paul/0000 0002 1575 3123; Dziegiel, Piotr/0000 0002 8292 1385;
   Zabel, Maciej/0000 0003 2004 0010; Podhorska Okolow,
   Marzenna/0000 0003 2215 5997; Stefanska, Katarzyna/0000 0002 8814 4935
FU Polish Ministry of Science and Higher Education [0070/DW/2018/02];
   National Institute of Food and Agriculture; Ministry of Education, Youth
   and Sports of the Czech Republic, Operational Program Research,
   Development and Education, project "EXCELLENCE in molecular aspects of
   the early development of vertebrates"
   [CZ.02.1.01/0.0/0.0/15_003/0000460]; Ministry of Science and Higher
   Education [0070/DW/2018/02]
FX This research was funded by the Polish Ministry of Science and Higher
   Education, grant number 0070/DW/2018/02, and by the National Institute
   of Food and Agriculture, grant number NC7082. The APC was funded by the
   National Institute of Food and Agriculture. This work was supported by
   the Ministry of Education, Youth and Sports of the Czech Republic,
   Operational Program Research, Development and Education, project
   "EXCELLENCE in molecular aspects of the early development of
   vertebrates" [grant number CZ.02.1.01/0.0/0.0/15_003/0000460] and the
   Ministry of Science and Higher Education [grant number 0070/DW/2018/02].
CR Afizadeh R, 2019, J CHEM NEUROANAT, V96, P126, DOI 10.1016/j.jchemneu.2019.01.003
   Al Ali MM, 2022, BMC GENOMIC DATA, V23, DOI 10.1186/s12863 022 01027 z
   Alvarez E, 2005, GENE, V357, P18, DOI 10.1016/j.gene.2005.05.012
   Amable PR, 2014, BMC CELL BIOL, V15, DOI 10.1186/s12860 014 0046 0
   Amable PR, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt442
   Ambele MA, 2016, STEM CELL RES, V16, P725, DOI 10.1016/j.scr.2016.04.011
   Ansari AS, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2406462
   Arutyunyan I, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6901286
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Benjamini Y, 2017, BIOSTATISTICS, V18, P91, DOI 10.1093/biostatistics/kxw030
   Bharti D, 2018, CELL TISSUE RES, V372, P51, DOI 10.1007/s00441 017 2699 4
   Binder BYK, 2014, TISSUE ENG PT A, V20, P1156, DOI [10.1089/ten.tea.2013.0487, 10.1089/ten.TEA.2013.0487]
   Bongso A, 2013, STEM CELL REV REP, V9, P226, DOI 10.1007/s12015 012 9418 z
   Budna J, 2017, ZYGOTE, V25, P331, DOI 10.1017/S096719941700020X
   Cabrera Pérez R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1450 3
   Can A, 2007, STEM CELLS, V25, P2886, DOI 10.1634/stemcells.2007 0417
   Chao KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001451
   Chen JF, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/1256002
   Chen JY, 2019, J MOL ENDOCRINOL, V62, pR239, DOI 10.1530/JME 18 0178
   Chen P, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13095
   Conconi M.T., 2011, The Open Tissue Engineering and Regenerative Medicine Journal, V4, P6, DOI [10.2174/1875043501104010006, DOI 10.2174/1875043501104010006]
   Conconi MT, 2006, INT J MOL MED, V18, P1089
   DAMSGAARD TME, 1992, APMIS, V100, P845, DOI 10.1111/j.1699 0463.1992.tb04009.x
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dogan A, 2018, ADV EXP MED BIOL, V1079, P1, DOI 10.1007/5584_2018_175
   Domínguez Castro M, 2022, BIOCHEM BIOPH RES CO, V637, P300, DOI 10.1016/j.bbrc.2022.11.029
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Feng J, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10323
   Fresno C, 2013, BIOINFORMATICS, V29, P2810, DOI 10.1093/bioinformatics/btt487
   Fu YS, 2004, J BIOMED SCI, V11, P652, DOI 10.1159/000079678
   Goesmann A, 2002, BIOINFORMATICS, V18, P124, DOI 10.1093/bioinformatics/18.1.124
   Golkar Narenji A, 2022, GENES BASEL, V13, DOI 10.3390/genes13020242
   Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Heidenreich S, 1997, J IMMUNOL, V159, P3178
   Hu Y, 2013, NEURAL REGEN RES, V8, P1783, DOI 10.3969/j.issn.1673 5374.2013.19.006
   Huang H, 2011, CELL PROLIFERAT, V44, P420, DOI 10.1111/j.1365 2184.2011.00769.x
   Huang P, 2010, J CELL BIOCHEM, V109, P747, DOI 10.1002/jcb.22453
   Jankowski M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081783
   Jarrige M, 2021, CELLS BASEL, V10, DOI 10.3390/cells10020240
   Jin LY, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658 017 0044 2
   Katagiri W, 2015, INT J MOL SCI, V16, P23250, DOI 10.3390/ijms161023250
   Kinoshita A, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.188755
   Kurakazu I, 2019, J BIOL CHEM, V294, P17555, DOI 10.1074/jbc.RA119.009409
   Lee J, 2010, LIFE SCI, V86, P416, DOI 10.1016/j.lfs.2010.01.012
   Lee MS, 2019, FASEB J, V33, P996, DOI 10.1096/fj.201800614R
   Li K, 2013, MOL CELL BIOCHEM, V376, P137, DOI 10.1007/s11010 013 1559 0
   Liang J, 2013, NEUROSCI LETT, V532, P59, DOI 10.1016/j.neulet.2012.11.014
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu S, 2014, MOL CELL BIOCHEM, V390, P123, DOI 10.1007/s11010 014 1963 0
   Liu TM, 2007, STEM CELLS, V25, P750, DOI 10.1634/stemcells.2006 0394
   Liu TM, 2011, ARTHRITIS RHEUM US, V63, P2711, DOI 10.1002/art.30430
   Lo Furno D, 2013, APOPTOSIS, V18, P578, DOI 10.1007/s10495 013 0830 x
   Lotan R, 2005, J BIOL CHEM, V280, P25802, DOI 10.1074/jbc.M501955200
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ludikhuize MC, 2021, ANTIOXID REDOX SIGN, V34, P1004, DOI 10.1089/ars.2020.8126
   Lyons FG, 2019, ADV EXP MED BIOL, V1169, P243, DOI 10.1007/978 3 030 24108 7_13
   Marofi F, 2019, J CELL PHYSIOL, V234, P6230, DOI 10.1002/jcp.27352
   Martin M., 2011, EMBnet.Journal, V17, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]
   Marupanthorn Kulisara, 2015, Journal of the Medical Association of Thailand, V98, pS34
   Mashhadikhan M, 2020, J ORAL BIOSCI, V62, P349, DOI 10.1016/j.job.2020.08.001
   MEYER FA, 1983, BIOCHIM BIOPHYS ACTA, V755, P376, DOI 10.1016/0304 4165(83)90241 6
   Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21 1 50
   Naderi A, 2010, INT J CANCER, V126, P1596, DOI 10.1002/ijc.24866
   Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534 5807(02)00401 X
   Nanaev AK, 1997, PLACENTA, V18, P53, DOI 10.1016/S0143 4004(97)90071 0
   Oliver L, 2013, STEM CELLS, V31, P800, DOI 10.1002/stem.1336
   Onizuka S, 2016, J CELL BIOCHEM, V117, P2423, DOI 10.1002/jcb.25634
   Pesarini JR, 2018, BIOMED PHARMACOTHER, V108, P914, DOI 10.1016/j.biopha.2018.09.083
   Pochon C, 2022, J CELL MOL MED, V26, P1339, DOI 10.1111/jcmm.17105
   Pomduk K, 2015, ANN HEMATOL, V94, P319, DOI 10.1007/s00277 014 2210 1
   Potier E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325
   Prasajak P, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/762196
   Qi ZP, 2019, RSC ADV, V9, P8315, DOI 10.1039/c8ra10103e
   Reppel L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0263 2
   Reppel L, 2014, CURR STEM CELL RES T, V9, P306, DOI 10.2174/1574888X09666140213204850
   Rucinski M, 2008, INT J MOL MED, V22, P553, DOI 10.3892/ijmm_00000055
   Shi Q, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0700 5
   Sidibeh CO, 2017, ENDOCRINE, V55, P839, DOI 10.1007/s12020 016 1172 6
   Siqueira MF, 2011, BONE, V48, P1043, DOI 10.1016/j.bone.2011.01.019
   Sobieszczuk DF, 2010, GENE DEV, V24, P206, DOI 10.1101/gad.554510
   Sobolewski K, 1997, BIOL NEONATE, V71, P11
   Stelcer E, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2022.13240
   Subramanian A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127992
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   TAKECHI K, 1993, PLACENTA, V14, P235, DOI 10.1016/S0143 4004(05)80264 4
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wang XY, 2008, BLOOD, V111, P2436, DOI 10.1182/blood 2007 07 099333
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Wu KH, 2007, J CELL BIOCHEM, V100, P608, DOI 10.1002/jcb.21078
   Wu LF, 2009, TISSUE ENG PT A, V15, P2865, DOI 10.1089/ten.TEA.2008.0579
   Young HE, 2004, ANAT REC PART A, V276A, P75, DOI 10.1002/ar.a.10134
   Zhang X, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01389 y
   Zhang YN, 2009, CYTOTHERAPY, V11, P548, DOI 10.1080/14653240903051533
   Zhao L, 2016, LIFE SCI, V151, P93, DOI 10.1016/j.lfs.2016.03.001
   Zhong L, 2016, STEM CELLS DEV, V25, P1808, DOI 10.1089/scd.2016.0222
   Zhou Q, 2016, IN VITRO CELL DEV AN, V52, P356, DOI 10.1007/s11626 015 9969 9
   Zhou XP, 2012, BIOCHEM BIOPH RES CO, V427, P574, DOI 10.1016/j.bbrc.2012.09.100
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu X, 2022, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.768711
NR 102
TC 3
Z9 3
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2023
VL 24
IS 12
AR 10023
DI 10.3390/ijms241210023
PG 27
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA K6KI2
UT WOS:001017505600001
PM 37373173
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Wang, J
   Deng, F
   Yan, ZJ
   Xia, YL
   Wang, ZL
   Ye, JX
   Deng, YL
   Zhang, ZL
   Qiao, M
   Li, RF
   Denduluri, SK
   Wei, Q
   Zhao, LG
   Lu, S
   Wang, X
   Tang, SL
   Liu, H
   Luu, HH
   Haydon, RC
   He, TC
   Jiang, L
AF Zhang, Qian
   Wang, Jing
   Deng, Fang
   Yan, Zhengjian
   Xia, Yinglin
   Wang, Zhongliang
   Ye, Jixing
   Deng, Youlin
   Zhang, Zhonglin
   Qiao, Min
   Li, Ruifang
   Denduluri, Sahitya K.
   Wei, Qiang
   Zhao, Lianggong
   Lu, Shun
   Wang, Xin
   Tang, Shengli
   Liu, Hao
   Luu, Hue H.
   Haydon, Rex C.
   He, Tong Chuan
   Jiang, Li
TI TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection
   Sensitivity and Amplification Efficiency of SYBR Green qPCR
SO PLOS ONE
LA English
DT Article
ID REAL TIME PCR; POLYMERASE CHAIN REACTION; MESENCHYMAL STEM CELLS; DENTAL
   APICAL PAPILLA; OSTEOGENIC DIFFERENTIATION; RT PCR; PROGENITOR CELLS;
   OSTEO/ODONTOBLASTIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION;
   RECOMBINANT ADENOVIRUSES
AB The advent of fluorescence based quantitative real time PCR (qPCR) has revolutionized the quantification of gene expression analysis in many fields, including life sciences, agriculture, forensic science, molecular diagnostics, and medicine. While SYBR Green based qPCR is the most commonly used platform due to its inexpensive nature and robust chemistry, quantifying the expression of genes with low abundance or RNA samples extracted from highly restricted or limited sources can be challenging because the detection sensitivity of SYBR Green based qPCR is limited. Here, we develop a novel and effective touchdown qPCR (TqPCR) protocol by incorporating a 4 cycle touchdown stage prior to the quantification amplification stage. Using the same cDNA templates, we find that TqPCR can reduce the average Cq values for Gapdh, Rps13, and Hprt1 reference genes by 4.45, 5.47, and 4.94 cycles, respectively, when compared with conventional qPCR; the overall average Cq value reduction for the three reference genes together is 4.95. We further find that TqPCR can improve PCR amplification efficiency and thus increase detection sensitivity. When the quantification of Wnt3A induced target gene expression in mesenchymal stem cells is analyzed, we find that, while both conventional qPCR and TqPCR can detect the up regulation of the relatively abundant target Axin2, only TqPCR can detect the up regulation of the lowly expressed targets Oct4 and Gbx2. Finally, we demonstrate that the MRQ2 and MRQ3 primer pairs derived from mouse reference gene Tbp can be used to validate the RNA/cDNA integrity of qPCR samples. Taken together, our results strongly suggest that TqPCR may increase detection sensitivity and PCR amplification efficiency. Overall, TqPCR should be advantageous over conventional qPCR in expression quantification, especially when the transcripts of interest are lowly expressed, and/or the availability of total RNA is highly restricted or limited.
C1 [Zhang, Qian; Wang, Zhongliang; He, Tong Chuan; Jiang, Li] Chongqing Med Univ, Childrens Hosp, Dept Neurol, Chongqing 400046, Peoples R China.
   [Zhang, Qian; Wang, Zhongliang; He, Tong Chuan; Jiang, Li] Chongqing Med Univ, Childrens Hosp, Minist Educ, Key Lab Child Dev & Disorders, Chongqing 400046, Peoples R China.
   [Zhang, Qian; Wang, Jing; Deng, Fang; Yan, Zhengjian; Wang, Zhongliang; Ye, Jixing; Deng, Youlin; Zhang, Zhonglin; Qiao, Min; Li, Ruifang; Denduluri, Sahitya K.; Wei, Qiang; Zhao, Lianggong; Lu, Shun; Wang, Xin; Tang, Shengli; Liu, Hao; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Wang, Jing; Yan, Zhengjian; Deng, Youlin; Qiao, Min; Wei, Qiang; Liu, Hao] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med, Chongqing 400016, Peoples R China.
   [Wang, Jing; Yan, Zhengjian; Deng, Youlin; Qiao, Min; Wei, Qiang; Liu, Hao] Chongqing Med Univ, Affiliated Hosp, Chongqing 400016, Peoples R China.
   [Deng, Fang] Third Mil Med Univ, Dept Cell Biol, Chongqing 400038, Peoples R China.
   [Xia, Yinglin] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
   [Ye, Jixing] Chongqing Univ, Sch Bioengn, Chongqing 400044, Peoples R China.
   [Zhang, Zhonglin; Li, Ruifang; Tang, Shengli] Wuhan Univ, Zhongnan Hosp, Dept Gen Surg, Wuhan 430071, Peoples R China.
   [Zhang, Zhonglin; Li, Ruifang; Tang, Shengli] Wuhan Univ, Zhongnan Hosp, Dept Neurol, Wuhan 430071, Peoples R China.
   [Zhao, Lianggong] Lanzhou Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Lanzhou 730000, Peoples R China.
   [Lu, Shun] Shandong Univ, Shandong Prov Hosp, Dept Orthopaed Surg, Jinan 250012, Peoples R China.
   [Wang, Xin] Sichuan Univ, West China Hosp, Dept Surg, Chengdu 610041, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; University
   of Chicago; University of Chicago Medical Center; Chongqing Medical
   University; Chongqing Medical University; Army Medical University;
   University of Rochester; Chongqing University; Wuhan University; Wuhan
   University; Lanzhou University; Shandong University; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Sichuan
   University
RP He, TC (通讯作者)，Chongqing Med Univ, Childrens Hosp, Dept Neurol, Chongqing 400046, Peoples R China.
EM tche@uchicago.edu; Dr_jiangli@hotmail.com
RI Wang, Zhongliang/J 8674 2012; Wei, Qiang/HII 4390 2022; Ye,
   Jixing/JAX 5357 2023
FU National Institutes of Health [AT004418, AR50142, AR054381]; National
   Natural Science Foundation of China (NSFC Grant) [81371452, 81271770];
   University of Chicago Core Facility grant from the National Center for
   Advancing Translational Sciences (NCATS) of the National Institutes of
   Health [UL1 TR000430]
FX The reported work was supported in part by research grants from the
   National Institutes of Health (AT004418, AR50142, AR054381 to TCH, RCH
   and HHL), and the National Natural Science Foundation of China (NSFC
   Grant # 81371452 81271770 to LJ). This work was also supported in part
   by The University of Chicago Core Facility Subsidy grant from the
   National Center for Advancing Translational Sciences (NCATS) of the
   National Institutes of Health through Grant UL1 TR000430.
CR Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cao XM, 2012, BIOCHEM BIOPH RES CO, V427, P366, DOI 10.1016/j.bbrc.2012.09.066
   Chen DL, 2011, J CELL PHYSIOL, V226, P2469, DOI 10.1002/jcp.22725
   Chen X, 2013, CELL PHYSIOL BIOCHEM, V32, P1083, DOI 10.1159/000354508
   Chen X, 2015, GENES DIS, V2, P96, DOI 10.1016/j.gendis.2014.12.001
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Gasparic MB, 2010, ANAL BIOANAL CHEM, V396, P2023, DOI 10.1007/s00216 009 3418 0
   Gentle A, 2001, BIOTECHNIQUES, V31, P502, DOI 10.2144/01313st03
   Guénin S, 2009, J EXP BOT, V60, P487, DOI 10.1093/jxb/ern305
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hecker KH, 1996, BIOTECHNIQUES, V20, P478
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Jacob F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059180
   Jensen EC, 2012, ANAT REC, V295, P1, DOI 10.1002/ar.21487
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kong YH, 2013, CELL PHYSIOL BIOCHEM, V32, P1187, DOI 10.1159/000354518
   Korbie DJ, 2008, NAT PROTOC, V3, P1452, DOI 10.1038/nprot.2008.133
   Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360
   Lamplot J.D., 2015, CELL TRANSPLANT
   Li B, 2009, DEVELOPMENT, V136, P3267, DOI 10.1242/dev.036954
   Li M, 2013, INT J MED SCI, V10, P1035, DOI 10.7150/ijms.6639
   Li R., 2014, CURR CANC DRUG TARGE
   Libus J, 2006, BIOTECHNIQUES, V41, P156, DOI 10.2144/000112232
   Liu X, 2013, J CELL MOL MED
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Malinen E, 2003, MICROBIOL SGM, V149, P269, DOI 10.1099/mic.0.25975 0
   Morrison TB, 1998, BIOTECHNIQUES, V24, P954
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Page RB, 2011, THESCIENTIFICWORLDJO, V11, P1383, DOI 10.1100/tsw.2011.124
   Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531 4536.2003
   Pfaffl MW, 2010, METHODS, V50, P215, DOI 10.1016/j.ymeth.2010.02.005
   Provenano M, 2007, ADV EXP MED BIOL, V593, P66
   Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045
   Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109 006 0097 6
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093608
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022
   Wang XJ, 2014, J BIOMED MATER RES A, V102, P1017, DOI 10.1002/jbm.a.34764
   Wang Y, 2013, J ORTHOP RES, V31, P1796, DOI 10.1002/jor.22427
   Weaver S, 2010, METHODS, V50, P271, DOI 10.1016/j.ymeth.2010.01.003
   Wen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094397
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang Y., 2014, ONCOL REP
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 77
TC 99
Z9 106
U1 1
U2 42
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2015
VL 10
IS 7
AR e0132666
DI 10.1371/journal.pone.0132666
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CN1QN
UT WOS:000358194900073
PM 26172450
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Xu, ZQ
   Wang, XH
   Liu, XM
   Cui, ZD
   Yang, XJ
   Yeung, KWK
   Chung, JC
   Chu, PK
   Wu, SL
AF Xu, Ziqiang
   Wang, Xiuhua
   Liu, Xiangmei
   Cui, Zhenduo
   Yang, Xianjin
   Yeung, Kelvin Wai Kwok
   Chung, Jonathan Chiyuen
   Chu, Paul K.
   Wu, Shuilin
TI Tannic Acid/Fe<SUP>3+</SUP>/Ag Nanofilm Exhibiting Superior Photodynamic
   and Physical Antibacterial Activity
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE antibacterial; implants; nanofilm; Ag nanoparticles; photodynamic
   therapy; infection
ID SILVER NANOPARTICLES; TITANIUM SURFACES; OSTEOBLAST FUNCTIONS; OXYGEN;
   BIOMATERIALS; NANOTUBES; MECHANISM; BACTERIA; BEHAVIOR; RELEASE
AB Silver nanoparticles (AgNPs) enwrapped in the biologically safe tannic acid (TA)/Fe3+ nanofilm are synthesized by an ultrafast, green, simple, and universal method. The physical antibacterial activity and photodynamic antibacterial therapy (PAT) efficacy of the TA/Fe3+/AgNPs nanofilm were investigated for the first time, which exhibited a strong physical antibacterial activity as well as great biocompatibility, through in vitro and in vivo studies. The results disclosed that this hybrid coating could possess high PAT capabilities upon irradiation under a visible light of 660 nm, which is longer than those of previously reported green and blue sensitization light, thus allowing deeper light penetration into biological tissues. Electron spin resonance (ESR) spectra proved that the PAT efficacy of the TA/Fe(3+/)AgNPs nanofilm was associated with the yields of singlet oxygen (102) under the irradiation of visible light (660 nm). A higher PAT efficiency of 100 and 94% against Escherichia coli and Staphylococcus aureus could be achieved within 20 min of illumination under 660 nm visible light, whereas the innate physical antibacterial activity of AgNPs could endow the implants with long term prevention of bacterial infection. The mechanism of PAT may be associated with the formation of oxidative stress and oxidative damage to key biomolecules (proteins and lipids) in bacteria. Our results reveal that the synergistic action of both PAT and physical action of AgNPs in this hybrid nanofilm is an effective way to inactivate bacteria, with minimal side effects.
C1 [Xu, Ziqiang; Wang, Xiuhua; Liu, Xiangmei; Wu, Shuilin] Hubei Univ, Hubei Collaborat Innovat Ctr Adv Organ Chem Mat, Key Lab Green Preparat & Applicat Funct Mat, Hubei Key Lab Polymer Mat,Sch Mat Sci & Engn,Mini, Wuhan 430062, Hubei, Peoples R China.
   [Cui, Zhenduo; Yang, Xianjin; Wu, Shuilin] Tianjin Univ, Sch Mat Sci & Engn, Tianjin 300072, Peoples R China.
   [Chung, Jonathan Chiyuen; Chu, Paul K.] City Univ Hong Kong, Dept Phys, Tat Chee Ave, Kowloon 999077, Hong Kong, Peoples R China.
   [Chung, Jonathan Chiyuen; Chu, Paul K.] City Univ Hong Kong, Dept Mat Sci & Engn, Tat Chee Ave, Kowloon 999077, Hong Kong, Peoples R China.
   [Yeung, Kelvin Wai Kwok] Univ Hong Kong, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Pokfulam 999077, Hong Kong, Peoples R China.
C3 Hubei University; Tianjin University; City University of Hong Kong; City
   University of Hong Kong; University of Hong Kong
RP Wu, SL (通讯作者)，Hubei Univ, Hubei Collaborat Innovat Ctr Adv Organ Chem Mat, Key Lab Green Preparat & Applicat Funct Mat, Hubei Key Lab Polymer Mat,Sch Mat Sci & Engn,Mini, Wuhan 430062, Hubei, Peoples R China.; Wu, SL (通讯作者)，Tianjin Univ, Sch Mat Sci & Engn, Tianjin 300072, Peoples R China.
EM shuilin.wu@gmail.com
RI ; wu, shuilin/LUZ 0692 2024; Yeung, Kelvin/JPA 1366 2023; Xiangmei,
   Liu/LUZ 0868 2024; WU, Shuilin/F 7897 2010; Chu, Paul/B 5923 2013;
   Chung, C.Y./H 1689 2011
OI Xu, Zi Qiang/0000 0002 2318 6886; wu, shuilin/0000 0002 1270 1870; liu,
   xiangmei/0000 0002 6469 2363; Yeung, Kelvin/0000 0003 0887 088X; Chu,
   Paul/0000 0002 5581 4883; Chung, C.Y./0000 0003 3639 5852
FU National Natural Science Foundation of China [51422102, 81271715,
   21603067]; National Key Research and Development Program of China
   [2016YFC1100600, 2016YFC1100604]; Hong Kong Research Grants Council
   (RGC) General Research Funds (GRF) [CityU 11301215]; City University of
   Hong Kong Applied Research Grant (ARG) [9667144]
FX This work is jointly supported by the National Natural Science
   Foundation of China nos. 51422102, 81271715, and 21603067, the National
   Key Research and Development Program of China no. 2016YFC1100600
   (subproject 2016YFC1100604), the Hong Kong Research Grants Council (RGC)
   General Research Funds (GRF) no. CityU 11301215, and the City University
   of Hong Kong Applied Research Grant (ARG) no. 9667144.
CR Cado G, 2013, ADV FUNCT MATER, V23, P4801, DOI 10.1002/adfm.201300416
   Choi BH, 2010, BIOMATERIALS, V31, P8980, DOI 10.1016/j.biomaterials.2010.08.027
   Creutz C, 2005, J PHYS CHEM B, V109, P10251, DOI 10.1021/jp050259+
   Edupuganti OP, 2007, BIOORG MED CHEM LETT, V17, P2692, DOI 10.1016/j.bmcl.2007.03.005
   Ejima H, 2013, SCIENCE, V341, P154, DOI 10.1126/science.1237265
   Fan WP, 2016, CHEM SOC REV, V45, P6488, DOI 10.1039/c6cs00616g
   Ferraris S, 2016, MAT SCI ENG C MATER, V61, P965, DOI 10.1016/j.msec.2015.12.062
   Flores CY, 2010, J COLLOID INTERF SCI, V350, P402, DOI 10.1016/j.jcis.2010.06.052
   Gao A, 2014, BIOMATERIALS, V35, P4223, DOI 10.1016/j.biomaterials.2014.01.058
   Huang YF, 2014, ANGEW CHEM INT EDIT, V53, P2353, DOI 10.1002/anie.201310097
   James R, 2015, RARE METALS, V34, P143, DOI 10.1007/s12598 015 0446 0
   Jia ZJ, 2016, BIOMATERIALS, V75, P203, DOI 10.1016/j.biomaterials.2015.10.035
   Jin JC, 2015, CARBON, V94, P129, DOI 10.1016/j.carbon.2015.05.084
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Kazemzadeh Narbat M, 2010, BIOMATERIALS, V31, P9519, DOI 10.1016/j.biomaterials.2010.08.035
   Konai MM, 2015, ACS INFECT DIS, V1, P469, DOI 10.1021/acsinfecdis.5b00056
   Lee JS, 2013, ADV MATER, V25, P1173, DOI 10.1002/adma.201203370
   Li M, 2016, ACS APPL MATER INTER, V8, P33972, DOI 10.1021/acsami.6b09457
   Li W, 2015, ADV FUNCT MATER, V25, P3775, DOI 10.1002/adfm.201500039
   Li Y, 2012, ACS NANO, V6, P5164, DOI 10.1021/nn300934k
   Liu JY, 2010, ACS NANO, V4, P6903, DOI 10.1021/nn102272n
   Liu K, 2013, ANGEW CHEM INT EDIT, V52, P8285, DOI 10.1002/anie.201303387
   Liu XM, 2013, APPL SURF SCI, V273, P748, DOI 10.1016/j.apsusc.2013.02.130
   Lu ZS, 2008, LANGMUIR, V24, P5445, DOI 10.1021/la704075r
   Mei SL, 2014, BIOMATERIALS, V35, P4255, DOI 10.1016/j.biomaterials.2014.02.005
   Munch E, 2008, SCIENCE, V322, P1516, DOI 10.1126/science.1164865
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Pazos E, 2016, J AM CHEM SOC, V138, P5507, DOI 10.1021/jacs.6b01570
   Perni S, 2011, PHOTOCH PHOTOBIO SCI, V10, P712, DOI 10.1039/c0pp00360c
   Piantanida G, 2013, J RAMAN SPECTROSC, V44, P1299, DOI 10.1002/jrs.4351
   Qu WT, 2017, RARE METALS, V36, P478, DOI 10.1007/s12598 017 0882 0
   Rainville L, 2013, RSC ADV, V3, P13953, DOI 10.1039/c3ra41677a
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168 3659(87)90035 6
   Roy X, 2011, J AM CHEM SOC, V133, P8420, DOI 10.1021/ja2016075
   Rycenga M, 2011, CHEM REV, V111, P3669, DOI 10.1021/cr100275d
   Sanchez C, 2005, NAT MATER, V4, P277, DOI 10.1038/nmat1339
   Shen H, 2015, J MATER CHEM A, V3, P16663, DOI 10.1039/c5ta04188k
   Silva FM, 2014, CELLULOSE, V21, P3551, DOI 10.1007/s10570 014 0378 0
   Skrabalak SE, 2007, NAT PROTOC, V2, P2182, DOI 10.1038/nprot.2007.326
   Vankayala R, 2011, ANGEW CHEM INT EDIT, V50, P10640, DOI 10.1002/anie.201105236
   Wang GM, 2017, BIOMATERIALS, V124, P25, DOI 10.1016/j.biomaterials.2017.01.028
   Wang Q, 2009, SURF REV LETT, V16, P775, DOI 10.1142/S0218625X09013244
   Wu SL, 2014, ADV FUNCT MATER, V24, P5464, DOI 10.1002/adfm.201400706
   Xiu ZM, 2012, NANO LETT, V12, P4271, DOI 10.1021/nl301934w
   Xu ZQ, 2016, ACS APPL MATER INTER, V8, P16584, DOI 10.1021/acsami.6b04161
   Ye Q, 2011, CHEM SOC REV, V40, P4244, DOI 10.1039/c1cs15026j
   Zaleski S, 2016, ACCOUNTS CHEM RES, V49, P2023, DOI 10.1021/acs.accounts.6b00327
   Zhang F, 2008, BIOMATERIALS, V29, P4751, DOI 10.1016/j.biomaterials.2008.08.043
   Zhang L, 2014, ACS APPL MATER INTER, V6, P17323, DOI 10.1021/am5045604
   Zhao CJ, 2013, APPL SURF SCI, V280, P8, DOI 10.1016/j.apsusc.2013.04.057
   Zhao LZ, 2011, BIOMATERIALS, V32, P5706, DOI 10.1016/j.biomaterials.2011.04.040
   Zhou PY, 2014, BIOMATERIALS, V35, P10033, DOI 10.1016/j.biomaterials.2014.09.009
   Zhou T, 2016, PROG MATER SCI, V83, P191, DOI 10.1016/j.pmatsci.2016.04.005
   Zhu P, 2016, ADV MATER INTERFACES, V3, DOI 10.1002/admi.201500494
NR 54
TC 83
Z9 84
U1 7
U2 239
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD NOV 15
PY 2017
VL 9
IS 45
BP 39657
EP 39671
DI 10.1021/acsami.7b10818
PG 15
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA FN7NB
UT WOS:000416203800060
PM 29063751
DA 2025 08 17
ER

PT J
AU Feig, JL
   Mediero, A
   Corciulo, C
   Liu, HL
   Zhang, J
   Perez Aso, M
   Picard, L
   Wilder, T
   Cronstein, B
AF Feig, Jessica L.
   Mediero, Aranzazu
   Corciulo, Carmen
   Liu, Hailing
   Zhang, Jin
   Perez Aso, Miguel
   Picard, Laura
   Wilder, Tuere
   Cronstein, Bruce
TI The antiviral drug tenofovir, an inhibitor of Pannexin 1 mediated ATP
   release, prevents liver and skin fibrosis by downregulating adenosine
   levels in the liver and skin
SO PLOS ONE
LA English
DT Article
ID HEPATIC STELLATE CELLS; EXTRACELLULAR ADENOSINE; OSTEOCLAST FORMATION;
   DISOPROXIL FUMARATE; PRODUCTION PLAYS; COLLAGEN CONTENT; DERMAL
   FIBROSIS; RECEPTOR; INFLAMMATION; EXPRESSION
AB Background
   Fibrosing diseases are a leading cause of morbidity and mortality worldwide and, therefore, there is a need for safe and effective antifibrotic therapies. Adenosine, generated extracellularly by the dephosphorylation of adenine nucleotides, ligates specific receptors which play a critical role in development of hepatic and dermal fibrosis. Results of recent clinical trials indicate that tenofovir, a widely used antiviral agent, reverses hepatic fibrosis/cirrhosis in patients with chronic hepatitis B infection. Belonging to the class of acyclic nucleoside phosphonates, tenofovir is an analogue of AMP. We tested the hypothesis that tenofovir has direct antifibrotic effects in vivo by interfering with adenosine pathways of fibrosis using two distinct models of adenosine and A2AR mediated fibrosis.
   Methods
   Thioacetamide (100mg/kg IP) treated mice were treated with vehicle, or tenofovir (75mg/kg, SubQ) (n = 5 10). Bleomycin (0.25U, SubQ) treated mice were treated with vehicle or tenofovir (75mg/kg, IP) (n = 5 10). Adenosine levels were determined by HPLC, and ATP release was quantitated as luciferase dependent bioluminescence. Skin breaking strength was analysed and H&E and picrosirus red stained slides were imaged. Pannexin 1expression was knocked down following retroviral mediated expression of of Pannexin 1 specific or scrambled siRNA.
   Results
   Treatment of mice with tenofovir diminished adenosine release from the skin of bleomycintreated mice and the liver of thioacetamide treated mice, models of diffuse skin fibrosis and hepatic cirrhosis, respectively. More importantly, tenofovir treatment diminished skin and liver fibrosis in these models. Tenofovir diminished extracellular adenosine concentrations by inhibiting, in a dose dependent fashion, cellular ATP release but not in cells lacking Pannexin 1.
   Conclusions
   These studies suggest that tenofovir, a widely used antiviral agent, could be useful in the treatment of fibrosing diseases.
C1 [Feig, Jessica L.; Mediero, Aranzazu; Corciulo, Carmen; Liu, Hailing; Zhang, Jin; Perez Aso, Miguel; Picard, Laura; Wilder, Tuere; Cronstein, Bruce] NYU, Langone Med Ctr, Div Translat Med, Dept Med, New York, NY 10003 USA.
   [Mediero, Aranzazu] IIS Fdn Jimenez Diaz UAM, Bone & Joint Res Unit, Madrid, Spain.
   [Zhang, Jin] Ningbo Univ, Med Sch, Dept Immmunol & Rheumatol, LiHuili Hosp, Ningbo, Zhejiang, Peoples R China.
C3 NYU Langone Medical Center; New York University; Fundacion Jimenez Diaz;
   Ningbo University
RP Cronstein, B (通讯作者)，NYU, Langone Med Ctr, Div Translat Med, Dept Med, New York, NY 10003 USA.
EM Bruce.Cronstein@nyumc.org
RI ; Cronstein, Bruce/D 4678 2011; Mediero, Aranzazu/AAA 8362 2020
OI Cronstein, Bruce/0000 0002 4295 7383; CORCIULO,
   CARMEN/0000 0002 1865 3494; Liu, Hailing/0000 0002 4717 3086; Mediero,
   Aranzazu/0000 0002 5368 574X; Perez Aso, Miguel/0000 0002 4703 4182; 
FU National Institute of Arthritis, Musculoskeletal and Skin Diseases
   [R01 AR054897, R01 AR056672]; NYU HHC Clinical and Translational Science
   Institute (from the National Center for Advancing Translational
   Sciences) [UL1 TR000038]; Gilead Pharmaceuticals; Institute de Salud
   Carlos III; Fondo Europeo de Desarrollo Regional (FEDER) through the
   "Miguel Server" program
FX This work was supported by grants from the National Institute of
   Arthritis, Musculoskeletal and Skin Diseases (R01 AR054897 and
   R01 AR056672), the NYU HHC Clinical and Translational Science Institute
   (UL1 TR000038 from the National Center for Advancing Translational
   Sciences) and Gilead Pharmaceuticals. Dr Mediero is funded by Institute
   de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER)
   through the "Miguel Server" program.The authors thank Judith Aberg, MD
   for her suggestions and discussions and Doreen Tivon, BA and Timothy
   Cardozo, MD, PhD for their computational biology work on this project.
   The authors also thank the Histopathology Core of the New York
   University Langone Medical Center. This work was supported by grants
   from the National Institute of Arthritis, Musculoskeletal and Skin
   Diseases (RO1 AR054897 and RO1 AR056672), the NYU HHC Clinical and
   Translational Science Institute (UL1 TR000038 from the National Center
   for Advancing Translational Sciences) and Gilead Pharmaceuticals. Dr
   Mediero is funded by Instituto de Salud Carlos III and Fondo Europeo de
   Desarrollo Regional (FEDER) through the "Miguel Servet" program.
CR Abudara V, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00306
   [Anonymous], 2005, PHARMACOL TOXICOL
   BALZARINI J, 1991, P NATL ACAD SCI USA, V88, P1499, DOI 10.1073/pnas.88.4.1499
   Bao Y, 2013, J BIOL CHEM, V288, P22650, DOI 10.1074/jbc.M113.476283
   Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815
   Boyd A, 2010, ANTIVIR THER, V15, P963, DOI 10.3851/IMP1649
   Chan ESL, 2006, ARTHRITIS RHEUM US, V54, P2632, DOI 10.1002/art.21974
   Chan ESL, 2006, BRIT J PHARMACOL, V148, P1144, DOI 10.1038/sj.bjp.0706812
   Chan ESL, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4229
   Chan ESL, 2011, ARTHRITIS RHEUM US, V63, pS907
   Che J, 2007, MOL PHARMACOL, V72, P1626, DOI 10.1124/mol.107.038760
   Clavin NW, 2008, AM J PHYSIOL HEART C, V295, pH2113, DOI 10.1152/ajpheart.00879.2008
   CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884
   Cronstein Bruce N, 2011, F1000 Biol Rep, V3, P21, DOI 10.3410/B3 21
   Cronstein BN, 2010, J HEPATOL, V53, P207, DOI 10.1016/j.jhep.2010.02.025
   CUNDY KC, 1995, ANTIMICROB AGENTS CH, V39, P2401, DOI 10.1128/AAC.39.11.2401
   EHRLICH HP, 1994, AM J PATHOL, V145, P105
   Ellis EL, 2012, J HEPATOL, V56, P1171, DOI 10.1016/j.jhep.2011.09.024
   Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021
   Ferrari D, 2015, FASEB JOURNAL OFFICI
   Grünig G, 2003, J CLIN INVEST, V112, P329, DOI 10.1172/JCI200319392
   Inc. GS, 2001, VIR TEN PROD MON
   JAMES J, 1990, LIVER, V10, P1
   Kmonícková E, 2006, EUR J PHARMACOL, V530, P179, DOI 10.1016/j.ejphar.2005.11.037
   Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809
   Li L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/691310
   Liaw YF, 2013, JOURNAL OF HEPATOLOG
   Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140 6736(12)61425 1
   Markova MS, 2004, J INVEST DERMATOL, V123, P1052, DOI 10.1111/j.0022 202X.2004.23494.x
   Mary Krause M, 2012, J CLIN DENSITOM, V15, P422, DOI 10.1016/j.jocd.2012.04.001
   Mediero A, 2015, FASEB J OFFICIAL PUB
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Montesinos MC, 1997, J EXP MED, V186, P1615, DOI 10.1084/jem.186.9.1615
   Nishida M, 2008, EMBO J, V27, P3104, DOI 10.1038/emboj.2008.237
   Nowak M, 2010, EUR J IMMUNOL, V40, P682, DOI 10.1002/eji.200939897
   Ohtsuka T, 2010, J IMMUNOL, V185, P1321, DOI 10.4049/jimmunol.0901847
   Palacios RS, 2008, LAB INVEST, V88, P1192, DOI 10.1038/labinvest.2008.91
   Peng ZS, 2008, NUCLEOS NUCLEOT NUCL, V27, P821, DOI 10.1080/15257770802146403
   Peng Z, 2008, FASEB J, V22, P2263, DOI 10.1096/fj.07 100685
   Perez Aso M, 2013, PURINERGIC SIGNALLIN
   Perez Aso M, 2013, PURINERG SIGNAL, V9, P573, DOI 10.1007/s11302 013 9368 1
   Perez Aso M, 2012, FASEB J, V26, P4254, DOI 10.1096/fj.12 209627
   PIERARD GE, 1989, MATRIX, V9, P68, DOI 10.1016/S0934 8832(89)80021 6
   Puhl SL, 2015, BRIT J PHARM
   Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009 9120(96)00003 6
   Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P612, DOI 10.1128/AAC.42.3.612
   Schafer JJ, 2013, PHARMACOTHERAPY, V33, P665, DOI 10.1002/phar.1257
   Sowa NA, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 20
   Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292
   STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009 8981(67)90167 2
   Takedachi M, 2011, J CELLULAR PHYSL
   Tang J, 2015, MOL MED REP, V11, P4397, DOI 10.3892/mmr.2015.3320
   Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915
   Van Rompay KKA, 2008, ANTIMICROB AGENTS CH, V52, P3144, DOI 10.1128/AAC.00350 08
   Wang GL, 2015, AM J PATHOL, V185, P3224, DOI 10.1016/j.ajpath.2015.08.002
   Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
   Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807
   Yamamoto T, 1999, J INVEST DERMATOL, V112, P456, DOI 10.1046/j.1523 1747.1999.00528.x
   Yan A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017201
   Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood 2007 03 081646
   Zhou Y., 2010, PLOS ONE, V5, P9224
   Zídek Z, 2004, EUR J PHARMACOL, V501, P79, DOI 10.1016/j.ejphar.2004.08.031
NR 63
TC 32
Z9 36
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 16
PY 2017
VL 12
IS 11
AR e0188135
DI 10.1371/journal.pone.0188135
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FM8YO
UT WOS:000415378800073
PM 29145453
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, DG
   Rowland, SE
   Clark, P
   Giroux, A
   Côté, B
   Guiral, S
   Salem, M
   Ducharme, Y
   Friesen, RW
   Méthot, N
   Mancini, J
   Audoly, L
   Riendeau, D
AF Xu, Daigen
   Rowland, Steven E.
   Clark, Patsy
   Giroux, Andre
   Cote, Bernard
   Guiral, Sebastien
   Salem, Myriam
   Ducharme, Yves
   Friesen, Richard W.
   Methot, Nathalie
   Mancini, Joseph
   Audoly, Laurent
   Riendeau, Denis
TI MF63
   [2 (6 chloro 1H phenanthro[9,10 d]imidazol 2 yl) isophthalonitril
   e], a selective microsomal prostaglandin E synthase 1 inhibitor,
   relieves pyresis and pain in preclinical models of inflammation
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID MICE LACKING; ANTIINFLAMMATORY DRUGS; PGE(2) SYNTHASE 1; FEBRILE
   RESPONSE; HEALTHY SUBJECTS; RODENT MODELS; HYPERALGESIA;
   LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; ROFECOXIB
AB Microsomal prostaglandin E synthase 1 (mPGES 1) is a terminal prostaglandin E 2 (PGE(2)) synthase in the cyclooxygenase pathway. Inhibitors of mPGES 1 may block PGE(2) production and relieve inflammatory symptoms. To test the hypothesis, we evaluated the antipyretic and analgesic properties of a novel and selective mPGES 1 inhibitor, MF63 [2 (6 chloro 1H phenanthro[ 9,10 d]imidazol 2 yl) isophthalonitrile], in animal models of inflammation. MF63 potently inhibited the human mPGES 1 enzyme (IC50 = 1.3 nM), with a high degree (>1000 fold) of selectivity over other prostanoid synthases. In rodent species, MF63 strongly inhibited guinea pig mPGES 1 (IC50 = 0.9 nM) but not the mouse or rat enzyme. When tested in the guinea pig and a knock in (KI) mouse expressing human mPGES 1, the compound selectively suppressed the synthesis of PGE2, but not other prostaglandins inhibitable by nonsteroidal anti inflammatory drugs (NSAIDs), yet retained NSAID like efficacy at inhibiting lipopolysaccharide induced pyresis, hyperalgesia, and iodoacetate induced osteoarthritic pain. In addition, MF63 did not cause NSAID like gastrointestinal toxic effects, such as mucosal erosions or leakage in the KI mice or nonhuman primates, although it markedly inhibited PGE(2) synthesis in the KI mouse stomach. Our data demonstrate that mPGES 1 inhibition leads to effective relief of both pyresis and inflammatory pain in preclinical models of inflammation and may be a useful approach for treating inflammatory diseases.
C1 [Xu, Daigen; Rowland, Steven E.; Clark, Patsy; Salem, Myriam; Audoly, Laurent; Riendeau, Denis] Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Kirkland, PQ H9H 3L1, Canada.
   [Guiral, Sebastien; Methot, Nathalie; Mancini, Joseph] Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada.
   [Giroux, Andre; Cote, Bernard; Ducharme, Yves; Friesen, Richard W.] Merck Frosst Ctr Therapeut Res, Dept Med Chem, Kirkland, PQ H9H 3L1, Canada.
C3 Merck & Company; Merck & Company Canada; Merck & Company; Merck &
   Company Canada; Merck & Company; Merck & Company Canada
RP Xu, DG (通讯作者)，Merck Frosst Ctr Therapeut Res, Dept Pharmacol, 16711 Trans Canada Hwy, Kirkland, PQ H9H 3L1, Canada.
EM daigen_xu@merck.com
CR Abe M, 2001, BRAIN RES, V916, P41, DOI 10.1016/S0006 8993(01)02861 X
   Ahmadi S, 2002, NAT NEUROSCI, V5, P34, DOI 10.1038/nn778
   Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200
   Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118
   Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140 6736(06)69666 9
   Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540
   Clark P, 2008, J PHARMACOL EXP THER, V325, P425, DOI 10.1124/jpet.107.134510
   Côté B, 2007, BIOORG MED CHEM LETT, V17, P6816, DOI 10.1016/j.bmcl.2007.10.033
   Couzin J, 2005, SCIENCE, V307, P1183
   Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632
   Engblom D, 2003, NAT NEUROSCI, V6, P1137, DOI 10.1038/nn1137
   FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288
   Francois H, 2007, J AM SOC NEPHROL, V18, P1466, DOI 10.1681/ASN.2006040343
   Guay J, 2004, J BIOL CHEM, V279, P24866, DOI 10.1074/jbc.M403106200
   Heinricher MM, 2004, PAIN, V110, P419, DOI 10.1016/j.pain.2004.04.026
   Hunt RH, 2000, AM J MED, V109, P201, DOI 10.1016/S0002 9343(00)00470 8
   Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220
   Jia ZJ, 2006, CIRC RES, V99, P1243, DOI 10.1161/01.RES.0000251306.40546.08
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kudo I, 2005, J BIOCHEM MOL BIOL, V38, P633
   Laine L, 1999, GASTROENTEROLOGY, V117, P776, DOI 10.1016/S0016 5085(99)70334 3
   Li S, 1999, BRAIN RES, V825, P86, DOI 10.1016/S0006 8993(99)01225 1
   Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894
   Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780
   Myers LK, 2000, ARTHRITIS RHEUM US, V43, P2687, DOI 10.1002/1529 0131(200012)43:12<2687::AID ANR8>3.0.CO;2 9
   Nakao K, 2007, J PHARMACOL EXP THER, V322, P686, DOI 10.1124/jpet.107.122010
   Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883
   Pulichino AM, 2006, J PHARMACOL EXP THER, V319, P1043, DOI 10.1124/jpet.106.110387
   Riendeau D, 2005, BIOORG MED CHEM LETT, V15, P3352, DOI 10.1016/j.bmcl.2005.05.027
   Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
   Rowland SE, 2007, EUR J PHARMACOL, V560, P216, DOI 10.1016/j.ejphar.2007.01.008
   Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1
   Scheiman JM, 2003, CURR PHARM DESIGN, V9, P2197, DOI 10.2174/1381612033454018
   Sigthorsson G, 2000, GUT, V47, P527, DOI 10.1136/gut.47.4.527
   Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469
   TAIWO YO, 1987, BRAIN RES, V423, P333, DOI 10.1016/0006 8993(87)90858 4
   Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100
   Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233
   WHITTLE BJR, 1984, ARCH TOXICOL, P315
   Yaksh TL, 2006, J PHARMACOL EXP THER, V316, P466, DOI 10.1124/jpet.105.091686
NR 40
TC 135
Z9 160
U1 0
U2 9
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD SEP
PY 2008
VL 326
IS 3
BP 754
EP 763
DI 10.1124/jpet.108.138776
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 338RB
UT WOS:000258524400009
PM 18524979
DA 2025 08 17
ER

PT J
AU Stolz, B
   Mader, M
   Volk, L
   Steinberg, T
   Mülhaupt, R
AF Stolz, Benjamin
   Mader, Markus
   Volk, Lukas
   Steinberg, Thorsten
   Muelhaupt, Rolf
TI Cryo 3D Printing of Hierarchically Porous Polyhydroxymethylene Scaffolds
   for Hard Tissue Regeneration
SO MACROMOLECULAR MATERIALS AND ENGINEERING
LA English
DT Article
DE 3D printing; polyhydroxymethylene; regenerative medicine; scaffolds;
   tissue engineering
ID TEMPERATURE; DESIGN; POLYURETHANE; POLYMERS; SYSTEM; WATER
AB High molecular weight polyhydroxymethylene (PHM) has a repeat unit identical to that of low molecular weight sugar alcohols and exhibits carbohydrate like properties. Herein, cryogenic extrusion based 3D printing is combined with a phase separation in water to fabricate hierarchically porous PHM scaffolds containing interconnected macro , micro , and nanopores. As PHM is infusible and insoluble in common solvents, its precursor polyvinylene carbonate (PVCA) dissolved in dimethylsulfoxide (DMSO) is used to 3D print hierarchically porous PVCA scaffolds that are converted into PHM by hydrolysis without impairing the pore architectures. Similar to low temperature deposition manufacturing, the PVCA/DMSO freezes on a build platform at  78 degrees C. However, instead of removing the frozen solvent by sublimation, the frozen scaffold is immersed in water to recover DMSO and to effect phase separation by precipitation. However, the computer guided printhead pathway controls macropore formation phase separation of frozen PVCA/DMSO upon contact with water accounts for simultaneous micro  and nanopore formation. Contrary to 3D printing of PVCA/DMSO at ambient temperature, this cryo 3D printing process does not require shear thinning additives and affords significantly improved build precision with macropore sizes variable between 200 and 1500 mu m. Cryo 3D printed PHM scaffolds are biocompatible and promote osteoblast proliferation.
C1 [Stolz, Benjamin; Mader, Markus; Muelhaupt, Rolf] Albert Ludwigs Univ Freiburg, Freiburg Mat Res Ctr FMF, Stefan Meier Str 21, D 79104 Freiburg, Germany.
   [Stolz, Benjamin; Mader, Markus; Muelhaupt, Rolf] Albert Ludwigs Univ, Inst Macromol Chem, Stefan Meier Str 31, D 31 Freiburg, Germany.
   [Volk, Lukas; Steinberg, Thorsten] Univ Freiburg, Univ Med Ctr Freiburg, Ctr Dent Med, Div Oral Biotechnol,Fac Med, Hugstetter Str 55, D 79106 Freiburg, Germany.
   [Volk, Lukas] Univ Freiburg, Fac Biol, Schaenzlestr 1, D 79104 Freiburg, Germany.
C3 University of Freiburg; University of Freiburg; University of Freiburg;
   University of Freiburg
RP Mülhaupt, R (通讯作者)，Albert Ludwigs Univ Freiburg, Freiburg Mat Res Ctr FMF, Stefan Meier Str 21, D 79104 Freiburg, Germany.; Mülhaupt, R (通讯作者)，Albert Ludwigs Univ, Inst Macromol Chem, Stefan Meier Str 31, D 31 Freiburg, Germany.
EM rolfmuelhaupt@web.de
RI ; Steinberg, Prof. Dr. Thorsten/LRC 1931 2024
OI Steinberg, Thorsten/0000 0003 1924 2694; Stolz,
   Benjamin/0000 0003 4382 5574
FU Baden Wurttemberg Foundation in Stuttgart, Germany; Projekt DEAL
FX The authors gratefully acknowledge the financial support by the
   Baden Wurttemberg Foundation in Stuttgart, Germany, for supporting the
   research on 3D and 4D printing and potential medical applications as
   part of the project IAF 2 (4DmultiMATS). The authors also thank Dr. Ralf
   Thomann for his enthusiastic support in mu CT imaging. Open access
   funding enabled and organized by Projekt DEAL.
CR Akkapeddi M. K., 1979, [No title captured], Patent No. [US4156708, 4156708]
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Angarano M, 2013, ADV FUNCT MATER, V23, P3277, DOI 10.1002/adfm.201202816
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Cheung HY, 2007, COMPOS PART B ENG, V38, P291, DOI 10.1016/j.compositesb.2006.06.014
   Chia HN, 2015, J BIOL ENG, V9, DOI 10.1186/s13036 015 0001 4
   Clements J. B., 1967, [No title captured], Patent No. [US3313756, 3313756]
   Clements JH, 2003, IND ENG CHEM RES, V42, P663, DOI 10.1021/ie020678i
   Creasy W. S., 1978, [No title captured], Patent No. [US4131669, 4131669]
   Gregor A, 2017, J BIOL ENG, V11, DOI 10.1186/s13036 017 0074 3
   HAAS HC, 1958, J POLYM SCI, V31, P237, DOI 10.1002/pol.1958.1203112245
   Hollister SJ, 2009, ADV MATER, V21, P3330, DOI 10.1002/adma.200802977
   Hung KC, 2016, BIOMATERIALS, V83, P156, DOI 10.1016/j.biomaterials.2016.01.019
   Jedrusik N, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700895
   Kang HW, 2016, NAT BIOTECHNOL, V34, P312, DOI 10.1038/nbt.3413
   Karande TS, 2004, ANN BIOMED ENG, V32, P1728, DOI 10.1007/s10439 004 7825 2
   Kim H, 2018, INT J BIOL MACROMOL, V120, P119, DOI 10.1016/j.ijbiomac.2018.07.159
   Kumru B, 2015, RSC ADV, V5, P30936, DOI 10.1039/c5ra02783g
   Landers R, 2000, MACROMOL MATER ENG, V282, P17, DOI 10.1002/1439 2054(20001001)282:1<17::AID MAME17>3.0.CO;2 8
   Landers R, 2002, BIOMATERIALS, V23, P4437, DOI 10.1016/S0142 9612(02)00139 4
   Lee J, 2008, BIOMATERIALS, V29, P1872, DOI 10.1016/j.biomaterials.2007.12.029
   Li JH, 2011, J BIOTECHNOL, V151, P87, DOI 10.1016/j.jbiotec.2010.10.080
   Li JH, 2020, MAT SCI ENG R, V140, DOI 10.1016/j.mser.2020.100543
   Liang YC, 2012, J WUHAN UNIV TECHNOL, V27, P265, DOI 10.1007/s11595 012 0450 2
   Ligon SC, 2017, CHEM REV, V117, P10212, DOI 10.1021/acs.chemrev.7b00074
   Liu C., 2019, Nanomater, V2019, P1
   Liu L, 2009, J BIOACT COMPAT POL, V24, P18, DOI 10.1177/0883911509102347
   Liu L, 2009, J BIOMED MATER RES B, V88B, P254, DOI 10.1002/jbm.b.31176
   Lopes AJ, 2012, RAPID PROTOTYPING J, V18, P129, DOI 10.1108/13552541211212113
   Mandrycky C, 2016, BIOTECHNOL ADV, V34, P422, DOI 10.1016/j.biotechadv.2015.12.011
   MARDER HL, 1960, J POLYM SCI, V44, P129, DOI 10.1002/pol.1960.1204414311
   Markstedt K, 2015, BIOMACROMOLECULES, V16, P1489, DOI 10.1021/acs.biomac.5b00188
   Mistry A. S., 2005, ADV BIOCH ENG BIOTEC
   Muelhaupt R., 2000, [No title captured], Patent No. [DE10018987 A1, 10018987]
   NEWMAN MS, 1955, J AM CHEM SOC, V77, P3789, DOI 10.1021/ja01619a032
   NEWMAN MS, 1953, J AM CHEM SOC, V75, P1263, DOI 10.1021/ja01101a526
   OHSAKU M, 1981, POLYM J, V13, P733, DOI 10.1295/polymj.13.733
   Paljevac M, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700306
   Pfister A, 2004, J POLYM SCI POL CHEM, V42, P624, DOI 10.1002/pola.10807
   Ratz H., 1969, [No title captured], Patent No. [US3455884, 3455884]
   REIMSCHUESSEL HK, 1979, J POLYM SCI POL CHEM, V17, P2769, DOI 10.1002/pol.1979.170170913
   Schaefgen J. R., 1962, [No title captured], Patent No. [US3069391, 3069391]
   Schulz S, 2014, TISSUE ENG PT A, V20, P1935, DOI [10.1089/ten.tea.2013.0594, 10.1089/ten.TEA.2013.0594]
   Shim JH, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960 1317/22/8/085014
   Simske SJ, 1997, MATER SCI FORUM, V250, P151, DOI 10.4028/www.scientific.net/MSF.250.151
   SMETS G, 1958, J POLYM SCI, V29, P257, DOI 10.1002/pol.1958.1202911919
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Stolz B, 2020, MACROMOL CHEM PHYS, V221, DOI 10.1002/macp.202000132
   Stolz B, 2020, MACROMOL MATER ENG, V305, DOI 10.1002/mame.201900740
   Strassburg S, 2019, J BIOMED MATER RES A, V107, P1605, DOI 10.1002/jbm.a.36676
   STRATHMANN H, 1975, DESALINATION, V16, P179, DOI 10.1016/S0011 9164(00)82092 5
   Susec M, 2013, MACROMOL RAPID COMM, V34, P938, DOI 10.1002/marc.201300016
   UNRUH CC, 1958, J ORG CHEM, V23, P625, DOI 10.1021/jo01098a612
   Wang X, 2017, COMPOS PART B ENG, V110, P442, DOI 10.1016/j.compositesb.2016.11.034
   Xing Q, 2014, SCI REP UK, V4, DOI 10.1038/srep04706
   Xiong Z, 2002, SCRIPTA MATER, V46, P771, DOI 10.1016/S1359 6462(02)00071 4
   Xu W, 2008, J BIOACT COMPAT POL, V23, P103, DOI 10.1177/0883911507088271
   Yang SF, 2001, TISSUE ENG, V7, P679, DOI 10.1089/107632701753337645
   Zhang SQ, 2019, SLAS TECHNOL, V24, P70, DOI 10.1177/2472630318799971
NR 59
TC 13
Z9 13
U1 7
U2 49
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1438 7492
EI 1439 2054
J9 MACROMOL MATER ENG
JI Macromol. Mater. Eng.
PD JAN
PY 2021
VL 306
IS 1
AR 2000541
DI 10.1002/mame.202000541
EA NOV 2020
PG 13
WC Materials Science, Multidisciplinary; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Polymer Science
GA PU7YE
UT WOS:000588413300001
OA hybrid
DA 2025 08 17
ER

PT J
AU Chao, X
   Tan, WL
   Tsang, JY
   Tse, GM
   Hu, JT
   Li, P
   Hou, JH
   Li, M
   He, JH
   Sun, P
AF Chao, Xue
   Tan, Wanlin
   Tsang, Julia Y.
   Tse, Gary M.
   Hu, Jintao
   Li, Ping
   Hou, Jinghui
   Li, Mei
   He, Jiehua
   Sun, Peng
TI Clinicopathologic and genetic features of metaplastic breast cancer with
   osseous differentiation: a series of 6 cases
SO BREAST CANCER
LA English
DT Article
DE Metaplastic breast cancer; Osseous differentiation; Genomic profile
ID SPINDLE CELL CARCINOMA; MESENCHYMAL TRANSITION; PHYLLODES TUMORS;
   AMPLIFICATION; INHIBITION; MUTATIONS; LANDSCAPE; REVEALS; PATHWAY; TRIAL
AB Aims Metaplastic breast cancer (MBC) comprises a heterogeneous group of tumors, of which MBC with osseous differentiation (MBC OD) is extremely rare that only few cases have been reported. This study aimed to present the clinicopathologic and molecular features of MBC OD. Methods We collected 6 cases of MBC OD from five different centers and described its clinicopathologic and molecular characteristics based on the next generation sequencing. Another 11 cases from the literature were also reviewed to better characterize the tumor. Results The tumor primarily showed an osteosarcoma like appearance, which composed of high cellularity with spindle cells and osteoblast like cells producing coarse lace like neoplastic bone (4/6) or osteoid matrix (6/6). 55 somatic mutations including 39 missenses (70.9%), 9 frameshifts (16.4%), 3 splice sites (5.5%), 3 in frame InDels (5.5%) and 1 nonsense (1.8%) were identified. TP53 was the most frequently mutated genes (5/6, 83.3%), followed by RB1 (3/6, 50.0%), BCOR (2/6, 33.3%), MED12 (2/6, 33.3%), PIK3CA (2/6, 33.3%), and TET2 (2/6, 33.3%). Genetic alterations suggesting therapies with clinical benefit, including mTOR inhibitors, tyrosine kinase inhibitors (TKI), and poly ADP ribose polymerase inhibitor (PARPi), were observed in five cases. The median follow up was 21 months (range, 3 80 months). Local recurrence was observed in two cases and three patients displayed distant metastasis. Two patients died of the disease at 3 months and 7 months, respectively. Conclusions Based on this series, MBC OD is a highly aggressive breast tumor with osteosarcoma like morphology and a high incidence of recurrent disease showing specific genetic profiles.
C1 [Chao, Xue; Tan, Wanlin; Li, Mei; He, Jiehua; Sun, Peng] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China.
   [Chao, Xue; Tan, Wanlin; Li, Mei; He, Jiehua; Sun, Peng] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510080, Peoples R China.
   [Tsang, Julia Y.; Tse, Gary M.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Hong Kong, Peoples R China.
   [Hu, Jintao] Jinan Univ, Shenzhen Peoples Hosp, Dept Pathol, Clin Med Coll 2, Shenzhen, Peoples R China.
   [Li, Ping] Peking Univ, Dept Pathol, Shenzhen Hosp, Shenzhen, Peoples R China.
   [Hou, Jinghui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pathol, Guangzhou, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University; Chinese
   University of Hong Kong; Prince of Wales Hospital; Jinan University;
   Peking University; Sun Yat Sen University
RP He, JH; Sun, P (通讯作者)，Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China.; He, JH; Sun, P (通讯作者)，Sun Yat Sen Univ, Dept Pathol, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510080, Peoples R China.
EM hejh@sysucc.org.cn; sunpeng1@sysucc.org.cn
RI ; Li, Mingyue/AFU 9483 2022; He, Rong han/HII 9967 2022; Sun,
   Peng/KDO 4243 2024
OI Tse, Gary/0000 0002 9405 9665; Chao, Xue/0000 0002 2784 9384; 
FU Guangdong Medical Research Foundation [A2018241]; National Natural
   Science Foundation of China [81902679]
FX This study was funded by the Guangdong Medical Research Foundation
   (A2018241) and National Natural Science Foundation of China (81902679)
   in the design of the study and collection, analysis, and interpretation
   of data and in writing the manuscript.
CR Avigdor BE, 2017, CLIN CANCER RES, V23, P4875, DOI 10.1158/1078 0432.CCR 17 0108
   Basho RK, 2018, ONCOLOGIST, V23, P1300, DOI 10.1634/theoncologist.2017 0498
   Basho RK, 2017, JAMA ONCOL, V3, P509, DOI 10.1001/jamaoncol.2016.5281
   Beca F, 2020, HISTOPATHOLOGY, V77, P321, DOI 10.1111/his.14088
   Board. WCoTE. World Health Organization Classification of Tumours, 2019, BREAST TUMOURS, V2
   Brown Glaberman U, 2010, BREAST J, V16, P663, DOI 10.1111/j.1524 4741.2010.00975.x
   Confavreux C, 2006, EUR J CANCER, V42, P2715, DOI 10.1016/j.ejca.2006.05.040
   Cortés J, 2015, LANCET ONCOL, V16, P1700, DOI 10.1016/S1470 2045(15)00373 3
   Dwyer JB, 2015, ARCH PATHOL LAB MED, V139, P552, DOI 10.5858/arpa.2013 0555 RS
   Erguvan Dogan B, 2005, AM J ROENTGENOL, V185, P1593, DOI 10.2214/AJR.05.0368
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Freedman RA, 2016, J CLIN ONCOL, V34, P945, DOI 10.1200/JCO.2015.63.0343
   Garcia Dios DA, 2018, BRIT J CANCER, V118, P277, DOI 10.1038/bjc.2017.450
   Geyer FC, 2010, J PATHOL, V220, P562, DOI 10.1002/path.2675
   He XX, 2019, BREAST CANCER RES TR, V173, P329, DOI 10.1007/s10549 018 5005 6
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008 5472.CAN 08 3441
   HERRINGTON CS, 1994, HISTOPATHOLOGY, V24, P282, DOI 10.1111/j.1365 2559.1994.tb00525.x
   Kao YC, 2018, AM J SURG PATHOL, V42, P604, DOI 10.1097/PAS.0000000000000965
   Kelten C, 2016, BREAST CARE, V11, P291, DOI 10.1159/000448236
   Krings G, 2018, MODERN PATHOL, V31, P1661, DOI 10.1038/s41379 018 0081 z
   Kurian KM, 2002, HISTOPATHOLOGY, V40, P58, DOI 10.1046/j.1365 2559.2002.01319.x
   Lang Ronggang, 2011, Tumori, V97, pe1, DOI 10.1700/950.10411
   Lee JH, 2008, BREAST, V17, P314, DOI 10.1016/j.breast.2007.09.006
   Lester TR, 2012, BREAST CANCER RES TR, V131, P41, DOI 10.1007/s10549 011 1393 6
   Leyrer CM, 2017, BREAST CANCER RES TR, V165, P499, DOI 10.1007/s10549 017 4367 5
   Li S, 2012, CHIN J CANCER, V31, P500, DOI 10.5732/cjc.012.10118
   Li YF, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 2069 y
   Matsumoto H, 2016, PATHOL INT, V66, P236, DOI 10.1111/pin.12370
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   McCart Reed AE, 2019, J PATHOL, V247, P214, DOI 10.1002/path.5184
   Mishima C, 2015, BREAST CANCER RES TR, V152, P305, DOI 10.1007/s10549 015 3469 1
   Moten AS, 2016, AM J SURG, V211, P716, DOI 10.1016/j.amjsurg.2015.11.023
   Moulder S, 2015, ANN ONCOL, V26, P1346, DOI 10.1093/annonc/mdv163
   Nelson RA, 2015, ANN SURG ONCOL, V22, P24, DOI 10.1245/s10434 014 3890 4
   Ng CKY, 2017, CLIN CANCER RES, V23, P3859, DOI 10.1158/1078 0432.CCR 16 2857
   Pezzi CM, 2007, ANN SURG ONCOL, V14, P166, DOI 10.1245/s10434 006 9124 7
   Piscuoglio S, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523 017 0048 0
   Reis JS, 2006, J PATHOL, V209, P445, DOI 10.1002/path.2004
   Reis JS, 2005, BREAST CANCER RES, V7, pR1028, DOI 10.1186/bcr1341
   Salih AM, 2017, INT J SURG CASE REP, V34, P100, DOI 10.1016/j.ijscr.2017.03.022
   Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159 8290.CD 13 0639
   Sohal DPS, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv332
   Soo K, 2013, J CLIN PATHOL, V66, P506, DOI 10.1136/jclinpath 2012 201084
   Tan J, 2015, NAT GENET, V47, P1341, DOI 10.1038/ng.3409
   Tsukuda K, 2009, ACTA MED OKAYAMA, V63, P367
   Weigelt B, 2015, MODERN PATHOL, V28, P607, DOI 10.1038/modpathol.2014.163
   Yadav S, 2017, BREAST CANCER RES TR, V164, P201, DOI 10.1007/s10549 017 4251 3
   Zhao J, 2020, CANCER LETT, V474, P158, DOI 10.1016/j.canlet.2020.01.020
NR 48
TC 5
Z9 5
U1 0
U2 7
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 1340 6868
EI 1880 4233
J9 BREAST CANCER TOKYO
JI Breast Cancer
PD SEP
PY 2021
VL 28
IS 5
BP 1100
EP 1111
DI 10.1007/s12282 021 01246 9
EA MAY 2021
PG 12
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA TY4KO
UT WOS:000646513200002
PM 33942253
DA 2025 08 17
ER

PT J
AU Ozgocmen, S
   Ardicoglu, O
   Erdogan, H
   Fadillioglu, E
   Gudul, H
AF Ozgocmen, S
   Ardicoglu, O
   Erdogan, H
   Fadillioglu, E
   Gudul, H
TI In vivo effect of celecoxib and tenoxicam on oxidant/anti oxidant status
   of patients with knee osteoarthritis
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE osteoarthritis; celecoxib; tenoxicam; oxidative stress; free radicals;
   nitric oxide
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NITRIC OXIDE; OXIDATIVE STRESS;
   ANTIOXIDANT PROPERTIES; LIPID PEROXIDATION; CELL DEATH; VITRO;
   CHEMILUMINESCENCE; REDUCTION; LUMINOL
AB The aim of this study was to compare the in vivo effects on free radical metabolism of 2 nonsteroidal anti inflammatory drugs (NSAIDs): tenoxicam, an oxicam preferentially cyclooxygenase 1 (COX1) inhibitor, and celecoxib, a sulfonamide selective COX 2 inhibitor. The serum levels of oxidative stress related enzymes (ie, xanthine oxidase (XO), superoxide dismutase (SOD), glutathione peroxidase (GSH Px)), of a lipid peroxidation marker (malondialdehyde (MDA)), and of nitric oxide (NO) in patients with knee osteoarthritis were studied at baseline and after a 4 wk course of treatment with celecoxib (n = 11) and tenoxicam (n = 12). Celecoxib treated patients had significant decrease in nitrite levels (p = 0.043), whereas SOD, XO, GSH Px enzyme activities, and MDA levels did not change significantly compared to baseline. Tenoxicam treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH Px enzyme activities, and MDA levels were unchanged from baseline. There was significant correlation between the patients' (n = 23) Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index, WOMAC pain scores, and MDA levels (r = 0.50, p = 0.014) and the patients' WOMAC stiffness scores and XO enzyme activity (r = 0.46, p = 0.027) at baseline. Significant improvement was found in pain VAS, patients' global assessment, and WOMAC pain, stiffness, and physical function scores in celecoxib and tenoxicam  treated groups. In summary, our study revealed that tenoxicam may have antioxidant effects, and that celecoxib and tenoxicam may reduce nitrite levels, indicating an alteration of NO pathways.
C1 Firat Univ, Fac Med, Dept Phys Med & Rehabil, Div Rheumatol, TR 23119 Elazig, Turkey.
   Gaziosmanpasa Univ, Fac Med, Dept Physiol, Tokat, Turkey.
   Inonu Univ, Fac Med, Dept Physiol, Malatya, Turkey.
C3 Firat University; Tokat Gaziosmanpasa University; Inonu University
RP Firat Univ, Fac Med, Dept Phys Med & Rehabil, Div Rheumatol, TR 23119 Elazig, Turkey.
EM sozgocmen@hotmail.com
RI Fadillioglu, Ersin/K 3817 2019; Erdogan, Hasan/AFN 9249 2022; Ozgocmen,
   Salih/K 9588 2015
OI Ozgocmen, Salih/0000 0002 4860 452X
CR Akyol Ö, 2001, JOINT BONE SPINE, V68, P311, DOI 10.1016/S1297 319X(01)00279 2
   Akyol Ö, 2002, PROG NEURO PSYCHOPH, V26, P995, DOI 10.1016/S0278 5846(02)00220 8
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Basivireddy J, 2004, BIOCHEM PHARMACOL, V67, P587, DOI 10.1016/j.bcp.2003.09.023
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Cimen MYB, 2003, DRUG CHEM TOXICOL, V26, P169, DOI 10.1081/DCT 120022645
   Clancy RM, 1998, ARTHRITIS RHEUM US, V41, P1141, DOI 10.1002/1529 0131(199807)41:7<1141::AID ART2>3.0.CO;2 S
   COLLI S, 1991, PHARMACOL RES, V23, P367, DOI 10.1016/1043 6618(91)90051 X
   CORTAS NK, 1990, CLIN CHEM, V36, P1440
   Del Carlo M, 2003, ARTHRITIS RHEUM US, V48, P3419, DOI 10.1002/art.11338
   Del Carlo M, 2002, ARTHRITIS RHEUM, V46, P394, DOI 10.1002/art.10056
   ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407
   Facino R M, 1993, Drugs, V46 Suppl 1, P15
   Facino RM, 1996, ARCH PHARM, V329, P457, DOI 10.1002/ardp.19963291007
   Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Henrotin YE, 2003, OSTEOARTHR CARTILAGE, V11, P747, DOI 10.1016/S1063 4584(03)00150 X
   Hinz B, 2004, CURR OPIN RHEUMATOL, V16, P628, DOI 10.1097/01.hco.0000136130.95746.14
   ICHIHARA S, 1989, DRUG METAB DISPOS, V17, P463
   Jovanovic DV, 2002, J RHEUMATOL, V29, P2165
   Karan A, 2003, CLIN RHEUMATOL, V22, P397, DOI 10.1007/s10067 003 0761 y
   Lane NE, 1997, J RHEUMATOL, V24, P20
   Lotz M, 1999, RHEUM DIS CLIN N AM, V25, P269, DOI 10.1016/S0889 857X(05)70067 3
   LUNEC J, 1981, J RHEUMATOL, V8, P233
   Mouithys Mickalad AML, 2000, FREE RADICAL RES, V33, P607, DOI 10.1080/10715760000301131
   Nakamura Y, 2003, FREE RADICAL BIO MED, V35, P997, DOI 10.1016/S0891 5849(03)00440 4
   Orhan H, 2001, EXP TOXICOL PATHOL, V53, P133, DOI 10.1078/0940 2993 00179
   Ozgocmen S, 2004, RHEUMATOL INT, V24, P80, DOI 10.1007/s00296 003 0335 y
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Parij N, 1998, EUR J PHARMACOL, V352, P299, DOI 10.1016/S0014 2999(98)00370 7
   Pelletier JP, 1999, J RHEUMATOL, V26, P2002
   PRAJDA N, 1975, FEBS LETT, V59, P245, DOI 10.1016/0014 5793(75)80385 1
   SUN Y, 1988, CLIN CHEM, V34, P497
   Takahashi T, 2004, INT J MOL MED, V14, P139
   Van Antwerpen P, 2004, EUR J PHARMACOL, V496, P55, DOI 10.1016/j.ejphar.2004.06.017
   Vane JR., 1998, AM J MED, V104, p2S, DOI DOI 10.1016/S0002 9343(97)00203 9
   Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200
   Zheng SX, 2000, OSTEOARTHR CARTILAGE, V8, P419, DOI 10.1053/joca.1999.0317
NR 38
TC 36
Z9 38
U1 0
U2 4
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091 7370
EI 1550 8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD SPR
PY 2005
VL 35
IS 2
BP 137
EP 143
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA 926LB
UT WOS:000229123600004
PM 15943176
DA 2025 08 17
ER

PT J
AU Lee, KH
   Choi, EM
AF Lee, Kyung Hee
   Choi, Eun Mi
TI Effects of bergenin on methylglyoxal induced damage in osteoblastic
   MC3T3 E1 cells
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Article
DE bergenin; glyoxalase; methylglyoxal; mitochondrial function;
   osteoblasts; oxidative stress
ID GLYCATION END PRODUCTS; OXIDATIVE STRESS; ENDOTHELIAL CELLS;
   GLYOXALASE I; MITOCHONDRIAL DYSFUNCTION; CARDIOVASCULAR DISEASE;
   ARDISIA JAPONICA; VASCULAR INJURY; RECEPTOR; PATHWAY
AB Bergenin is the main chemical constituent of plants in the genus Bergenia, which are used in traditional medicines. Methylglyoxal (MG), a highly reactive dicarbonyl compound, is the major precursor for forming advanced glycation end products (AGEs). Pretreating MC3T3 E1 cells with bergenin prevented MG induced protein adduct formation. Bergenin inhibited the MG induced soluble receptor for AGE (sRAGE), interleukin, reactive oxygen species and mitochondrial superoxide production. Additionally bergenin increased glyoxalase I activity, glutathione, heme oxygenase 1 and nuclear factor erythroid 2 related factor 2 levels in the presence of MG. Pretreatment with bergenin before MG exposure reduced MG induced mitochondrial dysfunction by preventing mitochondrial membrane potential dissipation, loss of adenosine triphosphate and reduced adenosine monophosphate activated protein kinase. These results demonstrate that bergenin may prevent the development of diabetic osteopathy.
   Pretreating MC3T3 E1 cells with bergenin prevented methylglyoxal (MG) induced protein adduct formation. Bergenin inhibited MG induced soluble receptor for AGE, interleukin, ROS, and mitochondrial superoxide production. Additionally bergenin increased glyoxalase I activity, glutathione, heme oxygenase 1, and nuclear factor erythroid 2 related factor 2 levels in the presence of MG. Bergenin reduced MG induced mitochondrial dysfunction by preventing mitochondrial membrane potential dissipation, loss of ATP, and reduced AMPK.
C1 [Lee, Kyung Hee] Kyung Hee Univ, Dept Food Serv Management, 1 Hoegi Dong, Seoul 130701, South Korea.
   [Choi, Eun Mi] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, 1 Hoegi Dong, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Choi, EM (通讯作者)，Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, 1 Hoegi Dong, Seoul 130701, South Korea.
EM cheunmi@hanmail.net
RI Lee, Kyung Hee/KVZ 1947 2024
FU Ministry of Education [NRF 2016R1D1A1B03930082]; Basic Science Research
   Program of the National Research Foundation of Korea (NRF)
FX Ministry of Education, Grant/Award Number: NRF 2016R1D1A1B03930082;
   Basic Science Research Program of the National Research Foundation of
   Korea (NRF)
CR Abordo EA, 1999, BIOCHEM PHARMACOL, V58, P641, DOI 10.1016/S0006 2952(99)00132 X
   Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792
   Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125 009 1458 9
   Bierhaus A, 1998, CARDIOVASC RES, V37, P586, DOI 10.1016/S0008 6363(97)00233 2
   Blatnik M, 2008, DIABETES, V57, P41, DOI 10.2337/db07 0838
   Brouwers O, 2011, J BIOL CHEM, V286, P1374, DOI 10.1074/jbc.M110.144097
   Cardoso S, 2014, J BIOENERG BIOMEMBR, V46, P347, DOI 10.1007/s10863 014 9551 2
   Chen JS, 2011, ATHEROSCLEROSIS, V214, P301, DOI 10.1016/j.atherosclerosis.2010.11.010
   Cornish W, 2014, CAN J DIABETES, V38, P94, DOI 10.1016/j.jcjd.2014.01.002
   Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275
   Dobler D, 2006, DIABETES, V55, P1961, DOI 10.2337/db05 1634
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI 10.1172/JCI20042162S
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Hamidie RDR, 2015, METABOLISM, V64, P1334, DOI 10.1016/j.metabol.2015.07.010
   Hardie DG, 2008, INT J OBESITY, V32, pS7, DOI 10.1038/ijo.2008.116
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Kalapos MP, 2008, CHEM BIOL INTERACT, V171, P251, DOI 10.1016/j.cbi.2007.11.009
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Khan H., 2016, OXID MED CELL LONGEV, V2016
   Kimzey MJ, 2011, CHEM BIOL INTERACT, V192, P122, DOI 10.1016/j.cbi.2010.09.032
   Kook YA, 2009, CELL BIOL INT, V33, P424, DOI 10.1016/j.cellbi.2008.12.007
   Lee C, 1998, J BIOL CHEM, V273, P25272, DOI 10.1074/jbc.273.39.25272
   Li RW, 2004, PLANTA MED, V70, P421, DOI 10.1055/s 2004 818969
   Li YF, 2005, J ASIAN NAT PROD RES, V7, P13, DOI 10.1080/10286020310001596033
   Lim HK, 2000, J ETHNOPHARMACOL, V72, P469, DOI 10.1016/S0378 8741(00)00260 9
   Liu K, 2011, J ETHNOPHARMACOL, V136, P473, DOI 10.1016/j.jep.2011.01.051
   Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106
   Nazir N, 2007, J ETHNOPHARMACOL, V112, P401, DOI 10.1016/j.jep.2007.02.023
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nin JWM, 2010, DIABETES, V59, P2027, DOI 10.2337/db09 1509
   Piacente S, 1996, J NAT PROD, V59, P565, DOI 10.1021/np960074h
   Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200
   Pu HL, 2002, PLANTA MED, V68, P372, DOI 10.1055/s 2002 26758
   Pun PBL, 2014, FREE RADICAL BIO MED, V67, P437, DOI 10.1016/j.freeradbiomed.2013.11.025
   Rabbani N, 2008, BIOCHEM SOC T, V36, P1045, DOI 10.1042/BST0361045
   Ramasamy R, 2006, CELL, V124, P258, DOI 10.1016/j.cell.2006.01.002
   Rosca MG, 2002, AM J PHYSIOL RENAL, V283, pF52, DOI 10.1152/ajprenal.00302.2001
   Schmidt AM, 2000, BBA MOL CELL RES, V1498, P99, DOI 10.1016/S0167 4889(00)00087 2
   Schöneich C, 2006, EXP GERONTOL, V41, P807, DOI 10.1016/j.exger.2006.07.002
   Schroeder P, 2007, FREE RADICAL BIO MED, V43, P128, DOI 10.1016/j.freeradbiomed.2007.04.002
   Sejersen H, 2009, BIOGERONTOLOGY, V10, P203, DOI 10.1007/s10522 008 9172 4
   Shirwany NA, 2010, ACTA PHARMACOL SIN, V31, P1075, DOI 10.1038/aps.2010.139
   Silva MS, 2013, BIOCHEM J, V453, P1, DOI 10.1042/BJ20121743
   Stefanson AL, 2014, NUTRIENTS, V6, P3777, DOI 10.3390/nu6093777
   Stern D, 2002, ADV DRUG DELIVER REV, V54, P1615, DOI 10.1016/S0169 409X(02)00160 6
   Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]
   Suh KS, 2014, FREE RADICAL RES, V48, P206, DOI 10.3109/10715762.2013.859387
   Suh K. S., 2017, CYTOTECHNOLOGY
   Thomas MC, 2005, CURR DRUG TARGETS, V6, P453, DOI 10.2174/1389450054021873
   Thornalley PJ, 2011, SEMIN CELL DEV BIOL, V22, P318, DOI 10.1016/j.semcdb.2011.02.006
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343
   THORNALLEY PJ, 1988, LEUKEMIA RES, V12, P897, DOI 10.1016/0145 2126(88)90016 1
   Uribarri J, 2007, J GERONTOL A BIOL, V62, P427, DOI 10.1093/gerona/62.4.427
   Vander Jagt DL, 2003, CHEM BIOL INTERACT, V143, P341, DOI 10.1016/S0009 2797(02)00212 0
   Wang H, 2009, BIOCHEM PHARMACOL, V77, P1709, DOI 10.1016/j.bcp.2009.02.024
   Wang YJ, 2010, J IMMUNOL, V185, P1822, DOI 10.4049/jimmunol.0903398
   Xie J X, 1981, Yao Xue Xue Bao, V16, P425
   Yan DB, 2014, CHIN J NAT MEDICINES, V12, P929, DOI 10.1016/S1875 5364(14)60136 9
   Ye P, 2014, MOL CELL BIOL, V34, P3421, DOI 10.1128/MCB.00221 14
   Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371
   Yu J, 2013, TOXICOL LETT, V218, P224, DOI 10.1016/j.toxlet.2013.01.028
   Zhang Q, 2010, TOXICOL APPL PHARM, V244, P84, DOI 10.1016/j.taap.2009.08.018
   Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05 4278fje
NR 63
TC 8
Z9 9
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0260 437X
EI 1099 1263
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD APR
PY 2018
VL 38
IS 4
BP 585
EP 593
DI 10.1002/jat.3565
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA FW1UI
UT WOS:000425084700015
PM 29148590
DA 2025 08 17
ER

PT J
AU Daudee, R
   Gonen, R
   German, U
   Orion, I
   Alfassi, ZB
   Priel, E
AF Daudee, Rotem
   Gonen, Rafi
   German, Uzi
   Orion, Itzhak
   Alfassi, Zeev B.
   Priel, Esther
TI DNA Topoisomerase IB as a Potential Ionizing Radiation Exposure and Dose
   Biomarker
SO RADIATION RESEARCH
LA English
DT Article
ID POLY(ADP RIBOSE) POLYMERASE; TRITIUM; PHOSPHORYLATION; COMPLEXES;
   CAMPTOTHECIN; GLCNACYLATION; DEGRADATION; ACTIVATION; MECHANISM; TARGET
AB In radiation exposure scenarios where physical dosimetry is absent or inefficient, dose estimation must rely on biological markers. A reliable biomarker is of utmost importance in correlating biological system changes with radiation exposure. Human DNA topoisomerase IB (topo I) is a ubiquitous nuclear enzyme, which is involved in essential cellular processes, including transcription, DNA replication and DNA repair, and is the target of anticancer drugs. It has been shown that the cellular activity of this enzyme is significantly sensitive to various DNA lesions, including radiation induced DNA damages. Therefore, we investigated the potential of topo I as a biomarker of radiation exposure and dose. We examined the effect of exposure of different human cells to beta, X ray and gamma radiation on the cellular catalytic activity of topo I. The results demonstrate a significant reduction in the DNA relaxation activity of topo I after irradiation and the level of the reduction was correlated with radiation dose. In normal human peripheral blood lymphocytes, exposure for 3 h to an integral dose of 0.065 mGy from tritium reduced the enzyme activity to less than 25%. In MG 63 osteoblast like cells and in human pulmonary fibroblast (HPF) cells exposed to gamma radiation from a Co 60 source (up to 2 Gy) or to X rays (up to 2.8 Gy), a significant decrease in topo I catalytic activity was also observed. We observed that the enzyme protein level was not altered but was partially posttranslational modified by ADP ribosylation of the enzyme protein that is known to reduce topo I activity. The results of this study suggest that the decrease in the cellular topo I catalytic activity after low dose exposure to different radiation types may be considered as a novel biomarker of ionizing radiation exposure and dose. For this purpose, a suitable ELISA based method for large scale analysis of radiation induced topo I modification is under development. (C) 2018 by Radiation Research Society
C1 [Daudee, Rotem; Gonen, Rafi; Priel, Esther] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Immunol Microbiol & Genet, Beer Sheva, Israel.
   [Daudee, Rotem; Gonen, Rafi; Orion, Itzhak; Alfassi, Zeev B.] Ben Gurion Univ Negev, Fac Engn, Dept Nucl Engn, Beer Sheva, Israel.
   [Daudee, Rotem; Gonen, Rafi; German, Uzi] Negev, Nucl Res Ctr, Beer Sheva, Israel.
C3 Ben Gurion University of the Negev; Ben Gurion University of the Negev
RP Priel, E (通讯作者)，Ben Gurion Univ Negev, Fac Hlth Sci, Dept Immunol Microbiol & Genet, POB 653, IL 84105 Beer Sheva, Israel.
EM priel@bgu.ac.il
RI Itzhak, Orion/F 2034 2012
CR Afriat R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072377
   [Anonymous], 2010, 282182010 ISO AM NAT
   Baranello L, 2013, TRANSCR AUSTIN, V4, P232, DOI 10.4161/trns.26598
   Bauer PI, 2001, FEBS LETT, V506, P239, DOI 10.1016/S0014 5793(01)02919 2
   Bendetz Nezer S, 2004, MOL PHARMACOL, V66, P627
   BOOTHMAN DA, 1994, CANCER RES, V54, P4618
   Brooks AL, 2001, RADIAT PROT DOSIM, V97, P39, DOI 10.1093/oxfordjournals.rpd.a006636
   Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369
   Chen SH, 2013, ANNU REV BIOCHEM, V82, P139, DOI 10.1146/annurev biochem 061809 100002
   COMMERFORD SL, 1977, RADIAT RES, V72, P333, DOI 10.2307/3574703
   Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341 2350.2003
   Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159
   Desai SD, 2001, CANCER RES, V61, P5926
   Durante M, 2003, PHYS MEDICA, V19, P191
   EAKINS JD, 1975, HEALTH PHYS, V28, P213, DOI 10.1097/00004032 197503000 00006
   Gonen R, 2007, RADIAT PROT DOSIM, V125, P460, DOI 10.1093/rpd/ncm148
   Gridley DailaS., 2005, Therapy, V3, P105
   Guipaud O, 2009, ANN I SUPER SANITA, V45, P278
   Hackbarth JS, 2008, J BIOL CHEM, V283, P16711, DOI 10.1074/jbc.M802246200
   Hagger JA, 2005, AQUAT TOXICOL, V74, P205, DOI 10.1016/j.aquatox.2005.05.013
   Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293
   Hwang J, 1994, Adv Pharmacol, V29A, P167
   Jahan Z, 2013, BIOCHEM BIOPH RES CO, V432, P545, DOI 10.1016/j.bbrc.2013.02.032
   Jha AN, 2006, MAR ENVIRON RES, V62, pS297, DOI 10.1016/j.marenvres.2006.04.023
   JOHNSTONE A, 1985, BIOSCIENCE REP, V5, P907, DOI 10.1007/BF01119903
   Levi I, 2012, GLYCOBIOLOGY, V22, P704, DOI 10.1093/glycob/cws008
   Liani Leibson K, 2014, CURR MOL MED, V14, P141, DOI 10.2174/1566524013666131118111241
   Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200
   Noach N, 2007, GLYCOBIOLOGY, V17, P1357, DOI 10.1093/glycob/cwm105
   Pastor N, 2002, CELL BIOL INT, V26, P547, DOI 10.1006/cbir.2002.0899
   Peleg R, 2014, INT J ONCOL, V44, P934, DOI 10.3892/ijo.2014.2244
   Pernot E, 2012, MUTAT RES REV MUTAT, V751, P258, DOI 10.1016/j.mrrev.2012.05.003
   POMMIER Y, 1990, J BIOL CHEM, V265, P9418
   Pommier Y, 1998, BBA GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167 4781(98)00129 8
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441
   Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516
   Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792
   Rana S, 2010, J PHARM BIOALLIED SC, V2, P189, DOI 10.4103/0975 7406.68500
   Reuveni I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068131
   SAITO M, 1986, RADIAT PROT DOSIM, V16, P131
   SCARPA G, 1981, Physics in Medicine and Biology, V26, P1137, DOI 10.1088/0031 9155/26/6/012
   Smith HM, 1999, CARCINOGENESIS, V20, P1439, DOI 10.1093/carcin/20.8.1439
   Sokhansanj BA, 2004, FREE RADICAL BIO MED, V37, P422, DOI 10.1016/j.freeradbiomed.2004.05.003
   Sordet O, 2004, CELL CYCLE, V3, P1095
   Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200
   Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200
   Sordet Olivier, 2003, Current Medicinal Chemistry   Anti Cancer Agents, V3, P271, DOI 10.2174/1568011033482378
   STENCEL JR, 1988, FUSION TECHNOL, V14, P1047, DOI 10.13182/FST88 A25276
   Thomson J., 2001, P INT C ADV LIQ SCIN
   Vaurijoux A, 2012, BIOL DOSIMETRY IONIZ
   Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223
   Yu DH, 2004, J BIOL CHEM, V279, P51851, DOI 10.1074/jbc.M404396200
   Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200
   Zehorai E, 2008, MOL NEUROBIOL, V38, P242, DOI 10.1007/s12035 008 8044 x
NR 55
TC 3
Z9 3
U1 0
U2 4
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033 7587
EI 1938 5404
J9 RADIAT RES
JI Radiat. Res.
PD JUN
PY 2018
VL 189
IS 6
BP 652
EP 660
DI 10.1667/RR14859.1
PG 9
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics; Radiology,
   Nuclear Medicine & Medical Imaging
GA GG5AC
UT WOS:000432706400011
PM 29633912
DA 2025 08 17
ER

PT J
AU Alcalá, AGD
   Gioda, L
   Dehman, A
   Beugnet, F
AF Alcala, Andrea Garcia de Salazar
   Gioda, Lucile
   Dehman, Alia
   Beugnet, Frederic
TI Assessment of the efficacy of firocoxib (Previcox®) and grapiprant
   (Galliprant®) in an induced model of acute arthritis in dogs
SO BMC VETERINARY RESEARCH
LA English
DT Article
DE Dog; Firocoxib; Grapiprant; Lameness ratio; Force plate; Osteoarthritis
ID INDUCED SYNOVITIS MODEL; PAIN; ROBENACOXIB; CARPROFEN; NSAIDS
AB Background Non steroidal anti inflammatory drugs (NSAIDs) are an important tool in the management of canine osteoarthritis, with the most recent introduction into the category being grapiprant, a piprant that selectively targets the EP4 prostaglandin receptor. To date there have been no efficacy studies comparing grapiprant with other NSAIDs. A randomized, two sequence, assessor blinded study involving two separate experiments was undertaken to measure the potency and persistence of acute pain control over 24 h resulting from a single oral dose of either firocoxib (Previcox (R)) or grapiprant (Galliprant (R)) in an acute arthritis model. Results Force plate derived lameness ratios (0, no force recorded on the plate; 1, normal force) for the untreated group remained at 0 for most post arthritis induction (PAI) assessments in both experiments. Throughout Experiment 1, mean PAI lameness ratios of the firocoxib treated group remained at or above 0.80. In the grapiprant treated group, ratios were 0 at 5 and 7 h PAI (7 and 9 h post treatment), and 0.16 at 10 h PAI (12 h post treatment). For lameness ratios, relative to the firocoxib group, the control and grapiprant group ratios were significantly lower at each PAI assessment (p <= 0.026 and p < 0.001, respectively), except at 1.5 h PAI at which acute pain was still not installed in untreated control dogs. In Experiment 2 the mean lameness ratios for the control group were 0 at 3, 5 and 7 h PAI, and in the grapiprant group at 5, 7 and 10 h PAI (i.e., 19, 21, and 24 h post treatment). In the firocoxib group the lowest mean lameness ratio of 0.36 occurred at 3 h PAI (i.e. 17 h post treatment). Except at 1.5 and 3 h PAI (i.e. 15.5 and 17 h post treatment), due to the needed time for pain to install in the untreated control dogs, the lameness ratio differences between the firocoxib and both the control and grapiprant groups were significant at all assessments (p <= 0.033 for both groups). No significant differences were detected between the grapiprant and control groups in either experiment. Conclusions Firocoxib treatment prior to induction of arthritis in dogs resulted in a high level of analgesia from the first post treatment assessment at 1.5 h through 24 h post treatment. The reduction in lameness provided by firocoxib was consistently superior to that provided by grapiprant, which was not significantly different from untreated controls.
C1 [Alcala, Andrea Garcia de Salazar; Gioda, Lucile] Avogadro LS, Parc Genibrat, F 31470 Fontenilles, France.
   [Dehman, Alia] Hyphen Stat, 195 Route Espagne,BP13669, F 31036 Toulouse 1, France.
   [Beugnet, Frederic] Boehringer Ingelheim Anim Hlth, 29 Ave Tony Garnier, F 69007 Lyon, France.
RP Beugnet, F (通讯作者)，Boehringer Ingelheim Anim Hlth, 29 Ave Tony Garnier, F 69007 Lyon, France.
EM frederic.beugnet@boehringer ingelheim.com
RI ; Beugnet, Frederic/AAD 7495 2019
OI Beugnet, Frederic/0000 0002 7040 7821; 
FU Boehringer Ingelheim; Previcox(R)
FX The study was funded by Merial (now part of Boehringer Ingelheim), the
   manufacturer of Previcox (R). The Contract Research Organization,
   Avogadro, conducted the study independently. The sponsor, FB, prepared
   the design of the study and was involved in analysing the results and
   drafting the publication.
CR Bergh MS, 2005, J VET INTERN MED, V19, P633, DOI 10.1892/0891 6640(2005)19[633:TCNPCA]2.0.CO;2
   Borer LR, 2017, J VET PHARMACOL THER, V40, P148, DOI 10.1111/jvp.12348
   Brown DC, 2013, J VET INTERN MED, V27, P22, DOI 10.1111/jvim.12004
   Dauteloup C, 2017, INT J APPL RES VET M, V15, P10
   Davila D, 2013, JAVMA J AM VET MED A, V243, P225, DOI 10.2460/javma.243.2.225
   Drag M, 2007, VET THER, V8, P41
   European Medicines Agency, 2018, GALL SUMM PROD CHAR
   European Medicines Agency, 2018, PREV SUMM PROD CHAR
   Hanson PD, 2006, VET THER, V7, P127
   Hazewinkel HAW, 2008, RES VET SCI, V84, P74, DOI 10.1016/j.rvsc.2007.02.005
   Heffernan AE, 2018, VET SURG, V47, P516, DOI 10.1111/vsu.12792
   Kennedy KC, 2018, AM J VET RES, V79, P893, DOI 10.2460/ajvr.79.8.893
   McCann ME, 2004, AM J VET RES, V65, P503, DOI 10.2460/ajvr.2004.65.503
   Pollmeier M, 2006, VET REC, V159, P547, DOI 10.1136/vr.159.17.547
   Rausch Derra L, 2016, J VET INTERN MED, V30, P756, DOI 10.1111/jvim.13948
   Rausch Derra LC, 2016, J VET PHARMACOL THER, V39, P566, DOI 10.1111/jvp.12306
   Ryan WG, 2010, INT J APPL RES VET M, V8, P114
   Toutain PL, 2001, J VET PHARMACOL THER, V24, P43, DOI 10.1046/j.1365 2885.2001.00304.x
NR 18
TC 13
Z9 13
U1 2
U2 29
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746 6148
J9 BMC VET RES
JI BMC Vet. Res.
PD AUG 29
PY 2019
VL 15
IS 1
AR 309
DI 10.1186/s12917 019 2052 0
PG 9
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA IU3QB
UT WOS:000483500400001
PM 31464629
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cray, J
   Burrows, AM
   Vecchione, L
   Lensie, E
   Decesare, GE
   Campbell, A
   Finegold, DN
   Losee, JE
   Siegel, MI
   Cooper, GM
   Mooney, MP
AF Cray, James, Jr.
   Burrows, Anne M.
   Vecchione, Lisa
   Lensie, Emily
   Decesare, Gary E.
   Campbell, Andrew
   Finegold, David N.
   Losee, Joseph E.
   Siegel, Michael I.
   Cooper, Gregory M.
   Mooney, Mark P.
TI Effects of Flutamide Therapy on Craniofacial Growth and Development in a
   Model of Craniosynostosis
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Androgens; coronal suture; hormone blocker; craniosynostosis;
   craniofacial growth
ID INHIBITS POSTOPERATIVE RESYNOSTOSIS; UNICORONAL SUTURE SYNOSTOSIS;
   INTRACRANIAL VOLUME; SURGICAL TREATMENT; RABBIT MODEL; ANDROGENS;
   ETHANOL; DIFFERENTIATION; PROLIFERATION; COMPLICATIONS
AB Research has implicated the faulty regulation of transforming growth factor A signaling as one mechanism for premature calvaria suture fusion. Androgens have been shown to increase the expression and activity of the transforming growth factor A, resulting in increased osteoblast proliferation and differentiation and possibly premature suture fusion. The present study was designed to test the hypothesis that flutamide, an androgen receptor blocking agent, would "rescue" a coronal suture destined to fuse and improve craniofacial growth in a familial rabbit model of craniosynostosis. Thirty rabbits with delayed onset, coronal suture synostosis were examined via longitudinal cephalometry. The rabbits were divided into 4 groups: (1) sham surgical controls (n = 10), (2) bovine serum albumin (500 ng) protein controls (n = 6), (3) flutamide diluent controls (n = 6), and (4) flutamide (15 mg dissolved in ethanol) experimental group (n = 8). At 10 days of age, radiopaque amalgam markers were implanted in all rabbits on either side of the coronal suture to monitor sutural growth. At 25 days of age, the bovine serum albumin, ethanol, and flutamide were combined with a slow resorbing collagen vehicle and injected subperiosteally above the coronal suture into the respective groups. Although results revealed a slight but significant increase in coronal suture marker separation in flutamide treated rabbits compared with controls at 42 days of age, few significant differences were noted for craniofacial growth and intracranial volume among groups. Results suggest that androgen receptor blocking using flutamide may only provide a transient rescue to suture fusion in this model. Further research is needed to investigate the effects of hormones on suture development and maintenance.
C1 [Cray, James, Jr.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Surg, Pediat Craniofacial Biol Lab,Rangos Res Ctr 3533, Pittsburgh, PA 15201 USA.
   [Cray, James, Jr.; Vecchione, Lisa; Lensie, Emily; Decesare, Gary E.; Losee, Joseph E.; Cooper, Gregory M.; Mooney, Mark P.] Univ Pittsburgh, Dept Surg, Div Plast & Reconstruct Surg, Pittsburgh, PA 15201 USA.
   [Burrows, Anne M.] Duquesne Univ, Dept Phys Therapy, Pittsburgh, PA 15219 USA.
   [Burrows, Anne M.; Siegel, Michael I.; Mooney, Mark P.] Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15201 USA.
   [Vecchione, Lisa; Losee, Joseph E.] Childrens Hosp Pittsburgh, Pittsburgh Cleft Craniofacial Res Ctr, Pittsburgh, PA 15213 USA.
   [Vecchione, Lisa; Siegel, Michael I.; Mooney, Mark P.] Univ Pittsburgh, Dept Orthodont & Dentofacial Orthoped, Pittsburgh, PA 15201 USA.
   [Decesare, Gary E.] Georgetown Univ, Dept Surg, Washington, DC USA.
   [Campbell, Andrew; Mooney, Mark P.] Univ Pittsburgh, Sch Dent Med, Dept Oral & Maxillofacial Surg, Pittsburgh, PA 15201 USA.
   [Finegold, David N.] Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh, Pittsburgh, PA 15201 USA.
   [Finegold, David N.] Univ Pittsburgh, Sch Dent Med, Dept Human Genet, Pittsburgh, PA 15201 USA.
   [Cooper, Gregory M.] Univ Pittsburgh, Sch Dent Med, Dept Bioengn, Pittsburgh, PA 15201 USA.
   [Cooper, Gregory M.; Mooney, Mark P.] Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Pittsburgh, PA 15201 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Duquesne University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Georgetown
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Cray, J (通讯作者)，Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Surg, Pediat Craniofacial Biol Lab,Rangos Res Ctr 3533, 530 45th St, Pittsburgh, PA 15201 USA.
EM James.Cray@chp.edu
RI Burrows, Anne/AAP 3577 2021; Cooper, Gregory/ABI 4744 2022
OI Finegold, David/0000 0001 9901 2578; 
FU Plastic Surgery Education Foundation [BRG56 08]
FX This study was funded by the Plastic Surgery Education Foundation
   Research Award BRG56 08.
CR BENZ DJ, 1991, ENDOCRINOLOGY, V128, P2723, DOI 10.1210/endo 128 6 2723
   Bonaventure Jacky, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403005751
   BURROWS AM, 1995, CLEFT PALATE CRAN J, V32, P235, DOI 10.1597/1545 1569(1995)032<0235:GOTCVI>2.3.CO;2
   Chatterjee JS, 2009, J PLAST RECONSTR AES, V62, P211, DOI 10.1016/j.bjps.2007.10.042
   Chong SL, 2003, ANAT REC PART A, V274A, P962, DOI 10.1002/ar.a.10113
   Cohen MJ., 2000, CRANIOSYNOSTOSIS DIA
   Cohen MM Jr, 2005, AM J MED GENET A, V136A, P313, DOI 10.1002/ajmg.a.30757
   Cooper GM, 2007, J BONE MINER RES, V22, P1046, DOI 10.1359/JBMR.070410
   Cray JJ, 2008, AM J PHYS ANTHROPOL, P83
   Esparza J, 2008, NEUROCIRUGIA, V19, P509
   Esparza J, 2008, CHILD NERV SYST, V24, P1421, DOI 10.1007/s00381 008 0691 8
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271
   Hofbauer LC, 1999, J BONE MINER RES, V14, P1330, DOI 10.1359/jbmr.1999.14.8.1330
   Inagaki T, 2007, CHILD NERV SYST, V23, P1455, DOI 10.1007/s00381 007 0436 0
   Kasperk CH, 1997, J BONE MINER RES, V12, P464, DOI 10.1359/jbmr.1997.12.3.464
   KASPERK CH, 1989, ENDOCRINOLOGY, V124, P1576, DOI 10.1210/endo 124 3 1576
   Kelleher MO, 2007, CHILD NERV SYST, V23, P1285, DOI 10.1007/s00381 007 0386 6
   Klein RF, 1997, ALCOHOL CLIN EXP RES, V21, P392
   Klein RF, 1996, ALCOHOL CLIN EXP RES, V20, P572, DOI 10.1111/j.1530 0277.1996.tb01095.x
   Lin IC, 2004, J CRANIOFAC SURG, V15, P922, DOI 10.1097/00001665 200411000 00006
   Lin IC, 2007, PLAST RECONSTR SURG, V120, P1137, DOI 10.1097/01.prs.0000279527.99734.bf
   Mooney M., CRANIOFACIAL GROWTH
   Mooney MP, 2007, PLAST RECONSTR SURG, V119, P1200, DOI 10.1097/01.prs.0000258403.49584.ec
   Mooney MP, 2007, J CRANIOFAC SURG, V18, P336, DOI 10.1097/scs.0b013e3180336047
   Mooney MP, 1998, CHILD NERV SYST, V14, P247, DOI 10.1007/s003810050220
   Mooney MP, 1998, J CRANIOFAC SURG, V9, P234, DOI 10.1097/00001665 199805000 00010
   Mooney MP, 1998, CHILD NERV SYST, V14, P236, DOI 10.1007/s003810050219
   Mooney MP, 1999, J CRANIOFAC SURG, V10, P104, DOI 10.1097/00001665 199903000 00003
   MOONEY MP, 1994, CLEFT PALATE CRAN J, V31, P8, DOI 10.1597/1545 1569(1994)031<0008:DOASOR>2.3.CO;2
   Mooney MP, 1996, J CRAN GENET DEV BIO, V16, P52
   Mooney MP, 1996, CLEFT PALATE CRAN J, V33, P369, DOI 10.1597/1545 1569(1996)033<0369:CSPASP>2.3.CO;2
   MOONEY MP, 1994, CLEFT PALATE CRAN J, V31, P1, DOI 10.1597/1545 1569(1994)031<0001:DOASOR>2.3.CO;2
   Moore K., 2007, WE ARE BORN ESSENTIA
   Morris J., 2009, Journal of Dental Research, V88A, P2798
   Morriss Kay GM, 2005, J ANAT, V207, P637, DOI 10.1111/j.1469 7580.2005.00475.x
   Murray DJ, 2007, J PLAST RECONSTR AES, V60, P991, DOI 10.1016/j.bjps.2007.02.003
   Opperman LA., 2002, UNDERSTANDING CRANIO, P497
   Owens M, 1996, J DENT RES, V75, P820
   Poisson E, 2004, CLEFT PALATE CRAN J, V41, P392, DOI 10.1597/02 140.1
   Rawlins Joseph T., 2008, V12, P178, DOI 10.1159/000115038
   Ricci D, 2007, DEV MED CHILD NEUROL, V49, P574, DOI 10.1111/j.1469 8749.2007.00574.x
   Rogers S., 1980, HUMAN SKULL
   Sperber G.H., 2001, CRANIOFACIAL DEV
   Vignesh RC, 2006, TOXICOLOGY, V220, P63, DOI 10.1016/j.tox.2005.11.026
NR 44
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1049 2275
EI 1536 3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD MAY
PY 2010
VL 21
IS 3
BP 711
EP 718
DI 10.1097/SCS.0b013e3181d80a36
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 601XV
UT WOS:000278102200019
PM 20485034
DA 2025 08 17
ER

PT J
AU Stricker, K
   Yu, S
   Krammer, G
AF Stricker, Kirstin
   Yu, Sue
   Krammer, Gerhard
TI A 6 week, multicentre, randomised, double blind, double dummy,
   active controlled, clinical safety study of lumiracoxib and rofecoxib in
   osteoarthritis patients
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THERAPEUTIC ARTHRITIS RESEARCH;
   GASTROINTESTINAL EVENT TRIAL; BLOOD PRESSURE; RHEUMATOID ARTHRITIS;
   ANALGESIC EFFICACY; METAANALYSIS; NAPROXEN; INHIBITORS; NSAIDS
AB Background: Lumiracoxib is a selective cyclooxygenase 2 inhibitor effective in the treatment of osteoarthritis (OA) with a superior gastrointestinal (GI) safety profile as compared to traditional nonsteroidal anti inflammatory drugs (NSAIDs, ibuprofen and naproxen). This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA. Rofecoxib was withdrawn worldwide due to an associated increased risk of CV events and lumiracoxib has been withdrawn from Australia, Canada, Europe and a few other countries following reports of suspected adverse liver reactions.
   Methods: This randomised, double blind study enrolled 309 patients (aged greater than or equal to 50 years) with primary OA across 51 centres in Europe. Patients were randomly allocated to receive either lumiracoxib 400 mg od (four times the recommended dose in OA) (n = 154) or rofecoxib 25 mg od (n = 155). The study was conducted for 6 weeks and assessments were performed at Weeks 3 and 6. The primary safety measures were the incidence of predefined GI adverse events (AEs) and peripheral oedema. The secondary safety measures included effect of treatment on the mean sitting systolic and diastolic blood pressure (msSBP and msDBP). Tolerability of lumiracoxib 400 mg was assessed by the incidence of AEs.
   Results: Lumiracoxib and rofecoxib displayed similar GI safety profiles with no statistically significant difference in predefined GI AEs between the two groups (43.5% vs. 37.4%, respectively). The incidence and severity of individual predefined GI AEs was comparable between the two groups. The incidence of peripheral oedema was low and identical in both the groups (n = 9, 5.8%). Only one patient in the lumiracoxib group and three patients in the rofecoxib group had a moderate or severe event. At Week 6 there was a significantly lower msSBP and msDBP in the lumiracoxib group compared to the rofecoxib group (p < 0.05). A similar percentage of patients in both groups showed an improvement in target joint pain and disease activity. The tolerability profile was similar in both the treatment groups.
   Conclusion: Lumiracoxib 400 mg od (four times the recommended dose in OA) provided a comparable GI safety profile to rofecoxib 25 mg od (therapeutic dose). However, lumiracoxib was associated with a significantly better BP profile as compared to rofecoxib.
C1 [Stricker, Kirstin; Krammer, Gerhard] Novartis Pharma AG Postfach, CH 4002 Basel, Switzerland.
   [Yu, Sue] Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA.
C3 Novartis; Novartis; Novartis USA
RP Krammer, G (通讯作者)，Novartis Pharma AG Postfach, CH 4002 Basel, Switzerland.
EM kirstin.stricker@novartis.com; sue.yu@novartis.com;
   gerhard.krammer@novartis.com
FU Novartis Pharma AG
FX The study and statistical analyses were funded by Novartis Pharma AG.
   The authors would like to thank the investigators (please see Appendix I
   for a list of full names), staff of the centres involved in this work,
   the clinical trial team for their expert collaboration and the patients
   who participated in the study. The authors would like to thank Godehard
   Hoexter, the clinical trial statistician and Elena Ehrsam the clinical
   trial leader for their expert contribution to the study and data
   analysis. In addition the authors would like to thank the medical
   writers Lakshmi Venkatraman and Vikrant Pallapotu (DOC India, Novartis)
   for their assistance with drafting the manuscript and incorporating
   subsequent revisions.
CR Altman RD, 2000, ARTHRITIS RHEUM US, V43, P1905
   Aw TJ, 2005, ARCH INTERN MED, V165, P490, DOI 10.1001/archinte.165.5.IOI50013
   Cannon CP, 2006, LANCET, V368, P1771, DOI 10.1016/S0140 6736(06)69666 9
   Chan VWS, 2005, ACTA ANAESTH SCAND, V49, P1491, DOI 10.1111/j.1399 6576.2005.00782.x
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   FARKOUH ME, ACRIARHP 2006 ANN SC
   Fleischmann R, 2006, OSTEOARTHR CARTILAGE, V14, pS165
   Goldstein JL, 2001, AM J GASTROENTEROL, V96, P1019
   Grover SA, 2005, HYPERTENSION, V45, P92, DOI 10.1161/01.HYP.0000149684.01903.b8
   Hawkey CJ, 2008, ALIMENT PHARM THER, V27, P838, DOI 10.1111/j.1365 2036.2008.03622.x
   HAWKEY CJ, 2007, DDW
   JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003 4819 121 4 199408150 00011
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kyle C, 2006, ANN RHEUM DIS, V65, P241
   Laine L, 2002, SEMIN ARTHRITIS RHEU, V32, P25, DOI 10.1053/sarh.2002.37217
   Laine L, 2001, GASTROENTEROLOGY, V120, P594, DOI 10.1053/gast.2001.21907
   Langman MJ, 1999, JAMA J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140 6736(02)11911 8
   MACDONALD TM, 2007, J CLIN HYPERTENS, V9, pA91
   *MERCK CO INC, MERCK ANN VOL WORLDW
   Pavelka K, 2005, ANN RHEUM DIS, V64, P353
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Singh G, 1999, J RHEUMATOL, V26, P18
   Singh G, 2003, J RHEUMATOL, V30, P714
   Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530
   Singh G, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2047
   TALLEY NJ, 1995, DIGEST DIS SCI, V40, P1345, DOI 10.1007/BF02065549
   Traversa G, 2003, BMJ BRIT MED J, V327, P18, DOI 10.1136/bmj.327.7405.18
   WHITEHEAD A, 2006, OSTEOARTHR CARTILAGE, V14, pS168
   Willburger RE, 2007, RHEUMATOLOGY, V46, P1126, DOI 10.1093/rheumatology/kem090
   Wolfe MM, 1996, HOSP PRACT, V31, P37, DOI 10.1080/21548331.1996.11443389
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Zacher J, 2005, ANN RHEUM DIS, V64, P483
   Zelenakas K, 2004, INT J CLIN PRACT, V58, P251, DOI 10.1111/j.1368 5031.2004.00156.x
NR 34
TC 6
Z9 7
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD SEP 8
PY 2008
VL 9
AR 118
DI 10.1186/1471 2474 9 118
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 349ZB
UT WOS:000259320700002
PM 18778469
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hoff, P
   Rakow, A
   Gaber, T
   Hahne, M
   Sentürk, U
   Strehl, C
   Fangradt, M
   Schmidt Bleek, K
   Huscher, D
   Winkler, T
   Matziolis, D
   Matziolis, G
   Badakhshi, H
   Burmester, GR
   Duda, GN
   Perka, C
   Buttgereit, F
AF Hoff, Paula
   Rakow, Anastasia
   Gaber, Timo
   Hahne, Martin
   Sentuerk, Ufuk
   Strehl, Cindy
   Fangradt, Monique
   Schmidt Bleek, Katharina
   Huscher, Doerte
   Winkler, Tobias
   Matziolis, Doerte
   Matziolis, Georg
   Badakhshi, Harun
   Burmester, Gerd Ruediger
   Duda, Georg N.
   Perka, Carsten
   Buttgereit, Frank
TI Preoperative irradiation for the prevention of heterotopic ossification
   induces local inflammation in humans
SO BONE
LA English
DT Article
DE Heterotopic ossification; Immune cells; Cytokines; Total hip
   arthroplasty; Inflammation
ID BONE FORMATION; HIP REPLACEMENT; B CELLS; INDOMETHACIN; COX 2; GAMMA;
   VEGF; DIFFERENTIATION; PROLIFERATION; EXPRESSION
AB Radiation of the hip is an established method to prevent heterotopic ossification (HO) following total hip arthroplasty (THA) but the precise mechanism is unclear. As inflammatory processes are suggested to be involved in the pathogenesis of HO, we hypothesized that the preoperative irradiation impacts local immune components. Therefore, we quantified immune cell populations and cytokines in hematomas resulting from the transection of the femur in two groups of patients receiving THA: patients irradiated preoperatively (THA X hematoma: THA X H group) in the hip region (7 Gy) in order to prevent HO and patients who were not irradiated (THA H group) but were postoperatively treated with non steroidal anti inflammatory drugs (NSAIDs). Radiation resulted in significantly increased frequencies of T cells, cytotoxic T cells, NKT cells and CD25 + CD127   T reg cells, whereas the number of naive CD45RA expressing cytotoxic T cells was reduced. These results indicate differential immune cell activation, corroborated by our findings of significantly higher concentrations of pro inflammatory cytokines (e.g. IL 6, IFN gamma) and chemokines (e.g. MCP 1, RANTES) in the THA X H group as compared to THA H group. In contrast, the concentration of the angiogenic VEGF was significantly suppressed in the THA X H group. We conclude that preoperative irradiation results in significant changes in immune cell composition and cytokine secretion in THA hematomas, establishing a specific   rather proinflammatory   milieu. This increase of inflammatory activity together with the observed suppression in VEGF secretion may contribute to the prevention of HO. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Hoff, Paula; Gaber, Timo; Hahne, Martin; Strehl, Cindy; Fangradt, Monique; Huscher, Doerte; Burmester, Gerd Ruediger; Buttgereit, Frank] Charite, Dept Rheumatol & Clin Immunol, D 10117 Berlin, Germany.
   [Hoff, Paula; Gaber, Timo; Hahne, Martin; Strehl, Cindy; Fangradt, Monique; Huscher, Doerte; Buttgereit, Frank] German Rheumatism Res Ctr DRFZ, Berlin, Germany.
   [Gaber, Timo; Hahne, Martin; Matziolis, Georg; Perka, Carsten; Buttgereit, Frank] Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.
   [Rakow, Anastasia; Sentuerk, Ufuk; Winkler, Tobias; Matziolis, Doerte; Matziolis, Georg; Duda, Georg N.; Perka, Carsten] Charite, Ctr Musculoskeletal Surg, D 10117 Berlin, Germany.
   [Schmidt Bleek, Katharina; Duda, Georg N.] Julius Wolff Inst, Berlin, Germany.
   [Badakhshi, Harun] Charite, Dept Radiotherapy, D 10117 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Leibniz Association; Deutsches
   Rheuma Forschungszentrum (DRFZ); Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Hoff, P (通讯作者)，Charite, Dept Rheumatol & Clin Immunol, Charitepl 1, D 10117 Berlin, Germany.
EM paula.hoff@charite.de
RI ; Duda, Georg/H 2085 2016; Burmester, Gerd/AAY 7514 2020; Perka,
   Carsten/ABG 6505 2021; Schmidt Bleek, Katharina/O 9816 2015; Winkler,
   Tobias/AAL 6324 2020
OI Perka, Carsten/0000 0002 0993 581X; Duda, Georg/0000 0001 7605 3908;
   Winkler, Tobias/0000 0003 0727 4680; Burmester,
   Gerd Rudiger/0000 0001 7518 1131; Buttgereit, Frank/0000 0003 2534 550X;
   Huscher, Dorte/0000 0001 9070 0761; 
FU Deutsche Forschungsgemeinschaft [Bu 1015/6 1]; DFG through the
   Berlin Brandenburg School for Regenerative Therapies [GSC 203]
FX We would like to thank Manuela Jakstadt for technical assistance. This
   work was supported by a grant from the Deutsche Forschungsgemeinschaft
   (Bu 1015/6 1) to FB, CP and GD. Contributions of MH were made possible
   by DFG funding through the Berlin Brandenburg School for Regenerative
   Therapies GSC 203.
CR Agematsu K, 2000, HISTOL HISTOPATHOL, V15, P573, DOI 10.14670/HH 15.573
   Allori AC, 2008, TISSUE ENG PART B RE, V14, P259, DOI 10.1089/ten.teb.2008.0082
   Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053
   BARBUL A, 1989, ANN SURG, V209, P479, DOI 10.1097/00000658 198904000 00015
   Bour Jordan H, 2009, IMMUNOL REV, V229, P41, DOI 10.1111/j.1600 065X.2009.00775.x
   Boyman O, 2009, EUR J IMMUNOL, V39, P2088, DOI 10.1002/eji.200939444
   Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood 2008 05 155408
   Clarkin CE, 2008, J CELL PHYSIOL, V214, P537, DOI 10.1002/jcp.21234
   Clarkin CE, 2013, CELL BIOCHEM FUNCT, V31, P1, DOI 10.1002/cbf.2911
   CLEMENT LT, 1992, J CLIN IMMUNOL, V12, P1, DOI 10.1007/BF00918266
   Donneys A, 2013, BONE, V52, P318, DOI 10.1016/j.bone.2012.10.014
   Facoetti A, 2009, INT J RADIAT BIOL, V85, P690, DOI 10.1080/09553000903020016
   Fayette M, 2005, EUR J CANCER, V41, P1109, DOI 10.1016/j.ejca.2005.02.017
   Fransen M, 2004, Cochrane Database Syst Rev, pCD001160, DOI 10.1002/14651858.CD001160.pub2
   Freeman TA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 17
   Furuya H, 2008, AM J MED GENET A, V146A, P459, DOI 10.1002/ajmg.a.32151
   Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Grohs JG, 2007, ACTA ORTHOP, V78, P95, DOI 10.1080/17453670610013484
   Ham AW, 1930, J BONE JOINT SURG, V12, P827
   Hill N, 2002, CURR OPIN IMMUNOL, V14, P791, DOI 10.1016/S0952 7915(02)00403 X
   Ishikawa H, 2010, VIROLOGY, V407, P325, DOI 10.1016/j.virol.2010.08.030
   Ivanov VN, 2010, CELL SIGNAL, V22, P1076, DOI 10.1016/j.cellsig.2010.02.010
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008 0576
   Kaplan Frederick S, 2009, Hum Mutat, V30, P379, DOI 10.1002/humu.20868
   Kienapfel H, 1999, ARCH ORTHOP TRAUM SU, V119, P296, DOI 10.1007/s004020050414
   Kim KM, 1995, ANN NY ACAD SCI, V766, P81, DOI 10.1111/j.1749 6632.1995.tb26651.x
   Kolar P, 2009, CLIN EXP RHEUMATOL, V27, P99
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Lacotte S, 2009, ANN NY ACAD SCI, V1173, P310, DOI 10.1111/j.1749 6632.2009.04813.x
   Lampropoulou V, 2010, IMMUNOL REV, V233, P146, DOI 10.1111/j.0105 2896.2009.00855.x
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mahida YR, 2000, INFLAMM BOWEL DIS, V6, P21, DOI 10.1097/00054725 200002000 00004
   Matsubara H, 2012, BONE, V51, P168, DOI 10.1016/j.bone.2012.02.017
   Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256 005 0958 z
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   MOED BR, 1994, J BONE JOINT SURG BR, V76B, P895, DOI 10.1302/0301 620X.76B6.7983114
   MOLAR P, 2009, ARTHRITIS RHEUM, V60, P123
   Mor A, 2012, INFLAMMATION, V35, P1706, DOI 10.1007/s10753 012 9488 8
   Moreno M, 2008, J IMMUNOL, V181, P2446, DOI 10.4049/jimmunol.181.4.2446
   MORIMOTO C, 1993, CLIN EXP RHEUMATOL, V11, P241
   Nam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040044
   Park JE, 2004, AM J SURG, V187, p11S, DOI 10.1016/S0002 9610(03)00296 4
   Pavlou G, 2012, HIP INT, V22, P50, DOI 10.5301/HIP.2012.9057
   Pellegrini VD, 1996, J BONE JOINT SURG AM, V78A, P870, DOI 10.2106/00004623 199606000 00010
   Rapuano BE, 2008, ARCH ORTHOP TRAUM SU, V128, P333, DOI 10.1007/s00402 007 0436 2
   ROSENDAHL S, 1977, ACTA ORTHOP SCAND, V48, P400, DOI 10.3109/17453677708992016
   Saha B, 2010, CYTOKINE, V50, P1, DOI 10.1016/j.cyto.2009.11.021
   Scarlett RF, 2004, CLIN ORTHOP RELAT R, P275, DOI 10.1097/01.blo.0000129557.38803.26
   Schäffer M, 1998, BJS BRIT J SURG, V85, P444
   Scheffold A, 2005, EUR J IMMUNOL, V35, P1336, DOI 10.1002/eji.200425887
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Schmidt Bleek K, 2012, CELL TISSUE RES, V347, P567, DOI 10.1007/s00441 011 1205 7
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065 2776(07)96002 2
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Simon Lee S., 2002, Journal of Rheumatology, V29, P1501
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Toomey DP, 2009, SURG J R COLL SURG E, V7, P174, DOI 10.1016/S1479 666X(09)80042 5
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Vavken P, 2009, CLIN ORTHOP RELAT R, V467, P3283, DOI 10.1007/s11999 009 0924 5
   Wu ZF, 2010, J MOL CELL BIOL, V2, P217, DOI 10.1093/jmcb/mjq012
   Yadav A, 2010, CLIN CHIM ACTA, V411, P1570, DOI 10.1016/j.cca.2010.07.006
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 68
TC 17
Z9 21
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2013
VL 55
IS 1
BP 93
EP 101
DI 10.1016/j.bone.2013.03.020
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 150DR
UT WOS:000319370900013
PM 23571050
DA 2025 08 17
ER

PT J
AU Feng, JY
   Wang, JW
   Xu, Y
   Lu, F
   Zhang, J
   Han, XX
   Zhang, C
   Wang, GW
AF Feng, Jinyan
   Wang, Jinwu
   Xu, Yao
   Lu, Feng
   Zhang, Jin
   Han, Xiuxin
   Zhang, Chao
   Wang, Guowen
TI Construction and validation of a novel cuproptosis mitochondrion
   prognostic model related with tumor immunity in osteosarcoma
SO PLOS ONE
LA English
DT Article
ID UP REGULATION; CELL DEATH; EXPRESSION; TOMM20; MFN2
AB BackgroundThe purpose of this study was to develop a new prognostic model for osteosarcoma based on cuproptosis mitochondrion genes. Materials and methodsThe data of osteosarcoma were obtained from TARGET database. By using Cox regression and LASSO regression analysis, a novel risk score was constructed based on cuproptosis mitochondrion genes. Kaplan Meier, ROC curve and independent prognostic analyses were performed to validate the risk score in GSE21257 dataset. Then, a predictive nomogram was constructed and further validated by calibration plot, C index and ROC curve. Based on the risk score, all patients were divided into high risk and low risk group. GO and KEGG enrichment, immune correlation and drug sensitivity analyses were performed between groups. Real time quantitative PCR verified the expression of cuproptosis mitochondrion prognostic model genes in osteosarcoma. And we explored the function of FDX1 in osteosarcoma by western blotting, CCK8, colony formation assay, wound healing assay and transwell assays. ResultsA total of six cuproptosis mitochondrion genes (FDX1, COX11, MFN2, TOMM20, NDUFB9 and ATP6V1E1) were identified. A novel risk score and associated prognostic nomogram were constructed with high clinical application value. Strong differences in function enrichment and tumor immune microenvironment were shown between groups. Besides, the correlation of cuproptosis mitochondrion genes and drug sensitivity were revealed to search for potential therapeutic target. The expression of FDX1, COX11, MFN2, TOMM20 and NDUFB9 at mRNA level was elevated in osteosarcoma cells compared with normal osteoblast hFOB1.19. The mRNA expression level of ATP6V1E1 was decreased in osteosarcoma. Compared with hFOB1.19, western blotting revealed that the expression of FDX1 was significantly elevated in osteosarcoma cells. Functional experiments indicated that FDX1 mainly promoted the migration of osteosarcoma rather than proliferation. ConclusionsWe developed a novel prognostic model of osteosarcoma based on cuproptosis mitochondrion genes, which provided great guidance in survival prediction and individualized treatment decision making for patients with osteosarcoma.
C1 [Feng, Jinyan; Wang, Jinwu; Xu, Yao; Lu, Feng; Zhang, Jin; Han, Xiuxin; Zhang, Chao; Wang, Guowen] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Bone & Soft Tissue Tumors, Tianjin, Peoples R China.
   [Feng, Jinyan; Wang, Jinwu; Xu, Yao; Lu, Feng; Zhang, Jin; Han, Xiuxin; Zhang, Chao; Wang, Guowen] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Feng, Jinyan; Wang, Jinwu; Xu, Yao; Lu, Feng; Zhang, Jin; Han, Xiuxin; Zhang, Chao; Wang, Guowen] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
C3 Tianjin Medical University
RP Zhang, C; Wang, GW (通讯作者)，Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Bone & Soft Tissue Tumors, Tianjin, Peoples R China.; Zhang, C; Wang, GW (通讯作者)，Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Zhang, C; Wang, GW (通讯作者)，Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
EM Zhangchao198409@163.com; wangguowen@tmu.edu.cn
RI Wang, Jinwu/AAG 4431 2021; wang, guowen/MGU 8324 2025
OI Feng, Jinyan/0000 0002 5334 5067
FU National Natural Science Foundation of China [81872184, 81773031]
FX This work was supported by the National Natural Science Foundation of
   China [grant nos. 81872184 and 81773031]. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahn SY, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e30
   Barresi V, 2016, FEBS OPEN BIO, V6, P794, DOI 10.1002/2211 5463.12060
   Bian ZL, 2022, GENES BASEL, V13, DOI 10.3390/genes13050851
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bustos RI, 2013, BIOCHEM BIOPH RES CO, V437, P426, DOI 10.1016/j.bbrc.2013.06.095
   Cheng L, 2022, INT IMMUNOPHARMACOL, V111, DOI 10.1016/j.intimp.2022.109169
   Da Rè C, 2014, J BIOL CHEM, V289, P29235, DOI 10.1074/jbc.M114.602938
   Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9
   Deng LL, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.855387
   Fan L, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.718624
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Geeleher P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107468
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Gu JZ, 1996, GENOMICS, V35, P6, DOI 10.1006/geno.1996.0316
   Han QC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00780 x
   Hu H, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1156455
   Huang W, 2023, FRONT MOL BIOSCI, V10, DOI 10.3389/fmolb.2023.963639
   Jiang YC, 2022, NANOMEDICINE UK, V17, P303, DOI 10.2217/nnm 2021 0374
   Jung KA, 2017, ANTIOXID REDOX SIGN, V27, P945, DOI 10.1089/ars.2016.6797
   Khouja HI, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11143 6
   Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059 016 1028 7
   Li LD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144441
   Li XJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.567970
   Liang XH, 2021, PHARMACOGEN PERS MED, V14, P695, DOI 10.2147/PGPM.S314860
   Lilienthal I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186885
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Liu D, 2023, FRONT GENET, V13, DOI 10.3389/fgene.2022.1082709
   Liu HR, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.952290
   Liu QY, 2018, MOL IMMUNOL, V103, P115, DOI 10.1016/j.molimm.2018.09.010
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mai SJ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.829175
   Matarneh SK, 2021, MEAT SCI, V172, DOI 10.1016/j.meatsci.2020.108316
   Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422 020 0370 1
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Micaily I, 2023, AM J CLIN PATHOL, V159, P492, DOI 10.1093/ajcp/aqac180
   Miller Benjamin J, 2013, J Bone Joint Surg Am, V95, pe89, DOI 10.2106/JBJS.L.01189
   Mizushima E, 2020, CANCER SCI, V111, P36, DOI 10.1111/cas.14229
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88
   Park SH, 2019, BMB REP, V52, P712, DOI 10.5483/BMBRep.2019.52.12.249
   Ping S, 2022, CANCER MED US, V11, P3529, DOI 10.1002/cam4.4706
   Qi XC, 2022, AM J CANCER RES, V12, P3947
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Rothlin CV, 2021, NAT REV IMMUNOL, V21, P292, DOI 10.1038/s41577 020 00456 0
   Sarkar J, 2016, MATRIX BIOL, V52 54, P234, DOI 10.1016/j.matbio.2015.11.004
   Shanbhag VC, 2021, BBA MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2020.118893
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang DL, 2022, CELL RES, V32, P417, DOI 10.1038/s41422 022 00653 7
   Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529
   Varhaug KN, 2020, MITOCHONDRION, V50, P58, DOI 10.1016/j.mito.2019.09.003
   Voli F, 2020, CANCER RES, V80, P4129, DOI 10.1158/0008 5472.CAN 20 0471
   Wang DJ, 2022, BMC MED GENOMICS, V15, DOI 10.1186/s12920 022 01261 5
   Wang YQ, 2022, CELL MOL IMMUNOL, V19, P867, DOI 10.1038/s41423 022 00866 1
   Wang YY, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 22 1095
   Wang Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00353
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108
   Xue Q, 2023, AUTOPHAGY, V19, P2175, DOI 10.1080/15548627.2023.2200554
   Yahiro K, 2020, CANCER IMMUNOL IMMUN, V69, P745, DOI 10.1007/s00262 020 02508 9
   Yan HZ, 2018, ONCOL REP, V39, P1671, DOI 10.3892/or.2018.6252
   Yang MY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.919231
   Yao YM, 2023, FRONT GENET, V14, DOI 10.3389/fgene.2023.1071694
   Yin CD, 2021, BIOENGINEERED, V12, P172, DOI 10.1080/21655979.2020.1864096
   Yong L, 2020, J BONE ONCOL, V25, DOI 10.1016/j.jbo.2020.100322
   You MH, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81469 0
   Zhang B, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 1576 0
   Zhang ZY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.749134
   Zhao Z, 2014, EJSO EUR J SURG ONC, V40, P1361, DOI 10.1016/j.ejso.2014.04.005
   Zou GP, 2021, J CANCER, V12, P7358, DOI 10.7150/jca.61379
NR 69
TC 6
Z9 7
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 5
PY 2023
VL 18
IS 7
AR e0288180
DI 10.1371/journal.pone.0288180
PG 25
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA L7XR0
UT WOS:001025358500004
PM 37405988
OA gold
DA 2025 08 17
ER

PT J
AU Schönrock, N
   Tillmans, F
   Sebens, S
   Kähler, W
   Klapa, S
   Rieger, B
   Scherthan, H
   Koch, A
AF Schoenrock, Nele
   Tillmans, Frauke
   Sebens, Susanne
   Kaehler, Wataru
   Klapa, Sebastian
   Rieger, Bente
   Scherthan, Harry
   Koch, Andreas
TI Analysis of Single  and Double Stranded DNA Damage in Osteoblastic Cells
   after Hyperbaric Oxygen Exposure
SO ANTIOXIDANTS
LA English
DT Article
DE oxidative stress; DNA damage; osteoblasts; gamma H2AX; hyperbaric
   hyperoxia; comet assay; DSBs
ID REGULATORY T CELLS; GROWTH FACTOR BETA; COMET ASSAY; HEME OXYGENASE 1;
   MOLECULAR BASIS; STRESS; REPAIR; DIFFERENTIATION; MECHANISMS; THERAPY
AB (1) Background: Hyperbaric oxygen (HBO) exposure induces oxidative stress that may lead to DNA damage, which has been observed in human peripheral blood lymphocytes or non human cells. Here, we investigated the impact of hyperbaric conditions on two human osteoblastic cell lines: primary human osteoblasts, HOBs, and the osteogenic tumor cell line SAOS 2. (2) Methods: Cells were exposed to HBO in an experimental hyperbaric chamber (4 ATA, 100% oxygen, 37 degrees C, and 4 h) or sham exposed (1 ATA, air, 37 degrees C, and 4 h). DNA damage was examined before, directly after, and 24 h after exposure with an alkaline comet assay and detection of gamma H2AX+53BP1 colocalizing double strand break (DSB) foci and apoptosis. The gene expression of TGFss 1, HO 1, and NQO1, involved in antioxidative functions, was measured with qRT PCR. (3) Results: The alkaline comet assay showed significantly elevated levels of DNA damage in both cell lines after 4 h of HBO, while the DSB foci were similar to sham. gamma H2AX analysis indicated a slight increase in apoptosis in both cell lines. The increased expression of HO 1 in HOB and SAOS 2 directly after exposure suggested the induction of an antioxidative response in these cells. Additionally, the expression of TGF ss1 was negatively affected in HOB cells 4 h after exposure. (4) Conclusions: in summary, this study indicates that osteoblastic cells are sensitive to the DNA damaging effects of hyperbaric hyperoxia, with the HBO induced DNA damage consisting largely of single strand DNA breaks that are rapidly repaired.
C1 [Schoenrock, Nele; Tillmans, Frauke; Kaehler, Wataru; Klapa, Sebastian; Rieger, Bente; Koch, Andreas] Naval Inst Maritime Med, D 24119 Kronshagen, Germany.
   [Tillmans, Frauke] Divers Alert Network, Durham, NC 27705 USA.
   [Sebens, Susanne] Univ Kiel, Inst Expt Canc Res, D 24118 Kiel, Germany.
   [Scherthan, Harry] Univ Ulm, Bundeswehr Inst Radiobiol, D 80937 Munich, Germany.
C3 University of Kiel; Ulm University
RP Schönrock, N; Tillmans, F (通讯作者)，Naval Inst Maritime Med, D 24119 Kronshagen, Germany.; Tillmans, F (通讯作者)，Divers Alert Network, Durham, NC 27705 USA.
EM nele.schoenrock@googlemail.com; ftillmans@dan.org
RI Tillmans, Frauke/B 6906 2015; Sebens, Susanne/C 1222 2010; Tillmans,
   Frauke/AAW 5367 2021
OI Tillmans, Frauke/0000 0002 2159 0834; Klapa,
   Sebastian/0000 0002 0012 0163; 
CR Ahmed EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039521
   Al Hadi H, 2015, J DENT, V43, P382, DOI 10.1016/j.jdent.2014.10.006
   Al Waili Noori S, 2006, Technol Health Care, V14, P489
   Anderson D, 2013, METHODS MOL BIOL, V1054, P209, DOI 10.1007/978 1 62703 565 1_14
   BIRCH MA, 1993, J BONE MINER RES, V8, P1155
   Ceponis P, 2017, ORAL DIS, V23, P141, DOI 10.1111/odi.12489
   Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098 2280(1997)30:2<139::AID EM6>3.0.CO;2 I
   Collins AR, 2008, MUTAGENESIS, V23, P143, DOI 10.1093/mutage/gem051
   Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249
   COLLINS AR, 1995, MUTAT RES DNA REPAIR, V336, P69, DOI 10.1016/0921 8777(94)00043 6
   De Bels D, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020282
   Dianov GL, 2013, NUCLEIC ACIDS RES, V41, P3483, DOI 10.1093/nar/gkt076
   Dusinska M, 2008, MUTAGENESIS, V23, P191, DOI 10.1093/mutage/gen007
   Eberlein U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123174
   FAIRBAIRN DW, 1995, MUTAT RES REV GENET, V339, P37, DOI 10.1016/0165 1110(94)00013 3
   Ganguly BJ, 2002, APOPTOSIS, V7, P499, DOI 10.1023/A:1020686908831
   Gonzalez Hunt Claudia P., 2018, Current Opinion in Toxicology, V7, P87, DOI 10.1016/j.cotox.2017.11.001
   Halliwell B, 2015, FREE RADICAL BIO MED
   Halliwell Barry, 2014, Biomed J, V37, P99, DOI 10.4103/2319 4170.128725
   Ikehata H, 2011, J RADIAT RES, V52, P115, DOI 10.1269/jrr.10175
   JOSEPH P, 1994, ONCOL RES, V6, P525
   Kähler W, 2013, UNDERSEA HYPERBAR M, V40, P231
   Kanamori M, 2016, TRENDS IMMUNOL, V37, P803, DOI 10.1016/j.it.2016.08.012
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Kassem M, 2000, EUR J CLIN INVEST, V30, P429
   Kiers D, 2015, SCI REP UK, V5, DOI 10.1038/srep17441
   Kuo LJ, 2008, IN VIVO, V22, P305
   Lamkowski A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087458
   Liu T, 2005, J PROTEOME RES, V4, P2070, DOI 10.1021/pr0502065
   Loboda A, 2008, ANTIOXID REDOX SIGN, V10, P1767, DOI 10.1089/ars.2008.2043
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Ma Q, 2012, PHARMACOL REV, V64, P1055, DOI 10.1124/pr.110.004333
   Magder S, 2006, CRIT CARE, V10, DOI 10.1186/cc3992
   Mathieu D, 2017, DIVING HYPERB MED, V47, P131, DOI 10.28920/dhm47.2.131 132
   Nikolova T, 2017, MUTAT RES GEN TOX EN, V822, P10, DOI 10.1016/j.mrgentox.2017.07.004
   Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200
   Qadan M, 2010, ANESTHESIOLOGY, V113, P369, DOI 10.1097/ALN.0b013e3181e19d1d
   Ross David, 2018, Current Opinion in Toxicology, V7, P67, DOI 10.1016/j.cotox.2017.10.005
   Ross D, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00595
   Rothfuss A, 2001, CARCINOGENESIS, V22, P1979, DOI 10.1093/carcin/22.12.1979
   Rothkamm K, 2015, ENVIRON MOL MUTAGEN, V56, P491, DOI 10.1002/em.21944
   Ryter SW, 2005, ANTIOXID REDOX SIGN, V7, P80, DOI 10.1089/ars.2005.7.80
   Savvidou OD, 2018, ORTHOPEDICS, V41, P193, DOI 10.3928/01477447 20180628 02
   Scherthan H, 2022, CANCERS, V14, DOI 10.3390/cancers14061545
   Scott TL, 2014, ANTIOXID REDOX SIGN, V20, P708, DOI 10.1089/ars.2013.5529
   Speit G, 2003, MUTAGENESIS, V18, P545, DOI 10.1093/mutage/geg028
   Speit G, 2002, MUTAT RES REV MUTAT, V512, P111, DOI 10.1016/S1383 5742(02)00045 5
   Speit Gunter, 2012, Methods Mol Biol, V920, P79, DOI 10.1007/978 1 61779 998 3_6
   Tillmans F, 2019, FREE RADICAL RES, V53, P522, DOI 10.1080/10715762.2019.1612890
   Tohidnezhad M, 2014, BONE, V65, P9, DOI 10.1016/j.bone.2014.04.029
   Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002
   Weber SU, 2009, APOPTOSIS, V14, P97, DOI 10.1007/s10495 008 0280 z
   Witte J, 2014, UNDERSEA HYPERBAR M, V41, P171
   Wu D, 2007, CONNECT TISSUE RES, V48, P206, DOI 10.1080/03008200701458749
   Yoshimura A, 2011, CURR TOP MICROBIOL, V350, P127, DOI 10.1007/82_2010_87
   Yoshimura A, 2010, J BIOCHEM, V147, P781, DOI 10.1093/jb/mvq043
   Zhang LJ, 2006, AUTOIMMUNITY, V39, P269, DOI 10.1080/08916930600753903
   Ziech D, 2011, MUTAT RES FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 60
TC 4
Z9 4
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD APR
PY 2023
VL 12
IS 4
AR 851
DI 10.3390/antiox12040851
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA E6EX2
UT WOS:000976463200001
PM 37107226
OA gold
DA 2025 08 17
ER

PT J
AU Kim, BH
   Bae, HC
   Wang, SY
   Jang, BS
   Chang, JH
   Chie, EK
   Yi, HS
   Kwon, J
   Han, HS
   Kim, HJ
AF Kim, Byoung Hyuck
   Bae, Hyun Cheol
   Wang, Sun Young
   Jang, Bum Sup
   Chang, Ji Hyun
   Chie, Eui Kyu
   Yi, Hyon Seung
   Kwon, Jeanny
   Han, Hyuk Soo
   Kim, Hak Jae
TI Low dose irradiation could mitigate osteoarthritis progression
   via anti inflammatory action that modulates mitochondrial
   function
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Osteoarthritis; Low dose radiotherapy; Chondrocyte; Mmp13; Gdf15
ID ADJUVANT INDUCED ARTHRITIS; RADIATION THERAPY; X IRRADIATION;
   RADIOTHERAPY; EXPRESSION; INVOLVEMENT; PATTERNS; CELLS
AB Purpose: The use of low dose radiation therapy (LDRT) for osteoarthritis (OA) are rarely implemented, except in some European regions. Its clinical effects are controversial but little is known about how LDRT affects actual disease progression. We conducted a preclinical study to reveal the potential underlying mechanisms related to its disease modifying abilities.
   Methods and Materials: Using primary cultured human chondrocytes and synovium derived cells obtained from OA patients, the effects of LDRT were measured by quantitative real time PCR, western blotting, and mRNA sequencing. For in vivo validation, a surgically induced isolated OA model was used after anterior cruciate ligament transection or surgical destabilization of the medial meniscus.
   Results: LDRT decreased the expression of pro inflammatory factor matrix metalloproteinase 13 (MMP13) in chondrocytes. By contrast, collagen type 2 (COL2) protein expression was increased. LDRT induced large transcriptomic changes in both chondrocytes/synoviocytes, especially in mitochondrial activities. Gene set variation analysis demonstrated inverted U shaped response in several categories, such as mitochondrial unfolded protein responses and extracellular matrix interactions. Growth differentiation factor 15 (GDF15), which is a mitohormetic signaling factor, was increased after LDRT and mediated the anti inflammatory effects. Aggrecan was increased in synoviocyte's medium and TNF alpha was decreased in chondrocyte's medium after LDRT. Conversely, knockdown of GDF15 did not result in decreased MMP13 expression by LDRT. Next, OA rats treated with LDRT exhibited a decreased OA severity when compared with the no irradiation group at 10 weeks post surgery (mean OARSI score 3.7 in 0 Gy, 2.8 in 0.5 Gy, and 1.8 in 1 Gy; p = 0.003). Osteoclast activity was significantly reduced in the LDRT group.
   Conclusions: Taken together, these data show that LDRT could mitigate osteoarthritis progression by exerting its anti inflammatory effects via mitochondrial function modulation. (c) 2022 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 170 (2022) 231 241
C1 [Kim, Byoung Hyuck] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Radiat Oncol, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
   [Bae, Hyun Cheol; Wang, Sun Young; Han, Hyuk Soo] Seoul Natl Univ, Dept Orthopaed Surg, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea.
   [Jang, Bum Sup] Seoul Natl Univ, Dept Radiat Oncol, Bundang Hosp, Seoul, South Korea.
   [Chang, Ji Hyun; Chie, Eui Kyu; Kim, Hak Jae] Seoul Natl Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea.
   [Yi, Hyon Seung] Chungnam Natl Univ, Sch Med, Lab Endocrinol & Immune Syst, Daejeon, South Korea.
   [Kwon, Jeanny] Chungnam Natl Univ, Dept Radiat Oncol, Coll Med, Daejeon, South Korea.
   [Kim, Hak Jae] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Chungnam
   National University; Chungnam National University; Seoul National
   University (SNU)
RP Kim, BH (通讯作者)，Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Radiat Oncol, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.; Han, HS (通讯作者)，Seoul Natl Univ, Dept Orthopaed Surg, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea.
EM karlly71@snu.ac.kr; oshawks7@snu.ac.kr
RI Han, Hyuk Soo/AAR 4112 2020; KIM, BYOUNG HYUCK/IRZ 5874 2023; Kim,
   HakJae/MHP 9197 2025; Kim, Hong/AAR 4892 2020; Yi,
   Hyon Seung/ABA 2729 2022
OI Chie, Eui Kyu/0000 0003 2027 7472; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [2018R1D1A1A02086095]; NRF  
   Korea government (Ministry of Science and ICT) [NRF2020R1F1A1073616]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2018R1D1A1A02086095 for B.H. Kim). This work was also
   supported by the NRF grants funded by the Korea government (Ministry of
   Science and ICT) (NRF2020R1F1A1073616 for E.K. Chie).
CR Abdus Salam AA, 2020, RADIAT ONCOL J, V38, P151, DOI 10.3857/roj.2020.00178
   Arenas M, 2012, STRAHLENTHER ONKOL, V188, P975, DOI 10.1007/s00066 012 0170 8
   Arenas M, 2008, RADIOTHER ONCOL, V86, P399, DOI 10.1016/j.radonc.2007.10.032
   Badakhshi Harun, 2014, Foot (Edinb), V24, P172, DOI 10.1016/j.foot.2014.07.005
   Blanco FJ, 2018, OSTEOARTHR CARTILAGE, V26, P989, DOI 10.1016/j.joca.2018.05.018
   Calabrese EJ, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105526
   Cash H, 2019, J BIOL ENG, V13, DOI 10.1186/s13036 018 0125 4
   Chung HK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17574 w
   Chung HK, 2017, J CELL BIOL, V216, P149, DOI 10.1083/jcb.201607110
   Cuttler JM, 2015, DOSE RESPONSE, V13, DOI 10.1177/1559325815615102
   Deloch L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103197
   Deloch L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01834
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Han HS, 2010, J ORTHOP RES, V28, P1283, DOI 10.1002/jor.21129
   Heyd R, 2007, STRAHLENTHER ONKOL, V183, P3, DOI 10.1007/s00066 007 1589 1
   Hildebrandt G, 2003, INT J RADIAT BIOL, V79, P993, DOI 10.1080/09553000310001636639
   Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117
   Jassal B, 2020, NUCLEIC ACIDS RES, V48, pD498, DOI 10.1093/nar/gkz1031
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Kang SG, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102181
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kriz J, 2018, ADV RADIAT ONCOL, V3, P240, DOI 10.1016/j.adro.2018.02.008
   Liebmann A, 2004, STRAHLENTHER ONKOL, V180, P165, DOI 10.1007/s00066 004 1197 2
   Liu ZJ, 2015, INT J MOL SCI, V16, P17857, DOI 10.3390/ijms160817857
   Luan HH, 2019, CELL, V178, P1231, DOI 10.1016/j.cell.2019.07.033
   Mahler EAM, 2019, ANN RHEUM DIS, V78, P83, DOI 10.1136/annrheumdis 2018 214104
   MATSUMOTO T, 1994, BONE, V15, P97, DOI 10.1016/8756 3282(94)90898 2
   Micke O, 2017, INT J RADIAT ONCOL, V98, P958, DOI 10.1016/j.ijrobp.2016.12.012
   Montero A, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis 2018 214873
   Moon JS, 2020, AGING CELL, V19, DOI 10.1111/acel.13195
   Niewald M, 2022, STRAHLENTHER ONKOL, V198, P370, DOI 10.1007/s00066 021 01866 2
   Oo WM, 2018, EXPERT OPIN EMERG DR, V23, P331, DOI 10.1080/14728214.2018.1547706
   Ott OJ, 2019, STRAHLENTHER ONKOL, V195, P285, DOI 10.1007/s00066 018 1412 1
   Ott OJ, 2014, STRAHLENTHER ONKOL, V190, P671, DOI 10.1007/s00066 014 0618 0
   Roedel F, 2002, INT J RADIAT BIOL, V78, P711, DOI 10.1080/09553000210137671
   Seegenschmiedt MH, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150080
   Toussirot E, 2017, CLIN RHEUMATOL, V36, P2531, DOI 10.1007/s10067 017 3789 0
   Wang DM, 2022, J ORTHOP SCI, V27, P249, DOI 10.1016/j.jos.2020.12.004
   Wang MN, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4133
   Weissmann T, 2021, FRONT IMMUNOL, V12, DOI [10.3389/fimmu.2021.777792777792, DOI 10.3389/FIMMU.2021.777792777792]
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Zhang D, 2020, BMC BIOINFORMATICS, V21, DOI [10.1186/s12859 020 3408 y, 10.1186/s12864 020 07251 0]
NR 43
TC 10
Z9 11
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167 8140
EI 1879 0887
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD MAY
PY 2022
VL 170
BP 231
EP 241
DI 10.1016/j.radonc.2022.02.039
EA MAY 2022
PG 11
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 3E6EG
UT WOS:000830075400032
PM 35259418
DA 2025 08 17
ER

PT J
AU Wang, HX
   Sun, DM
   Zhao, NN
   Yang, XC
   Shi, YZ
   Li, JF
   Su, ZQ
   Wei, G
AF Wang, Haixia
   Sun, Dianming
   Zhao, Nana
   Yang, Xinchao
   Shi, Yuzhou
   Li, Jingfeng
   Su, Zhiqiang
   Wei, Gang
TI Thermo sensitive graphene oxide polymer nanoparticle hybrids: synthesis,
   characterization, biocompatibility and drug delivery
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID CARBON NANOTUBES; GRAPHITE OXIDE; POLY(ETHYLENE OXIDE); CLICK CHEMISTRY;
   SHEETS; NANOCOMPOSITES; NANOSHEETS; MICELLES; RELEASE; SURFACE
AB We report the covalent interaction mediated assembly of thermo sensitive polymer nanoparticles (PNPs) on functionalized graphene oxide (GO) nanosheets to create novel GO PNP hybrids for drug delivery. To this end, thermo sensitive PNPs with an average diameter of about 50 +/  12 nm were first synthesized with the free radical polymerization reaction, and GO nanosheets were noncovalently modified with a bifunctional linker to provide reactive sites for the binding of PNPs. Finally, GO PNP hybrids were successfully synthesized by the covalent interaction mediated assembly of PNPs on GO nanosheets. Multi characterization techniques were utilized to identify the formation of PNPs, the modification of GO nanosheets, and the formation of GO PNP hybrids. Cell culture experiment with the mouse osteoblast like MC3T3 E1 cells indicates that the synthesized GO PNP hybrids have satisfactory biocompatibility. The loading efficiency of drug molecules (Adriamycin, ADR) with GO PNP (similar to 87%) is close to that with GO (similar to 91%), but significantly higher than that with PNPs (similar to 46%). The release efficiency of GO PNP hybrids with the highest surface coverage of PNPs (similar to 85 PNPs per mu m(2)) is about 22%, which is very close to that of PNPs (similar to 25%) and significantly higher than that of GO (similar to 11%). Our study indicates that this thermo sensitive GO PNP hybrid, when considering the drug loading and release comprehensively, has better performance than both PNPs and GO and thus can be used as a novel nanocarrier for temperature controllable drug release. The GO PNP hybrids with and without ADR were applied to kill cancer cells in vitro and the result shows that the GO PNP hybrid with ADR has an obvious effect on killing cancer cells, and its performance is obviously better than both GO and PNPs. It is expected that this new hybrid material based on GO and PNPs will have great potential for in vivo applications such as to kill target cancer cells by modifying with specific antibodies.
C1 [Wang, Haixia; Sun, Dianming; Zhao, Nana; Yang, Xinchao; Shi, Yuzhou; Li, Jingfeng; Su, Zhiqiang] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
   [Li, Jingfeng; Wei, Gang] Univ Bremen, Fac Prod Engn, Hybrid Mat Interface Grp, D 28359 Bremen, Germany.
C3 Beijing University of Chemical Technology; University of Bremen
RP Su, ZQ (通讯作者)，Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
EM suzq@mail.buct.edu.cn; wei@uni bremen.de
RI ; Sun, Dianming/H 8412 2016; Su, Zhiqiang/B 1781 2015; Wang,
   Haixia/AAY 8142 2020; Li, Jiangyu/B 3191 2008; Wei, Gang/C 8747 2011
OI Wei, Gang/0000 0002 9503 7951; Sun, Dianming/0000 0002 8128 9517; Wang,
   Haixia/0000 0002 5782 8242; Wei, Gang/0000 0002 3838 8659
FU Fundamental Research Funds for the Central Universities [ZZ1307];
   Beijing New Star Program of Science and Technology [2009B10]; German
   Academic Exchange Council (DAAD); China Scholarship Council (CSC)
FX We acknowledge the financial supports from the Fundamental Research
   Funds for the Central Universities (Project no. ZZ1307) and the Beijing
   New Star Program of Science and Technology (Grant no. 2009B10). We would
   like to thank the financial supports of the German Academic Exchange
   Council (DAAD) short term scholarship and the China Scholarship Council
   (CSC) PhD scholarship. The kind assistance of cell experiments by Prof.
   F. J. Xu and Prof. Q. Cai (BUCT) is greatly appreciated.
CR Bai H, 2010, CHEM COMMUN, V46, P2376, DOI 10.1039/c000051e
   Bao HQ, 2011, SMALL, V7, P1569, DOI 10.1002/smll.201100191
   Bao HQ, 2010, MACROMOLECULES, V43, P5679, DOI 10.1021/ma100894p
   Becerril HA, 2008, ACS NANO, V2, P463, DOI 10.1021/nn700375n
   Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109
   Chang YL, 2011, TOXICOL LETT, V200, P201, DOI 10.1016/j.toxlet.2010.11.016
   Chen CM, 2009, ADV MATER, V21, P3007, DOI 10.1002/adma.200803726
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   Chung JE, 1999, J CONTROL RELEASE, V62, P115, DOI 10.1016/S0168 3659(99)00029 2
   Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Griffith LG, 2000, ACTA MATER, V48, P263, DOI 10.1016/S1359 6454(99)00299 2
   HESKINS M, 1968, J MACROMOL SCI CHEM, V2, DOI DOI 10.1080/10601326808051910
   Hong CY, 2005, CHEM MATER, V17, P2247, DOI 10.1021/cm048054l
   Jin HJ, 2002, BIOMACROMOLECULES, V3, P1233, DOI 10.1021/bm025581u
   Jung I, 2008, J PHYS CHEM C, V112, P20264, DOI 10.1021/jp807525d
   Kim JH, 2002, BIOMATERIALS, V23, P2015, DOI 10.1016/S0142 9612(01)00330 1
   Kopelevich Y, 2007, ADV MATER, V19, P4559, DOI 10.1002/adma.200702051
   Kudin KN, 2008, NANO LETT, V8, P36, DOI 10.1021/nl071822y
   Lee SH, 2010, MACROMOL RAPID COMM, V31, P281, DOI 10.1002/marc.200900641
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li GY, 2008, J POLYM SCI POL CHEM, V46, P5028, DOI 10.1002/pola.22831
   Li SS, 2010, ACS NANO, V4, P3169, DOI 10.1021/nn100551j
   Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878
   Li ZF, 2004, J COLLOID INTERF SCI, V269, P62, DOI 10.1016/S0021 9797(03)00606 4
   Liu GL, 2006, NAT NANOTECHNOL, V1, P47, DOI [10.1038/nnano.2006.51, 10.1038/nnano.2006.170]
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Liu Z, 2007, ACS NANO, V1, P50, DOI 10.1021/nn700040t
   Lv X, 2009, SMALL, V5, P1682, DOI 10.1002/smll.200900044
   Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368
   Mortisen D, 2010, BIOMACROMOLECULES, V11, P1261, DOI 10.1021/bm100046n
   Pan YZ, 2011, ADV FUNCT MATER, V21, P2754, DOI 10.1002/adfm.201100078
   Pasricha R, 2009, SMALL, V5, P2253, DOI 10.1002/smll.200900726
   Putz KW, 2010, ADV FUNCT MATER, V20, P3322, DOI 10.1002/adfm.201000723
   Shi YM, 2009, SMALL, V5, P2005, DOI 10.1002/smll.200900294
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Stankovich S, 2006, NATURE, V442, P282, DOI 10.1038/nature04969
   Sun XM, 2008, NANO RES, V1, P203, DOI 10.1007/s12274 008 8021 8
   Wang CY, 2009, CHEM MATER, V21, P2604, DOI 10.1021/cm900764n
   Wang HX, 2013, RSC ADV, V3, P9304, DOI 10.1039/c3ra40997j
   Wang K, 2011, NANOSCALE RES LETT, V6, DOI 10.1007/s11671 010 9751 6
   Wei G, 2012, J MATER CHEM, V22, P17190, DOI 10.1039/c2jm32979d
   Wei G, 2010, CARBON, V48, P645, DOI 10.1016/j.carbon.2009.10.006
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Yang XY, 2008, J PHYS CHEM C, V112, P17554, DOI 10.1021/jp806751k
   Yang XY, 2009, J MATER CHEM, V19, P2710, DOI 10.1039/b821416f
   Zhang PP, 2013, J MATER CHEM B, V1, P6525, DOI 10.1039/c3tb21270j
   Zhuang XD, 2010, ADV MATER, V22, P1731, DOI 10.1002/adma.200903469
NR 48
TC 76
Z9 77
U1 1
U2 107
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2014
VL 2
IS 10
BP 1362
EP 1370
DI 10.1039/c3tb21538e
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AC0QN
UT WOS:000332199900009
PM 32261451
DA 2025 08 17
ER

PT J
AU Yuan, XY
   Ren, ZY
   Wu, YQ
   Bougault, C
   Brizuela, L
   Magne, D
   Buchet, R
   Mebarek, S
AF Yuan, Xiao Yu
   Ren, Zhongyuan
   Wu, Yuqing
   Bougault, Carole
   Brizuela, Leyre
   Magne, David
   Buchet, Rene
   Mebarek, Saida
TI Design, synthesis and biological evaluation of inhibitors of cathepsin K
   on dedifferentiated chondrocytes
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Azanitrile; Cathepsin K inhibitors; Chondrocyte; Dedifferentiation;
   Osteoarthritis
ID AZADIPEPTIDE NITRILE INHIBITORS; HUMAN ARTICULAR CHONDROCYTES; CARTILAGE
   FORMATION; HIGHLY POTENT; OSTEOPOROSIS; EXPRESSION; ODANACATIB;
   REDIFFERENTIATION; DEGENERATION; QUANTITIES
AB Selective proteinase inhibitors have demonstrated utility in the investigation of cartilage degeneration mechanisms and may have clinical use in the management of osteoarthritis. The cysteine protease cathepsin K (CatK) is an attractive target for arthritis therapy. Here we report the synthesis of two cathepsin K inhibitors (CKIs): racemic azanitrile derivatives CKI E and CKI F, which have better inhibition properties on CatK than the commercial inhibitor odanacatib (ODN). Their IC50 values and inhibition constants (K i) have been determined in vitro. Inhibitors demonstrate differential selectivity for CatK over cathepsin B, L and S in vitro, with Ki amounting to 1.14 and 7.21 nM respectively. We analyzed the effect of these racemic inhibitors on viability in different cell types. The human osteoblast like cell line MG63, MOVAS cells (a murine vascular smooth muscle cell line) or murine primary chondrocytes, were treated either with CKI E or with CKI F, which were not toxic at doses of up to 5 mu M. Primary chondrocytes subjected to several passages were used as a model of phenotypic loss of articular chondrocytes, occurring in osteoarthritic cartilage. The efficiency of CKIs regarding CatK inhibition and their specificity over other proteases were validated in primary chondrocytes subjected to several passages. Racemic CKI E and CKI F at 0.1 and 1 mu M significantly inhibited CatK activity in dedifferentiated chondrocytes, even better than the commercial CatK inhibitor ODN. The enzymatic activity of other proteases such as matrix metalloproteinases or aggrecanases were not affected. Taken together, these findings support the possibility to design CatK inhibitors for preventing cartilage degradation in different pathologies.
C1 [Yuan, Xiao Yu; Ren, Zhongyuan; Wu, Yuqing] Jilin Univ, State Key Lab Supramol Struct & Mat, Changchun 130012, Jilin, Peoples R China.
   [Bougault, Carole; Brizuela, Leyre; Magne, David; Buchet, Rene; Mebarek, Saida] Univ Claude Bernard Lyon 1, Univ Lyon, CNRS, ICBMS,UMR 5246, F 69622 Lyon, France.
   [Yuan, Xiao Yu] Henan Agr Univ, Coll Food Sci & Technol, Zhengzhou 450002, Henan, Peoples R China.
C3 Jilin University; Centre National de la Recherche Scientifique (CNRS);
   CNRS   Institute of Chemistry (INC); Institut National des Sciences
   Appliquees de Lyon   INSA Lyon; Universite Claude Bernard Lyon 1; Henan
   Agricultural University
RP Mebarek, S (通讯作者)，Univ Lyon 1, ICMBS, CNRS, UMR 5246, Batiment Raulin,43 Blvd 11 Novembre 1918, F 69622 Villeurbanne, France.
EM saida.mebarek@univ lyon1.fr
RI ; Mebarek, Saida/AAI 8237 2020; Rene, Buchet/I 9781 2019
OI Bougault, Carole/0000 0002 3221 0585; Buchet, Rene/0000 0002 7966 3856;
   Mebarek, Saida/0000 0001 8806 8904; /0000 0001 5227 8811; Yuan,
   Xiaoyu/0000 0002 1126 818X; Magne, David/0000 0002 6511 9390
FU NSFC [21373101]; National Student Fund Committee; PHC Cai Yuanpei
   [32065TD]
FX Yuqing Wu appreciates the financial support from the projects of NSFC
   (No. 21373101); Xiaoyu Yuan and Zhongyuan Ren appreciate the supports
   from National Student Fund Committee. The China France cooperation
   project was funded by PHC Cai Yuanpei (Project N 32065TD).
CR Ashraf S, 2016, OSTEOARTHR CARTILAGE, V24, P196, DOI 10.1016/j.joca.2015.07.008
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bourgoin SG, 2010, CURR OPIN INVEST DR, V11, P515
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Caron MMJ, 2012, OSTEOARTHR CARTILAGE, V20, P1170, DOI 10.1016/j.joca.2012.06.016
   Claus S, 2012, TISSUE ENG PART C ME, V18, P104, DOI [10.1089/ten.tec.2011.0259, 10.1089/ten.TEC.2011.0259]
   Connor JR, 2009, OSTEOARTHR CARTILAGE, V17, P1236, DOI 10.1016/j.joca.2009.03.015
   Cournil Henrionnet C, 2008, BIORHEOLOGY, V45, P513, DOI 10.3233/BIR 2008 0487
   Dancevic CM, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0429 9
   DOLBEARE FA, 1977, CLIN CHEM, V23, P1485
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   El Bakali J, 2014, FUTURE MED CHEM, V6, P1399, DOI [10.4155/FMC.14.84, 10.4155/fmc.14.84]
   Frizler M, 2011, CHEM EUR J, V17, P11419, DOI 10.1002/chem.201101350
   Frizler M, 2011, J MED CHEM, V54, P396, DOI 10.1021/jm101272p
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Jerome C, 2012, OSTEOPOROSIS INT, V23, P339, DOI 10.1007/s00198 011 1593 2
   Johnson VL, 2014, BEST PRACT RES CL RH, V28, P5, DOI 10.1016/j.berh.2014.01.004
   Kaupp G, 2003, CHEM EUR J, V9, P4156, DOI 10.1002/chem.200304793
   Konttinen YT, 2002, ARTHRITIS RHEUM, V46, P953, DOI 10.1002/art.10185
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Li WA, 2010, ANAL BIOCHEM, V401, P91, DOI 10.1016/j.ab.2010.02.035
   Lindström E, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1497 4
   Löser R, 2008, ANGEW CHEM INT EDIT, V47, P4331, DOI 10.1002/anie.200705858
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Malemud CJ, 2017, PROG MOL BIOL TRANSL, V148, P305, DOI 10.1016/bs.pmbts.2017.03.003
   McDougall JJ, 2010, OSTEOARTHR CARTILAGE, V18, P1355, DOI 10.1016/j.joca.2010.07.014
   Mead TJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.92941
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mueller MB, 2011, PM&R, V3, pS3, DOI 10.1016/j.pmrj.2011.05.009
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Novinec M, 2013, BIOL CHEM, V394, P1163, DOI 10.1515/hsz 2013 0134
   Novinec M, 2010, BIOCHEM J, V429, P379, DOI 10.1042/BJ20100337
   Rai V, 2017, J BIOMED MATER RES A, V105, P2343, DOI 10.1002/jbm.a.36087
   Ren XF, 2013, ORG BIOMOL CHEM, V11, P1143, DOI 10.1039/c2ob26624e
   Ren ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132513
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Schmitz J, 2014, ACS MED CHEM LETT, V5, P1076, DOI 10.1021/ml500238q
   Schulze Tanzil G, 2004, OSTEOARTHR CARTILAGE, V12, P448, DOI 10.1016/j.joca.2004.02.007
   Schulze Tanzil G, 2002, CELL TISSUE RES, V308, P371, DOI 10.1007/s00441 002 0562 7
   Stoch SA, 2013, BRIT J CLIN PHARMACO, V75, P1240, DOI 10.1111/j.1365 2125.2012.04471.x
   Tanaka M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1625 y
   Toth Marta, 2012, Methods Mol Biol, V878, P121, DOI [10.1385/1 59259 136 1:163, 10.1007/978 1 61779 854 2_8]
   Wang ZH, 2010, BIOTECHNOL BIOENG, V107, P730, DOI 10.1002/bit.22862
   Xie XW, 2017, CHEMMEDCHEM, V12, P1157, DOI 10.1002/cmdc.201700349
   Yang PY, 2012, CHEM EUR J, V18, P6528, DOI 10.1002/chem.201103322
   Yuan XY, 2013, ORG BIOMOL CHEM, V11, P5847, DOI 10.1039/c3ob41165f
   Zaucke F, 2001, BIOCHEM J, V358, P17, DOI 10.1042/0264 6021:3580017
   Zhang Y, 2012, BIOMATERIALS, V33, P7394, DOI 10.1016/j.biomaterials.2012.06.070
   Zhao JX, 2014, J BIOMED MATER RES A, V102, P373, DOI 10.1002/jbm.a.34711
NR 52
TC 6
Z9 7
U1 2
U2 20
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAR 15
PY 2019
VL 27
IS 6
BP 1034
EP 1042
DI 10.1016/j.bmc.2019.02.003
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA HQ5US
UT WOS:000462478700011
PM 30773420
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Chu, MD
   Ji, JN
   Cao, WH
   Zhang, HJ
   Meng, D
   Xie, BR
   Xu, SY
AF Chu, Mengdi
   Ji, Jiani
   Cao, Wenhao
   Zhang, Huojun
   Meng, Dan
   Xie, Bangruan
   Xu, Shuyun
TI Cyclic peptide *CRRETAWAC* attenuates fibronectin induced cytokine
   secretion of human airway smooth muscle cells by inhibiting FAK and p38
   MAPK
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE asthma; fibronectin; airway smooth muscle; integrin alpha 5 beta 1
ID EXTRACELLULAR MATRIX; OSTEOBLAST DIFFERENTIATION; MEDIATE ENHANCEMENT;
   THERAPEUTIC TARGETS; LIGAND BINDING; INTEGRIN; PROLIFERATION; ASTHMA;
   COLLAGEN; ALPHA 5 BETA 1
AB alpha 5 beta 1 integrin is highly expressed in airway smooth muscle cells and mediate the adhesion of airway smooth muscle cells to fibronectin to regulate airway remodelling in asthma. This study aimed to investigate the effects of synthetic cyclic peptide *CRRETAWAC* on fibronectin induced cytokine secretion of airway smooth muscle cells and the underlying mechanism. Human airway smooth muscle cells were isolated and treated with fibronectin, IL 13, *CRRETAWAC* peptide, 51 integrin blocking antibody, FAK inhibitor or p38 MAPK inhibitor. The transcription and secretion of eotaxin 1 and RANTES were detected by real time PCR and ELISA, respectively. The phosphorylation of FAK and MAPKs including p38, ERK1/2 and JNK1/2 was detected by Western blot analysis. The transcription and secretion of eotaxin 1 and RANTES increased in airway smooth muscle cells cultured in fibronectin coated plates. However, 51 integrin blocking antibody, *CRRETAWAC* peptide, FAK inhibitor or p38 MAPK inhibitor significantly reduced mRNA levels and the secretion of eotaxin 1 and RANTES in airway smooth muscle cells cultured in fibronectin coated plates. In addition, the phosphorylation of FAK and p38 MAPK was significantly increased in airway smooth muscle cells cultured in fibronectin coated plates compared to the cells cultured in uncoated plates and was significantly reduced in airway smooth muscle cells treated with *CRRETAWAC* peptide. Fibronectin induces cytokine synthesis and secretion of airway smooth muscle cells. Peptide *CRRETAWAC* antagonizes fibronectin induced cytokine synthesis and secretion of airway smooth muscle cells via the inhibition of FAK and p38 MAPK, and is a potential agent for the therapy of asthma.
C1 [Chu, Mengdi; Ji, Jiani; Cao, Wenhao; Zhang, Huojun; Meng, Dan; Xu, Shuyun] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan, Hubei, Peoples R China.
   [Chu, Mengdi] Lihuili Hosp, Ningbo Med Treatment Ctr, Ningbo, Zhejiang, Peoples R China.
   [Xie, Bangruan] Wuhan Med Treatment Ctr, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Xu, SY (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Resp & Crit Care Med, Wuhan, Hubei, Peoples R China.
EM sxu@hust.edu.cn
RI cao, wenhao/ISS 8650 2023; Xu, Shuyun/G 7081 2014
OI xu, shuyun/0000 0002 2647 754X
FU National Natural Science Foundation of China [81370134, 30500223];
   Natural Science Foundation of Hubei Province of China [2012FFB02422];
   Wuhan Science and Technology Bureau of China [2014060101010035]
FX This study was supported by grants from National Natural Science
   Foundation of China (No. 81370134 and No. 30500223) and Natural Science
   Foundation of Hubei Province of China (No. 2012FFB02422) and Wuhan
   Science and Technology Bureau of China (No. 2014060101010035).
CR Araujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807
   AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014 5793(90)80159 G
   Chan V, 2006, AM J RESP CRIT CARE, V174, P379, DOI 10.1164/rccm.200509 1420OC
   Cox D, 2010, NAT REV DRUG DISCOV, V9, P804, DOI 10.1038/nrd3266
   Dekkers BGJ, 2007, AM J PHYSIOL LUNG C, V292, pL1405, DOI 10.1152/ajplung.00331.2006
   Dekkers BGJ, 2013, J PHARMACOL EXP THER, V346, P86, DOI 10.1124/jpet.113.203042
   Dekkers BGJ, 2010, AM J RESP CRIT CARE, V181, P556, DOI 10.1164/rccm.200907 1065OC
   Dudash LA, 2014, J BIOMED MATER RES A, V102, P2857, DOI 10.1002/jbm.a.34960
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002
   Horton ER, 2016, J CELL SCI, V129, P4159, DOI 10.1242/jcs.192054
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312
   Klagas I, 2009, EUR RESPIR J, V34, P616, DOI 10.1183/09031936.00070808
   KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373
   Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664
   Nguyen TTB, 2005, AM J RESP CRIT CARE, V171, P217, DOI 10.1164/rccm.200408 1046OC
   Oenema TA, 2013, AM J RESP CELL MOL, V49, P18, DOI 10.1165/rcmb.2012 0261OC
   Peng Q, 2005, J IMMUNOL, V174, P2258, DOI 10.4049/jimmunol.174.4.2258
   Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200
   Saglani S, 2015, EUR RESPIR J, V46, P1796, DOI 10.1183/13993003.01196 2014
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Tran T, 2007, CAN J PHYSIOL PHARM, V85, P666, DOI 10.1139/Y07 050
   Wright DB, 2014, TRENDS PHARMACOL SCI, V35, P23, DOI 10.1016/j.tips.2014.09.006
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xu SY, 2004, CHINESE MED J PEKING, V117, P30
NR 26
TC 1
Z9 1
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2017
VL 21
IS 10
BP 2535
EP 2541
DI 10.1111/jcmm.13174
PG 7
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FI3OV
UT WOS:000411875400026
PM 28402030
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU French, HP
   Cunningham, J
   Bennett, K
   Cadogan, CA
   Clyne, B
   Doyle, F
   Moriarty, F
   Ryan, JM
   Smith, SM
   Passos, VL
AF French, H. P.
   Cunningham, J.
   Bennett, K.
   Cadogan, C. A.
   Clyne, B.
   Doyle, F.
   Moriarty, F.
   Ryan, J. M.
   Smith, S. M.
   Passos, V. Lima
TI Patterns of pain medication usage and self reported pain in older Irish
   adults with osteoarthritis: A latent class analysis of data from the
   Irish Longitudinal Study on Ageing
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Osteoarthritis; Medications; Pain; Latent class analysis; Clinical
   guidelines
ID KNEE OSTEOARTHRITIS; SLEEP DISTURBANCE; PHYSICAL ACTIVITY; HIP
   OSTEOARTHRITIS; AMERICAN COLLEGE; GLOBAL BURDEN; RATED HEALTH;
   PRIMARY CARE; MANAGEMENT; DEPRESSION
AB BackgroundThis study aimed to identify and describe links between pain medication use and self reported pain among people aged >= 50 years with osteoarthritis (OA) in an Irish population, and to examine the relationships between pain, medication usage and socioeconomic and clinical characteristics.MethodsSecondary data analysis of wave 1 cross sectional data from The Irish Longitudinal Study on Ageing (TILDA) was undertaken of 1042 people with self reported doctor diagnosed OA. We examined use of medications typically included in OA clinical guidelines, including non opioid analgesics (e.g. paracetamol), topical and oral non steroidal anti inflammatory drugs (NSAIDs), opioids and nutraceuticals. Latent Class Analysis (LCA) was used to identify underlying clinical subgroups based on medication usage patterns, and self reported pain severity. Multinomial logistic regression was used to explore sociodemographic and clinical characteristic links to latent class membership.ResultsA total of 358 (34.4%) of the 1042 people in this analysis were taking pain medications including oral NSAIDs (17.5%), analgesics (11.4%) and opioids (8.7%). Nutraceutical (glucosamine/chondroitin) use was reported by 8.6% and topical NSAID use reported by 1.4%. Three latent classes were identified: (1) Low medication use/no pain (n = 382, 37%), (2) low medication use/moderate pain (n = 523, 50%) and (3) moderate medication use/high pain (n = 137, 13%). Poorer self rated health and greater sleep disturbance were associated with classes 2 and 3; depressive symptoms and female gender were associated with class 2, and retirement associated with class 3.ConclusionsWhilst pain medication use varied with pain severity, different medication types reported broadly aligned with OA guidelines. The two subgroups exhibiting higher pain levels demonstrated poorer self rated health and greater sleep disturbance.
   Latent class analysis identified different subgroups based on pain severity and pain medication use, which may help to identify more targeted individualised pain management interventions.
C1 [French, H. P.; Cunningham, J.; Ryan, J. M.] Univ Med & Hlth Sci, Royal Coll Surg Ireland RCSI, Sch Physiotherapy, Dublin, Ireland.
   [Bennett, K.] RCSI Univ Med & Hlth Sci, Sch Populat Hlth, Data Sci Ctr, Dublin, Ireland.
   [Cadogan, C. A.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland.
   [Clyne, B.] RCSI Univ Med & Hlth Sci, Dept Publ Hlth & Epidemiol, Dublin, Ireland.
   [Doyle, F.] RCSI Univ Med & Hlth Sci, Sch Populat Hlth, Dept Hlth Psychol, Dublin, Ireland.
   [Moriarty, F.; Passos, V. Lima] RCSI Univ Med & Hlth Sci, Sch Pharm & Biomol Sci, Dublin, Ireland.
   [Moriarty, F.] Trinity Coll Dublin, Irish Longitudinal Study Ageing, Dublin, Ireland.
   [Smith, S. M.] Trinity Coll Dublin, Sch Med, Discipline Publ Hlth & Primary Care, Dublin, Ireland.
C3 Royal College of Surgeons   Ireland; Trinity College Dublin; Trinity
   College Dublin; Trinity College Dublin
RP French, HP (通讯作者)，Univ Med & Hlth Sci, Royal Coll Surg Ireland RCSI, Sch Physiotherapy, Dublin, Ireland.
EM hfrench@rcsi.ie
RI ; Lima Passos, Valeria/AFT 1000 2022; Moriarty, Frank/L 3180 2014;
   French, Helen/E 3401 2012; Smith, Susan/D 1872 2012
OI Lima Passos, Valeria/0000 0003 0580 6639; Moriarty,
   Frank/0000 0001 9838 3625; Clyne, Barbara/0000 0002 1186 9495
FU Health Research Board Ireland Investigator Led Project Award
   [ILP HSR 2019 012]
FX Health Research Board Ireland Investigator Led Project Award
   [ILP HSR 2019 012].
CR Al Omari B, 2021, PATIENT PREFER ADHER, V15, P197, DOI 10.2147/PPA.S287322
   Allen KD, 2008, J RHEUMATOL, V35, P1102
   [Anonymous], 2014, OSTEOARTHRITIS CARE
   Atiquzzaman M, 2019, ARTHRITIS RHEUMATOL, V71, P1835, DOI 10.1002/art.41027
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Barkin RL, 2010, DRUG AGING, V27, P775, DOI 10.2165/11539430 000000000 00000
   Barlow JH, 1998, BRIT J RHEUMATOL, V37, P985
   Bath PA, 1999, J GERONTOL A BIOL, V54, pM565, DOI 10.1093/gerona/54.11.M565
   Bichsel D, 2022, ARCH PHYS MED REHAB, V103, P559, DOI 10.1016/j.apmr.2021.07.801
   Blamey R, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 137
   Boyd C, 2019, J AM GERIATR SOC, V67, P665, DOI 10.1111/jgs.15809
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   da Costa BR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003115.pub4
   Dell'Isola A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1286 2
   EWING JA, 1984, JAMA J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905
   Fallach N, 2021, RHEUMATOL THER, V8, P1129, DOI 10.1007/s40744 021 00329 5
   Fayet M, 2021, PAIN MANAG, V11, DOI 10.2217/pmt 2020 0055
   Ferreira GE, 2021, BMJ BRIT MED J, V372, DOI 10.1136/bmj.m4825
   Finan PH, 2013, J PAIN, V14, P1539, DOI 10.1016/j.jpain.2013.08.007
   Fraenkel L, 2008, PATIENT, V1, P21, DOI 10.2165/01312067 200801010 00005
   French HP, 2016, EUR J PUBLIC HEALTH, V26, P192, DOI 10.1093/eurpub/ckv109
   Halford C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471 2458 12 1103
   Hall M, 2021, SEMIN ARTHRITIS RHEU, V51, P1023, DOI 10.1016/j.semarthrit.2021.07.007
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Joseph Gabby B, 2019, Osteoarthr Cartil Open, V1, P100006, DOI 10.1016/j.ocarto.2019.100006
   Kearney PM, 2011, INT J EPIDEMIOL, V40, P877, DOI 10.1093/ije/dyr116
   Kingsbury SR, 2014, RHEUMATOLOGY, V53, P937, DOI 10.1093/rheumatology/ket463
   Kingsbury SR, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4286
   Kingsbury Sarah R, 2012, Prim Health Care Res Dev, V13, P373, DOI 10.1017/S1463423612000072
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Kraus VB, 2019, MED SCI SPORT EXER, V51, P1324, DOI 10.1249/MSS.0000000000001944
   Laba TL, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 160
   Leech RD, 2019, BRIT J SPORT MED, V53, P806, DOI 10.1136/bjsports 2017 098051
   Leopoldino AO, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013273
   Majeed MH, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0794 5
   Marcum ZA, 2011, PAIN MED, V12, P1628, DOI 10.1111/j.1526 4637.2011.01249.x
   McDowell CP, 2018, EXP GERONTOL, V112, P68, DOI 10.1016/j.exger.2018.09.004
   Milder TY, 2011, ARTHRIT CARE RES, V63, P1280, DOI 10.1002/acr.20514
   Muckelt Paul Edward, 2020, J Comorb, V10, p2235042X20920456, DOI 10.1177/2235042X20920456
   nice, The Care and Management of Osteoarthritis in Adults
   O'Neill A, 2021, EUR J PAIN, DOI 10.1002/ejp.1714
   O'Neill TW, 2018, CURR OSTEOPOROS REP, V16, P611, DOI 10.1007/s11914 018 0477 1
   Overton C, 2022, RHEUM DIS CLIN N AM, V48, P637, DOI 10.1016/j.rdc.2022.03.009
   Parmelee PA, 2015, ARTHRIT CARE RES, V67, P358, DOI 10.1002/acr.22459
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Pickering ME, 2016, PAIN PRACT, V16, P237, DOI 10.1111/papr.12271
   Power JD, 2005, ARTHRIT RHEUM ARTHR, V53, P911, DOI 10.1002/art.21584
   Qato DM, 2009, J GERONTOL B PSYCHOL, V64, pI86, DOI 10.1093/geronb/gbp036
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Richardson J, 2009, WOMENS HEALTH, V5, P79, DOI 10.2217/17455057.5.1.79
   Riddle DL, 2013, ARTHRIT CARE RES, V65, P169, DOI 10.1002/acr.21661
   Rillo O, 2016, JCR J CLIN RHEUMATOL, V22, P345, DOI 10.1097/RHU.0000000000000449
   Riordan DO, 2017, BRIT J CLIN PHARMACO, V83, P1521, DOI 10.1111/bcp.13233
   Rosen IM, 2019, J CLIN SLEEP MED, V15, P1671, DOI 10.5664/jcsm.8062
   Safiri S, 2020, ANN RHEUM DIS, V79, P819, DOI 10.1136/annrheumdis 2019 216515
   Sale JEM, 2006, ARTHRIT RHEUM ARTHR, V55, P272, DOI 10.1002/art.21853
   Sharma A, 2016, OPEN ACCESS RHEUMATO, V8, P103, DOI 10.2147/OARRR.S93516
   Sinha P, 2021, CRIT CARE MED, V49, pE63, DOI 10.1097/CCM.0000000000004710
   Smith MT, 2009, CURR PAIN HEADACHE R, V13, P447, DOI 10.1007/s11916 009 0073 2
   Smith TO, 2018, MUSCULOSKELET CARE, V16, P450, DOI 10.1002/msc.1359
   Stubbs B, 2016, AGE AGEING, V45, P228, DOI 10.1093/ageing/afw001
   Swain S, 2020, ARTHRIT CARE RES, V72, P991, DOI 10.1002/acr.24008
   Thorlund JB, 2020, OSTEOARTHR CARTILAGE, V28, P146, DOI 10.1016/j.joca.2019.10.004
   Topinková E, 2012, DRUG AGING, V29, P477, DOI 10.2165/11632400 000000000 00000
   Tugwell PS, 2004, J RHEUMATOL, V31, P2002
   van Spil WE, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2143 0
   Vina ER, 2019, OSTEOARTHR CARTILAGE, V27, P1018, DOI 10.1016/j.joca.2019.01.010
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
   Wang ST, 2022, NEUROPSYCH DIS TREAT, V18, P375, DOI 10.2147/NDT.S346183
   Weller BE, 2020, J BLACK PSYCHOL, V46, P287, DOI 10.1177/0095798420930932
   Whelan BJ, 2013, J AM GERIATR SOC, V61, pS265, DOI 10.1111/jgs.12199
   Wilcox S, 2000, J AM GERIATR SOC, V48, P1241, DOI 10.1111/j.1532 5415.2000.tb02597.x
   Williams D, 2005, EUR J CLIN PHARMACOL, V61, P127, DOI 10.1007/s00228 004 0876 3
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600 0447.1983.tb09716.x
NR 77
TC 0
Z9 0
U1 2
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD OCT 2
PY 2024
VL 25
IS 1
AR 773
DI 10.1186/s12891 024 07854 8
PG 15
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA I0D0C
UT WOS:001327035900001
PM 39358713
OA gold
DA 2025 08 17
ER

PT J
AU Borcherding, K
   Marx, D
   Gätjen, L
   Bormann, N
   Wildemann, B
   Specht, U
   Salz, D
   Thiel, K
   Grunwald, I
AF Borcherding, Kai
   Marx, Dennis
   Gaetjen, Linda
   Bormann, Nicole
   Wildemann, Britt
   Specht, Uwe
   Salz, Dirk
   Thiel, Karsten
   Grunwald, Ingo
TI Burst Release of Antibiotics Combined with Long Term Release of Silver
   Targeting Implant Associated Infections: Design, Characterization and
   in vitro Evaluation of Novel Implant Hybrid Surface
SO MATERIALS
LA English
DT Article
DE implant associated infection; silver; gentamicin; osseointegration;
   titanium; surface coating; orthopedics; release
ID PERIPROSTHETIC INFECTION; COATED MEGAPROSTHESES; GENTAMICIN; TIBIA;
   ANTIBACTERIAL; OSTEOMYELITIS; BENEFIT; TRAUMA; FUTURE
AB Implant associated infections represent a serious risk in human medicine and can lead to complications, revisions and in worst cases, amputations. To target these risks, the objective was to design a hybrid implant surface that allows a local burst release of antibiotics combined with long term antimicrobial activity based on silver. The efficacy should be generated with simultaneous in vitro cytocompatibility. The investigations were performed on titanium K wires and plates and gentamicin was selected as an illustrative antibiotic. A gentamicin depot (max 553 mu g/cm(2)) was created on the surface using laser structuring. The antibiotic was released within 15 min in phosphate buffered saline (PBS) or agar medium. Metallic silver particles (4 mu g/cm(2)) in a titanium dioxide layer were deposited using plasma vapor deposition (PVD). About 16% of the silver was released within 28 days in the agar medium. The local efficacy of the incorporated silver was demonstrated in a direct contact assay with a reduction of more than 99.99% (Escherichia coli). The local efficacy of the hybrid surface was confirmed in a zone of inhibition (ZOI) assay using Staphylococcus cohnii. The biocompatibility of the hybrid surface was proven using fibroblasts and osteoblasts as cell systems. The hybrid surface design seems to be promising as treatment of implant associated infections, considering the achieved amount and release behavior of the active ingredients (gentamicin, silver). The generated in vitro results (efficacy, biocompatibility) proofed the concept. Further in vivo studies will be necessary translate the hybrid surface towards clinical applied research.
C1 [Borcherding, Kai; Marx, Dennis; Gaetjen, Linda; Specht, Uwe; Salz, Dirk; Thiel, Karsten] Fraunhofer Inst Mfg Technol & Adv Mat IFAM, Dept Adhes Bonding Technol & Surfaces, D 28359 Bremen, Germany.
   [Bormann, Nicole; Wildemann, Britt] Charite Univ Med Berlin, BIH Ctr Regenerat Therapies, Julius Wolff Inst, D 13353 Berlin, Germany.
   [Bormann, Nicole; Wildemann, Britt] Free Univ Berlin, D 13353 Berlin, Germany.
   [Bormann, Nicole; Wildemann, Britt] Humboldt Univ, D 13353 Berlin, Germany.
   [Bormann, Nicole; Wildemann, Britt] Berlin Inst Hlth, D 13353 Berlin, Germany.
   [Wildemann, Britt] Univ Hosp Jena, Dept Trauma Hand & Reconstruct Surg, Expt Trauma Surg, D 07747 Jena, Germany.
   [Grunwald, Ingo] Hsch Bremen City Univ Appl Sci, Ind & Environm Biol, Neustadswall 30, D 28199 Bremen, Germany.
C3 Fraunhofer Gesellschaft; Fraunhofer Germany; Fraunhofer Manufacturing
   Technology & Advanced Materials Bremen; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free
   University of Berlin; Humboldt University of Berlin; Humboldt University
   of Berlin; Free University of Berlin; Charite Universitatsmedizin
   Berlin; Berlin Institute of Health; Friedrich Schiller University of
   Jena; Bremen University of Applied Sciences
RP Borcherding, K (通讯作者)，Fraunhofer Inst Mfg Technol & Adv Mat IFAM, Dept Adhes Bonding Technol & Surfaces, D 28359 Bremen, Germany.
EM kai.borcherding@ifam.fraunhofer.de; Dennis.Marx@ifam.fraunhofer.de;
   Linda.Gaetjen@ifam.fraunhofer.de; Nicole.bormann@charite.de;
   Britt.Wildemann@med.uni jena.de; Uwe.Specht@ifam.fraunhofer.de;
   Dirk.Salz@ifam.fraunhofer.de; Karsten.Thiel@ifam.fraunhofer.de;
   i.grunwald@hs bremen.de
RI Wildemann, Britt/G 7732 2012; Borcherding, Kai/I 9866 2018; Grunwald,
   Ingo/C 5662 2012
OI Wildemann, Britt/0000 0002 8365 1188; Borcherding,
   Kai/0000 0001 6479 0257; Bormann, Nicole/0000 0001 8050 437X; Grunwald,
   Ingo/0000 0001 8267 2182
FU Federal Ministry of Education and Research, Germany [03VP03681,
   03VP03682]
FX This work was funded by the Federal Ministry of Education and Research,
   Germany, grant number 03VP03681 and 03VP03682.
CR Alt V, 2017, INJURY, V48, P599, DOI 10.1016/j.injury.2016.12.011
   Arens S., 2002, DIGITALE REVOLUTION, P738
   Barras F, 2018, ANTIBIOTICS BASEL, V7, DOI 10.3390/antibiotics7030079
   Beuttel E, 2019, MATERIALS, V12, DOI 10.3390/ma12071116
   Carver DC, 2017, ORTHOP CLIN N AM, V48, P137, DOI [10.1016/j.ocl.2016.12.005, 10.1016/j.oc1.2016.12.005]
   Cheng H, 2014, J BIOMED MATER RES A, V102, P3488, DOI 10.1002/jbm.a.35019
   Coathup M.J., 2012, ORTHOP P B, V94 B, P100, DOI [10.1302/1358 992X.94BSUPP_XXXVI.BORS2011 100, DOI 10.1302/1358 992X.94BSUPP_XXXVI.BORS2011 100]
   Craig J, 2014, INT ORTHOP, V38, P1025, DOI 10.1007/s00264 014 2293 2
   Crémet L, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv065
   Darouiche RO, 2001, CLIN INFECT DIS, V33, P1567, DOI 10.1086/323130
   Fassbender M, 2013, BONE, V55, P298, DOI 10.1016/j.bone.2013.04.018
   Fielding GA, 2012, ACTA BIOMATER, V8, P3144, DOI 10.1016/j.actbio.2012.04.004
   Fölsch C, 2015, INT ORTHOP, V39, P981, DOI 10.1007/s00264 014 2582 9
   Frutos P, 2000, J PHARMACEUT BIOMED, V21, P1149, DOI 10.1016/S0731 7085(99)00192 2
   Fuchs T, 2011, ARCH ORTHOP TRAUM SU, V131, P1419, DOI 10.1007/s00402 011 1321 6
   Goodman SB, 2013, BIOMATERIALS, V34, P3174, DOI 10.1016/j.biomaterials.2013.01.074
   Hardes J, 2017, J ARTHROPLASTY, V32, P2208, DOI 10.1016/j.arth.2017.02.054
   Hardes J, 2010, J SURG ONCOL, V101, P389, DOI 10.1002/jso.21498
   Heitemeyer U., 1990, AKTUELLE PROBLEME CH, P162
   K?hn KD., 2018, MANAGEMENT PERIPROST
   Kasch R, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 0962 6
   Kasch R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169558
   Khalilpour P, 2010, J BIOMED MATER RES B, V94B, P196, DOI 10.1002/jbm.b.31641
   Khosravi A. D., 2009, Research Journal of Microbiology, V4, P158, DOI 10.3923/jm.2009.158.163
   Kühn KD, 2017, UNFALLCHIRURG, V120, P561, DOI 10.1007/s00113 017 0372 8
   Kühn KD, 2014, BIOFUNCTIONAL SURFACE ENGINEERING, P121
   Lampé I, 2019, INT J NANOMED, V14, P4709, DOI 10.2147/IJN.S197782
   Lucke M, 2005, BONE, V36, P770, DOI 10.1016/j.bone.2005.01.008
   Mijnendonckx K, 2013, BIOMETALS, V26, P609, DOI 10.1007/s10534 013 9645 z
   Morawska Chochól A, 2014, MAT SCI ENG C MATER, V45, P15, DOI 10.1016/j.msec.2014.08.059
   Moriarty TF, 2016, EFORT OPEN REV, V1, P89, DOI 10.1302/2058 5241.1.000037
   Nast S, 2016, J BIOMATER APPL, V31, P45, DOI 10.1177/0885328216630912
   Obermeier A, 2012, J MATER SCI MATER M, V23, P1675, DOI 10.1007/s10856 012 4631 5
   Park JH, 2012, ACTA BIOMATER, V8, P1966, DOI 10.1016/j.actbio.2011.11.026
   Prabhu S, 2012, INT NANO LETT, V2, DOI 10.1186/2228 5326 2 32
   Schmidmaier G, 2017, INJURY, V48, P2235, DOI 10.1016/j.injury.2017.07.008
   Scoccianti G, 2016, INJURY, V47, pS11, DOI 10.1016/j.injury.2016.07.042
   Smeets R, 2017, INT J ORAL MAX IMPL, V32, P1338, DOI 10.11607/jomi.5533
   Specht U, 2014, MATERIALWISS WERKST, V45, P1116, DOI 10.1002/mawe.201400360
   Strobel C, 2011, J CONTROL RELEASE, V156, P37, DOI 10.1016/j.jconrel.2011.07.006
   Trampuz A, 2005, SWISS MED WKLY, V135, P243
   Vogel K, 2015, SURF INNOV, V3, P27, DOI 10.1680/si.14.00002
   Wafa H, 2015, BONE JOINT J, V97B, P252, DOI 10.1302/0301 620X.97B2.34554
   Wu Y, 2011, BIOMATERIALS, V32, P951, DOI 10.1016/j.biomaterials.2010.10.001
   Zheng Jiwen, 2011, J Nanomed Nanotechnol, V2011, P001
NR 45
TC 16
Z9 16
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1996 1944
J9 MATERIALS
JI Materials
PD DEC
PY 2019
VL 12
IS 23
AR 3838
DI 10.3390/ma12233838
PG 13
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA KG8DR
UT WOS:000510178700034
PM 31766488
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xie, JL
   Ma, R
   Xu, X
   Yang, MY
   Yu, H
   Wan, XJ
   Xu, K
   Guo, JF
   Xu, P
AF Xie, Jiale
   Ma, Rui
   Xu, Xin
   Yang, Mingyi
   Yu, Hui
   Wan, Xianjie
   Xu, Ke
   Guo, Junfei
   Xu, Peng
TI Identification of genetic association between mitochondrial dysfunction
   and knee osteoarthritis through integrating multi omics: a summary
   data based Mendelian randomization study
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Bayesian colocalization analysis; Knee osteoarthritis; Mendelian
   randomization; Mitochondrial dysfunction; Quantitative trait loci;
   Therapeutic targets
ID KINASE BINDING DOMAIN; OSTEOBLAST LIKE CELLS; NITRIC OXIDE; INHIBITION;
   DISEASE; VARIANT; AKAP10; RISK; LOCI; EQTL
AB ObjectiveAssociation between mitochondrial dysfunction and osteoarthritis (OA) has been consistently investigated, yet their genetic association remains obscure. In this study, mitochondrial related genes were used as instrumental variables to proxy for mitochondrial dysfunction, and summary data of knee OA (KOA) were used as outcome to examine their genetic association.MethodsWe obtained 1136 mitochondrial related genes from the human MitoCarta3.0 database. Genetic proxy instruments for mitochondrial related genes from studies of corresponding gene expression (n = 31,684) and protein (n = 35,559) quantitative trait locus (eQTLs and pQTLs), respectively. Aggregated data for KOA (62,497 KOA cases and 333,557 controls) were extracted from the largest OA genome wide association study (GWAS). We integrated QTL data with KOA GWAS data to estimate their genetic association using summary data based Mendelian randomization analysis (SMR). Additionally, we implemented Bayesian colocalization analysis to reveal whether suggestive mitochondrial related genes and KOA were driven by a same genetic variant. Finally, to validate the primary findings, replication study (24,955 cases and 378,169 controls) and multi SNP based SMR (SMR multi) test was performed.ResultsThrough SMR analysis, we found that the expression levels of 2 mitochondrial related genes were associated with KOA risk. Specifically, elevated gene expression levels of the IMMP2L (odds ratio [OR] = 1.056; 95% confidence interval [CI] = 1.030 1.082; P FDR = 0.004) increased the risk of KOA. Conversely, increased gene expression levels of AKAP10 decreased the risk of KOA (OR = 0.955; 95% CI, 0.934 0.977; P FDR = 0.019). Colocalization analysis demonstrated that AKAP10 (PP.H4 = 0.84) and IMMP2L (PP.H4 = 0.91) shared the same genetic variant with KOA. In addition, consistent results were found in replication study and SMR multi test, further demonstrating the reliability of our findings.ConclusionsIn summary, our analyses revealed the genetic association between mitochondrial dysfunction proxied by mitochondrial related genes and KOA, providing new insight into potential pathogenesis of KOA. Furthermore, these identified candidate genes offer the possibility of clinical drug target development for KOA.Key points center dot This is the first SMR study to explore the genetic association between mitochondrial dysfunction proxied by mitochondrial related genes and KOA.center dot Sufficient evidence to support genetic association between the expression levels of AKAP10 and IMMP2L, and KOA center dot Our MR analysis may provide novel new insight into potential pathogenesis of KOA.center dot These identified candidate genes offer the possibility of clinical drug target development for KOAConclusionsIn summary, our analyses revealed the genetic association between mitochondrial dysfunction proxied by mitochondrial related genes and KOA, providing new insight into potential pathogenesis of KOA. Furthermore, these identified candidate genes offer the possibility of clinical drug target development for KOA.Key points center dot This is the first SMR study to explore the genetic association between mitochondrial dysfunction proxied by mitochondrial related genes and KOA.center dot Sufficient evidence to support genetic association between the expression levels of AKAP10 and IMMP2L, and KOA center dot Our MR analysis may provide novel new insight into potential pathogenesis of KOA.center dot These identified candidate genes offer the possibility of clinical drug target development for KOA
C1 [Xie, Jiale; Ma, Rui; Xu, Xin; Yang, Mingyi; Yu, Hui; Wan, Xianjie; Xu, Ke; Guo, Junfei; Xu, Peng] Xi An Jiao Tong Univ, HongHui Hosp, Dept Joint Surg, Xian, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Xu, P (通讯作者)，Xi An Jiao Tong Univ, HongHui Hosp, Dept Joint Surg, Xian, Shaanxi, Peoples R China.
EM sousou369@163.com
RI Xu, Ke/HSH 1984 2023; Yang, Mingyi/JEF 3717 2023; Guo,
   Junfei/HZK 0972 2023
OI Xu, Peng/0000 0003 2487 9163
FU National Natural Science Foundation of China
FX The authors acknowledge the contribution of Zhang et al. to the
   development of SMR algorithm and tools. The authors thank the
   participants and investigators of all the public database.
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Amano H, 2019, REGEN THER, V11, P290, DOI 10.1016/j.reth.2019.08.007
   An FY, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1297024
   Averill Bates D., 2024, Review. Biochim. Biophys. Acta. Mol. Cell Res., V1871, DOI [10.1016/j.bbamcr.2023.119573, DOI 10.1016/J.BBAMCR.2023.119573]
   Bi SQ, 2024, BIOCHEM GENET, V62, P2314, DOI 10.1007/s10528 023 10486 7
   Boer CG, 2021, CELL, V184, P4784, DOI 10.1016/j.cell.2021.07.038
   Bonaz B, 2016, J PHYSIOL LONDON, V594, P5781, DOI 10.1113/JP271539
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Catheline SE, 2019, J BONE MINER RES, V34, P1676, DOI 10.1002/jbmr.3737
   Chen D, 2020, J ORTHOP TRANSL, V23, P132, DOI 10.1016/j.jot.2019.11.008
   Cui Z, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00229 6
   DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790
   Ferkingstad E, 2021, NAT GENET, V53, P1712, DOI 10.1038/s41588 021 00978 w
   Gao YY, 2024, CYTOTHERAPY, V26, P11, DOI 10.1016/j.jcyt.2023.10.004
   GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016, Lancet, V388, P1545, DOI 10.1016/S0140 6736(16)31678 6
   Hancock CM, 2008, CLIN J PAIN, V24, P353, DOI 10.1097/AJP.0b013e31815e5418
   Harbauer AB, 2014, CELL METAB, V19, P357, DOI 10.1016/j.cmet.2014.01.010
   He Q, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa119
   Jang S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052619
   Jiang HY, 2023, MOLECULES, V28, DOI 10.3390/molecules28041683
   Jiang N, 2022, MECH AGEING DEV, V205, DOI 10.1016/j.mad.2022.111688
   Jiang W, 2023, BIOMED PHARMACOTHER, V167, DOI 10.1016/j.biopha.2023.115552
   Kammerer S, 2003, P NATL ACAD SCI USA, V100, P4066, DOI 10.1073/pnas.2628028100
   Kim SH, 2011, J BIOL CHEM, V286, P8875, DOI 10.1074/jbc.M110.187815
   Langmia IM, 2015, J PERINATOL, V35, P700, DOI 10.1038/jp.2015.68
   Lauwers M, 2021, OSTEOARTHR CARTILAGE, V29, P643, DOI 10.1016/j.joca.2021.02.005
   Lawther AJ, 2023, GENES BASEL, V14, DOI 10.3390/genes14091717
   Li YN, 2023, EBIOMEDICINE, V88, DOI 10.1016/j.ebiom.2022.104432
   Lin AC, 2009, NAT MED, V15, P1421, DOI 10.1038/nm.2055
   Lin JF, 2023, BRAIN, V146, P3364, DOI 10.1093/brain/awad070
   Liu CL, 2016, AGING CELL, V15, P167, DOI 10.1111/acel.12426
   Liu L, 2023, REDOX BIOL, V62, DOI 10.1016/j.redox.2023.102663
   Liu L, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.1001212
   Losina E, 2013, ARTHRIT CARE RES, V65, P703, DOI 10.1002/acr.21898
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936
   Papadimitriou N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14389 8
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Sarma GN, 2010, STRUCTURE, V18, P155, DOI 10.1016/j.str.2009.12.012
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Tachmazidou I, 2019, NAT GENET, V51, P230, DOI 10.1038/s41588 018 0327 1
   Tan BG, 2024, NAT REV MOL CELL BIO, V25, P119, DOI 10.1038/s41580 023 00661 4
   Teng P, 2019, J IMMUNOL, V203, P485, DOI 10.4049/jimmunol.1801513
   Thangaraj G, 2016, CHEM BIOL INTERACT, V259, P313, DOI 10.1016/j.cbi.2016.03.027
   Tingley WG, 2007, P NATL ACAD SCI USA, V104, P8461, DOI 10.1073/pnas.0610393104
   Vosa U, 2021, NAT GENET, V53, P1300, DOI 10.1038/s41588 021 00913 z
   Wirtenberger M, 2007, CARCINOGENESIS, V28, P423, DOI 10.1093/carcin/bgl164
   Wu Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03371 0
   Xie N, 2022, NUTRIENTS, V14, DOI 10.3390/nu14235109
   Xu L, 2020, OSTEOARTHR CARTILAGE, V28, P1079, DOI 10.1016/j.joca.2019.11.011
   Xu S, 2023, BMC MED, V21, DOI 10.1186/s12916 023 02878 8
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Zeggini E, 2012, LANCET, V380, P815, DOI 10.1016/S0140 6736(12)60681 3
   Zengini E, 2018, NAT GENET, V50, P549, DOI 10.1038/s41588 018 0079 y
   Zhang DW, 2014, BIOCHEM BIOPH RES CO, V454, P115, DOI 10.1016/j.bbrc.2014.10.046
   Zhang YQ, 2018, AM J MED GENET B, V177, P93, DOI 10.1002/ajmg.b.32608
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 59
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770 3198
EI 1434 9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD NOV
PY 2024
VL 43
IS 11
BP 3487
EP 3496
DI 10.1007/s10067 024 07136 7
EA SEP 2024
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA J7W1X
UT WOS:001320734000001
PM 39259428
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhao, DD
   Lian, ZY
   Liu, LB
   Luo, L
   Li, HY
   Liu, J
   Zhou, HY
AF Zhao, Daidi
   Lian, Zhiyun
   Liu, Libin
   Luo, Li
   Li, Huiying
   Liu, Ju
   Zhou, Hongyu
TI In vitro study of micro dystrophin gene modified mesenchymal stem
   cells
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE Duchenne muscular dystrophy; mesenchymal stem cells; micro dystrophin;
   gene modification
ID DUCHENNE MUSCULAR DYSTROPHY; MDX MICE; MUSCLE CELLS; BONE MARROW;
   THERAPY; EXPRESSION; VECTOR; DNA
AB BACKGROUND: Studies have shown that the transplantation of mesenchymal stem cells (MSCs) improves dystrophin expression in muscle cell membrane of mdx mice and plays a role in ameliorating sport injuries to the myocyte. In addition, dystrophin gene plasmid injection exhibits therapeutic effect in mdx mice. However, these two methods exhibit shortcomings, such as low rate of post transplantation expression. Therefore, the present study determined the combinatorial effects of these two methods.
   OBJECTIVE: To transfect and observe effects of pSL139 plasmid carrying the micro dystrophin gene into MSCs, as well as in vitro micro dystrophin gene expression in transfected MSCs.
   DESIGN, TIME AND SETTING: A comparative, molecular biology study was performed at the Laboratory of Tissue Engineering, West China Medical Center, Sichuan University from March 2007 to February 2008.
   MATERIALS: The pSL139 plasmid was cloned and provided by the Department of Neurology, Washington University, USA. Lipofectamine 2000 was purchased from Invitrogen, USA. Mouse anti human dystrophin N based terminal monoclonal antibody was purchased from Chemicon, USA.
   METHODS: Differential velocity adherent technique and density gradient centrifugation were combined to separate and culture MSCs from C57/BL10 mice. The cells were induced to trans differentiate into osteoblasts. Subsequently, the Lipofectamine 2000 method was used to mediate transfection of plasmid pSL139 into third generation MSCs.
   MAIN OUTCOME MEASURES: Semi quantitative reverse transcription polymerase chain reaction and immunofluorescence were respectively employed to detect micro dystrophin mRNA and protein expressions in MSCs.
   RESULTS: At 48 hours after MSC transfection with plasmid pSL139, a 379 kb target band was observed by agarose gel electrophoresis. Immunofluorescence revealed micro dystrophin expression up to 45% 55%.
   CONCLUSION: Micro dystrophin mRNA and protein were highly expressed in pSL139 transfected MSCs, which provided a method for efficient expression of dystrophin.
C1 [Zhao, Daidi; Lian, Zhiyun; Liu, Libin; Luo, Li; Li, Huiying; Liu, Ju; Zhou, Hongyu] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University
RP Zhou, HY (通讯作者)，Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610041, Sichuan, Peoples R China.
EM hyzhou98@yahoo.com
RI Liu, Libin/U 9402 2019; Luo, Li/HZH 4864 2023; huiying, li/JVE 2788 2024
FU National Natural Science Foundation of China [0040205401040]
FX Supported by: the National Natural Science Foundation of China for Young
   Scholars, No. 0040205401040*
CR [Anonymous], 2006, GUID SUGG CAR US LAB
   Blankinship MJ, 2006, MOL THER, V13, P241, DOI 10.1016/j.ymthe.2005.11.001
   Bostick B, 2008, HUM GENE THER, V19, P851, DOI 10.1089/hum.2008.058
   Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399
   Davidson ZE, 2009, J HUM NUTR DIET, V22, P383, DOI 10.1111/j.1365 277X.2009.00979.x
   Dodds E, 1998, GENE THER, V5, P542, DOI 10.1038/sj.gt.3300604
   Farini A, 2009, J CELL PHYSIOL, V221, P526, DOI 10.1002/jcp.21895
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Gonçalves MAFV, 2006, HUM MOL GENET, V15, P213, DOI 10.1093/hmg/ddi438
   Goudenege S, 2009, MOL THER, V17, P1064, DOI 10.1038/mt.2009.67
   Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302 253
   Jiang ZL, 2004, MOL THER, V10, P688, DOI 10.1016/j.ymthe.2004.07.020
   KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0
   LIU HL, 2002, GENETICS NEUROLOGY, P207
   Liu YN, 2007, STEM CELLS DEV, V16, P695, DOI 10.1089/scd.2006.0118
   Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365 2141.2003.04669.x
   Neuhuber B, 2002, MUSCLE NERVE, V26, P136, DOI 10.1002/mus.10171
   O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Radley HG, 2007, INT J BIOCHEM CELL B, V39, P469, DOI 10.1016/j.biocel.2006.09.009
   Rando TA, 2007, BBA MOL BASIS DIS, V1772, P263, DOI 10.1016/j.bbadis.2006.07.009
   Sakamoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1265, DOI 10.1016/S0006 291X(02)00362 5
   SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758
   van Deutekom JCT, 2003, NAT REV GENET, V4, P774, DOI 10.1038/nrg1180
   WANG LF, 2001, PRINCIPLES MED MOL B, P722
   Watchko J, 2002, HUM GENE THER, V13, P1451, DOI 10.1089/10430340260185085
   Xiong Fu, 2008, Zhonghua Yixue Yichuanxue Zazhi, V25, P624
   YANG XG, 2003, SHENGWU JISHU TONGBA, P24
   Yin Xiao xue, 2004, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V18, P88
   Yoshimura M, 2004, MOL THER, V10, P821, DOI 10.1016/j.ymthe.2004.07.025
   Zhang Y, 2004, CHINESE MED J PEKING, V117, P882
NR 31
TC 0
Z9 0
U1 0
U2 10
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B 9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR E, MUMBAI, 400075,
   INDIA
SN 1673 5374
EI 1876 7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD APR 15
PY 2010
VL 5
IS 7
BP 496
EP 501
DI 10.3969/j.issn.1673 5374.2010.07.003
PG 6
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 593AY
UT WOS:000277425100003
DA 2025 08 17
ER

PT J
AU Kanda, Y
   Hinata, T
   Kang, SW
   Watanabe, Y
AF Kanda, Yasunari
   Hinata, Takashi
   Kang, Sang Won
   Watanabe, Yasuhiro
TI Reactive oxygen species mediate adipocyte differentiation in mesenchymal
   stem cells
SO LIFE SCIENCES
LA English
DT Article
DE Adipogenesis; CREB; Mesenchymal stem cells; NAD(P)H oxidase; Reactive
   oxygen species
ID MITOTIC CLONAL EXPANSION; VASCULAR SMOOTH MUSCLE; SIGNAL TRANSDUCTION;
   NADPH OXIDASE; ADIPOGENESIS; REQUIREMENT; ACTIVATION; MIGRATION;
   OBESITY; GROWTH
AB Aims: Mesenchymal stem cells (MSC) have the potential to differentiate into various cell lineages, including adipocytes and osteoblasts. The formation of adipose tissue involves the commitment of MSC to the preadipocyte lineage and the differentiation of preadipocytes into mature adipocytes. In the present study, we investigated the involvement of reactive oxygen species (ROS) in adipocyte differentiation from MSC.
   Main methods: ROS signaling was evaluated by the effects of antioxidant N acetyl L cysteine (NAC) or shRNA against NAD(P)H oxidase in the multipotent mesenchymal stem cell line 10T1/2 cells. Intracellular ROS was measured using an H(2)DCF dye.
   Key findings: We found that NAC blocked adipocyte differentiation in MSC. An H(2)DCF assay revealed that differentiation inducing agents induced ROS generation. These data suggest that ROS is involved in adipocyte differentiation in MSC. Next, we examined the source of ROS. Knockdown of NAD(P)H oxidase 4 (Nox4) by RNA interference inhibited ROS production and adipocyte differentiation by differentiation inducing agents. Furthermore, treatment with NAC blocked the transcriptional activation of CREB. and the expression of dominant negative mutants of CREB inhibited adipocyte differentiation.
   Significance: The findings suggest that the increase in the intracellular ROS level via Nox4 mediates adipocyte differentiation through CREB in MSC. This data will provide new insight into the drug development for obesity. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Kanda, Yasunari; Hinata, Takashi; Watanabe, Yasuhiro] Natl Def Med Coll, Dept Pharmacol, Saitama 3598513, Japan.
   [Kang, Sang Won] Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea.
   [Kang, Sang Won] Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.
   [Kanda, Yasunari] Natl Inst Hlth Sci, Div Pharmacol, Tokyo 1588501, Japan.
C3 National Defense Medical College   Japan; Ewha Womans University; Ewha
   Womans University; National Institute of Health Sciences   Japan
RP Kanda, Y (通讯作者)，1 18 1 Kamiyoga, Tokyo 1588501, Japan.
EM kanda@nihs.go.jp
RI Kanda, Yasunari/AAD 7514 2019
FU Smoking Research Foundation; Ministry of Education, Culture, Sports,
   Science, and Technology, Japan [2179025, 23590322]; Ministry of Health,
   Labour and Welfare, Japan; Grants in Aid for Scientific Research
   [23590322] Funding Source: KAKEN
FX We would like to thank Dr. Goodman, for providing the plasmids. This
   work was supported in part by a grant from the Smoking Research
   Foundation (Y.K. and Y.W.), a Grant in Aid for Scientific Research (No.
   2179025, 23590322) from the Ministry of Education, Culture, Sports,
   Science, and Technology, Japan (Y.K.) and a Health and Labour Sciences
   Research Grant from the Ministry of Health, Labour and Welfare, Japan
   (Y.K.).
CR Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908
   Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642
   Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Cho YC, 2004, J CELL BIOCHEM, V91, P336, DOI 10.1002/jcb.10743
   Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587
   DASILVA ML, 2003, BRIT J HAEMATOL, V123, P702
   GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092 8674(75)90087 2
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Kanda Y, 2005, BRIT J PHARMACOL, V146, P60, DOI 10.1038/sj.bjp.0706293
   Kuroda J, 2005, GENES CELLS, V10, P1139, DOI 10.1111/j.1365 2443.2005.00907.x
   LEE H, 2009, J BIOL CHEM, V284
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Mouche S, 2007, BBA MOL CELL RES, V1773, P1015, DOI 10.1016/j.bbamcr.2007.03.003
   Nishio E, 1997, BRIT J PHARMACOL, V121, P665, DOI 10.1038/sj.bjp.0701171
   PINNEY DF, 1989, ENVIRON HEALTH PERSP, V80, P221, DOI 10.2307/3430747
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008 1020.2000
   Rexrode KM, 1996, CURR OPIN CARDIOL, V11, P490, DOI 10.1097/00001573 199609000 00007
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   Rosen ED, 2000, GENE DEV, V14, P1293
   SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460 2075.1995.tb07046.x
   Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014 5793(00)01747 6
   Schroeder K, 2009, ARTERIOSCL THROM VAS, V29, P239, DOI 10.1161/ATVBAHA.108.174219
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092 8674(01)00240 9
   St Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296
   Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100
   TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092 8674(79)90317 9
   Zhang H, 2004, CIRC RES, V95, P989, DOI 10.1161/01.RES.0000147962.01036.bb
NR 31
TC 185
Z9 208
U1 0
U2 28
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
J9 LIFE SCI
JI Life Sci.
PD AUG 15
PY 2011
VL 89
IS 7 8
BP 250
EP 258
DI 10.1016/j.lfs.2011.06.007
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 806MD
UT WOS:000293811100006
PM 21722651
DA 2025 08 17
ER

PT J
AU Almousa, MA
   Alharbi, GK
   Alqahtani, AS
   Chachar, Y
   Alkadi, L
   Aboalela, A
AF Almousa, Mandlin Abdulaziz
   Alharbi, Ghadah Khalid
   Alqahtani, Amerah Saeed
   Chachar, Yusra
   Alkadi, Lubna
   Aboalela, Ali
TI Dental practitioners' and students' knowledge of medication related
   osteonecrosis of the jaw (MRONJ)
SO SAUDI PHARMACEUTICAL JOURNAL
LA English
DT Article
DE MRONJ; Knowledge; Bisphosphonates; Dental practitioners; Dental
   students; Cancer treatment; Side effects; Management
AB Background: Medication related osteonecrosis of the jaw (MRONJ) is a complication affecting patients who are being treated with antiresorptive or antiangiogenic medication. These patients require meticulous treatment planning and management strategies. This research aimed to assess the knowledge of dental practitioners and students in their professional years regarding MRONJ.
   Methods: A cross sectional study was conducted among 345 dental practitioners and students in their professional years of both genders, in governmental and private dental schools. The data was collected using an electronic and paper based self administered structured questionnaire with six sections. The data was entered and analyzed using SPSS Version 23, and a P value <0.05 was considered significant. A Chi square test was used to compare the categorical variables.
   Results: Though more than half of the sample 68% received information about antiresorptive and antiangiogenic drugs during their studies, the level of knowledge was low. The primary diseases targeted by antiresorptive and antiangiogenic medications were not known by the majority of the sample. Almost half of the sample could not identify any antiresorptive or antiangiogenic medication and only 28.1% knew the correct definition of MRONJ.
   Conclusion: The level of knowledge regarding MRONJ is a concern, necessitating more educational courses and workshops. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
C1 [Almousa, Mandlin Abdulaziz; Alharbi, Ghadah Khalid; Alqahtani, Amerah Saeed] King Saud Bin Abdulaziz Univ Hlth Sci, Dent Interns, Riyadh, Saudi Arabia.
   [Chachar, Yusra; Alkadi, Lubna; Aboalela, Ali] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Dent, Riyadh, Saudi Arabia.
   [Almousa, Mandlin Abdulaziz; Alharbi, Ghadah Khalid; Alqahtani, Amerah Saeed; Chachar, Yusra; Alkadi, Lubna; Aboalela, Ali] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
   [Alkadi, Lubna; Aboalela, Ali] Natl Guard Hlth Affairs, Riyadh, Saudi Arabia.
C3 King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin
   Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz
   University for Health Sciences; King Abdullah International Medical
   Research Center (KAIMRC); King Saud Bin Abdulaziz University for Health
   Sciences; King Abdulaziz Medical City   Riyadh; National Guard Health
   Affairs   Saudi Arabia; Ministry of National Guard   Health Affairs
RP Almousa, MA (通讯作者)，King Saud Bin Abdulaziz Univ Hlth Sci, Dent Interns, Riyadh, Saudi Arabia.
EM mandalinalmousa@gmail.com; Alhrbai133@ksau hs.edu.sa;
   Alqahtani111@ksau hs.edu.sa; chachary@ksau hs.edu.sa;
   kadil@ksau hs.edu.sa; Ali_aboalela@alumni.harvard.edu
RI Aboalela, Ali/AAV 3307 2020
OI Chachar, Yusra Sajid/0000 0003 1250 6036; Alkadi,
   Lubna/0000 0003 3206 8547; aboalela, ali/0000 0003 0963 5574
CR Beth Tasdogan NH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012432.pub2
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   de Lima PB, 2015, SUPPORT CARE CANCER, V23, P3421, DOI 10.1007/s00520 015 2689 6
   Franchi S, 2020, J STOMATOL ORAL MAXI, V121, P344, DOI 10.1016/j.jormas.2019.10.005
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Kang MH, 2018, J KOR ASSOC ORAL MAX, V44, P225, DOI 10.5125/jkaoms.2018.44.5.225
   López Jornet P, 2010, J EVAL CLIN PRACT, V16, P878, DOI 10.1111/j.1365 2753.2009.01203.x
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Pazianas M, 2007, CLIN THER, V29, P1548, DOI 10.1016/j.clinthera.2007.08.008
   Rosella Daniele, 2017, Eur J Dent, V11, P461, DOI 10.4103/ejd.ejd_27_17
   Rosella D, 2016, J INT SOC PREV COMMU, V6, P97, DOI 10.4103/2231 0762.178742
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Tsao C, 2013, J ORAL MAXIL SURG, V71, P1360, DOI 10.1016/j.joms.2013.02.016
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Voss PJ, 2017, J STOMATOL ORAL MAXI, V118, P232, DOI 10.1016/j.jormas.2017.06.012
   Wat Winnie Zee Man, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040038
NR 17
TC 6
Z9 6
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319 0164
EI 2213 7475
J9 SAUDI PHARM J
JI Saudi Pharm. J.
PD JAN
PY 2021
VL 29
IS 1
BP 96
EP 103
DI 10.1016/j.jsps.2020.12.012
EA FEB 2021
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QL3TW
UT WOS:000621003400011
PM 33603544
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Joshi, P
   Vijaykumar, A
   Enkhmandakh, B
   Shin, DG
   Mina, M
   Bayarsaihan, D
AF Joshi, Pujan
   Vijaykumar, Anushree
   Enkhmandakh, Badam
   Shin, Dong Guk
   Mina, Mina
   Bayarsaihan, Dashzeveg
TI The chromatin accessibility landscape in the dental pulp of mouse molars
   and incisors
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE dental pulp; ATAC seq; chromatin; gene body; promoter
ID TOOTH DEVELOPMENT; STEM CELLS; GENE; IDENTITY
AB The dental pulp is a promising source of progenitor cells for regenerative medicine. The natural function of dental pulp is to produce odontoblasts to generate reparative dentin. Stem cells within the pulp tissue originate from the migrating neural crest cells and possess mesenchymal stem cell properties with the ability to differentiate into multiple lineages. To elucidate the transcriptional control mechanisms underlying cell fate determination, we compared the transcriptome and chromatin accessibility in primary dental pulp tissue derived from 5 6 day old mice. Using RNA sequencing and assay for transposase accessible chromatin using sequencing (ATAC seq), we correlated gene expression with chromatin accessibility. We found that the majority of ATAC seq peaks were concentrated at genes associated with development and cell differentiation. Most of these genes were highly expressed in the mouse dental pulp. Surprisingly, we uncovered a group of genes encoding master transcription factors that were not expressed in the dental pulp but retained open chromatin states. Within this group, we identified key developmental genes important for specification of the neural crest, adipocyte, neural, myoblast, osteoblast and hepatocyte lineages. Collectively, our results uncover a complex relationship between gene expression and the chromatin accessibility landscape in the mouse dental pulp.
C1 [Joshi, Pujan; Shin, Dong Guk] Univ Connecticut, Comp Sci & Engn Dept, Storrs, CT 06269 USA.
   [Vijaykumar, Anushree; Mina, Mina] Univ Connecticut, Dept Craniofacial Sci, Hlth Ctr, Farmington, CT 06030 USA.
   [Enkhmandakh, Badam; Bayarsaihan, Dashzeveg] Univ Connecticut, Hlth Ctr, Dept Reconstruct Sci, Ctr Regenerat Med & Skeletal Dev, Farmington, CT 06030 USA.
   [Bayarsaihan, Dashzeveg] Univ Connecticut, Inst Syst Genom, Storrs, CT 06269 USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut
RP Bayarsaihan, D (通讯作者)，Univ Connecticut, Hlth Ctr, Dept Reconstruct Sci, Ctr Regenerat Med & Skeletal Dev, Farmington, CT 06030 USA.; Bayarsaihan, D (通讯作者)，Univ Connecticut, Inst Syst Genom, Storrs, CT 06269 USA.
EM dashzeveg@uchc.edu
OI Vijaykumar, Anushree/0000 0002 9311 8715
FU OVPR from the University of Connecticut [REP 40175420144 20,
   R01 DE016689]; Department of Computer Science and Engineering,
   University of Connecticut; NIH [HD098636]
FX This study was supported by OVPR from the University of Connecticut,
   REP 40175420144 20 to D.B., R01 DE016689 to M.M., a predoctoral
   fellowship from the Department of Computer Science and Engineering,
   University of Connecticut to P.J. and NIH grant no. HD098636 to D.G.
CR Arenas Mena C, 2021, BMC GENOMICS, V22, DOI 10.1186/s12864 021 07936 0
   Augustine R, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111425
   Balic A, 2015, CURR TOP DEV BIOL, V115, P157, DOI 10.1016/bs.ctdb.2015.07.006
   Balic A, 2010, BONE, V46, P1639, DOI 10.1016/j.bone.2010.02.019
   Bonaventura G, 2020, CELL TISSUE RES, V379, P421, DOI 10.1007/s00441 019 03109 4
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Farges JC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/230251
   Gan L, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8864572
   Guo C, 2017, CURR OPIN GENET DEV, V46, P50, DOI 10.1016/j.gde.2017.06.011
   Harada A, 2017, SEMIN CELL DEV BIOL, V72, P77, DOI 10.1016/j.semcdb.2017.10.022
   Hernández Hernández O, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.578712
   Hugues A, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.00262
   Klein DC, 2020, CURR TOP DEV BIOL, V138, P1, DOI 10.1016/bs.ctdb.2019.11.002
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Luo LH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/1731289
   Marinov GK, 2021, METHODS MOL BIOL, V2243, P183, DOI 10.1007/978 1 0716 1103 6_10
   Masuda K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052269
   Miao WW, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.742672
   Miletich Isabelle, 2004, Birth Defects Res C Embryo Today, V72, P200, DOI 10.1002/bdrc.20012
   Nagata M, 2021, CELL TISSUE RES, V383, P603, DOI 10.1007/s00441 020 03271 0
   Nair VD, 2021, GENOMICS, V113, P3827, DOI 10.1016/j.ygeno.2021.09.013
   Nikoloudaki G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031015
   Piunti A, 2016, SCIENCE, V352, DOI 10.1126/science.aad9780
   Potdar PD, 2015, WORLD J STEM CELLS, V7, P839, DOI 10.4252/wjsc.v7.i5.839
   Prasad MS, 2019, GENESIS, V57, DOI 10.1002/dvg.23276
   Simoes Costa M, 2015, DEVELOPMENT, V142, P242, DOI 10.1242/dev.105445
   Wang H, 2016, RENAL FAILURE, V38, P982, DOI 10.3109/0886022X.2016.1172973
   Yianni V, 2019, J DENT RES, V98, P1066, DOI 10.1177/0022034519862258
   Yu T, 2015, CURR TOP DEV BIOL, V115, P187, DOI 10.1016/bs.ctdb.2015.07.010
   Zhang C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24466 1
   Zhang JR, 2021, BIOCHEM BIOPH RES CO, V574, P63, DOI 10.1016/j.bbrc.2021.08.047
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
NR 33
TC 4
Z9 4
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1734 154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2022
VL 69
IS 1
BP 131
EP 138
DI 10.18388/abp.2020_5771
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA ZP1KV
UT WOS:000766184700018
PM 35226446
OA gold
DA 2025 08 17
ER

PT J
AU Tsuchida, S
   Arai, Y
   Kishida, T
   Takahashi, KA
   Honjo, K
   Terauchi, R
   Inoue, H
   Oda, R
   Mazda, O
   Kubo, T
AF Tsuchida, Shinji
   Arai, Yuji
   Kishida, Tsunao
   Takahashi, Kenji A.
   Honjo, Kuniaki
   Terauchi, Ryu
   Inoue, Hiroaki
   Oda, Ryo
   Mazda, Osam
   Kubo, Toshikazu
TI Silencing the expression of connexin 43 decreases inflammation and joint
   destruction in experimental arthritis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE connexin 43; gap junction; pro inflammatory cytokine; rheumatoid
   arthritis; collagen induced arthritis
ID COLLAGEN INDUCED ARTHRITIS; HUMAN SYNOVIAL CELLS; RHEUMATOID ARTHRITIS;
   GAP JUNCTIONS; II COLLAGEN; IN VITRO; KAPPA B; RATS; LIPOPOLYSACCHARIDE;
   COMMUNICATION
AB The objective of the present study was to determine whether the expression of connexin 43 (Cx43) effected on inflammatory conditions in rat fibroblast like synoviocytes (FLS) and on rat model of rheumatoid arthritis (RA). The expression of Cx43 in rat FLS stimulated with lipopolysaccharide (LPS) was confirmed by real time reverse transcriptase polymerase chain reaction (RT PCR). The effects of small interfering RNA targeting Cx43 (siCx43) on pro inflammatory cytokines and chemokine were assessed by real time RT PCR and enzyme linked immunosorbent assay (ELISA). The therapeutic and side effects of siCx43 in a rat model of collagen induced arthritis (CIA) were examined by in vivo electroporation method. LPS markedly enhanced Cx43 gene expression in rat FLS, with transfection of siCx43 suppressing the over expression of pro inflammatory cytokines and the chemokine. Treatment of CIA rats with siCx43 significantly ameliorated paw swelling, and significantly reduced histological arthritis scores and radiographic scores. In histological appearance of rat ankle joints, siCx43 treatment significantly decreased the number of tartrate resistant acid phosphatase (TRAP) positive (osteoclast like) cells. These findings indicated that siCx43 had anti inflammatory effects in rat FLS and efficiently inhibited the development of CIA. Cx43 may play an important role in the pathophysiology of RA, and may be a potential target molecule for novel RA therapies. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 525530, 2013
C1 [Tsuchida, Shinji; Arai, Yuji; Honjo, Kuniaki; Terauchi, Ryu; Inoue, Hiroaki; Oda, Ryo; Kubo, Toshikazu] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, Kyoto 6028566, Japan.
   [Kishida, Tsunao; Mazda, Osam] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Immunol, Kamigyo Ku, Kyoto 6028566, Japan.
   [Takahashi, Kenji A.] Nippon Med Sch, Dept Rheumatol, Bunkyo Ku, Tokyo 1138603, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine; Nippon Medical School
RP Arai, Y (通讯作者)，Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Orthopaed, Kamigyo Ku, Kyoto 6028566, Japan.
EM yarai89046@nike.eonet.ne.jp
FU KAKENHI [23659731]; Grants in Aid for Scientific Research [23591318,
   24659447, 25670656, 23659731] Funding Source: KAKEN
FX Grant sponsor: KAKENHI; Grant number: 23659731.
CR Alivernini S, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2848
   Bakharevski O, 1998, J RHEUMATOL, V25, P1945
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Cronin M, 2008, MOL CELL NEUROSCI, V39, P152, DOI 10.1016/j.mcn.2008.06.005
   Cuzzocrea S, 2003, ARTHRITIS RHEUM US, V48, P3544, DOI 10.1002/art.11351
   Danesh Meyer HV, 2008, J CLIN NEUROSCI, V15, P1253, DOI 10.1016/j.jocn.2008.08.002
   De Klerck B, 2005, ARTHRITIS RES THER, V7, pR1208, DOI 10.1186/ar1806
   Fujisawa K, 1996, ARTHRITIS RHEUM US, V39, P197, DOI 10.1002/art.1780390205
   Inoue A, 2005, BIOCHEM BIOPH RES CO, V336, P903, DOI 10.1016/j.bbrc.2005.08.198
   Inoue A, 2009, MOD RHEUMATOL, V19, P125, DOI 10.1007/s10165 008 0131 3
   JARA PI, 1995, P NATL ACAD SCI USA, V92, P7011, DOI 10.1073/pnas.92.15.7011
   JOHNSON WJ, 1990, ARTHRITIS RHEUM US, V33, P261, DOI 10.1002/art.1780330216
   Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652
   Kolomytkin OV, 2000, J CELL PHYSIOL, V184, P110, DOI 10.1002/(SICI)1097 4652(200007)184:1<110::AID JCP12>3.3.CO;2 #
   Li K, 2011, J BIOL CHEM, V286, P41552, DOI 10.1074/jbc.M111.274449
   Maeda S, 2011, CELL MOL LIFE SCI, V68, P1115, DOI 10.1007/s00018 010 0551 z
   Marino AA, 2003, BIOELECTROMAGNETICS, V24, P199, DOI 10.1002/bem.10085
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Nakagawa S, 2009, BIOCHEM BIOPH RES CO, V388, P467, DOI 10.1016/j.bbrc.2009.06.150
   Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590
   Ohashi S, 2002, BIOCHEM BIOPH RES CO, V293, P1530, DOI 10.1016/S0006 291X(02)00386 8
   Schajnovitz A, 2011, NAT IMMUNOL, V12, P391, DOI 10.1038/ni.2017
   Schilling AF, 2008, J CELL MOL MED, V12, P2497, DOI 10.1111/j.1582 4934.2008.00275.x
   Scott DL, 2012, CLIN PHARMACOL THER, V91, P30, DOI 10.1038/clpt.2011.278
   Sugatani T, 2003, J CELL BIOCHEM, V90, P59, DOI 10.1002/jcb.10613
   Tsuboi H, 2003, ANN RHEUM DIS, V62, P196, DOI 10.1136/ard.62.3.196
   Watkins M, 2011, MOL BIOL CELL, V22, P1240, DOI 10.1091/mbc.E10 07 0571
   Weinberger A, 2003, ARTHRITIS RHEUM US, V48, P846, DOI 10.1002/art.10850
NR 30
TC 49
Z9 54
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD APR
PY 2013
VL 31
IS 4
BP 525
EP 530
DI 10.1002/jor.22263
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 097UF
UT WOS:000315498300003
PM 23165424
OA Bronze
DA 2025 08 17
ER

PT J
AU Bae, YS
   Chang, J
   Park, SM
AF Bae, Ye Seul
   Chang, Jooyoung
   Park, Sang Min
TI Oral bisphosphonate use and the risk of female breast, ovarian, and
   cervical cancer: a nationwide population based cohort study
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Epidemiology; Bisphosphonate; Female breast cancer; Ovarian cancer;
   Cervical cancer
ID POSTMENOPAUSAL; OSTEOPOROSIS; ENDOMETRIAL; ALENDRONATE; EXPOSURE;
   PROSTATE
AB Bisphosphonate use was not associated with the risk of female breast, ovarian, or cervical cancer. The results according to bisphosphonate type or concurrent drug uses were not associated with the cancer risk. The protective effect of bisphosphonate use on female breast cancer was significant in the low comorbidity group.PurposeDespite the antitumor mechanisms, the effect of bisphosphonates on the risk of cancer is still unclear. We investigated the association between oral bisphosphonate use and the development of female breast, ovarian, and cervical cancer.MethodsWe accomplished a population based cohort study using the National Health Insurance Services (NHIS) database. A total of 204,525 participants were included in a cohort, and we identified the incident cases of each cancer from 2007 to 2013. We assessed cumulative bisphosphonate exposure from 2003 to 2006 using the defined daily dose (DDD) system. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were presented to assess the association between bisphosphonate use and cancer incidence using multivariate Cox proportional hazard regression models. Subgroup analyses were performed to assess cancer development according to risk factors and concurrent drug use.ResultsThere was a total of 1547, 266, and 370 incident cases of female breast, cervical, and ovarian cancer, respectively, during the study period of 1,367,294 person years. Bisphosphonate exposure was not significantly associated with risk of female breast (adjusted HR (aHR), 0.78; 95% CI, 0.60 1.02), ovarian (aHR, 1.30; 95% CI, 0.82 2.07), nor cervical cancer (aHR, 0.70; 95% CI, 0.44 1.12). Further subgroup analyses also revealed no statistically significant effects of bisphosphonate use with various risk factors and concurrent drug use.ConclusionsOur study showed no significant associations between bisphosphonate exposure and female breast, cervical, and ovarian cancer. In the future, large prospective studies or a meta analysis would be needed to verify the associations.
C1 [Bae, Ye Seul; Park, Sang Min] Seoul Natl Univ Hosp, Dept Family Med, 101 Daehak Ro, Seoul 03080, South Korea.
   [Chang, Jooyoung] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, 101 Daehak Ro, Seoul 03080, South Korea.
   [Park, Sang Min] Seoul Natl Univ, Coll Med, Dept Biomed Sci, 101 Daehak Ro, Seoul 03080, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU)
RP Park, SM (通讯作者)，Seoul Natl Univ Hosp, Dept Family Med, 101 Daehak Ro, Seoul 03080, South Korea.; Park, SM (通讯作者)，Seoul Natl Univ, Coll Med, Dept Biomed Sci, 101 Daehak Ro, Seoul 03080, South Korea.
EM smpark.snuh@gmail.com
RI ; Park, Sang/V 9194 2019
OI Chang, Jooyoung/0000 0002 8586 0645; 
CR [Anonymous], 2006, AN THER CHEM CLASS S
   Barba C, 2004, LANCET, V363, P157, DOI 10.1016/s0140 6736(03)15268 3
   Boissier S, 2000, CANCER RES, V60, P2949
   Cardwell CR, 2012, INT J CANCER, V131, pE717, DOI 10.1002/ijc.27389
   Chiang CH, 2012, J BONE MINER RES, V27, P1951, DOI 10.1002/jbmr.1645
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Hensley S, 2015, CANCER AM CANCER SOC, V121, P441, DOI 10.1002/cncr.28952
   Hue TF, 2014, JAMA INTERN MED, V174, P1550, DOI 10.1001/jamainternmed.2014.3634
   Kim, 2003, REPORT EVALUATION VA, P19
   Kim MH, 2018, AM J GASTROENTEROL, V113, P845, DOI [10.1038/s41395 018 0097 5, 10.14309/00000434 201806000 00015]
   Lee WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053032
   Lewiecki EM, 2010, THER ADV CHRONIC DIS, V1, P115, DOI 10.1177/2040622310374783
   Monsees GM, 2011, J NATL CANCER I, V103, P1752, DOI 10.1093/jnci/djr399
   Newcomb PA, 2010, BRIT J CANCER, V102, P799, DOI 10.1038/sj.bjc.6605555
   Newcomb PA, 2015, J CLIN ONCOL, V33, P1186, DOI 10.1200/JCO.2014.58.6842
   Ou YJ, 2017, PHARMACOEPIDEM DR S, V26, P1286, DOI 10.1002/pds.4302
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Rennert G, 2014, GYNECOL ONCOL, V133, P309, DOI 10.1016/j.ygyno.2014.02.014
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Shin JY, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3517
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055 9965.EPI 15 0578
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V88, P255, DOI 10.1007/s00223 011 9463 7
   Vinogradova Y, 2013, BRIT J CANCER, V109, P795, DOI 10.1038/bjc.2013.383
   Yancik R, 2001, JAMA J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885
NR 30
TC 7
Z9 7
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD MAR 19
PY 2019
VL 14
IS 1
AR 41
DI 10.1007/s11657 019 0588 z
PG 8
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA HP9CJ
UT WOS:000461989300001
PM 30888545
DA 2025 08 17
ER

PT J
AU Meng, L
   Shao, CY
   Cui, C
   Xu, F
   Lei, JD
   Yang, J
AF Meng, Lei
   Shao, Changyou
   Cui, Chen
   Xu, Feng
   Lei, Jiandu
   Yang, Jun
TI Autonomous Self Healing Silk Fibroin Injectable Hydrogels Formed via
   Surfactant Free Hydrophobic Association
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE silk fibroin; surfactant free; hydrophobic association; injectable;
   self healing
ID SACRIFICIAL BONDS; POLYMER; NANOPARTICLES; PERFORMANCE; NANOSCALE;
   MECHANISM; EVOLUTION; DYNAMICS; DELIVERY; BEHAVIOR
AB Many natural materials, such as silk, animal bone, nacre, and plant fibers, achieve outstanding strength and toughness through the rupture of sacrificial bonds between chain segments in the organic phase. In this work, we present a bioinspired strategy to fabricate silk fibroin based hydrophobic association (HA) hydrogels by incorporating the hydrophobic interaction as a sacrificial bond into the alginate ionic network, which not only enhanced the mechanical extensibility, strength, and toughness of the hydrogels but also enabled self recovery and self healing properties via reversible hydrophobic interactions without external stimuli at room temperature. The hydrophobic interaction system consisted of the hydrophobic monomer stearyl methacrylate (C18M) and an amphiphilic regenerated silk fibroin (RSF) solution. The mechanical tests and rheometry indicated that the hydrophobic interaction served as the sacrificial bond that preferentially ruptures prior to the alginate ionic network under an external load, which dissipated enormous amounts of energy and conferred an improved mechanical performance. Moreover, the structure of HA gels could be quickly recovered after injection due to the existence of hydrophobic interactions. In addition, the degradability of the HA gels in a protease XIV solution was strongly dependent upon the C18M component, which significantly promoted the degradation rate of HA gels. The biomimetic mineralization process of HA gels within a simulated body fluid (SBF), mimicking the inorganic composition of human blood plasma, was performed and the calcium phosphate nanoparticles on the hydrogel were observed. Importantly, in vivo experiments illustrated that the HA gels exhibited satisfactory biocompatibility, and the mouse osteoblasts (MC3T3 E1) could attach and spread on the hydrogels. Overall, the self healing, biocompatibility, and high mechanical properties of the HA gels render them potentially suitable for load bearing applications in drug delivery or other soft tissue engineering applications.
C1 [Meng, Lei; Shao, Changyou; Cui, Chen; Xu, Feng; Lei, Jiandu; Yang, Jun] Beijing Forestry Univ, Beijing Key Lab Lignocellulos Chem, Beijing 100083, Peoples R China.
C3 Beijing Forestry University
RP Yang, J (通讯作者)，Beijing Forestry Univ, Beijing Key Lab Lignocellulos Chem, Beijing 100083, Peoples R China.
EM yangjun11@bjfu.edu.cn
RI Meng, Lei/JPA 2801 2023; Xu, Feng/AFN 9478 2022; BADAwi,
   Nujud/AAZ 2452 2020
OI Meng, Lei/0000 0003 2672 8406; 
FU World Class Discipline Construction and Characteristic Development
   Guidance Funds for Beijing Forestry University [2019XKJS0330]; National
   Natural Science Foundation of China [21674013, 21978024]
FX This work was financially supported by the World Class Discipline
   Construction and Characteristic Development Guidance Funds for Beijing
   Forestry University (2019XKJS0330) and National Natural Science
   Foundation of China (21674013, 21978024).
CR Akay G, 2013, SOFT MATTER, V9, P2254, DOI 10.1039/c2sm27515e
   Anumolu R, 2011, ACS NANO, V5, P5374, DOI 10.1021/nn103585f
   Bilici C, 2016, MACROMOLECULES, V49, P7442, DOI 10.1021/acs.macromol.6b01539
   Can V, 2016, MACROMOLECULES, V49, P2281, DOI 10.1021/acs.macromol.6b00156
   Cao Y, 2014, ACS APPL MATER INTER, V6, P410, DOI 10.1021/am4044823
   Chang XH, 2018, MACROMOL RAPID COMM, V39, DOI 10.1002/marc.201700806
   Chen Q, 2016, CHEM MATER, V28, P5710, DOI 10.1021/acs.chemmater.6b01920
   Chen Q, 2015, J MATER CHEM B, V3, P3654, DOI 10.1039/c5tb00123d
   Chen Q, 2015, ADV FUNCT MATER, V25, P1598, DOI 10.1002/adfm.201404357
   Chen YF, 2019, ACS APPL MATER INTER, V11, P14608, DOI 10.1021/acsami.9b01532
   Cho SY, 2018, ACS APPL NANO MATER, V1, P5441, DOI 10.1021/acsanm.8b00784
   Dai XY, 2015, ADV MATER, V27, P3566, DOI 10.1002/adma.201500534
   Ding ZZ, 2017, ACS APPL MATER INTER, V9, P16914, DOI 10.1021/acsami.7b03932
   Ding ZZ, 2016, ACS APPL MATER INTER, V8, P24463, DOI 10.1021/acsami.6b08180
   Fantner GE, 2006, BIOPHYS J, V90, P1411, DOI 10.1529/biophysj.105.069344
   Fernández Colino A, 2014, BIOMACROMOLECULES, V15, P3781, DOI 10.1021/bm501051t
   Gryn'ova G, 2018, J PHYS CHEM LETT, V9, P2298, DOI 10.1021/acs.jpclett.8b00980
   Han JQ, 2019, CARBON, V149, P1, DOI 10.1016/j.carbon.2019.04.029
   Hao JK, 2011, MACROMOLECULES, V44, P9390, DOI 10.1021/ma202130u
   Huang J, 2016, MACROMOL RAPID COMM, V37, P1040, DOI 10.1002/marc.201600226
   Huang WW, 2017, ACCOUNTS CHEM RES, V50, P866, DOI 10.1021/acs.accounts.6b00616
   Jeon I, 2016, ADV MATER, V28, P4678, DOI 10.1002/adma.201600480
   Jin HJ, 2003, NATURE, V424, P1057, DOI 10.1038/nature01809
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Ling SJ, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201705291
   Liu J, 2016, MACROMOLECULES, V49, P8593, DOI 10.1021/acs.macromol.6b01576
   Liu YJ, 2019, ACS MACRO LETT, V8, P193, DOI 10.1021/acsmacrolett.9b00012
   Mehrotra S, 2019, ACS BIOMATER SCI ENG, V5, P2054, DOI 10.1021/acsbiomaterials.8b01560
   Mihajlovic M, 2018, MACROMOLECULES, V51, P4813, DOI 10.1021/acs.macromol.8b00892
   Neal JA, 2015, J AM CHEM SOC, V137, P4846, DOI 10.1021/jacs.5b01601
   Niu QQ, 2018, ACS NANO, V12, P11860, DOI 10.1021/acsnano.8b03943
   Owusu Nkwantabisah S, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.44800
   Palmeri MJ, 2010, ACS NANO, V4, P4256, DOI 10.1021/nn100661a
   Rössle M, 2004, BIOPOLYMERS, V74, P316, DOI 10.1002/bip.20083
   Sang YH, 2018, ACS APPL MATER INTER, V10, P9290, DOI 10.1021/acsami.7b19204
   Singh YP, 2019, ACS APPL MATER INTER, V11, P33684, DOI 10.1021/acsami.9b11644
   Singh YP, 2016, ACS APPL MATER INTER, V8, P21236, DOI 10.1021/acsami.6b08285
   Sirichaisit J, 2000, POLYMER, V41, P1223, DOI 10.1016/S0032 3861(99)00293 1
   So S, 2018, HELICOBACTER, V23
   Studart AR, 2015, ANGEW CHEM INT EDIT, V54, P3400, DOI 10.1002/anie.201410139
   Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409
   Tan XX, 2018, GREEN CHEM, V20, P3625, DOI 10.1039/c8gc01609g
   Tang ZH, 2016, MACROMOLECULES, V49, P1781, DOI 10.1021/acs.macromol.5b02756
   Tsuchiya K, 2017, BIOMACROMOLECULES, V18, P1002, DOI 10.1021/acs.biomac.6b01891
   Tuncaboylu DC, 2012, MACROMOLECULES, V45, P1991, DOI 10.1021/ma202672y
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   Wang HB, 2018, ADV SCI, V5, DOI 10.1002/advs.201800711
   Wang SH, 2015, ACS APPL MATER INTER, V7, P21254, DOI 10.1021/acsami.5b05335
   Wang Y, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201805305
   WINTER HH, 1987, POLYM ENG SCI, V27, P1698, DOI 10.1002/pen.760272209
   Wojtecki RJ, 2011, NAT MATER, V10, P14, DOI [10.1038/nmat2891, 10.1038/NMAT2891]
   Wu RH, 2019, SMALL, V15, DOI 10.1002/smll.201901558
   Xiong R, 2017, ACS NANO, V11, P12008, DOI 10.1021/acsnano.7b04235
   Yang J., 2019, ADV FUNCT MAT
   Yin YF, 2019, ANGEW CHEM, V131, P12835
   Zhang BY, 2018, MACROMOL MATER ENG, V303, DOI 10.1002/mame.201800072
   Zhang YY, 2015, ADV FUNCT MATER, V25, P471, DOI 10.1002/adfm.201401989
   Zhou XX, 2017, CHEM SOC REV, V46, P6301, DOI 10.1039/c7cs00276a
NR 58
TC 108
Z9 116
U1 6
U2 326
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JAN 8
PY 2020
VL 12
IS 1
BP 1628
EP 1639
DI 10.1021/acsami.9b19415
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA KC4JL
UT WOS:000507146100166
PM 31800210
DA 2025 08 17
ER

PT J
AU Ramaswamy, Y
   Roohani, I
   No, YJ
   Madafiglio, G
   Chang, F
   Zhang, FR
   Lu, ZF
   Zreiqat, H
AF Ramaswamy, Yogambha
   Roohani, Iman
   No, Young Jung
   Madafiglio, Genevieve
   Chang, Frank
   Zhang, Furong
   Lu, Zufu
   Zreiqat, Hala
TI Nature inspired topographies on hydroxyapatite surfaces regulate stem
   cells behaviour
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Stem cell; Biomaterials; Bioceramics; Scaffolds; Micropattern;
   Topography
ID FOCAL ADHESION; OSTEOGENIC DIFFERENTIATION; OSTEOPROGENITOR RESPONSE;
   OSTEOBLAST ALIGNMENT; CALCIUM PHOSPHATE; MICRO; MECHANOTRANSDUCTION;
   MECHANISMS; MORPHOLOGY; SCAFFOLDS
AB Surface topography is one of the key factors in regulating interactions between materials and cells. While topographies presented to cells in vivo are non symmetrical and in complex shapes, current fabrication techniques are limited to replicate these complex geometries. In this study, we developed a microcasting technique and successfully produced imprinted hydroxyapatite (HAp) surfaces with nature inspired (honeycomb, pillars, and isolated islands) topographies. The in vitro biological performance of the developed non symmetrical topographies was evaluated using adipose derived stem cells (ADSCs). We demonstrated that ADSCs cultured on all HAp surfaces, except honeycomb patterns, presented well defined stress fibers and expressed focal adhesion protein (paxillin) molecules. Isolated islands topographies significantly promoted osteogenic differentiation of ADSCs with increased alkaline phosphatase activity and upregulation of key osteogenic markers, compared to the other topographies and the control unmodified (flat) HAp surface. In contrast, honeycomb topographies hampered the ability of the ADSCs to proliferate and differentiate to the osteogenic lineage. This work presents a facile technique to imprint nature derived topographies on the surface of bioceramics which opens up opportunities for the development of bioresponsive interfaces in tissue engineering and regenerative medicine.
C1 [Ramaswamy, Yogambha; No, Young Jung; Madafiglio, Genevieve; Chang, Frank; Zhang, Furong; Lu, Zufu; Zreiqat, Hala] Univ Sydney, Sch Biomed Engn, Biomat & Tissue Engn Res Unit, Sydney, NSW 2006, Australia.
   [Ramaswamy, Yogambha; No, Young Jung; Lu, Zufu; Zreiqat, Hala] Univ Sydney, Australian Res Ctr Innovat Bioengn, Sydney, NSW 2006, Australia.
   [Roohani, Iman] Univ New South Wales, Australian Ctr Nanomed, Sch Chem, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; University of New South
   Wales Sydney
RP Zreiqat, H (通讯作者)，Univ Sydney, Sch Biomed Engn, Biomat & Tissue Engn Res Unit, Sydney, NSW 2006, Australia.; Roohani, I (通讯作者)，Univ New South Wales, Australian Ctr Nanomed, Sch Chem, Sydney, NSW, Australia.
EM iman.roohani@unsw.edu.au; hala.zreiqat@sydney.edu.au
RI ; Chang, Frank/B 1500 2018; Roohani, Iman/JMR 3441 2023
OI , Iman Roohani/0009 0000 3678 3455; Zreiqat, Hala/0000 0003 0521 7711;
   No, Young Jung/0000 0001 8135 4369; 
FU Australia National Health and Medical Research Council; Australian
   Research Council; Rebecca L Cooper Medical Research Foundation;
   Australian Research Council Training Centre for Innovative
   Bioengineering; Australian Centre for Microscopy and Microanalysis
   (ACMM) at the University of Sydney
FX The authors acknowledge the Australia National Health and Medical
   Research Council, Australian Research Council, and the Rebecca L Cooper
   Medical Research Foundation. The authors acknowledge the Australian
   Research Council Training Centre for Innovative Bioengineering and the
   Australian Centre for Microscopy and Microanalysis (ACMM) at the
   University of Sydney for their help with microscopic analysis.
CR Albuschies J, 2013, SCI REP UK, V3, DOI 10.1038/srep01658
   Bauer W, 1999, CERAM INT, V25, P201, DOI 10.1016/S0272 8842(98)00023 6
   Ber S, 2005, BIOMATERIALS, V26, P1977, DOI 10.1016/j.biomaterials.2004.07.007
   Biggs MJP, 2008, J R SOC INTERFACE, V5, P1231, DOI 10.1098/rsif.2008.0035
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Byun MR, 2014, CELL DEATH DIFFER, V21, P854, DOI 10.1038/cdd.2014.8
   Carrodeguas RG, 2011, ACTA BIOMATER, V7, P3536, DOI 10.1016/j.actbio.2011.06.019
   Cassidy JW, 2014, ACTA BIOMATER, V10, P651, DOI 10.1016/j.actbio.2013.11.008
   Charest JL, 2004, BIOMATERIALS, V25, P4767, DOI 10.1016/j.biomaterials.2003.12.011
   Chew SY, 2006, CURR PHARM DESIGN, V12, P4751, DOI 10.2174/138161206779026326
   Chiquet M, 2009, BBA MOL CELL RES, V1793, P911, DOI 10.1016/j.bbamcr.2009.01.012
   Cipriano AF, 2014, J BIOMED NANOTECHNOL, V10, P660, DOI 10.1166/jbn.2014.1760
   Coutinho R.L.R.D., 2011, MICRO NANOTECHNOLOGY
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2006, BIOMATERIALS, V27, P2980, DOI 10.1016/j.biomaterials.2006.01.010
   Dalby MJ, 2006, BIOMATERIALS, V27, P1306, DOI 10.1016/j.biomaterials.2005.08.028
   Davison MJ, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416652778
   De Luca AC, 2015, J BIOMED MATER RES A, V103, P2689, DOI 10.1002/jbm.a.35407
   Falconnet D, 2006, BIOMATERIALS, V27, P3044, DOI 10.1016/j.biomaterials.2005.12.024
   Feng P, 2014, SCI REP UK, V4, DOI 10.1038/srep05599
   Galli C, 2012, EUR CELLS MATER, V24, P46, DOI 10.22203/eCM.v024a04
   Gerecht S, 2007, BIOMATERIALS, V28, P4068, DOI 10.1016/j.biomaterials.2007.05.027
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hasturk O, 2016, ADV HEALTHC MATER, V5, P2972, DOI 10.1002/adhm.201600857
   Hlaing TT, 2014, ANN CLIN BIOCHEM, V51, P189, DOI 10.1177/0004563213515190
   Hu LY, 2013, CERAM INT, V39, P6287, DOI 10.1016/j.ceramint.2013.01.050
   Huang JY, 2019, CELL MOL LIFE SCI, V76, P505, DOI 10.1007/s00018 018 2945 2
   Kenar H, 2008, J BIOMED MATER RES A, V85A, P1001, DOI 10.1002/jbm.a.31638
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kirmizidis G, 2009, TISSUE ENG PT A, V15, P1427, DOI 10.1089/ten.tea.2008.0137
   Lasgorceix M, 2019, MAT SCI ENG C MATER, V95, P371, DOI 10.1016/j.msec.2018.03.004
   Lenhert S, 2005, BIOMATERIALS, V26, P563, DOI 10.1016/j.biomaterials.2004.02.068
   Li GW, 2017, ACTA BIOMATER, V49, P235, DOI 10.1016/j.actbio.2016.11.057
   Lin K, 2019, MATERIALS, V12, DOI 10.3390/ma12172660
   Lin XT, 2020, MATERIALIA, V14, DOI 10.1016/j.mtla.2020.100870
   Liu XN, 2017, ACS APPL MATER INTER, V9, P18521, DOI 10.1021/acsami.7b04027
   Lopez Heredia MA, 2008, BIOMATERIALS, V29, P2608, DOI 10.1016/j.biomaterials.2008.02.021
   Martínez E, 2009, ANN ANAT, V191, P126, DOI 10.1016/j.aanat.2008.05.006
   Matsuzaka K, 1999, BIOMATERIALS, V20, P1293, DOI 10.1016/S0142 9612(99)00029 0
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   Neira IS, 2009, CRYST GROWTH DES, V9, P466, DOI 10.1021/cg800738a
   Pan Z, 2012, BIOMATERIALS, V33, P1730, DOI 10.1016/j.biomaterials.2011.11.023
   Park JY, 2009, LAB CHIP, V9, P2043, DOI 10.1039/b820955c
   Pilia M, 2013, J BIOL ENG, V7, DOI 10.1186/1754 1611 7 23
   Ramaswamy Y, 2008, BIOMATERIALS, V29, P4392, DOI 10.1016/j.biomaterials.2008.08.006
   Roohani Esfahani SI, 2010, BIOMATERIALS, V31, P5498, DOI 10.1016/j.biomaterials.2010.03.058
   Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786
   Seo CH, 2014, BIOMATERIALS, V35, P2245, DOI 10.1016/j.biomaterials.2013.11.089
   Shuai CJ, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12010199
   Sia JR, 2016, BIOMATERIALS, V103, P1, DOI 10.1016/j.biomaterials.2016.06.034
   Silverwood RK, 2016, ADV HEALTHC MATER, V5, P947, DOI 10.1002/adhm.201500664
   Sjöström T, 2009, ACTA BIOMATER, V5, P1433, DOI 10.1016/j.actbio.2009.01.007
   Tamiello C, 2016, CELL MOL BIOENG, V9, P12, DOI 10.1007/s12195 015 0422 7
   Tamiello C, 2015, SCI REP UK, V5, DOI 10.1038/srep08752
   Teo BKK, 2013, ACS NANO, V7, P4785, DOI 10.1021/nn304966z
   Vrana NE, 2007, BIOMATERIALS, V28, P4303, DOI 10.1016/j.biomaterials.2007.06.013
   Werner M, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201900080
   Wilkinson A, 2011, ACTA BIOMATER, V7, P2919, DOI 10.1016/j.actbio.2011.03.026
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Zhao CC, 2018, ACTA BIOMATER, V73, P509, DOI 10.1016/j.actbio.2018.04.030
   Zhao CC, 2015, J MATER CHEM B, V3, P968, DOI 10.1039/c4tb01838a
   Zinger O, 2005, BIOMATERIALS, V26, P1837, DOI 10.1016/j.biomaterials.2004.06.035
NR 63
TC 46
Z9 49
U1 3
U2 101
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD APR
PY 2021
VL 6
IS 4
BP 1107
EP 1117
DI 10.1016/j.bioactmat.2020.10.001
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA QF0ZY
UT WOS:000616630300016
PM 33102949
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cao, XW
   Wang, ZY
   Bi, LY
   Bi, CL
   Du, Q
AF Cao, Xiaowei
   Wang, Zhenyu
   Bi, Liyan
   Bi, Caili
   Du, Qiu
TI Gold nanocage based surface enhanced Raman scattering probes for
   long term monitoring of intracellular microRNA during bone marrow stem
   cell differentiation
SO NANOSCALE
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; SERS DETECTION; NANOSTRUCTURES;
   AMPLIFICATION; NANOPARTICLES; FLUORESCENCE; SPECTROSCOPY; MIR 144 3P;
   EXPRESSION; SILVER
AB The ability to monitor the differentiation of living stem cells is essential for understanding stem cell biology and the practical application of stem cell therapies. However, conventional methods of analyzing biomarkers related to differentiation still require a large number of cells or cell lysates. This requirement leads to the unavoidable loss of cell sources and hinders the real time monitoring of cellular processes. In this study, we report an ultrasensitive surface enhanced Raman scattering (SERS) method for the long term detection and imaging of miR 144 3p in osteogenic differentiation of BMSCs, by using target miRNA induced gold nanocage (GNC) hairpin DNA1 (hpDNA1) hpDNA2 GNC assembly in living cells. The finite difference time domain method demonstrated that the electromagnetic intensities of the dimer and polymer of the GNCs were significantly enhanced compared to that of GNCs only, which theoretically confirmed the rational design of the SERS strategy. The hpDNA conjugated GNC probes were prepared and used to recognize the target and distinguish from other miRNAs. This method enabled excellent sensitivity and high selectivity toward miR 144 3p with a limit of detection of 13.6 aM and a broad range from 100 aM to 100 pM in cell lysates. Then, we used transmission electron microscopy images, fluorescence microscopy images, and dark field microscopy images to study the internalization of the probes in BMSCs. A Cell Counting Kit 8 experiment indicated that the probes were not cytotoxic in a certain concentration range. BMSCs were treated with an osteogenic inductor so that they would subsequently differentiate into osteocytes. Upon cellular uptake of these nanoprobes, we observed intense and time dependent SERS responses from the important osteogenic biomarker miR 144 3p, only in BMSCs undergoing osteogenic differentiation and living undifferentiated BMSCs but not in osteoblasts. Finally, the accuracy of SERS has been proved by a quantitative real time polymerase chain reaction experiment. The above results demonstrated that our nanoprobes are capable of long term tracking of the dynamic expression of miR 144 3p (21 days) in the differentiating BMSCs. SERS has broad application prospects in the long term detection of stem cell differentiation, and identification and isolation of specific cell types as well as in biomedical diagnosis.
C1 [Cao, Xiaowei; Wang, Zhenyu; Bi, Caili] Yangzhou Univ, Med Coll, Inst Translat Med, Yangzhou 225001, Jiangsu, Peoples R China.
   [Cao, Xiaowei; Wang, Zhenyu; Bi, Caili] Yangzhou Univ, Jiangsu Key Lab Integrated Tradit Chinese & Weste, Yangzhou 225001, Jiangsu, Peoples R China.
   [Cao, Xiaowei] Yangzhou Univ, Coll Vet Med, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.
   [Cao, Xiaowei; Wang, Zhenyu; Bi, Caili] Jiangsu Key Lab Expt Translat Noncoding RNA Res, Yangzhou 225001, Jiangsu, Peoples R China.
   [Cao, Xiaowei; Bi, Caili] Yangzhou Univ, Key Lab Syndrome Differentiat & Treatment Gastr C, State Adm Tradit Chinese Med, Yangzhou 225001, Jiangsu, Peoples R China.
   [Bi, Liyan] Binzhou Med Univ, Coll Special Educ, Transformat Otol & Neurosci Ctr, Yantai 264003, Peoples R China.
   [Du, Qiu] Yangzhou Univ, Affiliated Hosp, Dept Neurosurg, Yangzhou 225001, Jiangsu, Peoples R China.
C3 Yangzhou University; Yangzhou University; Yangzhou University; Yangzhou
   University; Binzhou Medical University; Yangzhou University
RP Cao, XW (通讯作者)，Yangzhou Univ, Med Coll, Inst Translat Med, Yangzhou 225001, Jiangsu, Peoples R China.; Cao, XW (通讯作者)，Yangzhou Univ, Jiangsu Key Lab Integrated Tradit Chinese & Weste, Yangzhou 225001, Jiangsu, Peoples R China.; Cao, XW (通讯作者)，Yangzhou Univ, Coll Vet Med, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.; Cao, XW (通讯作者)，Jiangsu Key Lab Expt Translat Noncoding RNA Res, Yangzhou 225001, Jiangsu, Peoples R China.; Cao, XW (通讯作者)，Yangzhou Univ, Key Lab Syndrome Differentiat & Treatment Gastr C, State Adm Tradit Chinese Med, Yangzhou 225001, Jiangsu, Peoples R China.
EM cxw19861121@163.com
OI Cao, Xiaowei/0000 0003 1845 9111
FU National Natural Science Foundation of China [81701825]; Social
   Development Foundation of Jiangsu [BE2018684]; Natural Science
   Foundation of the Jiangsu Higher Education Institutions of China
   [17KJB416012]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81701825), the Social Development Foundation of Jiangsu (No.
   BE2018684), the Natural Science Foundation of the Jiangsu Higher
   Education Institutions of China (No. 17KJB416012). In addition, I would
   like to thank my wife Yang Kong in particular for her support.
CR Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chen JY, 2019, BIOSENS BIOELECTRON, V143, DOI 10.1016/j.bios.2019.111619
   Chen SY, 2009, J PHYS CHEM C, V113, P12167, DOI 10.1021/jp901355g
   Cobley CM, 2008, ADV MATER, V20, P748, DOI 10.1002/adma.200702501
   Dong HF, 2013, CHEM REV, V113, P6207, DOI 10.1021/cr300362f
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   He Y, 2017, ANAL CHEM, V89, P2866, DOI 10.1021/acs.analchem.6b04082
   Henderson K., 2017, ADV HEALTHC MATER, V6, P22
   Hu F, 2015, SMALL, V11, P985, DOI 10.1002/smll.201401360
   Hu YW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094997
   Huang C, 2016, FEBS LETT, V590, P795, DOI 10.1002/1873 3468.12112
   Huang JY, 2011, CHEM COMMUN, V47, P5738, DOI 10.1039/c0cc05323f
   Huang P, 2011, BIOMATERIALS, V32, P9796, DOI 10.1016/j.biomaterials.2011.08.086
   Joseph D, 2019, SENSOR ACTUAT B CHEM, V281, P471, DOI 10.1016/j.snb.2018.10.092
   Kaneto CM, 2014, BMC MED GENET, V15, DOI 10.1186/1471 2350 15 45
   Kim JH, 2008, LANGMUIR, V24, P11147, DOI 10.1021/la8016497
   Larsen S, 2011, PATHOLOGY, V43, P592, DOI 10.1097/PAT.0b013e32834ab72d
   Li YS, 2010, J PHYS CHEM C, V114, P10463, DOI 10.1021/jp100499z
   Lin FX, 2016, AM J TRANSL RES, V8, P5098
   Lin LK, 2018, SENSOR ACTUAT B CHEM, V276, P222, DOI 10.1016/j.snb.2018.08.068
   Liu CH, 2018, ANAL CHEM, V90, P10591, DOI 10.1021/acs.analchem.8b02819
   Liu J, 2019, ANGEW CHEM INT EDIT, V58, P7757, DOI 10.1002/anie.201902776
   MacLaughlin CM, 2013, NANOMED NANOTECHNOL, V9, P55, DOI 10.1016/j.nano.2012.04.003
   Mahajan S, 2008, J AM CHEM SOC, V130, P15589, DOI 10.1021/ja805517q
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Moreton S, 2015, NANOSCALE, V7, P6075, DOI 10.1039/c5nr00091b
   Murphy CP, 2017, BIOL PSYCHIAT, V81, P979, DOI 10.1016/j.biopsych.2016.12.021
   Pang YF, 2016, BIOSENS BIOELECTRON, V79, P574, DOI 10.1016/j.bios.2015.12.052
   Rycenga M, 2009, PHYS CHEM CHEM PHYS, V11, P5903, DOI 10.1039/b903533h
   Shan YB, 2017, BIOPROC BIOSYST ENG, V40, P1813, DOI 10.1007/s00449 017 1835 6
   Song CY, 2009, BIOSENS BIOELECTRON, V25, P826, DOI 10.1016/j.bios.2009.08.035
   Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347
   Talley CE, 2004, ANAL CHEM, V76, P7064, DOI 10.1021/ac049093j
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Vendrell M, 2013, TRENDS BIOTECHNOL, V31, P249, DOI 10.1016/j.tibtech.2013.01.013
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang FX, 2019, J MATER CHEM A, V7, P11150, DOI 10.1039/c9ta00931k
   Wang ZY, 2019, NEW J CHEM, V43, P1733, DOI 10.1039/c8nj05353g
   Wen SP, 2019, ACS SENSORS, V4, P301, DOI 10.1021/acssensors.8b00682
   Willets KA, 2009, ANAL BIOANAL CHEM, V394, P85, DOI 10.1007/s00216 009 2682 3
   Wong SP, 2015, PHARMACOL THERAPEUT, V151, P107, DOI 10.1016/j.pharmthera.2015.03.006
   Yang Y, 2014, ACS APPL MATER INTER, V6, P3750, DOI 10.1021/am500506j
   Ye SJ, 2017, ANAL CHEM, V89, P5124, DOI 10.1021/acs.analchem.7b00697
   Zhang H, 2015, CHEM COMMUN, V51, P16836, DOI 10.1039/c5cc06225j
   Zhang Y, 2011, J ELECTROANAL CHEM, V656, P23, DOI 10.1016/j.jelechem.2011.01.037
   Zhou HB, 2014, ANAL CHEM, V86, P1525, DOI 10.1021/ac402935p
NR 48
TC 37
Z9 38
U1 4
U2 182
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD JAN 21
PY 2020
VL 12
IS 3
BP 1513
EP 1527
DI 10.1039/c9nr07791j
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KF9GI
UT WOS:000509545700025
PM 31854413
DA 2025 08 17
ER

PT J
AU Jankowski, M
   Kaczmarek, M
   Wasiatycz, G
   Dompe, C
   Mozdziak, P
   Jaskowski, JM
   Piotrowska Kempisty, H
   Kempisty, B
AF Jankowski, Maurycy
   Kaczmarek, Mariusz
   Wasiatycz, Grzegorz
   Dompe, Claudia
   Mozdziak, Paul
   Jaskowski, Jedrzej M.
   Piotrowska Kempisty, Hanna
   Kempisty, Bartosz
TI Expression Profile of New Marker Genes Involved in Differentiation of
   Canine Adipose Derived Stem Cells into Osteoblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE adipose; stem cells; RNAseq; transcriptome; analysis
ID INDUCTION; FAMILY
AB Next generation sequencing (RNAseq) analysis of gene expression changes during the long term in vitro culture and osteogenic differentiation of ASCs remains to be important, as the analysis provides important clues toward employing stem cells as a therapeutic intervention. In this study, the cells were isolated from adipose tissue obtained during routine surgical procedures and subjected to 14 day in vitro culture and differentiation. The mRNA transcript levels were evaluated using the Illumina platform, resulting in the detection of 19,856 gene transcripts. The most differentially expressed genes (fold change >|2|, adjusted p value < 0.05), between day 1, day 14 and differentiated cell cultures were extracted and subjected to bioinformatical analysis based on the R programming language. The results of this study provide molecular insight into the processes that occur during long term in vitro culture and osteogenic differentiation of ASCs, allowing the re evaluation of the roles of some genes in MSC progression towards a range of lineages. The results improve the knowledge of the molecular mechanisms associated with long term in vitro culture and differentiation of ASCs, as well as providing a point of reference for potential in vivo and clinical studies regarding these cells' application in regenerative medicine.
C1 [Jankowski, Maurycy; Kempisty, Bartosz] Poznan Univ Med Sci, Dept Anat, PL 60781 Poznan, Poland.
   [Kaczmarek, Mariusz] Poznan Univ Med Sci, Dept Canc Immunol, Chair Med Biotechnol, PL 61866 Poznan, Poland.
   [Kaczmarek, Mariusz] Greater Poland Canc Ctr, Dept Canc Diagnost & Immunol, Gene Therapy Lab, PL 61866 Poznan, Poland.
   [Wasiatycz, Grzegorz; Kempisty, Bartosz] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL 87100 Torun, Poland.
   [Dompe, Claudia] Univ Aberdeen, Sch Med Med Sci & Nutr, Aberdeen AB25 2ZD, Scotland.
   [Mozdziak, Paul; Kempisty, Bartosz] North Carolina State Univ, Coll Agr & Life Sci, Prestage Dept Poultry Sci, Raleigh, NC 27695 USA.
   [Jaskowski, Jedrzej M.] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Diagnost & Clin Sci, PL 87100 Torun, Poland.
   [Piotrowska Kempisty, Hanna] Poznan Univ Med Sci, Dept Toxicol, PL 60701 Poznan, Poland.
   [Piotrowska Kempisty, Hanna] Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Basic & Preclin Sci, PL 87100 Torun, Poland.
   [Kempisty, Bartosz] Poznan Univ Med Sci, Dept Histol & Embryol, PL 60781 Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences; Wielkopolskie Centrum Onkologii; Nicolaus Copernicus
   University; University of Aberdeen; North Carolina State University;
   Nicolaus Copernicus University; Poznan University of Medical Sciences;
   Nicolaus Copernicus University; Poznan University of Medical Sciences
RP Kempisty, B (通讯作者)，Poznan Univ Med Sci, Dept Anat, PL 60781 Poznan, Poland.; Kempisty, B (通讯作者)，Nicolaus Copernicus Univ Torun, Inst Vet Med, Dept Vet Surg, PL 87100 Torun, Poland.; Kempisty, B (通讯作者)，North Carolina State Univ, Coll Agr & Life Sci, Prestage Dept Poultry Sci, Raleigh, NC 27695 USA.; Kempisty, B (通讯作者)，Poznan Univ Med Sci, Dept Histol & Embryol, PL 60781 Poznan, Poland.
EM mjankowski@ump.edu.pl; markacz@ump.edu.pl; g.wasiatycz@umk.pl;
   claudia.dompe.16@abdn.ac.uk; pemozdzi@ncsu.edu; jmjaskowski@umk.pl;
   hpiotrow@ump.edu.pl; bkempisty@ump.edu.pl
RI ; Dompe, Claudia/JJC 5296 2023; Kaczmarek, Mariusz/G 2853 2014
OI Jankowski, Maurycy/0000 0001 9476 0235; Kaczmarek,
   Mariusz/0000 0002 6282 3251; mozdziak, paul/0000 0002 1575 3123
FU Polish Ministry of Science and Higher Education [DI2017018647]
FX This research was funded by the Polish Ministry of Science and Higher
   Education, grant number DI2017018647.
CR Ackema KB, 2008, STEM CELLS DEV, V17, P979, DOI 10.1089/scd.2007.0220
   Bae S, 2009, CELL TISSUE RES, V335, P565, DOI 10.1007/s00441 008 0729 y
   Bhatlekar S, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3569493
   Bogomolovas J, 2020, AM J PHYSIOL HEART C, V318, pH1509, DOI 10.1152/ajpheart.00249.2020
   Bonet F, 2018, DEV DYNAM, V247, P1135, DOI 10.1002/dvdy.24670
   Cai ZP, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00896
   Caley MP, 2015, ADV WOUND CARE, V4, P225, DOI 10.1089/wound.2014.0581
   Calloni R, 2013, STEM CELLS DEV, V22, P1455, DOI 10.1089/scd.2012.0637
   Chan SF, 2015, GENOM DATA, V3, P24, DOI 10.1016/j.gdata.2014.10.022
   Chen GL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.81
   Chen KN, 2019, PEERJ, V7, DOI 10.7717/peerj.7544
   Cotman CW, 2008, J ALZHEIMERS DIS, V15, P685
   de la Morena MT, 2011, HEMATOL ONCOL CLIN N, V25, P1, DOI 10.1016/j.hoc.2010.11.001
   Deng P, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00116 y
   Dompe C., 2019, MED J CELL BIOL, V7, P105, DOI DOI 10.2478/ACB 2019 0014
   Dyszkiewicz Konwinska M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041027
   Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004 0212
   Finnegan A, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00775
   Ge SX, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859 018 2486 6
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gómez C, 2017, MOL CELL NEUROSCI, V85, P127, DOI 10.1016/j.mcn.2017.09.006
   Griffin JN, 2018, DEV CELL, V44, P248, DOI 10.1016/j.devcel.2017.12.001
   Hayashi Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0088 z
   Hng CH, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68261 2
   Hofsteen P, 2018, ISCIENCE, V2, P88, DOI 10.1016/j.isci.2018.03.010
   Hwang JY, 2009, BONE, V45, P1098, DOI 10.1016/j.bone.2009.07.080
   Hytönen MK, 2016, RARE DIS, V4, DOI 10.1080/21675511.2016.1241362
   Im GI, 2021, BONE JOINT RES, V10, P134, DOI 10.1302/2046 3758.102.BJR 2020 0517.R1
   Ishida H, 2016, CELL REP, V16, P1026, DOI 10.1016/j.celrep.2016.06.050
   Jankowski M., 2018, MED J CELL BIOL, V6, P27, DOI [10.2478/acb 2018 0005, DOI 10.2478/ACB 2018 0005]
   Jankowski M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081783
   Jarrige M, 2021, CELLS BASEL, V10, DOI 10.3390/cells10020240
   Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 182
   Jin LY, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658 017 0044 2
   Kim I, 2018, CELL BIOL INT, V42, P303, DOI 10.1002/cbin.10895
   Kobayashi S, 2015, J BIOL CHEM, V290, P7443, DOI 10.1074/jbc.M114.592493
   Koressaar T, 2018, BIOINFORMATICS, V34, P1937, DOI 10.1093/bioinformatics/bty036
   Kranc W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122673
   Ku CS, 2011, J MED GENET, V48, P721, DOI 10.1136/jmedgenet 2011 100242
   Kulus M, 2018, MED J CELL BIOL, V6, P101, DOI DOI 10.2478/ACB 2018 0016
   Lai Ruenn Chai, 2012, Int J Proteomics, V2012, P971907, DOI 10.1155/2012/971907
   Lee H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12512 2
   Levy SE, 2016, ANNU REV GENOM HUM G, V17, P95, DOI 10.1146/annurev genom 083115 022413
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Liao WJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09228 8
   Lin HS, 2019, BIOMATER SCI UK, V7, P347, DOI 10.1039/c8bm01128a
   Lin X, 2017, CELL BIOL INT, V41, P534, DOI 10.1002/cbin.10757
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Man Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.621214
   Markway BD, 2015, J ORTHOP RES, V33, P1561, DOI 10.1002/jor.22930
   Marofi F, 2019, J CELL PHYSIOL, V234, P6230, DOI 10.1002/jcp.27352
   Marusina AI, 2020, STEM CELLS, V38, P231, DOI 10.1002/stem.3105
   Mauffrey P, 2019, NATURE, V569, P672, DOI 10.1038/s41586 019 1219 y
   Medvedev SP, 2010, ACTA NATURAE, V2, P18, DOI 10.32607/20758251 2010 2 2 18 27
   Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076
   Moncrieff L., 2019, MED J CELL BIOL, V7, P134, DOI [10.2478/acb 2019 0018, DOI 10.2478/ACB 2019 0018]
   Fideles SOM, 2019, J CELL BIOCHEM, V120, P11842, DOI 10.1002/jcb.28463
   Muller M., 2020, MED J CELL BIOL, V8, P124, DOI [10.2478/acb 2020 0016, DOI 10.2478/ACB 2020 0016]
   Nargesi AA, 2017, CURR GENE THER, V17, P29, DOI 10.2174/1566523217666170412110724
   Oñate B, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 625
   Onizuka S, 2016, J CELL BIOCHEM, V117, P2423, DOI 10.1002/jcb.25634
   Palmieri A, 2008, CELL BIOL INT, V32, P733, DOI 10.1016/j.cellbi.2008.02.003
   Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005
   Pilgaard L, 2009, EXP CELL RES, V315, P1937, DOI 10.1016/j.yexcr.2009.01.020
   Qian X, 2014, J CANCER RES CLIN, V140, P1151, DOI 10.1007/s00432 014 1685 4
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rojewska M., 2018, Med. J. Cell Biol, V6, P114, DOI [10.2478/acb 2018 0018, DOI 10.2478/ACB 2018 0018]
   Ruan BJ, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0771 y
   Sackmann Sala L, 2015, MOL ENDOCRINOL, V29, P667, DOI 10.1210/me.2015 1022
   Sanchez Pulido L, 2018, BIOINFORMATICS, V34, P721, DOI 10.1093/bioinformatics/btx689
   Secco M, 2009, STEM CELL REV REP, V5, P387, DOI 10.1007/s12015 009 9098 5
   Shah K, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7309201
   Sheikh A, 2016, CANCER SCI, V107, P1223, DOI 10.1111/cas.13003
   Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005
   Stefa nskaK., 2020, Medical Journal of Cell Biology, V8, P83
   Stefanska K., 2019, Medical Journal of Cell Biology, V7, P183, DOI 10.2478/acb 2019 0025
   Stefanska K., 2020, Med. J. Cell Biol, V8, P78, DOI [10.2478/acb 2020 0009, DOI 10.2478/ACB 2020 0009]
   Tadijan A., 2021, INT J BIOCHEM CELL B, P131
   Takeuchi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126562
   de la Torre P, 2021, GENES BASEL, V12, DOI 10.3390/genes12010006
   Vidal C, 2015, STEM CELLS, V33, P111, DOI 10.1002/stem.1836
   von der Heyde B, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68567 1
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Wang SS, 2013, FEBS J, V280, P2644, DOI 10.1111/febs.12256
   WOOD C, 1993, AUST NZ J OBSTET GYN, V33, P316, DOI 10.1111/j.1479 828X.1993.tb02097.x
   Yamada T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038280
   Yang Y, 2015, CELL REPROGRAM, V17, P69, DOI 10.1089/cell.2014.0043
   Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966
   Young HE, 2004, ANAT REC PART A, V276A, P75, DOI 10.1002/ar.a.10134
   Zhang DL, 2018, ELIFE, V7, DOI 10.7554/eLife.33432
   Zhao N, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw4636
NR 92
TC 4
Z9 4
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 13
AR 6663
DI 10.3390/ijms22136663
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TG0PZ
UT WOS:000671116700001
PM 34206369
OA Green Published
DA 2025 08 17
ER

PT J
AU Timkovich, AE
   Holling, GA
   Afzali, MF
   Kisiday, J
   Santangelo, KS
AF Timkovich, Ariel E.
   Holling, G. Aaron
   Afzali, Maryam F.
   Kisiday, John
   Santangelo, Kelly S.
TI TLR4 antagonism provides short term but not long term clinical benefit
   in a full depth cartilage defect mouse model
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Toll like receptor 4; joint surface defects; cartilage;
   damage associated molecular patterns; MCP 1
ID TOLL LIKE RECEPTORS; MOVEMENT INDUCED NOCICEPTION; OSTEOCLAST
   DIFFERENTIATION; KNEE OSTEOARTHRITIS; GENE EXPRESSION; MURINE MODEL;
   LIPOPOLYSACCHARIDE; INFLAMMATION; DECREASES; RESPONSES
AB Purpose/AimCartilage injury and subsequent osteoarthritis (OA) are debilitating conditions affecting millions worldwide. As there are no cures for these ailments, novel therapies are needed to suppress disease pathogenesis. Given that joint injuries are known to produce damage associated molecular patterns (DAMPs), our central premise is that the Toll like receptor 4 (TLR4) pathway is a principal driver in the early response to cartilage damage and subsequent pathology. We postulate that TLR4 activation is initiated/perpetuated by DAMPs released following joint damage. Thus, antagonism of the TLR4 pathway immediately after injury may suppress the development of joint surface defects.Materials and MethodsTwo groups were utilized: (1) 8 week old, male C57BL6 mice treated systemically with a known TLR4 antagonist and (2) mice injected with vehicle control. A full depth cartilage lesion on the midline of the patellofemoral groove was created in the right knee of each mouse. The left knee was used as a sham surgery control. Gait changes were evaluated over 4 weeks using a quantitative gait analysis system. At harvest, knee joints were processed for pathologic assessment, Nanostring (R) transcript expression, and immunohistochemistry (IHC).ResultsShort term treatment with a TLR4 antagonist at 14 days significantly improved relevant gait parameters; improved cartilage metrics and modified Mankin scores were also seen. Additionally, mRNA expression and IHC showed reduced expression of inflammatory mediators in animals treated with the TLR4 antagonist.ConclusionsCollectively, this work demonstrates that systemic treatment with a TLR4 antagonist is protective to further cartilage damage 14 days post injury in a murine model of induced disease.
C1 [Timkovich, Ariel E.; Holling, G. Aaron; Afzali, Maryam F.; Santangelo, Kelly S.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO USA.
   [Kisiday, John] Colorado State Univ, Dept Clin Sci, Ft Collins, CO USA.
   [Kisiday, John; Santangelo, Kelly S.] Colorado State Univ, Dept Microbiol Immunol & Pathol, 1682 Campus Delivery, Ft Collins, CO 80523 USA.
C3 Colorado State University System; Colorado State University Fort
   Collins; Colorado State University System; Colorado State University
   Fort Collins; Colorado State University System; Colorado State
   University Fort Collins
RP Kisiday, J; Santangelo, KS (通讯作者)，Colorado State Univ, Dept Microbiol Immunol & Pathol, 1682 Campus Delivery, Ft Collins, CO 80523 USA.
EM jkisiday@uwyo.edu; Kelly.Santangelo@colostate.edu
RI ; Afzali, Maryam/AAD 8162 2022
OI Afzali, Maryam F./0000 0002 1053 2612; Timkovich,
   Ariel/0000 0001 8652 5016; 
FU The authors would like to thank Matthew Truelove, Sara Wist, and
   Margaret Campbell for their technical assistance. We would also like to
   acknowledge the intellectual contributions and discussions provided by
   Drs. Anna Plaas and John Sandy while this projec
FX The authors would like to thank Matthew Truelove, Sara Wist, and
   Margaret Campbell for their technical assistance. We would also like to
   acknowledge the intellectual contributions and discussions provided by
   Drs. Anna Plaas and John Sandy while this project was being crafted.
CR Akhter N, 2018, J DIABETES METAB DIS, V17, P77, DOI 10.1007/s40200 018 0341 y
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Allen KD, 2010, TISSUE ENG PART B RE, V16, P81, DOI 10.1089/ten.teb.2009.0447
   Assirelli E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.535010
   Ayral X, 2005, OSTEOARTHR CARTILAGE, V13, P361, DOI 10.1016/j.joca.2005.01.005
   BAKER PJ, 1990, INFECT IMMUN, V58, P2862, DOI 10.1128/IAI.58.9.2862 2868.1990
   Barreto G, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9040065
   Brown TD, 2006, J ORTHOP TRAUMA, V20, P739, DOI 10.1097/01.bot.0000246468.80635.ef
   Chang EJ, 2007, J CELL SCI, V120, P166, DOI 10.1242/jcs.03310
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Eltawil NM, 2009, OSTEOARTHR CARTILAGE, V17, P695, DOI 10.1016/j.joca.2008.11.003
   Ferreira Gomes J, 2021, J PAIN RES, V14, P2615, DOI 10.2147/JPR.S317877
   Ferreira Gomes J, 2012, PHARMACOL BIOCHEM BE, V101, P617, DOI 10.1016/j.pbb.2012.03.003
   Frisbie DD, 1997, EQUINE VET J, V29, P349, DOI 10.1111/j.2042 3306.1997.tb03138.x
   Gamer LW, 2017, J ORTHOP RES, V35, P1683, DOI 10.1002/jor.23446
   Gangloff M, 2012, TRENDS BIOCHEM SCI, V37, P92, DOI 10.1016/j.tibs.2011.11.003
   Gómez R, 2015, NAT REV RHEUMATOL, V11, P159, DOI 10.1038/nrrheum.2014.209
   Grandi FC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5352
   Hajishengallis G, 2010, TRENDS IMMUNOL, V31, P154, DOI 10.1016/j.it.2010.01.002
   Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618
   Jacobs BY, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916 014 0456 x
   Juarranz Y, 2006, ANN NY ACAD SCI, V1070, P359, DOI 10.1196/annals.1317.045
   Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Kim HA, 2006, ARTHRITIS RHEUM US, V54, P2152, DOI 10.1002/art.21951
   Krock E, 2018, OSTEOARTHR CARTILAGE, V26, P1236, DOI 10.1016/j.joca.2018.06.002
   Lakes EH, 2016, OSTEOARTHR CARTILAGE, V24, P1837, DOI 10.1016/j.joca.2016.03.008
   Liu X, 2020, J CELL MOL MED, V24, P11489, DOI 10.1111/jcmm.15763
   Longobardi L, 2017, OSTEOARTHR CARTILAGE, V25, P914, DOI 10.1016/j.joca.2016.11.004
   Lu ZY, 2015, IMMUNOBIOLOGY, V220, P1246, DOI 10.1016/j.imbio.2015.06.016
   March L, 2014, BEST PRACT RES CL RH, V28, P353, DOI 10.1016/j.berh.2014.08.002
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987
   Miller RE, 2015, ARTHRITIS RHEUMATOL, V67, P2933, DOI 10.1002/art.39291
   Murphy SL, 2011, ARTHRIT CARE RES, V63, P1543, DOI 10.1002/acr.20583
   Muthuri SG, 2011, OSTEOARTHR CARTILAGE, V19, P1286, DOI 10.1016/j.joca.2011.07.015
   Nair A, 2012, ARTHRITIS RHEUM US, V64, P2268, DOI 10.1002/art.34495
   Nasi S, 2014, JOINT BONE SPINE, V81, P320, DOI 10.1016/j.jbspin.2014.01.018
   Ospelt C, 2008, ARTHRITIS RHEUM US, V58, P3684, DOI 10.1002/art.24140
   Plaas A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3286
   Pope MR, 2010, MOL IMMUNOL, V48, P356, DOI 10.1016/j.molimm.2010.07.004
   Radakovich LB, 2022, OSTEOARTHR CARTILAGE, V30, P1482, DOI 10.1016/j.joca.2022.08.007
   Santangelo KS, 2011, OSTEOARTHR CARTILAGE, V19, P439, DOI 10.1016/j.joca.2011.01.004
   Schelbergen RFP, 2012, ARTHRITIS RHEUM US, V64, P1477, DOI 10.1002/art.33495
   Sebastian A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092657
   Sorge RE, 2011, J NEUROSCI, V31, P15450, DOI 10.1523/JNEUROSCI.3859 11.2011
   Stolberg Stolberg J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04680 5
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tamaki Y, 2011, J RHEUMATOL, V38, P810, DOI 10.3899/jrheum.100732
   Thomas AC, 2017, J ATHL TRAINING, V52, P491, DOI 10.4085/1062 6050 51.5.08
   Turkiewicz A, 2019, OSTEOARTHR CARTILAGE, V27, P848, DOI 10.1016/j.joca.2019.02.793
   VANDERSLUIJS JA, 1992, J ORTHOPAED RES, V10, P58, DOI 10.1002/jor.1100100107
   Wang P, 2011, FASEB J, V25, P3401, DOI 10.1096/fj.11 184861
   Zaki S, 2022, OSTEOARTHR CARTILAGE, V30, P357, DOI 10.1016/j.joca.2021.03.024
   Zarebska JM, 2017, OSTEOARTHR CARTILAGE, V25, P406, DOI 10.1016/j.joca.2016.10.008
NR 55
TC 0
Z9 0
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD JAN 2
PY 2024
VL 65
IS 1
BP 26
EP 40
DI 10.1080/03008207.2023.2269257
EA OCT 2023
PG 15
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA GJ9P1
UT WOS:001088946300001
PM 37898909
DA 2025 08 17
ER

PT J
AU Hasan, M
   Schumacher, G
   Seekamp, A
   Taedken, T
   Siegmund, W
   Oswald, S
AF Hasan, Mahmoud
   Schumacher, Gitta
   Seekamp, Anne
   Taedken, Tobias
   Siegmund, Werner
   Oswald, Stefan
TI LC MS/MS method for the determination of clodronate in human plasma
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Clodronate; Etidronate; LC MS/MS; Plasma; Quantification
ID IONIZATION MASS SPECTROMETRY; DISODIUM CLODRONATE; RENAL FAILURE;
   BISPHOSPHONATES; PHARMACOKINETICS; CHROMATOGRAPHY; TOLERABILITY;
   VALIDATION; URINE
AB Clodronate belongs to the class of bisphosphonates which are used for the treatment of bone disorders. Due to its high polarity it has a low and highly variable oral bioavailability which results in low plasma concentrations and requires sensitive bioanalytical methods to characterize its pharmacokinetics in human. Here, we describe for the first time the development and validation of a LC MS/MS assay for the quantification of clodronate in human plasma. The bisphosphonate was isolated from the biological matrix by protein precipitation using perchloric acid (10%), and derivatized with trimethylorthoacetate prior sample clean up with liquid liquid extraction using methyl tert butyl ether.
   The chromatography was performed using an isocratic elution with ammonium acetate 5 mM (85% v/v, pH 3.8) and acetonitrile (15% v/v) as mobile phase with a flow rate of 300 mu l/min on a reversed phase column (Supelco Ascentis (R), C18) temporized at 50 C. The mass spectrometric detection was done using the API4000 triple quadruple mass spectrometer monitoring the mass/charge transitions 301.0/145 for clodronate and 305.2/137.1 for the internal standard etidronate.
   The analytical range was set to 5 800 ng/ml, allowing an evaluation of the plasma concentration time profiles of clodronate for approximately 7 8 half life (similar to 24 h). The method was validated according to current FDA/EMA guidelines on bioanalytical method validation with respect to specificity, linearity, intra  and inter day accuracy and precision, matrix effect, recovery as well as stability. The precision of the assay was 0.6 6.9% and 0.6 8.1% for the intra day and inter day variability, respectively. The intra day and inter day accuracy (error) was 0.6 8.8% and 2.2 4.5%. The recovery of the analyte was low (2 3%) but reproducible over the entire validation range and sufficient to monitor the target concentrations in human plasma. The drug was shown to be stable in plasma at room temperature for at least 3 h (96.0 +/  6%) and for at least 24 h when stored in the cooled autosampler at 4 degrees C (102.4 +/  4.5%). Clodronate can also undergo up to three freeze thaw cycles without impaired stability. Thus, the method was shown to possess sufficient specificity, sensitivity, accuracy, precision and stability to measure plasma concentrations of clodronate. Finally, the developed method was successfully applied to study the clodronate serum levels in a pharmacokinetic study in healthy volunteers. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Hasan, Mahmoud; Schumacher, Gitta; Seekamp, Anne; Taedken, Tobias; Siegmund, Werner; Oswald, Stefan] Univ Med, Ctr Drug Absorpt & Transport, Dept Clin Pharmacol, Greifswald, Germany.
   [Hasan, Mahmoud] Future Univ, Dept Pharmaceut Chem, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Future University in Egypt
RP Oswald, S (通讯作者)，Ernst Moritz Arndt Univ Greifswald, Ctr Drug Absorpt & Transport, Dept Clin Pharmacol, Felix Hausdorff Str 3, D 17487 Greifswald, Germany.
EM stefan.oswald@uni greifswald.de
FU German Federal Ministry for Education and Research [03IPT612A]; Future
   University in Egypt (Hassan Azazy scholarship)
FX The analytic part was supported by the grant 03IPT612A
   (InnoProfile Transfer) of the German Federal Ministry for Education and
   Research. Sponsored by Future University in Egypt (Hassan Azazy
   scholarship).
CR [Anonymous], 2012, GUIDELINE BIONALATYI
   [Anonymous], 2013, Guidance for industry # 213
   Ceponis A, 2001, ARTHRITIS RHEUM, V44, P1908
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fernandes C, 2007, J CHROMATOGR SCI, V45, P236, DOI 10.1093/chromsci/45.5.236
   Haber E, 2009, HUM REPROD, V24, P398, DOI 10.1093/humrep/den375
   Huikko K, 2002, J MASS SPECTROM, V37, P197, DOI 10.1002/jms.273
   Leis HJ, 2004, RAPID COMMUN MASS SP, V18, P2781, DOI 10.1002/rcm.1688
   Lovdahl MJ, 1999, J CHROMATOGR A, V850, P143, DOI 10.1016/S0021 9673(99)00622 6
   Mäkelä S, 2011, INT J CLIN PHARM TH, V49, P128, DOI 10.5414/CPP49128
   Muntoni E, 2004, J CHROMATOGR B, V799, P133, DOI 10.1016/j.jchromb.2003.10.035
   Poli G, 2004, EUR J DRUG METAB PH, V29, P145, DOI 10.1007/BF03190589
   Radicioni M, 2013, INT J CLIN PHARM TH, V51, P313, DOI 10.5414/CP201799
   Rizzoli R, 2011, QJM INT J MED, V104, P281, DOI 10.1093/qjmed/hcq259
   Rodríguez JAB, 2007, J PHARMACEUT BIOMED, V44, P305, DOI 10.1016/j.jpba.2007.02.021
   SAHA H, 1994, J BONE MINER RES, V9, P1953
   Tarcomnicu I, 2007, J CHROMATOGR A, V1160, P21, DOI 10.1016/j.chroma.2007.04.020
   Tarcomnicu I, 2009, J CHROMATOGR B, V877, P3159, DOI 10.1016/j.jchromb.2009.08.007
   Ulbrich W, 2011, TALANTA, V84, P437, DOI 10.1016/j.talanta.2011.01.049
   Villikka K, 2002, BONE, V31, P418, DOI 10.1016/S8756 3282(02)00841 4
   Ylitalo P, 1999, INT J CLIN PHARM TH, V37, P294
NR 22
TC 13
Z9 14
U1 0
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731 7085
EI 1873 264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD NOV
PY 2014
VL 100
BP 341
EP 347
DI 10.1016/j.jpba.2014.08.022
PG 7
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA AQ7TC
UT WOS:000343021100044
PM 25194348
DA 2025 08 17
ER

PT J
AU King, JN
   King, S
   Budsberg, SC
   Lascelles, BDX
   Bienhoff, SE
   Roycroft, LM
   Roberts, ES
AF King, Jonathan N.
   King, Stephen
   Budsberg, Steven C.
   Lascelles, B. Duncan X.
   Bienhoff, Stephen E.
   Roycroft, Linda M.
   Roberts, Elizabeth S.
TI Clinical safety of robenacoxib in feline osteoarthritis: results of a
   randomized, blinded, placebo controlled clinical trial
SO JOURNAL OF FELINE MEDICINE AND SURGERY
LA English
DT Article
ID DEGENERATIVE JOINT DISEASE; MUSCULOSKELETAL DISORDERS; ORAL ROBENACOXIB;
   ACUTE PAIN; CATS; MELOXICAM; KETOPROFEN
AB Objectives The objective of this study was to evaluate the clinical safety of the non steroidal anti inflammatory drug (NSAID) robenacoxib in cats with osteoarthritis. Degenerative joint disease, including osteoarthritis, is highly prevalent in cats and many cases have associated pain and impaired mobility. Although NSAIDs are used routinely to control pain and inflammation in cats with osteoarthritis, there are safety concerns because of the high concurrent prevalence of chronic kidney disease (CKD) and the paucity of data on the safety of these drugs in target clinical populations.
   Methods A total of 194 cats with osteoarthritis were recruited and randomly allocated to receive either robenacoxib at a dosage of 1.0 2.4 mg/kg (n = 95) or placebo (n = 99) tablets PO q24h for 28 days. Safety was assessed in 193 cats, including a subgroup of 40 animals with concurrent CKD, defined as serum creatinine concentration 1.6 mg/dl and urine specific gravity <1.030. Safety endpoints included reports of adverse events, results of clinical examinations, including body weight, and clinical chemistry and hematology variables.
   Results In all 193 cats and the subgroup of 40 animals with concurrent CKD, there were no differences between groups in frequencies of reported adverse events, body weight change or results of serum or urine chemistry or hematology variables.
   Conclusions and relevance Robenacoxib was well tolerated when administered daily for 1 month in cats with osteoarthritis, including cats with evidence of concurrent CKD. There was no clinical indication of damage to the gastrointestinal tract, kidney or liver.
C1 [King, Jonathan N.] Elanco Anim Hlth, Clin Dev, CH 4002 Basel, Switzerland.
   [King, Stephen; Bienhoff, Stephen E.; Roycroft, Linda M.; Roberts, Elizabeth S.] Elanco Anim Hlth, New Prod Dev, Greensboro, NC USA.
   [Budsberg, Steven C.] Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA USA.
   [Lascelles, B. Duncan X.] North Carolina State Univ, Dept Clin Sci, Coll Vet Med, Comparat Pain Res Lab, Raleigh, NC USA.
   [Lascelles, B. Duncan X.] North Carolina State Univ, Ctr Comparat Med & Translat Res, Raleigh, NC USA.
   [Lascelles, B. Duncan X.] Univ N Carolina, Sch Dent, Ctr Pain Res & Innovat, Chapel Hill, NC USA.
   [Bienhoff, Stephen E.] AlcheraBio LLC, Clin Serv, Edison, NJ USA.
C3 University System of Georgia; University of Georgia; North Carolina
   State University; North Carolina State University; University of North
   Carolina; University of North Carolina Chapel Hill
RP King, JN (通讯作者)，Elanco Anim Hlth, Clin Dev, CH 4002 Basel, Switzerland.
EM jonathan.king@novartis.com
OI Lascelles, B. Duncan X./0000 0002 2950 9009
FU Elanco Animal Health
FX The study was funded by Novartis Animal Health, now owned by Elanco
   Animal Health, which manufactures and markets robenacoxib (Onsior (R)).
CR Benito J, 2013, VET J, V196, P368, DOI 10.1016/j.tvjl.2012.12.015
   Benito J, 2013, J VET INTERN MED, V27, P474, DOI 10.1111/jvim.12077
   Charlton AN, 2013, J FELINE MED SURG, V15, P678, DOI 10.1177/1098612X12473994
   Clarke SP, 2006, J SMALL ANIM PRACT, V47, P439, DOI 10.1111/j.1748 5827.2006.00143.x
   Duncan B, 2007, VET ANAESTH ANALG, V34, P228, DOI 10.1111/j.1467 2995.2006.00322.x
   Giraudel JM, 2010, AM J VET RES, V71, P710, DOI 10.2460/ajvr.71.7.710
   Gowan RA, 2011, J FELINE MED SURG, V13, P752, DOI 10.1016/j.jfms.2011.06.008
   Gruen ME, 2014, J FELINE MED SURG, V16, P727, DOI 10.1177/1098612X14539499
   Gunew MN, 2008, J FELINE MED SURG, V10, P235, DOI 10.1016/j.jfms.2007.10.007
   International Renal Interest Society, IRIS staging of CKD (modified 2023)
   King JN, 2012, J VET PHARMACOL THER, V35, P290, DOI 10.1111/j.1365 2885.2011.01320.x
   King JN, 2013, AM J VET RES, V193, P397
   King S, 2012, ISRN VET SCI
   Lascelles BDX, 2007, J VET INTERN MED, V21, P410, DOI 10.1892/0891 6640(2007)21[410:EOCOMA]2.0.CO;2
   Lascelles BDX, 2010, VET SURG, V39, P535, DOI 10.1111/j.1532 950X.2010.00708.x
   Marino CL, 2014, J FELINE MED SURG, V16, P465, DOI 10.1177/1098612X13511446
   Sano T, 2012, VET J, V193, P397, DOI 10.1016/j.tvjl.2012.02.008
   Sul RM, 2014, VET COMP ORTHOPAED, V27, P20, DOI 10.3415/VCOT 12 11 0139
   Surdyk KK, 2013, AM J VET RES, V74, P648, DOI 10.2460/ajvr.74.4.648
   US Food and Drug Administration Center for Veterinary Medicine VICH GL9, 2001, GUID IND GOOD CLIN P
NR 20
TC 30
Z9 33
U1 0
U2 27
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1098 612X
EI 1532 2750
J9 J FELINE MED SURG
JI J. Feline Med. Surg.
PD AUG
PY 2016
VL 18
IS 8
BP 632
EP 642
DI 10.1177/1098612X15590870
PG 11
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA DS7VA
UT WOS:000380989800008
PM 26058587
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, HF
   Qing, FZ
   Zhao, H
   Fan, HS
   Liu, M
   Zhang, XD
AF Zhang, Huaifa
   Qing, Fangzhu
   Zhao, Huan
   Fan, Hongsong
   Liu, Ming
   Zhang, Xingdong
TI Cellular internalization of rod like nano hydroxyapatite particles and
   their size and dose dependent effects on pre osteoblasts
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID GOLD NANOPARTICLES; MC3T3 E1 CELLS; DRUG DELIVERY; POLY(ETHYLENE
   GLYCOL); COMPOSITE SCAFFOLDS; MATRIX REGULATION; CALCIUM; APOPTOSIS;
   PROLIFERATION; CYTOTOXICITY
AB Nano hydroxyapatite particles (n HA) have been reported to promote osteogenic activities of bonerelated cells, while inhibiting tumor cell growth, and the biological effects of n HA are related with the particle size, dose, culture time and cell type. In this work, we prepared n HA with a strictly controlled rod like shape and adjustable sizes without any surface chemical contaminations. Using the prepared n HA, we investigated the size and dose effect of the nano particles on pre osteoblasts for up to 7 days. We probed cell proliferation and gene expression in the presence of n HA, the cellular uptake pathways of n HA particles, as well as the extracellular and intracellular [Ca2+] ([Ca2+](i)) changes caused by the particles, in order to get a better understanding of the biological effects of n HA of various sizes. The n HA exhibited size and dose dependent impacts on MC3T3 E1 proliferation, intracellular reactive oxygen species (ROS) generation, mitochondrial membrane potential, and osteogenic gene expression. 40 nm n HA caused the slowest MC3T3 E1 growth, the highest intracellular ROS concentration, the largest mitochondrial membrane potential loss and the lowest level of osteogenic gene expression among the samples. The cytotoxicity of 40 nm n HA increased with the dose and culture time. 70 nm n HA showed beneficial effects on MC3T3 E1 growth, but the positive effect disappeared at the highest concentration on day 7. 100 nm n HA promoted cell growth and the promoting effect increased with the dose. Cells cultured with 100 nm n HA expressed the highest level of osteogenic gene expression among the experimental groups. We discovered that the presence of n HA increased [Ca2+] i but did not elevate extracellular [Ca2+]. The [Ca2+] i increased as the n HA size decreased. We also found that n HA may enter cells through two pathways and that the amount of engulfed particles depended on the particle size. The internalized n HA particles located in the cytosol, endosomes, lysosomes and nuclei. The particles dissolved in lysosomes and raised [Ca2+] i, which correlated with the cell death and osteogenic gene expression. In conclusion, the particle size, dose, and culture time influenced the biological effects of n HA on ME3T3 E1 cells, probably by changing the [Ca2+] i in the cells instead of the extracellular [Ca2+].
C1 [Zhang, Huaifa; Qing, Fangzhu; Zhao, Huan; Fan, Hongsong; Zhang, Xingdong] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Sichuan, Peoples R China.
   [Zhang, Huaifa] McGill Univ, Fac Dent, Montreal, PQ H2X 2C9, Canada.
   [Liu, Ming] Sichuan Univ, Analyt & Testing Ctr, Chengdu 610064, Sichuan, Peoples R China.
C3 Sichuan University; McGill University; Sichuan University
RP Fan, HS (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Sichuan, Peoples R China.; Liu, M (通讯作者)，Sichuan Univ, Analyt & Testing Ctr, Chengdu 610064, Sichuan, Peoples R China.
EM hsfan@scu.edu.cn; mingliu@scu.edu.cn
RI Liu, Ming/IXW 8752 2023
FU National Natural Science Foundation of China [51473098, 81190131];
   National Basic Research Program of China [2011CB606201]
FX This work was supported by the National Natural Science Foundation of
   China (Contract Grant No. 51473098, 81190131) and the National Basic
   Research Program of China (Grant No. 2011CB606201).
CR Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200
   Aguilar Frutis M, 2009, SURF COAT TECH, V204, P1116, DOI 10.1016/j.surfcoat.2009.07.021
   Alkilany AM, 2010, J NANOPART RES, V12, P2313, DOI 10.1007/s11051 010 9911 8
   Aronov D, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2196481
   Bao G, 2005, P NATL ACAD SCI USA, V102, P9997, DOI 10.1073/pnas.0504555102
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Bauer IW, 2008, J MATER SCI MATER M, V19, P1091, DOI 10.1007/s10856 007 3124 4
   Buzea C, 2007, BIOINTERPHASES, V2, pMR17, DOI 10.1116/1.2815690
   Cai YR, 2007, J MATER CHEM, V17, P3780, DOI 10.1039/b705129h
   Cao LF, 2010, RARE METALS, V29, P50, DOI [10.1007/S12598 010 0009 3, 10.1007/s12598 010 0009 3]
   Caswell KK, 2003, J AM CHEM SOC, V125, P13914, DOI 10.1021/ja037969i
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Cui XH, 2016, MAT SCI ENG C MATER, V67, P453, DOI 10.1016/j.msec.2016.05.034
   Curtin CM, 2012, ADV MATER, V24, P749, DOI 10.1002/adma.201103828
   Deng Y, 2013, MATER LETT, V104, P8, DOI 10.1016/j.matlet.2013.03.145
   Favi PM, 2015, J BIOMED MATER RES A, V103, P3940, DOI 10.1002/jbm.a.35518
   Favi PM, 2015, J BIOMED MATER RES A, V103, P3449, DOI 10.1002/jbm.a.35491
   Ginzburg VV, 2007, NANO LETT, V7, P3716, DOI 10.1021/nl072053l
   Harding IS, 2005, BIOMATERIALS, V26, P6818, DOI 10.1016/j.biomaterials.2005.04.060
   Janardhanan A, 2013, MATER SCI POLAND, V31, P173, DOI 10.2478/s13536 012 0085 1
   Jena NR, 2012, J BIOSCIENCES, V37, P503, DOI 10.1007/s12038 012 9218 2
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Johnson AJW, 2011, ACTA BIOMATER, V7, P16, DOI 10.1016/j.actbio.2010.07.012
   Kalia P, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0004
   Kalita SJ, 2007, MAT SCI ENG C BIO S, V27, P441, DOI 10.1016/j.msec.2006.05.018
   Kong LJ, 2006, EUR POLYM J, V42, P3171, DOI 10.1016/j.eurpolymj.2006.08.009
   Li Z., 2014, BIOMED MATER, V9
   Liu TY, 2005, J CONTROL RELEASE, V107, P112, DOI 10.1016/j.jconrel.2005.05.025
   Liu XC, 2012, INT J NANOMED, V7, P1239, DOI 10.2147/IJN.S28098
   Liu YK, 2004, MATER CHEM PHYS, V86, P69, DOI 10.1016/j.matchemphys.2004.02.009
   Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006
   Matsumoto T, 2004, BIOMATERIALS, V25, P3807, DOI 10.1016/j.biomaterials.2003.10.081
   Meena R, 2012, J NANOPART RES, V14, DOI 10.1007/s11051 011 0712 5
   Motskin M, 2009, BIOMATERIALS, V30, P3307, DOI 10.1016/j.biomaterials.2009.02.044
   Tran N, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/18/185102
   Pang XF, 2012, J NANOSCI NANOTECHNO, V12, P894, DOI 10.1166/jnn.2012.5154
   Panté N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01 06 0308
   Pezzatini S, 2006, J BIOMED MATER RES A, V76A, P656, DOI 10.1002/jbm.a.30524
   Pon On W, 2008, MATER CHEM PHYS, V112, P453, DOI 10.1016/j.matchemphys.2008.05.082
   Qing FZ, 2012, J MATER SCI MATER M, V23, P2245, DOI 10.1007/s10856 012 4703 6
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Saunders R, 2007, J CELL BIOCHEM, V100, P703, DOI 10.1002/jcb.21001
   Schwiertz J, 2009, BIOMATERIALS, V30, P3324, DOI 10.1016/j.biomaterials.2009.02.029
   Shi ZL, 2009, ACTA BIOMATER, V5, P338, DOI 10.1016/j.actbio.2008.07.023
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Tang W, 2014, NANOMEDICINE UK, V9, P397, DOI [10.2217/nnm.12.217, 10.2217/NNM.12.217]
   Voccoli V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.483
   Wang LT, 2012, NANOSCALE, V4, P2894, DOI 10.1039/c2nr00044j
   Wang TT, 2012, ACS NANO, V6, P1251, DOI 10.1021/nn203892h
   Wang XF, 2016, RSC ADV, V6, P6832, DOI 10.1039/c5ra21527g
   Wang XJ, 2002, BIOMATERIALS, V23, P4787, DOI 10.1016/S0142 9612(02)00229 6
   Wei GB, 2004, BIOMATERIALS, V25, P4749, DOI 10.1016/j.biomaterials.2003.12.005
   Xie GP, 2010, J MATER SCI MATER M, V21, P1875, DOI 10.1007/s10856 010 4038 0
   Xu ZL, 2012, J APPL TOXICOL, V32, P429, DOI 10.1002/jat.1745
   Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530
   Yan Y, 2006, ACTA PHARMACOL SIN, V27, P821, DOI 10.1111/j.1745 7254.2006.00390.x
   Yang Lijian, 2010, Wuhan University Journal of Natural Sciences, V15, P350, DOI 10.1007/s11859 010 0665 z
   Ye F, 2010, ACTA BIOMATER, V6, P2212, DOI 10.1016/j.actbio.2009.12.014
   Yin MZ, 2014, J NANOMATER, V2014, DOI 10.1155/2014/731897
   Yuan Y, 2010, BIOMATERIALS, V31, P730, DOI 10.1016/j.biomaterials.2009.09.088
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang CM, 2010, BIOMATERIALS, V31, P3374, DOI 10.1016/j.biomaterials.2010.01.044
   Zhang HQ, 2011, CERAM INT, V37, P279, DOI 10.1016/j.ceramint.2010.08.038
   Zhang HF, 2012, CRYST GROWTH DES, V12, P2204, DOI 10.1021/cg200917y
   Zhang HF, 2012, MATER LETT, V75, P26, DOI 10.1016/j.matlet.2012.01.110
   Zhang L, 2005, J MATER SCI MATER M, V16, P213, DOI 10.1007/s10856 005 6682 3
   Zhang SL, 2009, ADV MATER, V21, P419, DOI 10.1002/adma.200801393
   Zhao XX, 2013, ARCH TOXICOL, V87, P1037, DOI 10.1007/s00204 012 0827 1
NR 68
TC 24
Z9 24
U1 3
U2 47
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD FEB 14
PY 2017
VL 5
IS 6
BP 1205
EP 1217
DI 10.1039/c6tb01401a
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EN3NA
UT WOS:000395914000010
PM 32263590
DA 2025 08 17
ER

PT J
AU Park, YS
   Hwang, S
   Jin, YM
   Yu, Y
   Jung, SA
   Jung, SC
   Ryu, KH
   Kim, HS
   Jo, I
AF Park, Yoon Shin
   Hwang, Soojin
   Jin, Yoon Mi
   Yu, Yeonsil
   Jung, Sung Ae
   Jung, Sung Chul
   Ryu, Kyung Ha
   Kim, Han Su
   Jo, Inho
TI CCN1 Secreted by Tonsil Derived Mesenchymal Stem Cells Promotes
   Endothelial Cell Angiogenesis via Integrin αvβ3
   and AMPK
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID IMMEDIATE EARLY GENE; ACTIVATED PROTEIN KINASE; GROWTH FACTOR;
   OSTEOBLAST DIFFERENTIATION; SONIC HEDGEHOG; BREAST CANCER; CYR61 CCN1;
   MIGRATION; PRODUCT; ALPHA(6)BETA(1)
AB CCN1 is highly expressed in cancer cells and has been identified in the secretome of bone marrow derived mesenchymal stem cells (BM MSC). Although secreted CCN1 is known to promote angiogenesis, its underlying mechanism remains unclear. Here, we examined whether our recently established tonsil derived MSC (T MSC) secrete CCN1 and, if any, how CCN1 promotes the angiogenesis of human umbilical vein endothelial cells (HUVEC). Compared with untreated control T MSC, a higher level of CCN1 was secreted by T MSC treated with activin A and sonic hedgehog, drugs known to induce endodermal differentiation. Expectedly, conditioned medium collected from differentiated T MSC (DCM) significantly increased HUVEC migration and tube formation compared with that from control T MSC (CCM), and these stimulatory effects were reversed by neutralization with anti CCN1 antibody. Treatment with recombinant human CCN1 (rh CCN1) alone also mimicked the stimulatory effects of DCM. Furthermore, treatment with either DCM or rh CCN1 increased the phosphorylation of AMP kinase (AMPK), and ectopic expression of siRNA of the AMPK gene inhibited all observed effects of both DCM and rh CCN1. However, no alteration of intracellular ATP levels or phosphorylation of LKB1, a well known upstream factor of AMPK activation, was observed under our conditions. Finally, the neutralization of integrin (v3) with anti integrin (v3) antibody almost completely reversed the effects of CCN1 on AMPK phosphorylation, and EC migration and tube formation. Taken together, we demonstrated that T MSC increase the secretion of CCN1 in response to endodermal differentiation and that integrin (v3) and AMPK mediate CCN1 induced EC migration and tube formation independent of intracellular ATP levels alteration. J. Cell. Physiol. 229: 140 149, 2014. (c) 2014 Wiley Periodicals, Inc.
C1 [Park, Yoon Shin; Hwang, Soojin; Jin, Yoon Mi; Yu, Yeonsil; Jo, Inho] Ewha Womans Univ, Sch Med, Dept Mol Med, Seoul 158710, South Korea.
   [Park, Yoon Shin; Hwang, Soojin; Jin, Yoon Mi; Yu, Yeonsil; Jung, Sung Ae; Jung, Sung Chul; Ryu, Kyung Ha; Kim, Han Su; Jo, Inho] Ewha Womans Univ, Global Top Res Program 5, Seoul 158710, South Korea.
   [Jung, Sung Ae] Ewha Womans Univ, Dept Internal Med, Sch Med, Seoul 158710, South Korea.
   [Jung, Sung Chul] Ewha Womans Univ, Sch Med, Dept Biochem, Seoul 158710, South Korea.
   [Ryu, Kyung Ha] Ewha Womans Univ, Sch Med, Dept Pediat, Seoul 158710, South Korea.
   [Kim, Han Su] Ewha Womans Univ, Sch Med, Dept Otorhinolaryngol Head Neck Surg, Seoul 158710, South Korea.
C3 Ewha Womans University; Ewha Womans University; Ewha Womans University;
   Ewha Womans University; Ewha Womans University; Ewha Womans University
RP Jo, I (通讯作者)，Ewha Womans Univ, Sch Med, Dept Mol Med, 911 1,Mok 6 Dong, Seoul 158710, South Korea.
EM inhojo@ewha.ac.kr
RI Jo, Inho/R 3581 2019; Jung, Sung Chul/I 3277 2019; Kim,
   Han/AAT 3295 2021
OI Jo, Inho/0000 0001 6060 6416; Jung, Sung Chul/0000 0002 3174 8965; Ryu,
   Kyung Ha/0000 0001 8424 2303; 
FU National Research Foundation of Korea (NRF)   Ministry of Science, ICT &
   Future Planning [2012M3A9C6049728]; Ewha Womans University [RP 2013]
FX Contract grant sponsor: Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Science, ICT & Future Planning; Contract grant number: 2012M3A9C6049728.
   Contract grant sponsor: Ewha Womans University; Contract grant number:
   RP 2013.
CR Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355
   Bingham EL, 2009, STEM CELLS DEV, V18, P1071, DOI 10.1089/scd.2008.0337
   Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510
   Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169
   D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163
   Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796
   Eliceiri BP, 2000, CANCER J, V6, pS245
   Estrada R, 2009, J CELL PHYSIOL, V219, P563, DOI 10.1002/jcp.21701
   Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094
   Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008 5472.CAN 09 3570
   Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441
   Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006
   Hwang S, 2014, CANCER LETT, V346, P74, DOI 10.1016/j.canlet.2013.12.011
   Juric V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031303
   Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742 7843.2004.pto950502.x
   Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090
   Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018 011 0778 3
   Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200
   Maeshima K, 2004, ENDOCRINOLOGY, V145, P3739, DOI 10.1210/en.2004 0213
   Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238
   Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709 8720.2002
   Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200
   OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645
   OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569
   Pagès G, 2000, ANN NY ACAD SCI, V902, P187
   Park JH, 2013, NITRIC OXIDE BIOL CH, V32, P36, DOI 10.1016/j.niox.2013.04.003
   Renault MA, 2010, J MOL CELL CARDIOL, V49, P490, DOI 10.1016/j.yjmcc.2010.05.003
   ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163
   Ryu KH, 2012, CYTOTHERAPY, V14, P1193, DOI 10.3109/14653249.2012.706708
   Schutze Norbert, 2005, Cell Commun Signal, V3, P5, DOI 10.1186/1478 811X 3 5
   Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Su JL, 2010, J BIOL CHEM, V285, P31325, DOI 10.1074/jbc.M109.087122
   Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015
   Wang Shihua, 2011, Front Med, V5, P372, DOI 10.1007/s11684 011 0164 4
   Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766
   Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200
   Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200
   Yu Y, 2008, EXP CELL RES, V314, P3198, DOI 10.1016/j.yexcr.2008.08.001
NR 39
TC 30
Z9 35
U1 1
U2 56
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2015
VL 230
IS 1
BP 140
EP 149
DI 10.1002/jcp.24690
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA AQ4JN
UT WOS:000342762200013
PM 24909560
DA 2025 08 17
ER

PT J
AU Lemaire, I
   Falzoni, S
   Leduc, N
   Zhang, B
   Pellegatti, P
   Adinolfi, E
   Chiozzi, P
   Di Virgilio, F
AF Lemaire, Irma
   Falzoni, Simonetta
   Leduc, Natacha
   Zhang, Bin
   Pellegatti, Patrizia
   Adinolfi, Elena
   Chiozzi, Paola
   Di Virgilio, Francesco
TI Involvement of the purinergic P2X7 receptor in the formation
   of multinucleated giant cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ALVEOLAR MACROPHAGE DIFFERENTIATION; OSTEOCLAST FORMATION; IN VITRO;
   PHARMACOLOGICAL CHARACTERIZATION; INTERFERON GAMMA; PLASMA MEMBRANE; ATP
   RECEPTOR; P2 RECEPTORS; FUSION; EXPRESSION
AB Multinucleated giant cells (MGC), a hallmark of chronic inflammatory reactions, remain an enigma of cell biology. There is evidence implicating the purinergic P2X(7) receptor in the fusion process leading to MGC. To investigate this, we used HEK 293 cells stably transfected with either 1) the full length rat P2X(7) receptor (P2X(7) cells), 2) a rat P2X(7) receptor lacking the C terminal domain (P2X(7)TC), or 3) a mock vector, and rat alveolar macrophages (MA) expressing the native receptor. P2X(7) cells cultured in serum free medium formed increased numbers of MGC and displayed a higher fusion index compared with mock transfectants. Stimulation of P2X(7) pore forming activity in P2X(7) cells by polymyxin B (PMB) further increased significantly the formation of MGC. Conversely, blockers of P2X receptors including oxidized ATP, brilliant blue G, and pyridoxal phosphate 6 azophenyl 2' 4' disulfonic acid inhibited significantly MGC formation in both unstimulated and PMB stimulated P2X(7) transfected cells. In contrast, cells transfected with the truncated P2X(7)TC were devoid of pore forming activity, did not respond to PMB stimulation, and failed to form enhanced numbers of MGC, thus behaving as mock transfectants. As found for P2X(7) transfected cells, PMB also potentiated dose dependently the formation of multinucleated MA by rat alveolar MA. Pretreatment with oxidized ATP abrogated the PMB stimulatory effects. Together, these data demonstrate unequivocally the participation of P2X(7) receptor in the process of MGC formation. Our study also provides evidence suggesting that stimulation of the P2X(7) receptor pathway in MA may mediate increased formation of MGC during chronic inflammatory reactions.
C1 Univ Ottawa, Dept Cellular & Mol Med, Fac Med, Ottawa, ON K1H 8M5, Canada.
   Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I 44100 Ferrara, Italy.
   Univ Ferrara, Insterdisciplinary Ctr Study Inflammat, I 44100 Ferrara, Italy.
C3 University of Ottawa; University of Ferrara; University of Ferrara
RP Lemaire, I (通讯作者)，Univ Ottawa, Dept Cellular & Mol Med, Fac Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.
EM ilemaire@uottawa.ca
RI Adinolfi, Elena/F 9169 2010; Leduc, Nathalie/IAM 9683 2023; Pellegatti,
   Patrizia/A 1891 2011; DI VIRGILIO, Francesco/O 4634 2019; Di Virgilio,
   Francesco/J 3754 2018
OI Adinolfi, Elena/0000 0001 8129 9929; Falzoni,
   Simonetta/0000 0002 6594 0357; Chiozzi, Paola/0000 0003 4952 334X; Di
   Virgilio, Francesco/0000 0003 3566 1362
CR ADAMS DO, 1976, AM J PATHOL, V84, P164
   Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04 11 1025
   Anderson JM, 2000, CURR OPIN HEMATOL, V7, P40, DOI 10.1097/00062752 200001000 00008
   Bonnema H, 2003, J BIOMED MATER RES A, V64A, P502, DOI 10.1002/jbm.a.10404
   BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604
   Byrd TF, 1998, CELL IMMUNOL, V188, P89, DOI 10.1006/cimm.1998.1352
   CHAMBERS TJ, 1978, J PATHOL, V126, P125, DOI 10.1002/path.1711260302
   Chen YW, 2005, INFLAMM RES, V54, P119, DOI 10.1007/s00011 004 1332 7
   Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697
   Das M, 2004, PLACENTA, V25, P396, DOI 10.1016/j.placenta.2003.11.004
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   FAIS S, 1994, LAB INVEST, V71, P737
   FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770
   Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169
   Ferrari D, 2004, J IMMUNOL, V173, P4652, DOI 10.4049/jimmunol.173.7.4652
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.150
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Hiken JF, 2004, AM J PHYSIOL CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Itonaga I, 2000, ANN RHEUM DIS, V59, P26, DOI 10.1136/ard.59.1.26
   Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347
   Kyriakides TR, 2004, AM J PATHOL, V165, P2157, DOI 10.1016/S0002 9440(10)63265 8
   Lemaire I, 2003, DRUG DEVELOP RES, V59, P118, DOI 10.1002/ddr.10209
   Lemaire I, 1996, J IMMUNOL, V157, P5118
   Lemaire I, 1996, J LEUKOCYTE BIOL, V60, P509, DOI 10.1002/jlb.60.4.509
   LEMAIRE I, 1991, AM J PATHOL, V138, P487
   Luttikhuizen DT, 2004, CELL TISSUE RES, V317, P289, DOI 10.1007/s00441 004 0939 x
   Mackenzie AB, 2005, J BIOL CHEM, V280, P33968, DOI 10.1074/jbc.M502705200
   MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598
   McNally AK, 2002, AM J PATHOL, V160, P621, DOI 10.1016/S0002 9440(10)64882 1
   Mizuno K, 2004, BRIT J DERMATOL, V150, P205, DOI 10.1111/j.1365 2133.2004.05768.x
   Mizuno K, 2001, CLIN EXP IMMUNOL, V126, P151, DOI 10.1046/j.1365 2249.2001.01655.x
   MODDERMAN WE, 1994, CALCIFIED TISSUE INT, V55, P141, DOI 10.1007/BF00297190
   Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02 04 0061
   Most J, 1997, BLOOD, V89, P662, DOI 10.1182/blood.V89.2.662
   MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807
   MURCH AR, 1982, J PATHOL, V137, P177, DOI 10.1002/path.1711370302
   MURGIA M, 1993, J BIOL CHEM, V268, P8199
   Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05 03 0222
   Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482
   Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213
   STEINBERG TH, 1987, J BIOL CHEM, V262, P8884
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   van den Eijnde SM, 2001, J CELL SCI, V114, P3631
   Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 48
TC 63
Z9 72
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 15
PY 2006
VL 177
IS 10
BP 7257
EP 7265
DI 10.4049/jimmunol.177.10.7257
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 105DN
UT WOS:000242009700079
PM 17082644
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, JL
   Peng, W
   Li, XY
   Fan, WX
   Wei, DN
   Wu, B
   Fan, LH
   Wu, CJ
   Li, L
AF Wang, Jiaolong
   Peng, Wei
   Li, Xinyu
   Fan, Wenxiang
   Wei, Daneng
   Wu, Bo
   Fan, Linhong
   Wu, Chunjie
   Li, Liang
TI Towards to potential 2 cyano pyrimidines cathepsin K inhibitors: An
   in silico design and screening research based on comprehensive
   application of quantitative structure activity relationships, molecular
   docking and ADMET prediction
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE QSAR; Docking; Cathepsin K; Molecular fingerprint; Clustering; ADMET
   prediction
ID QSAR MODELS; DERIVATIVES; DISCOVERY; VALIDATION; 3D QSAR; OPTIMIZATION;
   EXPLORATION; SOLUBILITY; PRINCIPLES; DEFINE
AB Cathepsin K (CK) is the only cathepsin showing high expression in osteoclasts. CK is considered to be a drug target in treatment of osteoporosis, rheumatoid arthritis and osteoarthritis. Comprehensive application of quantitative structure activity relationships (QSAR), molecular docking and absorption, distribution, metabolism, excretion and toxicity (ADMET) prediction was conducted for designing and screening for potential CK inhibitors based on 2 cyano pyrimidine analogs. For the two dimensional (2D) QSAR study, a statistical model of PLS_FCFP was chosen for its best evaluated regression statistic values (r(2) = 0.759, q(2) = 0.637 and r(pred)(2) = 0.699). An equation that implied positive or negative contributions for several molecular descriptors was acquired. For the 3D QSAR study, based on two methods of generation of molecular poses, three fingerprint based cluster partitions, and two common substructures, 336 candidate CoMFA and CoMSIA models were generated for evaluation of statistic values. Among them, database Minimize_MDL_subs01 provided superior evaluated models: CoMFA model #41 (r(2) = 0.994, q(2) = 0.746 and r(pred)(2) = 0.8693) and CoMSIA model #42 (r(2) = 0.983, q(2) = 0.753 and r(pred)(2) = 0.8676). Informative clues for molecular design were derived from the created QSAR models and, based on them, an in house library containing 190 purposefully designed unknown compounds was built for screening for potential CK inhibitors. Based on a combination of activity prediction and calculation of binding affinity, unknown compound X139 emerged. Detailed molecular docking studies assisted in unveiling of the interactions between unknown compounds and the target protein. The strong pi pi conjugation and preferably formed hydrogen bonds provided evidence that compound X139 had higher predicted activity. The subsequent study of ADMET prediction suggested acceptable drug like properties for compound X139. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Wang, Jiaolong; Peng, Wei; Li, Xinyu; Fan, Wenxiang; Wei, Daneng; Wu, Bo; Fan, Linhong; Wu, Chunjie] Chengdu Univ Tradit Chinese Med, Sch Pharm, Chengdu 611137, Sichuan, Peoples R China.
   [Li, Liang] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine
RP Li, L (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
EM liliang@cdutcm.edu.cn
RI ; Peng, Wei/ABD 2833 2021; Wang, Jiaolong/NRY 6404 2025
OI Li, Liang/0000 0001 9013 0770; 
FU Science and Technology Development Foundation of Chengdu University of
   Traditional Chinese Medicine [030041167]
FX This research was funded and Science and Technology Development
   Foundation of Chengdu University of Traditional Chinese Medicine
   (030041167).
CR Abdelrahman MA, 2017, EUR J MED CHEM, V138, P698, DOI 10.1016/j.ejmech.2017.07.004
   Buolamwini JK, 2002, J MED CHEM, V45, P841, DOI 10.1021/jm010399h
   Chapurlat RD, 2016, RHEUMATOLOGY, V55, P1714, DOI 10.1093/rheumatology/kev410
   Cheng A, 2003, J COMPUT AID MOL DES, V17, P811, DOI 10.1023/B:JCAM.0000021834.50768.c6
   Cheng AL, 2003, J MED CHEM, V46, P3572, DOI 10.1021/jm020266b
   Chitre TS, 2017, COMPUT BIOL CHEM, V68, P211, DOI 10.1016/j.compbiolchem.2017.03.015
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Egan WJ, 2002, ADV DRUG DELIVER REV, V54, P273, DOI 10.1016/S0169 409X(02)00004 2
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Ghosh P, 2011, J MOL MODEL, V17, P1607, DOI 10.1007/s00894 010 0861 y
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Gramatica P, 2007, QSAR COMB SCI, V26, P694, DOI 10.1002/qsar.200610151
   Halperin I, 2002, PROTEINS, V47, P409, DOI 10.1002/prot.10115
   Hao CZ, 2018, J MOL STRUCT, V1173, P498, DOI 10.1016/j.molstruc.2018.05.072
   Huang SZ, 2017, J CHEM INF MODEL, V57, P669, DOI 10.1021/acs.jcim.6b00714
   Johannes A.S., 2008, CYTOKINE GROWTH F R, V19, P157
   Kang YW, 2015, EPIDEMIOL HLTH, V37
   Karaman B, 2015, EUR J MED CHEM, V93, P584, DOI 10.1016/j.ejmech.2015.02.045
   Khazaei A, 2017, ARAB J CHEM, V10, P801, DOI 10.1016/j.arabjc.2015.02.016
   Law S, 2019, BIOCHEM J, V476, P499, DOI 10.1042/BCJ20180851
   Liessi N, 2018, EUR J MED CHEM, V144, P179, DOI 10.1016/j.ejmech.2017.12.030
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Nagarajan SK, 2017, COMPUT BIOL CHEM, V71, P104, DOI 10.1016/j.compbiolchem.2017.10.005
   OPREA TI, 1994, J MED CHEM, V37, P2206, DOI 10.1021/jm00040a013
   Peng W, 2018, MED CHEM RES, V27, P2062, DOI 10.1007/s00044 018 2215 8
   Rankovic Z, 2010, BIOORG MED CHEM LETT, V20, P6237, DOI 10.1016/j.bmcl.2010.08.101
   Rankovic Z, 2010, BIOORG MED CHEM LETT, V20, P1524, DOI 10.1016/j.bmcl.2010.01.100
   Ravindra K.C., 2012, J SAUDI CHEM SOC, V20, P536, DOI [10. 1016/j.jscs.2012.07.015., DOI 10.1016/J.JSCS.2012.07.015]
   Roy K, 2011, COMB CHEM HIGH T SCR, V14, P450, DOI 10.2174/138620711795767893
   Roy PP, 2009, MOLECULES, V14, P1660, DOI 10.3390/molecules14051660
   Sahigara F, 2012, MOLECULES, V17, P4791, DOI 10.3390/molecules17054791
   Speck Planche A, 2013, EUR J PHARM SCI, V48, P812, DOI 10.1016/j.ejps.2013.01.011
   Sprous DG, 2008, J MOL GRAPH MODEL, V27, P225, DOI 10.1016/j.jmgm.2008.04.009
   Tachmazidou I, 2019, NAT GENET, V51, P230, DOI 10.1038/s41588 018 0327 1
   Tsai C. C., 1997, ANTIVIR RES, V34, P54
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang JL, 2019, COMPUT BIOL CHEM, V78, P297, DOI 10.1016/j.compbiolchem.2018.12.021
   Xia XY, 2004, J MED CHEM, V47, P4463, DOI 10.1021/jm0303195
   Zeng HH, 2011, CHEM BIOL DRUG DES, V78, P333, DOI 10.1111/j.1747 0285.2011.01139.x
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhou NN, 2015, INT J MOL SCI, V16, P13407, DOI 10.3390/ijms160613407
NR 44
TC 11
Z9 11
U1 1
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022 2860
EI 1872 8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD NOV 5
PY 2019
VL 1195
BP 914
EP 928
DI 10.1016/j.molstruc.2019.06.020
PG 15
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA II7AN
UT WOS:000475344800097
DA 2025 08 17
ER

PT J
AU Sun, FR
   Zhang, YJ
   Xu, LJ
   Li, SB
   Chen, X
   Zhang, L
   Wu, YF
   Li, J
AF Sun, Farui
   Zhang, Yuanjin
   Xu, Lijun
   Li, Songbai
   Chen, Xiang
   Zhang, Ling
   Wu, Yifan
   Li, Jun
TI Proteasome Inhibitor MG132 Enhances Cisplatin Induced Apoptosis in
   Osteosarcoma Cells and Inhibits Tumor Growth
SO ONCOLOGY RESEARCH
LA English
DT Article
DE MG132; Osteosarcoma (OS); Cisplatin; Synergistic efficacy; Cell
   viability; Apoptosis
ID TRAIL INDUCED APOPTOSIS; IN VITRO; CARCINOMA CELLS; MULTIPLE MYELOMA;
   BORTEZOMIB; CHEMOTHERAPY; RESISTANCE; PATHWAY; PROLIFERATION; AUTOPHAGY
AB Although cisplatin has been shown to be an integral part of chemotherapy regimen in osteosarcoma (OS) treatment, toxicity issues and chemoresistance have hindered therapeutic development for OS. Exploring novel combination therapy methods is needed to circumvent the limitations of cisplatin alone. The proteasome inhibitor MG132 has shown antitumor effects in many solid tumors. However. little is known about its effects in combination with cisplatin in OS cells. In this study, we examined the effects of MG132 in combination with cisplatin in human OS cells (MG 63 and HOS). MG132 and cisplatin were applied to OS cells, respectively or jointly. The results demonstrated that MG132 markedly inhibited cell viability in a dose  and time dependent manner, whereas viability of osteoblast cells was not affected, suggesting a selective toxicity of MG132 to cancerous cells. Mechanistically, MG132 arrested cells in the G(2)/M phase in association with increased p21(wa)(f1) and induced cell apoptosis, which was accompanied by cleaved PARP. In addition to its apoptotic effect alone, MG132 significantly enhanced cisplatin induced apoptosis in OS cells. Furthermore, cell viability of the combined application of 10 mu M MG132 and 5 mu g/ml cisplatin was markedly inhibited compared to that of the individual application. These events were accompanied by the downregulation of NF kappa B, mitochondrial antiapoptotic protein Bcl xL, and PI3K/Akt, which play a key role in cell survival. Finally, combination treatment of MG132 and cisplatin showed more anti proliferative effect than the single treatment in OS xenograft models. In summary. we concluded that MG132 interacted synergistically with cisplatin, which raised the possibility that combining the two drugs may represent a novel strategy in OS.
C1 [Sun, Farui; Zhang, Yuanjin; Xu, Lijun; Li, Songbai; Chen, Xiang; Zhang, Ling; Li, Jun] Hubei Polytech Univ, Huangshi Cent Hosp, Dept Orthoped, Affiliated Hosp,Edong Healthcare Grp, Huangshi, Hubei, Peoples R China.
   [Wu, Yifan] Hebei Finance Univ, Int Educ Coll, Baoding, Hebei, Peoples R China.
C3 Hubei Polytechnic University; Hebei Finance University
RP Li, J (通讯作者)，Hubei Polytech Univ, Dept Orthoped, Huangshi Cent Hosp, 141 Tianjin Rd, Huangshi 435000, Hubei, Peoples R China.
EM 412042771@qq.com
CR Bacci G, 2008, J PEDIAT HEMATOL ONC, V30, P908, DOI 10.1097/MPH.0b013e31817e4aee
   Baranski Z, 2015, J PATHOL, V236, P348, DOI 10.1002/path.4528
   Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019
   Chitra S, 2012, INT J RHEUM DIS, V15, P249, DOI 10.1111/j.1756 185X.2012.01737.x
   Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008 5472.CAN 06 4046
   Dang LF, 2014, INT J MOL MED, V33, P1083, DOI 10.3892/ijmm.2014.1678
   Fribley AM, 2006, J BIOL CHEM, V281, P31440, DOI 10.1074/jbc.M604356200
   Fujita M, 2007, J BIOL CHEM, V282, P5736, DOI 10.1074/jbc.M606175200
   Guo N, 2016, INT J GYNECOL CANCER, V26, P839, DOI 10.1097/IGC.0000000000000703
   Hanikoglu F, 2015, ANTI CANCER AGENT ME, V15, P527, DOI 10.2174/1871520615666150209111650
   Ji LL, 2008, TOXICOL APPL PHARM, V231, P393, DOI 10.1016/j.taap.2008.05.015
   Keremu A., 2017, BIOSCI REP
   Kim M, 2017, AUTOPHAGY, V13, P149, DOI 10.1080/15548627.2016.1239676
   Konac E, 2015, ONCOL LETT, V10, P560, DOI 10.3892/ol.2015.3250
   Li XC, 2013, BIOCHEM BIOPH RES CO, V439, P179, DOI 10.1016/j.bbrc.2013.08.066
   Lou ZY, 2013, J INT MED RES, V41, P1505, DOI 10.1177/0300060513490618
   Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008 5472.CAN 07 3096
   Mitsiades CS, 2006, J CLIN ENDOCR METAB, V91, P4013, DOI 10.1210/jc.2005 2472
   Navon A, 2009, J BIOL CHEM, V284, P33713, DOI 10.1074/jbc.R109.018481
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood 2005 08 3531
   Sevelda F, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0251 5
   Shapovalov Y, 2010, INT J CANCER, V127, P67, DOI 10.1002/ijc.25024
   Sheridan C, 2015, NAT BIOTECHNOL, V33, P1115, DOI 10.1038/nbt1115 1115
   Suh KS, 2013, CRIT REV ONCOL HEMAT, V87, P306, DOI 10.1016/j.critrevonc.2013.02.005
   Topkas E, 2016, ONCOTARGET, V7, P831, DOI 10.18632/oncotarget.5704
   Wang Y, 2016, EXP THER MED, V12, P81, DOI 10.3892/etm.2016.3303
   Wong VKW, 2010, J CELL BIOCHEM, V111, P899, DOI 10.1002/jcb.22778
   Yan XB, 2007, CELL BIOL INT, V31, P1136, DOI 10.1016/j.cellbi.2007.03.037
   Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008 5472.CAN 05 4529
   Zhang C, 2015, CELL CYCLE, V14, P2100, DOI 10.1080/15384101.2015.1041693
NR 30
TC 25
Z9 28
U1 1
U2 13
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965 0407
EI 1555 3906
J9 ONCOL RES
JI Oncol. Res.
PY 2018
VL 26
IS 4
BP 655
EP 664
DI 10.3727/096504017X15119525209765
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GG2QG
UT WOS:000432536800015
PM 29191257
OA Green Published
DA 2025 08 17
ER

PT J
AU Qiu, XY
   Yu, YJ
   Liu, HX
   Li, XC
   Sun, WB
   Wu, WL
   Liu, C
   Miao, LY
AF Qiu, Xinyi
   Yu, Yijun
   Liu, Hanxiao
   Li, Xincong
   Sun, Weibin
   Wu, Wenlei
   Liu, Chao
   Miao, Leiying
TI Remodeling the periodontitis microenvironment for osteogenesis by using
   a reactive oxygen species cleavable nanoplatform
SO ACTA BIOMATERIALIA
LA English
DT Article
DE ROS responsive polymeric vehicles; Self regulated drug release;
   Periodontal ligament stem cells; Bone regeneration; Inflammatory
   microenvironment
ID MESENCHYMAL STEM CELLS; NF KAPPA B; OXIDATIVE STRESS; DIFFERENTIATION;
   ROS; NANOPARTICLES; CROSSTALK; INFLAMMATION; DELIVERY; RELEASE
AB Modestly removing the excessive reactive oxygen species (ROS) plays a crucial role in regulating the mi croenvironment of periodontitis and provides favorable conditions for osteogenesis. However, the cur rent strategy for scavenging ROS is not controllable, substantially limiting the outcomes in periodontitis. Herein, we introduced a controllable ROS scavenging nanoplatform by encasing N acetylcysteine (NAC, (a well known ROS scavenger) into tailor made ROS cleavable amphiphilic polymer nanoparticles (PEG ss PCL NPs) as an intracellular delivery carrier. The existing ROS in the inflammatory microenvironment facilitated polymer degradation via breakage of thioketal bonds, and then led to encapsulated NAC re lease. NAC eliminated all ROS induced by lipopolysaccharide (LPS), while PssL NAC adjusted the ROS level slightly higher than that of the control group. The percentage of apoptotic cells cultured with NAC and PssL NAC decreased observably compared with that of cells cultured with 10 mu g/ml LPS. The microen vironment regulated by PssL NAC was highly suitable for osteogenic differentiation based on PCR and Western blot results, which showed higher expression levels of BMP2, Runx2, and PKA. Analysis of ALP activity and Alizarin red S staining showed consistent results. Additionally, the injection of PssL NAC into the periodontitis area could alleviate the tissue destruction induced by ligation of the maxillary second molar. PssL NAC showed a better ability to decrease osteoclast activity and inflammation, consequently improving the restoration of destroyed tissue. Our study suggests that ROS responsive polymer nanopar ticles loaded with NAC (PssL NAC) can be new promising materials for the treatment of periodontitis. Statement of significance More and more studies indicate that periodontal tissue damage is closely related to the high reactive oxygen species (ROS) environment. Excessive ROS will aggravate periodontal tissue damage and is not conducive to tissue repair. However, as an essential signal molecule in human physiological activities, ROS absence is also useless for tissue repair. In this study, we proposed to improve ROS imbalance in the environment of periodontitis as a strategy to promote periodontal regeneration and successfully synthe sized a smart drug releasing nanoplatform that can respond to ROS. Besides, we validated its ability to regulate the ROS environment and promote osteogenesis through experimental data in vivo and in vitro . (c) 2021 Published by Elsevier Ltd on behalf of Acta Materialia Inc.
C1 [Qiu, Xinyi; Yu, Yijun; Liu, Hanxiao; Li, Xincong; Miao, Leiying] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Dept Cariol & Endodont, Nanjing 210008, Jiangsu, Peoples R China.
   [Sun, Weibin; Wu, Wenlei] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Dept Periodontol, Nanjing 210008, Jiangsu, Peoples R China.
   [Liu, Chao] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Dept Orthodont, Nanjing 210008, Jiangsu, Peoples R China.
   [Qiu, Xinyi; Yu, Yijun; Liu, Hanxiao; Li, Xincong] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Cent Lab Stomatol, Nanjing 210008, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University; Nanjing
   University
RP Miao, LY (通讯作者)，Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Dept Cariol & Endodont, Nanjing 210008, Jiangsu, Peoples R China.; Liu, C (通讯作者)，Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Dept Orthodont, Nanjing 210008, Jiangsu, Peoples R China.
EM chaoliu@nju.edu.cn; lymiao@nju.edu.cn
RI Liu, Chao/KTH 9395 2024
OI Qiu, Xinyi/0000 0003 2006 7969
FU National Natural Science Foundation of China [51772144, 51972167];
   Project of Invigorating Health Care through Science, Technology and
   Education, Jiangsu Provincial Medical Youth Talent [QNRC2016120];
   Nanjing Clinical Research Center for Oral Diseases [2019060 0 09];
   Medical Science and Technology Development Foundation, Nanjing
   Department of Health [ZKX16054, ZKX19031, YKK18126, YKK20153]
FX This study was supported by the National Natural Science Foun dation of
   China under Grant [number 51772144, 51972167] ; the Project of
   Invigorating Health Care through Science, Technology and Education,
   Jiangsu Provincial Medical Youth Talent under Grant [number QNRC2016120]
   ; Nanjing Clinical Research Center for Oral Diseases (number 2019060 0
   09) ; Key Project supported by Medical Science and Technology
   Development Foundation, Nanjing Depart ment of Health under Grant
   [number ZKX16054, ZKX19031] ; and General Project supported by Medical
   Science and Technology De velopment Foundation , Nanjing Department of
   Health under Grant [number YKK18126, YKK20153] .
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Ballance WC, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119292
   Baltacioglu E, 2014, J PERIODONTOL, V85, P317, DOI 10.1902/jop.2013.130012
   Baser U, 2015, SAUDI MED J, V36, P856, DOI 10.15537/smj.2015.7.11954
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Bigarella CL, 2014, DEVELOPMENT, V141, P4206, DOI 10.1242/dev.107086
   Chio IIC, 2017, TRENDS MOL MED, V23, P411, DOI 10.1016/j.molmed.2017.03.004
   Chung MF, 2015, J AM CHEM SOC, V137, P12462, DOI 10.1021/jacs.5b08057
   Deng HZ, 2015, J MATER CHEM B, V3, P9397, DOI 10.1039/c5tb01939g
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   Feng SB, 2016, BIOMATERIALS, V105, P167, DOI 10.1016/j.biomaterials.2016.08.003
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Francetti L, 2019, CLIN ORAL IMPLAN RES, V30, P250, DOI 10.1111/clr.13411
   Genco RJ, 2010, NAT REV CARDIOL, V7, P479, DOI 10.1038/nrcardio.2010.120
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hishida A, 2009, CLIN EXP NEPHROL, V13, P118, DOI 10.1007/s10157 008 0108 8
   Huang RL, 2014, STEM CELLS DEV, V23, P277, DOI 10.1089/scd.2013.0345
   Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746
   Kanzaki H, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00351
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Kukolj T, 2018, J CELL PHYSIOL, V233, P447, DOI 10.1002/jcp.25904
   Li J, 2019, BIOCHIMIE, V156, P129, DOI 10.1016/j.biochi.2018.09.004
   Liao L, 2016, STEM CELLS, V34, P1054, DOI 10.1002/stem.2274
   Liu CC, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00439
   Liu Y, 2018, CHEM COMMUN, V54, P4329, DOI [10.1039/c8cc01432a, 10.1039/C8CC01432A]
   Madianos PN, 2013, J PERIODONTOL, V84, pS170, DOI [10.1111/jcpe.12082, 10.1902/jop.2013.1340015]
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Nagasaki Y, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/5/054505
   Nagatomo K, 2006, J PERIODONTAL RES, V41, P303, DOI 10.1111/j.1600 0765.2006.00870.x
   Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Ren HF, 2012, SOFT MATTER, V8, P1460, DOI 10.1039/c1sm06673k
   Ren SS, 2017, J BIOMED NANOTECHNOL, V13, P1725, DOI 10.1166/jbn.2017.2451
   Saita M, 2016, BIOMATERIALS, V76, P292, DOI 10.1016/j.biomaterials.2015.10.077
   Santos DM, 2013, MOL NEUROBIOL, V47, P313, DOI 10.1007/s12035 012 8353 y
   Shouhed D, 2005, J CELL BIOCHEM, V95, P1276, DOI 10.1002/jcb.20497
   Sivandzade F, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.017
   Tan DQ, 2018, ANTIOXID REDOX SIGN, V29, P149, DOI 10.1089/ars.2017.7273
   Tang HN, 2016, J CLIN PERIODONTOL, V43, P72, DOI 10.1111/jcpe.12501
   Toczewska J, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9050450
   Urao N, 2013, FREE RADICAL BIO MED, V54, P26, DOI 10.1016/j.freeradbiomed.2012.10.532
   Vergnes JN, 2019, LANCET DIABETES ENDO, V7, P174, DOI 10.1016/S2213 8587(19)30029 4
   Wang W, 2019, ACS APPL MATER INTER, V11, P2880, DOI 10.1021/acsami.8b20158
   Wang Y, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00910
   Wilson DS, 2010, NAT MATER, V9, P923, DOI [10.1038/NMAT2859, 10.1038/nmat2859]
   Xu QH, 2016, ADV HEALTHC MATER, V5, P1979, DOI 10.1002/adhm.201600292
   Yao YJ, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119726
   Yao YJ, 2019, J MATER CHEM B, V7, P5019, DOI 10.1039/c9tb00847k
   Yoshitomi T, 2014, ADV HEALTHC MATER, V3, P1149, DOI 10.1002/adhm.201300576
   Yu H, 2020, THERANOSTICS, V10, P2342, DOI 10.7150/thno.40395
NR 51
TC 57
Z9 58
U1 16
U2 137
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD NOV
PY 2021
VL 135
BP 593
EP 605
DI 10.1016/j.actbio.2021.08.009
EA NOV 2021
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA WX9BZ
UT WOS:000718884500007
PM 34390848
DA 2025 08 17
ER

PT J
AU Peng, B
   Zhu, H
   Klausen, C
   Ma, LY
   Wang, YL
   Leung, PCK
AF Peng, Bo
   Zhu, Hua
   Klausen, Christian
   Ma, Liyang
   Wang, Yan Ling
   Leung, Peter C. K.
TI GnRH regulates trophoblast invasion via RUNX2 mediated MMP2/9 expression
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article
DE GnRH; trophoblast; RUNX2; MMP; invasion
ID TRANSCRIPTION FACTOR RUNX2; HORMONE RECEPTOR GENE; HUMAN PLACENTA; CELL
   INVASION; EXTRACELLULAR MATRIX; 1ST TRIMESTER; GROWTH; BONE;
   OSTEOBLASTS; DECIDUA
AB STUDY HYPOTHESIS: We hypothesized that Runt related transcription factor 2 (RUNX2), matrix metalloproteinase (MMP)2 and MMP9 are involved in basal and gonadotrophin releasing hormone (GnRH) induced human extravillous trophoblast (EVT) cell invasion.
   STUDY FINDING: Our finding indicates that GnRH induced RUNX2 expression enhances the invasive capacity of EVT cells by modulating the expression of MMP2 and MMP9. what is known already: GnRH is expressed in first trimester placenta and exerts pro invasive effects on EVT cells in vitro. RUNX2 regulates MMP2 and MMP9 expression and is often associated with invasive phenotypes.
   STUDY DESIGN, SAMPLES/MATERIALS, METHODS: First trimester human placenta (n = 9) was obtained from women undergoing elective termination of pregnancy. The localization of RUNX2, MMP2 and MMP9 in first trimester human placenta was examined by immunohistochemistry. Primary or immortalized (HTR 8/SVneo) EVT cells were treated alone or in combination with GnRH, GnRH antagonist Antide, MAPK kinase inhibitor PD98095, phosphatidylinositol 3 kinase inhibitor LY294002, MMP2/9 inhibitor or small interfering RNAs (siRNAs) targeting RUNX2, MMP2 and/or MMP9. Protein and mRNA levels were measured by western blot and RT PCR, respectively. Cell invasiveness was evaluated by transwell Matrigel or collagen I invasion assays.
   MAIN RESULTS AND THE ROLE OF CHANCE: RUNX2, MMP2 and MMP9 were detected in the cell column regions of human first trimester placental villi. GnRH treatment increased RUNX2 mRNA and protein levels in HTR 8/SVneo cells and primary EVTs, and these effects were attenuated by co treatment with Antide, PD98095 or LY294002. Down regulation of RUNX2 by siRNA reduced basal and GnRH induced MMP2/9 expression and cell invasion. Moreover, pharmacological inhibition or siRNA mediated knockdown of MMP2/9 reduced basal and GnRH induced cell invasion.
   LIMITATIONS, REASONS FOR CAUTION: The lack of an in vivo model is the major limitation of our in vitro study.
   WIDER IMPLICATIONS OF THE FINDINGS: Our findings provide important insight into the functions of the GnRH   GnRH receptor system in early implantation and placentation.
   LARGE SCALE DATA: Not applicable.
   STUDY FUNDING AND COMPETING INTEREST(S): This research was supported by Canadian Institutes of Health Research (Grant #143317) to P.C.K.L. The authors have nothing to disclose.
C1 [Peng, Bo; Zhu, Hua; Klausen, Christian; Leung, Peter C. K.] Univ British Columbia, Child & Family Res Inst, Dept Obstet & Gynecol, Vancouver, BC V6H 3N1, Canada.
   [Ma, Liyang; Wang, Yan Ling] Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing 100101, Peoples R China.
C3 Child & Family Research Institute; University of British Columbia;
   Chinese Academy of Sciences; Institute of Zoology, CAS
RP Leung, PCK (通讯作者)，Univ British Columbia, Dept Obstet & Gynaecol, Room C420 4500 Oak St, Vancouver, BC V6H 3N1, Canada.
EM peter.leung@ubc.ca
RI ; Wang, Yanling/N 5854 2019; Peng, Bo/KCY 4712 2024; ma,
   liyang/GQH 8927 2022
OI Leung, Peter/0000 0003 3152 3800; Peng, Bo/0000 0002 3142 547X; 
FU Canadian Institutes of Health Research [143317]
FX This research was supported by Canadian Institutes of Health Research
   (Grant #143317) to P.C.K.L.
CR Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   APLIN JD, 1988, CELL TISSUE RES, V253, P231
   Bai SX, 2005, REPRODUCTION, V129, P103, DOI 10.1530/rep.1.00283
   Bamberger AM, 2004, MOL HUM REPROD, V10, P223, DOI 10.1093/molehr/gah011
   Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007
   Breen KM, 2010, ENDOCRINOLOGY, V151, P2669, DOI 10.1210/en.2009 0949
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Cheng KW, 2000, ENDOCRINOLOGY, V141, P2340, DOI 10.1210/en.141.7.2340
   Chou CS, 2004, J CLIN ENDOCR METAB, V89, P1459, DOI 10.1210/jc.2003 031636
   Chou CS, 2003, J CLIN ENDOCR METAB, V88, P4781, DOI 10.1210/jc.2003 030659
   Dilly M, 2010, MOL REPROD DEV, V77, P622, DOI 10.1002/mrd.21197
   Fluhr H, 2008, FERTIL STERIL, V90, P1384, DOI [10.1016/j.fertnstert.2007.07.1357, 10.1016/j.fertnstert.2007.08.023]
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Isaka K, 2003, PLACENTA, V24, P53, DOI 10.1053/plac.2002.0867
   Jeong JH, 2008, J CELL PHYSIOL, V217, P511, DOI 10.1002/jcp.21524
   KISALUS LL, 1987, ANAT RECORD, V218, P402, DOI 10.1002/ar.1092180408
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   LIN LS, 1995, J CLIN ENDOCR METAB, V80, P580, DOI 10.1210/jc.80.2.580
   Liu J, 2009, MOL ENDOCRINOL, V23, P1014, DOI 10.1210/me.2008 0451
   Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218
   Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04 2140fje
   Niger C, 2012, AM J PHYSIOL CELL PH, V302, pC1035, DOI 10.1152/ajpcell.00262.2011
   Niu DF, 2012, LAB INVEST, V92, P1181, DOI 10.1038/labinvest.2012.84
   Omran Ola M, 2011, Int J Health Sci (Qassim), V5, P21
   Park ES, 2010, MOL ENDOCRINOL, V24, P846, DOI 10.1210/me.2009 0392
   Peng B, 2015, ENDOCRINOLOGY, V156, P2269, DOI 10.1210/en.2014 1871
   Peng B, 2015, J CLIN ENDOCR METAB, V100, pE19, DOI 10.1210/jc.2014 1897
   Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Pratap J, 2003, CANCER RES, V63, P5357
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   Roth I, 1999, DEV BIOL, V205, P194, DOI 10.1006/dbio.1998.9122
   Shi Y, 2011, J CELL PHYSIOL, V226, P2159, DOI 10.1002/jcp.22551
   SHIMONOVITZ S, 1994, AM J OBSTET GYNECOL, V171, P832, DOI 10.1016/0002 9378(94)90107 4
   Shokry M, 2009, EXP MOL PATHOL, V87, P219, DOI 10.1016/j.yexmp.2009.08.001
   SILERKHODR TM, 1978, AM J OBSTET GYNECOL, V130, P216, DOI 10.1016/0002 9378(78)90369 1
   Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008 5472.CAN 06 1461
   Staun Ram Elsebeth, 2004, Reprod Biol Endocrinol, V2, P59, DOI 10.1186/1477 7827 2 59
   Suman P, 2012, PLACENTA, V33, P874, DOI 10.1016/j.placenta.2012.06.017
   Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756 3282(97)00267 6
   Weiss A, 2007, FRONT BIOSCI LANDMRK, V12, P649, DOI 10.2741/2089
NR 45
TC 34
Z9 41
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 1460 2407
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD FEB
PY 2016
VL 22
IS 2
BP 119
EP 129
DI 10.1093/molehr/gav070
PG 11
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA DF2OS
UT WOS:000371183800005
PM 26660506
OA Green Published
DA 2025 08 17
ER

PT J
AU Al Shaibani, MBH
AF Al Shaibani, Moyassar Basil Hadi
TI Three dimensional cell culture (3DCC) improves secretion of signaling
   molecules of mesenchymal stem cells (MSCs)
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
DE 3D cell culture; 3D culture scaffold; Conditioned media; Mesenchymal
   stem cells; MSC secretome
ID STROMAL CELLS; BONE; MICROENVIRONMENT; EXPRESSION; SPHEROIDS; SYSTEMS
AB Objectives The secretome of mesenchymal stem cells (MSCs), also called MSC conditioned media (MSC CM), represents one of the promising strategies for cellular therapy and tissue repair and regeneration. MSC CM contains growth factors and cytokines that control many cellular responses during development and regeneration. Traditional 2D cell culture (2DCC) has previously been used to generate MSC CM while evidence has proved that the physiological and biological behaviors of cells in 2DCC are significantly different from those in 3D cell culture (3DCC). Therefore, the objective is to compare the content of MSC CM generated from traditional 2DCC and 3DCC using a 3D scaffold. Methods Adipose tissue derived MSCs (AT MSCs) were isolated from four donors (N = 4) and characterized according to the criteria stipulated by the International Society for Cell Therapy (ISCT). MSCs at passage 3 were grown in traditional 2DCC until 70% confluence and MSC CM were collected at 24, 48, and 94 h. On the other hand, MSCs at passage 3 were grown on a polystyrene scaffold for 10 days to generate a 3D model of MSCs, and then MSC CM was collected at 24, 48, and 94 h. MSC CM from both 2DCC and 3DCC were analyzed for protein content using ELISA. Haematoxylin eosin (HE) staining and immunofluorescence (IF) were used to characterize the 3DCC of MSCs. Results MSCs from 2DCC were fibroblast like cells, and flow cytometry showed they were positive for CD73 and CD105 while being negative for CD14, CD19, and HLA DR. They were also able to differentiate into adipocytes, osteoblasts, and chondrocytes. HE and IF showed that MSCs formed 3D model structures on the polystyrene scaffold. MSC CM collected from both 2DCC and 3DCC contained growth factors, e.g., platelet derived growth factor (PDGF AB), transforming growth factor 1 (TGF 1), hepatocyte growth factor (HGF), stromal derived factor 1 (SDF 1), interleukin 1 (IL 1), and interleukin 6 (IL 6). Concentrations of biomolecules secreted by MSCs in 3DCC were significantly higher than in 2DCC. Conclusion It could be concluded that 3DCC of MSCs using a polystyrene scaffold is a novel approach to generate MSC secretome for therapeutic applications.
C1 [Al Shaibani, Moyassar Basil Hadi] Al Nahrain Univ, Coll Biotechnol, Dept Mol & Med Biotechnol, Baghdad, Iraq.
C3 Al Nahrain University
RP Al Shaibani, MBH (通讯作者)，Al Nahrain Univ, Coll Biotechnol, Dept Mol & Med Biotechnol, Baghdad, Iraq.
EM moyassar.basil@nahrainuniv.edu.iq
RI Al Shaibani, Moyassar/HNB 8077 2023
OI Al Shaibani, Moyassar/0000 0003 4380 9945
CR Akiyama K, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt131
   Al Shaibani MBH, 2020, INT EUR C BIOTCHN BI
   Baharvand H, 2006, INT J DEV BIOL, V50, P645, DOI 10.1387/ijdb.052072hb
   Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Bernacki SH, 2008, METHOD CELL BIOL, V86, P257, DOI 10.1016/S0091 679X(08)00011 3
   Bhadriraju K, 2002, DRUG DISCOV TODAY, V7, P612, DOI 10.1016/S1359 6446(02)02273 0
   Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009
   Bresciani G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00682
   Campuzano S, 2019, FRONT SUSTAIN FOOD S, V3, DOI 10.3389/fsufs.2019.00038
   DesRochers TM, 2014, ADV DRUG DELIVER REV, V69, P67, DOI 10.1016/j.addr.2013.12.002
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Hickey RJ, 2018, ACS BIOMATER SCI ENG, V4, P3726, DOI 10.1021/acsbiomaterials.8b00178
   Hwang JH, 2009, J KOREAN MED SCI, V24, P547, DOI 10.3346/jkms.2009.24.4.547
   Kapalczynska M, 2018, ARCH MED SCI, V14, P910, DOI 10.5114/aoms.2016.63743
   Kouroupis D, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.621748
   Lv DL, 2017, ONCOL LETT, V14, P6999, DOI 10.3892/ol.2017.7134
   Marushima H, 2011, INT J ONCOL, V39, P1327, DOI 10.3892/ijo.2011.1142
   Miranda JP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00018
   Mirbagheri M, 2019, MATER HORIZ, V6, P45, DOI 10.1039/c8mh00803e
   Nong Wang X, 2016, CYTOTHERAPY, V19, pe23, DOI [10.1016/j.jcyt.2017.03.062, DOI 10.1016/J.JCYT.2017.03.062]
   Qiu XY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0821 5
   Redondo Castro E, 2018, BIO PROTOCOL, V8, DOI 10.21769/BioProtoc.2968
   Sakai D, 2008, CURRENT PROTOCOLS ES
   Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581 018 0023 5
   Tietze S, 2019, ADV SCI, V6, DOI 10.1002/advs.201802104
   Trzyna A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11060878
   Weiss ARR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01191
   Ylöstalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191
NR 32
TC 11
Z9 12
U1 1
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141 5492
EI 1573 6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD JAN
PY 2022
VL 44
IS 1
BP 143
EP 155
DI 10.1007/s10529 021 03216 9
EA JAN 2022
PG 13
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA ZC3VS
UT WOS:000740382000001
PM 35000031
DA 2025 08 17
ER

PT J
AU Xiao, XX
   Ji, JJ
   Wang, HY
   Nangia, S
   Wang, HJ
   Libera, M
AF Xiao, Xixi
   Ji, Jingjing
   Wang, Haoyu
   Nangia, Shikha
   Wang, Hongjun
   Libera, Matthew
TI Self Defensive Antimicrobial Surfaces Using Polymyxin Loaded
   Poly(styrene sulfonate) Microgels
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article; Early Access
DE drug delivery; infection; microgel; antibiotic; complexation; contact
   transfer
ID VERSATILE TOOL; FORCE FIELD; MODEL; IMAGE; LINE
AB Self defensive antimicrobial surfaces are of interest because they can inhibit bacterial colonization while minimizing unnecessary antimicrobial release in the absence of a bacterial challenge. One self defensive approach uses self assembly to first deposit a submonolayer coating of polyelectrolyte microgels and subsequently load those microgels by complexation with small molecule antimicrobials. The microgel/antimicrobial complexation strength is a key parameter that controls the ability of the antimicrobial both to remain sequestered within the microgels when exposed to medium and to release in response to a bacterial challenge. Here we study the relative complexation strengths of two FDA approved cationic antibiotics colistin (polymyxin E) and polymyxin B with microgels of poly(styrene sulfonate) (PSS). These polymyxins are similar cyclic polypeptides with +5 charge at pH 7.4. However, polymyxin B substitutes an aromatic ring for a dimethyl moiety in colistin, and this aromaticity can influence complexation via pi and hydrophobic interactions. Coarse grained molecular dynamics shows that the free energy change associated with polymyxin B/PSS complexation is more negative than that of colistin/PSS complexation. Experimentally, in situ optical microscopy of microgel deswelling shows that both antibiotics load quickly from low ionic strength phosphate buffer. The enhanced polymyxin B/PSS complexation strength is then manifested by subsequent exposure to flowing antibiotic free buffer with varying NaCl concentration. Microgels loaded with polymyxin B remain stably deswollen to higher salt concentrations than do colistin/PSS microgels. Importantly, exposing loaded microgels to E. coli in nutrient free flowing phosphate buffer shows that bacteria are killed by physical contact with the loaded microgels consistent with the contact transfer mechanism of self defensiveness. In vitro culture experiments show that these same surfaces, nevertheless, support the adhesion, spreading and proliferation of human fetal osteoblasts. These findings suggest a pathway to create a self defensive antimicrobial surface effective under physiological conditions based on the nonmetabolic bacteria triggered release of FDA approved antibiotics.
C1 [Xiao, Xixi; Wang, Haoyu; Wang, Hongjun; Libera, Matthew] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
   [Ji, Jingjing; Nangia, Shikha] Syracuse Univ, Dept Biomed & Chem Engn, Syracuse, NY 13244 USA.
C3 Stevens Institute of Technology; Syracuse University
RP Libera, M (通讯作者)，Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
EM mlibera@stevens.edu
OI Libera, Matthew/0000 0001 5026 802X; nangia, Shikha/0000 0003 1170 8461
FU Army Research Office [W911NF2010277]; NIDDK Diabetic Complications
   Consortium [RRID:SCR _001415, DK076169, DK115255]; National Science
   Foundation [ACI 1053575]; NSF ERC Planning Grant (NSF) [1936926]; NSF
   GCR Grant (NSF) [2219014]; U.S. Department of Defense (DOD)
   [W911NF2010277] Funding Source: U.S. Department of Defense (DOD); Div Of
   Engineering Education and Centers; Directorate For Engineering [1936926]
   Funding Source: National Science Foundation
FX The Stevens portion of this work was supported by the Army Research
   Office (W911NF2010277) and by the NIDDK Diabetic Complications
   Consortium (RRID:SCR _001415, www.diacomp.org), grants DK076169 and
   DK115255. The computational component of the work was completed at
   Syracuse University through resources provided by Information and
   Technology (Eric Sedore, Larne Pekowsky, and Michael R. Brady) as well
   as by the Extreme Science and Engineering Discovery Environment (XSEDE),
   which is supported by National Science Foundation grant number
   ACI 1053575. Collaborative aspects of the work were supported in part by
   an NSF ERC Planning Grant (NSF #1936926) and an NSF GCR Grant (NSF
   #2219014).
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Akhoundsadegh N, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00935 19
   Albright V, 2017, ACTA BIOMATER, V61, P66, DOI 10.1016/j.actbio.2017.08.012
   Arciola CR, 2018, NAT REV MICROBIOL, V16, P397, DOI 10.1038/s41579 018 0019 y
   Borges J, 2014, CHEM REV, V114, P8883, DOI 10.1021/cr400531v
   Bryers JD, 2008, BIOTECHNOL BIOENG, V100, P1, DOI 10.1002/bit.21838
   Cado G, 2013, ADV FUNCT MATER, V23, P4801, DOI 10.1002/adfm.201300416
   Chang LW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01249 1
   de Jong DH, 2013, J CHEM THEORY COMPUT, V9, P687, DOI 10.1021/ct300646g
   Ebbensgaard A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02153
   Fan HL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13171 9
   Fu JC, 2017, MACROMOLECULES, V50, P1066, DOI 10.1021/acs.macromol.6b02445
   Graham JA, 2017, J CHEM INF MODEL, V57, P650, DOI 10.1021/acs.jcim.7b00096
   Herce HD, 2007, J BIOL PHYS, V33, P345, DOI 10.1007/s10867 008 9074 3
   Inzana JA, 2016, BIOMATERIALS, V81, P58, DOI 10.1016/j.biomaterials.2015.12.012
   Jenkins S. G., 2017, INFECT DIS NOR
   Kästner J, 2011, WIRES COMPUT MOL SCI, V1, P932, DOI 10.1002/wcms.66
   Kim S, 2017, ACS NANO, V11, P6764, DOI 10.1021/acsnano.7b01370
   Kwa A, 2007, EXPERT REV ANTI INFE, V5, P811, DOI 10.1586/14787210.5.5.811
   Liang J, 2019, BIOMATERIALS, V204, P25, DOI 10.1016/j.biomaterials.2019.03.006
   Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f
   May KL, 2018, P NATL ACAD SCI USA, V115, P8852, DOI 10.1073/pnas.1812779115
   Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x
   Nang SC, 2021, PHARMACOL REV, V73, P679, DOI 10.1124/pharmrev.120.000020
   Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593 656.2003
   Pavlukhina S, 2010, BIOMACROMOLECULES, V11, P3448, DOI 10.1021/bm100975w
   Periole Xavier, 2013, Methods Mol Biol, V924, P533, DOI 10.1007/978 1 62703 017 5_20
   Phelan DM, 2002, CLIN INFECT DIS, V34, P930, DOI 10.1086/339212
   Sadman K, 2017, MACROMOLECULES, V50, P9417, DOI 10.1021/acs.macromol.7b02031
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlenoff JB, 2019, MACROMOLECULES, V52, P9149, DOI 10.1021/acs.macromol.9b01755
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Séon L, 2015, LANGMUIR, V31, P12856, DOI 10.1021/acs.langmuir.5b02768
   Silhavy TJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000414
   Sing CE, 2017, ADV COLLOID INTERFAC, V239, P2, DOI 10.1016/j.cis.2016.04.004
   Tiller JC, 2001, P NATL ACAD SCI USA, V98, P5981, DOI 10.1073/pnas.111143098
   TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021 9991(77)90121 8
   TORRIE GM, 1974, CHEM PHYS LETT, V28, P578, DOI 10.1016/0009 2614(74)80109 0
   Velkov T, 2016, FUTURE MED CHEM, V8, P1017, DOI 10.4155/fmc 2016 0091
   Velkov T, 2010, J MED CHEM, V53, P1898, DOI 10.1021/jm900999h
   Wassenaar TA, 2015, J CHEM THEORY COMPUT, V11, P2144, DOI 10.1021/acs.jctc.5b00209
   Xiao XX, 2022, MACROMOLECULES, V55, P1736, DOI 10.1021/acs.macromol.1c02157
   Xiao XX, 2020, COLLOID SURFACE B, V192, DOI 10.1016/j.colsurfb.2020.110989
   Yang M, 2020, MACROMOLECULES, V53, P5465, DOI 10.1021/acs.macromol.0c00965
   Yang M, 2019, MACROMOLECULES, V52, P1930, DOI 10.1021/acs.macromol.8b02577
   Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2
   Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006 0295
   Yin JH, 2020, APPL MICROBIOL BIOT, V104, P3771, DOI 10.1007/s00253 020 10525 y
   Yount NY, 2013, ANN NY ACAD SCI, V1277, P127, DOI 10.1111/nyas.12005
   Yun B, 2018, ARCH TOXICOL, V92, P2259, DOI 10.1007/s00204 018 2192 1
   Zhao WH, 2022, ADV MATER INTERFACES, V9, DOI 10.1002/admi.202201662
   Zhao WH, 2022, J BIOMED MATER RES B, V110, P2472, DOI 10.1002/jbm.b.35104
NR 52
TC 3
Z9 5
U1 2
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD 2022 OCT 18
PY 2022
DI 10.1021/acsbiomaterials.2c00783
EA OCT 2022
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 5T8EZ
UT WOS:000876093700001
PM 36256955
DA 2025 08 17
ER

PT J
AU Dai, SQ
   Yu, TY
   Zhang, JW
   Lu, H
   Dou, JZ
   Zhang, MM
   Dong, C
   Di, JL
   Zhao, JL
AF Dai, Siqing
   Yu, Tongyao
   Zhang, Jiwei
   Lu, Hua
   Dou, Jiazhen
   Zhang, Mengmeng
   Dong, Chen
   Di, Jianglei
   Zhao, Jianlin
TI Real time and wide field mapping of cell substrate adhesion gap and its
   evolution via surface plasmon resonance holographic microscopy
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Living cell sensing; Surface plasmon resonance; Digital holographic
   microscopy; Cell substrate adhesion gap; Bottom membrane dynamics
ID REFLECTION FLUORESCENCE MICROSCOPY; MATERIAL INTERFACE; CONTACTS; PHASE;
   FIBROBLASTS; MIGRATION; CONTRAST; BINDING
AB As one of the most common biological phenomena, cell adhesion plays a vital role in the cellular activities such as the growth and apoptosis, attracting tremendous research interests over the past decades. Taking the cell evolution under drug injection as an example, the dynamics of cell substrate adhesion gap can provide valuable information in the fundamental research of cell contacts. A robust technique of monitoring the cell adhesion gap and its evolution in real time is highly desired. Herein, we develop a surface plasmon resonance holographic microscopy to achieve the novel functionality of real time and wide field mapping of the cell substrate adhesion gap and its evolution in situ. The cell adhesion gap images of mouse osteoblast cells and human breast cancer cells have been effectively extracted in a dynamic and label free manner. The proposed technique opens up a new avenue of revealing the cell substrate interaction mechanism and renders the wide applications in the biosensing area.
C1 [Dai, Siqing; Zhang, Jiwei; Lu, Hua; Dou, Jiazhen; Zhang, Mengmeng; Dong, Chen; Di, Jianglei; Zhao, Jianlin] Northwestern Polytech Univ, MOE Key Lab Mat Phys & Chem Extraordinary Condit, Sch Phys Sci & Technol, Xian 710129, Peoples R China.
   [Dai, Siqing; Zhang, Jiwei; Lu, Hua; Dou, Jiazhen; Zhang, Mengmeng; Dong, Chen; Di, Jianglei; Zhao, Jianlin] Northwestern Polytech Univ, Shaanxi Key Lab Opt Informat Technol, Sch Phys Sci & Technol, Xian 710129, Peoples R China.
   [Yu, Tongyao] Northwestern Polytech Univ, Inst Special Environm Biophys, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University
RP Di, JL; Zhao, JL (通讯作者)，Northwestern Polytech Univ, MOE Key Lab Mat Phys & Chem Extraordinary Condit, Sch Phys Sci & Technol, Xian 710129, Peoples R China.; Di, JL; Zhao, JL (通讯作者)，Northwestern Polytech Univ, Shaanxi Key Lab Opt Informat Technol, Sch Phys Sci & Technol, Xian 710129, Peoples R China.
EM jiangleidi@nwpu.edu.cn; jlzhao@nwpu.edu.cn
RI Zhang, Jiwei/Y 2721 2018; Dai, Siqing/JXM 4063 2024; zhao,
   jianlin/AAU 2454 2021; Lu, Hua/G 3042 2014; Di, Jianglei/F 9112 2012
OI Di, Jianglei/0000 0001 7651 6554; Dou, Jiazhen/0000 0003 2729 147X
FU National Natural Science Foundation of China NSFC [61927810]; NSAF Joint
   Fund [U1730137]; Fundamental Research Funds for the Central Universities
   [3102019ghxm018]
FX This work was supported by National Natural Science Foundation of China
   NSFC (61927810), NSAF Joint Fund (U1730137) and Fundamental Research
   Funds for the Central Universities (3102019ghxm018).
CR AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141
   Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600 0854.2001.21104.x
   Ayala R, 2011, BIOMATERIALS, V32, P3700, DOI 10.1016/j.biomaterials.2011.02.004
   Bocková M, 2019, ANNU REV ANAL CHEM, V12, P151, DOI 10.1146/annurev anchem 061318 115106
   Braun D, 1997, APPL PHYS A MATER, V65, P341, DOI 10.1007/s003390050589
   Braun D, 1998, PHYS REV LETT, V81, P5241, DOI 10.1103/PhysRevLett.81.5241
   Burmeister JS, 1998, BIOMATERIALS, V19, P307, DOI 10.1016/S0142 9612(97)00109 9
   Cao JT, 2014, BIOSENS BIOELECTRON, V51, P97, DOI 10.1016/j.bios.2013.07.025
   Chabot V, 2009, BIOSENS BIOELECTRON, V24, P1667, DOI 10.1016/j.bios.2008.08.025
   Dai SQ, 2019, OPT LETT, V44, P2982, DOI 10.1364/OL.44.002982
   Dai SQ, 2018, OPT EXPRESS, V26, P25437, DOI 10.1364/OE.26.025437
   DAVIES PF, 1993, J CLIN INVEST, V91, P2640, DOI 10.1172/JCI116503
   DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197
   den Braber ET, 1998, J BIOMED MATER RES, V40, P425, DOI 10.1002/(SICI)1097 4636(19980605)40:3<425::AID JBM13>3.0.CO;2 I
   García AJ, 1999, BIOMATERIALS, V20, P2427, DOI 10.1016/S0142 9612(99)00170 2
   Giebel KF, 1999, BIOPHYS J, V76, P509, DOI 10.1016/S0006 3495(99)77219 X
   Hassanzadeh A., 2009, PHOTONIC MICRODEVICE, V7322
   Hinman SS, 2018, ANAL CHEM, V90, P19, DOI 10.1021/acs.analchem.7b04251
   IZZARD CS, 1980, J CELL SCI, V42, P81
   IZZARD CS, 1976, J CELL SCI, V21, P129
   Jamil MMA, 2008, J STRUCT BIOL, V164, P75, DOI 10.1016/j.jsb.2008.06.005
   Kabashin AV, 2009, OPT EXPRESS, V17, P21191, DOI 10.1364/OE.17.021191
   Kreysing E, 2018, ACS NANO, V12, P8934, DOI 10.1021/acsnano.8b01396
   Li SP, 2012, BIOMED OPT EXPRESS, V3, P3190, DOI 10.1364/BOE.3.003190
   Liu RJ, 2017, BIOSENS BIOELECTRON, V87, P433, DOI 10.1016/j.bios.2016.08.090
   Lu H, 2019, NANOSCALE, V11, P4759, DOI 10.1039/c8nr09227c
   Mandracchia B, 2015, ANAL CHEM, V87, P4124, DOI 10.1021/acs.analchem.5b00095
   Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962 8924(97)01002 7
   Nikkhah M, 2012, BIOMATERIALS, V33, P5230, DOI 10.1016/j.biomaterials.2012.03.079
   Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Schnars U, 2002, MEAS SCI TECHNOL, V13, pR85, DOI 10.1088/0957 0233/13/9/201
   Schneckenburger H, 2005, CURR OPIN BIOTECH, V16, P13, DOI 10.1016/j.copbio.2004.12.004
   Son T, 2019, BIOSENS BIOELECTRON, V146, DOI 10.1016/j.bios.2019.111738
   Son T, 2018, OPT COMMUN, V422, P64, DOI 10.1016/j.optcom.2017.10.001
   Su YD, 2010, OPT EXPRESS, V18, P20125, DOI 10.1364/OE.18.020125
   Toma K, 2014, ACS NANO, V8, P12612, DOI 10.1021/nn505521e
   Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435
   Wang SP, 2010, P NATL ACAD SCI USA, V107, P16028, DOI 10.1073/pnas.1005264107
   Wang W, 2012, NAT CHEM, V4, P846, DOI [10.1038/nchem.1434, 10.1038/NCHEM.1434]
   Wang W, 2012, LANGMUIR, V28, P13373, DOI 10.1021/la301712h
   Watanabe K, 2012, BIOMED OPT EXPRESS, V3, P354, DOI 10.1364/BOE.3.000354
   Wrobel G, 2008, J R SOC INTERFACE, V5, P213, DOI 10.1098/rsif.2007.1094
   Yang YZ, 2015, SMALL, V11, P2878, DOI 10.1002/smll.201403016
   Yongabi D, 2020, ACS APPL MATER INTER, V12, P18258, DOI 10.1021/acsami.0c00353
   Yu H, 2014, ACS NANO, V8, P3427, DOI 10.1021/nn4062885
   Zeng YJ, 2019, BIOSENS BIOELECTRON, V145, DOI 10.1016/j.bios.2019.111717
   Zhang JW, 2018, OPT EXPRESS, V26, P13549, DOI 10.1364/OE.26.013549
   Zhang JW, 2017, OPT LETT, V42, P3462, DOI 10.1364/OL.42.003462
   Zhang JW, 2017, APPL OPTICS, V56, P3223, DOI 10.1364/AO.56.003223
NR 50
TC 20
Z9 23
U1 1
U2 61
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956 5663
EI 1873 4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD FEB 15
PY 2021
VL 174
AR 112826
DI 10.1016/j.bios.2020.112826
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology   Other Topics
GA PO9KZ
UT WOS:000605490200003
PM 33262060
DA 2025 08 17
ER

PT J
AU Wu, YL
   Hwang, DY
   Hsiao, HP
   Ting, WH
   Huang, CY
   Tsai, WY
   Chen, HC
   Chao, MC
   Lo, FS
   Tsai, JD
   Yang, S
   Shih, SL
   Lin, SP
   Lin, CL
   Lee, YJ
AF Wu, Yi Lei
   Hwang, Daw Yang
   Hsiao, Hui Pin
   Ting, Wei Hsin
   Huang, Chi Yu
   Tsai, Wen Yu
   Chen, Hung Chun
   Chao, Mei Chyn
   Lo, Fu Sung
   Tsai, Jeng Daw
   Yang, Stone
   Shih, Shin Lin
   Lin, Shuan Pei
   Lin, Chiung Ling
   Lee, Yann Jinn
TI Mutations in Pseudohypoparathyroidism 1a and
   Pseudopseudohypoparathyroidism in Ethnic Chinese
SO PLOS ONE
LA English
DT Article
ID ALBRIGHT HEREDITARY OSTEODYSTROPHY; GS ALPHA GENE; IDENTIFIES PDE4D
   MUTATIONS; NONSENSE MEDIATED DECAY; STIMULATORY G PROTEIN; HORMONE
   RESISTANCE; PARATHYROID HORMONE; MULTIPLE HORMONES; GNAS; DELETION
AB An inactivating mutation in the GNAS gene causes either pseudohypoparathyroidism 1a (PHP1A) when it is maternally inherited or pseudopseudohypoparathyroidism (PPHP) when it is paternally inherited. We investigated clinical manifestations and mutations of the GNAS gene in ethnic Chinese patients with PHP1A or PPHP. Seven patients from 5 families including 4 girls and 2 boys with PHP1A and 1 girl with PPHP were studied. All PHP1A patients had mental retardation. They were treated with calcitriol and CaCO3 with regular monitoring of serum Ca levels, urinary Ca/Cr ratios, and renal sonography. Among them, 5 patients also had primary hypothyroidism suggesting TSH resistance. One female patient had a renal stone which was treated with extracorporeal shockwave lithotripsy. She had an increased urinary Ca/Cr ratio of 0.481 mg/mg when the stone was detected. We detected mutations using PCR and sequencing as well as analysed a splice acceptor site mutation using RT PCR, sequencing, and minigene construct. We detected 5 mutations: c.85C>T (Q29*), c.103C>T (Q35*), c.840 2A>G (R280Sfs*21), c.1027_1028delGA (D343*), and c.1174G>A (E392K). Mutations c.840 2A>G and c.1027_1028delGA were novel. The c.840 2A>G mutation at the splice acceptor site of intron 10 caused retention of intron 10 in the minigene construct but skipping of exon 11 in the peripheral blood cells. The latter was the most probable mechanism which caused a frameshift, changing Arg to Ser at residue 280 and invoking a premature termination of translation at codon 300 (R280Sfs*21). Five GNAS mutations in ethnic Chinese with PHP1A and PPHP were reported. Two of them were novel. Mutation c.840 2A>G destroyed a spice acceptor site and caused exon skipping. Regular monitoring and adjustment in therapy are mandatory to achieve optimal therapeutic effects and avoid nephrolithiasis in patients with PHP1A.
C1 [Wu, Yi Lei; Ting, Wei Hsin; Huang, Chi Yu; Tsai, Jeng Daw; Lin, Shuan Pei; Lee, Yann Jinn] Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan.
   [Wu, Yi Lei] Changhua Christian Hosp, Dept Pediat, Changhua, Taiwan.
   [Hwang, Daw Yang; Chen, Hung Chun] Kaohsiung Med Univ Hosp, Dept Med, Div Nephrol, Kaohsiung, Taiwan.
   [Hsiao, Hui Pin] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Dept Pediat, Kaohsiung, Taiwan.
   [Tsai, Wen Yu] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan.
   [Chen, Hung Chun] Kaohsiung Med Univ, Coll Med, Dept Med, Fac Renal Care, Kaohsiung, Taiwan.
   [Chao, Mei Chyn] Kaohsiung Med Univ Hosp, Dept Pediat, Div Genet Endocrinol & Metab, Kaohsiung, Taiwan.
   [Chao, Mei Chyn] Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan.
   [Lo, Fu Sung] Chang Gung Mem Hosp, Dept Pediat, Taoyuan, Taiwan.
   [Lo, Fu Sung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Ting, Wei Hsin; Huang, Chi Yu; Lin, Shuan Pei] Mackay Jr Coll Med Nursing & Management, New Taipei City, Taiwan.
   [Yang, Stone] Mackay Mem Hosp, Dept Urol, Taipei, Taiwan.
   [Shih, Shin Lin] Mackay Mem Hosp, Dept Radiol, Taipei, Taiwan.
   [Lin, Shuan Pei; Lin, Chiung Ling; Lee, Yann Jinn] Mackay Mem Hosp, Dept Med Res, Taipei, Taiwan.
   [Lin, Shuan Pei] Natl Taipei Univ Nursing & Hlth, Dept Infant & Child Care, Taipei, Taiwan.
   [Tsai, Jeng Daw; Shih, Shin Lin; Lee, Yann Jinn] Taipei Med Univ, Coll Med, Taipei, Taiwan.
   [Lin, Shuan Pei; Lee, Yann Jinn] Mackay Med Coll, Inst Biomed Sci, New Taipei City, Taiwan.
   [Lin, Shuan Pei; Lee, Yann Jinn] Mackay Med Coll, Dept Med, New Taipei City, Taiwan.
C3 Mackay Memorial Hospital; Changhua Christian Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Municipal Siao Gang Hospital; National Taiwan
   University; National Taiwan University Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital; Kaohsiung Medical University; Chang Gung Memorial Hospital;
   Chang Gung University; Mackay Junior College of Medicine, Nursing &
   Management; Mackay Memorial Hospital; Mackay Memorial Hospital; Mackay
   Memorial Hospital; National Taipei University of Nursing & Health
   Science (NTUNHS); Taipei Medical University; Mackay Medical University;
   Mackay Medical University
RP Lee, YJ (通讯作者)，Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan.
EM yannlee@mmh.org.tw
RI Hsiao, Hui Pin/B 3892 2010; Hwang, Daw yang/IWM 6308 2023; Chen,
   Hung Chun/A 1326 2010; Chao, Mei Chyn/D 5490 2009
OI TSAI, WEN YU/0000 0003 1332 2650; 
FU Mackay Memorial Hospital [MMH E 10007, MMH10170]; Kaohsiung Medical
   University Hospital [KMUH 99 9M35]; KMUH Nephrology Research Fund from
   Kaohsiung Medical University Hospital
FX This work was supported by grants MMH E 10007 and MMH10170 from Mackay
   Memorial Hospital and KMUH 99 9M35 and KMUH Nephrology Research Fund
   from Kaohsiung Medical University Hospital. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adegbite NS, 2008, AM J MED GENET A, V146A, P1788, DOI 10.1002/ajmg.a.32346
   Albright F, 1942, ENDOCRINOLOGY, V30, P922
   Allgrove J, 2009, CLIN PEDIAT ENDOCRIN, P374
   Bastepe M, 2005, NAT GENET, V37, P25, DOI 10.1038/ng1487
   Bastepe M, 2003, J CLIN ENDOCR METAB, V88, P4055, DOI 10.1210/jc.2003 031271
   Bastepe M, 2002, MOL ENDOCRINOL, V16, P1912, DOI 10.1210/me.2002 0054
   Bastepe M, 2001, AM J HUM GENET, V68, P1283, DOI 10.1086/320117
   Bastepe M, 2013, ENDOCR DEV, V24, P11, DOI 10.1159/000342494
   Bertaux K, 2006, BONE, V38, P943, DOI 10.1016/j.bone.2005.11.025
   Bringhurst R., 2011, Williams Textbook of Endocrinology: Hormones and disorders of mineral metabolism, V12th, P1237
   Chen W, 2010, PEDIATR NEONATOL, V51, P69, DOI 10.1016/S1875 9572(10)60014 9
   Chillambhi S, 2010, J CLIN ENDOCR METAB, V95, P3993, DOI 10.1210/jc.2009 2205
   Cooper TA, 2005, METHODS, V37, P331, DOI 10.1016/j.ymeth.2005.07.015
   Craigen WJ, 1997, AM J MED GENET, V72, P63
   Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168 9525(98)01658 8
   D'Souza Li L, 2001, HUM MUTAT, V18, P411, DOI 10.1002/humu.1212
   de Sanctis L, 2004, J CLIN ENDOCR METAB, V89, P1650, DOI 10.1210/jc.2003 030850
   de Sanctis L, 2003, PEDIATR RES, V53, P749, DOI 10.1203/01.PDR.0000059752.07086.A2
   Elli FM, 2013, HUM MUTAT, V34, P411, DOI 10.1002/humu.22265
   Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306
   Fernández Rebollo E, 2013, J CLIN ENDOCR METAB, V98, pE996, DOI 10.1210/jc.2012 4164
   Fernández Rebollo E, 2011, J BONE MINER RES, V26, P1854, DOI 10.1002/jbmr.408
   Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438
   Gelfand IM, 2006, J PEDIATR US, V149, P877, DOI 10.1016/j.jpeds.2006.08.050
   Germain Lee EL, 2003, J CLIN ENDOCR METAB, V88, P4059, DOI 10.1210/jc.2003 030028
   Germain Lee EL, 2002, BIOCHEM BIOPH RES CO, V296, P67, DOI 10.1016/S0006 291X(02)00833 1
   Greer FR, 2006, PEDIATRICS, V117, P578, DOI 10.1542/peds.2005 2822
   Harries LW, 2004, DIABETES, V53, P500, DOI 10.2337/diabetes.53.2.500
   Hwang DY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025492
   Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092 8674(01)00475 5
   Ishikawa Y, 2001, J HUM GENET, V46, P426, DOI 10.1007/s100380170062
   Jin HY, 2011, CLIN ENDOCRINOL, V75, P207, DOI 10.1111/j.1365 2265.2011.04026.x
   KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081
   Lam ACF, 2006, HK J PAEDIAT, V11, P284
   Lee H, 2012, AM J HUM GENET, V90, P746, DOI 10.1016/j.ajhg.2012.03.004
   LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002 9343(83)91008 2
   LEVINE MA, 1988, P NATL ACAD SCI USA, V85, P617, DOI 10.1073/pnas.85.2.617
   Lim SHM, 2002, J PEDIATR ENDOCR MET, V15, P259
   Linglart A, 2005, AM J HUM GENET, V76, P804, DOI 10.1086/429932
   Linglart A, 2002, J CLIN ENDOCR METAB, V87, P189, DOI 10.1210/jc.87.1.189
   Linglart A, 2013, HORM RES PAEDIAT, V79, P119, DOI 10.1159/000348516
   Linglart A, 2011, NEW ENGL J MED, V364, P2218, DOI 10.1056/NEJMoa1012717
   Mantovani G, 2002, J CLIN ENDOCR METAB, V87, P4736, DOI 10.1210/jc.2002 020183
   Mantovani G, 2000, J CLIN ENDOCR METAB, V85, P4243, DOI 10.1210/jc.85.11.4243
   Mantovani G, 2011, J CLIN ENDOCR METAB, V96, P3020, DOI 10.1210/jc.2011 1048
   Miao ZM, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/509549
   Michot C, 2012, AM J HUM GENET, V90, P740, DOI 10.1016/j.ajhg.2012.03.003
   Nakamura Y, 2000, J Epidemiol, V10, P29
   Park CH, 2010, ANN CLIN LAB SCI, V40, P261
   PHELAN MC, 1995, AM J MED GENET, V58, P1, DOI 10.1002/ajmg.1320580102
   Richard N, 2012, J CLIN ENDOCR METAB, V97, pE863, DOI 10.1210/jc.2011 2804
   Romano M, 2001, NUCLEIC ACIDS RES, V29, P886, DOI 10.1093/nar/29.4.886
   STONE MD, 1993, BONE, V14, P727, DOI 10.1016/8756 3282(93)90204 N
   Strachan T, 2011, HUMAN MOLECULAR GENETICS 4TH EDITION, P405
   Sun LH, 2009, ENDOCRINE, V36, P25, DOI 10.1007/s12020 009 9193 z
   Thiele S, 2011, HUM MUTAT, V32, P653, DOI 10.1002/humu.21489
   Wu SJ, 2007, ASIA PAC J CLIN NUTR, V16, P518
NR 57
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2014
VL 9
IS 3
AR e90640
DI 10.1371/journal.pone.0090640
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AD6FV
UT WOS:000333352800019
PM 24651309
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Lee, KJ
   Yun, SI
AF Lee, Kyung Jin
   Yun, Seok Il
TI Nanocomposite hydrogels based on agarose and diphenylalanine
SO POLYMER
LA English
DT Article
DE Agarose; Diphenylalanine; Nanocomposite hydrogel
ID INTERPENETRATING NETWORK FORMATION; ASSEMBLED PEPTIDE NANOTUBES;
   NEUTRON SCATTERING; GEL COMPOSITES; DRUG DELIVERY; NANOWIRES; GELATION;
   MICROTUBES; TRANSITION; MECHANISM
AB Nanocomposite hydrogels were prepared by temperature induced self assembly of agarose and diphenylalanine (FF) mixtures in water. We investigated the mechanical and thermal properties, and the structure of agarose/FF composite systems. The FF assembly was significantly influenced by the existence of agarose molecules, which formed relatively thin FF nanowires (NWs) (microwires form from pure FF solutions) passing through meshes of agarose networks. The storage and compressive moduli of the nanocomposite gels significantly increased by increasing the FF content (up to 2 wt% for a 1 wt% agarose matrix). The nanocomposite gels did not fracture, even at a strain of 95%, but contracted uniformly by expelling most of the water during a compressive deformation. The highly compressed gels re swelled in water and slowly recovered their original cylindrical monolithic shape. The unusual viscoelastic and compressive behaviors of nanocomposite gels is attributed to the unique nanostructure of interpenetrating networks between rigid NWs and the agarose matrix. Osteoblast like cells (MG63) cultured on the nanocomposite hydrogels demonstrated that the FF assemblies could improve the cell viability of the agarose gel. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Lee, Kyung Jin; Yun, Seok Il] Sangmyung Univ, Dept Chem Engn & Mat Sci, Seoul 03016, South Korea.
C3 Sangmyung University
RP Yun, SI (通讯作者)，Sangmyung Univ, Dept Chem Engn & Mat Sci, Seoul 03016, South Korea.
EM yunsans@smu.ac.kr
RI Lee, Jae Uk/AAB 5674 2020
FU International Collaborative Research and Development Program   Ministry
   of Trade, Industry & Energy of Korea [N0001230]
FX For financial support of this research, we thank the International
   Collaborative Research and Development Program (N0001230) funded by the
   Ministry of Trade, Industry & Energy of Korea.
CR Adler Abramovich L, 2006, LANGMUIR, V22, P1313, DOI 10.1021/la052409d
   Amici E, 2002, BIOMACROMOLECULES, V3, P466, DOI 10.1021/bm010157z
   Amici E, 2000, BIOMACROMOLECULES, V1, P721, DOI 10.1021/bm000057d
   ARNOTT S, 1974, J MOL BIOL, V90, P269, DOI 10.1016/0022 2836(74)90372 6
   Azuri I, 2014, J AM CHEM SOC, V136, P963, DOI 10.1021/ja408713x
   Caron I, 2016, BIOMATERIALS, V75, P135, DOI 10.1016/j.biomaterials.2015.10.024
   Das D, 2012, SOFT MATTER, V8, P2348, DOI 10.1039/c1sm06639k
   Demirel G, 2011, LANGMUIR, V27, P12533, DOI 10.1021/la202750n
   DJABOUROV M, 1989, MACROMOLECULES, V22, P180, DOI 10.1021/ma00191a035
   Fatin Rouge N, 2006, J PHYS CHEM B, V110, P20133, DOI 10.1021/jp060362e
   FOORD SA, 1989, BIOPOLYMERS, V28, P1345, DOI 10.1002/bip.360280802
   GUENET JM, 1993, INT J BIOL MACROMOL, V15, P131, DOI 10.1016/0141 8130(93)90011 A
   Guo C, 2012, ACS NANO, V6, P3907, DOI 10.1021/nn300015g
   Hammouda B, 2004, MACROMOLECULES, V37, P6932, DOI 10.1021/ma049623d
   Hammouda B, 2006, BIOPHYS J, V91, P2237, DOI 10.1529/biophysj.106.083691
   Han TH, 2007, ADV MATER, V19, P3924, DOI 10.1002/adma.2007001839
   Hu T, 2017, SMALL, V13, DOI 10.1002/smll.201602610
   Huang RL, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556 276X 9 653
   Huang RL, 2011, SOFT MATTER, V7, P6418, DOI 10.1039/c1sm05752a
   Huang RL, 2011, SOFT MATTER, V7, P6222, DOI 10.1039/c1sm05375b
   Hule RA, 2009, MACROMOLECULES, V42, P7137, DOI 10.1021/ma9003242
   Kim J, 2010, ADV MATER, V22, P583, DOI 10.1002/adma.200901973
   Kimura T, 2010, CARBON, V48, P4015, DOI 10.1016/j.carbon.2010.07.005
   Kline SR, 2006, J APPL CRYSTALLOGR, V39, P895, DOI 10.1107/S0021889806035059
   Kol N, 2005, NANO LETT, V5, P1343, DOI 10.1021/nl0505896
   Kumaraswamy P, 2011, SOFT MATTER, V7, P2744, DOI 10.1039/c0sm00897d
   Le Goff KJ, 2015, CARBOHYD POLYM, V116, P117, DOI 10.1016/j.carbpol.2014.04.085
   Li Q, 2015, ACS NANO, V9, P2689, DOI 10.1021/acsnano.5b00623
   Li R, 2013, POLYM COMPOSITE, V34, P482, DOI 10.1002/pc.22439
   Li XD, 2005, NANOTECHNOLOGY, V16, P2020, DOI [10.1088/0957 4484/16/10/006, 10.1088/0957 4484/16/006]
   Ma XY, 2014, SPECTROCHIM ACTA A, V121, P657, DOI 10.1016/j.saa.2013.11.111
   Mason TO, 2014, ACS NANO, V8, P1243, DOI 10.1021/nn404237f
   Maurer S, 2012, FOOD HYDROCOLLOID, V29, P298, DOI 10.1016/j.foodhyd.2012.03.002
   Meena R, 2013, POLYM COMPOSITE, V34, P978, DOI 10.1002/pc.22504
   Mendes E, 2004, MACROMOLECULES, V37, P2643, DOI 10.1021/ma034411m
   Merino S, 2015, ACS NANO, V9, P4686, DOI 10.1021/acsnano.5b01433
   Nordqvist D, 2011, FOOD BIOPHYS, V6, P450, DOI 10.1007/s11483 011 9225 0
   Normand V, 2000, BIOMACROMOLECULES, V1, P730, DOI 10.1021/bm005583j
   Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387
   Rochas C, 1999, MACROMOL SYMP, V138, P157, DOI 10.1002/masy.19991380120
   Russ N, 2013, BIOMACROMOLECULES, V14, P4116, DOI 10.1021/bm4012776
   Shibayama M, 2012, SOFT MATTER, V8, P8030, DOI 10.1039/c2sm25325a
   Silva RF, 2013, LANGMUIR, V29, P10205, DOI 10.1021/la4019162
   Singh YP, 2016, ACS APPL MATER INTER, V8, P21236, DOI 10.1021/acsami.6b08285
   Sokolova A., 2016, Neutron News, V27, P9, DOI DOI 10.1080/10448632.2016.1163980
   Su Y, 2010, J MATER CHEM, V20, P6734, DOI [10.1039/c0jm0110d, 10.1039/c0jm00110d]
   Tam RY, 2017, ACCOUNTS CHEM RES, V50, P703, DOI 10.1021/acs.accounts.6b00543
   Zhang LM, 2012, CARBOHYD POLYM, V88, P1445, DOI 10.1016/j.carbpol.2012.02.050
NR 48
TC 15
Z9 15
U1 2
U2 75
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032 3861
EI 1873 2291
J9 POLYMER
JI Polymer
PD MAR 14
PY 2018
VL 139
BP 86
EP 97
DI 10.1016/j.polymer.2018.02.007
PG 12
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA FY3QF
UT WOS:000426735300011
DA 2025 08 17
ER

PT J
AU Sultana, S
   Ali, R
   Talegaonkar, S
   Ahmad, FJ
   Mittal, G
   Bhatnagar, A
AF Sultana, Shaheen
   Ali, Rashid
   Talegaonkar, Sushama
   Ahmad, Farhan Jalees
   Mittal, Gaurav
   Bhatnagar, Aseem
TI In vivo lung deposition and sub acute inhalation toxicity studies of
   nano sized alendronate sodium as an antidote for inhaled toxic
   substances in Sprague Dawley rats
SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Alendronate sodium; Technetium 99m; Biodistribution; Gamma scintigraphy;
   Sub acute inhalation toxicity; Histopathology
ID LEAF EXTRACT; BISPHOSPHONATES; DELIVERY; MECHANISMS
AB Introduction: Alendronate sodium is a bisphosphonate agent used for the treatment of osteoporosis and other bone diseases. It has a strong chelating property to bind or, to some extent, counteract the effects of substances, such as magnesium, calcium citrate, ferrous fumarate, carbonyl iron, as well as the zinc gluconate, sulfate and acetate salts. The objective of the present study was to evaluate lung deposition and sub acute inhalation toxicity of the alendronate sodium respiratory formulation.
   Methods: Particle dimension of aerosols of alendronate was measured using a particle size analyzer. Alendronate was radiolabeled using Technetium 99m for in vitro and in vivo biodistribution studies. Alendronate at doses, 0.5%, 1.0%, and 1.5% in ethanol saline respiratory formulation was inhaled twice a day up to 5 weeks for inhalation toxicity investigations. Hematological, biochemical and lung toxicity biomarkers in bronchoalveolar lavage (BAL) fluid were determined at the end of the experiment. Histopathological analysis of lung tissues was carried out to observe any microscopic changes
   Results: Particle size analysis revealed the size within 300 500 nm. Anderson cascade impactor results showed that the particles exhibited higher respirable fraction (55.52%) with MMAD of 4.66 mu m. Hematology, serum biochemistry and lung toxicity biomarkers in BAL fluid performed in the sub acute toxicity studies indicated no adverse effects of alendronate sodium inhalation except for a significant increase in cholesterol levels and marginal increase in BAL fluid protein. At autopsy, no histopathological changes in major organs were observed.
   Conclusions: The lung deposition and safety evaluation data observed from these studies suggested that aerosolized nanosized alendronate sodium by the inhalation route could be a new and promising route of administration as an antidote to radioactive substances through an increase in the bioavailability of the drug as well as a decrease in side effects on systemic delivery. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Sultana, Shaheen; Talegaonkar, Sushama; Ahmad, Farhan Jalees] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, Delhi 110062, India.
   [Ali, Rashid; Mittal, Gaurav; Bhatnagar, Aseem] DRDO, Dept Nucl Med, Inst Nucl Med & Allied Sci, Delhi 110054, India.
C3 Jamia Hamdard University; Defence Research & Development Organisation
   (DRDO); Institute of Nuclear Medicine & Allied Sciences (INMAS)
RP Bhatnagar, A (通讯作者)，DRDO, Dept Nucl Med, Inst Nucl Med & Allied Sci, Brig SK Mazumdar Marg, Delhi 110054, India.
EM shaheen634@yahoo.co.uk; rashidinmas@gmail.com; stalegaonkar@gmail.com;
   farhanja_2000@yahoo.com; gauravmitta123@gmail.com;
   dr.aseembhatnagar@gmail.com
RI Talegoankar, Sushama/AAW 8374 2020; Ahmad, Farhan/HMO 6565 2023
OI Talegaonkar, sushama/0000 0003 2211 5119; Talegaonkar,
   Sushama/0000 0001 5301 5298; Ahmad, Farhan/0000 0002 0740 8573
FU University Grant Commission
FX The authors are thankful to Institute of Nuclear Medicine and Allied
   Sciences (INMAS), Defence Research and Development Organization,
   Ministry of Defence, Government of India for providing the animals for
   in vivo studies to carry out this work. The authors are also thankful to
   University Grant Commission for awarding the financial support during
   this work.
CR Ali R, 2012, INT J DRUG DEV RES, V4, P358
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Choi WS, 2001, P NATL ACAD SCI USA, V98, P11103, DOI 10.1073/pnas.201413798
   Claiborne A., 1985, CRC HDB METHODS OXYG, P283
   Costabel U, 2001, Curr Opin Pulm Med, V7, P255, DOI 10.1097/00063198 200109000 00002
   Diallo A, 2010, TROP J PHARM RES, V9, P463
   Dogana I., 2005, IAEACN130115P ISTR
   Graham DY, 1999, ALIMENT PHARM THER, V13, P515
   Guney E, 2008, NEUROENDOCRINOL LETT, V29, P252
   Halim SZ, 2011, J MED PLANTS RES, V5, P1867
   Hayes A.W., 2007, Principles and methods of toxicology, Vfifth
   HENDERSON RF, 1995, TOXICOL APPL PHARM, V134, P170, DOI 10.1006/taap.1995.1181
   Hess DR, 2008, RESP CARE, V53, P699
   Houpert P, 2004, CAN J PHYSIOL PHARM, V82, P73, DOI 10.1139/Y03 113
   Jain D, 2008, Indian J Physiol Pharmacol, V52, P297
   Ji JH, 2007, INHAL TOXICOL, V19, P857, DOI 10.1080/08958370701432108
   Karie Svetlana, 2006, Nephrol Ther, V2, P368, DOI 10.1016/j.nephro.2006.07.013
   Kasahara DI, 2008, J IMMUNOL, V181, P736, DOI 10.4049/jimmunol.181.1.736
   Khilnani GC., 2008, Indian J Chest Dis Allied Sci, V50, P209
   KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076 6879(55)01072 0
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   Marcus C. S., 2006, RAD PROTECT MANAG, V21, P6
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   MONKKONEN J, 1990, PHARMACOL TOXICOL, V66, P294
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Pérez López FR, 2004, MATURITAS, V48, P179, DOI 10.1016/j.maturitas.2003.12.006
   Qamar W, 2008, CHEM BIOL INTERACT, V176, P79, DOI 10.1016/j.cbi.2008.08.011
   Raza M., 2002, SCI PHARM, V7, P135, DOI DOI 10.3797/SCIPHARM.AUT 02 16
   Reynolds H Y, 2008, Monaldi Arch Chest Dis, V69, P91
   Reynolds HY, 2000, LUNG, V178, P271, DOI 10.1007/s004080000032
   REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Sobha K., 2010, KATHMANDU U J SCI EN, V3
   Sole Pasquale De, 1996, J BRONCHOLOGY INTERV, V3, P192
   Suarez S, 2000, Respir Care, V45, P652
   Sultana S, 2010, CHROMATOGRAPHIA, V72, P321, DOI 10.1365/s10337 010 1656 0
   Telko Martin J, 2005, Respir Care, V50, P1209
   Teo S, 2002, TOXICOLOGY, V179, P183, DOI 10.1016/S0300 483X(02)00338 4
   Tsapis N, 2003, TUBERCULOSIS, V83, P379, DOI 10.1016/j.tube.2003.08.016
   Vasantharaja C., 2012, Journal of Pharmacy Research, V5, P2595
   von Wichert P, 2005, RESPIRATION, V72, P552, DOI 10.1159/000087685
   WRIGHT JR, 1981, ARCH BIOCHEM BIOPHYS, V206, P296, DOI 10.1016/0003 9861(81)90095 3
   Xu KM, 2008, INT J RADIAT BIOL, V84, P353, DOI 10.1080/09553000802029902
NR 45
TC 13
Z9 14
U1 0
U2 31
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1382 6689
EI 1872 7077
J9 ENVIRON TOXICOL PHAR
JI Environ. Toxicol. Pharmacol.
PD SEP
PY 2013
VL 36
IS 2
BP 636
EP 647
DI 10.1016/j.etap.2013.05.016
PG 12
WC Environmental Sciences; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Pharmacology & Pharmacy; Toxicology
GA 213TK
UT WOS:000324082900044
PM 23851119
DA 2025 08 17
ER

PT J
AU Guan, YT
   Xie, Y
   Li, DS
   Zhu, YY
   Zhang, XL
   Feng, YL
   Chen, YP
   Xu, LJ
   Liao, PF
   Wang, G
AF Guan, Yu Tao
   Xie, Yong
   Li, Dong Sheng
   Zhu, Yu Yuan
   Zhang, Xiao Lu
   Feng, Ying Lin
   Chen, Yang Ping
   Xu, Li Jiang
   Liao, Pin Fu
   Wang, Gang
TI Comparison of biological characteristics of mesenchymal stem cells
   derived from the human umbilical cord and decidua parietalis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE mesenchymal stem cells; umbilical cord; decidua parietalis; biological
   characteristics
ID STEM/PROGENITOR CELLS; STROMAL CELLS; MSCS; PROLIFERATION; REGENERATION;
   CYTOKINES; THERAPY; TISSUES; GROWTH; REPAIR
AB Mesenchymal stem cells (MSCs) are derived from the mesoderm and have the self renewal capacity and multi directional differentiation potential of adult stem cells. Stem cells from different sources have different molecular and growth characteristics; therefore, the mechanisms and effects of stem cell mediated repair and tissue regeneration may be different. The aim of the present study was to compare the biological characteristics of MSCs derived from the umbilical cord (UC MSCs) and MSCs derived from the decidua parietalis (DP MSCs), and to provide new evidence for the selection of seed cells in regenerative medicine. Growth curves, cell doubling times, colony formation rates, immunophenotypes, differentiation capacities and secretion factor levels of MSCs derived from the two sources were analysed. UC MSCs and DP MSCs exhibited similar properties with regards to morphology, spiral growth, immunophenotype, and potential to differentiate into osteoblasts and adipocytes. For each cell type, the positive rates of the cell surface markers CD73, CD90 and CD105 were >95%, whereas CD34 and CD45 positive rates were <1%. Analyses of in vitro growth kinetics revealed shorter cell doubling times, and higher proliferative rates and colony formation rates of UC MSCs compared with DP MSCs (P<0.05). The concentration of basic fibroblast growth factor in the supernatant from UC MSCs was higher compared with that from DP MSCs (P<0.05). However, UC MSC supernatants exhibited lower levels of of keratinocyte growth factor, vascular endothelial growth factor and stem cell factor compared with DP MSCs (P<0.05). In conclusion, in vitro characterization of MSCs from these tissue sources revealed a number of common biological properties. However, the results also demonstrated clear biological distinctions and suggested that UC MSCs may have more effective application prospects.
C1 [Guan, Yu Tao; Xie, Yong; Zhu, Yu Yuan; Zhang, Xiao Lu; Feng, Ying Lin; Chen, Yang Ping; Xu, Li Jiang; Wang, Gang] First Peoples Hosp Foshan, Dept Obstet & Gynecol, 81 L ingnan Ave North, Foshan 528000, Guangdong, Peoples R China.
   [Li, Dong Sheng; Liao, Pin Fu] Guangdong Vitalife Biotechnol Co Ltd, Foshan 528000, Guangdong, Peoples R China.
RP Wang, G (通讯作者)，First Peoples Hosp Foshan, Dept Obstet & Gynecol, 81 L ingnan Ave North, Foshan 528000, Guangdong, Peoples R China.
EM wallace1971@163.com
RI ; Zhang, Xiaolu/GLU 8330 2022; Li, Dongsheng/IWV 4273 2023
OI Li, Dongsheng/0000 0002 1578 1239; 
FU Science and Technology Programs of Foshan [2017AB002801]; Medical
   Research Foundation of Guangdong Province, China [B2018034]
FX This research was supported by the Science and Technology Programs of
   Foshan (grant no. 2017AB002801) and Medical Research Foundation of
   Guangdong Province, China (grant no. B2018034).
CR Alawadhi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096662
   Azizi R, 2018, BIOMED PHARMACOTHER, V102, P333, DOI 10.1016/j.biopha.2018.03.091
   Bao R, 2017, GYNECOL ENDOCRINOL, V34, P1
   Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168
   Blanco JF, 2010, SPINE, V35, P2259, DOI 10.1097/BRS.0b013e3181cb8828
   Carrington LM, 2005, J CATARACT REFR SURG, V31, P412, DOI 10.1016/j.jcrs.2004.04.072
   Chi Y, 2014, CELL TISSUE BANK, V15, P397, DOI 10.1007/s10561 013 9404 y
   Di Spigna G, 2017, J BIOL REG HOMEOS AG, V31, P911
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fu Y, 2017, TISSUE ENG PART B RE, V23, P515, DOI [10.1089/ten.TEB.2016.0365, 10.1089/ten.teb.2016.0365]
   Furtado MB, 2014, GENOM DATA, V2, P345, DOI 10.1016/j.gdata.2014.10.006
   Harris DT, 2013, CURR STEM CELL RES T, V8, P394
   Huntsman HD, 2013, AM J PHYSIOL HEART C, V304, pH72, DOI [10.1152/ajpheart.00541.2012, 10.1152/ajpheart.00541 2012]
   Joerger Messerli MS, 2016, BEST PRACT RES CL OB, V31, P30, DOI 10.1016/j.bpobgyn.2015.07.006
   Kim YJ, 2008, BIOCHEM BIOPH RES CO, V373, P104, DOI 10.1016/j.bbrc.2008.05.183
   Kristjásson B, 2017, WORLD J ORTHOP, V8, P674, DOI 10.5312/wjo.v8.i9.674
   Liao GP, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/1764523
   Lim IJ, 2014, CELL TRANSPLANT, V23, P497, DOI 10.3727/096368914X678346
   Mahmoud EE, 2019, CARTILAGE, V10, P61, DOI 10.1177/1947603517708333
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Marquez MP, 2017, STEM CELLS DEV, V26, P1578, DOI 10.1089/scd.2017.0071
   Miranda JP, 2015, CELL TRANSPLANT, V24, P865, DOI 10.3727/096368913X676231
   Prockop DJ, 2010, J CELL MOL MED, V14, P2190, DOI 10.1111/j.1582 4934.2010.01151.x
   Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62
   Sabry D, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170794
   Sahoo A K, 2017, Vet World, V10, P1533, DOI 10.14202/vetworld.2017.1533 1541
   Sekine W, 2013, SCI WORLD J, DOI 10.1155/2013/359109
   Sibov TT, 2012, CYTOTECHNOLOGY, V64, P511, DOI 10.1007/s10616 012 9428 3
   Uccelli A, 2010, CURR OPIN IMMUNOL, V22, P768, DOI 10.1016/j.coi.2010.10.012
   Wang JM, 2016, CELL PHYSIOL BIOCHEM, V39, P1553, DOI 10.1159/000447857
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 19
   Xu LN, 2015, GENET MOL RES, V14, P16553, DOI 10.4238/2015.December.11.2
   Yannarelli G, 2014, STEM CELL REV REP, V10, P304, DOI 10.1007/s12015 013 9483 y
   Yoon DS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.3
   Zanetta M, 2009, ACTA BIOMATER, V5, P1126, DOI 10.1016/j.actbio.2008.12.003
   Zhang JJ, 2017, ONCOTARGET, V8
NR 36
TC 42
Z9 50
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2019
VL 20
IS 1
BP 633
EP 639
DI 10.3892/mmr.2019.10286
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA II0DR
UT WOS:000474876100067
PM 31180542
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Benschop, RJ
   Collins, EC
   Darling, RJ
   Allan, BW
   Leung, D
   Conner, EM
   Nelson, J
   Gaynor, B
   Xu, J
   Wang, XF
   Lynch, RA
   Li, B
   McCarty, D
   Oskins, JL
   Lin, C
   Johnson, KW
   Chambers, MG
AF Benschop, R. J.
   Collins, E. C.
   Darling, R. J.
   Allan, B. W.
   Leung, D.
   Conner, E. M.
   Nelson, J.
   Gaynor, B.
   Xu, J.
   Wang, X F
   Lynch, R. A.
   Li, B.
   McCarty, D.
   Oskins, J. L.
   Lin, C.
   Johnson, K. W.
   Chambers, M. G.
TI Development of a novel antibody to calcitonin gene related peptide for
   the treatment of osteoarthritis related pain
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE CGRP; Antibody; Osteoarthritis; Pain; Meniscal tear; MIA model
ID CGRP RECEPTOR ANTAGONIST; ROOT GANGLION NEURONS; DERMAL BLOOD FLOW;
   PHARMACOLOGICAL CHARACTERIZATION; SENSORY INNERVATION;
   MONOCLONAL ANTIBODY; INFLAMMATORY PAIN; MODEL; RAT; JOINT
AB Objective: Investigate a role for calcitonin gene related peptide (CGRP) in osteoarthritis (OA) related pain.
   Design: Neutralizing antibodies to CGRP were generated de novo. One of these antibodies, LY2951742, was characterized in vitro and tested in pre clinical in vivo models of OA pain.
   Results: LY2951742 exhibited high affinity to both human and rat CGRP (K D of 31 and 246 pM, respectively). The antibody neutralized CGRP mediated induction of cAMP in SK N MC cells in vitro and capsaicin induced dermal blood flow in the rat. Neutralization of CGRP significantly reduced pain behavior as measured by weight bearing differential in the rat monoiodoacetate model of OA pain in a dose dependent manner. Moreover, pain reduction with neutralization of CGRP occurred independently of prostaglandins, since LY2951742 and NSAIDs worked additively in the NSAID responsive version of the model and CGRP neutralization remained effective in the NSAID non responsive version of the model. Neutralization of CGRP also provided dose dependent and prolonged (>60 days) pain reduction in the rat meniscal tear model of OA after only a single injection of LY2951742.
   Conclusions: LY2951742 is a high affinity, neutralizing antibody to CGRP. Neutralization of CGRP is efficacious in several OA pain models and works independently of NSAID mechanisms of action. LY2951742 holds promise for the treatment of pain in OA patients. (C) 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Benschop, R. J.; Collins, E. C.; Darling, R. J.; Lynch, R. A.; Li, B.; McCarty, D.; Oskins, J. L.; Lin, C.; Johnson, K. W.; Chambers, M. G.] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.
   [Allan, B. W.; Leung, D.; Conner, E. M.; Nelson, J.; Gaynor, B.; Xu, J.; Wang, X F] Eli Lilly & Co, Lilly Biotechnol Ctr, San Diego, CA 92121 USA.
C3 Eli Lilly; Lilly Research Laboratories; Eli Lilly
RP Benschop, RJ (通讯作者)，Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA.
EM rbenschop@lilly.com; collins_emily_catherine@lilly.com;
   darling_ryan@lilly.com; allan_barrett@lilly.com;
   leung_donmienne@lilly.com; conner_elaine_m@lilly.com;
   nelson_james@lilly.com; gaynor_barbra@lilly.com; xu_jianghuai@lilly.com;
   wang_xiao_fen@lilly.com; lynch_renee_a@lilly.com; li_baolin@lilly.com;
   drmccarty@aol.com; oskins_jennifer_leigh@lilly.com;
   lin_chaohua@lilly.com; johnson_kirk_w@lilly.com;
   chambers_mark_geoffrey@lilly.com
FU Eli Lilly Company
FX All authors are employees of Eli Lilly & Company which supplied the
   funding for these studies.
CR Ashraf S, 2011, ANN RHEUM DIS, V70, P523, DOI 10.1136/ard.2010.137844
   Bendele A. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P363
   Bove SE, 2006, OSTEOARTHR CARTILAGE, V14, P1041, DOI 10.1016/j.joca.2006.05.001
   Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   Bowler KE, 2013, NEUROSCIENCE, V228, P271, DOI 10.1016/j.neuroscience.2012.10.030
   Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003
   BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0
   Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487
   Chizh BA, 2007, PAIN, V132, P132, DOI 10.1016/j.pain.2007.06.006
   de Hoon JN, 2003, CLIN PHARMACOL THER, V73, P312, DOI 10.1016/S0009 9236(03)00007 9
   Ferreira Gomes J, 2010, ARTHRITIS RHEUM US, V62, P3677, DOI 10.1002/art.27713
   Hershey JC, 2005, REGUL PEPTIDES, V127, P71, DOI 10.1016/j.regpep.2004.10.010
   Hirsch S, 2013, PAIN, V154, P700, DOI 10.1016/j.pain.2013.01.002
   Ho TW, 2008, NEUROLOGY, V70, P1304, DOI 10.1212/01.WNL.0000286940.29755.61
   Hunter DJ, 2006, BMJ BRIT MED J, V332, P639, DOI 10.1136/bmj.332.7542.639
   Ivanavicius SP, 2007, PAIN, V128, P272, DOI 10.1016/j.pain.2006.12.022
   Ma WY, 2010, CALCITONIN GENE RELATED PEPTIDE FAMILY: FORM, FUNCTION AND FUTURE PERSPECTIVES, P151, DOI 10.1007/978 90 481 2909 6_10
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   MAPP PI, 1990, NEUROSCIENCE, V37, P143, DOI 10.1016/0306 4522(90)90199 E
   Natura G, 2005, PAIN, V116, P194, DOI 10.1016/j.pain.2005.04.002
   Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 134
   Pavelka K, 2012, CURR MED RES OPIN, V28, P163, DOI 10.1185/03007995.2011.649848
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   Saito T, 2000, CLIN ORTHOP RELAT R, P172
   Salmon AM, 2001, NAT NEUROSCI, V4, P357, DOI 10.1038/86001
   Saxler G, 2007, EUR J PAIN, V11, P67, DOI 10.1016/j.ejpain.2005.12.011
   Sinclair SR, 2010, BRIT J CLIN PHARMACO, V69, P15, DOI 10.1111/j.1365 2125.2009.03543.x
   Staton PC, 2007, EUR J PAIN, V11, P283, DOI 10.1016/j.ejpain.2006.03.006
   Takeshita M, 2012, RHEUMATOLOGY, V51, P1790, DOI 10.1093/rheumatology/kes173
   Thakur M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033730
   Van der Schueren BJ, 2008, J PHARMACOL EXP THER, V325, P248, DOI 10.1124/jpet.107.133868
   Van der Schueren BJ, 2007, BRIT J CLIN PHARMACO, V64, P580, DOI 10.1111/j.1365 2125.2007.02939.x
   Von Banchet GS, 2002, NEUROSCIENCE, V110, P131, DOI 10.1016/S0306 4522(01)00547 4
   Wu HR, 1999, J MOL BIOL, V294, P151, DOI 10.1006/jmbi.1999.3141
   Zeller J, 2008, BRIT J PHARMACOL, V155, P1093, DOI 10.1038/bjp.2008.334
   Zhang LP, 2001, PAIN, V89, P265, DOI 10.1016/S0304 3959(00)00378 X
NR 37
TC 106
Z9 119
U1 0
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD APR
PY 2014
VL 22
IS 4
BP 578
EP 585
DI 10.1016/j.joca.2014.01.009
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA AG1WT
UT WOS:000335207600007
PM 24508775
OA Bronze
DA 2025 08 17
ER

PT J
AU Shah, S
   Arshia
   Kazmi, NS
   Jabeen, A
   Faheem, A
   Dastagir, N
   Ahmed, T
   Khan, KM
   Ahmed, S
   Raza, A
   Perveen, S
AF Shah, Shazia
   Arshia
   Kazmi, Nida Siraj
   Jabeen, Almas
   Faheem, Aisha
   Dastagir, Nida
   Ahmed, Tariq
   Khan, Khalid Mohammed
   Ahmed, Shakil
   Raza, Abeer
   Perveen, Shahnaz
TI Diclofenac 1,3,4 Oxadiazole Derivatives; Biology Oriented Drug Synthesis
   (BIODS) in Search of Better Non Steroidal, Non Acid Antiinflammatory
   Agents
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE Synthesis; diclofenac; 1,3,4 oxadiazole; antiinflammatory parameters;
   ROS suppression; NO inhibition
ID ANTI TNF ALPHA; IN VITRO; IMMUNOMODULATORY PROPERTIES; INFLAMMATION;
   GENERATION; ANALOGS; SILICO
AB Background: Inflammation is defined as the response of immune system cells to damaged or injured tissues The major symptoms of inflammation include increased blood flow, cellular influx, edema, elevated cellular metabolism, reactive oxygen species (ROS) nitric oxide (NO) and vasodilation. This normally protective mechanism against harmful agents when this normal mechanism becomes dysregulated that can cause serious illnesses including ulcerative colitis, Crohn's disease, rheumatoid arthritis, osteoarthritis, sepsis, and chronic pulmonary inflammation.
   Method: In this study synthetic transformations on diclofenac were carried out in search of better non steroidal antiinflammatory drugs (NSAIDs), non acidic, antiinflammatory agents. For this purpose diclofenac derivatives (2 20) were synthesized from diclofenac (1). All derivatives (2 20) and parent diclofenac (1) were evaluated for their antiinflammatory effect using different parameters including suppression of intracellular reactive oxygen species (ROS), produced by whole blood phagocytes, produced by neutrophils, and inhibition of nitric oxide (NO) production from J774.2 macrophages. The most active compound also evaluated for cytotoxicity activity.
   Results: Diclofenac (1) inhibited the ROS with an IC50 of 3.9 +/  2.8, 1.2 +/  0.0 mu g/mL respectively and inhibited NO with an IC50 of 30.01 +/  0.01 mu g/mL. Among its derivatives 4, 5, 11, 16, and 20, showed better antiinflammatory potential. The compound 5 was found to be the most potent inhibitor of intracellular ROS as well as NO with IC50 values of 1.9 +/  0.9, 1.7 +/  0.4 mu g/mL respectively and 7.13 +/  1.0 mu g/mL, respectively, and showed good inhibitory activity than parent diclofenac. The most active compounds were tested for their toxic effect on NIH 3T3 cells where all compounds were found to be non toxic compared to the standard cytotoxic drug cyclohexamide.
   Conclusion: Five derivatives were found to be active. Compound 5 was found to be the most potent inhibitor of ROS and NO compared to parent diclofenac 1 and standard drugs ibuprofen and L NMIMA, respectively. The most active compounds 1, 4, 5, 11 and 20 were found to be non toxic on NIH 3T3 cells. Compound 4, 5, and 20 also showed good antiinflammatory potential, compound 11 and 16 showed moderate and low level of inhibition, respectively.
C1 [Shah, Shazia; Arshia; Kazmi, Nida Siraj; Jabeen, Almas; Khan, Khalid Mohammed; Raza, Abeer] Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
   [Faheem, Aisha; Dastagir, Nida; Ahmed, Tariq] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.
   [Shah, Shazia] Fed Urdu Univ Art Sci & Technol, Dept Chem, Karachi, Pakistan.
   [Ahmed, Shakil] Univ Karachi, Ind Analyt Ctr, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
   [Perveen, Shahnaz] PCSIR Labs Complex, Karachi 75280, Pakistan.
C3 University of Karachi; University of Karachi; University of Karachi;
   PCSIR Laboratories Complex
RP Khan, KM (通讯作者)，Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
EM khalid.khan@iccs.edu
RI Taha, Muhammad/O 8260 2016; Ahmed, Tariq Galadanchi/ABE 1962 2021;
   Perveen, Shahnaz/I 4922 2015
FU Higher Education Commission (HEC) Pakistan under the National Research
   Program for Universities [20 1910]
FX This work was supported by the Higher Education Commission (HEC)
   Pakistan (Project No. 20 1910), under the National Research Program for
   Universities.
CR Abd Ellah HS, 2017, BIOORG CHEM, V74, P15, DOI 10.1016/j.bioorg.2017.06.003
   Amir M, 2004, EUR J MED CHEM, V39, P535, DOI 10.1016/j.ejmech.2004.02.008
   [Anonymous], J BRASILEIRO FITOMED
   Azizuddin, 2012, J CHEM SOC PAKISTAN, V34, P971
   Barbaric M, 2007, EUR J MED CHEM, V42, P20, DOI 10.1016/j.ejmech.2006.08.009
   Boscá L, 2005, TOXICOLOGY, V208, P249, DOI 10.1016/j.tox.2004.11.035
   Choudhary MI, 2009, PHYTOTHER RES, V23, P1336, DOI 10.1002/ptr.2639
   Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470 2045(09)70035 X
   El Ashry ESH, 2013, J ENZYM INHIB MED CH, V28, P105, DOI 10.3109/14756366.2011.636361
   Ferrero Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365 2249.2006.03261.x
   Jabeen A, 2016, INT IMMUNOPHARMACOL, V36, P232, DOI 10.1016/j.intimp.2016.04.034
   Khan KM, 2010, EUR J MED CHEM, V45, P4058, DOI 10.1016/j.ejmech.2010.05.065
   Khan KM, 2006, J ENZYM INHIB MED CH, V21, P139, DOI 10.1080/14756360500480418
   Kumar PV, 2008, INDIAN J CHEM B, V47, P759
   Mesaik MA, 2012, CHEM BIOL DRUG DES, V79, P290, DOI 10.1111/j.1747 0285.2011.01310.x
   Mesaik MA, 2005, LETT DRUG DES DISCOV, V2, P490, DOI 10.2174/1570180054771554
   Mesaik MA, 2004, BIOORGAN MED CHEM, V12, P2049, DOI 10.1016/j.bmc.2004.02.034
   Moody TW, 2010, LUNG CANCER, V68, P154, DOI 10.1016/j.lungcan.2009.06.012
   Paino IMM, 2005, BRAZ J MED BIOL RES, V38, P543, DOI 10.1590/S0100 879X2005000400007
   Palkar MB, 2014, BIOORGAN MED CHEM, V22, P2855, DOI 10.1016/j.bmc.2014.03.043
   Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175
   Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313
   Sriram D, 2006, BIOORGAN MED CHEM, V14, P3113, DOI 10.1016/j.bmc.2005.12.042
   Suryawanshi S. B., 2014, Chem. Sci. Trans, V3, P562
   TAMMARA VK, 1994, J PHARM SCI US, V83, P644, DOI 10.1002/jps.2600830510
   TAMURA Y, 1984, CHEM PHARM BULL, V32, P1995
   Ullah S, 2016, MED CHEM RES, V25, P1468, DOI 10.1007/s00044 016 1571 5
   Vane JR, 1996, SCAND J RHEUMATOL, P9
NR 28
TC 14
Z9 14
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
EI 1875 6638
J9 MED CHEM
JI Med. Chem.
PY 2018
VL 14
IS 7
BP 674
EP 687
DI 10.2174/157340641466618032114155
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GQ3OR
UT WOS:000441575300003
DA 2025 08 17
ER

PT J
AU Awan, Z
   Alrasadi, K
   Francis, GA
   Hegele, RA
   McPherson, R
   Frohlich, J
   Valenti, D
   de Varennes, B
   Marcil, M
   Gagne, C
   Genest, J
   Couture, P
AF Awan, Z.
   Alrasadi, K.
   Francis, G. A.
   Hegele, R. A.
   McPherson, R.
   Frohlich, J.
   Valenti, D.
   de Varennes, B.
   Marcil, M.
   Gagne, C.
   Genest, J.
   Couture, P.
TI Vascular calcifications in homozygote familial hypercholesterolemia
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE aorta; calcification; familial hypercholesterolemia
ID CORONARY HEART DISEASE; AORTIC VALVE; CARDIOVASCULAR FEATURES; RECEPTOR
   GENE; UP REGULATION; LIPID LEVELS; ATHEROSCLEROSIS; MECHANISMS;
   MUTATIONS; SEVERITY
AB Background Patients with homozygous familial hypercholesterolemia (hmzFH) attributable to LDL receptor gene mutations have shown a remarkable increase in survival over the last 20 years. Early onset coronary heart disease (CHD) and calcific aortic valve stenosis are the major complications of this disorder. We now report extensive premature calcification of the aorta in patients with hmzFH.
   Methods and Results We examined 25 hmzFH patients from Canada; mean age was 32 years (range 5 to 54), and mean baseline cholesterol before treatment was 19 +/  5 mmol/L (737 +/  206 mg/dL). Aortic calcification was quantified using computed tomography (CT). An elevated mean calcium score was found in patients by age 20 and correlated with age (r(2) = 0.53, P = 0.001). One quarter (24%) of patients underwent aortic valve surgery.
   Conclusions We document premature severe aortic calcifications in all adult hmzFH patients studied. These presented considerable surgical management challenges. Strategies to identify and monitor aortic calcification in hmzFH by noninvasive techniques are required, as are clinical trials to determine whether additional or more intensive therapies will prevent the progression of such calcifications. Whether vascular calcifications in hmzFH subjects are related to sustained increases in LDL C levels or to other mechanisms, such as abnormal osteoblast activity, remains to be determined.
C1 [Awan, Z.; Alrasadi, K.; Valenti, D.; de Varennes, B.; Marcil, M.; Genest, J.] McGill Univ, Fac Med, Royal Victoria Hosp,Div Cardiol, Novartis Chair Med,McGill Univ Hlth Ctr, Montreal, PQ H3A 1A1, Canada.
   [Francis, G. A.] Univ Alberta, Edmonton, AB, Canada.
   [Hegele, R. A.] Robarts Res Inst, London, ON N6A 5C1, Canada.
   [McPherson, R.] Ottawa Heart Inst, Ottawa, ON, Canada.
   [Frohlich, J.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
   [Gagne, C.; Couture, P.] Univ Laval, Quebec City, PQ, Canada.
C3 Royal Victoria Hospital; McGill University; University of Alberta;
   Western University (University of Western Ontario); University Western
   Ontario Hospital; University of Ottawa; University of Ottawa Heart
   Institute; University of British Columbia; Laval University
RP Genest, J (通讯作者)，McGill Univ, Fac Med, Royal Victoria Hosp,Div Cardiol, Novartis Chair Med,McGill Univ Hlth Ctr, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.
EM Jacques.genest@muhc.mcgill.ca
RI Al Rasadi, Khalid/J 7194 2015; Al Rasadi, Khalid/ABB 7852 2020; Hegele,
   Robert/G 3301 2011
OI Al Rasadi, Khalid/0000 0003 0460 1236; Awan, Zuhier/0000 0002 4176 335X;
   Couture, Patrick/0000 0002 8414 3847; 
CR Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42
   Bilal MS, 2005, J HEART VALVE DIS, V14, P855
   BROOK GJ, 1989, CLIN CARDIOL, V12, P333, DOI 10.1002/clc.4960120608
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   Caira FC, 2006, J AM COLL CARDIOL, V47, P1707, DOI 10.1016/j.jacc.2006.02.040
   CLARKSON TB, 1981, EXP MOL PATHOL, V34, P345, DOI 10.1016/0014 4800(81)90052 6
   Elghobary Tamer, 2006, Ann Thorac Surg, V81, pe4, DOI 10.1016/j.athoracsur.2005.07.077
   Genest J, 1999, NEW ENGL J MED, V341, P490, DOI 10.1056/NEJM199908123410705
   Giachelli CM, 2004, J AM SOC NEPHROL, V15, P2959, DOI 10.1097/01.ASN.0000145894.57533.C4
   GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332
   Grenon SM, 2007, CAN J CARDIOL, V23, P1159
   Hadfield SG, 2005, CURR OPIN LIPIDOL, V16, P428, DOI 10.1097/01.mol.0000174152.76554.d6
   HAITAS B, 1990, Q J MED, V76, P731
   HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066
   Houslay ES, 2006, HEART, V92, P1207, DOI 10.1136/hrt.2005.080929
   Humphries SE, 2006, J MED GENET, V43, P943, DOI 10.1136/jmg.2006.038356
   Jensen JM, 2000, J INTERN MED, V247, P479, DOI 10.1046/j.1365 2796.2000.00630.x
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Kawaguchi A, 2003, THER APHER DIAL, V7, P439, DOI 10.1046/j.1526 0968.2003.00075.x
   Kawaguchi A, 1999, AM HEART J, V137, P410, DOI 10.1016/S0002 8703(99)70485 0
   LEHRMAN MA, 1987, J BIOL CHEM, V262, P401
   LEREN TP, 1993, J INTERN MED, V233, P195, DOI 10.1111/j.1365 2796.1993.tb00673.x
   MOORJANI S, 1989, ARTERIOSCLEROSIS, V9, P211, DOI 10.1161/01.ATV.9.2.211
   Naoumova RP, 2004, CURR OPIN LIPIDOL, V15, P413, DOI 10.1097/01.mol.0000137222.23784.2a
   O'Brien KD, 2006, ARTERIOSCL THROM VAS, V26, P1721, DOI 10.1161/01.ATV.0000227513.13697.ac
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rajamannan NM, 2002, CIRCULATION, V105, P2660, DOI 10.1161/01.CIR.0000017435.87463.72
   Rallidis L, 1998, HEART, V80, P583, DOI 10.1136/hrt.80.6.583
   Raper SE, 1996, ANN SURG, V223, P116, DOI 10.1097/00000658 199602000 00002
   Saito S, 2006, EUR J CARDIO THORAC, V29, P114, DOI 10.1016/j.ejcts.2005.11.001
   Schmidt HHJ, 1996, AM J CARDIOL, V77, P575, DOI 10.1016/S0002 9149(97)89309 5
   Scriver CR, 2001, ANNU REV GENOM HUM G, V2, P69, DOI 10.1146/annurev.genom.2.1.69
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   SPRECHER DL, 1984, AM J CARDIOL, V54, P20, DOI 10.1016/0002 9149(84)90298 4
   Stary HC, 2001, AM J CARDIOL, V88, p16E
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Thompsen J, 2006, ATHEROSCLEROSIS, V189, P31, DOI 10.1016/j.atherosclerosis.2006.02.030
   THOMPSON GR, 1985, BMJ BRIT MED J, V291, P1671, DOI 10.1136/bmj.291.6510.1671
   Tosi I, 2007, ATHEROSCLEROSIS, V194, P102, DOI 10.1016/j.atherosclerosis.2006.10.003
   Vattikuti R, 2004, AM J PHYSIOL ENDOC M, V286, pE686, DOI 10.1152/ajpendo.00552.2003
   Vohl MC, 1997, CLIN GENET, V52, P1, DOI 10.1111/j.1399 0004.1997.tb02506.x
   Wang J, 2005, J LIPID RES, V46, P366, DOI 10.1194/jlr.D400030 JLR200
   Weiss RM, 2006, CIRCULATION, V114, P2065, DOI 10.1161/CIRCULATIONAHA.106.634139
   WEST R, 1985, BMJ BRIT MED J, V291, P1079, DOI 10.1136/bmj.291.6502.1079
   Yasuda T, 2000, EUR J CARDIO THORAC, V18, P249, DOI 10.1016/S1010 7940(00)00456 5
   Yu L, 1999, ATHEROSCLEROSIS, V146, P125, DOI 10.1016/S0021 9150(99)00109 4
NR 46
TC 77
Z9 81
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079 5642
EI 1524 4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD APR
PY 2008
VL 28
IS 4
BP 777
EP 785
DI 10.1161/ATVBAHA.107.160408
PG 9
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 276YK
UT WOS:000254179400030
PM 18239150
OA Bronze
DA 2025 08 17
ER

PT J
AU Boucher, K
   Chad, SS
   Sharma, P
   Hauschka, PV
   Solomon, KR
AF Boucher, K
   Chad, SS
   Sharma, P
   Hauschka, PV
   Solomon, KR
TI HMG CoA reductase inhibitors induce apoptosis in pericytes
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE statin; cholesterol; mevalonate; isoprenoid; lipid raft; apoptosis;
   angiogenesis
ID SMOOTH MUSCLE CELLS; IN VITRO; ENDOTHELIAL CELLS; PDGF B;
   DIABETIC RETINOPATHY; BRAIN PERICYTES; LOVASTATIN; ANGIOGENESIS; BETA;
   EXPRESSION
AB Pericytes, which surround endothelial cells in precapillary arterioles, capillaries, and postcapillary venules, are important for the development, maturation, and maintenance of the vascular system. Pericytes are also pluripotent cells that can differentiate into a variety of mesenchymal cells including smooth muscle cells and osteoblasts. Possibly because of their vasculature regulating activities and ability to differentiate in situ, pericytes are implicated in several diseases with vascular complications, including diabetic retinopathy, as well as Reynaud's Syndrome, central nervous system dementias, and vascular calcification among others. Statin drugs, which block the conversion of HMG CoA to mevalonate in the cholesterol synthesis pathway, are known to have apoptotic and growth inhibitory effects oil cells in vitro and complex pleiotropic effects on cells and tissues in vivo. Recently, evidence has emerged that statin drug use in human patients results in a significant 20% reduction in cancer incidence. It is not known whether these results are due to direct statin action on normal tissue, growth inhibitory/pro apoptotic effects on tumor cells, and/or effects on angiogenesis. Because of the role of pericytes in angiogenesis and the effects of statins oil cancer incidence, we tested the direct effects of statins oil pericytes. Specifically, we demonstrate that 3 statins, simvastatin, lovastatin, and mevastatin induce dose dependent apoptosis in the TR PCT1 pericyte cell line, that simvastatin (empirically shown to be the most potent of the 3 statins) induces similar levels of apoptosis in freshly isolated pericytes, and that simvastatin induced apoptosis in pericytes is cholesterol, caspase 3, and caspase 7 mediated. (c) 2005 Elsevier Inc. All rights reserved.
C1 Childrens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
   Childrens Hosp, Dept Urol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02114 USA.
   Harvard Univ, Sch Dent Med, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital; Harvard University; Harvard University Medical
   Affiliates; Boston Children's Hospital; Harvard University; Harvard
   Medical School; Harvard University; Harvard School of Dental Medicine
RP Childrens Hosp, Dept Orthopaed Surg, Enders 1030,300 Longwood Ave, Boston, MA 02115 USA.
EM keith.solomon@childrens.harvard.edu
FU NCI NIH HHS [R01 CA101046] Funding Source: Medline; NIAMS NIH HHS [R01
   AR48799] Funding Source: Medline
CR Ahmad SA, 2002, SEMIN CANCER BIOL, V12, P105, DOI 10.1006/scbi.2001.0418
   Anderson CR, 2004, J HISTOCHEM CYTOCHEM, V52, P1063, DOI 10.1369/jhc.4A6250.2004
   Asashima T, 2003, J CELL PHYSIOL, V197, P69, DOI 10.1002/jcp.10343
   Asashima T, 2002, EUR J CELL BIOL, V81, P145, DOI 10.1078/0171 9335 00227
   Bassa BV, 1999, BBA MOL CELL RES, V1449, P137, DOI 10.1016/S0167 4889(99)00007 5
   Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005
   Blais L, 2000, ARCH INTERN MED, V160, P2363, DOI 10.1001/archinte.160.15.2363
   Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312
   BRIGHTON CT, 1986, J ORTHOP RES, V4, P27, DOI 10.1002/jor.1100040104
   BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287
   Cai J, 2002, EYE, V16, P242, DOI 10.1038/sj.eye.6700133
   Canfield AE, 1996, J CELL SCI, V109, P343
   Chang HN, 1997, AM J ORTHOD DENTOFAC, V111, P382, DOI 10.1016/S0889 5406(97)80020 0
   Crosby JR, 1999, AM J PATHOL, V154, P1315, DOI 10.1016/S0002 9440(10)65384 9
   Danesh FR, 2003, ARCH IMMUNOL THER EX, V51, P139
   Davidson MH, 2005, CIRCULATION, V111, P2280, DOI 10.1161/01.CIR.0000167560.93138.E7
   Desager JP, 1996, CLIN PHARMACOKINET, V31, P348, DOI 10.2165/00003088 199631050 00003
   DIAZFLORES L, 1992, CLIN ORTHOP RELAT R, P280
   Dohgu S, 2005, BRAIN RES, V1038, P208, DOI 10.1016/j.brainres.2005.01.027
   Feng D, 2001, J HISTOCHEM CYTOCHEM, V49, P293, DOI 10.1177/002215540104900303
   FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393
   Furuhashi M, 2004, CANCER RES, V64, P2725, DOI 10.1158/0008 5472.CAN 03 1489
   Gendron R L, 1999, Surv Ophthalmol, V44, P184
   Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027
   Guo P, 2003, AM J PATHOL, V162, P1083, DOI 10.1016/S0002 9440(10)63905 3
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Hellström M, 1999, DEVELOPMENT, V126, P3047
   Hellström M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543
   Hillman N, 2001, EYE, V15, P319, DOI 10.1038/eye.2001.103
   Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008 6363(96)00063 6
   HOEG JM, 1987, JAMA J AM MED ASSOC, V258, P3532, DOI 10.1001/jama.258.24.3532
   Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471 4159.2004.02343.x
   Huo R, 2004, ACTA PHARMACOL SIN, V25, P1077
   JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628
   KEYOMARSI K, 1991, CANCER RES, V51, P3602
   Knapp AC, 2000, ATHEROSCLEROSIS, V152, P217, DOI 10.1016/S0021 9150(99)00462 1
   Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955 0674(99)80061 1
   LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Macaulay RJB, 1999, J NEURO ONCOL, V42, P1, DOI 10.1023/A:1006164406202
   Mater P, 1998, CANCER BIOTHER RADIO, V13, P387, DOI 10.1089/cbr.1998.13.387
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C
   Prasanna P, 1996, J NEUROCHEM, V66, P710
   Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797
   Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898 6568(96)00088 5
   RICHARDSON RL, 1982, ACTA ANAT, V114, P41
   SCHOR AM, 1995, CLIN ORTHOP RELAT R, P81
   SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472
   Sims DE, 2000, CLIN EXP PHARMACOL P, V27, P842, DOI 10.1046/j.1440 1681.2000.03343.x
   SIRTORI CR, 1993, PHARMACOL THERAPEUT, V60, P431, DOI 10.1016/0163 7258(93)90031 8
   Skaletz Rorowski Adriane, 2004, Semin Vasc Med, V4, P395, DOI 10.1055/s 2004 869596
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Sundberg C, 1996, LAB INVEST, V74, P452
   Unlu S, 2001, J CARDIOVASC PHARM, V38, P161, DOI 10.1097/00005344 200108000 00001
   Verbeek MM, 1997, J NEUROCHEM, V68, P1135
   Virgintino D, 2002, NEUROSCIENCE, V115, P145, DOI 10.1016/S0306 4522(02)00374 3
   Waldman A, 2003, DRUGS, V63, P139, DOI 10.2165/00003495 200363020 00002
   WALLOW IHL, 1993, INVEST OPHTH VIS SCI, V34, P420
   Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000
   Whitfield JF, 2001, EXPERT OPIN INV DRUG, V10, P409, DOI 10.1517/13543784.10.3.409
   Wilkinson Berka JL, 2004, AM J PATHOL, V164, P1263, DOI 10.1016/S0002 9440(10)63214 2
   Yamagishi S, 1999, LAB INVEST, V79, P501
   Yamagishi S, 1999, BIOCHEM BIOPH RES CO, V258, P353, DOI 10.1006/bbrc.1999.0625
   Zhang MC, 2004, CELL RES, V14, P117, DOI 10.1038/sj.cr.7290210
NR 66
TC 31
Z9 34
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0026 2862
EI 1095 9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAR
PY 2006
VL 71
IS 2
BP 91
EP 102
DI 10.1016/j.mvr.2005.11.007
PG 12
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 039XV
UT WOS:000237342700004
PM 16427097
DA 2025 08 17
ER

PT J
AU Zhang, DW
   Leung, N
   Weber, E
   Saftig, P
   Brömme, D
AF Zhang, Dongwei
   Leung, Nelson
   Weber, Ekkehard
   Saftig, Paul
   Broemme, Dieter
TI The effect of cathepsin K deficiency on airway development and TGF β1
   degradation
SO RESPIRATORY RESEARCH
LA English
DT Article
DE lung airway; cathepsin K; TGF beta 1; extracellular matrix; protease
   inhibitors
ID EXTRACELLULAR MATRIX PROTEINS; INDUCED LUNG INJURY; CYSTEINE CATHEPSINS;
   CELL PROLIFERATION; PULMONARY FIBROSIS; EPITHELIAL CELL; ASTHMA; MUSCLE;
   EXPRESSION; COLLAGEN
AB Background: Cathepsin K, a cysteine protease predominantly expressed in osteoclasts, is a major drug target for the treatment of osteoporosis. Recent findings, however, indicate that cathepsin K is also involved in non skeletal metabolism. The development of fibrotic phenotypes in lung and skin is a concern for cathepsin K inhibitors presently evaluated in clinical trials. Cathepsin K is expressed in lung tissue and has been implicated in lung fibrosis. However, little is known about the role of cathepsin K in airway development and its effect on TGF beta 1 degradation.
   Methods: We investigated the effects of cathepsin K deficiency on alterations in airway integrity, extracellular matrix composition, and TGF beta 1 expression and degradation. Lung homogenates of wild type and cathepsin K deficient mice were used to evaluate their contents of collagen, glycosaminoglycans, and TGF beta 1. The accessibility of TGF beta 1 to cathepsin K mediated degradation was determined in vitro and lung fibroblast proliferations in wildtype and cathepsin K deficient cells were evaluated.
   Results: Lung airway cathepsin K expression in wild type mice remained constant between 1 and 6 months of age and the airway integrity was maintained. In contrast, after 2 months of age, all Ctsk( / ) mice demonstrated increased airway epithelium thickness by 16 28%, a lower structural airway integrity (1 2 score units lower), elevated cytokeratin expression of 12%, increased a actin and vimentin expression by 50% and 70%, increased area of smooth muscle cells by 15%, elevated hydroxyproline and GAGs content by 20% and 25%, and increased TGF beta 1 expression by 25%. TGF beta 1 proved an efficient substrate of cathepsin K and TGF beta 1 protein content in lung was increased by a potent cathepsin inhibitor. Lung fibroblasts from Ctsk( / ) mice after TGF beta 1 treatment showed increased proliferation rates, increased levels of TGF beta 1 by 30%, and increased ECM secretion.
   Conclusion: This study suggests that airway development is partly regulated by cathepsin K and that its expression contributes to the maintenance of the airway structural integrity. The anticipated use of therapeutic cathepsin K inhibitors needs to take potential changes in human lungs into consideration.
C1 [Zhang, Dongwei; Leung, Nelson; Broemme, Dieter] Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada.
   [Weber, Ekkehard] Univ Halle Wittenberg, Inst Biochem, Halle, Germany.
   [Saftig, Paul] Univ Kiel, Inst Biochem, Unit Mol Cell Biol & Transgen Res, D 24098 Kiel, Germany.
C3 University of British Columbia; Martin Luther University Halle
   Wittenberg; University of Kiel
RP Brömme, D (通讯作者)，Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada.
EM dbromme@interchange.ubc.ca
RI Saftig, Paul/A 7966 2010; Zhang, Dongwei/AAS 8384 2020
OI Weber, Ekkehard/0000 0002 4014 4303
FU ICSDP Canada; Canada Research Chair Award
FX The authors gratefully thank Dr. Lari Hakkinen and Andre K.S. Wong for
   their constructive suggestions. This work was supported by the ICSDP
   Canada grant and a Canada Research Chair Award (D. B.).
CR Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bromme D, 1996, BIOCHEM J, V315, P85
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Bühling F, 2004, AM J PATHOL, V164, P2203, DOI 10.1016/S0002 9440(10)63777 7
   Bühling F, 1999, AM J RESP CELL MOL, V20, P612
   Bühling F, 2002, DEV DYNAM, V225, P14, DOI 10.1002/dvdy.10134
   Bühling F, 2000, ADV EXP MED BIOL, V477, P281
   Burgess JK, 2006, AM J PHYSIOL LUNG C, V290, pL153, DOI 10.1152/ajplung.00287.2005
   CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405
   Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607 1062OC
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Deng H, 2010, AM J PHYSIOL LUNG C, V298, pL793, DOI 10.1152/ajplung.00108.2009
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Eastell R, 2011, J BONE MINER RES
   EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720
   Faouzi S, 1999, J HEPATOL, V30, P275, DOI 10.1016/S0168 8278(99)80074 9
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   Halayko AJ, 1996, AM J PHYSIOL LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040
   Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069
   Hirakawa H, 2007, AM J RESP CRIT CARE, V176, P778, DOI 10.1164/rccm.200704 519OC
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111
   Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312
   Kenyon NJ, 2003, TOXICOL APPL PHARM, V186, P90, DOI 10.1016/S0041 008X(02)00025 X
   Knaapi J, 2006, ACTA PAEDIATR, V95, P1298, DOI 10.1080/08035250600586492
   Koslowski R, 2003, EUR RESPIR J, V22, P427, DOI 10.1183/09031936.03.00112903
   Kotaru C, 2006, AM J RESP CRIT CARE, V173, P1208, DOI 10.1164/rccm.200508 1218OC
   Lagente V, 2010, J MOL CELL CARDIOL, V48, P440, DOI 10.1016/j.yjmcc.2009.09.017
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   Parameswaran K, 2006, CELL BIOCHEM BIOPHYS, V44, P139, DOI 10.1385/CBB:44:1:139
   Pardo A, 2002, FRONT BIOSCI LANDMRK, V7, pD1743, DOI 10.2741/pardo
   Peng Q, 2005, J IMMUNOL, V174, P2258, DOI 10.4049/jimmunol.174.4.2258
   Peroni A, 2008, J AM ACAD DERMATOL, V59, P125, DOI 10.1016/j.jaad.2008.03.009
   Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009 9120(96)00003 6
   Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437
   Royce SG, 2009, ANN ALLERG ASTHMA IM, V102, P238, DOI 10.1016/S1081 1206(10)60087 7
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sagara H, 2002, J ALLERGY CLIN IMMUN, V110, P249, DOI 10.1067/mai.2002.126078
   SKOLD CM, CLIN RESP J S1, V4, P20
   Srivastava M, 2008, RESP RES, V9, DOI 10.1186/1465 9921 9 54
   Sullivan DE, 2009, J CELL MOL MED, V13, P1866, DOI 10.1111/j.1582 4934.2009.00647.x
   Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811
   Ten Hacken NHT, 2003, CURR OPIN PULM MED, V9, P9, DOI 10.1097/00063198 200301000 00002
   Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038
   van den Brûle S, 2005, RESP RES, V6, DOI 10.1186/1465 9921 6 84
   Veillard F, 2008, INT J BIOCHEM CELL B, V40, P1079, DOI 10.1016/j.biocel.2007.10.030
   Vignola AM, 2003, CHEST, V123, p417S, DOI 10.1378/chest.123.3_suppl.417S
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Zou Y, 2008, J NEUROPATH EXP NEUR, V67, P144, DOI 10.1097/nen.0b013e3181634ef7
NR 49
TC 41
Z9 46
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 993X
EI 1465 9921
J9 RESP RES
JI Respir. Res.
PD MAY 31
PY 2011
VL 12
AR 72
DI 10.1186/1465 9921 12 72
PG 14
WC Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED)
SC Respiratory System
GA 785EJ
UT WOS:000292209900001
PM 21627832
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Choi, EM
AF Choi, Eun Mi
TI Honokiol protects osteoblastic MC3T3 E1 cells against antimycin
   A induced cytotoxicity
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Honokiol; Mitochondrial dysfunction; MC3T3 E1 cells; Oxidative stress;
   PI3K/CREB
ID OXIDATIVE STRESS; THIOREDOXIN REDUCTASE; RAT HEPATOCYTES; KAPPA B;
   MITOCHONDRIA; SUPEROXIDE; MAGNOLOL; TRANSCRIPTION; INHIBITION; COMPLEX
AB Objective Honokiol is a phenolic compound isolated from the bark of Magnolia officinalis, a plant widely used in traditional medicine. Antimycin A, which inhibits complex III of the electron transport system, has been used as a reactive oxygen species generator in biological systems. In the present study, we investigated the protective effects of honokiol on antimycin A induced dysfunction in osteoblastic MC3T3 E1 cells.
   Materials and methods Osteoblastic MC3T3 E1 cells were pre incubated with honokiol before treatment with antimycin A, and markers of mitochondrial function and oxidative damage were examined. In addition, the effects of honokiol on the activation of PI3K (phosphoinositide 3 kinase) and CREB (cAMP responsive element binding protein) were examined in MC3T3 E1 cells.
   Results Honokiol significantly (P < 0.05) increased cell viability and calcium deposition and decreased the production of ROS in the presence of antimycin A. Moreover, pretreatment with honokiol prior to antimycin A exposure significantly reduced antimycin A induced mitochondrial membrane potential (MMP) dissipation, complex IV inactivation, nitrotyrosine formation, and thioredoxin reductase inactivation. Honokiol also induced the activation of PI3K and CREB inhibited by antimycin A, which demonstrates that honokiol utilizes the PI3K and CREB pathway to augment metabolic activity inhibited by antimycin A.
   Conclusion Honokiol may reduce or prevent osteoblast degeneration in osteoporosis or other degenerative disorders.
C1 Kyung Hee Univ, Grad Sch Educ, Dept Food & Nutr, Seoul 130701, South Korea.
C3 Kyung Hee University
RP Choi, EM (通讯作者)，Kyung Hee Univ, Grad Sch Educ, Dept Food & Nutr, 1 Hoegi Dong, Seoul 130701, South Korea.
EM cheunmi@hanmail.net
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [20110005020]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology (20110005020).
CR Arnér ESJ, 2009, BBA GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   BROUILLET E, 1993, J NEUROCHEM, V60, P356, DOI 10.1111/j.1471 4159.1993.tb05859.x
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chiang J, 2009, EUR J PHARMACOL, V610, P119, DOI 10.1016/j.ejphar.2009.03.035
   Cooper Cyrus, 1996, P419
   DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961
   De Rasmo D, 2009, FEBS J, V276, P4325, DOI 10.1111/j.1742 4658.2009.07133.x
   Dikalov S, 2008, BIOCHEM PHARMACOL, V76, P589, DOI 10.1016/j.bcp.2008.06.012
   Dröse S, 2008, J BIOL CHEM, V283, P21649, DOI 10.1074/jbc.M803236200
   Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81
   GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825
   Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Liou KT, 2003, EUR J PHARMACOL, V475, P19, DOI 10.1016/S0014 2999(03)02121 6
   MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853
   Matsuo N, 2006, J BIOL CHEM, V281, P5445, DOI 10.1074/jbc.M509923200
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Myers CR, 2009, TOXICOLOGY, V257, P95, DOI 10.1016/j.tox.2008.12.013
   Park J, 2004, EUR J PHARMACOL, V496, P189, DOI 10.1016/j.ejphar.2004.05.047
   Pawson T, 2000, GENE DEV, V14, P1027
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Smith TS, 1997, BRAIN RES, V765, P183, DOI 10.1016/S0006 8993(97)00429 0
   Squires RF, 1999, NEUROCHEM RES, V24, P1593, DOI 10.1023/A:1021116502548
   Stambough JL, 1984, J ORTHOP RES, V45, P235
   TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421
   van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860
   vanderVliet A, 1996, METHOD ENZYMOL, V269, P175
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   WATANABE K, 1983, PLANTA MED, V49, P103, DOI 10.1055/s 2007 969825
   WUTHIER RE, 1985, J BIOL CHEM, V260, P5972
   Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200
NR 34
TC 11
Z9 12
U1 0
U2 15
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023 3830
J9 INFLAMM RES
JI Inflamm. Res.
PD NOV
PY 2011
VL 60
IS 11
BP 1005
EP 1012
DI 10.1007/s00011 011 0360 3
PG 8
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA 843WR
UT WOS:000296707800002
PM 21800176
DA 2025 08 17
ER

PT J
AU Albaqami, M
   Aguida, B
   Pourmostafa, A
   Ahmad, M
   Kishore, V
AF Albaqami, Maria
   Aguida, Blanche
   Pourmostafa, Ayda
   Ahmad, Margaret
   Kishore, Vipuil
TI Photobiomodulation effects of blue light on osteogenesis are induced by
   reactive oxygen species
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Photobiomodulation; Blue light; Osteogenesis; ROS; Saos 2 cells
ID THERAPY; CELLS; DIFFERENTIATION; INVOLVEMENT
AB Blue light mediated photobiomodulation (PBM) is a promising approach to promote osteogenesis. However, the underlying mechanisms of PBM in osteogenesis are poorly understood. In this study, a human osteosarcoma cell line (i.e., Saos 2 cells) was subjected to intermittent blue light exposure (2500 mu M/m(2)/s, 70 mW/cm(2), 4.2 J/cm(2), once every 48 h) and the effects on Saos 2 cell viability, metabolic activity, differentiation, and mineralization were investigated. In addition, this study addressed a possible role of blue light induced cellular oxidative stress as a mechanism for enhanced osteoblast differentiation and mineralization. Results showed that Saos 2 cell viability and metabolic activity were maintained upon blue light exposure compared to unilluminated controls, indicating no negative effects. To the contrary, blue light exposure significantly increased (p < 0.05) alkaline phosphatase activity and Saos 2 cell mediated mineralization. High performance liquid chromatography (HPLC) assay was used for measurement of reactive oxygen species (ROS) activity and showed a significant increase (p < 0.05) in superoxide (O 2(center dot  )) and hydrogen peroxide (H2O2) formed after blue light exposure. Together, these results suggest that the beneficial effects of blue light mediated PBM on osteogenesis may be induced by controlled release of ROS.
C1 [Albaqami, Maria; Pourmostafa, Ayda; Kishore, Vipuil] Florida Inst Technol, Dept Biomed & Chem Engn & Sci, 150 W Univ Blvd, Melbourne, FL 32901 USA.
   [Aguida, Blanche; Ahmad, Margaret] Sorbonne Univ, UMR8256, IBPS, CNRS, Paris, France.
C3 Florida Institute of Technology; Centre National de la Recherche
   Scientifique (CNRS); CNRS   National Institute for Biology (INSB);
   Sorbonne Universite
RP Kishore, V (通讯作者)，Florida Inst Technol, Dept Biomed & Chem Engn & Sci, 150 W Univ Blvd, Melbourne, FL 32901 USA.
EM vkishore@fit.edu
RI Kishore, Vipuil/F 8968 2016
OI Ahmad, Margaret/0000 0003 4524 5813
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Escudero JSB, 2019, INJURY, V50, P1853, DOI 10.1016/j.injury.2019.09.031
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chaves MED, 2014, AN BRAS DERMATOL, V89, P616, DOI 10.1590/abd1806 4841.20142519
   Dungel P, 2014, LASER SURG MED, V46, P773, DOI 10.1002/lsm.22299
   Fernandes DC, 2017, METHODS MOL BIOL, V1527, P233, DOI 10.1007/978 1 4939 6625 7_19
   Guo L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01910 5
   Hamblin MR, 2019, PHOTONICS BASEL, V6, DOI 10.3390/photonics6030077
   He Y, 2020, J CELL MOL MED, V24, P9958, DOI 10.1111/jcmm.15598
   Kishore V, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/5/055008
   Leyane TS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011223
   Magni G, 2022, LIFE BASEL, V12, DOI 10.3390/life12101564
   Magri AMP, 2021, J BIOMED MATER RES A, V109, P1765, DOI 10.1002/jbm.a.37170
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Mohamad SA, 2021, PHOTOCH PHOTOBIO SCI, V20, P699, DOI 10.1007/s43630 021 00047 5
   Nouri F, 2019, ADV PHARM BULL, V9, P76, DOI 10.15171/apb.2019.010
   Oh PS, 2015, J PHOTOCH PHOTOBIO B, V142, P197, DOI 10.1016/j.jphotobiol.2014.12.006
   Patrawalla NY, 2023, J BIOMED MATER RES A, V111, P224, DOI 10.1002/jbm.a.37452
   Pizzino G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8416763
   Pogorielov M., 2017, Advances in Tissue Engineering Regenerative Medicine: Open Access, V3, P330, DOI 10.15406/atroa.2017.03.00058
   Rajendran NK, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8120640
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Sies H, 2000, DEV CARDIOVASC MED, V224, P1
   Stern M, 2018, EUR J PREV CARDIOL, V25, P1875, DOI 10.1177/2047487318800072
   Nguyen TU, 2019, J BIOMED MATER RES A, V107, P1541, DOI 10.1002/jbm.a.36668
   Tonelli P, 2011, CLIN CASES MINER BON, V8, P24
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   Xu YK, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 83263 4
   Yang YY, 2020, LASER MED SCI, V35, P1981, DOI 10.1007/s10103 020 02995 3
   Yoshida A, 2013, J PHOTOCH PHOTOBIO B, V129, P1, DOI 10.1016/j.jphotobiol.2013.09.003
   Yuan Y, 2017, CELL PHYSIOL BIOCHEM, V43, P237, DOI 10.1159/000480344
   Zhang F, 2019, J CELL BIOCHEM, V120, P19902, DOI 10.1002/jcb.29298
   Zhao R, 2021, MOLECULES, V26, DOI 10.3390/molecules26103007
   Zhu TT, 2019, LASER MED SCI, V34, P1473, DOI 10.1007/s10103 019 02750 3
NR 36
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD DEC 13
PY 2023
VL 39
IS 1
AR 5
DI 10.1007/s10103 023 03951 7
PG 9
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA CB3B5
UT WOS:001122740800001
PM 38091111
DA 2025 08 17
ER

PT J
AU Dong, QY
   Chen, L
   Gao, GQ
   Wang, L
   Song, J
   Chen, B
   Xu, YX
   Sun, L
AF Dong, Qing Yu
   Chen, Li
   Gao, Guan Qi
   Wang, Lei
   Song, Jun
   Chen, Bo
   Xu, Yu Xin
   Sun, Lei
TI Allogeneic diabetic mesenchymal stem cells transplantation in
   streptozotocin induced diabetic rat
SO CLINICAL AND INVESTIGATIVE MEDICINE
LA English
DT Article
ID PANCREATIC BETA CELLS; MARROW STROMAL CELLS; INSULIN PRODUCING CELLS;
   BONE MARROW; IN VIVO; MIGRATION; MODEL; BRAIN; REGENERATION; THERAPY
AB Background: Bone marrow derived mesenchymal stem cells (BM MSCs) are multipotent stroma cells which can provide a potential therapy for diabetes mellitus. But the mechanism is still controversial. Also, the status of BM MSCs under hyperglycemia is not known. In the present study, we investigated the status of BM MSCs in experimental diabetic rat and demonstrated the rescue of experimental diabetes by diabetic MSCs transplantation.
   Methods: BM MSCs were cultured and the potential of multiple differentiation was identified through induction into osteoblasts. MSCs of passage 3 were used for the following experiment. The MSCs were labeled with 5 bromo 2' deoxyuridine (BrdU). Diabetes in rats was induced by STZ injection. The rats were divided into three groups: normal control group (no DM, rats treated with saline through tail vein, n= 10); DM control group (DM, no transplantation of MSCs, n= 20); experimental group (DM and transplantation of MSCs, n= 20). Body weight and blood glucose of the rats were monitored during the experiment after transplantation of MSCs. Paraffin sections of pancreas were obtained from rats of each group. Immunohistochemistry analysis and double immunofluorescence were used to detect the BM MSCs in the pancreatic tissue and their differentiating state.
   Results: MSCs were 89.5% labeled by BrdU and DAPI, which was green/blue double stained under fluorescent microscopy. Transplantation of diabetic MSCs resulted in a reduction of hyperglycemia on day 45 in experimental diabetic rats compared with control rats (17.7 mM +/  3.9 vs 27.8 mM +/  2.1, P < 0.05), There was also a difference between MSC treated experimental diabetic rats and control rats in body weight (232.7 g +/  19.7 vs 133.3g +/  13.1, P < 0.05). Histological and morphometric analysis of the pancreas of experimental diabetic rats showed the presence and differentiation of transplanted MSCs into insulin producing cells which evidenced by double staining of anti BrdU and insulin. Also, there were many small islets throughout the sections. Their mean area and diameter analysis revealed that they were smaller thancontrol islets (1835.7 +/  175.8 mu m(2) vs 13257.2 +/  1457.6 mu m(2); 43.5 +/  3.7 m vs 119.9 +/  5.8 mu m, respectively, P < 0.05).
   Conclusion: Allogeneic MSCs transplantation can reduce blood glucose level in recipient rats. A relatively small quantity of transplanted diabetic MSCs survive and trans differentiate into insulin producing cells in the pancreas of recipient rats. Upon transplantation these cells initiate endogenous pancreatic regeneration by neogenesis of islet of recipient origin. The present study demonstrates that diabetic MSCs retains its stemness and potential to induce pancreatic regeneration on transplantation.
C1 [Dong, Qing Yu; Chen, Li; Song, Jun; Xu, Yu Xin; Sun, Lei] Shandong Univ, Qilu Hosp, Dept Endocrinol & Metab, Jinan 250012, Shandong, Peoples R China.
   [Dong, Qing Yu; Gao, Guan Qi] Peoples Hosp Linyi City, Linyi 276003, Peoples R China.
   [Wang, Lei; Chen, Bo] Shandong Univ, Qilu Hosp, Dept Hepatobiliary & Pancreat Surg, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Chen, L (通讯作者)，Shandong Univ, Qilu Hosp, Dept Endocrinol, Wenhuaxilu 107, Jinan 250012, Shandong, Peoples R China.
EM nfmcl@163.com
RI chen, boyu/KCY 0814 2024; Xu, Yu Xin/G 4041 2010
CR Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21 3 337
   Asahara T, 2000, GENE THER, V7, P451, DOI 10.1038/sj.gt.3301142
   Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520
   Guz Y, 2001, ENDOCRINOLOGY, V142, P4956, DOI 10.1210/en.142.11.4956
   Hardikar AA, 2004, TRENDS ENDOCRIN MET, V15, P198, DOI 10.1016/j.tem.2004.05.001
   Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841
   Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227
   Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502
   Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22 3 415
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Koç ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   Kodama S, 2003, SCIENCE, V302, P1223, DOI 10.1126/science.1088949
   Krupnick AS, 2002, J HEART LUNG TRANSPL, V21, P233, DOI 10.1016/S1053 2498(01)00349 7
   Lazarus HM, 2005, BIOL BLOOD MARROW TR, V11, P389, DOI 10.1016/j.bbmt.2005.02.001
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lechner A, 2004, DIABETES, V53, P616, DOI 10.2337/diabetes.53.3.616
   Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175
   Mathews V, 2004, DIABETES, V53, P91, DOI 10.2337/diabetes.53.1.91
   Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102
   Muñoz Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060 03.2004
   Murphy JM, 2003, ARTHRITIS RHEUM US, V48, P3464, DOI 10.1002/art.11365
   Oh SH, 2004, LAB INVEST, V84, P607, DOI 10.1038/labinvest.3700074
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   SLACK JMW, 1995, DEVELOPMENT, V121, P1569
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Tang DQ, 2004, DIABETES, V53, P1721, DOI 10.2337/diabetes.53.7.1721
   Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii 247
   Zorina TD, 2003, STEM CELLS, V21, P377, DOI 10.1634/stemcells.21 4 377
NR 31
TC 60
Z9 69
U1 0
U2 2
PU CANADIAN SOC CLINICAL INVESTIGATION
PI OTTAWA
PA 114 CHEYENNE WAY, OTTAWA, ON K2J 0E9, CANADA
SN 0147 958X
EI 1488 2353
J9 CLIN INVEST MED
JI Clin. Invest. Med.
PY 2008
VL 31
IS 6
BP E328
EP E337
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 449US
UT WOS:000266356400002
PM 19032902
DA 2025 08 17
ER

PT J
AU Li, MY
   Zhu, F
   Hong, N
   Zhang, L
   Hong, YH
AF Li, Mingyou
   Zhu, Feng
   Hong, Ni
   Zhang, Lei
   Hong, Yunhan
TI Alternative transcription generates multiple Mitf isoforms with
   different expression patterns and activities in medaka
SO PIGMENT CELL & MELANOMA RESEARCH
LA English
DT Article
DE alternative transcription; isoform; melanocyte; mitf; pigmentation
ID WAARDENBURG SYNDROME TYPE 2; MOUSE MICROPHTHALMIA LOCUS; EMBRYONIC
   STEM CELLS; ORYZIAS LATIPES; MELANOCYTE DEVELOPMENT; CHIMERA FORMATION;
   EYE DEVELOPMENT; DRUG SELECTION; GERM CELLS; IN VITRO
AB Microphthalmia associated transcription factor (Mitf) is best known for distinct functions in multiple cell lineages including melanocytes, mast cells, and osteoclasts. In mammals, mitf produces multiple Mitf isoforms by alternative transcription and splicing. The fish medaka has two mitf genes, mitf1 and mitf2. Here, we report differential expression and activities of medaka Mitf isoforms. Molecular cloning identified four mitf1 variants encoding isoforms Mitf1A, MitfB, MitfH, and MitfM, and only one mitf2RNA encoding Mitf2M, which exhibited differential expression. Mitf1 isoforms and Mitf2M differed dramatically in activating the dazl and tyrosinase promoters DAZ and TYR. Interestingly, Mitf1N, an N terminus less Mitf1 mutant form, retained activity to activate TYR but not DAZ. Importantly, Mitf1B was also sufficient for inducing melanocyte differentiation and endogenous tyrosinase RNA expression in medaka embryonic stem cells. Intriguingly, Mitf1 isoforms possessed considerable differences in inducing the expression of multiple cell lineage marker genes. Therefore, alternative mitf transcription is a conserved mechanism from fish to mammals, and medaka Mitf1 isoforms show differences in expression and activity. We conclude that differential expression of isoforms contributes to multiple distinct functions of Mitf in vertebrates.
C1 [Li, Mingyou; Zhu, Feng; Hong, Ni; Zhang, Lei; Hong, Yunhan] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.
   [Li, Mingyou; Hong, Yunhan] Shanghai Ocean Univ, Coll Fisheries & Life Sci, Shanghai, Peoples R China.
C3 National University of Singapore; Shanghai Ocean University
RP Hong, YH (通讯作者)，Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.
EM dbshyh@nus.edu.sg
RI Hong, Ni/Y 6114 2018; Hong, Yunhan/D 4197 2009; Zhang,
   Lei/GYQ 7446 2022; Zhu, Feng/GOH 1593 2022
OI Hong, Ni/0000 0002 9404 3110; Zhu, Feng/0000 0002 8131 1219
FU National Research Foundation Singapore [NRF CRP7 2010 03]
FX We thank Jiaorong Deng for breeding fish. We acknowledge Yovita Ida
   Purwanti and Haobin Zhao for their participation in part of work. This
   research was supported by the National Research Foundation Singapore
   (NRF CRP7 2010 03).
CR Altschmied J, 2002, GENETICS, V161, P259
   Béjar J, 2003, DEVELOPMENT, V130, P6545, DOI 10.1242/dev.00872
   Ben J, 2003, MAR BIOTECHNOL, V5, P568, DOI 10.1007/s10126 002 0121 y
   Bharti K, 2008, DEVELOPMENT, V135, P1169, DOI 10.1242/dev.014142
   Braasch I, 2009, GENOME BIOL EVOL, V1, P479, DOI 10.1093/gbe/evp050
   Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406
   Fukamachi S, 2004, P NATL ACAD SCI USA, V101, P10661, DOI 10.1073/pnas.0401278101
   Fukamachi S, 2001, NAT GENET, V28, P381, DOI 10.1038/ng584
   Furutani Seiki M, 2004, MECH DEVELOP, V121, P647, DOI 10.1016/j.mod.2004.04.016
   Hallsson JH, 2000, GENETICS, V155, P291
   Hallsson JH, 2004, GENETICS, V167, P233, DOI 10.1534/genetics.167.1.233
   Hallsson JH, 2007, PIGM CELL RES, V20, P185, DOI 10.1111/j.1600 0749.2007.00373.x
   Hershey CL, 2005, GENE, V347, P73, DOI 10.1016/j.gene.2004.12.002
   HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092 8674(93)90429 T
   Hong N., 2012, STEM CELLS DEV, V22, P750
   Hong N, 2012, STEM CELLS DEV, V21, P2333, DOI 10.1089/scd.2011.0630
   Hong N, 2011, INT J BIOL SCI, V7, P392, DOI 10.7150/ijbs.7.392
   Hong YH, 1998, DEV GENES EVOL, V208, P595, DOI 10.1007/s004270050220
   Hong YH, 2004, P NATL ACAD SCI USA, V101, P8011, DOI 10.1073/pnas.0308668101
   Hong YH, 2004, TRANSGENIC RES, V13, P41, DOI 10.1023/B:TRAG.0000017172.71391.fa
   Hong YH, 1996, MECH DEVELOP, V60, P33, DOI 10.1016/S0925 4773(96)00596 5
   Hou L, 2008, CELL RES, V18, P1163, DOI 10.1038/cr.2008.303
   Iwamatsu T, 2004, MECH DEVELOP, V121, P605, DOI 10.1016/j.mod.2004.03.012
   Kasahara M, 2007, NATURE, V447, P714, DOI 10.1038/nature05846
   Kelsh RN, 2004, MECH DEVELOP, V121, P841, DOI 10.1016/j.mod.2004.01.004
   Koga A, 1997, PIGM CELL RES, V10, P377, DOI 10.1111/j.1600 0749.1997.tb00695.x
   Li M, 2012, CURR MOL MED, V12, P1040, DOI 10.2174/156652412802480853
   Li MY, 2013, INT J BIOL SCI, V9, P496, DOI 10.7150/ijbs.4668
   Li MY, 2013, J GENET GENOMICS, V40, P75, DOI 10.1016/j.jgg.2012.12.006
   Lister JA, 2001, DEV BIOL, V237, P333, DOI 10.1006/dbio.2001.0379
   Lister JA, 1999, DEVELOPMENT, V126, P3757
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654
   Planque N, 1999, CELL GROWTH DIFFER, V10, P525
   Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004
   Schartl M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037880
   Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446
   Steingrímsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717
   STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194 256
   Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996 50
   Takemoto CM, 2002, J BIOL CHEM, V277, P30244, DOI 10.1074/jbc.M201441200
   TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194 251
   Thoma EC, 2011, STEM CELLS DEV, V20, P1425, DOI 10.1089/scd.2010.0290
   Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225
   Ulveling D, 2011, BIOCHIMIE, V93, P633, DOI 10.1016/j.biochi.2010.11.004
   Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600 0749.2004.00164.x
   Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704
   Xu HY, 2010, SCI CHINA LIFE SCI, V53, P435, DOI 10.1007/s11427 010 0058 8
   Xu HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006097
   Xu HY, 2005, DEV DYNAM, V233, P872, DOI 10.1002/dvdy.20410
   Yamanoue Y, 2006, GENES GENET SYST, V81, P29, DOI 10.1266/ggs.81.29
   Yi MS, 2009, SCIENCE, V326, P430, DOI 10.1126/science.1175151
   Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630
   Yu JF, 2006, PIGM CELL RES, V19, P628, DOI 10.1111/j.1600 0749.2006.00346.x
   ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633
   Zhao HB, 2012, BIOCHIMIE, V94, P759, DOI 10.1016/j.biochi.2011.11.007
   Zhao HB, 2012, ANAL CHEM, V84, P987, DOI 10.1021/ac202541t
NR 57
TC 12
Z9 13
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1755 1471
EI 1755 148X
J9 PIGM CELL MELANOMA R
JI Pigment Cell Melanoma Res.
PD JAN
PY 2014
VL 27
IS 1
DI 10.1111/pcmr.12183
PG 12
WC Oncology; Cell Biology; Dermatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology; Dermatology
GA 274UG
UT WOS:000328631100011
PM 24118994
DA 2025 08 17
ER

PT J
AU von Minckwitz, G
   Rezai, M
   Tesch, H
   Huober, J
   Gerber, B
   Zahm, DM
   Hilfrich, J
   Costa, SD
   Dubsky, P
   Blohmer, JU
   Denkert, C
   Hanusch, C
   Jackisch, C
   Kümmel, S
   Fasching, PA
   Schneeweiss, A
   Paepke, S
   Untch, M
   Burchardi, N
   Mehta, K
   Loibl, S
AF von Minckwitz, G.
   Rezai, M.
   Tesch, H.
   Huober, J.
   Gerber, B.
   Zahm, D. M.
   Hilfrich, J.
   Costa, S. D.
   Dubsky, P.
   Blohmer, J. U.
   Denkert, C.
   Hanusch, C.
   Jackisch, C.
   Kuemmel, S.
   Fasching, P. A.
   Schneeweiss, A.
   Paepke, S.
   Untch, M.
   Burchardi, N.
   Mehta, K.
   Loibl, S.
CA German Breast Grp Austrian
TI Zoledronate for patients with invasive residual disease after
   anthracyclines taxane based chemotherapy for early breast cancer   The
   Phase III NeoAdjuvant Trial Add oN (NaTaN) study (GBG 36/ABCSG 29)
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Adjuvant treatment; Postneoadjuvant; Zoledronate; Early breast cancer
ID ADJUVANT BREAST; THERAPY; ACID
AB Background: Patients with invasive residual disease after neoadjuvant chemotherapy (NACT) are considered to have chemo resistant breast cancer. Bisphosphonates are an established treatment for bone metastases and are of potential benefit as adjuvant treatment in early breast cancer.
   Patients and methods: Patients who had invasive tumour residuals (ypT1 4 and/ or ypN+) after a minimum of four cycles of anthracycline taxane containing NACT were eligible for the NeoAdjuvant Trial Add oN study. Patients were randomised within 3 years after surgery to receive zoledronate 4 mg i.v. for 5 years versus observation. Zoledronate was given every 4 weeks for the first 6 months, every 3 months for the following 2 years, and every 6 months for the last 2.5 years. Primary objective was disease free survival.
   Results: After a median time of 54.7 months no difference in disease free survival was observed between the zoledronate and observation groups (hazard ratio [HR] 0.960, 95% confidence interval [CI] 0.709 1.30, log rank P=0.789). Various subgroups were examined without identifying a treatment effect of zoledronate. Patients over 55 years of age showed a HR of 0.832 in favour of zoledronate, but the result was not significant (P=0.480). A similar result was obtained for overall survival with a HR of 1.19 (95% CI 0.79 1.79; log rank P=0.408). Zoledronate was well tolerated and no new toxicity signal was identified.
   Conclusion: Postneoadjuvant treatment with zoledronate does not improve outcome in patients without pathological complete response after neoadjuvant anthracycline taxane based chemotherapy for early breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [von Minckwitz, G.; Burchardi, N.; Mehta, K.; Loibl, S.] German Breast Grp, Martin Behaim Str 12, D 63263 Neu Isenburg, Germany.
   [Rezai, M.] Luisenkrankenhaus Dusseldorf, Hans Gunther Sohl Str 6 10, D 40235 Dusseldorf, Germany.
   [Tesch, H.] Hamatol Onkol Gemeinschaftspraxis Bethanien, Prufling 17 19, D 60389 Frankfurt, Germany.
   [Huober, J.] Univ Frauenklin Ulm, Prittwitzstr 43, D 89081 Ulm, Germany.
   [Gerber, B.] Univ Frauenklin Rostock, Sudring 81, D 18059 Rostock, Germany.
   [Zahm, D. M.] SRH Wald Klinikum Gera GmbH, Str Friedens 122, D 07548 Gera, Germany.
   [Hilfrich, J.] Eilenriede Krankenhaus, Uhlemeyerstr 16, D 30175 Hannover, Germany.
   [Costa, S. D.] Univ Frauenklin Magdeburg, Gerhart Hauptmann Str 35, D 39108 Magdeburg, Germany.
   [Dubsky, P.] Med Univ Wien, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
   [Blohmer, J. U.; Denkert, C.] Charite, Campus Mitte,Charitepl 1, D 10117 Berlin, Germany.
   [Hanusch, C.] Rotkreuzklinikum Munchen, Taxisstr 3, D 80637 Munich, Germany.
   [Jackisch, C.] Klinikum Offenbach, Starkenburgring 66, D 63069 Offenbach, Germany.
   [Kuemmel, S.] Kliniken Essen Mitte, Brustzentrum, Henricistr 92, D 45136 Essen, Germany.
   [Fasching, P. A.] Univ Frauenklin Erlangen, Univ Str 21 23, D 91054 Erlangen, Germany.
   [Schneeweiss, A.] NCT, Neuenheimer Feld 460, D 69120 Heidelberg, Germany.
   [Paepke, S.] Tech Univ Munich, Univ Frauenklin Rechts Isar, Ismaninger Str 22, D 81675 Munich, Germany.
   [Untch, M.] Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, D 13125 Berlin, Germany.
C3 German Breast Group; Ulm University; University of Rostock; Medical
   University of Vienna; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Sana Klinikum Offenbach;
   Kliniken Essen Mitte; University of Erlangen Nuremberg; Helmholtz
   Association; German Cancer Research Center (DKFZ); Ruprecht Karls
   University Heidelberg; National Center for Tumor Diseases; Technical
   University of Munich; Helios Kliniken
RP von Minckwitz, G (通讯作者)，GBG Forsch GmbH, German Breast Grp, Martin Behaim Str 12, D 63263 Neu Isenburg, Germany.
EM gunter.vonminckwitz@gbg.de; dr.mahdi.rezai@luisenkrankenhaus.de;
   Hans.Tesch@chop studien.de; jens.huober@uniklinik ulm.de;
   bernd.gerber@med.uni rostock.de; dirk michael.zahm@wkg.srh.de;
   j.hilfrich@eilenriedeklinik.de; serban dan.costa@med.ovgu.de;
   peter.dubsky@meduniwien.ac.at; jens.blohmer@charite.de;
   carsten.denkert@charite.de; claus.hanusch@swmbrk.de;
   christian.jackisch@sana.de; s.kuemmel@kliniken essen mitte.de;
   Peter.Fasching@uk erlangen.de;
   Andreas.Schneeweiss@med.uni heidelberg.de;
   stefan.paepke@lrz.tu muenchen.de; michael.untch@helios kliniken.de;
   nicole.burchardi@gbg.de; Keyur.mehta@gbg.de; Sibylle.loibl@gbg.de
RI Kuemmel, Sherko/AFV 3420 2022; Schneeweiss, Andreas/HHS 4098 2022;
   Denkert, Carsten/AHE 2675 2022; Untch, Michael/HPG 9291 2023; Fasching,
   Peter/ABH 9912 2020; Loibl, Sibylle/ACQ 5609 2022
OI Blohmer, Jens Uwe/0000 0002 7969 250X; Denkert,
   Carsten/0000 0002 2249 0982; 
FU Novartis
FX Novartis provided study medication as well as financial funding for the
   study but was not involved in the design, conduct or analysis and
   interpretation of the data.
CR Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Geyer CE, 2013, CANCER RES, V73, DOI 10.1158/0008 5472.SABCS13 OT1 1 06
   Gnant Michael, 2011, Ther Adv Med Oncol, V3, P293, DOI 10.1177/1758834011420599
   Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523
   Kaufmann M, 2012, ANN SURG ONCOL, V19, P1508, DOI 10.1245/s10434 011 2108 2
   Kuerer HM, 1999, J CLIN ONCOL, V17, P460, DOI 10.1200/JCO.1999.17.2.460
   Mauri D, 2010, J NATL COMPR CANC NE, V8, P279, DOI 10.6004/jnccn.2010.0020
   Mittendorf EA, 2011, J CLIN ONCOL, V29, P1956, DOI 10.1200/JCO.2010.31.8469
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Parmar MKB, 2001, LANCET, V358, P375, DOI 10.1016/S0140 6736(01)05558 1
   Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235
   Symmans WF, 2013, CANCER RES, V73, DOI 10.1158/0008 5472.SABCS13 S6 02
   von Minckwitz G, 2013, CANCER RES, V73, DOI 10.1158/0008 5472.SABCS13 OT2 6 11
   von Minckwitz G, 2013, J CLIN ONCOL, V31, P3531, DOI 10.1200/JCO.2012.47.2167
   von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595
NR 19
TC 27
Z9 27
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD SEP
PY 2016
VL 64
BP 12
EP 21
DI 10.1016/j.ejca.2016.05.015
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DS4KU
UT WOS:000380750800002
PM 27323347
DA 2025 08 17
ER

PT J
AU Bühler, H
   Hoberg, C
   Fakhrian, K
   Adamietz, IA
AF Buehler, Helmut
   Hoberg, Clemens
   Fakhrian, Khashayar
   Adamietz, Irenaeus A.
TI Zoledronic Acid Inhibits the Motility of Cancer Stem like Cells from the
   Human Breast Cancer Cell Line MDA MB 231
SO IN VIVO
LA English
DT Article
DE Breast cancer stem cells; zoledronic acid; motility; breast cancer
   metastasis; tumor cell migration
ID ANTICANCER AGENTS; BISPHOSPHONATES; THERAPY; OSTEOPOROSIS; INVASION;
   TARGETS; TRIAL
AB Background/Aim: Various effects on tumor cells have been described for zoledronic acid (ZOL). However, only limited data exist regarding its influence on the motility of tumor cells. Since migration of tumor stem cells is a decisive step in metastasis, we examined whether ZOL reduces their motility. Materials and Methods: We investigated the effects of ZOL on stem like progenitor cells obtained via the formation of spheroids from the human breast cancer cell line MDA MB 231. Stem cell properties were verified by measurement of high CD44 expression and absence of CD24 expression. Motility was explored by time resolved videography, protein expression by western blotting. Results: ZOL strongly reduced the migration of stem like progenitor cells. Cellular velocity was reduced by 61% following exposure to 1 mu M ZOL and by 82% after exposure to 10 mu M ZOL. Accumulated distance traveled by the cells was reduced by 60% and 79% after exposure to 1 mu M and 10 mu M ZOL, respectively. The remaining cellular motility led to very little change in distance, with cellular activity appearing more as "stepping on the spot". The reduced motility might be due to reduced phosphorylation of focal adhesion kinase (FAK), an important enzyme in cellular migration. Conclusion: ZOL reduces the motility and cellular velocity of breast cancer cells in vitro. The reduced mobility might slow down or even stop metastasis, which is a known result of adjuvant ZOL therapy in breast cancer patients. In vivo studies are warranted to evaluate the impact of the reduced motility on the metastatic cascade.
C1 [Buehler, Helmut; Hoberg, Clemens; Fakhrian, Khashayar; Adamietz, Irenaeus A.] Ruhr Univ Bochum, Marien Hosp Herne, Inst Radiat Biol, Dept Radiat Oncol, Herne, Germany.
   [Fakhrian, Khashayar; Adamietz, Irenaeus A.] Ruhr Univ Bochum, Marien Hosp Herne, Dept Radiat Oncol, Herne, Germany.
C3 Ruhr University Bochum; St. Marien Hospital; Ruhr University Bochum; St.
   Marien Hospital
RP Bühler, H (通讯作者)，Ruhr Univ Bochum, Univ Clin, Marien Hosp Herne, Holkeskampring 40, D 44625 Herne, Germany.
EM helmut.buehler@elisabethgruppe.de
OI Buhler, Helmut/0000 0003 2094 8029; Adamietz,
   Irenaeus/0000 0002 7747 7259
FU BIOX Foundation
FX The Authors would like to thank Ms. Anja Kochannek and Ms. Bettina
   Priesch Grzeszkowiak for their excellent technical assistance and the
   BIOX Foundation for generous support of this work.
CR Body JJ, 2003, EXPERT OPIN PHARMACO, V4, P567, DOI 10.1517/eoph.4.4.567.22227
   Boissier S, 2000, CANCER RES, V60, P2949
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797 730
   Braun Stephan, 2012, Methods Mol Biol, V878, P63, DOI 10.1007/978 1 61779 854 2_4
   Bühler H, 2015, ANTICANCER RES, V35, P1977
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Ebert R, 2012, BONE, V50, P723, DOI 10.1016/j.bone.2011.11.025
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Hiraga T, 2011, ONCOL REP, V25, P289, DOI 10.3892/or_00001073
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458
   Koul HK, 2012, PROSTATE CANCER P D, V15, P111, DOI 10.1038/pcan.2011.41
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Li XY, 2012, MED ONCOL, V29, P714, DOI 10.1007/s12032 011 9904 1
   Liu SB, 2014, IEEE INT SYMP PARAL, P68, DOI 10.1109/ISPA.2014.18
   Mani J, 2012, PROSTATE CANCER P D, V15, P250, DOI 10.1038/pcan.2012.9
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Rietkötter E, 2013, ONCOTARGET, V4, P1449, DOI 10.18632/oncotarget.1201
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Santini D, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0634 8
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Wikman H, 2008, APMIS, V116, P754, DOI 10.1111/j.1600 0463.2008.01033.x
   Wilson C, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1066 7
NR 31
TC 9
Z9 9
U1 0
U2 2
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258 851X
EI 1791 7549
J9 IN VIVO
JI In Vivo
PD NOV DEC
PY 2016
VL 30
IS 6
BP 761
EP 768
DI 10.21873/invivo.10992
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EJ0UO
UT WOS:000392926200006
PM 27815459
OA gold
DA 2025 08 17
ER

PT J
AU Hotha, KK
   Dasari, VB
   Shaik, AN
   Syed, M
   Shivva, V
   Lakshmanarao, RK
   Korlakunta, JN
   Mullangi, R
AF Hotha, Kishore Kumar
   Dasari, Vijaya Bharathi
   Shaik, Abdul Naveed
   Syed, Muzeeb
   Shivva, Vittal
   Lakshmanarao, Ravindranath Krishnarao
   Korlakunta, Jayaveera Narasimhulu
   Mullangi, Ramesh
TI Species difference in the in vitro and in vivo metabolism
   of amtolmetin guacil
SO ARZNEIMITTEL FORSCHUNG DRUG RESEARCH
LA English
DT Article
DE Amtolmetin guacil, humans, metabolism, pharmacokinetics, rats; CAS
   26171 23 3; CAS 87344 06 7; Non steroidal anti inflammatory drugs;
   Tolmetin
ID NONSTEROIDAL ANTIINFLAMMATORY DRUG; TANDEM MASS SPECTROMETRY; TOLMETIN
   GLUCURONIDE; SERUM ALBUMIN; RATS; IDENTIFICATION; MECHANISM; PLASMA;
   DICLOFENAC; BINDING
AB Tolmetin (TMT, CAS 26171 23 3) is a non steroidal anti inflammatory drug (NSAID) indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and juvenile rheumatoid arthritis. As TMT causes gastro intestinal side effects like other NSAIDs, its nonacidic prodrug amtolmetin guacil (AMG, CAS 87344 06 7) was synthesized. AMG has similar NSAID properties like TMT with additional gastroprotective property. The aim of this study was to investigate whether TMT and AMG are differentially metabolised in rat and human plasma (fresh and acidified) and liver microsomes. TMT was found to be stable in all the matrices tested viz., rat and human plasma (fresh and acidified) and liver microsomes. AMG was found to be stable only in acidified rat and human plasma. On the contrary, in fresh human Plasma and human liver microsomes AMG was rapidly converted to two metabolites, which were subsequently identified as MED5 and MED5 methyl ester, without yielding any intact TMT. However, in rat fresh plasma and liver microsomes, AMG formed MED5 (predominant) and TMT. To corroborate the in vitro findings, in vivo pharmacokinetics (PK) studies were done following separate dosing of AMG in both rats and humans. In rats, the PK data substantiated that following oral administration of AMG it will be converted to TMT resulting in similar PK parameters observed for TMT when it was administered alone. In humans, however, AMG yields low levels of TMT which substantes the in vitro results. Levels of AMG were not detectable in the plasma. These results confirm the species differences in the in vitro and in vivo metabolism and disposition of AMG. More research work to further explore and understand AMG metabolism in humans is required.
C1 [Hotha, Kishore Kumar; Dasari, Vijaya Bharathi; Mullangi, Ramesh] Dr Reddys Labs Ltd, Bioanalyt Dept, Integrated Prod Dev, Hyderabad 500072, Andhra Pradesh, India.
   [Hotha, Kishore Kumar; Korlakunta, Jayaveera Narasimhulu] JNT Univ, Dept Chem, Anantapur, Andhra Pradesh, India.
   [Shaik, Abdul Naveed; Syed, Muzeeb; Shivva, Vittal] Dr Reddys Labs Ltd, Discovery Res, Hyderabad 500072, Andhra Pradesh, India.
   [Lakshmanarao, Ravindranath Krishnarao] SK Univ, Dept Chem, Anantapur, Andhra Pradesh, India.
C3 Dr. Reddy's Laboratories Ltd.; Jawaharlal Nehru Technological University
     Anantapur; Dr. Reddy's Laboratories Ltd.; Sri Krishnadevaraya
   University
RP Dasari, VB (通讯作者)，Dr Reddys Labs Ltd, Bioanalyt Dept, Integrated Prod Dev, Hyderabad 500072, Andhra Pradesh, India.
EM vijayabd@drreddys.com
RI Mullangi, Ramesh/AAB 1584 2021; Shaik, Abdul/I 1018 2019; hotha,
   kishore/D 1356 2014
OI Shaik, Abdul Naveed/0000 0002 3672 2246; 
CR ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001
   BURKERT U, 1982, ACS MONOGRAPH, V99
   Chen Q, 2006, DRUG METAB DISPOS, V34, P145, DOI 10.1124/dmd.105.004341
   Coruzzi G, 1999, NUTRITION, V15, P325
   DING A, 1993, P NATL ACAD SCI USA, V90, P3797, DOI 10.1073/pnas.90.9.3797
   DING A, 1995, DRUG METAB DISPOS, V23, P369
   GHIRARDINI M, 1990, DRUGS EXP CLIN RES S, V26, P19
   GRINDEL JM, 1981, DRUG METAB REV, V12, P363, DOI 10.3109/03602538108994037
   HOTHA KK, 2010, BIOMED CHRO IN PRESS
   HYNECK ML, 1987, J CHROMATOGR BIOMED, V420, P349, DOI 10.1016/0378 4347(87)80190 1
   Li YH, 2004, WORLD J GASTROENTERO, V10, P3616, DOI 10.3748/wjg.v10.i24.3616
   Lingetti M, 1993, Clin Ter, V142, P29
   MANCINELLI A, 1991, J CHROMATOGR, V553, P81, DOI 10.1016/S0021 9673(01)88475 2
   Meloni P, 1995, Clin Ter, V146, P453
   MIGDALOF BH, 1976, DRUG METAB DISPOS, V4, P468
   Nappi C, 1993, Clin Ter, V142, P47
   Olsen J, 2003, XENOBIOTICA, V33, P561, DOI 10.1080/0049825031000085942
   Olsen J, 2007, DRUG METAB DISPOS, V35, P758, DOI 10.1124/dmd.106.013334
   PETAZZI I, 1990, DRUGS EXPL CLIN RE S, V26, P25
   Pisano C, 1999, DIGEST DIS SCI, V44, P713, DOI 10.1023/A:1026653623516
   Porro GB, 1999, ITAL J GASTROENTEROL, V31, P378
   Rao MNVS, 2003, XENOBIOTICA, V33, P1233, DOI 10.1080/00498250310001636877
   Riezzo G, 2001, DIGEST DIS SCI, V46, P1797, DOI 10.1023/A:1010686411837
   *RXLIST INC, 2010, INT DRUG IND
   Tubaro E, 2000, EUR J PHARMACOL, V387, P233, DOI 10.1016/S0014 2999(99)00791 8
   Tubaro E, 2003, EUR J PHARMACOL, V467, P173, DOI 10.1016/S0014 2999(03)01598 X
   Tubaro E, 1995, ARZNEIMITTEL FORSCH, V45 2, P1298
   ZIAAMIRHOSSEINI P, 1995, NAT MED, V1, P2, DOI 10.1038/nm0195 2b
NR 28
TC 1
Z9 3
U1 0
U2 2
PU ECV EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI AULENDORF
PA BANDELSTOCKWEG 20, POSTFACH 1255, D 88322 AULENDORF, GERMANY
SN 0004 4172
J9 ARZNEIMITTEL FORSCH
JI Arzneimittelforschung
PY 2010
VL 60
IS 11
BP 667
EP 674
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 690UN
UT WOS:000285034000004
PM 21175039
DA 2025 08 17
ER

PT J
AU Wang, QZ
   Liu, JY
   Qi, SQ
   Liao, XJ
   Liu, DZ
   Pan, J
AF Wang, Qizhang
   Liu, Jiyuan
   Qi, Shuqun
   Liao, Xuejuan
   Liu, Dazhong
   Pan, Jian
TI Clinical analysis of medication related osteonecrosis of the jaws: A
   growing severe complication in China
SO JOURNAL OF DENTAL SCIENCES
LA English
DT Article
DE Bisphosphate; Osteonecrosis; Risk factor; Treatment
ID BISPHOSPHONATE RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; AMERICAN
   ASSOCIATION; RISK FACTORS; OSTEOMYELITIS; DENOSUMAB; BRONJ; LONG;
   THERAPY; UPDATE
AB Background/purpose: Medication related osteonecrosis of the jaws (MRONJ) is an unusual but quite serious complication. However, its mechanism remains unclear, and its treatment protocol is still controversial.
   Materials and methods: Our study involved 201 osteonecrosis of the jaw (ONJ) patients from September 2006 to March 2017. We analyzed risk factors, clinical characteristics, treatment, etc., by comparing MRONJ with other ONJs.
   Results: Among 201 patients, MRONJ accounted for 14.71% and it presented a consistent increase tendency. In comparison with other ONJs, we considered advanced age, maxilla lesion, diabetes mellitus, tooth extraction, especially multi teeth extraction as risk factors (P < 0.0125). Our study demonstrated that maxillary lesion was associated with an advanced stage and it was inclined to worse prognoses. We also found MRONJ had little correlation to Actinomyces infection. Surgical treatment could improve patients' condition successfully (P > 0.05). 81.3% patients with advanced stage showed complete or partial healing lesions after surgery.
   Conclusion: Advanced age, maxilla lesion, diabetes mellitus, tooth extraction seem to be important triggering factors for MRONJ. Clinicians and surgeons should pay attention to maxillary lesions as it is related to severe symptoms and unfavorable prognosis. Once diagnosed as MRONJ, surgery is an effective treatment for patients with advanced stage. (C) 2018 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V.
C1 [Wang, Qizhang; Liu, Jiyuan; Qi, Shuqun; Liao, Xuejuan; Pan, Jian] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Liu, Dazhong] Xindu Dist Peoples Hosp Chengdu, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University
RP Pan, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, 14,Sect 3rd,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
EM jianpancn@163.com
OI Wang, Qizhang/0000 0001 9529 976X
FU Scientific Research Foundation of the Science and Technology Department
   of Sichuan Province, China [2017SZ0094, 2017SZ0108]
FX This work was supported by the Scientific Research Foundation of the
   Science and Technology Department of Sichuan Province, China grant
   numbers 2017SZ0094, 2017SZ0108.
CR Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Anagnostis P, 2015, CLIMACTERIC, V18, P32, DOI 10.3109/13697137.2015.1099092
   Anavi Lev K, 2013, OR SURG OR MED OR PA, V115, P660, DOI 10.1016/j.oooo.2013.03.001
   Bagan J, 2016, ORAL DIS, V22, P324, DOI 10.1111/odi.12447
   Bejhed RS, 2016, ANN PHARMACOTHER, V50, P616, DOI 10.1177/1060028016649368
   De Ceulaer J, 2014, EUR J CLIN MICROBIOL, V33, P1873, DOI 10.1007/s10096 014 2160 5
   Holzinger D, 2013, ORAL ONCOL, V49, P66, DOI 10.1016/j.oraloncology.2012.07.008
   Howie RN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132520
   Janovska Z, 2015, BIOMED PAP, V159, P313, DOI 10.5507/bp.2013.069
   Junquera L, 2009, AM J OTOLARYNG, V30, P390, DOI 10.1016/j.amjoto.2008.07.014
   Krimmel M, 2014, ORAL MAXILLOFAC SURG, V18, P213, DOI 10.1007/s10006 013 0408 3
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Niibe K, 2015, J PROSTHODONT RES, V59, P3, DOI 10.1016/j.jpor.2014.08.001
   Nisi M, 2015, INT J ORAL MAX SURG, V44, P586, DOI 10.1016/j.ijom.2015.01.014
   O'Halloran M, 2014, AUST DENT J, V59, P516, DOI 10.1111/adj.12217
   Pichardo SEC, 2016, J CRANIO MAXILL SURG, V44, P1216, DOI 10.1016/j.jcms.2016.06.016
   Pichardo SEC, 2013, OR SURG OR MED OR PA, V116, P287, DOI 10.1016/j.oooo.2013.05.005
   Pigrau Serrallach C, 2014, ENFERM INFEC MICR CL, V32, P18, DOI 10.1016/j.eimc.2013.01.007
   Roberts J, 2016, CLIN ENDOCRINOL, V84, P509, DOI 10.1111/cen.13012
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Tardast A, 2015, J APPL ORAL SCI, V23, P310, DOI 10.1590/1678 775720140506
   Vidal Real C, 2015, MED ORAL PATOL ORAL, V20, pE267, DOI 10.4317/medoral.20092
   Walter C, 2014, CLIN ORAL INVEST, V18, P2221, DOI 10.1007/s00784 014 1205 6
   Wasserzug O, 2017, AM J RHINOL ALLERGY, V31, P36, DOI 10.2500/ajra.2017.31.4395
NR 25
TC 17
Z9 23
U1 0
U2 15
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1991 7902
EI 2213 8862
J9 J DENT SCI
JI J. Dental Sci.
PD SEP
PY 2018
VL 13
IS 3
BP 190
EP 197
DI 10.1016/j.jds.2017.12.003
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GV8OF
UT WOS:000446402700004
PM 30895120
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, XY
   Xie, L
   Xu, ZY
   Huo, FJ
   Shu, GQ
   He, K
   Fan, LL
   Zhang, RT
   Liu, SR
   Mai, Y
   He, M
   Liao, L
   Tang, W
   Tian, WD
AF Hu, Xingyu
   Xie, Li
   Xu, Zhaoyu
   Huo, Fangjun
   Shu, Guoqiang
   He, Kun
   Fan, Linli
   Zhang, Ruitao
   Liu, Suru
   Mai, Yao
   He, Min
   Liao, Li
   Tang, Wei
   Tian, Weidong
TI Lysosome Inspired Enclosed and Deep Surface Decontamination Strategy for
   Management of Peri Implant Infections
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE lysosome; oxygen deficient titanium dioxide; peri implant infections;
   re osseointegration; surface decontamination
ID RE OSSEOINTEGRATION; IN VITRO; SURGICAL THERAPY; BIOFILM; BONE;
   MECHANISMS; TOLERANCE; RADICALS; HEALTHY; MODEL
AB Surface decontamination is a crucial step in the treatment of peri implant infections, yet deep and mild cleansing techniques are lacking. Drawing inspiration from lysosomes, which enclose hydrolytic enzymes within their membranes to safely and effectively degrade organics within cells, the use of a near infrared (NIR)/H2O2 activated TiO2 x Alginate system for enclosed and deep surface decontamination is proposed. It leverages synergistically generated reactive oxygen species (ROS) to eliminate bacterial contaminants, mimicking the process of lysosomal digestion. By employing Ca2+ spray induced surface gelation, the TiO2 x and H2O2 around implant surface are enclosed, creating a membrane like isolation. This system robustly degrades extracellular polymeric substances (EPS) mimic biomacromolecules, removes organic residues (OR) from both mono species (Staphylococcus aureus and Porphyromonas gingivalis) biofilm and polymicrobial ex vivo biofilm of peri implantitis, while avoiding healthy tissue irritation. Encouragingly, this system has also demonstrated powerful decontamination capabilities when applied to clinic retrieved infected dental implants. Notably, this technique restores the pristine implant surface topography and chemical composition, which are further revealed by the minimal inflammation response observed in macrophage culture and subcutaneous implantation. Consequently, osteoblast functionalities are effectively restored, and re osseointegration in vivo is also greatly enhanced. Thus, this deep decontamination strategy holds great promise for clinical applications in managing peri implant infections.
   A pioneering lysosome inspired surface decontamination approach for infected implants is introduced, which encloses a high yield of powerful reactive oxygen species around contaminated implant surface through a vesicular like application form, effectively achieving a safe and deep cleaning effect simultaneously, thus mitigating inflammation response and ultimately promoting re osseointegration. This deep decontamination strategy holds great promise for clinical applications in managing peri implant infections.image
C1 [Hu, Xingyu; Xie, Li; Xu, Zhaoyu; Huo, Fangjun; He, Kun; Fan, Linli; Zhang, Ruitao; Liu, Suru; Mai, Yao; He, Min; Liao, Li; Tang, Wei; Tian, Weidong] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Engn Res Ctr Oral Translat Med,State Key Lab Oral, Chengdu 610041, Sichuan, Peoples R China.
   [Hu, Xingyu; Xie, Li; Xu, Zhaoyu; Huo, Fangjun; Zhang, Ruitao; Liu, Suru; Mai, Yao; He, Min; Liao, Li; Tang, Wei; Tian, Weidong] West China Hosp Stomatol, Natl Engn Lab Oral Regenerat Med, Chengdu 610041, Sichuan, Peoples R China.
   [Hu, Xingyu; Xu, Zhaoyu; Huo, Fangjun; Zhang, Ruitao; Liu, Suru; Mai, Yao; Tang, Wei; Tian, Weidong] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, Chengdu 610041, Peoples R China.
   [Shu, Guoqiang] Sichuan Univ, Sch Chem Engn, Low Carbon Technol & Chem React Engn Lab, Chengdu 610065, Sichuan, Peoples R China.
   [He, Kun] Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, Chengdu 610041, Sichuan, Peoples R China.
   [Fan, Linli] Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont 2, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University
RP Xie, L; Tang, W; Tian, WD (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Engn Res Ctr Oral Translat Med,State Key Lab Oral, Chengdu 610041, Sichuan, Peoples R China.; Xie, L; Tang, W; Tian, WD (通讯作者)，West China Hosp Stomatol, Natl Engn Lab Oral Regenerat Med, Chengdu 610041, Sichuan, Peoples R China.; Tang, W; Tian, WD (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, Chengdu 610041, Peoples R China.
EM samuelxl@scu.edu.cn; mydrtw@scu.edu.cn; drtwd@scu.edu.cn
RI Hu, xingyu/KIH 6207 2024; he, kun/KRP 3091 2024; Xie, Li/JCP 2636 2023;
   Huo, Fangjun/H 8330 2014; tang, wei/HZH 5205 2023
FU National Natural Science Foundation of China; National Key R&D Program
   of China [2022YFA1104400]; Sichuan Science and Technology Program
   [2022YFS0283]; Natural Science Foundation of Sichuan Province
   [2022NSFSC1540];  [81970968];  [32271415]
FX This study was supported by the National Natural Science Foundation of
   China (grant number 81970968, 32271415), the National Key R&D Program of
   China (grant number 2022YFA1104400), the Sichuan Science and Technology
   Program (grant number 2022YFS0283), the Natural Science Foundation of
   Sichuan Province (2022NSFSC1540).
CR Agarwalla P, 2022, NAT BIOTECHNOL, V40, P1250, DOI 10.1038/s41587 022 01245 x
   Anton K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035036
   Augthun M, 1998, J PERIODONTOL, V69, P857, DOI 10.1902/jop.1998.69.8.857
   Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580 019 0185 4
   Bandyopadhyay A, 2023, PROG MATER SCI, V133, DOI 10.1016/j.pmatsci.2022.101053
   Berglundh T, 2004, J CLIN PERIODONTOL, V31, P341, DOI 10.1111/j.1600 051X.2004.00486.x
   CARLONI P, 1993, RES CHEM INTERMEDIAT, V19, P395, DOI 10.1163/156856793X00181
   Ceccarelli G, 2023, ANTIBIOTICS BASEL, V12, DOI 10.3390/antibiotics12050937
   Chackartchi T, 2023, J PERIODONTOL, V94, P419, DOI 10.1002/JPER.22 0142
   Chen QQ, 2023, ADV SCI, V10, DOI 10.1002/advs.202206244
   Cheng M, 2016, CHEM ENG J, V284, P582, DOI 10.1016/j.cej.2015.09.001
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Costa RC, 2023, CRIT REV MICROBIOL, V49, P370, DOI 10.1080/1040841X.2022.2062219
   Costa RC, 2020, CLIN ORAL IMPLAN RES, V31, P1173, DOI 10.1111/clr.13663
   Costerton JW, 2005, INT J ARTIF ORGANS, V28, P1062, DOI 10.1177/039139880502801103
   de la Fuente M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179181
   Ding H, 2021, NANO RES, V14, P570, DOI 10.1007/s12274 020 3053 9
   Francis S, 2022, INT J ORAL MAX IMPL, V37, P76, DOI 10.11607/jomi.8969
   Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260
   Gao X., 2018, MEDICINE, V97
   Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945 053X(00)00108 6
   Gill SS, 2010, PLANT PHYSIOL BIOCH, V48, P909, DOI 10.1016/j.plaphy.2010.08.016
   Heitz Mayfield LJA, 2012, CLIN ORAL IMPLAN RES, V23, P205, DOI 10.1111/j.1600 0501.2011.02276.x
   Hou JY, 2021, ADV MATER, V33, DOI 10.1002/adma.202103727
   Hu CH, 2021, INT J BIOL MACROMOL, V177, P578, DOI 10.1016/j.ijbiomac.2021.02.086
   Hu XY, 2021, ACS APPL MATER INTER, V13, P35315, DOI 10.1021/acsami.1c06774
   Hwang G, 2017, ACS APPL MATER INTER, V9, P38270, DOI 10.1021/acsami.7b11558
   Jiang Q, 2019, J CHEM TECHNOL BIOT, V94, P2512, DOI 10.1002/jctb.6041
   Kim D, 2018, ISME J, V12, P1427, DOI [10.1038/S41396 018 0113 1, 10.1038/s41396 018 0113 1]
   Kotsakis GA, 2021, J PERIODONTOL, V92, P580, DOI 10.1002/JPER.20 0186
   Lang NP, 2011, CLIN ORAL IMPLAN RES, V22, P349, DOI 10.1111/j.1600 0501.2011.02172.x
   Lee EH, 2022, ACS APPL MATER INTER, V14, P27634, DOI 10.1021/acsami.2c05166
   Li BS, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.864012
   Liu HR, 2022, ACS APPL BIO MATER, V5, P4838, DOI 10.1021/acsabm.2c00566
   Liu M, 2022, ACS NANO, V16, P9479, DOI 10.1021/acsnano.2c02518
   Liu YF, 2018, J PROSTHODONT, V27, P42, DOI 10.1111/jopr.12488
   Londono R, 2015, ANN BIOMED ENG, V43, P577, DOI 10.1007/s10439 014 1103 8
   Makabenta JMV, 2021, NAT REV MICROBIOL, V19, P23, DOI 10.1038/s41579 020 0420 1
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579 022 00686 0
   Mayorga Martinez CC, 2023, ADV MATER, V35, DOI 10.1002/adma.202300191
   Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064
   Monje A, 2022, INT J ORAL IMPL, V15, P213
   Mou J, 2016, BIOMATERIALS, V84, P13, DOI 10.1016/j.biomaterials.2016.01.009
   Musial J, 2023, SCI TOTAL ENVIRON, V856, DOI 10.1016/j.scitotenv.2022.159122
   Nemesanszky E, 1976, Z Exp Chir, V9, P66
   OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0
   Pan JM, 2023, INORG CHEM, V62, P624, DOI 10.1021/acs.inorgchem.2c04000
   Pandiyan I, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.23318
   Parithimarkalaignan S, 2013, J Indian Prosthodont Soc, V13, P2, DOI 10.1007/s13191 013 0252 z
   Parlar A, 2009, CLIN ORAL IMPLAN RES, V20, P391, DOI 10.1111/j.1600 0501.2008.01655.x
   Qi H., 2023, CHEMISTRYSELECT, V8
   Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414
   Ren Z, 2019, J DENT RES, V98, P322, DOI 10.1177/0022034518818480
   Renvert S, 2009, CLIN ORAL IMPLAN RES, V20, P216, DOI 10.1111/j.1600 0501.2009.01786.x
   Rosli NA, 2022, J PHYS SCI, V33, P107, DOI 10.21315/jps2022.33.2.7
   Rupp F, 2018, DENT MATER, V34, P40, DOI 10.1016/j.dental.2017.09.007
   Ruvinov E, 2016, ADV DRUG DELIVER REV, V96, P54, DOI 10.1016/j.addr.2015.04.021
   Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406
   Schwarz F, 2022, PERIODONTOL 2000, V88, P145, DOI 10.1111/prd.12417
   Schwarz F, 2006, J CLIN PERIODONTOL, V33, P584, DOI 10.1111/j.1600 051X.2006.00956.x
   Serrano Puebla A, 2018, BIOCHEM SOC T, V46, P207, DOI 10.1042/BST20170130
   Shayman JA, 2013, BBA MOL CELL BIOL L, V1831, P602, DOI 10.1016/j.bbalip.2012.08.013
   Subramani K, 2012, INT J ORAL MAX IMPL, V27, P1043
   Sun JL, 2017, BIOMATERIALS, V113, P203, DOI 10.1016/j.biomaterials.2016.10.050
   Tang ZM, 2017, ADV MATER, V29, DOI 10.1002/adma.201701683
   Terasawa K, 2016, BIOCHEM BIOPH RES CO, V479, P489, DOI 10.1016/j.bbrc.2016.09.093
   Thurnheer T, 2016, CLIN ORAL IMPLAN RES, V27, P890, DOI 10.1111/clr.12715
   Tomilo Z. M., 1980, Journal of Engineering Physics, V38, P337, DOI 10.1007/BF00866456
   Wang JL, 2020, SCI TOTAL ENVIRON, V701, DOI 10.1016/j.scitotenv.2019.135023
   Wang XC, 2019, NANO LETT, V19, P2138, DOI 10.1021/acs.nanolett.9b00367
   Wei D, 2010, AUST DENT J, V55, P70, DOI 10.1111/j.1834 7819.2009.01123.x
   Wilensky A, 2023, J CLIN PERIODONTOL, V50, P336, DOI 10.1111/jcpe.13794
   Wong CO, 2017, CELL HOST MICROBE, V21, P719, DOI 10.1016/j.chom.2017.05.002
   Wu H, 2019, ACTA BIOMATER, V97, P597, DOI 10.1016/j.actbio.2019.08.009
   Xu ZY, 2022, CHEM ENG J, V431, DOI 10.1016/j.cej.2021.134119
   Yang T, 2023, MATER CHEM PHYS, V296, DOI 10.1016/j.matchemphys.2022.127242
   You TM, 2007, ORAL SURG ORAL MED O, V103, P34, DOI 10.1016/j.tripleo.2006.01.005
   Zhang CQ, 2016, ADV MATER, V28, P6292, DOI 10.1002/adma.201505555
   Zhang RT, 2023, MATER CHEM PHYS, V293, DOI 10.1016/j.matchemphys.2022.126893
   Zhang ZY, 2021, BIOFOULING, V37, P222, DOI 10.1080/08927014.2021.1893309
   Zhao SH, 2023, CHEM ENG J, V454, DOI 10.1016/j.cej.2022.140376
   Zhao YY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701466
   Zheng YY, 2022, NANO RES, V15, P2977, DOI 10.1007/s12274 021 3929 3
   Zhuang LF, 2016, CLIN ORAL IMPLAN RES, V27, P13, DOI 10.1111/clr.12508
NR 84
TC 2
Z9 2
U1 15
U2 59
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD APR
PY 2024
VL 34
IS 17
DI 10.1002/adfm.202314034
EA DEC 2023
PG 19
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA ZN3T4
UT WOS:001129454000001
DA 2025 08 17
ER

PT J
AU Wang, JY
   Chen, CM
   Chen, CF
   Wu, PK
   Chen, WM
AF Wang, Jir You
   Chen, Chao Ming
   Chen, Cheng Fong
   Wu, Po Kuei
   Chen, Wei Ming
TI Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation,
   Differentiation and Enhances the Chemosensitivity of P53 Positive U2OS
   Osteosarcoma Cell
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteosarcoma; estrogen receptors; chemotherapy
ID C MYC OVEREXPRESSION; OSTEOBLAST DIFFERENTIATION; DRUG RESISTANCE; P53
   MUTATIONS; CYCLE ARREST; STEM CELLS; DOXORUBICIN; EXPRESSION; APOPTOSIS;
   CANCER
AB Osteosarcoma is a highly malignant musculoskeletal tumor that is commonly noticed in adolescent children, young children, and elderly adults. Due to advances in surgery, chemotherapy and imaging technology, survival rates have improved to 70 80%, but chemical treatments do not enhance patient survival; in addition, the survival rate after chemical treatments is still low. The most obvious clinical feature of osteosarcoma is new bone formation, which is called "sun burst ". Estrogen receptor alpha (ER alpha) is an essential feature of osteogenesis and regulates cell growth in various tumors, including osteosarcoma. In this study, we sought to investigate the role of ER alpha in osteosarcoma and to determine if ER alpha can be used as a target to facilitate the chemosensitivity of osteosarcoma to current treatments. The growth rate of each cell clone was assayed by MTT and trypan blue cell counting, and cell cycle analysis was conducted by flow cytometry. Osteogenic differentiation was induced by osteogenic induction medium and quantified by ARS staining. The effects of ER alpha on the chemoresponse of OS cells treated with doxorubicin were evaluated by colony formation assay. Mechanistic studies were conducted by examining the levels of proteins by Western blot. The role of ER alpha on OS prognosis was investigated by an immunohistochemical analysis of OS tissue array. The results showed an impaired growth rate and a decreased osteogenesis ability in the ER alpha silenced P53(+) OS cell line U2OS, but not in P53( ) SAOS2 cells, compared with the parental cell line. Cotreatment with tamoxifen, an estrogen receptor inhibitor, increased the sensitivity to doxorubicin, which decreased the colony formation of P53(+) U2OS cells. Cell cycle arrest in the S phase was observed in P53(+) U2OS cells cotreated with low doses of doxorubicin and tamoxifen, while increased levels of apoptosis factors indicated cell death. Moreover, patients with ER /P53(+) U2OS showed better chemoresponse rates (necrosis rate > 90%) and impaired tumor sizes, which were compatible with the findings of basic research. Taken together, ER alpha may be a potential target of the current treatments for osteosarcoma that can control tumor growth and improve chemosensitivity. In addition, the expression of ER alpha in osteosarcoma can be a prognostic factor to predict the response to chemotherapy.</p>
C1 [Wang, Jir You; Chen, Chao Ming; Chen, Cheng Fong; Wu, Po Kuei; Chen, Wei Ming] Taipei Vet Gen Hosp, Dept Orthpaed, Taipei 112, Taiwan.
   [Wang, Jir You; Chen, Chao Ming; Chen, Cheng Fong; Wu, Po Kuei; Chen, Wei Ming] Taipei Vet Gen Hosp, Therapeut & Res Ctr Musculoskeletal Tumor, Dept Orthpaed, Taipei 112, Taiwan.
   [Wang, Jir You] Natl Yang Ming Chiao Tung Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan.
   [Chen, Chao Ming] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan.
   [Wu, Po Kuei] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei 112, Taiwan.
C3 Taipei Veterans General Hospital; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University
RP Wu, PK (通讯作者)，Taipei Vet Gen Hosp, Dept Orthpaed, Taipei 112, Taiwan.; Wu, PK (通讯作者)，Taipei Vet Gen Hosp, Therapeut & Res Ctr Musculoskeletal Tumor, Dept Orthpaed, Taipei 112, Taiwan.; Wu, PK (通讯作者)，Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei 112, Taiwan.
EM yollywang@gmail.com; drcmchen8@gmail.com; cf_chen@vghtpe.gov.tw;
   drwuvgh@gmail.com; wmchen@vghtpe.gov.tw
RI ; Wang, Jane/A 6530 2012
OI Chen, Chao Ming/0000 0001 8079 0062; Chen,
   Cheng Fong/0000 0002 2485 6159
FU Veterans General Hospital Taipei [V104C 001]
FX This research was funded by grants supported by Veterans General
   Hospital Taipei (V104C 001) and kindly financially supported by Sophie
   Chang and Morris Chang. The funding sources had no any involvement in
   this study.
CR Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931
   Auld KL, 2012, J MOL ENDOCRINOL, V48, P177, DOI 10.1530/JME 11 0140
   Bar On O, 2007, ANTI CANCER DRUG, V18, P1113, DOI 10.1097/CAD.0b013e3282ef4571
   Buondonno I, 2016, MOL CANCER THER, V15, P2640, DOI 10.1158/1535 7163.MCT 16 0048
   CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43
   Chen P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/616025
   Chen Z, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/4639575
   Dohi O, 2008, CANCER SCI, V99, P518, DOI 10.1111/j.1349 7006.2007.00673.x
   Fang DF, 2015, BIOCHEM BIOPH RES CO, V457, P500, DOI 10.1016/j.bbrc.2014.12.114
   Guijarro Maria V, 2014, Postdoc J, V2, P19
   Herber CB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08046 4
   Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Hu QY, 2017, MOL MED REP, V15, P1335, DOI 10.3892/mmr.2017.6115
   Hung GY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003420
   Johmura Y, 2018, J CLIN INVEST, V128, P5603, DOI 10.1172/JCI121679
   Kallio A, 2008, MOL CELL ENDOCRINOL, V289, P38, DOI 10.1016/j.mce.2008.03.005
   Kim HS, 2009, PHARMACOLOGY, V84, P300, DOI 10.1159/000245937
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Lin PI, 2018, ONCOTARGET, V9, P1169, DOI 10.18632/oncotarget.23453
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Marcellus RC, 1996, CELL GROWTH DIFFER, V7, P1643
   Martin Jeff W, 2012, Sarcoma, V2012, P627254, DOI 10.1155/2012/627254
   McDougall KE, 2002, AM J PHYSIOL ENDOC M, V283, pE817, DOI 10.1152/ajpendo.00071.2002
   Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553
   Mirabello L, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv101
   Mirabello LJ, 2015, CANCER RES, V75, DOI 10.1158/1538 7445.AM2015 5574
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Osuna MAL, 2019, CANCER RES, V79, P1054, DOI 10.1158/0008 5472.CAN 18 1255
   Ouyang ZX, 2013, ONCOL LETT, V6, P970, DOI 10.3892/ol.2013.1487
   Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100
   Patil AS, 2011, J CELL PHYSIOL, V226, P3094, DOI 10.1002/jcp.22698
   Pedrosa P, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29870 0
   Perry MJ, 2000, AM J PHYSIOL ENDOC M, V279, pE1159, DOI 10.1152/ajpendo.2000.279.5.E1159
   Piperdi S, 2017, CANCER RES, V77, DOI 10.1158/1538 7445.AM2017 1950
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Robl B, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1397 4
   Ruza E, 2003, J PEDIAT HEMATOL ONC, V25, P780, DOI 10.1097/00043426 200310000 00007
   Savage Sharon A., 2011, Sarcoma, V2011, P548151, DOI 10.1155/2011/548151
   SCHRECK RR, 1992, PEDIATR HEMAT ONCOL, V9, pR9, DOI 10.3109/08880019209018322
   Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312
   Solakidi S, 2005, BBA MOL CELL RES, V1745, P382, DOI 10.1016/j.bbamcr.2005.05.010
   Sun CC, 2015, ONCOTARGET, V6, P25533, DOI 10.18632/oncotarget.4575
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042 7158.2012.01567.x
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang QX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014442
   Tang Z, 2020, J DRUG TARGET, V28, P186, DOI 10.1080/1061186X.2019.1624970
   Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wang JY, 2017, STEM CELL TRANSL MED, V6, P512, DOI 10.5966/sctm.2015 0226
   Wang L, 2009, CANCER BIOL THER, V8, P543, DOI 10.4161/cbt.8.6.7695
   Windahl SH, 2013, J BONE MINER RES, V28, P291, DOI 10.1002/jbmr.1754
   Wu SM, 2015, J CELL BIOCHEM, V116, P1419, DOI 10.1002/jcb.25102
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yang MF, 2017, J BONE ONCOL, V9, P15, DOI 10.1016/j.jbo.2017.09.005
NR 60
TC 5
Z9 5
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2021
VL 22
IS 20
AR 11238
DI 10.3390/ijms222011238
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WS8YL
UT WOS:000715463300001
PM 34681897
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fu, W
   Ma, L
   Chu, BK
   Wang, X
   Bui, MM
   Gemmer, J
   Altiok, S
   Pledger, WJ
AF Fu, Wei
   Ma, Le
   Chu, Baoky
   Wang, Xue
   Bui, Marilyn M.
   Gemmer, Jennifer
   Altiok, Soner
   Pledger, W. Jackson
TI The Cyclin Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces
   the Apoptosis of Osteosarcoma Cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID RETINOBLASTOMA PROTEIN; R ROSCOVITINE; SELICICLIB CYC202;
   DOWN REGULATION; CANCER CELLS; SELECTIVE INHIBITOR; MULTIPLE MYELOMA;
   CDK INHIBITOR; PHOSPHORYLATION; MCL 1
AB Although rare, osteosarcoma is an aggressive cancer that often metastasizes to the lungs. Toward the goal of developing new treatment options for osteosarcoma, we show that the cyclin dependent kinase (CDK) inhibitor SCH 727965 (SCH) induces the apoptosis of several osteosarcoma cell lines including those resistant to doxorubicin and dasatinib. Cell lines prepared in our laboratory from patients who had received adjuvant chemotherapy and explants derived from a human osteosarcoma xenograft in mice were also responsive to SCH. Apoptosis occurred at low nanomolar concentrations of SCH, as did CDK inhibition, and was p53 independent. SCH activated the mitochondrial pathway of apoptosis as evidenced by caspase 9 cleavage and accumulation of cytoplasmic cytochrome c. Amounts of the apoptotic proteins Bax and Bim increased in mitochondria, whereas amounts of the antiapoptotic proteins Mcl 1 and Bcl x(L) declined. Osteosarcoma cells apoptosed when codepleted of CDK1 and CDK2 but not when depleted of other CDK combinations. We suggest that SCH triggers the apoptosis of osteosarcoma cells by inactivating CDK1 and CDK2 and that SCH may be useful for treatment of drug resistant osteosarcomas. SCH also induced the apoptosis of other sarcoma types but not of normal quiescent osteoblasts or fibroblasts. Mol Cancer Ther; 10(6); 1018 27. (C)2011 AACR.
C1 [Fu, Wei; Ma, Le; Chu, Baoky; Wang, Xue; Pledger, W. Jackson] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.
   [Bui, Marilyn M.; Gemmer, Jennifer; Altiok, Soner] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Expt Therapeut, Tampa, FL 33612 USA.
   [Bui, Marilyn M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Sarcoma Res Program,Gonzmart Res Lab,Dept Sarcoma, Tampa, FL 33612 USA.
C3 H Lee Moffitt Cancer Center & Research Institute; State University
   System of Florida; University of South Florida; State University System
   of Florida; University of South Florida; H Lee Moffitt Cancer Center &
   Research Institute; H Lee Moffitt Cancer Center & Research Institute;
   State University System of Florida; University of South Florida
RP Pledger, WJ (通讯作者)，Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Lane, Tampa, FL 33612 USA.
EM jack.pledger@moffitt.org
RI ; Ma, Letao/MHR 6356 2025
OI Fu, Wei/0000 0003 0506 5594; 
FU The V Foundation; Amandolee Weiss Foundation
FX The V Foundation and the Amandolee Weiss Foundation (W. J. Pledger).
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200
   Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood 2004 07 2713
   Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509
   Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002
   Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008 5472.CAN 06 1758
   Cai DP, 2006, CANCER RES, V66, P435, DOI 10.1158/0008 5472.CAN 05 1769
   Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821 846.2000
   Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200
   CHEN R, 2005, CANCER RES, V65, P5399
   ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287
   Eguchi T, 2009, MOL CANCER THER, V8, P1460, DOI 10.1158/1535 7163.MCT 08 1159
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200
   Hahntow IN, 2004, LEUKEMIA, V18, P747, DOI 10.1038/sj.leu.2403295
   Heath Engel HM, 2006, CELL DEATH DIFFER, V13, P1277, DOI 10.1038/sj.cdd.4401961
   Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kim LC, 2010, EXPERT OPIN INV DRUG, V19, P415, DOI 10.1517/13543781003592097
   Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460 2075.1996.tb01097.x
   Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092 8674(95)90141 8
   Lalioti V, 2010, CELL CYCLE, V9, P284, DOI 10.4161/cc.9.2.10466
   Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Li Y, 2007, INT J CANCER, V121, P1212, DOI 10.1002/ijc.22820
   MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008 5472.CAN 05 0233
   MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716
   Maude SL, 2005, CANCER RES, V65, P780
   Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432 1033.1997.t01 2 00527.x
   Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105
   Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165 4608(95)00216 2
   Mohapatra S, 2005, CANCER RES, V65, P7717, DOI 10.1158/0008 5472.CAN 05 0347
   Mohapatra S, 2007, MOL CANCER RES, V5, P145, DOI 10.1158/1541 7786.MCR 06 0300
   Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014 5793(01)02284 0
   Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181
   Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590
   Pan WJ, 2001, CANCER RES, V61, P2885
   Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535 7163.MCT 10 0324
   Paruch K, 2010, ACS MED CHEM LETT, V1, P204, DOI 10.1021/ml100051d
   Pepper C, 2003, CELL CYCLE, V2, P53, DOI 10.4161/cc.2.1.249
   Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood 2005 01 0320
   Sakamoto A, 2008, REV RECENT CLIN TRIA, V3, P228, DOI 10.2174/157488708785700267
   Senderowicz AM, 2000, JNCI J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376
   Seong YS, 2003, CANCER RES, V63, P7384
   Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689
   Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464
   Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008 5472.CAN 06 3469
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Tan ML, 2009, CANCER BIOL THER, V8, P106, DOI 10.4161/cbt.8.2.7385
   Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334
   Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266 7279.2001
   Wesierska Gqdek J, 2004, POL J PHARMACOL, V56, P635
   Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738
   Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058 6066.2004
NR 54
TC 70
Z9 78
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2011
VL 10
IS 6
BP 1018
EP 1027
DI 10.1158/1535 7163.MCT 11 0167
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 775AI
UT WOS:000291428000010
PM 21490307
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Ulutas, O
   Taskapan, MC
   Dogan, A
   Baysal, T
   Taskapan, H
AF Ulutas, O.
   Taskapan, M. C.
   Dogan, A.
   Baysal, T.
   Taskapan, H.
TI Vascular calcification is not related to serum fetuin A and osteopontin
   levels in hemodialysis patients
SO INTERNATIONAL UROLOGY AND NEPHROLOGY
LA English
DT Article
DE Vascular calcinosis; Fetuin A; Osteopontin; Hemodialysis
ID CORONARY ARTERY CALCIFICATION; STAGE RENAL DISEASE;
   MYOCARDIAL INFARCTION; INFLAMMATION
AB Vascular calcification (VC) in hemodialysis (HD) patients is a sign of severe cardiovascular disease and can predict cardiovascular outcomes. Fetuin A and osteopontin (OPN) inhibit VC. Serum fetuin A levels are lower in patients with end stage kidney disease (ESKD) and in those who are on chronic HD therapy. However, there are limited data concerning OPN in patients who are on dialysis. The aim of our study was to determine VC in HD patients, the relationship between VC and 25 OH vitamin D, fetuin A, and OPN levels, and independent predictors of VC.
   Ninety three patients with ESKD on HD therapy were recruited. Among these patients, 44 were male and 49 were female. The patient group was compared with a group of 20 healthy controls of similar age and sex. A plain radiograph of the hand was taken using a mammography machine for the evaluation of VC. Serum fetuin A, OPN, and 25 OH vitamin D levels of both patients and controls were measured.
   VC was detected in 45 (48.4%) HD patients. When patients were compared with healthy controls, fetuin A levels (p < 0.029) were significantly lower in patients, whereas OPN (p < 0.000) and VC (p < 0.002) were significantly higher in the patient group. Age [odds ratio (OR) 1.036], the presence of diabetes mellitus (DM) (OR 17.527), and high parathyroid hormone (PTH) levels (OR 1.002) were independent predictors of VC in a logistic regression model including the following factors: age, the presence of DM, HD duration, and serum albumin, phosphate, PTH, 25 OH vitamin D, fetuin A, OPN, and calcium levels. No significant correlation was found between patients with VC and patients without VC in terms of fetuin A, OPN, and 25 OH vitamin D levels.
   VC is a frequent sign in patients undergoing HD and is not related to serum fetuin A and osteopontin levels. Age, the presence of DM, and high PTH levels were independent predictors of VC in patients undergoing HD. Further studies are warranted to understand the mechanism underlying and the factors contributing to VC.
C1 [Ulutas, O.] Malatya Educ & Res Hosp, Div Nephrol, Malatya, Turkey.
   [Taskapan, M. C.] Inonu Univ, Div Biochem, Fac Med, Malatya, Turkey.
   [Dogan, A.] Inonu Univ, Div Internal Med, Fac Med, Malatya, Turkey.
   [Baysal, T.] Inonu Univ, Div Radiol, Fac Med, Malatya, Turkey.
   [Taskapan, H.] Inonu Univ, Div Nephrol, Fac Med, Malatya, Turkey.
C3 Malatya State Hospital; Inonu University; Inonu University; Inonu
   University; Inonu University
RP Ulutas, O (通讯作者)，Malatya Educ & Res Hosp, Div Nephrol, Malatya, Turkey.
EM drozkanulutas@yahoo.com
RI RAYMAN ERGÜN, Ahsen/AGF 6627 2022; taskapan, hulya/ABI 7737 2020;
   Taskapan, Mehmet/ABI 7747 2020; ulutas, ozkan/ABI 6332 2020
OI Ulutas, Ozkan/0000 0002 2155 8340; 
CR [Anonymous], 2003, AM J KIDNEY DIS, DOI DOI 10.1016/S0272 6386(03)80001 X
   Barreto DV, 2011, NEPHRON CLIN PRACT, V117, pC363, DOI 10.1159/000321520
   BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391
   Collins AJ, 2003, AM J KIDNEY DIS, V41, pV, DOI 10.1016/S0272 6386(03)80001 X
   Cozzolino M, 2006, AM J NEPHROL, V26, P423, DOI 10.1159/000095782
   DEMER LL, 1995, CIRCULATION, V92, P2029, DOI 10.1161/01.CIR.92.8.2029
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Herrmann SM, 2000, ARTERIOSCL THROM VAS, V20, P2386, DOI 10.1161/01.ATV.20.11.2386
   Jung HH, 2006, NEPHROL DIAL TRANSPL, V21, P1915, DOI 10.1093/ndt/gfl118
   Keough Ryan T, 2002, AM J KIDNEY DIS, V39, P1196, DOI 10.1053/ajkd.2002.33391
   Lee CT, 2013, DIS MARKERS, V34, P229, DOI [10.1155/2013/846059, 10.3233/DMA 130965]
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Mikami S, 2008, HYPERTENS RES, V31, P1163, DOI 10.1291/hypres.31.1163
   MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Ramirez Sandoval JC, 2016, PERITON DIALYSIS INT, V36, P262, DOI 10.3747/pdi.2014.00250
   Rivet J, 2006, ARCH DERMATOL, V142, P900, DOI 10.1001/archderm.142.7.900
   Rosenberg M, 2008, CIRC HEART FAIL, V1, P43, DOI 10.1161/CIRCHEARTFAILURE.107.746172
   Russo D, 2007, AM J NEPHROL, V27, P152, DOI 10.1159/000100044
   Shlipak MG, 2002, ANN INTERN MED, V137, P555, DOI 10.7326/0003 4819 137 7 200210010 00006
   Steitz SA, 2002, AM J PATHOL, V161, P2035, DOI 10.1016/S0002 9440(10)64482 3
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wang KX, 2008, CYTOKINE GROWTH F R, V19, P333, DOI 10.1016/j.cytogfr.2008.08.001
   Westenfeld R, 2009, J AM SOC NEPHROL, V20, P1264, DOI 10.1681/ASN.2008060572
   Wright RS, 2002, ANN INTERN MED, V137, P563, DOI 10.7326/0003 4819 137 7 200210010 00007
   Zheng SJ, 2009, AM J CARDIOL, V103, P46, DOI 10.1016/j.amjcard.2008.08.032
NR 26
TC 21
Z9 21
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 1623
EI 1573 2584
J9 INT UROL NEPHROL
JI Int. Urol. Nephrol.
PD JAN
PY 2018
VL 50
IS 1
BP 137
EP 142
DI 10.1007/s11255 017 1740 6
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA FS3TB
UT WOS:000419704800020
PM 29134617
DA 2025 08 17
ER

PT J
AU Hojo, K
   Tamai, R
   Kobayashi Sakamoto, M
   Kiyoura, Y
AF Hojo, Kentaro
   Tamai, Riyoko
   Kobayashi Sakamoto, Michiyo
   Kiyoura, Yusuke
TI Etidronate down regulates Toll like receptor (TLR) 2 ligand induced
   proinflammatory cytokine production by inhibiting NF κB activation
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Non NBPs; Etidronate; TLR; Proinflammatory cytokines; NF kappa B
ID PORPHYROMONAS GINGIVALIS; LIPOTEICHOIC ACID; IL 6 PRODUCTION; LIPID A;
   CELLS; BISPHOSPHONATES; BACTERIA; CLODRONATE; THERAPY;
   LIPOPOLYSACCHARIDE
AB Background: Etidronate is a non nitrogen containing bisphosphonate (non NBP) used for anti bone resorptive therapy as well as having inhibitory effects on atherosclerotic plaques. The present study examined the effects of etidronate on the production of proinflammatory cytokines and chemokines by the macrophage like cell line, J774.1, incubated with Pam(3)Cys Ser (Lys)(4) (Pam(3)CSK(4), a Toll like receptor (TLR) 2 agonist) and lipid A (a TLR4 agonist). Methods: J774.1 cells and human monocytic THP 1 cells were pretreated with or without etidronate for 5 min, and then incubated with or without Pam(3)CSK(4) or lipid A for 24 h. Levels of secreted interleukin 6 (IL 6), tumor necrosis factor alpha (TNF alpha), monocyte chemoattractant protein 1 (MCP 1 ), and macrophage inflammatory protein 1 alpha (MIP 1 alpha) in culture supernatants were measured by enzyme linked immunosorbent assay (ELISA). Cytotoxicity was determined by LDH activity in the supernatants. We also examined the effects of etidronate on the activation of nuclear factor kappa B (NF kappa B) and p38 mitogen activated protein kinase (MAPK) in J774.1 cells by ELISA and Western blotting.Results: Treatment of J774.1 cells with etidronate down regulated TLR2 ligand induced production of IL  6, TNF alpha, MCP 1, and MIP 1 alpha Etidronate also inhibited Pam(3)CSK(4) induced MCP 1 and TNF alpha production by THP 1 cells. However, etidronate did not induce cytotoxicity and reduced lipid A induced cytotoxicity in J774.1 cells. In addition, this agent did not down regulate TLR4 ligand induced proinflammatory cytokine production. Furthermore, etidronate inhibited the translocation of NF kappa B but not p38 MAPK in J774.1 cells stimulated with Pam(3)CSK(4) or lipid A.Conclusion: Etidronate likely inhibits proinflammatory cytokine production in J774.1 cells by suppressing NF kappa B activation in the TLR2 and not the TLR4 pathway. (C) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.
C1 [Hojo, Kentaro; Tamai, Riyoko; Kiyoura, Yusuke] Ohu Univ, Grad Sch Dent, Dept Infect Dis, 31 1 Misumido,Tomitamachi, Koriyama, Fukushima 9638611, Japan.
   [Tamai, Riyoko; Kobayashi Sakamoto, Michiyo; Kiyoura, Yusuke] Ohu Univ, Sch Dent, Dept Oral Med Sci, 31 1 Misumido,Tomitamachi, Koriyama, Fukushima 9638611, Japan.
RP Tamai, R (通讯作者)，Ohu Univ, Grad Sch Dent, Dept Infect Dis, 31 1 Misumido,Tomitamachi, Koriyama, Fukushima 9638611, Japan.; Tamai, R (通讯作者)，Ohu Univ, Sch Dent, Dept Oral Med Sci, 31 1 Misumido,Tomitamachi, Koriyama, Fukushima 9638611, Japan.
EM r tamai@den.ohu u.ac.jp
RI Tamai, Riyoko/B 7998 2013
OI Tamai, Riyoko/0000 0002 2782 2763
FU Ohu University School of Dentistry
FX This work was supported by a Grant in Aid for Young Scientists and a
   Grant in Aid for Scientific Research from the Ohu University School of
   Dentistry.
CR AIDA Y, 1986, MICROBIOL IMMUNOL, V30, P1199, DOI 10.1111/j.1348 0421.1986.tb03048.x
   Akula MK, 2016, NAT IMMUNOL, V17, P922, DOI 10.1038/ni.3487
   Bunk S, 2010, J IMMUNOL, V185, P3708, DOI 10.4049/jimmunol.0901660
   Burns E, 2006, J IMMUNOL, V177, P8296, DOI 10.4049/jimmunol.177.12.8296
   Chang YL, 2014, J CELL MOL MED, V18, P1344, DOI 10.1111/jcmm.12294
   Crépin S, 2010, EUR J CLIN PHARMACOL, V66, P547, DOI 10.1007/s00228 010 0822 5
   Deng X, 2009, TOXICOL APPL PHARM, V235, P97, DOI 10.1016/j.taap.2008.11.005
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   GALANOS C, 1979, ZBL BAKT INT J MED M, V243, P226
   Gibson FC, 2004, CIRCULATION, V109, P2801, DOI 10.1161/01.CIR.0000129769.17895.F0
   Hofmann SR, 2016, RHEUMATOL INT, V36, P769, DOI 10.1007/s00296 016 3466 7
   Johansson L, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1100 4
   Kawahara T, 2013, CIRCULATION, V127, P2327, DOI 10.1161/CIRCULATIONAHA.113.001534
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   Koshiyama H, 2000, J CLIN ENDOCR METAB, V85, P2793, DOI 10.1210/jc.85.8.2793
   Kurokawa K, 2012, J BIOL CHEM, V287, P13170, DOI 10.1074/jbc.M111.292235
   Li W, 2016, NEUROCHEM RES, V41, P844, DOI 10.1007/s11064 015 1761 4
   Li Y, 2011, J BIOL CHEM, V286, P31308, DOI 10.1074/jbc.M111.246124
   Marcuzzi A, 2011, APOPTOSIS, V16, P882, DOI 10.1007/s10495 011 0621 1
   Masuda T, 2009, INT IMMUNOPHARMACOL, V9, P1115, DOI 10.1016/j.intimp.2009.05.010
   Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200
   Mitra S, 2015, MICROBIOME, V3, DOI 10.1186/s40168 015 0100 y
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Nagata E, 2016, MOL ORAL MICROBIOL
   Nilsen NJ, 2015, J BIOL CHEM, V290, P3209, DOI 10.1074/jbc.M114.593426
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   Ogawa T, 2007, FRONT BIOSCI LANDMRK, V12, P3795, DOI 10.2741/2353
   Oizumi T, 2016, BIOL PHARM BULL, V39, P1549, DOI 10.1248/bpb.b16 00041
   Oizumi T, 2010, J ORAL MAXIL SURG, V68, P1043, DOI 10.1016/j.joms.2009.08.027
   Olmos JM, 1999, METHOD FIND EXP CLIN, V21, P519, DOI 10.1358/mf.1999.21.8.794832
   Park SY, 2013, BIOCHEM PHARMACOL, V86, P1320, DOI 10.1016/j.bcp.2013.08.017
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200
   Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097
   Shima K, 2016, BIOL PHARM BULL, V39, P770, DOI 10.1248/bpb.b15 00882
   Sugitharini V, 2016, CYTOKINE, V85, P191, DOI 10.1016/j.cyto.2016.06.024
   Suzuki Y, 2007, J ORTHOP SCI, V12, P568, DOI 10.1007/s00776 007 1180 8
   Tamai R, 2012, J DENT RES, V91, P709, DOI 10.1177/0022034512446486
   Tamai R, 2002, INFECT IMMUN, V70, P1272, DOI 10.1128/IAI.70.3.1272 1278.2002
   Tamai R, 2009, ANAEROBE, V15, P87, DOI 10.1016/j.anaerobe.2008.12.004
   Tamai R, 2011, MICROB PATHOGENESIS, V51, P250, DOI 10.1016/j.micpath.2011.06.009
   Tanaka Y, 2013, ARCH ORAL BIOL, V58, P628, DOI 10.1016/j.archoralbio.2012.11.010
   Tramullas M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155367
   Yamamoto K, 2006, RHEUMATOL INT, V26, P627, DOI 10.1007/s00296 005 0042 y
   Yin ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep27129
   Yokota T, 2016, GENE, V575, P369, DOI 10.1016/j.gene.2015.09.030
NR 46
TC 11
Z9 13
U1 0
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1734 1140
EI 2299 5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD AUG
PY 2017
VL 69
IS 4
BP 773
EP 778
DI 10.1016/j.pharep.2017.03.009
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FK7CE
UT WOS:000413661000025
PM 28587938
DA 2025 08 17
ER

PT J
AU Wu, YL
   Lin, CW
   Cheng, NC
   Yang, KC
   Yu, JS
AF Wu, Yen Lin
   Lin, Che Wei
   Cheng, Nai Chen
   Yang, Kai Chiang
   Yu, Jiashing
TI Modulation of keratin in adhesion, proliferation, adipogenic, and
   osteogenic differentiation of porcine adipose derived stem cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE keratin; adhesion; porcine adipose stem cell; differentiation
ID BUCCAL FAT PAD; STROMAL CELLS; TISSUE; PPAR GAMMA 2; MECHANISMS;
   EXPRESSION; ASSAY; RUNX2; GENE
AB Recently, keratin attracts tremendous interest because of its intrinsic ability to interact with different cells. It has the potential to serve as a controllable extracellular matrix protein that can be used to demonstrate cell mechanism and cell matrix interaction. However, there have been relatively few studies on the effects of keratin on stem cells. In the present work, we study the effects of human keratin on porcine adipose derived stem cells (pASCs) and a series of selective cell lines: 3T3 fibroblasts, Madin Darby canine kidney (MDCK) cells, and MG63 osteoblasts. Relative to un treated culture plate, our results showed that keratin coating substrates promote cell adhesion and proliferation to above cell lines. Keratin also improved pASCs adhesion, proliferation, and enhanced cell viability. Evaluation of genetic markers showed that adipogenic and osteogenic differentiations of pASCs can be successfully induced, thus demonstrating that keratin did not influence the stemness of pASCs. Furthermore, keratin improved adipogenic differentiations of pASCs in terms of up regulations in lipoprotein lipase, peroxisome proliferator activated receptor gamma, and CCAAT enhancer binding protein alpha. The osteogenic markers type I collagen, runt related transcription factor 2, and vitamin D receptor were also upregulated when pASCs cultured on keratin substrates. Therefore, keratin can serve as a biological derived material for surface modification and scaffold fabrication for biomedical purpose. The combination of keratin with stem cells may be a potential candidate for tissue repair in the field of regenerative medicine. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 180 192, 2017.
C1 [Wu, Yen Lin; Yu, Jiashing] Natl Taiwan Univ, Dept Chem Engn, Coll Engn, Taipei 10617, Taiwan.
   [Lin, Che Wei] Natl Taiwan Univ, Inst Biotechnol, Taipei 10617, Taiwan.
   [Cheng, Nai Chen] Natl Taiwan Univ Hosp, Dept Surg, Taipei 10031, Taiwan.
   [Yang, Kai Chiang] Taipei Med Univ, Coll Oral Med, Sch Dent Technol, Taipei 11031, Taiwan.
   [Yang, Kai Chiang] Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei 11031, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan
   University; National Taiwan University Hospital; Taipei Medical
   University; Taipei Medical University
RP Yu, JS (通讯作者)，Natl Taiwan Univ, Dept Chem Engn, Coll Engn, Taipei 10617, Taiwan.; Yang, KC (通讯作者)，Taipei Med Univ, Coll Oral Med, Sch Dent Technol, Taipei 11031, Taiwan.; Yang, KC (通讯作者)，Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei 11031, Taiwan.
EM jiayu@ntu.edu.tw
RI Wu, Yen Lin/ABH 4771 2020; Cheng, Naichen/H 7596 2013; Lin,
   Che Wei/U 3528 2017
OI Cheng, Naichen/0000 0003 4071 5628; 
FU National Science Council of Taiwan [MOST 102 2221 E 002 039, NSC
   101 2815 C 007 026 E]
FX Contract grant sponsor: the National Science Council of Taiwan; contract
   grant numbers: MOST 102 2221 E 002 039 and NSC 101 2815 C 007 026 E (to
   Y. L. Wu).
CR Aluigi A, 2007, INT J BIOL MACROMOL, V41, P266, DOI 10.1016/j.ijbiomac.2007.03.002
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Arrigoni E, 2009, CELL TISSUE RES, V338, P401, DOI 10.1007/s00441 009 0883 x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Cui L, 2007, BIOMATERIALS, V28, P5477, DOI 10.1016/j.biomaterials.2007.08.042
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003 9861(59)90090 6
   Farré Guasch E, 2010, TISSUE ENG PART C ME, V16, P1083, DOI [10.1089/ten.tec.2009.0487, 10.1089/ten.TEC.2009.0487]
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Hartrianti P, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/752424
   Hattori H, 2006, J BIOMED MATER RES B, V76B, P230, DOI 10.1002/jbm.b.30357
   Heydarkhan Hagvall S, 2008, CELLS TISSUES ORGANS, V187, P263, DOI 10.1159/000113407
   Hicok KC, 2004, TISSUE ENG, V10, P371, DOI 10.1089/107632704323061735
   Hill P, 2010, BIOMATERIALS, V31, P585, DOI 10.1016/j.biomaterials.2009.09.076
   Horst Sikorska W, 2007, J BONE MINER METAB, V25, P310, DOI 10.1007/s00774 007 0769 5
   Ikkai F, 2002, BIOMACROMOLECULES, V3, P482, DOI 10.1021/bm010160i
   Izawa I, 2006, CANCER SCI, V97, P167, DOI 10.1111/j.1349 7006.2006.00161.x
   Kim D, 2010, CELL TISSUE RES, V341, P359, DOI 10.1007/s00441 010 1015 3
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Li XM, 2012, BIOMATERIALS, V33, P4818, DOI 10.1016/j.biomaterials.2012.03.045
   Madonna R, 2009, ARTERIOSCL THROM VAS, V29, P1723, DOI 10.1161/ATVBAHA.109.187179
   Magin TM, 2007, EXP CELL RES, V313, P2021, DOI 10.1016/j.yexcr.2007.03.005
   Niada S, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt359
   Noort WA, 2012, J CELL MOL MED, V16, P1827, DOI 10.1111/j.1582 4934.2011.01455.x
   Ohlstein J, 2014, J MOL ENDOCRINOL, V20, P14
   Pace LA, 2013, BIOMATERIALS, V34, P5907, DOI 10.1016/j.biomaterials.2013.04.024
   Peplow PV, 2004, J MATER SCI MATER M, V15, P1217, DOI 10.1007/s10856 004 5803 8
   Qu CQ, 2007, IN VITRO CELL DEV AN, V43, P95, DOI 10.1007/s11626 006 9008 y
   Reichl S, 2009, BIOMATERIALS, V30, P6854, DOI 10.1016/j.biomaterials.2009.08.051
   Richter JR, 2011, BIOMATERIALS, V32, P7555, DOI 10.1016/j.biomaterials.2011.06.061
   Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216 002 1347 2
   Rubina K, 2009, TISSUE ENG PT A, V15, P2039, DOI 10.1089/ten.tea.2008.0359
   Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200
   Schäffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006 0589
   STEINERT PM, 1976, BIOCHEM BIOPH RES CO, V70, P221, DOI 10.1016/0006 291X(76)91131 1
   SYKES B, 1986, LANCET, V2, P69
   Tachibana A, 2002, J BIOTECHNOL, V93, P165, DOI 10.1016/S0168 1656(01)00395 9
   Taraballi F, 2012, ADV HEALTHC MATER, V1, P513, DOI 10.1002/adhm.201200043
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   Tsai WB, 2006, J MATER SCI MATER M, V17, P337, DOI 10.1007/s10856 006 8234 x
   ULUDAG H, 1990, BIOMATERIALS, V11, P708, DOI 10.1016/0142 9612(90)90032 L
   Verma V, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/2/025007
   Weber GF, 2012, DEV CELL, V22, P104, DOI 10.1016/j.devcel.2011.10.013
   Williams KJ, 2008, CELLS TISSUES ORGANS, V188, P251, DOI 10.1159/000121431
   Wu YL, 2017, J BIOMED MATER RES B, V105, P180, DOI 10.1002/jbm.b.33551
   Yamauchi K, 1998, J BIOMAT SCI POLYM E, V9, P259, DOI 10.1163/156856298X00640
   Yamauchi K, 1996, J BIOMED MATER RES, V31, P439, DOI 10.1002/(SICI)1097 4636(199608)31:4<439::AID JBM1>3.0.CO;2 M
   Yarak S, 2010, AN BRAS DERMATOL, V85, P647, DOI 10.1590/S0365 05962010000500008
   Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102
   Zhu YX, 2008, CELL BIOCHEM FUNCT, V26, P664, DOI 10.1002/cbf.1488
   Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 53
TC 24
Z9 25
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JAN
PY 2017
VL 105
IS 1
BP 180
EP 192
DI 10.1002/jbm.b.33551
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EH5HT
UT WOS:000391804200020
PM 26454254
DA 2025 08 17
ER

PT J
AU Moshfeghian, A
   Tillman, J
   Madihally, SV
AF Moshfeghian, Aliakbar
   Tillman, Jeremy
   Madihally, Sundararajan V.
TI Characterization of emulsified chitosan PLGA matrices formed using
   controlled rate freezing and lyophilization technique
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE scaffolds; matrices; tissue engineering; drug delivery; controlled rate
   freezing; chitosan; PLGA
ID IN VIVO DEGRADATION; EXTRACELLULAR MATRIX; GROWTH FACTOR; ACID);
   SCAFFOLDS; CELLS; VITRO; EXPRESSION; PROLIFERATION; OSTEOBLASTS
AB This study evaluated the formation of chitosan 50:50 poly lactic co glycolic acid (PLGA) blend matrices using controlled rate freezing and lyophilization technique (CRFLT). An emulsion system was used in the presence of 1,2 dimyristoyl sn glycero 3 phosphocholine (DMPC), a cellular component, as a stabilizer. Blended scaffolds showed an open pore morphology and homogenous interdispersion of PLGA and chitosan. Forming emulsions after dissolving PLGA in chloroform, benzene, or methylene chloride indicated better emulsion stability with benzene and chloroform. Scaffolds formed by freezing at  20,  78, and  196 degrees C from these emulsions showed significant influence of the solvent and freezing temperature on the microarchitecture of the scaffold. By controlling the concentration of chitosan, scaffolds with greater than 90% porosity were attained. Since the two polymers degrade by different mechanisms, formed scaffolds were analyzed for degradation characteristics for 4 weeks in presence of 10 mg/L lysozyme. These results showed no significant difference in the weight loss and dimension changes, as all scaffolds showed significant (a) weight loss and (b) nearly 60% reduction in volume. Further, pH of the incubation media decreased in all the samples. When cellular activity of green fluorescence protein transfected smooth muscle cells was analyzed, no apparent cytotoxicity was observed. However, the cell spreading area decreased. In summary, these results show promising potential in tissue engineering and drug delivery applications. (c) 2006 Wiley Periodicals, Inc.
C1 Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA.
C3 Oklahoma State University System; Oklahoma State University   Stillwater
RP Madihally, SV (通讯作者)，Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA.
EM sundar.madihally@okstate.edu
RI Madihally, Sundararajan/D 9285 2012
OI Madihally, Sundararajan/0000 0001 7498 5760
CR Agrawal CM, 1997, J BIOMED MATER RES, V38, P105, DOI 10.1002/(SICI)1097 4636(199722)38:2<105::AID JBM4>3.0.CO;2 U
   Cai KY, 2002, J BIOMED MATER RES, V60, P398, DOI 10.1002/jbm.10008
   CHANDY T, 1990, BIOMATER ARTIF CELL, V18, P1, DOI 10.3109/10731199009117286
   Chung TW, 2002, BIOMATERIALS, V23, P4803, DOI 10.1016/S0142 9612(02)00231 4
   DAVIES RC, 1969, BIOCHIM BIOPHYS ACTA, V178, P294, DOI 10.1016/0005 2744(69)90397 0
   HENRY J.B., 1991, CLIN DIAGNOSIS MANAG
   Huang Y, 2005, BIOMATERIALS, V26, P7616, DOI 10.1016/j.biomaterials.2005.05.036
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Kim SE, 2003, J CONTROL RELEASE, V91, P365, DOI 10.1016/S0168 3659(03)00274 8
   Lahiji A, 2000, J BIOMED MATER RES, V51, P586
   Lee CR, 2001, BIOMATERIALS, V22, P3145, DOI 10.1016/S0142 9612(01)00067 9
   Liley P. E., 1984, PERRYS CHEM ENG HDB, P3
   Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006 3495(00)76279 5
   Lu L, 2000, BIOMATERIALS, V21, P1837, DOI 10.1016/S0142 9612(00)00047 8
   Lu L, 1999, J BIOMED MATER RES, V46, P236, DOI 10.1002/(SICI)1097 4636(199908)46:2<236::AID JBM13>3.0.CO;2 F
   Madihally SV, 1999, STEM CELLS, V17, P295, DOI 10.1002/stem.170295
   Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142 9612(99)00011 3
   MASSIA SP, 1990, ANN NY ACAD SCI, V589, P261, DOI 10.1111/j.1749 6632.1990.tb24251.x
   MIKOS AG, 1994, POLYMER, V35, P1068, DOI 10.1016/0032 3861(94)90953 9
   Mizuno K, 2003, J BIOMED MATER RES A, V64A, P177, DOI 10.1002/jbm.a.10396
   Mooney DJ, 1996, BIOMATERIALS, V17, P1417, DOI 10.1016/0142 9612(96)87284 X
   Muzzarelli R., 1986, CHITIN NATURE TECHNO
   Nordtveit RJ, 1996, CARBOHYD POLYM, V29, P163, DOI 10.1016/0144 8617(96)00003 3
   O'Brien FJ, 2004, BIOMATERIALS, V25, P1077, DOI 10.1016/S0142 9612(03)00630 6
   PANGBURN SH, 1982, BIOMATERIALS, V3, P105, DOI 10.1016/0142 9612(82)90043 6
   Sarasam A, 2005, BIOMATERIALS, V26, P5500, DOI 10.1016/j.biomaterials.2005.01.071
   SHIGEMASA Y, 1994, INT J BIOL MACROMOL, V16, P43, DOI 10.1016/0141 8130(94)90010 8
   Sieminski AL, 2004, EXP CELL RES, V297, P574, DOI 10.1016/j.yexcr.2004.03.035
   Singla A, 2002, J BIOMED MATER RES, V60, P368, DOI 10.1002/jbm.10077
   Strand SP, 2005, BIOMACROMOLECULES, V6, P3357, DOI 10.1021/bm0503726
   Tomihata K, 1997, BIOMATERIALS, V18, P567, DOI 10.1016/S0142 9612(96)00167 6
   VandeVord PJ, 2002, J BIOMED MATER RES, V59, P585, DOI 10.1002/jbm.1270
   Wang YC, 2004, FASEB J, V18, P525, DOI 10.1096/fj.03 0490fje
   Wang YC, 2003, BIOMATERIALS, V24, P1047, DOI 10.1016/S0142 9612(02)00434 9
   YANNAS IV, 1989, P NATL ACAD SCI USA, V86, P933, DOI 10.1073/pnas.86.3.933
   Yoon JJ, 2001, J BIOMED MATER RES, V55, P401, DOI 10.1002/1097 4636(20010605)55:3<401::AID JBM1029>3.0.CO;2 H
   Zaleskas JM, 2001, EXP CELL RES, V270, P21, DOI 10.1006/excr.2001.5325
   Zhang YY, 2005, BJU INT, V96, P1120, DOI 10.1111/j.1464 410X.2005.05741.x
   Zhu HG, 2002, J BIOMED MATER RES, V62, P532, DOI 10.1002/jbm.10313
NR 39
TC 23
Z9 35
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2006
VL 79A
IS 2
BP 418
EP 430
DI 10.1002/jbm.a.30849
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 092YB
UT WOS:000241132500021
PM 16906526
OA Bronze
DA 2025 08 17
ER

PT J
AU Okajcekova, T
   Strnadel, J
   Pokusa, M
   Zahumenska, R
   Janickova, M
   Halasova, E
   Skovierova, H
AF Okajcekova, Terezia
   Strnadel, Jan
   Pokusa, Michal
   Zahumenska, Romana
   Janickova, Maria
   Halasova, Erika
   Skovierova, Henrieta
TI A Comparative In Vitro Analysis of the Osteogenic Potential of Human
   Dental Pulp Stem Cells Using Various Differentiation Conditions
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE dental pulp stem cells; differentiation; osteogenesis; regenerative
   medicine
ID OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; MARKERS; MECHANISMS
AB Dental pulp stem cells (DPSCs) have excellent proliferative properties, mineralization potential and can be easily obtained from third molar teeth. Recently, many studies have focused on isolation and differentiation of DPSCs. In our study, we focused on biological properties of non differentiated DPSCs in comparison with osteogenic differentiated cells from DPSCs. We analyzed morphology as well as mineralization potential using three varied osteogenic differentiation media. After fifteen days of differentiation, calcium deposit production was observed in all three osteogenic differentiation media. However, only one osteogenic medium, without animal serum supplement, showed rapid and strong calcification OsteoMAX XF (TM) Differentiation Medium. Therefore, we examined specific surface markers, and gene and protein expression of cells differentiated in this osteogenic medium, and compared them to non differentiated DPSCs. We proved a decrease in expression of CD9 and CD90 mesenchymal stem cell surface markers, as well as downregulation in the expression of pluripotency genes (NANOG and OCT 4) and increased levels of expression in osteogenic genes (ALP, BSP, OCN and RUNX2). Moreover, osteogenic proteins, such as BSP and OCN, were only produced in differentiated cells. Our findings confirm that carefully selected differentiation conditions for stem cells are essential for their translation into future clinical applications.
C1 [Okajcekova, Terezia; Zahumenska, Romana] Comenius Univ, Jessenius Fac Med Martin, Dept Med Biochem, Martin 03601, Slovakia.
   [Okajcekova, Terezia; Strnadel, Jan; Pokusa, Michal; Zahumenska, Romana; Halasova, Erika; Skovierova, Henrieta] Comenius Univ, Jessenius Fac Med Martin, Biomed Ctr Martin, Martin 03601, Slovakia.
   [Janickova, Maria] Univ Hosp Martin, Dept Stomatol & Maxillofacial Surg, Martin 0601, Slovakia.
   [Halasova, Erika] Comenius Univ, Jessenius Fac Med Martin, Dept Med Biol, Martin 03601, Slovakia.
C3 Comenius University Bratislava; Comenius University Bratislava; Comenius
   University Bratislava
RP Halasova, E (通讯作者)，Comenius Univ, Jessenius Fac Med Martin, Biomed Ctr Martin, Martin 03601, Slovakia.; Halasova, E (通讯作者)，Comenius Univ, Jessenius Fac Med Martin, Dept Med Biol, Martin 03601, Slovakia.
EM okajcekova1@uniba.sk; jan.strnadel@uniba.sk; michal.pokusa@uniba.sk;
   romana.zahumenska@gmail.com; maria.janickova@uniba.sk;
   erika.halasova@uniba.sk; henrieta.skovierova@uniba.sk
RI Pokusa, Michal/X 8193 2018; Škovierová, Henrieta/Y 1751 2018; Halašová,
   Erika/X 8250 2018; Janickova, Maria/X 6194 2018; Strnadel,
   Jan/Y 5172 2018
OI Janickova, Maria/0000 0003 1819 7780; 
FU Center of Excellence for Research in Personalized Therapy (CEVYPET);
   ERDF [ITMS: 26220120053];  [VEGA 1/0178/17];  [APVV 15 0217]
FX This work was supported by grants VEGA 1/0178/17, APVV 15 0217 and the
   Center of Excellence for Research in Personalized Therapy (CEVYPET)",
   ITMS: 26220120053 supported by the Operational Program Research and
   Innovation funded by the ERDF.
CR Ajlan SA, 2015, BMC ORAL HEALTH, V15, DOI 10.1186/s12903 015 0113 8
   Anitua E, 2018, CYTOTHERAPY, V20, P479, DOI 10.1016/j.jcyt.2017.12.011
   Castrén E, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0162 6
   Chieruzzi M, 2016, NANOMATERIALS BASEL, V6, DOI 10.3390/nano6070134
   Cimino M, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6597815
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Ghaneialvar H, 2018, INDIAN J CLIN BIOCHE, V33, P46, DOI 10.1007/s12291 017 0641 x
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Iwamoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177557
   Jensen J, 2016, SICOT J, V2, DOI 10.1051/sicotj/2016004
   Karamzadeh R, 2012, JOVE J VIS EXP, DOI 10.3791/4372
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kunimatsu R, 2018, BIOCHEM BIOPH RES CO, V501, P193, DOI 10.1016/j.bbrc.2018.04.213
   Liang Y, 2009, CRIT REV EUKAR GENE, V19, P289, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.30
   Lin CS, 2013, HISTOL HISTOPATHOL, V28, P1109, DOI 10.14670/HH 28.1109
   Maleki Masoud, 2014, International Journal of Stem Cells, V7, P118, DOI 10.15283/ijsc.2014.7.2.118
   Mizuno M, 2001, J BIOCHEM TOKYO, V129, P133, DOI 10.1093/oxfordjournals.jbchem.a002824
   Moraes DA, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0359 3
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Noda S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41741 w
   Oikonomopoulos A, 2015, SCI REP UK, V5, DOI 10.1038/srep16570
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Potdar PD, 2015, WORLD J STEM CELLS, V7, P839, DOI 10.4252/wjsc.v7.i5.839
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Suchanek Jakub, 2007, Acta Medica (Hradec Kralove), V50, P195
   Tucek Lubos, 2017, Acta Medica (Hradec Kralove), V60, P12, DOI 10.14712/18059694.2017.43
   Verma Kavita, 2014, Dent Res J (Isfahan), V11, P302
   Yamada Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051132
   Yasui T, 2017, INFLAMM REGEN, V37, DOI 10.1186/s41232 017 0039 4
NR 30
TC 21
Z9 21
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2020
VL 21
IS 7
AR 2280
DI 10.3390/ijms21072280
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LR3DN
UT WOS:000535574200022
PM 32224849
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zeng, YH
   Yang, YY
   Chen, LY
   Yin, DR
   Zhang, HH
   Tashiro, Y
   Inui, S
   Kusumoto, T
   Nishizaki, H
   Sekino, T
   Okazaki, J
   Komasa, S
AF Zeng, Yuhao
   Yang, Yuanyuan
   Chen, Luyuan
   Yin, Derong
   Zhang, Honghao
   Tashiro, Yuichiro
   Inui, Shihoko
   Kusumoto, Tetsuji
   Nishizaki, Hiroshi
   Sekino, Tohru
   Okazaki, Joji
   Komasa, Satoshi
TI Optimized Surface Characteristics and Enhanced in Vivo Osseointegration
   of Alkali Treated Titanium with Nanonetwork Structures
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE implant; alkali treatment; in vivo study; nanonetwork; osseointegration
ID PROTEIN ADSORPTION; OSTEOBLAST ADHESION; DENTAL IMPLANTS;
   HYDROXYAPATITE; NANOPARTICLES; ATTACHMENT; MEDICINE; COATINGS; GROWTH;
   ACID
AB Alkali treated titanium (Ti) with a porous, homogeneous, and uniform nanonetwork structure (TNS) that enables establishment of a more rapid and firmer osteointegration than titanium has recently been reported. However, the mechanisms underlying the enhanced osteogenic activity on TNS remains to be elucidated. This study aimed to evaluate the surface physicochemical properties of Ti and TNS, and investigate osteoinduction and osteointegration in vivo. Surface characteristics were evaluated using scanning electron microscopy (SEM), scanning probe microscopy (SPM), and X ray photoelectron spectrometry (XPS), and the surface electrostatic force of TNS was determined using solid zeta potential. This study also evaluated the adsorption of bovine serum albumin (BSA) and human plasma fibronectin (HFN) on Ti and TNS surfaces using quartz crystal microbalance (QCM) sensors, and apatite formation on Ti and TNS surfaces was examined using a simulated body fluid (SBF) test. Compared with Ti, the newly developed TNS enhanced BSA and HFN absorbance capacity and promoted apatite formation. Furthermore, TNS held less negative charge than Ti. Notably, sequential fluorescence labeling and microcomputed tomography assessment indicated that TNS screws implanted into rat femurs exhibited remarkably enhanced osteointegration compared with Ti screws. These results indicate that alkali treated titanium implant with a nanonetwork structure has considerable potential for future clinical applications in dentistry and orthopedics.
C1 [Zeng, Yuhao; Yang, Yuanyuan; Chen, Luyuan; Yin, Derong; Zhang, Honghao; Tashiro, Yuichiro; Inui, Shihoko; Okazaki, Joji; Komasa, Satoshi] Osaka Dent Univ, Dept Removable Prosthodont & Occlus, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka 5731121, Japan.
   [Kusumoto, Tetsuji; Nishizaki, Hiroshi] Osaka Dent Univ, Fac Hlth Sci, 1 4 4 Makino Honmachi, Hirakata, Osaka 5731144, Japan.
   [Sekino, Tohru] Osaka Univ, Inst Sci & Ind Res, Suita, Osaka 5650871, Japan.
C3 University of Osaka
RP Chen, LY (通讯作者)，Osaka Dent Univ, Dept Removable Prosthodont & Occlus, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka 5731121, Japan.
EM zeng yuhao@hotmail.com; yangyuanyuan0801@outlook.com;
   chen luyuan900115@foxmail.com; y.d.r.nld@hotmail.com;
   joecheung_asuka@hotmail.com; tashiro@cc.osaka dent.ac.jp;
   clair.de.lune.peridota@gmail.com; joji@cc.osaka dent.ac.jp;
   komasa s@cc.osaka dent.ac.jp; sekino@sanken.osaka u.ac.jp;
   joji@cc.osaka dent.ac.jp; komasa s@cc.osaka dent.ac.jp
RI 张, 洪浩/KYQ 4668 2024; Sekino, Tohru/AAP 3330 2021; yin,
   derong/HGB 0868 2022
OI Sekino, Tohru/0000 0002 6605 9166; 
FU Japan Society for Promotion of Science [18K09712, 18K09713]; Research
   Promotion Grant of Osaka Dental University [18 08 2018/04/25, 18 09
   2018/04/25]; Grants in Aid for Scientific Research [18K09713, 18K09712]
   Funding Source: KAKEN
FX We thank Tohru Sekino from Osaka University for preparing the TNS and
   providing helpful suggestions. The authors also thank Yasuyuki Kobayashi
   from Osaka Research Institute of Industrial Science and Technology
   Morinomiya Center for helpful suggestions. We are also grateful to the
   members of the Department of Removable Prosthodontics and Occlusion and
   the Department of Periodontology for their advice and assistance. This
   work was supported by the grants from Japan Society for Promotion of
   Science (18K09712, 18K09713), a Research Promotion Grant of Osaka Dental
   University (18 08 2018/04/25, 18 09 2018/04/25).
CR Albrektsson T, 1993, Int J Prosthodont, V6, P95
   Arias JL, 2003, BIOMATERIALS, V24, P3403, DOI 10.1016/S0142 9612(03)00202 3
   Balasundaram G, 2006, BIOMATERIALS, V27, P2798, DOI 10.1016/j.biomaterials.2005.12.008
   Bianchi M, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3579283
   Buser D, 2004, J DENT RES, V83, P529, DOI 10.1177/154405910408300704
   Cai KY, 2006, COLLOID SURFACE B, V49, P136, DOI 10.1016/j.colsurfb.2006.02.016
   Coelho Paulo G., 2005, J. Appl. Oral Sci., V13, P87
   Doundoulakis JH, 2003, J AM DENT ASSOC, V134, P1455, DOI 10.14219/jada.archive.2003.0073
   Engel E, 2008, TRENDS BIOTECHNOL, V26, P39, DOI 10.1016/j.tibtech.2007.10.005
   Gambardella A, 2016, MAT SCI ENG C MATER, V62, P444, DOI 10.1016/j.msec.2016.01.071
   Geetha M, 2009, PROG MATER SCI, V54, P397, DOI 10.1016/j.pmatsci.2008.06.004
   Hata K, 2007, J BIOMED MATER RES A, V81A, P446, DOI 10.1002/jbm.a.31086
   Kasuga T, 1998, LANGMUIR, V14, P3160, DOI 10.1021/la9713816
   Kasuga T, 1999, ADV MATER, V11, P1307, DOI 10.1002/(SICI)1521 4095(199910)11:15<1307::AID ADMA1307>3.0.CO;2 H
   Kim HM, 1996, J BIOMED MATER RES, V32, P409, DOI 10.1002/(SICI)1097 4636(199611)32:3<409::AID JBM14>3.0.CO;2 B
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   Komasa S, 2012, J PROSTHODONT RES, V56, P170, DOI 10.1016/j.jpor.2011.12.002
   Kusumoto T, 2017, J HARD TISSUE BIOL, V26, P355, DOI 10.2485/jhtb.26.355
   Kweon H, 2014, J ORAL MAXIL SURG, V72, P1928, DOI 10.1016/j.joms.2014.06.455
   Lang NP, 2011, CLIN ORAL IMPLAN RES, V22, P349, DOI 10.1111/j.1600 0501.2011.02172.x
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Lee SH, 2006, J BIOMATER APPL, V20, P195, DOI 10.1177/0885328206050518
   McFarland CD, 1998, J BIOMAT SCI POLYM E, V9, P1227, DOI 10.1163/156856298X00749
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Na Young, 2009, J Adv Prosthodont, V1, P91, DOI 10.4047/jap.2009.1.2.91
   Nanci A, 1998, J BIOMED MATER RES, V40, P324
   Nishio K, 2000, J BIOMED MATER RES, V52, P652, DOI 10.1002/1097 4636(20001215)52:4<652::AID JBM9>3.0.CO;2 W
   Patil S, 2007, BIOMATERIALS, V28, P4600, DOI 10.1016/j.biomaterials.2007.07.029
   Pattanayak DK, 2011, J MATER SCI MATER M, V22, P1803, DOI 10.1007/s10856 011 4372 x
   Pilliar RM, 2005, ORTHOP CLIN N AM, V36, P113, DOI 10.1016/j.ocl.2004.08.001
   Puleo DA, 1999, BIOMATERIALS, V20, P2311, DOI 10.1016/S0142 9612(99)00160 X
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   Rupp F, 2004, BIOMATERIALS, V25, P1429, DOI 10.1016/j.biomaterials.2003.08.015
   Scotchford CA, 2002, J BIOMED MATER RES, V59, P84, DOI 10.1002/jbm.1220
   Simonis P, 2010, CLIN ORAL IMPLAN RES, V21, P772, DOI 10.1111/j.1600 0501.2010.01912.x
   Sinha RK, 1996, BONE, V18, P451, DOI 10.1016/8756 3282(96)00044 0
   Svanborg LM, 2010, J BIOMED MATER RES B, V92B, P462, DOI 10.1002/jbm.b.31538
   Takeuchi M, 2005, J PHYS CHEM B, V109, P15422, DOI 10.1021/jp058075i
   Terada C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051274
   Thakral GK, 2014, J CLIN DIAGN RES, V8, pZE7, DOI 10.7860/JCDR/2014/8764.4355
   van Steenberghe D, 2002, CLIN ORAL IMPLAN RES, V13, P617, DOI 10.1034/j.1600 0501.2002.130607.x
   Vandrovcova M, 2012, J BIOMED MATER RES A, V100A, P1016, DOI 10.1002/jbm.a.34047
   WANG X, 2003, J BIOMED MATER RES, V54, P172, DOI DOI 10.1002/1097 4636(200102)54:2
   Wang XX, 2002, BIOMATERIALS, V23, P1353, DOI 10.1016/S0142 9612(01)00254 X
   Webster TJ, 2001, TISSUE ENG, V7, P291, DOI 10.1089/10763270152044152
   Xing HL, 2014, INT J NANOMED, V9, P1741, DOI 10.2147/IJN.S58502
   Yuan ZY, 2002, CHEM COMMUN, P1202, DOI 10.1039/b202489f
   Zhang HH, 2017, INT J NANOMED, V12, P4633, DOI 10.2147/IJN.S136273
   Zubkov T, 2005, J PHYS CHEM B, V109, P15454, DOI 10.1021/jp058101c
NR 50
TC 19
Z9 20
U1 1
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR 1
PY 2019
VL 20
IS 5
AR 1127
DI 10.3390/ijms20051127
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HQ6QE
UT WOS:000462542300126
PM 30841636
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Tao, SY
   Shen, ZQ
   Chen, J
   Shan, Z
   Huang, B
   Zhang, XY
   Zheng, L
   Liu, JH
   You, T
   Zhao, FD
   Hu, JM
AF Tao, Siyue
   Shen, Zhiqiang
   Chen, Jian
   Shan, Zhi
   Huang, Bao
   Zhang, Xuyang
   Zheng, Lin
   Liu, Junhui
   You, Tao
   Zhao, Fengdong
   Hu, Jinming
TI Red Light Mediated Photoredox Catalysis Triggers Nitric Oxide Release
   for Treatment of Cutibacterium Acne Induced Intervertebral
   Disc Degeneration
SO ACS NANO
LA English
DT Article; Early Access
DE nitric oxide; photoredox catalysis; Cutibacterium acnes; intervertebral
   disc degeneration; anti infection; anti inflammation;
   anti osteoclastogenesis
ID PROPIONIBACTERIUM ACNES; MODIC CHANGES; DELIVERY; THERAPY; INFLAMMATION;
   OSTEOPOROSIS; RESISTANCE; INFECTION; POLYMERS; BACTERIA
AB Intervertebral disc degeneration (IVDD) has been known as a highly prevalent and disabling disease, which is one of the main causes of low back pain and disability. Unfortunately, there is no effective cure to treat this formidable disease, and surgical interventions are typically applied. Herein, we report that the local administration of nitric oxide (NO) releasing micellar nanoparticles can efficiently treat IVDD associated with Modic changes in a rat model established by infection with Cutibacterium acnes (C. acnes). By covalent incorporation of palladium(II) meso tetraphenyltetrabenzoporphyrin photocatalyst and coumarin based NO donors into the core of micellar nanoparticles, we demonstrate that the activation of the UV absorbing coumarin based NO donors can be achieved under red light irradiation via photoredox catalysis, although it remains a great challenge to implement photoredox catalysis reactions in biological conditions due to the complex microenvironments. Notably, the local delivery of NO can not only efficiently eradicate C. acnes pathogens but also inhibit the inflammatory response and osteoclast differentiation in the intervertebral disc tissues, exerting antibacterial, anti inflammatory, and antiosteoclastogenesis effects. This work provides a feasible means to efficiently treat IVDD by the local administration of NO signaling molecules without resorting to a surgical approach.
C1 [Tao, Siyue; Chen, Jian; Shan, Zhi; Huang, Bao; Zhang, Xuyang; Zheng, Lin; Liu, Junhui; Zhao, Fengdong] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthoped Surg, Sch Med, Hangzhou 310016, Peoples R China.
   [Shen, Zhiqiang; Hu, Jinming] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Pharm, Hefei 230026, Anhui, Peoples R China.
   [Shen, Zhiqiang; Hu, Jinming] Univ Sci & Technol China, CAS Key Lab Soft Matter Chem, Dept Polymer Sci & Engn, Sch Chem & Mat Sci, Hefei 230026, Anhui, Peoples R China.
   [You, Tao] Univ Sci & Technol China, Dept Orthoped, Affiliated Hosp USTC 1, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.
C3 Zhejiang University; Chinese Academy of Sciences; University of Science
   & Technology of China, CAS; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS
RP Zhao, FD (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthoped Surg, Sch Med, Hangzhou 310016, Peoples R China.; Hu, JM (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Pharm, Hefei 230026, Anhui, Peoples R China.; Hu, JM (通讯作者)，Univ Sci & Technol China, CAS Key Lab Soft Matter Chem, Dept Polymer Sci & Engn, Sch Chem & Mat Sci, Hefei 230026, Anhui, Peoples R China.; You, T (通讯作者)，Univ Sci & Technol China, Dept Orthoped, Affiliated Hosp USTC 1, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.
EM youtao@ustc.edu.cn; zhaofengdong@zju.edu.cn; jmhu@ustc.edu.cn
RI Hu, Jinming/F 2137 2011
OI Zhao, Fengdong/0000 0002 2945 8707
FU National Key R&D Program of China [2020YFA0710700]; National Natural
   Scientific Foundation of China (NNSFC) [52273155, 52073270, 82072466];
   Joint Funds from Hefei National Synchrotron Radiation Laboratory
   [KY2060000197]; Collaborative Innovation Program of Hefei Science
   Center, CAS [2022HSC CIP012]; Anhui Province Natural Science Foundation
   [2008085MH246]; Key Projects of Research and Development Program of
   Anhui Province [201904a07020107]
FX We gratefully acknowledge the financial support of the National Key R &
   D Program of China (2020YFA0710700) ,the National Natural Scientific
   Foundation of China (NNSFC) Projects (52273155, 52073270, and 82072466)
   , the Joint Funds from Hefei National Synchrotron Radiation Laboratory
   (KY2060000197) and Collaborative Innovation Program of Hefei Science
   Center, CAS (2022HSC CIP012) , the Anhui Province Natural Science
   Foundation (2008085MH246) , and the Key Projects of Research and
   Development Program of Anhui Province (201904a07020107) .
CR Albert HB, 2013, EUR SPINE J, V22, P690, DOI 10.1007/s00586 013 2674 z
   Balagué F, 2012, LANCET, V379, P482, DOI 10.1016/S0140 6736(11)60610 7
   Bhunia BK, 2018, P NATL ACAD SCI USA, V115, P477, DOI 10.1073/pnas.1715912115
   Buchbinder R, 2018, LANCET, V391, P2384, DOI 10.1016/S0140 6736(18)30488 4
   Carpenter AW, 2012, CHEM SOC REV, V41, P3742, DOI 10.1039/c2cs15273h
   Chen GY, 2014, CHEM REV, V114, P5161, DOI 10.1021/cr400425h
   Chen Z, 2016, INT ORTHOP, V40, P1291, DOI 10.1007/s00264 016 3115 5
   Cheng L, 2017, INT ENDOD J, V50, P15, DOI 10.1111/iej.12587
   Dudli S, 2018, EUR SPINE J, V27, P1013, DOI 10.1007/s00586 017 5291 4
   Dudli S, 2016, EUR SPINE J, V25, P3723, DOI 10.1007/s00586 016 4459 7
   Fan J, 2016, ACS APPL MATER INTER, V8, P13804, DOI 10.1021/acsami.6b03737
   Fan WP, 2018, ANGEW CHEM INT EDIT, V57, P8383, DOI 10.1002/anie.201800594
   Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140 6736(18)30489 6
   Hickman TT, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.841831
   Hu DF, 2020, ACS NANO, V14, P347, DOI 10.1021/acsnano.9b05493
   Ieda N, 2020, ACS CHEM BIOL, V15, P2958, DOI 10.1021/acschembio.0c00601
   Ieda N, 2014, J AM CHEM SOC, V136, P7085, DOI 10.1021/ja5020053
   Jackson AR, 2018, J BIOMECH, V76, P259, DOI 10.1016/j.jbiomech.2018.06.008
   Jiang DW, 2020, CHEM SCI, V11, P8785, DOI 10.1039/c9sc06072c
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kim J, 2017, J CONTROL RELEASE, V263, P223, DOI 10.1016/j.jconrel.2016.12.026
   Kodela R, 2012, ACS MED CHEM LETT, V3, P257, DOI 10.1021/ml300002m
   Kwon WK, 2017, NEUROSURGERY, V81, P867, DOI 10.1093/neuros/nyx149
   Liu SX, 2022, ADV THER GERMANY, V5, DOI 10.1002/adtp.202100227
   Liu Y, 2021, BIOACT MATER, V6, P146, DOI 10.1016/j.bioactmat.2020.07.008
   Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140 6736(16)30970 9
   Nguyen TK, 2016, CHEM SCI, V7, P1016, DOI 10.1039/c5sc02769a
   Nichols SP, 2012, ADV DRUG DELIVER REV, V64, P1177, DOI 10.1016/j.addr.2012.03.002
   Oh Y, 2020, BIOMACROMOLECULES, V21, P4972, DOI 10.1021/acs.biomac.0c01176
   Oliver S, 2021, BIOMATER SCI UK, V9, P391, DOI 10.1039/d0bm01197e
   Parisi C, 2021, CHEM SCI, V12, DOI 10.1039/d0sc06970a
   Parker SL, 2015, CLIN ORTHOP RELAT R, V473, P1988, DOI 10.1007/s11999 015 4193 1
   Perry A, 2011, EXPERT REV ANTI INFE, V9, P1149, DOI [10.1586/ERI.11.137, 10.1586/eri.11.137]
   Qin M, 2015, J INVEST DERMATOL, V135, P2723, DOI 10.1038/jid.2015.277
   Radcliff KE, 2013, SPINE J, V13, P1339, DOI 10.1016/j.spinee.2013.03.020
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rao PJ, 2020, SPINE J, V20, P1544, DOI 10.1016/j.spinee.2020.03.013
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rieger J, 2008, MACROMOLECULES, V41, P4065, DOI 10.1021/ma800544v
   Sampara P, 2018, GENE THER, V25, P67, DOI 10.1038/s41434 018 0004 0
   Schmid B, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070186
   Scholz CFP, 2016, INT J SYST EVOL MICR, V66, P4422, DOI 10.1099/ijsem.0.001367
   Shan Z, 2017, J BONE JOINT SURG AM, V99, P472, DOI 10.2106/JBJS.16.00146
   Shea GKH, 2022, J ORTHOP RES, V40, P2924, DOI 10.1002/jor.25304
   Shen ZQ, 2021, ANGEW CHEM INT EDIT, V60, P20452, DOI 10.1002/anie.202107155
   Smith IG, 2022, EUR SPINE J, V31, P414, DOI 10.1007/s00586 021 07062 1
   Sortino S, 2010, CHEM SOC REV, V39, P2903, DOI 10.1039/b908663n
   Sun J, 2021, J AM CHEM SOC, V143, P868, DOI 10.1021/jacs.0c10517
   Tang GQ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/4657014
   Torkki M, 2016, EUR SPINE J, V25, P207, DOI 10.1007/s00586 015 3897 y
   Udby PM, 2022, J ORTHOP RES, V40, P301, DOI 10.1002/jor.25240
   Walter G, 2014, EUR J CLIN MICROBIOL, V33, P1355, DOI 10.1007/s10096 014 2073 3
   Wang JS, 2020, J IMMUNOL, V205, P968, DOI 10.4049/jimmunol.1901001
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang T, 2004, CALCIFIED TISSUE INT, V75, P205, DOI 10.1007/s00223 004 0240 8
   Wang ZQ, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00165 x
   Weinstain R, 2020, CHEM REV, V120, P13135, DOI 10.1021/acs.chemrev.0c00663
   Wideman NE, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9010194
   Williams FMK, 2013, ANN RHEUM DIS, V72, P1141, DOI 10.1136/annrheumdis 2012 201551
   Wo YQ, 2016, BIOMATER SCI UK, V4, P1161, DOI 10.1039/c6bm00271d
   Xiao ZF, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1701 1
   Yang T, 2020, SMALL, V16, DOI 10.1002/smll.201907635
   Zayzafoon M, 2005, IMMUNOL REV, V208, P267, DOI 10.1111/j.0105 2896.2005.00330.x
   Zhang X, 2019, ADV SCI, V6, DOI 10.1002/advs.201801122
   Zhang ZQ, 2016, ANAL CHEM, V88, P7274, DOI 10.1021/acs.analchem.6b01603
   Zhao ZN, 2021, CHEM EUR J, V27, P5453, DOI 10.1002/chem.202004698
   Zheng H, 2008, ORG LETT, V10, P2357, DOI 10.1021/ol800206x
   Zheng ZY, 2021, CELL DEATH DIFFER, V28, P2001, DOI 10.1038/s41418 020 00731 6
   Zhou EY, 2018, J AM CHEM SOC, V140, P11686, DOI 10.1021/jacs.8b05514
   Zhou ZY, 2021, J ORTHOP TRANSL, V26, P141, DOI 10.1016/j.jot.2020.08.003
   Zhu QQ, 2016, J BIOMECH, V49, P3079, DOI 10.1016/j.jbiomech.2016.07.012
NR 71
TC 24
Z9 27
U1 10
U2 83
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD 2022 DEC 5
PY 2022
DI 10.1021/acsnano.2c06328
EA DEC 2022
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 6U2TA
UT WOS:000894220300001
PM 36469724
DA 2025 08 17
ER

PT J
AU Belisario, DC
   Akman, M
   Godel, M
   Campani, V
   Patrizio, MP
   Scotti, L
   Hattinger, CM
   De Rosa, G
   Donadelli, M
   Serra, M
   Kopecka, J
   Riganti, C
AF Belisario, Dimas Carolina
   Akman, Muhlis
   Godel, Martina
   Campani, Virginia
   Patrizio, Maria Pia
   Scotti, Lorena
   Hattinger, Claudia Maria
   De Rosa, Giuseppe
   Donadelli, Massimo
   Serra, Massimo
   Kopecka, Joanna
   Riganti, Chiara
TI ABCA1/ABCB1 Ratio Determines Chemo  and Immune Sensitivity in Human
   Osteosarcoma
SO CELLS
LA English
DT Article
DE osteosarcoma; ABCB1; ABCA1; doxorubicin resistance; V gamma 9V delta 2
   T cells
ID HIGH GRADE OSTEOSARCOMA; SELF ASSEMBLING NANOPARTICLES;
   V GAMMA 9V DELTA 2 T CELLS; ZOLEDRONIC ACID; P GLYCOPROTEIN; RESISTANCE;
   DOXORUBICIN; CANCER; EVEROLIMUS; BISPHOSPHONATES
AB The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, and immunogenic cell death induced by the drug. The ATP Binding Cassette transporter A1 (ABCA1) effluxes isopentenyl pyrophosphate (IPP), a strong activator of anti tumor V gamma 9V delta 2 T cells. Recruiting this population may represent an alternative strategy to rescue doxorubicin efficacy in ABCB1 expressing osteosarcoma. In this work, we analyzed how ABCA1 and ABCB1 are regulated in osteosarcoma, and if increasing the ABCA1 dependent activation of V gamma 9V delta 2 T cells could be an effective strategy against ABCB1 expressing osteosarcoma. We used 2D cultured doxorubicin sensitive human U 2OS and Saos 2 cells, their doxorubicin resistant sublines (U 2OS/DX580 and Saos 2/DX580), and 3D cultures of U 2OS and Saos 2 cells. DX580 sublines and 3D cultures had higher levels of ABCB1 and higher resistance to doxorubicin than parental cells. Surprisingly, they had reduced ABCA1 levels, IPP efflux, and V gamma 9V delta 2 T cell induced killing. In these chemo immune resistant cells, the Ras/Akt/mTOR axis inhibits the ABCA1 transcription induced by Liver X Receptor alpha (LXR alpha); Ras/ERK1/2/HIF 1 alpha axis up regulates ABCB1. Targeting the farnesylation of Ras with self assembling nanoparticles encapsulating zoledronic acid (NZ) simultaneously inhibited both axes. In humanized mice, NZ reduced the growth of chemo immune resistant osteosarcomas, increased intratumor necro apoptosis, and ABCA1/ABCB1 ratio and V gamma 9V delta 2 T cell infiltration. We suggest that the ABCB1(high)ABCA1(low) phenotype is indicative of chemo immune resistance. We propose aminobisphosphonates as new chemo immune sensitizing tools against drug resistant osteosarcomas.
C1 [Belisario, Dimas Carolina; Akman, Muhlis; Godel, Martina; Kopecka, Joanna; Riganti, Chiara] Univ Torino, Dept Oncol, Via Santena 5 Bis, I 10126 Turin, Italy.
   [Campani, Virginia; Scotti, Lorena; De Rosa, Giuseppe] Univ Napoli Federico II, Dept Pharm, Via D Montesano 49, I 80131 Naples, Italy.
   [Patrizio, Maria Pia; Hattinger, Claudia Maria; Serra, Massimo] IRCCS Ist Ortoped Rizzoli, Lab Expt Oncol, Pharmacogen & Pharmacogenet Res Unit, Via Barbiano 1 10, I 40136 Bologna, Italy.
   [Donadelli, Massimo] Univ Verona, Sect Biochem, Dept Neurosci Biomed & Movement Sci, Piazzale LA Scuro 10, I 37134 Verona, Italy.
C3 University of Turin; University of Naples Federico II; University of
   Verona
RP Riganti, C (通讯作者)，Univ Torino, Dept Oncol, Via Santena 5 Bis, I 10126 Turin, Italy.
EM dimascarolina.belisario@unito.it; muhlis.akman@unito.it;
   martina.godel@edu.unito.it; virginia.campani@unina.it;
   mariapia.patrizio@ior.it; lorena.scotti@unina.it;
   claudia.hattinger@ior.it; gderosa@unina.it; massimo.donadelli@univr.it;
   massimo.serra@ior.it; joanna.kopecka@unito.it; chiara.riganti@unito.it
RI Serra, Massimo/J 4878 2016; Patrizio, Maria Pia/N 5340 2018; Donadelli,
   Massimo/AAC 2003 2022; DE ROSA, Francesco Giuseppe/AAC 7275 2022;
   campani, virginia/AAB 8654 2022; Hattinger, Claudia/Q 1212 2016
OI Serra, Massimo/0000 0003 0742 1177; Patrizio, Maria
   Pia/0000 0003 3291 7748; campani, virginia/0000 0002 9339 922X; Riganti,
   Chiara/0000 0001 9787 4836; Godel, Martina/0000 0002 2573 126X;
   Donadelli, Massimo/0000 0001 9224 9230; 
FU AIRC (Italian Association for Cancer Research) [IG21408]; Italian
   Ministry of University and Research (MIUR)
FX This research was funded by the AIRC (Italian Association for Cancer
   Research; grant IG21408 to CR); Italian Ministry of University and
   Research (MIUR; Intramural Grant 2018 to JK).
CR BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103
   Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187
   Campia I, 2012, BIOCHEM J, V447, P301, DOI 10.1042/BJ20120200
   Castella B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01492
   Castella B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15663
   Castella B, 2011, J IMMUNOL, V187, P1578, DOI 10.4049/jimmunol.1002514
   Cimini E, 2011, INT J IMMUNOPATH PH, V24, P139, DOI 10.1177/039463201102400116
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Gazzano E, 2018, J CONTROL RELEASE, V270, P37, DOI 10.1016/j.jconrel.2017.11.042
   Gelsomino G, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 137
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909
   Granados Principal S, 2010, FOOD CHEM TOXICOL, V48, P1425, DOI 10.1016/j.fct.2010.04.007
   Grignani G, 2015, LANCET ONCOL, V16, P98, DOI 10.1016/S1470 2045(14)71136 2
   Hafiane A, 2013, CHOLESTEROL, DOI 10.1155/2013/891403
   Halkias J, 2015, IMMUNOL CELL BIOL, V93, P716, DOI 10.1038/icb.2015.38
   Hattinger CM, 2019, EXPERT OPIN EMERG DR, V24, P153, DOI 10.1080/14728214.2019.1654455
   Hattinger CM, 2015, EXPERT OPIN EMERG DR, V20, P495, DOI 10.1517/14728214.2015.1051965
   Hayday AC, 2020, ANNU REV IMMUNOL, V38, P487, DOI 10.1146/annurev immunol 102819 023144
   Higuchi T, 2019, ANTICANCER RES, V39, P4781, DOI 10.21873/anticanres.13662
   Kopecka J, 2016, ONCOTARGET, V7, P20753, DOI 10.18632/oncotarget.8012
   Kopecka J, 2015, ONCOTARGET, V6, P31461, DOI 10.18632/oncotarget.5058
   Kopecka J, 2011, J CONTROL RELEASE, V149, P196, DOI 10.1016/j.jconrel.2010.10.003
   Li K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0071290
   Li S, 2016, ONCOL RES, V24, P279, DOI 10.3727/096504016X14666990347554
   Li SL, 2019, DNA CELL BIOL, V38, P1323, DOI 10.1089/dna.2019.4880
   Liu M, 2015, INT IMMUNOPHARMACOL, V28, P160, DOI 10.1016/j.intimp.2015.06.002
   Shiromizu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02389
   Molenaar JJ, 2012, GENE CHROMOSOME CANC, V51, P10, DOI 10.1002/gcc.20926
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Nussinov R, 2018, CANCER RES, V78, P593, DOI 10.1158/0008 5472.CAN 17 2727
   Pakos EE, 2003, CANCER AM CANCER SOC, V98, P581, DOI 10.1002/cncr.11546
   Pan PJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060900
   Pasello M, 2020, SEMIN CANCER BIOL, V60, P57, DOI 10.1016/j.semcancer.2019.10.004
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   Raverdeau M, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1080
   Riganti C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060975
   Rigoni M, 2015, ONCOTARGET, V6, P29833, DOI 10.18632/oncotarget.4006
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roncuzzi L, 2014, ONCOL REP, V32, P389, DOI 10.3892/or.2014.3181
   Salaroglio IC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0967 0
   Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0657 0
   Salaroglio IC, 2015, ONCOTARGET, V6, P1128, DOI 10.18632/oncotarget.2731
   Salzano G, 2011, INT J PHARMACEUT, V403, P292, DOI 10.1016/j.ijpharm.2010.10.046
   Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573 019 0038 z
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   SERRA M, 1993, ANTICANCER RES, V13, P323
   Serra M, 2003, J CLIN ONCOL, V21, P536, DOI 10.1200/JCO.2003.03.144
   Serra M, 2006, INT J ONCOL, V29, P1459
   Silva Santos B, 2015, NAT REV IMMUNOL, V15, P683, DOI 10.1038/nri3904
   Szakács G, 2014, CHEM REV, V114, P5753, DOI 10.1021/cr4006236
   Torres Adorno AM, 2019, ONCOGENE, V38, P2135, DOI 10.1038/s41388 018 0569 5
   Tosolini M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284723
   Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964
   Wang YM, 2017, ANTI CANCER DRUG, V28, P959, DOI 10.1097/CAD.0000000000000535
   Xiao X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0880 6
   Zhao YJ, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 017 1378 2
   Zhong BL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1917 2
NR 58
TC 36
Z9 40
U1 0
U2 8
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAR
PY 2020
VL 9
IS 3
AR 647
DI 10.3390/cells9030647
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LI2TV
UT WOS:000529337400124
PM 32155954
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Al Zer, H
   Apel, C
   Heiland, M
   Friedrich, RE
   Jung, O
   Kroeger, N
   Eichhorn, W
   Smeets, R
AF Al Zer, Heba
   Apel, Christian
   Heiland, Max
   Friedrich, Reinhard E.
   Jung, Ole
   Kroeger, Nadja
   Eichhorn, Wolfgang
   Smeets, Ralf
TI Enrichment and Schwann Cell Differentiation of Neural Crest derived
   Dental Pulp Stem Cells
SO IN VIVO
LA English
DT Article
DE Dental pulp; stem cells; neural crest; Schwann cells
ID IN VITRO; MECHANISMS; IDENTIFICATION; PROGENITORS; MELANOCYTES;
   RESPONSES; SURVIVAL; CULTURE; ORIGIN; SOX10
AB Background/Aim: As already described in previous studies, neural crest stem cells (NCSCs) can be found in adult human dental pulp. The present study investigated the methodology for enrichment and differentiation induction of the above mentioned cells. Materials and Methods: Dental pulp was extracted from human wisdom teeth of four patients and subsequently cultured as explants on fibronectin coated plates in neurobasal medium supplemented with B27, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin, l glutamine and neuregulin beta 1. The cells were then characterized by immunofluorescence, while their differentiation potential was tested by the attempt to induce cells into different lineages, i.e. osteogenic, melanocytic and glial. Results: The enriched cell population expressed nestin, CD271 and SOX10, which are well known markers for NCSCs. Consequently, the cells were successfully induced to differentiate into osteoblasts, melanocytes and Schwann cells, expressing the corresponding differentiation markers. Conclusion: Human adult dental pulp contains a population of stem cells with neural crest ontogeny, which can thus be recruited for multiple regenerative therapies.
C1 [Al Zer, Heba; Heiland, Max; Friedrich, Reinhard E.; Jung, Ole; Kroeger, Nadja; Eichhorn, Wolfgang; Smeets, Ralf] Univ Hamburg, Univ Med Ctr Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, Hamburg, Germany.
   [Apel, Christian] Rhein Westfal TH Aachen, Helmholtz Inst, Inst Appl Med Engn, Dept Tissue Engn & Text Implants, Aachen, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Helmholtz Association; RWTH Aachen University
RP Al Zer, H (通讯作者)，Univ Hamburg, Univ Med Ctr Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, Hamburg, Germany.
EM h.al zer@uke.de
RI ; Heiland, Max/E 8400 2013; Heiland, Max/IUM 8981 2023; Jung,
   Ole/AAJ 4138 2021; Alzer, Heba/B 5408 2016
OI Apel, Christian/0000 0002 1339 1990; Heiland, Max/0000 0002 4987 2913;
   Kroger, Nadja/0000 0001 8876 837X; Alzer, Heba/0000 0002 3841 5418
CR Abe S, 2012, CELL BIOL INT, V36, P927, DOI 10.1042/CBI20110506
   [Anonymous], 2009, NEURAL CREST NEURAL, DOI DOI 10.1006/DBIO.1998.9175
   Aquino JB, 2006, EXP NEUROL, V198, P438, DOI 10.1016/j.expneurol.2005.12.015
   Bai R, 2010, ASIAN AUSTRAL J ANIM, V23, P430, DOI 10.5713/ajas.2010.90465
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Berninger B, 2006, HANDB EXP PHARM, V174, P319
   Brohlin M, 2009, NEUROSCI RES, V64, P41, DOI 10.1016/j.neures.2009.01.010
   Chai Y, 2000, DEVELOPMENT, V127, P1671
   Cho SW, 2003, J ELECTRON MICROSC, V52, P567, DOI 10.1093/jmicro/52.6.567
   Cooper CD, 2009, SEMIN CELL DEV BIOL, V20, P105, DOI 10.1016/j.semcdb.2008.09.008
   Di Silvio L., 2001, HUMAN CELL CULTURE, P221
   Dupin E, 2012, DEV BIOL, V366, P83, DOI 10.1016/j.ydbio.2012.02.035
   Ernfors P, 2010, EXP CELL RES, V316, P1397, DOI 10.1016/j.yexcr.2010.02.042
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Gronthos S, 2011, METHODS MOL BIOL, V698, P107, DOI 10.1007/978 1 60761 999 4_9
   Hall B. K., 2009, The Neural Crest and Neural Crest Cells in Vertebrate Development and Evolution, P63
   Hall Brian K., 2009, P3
   Hauser S, 2012, STEM CELLS DEV, V21, P742, DOI 10.1089/scd.2011.0419
   Hsu Mei Yu, 2005, Methods Mol Med, V107, P13
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Janebodin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027526
   Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746
   Kim HA, 2001, J NEUROSCI, V21, P1110
   Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896 6273(03)00163 6
   Koutmani Y, 2004, EUR J NEUROSCI, V20, P2509, DOI 10.1111/j.1460 9568.2004.03724.x
   Krejcí E, 2010, FOLIA BIOL PRAGUE, V56, P149
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee G, 2007, NAT BIOTECHNOL, V25, P1468, DOI 10.1038/nbt1365
   LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092 8674(90)90662 X
   LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896 6273(95)90142 6
   Martin I, 2012, STEM CELL REV REP, V8, P1178, DOI 10.1007/s12015 012 9387 2
   MATSUYAMA T, 1990, CALCIFIED TISSUE INT, V47, P276, DOI 10.1007/BF02555909
   MIRSKY R, 1990, DEVELOPMENT, V109, P105
   Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092 8674(00)80583 8
   Nakashima M, 2009, CYTOKINE GROWTH F R, V20, P435, DOI 10.1016/j.cytogfr.2009.10.012
   Paino F, 2010, EUR CELLS MATER, V20, P295
   Paratore C, 2001, DEVELOPMENT, V128, P3949
   Pevny L.H., 2008, CSH PROTOC
   Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085
   Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699
   SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011
   SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092 8674(94)90150 3
   Shakhova O., 2010, STEMBOOK, P1, DOI DOI 10.3824/STEMBOOK.1.51.1
   Sjöblom T, 2005, CANC DRUG DISC DEV, P161
   Sloan AJ, 2009, INT J PAEDIATR DENT, V19, P61, DOI 10.1111/j.1365 263X.2008.00964.x
   Sonoyama W, 2007, CULTURE HUMAN STEM C, P187, DOI DOI 10.1002/9780470167526.CH8
   Spyra M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021099
   Stanisz H, 2012, J INVEST DERMATOL, V132, P1443, DOI 10.1038/jid.2011.478
   STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092 8674(92)90393 Q
   Stevens A, 2008, STEM CELLS DEV, V17, P1175, DOI 10.1089/scd.2008.0012
   Stiles CD, 2003, NEURON, V40, P447, DOI 10.1016/S0896 6273(03)00683 4
   Teng L, 2006, ADV EXP MED BIOL, V589, P206
   Thomas S, 2008, HUM MOL GENET, V17, P3411, DOI 10.1093/hmg/ddn235
   Trentin AG, 2013, RESIDENT STEM CELLS AND REGENERATIVE THERAPY, P157, DOI 10.1016/B978 0 12 416012 5.00009 8
   Waddington RJ, 2009, CELLS TISSUES ORGANS, V189, P268, DOI 10.1159/000151447
   Weiss S, 1996, J NEUROSCI, V16, P7599
   Widera D, 2009, STEM CELLS, V27, P1899, DOI 10.1002/stem.104
   Woodhoo A, 2004, MOL CELL NEUROSCI, V25, P30, DOI 10.1016/j.mcn.2003.09.006
   Yu JH, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 32
NR 59
TC 33
Z9 35
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258 851X
EI 1791 7549
J9 IN VIVO
JI In Vivo
PD MAY JUN
PY 2015
VL 29
IS 3
BP 319
EP 326
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CI1CS
UT WOS:000354479100002
PM 25977377
DA 2025 08 17
ER

PT J
AU Yi, MF
   Chen, LJ
   He, HL
   Shi, L
   Shao, CS
   Zhang, B
AF Yi, Man fei
   Chen, Liang jian
   He, Hui li
   Shi, Lei
   Shao, Chun sheng
   Zhang, Bo
TI Effects of grafting cell penetrate peptide and RGD on endocytosis and
   biological effects of Mg CaPNPs CKIP 1 siRNA carrier system in vitro
SO JOURNAL OF CENTRAL SOUTH UNIVERSITY
LA English
DT Article
DE calcium phosphate nanoparticles; adhesion peptide; cell penetrate
   peptide; endocytosis; siRNA
ID CALCIUM PHOSPHATE NANOPARTICLES; COMPLEMENT ACTIVATION; SUBSTITUTIONS;
   LIPOSOMES; THERAPY; DOMAINS; CKIP 1
AB Calcium phosphate nanoparticles (CaPNPs) have good biocompatibility as gene carriers; however, CaPNPs typically exhibit a low transfection efficiency. Cell penetrate peptide (TAT) can increase the uptake of nanoparticles but is limited by its non specificity. Grafting adhesion peptide adhesion peptide on carriers can enhance their targeting. The Plekho1 gene encodes casein kinase 2 interacting protein 1 (CKIP 1) , which can negatively regulate osteogenic differentiation. Based on the above, we produced a Mg CaPNPs RGD TAT CKIP 1 siRNA carrier system via hydrothermal synthesis, silanization and adsorption. The effects of this carrier system on cell endocytosis and biological effects were evaluated by cell culture in vitro. The results demonstrate that CaPNPs with 7% Mg (60 nm particle size, short rod shape and good dispersion) were suitable for use as gene carriers. The carrier system boosted the endocytosis of MG63 cells and was helpful for promoting the differentiation of osteoblasts, and the dual ligand system possessed a synergistic effect. The findings of this study show the tremendous potential of the Mg CaPNPs RGD TAT CKIP 1 siRNA carrier system for efficient delivery into cells and osteogenesis inducement.
C1 [Yi, Man fei; Chen, Liang jian; He, Hui li; Shi, Lei; Shao, Chun sheng; Zhang, Bo] Cent South Univ, Xiangya Hosp 3, Dept Stomatol, Changsha 410013, Peoples R China.
   [Chen, Liang jian] Cent South Univ, State Key Lab Powder Met, Changsha 410083, Peoples R China.
C3 Central South University; Central South University
RP Chen, LJ (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dept Stomatol, Changsha 410013, Peoples R China.; Chen, LJ (通讯作者)，Cent South Univ, State Key Lab Powder Met, Changsha 410083, Peoples R China.
EM jian007040@sina.com
RI Zhang, Bo/Q 7605 2018
CR Akhtar S, 2007, ADV DRUG DELIVER REV, V59, P164, DOI 10.1016/j.addr.2007.03.010
   Al Soraj M, 2012, J CONTROL RELEASE, V161, P132, DOI 10.1016/j.jconrel.2012.03.015
   Bakan F, 2017, COLLOID SURFACE B, V158, P175, DOI 10.1016/j.colsurfb.2017.06.028
   Bellis SL, 2011, BIOMATERIALS, V32, P4205, DOI 10.1016/j.biomaterials.2011.02.029
   Chen LJ, 2018, T NONFERR METAL SOC, V28, P125, DOI 10.1016/S1003 6326(18)64645 X
   Chen Tian, 2017, Journal of Central South University (Science and Technology), V48, P625, DOI 10.11817/j.issn.1672 7207.2017.03.010
   Chua PH, 2008, BIOMATERIALS, V29, P1412, DOI 10.1016/j.biomaterials.2007.12.019
   Fu C g., 2012, J CLIN STOMATOLOGY, V28, P506
   Fusaro M, 2011, CURR VASC PHARMACOL, V9, P763, DOI 10.2174/157016111797484134
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Hanifi A, 2010, J MATER SCI MATER M, V21, P2393, DOI 10.1007/s10856 010 4088 3
   Ho A, 2001, CANCER RES, V61, P474
   Huang J c., 2014, CHINESE J BIOCH PHAR, V34, P1
   Huang ZG, 2019, INT J PHARMACEUT, V556, P217, DOI 10.1016/j.ijpharm.2018.12.023
   Khan MA, 2016, J COLLOID INTERF SCI, V471, P48, DOI 10.1016/j.jcis.2016.03.007
   Kim W, 2019, INT J NANOMED, V14, P7375, DOI 10.2147/IJN.S224183
   Laskus A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122542
   Laurencin D, 2011, BIOMATERIALS, V32, P1826, DOI 10.1016/j.biomaterials.2010.11.017
   Li Q, 2019, COLLOID SURFACE B, V184, DOI 10.1016/j.colsurfb.2019.110510
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Lv H, 2014, INT J NANOMED, V9, P1311, DOI 10.2147/IJN.S59726
   Marcucci F, 2004, DRUG DISCOV TODAY, V9, P219, DOI 10.1016/S1359 6446(03)02988 X
   Marelli B, 2010, BIOMACROMOLECULES, V11, P1470, DOI 10.1021/bm1001087
   Neumann S, 2009, BIOMATERIALS, V30, P6794, DOI 10.1016/j.biomaterials.2009.08.043
   Ren F, 2010, ACTA BIOMATER, V6, P2787, DOI 10.1016/j.actbio.2009.12.044
   Retamal Marin RR, 2017, COLLOID SURFACE A, V532, P516, DOI 10.1016/j.colsurfa.2017.04.010
   Rojas Sánchez L, 2020, ACTA BIOMATER, V110, P254, DOI 10.1016/j.actbio.2020.04.021
   Sabourian P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218019
   Safi A, 2004, MOL CELL BIOL, V24, P1245, DOI 10.1128/MCB.24.3.1245 1255.2004
   SUZUKI T, 1981, J CHEM SOC FARAD T 1, V77, P1059, DOI 10.1039/f19817701059
   Szebeni J, 2002, J LIPOSOME RES, V12, P165, DOI 10.1081/LPR 120004790
   Taubenberger AV, 2010, BIOMATERIALS, V31, P2827, DOI 10.1016/j.biomaterials.2009.12.051
   Tite T, 2018, MATERIALS, V11, DOI 10.3390/ma11112081
   van den Hoven JM, 2013, EUR J PHARM SCI, V49, P265, DOI 10.1016/j.ejps.2013.03.007
   Wang H., 2010, CHINA MED HERALD, V7, P28
   Wilkinson AL, 2019, EUR J PHARMACOL, V842, P239, DOI 10.1016/j.ejphar.2018.10.045
   Wu DN, 2018, ACTA BIOMATER, V72, P266, DOI 10.1016/j.actbio.2018.03.030
   Yamano S, 2011, J CONTROL RELEASE, V152, P278, DOI 10.1016/j.jconrel.2011.02.004
   Zhang SL, 2009, ADV MATER, V21, P419, DOI 10.1002/adma.200801393
   Zhang WJ, 2014, J COLLOID INTERF SCI, V434, P122, DOI 10.1016/j.jcis.2014.07.031
   Zhou ZX, 2017, ADV DRUG DELIVER REV, V115, P115, DOI 10.1016/j.addr.2017.07.021
   Zou L, 2017, J MEMBRANE BIOL, V250, P115, DOI 10.1007/s00232 016 9940 z
NR 42
TC 4
Z9 4
U1 1
U2 29
PU JOURNAL OF CENTRAL SOUTH UNIV
PI HUNAN
PA EDITORIAL OFF, CHANGSHA, CHINA MAINLAND, HUNAN 410083, PEOPLES R CHINA
SN 2095 2899
EI 2227 5223
J9 J CENT SOUTH UNIV
JI J. Cent. South Univ.
PD MAY
PY 2021
VL 28
IS 5
BP 1291
EP 1304
DI 10.1007/s11771 021 4697 7
PG 14
WC Metallurgy & Metallurgical Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Metallurgy & Metallurgical Engineering
GA SV9HB
UT WOS:000664127800002
DA 2025 08 17
ER

PT J
AU Zhang, P
   Chen, HL
   Xie, B
   Zhao, WH
   Shang, Q
   He, JH
   Shen, GY
   Yu, X
   Zhang, ZD
   Zhu, GY
   Chen, GF
   Yu, FY
   Liang, D
   Tang, JJ
   Cui, JC
   Liu, ZX
   Ren, H
   Jiang, XB
AF Zhang, Peng
   Chen, Honglin
   Xie, Bin
   Zhao, Wenhua
   Shang, Qi
   He, Jiahui
   Shen, Gengyang
   Yu, Xiang
   Zhang, Zhida
   Zhu, Guangye
   Chen, Guifeng
   Yu, Fuyong
   Liang, De
   Tang, Jingjing
   Cui, Jianchao
   Liu, Zhixiang
   Ren, Hui
   Jiang, Xiaobing
TI Bioinformatics identification and experimental validation of m6A related
   diagnostic biomarkers in the subtype classification of blood monocytes
   from postmenopausal osteoporosis patients
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE postmenopausal osteoporosis; RNA N6 methyladenosine (m6A) modulators;
   subtype classification; risk prediction; experimental validation
ID BONE; CELLS
AB BackgroundPostmenopausal osteoporosis (PMOP) is a common bone disorder. Existing study has confirmed the role of exosome in regulating RNA N6 methyladenosine (m6A) methylation as therapies in osteoporosis. However, it still stays unclear on the roles of m6A modulators derived from serum exosome in PMOP. A comprehensive evaluation on the roles of m6A modulators in the diagnostic biomarkers and subtype identification of PMOP on the basis of GSE56815 and GSE2208 datasets was carried out to investigate the molecular mechanisms of m6A modulators in PMOP. MethodsWe carried out a series of bioinformatics analyses including difference analysis to identify significant m6A modulators, m6A model construction of random forest, support vector machine and nomogram, m6A subtype consensus clustering, GO and KEGG enrichment analysis of differentially expressed genes (DEGs) between different m6A patterns, principal component analysis, and single sample gene set enrichment analysis (ssGSEA) for evaluation of immune cell infiltration, experimental validation of significant m6A modulators by real time quantitative polymerase chain reaction (RT qPCR), etc. ResultsIn the current study, we authenticated 7 significant m6A modulators via difference analysis between normal and PMOP patients from GSE56815 and GSE2208 datasets. In order to predict the risk of PMOP, we adopted random forest model to identify 7 diagnostic m6A modulators, including FTO, FMR1, YTHDC2, HNRNPC, RBM15, RBM15B and WTAP. Then we selected the 7 diagnostic m6A modulators to construct a nomogram model, which could provide benefit with patients according to our subsequent decision curve analysis. We classified PMOP patients into 2 m6A subtypes (clusterA and clusterB) on the basis of the significant m6A modulators via a consensus clustering approach. In addition, principal component analysis was utilized to evaluate the m6A score of each sample for quantification of the m6A subgroups. The m6A scores of patients in clusterB were higher than those of patients in clusterA. Moreover, we observed that the patients in clusterA had close correlation with immature B cell and gamma delta T cell immunity while clusterB was linked to monocyte, neutrophil, CD56dim natural killer cell, and regulatory T cell immunity, which has close connection with osteoclast differentiation. Notably, m6A modulators detected by RT qPCR showed generally consistent expression levels with the bioinformatics results. ConclusionIn general, m6A modulators exert integral function in the pathological process of PMOP. Our study of m6A patterns may provide diagnostic biomarkers and immunotherapeutic strategies for future PMOP treatment.
C1 [Zhang, Peng; Chen, Honglin; Xie, Bin; Zhao, Wenhua; Shang, Qi; He, Jiahui; Zhu, Guangye; Chen, Guifeng; Yu, Fuyong] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Zhang, Peng; Chen, Honglin; Zhao, Wenhua; Shang, Qi; He, Jiahui; Chen, Guifeng; Yu, Fuyong; Ren, Hui; Jiang, Xiaobing] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   [Chen, Honglin; Shen, Gengyang; Yu, Xiang; Zhang, Zhida; Liang, De; Tang, Jingjing; Cui, Jianchao; Ren, Hui; Jiang, Xiaobing] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Liu, Zhixiang] Southern Med Univ, Affiliated Huadu Hosp, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Southern
   Medical University   China
RP Ren, H; Jiang, XB (通讯作者)，Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.; Ren, H; Jiang, XB (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Liu, ZX (通讯作者)，Southern Med Univ, Affiliated Huadu Hosp, Guangzhou, Peoples R China.
EM lzxdff688@163.com; renhuispine@163.com; spinedrjxb@sina.com
RI ; Zhida, Zhang/HME 3183 2023; Zhang, Peng/IZP 9286 2023
OI Shen, Gengyang/0000 0001 8940 7912; Zhang, Peng/0000 0003 1777 3790;
   Chen, Honglin/0000 0001 7300 5345
CR Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bao XW, 2020, MOL ONCOL, V14, P917, DOI 10.1002/1878 0261.12670
   Bhadricha H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 95640 0
   Bozec A, 2017, CURR OSTEOPOROS REP, V15, P121, DOI 10.1007/s11914 017 0356 1
   Brunetti G, 2020, J PATHOL, V250, P440, DOI 10.1002/path.5385
   Chen HL, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114195
   Chen SJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02847 6
   Chen X, 2022, ANN RHEUM DIS, V81, P87, DOI 10.1136/annrheumdis 2021 221091
   Chen X, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4970
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Dai B, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.634162
   Denny P, 2018, AUTOPHAGY, V14, P419, DOI 10.1080/15548627.2017.1415189
   Dong QQ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.899503
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Han JW, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772944
   He JJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01166
   Huang M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.783322
   Huidrom S, 2021, CURR DRUG TARGETS, V22, P816, DOI 10.2174/1389450121666201027124947
   Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029
   Jin MM, 2016, CLIN EXP PHARMACOL P, V43, P1145, DOI 10.1111/1440 1681.12651
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Leboucher A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00678
   Lee B, 2019, IMMUNOL LETT, V206, P33, DOI 10.1016/j.imlet.2018.12.003
   Li GC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28990 6
   Lisse TS, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.11
   Liu T, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04312 4
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Liu YZ, 2005, J BIOL CHEM, V280, P29011, DOI 10.1074/jbc.M501164200
   Liu ZC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.594785
   Lu Q, 2016, CALCIFIED TISSUE INT, V99, P500, DOI 10.1007/s00223 016 0173 z
   McNeil MA, 2021, ANN INTERN MED, V174, pITC97, DOI 10.7326/AITC202107200
   Meng LP, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 021 04484 z
   Mi BB, 2020, J CELL MOL MED, V24, P6385, DOI 10.1111/jcmm.15284
   Oerum S, 2021, NUCLEIC ACIDS RES, V49, P7239, DOI 10.1093/nar/gkab378
   Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Slupski W, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051609
   Sun ZY, 2021, AGING CELL, V20, DOI 10.1111/acel.13298
   Tian AX, 2021, ORTHOP SURG, V13, P1941, DOI 10.1111/os.13136
   Wang J, 2021, AGING US, V13, P21134, DOI 10.18632/aging.203377
   Wen Jun Ru, 2021, Sichuan Da Xue Xue Bao Yi Xue Ban, V52, P402, DOI 10.12182/20210560204
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xiao N, 2012, BLOOD, V119, P4898, DOI 10.1182/blood 2012 01 403089
   Xu T, 2022, MOL THER NUCL ACIDS, V27, P824, DOI 10.1016/j.omtn.2022.01.007
   Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422 018 0040 8
   Yin LJ, 2021, CLIN CHIM ACTA, V515, P80, DOI 10.1016/j.cca.2021.01.001
   Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01170 0
   Zhang FR, 2018, HUM MOL GENET, V27, P3936, DOI 10.1093/hmg/ddy292
   Zhang N, 2020, EUR REV MED PHARMACO, V24, P7497, DOI 10.26355/eurrev_202007_21922
   Zhang N, 2022, MOL NEUROBIOL, V59, P1925, DOI 10.1007/s12035 022 02739 0
   Zhang SY, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005287
   Zhang YF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.689067
   Zhou R, 2017, NUCLEIC ACIDS RES, V45, P606, DOI 10.1093/nar/gkw851
   Zhou Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19196 2
   Zhu L, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979 020 00202 z
NR 59
TC 9
Z9 9
U1 5
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAR 8
PY 2023
VL 14
AR 990078
DI 10.3389/fendo.2023.990078
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 9Z3GO
UT WOS:000951032500001
PM 36967763
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, Y
   Liu, PY
   Scarlett, CJ
   Malyukova, A
   Liu, B
   Marshall, GM
   MacKenzie, KL
   Biankin, AV
   Liu, T
AF Sun, Y.
   Liu, P. Y.
   Scarlett, C. J.
   Malyukova, A.
   Liu, B.
   Marshall, G. M.
   MacKenzie, K. L.
   Biankin, A. V.
   Liu, T.
TI Histone deacetylase 5 blocks neuroblastoma cell differentiation by
   interacting with N Myc
SO ONCOGENE
LA English
DT Article
DE N Myc; neuroblastoma; histone deacetylase 5
ID EMBRYONIC STEM CELLS; C MYC; MUSCLE DIFFERENTIATION; GENOMIC TARGETS;
   PROTEIN; REPRESSION; HDAC5; TRANSCRIPTION; EXPRESSION; INHIBITORS
AB The N Myc oncoprotein induces neuroblastoma, which arises from undifferentiated neuroblasts in the sympathetic nervous system, by modulating gene and protein expression and consequently causing cell differentiation block and cell proliferation. The class Ila histone deacetylase 5 (HDAC5) represses gene transcription, and blocks myoblast, osteoblast and leukemia cell differentiation. Here we showed that N Myc upregulated HDAC5 expression in neuroblastoma cells. Conversely, HDAC5 repressed the ubiquitin protein ligase NEDD4 gene expression, increased Aurora A gene expression and consequently upregulated N Myc protein expression. Genome wide gene expression analysis and protein co immunoprecipitation assays revealed that HDAC5 and N Myc repressed the expression of a common subset of genes by forming a protein complex, whereas HDAC5 and the class III HDAC SIRT2 independently repressed the expression of another common subset of genes without forming a protein complex. Moreover, HDAC5 blocked differentiation and induced proliferation in neuroblastoma cells. Taken together, our data identify HDAC5 as a novel co factor in N Myc oncogenesis, and provide the evidence for the potential application of HDAC5 inhibitors in the therapy of N Myc induced neuroblastoma and potentially other c Myc induced malignancies.
C1 [Sun, Y.; Liu, P. Y.; Malyukova, A.; Liu, B.; Marshall, G. M.; MacKenzie, K. L.; Liu, T.] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia.
   [Scarlett, C. J.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, NSW, Australia.
   [Scarlett, C. J.; Biankin, A. V.] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW, Australia.
   [Liu, B.] Kids Canc Alliance, Randwick, NSW, Australia.
   [Marshall, G. M.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia.
   [Biankin, A. V.] Bankstown Hosp, Dept Surg, Bankstown, NSW, Australia.
   [Biankin, A. V.] Univ New S Wales, Fac Med, South Western Sydney Clin Sch, Liverpool, NSW, Australia.
   [Liu, T.] Univ New S Wales, UNSW Med, Sch Womens & Childrens Hlth, Randwick, NSW, Australia.
C3 Children's Cancer Institute; University of Newcastle; Garvan Institute
   of Medical Research; NSW Health; Sydney Childrens Hospitals Network; NSW
   Health; Bankstown Lidcombe Hospital; University of New South Wales
   Sydney; University of New South Wales Sydney
RP Liu, T (通讯作者)，Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Sydney, NSW 2052, Australia.
EM tliu@unsw.edu.au
RI Liu, Tao/A 3922 2015; Malyukova, Alena/LUW 9047 2024; liu,
   peiyao/KFT 1810 2024; MacKenzie, Karen/N 5849 2019
OI Malyukova, Alena/0000 0003 0389 4129; Biankin,
   Andrew/0000 0002 0362 5597; Scarlett, Christopher/0000 0002 4140 7785;
   Liu, Tao/0000 0001 6244 7316; MacKenzie, Karen/0000 0003 2996 1617
FU National Health and Medical Research Council [1006002]; Cancer Council
   NSW project grant; ARC Future Fellowship; Cancer Institute New South
   Wales Fellowships; Cancer Research UK [17263] Funding Source:
   researchfish
FX We thank Dr Eric Olsen for the HDAC5 expression constructs. This work
   was supported by a National Health and Medical Research Council project
   grant 1006002 (T Liu and CJ Scarlett) and a Cancer Council NSW project
   grant. T Liu is a recipient of an ARC Future Fellowship, AV Biankin and
   CJ Scarlett are recipients of Cancer Institute New South Wales
   Fellowships. Children's Cancer Institute Australia is affiliated with
   University of New South Wales and Sydney Children's Hospital.
CR Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467
   Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868
   Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512
   Huang EY, 2000, GENE DEV, V14, P45
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kao HY, 2000, GENE DEV, V14, P55
   Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147
   Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104
   Liu T, 2009, EUR J CANCER, V45, P1846, DOI 10.1016/j.ejca.2009.03.002
   Long XC, 2007, P NATL ACAD SCI USA, V104, P16570, DOI 10.1073/pnas.0708253104
   Manji SSM, 2006, J NEUROSCI RES, V83, P181, DOI 10.1002/jnr.20721
   Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140 6736(07)60983 0
   Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332
   Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135
   Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613
   McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593
   Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078 0432.CCR 10 0395
   Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033
   Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005
   Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393
   Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032
   Silvagno F, 2002, FEBS LETT, V532, P153, DOI 10.1016/S0014 5793(02)03667 0
   SUMMERHILL EM, 1987, MOL BRAIN RES, V2, P99, DOI 10.1016/0169 328X(87)90002 7
   Tee AEL, 2010, J BIOL CHEM, V285, P3561, DOI 10.1074/jbc.M109.053041
   van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819
   Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902
   Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101
   Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727
   Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056
NR 38
TC 33
Z9 36
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD JUN 5
PY 2014
VL 33
IS 23
BP 2987
EP 2994
DI 10.1038/onc.2013.253
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AI9EL
UT WOS:000337232200005
PM 23812427
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, XS
   Cheng, XS
   Ma, WX
   Chen, CC
AF Chen, Xiaosong
   Cheng, Xunsheng
   Ma, Wuxiu
   Chen, Congcong
TI Effects of hyperbaric oxygen therapy on open tibial fractures in rabbits
   after transient seawater immersion
SO UNDERSEA AND HYPERBARIC MEDICINE
LA English
DT Article
DE seawater immersion; open fracture; hyperbaric oxygen
ID OSTEOMYELITIS
AB Objective: To explore the effect and mechanism of hyperbaric oxygen (HBO2) therapy of open tibial fractures in rabbits after transient seawater immersion.
   Methods: Forty eight (48) New Zealand rabbits were randomly and averagely divided into an HBO2 therapy group (Group A) and a control group (Group B). All rabbits were subjected to unilateral open tibial fractures, while immersed in artificial seawater (20 22 degrees C) for three hours prior to debridement and external fixation. Group A was treated with HBO2 at 2 atmosphere absolute (ATA) for 50 minutes once daily for two weeks; Group B received postoperative routine treatments only. The fracture zone in each group was compared by radiological, histological and immunohistochemical examinations.
   Results: In Group A, bony callus and mature osteo cytes without infiltration of inflammatory cells were observed in the fracture zone. Vascular endothelial growth factor (VEGF) was expressed mainly in the cytoplasm of osteoblasts, chondrocytes and osteo cytes, and exhibited significant changes at different time points. The gray value of bony callus in Group A was 190.58 +/  7.52; that of Group B was 144 +/  8.11. Difference between the groups was statistically significant (P<0.01). The content of malondialdehyde (MDA) in Group A was significantly lower than Group B (P<0.01), and the activity of superoxide dismutase (SOD) in Group A was higher than Group B (P<0.01) at four weeks. There were no significant differences in MDA content and SOD activity between groups at eight and 12 weeks.
   Conclusions: HBO2 treatment of open tibial fractures in seawater can reduce the inflammatory reaction and reperfusion injury, and promote osteo cytic proliferation and fracture healing.
C1 [Chen, Xiaosong; Cheng, Xunsheng; Ma, Wuxiu; Chen, Congcong] 105th Hosp Peoples Liberat Army, Dept Orthoped, Hefei 230031, Anhui, Peoples R China.
RP Cheng, XS (通讯作者)，105th Hosp Peoples Liberat Army, Dept Orthoped, Hefei 230031, Anhui, Peoples R China.
EM xun2015sheng@sina.com
FU Innovation of Science and Technology Project, Nanjing Military Region
   [11Z011]
FX This work was supported by grants from the Innovation of Science and
   Technology Project, Nanjing Military Region (Grant No.11Z011).
CR Ai JG, 2014, GENET MOL RES, V13, P5523, DOI 10.4238/2014.July.25.6
   BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249
   BIRD AD, 1965, LANCET, V1, P355
   Brancato SK, 2011, AM J PATHOL, V178, P19, DOI 10.1016/j.ajpath.2010.08.003
   Butler J, 2006, EMERG MED J, V23, P571, DOI 10.1136/emj.2006.038539
   Chen B, 2013, ANN SAUDI MED, V33, P277, DOI 10.5144/0256 4947.2013.277
   [陈肖松 CHEN Xiaosong], 2011, [中华航海医学与高气压医学杂志, Chinese Journal of Nautical Medicine and Hyperbaric Medicine], V18, P142
   Coulson D B, 1966, Surg Forum, V17, P449
   Di Nisio C, 2015, EUR J HISTOCHEM, V59, P45, DOI 10.4081/ejh.2015.2455
   Gesell LaurieB., 2008, Hyperbaric Oxygen Therapy Indications, V12th
   JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891 5849(90)90131 2
   Jin H, 2015, MILITARY MED RES, V2, DOI 10.1186/s40779 015 0048 z
   Kang Thomas S, 2004, Arch Facial Plast Surg, V6, P31, DOI 10.1001/archfaci.6.1.31
   Kawada S, 2008, J STRENGTH COND RES, V22, P66, DOI 10.1519/JSC.0b013e31815eefa2
   KNIGHTON DR, 1981, SURGERY, V90, P262
   Li Hui, 2002, Chin J Traumatol, V5, P219
   Liu Peng, 2005, Chin J Traumatol, V8, P311
   Liu Peng, 2005, Chin J Traumatol, V8, P186
   Lu CY, 2013, BONE, V52, P220, DOI 10.1016/j.bone.2012.09.037
   MADER JT, 1980, J INFECT DIS, V142, P915, DOI 10.1093/infdis/142.6.915
   Mendel V, 1999, UNDERSEA HYPERBAR M, V26, P169
   STRAUSS MB, 1983, J BONE JOINT SURG AM, V65, P656, DOI 10.2106/00004623 198365050 00011
   TAI YJ, 1992, ANN PLAS SURG, V28, P284, DOI 10.1097/00000637 199203000 00016
   Tompach PC, 1997, INT J ORAL MAX SURG, V26, P82, DOI 10.1016/S0901 5027(05)80632 0
   [王长生 Wang Changsheng], 2010, [中华航海医学与高气压医学杂志, Chinese Journal of Nautical Medicine and Hyperbaric Medicine], V17, P77
   Yu W., 2014, CHINA CONTINUING MED, V6, P61
   [朱方强 Zhu Fangqiang], 2005, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V27, P477
NR 27
TC 4
Z9 6
U1 0
U2 8
PU UNDERSEA & HYPERBARIC MEDICAL SOC INC
PI DURHAM
PA 21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA
SN 1066 2936
J9 UNDERSEA HYPERBAR M
JI Undersea Hyperb. Med.
PD MAY JUN
PY 2017
VL 44
IS 3
BP 235
EP 242
PG 8
WC Marine & Freshwater Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Marine & Freshwater Biology; Research & Experimental Medicine
GA EW1BT
UT WOS:000402225600004
PM 28779580
DA 2025 08 17
ER

PT J
AU Zhang, BB
   Han, R
   Liu, YK
   Gao, QW
   Li, B
AF Zhang, Bin Bin
   Han, Rui
   Liu, Ya Kun
   Gao, Quan Wen
   Li, Bing
TI Morphological Changes in the Midface of Beagle Dogs Treated by
   Trans Sutural Distraction
SO INTERNATIONAL JOURNAL OF MORPHOLOGY
LA English
DT Article
DE Suture diatraction osteogenesis; Extracranial traction frame; Midfacial
   hypoplasia; animal model
ID ANCHORED MAXILLARY PROTRACTION; COMPLETE CLEFT LIP; PALATE;
   OSTEOGENESIS; HYPOPLASIA
AB Trans sutural distraction is a biological process that induces the formation of new bone and changes the position of bone by pulling on growing suture under the action of external forces. Currently, therapy to midfacial hypoplasia treated by trans sutural distraction has been applied. In this study, Beagle dogs were selected as experimental animals, and a traction device designed by ourselves was applied to Beagle dogs to simulate the treatment process of trans sutural distraction in human face, so as to provide a basis for the subsequent research on the related mechanism of trans sutural distraction. The objective is that the animal model can provide the basis for the follow up study of trans sutural distraction. 45 month beagle dogs were randomly divided into two groups 3 in experiment group and 3 in control group. Implant nails were implanted as the bone marker in the bilateral zygomatic temporal suture, zygomandibular maxillary suture and palatine transverse suture in experimental group. The traction of the maxilla was carried out by the external cranial traction frame with canine fossa as bearing point, 800g force each side, elastic traction for 15 days. The control group only implanted the implant nail as the bone marker on both sides of the bone suture. The distance between two implant nails was measured by vernier calipers and X ray examination, compared with preoperative and postoperative changes. X ray and cephalometric measurements were used to measure change in the cranial basal angle. HE staining was used to observe the width of the bone seams, the morphology and structure of the cells and the tissue of the new bone under the phase contrast microscope. Then descriptive statistical analysis and t test between two independent samples are carried out for the measurement data. The experimental group had a good retention of the beagle traction frame. In the experimental group, the maxillaries of dogs were protrudent in the process of traction gradually and the occlusal relationship changed to type II malocclusion. When the traction is 15 days, the coverage distance is about 8 similar to 9 mm. Before and after the traction, the distance between landmark points indicated that the spacing between the transverse palatine suture was the largest (experimental group: 5.52 +/  0.19 mm control group 1.31 +/  0.06 mm P<0.05), and zygomaticotemporal suture was the second (experimental group: 3.12 +/  0.15 mm, control group 0.73 +/  0.04 mm, P<0.05), and zygomaticomaxillary suture was less (experimental group: 2.60 +/  0.34 mm, control group 0.53 +/  0.05 mm, P<0.05). The cranial basal angle was no change before and after operation (controlgroup: 32.3 +/  1.3 degrees, experimental group: 33.2 +/  1.1 degrees P>0.05. Histology showed that the collagenous fibers in the suture of the control group were denser and the osteoblasts were visible on the edge of the suture, showing osteogenic activity. The experimental group significantly widened suture (experimental group:1209.388 +/  42.714 mu m, control group 248.276 +/  22.864 mu m, P<0.05), the number of fibroblasts increased significantly with loose collagen fiber. The direction of cell and fiber arrangement were parallel to the traction force. There were many small blood vessels and marrow cavities, and the bone trabecula around the bone suture was thin (experimental group: 23.684 +/  3.774 mm, control group: 86.810 +/  9.219 mm, P < 0.05), showing active osteogenic activity.
   The growing beagle dog can be used to establish a suture traction animal model for experimental study. In the experiment, Kirschner wire was used to penetrate the bottom plane of the piriform hole of the maxilla (about the position of the canine fossa at the back) and the traction direction was basically the same as the growth direction, and the maxilla was basically parallel and moved forward.
C1 [Zhang, Bin Bin; Han, Rui; Liu, Ya Kun; Li, Bing] Shanxi Med Univ, Sch Dent, Dept Prosthodont, Taiyuan, Peoples R China.
   [Gao, Quan Wen] Gen Hosp PLA, Hosp 1, Dept Burns & Plast Surg, Beijing, Peoples R China.
C3 Shanxi Medical University
RP Li, B (通讯作者)，Shanxi Med Univ, Stomatol Hosp, 63 XinjianRd, Taiyuan 030001, Peoples R China.; Gao, QW (通讯作者)，Gen Hosp PL, Hosp 1, Dept Burns & Plast Surg, Beijing, Peoples R China.
EM gaoqw2000@126.com; libing 1975@163.com
FU Beijing Natural Science Foundation of China [7144249]; Institutes
   Foundation of Hospital of Stomatology Shanxi Medical University
   [KY201807]; Cultivate Scientific Research Excellence Programs of Higher
   Education Institutions in Shanxi [2019KJ024]
FX Beijing Natural Science Foundation of China, No. 7144249.The Institutes
   Foundation of Hospital of Stomatology Shanxi Medical University, No.
   KY201807.The Cultivate Scientific Research Excellence Programs of Higher
   Education Institutions in Shanxi, No. 2019KJ024
CR COBEN SE, 1971, AMER J ORTHODONTICS, V59, P470, DOI 10.1016/0002 9416(71)90083 2
   Garib D, 2018, AM J ORTHOD DENTOFAC, V153, P290, DOI 10.1016/j.ajodo.2016.10.044
   HATA S, 1987, AM J ORTHOD DENTOFAC, V91, P305, DOI 10.1016/0889 5406(87)90171 5
   Hou Min, 2003, Zhonghua Zheng Xing Wai Ke Za Zhi, V19, P360
   Hou Min, 2009, Zhonghua Zheng Xing Wai Ke Za Zhi, V25, P117
   Kasai K, 1998, AM J ORTHOD DENTOFAC, V113, P674, DOI 10.1016/S0889 5406(98)70228 8
   Leszczynska Madej B, 2010, J MICROSC OXFORD, V237, P399, DOI 10.1111/j.1365 2818.2009.03271.x
   Lin YF, 2016, AM J ORTHOD DENTOFAC, V150, P802, DOI 10.1016/j.ajodo.2016.03.031
   Liu CM, 2005, J CRANIOFAC SURG, V16, P537, DOI 10.1097/01.SCS.0000159083.21931.C5
   Liu Ren kai, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P605
   Marulanda J, 2018, ORAL DIS, V24, P78, DOI 10.1111/odi.12758
   Meazzini MC, 2019, CLEFT PALATE CRAN J, V56, P159, DOI 10.1177/1055665618772395
   NANDA R, 1984, ANGLE ORTHOD, V54, P199
   Pellerin P, 2001, Ann Chir Plast Esthet, V46, P277, DOI 10.1016/S0294 1260(01)00041 3
   Savoldi F, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25402 y
   Scolozzi P, 2008, J CRANIOFAC SURG, V19, P1199, DOI 10.1097/SCS.0b013e318184365d
   Tong HZ, 2015, J CRANIO MAXILL SURG, V43, P1749, DOI 10.1016/j.jcms.2015.08.027
   Yatabe M, 2017, AM J ORTHOD DENTOFAC, V152, P327, DOI 10.1016/j.ajodo.2016.12.024
NR 18
TC 0
Z9 0
U1 0
U2 4
PU SOC CHILENA ANATOMIA
PI TEMUCO
PA CASILLA 54 D, TEMUCO, 00000, CHILE
SN 0717 9502
EI 0717 9367
J9 INT J MORPHOL
JI Int. J. Morphol.
PD AUG
PY 2020
VL 38
IS 4
BP 947
EP 955
PG 9
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA MM1TC
UT WOS:000549940300023
DA 2025 08 17
ER

PT J
AU Tan, JL
   Xu, X
   Tong, ZC
   Lin, J
   Yu, QJ
   Lin, Y
   Kuang, W
AF Tan, Jiali
   Xu, Xin
   Tong, Zhongchun
   Lin, Jiong
   Yu, Qiujun
   Lin, Yao
   Kuang, Wei
TI Decreased osteogenesis of adult mesenchymal stem cells by reactive
   oxygen species under cyclic stretch: a possible mechanism of age related
   osteoporosis
SO BONE RESEARCH
LA English
DT Article
ID STRAIN; DIFFERENTIATION; MARROW; ADIPOGENESIS; EXPRESSION; THERAPIES;
   GROWTH
AB Age related defect of the osteogenic differentiation of mesenchymal stem cells (MSCs) plays a key role in osteoporosis. Mechanical loading is one of the most important physical stimuli for osteoblast differentiation. Here, we compared the osteogenic potential of MSCs from young and adult rats under three rounds of 2 h of cyclic stretch of 2.5% elongation at 1 Hz on 3 consecutive days. Cyclic stretch induced a significant osteogenic differentiation of MSCs from young rats, while a compromised osteogenesis in MSCs from the adult rats. Accordingly, there were much more reactive oxygen species (ROS) production in adult MSCs under cyclic stretch compared to young MSCs. Moreover, ROS scavenger N acetylcysteine rescued the osteogenic differentiation of adult MSCs under cyclic stretch. Gene expression analysis revealed that superoxide dismutase 1 (SOD1) was significantly downregulated in those MSCs from adult rats. In summary, our data suggest that reduced SOD1 may result in excessive ROS production in adult MSCs under cyclic stretch, and thus manipulation of the MSCs from the adult donors with antioxidant would improve their osteogenic ability.
C1 [Tan, Jiali; Tong, Zhongchun; Lin, Jiong; Lin, Yao] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Orthodont, Guangzhou 510275, Guangdong, Peoples R China.
   [Tan, Jiali; Tong, Zhongchun; Lin, Jiong; Lin, Yao] Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Xu, Xin] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China.
   [Yu, Qiujun] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc Med, Boston, MA 02115 USA.
   [Kuang, Wei] Guangzhou Gen Hosp, Guangzhou Mil Command, Dept Stomatol, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sichuan University; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Brigham & Women's
   Hospital; Southern Theater Command General Hospital
RP Tan, JL (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Orthodont, Guangzhou 510275, Guangdong, Peoples R China.
EM jasminenov@163.com; conversekw@gmail.com
RI Yu, Qiujun/B 6794 2015; xu, xin/HNQ 6671 2023
OI Yu, Qiujun/0000 0003 0690 138X; Xu, Xin/0000 0003 4608 4556
FU National Natural Science Foundation of China [81100240]; '985' project
   of Sun Yat Sen University grant; Sun Yat Sen university young teachers
   training project [13YKPY42]; Natural Science Foundation of Guangdong
   Province, China [S2012010009495]; Science and Technology Planning
   Project of Guangdong Province, China [2012B031800185]
FX This study was financially supported by National Natural Science
   Foundation of China (81100240), '985' project of Sun Yat Sen University
   grant, Sun Yat Sen university young teachers training project
   (13YKPY42), Natural Science Foundation of Guangdong Province, China
   (S2012010009495) and Science and Technology Planning Project of
   Guangdong Province, China (2012B031800185).
CR Alves H, 2013, TISSUE ENG PT A, V19, P928, DOI [10.1089/ten.tea.2011.0700, 10.1089/ten.TEA.2011.0700]
   Buxton PG, 2007, ORAL DIS, V13, P452, DOI 10.1111/j.1601 0825.2007.01403.x
   Crane JL, 2013, BONE RES, V1, DOI 10.4248/BR201302007
   Friedl G, 2007, OSTEOARTHR CARTILAGE, V15, P1293, DOI 10.1016/j.joca.2007.04.002
   Gao B, 2013, BONE RES, V1, DOI 10.4248/BR201302006
   Haasper C, 2008, EXP TOXICOL PATHOL, V59, P355, DOI [10.1016/j.etp.2007.11.008, 10.1016/j.etp.2007.11.013]
   Hosseinkhani H, 2006, BIOMATERIALS, V27, P4079, DOI 10.1016/j.biomaterials.2006.03.030
   Kearney EM, 2010, ANN BIOMED ENG, V38, P1767, DOI 10.1007/s10439 010 9979 4
   Kearney EM, 2008, J BIOMECH ENG T ASME, V130, DOI 10.1115/1.2979870
   Khan WS, 2009, INJURY, V40, P150, DOI 10.1016/j.injury.2008.05.029
   Lee JS, 2009, STEM CELLS, V27, P1963, DOI 10.1002/stem.121
   Leskelä HV, 2003, BIOCHEM BIOPH RES CO, V311, P1008, DOI 10.1016/j.bbrc.2003.10.095
   Li CJ, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.6
   Li Y, 2011, J BONE MINER RES, V26, P2656, DOI 10.1002/jbmr.480
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Nada RM, 2010, J CRANIO MAXILL SURG, V38, P83, DOI 10.1016/j.jcms.2009.03.014
   Qi MC, 2008, INT J ORAL MAX SURG, V37, P453, DOI 10.1016/j.ijom.2007.12.008
   Rochefort GY, 2005, RESP RES, V6, DOI 10.1186/1465 9921 6 125
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Schwarz S, 2014, INT J ORAL SCI, V6, P154, DOI 10.1038/ijos.2014.23
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Shand Jocelyn M, 2004, Oral Maxillofac Surg Clin North Am, V16, P525, DOI 10.1016/j.coms.2004.07.004
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Stenderup K, 2001, J BONE MINER RES, V16, P1120, DOI 10.1359/jbmr.2001.16.6.1120
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Suva Larry J, 2005, Curr Osteoporos Rep, V3, P46, DOI 10.1007/s11914 005 0003 0
   Swennen G, 2001, INT J ORAL MAX SURG, V30, P89, DOI 10.1054/ijom.2000.0033
   Tan JL, 2009, APOPTOSIS, V14, P764, DOI 10.1007/s10495 009 0345 7
   Zheng LW, 2014, INT J ORAL SCI, V6, P205, DOI 10.1038/ijos.2014.60
   Zheng LW, 2013, INT J ORAL SCI, V5, P1, DOI 10.1038/ijos.2013.14
NR 30
TC 88
Z9 98
U1 0
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD MAR 17
PY 2015
VL 3
AR 15003
DI 10.1038/boneres.2015.3
PG 6
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CG4WJ
UT WOS:000353287900001
PM 26273536
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Piper, SL
   Wang, MQ
   Yamamoto, A
   Malek, F
   Luu, A
   Kuo, AC
   Kim, HT
AF Piper, Samantha L.
   Wang, Miqi
   Yamamoto, Akira
   Malek, Farbod
   Luu, Andrew
   Kuo, Alfred C.
   Kim, Hubert T.
TI Inducible immortality in hTERT human mesenchymal stem cells
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE mesenchymal stem cell; telomerase; immortalized; multipotential
ID TELOMERASE REVERSE TRANSCRIPTASE; HUMAN TRABECULAR OSTEOBLASTS;
   LONG TERM CULTURES; HUMAN FIBROBLASTS; IN VIVO; STROMAL CELLS;
   EXPRESSION; DIFFERENTIATION; TRANSPLANTATION; PROLIFERATION
AB Human mesenchymal stem cells (hMSCs) are attractive candidates for tissue engineering and cell based therapy because of their multipotentiality and availability in adult donors. However, in vitro expansion and differentiation of these cells is limited by replicative senescence. The proliferative capacity of hMSCs can be enhanced by ectopic expression of telomerase, allowing for long term culture. However, hMSCs with constitutive telomerase expression demonstrate unregulated growth and even tumor formation. To address this problem, we used an inducible Tet On gene expression system to create hMSCs in which ectopic telomerase expression can be induced selectively by the addition of doxycycline (i hTERT hMSCs). i hTERT hMSCs have inducible hTERT expression and telomerase activity, and are able to proliferate significantly longer than wild type hMSCs when hTERT expression is induced. They stop proliferating when hTERT expression is turned off and can be rescued when expression is re induced. They retain multipotentiality in vitro even at an advanced age. We also used a selective inhibitor of telomere elongation to show that the mechanism driving immortalization of hMSCs by hTERT is dependent upon maintenance of telomere length. Thanks to their extended lifespan, preserved multipotentiality and controlled growth, i hTERT hMSCs may prove to be a useful tool for the development and testing of novel stem cell therapies. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:18791885, 2012
C1 [Piper, Samantha L.; Yamamoto, Akira; Kuo, Alfred C.; Kim, Hubert T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
   [Wang, Miqi; Malek, Farbod; Luu, Andrew; Kuo, Alfred C.; Kim, Hubert T.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco;
   US Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Kim, HT (通讯作者)，Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave, San Francisco, CA 94143 USA.
EM kimh@orthosurg.ucsf.edu
FU UCSF PACCTR
FX Grant sponsor: UCSF PACCTR
CR Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008 5472.CAN 04 2218
   Chiang YJ, 2004, MOL CELL BIOL, V24, P7024, DOI 10.1128/MCB.24.16.7024 7031.2004
   Christiansen M, 2000, J GERONTOL A BIOL, V55, pB194, DOI 10.1093/gerona/55.4.B194
   Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002 9440(10)65025 0
   Gronthos S, 2003, J BONE MINER RES, V18, P716, DOI 10.1359/jbmr.2003.18.4.716
   Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097 2765(04)00256 4
   Huang GP, 2008, CELL PROLIFERAT, V41, P625, DOI 10.1111/j.1365 2184.2008.00543.x
   Huang GP, 2008, J CELL BIOCHEM, V103, P1256, DOI 10.1002/jcb.21502
   Hung CJ, 2010, CYTOTHERAPY, V12, P455, DOI 10.3109/14653240903555827
   Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056
   Kassem M, 1997, OSTEOPOROSIS INT, V7, P514, DOI 10.1007/BF02652556
   Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024
   Knutsen G, 2004, J BONE JOINT SURG AM, V86A, P455, DOI 10.2106/00004623 200403000 00001
   Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365 2796.2007.01844.x
   Li N, 2009, CANCER AM CANCER SOC, V115, P4795, DOI 10.1002/cncr.24519
   Lindvall C, 2003, CANCER RES, V63, P1743
   Milyavsky M, 2003, CANCER RES, V63, P7147
   Mondello C, 2003, BIOCHEM BIOPH RES CO, V308, P914, DOI 10.1016/S0006 291X(03)01484 0
   Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063
   Nakahara H, 2009, TRANSPLANTATION, V88, P346, DOI 10.1097/TP.0b013e3181ae5ba2
   Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440
   Parsch D, 2004, J MOL MED JMM, V82, P49, DOI 10.1007/s00109 003 0506 z
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836
   Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Sipo I, 2006, J MOL MED, V84, P215, DOI 10.1007/s00109 005 0009 1
   Steinert AF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2195
   Tsai CC, 2010, J BIOMED SCI, V17, DOI 10.1186/1423 0127 17 64
   Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674
   White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167 7799(00)01541 9
   Yang JF, 2010, J BIOMED MATER RES A, V92A, P817, DOI 10.1002/jbm.a.32378
   Yudoh K, 2004, GENE THER, V11, P909, DOI 10.1038/sj.gt.3302234
NR 36
TC 27
Z9 31
U1 0
U2 23
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD DEC
PY 2012
VL 30
IS 12
BP 1879
EP 1885
DI 10.1002/jor.22162
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 027XO
UT WOS:000310387600003
PM 22674533
OA Bronze
DA 2025 08 17
ER

PT J
AU Chan, VWS
   Clark, AJ
   Davis, JC
   Wolf, RS
   Kellstein, D
   Jayawardene, S
AF Chan, VWS
   Clark, AJ
   Davis, JC
   Wolf, RS
   Kellstein, D
   Jayawardene, S
TI The post operative analgesic efficacy and tolerability of lumiracoxib
   compared with placebo and naproxen after total knee or hip arthroplasty
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article
DE lumiracoxib; naproxen; post operative pain; arthroplasty; selective
   cyclooxygenase 2 inhibitor; COX 2 inhibitor
ID THERAPEUTIC ARTHRITIS RESEARCH; EVENT TRIAL TARGET; DOUBLE BLIND;
   ROFECOXIB; CELECOXIB; IBUPROFEN; SAFETY; PAIN; OSTEOARTHRITIS; COX 2
AB Background: Lumiracoxib is a novel selective cyclooxygenase 2 (COX 2) inhibitor in development for the treatment of chronic and acute pain.
   Methods: This randomized, double blind multicentre study enrolled 180 patients (aged 18 80 years) with moderate to severe pain (>= 2 on a 4 point categorical scale) within 48 h of unilateral total knee or total hip arthroplasty. Patients were randomized to receive lumiracoxib 400 mg once daily (n = 60), placebo (n = 60) or naproxen 500 mg twice daily (n = 60). The study consisted of a 12 h single dose phase followed by a multiple dose phase (up to 96 h or until discontinuation). The primary efficacy measure was the summed (time weighted) pain intensity difference over 0 8 h after the first dose (SPID 8).
   Results: Lumiracoxib and naproxen were comparable and both treatments were superior to placebo for the primary efficacy measure, SPID 8. Both treatments were generally similar and also superior to placebo for the secondary efficacy measures during both the single  and multiple dose phases for up to 96 h. Both active treatments were well tolerated.
   Conclusions: Lumiracoxib is an effective alternative to traditional non selective non steroidal anti inflammatory drugs (NSAIDs) for the treatment of post operative pain.
C1 Univ Hlth Network, Toronto Western Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5T 2S8, Canada.
   Calgary Hlth Reg, Chron Pain Ctr, Calgary, AB, Canada.
   Capstone Clin Trials Inc, Alabama Orthoped Ctr, Birmingham, AL USA.
   Novartis Pharmaceut, E Hanover, NJ USA.
C3 University of Toronto; University Health Network Toronto; University of
   Calgary; Novartis; Novartis USA
RP Chan, VWS (通讯作者)，Univ Hlth Network, Toronto Western Hosp, Dept Anesthesia & Pain Management, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.
EM vincent.chan@uhn.on.ca
RI Clark, Allison/HGD 0741 2022
CR Afflitto L, 2000, Plast Surg Nurs, V20, P91
   Atherton C, 2004, CLIN GASTROENTEROL H, V2, P113, DOI 10.1016/S1542 3565(03)00318 5
   Baber SR, 2003, AM J PHYSIOL HEART C, V285, pH2399, DOI 10.1152/ajpheart.00294.2003
   Bensen WG, 2000, J RHEUMATOL, V27, P1876
   Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140 6736(04)16894 3
   FRICKE J, WORLD C PAIN WCP 200, P223
   Gimbel JS, 2001, CLIN THER, V23, P228, DOI 10.1016/S0149 2918(01)80005 9
   Grifka JK, 2004, CLIN EXP RHEUMATOL, V22, P589
   Hawkey CC, 2004, J RHEUMATOL, V31, P1804
   Katz WA, 2002, CLEV CLIN J MED, V69, P65
   Kellstein D, 2004, INT J CLIN PRACT, V58, P244, DOI 10.1111/j.1368 5031.2004.00155.x
   Knijff Dutmer EAJ, 2002, RHEUMATOLOGY, V41, P458, DOI 10.1093/rheumatology/41.4.458
   Langman MJ, 1999, JAMA J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929
   Mangold JB, 2004, DRUG METAB DISPOS, V32, P566, DOI 10.1124/dmd.32.5.566
   Marshall P.J., 2002, Ann. Rheum. Dis, V61, P259
   Miller RG, 1981, SURVIVAL ANAL, P74
   Reicin A, 2001, Am J Orthop (Belle Mead NJ), V30, P40
   Reuben SS, 2002, J ARTHROPLASTY, V17, P26, DOI 10.1054/arth.2002.27677
   Schnitzer TJ, 2004, ARTHRIT RHEUM ARTHR, V51, P549, DOI 10.1002/art.20525
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Scott G, 2004, CLIN PHARMACOKINET, V43, P467, DOI 10.2165/00003088 200443070 00003
   Scott G., 2003, P124
   SCOTT G, 2002, ANN RHEUM DIS S1, V61, P128
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Silverman DG, 2003, CAN J ANAESTH, V50, P1004, DOI 10.1007/BF03018363
   Sinatra R, 2002, J PAIN SYMPTOM MANAG, V24, pS18, DOI 10.1016/S0885 3924(02)00410 4
   Sinatra R., 2002, J AM ACAD ORTHOP SUR, V10, P117
   Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497
   Tannenbaum H, 2004, ANN RHEUM DIS, V63, P1419, DOI 10.1136/ard.2003.015974
   VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928
   WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542 199511000 00023
   Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407
   Zelenakas K, 2004, INT J CLIN PRACT, V58, P251, DOI 10.1111/j.1368 5031.2004.00156.x
NR 33
TC 23
Z9 23
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0001 5172
EI 1399 6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD NOV
PY 2005
VL 49
IS 10
BP 1491
EP 1500
DI 10.1111/j.1399 6576.2005.00782.x
PG 10
WC Anesthesiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology
GA 973YC
UT WOS:000232557500015
PM 16223396
DA 2025 08 17
ER

PT J
AU Velzenberger, E
   Vayssade, M
   Legeay, G
   Nagel, MD
AF Velzenberger, Elodie
   Vayssade, Muriel
   Legeay, Gilbert
   Nagel, Marie Danielle
TI Study of cell behaviour on a cellulose anti adhesive substratum
SO CELLULOSE
LA English
DT Article
DE carboxymethylcellulose; hydroxypropylmethylcellulose; three dimensional
   culture; cell adhesion; cell proliferation; apoptosis
ID ANCHORAGE INDEPENDENT GROWTH; MELANOMA CELLS; DIFFERENTIAL EXPRESSION;
   EXTRACELLULAR MATRIX; APOPTOTIC CELLS; DRUG DELIVERY; T LYMPHOCYTES;
   IN VITRO; SURVIVAL; ADHESION
AB Carboxymethylcellulose (CMC) is used as an anti adhesive in several biomaterial applications. We have shown that an original bi layered hydroxypropylmethylcellulose (HPMC) CMC coated substratum (CEL) is suitable for studying the molecular mechanisms underlying cell substratum and cell cell interactions. The present work was carried out to assess the anti adhesive properties of a CEL substratum by analysing the behaviour of three types of adherent cells (Swiss 3T3 fibroblasts, MC 3T3 E1 pre osteoblasts and B16F10 highly metastatic melanoma cells). Tissue culture polystyrene (tPS) was used as an adhesive control and poly(2 hydroxyethyl methacrylate) PolyHEMA as an anti adhesive control. Cell morphology, growth, cell cycle analysis and apoptosis were compared. The proliferation of cells on CEL was significantly decreased, cells were arrested in the G1 phase and underwent apoptosis (except for melanoma cells) 48 h post seeding. We conclude that CEL is an effective anti adhesive cellulose biomaterial that gives reproducible and demonstratable results, especially for apoptosis. Its advantage as a coating for culture devices is its long shelf live. It may therefore also be a very good candidate for other biomedical applications requiring adhesion resistant substrata.
C1 [Velzenberger, Elodie; Vayssade, Muriel; Nagel, Marie Danielle] Univ Technol Compiegne, CNRS, UMR Domaine Biomat Biocompatibil 6600, F 60205 Compiegne, France.
   [Legeay, Gilbert] Ctr Transfert Technol Mans, Dept Mat, Le Mans, France.
C3 Universite de Technologie de Compiegne; Centre National de la Recherche
   Scientifique (CNRS)
RP Nagel, MD (通讯作者)，Univ Technol Compiegne, CNRS, UMR Domaine Biomat Biocompatibil 6600, 20529, F 60205 Compiegne, France.
EM marie danielle.nagel@utc.fr
OI Vayssade, Muriel/0000 0003 2926 1776
CR Barbucci R, 2004, J BIOMAT SCI POLYM E, V15, P607, DOI 10.1163/156856204323046870
   Beck DE, 1997, EUR J SURG, V163, P49
   Bottaro DP, 2002, ANN NY ACAD SCI, V961, P143, DOI 10.1111/j.1749 6632.2002.tb03068.x
   Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264 6021:3390481
   Bretland AJ, 2001, CELL PROLIFERAT, V34, P199, DOI 10.1046/j.1365 2184.2001.00198.x
   Buckenmaier CC, 2000, AM SURGEON, V66, P1041
   Caruso DM, 2006, J BURN CARE RES, V27, P298, DOI 10.1097/01.BCR.0000216741.21433.66
   Chen CS, 2003, BIOCHEM BIOPH RES CO, V307, P355, DOI 10.1016/S0006 291X(03)01165 3
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Chiumiento A, 2006, J MATER SCI MATER M, V17, P427, DOI 10.1007/s10856 006 8470 0
   Datta N, 2005, BIOMATERIALS, V26, P971, DOI 10.1016/j.biomaterials.2004.04.001
   DEPAUWGILLET MCAJ, 1988, ANTICANCER RES, V8, P153
   Díaz Montero CM, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 39
   Draye JP, 1998, BIOMATERIALS, V19, P1677, DOI 10.1016/S0142 9612(98)00049 0
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   Faucheux N, 2004, BIOMATERIALS, V25, P2501, DOI 10.1016/j.biomaterials.2003.09.036
   Faucheux N, 2001, BIOMATERIALS, V22, P2993, DOI 10.1016/S0142 9612(01)00045 X
   FAUCHEUX N, 2006, BEHAV CELLS CULTURED, P35
   FEDERMENGUS C, 2007, BR J CANC
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   Frankfurt OS, 2001, J HISTOCHEM CYTOCHEM, V49, P369, DOI 10.1177/002215540104900311
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Gekas J, 2004, FEBS LETT, V563, P103, DOI 10.1016/S0014 5793(04)00276 5
   Ghosh S, 2005, ANN SURG, V242, P851, DOI 10.1097/01.sla.0000189571.84213.b0
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431
   Goldmann WH, 2002, CELL BIOL INT, V26, P313, DOI 10.1006/cbir.2002.0857
   Guest JF, 2005, CURR MED RES OPIN, V21, P281, DOI 10.1185/030079905X25532
   Guest JF, 2005, CURR MED RES OPIN, V21, P81, DOI 10.1185/030079904X15219
   Hindié A, 2005, BIOMOL ENG, V22, P205, DOI 10.1016/j.bioeng.2005.07.002
   Hindié M, 2006, J CELL BIOCHEM, V99, P96, DOI 10.1002/jcb.20833
   Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044
   Jorgensen K, 2005, BIOCHEM BIOPH RES CO, V329, P266, DOI 10.1016/j.bbrc.2005.01.143
   Krylov SN, 2000, ELECTROPHORESIS, V21, P767, DOI 10.1002/(SICI)1522 2683(20000301)21:4<767::AID ELPS767>3.0.CO;2 E
   LaRue KEA, 2004, CANCER RES, V64, P1621, DOI 10.1158/0008 5472.CAN 2902 2
   Liu LS, 2007, CELLULOSE, V14, P15, DOI 10.1007/s10570 006 9095 7
   Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962 8924(98)01362 2
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953
   Mousavi Shafaei P, 2006, ANTI CANCER DRUG, V17, P1031, DOI 10.1097/01.cad.0000231474.77159.e3
   Ravenscroft MJ, 2006, ANN ROY COLL SURG, V88, P18, DOI 10.1308/003588406X82989
   Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555 005 5134 3
   Rosso F, 2005, J CELL PHYSIOL, V203, P465, DOI 10.1002/jcp.20270
   Rosso F, 2004, J CELL PHYSIOL, V199, P174, DOI 10.1002/jcp.10471
   Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142 9612(03)00339 9
   Shiras A, 2002, CLIN EXP METASTAS, V19, P445, DOI 10.1023/A:1016305611858
   Szabo A, 2000, EUR SURG RES, V32, P125, DOI 10.1159/000008751
   Tsuchimochi K, 2005, MOL CELL BIOL, V25, P7344, DOI 10.1128/MCB.25.16.7344 7356.2005
   van't Riet M, 2003, ANN SURG, V237, P123, DOI 10.1097/00000658 200301000 00017
   VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022 1759(95)00072 I
   Wang LH, 2004, MT SINAI J MED, V71, P361
   Wu PC, 1998, DRUG DEV IND PHARM, V24, P179, DOI 10.3109/03639049809085604
   Zhan M, 2004, HISTOL HISTOPATHOL, V19, P973, DOI 10.14670/HH 19.973
   Zhang XD, 2004, MOL CANCER THER, V3, P187
NR 55
TC 17
Z9 18
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969 0239
EI 1572 882X
J9 CELLULOSE
JI Cellulose
PD APR
PY 2008
VL 15
IS 2
BP 347
EP 357
DI 10.1007/s10570 007 9182 4
PG 11
WC Materials Science, Paper & Wood; Materials Science, Textiles; Polymer
   Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Polymer Science
GA 267QR
UT WOS:000253524800017
DA 2025 08 17
ER

PT J
AU Avinash, H
   Sudha, V
   Laxminarayan, B
   Nandakrishna, B
   Shastry, BA
   Asha, K
   Hande, M
AF Avinash, Holla
   Sudha, Vidyasagar
   Laxminarayan, Bairy
   Nandakrishna, B.
   Shastry, B. A.
   Asha, Kamath
   Hande, Manjunath
TI The novel mechanism of steroid induced diabetes mellitus
SO INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES
LA English
DT Article
DE Steroid induced diabetes; Insulin resistance; Serum osteocalcin; Fasting
   insulin
ID INDUCED INSULIN RESISTANCE; SERUM OSTEOCALCIN LEVELS; PLASMA GLUCOSE;
   RISK FACTORS; METABOLISM
AB Background Steroid induced diabetes (SID) may be due to either insulin resistance (IR) or beta cell dysfunction or combination of both. Several studies have established that these effects of steroids may be mediated by an osteoblast derived protein called osteocalcin (OC). However, this effect has been described only in diabetic patients and has not been studied in SID patients. Aim and study design A prospective observational study was designed to evaluate the correlation between serum OC level and blood glucose profile, in patients on steroids. Results Out of a total of 88 subjects who were on steroid therapy, 42 (47.7%) subjects had their blood sugar levels in the diabetic range. Based on the glycemic status, subjects were divided into three groups, namely, normal, prediabetic, and diabetic. The patients who developed SID were older than normal (mean age 43.15 vs 39.27 years). The age (r =   0.105 p = 0.5), BMI (r =   0.3 p = 0.07), and abdominal obesity (r =   0.32 p = 0.04) were negatively correlated with serum osteocalcin in diabetic group. Dose of steroids was negatively correlated with OC in all three groups. Fasting plasma glucose, fasting insulin, and IR were negatively correlated with OC in diabetic group. Conclusion Decrease in serum osteocalcin level with increase in glycemic parameters in steroid induced diabetic group points to the novel mechanism of steroid induced diabetes.
C1 [Avinash, Holla; Sudha, Vidyasagar; Nandakrishna, B.; Shastry, B. A.; Hande, Manjunath] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Med, Manipal 576104, Karnataka, India.
   [Laxminarayan, Bairy] Pharmacol RAK Coll Med Sci, Ras Al Khaymah, U Arab Emirates.
   [Asha, Kamath] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Dept Stat, Manipal, India.
C3 Manipal Academy of Higher Education (MAHE); Kasturba Medical College,
   Manipal; Manipal Academy of Higher Education (MAHE)
RP Sudha, V (通讯作者)，Manipal Acad Higher Educ, Kasturba Med Coll, Dept Med, Manipal 576104, Karnataka, India.
EM vsagar33@yahoo.com
FU Research Society for the study of diabetes in India (RSSDI) grants
FX This study was financially supported by the Research Society for the
   study of diabetes in India (RSSDI) grants.
CR American Diabetes Association, 2015, Clin Diabetes, V33, P97, DOI 10.2337/diaclin.33.2.97
   Bao YQ, 2013, J CLIN ENDOCR METAB, V98, P345, DOI 10.1210/jc.2012 2906
   Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Donihi Amy Calabrese, 2006, Endocr Pract, V12, P358
   Ferris HA, 2012, J CLIN INVEST, V122, P3854, DOI 10.1172/JCI66180
   Geer EB, 2014, ENDOCRIN METAB CLIN, V43, P75, DOI 10.1016/j.ecl.2013.10.005
   Gonzalez Gonzalez JG, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758 5996 5 18
   Ha YJ, 2011, LUPUS, V20, P1027, DOI 10.1177/0961203311402246
   Katsuyama T, 2015, DIABETES RES CLIN PR, V108, P273, DOI 10.1016/j.diabres.2015.02.010
   Kim SY, 2011, J KOREAN MED SCI, V26, P264, DOI 10.3346/jkms.2011.26.2.264
   Kindblom JM, 2009, J BONE MINER RES, V24, P785, DOI 10.1359/JBMR.081234
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Maddaloni E, 2014, J ENDOCRINOL INVEST, V37, P661, DOI 10.1007/s40618 014 0092 7
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Parker L, 2019, J BONE MINER RES, V34, P49, DOI 10.1002/jbmr.3574
   Rao NK, 2016, ASIAN J PHARM CLIN R, V9, P262
   Sarkar PD, 2013, EUR REV MED PHARMACO, V17, P1631
   Shanbhogue Vikram V, 2010, J Assoc Physicians India, V58, P202
   Simmons Lisa R, 2012, ISRN Endocrinol, V2012, P910905, DOI 10.5402/2012/910905
   Takashi Y, 2017, J DIABETES INVEST, V8, P471, DOI 10.1111/jdi.12601
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Wang QG, 2013, SCI WORLD J, DOI 10.1155/2013/231768
   Wei JW, 2014, DIABETES, V63, P1021, DOI 10.2337/db13 0887
   Yeap BB, 2011, EUR J ENDOCRINOL, V164, P315, DOI 10.1530/EJE 10 0414e
   Zhou M, 2009, EUR J ENDOCRINOL, V161, P723, DOI 10.1530/EJE 09 0585
NR 25
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0973 3930
EI 1998 3832
J9 INT J DIABETES DEV C
JI Int. Diabetes Dev. Ctries.
PD SEP
PY 2020
VL 40
IS 3
BP 399
EP 405
DI 10.1007/s13410 019 00791 6
EA FEB 2020
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NS7PB
UT WOS:000515866000001
DA 2025 08 17
ER

PT J
AU Pabst, AM
   Krüger, M
   Sagheb, K
   Ziebart, T
   Jacobs, C
   Blatt, S
   Goetze, E
   Walter, C
AF Pabst, A. M.
   Krueger, M.
   Sagheb, K.
   Ziebart, T.
   Jacobs, C.
   Blatt, S.
   Goetze, E.
   Walter, C.
TI The influence of geranylgeraniol on microvessel sprouting after
   bisphosphonate substitution in an in vitro 3D angiogenesis assay
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Bisphosphonate; BP ONJ; Osteonecrosis; Isoprenoid; Geranylgeraniol;
   Angiogenesis
ID MEVALONATE KINASE DEFICIENCY; SURGEONS POSITION PAPER; INTUSSUSCEPTIVE
   ANGIOGENESIS; MOLECULAR MECHANISMS; AMERICAN ASSOCIATION; AVASCULAR
   NECROSIS; HYPERBARIC OXYGEN; OSTEOGENIC CELLS; OSTEONECROSIS; JAW
AB Recent studies focused on angiogenesis in the pathophysiology of bisphosphonate associated osteonecrosis of the jaws (BP ONJ) and identified geranylgeraniol (GGOH) as a feasible option for BP ONJ therapy. This study investigated the influence of GGOH on microvessel sprouting after BP incubation in vitro.
   Ten experimental set ups were randomly designed in an in vitro 3D angiogenesis assay. Two groups included HUVEC cell spheroids with and without (+/ ) GGOH substitution as controls and eight groups pairwise contained either clodronate or the nitrogen containing bisphosphonates (N BP) ibandronate, pamidronate, and zoledronate +/  GGOH. The size of the cell spheroids including the outbranching sprouts (SpS) as well as the density (SpD) and length of the sprouts (SpL) were analyzed by a grid system after 0, 24, 48, and 72 h.
   For controls and NN BP clodronate, no significant differences at any tested parameter and any point of measurement could be detected within the experimental set ups +/  GGOH (p each ae<yen>0.05). For N BP ibandronate, the experimental set ups +GGOH showed a significantly increased SpS, SpD, and SpL after 48 and 72 h (p each >= 0.002) compared to the experimental set ups  GGOH. For N BPs pamidronate and zoledronate, the experimental set ups + GGOH demonstrated a significantly increased SpS, SpD, and SpL after 24, 48, and 72 h (p each ae<currency>0.001) compared to the experimental set ups  GGOH.
   The strong negative influence of N BPs on microvessel sprouting could be significantly reversed by GGOH.
   Since supportive therapeutic options for BP ONJ are lacking, GGOH might be a promising substitute for BP ONJ prevention and therapy.
C1 [Pabst, A. M.] Fed Armed Forces Hosp, Dept Oral & Maxillofacial Surg, Rubenacherstr 170, D 56072 Koblenz, Germany.
   [Pabst, A. M.; Krueger, M.; Sagheb, K.; Blatt, S.; Goetze, E.; Walter, C.] Univ Med Ctr, Dept Oral & Maxillofacial Surg, Augustuspl 2, D 55131 Mainz, Germany.
   [Ziebart, T.] Univ Clin, Dept Oral & Maxillofacial Surg, Georg Voigt Str 3, D 35039 Marburg, Germany.
   [Jacobs, C.] Univ Med Ctr, Dept Orthodont, Augustuspl 2, D 55131 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz
RP Pabst, AM (通讯作者)，Fed Armed Forces Hosp, Dept Oral & Maxillofacial Surg, Rubenacherstr 170, D 56072 Koblenz, Germany.; Pabst, AM (通讯作者)，Univ Med Ctr, Dept Oral & Maxillofacial Surg, Augustuspl 2, D 55131 Mainz, Germany.
EM andipabst@me.com
RI ; Jacobs, Collin/KMY 3514 2024; Ziebart, Thomas/C 7048 2017; Krüger,
   Marcus/N 8667 2019
OI Ziebart, Thomas/0000 0003 3296 7630; Ziebart,
   Thomas/0000 0001 8504 4958; 
FU Department of Oral and Maxillofacial Surgery, University Medical Center,
   Mainz, Germany
FX No fundings were received for this study. The work was supported by the
   Department of Oral and Maxillofacial Surgery, University Medical Center,
   Augustusplatz 2, 55131 Mainz, Germany.
CR Ackermann M, 2014, ANGIOGENESIS, V17, P541, DOI 10.1007/s10456 013 9399 9
   Ackermann M, 2012, ANGIOGENESIS, V15, P685, DOI 10.1007/s10456 012 9294 9
   Ackermann M, 2011, INT J MOL MED, V27, P647, DOI 10.3892/ijmm.2011.641
   Agarwala S, 2002, RHEUMATOLOGY, V41, P346, DOI 10.1093/rheumatology/41.3.346 a
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Assaf AT, 2014, J CRANIO MAXILL SURG, V42, pE157, DOI 10.1016/j.jcms.2013.07.014
   Belcher R, 2014, J ORAL MAXIL SURG, V72, P306, DOI 10.1016/j.joms.2013.07.038
   Blus C, 2013, OPEN DENT J, V7, P94, DOI 10.2174/1874210601307010094
   Burri PH, 2002, MOL ASPECTS MED, V23, pS1
   Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008 6363(00)00281 9
   Draenert GF, 2012, J CRANIO MAXILL SURG, V40, pE369, DOI 10.1016/j.jcms.2012.01.028
   Ersan N, 2014, DENTOMAXILLOFAC RAD, V43, DOI 10.1259/dmfr.20130144
   Favia G, 2011, CLIN IMPLANT DENT R, V13, P58, DOI 10.1111/j.1708 8208.2009.00181.x
   Freiberger JJ, 2007, J ORAL MAXIL SURG, V65, P1321, DOI 10.1016/j.joms.2007.03.019
   Freiberger JJ, 2009, J ORAL MAXIL SURG, V67, P96, DOI 10.1016/j.joms.2008.12.003
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P1079, DOI 10.1007/s00784 014 1320 4
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Hamada H, 2014, J CRANIO MAXILL SURG, V42, P924, DOI 10.1016/j.jcms.2014.01.012
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Konerding MA, 2010, ANAT REC, V293, P849, DOI 10.1002/ar.21110
   Marcuzzi A, 2012, INT J DEV NEUROSCI, V30, P451, DOI 10.1016/j.ijdevneu.2012.06.002
   Marcuzzi A, 2010, INT IMMUNOPHARMACOL, V10, P639, DOI 10.1016/j.intimp.2010.03.008
   Marcuzzi A, 2010, INFLAMM RES, V59, P335, DOI 10.1007/s00011 010 0168 6
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Matos MA, 2007, ACTA CIR BRAS, V22, P115, DOI 10.1590/S0102 86502007000200007
   Pabst AM, 2015, CLIN ORAL INVEST, V19, P1625, DOI 10.1007/s00784 014 1394 z
   Pabst AM, 2014, CLIN ORAL INVEST, V18, P1015, DOI 10.1007/s00784 013 1060 x
   Pabst AM, 2012, CLIN ORAL INVEST, V16, P87, DOI 10.1007/s00784 010 0507 6
   Pabst AM, 2015, J CRANIO MAXILL SURG, V43, P688, DOI 10.1016/j.jcms.2015.03.014
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Staton CA, 2009, INT J EXP PATHOL, V90, P195, DOI 10.1111/j.1365 2613.2008.00633.x
   Tricarico PM, 2015, MOL MED REP, V12, P4238, DOI 10.3892/mmr.2015.3957
   Tricarico PM, 2014, INT J MOL SCI, V15, P6843, DOI 10.3390/ijms15046843
   Tricarico PM, 2013, INT J MOL SCI, V14, P23274, DOI 10.3390/ijms141223274
   Van Poznak C, 2010, BREAST CANCER RES TR, V122, P189, DOI 10.1007/s10549 010 0933 9
   Vescovi P, 2010, LASER MED SCI, V25, P101, DOI 10.1007/s10103 009 0687 y
   Voss PJ, 2016, CLIN ORAL INVEST, V20, P31, DOI 10.1007/s00784 015 1468 6
   Voss PJ, 2015, J CRANIO MAXILL SURG, V43, P1133, DOI 10.1016/j.jcms.2015.04.020
   Vyas Sheena, 2014, Dent Update, V41, P449
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Walter C, 2014, CLIN ORAL INVEST, V18, P2221, DOI 10.1007/s00784 014 1205 6
   Wehrhan F, 2011, ORAL DIS, V17, P433, DOI 10.1111/j.1601 0825.2010.01778.x
   Wehrhan F, 2011, ORAL SURG ORAL MED O, V112, P216, DOI 10.1016/j.tripleo.2011.02.028
   Wehrhan F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 96
   WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23
   Zanin V, 2012, INFLAMM RES, V61, P1363, DOI 10.1007/s00011 012 0537 4
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 50
TC 11
Z9 12
U1 0
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD APR
PY 2017
VL 21
IS 3
BP 771
EP 778
DI 10.1007/s00784 016 1842 z
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ER3PV
UT WOS:000398710700006
PM 27170294
DA 2025 08 17
ER

PT J
AU Wittwer, M
   Grandgirard, D
   Rohrbach, J
   Leib, SL
AF Wittwer, Matthias
   Grandgirard, Denis
   Rohrbach, Janine
   Leib, Stephen L.
TI Tracking the transcriptional host response from the acute to the
   regenerative phase of experimental pneumococcal meningitis
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID STREPTOCOCCUS PNEUMONIAE; BACTERIAL MENINGITIS; MATRIX
   METALLOPROTEINASES; IMMUNE RESPONSE; TGF BETA; TRANSFORMING
   GROWTH FACTOR BETA 1; DIFFERENTIATING OSTEOBLASTS; GLUCOCORTICOIDS
   INHIBIT; HIPPOCAMPAL APOPTOSIS; PROTEIN EXPRESSION
AB Background: Despite the availability of effective antibiotic therapies, pneumococcal meningitis ( PM) has a case fatality rate of up to 30% and causes neurological sequelae in up to half of the surviving patients. The underlying brain damage includes apoptosis of neurons in the hippocampus and necrosis in the cortex. Therapeutic options to reduce acute injury and to improve outcome from PM are severely limited. With the aim to develop new therapies a number of pharmacologic interventions have been evaluated. However, the often unpredictable outcome of interventional studies suggests that the current concept of the pathophysiologic events during bacterial meningitis is fragmentary. The aim of this work is to describe the transcriptomic changes underlying the complex mechanisms of the host response to pneumococcal meningitis in a temporal and spatial context using a well characterized infant rat model.
   Methods: Eleven days old nursing Wistar rats were infected by direct intracisternal injection of 2 x 10(6)cfu/ml of Streptococcus pneumoniae. Animals were sacrificed at 1, 3, 10 and 26 days after infection, the brain harvested and the cortex and hippocampus were sampled. The first two time points represent the acute and sub acute phase of bacterial meningitis, whereas the latter represent the recovery phase of the disease.
   Results: The major events in the regulation of the host response on a transcriptional level occur within the first 3 days after infection. Beyond this time, no differences in global gene expression in infected and control animals were detectable by microarray analysis. Whereas in the acute phase of the disease immunoregulatory processes prevail in the hippocampus and the cortex, we observed a strong activation of neurogenic processes in the hippocampal dentate gyrus, both by gene expression and immunohistology starting as early as 3 days after infection.
   Conclusions: Here we describe the cellular pathways involved in the host response to experimental pneumococcal meningitis in specified disease states and brain regions. With these results we hope to provide the scientific basis for the development of new treatment strategies which take the temporal aspects of the disease into account.
C1 [Wittwer, Matthias; Grandgirard, Denis; Rohrbach, Janine; Leib, Stephen L.] Univ Bern, Inst Infect Dis, CH 3010 Bern, Switzerland.
C3 University of Bern
RP Leib, SL (通讯作者)，Univ Bern, Inst Infect Dis, Friedbuehlstr 51, CH 3010 Bern, Switzerland.
EM stephen.leib@ifik.unibe.ch
RI ; Wittwer, Matthias/K 4512 2014; Grandgirard, Denis/AAB 8786 2020; Leib,
   Stephen/A 7866 2011
OI Grandgirard, Denis/0000 0002 4151 5196; Leib, Stephen
   Louis/0000 0002 1106 6123; 
FU UBS Optimus Foundation; Swiss National Science Foundation
   [310000 116257]
FX The authors would like to thank Angela Buhlmann, Kevin Oberson and
   Philippe Demougin for their excellent technical support. The study was
   supported by the UBS Optimus Foundation and by the Swiss National
   Science Foundation (310000 116257 to SLL).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bellac CL, 2007, NEUROBIOL DIS, V28, P175, DOI 10.1016/j.nbd.2007.07.005
   Bellac CL, 2006, NEUROBIOL DIS, V24, P395, DOI 10.1016/j.nbd.2006.07.014
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007
   Bifrare YD, 2005, J INFECT DIS, V191, P40, DOI 10.1086/426399
   Bonaguidi MA, 2005, DEVELOPMENT, V132, P5503, DOI 10.1242/dev.02166
   Böttner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471 4159.2000.0752227.x
   Brandenburg LO, 2008, J NEUROPATH EXP NEUR, V67, P1041, DOI 10.1097/NEN.0b013e31818b4801
   Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006
   Chen SZ, 2002, J NEUROIMMUNOL, V133, P46, DOI 10.1016/S0165 5728(02)00354 5
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   Culhane AC, 2005, BIOINFORMATICS, V21, P2789, DOI 10.1093/bioinformatics/bti394
   de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334
   Djukic M, 2006, BRAIN, V129, P2394, DOI 10.1093/brain/awl206
   Docagne F, 2002, MOL CELL NEUROSCI, V21, P634, DOI 10.1006/mcne.2002.1206
   Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161 5890(03)00109 3
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Gerber J, 2003, J NEUROSCI RES, V73, P441, DOI 10.1002/jnr.10682
   Gianinazzi C, 2003, ACTA NEUROPATHOL, V105, P499, DOI 10.1007/s00401 003 0672 7
   Grandgirard D, 2007, DEV NEUROSCI BASEL, V29, P134, DOI 10.1159/000096218
   Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074 7742(07)82002 2
   Hashimoto K, 2006, GLYCOBIOLOGY, V16, p63R, DOI 10.1093/glycob/cwj010
   Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805
   Hopwood B, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2301
   Hunter SM, 2008, J BIOCHEM BIOPH METH, V70, P1048, DOI 10.1016/j.jprot.2007.11.011
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kastenbauer S, 2003, BRAIN, V126, P1015, DOI 10.1093/brain/awg113
   Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346 04.2005
   Klein M, 2006, MICROBES INFECT, V8, P974, DOI 10.1016/j.micinf.2005.10.013
   Koedel U, 2004, BRAIN, V127, P1437, DOI 10.1093/brain/awh171
   Koedel U, 2003, J IMMUNOL, V170, P438, DOI 10.4049/jimmunol.170.1.438
   Koedel U, 2002, LANCET INFECT DIS, V2, P721, DOI 10.1016/S1473 3099(02)00450 4
   Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821
   Krieglstein K, 2002, J PHYSIOLOGY PARIS, V96, P25, DOI 10.1016/S0928 4257(01)00077 8
   Leib SL, 2003, PEDIATR RES, V54, P353, DOI 10.1203/01.PDR.0000079185.67878.72
   Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615 620.2000
   Leib SL, 2001, BRAIN, V124, P1734, DOI 10.1093/brain/124.9.1734
   Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891 5520(05)70093 3
   Leppert D, 2001, BRAIN RES REV, V36, P249, DOI 10.1016/S0165 0173(01)00101 1
   Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Manolidis Spiros, 2006, Ear Nose Throat J, V85, P586
   Michaelidis TM, 2008, CELL TISSUE RES, V331, P193, DOI 10.1007/s00441 007 0476 5
   Michel U, 2003, J NEUROCHEM, V86, P238, DOI 10.1046/j.1471 4159.2003.01834.x
   Mostany R, 2008, NEUROPHARMACOLOGY, V55, P18, DOI 10.1016/j.neuropharm.2008.04.012
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Ostergaard C, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471 2334 5 93
   Peltola H, 2007, CLIN INFECT DIS, V45, P1277, DOI 10.1086/522534
   Rückinger S, 2009, PEDIATR INFECT DIS J, V28, P118, DOI 10.1097/INF.0b013e318187e215
   Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   Spreer A, 2006, PEDIATR RES, V60, P210, DOI 10.1203/01.pdr.0000227553.47378.9f
   Swartz MN, 2004, NEW ENGL J MED, V351, P1826, DOI 10.1056/NEJMp048246
   Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611
   Takahashi K, 2007, PLOS MED, V4, P675, DOI 10.1371/journal.pmed.0040124
   Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365 2443.2001.00458.x
   Tauber SC, 2005, J NEUROPATH EXP NEUR, V64, P806, DOI 10.1097/01.jnen.0000178853.21799.88
   Ting L, 2009, MOL CELL PROTEOMICS, V8, P2227, DOI 10.1074/mcp.M800462 MCP200
   Unsicker K, 2002, ADV EXP MED BIOL, V513, P353
   van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2
   van de Beek D, 2010, LANCET NEUROL, V9, P254, DOI 10.1016/S1474 4422(10)70023 5
   van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8
   Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097 4547(20000815)61:4<430::AID JNR9>3.0.CO;2 3
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Weisfelt M, 2006, ANN NEUROL, V60, P456, DOI 10.1002/ana.20944
   Wexler EM, 2008, MOL PSYCHIATR, V13, P285, DOI 10.1038/sj.mp.4002093
   Zhu Y, 2004, NEUROSCIENCE, V123, P897, DOI 10.1016/j.neuroscience.2003.10.037
   Zysk G, 1996, J NEUROPATH EXP NEUR, V55, P722, DOI 10.1097/00005072 199606000 00006
NR 74
TC 16
Z9 16
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 17
PY 2010
VL 10
AR 176
DI 10.1186/1471 2334 10 176
PG 21
WC Infectious Diseases
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases
GA 666RA
UT WOS:000283134600001
PM 20565785
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ko, KR
   Lee, S
   Oh, SY
   Kim, KD
   Park, SH
   Lee, S
AF Ko, Kyung Rae
   Lee, Sangcheol
   Oh, Seo Yoon
   Kim, Ki duk
   Park, Sin Hyung
   Lee, Soonchul
TI Long Term Oral Bisphosphonate Compliance Focusing on Switching of
   Prescription Pattern
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE bisphosphonate; compliance; medication possession ratio; MPR
ID POSTMENOPAUSAL WOMEN; FRACTURE RATES; OSTEOPOROTIC WOMEN; PERSISTENCE;
   THERAPY; DENOSUMAB; ADHERENCE; RISK; MEDICATION; IMPACT
AB Background: Factors determining bisphosphonate compliance are not fully understood. We examined fluctuations in oral bisphosphonate dosing intervals to gauge therapeutic compliance in patients with osteoporosis. Materials and
   Methods: Hospital data accruing between 2010 and 2017 were accessed to retrospectively study patients >= 50 years old (N=1873), each prescribed bisphosphonate at initial diagnosis of osteoporosis. The medication possession ratio (MPR), calculated as total days supplied divided by length of follow up, served to measure therapeutic compliance. We compared MPRs of various prescription patterns (daily, weekly, monthly, and switch [ie, >= 1 change in pattern] groups). We also analyzed the impact of age, sex, fracture history, surgical history, and comorbidities. Multiple regression analysis was ultimately performed, using MPR as a dependent variable.
   Results: In our cohort (mean follow up=5.7 +/  2.4 years), once weekly dosing was the most common prescription pattern (1223/1873, 65.3%), as opposed to monthly (366/1873, 19.5%) or daily (164/1873, 8.8%) dosing. A total of 120 patients (6.4%) comprising the switch group changed dosing patterns during the study period. MPR was significantly higher in the switch group (32.8 +/  22.7) than in the other three groups (daily, 21.9 +/  25.9; weekly, 22.7 +/  27.3; monthly, 23.2 +/  27.7). In multiple regression analysis, younger age (P<0.001), female sex (P=0.004), and switching of prescription pattern (decrease or increase frequency) were factors significantly associated with higher MPR, signaling better compliance.
   Conclusion: Better bisphosphonate compliance was associated with physician modified dosing patterns. We therefore recommend adjustments of prescription intervals in poorly compliant patients requiring long term treatment.
C1 [Ko, Kyung Rae] Sungkyunkwan Univ, Samsung Med Ctr, Dept Orthopaed Surg, Sch Med, Seoul, South Korea.
   [Lee, Sangcheol; Lee, Soonchul] CHA Univ, CHA Bundang Med Ctr, Dept Orthopaed Surg, 59 Yatap Ro, Seongnam Si, Gyeonggi Do, South Korea.
   [Oh, Seo Yoon] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Kim, Ki duk; Park, Sin Hyung] Soonchunhyang Univ, Bucheon Hosp, Dept Orthopaed Surg, Sch Med, 170 Jomaru Ro, Bucheon Si, Gyeonggi Do, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Pochon Cha
   University; University of California System; University of California
   Berkeley; Soonchunhyang University
RP Lee, S (通讯作者)，CHA Univ, CHA Bundang Med Ctr, Dept Orthopaed Surg, 59 Yatap Ro, Seongnam Si, Gyeonggi Do, South Korea.; Park, SH (通讯作者)，Soonchunhyang Univ, Bucheon Hosp, Dept Orthopaed Surg, Sch Med, 170 Jomaru Ro, Bucheon Si, Gyeonggi Do, South Korea.
EM Sh0803@schmc.ac.kr; Lsceline78@gmail.com
OI Ko, Kyung Rae/0000 0002 6164 8674; Lee, Sangcheol/0000 0002 0421 8731;
   Park, Sin Hyung/0000 0003 1804 0986
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute   Ministry of Health & Welfare, South Korea
   [HI16C1559]; National Research Foundation of Korea   Korea government
   (Ministry of Science and ICT) [2019R1C1C1004017]
FX This study was supported by Korea Health Technology R&D Project through
   the Korea Health Industry Development Institute, funded by the Ministry
   of Health & Welfare, South Korea (No. HI16C1559) and by the National
   Research Foundation of Korea grant funded by the Korea government
   (Ministry of Science and ICT) (No. 2019R1C1C1004017).
CR Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230
   [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   Beest FJAPV, 2008, OSTEOPOROSIS INT, V19, P511, DOI 10.1007/s00198 007 0466 1
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Briesacher BA, 2010, AM J MED, V123, P275, DOI 10.1016/j.amjmed.2009.05.017
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Cheng LI, 2015, J MANAG CARE SPEC PH, V21, P824, DOI 10.18553/jmcp.2015.21.9.824
   Cho H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011470
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cotté FE, 2010, OSTEOPOROSIS INT, V21, P145, DOI 10.1007/s00198 009 0930 1
   Cotté FE, 2008, CLIN THER, V30, P2410, DOI 10.1016/j.clinthera.2008.12.019
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cramer JA, 2005, CURR MED RES OPIN, V21, P1453, DOI 10.1185/030079905X61875
   Cramer JA, 2007, CURR MED RES OPIN, V23, P2369, DOI 10.1185/030079907X226311
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Gold DT, 2007, CURR MED RES OPIN, V23, P585, DOI 10.1185/030079906X167615
   Hadji P, 2015, OSTEOPOROSIS INT, V26, P2479, DOI 10.1007/s00198 015 3164 4
   Hadji P, 2012, OSTEOPOROSIS INT, V23, P223, DOI 10.1007/s00198 011 1535 z
   Höer A, 2009, PATIENT PREFER ADHER, V3, P25
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   Ideguchi H, 2007, OSTEOPOROSIS INT, V18, P1421, DOI 10.1007/s00198 007 0406 0
   Imaz I, 2010, OSTEOPOROSIS INT, V21, P1943, DOI 10.1007/s00198 009 1134 4
   Iolascon G, 2013, AGING CLIN EXP RES, V25, pS137, DOI 10.1007/s40520 013 0127 5
   Karlsson L, 2015, OSTEOPOROSIS INT, V26, P2401, DOI 10.1007/s00198 015 3253 4
   Lakatos P, 2016, CALCIFIED TISSUE INT, V98, P215, DOI 10.1007/s00223 015 0082 6
   Li L, 2014, MENOPAUSE, V21, P1106, DOI [10.1097/GME.0000000000000214, 10.1097/gme.0000000000000214]
   Majumdar SR, 2007, OSTEOPOROSIS INT, V18, P261, DOI 10.1007/s00198 006 0248 1
   Papapoulos SE, 2011, ANN NY ACAD SCI, V1218, P15, DOI 10.1111/j.1749 6632.2010.05767.x
   Park EJ, 2014, YONSEI MED J, V55, P1049, DOI 10.3349/ymj.2014.55.4.1049
   Park SB, 2016, SPINE, V41, P328, DOI 10.1097/BRS.0000000000001291
   PECK WA, 1993, AM J MED, V94, P646
   Rabenda V, 2009, EXPERT OPIN PHARMACO, V10, P2303, DOI 10.1517/14656560903140533
   Scott LJ, 2014, DRUG AGING, V31, P555, DOI 10.1007/s40266 014 0191 3
   Silverman SL, 2015, OSTEOPOROSIS INT, V26, P361, DOI 10.1007/s00198 014 2871 6
   Silverman Stuart L, 2008, Curr Rheumatol Rep, V10, P118, DOI 10.1007/s11926 008 0021 x
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Weycker D, 2006, OSTEOPOROSIS INT, V17, P1645, DOI 10.1007/s00198 006 0179 x
NR 39
TC 0
Z9 0
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2020
VL 14
BP 2009
EP 2016
DI 10.2147/PPA.S266697
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA OE4EX
UT WOS:000580486700002
PM 33122894
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Burian, A
   Frangione, V
   Rovati, S
   Mautone, G
   Leuratti, C
   Vaccani, A
   Crevenna, R
   Keilani, M
   Burian, B
   Brunner, M
   Zeitlinger, M
AF Burian, Angela
   Frangione, Valeria
   Rovati, Stefano
   Mautone, Giuseppe
   Leuratti, Chiara
   Vaccani, Angelo
   Crevenna, Richard
   Keilani, Mohammad
   Burian, Bernhard
   Brunner, Martin
   Zeitlinger, Markus
TI An exploratory microdialysis study investigating the effect of repeated
   application of a diclofenac epolamine medicated plaster on prostaglandin
   concentrations in skeletal muscle after standardized physical exercise
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE diclofenac; microdialsis; pharmacokinetics; transdermal
ID CLINICAL PHARMACOKINETICS; PENETRATION; F 2 ISOPROSTANE; THROMBOXANE;
   TISSUE; PAIN; E 2; GEL
AB AIM
   Muscle injuries and extensive exercise are associated with cyclo oxygenase dependent formation of inflammatory prostaglandins. Since the effect of topical administration of non steroidal anti inflammatory drugs (NSAIDs) on local cyclo oxygenase is unknown, the present exploratory, open label, non randomized study set out to measure exercise induced release of prostaglandins before and after epicutaneous administration of diclofenac.
   METHODS
   Microdialysis was used to determine the local interstitial concentration of PGE(2) and 8 iso PGF(2 alpha) as well as diclofenac concentrations in the vastus lateralis under rest, dynamic exercise and during recovery in 12 healthy subjects at baseline and after a treatment phase applying a total of seven plasters medicated with 180 mg of diclofenac epolamine over 4 days.
   RESULTS
   At baseline PGE(2) concentrations were 1169 +/  780 pg ml( 1) at rest and 1287 +/  459 pg ml( 1) during dynamic exercise and increased to 2005 +/  1126 pg ml( 1) during recovery. After treatment average PGE(2) concentrations were 997 +/  588 pg ml( 1) at rest and 1339 +/  892 pg ml( 1) during exercise. In contrast with the baseline phase no increase in PGE(2) concentrations was recorded during the recovery period after treatment (PGE(2) 1134 +/  874 pg ml( 1)). 8 iso PGF(2 alpha) was neither affected by exercise nor by treatment with diclofenac. Local and systemic concentrations of diclofenac were highly variable but comparable with previous clinical pharmacokinetic studies.
   CONCLUSIONS
   We can hypothesize an effect of topical diclofenac epolamine plaster on limiting the increase of local concentrations of the pro inflammatory prostaglandin PGE(2) induced in the muscle of healthy human subjects following standardized physical exercise. No effect of diclofenac treatment on 8 iso PGF(2 alpha) concentrations was observed, mainly since isoprostane is produced by a free radical catalyzed lipid peroxidation mechanism independent of cyclo oxygenases.
C1 [Burian, Angela; Burian, Bernhard; Brunner, Martin; Zeitlinger, Markus] Med Univ Vienna, Dept Clin Pharmacol, A 1090 Vienna, Austria.
   [Crevenna, Richard; Keilani, Mohammad] Med Univ Vienna, Dept Phys Med & Rehabil, A 1090 Vienna, Austria.
   [Frangione, Valeria; Rovati, Stefano; Mautone, Giuseppe] IBSA Inst Biochim SA, Pambio Noranco, Switzerland.
   [Leuratti, Chiara; Vaccani, Angelo] CROSS SA, Mendrisio, Mendrisio, Switzerland.
C3 Medical University of Vienna; Medical University of Vienna
RP Zeitlinger, M (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
EM markus.zeitlinger@meduniwien.ac.at
RI Zeitlinger, Markus/GSN 3508 2022
OI Zeitlinger, Markus/0000 0002 1873 3953; Frangione,
   Valeria/0000 0003 0465 8953
FU IBSA Institut Biochimique SA.; IBSA Institut Biochimique SA as CRO;
   Medical University of Vienna
FX All authors have completed the Unified Competing Interest form at
   http://www.icmje.org/coi_disclosure.pdf (available on request from the
   corresponding author). Research funding for this study was sponsored by
   IBSA Institut Biochimique SA. VF, SR and GM are employees of IBSA
   Institut Biochimique SA. CL and AV are employees of CROSS SA, which has
   been contracted by IBSA Institut Biochimique SA as CRO for the
   conduction of this study and has received financial support for its
   services. AB, RC, MK, BB, MB and MZ are employees of the Medical
   University of Vienna, which, as an institution, received financial
   compensation for performing the study. The authors declare that they
   have no other relationships or activities that could appear to have
   influenced the submitted work.
CR Altman RD, 2009, J RHEUMATOL, V36, P1991, DOI 10.3899/jrheum.081316
   Bouw MR, 1998, PHARMACEUT RES, V15, P1673, DOI 10.1023/A:1011992125204
   Brunner M, 2005, BRIT J CLIN PHARMACO, V60, P573, DOI 10.1111/j.1365 2125.2005.02484.x
   Brunner M, 2011, BRIT J CLIN PHARMACO, V71, P852, DOI 10.1111/j.1365 2125.2011.03914.x
   Burian M, 2003, CLIN PHARMACOL THER, V74, P113, DOI 10.1016/S0009 9236(03)00165 6
   Dehghanyar P, 2004, INT J CLIN PHARM TH, V42, P353
   FINI A, 1993, DRUG EXP CLIN RES, V19, P81
   GALLACCHI G, 1993, DRUG EXP CLIN RES, V19, P95
   Green G A, 2001, Clin Cornerstone, V3, P50, DOI 10.1016/S1098 3597(01)90069 9
   Helmersson J, 2001, PROSTAG LEUKOTR ESS, V65, P99, DOI 10.1054/plef.2001.0295
   Karamouzis I, 2004, PROSTAG LEUKOTR ESS, V71, P87, DOI 10.1016/j.plefa.2003.12.006
   Karamouzis M, 2001, PROSTAG LEUKOTR ESS, V64, P259, DOI 10.1054/plef.2001.0269
   Karamouzis M, 2001, ACTA PHYSIOL SCAND, V171, P71
   Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170
   Langberg H, 2003, J PHYSIOL LONDON, V551, P683, DOI 10.1113/jphysiol.2003.046094
   Lionberger David R, 2011, J Pain Res, V4, P47, DOI 10.2147/JPR.S15380
   LONNROTH P, 1987, AM J PHYSIOL, V253, pE228, DOI 10.1152/ajpendo.1987.253.2.E228
   Maeder M, 2005, CHEST, V128, P2804, DOI 10.1378/chest.128.4.2804
   Mikkelsen UR, 2008, J APPL PHYSIOL, V104, P534, DOI 10.1152/japplphysiol.01016.2007
   Müller M, 1998, J RHEUMATOL, V25, P1833
   Muller M, 1997, CLIN PHARMACOL THER, V62, P293, DOI 10.1016/S0009 9236(97)90032 1
   MULLER M, 1995, CLIN PHARMACOL THER, V57, P371, DOI 10.1016/0009 9236(95)90205 8
   Petersen B, 2009, CLIN DRUG INVEST, V29, P1, DOI 10.2165/0044011 200929010 00001
   VERBEECK RK, 1983, CLIN PHARMACOKINET, V8, P297, DOI 10.2165/00003088 198308040 00003
   Weaver AL, 2008, AM J THER, V15, pS12, DOI 10.1097/MJT.0b013e31818be66f
   Zacher J, 2008, CURR MED RES OPIN, V24, P925, DOI 10.1185/030079908X273066 
NR 26
TC 6
Z9 8
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0306 5251
EI 1365 2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD DEC
PY 2013
VL 76
IS 6
BP 880
EP 887
DI 10.1111/bcp.12125
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 296IQ
UT WOS:000330178900005
PM 23551197
OA Green Published
DA 2025 08 17
ER

PT J
AU Shafiey, SI
   Mohamed, WR
   Abo Saif, AA
AF Shafiey, Sara I.
   Mohamed, Wafaa R.
   Abo Saif, Ali A.
TI Paroxetine and rivastigmine mitigates adjuvant induced rheumatoid
   arthritis in rats: Impact on oxidative stress, apoptosis and RANKL/OPG
   signals
SO LIFE SCIENCES
LA English
DT Article
DE Paroxetine; Rivastigmine; Rheumatoid arthritis; Apoptosis; RANKL/OPG
ID SEX HORMONES; ACETYLCHOLINESTERASE INHIBITOR; CASPASE 3 ACTIVATION;
   INFLAMMATION; MODEL; EXPRESSION; MATRIX; DRUGS; ANTIDEPRESSANTS;
   SYNOVIOCYTES
AB Rheumatoid arthritis (RA) is considered a form of inflammatory autoimmune disease with unknown etiology, but environmental and genetic causes are sharing. T cells, B cells, synovial cells, osteoclast, and chondrocytes are the main cell types in RA pathophysiology. The present study aimed to investigate the anti rheumatic effects of paroxetine, a selective serotonin reuptake inhibitor (SSRI), and rivastigmine, acetyl choline esterase inhibitor (AChEI), in complete Freund's adjuvant (CFA) induced RA. Adult female rats were categorized into five groups of eight rats each: normal control received vehicles only, RA control received CFA (0.4 ml, s.c) dexamethasone group (1 mg/kg/day, p.o), paroxetine group (10 mg/kg/day, i.p) and rivastigmine group (1 mg/kg/day, i.p). All treatments were administered for 13 consecutive days. Specific rheumatoid marker rheumatoid factor (RF), cartilage oligomeric protein (COMP) and matrix metalloproteinase 3 (MMP 3) were determined. Serum MDA and reduced GSH levels were investigated as oxidative stress biomarkers. IL 6, TNF alpha, and monocyte chemotactic protein 1 (MCP 1) were also determined as inflammatory biomarkers. Tissue Receptor activator of nuclear factor kappa B ligand/osteoprotegerin (RANKL/OPG) expression levels were detected using qRT PCR. Paroxetine and rivastigmine significantly reduced RF, COMP, MMP 3, IL 6, TNF a, and MCP 1 serum levels. Tested drugs also significantly reduced serum MDA and increased GSH levels. In addition, paroxetine and rivastigmine attenuated histopathological variations by reducing pannus formation and return synovial fluid near to normal. Administration of paroxetine or rivastigmine normalized caspase 3 and RANKL/OPG in CFA induced RA.
   In conclusion, paroxetine and rivastigmine possess antirheumatoid effects in CFA induced RA which is mediated through antioxidant, anti inflammatory, antiapoptotic and modulation of RANKL/OPG expression levels.
C1 [Shafiey, Sara I.; Abo Saif, Ali A.] Nahda Univ, Fac Pharm, Dept Pharmacol & Toxicol, Bani Suwayf 62514, Egypt.
   [Mohamed, Wafaa R.] Beni Suef Univ, Fac Pharm, Dept Pharmacol & Toxicol, Bani Suwayf 62514, Egypt.
C3 Egyptian Knowledge Bank (EKB); Beni Suef University
RP Mohamed, WR (通讯作者)，Beni Suef Univ, Fac Pharm, Dept Pharmacol & Toxicol, Bani Suwayf 62514, Egypt.
EM wafaa.mohamed@pharm.bsu.edu.eg
OI Mohamed, Wafaa/0000 0003 3652 6648
CR Abdel Salam OME, 2011, EXCLI J, V10, P290
   Ahmed YM, 2017, IMMUNOPHARM IMMUNOT, V39, P97, DOI 10.1080/08923973.2017.1286502
   [Anonymous], FACTA U
   Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010
   Arab HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122417
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bauerova K, 2015, AUTOIMMUNITY, V48, P46, DOI 10.3109/08916934.2014.939268
   BERCZI I, 1982, ARTHRITIS RHEUM, V25, P591, DOI 10.1002/art.1780250517
   Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113
   COHN DA, 1979, ARTHRITIS RHEUM, V22, P1218
   Cook CD, 2005, J PHARMACOL EXP THER, V313, P449, DOI 10.1124/jpet.104.077792
   Cutolo M, 2004, LUPUS, V13, P635, DOI 10.1191/0961203304lu1094oa
   da Silva SS, 2018, J PHARM PHARMACOL, V70, P768, DOI 10.1111/jphp.12896
   Dallé E, 2017, BEHAV BRAIN RES, V316, P189, DOI 10.1016/j.bbr.2016.08.005
   Duan HM, 2014, IMMUNOL LETT, V162, P258, DOI 10.1016/j.imlet.2014.09.018
   El Gaphar OAMA, 2018, EUR J PHARMACOL, V826, P85, DOI 10.1016/j.ejphar.2018.02.041
   Feng LJ, 2014, INFLAMM RES, V63, P335, DOI 10.1007/s00011 013 0705 1
   Gallagher JC, 2008, MATURITAS, V60, P65, DOI 10.1016/j.maturitas.2008.04.005
   García Vicuña R, 2004, ARTHRITIS RHEUM US, V50, P3866, DOI 10.1002/art.20615
   Gawel K, 2014, BEHAV BRAIN RES, V268, P169, DOI 10.1016/j.bbr.2014.04.019
   Ghosh M, 2018, MOLECULES, V23, DOI 10.3390/molecules23030615
   Gill JS, 2017, PHARMACOL REP, V69, P306, DOI 10.1016/j.pharep.2016.11.008
   Goldbergova MP, 2012, MOL IMMUNOL, V52, P273, DOI 10.1016/j.molimm.2012.06.006
   Gowayed MA, 2015, EUR J PHARMACOL, V764, P547, DOI 10.1016/j.ejphar.2015.07.038
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Hairul Islam MI, 2017, INT IMMUNOPHARMACOL, V53, P114, DOI 10.1016/j.intimp.2017.10.022
   Herbet M, 2016, PHARMACOL REP, V68, P172, DOI 10.1016/j.pharep.2015.08.004
   HOLMDAHL R, 1995, SCAND J IMMUNOL, V42, P104, DOI 10.1111/j.1365 3083.1995.tb03632.x
   Hong SJ, 2005, TOXICON, V46, P39, DOI 10.1016/j.toxicon.2005.03.015
   Kawashiri S. y., 2010, JOINT BONE SPINE, V77
   Kenis G, 2002, INT J NEUROPSYCHOPH, V5, P401, DOI 10.1017/S1461145702003164
   Khedr LH, 2015, NEUROPSYCH DIS TREAT, V11, P2887, DOI [10.2147/NDT.587089, 10.2147/NDT.S87089]
   Kim W., 2016, EVID BASED COMPL ALT, V2016
   Kizaki K, 2015, CLIN LAB, V61, P175, DOI 10.7754/Clin.Lab.2014.140822
   Kumar LD, 2016, BIOMED PHARMACOTHER, V79, P52, DOI 10.1016/j.biopha.2016.02.001
   Lampropoulos CE, 2015, CLIN EXP RHEUMATOL, V33, P216
   Lataro RM, 2015, AM J HYPERTENS, V28, P1201, DOI 10.1093/ajh/hpv017
   Li XQ, 2011, ACTA PHARMACOL SIN, V32, P217, DOI 10.1038/aps.2010.187
   Liu ZH, 2010, CHINESE MED J PEKING, V123, P1727, DOI 10.3760/cma.j.issn.0366 6999.2010.13.021
   Lu YX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186700
   Mahdy K, 2012, EUR REV MED PHARMACO, V16, P31
   Mohammad Shahi M, 2011, BIOIMPACTS, V1, P161, DOI 10.5681/bi.2011.022
   Nadeem RI, 2015, NEUROCHEM RES, V40, P1810, DOI 10.1007/s11064 015 1670 6
   Nizri E, 2006, NEUROPHARMACOLOGY, V50, P540, DOI 10.1016/j.neuropharm.2005.10.013
   Nizri E, 2005, NEUROSCI LETT, V376, P46, DOI 10.1016/j.neulet.2004.11.030
   Nizri E, 2008, J NEUROIMMUNOL, V203, P12, DOI 10.1016/j.jneuroim.2008.06.018
   Pavlov VA, 2009, BRAIN BEHAV IMMUN, V23, P41, DOI 10.1016/j.bbi.2008.06.011
   RAVECHE ES, 1979, ARTHRITIS RHEUM, V22, P1177, DOI 10.1002/art.1780221104
   Reale M, 2004, J NEUROIMMUNOL, V148, P162, DOI 10.1016/j.jneuroim.2003.11.003
   Riemekasten G, 2014, Z RHEUMATOL, V73, P600, DOI 10.1007/s00393 014 1357 4
   ROUBINIAN J, 1979, ARTHRITIS RHEUM, V22, P1162
   Sachdeva AK, 2015, J NUTR BIOCHEM, V26, P736, DOI 10.1016/j.jnutbio.2015.01.012
   Sacre S, 2010, ARTHRITIS RHEUM US, V62, P683, DOI 10.1002/art.27304
   Sato T, 2015, HELIYON, V1, DOI 10.1016/j.heliyon.2015.e00013
   Shin WS, 2002, ATHEROSCLEROSIS, V160, P91, DOI 10.1016/S0021 9150(01)00571 8
   Smith MT, 2015, J PHARM SCI US, V104, P2388, DOI 10.1002/jps.24502
   Snigdha S, 2012, NEUROSCI BULL, V28, P14, DOI 10.1007/s12264 012 1057 5
   STEINBERG AD, 1979, ARTHRITIS RHEUM, V22, P1170, DOI 10.1002/art.1780221103
   Su JF, 2003, BIOMED ENVIRON SCI, V16, P1
   Taler M, 2007, EUR NEUROPSYCHOPHARM, V17, P774, DOI 10.1016/j.euroneuro.2007.03.010
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Wahba MGF, 2016, PHARM BIOL, V54, P1705, DOI 10.3109/13880209.2015.1125931
   Wahba MGF, 2015, EUR J PHARMACOL, V765, P307, DOI 10.1016/j.ejphar.2015.08.026
   Xia ZL, 1996, IMMUNOPHARMACOLOGY, V34, P27, DOI 10.1016/0162 3109(96)00111 7
   Yu YH, 2015, INT IMMUNOPHARMACOL, V25, P74, DOI 10.1016/j.intimp.2015.01.005
NR 67
TC 35
Z9 36
U1 0
U2 16
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD NOV 1
PY 2018
VL 212
BP 109
EP 118
DI 10.1016/j.lfs.2018.09.046
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GX3TI
UT WOS:000447649400012
PM 30267788
DA 2025 08 17
ER

PT J
AU Zuo, J
   Vergara, S
   Kohno, S
   Holliday, LS
AF Zuo, Jian
   Vergara, Sandra
   Kohno, Shinya
   Holliday, L. Shannon
TI Biochemical and functional characterization of the actin binding
   activity of the B subunit of yeast vacuolar H<SUP>+</SUP> ATPase
SO JOURNAL OF EXPERIMENTAL BIOLOGY
LA English
DT Article
DE V ATPase; F actin; Saccharomyces cerevisiae; actin binding protein;
   cycloheximide; wortmannin; PI 3 kinase
ID V ATPASE; MICROFILAMENTS; ACIDIFICATION; EXPRESSION
AB Vacuolar H+ ATPase (V ATPase) is a fundamentally important enzyme in eukaryotic cells that is responsible for acidification of endocytic compartments. The B subunits of V ATPases from mammals and tobacco hornworm have been shown to bind actin filaments. Actin binding activity by the B subunit is required for targeting V ATPases to the plasma membrane of osteoclasts. Bacterially expressed B subunit from the yeast Saccharomyces cerevisiae bound actin filaments with a K d of 195 nmol l( 1). The actin binding domain of the B subunit was altered by mutations that reduced or eliminated the actin binding activity. Mutants assembled properly with endogenous yeast subunits when expressed in B subunit null yeast and bafilomycin sensitive ATPase activity was not significantly different from yeast transformed with wild type B subunit. Yeast containing the mutant subunits grew as well at pH 7.5 as wild type. Screening null yeast or null yeast transformed with wild type or mutant B subunits with sub lethal doses of various drugs revealed that yeast containing the mutant B subunits were more sensitive to cycloheximide and wortmannin than those transformed with wild type B subunits. These results suggest that actin binding activity confers on the B subunit of yeast a function that is distinct from its role in the enzymatic activity of the proton pump.
C1 [Zuo, Jian; Vergara, Sandra; Holliday, L. Shannon] Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA.
   [Kohno, Shinya] Hiroshima Univ, Dept Orthodont & Craniofacial Dev Biol, Hiroshima, Japan.
   [Holliday, L. Shannon] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; Hiroshima
   University; State University System of Florida; University of Florida
RP Holliday, LS (通讯作者)，Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA.
EM sholliday@dental.ufl.edu
RI Holliday, Lexie/GYQ 4972 2022
OI Holliday, Lexie/0000 0002 0844 1965
FU NIAMS NIH HHS [R01 AR47959, R01 AR047959] Funding Source: Medline
CR Adams DS, 2006, DEVELOPMENT, V133, P1657, DOI 10.1242/dev.02341
   Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955 0674(96)80060 3
   Chen SH, 2004, J BIOL CHEM, V279, P7988, DOI 10.1074/jbc.M305351200
   Gluck SL, 1998, ACTA PHYSIOL SCAND, V163, P203
   HARVEY WR, 1992, J EXP BIOL, V172, P1
   HOLLIDAY LS, 1993, BIOCHEM BIOPH RES CO, V196, P569, DOI 10.1006/bbrc.1993.2287
   Holliday LS, 2005, J BIOENERG BIOMEMBR, V37, P419, DOI 10.1007/s10863 005 9483 y
   Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200
   Inoue T, 2003, J BIOENERG BIOMEMBR, V35, P291, DOI 10.1023/A:1025720713747
   ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163 168.1983
   Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177 191.2006
   KANE PM, 1989, J BIOL CHEM, V264, P19236
   KANE PM, 1992, J BIOL CHEM, V267, P447
   KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531
   Lanzetti L, 2007, CURR OPIN CELL BIOL, V19, P453, DOI 10.1016/j.ceb.2007.04.017
   Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164
   Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127
   Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200
   Mitra P, 2004, J CELL BIOL, V166, P205, DOI 10.1083/jcb.200404150
   Nelson N, 1996, EXPERIENTIA, V52, P1101, DOI 10.1007/BF01952108
   Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361
   Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919
   Vitavska O, 2005, J BIOL CHEM, V280, P1070, DOI 10.1074/jbc.M406797200
   Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200
   Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003
   WANG ZQ, 1990, J BIOL CHEM, V265, P21957
   Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200
   YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737
   Zuo J, 2006, J BONE MINER RES, V21, P714, DOI 10.1359/JBMR.060201
NR 29
TC 17
Z9 22
U1 0
U2 1
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0022 0949
EI 1477 9145
J9 J EXP BIOL
JI J. Exp. Biol.
PD APR
PY 2008
VL 211
IS 7
BP 1102
EP 1108
DI 10.1242/jeb.013672
PG 7
WC Biology; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Zoology
GA 280YS
UT WOS:000254463300017
PM 18344484
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Ciobanu, GA
   Mogoanta, L
   Popescu, SM
   Ionescu, M
   Munteanu, CM
   Staicu, IE
   Mercut, R
   Georgescu, CC
   Scrieciu, M
   Vlad, D
   Camen, A
AF Ciobanu, George Adrian
   Mogoanta, Laurentiu
   Popescu, Sanda Mihaela
   Ionescu, Mihaela
   Munteanu, Cristina Maria
   Staicu, Ionela Elisabeta
   Mercut, Razvan
   Georgescu, Cristian Corneliu
   Scrieciu, Monica
   Vlad, Daniel
   Camen, Adrian
TI Correlations between Immune Response and Etiopathogenic Factors of
   Medication Related Osteonecrosis of the Jaw in Cancer Patients Treated
   with Zoledronic Acid
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE MRONJ; zoledronic acid; immunohistochemical markers
ID BISPHOSPHONATE RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; DELTA
   T CELLS; AMERICAN ASSOCIATION; IN VITRO; DISEASE; THERAPY;
   PATHOPHYSIOLOGY; OSTEOMYELITIS; MECHANISMS
AB Impairment of the immune response in MRONJ (medication related osteonecrosis of the jaws) is one of the still unclear etiopathogenic mechanisms of this condition encountered in cancer patients treated with bisphosphonates, with negative effects on the patient's quality of life. The aim of the present study was to correlate the immune response with etiopathogenic factors via immunohistochemical evaluation of the maxillary tissues in zoledronic acid osteonecrosis. The retrospective study included a group of 51 patients with various types of cancers, diagnosed with stage 2 or 3 MRONJ at zoledronic acid and treated surgically. Immunohistochemical expressions of alpha SMA, CD3, CD4, CD8, CD20, CD79 alpha, CD68, CD204, and tryptase were evaluated. Immunohistochemical markers expressions were statistically analyzed according to the duration of the treatment, the trigger factor, the location of the MRONJ, and the healing status. Analysis of the immune response included T lymphocytes, B lymphocytes, plasma cells, macrophages, and mast cells. The duration of treatment significantly influenced the immunohistochemical expression of most markers (p < 0.05). For an increasing trend in treatment duration, a decreasing trend in marker score was observed, suggesting an inverse correlation. The expression of the markers was different depending on the trigger factor, on MRONJ localization (maxilla/mandible), and the healing status, being more intense in patients cured per primam compared to those who had relapses. The patient's immune response was negatively influenced by the duration of the treatment, the trigger factor, the location of the lesion in the mandible, and the recurrence of MRONJ.
C1 [Ciobanu, George Adrian; Popescu, Sanda Mihaela] Univ Med & Pharm Craiova, Dept Oral Rehabil, Craiova 200349, Romania.
   [Ciobanu, George Adrian; Vlad, Daniel] Ovidius Univ Constanta, Dent Med Fac, Dept Oral & Maxillofacial Surg, Constanta 900470, Romania.
   [Mogoanta, Laurentiu] Univ Med & Pharm Craiova, Dept Histol, Craiova 200349, Romania.
   [Ionescu, Mihaela] Univ Med & Pharm Craiova, Dept Med Informat & Biostat, Craiova 200349, Romania.
   [Munteanu, Cristina Maria; Camen, Adrian] Univ Med & Pharm Craiova, Dept Oral & Maxillofacial Surg, Craiova 200349, Romania.
   [Staicu, Ionela Elisabeta] Univ Med & Pharm Craiova, Dept Orthodont, Craiova 200349, Romania.
   [Mercut, Razvan] Univ Med & Pharm Craiova, Dept Plast Surg, Craiova 200349, Romania.
   [Georgescu, Cristian Corneliu] Univ Med & Pharm Craiova, Dept Pharmacol, Craiova 200349, Romania.
   [Scrieciu, Monica] Univ Med & Pharm Craiova, Dept Prosthet Dent, Craiova 200349, Romania.
C3 University of Medicine & Pharmacy of Craiova; Ovidius University;
   University of Medicine & Pharmacy of Craiova; University of Medicine &
   Pharmacy of Craiova; University of Medicine & Pharmacy of Craiova;
   University of Medicine & Pharmacy of Craiova; University of Medicine &
   Pharmacy of Craiova; University of Medicine & Pharmacy of Craiova;
   University of Medicine & Pharmacy of Craiova
RP Popescu, SM (通讯作者)，Univ Med & Pharm Craiova, Dept Oral Rehabil, Craiova 200349, Romania.; Ionescu, M (通讯作者)，Univ Med & Pharm Craiova, Dept Med Informat & Biostat, Craiova 200349, Romania.
EM sanda.popescu@umfcv.ro; mihaela.ionescu@umfcv.ro
RI Popescu, Sanda Mihaela/B 9014 2011; Mogoanta, Laurentiu/M 5856 2017;
   Ionescu, Mihaela/AAO 6869 2021; Popescu, Sanda/B 9014 2011; Camen,
   Adrian/KJM 6006 2024
OI Popescu, Sanda Mihaela/0000 0003 3011 6322; 
FU University of Medicine and Pharmacy of Craiova, Romania
FX The Article Processing Charges were funded by the University of Medicine
   and Pharmacy of Craiova, Romania.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Banica AC, 2018, ROM J MORPHOL EMBRYO, V59, P811
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bellone F, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.748438
   Brody A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07375 1
   Bullock G, 2019, Ph.D. Thesis
   Buranaphatthana W, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116144
   Campisi G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165998
   Chang J, 2018, CURR OSTEOPOROS REP, V16, P584, DOI 10.1007/s11914 018 0474 4
   Cheung A, 2010, NEW ENGL J MED, V363, P2473, DOI 10.1056/NEJMc1002684
   Ciobanu GA, 2023, J CLIN MED, V12, DOI 10.3390/jcm12113747
   Ciobanu GA, 2023, J CLIN MED, V12, DOI 10.3390/jcm12103383
   Ciobanu GA, 2022, ROM J ORAL REHABIL, V14, P56
   Ciobanu George Adrian, 2021, Curr Health Sci J, V47, P117, DOI 10.12865/CHSJ.47.01.19
   De Bruyn L, 2018, OR SURG OR MED OR PA, V125, P268, DOI 10.1016/j.oooo.2017.11.022
   Ferreira VCD, 2021, CLIN ORAL INVEST, V25, P673, DOI 10.1007/s00784 020 03551 7
   Di Vito A, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720948497
   Du W, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00166 4
   Dutzan N, 2016, MUCOSAL IMMUNOL, V9, P1163, DOI 10.1038/mi.2015.136
   Fakatava N, 2023, J DENT SCI, V18, P567, DOI 10.1016/j.jds.2022.08.030
   Fantasia JE, 2015, ORAL MAXIL SURG CLIN, V27, P547, DOI 10.1016/j.coms.2015.06.004
   Farcas Berechet CM, 2019, ROM J MORPHOL EMBRYO, V60, P1191
   Fournier P, 2002, CANCER RES, V62, P6538
   Francisconi CF, 2018, J DENT RES, V97, P917, DOI 10.1177/0022034518759302
   Fusco V, 2022, SUPPORT CARE CANCER, V30, P7047, DOI 10.1007/s00520 022 06982 y
   Giudice A, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13120423
   Gkouveris I, 2022, CANCERS, V14, DOI 10.3390/cancers14020330
   Gruber R., 2022, CELL TO CELL COMMUNI
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P139, DOI 10.1007/s00784 014 1219 0
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   He LN, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 020 00093 2
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Hoefert S, 2010, CLIN ORAL INVEST, V14, P271, DOI 10.1007/s00784 009 0300 6
   Ikebe T, 2013, ORAL SCI INT, V10, P1, DOI 10.1016/S1348 8643(12)00045 6
   InoMed, 2019, Data
   InoMed IMAS, 2020, Perceptii si Atitudini cu Privire la Prevenirea, Diagnosticarea si Tratarea Cancerului Asociatia Centrul Pentru Inovatie in Medicina
   Kalyan S, 2016, J BONE MINER RES, V31, P1997, DOI 10.1002/jbmr.2875
   Kalyan S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0568 z
   Kalyan S, 2013, CELL MOL IMMUNOL, V10, P21, DOI 10.1038/cmi.2012.44
   Kim HY, 2021, ENDOCRINOL METAB, V36, P917, DOI 10.3803/EnM.2021.1170
   Kwack KH, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.731549
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Li MY, 2020, STEM CELLS DEV, V29, P156, DOI 10.1089/scd.2019.0151
   Limones A, 2020, MED ORAL PATOL ORAL, V25, pE326, DOI 10.4317/medoral.23324
   Lo Faro AF, 2019, J PHARMACEUT BIOMED, V162, P286, DOI 10.1016/j.jpba.2018.09.042
   Lorenzo Pouso AI, 2021, J CLIN MED, V10, DOI 10.3390/jcm10194367
   Marx R., 2022, DRUG INDUCED OSTEONE
   Mauceri R, 2022, SUPPORT CARE CANCER, V30, P6429, DOI 10.1007/s00520 022 06940 8
   McGowan K, 2018, ORAL DIS, V24, P527, DOI 10.1111/odi.12708
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mehta M, 2017, INNATE IMMUN LONDON, V23, P497, DOI 10.1177/1753425917722206
   Mirelli C, 2022, DENT J BASEL, V10, DOI 10.3390/dj10050089
   Moutsopoulos NM, 2018, TRENDS IMMUNOL, V39, P276, DOI 10.1016/j.it.2017.08.005
   Muratsu D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067906
   Ng TL, 2021, SUPPORT CARE CANCER, V29, P925, DOI 10.1007/s00520 020 05556 0
   Norton JT, 2012, J IMMUNOL, V188, P2977, DOI 10.4049/jimmunol.1100830
   O'Ryan FS, 2009, J ORAL MAXIL SURG, V67, P1363, DOI 10.1016/j.joms.2009.03.005
   Okawa H, 2022, ELIFE, V11, DOI 10.7554/eLife.76207
   On SW, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10050680
   Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928
   Otto S, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57050463
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   Park SM, 2022, J CLIN MED, V11, DOI 10.3390/jcm11092377
   Patntirapong S, 2018, ORAL DIS, V24, P1294, DOI 10.1111/odi.12908
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Pöllinger B, 2011, J IMMUNOL, V186, P2602, DOI 10.4049/jimmunol.1003370
   Roato I, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24097948
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rosales HD, 2023, J CLIN MED, V12, DOI 10.3390/jcm12041416
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P395, DOI 10.1007/s00223 012 9647 9
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P1, DOI 10.1016/j.joms.2009.03.001
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saccoa R, 2022, BRIT J ORAL MAX SURG, V60, pE216, DOI 10.1016/j.bjoms.2021.03.006
   Salesi N, 2006, ANTICANCER RES, V26, P3111
   Saravia J, 2019, CELL MOL IMMUNOL, V16, P634, DOI 10.1038/s41423 019 0220 6
   Schoenhof R, 2021, J CRANIO MAXILL SURG, V49, P508, DOI 10.1016/j.jcms.2021.02.018
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P1259, DOI 10.14219/jada.archive.2009.0049
   Shuster A, 2019, INT J ORAL MAX SURG, V48, P17, DOI 10.1016/j.ijom.2018.07.002
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Soma T, 2022, SCI REP UK, V12, DOI 10.1038/s41598 021 03966 6
   Srivichit B, 2022, ARCH TOXICOL, V96, P1227, DOI 10.1007/s00204 021 03220 y
   Taniguchi N, 2020, J PERIODONTOL, V91, P947, DOI 10.1002/JPER.19 0385
   Thiel Y, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153245
   Thumbigere Math V, 2014, J PERIODONTOL, V85, P226, DOI 10.1902/jop.2013.130017
   Uluçkan Ö, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8996
   Van Poznak CH, 2021, JAMA ONCOL, V7, P246, DOI 10.1001/jamaoncol.2020.6353
   Vincenzi B, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 56
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140 6736(07)61602 X
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Welton JL, 2013, J BONE MINER RES, V28, P464, DOI 10.1002/jbmr.1797
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Xian D, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.929684
   Yang LQ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001822
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhang WD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.606043
   Ziebart Thomas, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040036
NR 103
TC 3
Z9 3
U1 4
U2 14
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2023
VL 24
IS 18
AR 14345
DI 10.3390/ijms241814345
PG 28
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA T2EF8
UT WOS:001076158700001
PM 37762651
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Batra, H
   Antony, VB
AF Batra, Hitesh
   Antony, Veena B.
TI The pleural mesothelium in development and disease
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE pleural mesothelium; pleural mesothelial cells; idiopathic pulmonary
   fibrosis (IPF); Wilms tumor 1 (WT1); epithelial mesenchymal transition
   (EMT)
ID IDIOPATHIC PULMONARY FIBROSIS; TUMOR GENE WT1; SMOOTH MUSCLE CELLS;
   TO MESENCHYMAL TRANSFORMATION; WILMS TUMOR; EPICARDIAL CELLS; LUNG
   INJURY; IN VITRO; SEROSAL MESOTHELIUM; AVIAN EMBRYOS
AB The pleural mesothelium, derived from the embryonic mesoderm, is formed by a metabolically active monolayer of cells that blanket the chest wall and lungs on the parietal and visceral surfaces, respectively. The pleura and lungs are formed as a result of an intricate relationship between the mesoderm and the endoderm during development. Mesenchymal signaling pathways such as Wnt/B catenin, Bmp4, and sonic hedgehog appear to be quintessential for lung development. Pleural Mesothelial Cells (PMCs) are known to express Wilms tumor 1 (Wt1) gene and in lineage labeling studies of the developing embryo, PMCs were found to track into the lung parenchyma and undergo mesothelial mesenchymal transition (MMT) to form a smooth muscle actin (alpha SMA) positive cells of the mesenchyme and vasculature. There is definite evidence that mesothelial cells can differentiate and this seems to play an important role in pleural and parenchymal pathologies. Mesothelial cells can differentiate into adipocytes, chondrocytes, and osteoblasts; and have been shown to clonally generate fibroblasts and smooth muscle cells in murine models. This supports the possibility that they may also modulate lung injury repair by re activation of developmental programs in the adult reflecting an altered recapitulation of development, with implications for regenerative biology of the lung. In a mouse model of lung fibrosis using lineage tracing studies, PMCs lost their polarity and cell cell junctional complexes, migrated into lung parenchyma, and underwent phenotypic transition into myofibroblasts in response to the pro fibrotic mediator, transforming growth factor beta 1 (TGF beta 1). However, intra pleural heme oxygenase 1 (HO 1) induction inhibited PMC migration after intra tracheal fibrogenic injury. Intra pleural fluorescein isothiocyanate labeled nanoparticles decorated with a surface antibody to mesothelin, a surface marker of mesothelial cells, migrate into the lung parenchyma with PMCs supporting a potential role for pleural based therapies to modulate pleural mesothelial activation and parenchymal disease progression.
C1 [Batra, Hitesh; Antony, Veena B.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Batra, H (通讯作者)，Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA.
EM hiteshbatra921@gmail.com
CR AMIN KM, 1995, AM J PATHOL, V146, P344
   Antony VB, 2003, EUR RESPIR J, V21, P539, DOI 10.1183/09031936.03.00403902
   Bax NAM, 2011, J CELL MOL MED, V15, P2675, DOI 10.1111/j.1582 4934.2011.01266.x
   Bax NAM, 2011, BASIC RES CARDIOL, V106, P829, DOI 10.1007/s00395 011 0181 0
   Bellusci S, 1997, DEVELOPMENT, V124, P53
   Burwell EA, 2007, ONCOGENE, V26, P3423, DOI 10.1038/sj.onc.1210127
   Cai CL, 2008, NATURE, V454, P104, DOI 10.1038/nature06969
   CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092 8674(90)90601 A
   Colvin JS, 2001, DEVELOPMENT, V128, P2095
   Cool CD, 2006, AM J RESP CRIT CARE, V174, P654, DOI 10.1164/rccm.200602 205OC
   Decologne N, 2007, J IMMUNOL, V179, P6043, DOI 10.4049/jimmunol.179.9.6043
   Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801
   Dixit R, 2013, DEVELOPMENT, V140, P4398, DOI 10.1242/dev.098079
   Domyan ET, 2011, DEVELOPMENT, V138, P971, DOI 10.1242/dev.053694
   DONNA A, 1981, HISTOPATHOLOGY, V5, P31, DOI 10.1111/j.1365 2559.1981.tb01764.x
   Goss AM, 2009, DEV CELL, V17, P290, DOI 10.1016/j.devcel.2009.06.005
   HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092 8674(90)90690 G
   Hagiwara S, 2000, AM J RESP CRIT CARE, V162, P225, DOI 10.1164/ajrccm.162.1.9903129
   Havre PA, 2008, FRONT BIOSCI LANDMRK, V13, P1634, DOI 10.2741/2787
   Hecker L, 2009, NAT MED, V15, P1077, DOI 10.1038/nm.2005
   Herrick SE, 2004, INT J BIOCHEM CELL B, V36, P621, DOI 10.1016/j.biocel.2003.11.002
   Herriges M, 2014, DEVELOPMENT, V141, P502, DOI 10.1242/dev.098186
   Ito K, 2006, ONCOGENE, V25, P4217, DOI 10.1038/sj.onc.1209455
   Jantz MA, 2006, CLIN CHEST MED, V27, P181, DOI 10.1016/j.ccm.2005.12.003
   Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349 7006.2006.00169.x
   Kawaguchi M, 2007, DEV DYNAM, V236, P2973, DOI 10.1002/dvdy.21334
   King TE, 2011, LANCET, V378, P1949, DOI 10.1016/S0140 6736(11)60052 4
   King TE, 2001, AM J RESP CRIT CARE, V164, P1171, DOI 10.1164/ajrccm.164.7.2003140
   King TE, 2001, AM J RESP CRIT CARE, V164, P1025, DOI 10.1164/ajrccm.164.6.2001056
   Komiya E, 2014, BIOCHEM BIOPH RES CO, V447, P609, DOI 10.1016/j.bbrc.2014.04.037
   Licciulli S, 2010, J CLIN INVEST, V120, P3804, DOI 10.1172/JCI44901
   Liu J, 2006, LUNG CANCER, V51, P377, DOI 10.1016/j.lungcan.2005.11.006
   Loeb DM, 2001, CANCER RES, V61, P921
   Margetts PJ, 2005, J AM SOC NEPHROL, V16, P425, DOI 10.1681/ASN.2004060436
   Matsuoka H, 2002, AM J PHYSIOL LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001
   Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068
   Mohammed KA, 2007, LUNG, V185, P355, DOI 10.1007/s00408 007 9046 6
   Mubarak KK, 2012, EUR RESPIR J, V39, P133, DOI 10.1183/09031936.00141010
   Muñoz Chápuli R, 1999, DIFFERENTIATION, V64, P133, DOI 10.1046/j.1432 0436.1999.6430133.x
   Murakami S, 2006, AM J PHYSIOL LUNG C, V290, pL59, DOI 10.1152/ajplung.00042.2005
   Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440 1843.2002.00404.x
   Nasreen N, 2009, AM J PHYSIOL LUNG C, V297, pL115, DOI 10.1152/ajplung.90587.2008
   Ohuchi H, 2000, BIOCHEM BIOPH RES CO, V277, P643, DOI 10.1006/bbrc.2000.3721
   Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476
   PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893 415
   Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960 9822(98)70446 4
   Pérez Pomares JM, 2004, DEV DYNAM, V229, P465, DOI 10.1002/dvdy.10455
   Pérez Pomares JM, 2002, INT J DEV BIOL, V46, P1005
   PerezSoler R, 1997, CLIN CANCER RES, V3, P373
   Phan Sem H, 2008, Proc Am Thorac Soc, V5, P334, DOI 10.1513/pats.200708 146DR
   Que JW, 2008, P NATL ACAD SCI USA, V105, P16626, DOI 10.1073/pnas.0808649105
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009 040GL
   Rinkevich Y, 2012, NAT CELL BIOL, V14, P1251, DOI 10.1038/ncb2610
   Sally ML, 2011, J CELL MOL MED, V15, P2095, DOI 10.1111/j.1582 4934.2010.01212.x
   Schramm A, 2010, EUR J CARDIO THORAC, V37, P566, DOI 10.1016/j.ejcts.2009.08.027
   Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096
   Simler NR, 2002, EUR RESPIR J, V19, P1124, DOI 10.1183/09031936.02.00281602
   Ueda T, 2003, CANCER SCI, V94, P271, DOI 10.1111/j.1349 7006.2003.tb01432.x
   Wada AM, 2003, CIRC RES, V92, P525, DOI 10.1161/01.RES.0000060484.11032.0B
   Watanabe M, 2010, GENE THER, V17, P1042, DOI 10.1038/gt.2010.87
   Weaver M, 2000, DEVELOPMENT, V127, P2695
   Wilm B, 2005, DEVELOPMENT, V132, P5317, DOI 10.1242/dev.02141
   Yang AH, 2003, KIDNEY INT, V63, P1530, DOI 10.1046/j.1523 1755.2003.00861.x
   Zhang TF, 2003, ANTICANCER RES, V23, P3575
   Zhou B, 2011, J CLIN INVEST, V121, P1894, DOI 10.1172/JCI45529
   Zhou B, 2010, DEV BIOL, V338, P251, DOI 10.1016/j.ydbio.2009.12.007
   Zolak JS, 2013, AM J PATHOL, V182, P1239, DOI 10.1016/j.ajpath.2012.12.030
NR 67
TC 41
Z9 42
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD AUG 1
PY 2014
VL 5
AR 284
DI 10.3389/fphys.2014.00284
PG 6
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA AX7EB
UT WOS:000347078600001
PM 25136318
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kanno, H
   Matsumoto, S
   Yoshizumi, T
   Nakahara, K
   Shinonaga, M
   Kubo, A
   Fujii, S
   Ishizuka, Y
   Tanaka, M
   Ichihashi, M
   Murata, H
AF Kanno, Hiroshi
   Matsumoto, Shutaro
   Yoshizumi, Tetsuya
   Nakahara, Kimihiro
   Shinonaga, Masamichi
   Kubo, Atsuhiko
   Fujii, Satoshi
   Ishizuka, Yasuyuki
   Tanaka, Masaki
   Ichihashi, Masamitsu
   Murata, Hidetoshi
TI SOCS7 Derived BC Box Motif Peptide Mediated Cholinergic Differentiation
   of Human Adipose Derived Mesenchymal Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE adipose derived mesenchymal stem cells; SOCS7 derived BC box motif
   peptide; cholinergic differentiation; ubiquitination
ID NEURONAL DIFFERENTIATION; STROMAL CELLS; INTERNATIONAL SOCIETY;
   SCLEROSIS PATIENTS; EXPRESSION; SOCS; SUPPRESSORS; OVEREXPRESSION;
   PROTEINS; PATHWAYS
AB Adipose derived mesenchymal stem cells (ADMSCs) are a type of pluripotent somatic stem cells that differentiate into various cell types such as osteoblast, chondrocyte, and neuronal cells. ADMSCs as donor cells are used to produce regenerative medicines at hospitals and clinics. However, it has not been reported that ADMSCs were differentiated to a specific type of neuron with a peptide. Here, we report that ADMSCs differentiate to the cholinergic phenotype of neurons by the SOCS7 derived BC box motif peptide. At operations for patients with neurological disorders, a small amount of subcutaneous fat was obtained. Two weeks later, adipose derived mesenchymal stem cells (ADMSCs) were isolated and cultured for a further 1 to 2 weeks. Flow cytometry analysis for characterization of ADMSCs was performed with CD73, CD90, and CD105 as positive markers, and CD14, CD31, and CD56 as negative markers. The results showed that cultured cells were compatible with ADMSCs. Immunocytochemical studies showed naive ADMSCs immunopositive for p75NTR, RET, nestin, keratin, neurofilament M, and smooth muscle actin. ADMSCs were suggested to be pluripotent stem cells. A peptide corresponding to the amino acid sequence of BC box motif derived from SOCS7 protein was added to the medium at a concentration of 2 mu M. Three days later, immunocytochemistry analysis, Western blot analysis, ubiquitination assay, and electrophysiological analysis with patch cramp were performed. Immunostaining revealed the expression of neurofilament H (NFH), choline acetyltransferase (ChAT), and tyrosine hydroxylase (TH). In addition, Western blot analysis showed an increase in the expression of NFH, ChAT, and TH, and the expression of ChAT was more distinct than TH. Immunoprecipitation with JAK2 showed an increase in the expression of ubiquitin. Electrophysiological analysis showed a large holding potential at the recorded cells through path electrodes. The BC box motif peptide derived from SOCS7 promoted the cholinergic differentiation of ADMSCs. This novel method will contribute to research as well as regenerative medicine for cholinergic neuron diseases.
C1 [Kanno, Hiroshi; Matsumoto, Shutaro; Yoshizumi, Tetsuya] Yokohama City Univ, Dept Neurosurg, Yokohama 2360004, Japan.
   [Kanno, Hiroshi; Matsumoto, Shutaro; Fujii, Satoshi] Asahi Hosp, Dept Neurosurg, Tokyo 1210078, Japan.
   [Kanno, Hiroshi; Yoshizumi, Tetsuya; Nakahara, Kimihiro; Shinonaga, Masamichi] Int Univ Hlth & Welf Atami Hosp, Dept Neurosurg, Atami 4130012, Japan.
   [Yoshizumi, Tetsuya; Murata, Hidetoshi] St Marianna Med Univ Med, Dept Neurosurg, Kawasaki 2168511, Japan.
   [Kubo, Atsuhiko] Nerve Care Clin, Yokosuka 2380012, Japan.
   [Ishizuka, Yasuyuki] BioFuture Technol Ltd, Tokyo 1050014, Japan.
   [Tanaka, Masaki; Ichihashi, Masamitsu] BTR Arts Ginza Clin, Tokyo 1050004, Japan.
C3 Yokohama City University; International University of Health & Welfare
RP Kanno, H (通讯作者)，Yokohama City Univ, Dept Neurosurg, Yokohama 2360004, Japan.; Kanno, H (通讯作者)，Asahi Hosp, Dept Neurosurg, Tokyo 1210078, Japan.; Kanno, H (通讯作者)，Int Univ Hlth & Welf Atami Hosp, Dept Neurosurg, Atami 4130012, Japan.
EM hiroshikannomd@nifty.com
RI Tanaka, Masaki/K 6873 2016
OI Kanno, Hiroshi/0000 0002 4335 3899
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [21K09134]; Grants in Aid for Scientific Research [20K17938, 21K09134,
   21K09156] Funding Source: KAKEN
FX This study was supported by grants from the Basic Research (C) No.
   21K09134; Ministry of Education, Culture, Sports, Science, and
   Technology of Japan.
CR Bacakova L, 2018, BIOTECHNOL ADV, V36, P1111, DOI 10.1016/j.biotechadv.2018.03.011
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Bydon M, 2020, MAYO CLIN PROC, V95, P406, DOI 10.1016/j.mayocp.2019.10.008
   Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052 200312000 00009
   Chen KH, 2016, ONCOTARGET, V7, P74537, DOI 10.18632/oncotarget.12902
   Cianciulli A, 2017, CYTOKINE GROWTH F R, V37, P67, DOI 10.1016/j.cytogfr.2017.07.005
   Cui M, 2017, ACTA HISTOCHEM, V119, P680, DOI 10.1016/j.acthis.2017.08.003
   Cui M, 2014, CELL PHYSIOL BIOCHEM, V33, P528, DOI 10.1159/000358632
   de Celis Ruiz E, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen 2021 051790
   de Oliveira NB, 2021, MEMBRANES BASEL, V11, DOI 10.3390/membranes11090687
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fairchild CL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.155283
   Fernández O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195891
   Freitag J, 2019, REGEN MED, V14, P213, DOI 10.2217/rme 2018 0161
   Frisullo G, 2006, J NEUROSCI RES, V84, P1027, DOI 10.1002/jnr.20995
   Goldshmit Y, 2004, EUR J NEUROSCI, V20, P2260, DOI 10.1111/j.1460 9568.2004.03698.x
   Gupta S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026674
   Gutiérrez Fernández M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159
   Gutiérrez Fernández M, 2015, EXPERT OPIN BIOL TH, V15, P873, DOI 10.1517/14712598.2015.1040386
   Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114
   Jakkula E, 2010, AM J HUM GENET, V86, P285, DOI 10.1016/j.ajhg.2010.01.017
   Jang S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082434
   Jo CH, 2014, STEM CELLS, V32, P1254, DOI 10.1002/stem.1634
   Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872
   Kang YN, 2019, ANIM CELLS SYST, V23, P275, DOI 10.1080/19768354.2019.1626280
   Kanno H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020466
   Kanno H, 2009, PROTEIN PEPTIDE LETT, V16, P1291, DOI 10.2174/092986609789353691
   Kim Jong Hyeon, 2014, Exp Neurobiol, V23, P148, DOI 10.5607/en.2014.23.2.148
   Kokai LE, 2014, TRANSL RES, V163, P399, DOI 10.1016/j.trsl.2013.11.009
   Kubo A, 2009, STEM CELLS DEV, V18, P1523, DOI 10.1089/scd.2008.0379
   Lawrenson ID, 2017, CEREB CORTEX, V27, P576, DOI 10.1093/cercor/bhv253
   Marei HE, 2018, J CELL PHYSIOL, V233, P936, DOI 10.1002/jcp.25937
   Mishra KK, 2016, IUBMB LIFE, V68, P468, DOI 10.1002/iub.1505
   Nabavi SM, 2021, CELL J, V23, P772, DOI 10.22074/cellj.2021.7984
   Ntege EH, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104 020 05315 8
   Planas AM, 2006, BIOCHEM SOC T, V34, P1267, DOI 10.1042/BST0341267
   Polizzotto MN, 2000, J COMP NEUROL, V423, P348
   Rao VLR, 2002, J NEUROCHEM, V83, P1072, DOI 10.1046/j.1471 4159.2002.01208.x
   Rasmussen S, 2007, BRAIN, V130, P2816, DOI 10.1093/brain/awm219
   Scott HJ, 2006, BRAIN RES, V1067, P138, DOI 10.1016/j.brainres.2005.10.032
   Sekine K, 2014, NEUROSCI RES, V86, P50, DOI 10.1016/j.neures.2014.06.004
   Snyder EL, 2004, PHARM RES DORDR, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Turnley AM, 2001, NEUROREPORT, V12, P3443, DOI 10.1097/00001756 200111160 00013
   Vandenbroeck K, 2012, GENES IMMUN, V13, P21, DOI 10.1038/gene.2011.44
   Walker DG, 2015, NEUROSCIENCE, V302, P121, DOI 10.1016/j.neuroscience.2014.09.052
   Yoshizumi T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144947
   Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071
   Zhang Y, 2013, DIABETES, V62, P1159, DOI 10.2337/db12 0670
NR 48
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2023
VL 24
IS 3
AR 2786
DI 10.3390/ijms24032786
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 8Y6EF
UT WOS:000932787600001
PM 36769102
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mishra, D
   Dhir, V
   Naidu, GSRSNK
   Khullar, A
   Kumar, V
   Sharma, S
   Sharma, A
   Jain, S
AF Mishra, Debashish
   Dhir, Varun
   Naidu, G. S. R. S. N. K.
   Khullar, Aastha
   Kumar, Vishal
   Sharma, Shefali
   Sharma, Aman
   Jain, Sanjay
TI Efficacy of a step down regimen of oral prednisolone in axial
   spondyloarthritis: result of a double blind randomized controlled trial
   (COBRA AS Study)
SO RHEUMATOLOGY
LA English
DT Article
DE glucocorticoid; corticosteroid; axial spondyloarthritis; ankylosing
   spondylitis
ID METHYLPREDNISOLONE PULSE THERAPY; ANKYLOSING SPONDYLITIS; FRACTURE RISK;
   BATH; VALIDATION; MECHANISMS
AB Objectives. To evaluate the efficacy and safety of a step down regimen of oral prednisolone over 24weeks in patients of axial SpA (axSpA).
   Methods. This proof of concept double blind randomized controlled trial enrolled patients with active axSpA (BASDAI >= 4) having predominantly axial disease (<= 1 active joint currently) and inadequate response to NSAIDs. They were randomized to receive either oral prednisolone (n=32) or placebo (n=33) at a dose of 60, 40, 30, 20, 15 and 10mg daily for 1week each, following which they received 5mg prednisolone (or placebo) daily for 18weeks. The primary endpoint was a 50% improvement in the BASDAI (BASDAI50) at week 24. Analysis was intention to treat.
   Results. A BASDAI50 was achieved by 12 of 32 patients (37.5%) in the prednisolone arm and 3 of 33 patients (9.1%) in the placebo arm at 24weeks [difference 28.4% (95% CI 7.9, 46.7)]. However, there was no difference in achieving a 20 or 40% improvement in the Assessment of SpondyloArthritis international Society response between the groups. Although there was a significant intergroup difference in adjusted Delta BASDAI and Delta Ankylosing Spondylitis Disease Activity Score with CRP at 24weeks, there was no difference at 12weeks. There was also no significant difference in Delta BASFI, Delta BAS G or Delta BASMI at 12 or 24 weeks. No serious adverse events were noted. There was significant weight gain in the first 12 weeks in the prednisolone group vs placebo [0.9 (s.d. 0.4) kg], but not at 24 weeks.
   Conclusions. In this small study, oral prednisolone was efficacious in axSpA in achieving the primary outcome, but many crucial secondary outcomes such as functional improvement were not met. Its impact on bone loss was not studied.
C1 [Mishra, Debashish; Dhir, Varun; Naidu, G. S. R. S. N. K.; Khullar, Aastha; Sharma, Shefali; Sharma, Aman; Jain, Sanjay] Postgrad Inst Med Educ & Res, Dept Internal Med, Div Rheumatol & Clin Immunol, Chandigarh, India.
   [Kumar, Vishal] Postgrad Inst Med Educ & Res, Dept Orthoped, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh
RP Dhir, V (通讯作者)，Nehru Hosp, Div Rheumatol & Clin Immunol, Dept Internal Med, Postgrad Inst Med Educ & Res, Room 6,4th Floor, Chandigarh, India.
EM varundhir@gmail.com
RI KUMAR, VISHAL/AAB 7692 2022; SHARMA, AMAN/KOD 6414 2024; NAIDU,
   SHANKAR/H 9429 2019; Dhir, Varun/S 4795 2019
OI Dhir, Varun/0000 0002 3626 0694; Naidu, GSRSNK/0000 0002 9727 044X
CR Bandinelli F, 2016, DRUG DES DEV THER, V10, P3717, DOI 10.2147/DDDT.S115099
   Baraliakos X, 2017, RHEUMATOLOGY, V56, P95, DOI 10.1093/rheumatology/kew367
   Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140 6736(97)01300 7
   Braun J, 2002, ARTHRITIS RES, V4, P307, DOI 10.1186/ar592
   Bruner V, 2014, THER ADV MUSCULOSKEL, V6, P92, DOI 10.1177/1759720X14535512
   CALIN A, 1994, J RHEUMATOL, V21, P2281
   Canalis E, 2003, CURR OPIN RHEUMATOL, V15, P454, DOI 10.1097/00002281 200307000 00013
   Dhir V, 2012, CLIN RHEUMATOL, V31, P1511, DOI 10.1007/s10067 012 2043 z
   Dougados M, 2002, ANN RHEUM DIS, V61, P40
   Fendler C, 2011, CLIN EXP RHEUMATOL, V29, pS139
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Haibel H, 2014, ANN RHEUM DIS, V73, P243, DOI 10.1136/annrheumdis 2012 203055
   Haroon M, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1565 4
   Hinze Alicia M, 2016, Curr Treatm Opt Rheumatol, V2, P271, DOI 10.1007/s40674 016 0055 6
   JENKINSON TR, 1994, J RHEUMATOL, V21, P1694
   Jones SD, 1996, BRIT J RHEUMATOL, V35, P66
   Lukas C, 2009, ANN RHEUM DIS, V68, P18, DOI 10.1136/ard.2008.094870
   MINTZ G, 1981, ARTHRITIS RHEUM, V24, P734, DOI 10.1002/art.1780240521
   Noureldin B, 2018, RHEUMATOLOGY, V57, P10, DOI 10.1093/rheumatology/key217
   PETERS ND, 1992, SCAND J RHEUMATOL, V21, P134, DOI 10.3109/03009749209095085
   Pray C, 2017, CALCIFIED TISSUE INT, V101, P182, DOI 10.1007/s00223 017 0274 3
   Rademacher J, 2019, RHEUMATOLOGY, V58, P1556, DOI 10.1093/rheumatology/kez025
   Reveille JD, 2012, AM J MED SCI, V343, P371, DOI 10.1097/MAJ.0b013e3182514093
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   RICHTER MB, 1983, CLIN EXP IMMUNOL, V53, P51
   Rudwaleit M, 2004, ANN RHEUM DIS, V63, P665, DOI 10.1136/ard.2003.016386
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233
   Sieper J, 2009, ANN RHEUM DIS, V68, P1, DOI 10.1136/ard.2008.104018
   Stolwijk C, 2016, ARTHRIT CARE RES, V68, P1320, DOI 10.1002/acr.22831
   Taurog JD, 2016, NEW ENGL J MED, V374, P2563, DOI 10.1056/NEJMra1406182
   van der Heijde D, 2017, ANN RHEUM DIS, V76, P978, DOI 10.1136/annrheumdis 2016 210770
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   Ward MM, 2019, ARTHRITIS RHEUMATOL, V71, P1599, DOI [10.1002/art.41042, 10.1002/acr.24025]
NR 33
TC 9
Z9 11
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD APR
PY 2021
VL 60
IS 4
BP 1932
EP 1941
DI 10.1093/rheumatology/keaa685
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA RT6BQ
UT WOS:000644544400057
PM 33159796
DA 2025 08 17
ER

PT J
AU Kim, SB
   Lee, SH
   Gu, MJ
AF Kim, Sung Bum
   Lee, Si Hyung
   Gu, Mi Jin
TI Esophageal subepithelial lesion diagnosed as malignant gastrointestinal
   neuroectodermal tumor
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Subepithelial lesion; Esophagus; Malignant gastrointestinal
   neuroectodermal tumor; Ewing sarcoma break point region 1 gene;
   Fluorescence in situ hybridization
ID CLEAR CELL SARCOMA; OSTEOCLAST RICH TUMOR; SMALL BOWEL; SOFT PARTS;
   FEATURES; TRACT; STOMACH; FUSION; ILEUM
AB A 21 year old male visited our hospital with a complaint of aggravating dysphagia and odynophagia for a few days. Esophagogastroduodenoscopy showed huge bulging mucosa with an intact surface causing luminal narrowing at 35 cm from the incisor teeth. Endoscopic ultrasonography showed an about 35 mm sized irregular margined in homogenous hypoechoic lesion with an obscure layer of origin. Endoscopic ultrasonography fine needle aspiration revealed spindle cell proliferation without immunoreactivity for CD117, SMA, and cytokeratin. The patient underwent excision of the subepithelial lesion at the distal esophagus. On pathologic examination of the specimen, the tumor was composed of short fascicles of oval to spindle cells with eosinophilic and clear cytoplasm and vesicular nuclei. The tumor cells were positive for S 100 and SOX10 and negative for CD117, SMA, HMB 45, melan A, cytokeratin, and CD99. The split apart signal was detected in EWSR1 on FISH, suggesting a malignant gastrointestinal neuroectodermal tumor. At the time of writing, the patient is on radiation therapy at the operated site of esophagus and doing well, with no recurrence for three months. Malignant gastrointestinal neuroectodermal tumor is a rare gastrointestinal tumor with features of clear cell sarcoma, without melanocytic differentiation, and shows a poor prognosis. This is the first reported case of malignant gastrointestinal neuroectodermal tumor arising as subepithelial lesion in the esophagus.
C1 [Kim, Sung Bum; Lee, Si Hyung] Yeungnam Univ Hosp, Dept Internal Med, Daegu 705802, South Korea.
   [Gu, Mi Jin] Yeungnam Univ Hosp, Dept Pathol, Daegu 705802, South Korea.
C3 Yeungnam University; Yeungnam University Hospital; Yeungnam University;
   Yeungnam University Hospital
RP Lee, SH (通讯作者)，Yeungnam Univ Hosp, Dept Internal Med, 170 Hyeonchung Ro, Daegu 705802, South Korea.
EM dr9696@nate.com
RI Kim, Sung/I 2997 2017; Lee, Si/ABH 1408 2020
CR Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078 0432.CCR 05 2811
   Comin CE, 2007, VIRCHOWS ARCH, V451, P839, DOI 10.1007/s00428 007 0454 z
   Donner LR, 1998, AM J SURG PATHOL, V22, P121, DOI 10.1097/00000478 199801000 00016
   Friedrichs N, 2005, INT J SURG PATHOL, V13, P313, DOI 10.1177/106689690501300402
   Granville L, 2006, ULTRASTRUCT PATHOL, V30, P111, DOI 10.1080/01913120500406400
   Hawes RH, 2014, ENDOSONOGRAPHY EXPER, P400
   Hoda KM, 2009, GASTROINTEST ENDOSC, V69, P1218, DOI 10.1016/j.gie.2008.09.045
   Huang WB, 2006, VIRCHOWS ARCH, V448, P200, DOI 10.1007/s00428 005 0051 y
   Joo M, 2009, ANN DIAGN PATHOL, V13, P30, DOI 10.1016/j.anndiagpath.2008.10.003
   Lagmay JP, 2009, PEDIATR BLOOD CANCER, V53, P214, DOI 10.1002/pbc.22014
   Pauwels P, 2002, HISTOPATHOLOGY, V41, P526, DOI 10.1046/j.1365 2559.2002.01509.x
   Shenjere P, 2012, INT J SURG PATHOL, V20, P378, DOI 10.1177/1066896911425485
   Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac
   Terazawa K, 2009, J MED INVESTIG, V56, P70, DOI 10.2152/jmi.56.70
   Venkataraman G, 2005, APMIS, V113, P716, DOI 10.1111/j.1600 0463.2005.apm_243.x
   Zambrano E, 2003, INT J SURG PATHOL, V11, P75, DOI 10.1177/106689690301100202
NR 16
TC 13
Z9 14
U1 0
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007 9327
EI 2219 2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 14
PY 2015
VL 21
IS 18
BP 5739
EP 5743
DI 10.3748/wjg.v21.i18.5739
PG 5
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA CI5MF
UT WOS:000354800200036
PM 25987801
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhang, YF
   Wang, XY
   Zhu, SH
   Wang, L
   Jiang, JG
   Chen, JL
   Liu, XY
AF Zhang, Yifan
   Wang, Xiaoyou
   Zhu, Shuihong
   Wang, Lei
   Jiang, Jungang
   Chen, Junli
   Liu, Xiangyang
TI Serum albumin hydrogels designed by protein Re association for
   self powered intelligent interactive systems
SO ENERGY STORAGE MATERIALS
LA English
DT Article
DE Bovine serum albumin; Protein structure; Hydrogel; Remote monitoring;
   Interactive system
ID CLICK CHEMISTRY; BOVINE; DRUG; MICROSTRUCTURES; NANOCOMPOSITE; SURFACE;
   EQUINE; PH
AB Advancements in protein structural engineering have made it possible to design protein materials that can mediate between humans and intelligent systems, manifesting a combination of characteristics such as elastic recovery, electrical conductivity, and stability. This work describes the design of a hydrogel using bovine serum albumin (BSA), based on protein protein interactions and sulfhydryl alkene click reactions. The multiple alpha helices of BSA were intertwined together by the multi armed olefin derivatives, acting like Lego blocks to form a gel network and locking in bound water and ions, thus imparting mechanical recovery characteristics (demonstrating 80 % recovery after the compressive strain and 638 % after tensile strain), electrical conductivity, resistance to freezing (maintaining mechanical properties after being frozen at  20 C degrees for 48 h), biocompatibility (the cell viability of mouse pre osteoblast like cells in the hydrogels was 97.5 %), antimicrobial properties, and biodegradability to the BSA hydrogels. A multi channel wireless signal acquisition system based on BSA hydrogel devices designed for bioenergy conversion and harvesting was developed for the real time detection of human motion along with a human mechanics interaction system for manipulating robotic gestures with simple human finger movements. This restructuring of the BSA structure represents a significant advancement in the systematic exploration of protein structures and the development of protein materials. These applications serve as a secure bridge between humans and energy storage devices.
C1 [Zhang, Yifan; Wang, Xiaoyou; Wang, Lei; Jiang, Jungang] Hubei Univ Technol, Hubei Prov Key Lab Green Mat Light Ind, Wuhan 430068, Peoples R China.
   [Chen, Junli] Shanghai Dianji Univ, Sch Mech Engn, Shanghai 201306, Peoples R China.
   [Zhu, Shuihong; Liu, Xiangyang] Xiamen Univ, Shenzhen Res Inst, Coll Ocean & Earth Sci, Coll Phys Sci & Technol, Shenzhen Xiamen 361005, Peoples R China.
C3 Hubei University of Technology; Shanghai Dianji University; Xiamen
   University
RP Zhang, YF (通讯作者)，Hubei Univ Technol, Hubei Prov Key Lab Green Mat Light Ind, Wuhan 430068, Peoples R China.; Chen, JL (通讯作者)，Shanghai Dianji Univ, Sch Mech Engn, Shanghai 201306, Peoples R China.; Liu, XY (通讯作者)，Xiamen Univ, Shenzhen Res Inst, Coll Ocean & Earth Sci, Coll Phys Sci & Technol, Shenzhen Xiamen 361005, Peoples R China.
EM zhangyifan@hbut.edu.cn; chenjl@sdju.edu.cn; liuxy@xmu.edu.cn
RI Chen, Jiayi/GZM 5106 2022; Zhang, Yifan/KOC 2946 2024; LIU,
   Xiangyang/AAI 4872 2020; Jiang, Jungang/JJC 6589 2023
OI Zhang, Yifan/0000 0002 5908 9164; Chen, junli/0000 0002 3858 4844
FU National Natural Science Foundation of China [32201021]; Hubei
   Provincial Education Department Research Program [Q20329414]; Hubei
   Provincial Key Laboratory of Green Materials for Light Industry
   [2022 4303 00132]
FX This study was funded by the National Natural Science Foundation of
   China (32201021) , Hubei Provincial Education Department Research
   Program (Q20329414) , and Hubei Provincial Key Laboratory of Green
   Materials for Light Industry (2022 4303 00132) .
CR Beedle AEM, 2023, NAT REV MATER, V8, P10, DOI 10.1038/s41578 022 00488 z
   Belatik A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036723
   Bujacz A, 2014, PROTEINS, V82, P2199, DOI 10.1002/prot.24583
   Bujacz A, 2012, ACTA CRYSTALLOGR D, V68, P1278, DOI 10.1107/S0907444912027047
   CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
   Chen JL, 2021, NANO ENERGY, V80, DOI 10.1016/j.nanoen.2020.105446
   Cheng F, 2019, ACS SUSTAIN CHEM ENG, V7, P9112, DOI 10.1021/acssuschemeng.8b05550
   Chib R, 2015, J LUMIN, V168, P62, DOI 10.1016/j.jlumin.2015.07.030
   Cobo I, 2015, NAT MATER, V14, P143, DOI [10.1038/NMAT4106, 10.1038/nmat4106]
   Fleischer CC, 2014, ACCOUNTS CHEM RES, V47, P2651, DOI 10.1021/ar500190q
   Fu LL, 2023, NATURE, V618, P740, DOI 10.1038/s41586 023 06037 0
   Gao WC, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202303306
   Han X, 2023, ACS SUSTAIN CHEM ENG, V11, P8255, DOI 10.1021/acssuschemeng.2c07727
   IGLAMOVA NA, 1990, CHEM TECH FUELS OIL+, V26, P557, DOI 10.1007/BF01129439
   Iucci G, 2004, SURF INTERFACE ANAL, V36, P724, DOI 10.1002/sia.1747
   Jiang YJ, 2014, BIOMATERIALS, V35, P4969, DOI 10.1016/j.biomaterials.2014.03.001
   Jiang YJ, 2011, J PHARM SCI US, V100, P4631, DOI 10.1002/jps.22686
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586 021 03819 2
   Kim E, 2019, CHEM SCI, V10, P7835, DOI 10.1039/c9sc03368h
   Kong J, 2007, ACTA BIOCH BIOPH SIN, V39, P549, DOI 10.1111/j.1745 7270.2007.00320.x
   Kou SB, 2021, J MOL STRUCT, V1224, DOI 10.1016/j.molstruc.2020.129024
   Lay CL, 2016, ACS APPL MATER INTER, V8, P8145, DOI 10.1021/acsami.6b02306
   Lei M, 2022, ENERGY STORAGE MATER, V47, P551, DOI 10.1016/j.ensm.2022.02.031
   Li DQ, 2021, CARBOHYD POLYM, V268, DOI 10.1016/j.carbpol.2021.118244
   Li LL, 2011, AICHE J, V57, P3507, DOI 10.1002/aic.12543
   Li Q, 2021, ACS NANO, V15, P11992, DOI 10.1021/acsnano.1c03249
   Liu H, 2022, J MATER CHEM A, V10, P21874, DOI 10.1039/d2ta05770k
   Liu LB, 2020, SENSORS BASEL, V20, DOI 10.3390/s20205886
   Luo JJ, 2019, ENERGY STORAGE MATER, V23, P617, DOI 10.1016/j.ensm.2019.03.009
   Ma YJ, 2019, RSC ADV, V9, P36951, DOI 10.1039/c9ra06720e
   Manimekalai K, 2022, INORG CHEM COMMUN, V137, DOI 10.1016/j.inoche.2022.109207
   Naik PN, 2010, J PHOTOCH PHOTOBIO B, V100, P147, DOI 10.1016/j.jphotobiol.2010.05.014
   Niu SM, 2014, ADV FUNCT MATER, V24, P3332, DOI 10.1002/adfm.201303799
   Ovchinnikov S, 2017, SCIENCE, V355, P294, DOI 10.1126/science.aah4043
   Pan Z, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 40753 5
   Ramya R, 2018, BIOSENS BIOELECTRON, V108, P53, DOI 10.1016/j.bios.2018.02.044
   ROSSMURPHY SB, 1995, J RHEOL, V39, P1451, DOI 10.1122/1.550610
   Skrt M, 2012, FOOD CHEM, V135, P2418, DOI 10.1016/j.foodchem.2012.06.114
   Sun W, 2023, CARBOHYD POLYM, V303, DOI 10.1016/j.carbpol.2022.120446
   Swaidan A, 2019, SENSOR ACTUAT B CHEM, V294, P253, DOI 10.1016/j.snb.2019.05.052
   Thirumurugan P, 2013, CHEM REV, V113, P4905, DOI 10.1021/cr200409f
   Wan XF, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00141
   Wang MJ, 2023, NAT NANOTECHNOL, V18, DOI 10.1038/s41565 023 01329 y
   Wei SX, 2017, ACS APPL MATER INTER, V9, P42247, DOI 10.1021/acsami.7b14915
   Yeh AHW, 2023, NATURE, V614, P774, DOI 10.1038/s41586 023 05696 3
   Zhang CY, 2022, ACS APPL MATER INTER, V14, P26303, DOI 10.1021/acsami.2c06370
   Zhang Y, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34522 z
   Zhang YJ, 2023, NATURE, V620, P1001, DOI 10.1038/s41586 023 06295 y
   Zhao YQ, 2023, ADV MATER, V35, DOI 10.1002/adma.202211617
   Zhao ZH, 2022, ADV MATER, V34, DOI 10.1002/adma.202205376
   Zhou YM, 2013, CARBOHYD POLYM, V97, P429, DOI 10.1016/j.carbpol.2013.04.088
   Zhu SH, 2023, ADV SCI, V10, DOI 10.1002/advs.202207400
NR 52
TC 6
Z9 6
U1 3
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2405 8297
EI 2405 8289
J9 ENERGY STORAGE MATER
JI Energy Storage Mater.
PD MAR
PY 2024
VL 67
AR 103266
DI 10.1016/j.ensm.2024.103266
EA FEB 2024
PG 13
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA NR9C1
UT WOS:001202287600001
DA 2025 08 17
ER

PT J
AU Saito, S
   Kotake, S
AF Saito, Seiji
   Kotake, Shigeru
TI Is there evidence in support of the use of intra articular hyaluronate
   in treating rheumatoid arthritis of the knee? A meta analysis of the
   published literature
SO MODERN RHEUMATOLOGY
LA English
DT Article
DE Intra articular injection; Meta analysis; Osteoarthritis; Rheumatoid
   arthritis; Sodium hyaluronate
ID CLINICAL TRIALS; OSTEOARTHRITIS; ACID; INJECTIONS; MECHANISMS; NSAIDS;
   HYLAN; BIAS
AB Intra articular hyaluronate (HA) injections for treating rheumatoid knee are still debatable, and this meta analysis aims to elucidate the effectiveness of HA injection for rheumatoid knee. The meta analysis comprised randomized clinical trials (RCTs) that compared the efficacy of HA injections with that of a placebo. The articles were retrieved after systematic searches of databases, including MEDLINE, EMBASE, and Japana Centra Revuo Medicina. The outcomes were classified into four categories: evaluation of reduction in the intensity of pain, evaluation of reduction in the intensity of inflammation, overall evaluation of therapeutic efficacy, and evaluation of adverse effects. Effect sizes were calculated from the risk ratio (RR) of each of the above mentioned outcome categories. Five RCTs (720 participants) were pooled for the meta analysis. The pooled effect sizes were 1.64 (p = 0.01) for pain reduction, 1.61 (p = 0.001) for reduction in inflammation, and 1.50 (p = 0.004) for the overall evaluation of treatment effectiveness. No serious side effects were reported, while minor adverse effects were reported in patients after HA treatment (RR 0.98, p = 0.32). The results indicated that intra articular HA is an effective and safe alternative therapy for the rheumatoid knee.
C1 [Saito, Seiji; Kotake, Shigeru] Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan.
C3 Tokyo Women's Medical University
RP Saito, S (通讯作者)，Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10 22 Kawada Cho, Tokyo 1620054, Japan.
EM stcmsait@ior.twmu.ac.jp
CR [Anonymous], RINSHO RYUMACHI
   [Anonymous], RINSHO RYUMACHI
   [Anonymous], RINSHO RYUMACHI
   [Anonymous], RINSHO RYUMACHI
   [Anonymous], JPN PHARM THER
   [Anonymous], RHEUMATOLOGY
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Arrich J, 2005, CAN MED ASSOC J, V172, DOI 10.1503/cmaj.1041203
   Arroll B, 2004, BMJ BRIT MED J, V328, P869, DOI 10.1136/bmj.38039.573970.7C
   Bellamy N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321
   Buchbinder R, 2003, Cochrane Database Syst Rev, pCD004016
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006 341X.2000.00455.x
   Egger M, 1997, BMJ BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   HAKANSSON L, 1980, J CLIN INVEST, V66, P298, DOI 10.1172/JCI109857
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197 2456(95)00134 4
   Laurent Torvard C., 1996, Immunology and Cell Biology, V74, pA1, DOI 10.1038/icb.1996.32
   Lo GH, 2003, JAMA J AM MED ASSOC, V290, P3115, DOI 10.1001/jama.290.23.3115
   Lo V, 2006, J FAM PRACTICE, V55, P260
   Maheu E, 2002, INT J CLIN PRACT, V56, P804
   Mason L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 28
   Matsuno H, 1999, INFLAMM RES, V48, P154, DOI 10.1007/s000110050439
   Medina JM, 2006, J FAM PRACTICE, V55, P669
   Modawal A, 2005, J FAM PRACTICE, V54, P758
   Moreland LW, 2003, ARTHRITIS RES THER, V5, P54, DOI 10.1186/ar623
   PUNZI L, 1988, CURR THER RES CLIN E, V43, P643
   Punzi L, 2001, CLIN EXP RHEUMATOL, V19, P242
   Reichenbach S, 2007, ARTHRIT RHEUM ARTHR, V57, P1410, DOI 10.1002/art.23103
   SHIMAZU A, 1993, ARTHRITIS RHEUM, V36, P247, DOI 10.1002/art.1780360217
   Strand V, 2006, OSTEOARTHR CARTILAGE, V14, P859, DOI 10.1016/j.joca.2006.02.012
   Waddell DD, 2007, J MANAGE CARE PHARM, V13, P113, DOI 10.18553/jmcp.2007.13.2.113
   Wang CT, 2004, J BONE JOINT SURG AM, V86A, P538, DOI 10.2106/00004623 200403000 00012
NR 33
TC 11
Z9 11
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1439 7595
EI 1439 7609
J9 MOD RHEUMATOL
JI Mod. Rheumatol.
PD OCT
PY 2009
VL 19
IS 5
BP 493
EP 501
DI 10.1007/s10165 009 0189 6
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 505AM
UT WOS:000270659800006
PM 19548064
DA 2025 08 17
ER

PT J
AU Haque, M
   Song, JY
   Fino, K
   Sandhu, P
   Song, XM
   Lei, FY
   Zheng, SG
   Ni, B
   Fang, DY
   Song, JX
AF Haque, Mohammad
   Song, Jianyong
   Fino, Kristin
   Sandhu, Praneet
   Song, Xinmeng
   Lei, Fengyang
   Zheng, Songguo
   Ni, Bing
   Fang, Deyu
   Song, Jianxun
TI Stem cell derived tissue associated regulatory T cells ameliorate the
   development of autoimmunity
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ANTIGEN SPECIFIC EXPANSION; VERSUS HOST DISEASE; IMMUNE RESPONSES;
   CUTTING EDGE; SELF ANTIGEN; HEAT SHOCK PROTEIN 60; REGENERATION;
   LYMPHOCYTES; ACTIVATION; MODEL
AB Pluripotent stem cells (PSCs) have the potential to produce almost all of the cells in the body, including regulatory T cells (T regs). However, the exact conditions required for the development of antigen (Ag)specific T regs from PSCs (i. e., PSC T regs) are not well delineated. Ag specific PSC T regs can be tissue/organ associated and migrate to local inflamed tissues/ organs to suppress the autoimmune response after adoptive transfer, thereby avoiding potential overall immunosuppression from non specific T regs. In this study, we developed a new approach to generate functional Ag specific T regs from induced PSCs (iPSCs), i. e., iPSC T regs, which had the ability to generate an Ag specific immunosuppressive response in a murine model of arthritis. We retrovirally transduced murine iPSCs with a construct containing genes of Ag specific T cell receptor (TCR) and the transcriptional factor FoxP3. We differentiated the iPSCs into Ag specific iPSC T regs using in vitro or in vivo Notch signaling, and demonstrated that adoptive transfer of such T regs dramatically suppressed autoimmunity in a well established Ag induced arthritis model, including the inflammation, joint destruction, cartilage prostaglandin depletion, osteoclast activity, and Th17 production. Our results indicate that PSCs can be used to develop Ag specific T regs, which have a therapeutic potential for Treg based therapies of autoimmune disorders.
C1 [Haque, Mohammad; Fino, Kristin; Sandhu, Praneet; Song, Xinmeng; Lei, Fengyang; Song, Jianxun] Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.
   [Song, Jianyong; Ni, Bing] Third Mil Med Univ, Inst Irradiat, Chongqing 400038, Peoples R China.
   [Song, Jianyong; Ni, Bing] Third Mil Med Univ, Inst Immunol, Chongqing 400038, Peoples R China.
   [Zheng, Songguo] Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA.
   [Fang, Deyu] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Army Medical
   University; Army Medical University; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Northwestern University; Feinberg School of Medicine
RP Song, JY (通讯作者)，Third Mil Med Univ, Inst Irradiat, Chongqing 400038, Peoples R China.; Song, JY (通讯作者)，Third Mil Med Univ, Inst Immunol, Chongqing 400038, Peoples R China.
EM jus35@psu.edu
OI HAQUE, MOHAMMAD/0000 0003 0852 6368; Ni, Bing/0000 0002 4297 5346
FU National Institute of Health [R21AI109239, K18CA151798]; Leona M. and
   Harry B. Helmsley Charitable Trust [2014PG T1D049]; Pennsylvania
   Department of Health using Tobacco Settlement Fund [4100057673]
FX We thank the cores of Molecular and Histopathology and Flow Cytometry at
   The Pennsylvania State University College of Medicine for providing the
   histologic staining and cell sorting. This project was funded, in part,
   under grants with the National Institute of Health Grant R21AI109239 and
   K18CA151798, Leona M. and Harry B. Helmsley Charitable Trust
   2014PG T1D049, and the Pennsylvania Department of Health using Tobacco
   Settlement Fund SAP # 4100057673 to J.S.
CR Bacher P, 2014, MUCOSAL IMMUNOL, V7, P916, DOI 10.1038/mi.2013.107
   Bailey Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016
   Cassani B, 2008, BLOOD, V111, P4209, DOI 10.1182/blood 2007 05 092429
   Dominguez MD, 2011, AUTOIMMUNITY, V44, P471, DOI 10.3109/08916934.2010.550590
   Delpoux A, 2014, J IMMUNOL, V193, P5914, DOI 10.4049/jimmunol.1400477
   Golshayan D, 2007, BLOOD, V109, P827, DOI 10.1182/blood 2006 05 025460
   Hague M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00209
   Haque R, 2012, J IMMUNOL, V189, P1228, DOI 10.4049/jimmunol.1200633
   Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010
   Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119
   Hombach AA, 2009, GENE THER, V16, P1088, DOI 10.1038/gt.2009.75
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Huter EN, 2008, J IMMUNOL, V181, P8209, DOI 10.4049/jimmunol.181.12.8209
   Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077
   Jones CB, 2014, CLIN IMMUNOL, V153, P298, DOI 10.1016/j.clim.2014.05.006
   Kamphuis S, 2005, LANCET, V366, P50, DOI 10.1016/S0140 6736(05)66827 4
   Kasagi S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008895
   Kijima M, 2008, P NATL ACAD SCI USA, V105, P7010, DOI 10.1073/pnas.0709919105
   Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023
   Kim YC, 2015, BLOOD, V125, P1107, DOI 10.1182/blood 2014 04 566786
   Kim YC, 2012, BLOOD, V119, P2810, DOI 10.1182/blood 2011 09 377895
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Lapierre P, 2013, HEPATOLOGY, V57, P217, DOI 10.1002/hep.26023
   Lei FY, 2014, METHODS MOL BIOL, V1213, P365, DOI 10.1007/978 1 4939 1453 1_30
   Lei FY, 2012, JOVE J VIS EXP, DOI 10.3791/3986
   Lei FY, 2011, CANCER RES, V71, P4742, DOI 10.1158/0008 5472.CAN 11 0359
   Lei FY, 2009, CELL IMMUNOL, V260, P1, DOI 10.1016/j.cellimm.2009.09.005
   Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004
   Liu YJ, 2014, MOL CELL BIOL, V34, P3993, DOI 10.1128/MCB.00919 14
   Lorenzo N, 2012, AUTOIMMUNITY, V45, P449, DOI 10.3109/08916934.2012.697592
   Maeda Y, 2014, SCIENCE, V346, P1536, DOI 10.1126/science.aaa1292
   Nguyen TLM, 2011, J IMMUNOL, V187, P1745, DOI 10.4049/jimmunol.1004112
   Norell H, 2010, CANCER IMMUNOL IMMUN, V59, P851, DOI 10.1007/s00262 009 0810 8
   Passerini L, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007320
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Reynolds AD, 2010, J IMMUNOL, V184, P2261, DOI 10.4049/jimmunol.0901852
   Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996
   Ruzek MC, 2008, BLOOD, V111, P1726, DOI 10.1182/blood 2007 08 106526
   Samon JB, 2008, BLOOD, V112, P1813, DOI 10.1182/blood 2008 03 144980
   Samy ET, 2008, J IMMUNOL, V180, P4366, DOI 10.4049/jimmunol.180.7.4366
   Sekine C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3758
   Sela U, 2011, J EXP MED, V208, P2489, DOI 10.1084/jem.20110466
   Semitekolou M, 2009, J EXP MED, V206, P1769, DOI 10.1084/jem.20082603
   Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139
   Themeli M, 2013, NAT BIOTECHNOL, V31, P928, DOI 10.1038/nbt.2678
   van Herwijnen MJC, 2012, P NATL ACAD SCI USA, V109, P14134, DOI 10.1073/pnas.1206803109
   van Loenen MM, 2010, P NATL ACAD SCI USA, V107, P10972, DOI 10.1073/pnas.1005802107
   Vizcardo R, 2013, CELL STEM CELL, V12, P31, DOI 10.1016/j.stem.2012.12.006
   Wei J, 2007, P NATL ACAD SCI USA, V104, P18169, DOI 10.1073/pnas.0703642104
   Wieten L, 2010, ARTHRITIS RHEUM US, V62, P1026, DOI 10.1002/art.27344
   Wing JB, 2014, IMMUNITY, V41, P1013, DOI 10.1016/j.immuni.2014.12.006
   Wright GP, 2009, P NATL ACAD SCI USA, V106, P19078, DOI 10.1073/pnas.0907396106
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 53
TC 34
Z9 34
U1 1
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 5
PY 2016
VL 6
AR 20588
DI 10.1038/srep20588
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DC9AD
UT WOS:000369511600001
PM 26846186
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, X
   Shan, HJ
   Yin, G
   Zhang, XY
   Huang, YM
   Li, HJ
AF Sun, Xu
   Shan, Hua jian
   Yin, Gang
   Zhang, Xiang yang
   Huang, Yu min
   Li, Hai jun
TI The anti osteosarcoma cell activity by the sphingosine kinase 1
   inhibitor SKI V
SO CELL DEATH DISCOVERY
LA English
DT Article
ID INTRACELLULAR CA2+; GROWTH INHIBITION; ACTIVATES AMPK; CANCER CELLS;
   APOPTOSIS; SPHK1; SPHINGOSINE 1 PHOSPHATE; ONCOGENE; K6PC 5
AB Sphingosine kinase 1 (SphK1) expression and activity are elevated in human osteosarcoma (OS) and is a promising target of therapy. SKI V is a non competitive and highly efficient non lipid SphK1 inhibitor. The potential anti OS cell activity by the SphK1 inhibitor was studied here. In primary OS cells and immortalized cell lines, SKI V robustly suppressed cell survival, growth and proliferation as well as cell mobility, and inducing profound OS cell death and apoptosis. The SphK1 inhibitor was however non cytotoxic nor pro apoptotic in human osteoblasts. SKI V robustly inhibited SphK1 activation and induced accumulation of ceramides, without affecting SphK1 expression in primary OS cells. The SphK1 activator K6PC 5 or sphingosine 1 phosphate partially inhibited SKI V induced OS cell death. We showed that SKI V concurrently blocked Akt mTOR activation in primary OS cells. A constitutively active Akt1 (ca Akt1, S473D) construct restored Akt mTOR activation and mitigated SKI V mediated cytotoxicity in primary OS cells. In vivo, daily injection of SKI V potently suppressed OS xenograft tumor growth in nude mice. In SKI V administrated OS xenograft tissues, SphK1 inhibition, ceramide increase and Akt mTOR inhibition were detected. Together, SKI V exerts significant anti OS activity by inhibiting SphK1 and Akt mTOR cascades in OS cells.
C1 [Sun, Xu; Li, Hai jun] Nantong Univ, Hosp Affiliated 5, Taizhou Peoples Hosp, Dept Hand & Foot Surg, Taizhou, Peoples R China.
   [Shan, Hua jian] Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou, Peoples R China.
   [Yin, Gang] Jiangsu Univ, Wujin Hosp, Dept Orthopaed, Changzhou, Jiangsu, Peoples R China.
   [Zhang, Xiang yang] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept Orthopaed, Shanghai, Peoples R China.
   [Huang, Yu min] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Peoples R China.
C3 Nantong University; Soochow University   China; Jiangsu University;
   Shanghai Jiao Tong University; Nanjing Medical University
RP Li, HJ (通讯作者)，Nantong Univ, Hosp Affiliated 5, Taizhou Peoples Hosp, Dept Hand & Foot Surg, Taizhou, Peoples R China.; Huang, YM (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Peoples R China.
EM xiaoan19860820@126.com; lihaijuntz7@hotmail.com
RI han, jinli/AAA 4159 2022
FU Scientific research project of Changzhou Health Commission [QN201829];
   Clinical Technology Development Foundation of Jiangsu University
   [JLY20180009]
FX This work is supported by the financial support from The Scientific
   research project of Changzhou Health Commission (QN201829) and the
   Clinical Technology Development Foundation of Jiangsu University
   (JLY20180009).
CR Alemany R, 2007, N S ARCH PHARMACOL, V374, P413, DOI 10.1007/s00210 007 0132 3
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138
   Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226
   French KJ, 2006, J PHARMACOL EXP THER, V318, P596, DOI 10.1124/jpet.106.101345
   French KJ, 2003, CANCER RES, V63, P5962
   Gangoiti Patricia, 2008, Transl Oncogenomics, V3, P81
   Gao YY, 2021, THERANOSTICS, V11, P4599, DOI 10.7150/thno.55655
   Gazouli I, 2021, CANCERS, V13, DOI 10.3390/cancers13081757
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Gong L, 2014, CANCER CHEMOTH PHARM, V73, P69, DOI 10.1007/s00280 013 2318 3
   Gong ZH, 2021, AGING US, V13, P3726, DOI 10.18632/aging.202336
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   Gupte A, 2015, CLIN CANCER RES, V21, P3216, DOI 10.1158/1078 0432.CCR 14 3026
   Han QC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00780 x
   Hong JH, 2008, J INVEST DERMATOL, V128, P2166, DOI 10.1038/jid.2008.66
   Hu K, 2016, ONCOL REP, V36, P1219, DOI 10.3892/or.2016.4922
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007
   Jin S, 2007, APOPTOSIS, V12, P1317, DOI 10.1007/s10495 007 0062 z
   Ju TF, 2016, BIOCHEM BIOPH RES CO, V470, P728, DOI 10.1016/j.bbrc.2016.01.053
   Li PH, 2014, ASIAN PAC J CANCER P, V15, P10381, DOI 10.7314/APJCP.2014.15.23.10381
   Liu B, 2008, CELL BIOL INT, V32, P494, DOI 10.1016/j.cellbi.2007.10.008
   Liu H, 2018, CELL PHYSIOL BIOCHEM, V51, P1908, DOI 10.1159/000495716
   Liu ZJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2515 z
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875
   Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017
   Schnute ME, 2012, BIOCHEM J, V444, P79, DOI 10.1042/BJ20111929
   Shaikh AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040506
   Shan HJ, 2021, MOL THER NUCL ACIDS, V24, P385, DOI 10.1016/j.omtn.2021.03.006
   Shao JJ, 2015, DNA CELL BIOL, V34, P669, DOI 10.1089/dna.2015.2959
   Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402
   Siegel RL., 2021, CA CANCER J CLIN, V71
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Tamashiro PM, 2013, BIOMOLECULES, V3, P481, DOI 10.3390/biom3030481
   Tian ZC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01642
   Vadas M, 2008, BBA MOL CELL BIOL L, V1781, P442, DOI 10.1016/j.bbalip.2008.06.007
   Wei K, 2019, ANAT REC, V302, P1941, DOI 10.1002/ar.24200
   Xu YJ, 2011, REGUL PEPTIDES, V172, P58, DOI 10.1016/j.regpep.2011.08.009
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Yang L, 2015, BIOCHEM BIOPH RES CO, V460, P903, DOI 10.1016/j.bbrc.2015.03.114
   Yang YL, 2012, CANCER SCI, V103, P1538, DOI 10.1111/j.1349 7006.2012.02335.x
   Yao C, 2020, AGING US, V12, P5399, DOI 10.18632/aging.102961
   Yao C, 2012, MOL ONCOL, V6, P392, DOI 10.1016/j.molonc.2012.04.002
   Yu XB, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578 021 00600 w
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
   Zheng CX, 2020, BBA REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188405
   Zhou QA, 2010, MED ONCOL, V27, P1239, DOI 10.1007/s12032 009 9365 y
   Zhou WY, 2014, DISCOV MED, V17, P301
   Zhou Y, 2017, HUM CELL, V30, P30, DOI 10.1007/s13577 016 0148 4
   Zhu YR, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.659181
   Zhu YR, 2016, ONCOTARGET, V7, P49527, DOI 10.18632/oncotarget.10389
NR 51
TC 12
Z9 12
U1 0
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058 7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD FEB 3
PY 2022
VL 8
IS 1
AR 48
DI 10.1038/s41420 022 00838 4
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA YS7EQ
UT WOS:000750835900002
PM 35115496
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Yi, SW
   Oh, HJ
   Lee, JS
   Park, JS
   Park, KH
AF Kim, Hye Jin
   Yi, Se Won
   Oh, Hyun Jyung
   Lee, Jung Sun
   Park, Ji Sun
   Park, Keun Hong
TI Transfection of gene regulation nanoparticles complexed with pDNA and
   shRNA controls multilineage differentiation of hMSCs
SO BIOMATERIALS
LA English
DT Article
DE pDNA; shRNA; Multi lineage; MSC; Gene regulation nanoparticles
ID MESENCHYMAL STEM CELLS; RNA INTERFERENCE; CANCER THERAPY; CHONDROGENIC
   DIFFERENTIATION; PROGENITOR CELLS; CO DELIVERY; IN VIVO; SIRNA; TISSUE;
   POLYETHYLENIMINE
AB Overexpression and knockdown of specific proteins can control stem cell differentiation for therapeutic purposes. In this study, we fabricated RUNX2, SOX9, and C/EBP alpha plasmid DNAs (pDNAs) and ATF4 targeting shRNA (shATF4) to induce osteogenesis, chondrogenesis, and adipogenesis of human mesenchymal stem cells (hMSCs). The pDNAs and shATF4 were complexed with TRITC gene regulation nanoparticles (GRN). Osteogenesis related gene expression was reduced at early (12 h) and late (36 h) time points after co delivery of shATF4 and SOX9 or C/EBP alpha pDNA, respectively, and osteogenesis was inhibited in these hMSCs. By contrast, osteogenesis related genes were highly expressed upon co delivery of RUNX2 and ATF4 pDNAs. DEX in GRN enhanced chondrogenic differentiation. Expression of osteogenesis , chondrogenesis , and adipogenesis related genes was higher in hMSCs transfected with NPs complexed with RUNX2 and ATF4 pDNAs, shATF4 and SOX9 pDNA, and shATF4 and C/EBP alpha pDNA for 72 h than in control hMSCs, respectively. Moreover, delivery of these NPs also increased expression of osteogenesis , chondrogenesis , and adipogenesis related proteins. These alterations in expression led to morphological changes, indicating that hMSCs differentiated into osteoblasts, chondrocytes, and adipose cells. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kim, Hye Jin; Yi, Se Won; Oh, Hyun Jyung; Lee, Jung Sun; Park, Ji Sun; Park, Keun Hong] CHA Univ, Coll Life Sci, Dept Nanoregenerat Med Engn, 6F,CHA Biocomplex, Seongnam Si 13488, South Korea.
C3 Pochon Cha University
RP Park, JS; Park, KH (通讯作者)，CHA Univ, Coll Life Sci, Dept Nanoregenerat Med Engn, 6F,CHA Biocomplex, Seongnam Si 13488, South Korea.
EM pjs09@cha.ac.kr; pkh0410@cha.ac.kr
FU National Research Foundation of Korea (NRF)   Korean Government
   [NRF 2017R1A2A1A05001264, NRF 2017M3A9C6061360, NRF 2015R1A1A3A04000928,
   NRF  2017M3A9B4031169]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF) funded by the Korean Government (NRF 2017R1A2A1A05001264,
   NRF 2017M3A9C6061360, NRF 2015R1A1A3A04000928 & NRF  2017M3A9B4031169).
CR Agarwal T, 2016, ACS APPL MATER INTER, V8, P32132, DOI 10.1021/acsami.6b08512
   Alex MRA, 2017, BIOMATERIALS, V133, P94, DOI 10.1016/j.biomaterials.2017.04.022
   Boda SK, 2017, ACS APPL MATER INTER, V9, P19389, DOI 10.1021/acsami.6b08694
   Cai JL, 2013, DEV BIOL, V376, P62, DOI 10.1016/j.ydbio.2013.01.012
   Cai XJ, 2017, ACS APPL MATER INTER, V9, P9402, DOI 10.1021/acsami.6b16689
   Caron MMJ, 2013, OSTEOARTHR CARTILAGE, V21, P604, DOI 10.1016/j.joca.2013.01.009
   Chen ZH, 2016, BIOMATERIALS, V81, P125, DOI 10.1016/j.biomaterials.2015.11.022
   Christiansen L, 2017, METHODS MOL BIOL, V1551, P207, DOI 10.1007/978 1 4939 6750 6_12
   Dolega ME, 2015, BIOMATERIALS, V52, P347, DOI 10.1016/j.biomaterials.2015.02.042
   Dowdy SF, 2017, NAT BIOTECHNOL, V35, P222, DOI 10.1038/nbt.3802
   Gong MC, 2008, CANCER LETT, V272, P148, DOI 10.1016/j.canlet.2008.07.004
   Guo J, 2016, INT J NANOMED, V11, P5287, DOI 10.2147/IJN.S116902
   Huang X, 2015, BIOMATERIALS, V63, P70, DOI 10.1016/j.biomaterials.2015.06.006
   Jeon SY, 2014, BIOMATERIALS, V35, P8236, DOI 10.1016/j.biomaterials.2014.05.092
   Jeon SY, 2012, BIOMATERIALS, V33, P4413, DOI 10.1016/j.biomaterials.2012.02.051
   Ji MY, 2016, ACS APPL MATER INTER, V8, P9565, DOI 10.1021/acsami.5b11866
   Koelling S, 2009, CELL STEM CELL, V4, P324, DOI 10.1016/j.stem.2009.01.015
   Lennox KA, 2016, NUCLEIC ACIDS RES, V44, P863, DOI 10.1093/nar/gkv1206
   Ma W, 2017, J AM CHEM SOC, V139, P11752, DOI 10.1021/jacs.7b03617
   Müller K, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/46/464001
   Na L, 2009, J BIOL CHEM, V44, P30518
   Naito Yuki, 2012, Frontiers in Genetics, V3, P102, DOI 10.3389/fgene.2012.00102
   Pan T, 2016, ACS APPL MATER INTER, V8, P19217, DOI 10.1021/acsami.6b02969
   Ramaswamy J, 2015, BIOMATERIALS, V73, P120, DOI 10.1016/j.biomaterials.2015.09.021
   Schaser T, 2011, GENE THER, V18, P953, DOI 10.1038/gt.2011.48
   Siqi Y., 2017, STEM CELLS INT
   Sthanam LK, 2017, BIOMATERIALS, V119, P9, DOI 10.1016/j.biomaterials.2016.12.006
   SUN MZ, 2017, NAT COMMUN, V8
   Tang FC, 2004, STEM CELLS, V22, P93, DOI 10.1634/stemcells.22 1 93
   Tiscornia G, 2006, NAT PROTOC, V1, P234, DOI 10.1038/nprot.2006.36
   Toda H., 2017, ACTA BIOMATER, V17, P30178
   Valdmanis PN, 2017, HUM GENE THER, V28, P361, DOI 10.1089/hum.2016.171
   Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140 6736(03)14637 5
   Wang C, 2016, ACS APPL MATER INTER, V8, P11262, DOI 10.1021/acsami.6b01103
   Wang WG, 2012, DEVELOPMENT, V139, P601, DOI 10.1242/dev.069575
   Wang WG, 2009, DEVELOPMENT, V136, P4143, DOI 10.1242/dev.043281
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wu Y, 2016, ACTA BIOMATER, V46, P165, DOI 10.1016/j.actbio.2016.09.008
   Xiangli Y., 2004, CELL, V117, P387
   Xie LS, 2016, ACS APPL MATER INTER, V8, P29261, DOI 10.1021/acsami.6b08542
   Zhao X, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14998
   Zhao XL, 2016, SMALL, V12, P4662, DOI 10.1002/smll.201503629
   Zrazhevskiy P, 2016, ANGEW CHEM INT EDIT, V55, P8975, DOI 10.1002/anie.201603945
NR 43
TC 17
Z9 17
U1 0
U2 51
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2018
VL 177
BP 1
EP 13
DI 10.1016/j.biomaterials.2018.05.035
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GN8HY
UT WOS:000439401700001
PM 29883913
DA 2025 08 17
ER

PT J
AU Mikulcic, M
   Tabrizi Wizsy, NG
   Bernhart, EM
   Asslaber, M
   Trummer, C
   Windischhofer, W
   Sattler, W
   Malle, E
   Hrzenjak, A
AF Mikulcic, Mateja
   Tabrizi Wizsy, Nassim Ghaffari
   Bernhart, Eva M.
   Asslaber, Martin
   Trummer, Christopher
   Windischhofer, Werner
   Sattler, Wolfgang
   Malle, Ernst
   Hrzenjak, Andelko
TI 15d PGJ2 Promotes ROS Dependent Activation of MAPK Induced
   Early Apoptosis in Osteosarcoma Cell In Vitro and in an Ex Ovo CAM Assay
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE 15d PGJ(2); apoptosis; CAM assay; osteosarcoma; reactive oxygen species
ID 15 DEOXY DELTA(12,14) PROSTAGLANDIN J(2); PPAR GAMMA; CANCER; SURVIVAL;
   DIFFERENTIATION; PROSTAGLANDINS; PROLIFERATION; THIOREDOXIN; METABOLISM;
   MODULATION
AB Osteosarcoma (OS) is the most common type of bone tumor, and has limited therapy options. 15 Deoxy Delta(12,14) prostaglandin J(2) (15d PGJ(2)) has striking anti tumor effects in various tumors. Here, we investigated molecular mechanisms that mediate anti tumor effects of 15d PGJ(2) in different OS cell lines. Human U2 OS and Saos 2 cells were treated with 15d PGJ(2) and cell survival was measured by MTT assay. Cell proliferation and motility were investigated by scratch assay, the tumorigenic capacity by colony forming assay. Intracellular ROS was estimated by H(2)DCFDA. Activation of MAPKs and cytoprotective proteins was detected by immunoblotting. Apoptosis was detected by immunoblotting and Annexin V/PI staining. The ex ovo CAM model was used to study growth capability of grafted 15d PGJ(2) treated OS cells, followed by immunohistochemistry with hematoxylin/eosin and Ki 67. 15d PGJ(2) substantially decreased cell viability, colony formation and wound closure capability of OS cells. Non malignant human osteoblast was less affected by 15d PGJ(2). 15d PGJ(2) induced rapid intracellular ROS production and time dependent activation of MAPKs (pERK1/2, pJNK and pp38). Tempol efficiently inhibited 15d PGJ(2) induced ERK1/2 activation, while N acetylcystein and pyrrolidine dithiocarbamate were less effective. Early but weak activation of cytoprotective proteins was overrun by induction of apoptosis. A structural analogue, 9,10 dihydro 15d PGJ(2), did not show toxic effects in OS cells. In the CAM model, we grafted OS tumors with U2 OS, Saos 2 and MG 63 cells. 15d PGJ(2) treatment resulted in significant growth inhibition, diminished tumor tissue density, and reduced tumor cell proliferation for all cell lines. Our in vitro and CAM data suggest 15d PGJ(2) as a promising natural compound to interfere with OS tumor growth.
C1 [Mikulcic, Mateja; Hrzenjak, Andelko] Med Univ Graz, Div Pulmonol, Dept Internal Med, A 8036 Graz, Austria.
   [Tabrizi Wizsy, Nassim Ghaffari] Med Univ Graz, Div Immunol & Pathophysiol, Otto Loewi Res Ctr, A 8010 Graz, Austria.
   [Bernhart, Eva M.; Trummer, Christopher; Sattler, Wolfgang; Malle, Ernst] Med Univ Graz, Div Mol Biol & Biochem, Gottfried Schatz Res Ctr, A 8010 Graz, Austria.
   [Asslaber, Martin] Med Univ Graz, Diagnost & Res Inst Pathol, A 8010 Graz, Austria.
   [Windischhofer, Werner] Med Univ Graz, Dept Pediat & Adolescence Med, A 8036 Graz, Austria.
   [Hrzenjak, Andelko] Med Univ Graz, Ludwig Boltzmann Inst Lung Vasc Res, A 8010 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz; Medical University of Graz; Medical University of
   Graz; Ludwig Boltzmann Institute; Ludwig Boltzmann Institute for Lung
   Vascular Research; Medical University of Graz
RP Hrzenjak, A (通讯作者)，Med Univ Graz, Div Pulmonol, Dept Internal Med, A 8036 Graz, Austria.; Hrzenjak, A (通讯作者)，Med Univ Graz, Ludwig Boltzmann Inst Lung Vasc Res, A 8010 Graz, Austria.
EM mateja.mikulcic@medunigraz.at; nassim.ghaffari@medunigraz.at;
   eva.bernhart@medunigraz.at; martin.asslaber@medunigraz.at;
   christopher.trummer@medunigraz.at; werner.windischhofer@medunigraz.at;
   wolfgang.sattler@medunigraz.at; ernst.malle@medunigraz.at;
   andelko.hrzenjak@medunigraz.at
RI Ghaffari Tabrizi Wizsy, Nassim/J 7333 2017
OI Ghaffari Tabrizi Wizsy, Nassim/0000 0001 6696 8717; Mikulcic,
   Mateja/0000 0002 3913 4394; Hrzenjak, Andelko/0000 0002 8149 8191
FU Austrian National Bank (OeNB) [17600]
FX This research was funded by the Austrian National Bank (OeNB, Grant
   Number 17600 to E.M. and A.H.).
CR Aggarwal V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110735
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   Atmaca H, 2013, TOXICOL LETT, V221, P128, DOI 10.1016/j.toxlet.2013.06.213
   Balke Maurice, 2010, BMC Res Notes, V3, P58, DOI 10.1186/1756 0500 3 58
   Bie QL, 2018, AM J TRANSL RES, V10, P648
   Braicu C, 2019, CANCERS, V11, DOI 10.3390/cancers11101618
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Chen K, 2015, ONCOTARGETS THER, V8, P3585, DOI 10.2147/OTT.S92832
   Clay CE, 2002, J LIPID RES, V43, P1818, DOI 10.1194/jlr.M200224 JLR200
   Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418 008 0536 2
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Diers AR, 2010, BIOCHEM J, V430, P69, DOI 10.1042/BJ20091193
   Doyle K, 2010, J BIOL CHEM, V285, P17417, DOI 10.1074/jbc.M109.089250
   Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175
   Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211
   Grignani G, 2018, LANCET ONCOL, V19, P1360, DOI 10.1016/S1470 2045(18)30438 8
   Hattinger CM, 2019, EXPERT OPIN EMERG DR, V24, P153, DOI 10.1080/14728214.2019.1654455
   Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959 437X(01)00265 9
   Higuchi T, 2019, BIOCHEM BIOPH RES CO, V513, P326, DOI 10.1016/j.bbrc.2019.03.191
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Janeway KA, 2012, CANCER AM CANCER SOC, V118, P4597, DOI 10.1002/cncr.27414
   Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652
   Kawakita T, 2017, EXP THER MED, V13, P2939, DOI 10.3892/etm.2017.4346
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kim EH, 2021, CELLS BASEL, V10, DOI 10.3390/cells10030526
   Kitz K, 2011, FREE RADICAL BIO MED, V50, P854, DOI 10.1016/j.freeradbiomed.2010.12.039
   Koyani CN, 2016, BIOCHEM PHARMACOL, V104, P29, DOI 10.1016/j.bcp.2016.01.011
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049
   Li JJ, 2019, PPAR RES, V2019, DOI 10.1155/2019/7242030
   Lilienthal I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186885
   Lin TH, 2010, J CELL PHYSIOL, V222, P757, DOI 10.1002/jcp.22008
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Liu Q, 2019, CELL BIOL INT, V43, P1245, DOI 10.1002/cbin.11121
   Maier NK, 2015, J IMMUNOL, V194, P2776, DOI 10.4049/jimmunol.1401611
   Matsuzawa A, 2017, ARCH BIOCHEM BIOPHYS, V617, P101, DOI 10.1016/j.abb.2016.09.011
   Mayr Wohlfart U, 2001, J BIOMED MATER RES, V57, P132, DOI 10.1002/1097 4636(200110)57:1<132::AID JBM1152>3.0.CO;2 K
   Morgenstern J, 2018, ANAL BIOANAL CHEM, V410, P521, DOI 10.1007/s00216 017 0748 1
   Nakamura M, 2013, BIOMED PHARMACOTHER, V67, P66, DOI 10.1016/j.biopha.2012.10.012
   Orimo H, 2008, MOL GENET METAB, V94, P375, DOI 10.1016/j.ymgme.2008.03.015
   Perez M, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00246 z
   Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276 020 0384 2
   Picci P, 2010, ANN ONCOL, V21, P1366, DOI 10.1093/annonc/mdp502
   Shajahan Haq AN, 2017, ONCOTARGET, V8, P96865, DOI 10.18632/oncotarget.18292
   Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200
   Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658
   Shin SW, 2009, CLIN CANCER RES, V15, P5414, DOI 10.1158/1078 0432.CCR 08 3101
   Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978 0 12 405881 1.00002 1
   Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs
   Sys GML, 2013, JOVE J VIS EXP, DOI 10.3791/50522
   Uchida K, 2008, CHEM RES TOXICOL, V21, P138, DOI 10.1021/tx700177j
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wang B, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.642547
   Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100
   Wang JJ, 2011, PROSTAG OTH LIPID M, V94, P104, DOI 10.1016/j.prostaglandins.2011.01.004
   Whelan JS, 2012, ANN ONCOL, V23, P1607, DOI 10.1093/annonc/mdr491
   Wippel B, 2019, CANCER MED US, V8, P111, DOI 10.1002/cam4.1898
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
   Yen CC, 2014, ONCOTARGET, V5, P716, DOI 10.18632/oncotarget.1704
   Yue L, 2012, BONE, V51, P338, DOI 10.1016/j.bone.2012.06.003
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zimta AA, 2019, CANCERS, V11, DOI 10.3390/cancers11111755
NR 62
TC 8
Z9 9
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 11760
DI 10.3390/ijms222111760
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WX3OX
UT WOS:000718510500001
PM 34769194
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Clauw, DJ
   Hassett, AL
AF Clauw, D. J.
   Hassett, A. L.
TI The role of centralised pain in osteoarthritis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE chronic pain; osteoarthritis; fibromyalgia; centralised pain
ID CEREBROSPINAL FLUID LEVELS; FIBROMYALGIA SYNDROME; HIP ARTHROPLASTY;
   CONTROLLED TRIAL; CHRONIC FATIGUE; TOTAL KNEE; DEPRESSION; DISORDERS;
   COMMUNITY; INSOMNIA
AB The mechanisms underlying chronic pain states, including osteoarthritis, differ from those underlying acute pain. In chronic pain states, central nervous system (CNS) factors often play a particularly prominent role. In many individuals with chronic pain, pain can occur with minimal or no evidence of ongoing nociceptive input. Medical subspecialties have applied a wide range of labels to these pain conditions including fibromyalgia, irritable bowel syndrome and interstitial cystitis to name just a few. These same CNS processes can augment or magnify pain when there is ongoing nociceptive input, as in conditions such as osteoarthritis or autoimmune disorders. The hallmark of these 'centrally driven' pain conditions is a diffuse hyperalgesic state identifiable though the use of experimental sensory testing, that has been corroborated by functional neuroimaging. Characteristic symptoms of these central pain conditions include multifocal pain, fatigue, poor sleep, memory complaints and frequent co morbid mood and anxiety disorders. In contrast to acute and peripheral pain states that are responsive to non steroidal anti inflammatory drugs (NSAIDs) and opioids, central pain conditions respond best to CNS neuromodulating agents, such as serotonin norepinephrine reuptake inhibitors (SNRIs) and anticonvulsants. While osteoarthritis is generally considered a peripherally mediated pain state, a subset of these patients also manifests centrally driven pain characteristics. Thus, osteoarthritis can also be thought of as a "mixed" pain state and this requires a more tailored approach to treatment.
C1 [Clauw, D. J.] Univ Michigan, Rheumatol Chron Pain & Fatigue Res Ctr, Dept Anesthesiol & Med, Ann Arbor, MI 48109 USA.
   [Hassett, A. L.] Univ Michigan, Chron Pain & Fatigue Res Ctr, Dept Anesthesiol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Clauw, DJ (通讯作者)，Univ Michigan, 24 Frank Lloyd Wright Dr,POB 385, Ann Arbor, MI 48106 USA.
EM dclauw@umich.edu
OI CLAUW, Daniel/0000 0002 8114 7818
FU Pfizer; Cerephex; Tonix; Abbott; Aptinyx; Daiichi Sankyo; Samumed;
   Zynerba; Astellas Phama; Williams Connolly LLP; Theravance
FX D.J. Clauw has received consulting fees from Pfizer, Cerephex, Tonix,
   Abbott, Aptinyx, Daiichi Sankyo, Samumed, Zynerba, Astellas Phama,
   Williams & Connolly LLP and Theravance, and research support from
   Pfizer, Aptinyx and Cerephex.
CR Allen KD, 2008, J RHEUMATOL, V35, P1102
   Arendt Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003
   Arnold LM, 2006, J CLIN PSYCHIAT, V67, P1219, DOI 10.4088/JCP.v67n0807
   Baraniuk JN, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471 2474 5 48
   BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623 199072080 00008
   Brummett CM, 2015, ARTHRITIS RHEUMATOL, V67, P1386, DOI 10.1002/art.39051
   Brummett CM, 2013, ANESTHESIOLOGY, V119, P1434, DOI 10.1097/ALN.0b013e3182a8eb1f
   Chappell AS, 2009, PAIN, V146, P253, DOI 10.1016/j.pain.2009.06.024
   Clauw DJ, 1997, J PSYCHIAT RES, V31, P125, DOI 10.1016/S0022 3956(96)00051 9
   Creamer P, 1999, ARTHRIT CARE RES, V12, P3, DOI 10.1002/1529 0131(199902)12:1<3::AID ART2>3.0.CO;2 K
   Creamer P, 1997, BRIT J RHEUMATOL, V36, P726
   Creamer P, 1998, ARTHRIT CARE RES, V11, P60, DOI 10.1002/art.1790110110
   Diatchenko L, 2006, PAIN, V123, P226, DOI 10.1016/j.pain.2006.04.015
   Fishbain D, 2000, ANN MED, V32, P305, DOI 10.3109/07853890008995932
   Foerster BR, 2012, ARTHRITIS RHEUM US, V64, P579, DOI 10.1002/art.33339
   Fond G, 2014, EUR ARCH PSY CLIN N, V264, P651, DOI 10.1007/s00406 014 0502 z
   Geisser ME, 2008, PSYCHOSOMATICS, V49, P235, DOI 10.1176/appi.psy.49.3.235
   Goesling J, 2016, PAIN, V157, P1259, DOI 10.1097/j.pain.0000000000000516
   Greenspan JD, 2011, J PAIN, V12, pT61, DOI 10.1016/j.jpain.2011.08.006
   Gwilym SE, 2010, ARTHRITIS RHEUM US, V62, P2930, DOI 10.1002/art.27585
   Gwilym SE, 2009, ARTHRIT RHEUM ARTHR, V61, P1226, DOI 10.1002/art.24837
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849 07.2007
   HUDSON JI, 1994, BAILLIERE CLIN RHEUM, V8, P839, DOI 10.1016/S0950 3579(05)80051 2
   Kosek E, 2000, PAIN, V88, P69, DOI 10.1016/S0304 3959(00)00310 9
   Lee YC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3306
   Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012
   Neogi T, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b2844
   RUSSELL IJ, 1992, ARTHRITIS RHEUM, V35, P550, DOI 10.1002/art.1780350509
   RUSSELL IJ, 1994, ARTHRITIS RHEUM US, V37, P1593, DOI 10.1002/art.1780371106
   Sarchielli Paola, 2007, Curr Pain Headache Rep, V11, P343, DOI 10.1007/s11916 007 0216 2
   Sarchielli P, 2007, J PAIN, V8, P737, DOI 10.1016/j.jpain.2007.05.002
   Smith MT, 2015, ARTHRITIS RHEUMATOL, V67, P1221, DOI 10.1002/art.39048
   Vitiello MV, 2013, J AM GERIATR SOC, V61, P947, DOI 10.1111/jgs.12275
   Warren JW, 2009, UROLOGY, V73, P52, DOI 10.1016/j.urology.2008.06.031
   Williams DA, 2009, J PAIN, V10, P777, DOI 10.1016/j.jpain.2009.06.001
   Zhang YQ, 2008, RHEUM DIS CLIN N AM, V34, P515, DOI 10.1016/j.rdc.2008.05.007
NR 37
TC 66
Z9 66
U1 0
U2 6
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PY 2017
VL 35
IS 5
SU 107
BP S79
EP S84
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA FQ5SF
UT WOS:000418420600015
DA 2025 08 17
ER

PT J
AU Zhou, RY
   Ma, Y
   Qiu, S
   Gong, ZL
   Zhou, XS
AF Zhou, Renyi
   Ma, Yue
   Qiu, Shui
   Gong, Zunlei
   Zhou, Xiaoshu
TI Metformin promotes cell proliferation and osteogenesis under high
   glucose condition by regulating the ROS AKT mTOR axis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE metformin; reactive oxygen species; cell proliferation; osteogenesis;
   mitochondrial membrane potential
ID MC3T3 E1 CELLS; DIFFERENTIATION; OSTEOBLAST; PREVALENCE; AUTOPHAGY; FOOT
AB Metformin, a cost effective and safe orally administered antidiabetic drug used by millions of patients, has exhibited great interest for its potential osteogenic promoting properties in different types of cells, including mesenchymal stem cells (MSCs). Diabetic osteopathy is a common comorbidity of diabetes mellitus; however, the underlying molecular mechanisms of metformin on the physiological processes of MSCs, under high glucose condition, remain unknown. To determine the effects of metformin on the regulatory roles of proliferation and differentiation in MSCs, under high glucose conditions, osteogenesis after metformin treatment was detected with Alizarin Red S and ALP staining. The results demonstrated that high glucose levels significantly inhibited cell proliferation and osteogenic differentiation under high glucose conditions. Notably, addition of metformin reversed the inhibitory effects induced by high glucose levels on cell proliferation and osteogenesis. Furthermore, high glucose levels significantly decreased mitochondrial membrane potential (MMP), whereas treatment with metformin helped maintain MMP. Further analysis of mitochondrial function revealed that metformin significantly promoted ATP synthesis, mitochondrial DNA mass and mitochondrial transcriptional activity, which were inhibited by high glucose culture. Furthermore, metformin significantly scavenged reactive oxygen species (ROS) induced by high glucose levels, and regulated the ROS AKT mTOR axis inhibited by high glucose levels, suggesting the protective effects of metformin against high glucose levels via regulation of the ROS AKT mTOR axis. Taken together, the results of the present study demonstrated the protective role of metformin on the physiological processes of MSCs, under high glucose condition and highlighted the potential molecular mechanism underlying the effect of metformin in promoting cell proliferation and osteogenesis under high glucose condition.
C1 [Zhou, Renyi; Qiu, Shui; Gong, Zunlei; Zhou, Xiaoshu] China Med Univ, Dept Orthoped, Affiliated Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
   [Ma, Yue] China Med Univ, Dept Resp & Crit Care Med, Shengjing Hosp, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Zhou, XS (通讯作者)，China Med Univ, Dept Orthoped, Affiliated Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM 13889291613@163.com
CR Botushanov Nikolay P, 2009, Folia Med (Plovdiv), V51, P12
   Chen Y, 2017, CELL BIOL INT, V41, P822, DOI 10.1002/cbin.10779
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Dhaliwal R, 2014, OSTEOPOROSIS INT, V25, P1969, DOI 10.1007/s00198 014 2704 7
   Fiorini C, 2015, BBA MOL CELL RES, V1853, P549, DOI 10.1016/j.bbamcr.2014.12.016
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Madariaga AG, 2014, J CLIN ENDOCR METAB, V99, P923, DOI 10.1210/jc.2013 2409
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Harvey NCW, 2017, OSTEOPOROSIS INT, V28, P1507, DOI 10.1007/s00198 016 3894 y
   Jackuliak P, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/820615
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Li CL, 2019, J BIOL INORG CHEM, V24, P733, DOI 10.1007/s00775 019 01687 w
   Liu JK, 2009, ADV DRUG DELIVER REV, V61, P1343, DOI 10.1016/j.addr.2009.06.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Markowicz Piasecka M, 2017, PHARM RES DORDR, V34, P2614, DOI 10.1007/s11095 017 2199 y
   Park KR, 2011, CANCER LETT, V312, P178, DOI 10.1016/j.canlet.2011.08.001
   Renner K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01258
   Rosenbloom AL, 1996, ENDOCRIN METAB CLIN, V25, P473, DOI 10.1016/S0889 8529(05)70335 2
   Shao XY, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/453940
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Smith DG, 1997, FOOT ANKLE INT, V18, P342, DOI 10.1177/107110079701800606
   Sun HL, 2009, CELLS TISSUES ORGANS, V190, P69, DOI 10.1159/000178020
   Takanche JS, 2020, PHYTOMEDICINE, V66, DOI 10.1016/j.phymed.2019.153107
   Wang C, 2012, J BONE MINER METAB, V30, P630, DOI 10.1007/s00774 012 0374 0
   Wang XJ, 2016, MOL CELL ENDOCRINOL, V429, P62, DOI 10.1016/j.mce.2016.03.036
   Wybier M, 2008, J RADIOL, V89, P711, DOI 10.1016/S0221 0363(08)71507 5
   Yang JS, 2019, MOL MED REP, V20, P5084, DOI 10.3892/mmr.2019.10790
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
NR 28
TC 26
Z9 27
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2020
VL 22
IS 4
BP 3387
EP 3395
DI 10.3892/mmr.2020.11391
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA NW4US
UT WOS:000575004300085
PM 32945402
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Dongre, A
   Clements, D
   Fisher, AJ
   Johnson, SR
AF Dongre, Arundhati
   Clements, Debbie
   Fisher, Andrew J.
   Johnson, Simon R.
TI Cathepsin K in Lymphangioleiomyomatosis LAM Cell Fibroblast
   Interactions Enhance Protease Activity by Extracellular
   Acidification
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID CARBONIC ANHYDRASE IX; TUBEROUS SCLEROSIS COMPLEX; PULMONARY
   LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASES; CYSTEINE
   CATHEPSINS; TUMOR GROWTH; EXPRESSION; OSTEOCLASTS; INHIBITORS;
   ACTIVATION
AB Lymphangioleiomyomatosis (LAM) is a rare disease in which LAM cells and fibroblasts form Lung nodules and it is hypothesized that LAM nodule derived proteases cause cyst formation and tissue damage. On protease gene expression profiling in whole lung tissue, cathepsin K gene expression was 40 fold overexpressed in LAM compared with control Lung tissue (P <= 0.0001). Immunohistochemistry confirmed cathepsin K protein was expressed in LAM but not control lungs. Cathepsin K gene expression and protein and protease activity were detected in LAM associated fibroblasts but not the LAM cell Line 621 101. In lung nodules, cathepsin K immunoreactivity predominantly co localized with LAM associated fibroblasts. In vitro, fibroblast extracellular cathepsin K activity was minimal at pH 7.5 but significantly enhanced at pH 7 and 6. 621 101 cells reduced extracellutar pH with acidification dependent on 621 101 mechanistic target of rapamycin activity and net hydrogen ion exporters, particularly sodium bicarbonate co transporters and carbonic anhydrases, which were also expressed in LAM lung tissue. In LAM cell fibroblast co cultures, acidification paralleled cathepsin K activity, and both were reduced by sodium bicarbonate co transporter (P <= 0.0001) and carbonic anhydrase inhibitors (P = 0.0021). Our findings suggest that cathepsin K activity is dependent on LAM cell fibroblast interactions, and inhibitors of extracellutar acidification may be potential therapies for LAM.
C1 [Dongre, Arundhati; Clements, Debbie; Johnson, Simon R.] Univ Nottingham, Div Resp Med, Nottingham, England.
   [Dongre, Arundhati; Clements, Debbie; Johnson, Simon R.] Univ Nottingham, Resp Res Unit, Nottingham, England.
   [Fisher, Andrew J.] Freeman Rd Hosp, Inst Transplantat, Newcastle Upon Tyne, Tyne & Wear, England.
   [Fisher, Andrew J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
C3 University of Nottingham; University of Nottingham; Newcastle University
     UK; Newcastle Freeman Hospital; Newcastle University   UK
RP Dongre, A (通讯作者)，Univ Nottingham, Div Resp Med, Queens Med Ctr, D Floor,S Block, Nottingham NG7 2UH, England.
EM arundhati.dongre@nottingham.ac.uk
RI Clements, Debbie/KFB 7790 2024; Johnson, Simon/HNP 5584 2023; Fisher,
   Andrew/A 2160 2012
OI Johnson, Simon/0000 0002 9837 2763; 
FU LAM Action grant [LAM002]; University of Nottingham postgraduate
   studentship award [072]; Medical Research Council [MR/N005953/1] Funding
   Source: researchfish; MRC [MR/N005953/1] Funding Source: UKRI
FX Supported by LAM Action grant LAM002 and University of Nottingham
   postgraduate studentship award 072.
CR Akhenblit PJ, 2016, MOL IMAGING, V15, DOI 10.1177/1536012116645439
   Atochina Vasserman EN, 2015, AM J RESP CELL MOL, V53, P96, DOI 10.1165/rcmb.2014 0224OC
   Badri KR, 2013, AM J RESP CRIT CARE, V187, P663, DOI 10.1164/ajrccm.187.6.663
   Bee J, 2015, THORAX, V70, P1202, DOI 10.1136/thoraxjnl 2015 207171
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Chang WYC, 2014, EUR RESPIR J, V43, P1114, DOI 10.1183/09031936.00167413
   Chang WYC, 2012, RESP RES, V13, DOI 10.1186/1465 9921 13 34
   Chilosi M, 2009, MODERN PATHOL, V22, P161, DOI 10.1038/modpathol.2008.189
   Clements D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126025
   Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002 9440(10)63716 9
   Finlay G, 2004, AM J PHYSIOL LUNG C, V286, pL690, DOI 10.1152/ajplung.00311.2003
   Goldberg HJ, 2015, EUR RESPIR J, V46, P783, DOI 10.1183/09031936.00210714
   Goncharova E, 2004, AM J RESP CRIT CARE, V169, P224
   Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200
   Greenlee KJ, 2007, PHYSIOL REV, V87, P69, DOI 10.1152/physrev.00022.2006
   Hayashi T, 1997, HUM PATHOL, V28, P1071, DOI 10.1016/S0046 8177(97)90061 7
   Henske EP, 2012, J CLIN INVEST, V122, P3807, DOI 10.1172/JCI58709
   Inoue Y, 2002, AM J RESP CRIT CARE, V166, P765, DOI 10.1164/rccm.2010014
   Johnson SR, 2006, EUR RESPIR J, V27, P1056, DOI 10.1183/09031936.06.00113303
   Kaluz S, 2009, BBA REV CANCER, V1795, P162, DOI 10.1016/j.bbcan.2009.01.001
   Kang SA, 2013, SCIENCE, V341, P364, DOI 10.1126/science.1236566
   Kant S, 2014, MOL CELL BIOCHEM, V397, P167, DOI 10.1007/s11010 014 2184 2
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Lee PS, 2010, AM J RESP CELL MOL, V42, P227, DOI 10.1165/rcmb.2009 0050OC
   Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008 5472.CAN 10 4261
   Martignoni G, 2010, ARCH PATHOL LAB MED, V134, P33, DOI 10.1043/2008 0542 RAR1.1
   Matsui K, 2000, ARCH PATHOL LAB MED, V124, P267
   McCormack FX, 2012, AM J RESP CRIT CARE, V186, P1210, DOI 10.1164/rccm.201205 0848OE
   McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391
   McDonald PC, 2012, ONCOTARGET, V3, P84, DOI 10.18632/oncotarget.422
   McIntyre A, 2016, CANCER RES, V76, P3744, DOI 10.1158/0008 5472.CAN 15 1862
   Montgomery N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3199
   Odajima N, 2009, RESP MED, V103, P124, DOI 10.1016/j.rmed.2008.07.017
   Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319
   Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x
   Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108
   Pea M, 1997, ELECT J PATHOL HISTO, V3, P28, DOI [DOI 10.1016/J.EXER.2014.03.001, 10.1016/j.exer.2014.03.001]
   Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789
   Repnik U, 2015, J BIOL CHEM, V290, P13800, DOI 10.1074/jbc.M115.638395
   Riihonen R, 2007, BONE, V40, P1021, DOI 10.1016/j.bone.2006.11.028
   Romero MF, 2013, MOL ASPECTS MED, V34, P159, DOI 10.1016/j.mam.2012.10.008
   Touisni N, 2011, J MED CHEM, V54, P8271, DOI 10.1021/jm200983e
   Turk V, 2012, BBA PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Yu J, 2004, AM J PHYSIOL LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003
   Zhao QX, 2009, BIOCHEM BIOPH RES CO, V380, P721, DOI 10.1016/j.bbrc.2009.01.139
   Zhe XN, 2005, AM J RESP CELL MOL, V32, P28, DOI 10.1165/rcmb.2004 0289OC
NR 50
TC 26
Z9 29
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2017
VL 187
IS 8
BP 1750
EP 1762
DI 10.1016/j.ajpath.2017.04.014
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA FB3ZC
UT WOS:000406080300008
PM 28623674
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhao, WH
   Wang, HY
   Xiao, XX
   De Stefano, L
   Katz, J
   Lin, JS
   Barron, AE
   Schaer, TP
   Wang, HJ
   Libera, M
AF Zhao, Wenhan
   Wang, Haoyu
   Xiao, Xixi
   De Stefano, Lauren
   Katz, Jordan
   Lin, Jennifer S.
   Barron, Annelise E.
   Schaer, Thomas P.
   Wang, Hongjun
   Libera, Matthew
TI Peptoid Loaded Microgels Self Defensively Inhibit Staphylococcal
   Colonization of Titanium in a Model of Operating Room Contamination
SO ADVANCED MATERIALS INTERFACES
LA English
DT Article
DE antibacterials; drug delivery; implants; infection; microgel;
   self assembly
ID LAMINAR AIR FLOW; SURGICAL SITE INFECTIONS; RISK; ENVIRONMENT;
   TOPOGRAPHY; MECHANISM; DURATION; PEPTIDE; IMPACT; IMAGE
AB Bacterial contamination of an exposed implantable medical device by the atmosphere of an operating room (OR) is increasingly implicated as a cause of device associated infection. Here, OR contamination is modeled in vitro using an aerosolizing system to spray small quantities of staphylococci onto titanium rods. Contaminated rods always manifest culturable bacteria. Self assembly is used to create a self defensive Ti surface that substantially enhances the rod's resistance to such contamination. Poly(acrylic acid) microgels are electrostatically deposited onto small Ti rods and subsequently loaded by complexation with a cationic antimicrobial peptoid (TM1). The microgels are visualized in situ by optical microscopy, and changes in microgel diameter indicate the loading state. These measurements show that TM1 can be quickly loaded from low ionic strength buffer and subsequently remained sequestered within the microgels for up to 4 weeks when soaked in phosphate buffered saline. TM1 loaded microgel modified Ti surfaces are contaminated with aerosolized staphylococci, and subsequent assays indicate few or no culturable bacteria. In the absence of nutrients to enable metabolism, this finding suggests that bacteria trigger local TM1 release by contact transfer. The modified surfaces exhibit good in vitro cytocompatibility as manifested by the adhesion, spreading, and metabolic activity of human fetal osteoblasts.
C1 [Zhao, Wenhan; Xiao, Xixi; Libera, Matthew] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
   [Wang, Haoyu; Wang, Hongjun] Stevens Inst Technol, Dept Biomed Engn, Hoboken, NJ 07030 USA.
   [De Stefano, Lauren; Katz, Jordan] Orthobond Corp, Princeton, NJ 08852 USA.
   [Lin, Jennifer S.; Barron, Annelise E.] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA.
   [Schaer, Thomas P.] Univ Penn, Sch Vet Med, New Bolton Ctr, Dept Clin Studies, Kennett Sq, PA 19348 USA.
C3 Stevens Institute of Technology; Stevens Institute of Technology;
   Stanford University; University of Pennsylvania
RP Libera, M (通讯作者)，Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
EM mlibera@stevens.edu
RI Barron, Annelise/IQU 3611 2023; Schaer, Thomas/F 4519 2010
OI Lin, Jennifer/0000 0001 9169 7410; Barron, Annelise/0000 0002 0735 6873;
   Libera, Matthew/0000 0001 5026 802X
FU Army Research Office [W911NF2010277]; National Science Foundation
   [DMR 1608406]; U.S. Public Health Services (NIH/NIA) [1DP1 OD029517 01];
   Office of Science, Office of Basic Energy Sciences, of the U.S.
   Department of Energy [DE AC02 05CH11231]; U.S. Public Health Services
   (an NIH Pioneer award); U.S. Department of Defense (DOD) [W911NF2010277]
   Funding Source: U.S. Department of Defense (DOD)
FX The Stevens portion of this project was supported by the Army Research
   Office (Grant No. W911NF2010277) and by the National Science Foundation
   (DMR 1608406), which included supplemental funding to support Wenhan
   Zhao as an NSF Graduate Intern at Orthobond Corporation. A.E.B. and
   J.S.L. acknowledge funding from the U.S. Public Health Services (an NIH
   Pioneer award to Annelise Barron, NIH/NIA grant #1DP1 OD029517 01). The
   authors thank Dr. Josefine Eilso Nielsen for input on the manuscript.
   The authors thank Dr. Claudine Herlan and Dr. Natalia Molchanova for the
   TM1 synthesis at the Molecular Foundry, and the authors gratefully
   acknowledge the assistance of Dr. Michael Connolly there. Work at the
   Molecular Foundry was supported by the Office of Science, Office of
   Basic Energy Sciences, of the U.S. Department of Energy under Contract
   No. DE AC02 05CH11231.
CR Ahmed I, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2019 029727
   Ahmed W, 2019, MATER TODAY BIO, V2, DOI 10.1016/j.mtbio.2019.100017
   Albright V, 2017, ACTA BIOMATER, V61, P66, DOI 10.1016/j.actbio.2017.08.012
   Anis HK, 2019, J ARTHROPLASTY, V34, pS331, DOI 10.1016/j.arth.2018.11.022
   Arnold M., 2018, INT J ABDOM WALL HER, V1, P37
   Baldini A, 2019, J ARTHROPLASTY, V34, pS97, DOI 10.1016/j.arth.2018.09.059
   Barnes CL, 2019, J ARTHROPLASTY, V34, pS175, DOI 10.1016/j.arth.2018.09.068
   Berry CC, 2004, BIOMATERIALS, V25, P5781, DOI 10.1016/j.biomaterials.2004.01.029
   Biela SA, 2009, ACTA BIOMATER, V5, P2460, DOI 10.1016/j.actbio.2009.04.003
   Brady RRW, 2009, J HOSP INFECT, V71, P295, DOI 10.1016/j.jhin.2008.12.009
   Cado G, 2013, ADV FUNCT MATER, V23, P4801, DOI 10.1002/adfm.201300416
   Cahill TJ, 2016, LANCET, V387, P882, DOI 10.1016/S0140 6736(15)00067 7
   Chauveaux D, 2015, ORTHOP TRAUMATOL SUR, V101, pS77, DOI 10.1016/j.otsr.2014.07.028
   Cheng H, 2018, J SURG RES, V229, P134, DOI 10.1016/j.jss.2018.03.022
   Cheng H, 2017, SURG INFECT, V18, P722, DOI 10.1089/sur.2017.089
   Choi J, 2005, MACROMOLECULES, V38, P116, DOI 10.1021/ma048596o
   Chongsiriwatana NP, 2008, P NATL ACAD SCI USA, V105, P2794, DOI 10.1073/pnas.0708254105
   Choong J.K. L., 2018, Infections of the Ears, Nose, Throat, and Sinuses, DOI [10.1007/978 3 319 74835 1_30, DOI 10.1007/978 3 319 74835 1_30]
   Chow TT, 2004, J HOSP INFECT, V56, P85, DOI 10.1016/j.jhin.2003.09.020
   Cooper AM, 2019, J BONE JOINT SURG AM, V101, DOI 10.2106/JBJS.19.00572
   Diab Elschahawi M, 2011, AM J INFECT CONTROL, V39, pE25, DOI 10.1016/j.ajic.2010.10.035
   Diamond G, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14040304
   Doring M, 2018, DTSCH ARZTEBL INT, V115, P445, DOI 10.3238/arztebl.2018.0445
   FITZGERALD RH, 1979, ARCH SURG CHICAGO, V114, P772
   Gibbons JA, 1996, J PHARMACOL EXP THER, V277, P885
   Goswami K, 2020, J ARTHROPLASTY, V35, pS2, DOI 10.1016/j.arth.2019.10.061
   Gutierrez Murgas Y, 2014, J NEUROIMMUNOL, V276, P1, DOI 10.1016/j.jneuroim.2014.08.006
   Hoffman Kim D, 2010, ANNU REV BIOMED ENG, V12, P203, DOI 10.1146/annurev bioeng 070909 105351
   Hu YH, 2016, ACS APPL MATER INTER, V8, P21939, DOI 10.1021/acsami.5b12268
   Hubbard RE, 2010, J GERONTOL A BIOL, V65, P377, DOI 10.1093/gerona/glp186
   Kuijer R, 2007, BIOMATERIALS, V28, P5148, DOI 10.1016/j.biomaterials.2007.06.003
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Liang J, 2019, BIOMATERIALS, V204, P25, DOI 10.1016/j.biomaterials.2019.03.006
   Malanovic N, 2016, BBA BIOMEMBRANES, V1858, P936, DOI 10.1016/j.bbamem.2015.11.004
   McHugh SM, 2015, SURG J R COLL SURG E, V13, P52, DOI 10.1016/j.surge.2014.10.003
   MILLER SM, 1995, DRUG DEVELOP RES, V35, P20, DOI 10.1002/ddr.430350105
   Mookherjee N, 2020, NAT REV DRUG DISCOV, V19, P311, DOI 10.1038/s41573 019 0058 8
   Napoli C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471 2458 12 594
   Nielsen JE, 2022, ACS INFECT DIS, V8, P533, DOI 10.1021/acsinfecdis.1c00536
   Nikkhah M, 2012, BIOMATERIALS, V33, P5230, DOI 10.1016/j.biomaterials.2012.03.079
   Parvizi J., 2019, J ARTHROPLASTY, V34, pS110
   Parvizi J, 2017, AM J INFECT CONTROL, V45, P1267, DOI 10.1016/j.ajic.2017.06.027
   Pasquarella C, 2007, J HOSP INFECT, V66, P313, DOI 10.1016/j.jhin.2007.05.022
   Pavlukhina S, 2010, BIOMACROMOLECULES, V11, P3448, DOI 10.1021/bm100975w
   Ravi B., 2019, ECLINICALMEDICINE, V16, P7410
   Salzler MJ, 2018, J AM ACAD ORTHOP SUR, V26, P553, DOI 10.5435/JAAOS D 16 00730
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Séon L, 2015, LANGMUIR, V31, P12856, DOI 10.1021/acs.langmuir.5b02768
   Springer Bryan D, 2017, Arthroplast Today, V3, P137, DOI 10.1016/j.artd.2017.05.003
   W.H. Organization, 2017, GLOB GUID PREV SURG
   Wang QC, 2014, COLLOID SURFACE B, V118, P202, DOI 10.1016/j.colsurfb.2014.04.002
   Wang Y, 2011, ADV FUNCT MATER, V21, P3916, DOI 10.1002/adfm.201100659
   Weaving Paul, 2008, J Perioper Pract, V18, P199
   Wei T, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801381
   White HL, 2011, HEALTH PLACE, V17, P361, DOI 10.1016/j.healthplace.2010.11.016
   Wimley WC, 2010, ACS CHEM BIOL, V5, P905, DOI 10.1021/cb1001558
   Wu Y., 2013, MRS Online Proceedings Library, V1622, P1
   Xiao X., 2022, ACS BIOMATER S UNPUB
   Xiao XX, 2022, MACROMOLECULES, V55, P1736, DOI 10.1021/acs.macromol.1c02157
   Xiao XX, 2020, COLLOID SURFACE B, V192, DOI 10.1016/j.colsurfb.2020.110989
   Zhao W., 2022, J BIOMED MATER RES B, V10, P1
   Zhuk I, 2014, ACS NANO, V8, P7733, DOI 10.1021/nn500674g
NR 63
TC 3
Z9 3
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2196 7350
J9 ADV MATER INTERFACES
JI Adv. Mater. Interfaces
PD NOV
PY 2022
VL 9
IS 31
AR 2201662
DI 10.1002/admi.202201662
EA SEP 2022
PG 9
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 5W9UT
UT WOS:000853143800001
OA Bronze
DA 2025 08 17
ER

PT J
AU Sambandam, Y
   Sakamuri, S
   Balasubramanian, S
   Haque, A
AF Sambandam, Yuvaraj
   Sakamuri, Sashank
   Balasubramanian, Sundaravadivel
   Haque, Azizul
TI RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma
   Tumor Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE RANK LIGAND; ORAL SQUAMOUS CELL CARCINOMA (OSCC); AUTOPHAGOSOME; LC3;
   ATG5
ID OSTEOCLAST DIFFERENTIATION; PROSTATE CANCER; BREAST CANCER; EXPRESSION;
   METASTASIS; INHIBITION; THERAPY; ACCUMULATION; PATHOGENESIS; ACTIVATION
AB Autophagy is a cellular process to recycle nutrients and has been implicated in cancer treatment. Oral squamous cell carcinoma (OSCC) is the most common oral cancer which ranks 3% of cancers in men and 2% in women. In this study, immunohistochemical staining of OSCC tumor specimens from human subjects and an athymic mouse model demonstrated high levels of autophagy markers LC3 II and ATG5 expression. Further, we identified high levels LC3 II expression in OSCC tumor cell lines (SCC 1, SCC 12, and SCC 14a) compared to normal human epithelial (RWPE 1) cells. OSCC cells express high levels of RANK ligand (RANKL); however, a functional role in autophagy is unknown. Interestingly, RANKL stimulation significantly increased autophagosome related gene expressions such as LC3, ATG5, BECN1, and PI3KC3 mRNA expression in OSCC cells. Further, Western blot analysis of total cell lysates demonstrated a dose dependent increase in LC3 II and ATG5 expression in RANKL stimulated cells. In addition, RANKL increased expression of LC3 I and LC3 II, essential for autophagosome formation. Confocal microscopy analysis of LC3 II and localization with lysosome further confirms autophagosome formation in response to RANKL treatment in OSCC cells. Collectively, our results indicate a novel function of RANKL to induce autophagosome formation, and could be a potential therapeutic target to control OSCC tumor progression. (C) 2015 Wiley Periodicals, Inc.
C1 [Sambandam, Yuvaraj] Med Univ S Carolina, Darby Childrens Res Inst, Charleston, SC 29425 USA.
   [Sakamuri, Sashank; Haque, Azizul] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Sakamuri, Sashank; Haque, Azizul] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
   [Balasubramanian, Sundaravadivel] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; Medical University of
   South Carolina
RP Haque, A (通讯作者)，Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,BSB 208, Charleston, SC 29425 USA.
EM haque@musc.edu
FU National Center for Research Resources; Office of the Director of the
   National Institutes of Health [C06 RR015455]; National Institutes of
   Health [R01 CA129560]; Tissue Biorepository Shared Resource [P30
   CA138313]
FX Grant sponsor: National Center for Research Resources; Grant sponsor:
   Office of the Director of the National Institutes of Health; Grant
   number: C06 RR015455; Grant sponsor: National Institutes of Health;
   Grant number: R01 CA129560; Grant sponsor: Tissue Biorepository Shared
   Resource; Grant number: P30 CA138313.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600 0463.2007.00858.x
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Azim H, 2013, EXPERT REV ANTICANC, V13, P195, DOI [10.1586/era.12.177, 10.1586/ERA.12.177]
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Casimiro S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063153
   Chang YX, 2011, FEBS J, V278, P4811, DOI 10.1111/j.1742 4658.2011.08381.x
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Choi S, 2008, J DENT RES, V87, P14, DOI 10.1177/154405910808700104
   Deyama Y, 2008, ONCOL REP, V20, P663, DOI 10.3892/or_00000057
   Fossale E, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471 2202 5 57
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008 5472.CAN 06 1597
   Hiraishi Y, 2008, PATHOL ONCOL RES, V14, P39, DOI 10.1007/s12253 008 9020 5
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jiang LC, 2015, J ORAL PATHOL MED, V44, P361, DOI 10.1111/jop.12250
   Johnson NW, 2011, PERIODONTOL 2000, V57, P19, DOI 10.1111/j.1600 0757.2011.00401.x
   Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062
   Kraus JA, 2012, MODERN PATHOL, V25, P869, DOI 10.1038/modpathol.2011.219
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath 2014 202529
   Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600 0560.2009.01359.x
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Machiels Jean Pascal, 2014, F1000Prime Rep, V6, P44, DOI 10.12703/P6 44
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Nelson K, 2007, ORAL ONCOL, V43, P720, DOI 10.1016/j.oraloncology.2006.09.005
   Pandruvada SNM, 2010, INT J CANCER, V126, P2319, DOI 10.1002/ijc.24920
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12559, 10.1111/cas.12579]
   Sambandam Y, 2013, ONCOGENE, V32, P97, DOI 10.1038/onc.2012.24
   Schramek D, 2011, TRENDS ENDOCRIN MET, V22, P188, DOI 10.1016/j.tem.2011.02.007
   Shin M, 2011, CARCINOGENESIS, V32, P1634, DOI 10.1093/carcin/bgr198
   Tada T, 2005, INT J CANCER, V116, P253, DOI 10.1002/ijc.21008
   Wooten MW, 2008, J BIOL CHEM, V283, P6783, DOI 10.1074/jbc.M709496200
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007 1102
   Yoneda T, 2013, WORLD J ORTHOP, V4, P178, DOI 10.5312/wjo.v4.i4.178
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Yuvaraj S, 2009, MOL CANCER RES, V7, P1399, DOI 10.1158/1541 7786.MCR 08 0589
NR 39
TC 15
Z9 16
U1 0
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2016
VL 117
IS 1
BP 118
EP 125
DI 10.1002/jcb.25255
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DB0WX
UT WOS:000368229800012
PM 26095774
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Suh, KS
   Lee, YS
   Seo, SH
   Kim, YS
   Choi, EM
AF Suh, Kwang Sik
   Lee, Young Soon
   Seo, Seung Hwan
   Kim, Young Seol
   Choi, Eun Mi
TI Effect of Zinc Oxide Nanoparticles on the Function of MC3T3 E1
   Osteoblastic Cells
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Zinc oxide nanoparticles; MC3T3 E1 cells; Osteogenic differentiation
ID ALKALINE PHOSPHATASE ACTIVITY; REACTIVE OXYGEN; CANCER CELLS; IN VITRO;
   MITOCHONDRIA; APOPTOSIS; NAOH; CYTOTOXICITY; METABOLISM; MECHANISMS
AB Zinc oxide nanoparticles (ZnO NPs) can be ingested directly when used in food, food packaging, drug delivery, and cosmetics. This study evaluated the cellular effects of ZnO NPs (50 and 100 nm diameter particle sizes) on the function of osteoblastic MC3T3 E1 cells. ZnO NPs showed cytotoxicity at concentrations of above 50 mu g/ml, and there was no significant effect of the size on the cytotoxicity of ZnO NPs. Within the testing concentrations of 0.01 similar to 1 mu g/ml, which did not cause a marked drop in cell viability, ZnO NPs (0.1 mu g/ml) caused a significant elevation of alkaline phosphatase activity, collagen synthesis, mineralization, and osteocalcin content in the cells (P < 0.05). Moreover, pretreatment with ZnO NPs (0.01 similar to 1 mu g/ml) significantly reduced antimycin A induced cell damage by preventing mitochondrial membrane potential dissipation, complex IV inactivation, and ATP loss. Measurement of reactive oxygen species (ROS) indicated decrease in ROS level upon exposure to ZnO nanoparticles (0.01 mu g/ml). Hence, our study indicated that ZnO nanoparticles can have protective effects on osteoblasts at low concentrations where there are little or no observable cytotoxic effects.
C1 [Suh, Kwang Sik] Kyung Hee Univ, Res Inst Endocrinol, Seoul 130702, South Korea.
   [Lee, Young Soon; Choi, Eun Mi] Kyung Hee Univ, Dept Food & Nutr, Seoul 130701, South Korea.
   [Seo, Seung Hwan] Kyung Hee Univ, Coll Pharm, Dept Pharm, Seoul 130701, South Korea.
   [Kim, Young Seol] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung
   Hee University
RP Choi, EM (通讯作者)，Kyung Hee Univ, Dept Food & Nutr, 1 Hoegi Dong, Seoul 130701, South Korea.
EM cheunmi@hanmail.net
RI Kim, Myeong/AAS 1488 2021
FU National Research Foundation of Korea (NRF); Ministry of Education
   [2013004361]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2013004361).
CR Akhtar MJ, 2012, INT J NANOMED, V7, P845, DOI 10.2147/IJN.S29129
   Armstrong JS, 2006, BIOESSAYS, V28, P253, DOI 10.1002/bies.20370
   BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617
   BREMNER I, 1995, P NUTR SOC, V54, P489, DOI 10.1079/PNS19950017
   Colon G, 2006, J BIOMED MATER RES A, V78A, P595, DOI 10.1002/jbm.a.30789
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167 193.2002
   Gerloff K, 2009, NANOTOXICOLOGY, V3, P355, DOI 10.3109/17435390903276933
   Hall SL, 1999, CALCIFIED TISSUE INT, V64, P163, DOI 10.1007/s002239900597
   Hanley C, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/29/295103
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532 5415.1972.tb00787.x
   Horie M, 2009, CHEM RES TOXICOL, V22, P543, DOI 10.1021/tx800289z
   Hsiao IL, 2011, SCI TOTAL ENVIRON, V409, P1219, DOI 10.1016/j.scitotenv.2010.12.033
   Ito A, 2002, MAT SCI ENG C BIO S, V22, P21, DOI 10.1016/S0928 4931(02)00108 X
   John S, 2010, J NANOSCI NANOTECHNO, V10, P1707, DOI 10.1166/jnn.2010.2044
   Koeneman KS, 1999, PROSTATE, V39, P246
   Lin WS, 2009, J NANOPART RES, V11, P25, DOI 10.1007/s11051 008 9419 7
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   Miyazaki T, 2000, J BIOMED MATER RES, V50, P35, DOI 10.1002/(SICI)1097 4636(200004)50:1<35::AID JBM6>3.0.CO;2 8
   Nair S, 2009, J MATER SCI MATER M, V20, P235, DOI 10.1007/s10856 008 3548 5
   Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264 6021:3510183
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Pham NA, 2000, CYTOMETRY, V41, P245, DOI 10.1002/1097 0320(20001201)41:4<245::AID CYTO2>3.0.CO;2 #
   Reddy KM, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2742324
   Sharma V, 2012, APOPTOSIS, V17, P852, DOI 10.1007/s10495 012 0705 6
   Sharma V, 2009, TOXICOL LETT, V185, P211, DOI 10.1016/j.toxlet.2009.01.008
   Simbula G, 1997, AM J PHYSIOL CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479
   Takeuchi K, 2005, J BIOMED MATER RES A, V72A, P296, DOI 10.1002/jbm.a.30227
   Uchida M, 2002, BIOMATERIALS, V23, P313, DOI 10.1016/S0142 9612(01)00110 7
   Wallach Dayan SB, 2006, AM J PHYSIOL LUNG C, V290, pL790, DOI 10.1152/ajplung.00300.2004
   Wang XX, 2001, J BIOMED MATER RES, V54, P172, DOI 10.1002/1097 4636(200102)54:2<172::AID JBM3>3.0.CO;2 #
   Webster TJ, 2001, BIOMATERIALS, V22, P1327, DOI 10.1016/S0142 9612(00)00285 4
   YAMAGUCHI M, 1988, BIOCHEM PHARMACOL, V37, P4075, DOI 10.1016/0006 2952(88)90098 6
   YAMAGUCHI M, 1986, BIOCHEM PHARMACOL, V35, P773, DOI 10.1016/0006 2952(86)90245 5
   Yuan JH, 2010, COLLOID SURFACE B, V76, P145, DOI 10.1016/j.colsurfb.2009.10.028
NR 34
TC 31
Z9 34
U1 0
U2 31
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD NOV
PY 2013
VL 155
IS 2
BP 287
EP 294
DI 10.1007/s12011 013 9772 y
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 227HL
UT WOS:000325103100017
PM 23900646
DA 2025 08 17
ER

PT J
AU Thompson, J
   Wang, YD
   Dreischulte, T
   Barreiro, O
   Gonzalez, RJ
   Hanc, P
   Matysiak, C
   Neely, HR
   Rottenkolber, M
   Haskell, T
   Endres, S
   von Andrian, UH
AF Thompson, Jeffrey
   Wang, Yidi
   Dreischulte, Tobias
   Barreiro, Olga
   Gonzalez, Rodrigo J.
   Hanc, Pavel
   Matysiak, Colette
   Neely, Harold R.
   Rottenkolber, Marietta
   Haskell, Thomas
   Endres, Stefan
   von Andrian, Ulrich H.
TI Association between bisphosphonate use and COVID 19 related outcomes
SO ELIFE
LA English
DT Article
DE Bisphosphonate; COVID 19; retrospective cohort study
ID ZOLEDRONIC ACID; BONE MARROW; ETHNIC DISPARITIES; T CELLS; MORTALITY;
   ADHERENCE; THERAPY; RISK; POPULATION; MECHANISMS
AB Background: Although there are several efficacious vaccines against COVID 19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and emergence of viral variants. Repurposing of existing therapeutics that prevent or mitigate severe COVID 19 could help to address these challenges. The objective of this study was to determine whether prior use of bisphosphonates is associated with reduced incidence and/or severity of COVID 19.
   Methods: A retrospective cohort study utilizing payer complete health insurance claims data from 8,239,790 patients with continuous medical and prescription insurance January 1, 2019 to June 30, 2020 was performed. The primary exposure of interest was use of any bisphosphonate from January 1, 2019 to February 29, 2020. Bisphosphonate users were identified as patients having at least one bisphosphonate claim during this period, who were then 1:1 propensity score matched to bisphosphonate non users by age, gender, insurance type, primary care provider visit in 2019, and comorbidity burden. Main outcomes of interest included: (a) any testing for SARS CoV 2 infection; (b) COVID 19 diagnosis; and (c) hospitalization with a COVID 19 diagnosis between March 1, 2020 and June 30, 2020. Multiple sensitivity analyses were also performed to assess core study outcomes amongst more restrictive matches between BP users/non users, as well as assessing the relationship between BP use and other respiratory infections (pneumonia, acute bronchitis) both during the same study period as well as before the COVID outbreak.
   Results: A total of 7,906,603 patients for whom continuous medical and prescription insurance information was available were selected. A total of 450,366 bisphosphonate users were identified and 1:1 propensity score matched to bisphosphonate non users. Bisphosphonate users had lower odds ratios (OR) of testing for SARS CoV 2 infection (OR = 0.22; 95%CI:0.21 0.23; p<0.001), COVID 19 diagnosis (OR = 0.23; 95%CI:0.22 0.24; p<0.001), and COVID 19 related hospitalization (OR = 0.26; 95%CI:0.24 0.29; p<0.001). Sensitivity analyses yielded results consistent with the primary analysis. Bisphosphonate use was also associated with decreased odds of acute bronchitis (OR = 0.23; 95%CI:0.22 0.23; p<0.001) or pneumonia (OR = 0.32; 95%CI:0.31 0.34; p<0.001) in 2019, suggesting that bisphosphonates may protect against respiratory infections by a variety of pathogens, including but not limited to SARS CoV 2.
   Conclusions: Prior bisphosphonate use was associated with dramatically reduced odds of SARS CoV 2 testing, COVID 19 diagnosis, and COVID 19 related hospitalizations. Prospective clinical trials will be required to establish a causal role for bisphosphonate use in COVID 19 related outcomes.
C1 [Thompson, Jeffrey; Haskell, Thomas] Cerner Enviza, Malvern, PA USA.
   [Wang, Yidi; Barreiro, Olga; Gonzalez, Rodrigo J.; Hanc, Pavel; Matysiak, Colette; Neely, Harold R.; von Andrian, Ulrich H.] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA.
   [Dreischulte, Tobias; Rottenkolber, Marietta] Univ Munich, Univ Hosp Ludwig Maximilians, Inst Gen Practice & Family Med, Munich, Germany.
   [Endres, Stefan] Univ Hosp, Ctr Integrated Prot Sci Munich, LMU Munich, Munich, Germany.
   [Endres, Stefan] Ludwig Maximilians Univ Munchen, Univ Hosp, Div Clin Pharmacol, Munich, Germany.
C3 Harvard University; Harvard Medical School; University of Munich;
   University of Munich; University of Munich
RP von Andrian, UH (通讯作者)，Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA.
EM uva@hms.harvard.edu
RI ; von Andrian, Ulrich/A 5775 2008; Hanc, Pavel/IVU 9001 2023
OI Hanc, Pavel/0000 0002 0511 5566; von Andrian,
   Ulrich/0000 0003 4231 2283; 
FU National Institute of Allergy and Infectious Diseases [AR068383,
   AI155865]; NIH [CRI2453]; CRI Irvington postdoctoral fellowship
FX The authors acknowledge Ziqi Chen, Paris Pallis, and Flora Tierney for
   helpful discussions on the interpretation of study results. We are
   grateful to Komodo Health who provided all data used in this analysis at
   no cost, and we thank Vicki Guan and Ben Cohen from Komodo Health for
   facilitating this research. Special thanks to Kantar Health (now Cerner
   Enviza) who provided the support needed to complete this study with no
   associated financial requirements. This study was supported by NIH
   grants AR068383 and AI155865 (to UHvA) and a CRI Irvington postdoctoral
   fellowship CRI2453 (to PH).
CR Abdullah MI, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08649 9
   [Anonymous], 2021, RISK COVID 19 INFECT
   [Anonymous], 2021, United States COVID 19 Cases and Death by State Over Time
   [Anonymous], 2019, QUICKFACTS CALIFORNI
   Atmaca A, 2022, OSTEOPOROSIS INT, V33, P273, DOI 10.1007/s00198 021 06067 2
   Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Blanch Rubió J, 2020, AGING US, V12, P19923, DOI 10.18632/aging.104117
   Brufsky A, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02433 6
   Chadwick JW, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 75272 6
   Chen J, 2008, J MENT HEALTH POLICY, V11, P155
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Curtis JR, 2011, MED CARE, V49, P427, DOI 10.1097/MLR.0b013e318207ed9e
   Degli Esposti L, 2021, J BONE MINER RES, V36, P2177, DOI 10.1002/jbmr.4419
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Dormuth CR, 2009, CIRCULATION, V119, P2051, DOI 10.1161/CIRCULATIONAHA.108.824151
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Escobar GJ, 2021, ANN INTERN MED, V174, P786, DOI 10.7326/M20 6979
   Favot CL, 2013, INT J ORAL MAX SURG, V42, P619, DOI 10.1016/j.ijom.2012.12.011
   George S, 2015, J CLIN ENDOCR METAB, V100, P4163, DOI 10.1210/jc.2015 2680
   Gu A, 2017, CIRC CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003166
   Hermesh T, 2010, CELL HOST MICROBE, V7, P343, DOI 10.1016/j.chom.2010.04.006
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Hoertel N, 2021, MOL PSYCHIATR, V26, P5199, DOI 10.1038/s41380 021 01021 4
   Israel A, 2021, ELIFE, V10, DOI 10.7554/eLife.68165
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   Jacobson M, 2021, AM J PREV MED, V61, P644, DOI 10.1016/j.amepre.2021.05.015
   Karmakar M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.36462
   Kaufman HW, 2021, POPUL HEALTH MANAG, V24, P20, DOI 10.1089/pop.2020.0163
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kluberg SA, 2022, PHARMACOEPIDEM DR S, V31, P476, DOI 10.1002/pds.5401
   Kuiper JWP, 2012, BRIT J PHARMACOL, V165, P532, DOI 10.1111/j.1476 5381.2011.01592.x
   Ladova K, 2014, J EVAL CLIN PRACT, V20, P111, DOI 10.1111/jep.12095
   Lee P, 2016, J CLIN ENDOCR METAB, V101, P1945, DOI 10.1210/jc.2015 3467
   Liu H, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865 016 0183 7
   Lohia P, 2021, J CLIN LIPIDOL, V15, P451, DOI 10.1016/j.jacl.2021.03.002
   Mazo IB, 2005, IMMUNITY, V22, P259, DOI 10.1016/j.immuni.2005.01.008
   Meizlish ML, 2021, BLOOD ADV, V5, P1164, DOI 10.1182/bloodadvances.2020003568
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Muñoz Price LS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.21892
   Nada MH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425 017 0209 6
   Nau C, 2021, ANN INTERN MED, V174, P1183, DOI 10.7326/M20 8283
   No authors listed, 2021, MMWR Morbidity and Mortality Weekly Report, V70, DOI [10.15585/mmwr.mm7019a5, DOI 10.15585/MMWR.MM7019A5]
   Parsons L.S., 2001, Proceedings of the 26th Annual SAS Users Group International Conference, P214, DOI DOI 10.1016/J.MICINF.2011.07.011
   Petersen ML, 2012, STAT METHODS MED RES, V21, P31, DOI 10.1177/0962280210386207
   Poccia F, 2006, J INFECT DIS, V193, P1244, DOI 10.1086/502975
   Price Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Reid IR, 2021, CALCIFIED TISSUE INT, V109, P12, DOI 10.1007/s00223 021 00830 7
   Reitsma MB, 2021, HEALTH AFFAIR, V40, P870, DOI 10.1377/hlthaff.2021.00098
   Reusch N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652470
   Ribot JC, 2021, NAT REV IMMUNOL, V21, P221, DOI 10.1038/s41577 020 00452 4
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Rogers TN, 2020, WORLD MED HEALTH POL, V12, P311, DOI 10.1002/wmh3.358
   Rosenthal N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29058
   Rubin Miller Lily., 2020, KFF
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Saita Y, 2015, THER ADV CHRONIC DIS, V6, P185, DOI 10.1177/2040622315584114
   Salami JA, 2017, JAMA CARDIOL, V2, P56, DOI 10.1001/jamacardio.2016.4700
   Sarhan D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1338238
   Sbrocchi AM, 2010, PEDIATR INT, V52, P754, DOI 10.1111/j.1442 200X.2010.03174.x
   Selden TM, 2020, HEALTH AFFAIR, V39, P1624, DOI 10.1377/hlthaff.2020.00897
   Sing CW, 2020, J BONE MINER RES, V35, P1676, DOI 10.1002/jbmr.4030
   Sultana J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.588654
   Suresh E, 2014, RHEUMATOLOGY, V53, P19, DOI 10.1093/rheumatology/ket236
   Tonti E, 2013, CELL REP, V5, P323, DOI 10.1016/j.celrep.2013.09.004
   Tu WW, 2011, J EXP MED, V208, P1511, DOI 10.1084/jem.20110226
   US Bureau of Labor Statistics, 2019, BLS Reports October 2019: Labor force characteristics by race and ethnicity, 2018
   Wang H, 2011, J IMMUNOL, V187, P5099, DOI 10.4049/jimmunol.1002697
   Wolf AM, 2006, HAEMATOLOGICA, V91, P1165
   Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zhao ED, 2012, CELL MOL IMMUNOL, V9, P11, DOI 10.1038/cmi.2011.47
   Zheng J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135999
   Zimniak M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85049 0
NR 79
TC 6
Z9 6
U1 0
U2 7
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD AUG 3
PY 2023
VL 12
AR e79548
DI 10.7554/eLife.79548
PG 112
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA DU6I5
UT WOS:001134629400001
PM 37534876
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Solomon, DH
   Gleeson, T
   Iversen, M
   Avorn, J
   Brookhart, MA
   Lii, J
   Losina, E
   May, F
   Patrick, A
   Shrank, WH
   Katz, JN
AF Solomon, D. H.
   Gleeson, T.
   Iversen, M.
   Avorn, J.
   Brookhart, M. A.
   Lii, J.
   Losina, E.
   May, F.
   Patrick, A.
   Shrank, W. H.
   Katz, J. N.
TI A blinded randomized controlled trial of motivational interviewing to
   improve adherence with osteoporosis medications: design of the OPTIMA
   trial
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Education; Medication adherence; Osteoporosis; Randomized controlled
   trial
ID POSTMENOPAUSAL OSTEOPOROSIS; UNITED STATES; PERSISTENCE; THERAPY;
   BISPHOSPHONATES; FRACTURES; ACCURACY; IMPACT
AB We have designed an innovative randomized controlled trial for improving adherence with osteoporosis medications. Recruitment and randomization have been successful. Also, the counseling intervention has been well accepted by subjects randomized to this treatment arm.
   While many effective treatments exist for osteoporosis, most people do not adhere to such treatments long term. No proven interventions exist to improve osteoporosis medication adherence. We report here on the design and initial enrollment in an innovative randomized controlled trial aimed at improving adherence to osteoporosis treatments.
   The trial represents a collaboration between academic researchers and a state run pharmacy benefits program for low income older adults. Beneficiaries beginning treatment with a medication for osteoporosis are targeted for recruitment. We randomize consenting individuals to receive 12 months of mailed education (control arm) or an intervention consisting of one on one telephone based counseling and the mailed education. Motivational interviewing forms the basis for the counseling program which is delivered by seven trained and supervised health counselors over ten telephone calls. The counseling sessions include scripted dialog and open ended questions about medication adherence and its barriers, as well as structured questions. The primary end point of the trial is medication adherence measured over the 12 month intervention period. Secondary end points include fractures, nursing home admissions, health care resource utilization, and mortality.
   During the first 7 months of recruitment, we have screened 3,638 potentially eligible subjects. After an initial mailing, 1,115 (30.6%) opted out of telephone recruitment and 1,019 (28.0%) could not be successfully contacted. Of the remaining, 879 (24.2%) consented to participate and were randomized. Women comprise over 90% of all groups; mean ages range from 77 to 80 years old, and the majority in all groups was white. The distribution of osteoporosis medications was comparable across groups and the median number of different prescription drugs used in the prior year was eight to ten.
   We have developed a novel intervention for improving osteoporosis medication adherence. The intervention is currently being tested in a large scale randomized controlled trial. If successful, the intervention may represent a useful model for improving adherence to other chronic treatments.
C1 [Solomon, D. H.; Gleeson, T.; Iversen, M.; Losina, E.; Katz, J. N.] Brigham & Womens Hosp, Div Rheumatol, Dept Med, Boston, MA 02115 USA.
   [Solomon, D. H.; Avorn, J.; Brookhart, M. A.; Lii, J.; May, F.; Patrick, A.; Shrank, W. H.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol, Boston, MA 02115 USA.
   [Losina, E.; Katz, J. N.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Harvard University; Harvard University Medical
   Affiliates; Brigham & Women's Hospital; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital
RP Solomon, DH (通讯作者)，Brigham & Womens Hosp, Div Rheumatol, Dept Med, 75 Francis St, Boston, MA 02115 USA.
EM dsolomon@partners.org
RI iversen, maura daly/O 5388 2015; Solomon, Daniel/HTO 5518 2023; Iversen,
   Maura/O 5388 2015
OI iversen, maura daly/0000 0003 4708 9914; Losina,
   ELENA/0000 0002 3424 0892; 
FU NHLBI NIH HHS [K23 HL090505] Funding Source: Medline; NIAMS NIH HHS [P60
   AR047782, P60 AR 047782] Funding Source: Medline
CR Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532 5415.2003.51110.x
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Clowes JA, 2004, J CLIN ENDOCR METAB, V89, P1117, DOI 10.1210/jc.2003 030501
   Cook PF, 2007, AM J MED QUAL, V22, P445, DOI 10.1177/1062860607307990
   Cooper A, 2006, INT J CLIN PRACT, V60, P896, DOI 10.1111/j.1742 1241.2006.01059.x
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Curtis JR, 2008, J BONE MINER RES, V23, P1435, DOI 10.1359/JBMR.080418
   Delmas PD, 2007, J CLIN ENDOCR METAB, V92, P1296, DOI 10.1210/jc.2006 1526
   DiIorio C, 2008, AIDS CARE, V20, P273, DOI 10.1080/09540120701593489
   Guilera M, 2006, OSTEOPOROSIS INT, V17, P664, DOI 10.1007/s00198 005 0031 8
   Haynes RB, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000011.pub2, 10.1002/14651858.CD000011.pub3]
   Heather N, 1996, DRUG ALCOHOL REV, V15, P29, DOI 10.1080/09595239600185641
   Ivers RQ, 2002, J CLIN EPIDEMIOL, V55, P452, DOI 10.1016/S0895 4356(01)00518 2
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   McHorney CA, 2007, CURR MED RES OPIN, V23, P3137, DOI 10.1185/030079907X242890
   Miller WR, 1996, ADDICT BEHAV, V21, P835, DOI 10.1016/0306 4603(96)00044 5
   NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315
   Ogedegbe G, 2007, CONTEMP CLIN TRIALS, V28, P169, DOI 10.1016/j.cct.2006.04.002
   Peterson AM, 2007, VALUE HEALTH, V10, P3, DOI 10.1111/j.1524 4733.2006.00139.x
   Reid SC, 2005, J STUD ALCOHOL, V66, P833, DOI 10.15288/jsa.2005.66.833
   Samet JH, 2005, ANTIVIR THER, V10, P83
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198 007 0550 6
   Wolf R L, 2000, Curr Rheumatol Rep, V2, P74, DOI 10.1007/s11926 996 0072 9
NR 25
TC 22
Z9 25
U1 0
U2 16
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2010
VL 21
IS 1
BP 137
EP 144
DI 10.1007/s00198 009 0951 9
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Endocrinology & Metabolism
GA 527LB
UT WOS:000272367500015
PM 19436935
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, HY
   Xie, ZY
   Zhang, P
   Sun, J
   Chu, FM
   Guo, ZR
   Zhong, DF
AF Xu, HY
   Xie, ZY
   Zhang, P
   Sun, J
   Chu, FM
   Guo, ZR
   Zhong, DF
TI Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE imrecoxib; cytochrome P450; metabolism; liver microsomes
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COX 2 INHIBITORS; IN VITRO;
   MICROSOMES; CYCLOOXYGENASE 2; OSTEOARTHRITIS; ISOENZYMES; NSAIDS; VIVO
AB Aim: To investigate the in vitro metabolism of imrecoxib in rat liver microsomes and to identify the cytochrome P450 (CYP) forms involved in its metabolism. Methods: Liver microsomes of Wistar rats were prepared using an ultracentrifuge. The in vitro metabolism of imrecoxib was studied by incubation with rat liver microsomes. To characterize the CYP forms involved in the 4' methyl hydroxylation of imrecoxib, the effects of typical CYP inducers (such as dexamethasone, isoniazid and beta naphthoflavone) and of CYP inhibitors (such as ketoconazole, quinine, alpha naphthoflavone, methylpyrazole, and cimetidine) on the formation rate of 4' hydroxymethyl imrecoxib were investigated. Results: Imrecoxib was metabolized to 3 metabolites by rat liver microsomes: 4' hydroxymethyl imrecoxib (M4), 4' hydroxymethyl 5 hydoxyl imrecoxib (M3), and 4' hydroxymethyl 5 car bonyl imrecoxib (M5). Over the imrecoxib concentration range studied (5 600 mu mol/L), the rate of 4' methyl hydroxylation conformed to monophasic Michaelis Menten kinetics. Dexamethasone significantly induced the formation of M4. Ketoconazole markedly lowered the metabolic rate of imrecoxib in a concentration dependent manner. Moreover, a significant inhibitory effect of quinine on the formation of M4 was observed in microsomes obtained from control rats, isoniazid induced rats, and beta naphthoflavone induced rats. In contrast, alpha naphthoflavone, cimetidine, and methylpyrazole had no inhibitory effects on this metabolic pathway. Conclusion: Imrecoxib is metabolized via 4' methyl hydroxylation in rat liver microsomes. The reaction is mainly catalyzed by CYP 3 A. CYP 2D also played a role in control rats, in isoniazid induced rats and in beta naphthoflavone induced rats.
C1 Shenyang Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, Shenyang 110016, Peoples R China.
   Shenyang Pharmaceut Univ, Dept Biopharmaceut, Shenyang 110016, Peoples R China.
   Chinese Acad Med Sci, Inst Materia Medica, Beijing 100050, Peoples R China.
   Peking Union Med Coll, Beijing 100050, Peoples R China.
C3 Shenyang Pharmaceutical University; Shenyang Pharmaceutical University;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Materia Medica   CAMS; Chinese Academy of Medical Sciences
     Peking Union Medical College; Peking Union Medical College
RP Shenyang Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, Shenyang 110016, Peoples R China.
EM zhongdf@china.com
RI Zhong, Dafang/C 1304 2014
CR Bai AP, 2001, CHINESE CHEM LETT, V12, P775
   Bjornsson TD, 2003, DRUG METAB DISPOS, V31, P815, DOI 10.1124/dmd.31.7.815
   BOOBIS AR, 1990, XENOBIOTICA, V20, P1139, DOI 10.3109/00498259009046835
   Chen XH, 2004, ACTA PHARMACOL SIN, V25, P927
   Davies NM, 2004, J PHARM PHARM SCI, V7, P332
   Dogné JM, 2005, J MED CHEM, V48, P2251, DOI 10.1021/jm0402059
   Donnelly MT, 1997, ALIMENT PHARM THER, V11, P227, DOI 10.1046/j.1365 2036.1997.154330000.x
   Jouzeau JY, 1997, DRUGS, V53, P563, DOI 10.2165/00003495 199753040 00003
   Lane NE, 1997, J RHEUMATOL, V24, P20
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228
   NEEDLEMAN P, 1997, J RHEUMATOL, V24, P9
   OMURA T, 1964, J BIOL CHEM, V239, P2370
   Paul LD, 2004, EUR J PHARMACOL, V485, P69, DOI 10.1016/j.ejphar.2003.11.051
   Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp 75 9 1088
   Sandberg M, 2002, BRIT J CLIN PHARMACO, V54, P423, DOI 10.1046/j.1365 2125.2002.01660.x
   Shen F, 2002, ACTA PHARMACOL SIN, V23, P762
   Shimizu M, 2003, BIOL PHARM BULL, V26, P1448, DOI 10.1248/bpb.26.1448
   Simon LS, 1998, ARTHRITIS RHEUM US, V41, P1591, DOI 10.1002/1529 0131(199809)41:9<1591::AID ART9>3.0.CO;2 J
   SMITH JB, 1971, NATURE NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0
   Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065 2776(08)60430 7
   Szakács T, 2001, POL J PHARMACOL, V53, P11
   Szotáková B, 2004, J PHARM PHARMACOL, V56, P205, DOI 10.1211/0022357023060
   Thomas LG, 2005, LANCET, V365, P1538, DOI 10.1016/S0140 6736(05)66448 3
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Yamazaki H, 2001, DRUG METAB DISPOS, V29, P794
   YANAOKA K, 1981, J PHARMACOBIODYN, V4, P879
   Zhong DF, 2002, ACTA PHARMACOL SIN, V23, P455
NR 28
TC 6
Z9 7
U1 0
U2 9
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD MAR
PY 2006
VL 27
IS 3
BP 372
EP 380
DI 10.1111/j.1745 7254.2006.00265.x
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 015YK
UT WOS:000235587300017
PM 16490176
OA Bronze
DA 2025 08 17
ER

PT J
AU Kim, I
   Kim, H
   Lee, EH
   Jo, G
   Na, CS
   Kang, K
   Lee, TH
AF Kim, Inkyu
   Kim, Hansol
   Lee, Eunjoo H.
   Jo, Geonung
   Na, Chun Soo
   Kang, Kyungtae
   Lee, Tae Hoon
TI Anti Inflammatory Effect of Cudrania tricuspidata Extract and
   Stewartia koreana Extract Mixture in a Collagen Induced Arthritis
   Mouse Model
SO APPLIED SCIENCES BASEL
LA English
DT Article
DE Stewartia koreana extract; Cudrania tricuspidata extract;
   anti inflammation; rheumatoid arthritis
ID ETHYL ACETATE FRACTION; RHEUMATOID ARTHRITIS; OSTEOCLAST
   DIFFERENTIATION; NITRIC OXIDE; PATHOGENESIS; CYTOKINES; ANTIOXIDANT;
   MECHANISMS; EXPRESSION; COX 2
AB Cudrania tricuspidata extracts (CTE) and Stewartia koreana extracts (SKE) are viable drugs for managing inflammation. We investigated the nitric oxide levels of CTE and a mixture of CTE/SKE (CTE mix) against lipopolysaccharide induced RAW264.7 cells. In addition, we administered the CTE and CTE mix to mice with collagen induced arthritis to confirm an anti inflammatory effect against rheumatoid arthritis. We analyzed arthritis symptoms by oral administration of CTE mix using a CIA induced animal model and analyzed the inhibitory activity of NO production with in vitro experiments. Both the CTE and CTE mix decreased nitric oxide levels, and a 2:1 ratio of CTE mix was most effective in vivo among the varying ratios of CTE mix tested. The spleen size increased by about 2.1 times, and the lymph node size decreased by about 2.5 times relative compared to the vehicle group. In blood biochemical analyses, tumor necrosis factor alpha levels decreased by about three times, interleukin 1 beta and interleukin 6 levels were reduced by about eight times and three times, and PRG4 expression levels were increased by about 2.5 times relative to the vehicle group. We suggest that the CTE mix was superior to CTE alone and has potential as an anti inflammatory treatment for patients with rheumatoid arthritis.
C1 [Kim, Inkyu; Kang, Kyungtae; Lee, Tae Hoon] Kyung Hee Univ Yongin, Global Ctr Pharmaceut Ingredient Mat, Dept Appl Chem, Yongin 1732, South Korea.
   [Kim, Hansol; Lee, Eunjoo H.] Kyung Hee Univ Yongin, Grad Sch East West Med Sci, Yongin 1732, South Korea.
   [Jo, Geonung] Jeollanam Do Forest Resources Inst, Naju 58213, South Korea.
   [Na, Chun Soo] Lifetree Biotech Co Ltd, Suwon 16657, South Korea.
RP Kang, K; Lee, TH (通讯作者)，Kyung Hee Univ Yongin, Global Ctr Pharmaceut Ingredient Mat, Dept Appl Chem, Yongin 1732, South Korea.
EM 2013103244@khu.ac.kr; khanma1006@khu.ac.kr; ehwang@khu.ac.kr;
   nature5208@korea.kr; spectreena@hanmail.net; kkang@khu.ac.kr;
   thlee@khu.ac.kr
RI Lee, Tae/B 1160 2013
FU GRRC Program of Gyeonggi province [GRRC KyungHee 2018(B05)]; Korea
   Institute of Planning and Evaluation for Technology in Food, Agriculture
   and Forestry (IPET), Agri Bio Industry Technology Development program,
   Ministry of Agriculture, Food and Rural affairs [316007 05]
FX This research was funded by the GRRC Program of Gyeonggi province
   [GRRC KyungHee 2018(B05)], and Korea Institute of Planning and
   Evaluation for Technology in Food, Agriculture and Forestry (IPET),
   Agri Bio Industry Technology Development program, Ministry of
   Agriculture, Food and Rural affairs (No.316007 05).
CR Alquraini A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1301 5
   Alquraini A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0877 x
   Alunno A, 2017, BMC RHEUMATOL, V1, DOI 10.1186/s41927 017 0001 8
   Chang SH, 2008, J PHARM PHARMACOL, V60, P1221, DOI 10.1211/jpp.60.9.0015
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Cho SS, 2019, J MED FOOD, V22, P602, DOI 10.1089/jmf.2018.4322
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Feng ZL, 2020, MOLECULES, V25, DOI 10.3390/molecules25030598
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Firestein GS, 2005, ARTHRITIS RES THER, V7, P157, DOI 10.1186/ar1780
   Floris I, 2020, INT J RHEUMATOL, V2020, DOI 10.1155/2020/1594573
   Hilliquin P, 1997, ARTHRITIS RHEUM, V40, P1512, DOI 10.1002/art.1780400820
   Ikegawa S, 2000, CYTOGENET CELL GENET, V90, P291, DOI 10.1159/000056791
   Ivashkiv LB, 1996, ADV IMMUNOL, V63, P337, DOI 10.1016/S0065 2776(08)60859 7
   Kawai Shinichi, 2003, J Orthop Sci, V8, P259, DOI 10.1007/s007760300045
   Kim Joo Yun, 2019, Prev Nutr Food Sci, V24, P159, DOI 10.3746/pnf.2019.24.2.159
   Kim MH, 2014, NAT PROD RES, V28, P1409, DOI 10.1080/14786419.2014.905560
   Kim OK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010060
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee EG, 2010, BIOL RES, V43, P225, DOI /S0716 97602010000200010
   Lee Eun Gyeong, 2010, Korean Journal of Internal Medicine, V25, P93, DOI 10.3904/kjim.2010.25.1.93
   Lee J, 2012, FOOD CHEM TOXICOL, V50, P2109, DOI 10.1016/j.fct.2012.03.043
   Lee SI, 2010, BIOMOL THER, V18, P191, DOI 10.4062/biomolther.2010.18.2.191
   Lee TH, 2007, MOL CELLS, V23, P398
   Lee W, 2017, FOOD CHEM TOXICOL, V106, P404, DOI 10.1016/j.fct.2017.06.009
   Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091
   Lubberts E, 2003, ADV EXP MED BIOL, V520, P194
   Mateen S, 2016, CLIN CHIM ACTA, V455, P161, DOI 10.1016/j.cca.2016.02.010
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Park CK, 2007, INT IMMUNOPHARMACOL, V7, P1507, DOI 10.1016/j.intimp.2007.07.016
   Rubió L, 2013, CRIT REV FOOD SCI, V53, P943, DOI 10.1080/10408398.2011.574802
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shedoeva A, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2684108
   Vlachopoulos C, 2018, CLIN RHEUMATOL, V37, P515, DOI 10.1007/s10067 017 3657 y
   Zhang L, 2011, J AGR FOOD CHEM, V59, P12361, DOI 10.1021/jf203146e
NR 37
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3417
J9 APPL SCI BASEL
JI Appl. Sci. Basel
PD JUL
PY 2021
VL 11
IS 14
AR 6660
DI 10.3390/app11146660
PG 12
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA TN1GB
UT WOS:000675990100001
OA gold
DA 2025 08 17
ER

PT J
AU Carbone, A
   Rodeck, U
   Mauri, FA
   Sozzi, M
   Gaspari, F
   Srnirne, C
   Prati, A
   Addeo, A
   Novarino, A
   Robecchi, A
   Beretto, O
   Emanuelli, G
   Bellone, G
AF Carbone, A
   Rodeck, U
   Mauri, FA
   Sozzi, M
   Gaspari, F
   Srnirne, C
   Prati, A
   Addeo, A
   Novarino, A
   Robecchi, A
   Beretto, O
   Emanuelli, G
   Bellone, G
TI Human pancreatic carcinoma cells secrete bioactive interleukin 18 after
   treatment with 5 fluorouracil   Implications for anti tumor immune
   response
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE IL 18; pancreatic carcinoma; chemotherapy; tumor immunology; Caspase 1;
   Caspase 3
ID GAMMA INDUCING FACTOR; COLONY STIMULATING FACTOR; INTERFERON GAMMA;
   CANCER PATIENTS; T CELLS; IFN GAMMA; SERUM LEVELS; OSTEOCLAST FORMATION;
   HUMAN KERATINOCYTES; CONVERTING ENZYME
AB Recently we observed that pancreatic carcinoma cell lines constitutively express Interleukin 18 (IL 18). Bioactive IL 18 induces Interferon (IFN) gamma production, Fos Ligand (FasL) expression, and inhibits angiogenesis, raising the issue of anti tumor effects of a tumor derived cytokine and motivating a more detailed analysis of IL 18 production in pancreatic carcinoma cells. This analysis included the study of effects of chemotherapeutic drugs (5 fluorouracil [5 FU], gemcitabine, cisplatin) commonly used in the treatment of pancreatic cancer patients on IL 18 production and processing. IL 18 expression and post translational processing were determined using RT PCR, immunoblot and ELISA in pancreatic carcinoma cell lines and in tumor tissue and serum samples from pancreatic carcinoma patients in the presence and absence of chemotherapeutic drugs. We describe expression of IL 18 in pancreatic carcinoma cells and tissues associated with significantly elevated IL 18 levels in patients sera. Specifically, Capan 2 pancreatic tumor cells produced and secreted precursor IL 18 with no apparent biological activity. However, the chemotherapeutic agent 5 FU, by inducing Caspase 1 and Caspose 3 activation, induced secretion of proteolytically processed mature and degraded IL 18 species, respectively, in Capan 2 cells. Conditioned medium from 5 FU treated but not control Capan 2 cells induced IFN gamma production by activated T cells in an IL 18 dependent manner. Furthermore, adjuvant polychemotherapy including 5 FU significantly increased serum levels of mature, bioactive IL 18 in pancreatic carcinoma patients. Treatment of pancreatic cancer cells with 5 FU induced Caspase dependent processing of pro IL18 leading to the secretion of biologically active IL 18. These findings delineate a novel mechanism by which chemotherapeutic agents may modulate local anti tumor cell mediated immune responses.
C1 Univ Turin, Dept Clin Physiopathol, I 10126 Turin, Italy.
   Azienda Osped San Giovanni Battista, Dept Gastroenterol & Clin Nutr, Turin, Italy.
   Azienda Osped San Giovanni Battista, Dept Clin Oncol, Turin, Italy.
   Thomas Jefferson Univ, Dept Dermatol, Philadelphia, PA 19107 USA.
   Univ Turin, Dept Med Surg Disciplines, Turin, Italy.
   Hammersmith Hosp, Dept Histopathol, London W12 0HS, England.
C3 University of Turin; A.O.U. Citta della Salute e della Scienza di
   Torino; AOU San Giovanni Battista Molinette; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista Molinette; Thomas
   Jefferson University; University of Turin; Imperial College London
RP Bellone, G (通讯作者)，Univ Turin, Dept Clin Physiopathol, Via Genova 3, I 10126 Turin, Italy.
EM graziella.bellone@unito.fi
RI ; Addeo, Alfredo/AAE 2064 2020
OI Mauri, Francesco/0000 0003 4818 8500; bertetto,
   oscar/0000 0001 5133 2724; addeo, alfredo/0000 0003 0988 0828
CR Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595
   Alexandrakis MG, 2004, LEUKEMIA RES, V28, P259, DOI 10.1016/S0145 2126(03)00261 3
   Bellone G, 1999, AM J PATHOL, V155, P537, DOI 10.1016/S0002 9440(10)65149 8
   Bellone G, 2000, CLIN CANCER RES, V6, P2448
   Bellone G, 2004, CANCER BIOL THER, V3, P385, DOI 10.4161/cbt.3.4.727
   BELLONE G, UNPUB CYTOKINE EXPRE
   Cartee L, 1998, APOPTOSIS, V3, P439, DOI 10.1023/A:1009614703977
   Companjen AR, 2000, EUR CYTOKINE NETW, V11, P383
   Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169 328X(99)00034 0
   Cousin F, 2000, J CUTAN PATHOL, V27, P235, DOI 10.1034/j.1600 0560.2000.027005235.x
   Dao T, 1998, J IMMUNOL, V161, P2217
   Dao T, 1996, CELL IMMUNOL, V173, P230, DOI 10.1006/cimm.1996.0272
   Donoghue S, 1999, CANCER RES, V59, P5386
   Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324
   Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0
   Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206
   Günel N, 2003, AM J CLIN ONCOL CANC, V26, P416, DOI 10.1097/00000421 200308000 00023
   Hadjiloucas I, 2001, BRIT J CANCER, V85, P1522, DOI 10.1054/bjoc.2001.2115
   Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333
   Hoshino T, 1999, J IMMUNOL, V162, P5070
   Hunter CA, 1997, EUR J IMMUNOL, V27, P2787, DOI 10.1002/eji.1830271107
   KAMURA H, 1995, NATURE, V378, P88
   Kawabata T, 2001, CANCER, V92, P2050, DOI 10.1002/1097 0142(20011015)92:8<2050::AID CNCR1544>3.0.CO;2 5
   Kohyama M, 1998, JPN J CANCER RES, V89, P1041, DOI 10.1111/j.1349 7006.1998.tb00494.x
   Lebel Binay S, 2003, INT J CANCER, V106, P827, DOI 10.1002/ijc.11285
   Lissoni P, 2000, J BIOL REG HOMEOS AG, V14, P275
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martone T, 2004, HEAD NECK J SCI SPEC, V26, P494, DOI 10.1002/hed.20011
   Merendino RA, 2002, INT J BIOL MARKER, V17, P63, DOI 10.1177/172460080201700108
   Merendino RA, 2001, INT J BIOL MARKER, V16, P126, DOI 10.1177/172460080101600207
   Micallef MJ, 1998, ANTICANCER RES, V18, P4267
   Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736
   Moore MB, 2003, CANCER IMMUNOL IMMUN, V52, P107, DOI 10.1007/s00262 002 0361 8
   Naik SM, 1999, J INVEST DERMATOL, V113, P766, DOI 10.1046/j.1523 1747.1999.00750.x
   Nakagawara A, 1997, CANCER RES, V57, P4578
   Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359 6101(00)00015 0
   Novarino A, 2004, ANN ONCOL, V15, P474, DOI 10.1093/annonc/mdh106
   Ohtani T, 2000, ANTICANCER RES, V20, P3117
   Okamoto I, 1999, J IMMUNOL, V162, P3202
   Okamoto M, 2000, ANTI CANCER DRUG, V11, P165, DOI 10.1097/00001813 200003000 00004
   Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952 7915(98)80163 5
   Pagès F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097 0215(19990621)84:3<326::AID IJC22>3.0.CO;2 K
   Park H, 2001, IMMUNOL LETT, V79, P215, DOI 10.1016/S0165 2478(01)00278 4
   Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471 4159.1999.0722215.x
   Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379
   Riedel F, 2004, INT J MOL MED, V13, P267
   Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074 7613(00)80378 7
   Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Sözen S, 2004, NEOPLASMA, V51, P25
   Stoll S, 1998, EUR J IMMUNOL, V28, P3231, DOI 10.1002/(SICI)1521 4141(199810)28:10<3231::AID IMMU3231>3.0.CO;2 Q
   Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074 7613(00)80543 9
   Takubo T, 2000, ACTA HAEMATOL BASEL, V103, P162, DOI 10.1159/000041040
   Taniguchi M, 1997, J IMMUNOL METHODS, V206, P107, DOI 10.1016/S0022 1759(97)00094 X
   Thalmann GN, 2000, J UROLOGY, V164, P2129, DOI 10.1016/S0022 5347(05)66983 2
   Tomura M, 1998, J IMMUNOL, V160, P3759
   Tsai JY, 2003, SEMIN ONCOL, V30, P71, DOI 10.1016/S0093 7754(03)00273 2
   Tsuboi K, 2004, CANCER LETT, V205, P207, DOI 10.1016/j.canlet.2003.10.010
   Tsutsui H, 1999, IMMUNITY, V11, P359, DOI 10.1016/S1074 7613(00)80111 9
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Ungefroren H, 1999, ANN NY ACAD SCI, V880, P243, DOI 10.1111/j.1749 6632.1999.tb09529.x
   Ungefroren H, 1998, CANCER RES, V58, P1741
   von Bernstorff W, 2001, CLIN CANCER RES, V7, p925S
   Wang ZY, 2002, INT J CANCER, V98, P873, DOI 10.1002/ijc.10268
   Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701
   Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811
NR 66
TC 23
Z9 24
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4047
EI 1555 8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD FEB
PY 2005
VL 4
IS 2
BP 231
EP 241
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 957GX
UT WOS:000231359400016
PM 15684607
DA 2025 08 17
ER

PT J
AU Hoffmann, J
   Simon, P
   Zimmermann, AK
   Lemancyk, M
   Walter, T
   Beyer, M
   Hoffmeister, HF
   Ziemer, G
   Wendel, HP
AF Hoffmann, J
   Simon, P
   Zimmermann, AK
   Lemancyk, M
   Walter, T
   Beyer, M
   Hoffmeister, HF
   Ziemer, G
   Wendel, HP
TI Thrombospondin 1 as possible key factor in the hemocompatibility of
   endocoronary prostheses
SO BIOMATERIALS
LA English
DT Article
DE stent; biocompatibility; thrombospondin 1; DNA microarray
ID ENDOTHELIAL GROWTH FACTOR; GENE EXPRESSION; CORONARY ARTERIES; STENT;
   RESTENOSIS; ATHEROSCLEROSIS; ANGIOGENESIS; INFLAMMATION; OSTEOBLASTS;
   DISEASE
AB Intracoronary stenting has markedly improved the patency of native coronary arteries after percutaneous transluminal coronary angioplasty (PTCA). Advances in stent technology and design, including drug releasing stents, have contributed to reduce the long term restenosis rate. However, stenosis caused by neointimal hyperplasia, vascular remodeling and thrombosis is still a major problem after endocoronary stent procedures. This study focuses on differential gene expression of circulating peripheral blood cells after 90 min exposure to stents to search for initially activated cellular pathways, which may foster restenosis. Fresh human whole blood (1 IU heparin/ml), taken from non medicated healthy volunteers, was incubated under flow conditions in an in vitro closed loop stent testing model (modified Chandler Loop). Differential gene expression compared to resting conditions and to the experimental controls was investigated by a DNA microarray technique encoding for over 17,000 genes simultaneously. As expected, a large variety of genes showed differential gene expression. Interestingly, Thrombospondin 1 (TSP 1), which plays a key role in initial immune defense, was found to be the most markedly up regulated gene. We propose TSP 1 expression as an early indicator for the activation of immune responses following intracoronary stenting. After clarifying the participation of TSP 1 in vivo, future studies will therefore focus on TSP 1 as a potential prognostic factor, which may also help to develop and control new surface materials with an improved biocompatibility. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Tubingen Hosp, Dept Thorac Cardiac & Vasc Surg, D 72076 Tubingen, Germany.
   Univ Tubingen, Dept Sports Med, Med Clin, D 72076 Tubingen, Germany.
   Univ Tubingen, Dept Internal Med 3, D 72076 Tubingen, Germany.
   Klinikum Solingen, Dept Internal Med 2, D 42653 Solingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University of Tubingen
RP Wendel, HP (通讯作者)，Univ Tubingen Hosp, Dept Thorac Cardiac & Vasc Surg, D 72076 Tubingen, Germany.
EM jan.hoffmann@uni tuebingen.de; hp.wendel@uni tuebingen.de
RI Simon, Perikles/B 2293 2013; Wendel, Hans/C 5687 2009; Zimmermann,
   Anna/HGD 5709 2022
OI Simon, Perikles/0000 0002 7996 4034; 
CR Bickel C, 2001, J Interv Cardiol, V14, P407, DOI 10.1111/j.1540 8183.2001.tb00350.x
   Blindt R, 2002, J VASC RES, V39, P340, DOI 10.1159/000065546
   Bräsen JH, 2001, ARTERIOSCL THROM VAS, V21, P1720, DOI 10.1161/hq1101.098230
   Carinci F, 2004, CLIN ORAL IMPLAN RES, V15, P180, DOI 10.1111/j.1600 0501.2004.00997.x
   CHANDLER AB, 1958, LAB INVEST, V7, P110
   Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945 053X(00)00107 4
   CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156
   Cutlip DE, 2002, J AM COLL CARDIOL, V40, P2082, DOI 10.1016/S0735 1097(02)02597 4
   Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 1 r7
   Esemuede N, 2004, J SURG RES, V122, P135, DOI 10.1016/j.jss.2004.05.015
   Holmes DR, 2002, CIRCULATION, V106, P1243, DOI 10.1161/01.CIR.0000028335.31300.DA
   Ichii T, 2002, ARTERIOSCL THROM VAS, V22, P1286, DOI 10.1161/01.ATV.0000024684.67566.45
   Janicki C, 2003, MED PHYS, V30, P2622, DOI 10.1118/1.1607506
   Jia HY, 2004, J BIOL CHEM, V279, P36148, DOI 10.1074/jbc.M401538200
   Jiménez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582 4934.2002.tb00307.x
   Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843
   Moses Jeffrey W, 2002, Am J Cardiovasc Drugs, V2, P163, DOI 10.2165/00129784 200202030 00004
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pioletti DP, 2004, BIOMATERIALS, V25, P5803, DOI 10.1016/j.biomaterials.2004.01.053
   Rittersma SZH, 2004, AM J MED, V116, P499, DOI 10.1016/j.amjmed.2003.10.041
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   Santin M, 2004, J MATER SCI MATER M, V15, P473, DOI 10.1023/B:JMSM.0000021123.51752.11
   Sharif F, 2004, CARDIOVASC RES, V64, P208, DOI 10.1016/j.cardiores.2004.07.003
   Simon P, 2004, MOL VIS, V10, P588
   Simon P, 2003, BIOINFORMATICS, V19, P1439, DOI 10.1093/bioinformatics/btg157
   Tepe G, 2002, J VASC INTERV RADIOL, V13, P1029, DOI 10.1016/S1051 0443(07)61868 5
   Toutouzas K, 2004, EUR HEART J, V25, P1679, DOI 10.1016/j.ehj.2004.06.011
   Virmani Renu, 2004, Am Heart Hosp J, V2, P85, DOI 10.1111/j.1541 9215.2004.03632.x
   Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038
   Xie JW, 2004, J BIOMED MATER RES A, V71A, P108, DOI 10.1002/jbm.a.30140
NR 37
TC 10
Z9 11
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2005
VL 26
IS 25
BP 5240
EP 5250
DI 10.1016/j.biomaterials.2005.01.016
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 920OK
UT WOS:000228699800017
PM 15792551
DA 2025 08 17
ER

PT J
AU Tsuru, M
   Ono, A
   Umeyama, H
   Takeuchi, M
   Nagata, K
AF Tsuru, Michiyo
   Ono, Atsushi
   Umeyama, Hideaki
   Takeuchi, Masahiro
   Nagata, Kensei
TI Ubiquitin dependent proteolysis of CXCL7 leads to posterior longitudinal
   ligament ossification
SO PLOS ONE
LA English
DT Article
ID PROTEIN KINASE C; IN VITRO; OSTEOCLAST DIFFERENTIATION;
   DIABETIC NEPHROPATHY; CERVICAL SPINE; STEM CELLS; E3 LIGASE; BONE;
   EXPRESSION; AUTOPHAGY
AB Ossification of the posterior longitudinal ligament (OPLL), a spinal ligament, reduces the range of motion in limbs. No treatment is currently available for OPLL, which is why therapies are urgently needed. OPLL occurs in obesity, is more common in men, and has an onset after 40 years of age. The mechanisms underlying OPLL remain unclear. In this study, we performed a serum proteomic analysis in both OPLL patients and healthy subjects to identify factors potentially involved in the development of OPLL, and found reduced levels of a protein that might underlie the pathology of OPLL. We isolated the protein, determined its amino acid sequence, and identified it as chemokine (C X C motif) ligand 7 (CXCL7). Based on these proteomics findings, we generated a CXCL7 knockout mouse model to study the molecular mechanisms underlying OPLL. CXCL7 null mice presented with a phenotype of OPLL, showing motor impairment, heterotopic ossification in the posterior ligament tissue, and osteoporosis in vertebrate tissue. To identify the mechanisms of CXCL7 deficiency in OPLL, we searched for single nucleotide polymorphisms and altered DNA exons, but no abnormalities were found. Although miR 340 levels were found to be high in an miRNA array, they were insufficient to reduce CXCL7 levels. Ubiquitin C terminal hydrolasel (UCHL1) was found to be overexpressed in CXCL7 null mice and in the sera of patients with OPLL, and was correlated with OPLL severity. Post translational modifications of proteins with ubiquitin and ubiquitin like modifiers, orchestrated by a cascade of specialized ubiquitin activating enzyme (El), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3) enzymes, are thought to control a wide range of cellular processes, and alterations in the ubiquitin proteasome system have been associated with several degenerative disorders. In addition, the OPLL tissue of CXCL7 null mouse and its primary cells expressed the antibody to ubiquitin (linkage specific K48). Our data clearly show decreased CXCL7 levels in patients with OPLL, and that OPLL developed in mice lacking CXCL7. Tumor necrosis factor receptor associated factor (TRAF)6 expression was decreased in CXCL7null mouse primary cells. Furthermore, K48 polyubiquitination was found in posterior longitudinal ligament ossified tissue and primary cells from CXCL7 null mice. We performed a phosphoproteomics analysis in CXCL 7 deficient mice and identified increased phosphorylation of mitogen activated protein kinase kinase (ME3K)15, ubiquitin protein ligase E3C (UBE3C) and protein kinase C (PKC) alpha, suggesting that ubiquitin dependent degradation is involved in CXCL7 deficiency. Future studies in the CXCL 7 null mouse model are, therefore, warranted to investigate the role of ubiquitination in the onset of OPLL. In conclusion, CXCL7 levels may be useful as a serum marker for the progression of OPLL. This study also suggests that increasing CXCL7 levels in patients can serve as an effective therapeutic strategy for the treatment of OPLL.
C1 [Tsuru, Michiyo] Kurume Univ, Clin Prote & Gene Therapy Lab, Fukuoka, Fukuoka, Japan.
   [Ono, Atsushi] Hirosaki Mem Hosp, Dept Orthopaed Surg, Hirosaki, Aomori, Japan.
   [Umeyama, Hideaki] Chuo Univ, Dept Biol Sci, Tokyo, Japan.
   [Takeuchi, Masahiro] Kitasato Univ, Sch Pharm, Dept Clin Med Biostat, Tokyo, Japan.
   [Nagata, Kensei] Kurume Univ, Sch Med, Dept Orthopaed Surg, Fukuoka, Fukuoka, Japan.
C3 Kurume University; Chuo University; Kitasato University; Kurume
   University
RP Tsuru, M (通讯作者)，Kurume Univ, Clin Prote & Gene Therapy Lab, Fukuoka, Fukuoka, Japan.
EM michiyo@med.kurume u.ac.jp
OI Tsuru, Michiyo/0000 0002 1557 7131
FU Ministry of Health, Labour, Cabinet Office Special Coordination Funds
   for Promoting Science and Technology and Welfare Sciences; Japan Society
   for the Promotion of Science Kakenhi [24592215, 22591648]; Grants in Aid
   for Scientific Research [22591648, 24592215] Funding Source: KAKEN
FX This work was supported by a research grant for Disease Treatment and
   Ossification of Spinal Ligaments (2009 2013) from the Ministry of
   Health, Labour, Cabinet Office Special Coordination Funds for Promoting
   Science and Technology (2004 2009) and Welfare Sciences and the Japan
   Society for the Promotion of Science Kakenhi (Grant nos. 24592215 and
   22591648).
CR Akune T, 2002, J CELL BIOL, V159, P147, DOI 10.1083/jcb.200204046
   Akune T, 2001, J BONE JOINT SURG AM, V83A, P1537, DOI 10.2106/00004623 200110000 00013
   [Anonymous], 1987, LAB ANIM SCI, V37, P11
   Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960 9822(00)00398 5
   Bai T, 2016, AM J PHYSIOL ENDOC M, V310, pE473, DOI 10.1152/ajpendo.00467.2015
   BOISKIN I, 1989, CLIN NEPHROL, V31, P316
   Bourzac C, 2010, EQUINE VET J, V42, P519, DOI 10.1111/j.2042 3306.2010.00098.x
   Caramori ML, 2002, DIABETES, V51, P506, DOI 10.2337/diabetes.51.2.506
   Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014
   Ehara S, 1998, EUR J RADIOL, V27, P196, DOI 10.1016/S0720 048X(97)00164 2
   El Gedaily A, 2004, J LEUKOCYTE BIOL, V75, P495, DOI 10.1189/jlb.0603288
   Elliott AD, 2015, AM J PHYSIOL ENDOC M, V308, pE130, DOI 10.1152/ajpendo.00344.2014
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Fioretto P, 2007, SEMIN NEPHROL, V27, P195, DOI 10.1016/j.semnephrol.2007.01.012
   Gallot YS, 2017, ONCOTARGET, V8, P112565, DOI 10.18632/oncotarget.22575
   Genç B, 2016, ANN CLIN TRANSL NEUR, V3, P331, DOI 10.1002/acn3.298
   González Cortés C, 2012, IMMUNOBIOLOGY, V217, P394, DOI 10.1016/j.imbio.2011.10.015
   Hammond Martel I, 2012, CELL SIGNAL, V24, P410, DOI 10.1016/j.cellsig.2011.10.009
   Haÿ E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200
   HAYASHI K, 1977, J ANAT, V124, P633
   Herring CA, 2015, PROTEINS, V83, P1987, DOI 10.1002/prot.24913
   Hjerpe R, 2009, EMBO REP, V10, P1250, DOI 10.1038/embor.2009.192
   Huang GH, 2009, CYTOKINE, V48, P161, DOI 10.1016/j.cyto.2009.08.002
   Ikeda F, 2008, EMBO REP, V9, P536, DOI 10.1038/embor.2008.93
   Ikeda Y, 2011, EUR SPINE J, V20, P1450, DOI 10.1007/s00586 011 1688 7
   ISHIDA Y, 1993, J BONE MINER RES, V8, P1291
   ISHII Y, 1993, BIOMED RES TOKYO, V14, P85, DOI 10.1016/8756 3282(93)90232 Y
   Jain J, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360 017 0147 4
   Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731
   Kalb S, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10265
   Kaya HEK, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006438
   Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918
   KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303
   LANIR Y, 1979, J BIOMECH, V12, P423, DOI 10.1016/0021 9290(79)90027 7
   Lechtenberg BC, 2016, NATURE, V529, P546, DOI 10.1038/nature16511
   Lee Y, 2011, DIABETES, V60, P391, DOI 10.2337/db10 0426
   Mähler M, 2014, LAB ANIM UK, V48, P178, DOI 10.1177/0023677213516312
   Mao AP, 2010, J BIOL CHEM, V285, P9470, DOI 10.1074/jbc.M109.071043
   Medina Medina I, 2016, MOL CELL BIOL, V36, P2195, DOI 10.1128/MCB.00113 16
   MORIO Y, 1993, SPINE, V18, P2513, DOI 10.1097/00007632 199312000 00022
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakao K, 2009, BIOCHEM BIOPH RES CO, V378, P462, DOI 10.1016/j.bbrc.2008.11.083
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Ohishi H, 2003, J PHARMACOL EXP THER, V305, P818, DOI 10.1124/jpet.102.047142
   Ohtsuka K, 1986, Nihon Seikeigeka Gakkai Zasshi, V60, P1087
   OKAZAKI T, 1984, METABOLISM, V33, P710, DOI 10.1016/0026 0495(84)90209 9
   Park JH, 2017, MOL CELLS, V40, P706
   Paul PK, 2011, AUTOPHAGY, V7, P555, DOI 10.4161/auto.7.5.15102
   Pritchett Corning KR, 2014, J AM ASSOC LAB ANIM, V53, P633
   Reddy SS, 2014, BBA GEN SUBJECTS, V1840, P2924, DOI 10.1016/j.bbagen.2014.06.005
   Remoli AL, 2016, MBIO, V7, DOI 10.1128/mBio.01528 16
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Sato N, 2016, J PROTEOME RES, V15, P4709, DOI 10.1021/acs.jproteome.6b00806
   Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Shingyouchi Y, 1996, SPINE, V21, P2474, DOI 10.1097/00007632 199611010 00013
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Toichi K, 2013, J BIOL CHEM, V288, P4970, DOI 10.1074/jbc.M112.414235
   Tsuru M, 2013, STEM CELLS DEV, V22, P2057, DOI 10.1089/scd.2012.0695
   TSUYAMA N, 1984, CLIN ORTHOP RELAT R, P71
   VILLANUEVA AR, 1977, AM J MED TECHNOL, V43, P536
   Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794
   WITTERS LA, 1985, NATURE, V315, P777, DOI 10.1038/315777a0
   Xu CF, 2014, AUTOPHAGY, V10, P2239, DOI 10.4161/15548627.2014.981792
   Yoshimura N, 2014, OSTEOPOROSIS INT, V25, P1089, DOI 10.1007/s00198 013 2489 0
   Yu FB, 2015, J SPINAL DISORD TECH, V28, P389, DOI 10.1097/BSD.0000000000000031
   Zheng SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045437
NR 68
TC 11
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2018
VL 13
IS 5
AR e0196204
DI 10.1371/journal.pone.0196204
PG 23
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GG2QJ
UT WOS:000432537100004
PM 29782494
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Abdel Rafei, MK
   Thabet, NM
   Amin, MM
AF Abdel Rafei, Mohamed K.
   Thabet, Noura M.
   Amin, Mohamed M.
TI Concerted regulation of OPG/RANKL/NF κB/MMP 13 trajectories contribute
   to ameliorative capability of prodigiosin and/or low dose γ radiation
   against adjuvant  induced arthritis in rats
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Prodigiosin; Low dose radiation; AIA; OPG/RANKL; MMP 13, NF ?B
ID NF KAPPA B; COLLAGEN INDUCED ARTHRITIS; T CELL ACTIVATION;
   RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; ANTIINFLAMMATORY DRUG;
   GENE EXPRESSION; X IRRADIATION; INFLAMMATION; APOPTOSIS
AB Background: Prodigiosin (PDG) is a microbial red dye with antioxidant and anti inflammatory properties, although its effect on rheumatoid arthritis (RA) remains uncertain. Also, multiple doses of low dose gamma  radiation (LDR) have been observed to be as a successful intervention for RA. Thus, the purpose of this study was to investigate the ameliorative potential of PDG and/or LDR on adjuvant induced arthritis (AIA) in rats. Methods: The anti inflammatory and anti arthritic effects of PDG and/or LDR were examined in vitro and in vivo, respectively. In the AIA model, the arthritic indexes, paw swelling degrees, body weight gain, and histopatho logical assessment in AIA rats were assayed. The impact of PDG (200 mu g/kg; p.o) and/or LDR (0.5 Gy) on the levels of pro and anti inflammatory cytokines (IL 1 beta, TNF alpha, IL 6, IL 18, IL 17A, and IL 10) as well as the regulation of osteoprotegrin (OPG)/ receptor activator of nuclear factor kappa B ligand (RANKL)/ nuclear factor kappa B (NF kappa B)/MMP 13 pathways was determined. Methotrexate (MTX; 0.05 mg/kg; twice/week, i.p) was adminis tered concurrently as a standard anti arthritic drug. Results: PDG and/or LDR markedly diminished the arthritic indexes, paw edema, weigh loss in AIA rats, alleviated the pathological alterations in joints, reduced the levels of pro inflammatory cytokines IL 1 beta, TNF alpha, IL 6, IL 18, IL 17A, and RANKL in serum and synovial tissues, while increasing anti inflammatory cytokines IL 10 and OPG levels. Moreover, PDG and/or LDR down regulated the expression of RANKL, NF kappa Bp65, MMP13, caspase 3, and decreased the RANKL/OPG ratio, whereas OPG and collagen II were enhanced in synovial tissues.Conclusion: PDG and/or LDR exhibited obvious anti RA activity on AIA.
C1 [Abdel Rafei, Mohamed K.; Thabet, Noura M.] Egyptian Atom Energy Author, Natl Ctr Radiat Res & Technol NCRRT, Radiat Biol Dept, Cairo 11787, Egypt.
   [Amin, Mohamed M.] Med Res & Clin Studies Inst, Natl Res Ctr, Pharmacol Dept, Dokki, Egypt.
C3 Egyptian Knowledge Bank (EKB); Egyptian Atomic Energy Authority (EAEA);
   National Center for Radiation Research & Technology; Egyptian Knowledge
   Bank (EKB); National Research Centre (NRC)
RP Abdel Rafei, MK (通讯作者)，Egyptian Atom Energy Author, Natl Ctr Radiat Res & Technol NCRRT, Radiat Biol Dept, Cairo 11787, Egypt.
EM mohamed.marawan2011@yahoo.com
RI Thabet, Noura Magdy/P 8402 2015; Abdel Rafei, Mohamed/E 7738 2018;
   Thabet, Noura/P 8402 2015; Amin, Mohamed/O 2396 2018
OI Thabet, Noura Magdy/0000 0003 0073 7347; Amin,
   Mohamed/0000 0002 3602 5555
CR Abdelfattah MS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216737
   Al Omairi NE, 2022, BIOLOGY BASEL, V11, DOI 10.3390/biology11030354
   Alaa O., 2021, IRAQI J SCI, V62, P1103, DOI [10.24996/ijs.2021.62.4.7, DOI 10.24996/IJS.2021.62.4.7]
   Albrakati A, 2021, INT J NANOMED, V16, P8447, DOI 10.2147/IJN.S323436
   Alunno A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/751793
   Rosillo MA, 2016, FOOD FUNCT, V7, P2943, DOI [10.1039/C6FO00485G, 10.1039/c6fo00485g]
   Anoop M V., 2015, International Journal of Pharma Research Review, V4, P18, DOI DOI 10.22159/AJPCR.2018.V11I4.23583
   Arenas M, 2012, STRAHLENTHER ONKOL, V188, P975, DOI 10.1007/s00066 012 0170 8
   Asenso J, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108644
   Bakhtiari T, 2019, IRAN J ALLERGY ASTHM, V18, P639, DOI 10.18502/ijaai.v18i6.2176
   Bancroft J.D., 1990, THEORY PRACTICE HIST, V3rd
   Bao YRG, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153036
   Barker T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81382 6
   Bracht A, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064 016 1671 1
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Buckley KA, 2002, ANN CLIN BIOCHEM, V39, P551, DOI 10.1258/000456302760413324
   Calabrese EJ, 2013, INT J RADIAT BIOL, V89, P287, DOI 10.3109/09553002.2013.752595
   Caramés B, 2015, ARTHRITIS RHEUMATOL, V67, P1568, DOI 10.1002/art.39073
   Chandra K., 2015, International Journal of Pharmacognosy and Phytochemical Research, V7, P383
   Chang CC, 2011, TOXICOL APPL PHARM, V257, P137, DOI 10.1016/j.taap.2011.08.027
   Chang Y, 2016, SCI REP UK, V6, DOI 10.1038/srep26239
   Chang Y, 2015, MOL IMMUNOL, V64, P90, DOI 10.1016/j.molimm.2014.11.002
   Chatzidionysiou K, 2017, ANN RHEUM DIS, V76, P1102, DOI [10.1136/annrheumdis 2016 210711, 10.1136/annrheumdis 2016 210713]
   Chen XY, 2017, MOLECULES, V22, DOI 10.3390/molecules22050811
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Chiang HI, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111770
   CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Coates LC, 2016, SEMIN ARTHRITIS RHEU, V46, P291, DOI 10.1016/j.semarthrit.2016.05.012
   Compaore Moussa, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5020053
   Cook NL, 2009, MAGNESIUM RES, V22, P225, DOI 10.1684/mrh.2009.0189
   Cuevas A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176417
   Dai ML, 2018, BIOMATERIALS, V180, P91, DOI 10.1016/j.biomaterials.2018.07.011
   Darshan N, 2015, J FOOD SCI TECH MYS, V52, P5393, DOI 10.1007/s13197 015 1740 4
   Darwish SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079284
   de Gaetano G, 2003, TRENDS PHARMACOL SCI, V24, P245, DOI 10.1016/S0165 6147(03)00077 4
   Deloch L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01834
   Donaubauer AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740742
   Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165854
   Dong XW, 2020, CELL MOL IMMUNOL, V17, P261, DOI 10.1038/s41423 019 0201 9
   El Ghazaly MA, 2020, INT J RADIAT BIOL, V96, P857, DOI 10.1080/09553002.2020.1748911
   ELGHAZALY M, 1985, BRIT J PHARMACOL, V85, P45, DOI 10.1111/j.1476 5381.1985.tb08829.x
   Fang YW, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112104
   Frey B, 2009, AUTOIMMUNITY, V42, P346, DOI 10.1080/08916930902831738
   Frey B, 2015, CANCER LETT, V368, P230, DOI 10.1016/j.canlet.2015.04.010
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Fumoto T, 2014, J BONE MINER RES, V29, P830, DOI 10.1002/jbmr.2096
   Gao X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.710169
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   Gholap SS, 2016, EUR J MED CHEM, V110, P13, DOI 10.1016/j.ejmech.2015.12.017
   Ghosh G, 2015, PHARMACOGN RES, V7, P110, DOI 10.4103/0974 8490.147223
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Han JM, 2019, J ETHNOPHARMACOL, V231, P10, DOI 10.1016/j.jep.2018.11.003
   Han SB, 1998, INT J IMMUNOPHARMACO, V20, P1, DOI 10.1016/S0192 0561(97)00062 3
   Han SB, 2001, J PHARMACOL EXP THER, V299, P415
   Hasan H, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2408 1
   He H., 2022, EVID BASED COMPL ALT, P1
   He P., 2020, EVIDENCEBASED COMPLE, P1
   Hoekstra M, 2003, ANN RHEUM DIS, V62, P423, DOI 10.1136/ard.62.5.423
   Hu TY, 2019, PHYTOMEDICINE, V55, P214, DOI 10.1016/j.phymed.2018.08.001
   Huang CQ, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2086 z
   Huh JE, 2007, INT IMMUNOPHARMACOL, V7, P1825, DOI 10.1016/j.intimp.2007.09.002
   Hui WP, 2019, INT IMMUNOPHARMACOL, V68, P226, DOI 10.1016/j.intimp.2019.01.018
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Ilchovska D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102741
   Jenei Lanzl Z, 2019, CELL SIGNAL, V53, P212, DOI 10.1016/j.cellsig.2018.10.005
   Jia P, 2016, J ETHNOPHARMACOL, V193, P266, DOI 10.1016/j.jep.2016.08.006
   Jung SM, 2019, YONSEI MED J, V60, P88, DOI 10.3349/ymj.2019.60.1.88
   Kadhem M.A.H., 2016, IOSR J AGR VET SCI, V9, P1, DOI [10.9790/2380 0906020106, DOI 10.9790/2380 0906020106]
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   KATAOKA T, 1995, FEBS LETT, V359, P53, DOI 10.1016/0014 5793(94)01446 8
   Khader SZA, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108646
   Kim BH, 2022, RADIOTHER ONCOL, V170, P231, DOI 10.1016/j.radonc.2022.02.039
   Kvastad L, 2015, SCI REP UK, V5, DOI 10.1038/srep16519
   Lee DW, 2018, INT J MED SCI, V15, P723, DOI 10.7150/ijms.22713
   Lee HH, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106726
   Liebmann A, 2004, STRAHLENTHER ONKOL, V180, P165, DOI 10.1007/s00066 004 1197 2
   Liu H, 2018, CELL PHYSIOL BIOCHEM, V49, P501, DOI 10.1159/000492989
   Liu SM, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106047
   Liu XY, 2017, INT IMMUNOPHARMACOL, V44, P105, DOI 10.1016/j.intimp.2017.01.010
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lödermann B, 2012, INT J RADIAT BIOL, V88, P727, DOI 10.3109/09553002.2012.689464
   Ma GG, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.655551
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mirzaii Dizgah M R, 2022, Rev Esp Cir Ortop Traumatol, V66, P47, DOI 10.1016/j.recot.2021.02.003
   Mogana R, 2013, ISRN Biotechnol, V2013, P986361, DOI 10.5402/2013/986361
   Mori G, 2009, INT J IMMUNOPATH PH, V22, P95, DOI 10.1177/039463200902200111
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nakatsukasa H, 2008, J RADIAT RES, V49, P381, DOI 10.1269/jrr.08002
   Nakatsukasa H, 2010, RADIAT RES, V174, P313, DOI 10.1667/RR2121.1
   Nisha, 2015, RSC ADV, V5, P10899, DOI 10.1039/c4ra10296g
   Nogueira E, 2016, CURR MED CHEM, V23, P2190, DOI 10.2174/0929867323666160506125218
   Noser AA, 2021, MOLECULES, V26, DOI 10.3390/molecules26175332
   Nozaki Y, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010011
   Oh EJ, 2016, APPL BIOL CHEM, V59, P567, DOI 10.1007/s13765 016 0196 1
   Papadaki M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00097
   Patil M.V.K., 2012, Biomed. Aging Pathol., V2, P6, DOI [10.1016/j.biomag.2012.01.002, DOI 10.1016/J.BIOMAG.2012.01.002]
   Peng Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148531
   Popova V, 2019, RHEUMATOL INT, V39, P1723, DOI 10.1007/s00296 019 04367 9
   Pradeep S, 2014, BIORESOURCE TECHNOL, V171, P482, DOI 10.1016/j.biortech.2014.08.077
   Pudla M, 2019, INFLAMM RES, V68, P841, DOI 10.1007/s00011 019 01267 3
   Remuzgo Martínez S, 2016, SCI REP UK, V6, DOI 10.1038/srep29713
   Ren J, 2019, BIOMED PHARMACOTHER, V109, P555, DOI 10.1016/j.biopha.2018.10.112
   Rinotas V, 2014, J BONE MINER RES, V29, P1158, DOI 10.1002/jbmr.2112
   Roedel F, 2012, CURR MED CHEM, V19, P1741, DOI 10.2174/092986712800099866
   Rödel F, 2008, STRAHLENTHER ONKOL, V184, P41, DOI 10.1007/s00066 008 1776 8
   Rossi JF, 2015, CLIN CANCER RES, V21, P1248, DOI 10.1158/1078 0432.CCR 14 2291
   Roth SH, 2012, DRUGS, V72, P873, DOI 10.2165/11633740 000000000 00000
   Saleem A, 2019, PAK J PHARM SCI, V32, P1167
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schaue D, 2002, INT J RADIAT BIOL, V78, P567, DOI 10.1080/09553000210126457
   Scheinecker C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102376
   Schultz M, 2017, CLIN RHEUMATOL, V36, P1471, DOI 10.1007/s10067 017 3687 5
   Sevcikova B, 2004, ARCH MICROBIOL, V181, P384, DOI 10.1007/s00203 004 0669 1
   Shokry AA, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112456
   Shui XL, 2017, EUR REV MED PHARMACO, V21, P2329
   Siebert S, 2015, PHARMACOL REV, V67, P280, DOI 10.1124/pr.114.009639
   Stankovic N, 2014, APPL MICROBIOL BIOT, V98, P3841, DOI 10.1007/s00253 014 5590 1
   Sun SP, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10280
   Sun YW, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106384
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Tanaka M, 2001, J RHEUMATOL, V28, P1779
   Tawfik MK, 2015, INT IMMUNOPHARMACOL, V24, P80, DOI 10.1016/j.intimp.2014.11.018
   Terashima A, 2018, CALCIFIED TISSUE INT, V102, P503, DOI 10.1007/s00223 018 0417 1
   Tong ZW, 2018, J ETHNOPHARMACOL, V226, P90, DOI 10.1016/j.jep.2018.08.011
   Royo LT, 2020, REP PRACT ONCOL RADI, V25, P250, DOI 10.1016/j.rpor.2020.02.004
   Tu C, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172445
   Upton AR, 2012, RHEUMATOL INT, V32, P535, DOI 10.1007/s00296 010 1733 6
   Visser K, 2009, ANN RHEUM DIS, V68, P1094, DOI 10.1136/ard.2008.092668
   Wang B, 2021, J CELL PHYSIOL, V236, P4369, DOI 10.1002/jcp.30154
   Wang LY, 2021, J ETHNOPHARMACOL, V267, DOI 10.1016/j.jep.2020.113490
   Wang WY, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2019.153136
   Wei ZF, 2013, ACTA PHARMACOL SIN, V34, P403, DOI 10.1038/aps.2012.187
   Weissmann T, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.777792
   Weng L, 2010, ANN RHEUM DIS, V69, P1519, DOI 10.1136/ard.2009.121111
   Woo JT, 2008, J PHARMACOL SCI, V106, P547, DOI 10.1254/jphs.FM0070288
   Woo JT, 1997, BIOSCI BIOTECH BIOCH, V61, P400, DOI 10.1271/bbb.61.400
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Wunderlich R, 2015, CLIN EXP IMMUNOL, V179, P50, DOI 10.1111/cei.12344
   Xiang Y, 2016, J ETHNOPHARMACOL, V194, P1078, DOI 10.1016/j.jep.2016.11.011
   Xiu ZJ, 2015, CYTOKINE, V72, P185, DOI 10.1016/j.cyto.2014.12.026
   Yamamoto K, 2016, MATRIX BIOL, V56, P57, DOI 10.1016/j.matbio.2016.03.007
   Yamamura M, 2001, ARTHRITIS RHEUM, V44, P275, DOI 10.1002/1529 0131(200102)44:2<275::AID ANR44>3.3.CO;2 2
   Yan JY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.687033
   Yang CH, 2022, INT J PHARMACOL, V18, P587, DOI 10.3923/ijp.2022.588.597
   Yang L, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107463
   Yen ML, 2008, MOL IMMUNOL, V45, P2205, DOI 10.1016/j.molimm.2007.12.003
   Yen ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038048
   Yu H, 2011, ARTHRITIS RHEUM US, V63, P981, DOI 10.1002/art.30219
   Zampeli E, 2015, J AUTOIMMUN, V65, P1, DOI 10.1016/j.jaut.2015.10.003
   Zeng JZ, 2016, EXP THER MED, V12, P3101, DOI 10.3892/etm.2016.3739
   Zeng L, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6613527
   Zhang K, 2018, IRAN J BASIC MED SCI, V21, P130, DOI 10.22038/IJBMS.2018.23871.5991
   Zhang WH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 20 4255
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhao XL, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106436
   Zheng YR, 2021, J ETHNOPHARMACOL, V267, DOI 10.1016/j.jep.2020.113497
   Zhou J, 2019, EUR J PHARMACOL, V852, P179, DOI 10.1016/j.ejphar.2019.02.036
   Zhou W, 2016, J INVERTEBR PATHOL, V136, P92, DOI 10.1016/j.jip.2016.03.011
NR 160
TC 8
Z9 9
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2022
VL 111
AR 109068
DI 10.1016/j.intimp.2022.109068
EA AUG 2022
PG 23
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 3S1RE
UT WOS:000839379300002
PM 35944459
DA 2025 08 17
ER

PT J
AU Li, J
   Hsu, HC
   Yang, P
   Wu, Q
   Li, H
   Edgington, LE
   Bogyo, M
   Kimberly, RP
   Mountz, JD
AF Li, Jun
   Hsu, Hui Chen
   Yang, PingAr
   Wu, Qi
   Li, Hao
   Edgington, Laura E.
   Bogyo, Matthew
   Kimberly, Robert P.
   Mountz, John D.
TI Treatment of Arthritis by Macrophage Depletion and Immunomodulation
   Testing an Apoptosis Mediated Therapy in a Humanized Death Receptor
   Mouse Model
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; COLONY STIMULATING FACTOR;
   RHEUMATOID ARTHRITIS; SYNOVIAL FIBROBLASTS; INFLAMMATORY ARTHRITIS;
   MONOCLONAL ANTIBODY; ANTI DR5 ANTIBODY; NECROSIS FACTOR; T LYMPHOCYTES;
   C57BL/6 MICE
AB Objective. To determine the therapeutic efficacy and immunomodulatory effect of an anti human death receptor 5 (DR5) antibody, TRA 8, in eliminating macrophage subsets in a mouse model of type II collagen induced arthritis (CIA).
   Methods. A human/mouse chimeric DR5 transgenic mouse, under the regulation of a mouse 3 kb promoter and a loxP flanked STOP cassette, was generated and crossed with an ubiquitous Cre (Ubc.Cre) mouse and a lysozyme M Cre (LysM.Cre) transgenic mouse to achieve inducible or macrophage specific expression. Chicken type II collagen was used to induce CIA in mice, which were then treated with an anti human DR5 antibody, TRA 8. Clinical scores, histopathologic severity, macrophage apoptosis and depletion, and T cell subset development were evaluated.
   Results. In human/mouse DR5 transgenic Ubc.Cre mice with CIA, transgenic DR5 was most highly expressed on CD11b+ macrophages, with lower expression on CD4+ T cells. In human/mouse DR5 transgenic LysM.Cre mice, transgenic DR5 was restrictively expressed on macrophages. Both in vivo near infrared imaging of caspase activity and TUNEL staining demonstrated that TRA 8 rapidly induced apoptosis of macrophages in inflamed synovium. Depletion of pathogenic macrophages by TRA 8 led to significantly reduced clinical scores for arthritis; decreased macrophage infiltration, synovial hyperplasia, osteoclast formation, joint destruction, cathepsin activity, and inflammatory cytokine expression in joints; reduced numbers of Th17 cells; and an increased number of Treg cells in draining lymph nodes.
   Conclusion. The anti human DR5 antibody TRA 8 was efficacious in reducing the severity of arthritis via targeted depletion of macrophages and immunomodulation. Our data provide preclinical evidence that TRA 8 is a potential novel biologic agent for rheumatoid arthritis therapy.
C1 [Mountz, John D.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   [Hsu, Hui Chen; Yang, PingAr; Wu, Qi; Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA.
   [Edgington, Laura E.; Bogyo, Matthew] Stanford Univ, Stanford, CA 94305 USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Veterans Affairs Medical Center   Birmingham; Stanford University
RP Mountz, JD (通讯作者)，Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Suite 307,Shel Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM jdmountz@uab.edu
RI ; Li, Hao/N 7406 2015; Wu, Qi/C 8414 2017; Chen, jianhui/AAY 1195 2021
OI Edgington Mitchell, Laura/0000 0002 6810 6149; Bogyo,
   Matthew/0000 0003 3753 4412; Li, Hao/0000 0002 2171 8826; Kimberly,
   Robert/0000 0002 5330 3086; 
FU Lupus Research Institute; Daiichi Sankyo; Arthritis Foundation; American
   College of Rheumatology Research and Education Foundation; Alliance for
   Lupus Research; Department of Veterans Affairs [1I01BX000600 01]; NIH
   [R01 AI 083705 01A2, 1 R01 EB 005011 06, 1 AI 071110 01A1,
   ARRA R01 AI 71110 02S1, P30 AR 048311, P30 AR 046031]
FX Supported by grants from the Lupus Research Institute (to Dr. Hsu) and
   Daiichi Sankyo (to Dr. Mountz). Additional support was provided by the
   Arthritis Foundation (Postdoc Fellowship Award to Dr. J. Li), the
   American College of Rheumatology Research and Education Foundation
   (Within Our Reach grant), the Alliance for Lupus Research (Target
   Identification in Lupus grant), the Department of Veterans Affairs
   (Merit Review grant 1I01BX000600 01), and the NIH (grants
   R01 AI 083705 01A2 to Dr. Hsu, 1 R01 EB 005011 06 to Dr. Bogyo,
   1 AI 071110 01A1 and ARRA R01 AI 71110 02S1 to Dr. Mountz, P30 AR 048311
   to the Rheumatic Diseases Core Centers including Analytical Genomics and
   Transgenics Core, Comprehensive Flow Cytometry Core, and Analytic
   Imaging and Immunoreagent Core, and P30 AR 046031 to the Center for
   Metabolic Bone Disease Histomorphometry and Molecular Analysis Core).
CR Amm HM, 2011, MOL CANCER RES, V9, P403, DOI 10.1158/1541 7786.MCR 10 0133
   Barrera P, 2000, ARTHRITIS RHEUM US, V43, P1951, DOI 10.1002/1529 0131(200009)43:9<1951::AID ANR5>3.0.CO;2 K
   Bellail AC, 2009, REV RECENT CLIN TRIA, V4, P34, DOI 10.2174/157488709787047530
   Calero I, 2010, RHEUM DIS CLIN N AM, V36, P325, DOI 10.1016/j.rdc.2010.02.003
   Chan J, 1998, BLOOD, V92, P1423, DOI 10.1182/blood.V92.4.1423.416k31_1423_1431
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cohen SB, 2006, ARTHRITIS RHEUM US, V54, P2793, DOI 10.1002/art.22025
   Cook AD, 2011, ARTHRITIS RHEUM US, V63, P2340, DOI 10.1002/art.30354
   Cornelissen F, 2009, CURR OPIN INVEST DR, V10, P452
   Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311
   Dunay IR, 2008, IMMUNITY, V29, P306, DOI 10.1016/j.immuni.2008.05.019
   Edgington LE, 2009, NAT MED, V15, P967, DOI 10.1038/nm.1938
   Edwards JCW, 2001, RHEUMATOLOGY, V40, P205, DOI 10.1093/rheumatology/40.2.205
   Egan PJ, 2008, ARTHRITIS RHEUM US, V58, P3720, DOI 10.1002/art.24075
   Forero Torres A, 2010, CANCER BIOTHER RADIO, V25, P13, DOI 10.1089/cbr.2009.0673
   Hansen T, 2000, J RHEUMATOL, V27, P859
   Hillyer P, 2009, RHEUMATOLOGY, V48, P1581, DOI 10.1093/rheumatology/kep293
   Hsu HC, 2011, ARTHRITIS RHEUM US, V63, P2038, DOI 10.1002/art.30257
   Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000
   Ichikawa K, 2003, J IMMUNOL, V171, P1061, DOI 10.4049/jimmunol.171.2.1061
   Inglis JJ, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2319
   Inglis JJ, 2008, NAT PROTOC, V3, P612, DOI 10.1038/nprot.2008.19
   JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125
   Kiener HP, 2010, ARTHRITIS RHEUM US, V62, P742, DOI 10.1002/art.27285
   Kim H, 2008, RADIOLOGY, V248, P844, DOI 10.1148/radiol.2483071740
   Kinne RW, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2333
   Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86
   Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood 2008 01 133967
   Kohara H, 2011, IMMUNOL LETT, V137, P53, DOI 10.1016/j.imlet.2011.02.017
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   Lundy SK, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2107
   MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417
   Maruotti N, 2007, HISTOL HISTOPATHOL, V22, P581, DOI 10.14670/HH 22.581
   McInnes IB, 2000, ARTHRITIS RES, V2, P374, DOI 10.1186/ar115
   MORELAND LW, 1995, ARTHRITIS RHEUM, V38, P1581, DOI 10.1002/art.1780381109
   Nistala K, 2009, RHEUMATOLOGY, V48, P602, DOI 10.1093/rheumatology/kep028
   Notley CA, 2008, J EXP MED, V205, P2491, DOI 10.1084/jem.20072707
   Pap T, 2000, ARTHRITIS RES, V2, P361, DOI 10.1186/ar113
   Paradowska Gorycka A, 2010, SCAND J IMMUNOL, V71, P134, DOI 10.1111/j.1365 3083.2009.02361.x
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Shin EC, 2001, INT J CANCER, V93, P262, DOI 10.1002/ijc.1310
   Spierings DC, 2004, J HISTOCHEM CYTOCHEM, V52, P821, DOI 10.1369/jhc.3A6112.2004
   Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae
   Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457
   VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022 1759(89)90178 6
   Wu YL, 2005, ARTHRITIS RHEUM US, V52, P3257, DOI 10.1002/art.21354
   Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349 7006.2004.tb02181.x
NR 48
TC 49
Z9 57
U1 0
U2 6
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0004 3591
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD APR
PY 2012
VL 64
IS 4
BP 1098
EP 1109
DI 10.1002/art.33423
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 921KC
UT WOS:000302475500019
PM 22006294
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Varga, I
   Holly, D
   Vojtassák, J
   Böhmer, D
   Polák, S
   Danisovic, L
AF Varga, Ivan
   Holly, Dusan
   Vojtassak, Jan
   Boehmer, Daniel
   Polak, Stefan
   Danisovic, L'ubos
TI Morphological characterization of in vitro expanded human dental
   pulp derived stem cells
SO BIOLOGIA
LA English
DT Article
DE dental pulp; stem cells; in vitro cultivation; transmission electron
   microscopy; ultrastructure
ID TISSUE; DIFFERENTIATION; THERAPY; BIOLOGY; ARCHES
AB Stem cells play pivotal role in the development of tissues and organs, as well as they maintain homeostasis and integrity of multicellular organisms. Human dental pulp derived stem cells are capable of differentiation into osteoblasts, odontoblasts, adipocytes and neuronal like cells and can have potential use in tissue regeneration. The aim of this study was a detailed description of human dental pulp derived stem cells (HDPSCs) cultivated in vitro ultrastructural morphology. HDPSCs were isolated from the dental pulp of impacted third molars from healthy donors. Transmission electron microscopic analysis showed typical ultrastructural morphology similar to mesenchymal stem cells from other organs. The morphology of HDPSCs cells reflects their proteosynthetic and metabolic activity. Each cell contained spherical or irregularly shaped large pale nucleus with a large amount of euchromatine. Nuclei had noticeable nucleolus (or two nucleoli) located nearby the nuclear envelope. Abundant cisterns of rough endoplasmic reticulum and numerous coated matrix vesicles as well as granules of glycogen were present in their cytoplasm. Nearby the nucleus small, elongated mitochondria were placed. Most of HDPSCs created and secreted vesicles; in plasmalemma bounded amorphous electron lucide granules and also few glycogen granules. These secretory vesicles had around 0.5 mu m in diameter. We assume that it can be a special type of communication between cells, probably paracrine type of cell signalling, but its real function is still unknown.
C1 [Varga, Ivan; Danisovic, L'ubos] St Elizabeth Univ Hlth & Social Sci, Inst Lab Med, SK 81000 Bratislava, Slovakia.
   [Varga, Ivan; Polak, Stefan] Comenius Univ, Fac Med, Inst Histol & Embryol, SK 81108 Bratislava, Slovakia.
   [Varga, Ivan] Slovak Med Univ, Fac Med, Inst Histol & Embryol, SK 83303 Bratislava, Slovakia.
   [Holly, Dusan] Comenius Univ, Fac Med, Dept Stomatol & Maxillofacial Surg, SK 81250 Bratislava, Slovakia.
   [Vojtassak, Jan; Boehmer, Daniel; Danisovic, L'ubos] Comenius Univ, Fac Med, Inst Med Biol Genet & Clin Genet, SK 81108 Bratislava, Slovakia.
C3 Comenius University Bratislava; Comenius University Bratislava; Slovak
   Medical University Bratislava; Comenius University Bratislava; Comenius
   University Bratislava
RP Danisovic, L (通讯作者)，St Elizabeth Univ Hlth & Social Sci, Inst Lab Med, Palackeho 1, SK 81000 Bratislava, Slovakia.
EM lubos.danisovic@fmed.uniba.sk
OI Varga, Ivan/0000 0002 0918 741X; Danisovic, Lubos/0000 0002 5074 9621;
   Polak, Stefan/0000 0001 7489 1510
FU VEGA [1/0706/11]; Ministry of Health of the Slovak Republic
   [2007/36 UK 07]
FX This study was supported by grant VEGA No. 1/0706/11 and by Ministry of
   Health of the Slovak Republic under the project No. 2007/36 UK 07.
CR Arnold WH, 2010, ANN ANAT, V192, P215, DOI 10.1016/j.aanat.2010.05.004
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Danisovic L, 2008, BIOMED PAP, V152, P235, DOI 10.5507/bp.2008.036
   Deva V, 2006, Rom J Morphol Embryol, V47, P67
   Graham A, 2003, AM J MED GENET A, V119A, P251, DOI 10.1002/ajmg.a.10980
   Gromosová S, 2009, BIOLOGIA, V64, P1247, DOI 10.2478/s11756 009 0199 z
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Henon PR, 2003, ADV EXP MED BIOL, V534, P27
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   ITO K, 1993, DEV BIOL, V156, P191, DOI 10.1006/dbio.1993.1069
   Kadar K, 2009, J PHYSIOL PHARMACOL, V60, P167
   Kang P, 2005, J DENT RES, V84, P678, DOI 10.1177/154405910508400801
   Karaöz E, 2010, HISTOCHEM CELL BIOL, V133, P95, DOI 10.1007/s00418 009 0646 5
   Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742 7843.2004.pto950502.x
   Kues WA, 2005, BIOL REPROD, V72, P1020, DOI 10.1095/biolreprod.104.031229
   LYROUDIA K, 1995, ENDOD DENT TRAUMATOL, V11, P189
   Manolea H, 2008, ROM J MORPHOL EMBRYO, V49, P195
   Miletich Isabelle, 2004, Birth Defects Res C Embryo Today, V72, P200, DOI 10.1002/bdrc.20012
   Muthna D, 2010, STEM CELLS DEV, V19, P1855, DOI 10.1089/scd.2009.0449
   Repiská V, 2010, BIOLOGIA, V65, P919, DOI 10.2478/s11756 010 0095 6
   Shanti RM, 2007, J ORAL MAXIL SURG, V65, P1640, DOI 10.1016/j.joms.2007.04.008
   Suchanek J, 2009, BIOMED PAP, V153, P31, DOI 10.5507/bp.2009.005
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Ueki Shigeru, 1995, Okajimas Folia Anatomica Japonica, V71, P335
   Varga I, 2008, NEUROENDOCRINOL LETT, V29, P837
   You Q, 2009, J INT MED RES, V37, P105, DOI 10.1177/147323000903700112
   Zhang W, 2000, Shanghai Kou Qiang Yi Xue, V9, P158
   Zheng Y, 2009, J DENT RES, V88, P249, DOI 10.1177/0022034509333804
NR 30
TC 8
Z9 8
U1 0
U2 7
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A 1, 02 482 WARSAW, POLAND
SN 0006 3088
J9 BIOLOGIA
JI Biologia
PD AUG
PY 2011
VL 66
IS 4
BP 706
EP 711
DI 10.2478/s11756 011 0069 3
PG 6
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 775QY
UT WOS:000291479400020
DA 2025 08 17
ER

PT J
AU Ahmadi Abhari, S
   Luben, RN
   Wareham, NJ
   Khaw, KT
AF Ahmadi Abhari, Sara
   Luben, Robert N.
   Wareham, Nicholas J.
   Khaw, Kay Tee
TI C reactive protein and fracture risk: European Prospective Investigation
   into Cancer Norfolk Study
SO BONE
LA English
DT Article
DE C reactive protein; Fracture; Osteoporosis; Inflammation; Cohort study;
   Ageing
ID CORONARY HEART DISEASE; BONE MINERAL DENSITY; BODY FAT MASS;
   INFLAMMATORY MARKERS; EPIC NORFOLK; CIRCULATING LEVELS; DRIVING FORCE;
   HIP FRACTURE; WOMEN; OSTEOPOROSIS
AB Background: Serum C reactive protein (CRP) is a marker of general systemic inflammation. It has been suggested that inflammation may have a role in osteoporosis and subsequent fracture risk. We examined the prospective relationship between CRP and fracture risk in a large cohort study.
   Methods: The study populations were 18,586 men and women aged 40 79 enrolled between 1993 and 1997 in the European Prospective Investigation into Cancer in Norfolk study (EPIC Norfolk), who had high sensitivity serum CRP measured in frozen serum from baseline. After 261,563 person years of follow up (Median (inter quartile range) follow up time was 14.8 (13.6 16.1) years), 792 incident fractures (291 hip fractures) were ascertained by hospital record linkage. All multivariate regression models were adjusted for age, sex, body mass index, smoking, alcohol intake, physical activity, past history of fractures, history of osteoporosis, use of NSAIDs and corticosteroid medication, medical history of arthritis, cancer, myocardial infarction, stroke and diabetes, and in women only menopausal status and postmenopausal Hormone Replacement Therapy.
   Results: We found a U shaped association for CRP and fracture risk. The lowest risk of fracture was observed for men and women with baseline CRP levels in the range of 1.1 2 mg/L in fractional polynomial Cox proportional hazards regression analysis. Hazard ratios of all fractures for participants with CRP levels 0.1 0.5; 0.6 1; 1.1 2; 2.1 3; 3.1 10; and above 10 mg/L were 1.31 (1.03, 1.66); 1.21 (0.98, 1.51); 1.00 (referent category); 1.06 (0.82, 1.35); 1.22 (1.00, 1.51); and 1.29 (0.91, 1.81) respectively. Although a similar U shaped association was observed for hip fractures, the corresponding hazard ratios were not statistically significant.
   Conclusion: A U shaped association was observed between CRP and fracture risk. The increased risk of fracture observed at lower end of CRP compared to intermediate levels require further exploration, confirmation in other populations, and investigation into potential biological mechanisms. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Ahmadi Abhari, Sara; Luben, Robert N.; Khaw, Kay Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.
   [Wareham, Nicholas J.] MRC, Inst Metab Sci, Epidemiol Unit, Cambridge, England.
C3 University of Cambridge; University of Cambridge
RP Ahmadi Abhari, S (通讯作者)，Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Worts Causeway, Cambridge CB1 8RN, England.
EM sa540@medschl.cam.ac.uk
RI ; Khaw, Kay Tee/AAZ 3209 2021; Luben, Robert/KIC 1257 2024;
   Ahmadi Abhari, Sara/MSZ 0567 2025
OI Luben, Robert/0000 0002 5088 6343; Ahmadi Abhari,
   Sara/0000 0003 4440 4050
FU Medical Research Council; Cancer Research UK; British Heart Foundation;
   Wellcome trust; Gates Cambridge scholarship; Medical Research Council
   [G1000143, MC_UU_12015/1, G0401527, MC_U106179471] Funding Source:
   researchfish; MRC [MC_UU_12015/1] Funding Source: UKRI
FX We thank all study participants, general practitioners and the
   EPIC Norfolk study team for their contribution. The EPIC Norfolk study
   is supported by funding from the Medical Research Council, Cancer
   Research UK, the British Heart Foundation and the Wellcome trust. SA is
   supported by the Gates Cambridge scholarship. Funding sources did not
   have a role in the design and conduct of the study, the collection,
   management, analysis, and interpretation of the data or the preparation,
   review, approval, or decision to submit the manuscript. The authors
   declare that there is no conflict of interest associated with this
   manuscript.
CR Agrawal A, 2005, MOL IMMUNOL, V42, P927, DOI 10.1016/j.molimm.2004.09.028
   [Anonymous], 2010, BMC PUBLIC HEALTH, DOI DOI 10.1186/1471 2458 10 579
   Barbour KE, 2012, J BONE MINER RES, V27, P1167, DOI 10.1002/jbmr.1559
   Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003 4819 133 10 200011210 00012
   Cauley JA, 2007, J BONE MINER RES, V22, P1088, DOI 10.1359/JBMR.070409
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Dahl M, 2011, THORAX, V66, P197, DOI 10.1136/thx.2009.131193
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   Day N, 1999, BRIT J CANCER, V80, P95
   De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055
   De Martinis M, 2006, EXP MOL PATHOL, V80, P219, DOI 10.1016/j.yexmp.2005.11.004
   de PP, 2012, ARTHRITIS RHEUM, V10
   Dehghan A, 2007, DIABETES CARE, V30, P2695, DOI 10.2337/dc07 0348
   Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007 2325
   Goto M, 2008, BIOSCI TRENDS, V2, P218
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Heikkilä K, 2009, CANCER CAUSE CONTROL, V20, P15, DOI 10.1007/s10552 008 9212 z
   Il'yasova D, 2005, CANCER EPIDEM BIOMAR, V14, P2413, DOI 10.1158/1055 9965.EPI 05 0316
   Ishii S, 2013, J BONE MINER RES, V10
   Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140 6736(09)61717 7
   Khaw KT, 2004, LANCET, V363, P197, DOI 10.1016/S0140 6736(03)15325 1
   Koh JM, 2005, OSTEOPOROSIS INT, V16, P1263, DOI 10.1007/s00198 005 1840 5
   Kravitz BA, 2009, ALZHEIMERS DEMENT, V5, P318, DOI 10.1016/j.jalz.2009.04.1230
   Lane NE, 2006, NAT CLIN PRACT RHEUM, V2, P562, DOI 10.1038/ncprheum0298
   Lee CC, 2009, DIABETOLOGIA, V52, P1040, DOI 10.1007/s00125 009 1338 3
   Lencel P, 2011, MED HYPOTHESES, V76, P317, DOI 10.1016/j.mehy.2010.09.023
   Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004
   Moayyeri A, 2012, J INTERN MED, V271, P472, DOI 10.1111/j.1365 2796.2011.02443.x
   Moayyeri A, 2009, J BONE MINER RES, V24, P1319, DOI [10.1359/JBMR.090212, 10.1359/jbmr.090212]
   Nakamura K, 2011, OSTEOPOROSIS INT, V22, P2145, DOI 10.1007/s00198 010 1425 9
   Nilsson TK, 2005, THROMB RES, V116, P249, DOI 10.1016/j.thromres.2004.12.005
   Njeh CF, 1997, OSTEOPOROSIS INT, V7, P7, DOI 10.1007/BF01623454
   Ostan R, 2008, NEUROIMMUNOMODULAT, V15, P224, DOI 10.1159/000156466
   Pasco JA, 2006, JAMA J AM MED ASSOC, V296, P1353, DOI 10.1001/jama.296.11.1353
   Pou KM, 2007, CIRCULATION, V116, P1234, DOI 10.1161/CIRCULATIONAHA.107.710509
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Schett G, 2006, ARCH INTERN MED, V166, P2495, DOI 10.1001/archinte.166.22.2495
   Sesso HD, 2003, JAMA J AM MED ASSOC, V290, P2945, DOI 10.1001/jama.290.22.2945
   Stewart A, 2006, J BONE MINER RES, V21, P413, DOI 10.1359/JBMR.051205
   Szalai AJ, 2002, VASC PHARMACOL, V39, P105, DOI 10.1016/S1537 1891(02)00294 X
   van Durme YMTA, 2009, AM J RESP CRIT CARE, V179, P375, DOI 10.1164/rccm.200810 1540OC
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Wareham NJ, 2003, PUBLIC HEALTH NUTR, V6, P407, DOI 10.1079/PHN2002439
   Welch A, 2005, OSTEOPOROSIS INT, V16, P590, DOI 10.1007/s00198 004 1721 3
   Wilson PWF, 2005, ARCH INTERN MED, V165, P2473, DOI 10.1001/archinte.165.21.2473
NR 45
TC 17
Z9 19
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2013
VL 56
IS 1
BP 67
EP 72
DI 10.1016/j.bone.2013.05.009
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 189WS
UT WOS:000322299600011
PM 23702388
DA 2025 08 17
ER

PT J
AU Struckmann, VF
   Allouch Fey, S
   Kneser, U
   Harhaus, L
   Schulte, M
AF Struckmann, Victoria Franziska
   Allouch Fey, Stephanie
   Kneser, Ulrich
   Harhaus, Leila
   Schulte, Matthias
TI Indication Specific Effect of a Phytotherapeutic Remedy on Human Fetal
   Osteoblastic Cells: An in vitro Analysis
SO COMPLEMENTARY MEDICINE RESEARCH
LA English
DT Article
DE Osseous regeneration; Humane fetale Osteoblastenzellen; Spagyric remedy;
   Human fetal osteoblastic cells; Knochenheilung; Spagyrisches Heilmittel
ID CIMICIFUGA RACEMOSA EXTRACT; BONE MINERAL DENSITY; TRICALCIUM PHOSPHATE;
   EQUISETUM; OSTEOCLASTOGENESIS; DIFFERENTIATION; PROLIFERATION;
   ANTIBACTERIAL; ANTIOXIDANT; GENISTEIN
AB Background: Impaired fracture healing is a recurring interdisciplinary medical challenge. Alternative treatment concepts, apart from conventional medicine, are popular, but scientific evidence on their effects is still lacking. Plant derived substances are widely assumed to support bone homeostasis. To clarify the effects on bone healing mechanisms, a commercially available, homeopathic spagyric remedy, containing inter alia two herbal substances with assumed osteogenic potential, equisetum arvense and bellis perennis, was analyzed. Methods: Human fetal osteoblastic (hFOB) 1.19 cells were incubated with the test substance in serial dilutions from 10 to 0.00001%. Cell viability has been evaluated through ATP level (CTG assay) and MTT tetrazolium reduction. Cell proliferation was analyzed by BrdU incorporation and cell migration by wound healing assay (WHA) via image analysis. Additionally, determination of the expression of key genes via real time PCR and proteins via proteome array for inflammation, cell proliferation, and angiogenesis were performed. Results: An incubation of hFOB 1.19 cells with the test substance for 24/72 h showed no reduction in cell number, viability, or proliferation. Cell migration was unimpaired. The test substance induced inflammatory genes and growth factors along with genes of osseous regeneration (ALP, Col1, IL 1 alpha, IL 6, IL 8, IL 10, Osteocalcin, Osteonectin, RUMX2, TGF, VEGFA). Increased protein expression was found in multiple cytokines, chemokines, and acute phase proteins. Conclusion: The test substance did not impair cell vitality parameters (MTT, CTG, BrdU, and WHA). A tendency to activate growth factors, bone regeneration genes, and proteins was shown for osteoblasts, indicating a possible positive effect on osteogenic processes.
   Hintergrund: St & ouml;rungen des komplexen Prozesses der Knochenheilung stellen auch heutzutage noch eine interdisziplin & auml;re Herausforderung dar. Es existieren zahlreiche alternative Therapiekonzepte, deren Evidenz jedoch h & auml;ufig nicht belegt ist. Es wird davon ausgegangen, dass pflanzliche Substanzen die Knochenheilung unterst & uuml;tzen k & ouml;nnen. Wir analysierten die Wirkung eines kommerziellen, homeopathisch spagyrischen Heilmittels, welches unter anderen zwei Pflanzenstoffe enth & auml;lt, denen ein osteogenes Potential zugeschrieben wird (Equisetum arvense und Bellis perennis).Methoden: Es erfolgte eine Inkubation humaner fetaler Osteoblastenzellen (hFOB 1.19) mit der Testsubstanz in absteigender Verd & uuml;nnung von 10 bis 0.00001%. Die Zellvitalit & auml;t wurde anhand der Zellzahlbestimmung durch ATP abh & auml;ngige metabolische Aktivit & auml;t mittels CellTiter Glo (R) (CTG) Test sowie durch Tetrazolium Reduktion (MTT) evaluiert. Die Zellproliferation wurde durch Inkorporation von Bromdesoxyuridin (BrdU) in die DNA aktiver Zellen analysiert. Der Wound Healing Assay (WHA) diente der Quantifizierung der Zellmigration. Zus & auml;tzlich wurde die Expression bestimmter Schl & uuml;sselgene mittels real time PCR und die Proteinexpression via proteom array f & uuml;r Inflammation, Zellproliferation und Angiogenese erhoben.Ergebnisse: Die Inkubation von hFOB 1.19 mit der Testsubstanz f & uuml;r 24/72 Stunden f & uuml;hrte zu keiner Reduktion von Zellzahl,  vitalit & auml;t oder  proliferation. Auch die Zellmigration war unbeeintr & auml;chtigt. Es zeigte sich eine Induktion inflammatorischer Gene, Wachstumsfaktoren sowie Genen der kn & ouml;chernen Regeneration (ALP, Col1, IL 1 alpha, IL 6, IL 8, IL 10, Osteocalcin, Osteonectin, RUMX2, TGF, VEGFA). Verschiedene Zytokine, Chemokine und Akute Phase Proteine wurden vermehrt exprimiert.Schlussfolgerung: Die Testsubstanz hatte keine negativen Auswirkungen auf die gemessenen Zellvitalit & auml;tsparameter (MTT, CTG, BrdU and WHA). Es zeigte sich eine Aktivierungstendenz f & uuml;r Wachstumsfaktoren, Gene und Proteine der Knochenregeneration, die auf einen m & ouml;glichen positiven Effekt der Substanz auf den Prozess des Knochenheilung hinweisen.KeywordsKnochenheilung, Spagyrisches Heilmittel, Humane fetale Osteoblastenzellen
C1 [Struckmann, Victoria Franziska; Allouch Fey, Stephanie; Kneser, Ulrich; Harhaus, Leila; Schulte, Matthias] Heidelberg Univ, Dept Hand Plast & Reconstruct Surg, Dept Hand & Plast Surg, Burn Ctr,Microsurg,BG Clin Ludwigshafen, Ludwigshafen, Germany.
   [Schulte, Matthias] Andreas Wentzensen Res Inst, BG Clin Ludwigshafen, Ludwigshafen, Germany.
C3 Ruprecht Karls University Heidelberg
RP Struckmann, VF (通讯作者)，Heidelberg Univ, Dept Hand Plast & Reconstruct Surg, Dept Hand & Plast Surg, Burn Ctr,Microsurg,BG Clin Ludwigshafen, Ludwigshafen, Germany.
EM vfs@me.com
RI Harhaus, Leila/AFE 4956 2022
FU PEKANA Naturheilmittel GmbH (Kiszlig;legg, Germany)
FX This work was financially supported by PEKANA Naturheilmittel GmbH (Ki
   ss legg, Germany).
CR [Anonymous], 2004, Handbook on medicinal herbs with uses
   Avato P, 2019, MOLECULES, V24, DOI 10.3390/molecules24122251
   Pereira CB, 2012, CELL PROLIFERAT, V45, P386, DOI 10.1111/j.1365 2184.2012.00826.x
   Blumenthal M., 2000, Herbal medicine. Expanded Commission E monographs
   Chan BY, 2008, BONE, V43, P567, DOI 10.1016/j.bone.2008.04.018
   Costa Rodrigues J, 2012, CELL PROLIFERAT, V45, P566, DOI 10.1111/j.1365 2184.2012.00848.x
   Croes M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132781
   Dew TP, 2007, NUTR RES REV, V20, P89, DOI 10.1017/S0954422407738805
   Dong GC, 2008, J BIOMED MATER RES A, V84A, P167, DOI 10.1002/jbm.a.31261
   Duke J.A., 2002, HDB MED HERBS, V2 nd, DOI DOI 10.1201/9781420040463
   Ge WW, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12656
   Graefe EU, 1999, PHYTOMEDICINE, V6, P239, DOI 10.1016/S0944 7113(99)80015 4
   Habauzit Veronique, 2008, Phytochemistry Reviews, V7, P313, DOI 10.1007/s11101 007 9078 9
   Holzhüter G, 2003, ANAL BIOANAL CHEM, V376, P512, DOI 10.1007/s00216 003 1905 2
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Karakas FP, 2017, J HERB MED, V8, P31, DOI 10.1016/j.hermed.2016.11.003
   Karakas FP, 2012, PHARM BIOL, V50, P1031, DOI 10.3109/13880209.2012.656200
   Kim MH, 2009, BIOL TRACE ELEM RES, V128, P239, DOI 10.1007/s12011 008 8273 x
   Kolios L, 2010, PLANTA MED, V76, P850, DOI 10.1055/s 0029 1240798
   Kolios L, 2009, PLANTA MED, V75, P459, DOI 10.1055/s 0029 1185380
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li LD, 2011, METHODS MOL BIOL, V764, P169, DOI 10.1007/978 1 61779 188 8_11
   Mitich LW, 1997, WEED TECHNOL, V11, P626, DOI 10.1017/S0890037X00045541
   Morikawa T, 2008, J NAT PROD, V71, P828, DOI 10.1021/np8000333
   Moritz S, 2016, INTERDISCIPL SCI REV, V41, P13, DOI 10.1080/03080188.2016.1171579
   Oberbaum MGN., 2005, Planta Med, V63, P503
   Oliveira JA, 2023, BMC ORAL HEALTH, V23, DOI 10.1186/s12903 023 03072 1
   Pryer KM, 2001, NATURE, V409, P618, DOI 10.1038/35054555
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Rozenberg S, 2020, OSTEOPOROSIS INT, V31, P2271, DOI 10.1007/s00198 020 05497 8
   Sehmisch S, 2010, PHYTOTHER RES, V24, pS168, DOI 10.1002/ptr.3060
   Seidlová Wuttke D, 2003, EUR J ENDOCRINOL, V149, P351, DOI 10.1530/eje.0.1490351
   Seidlová Wuttke D, 2003, MATURITAS, V44, pS39, DOI 10.1016/S0378 5122(02)00347 X
   Seidlova Wuttke D, 2009, PLANTA MED, V75, P1279, DOI 10.1055/s 0029 1185561
   Sun JS, 2003, BIOMATERIALS, V24, P873, DOI 10.1016/S0142 9612(02)00372 1
   Sun JS, 2002, BIOMATERIALS, V23, P3377, DOI 10.1016/S0142 9612(02)00038 8
   Trouillas P, 2003, FOOD CHEM, V80, P399, DOI 10.1016/S0308 8146(02)00282 0
   Tutin TG., 1964, FLORA EUROPAEA
   VEIT M, 1995, BIOCHEM SYST ECOL, V23, P79, DOI 10.1016/0305 1978(95)93661 L
   Viereck V, 2005, J BONE MINER RES, V20, P2036, DOI 10.1359/JBMR.050716
   Wichtl M., 2004, Herbal Drugs and Phytopharmaceuticals. A Handbook for Practice on a ScientificBasis, V3rd
   Wu J, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 04021 y
   Wyk B. E. van, 2017, Medicinal plants of the world, DOI 10.1079/9781786393258.0000
   Yandong Mu LY., 2019, Osteogenesis and bone regeneration
   Yao CH, 2005, J BIOMED MATER RES B, V75B, P277, DOI 10.1002/jbm.b.30294
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
NR 47
TC 1
Z9 1
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 2504 2092
EI 2504 2106
J9 COMPLEMENT MED RES
JI Complement. Med. Res.
PD JUN
PY 2024
VL 31
IS 3
BP 222
EP 233
DI 10.1159/000535845
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA TN5J8
UT WOS:001241952800001
PM 38387452
DA 2025 08 17
ER

PT J
AU Dumont, VC
   Mansur, AAP
   Carvalho, SM
   Borsagli, FGLM
   Pereira, MM
   Mansur, HS
AF Dumont, Vitor C.
   Mansur, Alexandra A. P.
   Carvalho, Sandhra M.
   Medeiros Borsagli, Fernanda G. L.
   Pereira, Marivalda M.
   Mansur, Herman S.
TI Chitosan and carboxymethyl chitosan capping ligands: Effects on the
   nucleation and growth of hydroxyapatite nanoparticles for producing
   biocomposite membranes
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Chitosan; Carboxymethyl chitosan; Biocomposite; Nanoparticles;
   Nucleation and growth; Hydroxyapatite
ID QUANTUM DOTS; COMPOSITE SCAFFOLDS; IN VITRO; CHITIN; NANOMEDICINE;
   BIOCOMPATIBILITY; IDENTIFICATION; PRECIPITATION; COMPLEXATION;
   BIOMATERIALS
AB Synthetic biomaterials based on calcium phosphates (CaP) have been widely studied for bone tissue reconstruction therapies, but no definitive solution that fulfills all of the required properties has been identified. Thus, this study reports the synthesis of composite membranes based on nanohydroxyapatite particles (nHA) embedded in chitosan (CHI) and O carboxymethyl chitosan (CMC) matrices produced using a one step co precipitation method in water media. Biopolymers were used as capping ligands for simultaneously controlling the nucleation and growth of the nHA particles during the precipitation process and also to form the polymeric network of the biocomposites. The bionanocomposites were extensively characterized using light microscopy (LM), scanning and transmission electron microscopy (SEM/TEM), energy dispersive X ray spectroscopy (EDX), Fourier transform infrared spectroscopy (FTIR), X ray diffraction (XRD), atomic force microscopy (AFM), X ray micro CT analysis (mu CT), and MTT (3 (4,5 dimethylthiazolyl 2) 2,5 diphenyltetrazolium bromide) cell proliferation assays for cell cytotoxicity. The results demonstrated that the ligands used during the synthesis highly affected the composites produced, primarily due the changes in the mechanisms and kinetics of nucleation and growth of the HA particles at the nanoscale level. The SEM images revealed that the use of carboxyl functionalized chitosan (CMC) ligands significantly reduced the average size of the HA nanoparticles and caused the formation of a narrower size distribution (90 +/  20 nm) compared to the HA nanoparticles produced with chitosan ligands (220 +/  50 nm). The same trend was verified by the AFM analysis, where the nHA particles were formed evenly dispersed in the polymer matrix. However, the CMC based composites were more homogeneously distributed, which was endorsed by the images collected via X ray micro CT. The FTIR spectra and the XRD analysis indicated that nanosized hydroxyapatite was the predominant calcium phosphate phase produced during the co precipitation aqueous process for both the chitosan and CMC biocomposites. These novel hybrid systems based on chitosan and chitosan derivatives with nHA composites were non cytotoxic to a human osteoblast like model cell line (SACS) according to MTT in vitro assays. Moreover, the CMC nHA biocomposites revealed a striking improvement in the cell viability response compared to the CHI nHA biocomposite, which was attributed to the much higher surface area caused by the refinement of the nanoparticles size. Thus, the results of this study demonstrate that these novel bionanocomposite membranes offer promising perspectives as biomaterials for potential repair and replacement of cartilage and bone tissues. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Dumont, Vitor C.; Mansur, Alexandra A. P.; Carvalho, Sandhra M.; Medeiros Borsagli, Fernanda G. L.; Pereira, Marivalda M.; Mansur, Herman S.] Univ Fed Minas Gerais, Ctr Nanosci Nanotechnol & Innovat CeNano2I, Dept Met & Mat Engn, BR 31270901 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais
RP Mansur, HS (通讯作者)，Univ Fed Minas Gerais, Dept Met & Mat Engn, Av Antonio Carlos,6627 Escola Engn,Bloco 2, BR 31270901 Belo Horizonte, MG, Brazil.
EM hmansur@demet.ufmg.br
RI ; Mansur, Herman/HHY 7285 2022; , Marivalda/U 1142 2019; Borsagli,
   Fernanda/N 8837 2015; Guerra Lima Medeiros Borsagli,
   Fernanda/N 8837 2015; de Carvalho, Sandhra/AAZ 9362 2020; Mansur,
   Alexandra/MYQ 5862 2025
OI Mansur, Herman/0000 0002 3032 495X; Mansur,
   Alexandra/0000 0003 1526 2508; Guerra Lima Medeiros Borsagli,
   Fernanda/0000 0002 0202 2452; Pereira, Marivalda/0000 0001 8867 682X
FU CAPES [PROEX 433/2010]; FAPEMIG/Brazil [PPM 00202 13, BCN TEC 30030/12];
   CNPq [PQ1B  306306/2014 0, UNIVERSAL 457537/2014 0]; FINEP
   [CTINFRA PROINFRA/2008/2010]
FX The authors acknowledge the financial support from CAPES
   (PROEX 433/2010;PNPD), FAPEMIG/Brazil (PPM 00202 13;BCN TEC 30030/12),
   CNPq (PQ1B  306306/2014 0; UNIVERSAL 457537/2014 0) and FINEP
   (CTINFRA PROINFRA/2008/2010). The authors express their gratitude to the
   staff of the Microscopy Centre/UFMG for the TEM analysis, Prof D. B.
   Santos and P. Trigueiro for SEM images, and Breno R. Barrioni for the
   micro CT analysis.
CR Bamgbose JT, 2010, AFR J BIOTECHNOL, V9, P2560
   Benavente M., 2008, THESIS
   Berger J, 2004, EUR J PHARM BIOPHARM, V57, P35, DOI 10.1016/s0939 6411(03)00160 7
   Capanema NSV, 2015, MATERIALS, V8, P4191, DOI 10.3390/ma8074191
   Chen XG, 2003, CARBOHYD POLYM, V53, P355, DOI 10.1016/S0144 8617(03)00051 1
   Cooper JK, 2011, LANGMUIR, V27, P8486, DOI 10.1021/la201273x
   Costa ED, 2009, J MATER SCI MATER M, V20, P553, DOI 10.1007/s10856 008 3627 7
   Costa HS, 2008, J MATER SCI, V43, P510, DOI 10.1007/s10853 007 1849 6
   de Abreu FR, 2009, CARBOHYD POLYM, V75, P214, DOI 10.1016/j.carbpol.2008.06.009
   DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010 8545(00)80455 5
   Demirtas TT, 2015, MAT SCI ENG C MATER, V49, P713, DOI 10.1016/j.msec.2015.01.057
   Dorozhkin SV, 2002, ANGEW CHEM INT EDIT, V41, P3130, DOI 10.1002/1521 3773(20020902)41:17<3130::AID ANIE3130>3.0.CO;2 1
   Ehrlich H, 2006, J MEMBRANE SCI, V273, P124, DOI 10.1016/j.memsci.2005.11.050
   Emerich DF, 2005, EXPERT OPIN BIOL TH, V5, P1, DOI 10.1517/14712598.5.1.1
   Etheridge ML, 2013, NANOMED NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013
   Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623 200203000 00020
   Ge HC, 2005, CARBOHYD RES, V340, P1351, DOI 10.1016/j.carres.2005.02.025
   Guang S., 2015, J MATER SCI TECHNOL, P1
   Kadler KE, 1996, BIOCHEM J, V316, P1
   Kaya M, 2015, BIOTECHNOL BIOPROC E, V20, P168, DOI 10.1007/s12257 014 0391 z
   Kaya M, 2014, MAT SCI ENG C MATER, V45, P72, DOI 10.1016/j.msec.2014.09.004
   Kaya M, 2014, BIOTECHNOL BIOPROC E, V19, P58, DOI 10.1007/s12257 013 0488 9
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Kumar Singh Yadav Hemant, 2012, ISRN Pharm, V2012, P763127, DOI 10.5402/2012/763127
   LAMER VK, 1950, J AM CHEM SOC, V72, P4847, DOI 10.1021/ja01167a001
   Landis WJ, 2009, CELLS TISSUES ORGANS, V189, P20, DOI 10.1159/000151454
   LARSEN S, 1966, NATURE, V212, P605, DOI 10.1038/212605a0
   Li XY, 2012, INT J BIOL MACROMOL, V50, P43, DOI 10.1016/j.ijbiomac.2011.09.021
   Li Z, 2003, REACT FUNCT POLYM, V55, P35, DOI 10.1016/S1381 5148(02)00197 9
   Liang P, 2004, J CRYST GROWTH, V261, P571, DOI 10.1016/j.jcrysgro.2003.03.001
   Liao CJ, 1999, BIOMATERIALS, V20, P1807, DOI 10.1016/S0142 9612(99)00076 9
   Mansur AAP, 2015, EUR J INORG CHEM, P4555, DOI 10.1002/ejic.201500441
   Mansur HS, 2013, J MATER CHEM B, V1, P1696, DOI 10.1039/c3tb00498h
   Metcalfe AD, 2007, J R SOC INTERFACE, V4, P413, DOI 10.1098/rsif.2006.0179
   Moore WR, 2001, ANZ J SURG, V71, P354, DOI 10.1046/j.1440 1622.2001.2128.x
   Muzzarelli RAA, 1998, CARBOHYD POLYM, V36, P267, DOI 10.1016/S0144 8617(98)00008 3
   MUZZARELLI RAA, 1988, CARBOHYD POLYM, V8, P1, DOI 10.1016/0144 8617(88)90032 X
   Muzzarelli RAA, 2012, CARBOHYD POLYM, V87, P995, DOI 10.1016/j.carbpol.2011.09.063
   Oliveira JM, 2009, J BIOMED MATER RES A, V88A, P470, DOI 10.1002/jbm.a.31817
   Pina S, 2015, ADV MATER, V27, P1143, DOI 10.1002/adma.201403354
   Qi XN, 2014, J BIOMED MATER RES A, V102, P366, DOI 10.1002/jbm.a.34710
   Ramanery FP, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 014 2504 1
   Rangel Mendez JR, 2009, J HAZARD MATER, V162, P503, DOI 10.1016/j.jhazmat.2008.05.073
   Rodriguez Clemente R, 1998, J EUR CERAM SOC, V18, P1351, DOI 10.1016/S0955 2219(98)00064 8
   Santos JCC, 2013, MOLECULES, V18, P6550, DOI 10.3390/molecules18066550
   Su X, 2003, BONE, V32, P150, DOI 10.1016/S8756 3282(02)00945 6
   Tan SC, 1998, TALANTA, V45, P713, DOI 10.1016/S0039 9140(97)00288 9
   Thanh NTK, 2014, CHEM REV, V114, P7610, DOI 10.1021/cr400544s
   Uysal I, 2014, PROG NAT SCI MATER, V24, P340, DOI 10.1016/j.pnsc.2014.06.004
   Varma AJ, 2004, CARBOHYD POLYM, V55, P77, DOI 10.1016/j.carbpol.2003.08.005
   Viala S, 1996, CARBOHYD POLYM, V29, P197, DOI 10.1016/0144 8617(96)00023 9
   Wang F, 2014, J BIOMED MATER RES A, V102, P760, DOI 10.1002/jbm.a.34747
   Wang P, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.17
   Zaffagnini S, 2007, KNEE SURG SPORT TR A, V15, P175, DOI 10.1007/s00167 006 0144 4
   Zhang ZB, 1998, J PHYS CHEM B, V102, P10871, DOI 10.1021/jp982948+
NR 55
TC 67
Z9 72
U1 2
U2 123
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD FEB 1
PY 2016
VL 59
BP 265
EP 277
DI 10.1016/j.msec.2015.10.018
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CZ4XW
UT WOS:000367107400032
PM 26652373
DA 2025 08 17
ER

PT J
AU Vliek, SB
   Noordhoek, I
   Kranenbarg, EMK
   van Rossum, AGJ
   Dezentje, VO
   Jager, A
   Hokken, JWE
   Putter, H
   van der Velden, AWG
   Hendriks, MP
   Bakker, SD
   van Riet, YEA
   Tjan Heijnen, VCG
   Portielje, JEA
   Kroep, JR
   Nortier, JWR
   van de Velde, CJH
   Linn, SC
AF Vliek, Sonja B.
   Noordhoek, Iris
   Kranenbarg, Elma Meershoek Klein
   van Rossum, Annelot G. J.
   Dezentje, Vincent O.
   Jager, Agnes
   Hokken, J. W. Esmeralda
   Putter, Hein
   van der Velden, Annette W. G.
   Hendriks, Mathijs P.
   Bakker, Sandra D.
   van Riet, Yvonne E. A.
   Tjan Heijnen, Vivianne C. G.
   Portielje, Johanneke E. A.
   Kroep, Judith R.
   Nortier, Johan W. R.
   van de Velde, Cornelis J. H.
   Linn, Sabine C.
TI Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal
   Women With Estrogen Receptor Positive Breast Cancer (BOOG 2006 04):
   Randomized Phase III TEAM IIB Trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; ZOLEDRONIC ACID; MECHANISMS;
   METASTASES; CLODRONATE; TAMOXIFEN; DIAGNOSIS; JAW
AB PURPOSE For postmenopausal patients with breast cancer, previous subgroup analyses have shown a modest benefit from adjuvant bisphosphonate treatment. However, the efficacy of oral nitrogen containing bisphosphonates such as ibandronate is unclear in this setting. TEAM IIB investigates adjuvant ibandronate in postmenopausal women with estrogen receptor positive (ER+) breast cancer. METHODS TEAM IIB is a randomized, open label, multicenter phase III study. Postmenopausal women with stage I III ER+ breast cancer and an indication for adjuvant endocrine therapy (ET) were randomly assigned 1:1 to 5 years of ET with or without oral ibandronate 50 mg once daily for 3 years. Major ineligibility criteria were bilateral breast cancer, active gastroesophageal problems, and health conditions that might interfere with study treatment. Primary end point was disease free survival (DFS), analyzed in the intention to treat population. RESULTS Between February 1, 2007, and May 27, 2014, 1,116 patients were enrolled, 565 to ET with ibandronate (ibandronate arm) and 551 to ET alone (control arm). Median follow up was 8.5 years. DFS was not significantly different between the ibandronate and control arms (HR, 0.97; 95% CI, 0.76 to 1.24; log rank P = .811). Three years after random assignment, DFS was 94% in the ibandronate arm and 91% in the control arm. Five years after random assignment, this was 89% and 86%, respectively. In the ibandronate arm, 97/565 (17%) of patients stopped ibandronate early because of adverse events. Significantly more patients experienced GI issues, mainly dyspepsia, in the ibandronate arm than in the control arm (89 [16%] and 54 [10%], respectively; P < .003). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw. CONCLUSION In postmenopausal women with ER+ breast cancer, adjuvant ibandronate 50 mg once daily does not improve DFS and should not be recommended as part of standard treatment regimens.
C1 [Vliek, Sonja B.; van Rossum, Annelot G. J.; Dezentje, Vincent O.; Linn, Sabine C.] Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL 1066 CX Amsterdam, Netherlands.
   [Noordhoek, Iris; Portielje, Johanneke E. A.; Kroep, Judith R.; Nortier, Johan W. R.] Leiden Univ, Dept Med Oncol, Med Ctr, Leiden, Netherlands.
   [Noordhoek, Iris; Kranenbarg, Elma Meershoek Klein; van de Velde, Cornelis J. H.] Leiden Univ, Dept Surg, Med Ctr, Leiden, Netherlands.
   [Jager, Agnes] Dutch Breast Canc Res Grp, Amsterdam, Netherlands.
   [Hokken, J. W. Esmeralda] Groene Hart Ziekenhuis, Dept Med Oncol, Gouda, Netherlands.
   [Putter, Hein] Leiden Univ, Dept Med Stat, Med Ctr, Leiden, Netherlands.
   [van der Velden, Annette W. G.] Martini Hosp, Dept Internal Med, Groningen, Netherlands.
   [Hendriks, Mathijs P.] Northwest Clin, Dept Med Oncol, Alkmaar, Netherlands.
   [Bakker, Sandra D.] Zaans Med Ctr, Dept Internal Med, Zaandam, Netherlands.
   [van Riet, Yvonne E. A.] Catharina Hosp, Dept Surg Oncol, Eindhoven, Netherlands.
   [Tjan Heijnen, Vivianne C. G.] Maastricht Univ, Dept Med Oncol, Med Ctr, Maastricht, Netherlands.
   [Linn, Sabine C.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.
C3 Netherlands Cancer Institute; Leiden University   Excl LUMC; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University;
   Leiden University Medical Center (LUMC); Leiden University   Excl LUMC;
   Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); University of Groningen; Martini Hospital;
   Catharina Hospital; Maastricht University; Utrecht University; Utrecht
   University Medical Center
RP Linn, SC (通讯作者)，Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL 1066 CX Amsterdam, Netherlands.
EM s.linn@nki.nl
RI ; van de Velde, Cornelis/AAY 8360 2020; Putter, Hein/C 2244 2018;
   Hendriks, Mathijs/AGR 5663 2022
OI Kroep, Judith/0000 0003 2671 1903; Vliek, Sonja/0000 0002 7300 7436;
   Putter, Hein/0000 0001 5395 1422; Meershoek Klein Kranenbarg,
   Elma/0000 0002 1750 2221; Hendriks, Mathijs/0000 0001 6687 5393
FU Roche Nederland B.V.; Pfizer Nederland B.V.
FX Supported by Roche Nederland B.V. and Pfizer Nederland B.V. by means of
   unrestricted research grants.
CR [Anonymous], NATL BORSTKANKER OVE
   [Anonymous], MODELING SURVIVAL DA
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brockton NT, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1528 y
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman RE, 2018, J BONE ONCOL, V13, P123, DOI 10.1016/j.jbo.2018.09.008
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fontein DBY, 2014, EUR J CANCER, V50, P2190, DOI 10.1016/j.ejca.2014.05.010
   Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gourgou Bourgade S, 2015, ANN ONCOL, V26, P873, DOI 10.1093/annonc/mdv106
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Grey A, 2009, J CLIN ENDOCR METAB, V94, P538, DOI 10.1210/jc.2008 2241
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Payne KFB, 2017, BRIT J GEN PRACT, V67, P330, DOI 10.3399/bjgp17X691565
   Perez EA, 2006, ONCOLOGY NY, V20, P1029
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruggiero SL, 2007, CLIN CASES MINER BON, V4, P37
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   van de Velde CJH, 2011, LANCET, V377, P321, DOI 10.1016/S0140 6736(10)62312 4
   von Minckwitz G, 2013, J CLIN ONCOL, V31, P3531, DOI 10.1200/JCO.2012.47.2167
NR 27
TC 9
Z9 10
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 1
PY 2022
VL 40
IS 25
BP 2934
EP +
DI 10.1200/JCO.21.00311
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 4D1EV
UT WOS:000846888000009
PM 35442755
OA Green Published
DA 2025 08 17
ER

PT J
AU Su, SS
   Kong, WJ
   Zhang, J
   Wang, XG
   Guo, HM
AF Su, Shasha
   Kong, Wenjie
   Zhang, Jing
   Wang, Xinguo
   Guo, Hongmei
TI Integrated analysis of DNA methylation and gene expression profiles
   identified S100A9 as a potential biomarker in ulcerative colitis
SO BIOSCIENCE REPORTS
LA English
DT Article
ID LONG NONCODING RNA; DISEASE; DELETIONS; IMMUNE; P15; IBD
AB Ulcerative colitis (UC) is a prevalent relapsing remitting inflammatory bowel disease whose pathogenetic mechanisms remain elusive. In the present study, colonic biopsies samples from three UC patients treated in the Traditional Chinese Medicine Hospital and three healthy controls were obtained. The genome wide mRNA and lncRNA expression of the samples were profiled through Agilent gene expression microarray. Moreover, the genome wide DNA methylation dataset of normal and UC colon tissues was also downloaded from GEO for a collaborative analysis. Differential expression of lncRNA (DELs) and mRNAs (DEMs) in UC samples compared with healthy samples were identified by using limma Bioconductor package. Differentially methylated promoters (DMPs) in UC samples compared with controls were obtained through comparing the average methylation level of CpGs located at promoters by using t test. Functional enrichment analysis was performed by the DAVID. STRING database was applied to the construction of gene functional interaction network. As a result, 2090 DEMs and 1242 DELs were screened out in UC samples that were closely associated with processes related to complement and coagulation cascades, osteoclast differentiation vaccinia, and hemorrhagic diseases. A total of 90 DEMs and 72 DELs were retained for the construction of functional network for the promoters of their corresponding genes were identified as DMPs. S100A9, HECW2, SOD3 and HIX0114733 showed high interaction degrees in the functional network, and expression of S100A9 was confirmed to be significantly elevated in colon tissues of UC patients compared with that of controls by qRT PCR that was consistent with gene microarray analysis. These indicate that S100A9 could potentially be used as predictive biomarkers in UC.
C1 [Su, Shasha; Zhang, Jing; Wang, Xinguo; Guo, Hongmei] Xinjiang Med Univ, Dept Digest, Tradit Chinese Med Hosp, Urumqi 830099, Xinjiang, Peoples R China.
   [Kong, Wenjie] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Digest, Urumqi 830001, Xinjiang, Peoples R China.
C3 Xinjiang Medical University
RP Guo, HM (通讯作者)，Xinjiang Med Univ, Dept Digest, Tradit Chinese Med Hosp, Urumqi 830099, Xinjiang, Peoples R China.
EM guohongmeixj@yeah.net
RI kong, wenjie/NKP 5296 2025
FU Xinjiang natural science foundation [2017D01C111]
FX This study was funded by Xinjiang natural science foundation [grant
   number 2017D01C111].
CR Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32
   Geng H, 2018, GASTROENTEROLOGY, V155, P144, DOI 10.1053/j.gastro.2018.03.058
   Gomez JA, 2013, CELL, V152, P743, DOI 10.1016/j.cell.2013.01.015
   Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098 2264(199807)22:3<232::AID GCC9>3.0.CO;2 X
   Harris RA, 2014, EPIGENETICS US, V9, P1131, DOI 10.4161/epi.29446
   Holdt LM, 2010, ARTERIOSCL THROM VAS, V30, P620, DOI 10.1161/ATVBAHA.109.196832
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ishiguro Y, 1999, J GASTROENTEROL, V34, P66, DOI 10.1007/s005350050218
   Kang K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081291
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Mirza AH, 2015, GENOME MED, V7, DOI 10.1186/s13073 015 0162 2
   Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001
   Nayel S A, 1985, Asia Oceania J Obstet Gynaecol, V11, P65
   Neurath MF, 2019, SEMIN IMMUNOPATHOL, V41, P747, DOI 10.1007/s00281 019 00751 6
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   Okada K, 2016, J LEUKOCYTE BIOL, V100, P1093, DOI 10.1189/jlb.2A0415 170RRR
   Padua D, 2016, AM J PHYSIOL GASTR L, V311, pG446, DOI 10.1152/ajpgi.00212.2016
   Papamichael K, 2017, AM J GASTROENTEROL, V112, P673, DOI 10.1038/ajg.2017.21
   Rankin CR, 2019, LIFE SCI, V231, DOI 10.1016/j.lfs.2019.116571
   Rapicavoli NA, 2013, ELIFE, V2, DOI 10.7554/eLife.00762
   Rapozo DCM, 2017, WORLD J GASTROENTERO, V23, P2124, DOI 10.3748/wjg.v23.i12.2124
   Schenten V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00447
   Serada S, 2012, INFLAMM BOWEL DIS, V18, P2169, DOI 10.1002/ibd.22936
   Shiga Y, 2018, HUM MOL GENET, V27, P1486, DOI 10.1093/hmg/ddy053
   Singh S, 2017, NAT REV GASTRO HEPAT, V14, P110, DOI 10.1038/nrgastro.2016.181
   Tsujikawa Tomoyuki, 2006, Nihon Ronen Igakkai Zasshi, V43, P769, DOI 10.3143/geriatrics.43.769
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Wrensch M, 2009, NAT GENET, V41, P905, DOI 10.1038/ng.408
   Wu F, 2016, INFLAMM BOWEL DIS, V22, P782, DOI 10.1097/MIB.0000000000000691
   Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468
NR 30
TC 11
Z9 11
U1 0
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144 8463
EI 1573 4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD DEC 2
PY 2020
VL 40
AR BSR20202384
DI 10.1042/BSR20202384
PN 12
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QG6IP
UT WOS:000617687400001
PM 33185247
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, YY
   Zhu, TT
   Wu, Y
   Shu, CX
   Chen, Q
   Yang, J
   Luo, X
   Wang, Y
AF Yang, Yaoyao
   Zhu, Tingting
   Wu, Yan
   Shu, Chunxia
   Chen, Qiang
   Yang, Juan
   Luo, Xiang
   Wang, Yao
TI Irradiation with blue light emitting diode enhances osteogenic
   differentiation of stem cells from the apical papilla
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Mesenchymal stem cells; Stem cells from apical papilla; LED;
   Proliferation; Osteogenic differentiation
ID LEVEL LASER IRRADIATION; IN VITRO PROLIFERATION; DENTAL PULP; OSTEOBLAST
   PROLIFERATION; THERAPY; EXPRESSION; GROWTH; PHOTOBIOMODULATION;
   REGENERATION; MECHANISM
AB This study aimed to evaluate the effects of low energy blue LED irradiation on the osteogenic differentiation of stem cells from the apical papilla (SCAPs). SCAPs were derived from human tooth root tips and were irradiated with 0 (control group), 1 J/cm(2), 2 J/cm(2), 3 J/cm(2), or 4 J/cm(2)blue light in osteogenic induction medium. Cell proliferation was analyzed using the 3 [4,5 dimethylthiazol 2 yl] 2,5 diphenyl tetrazolium bromide (MTT) assay. Osteogenic differentiation activity was evaluated by monitoring alkaline phosphatase (ALP), alizarin red staining, and real time polymerase chain reaction (RT PCR). The results of the MTT assay indicated that SCAPs in the LED groups exhibited a lower proliferation rate than those in the control group, and there were statistically differences between the 2 J/cm(2), 3 J/cm(2), and 4 J/cm(2)groups and the control group (P < 0.05). The results of the ALP and alizarin red analyses showed that blue LED promoted osteogenic differentiation of the SCAPs. And 4 J/cm(2)blue light upregulates the expression levels of the osteogenic/dentinogenic genes ALP, dentin sialophosphoprotein (DSPP), dentin matrix protein 1 (DMP 1), and osteocalcin (OCN) in SCAPs. Our results confirmed that low energy blue LED at 1 J/cm(2), 2 J/cm(2), 3 J/cm(2), and 4 J/cm(2)could inhibit the proliferation of SCAPs and promotes osteogenic differentiation of SCAPs. Further in vitro studies are required to explore the mechanisms of the effects by low energy blue LED.
C1 [Yang, Yaoyao; Shu, Chunxia; Chen, Qiang; Yang, Juan; Luo, Xiang] Southwest Med Univ, Luzhou 646000, Peoples R China.
   [Yang, Yaoyao] Zunyi Med Univ, Hosp Sch Stomatol, Zunyi 563000, Guizhou, Peoples R China.
   [Zhu, Tingting] Yantai Stomatol Hosp, Yantai 264000, Peoples R China.
   [Wu, Yan] Sichuan Univ, West China Guangan Hosp, Guangan 638550, Peoples R China.
   [Wang, Yao] Southwest Med Univ, Hosp Stomatol, Luzhou 646000, Peoples R China.
C3 Southwest Medical University; Zunyi Medical University; Sichuan
   University; Southwest Medical University
RP Wang, Y (通讯作者)，Southwest Med Univ, Hosp Stomatol, Luzhou 646000, Peoples R China.
EM 438730587@qq.com
RI chen, qiang/JXY 6982 2024; Wang, Yinghui/Q 1723 2019; Zhu,
   Tingting/O 6989 2017
FU LuzhouMunicipal People's Government Southwest Medical University science
   and technology strategic cooperation projects of China [2017LZXNYDT03];
   Luzhou Municipal Science and Technology Bureau of China
   [2016 R 70(13/24)]; Southwest Medical University
FX This work was supported by the LuzhouMunicipal People's
   Government Southwest Medical University science and technology strategic
   cooperation projects of China (no. 2017LZXNYDT03), Luzhou Municipal
   Science and Technology Bureau of China (no. 2016 R 70(13/24)). The
   reagents of this study were supported by these funds that all came from
   Southwest Medical University.
CR AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Arnolda G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205432
   Bakopoulou A, 2011, ARCH ORAL BIOL, V56, P709, DOI 10.1016/j.archoralbio.2010.12.008
   Ballini A, 2015, J BIOL REG HOMEOS AG, V29, P813
   Basso FG, 2013, LASER MED SCI, V28, P367, DOI 10.1007/s10103 012 1057 8
   Borzabadi Farahani A, 2016, J PHOTOCH PHOTOBIO B, V162, P577, DOI 10.1016/j.jphotobiol.2016.07.022
   Chrepa V, 2017, J ENDODONT, V43, P561, DOI 10.1016/j.joen.2016.09.024
   Chueh LH, 2006, J ENDODONT, V32, P1205, DOI 10.1016/j.joen.2006.07.010
   Cui DX, 2018, CURR STEM CELL RES T, V13, P39, DOI 10.2174/1574888X12666170913150403
   Diao S, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12337
   Diogenes A, 2017, J ENDODONT, V43, pS95, DOI 10.1016/j.joen.2017.07.012
   Estrela Carlos, 2011, Braz. Dent. J., V22, P91
   Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003
   Barboza CAG, 2014, EINSTEIN SAO PAULO, V12, P75, DOI 10.1590/S1679 45082014AO2824
   Ginani F, 2018, LASER MED SCI, V33, P95, DOI 10.1007/s10103 017 2355 y
   Higuchi A, 2011, TISSUE ENG PT A, V17, P2593, DOI 10.1089/ten.tea.2011.0080
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Huang GTJ, 2008, J ENDODONT, V34, P645, DOI 10.1016/j.joen.2008.03.001
   Huang GTJ, 2010, TISSUE ENG PT A, V16, P605, DOI [10.1089/ten.tea.2009.0518, 10.1089/ten.TEA.2009.0518]
   Kim JE, 2017, LASER SURG MED, V49, P940, DOI 10.1002/lsm.22736
   Li RM, 2009, J ENDODONT, V35, P382, DOI 10.1016/j.joen.2008.11.031
   Li WT, 2007, P ANN INT IEEE EMBS, P5830
   Liebmann J, 2010, J INVEST DERMATOL, V130, P259, DOI 10.1038/jid.2009.194
   Lin LM, 2018, AUST ENDOD J, V44, P292, DOI 10.1111/aej.12252
   Lipovsky A, 2010, LASER SURG MED, V42, P467, DOI 10.1002/lsm.20948
   Marques MM, 2016, PHOTOMED LASER SURG, V34, P500, DOI 10.1089/pho.2015.4038
   Mvula B, 2008, LASER MED SCI, V23, P277, DOI 10.1007/s10103 007 0479 1
   Na S., 2013, J TISSUE ENG REGEN M, V10, P261, DOI [10.2217/rme 2022 0006, DOI 10.1002/TERM.1686]
   Nada OA, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00103
   Oliveira FA, 2016, J PHOTOCH PHOTOBIO B, V163, P14, DOI 10.1016/j.jphotobiol.2016.08.006
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Pagin MT, 2014, LASER MED SCI, V29, P55, DOI 10.1007/s10103 012 1238 5
   Pasternak Mnich K, 2019, LASERS SURG MED
   Pereira MCMC, 2010, J PHOTOCH PHOTOBIO B, V98, P188, DOI 10.1016/j.jphotobiol.2009.12.005
   Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728 200503000 00016
   Shiehzadeh Vahab, 2014, Indian J Dent Res, V25, P248, DOI 10.4103/0970 9290.135937
   Soares DM, 2015, LASER MED SCI, V30, P1171, DOI 10.1007/s10103 013 1436 9
   Soleimani M, 2012, LASER MED SCI, V27, P423, DOI 10.1007/s10103 011 0930 1
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Turrioni APS, 2014, J DENT, V42, P1292, DOI 10.1016/j.jdent.2014.07.014
   Wang L, 2013, CELL PROLIFERAT, V46, P214, DOI 10.1111/cpr.12016
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758
   Zaccara IM, 2015, LASER MED SCI, V30, P2259, DOI 10.1007/s10103 015 1803 9
   Zhu TT, 2019, LASER MED SCI, V34, P1473, DOI 10.1007/s10103 019 02750 3
NR 45
TC 21
Z9 21
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD DEC
PY 2020
VL 35
IS 9
BP 1981
EP 1988
DI 10.1007/s10103 020 02995 3
EA MAR 2020
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA ON9IB
UT WOS:000565569900001
PM 32173788
DA 2025 08 17
ER

PT J
AU Tuure, L
   Pemmari, A
   Hämäläinen, M
   Moilanen, T
   Moilanen, E
AF Tuure, Lauri
   Pemmari, Antti
   Hamalainen, Mari
   Moilanen, Teemu
   Moilanen, Eeva
TI Regulation of gene expression by MF63, a selective inhibitor of
   microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE mPGES 1; prostaglandins; gene expression; osteoarthritis; chondrocytes
ID PROSTAGLANDIN E SYNTHASE 1; CARDIOVASCULAR SAFETY; E 2 SYNTHASE 1;
   CARTILAGE; INFLAMMATION; MODEL; KNEE; PAIN
AB Background and Purpose mPGES1 catalyses the production of PGE(2), the most abundant prostanoid related to inflammation and pain in arthritis. mPGES1 is suggested to be a safer and more selective drug target in inflammatory conditions compared to the COX enzymes inhibited by NSAIDs. In the present study, we investigated the effects of the selective mPGES1 inhibitor MF63 on gene expression in primary human chondrocytes from patients with osteoarthritis (OA). Experimental Approach Chondrocytes were isolated from articular cartilage obtained from osteoarthritis patients undergoing knee replacement surgery. The effects of MF63 were studied in the primary chondrocytes with RNA sequencing based genome wide expression analysis. The main results were confirmed with qRT PCR and compared with the effects of the NSAID ibuprofen. Functional analysis was performed with the GO database and interactions between the genes were studied with STRING. Key Results MF63 enhanced the expression of multiple metallothionein 1 (MT1) isoforms as well as endogenous antagonists of IL 1 and IL 36. The expression of IL 6, by contrast, was down regulated. These genes were also essential in functional and interaction network analyses. The effects of MF63 were consistent in qRT PCR analysis, whereas the effects of ibuprofen overlapped only partly with MF63. There were no evident findings of catabolic effects by MF63. Conclusion and Implications Metallothionein 1 has been suggested to have anti inflammatory and protective effects in cartilage. Up regulation of the antagonists of IL 1 superfamily and down regulation of the pro inflammatory cytokine IL 6 also support novel anti inflammatory and possibly disease modifying effects of mPGES1 inhibitors in arthritis.
C1 [Tuure, Lauri; Pemmari, Antti; Hamalainen, Mari; Moilanen, Teemu; Moilanen, Eeva] Tampere Univ, Fac Med & Hlth Technol, Immunopharmacol Res Grp, Tampere, Finland.
   [Tuure, Lauri; Pemmari, Antti; Hamalainen, Mari; Moilanen, Teemu; Moilanen, Eeva] Tampere Univ Hosp, Tampere, Finland.
   [Moilanen, Teemu] Coxa Hosp Joint Replacement, Tampere, Finland.
C3 Tampere University; Tampere University; Tampere University Hospital;
   Coxa Hospital for Joint Replacement
RP Moilanen, E (通讯作者)，Tampere Univ, Fac Med & Hlth Technol, Immunopharmacol Res Grp, Tampere, Finland.
EM eeva.moilanen@tuni.fi
RI ; Pemmari, Antti/GQZ 6812 2022
OI Hamalainen, Mari/0000 0002 6409 3758; Moilanen,
   Eeva/0000 0002 8577 0316; Pemmari, Antti/0000 0002 8187 1216; Moilanen,
   Teemu/0000 0003 4899 1301
FU Finnish Medical Foundation; Paulo Foundation, Finland; Pirkanmaa
   Hospital District, Finland
FX The Finnish Medical Foundation; The Paulo Foundation, Finland; The
   Pirkanmaa Hospital District, Finland
CR Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS1, DOI 10.1111/bph.14747
   Ali SA, 2016, ARTHRITIS RHEUMATOL, V68, P127, DOI 10.1002/art.39337
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   AREND WP, 1990, ARTHRITIS RHEUM US, V33, P305, DOI 10.1002/art.1780330302
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Baron JA, 2008, LANCET, V372, P1756, DOI 10.1016/S0140 6736(08)61490 7
   Bassoy EY, 2018, IMMUNOL REV, V281, P169, DOI 10.1111/imr.12610
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chan DD, 2015, OSTEOARTHR CARTILAGE, V23, P1879, DOI 10.1016/j.joca.2015.06.021
   Chevalier X, 2009, ARTHRIT RHEUM ARTHR, V61, P344, DOI 10.1002/art.24096
   COYLE P, 1995, INFLAMM RES, V44, P475, DOI 10.1007/BF01837913
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Daheshia M, 2008, J RHEUMATOL, V35, P2306, DOI 10.3899/jrheum.080346
   David Raoudi M, 2009, ARTHRITIS RHEUM US, V60, P760, DOI 10.1002/art.24302
   de Munter W, 2016, RHEUMATOLOGY, V55, P16, DOI 10.1093/rheumatology/kev270
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Haseeb A, 2013, CLIN IMMUNOL, V146, P185, DOI 10.1016/j.clim.2012.12.011
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inoue KI, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/101659
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002
   Kawahara K., 2015, BBA MOL CELL BIOL L, V1851, P414, DOI [DOI 10.1016/J.BBALIP.2014.07.008, 10.1016/j.bbalip.2014.07.008]
   Kim JH, 2014, CELL, V156, P730, DOI 10.1016/j.cell.2014.01.007
   Koeberle A, 2015, BIOCHEM PHARMACOL, V98, P1, DOI 10.1016/j.bcp.2015.06.022
   Korotkova M, 2014, BASIC CLIN PHARMACOL, V114, P64, DOI 10.1111/bcpt.12162
   Li XF, 2005, J RHEUMATOL, V32, P887
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Louati K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000077
   Magne D, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1946
   Majeed MH, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926 018 0794 5
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Nakata K, 2018, OSTEOARTHR CARTILAGE, V26, P1263, DOI 10.1016/j.joca.2018.05.021
   Nissen SE, 2016, NEW ENGL J MED, V375, P2519, DOI 10.1056/NEJMoa1611593
   Ou YS, 2012, RHEUMATOL INT, V32, P2401, DOI 10.1007/s00296 011 1978 8
   Parrish WR, 2017, OSTEOARTHR CARTILAGE, V25, P554, DOI 10.1016/j.joca.2016.11.002
   Patrono C, 2017, CLIN PHARMACOL THER, V102, P238, DOI 10.1002/cpt.696
   Psarra A, 2017, EXPERT OPIN THER PAT, V27, P1047, DOI 10.1080/13543776.2017.1344218
   Ramos YFM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103056
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sabah Ozcan S, 2017, JCPSP J COLL PHYSICI, V27, P602, DOI 2717
   Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1
   Sanayama Y, 2014, ARTHRITIS RHEUMATOL, V66, P1421, DOI 10.1002/art.38400
   Schett G., 2018, RHEUMATOLOGY S2, V57, pii43
   Stirling C, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472 6963 10 122
   Sun JX, 2018, EUR J IMMUNOL, V48, P1550, DOI 10.1002/eji.201747151
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   The Gene Ontology Consortium, 2017, Nucleic acids research, V45, pD331, DOI 10.1093/nar/gkw1108
   Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03 0645rev
   Westman M, 2004, ARTHRITIS RHEUM US, V50, P1774, DOI 10.1002/art.20286
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Won Y, 2016, ANN RHEUM DIS, V75, P2045, DOI 10.1136/annrheumdis 2015 208406
   Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306
   Xu DG, 2008, J PHARMACOL EXP THER, V326, P754, DOI 10.1124/jpet.108.138776
   Yang CY, 2017, OSTEOARTHR CARTILAGE, V25, P1000, DOI 10.1016/j.joca.2017.02.791
   Ziller A, 2018, METALLOMICS, V10, P1549, DOI 10.1039/c8mt00165k
   Zou LX, 2018, MOL MED REP, V17, P3078, DOI 10.3892/mmr.2017.8209
NR 60
TC 6
Z9 7
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD SEP
PY 2020
VL 177
IS 18
BP 4134
EP 4146
DI 10.1111/bph.15142
EA AUG 2020
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ND7VF
UT WOS:000557489200001
PM 32449517
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Punke, JP
   Speas, AL
   Reynolds, LR
   Budsberg, SC
AF Punke, John P.
   Speas, Abbie L.
   Reynolds, Lisa R.
   Budsberg, Steven C.
TI Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and
   leukotriene production by duodenal mucosa and other tissues of
   osteoarthritic dogs
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE 2 INHIBITOR;
   SYNOVIAL FLUID; BLOOD; ENTEROPATHY; SELECTIVITY; INTEGRITY; INJURY;
   NSAIDS; MICE
AB Objective To evaluate the in vivo effects of firocoxib, meloxicam, and tepoxalin on prostaglandin (PG) and leukotriene production in duodenal mucosa and other target tissues in dogs with chronic osteoarthritis (OA).
   Animals 8 dogs with chronic, unilateral OA of the stifle joint.
   Procedures In a crossover design, each dog received placebo (no treatment), firocoxib, meloxicam, or tepoxalin for 7 days, followed by a 21 day washout period. On the first day of treatment (day 0; baseline) and days 2, 4, and 7, samples of whole blood, synovial fluid, and gastric and duodenal mucosae were collected. Prostaglandin E(2) concentrations were E(2) measured in synovial fluid of the stifle joint and after ex vivo stimulation of whole blood samples. Synthesis of PGE(1) and PGE(2) was measured in samples of gastric and duodenal mucosae. Concentrations of thromboxane B(2) (TxB(2)) were measured in whole blood samples. Leukotriene B(4) (LTB(4)) concentrations were measured in samples of whole blood (ex vivo stimulation) an gastric and duodenal mucosae.
   Results Firocoxib, meloxicam, and tepoxalin significantly suppressed whole blood concentrations of PGE(2), compared with baseline and placebo concentrations, at days 2, 4, and 7 Tepoxalin significantly suppressed serum TxB(2) concentrations, compared with baseline, firocoxib, meloxicam, and placebo, at all 3 time points. Production of PGE(1) and PGE(2) was significantly lower in duodenal versus gastric mucosa. Tepoxalin significantly decreased rates of PGE(1) and PGE(2) in duodenal and gastric mucosae, compared with baseline rates. Conclusions and Clinical Relevance PG production was lower in the duodenum than in the stomach. Firocoxib had a COX 1 sparing effect in vivo.
C1 [Punke, John P.; Speas, Abbie L.; Reynolds, Lisa R.; Budsberg, Steven C.] Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia
RP Budsberg, SC (通讯作者)，Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA 30602 USA.
FU Merial Limited, Duluth, Ga
FX Supported in part by Merial Limited, Duluth, Ga.
CR Adebayo D, 2006, POSTGRAD MED J, V82, P186, DOI 10.1136/pgmj.2005.039586
   Agnello KA, 2005, AM J VET RES, V66, P966, DOI 10.2460/ajvr.2005.66.966
   Akiba Y, 2000, AM J PHYSIOL GASTR L, V279, pG437, DOI 10.1152/ajpgi.2000.279.2.G437
   ARGENTIERI DC, 1994, J PHARMACOL EXP THER, V271, P1399
   Bergh MS, 2005, J VET INTERN MED, V19, P633, DOI 10.1892/0891 6640(2005)19[633:TCNPCA]2.0.CO;2
   Jones CJ, 2002, AM J VET RES, V63, P1527, DOI 10.2460/ajvr.2002.63.1527
   JONES RD, 1992, J AM VET MED ASSOC, V201, P475
   Kawai S, 1998, INFLAMM RES, V47, pS102
   Lascelles BDX, 2005, JAVMA J AM VET MED A, V227, P1112, DOI 10.2460/javma.2005.227.1112
   McCann ME, 2004, AM J VET RES, V65, P503, DOI 10.2460/ajvr.2004.65.503
   Narita T, 2006, J VET PHARMACOL THER, V29, P569, DOI 10.1111/j.1365 2885.2006.00805.x
   Scheiman JM, 1996, GASTROENTEROL CLIN N, V25, P279, DOI 10.1016/S0889 8553(05)70247 8
   Sessions JK, 2005, AM J VET RES, V66, P812, DOI 10.2460/ajvr.2005.66.812
   Sigthorsson G, 2002, GASTROENTEROLOGY, V122, P1913, DOI 10.1053/gast.2002.33647
   Streppa HK, 2002, AM J VET RES, V63, P91, DOI 10.2460/AJVR.2002.63.91
   Takeuchi K, 1999, GASTROENTEROLOGY, V117, P1128, DOI 10.1016/S0016 5085(99)70398 7
   Tries S, 2002, INFLAMM RES, V51, P135, DOI 10.1007/PL00000285
   Whittle BJR, 2004, EUR J PHARMACOL, V500, P427, DOI 10.1016/j.ejphar.2004.07.042
NR 18
TC 13
Z9 15
U1 0
U2 9
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173 4360 USA
SN 0002 9645
J9 AM J VET RES
JI Am. J. Vet. Res.
PD SEP
PY 2008
VL 69
IS 9
BP 1203
EP 1209
DI 10.2460/ajvr.69.9.1203
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 342PF
UT WOS:000258795300016
PM 18764695
OA Bronze
DA 2025 08 17
ER

PT J
AU Ponader, S
   Rosenlehner, K
   Vairaktaris, E
   von Wilmowsky, C
   Schlegel, KA
   Neukam, FW
   Schmidt, CD
   Schunk, T
   Hirsch, A
   Nkenke, E
AF Ponader, Sabine
   Rosenlehner, Karin
   Vairaktaris, Eleftherios
   von Wilmowsky, Cornelius
   Schlegel, Karl A.
   Neukam, Friedrich W.
   Schmidt, Cordula D.
   Schunk, Torsten
   Hirsch, Andreas
   Nkenke, Emeka
TI In vitro behavior of layer by layer deposited molecular oligoelectrolyte
   films on Ti 6Al 4V surfaces
SO JOURNAL OF MATERIALS SCIENCE MATERIALS IN MEDICINE
LA English
DT Article
ID TITANIUM; MODEL
AB Layer by layer self assembled films of molecular oligoelectrolytes were used to modify Ti 6Al 4V surfaces in order to test their ability as potential drug delivery system. With regard to medical application the in vitro behavior of the modified material was investigated. The Ti 6Al 4V (6% aluminium, 4% vanadium) material was treated in a layer by layer (LbL) process with 2, 4, 6 and 8 layers of molecular oligoelectrolytes 1 and 2 and thereby doped with a fluorescent reporter molecule 2. Human osteoblasts were cultured for a period up to 5 days on the modified material. Ti 6Al 4V surfaces without modification were used as control. In order to investigate the in vitro behavior of the coating as well as the influence of components of the coating on osteoblastic cells, respectively, cell proliferation, differentiation and attachment of hFOB cells were observed by means of cell number, osteoblastic gene expression and fluorescence microscopy. Degradation behavior of the OEM (oligoelectrolyte multilayer film) was examined using optical spectroscopy. Measurement data imply that the layer by layer coating was successfully assembled on the Ti surface and endures steam sterilization. The fluorescence signal in cell culture medium increased strictly linear with increasing pre assembled number of layers on the surface. Proliferation rates of the cells in experimental groups did not differ significantly from each other (P a parts per thousand yen 0.783). Differentiation pattern was not significantly changed by the coating. The fluorescent reporter component of the film was absorbed by osteoblastic cells and was detected by fluorescence microscopy.
C1 [Ponader, Sabine; von Wilmowsky, Cornelius; Schlegel, Karl A.; Neukam, Friedrich W.; Nkenke, Emeka] Univ Erlangen Nurnberg, Dept Oral & Maxillofacial Surg, D 91054 Erlangen, Germany.
   [Rosenlehner, Karin; Schmidt, Cordula D.; Schunk, Torsten; Hirsch, Andreas] Univ Erlangen Nurnberg, Dept Chem & Pharm, D 91054 Erlangen, Germany.
   [Rosenlehner, Karin; Schmidt, Cordula D.; Schunk, Torsten; Hirsch, Andreas] Univ Erlangen Nurnberg, ICMM, D 91054 Erlangen, Germany.
   [Vairaktaris, Eleftherios] Univ Athens, Sch Med, Dept Oral & Maxillofacial Surg, Athens 11521, Greece.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; National & Kapodistrian University of
   Athens
RP Ponader, S (通讯作者)，Univ Erlangen Nurnberg, Dept Oral & Maxillofacial Surg, Gluckstr 11, D 91054 Erlangen, Germany.
EM sabine.ponader@uk erlangen.de; andreas.hirsch@chemie.uni erlangen.de
RI Hirsch, Andreas/G 1675 2018; Schlegel, Karl/D 1015 2010; Nkenke,
   Emeka/A 1064 2014
OI Hirsch, Andreas/0000 0003 1458 8872; Wessendorf,
   Cordula/0000 0003 0399 615X; Nkenke, Emeka/0000 0001 9591 9359
FU DFG [NE 339/5 1, Hi 468/16 1]
FX The investigations were supported by the DFG GZ: NE 339/5 1 and Hi
   468/16 1. Cells were kindly provided by the Department for Functional
   Materials in Medicine and Dentistry, University of Wurzburg, Wurzburg,
   Germany. The authors gratefully acknowledge the excellent technical
   assistance of Ms. Andrea Krautheim Zenk and the likeable support of Mr.
   Peter Heinl in scanning electron microscopy.
CR Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Buser D, 2004, J DENT RES, V83, P529, DOI 10.1177/154405910408300704
   Chluba J, 2001, BIOMACROMOLECULES, V2, P800, DOI 10.1021/bm015529i
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   Frenkel SR, 2002, J BIOMED MATER RES, V63, P706, DOI 10.1002/jbm.10408
   Heinl P, 2007, ADV ENG MATER, V9, P360, DOI 10.1002/adem.200700025
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Kommireddy DS, 2006, BIOMATERIALS, V27, P4296, DOI 10.1016/j.biomaterials.2006.03.042
   Macdonald M, 2008, J CONTROL RELEASE, V131, P228, DOI 10.1016/j.jconrel.2008.07.032
   Maitz MF, 2002, SURF COAT TECH, V158, P151, DOI 10.1016/S0257 8972(02)00189 5
   Niinomi M, 1998, MAT SCI ENG A STRUCT, V243, P231, DOI 10.1016/S0921 5093(97)00806 X
   Park SY, 2002, LANGMUIR, V18, P9600, DOI 10.1021/la026111o
   Ponader S, 2008, J BIOMED MATER RES A, V84A, P1111, DOI 10.1002/jbm.a.31540
   Rosenlehner K, 2008, ORG BIOMOL CHEM, V6, P2697, DOI 10.1039/b804290j
   Ryan G, 2006, BIOMATERIALS, V27, P2651, DOI 10.1016/j.biomaterials.2005.12.002
   Salemi H, 2007, P ANN INT IEEE EMBS, P5854
   Schmidt CD, 2007, EUR J ORG CHEM, V2007, P5497, DOI 10.1002/ejoc.200700567
   Schwinté P, 2002, BIOMACROMOLECULES, V3, P1135, DOI 10.1021/bm025547f
   Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142 9612(03)00339 9
   Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113
   Yamamoto A, 1998, J BIOMED MATER RES, V39, P331, DOI 10.1002/(SICI)1097 4636(199802)39:2<331::AID JBM22>3.0.CO;2 E
   Zhu L, 2007, J BIOMED MATER RES A, V83A, P1165, DOI 10.1002/jbm.a.31401
NR 22
TC 5
Z9 8
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957 4530
EI 1573 4838
J9 J MATER SCI MATER M
JI J. Mater. Sci. Mater. Med.
PD DEC
PY 2009
VL 20
IS 12
BP 2455
EP 2463
DI 10.1007/s10856 009 3825 y
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 530UC
UT WOS:000272616800011
PM 19634005
DA 2025 08 17
ER

PT J
AU Nayak, S
   Roberts, MS
   Greenspan, SL
AF Nayak, Smita
   Roberts, Mark S.
   Greenspan, Susan L.
TI Cost Effectiveness of Different Screening Strategies for Osteoporosis in
   Postmenopausal Women
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID QUALITY OF LIFE; LOW BONE DENSITY; FRACTURE RISK; HIP FRACTURE;
   VERTEBRAL FRACTURES; ALENDRONATE THERAPY; HEALTH; BISPHOSPHONATES;
   DENSITOMETRY; POPULATION
AB Background: The best strategies to screen postmenopausal women for osteoporosis are not clear.
   Objective: To identify the cost effectiveness of various screening strategies.
   Design: Individual level state transition cost effectiveness model.
   Data Sources: Published literature.
   Target Population: U.S. women aged 55 years or older.
   Time Horizon: Lifetime.
   Perspective: Payer.
   Intervention: Screening strategies composed of alternative tests (central dual energy x ray absorptiometry [DXA], calcaneal quantitative ultrasonography [QUS], and the Simple Calculated Osteoporosis Risk Estimation [SCORE] tool) initiation ages, treatment thresholds, and rescreening intervals. Oral bisphosphonate treatment was assumed, with a base case adherence rate of 50% and a 5 year on/off treatment pattern.
   Outcome Measures: Incremental cost effectiveness ratios (2010 U.S. dollars per quality adjusted life year [QALY] gained).
   Results of Base Case Analysis: At all evaluated ages, screening was superior to not screening. In general, quality adjusted life days gained with screening tended to increase with age. At all initiation ages, the best strategy with an incremental cost effectiveness ratio (ICER) of less than $50 000 per QALY was DXA screening with a T score threshold of  2.5 or less for treatment and with follow up screening every 5 years. Across screening initiation ages, the best strategy with an ICER less than $50 000 per QALY was initiation of screening at age 55 years by using DXA  2.5 with rescreening every 5 years. The best strategy with an ICER less than $100 000 per QALY was initiation of screening at age 55 years by using DXA with a T score threshold of  2.0 or less for treatment and then rescreening every 10 years. No other strategy that involved treatment of women with osteopenia had an ICER less than $100 000 per QALY. Many other strategies, including strategies with SCORE or QUS prescreening, were also cost effective, and in general the differences in effectiveness and costs between evaluated strategies was small.
   Results of Sensitivity Analysis: Probabilistic sensitivity analysis did not reveal a consistently superior strategy. Limitations: Data were primarily from white women. Screening initiation at ages younger than 55 years were not examined. Only osteoporotic fractures of the hip, vertebrae, and wrist were modeled.
   Conclusion: Many strategies for postmenopausal osteoporosis screening are effective and cost effective, including strategies involving screening initiation at age 55 years. No strategy substantially outperforms another.
C1 [Nayak, Smita] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Nayak, S (通讯作者)，Univ Pittsburgh, Sch Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM nayaks@upmc.edu
FU National Center for Research Resources (a component of the National
   Institutes of Health) and National Institutes of Health Roadmap for
   Medical Research [KL2 RR024154]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [1R01AR060809 01]; National Institute
   of Diabetes and Digestive and Kidney Diseases [K24 DK062895]
FX Grant Support: By grant KL2 RR024154 from the National Center for
   Research Resources (a component of the National Institutes of Health)
   and National Institutes of Health Roadmap for Medical Research (Dr.
   Nayak), grant 1R01AR060809 01 from the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (Dr. Nayak), and grant K24
   DK062895 from the National Institute of Diabetes and Digestive and
   Kidney Diseases (Dr. Greenspan).
CR [Anonymous], OTABPH120 US C
   [Anonymous], PROSPECTIVE STUDY HL
   [Anonymous], 2013, Technical Report 202
   [Anonymous], 4 SOC ACT
   [Anonymous], WALM PHARM MED FIND
   [Anonymous], RED BOOK
   [Anonymous], OST FAST FACTS
   [Anonymous], NAT PHYS FEE SCHED
   [Anonymous], 2004, Bone health and osteoporosis: A report of the Surgeon General
   [Anonymous], OSTEOPOROS INT
   [Anonymous], GE FIN NURS HOM COST
   Arias Elizabeth, 2019, Natl Vital Stat Rep, V68, P1
   Barrett JA, 1999, J CLIN EPIDEMIOL, V52, P243, DOI 10.1016/S0895 4356(98)00167 X
   Berg AO, 2002, ANN INTERN MED, V137, P526, DOI 10.7326/0003 4819 137 6 200209170 00014
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532 5415.2003.51110.x
   Brazier JE, 2002, OSTEOPOROSIS INT, V13, P768, DOI 10.1007/s001980200107
   Brenneman Susan K, 2003, Dis Manag, V6, P159, DOI 10.1089/109350703322425509
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cadarette SM, 2001, JAMA J AM MED ASSOC, V286, P57, DOI 10.1001/jama.286.1.57
   CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Dolan P, 1999, OSTEOPOROSIS INT, V9, P196, DOI 10.1007/s001980050136
   Fraser LA, 2011, THER CLIN RISK MANAG, V7, P157, DOI 10.2147/TCRM.S19385
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Gabriel SE, 2002, OSTEOPOROSIS INT, V13, P323, DOI 10.1007/s001980200033
   Geusens P, 2002, MAYO CLIN PROC, V77, P629, DOI 10.4065/77.7.629
   Hanmer J, 2006, MED DECIS MAKING, V26, P391, DOI 10.1177/0272989X06290497
   Heron Melonie, 2009, Natl Vital Stat Rep, V57, P1
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P581, DOI 10.1007/s00198 004 1780 5
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P20, DOI 10.1007/s00198 003 1463 7
   Karpf DB, 1997, JAMA J AM MED ASSOC, V277, P1159
   Kraemer DF, 2006, OSTEOPOROSIS INT, V17, P68, DOI 10.1007/s00198 005 1922 4
   LaCroix AZ, 2005, MED CARE, V43, P293, DOI 10.1097/00005650 200503000 00012
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Liu H, 2006, ARCH INTERN MED, V166, P1209, DOI 10.1001/archinte.166.11.1209
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271
   Mobley LR, 2006, MED DECIS MAKING, V26, P194, DOI 10.1177/0272989X06286478
   Nayak S, 2006, ANN INTERN MED, V144, P832, DOI 10.7326/0003 4819 144 11 200606060 00009
   Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003 4819 137 6 200209170 00015
   Oleksik A, 2000, J BONE MINER RES, V15, P1384, DOI 10.1359/jbmr.2000.15.7.1384
   Schousboe John T, 2007, Curr Rheumatol Rep, V9, P50, DOI 10.1007/s11926 007 0022 1
   Schousboe JT, 2005, J AM GERIATR SOC, V53, P1697, DOI 10.1111/j.1532 5415.2005.53504.x
   Schousboe JT, 2005, ANN INTERN MED, V142, P734, DOI 10.7326/0003 4819 142 9 200505030 00008
   Schwartz AV, 2010, J BONE MINER RES, V25, P976, DOI 10.1002/jbmr.11
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947
   Tosteson ANA, 2001, OSTEOPOROSIS INT, V12, P849, DOI 10.1007/s001980170036
   Tosteson ANA, 2008, AM J MANAG CARE, V14, P605
   Watts Nelson B, 2010, Endocr Pract, V16, P1016
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Weinstein MC, 1996, JAMA J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253
NR 58
TC 103
Z9 113
U1 0
U2 16
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106 1572,
   UNITED STATES
SN 0003 4819
EI 1539 3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD DEC 6
PY 2011
VL 155
IS 11
BP 751
EP U176
DI 10.7326/0003 4819 155 11 201112060 00007
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 860ZS
UT WOS:000297988400004
PM 22147714
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hinton, A
   Sennoune, SR
   Bond, S
   Fang, M
   Reuveni, M
   Sahagian, GG
   Jay, D
   Martinez Zaguilan, R
   Forgac, M
AF Hinton, Ayana
   Sennoune, Souad R.
   Bond, Sarah
   Fang, Min
   Reuveni, Moshe
   Sahagian, G. Gary
   Jay, Daniel
   Martinez Zaguilan, Raul
   Forgac, Michael
TI Function of a Subunit Isoforms of the V ATPase in pH Homeostasis and
   in Vitro Invasion of MDA MB231 Human Breast Cancer Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID VACUOLAR H+ ATPASE; PROTON TRANSLOCATING ATPASE; PLASMA MEMBRANE; A3
   ISOFORM; OSTEOCLAST DIFFERENTIATION; CYSTEINE CATHEPSINS;
   MOLECULAR CLONING; VIVO DISSOCIATION; INTRACELLULAR PH; DRUG RESISTANCE
AB It has previously been shown that highly invasive MDA MB231 human breast cancer cells express vacuolar proton translocating ATPase (V ATPases) at the cell surface, whereas the poorly invasive MCF7 cell line does not. Bafilomycin, a specific V ATPase inhibitor, reduces the in vitro invasion of MB231 cells but not MCF7 cells. Targeting of V ATPases to different cellular membranes is controlled by isoforms of subunit a. mRNA levels for a subunit isoforms were measured in MB231 and MCF7 cells using quantitative reverse transcription PCR. The results show that although all four isoforms are detectable in both cell types, levels of a3 and a4 are much higher in MB231 than in MCF7 cells. Isoform specific small interfering RNAs (siRNA) were employed to selectively reduce mRNA levels for each isoform in MB231 cells. V ATPase function was assessed using the fluorescent indicators SNARF 1 and pyranine to monitor the pH of the cytosol and endosomal/lysosomal compartments, respectively. Cytosolic pH was decreased only on knockdown of a3, whereas endosome/lysosome pH was increased on knockdown of a1, a2, and a3. Treatment of cells with siRNA to a4 did not affect either cytosolic or endosome/lysosome pH. Measurement of invasion using an in vitro transwell assay revealed that siRNAs to both a3 and a4 significantly inhibited invasion of MB231 cells. Immunofluorescence staining of MB231 cells for V ATPase distribution revealed extensive intracellular staining, with plasma membrane staining observed in similar to 18% of cells. Knockdown of a4 had the greatest effect on plasma membrane staining, leading to a 32% reduction. These results suggest that the a4 isoform may be responsible for targeting V ATPases to the plasma membrane of MB231 cells and that cell surface V ATPases play a significant role in invasion. However, other V ATPases affecting the pH of the cytosol and intracellular compartments, particularly those containing a3, are also involved in invasion.
C1 [Hinton, Ayana; Bond, Sarah; Fang, Min; Sahagian, G. Gary; Jay, Daniel; Forgac, Michael] Tufts Univ, Dept Physiol, Sch Med, Boston, MA 02111 USA.
   [Sennoune, Souad R.; Martinez Zaguilan, Raul] Texas Tech Univ, Dept Cell Physiol & Mol Biophys, Lubbock, TX 79430 USA.
   [Reuveni, Moshe] ARO Volcani Ctr, Dept Ornamental Hort, IL 50250 Bet Dagan, Israel.
C3 Tufts University; Texas Tech University System; Texas Tech University;
   VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH
RP Forgac, M (通讯作者)，Tufts Univ, Dept Physiol, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.
EM michael.forgac@tufts.edu
RI FANG, MIN/NFT 0623 2025
FU National Institutes of Health [GM34478]; National Institutes of Health
   Ruth L. Kirschstein Institutional Research Training Grant [T32DK007542];
   National Institutes of Health Training in Education and Critical
   Research Skills Grant [K12GM074869]; American Heart Association [SD
   0435197N, GIA 0855168]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant GM34478 (to M. F.), post doctoral support (to A. H.) and
   pre doctoral support (to S. B.) from National Institutes of Health Ruth
   L. Kirschstein Institutional Research Training Grant T32DK007542, and
   post doctoral support (to A. H.) from National Institutes of Health
   Training in Education and Critical Research Skills Grant K12GM074869.
   This work was also supported by American Heart Association Grants SD
   0435197N (to S. R. S.) and GIA 0855168 (to R. M. Z.).
CR Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050
   GILLIES RJ, 1991, J BIOL CHEM, V266, P1551
   Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hu YW, 2005, FEBS LETT, V579, P4937, DOI 10.1016/j.febslet.2005.07.078
   Hurtado Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348
   Joyce JA, 2004, CELL CYCLE, V3, P1516, DOI 10.4161/cc.3.12.1289
   Kawasaki Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200
   Kubota S, 2000, BIOCHEM BIOPH RES CO, V278, P390, DOI 10.1006/bbrc.2000.3802
   Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008 5472.CAN 04 3822
   MANOLSON MF, 1994, J BIOL CHEM, V269, P14064
   Martínez Zaguilán R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006 2952(99)00022 2
   MARTINEZZAGUILAN R, 1991, AM J PHYSIOL, V260, pC297, DOI 10.1152/ajpcell.1991.260.2.C297
   Morel N, 2003, J CELL SCI, V116, P4751, DOI 10.1242/jcs.00791
   Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418
   Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824
   Ohta T, 1996, BRIT J CANCER, V73, P1511, DOI 10.1038/bjc.1996.285
   Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Philippe JM, 2002, GLIA, V37, P365, DOI 10.1002/glia.10041.abs
   Pietrement C, 2006, BIOL REPROD, V74, P185, DOI 10.1095/biolreprod.105.043752
   Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P1047, DOI 10.1016/S0006 2952(99)00021 0
   Rojas JD, 2006, AM J PHYSIOL HEART C, V291, pH1147, DOI 10.1152/ajpheart.00166.2006
   Sennoune SR, 2004, AM J PHYSIOL CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003
   Sennoune SR, 2004, CELL BIOCHEM BIOPHYS, V40, P185, DOI 10.1385/CBB:40:2:185
   Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200
   Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208
   Sun Wada GH, 2006, J CELL SCI, V119, P4531, DOI 10.1242/jcs.03234
   Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200
   Wang Y, 2008, J BIOL CHEM, V283, P20696, DOI 10.1074/jbc.M803258200
NR 34
TC 170
Z9 203
U1 1
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 12
PY 2009
VL 284
IS 24
BP 16400
EP 16408
DI 10.1074/jbc.M901201200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 455BM
UT WOS:000266730900037
PM 19366680
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Wei, BF
   Wei, W
AF Wei, Biaofang
   Wei, Wei
TI Identification of aberrantly expressed of serum microRNAs in patients
   with hormone induced non traumatic osteonecrosis of the femoral head
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE MicroRNA; Hormone induced non traumatic; osteonecrosis of the femoral
   head; (hormone NOFH); miR 423 5p; miRNA microchip
ID ADIPONECTIN; DIFFERENTIATION; CELLS; OSTEOCLAST; APOPTOSIS; RUNX2
AB Objective: The non translation RNA microRNA (miRNA) has been demonstrated to correlate to various disease occurrence in body. Serum miRNA was gradually considered as molecular markers for disease diagnosis. This study was designed to analyze differential serum miRNAs level in hormone induced non traumatic osteonecrosis of the femoral head (hormone NOFH) patients.
   Methods: We selected 30 patients with hormone NOFH as case group, and 30 healthy volunteers were recruited as control group. miRCURYTM LNA miRNA chip and quantitative RT PCR were used to examine differential miRNAs expression. Correlation assay was performed between miRNAs and NOFH trait.
   Results: We found that 9 miRNAs were upregulated while 3 miRNAs were downregulated in hormone TOFH patient serum by result of miRNA chip. QRT PCR assay revealed that the level of miR 423 5p was significantly increased and miR 10a 5p was significantly decreased. Using Spearman correlation analysis, we observed that miR 423 5p serum level is positive association to FHC levels whereas miR 10a 5p has no association with FHC levels. Furthermore, miR 423 5p is negatively correlated to its downstream molecule adiponectin.
   Conclusion: We report a miRNA profile of hormone NOFH and provide a new perspective to understand this intricate disease. This novel information suggests the potential roles of miR 423 5p in the diagnosis, prognosis biomarkers, or therapy targets of hormone NOFH. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Wei, Biaofang] Linyi Peoples Hosp, Dept Orthopaed, Linyi 276000, Peoples R China.
   [Wei, Wei] Guangzhou Univ Chinese Med, Sch Clin Med 1, Dept Orthopaed, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine
RP Wei, W (通讯作者)，Guangzhou Univ Chinese Med, Sch Clin Med 1, Dept Orthopaed, 16 Jichang Rd, Guangzhou 510405, Guangdong, Peoples R China.
EM weiw679@163.com
FU Science and Technology Develop Project of Shandong province
   [2014GSF119022]
FX This work was supported by Science and Technology Develop Project of
   Shandong province (No. 2014GSF119022).
CR Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Devaux Y, 2015, CRIT CARE, V19, DOI 10.1186/s13054 015 0767 2
   Dong J, 2013, J CELL BIOCHEM, V114, P2738, DOI 10.1002/jcb.24622
   Glueck CJ, 1999, CLIN ORTHOP RELAT R, P133
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Hupkes M, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471 2199 15 1
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43
   Kafchinski LA, 2014, ADV EXP MED BIOL, V804, P119, DOI 10.1007/978 3 319 04843 7_6
   Lenchik L, 2003, BONE, V33, P646, DOI 10.1016/S8756 3282(03)00237 0
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Mouzas Odysseas D, 2014, J Clin Med Res, V6, P336, DOI 10.14740/jocmr1851w
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Prats Puig A, 2013, J CLIN ENDOCR METAB, V98, pE1655, DOI 10.1210/jc.2013 1496
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Shuai B, 2010, J RHEUMATOL, V37, P2151, DOI 10.3899/jrheum.100342
   Sugatani T, 2007, J CELL BIOCHEM, V101, P996, DOI 10.1002/jcb.21335
   Sugatani T, 2013, J CELL BIOCHEM, V114, P1217, DOI 10.1002/jcb.24471
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   Tan G, 2012, CHINESE MED J PEKING, V125, P134, DOI 10.3760/cma.j.issn.0366 6999.2012.01.025
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Wang FS, 2013, ARTHRITIS RHEUM US, V65, P1530, DOI 10.1002/art.37948
   Wang LQ, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 52
   Yamasaki K, 2012, J ORTHOP RES, V30, P1263, DOI 10.1002/jor.22079
   Yuan HF, 2015, EXP MOL PATHOL, V98, P158, DOI 10.1016/j.yexmp.2015.01.002
   Zhang C, 2014, INT J MOL SCI, V15, P6544, DOI 10.3390/ijms15046544
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
NR 27
TC 29
Z9 31
U1 0
U2 5
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2015
VL 75
BP 191
EP 195
DI 10.1016/j.biopha.2015.07.016
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DA0TB
UT WOS:000367509300030
PM 26298803
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Rush, MN
   Coombs, KE
   Hedberg Dirk, EL
AF Rush, Matthew N.
   Coombs, Kent E.
   Hedberg Dirk, Elizabeth L.
TI Surface chemistry regulates valvular interstitial cell differentiation
   in vitro
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Valvular interstitial cells; Differentiation; Heart valve;
   Calcification; Self assembled monolayers
ID SELF ASSEMBLED MONOLAYERS; AORTIC VALVE CALCIFICATION;
   EXTRACELLULAR MATRIX; TRANSFORMING GROWTH FACTOR BETA 1; OSTEOBLAST
   DIFFERENTIATION; INTEGRIN BINDING; GROWTH FACTOR; HEART; FIBRONECTIN;
   HYDROGELS
AB The primary driver for valvular calcification is the differentiation of valvular interstitial cells (VICs) into a diseased phenotype. However, the factors leading to the onset of osteoblastic like VICs (obVICs) and resulting calcification are not fully understood. This study isolates the effect of substrate surface chemistry on in vitro VIC differentiation and calcified tissue formation. Using omega functionalized alkanethiol self assembled monolayers (SAMs) on gold [CH3 (hydrophobic), OH (hydrophilic), COOH (COO , negative at physiological pH), and NH2 (NH3+, positive at physiological pH)], we have demonstrated that surface chemistry modulates VIC phenotype and calcified tissue deposition independent of osteoblastic inducing media additives. Over seven days VICs exhibited surface dependent differences in cell proliferation (COO  = NH3+ > OH > CH3), morphology, and osteoblastic potential. Both NH(3)(+)and CH3 terminated SAMs promoted calcified tissue formation while COO  terminated SAMs showed no calcification. VICs on NH3+ SAMs exhibited the most osteoblastic phenotypic markers through robust nodule formation, up regulated osteocalcin and alpha smooth muscle actin expression, and adoption of a round/rhomboid morphology indicative of osteoblastic differentiation. With the slowest proliferation, VICs on CH3 SAMs promoted calcified aggregate formation through cell detachment and increased cell death indicative of dystrophic calcification. Furthermore, induction of calcified tissue deposition on NH3+ and CH3 SAMs was distinctly different than that of media induced osteoblastic VICs. These results demonstrate that substrate surface chemistry alters VIC behavior and plays an important role in calcified tissue formation. In addition, we have identified two novel methods of calcified VIC induction in vitro. Further study of these environments may yield new models for in vitro testing of therapeutics for calcified valve stenosis, although additional studies need to be conducted to correlate results to in vivo models.
   Statement of Significance
   Valvular interstitial cell (VIC) differentiation and aortic valve calcification is associated with increased risk of mortality and onset of other cardiovascular disorders. This research examines effects of in vitro substrate surface chemistry on VIC differentiation and has led to the identification of two materials based initiation mechanisms of osteoblastic like calcified tissue formation independent of soluble signaling methods. Such findings are important for their potential to study signaling cascades responsible for valvular heart disease initiation and progression as well providing in vitro disease models for drug development. We have also identified a VIC activating in vitro environment that does not exhibit confluence induced nodule formation with promise for the development of tissue regenerating scaffolds. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Rush, Matthew N.; Coombs, Kent E.; Hedberg Dirk, Elizabeth L.] Univ New Mexico, Ctr Biomed Engn, Albuquerque, NM 87131 USA.
   [Rush, Matthew N.; Hedberg Dirk, Elizabeth L.] Univ New Mexico, Nanosci & Microsyst Engn, Albuquerque, NM 87131 USA.
   [Coombs, Kent E.] Univ New Mexico, Biomed Sci Grad Program, Albuquerque, NM 87131 USA.
   [Hedberg Dirk, Elizabeth L.] Univ New Mexico, Chem & Biol Engn, Albuquerque, NM 87131 USA.
C3 University of New Mexico; University of New Mexico; University of New
   Mexico; University of New Mexico
RP Hedberg Dirk, EL (通讯作者)，1 Univ New Mexico, Ctr Biomed Engn, MSC01 1141, Albuquerque, NM 87131 USA.
EM mrush@unm.edu; kcoombs@salud.unm.edu; edirk@unm.edu
RI Rush, Matthew/AAF 6017 2021
OI Montoya Rush, Matthew/0000 0002 6801 595X
FU American Heart Association [10BG1A4570031]; NSF [NSF CBET1351947]; NSF
   IGERT [0504276]; NSF LS AMP [HER1026412]; NIH IMSD [5R25 GM060201]; NIH
   PREP [R25GM075149]; Direct For Education and Human Resources; Division
   Of Graduate Education [0504276] Funding Source: National Science
   Foundation
FX This research was partially funded by the American Heart Association
   (10BG1A4570031) and NSF Career Award (NSF CBET1351947). Educational
   support was provided by NSF IGERT (0504276), NSF LS AMP (HER1026412
   (BDVIII)), NIH IMSD (5R25 GM060201), and NIH PREP (R25GM075149)
   fellowships.
CR Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013
   BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049
   Benton JA, 2009, ARTERIOSCL THROM VAS, V29, P1950, DOI 10.1161/ATVBAHA.109.195271
   Benton JA, 2008, J HEART VALVE DIS, V17, P689
   Blevins TL, 2006, J HEART VALVE DIS, V15, P815
   Bowler MA, 2015, CARDIOVASC PATHOL, V24, P1, DOI 10.1016/j.carpath.2014.08.003
   Butcher JT, 2007, PHILOS T R SOC B, V362, P1489, DOI 10.1098/rstb.2007.2130
   Carabello BA, 1997, NEW ENGL J MED, V337, P32, DOI 10.1056/NEJM199707033370107
   Chen J, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4029115
   Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277
   Clark Greuel JN, 2007, ANN THORAC SURG, V83, P946, DOI 10.1016/j.athoracsur.2006.10.026
   Cloyd KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048154
   CREAGER SE, 1994, LANGMUIR, V10, P3675, DOI 10.1021/la00022a048
   DelRio FW, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3111440
   Desmouliere A, 1997, INT J BIOCHEM CELL B, V29, P19, DOI 10.1016/S1357 2725(96)00117 3
   Duan B, 2014, ACTA BIOMATER, V10, P1836, DOI 10.1016/j.actbio.2013.12.005
   Duan B, 2013, ACTA BIOMATER, V9, P7640, DOI 10.1016/j.actbio.2013.04.050
   Faucheux N, 2004, BIOMATERIALS, V25, P2721, DOI 10.1016/j.biomaterials.2003.09.069
   Fears KP, 2008, LANGMUIR, V24, P837, DOI 10.1021/la701760s
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Gould ST, 2012, ACTA BIOMATER, V8, P3201, DOI 10.1016/j.actbio.2012.05.009
   Gu XX, 2010, J BIOMED MATER RES A, V93A, P1620, DOI 10.1002/jbm.a.32660
   Gwanmesia P, 2010, TISSUE ENG PT A, V16, P3737, DOI [10.1089/ten.tea.2010.0304, 10.1089/ten.TEA.2010.0304]
   Hutcheson JD, 2013, ARTERIOSCL THROM VAS, V33, P114, DOI 10.1161/ATVBAHA.112.300278
   Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003 4975(02)04312 6
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537
   Khan MMT, 2011, ENVIRON SCI TECHNOL, V45, P1055, DOI 10.1021/es101389u
   Kielty CM, 2002, J CELL SCI, V115, P2817
   Lan MA, 2005, BIOMATERIALS, V26, P4523, DOI 10.1016/j.biomaterials.2004.11.028
   Latif N, 2006, CELL BIOCHEM BIOPHYS, V45, P255, DOI 10.1385/CBB:45:3:255
   Li C, 2013, CARDIOVASC PATHOL, V22, P1, DOI 10.1016/j.carpath.2012.06.005
   Lin JH, 2014, LANGMUIR, V30, P10328, DOI 10.1021/la5020362
   Liu AC, 2007, AM J PATHOL, V171, P1407, DOI 10.2353/ajpath.2007.070251
   Liu LY, 2005, J BIOMED MATER RES A, V74A, P23, DOI 10.1002/jbm.a.30221
   Mabry KM, 2015, BIOMATERIALS, V49, P47, DOI 10.1016/j.biomaterials.2015.01.047
   Merryman WD, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886 013 0355 5
   Mohler ER, 1999, J HEART VALVE DIS, V8, P254
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Monzack EL, 2011, J HEART VALVE DIS, V20, P449
   Moursi AM, 1997, J CELL SCI, V110, P2187
   Mrksich M, 1996, ANNU REV BIOPH BIOM, V25, P55, DOI 10.1146/annurev.bb.25.060196.000415
   Mrksich M, 2009, ACTA BIOMATER, V5, P832, DOI 10.1016/j.actbio.2009.01.016
   Nkomo VT, 2006, LANCET, V368, P1005, DOI 10.1016/S0140 6736(06)69208 8
   Novaro GM, 2003, CLEV CLIN J MED, V70, P471, DOI 10.3949/ccjm.70.5.471
   Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Rodriguez KJ, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471 2261 14 29
   Rodriguez KJ, 2009, J BIOMED MATER RES A, V90A, P1043, DOI 10.1002/jbm.a.32187
   Sabatier L, 2009, MOL BIOL CELL, V20, P846, DOI 10.1091/mbc.E08 08 0830
   Schoen FJ, 2005, ANN THORAC SURG, V79, P1072, DOI 10.1016/j.athoracsur.2004.06.033
   Schroeder JA, 2003, J MOL MED JMM, V81, P392, DOI 10.1007/s00109 003 0456 5
   Silin V, 1997, J COLLOID INTERF SCI, V185, P94, DOI 10.1006/jcis.1996.4586
   Thomas CH, 1997, J BIOMED MATER RES, V37, P81, DOI 10.1002/(SICI)1097 4636(199710)37:1<81::AID JBM10>3.0.CO;2 T
   Wang HE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048307
   Wirrig EE, 2011, J MOL CELL CARDIOL, V50, P561, DOI 10.1016/j.yjmcc.2010.12.005
   Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200
   Yip CYY, 2009, ARTERIOSCL THROM VAS, V29, P936, DOI 10.1161/ATVBAHA.108.182394
   Zheng XY, 2006, BIOTECHNOL PROGR, V22, P1294, DOI 10.1021/bp060121o
NR 59
TC 10
Z9 15
U1 0
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2015
VL 28
BP 76
EP 85
DI 10.1016/j.actbio.2015.09.031
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA CY0AS
UT WOS:000366069000008
PM 26428193
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Soares, IPM
   Anselmi, C
   Kitagawa, FA
   Ribeiro, RAD
   Leite, ML
   Costa, CAD
   Hebling, J
AF Soares, Igor Paulino Mendes
   Anselmi, Caroline
   Kitagawa, Fernanda Ali
   Ribeiro, Rafael Antonio de Oliveira
   Leite, Maria Luisa
   Costa, Carlos Alberto de Souza
   Hebling, Josimeri
TI Nano hydroxyapatite incorporated polycaprolactone nanofibrous scaffold
   as a dentin tissue engineering based strategy for vital pulp therapy
SO DENTAL MATERIALS
LA English
DT Article
DE Tissue engineering; Pulp capping agents; Scaffold; Nanofiber;
   Calcium phosphate ceramics; Hydroxyapatites; Cell homing therapy
ID MINERAL TRIOXIDE AGGREGATE; PROMOTE OSTEOGENIC DIFFERENTIATION;
   MESENCHYMAL STEM CELLS; IN VITRO; ODONTOGENIC DIFFERENTIATION;
   OSTEOBLAST DIFFERENTIATION; PROTEIN ADSORPTION; CALCIUM HYDROXIDE;
   PARTICLES; PROLIFERATION
AB Objectives: Targeting a tissue engineering based vital pulp therapy (VPT), this study investigated the incorporation of nano hydroxyapatite (nHA) into polycaprolactone (PCL) nanofibers, and the metabolism of human dental pulp cells (HDPCs) seeded on the scaffolds.Methods: PCL based solutions (10% w/v) containing nHA (0   control; 0.5; 1.0; or 2.0% w/v) were electrospun into nanofibrous scaffolds. The scaffolds were characterized for morphology and composition (MEV/EDS), solubility, the release of calcium/phosphate (C/P), and modulation of medium pH. Then, HDPCs were seeded on the scaffolds and evaluated for cell viability (alamarBlue and live/dead), adhesion and spreading (F actin), total protein (TP; Lowry), alkaline phosphatase activity (ALP; thymolphthalein assay), expression of odontogenic genes (RT qPCR), and formation of a mineralized matrix (Alizarin Red). Data were analyzed with ANOVA and post hocs (alpha = 5%).Results: Higher nHA concentrations roughened fiber surfaces, whereas PCL+ 2%nHA increased the interfibrillar spaces. PCL+ 1%nHA or PCL+ 2%nHA significantly released more C/P but the medium pH was maintained below 8.0. HDPCs viability was not affected by nHA, while cell adhesion/spreading was favored, especially for PCL+ 2%nHA. Higher protein content and ALP activity were seen for scaffolds incorporated with nHA, after 21 days. PCL+ 1%nHA and PCL+ 2%nHA upregulated the expression of DSPP and DMP1 in 14 days, and COL1A1, ALPL, and DMP1 in 21 days. The formation of a mineralized matrix was nHA concentration dependent, and it was about 9 x higher for PCL+ 2%nHA. Significance: nHA incorporated PCL nanofibrous scaffolds are cytocompatible and can stimulate the adhesion and odontogenic potential of HDPCs. PCL+ 2%nHA formulation is a bioactive tissue engineering based cell homing strategy for VPT.(c) 2022 The Academy of Dental Materials. Published by Elsevier Inc. All rights reserved.
C1 [Soares, Igor Paulino Mendes; Kitagawa, Fernanda Ali; Ribeiro, Rafael Antonio de Oliveira] Sao Paulo State Univ UNESP, Sch Dent, Dept Dent Mat & Prosthodont, Araraquara, Brazil.
   [Anselmi, Caroline; Hebling, Josimeri] Sao Paulo State Univ UNESP, Sch Dent, Dept Genet Morphol Orthodont & Pediat Dent, Araraquara, Brazil.
   [Leite, Maria Luisa] Univ British Columbia, Fac Dent, Dept Oral Hlth Sci, Vancouver, BC, Canada.
   [Costa, Carlos Alberto de Souza] Sao Paulo State Univ UNESP, Sch Dent, Dept Physiol & Pathol, Araraquara, Brazil.
   [Hebling, Josimeri] Sao Paulo State Univ UNESP, Sch Dent, Dept Genet Morphol Orthodont & Pediat Dent, Rua Humaita 1680, BR 14801903 Araraquara, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista;
   University of British Columbia; Universidade Estadual Paulista;
   Universidade Estadual Paulista
RP Hebling, J (通讯作者)，Sao Paulo State Univ UNESP, Sch Dent, Dept Genet Morphol Orthodont & Pediat Dent, Rua Humaita 1680, BR 14801903 Araraquara, SP, Brazil.
EM igor.soares@unesp.br; josimeri.hebling@unesp.br
RI ; Anselmi, Caroline/MYS 6563 2025; Hebling, Josimeri/C 7738 2012; Leite,
   Maria/F 5195 2017; Ribeiro, Rafael/KFS 7613 2024; de Alencar e Silva
   Leite, Maria Luisa/F 5195 2017; Mendes Soares, Igor/AAC 6917 2021
OI Ribeiro, Rafael/0000 0001 8100 3294; Mendes Soares, Igor
   Paulino/0000 0002 5748 5040; Anselmi, Caroline/0000 0002 3189 1542; de
   Alencar e Silva Leite, Maria Luisa/0000 0001 6650 3637; 
FU Sao Paulo Research Foundation (FAPESP) [2019/07400 0, 2019/16473 1];
   Brazilian Council for Scientific and Technological Development (CNPq)
   [303391/2019 7]; Brazilian Coordination for the Improvement of Higher
   Education Personnel (CAPES) [001]
FX The authors acknowledge the valuable financial support provided by the
   Sao Paulo Research Foundation (FAPESP; grants 2019/07400 0 and
   2019/16473 1) and the Brazilian Council for Scientific and Technological
   Development (CNPq; grant 303391/2019 7) . This study was also partially
   financed by the Brazilian Coordination for the Improvement of Higher
   Education Personnel (CAPES)  Finance Code 001.
CR Akpinar G, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/457059
   An SF, 2012, J MATER SCI MATER M, V23, P789, DOI 10.1007/s10856 011 4531 0
   Chuenjitkuntaworn B, 2016, J BIOMED MATER RES A, V104, P264, DOI 10.1002/jbm.a.35558
   Cushley S, 2021, INT ENDOD J, V54, P556, DOI 10.1111/iej.13449
   Costa CAD, 2008, AM J DENT, V21, P255
   Deligianni DD, 2001, BIOMATERIALS, V22, P87, DOI 10.1016/S0142 9612(00)00174 5
   Diana R, 2020, REGEN THER, V15, P243, DOI 10.1016/j.reth.2020.09.007
   Dwivedi Ruby, 2020, J Oral Biol Craniofac Res, V10, P381, DOI 10.1016/j.jobcr.2019.10.003
   Galler KM, 2014, J ENDODONT, V40, pS41, DOI 10.1016/j.joen.2014.01.014
   Gittings JP, 2009, ACTA BIOMATER, V5, P743, DOI 10.1016/j.actbio.2008.08.012
   Gopinath VK, 2021, DENT MATER J, V40, P312, DOI 10.4012/dmj.2020 005
   Guarino V, 2009, TISSUE ENG PT A, V15, P3655, DOI 10.1089/ten.TEA.2008.0543
   Gupte MJ, 2012, J DENT RES, V91, P227, DOI 10.1177/0022034511417441
   Gustavsson J, 2011, ACTA BIOMATER, V7, P4242, DOI 10.1016/j.actbio.2011.07.016
   Hanna SN, 2020, EUR ENDOD J, V5, P46, DOI 10.14744/eej.2019.44154
   Hassan MI, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205 017 0889 0
   Hilkens P, 2013, CELL TISSUE RES, V353, P65, DOI 10.1007/s00441 013 1630 x
   Hokmabad V, 2018, TISSUE ENG REGEN MED, V15, P735, DOI 10.1007/s13770 018 0140 z
   Jazayeri HE, 2020, DENT MATER, V36, pE47, DOI 10.1016/j.dental.2019.11.005
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Jung GY, 2010, J MATER SCI MATER M, V21, P1649, DOI 10.1007/s10856 010 4011 y
   Khoshniat S, 2011, BONE, V48, P894, DOI 10.1016/j.bone.2010.12.002
   Kim GH, 2015, J BIOMATER APPL, V29, P854, DOI 10.1177/0885328214546884
   Kim JJ, 2014, J BIOMATER APPL, V28, P1069, DOI 10.1177/0885328213495903
   KLEIN CPAT, 1990, BIOMATERIALS, V11, P509, DOI 10.1016/0142 9612(90)90067 Z
   Komabayashi T, 2016, DENT MATER J, V35, P1, DOI 10.4012/dmj.2015 013
   Kostopoulos V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020583
   Lee JH, 2010, MACROMOL BIOSCI, V10, P173, DOI 10.1002/mabi.200900169
   Lee KW, 2008, BIOMATERIALS, V29, P2839, DOI 10.1016/j.biomaterials.2008.03.030
   Lee LW, 2015, J ENDODONT, V41, P628, DOI 10.1016/j.joen.2015.01.007
   Lee W, 2012, ACTA BIOMATER, V8, P2986, DOI 10.1016/j.actbio.2012.04.032
   Leite ML, 2021, J BIOMED MATER RES B, V109, P1244, DOI 10.1002/jbm.b.34785
   Li N, 2019, DENT MATER J, V38, P534, DOI 10.4012/dmj.2018 155
   Li ZF, 2015, J ENDODONT, V41, P1412, DOI 10.1016/j.joen.2015.04.012
   Liang W, 2021, DRUG DES DEV THER, V15, P905, DOI 10.2147/DDDT.S299641
   Liu YK, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/2/025004
   Soares IPM, 2021, DENT MATER, V37, pE329, DOI 10.1016/j.dental.2021.01.014
   Mohamadyar Toupkanlou F, 2015, CELL MOL BIOL, V61, P1
   Mohamed DA, 2018, TANTA DENT J, V15, P91, DOI [10.4103/tdj.tdj, DOI 10.4103/TDJ.TDJ]
   Mondal D, 2016, INT J POLYM MATER PO, V65, P255, DOI 10.1080/00914037.2015.1103241
   Moussa DG, 2019, J TISSUE ENG REGEN M, V13, P58, DOI 10.1002/term.2769
   Müller P, 2008, J CELL MOL MED, V12, P281, DOI 10.1111/j.1582 4934.2007.00103.x
   Rodrigues EM, 2017, INT ENDOD J, V50, P780, DOI 10.1111/iej.12683
   Rouahi M, 2006, COLLOID SURFACE B, V47, P10, DOI 10.1016/j.colsurfb.2005.11.015
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Samavedi S, 2013, ACTA BIOMATER, V9, P8037, DOI 10.1016/j.actbio.2013.06.014
   SCHRODER U, 1985, J DENT RES, V64, P541, DOI 10.1177/002203458506400407
   Shitole AA, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6255 5
   Siddiqui N, 2018, MOL BIOTECHNOL, V60, P506, DOI 10.1007/s12033 018 0084 5
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Soares DG, 2021, CLIN ORAL INVEST, V25, P4749, DOI 10.1007/s00784 021 04013 4
   Soares DG, 2020, J BIOMED MATER RES B, V108, P2546, DOI 10.1002/jbm.b.34586
   Sunandhakumari Vishnu Jayakumar, 2018, Bioengineering Basel, V5, P54, DOI 10.3390/bioengineering5030054
   Suzuki S, 2012, ARCH ORAL BIOL, V57, P1165, DOI 10.1016/j.archoralbio.2012.03.005
   Turrioni AP, 2021, BRAZ ORAL RES, V35, DOI 10.1590/1807 3107bor 2021.vol35.0128
   Tuukkanen J, 2017, CURR PHARM DESIGN, V23, P3786, DOI [10.2174/1381612823666170615105454, 10.2174/1381612823666170609084016]
   Valizadeh A, 2014, IET NANOBIOTECHNOL, V8, P83, DOI 10.1049/iet nbt.2012.0040
   Wang J, 2011, BIOMATERIALS, V32, P7822, DOI 10.1016/j.biomaterials.2011.04.034
   Wang RX, 2019, J BIOMED NANOTECHNOL, V15, P405, DOI 10.1166/jbn.2019.2677
   Wiesmann HP, 2005, INT REV CYTOL, V242, P121
   Woo KM, 2003, MATER RES SOC SYMP P, V735, P69
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Wutticharoenmongkol P, 2006, J NANOSCI NANOTECHNO, V6, P514, DOI 10.1166/jnn.2006.090
   Wutticharoenmongkol P, 2007, BIOMACROMOLECULES, V8, P2602, DOI 10.1021/bm700451p
   Yang XC, 2010, J BIOMED MATER RES A, V93A, P247, DOI 10.1002/jbm.a.32535
   Yoshida S, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9070160
NR 66
TC 25
Z9 26
U1 1
U2 19
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0109 5641
EI 1879 0097
J9 DENT MATER
JI Dent. Mater.
PD JUN
PY 2022
VL 38
IS 6
BP 960
EP 977
DI 10.1016/j.dental.2022.03.006
EA MAY 2022
PG 18
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 1W4HB
UT WOS:000806735000005
PM 35331551
DA 2025 08 17
ER

PT J
AU Fujiwara, T
   Fukushi, J
   Yamamoto, S
   Matsumoto, Y
   Setsu, N
   Oda, Y
   Yamada, H
   Okada, S
   Watari, K
   Ono, M
   Kuwano, M
   Kamura, S
   Iida, K
   Okada, Y
   Koga, M
   Iwamoto, Y
AF Fujiwara, Toshifumi
   Fukushi, Jun ichi
   Yamamoto, Shunsaku
   Matsumoto, Yoshihiro
   Setsu, Nokitaka
   Oda, Yoshinao
   Yamada, Hisakata
   Okada, Seiji
   Watari, Kosuke
   Ono, Mayumi
   Kuwano, Michihiko
   Kamura, Satoshi
   Iida, Keiichiro
   Okada, Yuko
   Koga, Mihoko
   Iwamoto, Yukihide
TI Macrophage Infiltration Predicts a Poor Prognosis for Human Ewing
   Sarcoma
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID TUMOR ASSOCIATED MACROPHAGES; MONOCYTE CHEMOATTRACTANT PROTEIN 1;
   BREAST CANCER METASTASIS; GROWTH FACTOR; POSSIBLE INVOLVEMENT;
   OSTEOCLAST FORMATION; CELL INFILTRATION; IN VITRO; ANGIOGENESIS;
   EXPRESSION
AB Ewing sarcoma primitive neuroectodermal tumor (EWS) is associated with the most unfavorable prognosis of all primary musculoskeletal tumors. The objective of the present study was to investigate whether tumor associated macrophages (TAMs) affect the development of EWS. TAMs were isolated from mouse xenografts using CD11b magnetic beads and examined for their cytokine expression and osteoclastic differentiation. To evaluate the role of TAMs in xenograft formation, liposome encapsulated clodronate was used to deplete TAMs in mice. Macrophage infiltration and tumor microvascular density were histologically evaluated in 41 patients with EWS, and association with prognosis was examined using Kaplan Meier survival analysis. In mouse EWS xenografts, TAMs expressed higher concentrations of cytokines including interleukin 6, keratinocyte derived chemokine, and monocyte chemotactic protein 1. TAMs were more capable than normal monocytes of differentiating into tartrate resistant acid phosphatase positive giant cells. Depleting macrophages using liposome encapsulated clodronate significantly inhibited development of EWS xenografts. In human EWS samples, higher levels of CD68 positive macrophages were associated with poorer overall survival. In addition, enhanced vascularity, increase in the amount of C reactive protein, and higher white blood cell counts were also associated with poor prognosis and macrophage infiltration. TAMs seem to enhance the progression of EWS by stimulating both angiogenesis and osteoclastogenesis. Further investigation of the behavior of TAMs may lead to development of biologically targeted therapies for EWS. (Am J Pathol 2011, 170:1157 1170; 10.1016/j.ajpath.2011.05.034)
C1 [Fujiwara, Toshifumi; Fukushi, Jun ichi; Yamamoto, Shunsaku; Matsumoto, Yoshihiro; Kamura, Satoshi; Iida, Keiichiro; Okada, Yuko; Koga, Mihoko; Iwamoto, Yukihide] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan.
   [Setsu, Nokitaka; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan.
   [Okada, Seiji] Kyushu Univ, Grad Sch Med Sci, Adv Med Initiat, Fukuoka 8128582, Japan.
   [Yamada, Hisakata] Kyushu Univ, Grad Sch Med Sci, Div Host Def, Fukuoka 8128582, Japan.
   [Watari, Kosuke; Ono, Mayumi] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut Oncol, Fukuoka 8128582, Japan.
   [Kuwano, Michihiko] Kyushu Univ, Grad Sch Pharmaceut Sci, Lab Mol Canc Biol, Dept Pharmaceut, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Kyushu
   University; Kyushu University; Kyushu University
RP Fukushi, J (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Maidashi 3 1 1, Fukuoka 8128582, Japan.
EM fukushi@med.kyushu u.ac.jp
RI Fukushi, Jun ichi/KLC 0550 2024
OI Watari, Kosuke/0000 0003 0260 2323; Okada, Seiji/0000 0002 5107 8209
FU Japan Society for the Promotion of Science [19390397]; Ministry of
   Health, Labour and Welfare of Japan; Grants in Aid for Scientific
   Research [23123516, 19390397, 23650327, 22390292, 23300350] Funding
   Source: KAKEN
FX Supported by a Grant in Aid for Scientific Research (No. 19390397) from
   the Japan Society for the Promotion of Science and a Grant in Aid for
   Clinical Research Evidence Based Medicine and Cancer Research from the
   Ministry of Health, Labour and Welfare of Japan (both to Y.I.).
CR Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600 065X.2008.00607.x
   López Guerrero JA, 2011, INT J CANCER, V128, P1139, DOI 10.1002/ijc.25424
   Avnet S, 2008, INT J ONCOL, V33, P1231, DOI 10.3892/ijo_00000113
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Bacci G, 2006, ACTA ONCOL, V45, P469, DOI 10.1080/02841860500519760
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140 6736(00)04046 0
   Barillé Nion S, 2003, LEUKEMIA LYMPHOMA, V44, P1463, DOI 10.1080/1042819031000082966
   Berghuis D, 2011, J PATHOL, V223, P347, DOI 10.1002/path.2819
   Berghuis D, 2009, J PATHOL, V218, P222, DOI 10.1002/path.2537
   Bishop E T, 1999, Angiogenesis, V3, P335, DOI 10.1023/A:1026546219962
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Clahsen T, 2008, J LEUKOCYTE BIOL, V84, P1521, DOI 10.1189/jlb.0308178
   Cortés Funes H, 2009, CLIN TRANSL ONCOL, V11, P349, DOI 10.1007/s12094 009 0368 0
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DAVIDSON SE, 1992, INT J CANCER, V50, P10, DOI 10.1002/ijc.2910500104
   de Visser KE, 2008, CANCER IMMUNOL IMMUN, V57, P1531, DOI 10.1007/s00262 008 0501 x
   El Tanani MK, 2008, FRONT BIOSCI, V13, P4276, DOI 10.2741/3004
   Fuchs B, 2004, CLIN CANCER RES, V10, P1344, DOI 10.1158/1078 0432.CCR 03 0038
   Fujimoto J, 2000, CANCER RES, V60, P2632
   Furuichi K, 2008, J IMMUNOL, V181, P8670, DOI 10.4049/jimmunol.181.12.8670
   FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006 291X(89)92430 3
   Futagami S, 2008, J GASTROENTEROL, V43, P216, DOI 10.1007/s00535 007 2151 8
   Goto Takahiro, 2004, Gan To Kagaku Ryoho, V31, P346
   Guan H, 2005, CLIN CANCER RES, V11, P2662, DOI 10.1158/1078 0432.CCR 04 1206
   Guan H, 2009, ONCOL RES, V18, P117, DOI 10.3727/096504009789954627
   Hanada T, 2000, INT J UROL, V7, P263, DOI 10.1046/j.1442 2042.2000.00190.x
   Hiraoka K, 2008, CANCER SCI, V99, P1595, DOI 10.1111/j.1349 7006.2008.00880.x
   Holzer G, 2001, MED PEDIATR ONCOL, V36, P601, DOI 10.1002/mpo.1136
   Huang H, 2010, CANCER SCI, V101, P1314, DOI 10.1111/j.1349 7006.2010.01524.x
   Ishida N, 2006, J BONE MINER RES, V21, P48, DOI 10.1359/JBMR.051001
   Iwamoto Y, 2007, JPN J CLIN ONCOL, V37, P79, DOI 10.1093/jjco/hyl142
   Jin G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010993
   Kamura S, 2010, BRIT J CANCER, V103, P370, DOI 10.1038/sj.bjc.6605775
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200
   Kleer CG, 2008, CLIN CANCER RES, V14, P5357, DOI 10.1158/1078 0432.CCR 08 0732
   Kuroda T, 2005, CLIN CANCER RES, V11, P7629, DOI 10.1158/1078 0432.CCR 05 0798
   Lau YS, 2007, BRIT J CANCER, V96, P1716, DOI 10.1038/sj.bjc.6603774
   Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096 9896(200003)190:4<430::AID PATH538>3.0.CO;2 6
   Leek RD, 1996, CANCER RES, V56, P4625
   Maheshwari AV, 2010, J AM ACAD ORTHOP SUR, V18, P94, DOI 10.5435/00124635 201002000 00004
   MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167 5699(92)90008 U
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Matsumoto Y, 2002, J IMMUNOL, V168, P5824, DOI 10.4049/jimmunol.168.11.5824
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Mikulic D, 2006, J PEDIATR SURG, V41, P524, DOI 10.1016/j.jpedsurg.2005.11.058
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Nagano A, 2010, INT J CANCER, V126, P2790, DOI 10.1002/ijc.24781
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Nishie A, 1999, CLIN CANCER RES, V5, P1107
   Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676
   Onan D, 2009, ENDOCRINOLOGY, V150, P2244, DOI 10.1210/en.2008 1597
   Ono M, 2008, CANCER SCI, V99, P1501, DOI 10.1111/j.1349 7006.2008.00853.x
   Pardali E, 2011, ONCOGENE, V30, P334, DOI 10.1038/onc.2010.418
   Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045
   Polverini P J, 1997, EXS, V79, P11
   Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008 5472.CAN 05 1734
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   de Hooge ASK, 2007, CLIN CANCER RES, V13, P206, DOI 10.1158/1078 0432.CCR 06 1457
   Shimura S, 2000, CANCER RES, V60, P5857
   Silzle T, 2004, INT J CANCER, V108, P173, DOI 10.1002/ijc.11542
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163 7258(91)90077 Y
   Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097 0215(20000115)85:2<182::AID IJC6>3.3.CO;2 D
   Tow B P B, 2005, J Orthop Surg (Hong Kong), V13, P88
   Ueno T, 2000, CLIN CANCER RES, V6, P3282
   van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008 5472.CAN 05 2468
   van Dongen M, 2010, INT J CANCER, V127, P899, DOI 10.1002/ijc.25113
   Verhoeven DHJ, 2008, MOL IMMUNOL, V45, P3917, DOI 10.1016/j.molimm.2008.06.016
   Watari K, 2008, BIOCHEM BIOPH RES CO, V377, P826, DOI 10.1016/j.bbrc.2008.10.077
   Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103
NR 73
TC 123
Z9 131
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD SEP
PY 2011
VL 179
IS 3
BP 1157
EP 1170
DI 10.1016/j.ajpath.2011.05.034
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 865JN
UT WOS:000298307300011
PM 21771572
OA Green Published
DA 2025 08 17
ER

PT J
AU Guo, X
   You, MY
   Zhang, L
   Yuan, GY
   Pei, J
AF Guo, Xin
   You, Mingyu
   Zhang, Lei
   Yuan, Guangyin
   Pei, Jia
TI Enhanced Adsorption Stability and Biofunction Durability with
   Phosphonate Grafted, PEGylated Copolymer on Hydroxyapatite Surface
SO LANGMUIR
LA English
DT Article
ID POLYMER
AB Nonfouling surfaces are crucial in applications such as biosensors, medical implants, marine coatings, and drug delivery vehicles. However, their long term coating stability and robust surface binding strength in physiological media remain challenging. Herein, a phosphonate grafted, PEGylated copolymer on the hydroxyapatite (HA) surface is proposed to significantly improve the adsorption stability and thus enhance the biofunction durability accordingly. The phosphoryl ( PO3) grafted branch is employed in the functional polymer to facilitate attaching to the HA substrate. In addition, the polymer integrates the nonfouling polymer brushes of poly(ethylene glycol) (PEG) with the cell adhesive moiety of cyclic Arg Gly Asp d Phe Cys peptides (cRGD). A systematic study on the as synthesized PEGylated graft copolymer indicates a synergistic binding mechanism of the NH2 and PO3 groups to HA, achieving a high surface coverage with desirable adsorption stability. The cRGD/PEGylated copolymers of optimized grafting architecture are proven to effectively adsorb to HA surfaces as a self assembled copolymer monolayer, showing stability with minimal desorption even in a complex, physiological medium and effectively preventing nonspecific protein adsorption as examined with X ray photoelectron spectroscopy (XPS) and a quartz crystal microbalance with dissipation (QCM D). Direct adhesion assays further confirm that the enhanced coating stability and biofunction durability of the phosphonate grafted, cRGD PEGylated copolymer can considerably promote osteoblast attachment on HA surfaces, meanwhile preventing microbial adhesion. This research has resulted in a solution of self assembly polymer structure optimization that exhibits stable nonfouling characteristics.
C1 [Guo, Xin; You, Mingyu; Zhang, Lei; Yuan, Guangyin; Pei, Jia] Shanghai Jiao Tong Univ, Natl Engn Res Ctr Light Alloy Net Forming, Sch Mat Sci & Engn, Shanghai 200240, Peoples R China.
   [Guo, Xin; You, Mingyu; Zhang, Lei; Yuan, Guangyin; Pei, Jia] Shanghai Jiao Tong Univ, Sch Mat Sci & Engn, State Key Lab Met Matrix Composite, Shanghai 200240, Peoples R China.
   [Pei, Jia] Shanghai Jiao Tong Univ, Natl Engn Res Ctr Adv Magnet Resonance Technol Dia, Shanghai 200240, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Pei, J (通讯作者)，Shanghai Jiao Tong Univ, Natl Engn Res Ctr Light Alloy Net Forming, Sch Mat Sci & Engn, Shanghai 200240, Peoples R China.; Pei, J (通讯作者)，Shanghai Jiao Tong Univ, Sch Mat Sci & Engn, State Key Lab Met Matrix Composite, Shanghai 200240, Peoples R China.; Pei, J (通讯作者)，Shanghai Jiao Tong Univ, Natl Engn Res Ctr Adv Magnet Resonance Technol Dia, Shanghai 200240, Peoples R China.
EM jpei@sjtu.edu.cn
RI GUO, xin/AAN 7366 2020; You, Mingyu/IYS 1568 2023
FU National Natural Science Foundation of China [2021YFE0204900]; National
   Key Research and Development Program of China [52222108, 51971141];
   National Natural Science Foundation of China [EG 18 122016]; SSSTC
   international cooperation project
FX This work was financially supported by the National Key Research and
   Development Program of China (2021YFE0204900), the National Natural
   Science Foundation of China (Grant No. 52222108, 51971141), and SSSTC
   international cooperation project (EG 18 122016). The authors would like
   to express their gratitude to Yi Yao and Yaqiong Zhang from Shanghai
   University for their valuable technical assistance in QCM D
   measurements.
CR Albu AM, 2019, MAT SCI ENG C MATER, V98, P461, DOI 10.1016/j.msec.2019.01.014
   Ali AAH., 2023, J. Trace Elem. Med. Biol, V4, P100076, DOI [DOI 10.1016/J.JTEMIN.2023.100076, 10.1016/j.jtemin.2023.100076]
   Alt M, 2016, ADV FUNCT MATER, V26, P3172, DOI 10.1002/adfm.201505386
   Bauer KN, 2017, PROG POLYM SCI, V73, P61, DOI 10.1016/j.progpolymsci.2017.05.004
   Boozer C, 2003, SENSOR ACTUAT B CHEM, V90, P22, DOI 10.1016/S0925 4005(03)00017 0
   Chen HM, 2023, J MOL LIQ, V389, DOI 10.1016/j.molliq.2023.122885
   Chen SF, 2010, POLYMER, V51, P5283, DOI 10.1016/j.polymer.2010.08.022
   Chiatti F, 2012, J PHYS CHEM C, V116, P6108, DOI 10.1021/jp212595d
   Cui LS, 2023, ACS APPL MATER INTER, V15, P20625, DOI 10.1021/acsami.2c22947
   Devillers S, 2009, J ELECTROCHEM SOC, V156, pP177, DOI 10.1149/1.3236479
   Gillich T, 2011, J AM CHEM SOC, V133, P10940, DOI 10.1021/ja202760x
   Hanson EL, 2003, J AM CHEM SOC, V125, P16074, DOI 10.1021/ja035956z
   Hao XH, 2015, ACS NANO, V9, P9614, DOI 10.1021/nn507485j
   Keikhosravani P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179214
   Kenausis GL, 2000, J PHYS CHEM B, V104, P3298, DOI 10.1021/jp993359m
   Lewis AL, 2000, COLLOID SURFACE B, V18, P261, DOI 10.1016/S0927 7765(99)00152 6
   Liang HJ, 2023, SMALL, V19, DOI 10.1002/smll.202207195
   Mashak A, 2022, B MATER SCI, V45, DOI 10.1007/s12034 022 02758 6
   Müller WEG, 2019, CHEM REV, V119, P12337, DOI 10.1021/acs.chemrev.9b00460
   Qi C, 2019, CHEM SOC REV, V48, P2698, DOI 10.1039/c8cs00489g
   Raina DB, 2020, ACTA ORTHOP, V91, P126, DOI 10.1080/17453674.2019.1686865
   RATNER BD, 1993, J BIOMED MATER RES, V27, P283, DOI 10.1002/jbm.820270302
   Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027
   Salloum DS, 2004, BIOMACROMOLECULES, V5, P1089, DOI 10.1021/bm034522t
   Serrano A, 2016, MACROMOL RAPID COMM, V37, P622, DOI 10.1002/marc.201500683
   Serrano A, 2013, ADV FUNCT MATER, V23, P5706, DOI 10.1002/adfm.201203470
   Smith RS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004120
   Szczes A, 2017, ADV COLLOID INTERFAC, V249, P321, DOI 10.1016/j.cis.2017.04.007
   Vonhören B, 2015, LANGMUIR, V31, P13625, DOI 10.1021/acs.langmuir.5b03924
   Wisniewski N, 2000, COLLOID SURFACE B, V18, P197, DOI 10.1016/S0927 7765(99)00148 4
   Xu JL, 2011, WOODHEAD PUBL MATER, P99
   You MY, 2022, APPL SURF SCI, V606, DOI 10.1016/j.apsusc.2022.154836
   You MY, 2021, MAT SCI ENG C MATER, V120, DOI 10.1016/j.msec.2020.111734
   Zeng Q, 2018, BIOMACROMOLECULES, V19, P2805, DOI 10.1021/acs.biomac.8b00399
NR 34
TC 0
Z9 0
U1 4
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743 7463
EI 1520 5827
J9 LANGMUIR
JI Langmuir
PD JAN 31
PY 2024
VL 40
IS 6
BP 3190
EP 3201
DI 10.1021/acs.langmuir.3c03659
EA JAN 2024
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA HP2C4
UT WOS:001158970700001
PM 38294184
DA 2025 08 17
ER

PT J
AU Xiong, LF
   Dai, BW
   Yin, BD
   Yie, KHR
   Sun, HB
   Liu, Y
   Liu, ZY
   Mahany, AS
   Cheng, H
   Xu, LH
   Gao, P
   Lu, L
   Liu, JS
AF Xiong, Lifeng
   Dai, Binwei
   Yin, Baodi
   Yie, Kendrick Hii Ru
   Sun, Haobo
   Liu, Yang
   Liu, Zheyuan
   Mahany, Ahmed S.
   Cheng, Huan
   Xu, Lihua
   Gao, Peng
   Lu, Lei
   Liu, Jinsong
TI Enhancing osseointegration and angiogenesis of Titanium implants through
   KMnO4 Modified Montmorillonite nano clay coating
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Titanium; Micro arc oxidation; Montmorillonite; Manganese; Angiogenesis;
   Osteogenesis
ID MICRO ARC OXIDATION; FORMATION MECHANISM
AB Titanium (Ti) is a widely used and favored material for dental implants, with research efforts focusing on enhancing its osseointegration capabilities. Montmorillonite (MMT), a nano clay, has shown significant potential in drug delivery, wound healing, and other biomedical applications. Implant coatings based on MMT have demonstrated promising results; however, challenges remain in terms of surface bond strength, stability, and uniformity. Studies have indicated that manganese (Mn) can enhance cell viability, proliferation, and adhesion by activating integrin receptors. Here, a KMnO4 modified MMT (MAO MMT Mn) coating was developed on Ti through the micro arc oxidation (MAO) technique. The MAO MMT Mn coating significantly strengthens its bond, enabling it to withstand greater loads. The incorporation of Mn, silicon (Si) and phosphorus (P) resulted in the formation of uniformly distributed lamellar MMT, facilitating the sustained release of these elements. In vitro experiments demonstrated that the MAO MMT Mn coating promoted osteoblast adhesion and endothelial cell migration, and led to a significant increase in the expression of osteogenic and angiogenic genes compared to uncoated Ti. Moreover, in vivo assessments using micro CT scans and histological staining revealed improved local osseointegration and angiogenesis after 4 weeks of implantation. In conclusion, the MAO MMT Mn coating offers a safe, simple, and cost effective method to enhance the surfaces of Ti implants, thereby potentially enhancing the clinical outcomes of dental implant procedures.
C1 [Xiong, Lifeng; Dai, Binwei; Yin, Baodi; Yie, Kendrick Hii Ru; Sun, Haobo; Liu, Yang; Liu, Zheyuan; Mahany, Ahmed S.; Cheng, Huan; Gao, Peng; Lu, Lei; Liu, Jinsong] Wenzhou Med Univ, Sch & Hosp Stomatol, Wenzhou 325027, Zhejiang, Peoples R China.
   [Xu, Lihua] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gen Med, Wenzhou 325000, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Gao, P; Lu, L; Liu, JS (通讯作者)，Wenzhou Med Univ, Sch & Hosp Stomatol, Wenzhou 325027, Zhejiang, Peoples R China.
EM penggaocake@foxmail.com; llu2@foxmail.com; jinsong0719@wmu.edu.cn
RI liu, zheyuan/GZL 9719 2022; Hobo, Sun/GYJ 4954 2022; Xu,
   Lihua/P 8054 2019; Gao, Peng/F 7848 2018
FU National Natural Science Foundation of China [82071170, 82371016,
   82301156]; Zhe jiang Provincial Natural Science Foundation of China
   [LTGY23H140001]; Fundamental Research Funds for Wenzhou Medical
   University [KYYW202208]; Wenzhou Public Welfare Science and Technology
   Project [Y20210114]
FX This work was supported by the National Natural Science Foundation of
   China (No. 82071170, No. 82371016, and No. 82301156) , the Zhe jiang
   Provincial Natural Science Foundation of China (No. LTGY23H140001) , and
   the Fundamental Research Funds for Wenzhou Medical University
   (KYYW202208) , Wenzhou Public Welfare Science and Technology Project
   (Y20210114) .
CR Abbasi S, 2013, MAT SCI ENG C MATER, V33, P2555, DOI 10.1016/j.msec.2013.02.018
   Abhinand CS, 2023, J CELL COMMUN SIGNAL, V17, P1067, DOI 10.1007/s12079 023 00736 z
   Aguzzi C, 2007, APPL CLAY SCI, V36, P22, DOI 10.1016/j.clay.2006.06.015
   Anirudhan TS, 2011, NEW J CHEM, V35, P2869, DOI 10.1039/c1nj20672a
   Bae JH, 2006, NEUROSCI LETT, V398, P151, DOI 10.1016/j.neulet.2005.12.067
   Carretero M.I., 2013, Developments in Clay Science, V5, P711, DOI [DOI 10.1016/B978 0 08 098259 5.00025 1, 10.1016/B978 0 08 098259 5.00025 1]
   Chang EI, 2007, CIRCULATION, V116, P2818, DOI 10.1161/CIRCULATIONAHA.107.715847
   Chung YL, 2010, CARBOHYD POLYM, V79, P391, DOI 10.1016/j.carbpol.2009.08.021
   Tardelli JDC, 2021, J PROSTHET DENT, V125, P421, DOI 10.1016/j.prosdent.2020.02.001
   da Silva LM, 2020, MATER RES IBERO AM J, V23, DOI [10.1590/1980 5373 MR 2020 0083, 10.1590/1980 5373 mr 2020 0083]
   Demir AK, 2018, MAT SCI ENG C MATER, V89, P8, DOI 10.1016/j.msec.2018.03.021
   Eren E, 2008, DYES PIGMENTS, V76, P220, DOI 10.1016/j.dyepig.2006.08.019
   Fan LJ, 2022, J MATER SCI TECHNOL, V111, P167, DOI 10.1016/j.jmst.2021.08.089
   Feng Y, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 40794 w
   Fu X, 2020, INT J NANOMED, V15, P4171, DOI 10.2147/IJN.S252936
   Guglielmotti MB, 2019, PERIODONTOL 2000, V79, P178, DOI 10.1111/prd.12254
   Han Y, 2008, ELECTROCHEM COMMUN, V10, P510, DOI 10.1016/j.elecom.2008.01.026
   Hao K, 2023, ACS APPL MATER INTER, V15, P29700, DOI 10.1021/acsami.2c19677
   Huang J., 2017, Cell Biosci., V7, P1
   Huang JM, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202302328
   Jayrajsinh S, 2017, J DRUG DELIV SCI TEC, V39, P200, DOI 10.1016/j.jddst.2017.03.023
   Jiang PL, 2023, BIOACT MATER, V27, P15, DOI 10.1016/j.bioactmat.2023.03.006
   Prakash CGJ, 2021, J MATER SCI, V56, P108, DOI 10.1007/s10853 020 05116 1
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433 020 01377 x
   Kaur M, 2019, MAT SCI ENG C MATER, V102, P844, DOI 10.1016/j.msec.2019.04.064
   Li GQ, 2019, SURF COAT TECH, V375, P74, DOI 10.1016/j.surfcoat.2019.06.096
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Li LH, 2004, BIOMATERIALS, V25, P2867, DOI 10.1016/j.biomaterials.2003.09.048
   Li RM, 2024, ADV SCI, V11, DOI 10.1002/advs.202305890
   Li XD, 2020, INT J NANOMED, V15, P6593, DOI 10.2147/IJN.S255486
   Li XZ, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110722
   Liu FF, 2023, IMMUN INFLAMM DIS, V11, DOI 10.1002/iid3.1064
   Liu W, 2019, J BIOMED NANOTECHNOL, V15, P1172, DOI 10.1166/jbn.2019.2767
   Liu YT, 2013, J ALLOY COMPD, V581, P459, DOI 10.1016/j.jallcom.2013.07.106
   Lüthen F, 2007, BIOMOL ENG, V24, P531, DOI 10.1016/j.bioeng.2007.08.003
   Mombelli A, 2018, CLIN ORAL IMPLAN RES, V29, P37, DOI 10.1111/clr.13305
   Muthusamy S, 2021, MAT SCI ENG C MATER, V126, DOI 10.1016/j.msec.2021.112149
   Najafpour MM, 2015, DALTON T, V44, P15441, DOI 10.1039/c5dt02336j
   Paluszkiewicz C, 2010, J MOL STRUCT, V976, P301, DOI 10.1016/j.molstruc.2010.04.001
   Park JW, 2012, CLIN ORAL IMPLAN RES, V23, P294, DOI 10.1111/j.1600 0501.2010.02144.x
   Qin J, 2023, SURF COAT TECH, V466, DOI 10.1016/j.surfcoat.2023.129655
   Rokosz K, 2020, MATERIALS, V13, DOI 10.3390/ma13040828
   Saji VS, 2020, ADV COLLOID INTERFAC, V283, DOI 10.1016/j.cis.2020.102245
   Song JP, 2020, J HAZARD MATER, V391, DOI 10.1016/j.jhazmat.2019.121692
   Souza JCM, 2019, ACTA BIOMATER, V94, P112, DOI 10.1016/j.actbio.2019.05.045
   Sul YT, 2005, BIOMATERIALS, V26, P6720, DOI 10.1016/j.biomaterials.2005.04.058
   Tan W, 2008, COMPOS SCI TECHNOL, V68, P2917, DOI 10.1016/j.compscitech.2007.10.007
   Thukkaram M, 2020, ACS APPL MATER INTER, V12, P30155, DOI 10.1021/acsami.0c07234
   Tsui AKY, 2011, P NATL ACAD SCI USA, V108, P17544, DOI 10.1073/pnas.1114026108
   Varadwaj GBB, 2013, DALTON T, V42, P5122, DOI 10.1039/c3dt32495h
   Wang YP, 2017, APPL SURF SCI, V412, P29, DOI 10.1016/j.apsusc.2017.03.191
   Wen XY, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1282590
   Wu ZC, 2021, RESEARCH CHINA, V2021, DOI 10.34133/2021/9780943
   Xu FX, 2023, J ETHNOPHARMACOL, V311, DOI 10.1016/j.jep.2023.116451
   Yan XH, 2024, ACS OMEGA, V9, P15818, DOI 10.1021/acsomega.3c07467
   Yan YF, 2019, BIOMATERIALS, V190, P97, DOI 10.1016/j.biomaterials.2018.10.033
   Yu YQ, 2016, J MATER CHEM B, V4, P801, DOI 10.1039/c5tb02190a
   Zhang J, 2022, ADV MATER, V34, DOI 10.1002/adma.202202044
   Zhang XX, 2020, MAT SCI ENG C MATER, V117, DOI 10.1016/j.msec.2020.111321
   Zhao QM, 2020, NANOTOXICOLOGY, V14, P289, DOI 10.1080/17435390.2019.1690065
   Zhao X, 2019, PROG ORG COAT, V133, P249, DOI 10.1016/j.porgcoat.2019.04.048
   Zhou ZX, 2023, CERAM INT, V49, P8886, DOI 10.1016/j.ceramint.2022.11.044
NR 62
TC 2
Z9 2
U1 7
U2 28
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD OCT 15
PY 2024
VL 498
AR 155034
DI 10.1016/j.cej.2024.155034
EA AUG 2024
PG 16
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA E6R2K
UT WOS:001304251200001
DA 2025 08 17
ER

PT J
AU Reid, IR
   Horne, AM
   Mihov, B
   Stewart, A
   Bastin, S
   Gamble, GD
AF Reid, Ian R.
   Horne, Anne M.
   Mihov, Borislav
   Stewart, Angela
   Bastin, Sonja
   Gamble, Gregory D.
TI Effect of Zoledronate on Lower Respiratory Infections in Older Women:
   Secondary Analysis of a Randomized Controlled Trial
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bisphosphonate; Pneumonia; Infection; Osteoporosis
ID ACID; MORTALITY
AB A recent observational study of the incidence of pneumonia in patients with previous hip fractures found that bisphosphonate use reduced pneumonia risk by about one quarter, in comparisons with those either not receiving osteoporosis treatment or receiving treatment with non bisphosphonate drugs. Mortality from pneumonia was similarly reduced. It was hypothesized that effects of these drugs on immune or inflammatory function might mediate this effect. We have used the adverse event database from our recent 6 year randomized controlled trial of zoledronate in 2000 women over the age of 65 years, to determine whether a similar effect is observed using this more rigorous study design. Seventy five women had at least one episode of pneumonia (32 [3.2%] zoledronate, 43 [4.3%] placebo) and 119 women had at least one episode of either pneumonia or a lower respiratory tract infection (57 [5.7%] zoledronate, 62 [6.2%] placebo). There were 93 pneumonia events and 167 pneumonia/lower respiratory infection events. For pneumonia, the hazard ratio associated with randomization to zoledronate was 0.73 (95% confidence interval, 0.46 1.16; P = 0.18) and the rate ratio was 0.69 (0.45, 1.04; P = 0.073). For the composite endpoint of pneumonia or lower respiratory infection, the hazard ratio was 0.90 (0.61, 1.30; P = 0.58) and the rate ratio 0.74 (0.54, 0.997; P = 0.048). The proportion of people with events changed approximately linearly over time in both groups, suggesting a progressive divergence in cumulative incidence during the study. In conclusion, these findings lend support to the hypothesis that bisphosphonate use reduces the number of lower respiratory tract infections in older women, though the present study is under powered for this endpoint and the findings are of borderline statistical significance. Further analysis of other trials of bisphosphonates is necessary to test this possibility further, and exploration of the possible underlying mechanisms is needed.
C1 [Reid, Ian R.; Horne, Anne M.; Mihov, Borislav; Stewart, Angela; Gamble, Gregory D.] Univ Auckland, Dept Med, Fac Med & Hlth Sci, Private Bag 92019, Auckland, New Zealand.
   [Reid, Ian R.; Bastin, Sonja] Auckland Dist Hlth Board, Auckland, New Zealand.
C3 University of Auckland; Auckland District Health Board
RP Reid, IR (通讯作者)，Univ Auckland, Dept Med, Fac Med & Hlth Sci, Private Bag 92019, Auckland, New Zealand.; Reid, IR (通讯作者)，Auckland Dist Hlth Board, Auckland, New Zealand.
EM i.reid@auckland.ac.nz; a.horne@auckland.ac.nz; b.mihov@auckland.ac.nz;
   angela.stewart@auckland.ac.nz; sonjab@adhb.govt.nz;
   gd.gamble@auckland.ac.nz
OI Reid, Ian/0000 0001 6021 5458; Mihov, Borislav/0000 0002 0147 0595
FU Health Research Council of New Zealand
FX This work was supported by grants from the Health Research Council of
   New Zealand. Trial medication was supplied by Novartis. We thank Leanne
   Purvis for her contributions to the organization and conduct of the
   trial.
CR Adami G, 2020, J BONE MINER RES, V35, P2082, DOI 10.1002/jbmr.4163
   Billington EO, 2020, CURR OSTEOPOROS REP, V18, P587, DOI 10.1007/s11914 020 00612 4
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Giollo A, 2019, J RHEUMATOL, V46, P318, DOI 10.3899/jrheum.180324
   Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839
   Lubas B, 2006, CTR DRUG EVALUATION, DOI DOI 10.1056/NEJMoa1808082
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Reid IR, 2020, J BONE MINER RES, V35, P20, DOI 10.1002/jbmr.3860
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P249, DOI 10.1007/s00223 013 9750 6
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P395, DOI 10.1007/s00223 012 9647 9
   Sapey E, 2019, AM J RESP CRIT CARE, V200, P1282, DOI 10.1164/rccm.201812 2328OC
   Sing CW, 2020, J BONE MINER RES, V35, P1676, DOI 10.1002/jbmr.4030
NR 13
TC 9
Z9 10
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUL
PY 2021
VL 109
IS 1
BP 12
EP 16
DI 10.1007/s00223 021 00830 7
EA MAR 2021
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA SY3BW
UT WOS:000628093400001
PM 33712919
DA 2025 08 17
ER

PT J
AU Lai, CF
   Shen, J
   Balic, A
   Pagella, P
   Schwab, ME
   Mitsiadis, TA
AF Lai, Chai Foong
   Shen, Juliet
   Balic, Anamaria
   Pagella, Pierfrancesco
   Schwab, Martin E.
   Mitsiadis, Thimios A.
TI Nogo A Regulates the Fate of Human Dental Pulp Stem Cells toward
   Osteogenic, Adipogenic, and Neurogenic Differentiation
SO CELLS
LA English
DT Article
DE Nogo A; human; tooth; dental pulp; human dental pulp stem cells; single
   cell RNA sequencing; anti Nogo A antibody; osteogenic potential;
   adipogenic potential; neurogenic potential; stem cell fates;
   differentiation; in vitro
ID RECEPTOR FAMILY MEMBER; BONE MARROW; OSTEOBLAST DIFFERENTIATION;
   FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; TOOTH DEVELOPMENT; IN VITRO;
   REPAIR; REGENERATION; MECHANISMS
AB Human teeth are highly innervated organs that contain a variety of mesenchymal stem cell populations that could be used for cell based regenerative therapies. Specific molecules are often used in these treatments to favorably modulate the function and fate of stem cells. Nogo A, a key regulator of neuronal growth and differentiation, is already used in clinical tissue regeneration trials. While the functions of Nogo A in neuronal tissues are extensively explored, its role in teeth still remains unknown. In this work, we first immunohistochemically analyzed the distribution of Nogo A protein in the dental pulp of human teeth. Nogo A is localized in a variety of cellular and structural components of the dental pulp, including odontoblasts, fibroblasts, neurons and vessels. We also cross examined Nogo expression in the various pulp cell clusters in a single cell RNA sequencing dataset of human dental pulp, which showed high levels of expression in all cell clusters, including that of stem cells. We then assessed the role of Nogo A on the fate of human dental pulp stem cells and their differentiation capacity in vitro. Using immunostaining, Alizarin Red S, Nile Red and Oil Red O staining we showed that Nogo A delayed the differentiation of cultured dental pulp stem cells toward the osteogenic, adipogenic and neurogenic lineages, while addition of the blocking anti Nogo A antibody had opposite effects. These results were further confirmed by qRT PCR, which demonstrated overexpression of genes involved in osteogenic (RUNX2, ALP, SP7/OSX), adipogenic (PPAR gamma 2, LPL) and neurogenic (DCX, TUBB3, NEFL) differentiation in the presence of the anti Nogo A antibody. Conversely, the osteogenic and adipogenic genes were downregulated by Nogo A. Taken together, our results show that the functions of Nogo A are not restricted to neuronal cells but are extended to other cell populations, including dental pulp stem cells. We show that Nogo A regulates their fates toward osteogenic, adipogenic and neurogenic differentiation, thus indicating its potential use in clinics.
C1 [Lai, Chai Foong; Shen, Juliet; Balic, Anamaria; Pagella, Pierfrancesco; Mitsiadis, Thimios A.] Univ Zurich, Med Fac, Ctr Dent Med, Inst Oral Biol,Orofacial Dev & Regenerat, Plattenstr 11, CH 8032 Zurich, Switzerland.
   [Pagella, Pierfrancesco] Univ Linkoping, Wallenberg Ctr Mol Med, S 58183 Linkoping, Sweden.
   [Schwab, Martin E.] Univ Zurich, Inst Regenerat Med IREM, Wagistr 12, CH 8952 Schlieren, Switzerland.
C3 University of Zurich; Linkoping University
RP Mitsiadis, TA (通讯作者)，Univ Zurich, Med Fac, Ctr Dent Med, Inst Oral Biol,Orofacial Dev & Regenerat, Plattenstr 11, CH 8032 Zurich, Switzerland.
EM thimios.mitsiadis@zzm.uzh.ch
RI Mitsiadis, Thimios/B 5564 2016; Pagella, Pierfrancesco/Q 1957 2019;
   Schwab, Martin/B 6818 2016; Balic, Anamaria/JCE 5587 2023
OI Mitsiadis, Thimios/0000 0002 9812 9982; Pagella,
   Pierfrancesco/0000 0001 6912 0957; 
FU University of Zurich (UZH); Swiss National Science Foundation
   [31003A_179389]; Swiss Dental Association (SSO) [313 19]; Swiss National
   Science Foundation (SNF) [31003A_179389] Funding Source: Swiss National
   Science Foundation (SNF)
FX This work was financially supported by institutional funds from the
   University of Zurich (UZH), the Swiss National Science Foundation (SNSF;
   grant number 31003A_179389), and the Swiss Dental Association (SSO;
   grant number 313 19).
CR Ai CJ, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13351
   Al Halabiah H, 2005, GENE EXPR PATTERNS, V5, P561, DOI 10.1016/j.modgep.2004.10.010
   Angelova Volponi Ana, 2018, Curr Oral Health Rep, V5, P295, DOI 10.1007/s40496 018 0196 9
   Arimura Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251356
   Augello A, 2010, EUR CELLS MATER, V20, P121
   Ayanlaja AA, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00199
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Basu A, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148 021 01131 4
   Bautch VL, 2011, NAT MED, V17, P1437, DOI 10.1038/nm.2539
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Bluteau G, 2008, EUR CELLS MATER, V16, P1
   Boghdadi AG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27245 0
   Bronfman FC, 2004, EMBO REP, V5, P867, DOI 10.1038/sj.embor.7400219
   Chalise JP, 2019, P NATL ACAD SCI USA, V116, P15128, DOI 10.1073/pnas.1906712116
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219
   Cossu G, 2018, LANCET, V391, P883, DOI 10.1016/S0140 6736(17)31366 1
   d'Aquino R, 2009, EUR CELLS MATER, V18, P75, DOI 10.22203/eCM.v018a07
   Delekate A, 2011, P NATL ACAD SCI USA, V108, P2569, DOI 10.1073/pnas.1013322108
   Delle Monache S, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10051056
   Delle Monache S, 2019, STEM CELLS DEV, V28, P695, DOI 10.1089/scd.2018.0192
   El Haj AJ, 2019, TISSUE ENG PT A, V25, P1067, DOI [10.1089/ten.TEA.2019.0134, 10.1089/ten.tea.2019.0134]
   Filipovic Radmila, 2014, Curr Protoc Stem Cell Biol, V29, DOI 10.1002/9780470151808.sc01h07s29
   Foudah D, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/987678
   Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072
   Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   Grandpré T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507
   Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Guo MF, 2020, J INTEGR NEUROSCI, V19, P651, DOI 10.31083/j.jin.2020.04.243
   Iohara K, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00983
   Iohara K, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0855 8
   Iohara K, 2013, STEM CELL TRANSL MED, V2, P521, DOI 10.5966/sctm.2012 0132
   Jaiswal J, 2022, BIOSENS BIOELECTRON, V206, DOI 10.1016/j.bios.2022.114134
   Jimenez Rojo L, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101302
   Jin QQ, 2019, ARTIF CELL NANOMED B, V47, P1577, DOI 10.1080/21691401.2019.1594861
   Jussila M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008425
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Kempf A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001763
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kucher K, 2018, NEUROREHAB NEURAL RE, V32, P578, DOI 10.1177/1545968318776371
   Labedz Maslowska A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176172
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li Y, 2014, ATHEROSCLEROSIS, V237, P597, DOI 10.1016/j.atherosclerosis.2014.10.016
   Lin CS, 2013, HISTOL HISTOPATHOL, V28, P1109, DOI 10.14670/HH 28.1109
   Luzuriaga J, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110483
   Madl CM, 2018, NATURE, V557, P335, DOI 10.1038/s41586 018 0089 z
   Mason C, 2008, REGEN MED, V3, P1, DOI 10.2217/17460751.3.1.1
   Mattei V, 2015, EXP CELL RES, V339, P231, DOI 10.1016/j.yexcr.2015.11.012
   Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188
   Mitsiadis TA, 2015, EUR CELLS MATER, V30, P248, DOI 10.22203/eCM.v030a17
   Mitsiadis T A, 2011, Adv Dent Res, V23, P275, DOI 10.1177/0022034511405386
   Mitsiadis TA, 2004, J DENT RES, V83, P896, DOI 10.1177/154405910408301202
   MITSIADIS TA, 1992, DIFFERENTIATION, V49, P47, DOI 10.1111/j.1432 0436.1992.tb00768.x
   Mitsiadis TA, 2003, EXP CELL RES, V282, P101, DOI 10.1016/S0014 4827(02)00012 5
   Mitsiadis TA, 2007, EXP CELL RES, V313, P3377, DOI 10.1016/j.yexcr.2007.07.027
   Mitsiadis TA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 01455 3
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Monterubbianesi R, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37981 x
   Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471 2202 10 16
   Moraes DA, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0359 3
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Morrison SJ, 1997, CURR OPIN IMMUNOL, V9, P216, DOI 10.1016/S0952 7915(97)80138 0
   Nagaraj V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155417
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima M, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0506 5
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Nery AA, 2013, CYTOM PART A, V83A, P48, DOI 10.1002/cyto.a.22205
   Noda S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41741 w
   Nombela Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049
   Oertle T, 2003, J NEUROSCI, V23, P5393
   Orsini G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01102
   Orsini G, 2018, AM J MED, V131, P1425, DOI 10.1016/j.amjmed.2018.05.042
   Pagella P, 2021, EUR CELLS MATER, V40, P502, DOI 10.22203/eCM.v041a32
   Pagella P, 2015, EUR CELLS MATER, V29, P213, DOI 10.22203/eCM.v029a16
   Pagella P, 2021, STEM CELL TRANSL MED, V10, P1433, DOI 10.1002/sctm.21 0086
   Pagella P, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102405
   Pagella P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063024
   Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040
   Pera MF, 2010, NATURE, V465, P713, DOI 10.1038/nature09228
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0083 6
   Rafiee F, 2020, INT J NEUROSCI, V130, P107, DOI 10.1080/00207454.2019.1664518
   Rolando C, 2012, J NEUROSCI, V32, P17788, DOI 10.1523/JNEUROSCI.3142 12.2012
   Rust R, 2019, P NATL ACAD SCI USA, V116, P14270, DOI 10.1073/pnas.1905309116
   Saalbach A, 2019, FASEB J, V33, P6689, DOI 10.1096/fj.201802224R
   Sadie Van Gijsen H, 2013, BONE, V56, P255, DOI 10.1016/j.bone.2013.06.016
   Sainio MT, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.820105
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwab ME, 2014, CURR OPIN NEUROBIOL, V27, P53, DOI 10.1016/j.conb.2014.02.011
   Seiler S, 2016, BIOCHEM PHARMACOL, V100, P28, DOI 10.1016/j.bcp.2015.08.113
   Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050
   Sharpe PT, 2016, DEVELOPMENT, V143, P2273, DOI 10.1242/dev.134189
   Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601 6343.2005.00331.x
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Signer RAJ, 2013, CELL STEM CELL, V12, P152, DOI 10.1016/j.stem.2013.01.001
   Stefková K, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/628368
   Tang HM, 2020, NEUROSCIENCE, V449, P21, DOI 10.1016/j.neuroscience.2020.09.057
   Thesleff I, 2018, EUR J ORAL SCI, V126, P67, DOI 10.1111/eos.12421
   Touré SB, 2018, REGEN MED, V13, P741, DOI 10.2217/rme 2017 0129
   Ullah HMA, 2021, CELLS BASEL, V10, DOI 10.3390/cells10020282
   Voshol PJ, 2009, BBA MOL CELL BIOL L, V1791, P479, DOI 10.1016/j.bbalip.2008.12.015
   Wälchli T, 2013, P NATL ACAD SCI USA, V110, pE1943, DOI 10.1073/pnas.1216203110
   Wahl AS, 2014, SCIENCE, V344, P1250, DOI 10.1126/science.1253050
   Wang JL, 2021, J MOL HISTOL, V52, P521, DOI 10.1007/s10735 021 09960 6
   Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176
   Waters SL, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00134 2
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Wells JM, 2018, NATURE, V557, P322, DOI 10.1038/s41586 018 0073 7
   Wu QQ, 2020, MOL MED REP, V21, P77, DOI 10.3892/mmr.2019.10825
   Xiao PY, 2022, AUTOPHAGY, V18, P2711, DOI 10.1080/15548627.2022.2047344
   Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045
   Yang J, 2020, DIFFERENTIATION, V113, P38, DOI 10.1016/j.diff.2020.03.003
   Yang YH, 2010, ANN NEUROL, V67, P498, DOI 10.1002/ana.21935
   Yasui T, 2016, J DENT RES, V95, P206, DOI 10.1177/0022034515610748
   Yu SX, 2016, BIOCHEM BIOPH RES CO, V473, P482, DOI 10.1016/j.bbrc.2016.03.037
   Zayed M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02240 w
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang N, 2022, CELL MOL NEUROBIOL, V42, P2439, DOI 10.1007/s10571 021 01124 0
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
NR 122
TC 6
Z9 6
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD NOV
PY 2022
VL 11
IS 21
AR 3415
DI 10.3390/cells11213415
PG 23
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 6E5MW
UT WOS:000883425000001
PM 36359811
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Khorolsuren, Z
   Lang, O
   Pallinger, E
   Foldes, A
   Szabolcs, GG
   Varga, G
   Mezo, G
   Vag, J
   Kohidai, L
AF Khorolsuren, Zambaga
   Lang, Orsolya
   Pallinger, Eva
   Foldes, Anna
   Szabolcs, Gyulai Gaal
   Varga, Gabor
   Mezo, Gabor
   Vag, Janos
   Kohidai, Laszlo
TI Functional and cell surface characteristics of periodontal ligament
   cells (PDLCs) on RGD synthetic polypeptide conjugate coatings
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE adhesion; osteogenic differentiation; periodontal ligament cells;
   RGD peptide conjugates
ID MESENCHYMAL STEM CELLS; PEPTIDE POLYMER; DENTAL ORIGIN; DIFFERENTIATION;
   ADHESION; RECOGNITION; ATTACHMENT; INTEGRINS; MIGRATION
AB Background and Objective Periodontal ligament cells (PDLCs) are an important source for periodontal tissue healing and regeneration. Proper cell adhesion is a key for survival of anchorage dependent cells and also initiates further intracellular signals for essential cellular functions. We aimed to test 3 different synthetic conjugates with integrin binding RGD sequence (SAK c[RGDfC], AK c[RGDfC], and SAK opn on the adhesion of human PDLCs and subsequent events including proliferation, migration, behavior of cell surface molecules, and osteogenic differentiation.
   Materials and Methods Synthetic peptides were synthesized by solid phase technique and attached to branched chain polymeric polypeptides via thioether linkage. Simple adsorption method was used to coat tissue culture plastic or electric arrays. PDLCs were isolated from 24 surgically extracted human third molars. Cell adhesion and proliferation were measured with real time impedimetric xCELLigence SP system. Cell migration assay was performed with Ibidi(R) Culture inserts. Cell surface antigens were detected using flow cytometry analysis. Osteogenic differentiation was assessed with alkaline phosphatase (ALP) assay and Alizarin Red S staining, and real time qPCR was performed to analyze the osteoblast related gene expression. Osteogenic differentiation and adipogenic differentiation of PDLCs were monitored by real time Electrical Cell Substrate Impedance Spectroscopy (ECIS).
   Results Primary outcome of this study relies on that all three synthetic RGD peptides improved PDLC adhesion (P < .05). When animal serum is absent in culture medium, SAK c[RGDfC] and AK c[RGDfC] elevated cell adhesion (P < .05). Cell migration was enhanced by SAK c[RGDfC] and AK c[RGDfC] (P < .05). After 1 week treatment, all synthetic peptides elevated CD105 (1.7  to 2.2 fold) and CD146 (1.3  to 1.5 fold) markers and caused different integrin patterns. ALP activity (1.4 fold) and ARS (1.8  and 2.0 fold) were increased by SAK c[RGDfC] and AK c[RGDfC] in absence of osteogenic supplements, and all the peptides supported the mineralization under osteogenic condition (P < .05). RT qPCR revealed the upregulation of bone sialoprotein (5.0  to 7.8 fold), osteocalcin (2.3  to 2.7 fold), and ALP (1.9  to 2.3 fold) gene expression in osteogenesis induced PDLCs. ECIS monitoring showed that higher impedance was generated by the osteogenic induction compared with the adipogenic or the non induced (P < .05).
   Conclusions Our study demonstrates that SAK c[RGDfC] and AK c[RGDfC] improved adhesion and migration of PDLCs and supported osteogenic differentiation of PDLCs. These cyclic RGD peptides proved to be applicable biocompatible material in regenerative medicine.
C1 [Khorolsuren, Zambaga; Lang, Orsolya; Pallinger, Eva; Kohidai, Laszlo] Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary.
   [Khorolsuren, Zambaga; Vag, Janos] Semmelweis Univ, Dept Conservat Dent, Budapest, Hungary.
   [Foldes, Anna; Varga, Gabor] Semmelweis Univ, Dept Oral Biol, Budapest, Hungary.
   [Mezo, Gabor] MTA ELTE Res Grp Peptide Chem, Budapest, Hungary.
   [Szabolcs, Gyulai Gaal] Semmelweis Univ, Fac Dent, Dept Oral Diagnost, Budapest, Hungary.
C3 Semmelweis University; Semmelweis University; Semmelweis University;
   Eotvos Lorand University; Semmelweis University
RP Kohidai, L (通讯作者)，Semmelweis Univ, Dept Genet Cell & Immunobiol, Budapest, Hungary.
EM kohlasz2@gmail.com
RI Vag, Janos/K 5531 2012; Varga, Gábor/O 8858 2017; László,
   Kőhidai/J 2099 2019
OI Vag, Janos/0000 0002 6183 7598; Varga, Gabor/0000 0002 5506 8198;
   Kohidai, Laszlo/0000 0002 9002 0296; Foldes, Anna/0000 0002 4182 7886
FU Hungarian Scientific Research Fund [K112364]; Stipendium Hungaricum
   Tempus Public Foundation
FX Hungarian Scientific Research Fund, Grant/Award Number: K112364;
   Stipendium Hungaricum Tempus Public Foundation
CR Angstmann M, 2011, CYTOTHERAPY, V13, P1074, DOI 10.3109/14653249.2011.584863
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014 5793(91)81101 D
   Bagnaninchi PO, 2011, P NATL ACAD SCI USA, V108, P6462, DOI 10.1073/pnas.1018260108
   Bellis SL, 2011, BIOMATERIALS, V32, P4205, DOI 10.1016/j.biomaterials.2011.02.029
   Brunner D, 2010, ALTEX ALTERN ANIM EX, V27, P53
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Földes A, 2016, CURR NEUROPHARMACOL, V14, P914, DOI 10.2174/1570159X14666160121115210
   Galli D, 2011, J BIOMED MATER RES A, V97A, P118, DOI 10.1002/jbm.a.32996
   Gay IC, 2007, ORTHOD CRANIOFAC RES, V10, P149, DOI 10.1111/j.1601 6343.2007.00399.x
   Gibon E, 2012, TISSUE ENG PT A, V18, P968, DOI [10.1089/ten.tea.2011.0545, 10.1089/ten.TEA.2011.0545]
   Goodman SL, 2002, J MED CHEM, V45, P1045, DOI 10.1021/jm0102598
   Grimm W, 2011, INT J PERIODONT REST, V31, P94
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092 8674(92)90115 S
   Ivanovski S, 2006, ORAL DIS, V12, P358, DOI 10.1111/j.1601 0825.2006.01253.x
   Iwamoto DV, 2015, CURR OPIN CELL BIOL, V36, P41, DOI 10.1016/j.ceb.2015.06.009
   Kadar K, 2009, J PHYSIOL PHARMACOL, V60, P167
   Karamzadeh R, 2012, JOVE J VIS EXP, DOI 10.3791/4372
   Liu OS, 2013, STEM CELLS, V31, P1371, DOI 10.1002/stem.1387
   Markó K, 2008, BIOCONJUGATE CHEM, V19, P1757, DOI 10.1021/bc8000134
   Markó K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028538
   Mezö G, 2003, BIOCONJUGATE CHEM, V14, P1260, DOI 10.1021/bc0341122
   Mezo G, 1997, BIOPOLYMERS, V42, P719, DOI 10.1002/(SICI)1097 0282(199711)42:6<719::AID BIP9>3.0.CO;2 X
   Ng TK, 2015, SCI REP UK, V5, DOI 10.1038/srep07828
   Pallu S, 2003, PEPTIDES, V24, P1349, DOI 10.1016/j.peptides.2003.09.003
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Poly W, 1985, COLLECT CZECH CHEM C, V50, P103
   Porté Durrieu MC, 2004, BIOMATERIALS, V25, P4837, DOI 10.1016/j.biomaterials.2003.11.037
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Sekiya I, 2004, J BONE MINER RES, V19, P256, DOI 10.1359/JBMR.0301220
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142 9612(03)00339 9
   Tátrai P, 2013, J MATER SCI MATER M, V24, P479, DOI 10.1007/s10856 012 4809 x
   Tsuji K, 2017, CELL TRANSPLANT, V26, P1089, DOI 10.3727/096368917X694831
   Verrier S, 2002, BIOMATERIALS, V23, P585, DOI 10.1016/S0142 9612(01)00145 4
   Vicente Manzanares M, 2009, J CELL SCI, V122, P1473, DOI 10.1242/jcs.052894
   VINA JA, 2014, J CLIN EXP DENT, V6, P60
   Wacker BK, 2008, BIOPHYS J, V94, P273, DOI 10.1529/biophysj.107.109074
   Yu CH, 2011, P NATL ACAD SCI USA, V108, P20585, DOI 10.1073/pnas.1109485108
   Zhu WJ, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/972313
NR 42
TC 10
Z9 10
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD OCT
PY 2020
VL 55
IS 5
BP 713
EP 723
DI 10.1111/jre.12760
EA MAY 2020
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA NK6MI
UT WOS:000532547000001
PM 32406091
OA hybrid
DA 2025 08 17
ER

PT J
AU Shang, WQ
   Li, H
   Liu, LB
   Chang, KK
   Yu, JJ
   Xie, F
   Li, MQ
   Yu, JJ
AF Shang, Wen Qing
   Li, Hui
   Liu, Li Bing
   Chang, Kai Kai
   Yu, Jia Jun
   Xie, Feng
   Li, Ming Qing
   Yu, Jin Jin
TI RANKL/RANK interaction promotes the growth of cervical cancer cells by
   strengthening the dialogue between cervical cancer cells and regulation
   of IL 8 secretion
SO ONCOLOGY REPORTS
LA English
DT Article
DE RANKL; RANK; cervical cancer cells; viability; apoptosis; IL 8
ID OSTEOCLAST DIFFERENTIATION; CARCINOMA CELLS; OSTEOPROTEGERIN LIGAND;
   EPITHELIAL CELLS; RANK; MIGRATION; INFLAMMATION; METASTASIS; EXPRESSION;
   CHEMOKINES
AB Receptor activator for nuclear factor kappa B ligand (RANKL) is a member of the tumor necrosis factor (TNF) family. The interaction between RANKL and its receptor RANK plays an important role in the development and function of diverse tissues. However, the expression and role of RANKL in cervical cancer are still unknown. In the present study, we found that RANKL and RANK were highly co expressed in cervical cancer. HeLa and SiHa cells secreted soluble RANKL (sRANKL), expressed member RANKL (mRANKL) and RANK. Recombinant human RANKL protein had no effect on the viability of HeLa and SiHa cells. Yet, blocking RANKL with an anti human RANKL neutralizing antibody (alpha RANKL) or recombinant human osteoprotegrin (OPG) protein resulted in the downregulation of Ki 67 and B cell lymphoma 2 (Bcl 2) expression and an increase in Fas and Fas ligand (FasL) expression, as well as a high level of viability and a low level of apoptosis in the HeLa and SiHa cells. In addition, alpha RANKL led to a decrease in IL 8 secretion. Recombinant human IL 8 protein reversed the effect of alpha RANKL on the expression of proliferation  and apoptosis related molecules, and proliferation and apoptosis in the HeLa and SiHa cells. The present study suggests that a high level of mRANKL/RANK expression in cervical cancer lesions plays an important role in the rapid growth of cervical cancer cells possibly through strengthening the dialogue between cervical cancer cells and regulation of IL 8 secretion, which may be a possible target for cervical cancer therapy.
C1 [Shang, Wen Qing; Yu, Jin Jin] Jiangnan Univ, Affiliated Hosp, Dept Obstet & Gynecol, Wuxi 214062, Jiangsu, Peoples R China.
   [Shang, Wen Qing; Li, Hui; Liu, Li Bing; Chang, Kai Kai; Yu, Jia Jun; Li, Ming Qing] Fudan Univ, Shanghai Med Coll, Hosp Obstet & Gynecol, Lab Reprod Immunol, Shanghai 200011, Peoples R China.
   [Xie, Feng] Fudan Univ, Hosp Obstet & Gynecol, Med Ctr Diag & Treatment Cerv Dis, Shanghai 200011, Peoples R China.
   [Li, Ming Qing] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China.
   [Li, Ming Qing] Shanghai Inst Planned Parenthood Res, NPFPC Key Lab Contracept Drugs & Devices, Shanghai, Peoples R China.
C3 Jiangnan University; Fudan University; Fudan University; Shanghai
   Academy of Science & Technology
RP Li, MQ (通讯作者)，Fudan Univ, Shanghai Med Coll, Hosp Obstet & Gynecol, Lab Reprod Immunol, 413 Zhaozhou Rd, Shanghai 200011, Peoples R China.
EM mqli@fudan.edu.cn; yujjwx@126.com
RI 刘, 礼兵/HHS 9876 2022; huiping, li/GZM 9712 2022; Li,
   Mingqing/AFK 9650 2022; YU, Jiajun/GXN 4490 2022
OI Li, Ming Qing/0000 0002 9276 0722; 
FU National Natural Science Foundation of China (NSFC) [81471513]; Training
   Program for Young Talents of Shanghai Health System [XYQ2013104];
   Program for Zhuoxue of Fudan University; NSFC [81302260]; Research
   Program for Maternal and Child of Jiangsu Province [F201429]
FX The present study was supported by the National Natural Science
   Foundation of China (NSFC) (81471513), the Training Program for Young
   Talents of Shanghai Health System (XYQ2013104) and the Program for
   Zhuoxue of Fudan University (all to M. Q. Li), the NSFC 81302260 (to F.
   Xie), and the Research Program for Maternal and Child of Jiangsu
   Province (F201429) (to J. J. Yu).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   [Anonymous], 2014, IARC NONSERIAL PUBLI
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bouganim N, 2011, FUTURE ONCOL, V7, P381, DOI [10.2217/FON.10.192, 10.2217/fon.10.192]
   Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152
   Chen LM, 2011, J CELL BIOCHEM, V112, P933, DOI 10.1002/jcb.23009
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Chu GCY, 2014, CANCER METAST REV, V33, P497, DOI 10.1007/s10555 013 9488 7
   Deivendran S, 2014, ADV EXP MED BIOL, V816, P377, DOI 10.1007/978 3 0348 0837 8_15
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fu ZC, 2015, MED SCI MONITOR, V21, P318, DOI 10.12659/MSM.893265
   Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109 011 0749 z
   Hsu CJ, 2010, J CELL BIOCHEM, V111, P138, DOI 10.1002/jcb.22677
   Husseinzadeh N, 2014, GYNECOL ONCOL, V135, P359, DOI 10.1016/j.ygyno.2014.08.013
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kim SH, 2009, ANN NY ACAD SCI, V1171, P495, DOI 10.1111/j.1749 6632.2009.04899.x
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu LB, 2014, INT J CLIN EXP PATHO, V7, P575
   Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007
   Meng YH, 2013, PLACENTA, V34, P663, DOI 10.1016/j.placenta.2013.04.020
   Murdoch C, 2000, BLOOD, V95, P3032
   Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091 6749(99)70281 2
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Rashmi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092948
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Secchiero P, 2006, J CELL PHYSIOL, V207, P158, DOI 10.1002/jcp.20547
   Sordillo EM, 2003, CANCER S, V97, pS802
   Tang ZN, 2011, BIOCHEM BIOPH RES CO, V408, P411, DOI 10.1016/j.bbrc.2011.04.035
   Vicari AP, 2002, CYTOKINE GROWTH F R, V13, P143, DOI 10.1016/S1359 6101(01)00033 8
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang L, 2013, MOL CELL BIOCHEM, V379, P7, DOI 10.1007/s11010 013 1621 y
   Xie F, 2013, AM J REPROD IMMUNOL, V70, P69, DOI 10.1111/aji.12104
NR 34
TC 13
Z9 15
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2015
VL 34
IS 6
BP 3007
EP 3016
DI 10.3892/or.2015.4303
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CV9OR
UT WOS:000364617000023
PM 26398902
OA Bronze
DA 2025 08 17
ER

PT J
AU Shanmugam, H
   Narmadha, R
   Ravikumar, C
   Ariyaperumal, K
   Selvakumar, R
   Mannu, J
AF Shanmugam, Haripriya
   Narmadha, R.
   Ravikumar, Caroline
   Ariyaperumal, Kiruthika
   Selvakumar, R.
   Mannu, Jayakanthan
TI Anti proliferative effect of leaf phytochemicals of soursop (Annona
   muricata L.) against human osteosarcoma in vitro
SO CHEMICAL PAPERS
LA English
DT Article
DE Soursop leaves; Annona muricata; GC MS chemoprofiling; Annonacin;
   Osteosarcoma; PDGFRA; Molecular docking; ADMET analysis; MG 63 cell
   lines; Nuclear imaging
ID ACETOGENINS; CYTOTOXICITY; LEAVES
AB Leaves of soursop (Annona muricata) is a potential anti cancer agent. However, there is no report on the effect of soursop leaf phytochemicals against osteosarcoma, a musculoskeletal cancer commonly affecting children and adults. The current study identified 28 metabolites from ethyl acetate leaf (EAL) extract through GC MS chemoprofiling and subjected to in silico analysis against the potential protein target, platelet derived growth factor receptor alpha (PDGFRA) of osteosarcoma, including absorption, distribution, metabolism, and excretion and toxicity (ADMET) analysis to identify the possible hit compounds. This resulted in three hit leaf bioactives, namely 2' hydroxy 5' methyl chalcone, linoleic acid and annonacin showing good binding affinity with a docking score of   7.4,   7.0 and   6.9 kcal/mol, respectively. With ADMET analysis, 2' hydroxy 5' methyl chalcone and linoleic acid obeyed Lipinski's rule of five, whereas annonacin showed a slight violation. Among the three docked complexes, annonacin shows good stability during molecular dynamic simulation performed with PDGFRA. The concentration of the key marker compound, annonacin in EAL concentrate is found to be 5.032 +/  0.13 mg/g of leaf sample and is used for cytotoxicity assessment. Further, EAL concentrate exhibits cytotoxicity (IC50 value) on MG 63 osteosarcoma cells in vitro for concentrations ranging from 10 to 25 mu g/mL. Nuclear imaging of osteoblast cells treated with EAL concentrate at 25 mu g/mL concentration shows typical symptoms of apoptosis. In vitro cytotoxicity along with nuclear imaging confirmed EAL concentrate from soursop to be a potential drug candidate in developing new anti cancer agent against osteosarcoma.
C1 [Shanmugam, Haripriya] Tamil Nadu Agr Univ, Ctr Agr Nanotechnol, Coimbatore 641003, India.
   [Narmadha, R.; Selvakumar, R.] PSG Inst Adv Studies, Tissue Engn Lab, Coimbatore 641004, India.
   [Ravikumar, Caroline; Ariyaperumal, Kiruthika; Mannu, Jayakanthan] Tamil Nadu Agr Univ, Ctr Plant Mol Biol & Biotechnol, Coimbatore 641003, India.
C3 Tamil Nadu Agricultural University; Tamil Nadu Agricultural University
RP Shanmugam, H (通讯作者)，Tamil Nadu Agr Univ, Ctr Agr Nanotechnol, Coimbatore 641003, India.
EM haripriya.s@tnau.ac.in
RI Mannu, Jayakanthan/E 6813 2010; R, Selvakumar/AAY 5154 2021; Shanmugam,
   Haripriya/T 6022 2017; M, Jayakanthan/AAC 7491 2022
OI Mannu, Jayakanthan/0000 0001 7444 9343; Shanmugam,
   Haripriya/0000 0003 0541 4221; 
CR Alali FQ, 1999, J NAT PROD, V62, P504, DOI 10.1021/np980406d
   Baxter L. C., 2002, European Cells & Materials, V4, P1
   Bielack SS, 2015, J CLIN ONCOL, V33, P2279, DOI 10.1200/JCO.2014.60.0734
   Blumenthal NM, 2002, J PERIODONTOL, V73, P1494, DOI 10.1902/jop.2002.73.12.1494
   Bonneau N, 2017, PHYTOCHEM ANALYSIS, V28, P251, DOI 10.1002/pca.2668
   Cai L, 2019, ACS OMEGA, V4, P12036, DOI 10.1021/acsomega.9b01142
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978 1 4939 2269 7_19
   de Sousa OV, 2010, INT J MOL SCI, V11, P2067, DOI 10.3390/ijms11052067
   Dewi FRP, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11418
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   Gutiérrez MT, 2020, MOLECULES, V25, DOI 10.3390/molecules25204861
   Henry JP., 2020, Histology, osteoblasts
   Ilango S, 2022, CANCERS, V14, DOI 10.3390/cancers14184539
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Ko YM, 2011, J ETHNOPHARMACOL, V137, P1283, DOI 10.1016/j.jep.2011.07.056
   Laus A, 2023, ARCH PHARM, V356, DOI 10.1002/ardp.202300256
   Lee CC, 2005, J ETHNOPHARMACOL, V100, P237, DOI 10.1016/j.jep.2005.01.064
   Marques C, 2014, INT J NANOMED, V9, P2713, DOI 10.2147/IJN.S55943
   Mishra S., 2013, The Global Journal of Pharmaceutical Research, V2, P1613, DOI 10.3390/cancers14184539
   Mohitha P, 2023, CHEM PAP, V77, P6069, DOI 10.1007/s11696 023 02922 0
   Nordin Noraziah, 2021, Current Drug Discovery Technologies, V18, pe010921191171, DOI 10.2174/1570163818666210204202426
   OBERLIES NH, 1995, CANCER LETT, V96, P55, DOI 10.1016/0304 3835(95)92759 7
   Mora DPP, 2019, PHYTOTHER RES, V33, P591, DOI 10.1002/ptr.6246
   Pieme CA, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 516
   Potts LF, 2012, NEUROTOXICOLOGY, V33, P53, DOI 10.1016/j.neuro.2011.10.009
   Purschke M, 2010, PHOTOCH PHOTOBIO SCI, V9, P1634, DOI 10.1039/c0pp00234h
   Rathore R, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061182
   Ricci C, 2015, VASC PHARMACOL, V70, P1, DOI 10.1016/j.vph.2015.02.002
   RUPPRECHT JK, 1990, J NAT PROD, V53, P237, DOI 10.1021/np50068a001
   Rusanov AL, 2017, B EXP BIOL MED+, V163, P284, DOI 10.1007/s10517 017 3785 z
   Ségaliny AI, 2015, J BONE ONCOL, V4, P1, DOI 10.1016/j.jbo.2015.01.001
   Shanmugam H., 2022, VIRAL ANTIVIRAL NANO, P307
   Shanmugam H, 2019, CHEM BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108750
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Wilson EA, 2018, BIOORG MED CHEM LETT, V28, P1781, DOI 10.1016/j.bmcl.2018.04.030
   Xu J, 2018, CLIN SARCOMA RES, V8, DOI 10.1186/s13569 018 0102 1
   Yang CH, 2015, CARCINOGENESIS, V36, P656, DOI 10.1093/carcin/bgv046
   Zhou XW, 2021, PHYTOCHEM ANALYSIS, V32, P339, DOI 10.1002/pca.2980
NR 39
TC 2
Z9 2
U1 1
U2 2
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 0366 6352
EI 2585 7290
J9 CHEM PAP
JI Chem. Pap.
PD APR
PY 2024
VL 78
IS 6
BP 3787
EP 3797
DI 10.1007/s11696 024 03349 x
EA FEB 2024
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA UA7V8
UT WOS:001171601000001
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Chen, BX
   Pu, B
   Li, SS
   Gong, Y
   Dong, H
AF Chen, Baixing
   Pu, Bin
   Li, Shaoshuo
   Gong, Yu
   Dong, Hang
TI The role of NSAID in mediating the effect of genetically predicted major
   depressive disorder on osteomyelitis: A Mendelian randomization study
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Major depressive disorder; Osteomyelitis; NSAIDs; Mendelian
   randomization; Mediation
ID TOTAL JOINT ARTHROPLASTY; C REACTIVE PROTEIN; INFLAMMATION;
   METAANALYSIS; NONUNION; RISK; ACETAMINOPHEN; VARIANTS; RATES
AB Background: Osteomyelitis and major depressive disorder (MDD) are significant health concerns with potential interconnections. However, the underlying mechanisms linking these conditions remain unknown. This study aimed to investigate the potential mediating role of non steroidal anti inflammatory drug (NSAID) medication in the association between MDD and the risk of osteomyelitis. Methods: We utilized summary data from large scale genome wide association studies (GWAS) to perform Mendelian randomization (MR) mediation analysis. Instrumental variables were selected based on genome wide significance, and instrumental strength was assessed using F statistics. Univariable and multivariable MR analyses were conducted to estimate causal effects and proportions mediated by NSAID medication. Results: The univariable MR analysis revealed significant associations between MDD and osteomyelitis (odds ratio [OR] = 1.44, 95 % confidence interval [CI]: 1.18 1.874) and between MDD and NSAID medication (OR = 1.36, 95 % CI 1.24 1.49). In the multivariable MR analysis, the direct effect of MDD on osteomyelitis was OR 1.35 (95 % CI: 1.09, 1.67) after adjusting for NSAID medication. The proportion of mediation by NSAID medication was 23 % (95 % CI: 0.05 %, 38.6 %). Conclusion: This MR study provides evidence for a genetically predicted causal association between MDD, NSAID medication, and osteomyelitis. The findings emphasize the need for a comprehensive approach in managing individuals with comorbid depression and osteomyelitis, considering the potential risks and benefits of NSAID medication. Future research should address limitations and explore additional mediators and confounding factors to enhance understanding of this complex relationship.
C1 [Chen, Baixing] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium.
   [Pu, Bin] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Li, Shaoshuo] Nanjing Univ Tradit Chinese Med, Wuxi Affiliated Hosp, Wuxi, Peoples R China.
   [Gong, Yu; Dong, Hang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
C3 KU Leuven; Guangzhou University of Chinese Medicine; Nanjing University
   of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Dong, H (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM baixing.chen@kuleuven.be; pubin@stu.gzucm.edu.cn; 20193139@njucm.edu.cn;
   donghang5018@gzucm.edu.cn
OI Chen, Baixing/0000 0002 4158 6816
FU National Natural Science Foundation of China [82004390]; National Studio
   Construction projects for the famous experts in Traditional Chinese
   Medicine (Huang Feng studio); China Scholarship Council;  [N75]
FX This work was funded by National Natural Science Foundation of China
   (82004390) , National Studio Construction projects for the famous
   experts in Traditional Chinese Medicine (Huang Feng studio N75, 2022)
   and China Scholarship Council.
CR Benros ME, 2013, JAMA PSYCHIAT, V70, P812, DOI 10.1001/jamapsychiatry.2013.1111
   Beurel E, 2020, NEURON, V107, P234, DOI 10.1016/j.neuron.2020.06.002
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Browne JA, 2014, J ARTHROPLASTY, V29, P481, DOI 10.1016/j.arth.2013.08.025
   Buller LT, 2015, J ARTHROPLASTY, V30, P165, DOI 10.1016/j.arth.2014.08.034
   Burgess S, 2015, INT J EPIDEMIOL, V44, P484, DOI 10.1093/ije/dyu176
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Carter AR, 2021, EUR J EPIDEMIOL, V36, P465, DOI 10.1007/s10654 021 00757 1
   Díaz Rodríguez L, 2010, ACTA PHARMACOL SIN, V31, P1495, DOI 10.1038/aps.2010.129
   Dodwell ER, 2010, CALCIFIED TISSUE INT, V87, P193, DOI 10.1007/s00223 010 9379 7
   FinnGen, Documentation of R6 release
   Haapakoski R, 2015, BRAIN BEHAV IMMUN, V49, P206, DOI 10.1016/j.bbi.2015.06.001
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   Haycock PC, 2016, AM J CLIN NUTR, V103, P965, DOI 10.3945/ajcn.115.118216
   Howard DM, 2019, NAT NEUROSCI, V22, P343, DOI 10.1038/s41593 018 0326 7
   IsHak WW, 2018, HARVARD REV PSYCHIAT, V26, P352, DOI 10.1097/HRP.0000000000000198
   Iyengar RL, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2013.02.037
   Jeffcoach DR, 2014, J TRAUMA ACUTE CARE, V76, P779, DOI 10.1097/TA.0b013e3182aafe0d
   Kim H, 2021, J BONE JOINT SURG AM, V103, P1402, DOI 10.2106/JBJS.20.01663
   Köhler O, 2016, CURR NEUROPHARMACOL, V14, P732, DOI 10.2174/1570159X14666151208113700
   Köhler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611
   Köhler Forsherg O, 2019, ACTA PSYCHIAT SCAND, V139, P404, DOI 10.1111/acps.13016
   Massaccesi L, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11061061
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579 022 00686 0
   Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5
   Nakatsu Y, 2018, PHARMACOL REP, V70, P29, DOI 10.1016/j.pharep.2017.07.006
   Otte C, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.65
   Panteli M, 2016, EFORT OPEN REV, V1, P128, DOI 10.1302/2058 5241.1.000017
   Pasco JA, 2010, BRIT J PSYCHIAT, V197, P372, DOI 10.1192/bjp.bp.109.076430
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Rasouli MR, 2016, J ARTHROPLASTY, V31, P533, DOI 10.1016/j.arth.2015.09.015
   Rosoff DB, 2021, JAMA PSYCHIAT, V78, P151, DOI 10.1001/jamapsychiatry.2020.3554
   Sanderson E, 2019, INT J EPIDEMIOL, V48, P713, DOI 10.1093/ije/dyy262
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Sultan AR, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 84505 1
   Suneson K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041640
   Tseng CH, 2014, J PSYCHOSOM RES, V77, P535, DOI 10.1016/j.jpsychores.2014.09.008
   Urish KL, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00932 19
   Van Asten SAV, 2017, INT WOUND J, V14, P40, DOI 10.1111/iwj.12545
   Walker Venexia M, 2019, Wellcome Open Res, V4, P113, DOI 10.12688/wellcomeopenres.15334.2
   Walter N, 2022, J PSYCHOSOM RES, V157, DOI 10.1016/j.jpsychores.2022.110806
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   Zheng Jie, 2017, Curr Epidemiol Rep, V4, P330, DOI 10.1007/s40471 017 0128 6
NR 44
TC 8
Z9 9
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165 0327
EI 1573 2517
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD NOV 15
PY 2023
VL 341
BP 62
EP 66
DI 10.1016/j.jad.2023.08.121
EA AUG 2023
PG 5
WC Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Psychiatry
GA HY9D9
UT WOS:001163181700001
PM 37634817
OA hybrid
DA 2025 08 17
ER

PT J
AU Lu, MZ
   Wang, WT
   Fang, XL
   Xuan, Y
   Chen, LY
   Wang, XJ
   Wang, JH
   Wang, C
AF Lu, Mingzhou
   Wang, Weitao
   Fang, Xiuling
   Xuan, Yang
   Chen, Liying
   Wang, Xiaojing
   Wang, Jianhao
   Wang, Cheng
TI Facile one pot synthesis of multifunctional tetracycline hydrochloride
   nanoparticles with high stability and photothermal effect for
   synergistically improved antibacterial performance and sustainability
SO SUSTAINABLE CHEMISTRY AND PHARMACY
LA English
DT Article
DE Tetracycline; Nanoparticle; Photothermal; Antibacterial; Stability
ID OSTEOBLAST PROMOTION; CALCIUM SUPPLEMENT; ANTIBIOTICS; ENVIRONMENT;
   MECHANISMS; BACTERIA; REMOVAL
AB Tetracycline hydrochloride (TC) is a widely applied antibiotic. However, its instability requires overdose upon practical application, which raises the risk for the evolution of superbacteria. The solution to this matter lies in reducing the dosage of TC while maintaining its efficacy, which can be solved from two ways: 1) increasing the stability of TC; 2) improving the antibacterial ability of TC. Here in this study, with the aim to improve the stability of TC while with additional antibacterial ability, TC was assembled with ferric ion and polyvinylpyrrolidone (PVP) into TC multifunctional nanoparticles (TCFNPs). The Box Behnken Design (BBD) was firstly introduced to recognize the crucial formulation variables on the influencing of particle size of TCFNPs. Under the optimized condition, TCFNPs with size of 9.95 nm can be obtained and showed high storage stability. The as prepared TCFNPs not only showed comparable chemotherapeutic effects to free TC on both Gram positive strain (Staphylococcus aureus, S. aureus) and Gram negative strain of (Escherichia coli, E. coli), but also showed improved stability under room temperature upon light irradiation. Moreover, TCFNPs also exert photothermal effects which can synergistically provide enhanced antibacterial performance due to the combination of chemotherapy and photothermal therapy. Therefore, our study represents a new way to reform antibiotics with better stability and additional antibacterial ability for the better application of traditional antibacterial in agriculture.
C1 [Lu, Mingzhou; Fang, Xiuling; Wang, Jianhao; Wang, Cheng] Changzhou Univ, Sch Pharm, Changzhou 213164, Jiangsu, Peoples R China.
   [Lu, Mingzhou; Fang, Xiuling; Wang, Jianhao; Wang, Cheng] Changzhou Univ, Sch Biol & Food Engn, Changzhou 213164, Jiangsu, Peoples R China.
   [Wang, Weitao; Wang, Xiaojing] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Wang, Weitao; Chen, Liying] Tianjin Pharmaceut Res Inst Co Ltd, Tianjin 300301, Peoples R China.
   [Lu, Mingzhou] Changzhou Univ, Hua Lookeng Honors Coll, Changzhou 213164, Jiangsu, Peoples R China.
   [Wang, Jianhao] Jiangsu Traumark Med Instrument Co Ltd, Changzhou 213149, Jiangsu, Peoples R China.
   [Xuan, Yang] Dalian Minzu Univ, Coll Life Sci, Key Lab Biotechnol & Bioresources Utilizat, Minist Educ, Dalian 116600, Liaoning, Peoples R China.
C3 Changzhou University; Changzhou University; Tianjin University;
   Changzhou University; Dalian Minzu University
RP Wang, JH; Wang, C (通讯作者)，Changzhou Univ, Sch Pharm, Changzhou 213164, Jiangsu, Peoples R China.; Wang, JH; Wang, C (通讯作者)，Changzhou Univ, Sch Biol & Food Engn, Changzhou 213164, Jiangsu, Peoples R China.; Wang, XJ (通讯作者)，Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM tdxjwang@163.com; minuswan@cczu.edu.cn; wangc90@cczu.edu.cn
RI Wang, Weitao/B 2762 2010; Xuan, Yang/X 9965 2019; Chen,
   Liying/LEM 4496 2024
FU Project of Jiangsu Province Key Laboratory of Radiation Medicine and
   Protection, Soochow University [KJS2104]; Scientific Research Foundation
   of Jiangsu Provincial Education Department, China [21KJD350003]; Open
   Fund of Key Laboratory of Biotechnology and Bioresources Utilization
   (Dalian Minzu University) , Ministry of Education, China [KF2022001]
FX The authors acknowledge the FTIR and XRD results provided by SCI  GO
   (https:// www.sci go.com /) . The authors also acknowledge the support
   from Project of Jiangsu Province Key Laboratory of Radiation Medicine
   and Protection, Soochow University (No.KJS2104) ; Scientific Research
   Foundation of Jiangsu Provincial Education Department, China (No.
   21KJD350003) ; the Open Fund of Key Laboratory of Biotechnology and
   Bioresources Utilization (Dalian Minzu University) , Ministry of
   Education (No. KF2022001) , China.
CR Arana L, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11051251
   Chen H, 2011, J HAZARD MATER, V192, P44, DOI 10.1016/j.jhazmat.2011.04.089
   Chen XL, 2022, SCI TOTAL ENVIRON, V814, DOI 10.1016/j.scitotenv.2021.152852
   Da Cunha V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5544
   da Silva Junior R.C., 2020, ACS
   Daghrir R, 2013, ENVIRON CHEM LETT, V11, P209, DOI 10.1007/s10311 013 0404 8
   DAGRACA JV, 1991, ANNU REV PHYTOPATHOL, V29, P109, DOI 10.1146/annurev.py.29.090191.000545
   Deng LE, 2018, J INORG MATER, V33, P825, DOI 10.15541/jim20170498
   DOLUISIO JT, 1963, J MED CHEM, V6, P16, DOI 10.1021/jm00337a003
   Ema, 2016, EUR SURV VET ANT CON
   Fauci AS, 2014, JAMA J AM MED ASSOC, V311, P1853, DOI 10.1001/jama.2014.2465
   Feng WL, 2022, ADV MATER, V34, DOI 10.1002/adma.202109789
   Fernandes P, 2006, NAT BIOTECHNOL, V24, P1497, DOI 10.1038/nbt1206 1497
   Gharatape A, 2016, RSC ADV, V6, P111482, DOI 10.1039/c6ra18760a
   Ghosh D K., 2018, Advanced Agricultural Research Technology Journal, V2, P83
   Guo QL, 2022, MATER DESIGN, V224, DOI 10.1016/j.matdes.2022.111366
   Halling Sorensen B, 2002, ARCH ENVIRON CON TOX, V42, P263, DOI 10.1007/s00244 001 0017 2
   Haohua W.M.L.Y.W., 2004, J CHUXIONG NORMAL U, V19, P25
   Haris M, 2023, SCI TOTAL ENVIRON, V857, DOI 10.1016/j.scitotenv.2022.159639
   Huang DL, 2019, CHEM ENG J, V375, DOI 10.1016/j.cej.2019.121991
   Jechalke S, 2014, TRENDS MICROBIOL, V22, P536, DOI 10.1016/j.tim.2014.05.005
   Kuzma J., 2006, NANOTECHNOLOGY AGR F
   Liu B, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02356 17;e02356 17
   Liu DD, 2023, BIOMATERIALS, V292, DOI 10.1016/j.biomaterials.2022.121917
   Lyu JC, 2019, J PHYS CHEM SOLIDS, V129, P61, DOI 10.1016/j.jpcs.2018.12.041
   [马瑞 Ma Rui], 2005, [上海第二医科大学学报, Acta Universitatis Medicinalis Secondae Shanghai], V25, P826
   Marei N, 2019, INT J BIOL MACROMOL, V126, P262, DOI 10.1016/j.ijbiomac.2018.12.204
   Maya S, 2012, INT J BIOL MACROMOL, V51, P392, DOI 10.1016/j.ijbiomac.2012.06.009
   Mohamed MM, 2017, INT J VET SCI MED, V5, P23, DOI 10.1016/j.ijvsm.2017.02.003
   Ning SP, 2022, ACTA BIOMATER, V152, P562, DOI 10.1016/j.actbio.2022.08.067
   Peak D, 1999, J COLLOID INTERF SCI, V218, P289, DOI 10.1006/jcis.1999.6405
   Qing GC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12313 3
   Raveesha HR, 2019, J SCI ADV MATER DEV, V4, P57, DOI 10.1016/j.jsamd.2019.01.003
   Roberts MC, 2016, J ENVIRON QUAL, V45, P576, DOI 10.2134/jeq2015.04.0207
   Samadi N, 2020, INT J PHARMACEUT, V579, DOI 10.1016/j.ijpharm.2020.119136
   Shah MA, 2022, J ADV RES, V38, P55, DOI 10.1016/j.jare.2022.01.008
   Shao SC, 2020, CRIT REV BIOTECHNOL, V40, P1010, DOI 10.1080/07388551.2020.1805585
   Song JX, 2017, ENVIRON SCI TECHNOL, V51, P3040, DOI 10.1021/acs.est.6b05342
   Tang SH, 2019, COLLOID SURFACE B, V183, DOI 10.1016/j.colsurfb.2019.110429
   Tao S, 2021, J CONTROL RELEASE, V329, P121, DOI 10.1016/j.jconrel.2020.11.059
   Wang C, 2021, SMALL, V17, DOI 10.1002/smll.202007953
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Wang XW, 2021, CHEM SOC REV, V50, P8669, DOI 10.1039/d0cs00461h
   Worrall EA, 2018, AGRONOMY BASEL, V8, DOI 10.3390/agronomy8120285
   Xie Z., 2008, J S MED U, V28, P353
   Xiong H, 2021, J CONTROL RELEASE, V332, P539, DOI 10.1016/j.jconrel.2021.03.007
   Zarebkohan A, 2021, J DRUG DELIV SCI TEC, V66, DOI 10.1016/j.jddst.2021.102846
NR 47
TC 8
Z9 8
U1 3
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2352 5541
J9 SUSTAIN CHEM PHARM
JI SUSTAIN. CHEM. PHARM.
PD JUN
PY 2023
VL 33
AR 101120
DI 10.1016/j.scp.2023.101120
EA MAY 2023
PG 13
WC Chemistry, Multidisciplinary; Green & Sustainable Science & Technology;
   Environmental Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Environmental Sciences &
   Ecology
GA K5YW5
UT WOS:001017205200001
DA 2025 08 17
ER

PT J
AU Lee, J
   Youn, K
   Choi, NK
   Lee, JH
   Kang, D
   Song, HJ
   Park, BJ
AF Lee, Joongyub
   Youn, KyungEun
   Choi, Nam Kyong
   Lee, Jin Ho
   Kang, DongYoon
   Song, Hong Ji
   Park, Byung Joo
TI A population based case control study: proton pump inhibition and risk
   of hip fracture by use of bisphosphonate
SO JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Proton pump inhibitor; Hip fracture; Bisphosphonate
ID PEPTIC ULCER; THERAPY; METAANALYSIS; CALCIUM; OMEPRAZOLE; OSTEOPOROSIS;
   DETERMINANTS; ABSORPTION; RESORPTION; SECRETION
AB Studies on the risk of osteoporotic fractures related to the use of proton pump inhibitors (PPIs) have been inconsistent. One recent cohort study reported that there was an interaction between PPIs and bisphosphonates (BPs). Thus we performed a case control study aimed at evaluating the risk of hip fractures related to PPIs and exploring the interaction between PPIs and BPs.
   A case control study was performed using the Korean Health Insurance Review and Assessment Service database from 2005 January to 2006 June. The cases were all incident hip fractures identified from July 2005 to June 2006, and up to four controls were matched to each case by age, gender, and osteoporosis. Conditional logistic regression was used to calculate the adjusted odds ratio (aOR) and its 95 % confidence intervals.
   A total of 24,710 cases were identified and 98,642 controls were matched to the cases. The aOR and its 95 % CI of hip fractures related to the use of PPIs was 1.34 (95 % CI 1.24 1.44). When the study participants were stratified according to BP use, the aOR was 1.30 (95 % CI 1.19 1.42) in BP non users, which was significantly different from the 1.71 (95 % CI 1.31 2.23) of BP users. Only BP users showed a decreasing tendency toward fracture risk as exposure to PPI became less recent, and a trend of increasing risk with increasing cumulative doses.
   Our results suggest that the mechanism for increased risk of hip fracture by PPIs may arise mainly from interaction of BP and PPIs.
C1 [Lee, Joongyub; Choi, Nam Kyong; Park, Byung Joo] Seoul Natl Univ Hosp, Div Clin Epidemiol, Med Res Collaborating Ctr, Seoul 110744, South Korea.
   [Lee, Joongyub; Choi, Nam Kyong; Park, Byung Joo] Seoul Natl Univ, Coll Med, Seoul 110799, South Korea.
   [Youn, KyungEun] Korea Food & Drug Adm, Pharmaceut Management Div, Pharmaceut Safety Bur, Cheongwongun, South Korea.
   [Choi, Nam Kyong] Seoul Natl Univ, Inst Environm Med, Med Res Ctr, Seoul 110799, South Korea.
   [Lee, Jin Ho] Dongguk Univ, Dept Internal Med, Sch Med, Seoul, South Korea.
   [Kang, DongYoon; Park, Byung Joo] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul 110799, South Korea.
   [Song, Hong Ji] Hallym Univ, Dept Family Med, Coll Med, Chunchon, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU);
   Dongguk University; Seoul National University (SNU); Hallym University
RP Park, BJ (通讯作者)，Seoul Natl Univ, Coll Med, Dept Prevent Med, 28 Yeongon Dong, Seoul 110799, South Korea.
EM bjpark@snu.ac.kr
RI Park, Byung Joo/E 5438 2011
OI Choi, Nam Kyong/0000 0003 1153 9928; Kang, Dong Yoon/0000 0003 4283 2633
FU Korean Food and Drug Administration [07072KFDA224]
FX This study was supported by a grant from the Korean Food and Drug
   Administration (07072KFDA224)
CR Abrahamsen B, 2011, ARCH INTERN MED, V171, P998, DOI 10.1001/archinternmed.2011.20
   Bhatt DL, 2008, CIRCULATION, V118, P1894, DOI 10.1161/CIRCULATIONAHA.108.191087
   Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532 5415.2003.51110.x
   Chiu HF, 2010, PHARMACOEPIDEM DR S, V19, P1131, DOI 10.1002/pds.2026
   El Serag H, 2010, ALIMENT PHARM THER, V32, P720, DOI 10.1111/j.1365 2036.2010.04406.x
   Eom CS, 2011, ANN FAM MED, V9, P257, DOI 10.1370/afm.1243
   Gisbert JP, 2005, ALIMENT PHARM THER, V21, P795, DOI 10.1111/j.1365 2036.2005.02418.x
   Graziani G, 2002, NEPHRON, V91, P474, DOI 10.1159/000064290
   Hardy P, 1998, ARTIF ORGANS, V22, P569, DOI 10.1046/j.1525 1594.1998.06200.x
   JACOBSEN SJ, 1990, AM J PUBLIC HEALTH, V80, P871, DOI 10.2105/AJPH.80.7.871
   Kaye JA, 2008, PHARMACOTHERAPY, V28, P951, DOI 10.1592/phco.28.8.951
   Kwon S, 2003, HEALTH POLICY PLANN, V18, P84, DOI 10.1093/heapol/18.1.84
   Leontiadis GI, 2005, BMJ BRIT MED J, V330, P568, DOI 10.1136/bmj.38356.641134.8F
   Mamdani M, 2003, PHARMACOTHERAPY, V23, P1, DOI 10.1592/phco.23.1.1.31922
   MATTSSON JP, 1991, BIOCHIM BIOPHYS ACTA, V1065, P261, DOI 10.1016/0005 2736(91)90238 4
   Moayyedi P, 2008, AM J GASTROENTEROL, V103, P2428, DOI 10.1111/j.1572 0241.2008.02031.x
   Ngamruengphong S, 2011, AM J GASTROENTEROL, V106, P1209, DOI 10.1038/ajg.2011.113
   Penning van Beest FJA, 2006, CLIN THER, V28, P236, DOI 10.1016/j.clinthera.2006.01.002
   RECKER RR, 1985, NEW ENGL J MED, V313, P70, DOI 10.1056/NEJM198507113130202
   Roche JJW, 2005, BMJ BRIT MED J, V331, P1374, DOI 10.1136/bmj.38643.663843.55
   Rossini M, 2006, OSTEOPOROSIS INT, V17, P914, DOI 10.1007/s00198 006 0073 6
   Rzeszutek K, 2003, J CRANIOFAC SURG, V14, P301, DOI 10.1097/00001665 200305000 00007
   SERFATYLACROSNIERE C, 1995, J AM COLL NUTR, V14, P364
   Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330
   Targownik LE, 2011, EXPERT OPIN DRUG SAF, V10, P901, DOI 10.1517/14740338.2011.586628
   Targownik LE, 2010, GASTROENTEROLOGY, V138, P896, DOI 10.1053/j.gastro.2009.11.014
   TUUKKANEN J, 1986, CALCIFIED TISSUE INT, V38, P123, DOI 10.1007/BF02556841
   Vestergaard P, 2006, CALCIFIED TISSUE INT, V79, P76, DOI 10.1007/s00223 006 0021 7
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
   Yu EW, 2008, CALCIFIED TISSUE INT, V83, P251, DOI 10.1007/s00223 008 9170 1
   Yu EW, 2011, AM J MED, V124, P519, DOI 10.1016/j.amjmed.2011.01.007
NR 31
TC 38
Z9 42
U1 0
U2 8
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0944 1174
J9 J GASTROENTEROL
JI J. Gastroenterol.
PD SEP
PY 2013
VL 48
IS 9
BP 1016
EP 1022
DI 10.1007/s00535 012 0722 9
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 220GQ
UT WOS:000324571200003
PM 23307040
DA 2025 08 17
ER

PT J
AU Wang, YL
   Nguyen, USDT
   Lane, NE
   Lu, N
   Wei, J
   Lei, GH
   Zeng, C
   Zhang, YQ
AF Wang, Yilun
   Nguyen, Uyen Sa D. T.
   Lane, Nancy E.
   Lu, Na
   Wei, Jie
   Lei, Guanghua
   Zeng, Chao
   Zhang, Yuqing
TI Knee Osteoarthritis, Potential Mediators, and Risk of All Cause
   Mortality: Data From the Osteoarthritis Initiative
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID DISEASE SPECIFIC MORTALITY; LEUKOCYTE TELOMERE LENGTH; HIP
   OSTEOARTHRITIS; ASSOCIATION; BURDEN; NSAIDS
AB Objective To assess the relation of symptomatic knee osteoarthritis (OA), knee pain, and radiographic knee OA to All cause mortality and to identify mediators in the causal pathway.
   Methods Participants from the Osteoarthritis Initiative were divided into 4 groups: 1) symptomatic knee OA (i.e., both radiographic knee OA [Kellgren/Lawrence grade >= 2] and knee pain); 2) knee pain only; 3) radiographic knee OA only; and 4) neither radiographic knee OA nor knee pain. We examined the relation of knee OA status to All cause mortality using a multivariable Cox proportional hazards model and assessed the extent to which the association was mediated by disability, physical component summary (PCS) and mental component summary (MCS) scores for quality of life (QoL), and use of oral pain relief medications (i.e., nonsteroidal antiinflammatory drugs and opioids).
   Results Among 4,796 participants, 282 died over the 96 month follow up period. Compared with those with neither radiographic knee OA nor knee pain, multivariable adjusted hazard ratios (HRs) of mortality were 2.2 (95% confidence interval [95% CI] 1.6 3.1) for symptomatic knee OA, 0.9 (95% CI 0.6 1.4) for knee pain only, and 2.0 (95% CI 1.4 2.9) for radiographic knee OA only, respectively. Indirect effects (HRs) of symptomatic knee OA on mortality via disability and PCS of QoL were 1.1 (95% CI 1.0 1.4) and 1.2 (95% CI 1.0 1.4), respectively. No apparent mediation effect was observed through either MCS of QoL or oral pain relief medications use.
   Conclusion Participants with either symptomatic or radiographic knee OA were at an increased risk of All cause mortality. Increased risk of mortality from symptomatic knee OA was partially mediated through its effect on disability and PCS of QoL.
C1 [Wang, Yilun; Wei, Jie; Zeng, Chao] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China.
   [Nguyen, Uyen Sa D. T.] Univ North Texas, Hlth Sci Ctr, Ft Worth, TX USA.
   [Nguyen, Uyen Sa D. T.] Boston Univ, Sch Med, Boston, MA USA.
   [Lane, Nancy E.] Univ Calif Davis, Davis, CA USA.
   [Lu, Na] Arthrit Res Canada, Richmond, BC, Canada.
   [Wei, Jie; Zeng, Chao; Zhang, Yuqing] Harvard Med Sch, Mongan Inst, Massachusetts Gen Hosp, Boston, MA USA.
   [Lei, Guanghua] Cent South Univ, Xiangya Hosp, Hunan Key Lab Joint Degenerat & Injury, Changsha, Peoples R China.
   [Lei, Guanghua] Natl Clin Res Ctr Geriatr Disorders Xiangya, Changsha, Peoples R China.
C3 Central South University; University of North Texas System; University
   of North Texas Denton; Boston University; University of California
   System; University of California Davis; Arthritis Research Canada;
   Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Central South University
RP Zeng, C (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthopaed, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.; Zhang, YQ (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, 55 Fruit St, Boston, MA 02114 USA.
EM zengchao@csu.edu.cn; yzhang108@mgh.harvard.edu
RI ; WANG, YILUN/KFB 0627 2024; Wei, Jie/ACR 8087 2022
OI Nguyen, Uyen Sa/0000 0003 2715 9073; Wei, Jie/0000 0003 3510 8241;
   Zhang, Yuqing/0000 0001 7638 0888; Lei, Guanghua/0000 0003 2987 138X
FU National Natural Science Foundation of China [81772413, 81601941,
   81702207, 81702206]; Innovation Foundation of the Central South
   University [2018zzts045]
FX Supported by the National Natural Science Foundation of China (grants
   81772413, 81601941, 81702207, and 81702206) and the Innovation
   Foundation of the Central South University (postgraduate grant
   2018zzts045).
CR [Anonymous], 1995, SF 12: how to score the SF 12 physical and mental health summary scales
   Barbour KE, 2015, ARTHRITIS RHEUMATOL, V67, P1798, DOI 10.1002/art.39113
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140 6736(03)12384 7
   Cleveland RJ, 2019, OSTEOARTHR CARTILAGE, V27, P593, DOI 10.1016/j.joca.2018.12.008
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis 2013 204763
   Eckstein F, 2009, ANN RHEUM DIS, V68, P674, DOI 10.1136/ard.2008.089904
   Fitzpatrick AL, 2011, J GERONTOL A BIOL, V66, P421, DOI 10.1093/gerona/glq224
   GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017, Lancet, V390, P1211, DOI 10.1016/S0140 6736(17)32154 2
   Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140 6736(17)32130 X
   Institute for Health Metrics and Evaluation, 2013, GLOB BURD DIS GEN EV, P1
   Katz JN, 1996, MED CARE, V34, P73, DOI 10.1097/00005650 199601000 00006
   Kerr SJ, 2011, BRIT J CLIN PHARMACO, V71, P936, DOI 10.1111/j.1365 2125.2010.03702.x
   Kluzek S, 2016, ANN RHEUM DIS, V75, P1749, DOI 10.1136/annrheumdis 2015 208056
   Lange T, 2012, AM J EPIDEMIOL, V176, P190, DOI 10.1093/aje/kwr525
   Lee TA, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.03.003
   Liu Q, 2015, OSTEOARTHR CARTILAGE, V23, P1154, DOI 10.1016/j.joca.2015.03.021
   Liu Q, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03110 3
   Mendy A, 2018, INT J EPIDEMIOL, V47, P1821, DOI 10.1093/ije/dyy187
   Nevitt M., 2006, OSTEOARTHRITIS INITI
   Nüesch E, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d1165
   Piera Velazquez S, 2002, ARTHRITIS RHEUM, V46, P683, DOI 10.1002/art.10116
   Price JS, 2002, AGING CELL, V1, P57, DOI 10.1046/j.1474 9728.2002.00008.x
   Puig Junoy J, 2015, SEMIN ARTHRITIS RHEU, V44, P531, DOI 10.1016/j.semarthrit.2014.10.012
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Sattler M, 2012, OSTEOARTHR CARTILAGE, V20, P532, DOI 10.1016/j.joca.2012.02.635
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   Tsuboi M, 2011, J BONE MINER METAB, V29, P217, DOI 10.1007/s00774 010 0214 z
   Turkiewicz A, 2016, EPIDEMIOLOGY, V27, P479, DOI 10.1097/EDE.0000000000000477
   VanderWeele TJ, 2016, ANNU REV PUBL HEALTH, V37, P17, DOI 10.1146/annurev publhealth 032315 021402
   Veronese N, 2017, AM J CLIN NUTR, V106, P162, DOI 10.3945/ajcn.117.154872
   Veronese N, 2016, SEMIN ARTHRITIS RHEU, V46, P160, DOI 10.1016/j.semarthrit.2016.04.002
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650 199603000 00003
   Weischer M, 2012, ARTERIOSCL THROM VAS, V32, P822, DOI 10.1161/ATVBAHA.111.237271
   Willeit P, 2010, JAMA J AM MED ASSOC, V304, P69, DOI 10.1001/jama.2010.897
   WOLFE F, 1990, ARTHRITIS RHEUM US, V33, P160, DOI 10.1002/art.1780330203
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Zhai G, 2006, ANN RHEUM DIS, V65, P1444, DOI 10.1136/ard.2006.056903
NR 39
TC 42
Z9 49
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2151 464X
EI 2151 4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD APR
PY 2021
VL 73
IS 4
BP 566
EP 573
DI 10.1002/acr.24151
EA MAR 2021
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Rheumatology
GA RD5SH
UT WOS:000628341000001
PM 31961495
OA Green Submitted, Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Peng, SW
   Guo, XY
   Shang, GG
   Li, JA
   Xu, XY
   You, ML
   Li, P
   Chen, GQ
AF Peng, Si Wu
   Guo, Xiao Yong
   Shang, Guan Guan
   Li, Jian
   Xu, Xian Yi
   You, Ming Liang
   Li, Ping
   Chen, Guo Qiang
TI An assessment of the risks of carcinogenicity associated with
   polyhydroxyalkanoates through an analysis of DNA aneuploid and
   telomerase activity
SO BIOMATERIALS
LA English
DT Article
DE Polyhydroxyalkanoates; Proliferation; Carcinogenesis; PHB; Telomerase;
   PHBHHx
ID IMMORTALIZED HUMAN FIBROBLASTS; SMOOTH MUSCLE CELLS; L929 CELLS; GROWTH;
   PROLIFERATION; SUBSTRATE; ADHESION; 3 HYDROXYBUTYRATE; DIFFERENTIATION;
   MECHANISMS
AB Polyhydroxyalkanoates (PHA) are aliphatic polyesters synthesized by many bacteria. Because of their flexible mechanical strengths, superior elastic property, biodegradability and biocompatibility, PHA have been developed for applications as medical implants, drug delivery matrices, and devices to support cell growth. Lots of studies showed that PHA matrices improved cell proliferation and tissue regeneration. However, the possibility of whether rapid cell proliferation on PHA matrices will induce tumor formation is unclear. Here we confirmed that proliferating rat osteoblasts grown on films of various PHA including PHB, PHBV, P3HB4HB, PHBHHx and PHBVHHx did not lead to cancer induction at least for p8th. Cell proliferation was evaluated by the incorporation of 5 bromodeoxyuridine (BrdU), the transcript expression of cancer related genes Ki67, p53 and c Fos was monitored by quantitative Real time PCR, the results showed the cells proliferating on the PHA films were under normal cell cycle regulation. Moreover, DNA aneuploid and telomerase activity were only detected in the positive control UMR 108 cells; compared with cells grown on films, UMR 108 cells had longer telomeres, further demonstrated the normal status of cells proliferating on the PHA films. It indicated that the above PHA family members could be used to support cell growth without indication of susceptibility to tumor induction. These results will be important for promoting the application of PHA as new members of biomaterials. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Chen, Guo Qiang] Tsinghua Univ, Dept Biol Sci & Biotechnol, Sch Life Sci, Beijing 100084, Peoples R China.
   [Peng, Si Wu; Guo, Xiao Yong; Shang, Guan Guan; Li, Jian; Xu, Xian Yi; You, Ming Liang; Li, Ping] Shantou Univ, Multidisciplinary Res Ctr, Shantou 515063, Guangdong, Peoples R China.
C3 Tsinghua University; Shantou University
RP Chen, GQ (通讯作者)，Tsinghua Univ, Dept Biol Sci & Biotechnol, Sch Life Sci, Beijing 100084, Peoples R China.
EM chengq@mail.tsinghua.edu.cn
RI Guo, Xiaoyong/NTQ 2052 2025; LI, Junfeng/GSE 0020 2022; Peng,
   Siwu/G 6369 2015; Chen, Guo Qiang/M 3777 2016
OI Li, Jian/0009 0006 3162 538X; You, Mingliang/0000 0002 7051 6825; 
FU Li Ka Shing Foundation; National High Tech 863 Grants [2006AA020104,
   2007BAE42B03, 2010AA101607]; State Basic Science Foundation
   [2007CB707804]
FX The research was supported by Li Ka Shing Foundation, National High Tech
   863 Grants (Project No. 2006AA020104, 2007BAE42B03 and 2010AA101607) and
   the State Basic Science Foundation 973 (Grant No. 2007CB707804). We
   thank Mrs. Yuejuan Lin in the Analysis Center of Shantou University for
   assistance in many SEM studies.
CR ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751 1097.1990.tb08452.x
   BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435
   Binz N, 2005, EUR J CANCER, V41, P2873, DOI 10.1016/j.ejca.2005.08.025
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Chen GQ, 2005, BIOMATERIALS, V26, P6565, DOI 10.1016/j.biomaterials.2005.04.036
   Chen GQ, 2009, CHEM SOC REV, V38, P2434, DOI 10.1039/b812677c
   CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847
   Cheng S, 2006, BIOMATERIALS, V27, P3758, DOI 10.1016/j.biomaterials.2006.02.046
   Cheng S, 2005, BIOMACROMOLECULES, V6, P593, DOI 10.1021/bm049465y
   Cheng ST, 2008, BIOMATERIALS, V29, P4187, DOI 10.1016/j.biomaterials.2008.07.022
   Dahse R, 1996, CELL MOL BIOL, V42, P477
   Dahse R, 1997, CLIN CHEM, V43, P708
   DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529
   Endl E, 2000, EXP CELL RES, V257, P231, DOI 10.1006/excr.2000.4888
   FRANKFURT OS, 1984, CYTOMETRY, V5, P71, DOI 10.1002/cyto.990050111
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Köse GT, 2005, BIOMATERIALS, V26, P5187, DOI 10.1016/j.biomaterials.2005.01.037
   Lehnert D, 2004, J CELL SCI, V117, P41, DOI 10.1242/jcs.00836
   Misra SK, 2006, BIOMACROMOLECULES, V7, P2249, DOI 10.1021/bm060317c
   Ni Y, 2007, SOFT MATTER, V3, P1285, DOI 10.1039/b703376a
   Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440
   Novikova LN, 2008, BIOMATERIALS, V29, P1198, DOI 10.1016/j.biomaterials.2007.11.033
   Pan JY, 2009, BIOMATERIALS, V30, P2975, DOI 10.1016/j.biomaterials.2009.02.005
   Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661
   Peng SW, 2009, ENDOCRINOLOGY, V150, P3058, DOI 10.1210/en.2008 1731
   Qu XH, 2006, BIOMATERIALS, V27, P2944, DOI 10.1016/j.biomaterials.2006.01.013
   Serrano F, 2007, BIOMATERIALS, V28, P650, DOI 10.1016/j.biomaterials.2006.09.018
   Shan C, 2006, POLYM DEGRAD STABIL, V91, P3191, DOI 10.1016/j.polymdegradstab.2006.07.010
   Sugihara S, 1996, HUM GENET, V97, P1
   Sun J, 2007, BIOMATERIALS, V28, P3896, DOI 10.1016/j.biomaterials.2007.05.011
   Vasa M, 2000, CIRC RES, V87, P540, DOI 10.1161/01.RES.87.7.540
   VIM DG, 1991, BIOMATERIALS, V12, P731
   Wan YQ, 2005, BIOMATERIALS, V26, P4453, DOI 10.1016/j.biomaterials.2004.11.016
   Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027
   Xiao XQ, 2007, BIOMATERIALS, V28, P3608, DOI 10.1016/j.biomaterials.2007.04.046
   Xu XY, 2010, BIOMATERIALS, V31, P3967, DOI 10.1016/j.biomaterials.2010.01.132
   Ye C, 2009, BIOMATERIALS, V30, P4401, DOI 10.1016/j.biomaterials.2009.05.001
   Zhang HF, 2009, BIOTECHNOL BIOENG, V104, P582, DOI 10.1002/bit.22409
   Zhao Y, 2007, BIOMATERIALS, V28, P3063, DOI 10.1016/j.biomaterials.2007.03.003
   Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430
NR 43
TC 41
Z9 46
U1 2
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2011
VL 32
IS 10
BP 2546
EP 2555
DI 10.1016/j.biomaterials.2010.12.051
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 725EG
UT WOS:000287627400012
PM 21251707
DA 2025 08 17
ER

PT J
AU Osera, C
   Fassina, L
   Amadio, M
   Venturini, L
   Buoso, E
   Magenes, G
   Govoni, S
   Ricevuti, G
   Pascale, A
AF Osera, Cecilia
   Fassina, Lorenzo
   Amadio, Marialaura
   Venturini, Letizia
   Buoso, Erica
   Magenes, Giovanni
   Govoni, Stefano
   Ricevuti, Giovanni
   Pascale, Alessia
TI Cytoprotective Response Induced by Electromagnetic Stimulation on
   SH SY5Y Human Neuroblastoma Cell Line
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; HUMAN SAOS 2 OSTEOBLASTS; MAGNETIC FIELD
   EXPOSURE; PLASMA SPRAY SURFACE; ALZHEIMERS DISEASE;
   OCCUPATIONAL EXPOSURE; EXTRACELLULAR MATRIX; MECHANICAL CONTROL; UTILITY
   WORKERS; BREAST CANCER
AB It is well known that physiological functions and pathological conditions of cells and tissues can be influenced not only by chemical molecules, but also by physical stimuli such as electromagnetic waves. In particular, epidemiological studies suggest possible associations between exposure to electromagnetic fields and an increased risk of tumors and neurodegenerative disorders, such as Alzheimer's disease. However, depending on the dose and on the length of treatment, the electromagnetic stimuli can be harmful or induce a cytoprotective cellular response, suggesting a possible application in medical therapy. In this study, under a tissue engineering viewpoint, we investigated the effects of an electromagnetic wave (magnetic field intensity, 2 mT; frequency, 75 Hz) on a neuronal cellular model characterized by the overexpression of the amyloid precursor protein (APP). After a prolonged electromagnetic treatment, lower mitochondrial activity and proliferation rate, resulting in a higher cellular quiescence, were observed. Focusing on the stress and oxidative pathways, we detected an overall increase of two fundamental proteins, the chaperone heat shock protein HSP70 and the free radical scavenger superoxide dismutase 1 enzyme (SOD 1). Interestingly, we found that the electromagnetic stimulation promotes the nonamyloidogenic processing of APP through an increased expression of the alpha secretase ADAM10 and an enhanced release of the soluble neurotrophic factor sAPP alpha (a product of the ADAM10 mediated cleavage of APP). In conclusion, these findings suggest that the electromagnetic stimulus, if properly administered in terms of dose and timing, is able to induce a cytoprotective response in the cell. Moreover, these results suggest a possible use of this particular physical stimulation to improve the functional capability of the cells to face noxae.
C1 [Osera, Cecilia; Amadio, Marialaura; Buoso, Erica; Govoni, Stefano; Pascale, Alessia] Univ Pavia, Dipartimento Sci Farmaco, Sez Farmacol, I 27100 Pavia, Italy.
   [Fassina, Lorenzo; Magenes, Giovanni] Univ Pavia, Dipartimento Informat & Sistemist, I 27100 Pavia, Italy.
   [Fassina, Lorenzo; Magenes, Giovanni] Univ Pavia, CIT, I 27100 Pavia, Italy.
   [Venturini, Letizia; Ricevuti, Giovanni] Univ Pavia, Dipartimento Med Interna & Terapia Med, Sez Gerontol & Geriatria, IDR S Margherita, I 27100 Pavia, Italy.
   [Venturini, Letizia; Ricevuti, Giovanni] Univ Pavia, Lab Fisiopatol Cellulare & Immunol Clin, IRCCS S Matteo, I 27100 Pavia, Italy.
C3 University of Pavia; University of Pavia; University of Pavia;
   University of Pavia; University of Pavia; IRCCS Fondazione San Matteo
RP Pascale, A (通讯作者)，Univ Pavia, Dipartimento Sci Farmaco, Sez Farmacol, Viale Taramelli 14, I 27100 Pavia, Italy.
EM alessia.pascale@unipv.it
RI ; Magenes, Giovanni/C 4202 2012; Osera, Cecilia/K 3677 2016; Ricevuti,
   Giovanni/AAK 7707 2021; Fassina, Lorenzo/K 9283 2015; Govoni,
   Stefano/K 2965 2015
OI Buoso, Erica/0000 0003 1728 0443; Osera, Cecilia/0000 0002 7406 7166;
   Fassina, Lorenzo/0000 0002 5587 4632; Govoni,
   Stefano/0000 0002 7243 6837
FU INAIL
FX The authors are grateful to Dr. R. Cadossi and Dr. S. Setti, who
   presented us, generously, with the Biostim SPT pulse generator (Igea).
   This study was supported by INAIL Grant 2010 to Prof. G.R.
CR ALENGHAT FJ, 2002, SCI STKE, pE6
   Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737
   Amadio M, 2008, CURR PHARM DESIGN, V14, P2651, DOI 10.2174/138161208786264052
   Amadio M, 2009, J ALZHEIMERS DIS, V16, P409, DOI 10.3233/JAD 2009 0967
   Arendash GW, 2010, J ALZHEIMERS DIS, V19, P191, DOI 10.3233/JAD 2010 1228
   Cakir DU, 2009, ARCH MED RES, V40, P352, DOI 10.1016/j.arcmed.2009.07.001
   Carmody S, 2000, J CELL BIOCHEM, V79, P453, DOI 10.1002/1097 4644(20001201)79:3<453::AID JCB100>3.0.CO;2 M
   Cenini G, 2010, AMINO ACIDS, V39, P271, DOI 10.1007/s00726 009 0438 1
   Cornaglia AI, 2006, EUR J HISTOCHEM, V50, P199
   Coulton LA, 2004, RADIAT RES, V161, P430, DOI 10.1667/RR3145
   Davanipour Z, 1997, BIOELECTROMAGNETICS, V18, P28, DOI 10.1002/(SICI)1521 186X(1997)18:1<28::AID BEM6>3.0.CO;2 7
   Davanipour Z, 2007, BMC NEUROL, V7, DOI 10.1186/1471 2377 7 13
   Del Giudice E, 2007, NEUROSCI LETT, V418, P9, DOI 10.1016/j.neulet.2007.02.057
   DiCarlo AL, 1999, CIRCULATION, V99, P813, DOI 10.1161/01.CIR.99.6.813
   Fanelli C, 1999, FASEB J, V13, P95, DOI 10.1096/fasebj.13.1.95
   Fassina L, 2007, Technol Health Care, V15, P33
   Fassina L, 2008, J BIOMED MATER RES A, V87A, P750, DOI 10.1002/jbm.a.31827
   Fassina L, 2007, P ANN INT IEEE EMBS, P6415
   Fassina L, 2006, TISSUE ENG, V12, P1985, DOI 10.1089/ten.2006.12.1985
   Fassina L, 2010, J BIOMED MATER RES A, V93A, P1272, DOI 10.1002/jbm.a.32620
   Fassina L, 2008, IEEE ENG MED BIO, P3582, DOI 10.1109/IEMBS.2008.4649980
   Fassina L, 2009, TISSUE ENG PART C ME, V15, P233, DOI 10.1089/ten.tec.2008.0398
   García AM, 2008, INT J EPIDEMIOL, V37, P329, DOI 10.1093/ije/dym295
   Goodman R, 2002, J CELL PHYSIOL, V192, P16, DOI 10.1002/jcp.10098
   Goodman R, 2009, INT J RADIAT BIOL, V85, P851, DOI [10.3109/09553000903072488, 10.1080/09553000903072488]
   Greenland S, 2000, EPIDEMIOLOGY, V11, P624, DOI 10.1097/00001648 200011000 00003
   Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043
   Huang S, 2005, CANCER CELL, V8, P175, DOI 10.1016/j.ccr.2005.08.009
   Huss A, 2009, AM J EPIDEMIOL, V169, P167, DOI 10.1093/aje/kwn297
   Ingber D, 1998, J CELL BIOCHEM, P232, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<232::AID JCB28>3.0.CO;2 O
   Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di
   Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333
   Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360
   Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359
   Johansen C, 2007, OCCUP ENVIRON MED, V64, P782, DOI 10.1136/oem.2006.029116
   Kaszuba Zwoinska J, 2008, J PHYSIOL PHARMACOL, V59, P177
   Kheifets L, 2008, J OCCUP ENVIRON MED, V50, P677, DOI 10.1097/JOM.0b013e3181757a27
   Lacy Hulbert A, 1998, FASEB J, V12, P395, DOI 10.1096/fasebj.12.6.395
   Lange S, 2004, CELL PROLIFERAT, V37, P337, DOI 10.1111/j.1365 2184.2004.00317.x
   Lange S, 2002, RADIAT ENVIRON BIOPH, V41, P131, DOI 10.1007/s00411 002 0145 8
   Lele TP, 2006, J CELL BIOCHEM, V97, P1175, DOI 10.1002/jcb.20761
   Mammoto A, 2009, CURR OPIN CELL BIOL, V21, P864, DOI 10.1016/j.ceb.2009.08.001
   Mammoto T, 2010, DEVELOPMENT, V137, P1407, DOI 10.1242/dev.024166
   Mannerling AC, 2010, RADIAT ENVIRON BIOPH, V49, P731, DOI 10.1007/s00411 010 0306 0
   Panagopoulos DJ, 2002, BIOCHEM BIOPH RES CO, V298, P95, DOI 10.1016/S0006 291X(02)02393 8
   Papp E, 2003, BIOFACTORS, V17, P249, DOI 10.1002/biof.5520170124
   Pascale A, 1996, NEUROSCI LETT, V214, P99, DOI 10.1016/0304 3940(96)12901 3
   Pasquini R, 2003, TOXICOL IN VITRO, V17, P581, DOI 10.1016/S0887 2333(03)00137 1
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Perez FP, 2008, EXP GERONTOL, V43, P307, DOI 10.1016/j.exger.2008.01.004
   Pollán M, 2001, AM J IND MED, V39, P276, DOI 10.1002/1097 0274(200103)39:3<276::AID AJIM1015>3.0.CO;2 B
   Racchi M, 2003, MOL PSYCHIATR, V8, P209, DOI 10.1038/sj.mp.4001204
   Rao S, 1996, J CELL BIOCHEM, V63, P358
   Rattan SIS, 2004, ANN NY ACAD SCI, V1019, P554, DOI 10.1196/annals.1297.103
   Savitz DA, 1999, AM J EPIDEMIOL, V149, P135
   Simkó M, 2004, J CELL BIOCHEM, V93, P83, DOI 10.1002/jcb.20198
   Simkó M, 2007, CURR MED CHEM, V14, P1141, DOI 10.2174/092986707780362835
   Sobel E, 1996, NEUROLOGY, V47, P1477, DOI 10.1212/WNL.47.6.1477
   Sorahan T, 2007, OCCUP ENVIRON MED, V64, P820, DOI 10.1136/oem.2006.031559
   Tokalov SV, 2004, ENVIRON RES, V94, P145, DOI 10.1016/S0013 9351(03)00088 4
   Touitou Y, 2006, CANCER CAUSE CONTROL, V17, P547, DOI 10.1007/s10552 005 9014 5
   Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301 0082(03)00089 3
   Webster NJ, 2004, MOL BRAIN RES, V130, P161, DOI 10.1016/j.molbrainres.2004.06.042
NR 63
TC 39
Z9 40
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD OCT
PY 2011
VL 17
IS 19 20
BP 2573
EP 2582
DI 10.1089/ten.tea.2011.0071
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 823VW
UT WOS:000295155800020
PM 21615217
DA 2025 08 17
ER

PT J
AU Kazek Kesik, A
   Nosol, A
   Plonka, J
   Smiga Matuszowicz, M
   Student, S
   Brzychczy Wloch, M
   Krok Borkowicz, M
   Pamula, E
   Simka, W
AF Kazek Kesik, Alicja
   Nosol, Agnieszka
   Plonka, Joanna
   Smiga Matuszowicz, Monika
   Student, Sebastian
   Brzychczy Wloch, Monika
   Krok Borkowicz, Malgorzata
   Pamula, Elzbieta
   Simka, Wojciech
TI Physico chemical and biological evaluation of doxycycline loaded into
   hybrid oxide polymer layer on Ti Mo alloy
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Biomaterials; Titanium alloy; Plasma electrolytic oxidation;
   Oxide polymer hybrid coatings; Doxycycline
ID PLASMA ELECTROLYTIC OXIDATION; ANTIBACTERIAL ACTIVITY; TITANIUM; PLGA;
   BIOCOMPATIBILITY; BIOACTIVITY; RELEASE; MECHANISM
AB Oxide polymer coatings were formed on the surface of the vanadium free Ti 15Mo titanium alloy. The Ti alloy surface was modified by the plasma electrolytic oxidation process, and then, the polymer layer of a poly (D, L lactide co glycolide) with doxycycline was formed. The polymer evenly covered the porous oxide layer and filled some of the pores. However, the microstructure of the polymer surface was completely different from that of the PEO layer. The surface morphology, roughness and microstructure of the polymer layer were examined by scanning electron microscopy (SEM) and a confocal microscope. The results confirmed the effectiveness of polymer and doxycycline deposition in their stable chemical forms. The drug analysis was performed by high performance liquid chromatography. The 1H NMR technique was used to monitor the course of hydrolytic degradation of PLGA. It was shown that the PLGA layer is hydrolysed within a few weeks, and the polyglycolidyl part of the copolymer is hydrolysed to glycolic acid as first and much faster than the polylactide one to lactic acid. This paper presents influence of different microstructures on the biological properties of modified titanium alloys. Cytocompatibility and bacterial adhesion tests were evaluated using osteoblast like MG 63 cells and using the reference S. aureus and S. epidermidis strains. The results showed that the optimum concentration of doxycycline was found to inhibit the growth of the bacteria and that the layer is still cytocompatible.
C1 [Kazek Kesik, Alicja; Nosol, Agnieszka; Plonka, Joanna; Simka, Wojciech] Silesian Tech Univ, Fac Chem, B Krzywoustego St 6, PL 44100 Gliwice, Poland.
   [Kazek Kesik, Alicja; Student, Sebastian] Silesian Tech Univ, Biotechnol Ctr, Krzywoustego 8 St, PL 44100 Gliwice, Poland.
   [Smiga Matuszowicz, Monika] Silesian Tech Univ, Fac Chem, M Strzody 9 St, PL 44100 Gliwice, Poland.
   [Student, Sebastian] Silesian Tech Univ, Fac Automat Control Elect & Comp Sci, Dept Syst Biol & Engn, Akad 16 St, PL 44100 Gliwice, Poland.
   [Brzychczy Wloch, Monika] Jagiellonian Univ Med Coll, Dept Microbiol, Czysta 18 St, PL 31121 Krakow, Poland.
   [Krok Borkowicz, Malgorzata; Pamula, Elzbieta] AGH Univ Sci & Technol, Fac Mat Sci & Ceram, Mickiewicza Av 30, PL 30059 Krakow, Poland.
C3 Silesian University of Technology; Silesian University of Technology;
   Silesian University of Technology; Silesian University of Technology;
   Jagiellonian University; Collegium Medicum Jagiellonian University; AGH
   University of Krakow
RP Kazek Kesik, A (通讯作者)，Silesian Tech Univ, Biotechnol Ctr, Krzywoustego 8 St, PL 44100 Gliwice, Poland.
EM alicja.kazek kesik@polsl.pl
RI Pamuła, Elżbieta/A 2813 2017; Simka, Wojciech/AAW 9951 2020;
   Śmiga Matuszowicz, Monika/R 9838 2018; Kazek Kesik, Alicja/C 5610 2017;
   Płonka, Joanna/S 7456 2018; Pamula, Elzbieta/A 2813 2017; Student,
   Sebastian/H 7895 2013; Plonka, Joanna/S 7456 2018
OI Kazek Kesik, Alicja/0000 0001 9971 7279; Pamula,
   Elzbieta/0000 0002 0464 6189; Simka, Wojciech/0000 0002 2648 5523;
   Krok Borkowicz, Malgorzata/0000 0002 9415 0282; Plonka,
   Joanna/0000 0002 2507 2508
FU National Science Centre, Poland [UMO 2016/21/D/ST5/01652]; Rector's
   Grant in the field of research and development (Silesian University of
   Technology, Poland) [04/010/RGJ19/0095]
FX This work was supported by the National Science Centre, Poland
   (UMO 2016/21/D/ST5/01652).This work was supported by Rector's Grant in
   the field of research and development (Silesian University of
   Technology, Poland, 04/010/RGJ19/0095).
CR Bakhsheshi Rad HR, 2018, MATER DESIGN, V139, P212, DOI 10.1016/j.matdes.2017.10.072
   Brunette D.M., 2001, Titanium in Medicine. Engineering Materials
   Catauro M, 2015, J SOL GEL SCI TECHN, V76, P241, DOI 10.1007/s10971 015 3771 8
   Catauro M, 2015, MAT SCI ENG C MATER, V48, P548, DOI 10.1016/j.msec.2014.12.035
   Catauro M, 2014, J BIOMED MATER RES A, V102, P4473, DOI 10.1002/jbm.a.35116
   Chukwudi CU, 2016, ANTIMICROB AGENTS CH, V60, P4433, DOI 10.1128/AAC.00594 16
   Santis R, 2013, POLYM COMPOSITE, V34, P1413, DOI 10.1002/pc.22446
   El Neweshy MS, 2013, INT J EXP PATHOL, V94, P109, DOI 10.1111/iep.12013
   Hassani M, 2008, J AGR FOOD CHEM, V56, P2676, DOI 10.1021/jf800008p
   Jahromi LP, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03451
   Ji W, 2012, BIOMATERIALS, V33, P6604, DOI 10.1016/j.biomaterials.2012.06.018
   Kapoor DN, 2015, THER DELIV, V6, P41, DOI [10.4155/TDE.14.91, 10.4155/tde.14.91]
   Kazek Kesik A, 2019, MAT SCI ENG C MATER, V94, P998, DOI 10.1016/j.msec.2018.10.049
   Kazek Kesik A, 2016, SURF COAT TECH, V302, P158, DOI 10.1016/j.surfcoat.2016.05.073
   Kazek Kesik A, 2014, MAT SCI ENG C MATER, V39, P259, DOI 10.1016/j.msec.2014.03.008
   Keceli Sema Akin, 2004, Turkish Journal of Engineering and Environmental Sciences, V28, P49
   Misra R, 2012, METHOD ENZYMOL, V509, P61, DOI 10.1016/B978 0 12 391858 1.00004 6
   Mortazavi G, 2019, APPL SURF SCI, V488, P370, DOI 10.1016/j.apsusc.2019.05.250
   Phaechamud T, 2019, INT J BIOL MACROMOL, V135, P1261, DOI 10.1016/j.ijbiomac.2018.11.098
   Pouilleau J, 1997, MAT SCI ENG B SOLID, V47, P235, DOI 10.1016/S0921 5107(97)00043 3
   Quintero D, 2014, SURF COAT TECH, V258, P1223, DOI 10.1016/j.surfcoat.2014.06.058
   Ramírez Agudelo R, 2018, MAT SCI ENG C MATER, V83, P25, DOI 10.1016/j.msec.2017.08.012
   Raval JP, 2014, J SAUDI CHEM SOC, V18, P566, DOI 10.1016/j.jscs.2011.11.004
   Smith LJ, 2007, INT J NANOMED, V2, P493
   Snizhko LO, 2004, ELECTROCHIM ACTA, V49, P2085, DOI 10.1016/j.electacta.2003.11.027
   Tamimi F, 2008, J BIOMED MATER RES A, V85A, P707, DOI 10.1002/jbm.a.31610
   Vey E, 2011, POLYM DEGRAD STABIL, V96, P1882, DOI 10.1016/j.polymdegradstab.2011.07.011
   Wang TT, 2017, BIOACT MATER, V2, P44, DOI 10.1016/j.bioactmat.2017.02.001
   Xing R, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/5/055003
   Zhao L, 2011, J MATER SCI, V46, P4986, DOI 10.1007/s10853 011 5416 9
NR 30
TC 28
Z9 29
U1 2
U2 28
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD SEP
PY 2020
VL 5
IS 3
BP 553
EP 563
DI 10.1016/j.bioactmat.2020.04.009
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA MH2QH
UT WOS:000546576100011
PM 32373761
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zainudin, NHM
   Sisin, NNT
   Ab Rashid, R
   Jamil, A
   Anuar, MAK
   Razak, KA
   Abdullah, R
   Rahman, WN
AF Zainudin, Nur Hamizah Mohd
   Sisin, Noor Nabilah Talik
   Ab Rashid, Raizulnasuha
   Jamil, Amirah
   Anuar, Muhammad Afiq Khairil
   Razak, Khairunisak Abdul
   Abdullah, Reduan
   Rahman, Wan Nordiana
TI Cellular analysis on the radiation induced bystander effects due to
   bismuth oxide nanoparticles with 6 MV photon beam radiotherapy
SO JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES
LA English
DT Article
DE Radiotherapy; Bystander effect; Bismuth oxide nanoparticles; MCF 7; hFOB
   1.19
ID DNA DAMAGE; GOLD NANOPARTICLES; CANCER CELLS; RADIOSENSITIZATION;
   IRRADIATION; THERAPY; MCF 7
AB Background: The therapeutic strategies in killing the cancerous tissue while keeping the normal healthy tissue uninterrupted can be further improved by introducing nanoparticles as radiosensitizer in radiotherapy. Never theless, healthy cells might still be affected by radiation induced bystander effect (RIBE) response due the presence of nanoparticles. Thus, the potential negative effects in non irradiated adjacent cells must be investigated. Aim: The current study aims to explore the cellular effects of bismuth oxide nanoparticles (Bi2O3 NPs) on human breast cancer (MCF 7) and human foetal osteoblast (hFOB 1.19) cells due to the RIBE after irradiation with 6 MV clinical photon beam. Materials and methods: The irradiated cell conditioned medium (ICCM) treated with and without Bi2O3 NPs from the irradiated cells were collected and then transferred into the non targeted cells. The ability of the bystander cells to proliferate and their ROS generation were analyzed. DNA status of the cells and the possibility of apoptosis were evaluated using FTIR spectroscopy and MUSE Cell Analyzer, respectively. Results: The current study revealed that MCF 7 and hFOB 1.19 bystander cells may continue to proliferate and survive following short and long term incubation with ICCM treatment with Bi2O3 NPs. The survival rate of the treated bystander cells increased approximately 3% 8% compared to the untreated group. Although the bystander cells exhibited an increase in ROS and apoptosis, the addition of Bi2O3 NPs had no significant detri mental influence on the cells. Variation in the DNA vibrational amplitude detected by FTIR in bystander cells was less than 5% compared to the control group. Conclusion: This study discovered that the application of Bi2O3 NPs as a radiosensitizer did not give a negative impact on the bystander cells. This outcome may give an advantage to the application of Bi2O3 NPs as radio  sensitizer in radiotherapy to enhance cancer cells death without introducing further detrimental effects to the non targeted cells.
C1 [Zainudin, Nur Hamizah Mohd; Sisin, Noor Nabilah Talik; Ab Rashid, Raizulnasuha; Jamil, Amirah; Anuar, Muhammad Afiq Khairil; Rahman, Wan Nordiana] Univ Sains Malaysia, Sch Hlth Sci, Med Radiat Programme, Hlth Campus, Kubang Kerian, Kelantan, Malaysia.
   [Razak, Khairunisak Abdul] Univ Sains Malaysia, Sch Mat & Mineral Resources Engn, George Town, Malaysia.
   [Abdullah, Reduan] Hosp Univ Sains Malaysia, Nucl Med Radiotherapy & Oncol Dept, Kubang Kerian, Kelantan, Malaysia.
   [Zainudin, Nur Hamizah Mohd] Univ Sultan Zainal Abidin, Fac Hlth Sci, Gong Badak Campus, Kuala Nerus, Malaysia.
   [Rahman, Wan Nordiana] Univ Sci Malaysia, Sch Hlth Sci, Med Radiat Programme, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
C3 Universiti Sains Malaysia; Universiti Sains Malaysia; Universiti Sains
   Malaysia; Universiti Sultan Zainal Abidin; Universiti Sains Malaysia
RP Rahman, WN (通讯作者)，Univ Sci Malaysia, Sch Hlth Sci, Med Radiat Programme, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
EM wandiana@usm.my
RI ; abdullah, reduan/F 3672 2016; Rahman, Wan/F 3036 2012; Mohd zainudin,
   Nur hamizah/GOK 2645 2022; Muhammad Afiq, Khairil Anuar/H 3961 2016;
   SISIN, NOOR NABILAH TALIK/Z 1467 2018; Razak, Khairunisak/M 9602 2019
OI mohd zainudin, nur hamizah/0000 0001 5399 0659; 
FU Ministry of Higher Education Malaysia [FRGS/1/2020/STG07/USM/02/2]
FX This research was funded by the Ministry of Higher Education Malaysia
   for Fundamental Research Grant Scheme (FRGS/1/2020/STG07/USM/02/2) and
   we would like to thank Hospital Universiti Sains Malaysia for their
   generosity in allowing us to utilize their facilities for this study.
CR Abdul Rashid Raizulnasuha, 2019, OpenNano, V4, DOI 10.1016/j.onano.2018.100027
   Abidin S. Z., 2017, MATER TODAY PROC, V00
   Abidin SZ, 2019, MATER TODAY PROC, V16, P1640, DOI 10.1016/j.matpr.2019.06.029
   Abudayyak M, 2017, CHEMOSPHERE, V169, P117, DOI 10.1016/j.chemosphere.2016.11.018
   Afiq KAM, 2018, RADIAT PHYS CHEM, V150, P40, DOI 10.1016/j.radphyschem.2018.04.018
   Calatayud MP, 2016, CURR NANOSCI, V12, P372, DOI 10.2174/1573413712666151124195846
   Chen B, 2020, ACTA ASTRONAUT, V166, P599, DOI 10.1016/j.actaastro.2018.12.005
   Fale PL, 2015, BBA MOL CELL RES, V1853, P2640, DOI 10.1016/j.bbamcr.2015.07.018
   Feiock C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163233
   Gault N, 2005, INT J RADIAT BIOL, V81, P767, DOI 10.1080/09553000500515368
   Gómez Millán J, 2012, RADIOTHER ONCOL, V102, P450, DOI 10.1016/j.radonc.2011.11.002
   Heuskin AC, 2013, RADIAT RES, V180, P491, DOI 10.1667/RR13358.1
   Jackson PA, 2010, EUR J RADIOL, V75, P104, DOI 10.1016/j.ejrad.2009.03.057
   Lara GG, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6134 5
   Lipiec E, 2015, RADIAT RES, V184, P73, DOI 10.1667/RR13798.1
   Lipiec E, 2013, RADIAT PHYS CHEM, V93, P135, DOI 10.1016/j.radphyschem.2013.03.037
   Marín A, 2015, REP PRACT ONCOL RADI, V20, P12, DOI 10.1016/j.rpor.2014.08.004
   McMahon SJ, 2016, NANOSCALE, V8, P581, DOI 10.1039/c5nr07089a
   Mesbahi A, 2010, REP PRACT ONCOL RADI, V15, P176, DOI 10.1016/j.rpor.2010.09.001
   Mi Yu, 2016, Cancer Nanotechnol, V7, P11, DOI 10.1186/s12645 016 0024 7
   Mihoubi W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180680
   Mitchell SA, 2004, RADIAT RES, V161, P397, DOI 10.1667/RR3137
   Mladenov E, 2018, INT J RADIAT BIOL, V94, P719, DOI 10.1080/09553002.2018.1434323
   Najafi M, 2014, J Biomed Phys Eng, V4, P163
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Paro AD, 2017, METHODS MOL BIOL, V1530, P391, DOI 10.1007/978 1 4939 6646 2_25
   Ricciardi V, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10082974
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Rosa S, 2017, CANCER NANOTECHNOL, V8, DOI 10.1186/s12645 017 0026 0
   Rostami A, 2016, RADIAT ENVIRON BIOPH, V55, P461, DOI 10.1007/s00411 016 0669 y
   Sabbatini S, 2017, BIOMED SPECTROSC IMA, V6, P85, DOI 10.3233/BSI 170171
   Sisin NNT, 2019, INT J NANOMED, V14, P9941, DOI 10.2147/IJN.S228919
   Soleymanifard S, 2012, J MED PHYS, V37, P102, DOI 10.4103/0971 6203.94745
   Song GS, 2017, ADV MATER, V29, DOI 10.1002/adma.201700996
   Stewart C, 2016, PHYS MEDICA, V32, P1444, DOI 10.1016/j.ejmp.2016.10.015
   Yang SN, 2015, CELL BIOCHEM BIOPHYS, V72, P877, DOI 10.1007/s12013 015 0555 2
   Zainudin NHM, 2020, RADIAT PHYS CHEM, V177, DOI 10.1016/j.radphyschem.2020.109143
   Zulkifli ZA, 2018, J PHYS CONF SER, V1082, DOI 10.1088/1742 6596/1082/1/012103
NR 38
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1687 8507
J9 J RADIAT RES APPL SC
JI J. Radiat. Res. Appl. Sci.
PD SEP
PY 2022
VL 15
IS 3
BP 318
EP 325
DI 10.1016/j.jrras.2022.08.003
EA AUG 2022
PG 8
WC Multidisciplinary Sciences; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 5A9PI
UT WOS:000863210600003
OA gold
DA 2025 08 17
ER

PT J
AU Haartmans, MJJ
   Timur, UT
   Emanuel, KS
   Caron, MMJ
   Jeuken, RM
   Welting, TJM
   Van Osch, GJVM
   Heeren, RMA
   Cillero Pastor, B
   Emans, PJ
AF Haartmans, Mirella J. J.
   Timur, Ufuk Tan
   Emanuel, Kaj S.
   Caron, Marjolein M. J.
   Jeuken, Ralph M.
   Welting, Tim J. M.
   van Osch, Gerjo J. V. M.
   Heeren, Ron M. A.
   Cillero Pastor, Berta
   Emans, Pieter J.
TI Evaluation of the Anti Inflammatory and Chondroprotective Effect of
   Celecoxib on Cartilage Ex Vivo and in a Rat Osteoarthritis Model
SO CARTILAGE
LA English
DT Article
DE knee osteoarthritis; NSAIDs; prostanoid; joint inflammation; proteomics
ID SELECTIVE COX 2 INHIBITION; ARTICULAR CARTILAGE; CHONDROCYTE SENESCENCE;
   PROSTAGLANDIN E 2; CYCLOOXYGENASE 2; EXPRESSION; KNEE; AGGRECANASES;
   ARTHRITIS; DELIVERY
AB Objective The potential chondroprotective effect of celecoxib, a nonsteroidal anti inflammatory drug and selective cyclooxygenase 2 inhibitor used to reduce pain and inflammation in knee osteoarthritis patients, is disputed. This study aimed at investigating the chondroprotective effects of celecoxib on (1) human articular cartilage explants and (2) in an in vivo osteoarthritis rat model. Design Articular cartilage explants from 16 osteoarthritis patients were cultured for 24 hours with celecoxib or vehicle. Secreted prostaglandins (prostaglandin E 2, prostaglandin F 2 alpha, prostaglandin D 2) and thromboxane B2 (TXB2) concentrations were determined in medium by ELISA, and protein regulation was measured with label free proteomics. Cartilage samples from 7 of these patients were analyzed for gene expression using real time quantitative polymerase chain reaction. To investigate the chondroprotective effect of celecoxib in vivo, 14 rats received an intra articular injection of celecoxib or 0.9% NaCl after osteoarthritis induction by anterior cruciate ligament transection and partial medial meniscectomy (ACLT/pMMx model). Histopathological scoring was used to evaluate osteoarthritis severity 12 weeks after injection. Results Secretion of prostaglandins, target of Nesh SH3 (ABI3BP), and osteonectin proteins decreased, whereas tissue inhibitor of metalloproteinase 2 (TIMP 2) increased significantly after celecoxib treatment in the human (ex vivo) explant culture. Gene expression of a disintegrin and metalloproteinase with thrombospondin motifs 4 and 5 (ADAMTS4/5) and metalloproteinase 13 (MMP13) was significantly reduced after celecoxib treatment in human cartilage explants. Cartilage degeneration was reduced significantly in an in vivo osteoarthritis knee rat model. Conclusions Our data demonstrated that celecoxib acts chondroprotective on cartilage ex vivo and a single intra articular bolus injection has a chondroprotective effect in vivo.
C1 [Haartmans, Mirella J. J.; Timur, Ufuk Tan; Emanuel, Kaj S.; Caron, Marjolein M. J.; Jeuken, Ralph M.; Welting, Tim J. M.] Maastricht Univ, Dept Orthopaed Surg, Lab Expt Orthoped, Maastricht, Netherlands.
   [Haartmans, Mirella J. J.; Heeren, Ron M. A.; Cillero Pastor, Berta] Maastricht Univ, Div Imaging Mass Spectrometry, Maastricht MultiModal Mol Imaging Inst M4i, Maastricht, Netherlands.
   [Emanuel, Kaj S.] Univ Amsterdam, Dept Orthopaed Surg, Amsterdam UMC, Amsterdam Movement Sci, Amsterdam, Netherlands.
   [van Osch, Gerjo J. V. M.] Univ Med Ctr Rotterdam, Dept Orthopaed & Sports Med, Erasmus MC, Rotterdam, Netherlands.
   [van Osch, Gerjo J. V. M.] Univ Med Ctr Rotterdam, Dept Otorhinolaryngol, Erasmus MC, Rotterdam, Netherlands.
   [Cillero Pastor, Berta] Maastricht Univ, MERLN Inst Technol Inspired Regenerat Med, Dept Cell Biol Inspired Tissue Engn, Univ Ssingel 40, NL 6229 ER Maastricht, Netherlands.
   [Emans, Pieter J.] Maastricht Univ Med Ctr, Dept Orthopaed Surg, Lab Expt Orthoped, Joint Preserving Clin, Maastricht, Netherlands.
C3 Maastricht University; Maastricht University; University of Amsterdam;
   Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Maastricht University;
   Maastricht University Medical Centre (MUMC); Maastricht University;
   Maastricht University Medical Centre (MUMC)
RP Cillero Pastor, B (通讯作者)，Maastricht Univ, Div Imaging Mass Spectrometry, Maastricht MultiModal Mol Imaging Inst M4i, Maastricht, Netherlands.; Cillero Pastor, B (通讯作者)，Maastricht Univ, MERLN Inst Technol Inspired Regenerat Med, Dept Cell Biol Inspired Tissue Engn, Univ Ssingel 40, NL 6229 ER Maastricht, Netherlands.; Cillero Pastor, B (通讯作者)，POB 6200, NL 6200 MD Maastricht, Netherlands.
EM b.cilleropastor@maastrichtuniversity.nl
RI ; Heeren, Ron/ABA 4858 2020
OI Emanuel, Kaj/0000 0002 4970 4303; Jeuken, Ralph/0000 0001 7729 8800;
   Caron, Marjolein/0000 0001 5316 9211; Haartmans,
   Mirella/0000 0001 8179 7098; Cillero Pastor, Berta/0000 0002 7407 1165
FU academic fund of Maastricht University Medical Center, Dutch Arthritis
   Foundation [LLP14]; Annadal Foundation; Dutch Research Council (NWO)
   domain Applied and Engineering Sciences [P15 23]; Dutch Province of
   Limburg through the LINK (Limburg INvesteert in haar Kenniseconomie)
   program
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the academic fund of Maastricht University Medical
   Center, Dutch Arthritis Foundation (LLP14), and Annadal Foundation, as
   well as by the Dutch Research Council (NWO) domain Applied and
   Engineering Sciences (P15 23). The research conducted at the M4i
   institute was funded by the Dutch Province of Limburg through the LINK
   (Limburg INvesteert in haar Kenniseconomie) program.
CR Alvarez Soria MA, 2008, RHEUMATOLOGY, V47, P627, DOI 10.1093/rheumatology/ken116
   Attur M, 2008, J IMMUNOL, V181, P5082, DOI 10.4049/jimmunol.181.7.5082
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Cabral Pacheco GA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249739
   Rodriguez Merchan EC, 2016, EXPERT REV HEMATOL, V9, P59, DOI 10.1586/17474086.2016.1112263
   Caron MMJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153162
   Dave M, 2013, IMMUNOL LETT, V152, P47, DOI 10.1016/j.imlet.2013.04.002
   de Boer TN, 2009, OSTEOARTHR CARTILAGE, V17, P482, DOI 10.1016/j.joca.2008.09.002
   Dong J, 2013, INT J PHARMACEUT, V441, P285, DOI 10.1016/j.ijpharm.2012.11.031
   Eveque Mourroux MR, 2021, J PROTEOME RES, V20, P2973, DOI 10.1021/acs.jproteome.1c00186
   Fosang AJ, 2008, NAT CLIN PRACT RHEUM, V4, P420, DOI 10.1038/ncprheum0841
   Fukai A, 2012, ARTHRITIS RHEUM US, V64, P198, DOI 10.1002/art.33324
   Gerwin N, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.05.030
   Giudici C, 2008, J BIOL CHEM, V283, P19551, DOI 10.1074/jbc.M710001200
   Goldenberg MM, 1999, CLIN THER, V21, P1497, DOI 10.1016/S0149 2918(00)80005 3
   Goldring Mary B, 2012, HSS J, V8, P7, DOI 10.1007/s11420 011 9250 z
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   Hissnauer TN, 2010, OSTEOARTHR CARTILAGE, V18, P1630, DOI 10.1016/j.joca.2010.10.002
   Hu QC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041742
   Jakob M, 2004, RHEUMATOLOGY, V43, P852, DOI 10.1093/rheumatology/keh197
   Janssen M, 2016, J CONTROL RELEASE, V244, P30, DOI 10.1016/j.jconrel.2016.11.003
   Jiang DH, 2010, INT J MOL SCI, V11, P4106, DOI 10.3390/ijms11104106
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kloppenburg M, 2020, OSTEOARTHR CARTILAGE, V28, P242, DOI 10.1016/j.joca.2020.01.002
   LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487
   Latini FRM, 2008, ENDOCR RELAT CANCER, V15, P787, DOI 10.1677/ERC 08 0079
   Li X, 2009, ARTHRITIS RHEUM US, V60, P513, DOI 10.1002/art.24258
   Manferdini C, 2013, ARTHRITIS RHEUM US, V65, P1271, DOI 10.1002/art.37908
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Martel Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049 0172(03)00134 3
   Martin JA, 2003, J BONE JOINT SURG AM, V85A, P106, DOI 10.2106/00004623 200300002 00014
   Mastbergen SC, 2006, RHEUMATOLOGY, V45, P405, DOI 10.1093/rheumatology/kei187
   Mastbergen SC, 2002, RHEUMATOLOGY, V41, P801, DOI 10.1093/rheumatology/41.7.801
   Mateos JL, 2010, DRUG TODAY, V46, P1
   Mehana ESE, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116786
   Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630
   Nakata K, 2018, OSTEOARTHR CARTILAGE, V26, P1263, DOI 10.1016/j.joca.2018.05.021
   Nanba Y, 1997, ACTA MED OKAYAMA, V51, P239
   Nishitani K, 2010, J CELL BIOCHEM, V109, P425, DOI 10.1002/jcb.22421
   Oo WM., 2019, CLIN EXP RHEUMATOL, V37
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Price JS, 2002, AGING CELL, V1, P57, DOI 10.1046/j.1474 9728.2002.00008.x
   Pruitt KD, 2009, NUCLEIC ACIDS RES, V37, pD32, DOI 10.1093/nar/gkn721
   Raynauld JP, 2010, SEMIN ARTHRITIS RHEU, V40, P185, DOI 10.1016/j.semarthrit.2009.10.003
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Sachs L., 1984, Applied Statistics a handbook of techniques
   Sato T, 2011, ANN RHEUM DIS, V70, P221, DOI 10.1136/ard.2009.118620
   Tellegen AR, 2018, DRUG DELIV, V25, P1438, DOI 10.1080/10717544.2018.1482971
   Timur UT, 2018, OSTEOARTHR CARTILAGE, V26, P697, DOI 10.1016/j.joca.2018.01.025
   Timur UT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186962
   Troeberg Linda, 2007, V135, P251
   Tsutsumi R, 2008, RHEUMATOL INT, V28, P727, DOI 10.1007/s00296 007 0511 6
   Verma P, 2011, J CELL BIOCHEM, V112, P3507, DOI 10.1002/jcb.23298
   Welting T J M, 2011, Eur Cell Mater, V22, P420
   Yang SF, 2008, CLIN BIOCHEM, V41, P109, DOI 10.1016/j.clinbiochem.2007.10.011
   Zarghi A, 2011, IRAN J PHARM RES, V10, P655
   Zweers MC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3437
NR 57
TC 13
Z9 15
U1 1
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1947 6035
EI 1947 6043
J9 CARTILAGE
JI Cartilage
PD JUL
PY 2022
VL 13
IS 3
AR 19476035221115541
DI 10.1177/19476035221115541
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 3R6SZ
UT WOS:000839041200001
PM 35932105
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lee, PT
   Lin, HH
   Jiang, ST
   Lu, PJ
   Chou, KJ
   Fang, HC
   Chiou, YY
   Tang, MJ
AF Lee, Po Tsang
   Lin, Hsi Hui
   Jiang, Si Tse
   Lu, Pei Jung
   Chou, Kang Ju
   Fang, Hua Chang
   Chiou, Yuan Yow
   Tang, Ming Jer
TI Mouse Kidney Progenitor Cells Accelerate Renal Regeneration and Prolong
   Survival After Ischemic Injury
SO STEM CELLS
LA English
DT Article
DE Adult stem cell; Kidney; Acute renal failure; Cell therapy; Reperfusion
   injury
ID ACUTE TUBULAR INJURY; LONG TERM OUTCOMES; HEAVY CHAIN IIA; STEM CELLS;
   GLOMERULAR NUMBER; ENDOTHELIAL CELLS; ADULT KIDNEY; FAILURE; PROTECT;
   MARROW
AB Acute tubular necrosis is followed by regeneration of damaged renal tubular epithelial cells, and renal stem cells are supposed to contribute to this process. The purpose of our study is to test the hypothesis that renal stem cells isolated from adult mouse kidney accelerate renal regeneration via participation in the repair process. A unique population of cells exhibiting characteristics consistent with renal stem cells, mouse kidney progenitor cells (MKPC), was isolated from Myh9 targeted mutant mice. Features of these cells include (1) spindle shaped morphology, (2) self renewal of more than 100 passages without evidence of senescence, and (3) expression of Oct 4, Pax 2, Wnt 4, WT 1, vimentin, alpha smooth muscle actin, CD29, and S100A4 but no SSEA 1, c kit, or other markers of more differentiated cells. MKPC exhibit plasticity as demonstrated by the ability to differentiate into endothelial cells and osteoblasts in vitro and endothelial cells and tubular epithelial cells in vivo. The origin of the isolated MKPC was from the interstitium of medulla and papilla. Importantly, intrarenal injection of MKPC in mice with ischemic injury rescued renal damage, as manifested by decreases in peak serum urea nitrogen, the infarct zone, and the necrotic injury. Seven days after the injury, some MKPC formed vessels with red blood cells inside and some incorporated into renal tubules. In addition, MKPC treatment reduces the mortality in mice after ischemic injury. Our results indicate that MKPC represent a multipotent adult stem cell population, which may contribute to the renal repair and prolong survival after ischemic injury. STEM CELLS 2010; 28: 573 584
C1 [Lin, Hsi Hui; Tang, Ming Jer] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan.
   [Lee, Po Tsang; Lu, Pei Jung] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan.
   [Lee, Po Tsang; Chou, Kang Ju; Fang, Hua Chang] Kaohsiung Vet Gen Hosp, Dept Med, Div Nephrol, Kaohsiung, Taiwan.
   [Lee, Po Tsang; Chou, Kang Ju; Fang, Hua Chang] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Chiou, Yuan Yow] Natl Cheng Kung Univ, Med Ctr, Dept Pediat, Tainan 70101, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University;
   Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung
   University; National Cheng Kung University
RP Tang, MJ (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Da Hsueh Rd, Tainan 701, Taiwan.
EM mjtang1@mail.ncku.edu.tw
RI Lee, Po Tsang/ACJ 3834 2022
OI Tang, Ming Jer/0000 0002 0883 4363; Jiang, Si Tse/0000 0002 5145 258X;
   Lin, Hsi Hui/0000 0002 4880 3481
FU Kaohsiung Veterans General Hospital [VGHKS96 21, VGHKS97 28,
   VGHKS98 26]; National Science Council [NSC 97 2314 B 075B 005]
FX We are grateful to Dr. Norimoto Yanagawa for helpful discussions on this
   study and critical comments on the manuscript. We also thank Hui Chuan
   Cheng, Kuei Fang Chiang, and Dr. Shiaw Min Hwang for technical
   assistance. This work was supported by grants from Kaohsiung Veterans
   General Hospital (VGHKS96 21, VGHKS97 28, and VGHKS98 26) and the
   National Science Council (NSC 97 2314 B 075B 005) to P. T.L.
CR Alexandre CS, 2009, STEM CELLS, V27, P682, DOI 10.1634/stemcells.2008 0496
   Alvarez Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896 6273(04)00111 4
   Arrondel C, 2002, J AM SOC NEPHROL, V13, P65, DOI 10.1681/ASN.V13165
   Basile DP, 2007, KIDNEY INT, V72, P151, DOI 10.1038/sj.ki.5002312
   BERTRAM JF, 1992, CELL TISSUE RES, V270, P37, DOI 10.1007/BF00381877
   Bi B, 2007, J AM SOC NEPHROL, V18, P2486, DOI 10.1681/ASN.2007020140
   Brodsky SV, 2002, AM J PHYSIOL RENAL, V282, pF1140, DOI 10.1152/ajprenal.00329.2001
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798
   Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002 9440(10)62276 6
   Byrne JA, 2003, CURR BIOL, V13, P1206, DOI 10.1016/S0960 9822(03)00462 7
   Chen J, 2008, KIDNEY INT, V74, P879, DOI 10.1038/ki.2008.304
   D'Apolito M, 2002, GENE, V286, P215, DOI 10.1016/S0378 1119(02)00455 9
   Dekel B, 2006, J AM SOC NEPHROL, V17, P3300, DOI 10.1681/ASN.2005020195
   Dressler GR, 2006, ANNU REV CELL DEV BI, V22, P509, DOI 10.1146/annurev.cellbio.22.010305.104340
   Gupta S, 2006, J AM SOC NEPHROL, V17, P3028, DOI 10.1681/ASN.2006030275
   HERZLINGER D, 1992, DEVELOPMENT, V114, P565
   Hishikawa K, 2005, J CELL BIOL, V169, P921, DOI 10.1083/jcb.200412167
   Hiyama E, 2007, BRIT J CANCER, V96, P1020, DOI 10.1038/sj.bjc.6603671
   Hughson M, 2003, KIDNEY INT, V63, P2113, DOI 10.1046/j.1523 1755.2003.00018.x
   JABLONSKI P, 1983, TRANSPLANTATION, V35, P198, DOI 10.1097/00007890 198303000 00002
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jones CH, 1998, AM J KIDNEY DIS, V31, P227, DOI 10.1053/ajkd.1998.v31.pm9469492
   Keller G, 2003, NEW ENGL J MED, V348, P101, DOI 10.1056/NEJMoa020549
   Kitamura S, 2005, FASEB J, V19, P1789, DOI 10.1096/fj.05 3942com
   Lazzeri E, 2007, J AM SOC NEPHROL, V18, P3128, DOI 10.1681/ASN.2007020210
   Morgera S, 2002, AM J KIDNEY DIS, V40, P275, DOI 10.1053/ajkd.2002.34505
   Morgera S, 2008, CRIT CARE MED, V36, pS193, DOI 10.1097/CCM.0b013e318168cae2
   Morigi M, 2008, STEM CELLS, V26, P2075, DOI 10.1634/stemcells.2007 0795
   NADASDY T, 1994, J AM SOC NEPHROL, V4, P2032
   NYENGAARD JR, 1992, ANAT REC, V232, P194, DOI 10.1002/ar.1092320205
   Okuda T, 2004, MOL BRAIN RES, V132, P18, DOI 10.1016/j.molbrainres.2004.08.021
   Oliver JA, 2002, AM J PHYSIOL RENAL, V283, pF799, DOI 10.1152/ajprenal.00375.2001
   Oliver JA, 2004, J CLIN INVEST, V114, P795, DOI 10.1172/JCI200420921
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089
   Schiffl H, 2006, NEPHROL DIAL TRANSPL, V21, P1248, DOI 10.1093/ndt/gfk069
   Sellers JR, 2000, BBA MOL CELL RES, V1496, P3, DOI 10.1016/S0167 4889(00)00005 7
   Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505
   Sutton TA, 2003, AM J PHYSIOL RENAL, V285, pF191, DOI 10.1152/ajprenal.00042.2003
   Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321
   Tögel F, 2005, AM J PHYSIOL RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Vigneau C, 2007, J AM SOC NEPHROL, V18, P1709, DOI 10.1681/ASN.2006101078
   Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Wurmser AE, 2004, SCIENCE, V304, P1253, DOI 10.1126/science.1099344
NR 45
TC 52
Z9 57
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD MAR 31
PY 2010
VL 28
IS 3
BP 573
EP 584
DI 10.1002/stem.310
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 588SJ
UT WOS:000277093700020
PM 20099318
DA 2025 08 17
ER

PT J
AU Ma, D
   Tremblay, P
   Mahngar, K
   Collins, J
   Hudlicky, T
   Pandey, S
AF Ma, Dennis
   Tremblay, Phillip
   Mahngar, Kevinjeet
   Collins, Jonathan
   Hudlicky, Tomas
   Pandey, Siyaram
TI Selective Cytotoxicity against Human Osteosarcoma Cells by a Novel
   Synthetic C 1 Analogue of 7 Deoxypancratistatin Is Potentiated by
   Curcumin
SO PLOS ONE
LA English
DT Article
ID PANCRATISTATIN INDUCES APOPTOSIS; OXYGEN SPECIES ROS; CANCER CELLS;
   AUTOPHAGY; MITOCHONDRIA; BIOLOGY; GROWTH; CHEMOTHERAPY; ACTIVATION;
   CHILDHOOD
AB The natural compound pancratistatin (PST) is a non genotoxic inducer of apoptosis in a variety of cancers. It exhibits cancer selectivity as non cancerous cells are markedly less sensitive to PST. Nonetheless, PST is not readily synthesized and is present in very low quantities in its natural source to be applied clinically. We have previously synthesized and evaluated several synthetic analogues of 7 deoxypancratistatin, and found that JC TH acetate 4 (JCTH 4), a C 1 acetoxymethyl analogue, possessed similar apoptosis inducing activity compared to PST. In this study, notoriously chemoresistant osteosarcoma (OS) cells (Saos 2, U 2 OS) were substantially susceptible to JCTH 4 induced apoptosis through mitochondrial targeting; JCTH 4 induced collapse of mitochondrial membrane potential (MMP), increased reactive oxygen species (ROS) production in isolated mitochondria, and caused release of apoptosis inducing factor (AIF) and endonuclease G (EndoG) from isolated mitochondria. Furthermore, JCTH 4 selectively induced autophagy in OS cells. Additionally, we investigated the combinatory effect of JCTH 4 with the natural compound curcumin (CC), a compound found in turmeric spice, previously shown to possess antiproliferative properties. CC alone had no observable effect on Saos 2 and U 2 OS cells. However, when present with JCTH 4, CC was able to enhance the cytotoxicity of JCTH 4 selectively in OS cells. Such cytotoxicity by JCTH 4 alone and in combination with CC was not observed in normal human osteoblasts (HOb) and normal human fetal fibroblasts (NFF). Therefore, this report illustrates a new window in combination therapy, utilizing a novel synthetic analogue of PST with the natural compound CC, for the treatment of OS.
C1 [Ma, Dennis; Tremblay, Phillip; Mahngar, Kevinjeet; Pandey, Siyaram] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.
   [Collins, Jonathan; Hudlicky, Tomas] Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada.
   [Collins, Jonathan; Hudlicky, Tomas] Brock Univ, Ctr Biotechnol, St Catharines, ON L2S 3A1, Canada.
C3 University of Windsor; Brock University; Brock University
RP Ma, D (通讯作者)，Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.
EM spandey@uwindsor.ca
RI ; Pandey, Siyaram/AAI 5491 2020
OI Collins, Jonathan/0000 0002 5591 5772; 
FU Canadian Institutes of Health Research (CIHR); Charles Best Canada
   Graduate Scholarship
FX Funding of this work has been provided as a generous gift by the Knights
   of Columbus Chapter 9671 (Windsor, ON, Canada). This work has also been
   supported by a Canadian Institutes of Health Research (CIHR) Frederick
   Banting and Charles Best Canada Graduate Scholarship awarded to Dennis
   Ma. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal BB, 2007, J CELL BIOCHEM, V102, P580, DOI 10.1002/jcb.21500
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200
   BAUM ES, 1981, CANCER TREAT REP, V65, P815
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Borst P, 2004, DRUG RESIST UPDATE, V7, P321, DOI 10.1016/j.drup.2004.11.003
   Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197 0186(01)00118 8
   Chatterjee SJ, 2011, EVID BASED COMPL ALT, V2011, DOI 10.1155/2011/129045
   Chatterjee S.J., 2010, Melanoma research
   Chen G, 2010, MITOCHONDRION, V10, P614, DOI 10.1016/j.mito.2010.08.001
   Cochemé HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200
   Collins J, 2010, J ORG CHEM, V75, P3069, DOI 10.1021/jo1003136
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Earnshaw WC, 1999, NATURE, V397, P387, DOI 10.1038/17015
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Flombaum CD, 1999, J CLIN ONCOL, V17, P1589, DOI 10.1200/JCO.1999.17.5.1589
   Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006
   Gogvadze V, 2010, MOL ASPECTS MED, V31, P60, DOI 10.1016/j.mam.2009.12.004
   GOORIN AM, 1991, J CLIN ONCOL, V9, P600, DOI 10.1200/JCO.1991.9.4.600
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365 2567.2004.01959.x
   Griffin C, 2011, INT J ONCOL, V38, P1549, DOI 10.3892/ijo.2011.977
   Griffin C, 2011, MOL CANCER THER, V10, P57, DOI 10.1158/1535 7163.MCT 10 0735
   Griffin C, 2010, CANCER CELL INT, V10, DOI 10.1186/1475 2867 10 6
   Gurjal A, 1999, LUNG CANCER J IASLC, V26, P109, DOI 10.1016/S0169 5002(99)00081 1
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kekre N, 2005, CANCER CHEMOTH PHARM, V56, P29, DOI 10.1007/s00280 004 0941 8
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kurien BT, 2007, ASSAY DRUG DEV TECHN, V5, P567, DOI 10.1089/adt.2007.064
   KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304 3835(85)90159 4
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   Loebstein R, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.6.e8
   Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716
   McLachlan A, 2005, APOPTOSIS, V10, P619, DOI 10.1007/s10495 005 1896 x
   MEISTRICH ML, 1989, CANCER AM CANCER SOC, V63, P2115, DOI 10.1002/1097 0142(19890601)63:11<2115::AID CNCR2820631108>3.0.CO;2 A
   Navaraj A, 2005, CANCER BIOL THER, V4, P1409, DOI 10.4161/cbt.4.12.2378
   Ovadje P, 2011, J ETHNOPHARMACOL, V133, P86, DOI 10.1016/j.jep.2010.09.005
   Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200
   Patel BB, 2009, NUTR CANCER, V61, P842, DOI 10.1080/01635580903285106
   Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74
   Pollack M., 2001, Journal of Gerontology, V11, P475
   Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248 009 9128 x
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002 9440(10)64779 7
   Siedlakowski P, 2008, CANCER BIOL THER, V7, P376, DOI 10.4161/cbt.7.3.5364
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307
   Singh S, 2007, CELL, V130, P765, DOI 10.1016/j.cell.2007.08.024
   SMITH MA, 1991, JNCI J NATL CANCER I, V83, P1460, DOI 10.1093/jnci/83.20.1460
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Ta LE, 2006, NEUROTOXICOLOGY, V27, P992, DOI 10.1016/j.neuro.2006.04.010
   Thayyullathil F, 2008, FREE RADICAL BIO MED, V45, P1403, DOI 10.1016/j.freeradbiomed.2008.08.014
   Walters DK, 2008, INVEST NEW DRUG, V26, P289, DOI 10.1007/s10637 007 9099 7
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01
   Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883
NR 70
TC 26
Z9 30
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 21
PY 2011
VL 6
IS 12
AR e28780
DI 10.1371/journal.pone.0028780
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 876NF
UT WOS:000299113600033
PM 22205968
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zaragosi, LE
   Billon, N
   Ailhaud, G
   Dani, C
AF Zaragosi, Laure Emmanuelle
   Billon, Nathalie
   Ailhaud, Gerard
   Dani, Christian
TI Nucleofection is a valuable transfection method for transient and stable
   transgene expression in adipose tissue derived stem cells
SO STEM CELLS
LA English
DT Article
DE adult stem cells; adipose tissue; nucleofection; transgene expression;
   transient; stable; secretion
ID GENE TRANSFER; ELECTROPORATION; PERSPECTIVES; DELIVERY; THERAPY; SYSTEM;
   MOUSE
AB Adipose tissue derived stem cells are a powerful tool for in vitro study of adult stem cell biology. So far, they have not been extensively used for gain or loss of function studies since they are resistant to most common transfection methods. Herein, we tested several classic transfection methods on human multipotent adipose tissue derived stem (hMADS) cells. Our results showed that lipofectants and calcium phosphate were poorly efficient for transgene delivery in hMADS cells. In contrast, nucleofection, an electroporation based method that is assumed to target plasmid DNA directly to the cell nucleus, led to a significant transient transgene expression in hMADS cells (up to 76% enhanced green fluorescent protein [EGFP] positive cells were detected). Furthermore, after selection of hMADS cells that were nucleofected with a selectable plasmid coding for EGFP, stable EGFP expressing clones could be propagated in culture and efficiently induced to differentiate into EGFP positive adipocytes; and osteoblasts. Finally, we verified that nucleofected hMADS cells could produce a functional, transgene encoded, secreted protein. To this aim, hMADS cells were nucleofected with a plasmid coding for leukemia inhibitory factor (LIF). This protein was detected at high concentrations in supernatants from pCAG LIF transfected hMADS cells. Moreover, supernatants were able to maintain mouse embryonic stem cells' undifferentiated phenotype, indicating that hMADS cells could secrete a functional LIF protein. Taken together, our data demonstrate that nucleofection allows both transient and stable gene expression in adipose tissue derived stem cells, without impairing their differentiation potential.
C1 Univ Nice Sophia Antipolis, CNRS, UMR 6543,Inst Rech Signalisat Biol Dev Canc, Ctr Biochim,Fac Sci, F 06108 Nice 2, France.
C3 Universite Cote d'Azur; Centre National de la Recherche Scientifique
   (CNRS)
RP Dani, C (通讯作者)，Univ Nice Sophia Antipolis, CNRS, UMR 6543,Inst Rech Signalisat Biol Dev Canc, Ctr Biochim,Fac Sci, F 06108 Nice 2, France.
EM dani@unice.fr
RI ; DANI, Christian/G 3639 2014; zaragosi, laure emmanuelle/P 9887 2016;
   Zaragosi, Laure Emmanuelle/P 9887 2016
OI Ailhaud, Gerard/0000 0003 0596 2906; zaragosi,
   laure emmanuelle/0000 0001 6747 7928; Dani,
   Christian/0000 0003 3228 0230
CR Abderrahim Ferkoune A, 2003, J LIPID RES, V44, P994, DOI 10.1194/jlr.M200382 JLR200
   Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168 8278(98)80165 7
   Aluigi M, 2006, STEM CELLS, V24, P454, DOI 10.1634/stemcells.2005 0198
   Aslan H, 2006, TISSUE ENG, V12, P877, DOI 10.1089/ten.2006.12.877
   Bjerknes M, 2005, AM J PHYSIOL GASTR L, V289, pG381, DOI 10.1152/ajpgi.00160.2005
   Brielmeier M, 1998, NUCLEIC ACIDS RES, V26, P2082, DOI 10.1093/nar/26.9.2082
   Cesnulevicius K, 2006, STEM CELLS, V24, P2776, DOI 10.1634/stemcells.2006 0176
   Chambers I, 2004, CLONING STEM CELLS, V6, P386, DOI 10.1089/clo.2004.6.386
   CHEN CA, 1988, BIOTECHNIQUES, V6, P632
   Distler JHW, 2005, EXP DERMATOL, V14, P315, DOI 10.1111/j.0906 6705.2005.00276.x
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Gehl J, 2003, ACTA PHYSIOL SCAND, V177, P437, DOI 10.1046/j.1365 201X.2003.01093.x
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Hamm A, 2002, TISSUE ENG, V8, P235, DOI 10.1089/107632702753725003
   Huang X, 2006, BLOOD, V107, P483, DOI 10.1182/blood 2005 05 2133
   Lai W, 2003, J IMMUNOL METHODS, V282, P93, DOI 10.1016/j.jim.2003.07.015
   Lorenz P, 2004, BIOTECHNOL LETT, V26, P1589, DOI 10.1023/B:BILE.0000045658.33723.d6
   Peister A, 2004, GENE THER, V11, P224, DOI 10.1038/sj.gt.3302163
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quenneville SP, 2004, MOL THER, V10, P679, DOI 10.1016/j.ymthe.2004.05.034
   Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007
   Rodriguez AM, 2005, J EXP MED, V201, P1397, DOI 10.1084/jem.20042224
   Rodriguez AM, 2004, BIOCHEM BIOPH RES CO, V315, P255, DOI 10.1016/j.bbrc.2004.01.053
   Suda T, 2005, TRENDS IMMUNOL, V26, P426, DOI 10.1016/j.it.2005.06.006
   Tolar J, 2005, MOL THER, V12, P42, DOI 10.1016/j.ymthe.2005.02.023
   Tomanin R, 2004, CURR GENE THER, V4, P357
   Wdziekonski B, 2003, METHOD ENZYMOL, V365, P268
   Zaragosi LE, 2006, STEM CELLS, V24, P2412, DOI 10.1634/stemcells.2006 0006
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 30
TC 43
Z9 50
U1 0
U2 11
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701 2884 USA
SN 1066 5099
J9 STEM CELLS
JI Stem Cells
PD MAR
PY 2007
VL 25
IS 3
BP 790
EP 797
DI 10.1634/stemcells.2006 0235
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 145EC
UT WOS:000244847100029
PM 17158239
DA 2025 08 17
ER

PT J
AU Bian, DL
   Wang, XM
   Huang, K
   Zhai, QX
   Yu, GB
   Wu, CH
AF Bian, Dong Lin
   Wang, Xue Mei
   Huang, Kun
   Zhai, Qi Xi
   Yu, Gui Bo
   Wu, Cheng Hua
TI Expression and regulatory effects of microRNA 182 in osteosarcoma cells:
   A pilot study
SO ONCOLOGY LETTERS
LA English
DT Article
DE osteosarcoma; microRNA 182; biological behaviors of neoplasms; gene
   expression
ID BIOGENESIS; TARGETS; CANCER; IDENTIFICATION; PROLIFERATION;
   DEREGULATION; SURVIVAL; MIRNAS; GROWTH; GENES
AB The aim of the present study was to evaluate the expression level of microRNA 182 (miRNA 182) in human osteosarcoma (OS) MG 63 cells and OS tissues, and to elucidate the effect of miRNA 182 on the biological activity of tumors. In the present study, the expression of miRNA 182 in human OS MG 63 cells, OS tissues and normal osteoblast hFOB1.19 cells was determined using quantitative polymerase chain reaction. Subsequently, a miRNA 182 mimic and inhibitor were utilized to regulate the expression level of this miRNA in MG 63 cells. Cell viability and proliferation were examined using cell counting kit 8 assays, and cell apoptosis was detected by flow cytometry. Cell invasion and migration assays were performed using Transwell chambers to analyze the biological functions of miRNA 182 in vitro. The present study demonstrated that the expression level of miRNA 182 in MG 63 cells and OS tissues was significantly increased compared with the hFOB1.19 cell line (P<0.05). The present study successfully performed cell transfections of miRNA 182 inhibitor and miRNA 182 mimic into MG 63 cells and achieved the desired transfection efficiency. The present study confirmed that upregulation of miRNA 182 promotes cell apoptosis and inhibits cell viability, proliferation, invasion and migration. The present findings additionally demonstrated that miRNA 182 is a tumor suppressor gene in OS. Therefore, regulating the expression of miRNA 182 may affect the biological behavior of OS cells, which suggests a potential role for miRNA 182 in molecular therapy for malignant tumors.
C1 [Bian, Dong Lin; Wang, Xue Mei; Huang, Kun; Zhai, Qi Xi] China Med Univ, Affiliated Hosp 1, Dept Ultrasound, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
   [Yu, Gui Bo] China Med Univ, Affiliated Hosp 1, Key Lab Diag & Intervent Therapy Liaoning Prov, Shenyang 110001, Liaoning, Peoples R China.
   [Wu, Cheng Hua] China Med Univ, Affiliated Hosp 1, Dept Radiol, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Wang, XM (通讯作者)，China Med Univ, Affiliated Hosp 1, Dept Ultrasound, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM 758839160@qq.com
RI Huang, Kun/H 4427 2012
CR Akçakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043
   Babar IA, 2008, FUTURE ONCOL, V4, P289, DOI 10.2217/14796694.4.2.289
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bramwell VHC, 2000, CURR OPIN ONCOL, V12, P330, DOI 10.1097/00001622 200007000 00009
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Cekaite L, 2012, NEOPLASIA, V14, P868, DOI 10.1593/neo.121094
   Duffy MJ, 2011, CANCER TREAT REV, V37, P151, DOI 10.1016/j.ctrv.2010.07.004
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Endicott M, 2003, CLIN TECH SMALL AN P, V18, P110, DOI 10.1053/svms.2003.36626
   Faller M, 2008, BBA GENE REGUL MECH, V1779, P663, DOI 10.1016/j.bbagrm.2008.08.005
   Guled Mohamed, 2013, Duodecim, V129, P1661
   Guo DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091354
   Guo Y, 2013, CELL PHYSIOL BIOCHEM, V32, P581, DOI 10.1159/000354462
   Hartford CM, 2006, J PEDIAT HEMATOL ONC, V28, P43
   He Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1485, DOI 10.1159/000366353
   Hu X, 2013, SCI REP UK, V3, DOI 10.1038/srep03423
   Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140
   Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912
   Kiselev F L, 2014, Mol Biol (Mosk), V48, P232
   Kobayashi Eisuke, 2012, Sarcoma, V2012, P359739, DOI 10.1155/2012/359739
   Kong WQ, 2012, FEBS J, V279, P1252, DOI 10.1111/j.1742 4658.2012.08519.x
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Liu HL, 2013, TUMOR BIOL, V34, P1713, DOI 10.1007/s13277 013 0708 0
   Liu RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068982
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Lund E, 2006, COLD SPRING HARB SYM, V71, P59, DOI 10.1101/sqb.2006.71.050
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Mraz M, 2012, EXPERT REV HEMATOL, V5, P579, DOI [10.1586/ehm.12.54, 10.1586/EHM.12.54]
   Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003
   Nikitina E. G., 2012, Experimental Oncology, V34, P2
   Ning FL, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746 1596 9 143
   Perng DW, 2012, TISSUE ENG PT A, V18, P2259, DOI [10.1089/ten.TEA.2011.0634, 10.1089/ten.tea.2011.0634]
   Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798
   Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83
   Szczesniak Michal Wojciech, 2012, Postepy Biochem, V58, P91
   Tang T, 2013, GYNECOL ONCOL, V129, P199, DOI 10.1016/j.ygyno.2012.12.043
   Wang XJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 9 r65
   Wang ZF, 2013, CANCER LETT, V331, P1, DOI 10.1016/j.canlet.2012.12.006
   Wu HL, 2009, EXPERT OPIN THER TAR, V13, P1439, DOI 10.1517/14728220903338777
   Yan DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040967
   Yang MH, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 109
NR 46
TC 7
Z9 7
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2016
VL 11
IS 5
BP 3040
EP 3048
DI 10.3892/ol.2016.4375
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DJ1TG
UT WOS:000373986400015
PM 27123060
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kim, JH
   Jeong, HE
   Baek, YH
   Cho, SW
   Lim, H
   Shin, JY
AF Kim, Ju Hwan
   Jeong, Han Eol
   Baek, Yeon Hee
   Cho, Sun Wook
   Lim, Hyuna
   Shin, Ju Young
TI Treatment pattern in postmenopausal women with osteoporosis: a
   population based cohort study in South Korea
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteoporosis; Bisphosphonate; Treatment pattern; Postmenopausal women
ID NATIONAL SCREENING PROGRAM; BISPHOSPHONATE THERAPY; FRACTURE RISK;
   PERSISTENCE; ADHERENCE; HEALTH; RALOXIFENE; PREVENTION; DIAGNOSIS; RATES
AB Introduction The treatment landscape of postmenopausal osteoporosis (OP) in an Asian population is yet to be explored. Materials and methods We conducted a retrospective cohort study to explore treatment patterns and characteristics associated with treatment interruption in postmenopausal women diagnosed with OP between 2008 and 2014. Treatment pattern assessment included the initial distribution of OP medications and treatment interruption rate according to the treatment groups during a 3 year follow up period. We used multivariate logistic regression to estimate odds ratio (OR) and 95% confidence interval (CI) to identify factors associated with treatment interruption. Results Of 21,813 patients, 87.9% initiated oral bisphosphonates (BP), followed by ibandronate intravenous (IV; 5.4%), selective estrogen receptor modulators (SERMs; 5.2%), pamidronate IV (1.4%) and zoledronic acid (0.06%). Treatment interruption was most notable in the first year of treatment, with cumulative treatment interruption rates highest for oral BP (76.3%) and lowest for pamidronate IV (50.5%). Compared to oral BP users, users of ibandronate IV (OR 0.34, 95% CI 0.30 0.39), pamidronate IV (0.49, 0.39 0.63), zoledronic acid (0.26, 0.09 0.77), and SERMs (0.50, 0.44 0.57) were less likely to interrupt treatment. Of characteristics assessed, presence of rheumatoid arthritis increased the odds of treatment interruption in ibandronate IV group (3.94, 2.12 7.33), and concomitant use of glucocorticoids for oral BP (1.11, 1.03 1.19) and pamidronate IV (2.04, 1.06 3.93) groups, respectively. Conclusion Given the frequent treatment interruptions across all OP medications, our findings on the factors associated with treatment interruption will serve to implement targeted interventions in reinforcing persistence to OP treatment.
C1 [Kim, Ju Hwan; Jeong, Han Eol; Baek, Yeon Hee; Shin, Ju Young] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea.
   [Cho, Sun Wook] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.
   [Cho, Sun Wook] Seoul Natl Univ, Coll Med, Seoul, South Korea.
   [Lim, Hyuna] Amgen Korea Ltd, Seoul, South Korea.
   [Shin, Ju Young] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Clin Res Design & Evaluat, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU);
   Sungkyunkwan University (SKKU); Samsung Medical Center
RP Shin, JY (通讯作者)，Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea.; Shin, JY (通讯作者)，Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Clin Res Design & Evaluat, Seoul, South Korea.
EM shin.jy@skku.edu
RI ; Cho, Sun/HPB 9019 2023; Kim, Ju Hwan/ADG 3199 2022
OI Baek, Yeon Hee/0000 0001 9597 6310; Jeong, Han Eol/0000 0001 6678 0941;
   Kim, Ju Hwan/0000 0001 7253 6515
FU Amgen Korea, Ltd.
FX This study received funding from Amgen Korea, Ltd.
CR Bachmann G, 2011, MENOPAUSE, V18, P851, DOI 10.1097/gme.0b013e31820b80f1
   Balasubramanian A, 2013, INT J GEN MED, V6, P839, DOI 10.2147/IJGM.S36944
   Berry SD, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0528 3
   Burden AM, 2012, OSTEOPOROSIS INT, V23, P1075, DOI 10.1007/s00198 011 1645 7
   Choi YJ, 2012, J BONE MINER RES, V27, P1879, DOI 10.1002/jbmr.1635
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Durden E, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0316 5
   Epstein S, 2009, CURR MED RES OPIN, V25, P2951, DOI 10.1185/03007990903361307
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Ferrari S, 2011, J BONE MINER METAB, V29, P561, DOI 10.1007/s00774 010 0249 1
   Foster SA, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472 6874 13 15
   Foster Shonda A, 2008, BMC Womens Health, V8, P24, DOI 10.1186/1472 6874 8 24
   Fujiwara S, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0443 7
   Gleason LJ, 2012, GERIATR ORTHOP SURG, V3, P79, DOI 10.1177/2151458512454878
   Hippisley Cox J, 2012, BMJ BRIT MED J, V344, DOI 10.1136/bmj.e3427
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Kim H, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0094978, 10.1371/journal.pone.0098043]
   Kim HS, 2012, J KOREAN MED SCI, V27, pS70, DOI 10.3346/jkms.2012.27.S.S70
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Ladova K, 2014, J EVAL CLIN PRACT, V20, P111, DOI 10.1111/jep.12095
   Melo M, 2006, J AM GERIATR SOC, V54, P1015, DOI 10.1111/j.1532 5415.2006.00758.x
   Park EC., 2017, REPORT EVALUATION VA
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Raterman HG, 2019, DRUG AGING, V36, P1061, DOI 10.1007/s40266 019 00714 4
   Reyes C, 2017, OSTEOPOROSIS INT, V28, P2997, DOI 10.1007/s00198 017 4144 7
   Richards JS, 2012, ARTHRIT CARE RES, V64, P1864, DOI 10.1002/acr.21777
   Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 016640
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Siris ES, 2014, CURR MED RES OPIN, V30, P123, DOI 10.1185/03007995.2013.851074
   Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414
   Stein JD, 2014, OPHTHALMOLOGY, V121, P1134, DOI 10.1016/j.ophtha.2013.11.038
   Szklo Moyses., 2007, Epidemiology: Beyond the Basics, VSecond
   Trémollieres FA, 2010, J BONE MINER RES, V25, P1002, DOI 10.1002/jbmr.12
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wysowski DK, 2013, BONE, V57, P423, DOI 10.1016/j.bone.2013.09.008
   Yun HF, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 112
NR 40
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2022
VL 40
IS 1
BP 109
EP 119
DI 10.1007/s00774 021 01259 6
EA AUG 2021
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA YH3DF
UT WOS:000687495200003
PM 34424415
DA 2025 08 17
ER

PT J
AU Nishimori, I
   Minakuchi, T
   Onishi, S
   Vullo, D
   Scozzafava, A
   Supuran, CT
AF Nishimori, Isao
   Minakuchi, Tomoko
   Onishi, Saburo
   Vullo, Daniela
   Scozzafava, Andrea
   Supuran, Claudiu T.
TI Carbonic anhydrase inhibitors. DNA cloning, characterization, and
   inhibition studies of the human secretory isoform VI, a new target for
   sulfonamide and sulfamate inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ISOZYME II; ACTIVE SITE; ISOENZYME VI; TRANSMEMBRANE; EXPRESSION;
   ENZYME; IX; OSTEOCLASTS; ANTITUMOR; DESIGN
AB The secretory isozyme of human carbonic anhydrase (hCA, EC 4.2.1.1), hCA VI, has been cloned, expressed, and purified in a bacterial expression system. The kinetic parameters for the CO2 hydration reaction proved hCA VI to possess a k(cat) of 3.4 x 10(5) s( 1) and k(cat)/K M of 4.9 x 10(7) M 1 s( 1) (at pH 7.5 and 20 degrees C). hCA VI has a significant catalytic activity for the physiological reaction on the same order of magnitude as the ubiquitous isoform CA I or the transmembrane, tumor associated isozyme CA IX. A series of sulfonamides and one sulfamate have been tested for their interaction with this isozyme. Simple benzenesulfonamides were rather ineffective hCA VI inhibitors, with inhibition constants in the range of 1090 6680 nM. Better inhibitors were detected among such derivatives bearing 2  or 4 amino , 4 aminomethyl , or 4 hydroxymethyl moieties or among halogenated sulfanilamides (K I values of 608 955 nM). Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective hCA VI inhibitory activity, with inhibition constants of 0.8 79 nM. The best inhibitors were brinzolamide and sulpiride (K I values of 0.8 0.9 nM), the latter compound being also a CA VI selective inhibitor. The metallic taste reported as a side effect after the treatment with systemic sulfonamides may be due to the inhibition of the salivary CA VI. Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel CA VI, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.
C1 Univ Florence, Lab Chim Bioinorgan, I 50019 Florence, Italy.
   Kochi Med Sch, Dept Gastroenterol & Hepatol, Nankoku, Kochi 7858505, Japan.
C3 University of Florence; Kochi University
RP Supuran, CT (通讯作者)，Univ Florence, Lab Chim Bioinorgan, Rm 188,Via Lastruccia 3, I 50019 Florence, Italy.
EM claudiu.supuran@unifi.it
RI Scozzafava, Andrea/AFS 1058 2022; Supuran, Claudiu/A 5151 2008
OI Scozzafava, Andrea/0000 0001 5020 3322
CR Abbate F, 2004, BIOORG MED CHEM LETT, V14, P337, DOI 10.1016/j.bmcl.2003.11.014
   Abbate F, 2004, BIOORG MED CHEM LETT, V14, P217, DOI 10.1016/j.bmcl.2003.09.062
   ALDRED P, 1991, BIOCHEMISTRY US, V30, P569, DOI 10.1021/bi00216a035
   Bahn YS, 2006, CURR OPIN MICROBIOL, V9, P572, DOI 10.1016/j.mib.2006.09.003
   Casini A, 2003, BIOORG MED CHEM LETT, V13, P841, DOI 10.1016/S0960 894X(03)00029 5
   Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232
   FERNLEY RT, 1991, CARBONIC ANHYDRASE, P178
   FERNLEY RT, 1979, FEBS LETT, V105, P299, DOI 10.1016/0014 5793(79)80634 1
   GAY CV, 1974, SCIENCE, V183, P432, DOI 10.1126/science.183.4123.432
   Hilvo M, 2005, BIOCHEM J, V392, P83, DOI 10.1042/BJ20051102
   HOOPER LV, 1995, J BIOL CHEM, V270, P5985, DOI 10.1074/jbc.270.11.5985
   HUNTER SJ, 1991, J BONE MINER RES, V6, P61
   Ilies M, 2004, CRC ENZYM INHIB SER, P317
   Ilies MA, 2003, J MED CHEM, V46, P2187, DOI 10.1021/jm021123s
   Karhumaa P, 2001, P NATL ACAD SCI USA, V98, P11604, DOI 10.1073/pnas.121172598
   KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561
   KHALIFAH RG, 1977, BIOCHEMISTRY US, V16, P2241, DOI 10.1021/bi00629a031
   Kimoto M, 2006, ARCH ORAL BIOL, V51, P117, DOI 10.1016/j.archoralbio.2005.04.007
   Kivelä J, 2003, ARCH ORAL BIOL, V48, P547, DOI 10.1016/s0003 9969(03)00096 7
   Kivelä J, 1999, CARIES RES, V33, P178, DOI 10.1159/000016514
   Kivelä J, 1999, J PHYSIOL LONDON, V520, P315, DOI 10.1111/j.1469 7793.1999.t01 1 00315.x
   Lehtonen J, 2004, J BIOL CHEM, V279, P2719, DOI 10.1074/jbc.M308984200
   Leinonen J, 1999, CARIES RES, V33, P185, DOI 10.1159/000016515
   Menchise V, 2005, J MED CHEM, V48, P5721, DOI 10.1021/jm050333c
   MURAKAMI H, 1987, J BIOL CHEM, V262, P1382
   NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005
   Nishimori I, 2004, CRC ENZYM INHIB SER, P25, DOI 10.1201/9780203475300.ch2
   Nishimori I, 2005, BIOORG MED CHEM LETT, V15, P3828, DOI 10.1016/j.bmcl.2005.06.055
   Nishimori I, 2006, J MED CHEM, V49, P2117, DOI 10.1021/jm0512600
   Nishimori I, 2005, J MED CHEM, V48, P7860, DOI 10.1021/jm050483n
   NISHIMORI I, 2007, BIOORG MED CHEM LETT, V17
   Ogawa Y, 2002, J HISTOCHEM CYTOCHEM, V50, P821, DOI 10.1177/002215540205000608
   Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540
   PIERCE WM, 1991, J BONE MINER RES, V6, P347
   Potter CPS, 2003, BRIT J CANCER, V89, P2, DOI 10.1038/sj.bjc.6600936
   Reginster JY, 2003, DRUG TODAY, V39, P89, DOI 10.1358/dot.2003.39.2.799416
   Scozzafava A, 2004, EXPERT OPIN THER PAT, V14, P667, DOI 10.1517/eotp.14.5.667.31276
   Scozzafava A, 1999, J MED CHEM, V42, P2641, DOI 10.1021/jm9900523
   Scozzafava A, 1999, J MED CHEM, V42, P3690, DOI 10.1021/jm9901879
   SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111
   Smith CE, 2006, EUR J ORAL SCI, V114, P147, DOI 10.1111/j.1600 0722.2006.00273.x
   Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184
   Supuran CT, 2004, J ENZYM INHIB MED CH, V19, P237, DOI 10.1080/14756360410001689603
   Supuran CT, 2000, EXS, V90, P197
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575
   Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025
   Supuran CT, 2004, CRC ENZYM INHIB SER, P1, DOI 10.1201/9780203475300.ch1
   Supuran CT, 2004, CRC ENZYM INHIB SER, P67
   TASHIAN RE, 1990, PROG CLIN BIOL RES, V344, P159
   Temperini C, 2006, J MED CHEM, V49, P3019, DOI 10.1021/jm0603320
   Vullo D, 2004, J MED CHEM, V47, P1272, DOI 10.1021/jm031057+
   Vullo D, 2005, BIOORG MED CHEM LETT, V15, P963, DOI 10.1016/j.bmcl.2004.12.053
   Vullo D, 2003, BIOORG MED CHEM LETT, V13, P1005, DOI 10.1016/S0960 894X(03)00091 X
   Winum JY, 2006, MINI REV MED CHEM, V6, P921, DOI 10.2174/138955706777934946
   Winum JY, 2005, J MED CHEM, V48, P2121, DOI 10.1021/jm0494826
   Wykoff CC, 2000, CANCER RES, V60, P7075
NR 56
TC 80
Z9 85
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 25
PY 2007
VL 50
IS 2
BP 381
EP 388
DI 10.1021/jm0612057
PG 8
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 126SK
UT WOS:000243535600024
PM 17228881
DA 2025 08 17
ER

PT J
AU Wyles, CC
   Paradise, CR
   Houdek, MT
   Slager, SL
   Terzic, A
   Behfar, A
   van Wijnen, AJ
   Sierra, RJ
AF Wyles, Cody C.
   Paradise, Christopher R.
   Houdek, Matthew T.
   Slager, Susan L.
   Terzic, Andre
   Behfar, Atta
   van Wijnen, Andre J.
   Sierra, Rafael J.
TI CORR® ORS Richard A. Brand Award: Disruption in Peroxisome
   Proliferator Activated Receptor γ (PPARG) Increases Osteonecrosis
   Risk Through Genetic Variance and Pharmacologic Modulation
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID GENOME WIDE ASSOCIATION; STEROID INDUCED OSTEONECROSIS; CYTOCHROME P450
   3A ACTIVITY; FEMORAL HEAD; AVASCULAR NECROSIS; NONTRAUMATIC
   OSTEONECROSIS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   IDIOPATHIC OSTEONECROSIS; NATURAL HISTORY
AB Background The pathophysiology of osteonecrosis of the femoral head (ONFH) is poorly understood, and the diagnosis is idiopathic in as many as 40% of patients. Genetic and epigenetic etiologies have been postulated, yet no single nucleotide polymorphisms (SNPs) with intuitive biologic implications have been elucidated.
   Questions/purposes (1) Do individuals with ONFH share common biologically relevant genetic variants associated with disease development? (2) What is the mechanism by which these SNPs may impact the expression or function of the affected gene or protein?
   Methods This retrospective genome wide association study (GWAS) evaluated participants from the Mayo Clinic Biobank and Mayo Clinic Genome Consortium between August 2009 and March 2017. We included every patient with atraumatic ONFH in each of these respective registries and every control patient in a previous GWAS with an acceptable platform to perform statistical imputation. The study was performed in two phases, with an initial discovery cohort and a subsequent validation cohort. The initial discovery cohort consisted of 102 patients with ONFH and 4125 controls. A logistic regression analysis was used to evaluate associations between SNPs and the risk of ONFH, adjusted for age and sex. Seven SNPs were identified in a gene of biological interest, peroxisome proliferator activated receptor gamma (PPARG), which were then evaluated in a subsequent validation cohort of 38 patients with ONFH and 464 controls. Age, sex, race, and previous steroid exposure were similar between patients with ONFH and controls in both the discovery and validation cohorts. Separate from the two phase genetic investigation, we performed targeted pharmacosurveillance to evaluate the risk association between the use of antidiabetic thiazolidinediones, a class of PPARG agonists, and development of ONFH by referencing 9,638,296 patient records for individuals treated at Mayo Clinic.
   Results A combined analysis of the discovery and validation cohorts revealed that seven SNPs were tightly clustered adjacent to the 3' end of PPARG, suggesting an association with the risk of ONFH (p = 1.58 x 10( 2)  5.50 x10( 6) ). PPARG gene level significance was achieved (p = 3.33 x 10( 6) ) when all seven SNPs were considered. SNP rs980990 had the strongest association with the risk of ONFH (odds ratio [OR], 1.95; 95% CI, 1.46 2.59; p = 5.50 x 10( 6)).
   The seven identified SNPs were mapped to a region near the PPARG gene and fell in a highly conserved region consisting of several critical transcription factor binding sites. Nucleotide polymorphisms at these sites may compromise three dimensional chromatin organization and alter PPARG 3' end interactions with its 5' promoter and transcription start site. Pharmacosurveillance identified that patients who were exposed to thiazolidinediones had an increased relative risk of developing ONFH of 5.6 (95% CI, 4.5 7.1).
   Conclusions We found that disruption of PPARG regulatory domains is linked to an increased risk of ONFH. Mechanistically, aberrant regulation of PPARG compromises musculoskeletal differentiation because this master regulator creates a proadipogenic and antiosteogenic state. Furthermore, PPARG alters steroid metabolism and vasculogenesis, processes that are inextricably linked with ONFH. Pharmacologically, predisposition to ONFH was further exposed with thiazolidinedione use, which upregulates the expression of PPARG and is known to alter bone metabolism. Collectively, these findings provide a foundation to perform confirmatory studies of our proposed mechanism in preclinical models to develop screening diagnostics and potential therapies in patients with limited options.
C1 [Wyles, Cody C.; Houdek, Matthew T.; van Wijnen, Andre J.; Sierra, Rafael J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Paradise, Christopher R.] Mayo Clin, Grad Sch Biomed Sci, Rochester, MN 55905 USA.
   [Slager, Susan L.] Mayo Clin, Div Biostat & Informat, Rochester, MN 55905 USA.
   [Terzic, Andre; Behfar, Atta] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA.
   [Wyles, Cody C.; Houdek, Matthew T.; Terzic, Andre; Behfar, Atta; van Wijnen, Andre J.; Sierra, Rafael J.] Mayo Clin, Ctr Regenerat Med, 200 1st St SW, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Sierra, RJ (通讯作者)，Mayo Clin, Ctr Regenerat Med, 200 1st St SW, Rochester, MN 55905 USA.
EM sierra.rafael@mayo.edu
RI ; van Wijnen, Andre/AAG 3578 2019
OI Paradise, Christopher/0000 0002 5882 709X; Behfar,
   Atta/0000 0003 3775 5784; van Wijnen, Andre J./0000 0002 4458 0946; 
FU Mayo Clinic Center for Regenerative Medicine; Mayo Clinic Center for
   Regenerative Medicine (Rochester, MN, USA); CTSA Grant from the National
   Center for Advancing Translational Sciences (NCATS), a component of the
   NIH [UL1 TR000135]
FX The institution of one or more of the authors (RJS, CCW, MTH, AB) has
   received, during the study period, funding from the Mayo Clinic Center
   for Regenerative Medicine in the form of an Accelerated Regenerative
   Medicine Grant to support this work.This study was supported by an
   Accelerated Regenerative Medicine Grant from the Mayo Clinic Center for
   Regenerative Medicine (Rochester, MN, USA). This publication was made
   possible by CTSA Grant Number UL1 TR000135 from the National Center for
   Advancing Translational Sciences (NCATS), a component of the NIH. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official view of NIH.
CR Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Bielinski SJ, 2011, MAYO CLIN PROC, V86, P606, DOI 10.4065/mcp.2011.0178
   Bozic KJ, 1999, J BONE JOINT SURG AM, V81A, P200, DOI 10.2106/00004623 199902000 00007
   Chao YC, 2003, ALCOHOL ALCOHOLISM, V38, P431, DOI 10.1093/alcalc/agg106
   Chen HL, 2015, PLASMONICS, V10, P57, DOI 10.1007/s11468 014 9777 1
   CRUESS RL, 1978, CLIN ORTHOP RELAT R, P86
   CRUESS RL, 1981, CAN J SURG, V24, P567
   de Wit E, 2015, MOL CELL, V60, P676, DOI 10.1016/j.molcel.2015.09.023
   Deng WL, 2014, CELL, V158, P849, DOI 10.1016/j.cell.2014.05.050
   Dubois Chevalier J, 2015, NUCLEUS PHILA, V6, P15, DOI 10.1080/19491034.2015.1004258
   Dubois Chevalier J, 2014, NUCLEIC ACIDS RES, V42, P10943, DOI 10.1093/nar/gku780
   FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301 620X.67B1.3155745
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Glueck CJ, 2008, J BONE JOINT SURG AM, V90A, P2220, DOI 10.2106/JBJS.G.00616
   Glueck CJ, 2005, CLIN ORTHOP RELAT R, P164, DOI 10.1097/01.blo.0000157539.67567.03
   GLUECK CJ, 1994, THROMB HAEMOSTASIS, V71, P195
   GLUECK CJ, 1995, AM J HEMATOL, V48, P213, DOI 10.1002/ajh.2830480402
   Habib ZA, 2010, J CLIN ENDOCR METAB, V95, P592, DOI 10.1210/jc.2009 1385
   Hernigou P, 2003, J BONE JOINT SURG AM, V85A, P500, DOI 10.2106/00004623 200303000 00016
   Houdek MT, 2016, J ARTHROPLASTY, V31, P893, DOI 10.1016/j.arth.2015.08.017
   Houdek MT, 2014, STEM CELLS CLONING, V7, P65, DOI 10.2147/SCCAA.S36584
   HUNGERFORD DS, 1978, CLIN ORTHOP RELAT R, P144
   Ionita Laza I, 2013, AM J HUM GENET, V92, P841, DOI 10.1016/j.ajhg.2013.04.015
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Ito H, 2003, J BONE JOINT SURG BR, V85B, P796, DOI 10.1302/0301 620X.85B6.13794
   Jones LC, 2004, CURR OPIN RHEUMATOL, V16, P443, DOI 10.1097/01.moo.0000127829.34643.fd
   Jones LC, 2003, J RHEUMATOL, V30, P783
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07 2270
   Kaneshiro Y, 2006, CLIN PHARMACOL THER, V80, P396, DOI 10.1016/j.clpt.2006.07.004
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Koo KH, 2006, J ORTHOP RES, V24, P1722, DOI 10.1002/jor.20164
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lavernia C J, 1999, J Am Acad Orthop Surg, V7, P250
   Lee MJ, 2013, J CELL MOL MED, V17, P1188, DOI 10.1111/jcmm.12098
   Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001
   Liu YF, 2005, NEW ENGL J MED, V352, P2294, DOI 10.1056/NEJMoa042480
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523
   Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980
   McDonough AK, 2008, NAT CLIN PRACT ENDOC, V4, P507, DOI 10.1038/ncpendmet0920
   Mieczkowska A, 2012, J BIOL CHEM, V287, P23517, DOI 10.1074/jbc.M111.324814
   MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623 199503000 00018
   Mont MA, 1998, CLIN ORTHOP RELAT R, pS314
   Mont MA, 2010, J BONE JOINT SURG AM, V92A, P2165, DOI 10.2106/JBJS.I.00575
   Olson JE, 2013, MAYO CLIN PROC, V88, P952, DOI 10.1016/j.mayocp.2013.06.006
   Paria Nandina, 2014, J Bone Joint Surg Am, V96, pe38, DOI 10.2106/JBJS.M.00398
   Pearson TA, 2008, JAMA J AM MED ASSOC, V299, P1335, DOI 10.1001/jama.299.11.1335
   Pritchett JW, 2001, CLIN ORTHOP RELAT R, P173
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   R Development Core Team, 2014, R LANG ENV STAT COMP
   Raney BJ, 2014, BIOINFORMATICS, V30, P1003, DOI 10.1093/bioinformatics/btt637
   Samadfam R, 2012, J ENDOCRINOL, V212, P179, DOI 10.1530/JOE 11 0356
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Smith SY, 2015, J BONE MINER METAB, V33, P625, DOI 10.1007/s00774 014 0632 4
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tokuhara Y, 2009, J ORTHOP SCI, V14, P794, DOI 10.1007/s00776 009 1400 5
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pD171, DOI 10.1093/nar/gks1221
   Wang J, 2012, GENOME RES, V22, P1798, DOI 10.1101/gr.139105.112
   Wyles CC, 2015, CLIN ORTHOP RELAT R, V473, P3080, DOI 10.1007/s11999 015 4385 8
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zhu ZN, 2014, BONE, V68, P115, DOI 10.1016/j.bone.2014.08.010
   Zuin J, 2014, P NATL ACAD SCI USA, V111, P996, DOI 10.1073/pnas.1317788111
NR 64
TC 8
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD AUG
PY 2019
VL 477
IS 8
BP 1800
EP 1812
DI 10.1097/CORR.0000000000000713
PG 13
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA KG0XA
UT WOS:000509664400010
PM 31135556
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Di Virgilio, AL
   Rivadeneira, J
   Muglia, CI
   Reigosa, MA
   Butenko, N
   Cavaco, I
   Etcheverry, SB
AF Di Virgilio, Ana L.
   Rivadeneira, Josefina
   Muglia, Cecilia I.
   Reigosa, Miguel A.
   Butenko, Nataliya
   Cavaco, Isabel
   Etcheverry, Susana B.
TI Cyto  and genotoxicity of a vanadyl(IV) complex with oxodiacetate in
   human colon adenocarcinoma (Caco 2) cells: potential use in cancer
   therapy
SO BIOMETALS
LA English
DT Article
DE Vanadyl(IV) cation; Multidentate ligands; Cytotoxicity; Genotoxicity;
   Caco 2 tumoral cells
ID OSTEOBLAST LIKE CELLS; VANADIUM COMPLEXES; DNA DAMAGE; GROWTH;
   CYTOTOXICITY; CHEMISTRY; APOPTOSIS; ASSAY; ACID; PROLIFERATION
AB The complex of vanadyl(IV) cation with oxodiacetate, VO(oda) caused an inhibitory effect on the proliferation of the human colon adenocarcinoma cell line Caco 2 in the range of 25 100 mu M (P < 0.001). This inhibition was partially reversed by scavengers of free radicals. The difference in cell proliferation in the presence and the absence of scavengers was statistically significant in the range of 50 100 mu M (P < 0.05). VO(oda) altered lysosomal and mitochondria metabolisms (neutral red and MTT bioassays) in a dose response manner from 10 mu M (P < 0.001). Morphological studies showed important transformations that correlated with the disassembly of actin filaments and a decrease in the number of cells in a dose response manner. Moreover, VO(oda) caused statistically significant genotoxic effects on Caco 2 cells in the low range of concentration (5 25 mu M) (Comet assay). Increment in the oxidative stress and a decrease in the GSH level are the main cytotoxic mechanisms of VO(oda). These effects were partially reversed by scavengers of free radicals in the range of 50 100 mu M (P < 0.05). Besides, VO(oda) interacted with plasmidic DNA causing single and double strand cleavage, probably through the action of free radical species. Altogether, these results suggest that VO(oda) is a good candidate to be evaluated for alternative therapeutics in cancer treatment.
C1 [Di Virgilio, Ana L.; Rivadeneira, Josefina; Muglia, Cecilia I.; Etcheverry, Susana B.] UNLP, Catedra Bioquim Patol, Fac Ciencias Exactas, RA 1900 La Plata, Buenos Aires, Argentina.
   [Rivadeneira, Josefina; Etcheverry, Susana B.] UNLP, CEQUINOR CONICET UNLP, Fac Ciencias Exactas, RA 1900 La Plata, Buenos Aires, Argentina.
   [Reigosa, Miguel A.] Inst Multidisciplinario Biol Celular IMBICE, La Plata, Buenos Aires, Argentina.
   [Butenko, Nataliya; Cavaco, Isabel] Univ Algarve, Dept Quim Bioquim & Farm, P 8005139 Faro, Portugal.
   [Butenko, Nataliya; Cavaco, Isabel] Univ Tecn Lisboa, Ctr Quim Estrutural, Inst Super Tecn, P 1049001 Lisbon, Portugal.
C3 National University of La Plata; National University of La Plata;
   Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   Universidade do Algarve; Universidade de Lisboa
RP Etcheverry, SB (通讯作者)，UNLP, Catedra Bioquim Patol, Fac Ciencias Exactas, 47 & 115, RA 1900 La Plata, Buenos Aires, Argentina.
EM etcheverry@biol.unlp.edu.ar
RI Cavaco, Isabel/H 9087 2012
OI Cavaco, Isabel/0000 0001 8651 9054
FU UNLP, CONICET [PIP 1125]; ANPCyT [PICT 2218]; Erasmus Mundus Programme,
   EMQAL [2008 0095]; CONICET, Argentina
FX The authors would like to thank Prof. Dr. E.J. Baran for the preparation
   of VO(oda) complex and Prof. Dr. L. Bruzzone for the fluorometric
   measurements of DHR experiments. This work was supported by UNLP,
   CONICET (PIP 1125) and ANPCyT (PICT 2218), and the Erasmus Mundus
   Programme, EMQAL 2008 0095, for mobility funding. JR is a postdoctoral
   fellowship from CONICET, Argentina. ALDV, CIM and SBE are members of the
   Carrera del Investigador, CONICET, Argentina. MAR is a member of Carrera
   de Personal de Apoyo, CONICET, Argentina. NB is a doctoral student of
   the Erasmus Mundus External Cooperation Window Lot 6. IC is Prof. of the
   Algarve University, Faro, Portugal.
CR Altamirano Lozano M, 1999, TERATOGEN CARCIN MUT, V19, P243, DOI 10.1002/(SICI)1520 6866(1999)19:4<243::AID TCM1>3.0.CO;2 J
   Aubrecht J, 1999, TOXICOL APPL PHARM, V154, P228, DOI 10.1006/taap.1998.8592
   Baggio R, 2003, ACTA CRYSTALLOGR C, V59, P30
   Barrio DA, 2003, J BIOL INORG CHEM, V8, P459, DOI 10.1007/s00775 002 0438 z
   BERNADOU J, 1989, BIOCHEMISTRY US, V28, P7268, DOI 10.1021/bi00444a019
   Bishayee A, 1999, ONCOL RES, V11, P41
   Borenfreund E., 1985, J TISSUE CULT METHOD, V9, P7, DOI DOI 10.1007/BF01666038
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Butenko N, 2009, J INORG BIOCHEM, V103, P622, DOI 10.1016/j.jinorgbio.2009.01.003
   Cavaco I, 2009, J BIOL INORG CHEM, V14, pS183
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300 483X(00)00181 5
   Cortizo MS, 2001, J BIOMAT SCI POLYM E, V12, P945, DOI 10.1163/156856201753252499
   Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n
   Crans DC, 2000, J INORG BIOCHEM, V80, P123, DOI 10.1016/S0162 0134(00)00048 9
   del Río D, 2003, DALTON T, P1813, DOI 10.1039/b300914a
   Dharwan S, 1997, EUR IMMUNOL, V27, P2172
   DJORDJEVIC C, 1995, MET IONS BIOL SYST, V31, P595
   El Naggar MM, 1998, CANCER LETT, V133, P71, DOI 10.1016/S0304 3835(98)00213 4
   Etcheverry SB, 1998, ADV ENV SCI, V30, P359
   Etcheverry SB, 2007, BIOORGAN MED CHEM, V15, P6418, DOI 10.1016/j.bmc.2007.06.056
   Evangelou A, 1997, CANCER LETT, V119, P221, DOI 10.1016/S0304 3835(97)00278 4
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   Farrell NP, 1999, USES INORGANIC CHEM, P16
   Fisher MB, 1998, ARCH BIOCHEM BIOPHYS, V356, P63, DOI 10.1006/abbi.1998.0742
   Fu Y, 2008, J BIOL INORG CHEM, V13, P1001, DOI 10.1007/s00775 008 0387 2
   Ghosh P, 2000, CLIN CANCER RES, V6, P1536
   Halliwell B., 2000, FREE RADICAL BIO MED, V3rd
   HANAUSKE U, 1987, INT J CELL CLONING, V5, P170, DOI 10.1002/stem.5530050209
   HARDING MM, 1993, FEBS LETT, V322, P291, DOI 10.1016/0014 5793(93)81588 Q
   Harding MM, 2000, CURR MED CHEM, V7, P1289, DOI 10.2174/0929867003374066
   Henderson L, 1998, MUTAGENESIS, V13, P89, DOI 10.1093/mutage/13.1.89
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003 2697(76)90326 2
   Holko P, 2008, POL J PATHOL, V59, P3
   Jiang C, 2003, INORG CHEM COMMUN, V6, P706, DOI 10.1016/S1387 7003(03)00080 7
   Klein A, 2008, FOLIA BIOL KRAKOW, V56, P115, DOI 10.3409/fb.56_3 4.115 121
   KOPFMAIER P, 1981, CANCER CHEMOTH PHARM, V5, P237, DOI 10.1007/BF00434391
   Kostova I, 2009, ANTI CANCER AGENT ME, V9, P827, DOI 10.2174/187152009789124646
   Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016
   Lippard SL, 1984, PRINCIPLES BIOINORGA
   Lloyd DR, 1997, CHEM RES TOXICOL, V10, P393, DOI 10.1021/tx960158q
   Luber B, 2000, CELL ADHES COMMUN, V7, P391, DOI 10.3109/15419060009109021
   Majumder S, 2006, CHEM BIOL INTERACT, V159, P90, DOI 10.1016/j.cbi.2005.10.044
   Molinuevo MS, 2008, CANCER CHEMOTH PHARM, V61, P767, DOI 10.1007/s00280 007 0532 6
   Molinuevo MS, 2004, CANCER CHEMOTH PHARM, V53, P163, DOI 10.1007/s00280 003 0708 7
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mueller S, 1997, ANAL BIOCHEM, V245, P55, DOI 10.1006/abio.1996.9939
   MURRAY JH, 1994, J MED CHEM, V37, P1936, DOI 10.1021/jm00039a005
   Narla RK, 2001, CLIN CANCER RES, V7, P1094
   Navara CS, 2001, ANTI CANCER DRUG, V12, P369, DOI 10.1097/00001813 200104000 00010
   OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201
   Pessoa JC, 2007, ACS SYM SER, V974, P340
   Rivadeneira J, 2007, BIOL TRACE ELEM RES, V118, P159, DOI 10.1007/s12011 007 0025 9
   Rivadeneira J, 2010, MED CHEM, V6, P9, DOI 10.2174/157340610791208754
   Rodríguez Mercado JJ, 2003, TOXICOL LETT, V144, P359, DOI 10.1016/S0378 4274(03)00255 8
   Rojas E, 1996, MUTAT RES ENVIR MUTA, V359, P77, DOI 10.1016/S0165 1161(96)90254 X
   SAKURAI H, 1995, BIOCHEM BIOPH RES CO, V206, P133, DOI 10.1006/bbrc.1995.1019
   SAKURAI H, 1994, ENVIRON HEALTH PERSP, V102, P35, DOI 10.1289/ehp.94102s335
   Samanta S, 2008, BBA GEN SUBJECTS, V1780, P1106, DOI 10.1016/j.bbagen.2008.05.003
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014 4827(88)90265 0
   Sit KH, 1996, ANAT RECORD, V245, P1, DOI 10.1002/(SICI)1097 0185(199605)245:1<1::AID AR1>3.0.CO;2 2
   Soares SS, 2008, CHEM RES TOXICOL, V21, P607, DOI 10.1021/tx700204r
   TONEY JH, 1986, J AM CHEM SOC, V108, P7263, DOI 10.1021/ja00283a022
   Wozniak K, 2004, ARCH TOXICOL, V78, P7, DOI 10.1007/s00204 003 0506 3
   Yang XG, 2004, PHARM RES DORDR, V21, P1026, DOI 10.1023/B:PHAM.0000029293.89113.d5
   YOUNES M, 1991, TOXICOLOGY, V70, P141, DOI 10.1016/0300 483X(91)90041 X
NR 65
TC 14
Z9 14
U1 1
U2 19
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0966 0844
EI 1572 8773
J9 BIOMETALS
JI Biometals
PD DEC
PY 2011
VL 24
IS 6
BP 1153
EP 1168
DI 10.1007/s10534 011 9474 x
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 849HR
UT WOS:000297117100016
PM 21755303
OA Green Published
DA 2025 08 17
ER

PT J
AU Tsai, MT
   Chen, YY
   Chang, WJ
   Li, SY
AF Tsai, Ming Tsun
   Chen, Ying Ying
   Chang, Wei Jeng
   Li, Szu Yuan
TI Warfarin accelerated vascular calcification and worsened cardiac
   dysfunction in remnant kidney mice
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE Left ventricular dysfunction; Uremia; Vascular calcification; Warfarin
ID THIOREDOXIN INTERACTING PROTEIN; ASSOCIATION TASK FORCE;
   SMOOTH MUSCLE CELLS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE;
   HEMODIALYSIS PATIENTS; PRACTICE GUIDELINES; AMERICAN COLLEGE;
   MECHANISMS; INHIBITION
AB Background: Vascular calcification is highly prevalent in end stage renal disease (ESRD) and is a significant risk factor for future cardiovascular events and death. Warfarin use results in dysfunction of matrix Gla protein, an inhibitor of vascular calcification. However, the effect of warfarin on vascular calcification in patients with ESRD is still not well characterized. Thus we investigated whether arterial calcification can be accelerated by warfarin treatment both in vitro and in vivo using a mouse remnant kidney model.
   Methods: Human aortic smooth muscle cells (HASMC) were cultured in medium supplemented with warfarin and phosphate to investigate the potential role of this drug in osteoblast transdifferentiation. For in vivo study, adult male C57BL/6 mice underwent 5/6 nephrectomy were treated with active vitamin D3 plus warfarin to determine the extent of vascular calcification and parameters of cardiovascular function.
   Results: We found that the expressions of Runx2 and osteocalcin in HASMC were markedly enhanced in the culture medium containing warfarin and high phosphate concentration. Warfarin induced calcification of cultured HASMC in the presence of high phosphate levels, and this effect is inhibited by vitamin K2. Severe aortic calcification and reduced left ventricular ejection fractions were also noted in 5/6 nephrectomy mice treated with warfarin and active vitamin D3.
   Conclusion: Warfarin treatment contributes to the accelerated vascular calcification in animal models of advanced chronic kidney disease. Clinicians should therefore be aware of the profound risk of warfarin use on vascular calcification and cardiac dysfunction in patients with ESRD and atrial fibrillation. Copyright (C) 2018, the Chinese Medical Association. Published by Elsevier Taiwan LLC.
C1 [Tsai, Ming Tsun] Taipei Vet Gen Hosp, Taoyuan Branch, Dept Med, Div Nephrol, Taoyuan, Taiwan.
   [Tsai, Ming Tsun; Chen, Ying Ying; Li, Szu Yuan] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Chen, Ying Ying; Li, Szu Yuan] Taipei Vet Gen Hosp, Div Nephrol, Dept Med, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
   [Chang, Wei Jeng] Natl Appl Res Labs, Natl Lab Anim Ctr, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital; National Applied Research
   Laboratories   Taiwan
RP Li, SY (通讯作者)，Taipei Vet Gen Hosp, Div Nephrol, Dept Med, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
EM syli@vghtpe.gov.tw
RI Li, szuyuan/LWJ 8205 2024
OI Tsai, Ming Tsun/0000 0002 8597 4132
FU Taipei Veterans General Hospital [V105C 013]
FX This study was supported in part by research grants from Taipei Veterans
   General Hospital (V105C 013).
CR Anderson JL, 2013, J AM COLL CARDIOL, V61, P1935, DOI 10.1016/j.jacc.2013.02.001
   Chan KE, 2009, J AM SOC NEPHROL, V20, P2223, DOI 10.1681/ASN.2009030319
   Chen NX, 2006, KIDNEY INT, V70, P1046, DOI 10.1038/sj.ki.5001663
   Chong CR, 2014, CARDIOVASC DRUG THER, V28, P347, DOI 10.1007/s10557 014 6538 5
   Crouthamel MH, 2013, ARTERIOSCL THROM VAS, V33, P2625, DOI 10.1161/ATVBAHA.113.302249
   Dahal K, 2016, CHEST, V149, P951, DOI 10.1378/chest.15 1719
   Danziger J, 2008, CLIN J AM SOC NEPHRO, V3, P1504, DOI 10.2215/CJN.00770208
   Estes NAM, 2008, J AM COLL CARDIOL, V51, P865, DOI 10.1016/j.jacc.2008.01.006
   FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469
   Fuster V, 2006, EUR HEART J, V27, P1979, DOI 10.1093/eurheartj/ehl176
   Herzog CA, 2011, KIDNEY INT, V80, P572, DOI 10.1038/ki.2011.223
   KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703
   Ketteler M, 2014, NEPHROL DIAL TRANSPL, V29, P1267, DOI 10.1093/ndt/gfu053
   Ketteler M, 2011, NAT REV NEPHROL, V7, P509, DOI 10.1038/nrneph.2011.91
   Kovacic JC, 2011, CIRCULATION, V123, P1900, DOI 10.1161/CIRCULATIONAHA.110.009118
   Lee KH, 2017, J CHIN MED ASSOC, V80, P277, DOI 10.1016/j.jcma.2016.10.012
   London GM, 2005, CURR OPIN NEPHROL HY, V14, P525, DOI 10.1097/01.mnh.0000168336.67499.c0
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854
   Nigwekar SU, 2016, J AM SOC NEPHROL, V27, P3421, DOI 10.1681/ASN.2015091065
   Olesen JB, 2012, NEW ENGL J MED, V367, P625, DOI 10.1056/NEJMoa1105594
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Schurgers LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043229
   Shobeiri N, 2010, AM J NEPHROL, V31, P471, DOI 10.1159/000299794
   Shroff RC, 2007, SEMIN DIALYSIS, V20, P103, DOI 10.1111/j.1525 139X.2007.00255.x
   Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Winkelmayer WC, 2011, CLIN J AM SOC NEPHRO, V6, P2662, DOI 10.2215/CJN.04550511
   Winkelmayer WC, 2011, J AM SOC NEPHROL, V22, P349, DOI 10.1681/ASN.2010050459
   Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477
   Zitman Gal T, 2010, NEPHROL DIAL TRANSPL, V25, P2141, DOI 10.1093/ndt/gfp768
NR 32
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726 4901
EI 1728 7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD APR
PY 2018
VL 81
IS 4
BP 324
EP 330
DI 10.1016/j.jcma.2017.08.021
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GD6VU
UT WOS:000430647400006
PM 29395943
OA hybrid
DA 2025 08 17
ER

PT J
AU Hjortnaes, J
   Goettsch, C
   Hutcheson, JD
   Camci Unal, G
   Lax, L
   Scherer, K
   Body, S
   Schoen, FJ
   Kluin, J
   Khademhosseini, A
   Aikawa, E
AF Hjortnaes, Jesper
   Goettsch, Claudia
   Hutcheson, Joshua D.
   Camci Unal, Gulden
   Lax, Lilian
   Scherer, Katrin
   Body, Simon
   Schoen, Frederick J.
   Kluin, Jolanda
   Khademhosseini, Ali
   Aikawa, Elena
TI Simulation of early calcific aortic valve disease in a 3D platform: A
   role for myofibroblast differentiation
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Aortic valve stenosis; Calcific aortic valve disease; Tissue
   engineering; Hydrogels; Valvular interstitial cells
ID VALVULAR INTERSTITIAL CELLS; EXTRACELLULAR MATRIX; CARDIAC VALVE;
   HEART VALVES; GELATIN METHACRYLATE; IN VITRO; HYDROGELS; STENOSIS;
   PHENOTYPE; PATHOBIOLOGY
AB Purpose: Calcific aortic valve disease (CAVD) is the most prevalent valve disease in the Western world. Recent difficulty in translating experimental results on statins to beneficial clinical effects warrants the need for understanding the role of valvular interstitial cells (VICs) in CAVD. In two dimensional culture conditions, VICs undergo spontaneous activation similar to pathological differentiation, which intrinsically limits the use of in vitro models to study CAVD. Here, we hypothesized that a three dimensional (3D) culture system based on naturally derived extracellular matrix polymers, mimicking the microenvironment of native valve tissue, could serve as a physiologically relevant platform to study the osteogenic differentiation of VICs.
   Principal results: Aortic VICs loaded into 3D hydrogel constructs maintained a quiescent phenotype, similar to healthy human valves. In contrast, osteogenic environment induced an initial myofibroblast differentiation (hallmarked by increased alpha smooth muscle actin [alpha SMA] expression), followed by an osteoblastic differentiation, characterized by elevated Runx2 expression, and subsequent calcific nodule formation recapitulating CAVD conditions. Silencing of alpha SMA under osteogenic conditions diminished VIC osteoblast like differentiation and calcification, indicating that a VIC myofibroblast like phenotype may precede osteogenic differentiation in CAVD.
   Major conclusions: Using a 3D hydrogel model, we simulated events that occur during early CAVD in vivo and provided a platform to investigate mechanisms of CAVD. Differentiation of valvular interstitial cells to myofibroblasts was a key mechanistic step in the process of early mineralization. This novel approach can provide important insight into valve pathobiology and serve as a promising tool for drug screening. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Hjortnaes, Jesper; Lax, Lilian; Scherer, Katrin; Aikawa, Elena] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Vasc Biol,Dept Med, Boston, MA 02115 USA.
   [Hjortnaes, Jesper; Camci Unal, Gulden; Khademhosseini, Ali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Biomed Engn,Dept Med, Boston, MA 02115 USA.
   [Hjortnaes, Jesper; Kluin, Jolanda] Univ Med Ctr Utrecht, Dept Cardiothorac Surg, Utrecht, Netherlands.
   [Goettsch, Claudia; Hutcheson, Joshua D.; Aikawa, Elena] Brigham & Womens Hosp, Dept Med, Ctr Interdisciplinary Cardiovasc Sci, 75 Francis St, Boston, MA 02115 USA.
   [Camci Unal, Gulden; Khademhosseini, Ali] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Body, Simon] Harvard Univ, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Sch Med, Boston, MA 02115 USA.
   [Schoen, Frederick J.] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA.
   [Khademhosseini, Ali] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Brigham & Women's Hospital; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Harvard
   Medical School; Utrecht University; Utrecht University Medical Center;
   Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Massachusetts Institute of Technology (MIT); Harvard
   University; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Harvard
   University; Harvard University Medical Affiliates; Brigham & Women's
   Hospital; Harvard Medical School; Harvard University
RP Khademhosseini, A; Aikawa, E (通讯作者)，Harvard Univ, Brigham & Womens Hosp, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM alik@bwh.harvard.edu; eaikawa@partners.org
RI ; Khademhosseini, Ali/A 9435 2010; Goettsch, Claudia/AAD 9658 2019;
   Body, Simon/AAQ 7572 2020; Aikawa, Elena/L 6173 2019
OI Goettsch, Claudia/0000 0002 7973 1329; Kluin,
   Jolanda/0000 0002 5942 4727; Khademhosseini, Ali/0000 0002 2692 1524;
   Atlan, Lilian/0000 0002 3978 2818; Aikawa, Elena/0000 0001 7835 2135;
   Hutcheson, Joshua/0000 0002 8383 4435; Khademhosseini,
   Ali/0000 0001 6322 8852; Hjortnaes, Jesper/0000 0002 6722 918X
FU Dutch Heart Foundation (DHF); Netherlands Scientific Council (NWO);
   Office of Naval Research; Presidential Early Career Award for Scientists
   and Engineers (PECASE); National Science Foundation [DMR 0847287];
   National Institutes of Health [EB012597, HL092836, DE019024, HL099073,
   AR057837, EB008392, DE021468, NIH R01 HL114805, NIH R01 HL109506]
FX This work was supported by the Dutch Heart Foundation (DHF) and
   Netherlands Scientific Council (NWO) (to J.H.), the Office of Naval
   Research Young National Investigator Award, the Presidential Early
   Career Award for Scientists and Engineers (PECASE), the National Science
   Foundation CAREER Award (DMR 0847287), and the National Institutes of
   Health (EB012597, HL092836, DE019024, HL099073, AR057837, EB008392,
   DE021468, to A.K.; NIH R01 HL114805 and NIH R01 HL109506, to E.A.).
CR Aikawa E, 2007, CIRCULATION, V115, P377, DOI 10.1161/CIRCULATIONAHA.106.654913
   Al Aly Z, 2007, ARTERIOSCL THROM VAS, V27, P2589, DOI 10.1161/ATVBAHA.107.153668
   Balachandran K, 2011, P NATL ACAD SCI USA, V108, P19943, DOI 10.1073/pnas.1106954108
   Benton JA, 2009, BIOMATERIALS, V30, P6593, DOI 10.1016/j.biomaterials.2009.08.031
   Benton JA, 2008, J HEART VALVE DIS, V17, P689
   Camci Unal G., 2012, Journal of Tissue Engineering and Regenerative Medicine
   Camci Unal G, 2013, BIOMACROMOLECULES, V14, P1085, DOI 10.1021/bm3019856
   Chen JH, 2011, CIRC RES, V108, P1510, DOI 10.1161/CIRCRESAHA.110.234237
   Chester AH, 2007, PHILOS T R SOC B, V362, P1437, DOI 10.1098/rstb.2007.2126
   Cushing MC, 2005, MATRIX BIOL, V24, P428, DOI 10.1016/j.matbio.2005.06.007
   Hjortnaes J, 2015, ADV HEALTHC MATER, V4, DOI 10.1002/adhm.201400029
   Hjortnaes J, 2010, EUR HEART J, V31, P1975, DOI 10.1093/eurheartj/ehq237
   Hoerstrup SP, 2000, CIRCULATION, V102, P44
   Hutcheson JD, 2014, NAT REV CARDIOL, V11, P218, DOI 10.1038/nrcardio.2014.1
   Hutcheson JD, 2013, ARTERIOSCL THROM VAS, V33, P114, DOI 10.1161/ATVBAHA.112.300278
   Kloxin AM, 2010, BIOMATERIALS, V31, P1, DOI 10.1016/j.biomaterials.2009.09.025
   Masters KS, 2005, BIOMATERIALS, V26, P2517, DOI 10.1016/j.biomaterials.2004.07.018
   Masters KS, 2004, J BIOMED MATER RES A, V71A, P172, DOI 10.1002/jbm.a.30149
   Merryman WD, 2007, CARDIOVASC PATHOL, V16, P268, DOI 10.1016/j.carpath.2007.03.006
   Miller JD, 2008, J AM COLL CARDIOL, V52, P843, DOI 10.1016/j.jacc.2008.05.043
   Mohler ER, 1999, J HEART VALVE DIS, V8, P254
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Monzack EL, 2011, J HEART VALVE DIS, V20, P449
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   Otto CM, 2008, NEW ENGL J MED, V359, P1395, DOI 10.1056/NEJMe0807001
   OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844
   Rabkin E, 2002, J HEART VALVE DIS, V11, P308
   Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489
   Rabkin Aikawa E, 2004, J HEART VALVE DIS, V13, P841
   Rajamannan NM, 2011, J CELL BIOCHEM, V112, P2222, DOI 10.1002/jcb.23182
   Rajamannan NM, 2005, CIRCULATION, V112, pI229, DOI 10.1161/01.CIRCULATIONAHA.104.524306
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Ramón Azcón J, 2012, LAB CHIP, V12, P2959, DOI 10.1039/c2lc40213k
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   Schoen FJ, 2008, CIRCULATION, V118, P1864, DOI 10.1161/CIRCULATIONAHA.108.805911
   Shah DN, 2008, BIOMATERIALS, V29, P2060, DOI 10.1016/j.biomaterials.2008.01.001
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735 1097(96)00563 3
   Thayer P, 2011, ANN BIOMED ENG, V39, P1654, DOI 10.1007/s10439 011 0273 x
   Torre M, 2016, CARDIOVASC PATHOL, V25, P18, DOI 10.1016/j.carpath.2015.08.008
   Walker GA, 2004, CIRC RES, V95, P253, DOI 10.1161/01.RES.0000136520.07995.aa
   Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636
   Yip CYY, 2009, ARTERIOSCL THROM VAS, V29, P936, DOI 10.1161/ATVBAHA.108.182394
   Yutzey KE, 2014, ARTERIOSCL THROM VAS, V34, P2387, DOI 10.1161/ATVBAHA.114.302523
   Zhao RG, 2011, ACTA BIOMATER, V7, P1220, DOI 10.1016/j.actbio.2010.11.004
NR 45
TC 63
Z9 75
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022 2828
EI 1095 8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD MAY
PY 2016
VL 94
BP 13
EP 20
DI 10.1016/j.yjmcc.2016.03.004
PG 8
WC Cardiac & Cardiovascular Systems; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Cell Biology
GA DN1PX
UT WOS:000376839000003
PM 26996755
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Lei, X
   Miao, S
   Wang, XL
   Gao, Y
   Wu, H
   Cheng, PZ
   Song, Y
   Bi, L
   Pei, GX
AF Lei, Xing
   Miao, Sheng
   Wang, Xiuli
   Gao, Yi
   Wu, Hao
   Cheng, Pengzhen
   Song, Yue
   Bi, Long
   Pei, Guoxian
TI Microgroove Cues Guiding Fibrogenesis of Stem Cells via Intracellular
   Force
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE groove patterns; stem cells; intracellular force; focal adhesions;
   fibrosis
ID IN VITRO; NANOSCALE TOPOGRAPHY; ADHESION FORMATION; DIFFERENTIATION;
   PROMOTE; OSTEOBLASTS; DYNAMICS; SURFACE; NANOTOPOGRAPHY; FIBROBLASTS
AB Groove patterns are widely used in material surface modifications. However, the independent role of ditches/ridges in regulating fibrosis of soft tissues is not well understood, especially the lack of linkage evidence in vitro and in vivo. Herein, two kinds of combinational microgroove chips with the gradient ditch/ridge width were fabricated by photolithography technology, termed R and G groups, respectively. In group R, the ridge width was 1, 5, 10, and 30 mu m, with a ditch width of 30 mu m; in group G, the groove width was 5, 10, 20, and 30 mu m, and the ridge width was 5 mu m. The effect of microgrooves on the morphology, proliferation, and expression of fibrous markers of stem cells was systematically investigated in vitro. Moreover, thicknesses of fibrous capsules were evaluated after chips were implanted into the muscular pouches of rats for 5 months. The results show that microgrooves have almost no effect on cell proliferation but significantly modulate the morphology of cells and focal adhesions (FAs) in vitro, as well as fibrosis differentiation. In particular, the differentiation of stem cells is attenuated after the intracellular force caused by stress fibers and FAs is interfered by drugs, such as rotenone and blebbistatin. Histological analysis shows that patterns of high intracellular force can apparently stimulate soft tissue fibrosis in vivo. This study not only reveals the specific rules and mechanisms of ditch/ridge regulating stem cell behaviors but also offers insight into tailoring implant surface patterns to induce controlled soft tissue fibrosis.
C1 [Lei, Xing; Miao, Sheng; Wu, Hao; Cheng, Pengzhen; Song, Yue; Bi, Long; Pei, Guoxian] Ait Force Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.
   [Lei, Xing] Linyi Peoples Hosp, Dept Orthoped Surg, Linyi 276000, Peoples R China.
   [Miao, Sheng; Wu, Hao; Pei, Guoxian] Air Force Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.
   [Gao, Yi; Pei, Guoxian] Fudan Univ, Dept Macromol Sci, State Key Lab Mol Engn Polymers, Shanghai 200438, Peoples R China.
   [Gao, Yi; Pei, Guoxian] Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Peoples R China.
   [Gao, Yi; Pei, Guoxian] Southern Univ Sci & Technol Hosp, Shenzhen 518055, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Fudan
   University; Southern University of Science & Technology; Southern
   University of Science & Technology
RP Bi, L; Pei, GX (通讯作者)，Ait Force Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.; Pei, GX (通讯作者)，Air Force Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.; Pei, GX (通讯作者)，Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Peoples R China.; Pei, GX (通讯作者)，Southern Univ Sci & Technol Hosp, Shenzhen 518055, Peoples R China.
EM bilong@fmmu.edu.cn; nfperry@163.com
RI lei, xh/KFR 2496 2024
OI Pei, Guoxian/0000 0002 5089 5012; lei, xing/0000 0002 5139 1465
FU National Key R&D Program of China [2016YFC1100304]; Shandong Provincial
   Natural Science Foundation [ZR2022MH071]; Shenzhen Hong Kong
   [SGDX20211123114204007]; National Science Foundation of China
   [81902202]; Linyi Municipal Science and Technology Develop ment Plan
   [201818015]
FX ACKNOWLEDGMENTS This work was financially supported by the National Key
   R&D Program of China (grant no. 2016YFC1100304) , the Shandong
   Provincial Natural Science Foundation (grant no. ZR2022MH071) , the
   Shenzhen Hong Kong joint funding project (Class A) (grant no.
   SGDX20211123114204007) , the National Science Foundation of China (grant
   no. 81902202) , and the Linyi Municipal Science and Technology
   Develop ment Plan (grant no. 201818015) .
CR Abagnale G, 2015, BIOMATERIALS, V61, P316, DOI 10.1016/j.biomaterials.2015.05.030
   Akasaka Y, 2022, ADV WOUND CARE, V11, P561, DOI 10.1089/wound.2021.0037
   Alarcon Martinez L, 2018, ELIFE, V7, DOI 10.7554/eLife.34861
   [Anonymous], 2018, J GEOTECH ENG ASCE, V115, P1569
   Atherton P, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201903134
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Carisey A, 2013, CURR BIOL, V23, P271, DOI 10.1016/j.cub.2013.01.009
   Cun XL, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10102070
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   Dekoninck S, 2019, NAT CELL BIOL, V21, P18, DOI 10.1038/s41556 018 0237 6
   Dong LQ, 2019, BIOMATERIALS, V222, DOI 10.1016/j.biomaterials.2019.119456
   El Agha E, 2017, CELL STEM CELL, V21, P166, DOI 10.1016/j.stem.2017.07.011
   Fischer R. S., P NATL ACAD SCI US
   Gao HC, 2015, LANGMUIR, V31, P6797, DOI 10.1021/acs.langmuir.5b01018
   Griffin MF, 2015, WORLD J STEM CELLS, V7, P37, DOI 10.4252/wjsc.v7.i1.37
   Hamilton DW, 2007, BIOMATERIALS, V28, P2281, DOI 10.1016/j.biomaterials.2007.01.026
   Henderson NC, 2020, NATURE, V587, P555, DOI 10.1038/s41586 020 2938 9
   Hou TY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062952
   Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621
   Kang S, 2020, NANOSCALE, V12, P6385, DOI 10.1039/c9nr10305h
   Kim J., ADV HEALTHC MATER
   Kim J, 2013, BIOMATERIALS, V34, P7257, DOI 10.1016/j.biomaterials.2013.06.029
   Kumar A., LOCAL TENSION TALIN
   Lee CH, 2010, J CLIN INVEST, V120, P3340, DOI 10.1172/JCI43230
   Lee HH, 2013, P NATL ACAD SCI USA, V110, P2840, DOI 10.1073/pnas.1222164110
   Lee MR, 2010, BIOMATERIALS, V31, P4360, DOI 10.1016/j.biomaterials.2010.02.012
   Lee SW, 2009, CLIN ORAL IMPLAN RES, V20, P458, DOI 10.1111/j.1600 0501.2008.01671.x
   Legerstee K, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10111189
   Lei X, 2020, CELL ADHES MIGR, V14, P12, DOI 10.1080/19336918.2020.1713532
   Li DL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0999 6
   Li SS, 2017, BIOMATER SCI UK, V5, P2056, DOI 10.1039/c7bm00134g
   Li SH, 2021, SMALL, V17, DOI 10.1002/smll.202104359
   Li Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0356 6
   Liu W, 2022, SMALL, V18, DOI 10.1002/smll.202104328
   Lou JZ, 2018, BIOMATERIALS, V154, P213, DOI 10.1016/j.biomaterials.2017.11.004
   Majd H, 2015, BIOMATERIALS, V54, P136, DOI 10.1016/j.biomaterials.2015.03.027
   Morke C., 2017, ACS APPL MATER INTER, V9
   Nie XJ, 2020, REGEN BIOMATER, V7, P53, DOI 10.1093/rb/rbz033
   Oeztuerk Winder F, 2012, BIOCHEM J, V445, P1, DOI 10.1042/BJ20120401
   Park JS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09101 4
   Pendegrass CJ, 2006, BIOMATERIALS, V27, P4183, DOI 10.1016/j.biomaterials.2006.03.041
   Peterson AF, 2022, CELL SYST, V13, P885, DOI 10.1016/j.cels.2022.10.003
   Rape AD, 2011, BIOMATERIALS, V32, P2043, DOI 10.1016/j.biomaterials.2010.11.044
   Ray A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14923
   Revach OY, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244848
   Rothenberg KE, 2018, BIOPHYS J, V114, P1680, DOI 10.1016/j.bpj.2018.02.019
   Song Y, 2020, ACS APPL MATER INTER, V12, P16058, DOI 10.1021/acsami.0c00470
   Spanjaard E, 2013, CURR BIOL, V23, pR159, DOI 10.1016/j.cub.2013.01.020
   Varma R, 2022, BIOMATER SCI UK, V10, P396, DOI 10.1039/d1bm01327k
   Vermeulen S, 2023, ADV SCI, V10, DOI 10.1002/advs.202203880
   Wang PY, 2012, J MATER SCI MATER M, V23, P3015, DOI 10.1007/s10856 012 4748 6
   Wang XL, 2019, INVEST OPHTH VIS SCI, V60, P3669, DOI 10.1167/iovs.19 26983
   Wang XZ, 2023, BIOACT MATER, V22, P168, DOI 10.1016/j.bioactmat.2022.09.022
   Wang YF, 2021, MAT SCI ENG C MATER, V128, DOI 10.1016/j.msec.2021.112349
   Weidt A, 2019, ACS APPL BIO MATER, V2, P1066, DOI 10.1021/acsabm.8b00667
   Yang K, 2017, NANOSCALE, V9, P18737, DOI 10.1039/c7nr05446g
   Yang K, 2014, ACS NANO, V8, P7809, DOI 10.1021/nn501182f
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yuda A, 2015, J CELL PHYSIOL, V230, P150, DOI 10.1002/jcp.24693
   Zhang L, 2019, STEM CELL RES, V37, DOI 10.1016/j.scr.2019.101433
   Zhang Q, 2015, ACS APPL MATER INTER, V7, P23336, DOI 10.1021/acsami.5b07976
   Zheng XH, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac075
   Zhou DW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22602 5
   Zhu MY, 2019, ACS APPL MATER INTER, V11, P43888, DOI 10.1021/acsami.9b16050
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 65
TC 6
Z9 6
U1 4
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD APR 5
PY 2023
VL 15
IS 13
BP 16380
EP 16393
DI 10.1021/acsami.2c20903
EA MAR 2023
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA D0FD4
UT WOS:000959547500001
PM 36961871
DA 2025 08 17
ER

PT J
AU Chávez García, D
   Juarez Moreno, K
   Calderón Osuna, I
   Navarro, P
   Hirata, GA
AF Chavez Garcia, Dalia
   Juarez Moreno, Karla
   Calderon Osuna, Itamar
   Navarro, Patricia
   Hirata, Gustavo A.
TI Nanotoxicological study of downconversion
   Y2O3:Eu<SUP>3+</SUP>luminescent nanoparticles
   functionalized with folic acid for cancer cells bioimaging
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE cell culture; nanobiology; nanotechnology
ID UP CONVERSION NANOPARTICLES; CDTE QUANTUM DOTS; LUMINESCENCE PROPERTIES;
   DRUG DELIVERY; SIZE; ER; PHOTOLUMINESCENCE; NANOMATERIALS; GENOTOXICITY;
   MECHANISM
AB Luminescent lanthanide downconversion nanoparticles (DCNPs) provide a combination of high luminescence intensity, sharp emission peaks with narrow bandwidth and a large Stokes' shift, leading to high performance biomedical applications mainly for imaging. The purpose of this study is to present a nanotoxicological study of DCNPs Y2O3 codoped with Eu3+ and functionalized with folic acid (FA). These assessments include cytotoxicity, genotoxicity, hemocompatibility, and in vitro inflammatory studies. We demonstrated by flow cytometry and confocal microscope the internalization of FA DCNPs in breast cancer and melanoma cells. They were synthesized by sol gel method and coated with a thin silica shell to make them biocompatible; also they were functionalized with amino groups and FA ligands that bind to the folate receptors (FR) located on the surface of the cancer cells studied. This functionalization enables the DCNPs to be internalized into the cancer cells via endocytosis by the conjugation FA FR. The DCNPs were characterized with transmission electron microscope, Fourier transform infrared spectroscopy and photoluminescence. The nanotoxicological assessments demonstrated that both nanoparticles (bare and functionalized) are no cytotoxic and no genotoxic at the tested concentrations (0.01 20 mu g/mL) in three cell lines (breast, skin cancer, and osteoblasts). Also they are hemocompatible and do not exert nitric oxide production in vitro by macrophages. The FA DCNPs were clearly localized into the cell cytoplasm with bright red luminescence. Thus, herein we present a complete nanotoxicological study of FA DCNPs Y2O3 codoped with Eu3+ and we conclude that these nanoparticles are biocompatible and can be further used for cancer cells bioimaging.
C1 [Chavez Garcia, Dalia; Calderon Osuna, Itamar; Navarro, Patricia] CETYS, Sch Engn, Ensenada, Baja California, Mexico.
   [Juarez Moreno, Karla] UNAM, CNyN, Bionanotechnol Dept, Ensenada, Baja California, Mexico.
   [Juarez Moreno, Karla] CONACYT CNyN UNAM, Catedras, Ensenada, Baja California, Mexico.
   [Hirata, Gustavo A.] UNAM, CNyN, Physicochem Dept, Ensenada, Baja California, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma
   de Mexico
RP Chávez García, D (通讯作者)，CETYS, Camino Microondas Trinidad S N Km 1,Moderna Oeste, Ensenada 22860, Baja California, Mexico.; Juarez Moreno, K (通讯作者)，UNAM, CNyN, Km 107 Carretera Tijuana Ensenada, Ensenada 22860, BC, Mexico.
EM dalia.chavez@cetys.mx; kjuarez@cnyn.unam.mx
RI Juarez Moreno, Karla/E 2730 2016; Chávez García, Dalia/T 3640 2019;
   Hirata, Gustavo/E 2532 2016; Juarez Moreno, Karla Oyuky/E 2730 2016;
   CHAVEZ, DALIA/O 6260 2017
OI Juarez Moreno, Karla/0000 0002 6171 8601; HIRATA,
   Gustavo/0000 0002 5120 1027; CHAVEZ, DALIA/0000 0002 1258 7238
FU DGAPA UNAM [IN 115520]; Consejo Nacional de Ciencia y Tecnologia CONACyT
   [284548, 269071, 53]
FX The authors wish to acknowledge the financial support from DGAPA UNAM
   (Grant No. IN 115520) and the Consejo Nacional de Ciencia y Tecnologia
   CONACyT Grant Nos. 284548, 269071 and Catedras No. 53. The technical
   support provided by Eloisa Aparicio, Pedro Casillas, Francisco Ruiz,
   Jose Romo, Katrin Quester, Mario Guzman, Diego Delgado (National
   Laboratory for Advanced Microscopy at CICESE) and David Dominguez is
   gratefully acknowledged.
CR Achilefu S, 2010, CHEM REV, V110, P2575, DOI 10.1021/cr1001113
   Adam J, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7020026
   Ai XZ, 2016, PHOSPHORS, UP CONVERSION NANO PARTICLES, QUANTUM DOTS AND THEIR APPLICATIONS, VOL 2, P363, DOI 10.1007/978 981 10 1590 8_12
   Alexis F, 2008, UROL ONCOL SEMIN ORI, V26, P74, DOI 10.1016/j.urolonc.2007.03.017
   Ansari GF, 2011, J FLUORESC, V21, P1337, DOI 10.1007/s10895 011 0864 9
   Blasse G., 2011, LUMINESCENT MAT, V10, P195
   Bouzigues C, 2011, ACS NANO, V5, P8488, DOI 10.1021/nn202378b
   Chavez D., 2016, MRS P, V1817
   Chavez D., 2017, MRS SPRING M
   Chávez DH, 2016, NANOMATER NANOTECHNO, V6, DOI 10.5772/62188
   Chavez Dalia Holanda, 2016, Nanobiomedicine (Rij), V3, P1, DOI 10.5772/62252
   Chávez García D, 2018, J MATER SCI, V53, P6665, DOI 10.1007/s10853 017 1946 0
   Cheung A, 2016, ONCOTARGET, V7, P52553, DOI 10.18632/oncotarget.9651
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Costantino L, 2009, PROG BRAIN RES, V180, P35, DOI 10.1016/S0079 6123(08)80003 9
   Dai Z., 2016, ADV NANOTHERANOSTICS, DOI DOI 10.1007/978 981 10 0063 8
   De Stefano D, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/167896
   deMello JC, 1997, ADV MATER, V9, P230, DOI 10.1002/adma.19970090308
   Eggeling C, 1998, ANAL CHEM, V70, P2651, DOI 10.1021/ac980027p
   Fleisher T. A., 2019, CLIN IMMUNOLOGY
   Gowd GS, 2012, J LUMIN, V132, P2023, DOI 10.1016/j.jlumin.2012.03.004
   Hanninen P., 2011, LANTHANIDE LUMINESCE
   He CA, 2003, MATER RES BULL, V38, P973, DOI 10.1016/S0025 5408(03)00089 8
   Hemmer E, 2013, NANOSCALE, V5, P11339, DOI 10.1039/c3nr02286b
   Hirata GA, 1997, APPL SURF SCI, V113, P509, DOI 10.1016/S0169 4332(96)00829 X
   Hsiao IL, 2015, ENVIRON SCI TECHNOL, V49, P3813, DOI 10.1021/es504705p
   Ivanov VM, 2004, J ANAL CHEM+, V59, P1002, DOI 10.1023/B:JANC.0000043920.77446.d7
   Jadhav AP, 2009, J PHYS CHEM C, V113, P13600, DOI 10.1021/jp903067j
   Jain A, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0359 9
   Ju GF, 2012, J LUMIN, V132, P1853, DOI 10.1016/j.jlumin.2012.03.020
   Juarez Moreno K, 2017, HUM EXP TOXICOL, V36, P931, DOI 10.1177/0960327116675206
   Karlsson HL, 2015, ENVIRON MOL MUTAGEN, V56, P82, DOI 10.1002/em.21933
   Kumar A, 2011, CYTOM PART A, V79A, P707, DOI 10.1002/cyto.a.21085
   Li ZJ, 2016, SPRING SER BIOMAT S, V6, P139, DOI 10.1007/978 3 662 48544 6_4
   Liang HY, 2015, FUTUR SCI OA, V1, DOI [10.4155/fso.15.54, 10.4155/FSO.15.54]
   Liu HQ, 2007, MATER LETT, V61, P3629, DOI 10.1016/j.matlet.2006.12.018
   Liu R. S., 2017, PHOSPHORS CONVERSION, P593
   Liu T, 2014, BIOMATERIALS, V35, P2942, DOI 10.1016/j.biomaterials.2013.12.007
   Liu YS, 2010, ADV MATER, V22, P3266, DOI 10.1002/adma.201000128
   Lu M, 2014, NEW J CHEM, V38, P4519, DOI 10.1039/c4nj00416g
   Lu YJ, 2004, ADV DRUG DELIVER REV, V56, P1161, DOI 10.1016/j.addr.2004.01.009
   Matsuura D, 2002, APPL PHYS LETT, V81, P4526, DOI 10.1063/1.1527976
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Panas A, 2014, BEILSTEIN J NANOTECH, V5, P1590, DOI 10.3762/bjnano.5.171
   Pires AM, 2006, J FLUORESC, V16, P461, DOI 10.1007/s10895 006 0085 9
   Rad AT, 2019, ACS APPL MATER INTER, V11, P10505, DOI 10.1021/acsami.8b21609
   Shan JN, 2008, J APPL PHYS, V104, DOI 10.1063/1.3008028
   Shen J, 2008, DALTON T, P5687, DOI 10.1039/b805306e
   Som S, 2015, RSC ADV, V5, P70887, DOI 10.1039/c5ra13247a
   Song CX, 2017, NANOTECHNOL REV, V6, P233, DOI 10.1515/ntrev 2016 0043
   Speit Gunter, 2006, Methods Mol Biol, V314, P275
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Subik K, 2010, BREAST CANCER BASIC, V4, P35
   Sudimack J, 2000, ADV DRUG DELIVER REV, V41, P147, DOI 10.1016/S0169 409X(99)00062 9
   Suzuki H, 2007, ENVIRON SCI TECHNOL, V41, P3018, DOI 10.1021/es0625632
   Taxak VB, 2009, J ALLOY COMPD, V469, P224, DOI 10.1016/j.jallcom.2008.01.088
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Vu Quang H., 2019, POLYMERS BASEL, P11
   Warheit DB, 2010, NANOTOXICOLOGY, V4, P409, DOI 10.3109/17435390.2010.485704
   Westin S. N., 2018, CLIN GYNECOLOGIC ONC, DOI DOI 10.1016/B978 0 323 40067 1.00018 8
   Xia JM, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604 018 2743 4
   Yee K, 2013, BIOMATERIALS, V34, P4860
   Zhang C, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064 015 1116 2
   Zucker RM, 2010, CYTOM PART A, V77A, P677, DOI 10.1002/cyto.a.20927
NR 64
TC 18
Z9 18
U1 2
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD AUG
PY 2020
VL 108
IS 6
BP 2396
EP 2406
DI 10.1002/jbm.b.34572
EA FEB 2020
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ME5KP
UT WOS:000510719000001
PM 32017405
DA 2025 08 17
ER

PT J
AU Tan, F
   O'Neill, F
   Naciri, M
   Dowling, D
   Al Rubeai, M
AF Tan, Fei
   O'Neill, Feidhlim
   Naciri, Mariam
   Dowling, Denis
   Al Rubeai, Mohamed
TI Cellular and transcriptomic analysis of human mesenchymal stem cell
   response to plasma activated hydroxyapatite coating
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Plasma activation; Polymerase chain reaction array; Osteogenic genes;
   Mesenchymal stem cells; Cell cycle
ID ATMOSPHERIC PRESSURE; OSTEOBLAST ADHESION; SURFACE TREATMENT;
   GROWTH FACTOR; JET TREATMENT; DIFFERENTIATION; FIBRONECTIN; COLLAGEN;
   DISCHARGES; STRENGTH
AB Atmospheric pressure plasma has recently emerged as a technique with a promising future in the medical field. In this work we used the technique as a post deposition modification process as a means to activate hydroxyapatite (HA) coatings. Contact angle goniometry, optical profilometry, scanning electron microscopy morphology imaging and X ray photoelectron spectroscopy analysis demonstrate that surface wettability is improved after treatment, without inducing any concomitant damage to the coating. The protein adsorption pattern has been found to be preferable for MSC, and this may result in greater cell attachment and adhesion to plasma activated HA than to untreated samples. Cell cycle distribution analysis using flow cytometry reveals a faster transition from G(1) to S phase, thus leading to a faster cell proliferation rate on plasma activated HA. This indicates that the improvement in surface wettability independently enhances cell attachment and cell proliferation, which is possibly mediated by FAK phosphorylation. Pathway specific polymerase chain reaction arrays revealed that wettability has a substantial influence on gene expression during osteogenic differentiation of human MSC. Plasma activated HA tends to enhance this process by systemically deregulating multiple genes. In addition, the majority of these deregulated genes had been appropriately translated, as confirmed by ELISA protein quantification. Lastly, alizarin red staining showed that plasma activated HA is capable of improving mineralization for up to 3 weeks of in vitro culture. It was concluded from this study that atmospheric pressure plasma is a potent tool for modifying the biological function of a material without causing thermal damage, such that adhesion molecules and drugs might be deposited on the original coating to improve performance. (C) 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Tan, Fei; Naciri, Mariam; Al Rubeai, Mohamed] Univ Coll Dublin, Sch Chem & Bioproc Engn, Dublin 4, Ireland.
   [Tan, Fei; Naciri, Mariam; Al Rubeai, Mohamed] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.
   [Tan, Fei] Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland.
   [O'Neill, Feidhlim; Dowling, Denis] Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 4, Ireland.
C3 University College Dublin; University College Dublin; University College
   Dublin; University College Dublin
RP Al Rubeai, M (通讯作者)，Univ Coll Dublin, Sch Chem & Bioproc Engn, Dublin 4, Ireland.
EM m.al rubeai@ucd.ie
RI ; Dowling, Denis/T 1480 2018; tan, fei/KOD 4737 2024
OI Tan, Fei/0000 0003 1010 0163; Dowling, Denis/0000 0001 7853 2478; 
FU Science Foundation Ireland [08/SRC/I1411]
FX This work was supported by Science Foundation Ireland (Grant No.
   08/SRC/I1411). The authors wish to thank EnBIO (Cork, Ireland) for
   providing technical assistance regarding HA coating deposition.
CR Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Bilezikian J.P., 2008, Principles of Bone Biology
   Bodhak S, 2009, ACTA BIOMATER, V5, P2178, DOI 10.1016/j.actbio.2009.02.023
   Brett PM, 2004, BONE, V35, P124, DOI 10.1016/j.bone.2004.03.009
   Bringmann P, 2009, PLASMA PROCESS POLYM, V6, pS496, DOI 10.1002/ppap.200931105
   Burmeister JS, 1996, J BIOMED MATER RES, V30, P13, DOI 10.1002/(SICI)1097 4636(199601)30:1<13::AID JBM3>3.0.CO;2 U
   CARLSSON R, 1981, P NATL ACAD SCI BIOL, V78, P2403, DOI 10.1073/pnas.78.4.2403
   Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097 0177(200006)218:2<213::AID DVDY1>3.0.CO;2 R
   Compton KT, 1930, REV MOD PHYS, V2, P0123, DOI 10.1103/RevModPhys.2.123
   Dee KC, 2003, PROTEIN SURFACE INTE
   Dowling DP, 2011, PLASMA PROCESS POLYM, V8, P718, DOI 10.1002/ppap.201000145
   Eliaz N, 2009, ACTA BIOMATER, V5, P3178, DOI 10.1016/j.actbio.2009.04.005
   Fernandes JC, 2008, J BONE MINER METAB, V26, P543, DOI 10.1007/s00774 008 0866 0
   Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090 006 9024 4
   Grigor'ian A S, 2001, Stomatologiia (Mosk), V80, P80
   Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208
   Heberlein J, 2002, PURE APPL CHEM, V74, P327, DOI 10.1351/pac200274030327
   Heng BC, 2004, J BONE MINER RES, V19, P1379, DOI 10.1359/JBMR.040714
   Hsiao WK, 2011, J PERIODONTOL, V82, P854, DOI 10.1902/jop.2010.100208
   HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169 6009(92)90844 4
   Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kieft IE, 2005, IEEE T PLASMA SCI, V33, P771, DOI 10.1109/TPS.2005.844528
   Kieft IE, 2006, IEEE T PLASMA SCI, V34, P1331, DOI 10.1109/TPS.2006.876511
   Kilpadi KL, 2001, J BIOMED MATER RES, V57, P258, DOI 10.1002/1097 4636(200111)57:2<258::AID JBM1166>3.0.CO;2 R
   Kim B, 2004, P ANN INT IEEE EMBS, V26, P5013
   KOKUBO T, 1991, BIOMATERIALS, V12, P155, DOI 10.1016/0142 9612(91)90194 F
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kong M.G., 2009, NEW J PHYS, V11, P1, DOI DOI 10.1088/1367 2630/11/11/115012
   Koyama Y, 2004, J NEUROCHEM, V90, P904, DOI 10.1111/j.1471 4159.2004.02546.x
   Lan CW, 2003, ARTIF CELL BLOOD SUB, V31, P59, DOI 10.1081/BIO 120018003
   Lim JY, 2008, BIOMATERIALS, V29, P1776, DOI 10.1016/j.biomaterials.2007.12.026
   Lim JY, 2004, J BIOMED MATER RES A, V68A, P504, DOI 10.1002/jbm.a.20087
   Liu XM, 2007, BIOMATERIALS, V28, P4535, DOI 10.1016/j.biomaterials.2007.06.016
   Lommatzsch U, 2007, PLASMA PROCESS POLYM, V4, pS1041, DOI 10.1002/ppap.200732402
   Lu LL, 2006, HAEMATOLOGICA, V91, P1017
   Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945 053X(01)00151 2
   Massines F, 1998, J PHYS D APPL PHYS, V31, P3411, DOI 10.1088/0022 3727/31/24/003
   Morgan D. O., 2007, CELL CYCLE PRINCIPLE
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   Noeske M, 2004, INT J ADHES ADHES, V24, P171, DOI 10.1016/j.ijadhadh.2003.09.006
   O'Hare P, 2010, BIOMATERIALS, V31, P515, DOI 10.1016/j.biomaterials.2009.09.067
   O'Neill L, 2009, SURF COAT TECH, V204, P484, DOI 10.1016/j.surfcoat.2009.08.014
   Okabe Y, 2005, SURF COAT TECH, V196, P303, DOI 10.1016/j.surfcoat.2004.08.190
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Pradet Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968 0004(00)01776 X
   Redey SA, 2000, J BIOMED MATER RES, V50, P353, DOI 10.1002/(SICI)1097 4636(20000605)50:3<353::AID JBM9>3.3.CO;2 3
   Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood 2006 10 051060
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schütze A, 1998, IEEE T PLASMA SCI, V26, P1685, DOI 10.1109/27.747887
   Scopece P, 2009, PLASMA PROCESS POLYM, V6, pS705, DOI 10.1002/ppap.200931707
   Shi ST, 1996, J BONE MINER RES, V11, P1139, DOI 10.1002/jbmr.5650110813
   Stoffels E, 2008, PLASMA PROCESS POLYM, V5, P599, DOI 10.1002/ppap.200800028
   Sun H, 2008, TRANSPL P, V40, P2645, DOI 10.1016/j.transproceed.2008.07.096
   Sun LM, 2001, J BIOMED MATER RES, V58, P570, DOI 10.1002/jbm.1056
   Sun LM, 2003, MAT SCI ENG A STRUCT, V360, P70, DOI 10.1016/S0921 5093(03)00439 8
   Tan F, 2012, BIOTECHNOL ADV, V30, P352, DOI 10.1016/j.biotechadv.2011.07.008
   Tan F, 2011, BIOTECHNOL BIOENG, V108, P454, DOI 10.1002/bit.22955
   Tendero C, 2006, SPECTROCHIM ACTA B, V61, P2, DOI 10.1016/j.sab.2005.10.003
   Tihan TG, 2009, MATER CHEM PHYS, V118, P265, DOI 10.1016/j.matchemphys.2009.03.019
   TRUSKEY GA, 1993, BIOMATERIALS, V14, P243, DOI 10.1016/0142 9612(93)90114 H
   Villermet A, 2003, SURF COAT TECH, V174, P899, DOI 10.1016/S0257 8972(03)00363 3
   Vohra S, 2008, J MATER SCI MATER M, V19, P3567, DOI 10.1007/s10856 008 3525 z
   Weltmann KD, 2010, PURE APPL CHEM, V82, P1223, DOI 10.1351/PAC CON 09 10 35
   Wiesner TF, 1997, P NATL ACAD SCI USA, V94, P3726, DOI 10.1073/pnas.94.8.3726
   ZHANG Z, 1993, BIOTECHNOL BIOENG, V42, P987, DOI 10.1002/bit.260420809
   Zhao G, 2005, J BIOMED MATER RES A, V74A, P49, DOI 10.1002/jbm.a.30320
NR 69
TC 30
Z9 32
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD APR
PY 2012
VL 8
IS 4
BP 1627
EP 1638
DI 10.1016/j.actbio.2011.12.014
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 913JG
UT WOS:000301873000024
PM 22202907
DA 2025 08 17
ER

PT J
AU Piatkowski, J
   Podsiadly, H
   Bukietynska, K
AF Piatkowski, Jerzy
   Podsiadly, Halina
   Bukietynska, Krystyna
TI The effect of V(III) adenine complex on yeast as a model of eukaryotic
   cells
SO JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE adenine; anti cancer drugs; cancer treatment; vanadium complex compound;
   yeast
ID OSTEOBLAST LIKE CELLS; COMPLETE DNA SEQUENCE; VANADIUM COMPOUNDS;
   INSULIN; INHIBITION; COMPOUND; GROWTH; STRAIN
AB The dinuclear mu okso vanadium (III) complex compound H4V2OCl4(Ad)(2) synthesized in our laboratory was investigated as a potential cytotoxic agent against yeast cells. The results of these studies could be helpful in the explanation of the mechanism governing the V (III) compound action on yeast as a simple model of eukaryotic cells. The important factors influencing the toxicity of this complex compound are: the stage of the yeast life cycle, the rate of growth and the pH of reaction mixture. The lethal effect was distinctly stronger when the reaction mixture was slightly acidic (pH = 4). In such solutions V(111) mononuclear species with adenine was relatively stable, and during the time of experiment possibly only a slow oxidation process to V(IV) occurred. In the solutions with pH = 7, several hydrolytic, perhaps mixed valence, polynuclear species were present and their action on the yeast cells was rather weak. The increased lethal activity of this compound in acidic solutions may be useful in specific treatment against cancer cells whose cytoplasm and/or closest surrounding has lower pH value. The next important result was an observation that the killing activity of this compound was enhanced for yeast cells being in log phase. Also these which had a slower rate of growth (possessing some auxotrophic mutations) were more resistant than those growing faster. The extent of yeast mutagenesis caused by the complex compound is negligible, as the number of mutants found in experiments was within the limit of experimental error. These results are promising and the investigated complex can be considered as a potential anti cancer agent.
C1 Univ Wroclaw, Inst Genet & Microbiol, PL 51148 Wroclaw, Poland.
   Univ Wroclaw, Krystyna Bukietypska & Halina Podsialy, Fac Chem, PL 50383 Wroclaw, Poland.
C3 University of Wroclaw; University of Wroclaw
RP Piatkowski, J (通讯作者)，Univ Wroclaw, Inst Genet & Microbiol, Ul Przybyszewskiego 63 77, PL 51148 Wroclaw, Poland.
EM jurekp@microb.uni.wroc.pl
CR Alberts Bruce, 2017, Molecular Biology of the Cell
   Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0
   Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259
   Bukietynska K, 2001, POLYHEDRON, V20, P2353, DOI 10.1016/S0277 5387(01)00840 3
   Crans DC, 2004, J INORG BIOCHEM, V98, P1837, DOI 10.1016/j.jinorgbio.2004.08.010
   Crans DC, 2004, CHEM REV, V104, P849, DOI 10.1021/cr020607t
   Crans DC, 2003, COORDIN CHEM REV, V237, P13, DOI 10.1016/S0010 8545(02)00292 8
   DJORDJEVIC C, 1995, METAL IONS BIOL SYST, V31
   Dougherty TJ, 1998, JNCI J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0
   El Naggar MM, 1998, CANCER LETT, V133, P71, DOI 10.1016/S0304 3835(98)00213 4
   Etcheverry SB, 1997, ARCH BIOCHEM BIOPHYS, V338, P7, DOI 10.1006/abbi.1996.9778
   Evangelou A, 1997, CANCER LETT, V119, P221, DOI 10.1016/S0304 3835(97)00278 4
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040 8428(01)00221 9
   FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460 2075.1994.tb06923.x
   Friberg EG, 2003, CANCER LETT, V195, P73, DOI 10.1016/S0304 3835(03)00150 2
   Hall IH, 2003, J INORG BIOCHEM, V93, P125, DOI 10.1016/S0162 0134(02)00565 2
   MEHTA RD, 1985, EVALUATION SHORT TER, V5, P271
   Melchior M, 2001, INORG CHEM, V40, P4686, DOI 10.1021/ic000984t
   Osinska Królicka I, 2004, J INORG BIOCHEM, V98, P2087, DOI 10.1016/j.jinorgbio.2004.09.013
   Papaioannou A, 2004, J INORG BIOCHEM, V98, P959, DOI 10.1016/j.jinorgbio.2004.02.011
   Sakurai H, 2003, COORDIN CHEM REV, V245, P31, DOI 10.1016/S0010 8545(03)00031 6
   Shechter Y, 2003, COORDIN CHEM REV, V237, P3, DOI 10.1016/S0010 8545(02)00302 8
   Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081
   Thompson KH, 1999, CHEM REV, V99, P2561, DOI 10.1021/cr980427c
   Thompson KH, 2001, COORDIN CHEM REV, V219, P1033, DOI 10.1016/S0010 8545(01)00395 2
   Williams PAM, 2004, J INORG BIOCHEM, V98, P333, DOI 10.1016/j.jinorgbio.2003.10.019
   WILLSKY GR, 1984, J BIOL CHEM, V259, P3273
   Xie MJ, 2005, J INORG BIOCHEM, V99, P546, DOI 10.1016/j.jinorgbio.2004.10.033
   ZIMMERMANN FK, 1975, MUTAT RES, V28, P381, DOI 10.1016/0027 5107(75)90232 8
   ZIMMERMANN FK, 1973, MUTAT RES, V21, P263, DOI 10.1016/0165 1161(73)90021 6
   ZIMMERMANN FK, 1971, MUTAT RES, V11, P327
NR 32
TC 5
Z9 5
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0021 924X
EI 1756 2651
J9 J BIOCHEM
JI J. Biochem.
PD APR
PY 2007
VL 141
IS 4
BP 545
EP 552
DI 10.1093/jb/mvm062
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 168KN
UT WOS:000246523600012
PM 17317691
DA 2025 08 17
ER

PT J
AU Salimi, F
   Hamedi, J
   Motevaseli, E
   Mohammadipanah, F
AF Salimi, F.
   Hamedi, J.
   Motevaseli, E.
   Mohammadipanah, F.
TI Isolation and screening of rare Actinobacteria, a new insight for
   finding natural products with antivascular calcification activity
SO JOURNAL OF APPLIED MICROBIOLOGY
LA English
DT Article
DE Actinobacteria; apoptosis; Kribbella sp; vascular calcification;
   vascular smooth muscle cells
ID VASCULAR CALCIFICATION; EXPRESSION; APOPTOSIS; IDENTIFICATION;
   ASSOCIATION; ANTIOXIDANT; METABOLITES; MECHANISMS; PATTERNS; GROWTH
AB AimVascular calcification (VC) is a significant pathological process in some life threatening diseases. Several pathological mechanisms, including transdifferentiation of vascular smooth muscle cells to osteoblast like cells and apoptosis are involved in VC. Compounds with an inhibitory effect on these processes are potentially efficient medications. In consideration of the multiple biological activities of Actinobacteria, this research was aimed at finding anti VC metabolite producing Actinobacteria.
   Methods and ResultsAfter the isolation and identification of Actinobacteria, the effect of their fermentation broth extracts on the apoptosis rate was measured using various methods, for example, ethidium bromide/acridine orange staining, DNA laddering and diphenylamine assays. The effect of the most effective fermentation broth extract of Actinobacteria (FBEA) on the mRNA expression of runt related transcription factor 2 (Runx2) and osteopontin (OPN) was examined. Finally, the most effective FBEA was fractionated and the chemical composition of anti VC fractions was analysed using GC MS. Various VC inhibition rates were observed in the tested FBEA (20gml( 1); 179 6015%). The inhibition of DNA fragmentation was 7 48%. The FBE with the greatest anticalcification activity belonged to Kribbella sp. UTMC 267 and, according to 16S rRNA analysis, Kribbella sancticallisti with a similarity of 9853% is its nearest neighbour. The FBE of Kribbella sp. UTMC 267 reduced Runx2 mRNA expression by 295 fold and OPN mRNA expression by 2857 fold, both of which are considered significant (P<005). Finally, GC MS analysis showed the existence of potent anti oxidative and anti inflammation agents in FBE of Kribbella sp. UTMC 267.
   ConclusionsActinobacterial metabolites can provide a new strategy for treating VC diseases by reducing the expression of osteogenic genes, the apoptosis rate and oxidative stress.
   Significance and Impact of the StudyThis study highlights the therapeutic potential of Kribbella sp. metabolites and Actinobacteria as a new natural source for drug discovery programs in the nonantibiotic bioactivity field.
C1 [Salimi, F.; Hamedi, J.; Mohammadipanah, F.] Univ Tehran, Coll Sci, Sch Biol, Dept Microbial Biotechnol, Tehran, Iran.
   [Salimi, F.; Hamedi, J.; Mohammadipanah, F.] Univ Tehran, Coll Sci, Ctr Excellence Phylogeny Living Organisms, Tehran, Iran.
   [Salimi, F.; Hamedi, J.; Mohammadipanah, F.] Univ Tehran, Microbial Technol & Prod Res Ctr, Tehran, Iran.
   [Motevaseli, E.] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Mol Med, Tehran, Iran.
C3 University of Tehran; University of Tehran; University of Tehran; Tehran
   University of Medical Sciences
RP Hamedi, J (通讯作者)，Univ Tehran, Coll Sci, Sch Biol, Dept Microbial Biotechnol, Tehran, Iran.; Motevaseli, E (通讯作者)，Univ Tehran Med Sci, Sch Adv Technol Med, Dept Mol Med, Tehran, Iran.
EM jhamedi@ut.ac.ir; e_motevaseli@tums.ac.ir
RI Salimi, Fatemeh/HKO 8512 2023; Hamedi, Javad/M 4042 2018
CR [Anonymous], RELATED ISOLATION PR
   Aparna V, 2012, CHEM BIOL DRUG DES, V80, P434, DOI 10.1111/j.1747 0285.2012.01418.x
   Arndt C, 1999, MICROBIOL SGM, V145, P1989, DOI 10.1099/13500872 145 8 1989
   Azarakhsh Y, 2017, J APPL MICROBIOL, V122, P1595, DOI 10.1111/jam.13458
   Bendheim PE, 2002, J MOL NEUROSCI, V19, P213, DOI 10.1007/s12031 002 0036 0
   Bérdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1
   BossU P, 1998, QUALITATIVE ANAL DNA, P4
   Budoff MJ, 2004, PREV MED, V39, P985, DOI 10.1016/j.ypmed.2004.04.012
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Carlsohn M.R., 2011, ISOLATION CHARACTERI
   CASSINELLI G, 1970, ARCH MIKROBIOL, V70, P197, DOI 10.1007/BF00407710
   Deas DS, 2015, VASC MED, V20, P326, DOI 10.1177/1358863X15581448
   Duan XH, 2013, APOPTOSIS, V18, P1132, DOI 10.1007/s10495 013 0861 3
   Eftekharzadeh B, 2010, APPL MICROBIOL BIOT, V86, P1805, DOI 10.1007/s00253 010 2456 z
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Engelse MA, 2001, CARDIOVASC RES, V52, P281, DOI 10.1016/S0008 6363(01)00375 3
   Gercel Taylor C, 2005, METH MOLEC MED, V111, P79
   Govindappa M., 2014, INT J BIOL PHARM RES, V5, P861
   Han KH, 2015, VASC MED, V20, P527, DOI 10.1177/1358863X15597076
   Igarashi M, 2017, J ANTIBIOT, V70, P582, DOI 10.1038/ja.2016.161
   Johnson K, 2001, ARTHRITIS RHEUM, V44, P1071, DOI 10.1002/1529 0131(200105)44:5<1071::AID ANR187>3.0.CO;2 3
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Kim YG, 2012, APPL MICROBIOL BIOT, V96, P1607, DOI 10.1007/s00253 012 4225 7
   Kumar P. P., 2010, African Journal of Biochemistry Research, V4, P191
   Li JX, 2004, HEART VESSELS, V19, P125, DOI 10.1007/s00380 003 0744 6
   Li X, 2014, ACTA CRYSTALLOGR C, V70, P1050, DOI 10.1107/S2053229614021445
   Mohammadi E, 2015, CELL TISSUE RES, V362, P597, DOI 10.1007/s00441 015 2228 2
   Mohler ER, 1997, ARTERIOSCL THROM VAS, V17, P547, DOI 10.1161/01.ATV.17.3.547
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   N SJ., 2011, Journal of Pharmacy Research, V4, P1285
   Naik N., 2012, Der Pharma Chem, V4, P783
   Narayana KJP, 2008, POL J MICROBIOL, V57, P35
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Padmavathi AR, 2014, BIOFOULING, V30, P1111, DOI 10.1080/08927014.2014.972386
   Park YH, 1999, INT J SYST BACTERIOL, V49, P743, DOI 10.1099/00207713 49 2 743
   Price PA, 2002, CIRC RES, V91, P547, DOI 10.1161/01.RES.0000033987.22436.50
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Rahuman A. Abdul, 2000, Fitoterapia, V71, P553, DOI 10.1016/S0367 326X(00)00164 7
   Rangel Sánchez G, 2014, J PLANT PHYSIOL, V171, P189, DOI 10.1016/j.jplph.2013.07.004
   Renvoize C, 1998, CELL BIOL TOXICOL, V14, P111, DOI 10.1023/A:1007429904664
   Roman Garcia P, 2011, J NEPHROL, V24, P669, DOI 10.5301/jn.5000029
   Saeed NM, 2012, TOXICOL APPL PHARM, V264, P84, DOI 10.1016/j.taap.2012.07.020
   SCHUPP T, 1987, FEMS MICROBIOL LETT, V42, P135
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   Shao L, 2012, APPL ENVIRON MICROB, V78, P2034, DOI 10.1128/AEM.06904 11
   SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Sova M, 2012, MINI REV MED CHEM, V12, P749, DOI 10.2174/138955712801264792
   Suenobu N, 1999, ARTERIOSCL THROM VAS, V19, P140, DOI 10.1161/01.ATV.19.1.140
   Trion A, 2004, AM HEART J, V147, P808, DOI 10.1016/j.ahj.2003.10.047
   Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31
   Urzì C, 2008, INT J SYST EVOL MICR, V58, P2090, DOI 10.1099/ijs.0.65613 0
   WILKERSON WW, 1993, BIOORG MED CHEM LETT, V3, P711, DOI 10.1016/S0960 894X(01)81260 9
NR 53
TC 12
Z9 14
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1364 5072
EI 1365 2672
J9 J APPL MICROBIOL
JI J. Appl. Microbiol.
PD JAN
PY 2018
VL 124
IS 1
BP 254
EP 266
DI 10.1111/jam.13605
PG 13
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA FQ6DK
UT WOS:000418453800023
PM 28990259
DA 2025 08 17
ER

PT J
AU Tuscher, R
   Khang, A
   West, TM
   Camillo, C
   Ferrari, G
   Sacks, MS
AF Tuscher, Robin
   Khang, Alex
   West, Toni M.
   Camillo, Chiara
   Ferrari, Giovanni
   Sacks, Michael S.
TI Functional differences in human aortic valve interstitial cells from
   patients with varying calcific aortic valve disease
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE aortic valve; bicuspid aortic valve; aortic valve interstitial cells;
   contractility; stress fibers; calcific aortic valve disease (CAVD);
   basal tonus
ID STIFFNESS
AB Calcific aortic valve disease (CAVD) is characterized by progressive stiffening of aortic valve (AV) tissues, inducing stenosis and insufficiency. Bicuspid aortic valve (BAV) is a common congenital defect in which the AV has two leaflets rather than three, with BAV patients developing CAVD decades years earlier than in the general population. Current treatment for CAVD remains surgical replacement with its continued durability problems, as there are no pharmaceutical therapies or other alternative treatments available. Before such therapeutic approaches can be developed, a deeper understanding of CAVD disease mechanisms is clearly required. It is known that AV interstitial cells (AVICs) maintain the AV extracellular matrix and are typically quiescent in the normal state, transitioning into an activated, myofibroblast like state during periods of growth or disease. One proposed mechanism of CAVD is the subsequent transition of AVICs into an osteoblast like phenotype. A sensitive indicator of AVIC phenotypic state is enhanced basal contractility (tonus), so that AVICs from diseased AV will exhibit a higher basal tonus level. The goals of the present study were thus to assess the hypothesis that different human CAVD states lead to different biophysical AVIC states. To accomplish this, we characterized AVIC basal tonus behaviors from diseased human AV tissues embedded in 3D hydrogels. Established methods were utilized to track AVIC induced gel displacements and shape changes after the application of Cytochalasin D (an actin polymerization inhibitor) to depolymerize the AVIC stress fibers. Results indicated that human diseased AVICs from the non calcified region of TAVs were significantly more activated than AVICs from the corresponding calcified region. In addition, AVICs from the raphe region of BAVs were more activated than from the non raphe region. Interestingly, we observed significantly greater basal tonus levels in females compared to males. Furthermore, the overall AVIC shape changes after Cytochalasin suggested that AVICs from TAVs and BAVs develop different stress fiber architectures. These findings are the first evidence of sex specific differences in basal tonus state in human AVICs in varying disease states. Future studies are underway to quantify stress fiber mechanical behaviors to further elucidate CAVD disease mechanisms.
C1 [Tuscher, Robin; Khang, Alex; West, Toni M.; Sacks, Michael S.] Univ Texas Austin, Oden Inst Computat Engn & Sci, James T Willerson Ctr Cardiovasc Modeling & Simula, Dept Biomed Engn, Austin, TX 78712 USA.
   [Camillo, Chiara; Ferrari, Giovanni] Columbia Univ, Dept Surg, Seymour Cohn Cardiovasc Res Lab, New York, NY USA.
C3 University of Texas System; University of Texas Austin; Columbia
   University
RP Sacks, MS (通讯作者)，Univ Texas Austin, Oden Inst Computat Engn & Sci, James T Willerson Ctr Cardiovasc Modeling & Simula, Dept Biomed Engn, Austin, TX 78712 USA.
EM msacks@oden.utexas.edu
OI Khang, Alex/0000 0002 1211 5740
FU National Institutes of Health, United States [HL 142504, 826414]; Ruth
   L. Kirschstein Postdoctoral Fellowship [F32HL149210]; American Heart
   Association [HL 131872]; American Heart Association (AHA) [826414]
   Funding Source: American Heart Association (AHA)
FX The authors would like to acknowledge the following funding sources:
   National Institutes of Health, United States, (Grant No. HL 142504)
   awarded to MS, National Institutes of Health, United States, Ruth L.
   Kirschstein Postdoctoral Fellowship awarded to TW, American Heart
   Association post doctoral fellowship (Grant No. 826414) awarded to TW,
   National Institutes of Health, United States, Ruth L. Kirschstein
   Postdoctoral Fellowship (Grant No. F32HL149210) awarded to Daniel P.
   Howsmon, and National Institutes of Health, United States, R01 Research
   Grant (Grant No. HL 131872) awarded to GF.
CR Aggarwal A, 2014, ANN BIOMED ENG, V42, P986, DOI 10.1007/s10439 014 0973 0
   Aguado BA, 2022, CIRCULATION, V145, P513, DOI 10.1161/CIRCULATIONAHA.121.054108
   Ayoub S, 2021, BIOMECH MODEL MECHAN, V20, P135, DOI 10.1007/s10237 020 01373 w
   Ayoub S, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0580
   Bourguignon T, 2015, ANN THORAC SURG, V99, P831, DOI 10.1016/j.athoracsur.2014.09.030
   Braverman AC, 2005, CURR PROB CARDIOLOGY, V30, P470, DOI 10.1016/j.cpcardiol.2005.06.002
   Duan B, 2016, ACTA BIOMATER, V36, P42, DOI 10.1016/j.actbio.2016.03.007
   Head SJ, 2017, EUR HEART J, V38, P2183, DOI 10.1093/eurheartj/ehx141
   Hinz B, 2003, MOL BIOL CELL, V14, P2508, DOI 10.1091/mbc.E02 11 0729
   Jamieson WRE, 1998, ANN THORAC SURG, V66, pS49, DOI 10.1016/S0003 4975(98)01127 8
   Khang A., 2022, SB3C P BOOK
   Khang A., 2022, ACTA BIOMATER, V163, P194, DOI [10.1016/j.actbio.2022.01.039, DOI 10.1016/J.ACTBIO.2022.01.039]
   Khang A, 2023, ACTA BIOMATER, V160, P123, DOI 10.1016/j.actbio.2023.01.043
   Khang A, 2019, ACTA BIOMATER, V96, P354, DOI 10.1016/j.actbio.2019.07.010
   Lam NT, 2016, INTEGR BIOL UK, V8, P1079, DOI 10.1039/c6ib00120c
   Lee CH, 2015, J THEOR BIOL, V373, P26, DOI 10.1016/j.jtbi.2015.03.004
   Lejeune E, 2020, SOFTWAREX, V11, DOI 10.1016/j.softx.2020.100417
   Lerman DA, 2015, EUR CARDIOL REV, V10, P108, DOI 10.15420/ecr.2015.10.2.108
   Merryman WD, 2007, TISSUE ENG, V13, P2281, DOI 10.1089/ten.2006.0324
   Merryman WD, 2006, AM J PHYSIOL HEART C, V290, pH224, DOI 10.1152/ajpheart.00521.2005
   Rego BV, 2022, ANN BIOMED ENG, V50, P1, DOI 10.1007/s10439 021 02882 0
   Sakamoto Y, 2017, J BIOMECH ENG T ASME, V139, DOI 10.1115/1.4035557
   Sakamoto Y, 2016, J MECH BEHAV BIOMED, V54, P244, DOI 10.1016/j.jmbbm.2015.09.027
   Stephens EH, 2007, J HEART VALVE DIS, V16, P175
   Tasoudis PT, 2022, EUR J CARDIO THORAC, V62, DOI 10.1093/ejcts/ezac268
   West TM, 2023, APL BIOENG, V7, DOI 10.1063/5.0138030
NR 26
TC 4
Z9 4
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD JUN 19
PY 2023
VL 14
AR 1168691
DI 10.3389/fphys.2023.1168691
PG 15
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA L3KM7
UT WOS:001022282300001
PM 37405132
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Guo, S
   Zhang, ER
   Zhang, B
   Liu, QR
   Meng, Z
   Li, Z
   Wang, C
   Gong, ZT
   Wu, YJ
AF Guo, Shuai
   Zhang, Erli
   Zhang, Bin
   Liu, Qingrong
   Meng, Zhen
   Li, Ziang
   Wang, Can
   Gong, Zhaoting
   Wu, Yongjian
TI Identification of Key Non coding RNAs and Transcription Factors in
   Calcific Aortic Valve Disease
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE calcific aortic valve disease; non coding RNA; transcription factor;
   epigenetics; bioinformatics
ID INTERSTITIAL CELLS; OSTEOBLAST DIFFERENTIATION; MATRIX
   METALLOPROTEINASES; EXPRESSION; STENOSIS; PROMOTES; PROGRESSION; MICE;
   CHONDROCYTES; PATHOGENESIS
AB BackgroundCalcific aortic valve disease (CAVD) is one of the most frequently occurring valvular heart diseases among the aging population. Currently, there is no known pharmacological treatment available to delay or reverse CAVD progression. The regulation of gene expression could contribute to the initiation, progression, and treatment of CAVD. Non coding RNAs (ncRNAs) and transcription factors play essential regulatory roles in gene expression in CAVD; thus, further research is urgently needed. Materials and MethodsThe gene expression profiles of GSE51472 and GSE12644 were obtained from the Gene Expression Omnibus database, and differentially expressed genes (DEGs) were identified in each dataset. A protein protein interaction (PPI) network of DEGs was then constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins database, and functional modules were analyzed with ClusterOne plugin in Cytoscape. Furthermore, Gene Ontology functional annotation and Kyoto Encyclopedia of Genes and Genomes pathway analysis were conducted for each functional module. Most crucially, ncRNAs and transcription factors acting on each functional module were separately identified using the RNAInter and TRRUST databases. The expression of predicted transcription factors and key genes was validated using GSE51472 and GSE12644. Furthermore, quantitative real time PCR (qRT PCR) experiments were performed to validate the differential expression of most promising candidates in human CAVD and control samples. ResultsAmong 552 DEGs, 383 were upregulated and 169 were downregulated. In the PPI network, 15 functional modules involving 182 genes and proteins were identified. After hypergeometric testing, 45 ncRNAs and 33 transcription factors were obtained. Among the predicted transcription factors, CIITA, HIF1A, JUN, POU2F2, and STAT6 were differentially expressed in both the training and validation sets. In addition, we found that key genes, namely, CD2, CD86, CXCL8, FCGR3B, GZMB, ITGB2, LY86, MMP9, PPBP, and TYROBP were also differentially expressed in both the training and validation sets. Among the most promising candidates, differential expressions of ETS1, JUN, NFKB1, RELA, SP1, STAT1, ANCR, and LOC101927497 were identified via qRT PCR experiments. ConclusionIn this study, we identified functional modules with ncRNAs and transcription factors involved in CAVD pathogenesis. The current results suggest candidate molecules for further research on CAVD.
C1 [Guo, Shuai; Zhang, Erli; Zhang, Bin; Liu, Qingrong; Meng, Zhen; Li, Ziang; Wang, Can; Gong, Zhaoting; Wu, Yongjian] Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College; Fu
   Wai Hospital   CAMS; Peking Union Medical College
RP Wu, YJ (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China.
EM yongjianwu_nccd@163.com
CR Avci A, 2014, ECHOCARDIOGR J CARD, V31, P1031, DOI 10.1111/echo.12534
   Balachandran K, 2009, AM J PHYSIOL HEART C, V296, pH756, DOI 10.1152/ajpheart.00900.2008
   Bartoli Leonard F, 2021, CARDIOVASC RES, V117, P2506, DOI 10.1093/cvr/cvab273
   Bossé Y, 2009, CIRC CARDIOVASC GENE, V2, P489, DOI 10.1161/CIRCGENETICS.108.820795
   Brady M, 2003, CARDIOVASC RES, V60, P347, DOI 10.1016/S0008 6363(03)00529 7
   Carrion K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096577
   Chen JH, 2011, CIRC RES, V108, P1510, DOI 10.1161/CIRCRESAHA.110.234237
   Chistiakov DA, 2016, J MOL CELL CARDIOL, V97, P47, DOI 10.1016/j.yjmcc.2016.05.007
   Coffey S, 2014, J AM COLL CARDIOL, V63, P2852, DOI 10.1016/j.jacc.2014.04.018
   Derbali H, 2010, AM J PATHOL, V176, P2638, DOI 10.2353/ajpath.2010.090541
   dos Santos AM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/497280
   Esmerats JF, 2019, ARTERIOSCL THROM VAS, V39, P467, DOI 10.1161/ATVBAHA.118.312233
   Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024
   Fondard O, 2005, EUR HEART J, V26, P1333, DOI 10.1093/eurheartj/ehi248
   Freeman RV, 2005, CIRCULATION, V111, P3316, DOI 10.1161/CIRCULATIONAHA.104.486738
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Gao GC, 2019, J CELL BIOCHEM, V120, P17167, DOI 10.1002/jcb.28977
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gharibeh L, 2018, CIRCULATION, V138, P1025, DOI 10.1161/CIRCULATIONAHA.117.029506
   Ghazvini Boroujerdi M, 2004, J HEART VALVE DIS, V13, P894
   Gross L, 1931, AM J PATHOL, V7, P0445
   Guo X, 2017, EUR J VASC ENDOVASC, V54, P303, DOI 10.1016/j.ejvs.2017.06.010
   Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013
   He WL, 2020, MOL CELL PROBE, V50, DOI 10.1016/j.mcp.2020.101509
   He WL, 2021, J PHYSIOL BIOCHEM, V77, P461, DOI 10.1007/s13105 021 00821 0
   Hutson HN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163858
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Kolde Raivo, 2019, CRAN
   Kopytek M, 2019, INT J CARDIOL, V286, P121, DOI 10.1016/j.ijcard.2019.03.047
   Kraler S, 2022, EUR HEART J, V43, P683, DOI 10.1093/eurheartj/ehab757
   Lacraz GPA, 2017, CIRCULATION, V136, P1396, DOI 10.1161/CIRCULATIONAHA.117.027832
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li SJ, 2017, INT J CARDIOL, V232, P271, DOI 10.1016/j.ijcard.2017.01.005
   Lin YQ, 2020, NUCLEIC ACIDS RES, V48, pD189, DOI 10.1093/nar/gkz804
   Lindman BR, 2021, CIRCULATION, V143, P1455, DOI 10.1161/CIRCULATIONAHA.120.052531
   Lindman BR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.6
   Liu CY, 2019, YONSEI MED J, V60, P1081, DOI 10.3349/ymj.2019.60.11.1081
   Liu PY, 2004, CLIN SCI, V107, P415, DOI 10.1042/CS20040098
   Liu ZT, 2020, INT J MED SCI, V17, P3065, DOI 10.7150/ijms.49533
   Mahler GJ, 2014, BIOTECHNOL BIOENG, V111, P2326, DOI 10.1002/bit.25291
   Mahmut A, 2014, J AM COLL CARDIOL, V63, P460, DOI 10.1016/j.jacc.2013.05.105
   Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1348 2
   Miller JD, 2011, CIRC RES, V108, P1392, DOI 10.1161/CIRCRESAHA.110.234138
   Mito S, 2008, HYPERTENSION, V51, P1570, DOI 10.1161/HYPERTENSIONAHA.107.102566
   Moraes C, 2013, INTEGR BIOL UK, V5, P673, DOI 10.1039/c3ib20254b
   Nagy E, 2017, AM J PATHOL, V187, P1413, DOI 10.1016/j.ajpath.2017.02.012
   Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/nmeth.1938, 10.1038/NMETH.1938]
   Nkomo VT, 2006, LANCET, V368, P1005, DOI 10.1016/S0140 6736(06)69208 8
   Nsaibia MJ, 2017, CARDIOVASC RES, V113, P1351, DOI 10.1093/cvr/cvx089
   Ohukainen P, 2015, J HEART VALVE DIS, V24, P612
   Ohukainen P, 2015, ANN MED, V47, P423, DOI 10.3109/07853890.2015.1059955
   OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735 1097(94)90606 8
   Pan SC, 2018, EUR REV MED PHARMACO, V22, P6983, DOI 10.26355/eurrev_201810_16169
   Parra Izquierdo I, 2019, BBA MOL BASIS DIS, V1865, P2168, DOI 10.1016/j.bbadis.2019.04.014
   Perrotta I, 2015, ULTRASTRUCT PATHOL, V39, P198, DOI 10.3109/01913123.2014.991884
   Phipson B, 2016, ANN APPL STAT, V10, P946, DOI 10.1214/16 AOAS920
   Qiang L, 2012, J BIOL CHEM, V287, P13944, DOI 10.1074/jbc.M111.332767
   Qiao E, 2022, GENE, V808, DOI 10.1016/j.gene.2021.145987
   Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Rysä J, 2016, GENOM DATA, V7, P107, DOI 10.1016/j.gdata.2015.12.015
   Savai R, 2014, NAT MED, V20, P1289, DOI 10.1038/nm.3695
   Schlotter F, 2018, CIRCULATION, V138, P377, DOI 10.1161/CIRCULATIONAHA.117.032291
   Stephens EH, 2012, PATHOL RES PRACT, V208, P642, DOI 10.1016/j.prp.2012.08.001
   Strange G, 2019, J AM COLL CARDIOL, V74, P1851, DOI 10.1016/j.jacc.2019.08.004
   Sun DJ, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23608
   Sun L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084433
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tsai CL, 2018, EUR CYTOKINE NETW, V29, P36, DOI 10.1684/ecn.2018.0407
   Tsuchiya K, 2012, CELL METAB, V15, P372, DOI 10.1016/j.cmet.2012.01.018
   Uchida S, 2015, CIRC RES, V116, P737, DOI 10.1161/CIRCRESAHA.116.302521
   Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839
   Wang H, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4820275
   Weinberg EJ, 2010, CARDIOVASC ENG, V10, P5, DOI 10.1007/s10558 009 9089 9
   Wickham H., 2016, SPRINGER, DOI [DOI 10.18637/JSS.V077.B02, DOI 10.1007/978 3 319 24277 4, 10.1007/978 3 319 24277 4, DOI 10.18637/JSS.V035.B01]
   Xiao XX, 2017, INT J CARDIOL, V243, P404, DOI 10.1016/j.ijcard.2017.05.037
   Xie CY, 2014, NUCLEIC ACIDS RES, V42, pD98, DOI 10.1093/nar/gkt1222
   Ye SQ, 2002, CELL RES, V12, P105, DOI 10.1038/sj.cr.7290116
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhan Q, 2017, AM J PHYSIOL CELL PH, V312, pC407, DOI 10.1152/ajpcell.00230.2016
NR 82
TC 5
Z9 5
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2297 055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD JUN 29
PY 2022
VL 9
AR 826744
DI 10.3389/fcvm.2022.826744
PG 17
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 2Z9FC
UT WOS:000826873200001
PM 35845040
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jeffrey, JE
   Aspden, RM
AF Jeffrey, Janet E.
   Aspden, Richard M.
TI Cyclooxygenase inhibition lowers prostaglandin E2 release
   from articular cartilage and reduces apoptosis but not proteoglycan
   degradation following an impact load in vitro
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID HUMAN OSTEOARTHRITIC CARTILAGE; SELECTIVE COX 2 INHIBITION;
   NITRIC OXIDE; CHONDROCYTE APOPTOSIS; TISSUE INHIBITOR; JOINT FLUID;
   CELL DEATH; MATRIX; INDUCTION; EXPRESSION
AB This study investigated the release of prostaglandin E 2 (PGE(2)) from cartilage following an impact load in vitro and the possible chondroprotective effect of COX 2 inhibition using nonsteroidal anti inflammatory drugs (NSAIDs).
   Explants of human articular cartilage were subjected to a single impact load in a drop tower and then cultured for 6 days in the presence of either a selective COX 2 inhibitor, celecoxib, (0.01, 0.1, 1.0 and 10 mu M) or the non selective COX inhibitor indomethacin (0.1 and 10 mu M). The concentrations of PGE2 and glycosaminoglycans (GAGs), a measure of cartilage breakdown, were measured in the explant culture medium at 3 and 6 days post impact. Apoptotic cell death was measured in frozen explant sections by the TUNEL method.
   PGE(2) levels were increased more than 20 fold in the medium of explants at both 3 (P = 0.012) and 6 days (P = 0.004) following impact compared with unloaded controls. In the presence of celecoxib and indomethacin the PGE(2) levels were reduced in a dose related manner. These inhibitors, however, had no effect in reducing the impact induced release of GAGs from the cartilage matrix. Addition of celecoxib and indomethacin significantly reduced the number of trauma induced apoptotic chondrocytes in cartilage explant sections.
   In this study, a marked increase in PGE(2) was measured in the medium following an impact load on articular cartilage, which was abolished by both the selective COX 2 inhibitor, celecoxib, and non selective indomethacin. These inhibitors reduced chondrocyte apoptosis but no change was observed in the release of GAGs from the explants, suggesting that the COX/PGE(2) pathway is not directly responsible for cartilage breakdown following traumatic injury. Our in vitro study showed that it is unlikely that COX 2 inhibition alone would slow down or prevent the development of secondary osteoarthritis.
C1 [Jeffrey, Janet E.; Aspden, Richard M.] Univ Aberdeen, Inst Med Sci, Dept Orthopaed Surg, Aberdeen AB25 2ZD, Scotland.
C3 University of Aberdeen
RP Jeffrey, JE (通讯作者)，Univ Aberdeen, Inst Med Sci, Dept Orthopaed Surg, Aberdeen AB25 2ZD, Scotland.
EM j.e.jeffrey@abdn.ac.uk
RI Aspden, Richard/AFS 5583 2022
OI Aspden, Richard/0000 0002 0693 1194
CR Attur MG, 1998, P ASSOC AM PHYSICIAN, V110, P65
   BENNETT KA, 2003, OSTEOARTHR CARTILAGE, V11, pS17
   Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529 0131(199802)41:2<284::AID ART12>3.3.CO;2 K
   BLANCO FJ, 1995, EXP CELL RES, V218, P319, DOI 10.1006/excr.1995.1161
   Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835
   Burgin LV, 2007, MED ENG PHYS, V29, P525, DOI 10.1016/j.medengphy.2006.06.002
   Chen CT, 2001, J ORTHOPAED RES, V19, P703, DOI 10.1016/S0736 0266(00)00066 8
   D'Lima DD, 2001, J BONE JOINT SURG AM, V83A, P19, DOI 10.2106/00004623 200100021 00004
   D'Lima DD, 2001, OSTEOARTHR CARTILAGE, V9, P712, DOI 10.1053/joca.2001.0468
   DAHLBERG L, 1994, BRIT J RHEUMATOL, V33, P1107
   DIBATTISTA JA, 1991, J RHEUMATOL, V18, P102
   DiBattista JA, 1997, J CELL BIOCHEM, V65, P408, DOI 10.1002/(SICI)1097 4644(19970601)65:3<408::AID JCB10>3.3.CO;2 H
   DiBattista JA, 1996, MOL CELL ENDOCRINOL, V123, P27, DOI 10.1016/0303 7207(96)03887 7
   Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161
   El Hajjaji H, 2003, J RHEUMATOL, V30, P2444
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304 4165(86)90306 5
   Fermor B, 2002, OSTEOARTHR CARTILAGE, V10, P792, DOI 10.1053/joca.2002.0832
   Gelber AC, 2000, ANN INTERN MED, V133, P321, DOI 10.7326/0003 4819 133 5 200009050 00007
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   Hashimoto S, 1998, ARTHRITIS RHEUM US, V41, P1266, DOI 10.1002/1529 0131(199807)41:7<1266::AID ART18>3.0.CO;2 Y
   Hashimoto S, 1998, ARTHRITIS RHEUM US, V41, P1632, DOI 10.1002/1529 0131(199809)41:9<1632::AID ART14>3.0.CO;2 A
   Haut RC, 1995, J BIOMECH ENG T ASME, V117, P402, DOI 10.1115/1.2794199
   HELLEBERG L, 1981, CLIN PHARMACOKINET, V6, P245, DOI 10.2165/00003088 198106040 00001
   Héraud F, 2000, ANN RHEUM DIS, V59, P959, DOI 10.1136/ard.59.12.959
   Jeffrey JE, 2006, P I MECH ENG H, V220, P677, DOI 10.1243/09544119JEIM31
   Jeffrey JE, 1997, BBA GEN SUBJECTS, V1334, P223, DOI 10.1016/S0304 4165(96)00097 9
   JEFFREY JE, 1995, ARCH BIOCHEM BIOPHYS, V322, P87, DOI 10.1006/abbi.1995.1439
   Jeffrey JE, 2004, OSTEOARTHR CARTILAGE, V12, pS48
   Levin A, 2001, OSTEOARTHR CARTILAGE, V9, P702, DOI 10.1053/joca.2001.0467
   Loening AM, 2000, ARCH BIOCHEM BIOPHYS, V381, P205, DOI 10.1006/abbi.2000.1988
   LOHMANDER LS, 1993, J RHEUMATOL, V20, P1362
   Lohmander LS, 1996, J RHEUMATOL, V23, P1765
   López Armada MJ, 2006, OSTEOARTHR CARTILAGE, V14, P660, DOI 10.1016/j.joca.2006.01.005
   Lotz M, 1999, OSTEOARTHR CARTILAGE, V7, P389, DOI 10.1053/joca.1998.0220
   Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208
   Macfarland A. K., 1994, Matrix Biology, V14, P378, DOI 10.1016/0945 053X(94)90089 2
   MacFarland AK, 1996, MATRIX BIOL, V15, P172, DOI 10.1016/S0945 053X(96)90053 0
   MACFARLAND AK, 1995, INT J EXP PATHOL, V76, pA26
   Martel Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049 0172(03)00134 3
   Mastbergen SC, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1846
   Mastbergen SC, 2005, OSTEOARTHR CARTILAGE, V13, P519, DOI 10.1016/j.joca.2005.02.004
   Mastbergen SC, 2002, RHEUMATOLOGY, V41, P801, DOI 10.1093/rheumatology/41.7.801
   MCKENZIE LS, 1976, ANN RHEUM DIS, V35, P487, DOI 10.1136/ard.35.6.487
   MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693
   MITROVIC D, 1982, PROSTAG OTH LIPID M, V23, P17, DOI 10.1016/0090 6980(82)90018 1
   Miwa M, 2000, OSTEOARTHR CARTILAGE, V8, P17, DOI 10.1053/joca.1999.0266
   Mrosek EH, 2006, OSTEOARTHR CARTILAGE, V14, P171, DOI 10.1016/j.joca.2005.08.004
   Notoya K, 2000, J IMMUNOL, V165, P3402, DOI 10.4049/jimmunol.165.6.3402
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   Saha N, 1999, ARTHRITIS RHEUM, V42, P1577, DOI 10.1002/1529 0131(199908)42:8<1577::AID ANR3>3.0.CO;2 Z
   STONE JE, 1994, ANN CLIN BIOCHEM, V31, P147, DOI 10.1177/000456329403100206
   Takahashi T, 2005, INT J MOL MED, V15, P213
   Tchetina EV, 2006, AM J PATHOL, V168, P131, DOI 10.2353/ajpath.2006.050369
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692
NR 55
TC 41
Z9 47
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2007
VL 9
IS 6
AR R129
DI 10.1186/ar2346
PG 29
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 252TQ
UT WOS:000252469900020
PM 18096078
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Paskalev, M
   Goranov, N
AF Paskalev, Mihail
   Goranov, Nikolay
TI MODULATION OF NITRIC OXIDE PRODUCTION BY THERAPEUTIC PULSED ULTRASOUND
   IN A CANINE TIBIA FRACTURE MODEL
SO VETERINARIJA IR ZOOTECHNIKA
LA English
DT Article
DE dogs; osteosynthesis; therapeutic ultrasound; nitric oxide
ID HUMAN OSTEOBLASTS; SYNTHASE PATHWAY; L ARGININE; LOCALIZATION;
   ACTIVATION; EXPRESSION
AB The purpose of the present experiment was to monitor the effect of therapeutic ultrasound application on the time course of blood nitric oxide concentrations in an experimental fracture model in dogs. In 24 male mixed breed adult dogs, transperiosteal osteotomies of right tibia and fibula were performed. After being operated, dogs were allotted to 4 groups: in Group 1 ([MO control; n=6) the osteotomies were fixed with a Kuntscher nail (intramedullar osteosynthesis; IMO). In Group 2 (PLO control; n=6), the osteotomies were fixed with a plate and 6 cortical screws. In dogs from Group 3 (IMO+U; n=6), fractures were fixed with Kuntscher nails and a low intensity ultrasound therapy was applied at the fracture site. Osteotomies of dogs from Group 4 (PLO+U; n=6) were fixed by plate osteosynthesis and submitted to ultrasound therapy. Blood serum nitric oxide concentrations were assayed prior to the surgery, by post operative weeks 1, 2 and post operative months 1, 2 and 3. In control groups (IMO and PLO), serum NO increased statistically significantly as early as the first week and persisted high until the end of the second week. In the groups treated with ultrasound, the increase was significant by the end of the second post operative week for both osteosynthesis techniques used. For the PLO+U group only, they remained higher vs preoperative values until the end of the second month. Serum NO concentrations differed considerably between ultrasound treated and control groups by the first post operative week (p<0.01 in both methods of osteosynthesis) and by the end of the 2nd and the 3rd months (p<0.01 for PLO groups). In the early fracture healing stage, NO levels were higher in control groups, whereas in late stages in ultrasound treated groups. In conclusion, despite the osteosynthesis technique used, the application of therapeutic ultrasound reduced the production of nitric oxide during the early inflammation stage of fracture healing but stimulated its formation at later stages of callus formation. It could therefore be successfully utilized as a physical therapeutic adjunct to operative treatment of such traumas in a clinical setting.
C1 [Paskalev, Mihail; Goranov, Nikolay] Trakia Univ, Fac Vet Med, Dept Vet Surg, Stara Zagora 6000, Bulgaria.
C3 Trakia University
RP Paskalev, M (通讯作者)，Trakia Univ, Fac Vet Med, Dept Vet Surg, Stara Zagora 6000, Bulgaria.
EM paskalev@uni sz.bg
OI Goranov, Nikolay/0000 0001 5277 3636
CR Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264 6021:3570593
   Andican G, 2005, WORLD J GASTROENTERO, V11, P2340, DOI 10.3748/wjg.v11.i15.2340
   Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529 0131(200112)44:12<2790::AID ART466>3.0.CO;2 X
   Bigham A, 2009, COMP CLIN PATHOL, V18, P377, DOI DOI 10.1007/S00580 009 0821 Z
   COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305
   Corbett SA, 1999, J BONE JOINT SURG BR, V81B, P531, DOI 10.1302/0301 620X.81B3.8852
   de Sousa VL, 2008, CIENC RURAL, V38, P1030, DOI 10.1590/S0103 84782008000400019
   Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342
   Ghasemi A., 2007, J Med Sci Res, V2, P29
   Hantes ME, 2004, J BONE JOINT SURG AM, V86A, P2275, DOI 10.2106/00004623 200410000 00021
   Heybeli N, 2002, J ULTRAS MED, V21, P1357, DOI 10.7863/jum.2002.21.12.1357
   Kdolsky RK, 2005, WIEN KLIN WOCHENSCHR, V117, P693, DOI 10.1007/s00508 005 0431 y
   Keskin D, 2007, TOHOKU J EXP MED, V213, P283, DOI 10.1620/tjem.213.283
   de Albornoz PM, 2011, BRIT MED BULL, V100, P39, DOI 10.1093/bmb/ldr006
   Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750
   Miranda KM, 2001, NITRIC OXIDE BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   Mundi R, 2009, INDIAN J ORTHOP, V43, P132, DOI 10.4103/0019 5413.50847
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Sinha S, 2009, INDIAN J ORTHOP, V43, P328, DOI 10.4103/0019 5413.55972
   STAMLER JS, 1994, CIRCULATION, V89, P2035, DOI 10.1161/01.CIR.89.5.2035
   van't Hof RJ, 2000, P NATL ACAD SCI USA, V97, P7993, DOI 10.1073/pnas.130511497
   Viola G, 2000, HEPATO GASTROENTEROL, V47, P1250
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   YANG KH, 1994, T ORTHOP RES SOC, V19, P519
   Zhu W, 2002, J BONE MINER RES, V17, P1470, DOI 10.1359/jbmr.2002.17.8.1470
   Zhu W, 2001, J BONE MINER RES, V16, P535, DOI 10.1359/jbmr.2001.16.3.535
NR 28
TC 0
Z9 0
U1 0
U2 5
PU LITHUANIAN VETERINARY ACAD
PI KAUNAS
PA TILZES G 18, KAUNAS, LT 47181, LITHUANIA
SN 1392 2130
J9 VET ZOOTECH LITH
JI Vet. Zootec.
PY 2012
VL 58
IS 80
BP 54
EP 58
PG 5
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 970QO
UT WOS:000306147600009
DA 2025 08 17
ER

PT J
AU Balmayor, ER
   Pashkuleva, I
   Frias, AM
   Azevedo, HS
   Reis, RL
AF Balmayor, Elizabeth R.
   Pashkuleva, Iva
   Frias, Ana M.
   Azevedo, Helena S.
   Reis, Rui L.
TI Synthesis and functionalization of superparamagnetic poly ε caprolactone
   microparticles for the selective isolation of subpopulations of human
   adipose derived stem cells
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE particulate materials; magnetic properties; surface chemistry; cell
   recognition
ID BOVINE SERUM ALBUMIN; BIOMEDICAL APPLICATIONS; MAGNETIC NANOPARTICLES;
   SURFACE MODIFICATION; ENDOTHELIAL CELLS; DRUG DELIVERY; PARTICLES;
   ADSORPTION; PROTEINS; LATEXES
AB There has been a growing interest in using biofunctionalized magnetic particles for cell isolation. This paper describes the synthesis and characterization of magnetite polymer (Fe(3)O(4) poly epsilon caprolactone, magnetite PCL) microparticles surface functionalized with amino and epoxy groups allowing easy covalent attachment of specific antibodies and subsequent ability to bind target cells. Particles with different sizes (4 135 mu m), spherical shape and superparamagnetic behaviour (magnetite content of about 13 wt%) were obtained. The functionalized microparticles presented high protein binding capacity (coupling efficiency of 47% for epoxy and 71% for amino functionalized particles) with a low level of non specific binding. We have further investigated the influence of initial protein concentration, pH, ionic strength, temperature and incubation time on the capacity of amino functionalized particles to bind protein molecules. The results showed that maximum protein coupling is rapidly achieved (<= 5 h) at pH 5.5 and low ionic strength (0.05 M NaCl). Furthermore, when cultured in direct contact with osteoblast like cells (Saos 2) or human derived adipose stem cells (ASCs), the amino functionalized particles did not affect the proliferation and morphology of the cells. As a proof of principle for the application of magnetic microparticles for cell isolation, CD105 (endoglin) antibody was coupled to the magnetic particle surface to bind subpopulations of human ASCs expressing the CD105 antigen. The isolation of CD105+ ASCs from a heterogeneous cell population was confirmed by flow cytometry analysis. Given the demonstrated potential of functionalized magnetite PCL microparticles for selective cell isolation, we expect that these particles may be further applied in immuno magnetic cell separation owing to their versatility and ease of surface modification.
C1 [Balmayor, Elizabeth R.; Pashkuleva, Iva; Frias, Ana M.; Azevedo, Helena S.; Reis, Rui L.] Univ Minho, 3Bs Res Grp Biomat Biodegradables & Biomimet, Headquarters European Inst Excellence Tissue Engn, P 4806909 Taipas, Guimaraes, Portugal.
   [Balmayor, Elizabeth R.; Pashkuleva, Iva; Frias, Ana M.; Azevedo, Helena S.; Reis, Rui L.] IBB Inst Biotechnol & Bioengn, PT Govt Associated Lab, Guimaraes, Portugal.
C3 Universidade do Minho
RP Balmayor, ER (通讯作者)，Univ Minho, 3Bs Res Grp Biomat Biodegradables & Biomimet, Headquarters European Inst Excellence Tissue Engn, P 4806909 Taipas, Guimaraes, Portugal.
EM erosado@dep.uminho.pt; hazevedo@dep.uminho.pt
RI ; Azevedo, Helena/A 8298 2011; Balmayor, E./N 9283 2015; Reis, Rui
   L./A 8938 2008; Rosado Balmayor, Elizabeth/N 9283 2015; Pashkuleva,
   Iva/B 5590 2008; Reis, Rui/A 8938 2008
OI Pashkuleva, Iva/0000 0001 6818 3374; Azevedo,
   Helena/0000 0002 5470 1844; Reis, Rui L./0000 0002 4295 6129; UMinho,
   3B's Research Group/0000 0002 5195 3456; Rosado Balmayor,
   Elizabeth/0000 0002 0484 4847; 
FU European Union [MEST CT 2004 008104, NMP3 CT 2004 500283]; Portuguese
   Foundation for Science Technology [SFRH/BPD/45206/2008]; Fundação para a
   Ciência e a Tecnologia [SFRH/BPD/45206/2008] Funding Source: FCT
FX This work was supported through the European Union funded projects:
   Marie Curie Host Fellowships for Early Stage Research Training (EST)
   'Alea Jacta EST' (MEST CT 2004 008104), which provided E. R. Balmayor
   with a PhD Fellowship, and Network of Excellence EXPERTISSUES
   (NMP3 CT 2004 500283). A. M. Frias thanks the Portuguese Foundation for
   Science Technology for a post doctoral fellowship (SFRH/BPD/45206/2008).
   The authors are grateful to Prof. Bernardo G. Almeida from the Physics
   Department at University of Minho for his assistance with vibrational
   magnetometry studies.
CR Androde JD, 1985, SURFACE INTERFACIAL, P1
   Balmayor ER, 2009, ACTA BIOMATER, V5, P1035, DOI 10.1016/j.actbio.2008.11.006
   Basinska T, 2005, MACROMOL BIOSCI, V5, P1145, DOI 10.1002/mabi.200500138
   Bayramoglu G, 2007, COLLOID SURFACE A, V297, P55, DOI 10.1016/j.colsurfa.2006.10.023
   Benoit MA, 1999, INT J PHARMACEUT, V184, P73, DOI 10.1016/S0378 5173(99)00109 X
   Carrot G, 1999, MACROMOLECULES, V32, P5264, DOI 10.1021/ma990198b
   Caruso F, 2001, CHEM MATER, V13, P109, DOI 10.1021/cm001164h
   Chen DR, 2000, POLYM DEGRAD STABIL, V67, P455, DOI 10.1016/S0141 3910(99)00145 7
   Cortez C, 2007, ACS NANO, V1, P93, DOI 10.1021/nn700060m
   DESANTAMARIA LC, 2004, MATER LETT, V58, P3001, DOI DOI 10.1016/J.MATLET.2004.05.028
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   *DYNALBIOTECH, 2008, PRINC DYN
   Franzreb M, 2006, APPL MICROBIOL BIOT, V70, P505, DOI 10.1007/s00253 006 0344 3
   Gu HW, 2006, CHEM COMMUN, P941, DOI 10.1039/b514130c
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Häfeli UO, 2004, INT J PHARMACEUT, V277, P19, DOI 10.1016/S0378 5173(04)00127 9
   Hamoudeh M, 2006, J COLLOID INTERF SCI, V300, P584, DOI 10.1016/j.jcis.2006.04.024
   Hermanson G., 1996, Bioconjugate Techniques, V1st, P114
   Horák D, 2007, J SEP SCI, V30, P1751, DOI 10.1002/jssc.200700088
   Khalafalla SE, 1974, US Patent, Patent No. 3843540
   Kim DH, 2006, CURR APPL PHYS, V6, pE242, DOI 10.1016/j.cap.2006.01.048
   Konishi Y, 2002, AM J PATHOL, V161, P1567, DOI 10.1016/S0002 9440(10)64435 5
   Landfester K, 2003, J PHYS CONDENS MAT, V15, pS1345, DOI 10.1088/0953 8984/15/15/304
   Larson BJ, 2005, BIOSENS BIOELECTRON, V21, P796, DOI 10.1016/j.bios.2005.02.005
   Lewis D.H., 1990, Biodegradable polymers as drug delivery systems, P1
   Li Y, 2008, J PHYS CHEM B, V112, P3797, DOI 10.1021/jp077392h
   Luong Van E, 2006, BIOMATERIALS, V27, P2042, DOI 10.1016/j.biomaterials.2005.10.028
   Mohamed A, 2007, POLYM DEGRAD STABIL, V92, P1177, DOI 10.1016/j.polymdegradstab.2007.04.012
   Mornet S, 2004, J MATER CHEM, V14, P2161, DOI 10.1039/b402025a
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Neuberger T, 2005, J MAGN MAGN MATER, V293, P483, DOI 10.1016/j.jmmm.2005.01.064
   OLSVIK O, 1994, CLIN MICROBIOL REV, V7, P43, DOI 10.1128/CMR.7.1.43 54.1994
   ORTEGAVINUESA JL, 1995, J COLLOID INTERF SCI, V176, P240, DOI 10.1006/jcis.1995.0027
   ORTEGAVINUESA JL, 1995, BIOTECHNOL BIOENG, V47, P633, DOI 10.1002/bit.260470604
   Pamme N, 2006, LAB CHIP, V6, P974, DOI 10.1039/b604542a
   Park BH, 2008, COLLOID SURFACE A, V313, P145, DOI 10.1016/j.colsurfa.2007.04.152
   Park TJ, 2006, CHEM MATER, V18, P5289, DOI 10.1021/cm061503s
   Peng ZG, 2004, COLLOID SURFACE B, V33, P15, DOI 10.1016/j.colsurfb.2003.08.007
   Peula JM, 1998, J COLLOID INTERF SCI, V201, P132, DOI 10.1006/jcis.1997.5388
   Pitt C.G., 1990, BIODEGRADABLE POLYM, P71, DOI DOI 10.1016/0223 5234(91)90162 G
   Rada T, 2009, J TISSUE ENG REGEN M, V3, P158, DOI 10.1002/term.141
   Ramírez LP, 2003, MACROMOL CHEM PHYSIC, V204, P22, DOI 10.1002/macp.200290052
   Redl FX, 2004, J AM CHEM SOC, V126, P14583, DOI 10.1021/ja046808r
   Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007
   Safarik I, 1999, J CHROMATOGR B, V722, P33, DOI 10.1016/S0378 4347(98)00338 7
   Safarik Ivo, 2004, Biomagn Res Technol, V2, P7, DOI 10.1186/1477 044X 2 7
   Santiago LY, 2006, BIOMATERIALS, V27, P2962, DOI 10.1016/j.biomaterials.2006.01.011
   Sarobe J, 1998, MACROMOLECULES, V31, P4282, DOI 10.1021/ma9707143
   Schillinger U, 2005, J MAGN MAGN MATER, V293, P501, DOI 10.1016/j.jmmm.2005.01.032
   SHI Y, 2006, THESIS U ADELAIDE SA
   Su YL, 2008, REACT FUNCT POLYM, V68, P161, DOI 10.1016/j.reactfunctpolym.2007.10.001
   Tokairin T, 2002, J HEPATOL, V36, P725, DOI 10.1016/S0168 8278(02)00048 X
   Yang J, 2006, INT J PHARMACEUT, V324, P185, DOI 10.1016/j.ijpharm.2006.06.029
   Yang TI, 2008, J MAGN MAGN MATER, V320, P2714, DOI 10.1016/j.jmmm.2008.06.008
   Zhu YB, 2002, BIOMACROMOLECULES, V3, P1312, DOI 10.1021/bm020074y
NR 55
TC 20
Z9 22
U1 0
U2 16
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742 5689
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD JUN 6
PY 2011
VL 8
IS 59
BP 896
EP 908
DI 10.1098/rsif.2010.0531
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 752EL
UT WOS:000289672200012
PM 21208971
OA Green Published
DA 2025 08 17
ER

PT J
AU Huang, CS
   Hsieh, SC
   Teng, NC
   Lee, WF
   Negi, P
   Belem, WF
   Wu, HC
   Yang, JC
AF Huang, Ching Shuan
   Hsieh, Sung Chih
   Teng, Nai Chia
   Lee, Wei Fang
   Negi, Poonam
   Belem, Wendimi Fatimata
   Wu, Hsuan Chen
   Yang, Jen Chang
TI A Silk Fibroin Based Hydration Accelerator for Root Canal Filling
   Materials
SO POLYMERS
LA English
DT Article
DE mineral trioxide aggregate; silk fibroin; SavDen((R)) MTA; ProRoot((R))
   MTA
ID MINERAL TRIOXIDE AGGREGATE; BOMBYX MORI; ENTEROCOCCUS FAECALIS; SEALING
   ABILITY; PROROOT MTA; BIOMATERIALS; MECHANISMS; BIODENTINE; REPAIR;
   CHAIN
AB Mineral trioxide aggregate (MTA) is widely used in various dental endodontic applications such as root end filling, furcal perforation repair, and vital pulp therapy. In spite of many attempts to improve handling properties and reduce the discoloration of MTA, the ideal root canal filling material has yet to be fully developed. The objective of this study was to investigate the setting time, mechanical properties, and biocompatibility of MTA set by a silk fibroin solution. A 5 wt% silk fibroin (SF) solution (a novel hydration accelerant) was used to set SavDen((R)) MTA and ProRoot((R)) white MTA (WMTA). Changes in setting time, diametral tensile strength (DTS), material crystallization, in vitro cell viability, and cell morphology were assessed by Vicat needle measurement, a universal testing machine, scanning electron microscopy (SEM), and WST 1 assay, respectively. The initial setting time of ProRoot((R)) MTA and SavDen((R)) MTA experienced a drastic decrease of 83.9% and 42.1% when deionized water was replaced by 5 wt% SF solution as the liquid phase. The DTS of SavDen((R)) MTA showed a significant increase after set by the SF solution in 24 h. A human osteoblast like cell (MG 63) based WST 1 assay revealed that both ProRoot((R)) MTA and SavDen((R)) MTA hydrated using SF solution did not significantly differ (p > 0.05) in cell viability. MG 63 cells with pseudopodia attachments and nuclear protrusions represent a healthier and more adherent status on the surface of MTA when set with SF solution. The results suggest that the 5 wt% SF solution may be used as an alternative hydration accelerant for MTA in endodontic applications.
C1 [Huang, Ching Shuan; Hsieh, Sung Chih; Teng, Nai Chia] Taipei Med Univ, Sch Dent, Coll Oral Med, Taipei 11031, Taiwan.
   [Hsieh, Sung Chih] Taipei Municipal Wan Fang Hosp, Dept Dent, Taipei 11696, Taiwan.
   [Teng, Nai Chia] Taipei Med Univ Hosp, Dept Dent, Taipei 11031, Taiwan.
   [Lee, Wei Fang] Taipei Med Univ, Sch Dent Technol, Coll Oral Med, Taipei 110, Taiwan.
   [Negi, Poonam] Shoolini Univ Biotechnol & Management Sci, Sch Pharmaceut Sci, Solan 173212, India.
   [Belem, Wendimi Fatimata; Yang, Jen Chang] Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei 11031, Taiwan.
   [Wu, Hsuan Chen] Natl Taiwan Univ, Dept Biochem Sci & Technol, Taipei 106, Taiwan.
   [Yang, Jen Chang] Taipei Med Univ, Grad Inst Nanomed & Med Engn, Coll Biomed Engn, Taipei 11031, Taiwan.
   [Yang, Jen Chang] Taipei Med Univ, Res Ctr Biomed Device, Taipei 11052, Taiwan.
   [Yang, Jen Chang] Taipei Med Univ, Res Ctr Digital Oral Sci & Technol, Taipei 11052, Taiwan.
C3 Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei
   Medical University; Taipei Medical University Hospital; Taipei Medical
   University; Shoolini University; Taipei Medical University; National
   Taiwan University; Taipei Medical University; Taipei Medical University;
   Taipei Medical University
RP Yang, JC (通讯作者)，Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei 11031, Taiwan.; Yang, JC (通讯作者)，Taipei Med Univ, Grad Inst Nanomed & Med Engn, Coll Biomed Engn, Taipei 11031, Taiwan.; Yang, JC (通讯作者)，Taipei Med Univ, Res Ctr Biomed Device, Taipei 11052, Taiwan.; Yang, JC (通讯作者)，Taipei Med Univ, Res Ctr Digital Oral Sci & Technol, Taipei 11052, Taiwan.
EM jollyhuangtw12@gmail.com; endo@tmu.edu.tw; tengnaichia@hotmail.com;
   weiwei@tmu.edu.tw; poonam.546@shooliniuniversity.com;
   belemfatimataw@gmail.com; hcwu7@ntu.edu.tw; Yang820065@tmu.edu.tw
RI ; Negi, Poonam/AAA 9536 2021
OI Negi, Poonam/0000 0003 3722 991X; Yang, Jen Chang/0000 0001 9931 1703;
   Teng, Naichia/0000 0003 0361 7404; Hsieh, Sung Chih/0000 0003 1627 1844
FU Ministry of Science and Technology, Taiwan MOST [108 2218 E 038 002]
FX Support for this work was provided by the Ministry of Science and
   Technology, Taiwan MOST 108 2218 E 038 002.
CR Ajisawa A., 1998, Journal of Sericultural Science of Japan, V67, P91, DOI DOI 10.11416/KONTYUSHIGEN1930.67.91
   Al Hezaimi K, 2006, J ENDODONT, V32, P1053, DOI 10.1016/j.joen.2006.06.004
   Ali MS, 2019, WOODH PUBL SER BIOM, P255, DOI 10.1016/B978 0 08 102476 8.00012 8
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142 9612(02)00353 8
   Ber BS, 2007, J ENDODONT, V33, P1231, DOI 10.1016/j.joen.2007.06.012
   Bullard JW, 2008, J AM CERAM SOC, V91, P2088, DOI 10.1111/j.1551 2916.2008.02419.x
   Butt Naziya, 2014, Indian J Dent Res, V25, P692, DOI 10.4103/0970 9290.152163
   Camilleri J, 2007, INT ENDOD J, V40, P462, DOI 10.1111/j.1365 2591.2007.01248.x
   Camilleri J, 2015, J ENDODONT, V41, P1139, DOI 10.1016/j.joen.2015.02.032
   Chang Seok Woo, 2012, Restor Dent Endod, V37, P188, DOI 10.5395/rde.2012.37.4.188
   Chang SC, 2016, PROCEEDINGS OF THE 2016 INTERNATIONAL CONFERENCE ON ARTIFICIAL LIFE AND ROBOTICS (ICAROB 2016), P1
   Chong B.S., 2019, MANAGING ENDODONTIC
   Economides N, 2003, INT ENDOD J, V36, P44, DOI 10.1046/j.0143 2885.2003.00611.x
   Fuks AB, 2008, J ENDODONT, V34, pS18, DOI 10.1016/j.joen.2008.02.031
   Hsieh SC, 2009, J ENDODONT, V35, P1292, DOI 10.1016/j.joen.2009.06.007
   Inoue S, 2000, J BIOL CHEM, V275, P40517, DOI 10.1074/jbc.M006897200
   Ji DY, 2011, J ENDODONT, V37, P851, DOI 10.1016/j.joen.2011.03.015
   Jimenez Sanchez Maria Del Carmen, 2019, J Clin Exp Dent, V11, pe739, DOI 10.4317/jced.56013
   Kahler B, 2017, MATERIALS, V10, DOI 10.3390/ma10121389
   Khurshid Z, 2019, WOODH PUBL SER BIOM, P1, DOI 10.1016/B978 0 08 102476 8.00001 3
   Kim Min Hee, 2017, Biomater Res, V21, P12, DOI 10.1186/s40824 017 0098 2
   Kirchheim AP, 2009, J MATER SCI, V44, P2038, DOI 10.1007/s10853 009 3292 3
   Kogan P, 2006, J ENDODONT, V32, P569, DOI 10.1016/j.joen.2005.08.006
   Lee BN, 2014, J ENDODONT, V40, P2019, DOI 10.1016/j.joen.2014.08.014
   Lee BN, 2011, J ENDODONT, V37, P1433, DOI 10.1016/j.joen.2011.06.013
   LEE SJ, 1993, J ENDODONT, V19, P541, DOI 10.1016/S0099 2399(06)81282 3
   Lee YL, 2004, BIOMATERIALS, V25, P787, DOI 10.1016/S0142 9612(03)00591 X
   Lee YL, 2017, J FORMOS MED ASSOC, V116, P424, DOI 10.1016/j.jfma.2016.07.009
   Linsuwanont Pairoj, 2003, Aust Endod J, V29, P45
   Lovschall H., 2014, GILLMORE TESTING INI
   Mieszawska AJ, 2010, BIOMATERIALS, V31, P8902, DOI 10.1016/j.biomaterials.2010.07.109
   Nagas E, 2016, J ENDODONT, V42, P1673, DOI 10.1016/j.joen.2016.08.002
   Ngamwongsatit P, 2008, J MICROBIOL METH, V73, P211, DOI 10.1016/j.mimet.2008.03.002
   Oliveira TM, 2008, J DENT CHILD, V75, P188
   Parirokh M, 2010, J ENDODONT, V36, P16, DOI 10.1016/j.joen.2009.09.006
   Rabbany SY, 2010, CELL TRANSPLANT, V19, P399, DOI 10.3727/096368909X481782
   Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379
   Saatchi M, 2014, J APPL ORAL SCI, V22, P356
   Saunders WP, 2008, J ENDODONT, V34, P660, DOI 10.1016/j.joen.2008.03.002
   Schmitt D, 2001, Pediatr Dent, V23, P326
   Shayegan A, 2008, ORAL SURG ORAL MED O, V105, P536, DOI 10.1016/j.tripleo.2007.10.008
   Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097 4636(200101)54:1<139::AID JBM17>3.0.CO;2 7
   Taylor H., 1997, CEMENT CHEM, V2
   TORABINEJAD M, 1993, J ENDODONT, V19, P591, DOI 10.1016/S0099 2399(06)80271 2
   Torabinejad M, 1999, J ENDODONT, V25, P197, DOI 10.1016/S0099 2399(99)80142 3
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   Wang YZ, 2006, BIOMATERIALS, V27, P6064, DOI 10.1016/j.biomaterials.2006.07.008
   Wiltbank KB, 2007, J ENDODONT, V33, P1235, DOI 10.1016/j.joen.2007.06.016
   Zafar MS, 2019, WOODH PUBL SER BIOM, P7, DOI 10.1016/B978 0 08 102476 8.00002 5
   Zafar MS, 2015, BIOMACROMOLECULES, V16, P606, DOI 10.1021/bm501667j
   Zafar MS, 2014, J TAIBAH UNIV MED SC, V9, P171, DOI 10.1016/j.jtumed.2014.01.003
NR 51
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4360
J9 POLYMERS BASEL
JI Polymers
PD APR
PY 2020
VL 12
IS 4
AR 994
DI 10.3390/polym12040994
PG 11
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA LR3IS
UT WOS:000535587700264
PM 32344691
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Song, JL
   Liu, H
   Lei, M
   Tan, HQ
   Chen, ZY
   Antoshin, A
   Payne, GF
   Qu, X
   Liu, CS
AF Song, Jialin
   Liu, Huan
   Lei, Miao
   Tan, Haoqi
   Chen, Zhanyi
   Antoshin, Artem
   Payne, Gregory F.
   Qu, Xue
   Liu, Changsheng
TI Redox Channeling Polydopamine Ferrocene (PDA Fc) Coating To Confer
   Context Dependent and Photothermal Antimicrobial Activities
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE implant; antibacterial; redox; polydopamine; hydroxy radical;
   photothermal; chemodynamic therapy
ID TIO2 NANORODS; ANTIBACTERIAL; SURFACE; FILMS; NANOPARTICLES;
   FLUORESCENCE; DOPAMINE; RELEASE; BENIGN; DOTS
AB Microbial disinfection associated with medical device surfaces has been an increasing need, and surface modification strategies such as antibacterial coatings have gained great interest. Here, we report the development of polydopamine ferrocene (PDA Fc) functionalized TiO2 nanorods (Ti Nd PDA Fc) as a context dependent antibacterial system on implant to combat bacterial infection and hinder biofilm formation. In this work, two synergistic antimicrobial mechanisms of the PDA Fc coating are proposed. First, the PDA Fc coating is redox active and can be locally activated to release antibacterial reactive oxygen species (ROS), especially center dot OH in response to the acidic microenvironment induced by bacteria colonization and host immune responses. The results demonstrate that redox based antimicrobial activity of Ti Nd PDA Fc offers antibacterial efficacy of over 95 and 92% against methicillin resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli), respectively. Second, the photothermal effect of PDA can enhance the antibacterial capability upon near infrared (NIR) irradiation, with over 99% killing efficacy against MRSA and E. coli, and even suppress the formation of biofilm through both localized hyperthermia and enhanced center dot OH generation. Additionally, Ti Nd PDA Fc is biocompatible when tested with model pre osteoblast MC 3T3 E1 cells and promotes cell adhesion and spreading presumably due to its nanotopographical features. The MRSA infected wound model also indicates that Ti Nd PDA Fc with NIR irradiation can effectively eliminate bacterial infection and suppress host inflammatory responses. We believe that this study demonstrates a simple means to create biocompatible redox active coatings that confer context dependent antibacterial activities to implant surfaces.
C1 [Song, Jialin; Liu, Huan; Lei, Miao; Tan, Haoqi; Chen, Zhanyi; Qu, Xue; Liu, Changsheng] East China Univ Sci & Technol, Key Lab Ultrafine Mat, Engn Res Ctr Biomed Mat, Minist Educ,Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
   [Antoshin, Artem] Sechenov Univ, Inst Regenerat Med, Moscow 119991, Russia.
   [Payne, Gregory F.] Inst Biosyst & Biotechnol Res & Fischell, Dept Bioengn, College Pk, MD 20742 USA.
C3 East China University of Science & Technology; Sechenov First Moscow
   State Medical University
RP Qu, X; Liu, CS (通讯作者)，East China Univ Sci & Technol, Key Lab Ultrafine Mat, Engn Res Ctr Biomed Mat, Minist Educ,Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
EM quxue@ecust.edu.cn; liucs@ecust.edu.cn
RI qu, xue/KLE 2817 2024; Miao, Lei/IWU 6565 2023; Antoshin,
   Artem/Q 8696 2017
OI Payne, Gregory F./0000 0001 6638 9459; Antoshin,
   Artem/0000 0003 0575 0321
FU National Natural Science Foundation of China [51621002, 31922041,
   11932012, 51573047]; 111 Project [B14018]; Science and Technology
   Innovation Project of Shanghai Science and Technology Committee
   [18441908300]; United States National Science Foundation [DMREF 1435957,
   ECCS 1807604]
FX The support from the National Natural Science Foundation of China
   (51621002, 31922041, 11932012, and 51573047), 111 Project (B14018), the
   Science and Technology Innovation Project of Shanghai Science and
   Technology Committee (18441908300), and the United States National
   Science Foundation (DMREF 1435957; ECCS 1807604) is acknowledged.
CR Arciola CR, 2018, NAT REV MICROBIOL, V16, P397, DOI 10.1038/s41579 018 0019 y
   Branitzki Heinemann K, 2020, METHODS MOL BIOL, V2087, P223, DOI 10.1007/978 1 0716 0154 9_17
   Coad BR, 2014, BIOTECHNOL ADV, V32, P296, DOI 10.1016/j.biotechadv.2013.10.015
   Ding XK, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201802140
   Ding X, 2012, BIOMATERIALS, V33, P6593, DOI 10.1016/j.biomaterials.2012.06.001
   Dong LQ, 2011, THIN SOLID FILMS, V519, P4634, DOI 10.1016/j.tsf.2011.01.008
   Dryden M, 2017, CURR OPIN INFECT DIS, V30, P143, DOI [10.1097/QCO.0000000000000350, 10.1097/qco.0000000000000350]
   Fathi M, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109743
   Forooshani PK, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00631
   Gao G, 2019, BIOMATERIALS, V188, P83, DOI 10.1016/j.biomaterials.2018.09.045
   Gao Q, 2020, BIOMATER SCI UK, V8, P278, DOI 10.1039/c9bm01396b
   Gao Q, 2017, POLYM CHEM UK, V8, P6386, DOI 10.1039/c7py01495c
   Gatadi S, 2019, BIOORG CHEM, V92, DOI 10.1016/j.bioorg.2019.103252
   Gu J, 2017, ACS APPL MATER INTER, V9, P198, DOI 10.1021/acsami.6b13552
   Guan M, 2019, INT J NANOMED, V14, P2903, DOI 10.2147/IJN.S202625
   Hall Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821
   Hu JJ, 2019, BIOMATER SCI UK, V7, P581, DOI 10.1039/c8bm01211c
   Jansson T, 2012, J NANOSCI NANOTECHNO, V12, P7132, DOI 10.1166/jnn.2012.6587
   Jia RN, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801591
   Kempf VAJ, 2005, CIRCULATION, V111, P1054, DOI 10.1161/01.CIR.0000155608.07691.B7
   Kim YW, 2019, POLYMER, V166, P55, DOI 10.1016/j.polymer.2019.01.046
   Kumar TN, 2014, J MATER CHEM B, V2, P6081, DOI 10.1039/c4tb00823e
   Kwon B, 2016, ACS APPL MATER INTER, V8, P5887, DOI 10.1021/acsami.5b12523
   Kwon HJ, 2017, ACTA BIOMATER, V61, P169, DOI 10.1016/j.actbio.2017.08.007
   Lei M, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201900065
   Li M, 2016, ACS APPL MATER INTER, V8, P33972, DOI 10.1021/acsami.6b09457
   Li M, 2019, ADV SCI, V6, DOI 10.1002/advs.201900599
   Liu B, 2009, J AM CHEM SOC, V131, P3985, DOI 10.1021/ja8078972
   Liu H, 2019, ACTA BIOMATER, V88, P181, DOI 10.1016/j.actbio.2019.02.032
   Liu MY, 2016, NANOSCALE, V8, P16819, DOI 10.1039/c5nr09078d
   Liu XP, 2019, ACS NANO, V13, P5222, DOI 10.1021/acsnano.8b09501
   Lu YM, 2015, BIOMATERIALS, V45, P64, DOI 10.1016/j.biomaterials.2014.12.048
   Mao CY, 2019, ACS APPL MATER INTER, V11, P17902, DOI 10.1021/acsami.9b05787
   Meng H, 2019, ACTA BIOMATER, V83, P109, DOI 10.1016/j.actbio.2018.10.037
   Qi F, 2019, ACS APPL MATER INTER, V11, P18907, DOI 10.1021/acsami.9b02915
   Sadrearhami Z, 2019, ACS APPL MATER INTER, V11, P7320, DOI 10.1021/acsami.8b16853
   Schierholz JM, 2001, J HOSP INFECT, V49, P87, DOI 10.1053/jhin.2001.1052
   Sies H, 2017, REDOX BIOL, V11, P613, DOI 10.1016/j.redox.2016.12.035
   Srisuk P, 2016, NAT PROD RES, V30, P982, DOI 10.1080/14786419.2015.1079185
   Su YJ, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601173
   Sun HJ, 2014, ACS NANO, V8, P6202, DOI 10.1021/nn501640q
   Tang ZM, 2019, ANGEW CHEM INT EDIT, V58, P946, DOI 10.1002/anie.201805664
   Tang ZM, 2017, ADV MATER, V29, DOI 10.1002/adma.201701683
   Thallinger B, 2013, BIOTECHNOL J, V8, P97, DOI 10.1002/biot.201200313
   Tong W, 2019, BIOMATER SCI UK, V7, P1905, DOI 10.1039/c8bm01483c
   Wang BL, 2013, ACS APPL MATER INTER, V5, P4136, DOI 10.1021/am4000547
   Wang H, 2018, NANO LETT, V18, P3344, DOI 10.1021/acs.nanolett.7b05095
   Wang Q, 2014, IND ENG CHEM RES, V53, P643, DOI 10.1021/ie403402q
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang YL, 2016, NANOSCALE, V8, P11143, DOI 10.1039/c6nr01114d
   Wei T, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801381
   Xi JQ, 2019, NANO LETT, V19, P7645, DOI 10.1021/acs.nanolett.9b02242
   Xie XZ, 2018, ACS CENTRAL SCI, V4, P724, DOI 10.1021/acscentsci.8b00177
   Yang C, 2014, ADV MATER, V26, P7346, DOI 10.1002/adma.201402059
   Yang JJ, 2019, CARBON, V146, P827, DOI 10.1016/j.carbon.2019.02.040
   Yuan Z, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119290
   Zhang HL, 2019, ACS APPL MATER INTER, V11, P17283, DOI 10.1021/acsami.9b04428
   Zhang XD, 2016, ADV FUNCT MATER, V26, P5958, DOI 10.1002/adfm.201602185
   Zhao J, 2015, ACS APPL MATER INTER, V7, P18467, DOI 10.1021/acsami.5b04633
   Zhuk I, 2014, ACS NANO, V8, P7733, DOI 10.1021/nn500674g
NR 60
TC 76
Z9 78
U1 5
U2 295
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB 19
PY 2020
VL 12
IS 7
BP 8915
EP 8928
DI 10.1021/acsami.9b22339
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA KO0CQ
UT WOS:000515214300115
PM 31971763
DA 2025 08 17
ER

PT J
AU Cao, L
   Feng, XM
   Zhang, Q
   Fang, JB
   Chu, CH
   Lv, JL
   Ma, YY
   Lu, G
   Yang, KC
   Pan, RL
AF Cao, Liang
   Xiaoming Feng
   Zhang, Qiang
   Fang, Junbiao
   Chu, Chunhua
   Lv, Jinlong
   Ma, Yuyuan
   Lu, Gang
   Yang, Kaichuang
   Pan, Ruolang
TI An Optimized Method for Adipose Stromal Vascular Fraction Isolation and
   its Application in Fat Grafting
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article
DE Adipose tissue; Stromal vascular fraction; Isolation; ADSCs; Fat
   grafting
ID MESENCHYMAL STEM CELLS; INTERNATIONAL SOCIETY; TISSUE
AB Background The stromal vascular fraction (SVF) derived from adipose tissue contains heterogeneous cell populations and has enormous potential for clinical therapy. There are two main methods for SVF isolation: enzymatic isolation and mechanical isolation, both of which have shortcomings. In this study, optimized conditions for the isolation of high quality SVF were established, and applications in fat grafting were evaluated.
   Methods Adipose tissue was chopped into small pieces and then ground into an erosive shape using a syringe. The pieces were digested with 0.15% type II collagenase for 35 min at 37 degrees C. After centrifugation, the pellets were resuspended in DMEM and passed through a 100 mu m strainer. The filtered cells were analyzed by flow cytometry. The fat graft was enriched with isolated SVF and subcutaneously transplanted into nude mice. Three weeks after transplantation, grafts were isolated, and H&E staining, immunocytochemistry, and western blotting were conducted.
   Results The harvested SVF cells reached > 2 x 10(6)/ml of adipose tissue within 90 min of operation. The number of CD34(+) ADSCs in our SVF pellets was > 6 x 10(5)/ml of adipose tissue, which has the potential for differentiating into osteoblasts, adipocytes, and chondrocytes. Freshly collected adipose tissue is better for SVF isolation, and isolated SVF should also be kept at 4 degrees C and used as soon as possible. SVF may promote revascularization after fat grafting. The adipose tissue of an SVF co transplanted group had an integral structure, clear capillaries, and higher VEGF expression. SVF co transplantation inhibited adipose cell apoptosis.
   Conclusion Our study provides an efficient procedure for SVF isolation, its application in fat grafting, and possible underlying mechanisms.
C1 [Cao, Liang; Chu, Chunhua; Lv, Jinlong] Zhejiang Prov Peoples Hosp, Dept Acupuncture & Moxibust, Hangzhou, Zhejiang, Peoples R China.
   [Cao, Liang; Chu, Chunhua; Lv, Jinlong] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Xiaoming Feng] Jiaxing Univ, Affiliated Hosp, Hosp Jiaxing 1, Dept Neurosurg, Jiaxing, Zhejiang, Peoples R China.
   [Zhang, Qiang; Pan, Ruolang] Inst Cell Based Drug Dev Zhejiang Prov, S Evans Biosci, Hangzhou, Peoples R China.
   [Zhang, Qiang; Pan, Ruolang] Key Lab Cell Based Drug & Appl Technol Dev Zhejia, Hangzhou, Peoples R China.
   [Fang, Junbiao] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China.
   [Fang, Junbiao] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Ma, Yuyuan; Lu, Gang; Yang, Kaichuang] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Ma, Yuyuan; Lu, Gang; Yang, Kaichuang] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital;
   Hangzhou Medical College; Jiaxing University; Hangzhou Medical College;
   Zhejiang Provincial People's Hospital; Hangzhou Medical College;
   Hangzhou Medical College; Zhejiang Provincial People's Hospital;
   Hangzhou Medical College
RP Pan, RL (通讯作者)，Inst Cell Based Drug Dev Zhejiang Prov, S Evans Biosci, Hangzhou, Peoples R China.; Pan, RL (通讯作者)，Key Lab Cell Based Drug & Appl Technol Dev Zhejia, Hangzhou, Peoples R China.; Yang, KC (通讯作者)，Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.; Yang, KC (通讯作者)，Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
EM kfemme@zju.edu.cn; ruolang_pan@163.com
RI Lv, Jinlong/LSM 3970 2024; Feng, Xiaoming/JPX 0968 2023; Cao,
   Liang/S 3908 2017
FU General Project Funds from the Health Department of Zhejiang Province
   [2021KY034]; National Key Research and Development Program of China
   [2018YFC2001904, 2016YFC1000810]; Key Technologies R&D Program of
   Zhejiang Province [2019C03041]
FX This work was supported by the General Project Funds from the Health
   Department of Zhejiang Province (grant number 2021KY034); National Key
   Research and Development Program of China (grant number 2018YFC2001904;
   2016YFC1000810); and the Key Technologies R&D Program of Zhejiang
   Province (grant number 2019C03041).
CR Alexander RW, 2016, PHYS MED REH CLIN N, V27, P871, DOI 10.1016/j.pmr.2016.06.005
   Aronowitz JA, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064 015 1509 2
   Baptista LS, 2009, CYTOTHERAPY, V11, P706, DOI 10.3109/14653240902981144
   Bora P, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0598 y
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Carstens MH, 2021, STEM CELL TRANSL MED, V10, P1138, DOI 10.1002/sctm.20 0497
   Casteilla Louis, 2011, World J Stem Cells, V3, P25, DOI 10.4252/wjsc.v3.i4.25
   Dai R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6737345
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dong ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080364
   Faustini M, 2010, TISSUE ENG PART C ME, V16, P1515, DOI [10.1089/ten.tec.2010.0214, 10.1089/ten.TEC.2010.0214]
   Frese L, 2016, TRANSFUS MED HEMOTH, V43, P268, DOI 10.1159/000448180
   Gentile P, 2015, PRS GLOB OPEN, V3, DOI 10.1097/GOX.0000000000000285
   Guo J, 2016, J PLAST RECONSTR AES, V69, P180, DOI 10.1016/j.bjps.2015.10.014
   Han S, 2015, CRIT REV EUKAR GENE, V25, P145, DOI 10.1615/CritRevEukaryotGeneExpr.2015013057
   Illouz YG, 2009, AESTHET PLAST SURG, V33, P706, DOI 10.1007/s00266 009 9377 1
   Kim B, 2017, METHODS MOL BIOL, V1606, P133, DOI 10.1007/978 1 4939 6990 6_9
   Li X, 2018, CRIT REV EUKAR GENE, V28, P285, DOI 10.1615/CritRevEukaryotGeneExpr.2018023572
   Ma YY, 2019, J CELL PHYSIOL, V234, P15235, DOI 10.1002/jcp.28167
   Markarian CF, 2014, BIOTECHNOL LETT, V36, P693, DOI 10.1007/s10529 013 1425 x
   Meissburger B, 2016, BBA MOL CELL BIOL L, V1861, P1121, DOI 10.1016/j.bbalip.2016.06.010
   Nguyen A, 2016, J PLAST RECONSTR AES, V69, P170, DOI 10.1016/j.bjps.2015.10.015
   Oberbauer Eleni, 2015, Cell Regen, V4, P7, DOI 10.1186/s13619 015 0020 0
   Paik KJ, 2015, PLAST RECONSTR SURG, V136, P67, DOI 10.1097/PRS.0000000000001367
   Pak J, 2016, BIOMED RES INT UK, V2016, DOI 10.1155/2016/4702674
   Prasai A, 2017, STEM CELL REV REP, V13, P781, DOI 10.1007/s12015 017 9721 9
   Ramakrishnan VM, 2018, TISSUE ENG PART B RE, V24, P289, DOI [10.1089/ten.TEB.2017.0061, 10.1089/ten.teb.2017.0061]
   Raposio E, 2017, ANN MED SURG, V20, P87, DOI 10.1016/j.amsu.2017.07.018
   Shimizu M, 2018, WOUND REPAIR REGEN, V26, P446, DOI 10.1111/wrr.12665
   Suga H, 2009, STEM CELLS DEV, V18, P1201, DOI 10.1089/scd.2009.0003
   SundarRaj S, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/109353
   Tonnard P, 2013, PLAST RECONSTR SURG, V132, P1017, DOI 10.1097/PRS.0b013e31829fe1b0
   Travers RL, 2015, INT J OBESITY, V39, P762, DOI 10.1038/ijo.2014.195
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 36
TC 10
Z9 11
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0364 216X
EI 1432 5241
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD OCT
PY 2022
VL 46
IS 5
BP 2500
EP 2508
DI 10.1007/s00266 021 02738 x
EA JAN 2022
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 5Z8EM
UT WOS:000737709500004
PM 34981156
DA 2025 08 17
ER

PT J
AU Zhang, XY
   Liu, ZJ
   Xu, B
   Sun, ZL
   Gong, YQ
   Shao, CS
AF Zhang, Xiyu
   Liu, Zhaojian
   Xu, Bing
   Sun, Zhaoliang
   Gong, Yaoqin
   Shao, Changshun
TI Neferine, an alkaloid ingredient in lotus seed embryo, inhibits
   proliferation of human osteosarcoma cells by promoting p38 MAPK mediated
   p21 stabilization
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Neferine; Osteosarcoma; Cell cycle arrest; p38MAPK; p21
ID SMOOTH MUSCLE CELLS; PROTEIN STABILITY; ARREST; P21(WAF1/CIP1);
   PHOSPHORYLATION; EXPRESSION; MUTATIONS; LYMPHOMA; KINASES; MICE
AB Identification of natural products that have antitumor activity is invaluable to the chemoprevention and therapy of cancer. The embryos of lotus (Nelumbo nucifera) seeds are consumed in beverage in some parts of the world for their presumed health benefiting effects. In this report we studied the effects of neferine, a major alkaloid component in lotus embryos, on human osteosarcoma cells and the underlying mechanisms. We found that neferine possessed a potent growth inhibitory effect on human osteosarcoma cells, but not on non neoplastic human osteoblast cells. The inhibitory effect of neferine on human osteosarcoma cells was largely attributed to cell cycle arrest at G1. The induction of G1 arrest was p21(WAF1/CIP1) dependent, but was independent of p53 or RB (retinoblastoma associated protein). The up regulation of p21 by neferine was due to an increase in the half life of p21 protein. We examined four kinases that are known to affect the stabilization of p21, and found that p38 MAPK and JNK were activated by neferine. However, only SB203580 (an inhibitor of p38), but not SP600125 (the inhibitor of JNK), can attenuate the up regulation of p21 in response to neferine. Furthermore, the p21 stabilizing effect of neferine was abolished when p38 was silenced by RNA interference. Finally, we showed that neferine treatment led to an increased phosphorylation of p21 at Ser130 that was dependent on p38. Our results for the first time showed a direct antitumor effect of neferine, suggesting that consumption of neferine may have cancer preventive and cancer therapeutic benefit. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Zhang, Xiyu; Liu, Zhaojian; Xu, Bing; Sun, Zhaoliang; Gong, Yaoqin; Shao, Changshun] Shandong Univ, Sch Med, Key Lab Expt Teratol, Minist Educ,Inst Mol Med & Genet, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University
RP Gong, YQ (通讯作者)，Shandong Univ, Sch Med, Key Lab Expt Teratol, Minist Educ,Inst Mol Med & Genet, Jinan 250012, Shandong, Peoples R China.
EM yxg8@sdu.edu.cn; changshun.shao@gmail.com
RI , Owen/AHE 6976 2022; Shao, Changshun/AAD 8977 2022
OI Shao, Changshun/0000 0003 2618 9342
FU National Basic Research Program of China [2007CB512001, 2011CB966200];
   National High tech Research and Development Program of China
   [2006AA02A406]; Shandong Province Foundation of outstanding Young
   Scientists [BS2010YY043]
FX This work was supported by National Basic Research Program of China;
   grant numbers: 2007CB512001 and 2011CB966200, National High tech
   Research and Development Program of China; grant number: 2006AA02A406;
   Shandong Province Foundation of outstanding Young Scientists, grant
   number: BS2010YY043.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Ai Xiao Hong, 2007, Ai Zheng, V26, P357
   Cao JG, 2004, WORLD J GASTROENTERO, V10
   Chen J, 2007, ANDROLOGIA, V39, P141, DOI 10.1111/j.1439 0272.2007.00781.x
   Choi BH, 2008, CANCER RES, V68, P1369, DOI 10.1158/0008 5472.CAN 07 5222
   Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189
   De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432
   Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008 5472.CAN 08 3363
   Hideshima T, 2003, CANCER RES, V63, P8428
   Kim DI, 2008, CARCINOGENESIS, V29, P1701, DOI 10.1093/carcin/bgn055
   Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200
   Kuntzen C, 2005, CANCER RES, V65, P6780, DOI 10.1158/0008 5472.CAN 04 2618
   Li XC, 2010, ACTA PHARMACOL SIN, V31, P679, DOI 10.1038/aps.2010.57
   Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200
   Liu ZJ, 2009, MUTAT RES FUND MOL M, V662, P75, DOI 10.1016/j.mrfmmm.2008.12.009
   Martín Caballero J, 2001, CANCER RES, V61, P6234
   Mukhopadhyay I, 2006, J BIOL CHEM, V281, P37330, DOI 10.1074/jbc.M605569200
   Shao CS, 2009, MUTAT RES FUND MOL M, V670, P103, DOI 10.1016/j.mrfmmm.2009.09.001
   SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6
   Stabile E, 2003, CIRC RES, V93, P1059, DOI 10.1161/01.RES.0000105086.31909.1B
   VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103
   Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618
   Wang J L, 1992, Yao Xue Xue Bao, V27, P881
   Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590
   Weglarz Ludmila, 2006, Acta Pol Pharm, V63, P443
   Young NP, 2011, CANCER RES, V71, P4040, DOI 10.1158/0008 5472.CAN 10 4563
   Yu J., 1997, Yaoxue Xuebao, V32, P1
   Zhang Chun Lin, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P524
   Zhao LB, 2010, EUR J PHARMACOL, V627, P304, DOI 10.1016/j.ejphar.2009.11.007
NR 29
TC 73
Z9 85
U1 1
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD FEB 29
PY 2012
VL 677
IS 1 3
BP 47
EP 54
DI 10.1016/j.ejphar.2011.12.035
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 898HJ
UT WOS:000300731200007
PM 22227330
DA 2025 08 17
ER

EF